Sie sind auf Seite 1von 1139

Code Level1 Level2 Level3 TGM

10102 Alimentary Tract and Metabolism Antacids and Antiflatulants Antacids and Reflux Barrier Agents Caro
10104 Alimentary Tract and Metabolism Antacids and Antiflatulants Phosphate Binding Agents Caro
10401 Alimentary Tract and Metabolism Antidiarrhoeals Agents Which Reduce Motility Caro
10404 Alimentary Tract and Metabolism Antidiarrhoeals Rectal and Colonic Anti-inflammatories Caro
10501 Alimentary Tract and Metabolism Local preparations for Anal and Rectal Disorders Antihaemorrhoidal Preparations Caro
10502 Alimentary Tract and Metabolism Local preparations for Anal and Rectal Disorders Management of Anal Fissures Caro
10503 Alimentary Tract and Metabolism Local preparations for Anal and Rectal Disorders Rectal Sclerosants Caro
10507 Alimentary Tract and Metabolism Local preparations for Anal and Rectal Disorders Soothing Agents Caro
10701 Alimentary Tract and Metabolism Antispasmodics and Other Agents Altering Gut Motility Antispasmodics and Other Agents Altering Gut Motility Caro
11001 Alimentary Tract and Metabolism Antiulcerants Antisecretory and Cytoprotective Caro
11002 Alimentary Tract and Metabolism Antiulcerants Helicobacter Pylori Eradication Caro
11003 Alimentary Tract and Metabolism Antiulcerants H2 Antagonists Caro
11007 Alimentary Tract and Metabolism Antiulcerants M1 Antagonists Caro
11010 Alimentary Tract and Metabolism Antiulcerants Proton Pump Inhibitors Caro
11013 Alimentary Tract and Metabolism Antiulcerants Site Protective Agents Caro
11301 Alimentary Tract and Metabolism Diabetes Hyperglycaemic Agents Greg
11303 Alimentary Tract and Metabolism Diabetes Insulin - Short-acting Preparations Greg
11305 Alimentary Tract and Metabolism Diabetes Insulin - Intermediate-acting Preparations Greg
11307 Alimentary Tract and Metabolism Diabetes Insulin - Long-acting Preparations Greg
11309 Alimentary Tract and Metabolism Diabetes Insulin - Rapid Acting Preparations Greg
11311 Alimentary Tract and Metabolism Diabetes Alpha Glucosidase Inhibitors Greg
11312 Alimentary Tract and Metabolism Diabetes Oral Hypoglycaemic Agents Greg
11501 Alimentary Tract and Metabolism Diabetes Management Glucose/Urine Testing Greg
11504 Alimentary Tract and Metabolism Diabetes Management Ketone Testing Greg
11507 Alimentary Tract and Metabolism Diabetes Management Blood Glucose Testing Greg
11509 Alimentary Tract and Metabolism Diabetes Management Insulin Syringes and Needles Greg
11512 Alimentary Tract and Metabolism Diabetes Management Insulin Pumps Greg
11515 Alimentary Tract and Metabolism Diabetes Management Insulin Pump Consumables Greg
12201 Alimentary Tract and Metabolism Digestives Including Enzymes Digestives Including Enzymes Caro
12501 Alimentary Tract and Metabolism Laxatives Bulk-forming Agents Caro
12504 Alimentary Tract and Metabolism Laxatives Faecal Softeners Caro
12507 Alimentary Tract and Metabolism Laxatives Osmotic Laxatives Caro
12510 Alimentary Tract and Metabolism Laxatives Stimulant Laxatives Caro
12802 Alimentary Tract and Metabolism Metabolic Disorder Agents Gaucher's Disease Caro
13101 Alimentary Tract and Metabolism Mouth and Throat Agents Used in Mouth Ulceration Caro
13107 Alimentary Tract and Metabolism Mouth and Throat Oropharyngeal Anti-infectives Caro
13109 Alimentary Tract and Metabolism Mouth and Throat Other Oral Agents Caro
13701 Alimentary Tract and Metabolism Vitamins Vitamin A Caro
13704 Alimentary Tract and Metabolism Vitamins Vitamin B Caro
13707 Alimentary Tract and Metabolism Vitamins Vitamin C Caro
13710 Alimentary Tract and Metabolism Vitamins Vitamin D Caro
13713 Alimentary Tract and Metabolism Vitamins Vitamin E Caro
13719 Alimentary Tract and Metabolism Vitamins Multivitamin Preparations Caro
13810 Alimentary Tract and Metabolism Minerals Calcium Caro
13820 Alimentary Tract and Metabolism Minerals Fluoride Caro
13825 Alimentary Tract and Metabolism Minerals Iodine Caro
13830 Alimentary Tract and Metabolism Minerals Iron Caro
13840 Alimentary Tract and Metabolism Minerals MagnesiumCaro
13850 Alimentary Tract and Metabolism Minerals Zinc Caro
40101 Blood and Blood Forming Organs Antianaemics Hypoplastic and Haemolytic Sue Anne
40103 Blood and Blood Forming Organs Antianaemics Iron Therapy Sue Anne
40104 Blood and Blood Forming Organs Antianaemics Megaloblastic Sue Anne
40401 Blood and Blood Forming Organs Antifibrinolytics, Haemostatics and Local Sclerosants Antifibrinolytics, Haemostatics and Local Sclerosants Sue Anne
40403 Blood and Blood Forming Organs Antifibrinolytics, Haemostatics and Local Sclerosants Vitamin K Sue Anne
40701 Blood and Blood Forming Organs Antithrombotic Agents Antiplatelet Agents Sue Anne
40704 Blood and Blood Forming Organs Antithrombotic Agents Heparin and Antagonist Preparations Sue Anne
40707 Blood and Blood Forming Organs Antithrombotic Agents Oral Anticoagulants Sue Anne
40803 Blood and Blood Forming Organs Blood Colony-stimulating Factors Blood Colony-stimulating Factors Sue Anne
41001 Blood and Blood Forming Organs Fluids and Electrolytes Intravenous Administration Sue Anne
41004 Blood and Blood Forming Organs Fluids and Electrolytes Oral Administration Sue Anne
70101 Cardiovascular System Adrenergic Neurone Blockers Adrenergic Neurone Blockers Katie
70401 Cardiovascular System Alpha Adrenoceptor Blockers Alpha Adrenoceptor Blockers Katie
70701 Cardiovascular System Agents Affecting the Renin-Angiotensin System ACE Inhibitors Katie
70702 Cardiovascular System Agents Affecting the Renin-Angiotensin System ACE Inhibitors with Diuretics Katie
70703 Cardiovascular System Agents Affecting the Renin-Angiotensin System Angiotensin II Antagonists Katie
70705 Cardiovascular System Agents Affecting the Renin-Angiotensin System Angiotensin II Antagonists with Diuretics Katie
71301 Cardiovascular System Antiarrhythmics Antiarrhythmics Katie
71501 Cardiovascular System Antihypotensives Antihypotensives Katie
71601 Cardiovascular System Beta Adrenoceptor Blockers Beta Adrenoceptor Blockers Katie
71901 Cardiovascular System Beta Adrenoceptor Blockers with Diuretics Beta Adrenoceptor Blockers with Diuretics Katie
72201 Cardiovascular System Calcium Channel Blockers Dihydropyridine Calcium Channel Blockers Katie
72202 Cardiovascular System Calcium Channel Blockers Other Calcium Channel Blockers Katie
72801 Cardiovascular System Centrally-Acting Agents Centrally-Acting Agents Katie
73101 Cardiovascular System Diuretics Loop Diuretics Katie
73104 Cardiovascular System Diuretics Potassium Sparing Diuretics Katie
73107 Cardiovascular System Diuretics Potassium Sparing Combination Diuretics Katie
73110 Cardiovascular System Diuretics Thiazide and Related Diuretics Katie
73201 Cardiovascular System Lipid-Modifying Agents Fibrates Katie
73202 Cardiovascular System Lipid-Modifying Agents Other Lipid-Modifying Agents Katie
73203 Cardiovascular System Lipid-Modifying Agents Resins Katie
73204 Cardiovascular System Lipid-Modifying Agents HMG CoA Reductase Inhibitors (Statins) Katie
73208 Cardiovascular System Lipid-Modifying Agents Selective Cholesterol Absorption Inhibitors Katie
73401 Cardiovascular System Nitrates Nitrates Katie
73701 Cardiovascular System Sympathomimetics Sympathomimetics Katie
74001 Cardiovascular System VasodilatorsVasodilatorsKatie
74005 Cardiovascular System VasodilatorsEndothelin Receptor Antagonists Katie
74007 Cardiovascular System VasodilatorsPhosphodiesterase Type 5 Inhibitors Katie
74009 Cardiovascular System VasodilatorsProstacyclin Analogues Katie
100101 Dermatologicals Antiacne Preparations Antiacne Preparations Bronwyn
100401 Dermatologicals Antibacterials Topical Antibacterials Topical Bronwyn
100701 Dermatologicals Antifungals Topical Antifungals Topical Bronwyn
100801 Dermatologicals Antipruritic Preparations Antipruritic Preparations Bronwyn
101001 Dermatologicals Antivirals Topical Antivirals Topical Bronwyn
101101 Dermatologicals Corticosteroids Topical Corticosteroids - Plain Bronwyn
101104 Dermatologicals Corticosteroids Topical Corticosteroids - Combination Bronwyn
101301 Dermatologicals Disinfecting and Cleansing Agents Disinfecting and Cleansing Agents Bronwyn
101401 Dermatologicals Dusting Powders Dusting Powders Bronwyn
101502 Dermatologicals Barrier Creams and Emollients Barrier Creams Bronwyn
101504 Dermatologicals Barrier Creams and Emollients Emollients Bronwyn
101506 Dermatologicals Barrier Creams and Emollients Other Dermatological Bases Bronwyn
101601 Dermatologicals Minor Skin Infections Minor Skin Infections Bronwyn
101701 Dermatologicals Parasiticidal Preparations Parasiticidal Preparations Bronwyn
101901 Dermatologicals Psoriasis and Eczema Preparations Psoriasis and Eczema Preparations Bronwyn
102201 Dermatologicals Scalp Preparations Scalp Preparations Bronwyn
102501 Dermatologicals SunscreensSunscreensBronwyn
102801 Dermatologicals Wart Preparations Wart Preparations Bronwyn
103103 Dermatologicals Other Skin Preparations Antineoplastics Bronwyn
103104 Dermatologicals Other Skin Preparations Antiperspirants Bronwyn
103107 Dermatologicals Other Skin Preparations Wound Management Products Bronwyn
130101 Genito-Urinary System Contraceptives - Non-hormonal Condoms Bronwyn
130105 Genito-Urinary System Contraceptives - Non-hormonal Spermicidal Agents Bronwyn
130107 Genito-Urinary System Contraceptives - Non-hormonal Contraceptive Devices Bronwyn
130802 Genito-Urinary System Contraceptives - Hormonal Combined Oral Contraceptives Bronwyn
130804 Genito-Urinary System Contraceptives - Hormonal Progestogen-only Contraceptives Bronwyn
130805 Genito-Urinary System Contraceptives - Hormonal Emergency Contraceptives Bronwyn
130902 Genito-Urinary System Antiandrogen Oral Contraceptives Antiandrogen Oral Contraceptives Bronwyn
131001 Genito-Urinary System Gynaecological Anti-infectives Gynaecological Anti-infectives Bronwyn
131202 Genito-Urinary System Impotence Treatment Impotence Treatment Bronwyn
131402 Genito-Urinary System Myometrial and Vaginal Hormone Preparations Myometrial and Vaginal Hormone Preparations Bronwyn
131602 Genito-Urinary System Pregnancy Tests - hCG Urine Pregnancy Tests - hCG Urine Bronwyn
131901 Genito-Urinary System Urinary Agents 5-Alpha Reductase Inhibitors Bronwyn
131902 Genito-Urinary System Urinary Agents Alpha-1A Adrenoreceptor Blockers Bronwyn
131904 Genito-Urinary System Urinary Agents Other Urinary Agents Bronwyn
132201 Genito-Urinary System Detection of Substances in Urine Detection of Substances in Urine Bronwyn
140101 Hormone Preparations - Systemic Excluding Contraceptive Hormones Anabolic Agents Anabolic Agents Bronwyn
140404 Hormone Preparations - Systemic Excluding Contraceptive Hormones Calcium Homeostasis Calcium Homeostasis Bronwyn
140701 Hormone Preparations - Systemic Excluding Contraceptive Hormones Corticosteroids and Related Agents for Systemic Use Corticosteroids and Related Agents for Systemic Use Bronwyn
141001 Hormone Preparations - Systemic Excluding Contraceptive Hormones Sex Hormones Non Contraceptive Androgen Agonists and Antagonists Bronwyn
141104 Hormone Preparations - Systemic Excluding Contraceptive Hormones Hormone Replacement Therapy - Systemic OestrogensBronwyn
141109 Hormone Preparations - Systemic Excluding Contraceptive Hormones Hormone Replacement Therapy - Systemic Progestogens Bronwyn
141114 Hormone Preparations - Systemic Excluding Contraceptive Hormones Hormone Replacement Therapy - Systemic Progestogen and Oestrogen Combined Preparations Bronwyn
141201 Hormone Preparations - Systemic Excluding Contraceptive Hormones Other Oestrogen Preparations Other Oestrogen Preparations Bronwyn
141301 Hormone Preparations - Systemic Excluding Contraceptive Hormones Other Progestogen Preparations Other Progestogen Preparations Bronwyn
141401 Hormone Preparations - Systemic Excluding Contraceptive Hormones Thyroid and Antithyroid Agents Thyroid and Antithyroid Agents Bronwyn
141602 Hormone Preparations - Systemic Excluding Contraceptive Hormones Trophic Hormones Growth Hormones Bronwyn
141603 Hormone Preparations - Systemic Excluding Contraceptive Hormones Trophic Hormones GnRH Analogues Bronwyn
141901 Hormone Preparations - Systemic Excluding Contraceptive Hormones Vasopressin Agonists Vasopressin Agonists Bronwyn
142101 Hormone Preparations - Systemic Excluding Contraceptive Hormones Other Endocrine Agents Other Endocrine Agents Bronwyn
Trial Version
Not all rows exported
Code FullID FormulationCode Name Manufacturer Distributor Stamp
10010101 07160110010101 100101 Sectral 155 10556006517998354432
10010102 07160110010102 100101 ACB 200 17720948751633219584
10010201 07160110010201 100102 Sectral 155 10628064112036282368
10010202 07160110010202 100102 ACB 200 17793006345671147520
10010301 07160110010301 100103 Sectral 155 10700121706074210304
10010302 07160110010302 100103 ACB 200 17865063939709075456
10020101 22070310020101 100201 Lamictal 104 7193157901026852864
10020201 22070310020201 100202 Lamictal 104 7265215495064780800
10020301 22070310020301 100203 Lamictal 104 7337273089102708736
10022501 22070210022501 100225 Lamictal 143 479470632594046976
10022525 22070210022525 100225 Arrow-Lamotrigine163 7029388942604500992
10022601 22070210022601 100226 Lamictal 143 551528226631974912
10022625 22070210022625 100226 Arrow-Lamotrigine163 7101446536642428928
10022626 22070210022626 100226 Mogine 35 7822022477021708288
10022627 22070210022627 100226 Logem 200 17504775969519435776
10022701 22070210022701 100227 Lamictal 143 623585820669902848
10022725 22070210022725 100227 Mogine 35 7894080071059636224
10022726 22070210022726 100227 Arrow-Lamotrigine163 7173504130680356864
10022727 22070210022727 100227 Logem 200 17576833563557363712
10022801 22070210022801 100228 Lamictal 143 695643414707830784
10022825 22070210022825 100228 Arrow-Lamotrigine163 7245561724718284800
10022826 22070210022826 100228 Mogine 35 7966137665097564160
10022827 22070210022827 100228 Logem 200 17648891157595291648
10022925 22070210022925 100229 Arrow-Lamotrigine163 7317619318756212736
10022926 22070210022926 100229 Mogine 35 8038195259135492096
10023025 22070210023025 100230 Lamictal 143 3653655148867092480
10030101 31030610030101 100301 Diamox 157 13825917815120461824
10030102 31030610030102 100301 Glaucomide 200 17937121533747003392
10030201 31030610030201 100302 Diamox 177 4190153051547369472
10040101 22070210040101 100401 Sabril 155 5249060814421229568
10050101 07190110050101 100501 Secadrex 155 10772179300112138240
10060101 13100110060101 100601 Aci-Jel 99 5750671213152174080
10090101 14160310090101 100901 Lucrin Depot 2 10507807226771537920
10090201 14160310090201 100902 Lucrin Depot 2 10579864820809465856
10092525 14160310092525 100925 Eligard 227 12486419082884677632
10092625 14160310092625 100926 Eligard 227 12558476676922605568
10092725 14160310092725 100927 Eligard 227 12630534270960533504
10092825 14160310092825 100928 Eligard 227 12702591864998461440
10092925 14160310092925 100929 Lucrin Depot PDS 2 10240191594128998400
10093025 14160310093025 100930 Lucrin Depot PDS 2 10456364376242782208
10093125 14160310093125 100931 Lucrin Depot PDS 2 10672537158356566016
10100101 28490210100101 101001 Pulmozyme 30 17732192357538856960
10110101 22220110110101 101101 Risperdal 69 18019296833783726080
10110125 22220110110125 101101 Ridal 35 8614656011438915584
10110126 22220110110126 101101 Dr Reddy's Risperidone 178 7705513826896052224
10110127 22220110110127 101101 Apo-Risperidone 10 9169747755256512512
10110201 22220110110201 101102 Risperdal 69 18091354427821654016
10110225 22220110110225 101102 Ridal 35 8686713605476843520
10110226 22220110110226 101102 Dr Reddy's Risperidone 178 7633456232858124288
10110227 22220110110227 101102 Apo-Risperidone 10 11940586326484582400
10110301 22220110110301 101103 Risperdal 69 18163412021859581952
10110325 22220110110325 101103 Ridal 35 8758771199514771456
10110326 22220110110326 101103 Dr Reddy's Risperidone 178 7561398638820196352
10110327 22220110110327 101103 Apo-Risperidone 10 12156759108598366208
10110401 22220110110401 101104 Risperdal 69 18235469615897509888
10110425 22220110110425 101104 Ridal 35 8830828793552699392
10110426 22220110110426 101104 Dr Reddy's Risperidone 178 7489341044782268416
10110427 22220110110427 101104 Apo-Risperidone 10 12372931890712150016
10110501 22220110110501 101105 Risperdal 69 18307527209935437824
10110525 22220110110525 101105 Risperon 200 5460184639140265984
10110526 22220110110526 101105 Apo-Risperidone 10 12589104672825933824
10112525 22220110112525 101125 Risperdal 69 17154605705328590848
10112526 22220110112526 101125 Ridal 35 8542598417400987648
10112527 22220110112527 101125 Apo-Risperidone 10 11508240762257014784
10112528 22220110112528 101125 Dr Reddy's Risperidone 178 16676125732711170048
10112625 22220410112625 101126 Risperdal Consta 69 13028131969215496192
10112725 22220410112725 101127 Risperdal Consta 69 13100189563253424128
10112825 22220410112825 101128 Risperdal Consta 69 13172247157291352064
10112925 22220110112925 101129 Risperdal Quicklet 69 2499112964120903680
10113025 22220110113025 101130 Risperdal Quicklet 69 2571170558158831616
10113125 22220110113125 101131 Risperdal Quicklet 69 2643228152196759552
10120101 07150110120101 101201 Gutron 35 2739427723045765120
10120201 07150110120201 101202 Gutron 35 2811485317083693056
10130301 07010110130301 101303 Ismelin 116 8106048320708804608
10150101 07370110150101 101501 Hospira 174 7493327873944584192
10150102 07370110150102 101501 AstraZeneca 144 10700403181050920960
10150125 07370110150125 101501 Aspen Adrenaline 157 6465888133857673216
10150201 07370110150201 101502 Hospira 174 7565385467982512128
10150225 07370110150225 101502 Aspen Adrenaline 157 8507737301730721792
10150301 28010110150301 101503 Medihaler-Epi 1 12686206942721343488
10160101 31030910160101 101601 Eppy N 88 9642269474363015168
10160201 31030910160201 101602 Eppy N 88 9714327068400943104
10170101 31030910170101 101701 Epifrin 5 9786384662438871040
10190301 10110110190301 101903 Logoderm 40 8216367819881709568
10190401 10110110190401 101904 Logoderm 40 8288425413919637504
10200101 01371010200101 102001 One-Alpha 29 15827456687695986688
10200201 01371010200201 102002 One-Alpha 29 6468639111950368768
10200301 01371010200301 102003 One-Alpha 29 6540696705988296704
10210101 01010210210101 102101 Gaviscon 162 6921317944710397952
10210201 01010210210201 102102 Gaviscon Infant 162 6993375538748325888
10210301 01010210210301 102103 Gaviscon Infant 23 7065433132786253824
10220101 01101010220101 102201 Zoton 14 4648985850888060928
10220125 01101010220125 102201 Solox 35 6472861236601028608
10220126 01101010220126 102201 Lanzol Relief 200 9516533722657062912
10222525 01101010222525 102225 Solox 35 7208669811071516672
10222526 01101010222526 102225 Lanzol Relief 200 9300360940543279104
10230101 01010210230101 102301 Gastrobrom 19 7137490726824181760
10240101 22010110240101 102401 Mayne 174 10065406628707958784
10242525 22010110242525 102425 APO-go 174 10137464222745886720
10242526 22010110242526 102425 Apomine 174 10209521816783814656
10250101 28400110250101 102501 Tilade 155 17573459162371719168
10250201 28400110250201 102502 Tilade 155 17645516756409647104
10260101 19130110260101 102601 Progout 200 18009179127784931328
10260102 19130110260102 102601 Allorin 35 9083310748150530048
10260103 19130110260103 102601 Zyloprim 157 9763654458557857792
10260104 19130110260104 102601 Apo-Allopurinol 10 9227425936226385920
10260125 19130110260125 102601 Allohexal 116 16708768033916583936
10260201 19130110260201 102602 Allorin 35 9299483530264313856
10260202 19130110260202 102602 Apo-Allopurinol 10 9371541124302241792
10260203 19130110260203 102602 Progout 200 18081236721822859264
10260205 19130110260205 102602 Zyloprim Z300 157 9835712052595785728
10260225 19130110260225 102602 Allohexal 116 16780825627954511872
10260226 19130110260226 102602 Apo-Allopurinol S2910 14042090597234245632
10270201 31031310270201 102702 Tears Plus 5 12236342859728420864
10290101 07160110290101 102901 Aptin CR 11 3748234039576756224
10310101 07070110310101 103101 Gopten 2 10866460223170674688
10310102 07070110310102 103101 Odrik 105 15493340392782299136
10310201 07070110310201 103102 Gopten 2 3002328649828401152
10310202 07070110310202 103102 Odrik 105 15637455580858155008
10310301 07070110310301 103103 Gopten 2 3074386243866329088
10310302 07070110310302 103103 Odrik 105 15781570768934010880
10320101 22010110320101 103201 Permax 157 10281579410821742592
10320201 22010110320201 103202 Permax 157 10353637004859670528
10330101 28510210330101 103301 Betnesol Aqueous 37 2240091114361061376
10340101 25070110340101 103401 Cellcept 30 16074586219689803776
10340125 25070110340125 103401 Myaccord 35 4149645943668473856
10340126 25070110340126 103401 Ceptolate 200 8286491372966379520
10342625 25070110342625 103426 Cellcept 30 15930471031613947904
10342626 25070110342626 103426 Myaccord 35 4365818725782257664
10342627 25070110342627 103426 Ceptolate 200 7998260996814667776
10342725 25070110342725 103427 Cellcept 30 16002528625651875840
10360101 10310410360101 103601 Hidrosol 200 18153294315860787200
10360201 38010110360201 103602 Aluminium chloride155 10844236894150066176
10370101 19080210370101 103701 Fosamax 72 6591705249424080896
10370201 19080410370201 103702 Fosamax 72 11051115504474259456
10372525 19080210372525 103725 Fosamax 72 6663762843462008832
10380201 01010210380201 103802 Amphogel 14 4721043444925988864
10380401 01010410380401 103804 Alu-Tab 35 5091716302439972864
10390101 01010210390101 103901 Aludrox 14 4793101038963916800
10400101 01010210400101 104001 Mylanta 133 3854931747447767040
10400201 01010210400201 104002 Mylanta 133 3710816559371911168
10400225 01010210400225 104002 Mylanta P 133 3782874153409839104
10400301 01010210400301 104003 Aludrox Plus 14 4865158633001844736
10410101 01010210410101 104101 Gastrogel 19 7569836291051749376
10430101 16190710430101 104301 Valtrex 143 4098968353232650240
10480101 22010110480101 104801 Symmetrel 116 10425694598897598464
10500101 07310410500101 105001 Midamor 72 6108914091714150400
10500125 07310410500125 105001 Apo-Amiloride 10 15703382298059603968
10500401 07310410500401 105004 Biomed 102 6180971685752078336
10510101 07310710510101 105101 Frumil 155 4478383427699081216
10530101 07310710530101 105301 Amizide 200 18225351909898715136
10530102 07310710530102 105301 Hydrozide 35 6757432438055501824
10530103 07310710530103 105301 Moduretic 157 15523204228104323072
10540101 04040110540101 105401 Amicar 31 3675613495585406976
10550101 25040110550101 105501 Cytadren 116 8178105914746732544
10560101 28430210560101 105601 DBL Aminophylline174 846546987573575680
10560401 28430210560401 105604 Biomed 102 14345485437756243968
10570101 07130110570101 105701 Cordarone-X 155 6028465024933036032
10570102 07130110570102 105701 Aratac 200 18297409503936643072
10570201 07130110570201 105702 Cordarone-X 155 6100522618970963968
10570202 07130110570202 105702 Aratac 200 18369467097974571008
10570301 07130110570301 105703 Cordarone-X 155 4622498615774937088
10590101 22050110590101 105901 Tryptanol 72 1950171888349085696
10590103 22050110590103 105901 Amitrip 200 139177281355513856
10590125 22050110590125 105901 Amirol 127 15246777109276786688
10590126 22050110590126 105901 Arrow Amitriptyline163 5452338524164456448
10590201 22050110590201 105902 Amitrip 200 211234875393441792
10590203 22050110590203 105902 Tryptanol 72 2166344670462869504
10590301 22050110590301 105903 Amitrip 200 283292469431369728
10590303 22050110590303 105903 Tryptanol 72 2310459858538725376
10590401 22050110590401 105904 Tryptanol 72 2382517452576653312
10590501 22050110590501 105905 Tryptanol 72 2454575046614581248
10600101 22070210600101 106001 Neurontin 14 9184096381998989312
10600201 22070210600201 106002 Neurontin 14 9256153976036917248
10602525 22070210602525 106025 Neurontin 14 9328211570074845184
10602625 22070210602625 106026 Neurontin 14 9400269164112773120
10610101 07070310610101 106101 Cozaar 72 7765957279609782272
10610125 07070310610125 106101 Lostaar 200 17248376454991839232
10610201 07070310610201 106102 Cozaar 72 7838014873647710208
10610225 07070310610225 106102 Lostaar 200 16816030890764271616
10612525 07070310612525 106125 Cozaar 72 7693899685571854336
10612526 07070310612526 106125 Lostaar 200 17464549237105623040
10612625 07070310612625 106126 Cozaar 72 4691180709115592704
10612626 07070310612626 106126 Lostaar 200 17032203672878055424
10620125 22070210620125 106201 Nupentin 200 16712142435102228480
10620126 22070210620126 106201 Arrow-Gabapentin191 3530160201858547712
10620225 22070210620225 106202 Nupentin 200 17288884662382362624
10620226 22070210620226 106202 Arrow-Gabapentin191 3746332983972331520
10622526 22070210622526 106225 Nupentin 200 16640084841064300544
10622527 22070210622527 106225 Arrow-Gabapentin191 3313987419744763904
10630101 07320410630101 106301 Lescol 36 6962172498263670784
10630102 07320410630102 106301 Vastin 11 7034230092301598720
10630202 07320410630202 106302 Lescol 36 7106287686339526656
10630203 07320410630203 106302 Vastin 11 7178345280377454592
10640101 31030410640101 106401 Maxitrol 3 6615850524770041856
10640201 31030410640201 106402 Maxitrol 3 6687908118807969792
10650101 28100110650101 106501 Flixotide 143 2773786361902137344
10650201 28100110650201 106502 Flixotide 143 2845843955940065280
10650301 28100110650301 106503 Flixotide 143 2989959144015921152
10650401 28100110650401 106504 Flixotide 143 3062016738053849088
10650501 28100110650501 106505 Flixotide 143 17700954132682113024
10650601 28100110650601 106506 Flixotide 143 2557613579788353536
10650707 28100110650707 106507 Flixotide 143 2629671173826281472
10650801 28100110650801 106508 Flixotide 143 2701728767864209408
10650901 28100110650901 106509 Flixotide 143 17989184508833824768
10651001 28100110651001 106510 Flixotide 143 18061242102871752704
10651101 28100110651101 106511 Flixotide Accuhaler143 2917901549977993216
10651201 28100110651201 106512 Flixotide Accuhaler143 17917126914795896832
10651301 28100110651301 106513 Flixotide Accuhaler143 18133299696909680640
10652525 28100110652525 106525 Flixotide 143 17773011726720040960
10660101 28240210660101 106601 Serevent 143 8632674807994908672
10660201 28240210660201 106602 Serevent 143 8560617213956980736
10660301 28240210660301 106603 Serevent Accuhaler 143 8704732402032836608
10662525 28240210662525 106625 Serevent 143 7716186786266873856
10670101 31030410670101 106701 Blephamide SOP 5 6759965712845897728
10680525 07070510680525 106805 Hyzaar 72 15032623030511599616
10680526 07070510680526 106805 Arrow-Losartan & Hydrochlorothiazide 163 14960565436473671680
10690101 22050110690101 106901 Asendin 14 4937216227039772672
10690201 22050110690201 106902 Asendin 14 5009273821077700608
10690301 22050110690301 106903 Asendin 14 5081331415115628544
10700101 16030710700101 107001 Augmentin 143 6388752995122675712
10700102 16030710700102 107001 Alpha-Amoxyclav 91 8343543931820048384
10700103 16030710700103 107001 Synermox 35 8415601525857976320
10700125 16030710700125 107001 Curam Duo 116 8723910083844505600
10700201 16030710700201 107002 Augmentin 143 6244637807046819840
10700202 16030710700202 107002 Alpha-Amoxyclav 91 8559716713933832192
10700203 16030710700203 107002 Synermox 35 8631774307971760128
10700225 16030710700225 107002 Curam 36 2732411739348926464
10700301 16030710700301 107003 Augmentin 143 6316695401084747776
10700302 16030710700302 107003 Alpha-Amoxyclav 91 8775889496047616000
10700303 16030710700303 107003 Synermox 35 8847947090085543936
10700325 16030710700325 107003 Curam 36 2948584521462710272
10720101 16030710720101 107201 Amoxil 47 8920004684123471872
10720201 16030710720201 107202 Amoxil 47 8992062278161399808
10720202 16030710720202 107202 Moxlin 200 355350063469297664
10720204 16030710720204 107202 Penamox 35 9136177466237255680
10720205 16030710720205 107202 Apo-Amoxi 10 9208235060275183616
10720225 16030710720225 107202 Ospamox 36 12422177917008609280
10720226 16030710720226 107202 Alphamox 200 6753008003265331200
10720301 16030710720301 107203 Amoxil 47 9352350248351039488
10720302 16030710720302 107203 Moxlin 200 427407657507225600
10720304 16030710720304 107203 Penamox 35 9496465436426895360
10720305 16030710720305 107203 Apo-Amoxi 10 9568523030464823296
10720325 16030710720325 107203 Ospamox 116 9640580624502751232
10720326 16030710720326 107203 Alphamox 200 6969180785379115008
10720401 16030710720401 107204 Amoxil Paediatric Drops 143 6172580213008891904
10720425 16030710720425 107204 Ospamox Paediatric Drops 116 11012210385037033472
10720501 16030710720501 107205 Amoxil 47 9784695812578607104
10720502 16030710720502 107205 Moxlin 200 499465251545153536
10720503 16030710720503 107205 Penamox 35 9928811000654462976
10720525 16030710720525 107205 Ospamox 36 1867158760451997696
10720526 16030710720526 107205 Ranbaxy Amoxicillin10 6300891020947095552
10720527 16030710720527 107205 Amoxicillin Actavis 90 7558356290146140160
10720601 16030710720601 107206 Amoxil 47 10072926188730318848
10720602 16030710720602 107206 Moxlin 200 571522845583081472
10720603 16030710720603 107206 Penamox 35 10217041376806174720
10720625 16030710720625 107206 Ospamox 116 10289098970844102656
10720626 16030710720626 107206 Ranbaxy Amoxicillin10 6517063803060879360
10720627 16030710720627 107206 Amoxicillin Actavis 90 7630413884184068096
10720701 16030710720701 107207 Amoxil 47 10361156564882030592
10720801 16030710720801 107208 Ibiamox 35 10433214158919958528
10720901 16030710720901 107209 Ibiamox 35 10505271752957886464
10721001 16030710721001 107210 Ibiamox 35 10577329346995814400
10740101 01310710740101 107401 Fungilin 157 11231844429755056128
10740201 01310710740201 107402 Fungilin 22 3370162568319467520
10760101 31030610760101 107601 Trusopt 72 9137866316097519616
10770101 16200510770101 107701 Invirase 30 7479134278341623808
10770125 16200510770125 107701 Fortovase 30 7551191872379551744
10772525 16200510772525 107725 Invirase 30 14124528680550006784
10780101 22220110780101 107801 Clozaril 116 18379584803973365760
10780125 22220110780125 107801 Clopine 35 4400693035592056832
10780201 22220110780201 107802 Clozaril 116 77237393316380672
10780225 22220110780225 107802 Clopine 35 4472750629629984768
10782525 22220110782525 107825 Clopine 35 8398483229325131776
10782625 22220110782625 107826 Clopine 35 8470540823363059712
10782725 22220110782725 107827 Clopine 35 18069129999289417728
10800101 22280110800101 108001 Amytal 45 8724148677867732992
10810201 16030110810201 108102 Zinnat 143 16331859845961482240
10820101 10110110820101 108201 Advantan 29 8360483007957565440
10820201 10110110820201 108202 Advantan 29 3928381323206459392
10830101 28240210830101 108301 Foradil 116 7500014004153090048
10830201 28240210830201 108302 Oxis Turbuhaler 144 11204806339316416512
10830301 28240210830301 108303 Oxis Turbuhaler 144 17556838944606257152
10840101 01370710840101 108401 PSM 16 5892178359646945280
10840102 01370710840102 108401 Douglas 35 5964235953684873216
10840103 01370710840103 108401 Apo-Ascorbic Acid 10 6036293547722801152
10840125 01370710840125 108401 Alpha Ascorbic Acid91 6252466329836584960
10840126 01370710840126 108401 Vitala-C 185 14514397911573331968
10840127 01370710840127 108401 Cvite 185 16423395288485462016
10840201 01370710840201 108402 Apo-Ascorbic Acid 10 6108351141760729088
10840202 01370710840202 108402 PSM 16 6180408735798657024
10840301 38010110840301 108403 PSM 16 15640286823299678208
10842525 01370710842525 108425 Apo-Ascorbic Acid 10 5820120765609017344
10850101 04040110850101 108501 Trasylol 15 3747671089623334912
10860101 16200510860101 108601 Norvir 2 7623249466417479680
10860201 16200510860201 108602 Norvir 2 7695307060455407616
10862525 16200510862525 108625 Norvir 2 16433781275321434112
10870101 22040410870101 108701 Solprin 162 4210147670498476032
10870102 22040410870102 108701 Aspro Clear 30 2004781332365836288
10870103 22040410870103 108701 Disprin 162 4282205264536403968
10870125 22040410870125 108701 Ethics Aspirin 120 4238566747541602304
10870201 22040410870201 108702 HMG 16 2148896520441692160
10870501 22040410870501 108705 Aspec 300 179 11076173374471274496
10870601 22040410870601 108706 Ecotrin 185 2293011708517548032
10870701 22040410870701 108707 SRA 53 2365069302555475968
10872525 04070110872525 108725 Ethics Aspirin EC 120 8719645078240362496
10872526 04070110872526 108725 Cartia 186 757847185537630208
10880101 25070610880101 108801 Prograf 69 4021495664427925504
10880125 25070610880125 108801 Tacrolimus Sandoz116 12759732384782352384
10880201 25070610880201 108802 Prograf 69 4093553258465853440
10880225 25070610880225 108802 Tacrolimus Sandoz116 12975905166896136192
10882525 25070610882525 108825 Prograf 69 10416095862387113984
10882526 25070610882526 108825 Tacrolimus Sandoz158 12543559602668568576
10920101 22040510920101 109201 Codcomol 104 4236824021611577344
10940101 07160110940101 109401 Anselol 35 3820291633614684160
10940102 07160110940102 109401 Loten 200 643580439621009408
10940103 07160110940103 109401 Apo-Atenolol 10 3964406821690540032
10940104 07160110940104 109401 Tenormin 65 4036464415728467968
10940105 07160110940105 109401 Global Atenolol 128 4108522009766395904
10940125 07160110940125 109401 Mylan Atenolol 200 14590137770052681728
10940126 07160110940126 109401 Noten 200 17432718375481507840
10940127 07160110940127 109401 Atenolol Tablet USP 200 5378000543010521088
10940201 07160110940201 109402 Tenormin 65 4180579603804323840
10940202 07160110940202 109402 Loten 200 715638033658937344
10940203 07160110940203 109402 Apo-Atenolol 10 4324694791880179712
10940204 07160110940204 109402 Anselol 35 4396752385918107648
10940205 07160110940205 109402 Global Atenolol 128 4468809979956035584
10940225 07160110940225 109402 Mylan Atenolol 200 14662195364090609664
10940226 07160110940226 109402 Atenolol Tablet USP 200 5594173325124304896
10940301 07160110940301 109403 Tenormin 65 4540867573993963520
10942525 07160110942525 109425 Atenolol AFT 127 3254020055565860864
10950101 07190110950101 109501 Tenoretic 65 9729014344724774912
10950102 07190110950102 109501 Loten-C 200 787695627696865280
10950201 07190110950201 109502 Tenoret 50 65 9873129532800630784
10950202 07190110950202 109502 Loten-C 200 859753221734793216
10970101 07130110970101 109701 Fawns and McAllan 130 10420937012084211712
10970202 07130110970202 109702 AstraZeneca 144 10492994606122139648
10970301 07130110970301 109703 AstraZeneca 144 10565052200160067584
10970302 07130110970302 109703 Baxter 12 10637109794197995520
10970401 07130110970401 109704 AstraZeneca 144 10709167388235923456
10970501 31031010970501 109705 Atropt 19 4910728991926648832
10970601 31031010970601 109706 Atropt 157 13897975409158389760
10980101 01101010980101 109801 Somac 200 14487375214297481216
10980125 01101010980125 109801 Dr Reddy's Pantoprazole 178 11140050601998548992
10980126 01101010980126 109801 Pantoprazole Actavis 40 191 14099268500413480960
10980201 01101010980201 109802 Somac 200 14559432808335409152
10980225 01101010980225 109802 Dr Reddy's Pantoprazole 178 13357525861687885824
10980226 01101010980226 109802 Pantoprazole Actavis 20 191 14171326094451408896
10982525 01101010982525 109825 Pantocid IV 179 7791917848653201408
10990101 19070110990101 109901 Ridaura 185 613731997461774336
10990125 19070110990125 109901 Ridaura s29 185 17570677397953445888
11000101 25070111000101 110001 Imuran 157 13524716500295876608
11000102 25070111000102 110001 Azamun 35 16218701407765659648
11000103 25070111000103 110001 Thioprine 200 1003868409810649088
11000125 25070111000125 110001 Imuprine 200 9614762991970942976
11000201 25070111000201 110002 Imuran 157 9331308894330290176
11010101 10170111010101 110101 Derbac-M 168 16385352186164412416
11010125 10170111010125 110101 A-Lices 127 18333731870560223232
11012525 10170111012525 110125 A-Lices 127 3809596684011307008
11012601 10170111012601 110126 Prioderm 19 4169884654200946688
11020101 16200511020101 110201 Crixivan 72 7767364654493335552
11020201 16200511020201 110202 Crixivan 72 7839422248531263488
11030101 31030411030101 110301 Lomide 3 6832023306883825664
11050101 13010511050101 110501 Ortho 69 16629604296228339712
11070101 22160111070101 110701 Navoban 116 13623502122493411328
11080101 28100111080101 110801 Becotide Junior 76 3969191896294621184
11080102 28100111080102 110801 Atomide Junior 35 4041249490332549120
11080125 28100111080125 110801 Beclazone 50 132 5770631747242819584
11080201 28100111080201 110802 Becotide 100 76 4113307084370477056
11080202 28100111080202 110802 Atomide 35 4185364678408404992
11080203 28100111080203 110802 Respocort 100 1 6448723657836462080
11080225 28100111080225 110802 Beclazone 100 132 5842689341280747520
11080301 28100111080301 110803 Becloforte 76 4329479866484260864
11080302 28100111080302 110803 Atomide Forte 35 4401537460522188800
11080303 28100111080303 110803 Respocort Forte 1 6664896439950245888
11080325 28100111080325 110803 Respocort 250 1 6736954033988173824
11080326 28100111080326 110803 Beclazone 250 132 5554458965129035776
11080401 28100111080401 110804 Respocort Junior Autohaler 1 6376666063798534144
11080501 28100111080501 110805 Respocort 100 Autohaler 1 6520781251874390016
11080601 28100111080601 110806 Respocort Forte Autohaler 1 6809011628026101760
11080701 28100111080701 110807 Becodisk Junior 104 4833883024749756416
11080801 28100111080801 110808 Becodisk 200 76 4905940618787684352
11080901 28100111080901 110809 Becodisk Forte 76 4977998212825612288
11081102 28510211081102 110811 Atomase 35 2312148708398989312
11081103 28510211081103 110811 Aldecin 40 2384206302436917248
11081104 28510211081104 110811 Beconase 104 2456263896474845184
11081201 28510211081201 110812 Beconase 100 104 2528321490512773120
11081301 28510211081301 110813 Alanase 200 1075926003848577024
11081302 28510211081302 110813 Atomase Aqueous 35 2672436678588628992
11081303 28510211081303 110813 Beconase Aqueous 104 2744494272626556928
11081304 28510211081304 110813 Aldecin Aqueous 40 2816551866664484864
11081401 28510211081401 110814 Alanase 200 1147983597886504960
11081402 28510211081402 110814 Atomase Forte Aqueous 35 2960667054740340736
11081403 28510211081403 110814 Beconase 100 Aqueous 104 3032724648778268672
11081501 28100111081501 110815 Respocort 100-S 1 6592838845912317952
11081601 28100111081601 110816 Respocort Forte-S 1 6881069222064029696
11082525 28100111082525 110825 Beclazone 50 132 15422707765813968896
11082625 28100111082625 110826 Beclazone 100 132 16647686864458743808
11082725 28100111082725 110827 Beclazone 250 132 17957389931093426176
11090101 16200311090101 110901 Zerit 22 6037982397583065088
11090201 16200311090201 110902 Zerit 22 6110039991620993024
11090301 16200311090301 110903 Zerit 22 6182097585658920960
11090401 16200311090401 110904 Zerit 22 6254155179696848896
11090501 16200311090501 110905 Zerit 22 6326212773734776832
11100101 01150911100101 111001 B-D Micro-Fine 119 15547614485752578048
11100125 01150911100125 111001 ABM 167 1922310263701241856
11100126 01150911100126 111001 SC Profi-Fine 19 5638639774374821888
11100201 01150911100201 111002 B-D Micro-Fine 119 15619672079790505984
11100226 01150911100226 111002 ABM 167 625273571018539008
11100227 01150911100227 111002 SC Profi-Fine 19 6070985338602389504
11102525 01150911102525 111025 B-D Micro-Fine 119 15475556891714650112
11102526 01150911102526 111025 SC Profi-Fine 19 5854812556488605696
11102625 01150911102625 111026 NovoFine 8 120870412753043456
11102626 01150911102626 111026 ABM 167 2642886204080521216
11102627 01150911102627 111026 Fine Ject 19 4002709408755744768
11102725 01150911102725 111027 B-D Micro-Fine 39 13380337429429354496
11120101 28010111120101 111201 Allpyral 39 12758264536759271424
11160101 07311011160101 111601 Neo-Naclex 143 6676983371274387456
11160125 07311011160125 111601 Arrow-Bendrofluazide 163 5427539039399968768
11160201 07311011160201 111602 Neo-Naclex 143 6749040965312315392
11160225 07311011160225 111602 Arrow-Bendrofluazide 163 5643711821513752576
11200101 16030711200101 112001 Penadur LA 14 5153389009153556480
11200201 16030711200201 112002 Penadur LA 14 5225446603191484416
11200202 16030711200202 112002 Bicillin 157 10654825125544722432
11200225 16030711200225 112002 Bicillin LA 14 17529850332190867456
11202525 16030711202525 112025 Pan Benzathine Benzylpenicillin 177 6893156153388171264
11220101 01100211220101 112201 Helidac 14 14663289378160246784
11240101 16030711240101 112401 Diclocil 22 10865559723147526144
11240201 16030711240201 112402 Diclocil 22 10937617317185454080
11240301 16030711240301 112403 Diclocil 22 11009674911223382016
11240401 16030711240401 112404 Diclocil 22 11081732505261309952
11240501 16030711240501 112405 Diclocil 22 11153790099299237888
11240601 16030711240601 112406 Diclocil 22 11225847693337165824
11250101 22050711250101 112501 Serzone 22 15405751097490407424
11250201 22050711250201 112502 Serzone 22 15477808691528335360
11260101 01220111260101 112601 Actigall 116 12033448879543287808
11262525 01220111262525 112625 Ursosan 167 8291564519616937984
11270101 07070211270101 112701 Inhibace Plus 30 7189496527306358784
11270125 07070211270125 112701 Apo-Cilazapril/Hydrochlorothiazide 10 4199509895499743232
11280101 10010111280101 112801 Benoxyl 10 30 5408108469913911296
11280201 10010111280201 112802 Benoxyl 5 30 5480166063951839232
11280301 10010111280301 112803 Panoxyl 30 5552223657989767168
11280401 10010111280401 112804 Panoxyl 30 5624281252027695104
11280503 10010111280503 112805 Panoxyl 30 5696338846065623040
11280505 10010111280505 112805 Benzac W5 200 5768396440103550976
11300101 22010411300101 113001 Cogentin 72 10569809786973454336
11300125 22010411300125 113001 Benztrop 127 10497752192935526400
11300201 22010411300201 113002 Cogentin 218 17952068294814990336
11320101 01310111320101 113201 Difflam 35 5271016962116288512
11330101 22070211330101 113301 Topamax 69 16367036521468919808
11330125 22070211330125 113301 Arrow-Topiramate163 10434133350640779264
11330201 22070211330201 113302 Topamax 69 16439094115506847744
11330225 22070211330225 113302 Arrow-Topiramate163 10650306132754563072
11330301 22070211330301 113303 Topamax 69 16511151709544775680
11330325 22070211330325 113303 Arrow-Topiramate163 10866478914868346880
11330401 22070211330401 113304 Topamax 69 16583209303582703616
11330425 22070211330425 113304 Arrow-Topiramate163 11082651696982130688
11332525 22070211332525 113325 Topamax 69 16655266897620631552
11332625 22070211332625 113326 Topamax 69 16727324491658559488
11360101 16030711360101 113601 Sandoz 116 6088717162623533056
11360102 16030711360102 113601 Benpen 29 11369962881413021696
11370101 07320411370101 113701 Lipitor 14 7250402874415382528
11370125 07320411370125 113701 Lorstat 10 200 7322460468453310464
11370126 07320411370126 113701 Dr Reddy's Atorvastatin 178 7394518062491238400
11370127 07320411370127 113701 Zarator 14 7466575656529166336
11370201 07320411370201 113702 Lipitor 14 7538633250567094272
11370225 07320411370225 113702 Lorstat 20 200 7610690844605022208
11370226 07320411370226 113702 Dr Reddy's Atorvastatin 178 7682748438642950144
11370227 07320411370227 113702 Zarator 14 7754806032680878080
11370301 07320411370301 113703 Lipitor 14 7826863626718806016
11370325 07320411370325 113703 Lorstat 40 200 7898921220756733952
11370326 07320411370326 113703 Dr Reddy's Atorvastatin 178 7970978814794661888
11370327 07320411370327 113703 Zarator 14 8043036408832589824
11372525 07320411372525 113725 Lipitor 14 8115094002870517760
11372526 07320411372526 113725 Lorstat 80 200 8187151596908445696
11372527 07320411372527 113725 Dr Reddy's Atorvastatin 178 8259209190946373632
11372528 07320411372528 113725 Zarator 14 8331266784984301568
11380101 22010111380101 113801 Tasmar 211 10713924975049310208
11400101 22220111400101 114001 Zyprexa 45 149294987354308608
11400125 22220111400125 114001 Dr Reddy's Olanzapine 178 13991989150891376640
11400126 22220111400126 114001 Olanzine 200 14208161933005160448
11400127 22220111400127 114001 Zypine 200 11384437951992692736
11400201 22220111400201 114002 Zyprexa 45 221352581392236544
11400225 22220111400225 114002 Dr Reddy's Olanzapine 178 14424334715118944256
11400226 22220111400226 114002 Olanzine 200 14640507497232728064
11400227 22220111400227 114002 Zypine 200 11816783516220260352
11400301 22220111400301 114003 Zyprexa 45 293410175430164480
11400325 22220111400325 114003 Dr Reddy's Olanzapine 178 13559643586663809024
11400326 22220111400326 114003 Olanzine 200 13775816368777592832
11400327 22220111400327 114003 Zypine 200 11168265169878908928
11401525 22220411401525 114015 Zyprexa Relprevv 45 2084499223914479616
11401625 22220411401625 114016 Zyprexa Relprevv 45 2012441629876551680
11401725 22220411401725 114017 Zyprexa Relprevv 45 1940384035838623744
11402725 22220111402725 114027 Dr Reddy's Olanzapine 178 2859400934310543360
11402726 22220111402726 114027 Olanzine-D 200 2931458528348471296
11402727 22220111402727 114027 Zypine ODT 200 11600610734106476544
11402728 22220111402728 114027 Zyprexa Zydis 45 1361966152837758976
11402825 22220111402825 114028 Dr Reddy's Olanzapine 178 3003516122386399232
11402826 22220111402826 114028 Olanzine-D 200 3075573716424327168
11402827 22220111402827 114028 Zypine ODT 200 12032956298334044160
11402828 22220111402828 114028 Zyprexa Zydis 45 929620588610191360
11410101 31020111410101 114101 Ultrazon N 35 6851777132788449280
11410102 31020111410102 114101 Betnesol-N 104 6923834726826377216
11431001 10220111431001 114310 Diprosone 40 12684220125209952256
11431101 10220111431101 114311 Diprolene 40 12756277719247880192
11431201 10110111431201 114312 Diprosone 72 17828802046225022976
11431301 10110111431301 114313 Diprosone 72 17900859640262950912
11431401 10110111431401 114314 Diprolene 72 17972917234300878848
11431425 10110111431425 114314 Diprosone OV 72 18044974828338806784
11431501 10110111431501 114315 Diprolene 40 8720770978147205120
11431525 10110111431525 114315 Diprosone OV 40 8072252631805853696
11440101 14070111440101 114401 Betnesol 104 11388027857457381376
11440201 14070111440201 114402 Betnesol 104 11460085451495309312
11440701 31020111440701 114407 Ultrazon 35 6995892320864305152
11440702 31020111440702 114407 Betnesol 104 7067949914902233088
11450101 10110411450101 114501 Lotricomb 40 15945103332356390912
11460201 10110411460201 114602 Betnovate-C 143 5415132150192144384
11460301 10110411460301 114603 Betnovate-C 143 5487189744230072320
11472501 10110411472501 114725 Garamycin V 40 16161276114470174720
11480101 10110411480101 114801 Fucicort 29 16233333708508102656
11490101 31030511490101 114901 Betoptic S 19 3496035758978891776
11490201 31030511490201 114902 Betoptic 19 3568093353016819712
11490225 31030511490225 114902 Apo-Betaxolol 10 7768772029376888832
11500101 10110411500101 115001 Diprosalic 40 16305391302546030592
11500201 10110411500201 115002 Diprosalic 40 16377448896583958528
11510101 07320111510101 115101 Bezalip 20 5448963023467184128
11510102 07320111510102 115101 Fibalip 200 5521020617505112064
11510201 07320111510201 115102 Bezalip Retard 191 5593078211543040000
11560101 14110411560101 115601 Progynova 15 4432784481471954944
11560201 14110411560201 115602 Progynova 15 4504842075509882880
11580101 25040411580101 115801 Arimidex 144 3447927727217180672
11580125 25040411580125 115801 DP-Anastrozole 35 3303812539141324800
11580126 25040411580126 115801 Aremed 127 11580303853853081600
11590101 01101311590101 115901 Roter 6 7116875983315009536
11590201 38010111590201 115902 PSM 16 15712344417337606144
11660101 22250111660101 116601 Lexotan 30 5265384164047192064
11660201 22250111660201 116602 Lexotan 30 5337441758085120000
11670101 22010111670101 116701 Parlodel 116 10930097757163094016
11670102 22010111670102 116701 Apo-Bromocriptine 91 10858040163125166080
11670103 22010111670103 116701 Alpha-Bromocriptine10 10785982569087238144
11670301 22010111670301 116703 Apo-Bromcriptine 10 11074212945238949888
11670302 22010111670302 116703 Alpha-Bromocriptine10 11002155351201021952
11670401 22010111670401 116704 Parlodel 116 11146270539276877824
11672525 22010111672525 116725 Apo-Bromocriptine 10 11218328133314805760
11680101 28100111680101 116801 Pulmicort 144 10196000022785425408
11680201 28100111680201 116802 Pulmicort Turbuhaler 144 15904577532779823104
11680301 28100111680301 116803 Pulmicort Turbuhaler 144 15976635126817751040
11680325 28100111680325 116803 Budenocort 127 9923542140934160384
11680401 28100111680401 116804 Pulmicort Turbuhaler 144 16048692720855678976
11680425 28100111680425 116804 Budenocort 127 7617699131720466432
11680501 28100111680501 116805 Pulmicort 144 10268057616823353344
11680701 28510211680701 116807 Rhinocort Aqueous 11 3104782242816196608
11680702 28510211680702 116807 Eltair 35 3176839836854124544
11680703 28510211680703 116807 Butacort Aqueous 200 1436213974038216704
11680801 28510211680801 116808 Eltair Forte 35 3320955024929980416
11680802 28510211680802 116808 Rhinocort Aqueous 11 3393012618967908352
11680803 28510211680803 116808 Butacort Aqueous 200 1508271568076144640
11680901 01040411680901 116809 Entocort CIR 144 5919535308457639936
11700101 16200111700101 117001 Viramune 17 7065416640111837184
11700125 16200111700125 117001 Nevirapine Alphapharm 200 13581053277079863296
11702525 16200111702525 117025 Viramune Suspension 17 6993359046073909248
11710101 07310111710101 117101 Burinex 29 1154442129188061184
11710201 07310111710201 117102 Burinex 29 1226499723225989120
11720101 16200511720101 117201 Viracept 30 7911479842569191424
11720201 16200511720201 117202 Viracept 30 7983537436607119360
11730101 25010111730101 117301 Myleran 157 4729482196669169664
11740101 28010111740101 117401 Albay 39 12830322130797199360
11740201 28010111740201 117402 Albay 39 12902379724835127296
11770101 01100211770101 117701 Helicosec 144 10340115210861281280
11780101 16030411780101 117801 Zithromax 14 5198959368078360576
11780125 16030411780125 117801 Arrow-Azithromycin163 6741158566452789248
11780126 16030411780126 117801 Apo-Azithromycin 10 2246620014406795264
11782525 16030411782525 117825 Zithromax 14 17642734991991373824
11782625 16030411782625 117826 Apo-Azithromycin 10 2030447232293011456
11790101 10080111790101 117901 PSM 16 17871803945987342336
11790125 10080111790125 117901 ABM 167 4219142775125311488
11790126 10080111790126 117901 healthE 202 2314137724933636096
11790127 10080111790127 117901 Home Essential 179 8059356459923668992
11790128 10080111790128 117901 Pharmacy Health 179 18350929331930267648
11790201 10080111790201 117902 PSM 179 1862684847638577152
11790225 10080111790225 117902 ABM 167 4291200369163239424
11790301 10080111790301 117903 PSM 16 18015919134063198208
11790401 38010111790401 117904 PSM 16 15784402011375534080
11810101 25040411810101 118101 Femara 116 3519985321255108608
11810125 25040411810125 118101 Letara 35 3375870133179252736
11810126 25040411810126 118101 Letraccord 163 514144831287590912
11830101 22220111830101 118301 Seroquel 144 3073544017959452672
11830125 22220111830125 118301 Quetapel 200 17000372811253940224
11830126 22220111830126 118301 Dr Reddy's Quetiapine 178 15955831267308601344
11830201 22220111830201 118302 Seroquel 144 3145601611997380608
11830225 22220111830225 118302 Quetapel 200 17793287820647858176
11830226 22220111830226 118302 Dr Reddy's Quetiapine 178 16027888861346529280
11830301 22220111830301 118303 Seroquel 144 3289716800073236480
11830325 22220111830325 118303 Quetapel 200 17072430405291868160
11830326 22220111830326 118303 Dr Reddy's Quetiapine 178 16099946455384457216
11830401 22220111830401 118304 Seroquel 144 3217659206035308544
11832525 22220111832525 118325 Seroquel 144 725755739657732096
11832526 22220111832526 118325 Quetapel 200 7489051873224163328
11832527 22220111832527 118325 Dr Reddy's Quetiapine 178 16172004049422385152
11850101 38010111850101 118501 Isopropyl alcohol 16 15856459605413462016
11870101 01371011870101 118701 HMG 16 6612754300026224640
11870125 01371011870125 118701 Cal-d-Forte 179 712263632473292800
11880201 14040411880201 118802 Miacalcic 116 1219808095459344384
11880301 19080611880301 118803 Calcitare 155 10916294488187994112
11880401 19080611880401 118804 Calsynar 155 10988352082225922048
11890101 01371011890101 118901 Rocaltrol 30 6684811894064152576
11890125 01371011890125 118901 Calcitriol-AFT 127 5364142298454032384
11890126 01371011890126 118901 Airflow 132 6452386131068583936
11890201 01371011890201 118902 Rocaltrol 30 6756869488102080512
11890225 01371011890225 118902 Calcitriol-AFT 127 5580315080567816192
11890226 01371011890226 118902 Airflow 132 6668558913182367744
11890301 01371011890301 118903 Rocaltrol solution 30 6828927082140008448
11910201 01381011910201 119102 Calforte 200 7269793861482840064
11910202 01381011910202 119102 Oscal-500 105 7341851455520768000
11910203 01381011910203 119102 Cal-Sup 1 7413909049558695936
11910204 01381011910204 119102 Oscal Chewable 105 7485966643596623872
11910205 01381011910205 119102 Osteo~500 59 7558024237634551808
11910225 01381011910225 119102 Calci-Tab 500 127 6981563485331128320
11910226 01381011910226 119102 Arrow-Calcium 163 6232572865955233792
11910301 01381011910301 119103 Caltrate 31 7630081831672479744
11910302 01381011910302 119103 Osteo~600 59 7702139425710407680
11910325 01381011910325 119103 Calci-Tab 600 127 8638888148203470848
11910401 38010111910401 119104 PSM 16 15928517199451389952
11912525 01381011912525 119125 Calci-Tab Effervescent 127 7053621079369056256
11912601 01381011912601 119126 Calcium-Sandoz 1000 116 7918312207824191488
11912625 01381011912625 119126 Calsource 158 7197736267444912128
11912725 01010411912725 119127 Roxane 220 11342765361788354560
11920101 01130911920101 119201 Humalog 45 2287388806053101568
11920201 01130911920201 119202 Humalog 45 2359446400091029504
11930101 22050711930101 119301 Cipramil 134 15549866285566263296
11930125 22050711930125 119301 Celapram 200 16279796870874660864
11930126 22050711930126 119301 Arrow-Citalopram 163 6669100972414861312
11930127 22050711930127 119301 Citalopram - Rex 166 6597043378376933376
11940101 28040111940101 119401 Telfast 155 8978330477442105344
11940201 28040111940201 119402 Telfast 155 9122445665517961216
11940301 28040111940301 119403 Telfast 155 9050388071480033280
11950101 22160111950101 119501 Serc 135 13767617310569267200
11950125 22160111950125 119501 Vergo 16 200 1652386756152000512
11950201 22160111950201 119502 Serc 33 13695559716531339264
11970101 01381011970101 119701 Mayne 12 7774197019748335616
11980101 25010411980101 119801 Leucovorin 31 5822654040399413248
11980102 25010411980102 119801 DBL Leucovorin Calcium 174 17275396953244434432
11980103 25010411980103 119801 Rescuvolin 144 8555558360957583360
11980104 25010411980104 119801 Refolinon 14 14807404566236102656
11980201 25010411980201 119802 Hospira 174 8213903814323863552
11980301 25010411980301 119803 Mayne 12 11034238000987897856
11980401 25010411980401 119804 Leucovorin 31 6254999604626980864
11980402 25010411980402 119804 Mayne 12 6327057198664908800
11980425 25010411980425 119804 Calcium Folinate Ebewe 36 3107070326513598464
11982525 25010411982525 119825 Mayne 174 11106295595025825792
11982526 25010411982526 119825 Calcium Folinate Ebewe 36 3179127920551526400
11982625 25010411982625 119826 Baxter 12 9281418554219954176
11982626 25010411982626 119826 Biomed 102 14393064604424994816
11982725 25010411982725 119827 Calcium Folinate Ebewe 36 3323243108627382272
11982825 25010411982825 119828 Calcium Folinate Ebewe 36 3251185514589454336
11990101 01381011990101 119901 Hospira 174 7060982309717016576
12050101 04100412050101 120501 Calcium Resonium155 15416517515349590016
12090101 16160112090101 120901 Capastat 45 17153198330445037568
12160101 31030912160101 121601 Isopto Carbachol 3 9858442256476798976
12160201 31030912160201 121602 Isopto Carbachol 3 9930499850514726912
12170301 22070212170301 121703 Tegretol 158 2544652536720130048
12170401 22070212170401 121704 Teril 200 2012674726341640192
12170402 22070212170402 121704 Tegretol 116 17423363730552389632
12170501 22070212170501 121705 Tegretol CR 116 17495421324590317568
12170601 22070212170601 121706 Teril 200 2084732320379568128
12170602 22070212170602 121706 Tegretol 116 17639536512666173440
12170701 22070212170701 121707 Tegretol CR 116 17711594106704101376
12210101 14140112210101 122101 Neo-Mercazole 127 18411676249853263872
12210125 14140112210125 122101 AFT 127 4415682677613527040
12230101 16200312230101 122301 Combivir 143 11442920975474098176
12230125 16200312230125 122301 Alphapharm 200 16646034298482196480
12240101 10220112240101 122401 Seborrol 35 12828335313285808128
12280101 16030112280101 122801 Ceclor 45 8938632610121252864
12280125 16030112280125 122801 Clorotir 116 10740072461069451264
12280126 16030112280126 122801 Ranbaxy-Cefaclor 35 10668014867031523328
12280127 16030112280127 122801 Cefaclor Sandoz 36 15785262928980082688
12280201 16030112280201 122802 Ceclor 45 9010690204159180800
12280225 16030112280225 122802 Clorotir 116 11100360431259090944
12280226 16030112280226 122802 Ranbaxy-Cefaclor 35 11172418025297018880
12300101 16030112300101 123001 Mandol 45 9082747798197108736
12300202 16030112300202 123002 Mandol 45 9154805392235036672
12300203 16030112300203 123002 Baxter 12 9226862986272964608
12310101 16030112310101 123101 Mefoxin 72 9298920580310892544
12310125 16030112310125 123101 Mayne 153 10884187649145307136
12320101 16030112320101 123201 Rocephin IM 30 9370978174348820480
12320102 16030112320102 123201 Rocephin IV 30 9443035768386748416
12320201 16030112320201 123202 Rocephin 30 9515093362424676352
12320225 16030112320225 123202 Novartis 116 11460648401448730624
12320226 16030112320226 123202 AFT 127 8722459828007469056
12320227 16030112320227 123202 Veracol 120 12405869960545435648
12320228 16030112320228 123202 Ceftriaxone-AFT 127 6361237716637581312
12320301 16030112320301 123203 Rocephin IM 30 9587150956462604288
12320325 16030112320325 123203 Novartis 116 11532705995486658560
12320326 16030112320326 123203 Rocephin 30 10812130055107379200
12320327 16030112320327 123203 AFT 127 8794517422045396992
12320328 16030112320328 123203 Aspen Ceftriaxone157 16459952950597386240
12320329 16030112320329 123203 Ceftriaxone-AFT 127 3359875537529995264
12330101 16030112330101 123301 Zinacef 104 9659208550500532224
12330125 16030112330125 123301 Mayne 12 11244475619334946816
12330201 16030112330201 123302 Zinacef 143 16403917439999410176
12330225 16030112330225 123302 Mayne 153 10956245243183235072
12330226 16030112330226 123302 m-Cefuroxime 120 5692986435112534016
12330301 16030112330301 123303 Zinacef 143 16475975034037338112
12330325 16030112330325 123303 Mayne 12 11316533213372874752
12330326 16030112330326 123303 Mylan 200 2913421040094806016
12340101 16030112340101 123401 Keflex 45 9875381332614316032
12340201 16030112340201 123402 Keflex 45 9947438926652243968
12340301 16030112340301 123403 Keflex 45 10019496520690171904
12340325 16030112340325 123403 Cefalexin Sandoz 36 7100904477409935360
12340401 16030112340401 123404 Keflex 45 10091554114728099840
12340425 16030112340425 123404 Cefalexin Sandoz 36 7317077259523719168
12342525 16030112342525 123425 Cephalexin ABM 167 7578292634980974592
12350101 16030112350101 123501 Keflin 45 10163611708766027776
12360101 16030112360101 123601 Kefzol 45 10235669302803955712
12360125 16030112360125 123601 Baxter 12 11028302837221163008
12360126 16030112360126 123601 Novartis 116 11604763589524586496
12360127 16030112360127 123601 m-Cefazolin 120 8650402233969541120
12360128 16030112360128 123601 Hospira 174 17528132895028281344
12360129 16030112360129 123601 AFT 127 2954516386694561792
12360201 16030112360201 123602 Kefzol 45 10307726896841883648
12360225 16030112360225 123602 Hospira 174 18248708835407560704
12360226 16030112360226 123602 Novartis 116 11676821183562514432
12360227 16030112360227 123602 m-Cefazolin 120 11748878777600442368
12360228 16030112360228 123602 AFT 127 3170689168808345600
12370101 16030112370101 123701 Velosef 22 10379784490879811584
12370201 16030112370201 123702 Velosef 22 10451842084917739520
12370301 16030112370301 123703 Velosef 22 10523899678955667456
12370401 16030112370401 123704 Velosef 22 10595957272993595392
12380101 01280212380101 123801 Cerezyme 138 4539741674087120896
12382525 01280212382525 123825 Cerezyme 138 9418576032715243520
12390101 38010112390101 123901 David Craig 120 16144689981565173760
12390125 38010112390125 123901 Midwest 152 1198147716392157184
12400101 38010112400101 124001 PSM 179 1216666790738788352
12400125 38010112400125 124001 ABM 167 15424114041185894400
12400126 38010112400126 124001 Midwest 152 4989006523242905600
12440101 10130112440101 124401 Hibitane 65 13332456996574593024
12440201 10130112440201 124402 Hibiclens 144 11276863933354344448
12440225 10130112440225 124402 Orion 141 13476572184650448896
12440301 10130112440301 124403 Hibitane Concentrate 65 13548629778688376832
12440401 10130112440401 124404 Hibitane 65 13620687372726304768
12440402 10130112440402 124404 Multichem 120 13692744966764232704
12440601 10130112440601 124406 Microshield Handrub 133 13764802560802160640
12442525 10130112442525 124425 Orion 78 13260399402536665088
12442526 10130112442526 124425 healthE 202 10466784447939215360
12442601 01310112442601 124426 Rivacol 141 6044533287861354496
12442602 01310112442602 124426 Delta West 14 14735346972198174720
12442625 01310112442625 124426 healthE 202 17654840615013187584
12470101 01131112470101 124701 Glucobay 15 11103178479561080832
12470125 01131112470125 124701 Accarb 200 7062092816461070336
12470201 01131112470201 124702 Glucobay 15 11656504407704469504
12470225 01131112470225 124702 Accarb 200 7278265598574854144
12480101 22260112480101 124801 Avonex 180 11009733185339654144
12482525 22260112482525 124825 Avonex 180 11081790779377582080
12482625 22260112482625 124826 Avonex Pen 180 2282648811425759232
12500101 31030812500101 125001 Xalatan 14 12162086242434940928
12500125 31030812500125 125001 Hysite 14 777003976628371456
12510101 01100212510101 125101 Klacid Hp7 2 3802226657570324480
12510102 01100212510102 125101 Losec Hp7 OAC 144 2641198453731885056
12540101 07070312540101 125401 Atacand 144 16043629469809770496
12540125 07070312540125 125401 Candestar 200 7980248797328441344
12540201 07070312540201 125402 Atacand 144 16187744657885626368
12540225 07070312540225 125402 Candestar 200 8196421579442225152
12540301 07070312540301 125403 Atacand 144 16259802251923554304
12540325 07070312540325 125403 Candestar 200 8412594361556008960
12542525 07070312542525 125425 Atacand 144 16115687063847698432
12542526 07070312542526 125425 Candestar 200 8628767143669792768
12550101 25010112550101 125501 Leukeran 157 4513309414555385856
12550125 25010112550125 125501 Leukeran FC 157 4585367008593313792
12550201 25010112550201 125502 Leukeran 157 4657424602631241728
12570101 31030112570101 125701 Chloroptic-P 5 6924116201803087872
12580101 31030112580101 125801 Chloromyxin 58 6996173795841015808
12580201 31030112580201 125802 Chloromyxin 58 7068231389878943744
12580301 31010112580301 125803 Chloromyxin 58 11317112656000712704
12590102 31030112590102 125901 Chlorsig 177 18267561061777408000
12590103 31030112590103 125901 Chloromycetin 14 3494643777258127360
12590104 31030112590104 125901 Chloroptic 5 7284404171992727552
12590105 31030112590105 125901 Isopto-Fenicol 3 7356461766030655488
12590125 31030112590125 125901 Chlorafast 163 11796476635966865408
12590202 31010112590202 125902 Chloromycetin 14 3350528589182271488
12590402 31030112590402 125904 Chloromycetin 14 3422586183220199424
12590403 31030112590403 125904 Chlorsig 157 13753860221082533888
12590404 31030112590404 125904 Chloroptic 5 7572634548144439296
12590601 16031312590601 125906 Chloromycetin 14 3134355807068487680
12590701 16031312590701 125907 Chloromycetin 14 3206413401106415616
12610101 16031312610101 126101 Chloromycetin 14 3278470995144343552
12730101 22280112730101 127301 Hemineurin 11 8796206271905660928
12730201 22280112730201 127302 Hemineurin 11 8868263865943588864
12730301 22280112730301 127303 Hemineurin 11 8940321459981516800
12750101 01010212750101 127501 Titralac 35 7641893885089677312
12760101 01010212760101 127601 Titralac-Sil 1 7097242004177813504
12800101 16100112800101 128001 Nivaquine 155 11060409676263849984
12800201 16100112800201 128002 Avloclor 65 14487067351041703936
12800301 16100112800301 128003 Nivaquine 155 11132467270301777920
12820101 07311012820101 128201 Chlotride 72 7261835596320997376
12820201 07311012820201 128202 Biomed 102 7333893190358925312
12830101 22220112830101 128301 Largactil 155 8847436916690255872
12830201 22220112830201 128302 Largactil 155 8919494510728183808
12830301 22220112830301 128303 Largactil 155 11204524864339705856
12830401 22220112830401 128304 Largactil 155 8991552104766111744
12830501 22220112830501 128305 Largactil Forte 155 11276582458377633792
12830601 22220112830601 128306 Largactil 155 8775379322652327936
12880101 10040112880101 128801 Aureomycin 31 11170447700460044288
12900101 07311012900101 129001 Hygroton 127 10764326588066562048
12900125 07311012900125 129001 Igroton 127 7139497335544872960
12910101 07320312910101 129101 Questran Light 145 6745999716149886976
12910125 07320312910125 129101 Questran-Lite 22 6818057310187814912
12920101 28450212920101 129201 Brondecon 133 3062298213030559744
12970101 01100312970101 129701 Duomet 200 2228847508455424000
12970102 01100312970102 129701 Tagamet 47 4162514627759964160
12970103 01100312970103 129701 Cytine 35 4234572221797892096
12970104 01100312970104 129701 Apo-Cimetidine 10 4306629815835820032
12970201 01100312970201 129702 Duomet 200 2300905102493351936
12970202 01100312970202 129702 Tagamet 47 4450745003911675904
12970203 01100312970203 129702 Cytine 35 4522802597949603840
12970204 01100312970204 129702 Apo-Cimetidine 10 4594860191987531776
12970301 01100312970301 129703 Tagamet 47 4666917786025459712
12970302 01100312970302 129703 Cytine 35 4738975380063387648
12970304 01100312970304 129703 Apo-Cimetidine 10 4811032974101315584
12970401 01100312970401 129704 Tagamet 47 4883090568139243520
13030101 16031313030101 130301 Dalacin C 14 9423897668993679360
13030125 16031313030125 130301 Clindamycin ABM167 9156255648072073216
13030201 16031313030201 130302 Dalacin C 14 14879462160274030592
13030301 16031313030301 130303 Dalacin C 14 14951519754311958528
13060101 10010113060101 130601 Dalacin-T 14 15023577348349886464
13060301 10010113060301 130603 Dalacin T 14 15095634942387814400
13080101 22070213080101 130801 Frisium 155 9495955263031607296
13090201 10220113090201 130902 Dermovate 143 2413498391712497664
13090202 10220113090202 130902 Dermol 200 2372962696531279872
13090301 10110113090301 130903 Dermol 200 2445020290569207808
13090302 10110113090302 130903 Dermovate 143 2269383203636641792
13090401 10110113090401 130904 Dermol 200 2517077884607135744
13090402 10110113090402 130904 Dermovate 143 2341440797674569728
13100201 10110113100201 131002 Eumovate 143 16548032628075266048
13100301 10110113100301 131003 Eumovate 143 2485555985750425600
13120101 16160113120101 131201 Lamprene 116 8250163508784660480
13130101 07320213130101 131301 Atromid-S 65 5953366181732679680
13140101 14210113140101 131401 Clomid 105 9010408729182470144
13140102 14210113140102 131401 Phenate 200 2589135478645063680
13140103 14210113140103 131401 Serophene 85 9154523917258326016
13150101 22050113150101 131501 Anafranil 116 8322221102822588416
13150125 22050113150125 131501 Clopress 200 8858146159944794112
13150126 22050113150126 131501 Apo-Clomipramine 10 5083573319324663808
13150201 22050113150201 131502 Anafranil 116 8394278696860516352
13150202 22050113150202 131502 Clopress 200 2661193072682991616
13150225 22050113150225 131502 Apo-Clomipramine 10 5299746101438447616
13160101 22250113160101 131601 Rivotril 30 4948498315852382208
13160125 22250113160125 131601 Paxam 200 4876440721814454272
13160201 22250113160201 131602 Rivotril 30 5092613503928238080
13160225 22250113160225 131602 Paxam 200 5020555909890310144
13160301 22070213160301 131603 Rivotril 30 17999824482855813120
13160401 22070113160401 131604 Rivotril 30 8795643321952239616
13170201 07280113170201 131702 Catapres-TTS-1 17 14989218709493514240
13170301 07280113170301 131703 Catapres-TTS-2 17 15061276303531442176
13170401 07280113170401 131704 Catapres-TTS-3 17 15133333897569370112
13180101 07280113180101 131801 Catapres 17 14917161115455586304
13180501 07280113180501 131805 Catapres 17 15205391491607298048
13180801 07280113180801 131808 Dixarit 17 11793969749455536128
13180825 07280113180825 131808 Clonidine BNM 185 18119570095213641728
13200101 13100113200101 132001 Canesten 15 17656757063780401152
13200102 13100113200102 132001 Gyne Lotremin 40 17728814657818329088
13200103 13100113200103 132001 Fungizid 35 17800872251856257024
13200125 13100113200125 132001 Clotrihexal 116 17069056004106223616
13200201 13100113200201 132002 Canesten 1 15 17872929845894184960
13200225 13100113200225 132002 Clotrihexal 116 17213171192182079488
13200301 13100113200301 132003 Canesten 15 17944987439932112896
13200302 13100113200302 132003 Clocreme 200 2733250666720919552
13200303 13100113200303 132003 Gyne Lotremin 40 18089102628007968768
13200304 13100113200304 132003 Clotrimaderm 1% 127 18161160222045896704
13200325 13100113200325 132003 Clomazol 120 17584699469742473216
13200401 13100113200401 132004 Canesten 3 15 18233217816083824640
13200402 13100113200402 132004 Clotrimaderm 2% 127 18305275410121752576
13200425 13100113200425 132004 Clomazol 120 1134748776422965248
13200601 10070113200601 132006 Canesten 15 13620405897749594112
13200701 10070113200701 132007 Canesten 15 13692463491787522048
13200702 10070113200702 132007 Clocreme 200 2805308260758847488
13200704 10070113200704 132007 Lotremin 40 13836578679863377920
13200705 10070113200705 132007 AFT 127 13908636273901305856
13200725 10070113200725 132007 Clomazol 120 13548348303711666176
13240101 10190113240101 132401 Egopsoryl TA 35 9657801175616978944
13320101 22040713320101 133201 Douglas 35 5461803120256352256
13320102 22040713320102 133201 PSM 179 13069295485536174080
13320103 22040713320103 133201 Alpha-codeine phosphate 10 5605918308332208128
13320201 22040713320201 133202 Douglas 35 5677975902370136064
13320202 22040713320202 133202 PSM 179 13141353079574102016
13320203 22040713320203 133202 Alpha-codeine phosphate 10 5822091090445991936
13320301 22040713320301 133203 Douglas 35 5894148684483919872
13320302 22040713320302 133203 PSM 179 13213410673612029952
13320303 22040713320303 133203 Alpha-codeine phosphate 10 6038263872559775744
13320401 28470213320401 133204 PSM 16 16795443635045793792
13320501 38010113320501 133205 Douglas 35 16288805169641029632
13320602 28470213320602 133206 PSM 16 16867501229083721728
13410101 19130113410101 134101 Abbott 2 9659771500453953536
13412525 19130113412525 134125 Colgout 151 9587713906416025600
13450101 07320313450101 134501 Colestid 14 6890114904225742848
13460101 16031313460101 134601 Colymycin-M 154 15261072959461130240
13460125 16031313460125 134601 Colistin-Link 154 5444121873770086400
13470101 31010113470101 134701 Colymycin-S Otic 58 11461227844076568576
13570101 01150113570101 135701 Clinitest 15 11781267091619840000
13590101 14070113590101 135901 Acthargel 155 11348640052415561728
13600101 14070113600101 136001 Douglas 35 11604200639571165184
13600201 14070113600201 136002 Douglas 35 11676258233609093120
13610101 16031313610101 136101 Trisul 200 2877365854796775424
13610102 16031313610102 136101 Bactrim 30 15405188147536986112
13610103 16031313610103 136101 Septrin 104 15477245741574914048
13610125 16031313610125 136101 Deprim 127 6368781465915752448
13610201 16031313610201 136102 Trisul 200 2949423448834703360
13610203 16031313610203 136102 Trimel 35 15621360929650769920
13610204 16031313610204 136102 Bactrim 30 15693418523688697856
13610205 16031313610205 136102 Septrin 104 15765476117726625792
13610206 16031313610206 136102 Apo-Sulfatrim 10 15837533711764553728
13610301 16031313610301 136103 Apo-Sulfatrim DS 10 15909591305802481664
13610401 16031313610401 136104 Trisul 200 3021481042872631296
13630101 10080113630101 136301 Eurax 158 2760825318833913856
13630125 10080113630125 136301 Itch-Soothe 127 9241805349294440448
13630201 10080113630201 136302 Eurax 158 2832882912871841792
13670101 07311013670101 136701 Prothiazide 200 3093538636910559232
13670102 07311013670102 136701 Navidrex 116 8466336290898444288
13690101 25010113690101 136901 Cycloblastin 14 11460946369099857920
13690125 25010113690125 136901 Procytox 226 970144189163503616
13690126 25010113690126 136901 Endoxan 12 17125405975029743616
13690201 25010113690201 136902 Cytoxan 22 11533003963137785856
13690202 25010113690202 136902 Cycloblastin 14 15167692536425742336
13690225 25010113690225 136902 Endoxan 12 9299218547962019840
13690301 25010113690301 136903 Cycloblastin 14 15239750130463670272
13690401 25010113690401 136904 Cytoxan 22 11749176745251569664
13690402 25010113690402 136904 Cycloblastin 14 15311807724501598208
13692525 25010113692525 136925 Endoxan 12 9227160953924091904
13692625 25010113692625 136926 Baxter 12 9875679300265443328
13692626 25010113692626 136926 Biomed 102 12325637497554993152
13700101 31031013700101 137001 Cyclogyl 3 11803997295500853248
13710101 25010413710101 137101 Cytosar U 14 15383865318539526144
13710102 25010413710102 137101 Hospira 174 8358019002399719424
13710103 25010413710103 137101 Pfizer 14 9544111673304940544
13710201 25010413710201 137102 Cytosar U 14 15455922912577454080
13710202 25010413710202 137102 Pharmacia 14 15527980506615382016
13710225 25010413710225 137102 Pfizer 14 7598556634280886272
13710226 25010413710226 137102 Hospira 174 8574191784513503232
13710301 25010413710301 137103 Cytosar U 14 15600038100653309952
13710302 25010413710302 137103 Hospira 174 8430076596437647360
13710325 25010413710325 137103 Pharmacia 14 15672095694691237888
13710326 25010413710326 137103 Pfizer 14 7166211070053318656
13710401 25010413710401 137104 Hospira 174 8502134190475575296
13710402 25010413710402 137104 Pharmacia 14 15744153288729165824
13710425 25010413710425 137104 Pfizer 14 7382383852167102464
13712625 25010413712625 137126 Baxter 12 5102078100020133888
13712626 25010413712626 137126 Biomed 102 14537179792500850688
13712725 25010413712725 137127 Baxter 12 5174135694058061824
13712726 25010413712726 137127 Biomed 102 14609237386538778624
13720101 14210113720101 137201 Danocrine 50 9226581511296253952
13720102 14210113720102 137201 D-Zol 200 3165596230948487168
13720125 14210113720125 137201 Azol 200 2492588462121680896
13720201 14210113720201 137202 Danocrine 50 9370696699372109824
13720202 14210113720202 137202 D-Zol 200 3237653824986415104
13720225 14210113720225 137202 Azol 200 10217960568526995456
13730101 19160113730101 137301 Dantrium 14 9928300827259174912
13730201 19160113730201 137302 Dantrium 14 10000358421297102848
13740101 16160113740101 137401 Dapsone 154 17297313518520893440
13742525 16160113742525 137425 Dapsone 154 16937025548331253760
13750101 16100113750101 137501 Maloprim 104 14631182539117559808
13780101 35040813780101 137801 Desferal 116 1003635313345560576
13780102 35040813780102 137801 Hospira 174 9006537348741070848
13790101 22050113790101 137901 Pertofran 116 8610451478974300160
13810101 31020113810101 138101 Sofradex 155 17216544493856096256
13810201 31020113810201 138102 Sofradex 155 10072416015335030784
13830101 14070113830101 138301 Douglas 35 11748315827647021056
13830201 14070113830201 138302 Douglas 35 11820373421684948992
13830301 31030413830301 138303 Maxidex 3 6904080900921753600
13830501 14070113830501 138305 Biomed 102 11892431015722876928
13830601 31030413830601 138306 Maxidex 3 6976138494959681536
13850101 14070113850101 138501 Hospira 174 9760284455418724352
13850125 14070113850125 138501 Dexamethasone-hameln 201 13822577498795278336
13850201 14070113850201 138502 Hospira 174 9832342049456652288
13850225 14070113850225 138502 Dexamethasone-hameln 201 13606404716681494528
13890101 22310113890101 138901 PSM 179 640206038435364864
13890125 22310113890125 138901 PSM S29 90 15844698129531142144
13900101 22040713900101 139001 Palfium 35 6110321466597703680
13910101 22040713910101 139101 Doloxene 45 6182379060635631616
13920101 22040713920101 139201 Capadex 145 4138101071576825856
13920201 22040713920201 139202 Apo-Paradex 10 6326494248711487488
13920202 22040713920202 139202 Di-Gesic 45 6398551842749415424
13920203 22040713920203 139202 Paradex 179 11148230968509202432
13930101 04100113930101 139301 Mayne 153 14700425383388381184
13930125 04100113930125 139301 Biomed 102 14196022225122885632
13930201 38010113930201 139302 PSM 16 16360862763678957568
13932525 04100113932525 139325 Biomed 102 14628367789350453248
13940101 04100413940101 139401 Pedialyte 2 16556702277260279808
13940102 04100413940102 139401 Plasma-Lyte Oral 12 16628759871298207744
13940103 04100413940103 139401 Pedialyte - Fruit 2 3901072752907386880
13940125 04100413940125 139401 Pedialyte - Bubblegum2 3973130346945314816
13940126 04100413940126 139401 Pedialyte - Plain 2 4333418317134954496
13970103 22250113970103 139701 D-Pam 35 5409499352123047936
13970104 22250113970104 139701 Pro-Pam 200 3309711419024343040
13970125 22250113970125 139701 Arrow-Diazepam 163 9226036153528877056
13970201 22250113970201 139702 Pro-Pam 200 3381769013062270976
13970203 22250113970203 139702 D-Pam 35 5625672134236831744
13970225 22250113970225 139702 Arrow-Diazepam 163 9153978559490949120
13970302 22250113970302 139703 D-Pam 35 5697729728274759680
13970303 22250113970303 139703 Pro-Pam 200 3453826607100198912
13970401 22070113970401 139704 Stesolid 191 2560989080485625856
13970501 22070113970501 139705 Stesolid 191 2633046674523553792
13970601 22070113970601 139706 Hospira 174 7781558250096295936
13970602 22070113970602 139706 Diazemuls 29 9083873698103951360
14000101 31030114000101 140001 Brolene 155 11420697646453489664
14010101 19040114010101 140101 Diclax 35 17585825369649315840
14010102 19040114010102 140101 Voltaren 116 8682509073012228096
14010103 19040114010103 140101 Apo-Diclo 10 17729940557725171712
14010104 19040114010104 140101 Flameril 116 17801998151763099648
14010125 19040114010125 140101 Diclohexal 36 15240596754417057792
14010126 19040114010126 140101 Diclofenac Sandoz 36 16533698294983950336
14010201 19040114010201 140102 Voltaren 116 8754566667050156032
14010202 19040114010202 140102 Diclax 35 17946113339838955520
14010203 19040114010203 140102 Apo-Diclo 10 18018170933876883456
14010204 19040114010204 140102 Flameril 116 18090228527914811392
14010225 19040114010225 140102 Diclohexal 36 15456769536530841600
14010226 19040114010226 140102 Diclofenac Sandoz 36 16749871077097734144
14010301 19040114010301 140103 Diclax SR 35 18162286121952739328
14010302 19040114010302 140103 Voltaren SR 116 8826624261088083968
14010303 19040114010303 140103 Apo-Diclo SR 10 18306401310028595200
14010304 19040114010304 140103 Flameril Retard 116 18378458904066523136
14010501 19040114010501 140105 Voltaren 116 4144841077855092736
14010601 19040114010601 140106 Voltaren 116 4216898671893020672
14010701 19040114010701 140107 Voltaren 116 4288956265930948608
14010801 19040114010801 140108 Voltaren 116 4361013859968876544
14010901 19040114010901 140109 Voltaren 116 4433071454006804480
14011001 31030414011001 140110 Voltaren Ophtha 116 4505129048044732416
14011101 19040114011101 140111 Voltaren D 116 11047740003776987136
14011201 19040114011201 140112 Diclax SR 35 508457057637105664
14011202 19040114011202 140112 Voltaren SR 116 8898681855126011904
14011203 19040114011203 140112 Apo-Diclo SR 10 652572245712961536
14011204 19040114011204 140112 Flameril Retard 116 724629839750889472
14011301 19040114011301 140113 Anfenax SR 35 796687433788817408
14050101 07130114050101 140501 Merbentyl 19 10781224982273851392
14050201 07130114050201 140502 Merbentyl Dospan 19 10853282576311779328
14050301 07130114050301 140503 Merbentyl 105 10925340170349707264
14070101 13140214070101 140701 Janssen-Cilag 69 4758729205968011264
14080101 16010114080101 140801 Hetrazan 31 10668594309659361280
14090301 10110114090301 140903 Nerisone 29 1046077561689341952
14090401 10110114090401 140904 Nerisone 29 16620090222113193984
14090501 10110114090501 140905 Nerisone 29 16692147816151121920
14100101 10110414100101 141001 Nerisone C 15 7025465885116596224
14110101 19040114110101 141101 Dolobid 72 868745027826745344
14110201 19040114110201 141102 Dolobid 72 940802621864673280
14110202 19040114110202 141102 Ansal 200 3525884201138126848
14120101 07130114120101 141201 Lanoxin PG 157 13380601312220020736
14120201 07130114120201 141202 Lanoxin 157 13452658906257948672
14120301 07130114120301 141203 Lanoxin 157 9691596864519929856
14120401 07130114120401 141204 Lanoxin 157 9547481676444073984
14120501 07130114120501 141205 Lanoxin 157 9619539270482001920
14180101 22160114180101 141801 Dramamine 14 10576819173600526336
14200101 10150214200101 142001 DP Barrier Cream 35 3172617712203464704
14200102 10150214200102 142001 Barrier Cream 555 16 3244675306241392640
14200201 10150214200201 142002 DP Barrier Cream 35 3316732900279320576
14200202 10150214200202 142002 555 Barrier Cream 16 3388790494317248512
14200301 10150214200301 142003 PSM 16 3460848088355176448
14200401 38010114200401 142004 PSM 16 16432920357716885504
14202525 10150214202525 142025 healthE Dimethicone 5% 202 13390231934567710720
14230101 10140114230101 142301 Prantal 40 15350069629636575232
14240101 01040114240101 142401 Lomotil 55 13113749840158785536
14240102 01040114240102 142401 Diastop 200 3597941795176054784
14250101 31030914250101 142501 Propine 5 10002557444552654848
14250103 31030914250103 142501 Dipoquin 200 3669999389213982720
14270101 04070114270101 142701 Persantin 17 8863760266316218368
14270301 04070114270301 142703 Persantin 17 8935817860354146304
14270401 04070114270401 142704 Pytazen SR 35 9007875454392074240
14270501 04070114270501 142705 Persantin PL 17 9079933048430002176
14280101 07130114280101 142801 Rythmodan Retard155 15844076905461448704
14280201 07130114280201 142802 Pyramide 200 3742056983251910656
14280202 07130114280202 142802 Rythmodan 155 15627904123347664896
14280401 07130114280401 142804 Rythmodan 155 15772019311423520768
14280501 07130114280501 142805 Rythmodan 155 15699961717385592832
14280601 07130114280601 142806 Diso Durules 11 1226218248249278464
14310102 19010114310102 143101 Ubretid 155 11492755240491417600
14310201 19010114310201 143102 Ubretid 155 11564812834529345536
14320101 22340114320101 143201 Antabuse 191 17533214837771862016
14360101 22160114360101 143601 Motilium 69 14055847686720978944
14360125 22160114360125 143601 Prokinex 132 7542571701217787904
14370101 22050114370101 143701 Prothiaden 107 3031035798918004736
14370102 22050114370102 143701 Dopress 200 3814114577289838592
14370201 22050114370201 143702 Prothiaden 107 3175150986993860608
14370202 22050114370202 143702 Dopress 200 3886172171327766528
14380101 22050114380101 143801 Anten 200 3958229765365694464
14380201 22050114380201 143802 Sinequan 14 3391323769107644416
14380202 22050114380202 143802 Anten 200 4030287359403622400
14380301 22050114380301 143803 Anten 200 4102344953441550336
14380401 22050114380401 143804 Anten 200 4174402547479478272
14380402 22050114380402 143804 Sinequan 14 3679554145259356160
14410101 14130114410101 144101 Duphaston 177 17595139332648206336
14430101 13100114430101 144301 Ecostatin 22 18377333004159680512
14430102 13100114430102 144301 Gyno-Pevaryl 143 7962214607609659392
14430125 13100114430125 144301 Pevaryl Ovules 200 16351854464912588800
14430201 13100114430201 144302 Gyno- Pervaryl 143 7890157013571731456
14430301 13100114430301 144303 Ecostatin 22 219100781578551296
14430601 10070114430601 144306 Pevaryl 200 4246460141517406208
14430701 10070114430701 144307 Pevaryl 200 4318517735555334144
14431002 10070114431002 144310 Pevaryl 211 5596453712240312320
14431003 10070114431003 144310 Ecreme 200 4462632923631190016
14431004 10070114431004 144310 Ecostatin 22 14268924244090945536
14431102 10070114431102 144311 Pevaryl 200 4534690517669117952
14460101 04100414460101 144601 Gastrolyte (Natural) 155 11636870428567273472
14460102 04100414460102 144601 Gastrolyte (Fruit) 2 16844932653411991552
14460103 04100414460103 144601 Gastrolyte (Orange) 2 16916990247449919488
14460125 04100414460125 144601 Enerlyte 120 16412587089184423936
14462525 04100414462525 144625 Electral 163 4211577035614584832
14462526 04100414462526 144625 Enerlyte 120 2377238697251700736
14480101 13190414480101 144801 Cetiprin Novum 14 15816210882767093760
14530101 28450214530101 145301 PSM 16 16146925288704442368
14530201 28450214530201 145302 PSM 16 16218982882742370304
14530301 38010114530301 145303 PSM 16 16504977951754813440
14560101 13140214560101 145601 DBL Ergometrine 174 7763794540237946880
14580601 22130114580601 145806 Medihaler-Ergotamine 1 12182350241734852608
14590101 22130114590101 145901 Migril 104 12254407835772780544
14600101 22130114600101 146001 Ergodryl 58 12326465429810708480
14620301 22130114620301 146203 Cafergot 127 2103585646261043200
14650301 10010114650301 146503 Stiemycin 30 5984569222217334784
14650401 16030414650401 146504 Emu-V 14 15888268476805021696
14650501 16030414650501 146505 Eryc 58 6181816110682210304
14660201 16030414660201 146602 Eromycin 45 6253873704720138240
14660301 16030414660301 146603 Eromycin 45 6325931298758066176
14660401 16030414660401 146604 Eromycin 45 6397988892795994112
14660501 16030414660501 146605 Eromycin 45 6470046486833922048
14680101 16160114680101 146801 Myambutol 145 18366092696788926464
14680201 16160114680201 146802 Apo-Ethambutol 10 17441428706596749312
14680202 16160114680202 146802 Myambutol 145 18438150290826854400
14750801 13080214750801 147508 Brevinor 21 14 17250043314619547648
14750901 13080214750901 147509 Brevinor 28 52 11315688788442742784
14750902 13080214750902 147509 Norimin 14 15664776245785133056
14751001 13080214751001 147510 Synphasic 28 14 4287277311675334656
14751101 13080214751101 147511 Brevinor 1/21 14 17394158502695403520
14751201 13080214751201 147512 Brevinor 1/28 14 17322100908657475584
14760101 13080214760101 147601 Ovulen 0.5/50 55 11675976758632382464
14760201 13080214760201 147602 Ovulen 1/50 55 11748034352670310400
14770101 13080214770101 147701 Mercilon 21 40 10022887414550233088
14770201 13080214770201 147702 Mercilon 28 40 10094945008588161024
14770301 13080214770301 147703 Marvelon 21 40 9878772226474377216
14770401 13080214770401 147704 Marvelon 28 40 9950829820512305152
14780101 14120114780101 147801 NZ Medical and Scientific 6 2164937295579316224
14790101 13080214790101 147901 Femodene 21 15 6737235508964884480
14790102 13080214790102 147901 Minulet 21 14 5585734573381124096
14790201 13080214790201 147902 Femodene 28 15 1262250343803125760
14790202 13080214790202 147902 Minulet 28 14 5657792167419052032
14790301 13080214790301 147903 Melodene 15 15702819348106182656
14810101 22070214810101 148101 Zarontin 14 2846125430916775936
14810201 22070214810201 148102 Zarontin 58 18143939670931668992
14840101 13080414840101 148401 Femulen 14 4503450093789118464
14870101 19080614870101 148701 Didronel 14 7096108407689576448
14870125 19080614870125 148701 Etidrate 200 4606748111707045888
14870126 19080614870126 148701 Arrow-Etidronate 163 3164757303576494080
14920101 28340114920101 149201 Atrovent 17 12399930398732189696
14920201 28340114920201 149202 Atrovent Forte 17 12471987992770117632
14920301 28340114920301 149203 Atrovent Respules 17 12544045586808045568
14920302 28340114920302 149203 Ipratropium Steri-Neb 132 12616103180845973504
14920325 28340114920325 149203 Ipra 500 200 16135681682798804992
14920326 28340114920326 149203 Univent 166 10047108556198510592
14920401 28340114920401 149204 Atrovent Respules 17 12688160774883901440
14920501 28510214920501 149205 Atrovent Nasal 17 3537127807043764224
14920601 28510214920601 149206 Atrovent Nasal Aqueous 17 3609185401081692160
14920625 28510214920625 149206 Apo-Ipravent 10 2168033520323133440
14920626 28510214920626 149206 Univent 166 11604797674385047552
14920701 28340114920701 149207 Ipratropium Steri-Neb 132 12760218368921829376
14920725 28340114920725 149207 Ipra 250 200 16063624088760877056
14920726 28340114920726 149207 Univent 166 9830935774084726784
14922525 28340114922525 149225 Atrovent 17 12327872804694261760
14980101 04010414980101 149801 Douglas 35 10431806784036405248
14980102 04010414980102 149801 PSM 16 10503864378074333184
14980103 04010414980103 149801 Apo-Folic Acid 10 10575921972112261120
14980125 04010414980125 149801 Healtheries 10 10287691595960549376
14980201 04010414980201 149802 Abbott 2 10647979566150189056
14980301 04010414980301 149803 Biomed 102 10720037160188116992
14982525 04010414982525 149825 Apo-Folic Acid 10 10215634001922621440
14982526 04010414982526 149825 Apo-Folic Acid (s29) 10 10651922414847393792
14990101 04010314990101 149901 Fergon 143 8898963330102722560
14990201 04010314990201 149902 Fergon 143 8610732953951010816
15010101 01383015010101 150101 Ferrograd F 2 154124042423500800
15080101 10310715080101 150801 Elase 58 8667567809502380032
15080301 10310715080301 150803 Elase 58 8739625403540307968
15090101 10150415090101 150901 Ungvita 30 741232465330307072
15100102 07130115100102 151001 Tabco 200 4678805705744973824
15100103 07130115100103 151001 Tambocor 211 13449330684560670720
15100202 07130115100202 151002 Tabco 200 4750863299782901760
15100203 07130115100203 151002 Tambocor 211 13521388278598598656
15100301 07130115100301 151003 Tambocor 211 13377273090522742784
15100401 07130115100401 151004 Tambocor CR 211 13233157902446886912
15100501 07130115100501 151005 Tambocor CR 211 13305215496484814848
15110101 16030715110101 151101 Floxapen 143 7385753855306235904
15110201 16030715110201 151102 Floxapen 143 7457811449344163840
15120101 16030715120101 151201 Floxapen 143 7529869043382091776
15120102 16030715120102 151201 Flucloxin 35 11658193257564733440
15120104 16030715120104 151201 Staphlex 200 4822920893820829696
15120105 16030715120105 151201 HSSL 115 11802308445640589312
15120125 16030715120125 151201 AFT 127 10086509555379863552
15120201 16030715120201 151202 Floxapen 143 7601926637420019712
15120202 16030715120202 151202 Flucloxin 35 11946423633716445184
15120204 16030715120204 151202 Staphlex 200 4894978487858757632
15120205 16030715120205 151202 HSSL 115 12090538821792301056
15120225 16030715120225 151202 AFT 127 10302682337493647360
15120301 16030715120301 151203 Flucloxin 35 12162596415830228992
15120302 16030715120302 151203 Staphlex 200 5111151269972541440
15120325 16030715120325 151203 AFT 127 8055313555668336640
15120401 16030715120401 151204 Flucloxin 35 12306711603906084864
15120402 16030715120402 151204 Staphlex 200 5183208864010469376
15120425 16030715120425 151204 AFT 127 13531690702550859776
15120501 16030715120501 151205 Floxapen 143 7673984231457947648
15120502 16030715120502 151205 Flucloxin 35 12522884386019868672
15120601 16030715120601 151206 Floxapen 143 7746041825495875584
15120602 16030715120602 151206 Flucloxin 35 12666999574095724544
15120701 16030715120701 151207 Floxapen 143 7818099419533803520
15120702 16030715120702 151207 Flucloxin 35 12811114762171580416
15130101 16040115130101 151301 Alcobon 30 12829742688169361408
15150101 14070115150101 151501 Florinef 157 12240650746286047232
15160101 31010115160101 151601 Locorten-Vioform 127 11533285438114496512
15160125 31010115160125 151601 Locacorten-Viaform ED's 127 16708494255521267712
15170101 28510215170101 151701 Rhinalar 52 3681242995119620096
15180301 10220115180301 151803 Synalar Gel 65 13044508095399591936
15180401 10110115180401 151804 Synalar 16 9441346918526484480
15180501 10110115180501 151805 Synalar 16 9513404512564412416
15210101 01050115210101 152101 Ultraproct 29 1982826284182405120
15210201 01050115210201 152102 Ultraproct 29 1910768690144477184
15270101 31030415270101 152701 FML 5 7120253683035537408
15270102 31030415270102 152701 Flucon 3 7192311277073465344
15290101 10310315290101 152901 Efudix 211 4258576759655497728
15290201 25010415290201 152902 Mayne 12 7335863515195899904
15290202 25010415290202 152902 Pharmacia 14 15960326070842949632
15290301 25010415290301 152903 Mayne 153 2054883878220333056
15290302 25010415290302 152903 Adrucil 14 16032383664880877568
15290401 25010415290401 152904 Pharmacia 14 16104441258918805504
15290402 25010415290402 152904 Mayne 153 2126941472258260992
15292525 25010415292525 152925 Hospira 174 8646249378551431168
15292625 25010415292625 152926 Mayne 153 9209360960182026240
15292626 25010415292626 152926 Fluorouracil Ebewe36 4332049425158373376
15292725 25010415292725 152927 Mayne 175 15880949027898916864
15292726 25010415292726 152927 Fluorouracil Ebewe36 4259991831120445440
15292825 25010415292825 152928 Baxter 12 5246193288095989760
15292826 25010415292826 152928 Biomed 102 14681294980576706560
15292925 25010415292925 152929 Fluorouracil Ebewe36 4115876643044589568
15293025 25010415293025 152930 Fluorouracil Ebewe36 4187934237082517504
15320101 22220415320101 153201 Depixol 14 13316362345367207936
15320125 22220415320125 153201 Fluanxol 134 13865582697092481024
15320201 22220415320201 153202 Depixol 14 13460477533443063808
15320225 22220415320225 153202 Fluanxol 134 13937640291130408960
15320301 22220415320301 153203 Depixol Conc 14 13604592721518919680
15320325 22220415320325 153203 Fluanxol 134 14009697885168336896
15330101 22220415330101 153301 Modecate 22 13748707909594775552
15330102 22220415330102 153301 Baxter 12 13820765503632703488
15330201 22220415330201 153302 Modecate 22 13892823097670631424
15330202 22220415330202 153302 Baxter 12 13964880691708559360
15330301 22220415330301 153303 Mayne 12 14036938285746487296
15330401 22220415330401 153304 Modecate 22 14108995879784415232
15330402 22220415330402 153304 Baxter 12 14181053473822343168
15350101 22220115350101 153501 Anatensol 22 1230158897923227648
15350201 22220115350201 153502 Anatensol 22 1302216491961155584
15360101 19040115360101 153601 Froben 107 1156975403978457088
15360201 19040115360201 153602 Froben 107 1229032998016385024
15360301 19040115360301 153603 Froben SR 107 1301090592054312960
15370101 25040115370101 153701 Eulexin 40 1374837035952504832
15370102 25040115370102 153701 Flutol 35 1446894629990432768
15370103 25040115370103 153701 Flutamin 200 5255266458048397312
15370125 25040115370125 153701 Flutamin S29 90 12366773526084976640
15420301 10040115420301 154203 Soframycin 155 15555846529309736960
15422501 10040115422501 154225 Soframycin 105 11386620482573828096
15440101 07310115440101 154401 Frusid 35 1298557317263917056
15440102 07310115440102 154401 Lasix 105 1370614911301844992
15440103 07310115440103 154401 Diurin 40 200 5327324052086325248
15440105 07310115440105 154401 Apo-Frusemide 10 1514730099377700864
15440201 07310115440201 154402 Lasix 105 1586787693415628800
15440202 07310115440202 154402 Diurin 500 200 5399381646124253184
15440203 07310115440203 154402 Frusid Forte 35 1730902881491484672
15440225 07310115440225 154402 Urex Forte 157 11808305182058479616
15440301 07310115440301 154403 Lasix 155 11081222331866021888
15440401 07310115440401 154404 Mayne 174 6145576207430713344
15440402 07310115440402 154404 Frusid 35 1947075663605268480
15440403 07310115440403 154404 Lasix 105 2019133257643196416
15440425 07310115440425 154404 Frusemide-Claris 127 12189697178431651840
15440501 07310115440501 154405 Frusid 35 2091190851681124352
15440601 07310115440601 154406 Lasix 155 11009164737828093952
15460101 16031315460101 154601 Fucidin 29 16125764087916265472
15460201 16031315460201 154602 Fucidin 29 16197821681954193408
15460301 16031315460301 154603 Fucidin 29 16269879275992121344
15460401 31030115460401 154604 Fucithalmic 29 7716749736220295168
15460801 10040115460801 154608 Fucidin 29 11458678076611756032
15460825 10040115460825 154608 Foban 127 11963081234877251584
15460901 10040115460901 154609 Fucidin 29 11530735670649683968
15460925 10040115460925 154609 Foban 127 11242505294497972224
15461001 10040115461001 154610 Fucidin 29 11602793264687611904
15490101 10170115490101 154901 Quellada 49 7640188542554996736
15490201 10170115490201 154902 Benhex 179 1072551602662932480
15530101 07320115530101 155301 Lopid 125 5665135805580967936
15530102 07320115530102 155301 Apo-Gemfibrozil 10 5737193399618895872
15530103 07320115530103 155301 Gemizol 200 5809250993656823808
15532525 07320115532525 155325 Lipazil 35 5881308587694751744
15540101 16031315540101 155401 Hospira 174 7709500656058368000
15540201 16031315540201 155402 Mayne 12 16413994464067977216
15540202 16031315540202 155402 Cidomycin 155 16276422469689016320
15540225 16031315540225 155402 APP Pharmaceuticals 90 15753198970890878976
15540301 16031315540301 155403 Pfizer 14 12237468759635263488
15540302 16031315540302 155403 Baxter 12 16630167246181761024
15540303 16031315540303 155403 Cidomycin 155 16348480063726944256
15540501 31030115540501 155405 Genoptic 5 2198999066296188928
15540701 10040115540701 155407 Garamycin 40 11674850858725539840
15540801 10040115540801 155408 Garamycin 40 11746908452763467776
15670101 01131215670101 156701 Semi-Daonil 105 11872677189818253312
15670102 01131215670102 156701 Apo-Glibenclamide 10 11944734783856181248
15670104 01131215670104 156701 Gliben 200 5543496834200109056
15670201 01131215670201 156702 Gliben 200 5615554428238036992
15670202 01131215670202 156702 Daonil 155 9112038787961061376
15670204 01131215670204 156702 Apo-Glibenclamide 10 12232965160007892992
15680101 01131215680101 156801 Diamicron 46 12305022754045820928
15680125 01131215680125 156801 Apo-Gliclazide 10 12521195536159604736
15680126 01131215680126 156801 Nidem 10 12590783627081547776
15690101 01131215690101 156901 Glipid 200 5687612022275964928
15690102 01131215690102 156901 Minidiab 14 11441510302055661568
15700101 01130115700101 157001 Eli Lilly 45 3818883159219503104
15700301 01130115700301 157003 Novo 8 3890940753257431040
15700401 01130115700401 157004 Glucagen Hypokit 8 3962998347295358976
15700402 01130115700402 157004 Novo Hypokit 8 4035055941333286912
15720101 01150115720101 157201 Clinistix 15 11709209497581912064
15720102 01150115720102 157201 Diastix 15 11637151903543984128
15720201 01150115720201 157202 Tes-Tape 45 10592296998784729088
15720202 01150115720202 157202 Diabur 5000 164 1837037639409074176
15720303 01150715720303 157203 Accutrend 164 207860474207797248
15720304 01150715720304 157203 Advantage 20 5138457641248358400
15720305 01150715720305 157203 BM-Test Glycemie 1-44 164 279918068245725184
15720306 01150715720306 157203 Glucocard 6 5282572829324214272
15720307 01150715720307 157203 Glucofilm 15 11925382279695695872
15720308 01150715720308 157203 Glucostix 15 11997439873733623808
15720309 01150715720309 157203 Glucopat 6 5498745611437998080
15720310 01150715720310 157203 Glucometer Elite 15 12069497467771551744
15720311 01150715720311 157203 Glucometer Esprit 15 12141555061809479680
15720313 01150715720313 157203 Exactech 71 5714918393551781888
15720314 01150715720314 157203 Medisense-2 (new) 71 5786975987589709824
15720315 01150715720315 157203 Precision Plus 71 5859033581627637760
15720325 01150715720325 157203 Ascensia Glucodisc15 12213612655847407616
15720401 01150415720401 157204 Keto-Diastix 15 11853324685657767936
15721001 01150415721001 157210 Keto-Diabur 5000 164 351975662283653120
15740101 01250715740101 157401 PSM 16 631973994878205952
15740201 01250715740201 157402 PSM 16 704031588916133888
15740301 01250715740301 157403 PSM 179 784321226511220736
15740401 01250715740401 157404 PSM 16 848146776991989760
15740501 01250715740501 157405 PSM 16 920204371029917696
15740601 38010115740601 157406 PSM 179 1288724384776716288
15740602 38010115740602 157406 David Craig 120 16649093139830669312
15740625 38010115740625 157406 MidWest 152 10020075963318009856
15740626 38010115740626 157406 ABM 167 15279998853110038528
15740627 38010115740627 157406 healthE 202 9719752058772389888
15740701 01250715740701 157407 Fleet Glycerin Suppositories 12 18017374887458373632
15740801 01250715740801 157408 Fleet Glycerin Suppositories 12 1064319559105773568
15750101 10150415750101 157501 QV 35 813290059368235008
15770102 07340115770102 157701 Nitrocor 1 2307363633794908160
15770103 07340115770103 157701 Nitroderm TTS 158 3193170883061481472
15770104 07340115770104 157701 Nitro-Dur 40 2451478821870764032
15770105 07340115770105 157701 Minitran 1 2523536415908691968
15770201 07340115770201 157702 Anginine 143 2053210421522857984
15770225 07340115770225 157702 Lycinate 157 11880362776096407552
15770301 07340115770301 157703 Nitrobid 105 2667651603984547840
15770401 07340115770401 157704 Nitrolingual 35 2739709198022475776
15770502 07340115770502 157705 Nitroderm TTS 158 3265228477099409408
15770503 07340115770503 157705 Nitrocor 1 2883824386098331648
15770504 07340115770504 157705 Nitro-Dur 40 2955881980136259584
15770505 07340115770505 157705 Minitran 1 3027939574174187520
15770601 07340115770601 157706 Nitrolingual Pumpspray 35 3099997168212115456
15772525 07340115772525 157725 Glytrin 127 3964688296667250688
15772625 01050215772625 157726 Rectogesic 224 7879220171410243584
15790201 16040115790201 157902 Griseostatin 40 12901800282207289344
15790301 16040115790301 157903 Grisovin 500 104 12973857876245217280
15800101 28430215800101 158001 Nuelin 35 10289999470867251200
15800301 28430215800301 158003 Nuelin-SR 35 10362057064905179136
15800401 28430215800401 158004 Nuelin-SR 35 10434114658943107072
15800501 28430215800501 158005 Theostat 200 5831727210351820800
15800502 28430215800502 158005 Theo-Dur 11 14705773407945883648
15800601 28430215800601 158006 Nuelin-SR 35 10506172252981035008
15800701 28430215800701 158007 Theostat 200 5903784804389748736
15800702 28430215800702 158007 Theo-Dur 11 14921946190059667456
15800801 28430215800801 158008 Nuelin-SR 35 10578229847018962944
15800901 28430215800901 158009 Nuelin-SR 35 10650287441056890880
15801101 28430215801101 158011 Theo-Dur 1 15138118972173451264
15801201 28430215801201 158012 Nuelin-SR Sprinkle 35 9929711500677611520
15801202 28430215801202 158012 Theo-24 55 15282234160249307136
15801301 28430215801301 158013 Nuelin-SR Sprinkle 35 10001769094715539456
15801302 28430215801302 158013 Nuelin-24 35 10073826688753467392
15801401 28430215801401 158014 Nuelin-24 35 10145884282791395328
15801501 28430215801501 158015 Nuelin 35 10217941876829323264
15830101 22220115830101 158301 Serenace 157 13105341874741182464
15830201 22220115830201 158302 Serenace 157 13177399468779110400
15830301 22220115830301 158303 Serenace 157 13249457062817038336
15830401 22220115830401 158304 Serenace 157 13321514656854966272
15830601 22220115830601 158306 Serenace 157 13393572250892894208
15890101 04070415890101 158901 Hospira 174 7205097497792872448
15890102 04070415890102 158901 Monoparin 108 12449419417098387456
15890103 04070415890103 158901 Multiparin 108 12521477011136315392
15890125 04070415890125 158901 Pfizer 14 18358775446906077184
15890203 04070415890203 158902 Hospira 174 7277155091830800384
15890301 04070415890301 158903 Hospira 174 7349212685868728320
15890402 04070415890402 158904 Multiparin 108 12737649793250099200
15890403 04070415890403 158904 Mayne 12 12809707387288027136
15890404 04070415890404 158904 Leo 29 12881764981325955072
15890425 04070415890425 158904 Pfizer 14 344658412400803840
15890501 04070415890501 158905 Baxter 12 12953822575363883008
15890601 04070415890601 158906 Hospira 174 7421270279906656256
15890602 04070415890602 158906 Monoparin 51 13097937763439738880
15890603 04070415890603 158906 Minihep (10s) 29 13169995357477666816
15890701 04070415890701 158907 Multiparin 108 13242052951515594752
15890702 04070415890702 158907 Leo 29 13314110545553522688
15940101 16230115940101 159401 Hiprex 35 14805989494771154944
15980201 28100115980201 159802 Ipradol 105 5626516559166963712
15980301 28100115980301 159803 Ipradol 105 5698574153204891648
16000101 31031016000101 160001 Isopto Homatropine 3 11876054889538781184
16000201 31031016000201 160002 Isopto Homatropine 3 11948112483576709120
16030101 19110116030101 160301 Hyalase 108 8434792401809178624
16040101 07400116040101 160401 Alphapress 200 5975842398427676672
16040102 07400116040102 160401 Apresoline 127 2391816022412754944
16040125 07400116040125 160401 Hydralazine 90 9844195884315705344
16040126 07400116040126 160401 Onelink 220 12039139951728656384
16040201 07400116040201 160402 Alphapress 200 6047899992465604608
16040301 07400116040301 160403 Apresoline 127 2319758428374827008
16060101 01040416060101 160601 Colifoam 49 343462143749783552
16060201 01040416060201 160602 Colifoam 157 2847517412637540352
16110101 10110416110101 161101 Micreme H 200 6119957586503532544
16110102 10110416110102 161101 Daktacort 69 16665679272735670272
16120201 10110416120201 161202 Pimafucort 29 2991632600713396224
16120301 10110416120301 161203 Pimafucort 29 3063690194751324160
16130101 10110116130101 161301 DP Lotn HC 35 9585462106602340352
16130102 10110116130102 161301 BK Lotn HC 1 9657519700640268288
16140101 10110116140101 161401 Locoid 29 4299082768022765568
16140201 10110116140201 161402 Locoid 29 4154967579946909696
16140601 10220116140601 161406 Locoid 29 4515255550136549376
16140701 10110116140701 161407 Locoid Lipocream 29 4227025173984837632
16142525 10110116142525 161425 Locoid Crelo 29 4371140362060693504
16150201 10110416150201 161502 Locoid C 29 4443197956098621440
16170101 14070116170101 161701 Douglas 35 12180661391874588672
16170201 14070116170201 161702 Douglas 35 12252718985912516608
16170501 10110116170501 161705 Cortaid 16 10017807670829907968
16170502 10110116170502 161705 PSM 16 10089865264867835904
16170601 10110116170601 161706 Pharmacia 14 16176498852956733440
16170602 10110116170602 161706 Apo-Hydrocortisone10 10233980452943691776
16170603 10110116170603 161706 PSM 16 10306038046981619712
16170604 10110116170604 161706 Douglas 35 10378095641019547648
16170625 10110116170625 161706 m-Hydrocortisone 120 4435315557239095296
16170626 10110116170626 161706 ABM 167 17719261001284583424
16171601 14070116171601 161716 Solu-Cortef 14 16248556446994661376
16171701 14070116171701 161717 Solu-Cortef 14 16320614041032589312
16171801 14070116171801 161718 Solu-Cortef 14 16392671635070517248
16171901 10110116171901 161719 Douglas 35 10450153235057475584
16171902 10110116171902 161719 PSM 179 12853122703422390272
16171903 10110116171903 161719 Cortef 14 16464729229108445184
16171904 10110116171904 161719 Egocort 35 10666326017171259392
16171925 10110116171925 161719 Lemnis Fatty Cream HC 29 12256099984167927808
16171926 10110116171926 161719 Pharmacy Health 179 10001787786413211648
16190101 01050716190101 161901 Anusol 182 5257234583862116352
16190201 01050716190201 161902 Anusol 182 5329292177900044288
16190402 38010116190402 161904 PSM 16 16721150733868597248
16200101 10070116200101 162001 Daktarin 182 8756814068817330176
16200201 10070116200201 162002 Daktarin 182 8972986850931113984
16200301 10070116200301 162003 Daktarin 182 8900929256893186048
16200302 10070116200302 162003 Micreme 200 6192015180541460480
16200303 10070116200303 162003 AFT 127 14701269808318513152
16200325 10070116200325 162003 Multichem 120 16286536877152927744
16200401 10070116200401 162004 Daktarin 182 8828871662855258112
16200501 13100116200501 162005 Gyno-Daktarin-7 69 291158375616479232
16200601 13100116200601 162006 Gyno-Daktarin-7 69 363215969654407168
16200602 13100116200602 162006 Micreme 200 6264072774579388416
16200603 13100116200603 162006 Micozole 127 507331157730263040
16240101 01370416240101 162401 Neo-Cytamen 143 3710535084395200512
16240125 01370416240125 162401 Goldshield 153 13833200980142850048
16240126 01370416240126 162401 Neo-B12 153 16984591520860471296
16240127 01370416240127 162401 ABM Hydroxocobalamin 167 4258835144888025088
16250101 19070116250101 162501 Plaquenil 143 1147750501421416448
16260101 25010716260101 162601 Hydrea 22 12740183068040495104
16290101 22160116290101 162901 Scopoderm TTS 158 4177270073804718080
16290201 31031016290201 162902 Isopto Hyoscine 3 14320221959084834816
16290301 22160116290301 162903 Hospira 174 7997731032210079744
16300101 31031316300101 163001 Poly-Tears 3 3597708698710966272
16310101 01070116310101 163101 Buscopan 17 10362956465416699904
16310125 01070116310125 163101 Gastrosoothe 127 10435014059454627840
16310201 01070116310201 163102 Buscopan 17 10507071653492555776
16320101 01050116320101 163201 Proctosedyl 155 16132307281613160448
16320401 01050116320401 163204 Proctosedyl 155 16204364875651088384
16320501 01050116320501 163205 Proctosedyl 155 16060249687575232512
16330101 31031316330101 163301 Tears Naturale 3 12308400453766348800
16330202 31031316330202 163302 Isopto Tears 3 12452515641842204672
16330203 31031316330203 163302 Methopt 157 13970033003196317696
16330301 31031316330301 163303 Methopt Forte 19 12596630829918060544
16340101 01050116340101 163401 Xyloproct 11 503952358498107392
16340201 01050116340201 163402 Xyloproct 11 576009952536035328
16390301 31030116390301 163903 Stoxil 47 7860864924296151040
16420101 22050116420101 164201 Imipramin 29 3751611739297284096
16420125 22050116420125 164201 Tofranil 127 1815355270109331456
16420201 22050116420201 164202 Imipramin 29 3895726927373139968
16420225 22050116420225 164202 Tofranil 127 1959470458185187328
16430101 07311016430101 164301 Natrilix 46 7622123566510637056
16430102 07311016430102 164301 Napamide 35 7694181160548564992
16430103 07311016430103 164301 Naplin 200 6336130368617316352
16430125 07311016430125 164301 Dapa-Tabs 200 2192830806064365568
16450102 19040216450102 164501 Indocid 72 15045181652324057088
16450103 19040216450103 164501 Rheumacin 200 6480245556693172224
16450201 19040216450201 164502 Rheumacin 200 6552303150731100160
16450202 19040216450202 164502 Indocid 72 15261354434437840896
16450301 19040216450301 164503 Indocid-R 72 15333412028475768832
16450302 19040216450302 164503 Rheumacin SR 200 6624360744769028096
16450401 19040216450401 164504 Indocid 72 15477527216551624704
16450402 19040216450402 164504 Arthrexin 200 6696418338806956032
16480101 01130316480101 164801 Actrapid 8 7693336735618433024
16480102 01130316480102 164801 Humulin R 45 7765394329656360960
16480201 01130316480201 164802 Actrapid Penfill 8 7837451923694288896
16480202 01130316480202 164802 Humulin R 45 7909509517732216832
16480204 01130316480204 164802 Actrapid 8 7981567111770144768
16480301 01130316480301 164803 Actrapid Penfill 8 8053624705808072704
16480302 01130316480302 164803 Humulin R 45 8125682299846000640
16482501 01130316482501 164825 Velosulin 8 8197739893883928576
16482502 01130316482502 164825 Actrapid 8 8269797487921856512
16490201 01130516490201 164902 Humulin N 45 2558390934509191168
16490203 01130516490203 164902 Protaphane Penfill 8 2630448528547119104
16490301 01130516490301 164903 Protaphane Penfill 8 2702506122585047040
16490302 01130516490302 164903 Humulin N 45 2774563716622974976
16490325 01130516490325 164903 Humulin NPH 45 2270160558357479424
16490401 01130516490401 164904 Humulin N 45 2846621310660902912
16490402 01130516490402 164904 Protaphane 8 11895812013978288128
16490425 01130516490425 164904 Humulin NPH 45 2486333340471263232
16492501 01130516492501 164925 Insulatard 8 2990736498736758784
16492503 01130516492503 164925 Protaphane 8 3134851686812614656
16530101 01150916530101 165301 VAN 39 13599589943612538880
16550101 01130516550101 165501 Humulin L 45 3206909280850542592
16550102 01130516550102 165501 Monotard 8 3278966874888470528
16550201 01130516550201 165502 Humulin U 45 3351024468926398464
16550202 01130516550202 165502 Ultratard 8 3423082062964326400
16760101 01383016760101 167601 Ferrum H 157 8062427395900047360
16760125 01383016760125 167601 Ferrosig 145 6765390703217344512
16780101 13100116780101 167801 Gyno-Travogen Ovule 38 579388751768190976
16790101 16160116790101 167901 PSM 179 424033256321581056
16790201 16160116790201 167902 Rifinah 155 15916134499499376640
16790301 16160116790301 167903 Rifinah 155 15988192093537304576
16820101 07370116820101 168201 Isuprel 103 13437469153120223232
16860101 10150416860101 168601 QV 35 885347653406162944
16860201 10150416860201 168602 QV 35 957405247444090880
16860202 10150416860202 168602 QV Spray Pack 35 1029462841482018816
16880101 10010116880101 168801 Roaccutane 30 6056626816255262720
16880125 10010116880125 168801 Oratane 35 6633087568558686208
16880126 10010116880126 168801 Isotane 10 200 6561029974520758272
16880201 10010116880201 168802 Roaccutane 30 6128684410293190656
16880202 10010116880202 168802 Oratane 35 6200742004331118592
16880225 10010116880225 168802 Isotane 20 200 5336050875875983360
16960101 16040116960101 169601 Nizoral 69 13045915470283145216
16960201 10070116960201 169602 Nizoral 69 14845384996394369024
16960301 10220116960301 169603 Nizoral 69 13188623283475447808
16960302 10220116960302 169603 Sebizole 35 13260680877513375744
16960325 10220116960325 169603 Ketopine 127 12612162531172024320
16970101 19040116970101 169701 Orudis 155 11708928022605201408
16970302 19040116970302 169703 Kefen SR 200 6768475932844883968
16970303 19040116970303 169703 Oruvail SR 155 1397108743484735488
16970505 19040116970505 169705 Oruvail 155 11780985616643129344
16970601 19040116970601 169706 Oruvail EC 155 11853043210681057280
16970701 19040116970701 169707 Orudis 155 11925100804718985216
16970801 19040116970801 169708 Oruvail SR 155 1325051149446807552
16980101 28040116980101 169801 Zasten 36 150139412284440576
16980201 28040116980201 169802 Zasten 36 222197006322368512
16980202 28040116980202 169802 Asmafen 200 6840533526882811904
16990101 07160116990101 169901 Trandate 157 5089770166858809344
16990102 07160116990102 169901 Hybloc 200 6912591120920739840
16990201 07160116990201 169902 Trandate 157 5161827760896737280
16990202 07160116990202 169902 Hybloc 200 6984648714958667776
16990301 07160116990301 169903 Hybloc 200 7056706308996595712
16990302 07160116990302 169903 Albetol 35 4973213138221531136
16990303 07160116990303 169903 Trandate 157 5233885354934665216
16990401 07160116990401 169904 Albetol 35 5117328326297387008
16990402 07160116990402 169904 Trandate 157 5305942948972593152
16990403 07160116990403 169904 Hybloc 200 7128763903034523648
16990501 07160116990501 169905 Trandate 157 5017712572820881408
16992525 07160116992525 169925 Trandate 157 4945654978782953472
17150101 22020117150101 171501 EMLA 144 9056600312176967680
17150201 22020117150201 171502 EMLA 144 9128657906214895616
17160101 31030517160101 171601 Betagan 5 7984944811490672640
17160201 31030517160201 171602 Betagan 5 8057002405528600576
17160225 31030517160225 171602 Alcon-Levobunolol 3 8129059999566528512
17170201 22010117170201 171702 Madopar 250 30 11290385727352733696
17170601 22010117170601 171706 Madopar 125 30 11362443321390661632
17170701 22010117170701 171707 Madopar HBS 30 11434500915428589568
17170801 22010117170801 171708 Madopar 62.5 30 11506558509466517504
17170901 22010117170901 171709 Madopar Rapid 30 13490996677695242240
17180201 13080217180201 171802 Triphasil 21 14 5729849761456979968
17180301 13080217180301 171803 Biphasil 21 14 5801907355494907904
17180401 13080217180401 171804 Biphasil 28 14 5873964949532835840
17180501 13080217180501 171805 Triphasil 28 14 5946022543570763776
17180502 13080217180502 171805 Triquilar ED 15 12684783075163373568
17180503 13080217180503 171805 Trifeme 14 6018080137608691712
17180601 13080217180601 171806 Microgynon 50 15 1334307937841053696
17180701 13080217180701 171807 Microgynon 50 ED 15 1406365531878981632
17180801 13080217180801 171808 Microgynon 30 15 1622538313992765440
17180802 13080217180802 171808 Nordette 21 14 6090137731646619648
17180901 13080217180901 171809 Microgynon 30 ED 15 1478423125916909568
17180902 13080217180902 171809 Nordette 28 14 6162195325684547584
17180903 13080217180903 171809 Monofeme 14 6234252919722475520
17180904 13080217180904 171809 Levlen ED 15 1694595908030693376
17180925 13080217180925 171809 Ava 30 ED 163 4333464496623321088
17181001 13080217181001 171810 Nordiol 21 14 6306310513760403456
17181101 13080217181101 171811 Nordiol 28 14 6378368107798331392
17181201 13080217181201 171812 Loette 14 15774876942144110592
17181202 13080217181202 171812 Microgynon 20 ED 15 15846934536182038528
17181225 13080217181225 171812 Ava 20 ED 163 15918992130219966464
17190101 07130117190101 171901 Xylocard 144 9907769646633713664
17190201 07130117190201 171902 Xylocard 144 9979827240671641600
17190401 22020117190401 171904 Xylocaine 144 9200715500252823552
17190601 22020117190601 171906 Xylocaine 0.5% 144 9272773094290751488
17190701 22020117190701 171907 Xylocaine 144 9344830688328679424
17190725 22020117190725 171907 Lidocaine-Claris 120 18080719951357804544
17190801 22020117190801 171908 Xylocaine 144 9416888282366607360
17191001 22020117191001 171910 Xylocaine 144 9488945876404535296
17191025 22020117191025 171910 Lidocaine-Claris 120 17864547169244020736
17192525 22020117192525 171925 Xylocaine 144 9561003470442463232
17192526 22020117192526 171925 Lidocaine-Claris 120 11822967169614872576
17192625 22020117192625 171926 Xylocaine 144 9633061064480391168
17192626 22020117192626 171926 Lidocaine-Claris 120 12111197545766584320
17192725 22020117192725 171927 Xylocaine Viscous144 9705118658518319104
17200201 16031317200201 172002 Lincocin 14 16536786823146373120
17200301 16031317200301 172003 Lincocin 14 16608844417184301056
17210101 14140117210101 172101 Tertroxin 143 3782592678433128448
17230101 22010117230101 172301 Sindopa 200 11650673697542373376
17230102 22010117230102 172301 Sinemet 72 11722731291580301312
17230201 22010117230201 172302 Sinemet 72 11794788885618229248
17230301 22010117230301 172303 Sinemet CR 72 11866846479656157184
17240101 13080417240101 172401 Microlut 15 839758602783686656
17240102 13080417240102 172401 Microval 14 6522483295874187264
17242525 13080517242525 172425 Postinor-2 15 12111984796092071936
17242526 13080517242526 172425 Next Choice 163 408869891462922240
17242625 14130117242625 172426 Mirena 15 767701008745758720
17242725 13080517242725 172427 Postinor-1 15 17445374853828837376
17242825 13080417242825 172428 Jadelle 15 16243780168483602432
17280101 01040117280101 172801 Imodium 69 13257865028234641408
17280102 01040117280102 172801 Dicap 200 7272879091110379520
17280125 01040117280125 172801 Diamide Relief 200 5888316874810195968
17280201 01040117280201 172802 Apo-Loperamide 69 13401980216310497280
17280225 01040117280225 172802 Nodia 120 13041692246120857600
17290101 22280117290101 172901 Dormonoct 105 9084436648057372672
17300101 22250117300101 173001 Ativan 14 6594540889912115200
17300201 22250117300201 173002 Ativan 157 13465629844930822144
17300202 22250117300202 173002 Lorapam 200 7344936685148307456
17300401 22250117300401 173004 Lorapam 200 7416994279186235392
17300402 22250117300402 173004 Lorzem 35 6202132886540255232
17300403 22250117300403 173004 Ativan 157 13537687438968750080
17300501 22250117300501 173005 Ativan 14 6666598483950043136
17310101 22280117310101 173101 Noctamid 15 3712208541092675584
17320101 22220117320101 173201 Loxapac 31 1734562056188723200
17320201 22220117320201 173202 Loxapac 31 1806619650226651136
17320301 22220117320301 173203 Loxapac 31 1878677244264579072
17330101 16031017330101 173301 Tetralysal 14 16680902011222228992
17600101 22050117600101 176001 Ludiomil 127 2175643240298971136
17600201 22050117600201 176002 Ludiomil 127 2247700834336899072
17620101 16010117620101 176201 Vermox 112 10740651903697289216
17620201 16010117620201 176202 Mindol 200 10812709497735217152
17620202 16010117620202 176202 Vermox 112 10884767091773145088
17620225 16010117620225 176202 De-Worm 120 10596536715621433344
17660101 14130117660101 176601 Provera 14 12666489400700436480
17660102 14130117660102 176601 Farlutal 14 16752959605260156928
17660201 14130117660201 176602 Provera 14 12738546994738364416
17660202 14130117660202 176602 Farlutal 14 16825017199298084864
17660301 14130117660301 176603 Provera 14 16897074793336012800
17660401 14130117660401 176604 Farlutal 14 16969132387373940736
17660501 14110917660501 176605 Provera 14 12450316618586652672
17660601 14110917660601 176606 Provera 14 12522374212624580608
17660701 14110917660701 176607 Provera 14 12594431806662508544
17660801 13080417660801 176608 Depo-Provera 14 12378259024548724736
17662525 13080417662525 176625 Depo-Provera 14 17105928126543691776
17690101 19040117690101 176901 Ponstan 14 2918183024954703872
17690102 19040117690102 176901 Mefic 58 1949608938395664384
17720101 25040117720101 177201 Megostat 22 1591009818066288640
17720125 25040117720125 177201 Megace 22 1663067412104216576
17720126 25040117720126 177201 Apo-Megestrol 10 16303168090034667520
17730101 25010117730101 177301 Alkeran 157 4225079038403674112
17730201 25010117730201 177302 Alkeran 157 4297136632441602048
17732525 25010117732525 177325 Alkeran 157 4153021444365746176
17800101 22250117800101 178001 Equanil 14 6738656077987971072
17810101 25010417810101 178101 Puri-nethol 157 3417846188592857088
17810201 25010417810201 178102 Puri-nethol 157 5471206143697092608
17920101 14100117920101 179201 Proviron 38 15927656281846841344
17930101 07370117930101 179301 Aramine 72 4469091454932746240
17940101 01131217940101 179401 Glucophage 200 7633167061300019200
17940103 01131217940103 179401 Metomin 200 7705224655337947136
17940104 01131217940104 179401 Glucomet 35 12737368318273388544
17940105 01131217940105 179401 Apo-Metformin 10 12809425912311316480
17940106 01131217940106 179401 3M 1 12881483506349244416
17940125 01131217940125 179401 Arrow-Metformin 163 2633875706290896896
17940126 01131217940126 179401 Apotex 10 5902945877017755648
17940201 01131217940201 179402 Glucophage 200 7777282249375875072
17940203 01131217940203 179402 Metomin 200 7849339843413803008
17940204 01131217940204 179402 Glucomet 35 13097656288463028224
17940205 01131217940205 179402 Apo-Metformin 10 13169713882500956160
17940206 01131217940206 179402 3M 1 13241771476538884096
17940225 01131217940225 179402 Diabex 200 15199214435282452480
17940226 01131217940226 179402 Arrow-Metformin 163 2705933300328824832
17940227 01131217940227 179402 Apotex 10 6119118659131539456
17950101 22040717950101 179501 Methatabs 179 13285468267649957888
17950102 22040717950102 179501 Pallidone 35 6614724624863199232
17950201 22040717950201 179502 AFT 127 3856323729168531456
17950225 22040717950225 179502 Martindale 12 4741227179877072896
17950301 22040717950301 179503 PSM 16 6758839812939055104
17950401 38010117950401 179504 PSM 16 16793208327906525184
17950402 38010117950402 179504 Douglas 35 16865265921944453120
17950425 38010117950425 179504 AFT 127 18162302614627155968
17950501 22040717950501 179505 Biodone 102 6830897406976983040
17950502 22040717950502 179505 Methaforte 16 6902955001014910976
17950525 22040717950525 179505 PSM Methaforte 16 6975012595052838912
17950601 22040717950601 179506 GlaxoWellcome 143 3134074332091777024
17950602 22040717950602 179506 Biodone Forte 102 7119127783128694784
17950625 22040717950625 179506 PSM Methaforte 16 7191185377166622720
17950701 22040717950701 179507 Biodone Extra Forte 102 7263242971204550656
17950725 22040717950725 179507 PSM Methaforte 16 7335300565242478592
17970101 25010417970101 179701 Ledertrexate 31 7912324267499323392
17970102 25010417970102 179701 Baxter 12 7984381861537251328
17970103 25010417970103 179701 Methoblastin 14 2818540883199131648
17970125 25010417970125 179701 Trexate 166 7586502688305577984
17970201 25010417970201 179702 Methoblastin 14 12810604588776292352
17970225 25010417970225 179702 Trexate 166 7802675470419361792
17970401 25010417970401 179704 Hospira 174 8718306972589359104
17970501 25010417970501 179705 Mayne 12 8272612237688963072
17970701 25010417970701 179707 Hospira 174 13774964247266066432
17970703 25010417970703 179707 Pharmacia 14 17041189981411868672
17970901 25010417970901 179709 Mayne 12 8488785019802746880
17971001 25010417971001 179710 Hospira 174 13847021841303994368
17971002 25010417971002 179710 Pharmacia 14 17113247575449796608
17971101 25010417971101 179711 Mayne 12 8704957801916530688
17971125 25010417971125 179711 Methotrexate Ebewe36 2242379198058463232
17971201 25010417971201 179712 Mayne 12 8777015395954458624
17971202 25010417971202 179712 Pharmacia 14 17185305169487724544
17971225 25010417971225 179712 Methotrexate Ebewe36 2314436792096391168
17972525 25010417972525 179725 Baxter 12 5318250882133917696
17972526 25010417972526 179725 Biomed 102 14753352574614634496
17972625 25010417972625 179726 Baxter 12 5390308476171845632
17972626 25010417972626 179726 Biomed 102 14825410168652562432
17972725 25010417972725 179727 Methotrexate Ebewe36 2386494386134319104
17972825 25010417972825 179728 DBL Methotrexate116 15721371407801647104
17972925 25010417972925 179729 Methotrexate Sandoz 116 11329268856557404160
17973025 25010417973025 179730 Methotrexate Sandoz 116 11545441638671187968
17973125 25010417973125 179731 Methotrexate Sandoz 116 11761614420784971776
17973225 25010417973225 179732 Methotrexate Sandoz 116 11977787202898755584
17973325 25010417973325 179733 Methotrexate Sandoz 116 12193959985012539392
17973425 25010417973425 179734 Methotrexate Sandoz 116 12410132767126323200
17990101 22220117990101 179901 Nozinan 155 11997158398756913152
17990201 22220117990201 179902 Nozinan 155 12069215992794841088
17990301 22220117990301 179903 Nozinan 155 12141273586832769024
18000101 10190118000101 180001 Oxsoralen 200 15195558559120097280
18010101 07311018010101 180101 Enduron 2 7838296348624420864
18050101 07280118050101 180501 Hydromet 72 15277449085645225984
18060101 07280118060101 180601 Douglas 35 15349506679683153920
18060103 07280118060103 180601 Aldomet 72 15421564273721081856
18060104 07280118060104 180601 Prodopa 200 7921397437451730944
18060201 07280118060201 180602 Prodopa 200 7993455031489658880
18060202 07280118060202 180602 Aldomet 72 15637737055834865664
18060204 07280118060204 180602 Douglas 35 15709794649872793600
18060301 07280118060301 180603 Douglas 35 15781852243910721536
18060303 07280118060303 180603 Aldomet 72 15853909837948649472
18060304 07280118060304 180603 Prodopa 200 8065512625527586816
18090101 22310118090101 180901 Ritalin 116 12038798003612418048
18090125 22310118090125 180901 Rubifen 127 12110855597650345984
18092525 22310118092525 180925 Ritalin SR 116 12182913191688273920
18092526 22310118092526 180925 Rubifen SR 127 11750567627460706304
18092625 22310118092625 180926 Rubifen 127 11678510033422778368
18092725 22310118092725 180927 Rubifen 127 12471143567839985664
18100101 14070118100101 181001 Depo-Medrol 14 17257362763525652480
18100201 14070118100201 181002 Depo-Medrol 14 17329420357563580416
18100301 14070118100301 181003 Depo-Medrol 14 17401477951601508352
18100401 14070118100401 181004 Depo-Medrol 14 17473535545639436288
18100501 14070118100501 181005 Depo-Medrol 14 13026777370890076160
18110101 14070118110101 181101 Medrol 14 12882662182814220288
18110201 14070118110201 181102 Medrol 14 12954719776852148224
18120101 14070118120101 181201 Solu-Medrol 14 13170892558965932032
18120201 14070118120201 181202 Solu-Medrol 14 13242950153003859968
18120301 14070118120301 181203 Solu-Medrol 14 17545593139677364224
18120401 14070118120401 181204 Solu-Medrol 14 13315007747041787904
18120402 14070118120402 181204 Baxter 12 13405640490519363584
18120501 14070118120501 181205 Solu-Medrol 14 1862353894638616576
18120502 14070118120502 181205 Baxter 12 13549755678595219456
18130101 22130418130101 181301 Deseril 116 4719622875902902272
18140101 22160118140101 181401 Maxolon 143 8250444983761371136
18140102 22160118140102 181401 Metamide 200 8137570219565514752
18140201 22160118140201 181402 Maxolon 143 8106329795685515264
18140301 22160118140301 181403 Maxolon 143 8034272201647587328
18140302 22160118140302 181403 Pfizer 14 1934411488676544512
18140325 22160118140325 181403 AstraZeneca 144 13551444528455483392
18140501 22160118140501 181405 Maxolon 143 8178387389723443200
18150101 22130118150101 181501 Paramax 143 1416219355087110144
18160601 14070118160601 181606 Depo-Medrol with Lidocaine 14 8766682185676619776
18170101 07160118170101 181701 Betaloc CR 144 1560334543162966016
18170125 07160118170125 181701 Metoprolol - AFT CR 127 9006483472671309824
18170126 07160118170126 181701 Myloc CR 200 8001917972488650752
18170201 07160118170201 181702 Betaloc CR 144 1632392137200893952
18170225 07160118170225 181702 Metoprolol - AFT CR 127 9222656254785093632
18170226 07160118170226 181702 Myloc CR 200 8218090754602434560
18170301 07160118170301 181703 Betaloc CR 144 1704449731238821888
18170325 07160118170325 181703 Metoprolol - AFT CR 127 9438829036898877440
18170326 07160118170326 181703 Myloc CR 200 8434263536716218368
18172525 07160118172525 181725 Betaloc CR 144 1488276949125038080
18172526 07160118172526 181725 Metoprolol - AFT CR 127 8790310690557526016
18172527 07160118172527 181725 Myloc CR 200 7785745190374866944
18180101 07160118180101 181801 Lopresor 116 4124329688438931456
18180102 07160118180102 181801 Mycol 200 8281685407641370624
18180201 07160118180201 181802 Lopresor 116 4196387282476859392
18180202 07160118180202 181802 Mycol 200 8353743001679298560
18180301 07160118180301 181803 Slow-Lopresor 116 11099544593631281152
18180401 07160118180401 181804 Betaloc 144 1776507325276749824
18180425 07160118180425 181804 Lopresor 116 10123964418980052992
18200102 16130118200102 182001 Trichozole 200 8425800595717226496
18200103 16130118200103 182001 Flagyl 155 12213331180870696960
18200202 16130118200202 182002 Trichozole 200 8497858189755154432
18200203 16130118200203 182002 Flagyl 155 12285388774908624896
18200301 16130118200301 182003 Flagyl-S 155 2150584270790328320
18200401 16130118200401 182004 Flagyl 155 2294699458866184192
18200501 16130118200501 182005 Flagyl 155 2222641864828256256
18220101 14210118220101 182201 Metopirone 226 15371522201006112768
18230101 07130118230101 182301 Mexitil 17 1946794188628557824
18230201 07130118230201 182302 Mexitil 17 2018851782666485760
18230301 07130118230301 182303 Mexitil PL 17 2090909376704413696
18232525 07130118232525 182325 Mexiletine Hydrochloride USP 154 17222495050785619968
18232625 07130118232625 182326 Mexiletine Hydrochloride USP 154 17438667832899403776
18240101 22050118240101 182401 Tolvon 40 4174962198898016256
18250102 01310718250102 182501 Daktarin 69 3442220162357395456
18250125 01310718250125 182501 Decozol 127 1165756103837876224
18260101 28530218260101 182601 Breath-A-Tech (with mask) 132 8322524568031854592
18260125 28530218260125 182601 Space Chamber 132 9115158102449061888
18270101 28530218270101 182701 Personal Best 90 4329761341460971520
18270103 28530218270103 182701 Assess 74 10774426701879312384
18270104 28530218270104 182701 Mini Wright 39 10846484295917240320
18270108 28530218270108 182701 Breath-Alert 132 10704326238538825728
18270125 28530218270125 182701 Air-O-Breath PocketPeak 140 4617991717612683264
18270126 28530218270126 182701 Vitalograph 136 4690049311650611200
18270201 28530218270201 182702 Breath-Alert 132 10776383832576753664
18270202 28530218270202 182702 Personal Best 90 4834164499726467072
18270203 28530218270203 182702 Mini Wright 39 10918541889955168256
18270225 28530218270225 182702 Air-O-Breath PocketPeak 140 4978279687802322944
18270226 28530218270226 182702 Vitalograph 136 5050337281840250880
18280101 16031018280101 182801 Mino-tabs 157 12672996310513614848
18280201 16031018280201 182802 Minomycin 157 12745053904551542784
18292525 28530218292525 182925 Space Chamber 132 12359693770713726976
18292526 28530218292526 182925 Space Chamber Plus 132 8466358281130999808
18292625 28530218292625 182926 Volumatic 143 3533486224532570112
18300101 22040718300101 183001 RA-Morph 14 2438814646942040064
18300201 22040718300201 183002 RA-Morph 14 2510872240979968000
18300301 22040718300301 183003 RA-Morph 14 2582929835017895936
18300401 22040718300401 183004 RA-Morph 14 2654987429055823872
18300501 38010118300501 183005 PSM 16 16937323515982381056
18300502 38010118300502 183005 Douglas 35 17009381110020308992
18310101 22040718310101 183101 MST Continus 35 7695588535432118272
18310102 22040718310102 183101 LA-Morph 35 4148212180505853952
18310125 22040718310125 183101 Arrow-Morphine LA163 6282108063809798144
18310201 22040718310201 183102 MST Continus 35 7839703723507974144
18310202 22040718310202 183102 LA-Morph 35 4220269774543781888
18310225 22040718310225 183102 Arrow-Morphine LA163 6498280845923581952
18310301 22040718310301 183103 MST Continus 35 7983818911583830016
18310302 22040718310302 183103 LA-Morph 35 4292327368581709824
18310325 22040718310325 183103 Arrow-Morphine LA163 6714453628037365760
18310401 22040718310401 183104 MST Continus 35 8127934099659685888
18310402 22040718310402 183104 LA-Morph 35 4364384962619637760
18310425 22040718310425 183104 Arrow-Morphine LA163 6930626410151149568
18310501 22040718310501 183105 MST Continus 35 8272049287735541760
18310601 22040718310601 183106 Baxter 12 8344106881773469696
18310701 22040718310701 183107 DBL Morphine Sulphate 174 11799019806361911296
18310801 22040718310801 183108 DBL Morphine Sulphate 174 11871077400399839232
18310802 22040718310802 183108 AstraZeneca 144 10844518369126776832
18310901 22040718310901 183109 Baxter 12 8632337257925181440
18311001 22040718311001 183110 DBL Morphine Sulphate 174 12303422964627406848
18311002 22040718311002 183110 AstraZeneca 144 10916575963164704768
18311101 22040718311101 183111 DBL Morphine Sulphate 174 12663710934817046528
18311102 22040718311102 183111 AstraZeneca 144 10988633557202632704
18311201 22040718311201 183112 RMS 12 8992625228114821120
18311301 22040718311301 183113 RMS 12 9064682822152749056
18311325 22040718311325 183113 Martindale 12 8615214563345825792
18311401 22040718311401 183114 RMS 12 9136740416190676992
18311425 22040718311425 183114 Martindale 12 4669169585839144960
18311501 22040718311501 183115 RMS 12 9208798010228604928
18311525 22040718311525 183115 Martindale 12 10722007485025091584
18311601 38010118311601 183116 Douglas 35 17081438704058236928
18311701 22040718311701 183117 Kapanol 143 3278189520167632896
18311801 22040718311801 183118 Kapanol 143 3350247114205560832
18311901 22040718311901 183119 Kapanol 143 3422304708243488768
18311925 22040718311925 183119 m-Eslon 120 4813284773915000832
18312001 22040718312001 183120 Sevredol 35 9497028386380316672
18312101 22040718312101 183121 Sevredol 35 9569085980418244608
18312201 22040718312201 183122 Kapanol 143 3206131926129704960
18312225 22040718312225 183122 m-Eslon 120 5389745526218424320
18312525 22040718312525 183125 m-Eslon 120 10866122673100947456
18312625 22040718312625 183126 m-Eslon 120 10794065079063019520
18312725 22040718312725 183127 m-Eslon 120 11586698613480226816
18320225 28530218320225 183202 EZ-fit Paediatric Mask 132 16536808813378928640
18350101 10040118350101 183501 Bactroban 143 1920622513352605696
18380101 07160118380101 183801 Corgard 22 6054077048790450176
18380102 07160118380102 183801 Apo-Nadolol 10 6126134642828378112
18380201 07160118380201 183802 Corgard 22 6198192236866306048
18380202 07160118380202 183802 Apo-Nadolol 10 6270249830904233984
18390101 16230118390101 183901 Negram 50 14878047088809082880
18410101 22330118410101 184101 Narcan Neonatal 127 8840427530063183872
18410125 22330118410125 184101 Mayne 12 8768369936025255936
18410201 35040418410201 184102 Narcan 53 138944184890425344
18410202 35040418410202 184102 Hospira 174 9078594942778998784
18430101 31031718430101 184301 Albalon 5 12884861206069772288
18430102 31031718430102 184301 Naphcon Forte 19 4144554105320243200
18490101 22040418490101 184901 Acupan 35 2064737701428461568
18490201 22040418490201 184902 Acupan 35 1992680107390533632
18520101 16031318520101 185201 Neosulf 200 8569915783793082368
18520102 16031318520102 185201 Mycifradin 14 17617650733715292160
18530601 38010118530601 185306 Douglas 35 17153496298096164864
18540101 10040118540101 185401 Spersin 19 11891023640839323648
18570202 19010118570202 185702 AstraZeneca 144 10772460775088848896
18570301 19010118570301 185703 AstraZeneca 144 8218354637393100800
18590101 16010118590101 185901 Yomesan 15 10956824685811073024
18600101 01370418600101 186001 Apo-Nicotinamide 10 4234853696774602752
18600201 01370418600201 186002 Apo-Nicotinamide 10 4306911290812530688
18600301 38010118600301 186003 PSM 16 17225553892134092800
18610101 07320218610101 186101 Apo-Nicotinic Acid 10 6025423775770607616
18610102 07320218610102 186101 PSM 16 6097481369808535552
18610201 07320218610201 186102 Apo-Nicotinic Acid 10 6169538963846463488
18610202 07320218610202 186102 PSM 16 6241596557884391424
18610301 07320218610301 186103 Apo-Nicotinic Acid 10 6313654151922319360
18610302 07320218610302 186103 PSM 16 6385711745960247296
18610401 07320218610401 186104 PSM 16 6457769339998175232
18610402 07320218610402 186104 Apo-Nicotinic Acid 10 6529826934036103168
18610425 07320218610425 186104 Niacin-Odan 10 6601884528074031104
18620101 07400118620101 186201 Ronicol Timespan 30 4973494613198241792
18630101 07220118630101 186301 Adalat Retard 15 13187778858545315840
18630125 07220118630125 186301 Adalat 10 15 13980412392962523136
18630201 07220118630201 186302 Adalat Retard 15 13259836452583243776
18630202 07220118630202 186302 Apo-Nifedipine Retard 10 13331894046621171712
18630203 07220118630203 186302 Nyefax Retard 35 13403951640659099648
18630204 07220118630204 186302 Alpha-Nifedipine 10 13476009234697027584
18630301 07220118630301 186303 Adalat Oros 15 13548066828734955520
18630325 07220118630325 186303 Arrow-Nifedipine XR 163 3714739616859815936
18630326 07220118630326 186303 Adefin XL 200 16495969652988444672
18630401 07220118630401 186304 Adalat Oros 15 13620124422772883456
18630425 07220118630425 186304 Arrow-Nifedipine XR 163 3786797210897743872
18630426 07220118630426 186304 Adefin XL 200 16568027247026372608
18630501 07220118630501 186305 Adalat 15 13692182016810811392
18630601 07220118630601 186306 Adalat 15 13764239610848739328
18630602 07220118630602 186306 Nical 200 8641973377831010304
18630603 07220118630603 186306 Nyefax 35 13908354798924595200
18640101 16130118640101 186401 Naxogin 14 17689708327753220096
18650102 22280118650102 186501 Insoma 200 8714030971868938240
18650104 22280118650104 186501 Nitrados 35 9300609430171156480
18670101 16230118670101 186701 Nifuran 57 14950104682847010816
18670201 16230118670201 186702 Nifuran 57 15022162276884938752
18670301 16230118670301 186703 Furadantin 14 17761765921791148032
18710101 13080418710101 187101 Noriday 28 14 1847164141500891136
18710201 14130118710201 187102 Primolut N 15 4216611699358171136
18730101 13080218730101 187301 Norinyl-1/21 14 17466216096733331456
18730201 13080218730201 187302 Norinyl-1/28 14 17538273690771259392
18740101 16230118740101 187401 Noroxin 72 15166277464960794624
18740125 16230118740125 187401 Arrow-Norfloxacin163 15238335058998722560
18750101 13080218750101 187501 Ovral 14 6810713672025899008
18760101 22050118760101 187601 Allegron 45 4256014897562779648
18760125 22050118760125 187601 Norpress 200 17072711880268578816
18760201 22050118760201 187602 Allegron 45 4328072491600707584
18760202 22050118760202 187602 Norpress 200 8786088565906866176
18760301 22050118760301 187603 Allegron 45 4472187679676563456
18810201 10070118810201 188102 Mycostatin 22 14917442590432296960
18810301 10070118810301 188103 Mycostatin 22 14989500184470224896
18810401 01310718810401 188104 Mycostatin 22 3514277756395323392
18810501 01310718810501 188105 Mycostatin 22 3586335350433251328
18810502 01310718810502 188105 Nilstat 157 11303902023792984064
18810601 16040118810601 188106 Nilstat 145 18221977508713070592
18810701 13100118810701 188107 Mycostatin 22 651446345806118912
18810702 13100118810702 188107 Nilstat 145 18149919914675142656
18810801 13100118810801 188108 Mycostatin 22 795561533881974784
18810901 13100118810901 188109 Nilstat 157 12168593152248119296
18811301 10070118811301 188113 Nilstat 145 17933747132561358848
18811302 10070118811302 188113 Mycostatin 157 11952420370134335488
18811401 10070118811401 188114 Nilstat 145 18005804726599286784
18811402 10070118811402 188114 Mycostatin 22 15277730560621936640
18812501 16040118812501 188125 Mycostatin 22 13190030658359001088
18812502 16040118812502 188125 Nilstat 157 12817111498589470720
18812601 16040118812601 188126 Nilstat 157 12889169092627398656
18860101 14120118860101 188601 Organon 19 2236994889617244160
18860201 14120118860201 188602 Organon 19 2309052483655172096
18860501 14110418860501 188605 Estraderm TTS 25116 8970739449163939840
18860525 14110418860525 188605 Estradot 116 10341535779884367872
18860601 14110418860601 188606 Estraderm TTS 50116 9042797043201867776
18860625 14110418860625 188606 Estradot 50 mcg 116 15915860721104060416
18860701 14110418860701 188607 Estraderm TTS 100 116 9114854637239795712
18860725 14110418860725 188607 Estradot 116 10557708561998151680
18860801 14110418860801 188608 Femtran 1 1228188573086253056
18860802 14110418860802 188608 Climara 50 15 4288669293396099072
18860803 14110418860803 188608 Femtran 50 35 2208852889504317440
18860901 14110418860901 188609 Femtran 1 1444361355200036864
18860902 14110418860902 188609 Climara 100 15 4360726887434027008
18860903 14110418860903 188609 Femtran 100 35 2280910483542245376
18861001 14110418861001 188610 Estrofem 8 1660534137313820672
18861101 14110418861101 188611 Estrofem 8 1732591731351748608
18880102 14110418880102 188801 Premarin 14 6882771266063826944
18880202 14110418880202 188802 Premarin 14 6954828860101754880
18880302 14110418880302 188803 Premarin 14 7026886454139682816
18880501 13140218880501 188805 Premarin 14 7098944048177610752
19030101 28450219030101 190301 Alupent 17 16291040476780298240
19060101 16130119060101 190601 Tiberal 30 16072334419876118528
19060125 16130119060125 190601 Arrow-Ornidazole 163 6065935281696014336
19080101 19160119080101 190801 Norflex 35 7241357192253669376
19080201 19160119080201 190802 Norflex 35 7169299598215741440
19090101 22010419090101 190901 Disipal 29 11938904073694085120
19100101 13220119100101 191001 Hemastix 13 13941872311385718784
19110101 22250119110101 191101 Serepax 14 7171001642215538688
19110102 22250119110102 191101 Ox-Pam 35 6562420856729894912
19110103 22250119110103 191101 Benzotran 200 8930203753982722048
19110201 22250119110201 191102 Benzotran 200 9002261348020649984
19110202 22250119110202 191102 Ox-Pam 35 6778593638843678720
19110203 22250119110203 191102 Serepax 14 7243059236253466624
19110301 22250119110301 191103 Serepax 14 7315116830291394560
19110302 22250119110302 191103 Ox-Pam 35 6994766420957462528
19110303 22250119110303 191103 Benzotran 200 9074318942058577920
19120101 07160119120101 191201 Captol 40 200 9146376536096505856
19120102 07160119120102 191201 Trasicor 116 9186912231277723648
19120201 07160119120201 191202 Captol 80 200 9218434130134433792
19120202 07160119120202 191202 Trasicor 116 9258969825315651584
19120401 07160119120401 191204 Captol SR 200 9290491724172361728
19120402 07160119120402 191204 Slow Trasicor 116 6702595395131801600
19140101 13190419140101 191401 Ditropan 105 9442472818433327104
19140102 13190419140102 191401 Apo-Oxybutynin 10 9514530412471255040
19140201 13190419140201 191402 Ditropan 105 9586588006509182976
19140202 13190419140202 191402 Apo-Oxybutynin 10 9658645600547110912
19150101 22040719150101 191501 Proladone 107 9713201168494100480
19160101 28510419160101 191601 Drixine 40 2004164506342653952
19160601 28510419160601 191606 Drixine 40 2076222100380581888
19160701 28510419160701 191607 Drixine 40 2148279694418509824
19160801 28510419160801 191608 Drixine 40 2220337288456437760
19170101 14010119170101 191701 Anapolon 52 10452421527545577472
19220101 13140219220101 192201 Syntocinon 116 2088679567123283968
19220125 13140219220125 192201 Oxytocin BNM 185 2881641855517196288
19220201 13140219220201 192202 Syntocinon 116 2160737161161211904
19220225 13140219220225 192202 BNM 185 10670062157682442240
19220301 13140219220301 192203 Syntometrine 179 3787994579060391936
19250101 01220119250101 192501 Viokase 14 7387174424329322496
19250201 01220119250201 192502 Viokase 14 7459232018367250432
19250301 01220119250301 192503 Viokase 14 7531289612405178368
19250401 01220119250401 192504 Pancrex V 6 12321679255694999552
19250501 01220119250501 192505 Pancrex V Forte 6 12393736849732927488
19250601 01220119250601 192506 Pancrex V 6 12465794443770855424
19250702 01220119250702 192507 Pancrex 6 12537852037808783360
19250802 01220119250802 192508 Pancrex V 6 12609909631846711296
19250901 01220119250901 192509 Combizym 29 12681967225884639232
19251001 01220119251001 192510 Combizym Compositum 29 12754024819922567168
19251101 01220119251101 192511 Cotazym ECS 40 9734657038398521344
19251201 01220119251201 192512 Creon 17 12898140007998423040
19251301 01220119251301 192513 Creon Forte 17 12970197602036350976
19251325 01220119251325 192513 Creon 25000 2 3983337113385959424
19251401 01220119251401 192514 Pancrease 69 13042255196074278912
19251501 01220119251501 192515 Panzytrat 15 7097523479154524160
19252525 01220119252525 192525 Creon 10000 17 13186370384150134784
19270101 22040719270101 192701 Baxter 12 9785258762532028416
19280101 07400119280101 192801 Hospira 174 7637443062020440064
19290201 22040419290201 192902 Panadol 186 2653299678707187712
19290202 22040419290202 192902 PSM Paracetamol Elixir Paediatric 16 2725357272745115648
19290203 22040419290203 192902 Pamol 133 3926989341485694976
19290204 22040419290204 192902 Panadol Colourfree47 2869472460820971520
19290205 22040419290205 192902 Douglas 35 2941530054858899456
19290206 22040419290206 192902 PSM Paracetamol Junior Suspension 16 3013587648896827392
19290207 22040419290207 192902 Paracare Junior 179 1050871432386445312
19290225 22040419290225 192902 Junior Parapaed 127 4166509153503674368
19290226 22040419290226 192902 Ethics Paracetamol 120 531296113169268736
19290301 22040419290301 192903 Pamol 133 3999046935523622912
19290302 22040419290302 192903 Panadol 186 3229760431010611200
19290303 22040419290303 192903 PSM Paracetamol Double Strength 16 3301818025048539136
19290304 22040419290304 192903 Douglas 35 3373875619086467072
19290305 22040419290305 192903 Paracare Double Strength 179 1122929026424373248
19290325 22040419290325 192903 Six Plus Parapaed127 1860666144289980416
19290401 22040419290401 192904 Panadol 186 3517990807162322944
19290501 22040419290501 192905 Panadol 186 3590048401200250880
19290601 22040419290601 192906 HMG 16 3662105995238178816
19290625 22040419290625 192906 Paracare 179 5656090123419254784
19290701 38010119290701 192907 PSM 16 17297611486172020736
19290801 22040419290801 192908 Pamol 133 4071104529561550848
19290802 22040419290802 192908 Panadol 186 3806221183314034688
19290803 22040419290803 192908 Apo-Paracetamol 10 3878278777351962624
19290804 22040419290804 192908 Douglas 35 3950336371389890560
19290805 22040419290805 192908 Disprol 162 4354262858574331904
19290825 22040419290825 192908 Pacimol 120 2437126896593403904
19290826 22040419290826 192908 Pharmacare 179 978813838348517376
19290827 22040419290827 192908 Parafast 163 12600380164568776704
19310101 22040719310101 193101 Panadeine 143 9043078518178578432
19310102 22040719310102 193101 Apo-Paracodeine 10 5823833816376016896
19310103 22040719310103 193101 Pamol Plus 104 5895891410413944832
19310105 22040719310105 193101 Codral Pain 104 5967949004451872768
19310125 22040719310125 193101 Codalgin 145 6040006598489800704
19310126 22040719310126 193101 ParaCode 163 10518855119607431168
19310127 22040719310127 193101 Paracetamol + Codeine (Relieve) 200 8649314816969670656
19420301 19070119420301 194203 D-Penamine 200 9362549318210289664
19420325 19070119420325 194203 Distamine 200 16784481504116867072
19420401 19070119420401 194204 D-Penamine 200 9434606912248217600
19420425 19070119420425 194204 Distamine 200 16856539098154795008
19440101 22040719440101 194401 Fortral 143 8754848142026866688
19440201 22040719440201 194402 Fortral 143 8826905736064794624
19440301 22040719440301 194403 Fortral 143 8682790547988938752
19490102 07220219490102 194901 Pexid (Sigma) 19 1497228073286762496
19490125 07220219490125 194901 Pexsig 157 11736247588020551680
19500101 22220119500101 195001 Neulactil 155 12544330360319639552
19500201 22220119500201 195002 Neulactil 155 12616387954357567488
19530101 22040719530101 195301 PSM 179 496090850359508992
19530102 22040719530102 195301 Douglas 35 10145546732721668096
19530201 22040719530201 195302 PSM 179 568148444397436928
19530202 22040719530202 195302 Douglas 35 10289661920797523968
19530301 22040719530301 195303 DBL Pethidine Hydrochloride 174 13096056499044614144
19530302 22040719530302 195303 AstraZeneca 144 11060691151240560640
19530401 22040719530401 195304 Mayne 174 12760503142433423360
19530501 22040719530501 195305 DBL Pethidine Hydrochloride 174 14176920409613533184
19530502 22040719530502 195305 AstraZeneca 144 11132748745278488576
19550101 22050419550101 195501 Nardil 154 12904618330509279232
19560401 22070119560401 195604 Gardenal Sodium 155 12357446368946552832
19560501 38010119560501 195605 PSM 16 17369669080209948672
19560525 38010119560525 195605 MidWest 152 10164191151393865728
19562525 22280119562525 195625 Martindale 201 1292144965450727424
19660101 07040119660101 196601 Dibenyline 185 2065579927335337984
19660125 07040119660125 196601 BNM 185 11102407721910009856
19700101 16030719700101 197001 Compocillin VK 2 12883172356209508352
19700201 16030719700201 197002 Compocillin VK 2 12955229950247436288
19700301 16030719700301 197003 Compocillin V 2 13027287544285364224
19700401 16030719700401 197004 Compocillin V 2 13099345138323292160
19702525 16030719702525 197025 Cilicaine VK 157 12456823528399831040
19702625 16030719702625 197026 Cilicaine VK 157 12528881122437758976
19702725 16030719702725 197027 AFT 127 8127371149706264576
19702825 16030719702825 197028 AFT 127 8199428743744192512
19710101 07040119710101 197101 Regitine 116 10823144962594439168
19720101 31031719720101 197201 Isopto Frin 3 13028976394145628160
19720102 31031719720102 197201 Prefrin 5 13101033988183556096
19730101 31031719730101 197301 Prefrin-Z 5 13173091582221484032
19730102 31031719730102 197301 Zincfrin 3 13245149176259411968
19780101 22070219780101 197801 Dilantin Infatab 14 3303505775397175296
19780201 22070219780201 197802 Dilantin 14 3087332993283391488
19780301 22070219780301 197803 Dilantin 14 3159390587321319424
19780401 22070219780401 197804 Dilantin 14 3231448181359247360
19780501 22070219780501 197805 Dilantin Forte 14 3566701371296055296
19780601 22070119780601 197806 Dilantin 14 13048733518585135104
19780625 22070119780625 197806 Hospira 174 7853615844134223872
19780701 22070119780701 197807 Dilantin 14 13120791112623063040
19780725 22070119780725 197807 Hospira 174 7925673438172151808
19850101 19010119850101 198501 Mayne 12 8290412231431028736
19860101 04040319860101 198601 Konakion 30 11296497912491540480
19860201 04040319860201 198602 Konakion 30 11368555506529468416
19860302 04040319860302 198603 Konakion MM 30 11440613100567396352
19862525 04040319862525 198625 Konakion MM 30 11512670694605324288
19870101 31030919870101 198701 Isopto Carpine 3 10146672632628510720
19870102 31030919870102 198701 PV Carpine 5 10218730226666438656
19870103 31030919870103 198701 Pilopt 19 10290787820704366592
19870201 31030919870201 198702 Isopto Carpine 3 10362845414742294528
19870202 31030919870202 198702 PV Carpine 5 10434903008780222464
19870203 31030919870203 198702 Pilopt 19 10506960602818150400
19870301 31030919870301 198703 Isopto Carpine 3 10579018196856078336
19870302 31030919870302 198703 PV Carpine 5 10651075790894006272
19870303 31030919870303 198703 Pilopt 19 10723133384931934208
19870401 31030919870401 198704 Isopto Carpine 3 10795190978969862144
19870402 31030919870402 198704 PV Carpine 5 10867248573007790080
19870403 31030919870403 198704 Pilopt 19 10939306167045718016
19870501 31030919870501 198705 Isopto Carpine 3 11011363761083645952
19870502 31030919870502 198705 PV Carpine 5 11083421355121573888
19870503 31030919870503 198705 Pilopt 19 11155478949159501824
19870601 31030919870601 198706 Isopto Carpine 3 11227536543197429760
19870602 31030919870602 198706 PV Carpine 5 11299594137235357696
19870603 31030919870603 198706 Pilopt 19 11371651731273285632
19870701 31030919870701 198707 Minims 87 11443709325311213568
19870801 31030919870801 198708 Ocusert Pilo 40 5 11515766919349141504
19890101 07190119890101 198901 Viskaldix 36 10017244720876486656
19900101 22220119900101 199001 Orap 69 2311022808492146688
19900201 22220119900201 199002 Orap 69 2383080402530074624
19902525 22220119902525 199025 Orap Forte 69 8902886387590627328
19910401 07160119910401 199104 Visken 36 6774652989169729536
19910402 07160119910402 199104 Pindol 200 9506664506286145536
19910403 07160119910403 199104 Apo-Pindolol 10 6918768177245585408
19910404 07160119910404 199104 Vypen 35 6990825771283513344
19910501 07160119910501 199105 Apo-Pindolol 10 7062883365321441280
19910503 07160119910503 199105 Pindol 200 9578722100324073472
19910504 07160119910504 199105 Visken 116 7206998553397297152
19910505 07160119910505 199105 Vypen 35 7279056147435225088
19910601 07160119910601 199106 Apo-Pindolol 10 7351113741473153024
19910603 07160119910603 199106 Pindol 200 9650779694362001408
19910604 07160119910604 199106 Visken 36 7495228929549008896
19930102 10170119930102 199301 Lyban 155 12429503962984480768
19940101 22220419940101 199401 Piportil 155 12501561557022408704
19940201 22220419940201 199402 Piportil 155 12573619151060336640
19950101 01100719950101 199501 Gastrozepin 17 6540415231011586048
19960301 19040219960301 199603 Feldene 14 15621642404627480576
19960401 19040219960401 199604 Candyl D 35 15693699998665408512
19960402 19040219960402 199604 Piram-D 200 9722837288399929344
19960501 19040219960501 199605 Douglas 35 15837815186741264384
19960601 19040219960601 199606 Candyl D 35 15909872780779192320
19960602 19040219960602 199606 Piram-D 200 9794894882437857280
19960701 19040219960701 199607 Douglas 35 16053987968855048192
19960702 19040219960702 199607 Feldene 14 16126045562892976128
19980101 16030719980101 199801 Pondocillin 29 13315517920437075968
20000101 22130420000101 200001 Sandomigran 116 5728429192433893376
20000201 22130420000201 200002 Sandomigran 116 5656371598395965440
20040101 31030120040101 200401 Neosporin 104 7932922518334078976
20080101 10040120080101 200801 Ponoxylan 155 12645676745098264576
20100201 31031320100201 201002 Liquifilm Tears 5 12668688423955988480
20100225 31031320100225 201002 Vistil 127 3293909237909946368
20100301 31031320100301 201003 Liquifilm Forte 5 12740746017993916416
20100325 31031320100325 201003 Vistil Forte 127 3510082020023730176
20130101 04100420130101 201301 Phosphate-Sandoz116 5584314004358037504
20160101 04100420160101 201601 Chlorvescent 151 17061105435525775360
20160201 04100420160201 201602 K-SR 200 9866952476475785216
20160202 04100420160202 201602 Slow K 116 9331027419353579520
20160203 04100420160203 201602 Span-K 157 2137637521373265920
20160301 04100120160301 201603 Pharmacia 14 17833823515829075968
20160302 04100120160302 201603 AstraZeneca 144 2785313641807740928
20160401 04100120160401 201604 Pharmacia 14 17905881109867003904
20160402 04100120160402 201604 AstraZeneca 144 2857371235845668864
20160501 38010120160501 201605 PSM 16 17441726674247876608
20310101 07040120310101 203101 Hyprosin 200 9939010070513713152
20310201 07040120310201 203102 Hyprosin 200 10011067664551641088
20310202 07040120310202 203102 Minipress 14 6702313920155090944
20310203 07040120310203 203102 Pratsiol 35 6774371514193018880
20310225 07040120310225 203102 Apo-Prazo 10 8131364575938347008
20310226 07040120310226 203102 Apo-Prazosin 10 13450750154072129536
20310301 07040120310301 203103 Pratsiol 35 6846429108230946816
20310302 07040120310302 203103 Minipress 14 6918486702268874752
20310303 07040120310303 203103 Hyprosin 200 10083125258589569024
20310325 07040120310325 203103 Apo-Prazo 10 9644574050734833664
20310326 07040120310326 203103 Apo-Prazosin 10 13666922936185913344
20310401 07040120310401 203104 Hyprosin 200 10155182852627496960
20310402 07040120310402 203104 Minipress 14 7134659484382658560
20310403 07040120310403 203104 Pratsiol 35 7206717078420586496
20310425 07040120310425 203104 Apo-Prazo 10 10725437961303752704
20310426 07040120310426 203104 Apo-Prazosin 10 13883095718299697152
20320101 31030420320101 203201 Pred Mild 5 7264368871111393280
20320201 31030420320201 203202 Pred Forte 5 7336426465149321216
20330101 31030420330101 203301 Predmycin-P 5 7408484059187249152
20340101 01040420340101 203401 Predsol 104 487577331825639424
20340201 01040420340201 203402 Predsol 104 559634925863567360
20342525 14070120342525 203425 Redipred 157 2890598477237059584
20350101 31030420350101 203501 Blephamide 5 7480541653225177088
20360101 14070120360101 203601 PSM 16 13693870866671075328
20380101 14070120380101 203801 Origen Prednisone104 13765928460709003264
20380102 14070120380102 203801 Apo-Prednisone 10 13837986054746931200
20380103 14070120380103 203801 Douglas 35 13910043648784859136
20380125 14070120380125 203801 Apo-Prednisone S2910 4498710099161776128
20380202 14070120380202 203802 Douglas 35 13982101242822787072
20380203 14070120380203 203802 Apo-Prednisone 10 14054158836860715008
20380204 14070120380204 203802 Deltasone 14 17977938703904931840
20380301 14070120380301 203803 Douglas 35 14198274024936570880
20380302 14070120380302 203803 Apo-Prednisone 10 14270331618974498816
20380303 14070120380303 203803 Origen Prednisone104 14342389213012426752
20380304 14070120380304 203803 Deltasone 14 18049996297942859776
20380401 14070120380401 203804 Douglas 35 14486504401088282624
20380402 14070120380402 203804 Origen Prednisone104 14558561995126210560
20380403 14070120380403 203804 Apo-Prednisone 10 14630619589164138496
20380404 14070120380404 203804 Deltasone 14 18122053891980787712
20380501 14070120380501 203805 Deltasone 14 18194111486018715648
20380601 14070120380601 203806 Deltasone 14 18266169080056643584
20410101 22070220410101 204101 Mysoline 65 201880230464323584
20410125 22070220410125 204101 Apo-Primidone 10 17135133354400677888
20420101 19130120420101 204201 Benemid 72 9731829094491881472
20420125 19130120420125 204201 Probenecid-AFT 127 6116590881899282432
20440101 07130120440101 204401 Procainamide Durules 11 2162966970742341632
20450101 14111420450101 204501 Prempak-C 14 7603347206443106304
20450201 14111420450201 204502 Prempak-C 14 7675404800481034240
20460101 16030720460101 204601 Cilicaine 145 2929428829883596800
20460201 16030720460201 204602 Cilicaine 157 12600938716475686912
20470101 25010720470101 204701 Natulan 127 12812240662078423040
20490101 22010420490101 204901 Kemadrin 157 12010961667732013056
20500201 14111420500201 205002 Menoprem 14 7819519988556890112
20500202 14111420500202 205002 Provette 14 18410284268132499456
20500301 14111420500301 205003 Premia 2.5 Continuous 14 7891577582594818048
20500401 14111420500401 205004 Premia 5 Continuous 14 7963635176632745984
20500411 14111420500411 205004 Menoprem Continuous 14 7747462394518962176
20500412 14111420500412 205004 Provette Continuous14 18338226674094571520
20500501 14111420500501 205005 Premia 5 14 8035692770670673920
20520101 14130120520101 205201 Gestone 6 3245801206148235264
20520201 14130120520201 205202 Gestone 6 3317858800186163200
20522525 14130120522525 205225 Utrogestan 19 1400233555530874880
20530101 14111420530101 205301 Nuvelle 15 4576899669547810816
20540101 22160120540101 205401 Avomine 155 3663793745586814976
20560101 14111420560101 205601 Estrapak 116 9403085013391507456
20560201 14111420560201 205602 Trisequens 8 15260791484484419584
20560301 14111420560301 205603 Kliogest 8 15332849078522347520
20560325 14111420560325 205603 Cliane 15 5728147717457182720
20560401 14111420560401 205604 Kliovance 8 15476964266598203392
20570101 31030120570101 205701 Brolene 155 3735851339624742912
20580101 31010120580101 205801 Vosol Otic 34 11605343032152424448
20580201 31010120580201 205802 Vosol 131 11677400626190352384
20590101 22070120590101 205901 AFT 127 5081302827813306368
20600101 07160120600101 206001 Inderal 65 7567286523586936832
20600102 07160120600102 206001 Angilol 35 7639344117624864768
20600103 07160120600103 206001 Cardinol 200 10227240446665424896
20600104 07160120600104 206001 Apo-Propranolol 10 7783459305700720640
20600201 07160120600201 206002 Inderal 65 7855516899738648576
20600202 07160120600202 206002 Angilol 35 7927574493776576512
20600203 07160120600203 206002 Apo-Propranolol 10 7999632087814504448
20600204 07160120600204 206002 Cardinol 200 10299298040703352832
20600401 07160120600401 206004 Inderal 65 8143747275890360320
20600501 07160120600501 206005 Angilol 35 8215804869928288256
20600502 07160120600502 206005 Cardinol 160 200 10371355634741280768
20600503 07160120600503 206005 Inderal 65 8359920058004144128
20600601 07160120600601 206006 Angilol LA 35 8431977652042072064
20600602 07160120600602 206006 Cardinol LA 200 10443413228779208704
20600603 07160120600603 206006 Inderal LA 65 8576092840117927936
20602525 07160120602525 206025 Roxane 220 15608521932373229568
20620101 14140120620101 206201 Abbott 2 3678146770375802880
20620125 14140120620125 206201 PTU 127 11052556964218273792
20630101 04070420630101 206301 Artex 108 13386168139591450624
20660101 28510420660101 206601 Sudomyl 16 2292394882494365696
20660202 28510420660202 206602 Sudafed 104 2364452476532293632
20680101 16010120680101 206801 Combantrin 14 11028882279849000960
20680201 16010120680201 206802 Combantrin 14 11100939873886928896
20680301 16010120680301 206803 Combantrin 14 11172997467924856832
20680401 16010120680401 206804 Combantrin 14 11245055061962784768
20690101 16160120690101 206901 Zinamide 72 17801716676786388992
20690125 16160120690125 206901 AFT-Pyrazinamide127 17081140736407109632
20700101 19010120700101 207001 Mestinon 211 5524396118202384384
20710101 01370420710101 207101 PSM 16 4378968884850458624
20710201 01370420710201 207102 PSM 16 4451026478888386560
20710202 01370420710202 207102 Apo-Pyridoxine 10 4523084072926314496
20710225 01370420710225 207102 Healtheries 59 4595141666964242432
20710226 01370420710226 207102 PyridoxADE 185 8862389175316381696
20710301 01370420710301 207103 PSM 16 4667199261002170368
20710302 01370420710302 207103 Apo-Pyridoxine 10 4739256855040098304
20710303 01370420710303 207103 Douglas 35 4811314449078026240
20710401 01370420710401 207104 PSM 16 4883372043115954176
20710402 01370420710402 207104 Apo-Pyridoxine 10 4955429637153882112
20710403 01370420710403 207104 Douglas 35 5027487231191810048
20710501 38010120710501 207105 PSM 16 17513784268285804544
20730101 16100120730101 207301 Fansidar 30 14775297727193415680
20770101 07130120770101 207701 Kinidin Durules 11 2235024564780269568
20780101 07130120780101 207801 Douglas 35 2307082158818197504
20780201 07130120780201 207802 Douglas 35 2379139752856125440
20790101 16120420790101 207901 Quinoc F 35 1291865689497272320
20790102 16120420790102 207901 Apo-Quinine 10 1363923283535200256
20790103 16120420790103 207901 Quinoc S 35 1435980877573128192
20790104 16120420790104 207901 Q 200 200 1508038471611056128
20790202 16120420790202 207902 Quinoc S 35 1580096065648984064
20790204 16120420790204 207902 PSM 16 1652153659686912000
20790205 16120420790205 207902 Q 300 200 1724211253724839936
20790206 16120420790206 207902 Apo-Quinine 10 1796268847762767872
20790207 16120420790207 207902 Quinoc F 35 1868326441800695808
20800301 01100320800301 208003 Zantac 143 3433831988149092352
20800325 01100320800325 208003 Peptisoothe 127 14372507035520466944
20800401 01100320800401 208004 Zantac 143 15306734577851039744
20800501 01100320800501 208005 Zantac 143 4070823054584840192
20800502 01100320800502 208005 Apo-Ranitidine 10 5171320944290955264
20800503 01100320800503 208005 Zanidin 200 10659586010892992512
20800525 01100320800525 208005 Arrow-Ranitidine 163 2201530142063329280
20800601 01100320800601 208006 Zantac 143 4142880648622768128
20800602 01100320800602 208006 Apo-Ranitidine 10 5387493726404739072
20800603 01100320800603 208006 Zanidin 200 10731643604930920448
20800625 01100320800625 208006 Arrow-Ranitidine 163 13595086343985168384
20802501 01100320802501 208025 Zantac-C 143 3361774394111164416
20802502 01100320802502 208025 Douglas 35 5603666508518522880
20802601 01100320802601 208026 Zantac-C 143 3998765460546912256
20802602 01100320802602 208026 Douglas 35 5747781696594378752
20870101 01370420870101 208701 PSM 16 5099544825229737984
20880101 16160120880101 208801 Rifadin 105 17873774270824316928
20880201 16160120880201 208802 Rifadin 155 4240254497890238464
20880301 16160120880301 208803 Rifadin 155 4024081715776454656
20880401 16160120880401 208804 Rifadin 155 4096139309814382592
20880501 16160120880501 208805 Rifadin 155 4168196903852310528
20900101 16031020900101 209001 Reverin 105 14036093860816355328
20960102 28300120960102 209601 Volmax 143 2569983085600833536
20960201 28300120960201 209602 Volmax 143 2642040679638761472
20960301 28300120960301 209603 Ventolin 143 14770863396798595072
20960325 28300120960325 209603 Salapin 127 10310260171632279552
20960326 28300120960326 209603 Broncolin 90 14744105681825038336
20960401 28300120960401 209604 Ventolin 143 8056214055691485184
20960501 28300120960501 209605 Ventolin 143 7984156461653557248
20960601 28301020960601 209606 Ventolin 143 8200329243767341056
20960602 28301020960602 209606 Asmol 200 10803701198968848384
20960603 28301020960603 209606 Salbuvent 35 1196083933066821632
20960604 28301020960604 209606 Respolin 1 6953126816101957632
20960901 28301020960901 209609 Ventolin Forte 143 8344444431843196928
20960902 28301020960902 209609 Salbuvent Forte 35 14958802919334346752
20961101 28301020961101 209611 Respolin Autohaler 1 7025184410139885568
20961201 28301020961201 209612 Ventodisk 76 16760242770282545152
20961302 28301020961302 209613 Ventodisk 75 17985221868927320064
20961401 28301020961401 209614 Respax 14 107936857475514368
20961402 28301020961402 209614 Ventolin Nebules 143 8416502025881124864
20961403 28301020961403 209614 Asmol 200 10875758793006776320
20961425 28301020961425 209614 Pharmacia 14 2485837460727136256
20961426 28301020961426 209614 Asthalin 166 10488153456425041920
20961501 28301020961501 209615 Respax 14 179994451513442304
20961502 28301020961502 209615 Ventolin Nebules 143 8488559619919052800
20961503 28301020961503 209615 Asmol 200 10947816387044704256
20961525 28301020961525 209615 Pharmacia 14 900570391892721664
20961526 28301020961526 209615 Asthalin 166 10560211050462969856
20961601 28301020961601 209616 Airomir 1 6016378093608894464
20961625 28301020961625 209616 Ventolin 143 8272386837805268992
20961626 28301020961626 209616 Salamol 132 15030860513372274688
20961627 28301020961627 209616 Respigen 200 17144487999329796096
20961701 28301020961701 209617 Salbutamol Turbuhaler 11 17120530740472184832
21140101 10040121140101 211401 Silvazine 87 12107196422953107456
21142525 10040121142525 211425 Flamazine 87 9870336773266079744
21250101 01010221250101 212501 Gaviscon 162 7786009073165533184
21252525 01010221252525 212525 Acidex 127 6777202756634542080
21252625 01010221252625 212526 Gaviscon Double Strength 162 6849260350672470016
21260101 19070121260101 212601 Myocrisin 155 4312312091928166400
21260201 19070121260201 212602 Myocrisin 155 4384369685966094336
21260301 19070121260301 212603 Myocrisin 155 4456427280004022272
21280101 04100121280101 212801 AstraZeneca 144 10484230398937137152
21280102 04100121280102 212801 Mayne 12 15132770947615948800
21280125 04100121280125 212801 Pharmalab 153 14123964631084957696
21280201 04100121280201 212802 Mayne 12 15204828541653876736
21280225 04100121280225 212802 Biomed 102 14340137413198741504
21280301 38010121280301 212803 PSM 16 17585841862323732480
21282525 38010121282525 212825 David Craig 120 18306417802703011840
21282526 38010121282526 212825 Biomed 102 16072632387527245824
21282527 38010121282527 212825 ABM 167 15496171635223822336
21282528 38010121282528 212825 Midwest 152 6069870433811824640
21282625 04100121282625 212826 Biomed 102 14268079819160813568
21282725 04100421282725 212827 Sodibic 157 18025799345550393344
21320101 35040821320101 213201 Calcium Disodium Versenate 35 571289749117992960
21330201 01310121330201 213302 Orabase 22 10016118820969644032
21330203 01310121330203 213302 Stomahesive 22 10088176415007571968
21330701 01310121330701 213307 Stomahesive 143 8466617765875154944
21350101 04100421350101 213501 PSM 16 17349335811677487104
21350201 04100121350201 213502 AstraZeneca 144 10556287992975065088
21350301 04100121350301 213503 AstraZeneca 144 8848847590108692480
21350302 04100121350302 213503 Pfizer 14 8410332666137673728
21350325 04100121350325 213503 Multichem 120 12828367199123013632
21350401 04100121350401 213504 Pfizer 14 8986793418441097216
21350402 04100121350402 213504 AstraZeneca 144 8920905184146620416
21350425 04100121350425 213504 Multichem 120 13044539981236797440
21350501 04100121350501 213505 Pharmacia 14 396167233627226112
21350502 04100121350502 213505 AstraZeneca 144 10628345587012993024
21350503 04100121350503 213505 Baxter 12 15781289293957300224
21350525 04100121350525 213505 Multichem 120 14804852599748034560
21350601 04100121350601 213506 Baxter 12 15853346887995228160
21350701 38010121350701 213507 PSM 16 17657899456361660416
21350901 04100121350901 213509 Baxter 12 15925404482033156096
21352525 04100121352525 213525 Biomed 102 14051907037047029760
21352625 28490221352625 213526 Biomed 102 1983136346461437952
21400101 01250721400101 214001 Microlax 14 468224827665154048
21400102 01250721400102 214001 Fleet 12 1208434747181629440
21400125 01250721400125 214001 Micolette 127 14298225129459548160
21420101 13190421420101 214201 Citravescent 200 11019873981082632192
21420102 13190421420102 214201 Ural 157 2637610747290451968
21440201 28400121440201 214402 Intal Spincaps 35 2714098273676689408
21440301 28400121440301 214403 Intal Forte CFC Free51 14140335259710914560
21440302 28400121440302 214403 Vicrom S 51 13552851903339036672
21440401 28400121440401 214404 Vicrom 51 13624909497376964608
21440501 28400121440501 214405 Intal 155 17861689538523430912
21440601 01040421440601 214406 Nalcrom 35 2786155867714617344
21440701 31030421440701 214407 Opticrom 155 12789791933174120448
21440725 31030421440725 214407 Cromolux 127 10848441426614681600
21440726 31030421440726 214407 Rexacrom 166 13270561089000570880
21440801 31030421440801 214408 Opticrom 155 12861849527212048384
21440901 28510221440901 214409 Rynacrom 155 17717574350447575040
21441201 28510221441201 214412 Rynacrom Forte 155 17789631944485502976
21441225 28510221441225 214412 Rex 166 10632268644500897792
21441301 28400121441301 214413 Vicrom 155 10004911498947723264
21441325 28400121441325 214413 Intal Forte CFC Free 155 10076969092985651200
21490101 01382021490101 214901 F-Tab 206 8206542583975903232
21490125 01382021490125 214901 PSM 179 8278600178013831168
21490201 01382021490201 214902 Hi-Fluor 200 8350657772051759104
21490301 38010121490301 214903 Sodium fluoride 120 17729957050399588352
21580101 01150421580101 215801 Ketur-Test 164 5468062639953281024
21580102 01150421580102 215801 Ketostix 15 11493036715468128256
21582525 01150421582525 215825 Ketostix 15 11565094309506056192
21582526 01150421582526 215825 Accu-Chek Ketur-Test 164 18147138150256869376
21600101 04100421600101 216001 Resonium-A 155 4528484874041950208
21640101 04040121640101 216401 Fibro-vein 6 3819728683661262848
21640201 04040121640201 216402 Fibro-vein 6 3891786277699190784
21640301 04040121640301 216403 STD 6 3963843871737118720
21640401 04040121640401 216404 Fibro-vein 6 4035901465775046656
21660101 22070221660101 216601 Epilim Crushable 162 4714550828763971584
21660201 22070221660201 216602 Epilim 162 4786608422801899520
21660202 22070221660202 216602 Valpro 200 11163989169158488064
21660301 22070221660301 216603 Epilim 162 4858666016839827456
21660302 22070221660302 216603 Valpro 200 11236046763196416000
21660401 22070221660401 216604 Epilim S/F Liquid 162 4570435640688115712
21660402 22070221660402 216604 Epilim Syrup 162 4642493234726043648
21660501 22070221660501 216605 Epilim IV 162 4498378046650187776
21690101 07160121690101 216901 Sotacor 22 8648150434155855872
21690102 07160121690102 216901 Mylan 200 12828915855425273856
21690125 07160121690125 216901 Apo-Sotalol 10 2955600505159548928
21690201 07160121690201 216902 Sotacor 22 8792265622231711744
21690202 07160121690202 216902 Mylan 200 12900973449463201792
21690225 07160121690225 216902 Apo-Sotalol 10 3027658099197476864
21690301 07160121690301 216903 Sotacor 157 11664189993982623744
21710101 16031321710101 217101 Trobicin 14 540282421703081984
21730101 16031321730101 217301 Rovamycin 155 13005964715287904256
21730201 16031321730201 217302 Rovamycin 155 13078022309325832192
21760101 07310421760101 217601 Spirotone 200 11452219545310199808
21760102 07310421760102 217601 Aldactone 55 6325086873827934208
21760125 07310421760125 217601 Spiractin 200 9655055695082422272
21760201 07310421760201 217602 Spirotone 200 11524277139348127744
21760203 07310421760203 217602 Aldactone 55 6469202061903790080
21760225 07310421760225 217602 Spiractin 200 9871228477196206080
21760301 07310421760301 217603 Biomed 102 6541259655941718016
21830101 25040121830101 218301 PSM 16 1951297788255928320
21880101 10310721880101 218801 Varidase 31 8811682997578235904
21910101 01101321910101 219101 Carafate 151 7188933577352937472
21930101 19040121930101 219301 Clinoril 72 2021666532433592320
21930102 19040121930102 219301 Daclin 200 13791014918008340480
21930103 19040121930103 219301 Saldac 35 2165781720509448192
21930125 19040121930125 219301 Aclin 200 16850101457574166528
21930201 19040121930201 219302 Daclin 200 13863072512046268416
21930202 19040121930202 219302 Clinoril 72 2309896908585304064
21930203 19040121930203 219302 Saldac 35 2381954502623232000
21930225 19040121930225 219302 Aclin 90 4179776960316047360
21940101 31030121940101 219401 Acetopt 19 8077037706409934848
21940102 31030121940102 219401 Bleph 10 5 8149095300447862784
21940201 38010121940201 219402 PSM 16 17802014644437516288
22050101 01040422050101 220501 Salazopyrin 14 4672600062117806080
22050102 01040422050102 220501 Colizine 200 11740449921461911552
22050201 01040422050201 220502 Salazopyrin EN 14 4744657656155734016
22050202 01040422050202 220502 Colizine EC 200 11812507515499839488
22050301 01040422050301 220503 Salazopyrin 14 612340015741009920
22050401 01040422050401 220504 Salazopyrin 14 4600542468079878144
22060101 19130122060101 220601 SPZ 116 9475142607429435392
22060102 19130122060102 220601 Anturan 116 9547200201467363328
22060201 19130122060201 220602 SPZ 116 9619257795505291264
22120101 22070222120101 221201 Ospolot 15 850398576805675008
22120201 22070222120201 221202 Ospolot 15 922456170843602944
22130101 10250122130101 221301 R V Paque 200 11884565109537767424
22130201 10250122130201 221302 Eversun 15+ 30 14990063134423646208
22130202 10250122130202 221302 Aquasun 30+ 112 4233517790146854912
22130203 10250122130203 221302 Aquasun 15+ 112 12647924146865438720
22130204 10250122130204 221302 Hamilton Sunscreen 167 2873991453611130880
22130205 10250122130205 221302 Elizabeth Arden Suncare 90 12719981740903366656
22130206 10250122130206 221302 UV Triplegard SPF 15+ 162 12792039334941294592
22130225 10250122130225 221302 Aquasun Oil Free Faces SPF30+ 112 4161460196108926976
22130401 10250122130401 221304 Aquasun 15 112 4305575384184782848
22130402 10250122130402 221304 Eversun 15+ 90 12936154523017150464
22130403 10250122130403 221304 Le Tan SPF 15+ 131 13008212117055078400
22130404 10250122130404 221304 UV Triplegard SPF 15+ 162 13080269711093006336
22130405 10250122130405 221304 Aquasun 30+ 112 4377632978222710784
22130406 10250122130406 221304 Aquasun Sensitive SPF 30+ 112 4449690572260638720
22130425 10250122130425 221304 Marine Blue Lotion SPF 30+ 167 5753463972686725120
22132526 10250122132526 221325 Marine Blue Lotion SPF 50+ 167 15828650757323751424
22180101 25040122180101 221801 Nolvadex 65 2023355382293856256
Trial Version
Not all rows exported
Code Name
1001 Acebutolol
1002 Lamotrigine
1003 Acetazolamide
1004 Vigabatrin
1005 Acebutolol with hydrochlorothiazide
1006 Acetic acid with hydroxyquinoline and ricinoleic acid
1009 Leuprorelin
1010 Dornase alfa
1011 Risperidone
1012 Midodrine
1013 Guanethidine sulphate
1015 Adrenaline
1016 Adrenaline borate
1017 Adrenaline hydrochloride
1019 Alclometasone dipropionate
1020 Alfacalcidol
1021 Alginic acid
1022 Lansoprazole
1023 Milk dextrin
1024 Apomorphine hydrochloride
1025 Nedocromil
1026 Allopurinol
1027 Polyvinyl alcohol with povidone
1029 Alprenolol
1031 Trandolapril
1032 Pergolide
1033 Betamethasone
1034 Mycophenolate mofetil
1036 Aluminium chloride
1037 Alendronate sodium
1038 Aluminium hydroxide
1039 Aluminium hydroxide with magnesium hydroxide
1040 Simethicone
1041 Polysiloxane
1043 Valaciclovir
1048 Amantadine hydrochloride
1050 Amiloride hydrochloride
1051 Amiloride hydrochloride with furosemide
1053 Amiloride hydrochloride with hydrochlorothiazide
1054 Aminocaproic acid
1055 Aminoglutethimide
1056 Aminophylline
1057 Amiodarone hydrochloride
1059 Amitriptyline
1060 Gabapentin (Neurontin)
1061 Losartan potassium
1062 Gabapentin
1063 Fluvastatin
1064 Dexamethasone with neomycin sulphate and polymyxin B sulphate
1065 Fluticasone
1066 Salmeterol
1067 Prednisolone acetate with sulphacetamide
1068 Losartan potassium with hydrochlorothiazide
1069 Amoxapine
1070 Amoxicillin clavulanate
1072 Amoxicillin
1074 Amphotericin B
1076 Dorzolamide hydrochloride
1077 Saquinavir
1078 Clozapine
1080 Amylobarbitone sodium
1081 Cefuroxime axetil
1082 Methylprednisolone aceponate
1083 Eformoterol fumarate
1084 Ascorbic acid
1085 Aprotinin
1086 Ritonavir
1087 Aspirin
1088 Tacrolimus
1092 Aspirin with paracetamol and codeine
1094 Atenolol
1095 Atenolol with chlorthalidone
1097 Atropine sulphate
1098 Pantoprazole
1099 Auranofin
1100 Azathioprine
1101 Malathion
1102 Indinavir
1103 Lodoxamide
1105 Applicator
1107 Tropisetron
1108 Beclomethasone dipropionate
1109 Stavudine [d4T]
1110 Insulin pen needles
1112 Allergy treatment set
1116 Bendroflumethiazide [Bendrofluazide]
1120 Benzathine benzylpenicillin
1122 Bismuth subcitrate, metronidazole and tetracycline
1124 Dicloxacillin
1125 Nefazodone
1126 Ursodeoxycholic acid
1127 Cilazapril with hydrochlorothiazide
1128 Benzoyl peroxide
1130 Benztropine mesylate
1132 Benzydamine hydrochloride
1133 Topiramate
1136 Benzylpenicillin sodium (penicillin G)
1137 Atorvastatin
1138 Tolcapone
1140 Olanzapine
1141 Betamethasone sodium phosphate with neomycin
1143 Betamethasone dipropionate
1144 Betamethasone sodium phosphate
1145 Betamethasone dipropionate with clotrimazole
1146 Betamethasone valerate with clioquinol
1147 Betamethasone valerate with gentamicin
1148 Betamethasone valerate with fusidic acid
1149 Betaxolol
1150 Betamethasone dipropionate with salicylic acid
1151 Bezafibrate
1156 Oestradiol valerate
1158 Anastrozole
1159 Bismuth subnitrate
1166 Bromazepam
1167 Bromocriptine mesylate
1168 Budesonide
1170 Nevirapine
1171 Bumetanide
1172 Nelfinavir
1173 Busulphan
1174 Wasp venom allergy treatment
1177 Omeprazole, amoxycillin and metronidazole
1178 Azithromycin
1179 Calamine
1181 Letrozole
1183 Quetiapine
1185 Isopropyl alcohol
1187 Cholecalciferol
1188 Calcitonin
1189 Calcitriol
1191 Calcium carbonate
1192 Insulin lispro
1193 Citalopram hydrobromide
1194 Fexofenadine hydrochloride
1195 Betahistine dihydrochloride
1197 Calcium chloride
1198 Calcium folinate
1199 Calcium gluconate
1205 Calcium polystyrene sulphonate
1209 Capreomycin sulphate
1216 Carbachol
1217 Carbamazepine
1221 Carbimazole
1223 Zidovudine [AZT] with lamivudine
1224 Castor oil with resorcinol, salicylic acid and undecylenic alkanolamide
1228 Cefaclor monohydrate
1230 Cefamandole nafate
1231 Cefoxitin sodium
1232 Ceftriaxone
1233 Cefuroxime sodium
1234 Cefalexin monohydrate
1235 Cephalothin sodium
1236 Cefazolin
1237 Cephradine
1238 Imiglucerase
1239 Compound hydroxybenzoate
1240 Propylene glycol
1244 Chlorhexidine gluconate
1247 Acarbose
1248 Interferon beta-1-alpha
1250 Latanoprost
1251 Omeprazole, amoxycillin and clarithromycin
1254 Candesartan cilexetil
1255 Chlorambucil
1257 Chloramphenicol with prednisolone
1258 Chloramphenicol with polymyxin b sulphate
1259 Chloramphenicol
1261 Chloramphenicol sodium succinate
1273 Chlormethiazole edisylate
1275 Calcium carbonate with aminoacetic acid
1276 Calcium carbonate with aminoacetic acid and dimethicone
1280 Chloroquine
1282 Chlorothiazide
1283 Chlorpromazine hydrochloride
1288 Chlortetracycline
1290 Chlortalidone [Chlorthalidone]
1291 Cholestyramine
1292 Choline theophyllinate
1297 Cimetidine
1303 Clindamycin
1306 Clindamycin phosphate
1308 Clobazam
1309 Clobetasol propionate
1310 Clobetasone butyrate
1312 Clofazimine
1313 Clofibrate
1314 Clomiphene citrate
1315 Clomipramine hydrochloride
1316 Clonazepam
1317 Clonidine
1318 Clonidine hydrochloride
1320 Clotrimazole
1324 Coal tar with allantoin, menthol, phenol and sulphur
1332 Codeine phosphate
1341 Colchicine
1345 Colestipol hydrochloride
1346 Colistin sulphomethate
1347 Colistin sulphate with neomycin and hydrocortisone
1357 Copper
1359 Corticotrophin
1360 Cortisone acetate
1361 Co-trimoxazole
1363 Crotamiton
1367 Cyclopenthiazide
1369 Cyclophosphamide
1370 Cyclopentolate hydrochloride
1371 Cytarabine
1372 Danazol
1373 Dantrolene
1374 Dapsone
1375 Dapsone with pyrimethamine
1378 Desferrioxamine mesylate
1379 Desipramine hydrochloride
1381 Dexamethasone with framycetin and gramicidin
1383 Dexamethasone
1385 Dexamethasone phosphate
1389 Dexamphetamine sulphate
1390 Dextromoramide acid tartrate
1391 Dextropropoxyphene
1392 Dextropropoxyphene with paracetamol
1393 Dextrose
1394 Dextrose with electrolytes
1397 Diazepam
1400 Dibromopropamidine isethionate
1401 Diclofenac sodium
1405 Dicyclomine hydrochloride
1407 Dienoestrol
1408 Diethylcarbamazine citrate
1409 Diflucortolone valerate
1410 Diflucortolone valerate with chlorquinaldol
1411 Diflunisal
1412 Digoxin
1418 Dimenhydrinate
1420 Dimethicone
1423 Diphemanil methylsulphate
1424 Diphenoxylate hydrochloride with atropine sulphate
1425 Dipivefrin hydrochloride
1427 Dipyridamole
1428 Disopyramide phosphate
1431 Distigmine bromide
1432 Disulfiram
1436 Domperidone
1437 Dothiepin hydrochloride
1438 Doxepin hydrochloride
1441 Dydrogesterone
1443 Econazole nitrate
1446 Compound electrolytes
1448 Emepronium carrageenate
1453 Ephedrine hydrochloride
1456 Ergometrine maleate
1458 Ergotamine tartrate
1459 Ergotamine tartrate with cyclizine
1460 Ergotamine tartrate with diphenhydramine
1462 Ergotamine tartrate with caffeine
1465 Erythromycin
1466 Erythromycin estolate
1468 Ethambutol
1475 Ethinyloestradiol with norethisterone
1476 Ethinyloestradiol with ethynodiol diacetate
1477 Ethinyloestradiol with desogestrel
1478 Ethinyloestradiol
1479 Ethinyloestradiol with gestodene
1481 Ethosuximide
1484 Ethynodiol diacetate
1487 Etidronate disodium
1492 Ipratropium bromide
1498 Folic acid
1499 Ferrous gluconate
1501 Ferrous sulphate with folic acid
1508 Fibrinolysin
1509 Fish liver oil
1510 Flecainide acetate
1511 Flucloxacillin magnesium
1512 Flucloxacillin
1513 Flucytosine
1515 Fludrocortisone acetate
1516 Flumetasone pivalate
1517 Flunisolide
1518 Fluocinolone acetonide
1521 Fluocortolone caproate with fluocortolone pivalate and cinchocaine
1527 Fluorometholone
1529 Fluorouracil sodium
1532 Flupenthixol decanoate
1533 Fluphenazine decanoate
1535 Fluphenazine hydrochloride
1536 Flurbiprofen
1537 Flutamide
1542 Framycetin sulphate with gramicidin
1544 Furosemide [Frusemide]
1546 Fusidic acid
1549 Gamma benzene hexachloride
1553 Gemfibrozil
1554 Gentamicin sulphate
1567 Glibenclamide
1568 Gliclazide
1569 Glipizide
1570 Glucagon hydrochloride
1572 Glucose oxidase
1574 Glycerol
1575 Glycerol with paraffin and cetyl alcohol
1577 Glyceryl trinitrate
1579 Griseofulvin
1580 Theophylline
1583 Haloperidol
1589 Heparin sodium
1594 Hexamine hippurate
1598 Hexoprenaline sulphate
1600 Homatropine hydrobromide
1603 Hyaluronidase
1604 Hydralazine hydrochloride
1606 Hydrocortisone acetate
1611 Hydrocortisone with miconazole
1612 Hydrocortisone with natamycin and neomycin
1613 Hydrocortisone with wool fat and mineral oil
1614 Hydrocortisone butyrate
1615 Hydrocortisone butyrate with chlorquinaldol
1617 Hydrocortisone
1619 Zinc oxide
1620 Miconazole nitrate
1624 Hydroxocobalamin
1625 Hydroxychloroquine
1626 Hydroxyurea
1629 Hyoscine hydrobromide
1630 Hypromellose with Dextran
1631 Hyoscine N-butylbromide
1632 Hydrocortisone with cinchocaine
1633 Hypromellose
1634 Hydrocortisone with lidocaine [Lignocaine], aluminium and zinc
1639 Idoxuridine
1642 Imipramine hydrochloride
1643 Indapamide
1645 Indomethacin
1648 Insulin neutral
1649 Insulin isophane
1653 Insulin syringes, non-disposable
1655 Insulin zinc suspension
1676 Iron polymaltose
1678 Isoconazole nitrate
1679 Isoniazid
1682 Isoprenaline
1686 Isopropyl myristate with mineral and pine needle oils
1688 Isotretinoin
1696 Ketoconazole
1697 Ketoprofen
1698 Ketotifen
1699 Labetalol
1715 Lidocaine [Lignocaine] with prilocaine
1716 Levobunolol
1717 Levodopa with benserazide
1718 Ethinyloestradiol with levonorgestrel
1719 Lidocaine [Lignocaine] hydrochloride
1720 Lincomycin hydrochloride
1721 Liothyronine
1723 Levodopa with carbidopa
1724 Levonorgestrel
1728 Loperamide hydrochloride
1729 Loprazolam mesylate
1730 Lorazepam
1731 Lormetazepam
1732 Loxapine succinate
1733 Lymecycline
1760 Maprotiline hydrochloride
1762 Mebendazole
1766 Medroxyprogesterone acetate
1769 Mefenamic acid
1772 Megestrol acetate
1773 Melphalan
1780 Meprobamate
1781 Mercaptopurine
1792 Mesterolone
1793 Metaraminol tartrate
1794 Metformin hydrochloride
1795 Methadone hydrochloride
1797 Methotrexate
1799 Levomepromazine maleate
1800 Methoxsalen
1801 Methyclothiazide
1805 Methyldopa with hydrochlorothiazide
1806 Methyldopa
1809 Methylphenidate hydrochloride
1810 Methylprednisolone acetate
1811 Methylprednisolone
1812 Methylprednisolone sodium succinate
1813 Methysergide dimaleate
1814 Metoclopramide hydrochloride
1815 Metoclopramide hydrochloride with paracetamol
1816 Methylprednisolone acetate with lidocaine [Lignocaine]
1817 Metoprolol succinate
1818 Metoprolol tartrate
1820 Metronidazole
1822 Metyrapone
1823 Mexiletine hydrochloride
1824 Mianserin hydrochloride
1825 Miconazole
1826 Spacer device autoclavable
1827 Peak flow meter
1828 Minocycline hydrochloride
1829 Spacer device
1830 Morphine hydrochloride
1831 Morphine sulphate
1832 Mask for spacer device
1835 Mupirocin
1838 Nadolol
1839 Nalidixic acid
1841 Naloxone hydrochloride
1843 Naphazoline hydrochloride
1849 Nefopam hydrochloride
1852 Neomycin sulphate
1853 Neomycin
1854 Neomycin with bacitracin and polymyxin b sulphate
1857 Neostigmine metilsulfate
1859 Niclosamide
1860 Nicotinamide
1861 Nicotinic acid
1862 Nicotinyl alcohol tartrate
1863 Nifedipine
1864 Nimorazole
1865 Nitrazepam
1867 Nitrofurantoin
1871 Norethisterone
1873 Norethisterone with mestranol
1874 Norfloxacin
1875 Ethinyloestradiol with norgestrel
1876 Nortriptyline hydrochloride
1881 Nystatin
1886 Oestradiol
1888 Oestrogens
1903 Orciprenaline sulphate
1906 Ornidazole
1908 Orphenadrine citrate
1909 Orphenadrine hydrochloride
1910 Ortho-tolidine
1911 Oxazepam
1912 Oxprenolol
1914 Oxybutynin
1915 Oxycodone pectinate
1916 Oxymetazoline hydrochloride
1917 Oxymetholone
1922 Oxytocin
1925 Pancreatic enzyme
1927 Papaveretum
1928 Papaverine hydrochloride
1929 Paracetamol
1931 Paracetamol with codeine
1942 Penicillamine
1944 Pentazocine
1949 Perhexiline maleate
1950 Pericyazine
1953 Pethidine hydrochloride
1955 Phenelzine sulphate
1956 Phenobarbitone sodium
1966 Phenoxybenzamine hydrochloride
1970 Phenoxymethylpenicillin (Penicillin V)
1971 Phentolamine mesylate
1972 Phenylephrine hydrochloride
1973 Phenylephrine hydrochloride with zinc sulphate
1978 Phenytoin sodium
1985 Physostigmine salicylate
1986 Phytomenadione
1987 Pilocarpine hydrochloride
1989 Pindolol with clopamide
1990 Pimozide
1991 Pindolol
1993 Piperonyl butoxide
1994 Pipothiazine palmitate
1995 Pirenzepine dihydrochloride
1996 Piroxicam
1998 Pivampicillin
2000 Pizotifen
2004 Polymyxin b sulphate with neomycin and gramicidin
2008 Polynoxylin
2010 Polyvinyl alcohol
2013 Phosphorus
2016 Potassium chloride
2031 Prazosin
2032 Prednisolone acetate
2033 Prednisolone acetate with neomycin and polymyxin b sulphate
2034 Prednisolone sodium phosphate
2035 Prednisolone acetate with phenylephrine and sulphacetamide
2036 Prednisolone
2038 Prednisone
2041 Primidone
2042 Probenecid
2044 Procainamide hydrochloride
2045 Oestrogens with norgestrel
2046 Procaine penicillin
2047 Procarbazine hydrochloride
2049 Procyclidine hydrochloride
2050 Oestrogens with medroxyprogesterone
2052 Progesterone
2053 Oestradiol with levonorgestrel
2054 Promethazine theoclate
2056 Oestradiol with norethisterone
2057 Propamidine isethionate
2058 Acetic acid with 1, 2- propanediol diacetate and benzethonium
2059 Paraldehyde
2060 Propranolol
2062 Propylthiouracil
2063 Protamine sulphate
2066 Pseudoephedrine hydrochloride
2068 Pyrantel embonate
2069 Pyrazinamide
2070 Pyridostigmine bromide
2071 Pyridoxine hydrochloride
2073 Pyrimethamine with sulphadoxine
2077 Quinidine bisulphate
2078 Quinidine sulphate
2079 Quinine sulphate
2080 Ranitidine
2087 Riboflavine
2088 Rifampicin
2090 Rolitetracycline
2096 Salbutamol
2114 Silver sulphadiazine
2125 Sodium alginate
2126 Sodium aurothiomalate
2128 Sodium bicarbonate
2132 Sodium calcium edetate
2133 Sodium carboxymethylcellulose
2135 Sodium chloride
2140 Sodium citrate with sodium lauryl sulphoacetate
2142 Sodium citro-tartrate
2144 Sodium cromoglycate
2149 Sodium fluoride
2158 Sodium nitroprusside
2160 Sodium polystyrene sulphonate
2164 Sodium tetradecyl sulphate
2166 Sodium valproate
2169 Sotalol
2171 Spectinomycin hydrochloride
2173 Spiramycin
2176 Spironolactone
2183 Stilboestrol
2188 Streptodornase
2191 Sucralfate
2193 Sulindac
2194 Sulphacetamide sodium
2205 Sulphasalazine
2206 Sulphinpyrazone
2212 Sulthiame
2213 Sunscreens, proprietary
2218 Tamoxifen citrate
2220 Tar with triethanolamine lauryl sulphate and fluorescein
2221 Tar with cade oil
2224 Temazepam
2237 Tetrabenazine
2238 Tetrabromophenol
2239 Tetracosactrin
2241 Tetracycline hydrochloride
2250 Thiamine hydrochloride
2252 Thioguanine
2255 Thioridazine hydrochloride
2257 Thiotepa
2260 Thiothixene
2262 Thymol glycerin
2263 Levothyroxine
2266 Timolol
2268 Timolol maleate with pilocarpine
2269 Tinidazole
2270 Tioconazole
2274 Tobramycin
2275 Tocainide hydrochloride
2277 Tolbutamide
2285 Tranylcypromine sulphate
2286 Tretinoin
2291 Triamcinolone hexacetonide
2293 Triamterene with hydrochlorothiazide
2295 Triazolam
2298 Trifluoperazine hydrochloride
2300 Trimethoprim
2301 Trimipramine maleate
2302 Trioxsalen
2304 Tripotassium dicitratobismuthate
2305 Tropicamide
2310 Tyloxapol
2312 Urea
2314 Vancomycin hydrochloride
2316 Vasopressin
2317 Verapamil hydrochloride
2318 Vidarabine
2319 Vinblastine sulphate
2320 Vincristine sulphate
2321 Vitamin A acetate
2322 Vitamin A with vitamins D and C
2328 Vitamin B complex
2330 Vitamins
2331 Warfarin sodium
2332 Water
2339 Wool fat with mineral oil
2340 Xylometazoline hydrochloride
2354 Zinc sulphate
2362 Acipimox
2363 Acitretin
2364 Baclofen
2367 Calcium carbimide
2373 Famotidine
2374 Fenoterol hydrobromide
2375 Fenoterol hydrobromide with ipratropium bromide
2377 Isosorbide dinitrate
2381 Mebeverine hydrochloride
2383 Morphine tartrate
2384 Olsalazine
2385 Povidone iodine
2387 Triamcinolone acetonide with gramicidin, neomycin and nystatin
2388 Tolciclate
2389 Triamcinolone acetonide
2390 Triamcinolone acetonide with lidocaine [Lignocaine] and nystatin
2394 Ciclopirox olamine
2398 Felodipine
2404 Terbutaline sulphate
2413 Alpha tocopheryl acetate
2414 Charcoal
2419 Chenodeoxycholic acid
Trial Version
Not all rows exported
Code ChemicalCode Name Units ATCCode Weight
100101 1001 Tab 400 mgtab 71601 400
100102 1001 Cap 100 mgcap 71601 100
100103 1001 Cap 200 mgcap 71601 200
100201 1002 Tab 25 mg tab 220703 25
100202 1002 Tab 50 mg tab 220703 50
100203 1002 Tab 100 mgtab 220703 100
100225 1002 Tab dispersible 5 mg tab 220702 5
100226 1002 Tab dispersible 25 mg tab 220702 25
100227 1002 Tab dispersible 50 mg tab 220702 50
100228 1002 Tab dispersible 100 mg tab 220702 100
100229 1002 Tab dispersible 200 mg tab 220702 200
100230 1002 Tab dispersible 2 mg tab 220702 2
100301 1003 Tab 250 mgtab 310306 250
100302 1003 Sodium inj 500 mg inj 310306 500
100401 1004 Tab 500 mgtab 220702 500
100501 1005 Tab 200 mg with hydrochlorothiazide 12.5 mg tab 71901 200
100601 1006 Jelly with glacial acetic acid 0.94%, hydroxyquinoline sulphate 0.025%, glycerol 5% and ricinoleic acid 0.75% with applicator g 131001
100901 1009 Inj 3.75 mginj 141603 3.75
100902 1009 Inj 11.25 mginj 141603 11.25
100925 1009 Inj 7.5 mg inj 141603 7.5
100926 1009 Inj 22.5 mginj 141603 22.5
100927 1009 Inj 30 mg inj 141603 30
100928 1009 Inj 45 mg inj 141603 45
100929 1009 Inj 3.75 mg prefilled syringe inj 141603 3.75
100930 1009 Inj 11.25 mg prefilled syringe inj 141603 11.25
100931 1009 Inj 30 mg prefilled syringe inj 141603 30
101001 1010 Nebuliser soln, 2.5 mg per 2.5 ml ampoule amp 284902 2.5
101101 1011 Tab 1 mg tab 222201 1
101102 1011 Tab 2 mg tab 222201 2
101103 1011 Tab 3 mg tab 222201 3
101104 1011 Tab 4 mg tab 222201 4
101105 1011 Oral liq 1 mg per ml ml 222201 1
101125 1011 Tab 0.5 mgtab 222201 0.5
101126 1011 Inj 25 mg vial inj 222204 25
101127 1011 Inj 37.5 vialinj 222204 37
101128 1011 Inj 50 mg vial inj 222204 50
101129 1011 Tab orodispersible 0.5 mg tab 222201
101130 1011 Tab orodispersible 1 mg tab 222201 1
101131 1011 Tab orodispersible 2 mg tab 222201 2
101201 1012 Tab 2.5 mgtab 71501 2.5
101202 1012 Tab 5 mg tab 71501 5
101303 1013 Inj 10 mg per ml 1 ml inj 70101 10
101501 1015 Inj 1 in 1,000, 1 ml ampoule inj 73701
101502 1015 Inj 1 in 10,000, 10 ml ampoule inj 73701
101503 1015 Aerosol inhaler dose 280101
101601 1016 Eye drops 0.5% ml 310309
101602 1016 Eye drops 1% ml 310309
101701 1017 Eye drops 1% ml 310309
101903 1019 Crm 0.05%g 101101
101904 1019 Oint 0.05%g 101101
102001 1020 Cap 0.25 mcg cap 13710 0.25
102002 1020 Cap 1 mcg cap 13710 1
102003 1020 Oral drops 2 mcg per ml ml 13710
102101 1021 Tab 500 mg with magnesium trisil 25 mg, aluminium hydroxide gel, dried 100 mg, and sodium bicarbonate 170 mg -- peppermint flavour tab 10102 500
102102 1021 Powder 1 g with magnesium trisil 50 mg, aluminium hydroxide gel, dried, 200 mg and sodium bicarbonate 340 mg per 2 g g 10102 25
102103 1021 Sodium alginate 225 mg and magnesium alginate 87.5 mg per sachet sach 10102 225
102201 1022 Cap 30 mg cap 11010 30
102225 1022 Cap 15 mg cap 11010 15
102301 1023 Tab. 1.3 g dried milk with glucose and dextrins, 130 mg magnesium trisilicate, 100 mg magnesium hydroxide, 65 mg magnesium carbonate, 65 mg calcium carbonate tab 10102 130
102401 1024 Inj 10 mg per ml, 1 ml inj 220101 10
102425 1024 Inj 10 mg per ml, 2 ml inj 220101
102501 1025 Aerosol inhaler, 2 mg per dose dose 284001 2
102502 1025 Aerosol inhaler, 2 mg per dose CFC-free dose 284001 2
102601 1026 Tab 100 mgtab 191301 100
102602 1026 Tab 300 mgtab 191301 300
102702 1027 Eye drops 1.4% with povidone 0.6% ml 310313
102901 1029 Tab long-acting 260 mg tab 71601 260
103101 1031 Cap 0.5 mgcap 70701 0.5
103102 1031 Cap 1 mg cap 70701 1
103103 1031 Cap 2 mg cap 70701 2
103201 1032 Tab 0.25 mg tab 220101 0.25
103202 1032 Tab 1 mg tab 220101 1
103301 1033 Metered aqueous nasal spray 0.02% with naphazoline nitrate 0.02% dose 285102
103401 1034 Cap 250 mgcap 250701 250
103426 1034 Tab 500 mgtab 250701 500
103427 1034 Powder for oral liq 1 g per 5 ml ml 250701
103601 1036 Soln 20% ml 103104
103602 1036 powder g 380101
103701 1037 Tab 10 mg tab 190802 10
103702 1037 Tab 40 mg tab 190804 40
103725 1037 Tab 70 mg tab 190802 70
103802 1038 Gel ml 10102
103804 1038 Tab 600 mgtab 10104 600
103901 1039 Gel ml 10102
104001 1040 Tab aluminium hydroxide 200 mg with magnesium hydroxide 200 mg and activated simethicone 20 mg tab 10102 200
104002 1040 Oral liq aluminium hydroxide 200 mg with magnesium hydroxide 200 mg and activated simethicone 20 mg per 5 ml ml 10102 200
104003 1040 Oral liq aluminium hydroxide 215 mg with magnesium hydroxide 80 mg and activated simethicone 25 mg per 5 ml ml 10102 215
104101 1041 Tab aluminium hydroxide 250 mg with magnesium trisil 120 mg, magnesium hydroxide 120 mg and polysiloxane 10 mg tab 10102 250
104301 1043 Tab 500 mgtab 161907 500
104801 1048 Cap 100 mgcap 220101 100
105001 1050 Tab 5 mg tab 73104 5
105004 1050 Oral liq 1 mg per ml ml 73104
105101 1051 Tab 5 mg with furosemide 40 mg tab 73107 5
105301 1053 Tab 5 mg with hydrochlorothiazide 50 mg tab 73107 5
105401 1054 Tab 500 mgtab 40401 500
105501 1055 Tab 250 mgtab 250401 250
105601 1056 Inj 25 mg per ml, 10 ml inj 284302 250
105604 1056 Oral liq 25 mg per ml ml 284302
105701 1057 Tab 100 mgtab 71301 100
105702 1057 Tab 200 mgtab 71301 200
105703 1057 Inj 50 mg per ml, 3 ml ampoule inj 71301 150
105901 1059 Tab 10 mg tab 220501 10
105902 1059 Tab 25 mg tab 220501 25
105903 1059 Tab 50 mg tab 220501 50
105904 1059 Cap 75 mg cap 220501 75
105905 1059 Oral liq 10 mg per 5 ml ml 220501 2
106001 1060 Cap 300 mgcap 220702 300
106002 1060 Cap 400 mgcap 220702 400
106025 1060 Cap 100 mgcap 220702 100
106026 1060 Tab 600 mgtab 220702
106101 1061 Tab 50 mg tab 70703 50
106102 1061 Tab 12.5 mg tab 70703 12.5
106125 1061 Tab 100 mgtab 70703 100
106126 1061 Tab 25 mg tab 70703 25
106201 1062 Cap 300 mgcap 220702 300
106202 1062 Cap 400 mgcap 220702 400
106225 1062 Cap 100 mgcap 220702 100
106301 1063 Cap 20 mg cap 73204 20
106302 1063 Cap 40 mg cap 73204 40
106401 1064 Eye drops 0.1% with neomycin sulphate 0.35% and polymyxin b sulphate 6,000 u per ml ml 310304
106402 1064 Eye oint 0.1% with neomycin sulphate 0.35% and polymyxin b sulphate 6,000 u per g g 310304
106501 1065 Aerosol inhaler, 25 mcg per dose dose 281001 25
106502 1065 Aerosol inhaler, 50 mcg per dose dose 281001 50
106503 1065 Aerosol inhaler, 125 mcg per dose dose 281001 125
106504 1065 Aerosol inhaler, 250 mcg per dose dose 281001 250
106505 1065 Powder for inhalation, 50 mcg per dose, 4 doses per disk disk 281001
106506 1065 Powder for inhalation, 100 mcg per dose, 4 doses per disk disk 281001
106507 1065 Powder for inhalation, 250 mcg per dose, 4 doses per disk disk 281001
106508 1065 Powder for inhalation, 500 mcg per dose, 4 doses per disk disk 281001
106509 1065 Aerosol inhaler, 125 mcg per dose CFC-free dose 281001 125
106510 1065 Aerosol inhaler, 250 mcg per dose CFC-free dose 281001 250
106511 1065 Powder for inhalation, 50 mcg per dose dose 281001 50
106512 1065 Powder for inhalation, 100 mcg per dose dose 281001 100
106513 1065 Powder for inhalation, 250 mcg per dose dose 281001 250
106525 1065 Aerosol inhaler, 50 mcg per dose CFC-free dose 281001 50
106601 1066 Aerosol inhaler, 25 mcg per dose dose 282402 25
106602 1066 Powder for inhalation, 50 ug per dose, 4 doses per disk disk 282402
106603 1066 Powder for inhalation, 50 mcg per dose, breath activated dose 282402 50
106625 1066 Aerosol inhaler CFC-free, 25 mcg per dose dose 282402
106701 1067 Eye oint 0.2% with sulphacetamide sodium 10% g 310304
106805 1068 Tab 50 mg with hydrochlorothiazide 12.5 mg tab 70705 50
106901 1069 Tab 25 mg tab 220501 25
106902 1069 Tab 50 mg tab 220501 50
106903 1069 Tab 100 mgtab 220501 100
107001 1070 Tab amoxicillin 500 mg with potassium clavulanate 125 mg tab 160307 500
107002 1070 Grans for oral liq amoxicillin 125 mg with potassium clavulanate 31.25 mg per 5 ml ml 160307
107003 1070 Grans for oral liq amoxicillin 250 mg with potassium clavulanate 62.5 mg per 5 ml ml 160307
107201 1072 Tab chewable 250 mg tab 160307 250
107202 1072 Cap 250 mgcap 160307 250
107203 1072 Cap 500 mgcap 160307 500
107204 1072 Drops 125 mg per 1.25 ml ml 160307 100
107205 1072 Grans for oral liq 125 mg per 5 ml ml 160307
107206 1072 Grans for oral liq 250 mg per 5 ml ml 160307
107207 1072 Sachets 3 gsach 160307
107208 1072 Inj 1 g inj 160307 1000
107209 1072 Inj 500 mg inj 160307 500
107210 1072 Inj 250 mg inj 160307 250
107401 1074 Lozenges 10 mg tab 13107 10
107402 1074 Oral liq 100 mg per ml ml 13107
107601 1076 Eye drops 2% ml 310306
107701 1077 Cap 200 mgcap 162005 200
107725 1077 Tab 500 mgtab 162005 500
107801 1078 Tab 25 mg tab 222201 25
107802 1078 Tab 100 mgtab 222201 100
107825 1078 Tab 50 mg tab 222201 50
107826 1078 Tab 200 mgtab 222201 200
107827 1078 Suspension 50 mg per ml ml 222201 100
108001 1080 Inj 500 mg inj 222801 500
108102 1081 Tab 250 mgtab 160301 250
108201 1082 Crm 0.1% g 101101
108202 1082 Oint 0.1% g 101101
108301 1083 Powder for inhalation, 12 mcg per dose, and monodose device dose 282402 12
108302 1083 Powder for inhalation, 12 mcg per dose, breath activated dose 282402 12
108303 1083 Powder for inhalation, 6 mcg per dose, breath activated dose 282402 6
108401 1084 Tab 100 mgtab 13707 100
108402 1084 Tab 50 mg tab 13707 50
108403 1084 Powder g 380101
108425 1084 Tab 250 mgtab 13707 250
108501 1085 Inj 10,000 mcg per ml 50 ml inj 40401 10000
108601 1086 Cap 100 mgcap 162005 100
108602 1086 Oral liq 80 mg per ml ml 162005 80
108625 1086 Tab 100 mgtab 162005 100
108701 1087 Tab dispersible 300 mg tab 220404 300
108702 1087 Tab 300 mgtab 220404 300
108705 1087 Tab EC 300 mg tab 220404 300
108706 1087 Tab EC 650 mg tab 220404 650
108707 1087 Tab SR 650 mg tab 220404 650
108725 1087 Tab 100 mgtab 40701
108801 1088 Cap 1 mg cap 250706 1
108802 1088 Cap 5 mg cap 250706 5
108825 1088 Cap 0.5 mgcap 250706 0.5
109201 1092 Tab aspirin 250 mg with paracetamol 250 mg and codeine phosphate 8 mg tab 220405 250
109401 1094 Tab 50 mg tab 71601 50
109402 1094 Tab 100 mgtab 71601 100
109403 1094 Inj 0.5 mg per ml, 10 ml inj 71601 5
109425 1094 Oral liq 25 mg per 5 ml ml 71601
109501 1095 Tab 100 mg with chlorthalidone 25 mg tab 71901 100
109502 1095 Tab 50 mg with chlorthalidone 12.5 mg tab 71901 50
109701 1097 Tab 600 mcg tab 71301 600
109702 1097 Inj 400 mcg, 1 ml inj 71301 400
109703 1097 Inj 600 mcg per ml, 1 ml ampoule inj 71301 600
109704 1097 Inj 1200 mcg, 1 ml inj 71301 1200
109705 1097 Eye drops 0.5% ml 310310
109706 1097 Eye drops 1% ml 310310
109801 1098 Tab EC 40 mg tab 11010 40
109802 1098 Tab EC 20 mg tab 11010 20
109825 1098 Inj 40 mg inj 11010
109901 1099 Tab 3 mg tab 190701 3
110001 1100 Tab 50 mg tab 250701 50
110002 1100 Inj 50 mg inj 250701 50
110101 1101 Liq 0.5% ml 101701
110125 1101 Shampoo 1% ml 101701
110126 1101 Crm shampoo 1% g 101701
110201 1102 Cap 200 mgcap 162005 200
110202 1102 Cap 400 mgcap 162005 400
110301 1103 Eye drops 0.1% ml 310304
110501 1105 Applicator dev 130105
110701 1107 Cap 5 mg cap 221601 5
110801 1108 Aerosol inhaler, 50 mcg per dose dose 281001 50
110802 1108 Aerosol inhaler, 100 mcg per dose dose 281001 100
110803 1108 Aerosol inhaler, 250 mcg per dose dose 281001 250
110804 1108 Aerosol inhaler, 50 mcg per dose, breath activated dose 281001 50
110805 1108 Aerosol inhaler, 100 mcg per dose, breath activated dose 281001 100
110806 1108 Aerosol inhaler, 250 mcg per dose, breath activated dose 281001 250
110807 1108 Powder for inhalation, 100 mcg per dose, 8 doses per disk disk 281001 100
110808 1108 Powder for inhalation, 200 mcg per dose, 8 doses per disk disk 281001 200
110809 1108 Powder for inhalation, 400 mcg per dose, 8 doses per disk disk 281001 400
110811 1108 Metered aerosol nasal spray 50 mcg per dose dose 285102
110812 1108 Metered aerosol nasal spray 100 mcg per dose dose 285102
110813 1108 Metered aqueous nasal spray, 50 mcg per dose dose 285102 50
110814 1108 Metered aqueous nasal spray, 100 mcg per dose dose 285102 100
110815 1108 Aerosol inhaler with spacer, 100 mcg per dose dose 281001 100
110816 1108 Aerosol inhaler with spacer, 250 mcg per dose dose 281001 250
110825 1108 Aerosol inhaler, 50 mcg per dose CFC-free dose 281001 50
110826 1108 Aerosol inhaler, 100 mcg per dose CFC-free dose 281001 100
110827 1108 Aerosol inhaler, 250 mcg per dose CFC-free dose 281001 250
110901 1109 Cap 15 mg cap 162003 15
110902 1109 Cap 20 mg cap 162003 20
110903 1109 Cap 30 mg cap 162003 30
110904 1109 Cap 40 mg cap 162003 40
110905 1109 Powder for oral soln 1 mg per ml ml 162003
111001 1110 29 g x 12.7 mm dev 11509
111002 1110 31 g x 8 mmdev 11509
111025 1110 31 g x 5 mmdev 11509
111026 1110 31 g x 6 mmdev 11509
111027 1110 32 g x 4 mmdev 11509
111201 1112 Extract of inhaled allergens txpk 280101
111601 1116 Tab 2.5 mgtab 73110 2.5
111602 1116 Tab 5 mg tab 73110 5
112001 1120 Inj 600,000 u inj 160307 600000
112002 1120 Inj 1.2 mega u per 2.3 ml inj 160307 1200000
112025 1120 Injection 1.2 mega u inj 160307
112201 1122 Bismuth subcitrate tab 120 mg x 56, metronidazole tab 400 mg x 42 and tetracycline cap 250 mg x 112 txpk 11002 120
112401 1124 Cap 250 mgcap 160307 250
112402 1124 Cap 500 mgcap 160307 500
112403 1124 Grans for oral liq 62.5 mg per 5 ml ml 160307 12.5
112404 1124 Grans for oral liq 125 mg per 5 ml ml 160307 25
112405 1124 Inj 500 mg inj 160307 500
112406 1124 Inj 1 g inj 160307 1000
112501 1125 Tab 100 mgtab 220507 100
112502 1125 Tab 200 mgtab 220507 200
112601 1126 Cap 300 mgcap 12201 300
112625 1126 Cap 250 mgcaps 12201
112701 1127 Tab 5 mg with hydrochlorothiazide 12.5 mg tab 70702 5
112801 1128 Lotn 10% ml 100101
112802 1128 Lotn 5% ml 100101
112803 1128 Gel 10% g 100101
112804 1128 Gel 2.5% g 100101
112805 1128 Gel 5% g 100101
113001 1130 Tab 2 mg tab 220104 2
113002 1130 Inj 1 mg per ml, 2 ml inj 220104 2
113201 1132 Soln 0.15%ml 13101
113301 1133 Tab 25 mg tab 220702 25
113302 1133 Tab 50 mg tab 220702 50
113303 1133 Tab 100 mgtab 220702 100
113304 1133 Tab 200 mgtab 220702 200
113325 1133 Sprinkle cap 15 mg cap 220702
113326 1133 Sprinkle cap 25 mg cap 220702
113601 1136 Inj 600 mg (1 million units) vial inj 160307 600
113701 1137 Tab 10 mg tab 73204 10
113702 1137 Tab 20 mg tab 73204 20
113703 1137 Tab 40 mg tab 73204 40
113725 1137 Tab 80 mg tab 73204 80
113801 1138 Tab 100 mgtab 220101 100
114001 1140 Tab 5 mg tab 222201 5
114002 1140 Tab 10 mg tab 222201 10
114003 1140 Tab 2.5 mgtab 222201 2.5
114015 1140 Inj 210 mg vial inj 222204 210
114016 1140 Inj 300 mg vial inj 222204 300
114017 1140 Inj 405 mg vial inj 222204 405
114027 1140 Tab orodispersible 5 mg tab 222201 5
114028 1140 Tab orodispersible 10 mg tab 222201 10
114101 1141 Ear/Eye drops 0.1% with neomycin sulphate 0.5% ml 310201
114310 1143 Scalp lotn 0.05% ml 102201
114311 1143 Scalp lotn propylene glycol base 0.05% ml 102201
114312 1143 Crm 0.05%g 101101
114313 1143 Oint 0.05%g 101101
114314 1143 Crm 0.05% in propylene glycol base g 101101
114315 1143 Oint 0.05% in propylene glycol base g 101101
114401 1144 Tab 500 mcg tab 140701 500
114402 1144 Inj 4 mg per ml, 1 ml inj 140701 4
114407 1144 Ear/Eye drops 0.1% ml 310201
114501 1145 Crm 0.05% with clotrimazole 1% g 101104
114602 1146 Crm 0.1% with clioquinol 3% g 101104
114603 1146 Oint 0.1% with clioquinol 3% g 101104
114725 1147 Crm 0.05% with gentamicin sulphate 0.1% g 101104
114801 1148 Crm 0.1% with fusidic acid 2% g 101104
114901 1149 Eye drops 0.25% ml 310305
114902 1149 Eye drops 0.5% ml 310305
115001 1150 Lotn 0.05% with salicylic acid 2% ml 101104
115002 1150 Oint 0.05% with salicylic acid 3% g 101104
115101 1151 Tab 200 mgtab 73201 200
115102 1151 Tab long-acting 400 mg tab 73201 400
115601 1156 Tab 1 mg tab 141104 1
115602 1156 Tab 2 mg tab 141104 2
115801 1158 Tab 1 mg tab 250404 1
115901 1159 Tab 300 mg with frangula bark 25 mg, magnesium carbonate 400 mg and sodium bicarbonate 200 mg tab 11013 300
115902 1159 Bismuth subnitrate g 380101
116601 1166 Tab 1.5 mgtab 222501
116602 1166 Tab 3 mg tab 222501
116701 1167 Tab 2.5 mgtab 220101 2.5
116703 1167 Tab 10 mg tab 220101 10
116704 1167 Cap 10 mg cap 220101 10
116725 1167 Cap 5 mg cap 220101 5
116801 1168 Aerosol inhaler, 200 mcg per dose dose 281001 200
116802 1168 Powder for inhalation, 100 mcg per dose dose 281001 100
116803 1168 Powder for inhalation, 200 mcg per dose dose 281001 200
116804 1168 Powder for inhalation, 400 mcg per dose dose 281001 400
116805 1168 Nebuliser soln, 500 mcg per ml, 2 ml neb 281001 1000
116807 1168 Metered aqueous nasal spray, 50 mcg per dose dose 285102 50
116808 1168 Metered aqueous nasal spray, 100 mcg per dose dose 285102 100
116809 1168 Cap 3 mg cap 10404 3
117001 1170 Tab 200 mgtab 162001 200
117025 1170 Oral suspension 10 mg per ml ml 162001 10
117101 1171 Tab 1 mg tab 73101 1
117102 1171 Inj 500 mcg per ml, 4 ml vial inj 73101 2000
117201 1172 Tab 250 mgtab 162005 250
117202 1172 Powder 50 mg per g g 162005 50
117301 1173 Tab 2 mg tab 250101 2
117401 1174 Treatment kit (Yellow jacket venom) - 1 vial 550 mcg freeze dried vespula venom, 1 diluent 9 ml, 1 diluent 1.8 ml txpk 280101
117402 1174 Treatment kit (Paper wasp venom) - 1 vial 550 mcg freeze dried polister venom, 1 diluent 9 ml, 1 diluent 1.8 ml txpk 280101
117701 1177 Omeprazole cap 40 mg x 7, amoxycillin cap 500 mg x 21, metronidazole tab 400 mg x 21 txpk 11002 40
117801 1178 Tab 500 mgtab 160304 500
117825 1178 Grans for oral liq 200 mg per 5 ml ml 160304 600
117826 1178 Tab 250 mgtab 160304 250
117901 1179 Crm, aqueous, BP g 100801
117902 1179 Lotn, BP ml 100801
117903 1179 Lotn, oily BPml 100801
117904 1179 Calamine g 380101
118101 1181 Tab 2.5 mgtab 250404 2.5
118301 1183 Tab 25 mg tab 222201 25
118302 1183 Tab 100 mgtab 222201 100
118303 1183 Tab 200 mgtab 222201 200
118304 1183 Tab 150 mgtab 222201 150
118325 1183 Tab 300 mgtab 222201 300
118501 1185 purified ml 380101
118701 1187 Tab 1.25 mg (50,000 iu) tab 13710 50000
118802 1188 Inj 100 iu per ml, 1 ml inj 140404 100
118803 1188 Inj 160 iu per ml, 2 ml inj 190806 320
118804 1188 Inj 400 iu per 2 ml, 2 ml inj 190806 400
118901 1189 Cap 0.25 mcg cap 13710 0.25
118902 1189 Cap 0.5 mcg cap 13710 0.5
118903 1189 Oral liq 1 mcg per ml ml 13710 1
119102 1191 Tab 1.25 g (500 mg elemental) tab 13810 1250
119103 1191 Tab 1.5 g (600 mg elemental) tab 13810 1500
119104 1191 powder g 380101
119125 1191 Tab dispersible 2.5 g tab 13810 2500
119126 1191 Tab eff 1.75 g (1 g elemental) tab 13810 1000
119127 1191 Oral liq 1,250 mg per 5 ml (500 mg elemental per 5 ml) ml 10104 1250
119201 1192 Inj 100 u per ml, 3 ml inj 11309 300
119202 1192 Inj 100 u per ml, 10 ml ml 11309
119301 1193 Tab 20 mg tab 220507 20
119401 1194 Cap 60 mg cap 280401 60
119402 1194 Tab 120 mgtab 280401 120
119403 1194 Tab 60 mg tab 280401 60
119501 1195 Tab 16 mg tab 221601 16
119502 1195 Tab 4 mg tab 221601 4
119701 1197 Inj 10%, 10 ml inj 13810 10
119801 1198 Tab 15 mg tab 250104 15
119802 1198 Inj 3 mg per ml, 1 ml inj 250104 3
119803 1198 Inj 15 mg inj 250104 15
119804 1198 Inj 50 mg inj 250104 50
119825 1198 Inj 300 mg inj 250104 300
119826 1198 Inj 1 mg for ECP mg 250104 1
119827 1198 Inj 100 mg inj 250104 100
119828 1198 Inj 1 g inj 250104 1000
119901 1199 Inj 10%, 10 ml inj 13810 10
120501 1205 Powder g 41004
120901 1209 Inj 1 g inj 161601
121601 1216 Eye drops 1.5% ml 310309
121602 1216 Eye drops 3% ml 310309
121703 1217 Oral liq 100 mg per 5 ml ml 220702 20
121704 1217 Tab 200 mgtab 220702 200
121705 1217 Tab long-acting 200 mg tab 220702 200
121706 1217 Tab 400 mgtab 220702 400
121707 1217 Tab long-acting 400 mg tab 220702 400
122101 1221 Tab 5 mg tab 141401 5
122301 1223 Tab 300 mg with lamivudine 150 mg tab 162003 300
122401 1224 Soln 2.5% with resorcinol 0.5%, salicylic acid 1.5% and undecylenic alkanolamide 0.25% ml 102201
122801 1228 Cap 250 mgcap 160301 250
122802 1228 Grans for oral liq 125 mg per 5 ml ml 160301 25
123001 1230 Inj 500 mg inj 160301 500
123002 1230 Inj 1 g inj 160301 1000
123101 1231 Inj 1 g inj 160301 1000
123201 1232 Inj 250 mg inj 160301 250
123202 1232 Inj 500 mg vial inj 160301 500
123203 1232 Inj 1 g vial inj 160301 1000
123301 1233 Inj 250 mg inj 160301 250
123302 1233 Inj 750 mg inj 160301 750
123303 1233 Inj 1.5 g inj 160301 1500
123401 1234 Tab 500 mgtab 160301 500
123402 1234 Cap 250 mgcap 160301 250
123403 1234 Grans for oral liq 125 mg per 5 ml ml 160301 625
123404 1234 Grans for oral liq 250 mg per 5 ml ml 160301 1250
123425 1234 Cap 500 mgcap 160301 500
123501 1235 Inj 1 g inj 160301 1000
123601 1236 Inj 500 mg vial inj 160301 500
123602 1236 Inj 1 g vial inj 160301 1000
123701 1237 Cap 250 mgcap 160301 250
123702 1237 Cap 500 mgcap 160301 500
123703 1237 Inj 500 mg inj 160301 500
123704 1237 Inj 1 g inj 160301 1000
123801 1238 Inj 40 iu per ml, 200 iu vial inj 12802 200
123825 1238 Inj 40 iu per ml, 400 iu vial inj 12802 400
123901 1239 Soln ml 380101
124001 1240 Liq ml 380101
124401 1244 Obstetric crm 1% ml 101301
124402 1244 Soln 4% ml 101301
124403 1244 Soln 5% ml 101301
124404 1244 Soln 20% ml 101301
124406 1244 Handrub 0.5% with ethanol 70% ml 101301
124425 1244 Handrub 1% with ethanol 70% ml 101301
124426 1244 Mouthwash 0.2% ml 13101 0.2
124701 1247 Tab 50 mg tab 11311 50
124702 1247 Tab 100 mgtab 11311 100
124801 1248 Inj 6 million iu per vial inj 222601 6000000
124825 1248 Inj 6 million iu prefilled syringe inj 222601
124826 1248 Injection 6 million iu per 0.5 ml pen injector inj 222601
125001 1250 Eye drops 50 mcg per ml, 2.5 ml ml 310308
125101 1251 Omeprazole cap 20 mg x 14, amoxycillin cap 500 mg x 28 and clarithromycin tab 500 mg x 14 txpk 11002 20
125401 1254 Tab 4 mg tab 70703 4
125402 1254 Tab 8 mg tab 70703 8
125403 1254 Tab 16 mg tab 70703 16
125425 1254 Tab 32 mg tab 70703 32
125501 1255 Tab 2 mg tab 250101 2
125502 1255 Tab 5 mg tab 250101 5
125701 1257 Eye oint 1% with prednisolone 0.5% g 310301
125801 1258 Eye drops 0.5% with polymyxin B sulphate 5,000 u per ml ml 310301
125802 1258 Eye oint 1% with polymyxin B sulphate 5,000 u per g g 310301
125803 1258 Ear drops 0.5% with polymyxin B sulphate 5000 u per ml ml 310101
125901 1259 Eye drops 0.5% ml 310301
125902 1259 Ear drops 0.5% ml 310101
125904 1259 Eye oint 1%g 310301
125906 1259 Cap 250 mgcap 160313 250
125907 1259 Oral liq palmitate 125 mg per 5 ml ml 160313
126101 1261 Inj 1.2 g inj 160313
127301 1273 Cap 192 mgcap 222801 192
127302 1273 Oral liq 250 mg per 5 ml ml 222801 50
127303 1273 Infusion 0.8% 500 ml ml 222801
127501 1275 Tab 420 mg with aminoacetic acid 180 mg tab 10102 420
127601 1276 Tab 420 mg with aminoacetic acid 180 mg and dimethicone 21 mg tab 10102 420
128001 1280 Tab 200 mgtab 161001 200
128002 1280 Tab 250 mgtab 161001 250
128003 1280 Oral liq 68 mg per 5 ml ml 161001 13
128201 1282 Tab 500 mgtab 73110 500
128202 1282 Oral liq 50 mg per ml ml 73110 50
128301 1283 Tab 10 mg tab 222201 10
128302 1283 Tab 25 mg tab 222201 25
128303 1283 Tab 50 mg tab 222201 50
128304 1283 Tab 100 mgtab 222201 100
128305 1283 Oral liq 100 mg per 5 ml ml 222201 20
128306 1283 Inj 25 mg per ml, 2 ml inj 222201 50
128801 1288 Oint 3% g 100401
129001 1290 Tab 25 mg tab 73110 25
129101 1291 Powder for oral liq 4 g sach 73203
129201 1292 Oral liq 50 mg with guaiphenesin 25 mg per 5 ml ml 284502 10
129701 1297 Tab 200 mgtab 11003 200
129702 1297 Tab 400 mgtab 11003 400
129703 1297 Tab 800 mgtab 11003 800
129704 1297 Inj 100 mg per ml 2 ml inj 11003 100
130301 1303 Cap hydrochloride 150 mg cap 160313 150
130302 1303 Grans palmitate hydrochloride for oral liq 75 mg per 5 ml ml 160313 15
130303 1303 Inj phosphate 150 mg per ml, 4 ml inj 160313 150
130601 1306 Soln 1% ml 100101
130603 1306 Lotn 1% ml 100101
130801 1308 Tab 10 mg tab 220702 10
130902 1309 Scalp app 0.05% ml 102201
130903 1309 Crm 0.05%g 101101
130904 1309 Oint 0.05%g 101101
131002 1310 Crm 0.05%g 101101
131003 1310 Oint 0.05%g 101101
131201 1312 Cap 50 mg cap 161601 50
131301 1313 Cap 500 mgcap 73202 500
131401 1314 Tab 50 mg tab 142101 50
131501 1315 Tab 10 mg tab 220501 10
131502 1315 Tab 25 mg tab 220501 25
131601 1316 Tab 500 mcg tab 222501 0.5
131602 1316 Tab 2 mg tab 222501 2
131603 1316 Oral drops 2.5 mg per ml ml 220702 2
131604 1316 Inj 1 mg per ml, 1 ml inj 220701 1
131702 1317 Patch 2.5 mg, 100 mcg per day patch 72801 2.5
131703 1317 Patch 5 mg, 200 mcg per day patch 72801 5
131704 1317 Patch 7.5 mg, 300 mcg per day patch 72801 7.5
131801 1318 Tab 150 mcg tab 72801 150
131805 1318 Inj 150 mcg per ml, 1 ml ampoule inj 72801 150
131808 1318 Tab 25 mcgtab 72801 25
132001 1320 Pessaries 100 mg with applicator pess 131001
132002 1320 Pessaries 500 mg with applicator pess 131001
132003 1320 Vaginal crm 1% with applicators g 131001
132004 1320 Vaginal crm 2% with applicators g 131001
132006 1320 Soln 1% ml 100701
132007 1320 Crm 1% g 100701
132401 1324 Soln 5% with sulphur 0.5%, menthol 0.75%, phenol 0.5% and allantoin crm 2.5% g 101901
133201 1332 Tab 15 mg tab 220407 15
133202 1332 Tab 30 mg tab 220407 30
133203 1332 Tab 60 mg tab 220407 60
133204 1332 Syrup 25 mg per 5 ml ml 284702 5
133205 1332 Powder g 380101
133206 1332 Linctus BP ml 284702
134101 1341 Tab 600 mcg tab 191301 600
134125 1341 Tab 500 mcg tab 191301
134501 1345 Grans for oral liq 5 g sach 73203
134601 1346 Inj 150 mg inj 160313 150
134701 1347 Ear drops 3 mg with neomycin sulphate 3.3 mg and hydrocortisone acetate 10 mg per ml ml 310101
135701 1357 Tab, diagnostic tab 11501
135901 1359 Inj in 16 gelatin 40 iu per ml, 5 ml inj 140701 200
136001 1360 Tab 5 mg tab 140701 5
136002 1360 Tab 25 mg tab 140701 25
136101 1361 Oral liq trimethoprim 40 mg and sulphamethoxazole 200 mg per 5 ml ml 160313
136102 1361 Tab trimethoprim 80 mg and sulphamethoxazole 400 mg tab 160313 80
136103 1361 Tab trimethoprim 160 mg and sulphamethoxazole 800 mg tab 160313 160
136104 1361 Oral liq sugar-free trimethoprim 40 mg and sulphamethoxazole 200 mg per 5 ml ml 160313
136301 1363 Crm 10% g 100801
136302 1363 Lotn 10% ml 100801
136701 1367 Tab 0.5 mgtab 73110 0.5
136901 1369 Tab 50 mg tab 250101 50
136902 1369 Inj 1 g inj 250101 1000
136903 1369 Inj 200 mg inj 250101 200
136904 1369 Inj 500 mg inj 250101 500
136925 1369 Inj 2 g inj 250101 2000
136926 1369 Inj 1 mg for ECP mg 250101 1
137001 1370 Eye drops 1% ml 310310
137101 1371 Inj 20 mg per ml, 5 ml vial inj 250104 100
137102 1371 Inj 100 mg per ml, 20 ml vial inj 250104 2000
137103 1371 Inj 500 mg inj 250104 500
137104 1371 Inj 100 mg per ml, 10 ml vial inj 250104 1000
137126 1371 Inj 1 mg for ECP mg 250104 1
137127 1371 Inj 100 mg intrathecal syringe for ECP mg 250104 100
137201 1372 Cap 100 mgcap 142101 100
137202 1372 Cap 200 mgcap 142101 200
137301 1373 Cap 25 mg cap 191601 25
137302 1373 Cap 50 mg cap 191601 50
137401 1374 Tab 100 mgtab 161601 100
137425 1374 Tab 25 mg tab 161601 25
137501 1375 Tab 100 mg with pyrimethamine 12.5 mg tab 161001 100
137801 1378 Inj 500 mg inj 350408 500
137901 1379 Tab 25 mg tab 220501 25
138101 1381 Ear/Eye drops 500 mcg with framycetin sulphate 5 mg and gramicidin 50 mcg per ml ml 310201
138102 1381 Ear/Eye oint 500 mcg with framycetin sulphate 5 mg and gramicidin 50 mcg per g g 310201
138301 1383 Tab 1 mg tab 140701 1
138302 1383 Tab 4 mg tab 140701 4
138303 1383 Eye drops 0.1% ml 310304
138305 1383 Oral liq 1 mg per ml ml 140701
138306 1383 Eye oint 0.1% g 310304
138501 1385 Inj 4 mg per ml, 1 ml ampoule inj 140701 4
138502 1385 Inj 4 mg per ml, 2 ml ampoule inj 140701 8
138901 1389 Tab 5 mg tab 223101 5
139001 1390 Tab 5 mg tab 220407 5
139101 1391 Cap napsylate 100 mg cap 220407 100
139201 1392 Cap hydrochloride 32.5 mg with paracetamol 325 mg cap 220407 32.5
139202 1392 Tab napsylate 50 mg with paracetamol 325 mg tab 220407 50
139301 1393 Inj 50%, 10 ml inj 41001 10
139302 1393 Dextrose g 380101
139325 1393 Inj 50%, 90 ml inj 41001 90
139401 1394 Soln with electrolytes ml 41004
139701 1397 Tab 2 mg tab 222501 2
139702 1397 Tab 5 mg tab 222501 5
139703 1397 Tab 10 mg tab 222501 10
139704 1397 Rectal tubes 5 mg tube 220701 5
139705 1397 Rectal tubes 10 mg tube 220701 10
139706 1397 Inj 5 mg per ml, 2 ml inj 220701 10
140001 1400 Eye oint 0.15% g 310301
140101 1401 Tab EC 25 mg tab 190401 25
140102 1401 Tab EC 50 mg tab 190401 50
140103 1401 Tab long-acting 75 mg tab 190401 75
140105 1401 Inj 25 mg per ml, 3 ml inj 190401 75
140106 1401 Suppos 12.5 mg supp 190401 12.5
140107 1401 Suppos 25 mg supp 190401 25
140108 1401 Suppos 50 mg supp 190401 50
140109 1401 Suppos 100 mg supp 190401 100
140110 1401 Eye drops 0.1% ml 310304
140111 1401 Tab 50 mg dispersible tab 190401 50
140112 1401 Tab long-acting 100 mg tab 190401 100
140113 1401 Cap long-acting 100 mg cap 190401 100
140501 1405 Tab 10 mg tab 71301 10
140502 1405 Tab long-acting 40 mg tab 71301 40
140503 1405 Oral liq 10 mg per 5 ml ml 71301 10
140701 1407 Crm 100 mcg per g with applicator g 131402
140801 1408 Tab 50 mg tab 160101 50
140903 1409 Oint 0.1% g 101101
140904 1409 Crm 0.1% g 101101
140905 1409 Fatty oint 0.1% g 101101
141001 1410 Crm 0.1% with chlorquinaldol 1% g 101104
141101 1411 Tab 250 mgtab 190401 250
141102 1411 Tab 500 mgtab 190401 500
141201 1412 Tab 62.5 mcg tab 71301
141202 1412 Tab 250 mcg tab 71301 250
141203 1412 Oral liq 50 mcg per ml ml 71301 50
141204 1412 Inj 25 mcg per ml, 2 ml inj 71301 50
141205 1412 Inj 250 mcg per ml, 2 ml inj 71301 500
141801 1418 Tab 50 mg tab 221601 50
142001 1420 Crm 5% 400 g g 101502
142002 1420 Crm 5% g 101502
142003 1420 Crm 10% BPC g 101502
142004 1420 Fluid 350 ml 380101
142025 1420 Crm 5% pump bottle ml 101502
142301 1423 Powder 2%g 101401
142401 1424 Tab 2.5 mg with atropine sulphate 25 mcg tab 10401 2.5
142501 1425 Eye drops 0.1% ml 310309
142701 1427 Tab 25 mg tab 40701 25
142703 1427 Inj 5 mg per ml 2 ml inj 40701 5
142704 1427 Tab long-acting 150 mg tab 40701 150
142705 1427 Cap long-acting 150 mg cap 40701 150
142801 1428 Tab long-acting 250 mg tab 71301 250
142802 1428 Cap 100 mgcap 71301 100
142804 1428 Inj 10 mg per ml 5 ml inj 71301 10
142805 1428 Cap 150 mgcap 71301 150
142806 1428 Tab long-acting 150 mg tab 71301 150
143101 1431 Tab 5 mg tab 190101 5
143102 1431 Inj 500 mcg per ml, 1 ml inj 190101 500
143201 1432 Tab 200 mgtab 223401 200
143601 1436 Tab 10 mg tab 221601 10
143701 1437 Tab 75 mg tab 220501 75
143702 1437 Cap 25 mg cap 220501 25
143801 1438 Cap 10 mg cap 220501 10
143802 1438 Cap 25 mg cap 220501 25
143803 1438 Cap 50 mg cap 220501 50
143804 1438 Cap 75 mg cap 220501 75
144101 1441 Tab 10 mg tab 141301 10
144301 1443 Pessaries 150 mg with applicators pess 131001
144302 1443 Vaginal crm 1% with applicator(s) g 131001
144303 1443 Vaginal crm 1.5% with applicator g 131001
144306 1443 Soln 1% ml 100701
144307 1443 Foaming soln 1%, 10 ml sachets ea 100701
144310 1443 Crm 1% g 100701
144311 1443 Powder 1%g 100701
144601 1446 Powder for soln for oral use 5 g sach 41004 5
144625 1446 Powder for oral soln sach 41004 4.4
144801 1448 Tab 200 mgtab 131904 200
145301 1453 Tab 15 mg tab 284502 15
145302 1453 Tab 30 mg tab 284502 30
145303 1453 Powder g 380101
145601 1456 Inj 500 mcg per ml, 1 ml inj 131402 500
145806 1458 Aerosol inhaler 360 mcg per dose dose 221301
145901 1459 Tab 2 mg with caffeine 100 mg and cyclizine hydrochloride 50 mg tab 221301 2
146001 1460 Cap 1 mg with caffeine citrate 100 mg and diphenhydramine hydrochloride 25 mg cap 221301 1
146203 1462 Tab 1 mg with caffeine 100 mg tab 221301 1
146503 1465 Soln 2% ml 100101
146504 1465 Tab 250 mgtab 160304 250
146505 1465 Cap 250 mgcap 160304 250
146602 1466 Tab 500 mgtab 160304 500
146603 1466 Oral liq 125 mg per 5 ml ml 160304 25
146604 1466 Oral liq 250 mg per 5 ml ml 160304 50
146605 1466 Cap 250 mgcap 160304 250
146801 1468 Tab 100 mgtab 161601 100
146802 1468 Tab 400 mgtab 161601 400
147508 1475 Tab 35 mcg with norethisterone 500 mcg tab 130802 35
147509 1475 Tab 35 mcg with norethisterone 500 mcg and 7 inert tab tab 130802 35
147510 1475 Tab ethinyloestradiol 35 mcg with norethisterone 500 mcg (7) and tab ethinyloestradiol 35 mcg with norethisterone 1 mg (9) and tab ethinyloestradiol 35 mcg with norethisterone 500 mcg (5) and 7 inert tab 130802 35
147511 1475 Tab 35 mcg with norethisterone 1 mg tab 130802 35
147512 1475 Tab 35 mcg with norethisterone 1 mg and 7 inert tab tab 130802 35
147601 1476 Tab 50 mcg with ethynodiol diacetate 0.5 mg tab 130802 50
147602 1476 Tab 50 mcg with ethynodiol diacetate 1 mg tab 130802 50
147701 1477 Tab 20 mcg with desogestrel 150 mcg tab 130802 20
147702 1477 Tab 20 mcg with desogestrel 150 mcg and 7 inert tab tab 130802 20
147703 1477 Tab 30 mcg with desogestrel 150 mcg tab 130802 30
147704 1477 Tab 30 mcg with desogestrel 150 mcg and 7 inert tab tab 130802 30
147801 1478 Tab 10 mcgtab 141201 0.01
147901 1479 Tab 30 mcg with gestodene 75 mcg tab 130802 30
147902 1479 Tab 30 mcg with gestodene 75 mcg and 7 inert tab tab 130802 30
147903 1479 Tab 20 mcg with gestodene 75 mcg and 7 inert tab tab 130802 20
148101 1481 Cap 250 mgcap 220702 250
148102 1481 Oral liq 250 mg per 5 ml ml 220702 50
148401 1484 Tab 500 mcg tab 130804 500
148701 1487 Tab 200 mgtab 190806 200
149201 1492 Aerosol inhaler, 20 mcg per dose dose 283401 20
149202 1492 Aerosol inhaler, 40 mcg per dose dose 283401 40
149203 1492 Nebuliser soln, 250 mcg per ml, 2 ml neb 283401 500
149204 1492 Nebuliser soln, 250 mcg per 2 ml, 2 ml neb 283401 125
149205 1492 Aerosol nasal spray, 20 mcg per dose dose 285102
149206 1492 Aqueous nasal spray, 0.03% ml 285102
149207 1492 Nebuliser soln, 250 mcg per ml, 1 ml neb 283401 250
149225 1492 Aerosol inhaler, 20 mcg per dose CFC-free dose 283401 20
149801 1498 Tab 5 mg tab 40104 5
149802 1498 Inj 15 mg per ml 1 ml inj 40104 15
149803 1498 Oral liq 50 mcg per ml ml 40104 50
149825 1498 Tab 0.8 mgtab 40104
149901 1499 Tab 300 mgtab 40103 300
149902 1499 Oral liq 300 mg per 5 ml ml 40103 60
150101 1501 Tab long-acting 325 mg (105 mg elemental) with folic acid 350 mcg tab 13830 325
150801 1508 Oint 10 u with desoxyribonuclease 6666 u per g g 103107
150803 1508 Powder for soln 25 u with desoxyribonuclease 1500 u g 103107
150901 1509 Oint 1,800 iu vitamin A per g g 101504
151001 1510 Tab 50 mg tab 71301 50
151002 1510 Tab 100 mgtab 71301 100
151003 1510 Inj 10 mg per ml, 15 ml ampoule inj 71301 10
151004 1510 Cap long-acting 100 mg cap 71301 100
151005 1510 Cap long-acting 200 mg cap 71301 200
151101 1511 Grans for oral liq 125 mg per 5 ml ml 160307
151102 1511 Grans for oral liq 250 mg per 5 ml ml 160307
151201 1512 Cap 250 mgcap 160307 250
151202 1512 Cap 500 mgcap 160307 500
151203 1512 Grans for oral liq 125 mg per 5 ml ml 160307
151204 1512 Grans for oral liq 250 mg per 5 ml ml 160307
151205 1512 Inj 250 mg vial inj 160307 250
151206 1512 Inj 500 mg vial inj 160307 500
151207 1512 Inj 1 g vial inj 160307 1000
151301 1513 Tab 500 mgtab 160401 500
151501 1515 Tab 100 mcg tab 140701 100
151601 1516 Ear drops 0.02% with clioquinol 1% ml 310101
151701 1517 Metered nasal spray, 25 mcg per dose dose 285102
151803 1518 Gel 0.02% g 102201
151804 1518 Crm 0.025%g 101101
151805 1518 Oint 0.025%g 101101
152101 1521 Suppos 630 mcg, with fluocortolone pivalate 610 mcg, and cinchocaine hydrochloride 1 mg supp 10501 630
152102 1521 Oint 950 mcg, with fluocortolone pivalate 920 mcg, and cinchocaine hydrochloride 5 mg per g g 10501
152701 1527 Eye drops 0.1% ml 310304
152901 1529 Crm 5% g 103103
152902 1529 Inj 250 mg per 10 ml inj 250104 250
152903 1529 Inj 500 mg per 10 ml inj 250104 500
152904 1529 Inj 500 mg per 20 ml inj 250104 500
152925 1529 Inj 25 mg per ml, 100 ml inj 250104 2500
152926 1529 Inj 50 mg per ml, 20 ml inj 250104 1000
152927 1529 Inj 50 mg per ml, 50 ml inj 250104 2500
152928 1529 Inj 1 mg for ECP mg 250104 1
152929 1529 Inj 50 mg per ml, 10 ml inj 250104 500
152930 1529 Inj 50 mg per ml, 100 ml inj 250104 5000
153201 1532 Inj 20 mg per ml, 1 ml inj 222204 20
153202 1532 Inj 20 mg per ml, 2 ml inj 222204 40
153203 1532 Inj 100 mg per ml, 1 ml inj 222204 100
153301 1533 Inj 12.5 mg per 0.5 ml, 0.5 ml inj 222204 12.5
153302 1533 Inj 25 mg per ml, 1 ml inj 222204 25
153303 1533 Inj 25 mg per ml, 2 ml inj 222204 50
153304 1533 Inj 100 mg per ml, 1 ml inj 222204 100
153501 1535 Tab 1 mg tab 222201 1
153502 1535 Tab 5 mg tab 222201 5
153601 1536 Tab 50 mg tab 190401 50
153602 1536 Tab 100 mgtab 190401 100
153603 1536 Cap long-acting 200 mg cap 190401 200
153701 1537 Tab 250 mgtab 250401 250
154203 1542 Oint 1.5% with gramicidin 0.005% g 100401
154225 1542 Crm 1.5% with gramicidin 0.005% g 100401
154401 1544 Tab 40 mg tab 73101 40
154402 1544 Tab 500 mgtab 73101 500
154403 1544 Oral liq 10 mg per ml ml 73101
154404 1544 Inj 10 mg per ml, 2 ml ampoule inj 73101 20
154405 1544 Inj 20 mg per ml, 2 ml inj 73101 40
154406 1544 Inj 10 mg per ml, 25 ml ampoule inf 73101 250
154601 1546 Tab 250 mgtab 160313 250
154602 1546 Oral liq 250 mg per 5 ml ml 160313
154603 1546 Inj 500 mg sodium fusidate per 10 ml inj 160313 500
154604 1546 Eye drops 1% g 310301
154608 1546 Crm 2% g 100401
154609 1546 Oint 2% g 100401
154610 1546 Gel 2% g 100401
154901 1549 Lotn 1% ml 101701
154902 1549 Crm 1% g 101701
155301 1553 Cap 300 mgcap 73201 300
155325 1553 Tab 600 mgtab 73201 600
155401 1554 Inj 10 mg per ml, 1 ml inj 160313 10
155402 1554 Inj 10 mg per ml, 2 ml inj 160313 20
155403 1554 Inj 40 mg per ml, 2 ml inj 160313 80
155405 1554 Eye drops 0.3% ml 310301
155407 1554 Crm 0.1% g 100401
155408 1554 Oint 0.1% g 100401
156701 1567 Tab 2.5 mgtab 11312 2.5
156702 1567 Tab 5 mg tab 11312 5
156801 1568 Tab 80 mg tab 11312 80
156901 1569 Tab 5 mg tab 11312 5
157001 1570 Inj 1 mg inj 11301 1
157003 1570 Inj 10 mg inj 11301 10
157004 1570 Inj 1 mg syringe kit kit 11301 1
157201 1572 Urine diagnostic test with peroxidase strip 11501
157202 1572 Urine diagnostic test strip 11501
157203 1572 Blood diagnostic test with peroxidase test 11507
157204 1572 Urine diagnostic test with peroxidase, potassium iodide, sodium nitroprusside and aminoacetic acid strip 11504
157210 1572 Urine diagnostic test with peroxidase, sodium nitroprusside and aminoacetic acid stick 11504
157401 1574 Suppos 1 gsupp 12507
157402 1574 Suppos 2 gsupp 12507
157403 1574 Suppos 3.6 g supp 12507
157404 1574 Suppos 4 gsupp 12507
157405 1574 Suppos 8 gsupp 12507
157406 1574 Liquid ml 380101
157407 1574 Suppos 1.27 g supp 12507
157408 1574 Suppos 2.55 g supp 12507
157501 1575 Lotn 5% with paraffin liq 5% and cetyl alcohol 2% ml 101504
157701 1577 Patch 50 mg, 10 mg per day patch 73401 10
157702 1577 Tab 600 mcg tab 73401 600
157703 1577 Oint 2% g 73401 2
157704 1577 Oral spray aerosol 400 mcg per dose dose 73401
157705 1577 Patch 25 mg, 5 mg per day patch 73401 5
157706 1577 Oral pump spray 400 mcg per dose dose 73401
157725 1577 Oral spray, 400 mcg per dose dose 73401
157726 1577 Oint 0.2% g 10502
157902 1579 Tab 330 mgtab 160401 330
157903 1579 Tab 500 mgtab 160401 500
158001 1580 Tab 125 mgtab 284302 125
158003 1580 Tab long-acting 125 mg tab 284302 125
158004 1580 Tab long-acting 175 mg tab 284302 175
158005 1580 Tab long-acting 200 mg tab 284302 200
158006 1580 Tab long-acting 250 mg tab 284302 250
158007 1580 Tab long-acting 300 mg tab 284302 300
158008 1580 Tab long-acting 350 mg tab 284302 350
158009 1580 Tab long-acting 500 mg tab 284302 500
158011 1580 Cap long-acting 75 mg cap 284302 75
158012 1580 Cap long-acting 100 mg cap 284302 100
158013 1580 Cap long-acting 200 mg cap 284302 200
158014 1580 Cap long-acting 300 mg cap 284302 300
158015 1580 Oral liq 80 mg per 15 ml ml 284302
158301 1583 Tab 500 mcg tab 222201 0.5
158302 1583 Tab 1.5 mgtab 222201 1.5
158303 1583 Tab 5 mg tab 222201 5
158304 1583 Oral liq 2 mg per ml ml 222201 2
158306 1583 Inj 5 mg per ml, 1 ml inj 222201 5
158901 1589 Inj 1,000 iu per ml, 5 ml inj 40704 99
158902 1589 Inj 1,000 iu per ml, 35 ml inj 40704 100
158903 1589 Inj 5,000 iu per ml, 1 ml inj 40704 500
158904 1589 Inj 5,000 iu per ml, 5 ml inj 40704 500
158905 1589 Inj 10,000 iu per ml, 0.5 ml inj 40704 1000
158906 1589 Inj 25,000 iu per ml, 0.2 ml inj 40704 2500
158907 1589 Inj 25,000 iu per ml, 5 ml inj 40704 2500
159401 1594 Tab 1 g tab 162301
159802 1598 Aerosol inhaler, 100 mcg per dose dose 281001 100
159803 1598 Aerosol inhaler, 200 mcg per dose dose 281001 200
160001 1600 Eye drops 2% ml 310310
160002 1600 Eye drops 5% ml 310310
160301 1603 Inj 1,500 iu per ml inj 191101 1500
160401 1604 Tab 25 mg tab 74001 25
160402 1604 Tab 50 mg tab 74001 50
160403 1604 Inj 20 mg ampoule inj 74001 20
160601 1606 Aerosol rectal foam 10% g 10404 10
160602 1606 Rectal foam 10%, CFC-Free (14 applications) g 10404
161101 1611 Crm 1% with miconazole nitrate 2% g 101104
161202 1612 Crm 1% with natamycin 1% and neomycin sulphate 0.5% g 101104
161203 1612 Oint 1% with natamycin 1% and neomycin sulphate 0.5% g 101104
161301 1613 Lotn 1% with wool fat hydrous 3% and mineral oil ml 101101
161401 1614 Oint 0.1% g 101101
161402 1614 Crm 0.1% g 101101
161406 1614 Scalp lotn 0.1% ml 102201
161407 1614 Lipocream 0.1% g 101101
161425 1614 Milky emul 0.1% ml 101101
161502 1615 Crm 0.1% with chlorquinaldol 3% g 101104
161701 1617 Tab 5 mg tab 140701 5
161702 1617 Tab 20 mg tab 140701 20
161705 1617 Crm 0.5% g 101101
161706 1617 Powder g 101101
161716 1617 Inj 100 ml vial inj 140701 100
161717 1617 Inj 125 mg per ml, 2 ml inj 140701 250
161718 1617 Inj 125 mg per ml, 4 ml inj 140701 500
161719 1617 Crm 1% g 101101
161901 1619 Oint zinc oxide with balsam peru g 10507
161902 1619 Suppos zinc oxide with balsam peru supp 10507
161904 1619 Zinc oxide g 380101
162001 1620 Lotn 2% ml 100701
162002 1620 Tinct 2% ml 100701
162003 1620 Crm 2% g 100701
162004 1620 Powder 2%g 100701
162005 1620 Pessaries 100 mg pess 131001
162006 1620 Vaginal crm 2% with applicator g 131001
162401 1624 Inj 1 mg per ml, 1 ml inj 13704 1
162501 1625 Tab 200 mgtab 190701 200
162601 1626 Cap 500 mgcap 250107 500
162901 1629 Patch 1.5 mg patch 221601
162902 1629 Eye drops 0.25% ml 310310
162903 1629 Inj 400 mcg per ml, 1 ml inj 221601 400
163001 1630 Eye drops 0.3% with dextran 0.1% ml 310313
163101 1631 Tab 10 mg tab 10701 10
163102 1631 Inj 20 mg, 1 ml inj 10701 20
163201 1632 Oint 5 mg with cinchocaine hydrochloride 5 mg per g g 10501
163204 1632 Suppos 5 mg with cinchocaine hydrochloride 5 mg per g supp 10501 5
163205 1632 Oint 5 mg with cinchocaine hydrochloride 5 mg per g, 2 g ea 10501
163301 1633 Eye drops 0.3% ml 310313
163302 1633 Eye drops 0.5% ml 310313
163303 1633 Eye drops 1% ml 310313
163401 1634 Oint 0.25% with lidocaine [lignocaine] hydrochloride 5% aluminium subacet 3.5% and zinc oxide 18% g 10501
163402 1634 Suppos 0.25% with lidocaine [lignocaine] hydrochloride 5% aluminium subacet 3.5% and zinc oxide 18% supp 10501
163903 1639 Eye oint 0.5% g 310301
164201 1642 Tab 10 mg tab 220501 10
164202 1642 Tab 25 mg tab 220501 25
164301 1643 Tab 2.5 mgtab 73110 2.5
164501 1645 Cap 25 mg cap 190402 25
164502 1645 Cap 50 mg cap 190402 50
164503 1645 Cap long-acting 75 mg cap 190402 75
164504 1645 Suppos 100 mg supp 190402 100
164801 1648 Inj human 100 u per ml ml 11303 100
164802 1648 Inj human 100 u per ml, 1.5 ml inj 11303 150
164803 1648 Inj human 100 u per ml, 3 ml inj 11303 300
164825 1648 Inj animal (pork) 100 u per ml, 10 ml ml 11303 1000
164902 1649 Inj human 100 u per ml, 1.5 ml inj 11305 150
164903 1649 Inj human 100 u per ml, 3 ml inj 11305 300
164904 1649 Inj human 100 u per ml ml 11305
164925 1649 Inj animal (pork) 100 u per ml ml 11305 1000
165301 1653 Syringe 1 ml dev 11509
165501 1655 Inj human 100 u per ml ml 11305
165502 1655 Inj crystalline human 100 u per ml ml 11305
167601 1676 Inj 50 mg per ml, 2 ml ampoule inj 13830 50
167801 1678 Pessaries 600 mg with applicator pess 131001
167901 1679 Tab 100 mgtab 161601 100
167902 1679 Tab 100 mg with rifampicin 150 mg tab 161601 100
167903 1679 Tab 150 mg with rifampicin 300 mg tab 161601 150
168201 1682 Inj 200 mcg per ml, 1 ml ampoule inj 73701 200
168601 1686 Synthetic bath oil, 1 ltr ml 101504
168602 1686 Synthetic bath oil ml 101504
168801 1688 Cap 10 mg cap 100101 10
168802 1688 Cap 20 mg cap 100101 20
169601 1696 Tab 200 mgtab 160401 200
169602 1696 Crm 2% g 100701
169603 1696 Shampoo 2% ml 102201
169701 1697 Cap 50 mg cap 190401 50
169703 1697 Cap long-acting 200 mg cap 190401 200
169705 1697 Suppos 100 mg supp 190401
169706 1697 Tab EC 100 mg tab 190401 100
169707 1697 Cap 100 mgcap 190401 100
169708 1697 Cap long-acting 100 mg cap 190401 100
169801 1698 Tab 1 mg tab 280401 1
169802 1698 Oral liq 1 mg per 5 ml ml 280401 0.2
169901 1699 Tab 50 mg tab 71601 50
169902 1699 Tab 100 mgtab 71601 100
169903 1699 Tab 200 mgtab 71601 200
169904 1699 Tab 400 mgtab 71601 400
169905 1699 Inj 5 mg per ml, 20 ml ampoule inj 71601 100
169925 1699 Inj 5 mg per ml, 5 ml inj 71601
171501 1715 Crm 2.5% with prilocaine 2.5% g 220201 2.5
171502 1715 Crm 2.5% with prilocaine 2.5% (5 g tubes) tube 220201 2.5
171601 1716 Eye drops 0.25% ml 310305
171602 1716 Eye drops 0.5% ml 310305
171702 1717 Cap 200 mg with benserazide 50 mg cap 220101 200
171706 1717 Cap 100 mg with benserazide 25 mg cap 220101 100
171707 1717 Cap long-acting 100 mg with benserazide 25 mg cap 220101 100
171708 1717 Cap 50 mg with benserazide 12.5 mg cap 220101 50
171709 1717 Tab dispersible 50 mg with benserazide 12.5 mg tab 220101 50
171802 1718 Tab ethinyloestradiol 30 mcg with levonorgestrel 50 mcg (6) and ethinyloestradiol 40 mcg with levonorgestrel 75 mcg (5), and ethinyloestradiol 30 mcg with levonorgestrel 125 mcg (10) tab 130802 50
171803 1718 Tab 50 mcg with ethinyloestradiol 50 mcg and levonorgestrel 125 mcg with ethinyloestradiol 50 mcg tab 130802 50
171804 1718 Tab ethinyloestradiol 50 mcg with levonorgestrel 50 mcg (11) and ethinyloestradiol 50 mcg with levonorgestrel 125 mcg (10) and 7 inert tab tab 130802 50
171805 1718 Tab ethinyloestradiol 30 mcg with levonorgestrel 50 mcg (6) and tab ethinyloestradiol 40 mcg with levonorgestrel 75 mcg (5), and tab ethinyloestradiol 30 mcg with levonorgestrel 125 mcg (10) and 7 ine tab 130802 50
171806 1718 Tab 125 mcg with ethinyloestradiol 50 mcg tab 130802 125
171807 1718 Tab 50 mcg with levonorgestrel 125 mcg and 7 inert tab tab 130802 125
171808 1718 Tab 30 mcg with levonorgestrel 150 mcg tab 130802 150
171809 1718 Tab 30 mcg with levonorgestrel 150 mcg and 7 inert tab tab 130802 150
171810 1718 Tab 50 mcg with levonorgestrel 250 mcg tab 130802 250
171811 1718 Tab 50 mcg with levonorgestrel 250 mcg and 7 inert tab tab 130802 250
171812 1718 Tab 20 mcg with levonorgestrel 100 mcg and 7 inert tab tab 130802 100
171901 1719 Inj 10% 5 ml inj 71301 10
171902 1719 Inj twin pack 100 mg per 5ml inj 71301 20
171904 1719 Inj 0.5%, 5 ml inj 220201 2
171906 1719 Inj 0.5%, 20 ml vial inj 220201 10
171907 1719 Inj 1%, 20 ml ampoule inj 220201 20
171908 1719 Inj 1%, 50 ml vial inj 220201 50
171910 1719 Inj 1%, 5 ml ampoule inj 220201 5
171925 1719 Inj 2%, 5 ml ampoule inj 220201 10
171926 1719 Inj 2%, 20 ml ampoule inj 220201 40
171927 1719 Oral (viscous) soln 2% ml 220201
172002 1720 Cap 500 mgcap 160313 500
172003 1720 Inj 300 mg per ml 2 ml inj 160313 300
172101 1721 Tab 20 mcgtab 141401 20
172301 1723 Tab 100 mg with carbidopa 25 mg tab 220101 100
172302 1723 Tab 250 mg with carbidopa 25 mg tab 220101 250
172303 1723 Tab long-acting 200 mg with carbidopa 50 mg tab 220101 200
172401 1724 Tab 30 mcgtab 130804 30
172425 1724 Tab 750 mcg tab 130805 750
172426 1724 Levonorgestrel - releasing intrauterine system 20 mcg/24 hr dev 141301
172427 1724 Tab 1.5 mgtab 130805 1
172428 1724 Subdermal implant (2 x 75 mg rods) pack 130804
172801 1728 Cap 2 mg cap 10401 2
172802 1728 Tab 2 mg tab 10401 2
172901 1729 Tab 1 mg tab 222801 1
173001 1730 Tab 500 mcg tab 222501 500
173002 1730 Tab 2.5 mgtab 222501 2.5
173004 1730 Tab 1 mg tab 222501 1
173005 1730 Tab sublingual 1 mg tab 222501 1
173101 1731 Tab 1 mg tab 222801 1
173201 1732 Tab 10 mg tab 222201 10
173202 1732 Cap 25 mg cap 222201 25
173203 1732 Cap 50 mg cap 222201 50
173301 1733 Cap 300 mgcap 160310 300
176001 1760 Tab 25 mg tab 220501 25
176002 1760 Tab 75 mg tab 220501 75
176201 1762 Oral liq 100 mg per 5 ml ml 160101 20
176202 1762 Tab 100 mgtab 160101 100
176601 1766 Tab 100 mgtab 141301 100
176602 1766 Tab 200 mgtab 141301 200
176603 1766 Tab 400 mgtab 141301 400
176604 1766 Tab 500 mgtab 141301 500
176605 1766 Tab 2.5 mgtab 141109 2.5
176606 1766 Tab 5 mg tab 141109 5
176607 1766 Tab 10 mg tab 141109 10
176608 1766 Inj 150 mg per ml, 1 ml syringe inj 130804 150
176625 1766 Inj 150 mg per ml, 1 ml inj 130804 150
176901 1769 Cap 250 mgcap 190401 250
177201 1772 Tab 160 mgtab 250401 160
177301 1773 Tab 2 mg tab 250101 2
177302 1773 Tab 5 mg tab 250101 5
177325 1773 Inj 50 mg inj 250101 50
178001 1780 Tab 400 mgtab 222501 400
178101 1781 Tab 10 mg tab 250104 10
178102 1781 Tab 50 mg tab 250104 50
179201 1792 Tab 25 mg tab 141001
179301 1793 Inj 10 mg per ml, 1 ml inj 73701 10
179401 1794 Tab immediate-release 500 mg tab 11312 500
179402 1794 Tab immediate-release 850 mg tab 11312 850
179501 1795 Tab 5 mg tab 220407 5
179502 1795 Inj 10 mg per ml, 1 ml inj 220407 10
179503 1795 Linctus BPC 2 mg per 5 ml ml 220407 0.4
179504 1795 Powder g 380101
179505 1795 Oral liq 2 mg per ml ml 220407 2
179506 1795 Oral liq 5 mg per ml ml 220407 5
179507 1795 Oral liq 10 mg per ml ml 220407 10
179701 1797 Tab 2.5 mgtab 250104 2.5
179702 1797 Tab 10 mg tab 250104 10
179704 1797 Inj 2.5 mg per ml, 2 ml inj 250104 2.5
179705 1797 Inj 10 mg per ml, 2 ml inj 250104 20
179707 1797 Inj 25 mg per ml, 2 ml inj 250104 50
179709 1797 Inj 25 mg per ml, 4 ml inj 250104 100
179710 1797 Inj 25 mg per ml, 20 ml inj 250104 500
179711 1797 Inj 100 mg per ml, 50 ml inj 250104 5000
179712 1797 Inj 100 mg per ml, 10 ml inj 250104 1000
179725 1797 Inj 1 mg for ECP mg 250104 1
179726 1797 Inj 5 mg intrathecal syringe for ECP mg 250104 5
179727 1797 Inj 100 mg per ml, 5 ml inj 250104 500
179728 1797 Inj 25 mg per ml, 40 ml inj 250104 1000
179729 1797 Inj 7.5 mg prefilled syringe inj 250104 7
179730 1797 Inj 10 mg prefilled syringe inj 250104 10
179731 1797 Inj 15 mg prefilled syringe inj 250104 15
179732 1797 Inj 20 mg prefilled syringe inj 250104 20
179733 1797 Inj 25 mg prefilled syringe inj 250104 25
179734 1797 Inj 30 mg prefilled syringe inj 250104 30
179901 1799 Tab 25 mg tab 222201 25
179902 1799 Tab 100 mgtab 222201 100
179903 1799 Inj 25 mg per ml, 1 ml inj 222201 25
180001 1800 Cap 10 mg cap 101901 10
180101 1801 Tab 5 mg tab 73110 5
180501 1805 Tab 250 mg with hydrochlorothiazide 15 mg tab 72801 250
180601 1806 Tab 125 mgtab 72801 125
180602 1806 Tab 250 mgtab 72801 250
180603 1806 Tab 500 mgtab 72801 500
180901 1809 Tab immediate-release 10 mg tab 223101 10
180925 1809 Tab sustained-release 20 mg tab 223101 20
180926 1809 Tab immediate-release 5 mg tab 223101 5
180927 1809 Tab immediate-release 20 mg tab 223101 20
181001 1810 Inj 20 mg per ml, 1 ml inj 140701 20
181002 1810 Inj 20 mg per ml, 5 ml inj 140701 100
181003 1810 Inj 40 mg per ml, 2 ml inj 140701 80
181004 1810 Inj 40 mg per ml, 5 ml inj 140701 200
181005 1810 Inj 40 mg per ml, 1 ml inj 140701 40
181101 1811 Tab 4 mg tab 140701 4
181102 1811 Tab 100 mgtab 140701 100
181201 1812 Inj 40 mg per ml, 1 ml inj 140701 40
181202 1812 Inj 62.5 mg per ml, 2 ml inj 140701 125
181203 1812 Inj 62.5 mg per ml, 4 ml inj 140701 250
181204 1812 Inj 500 mg inj 140701 500
181205 1812 Inj 1 g inj 140701 1000
181301 1813 Tab 1 mg tab 221304 1
181401 1814 Tab 10 mg tab 221601 10
181402 1814 Oral liq 5 mg per 5 ml ml 221601 5
181403 1814 Inj 5 mg per ml, 2 ml ampoule inj 221601 10
181405 1814 Suppos 10 mg supp 221601 10
181501 1815 Tab 5 mg with paracetamol 500 mg tab 221301 5
181606 1816 Inj 40 mg per ml with lidocaine [lignocaine] 1 ml inj 140701 40
181701 1817 Tab long-acting 47.5 mg tab 71601 47.5
181702 1817 Tab long-acting 95 mg tab 71601 95
181703 1817 Tab long-acting 190 mg tab 71601 190
181725 1817 Tab long-acting 23.75 mg tab 71601
181801 1818 Tab 50 mg tab 71601 50
181802 1818 Tab 100 mgtab 71601 100
181803 1818 Tab long-acting 200 mg tab 71601 200
181804 1818 Inj 1 mg per ml, 5 ml vial inj 71601 1
182001 1820 Tab 200 mgtab 161301 200
182002 1820 Tab 400 mgtab 161301 400
182003 1820 Oral liq benzoate 200 mg per 5 ml ml 161301 40
182004 1820 Suppos 1 gsupp 161301 1000
182005 1820 Suppos 500 mg supp 161301 500
182201 1822 Cap 250 mgcap 142101 250
182301 1823 Cap 50 mg cap 71301 50
182302 1823 Cap 200 mgcap 71301 200
182303 1823 Cap long-acting 360 mg cap 71301 360
182325 1823 Cap 150 mgcap 71301 150
182326 1823 Cap 250 mgcap 71301 250
182401 1824 Tab 30 mg tab 220501 30
182501 1825 Oral gel 20 mg per g g 13107
182601 1826 230 ml (autoclavable) dev 285302
182701 1827 Low range dev 285302
182702 1827 Normal range dev 285302
182801 1828 Tab 50 mg tab 160310 50
182802 1828 Cap 100 mgcap 160310 100
182925 1829 230 ml (single patient) dev 285302
182926 1829 800 ml dev 285302
183001 1830 Oral liq 1 mg per ml ml 220407 1
183002 1830 Oral liq 2 mg per ml ml 220407 2
183003 1830 Oral liq 5 mg per ml ml 220407 5
183004 1830 Oral liq 10 mg per ml ml 220407 10
183005 1830 Powder g 380101
183101 1831 Tab long-acting 10 mg tab 220407 10
183102 1831 Tab long-acting 30 mg tab 220407 30
183103 1831 Tab long-acting 60 mg tab 220407 60
183104 1831 Tab long-acting 100 mg tab 220407 100
183105 1831 Tab long-acting 200 mg tab 220407 200
183106 1831 Inj 2 mg per ml, 1 ml inj 220407 2
183107 1831 Inj 5 mg per ml, 1 ml inj 220407 5
183108 1831 Inj 10 mg per ml, 1 ml inj 220407 10
183109 1831 Inj 10 mg per ml, 5 ml inj 220407 50
183110 1831 Inj 15 mg per ml, 1 ml inj 220407 15
183111 1831 Inj 30 mg per ml, 1 ml inj 220407 30
183112 1831 Suppos 5 mg supp 220407 5
183113 1831 Suppos 10 mg supp 220407 10
183114 1831 Suppos 20 mg supp 220407 20
183115 1831 Suppos 30 mg supp 220407 30
183116 1831 Morphine sulphate g 380101
183117 1831 Cap long-acting 20 mg cap 220407 20
183118 1831 Cap long-acting 50 mg cap 220407 50
183119 1831 Cap long-acting 100 mg cap 220407 100
183120 1831 Tab immediate-release 10 mg tab 220407 10
183121 1831 Tab immediate-release 20 mg tab 220407 20
183122 1831 Cap long-acting 10 mg cap 220407 10
183125 1831 Cap long-acting 200 mg cap 220407 200
183126 1831 Cap long-acting 30 mg cap 220407 30
183127 1831 Cap long-acting 60 mg cap 220407 60
183202 1832 Size 2 dev 285302
183501 1835 Oint 2% g 100401
183801 1838 Tab 40 mg tab 71601 40
183802 1838 Tab 80 mg tab 71601 80
183901 1839 Tab 500 mgtab 162301 500
184101 1841 Inj 20 mcg per ml, 2 ml inj 223301 40
184102 1841 Inj 400 mcg per ml, 1 ml inj 350404 400
184301 1843 Eye drops 0.1% ml 310317
184901 1849 Tab 30 mg tab 220404 30
184902 1849 Inj 20 mg per ml, 1 ml inj 220404 20
185201 1852 Tab 500 mgtab 160313 500
185306 1853 Powder g 380101
185401 1854 Oint 5 mg with polymyxin B sulphate 5000 u with bacitracin 400 u per g g 100401
185702 1857 Inj 2.5 mg per ml, 1 ml (Polyamp Luer Fit) inj 190101 2.5
185703 1857 Inj 2.5 mg per ml, 1 ml ampoule inj 190101 2
185901 1859 Tab 500 mgtab 160101 500
186001 1860 Tab 25 mg tab 13704 25
186002 1860 Tab 50 mg tab 13704 50
186003 1860 Nicotinamide g 380101
186101 1861 Tab 25 mg tab 73202 25
186102 1861 Tab 50 mg tab 73202 50
186103 1861 Tab 100 mgtab 73202 100
186104 1861 Tab 500 mgtab 73202 500
186201 1862 Tab long-acting 150 mg tab 74001 150
186301 1863 Tab long-acting 10 mg tab 72201 10
186302 1863 Tab long-acting 20 mg tab 72201 20
186303 1863 Tab long-acting 30 mg tab 72201 30
186304 1863 Tab long-acting 60 mg tab 72201 60
186305 1863 Cap 5 mg cap 72201 5
186306 1863 Cap 10 mg cap 72201 10
186401 1864 Tab 500 mgtab 161301 500
186501 1865 Tab 5 mg tab 222801 5
186701 1867 Tab 50 mg tab 162301 50
186702 1867 Tab 100 mgtab 162301 100
186703 1867 Oral liq 25 mg per 5 ml ml 162301
187101 1871 Tab 350 mcg tab 130804 0.35
187102 1871 Tab 5 mg tab 141301 5
187301 1873 Tab 1 mg with mestranol 50 mcg tab 130802 1
187302 1873 Tab 1 mg with mestranol 50 mcg and 7 inert tab tab 130802 1
187401 1874 Tab 400 mgtab 162301 400
187501 1875 Tab 50 mcg with norgestrel 500 mcg tab 130802 500
187601 1876 Tab 10 mg tab 220501 10
187602 1876 Tab 25 mg tab 220501 25
187603 1876 Oral liq 10 mg per 5 ml ml 220501 2
188102 1881 Paste 100,000 u per g g 100701
188103 1881 Topical powder 100,000 u per g g 100701
188104 1881 Pastilles 100,000 u tab 13107 100000
188105 1881 Oral liq 100,000 u per ml ml 13107 100000
188106 1881 Oral powder 5,520 u per mg (for reconstitution) g 160401
188107 1881 Pessaries 100,000 u pess 131001
188108 1881 Vaginal crm 100,000 u per 4 g with applicator g 131001
188109 1881 Vaginal crm 100,000 u per 5 g with applicator(s) g 131001
188113 1881 Crm 100,000 u per g g 100701
188114 1881 Oint 100,000 u per g g 100701
188125 1881 Tab 500,000 u tab 160401 500000
188126 1881 Cap 500,000 u cap 160401 500000
188601 1886 Implant 50 mg unit 141201 50
188602 1886 Implant 100 mg unit 141201 100
188605 1886 TDDS 25 mcg per day patch 141104 25
188606 1886 TDDS 50 mcg per day patch 141104 50
188607 1886 TDDS 100 mcg per day patch 141104 100
188608 1886 TDDS 3.9 mg (releases 50 mcg of oestradiol per day) patch 141104 49
188609 1886 TDDS 7.8 mg (releases 100 mcg of oestradiol per day) patch 141104 99
188610 1886 Tab 2 mg tab 141104 2
188611 1886 Tab 1 mg tab 141104 1
188801 1888 Conjugated, equine tab 300 mcg tab 141104 0.3
188802 1888 Conjugated, equine tab 625 mcg tab 141104 0.625
188803 1888 Conjugated, equine tab 1.25 mg tab 141104 1.25
188805 1888 Conjugated, equine vaginal crm 625 mcg per g with applicator g 131402
190301 1903 Aerosol inhaler 750 mcg per dose dose 284502 750
190601 1906 Tab 500 mgtab 161301 500
190801 1908 Tab 100 mgtab 191601 100
190802 1908 Inj 30 mg per ml, 2 ml inj 191601 60
190901 1909 Tab 50 mg tab 220104 50
191001 1910 Compound diagnostic sticks test 132201
191101 1911 Tab 10 mg tab 222501 10
191102 1911 Tab 15 mg tab 222501 15
191103 1911 Tab 30 mg tab 222501 30
191201 1912 Tab 40 mg tab 71601 40
191202 1912 Tab 80 mg tab 71601 80
191204 1912 Tab long-acting 160 mg tab 71601 160
191401 1914 Tab 5 mg tab 131904 5
191402 1914 Oral liq 5 mg per 5 ml ml 131904 1
191501 1915 Suppos 30 mg supp 220407
191601 1916 Nasal drops, 0.025% ml 285104 0.025
191606 1916 Nasal spray, 0.05% ml 285104 0.05
191607 1916 Metered nasal spray, 0.05% ml 285104 0.05
191608 1916 Nasal drops, 0.05% ml 285104 0.05
191701 1917 Tab 50 mg tab 140101 50
192201 1922 Inj 5 iu per ml, 1 ml ampoule inj 131402 5
192202 1922 Inj 10 iu per ml, 1 ml ampoule inj 131402 10
192203 1922 Inj 5 iu with ergometrine maleate 500 mcg per ml, 1 ml inj 131402 500
192501 1925 Tab 325 mgtab 12201 325
192502 1925 Cap 305 mgcap 12201 305
192503 1925 Powder g 12201
192504 1925 Tab EC 1,900 BP u lipase, 1,700 BP u amylase, 110 BP u protease tab 12201
192505 1925 Tab EC 5,600 BP u lipase, 5,000 BP u amylase, 330 BP u protease tab 12201
192506 1925 Cap 8,000 BP u lipase, 9,000 BP u amylase, 430 BP u protease cap 12201
192507 1925 Grans EC g 12201
192508 1925 Powder, strong g 12201
192509 1925 Tab EC 7,400 FIP u lipase, 7,000 FIP u amylase, 420 FIP u protease tab 12201
192510 1925 Tab EC 13,500 FIP u lipase, 13,000 FIP u amylase, 760 FIP u protease tab 12201
192511 1925 Cap 8,000 USP u lipase, 30,000 USP u amylase, 30,000 USP u protease cap 12201 8000
192512 1925 Cap EC 8,000BP u lipase, 9,000BP u amylase, 210BP u protease cap 12201 8000
192513 1925 Cap EC 25,000 BP u lipase, 18,000 BP u amylase, 1,000 BP u protease cap 12201 25000
192514 1925 Cap EC 5,000 BP u lipase, 3,000 BP u amylase, 350 BP u protease cap 12201 5000
192515 1925 Cap EC 25,000 BP u lipase, 22,500 BP u amylase, 1,250 BP u protease cap 12201 25000
192525 1925 Cap EC 10,000 BP u lipase, 9,000 BP u amylase and 210 BP u protease cap 12201 10000
192701 1927 Inj 20 mg per ml, 1 ml inj 220407 20
192801 1928 Inj 12 mg per ml, 10 ml ampoule inj 74001 120
192902 1929 Oral liq 120 mg per 5 ml ml 220404 24
192903 1929 Oral liq 250 mg per 5 ml ml 220404 50
192904 1929 Suppos 125 mg supp 220404 125
192905 1929 Suppos 250 mg supp 220404 250
192906 1929 Suppos 500 mg supp 220404 500
192907 1929 Powder g 380101
192908 1929 Tab 500 mgtab 220404 500
193101 1931 Tab paracetamol 500 mg with codeine phosphate 8 mg tab 220407 500
194203 1942 Tab 125 mgtab 190701 125
194204 1942 Tab 250 mgtab 190701 250
194401 1944 Tab 25 mg tab 220407 25
194402 1944 Tab 50 mg tab 220407 50
194403 1944 Inj 30 mg per ml, 2 ml inj 220407 60
194901 1949 Tab 100 mgtab 72202 100
195001 1950 Tab 2.5 mgtab 222201 2.5
195002 1950 Tab 10 mg tab 222201 10
195301 1953 Tab 50 mg tab 220407 50
195302 1953 Tab 100 mgtab 220407 100
195303 1953 Inj 50 mg per ml, 1 ml inj 220407 50
195304 1953 Inj 50 mg per ml, 1.5 ml inj 220407 75
195305 1953 Inj 50 mg per ml, 2 ml inj 220407 100
195501 1955 Tab 15 mg tab 220504 15
195604 1956 Inj 200 mg per ml, 1 ml inj 220701 200
195605 1956 Powder g 380101
195625 1956 Inj 200 mg per ml, 1 ml ampoule inj 222801
196601 1966 Cap 10 mg cap 70401 10
197001 1970 Tab 250 mgtab 160307 250
197002 1970 Tab 500 mgtab 160307 500
197003 1970 Oral 125 mg per 5 ml ml 160307
197004 1970 Oral liq 250 mg per 5 ml ml 160307
197025 1970 Cap potassium salt 250 mg cap 160307 250
197026 1970 Cap potassium salt 500 mg cap 160307 500
197027 1970 Grans for oral liq 125 mg per 5 ml ml 160307 125
197028 1970 Grans for oral liq 250 mg per 5 ml ml 160307 250
197101 1971 Inj 10 mg per ml, 1 ml inj 70401 10
197201 1972 Eye drops 0.12% ml 310317
197301 1973 Eye drops 0.12% with zinc sulphate 0.25% ml 310317
197801 1978 Tab 50 mg tab 220702 50
197802 1978 Cap 30 mg cap 220702 30
197803 1978 Cap 100 mgcap 220702 100
197804 1978 Oral liq 30 mg per 5 ml ml 220702 6
197805 1978 Oral liq 100 mg per 5 ml ml 220702 20
197806 1978 Inj 50 mg per ml, 2 ml inj 220701 100
197807 1978 Inj 50 mg per ml, 5 ml inj 220701 250
198501 1985 Inj 500 mcg per ml, 2 ml inj 190101 1000
198601 1986 Tab 10 mg tab 40403 10
198602 1986 Inj 1 mg per 0.5 ml, 0.5 ml inj 40403 1
198603 1986 Inj 10 mg per ml, 1 ml inj 40403 10
198625 1986 Inj 2 mg per 0.2 ml inj 40403 2
198701 1987 Eye drops 0.5% ml 310309
198702 1987 Eye drops 1% ml 310309
198703 1987 Eye drops 2% ml 310309
198704 1987 Eye drops 3% ml 310309
198705 1987 Eye drops 4% ml 310309
198706 1987 Eye drops 6% ml 310309
198707 1987 Eye drops 2% single dose dose 310309
198708 1987 Eye inserts dev 310309
198901 1989 Tab 10 mg with clopamide 5 mg tab 71901 10
199001 1990 Tab 2 mg tab 222201 2
199002 1990 Tab 10 mg tab 222201 10
199025 1990 Tab 4 mg tab 222201
199104 1991 Tab 5 mg tab 71601 5
199105 1991 Tab 10 mg tab 71601 10
199106 1991 Tab 15 mg tab 71601 15
199301 1993 2% with pyrethrins I and II 0.165% shampoo ml 101701
199401 1994 Inj 50 mg per ml, 1 ml inj 222204 50
199402 1994 Inj 50 mg per ml, 2 ml inj 222204 100
199501 1995 Tab 50 mg tab 11007 50
199603 1996 Inj 20 mg per ml 1 ml inj 190402 20
199604 1996 Tab dispersible 10 mg tab 190402 10
199605 1996 Cap 10 mg cap 190402 10
199606 1996 Tab dispersible 20 mg tab 190402 20
199607 1996 Cap 20 mg cap 190402 20
199801 1998 Tab 500 mgtab 160307 500
200001 2000 Tab 500 mcg tab 221304 500
200002 2000 Tab 1 mg tab 221304 1
200401 2004 Eye drops 5,000 u with neomycin sulphate 2700 mcg and gramicidin 25 mcg per ml ml 310301
200801 2008 Gel g 100401
201002 2010 Eye drops 1.4% ml 310313
201003 2010 Eye drops 3% ml 310313
201301 2013 Tab eff 500 mg (16 mmol) tab 41004 300
201601 2016 Tab eff 548 mg (14 m eq) with chloride 285 mg (8 m eq) tab 41004 548
201602 2016 Tab long-acting 600 mg tab 41004 600
201603 2016 Inj 75 mg per ml, 10 ml inj 41001 750
201604 2016 Inj 150 mg per ml, 10 ml inj 41001 1500
201605 2016 Potassium chloride g 380101
203101 2031 Tab 0.5 mgtab 70401 0.5
203102 2031 Tab 1 mg tab 70401 1
203103 2031 Tab 2 mg tab 70401 2
203104 2031 Tab 5 mg tab 70401 5
203201 2032 Eye drops 0.12% ml 310304
203202 2032 Eye drops 1% ml 310304
203301 2033 Eye drops 0.5% with neomycin sulphate 0.5% and polymyxin B sulphate 5,000 u per ml ml 310304
203401 2034 Suppos 5 mg supp 10404
203402 2034 Enema 20 mg 100 ml en 10404 20
203425 2034 Oral liq 5 mg per ml ml 140701 5
203501 2035 Eye drops 0.2% with sulphacetamide sodium 10% and phenylephrine hydrochloride 0.12% ml 310304
203601 2036 Tab 5 mg tab 140701 5
203801 2038 Tab 1 mg tab 140701 1
203802 2038 Tab 2.5 mgtab 140701 2.5
203803 2038 Tab 5 mg tab 140701 5
203804 2038 Tab 20 mg tab 140701 20
203805 2038 Tab 10 mg tab 140701 10
203806 2038 Tab 50 mg tab 140701 50
204101 2041 Tab 250 mgtab 220702 250
204201 2042 Tab 500 mgtab 191301 500
204401 2044 Tab long-acting 500 mg tab 71301 500
204501 2045 Tab 625 mcg conjugated equine (28) and 150 mcg norgestrel tab (12) tab 141114
204502 2045 Tab 1.25 mg conjugated equine (28) and 150 mcg norgestrel tab (12) tab 141114 1
204601 2046 Inj 1 mega uinj 160307 1000000
204602 2046 Inj 1.5 g in 3.4 ml syringe inj 160307 1500000
204701 2047 Cap 50 mg cap 250107 50
204901 2049 Tab 5 mg tab 220104 5
205002 2050 Tab 625 mcg conjugated equine (28) and 10 mg medroxyprogesterone acetate tab (14) tab 141114
205003 2050 Tab 625 mcg conjugated equine with 2.5 mg medroxyprogesterone acetate tab (28) tab 141114
205004 2050 Tab 625 mcg conjugated equine with 5 mg medroxyprogesterone acetate tab (28) tab 141114
205005 2050 Tab 625 mcg conjugated equine (14) and 5 mg medroxyprogesterone acetate tab (14) tab 141114
205201 2052 Inj 50 mg per ml, 2 ml inj 141301 100
205202 2052 Inj 25 mg per ml, 1 ml inj 141301 25
205225 2052 Cap 100 mgcap 141301 100
205301 2053 Tab 2 mg with 75 mcg levonorgestrel (36) and tab 2 mg oestradiol (48) tab 141114 2
205401 2054 Tab 25 mg tab 221601 25
205601 2056 TDDS 50 mcg 10, and 1 mg norethisterone tab 12 txpk 141114
205602 2056 Tab 2 mg with 1 mg norethisterone acetate (10), and 2 mg oestradiol tab (12) and 1 mg oestradiol tab (6) tab 141114 2
205603 2056 Tab 2 mg with 1 mg norethisterone acetate tab 141114 2
205604 2056 Tab 1 mg with 0.5 mg norethisterone acetate tab 141114 1
205701 2057 Eye drops 0.1% ml 310301
205801 2058 Ear drops 2% with 1,2 - propanediol diacetate 3% and benzethonium chloride 0.02% ml 310101
205802 2058 Ear drops 2% with 1, 2-Propanediol diacetate 3% and benzethonium chloride 0.02% ml 310101
205901 2059 Inj 5 ml inj 220701
206001 2060 Tab 10 mg tab 71601 10
206002 2060 Tab 40 mg tab 71601 40
206004 2060 Inj 1 mg per ml, 1 ml inj 71601 1
206005 2060 Tab 160 mgtab 71601 160
206006 2060 Cap long-acting 160 mg cap 71601 160
206025 2060 Oral liq 4 mg per ml ml 71601 4
206201 2062 Tab 50 mg tab 141401 50
206301 2063 Inj 10 mg per ml, 5 ml inj 40704 50
206601 2066 Tab 60 mg tab 285104 60
206602 2066 Oral liq 30 mg per 5 ml ml 285104 6
206801 2068 Tab 125 mgtab 160101 125
206802 2068 Tab 250 mgtab 160101 250
206803 2068 Oral liq 50 mg per ml ml 160101 50
206804 2068 Sachets 2.5 g sach 160101
206901 2069 Tab 500 mgtab 161601 500
207001 2070 Tab 60 mg tab 190101 60
207101 2071 Tab 10 mg tab 13704 10
207102 2071 Tab 25 mg tab 13704 25
207103 2071 Tab 50 mg tab 13704 50
207104 2071 Tab 100 mgtab 13704 100
207105 2071 Pyridoxine hydrochloride g 380101
207301 2073 Tab 25 mg with sulphadoxine 500 mg tab 161001
207701 2077 Tab long-acting 250 mg tab 71301 250
207801 2078 Tab 200 mgtab 71301 200
207802 2078 Tab 300 mgtab 71301 300
207901 2079 Tab 200 mgtab 161204 200
207902 2079 Tab 300 mgtab 161204 300
208003 2080 Oral liq 150 mg per 10 ml ml 11003 15
208004 2080 Inj 25 mg per ml, 2 ml inj 11003 50
208005 2080 Tab 150 mgtab 11003 150
208006 2080 Tab 300 mgtab 11003 300
208025 2080 Cap 150 mgcap 11003 150
208026 2080 Cap 300 mgcap 11003 300
208701 2087 Tab 10 mg tab 13704 10
208801 2088 Tab 450 mgtab 161601 450
208802 2088 Tab 600 mgtab 161601 600
208803 2088 Cap 150 mgcap 161601 150
208804 2088 Cap 300 mgcap 161601 300
208805 2088 Oral liq 100 mg per 5 ml ml 161601
209001 2090 Inj 275 mg and 10 ml diluent inj 160310 275
209601 2096 Tab long-acting 4 mg tab 283001 4
209602 2096 Tab long-acting 8 mg tab 283001 8
209603 2096 Oral liq 400 mcg per ml ml 283001 0.4
209604 2096 Inj 500 mcg per ml, 1 ml inj 283001 500
209605 2096 Infusion 1 mg per ml, 5 ml inf 283001 5
209606 2096 Aerosol Inhaler, 100 mcg per dose dose 283010 100
209609 2096 Aerosol inhaler, 200 mcg per dose dose 283010 200
209611 2096 Aerosol inhaler, 100 mcg per dose, breath activated dose 283010 100
209612 2096 Powder for inhalation, 200 mcg per dose, 8 doses per disk disk 283010
209613 2096 Powder for inhalation, 400 mcg per dose, 8 doses per disk disk 283010
209614 2096 Nebuliser soln, 1 mg per ml, 2.5 ml neb 283010 2.5
209615 2096 Nebuliser soln, 2 mg per ml, 2.5 ml neb 283010 5
209616 2096 Aerosol inhaler, 100 mcg per dose CFC free dose 283010 100
209617 2096 Powder for inhalation, 50 mcg per dose, breath activated dose 283010 50
211401 2114 Crm 1% with chlorhexidine digluconate 0.2% g 100401
211425 2114 Crm 1% g 100401
212501 2125 Oral liq 500 mg with sodium bicarbonate 267 mg per 10 ml (aniseed) ml 10102 500
212525 2125 Oral liq 500 mg with sodium bicarbonate 267 mg and calcium carbonate 160 mg per 10 ml ml 10102
212526 2125 Tab 500 mg with sodium bicarbonate 267 mg and calcium carbonate 160 mg - peppermint flavour tab 10102
212601 2126 Inj 10 mg in 0.5 ml ampoule inj 190701 20
212602 2126 Inj 20 mg in 0.5 ml ampoule inj 190701 40
212603 2126 Inj 50 mg in 0.5 ml ampoule inj 190701 100
212801 2128 Inj 8.4%, 10 ml inj 41001 8.4
212802 2128 Inj 8.4%, 100 ml inj 41001 8.4
212803 2128 Powder g 380101
212825 2128 Powder BPg 380101
212826 2128 Inj 8.4%, 50 ml inj 41001
212827 2128 Cap 840 mgtab 41004
213201 2132 Inj 200 mg per ml, 5 ml inj 350408 1000
213302 2133 With pectin and gelatin paste g 13101
213307 2133 With pectin and gelatin powder g 13101
213501 2135 Tab 300 mgtab 41004 300
213502 2135 Inj 0.9%, 2 ml inj 41001 0.18
213503 2135 Inj 0.9%, 5 ml inj 41001 0.45
213504 2135 Inj 0.9%, 10 ml inj 41001 0.9
213505 2135 Inj 0.9%, 20 ml inj 41001 1.8
213506 2135 Inj 20%, 10 ml inj 41001 20
213507 2135 Powder g 380101
213509 2135 Inf 0.9% ml 41001
213525 2135 Inj 23.4%, 20 ml inj 41001
213526 2135 Soln 7% ml 284902 7
214001 2140 Enema 90 mg with sodium lauryl sulphoacetate 9 mg per ml, 5 ml en 12507 450
214201 2142 Grans eff 4 g sachets sach 131904
214402 2144 Powder for inhalation, 20 mg per dose dose 284001
214403 2144 Aerosol inhaler, 1 mg per dose dose 284001 1
214404 2144 Aerosol inhaler, 5 mg per dose dose 284001 5
214405 2144 Nebuliser soln, 10 mg per ml, 2 ml neb 284001 20
214406 2144 Cap 100 mgcap 10404 100
214407 2144 Eye drops 2% ml 310304
214408 2144 Eye oint 4%g 310304
214409 2144 Nasal drops, 2% ml 285102
214412 2144 Nasal spray, 4% ml 285102
214413 2144 Aerosol inhaler, 5 mg per dose CFC-free dose 284001 5
214901 2149 Tab 1.1 mg (0.5 mg elemental) tab 13820 1.1
214902 2149 Tab 20 mg tab 13820 20
214903 2149 Sodium fluoride g 380101
215801 2158 Urine diagnostic strips, buffered strip 11504
215825 2158 Test strip strip 11504
216001 2160 Powder g 41004
216401 2164 Inj 0.5% 2 ml inj 40401 0.5
216402 2164 Inj 1% 2 ml inj 40401 1
216403 2164 Inj 3% 1 ml inj 40401 3
216404 2164 Inj 3% 2 ml inj 40401 3
216601 2166 Tab 100 mgtab 220702 100
216602 2166 Tab 200 mg EC tab 220702 200
216603 2166 Tab 500 mg EC tab 220702 500
216604 2166 Oral liq 200 mg per 5 ml ml 220702 40
216605 2166 Inj 100 mg per ml, 4 ml inj 220702 400
216901 2169 Tab 80 mg tab 71601 80
216902 2169 Tab 160 mgtab 71601 160
216903 2169 Inj 10 mg per ml, 4 ml ampoule inj 71601 40
217101 2171 Inj 2 g inj 160313
217301 2173 Tab 250 mgtab 160313 250
217302 2173 Tab 500 mgtab 160313 500
217601 2176 Tab 25 mg tab 73104 25
217602 2176 Tab 100 mgtab 73104 100
217603 2176 Oral liq 5 mg per ml ml 73104
218301 2183 Tab 1 mg tab 250401 1
218801 2188 Powder 25,000 u with streptokinase 100,000u g 103107
219101 2191 Tab 1 g tab 11013 1000
219301 2193 Tab 100 mgtab 190401 100
219302 2193 Tab 200 mgtab 190401 200
219401 2194 Eye drops 10% ml 310301
219402 2194 Sulphacetamide sodium g 380101
220501 2205 Tab 500 mgtab 10404 500
220502 2205 Tab EC 500 mg tab 10404 500
220503 2205 Suppos 500 mg supp 10404 500
220504 2205 Enema 3 g per 100 ml en 10404 3000
220601 2206 Tab 100 mgtab 191301 100
220602 2206 Tab 200 mgtab 191301 200
221201 2212 Tab 50 mg tab 220702 50
221202 2212 Tab 200 mgtab 220702 200
221301 2213 Oint g 102501
221302 2213 Crm g 102501
221304 2213 Lotn ml 102501
221325 2213 Lotn, g 102501
221801 2218 Tab 10 mg tab 250401 10
221802 2218 Tab 20 mg tab 250401 20
222002 2220 Soln 2.3% with triethanolamine lauryl sulphate and fluorescein sodium ml 101901
222101 2221 Bath emul 7.5% coal tar, 2.5% cade oil, 7.5% compound ml 101901
222401 2224 Cap 10 mg cap 222801 10
222402 2224 Cap 20 mg cap 222801 20
222425 2224 Tab 10 mg tab 222801 10
223701 2237 Tab 25 mg tab 220107 25
223801 2238 Blue diagnostic strips test 132201
223901 2239 Inj 250 mcg per ml, 1 ml ampoule inj 140701 0.25
223903 2239 Inj 1 mg per ml, 1 ml inj 140701 1
224101 2241 Cap 250 mgcap 160310 250
224103 2241 Ear/eye oint 1% g 310201
225001 2250 Tab 10 mg tab 13704 10
225002 2250 Tab 25 mg tab 13704 25
225003 2250 Tab 50 mg tab 13704 50
225004 2250 Thiamine hydrochloride g 380101
225201 2252 Tab 40 mg tab 250104 40
225501 2255 Tab 10 mg tab 222201 10
225502 2255 Tab 25 mg tab 222201 25
225503 2255 Tab 50 mg tab 222201 50
225504 2255 Tab 100 mgtab 222201 100
225505 2255 Tab long-acting 200 mg tab 222201 200
225506 2255 Oral liq 1%ml 222201
225507 2255 Oral liq 3%ml 222201
225701 2257 Inj 15 mg inj 250101 15
225702 2257 Eye drops 15 mg ml 310317 15
226001 2260 Tab 2 mg tab 222201 2
226002 2260 Tab 10 mg tab 222201 10
226201 2262 Compound, BPC ml 13109
226202 2262 Compound BP ml 380101
226301 2263 Tab 50 mcgtab 141401 0.05
226302 2263 Tab 100 mcg tab 141401 0.1
226325 2263 Tab 25 mcgtab 141401 0.03
226601 2266 Tab 10 mg tab 71601 10
226602 2266 Eye drops 0.25% ml 310305
226604 2266 Eye drops 0.5% ml 310305
226605 2266 Eye drops 0.25%, gel forming ml 310305
226606 2266 Eye drops 0.5%, gel forming ml 310305
226801 2268 Eye drops 0.5% with pilocarpine 2% ml 310305
226802 2268 Eye drops 0.5% with pilocarpine 4% ml 310305
226901 2269 Tab 500 mgtab 161301 500
227001 2270 Pessaries 100 mg with applicator pess 131001
227002 2270 Vaginal oint 6.5% with applicator g 131001
227003 2270 Lotn 1% ml 100701
227004 2270 Crm 1% g 100701
227401 2274 Inj 40 mg per ml, 1 ml inj 160313 40
227402 2274 Inj 40 mg per ml, 2 ml inj 160313 80
227404 2274 Eye drops 0.3% ml 310301
227405 2274 Eye oint 0.3% g 310301
227501 2275 Tab 400 mgtab 71301 400
227701 2277 Tab 500 mgtab 11312 500
228501 2285 Tab 10 mg tab 220504 10
228601 2286 Liq 0.05% g 100101
228602 2286 Lotn 0.05%ml 100101
228603 2286 Crm 0.05%g 100101
228604 2286 Gel 0.025%g 100101
228625 2286 Cap 10 mg cap 250107 10
228626 2286 Crm 0.5 mg per g g 100101
229101 2291 Inj 20 mg per ml, 1 ml inj 191001 20
229301 2293 Tab 50 mg with hydrochlorothiazide 25 mg tab 73107 50
229501 2295 Tab 125 mcg tab 222801 125
229502 2295 Tab 250 mcg tab 222801 250
229801 2298 Tab 1 mg tab 222201 1
229802 2298 Tab 2 mg tab 222201 2
229803 2298 Tab 5 mg tab 222201 5
229804 2298 Cap long-acting 15 mg cap 222201 15
229805 2298 Oral liq 1 mg per ml ml 222201 1
230001 2300 Tab 100 mgtab 160313 100
230002 2300 Tab 300 mgtab 160313 300
230101 2301 Tab 10 mg tab 220501 10
230103 2301 Cap 50 mg cap 220501 50
Trial Version
Not all rows exported
Pharmacode BrandCodeQuantity Multiple Specified Stamp
200034 22410301 3.5 0 TRUE 14007372418075590656
200069 18630601 100 0 TRUE 14079430012113518592
200131 22860201 50 0 TRUE 14151487606151446528
200182 18430101 15 0 TRUE 18177163613788176384
200190 22380102 100 0 TRUE 18249221207826104320
200212 21760102 100 0 TRUE 14223545200189374464
200220 21760203 100 0 TRUE 14295602794227302400
200247 11081103 200 0 TRUE 14367660388265230336
200255 18060103 100 0 TRUE 14439717982303158272
200263 18060303 100 0 TRUE 14511775576341086208
200271 17730101 25 0 TRUE 14583833170379014144
200298 17730201 25 0 TRUE 14655890764416942080
200301 18760301 500 0 TRUE 14727948358454870016
200328 18760101 250 0 FALSE 14760566470404472832
200336 18760201 250 0 FALSE 14832624064442400768
200379 19030101 300 0 TRUE 18321278801864032256
200417 10380401 100 0 TRUE 14800005952492797952
200506 10530101 500 0 TRUE 14872063546530725888
200549 10800101 1 1 TRUE 12331260400019439616
200573 13150101 100 0 TRUE 15016178734606581760
200581 13150201 100 0 TRUE 15088236328644509696
200603 19170101 100 0 TRUE 15160293922682437632
200638 27070101 50 0 TRUE 15232351516720365568
200689 15770201 100 0 TRUE 15304409110758293504
200751 22060102 100 0 TRUE 15376466704796221440
200891 10970501 15 0 TRUE 18393336395901960192
200905 10970601 15 0 TRUE 90988985244975104
200980 20420101 100 0 TRUE 15448524298834149376
200999 11280201 30 0 TRUE 13193884446614355968
201022 19110103 500 0 TRUE 15520581892872077312
201030 19110201 500 0 TRUE 15592639486910005248
201049 19110303 100 0 TRUE 15664697080947933184
201103 23740201 300 0 TRUE 163046579282903040
201111 23740501 20 0 TRUE 15736754674985861120
201200 27160302 100 0 TRUE 15808812269023789056
201286 17180401 84 28 TRUE 756388133607571456
201308 38122525 10 TRUE 9456204619152621568
201316 11670401 100 0 TRUE 15880869863061716992
201324 11670101 30 0 TRUE 15952927457099644928
201413 17170801 100 0 TRUE 16024985051137572864
201421 17170601 100 0 TRUE 16097042645175500800
201448 17170201 100 0 TRUE 16169100239213428736
201472 11730101 100 0 TRUE 16241157833251356672
201499 11890101 100 0 TRUE 16313215427289284608
201502 11890201 100 0 TRUE 16385273021327212544
201510 12050101 300 0 TRUE 1370902983348322304
201529 12090101 1 1 TRUE 12403317994057367552
201588 12170402 200 0 FALSE 13149227781852233728
201642 20350101 5 0 TRUE 235104173320830976
201669 12610101 1 1 TRUE 4837552095051644928
201677 12580101 10 0 TRUE 16745560991516852224
201685 12580201 4 0 TRUE 16817618585554780160
201693 12590104 10 0 TRUE 16889676179592708096
201707 12590404 3.5 0 TRUE 16961733773630636032
201715 12570101 3.5 0 TRUE 307161767358758912
201731 11300201 1 1 FALSE 18024125888852918272
201758 11300101 100 0 TRUE 17105848961706491904
201766 15890101 10 1 TRUE 7813041666046033920
201782 10550101 100 0 TRUE 17249964149782347776
201804 10030101 50 0 FALSE 17322021743820275712
201820 11980103 10 0 TRUE 17394079337858203648
201839 11431201 15 0 TRUE 8029214448159817728
201847 11431001 100 0 TRUE 451276955434614784
201855 13240101 30 0 TRUE 523334549472542720
201863 13240101 75 0 TRUE 8677732794501169152
201871 13240101 500 0 TRUE 667449737548398592
201928 10160101 7.5 0 TRUE 17466136931896131584
201936 10160201 7.5 0 TRUE 17538194525934059520
201960 10740101 20 0 TRUE 17610252119971987456
201979 10740201 12 0 TRUE 17682309714009915392
202029 11472501 15 0 TRUE 17754367308047843328
202045 10210201 100 0 TRUE 17826424902085771264
202096 10360101 50 0 TRUE 17898482496123699200
202118 11000201 1 1 TRUE 6960153794915074048
202126 11000101 100 0 TRUE 18042597684199555072
202185 12800201 100 0 TRUE 18114655278237483008
202193 12920101 500 0 TRUE 18186712872275410944
202215 13200701 20 0 TRUE 739507331586326528
202223 13200601 20 0 TRUE 811564925624254464
202231 13200301 35 0 TRUE 883622519662182400
202258 13200101 6 0 TRUE 18258770466313338880
202266 13180501 5 1 TRUE 4870202092838453248
202274 13180101 100 0 TRUE 18402885654389194752
202320 12820101 100 0 TRUE 100538243732209664
202371 12440301 500 0 TRUE 172595837770137600
202436 10260104 250 0 FALSE 8786676804627726336
202452 24690101 100 0 TRUE 316711025845993472
202479 24690201 100 0 TRUE 388768619883921408
202487 10260202 100 0 FALSE 8858734398665654272
202525 12830601 10 1 TRUE 4366080409549668352
202576 12830201 100 0 TRUE 604941401997705216
202584 12830301 100 0 TRUE 676998996035633152
202592 12830401 100 0 TRUE 749056590073561088
202614 12550101 25 0 TRUE 821114184111489024
202622 12550201 25 0 TRUE 893171778149416960
202665 23640102 100 0 TRUE 965229372187344896
202681 60470201 10 1 TRUE 8113075299521921024
202746 10150301 1 0 TRUE 1109344560263200768
202770 17180801 63 21 TRUE 18194044415809421312
202800 17180601 63 21 TRUE 18266102009847349248
202827 17180701 84 28 TRUE 828445727645499392
202878 10530103 500 0 FALSE 15595261822142251008
202967 11160101 500 0 TRUE 1397574936414912512
202975 11160201 500 0 TRUE 1469632530452840448
203017 17180802 63 21 TRUE 18338159603885277184
203033 17180902 84 28 TRUE 900503321683427328
203041 17181001 63 21 TRUE 18410217197923205120
203068 17181101 84 28 TRUE 972560915721355264
203084 10200101 100 0 TRUE 1685805312566624256
203092 10200201 100 0 TRUE 1757862906604552192
203106 15670202 100 0 TRUE 17248916315201077248
203122 20600502 250 0 TRUE 1901978094680408064
203149 13610102 100 0 TRUE 1974035688718336000
203211 20600103 500 0 FALSE 826994372296835072
203238 20600502 50 0 FALSE 2046093282756263936
203270 24190101 100 0 TRUE 2118150876794191872
203300 24830701 56 0 TRUE 2190208470832119808
203343 38462525 1 TRUE 10879629073936547840
203351 13700101 15 0 TRUE 955680113700110336
203386 13710101 1 0 TRUE 2262266064870047744
203416 13030201 100 0 TRUE 2334323658907975680
203432 13720201 100 0 TRUE 2406381252945903616
203483 10700103 100 0 TRUE 2478438846983831552
203505 13180801 100 0 TRUE 16932480167262027776
203513 13610401 500 0 TRUE 2622554035059687424
203610 15440402 5 1 FALSE 5014317280914309120
203629 15440402 25 1 TRUE 5086374874952237056
203637 15440501 5 1 FALSE 4909609689089572864
203645 15440501 25 1 TRUE 4981667283127500800
203696 15440101 250 0 FALSE 2982842005249327104
203718 15440101 1000 0 TRUE 3054899599287255040
203726 15440203 50 0 TRUE 3126957193325182976
203734 15460801 15 0 TRUE 1027737707738038272
203742 29270501 100 0 TRUE 1099795301775966208
203882 29270401 100 0 TRUE 1171852895813894144
203890 14430102 3 0 TRUE 3199014787363110912
203912 22950101 100 0 TRUE 3271072381401038848
203920 22950201 100 0 TRUE 17337195004283584512
203939 29040101 200 0 TRUE 1243910489851822080
203947 16260101 100 0 TRUE 3343129975438966784
203971 29050703 500 0 TRUE 3415187569476894720
203998 21440201 50 0 TRUE 3487245163514822656
204102 38332525 1 TRUE 14145579930175406080
204129 12300101 1 1 TRUE 5053724877165428736
204137 12300202 1 1 TRUE 5125782471203356672
204153 29050102 25 0 TRUE 3703417945628606464
204188 11280503 40 0 TRUE 13410057228728139776
204218 11780101 2 0 TRUE 5126901774040432640
204277 22680101 5 0 TRUE 1388025677927677952
204315 17280201 100 0 TRUE 3775475539666534400
204331 22680201 5 0 TRUE 1460083271965605888
204366 22660501 2.5 0 TRUE 1532140866003533824
204374 22660601 2.5 0 TRUE 1604198460041461760
204404 13670101 100 0 FALSE 3847533133704462336
204412 13670101 500 0 TRUE 3919590727742390272
204420 32640801 100 0 TRUE 1676256054079389696
204471 13160401 5 1 TRUE 3069043716866965504
204498 13160301 10 0 TRUE 1748313648117317632
204501 13160101 100 0 TRUE 4063705915818246144
204528 18760301 100 0 FALSE 4135763509856174080
204536 13160201 100 0 TRUE 4207821103894102016
204544 38012525 5 0 TRUE 4279878697932029952
204595 10010201 100 0 TRUE 4351936291969957888
204617 10010301 100 0 TRUE 4423993886007885824
204625 10010101 28 0 TRUE 4496051480045813760
204641 13610103 100 0 TRUE 4568109074083741696
204676 13610205 500 0 TRUE 4640166668121669632
204706 17230201 100 0 FALSE 6029362226421301248
204714 10870101 1000 0 FALSE 4784281856197525504
204730 38012625 5 0 TRUE 4856339450235453440
204757 12970401 10 1 TRUE 5197840065241284608
204781 10940104 100 0 TRUE 5000454638311309312
204803 38012725 5 0 TRUE 5072512232349237248
204838 17180201 63 21 TRUE 107869787266220032
204846 10590401 100 0 TRUE 5216627420425093120
204854 10590101 100 0 TRUE 5288685014463021056
204870 10590203 100 0 TRUE 5360742608500948992
204889 38012825 5 0 TRUE 5432800202538876928
204897 10590303 100 0 TRUE 5504857796576804864
204919 24680201 500 0 FALSE 4824504190564827136
204927 24680101 100 0 FALSE 5400964942868250624
204935 10260103 100 0 TRUE 5576915390614732800
204943 22550101 84 0 TRUE 9473344905918021632
204951 15150101 100 0 TRUE 5648972984652660736
204986 22550201 84 0 TRUE 9113056935728381952
204994 22550301 84 0 TRUE 8176308213235318784
205001 22550402 84 0 TRUE 8032193025159462912
205028 21940101 15 0 TRUE 5436177902259404800
205044 14431004 15 0 TRUE 1820371242155245568
205052 14431004 30 0 FALSE 1892428836193173504
205095 14430101 3 0 TRUE 5721030578690588672
205133 60260201 50 0 TRUE 5793088172728516608
205141 60260301 100 0 TRUE 5865145766766444544
205168 60260301 150 0 TRUE 5937203360804372480
205257 60270401 100 0 TRUE 6009260954842300416
205265 28320201 20 0 TRUE 6081318548880228352
205273 60270301 100 0 TRUE 6153376142918156288
205311 60270202 100 0 TRUE 6225433736956084224
205346 60260601 5 1 TRUE 5269897659279212544
205354 14600101 50 0 TRUE 6369548925031940096
205370 20520201 10 1 TRUE 5341955253317140480
205397 20520101 10 1 TRUE 5414012847355068416
205494 15890103 10 1 TRUE 17696172356612915200
205508 15890402 1 1 FALSE 17768229950650843136
205516 15890701 1 1 FALSE 5486070441392996352
205524 15890103 1 1 FALSE 17840287544688771072
205567 15890404 1 1 FALSE 17912345138726699008
205575 15890702 1 1 TRUE 5558128035430924288
205621 16170101 100 0 TRUE 7018067271373291520
205648 16170201 100 0 TRUE 7090124865411219456
205664 17300401 100 0 FALSE 7162182459449147392
205672 17300401 500 0 FALSE 7234240053487075328
205680 17300202 100 0 TRUE 7306297647525003264
205737 17320201 100 0 TRUE 7378355241562931200
205745 17320301 100 0 TRUE 7450412835600859136
205893 15350101 50 0 FALSE 7522470429638787072
205915 15350201 50 0 FALSE 7594528023676715008
205966 10540101 100 0 TRUE 7666585617714642944
205982 16170604 25 0 TRUE 7738643211752570880
205990 16170601 25 0 TRUE 7810700805790498816
206024 24720101 500 0 TRUE 7882758399828426752
206032 18180102 50 0 TRUE 7954815993866354688
206040 22130205 100 0 TRUE 1964486430231101440
206075 16290201 15 0 TRUE 14392279553122762752
206083 14000101 5 0 TRUE 2108601618306957312
206105 14620301 100 0 TRUE 8026873587904282624
206180 60250101 25 0 TRUE 8098931181942210560
206229 14120501 5 1 TRUE 5630185629468852224
206245 14120201 250 0 FALSE 3702951752698429440
206261 24230101 100 0 TRUE 8315103964055994368
206318 11870101 100 0 FALSE 8387161558093922304
206326 11870101 500 0 FALSE 8459219152131850240
206377 15890404 5 1 FALSE 17984402732764626944
206474 10720201 100 0 FALSE 8603334340207706112
206482 10720201 500 0 TRUE 8675391934245634048
206504 10720301 100 0 TRUE 8747449528283561984
206512 10720401 20 0 TRUE 2180659212344885248
206547 13890101 100 0 TRUE 3420220034197225472
206563 13920101 100 0 TRUE 11271806179866574848
206571 13920101 500 0 TRUE 8891564716359417856
206660 13320101 100 0 TRUE 9140362207492571136
206687 13320201 100 0 TRUE 8963622310397345792
206709 13320301 100 0 TRUE 9035679904435273728
206717 13320102 100 0 TRUE 2267585502125228032
206725 13320102 500 0 FALSE 2339643096163155968
206733 13320202 100 0 TRUE 13353909567944130560
206741 13320202 500 0 FALSE 2411700690201083904
206776 13320302 100 0 TRUE 9107737498473201664
206830 13600101 100 0 TRUE 9179795092511129600
206857 13600201 100 0 TRUE 9251852686549057536
206865 16040102 100 0 TRUE 9323910280586985472
207012 14070101 85 0 TRUE 2252716806382813184
207020 13920202 500 0 TRUE 9395967874624913408
207152 13910101 100 0 TRUE 9468025468662841344
207195 13970103 100 0 FALSE 9540083062700769280
207209 13970103 500 0 TRUE 9612140656738697216
207217 13970203 100 0 FALSE 9684198250776625152
207225 13970203 500 0 TRUE 9756255844814553088
207233 13970302 100 0 TRUE 9828313438852481024
207276 14180101 100 0 FALSE 13598639965566140416
207357 13750101 10 0 TRUE 9900371032890408960
207373 13830601 3.5 0 TRUE 2324774400420741120
207381 10640201 3.5 0 TRUE 2396831994458669056
207403 14580601 75 0 TRUE 9972428626928336896
207411 14050301 1000 0 TRUE 10044486220966264832
207446 13830301 5 0 TRUE 2468889588496596992
207454 10640101 5 0 TRUE 2540947182534524928
207462 16330203 15 0 TRUE 2613004776572452864
207470 14590101 100 0 TRUE 10116543815004192768
207489 24240201 2.5 0 TRUE 2685062370610380800
207519 14680101 100 0 TRUE 10188601409042120704
207527 14680202 100 0 TRUE 10260659003080048640
207578 18530601 25 0 TRUE 10332716597117976576
207594 14090401 15 0 FALSE 9302492893589536768
207608 14090401 50 0 TRUE 2757119964648308736
207624 14090501 50 0 TRUE 2829177558686236672
207632 14090301 15 0 FALSE 9230435299551608832
207640 14090301 50 0 TRUE 2901235152724164608
207659 14100101 15 0 TRUE 2973292746762092544
207756 18610102 100 0 FALSE 10404774191155904512
207764 18610102 500 0 TRUE 10476831785193832448
207780 18610202 500 0 TRUE 10548889379231760384
207799 18610302 100 0 TRUE 10620946973269688320
207829 18610401 500 0 TRUE 10693004567307616256
207950 14760101 21 0 TRUE 10765062161345544192
207977 14760201 21 0 TRUE 10837119755383472128
208043 14270301 5 1 TRUE 5702243223506780160
208051 14270101 100 0 FALSE 17416937085088038912
208086 14431002 15 0 TRUE 3045350340800020480
208094 14431002 30 0 TRUE 3117407934837948416
208108 14431102 30 0 TRUE 11053292537497255936
208116 14430601 10 0 TRUE 3189465528875876352
208124 14430601 30 0 TRUE 3261523122913804288
208159 24780401 10 1 TRUE 5774300817544708096
208183 24780101 250 0 FALSE 14184105718101049344
208205 24780201 250 0 FALSE 11197407725573111808
208264 16250101 100 0 TRUE 11269465319611039744
208272 24710301 500 0 FALSE 3095121933654556672
208280 24710101 100 0 FALSE 3671582685957980160
208329 14230101 50 0 TRUE 3333580716951732224
208361 16320101 15 0 FALSE 3405638310989660160
208388 16320101 30 0 TRUE 3477695905027588096
208396 16320401 12 0 TRUE 11341522913648967680
208469 14370201 500 0 TRUE 11413580507686895616
208590 14280501 100 0 TRUE 11485638101724823552
208604 14280401 5 1 TRUE 5846358411582636032
208663 14380201 100 0 TRUE 11629753289800679424
208728 13810101 8 0 TRUE 3549753499065516032
208736 13810201 5 0 TRUE 3621811093103443968
208752 16330202 15 0 TRUE 3693868687141371904
208760 16330101 15 0 TRUE 3765926281179299840
208841 16340101 35 0 TRUE 3837983875217227776
208868 16340201 10 0 TRUE 11701810883838607360
208876 14810101 200 0 TRUE 11773868477876535296
208884 14810201 250 0 FALSE 182985123140993024
208914 15080301 10 0 TRUE 11845926071914463232
208965 10170101 10 0 TRUE 11917983665952391168
209058 14990101 100 0 FALSE 11990041259990319104
209066 15010101 150 0 FALSE 17358614590304288768
209074 32910501 150 0 FALSE 16704881260312395776
209082 16760101 5 1 TRUE 14525638218944086016
209120 15120101 100 0 TRUE 12278271636142030848
209244 15540701 15 0 TRUE 12350329230179958784
209317 15540801 15 0 TRUE 12422386824217886720
209538 15940101 100 0 TRUE 12494444418255814656
209546 16000101 15 0 TRUE 3910041469255155712
209554 16000201 15 0 TRUE 3982099063293083648
209570 11440702 5 0 TRUE 4054156657331011584
209597 11440201 5 1 TRUE 5918416005620563968
209600 11440101 100 0 TRUE 12638559606331670528
209635 11410102 5 0 TRUE 4126214251368939520
209686 16450102 500 0 TRUE 12710617200369598464
209694 16450202 100 0 TRUE 12782674794407526400
209708 16450401 30 0 TRUE 12854732388445454336
209716 16450301 100 0 TRUE 12926789982483382272
209724 11460301 15 0 TRUE 4198271845406867456
209759 11460201 15 0 TRUE 4270329439444795392
209775 15980201 400 0 TRUE 12998847576521310208
209783 15980301 400 0 TRUE 13070905170559238144
209813 17180301 63 21 TRUE 179927381304147968
209880 29390202 400 0 TRUE 4342387033482723328
209910 15720401 100 0 FALSE 4414444627520651264
209937 15440403 5 1 TRUE 4942259686876381184
209945 15440301 30 0 TRUE 13287077952673021952
209953 15440102 250 0 TRUE 13359135546710949888
209961 15440201 50 0 TRUE 13431193140748877824
210021 18140325 50 1 TRUE 3789619657246244864
210110 27160801 50 0 TRUE 4486502221558579200
210188 17200201 100 0 TRUE 13503250734786805760
210218 17200301 1 1 TRUE 5990473599658491904
210250 16140201 15 0 TRUE 13647365922862661632
210269 16140201 30 0 TRUE 4558559815596507136
210277 16140201 100 0 TRUE 4630617409634435072
210285 16140201 350 0 TRUE 4702675003672363008
210307 16140601 100 0 TRUE 4774732597710290944
210323 11710101 100 0 TRUE 13719423516900589568
210331 16140601 250 0 FALSE 6958735424915243008
210374 16140101 30 0 TRUE 13791481110938517504
210382 16140101 100 0 TRUE 4918847785786146816
210439 13030301 1 1 FALSE 6773281898169892864
210463 12160101 15 0 TRUE 4990905379824074752
210471 12160201 15 0 TRUE 5062962973862002688
210536 12590103 10 0 TRUE 13935596299014373376
210544 12590402 4 0 TRUE 14007653893052301312
210552 12590701 100 0 TRUE 14079711487090229248
210587 23310102 100 0 TRUE 14151769081128157184
210595 23310501 100 0 TRUE 14223826675166085120
210609 23310602 100 0 TRUE 14295884269204013056
210625 18140301 10 1 TRUE 3861677251284172800
210633 18140101 100 0 TRUE 14439999457279868928
210641 18140101 500 0 FALSE 14512057051317796864
210668 18140201 100 0 TRUE 14584114645355724800
210692 18110101 100 0 TRUE 14656172239393652736
210773 13090402 30 0 TRUE 14728229833431580672
210838 18230101 100 0 TRUE 14800287427469508608
210846 10030201 1 1 TRUE 6062531193696419840
210854 10500101 100 0 TRUE 14944402615545364480
210870 11431201 50 0 TRUE 5135020567899930624
210889 11431301 15 0 TRUE 8101272042197745664
210897 11431301 50 0 TRUE 5279135755975786496
210935 15330101 5 1 TRUE 5374886726080659456
210943 15330201 5 1 TRUE 5446944320118587392
210951 15330401 5 1 TRUE 5519001914156515328
211036 18810301 15 0 TRUE 15232632991697076224
211044 18811302 15 0 TRUE 5351193350013714432
211060 18811402 15 0 TRUE 5423250944051642368
211109 18810201 30 0 TRUE 5495308538089570304
211133 18810501 24 0 TRUE 5567366132127498240
211168 18810801 60 0 TRUE 15304690585735004160
211176 18810701 15 0 TRUE 15376748179772932096
211192 10410101 500 0 TRUE 15448805773810860032
211206 10400101 50 0 FALSE 15520863367848787968
211214 10400101 100 0 TRUE 3003935036316581888
211265 18430102 15 0 TRUE 5639423726165426176
211303 27820901 500 0 FALSE 12169595906852651008
211354 18410201 10 1 TRUE 7680729735294353408
211362 18410101 10 1 TRUE 6134588787734347776
211389 19550101 100 TRUE 8175231791351726080
211443 22740202 1 1 TRUE 15390610822375931904
211486 18390101 56 0 TRUE 15809093744000499712
211559 12730301 1 0 TRUE 15881151338038427648
211575 12440401 500 0 FALSE 15953208932076355584
211591 12440401 500 0 FALSE 16025266526114283520
211648 28600101 14 0 TRUE 16097324120152211456
211842 11360101 5 1 FALSE 12724479842972598272
211850 29390204 900 0 TRUE 5711481320203354112
211869 29390203 260 0 TRUE 16241439308228067328
211877 23171102 60 0 FALSE 16313496902265995264
212032 60030202 100 0 TRUE 16385554496303923200
212040 60030103 50 0 TRUE 16457612090341851136
212059 29050602 500 0 TRUE 5783538914241282048
212156 60320501 10 1 TRUE 6206646381772275712
212172 60320401 10 1 TRUE 6278703975810203648
212180 25100501 10 1 TRUE 15563168177239097344
212229 25280201 90 0 FALSE 6275226220531548160
212415 20540101 10 0 TRUE 16745842466493562880
212555 29340101 1000 0 TRUE 16817900060531490816
212741 23850103 25 0 TRUE 5855596508279209984
213071 11950101 25 0 TRUE 16889957654569418752
213098 18630301 30 0 TRUE 16962015248607346688
213101 18630401 30 0 TRUE 17034072842645274624
213128 18630101 60 0 TRUE 17106130436683202560
214396 10260201 90 0 FALSE 17178188030721130496
214507 60080301 20 0 TRUE 17250245624759058432
214515 60080401 20 0 TRUE 17322303218796986368
214531 24450101 5 0 TRUE 17394360812834914304
214558 11490101 5 0 TRUE 5927654102317137920
214728 60220101 250 0 FALSE 17466418406872842240
214736 60220101 500 0 FALSE 17538476000910770176
214833 28360101 100 0 TRUE 17610533594948698112
214949 10870103 24 0 TRUE 5320223405994147840
214965 10870103 48 0 FALSE 17682591188986626048
215112 14180101 10 0 TRUE 13526582371528212480
215929 24790201 100 0 TRUE 17754648783024553984
216518 39512525 1 TRUE 14777316430542012416
216836 10260201 30 0 FALSE 17826706377062481920
216879 15440101 30 0 FALSE 17898763971100409856
216909 39652525 1 TRUE 8104954306639167488
217050 20380301 30 0 FALSE 17970821565138337792
217093 20380401 30 0 FALSE 18042879159176265728
217107 10720204 30 0 FALSE 18114936753214193664
217158 10720304 30 0 FALSE 18186994347252121600
217379 15120102 30 0 FALSE 18259051941290049536
217387 15120202 30 0 FALSE 18331109535327977472
217867 22370101 112 0 FALSE 18403167129365905408
217875 17970103 30 0 TRUE 17553367786397368320
218235 14010901 20 0 FALSE 9747503732257456128
218278 60100101 10 0 TRUE 100819718708920320
218294 24710101 50 0 FALSE 5686773094903971840
218308 24710201 50 0 TRUE 172877312746848256
218375 28370301 15 0 TRUE 5999711696355065856
218383 28370401 15 0 TRUE 6071769290392993792
218405 24450901 5 0 TRUE 244934906784776192
218448 14370201 50 0 FALSE 316992500822704128
218510 24451001 5 0 TRUE 389050094860632064
218529 24451201 5 0 TRUE 461107688898560000
218537 24451101 5 0 TRUE 533165282936487936
219584 24450701 1 0 FALSE 605222876974415872
219843 38482625 1 TRUE 12320780954695106560
219916 38482525 1 TRUE 12104608172581322752
219924 28540101 30 0 TRUE 677280471012343808
220086 12320101 5 1 TRUE 6422819163886059520
220582 19310101 50 0 FALSE 821395659088199680
220590 19310101 100 0 FALSE 893453253126127616
220612 19290802 20 0 FALSE 965510847164055552
220620 19290802 50 0 FALSE 1037568441201983488
220639 19290802 100 0 FALSE 1109626035239911424
220922 32010101 100 0 FALSE 1181683629277839360
220930 32020101 100 0 FALSE 1253741223315767296
221058 10840301 25 0 FALSE 1325798817353695232
221066 10840301 50 0 FALSE 1397856411391623168
221074 10840301 100 0 FALSE 1469914005429551104
221155 32420101 100 0 FALSE 1541971599467479040
221198 32620101 50 0 TRUE 1614029193505406976
221201 32630101 25 0 TRUE 1686086787543334912
221244 32660101 50 0 FALSE 1758144381581262848
221252 32660101 100 0 FALSE 1830201975619190784
221260 32660101 500 0 TRUE 1902259569657118720
221368 32880101 25 0 FALSE 1974317163695046656
221376 32880101 50 0 FALSE 2046374757732974592
221392 32210301 50 0 TRUE 11920324526207926272
221503 15740601 100 0 TRUE 12064439714283782144
221511 15740601 200 0 TRUE 12136497308321710080
221554 63010101 100 0 FALSE 2262547539846758400
221562 63010101 500 0 TRUE 13029494264122310656
221570 33030201 100 0 TRUE 8821847982577025024
221589 33090101 25 0 FALSE 2406662727922614272
221619 18150101 6 0 FALSE 2478720321960542208
221686 33440101 50 0 FALSE 2550777915998470144
221694 33440101 100 0 FALSE 2622835510036398080
221708 33440101 200 0 FALSE 2694893104074326016
221740 33490601 200 0 FALSE 2766950698112253952
221759 33490601 500 0 FALSE 2839008292150181888
221775 16820101 25 1 TRUE 5662835627255660544
221783 33490301 500 0 TRUE 17913655756587008000
221813 33730101 25 0 TRUE 1328583880306851840
221856 24520801 30 0 FALSE 2983123480226037760
221864 33970101 500 0 TRUE 3055181074263965696
221872 34110301 100 0 FALSE 3127238668301893632
221880 28590101 30 0 FALSE 3199296262339821568
221945 32990101 100 0 FALSE 3271353856377749504
221953 32990101 200 0 FALSE 3343411450415677440
221961 32990101 500 0 FALSE 3415469044453605376
222011 29362525 100 TRUE 1811684000784187392
222240 10870102 24 0 TRUE 9851665966314815488
222445 15490101 100 0 TRUE 3487526638491533312
222666 23980302 30 0 TRUE 3559584232529461248
222976 63000301 10 0 TRUE 3631641826567389184
222992 63000302 10 0 TRUE 3703699420605317120
223018 63000101 5 1 TRUE 6494876757923987456
223034 63000104 5 1 TRUE 12475375588095295488
223042 63000305 10 0 TRUE 3919872202719100928
223166 12970101 60 0 TRUE 3991929796757028864
223174 12970201 60 0 TRUE 4063987390794956800
223549 24680101 50 0 TRUE 5473022536906178560
223689 11590101 120 0 TRUE 4136044984832884736
224553 19290301 100 0 FALSE 4208102578870812672
224715 25430302 28 0 TRUE 1885621759705612288
224731 25430702 28 0 TRUE 4280160172908740608
225045 29260101 150 0 TRUE 6143826884430921728
225053 21660202 100 0 TRUE 4352217766946668544
225061 21660302 100 0 TRUE 4424275360984596480
225088 22660204 5 0 TRUE 6215884478468849664
225096 22660404 5 0 TRUE 6287942072506777600
225118 21690102 60 0 FALSE 16914148009892118528
225126 21690202 60 0 FALSE 16842090415854190592
225134 15690101 90 0 TRUE 4496332955022524416
225142 16980202 200 0 TRUE 4568390549060452352
225231 13610101 500 0 TRUE 4640448143098380288
225665 18490101 90 0 TRUE 13745577599990497280
225762 10840202 100 0 FALSE 4712505737136308224
225770 10840101 100 0 FALSE 4784563331174236160
226173 10850101 1 1 TRUE 16615308446043996160
226203 12970104 120 0 FALSE 426180602530627584
226211 12970204 60 0 FALSE 570295790606483456
226238 12970304 30 0 FALSE 1146756542909906944
226262 14010303 30 0 FALSE 17587422960044474368
226297 14011203 30 0 FALSE 9158377705513680896
226572 21441201 22 0 TRUE 6359999666544705536
226610 10950202 30 0 TRUE 4928678519250092032
226645 10950102 30 0 TRUE 5000736113288019968
227048 17230101 50 0 TRUE 5072793707325947904
228435 15100102 60 0 TRUE 5144851301363875840
228443 15100202 60 0 TRUE 5216908895401803776
229040 13090401 30 0 TRUE 6432057260582633472
229059 13090301 30 0 TRUE 6504114854620561408
229075 16300101 15 0 TRUE 3669766292748894208
229253 27580401 6 1 TRUE 12547433182133223424
229369 27580101 6 1 FALSE 12619490776171151360
229385 27580201 6 1 TRUE 12691548370209079296
229504 27580301 6 1 TRUE 12763605964247007232
229520 27580801 6 1 FALSE 12004185377570029568
229644 16030101 10 1 TRUE 16471474732944850944
229652 15530102 100 0 TRUE 5721312053667299328
229660 27580501 6 1 FALSE 11643897407380389888
229687 27580601 6 1 FALSE 11715955001418317824
229695 12170301 300 0 FALSE 9026927791878176768
229709 27580701 6 1 FALSE 11788012595456245760
229717 26420102 100 0 TRUE 5937484835781083136
230391 18760101 50 0 TRUE 14688508876366544896
230413 18760201 50 0 TRUE 14904681658480328704
230707 20500412 168 0 FALSE 12467726285700857856
230731 12970104 100 0 TRUE 498238196568555520
230820 12970204 100 0 TRUE 642353384644411392
230855 12970304 100 0 TRUE 1651159701175402496
232165 12970103 30 0 TRUE 6081600023856939008
232246 12970203 30 0 FALSE 6153657617894866944
234524 17810101 100 0 TRUE 6225715211932794880
234532 15100401 30 0 TRUE 6297772805970722816
234540 15100501 30 0 TRUE 6369830400008650752
234672 29290801 200 0 TRUE 12205466374197215232
234680 29290201 200 0 TRUE 11556948027855863808
234788 29290501 200 0 TRUE 12133408780159287296
234885 29290101 200 0 TRUE 11124602463628296192
234893 29290401 200 0 TRUE 11701063215931719680
234907 13940125 1000 TRUE 4045187940983242752
235075 14980125 60 0 FALSE 11084267979074961408
235229 22862525 100 TRUE 9654649975291772928
236586 38282525 1 TRUE 15258249413601001472
236616 29270301 250 0 TRUE 17353399606653747200
236640 24700101 100 0 TRUE 6441887994046578688
236667 29270201 250 0 TRUE 17281342012615819264
236772 29270101 250 0 TRUE 17425457200691675136
237523 39382525 28 TRUE 10519713838188724224
238007 38422525 1 TRUE 8645843658760781824
238058 38422625 1 TRUE 8862016440874565632
238074 15720315 100 0 TRUE 7224690794999840768
238147 29330101 200 0 FALSE 5612469198610497536
238481 18130101 60 0 FALSE 6513945588084506624
238732 40172525 56 TRUE 826029001087647744
239070 10100101 6 0 TRUE 6586003182122434560
239852 17620101 15 0 TRUE 10152148200534835200
240206 12970102 10 0 FALSE 6658060776160362496
240311 24690301 500 0 TRUE 6730118370198290432
241113 25330401 100 0 TRUE 6802175964236218368
241172 21350402 50 1 TRUE 2636416677662687232
241180 23320302 50 1 TRUE 2708474271700615168
241202 16530101 1 0 TRUE 4078879176281554944
242675 18312001 10 0 TRUE 6946291152312074240
242756 18312101 10 0 TRUE 7018348746350002176
242993 10120101 100 0 TRUE 7090406340387930112
243000 10120201 100 0 TRUE 7162463934425858048
243078 60260302 100 0 TRUE 7234521528463785984
243086 60260502 100 0 TRUE 7306579122501713920
243094 60260102 100 0 TRUE 7378636716539641856
243108 15292525 1 TRUE 3763654690156314624
244368 28090201 70 0 TRUE 7450694310577569792
244457 28190401 5 0 TRUE 7368805983075696640
244481 20500411 168 0 FALSE 11963323127435362304
244651 29370201 200 0 TRUE 7594809498653425664
244805 25330301 1 0 FALSE 7666867092691353600
244937 10940105 300 0 FALSE 7738924686729281536
245283 10940205 150 0 FALSE 7810982280767209472
245356 10110101 20 0 FALSE 7883039874805137408
245364 10110101 60 0 TRUE 7955097468843065344
245372 10110201 60 0 TRUE 8027155062880993280
245380 10110301 60 0 TRUE 8099212656918921216
245402 10110401 60 0 TRUE 4798988923730657280
245410 33850101 250 0 TRUE 15335337273336004608
247510 38562825 5 TRUE 17192553150138023936
249033 38562625 5 TRUE 16760207585910456320
249068 27960401 30 0 TRUE 7440863577113624576
249076 27960401 100 0 TRUE 7512921171151552512
249572 38562725 5 TRUE 16976380368024240128
249890 13690201 1 0 FALSE 8243327844994777088
249904 24900101 60 0 TRUE 8315385439032705024
249912 24900201 30 0 TRUE 8387443033070632960
249955 18490101 100 0 FALSE 13817635194028425216
249998 29030101 250 0 TRUE 7584978765189480448
250007 29050701 500 0 TRUE 7657036359227408384
250023 23120101 100 0 TRUE 7729093953265336320
250066 23890801 100 0 TRUE 7801151547303264256
250074 23891001 30 0 TRUE 8459500627108560896
250082 23890901 100 0 TRUE 7873209141341192192
250090 23891101 30 0 TRUE 8531558221146488832
250112 17300403 100 0 FALSE 1867341279382208512
250120 17300201 100 0 TRUE 8603615815184416768
250139 10970101 100 0 TRUE 8675673409222344704
250163 10970302 5 1 TRUE 13516831902413094912
250201 14920101 200 0 TRUE 7945266735379120128
250244 60020101 50 0 TRUE 8819788597298200576
250252 60030102 50 0 TRUE 8891846191336128512
250260 60020201 50 0 TRUE 8963903785374056448
250287 22630101 1000 0 TRUE 9035961379411984384
250295 22630201 1000 0 TRUE 9108018973449912320
250309 17800101 100 0 TRUE 9180076567487840256
250422 24740101 50 0 TRUE 9252134161525768192
250511 18200501 10 0 TRUE 9324191755563696128
250538 18200401 10 0 TRUE 9396249349601624064
250554 18200103 100 0 FALSE 9468306943639552000
250570 18200203 100 0 TRUE 9540364537677479936
250678 19440101 50 0 TRUE 9612422131715407872
250686 19440201 50 0 TRUE 9684479725753335808
250732 18670301 200 0 TRUE 9756537319791263744
250767 17940101 100 0 TRUE 9828594913829191680
250775 17940201 60 0 TRUE 9900652507867119616
250821 28591002 250 0 TRUE 8017324329417048064
250848 16200601 40 0 TRUE 9972710101905047552
250856 16200501 7 0 TRUE 10044767695942975488
250872 19100101 50 0 TRUE 8089381923454976000
250880 21490201 100 0 TRUE 10116825289980903424
250929 11080101 200 0 TRUE 8161439517492903936
250937 18050101 100 0 TRUE 10188882884018831360
251003 17280101 60 0 TRUE 10260940478056759296
251011 20700101 100 0 TRUE 14586618233332170752
251089 21600101 450 0 TRUE 10332998072094687232
251097 22860301 20 0 TRUE 10405055666132615168
251100 22860401 60 0 TRUE 10477113260170543104
251119 22860101 30 0 TRUE 10549170854208471040
251178 15170101 200 0 TRUE 10621228448246398976
251186 20880301 100 0 TRUE 10693286042284326912
251194 20880401 100 0 TRUE 10765343636322254848
251208 20880501 60 0 TRUE 10837401230360182784
251216 20880101 30 0 TRUE 10909458824398110720
251224 20880201 30 0 TRUE 10981516418436038656
251232 16790201 100 0 TRUE 11053574012473966592
251240 16790301 100 0 TRUE 11125631606511894528
251321 23210101 100 0 TRUE 11197689200549822464
251410 18620101 100 0 TRUE 11269746794587750400
251461 22130101 14 0 TRUE 8233497111530831872
251534 21440901 15 0 TRUE 11341804388625678336
251585 22050201 100 0 TRUE 11413861982663606272
251593 22050301 10 0 TRUE 11485919576701534208
251615 22050101 100 0 TRUE 15111849440362627072
251623 22050101 500 0 FALSE 15183907034400555008
251666 20000101 100 0 TRUE 11557977170739462144
251704 11950201 100 0 TRUE 18095529273472319488
251763 17190601 10 1 FALSE 12835663558284935168
251771 17190701 10 1 FALSE 16615589921020706816
251801 17190801 10 1 FALSE 12907721152322863104
251917 17180501 84 28 TRUE 1044618509759283200
251933 15130101 100 0 TRUE 11918265140929101824
251976 12760101 40 0 FALSE 11990322734967029760
251984 12760101 100 0 TRUE 8449918383272493056
252018 12750101 40 0 FALSE 6207765684609351680
252026 12750101 100 0 TRUE 964461913071157248
252050 12750101 1000 0 FALSE 1036519507109085184
252077 12880101 15 0 TRUE 8305554705568759808
252115 22660105 100 0 TRUE 15995731444768964608
252204 20570101 10 0 TRUE 8377612299606687744
252212 27980101 500 0 TRUE 12350610705156669440
252220 17180901 84 28 TRUE 1116676103797211136
252247 27980202 250 0 FALSE 16184273499676737536
252263 24040601 400 0 TRUE 8449669893644615680
252271 24040401 1000 0 TRUE 12422668299194597376
252301 24040501 5 1 TRUE 12979778746360791040
252328 16310101 100 0 TRUE 12566783487270453248
252336 24040801 50 0 TRUE 8521727487682543616
252344 24040101 100 0 TRUE 12638841081308381184
252360 24040201 100 0 TRUE 12710898675346309120
252395 21320101 6 1 TRUE 7752787329332281344
252409 13730101 100 0 TRUE 12855013863422164992
252417 13730201 100 0 TRUE 12927071457460092928
252433 11912601 30 0 TRUE 2545516752859561984
252468 23120104 100 0 TRUE 8593785081720471552
252492 15460101 36 0 FALSE 1513514039517380608
252506 19870101 15 0 TRUE 13071186645535948800
252514 19870201 15 0 TRUE 13143244239573876736
252522 19870301 15 0 TRUE 13215301833611804672
252530 19870401 15 0 TRUE 13287359427649732608
252549 19870501 15 0 TRUE 13359417021687660544
252557 19870601 15 0 TRUE 13431474615725588480
252581 20040101 10 0 TRUE 13503532209763516416
252654 12970202 60 0 TRUE 13575589803801444352
252662 23770101 100 0 FALSE 13647647397839372288
252670 23770203 100 0 TRUE 13719704991877300224
252700 33200301 60 0 TRUE 13791762585915228160
252719 20160101 30 0 FALSE 13863820179953156096
252727 20460101 5 1 TRUE 13051836340398718976
252735 20460201 5 1 TRUE 12652422248934670336
252751 15720101 100 0 FALSE 8665842675758399488
252786 21930101 500 0 FALSE 824462197018066944
252808 13410101 100 0 TRUE 14079992962066939904
252816 24300401 30 0 TRUE 13886094086508642304
252824 24290601 100 0 TRUE 8809957863834255360
252832 24290101 100 0 TRUE 182986222652620800
252840 24290101 500 0 FALSE 255043816690548736
252859 24290201 100 0 TRUE 759446974956044288
252867 24290201 500 0 FALSE 831504568993972224
252891 20680101 6 0 FALSE 14152050556104867840
252905 20680101 18 0 TRUE 14224108150142795776
252913 20680201 6 0 TRUE 14296165744180723712
252956 19700401 500 0 FALSE 300354690871197696
252972 19700401 500 0 FALSE 18314471725376471040
253022 19700101 500 0 TRUE 14368223338218651648
253049 19700201 100 0 TRUE 14440280932256579584
253065 15290101 20 0 TRUE 8882015457872183296
253073 29320701 400 0 FALSE 7115557668873306112
253081 23100101 15 0 TRUE 9026130645948039168
253154 60280102 1 1 TRUE 12508307060858814464
253162 60280202 1 1 TRUE 12580364654896742400
253197 13630201 50 0 TRUE 14656453714370363392
253251 16200301 20 0 TRUE 9098188239985967104
253278 16200101 30 0 TRUE 9170245834023895040
253286 16200401 20 0 TRUE 14728511308408291328
253294 16200201 30 0 TRUE 9242303428061822976
253308 11680703 200 0 TRUE 9314361022099750912
253332 20730101 12 0 TRUE 14800568902446219264
253367 11680803 200 0 TRUE 9386418616137678848
253375 19560401 10 1 TRUE 13123893934436646912
253383 20600401 10 1 TRUE 13195951528474574848
253464 24520202 150 0 FALSE 9458476210175606784
253480 23170701 5 1 TRUE 4798144498800525312
253499 23170101 100 0 TRUE 15088799278597931008
253502 23170203 100 0 TRUE 15160856872635858944
253529 22550701 50 0 FALSE 15232914466673786880
253545 22550601 500 0 TRUE 15304972060711714816
253553 22550101 100 0 FALSE 9185114529766309888
253588 22550201 100 0 FALSE 8824826559576670208
253596 23870301 15 0 TRUE 9530533804213534720
253634 23870101 7.5 0 TRUE 9602591398251462656
253642 22550301 100 0 FALSE 8248365807273246720
253650 23870401 15 0 TRUE 9674648992289390592
253685 22550402 100 0 FALSE 8104250619197390848
253723 22550501 100 0 TRUE 15377029654749642752
253731 23890201 1 1 TRUE 7968678636469354496
253766 23890301 5 1 TRUE 8040736230507282432
253774 20700101 200 0 FALSE 14658675827370098688
253782 23890401 1 1 TRUE 13268009122512502784
253790 23890501 5 0 TRUE 9746706586327318528
253804 23900101 30 0 TRUE 9818764180365246464
253820 18230201 100 0 TRUE 15665260030901354496
253839 21580102 100 0 TRUE 1575849751742513152
253847 21580101 50 0 TRUE 9962879368441102336
253855 20770101 100 0 TRUE 15737317624939282432
253898 21400101 12 0 TRUE 15809375218977210368
253936 20310202 500 0 TRUE 15881432813015138304
253952 20310302 100 0 TRUE 15953490407053066240
253979 20310402 100 0 TRUE 16025548001090994176
253987 24880201 3.5 0 TRUE 10034936962479030272
253995 23050101 15 0 TRUE 10106994556516958208
254002 23050201 15 0 TRUE 10179052150554886144
254037 21260101 10 1 TRUE 16039129168717283328
254045 30000201 25 0 TRUE 16169663189166850048
254053 21260201 10 1 TRUE 16111186762755211264
254061 21260301 10 1 TRUE 16183244356793139200
254088 20100201 15 0 TRUE 10251109744592814080
254126 11670103 30 0 FALSE 16385835971280633856
254134 11670302 100 0 TRUE 16457893565318561792
254142 32640502 200 0 TRUE 18198809699204202496
254169 14240101 100 0 TRUE 16529951159356489728
254193 24470105 500 0 TRUE 16602008753394417664
254215 22180105 30 0 TRUE 16674066347432345600
254231 22180205 30 0 TRUE 16746123941470273536
254258 15830601 10 1 TRUE 4438138003587596288
254274 15830401 15 0 FALSE 635869564575416320
254290 15830401 100 0 TRUE 203524000347848704
254320 15830101 100 0 TRUE 16890239129546129408
254339 15830201 50 0 FALSE 16962296723584057344
254347 15830201 250 0 FALSE 5092483761556160512
254355 15830301 100 0 TRUE 17034354317621985280
254363 23640104 50 0 FALSE 17106411911659913216
254371 19110101 100 0 FALSE 17178469505697841152
254398 10780125 100 0 FALSE 15018771383024877568
254401 19110101 500 0 TRUE 17250527099735769088
254428 19110203 100 0 FALSE 17322584693773697024
254444 19110203 500 0 TRUE 17394642287811624960
254452 10780225 100 0 FALSE 15162886571100733440
254460 19110301 100 0 TRUE 17466699881849552896
254509 23640104 250 0 TRUE 17538757475887480832
254576 18630204 60 0 TRUE 17610815069925408768
254584 25280501 30 0 TRUE 17682872663963336704
254592 25280601 30 0 TRUE 17754930258001264640
254657 40072525 90 TRUE 7751150156518522880
254665 19500101 100 0 TRUE 17826987852039192576
254673 19500201 100 0 TRUE 17899045446077120512
254703 20160202 500 0 TRUE 17971103040115048448
254738 18670101 100 0 TRUE 18043160634152976384
254754 18670201 100 0 TRUE 18115218228190904320
254819 18811301 15 0 TRUE 10323167338630742016
254827 15422501 15 0 TRUE 18187275822228832256
254835 18811401 15 0 TRUE 10395224932668669952
254843 15420301 15 0 TRUE 10467282526706597888
254851 18810502 24 0 TRUE 10539340120744525824
254894 24400301 8 0 TRUE 10611397714782453760
254908 18810901 75 0 TRUE 10683455308820381696
254916 33600202 2000 0 TRUE 18259333416266760192
254924 33600302 2000 0 TRUE 18331391010304688128
254932 22370101 500 0 TRUE 18403448604342616064
254940 24400501 5 0 TRUE 10755512902858309632
254959 15770301 60 0 TRUE 101101193685630976
254967 34310105 500 0 TRUE 173158787723558912
254975 24400201 6 1 TRUE 13340066716550430720
254983 12970102 20 0 FALSE 317273975799414784
254991 19080201 3 1 TRUE 16543532326982778880
255009 19080101 100 0 TRUE 461389163875270656
255033 18730101 63 21 TRUE 251984975342075904
255092 15801501 500 0 TRUE 605504351951126528
255114 15800101 100 0 TRUE 677561945989054464
255130 15800401 100 0 TRUE 749619540026982400
255149 15800601 100 0 TRUE 821677134064910336
255157 15800901 100 0 TRUE 893734728102838272
255165 20160203 500 0 FALSE 14675580818647154688
255173 18540101 15 0 TRUE 965792322140766208
255246 22980501 100 0 FALSE 1037849916178694144
255254 22980501 1000 0 TRUE 1109907510216622080
255262 22980101 100 0 FALSE 11646140411101052928
255270 22980101 500 0 FALSE 3615004016615882752
255289 22980201 100 0 FALSE 9376594479743500288
255297 22980201 500 0 FALSE 1254022698292477952
255300 22980301 100 0 FALSE 8721879285868003328
255319 22980301 500 0 FALSE 17121022222169800704
255327 22980401 50 0 TRUE 1326080292330405888
255335 60120601 10 1 TRUE 3933734845322100736
255408 60120202 100 0 FALSE 9715408987842674688
255416 60120301 100 0 TRUE 1470195480406261760
255424 23120103 100 0 TRUE 10827570496896237568
255432 23120103 500 0 FALSE 13735153130247553024
255459 19870801 8 0 TRUE 1542253074444189696
255599 21330201 15 0 TRUE 10899628090934165504
255629 21330201 80 0 FALSE 10971685684972093440
255718 19900101 50 0 TRUE 1068215128802983936
255742 19900101 500 0 FALSE 1140272722840911872
255815 16390301 5 0 FALSE 11043743279010021376
255831 16390301 5 0 TRUE 11115800873047949312
255874 16970101 100 0 TRUE 1614310668482117632
255904 16970701 100 0 TRUE 1686368262520045568
255939 22120101 200 0 TRUE 1758425856557973504
255955 22120201 200 0 TRUE 1830483450595901440
256021 23010301 100 0 FALSE 1902541044633829376
256048 23010101 100 0 TRUE 1974598638671757312
256056 23400101 10 0 TRUE 2046656232709685248
256064 23010501 100 0 FALSE 17305665408845479936
256072 27650101 1 1 TRUE 8833369764924489728
256080 27100101 10 0 TRUE 2190771420785541120
256099 27100302 20 0 TRUE 2262829014823469056
256110 15180401 50 0 TRUE 2334886608861396992
256129 15180301 30 0 TRUE 11187858467085877248
256161 15180501 50 0 TRUE 2406944202899324928
256218 19220101 5 1 TRUE 6311353973597011968
256226 18750101 21 0 TRUE 2551059390975180800
256234 19220201 5 1 TRUE 6383411567634939904
256250 19110102 100 0 TRUE 2695174579051036672
256269 19220301 5 1 TRUE 6455469161672867840
256285 19110202 100 0 TRUE 2839289767126892544
256323 19110302 100 0 TRUE 2911347361164820480
256366 18000101 25 0 TRUE 2983404955202748416
256390 19310101 1000 0 FALSE 3055462549240676352
256412 19290802 1000 0 FALSE 3127520143278604288
256439 19250702 100 0 TRUE 3199577737316532224
256498 17210101 100 0 TRUE 3271635331354460160
256528 19250802 100 0 TRUE 3343692925392388096
256552 19250401 100 0 FALSE 3415750519430316032
256684 19290205 2000 0 TRUE 3487808113468243968
256692 19290304 2000 0 TRUE 3559865707506171904
256706 27160903 30 0 TRUE 11259916061123805184
256714 27160903 100 0 TRUE 11331973655161733120
256722 27161003 30 0 TRUE 11404031249199661056
256749 27161003 100 0 TRUE 11476088843237588992
256811 22570101 1 0 TRUE 3631923301544099840
256838 22570201 1 0 TRUE 3703980895582027776
256846 22660202 5 0 TRUE 11548146437275516928
256854 22660402 5 0 TRUE 11620204031313444864
256862 60210201 20 0 TRUE 11692261625351372800
256870 60210301 20 0 TRUE 3776038489619955712
256889 60210101 10 0 TRUE 11764319219389300736
256900 22690101 40 0 FALSE 3848096083657883648
256919 18240101 30 0 TRUE 3920153677695811584
256951 16990501 5 1 TRUE 4654029310724669440
256978 16990201 250 0 TRUE 4064268865771667456
256986 16990303 250 0 TRUE 4136326459809595392
257028 19120102 100 0 TRUE 4208384053847523328
257036 19120202 100 0 TRUE 4280441647885451264
257168 23020101 28 0 TRUE 4352499241923379200
257222 14310201 10 1 TRUE 13412124310588358656
257249 14310102 100 0 TRUE 4496614429999235072
257362 16880202 60 0 FALSE 8160655565702299648
257443 15210201 10 0 TRUE 4640729618075090944
257451 15210201 30 0 TRUE 11836376813427228672
257478 15210101 12 0 TRUE 4712787212113018880
257494 21420102 25 0 FALSE 2317967323933179904
257796 21880101 1 0 TRUE 4784844806150946816
257826 23190101 1 0 TRUE 4856902400188874752
257885 12370301 5 1 TRUE 13484181904626286592
257893 12370401 5 1 TRUE 13556239498664214528
257907 20960601 200 0 TRUE 11908434407465156608
257915 20960401 5 1 TRUE 7392499359142641664
257923 20960501 10 0 TRUE 5145132776340586496
258024 17990101 100 0 TRUE 5217190370378514432
258032 17990201 100 0 TRUE 5289247964416442368
258040 17620202 6 0 TRUE 3490593176421400576
258059 17620202 100 0 FALSE 3562650770459328512
258067 19250301 250 0 TRUE 11980492001503084544
258075 19250201 500 0 TRUE 5361305558454370304
258083 19250101 500 0 TRUE 5433363152492298240
258091 23180101 3.5 0 TRUE 5505420746530226176
258156 19910401 100 0 FALSE 5577478340568154112
258164 19910401 1000 0 TRUE 5649535934606082048
258199 19910604 100 0 TRUE 5721593528644009984
258245 19730102 15 0 TRUE 12052549595541012480
258253 23540101 100 0 TRUE 5793651122681937920
258296 18590101 4 0 TRUE 5865708716719865856
258318 17190201 2 1 TRUE 13628297092702142464
258326 17190101 5 1 TRUE 13700354686740070400
258407 19250901 100 0 TRUE 6081881498833649664
258490 15320101 10 1 TRUE 5158713943966875648
258504 15320201 10 1 TRUE 5230771538004803584
258512 18130101 100 0 TRUE 6298054280947433472
258555 15720102 100 0 FALSE 12124607189578940416
258563 19660101 100 0 TRUE 7957156854121889792
258571 19780201 200 0 TRUE 6442169469023289344
258598 19780301 200 0 TRUE 6514227063061217280
258601 18861101 28 0 TRUE 12196664783616868352
258628 19780101 200 0 TRUE 6586284657099145216
258636 19780601 1 1 TRUE 2924928528791109632
258644 19780701 1 1 TRUE 2996986122829037568
258652 19780401 500 0 TRUE 6802457439212929024
258660 19780501 500 0 TRUE 6874515033250856960
258679 19090101 250 0 TRUE 6946572627288784896
258717 19420301 100 0 FALSE 4909596494950039552
258725 19420401 100 0 FALSE 4981654088987967488
258814 19160801 15 0 TRUE 7162745409402568704
258830 19160101 15 0 TRUE 7234803003440496640
258865 19160601 15 0 TRUE 7306860597478424576
258954 12310101 1 1 TRUE 10706867209910616064
259012 11880201 5 1 TRUE 6671641943786651648
259144 16290301 5 1 TRUE 4321385261880573952
259160 16420101 100 0 TRUE 7595090973630136320
259179 23300101 1000 0 TRUE 7667148567668064256
259276 19720101 15 0 TRUE 12268722377654796288
259292 16820101 5 1 FALSE 5734893221293588480
259349 21440601 100 0 TRUE 7811263755743920128
259403 12340201 100 0 FALSE 12185078130083364864
259438 22240101 100 0 TRUE 7883321349781848064
259446 12340301 100 0 TRUE 7955378943819776000
259462 12340401 100 0 TRUE 8027436537857703936
259470 12340101 100 0 FALSE 12617423694310932480
259667 60180101 100 0 TRUE 8099494131895631872
259705 22850101 250 0 FALSE 16832791846018088960
259713 22520101 25 0 TRUE 8171551725933559808
259772 20560401 28 0 TRUE 15535755153335386112
259799 15160101 7.5 0 TRUE 12340779971692724224
259896 19490102 100 0 TRUE 8243609319971487744
259942 19530101 10 0 TRUE 8315666914009415680
259950 19530201 10 0 TRUE 8387724508047343616
259977 20961403 20 0 TRUE 8459782102085271552
259985 15370103 100 0 TRUE 8531839696123199488
259993 20961503 20 0 TRUE 8603897290161127424
260002 15790301 100 0 FALSE 8675954884199055360
260061 33600201 2000 0 TRUE 6948794740288520192
260088 33600301 2000 0 TRUE 6804679552212664320
260134 19870103 15 0 TRUE 12412837565730652160
260142 19870203 15 0 TRUE 12484895159768580096
260150 19870303 15 0 TRUE 12556952753806508032
260169 19870403 15 0 TRUE 12629010347844435968
260177 19870503 15 0 TRUE 12701067941882363904
260185 19870603 15 0 TRUE 12773125535920291840
260223 13610401 100 0 FALSE 8748012478236983296
260266 16120201 15 0 TRUE 12845183129958219776
260282 16120301 15 0 TRUE 12917240723996147712
260304 22200201 100 0 FALSE 12989298318034075648
260312 22200201 200 0 FALSE 13061355912072003584
260320 22200201 500 0 FALSE 13133413506109931520
260347 22200204 200 0 TRUE 13205471100147859456
260363 23160101 5 1 TRUE 13772412280777998336
260479 17690101 100 0 FALSE 2936217214673485824
260525 20330101 5 0 TRUE 13277528694185787392
260533 20320201 5 0 TRUE 13349586288223715328
260541 20320101 5 0 TRUE 13421643882261643264
260614 20360101 500 0 TRUE 8964185260350767104
260622 20380103 100 0 FALSE 9036242854388695040
260630 20380103 500 0 TRUE 9108300448426622976
260649 20380202 100 0 TRUE 9180358042464550912
260665 20380301 100 0 FALSE 9252415636502478848
260673 20380301 500 0 TRUE 9324473230540406784
260762 20340201 7 0 TRUE 9396530824578334720
260770 19730101 15 0 TRUE 13493701476299571200
260789 19720102 20 0 TRUE 9468588418616262656
260800 29450104 454 0 TRUE 6051576759348887552
260819 18880102 100 0 FALSE 9491357105404248064
260827 18880202 60 0 FALSE 9540646012654190592
260835 18880302 60 0 FALSE 9612703606692118528
260851 24660301 100 0 TRUE 9684761200730046464
260886 18710201 100 0 FALSE 1278582489522110464
260940 11012601 40 0 TRUE 4241942248238874624
260983 20440101 100 0 TRUE 9828876388805902336
261017 18060304 100 0 TRUE 9900933982843830272
261130 17660601 100 0 TRUE 9972991576881758208
261149 17660101 100 0 TRUE 10045049170919686144
261165 17920101 50 0 TRUE 10117106764957614080
261270 17810201 25 0 TRUE 10189164358995542016
261289 20710101 100 0 TRUE 10261221953033469952
261297 20710201 100 0 TRUE 10333279547071397888
261319 20710301 100 0 FALSE 10405337141109325824
261327 20710301 500 0 TRUE 10477394735147253760
261335 20710401 100 0 FALSE 10549452329185181696
261467 21350101 100 0 TRUE 10621509923223109632
261475 20780101 100 0 TRUE 10693567517261037568
261505 20780201 100 0 TRUE 10765625111298965504
261556 20790103 100 0 TRUE 10837682705336893440
261564 20790101 500 0 TRUE 10909740299374821376
261572 20790202 100 0 FALSE 10981797893412749312
261580 20790202 500 0 TRUE 11053855487450677248
261645 18090101 100 0 FALSE 9658381717756444672
261769 13780101 10 1 TRUE 7608672141256425472
261777 14650401 100 0 FALSE 11270028269564461056
261793 14650401 500 0 TRUE 11342085863602388992
261890 24470101 500 0 FALSE 12287090818908422144
261998 33620101 25 0 TRUE 11486201051678244864
262005 20620101 100 0 TRUE 11558258645716172800
262102 13460101 1 1 TRUE 15534726010451787776
262307 21490101 250 0 FALSE 11702373833792028672
262315 21490101 425 0 TRUE 11774431427829956608
262382 15740101 36 0 TRUE 11846489021867884544
262390 15740201 12 0 FALSE 11918546615905812480
262404 15740201 36 0 TRUE 11990604209943740416
262412 15740401 12 0 FALSE 12062661803981668352
262420 15740401 36 0 FALSE 12134719398019596288
262439 15740401 72 0 FALSE 12206776992057524224
262447 15740401 144 0 TRUE 12278834586095452160
262463 14660501 100 0 FALSE 12350892180133380096
262471 14660501 500 0 TRUE 12422949774171308032
262544 14660301 500 0 TRUE 12495007368209235968
262552 14660401 500 0 TRUE 12567064962247163904
262579 14660201 10 0 TRUE 3896761567814877184
262587 14660201 100 0 FALSE 3968819161852805120
262609 14980101 100 0 FALSE 12639122556285091840
262617 14980101 500 0 TRUE 12711180150323019776
262625 25290302 100 0 FALSE 12783237744360947712
262641 25290302 100 0 TRUE 12855295338398875648
262668 14980102 500 0 TRUE 12927352932436803584
262692 15360101 100 0 TRUE 12999410526474731520
262706 15360201 100 0 TRUE 13071468120512659456
262714 13140102 5 0 TRUE 13143525714550587392
262749 60070101 100 0 TRUE 13215583308588515328
262765 60070201 100 0 TRUE 13287640902626443264
262781 12350101 1 1 TRUE 13844469874815926272
262803 60180101 500 0 FALSE 13431756090702299136
262854 11980401 1 0 TRUE 13503813684740227072
262870 11980101 10 0 TRUE 13575871278778155008
262943 21140101 100 0 TRUE 13709874258413355008
263338 22500301 100 0 FALSE 13647928872816082944
263346 22500301 500 0 TRUE 13719986466854010880
263478 20580101 15 0 TRUE 13792044060891938816
263486 14010501 5 1 TRUE 15967071574679355392
263605 15740501 12 0 TRUE 13936159248967794688
263710 29170201 250 0 FALSE 11925878159439822848
263907 16170501 500 0 TRUE 14008216843005722624
263966 13570101 36 0 TRUE 13781931852451282944
263974 13570101 36 0 FALSE 13853989446489210880
264032 60420101 12 1 TRUE 13916527468853854208
264067 20600204 500 0 FALSE 1331397530562330624
264075 12360101 1 1 TRUE 10778924803948544000
264083 12360201 1 1 TRUE 10850982397986471936
264105 15670202 500 0 FALSE 14296447219157434368
264121 27630201 1 1 FALSE 7094153476015390720
264172 15320301 10 1 TRUE 5302829132042731520
264180 18100101 1 1 TRUE 13988585062891782144
264199 18100201 1 1 TRUE 14060642656929710080
264210 18100401 1 1 TRUE 14132700250967638016
264229 18160601 1 1 TRUE 7536333072241786880
264318 14780101 100 0 TRUE 14800850377422929920
264407 20560401 84 0 FALSE 15463697559297458176
264415 15270101 5 0 TRUE 13926047040527138816
264423 10230101 72 0 TRUE 14872907971460857856
264512 16420201 200 0 TRUE 14944965565498785792
264539 12830101 100 0 TRUE 15017023159536713728
264547 15440601 5 0 TRUE 15089080753574641664
264598 14050201 100 0 TRUE 15161138347612569600
264709 20410101 100 0 FALSE 15233195941650497536
264776 21440701 10 0 TRUE 13998104634565066752
264792 19290202 2000 0 TRUE 15305253535688425472
264881 20340101 10 0 TRUE 4150936770319482880
264903 15770601 200 0 FALSE 8305042333150216192
264911 28610101 100 0 TRUE 15377311129726353408
264962 20490101 100 0 TRUE 15449368723764281344
265020 19870102 15 0 TRUE 15521426317802209280
265039 19870202 15 0 TRUE 15593483911840137216
265055 19870302 15 0 TRUE 15665541505878065152
265071 19870402 15 0 TRUE 15737599099915993088
265128 19870502 15 0 TRUE 15809656693953921024
265136 19870602 15 0 TRUE 15881714287991848960
265233 17230102 100 0 FALSE 5164671097966166016
265284 16171601 1 1 TRUE 7608390666279714816
265292 16171701 1 1 TRUE 14204757845005565952
265306 16171801 1 1 TRUE 14276815439043493888
265322 18120101 1 1 FALSE 7680448260317642752
265330 18120201 1 1 FALSE 7752505854355570688
265349 18120401 1 1 FALSE 7529609558637936640
265357 18120501 1 1 TRUE 7896621042431426560
265373 10870701 100 0 FALSE 16386117446257344512
265381 10870701 500 0 TRUE 16458175040295272448
265438 21640301 10 1 TRUE 14348873033081421824
265586 12910101 60 0 TRUE 16602290228371128320
265594 15720201 100 0 TRUE 16674347822409056256
265659 21710101 1 1 TRUE 14420930627119349760
266124 11280301 40 0 TRUE 13049769258538500096
266167 19250501 300 0 TRUE 16818463010484912128
266175 18060202 500 0 TRUE 16890520604522840064
266507 10920101 1200 0 TRUE 16962578198560768000
266949 10700203 100 0 TRUE 17034635792598695936
266973 11050101 1 0 TRUE 14142219822640922624
267007 60410102 1 0 FALSE 17106693386636623872
267201 24610101 100 0 TRUE 6083822136856674304
267236 10700303 100 0 TRUE 17178750980674551808
267430 24620202 1 0 TRUE 17250808574712479744
267473 16790101 100 0 TRUE 17322866168750407680
267538 60420101 10 1 FALSE 14492988221157277696
267570 20870101 100 0 TRUE 17466981356826263552
267600 18180301 30 0 FALSE 8614006200066899968
267961 22380101 50 0 TRUE 14214277416678850560
268003 23391602 1000 0 TRUE 17539038950864191488
268011 23391701 2000 0 TRUE 17611096544902119424
268070 23391901 1000 0 TRUE 17683154138940047360
268194 23000201 50 0 TRUE 17755211732977975296
268321 15090101 50 0 TRUE 17827269327015903232
268380 15720304 50 0 TRUE 17899326921053831168
268887 23280202 500 0 TRUE 17971384515091759104
268925 23280101 500 0 TRUE 18043442109129687040
269026 10870102 20 0 FALSE 18115499703167614976
269328 20630101 10 1 TRUE 18056460326802554880
269549 15080101 10 0 TRUE 18259614891243470848
269557 15080101 30 0 TRUE 18331672485281398784
269603 15800301 100 0 TRUE 18403730079319326720
269689 18650104 100 0 TRUE 101382668662341632
269859 14280201 100 0 TRUE 173440262700269568
269905 14011101 20 0 TRUE 245497856738197504
270377 24820201 6 0 TRUE 317555450776125440
270385 24820301 6 0 TRUE 5822728807190102016
270393 24820301 50 0 FALSE 5894786401228029952
270407 24820301 200 0 FALSE 9581429097951657984
270415 24820101 30 0 FALSE 461670638851981312
270423 24820101 100 0 FALSE 533728232889909248
270555 14280601 100 0 TRUE 605785826927837184
270563 21940102 15 0 TRUE 5508235496297332736
270598 23770401 100 0 TRUE 677843420965765120
270687 63030101 5 0 TRUE 1335907727259467776
270695 63030101 50 0 FALSE 1407965321297395712
270849 33200101 1 0 TRUE 749901015003693056
270865 33330102 25 0 TRUE 821958609041620992
270903 33470101 1 0 TRUE 894016203079548928
270954 33560602 500 0 TRUE 966073797117476864
270989 33850102 500 0 TRUE 1038131391155404800
271004 15700101 1 1 TRUE 14565045815195205632
271012 21282525 500 0 TRUE 1182246579231260672
271020 15700301 1 1 TRUE 14637103409233133568
271314 20600603 28 0 TRUE 1326361767307116544
271373 17950102 10 0 FALSE 1398419361345044480
271454 17950201 5 1 FALSE 18417029771968905216
271691 17660801 1 1 TRUE 6095181191483228160
272175 14280101 100 0 TRUE 1614592143458828288
272353 60240101 14 0 TRUE 1686649737496756224
272396 34290301 1 0 TRUE 1758707331534684160
272426 32750101 1 0 TRUE 1830764925572612096
273104 14530101 100 0 TRUE 1902822519610540032
273147 15720314 100 0 TRUE 1974880113648467968
273155 16170603 25 0 TRUE 2046937707686395904
273503 20900101 1 1 TRUE 14709161003271061504
273511 18730201 84 28 TRUE 1188733697835139072
273546 13140101 5 0 TRUE 2191052895762251776
273600 10840102 100 0 TRUE 2263110489800179712
273996 60390112 12 0 TRUE 2335168083838107648
274062 28330101 30 0 TRUE 2407225677876035584
274135 17660701 30 0 TRUE 2479283271913963520
274143 39752525 60 TRUE 13835788131003006976
274151 39752625 60 TRUE 14051960913116790784
274186 17660501 30 0 TRUE 2551340865951891456
274437 11081501 200 0 TRUE 14286335010716778496
274445 11081601 200 0 TRUE 14358392604754706432
274550 16040301 5 1 FALSE 11242295287777067008
275182 11790201 100 0 FALSE 2695456054027747328
275190 11790201 200 0 FALSE 2767513648065675264
275298 24520205 500 0 TRUE 14430450198792634368
275301 28591001 200 0 TRUE 14502507792830562304
275328 28591001 500 0 TRUE 14574565386868490240
275336 14530201 100 0 TRUE 2839571242103603200
275654 22910101 1 1 TRUE 14781218597308989440
275670 25290303 100 0 TRUE 2983686430179459072
275700 25290402 100 0 TRUE 3055744024217387008
275719 25290404 100 0 TRUE 3127801618255314944
275743 10840202 100 0 TRUE 3199859212293242880
275778 10840101 500 0 TRUE 3271916806331170816
275808 14920501 200 0 TRUE 14646622980906418176
275824 28650101 2 0 TRUE 10479172645449367552
275840 28650101 8 0 TRUE 3416031994407026688
275859 10690101 100 0 TRUE 3488089588444954624
275867 10690201 100 0 TRUE 3560147182482882560
275875 10690301 100 0 TRUE 3632204776520810496
275921 17300501 100 0 TRUE 3704262370558738432
276170 10260205 30 0 TRUE 3776319964596666368
276332 12330101 5 1 TRUE 10202464051645120512
276340 12330201 5 1 TRUE 10274521645683048448
276359 12330301 1 1 TRUE 10346579239720976384
276626 32010101 500 0 FALSE 3920435152672522240
276634 32010101 2000 0 TRUE 3992492746710450176
276642 32020101 500 0 FALSE 4064550340748378112
276723 10840301 500 0 TRUE 4136607934786306048
276774 21280301 500 0 FALSE 4208665528824233984
276847 21280301 5000 0 TRUE 4280723122862161920
276898 13320602 2000 0 FALSE 4352780716900089856
276928 15350101 100 0 TRUE 4424838310938017792
276936 60380202 1 0 TRUE 14718680574944346112
276944 13670102 100 0 FALSE 9355402492629745664
276960 15740601 500 0 TRUE 12208554902359638016
276979 15740601 2000 0 TRUE 1484805790916149248
276995 33910101 500 0 TRUE 4496895904975945728
277002 16171926 500 0 TRUE 7908191203290513408
277010 16171902 2000 0 TRUE 7764076015214657536
277045 33030201 500 0 TRUE 18368811789044416512
277053 33030201 2000 0 FALSE 18440869383082344448
277088 33040101 250 0 TRUE 4568953499013873664
277142 33100201 500 0 TRUE 4641011093051801600
277169 11850101 500 0 FALSE 4713068687089729536
277177 11850101 2000 0 TRUE 4785126281127657472
277258 29290802 200 0 FALSE 14790738168982274048
277282 33160101 25 0 TRUE 4857183875165585408
277320 29290102 200 0 FALSE 14862795763020201984
277339 29290701 200 0 FALSE 14934853357058129920
277355 29290502 200 0 FALSE 15006910951096057856
277428 33250101 450 0 FALSE 4929241469203513344
277436 33290201 500 0 FALSE 16440974280390344704
277452 33300301 500 0 TRUE 5001299063241441280
277479 33330101 25 0 TRUE 11301560064025821184
277495 33330101 100 0 FALSE 11373617658063749120
277762 13900101 10 0 TRUE 5073356657279369216
277878 13830201 100 0 TRUE 5145414251317297152
277916 17970101 100 0 FALSE 8842838759062896640
277932 12800101 28 0 TRUE 5217471845355225088
277940 29080101 500 0 TRUE 5289529439393153024
277983 23730103 100 0 FALSE 16812521249648410624
277991 23730203 100 0 FALSE 17100751625800122368
278017 33420102 500 0 TRUE 5361587033431080960
278068 29080105 200 0 TRUE 5433644627469008896
278114 29170302 1000 0 TRUE 15078968545133985792
278254 33290201 80 0 TRUE 16513031874428272640
278572 14200101 400 0 TRUE 5505702221506936832
278661 25430302 30 0 FALSE 1957679353743540224
278688 29050101 100 0 FALSE 5577759815544864768
278696 29050101 100 0 TRUE 5649817409582792704
278734 19530102 10 0 TRUE 5721875003620720640
278742 19530202 10 0 TRUE 5793932597658648576
278750 20600102 100 0 FALSE 5865990191696576512
278769 20600102 500 0 TRUE 5938047785734504448
278777 20600202 100 0 FALSE 6010105379772432384
278785 20600202 500 0 TRUE 6082162973810360320
278793 20600501 50 0 FALSE 6154220567848288256
278807 20600501 250 0 TRUE 6226278161886216192
278882 60400108 12 0 TRUE 6298335755924144128
279269 29370102 225 0 TRUE 15151026139171913728
279285 29320101 237 0 TRUE 15223083733209841664
279307 29320201 237 0 TRUE 15295141327247769600
279552 29320301 237 0 TRUE 15367198921285697536
279587 14410101 28 0 TRUE 5283423851324112896
279625 29290203 237 0 TRUE 15439256515323625472
279633 21930202 500 0 FALSE 18110966416726294528
279668 12440201 500 0 TRUE 6442450944000000000
279676 12440201 5000 0 FALSE 6514508538037927936
279722 18860801 4 0 TRUE 6586566132075855872
279730 29290503 237 0 TRUE 15511314109361553408
279757 29290803 237 0 TRUE 15583371703399481344
279781 18860901 4 0 TRUE 6658623726113783808
279889 18812501 50 0 TRUE 6730681320151711744
280089 24520101 275 0 TRUE 15655429297437409280
280542 27090101 28 0 TRUE 11423125368127619072
280690 29020109 237 0 FALSE 6802738914189639680
280712 29020109 1000 0 TRUE 6874796508227567616
280739 29020117 1000 0 TRUE 6946854102265495552
280755 29410102 237 0 TRUE 15727486891475337216
280771 29410202 237 0 TRUE 15799544485513265152
281506 29410302 237 0 TRUE 15871602079551193088
281522 24520201 300 0 FALSE 17127050844424896512
281891 11081104 200 0 TRUE 7018911696303423488
281956 22390301 1 1 TRUE 8112793824545210368
281964 16450402 30 0 TRUE 7163026884379279360
281972 32180101 100 0 FALSE 7235084478417207296
281980 21420101 25 0 TRUE 7307142072455135232
281999 14240102 100 0 TRUE 16107248312104517632
282014 15440103 1000 0 TRUE 7451257260530991104
282022 10030102 100 0 TRUE 7523314854568919040
282030 18650102 100 0 TRUE 7595372448606846976
282049 18650102 250 0 FALSE 7667430042644774912
282057 33520101 100 0 TRUE 7739487636682702848
282065 32830101 100 0 FALSE 7811545230720630784
282073 34110201 100 0 TRUE 15983855619677356032
282081 18140102 100 0 TRUE 7883602824758558720
282103 32700101 100 0 TRUE 7955660418796486656
282111 13970104 500 0 TRUE 7657833505157545984
282138 13970201 500 0 FALSE 8027718012834414592
282146 13970303 100 0 TRUE 8099775606872342528
282154 33700101 100 0 TRUE 8171833200910270464
282162 10260101 100 0 FALSE 8243890794948198400
282170 10260101 250 0 FALSE 8315948388986126336
282189 10260203 30 0 FALSE 8388005983024054272
282197 10260203 100 0 FALSE 8460063577061982208
282200 16450103 250 0 FALSE 9007503819461885952
282219 16450201 100 0 TRUE 8532121171099910144
282235 33230101 100 0 TRUE 8604178765137838080
282251 18200102 100 0 TRUE 8676236359175766016
282405 60120201 100 0 FALSE 1331118254608875520
282413 29020106 237 0 TRUE 8748293953213693952
282499 23890101 5 1 TRUE 8184851418583138304
282561 11200202 10 1 FALSE 12796537437010526208
282588 14990101 1000 0 TRUE 8964466735327477760
282642 29020105 1000 0 TRUE 9036524329365405696
282766 63000206 5 1 TRUE 9842457556432191488
282790 16480302 5 1 TRUE 8833651239901200384
282820 16490302 5 1 TRUE 9698342368356335616
282855 63000207 5 1 TRUE 9770399962394263552
282928 10590501 100 0 TRUE 9396812299555045376
282936 19120101 100 0 TRUE 9468869893592973312
282944 19120201 100 0 TRUE 9540927487630901248
282952 22770101 500 0 FALSE 3891414642769002496
282960 14240102 20 0 FALSE 9612985081668829184
283118 14120101 250 0 FALSE 10020936880922558464
283169 15460301 1 1 TRUE 15246495634300076032
283177 15460201 90 0 TRUE 9829157863782612992
283185 19251001 100 0 TRUE 9901215457820540928
283207 29020107 250 0 TRUE 16015717267627048960
283223 12280101 100 0 TRUE 9973273051858468864
283258 19940101 10 1 TRUE 5591059508194443264
283274 19940201 10 1 TRUE 5663117102232371200
283339 18250102 40 0 TRUE 16087774861664976896
283347 16960101 30 0 TRUE 10117388239934324736
283363 13610201 500 0 TRUE 10189445833972252672
283428 15540303 5 1 TRUE 15174438040262148096
283436 15540202 5 1 TRUE 14853276191346917376
283444 29020108 1000 0 TRUE 16159832455702904832
283533 22600101 100 0 TRUE 10405618616086036480
283568 22600201 100 0 TRUE 10477676210123964416
283584 60220101 5000 0 TRUE 10549733804161892352
283622 10570201 30 0 TRUE 10621791398199820288
283649 15120102 100 0 TRUE 10693848992237748224
283657 15120202 50 0 TRUE 10765906586275676160
283711 29120101 237 0 TRUE 10837964180313604096
283770 29120102 1000 0 TRUE 10910021774351532032
283827 29120103 250 0 TRUE 16231890049740832768
283878 29120104 1000 0 TRUE 16303947643778760704
283886 10670101 3.5 0 TRUE 16376005237816688640
283908 29400102 1000 0 TRUE 10982079368389459968
283916 18300502 1 0 TRUE 11054136962427387904
283924 18311601 1 0 TRUE 11126194556465315840
283940 22060101 100 0 TRUE 11198252150503243776
283967 22060201 100 0 TRUE 11270309744541171712
283975 29020110 500 0 TRUE 16448062831854616576
284025 29020110 1000 0 TRUE 16520120425892544512
284041 29280101 80.4 0 TRUE 16592178019930472448
284076 29280201 80.4 0 TRUE 16664235613968400384
284157 29280301 80.4 0 TRUE 16736293208006328320
284173 29280501 80.4 0 TRUE 16808350802044256256
284211 29300201 237 0 TRUE 16880408396082184192
284246 29300301 237 0 TRUE 16952465990120112128
284262 29300401 237 0 TRUE 17024523584158040064
284270 60120401 5 0 TRUE 17048964628131872768
284424 60120501 5 0 TRUE 13632421360817930240
284459 29090102 1000 0 TRUE 17096581178195968000
284521 10400201 375 0 FALSE 11342367338579099648
284548 10400201 2000 0 TRUE 11414424932617027584
284610 12760101 1000 0 FALSE 8521975977310420992
284629 18100501 1 1 TRUE 8256909012621066240
284661 63110101 200 0 TRUE 17168638772233895936
284688 15670201 100 0 TRUE 4972278553337921536
284726 27821101 250 0 FALSE 4184991943966588928
284734 23120101 500 0 FALSE 18091826118309969920
284823 63100101 21 0 TRUE 11558540120692883456
284866 15270102 5 0 TRUE 17240696366271823872
285048 25290401 100 0 FALSE 13508286498042019840
285056 25290401 100 0 FALSE 11630597714730811392
285153 21350901 500 0 TRUE 11702655308768739328
285161 21350901 1000 0 TRUE 11774712902806667264
285196 33740101 1 0 TRUE 11846770496844595200
285226 10760101 5 0 TRUE 17312753960309751808
285234 23670101 50 0 TRUE 11918828090882523136
285242 16170502 500 0 TRUE 11990885684920451072
285285 10370101 30 0 TRUE 12062943278958379008
285293 10610101 30 0 TRUE 12135000872996306944
285382 32090201 500 0 TRUE 12207058467034234880
285544 22500401 25 0 TRUE 12279116061072162816
285595 32120101 500 0 TRUE 12351173655110090752
285641 32130102 500 0 FALSE 12423231249148018688
285668 32130102 2000 0 TRUE 12495288843185946624
285684 32180101 500 0 TRUE 12567346437223874560
285730 15490201 50 0 TRUE 17384811554347679744
285811 32220101 500 0 FALSE 12639404031261802496
285838 32220101 2000 0 TRUE 12711461625299730432
285889 11590201 500 0 TRUE 12783519219337658368
285927 33430101 1 0 TRUE 12855576813375586304
285986 11790101 500 0 TRUE 12927634407413514240
285994 11790201 2000 0 TRUE 12999692001451442176
286001 11790301 500 0 TRUE 8270317556921794560
286028 11790401 500 0 TRUE 13071749595489370112
286044 11910401 500 0 TRUE 13143807189527298048
286060 24840101 30 0 TRUE 18093800841193455616
286168 32370101 500 0 TRUE 13215864783565225984
286176 32380101 500 0 TRUE 13287922377603153920
286249 32420101 2000 0 TRUE 13359979971641081856
286257 32420101 500 0 FALSE 13432037565679009792
286311 32410101 500 0 TRUE 13504095159716937728
286400 32440201 1000 0 TRUE 13576152753754865664
286435 32450101 500 0 TRUE 13648210347792793600
286494 32460101 500 0 TRUE 13720267941830721536
286575 32480101 500 0 TRUE 13792325535868649472
286648 32560101 50 0 TRUE 13864383129906577408
286664 32570101 500 0 TRUE 13936440723944505344
286699 32570401 500 0 TRUE 17580998513603379200
286710 32590101 500 0 TRUE 14080555912020361216
286753 32600101 100 0 TRUE 14152613506058289152
286826 14010201 100 0 TRUE 14224671100096217088
287180 25280902 90 0 TRUE 14296728694134145024
287199 29360103 120 0 TRUE 17456869148385607680
287350 32710101 500 0 TRUE 14368786288172072960
287377 13930201 500 0 TRUE 14440843882210000896
287407 14200301 500 0 FALSE 14512901476247928832
287415 14200301 500 0 TRUE 14584959070285856768
287423 14200401 100 0 TRUE 14657016664323784704
287504 32800301 25 0 TRUE 14729074258361712640
287520 32820102 500 0 FALSE 14801131852399640576
287539 32820102 1000 0 FALSE 14873189446437568512
287547 32820102 2000 0 TRUE 14945247040475496448
287555 32830101 100 0 TRUE 15017304634513424384
287563 32440301 100 0 TRUE 15089362228551352320
287598 14530301 25 0 TRUE 15161419822589280256
287636 32870101 500 0 FALSE 15233477416627208192
287644 29210301 250 0 TRUE 17528926742423535616
287652 32870101 500 0 TRUE 15305535010665136128
287660 32880101 500 0 TRUE 15377592604703064064
287733 29210401 250 0 TRUE 17600984336461463552
287962 15670201 500 0 FALSE 4611990583148281856
288012 13320401 2000 0 TRUE 15449650198740992000
288098 32210301 500 0 TRUE 12838094578493947904
288217 32730101 25 0 TRUE 15521707792778919936
288233 32730201 50 0 TRUE 15593765386816847872
288306 33380101 1 0 FALSE 15665822980854775808
288357 63010101 1000 0 FALSE 13101551858160238592
288381 33030101 100 0 TRUE 11205548509665165312
288403 33030101 500 0 FALSE 11277606103703093248
288640 22750101 100 0 TRUE 15737880574892703744
288691 33130101 500 0 TRUE 15809938168930631680
288713 34290101 500 0 TRUE 15881995762968559616
288721 34290201 500 0 TRUE 15954053357006487552
289159 29210501 250 0 TRUE 17673041930499391488
289175 29210601 250 0 TRUE 17745099524537319424
289191 29211001 250 0 TRUE 17817157118575247360
289213 29211401 250 0 TRUE 17889214712613175296
289248 29211701 250 0 TRUE 17961272306651103232
289256 12470101 90 0 TRUE 16026110951044415488
289272 29210701 250 0 TRUE 18033329900689031168
289353 29211801 250 0 TRUE 18105387494726959104
289647 12470201 90 0 TRUE 16098168545082343424
289655 29210801 250 0 TRUE 18177445088764887040
289752 15800502 100 0 TRUE 16170226139120271360
289760 15800702 100 0 TRUE 16242283733158199296
289825 25430501 14 0 TRUE 18249502682802814976
290033 34340101 500 0 TRUE 16314341327196127232
290114 33360101 2000 0 FALSE 16386398921234055168
290122 33360101 5000 0 TRUE 16458456515271983104
290270 18600301 25 0 TRUE 16530514109309911040
290319 29210201 250 0 TRUE 18321560276840742912
290483 33420101 500 0 TRUE 16602571703347838976
290513 17192725 200 TRUE 13126445900924715008
290548 33460101 100 0 TRUE 16674629297385766912
290599 33470201 200 0 TRUE 16746686891423694848
290610 33440101 2000 0 TRUE 16818744485461622784
290645 32070101 100 0 TRUE 16890802079499550720
290688 19290202 100 0 FALSE 16962859673537478656
290750 33630101 500 0 TRUE 17034917267575406592
290777 33490601 2000 0 TRUE 17106974861613334528
290785 27700201 28 0 TRUE 5461585416954052608
290807 27700301 28 0 TRUE 7190967673864323072
290815 33490201 2000 0 TRUE 17323147643727118336
290874 13320303 100 0 TRUE 17395205237765046272
290882 24890101 2000 0 TRUE 17467262831802974208
290890 33490101 500 0 TRUE 17539320425840902144
290912 33500101 2000 0 TRUE 17611378019878830080
290939 33510101 25 0 TRUE 17683435613916758016
290955 13320203 100 0 FALSE 17755493207954685952
291005 13320103 100 0 TRUE 17827550801992613888
291293 10530101 100 0 FALSE 17899608396030541824
291315 19110103 100 0 FALSE 17971665990068469760
291323 19110201 100 0 FALSE 18043723584106397696
291331 20600103 100 0 TRUE 754936778258907136
291358 20600204 100 0 TRUE 1259339936524402688
291366 13970104 100 0 FALSE 7729891099195473920
291374 13970201 100 0 FALSE 18115781178144325632
291528 19290801 20 0 FALSE 18187838772182253568
293660 19290701 100 0 TRUE 18259896366220181504
293687 33110301 200 0 FALSE 18331953960258109440
293695 17290101 28 0 FALSE 18404011554296037376
293822 16880201 60 0 FALSE 101664143639052288
296325 19250401 300 0 TRUE 173721737676980224
296333 28390101 1 1 TRUE 14925333785384845312
296341 39602525 1 TRUE 7355665719612145664
296368 32800302 10 0 TRUE 317836925752836096
296791 14790301 84 28 FALSE 1260791291873067008
296899 17181202 28 0 FALSE 15319582371221602304
296910 17180904 112 28 FALSE 5871585606370328576
296937 23010301 50 0 TRUE 389894519790764032
297178 20961601 200 0 TRUE 18393617870878670848
297887 38022526 50 0 TRUE 91270460221685760
298093 29350201 500 0 FALSE 6359487294126161920
298115 24840102 30 0 TRUE 461952113828691968
298131 25150102 28 0 TRUE 534009707866619904
298158 25150202 28 0 TRUE 606067301904547840
298166 25150302 28 0 TRUE 678124895942475776
298204 19860302 5 1 TRUE 16759423634119852032
298212 15530103 100 0 TRUE 822240084018331648
298638 21420102 28 0 TRUE 2245909729895251968
299022 10310302 28 0 TRUE 14247181401651675136
299030 10310202 28 0 TRUE 894297678056259584
299057 10310102 28 0 TRUE 966355272094187520
299308 38272525 1 TRUE 15042076631487217664
299448 10240101 5 1 TRUE 4077850033397956608
299456 12310125 5 1 TRUE 10418636833758904320
300411 24510101 100 0 TRUE 1110470460170043392
300438 24510201 100 0 TRUE 1182528054207971328
300446 23000101 100 0 TRUE 1254585648245899264
300454 20660202 500 0 FALSE 1326643242283827200
300497 13200201 1 0 TRUE 1398700836321755136
300616 16970801 100 0 TRUE 1470758430359683072
300632 15090101 100 0 TRUE 1542816024397611008
300799 15120201 100 0 TRUE 1614873618435538944
300802 18280201 50 0 FALSE 1686931212473466880
300926 20160501 500 0 TRUE 1758988806511394816
300977 33720101 100 0 TRUE 1831046400549322752
301043 33730101 500 0 FALSE 1400641474344779776
301108 12400101 500 0 TRUE 1903103994587250688
301140 20710501 100 0 TRUE 1975161588625178624
301175 33770101 2000 0 TRUE 2047219182663106560
301213 33780101 50 0 TRUE 2119276776701034496
301353 60390601 12 0 TRUE 9470366328918376448
301361 33850101 500 0 FALSE 15407394867373932544
301426 60400107 12 0 TRUE 2263391964776890368
301485 33930101 500 0 TRUE 2335449558814818304
301558 21350701 500 0 TRUE 2407507152852746240
301604 34010101 500 0 TRUE 2479564746890674176
301620 34020101 500 0 TRUE 2551622340928602112
301701 21940201 25 0 TRUE 2623679934966530048
301787 18860101 1 0 TRUE 2695737529004457984
301809 34050101 2000 0 FALSE 2767795123042385920
301817 34050101 2000 0 TRUE 2839852717080313856
301833 33450101 2000 0 FALSE 2911910311118241792
301906 34070101 500 0 TRUE 2983967905156169728
301922 23140302 1 1 FALSE 15318553228338003968
302031 24450601 5 0 TRUE 3128083093232025600
302058 33440101 500 0 FALSE 3200140687269953536
302066 18810702 15 0 TRUE 3272198281307881472
302074 21440301 200 0 TRUE 3344255875345809408
302082 24450701 5 0 TRUE 3416313469383737344
302104 20800503 60 0 FALSE 3488371063421665280
302112 20800603 30 0 FALSE 3560428657459593216
302139 34080101 500 0 TRUE 3632486251497521152
302244 34110201 500 0 FALSE 15911798025639428096
302252 34110301 500 0 TRUE 3704543845535449088
302295 33900101 2000 0 TRUE 3776601439573377024
302325 33870101 25 0 TRUE 3848659033611304960
302414 32640501 500 0 TRUE 3920716627649232896
302449 20000201 100 0 TRUE 3992774221687160832
302457 19251401 250 0 TRUE 4064831815725088768
302465 15770502 10 0 FALSE 4136889409763016704
302481 27640101 60 0 TRUE 4208947003800944640
302716 33200201 500 0 TRUE 4281004597838872576
302775 33080101 25 0 TRUE 4353062191876800512
302805 33080401 500 0 TRUE 4425119785914728448
302821 33090101 500 0 TRUE 4497177379952656384
302899 14250101 7 0 FALSE 3020262783989055488
303070 19060101 10 0 TRUE 4569234973990584320
303127 19290802 1440 0 FALSE 6467575884206309376
303488 23120102 100 0 TRUE 4713350162066440192
303518 14750801 63 21 TRUE 324042569380003840
303542 14751201 84 28 TRUE 1332848885910994944
303550 14750901 84 28 TRUE 1404906479948922880
303569 15670101 100 0 TRUE 4857465350142296064
303623 22410101 100 0 FALSE 4929522944180224000
303631 22410101 500 0 TRUE 5001580538218151936
303666 16990201 168 0 FALSE 5073638132256079872
303674 16990303 168 0 FALSE 5145695726294007808
303690 15890602 10 1 TRUE 18416748296992194560
303763 18060104 100 0 TRUE 5289810914369863680
303984 10840201 500 0 FALSE 17791779290694549504
303992 10840103 500 0 TRUE 5361868508407791616
304093 13920201 500 0 TRUE 5433926102445719552
304123 14680201 100 0 TRUE 5505983696483647488
304131 14980103 500 0 TRUE 5578041290521575424
304166 15440105 1000 0 TRUE 5650098884559503360
304174 23300102 1000 0 TRUE 5722156478597431296
304182 18600101 500 0 TRUE 5794214072635359232
304190 18600201 100 0 FALSE 5866271666673287168
304204 18600201 500 0 TRUE 5938329260711215104
304239 18610101 500 0 TRUE 6010386854749143040
304247 18610201 100 0 TRUE 4329107132042444800
304255 18610201 500 0 FALSE 4401164726080372736
304263 18610301 100 0 TRUE 5049683072421724160
304271 18610301 500 0 FALSE 5121740666459652096
304298 19290803 1000 0 TRUE 6082444448787070976
304301 19310102 1000 0 TRUE 6154502042824998912
304328 20380302 500 0 TRUE 6226559636862926848
304336 19310101 1440 0 TRUE 6298617230900854784
304344 20710202 100 0 TRUE 6473144910600994816
304352 20710202 500 0 FALSE 1723217295213330432
304360 20710302 100 0 FALSE 6370674824938782720
304379 20710302 500 0 TRUE 6442732418976710656
304441 22500201 500 0 FALSE 6514790013014638592
304468 22500302 100 0 TRUE 6586847607052566528
304476 22500302 500 0 FALSE 6658905201090494464
304786 19290207 500 0 FALSE 6730962795128422400
304859 32860101 500 0 TRUE 6803020389166350336
304905 19290207 1000 0 TRUE 6875077983204278272
304913 20130101 100 0 TRUE 6947135577242206208
304948 12590202 5 0 TRUE 235385648297541632
305197 60412525 1 0 TRUE 14514679386550042624
305200 60412626 1 0 TRUE 14586736980587970560
305219 20380401 100 0 TRUE 7019193171280134144
305316 19140101 100 0 TRUE 7091250765318062080
305367 19290305 500 0 FALSE 7163308359355990016
305375 13320501 5 0 TRUE 11992382120245854208
305502 34130101 500 0 TRUE 7307423547431845888
305537 34130201 500 0 TRUE 7379481141469773824
305545 34130201 5 0 FALSE 7451538735507701760
305618 34150101 500 0 TRUE 7523596329545629696
305634 22620201 2000 0 TRUE 7595653923583557632
305642 34180101 100 0 TRUE 7667711517621485568
305707 34210201 500 0 TRUE 7739769111659413504
305723 34220101 25 0 TRUE 7811826705697341440
305774 34240102 2000 0 TRUE 7883884299735269376
305782 34240102 500 0 FALSE 7955941893773197312
305847 23120202 500 0 TRUE 8027999487811125248
305960 32200301 500 0 TRUE 8100057081849053184
305987 34280201 500 0 TRUE 8172114675886981120
306002 34310101 500 0 TRUE 8244172269924909056
306010 34300101 500 0 TRUE 8316229863962836992
306029 34300201 500 0 TRUE 8388287458000764928
306088 19290305 1000 0 TRUE 8460345052038692864
306096 34210101 100 0 TRUE 8532402646076620800
306762 32990101 2000 0 TRUE 8604460240114548736
306770 14370101 98 0 TRUE 2788043729179508736
306797 13710301 1 0 TRUE 8676517834152476672
306835 60120501 10 0 FALSE 13704478954855858176
306843 37632625 30 0 TRUE 5879756077276332032
306851 28410201 90 0 FALSE 8748575428190404608
307068 10210101 60 0 TRUE 8820633022228332544
307084 13720101 100 0 TRUE 8892690616266260480
307173 23770101 250 0 TRUE 8964748210304188416
307181 22240202 100 0 TRUE 9036805804342116352
307211 19150101 12 0 TRUE 9108863398380044288
307335 19870701 20 0 TRUE 9180920992417972224
307521 24830401 4.5 0 TRUE 451558430411325440
307548 22180202 30 0 TRUE 9252978586455900160
307645 29002525 28 0 TRUE 9325036180493828096
307661 22200201 500 0 TRUE 9397093774531756032
307696 29000225 240 0 TRUE 9469151368569683968
307769 22200201 1000 0 TRUE 8749790388539097088
307785 38172525 2 TRUE 11257644470100819968
307831 38172625 1 TRUE 11473817252214603776
307939 27582525 6 1 FALSE 12292415753721741312
307947 17970101 30 0 TRUE 8770781165024968704
307963 12230101 60 0 TRUE 9613266556645539840
308021 18180201 30 0 FALSE 5672874168417255424
308218 11100101 30 0 TRUE 6588062567401259008
308390 22740401 5 0 TRUE 523616024449253376
308455 29290801 237 0 TRUE 595673618487181312
308633 32770101 100 0 TRUE 9685324150683467776
308641 33070101 1 0 TRUE 9757381744721395712
309281 18880501 42.5 0 TRUE 667731212525109248
309508 17950402 1 0 TRUE 9829439338759323648
309540 12510101 1 0 TRUE 739788806563037184
309591 10940301 10 1 TRUE 14997391379422773248
309729 14650501 100 0 TRUE 9973554526835179520
309796 28410301 90 0 FALSE 10045612120873107456
309923 18200202 100 0 TRUE 10117669714911035392
309931 60380203 1 0 TRUE 811846400600965120
309958 17310101 30 0 TRUE 10189727308948963328
310018 14770301 63 21 TRUE 396100163417931776
310034 13200704 20 0 TRUE 10333842497024819200
310042 24830809 35 0 TRUE 5013402487239999488
310050 13200102 6 0 TRUE 10405900091062747136
310069 13200303 35 0 TRUE 10477957685100675072
310077 22240102 100 0 TRUE 10550015279138603008
310085 22240201 100 0 TRUE 10622072873176530944
310115 11081303 200 0 TRUE 10694130467214458880
310190 12580301 10 0 TRUE 10766188061252386816
310204 13060101 30 0 TRUE 10838245655290314752
310786 27980202 50 0 FALSE 7675876490969350144
311197 17190401 50 1 TRUE 16687647515058634752
311219 17191001 50 1 TRUE 16759705109096562688
311235 17192525 50 TRUE 12694100336697147392
311243 23320202 50 1 TRUE 3212877429966110720
311251 21350301 50 1 TRUE 3284935024004038656
311278 21350201 50 1 FALSE 15069448973460701184
311286 10970202 50 1 TRUE 15141506567498629120
311294 10970301 50 1 TRUE 13588889496451022848
311308 10970401 50 1 TRUE 8185132893559848960
311316 18570301 50 1 TRUE 15895013980641427456
311324 60190101 50 1 TRUE 17335884386423275520
311340 20160302 50 1 TRUE 3068762241890254848
311359 20160402 50 1 TRUE 3140819835928182784
311472 16290101 2 0 TRUE 4393442855918501888
311480 19530502 50 1 TRUE 18128799395817193472
311502 19530302 10 1 FALSE 18200856989855121408
311529 19530302 50 1 FALSE 18272914583893049344
311545 19530502 10 1 FALSE 18344972177930977280
311669 10310101 28 0 TRUE 11774994377783377920
311677 10310201 28 0 TRUE 11847051971821305856
311685 19290802 1000 0 FALSE 4789882768429416448
311693 60412625 1 0 TRUE 14658794574625898496
311707 60412725 1 0 TRUE 14730852168663826432
311715 60412825 1 0 TRUE 14802909762701754368
311723 60412925 1 0 TRUE 14874967356739682304
311731 60413025 1 0 TRUE 14947024950777610240
311758 60413125 1 0 TRUE 15019082544815538176
311766 60413225 1 0 TRUE 15091140138853466112
311774 10310301 28 0 TRUE 11919109565859233792
311804 60410102 1 0 FALSE 11991167159897161728
311812 60410102 1 0 FALSE 12063224753935089664
311820 60410102 1 0 FALSE 12135282347973017600
311839 60410102 1 0 FALSE 12207339942010945536
311847 60410102 1 0 FALSE 12279397536048873472
311855 60410102 1 0 FALSE 12351455130086801408
311871 60412726 1 0 TRUE 15163197732891394048
311898 60412826 1 0 TRUE 15235255326929321984
311901 60412926 1 0 TRUE 15307312920967249920
311928 60413026 1 0 TRUE 15379370515005177856
311944 60413126 1 0 TRUE 15451428109043105792
311952 60413226 1 0 TRUE 15523485703081033728
312193 19960401 30 0 FALSE 12423512724124729344
312304 33490301 2000 0 FALSE 17841598162549080064
312355 33560601 500 0 TRUE 12495570318162657280
312363 33560101 1 0 TRUE 12567627912200585216
312495 19560501 25 0 TRUE 12639685506238513152
312649 33300101 2000 0 TRUE 12711743100276441088
312673 11080203 200 0 TRUE 1820652717131956224
312681 11080303 200 0 TRUE 12783800694314369024
312762 20800501 60 0 TRUE 12510174031602778112
313130 23010501 50 0 TRUE 17233607814807552000
313165 32570101 100 0 FALSE 12855858288352296960
313181 32170101 100 0 TRUE 12927915882390224896
313653 19910504 30 0 TRUE 12999973476428152832
313661 10590201 100 0 TRUE 13805245897006645248
313688 10590201 500 0 FALSE 13877303491044573184
313696 10590301 100 0 TRUE 13072031070466080768
313939 10090101 1 1 TRUE 9770118487417552896
314293 10250101 112 0 TRUE 13216146258541936640
314722 15120501 1 1 TRUE 12868595031048454144
314730 15120601 1 1 TRUE 12940652625086382080
314773 11080301 200 0 TRUE 1892710311169884160
314803 19440301 10 1 TRUE 15213564161536557056
314846 23170104 100 0 TRUE 13504376634693648384
314854 23170202 100 0 TRUE 13576434228731576320
314935 33110301 500 0 TRUE 13648491822769504256
315125 60120401 10 0 FALSE 16976907034093944832
315508 27820701 500 0 FALSE 16328388687752593408
315559 12320301 5 1 FALSE 10490694427796832256
315567 12320102 5 1 FALSE 15285621755574484992
315575 12320201 5 1 TRUE 10562752021834760192
315583 12320301 5 1 TRUE 10634809615872688128
315648 24520901 375 0 FALSE 9556942974001086464
315672 22180101 30 0 TRUE 13936722198921216000
315680 11000103 100 0 TRUE 14008779792959143936
315699 14280202 100 0 TRUE 14080837386997071872
315753 60400106 12 0 TRUE 14152894981034999808
315761 10200301 20 0 TRUE 1964767905207812096
316059 14480101 50 0 TRUE 14224952575072927744
316091 18230301 50 0 TRUE 14297010169110855680
316164 27830102 250 0 FALSE 5291751552392888320
316199 21660301 100 0 TRUE 14369067763148783616
316318 15440102 100 0 FALSE 14441125357186711552
316512 25390301 5 1 TRUE 6383693042611650560
316644 23940501 3.5 0 FALSE 7982787569676976128
316652 20160501 100 0 TRUE 14585240545262567424
316660 24710101 30 0 FALSE 14657298139300495360
316679 24710201 18 0 FALSE 14729355733338423296
316687 24710301 100 0 TRUE 3023064339616628736
316709 33370102 100 0 TRUE 14801413327376351232
316717 33150102 100 0 TRUE 14873470921414279168
316725 20800401 5 1 TRUE 8689536051825344512
316741 28000201 4 0 TRUE 15017586109490135040
316881 13320501 25 0 TRUE 15089643703528062976
316962 12390101 100 0 TRUE 15161701297565990912
316970 14410101 50 0 FALSE 5355481445362040832
316989 17240102 84 28 TRUE 1476964073986850816
317071 10720201 20 0 FALSE 15377874079679774720
317160 15890404 5 1 FALSE 17479999574499131392
317365 10720301 20 0 FALSE 15521989267755630592
317381 18312201 10 0 TRUE 15594046861793558528
317535 16450302 100 0 TRUE 15666104455831486464
317659 20342525 30 0 TRUE 15738162049869414400
317756 12380101 1 1 TRUE 14021235060678590464
317764 25140102 30 0 FALSE 1833268513549058048
317845 26360202 30 0 TRUE 15882277237945270272
317918 26360102 30 0 TRUE 15954334831983198208
318094 10250201 112 0 TRUE 2108883093283667968
318116 21441301 112 0 TRUE 2180940687321595904
318515 13590101 1 1 TRUE 15357679349612412928
318558 10320201 100 0 TRUE 16098450020059054080
318566 10320101 100 0 TRUE 16170507614096982016
318647 24830301 2 0 TRUE 16242565208134909952
318663 24830601 25 0 FALSE 7021466961326374912
318752 29190101 1000 0 TRUE 2325055875397451776
318809 17600201 30 0 TRUE 16314622802172837888
318817 17600101 100 0 TRUE 16386680396210765824
319228 27160925 30 0 TRUE 2397113469435379712
319309 27160925 100 0 TRUE 2469171063473307648
319325 14870101 60 0 TRUE 16458737990248693760
319333 27820904 500 0 TRUE 5186810864103063552
319406 16880101 100 0 FALSE 18033845571642458112
319414 16880201 100 0 FALSE 17529442413376962560
319449 88560101 1 1 TRUE 15429736943650340864
319457 88560201 1 1 TRUE 15501794537688268800
319465 15120701 1 1 TRUE 13012710219124310016
319473 10700201 100 0 TRUE 16746968366400405504
319481 10700301 100 0 TRUE 16819025960438333440
319503 10700101 100 0 FALSE 4245233086540808192
319546 14270501 60 0 TRUE 16891083554476261376
319562 10990101 60 0 TRUE 16963141148514189312
319627 22700401 30 0 TRUE 2541228657511235584
319635 22700201 4.6 0 TRUE 2613286251549163520
319643 22700101 3 0 TRUE 17035198742552117248
319783 33920101 100 0 TRUE 17107256336590045184
319880 11910401 100 0 TRUE 17179313930627973120
319899 33040101 100 0 TRUE 17251371524665901056
319902 33120201 100 0 FALSE 17323429118703828992
319910 34280101 1 0 TRUE 17395486712741756928
319953 33380101 1 0 TRUE 17467544306779684864
320056 32570401 100 0 TRUE 17653056107641307136
320064 33770101 500 0 TRUE 17611659494855540736
320102 34240102 100 0 FALSE 17683717088893468672
320137 23120202 100 0 FALSE 17755774682931396608
320161 34080101 100 0 TRUE 17827832276969324544
320625 32120101 100 0 TRUE 17899889871007252480
320684 32640501 100 0 FALSE 17971947465045180416
320692 32450101 100 0 TRUE 18044005059083108352
320706 32460102 100 0 TRUE 18116062653121036288
321249 18740101 100 0 FALSE 11517732846139604992
321397 14430301 35 0 TRUE 18260177841196892160
321567 17660201 30 0 TRUE 18332235435234820096
321869 33200201 100 0 FALSE 18404293029272748032
321974 34210201 100 0 TRUE 101945618615762944
322075 34340101 100 0 TRUE 174003212653690880
322083 33530102 100 0 TRUE 246060806691618816
322113 32590101 100 0 TRUE 318118400729546752
322156 27161025 30 0 TRUE 2685343845587091456
323047 15460901 15 0 TRUE 2757401439625019392
323071 27821103 250 0 TRUE 5835329210444414976
323152 10840201 100 0 TRUE 17431491320504909824
323160 10840103 100 0 FALSE 390175994767474688
323446 10870102 40 0 FALSE 9779608372276887552
323454 16170602 25 0 TRUE 462233588805402624
323748 21140101 50 0 TRUE 2829459033662947328
323756 21140101 500 0 TRUE 2901516627700875264
323950 12970102 120 0 TRUE 534291182843330560
323985 27161025 100 0 TRUE 2973574221738803200
324760 10220101 28 0 FALSE 9677410965498363904
325155 20800503 60 0 TRUE 606348776881258496
325163 20800603 30 0 TRUE 678406370919186432
325244 23391302 250 0 TRUE 750463964957114368
325260 23391603 1000 0 TRUE 822521558995042304
325295 23391903 250 0 TRUE 3045631815776731136
325309 23391903 1000 0 TRUE 894579153032970240
325988 15721001 50 0 TRUE 3117689409814659072
325996 15720202 50 0 TRUE 3189747003852587008
326038 13610101 100 0 FALSE 966636747070898176
326062 20600602 30 0 FALSE 1038694341108826112
326070 20600602 100 0 TRUE 1110751935146754048
326747 29140101 76 0 TRUE 3261804597890514944
326755 29440126 237 TRUE 13613712070959693824
326844 10830101 60 0 TRUE 1254867123222609920
326852 23730203 50 0 FALSE 1326924717260537856
326860 23730103 50 0 FALSE 1398982311298465792
326887 20310201 100 0 TRUE 12283870349350666240
326895 20310303 100 0 TRUE 1471039905336393728
326909 20310401 100 0 TRUE 1543097499374321664
326992 11910202 100 0 TRUE 1615155093412249600
327050 60392725 12 0 TRUE 9182135952766664704
327476 11280401 40 0 TRUE 13121826852576428032
327611 14770401 84 28 TRUE 1549021668024778752
327670 19860101 10 0 TRUE 1687212687450177536
327794 23391903 125 0 TRUE 3333862191928442880
327816 23400201 10 0 TRUE 1759270281488105472
327832 20710402 100 0 TRUE 2587908423668465664
327859 18861001 28 0 TRUE 3405919785966370816
327883 18180401 5 1 TRUE 4581971716686741504
327948 24210301 50 0 TRUE 4439167146471194624
328235 14011202 30 0 TRUE 1903385469563961344
328286 22130403 125 0 TRUE 3477977380004298752
328421 32390101 1000 0 TRUE 1975443063601889280
328448 32390401 1000 0 TRUE 2047500657639817216
328456 32390501 1000 0 TRUE 2119558251677745152
328464 32390601 1000 0 TRUE 2191615845715673088
328626 16990101 180 0 TRUE 2263673439753601024
328634 16990402 100 0 TRUE 2335731033791528960
328685 20080101 15 0 TRUE 3550034974042226688
328898 28451101 5 0 TRUE 2407788627829456896
329134 18490201 3 1 FALSE 17624396237551697920
329150 12440101 500 0 TRUE 2479846221867384832
329223 18310101 10 0 TRUE 2551903815905312768
329231 18310201 10 0 TRUE 2623961409943240704
329258 18310301 10 0 TRUE 2696019003981168640
329266 18310401 10 0 TRUE 2768076598019096576
329320 25362525 5 TRUE 16998326620114649088
329401 28200101 3 1 TRUE 15573852131726196736
329428 60260501 100 0 TRUE 2912191786094952448
329436 24040301 100 0 TRUE 2984249380132880384
329444 15770401 200 0 TRUE 3056306974170808320
329622 16330301 15 0 TRUE 3622092568080154624
329983 12900101 28 0 FALSE 2311494498980462592
329991 27980302 100 0 FALSE 360963070329094144
330019 11660101 100 0 TRUE 3200422162246664192
330027 11660201 100 0 TRUE 3272479756284592128
330116 14751101 63 21 TRUE 468157757455859712
330167 13940102 500 0 TRUE 3694150162118082560
330175 16171903 100 0 TRUE 3416594944360448000
330183 20380601 100 0 TRUE 3488652538398375936
330191 20380404 100 0 TRUE 3560710132436303872
330221 20380501 100 0 TRUE 3632767726474231808
330248 20380304 100 0 TRUE 3704825320512159744
330299 20380204 100 0 TRUE 3776882914550087680
330302 10390101 500 0 TRUE 3848940508588015616
330310 10380201 500 0 TRUE 3920998102625943552
330329 32860101 100 0 FALSE 3993055696663871488
331007 14660501 20 0 FALSE 4065113290701799424
331740 14920601 15 0 TRUE 3766207756156010496
331759 16450103 100 0 TRUE 9367791789651525632
331767 22740501 3.5 0 TRUE 3838265350193938432
331791 12280201 100 0 TRUE 4137170884739727360
331848 15120502 10 1 TRUE 9385906243719135232
331856 15120602 10 1 TRUE 9241791055643279360
331872 17290101 30 0 TRUE 4353343666853511168
331899 19950101 100 0 TRUE 4425401260891439104
331902 12240101 100 0 TRUE 4497458854929367040
331929 15120702 10 1 TRUE 9169733461605351424
331937 12970301 30 0 TRUE 4641574043005222912
331945 14110201 100 0 TRUE 4713631637043150848
332062 15100301 5 1 TRUE 4437856528610885632
332070 60340101 100 0 TRUE 4857746825119006720
332232 16140701 30 0 TRUE 3910322944231866368
332623 29020112 946 0 TRUE 3982380538269794304
332631 16490402 10 0 FALSE 7740984072008105984
332658 16550102 10 0 FALSE 4929804419156934656
332690 24330101 20 0 TRUE 5001862013194862592
332704 24330201 10 0 TRUE 5073919607232790528
332712 24330301 10 0 TRUE 5145977201270718464
332771 38382525 20 TRUE 6484115837622943744
332798 38382625 20 TRUE 6700288619736727552
332801 38372525 1 TRUE 6051770273395376128
332917 29360101 400 0 TRUE 4126495726345650176
332925 21690301 5 1 TRUE 4509914122648813568
332984 13890101 1000 0 FALSE 972232161744650240
333026 15770103 10 0 FALSE 5290092389346574336
333042 10560101 50 1 FALSE 7536614547218497536
333085 15890601 5 1 TRUE 16519326578497290240
333131 13850101 5 1 TRUE 8328966606658994176
333158 13850201 5 1 TRUE 8401024200696922112
333174 15290201 5 0 TRUE 5578322765498286080
333182 15290402 10 0 TRUE 5650380359536214016
333190 15540302 5 1 TRUE 15030322852186292224
333204 15890403 50 1 TRUE 17407941980461203456
333212 11980201 5 0 TRUE 5794495547612069888
333220 11980301 5 0 TRUE 5866553141649997824
333239 11980402 1 0 TRUE 18426217291130601472
333247 17970401 5 0 TRUE 5938610735687925760
333255 17970701 5 0 TRUE 6010668329725853696
333263 17971001 1 0 TRUE 6082725923763781632
333271 17970901 5 0 TRUE 6154783517801709568
333298 17970501 5 0 TRUE 6226841111839637504
333328 19280101 5 1 TRUE 5951066003407372288
333336 20590101 5 1 TRUE 3141101310904893440
333344 19850101 5 1 TRUE 15645909725764124672
333956 10560101 5 1 TRUE 7464556953180569600
333964 16970303 100 0 FALSE 16765399479816814592
334111 18380201 30 0 TRUE 6587129082029277184
334138 18380101 30 0 TRUE 6659186676067205120
334405 23040101 112 0 TRUE 6731244270105133056
335142 12590102 10 0 TRUE 6803301864143060992
335150 12590403 4 0 TRUE 4198553320383578112
335320 24780201 50 0 TRUE 6875359458180988928
335339 24780201 25 0 FALSE 6947417052218916864
335347 24780101 25 0 FALSE 7019474646256844800
335355 24780101 50 0 TRUE 14112048124063121408
335363 34300301 100 0 TRUE 7091532240294772736
335428 11910301 120 0 TRUE 7163589834332700672
335665 29290804 235 0 TRUE 4270610914421506048
336025 18150101 60 0 TRUE 7235647428370628608
336262 22690102 40 0 TRUE 7307705022408556544
336351 29290204 235 0 TRUE 4342668508459433984
336416 24140101 100 0 TRUE 7379762616446484480
336548 20470101 50 0 TRUE 7451820210484412416
336874 11260101 100 0 TRUE 7523877804522340352
337285 13630101 20 0 TRUE 4414726102497361920
337307 27960301 30 0 TRUE 4486783696535289856
337315 27960301 60 0 FALSE 11198650173712498688
337455 39572525 1 TRUE 6707147373270794240
337463 23400601 10 0 TRUE 7595935398560268288
337471 23400501 10 0 TRUE 7667992992598196224
337951 25280201 100 0 TRUE 6203168626493620224
338001 12440401 500 0 TRUE 7740050586636124160
338052 20600601 100 0 TRUE 7812108180674052096
338192 24240301 10 1 TRUE 10130406457607192576
338435 24470102 500 0 FALSE 15678019863341694976
338583 13940101 500 0 TRUE 8028280962787835904
339326 14751001 84 28 TRUE 1621079262062706688
339350 22700301 30 0 TRUE 4630898884611145728
339431 23170102 100 0 FALSE 8100338556825763840
339458 23170102 500 0 TRUE 8172396150863691776
339466 23170201 100 0 FALSE 8244453744901619712
339474 23170201 500 0 TRUE 8316511338939547648
339482 23170301 100 0 TRUE 8388568932977475584
340405 38602525 28 TRUE 3169198231041081344
340413 19140202 473 0 TRUE 8460626527015403520
340529 10870101 1200 0 FALSE 9365256315837874176
340537 60120101 50 0 TRUE 5579137503614468096
341010 20800601 30 0 TRUE 13158692377944129536
341126 22950101 50 0 FALSE 8532684121053331456
341614 38142525 1 TRUE 9960607777418117120
341622 38142625 1 TRUE 10176780559531900928
341711 13710226 1 TRUE 15236661602301247488
341754 11980402 1 0 FALSE 123869880473616384
341770 23140302 10 1 TRUE 15102380446224220160
341878 16980101 100 0 TRUE 8676799309129187328
341940 22180103 100 0 TRUE 8748856903167115264
341967 22180204 100 0 TRUE 8820914497205043200
342289 27830202 250 0 FALSE 5435866740468744192
342939 11580101 28 0 FALSE 7854591110948061184
343021 60380101 1 0 TRUE 8892972091242971136
343048 28060201 30 0 TRUE 8965029685280899072
343072 28410101 90 0 FALSE 9037087279318827008
343129 63100201 10 0 TRUE 9109144873356754944
343773 18810601 36 0 TRUE 4702956478649073664
343889 21830101 100 0 TRUE 9181202467394682880
344303 29280401 80.4 0 TRUE 4775014072687001600
344338 29450106 48.5 0 TRUE 6123634353386815488
344540 11910301 30 0 FALSE 9253260061432610816
344621 25280403 30 0 TRUE 9325317655470538752
344710 10500401 25 0 TRUE 4919129260762857472
344729 10560401 25 0 TRUE 4991186854800785408
344818 12820201 25 0 TRUE 5063244448838713344
344842 13830501 25 0 TRUE 5135302042876641280
344850 14980301 25 0 TRUE 5207359636914569216
344877 21760301 25 0 TRUE 5279417230952497152
344885 15770504 30 0 TRUE 9397375249508466688
344893 15770104 30 0 TRUE 9469432843546394624
345571 33450101 2000 0 TRUE 9541490437584322560
345628 33600201 100 0 FALSE 9613548031622250496
345881 18200103 250 0 TRUE 9685605625660178432
345946 19290204 1000 0 TRUE 9757663219698106368
346373 25280902 30 0 FALSE 9829720813736034304
346381 25280502 30 0 TRUE 9901778407773962240
346403 25280602 30 0 TRUE 9973836001811890176
346632 20310201 500 0 FALSE 12355927943388594176
346659 10150101 50 1 FALSE 5806950815331516416
346756 18310102 10 0 FALSE 1925614296142708736
346764 18310202 10 0 FALSE 1997671890180636672
346772 18310302 10 0 FALSE 2069729484218564608
346780 18310402 10 0 FALSE 2141787078256492544
346802 27110301 30 0 FALSE 10045893595849818112
346829 18310801 50 1 FALSE 17768511425627553792
346845 18311101 50 1 FALSE 17840569019665481728
346853 19530301 50 1 FALSE 17912626613703409664
346861 19530401 50 1 FALSE 17984684207741337600
346888 19530501 50 1 FALSE 18056741801779265536
346896 60570101 5 1 TRUE 15717967319802052608
346942 21280102 50 1 TRUE 15790024913839980544
346950 21280201 1 1 TRUE 2780531865738543104
346977 29080104 5000 0 TRUE 74067501293502464
346993 21350503 5 1 TRUE 2852589459776471040
347027 23320101 50 1 TRUE 2924647053814398976
347051 23320401 5 1 FALSE 2996704647852326912
347086 27110201 30 0 FALSE 10766469536229097472
347140 33290301 50 1 TRUE 14741811001057869824
347159 11970101 50 1 FALSE 15862082507877908480
347183 27110101 30 0 FALSE 10910584724304953344
347876 18150101 10 0 FALSE 10982642318342881280
347914 10842525 100 TRUE 6478199365553881088
347922 18310601 5 1 TRUE 15934140101915836416
347930 18310701 5 1 TRUE 17696453831589625856
348554 14380202 100 0 TRUE 16760734251980161024
348562 14380202 500 0 FALSE 16688676657942233088
348570 14380301 100 0 TRUE 11198815100456665088
348880 10340101 300 0 FALSE 16567354345910173696
349186 29230101 900 0 TRUE 5351474824990425088
349291 28310101 10 0 TRUE 4511224740509122560
349453 21440302 200 0 TRUE 11270872694494593024
349658 18880302 84 0 FALSE 11004566580200734720
349933 11200101 10 1 TRUE 16006197695953764352
349941 11200201 10 1 TRUE 13372998189313949696
350125 19140201 300 0 TRUE 11487045476608376832
350133 15670202 1000 0 FALSE 17320973909239005184
350338 29060103 500 0 TRUE 5423532419028353024
350516 10340101 100 0 TRUE 16639411939948101632
351806 26360101 30 0 TRUE 11631160664684232704
351830 16482501 10 0 TRUE 11703218258722160640
351857 63000502 10 0 TRUE 5495590013066280960
351865 16492501 10 0 TRUE 11775275852760088576
351970 32440101 2000 0 FALSE 15431886488882642944
352004 20310101 100 0 TRUE 11847333446798016512
352292 11360102 5 1 TRUE 13445055783351877632
352500 13320203 500 0 TRUE 11991448634873872384
352691 37932525 30 0 TRUE 12063506228911800320
352713 19490125 100 0 TRUE 12135563822949728256
352802 11670103 100 0 TRUE 12207621416987656192
353582 17940105 100 0 TRUE 5705384528227336192
353701 17940205 60 0 TRUE 5777442122265264128
353760 23980301 30 0 TRUE 12423794199101440000
354333 11510201 30 0 TRUE 12495851793139367936
354619 11020101 360 0 TRUE 12567909387177295872
354627 11020201 180 0 TRUE 16112215905638809600
355488 11830101 60 0 TRUE 8730530243355344896
355518 18270203 1 0 TRUE 5567647607104208896
356522 16980201 200 0 TRUE 12639966981215223808
356921 29250103 227 0 TRUE 290240283407286272
357251 20710402 500 0 FALSE 2227620453478825984
358061 28450801 1 0 TRUE 12712024575253151744
358088 28450501 1 0 TRUE 12784082169291079680
358096 28450601 1 0 TRUE 12856139763329007616
358118 28450701 1 0 TRUE 12928197357366935552
358215 11560201 56 0 FALSE 11170237693739139072
358223 11560101 56 0 FALSE 11098180099701211136
358258 22200201 1000 0 FALSE 6231034649187975168
358312 10570301 10 1 FALSE 10838362203522859008
358347 32570301 500 0 TRUE 17436883325527523328
358355 16430101 30 0 TRUE 13144370139480719360
358444 25210101 5 1 TRUE 1483776648032550912
358797 11830201 60 0 TRUE 13288485327556575232
358800 11830301 60 0 TRUE 13360542921594503168
358827 21490125 100 0 TRUE 13432600515632431104
358975 27820902 100 0 FALSE 14105865570180136960
358991 10260102 100 0 TRUE 13504658109670359040
359009 23891201 5 0 TRUE 5639705201142136832
359017 14431002 100 0 TRUE 13576715703708286976
359122 10400101 300 0 FALSE 1923352600724373504
359335 10870601 100 0 TRUE 13648773297746214912
359823 15100203 60 0 TRUE 13720830891784142848
359866 16060101 25 0 TRUE 13792888485822070784
359912 32390701 1000 0 TRUE 13864946079859998720
360023 23280203 500 0 TRUE 13937003673897926656
360082 60110101 5 1 TRUE 3717562063208316928
360597 60320701 10 1 TRUE 16078255289991692288
360619 60320601 10 1 TRUE 16150312884029620224
360694 33650101 500 0 TRUE 14225234050049638400
360805 11850101 50 0 FALSE 14297291644087566336
361372 17950501 200 0 TRUE 2457021459986382848
361399 10430101 42 0 FALSE 7958215683819438080
361461 24810101 20 0 FALSE 14441406832163422208
361925 18270104 1 0 TRUE 5711762795180064768
361933 14380402 100 0 TRUE 14513464426201350144
362069 60120101 10 0 FALSE 5651195097652396032
362107 25400201 1 1 TRUE 9626003299341697024
362948 26360104 30 0 TRUE 14657579614277206016
363707 63070102 1 0 TRUE 14729637208315133952
363804 24820401 12 0 TRUE 14801694802353061888
364304 10400101 20 0 FALSE 14873752396390989824
365041 15370102 90 0 TRUE 14945809990428917760
365068 17950502 200 0 TRUE 15017867584466845696
365769 10330101 15 0 TRUE 15089925178504773632
367958 29330103 500 0 TRUE 362297877445214208
368466 18200103 21 0 FALSE 15161982772542701568
368830 33030202 500 0 TRUE 15234040366580629504
369470 37632525 30 0 TRUE 11076063423308496896
369543 16880125 60 0 FALSE 7944482783588515840
369659 10770101 270 0 TRUE 15306097960618557440
369748 29370101 285 0 TRUE 5783820389217992704
370010 23171101 30 0 FALSE 15378155554656485376
370215 16190402 100 0 TRUE 15450213148694413312
370223 32130106 500 0 TRUE 15522270742732341248
370517 32820105 500 0 TRUE 15594328336770269184
370614 25280501 28 0 FALSE 15666385930808197120
371114 18860802 4 0 TRUE 15738443524846125056
371122 18860902 4 0 TRUE 15810501118884052992
371289 25280801 30 0 TRUE 15882558712921980928
371297 25280701 30 0 TRUE 15954616306959908864
372366 38082625 120 TRUE 14283781944717082624
372382 38082525 60 TRUE 11473535777237893120
372412 17970102 30 0 TRUE 17481310192359440384
373427 23320202 5 1 FALSE 546746450562777088
373540 37632725 3 0 TRUE 16098731495035764736
374296 14010103 30 0 FALSE 16170789089073692672
374326 17690102 100 0 TRUE 16242846683111620608
374334 14010203 30 0 FALSE 16314904277149548544
374466 20380403 500 0 TRUE 16386961871187476480
374474 20790206 100 0 FALSE 16459019465225404416
374482 22500201 100 0 TRUE 16531077059263332352
374741 16142525 30 0 FALSE 3062021136100360192
375519 17320101 100 0 TRUE 16603134653301260288
376574 27110201 90 0 TRUE 16675192247339188224
376671 29211301 250 0 TRUE 506413065521070080
376744 29211201 250 0 TRUE 578470659558998016
376779 29211101 150 0 TRUE 650528253596925952
377074 21440801 5 0 TRUE 16747249841377116160
377090 38262525 1 TRUE 13961212720918298624
377449 29120104 1000 0 FALSE 16819307435415044096
377481 29020108 1000 0 FALSE 10149287271279362048
377546 16550202 10 0 FALSE 16891365029452972032
377937 11320101 200 0 TRUE 7524811289894322176
377953 20560325 28 0 TRUE 5927935577293848576
378038 37312525 60 0 TRUE 3172804629180186624
378127 12510102 1 0 TRUE 5999993171331776512
378135 17660601 56 0 FALSE 16963422623490899968
378186 17660701 100 0 FALSE 17035480217528827904
378224 24820325 12 0 TRUE 10842718468592107520
378275 10770125 180 0 TRUE 4902186886090457088
378690 37372525 100 0 TRUE 14743959446778544128
379042 22390101 10 1 TRUE 8473081794734850048
379050 22050102 100 0 TRUE 17179595405604683776
380008 15540501 5 0 TRUE 6072050765369704448
380032 13150202 500 0 TRUE 17251652999642611712
380075 23171102 250 0 TRUE 17323710593680539648
380148 15120204 250 0 FALSE 15630623215603154944
380342 19960602 100 0 TRUE 17395768187718467584
380423 13060101 60 0 TRUE 17467825781756395520
380431 17940203 250 0 TRUE 17539883375794323456
380482 17940103 500 0 TRUE 17611940969832251392
380539 15440202 100 0 TRUE 17683998563870179328
380571 25290401 250 0 TRUE 17756056157908107264
380636 10260101 500 0 TRUE 17828113751946035200
380679 10260203 500 0 TRUE 17900171345983963136
380776 27980103 1584 0 TRUE 17972228940021891072
380814 12590105 10 0 TRUE 6144108359407632384
381152 15801202 100 0 TRUE 18044286534059819008
381454 20310203 100 0 TRUE 18116344128097746944
381470 20310301 100 0 TRUE 18188401722135674880
381500 20310403 100 0 TRUE 18260459316173602816
381543 20960603 200 0 TRUE 6216165953445560320
381586 37102625 300 0 TRUE 18332516910211530752
381624 37102525 100 0 TRUE 18404574504249458688
382167 20710401 500 0 TRUE 102227093592473600
382175 21660201 100 0 TRUE 174284687630401536
383007 10720205 100 0 FALSE 246342281668329472
383015 10720205 500 0 TRUE 318399875706257408
383031 10720305 100 0 FALSE 4507866831997894656
383678 38922525 30 0 FALSE 3525651104673038336
383864 19120402 100 0 TRUE 390457469744185344
383872 14430701 3 0 TRUE 462515063782113280
384305 23170302 100 0 TRUE 534572657820041216
384313 24860101 3.5 0 TRUE 6288223547483488256
384909 15890404 50 1 TRUE 114400886335209472
385034 13610206 100 0 FALSE 678687845895897088
385220 13610301 50 0 TRUE 750745439933825024
386561 10720325 100 0 TRUE 822803033971752960
386596 10720225 500 0 TRUE 894860628009680896
386731 39152525 30 TRUE 10211209567132450816
387118 22180102 30 0 FALSE 4906426602927161344
387177 27821102 100 0 FALSE 3092311581933961216
387231 20690101 100 0 TRUE 966918222047608832
387509 17300401 250 0 TRUE 1038975816085536768
387630 13970201 250 0 TRUE 1111033410123464704
387851 25290102 30 0 FALSE 1183091004161392640
387886 22600102 100 0 TRUE 1255148598199320576
387908 22600202 100 0 TRUE 1327206192237248512
387924 60390106 24 0 TRUE 1399263786275176448
387959 32920101 2000 0 FALSE 1471321380313104384
387967 32920101 5000 0 FALSE 1543378974351032320
387983 32170201 500 0 TRUE 1615436568388960256
388130 18220101 50 0 TRUE 1687494162426888192
388181 60130101 75 0 TRUE 6360281141521416192
388238 14310102 30 0 FALSE 1759551756464816128
388513 37722725 30 0 TRUE 1831609350502744064
388548 37722525 30 0 TRUE 1903666944540672000
388610 14360101 100 0 TRUE 1975724538578599936
388874 10820201 15 0 TRUE 6432338735559344128
388920 12730201 300 0 TRUE 2047782132616527872
389072 10720204 100 0 TRUE 2119839726654455808
389099 10720304 100 0 TRUE 2191897320692383744
389366 38933025 10 TRUE 2601805151131926528
389390 38933125 10 TRUE 2817977933245710336
389439 10820101 15 0 TRUE 6504396329597272064
389447 60320801 3 1 FALSE 16222370478067548160
389455 60320801 10 1 TRUE 16294428072105476096
389498 24200501 3 1 TRUE 16366485666143404032
389536 17160225 5 0 TRUE 2480127696844095488
389579 60320901 3 1 FALSE 16438543260181331968
389587 60320901 10 1 TRUE 16510600854219259904
389749 22210101 350 0 TRUE 2696300478957879296
389781 16480204 5 1 TRUE 16582658448257187840
390003 11000102 100 0 TRUE 2840415667033735168
390119 17160101 5 0 TRUE 6576453923635200000
390178 21280102 5 1 FALSE 16654716042295115776
390291 17160201 5 0 FALSE 6648511517673127936
390305 26320101 100 0 TRUE 2984530855109591040
390313 26320201 100 0 TRUE 3056588449147518976
390321 26320301 100 0 TRUE 10383934047763038208
390372 38982525 100 TRUE 8520943535891939328
390534 10720625 100 0 TRUE 3128646043185446912
390623 10720525 100 0 TRUE 3200703637223374848
391646 19780725 5 1 TRUE 2564640558601469952
391654 19780625 5 1 TRUE 2636698152639397888
391727 15740801 12 0 TRUE 7932268308915552256
392006 16990302 180 0 TRUE 3416876419337158656
392235 19290203 200 0 FALSE 3488934013375086592
392243 19290203 100 0 FALSE 3560991607413014528
392391 17950601 200 0 TRUE 3633049201450942464
393037 20790104 100 0 FALSE 2028623142502531072
393088 20790205 100 0 FALSE 3705106795488870400
393118 20790205 500 0 TRUE 3777164389526798336
393584 16990202 100 0 TRUE 3849221983564726272
393592 16990301 100 0 TRUE 3921279577602654208
393991 24130601 50 0 TRUE 6720569111711055872
394467 10870103 96 0 FALSE 6953293941869379584
394920 13970602 10 1 TRUE 2708755746677325824
394947 13830101 100 0 TRUE 4065394765678510080
394971 19530501 5 1 TRUE 3646417063821443072
394998 18311101 5 1 TRUE 1627891836108406784
395005 18311001 5 1 TRUE 1699949430146334720
395013 18310801 5 1 TRUE 1772007024184262656
395080 23320101 5 1 FALSE 618804044600705024
395250 15800801 100 0 TRUE 4281567547792293888
395528 28630101 750 0 FALSE 4353625141830221824
395552 22050401 7 0 TRUE 4425682735868149760
395587 22660102 100 0 TRUE 15203097910351757312
395633 10590103 100 0 TRUE 2666435544124227584
395838 60120201 500 0 TRUE 1403175848646803456
396303 15720308 25 0 TRUE 4569797923944005632
396524 29260301 100 0 TRUE 4641855517981933568
396842 20100301 15 0 TRUE 6792626705748983808
397083 10570101 30 0 TRUE 4713913112019861504
397148 16970303 28 0 TRUE 12802231807730778112
397172 32020102 100 0 FALSE 4858028300095717376
397202 63010101 500 0 FALSE 4930085894133645312
397210 63010101 100 0 FALSE 5002143488171573248
398322 18710101 84 28 TRUE 1693136856100634624
398462 13690101 50 0 TRUE 5146258676247429120
398608 60220101 125 0 FALSE 5218316270285357056
398837 15120104 100 0 FALSE 15414450433489371136
398845 15120204 50 0 FALSE 5290373864323284992
398969 22500101 100 0 TRUE 5362431458361212928
399019 13970601 5 1 TRUE 2780813340715253760
399027 28360303 30 0 TRUE 5434489052399140864
399043 18311701 10 0 TRUE 5506546646437068800
399051 18311801 10 0 TRUE 5578604240474996736
399108 18311901 10 0 TRUE 5650661834512924672
399485 29000101 60 0 TRUE 5722719428550852608
399930 11070101 5 0 TRUE 5794777022588780544
400483 21400102 12 0 TRUE 5866834616626708480
400564 10630101 28 0 TRUE 18406233667295772672
400572 10630202 28 0 FALSE 5938892210664636416
401692 15890702 5 1 FALSE 16726773636333043712
402281 27580801 1 1 FALSE 14885926189133725696
402303 27580701 1 1 FALSE 14957983783171653632
402516 10650101 120 0 TRUE 6864684299786911744
402699 10650201 120 0 TRUE 6936741893824839680
402702 10650301 120 0 TRUE 6227122586816348160
402710 10650401 120 0 TRUE 3790648800129843200
402737 10650501 15 0 TRUE 3862706394167771136
402761 10650601 15 0 TRUE 6299180180854276096
402796 10650707 15 0 TRUE 6371237774892204032
402826 10650801 15 0 TRUE 6443295368930131968
402958 10651101 60 0 TRUE 7008799487862767616
402974 10651201 60 0 TRUE 7080857081900695552
402990 10651301 60 0 TRUE 7152914675938623488
403490 16492503 10 0 TRUE 7224972269976551424
403660 16482502 10 0 TRUE 7297029864014479360
403903 23640101 100 0 TRUE 8214870285044678656
403989 34090101 1 0 TRUE 6515352962968059904
405663 20160101 60 0 TRUE 6587410557005987840
405701 17720125 30 0 FALSE 13795768106775216128
406287 63110201 20 0 TRUE 6731525745081843712
406708 33600201 2500 0 FALSE 6876737146250592256
406716 13320602 2500 0 TRUE 6803583339119771648
406732 33600301 2500 0 FALSE 6732621958174736384
407860 18610402 100 0 TRUE 6875640933157699584
408050 29080106 400 0 TRUE 7369087458052407296
408638 10870101 1152 0 TRUE 9437313909875802112
409200 11300101 60 0 FALSE 6947698527195627520
409308 11912601 10 0 FALSE 2617574346897489920
409324 40302525 1 TRUE 1866369311103254528
409359 29320401 400 0 TRUE 7441145052090335232
409367 29320501 400 0 FALSE 5890578570228531200
409375 29320601 400 0 TRUE 7585260240166191104
409448 39032525 120 TRUE 13093507831091429376
409499 26420103 100 0 TRUE 7091813715271483392
409510 26360201 30 0 TRUE 7163871309309411328
409634 16990303 100 0 FALSE 7235928903347339264
409642 16990201 100 0 FALSE 7307986497385267200
410225 20500411 56 0 FALSE 12035380721473290240
410268 20500201 42 0 FALSE 7452101685461123072
410284 18880202 28 0 FALSE 12639802054471057408
410292 18880102 28 0 FALSE 7866830874388463616
410314 18880302 28 0 TRUE 10932508986162806784
410322 20450201 40 0 TRUE 7657317834204119040
410357 20450101 40 0 TRUE 7729375428242046976
410470 29190102 1000 0 TRUE 7801433022279974912
410691 14750902 84 28 TRUE 1765194450138562560
411388 30000102 1 0 TRUE 7524159279499051008
412325 17950701 200 0 TRUE 7596216873536978944
412341 17950602 200 0 TRUE 7668274467574906880
413453 29290202 200 0 FALSE 7873490616317902848
413631 29290601 200 0 FALSE 7945548210355830784
413658 29470101 200 0 FALSE 4285322380001148928
413739 29120107 500 0 TRUE 7740332061612834816
413755 29130103 500 0 TRUE 8089663398431686656
413763 29012525 1000 0 TRUE 10170129613695483904
413798 29110102 500 0 TRUE 8233778586507542528
413844 29020115 1000 0 TRUE 7812389655650762752
413852 29020115 500 0 TRUE 7884447249688690688
413860 29020114 126 0 TRUE 7956504843726618624
413933 29170303 500 0 TRUE 8305836180545470464
413992 29020111 500 0 FALSE 5615321331772948480
414018 29020111 1000 0 TRUE 8449951368621326336
414085 15180401 30 0 TRUE 8522008962659254272
414093 15180501 30 0 TRUE 8594066556697182208
415855 15790301 500 0 TRUE 8028562437764546560
416762 27910301 60 0 TRUE 8100620031802474496
416991 38932725 10 TRUE 1953286804790575104
417009 38932825 10 TRUE 2169459586904358912
417017 38932925 10 TRUE 2385632369018142720
417289 33710101 1 0 TRUE 8172677625840402432
417300 34000101 1 0 TRUE 8244735219878330368
417866 10022601 56 0 TRUE 16407567818603626496
418021 10022701 56 0 TRUE 16984028570907049984
418498 10022801 56 0 TRUE 17560489323210473472
421405 10110501 100 0 FALSE 10397986905877643264
421464 63070301 100 0 TRUE 8532965596030042112
421472 63070701 100 0 TRUE 8605023190067970048
421480 63070501 100 0 TRUE 8677080784105897984
421812 10370201 30 0 TRUE 8749138378143825920
421979 32250101 100 0 FALSE 8821195972181753856
422428 33360101 2 0 FALSE 8893253566219681792
422452 32440101 500 0 TRUE 15359828894844715008
422762 32250101 500 0 TRUE 8965311160257609728
422770 32260101 100 0 FALSE 9037368754295537664
422789 32260101 500 0 TRUE 9109426348333465600
422851 15120105 100 0 TRUE 9181483942371393536
423092 15120205 50 0 TRUE 9253541536409321472
423351 60392625 12 0 TRUE 9110078358728736768
423378 38112625 1 TRUE 7942995144356134912
423416 28410201 60 0 TRUE 9325599130447249408
423424 28410301 60 0 TRUE 9397656724485177344
423432 28410101 60 0 TRUE 9469714318523105280
423440 28400102 30 0 FALSE 9541771912561033216
423947 10022501 28 0 FALSE 18136950075513896960
424374 19930102 100 0 TRUE 9613829506598961152
424463 27580401 1 1 FALSE 16798831230370971648
424498 27580501 1 1 FALSE 15030041377209581568
424501 27580601 1 1 FALSE 15102098971247509504
424544 11030101 10 0 TRUE 8666124150735110144
424730 24520901 336 0 TRUE 8738181744773038080
424803 38402525 7 TRUE 7853210124343574528
425303 18610402 500 0 FALSE 9830002288712744960
425672 29450101 400 0 TRUE 6195691947424743424
425826 28300101 28 0 FALSE 13601462411914641408
425869 13970501 5 0 TRUE 9902059882750672896
425877 13970401 5 0 TRUE 9974117476788600832
426202 10860101 168 0 FALSE 1850252669663313920
426342 23840201 100 0 TRUE 10046175070826528768
426350 10980101 28 0 FALSE 14743121618918178816
426393 22180106 30 0 TRUE 10118232664864456704
426482 22180206 30 0 TRUE 10190290258902384640
426490 14120301 60 0 TRUE 17617817859482714112
426504 27610201 3 1 TRUE 16870888824408899584
427365 34300301 500 0 TRUE 10334405446978240512
427454 28280201 50 0 TRUE 8882296932848893952
427527 11940101 20 0 TRUE 10406463041016168448
427721 11010101 50 0 TRUE 8954354526886821888
427748 11010101 200 0 TRUE 8463247762736021504
427802 25290102 30 0 TRUE 10550578229092024320
427918 11400101 30 0 FALSE 6443072168069693440
427926 11400201 30 0 FALSE 6515129762107621376
427942 25100801 1 1 TRUE 16860204869921800192
427950 25101001 1 1 TRUE 18373414344718286848
428736 33320101 1000 0 TRUE 10910866199281664000
428841 18300501 1 0 TRUE 10982923793319591936
428914 34390101 25 0 TRUE 11054981387357519872
429198 33670101 500 0 TRUE 11127038981395447808
429317 34120101 1 0 TRUE 11199096575433375744
429368 11090401 60 0 TRUE 11271154169471303680
429376 11090301 60 0 TRUE 11343211763509231616
429392 11090201 60 0 TRUE 11415269357547159552
429406 11090101 60 0 TRUE 11487326951585087488
429414 11090501 200 0 TRUE 11559384545623015424
431311 32210201 500 0 TRUE 13482114822766067712
431842 30000202 25 0 TRUE 11631442139660943360
431877 30000203 25 0 TRUE 11703499733698871296
433667 26360103 30 0 FALSE 17253312162688925696
433748 11360101 10 1 TRUE 13300940595276021760
433802 11102525 100 0 TRUE 11775557327736799232
433934 11870101 12 0 TRUE 11847614921774727168
434434 32980101 500 0 TRUE 11919672515812655104
434566 33010101 500 0 FALSE 11991730109850583040
435031 28080101 1 0 TRUE 9026412120924749824
435309 18260125 1 0 TRUE 9187215696486989824
435333 25130301 30 0 TRUE 12010279970522791936
435368 25130401 30 0 TRUE 12063787703888510976
435686 14010204 100 0 TRUE 12135845297926438912
435694 14010304 30 0 TRUE 12207902891964366848
435716 33310201 500 0 TRUE 12279960486002294784
435724 14011204 30 0 TRUE 12352018080040222720
435732 14010104 100 0 TRUE 12424075674078150656
436445 12320327 1 1 TRUE 11067155180100255744
436461 12320226 1 1 TRUE 11139212774138183680
436534 11940201 30 0 TRUE 17769540568511152128
437026 33540501 500 0 TRUE 12496133268116078592
437204 18090125 30 0 TRUE 12568190862154006528
437212 11332525 60 0 TRUE 12640248456191934464
437239 11332625 60 0 TRUE 12712306050229862400
437271 15320325 5 1 TRUE 4726368379739308032
437298 15320125 5 1 TRUE 4798425973777235968
437301 15320225 5 1 TRUE 4870483567815163904
437328 11080325 200 0 TRUE 9098469714962677760
437352 29050501 400 0 TRUE 9170527309000605696
438111 11120101 1 0 TRUE 9242584903038533632
438138 20500201 42 0 TRUE 9314642497076461568
438146 20500201 126 0 FALSE 13000536426381574144
438154 20500411 56 0 TRUE 12107438315511218176
438162 20500411 168 0 FALSE 12179495909549146112
438189 24830625 25 0 FALSE 9458757685152317440
438197 24830725 56 0 FALSE 4762311414851305472
438227 24830825 35 0 FALSE 4941344893202071552
438243 33920101 500 0 TRUE 13144651614457430016
439118 17180904 84 28 TRUE 13362036058385022976
439169 37072525 15 1 TRUE 6167520260497866752
439177 15440401 5 1 FALSE 5158432468990164992
439886 33540401 500 0 TRUE 13288766802533285888
440507 60390201 144 0 TRUE 1658846386965184512
440515 60390125 144 0 TRUE 13432881990609141760
440612 13940126 1000 TRUE 4405475911172882432
440701 10220101 30 0 TRUE 9605353371460435968
443123 33600101 25 0 FALSE 13504939584647069696
443131 33600101 25 0 TRUE 13576997178684997632
452866 22660225 5 0 TRUE 9530815279190245376
452955 22660425 5 0 TRUE 9602872873228173312
454680 10780101 50 0 TRUE 14273724711857815552
454699 10780201 50 0 TRUE 14345782305895743488
454745 22770101 100 0 TRUE 4179645018920714240
455024 22130405 125 0 TRUE 9674930467266101248
455091 22130406 125 0 TRUE 9746988061304029184
455563 24210302 50 0 TRUE 13793169960798781440
455571 24210202 50 0 TRUE 13865227554836709376
455598 24210102 50 0 TRUE 13937285148874637312
456128 20680301 50 0 FALSE 2998571618596290560
456152 20680301 15 0 TRUE 3070629212634218496
456160 39152625 30 TRUE 10427382349246234624
456241 15690102 30 0 FALSE 14009342742912565248
456756 29020101 237 0 TRUE 14081400336950493184
456845 29050202 454 0 TRUE 9819045655341957120
457809 29190104 1000 0 TRUE 11607581637826576384
457833 18260101 1 0 TRUE 8394582162069782528
457841 18260101 1 0 FALSE 8466639756107710464
458015 29410201 237 0 FALSE 17038094856179679232
458023 29410101 237 0 FALSE 15188239110213992448
458767 15680101 100 0 TRUE 14153457930988421120
458872 15801201 100 0 TRUE 14225515525026349056
459046 15801101 100 0 TRUE 14297573119064276992
459348 33810101 500 0 TRUE 14369630713102204928
459410 29130101 1000 0 FALSE 10179333625531596800
459771 15720311 50 0 TRUE 10251391219569524736
459801 29050702 500 0 TRUE 4163147946457563136
459828 29050704 500 0 TRUE 10395506407645380608
460265 11100201 30 0 TRUE 6660120161439186944
461148 63070301 10 0 FALSE 14441688307140132864
461156 63070501 10 0 FALSE 14513745901178060800
461164 63070701 10 0 FALSE 14585803495215988736
461253 39332525 25 TRUE 11278284502377431040
461288 17950501 500 0 FALSE 2529079054024310784
461504 16960302 100 0 TRUE 10467564001683308544
461598 13780102 10 1 TRUE 7824844923370209280
461946 17940206 60 0 TRUE 14729918683291844608
461954 17940106 100 0 TRUE 14801976277329772544
461962 25050101 100 0 TRUE 14874033871367700480
462519 15700401 1 0 TRUE 14946091465405628416
462535 25330302 1 0 TRUE 10539621595721236480
462543 25330501 20 0 TRUE 15018149059443556352
462675 10430101 10 0 TRUE 15090206653481484288
462756 24520206 325 0 FALSE 1855344508011544576
462764 24520102 425 0 TRUE 10683736783797092352
462829 16060201 21.1 0 TRUE 2004522947133308928
463493 11220101 1 0 TRUE 15162264247519412224
464988 13940103 1000 TRUE 4189303129059098624
465070 10040101 120 0 FALSE 4660138197328592896
465631 24870301 500 0 TRUE 15234321841557340160
466050 21490301 100 0 TRUE 15306379435595268096
468185 10870103 48 0 TRUE 8899130455870144512
469149 22130204 100 0 TRUE 10827851971872948224
469513 29320702 860 0 FALSE 10899909565910876160
469521 29430101 250 0 TRUE 10971967159948804096
469548 29120108 500 0 FALSE 5687378925810876416
469556 29120108 1000 0 TRUE 11116082348024659968
469564 29060102 500 0 TRUE 11188139942062587904
469572 29050401 200 0 TRUE 11260197536100515840
469580 29050801 1 0 TRUE 11332255130138443776
469602 11250101 14 0 FALSE 15378437029633196032
469610 11250201 56 0 TRUE 15450494623671123968
470694 60040501 1 0 TRUE 11404312724176371712
470988 11330101 60 0 TRUE 15522552217709051904
470996 11330201 60 0 TRUE 15594609811746979840
471003 11330301 60 0 TRUE 15666667405784907776
471011 11330401 60 0 TRUE 15738724999822835712
471038 10880101 100 0 TRUE 15810782593860763648
471046 10880201 50 0 TRUE 15882840187898691584
471151 11830401 60 0 TRUE 15954897781936619520
471259 20500412 56 0 TRUE 12539783879738785792
471267 20500202 42 0 FALSE 11548427912252227584
471631 37132525 5 0 TRUE 11620485506290155520
471674 12280226 100 0 TRUE 16026955375974547456
471690 24830702 56 0 TRUE 16099012970012475392
471704 24830602 25 0 TRUE 18105106019750248448
471712 24830810 35 0 TRUE 5085460081277927424
471739 19910504 28 0 FALSE 16171070564050403328
471747 29320602 860 0 TRUE 11692543100328083456
471755 29320502 860 0 TRUE 11764600694366011392
471828 60460101 1 1 TRUE 17087061606522683392
472212 18280101 60 0 TRUE 12157488084807581696
472476 10260201 30 0 FALSE 16315185752126259200
472514 13670102 28 0 TRUE 9283344898591817728
472530 19140102 100 0 FALSE 11111255491978723328
472565 29020113 1000 0 FALSE 11836658288403939328
472735 26390401 30 0 TRUE 16387243346164187136
472743 26390501 30 0 TRUE 16459300940202115072
472786 38542625 45 TRUE 2605501709224509440
472794 11240101 24 0 TRUE 16531358534240043008
472808 11240201 24 0 TRUE 16603416128277970944
472816 11240301 100 0 TRUE 16675473722315898880
472824 11240401 100 0 TRUE 16747531316353826816
472832 11240501 5 1 TRUE 17159119200560611328
472840 11240601 5 1 TRUE 17231176794598539264
472859 10650901 120 0 TRUE 11908715882441867264
472867 10651001 120 0 TRUE 11980773476479795200
472875 15532525 60 TRUE 8910797373752475648
472891 38152525 1 TRUE 10392953341645684736
472905 11680901 100 0 FALSE 2296387209214820352
472956 38072525 1 0 TRUE 17035761692505538560
472972 10400201 500 0 FALSE 17107819286543466496
474088 60230101 1 1 TRUE 17303234388636467200
474134 20500301 28 0 TRUE 12052831070517723136
474142 20500401 28 0 TRUE 12124888664555651072
474150 20500501 28 0 TRUE 12196946258593579008
474223 11510101 90 0 TRUE 7856548241645502464
474320 29002601 240 0 TRUE 17251934474619322368
474398 12500101 2.5 0 TRUE 12269003852631506944
474436 24610101 20 0 TRUE 7452753695856394240
474703 12330301 1 1 FALSE 10923039992024399872
474711 12330201 1 1 FALSE 10995097586062327808
475017 11380101 30 0 FALSE 17468107256733106176
475238 29080104 25000 0 TRUE 12280612496397565952
475378 14250101 10 0 TRUE 17540164850771034112
475963 29350301 500 0 TRUE 12341061446669434880
475971 10600101 100 0 TRUE 9472326758150701056
475998 29060201 200 0 TRUE 2927379340209422336
476005 29050601 500 0 TRUE 4235205540495491072
476285 29260201 100 0 FALSE 13826190494004150272
476552 21582525 20 0 FALSE 1143504187514945536
476579 28360304 30 0 FALSE 7678673648550412288
476587 60120202 25 0 TRUE 9643351393804746752
476625 63020101 100 0 TRUE 17684280038846889984
476986 10600201 100 0 TRUE 9544384352188628992
477028 29160101 400 0 TRUE 12557234228783218688
477672 19720102 15 0 TRUE 12629291822821146624
478008 23320501 1 0 TRUE 11372498355226673152
478369 10430101 30 0 TRUE 17900452820960673792
478474 11740201 1 0 TRUE 12701349416859074560
478490 39672725 28 TRUE 7168487059122814976
478504 39672625 28 TRUE 6952314277009031168
478547 12442601 200 0 TRUE 12773407010897002496
478717 11510102 90 0 FALSE 13650718333815750656
479209 16990403 100 0 TRUE 17972510414998601728
479217 10010102 100 0 TRUE 18044568009036529664
479233 28280102 30 0 TRUE 12845464604934930432
479438 10980101 30 0 TRUE 14815179212956106752
479446 23320401 1 1 FALSE 690861638638632960
479489 10660301 60 0 TRUE 12917522198972858368
479497 24870201 72 0 TRUE 18188683197112385536
479616 21400101 2 0 FALSE 18260740791150313472
480223 29150202 400 0 TRUE 4109292767417466880
480304 11400301 30 0 FALSE 6371014574031765504
480533 24041001 200 0 TRUE 12989579793010786304
480541 10630102 28 0 TRUE 18404855979226169344
480568 10630203 28 0 TRUE 102508568569184256
480576 13920203 500 0 TRUE 174566162607112192
480797 26380301 60 0 TRUE 246623756645040128
481017 11370101 30 0 FALSE 7146799192264933376
481076 11370201 30 0 FALSE 7362971974378717184
481084 11370301 30 0 FALSE 7579144756492500992
481114 38792525 12 TRUE 12291852803768320000
481386 24830202 56 0 FALSE 13344190984666218496
481394 24830502 35 0 FALSE 13061637387048714240
481599 11810101 30 0 TRUE 534854132796751872
481793 25110501 1 1 TRUE 14532158322896797696
481807 25110401 1 1 TRUE 14604215916934725632
481815 25110601 1 1 TRUE 14676273510972653568
482188 15350201 100 0 TRUE 823084508948463616
482358 21350301 5 1 FALSE 762919232676560896
482412 20800501 100 0 FALSE 12582231625640706048
482420 20800601 100 0 FALSE 13086634783906201600
483206 28451301 1 0 TRUE 967199697024319488
483214 28451601 1 0 TRUE 1039257291062247424
483222 28451401 1 0 TRUE 1111314885100175360
483230 28451501 1 0 TRUE 1183372479138103296
483451 29060103 200 0 FALSE 13133694981086642176
483540 13610206 500 0 TRUE 1255430073176031232
483699 20580201 35 0 TRUE 13205752575124570112
483966 11930101 28 0 TRUE 1327487667213959168
484547 12340201 20 0 TRUE 12257135724121292800
484555 12340101 20 0 TRUE 12689481288348860416
485268 14250103 10 0 TRUE 13277810169162498048
485276 19290206 1000 0 TRUE 1399545261251887104
485284 19290303 1000 0 TRUE 1471602855289815040
485357 11720101 270 0 TRUE 1543660449327742976
485365 11720201 144 0 TRUE 1615718043365670912
485403 27720102 28 0 TRUE 1687775637403598848
485411 28032525 150 TRUE 16617328248904220672
485772 13200705 15 0 TRUE 13349867763200425984
485780 13200304 45 0 TRUE 13421925357238353920
485799 13200402 25 0 TRUE 13493982951276281856
485802 16200603 45 0 TRUE 13566040545314209792
485810 16200303 15 0 TRUE 13638098139352137728
485837 29150101 400 0 TRUE 1759833231441526784
485896 21350302 5 1 FALSE 834976826714488832
485926 21350501 6 1 TRUE 7885099260083961856
485942 10740201 24 0 TRUE 1976006013555310592
485950 30000103 20 0 TRUE 2048063607593238528
485985 20800502 20 0 FALSE 2120121201631166464
486329 11700101 60 0 TRUE 2192178795669094400
486396 29050201 400 0 TRUE 2264236389707022336
486566 17950725 200 0 TRUE 2336293983744950272
486574 17950525 200 0 TRUE 2408351577782878208
486582 17950625 200 0 TRUE 2480409171820806144
487074 11102625 100 0 TRUE 192928006790971392
487139 27700201 98 0 FALSE 2624524359896662016
487163 29050901 20 0 TRUE 13710155733390065664
487171 29350401 500 0 TRUE 13782213327427993600
487236 11380101 100 0 TRUE 2696581953934589952
487945 17181201 84 28 TRUE 1909309638214418432
487953 17180503 84 28 TRUE 1981367232252346368
487961 17180903 84 28 TRUE 2053424826290274304
490091 10610201 30 0 TRUE 2768639547972517888
490113 20800602 500 0 FALSE 16524290873496698880
490148 10940105 100 0 FALSE 2840697142010445824
490156 10940105 1000 0 TRUE 2912754736048373760
490164 10940205 100 0 FALSE 2984812330086301696
490172 10940205 500 0 TRUE 3056869924124229632
490180 24830203 56 0 TRUE 3128927518162157568
490199 24830503 35 0 TRUE 13854270921465921536
490202 11270101 28 0 TRUE 3200985112200085504
490504 11940201 10 0 TRUE 11848266932169998336
490555 10860201 240 0 FALSE 9056012073456107520
490563 17190801 1 1 FALSE 17591464764788178944
490857 11920201 10 0 TRUE 13998386109541777408
490865 11920101 5 1 TRUE 13949177466640662528
491179 20800502 1000 0 FALSE 16380175685420843008
492310 10630202 30 0 TRUE 3417157894313869312
492329 10630101 30 0 FALSE 103886256638787584
492337 27910601 60 0 TRUE 3489215488351797248
492345 27910501 60 0 TRUE 3561273082389725184
492388 15770505 30 0 TRUE 3633330676427653120
492396 15770105 30 0 TRUE 3705388270465581056
492558 21350402 1 1 FALSE 474688856524849152
492566 38112525 1 TRUE 6429785669559648256
492582 12480101 4 1 TRUE 6239577854535794688
492620 24242625 30 TRUE 4516725597182885888
492639 24242725 30 TRUE 4732898379296669696
493139 60390401 12 0 TRUE 9326251140842520576
493147 60390401 144 0 TRUE 6126417217316716544
493155 60400109 12 0 TRUE 4065676240655220736
493163 60390301 144 0 TRUE 4685265336558157824
493171 60390601 144 0 TRUE 6630820375582212096
493252 11200202 1 1 TRUE 13517113377389805568
493295 22850101 50 0 TRUE 16904849440056016896
493589 10980201 28 0 FALSE 14599006430842322944
493597 11080125 200 0 TRUE 4353906616806932480
493600 11080225 200 0 TRUE 4425964210844860416
493619 11080326 200 0 TRUE 4498021804882788352
493635 14920302 20 0 TRUE 4570079398920716288
493643 14920701 20 0 TRUE 4642136992958644224
493724 11770101 1 0 TRUE 14070443703579705344
493732 10830201 60 0 TRUE 14142501297617633280
493740 10830301 60 0 TRUE 14214558891655561216
493759 20961701 200 0 TRUE 14286616485693489152
493937 38492525 1 0 FALSE 13082785393697357824
493945 38492625 1 0 FALSE 13154842987735285760
493953 38472525 1 TRUE 11672262608353755136
494054 10090201 1 1 TRUE 9698060893379624960
494232 18270101 1 0 TRUE 14358674079731417088
494259 18270103 1 0 TRUE 14430731673769345024
494275 10210301 30 0 TRUE 4786252181034500096
494712 38902525 4 TRUE 6704020362201399296
494720 38902625 4 TRUE 6920193144315183104
494739 38902725 4 TRUE 7136365926428966912
495298 18092525 100 0 TRUE 5945050575291809792
495409 10700202 100 0 TRUE 4858309775072428032
495417 10700302 100 0 TRUE 4930367369110355968
495425 10700102 21 0 TRUE 5002424963148283904
495646 11910205 100 0 TRUE 5074482557186211840
495654 22130202 50 0 TRUE 14502789267807272960
495662 24451401 1 0 TRUE 5146540151224139776
495670 24451301 1 0 TRUE 5218597745262067712
495697 24451501 1 0 TRUE 5290655339299995648
495700 24451601 1 0 TRUE 5362712933337923584
496103 17190601 5 1 TRUE 17663522358826106880
496111 17190701 5 1 FALSE 16903820297172418560
496138 17190801 5 1 TRUE 17735579952864034816
496189 38032525 5 1 TRUE 4582253191663452160
496219 11910302 60 0 TRUE 2832860922639286272
496251 17190601 1 1 FALSE 17807637546901962752
496278 17190701 1 1 FALSE 16831762703134490624
496324 11832525 60 TRUE 9029490753482522624
496383 11250101 56 0 TRUE 5867116091603419136
500356 13930101 5 1 TRUE 402631262486921216
500364 13970601 50 1 FALSE 2852870934753181696
500372 14560101 5 1 TRUE 6527526755710795776
500410 19270101 5 1 TRUE 17879695140939890688
500429 19530301 5 1 TRUE 1123488677842911232
500437 19530401 5 1 TRUE 1195546271880839168
501409 22930102 100 0 TRUE 10160425324068732928
501417 22930102 500 0 FALSE 9800137353879093248
501425 18630602 100 0 TRUE 6227404061793058816
501816 10720701 2 0 TRUE 6299461655830986752
501824 10720101 20 0 TRUE 6371519249868914688
501859 23170801 100 0 TRUE 6443576843906842624
502669 11910203 60 0 TRUE 6515634437944770560
502774 10720202 100 0 FALSE 6587692031982698496
502782 10720202 500 0 TRUE 6659749626020626432
502790 10720302 100 0 TRUE 6731807220058554368
503002 17660401 56 0 TRUE 6803864814096482304
503649 12170301 250 0 TRUE 9098985385916104704
503827 11910301 60 0 FALSE 6875922408134410240
503940 14840101 84 28 TRUE 2125482420328202240
504378 17160201 5 0 TRUE 14574846861845200896
504475 60080601 75 0 TRUE 7020037596210266112
504955 16110102 15 0 TRUE 14646904455883128832
505668 15720308 50 0 TRUE 14718962049921056768
507261 23850202 500 0 TRUE 7092095190248194048
507288 23850101 25 0 TRUE 14791019643958984704
507296 23850101 100 0 FALSE 4285851245094109184
509256 18630201 60 0 TRUE 7164152784286121984
509272 22550102 100 0 FALSE 2004963851296047104
509280 22550202 100 0 FALSE 1572618287068479488
509299 22550302 100 0 FALSE 2306147573934587904
509302 22550401 100 0 FALSE 15422877090604646400
510130 20600104 500 0 TRUE 7236210378324049920
510149 20600203 500 0 TRUE 7308267972361977856
510203 23850202 15 0 TRUE 8245387230273601536
510300 23850202 4500 0 FALSE 14485691861995356160
510327 23850401 100 0 TRUE 8461560012387385344
510335 23850401 500 0 TRUE 7596498348513689600
510513 10190301 30 0 TRUE 7668555942551617536
510548 10190401 30 0 TRUE 7740613536589545472
510564 27820501 100 0 FALSE 7812671130627473408
510572 16990201 60 0 FALSE 7884728724665401344
510580 16990303 60 0 FALSE 7956786318703329280
510599 13170201 4 0 TRUE 14750785214963777536
510602 13170301 4 0 TRUE 15327245967267201024
510610 13170401 4 0 TRUE 15903706719570624512
510637 11680101 200 0 TRUE 14935134832034840576
510645 27980501 200 0 TRUE 8245016694855041024
510858 19710101 5 1 TRUE 4293741340535029760
510866 10130301 5 1 TRUE 17951752734977818624
510890 23171001 100 0 TRUE 8461189476968824832
510904 21250101 500 0 TRUE 8533247071006752768
512044 15461001 15 0 TRUE 15007192426072768512
512478 11280505 50 0 TRUE 13337999634690211840
512788 10360201 1 0 TRUE 8605304665044680704
512850 23770102 100 0 TRUE 8677362259082608640
512869 23770201 100 0 TRUE 3314953890465579008
512877 27160301 100 0 TRUE 15079250020110696448
512885 13200702 20 0 TRUE 15151307614148624384
513601 11080201 200 0 TRUE 15223365208186552320
513628 28550201 5 1 FALSE 16975877891210346496
513636 28550101 5 1 FALSE 17047935485248274432
513652 11970101 5 1 TRUE 18023810329015746560
517267 17660301 30 0 TRUE 8893535041196392448
518913 16480102 10 0 TRUE 8965592635234320384
518921 16490401 10 0 TRUE 15295422802224480256
519049 17330101 100 0 TRUE 9037650229272248320
519219 11910204 60 0 TRUE 9109707823310176256
519308 15120301 100 0 TRUE 9181765417348104192
519316 15120401 100 0 TRUE 9253823011386032128
519863 10260201 100 0 TRUE 9325880605423960064
519952 23010401 100 0 TRUE 9397938199461888000
519960 23010302 100 0 TRUE 9469995793499815936
520810 14080101 100 0 TRUE 9542053387537743872
520896 22130403 300 0 TRUE 15367480396262408192
521361 12730101 50 0 TRUE 9614110981575671808
521647 29080107 350 0 TRUE 15439537990300336128
521957 16140701 100 0 TRUE 15511595584338264064
522260 15530101 100 0 TRUE 9686168575613599744
522678 10720503 100 0 TRUE 9758226169651527680
522686 10720603 100 0 TRUE 9830283763689455616
522902 15120302 100 0 TRUE 9902341357727383552
522910 14110202 100 0 TRUE 9974398951765311488
523690 15110201 100 0 TRUE 10046456545803239424
523704 18140501 10 0 TRUE 10118514139841167360
523712 18350101 15 0 TRUE 15583653178376192000
523836 25280203 100 0 TRUE 10190571733879095296
524328 10150201 50 1 TRUE 5446662845141876736
524336 20960902 200 0 TRUE 15655710772414119936
524344 10530102 100 0 TRUE 10334686921954951168
524417 18060101 100 0 TRUE 10406744515992879104
524433 18060204 100 0 FALSE 10478802110030807040
524441 18060204 500 0 TRUE 10550859704068734976
524468 18060301 100 0 TRUE 10622917298106662912
524492 14320101 100 0 TRUE 10694974892144590848
524980 24670101 10 0 FALSE 10767032486182518784
524999 24670101 30 0 TRUE 10839090080220446720
526703 10720502 100 0 TRUE 10911147674258374656
526711 10720602 100 0 TRUE 10983205268296302592
526738 13200702 300 0 FALSE 18381480362019651584
527068 23640101 50 0 FALSE 11055262862334230528
527564 23171101 60 0 TRUE 11127320456372158464
527580 11510101 100 0 FALSE 7784490647607574528
527599 23750101 200 0 TRUE 15727768366452047872
527610 23750201 20 0 TRUE 4367109552433266688
527831 23220101 10 0 TRUE 15799825960489975808
527858 18170201 30 0 TRUE 11199378050410086400
528048 38262625 1 TRUE 14177385503032082432
528323 10940101 100 0 TRUE 11271435644448014336
528331 10940204 100 0 TRUE 11343493238485942272
528358 18630603 100 0 TRUE 11415550832523870208
528366 27830103 100 0 TRUE 11487608426561798144
528609 22930103 100 0 TRUE 11559666020599726080
529435 18630203 100 0 TRUE 11631723614637654016
529516 17720101 30 0 TRUE 11703781208675581952
529613 18292625 1 TRUE 3605543818570498048
531618 17300101 100 0 FALSE 11775838802713509888
531626 17300101 250 0 TRUE 11847896396751437824
532320 15110101 100 0 TRUE 11919953990789365760
533173 24200101 3 1 TRUE 18095867923053674496
533181 24200301 3 1 TRUE 18167925517091602432
533343 10050101 28 0 TRUE 12136126772903149568
533637 16550101 10 0 TRUE 12208184366941077504
533645 16550201 10 0 TRUE 12280241960979005440
533653 22180203 30 0 FALSE 4978484196965089280
533742 14050101 100 0 TRUE 12352299555016933376
533874 11990101 50 1 FALSE 14453580624906158080
533955 17660102 100 0 TRUE 12496414743092789248
534196 10150201 5 1 TRUE 5590778033217732608
534269 15690102 90 0 FALSE 13728968377341313024
534323 22950201 500 0 FALSE 17265137410245656576
534331 22950101 500 0 FALSE 12640529931168645120
535273 21910101 120 0 TRUE 12712587525206573056
535427 10010202 100 0 TRUE 12784645119244500992
535435 10010302 100 0 TRUE 12856702713282428928
535672 19960501 100 0 TRUE 12928760307320356864
535680 19960701 100 0 TRUE 13000817901358284800
535982 11490201 5 0 TRUE 15871883554527903744
536059 15720309 50 0 TRUE 13072875495396212736
536709 23740701 100 0 TRUE 13144933089434140672
536733 20380303 500 0 TRUE 13216990683472068608
536938 16130102 100 0 TRUE 13289048277509996544
536954 18640101 6 0 TRUE 13361105871547924480
536962 10060101 100 0 TRUE 15943941148565831680
536970 23850202 100 0 TRUE 8389502418349457408
537233 60260101 100 0 TRUE 13505221059623780352
537330 11081304 200 0 TRUE 13577278653661708288
537683 19160701 15 0 TRUE 13649336247699636224
537934 15801301 100 0 TRUE 13721393841737564160
538272 18760202 100 0 FALSE 13793451435775492096
538558 18010101 50 0 TRUE 13865509029813420032
538620 13080101 50 0 TRUE 13937566623851347968
538825 11320101 500 0 TRUE 14009624217889275904
539724 21660101 100 0 TRUE 14081681811927203840
539864 10940102 100 0 FALSE 6515323276154109952
539880 10940202 100 0 FALSE 6587380870192037888
540226 29050203 454 0 TRUE 16015998742603759616
541028 23400601 15 0 TRUE 14153739405965131776
541168 16990401 90 0 TRUE 14225797000003059712
542474 14120401 5 1 TRUE 18239983111129530368
543209 19890101 30 0 TRUE 14369912188078915584
544302 10950201 28 0 FALSE 14441969782116843520
544345 34310103 500 0 TRUE 14514027376154771456
544388 10260201 30 0 FALSE 14586084970192699392
544485 10720501 100 0 TRUE 14658142564230627328
544493 10720601 100 0 TRUE 14730200158268555264
545341 18520102 25 0 TRUE 14802257752306483200
547190 21440401 112 0 TRUE 14874315346344411136
547549 13610203 100 0 TRUE 14946372940382339072
547840 24520202 450 0 TRUE 16088056336641687552
548790 34230101 500 0 TRUE 15018430534420267008
548839 24810101 10 0 FALSE 15090488128458194944
548936 15740602 2000 0 TRUE 15162545722496122880
548995 17620101 25 0 FALSE 6306187368458092544
549142 17990301 10 1 TRUE 4510195597625524224
549355 13710201 1 0 TRUE 15306660910571978752
550639 18860201 1 0 TRUE 15378718504609906688
551058 20680301 25 0 FALSE 15450776098647834624
551201 19290804 1000 0 FALSE 15522833692685762560
552232 15540201 5 1 TRUE 18312040705167458304
552240 15540302 5 1 FALSE 14814150070072508416
552275 15330402 5 1 TRUE 4654310785701380096
552372 15540302 50 1 FALSE 14742092476034580480
552402 15890301 5 1 FALSE 186458480373137408
552410 17971101 1 0 TRUE 15883121662875402240
552437 18310901 50 1 TRUE 18384098299205386240
552453 23830201 5 1 TRUE 1267603865918767104
552666 24640101 100 0 TRUE 16027236850951258112
555134 21730101 20 0 TRUE 16099294444989186048
555185 23190102 1 0 TRUE 11632094150056214528
555207 17971201 1 0 TRUE 16243409633065041920
555215 15440401 50 1 TRUE 5230490063028092928
555290 15370101 100 0 TRUE 16315467227102969856
555355 24200102 3 1 TRUE 81750888548401152
555363 24200201 3 1 TRUE 153808482586329088
555371 24200401 3 1 TRUE 225866076624257024
555398 24200502 1 1 FALSE 297923670662184960
556009 17620202 2 0 FALSE 16675755197292609536
556270 16490203 5 1 FALSE 369981264700112896
556289 10290101 250 0 TRUE 16819870385368465408
559806 22690101 40 0 TRUE 16891927979406393344
559814 13060301 30 0 TRUE 16963985573444321280
561630 25460101 120 0 TRUE 17036043167482249216
565091 23140301 1 1 TRUE 14886207664110436352
565296 21350601 50 1 TRUE 442038858738040832
565318 23140302 1 1 FALSE 14958265258148364288
573027 20960201 56 0 TRUE 17324273543633960960
581259 11080701 15 0 TRUE 17396331137671888896
581267 11080801 15 0 TRUE 17468388731709816832
581372 20961201 15 0 TRUE 17540446325747744768
581380 20961302 15 0 TRUE 17612503919785672704
585726 32900101 500 0 TRUE 17684561513823600640
585742 27110301 90 0 TRUE 17756619107861528576
585823 24680101 20 0 FALSE 17828676701899456512
585866 29390202 1000 0 TRUE 16160113930679615488
586048 17300402 100 0 TRUE 17900734295937384448
586056 17300402 500 0 TRUE 17972791889975312384
587575 23810101 90 0 TRUE 18044849484013240320
587583 15890402 10 1 TRUE 258516074411065344
588296 10721001 5 1 FALSE 13793525103054553088
588318 10720901 5 1 FALSE 2431785469105668096
588326 10720801 5 1 FALSE 4377059033153011712
588547 16970601 100 0 TRUE 18405137454202880000
588555 16970505 10 0 TRUE 102790043545894912
588679 23840101 100 0 TRUE 174847637583822848
588822 15890701 10 1 TRUE 514096452775968768
589128 17180502 84 28 TRUE 2197540014366130176
589136 21930102 100 0 TRUE 3459069078541434880
589144 21930102 500 0 FALSE 3531126672579362816
589152 21930201 100 0 TRUE 318962825659678720
589179 12170401 100 0 TRUE 9728079759841165312
589187 16990102 100 0 TRUE 391020419697606656
589209 14380101 100 0 TRUE 463078013735534592
589225 14380401 100 0 TRUE 535135607773462528
589233 23170902 100 0 FALSE 11626631776289423360
589241 23171102 100 0 FALSE 607193201811390464
589268 14180101 10 0 FALSE 679250795849318400
589942 34300102 500 0 TRUE 751308389887246336
590347 34300202 500 0 TRUE 823365983925174272
594067 10400301 500 0 TRUE 895423577963102208
594091 18100301 1 1 TRUE 586154046813896704
594148 11280101 30 0 TRUE 13265942040652283904
594415 29220201 400 0 TRUE 1039538766038958080
594423 12210101 100 0 TRUE 1111596360076886016
597023 11910203 30 0 FALSE 1183653954114813952
597104 18280101 84 0 FALSE 12229545678845509632
597600 19290801 1000 0 FALSE 1255711548152741888
598054 33280101 500 0 TRUE 1327769142190669824
598518 13940103 946 0 FALSE 3252835881542746112
598593 20680401 20 0 TRUE 1471884330266525696
599328 29370301 275 0 TRUE 16232171524717543424
599336 29430102 237 0 TRUE 16304229118755471360
599344 29140102 79 0 TRUE 16376286712793399296
599891 18170101 30 0 TRUE 1543941924304453632
599905 18170301 30 0 TRUE 1615999518342381568
599948 16780101 1 0 TRUE 16448344306831327232
599956 24670101 6 0 FALSE 1688057112380309504
600199 18630501 100 0 TRUE 1760114706418237440
600253 28630101 750 0 FALSE 1832172300456165376
600326 28630101 1500 0 FALSE 1904229894494093312
600334 28630101 2500 0 TRUE 4908384833136230400
600342 28630101 1500 0 FALSE 1976287488532021248
600369 28630101 2500 0 FALSE 2048345082569949184
600512 60410102 1 0 TRUE 2120402676607877120
600776 23640102 30 0 FALSE 2192460270645805056
601136 10940102 30 0 FALSE 2264517864683732992
601144 10940202 30 0 FALSE 2336575458721660928
601160 18060201 100 0 TRUE 2408633052759588864
601330 10920101 30 0 FALSE 2480690646797516800
601349 10920101 50 0 FALSE 2552748240835444736
602000 32910101 500 0 TRUE 2624805834873372672
603325 23940401 20 0 TRUE 16520401900869255168
603333 23940301 20 0 TRUE 16592459494907183104
603341 10150101 5 1 TRUE 5518720439179804672
603716 23730101 60 0 TRUE 2696863428911300608
603724 23730201 30 0 TRUE 2768921022949228544
603791 29360102 454 0 TRUE 16664517088945111040
603961 88610101 1 1 TRUE 658211640851824640
604321 32910501 30 0 TRUE 7668926477970178048
604585 23200101 5 0 TRUE 2985093805063012352
604593 23200201 5 0 TRUE 3057151399100940288
606642 20600503 250 0 TRUE 3129208993138868224
606650 27970102 90 0 TRUE 3201266587176796160
606669 27970202 30 0 FALSE 3273324181214724096
606685 27970202 90 0 TRUE 3345381775252652032
606693 27970302 30 0 FALSE 3417439369290579968
606707 27970302 90 0 TRUE 3489496963328507904
607541 27160901 100 0 TRUE 16736574682983038976
607568 27161001 100 0 TRUE 16808632277020966912
607576 27160302 250 0 TRUE 3561554557366435840
608505 14790101 63 21 TRUE 540215351493787648
608513 14790201 84 28 TRUE 2269597608404058112
608599 27830101 100 0 TRUE 3633612151404363776
608602 27830201 100 0 TRUE 3705669745442291712
608637 16200302 20 0 TRUE 16880689871058894848
608750 13610201 100 0 FALSE 3777727339480219648
609498 23980101 30 0 TRUE 3849784933518147584
609501 23980202 30 0 TRUE 3921842527556075520
609625 23750301 100 0 TRUE 12241653500890578944
609641 23620101 30 0 FALSE 12342303894808821760
609668 23980102 30 0 FALSE 1141827432282587136
609676 23980201 30 0 FALSE 1069769838244659200
609684 19251101 250 0 TRUE 4210072903707787264
609706 25290301 100 0 TRUE 4282130497745715200
609757 23830101 50 1 FALSE 1339661459956695040
609765 25390101 100 0 TRUE 4354188091783643136
609781 60120701 21 0 TRUE 4426245685821571072
609935 20960604 400 0 TRUE 4498303279859499008
610097 24550101 90 0 FALSE 6745296028708110336
612634 15800501 100 0 TRUE 4570360873897426944
612642 15800701 100 0 TRUE 4642418467935354880
612650 14431003 15 0 TRUE 16952747465096822784
612669 14431003 30 0 TRUE 4714476061973282816
612685 15670104 100 0 TRUE 4786533656011210752
612960 14790102 63 21 TRUE 612272945531715584
613428 14790202 84 28 TRUE 2341655202441986048
615137 23830101 5 1 TRUE 1411719053994622976
615641 20800301 300 0 TRUE 4930648844087066624
615986 16860201 200 0 TRUE 5002706438124994560
615994 16860202 200 0 TRUE 5074764032162922496
616001 16860101 1000 0 TRUE 5146821626200850432
616133 20960102 56 0 TRUE 5218879220238778368
616168 17690101 20 0 TRUE 11199748585828646912
616222 63040101 30 0 FALSE 5362994408314634240
616249 63040101 90 0 TRUE 5435052002352562176
616575 15890102 10 1 TRUE 330573668448993280
616796 19290805 1000 0 TRUE 5579167190428418048
616842 19980101 12 0 TRUE 5651224784466345984
616923 17690102 30 0 FALSE 5723282378504273920
617962 24680201 100 0 TRUE 4896561784602755072
618268 10190301 100 0 TRUE 5795339972542201856
618438 11431501 30 0 TRUE 17024805059134750720
618675 15740602 100 0 FALSE 5867397566580129792
618683 15740602 200 0 FALSE 5939455160618057728
619124 22550701 50 0 TRUE 6011512754655985664
619272 15540101 5 1 TRUE 14670034881996652544
619310 29050204 454 0 TRUE 17096862653172678656
619515 60470201 100 1 FALSE 8041017705483993088
619523 15120102 50 0 FALSE 6227685536769769472
619647 11880401 1 1 TRUE 730269234889752576
619671 14920301 20 0 TRUE 6371800724845625344
619779 23391904 250 0 TRUE 17168920247210606592
619787 23391904 1000 0 TRUE 6443858318883553280
Trial Version
Not all rows exported
Scope Effective Expiry RestrictionCode
0101021038 6/1/2012 522
010102104010/1/2003 522
010102104110/1/2003 522
010102127510/1/2003 522
010102127501 10/1/2003 3/31/2007 656
010102127501 4/1/2007 860
010102127610/1/2003 522
010102212510/1/2003 522
0101041038 6/1/2012 522
010104119127 12/1/2012 1281
010401142410/1/2003 522
010401142401 5/16/1994 7/31/1999 38
01040114240102 12/1/2002 6/30/2005 421
01040114240102 10/1/2005 6/30/2008 421
01040114240102 10/1/2008 ######## 29
0104011728 7/1/1996 10030
010401172810/1/2003 522
010401172801 5/16/1994 7/31/1999 40
01040117280102 11/1/1999 6/30/2001 400
01040117280102 12/1/2001 6/30/2004 421
01040117280125 3/1/2011 6/30/2013 421
01040117280125 8/1/2014 6/30/2016 421
01040117280225 6/1/2006 6/30/2007 421
01040117280225 10/1/2007 6/30/2010 421
010404116809 3/1/1999 8/31/1999 459
010404116809 9/1/1999 1/31/2000 488
010404116809 2/1/2000 4/30/2004 512
010404116809 5/1/2004 6/30/2008 698
010404116809 7/1/2008 8/31/2011 913
010404116809 9/1/2011 1155
01040416060201 1/1/2007 6/30/2009 421
01040416060201 1/1/2010 6/30/2012 421
01040416060201 2/1/2013 6/30/2015 421
010404203410/1/2003 522
010404214406 5/16/1994 6/30/2008 23
010404214406 1/1/1999 6/30/2008 227
010404220510/1/2003 522
010404220501 12/1/2011 10
01040422050101 11/1/1999 6/30/2002 421
01040422050101 11/1/2002 6/30/2005 421
01040422050101 10/1/2006 6/30/2009 421
01040422050101 11/1/2013 6/30/2016 421
01040422050201 11/1/1999 6/30/2002 421
01040422050201 11/1/2002 6/30/2005 421
01040422050201 10/1/2006 6/30/2009 421
01040422050201 11/1/2013 6/30/2016 421
010404220504 6/13/1995 24
01040423845/16/1994 6/30/2008 24
01040423840101 11/1/2002 6/30/2005 421
01040423840201 11/1/2002 6/30/2005 421
010404253301 5/16/1994 24
010404253302 5/16/1994 6/30/2009 24
010404253303 5/16/1994 6/30/2009 24
01040425330301 12/1/2006 6/30/2009 421
01040425330301 10/1/2009 6/30/2012 421
01040425330301 10/1/2012 6/30/2015 421
01040425330302 2/1/2004 6/30/2006 421
010404253304 5/16/1994 6/30/2009 24
01040425330501 10/1/2011 6/30/2014 421
01050115210101 4/1/2005 6/30/2007 421
01050115210101 10/1/2007 6/30/2010 421
01050115210201 4/1/2005 6/30/2007 421
01050115210201 10/1/2007 6/30/2010 421
01050116320101 12/1/2001 6/30/2004 421
01050116320401 12/1/2001 6/30/2004 421
010502157710/1/2003 522
0105021577 4/1/2013 1329
010503605710/1/2003 522
01050360570101 12/1/2002 6/30/2005 421
010701163110/1/2003 522
01070116310101 1/1/2009 6/30/2011 421
01070116310125 9/1/2007 6/30/2008 421
01070116310125 1/1/2009 6/30/2011 421
01070116310125 10/1/2011 6/30/2014 421
010701163102 7/1/1996 3/31/2001 10006
010701163102 4/1/2001 10005
01070116310201 1/1/2006 6/30/2008 421
01070116310201 1/1/2009 6/30/2011 421
01070116310201 12/1/2011 6/30/2014 421
0107012381 5/9/1995 6/30/2008 24
010701238110/1/2003 522
01070123810101 1/1/2009 6/30/2011 421
01070123810101 10/1/2011 6/30/2014 421
01100125465/16/1994 6/30/2008 24
011001254610/1/2003 522
01100125460101 12/1/2002 6/30/2005 421
01100125460101 10/1/2006 6/30/2009 421
011002280925 10/1/2009 2/22/2011 137
011002280925 10/1/2009 9/13/2011 992
011002280925 2/23/2011 4/30/2011 1089
011002280925 5/1/2011 9/13/2011 137
011002280925 9/14/2011 ######## 1164
011002280925 9/14/2011 ######## 1166
011002280925 11/1/2011 137
011002280925 11/1/2011 992
01100228092526 6/1/2012 6/30/2014 421
011003 3/1/1996 3/31/1996 286
01100312975/16/1994 ######## 21
01100312975/16/1994 4/30/2005 27
011003129710/1/2003 522
0110031297 5/1/2005 22
011003129701 5/16/1994 ######## 26
01100312970104 9/1/1998 8/31/2001 400
011003129702 5/16/1994 ######## 37
01100312970204 9/1/1998 8/31/2001 400
01100312970304 9/1/1998 8/31/2001 400
011003129704 5/16/1994 ######## 26
01100320805/16/1994 ######## 21
01100320805/16/1994 22
011003208010/1/2003 522
011003208003 5/16/1994 ######## 30
011003208003 5/16/1994 2/28/2002 31
011003208003 3/1/2002 6/30/2008 624
01100320800325 4/1/2008 6/30/2010 421
01100320800325 10/1/2011 6/30/2014 421
011003208005 5/16/1994 ######## 30
01100320800502 9/1/1998 8/31/2001 400
01100320800525 1/1/2004 6/30/2005 421
01100320800525 10/1/2005 6/30/2008 421
01100320800525 10/1/2011 6/30/2014 421
01100320800602 9/1/1998 8/31/2001 400
01100320800625 1/1/2004 6/30/2005 421
01100320800625 10/1/2005 6/30/2008 421
01100320800625 10/1/2011 6/30/2014 421
011003208025 5/16/1994 ######## 30
01100323735/16/1994 ######## 21
01100323735/16/1994 22
011003237310/1/2003 522
011003237301 5/16/1994 ######## 42
01100323730103 2/1/2005 6/30/2007 421
01100323730104 9/1/1998 8/31/2001 400
01100323730203 1/1/2005 6/30/2007 421
01100323730204 9/1/1998 8/31/2001 400
01100324905/16/1994 ######## 21
01100324905/16/1994 22
011003249001 5/16/1994 ######## 30
01100719955/16/1994 21
01100719955/16/1994 22
011007199501 5/16/1994 32
011010102210/1/1995 ######## 270
0110101022 1/1/1998 8/31/1998 382
0110101022 9/1/1998 ######## 423
011010102210/1/2003 522
01101010220125 4/1/2013 6/30/2015 421
01101010222525 4/1/2013 6/30/2015 421
0110101098 7/1/1997 8/31/1998 350
011010109810/1/2003 522
01101010980125 6/1/2008 6/30/2010 421
01101010980125 10/1/2010 6/30/2013 421
01101010980126 8/1/2014 6/30/2016 421
01101010980225 6/1/2008 6/30/2010 421
01101010980225 10/1/2010 6/30/2013 421
01101010980226 8/1/2014 6/30/2016 421
01101010982525 5/1/2009 6/30/2010 421
01101010982525 10/1/2011 6/30/2014 421
011010263912/1/1995 6/30/1996 278
011010263912/1/1995 ######## 280
011010263910/1/2003 522
0110102639 8/1/2006 5020
011010263901 1/29/1995 ######## 35
01101026390126 5/1/2009 6/30/2011 421
01101026390127 1/1/2012 6/30/2014 421
01101026390325 5/1/2009 6/30/2011 421
01101026390325 10/1/2011 6/30/2014 421
01101026390426 5/1/2009 6/30/2011 421
01101026390427 1/1/2012 6/30/2014 421
01101026390526 5/1/2009 6/30/2011 421
01101026390527 1/1/2012 6/30/2014 421
011010263925 7/1/2011 745
01101026392525 10/1/2011 6/30/2014 421
01101311595/16/1994 6/30/1999 21
011013219101 5/16/1994 6/30/1999 21
011013230401 5/16/1994 6/30/1999 21
01101339972525 4/1/2013 29
01101339972525 4/1/2013 429
011301157001 7/1/1996 10005
011301157003 7/1/1996 1/31/1997 10005
011301157004 3/1/1997 10005
0113013996 4/1/2013 1320
01130139962525 4/1/2013 29
01130139962525 4/1/2013 429
011301399626 4/1/2013 6/30/2014 10
01130139962625 4/1/2013 29
01130139962625 4/1/2013 429
01130139962725 7/1/2014 29
0113031648 7/1/1996 533
011303164825 9/1/1995 9/30/1996 269
011303164825 10/1/1996 ######## 11
011303164825 11/1/2004 8/31/2006 750
0113051649 7/1/1996 533
0113051655 7/1/1996 533
011305388225 11/1/2008 533
011305388226 11/1/2008 533
011305398211/1/2002 533
0113056300 7/1/1996 533
011305630005 7/1/1996 9/30/1996 269
011305630005 10/1/1996 ######## 11
011305630005 11/1/2004 8/31/2006 750
0113073857 7/1/2006 533
0113073857 7/1/2006 7/31/2010 834
0113073857 8/1/2010 1/31/2012 1022
011309 11/1/2002 8/31/2006 641
011309 4/1/2004 8/31/2006 684
0113091192 5/1/1999 ######## 464
0113091192 5/1/1999 533
011309378311/1/2002 533
0113093908 8/1/2010 533
0113111247 9/1/1999 8/31/2008 490
011311124710/1/2003 522
0113111247 9/1/2008 8/31/2010 925
0113111247 3/1/2013 5/31/2013 1298
01131112470101 8/1/2009 6/30/2012 421
01131112470125 3/1/2013 5/30/2015 421
01131112470201 8/1/2009 6/30/2012 421
01131112470225 3/1/2013 6/30/2015 421
011312156710/1/2003 522
01131215670104 11/1/1999 6/30/2002 421
01131215670104 11/1/2002 6/30/2005 421
01131215670201 11/1/1999 6/30/2002 421
01131215670201 11/1/2002 6/30/2005 421
011312156810/1/2003 522
01131215680125 5/1/2003 6/30/2005 421
01131215680125 2/1/2006 6/30/2008 421
01131215680125 10/1/2008 6/30/2011 421
01131215680125 10/1/2011 6/30/2014 421
011312156910/1/2003 522
01131215690102 4/1/2003 6/30/2005 421
01131215690102 10/1/2005 6/30/2008 421
01131215690102 10/1/2008 6/30/2011 421
01131215690102 1/1/2013 6/30/2015 421
0113121794 4/1/2004 522
01131217940103 11/1/2000 6/30/2003 421
01131217940103 11/1/2003 6/30/2006 421
01131217940105 1/1/2013 6/30/2015 421
01131217940125 1/1/2008 6/30/2009 421
01131217940126 5/1/2010 6/30/2012 421
01131217940126 1/1/2013 6/30/2015 421
01131217940203 11/1/2000 6/30/2003 421
01131217940203 11/1/2003 6/30/2006 421
01131217940205 1/1/2013 6/30/2015 421
01131217940226 1/1/2008 6/30/2009 421
01131217940227 5/1/2010 6/30/2012 421
01131217940227 1/1/2013 6/30/2015 421
011312227710/1/2003 522
01131222770101 10/1/2003 6/30/2006 421
0113123800 9/1/2004 7/31/2005 738
0113123800 8/1/2005 ######## 781
0113123800 1/1/2006 3/31/2007 819
0113123800 4/1/2007 6/30/2009 859
0113123800 7/1/2009 ######## 959
0113123800 6/1/2012 522
01131238002526 12/1/2009 6/30/2012 421
01131238002526 10/1/2012 6/30/2015 421
01131238002626 12/1/2009 6/30/2012 421
01131238002626 10/1/2012 6/30/2015 421
01131238002726 12/1/2009 6/30/2012 421
01131238002726 10/1/2012 6/30/2015 421
01150113576/13/1995 6/30/2001 160
011501135710/1/2003 522
011501135701 5/16/1994 141
011501157201 5/16/1994 141
011501157202 5/16/1994 141
011504157204 5/16/1994 141
011504157210 5/16/1994 141
011504215810/1/2003 522
0115042158 8/1/2010 ######## 1023
011504215811/1/2011 1167
011504215801 5/16/1994 141
011504215825 8/1/2009 141
0115043888 7/1/2009 8/31/2009 971
0115043888 9/1/2009 7/31/2010 986
0115043888 8/1/2010 1023
0115043888 7/1/2013 10010
011504388825 8/1/2009 141
011504398312/1/2012 ######## 1278
0115043983 7/1/2013 10001
0115043983 1/1/2014 1413
011507157203 6/1/2005 771
0115073802 6/1/2005 6/30/2009 771
0115073802 7/1/2009 8/31/2012 972
0115073802 9/1/2012 ######## 1250
011507380211/1/2012 2/28/2014 1268
0115073802 7/1/2013 10050
0115073802 3/1/2014 1419
011507380225 7/1/2013 1390
01150738022527 3/1/2013 1294
01150738022528 3/1/2013 1291
01150738022531 3/1/2013 6/30/2015 421
01150738022532 3/1/2013 6/30/2015 421
0115073807 4/1/2005 6/30/2009 766
011507380712/1/2007 902
0115073807 7/1/2009 8/31/2012 966
0115073807 9/1/2012 2/28/2013 1251
0115073807 7/1/2013 1342
0115073807 7/1/2013 10001
011507380726 9/1/2012 6/30/2013 549
011507380726 7/1/2013 1389
01150738072625 9/1/2012 6/30/2013 1253
01150738072625 12/1/2012 6/30/2015 421
01150738072625 3/1/2013 6/30/2015 421
01150738072626 9/1/2012 6/30/2013 1254
01150738072626 12/1/2012 6/30/2015 421
01150738072627 9/1/2012 6/30/2013 1255
01150738072627 12/1/2012 6/30/2015 421
0115073809 9/1/2012 ######## 1236
011507380911/1/2012 2/28/2014 1267
0115073809 3/1/2014 1419
011509 12/1/1997 2/28/2014 375
011509 3/1/2014 1420
0115091110 9/1/1997 ######## 360
011509111012/1/1997 9/30/1999 380
011509111010/1/1999 2/28/2005 496
011509111010/1/2003 522
0115091110 3/1/2005 764
011509111001 10/1/1999 9/30/2003 533
011509111002 10/1/1999 9/30/2003 533
011509165312/1/1995 ######## 80
011509165312/1/1995 ######## 81
011509165312/1/1997 206
011509165301 5/16/1994 ######## 81
011509165301 7/1/1996 533
011509630712/1/1995 ######## 359
011509630712/1/1997 9/30/1999 378
011509630710/1/1999 2/28/2005 495
011509630710/1/2003 522
0115096307 3/1/2005 763
011509630701 7/1/1996 8/31/1997 533
011509630702 10/1/1999 9/30/2003 533
011509630703 10/1/1999 9/30/2003 533
011509630704 10/1/1999 9/30/2003 533
011509630705 10/1/1999 9/30/2003 533
011509630706 10/1/1999 9/30/2003 533
011509630707 10/1/1999 9/30/2003 533
0115123968 9/1/2012 22
0115123968 9/1/2012 1237
0115123968 9/1/2012 1238
0115123968 9/1/2012 1239
011515 9/1/2012 1240
0115153969 9/1/2012 22
0115153969 9/1/2012 1241
0115153969 9/1/2012 7/31/2013 1242
0115153969 9/1/2012 7/31/2013 1243
0115153969 8/1/2013 1395
0115153970 9/1/2012 22
0115153970 9/1/2012 1244
0115153970 9/1/2012 7/31/2013 1245
0115153970 9/1/2012 7/31/2013 1246
0115153970 8/1/2013 1398
0115153971 9/1/2012 22
0115153971 9/1/2012 1247
0115153971 9/1/2012 1248
0115153984 1/1/2013 22
0115153984 1/1/2013 1241
0115153984 1/1/2013 7/31/2013 1242
0115153984 1/1/2013 7/31/2013 1243
0115153984 8/1/2013 1395
0115153985 1/1/2013 22
0115153985 1/1/2013 1241
0115153985 1/1/2013 7/31/2013 1242
0115153985 1/1/2013 7/31/2013 1243
0115153985 8/1/2013 1395
0115153986 1/1/2013 22
0115153986 1/1/2013 1241
0115153986 1/1/2013 7/31/2013 1242
0115153986 1/1/2013 7/31/2013 1243
0115153986 8/1/2013 1395
0115153987 1/1/2013 22
0115153987 1/1/2013 1241
0115153987 1/1/2013 7/31/2013 1242
0115153987 1/1/2013 7/31/2013 1243
0115153987 8/1/2013 1395
0122011126 3/1/1999 8/31/2006 458
0122011126 3/1/2005 3/31/2005 124
0122011126 4/1/2005 8/31/2006 767
0122011126 9/1/2006 6/30/2008 841
0122011126 7/1/2008 2/28/2010 914
0122011126 3/1/2010 2/29/2012 1003
0122011126 3/1/2012 6/30/2013 1188
0122011126 8/1/2012 ######## 1231
0122011126 7/1/2013 1383
012201112601 3/1/1999 2/28/2005 759
012201112601 12/1/2011 10
01220111260101 1/1/2006 6/30/2008 421
01220111260101 10/1/2008 6/30/2011 421
012201112625 3/1/2012 10
01220111262525 8/1/2012 6/30/2014 421
012201192501 5/10/1995 24
012201192502 5/10/1995 24
012201192503 5/10/1995 24
012201192509 5/10/1995 24
012201192510 5/10/1995 24
012201192511 5/10/1995 5/31/2010 24
012201192512 5/10/1995 24
012201192513 5/10/1995 5/31/2010 24
012201192514 5/10/1995 24
012201192515 5/10/1995 5/31/2010 24
012201192525 5/1/2000 5/31/2010 24
012201192525 8/1/2012 204
01220124195/16/1994 46
01250124525/16/1994 22
012501245210/1/2003 522
01250124520206 2/1/2011 6/30/2013 421
01250124520206 10/1/2013 6/30/2016 421
012501285910/1/2003 522
01250424295/16/1994 22
012504242910/1/2003 522
01250424290101 3/1/2003 6/30/2005 421
01250424290101 1/1/2006 6/30/2008 421
01250424290201 3/1/2003 6/30/2005 421
01250424290201 1/1/2006 6/30/2008 421
01250424290325 9/1/2010 6/30/2011 421
01250424290325 10/1/2011 6/30/2014 421
01250424290425 9/1/2010 6/30/2011 421
01250424290425 10/1/2011 6/30/2014 421
01250424290601 3/1/2003 6/30/2005 421
01250424305/16/1994 22
012504243010/1/2003 522
012504243011/1/2011 1168
012504243004 5/16/1994 6/30/1999 44
01250424300401 3/1/2003 6/30/2005 421
01250424300401 10/1/2005 6/30/2008 421
01250424300401 1/1/2009 6/30/2011 421
01250424300401 10/1/2011 6/30/2014 421
012504248901 5/16/1994 22
012504630310/1/2003 522
01250463030101 3/1/2003 6/30/2005 421
012504630410/1/2003 522
01250463040125 12/1/2002 6/30/2004 421
01250463040125 10/1/2004 6/30/2007 421
01250463040125 7/1/2010 6/30/2013 421
012507157410/1/2003 522
012507157401 9/16/1994 22
012507157402 9/16/1994 22
012507157403 9/16/1994 22
01250715740301 11/1/2004 6/30/2007 421
01250715740301 2/1/2013 6/30/2015 421
012507157404 9/16/1994 22
012507157405 9/16/1994 22
012507157407 9/16/1994 22
012507157408 9/16/1994 22
01250721405/16/1994 22
01250721400101 11/1/1999 6/30/2002 421
01250721400101 10/1/2003 6/30/2006 421
01250721400125 1/1/2011 6/30/2013 421
01250721400125 10/1/2013 6/30/2016 421
01250724475/16/1994 22
012507244710/1/2003 522
01250724470101 3/1/2008 6/30/2010 421
01250724470102 3/1/2005 6/30/2007 421
01250724470102 6/1/2011 6/30/2013 421
01250724470102 5/1/2014 6/30/2016 421
01250724470104 12/1/2000 6/30/2003 421
01250724625/10/1995 22
01250724620202 12/1/2002 6/30/2005 421
012507248701 5/16/1994 1/31/1998 22
012507248702 5/10/1995 159
012507387410/1/2007 891
012507387425 10/1/2007 892
01250738742526 3/1/2013 5/31/2013 421
01250738742526 12/1/2013 6/30/2014 421
01251024615/16/1994 22
012510246110/1/2003 522
01251024825/16/1994 22
012510248210/1/2003 522
01251024820125 2/1/2005 6/30/2007 421
01251024820126 10/1/2006 6/30/2007 421
01251024820126 10/1/2007 6/30/2010 421
01251024820126 10/1/2010 6/30/2013 421
01251024820325 12/1/2001 6/30/2004 421
01251024820325 11/1/2004 6/30/2007 421
01251028345/12/1995 22
0125102834 6/9/1995 1/31/2007 43
0125102834 7/1/2010 1014
01251028340101 3/1/2005 6/30/2007 421
01251028340125 2/1/2002 6/30/2004 421
01251028340201 3/1/2005 6/30/2007 421
01251028340225 2/1/2002 6/30/2004 421
0128021238 1/1/1999 5/31/2005 228
0128021238 8/1/1999 473
0128021238 6/1/2005 7/31/2010 225
01280212382525 10/1/2010 2/28/2011 29
0131011132 1/1/1996 6/30/2008 124
01310112442601 12/1/2006 6/30/2009 421
01310112442625 3/1/2013 6/30/2015 421
01310123891201 1/1/2003 6/30/2005 421
01310123891201 10/1/2005 6/30/2008 421
01310123891201 10/1/2008 6/30/2011 421
01310123891201 10/1/2011 6/30/2014 421
013101601410/1/2003 522
01310710740101 10/1/2003 6/30/2006 421
01310718250102 12/1/2001 6/30/2004 421
01310718250102 8/1/2004 6/30/2007 421
01310718250125 5/1/2013 6/30/2015 421
01310718815/18/1995 9/30/1999 163
01310718810501 12/1/2002 6/30/2005 421
01310718810502 12/1/2005 6/30/2008 421
01310718810502 1/1/2009 6/30/2011 421
01310718810502 10/1/2011 6/30/2014 421
013109 8/1/2006 5017
013109226210/1/2003 522
013109330310/1/2003 522
013109330301 8/1/1999 478
0137 8/1/2011 1153
0137012322 6/1/2012 522
013701232201 8/1/2010 204
013701630110/1/2003 522
01370416245/18/1995 7/31/1999 162
013704162410/1/2003 522
013704162401 7/1/2008 10006
01370416240125 3/1/2007 29
01370416240125 4/1/2013 429
01370416240127 7/1/2010 6/30/2012 421
01370416240127 10/1/2012 6/30/2015 421
01370418606/28/1995 22
013704186001 5/16/1994 9/30/1999 105
013704186001 5/16/1994 112
013704186001 5/16/1994 9/30/1999 123
013704186002 5/16/1994 9/30/1999 104
013704186002 5/16/1994 112
013704186002 5/16/1994 9/30/1999 116
01370420715/16/1994 113
01370420715/16/1994 132
013704207110/1/2003 522
013704207102 8/1/2005 549
013704207102 8/1/2010 204
01370420710226 10/1/2011 6/30/2014 421
013704207103 8/1/2010 204
01370420710302 12/1/2006 6/30/2009 421
01370420710302 10/1/2011 6/30/2014 421
013704208701 5/16/1994 114
013704208701 5/16/1994 135
013704225010/1/1999 22
013704225010/1/2003 522
013704225001 5/16/1994 9/30/1999 111
013704225001 5/16/1994 9/30/1999 130
013704225002 5/16/1994 9/30/1999 105
013704225002 5/16/1994 9/30/1999 123
013704225003 5/16/1994 9/30/1999 104
013704225003 5/16/1994 9/30/1999 116
013704225003 8/1/2010 204
01370422500302 1/1/2007 6/30/2009 421
013704232810/1/2003 522
013704232802 8/1/2010 204
01370423280203 1/1/2001 6/30/2003 421
01370423280203 3/1/2007 6/30/2009 421
01370423280225 2/1/2011 6/30/2013 421
01370423280226 1/1/2014 6/30/2016 421
01370463021/30/1995 110
01370710845/16/1994 7/31/2005 113
01370710845/16/1994 132
013707108410/1/2003 522
0137071084 8/1/2005 7/31/2006 785
0137071084 8/1/2006 113
013707108401 8/1/2010 204
01370710840103 2/1/2007 6/30/2009 421
01370710840126 1/1/2011 6/30/2013 421
01370710840127 1/1/2014 6/30/2016 421
0137073737 2/1/2001 113
0137073737 2/1/2001 132
013707373710/1/2003 522
01371010205/16/1994 6/30/2008 24
0137101020 6/1/2012 522
01371010200101 10/1/2003 6/30/2006 421
01371010200201 10/1/2003 6/30/2006 421
01371010200301 10/1/2003 6/30/2006 421
013710118710/1/2003 522
013710118701 5/1/2000 537
01371011870125 2/1/2006 6/30/2007 421
0137101189 5/1/2002 6/30/2008 24
013710118910/1/2003 522
013710118901 5/16/1994 4/30/2002 24
01371011890125 5/1/2007 6/30/2009 421
01371011890126 5/1/2010 6/30/2012 421
013710118902 5/16/1994 4/30/2002 24
01371011890225 5/1/2007 6/30/2009 421
01371011890226 5/1/2010 6/30/2012 421
013710118903 5/16/1994 4/30/2002 115
01371011890301 10/1/2003 6/30/2006 421
0137132413 8/1/1995 5/31/1999 264
0137132413 1/1/1999 7/31/2010 227
0137132413 6/1/1999 6/30/2008 264
0137132413 7/1/2008 915
013713241306 8/1/2010 204
013719233010/1/2003 522
013719233001 8/1/2010 204
01371923300125 5/1/2002 6/30/2004 421
01371923300125 11/1/2006 6/30/2009 421
01371923300126 4/1/2011 6/30/2013 421
01371923300127 1/1/2014 6/30/2016 421
013719233025 3/1/2010 1002
013719233025 8/1/2010 204
01371929265/16/1994 6/30/2009 600
0137192926 1/1/1999 6/30/2009 227
0137192926 7/1/2009 8/31/2010 963
0137192926 9/1/2010 1036
0137192926 6/1/2012 522
013719292601 8/1/2010 204
013719292602 8/1/2010 204
013719292603 8/1/2010 204
013810119110/1/2003 522
013810119102 8/1/2010 204
01381011910205 5/1/1999 6/30/2001 421
01381011910225 12/1/2006 6/30/2008 421
01381011910225 11/1/2010 6/30/2011 421
01381011910226 5/1/2012 6/30/2014 421
013810119103 8/1/2010 4/30/2012 204
01381011910302 5/1/1999 6/30/2001 421
01381011910325 12/1/2006 6/30/2008 421
01381011910325 11/1/2010 6/30/2011 421
01381011912525 1/1/2007 6/30/2008 421
013810119126 8/1/2010 204
01381011912625 12/1/2008 6/30/2011 421
01381011912625 12/1/2011 6/30/2014 421
013810119710/1/2003 522
013810119910/1/2003 522
0138202149 6/1/2012 522
013820214901 8/1/2010 204
0138253907 6/1/2012 522
013825390725 8/1/2012 204
013830150110/1/2003 522
013830150101 8/1/2010 204
0138301676 6/1/2012 522
01383016760101 12/1/2008 6/30/2011 421
01383016760101 11/1/2011 6/30/2014 421
01383016760125 3/1/2004 6/30/2006 421
013830329110/1/2003 522
013830329105 8/1/2010 204
013830329125 7/1/2003 530
013830329125 8/1/2010 204
01383032912525 7/1/2003 ######## 29
01383032912525 4/1/2008 6/30/2010 421
01383032912525 10/1/2010 6/30/2013 421
01383032912525 5/1/2014 6/30/2016 421
01383032912526 11/1/2005 6/30/2007 421
013830373610/1/2003 522
0138303831 6/1/2012 522
013830383125 8/1/2010 204
01383038312525 5/1/2006 6/30/2007 421
0138303862 6/1/2012 522
013830386225 8/1/2010 204
013840 8/1/2006 5018
0138403329 6/1/2012 522
01384033290301 12/1/2002 6/30/2005 421
01384033290301 11/1/2006 6/30/2009 421
013850235410/1/2003 522
01385023540101 1/1/2006 6/30/2008 421
01385023540101 1/1/2009 6/30/2011 421
01385023540101 12/1/2011 6/30/2014 421
04 7/1/2007 3/31/2009 6001
040101 4/1/2002 ######## 626
040101 9/1/2008 922
04010127585/16/1994 ######## 100
040101275812/1/1996 3/31/2002 317
0401012758 1/1/1999 7/31/2010 227
040101275812/1/2002 8/31/2008 626
0401013771 1/1/1999 7/31/2010 227
040101377112/1/2002 ######## 645
0401013771 1/1/2003 ######## 646
040101377112/1/2006 8/31/2008 851
040103149902 7/1/1996 530
040104149810/1/2003 ######## 522
040104149801 1/1/2005 522
04010414980103 2/1/2001 6/30/2003 421
04010414980103 12/1/2003 6/30/2006 421
04010414980103 10/1/2006 6/30/2009 421
040104149802 1/1/2005 522
040104149803 3/1/1996 ######## 289
04010414980301 12/1/2002 ######## 421
040104149825 1/1/2005 522
040104149825 8/1/2012 204
04010414982525 12/1/2003 6/30/2006 421
04010414982525 10/1/2006 6/30/2009 421
04010414982526 2/1/2006 29
04010414982526 4/1/2013 429
04040110545/16/1994 7/31/1997 23
04040110855/12/1995 23
0404011085 1/1/1999 227
040401108510/1/2003 522
04040121645/16/1994 ######## 24
040401216410/1/2003 522
04040125055/12/1995 ######## 23
04040125050101 11/1/2001 6/30/2004 421
04040125050101 12/1/2004 6/30/2007 421
04040125050101 7/1/2010 6/30/2013 421
040401401812/1/2013 756
040401401812/1/2013 1406
040401401912/1/2013 756
040401401912/1/2013 1406
040401402012/1/2013 756
040401402012/1/2013 1406
040401402112/1/2013 756
040401402112/1/2013 1406
040401402212/1/2013 756
040401402212/1/2013 1406
0404014024 1/1/2014 429
0404014024 1/1/2014 2/28/2014 1412
0404014024 3/1/2014 1418
04040319860101 10/1/2003 6/30/2006 421
040403198602 7/1/1996 10005
040403198603 7/1/1996 10005
040403198603 10/1/2009 ######## 989
04040319860302 10/1/2003 6/30/2006 421
040403198625 6/1/2000 10005
040403198625 10/1/2009 ######## 989
04040319862525 10/1/2003 6/30/2006 421
040403601810/1/2003 522
04040360180101 12/1/2002 6/30/2005 421
040701108710/1/2003 522
04070110872525 4/1/2008 6/30/2010 421
04070110872525 10/1/2010 6/30/2013 421
04070110872525 4/1/2014 6/30/2016 421
04070114275/16/1994 ######## 24
0407011427 9/1/1999 ######## 489
040701142711/1/2001 4/30/2003 616
0407011427 4/1/2004 522
040701142701 5/1/1995 5/31/1997 150
040701142701 6/1/1997 ######## 153
040701142701 12/1/1998 2/28/1999 436
040701142701 3/1/1999 8/31/1999 460
040701142701 5/1/2003 ######## 648
040701142701 11/1/2008 6/30/2009 930
040701142701 12/1/2011 10
040701142704 5/1/1995 5/31/1997 150
040701142704 6/1/1997 ######## 153
040701142704 12/1/1998 2/28/1999 436
040701142704 3/1/1999 8/31/1999 460
040701142704 5/1/2003 ######## 649
040701142704 11/1/2008 6/30/2009 929
04070114270401 7/1/2003 6/30/2005 421
04070114270401 11/1/2005 6/30/2008 421
04070114270401 11/1/2008 6/30/2011 421
04070114270401 11/1/2011 6/30/2014 421
040701142705 5/1/1995 5/31/1997 150
040701142705 6/1/1997 ######## 153
040701142705 12/1/1998 2/28/1999 436
040701142705 3/1/1999 8/31/1999 460
040701142705 5/1/2003 649
040701386010/1/2006 6/30/2007 847
0407013860 7/1/2007 8/31/2010 867
0407013860 6/1/2012 522
040701386025 2/1/2011 4/30/2011 1082
040701386025 12/1/2011 10
04070138602526 2/1/2011 6/30/2013 421
04070138602528 3/1/2014 6/30/2016 421
0407013945 4/1/2012 5/31/2012 1194
0407013945 6/1/2012 1201
0407014008 7/1/2013 522
0407014008 7/1/2013 1382
040704158906 6/27/1995 ######## 23
040704158906 1/1/1999 ######## 227
040704158907 6/27/1995 23
040704158907 1/1/1999 227
040704206310/1/2003 522
04070420630101 7/1/2013 29
04070420630101 7/1/2013 429
0407043893 8/1/2009 ######## 975
040704389312/1/2011 1174
04070438932525 8/1/2009 6/30/2012 421
04070438932525 10/1/2012 6/30/2015 421
04070438932625 8/1/2009 6/30/2012 421
04070438932625 10/1/2012 6/30/2015 421
04070438932725 8/1/2009 6/30/2012 421
04070438932725 10/1/2012 6/30/2015 421
04070438932825 8/1/2009 6/30/2012 421
04070438932825 10/1/2012 6/30/2015 421
04070438932925 8/1/2009 6/30/2012 421
04070438932925 10/1/2012 6/30/2015 421
04070438933025 8/1/2009 6/30/2012 421
04070438933025 10/1/2012 6/30/2015 421
04070438933125 8/1/2009 6/30/2012 421
04070438933125 10/1/2012 6/30/2015 421
040704397611/1/2012 1270
040704601910/1/2003 522
04070460190101 12/1/2002 6/30/2005 421
04070460190101 10/1/2006 6/30/2009 421
04070460192525 6/1/2008 29
04070460192525 4/1/2013 429
04070723315/20/1995 168
040707233110/1/2003 522
040707233101 7/1/1996 9/30/2003 533
040707233103 7/1/1996 9/30/2003 533
040707233104 7/1/1996 9/30/2003 533
040707233105 7/1/1996 9/30/2003 533
040707233106 7/1/1996 9/30/2003 533
040707392412/1/2010 1066
0407073937 7/1/2011 6/30/2012 1137
040707393725 7/1/2011 1136
0408033974 9/1/2012 9/30/2012 1252
040803397410/1/2012 1259
04080339742525 9/1/2012 ######## 421
04080339742625 9/1/2012 ######## 421
0408034009 7/1/2013 1384
0410011393 6/7/1995 9/30/1998 183
041001139310/1/2003 522
041001139301 7/1/1996 10005
04100113930125 8/1/2008 6/30/2011 421
04100113930125 10/1/2011 6/30/2014 421
041001139325 2/1/2007 10005
041001201610/1/2003 522
04100120160302 12/1/2002 6/30/2005 421
04100120160302 10/1/2005 6/30/2008 421
04100120160402 12/1/2002 6/30/2005 421
04100120160402 10/1/2005 6/30/2008 421
041001212801 10/1/2004 48
04100121280125 4/1/2006 29
04100121280125 4/1/2013 429
041001212802 10/1/2004 48
041001212802 1/1/2007 10005
041001212826 1/1/2007 48
041001212826 1/1/2007 10005
04100121356/14/1995 6/30/1999 102
041001213511/1/2011 1169
041001213503 2/1/2001 10005
04100121350301 12/1/2006 6/30/2009 421
04100121350302 12/1/2001 6/30/2004 421
041001213504 2/1/2001 10005
04100121350401 12/1/2001 6/30/2004 421
04100121350402 12/1/2006 6/30/2009 421
041001213505 10/1/2010 ######## 10005
04100121350501 12/1/2001 6/30/2004 421
041001213509 10/3/1997 2/28/2001 541
041001213509 2/1/2001 12000
041001213509 3/1/2001 564
041001213525 5/1/2012 5030
041001213525 8/1/2012 204
04100121352525 12/1/2010 6/30/2013 421
04100121352525 10/1/2013 6/30/2016 421
04100123325/16/1994 6/30/1999 103
0410012332 7/1/1999 469
041001233201 7/1/1996 10005
041001233202 7/1/1996 10005
04100123320201 12/1/2001 6/30/2004 421
04100123320202 4/1/2005 6/30/2007 421
041001233203 7/1/1996 10005
04100123320301 12/1/2001 6/30/2004 421
04100123320302 4/1/2005 6/30/2007 421
041001233204 7/1/1996 10005
04100123320402 12/1/2001 6/30/2004 421
04100123320425 6/1/2007 6/30/2009 421
0410012808 7/1/1996 8/31/2006 610
0410012808 1/1/1999 7/31/2010 225
0410012808 9/1/2006 7/31/2010 23
0410012808 8/1/2010 24
04100412055/16/1994 ######## 24
041004139401 8/1/2010 204
04100413940103 1/1/2008 6/30/2010 421
04100413940103 10/1/2010 6/30/2013 421
04100413940125 1/1/2008 6/30/2010 421
04100413940125 10/1/2010 6/30/2013 421
04100413940125 12/1/2013 6/30/2016 421
04100413940126 1/1/2008 6/30/2010 421
04100413940126 10/1/2010 6/30/2013 421
041004144601 5/16/1994 10010
041004144601 8/1/2010 204
04100414460125 12/1/2005 6/30/2007 421
04100414460125 10/1/2007 6/30/2010 421
041004144625 5/1/2011 204
041004144625 5/1/2011 10010
04100414462525 10/1/2011 6/30/2013 421
04100414462526 5/1/2014 6/30/2016 421
04100420135/16/1994 ######## 24
041004201301 11/1/2008 5/31/2014 931
041004201301 8/1/2010 204
041004201610/1/2003 522
041004201601 8/1/2010 204
041004201602 8/1/2010 204
04100420160203 7/1/2004 6/30/2006 421
04100420160203 1/1/2007 6/30/2009 421
04100420160203 1/1/2010 6/30/2012 421
04100420160203 11/1/2012 6/30/2015 421
04100421356/14/1995 6/30/1999 102
04100421605/16/1994 ######## 24
04100437645/16/1994 621
07 1/1/1996 6/30/2007 6001
070101101310/1/2003 522
070401196610/1/2003 522
07040119660101 3/1/2008 29
07040119660101 4/1/2013 429
07040119660125 5/1/2014 29
07040119660125 5/1/2014 429
070401197110/1/2003 522
070401203110/1/2003 522
07040120310201 12/1/2001 6/30/2004 421
07040120310201 10/1/2004 6/30/2007 421
07040120310203 8/1/1998 6/30/2001 421
07040120310225 8/1/2008 6/30/2010 421
07040120310301 8/1/1998 6/30/2001 421
07040120310303 12/1/2001 6/30/2004 421
07040120310303 10/1/2004 6/30/2007 421
07040120310325 8/1/2008 6/30/2010 421
07040120310401 12/1/2001 6/30/2004 421
07040120310401 10/1/2004 6/30/2007 421
07040120310403 8/1/1998 6/30/2001 421
07040120310425 8/1/2008 6/30/2010 421
070401251510/1/2003 522
07040125150225 11/1/2001 6/30/2004 421
07040125150225 2/1/2005 6/30/2007 421
07040125150226 4/1/2008 6/30/2010 421
07040125150226 7/1/2011 6/30/2014 421
07040125150325 11/1/2001 6/30/2004 421
07040125150325 2/1/2005 6/30/2007 421
07040125150326 4/1/2008 6/30/2010 421
07040125150326 7/1/2011 6/30/2014 421
070401254310/1/2003 522
0704012543 1/1/2011 3/31/2011 1076
07040125430325 10/1/2009 6/30/2010 421
07040125430326 1/1/2011 6/30/2013 421
07040125430326 10/1/2013 6/30/2016 421
07040125430725 10/1/2009 6/30/2010 421
07040125430726 1/1/2011 6/30/2013 421
07040125430726 10/1/2013 6/30/2016 421
07040125432526 1/1/2011 6/30/2013 421
07040125432526 10/1/2013 6/30/2016 421
070701 6/1/1998 4/30/2000 420
070701 5/1/2000 3/31/2001 535
070701 4/1/2001 7/31/2012 825
0707011031 4/1/2001 4/30/2013 566
070701103110/1/2003 522
0707011031 5/1/2013 1345
070701271110/1/2003 8/31/2013 522
070701271111/1/2010 1/31/2011 1057
0707012711 9/1/2013 ######## 1399
070701271110/1/2013 522
07070127110125 12/1/2001 ######## 421
07070127110126 3/1/2004 6/30/2006 421
07070127110126 10/1/2006 6/30/2009 421
07070127110126 3/1/2013 8/12/2013 421
07070127110127 11/1/2010 6/30/2012 421
07070127110225 12/1/2001 ######## 421
07070127110226 3/1/2004 6/30/2006 421
07070127110226 10/1/2006 6/30/2009 421
07070127110226 3/1/2013 8/12/2013 421
07070127110227 11/1/2010 6/30/2012 421
070701271103 12/1/2011 10
07070127110325 12/1/2001 ######## 421
07070127110326 3/1/2004 6/30/2006 421
07070127110326 10/1/2006 6/30/2009 421
07070127110326 3/1/2013 8/12/2013 421
07070127110327 11/1/2010 6/30/2012 421
070701277010/1/2003 522
0707012770 3/1/2011 5/31/2011 1088
07070127700125 3/1/2011 6/30/2013 421
07070127700125 10/1/2013 6/30/2016 421
07070127700225 3/1/2011 6/30/2013 421
07070127700225 10/1/2013 6/30/2016 421
07070127700325 3/1/2011 6/30/2013 421
07070127700325 10/1/2013 6/30/2016 421
070701277210/1/2003 522
0707012772 7/1/2013 9/30/2013 1385
07070127720101 9/1/2005 6/30/2008 421
07070127720101 11/1/2008 6/30/2011 421
07070127720125 7/1/2013 6/30/2015 421
07070127720201 9/1/2005 6/30/2008 421
07070127720201 11/1/2008 6/30/2011 421
07070127720225 7/1/2013 6/30/2015 421
07070127720301 9/1/2005 6/30/2008 421
07070127720301 11/1/2008 6/30/2011 421
07070127720325 7/1/2013 6/30/2015 421
070701279710/1/2003 522
07070127970125 9/1/2007 6/30/2009 421
07070127970125 10/1/2009 6/30/2012 421
07070127970125 2/1/2013 6/30/2015 421
07070127970225 9/1/2007 6/30/2009 421
07070127970225 10/1/2009 6/30/2012 421
07070127970225 2/1/2013 6/30/2015 421
07070127970325 9/1/2007 6/30/2009 421
07070127970325 10/1/2009 6/30/2012 421
07070127970325 2/1/2013 6/30/2015 421
0707012806 4/1/2001 4/30/2013 568
070701280610/1/2003 522
0707012806 8/1/2013 9/30/2013 1396
0707012841 4/1/2001 9/30/2001 568
070701284110/1/2003 522
070701284101 4/1/2011 6/30/2011 1114
07070128410125 1/1/2002 6/30/2004 421
07070128410126 3/1/2005 6/30/2007 421
07070128410126 1/1/2008 6/30/2010 421
07070128410127 4/1/2011 6/30/2013 421
070701284102 4/1/2011 6/30/2011 1114
07070128410225 1/1/2002 6/30/2004 421
07070128410226 3/1/2005 6/30/2007 421
07070128410226 1/1/2008 6/30/2010 421
07070128410227 4/1/2011 6/30/2013 421
070701284103 4/1/2011 6/30/2011 1114
07070128410325 1/1/2002 6/30/2004 421
07070128410326 3/1/2005 6/30/2007 421
07070128410326 1/1/2008 6/30/2010 421
07070128410327 4/1/2011 6/30/2013 421
070701284106 5/16/1994 4/30/2002 36
070701284106 7/1/1996 530
070701284106 5/1/2002 634
07070128410601 12/1/2010 6/30/2013 421
070701284107 11/1/1999 36
070702112710/1/2003 522
070702112701 6/1/2014 8/31/2014 1432
07070211270101 11/1/2010 6/30/2013 421
07070211270125 6/1/2014 6/30/2016 421
070702270810/1/2003 522
070702374910/1/2003 522
07070237492525 9/1/2005 6/30/2008 421
07070237492525 11/1/2008 6/30/2011 421
07070237492525 9/1/2012 6/30/2015 421
07070237492625 9/1/2005 6/30/2008 421
07070237492625 11/1/2008 6/30/2011 421
07070237492625 9/1/2012 6/30/2015 421
0707031061 8/1/1999 3/31/2002 472
0707031061 4/1/2002 4/30/2004 628
0707031061 5/1/2004 4/30/2007 706
0707031061 6/1/2008 ######## 911
0707031061 3/1/2012 5/31/2012 1185
070703106101 10/1/2003 522
070703106101 5/1/2007 5/31/2008 862
07070310610125 3/1/2012 6/30/2014 421
070703106102 10/1/2003 522
070703106102 5/1/2007 5/31/2008 862
07070310610225 3/1/2012 6/30/2014 421
070703106125 10/1/2003 522
070703106125 5/1/2007 5/31/2008 862
07070310612526 3/1/2012 6/30/2014 421
070703106126 6/1/2008 522
07070310612626 3/1/2012 6/30/2014 421
070703125412/1/1999 6/30/2004 508
070703125410/1/2003 522
0707031254 7/1/2004 1/31/2005 725
0707031254 2/1/2005 4/30/2007 706
0707031254 5/1/2007 ######## 862
070703125411/1/2008 7/31/2012 933
0707031254 8/1/2012 1223
070703125411/1/2012 1/31/2013 1275
070703125401 7/1/2004 7/31/2012 730
07070312540125 11/1/2012 6/30/2015 421
070703125402 7/1/2004 7/31/2012 730
07070312540225 11/1/2012 6/30/2015 421
070703125403 7/1/2004 7/31/2012 731
07070312540325 11/1/2012 6/30/2015 421
070703125425 8/1/2006 7/31/2012 731
07070312542526 11/1/2012 6/30/2015 421
070705106805 5/1/2004 5/31/2008 703
070705106805 6/1/2008 6/30/2008 522
0713 9/1/2002 5002
07130110575/16/1994 4/30/2006 24
071301105701 7/1/1996 533
071301105701 5/1/2006 24
071301105702 7/1/1996 533
071301105702 5/1/2006 24
071301105703 5/1/2006 ######## 10005
071301105703 12/1/2012 10006
07130110570301 9/1/2013 6/30/2016 421
071301109710/1/2003 522
071301109702 5/16/1994 10005
07130110970202 12/1/2002 6/30/2005 421
071301109703 5/16/1994 10005
07130110970301 12/1/2002 6/30/2005 421
07130110970301 1/1/2007 6/30/2009 421
07130110970301 1/1/2010 6/30/2012 421
07130110970301 2/1/2013 6/30/2015 421
071301109704 5/16/1994 10005
07130110970401 12/1/2002 6/30/2005 421
07130110970401 1/1/2007 6/30/2009 421
071301140510/1/2003 522
071301140501 7/1/1996 10030
07130114050101 12/1/2002 6/30/2005 421
071301141210/1/2003 522
071301141201 7/1/1996 10030
071301141202 7/1/1996 10030
071301141203 7/1/1996 530
071301141204 7/1/1996 2/28/2001 10005
071301141205 7/1/1996 2/28/2001 10005
071301142810/1/2001 533
071301142801 7/1/1996 9/30/2001 533
071301142802 7/1/1996 9/30/2001 533
071301142804 5/16/1994 24
071301142805 9/18/1997 9/30/2001 533
071301142806 9/18/1997 9/30/2001 533
07130115106/14/1995 24
071301151001 7/1/1996 533
071301151002 7/1/1996 533
071301151002 12/1/2011 10
071301151004 7/1/1996 533
071301151005 7/1/1996 533
07130117195/16/1994 7/31/1996 33
071301171901 7/1/1996 10005
071301171901 8/1/1996 61
071301171901 8/1/1996 155
071301171902 7/1/1996 3/31/2002 10005
071301171902 8/1/1996 61
071301171902 8/1/1996 155
071301171902 4/1/2002 10006
0713011823 7/1/1996 9/30/2012 533
071301182310/1/2012 533
07130118230101 1/1/2006 6/30/2008 421
07130118230201 1/1/2006 6/30/2008 421
07130118232525 10/1/2012 29
07130118232525 4/1/2013 429
07130118232625 10/1/2012 29
07130118232625 4/1/2013 429
07130120445/16/1994 1/31/1998 24
071301204401 7/1/1996 1/31/1998 533
071301207701 7/1/1996 533
071301207801 7/1/1996 533
071301207802 7/1/1996 1/31/1998 533
07130122755/16/1994 24
071301227501 7/1/1996 533
07130127815/16/1994 2/28/2002 21
07130127815/16/1994 2/28/2002 24
0713012781 3/1/2002 4/30/2004 623
0713012781 5/1/2004 699
07130128105/16/1994 24
0713012810 7/1/1996 533
071501101210/1/1997 ######## 361
0715011012 1/1/1999 7/31/2010 227
071501101211/1/2008 934
07150110120101 10/1/2006 6/30/2009 421
07150110120201 10/1/2006 6/30/2009 421
0716 2/26/1997 9/30/2003 324
071601100110/1/2003 522
071601100101 7/1/1996 9/30/2003 533
07160110010102 8/1/1998 6/30/2001 421
071601100102 7/1/1996 9/30/2003 533
07160110010202 8/1/1998 6/30/2001 421
071601100103 7/1/1996 9/30/2003 533
07160110010302 8/1/1998 6/30/2001 421
071601102901 7/1/1996 533
071601109410/1/2003 522
071601109401 7/1/1996 9/30/2003 533
07160110940102 3/1/2001 6/30/2003 421
07160110940102 10/1/2003 6/30/2006 421
07160110940102 10/1/2006 6/30/2009 421
07160110940105 11/1/1998 400
07160110940125 9/1/2008 6/9/2009 421
07160110940125 11/1/2009 5/27/2010 421
07160110940125 11/1/2012 6/30/2015 421
07160110940126 12/1/2008 29
07160110940126 4/1/2013 429
07160110940127 5/28/2010 6/30/2012 421
071601109402 7/1/1996 9/30/2003 533
07160110940202 3/1/2001 6/30/2003 421
07160110940202 10/1/2003 6/30/2006 421
07160110940202 10/1/2006 6/30/2009 421
07160110940205 11/1/1998 400
07160110940225 9/1/2008 6/30/2009 421
07160110940225 11/1/2009 5/27/2010 421
07160110940225 11/1/2012 6/30/2015 421
07160110940226 5/28/2010 6/30/2012 421
071601109425 2/1/2013 1288
07160110942525 2/1/2013 5/31/2014 29
07160110942525 4/1/2013 5/31/2014 429
071601169910/1/2003 522
071601169901 7/1/1996 9/30/2003 533
07160116990102 8/1/1998 6/30/2001 421
07160116990102 11/1/2003 6/30/2006 421
071601169902 7/1/1996 9/30/2003 533
071601169902 12/1/2011 10
07160116990202 8/1/1998 6/30/2001 421
07160116990202 11/1/2003 6/30/2006 421
071601169903 7/1/1996 9/30/2003 533
07160116990301 8/1/1998 6/30/2001 421
07160116990301 11/1/2003 6/30/2006 421
071601169904 7/1/1996 9/30/2003 533
07160116990403 5/1/1998 6/30/2001 421
07160116990403 11/1/2003 6/30/2006 421
07160116992525 10/1/2005 29
07160116992525 4/1/2013 429
071601181710/1/2003 522
071601181710/1/2007 ######## 897
071601181710/1/2007 3/31/2008 898
071601181712/1/2007 8/31/2009 903
0716011817 9/1/2012 ######## 1256
071601181701 7/1/1996 9/30/2003 533
07160118170125 9/1/2012 6/30/2015 421
071601181702 7/1/1996 9/30/2003 533
07160118170225 9/1/2012 6/30/2015 421
071601181703 7/1/1996 9/30/2003 533
07160118170325 9/1/2012 6/30/2015 421
071601181725 7/1/2001 9/30/2003 533
07160118172526 9/1/2012 6/30/2015 421
071601181810/1/2003 522
071601181801 7/1/1996 9/30/2003 533
071601181801 12/1/2011 10
07160118180101 8/1/2012 6/30/2015 421
071601181802 7/1/1996 9/30/2003 533
07160118180201 8/1/2012 6/30/2015 421
071601181803 7/1/1996 9/30/2003 533
07160118180301 10/1/2003 6/30/2006 421
07160118180301 10/1/2006 6/30/2009 421
07160118180301 8/1/2012 6/30/2015 421
07160118180425 8/1/2012 6/30/2015 421
071601183810/1/2003 522
071601183801 7/1/1996 9/30/2003 533
07160118380102 8/1/1998 6/30/2001 421
07160118380102 12/1/2001 6/30/2004 421
07160118380102 10/1/2004 6/30/2007 421
07160118380102 10/1/2007 6/30/2010 421
07160118380102 5/1/2013 6/30/2015 421
071601183802 7/1/1996 9/30/2003 533
07160118380202 8/1/1998 6/30/2001 421
07160118380202 12/1/2001 6/30/2004 421
07160118380202 10/1/2004 6/30/2007 421
07160118380202 10/1/2007 6/30/2010 421
07160118380202 5/1/2013 6/30/2015 421
071601191210/1/2003 522
071601191201 7/1/1996 9/30/2003 533
07160119120101 8/1/1998 6/30/2001 421
071601191202 7/1/1996 9/30/2003 533
07160119120201 8/1/1998 6/30/2001 421
071601191204 10/4/1997 9/30/2003 533
071601199110/1/2003 522
071601199104 7/1/1996 9/30/2003 533
07160119910402 12/1/2001 6/30/2004 421
07160119910402 9/1/2004 6/30/2007 421
07160119910403 8/1/1998 6/30/2001 421
07160119910403 6/1/2010 6/30/2012 421
07160119910403 12/1/2013 6/30/2016 421
071601199105 7/1/1996 9/30/2003 533
07160119910501 6/1/2010 6/30/2012 421
07160119910501 12/1/2013 6/30/2016 421
07160119910503 8/1/1998 6/30/2001 421
07160119910503 11/1/2004 6/30/2007 421
071601199106 7/1/1996 9/30/2003 533
07160119910601 6/1/2010 6/30/2012 421
07160119910601 12/1/2013 6/30/2016 421
07160119910603 8/1/1998 6/30/2001 421
07160119910603 11/1/2004 6/30/2007 421
071601206010/1/2003 2/29/2012 522
071601206001 7/1/1996 9/30/2003 533
071601206001 4/1/2012 522
07160120600103 8/1/1998 6/30/2001 421
07160120600103 10/1/2004 6/30/2007 421
07160120600104 4/1/2012 29
07160120600104 4/1/2013 429
071601206002 7/1/1996 9/30/2003 533
071601206002 4/1/2012 522
07160120600203 4/1/2012 29
07160120600203 4/1/2013 429
07160120600204 8/1/1998 6/30/2001 421
07160120600204 10/1/2004 6/30/2007 421
071601206005 10/4/1997 7/31/1998 533
071601206005 3/1/2012 522
071601206006 10/4/1997 9/30/2003 533
071601206006 3/1/2012 522
07160120600602 8/1/1998 6/30/2001 421
07160120600602 10/1/2004 6/30/2007 421
071601206025 4/1/2013 522
071601206025 4/1/2013 1327
07160120602525 4/1/2013 29
07160120602525 8/1/2013 429
071601216910/1/2003 522
071601216901 7/1/1996 9/30/2003 533
071601216901 12/1/2011 10
07160121690102 1/1/2004 6/30/2006 421
07160121690102 10/1/2009 6/30/2012 421
071601216902 7/1/1996 9/30/2003 533
07160121690202 1/1/2004 6/30/2006 421
07160121690202 10/1/2009 6/30/2012 421
071601226610/1/2003 522
071601226601 7/1/1996 9/30/2003 533
07160122660102 8/1/1998 6/30/2001 421
07160122660104 1/1/2004 6/30/2006 421
07160122660104 10/1/2006 6/30/2009 421
07160122660104 10/1/2009 6/30/2012 421
071601251410/1/2003 522
071601251401 7/1/1996 9/30/2003 533
07160125140102 12/1/2001 6/30/2004 421
07160125140102 10/1/2004 6/30/2007 421
0716013772 4/1/2002 1/31/2007 633
0716013772 6/1/2012 522
071601377227 12/1/2011 10
07160139492525 8/1/2012 6/30/2013 421
07160139492625 8/1/2012 6/30/2013 421
07160139492725 8/1/2012 6/30/2013 421
0722011863 6/1/1999 ######## 466
072201186312/1/1999 8/31/2006 510
072201186310/1/2003 522
07220118630203 12/1/2000 6/30/2003 421
07220118630203 10/1/2003 6/30/2006 421
07220118630203 12/1/2006 6/30/2009 421
072201186303 12/1/1999 8/31/2006 686
072201186303 9/1/2006 2/28/2007 844
072201186304 12/1/1999 8/31/2006 686
072201186304 9/1/2006 2/28/2007 844
072201186306 7/1/1996 ######## 10030
072201239810/1/2003 522
072201239801 1/1/2013 3/31/2013 1284
07220123980102 1/1/2013 6/30/2015 421
07220123980125 4/1/2005 6/30/2007 421
07220123980125 10/1/2009 6/30/2012 421
072201239802 1/1/2013 3/31/2013 1284
07220123980201 1/1/2013 6/30/2015 421
07220123980225 4/1/2005 6/30/2007 421
07220123980225 10/1/2009 6/30/2012 421
072201239803 6/1/2004 6/30/2012 718
07220123980301 12/1/2012 6/30/2015 421
0722012771 6/1/2012 522
072201279312/1/1999 4/30/2006 510
072201279310/1/2003 522
072201279301 12/1/1999 4/30/2006 687
072201279301 12/1/2011 10
07220127930125 5/1/2006 6/30/2008 421
07220127930126 4/1/2009 6/30/2011 421
07220127930126 11/1/2011 6/30/2014 421
072201279302 12/1/1999 4/30/2006 687
07220127930225 5/1/2006 6/30/2008 421
07220127930226 4/1/2009 6/30/2011 421
07220127930226 11/1/2011 6/30/2014 421
07220127932525 4/1/2012 6/30/2014 421
07220219496/14/1995 6/30/1996 24
0722021949 7/1/1995 9/30/2012 256
0722021949 7/1/1995 ######## 701
0722021949 1/1/1999 7/31/2010 227
072202194910/1/2003 522
072202194910/1/2012 1260
07220219490125 10/1/2003 6/30/2006 421
07220219490125 1/1/2007 6/30/2009 421
072202231710/1/2003 522
07220223170101 10/1/2011 6/30/2014 421
07220223170104 12/1/2000 6/30/2003 421
07220223170104 10/1/2003 6/30/2006 421
072202231702 12/1/2011 10
07220223170202 12/1/2000 6/30/2003 421
07220223170202 10/1/2003 6/30/2006 421
07220223170203 10/1/2011 6/30/2014 421
072202231707 7/1/1996 10005
07220223170701 10/1/2003 6/30/2006 421
07220223170902 1/1/2003 6/30/2005 421
07220223170902 10/1/2005 6/30/2008 421
07220223171102 12/1/2000 6/30/2003 421
07220223171102 10/1/2003 6/30/2006 421
072202252810/1/2003 ######## 522
0722022528 5/1/2014 522
072202252801 1/1/2014 3/31/2014 522
07220225280101 2/1/2002 6/30/2004 421
07220225280101 1/1/2005 6/30/2007 421
07220225280101 6/1/2009 ######## 421
07220225280101 10/1/2012 6/30/2015 421
072202252802 12/1/2011 10
072202252802 1/1/2014 3/31/2014 522
07220225280201 6/1/2009 ######## 421
07220225280203 2/1/2002 6/30/2004 421
07220225280203 1/1/2005 6/30/2007 421
07220225280203 6/1/2009 ######## 421
07220225280203 10/1/2012 6/30/2015 421
072202252803 1/1/2014 522
072202252804 5/1/2013 7/31/2013 1343
07220225280403 6/1/2009 ######## 421
07220225280425 5/1/2013 ######## 421
072202252805 5/1/2013 7/31/2013 1343
072202252805 1/1/2014 3/31/2014 522
07220225280501 6/1/2009 ######## 421
07220225280525 5/1/2013 3/31/2014 421
072202252806 5/1/2013 7/31/2013 1343
072202252806 1/1/2014 3/31/2014 522
07220225280601 6/1/2009 ######## 421
07220225280625 5/1/2013 3/31/2014 421
072202252807 1/1/2014 522
072202252808 1/1/2014 522
072202252809 1/1/2014 522
07220225280901 2/1/2002 6/30/2004 421
072801131710/1/2003 522
072801131702 5/16/1994 9/30/1999 58
072801131702 5/16/1994 9/30/1999 62
072801131702 10/1/1999 497
07280113170201 1/1/2006 6/30/2008 421
07280113170201 1/1/2010 6/30/2012 421
07280113170201 8/1/2014 6/30/2017 421
072801131703 5/16/1994 9/30/1999 58
072801131703 5/16/1994 9/30/1999 62
072801131703 10/1/1999 497
07280113170301 1/1/2006 6/30/2008 421
07280113170301 1/1/2010 6/30/2012 421
07280113170301 8/1/2014 6/30/2017 421
072801131704 5/16/1994 9/30/1999 58
072801131704 5/16/1994 9/30/1999 62
072801131704 10/1/1999 497
07280113170401 1/1/2006 6/30/2008 421
07280113170401 1/1/2010 6/30/2012 421
07280113170401 8/1/2014 6/30/2017 421
072801131810/1/2003 522
07280113180101 11/1/2002 6/30/2005 421
07280113180101 1/1/2006 6/30/2008 421
07280113180101 1/1/2010 6/30/2012 421
07280113180101 3/1/2013 6/30/2015 421
07280113180501 1/1/2006 6/30/2008 421
07280113180501 1/1/2010 6/30/2012 421
07280113180501 12/1/2012 6/30/2015 421
07280113180801 11/1/2002 6/30/2005 421
07280113180801 1/1/2006 6/30/2008 421
07280113180801 1/1/2010 6/30/2012 421
07280113180825 10/1/2013 6/30/2015 421
072801180510/1/2003 522
072801180610/1/2003 522
07280118060104 1/1/2001 6/30/2003 421
07280118060104 1/1/2006 6/30/2008 421
07280118060104 1/1/2009 6/30/2011 421
07280118060201 1/1/2001 6/30/2003 421
07280118060201 1/1/2006 6/30/2008 421
07280118060201 1/1/2009 6/30/2011 421
07280118060304 1/1/2001 6/30/2003 421
07280118060304 1/1/2006 6/30/2008 421
07280118060304 1/1/2009 6/30/2011 421
073101117110/1/2003 522
073101154410/1/2003 522
073101154401 2/1/2001 10030
07310115440103 12/1/2000 6/30/2003 421
07310115440103 10/1/2003 6/30/2006 421
07310115440103 8/1/2009 6/30/2012 421
07310115440103 10/1/2012 6/30/2015 421
073101154402 5/17/1995 ######## 24
07310115440202 12/1/2000 6/30/2003 421
07310115440202 10/1/2003 6/30/2006 421
07310115440225 12/1/2009 7/31/2010 29
07310115440225 3/1/2013 6/30/2015 421
073101154403 7/1/1996 530
073101154404 7/1/1996 10005
07310115440401 11/1/2004 6/30/2007 421
07310115440425 2/1/2011 6/30/2013 421
073101154405 7/1/1996 10005
073101154406 5/17/1995 ######## 24
073104105010/1/2003 ######## 522
073104105001 7/1/2013 522
073104105004 3/1/1996 3/31/1996 283
073104105004 4/1/1996 ######## 289
073104105004 7/1/1996 530
07310410500401 1/1/2003 ######## 421
073104217610/1/2003 ######## 522
073104217601 1/1/2005 522
07310421760101 7/1/2001 6/30/2003 421
07310421760101 11/1/2003 6/30/2006 421
07310421760101 10/1/2010 6/30/2013 421
07310421760101 10/1/2013 1/31/2014 421
07310421760125 2/1/2014 6/30/2016 421
073104217602 1/1/2005 522
07310421760201 7/1/2001 6/30/2003 421
07310421760201 11/1/2003 6/30/2006 421
07310421760201 10/1/2010 6/30/2013 421
07310421760201 10/1/2013 6/30/2016 421
07310421760225 10/1/2013 6/30/2016 421
073104217603 3/1/1996 3/31/1996 124
073104217603 4/1/1996 ######## 289
073104217603 7/1/1996 530
07310421760301 12/1/2002 ######## 421
0731044006 4/1/2013 5/31/2013 1323
0731044006 6/1/2013 1349
07310440062525 4/1/2013 29
07310440062525 8/1/2013 429
07310440062526 5/1/2013 29
07310440062526 8/1/2013 429
073107105110/1/2003 522
073107105310/1/2003 522
07310710530101 12/1/2000 6/30/2003 421
07310710530101 10/1/2003 6/30/2006 421
07310710530103 8/1/2010 8/31/2010 29
073107229310/1/2003 522
07310722930102 1/1/2001 6/30/2003 421
07310722930102 11/1/2003 6/30/2006 421
073110111610/1/2003 522
073110111601 6/1/1998 857
073110111601 6/1/1998 10150
07311011160125 10/1/2010 6/30/2011 421
07311011160125 10/1/2011 6/30/2014 421
07311011160225 10/1/2010 6/30/2011 421
07311011160225 10/1/2011 6/30/2014 421
073110128210/1/2003 ######## 522
073110128202 3/1/1996 3/31/1996 124
073110128202 4/1/1996 ######## 289
073110128202 7/1/1996 530
07311012820201 1/1/2003 ######## 421
073110129010/1/2003 522
07311012900101 12/1/2006 6/30/2009 421
07311012900125 9/1/2012 29
07311012900125 4/1/2013 429
073110136710/1/2003 522
073110164310/1/2003 522
0731101643 1/1/2011 3/31/2011 1077
07311016430102 2/1/2004 6/30/2006 421
07311016430102 1/1/2007 6/30/2009 421
07311016430103 12/1/2000 6/30/2003 421
07311016430125 1/1/2011 6/30/2013 421
07311016430125 11/1/2013 6/30/2016 421
073201 6/14/1995 9/30/1997 24
073201115110/1/2003 522
07320111510101 11/1/1999 6/30/2002 421
07320111510101 6/1/2013 6/30/2015 421
07320111510102 3/1/2003 6/30/2005 421
07320111510102 1/1/2006 6/30/2008 421
07320111510102 1/1/2009 6/30/2011 421
07320111510201 11/1/2012 6/30/2015 421
0732011553 6/1/2012 522
07320115530103 3/1/2000 6/30/2002 421
07320115532525 3/1/2011 6/30/2013 421
07320115532525 12/1/2013 6/30/2016 421
0732021313 6/1/1995 9/30/1996 24
073202131310/1/1996 301
073202186110/1/2003 522
07320218610101 12/1/2001 6/30/2004 421
07320218610201 12/1/2001 6/30/2004 421
07320218610201 1/1/2007 6/30/2009 421
07320218610201 10/1/2011 6/30/2014 421
07320218610301 12/1/2001 6/30/2004 421
07320218610402 12/1/2001 6/30/2004 421
07320218610402 3/1/2007 6/30/2009 421
07320218610402 10/1/2011 6/30/2014 421
07320218610425 6/1/2004 29
07320218610425 4/1/2013 429
0732022362 6/1/1995 ######## 24
073202236210/1/2003 522
07320223620101 12/1/2001 6/30/2004 421
07320223620101 10/1/2005 6/30/2008 421
07320223620101 1/1/2014 3/31/2014 429
073203 5/16/1994 9/30/1997 24
07320313450101 12/1/2001 6/30/2004 421
07320313450101 1/1/2008 6/30/2010 421
073204 5/16/1994 ######## 28
073204 12/1/1995 ######## 274
073204 11/1/1997 ######## 402
073204 1/1/1998 5/31/1998 383
073204 12/1/1998 3/31/2002 430
073204 4/1/2002 6/30/2002 627
073204 6/1/2004 716
0732041063 7/1/2002 627
0732041137 7/1/2002 5/31/2004 637
073204113710/1/2003 522
0732041137 6/1/2004 6/30/2004 717
0732041137 6/1/2004 9/30/2004 719
0732041137 7/1/2004 8/31/2005 724
0732041137 9/1/2005 8/31/2010 788
07320411370127 1/1/2013 6/30/2015 421
07320411370227 1/1/2013 6/30/2015 421
07320411370327 1/1/2013 6/30/2015 421
07320411372528 1/1/2013 6/30/2015 421
0732042513 6/1/1998 1/31/2000 411
0732042513 7/1/2002 5/31/2004 627
073204251310/1/2003 522
07320425130127 8/1/2009 6/30/2011 421
07320425130127 10/1/2011 6/30/2014 421
07320425130227 8/1/2009 6/30/2011 421
07320425130227 10/1/2011 6/30/2014 421
07320425130427 8/1/2009 6/30/2011 421
07320425130427 10/1/2011 6/30/2014 421
07320425132527 8/1/2009 6/30/2011 421
07320425132527 10/1/2011 6/30/2014 421
0732042780 6/1/1998 1/31/2001 411
0732042780 2/1/2001 5/31/2002 612
0732042780 7/1/2002 5/31/2004 627
073204278011/1/2006 ######## 849
073204278011/1/2008 ######## 932
0732042780 6/1/2012 522
07320427800326 2/1/2012 6/30/2014 421
07320427802526 2/1/2012 6/30/2014 421
0732083799 7/1/2004 9/30/2005 723
073208379910/1/2005 9/30/2010 796
073208379910/1/2010 1045
0732083853 2/1/2006 9/30/2010 826
073208385310/1/2010 1046
073401157710/1/2003 522
073401157701 7/1/1996 9/30/1999 39
073401157701 7/1/1996 9/30/2003 533
07340115770103 2/1/2002 6/30/2004 421
07340115770103 2/1/2005 6/30/2007 421
07340115770103 8/1/2008 6/30/2011 421
07340115770103 10/1/2011 6/30/2014 421
07340115770105 8/1/1998 6/30/2001 421
073401157702 7/1/1996 9/30/2003 533
073401157702 7/1/1996 10100
07340115770225 8/1/2008 2/28/2009 29
07340115770225 3/1/2009 6/30/2011 421
07340115770225 10/1/2011 6/30/2014 421
073401157703 7/1/1996 9/30/2003 533
073401157704 7/1/1996 6/30/1998 533
073401157705 7/1/1996 9/30/2003 533
07340115770502 2/1/2002 6/30/2004 421
07340115770502 2/1/2005 6/30/2007 421
07340115770502 8/1/2008 6/30/2011 421
07340115770502 10/1/2011 6/30/2014 421
07340115770505 8/1/1998 6/30/2001 421
073401157706 7/1/1997 9/30/2003 533
073401157706 11/1/2003 10250
07340115770601 1/1/2005 6/30/2007 421
07340115770601 11/1/2008 6/30/2011 421
073401157725 6/1/2002 9/30/2003 533
073401157725 11/1/2003 ######## 10200
073401157725 1/1/2012 10250
07340115772525 6/1/2012 6/30/2014 421
073401237710/1/2003 522
073401237701 7/1/1996 9/30/2003 533
073401237702 7/1/1996 9/30/2003 533
073401237704 7/1/1996 9/30/2003 533
073401283610/1/2003 522
073401283601 7/1/1996 9/30/2003 533
07340128360101 11/1/2000 6/30/2003 421
07340128360101 11/1/2003 6/30/2006 421
07340128360101 7/1/2011 6/30/2014 421
073401283602 7/1/1996 9/30/2003 533
07340128360201 7/1/2011 1/31/2014 421
073401283603 7/1/1996 9/30/2003 533
07340128360304 11/1/2000 6/30/2003 421
07340128360304 2/1/2004 6/30/2006 421
07340128360304 10/1/2006 6/30/2009 421
073701101501 5/16/1994 10005
073701101502 5/16/1994 10005
073701168210/1/2003 522
073701179310/1/2003 522
07370125385/16/1994 6/30/1999 23
074001160410/1/2003 522
074001160401 4/1/2013 1321
07400116040126 5/1/2013 29
07400116040126 8/1/2013 429
07400116040301 10/1/2013 ######## 429
074001192810/1/2003 522
07400124515/16/1994 ######## 41
074001245111/1/2012 533
074001245111/1/2012 1271
07400124555/16/1994 8/31/2006 125
0740012455 1/1/1999 7/31/2010 227
074001397510/1/2012 533
074001397510/1/2012 1263
074001600110/1/2003 522
074005 7/1/2009 7/31/2010 225
074005 7/1/2009 967
074007 7/1/2009 7/31/2010 225
074007 7/1/2009 2/28/2011 968
074007 3/1/2011 1/31/2013 1086
074007 3/1/2013 1293
07400738902526 5/1/2013 6/30/2014 421
07400738902626 5/1/2013 6/30/2014 421
074007389027 12/1/2011 10
07400738902726 5/1/2013 6/30/2014 421
074009 7/1/2009 7/31/2010 225
074009 7/1/2009 969
1001 9/1/2002 5007
10010114655/25/1995 7/31/1999 169
10010116885/16/1994 2/28/2009 281
1001011688 1/1/1999 2/28/2009 227
1001011688 3/1/2009 3/31/2009 947
1001011688 4/1/2009 955
10010116880125 2/1/2010 6/30/2012 421
10010116880125 4/1/2013 6/30/2015 421
10010116880126 5/1/2004 6/30/2006 421
10010116880126 10/1/2006 6/30/2009 421
10010116880202 2/1/2010 6/30/2012 421
10010116880202 4/1/2013 6/30/2015 421
10010116880225 5/1/2004 6/30/2006 421
10010116880225 10/1/2006 6/30/2009 421
1001012286 1/1/2006 6/30/2010 15
1001012286 1/1/2006 6/30/2010 23
100101228626 7/1/2010 1020
10010122862625 10/1/2013 6/30/2016 421
100101391510/1/2010 176
100101391510/1/2010 1043
1004 9/1/2002 5007
10040112885/16/1994 22
100401128801 6/1/2002 48
100401154203 5/16/1994 22
100401154203 6/1/2002 48
100401154225 5/16/1994 22
100401154225 6/1/2002 48
100401154608 10/1/1997 ######## 127
100401154608 12/1/1998 176
100401154608 12/1/1998 432
100401154608 6/1/2002 48
10040115460825 11/1/2005 6/30/2007 421
10040115460825 10/1/2007 6/30/2010 421
10040115460825 10/1/2010 6/30/2013 421
100401154609 10/1/1997 ######## 127
100401154609 12/1/1998 176
100401154609 12/1/1998 432
100401154609 6/1/2002 48
10040115460925 11/1/2005 6/30/2007 421
10040115460925 10/1/2007 6/30/2010 421
10040115460925 10/1/2010 6/30/2013 421
10040115460925 10/1/2013 6/30/2016 421
100401154610 10/1/1997 ######## 127
100401154610 12/1/1998 176
100401154610 12/1/1998 432
100401154610 6/1/2002 48
100401155407 6/1/2002 22
100401155407 6/1/2002 48
100401155408 6/1/2002 22
100401155408 6/1/2002 48
100401183501 5/16/1994 22
100401183501 6/1/2002 48
10040118546/29/1995 6/30/1999 22
100401185401 6/1/2002 22
100401185401 6/1/2002 48
100401200801 6/1/2002 22
100401200801 6/1/2002 48
100401211401 5/16/1994 8/31/2004 61
100401211401 7/1/1996 10500
100401211401 6/1/2002 48
10040121140101 11/1/2004 6/30/2007 421
100401211425 1/1/2010 48
100401211425 1/1/2010 10250
100401330310/1/2003 522
1007 9/1/2002 5009
100701132010/1/2003 522
100701132006 6/1/2002 22
100701132006 6/1/2002 48
100701132007 6/1/2002 22
100701132007 6/1/2002 48
10070113200702 12/1/2002 6/30/2005 421
10070113200725 4/1/2006 6/30/2008 421
10070113200725 10/1/2008 6/30/2011 421
10070113200725 12/1/2011 6/30/2014 421
100701144306 6/1/2002 22
100701144306 6/1/2002 48
100701144307 6/1/2002 22
100701144307 6/1/2002 48
100701144310 6/1/2002 22
100701144310 6/1/2002 48
100701144311 6/1/2002 22
100701144311 6/1/2002 48
100701162010/1/2003 522
100701162001 6/1/2002 22
100701162001 6/1/2002 48
100701162002 6/1/2002 22
100701162002 6/1/2002 48
100701162003 6/1/2002 22
100701162003 6/1/2002 48
10070116200302 12/1/2002 6/30/2005 421
10070116200325 4/1/2006 6/30/2008 421
10070116200325 10/1/2008 6/30/2011 421
10070116200325 12/1/2011 6/30/2014 421
100701162004 6/1/2002 22
100701162004 6/1/2002 48
100701169602 6/1/2002 22
100701169602 6/1/2002 48
10070118815/18/1995 9/30/1999 163
100701188102 6/1/2002 22
100701188102 6/1/2002 48
100701188103 6/1/2002 22
100701188103 6/1/2002 48
100701188113 6/1/2002 22
100701188113 6/1/2002 48
100701188114 6/1/2002 22
100701188114 6/1/2002 48
100701227003 6/1/2002 22
100701227003 6/1/2002 48
100701227004 6/1/2002 22
100701227004 6/1/2002 48
100701238810/1/2003 522
100701238801 6/1/2002 22
100701238801 6/1/2002 48
100701238802 6/1/2002 22
100701238802 6/1/2002 48
100701238803 6/1/2002 22
100701238803 6/1/2002 48
1007012394 6/1/2002 22
1007012394 6/1/2002 48
10070123940501 8/1/2009 6/30/2012 421
10070123942525 10/1/2013 6/30/2015 421
1007012832 6/1/2002 22
1007012832 6/1/2002 48
100701602101 6/1/2002 22
100701602101 6/1/2002 48
100701602102 6/1/2002 22
100701602102 6/1/2002 48
100701602103 6/1/2002 22
100701602103 6/1/2002 48
1008011179 6/1/2002 22
1008011179 6/1/2002 48
10080111790125 2/1/2007 6/30/2009 421
10080111790126 1/1/2010 6/30/2012 421
10080111790201 1/1/2010 6/30/2012 421
10080111790201 12/1/2012 6/30/2015 421
10080111790225 3/1/2007 6/30/2009 421
1008011363 6/1/2002 22
1008011363 6/1/2002 48
10080113630125 8/1/2010 6/30/2012 421
10080113630125 10/1/2012 6/30/2015 421
1008013333 8/1/1999 484
101001248310/1/2003 522
101001248303 5/1/1994 7/31/1994 24
101001248303 5/1/1994 7/31/1996 152
101001248303 5/1/1994 7/31/1996 223
1011 9/1/2002 5010
10110110820101 12/1/2003 6/30/2006 421
10110110820101 10/1/2006 6/30/2009 421
10110110820201 12/1/2003 6/30/2006 421
10110110820201 10/1/2006 6/30/2009 421
101101130910/1/2003 522
10110113090301 12/1/2000 6/30/2003 421
10110113090301 10/1/2003 6/30/2006 421
10110113090301 1/1/2007 6/30/2009 421
10110113090301 1/1/2010 6/30/2012 421
10110113090401 12/1/2000 6/30/2003 421
10110113090401 1/1/2006 6/30/2008 421
10110113090401 1/1/2010 6/30/2012 421
10110116136/16/1995 2/28/2007 206
101101161301 3/1/2007 22
10110116130101 1/1/2001 6/30/2003 421
10110116130101 1/1/2006 6/30/2008 421
10110116130101 10/1/2008 6/30/2011 421
10110116130101 10/1/2011 6/30/2014 421
10110116140101 4/1/2013 6/30/2015 421
10110116140701 4/1/2013 6/30/2015 421
10110116142525 4/1/2013 6/30/2015 421
101101161710/1/2003 522
101101161705 5/1/1996 22
101101161706 8/1/1999 483
10110116170625 4/1/2003 6/30/2005 421
10110116170625 10/1/2005 6/30/2008 421
10110116170626 11/1/2009 6/30/2011 421
10110116170626 12/1/2011 6/30/2014 421
101101161719 5/1/1996 22
10110116171902 10/1/2008 6/30/2011 421
10110116171926 12/1/2011 6/30/2014 421
10110123890801 10/1/2005 6/30/2008 421
10110123890801 1/1/2009 6/30/2011 421
10110123890801 10/1/2011 6/30/2014 421
10110123890901 10/1/2005 6/30/2008 421
10110123890901 1/1/2009 6/30/2011 421
10110123890901 10/1/2011 6/30/2014 421
101101271610/1/2003 522
10110127160925 8/1/2000 2/28/2002 421
10110127160925 1/1/2003 6/30/2005 421
10110127160925 5/1/2006 6/30/2008 421
10110127161025 8/1/2000 2/28/2002 421
10110127161025 1/1/2003 6/30/2005 421
10110127161025 5/1/2006 6/30/2008 421
10110128370325 4/1/2010 6/30/2012 421
10110128370325 10/1/2012 6/30/2015 421
10110128370425 4/1/2010 6/30/2012 421
10110128370425 10/1/2012 6/30/2015 421
1011041145 6/1/2002 22
10110411466/15/1995 22
101104114725 6/15/1995 211
101104114725 6/15/1995 542
101104114801 6/15/1995 ######## 127
101104114801 12/1/1998 176
101104114801 12/1/1998 432
1011041150 6/1/2002 22
10110414105/16/1994 22
10110416116/16/1995 22
101104161110/1/2003 522
10110416110101 11/1/2001 6/30/2004 421
10110416110101 5/1/2005 6/30/2007 421
10110416110101 10/1/2010 6/30/2013 421
10110416126/16/1995 22
10110416156/16/1995 22
101104238703 9/26/1995 22
10110423870325 5/1/2003 6/30/2005 421
101104238704 9/26/1995 22
10110423870401 5/1/2006 6/30/2008 421
10110423870425 5/1/2003 6/30/2005 421
1013011244 6/7/1995 7/31/1999 147
1013011244 6/7/1995 7/31/1999 185
1013011244 6/7/1995 7/31/1999 187
101301124410/1/2003 522
1013011244 2/1/2004 198
1013011244 2/1/2004 493
101301124401 5/18/1995 480
101301124401 6/7/1995 7/31/1999 166
101301124402 6/7/1995 7/31/1999 166
101301124402 10/1/1999 1/31/2004 198
101301124402 10/1/1999 1/31/2004 493
10130112440225 10/1/2005 6/30/2008 421
10130112440225 11/1/2008 6/30/2011 421
10130112440225 10/1/2011 6/30/2014 421
101301124403 5/18/1995 480
101301124403 6/7/1995 7/31/1999 166
101301124404 5/16/1994 5/18/1995 23
101301124404 5/18/1995 480
101301124404 6/7/1995 7/31/1999 166
101301124406 6/7/1995 7/31/1999 166
101301124406 5/1/1999 1/31/2004 182
101301124406 5/1/1999 1/31/2004 465
10130112442525 12/1/2006 6/30/2009 421
10130112442526 8/1/2010 6/30/2012 421
10130112442526 1/1/2013 6/30/2015 421
10130128636/27/1995 5/31/2000 22
10130128636/27/1995 5/31/2000 222
1013012863 6/1/2000 540
101301286310/1/2003 522
1013013909 8/1/2010 474
1013013909 8/1/2010 1030
10130160226/16/1995 208
101301602201 12/1/1995 154
101301602201 12/1/1995 279
10140114235/16/1994 126
1015021420 2/1/2014 522
10150214202525 7/1/2014 6/30/2016 421
1015023431 6/1/2012 522
10150234310101 12/1/2008 6/30/2011 421
10150234310103 1/1/2006 6/30/2008 421
10150234310103 8/1/2012 6/30/2014 421
10150234310104 12/1/2002 6/30/2005 421
10150415756/16/1995 2/28/2007 206
101504157510/1/2003 522
1015041575 3/1/2007 22
10150416866/16/1995 ######## 206
101504231210/1/2003 522
10150423120103 12/1/2002 6/30/2005 421
10150423120103 12/1/2005 6/30/2008 421
10150423120125 5/1/2014 6/30/2016 421
10150423395/16/1994 2/28/2007 206
101504233910/1/2003 522
1015042339 3/1/2007 22
101504321310/1/2003 522
10150432130106 3/1/2000 6/30/2002 421
10150432130125 2/1/2003 6/30/2005 421
10150432130125 4/1/2009 6/30/2011 421
10150432130125 10/1/2011 6/30/2014 421
10150432130126 2/1/2006 6/30/2008 421
101504324410/1/2003 522
10150432440101 12/1/2007 6/30/2010 421
10150432440101 10/1/2010 6/30/2013 421
101504328210/1/2003 522
10150432820105 3/1/2000 6/30/2002 421
10150432820125 2/1/2003 6/30/2005 421
10150432820125 10/1/2005 6/30/2008 421
10150432820125 10/1/2008 6/30/2011 421
10150432820125 10/1/2011 6/30/2014 421
101504334210/1/2003 522
101504374310/1/2003 522
10150437432526 1/1/2013 6/30/2015 421
101506334903 9/1/1999 688
101601238501 5/20/1995 134
101601238501 5/20/1995 136
101601238502 5/20/1995 9/30/1999 166
101601238502 1/1/1996 9/30/1999 167
101601238504 5/20/1995 9/30/1999 166
101601238504 1/1/1996 9/30/1999 167
10170111010101 12/1/2007 6/30/2010 421
10170111010125 3/1/2005 6/30/2007 421
10170111010125 1/1/2011 6/30/2013 421
10170111012525 9/1/2005 6/30/2007 421
10170111012525 10/1/2007 6/30/2010 421
10170111012525 10/1/2010 6/30/2013 421
10170128285/16/1994 6/30/1997 133
1017012828 7/1/1997 ######## 345
10170128280102 6/1/1998 5/31/2000 400
10170128280102 11/1/2004 6/30/2007 421
10170128280102 10/1/2011 6/30/2014 421
10170128280225 5/1/2010 6/30/2011 421
10170128280225 10/1/2011 6/30/2014 421
1017013964 8/1/2012 1225
101701396425 8/1/2012 1229
101701396425 8/1/2012 10100
10190118005/16/1994 24
10190122205/16/1994 2/28/2007 206
101901222010/1/2003 522
1019012220 3/1/2007 22
10190122200201 8/1/1999 6/30/2002 421
10190122200201 1/1/2003 6/30/2005 421
10190122200201 1/1/2006 6/30/2008 421
10190122200201 1/1/2009 6/30/2011 421
10190122200201 12/1/2011 6/30/2014 421
10190123025/19/1994 6/30/1998 24
1019012363 1/1/1996 2/28/2009 281
1019012363 1/1/1999 2/28/2009 227
1019012363 3/1/2009 3/31/2009 946
1019012363 4/1/2009 954
10190123630101 12/1/2001 6/30/2004 421
10190123630101 10/1/2005 6/30/2008 421
10190123630201 12/1/2001 6/30/2004 421
10190123630201 10/1/2005 6/30/2008 421
101901326405 8/1/1999 481
10190132640525 12/1/2010 6/30/2013 421
10190132640525 6/1/2014 6/30/2016 421
1019013280 6/7/1995 7/31/1999 191
101901338501 8/1/1999 9/30/2006 486
101901338501 10/1/2006 6/30/2014 848
101901338501 7/1/2014 1453
101901341102 8/1/1999 487
102201130910/1/2003 522
10220113090202 11/1/1999 6/30/2002 421
10220113090202 11/1/2002 6/30/2005 421
10220113090202 1/1/2006 6/30/2008 421
10220113090202 1/1/2010 6/30/2012 421
10220116140601 12/1/2007 6/30/2010 421
10220116140601 4/1/2013 6/30/2015 421
102201169603 3/1/1998 ######## 174
102201169603 3/1/1998 ######## 392
102201169603 12/1/1998 179
102201169603 12/1/1998 455
10220116960302 11/1/1999 6/30/2002 421
10220116960302 1/1/2009 6/30/2011 421
10220116960302 10/1/2011 6/30/2014 421
10220116960325 6/1/2004 6/30/2005 421
10220116960325 12/1/2005 6/30/2008 421
102201271610/1/2003 522
10220127160301 11/1/1999 6/30/2002 421
10220127160301 10/1/2003 6/30/2006 421
10220127160301 1/1/2007 6/30/2009 421
10220127160301 1/1/2010 6/30/2012 421
10250122135/16/1994 2/29/2008 24
1025012213 3/1/2008 905
102801 8/1/2006 5025
102801251601 6/16/1995 ######## 129
102801251601 1/1/1996 142
102801251601 1/1/1996 143
10280125160101 10/1/2003 6/30/2006 421
1028013292 6/7/1995 7/31/1999 22
102801329201 8/1/1999 188
102801329201 8/1/1999 197
102801329201 8/1/1999 479
1028013879 9/1/2008 923
10280138792525 12/1/2011 6/30/2014 421
10310315295/16/1994 ######## 24
10310315290101 3/1/2013 6/30/2015 421
103107286001 3/1/1996 2/28/1998 137
103107286001 3/1/1996 2/28/1998 139
103107330310/1/2003 522
103107330302 8/1/1999 474
1031073329 6/1/2012 522
10310760246/16/1995 2/28/1998 22
103107602401 5/16/1994 2/28/1998 137
103107602401 5/16/1994 2/28/1998 139
1301 5/16/1994 ######## 550
1301 1/1/2013 1282
1301016039 8/1/2004 522
130101603901 5/16/1994 3/31/2006 10072
130101603901 4/1/2006 10144
130101603902 9/1/2000 10144
130101603903 5/16/1994 3/31/2006 10072
130101603903 4/1/2006 10144
130101603904 5/16/1994 3/31/2006 10072
130101603904 4/1/2006 10144
130101603905 5/16/1994 3/31/2006 10072
130101603905 4/1/2006 10144
130101603906 5/16/1994 3/31/2006 10072
130101603906 4/1/2006 10144
130101603925 2/1/2008 10144
130101603926 5/1/2008 10144
130101603927 5/1/2008 10144
130101603928 6/1/2008 10144
130101603929 6/1/2008 10144
130101603930 8/1/2008 10144
130101603932 2/1/2009 10144
130101604001 5/16/1994 ######## 10072
13010511055/16/1994 158
1301051105 8/1/2004 522
130105110501 9/1/2006 10001
13010511050101 2/1/2006 6/30/2008 421
130105600803 7/1/1996 10001
130105600804 7/1/1996 10001
130105600805 7/1/1996 10012
130105600806 7/1/1996 10075
130105600825 6/1/2004 720
13010560082525 1/1/2006 6/30/2008 421
130105601301 7/1/1996 10075
13010760375/22/1995 82
13010760385/23/1995 7/31/2010 82
1301076038 8/1/2004 522
1301076038 8/1/2010 61
1301076038 8/1/2010 1024
130107603802 4/1/2007 7/31/2010 861
1301076041 7/1/1996 10001
1301076041 8/1/2004 522
1301076041 4/1/2007 858
13010760412525 2/1/2003 6/30/2005 421
13010760412525 10/1/2005 6/30/2008 421
13010760412625 2/1/2003 6/30/2005 421
13010760412625 10/1/2005 6/30/2008 421
13010760412626 2/1/2003 6/30/2005 421
13010760412626 10/1/2005 6/30/2008 421
13010760412725 2/1/2003 6/30/2005 421
13010760412725 10/1/2005 6/30/2008 421
13010760412726 2/1/2003 6/30/2005 421
13010760412726 10/1/2005 6/30/2008 421
13010760412825 2/1/2003 6/30/2005 421
13010760412825 10/1/2005 6/30/2008 421
13010760412826 2/1/2003 6/30/2005 421
13010760412826 10/1/2005 6/30/2008 421
13010760412925 2/1/2003 6/30/2005 421
13010760412925 10/1/2005 6/30/2008 421
13010760412926 2/1/2003 6/30/2005 421
13010760412926 10/1/2005 6/30/2008 421
13010760413025 2/1/2003 6/30/2005 421
13010760413025 10/1/2005 6/30/2008 421
13010760413026 2/1/2003 6/30/2005 421
13010760413026 10/1/2005 6/30/2008 421
13010760413125 2/1/2003 6/30/2005 421
13010760413125 10/1/2005 6/30/2008 421
13010760413126 2/1/2003 6/30/2005 421
13010760413126 10/1/2005 6/30/2008 421
13010760413225 2/1/2003 6/30/2005 421
13010760413225 10/1/2005 6/30/2008 421
13010760413226 2/1/2003 6/30/2005 421
13010760413226 10/1/2005 6/30/2008 421
1308 5/16/1994 ######## 550
1308 1/1/2013 1282
130802 8/1/1995 ######## 265
130802 11/1/1999 500
1308021475 8/1/2004 522
130802147508 7/1/1996 532
130802147508 7/1/1996 10063
13080214750801 9/1/2007 6/30/2010 421
130802147509 7/1/1996 532
130802147509 7/1/1996 10084
13080214750902 7/1/2003 6/30/2005 421
13080214750902 12/1/2005 6/30/2008 421
130802147510 7/1/1996 532
130802147510 7/1/1996 10084
130802147511 7/1/1996 532
130802147511 7/1/1996 10063
13080214751101 9/1/2007 6/30/2010 421
130802147512 7/1/1996 532
130802147512 7/1/1996 10084
13080214751201 9/1/2007 6/30/2010 421
130802147601 7/1/1996 532
130802147601 7/1/1996 4/30/1998 10063
130802147602 7/1/1996 532
130802147602 7/1/1996 4/30/1998 10063
1308021477 8/1/2004 522
130802147701 7/1/1996 532
130802147701 7/1/1996 10063
130802147702 7/1/1996 532
130802147702 7/1/1996 10084
130802147703 7/1/1996 532
130802147703 7/1/1996 10063
130802147704 7/1/1996 532
130802147704 7/1/1996 10084
1308021479 8/1/2004 522
130802147901 7/1/1996 532
130802147901 7/1/1996 10063
130802147902 7/1/1996 532
130802147902 7/1/1996 10084
130802147903 8/1/1999 532
130802147903 8/1/1999 10084
1308021718 8/1/2004 522
130802171802 7/1/1996 532
130802171802 7/1/1996 10063
130802171803 7/1/1996 532
130802171803 7/1/1996 5/31/1998 10063
130802171804 7/1/1996 532
130802171804 7/1/1996 10084
130802171805 7/1/1996 532
130802171805 7/1/1996 10084
130802171806 7/1/1996 532
130802171806 7/1/1996 10063
130802171807 7/1/1996 532
130802171807 7/1/1996 10084
130802171808 7/1/1996 532
130802171808 7/1/1996 10063
130802171809 7/1/1996 532
130802171809 7/1/1996 10084
130802171809 9/1/2012 2/28/2013 1257
13080217180925 9/1/2012 6/30/2014 421
130802171810 7/1/1996 532
130802171810 7/1/1996 10063
130802171811 7/1/1996 532
130802171811 7/1/1996 10084
130802171812 10/1/1998 532
130802171812 10/1/1998 10084
130802171812 12/1/2012 5/30/2013 1280
13080217181225 12/1/2012 6/30/2014 421
1308021873 8/1/2004 522
130802187301 7/1/1996 532
130802187301 7/1/1996 10063
130802187302 7/1/1996 532
130802187302 7/1/1996 10084
130802187501 7/1/1996 532
130802187501 7/1/1996 10063
130804 8/1/1995 ######## 265
130804 11/1/1999 500
1308041484 8/1/2004 522
130804148401 7/1/1996 532
130804148401 7/1/1996 10084
13080414840101 11/1/2002 6/30/2005 421
1308041724 8/1/2004 522
130804172401 7/1/1996 532
130804172401 7/1/1996 10084
13080417242825 8/1/2010 ######## 421
130804176610/1/2003 522
130804176608 7/1/1996 532
130804176608 7/1/1996 10005
13080417660801 12/1/2001 6/30/2004 421
13080417660801 12/1/2005 6/30/2007 421
13080417660801 10/1/2013 6/30/2016 421
130804176625 3/1/2003 10005
1308041871 8/1/2004 522
130804187101 7/1/1996 532
130804187101 7/1/1996 10084
13080418710101 2/1/2003 6/30/2005 421
13080418710101 11/1/2006 6/30/2009 421
13080418710101 10/1/2009 6/30/2012 421
13080418710101 10/1/2012 6/30/2015 421
1308051724 8/1/2004 522
130805172425 8/1/2000 ######## 548
130805172425 8/1/2000 ######## 10010
130805172427 6/1/2008 6/30/2008 902
130805172427 6/1/2008 10005
130805172427 7/1/2008 917
13080517242725 10/1/2013 6/30/2016 421
130902 2/1/2005 ######## 760
130902 1/1/2013 1283
13090227066/15/1995 3/31/1998 22
13090227066/15/1995 3/31/1998 118
13090227066/15/1995 3/31/1998 128
1309022706 4/1/1998 ######## 396
1309022706 4/1/1998 9/30/2001 410
130902270610/1/2001 ######## 613
130902270612/1/2001 1/31/2005 620
1309022706 2/1/2005 522
130902270602 7/1/2013 10084
13090227060225 3/1/2002 6/30/2004 421
13090227060225 10/1/2004 6/30/2007 421
13090227060226 4/1/2010 6/30/2011 421
13090227060226 10/1/2011 6/30/2014 421
131001132010/1/2003 522
131001132001 5/16/1994 2/28/2001 10012
13100113200125 1/1/2002 6/30/2004 421
13100113200225 1/1/2002 6/30/2004 421
13100113200302 12/1/2001 6/30/2004 421
13100113200325 4/1/2005 6/30/2007 421
13100113200325 10/1/2007 6/30/2010 421
13100113200325 10/1/2010 6/30/2013 421
13100113200325 1/1/2014 6/30/2016 421
13100113200402 12/1/2001 6/30/2004 421
13100113200402 10/1/2004 6/30/2007 421
13100113200425 4/1/2009 6/30/2010 421
13100113200425 10/1/2010 6/30/2013 421
13100113200425 1/1/2014 6/30/2016 421
131001162010/1/2003 522
13100118815/18/1995 9/30/1999 163
13100118810901 12/1/2006 6/30/2009 421
131402145601 7/1/1996 10005
13140214560101 1/1/2003 6/30/2005 421
13140214560101 10/1/2006 6/30/2009 421
13140214560101 12/1/2011 6/30/2014 421
131402188810/1/2003 522
1314021922 7/1/1996 10005
13140219220101 10/1/2003 6/30/2006 421
13140219220101 6/1/2007 6/30/2009 421
13140219220101 1/1/2010 6/30/2012 421
13140219220125 5/1/2014 6/30/2015 421
13140219220201 10/1/2003 6/30/2006 421
13140219220201 6/1/2007 6/30/2009 421
13140219220201 1/1/2010 6/30/2012 421
13140219220225 5/1/2014 6/30/2015 421
13140219220301 10/1/2003 6/30/2006 421
13140219220301 6/1/2007 6/30/2009 421
13140219220301 1/1/2010 6/30/2012 421
13140219220301 11/1/2012 6/30/2015 421
13140224415/16/1994 94
1314022441 1/1/1999 225
131402278410/1/2003 522
131402387525 1/1/2008 10010
13140238752525 1/1/2008 29
13140238752525 4/1/2013 429
13160230006/29/1995 1/31/2010 82
1316023000 2/1/2010 61
1316023000 2/1/2010 10200
13160230000202 4/1/2003 6/30/2005 421
13160230000202 9/1/2006 6/30/2009 421
13160230000202 4/1/2008 1/31/2010 910
13160230000226 8/1/2010 6/30/2012 421
1319 9/1/2002 5003
131901388110/1/2008 928
1319013881 6/1/2012 522
13190138812525 1/1/2009 6/30/2011 421
13190138812526 2/1/2012 6/30/2014 421
1319023910 8/1/2010 1032
1319023910 6/1/2012 522
13190239102525 11/1/2010 6/30/2013 421
13190239102525 3/1/2014 6/30/2016 421
13190414485/16/1994 24
131904191410/1/2003 522
13190419140102 11/1/1999 6/30/2002 421
13190419140102 10/1/2004 6/30/2007 421
13190419140102 1/1/2008 6/30/2010 421
13190419140102 7/1/2013 6/30/2016 421
13190419140202 10/1/2004 6/30/2007 421
13190419140202 1/1/2008 6/30/2010 421
13190419140202 7/1/2013 6/30/2016 421
131904214210/1/2003 522
13190421420102 11/1/2004 6/30/2007 421
13190421420102 10/1/2007 6/30/2010 421
13190421420102 12/1/2010 6/30/2013 421
131904337025 2/1/2011 1083
1319043902 1/1/2010 998
131904397711/1/2012 1272
132201191010/1/2003 522
132201223810/1/2003 522
14010119175/16/1994 1/31/1997 24
14010127635/16/1994 24
14010127630201 6/1/2010 29
14010127630201 4/1/2013 429
14040411885/16/1994 2/28/2009 23
1404041188 1/1/1999 2/28/2009 227
140404118810/1/2003 522
14040411880201 1/1/2009 6/30/2011 421
14040411880201 10/1/2011 6/30/2014 421
140701114401 5/16/1994 533
140701114401 5/16/1994 10030
140701136010/1/2003 522
140701136001 7/1/1996 9/30/2003 533
140701136002 7/1/1996 9/30/2003 533
14070113836/29/1995 9/30/2007 24
140701138310/1/2003 ######## 522
140701138301 2/1/2001 9/30/2003 533
140701138301 2/1/2001 10030
140701138301 1/1/2005 522
140701138301 10/1/2007 24
14070113830101 9/1/2012 6/30/2015 421
140701138302 2/1/2001 9/30/2003 533
140701138302 2/1/2001 10030
140701138302 1/1/2005 522
140701138302 10/1/2007 24
14070113830201 9/1/2012 6/30/2015 421
140701138305 3/1/1996 3/31/1996 283
140701138305 4/1/1996 544
140701138305 10/1/2007 24
14070113830501 1/1/2003 ######## 421
14070113855/16/1994 1/31/2001 82
1407011385 2/1/2001 2/28/2001 214
1407011385 2/1/2001 2/28/2001 561
1407011385 3/1/2001 3/31/2001 61
1407011385 4/1/2001 6/30/2001 216
1407011385 4/1/2001 6/30/2001 570
1407011385 7/1/2001 9/30/2006 10005
1407011385 4/1/2004 522
140701138511/1/2011 1170
140701138501 2/1/2001 10005
14070113850101 9/1/2006 6/30/2009 421
14070113850101 9/1/2010 6/30/2013 421
14070113850125 7/1/2014 6/30/2016 421
140701138502 2/1/2001 10005
14070113850201 9/1/2006 6/30/2009 421
14070113850201 9/1/2010 3/30/2013 421
14070113850225 7/1/2014 6/30/2016 421
140701151510/1/2003 522
140701151501 7/1/1996 9/30/2003 533
14070115150101 10/1/2003 6/30/2006 421
140701161710/1/2003 522
140701161701 7/1/1996 9/30/2003 533
14070116170101 7/1/1999 6/30/2002 421
14070116170101 9/1/2003 6/30/2006 421
14070116170101 1/1/2007 6/30/2009 421
14070116170101 1/1/2010 6/30/2012 421
14070116170101 12/1/2012 6/30/2015 421
140701161702 7/1/1996 9/30/2003 533
140701161702 12/1/2011 10
14070116170201 7/1/1999 6/30/2002 421
14070116170201 9/1/2003 6/30/2006 421
14070116170201 1/1/2007 6/30/2009 421
14070116170201 1/1/2010 6/30/2012 421
14070116170201 12/1/2012 6/30/2015 421
140701161716 5/23/1995 61
140701161716 7/1/1996 10005
14070116171601 1/1/2001 6/30/2003 421
14070116171601 12/1/2010 6/30/2013 421
14070116171601 11/1/2013 6/30/2016 421
140701161717 5/23/1995 61
140701161717 7/1/1996 10005
14070116171701 1/1/2001 ######## 421
140701161718 5/23/1995 61
140701161718 7/1/1996 10005
14070116171801 1/1/2001 ######## 421
14070118100501 1/1/2003 6/30/2005 421
14070118100501 10/1/2005 6/30/2008 421
14070118100501 10/1/2008 6/30/2011 421
14070118100501 11/1/2012 6/30/2015 421
14070118115/16/1994 24
140701181110/1/2003 522
140701181101 7/1/1996 9/30/2003 533
14070118110101 1/1/2003 6/30/2005 421
14070118110101 10/1/2006 6/30/2009 421
14070118110101 10/1/2009 6/30/2012 421
14070118110101 11/1/2012 6/30/2015 421
140701181102 7/1/1996 9/30/2003 533
14070118110201 1/1/2003 6/30/2005 421
14070118110201 10/1/2006 6/30/2009 421
14070118110201 10/1/2009 6/30/2012 421
14070118110201 11/1/2012 6/30/2015 421
14070118125/16/1994 24
14070118120101 1/1/2003 6/30/2005 421
14070118120101 10/1/2006 6/30/2009 421
14070118120101 1/1/2010 6/30/2012 421
14070118120101 1/1/2013 6/30/2015 421
14070118120201 1/1/2003 6/30/2005 421
14070118120201 10/1/2006 6/30/2009 421
14070118120201 1/1/2010 6/30/2012 421
14070118120201 1/1/2013 6/30/2015 421
14070118120401 1/1/2003 6/30/2005 421
14070118120401 10/1/2006 6/30/2009 421
14070118120401 1/1/2010 6/30/2012 421
14070118120401 1/1/2013 6/30/2015 421
14070118120501 1/1/2003 6/30/2005 421
14070118120501 10/1/2006 6/30/2009 421
14070118120501 1/1/2010 6/30/2012 421
14070118120501 1/1/2013 6/30/2015 421
14070118160601 1/1/2003 6/30/2005 421
14070118160601 10/1/2005 6/30/2008 421
14070118160601 10/1/2008 6/30/2011 421
14070118160601 11/1/2012 6/30/2015 421
140701203410/1/2003 522
140701203425 7/1/2000 545
140701203425 2/1/2001 10030
14070120342525 10/1/2004 6/30/2007 421
14070120342525 10/1/2009 6/30/2012 421
140701203601 7/1/1996 5/31/1999 533
140701203810/1/2003 6/30/2013 522
140701203801 7/1/1996 9/30/2003 533
140701203801 8/1/2013 522
14070120380102 11/1/2002 6/30/2005 421
14070120380102 10/1/2005 6/30/2008 421
14070120380102 1/1/2009 6/30/2011 421
14070120380125 8/1/2013 29
14070120380125 8/1/2013 429
140701203802 7/1/1996 9/30/2003 533
140701203802 7/1/2013 522
14070120380203 11/1/2002 6/30/2005 421
14070120380203 10/1/2005 6/30/2008 421
14070120380203 1/1/2009 6/30/2011 421
140701203803 7/1/1996 9/30/2003 533
140701203803 7/1/1996 10030
140701203803 7/1/2013 522
14070120380302 11/1/2002 6/30/2005 421
14070120380302 10/1/2005 6/30/2008 421
14070120380302 1/1/2009 6/30/2011 421
140701203804 7/1/1996 9/30/2003 533
140701203804 7/1/2013 522
14070120380403 11/1/2002 6/30/2005 421
14070120380403 10/1/2005 6/30/2008 421
14070120380403 1/1/2009 6/30/2011 421
140701203805 7/1/1997 9/30/2003 533
140701203806 7/1/1997 9/30/2003 533
140701223910/1/2003 522
14070122390101 10/1/2003 6/30/2006 421
14070122390101 10/1/2008 6/30/2011 421
14070122390101 10/1/2011 6/30/2014 421
14070122390301 10/1/2003 6/30/2006 421
14070122390301 10/1/2008 6/30/2011 421
14070122390301 10/1/2011 6/30/2014 421
14070123890101 5/1/2012 6/30/2014 421
140701238903 7/1/1996 2/28/2001 10005
14070123890301 1/1/2009 6/30/2011 421
14070123890301 5/1/2012 6/30/2014 421
140701286410/1/2003 522
14100117925/16/1994 7/31/1997 24
14100127075/16/1994 2/29/2004 514
1410012707 1/1/1999 7/31/2010 227
1410012707 3/1/2004 7/31/2010 23
1410012707 8/1/2010 24
14100127070125 1/1/2002 6/30/2003 421
14100127070125 1/1/2007 6/30/2009 421
14100127070125 10/1/2009 6/30/2012 421
14100127070125 11/1/2012 6/30/2015 421
14100127070126 3/1/2004 6/30/2006 421
14100127072525 10/1/2009 6/30/2012 421
14100127072525 11/1/2012 6/30/2015 421
14100127615/16/1994 24
14100127625/16/1994 24
14100127620101 1/1/2003 6/30/2005 421
14100127620101 10/1/2008 6/30/2011 421
14100127620101 3/1/2012 6/30/2014 421
14100127645/16/1994 24
14100127640125 1/1/2013 6/30/2015 421
14100127640126 10/1/2010 6/30/2012 421
14100127655/16/1994 24
1411 12/1/1996 6/30/2010 312
1411 9/1/2004 740
1411 7/1/2010 1018
141104115610/1/2003 522
141104188610/1/2003 522
141104188605 3/1/1995 83
141104188605 3/1/1995 101
141104188605 3/1/1995 106
141104188605 3/1/1995 ######## 157
141104188605 6/17/1995 ######## 24
141104188605 12/1/1996 ######## 313
141104188606 6/17/1995 ######## 24
141104188606 12/1/1996 156
141104188606 12/1/1996 161
141104188606 12/1/1996 314
141104188607 6/17/1995 ######## 24
141104188607 12/1/1996 164
141104188607 12/1/1996 165
141104188607 12/1/1996 315
141104188608 3/1/1995 ######## 24
141104188608 3/1/1995 34
141104188608 3/1/1995 58
141104188608 3/1/1995 62
141104188609 3/1/1995 ######## 24
141104188609 3/1/1995 207
141104188609 3/1/1995 209
141104188609 3/1/1995 515
141104188810/1/2003 522
141109176610/1/2003 522
14110917660501 9/1/2003 6/30/2006 421
14110917660501 10/1/2007 6/30/2010 421
14110917660501 10/1/2013 6/30/2016 421
14110917660601 9/1/2003 6/30/2006 421
14110917660601 10/1/2007 6/30/2010 421
14110917660601 10/1/2013 6/30/2016 421
14110917660701 9/1/2003 6/30/2006 421
14110917660701 10/1/2007 6/30/2010 421
14110917660701 10/1/2013 6/30/2016 421
141114204510/1/2003 522
141114205010/1/2003 522
141114205310/1/2003 522
141114205610/1/2003 522
141114205601 5/25/1995 84
141114205601 5/25/1995 107
141114205601 5/25/1995 109
141114205601 6/17/1995 ######## 24
141201147810/1/2003 522
14120114780101 12/1/2006 6/30/2009 421
14120114780101 10/1/2009 6/30/2012 421
14120114780101 11/1/2012 6/30/2015 421
141201188610/1/2003 522
141201278410/1/2003 522
1413011724 8/1/2004 522
141301172426 10/1/2002 7/31/2005 639
141301172426 8/1/2005 782
141301176610/1/2003 522
141301176601 5/25/1995 24
14130117660101 12/1/2002 6/30/2005 421
14130117660101 10/1/2007 6/30/2010 421
14130117660101 10/1/2013 6/30/2016 421
141301176602 5/25/1995 24
14130117660201 10/1/2007 6/30/2010 421
141301176603 5/25/1995 24
141301176604 5/25/1995 24
1413011871 8/1/2004 522
141301187102 7/1/1996 10030
14130118710201 2/1/2003 6/30/2005 421
14130118710201 11/1/2005 6/30/2008 421
14130118710201 10/1/2008 6/30/2011 421
14130118710201 12/1/2011 6/30/2014 421
141301205225 8/1/2013 1392
1414011221 4/1/2004 ######## 522
14140112210125 1/1/2014 29
14140112210125 1/1/2014 429
141401172110/1/2003 522
1414012062 5/1/2012 1199
1414012062 7/1/2013 1369
14140120620125 5/1/2012 29
14140120620125 4/1/2013 429
141401226310/1/2003 522
141401226301 11/1/1997 370
141401226302 11/1/1997 370
141401226325 8/1/2009 370
141602 12/1/2004 ######## 755
141602 3/1/2005 6/30/2014 756
141602 3/1/2005 ######## 765
141602 12/1/2012 6/30/2014 1279
14160224205/16/1994 9/30/1997 86
141602242010/1/1997 366
1416022509 7/1/2014 522
1416022509 7/1/2014 549
1416022509 7/1/2014 1451
14160225105/16/1994 ######## 85
141602251012/1/1998 ######## 516
1416022510 1/1/1999 2/28/2005 225
1416022510 9/1/2008 522
1416022510 7/1/2014 756
1416022510 7/1/2014 1279
14160225100901 7/1/2010 ######## 421
14160225101101 7/1/2010 ######## 421
14160228395/16/1994 9/30/1997 87
14160260325/16/1994 9/30/1997 88
141602603210/1/1997 6/30/1999 366
141603 5/16/1994 8/31/1996 89
141603 9/1/1996 ######## 300
141603 12/1/1996 1/31/1998 311
141603 2/1/1998 6/30/1999 387
141603 7/1/1999 6/30/2006 471
1416031009 1/1/1999 7/31/2010 227
1416031009 7/1/2006 7/31/2009 837
141603100901 2/1/1998 ######## 388
14160310090101 11/1/2004 6/30/2007 421
141603100902 2/1/1998 ######## 386
141603100902 1/1/2006 6/30/2006 822
14160310090201 11/1/2004 6/30/2007 421
1416032540 1/1/1999 7/31/2010 227
1416032540 7/1/2006 7/31/2006 836
1416032540 8/1/2006 8/31/2009 839
141603254002 2/1/1998 6/30/2006 386
1416032679 1/1/1999 7/31/2010 227
1416032679 7/1/2006 8/31/2010 835
1419012424 9/1/2013 1401
141901242401 5/16/1994 24
141901242401 7/1/1996 533
141901242402 5/16/1994 24
141901242402 7/1/1996 533
141901242403 5/16/1994 8/31/2013 90
141901242403 1/1/1999 7/31/2010 227
141901242403 9/1/2013 618
141901242425 4/1/2006 24
141901242425 4/1/2006 533
14190124242525 9/1/2006 6/30/2008 421
14190124242525 10/1/2008 6/30/2011 421
14190124242525 10/1/2011 6/30/2014 421
141901242426 9/1/2013 618
141901242427 9/1/2013 618
14210113145/16/1994 6/30/2010 24
14210113145/16/1994 6/30/2010 681
14210113140102 11/1/1999 6/30/2002 421
14210113140102 9/1/2003 6/30/2006 421
14210113140103 10/1/2013 6/30/2016 421
14210113725/16/1994 6/30/2013 24
14210113720102 1/1/2003 6/30/2005 421
14210113720202 1/1/2003 6/30/2005 421
142101182201 5/16/1994 7/31/2010 23
142101182201 1/1/1999 7/31/2010 227
142101182201 8/1/2010 24
14210118220101 10/1/2003 6/30/2006 421
14210118220101 12/1/2006 6/30/2009 421
14210128165/16/1994 24
14210128656/17/1995 7/31/2010 175
1421012865 8/1/2010 6/30/2013 1031
1421012865 7/1/2013 1370
142101286501 6/17/1995 210
14210128650101 12/1/2012 6/30/2015 421
1601011762 5/1/2000 22
160101176201 5/16/1994 4/30/2000 22
160101176201 5/16/1994 4/30/2000 73
160101176202 5/16/1994 4/30/2000 74
160101176202 5/16/1994 4/30/2000 95
16010117620225 8/1/2009 6/30/2011 421
16010117620225 12/1/2011 6/30/2014 421
1601013990 4/1/2013 1318
16010139902525 4/1/2013 29
16010139902525 4/1/2013 429
1603 9/1/2002 5011
1603 9/1/2002 5022
160301108110/1/1999 491
16030112280101 5/1/1998 6/30/2001 421
16030112280125 3/1/2002 6/30/2004 421
16030112280126 3/1/2005 6/30/2007 421
16030112280126 10/1/2007 6/30/2010 421
16030112280126 1/1/2014 6/30/2016 421
160301122802 5/16/1994 429
16030112280201 5/1/1998 6/30/2001 421
16030112280225 3/1/2002 6/30/2004 421
16030112280226 3/1/2005 6/30/2007 421
16030112280226 10/1/2007 6/30/2010 421
16030112280226 10/1/2010 6/30/2013 421
16030112280226 1/1/2014 6/30/2016 421
16030112305/16/1994 23
16030112305/16/1994 67
1603011230 1/1/1999 227
16030112300202 12/1/2002 6/30/2005 421
16030112315/16/1994 7/31/2010 23
16030112315/16/1994 67
1603011231 1/1/1999 7/31/2010 227
1603011231 8/1/2010 24
16030112325/16/1994 9/30/2005 23
16030112325/16/1994 9/30/2005 67
1603011232 1/1/1999 7/31/2010 227
160301123210/1/2005 ######## 793
160301123210/1/2005 10005
160301123212/1/2005 6/30/2013 806
1603011232 7/1/2013 1354
16030112320102 10/1/2003 6/30/2006 421
16030112320225 12/1/2002 6/30/2005 421
16030112320226 1/1/2007 6/30/2008 421
16030112320227 2/1/2011 6/30/2013 421
16030112320228 6/1/2014 6/30/2016 421
16030112320325 12/1/2002 6/30/2005 421
16030112320327 1/1/2007 6/30/2008 421
16030112320328 1/1/2011 6/30/2013 421
16030112320329 6/1/2014 6/30/2016 421
16030112335/16/1994 ######## 23
16030112335/16/1994 ######## 67
1603011233 1/1/1999 7/31/2010 227
160301123301 11/1/1999 502
160301123302 11/1/1999 234
16030112330201 12/1/2002 6/30/2005 421
16030112330201 11/1/2008 6/30/2011 421
16030112330226 6/1/2012 6/30/2014 421
160301123303 11/1/1999 7/31/2010 23
160301123303 11/1/1999 7/31/2010 235
160301123303 8/1/2010 24
160301123303 8/1/2010 67
16030112330301 11/1/2008 6/30/2011 421
1603011234 1/1/1999 7/31/2010 227
16030112340101 12/1/2002 6/30/2005 421
16030112340201 12/1/2002 6/30/2005 421
160301123403 5/16/1994 429
160301123403 5/1/2014 1430
16030112340301 12/1/2002 6/30/2005 421
16030112340325 3/1/2010 6/30/2012 421
16030112340325 11/1/2013 6/30/2015 421
160301123404 5/16/1994 429
160301123404 5/1/2014 1430
16030112340401 12/1/2002 6/30/2005 421
16030112340425 3/1/2010 6/30/2012 421
16030112340425 11/1/2013 6/30/2015 421
16030112342525 11/1/2013 6/30/2016 421
16030112355/16/1994 67
1603011235 1/1/1999 227
16030112365/16/1994 6/30/2013 67
1603011236 1/1/1999 7/31/2010 227
1603011236 7/1/2013 1353
16030112360126 12/1/2002 6/30/2005 421
16030112360127 12/1/2006 6/30/2008 421
16030112360128 3/1/2009 6/30/2011 421
16030112360129 6/1/2012 6/30/2014 421
16030112360225 3/1/2009 6/30/2011 421
16030112360226 12/1/2002 6/30/2005 421
16030112360227 12/1/2006 6/30/2008 421
16030112360228 6/1/2012 6/30/2014 421
1603011237 1/1/1999 227
16030112370101 10/1/2003 6/30/2006 421
16030112370201 10/1/2003 6/30/2006 421
160301123703 5/16/1994 68
16030112370301 10/1/2003 6/30/2006 421
160301123704 5/16/1994 68
16030112370401 10/1/2003 6/30/2006 421
1603041178 7/1/2004 5/31/2012 726
160304117810/1/2005 8/31/2010 795
160304117812/1/2005 5/31/2012 807
1603041178 7/1/2009 5/31/2011 964
1603041178 9/1/2010 5/31/2012 1037
1603041178 6/1/2011 5/31/2012 1130
160304117812/1/2012 2/28/2013 1269
1603041178 3/1/2013 1292
160304117801 1/1/1999 6/30/2004 177
160304117801 1/1/1999 6/30/2004 446
160304117801 7/1/2004 ######## 219
160304117801 6/1/2012 ######## 726
160304117801 6/1/2012 ######## 807
160304117801 6/1/2012 1037
160304117801 6/1/2012 ######## 1130
16030411780125 2/1/2008 6/30/2009 421
16030411780125 10/1/2009 6/30/2012 421
16030411780126 5/1/2013 6/30/2015 421
160304117825 6/1/2012 429
160304117825 6/1/2012 7/31/2012 1202
160304117825 8/1/2012 ######## 1222
160304117825 11/1/2012 ######## 1269
16030414655/25/1995 7/31/1999 169
160304146504 10/4/1997 10030
160304146505 10/4/1997 10030
16030414665/25/1995 7/31/1999 169
16030414660201 12/1/2001 ######## 421
160304146603 7/1/1996 10200
160304146605 10/4/1997 7/31/1999 10030
16030427900125 2/1/2001 6/30/2002 421
16030427900125 1/1/2004 6/30/2006 421
16030427900126 8/1/2007 6/30/2009 421
16030427900126 10/1/2009 6/30/2012 421
16030427900126 10/1/2012 6/30/2015 421
16030427900225 2/1/2001 6/30/2002 421
16030427900225 1/1/2004 6/30/2006 421
16030427900226 8/1/2007 6/30/2009 421
16030427900226 10/1/2009 6/30/2012 421
16030427900226 10/1/2012 6/30/2015 421
160304280911/1/1999 9/30/2009 657
160304280912/1/2003 503
160304280910/1/2009 5/31/2011 988
1603042809 6/1/2011 1131
160304280901 5/15/1994 ######## 70
160304280901 5/16/1994 6/30/1997 6
160304280901 12/1/1996 6/30/1997 349
160304280901 3/1/1998 ######## 394
160304280901 11/1/1999 ######## 503
16030428090125 4/1/2006 6/30/2007 421
16030428090126 6/1/2008 6/30/2010 421
16030428090127 4/1/2012 6/30/2014 421
160304280902 5/15/1994 ######## 70
160304280902 12/1/1996 6/30/1997 349
160304280902 7/1/1997 2/28/1998 348
160304280902 3/1/1998 ######## 443
160304280902 1/1/1999 ######## 227
160304280902 7/1/2003 429
16030428090201 10/1/2007 6/30/2010 421
16030460265/25/1995 7/31/1999 169
160304602601 2/1/1997 ######## 10030
160304602601 12/1/2013 1405
160304602601 12/1/2013 10020
16030460260102 8/1/1999 6/30/2002 421
16030460260102 12/1/2002 6/30/2005 421
16030460260102 8/1/2009 6/30/2012 421
160304602603 5/1/1994 429
160304602603 7/1/1996 ######## 10200
160304602603 12/1/2013 1405
160304602603 12/1/2013 10300
16030460260302 8/1/1999 6/30/2002 421
16030460260302 12/1/2002 6/30/2005 421
16030460260302 1/1/2006 6/30/2008 421
16030460260302 1/1/2009 6/30/2011 421
160304602605 5/1/1994 429
160304602605 2/1/2001 10200
16030460260502 8/1/1999 6/30/2002 421
16030460260502 12/1/2002 6/30/2005 421
16030460260502 1/1/2006 6/30/2008 421
16030460260502 1/1/2009 6/30/2011 421
16030460275/25/1995 7/31/1999 169
160304602703 10/4/1997 10030
160304602704 10/4/1997 10030
16030460285/25/1995 7/31/1999 169
16030460280202 4/1/2004 6/30/2006 421
160307107001 5/16/1994 10030
16030710700101 6/1/2003 6/30/2005 421
16030710700103 10/1/1999 6/30/2002 421
16030710700103 8/1/2009 6/30/2011 421
16030710700125 12/1/2012 6/30/2014 421
160307107002 5/1/1994 429
160307107002 5/16/1994 10200
16030710700201 6/1/2003 6/30/2005 421
16030710700201 2/1/2013 6/30/2015 421
16030710700203 6/1/2000 6/30/2002 421
16030710700225 4/1/2010 6/30/2012 421
160307107003 5/1/1994 429
160307107003 2/1/2001 10200
16030710700301 6/1/2003 6/30/2005 421
16030710700301 2/1/2013 6/30/2015 421
16030710700303 6/1/2000 6/30/2002 421
16030710700325 4/1/2010 6/30/2012 421
160307107202 5/16/1994 10030
160307107202 12/1/2013 1407
16030710720205 2/1/2005 6/30/2007 421
16030710720205 10/1/2007 6/30/2010 421
16030710720205 6/1/2014 6/30/2016 421
16030710720225 1/1/2001 6/30/2003 421
16030710720226 3/1/2011 6/30/2013 421
160307107203 12/1/2013 1407
160307107203 12/1/2013 10030
16030710720305 2/1/2005 6/30/2007 421
16030710720305 10/1/2007 6/30/2010 421
16030710720325 1/1/2001 6/30/2003 421
16030710720326 3/1/2011 6/30/2013 421
16030710720425 1/1/2003 6/30/2005 421
16030710720425 4/1/2009 6/30/2011 421
160307107205 5/1/1994 429
160307107205 5/16/1994 10200
16030710720525 2/1/2001 6/30/2003 421
16030710720525 12/1/2003 6/30/2006 421
16030710720526 5/1/2007 6/30/2009 421
160307107206 5/1/1994 429
160307107206 2/1/2001 ######## 10200
160307107206 12/1/2013 1407
160307107206 12/1/2013 10300
16030710720625 2/1/2001 6/30/2003 421
16030710720625 12/1/2003 6/30/2006 421
16030710720625 5/1/2010 6/30/2012 421
16030710720626 5/1/2007 6/30/2009 421
160307107208 5/26/1995 10005
16030710720801 1/1/2003 6/30/2005 421
16030710720801 8/1/2006 6/30/2008 421
16030710720801 4/1/2009 6/30/2011 421
16030710720801 12/1/2011 6/30/2014 421
160307107209 5/26/1995 2/28/2001 10005
16030710720901 1/1/2003 6/30/2005 421
16030710720901 8/1/2006 6/30/2008 421
16030710720901 4/1/2009 6/30/2011 421
16030710720901 12/1/2011 6/30/2014 421
160307107210 7/1/1996 2/28/2001 10005
16030710721001 1/1/2003 6/30/2005 421
16030710721001 8/1/2006 6/30/2008 421
16030710721001 4/1/2009 6/30/2011 421
16030710721001 12/1/2011 6/30/2014 421
160307112002 5/16/1994 10005
16030711200225 10/1/2012 6/30/2015 421
160307112025 11/1/2006 10005
160307112401 1/1/1998 2/28/2001 10030
160307112403 1/1/1998 429
160307112404 1/1/1998 429
160307112405 1/1/1998 2/28/2001 10005
160307112406 1/1/1998 2/28/2001 10005
160307113601 5/16/1994 10005
16030711360101 3/1/2004 6/30/2006 421
16030711360101 1/1/2009 6/30/2011 421
16030711360101 12/1/2011 6/30/2014 421
160307151101 5/16/1994 429
160307151101 2/1/2001 10200
16030715110101 8/1/1999 6/30/2002 421
160307151102 5/16/1994 429
160307151102 2/1/2001 10200
160307151201 7/1/1996 10030
16030715120104 12/1/2000 6/30/2003 421
16030715120104 5/1/2004 6/30/2006 421
16030715120104 10/1/2006 6/30/2009 421
16030715120104 1/1/2013 6/30/2015 421
16030715120125 6/1/2010 6/30/2012 421
16030715120204 12/1/2000 6/30/2003 421
16030715120204 5/1/2004 6/30/2006 421
16030715120204 10/1/2006 6/30/2009 421
16030715120204 1/1/2013 6/30/2015 421
16030715120225 6/1/2010 6/30/2012 421
160307151203 5/1/1994 429
160307151203 2/1/2001 10200
16030715120325 4/1/2004 6/30/2006 421
16030715120325 10/1/2006 6/30/2009 421
16030715120325 1/1/2010 6/30/2012 421
16030715120325 10/1/2012 6/30/2015 421
160307151204 5/1/1994 429
160307151204 2/1/2001 10200
16030715120425 4/1/2004 6/30/2006 421
16030715120425 10/1/2006 6/30/2009 421
16030715120425 1/1/2010 6/30/2012 421
16030715120425 10/1/2012 6/30/2015 421
160307151205 7/1/1996 2/28/2001 10005
16030715120502 12/1/2000 6/30/2003 421
16030715120502 10/1/2003 6/30/2006 421
16030715120502 3/1/2009 6/30/2011 421
16030715120502 12/1/2011 6/30/2014 421
160307151206 7/1/1996 2/28/2001 10005
16030715120602 12/1/2000 6/30/2003 421
16030715120602 10/1/2003 6/30/2006 421
16030715120602 3/1/2009 6/30/2011 421
16030715120602 12/1/2011 6/30/2014 421
160307151207 7/1/1996 6/30/2014 10005
160307151207 7/1/2014 10010
16030715120702 12/1/2000 6/30/2003 421
16030715120702 10/1/2003 6/30/2006 421
16030715120702 3/1/2009 6/30/2011 421
16030715120702 12/1/2011 6/30/2014 421
16030719705/26/1995 7/31/1999 170
160307197001 7/1/1996 10030
160307197003 7/1/1996 10200
16030719700301 2/1/2000 6/30/2001 400
160307197004 2/1/2001 10200
16030719700401 2/1/2000 6/30/2001 400
160307197025 6/1/2000 10030
16030719702525 11/1/2000 6/30/2002 421
16030719702525 10/1/2003 6/30/2006 421
16030719702525 10/1/2007 6/30/2010 421
16030719702525 12/1/2010 6/30/2013 421
160307197026 12/1/2013 1405
160307197026 12/1/2013 10020
16030719702625 11/1/2000 6/30/2002 421
16030719702625 10/1/2003 6/30/2006 421
16030719702625 10/1/2007 6/30/2010 421
16030719702625 12/1/2010 6/30/2013 421
160307197027 7/1/1996 10200
160307197027 10/1/2001 429
16030719702725 3/1/2002 6/30/2004 421
16030719702725 10/1/2004 6/30/2007 421
16030719702725 1/1/2008 6/30/2010 421
16030719702725 10/1/2010 6/30/2013 421
16030719702725 5/1/2014 6/30/2016 421
160307197028 7/1/1996 ######## 10200
160307197028 10/1/2001 429
160307197028 12/1/2013 1405
160307197028 12/1/2013 10300
16030719702825 3/1/2002 6/30/2004 421
16030719702825 10/1/2004 6/30/2007 421
16030719702825 1/1/2008 6/30/2010 421
16030719702825 10/1/2010 6/30/2013 421
16030719702825 5/1/2014 6/30/2016 421
16030719985/26/1995 7/31/1999 170
160307204601 7/1/1996 2/28/2001 10005
160307204602 7/1/1996 10005
16030720460201 12/1/2002 6/30/2005 421
16030720460201 10/1/2005 6/30/2008 421
16030720460201 1/1/2009 6/30/2011 421
16030720460201 12/1/2011 6/30/2014 421
160307398825 1/1/2013 10005
160310182810/1/2003 522
160310182801 7/1/2013 1355
160310224101 7/1/1996 2/28/2001 10030
16031024235/16/1994 5/31/1999 69
160310252910/1/2003 522
160310252901 7/1/1996 10030
160310252903 10/4/1997 10030
16031025290302 12/1/2000 4/30/2001 421
160310252904 10/4/1997 10030
16031025290401 12/1/2000 6/30/2003 421
16031025290401 10/1/2003 6/30/2006 421
16031025290401 10/1/2011 6/30/2014 421
1603103999 4/1/2013 1332
16031039992525 4/1/2013 29
16031039992525 4/1/2013 429
160313 9/1/2002 5029
160313125906 7/1/1996 24
16031312616/22/1995 24
16031313035/16/1994 ######## 24
160313130301 11/1/1999 ######## 504
160313130301 12/1/2008 944
16031313030101 1/1/2003 6/30/2005 421
16031313030101 10/1/2005 6/30/2008 421
16031313030125 8/1/2012 6/30/2013 421
16031313030125 11/1/2013 6/30/2016 421
160313130302 5/1/1994 429
160313130302 11/1/1999 233
160313130303 11/1/1999 24
16031313030301 1/1/2003 6/30/2005 421
16031313030301 10/1/2005 6/30/2008 421
16031313030301 10/1/2013 6/30/2016 421
16031313465/16/1994 7/31/2010 23
16031313465/16/1994 67
1603131346 1/1/1999 7/31/2010 227
1603131346 8/1/2010 24
16031313460125 1/1/2008 6/30/2010 421
160313136110/1/2003 522
160313136101 5/16/1994 10200
160313136102 5/16/1994 10030
16031313610201 2/1/2003 6/30/2005 421
16031313610201 10/1/2005 6/30/2008 421
16031313610206 11/1/1999 6/30/2002 421
160313136104 1/1/1999 10200
16031313610401 11/1/1999 6/30/2002 421
16031313610401 12/1/2002 6/30/2005 421
16031313610401 10/1/2005 6/30/2008 421
160313154601 5/26/1995 7/31/2010 23
160313154601 1/1/1999 7/31/2010 227
160313154601 8/1/2010 24
16031315460101 10/1/2003 6/30/2006 421
16031315460101 4/1/2013 1299
160313154602 5/26/1995 23
160313154602 1/1/1999 227
160313154603 5/26/1995 7/31/2010 23
160313154603 5/26/1995 518
160313154603 1/1/1999 7/31/2010 227
160313154603 8/1/2010 24
160313155401 5/16/1994 ######## 67
160313155401 1/1/1999 7/31/2010 227
160313155401 11/1/1999 6/30/2013 505
160313155401 7/1/2013 1356
160313155402 5/16/1994 ######## 67
160313155402 1/1/1999 7/31/2010 227
160313155402 11/1/1999 6/30/2013 505
160313155402 7/1/2013 1356
16031315540225 3/1/2013 29
16031315540225 4/1/2013 429
160313155403 5/16/1994 ######## 67
160313155403 1/1/1999 7/31/2010 227
160313155403 11/1/1999 6/30/2013 505
160313155403 7/1/2013 1356
16031315540301 1/1/2003 6/30/2005 421
16031315540301 9/1/2006 6/30/2009 421
16031315540301 1/1/2010 6/30/2012 421
16031315540301 10/1/2012 6/30/2015 421
16031317206/22/1995 7/31/1999 170
1603131852 1/1/1999 227
160313217101 5/16/1994 ######## 24
160313227401 5/16/1994 67
160313227402 5/16/1994 67
160313227402 1/1/1999 7/31/2010 227
16031322740203 10/1/2011 6/30/2014 421
160313230010/1/2003 522
160313230002 7/1/1996 10030
16031323000202 8/1/1999 6/30/2002 421
16031323000202 12/1/2002 6/30/2005 421
16031323000202 1/1/2006 6/30/2008 421
16031323000202 1/1/2009 6/30/2011 421
16031323145/16/1994 ######## 71
1603132314 1/1/1999 7/31/2010 227
160313231411/1/1999 6/30/2013 506
1603132314 7/1/2013 1357
16031323140101 12/1/2001 6/30/2004 421
16031323140201 12/1/2001 6/30/2004 421
16031323140301 12/1/2001 6/30/2004 421
16031323140325 7/1/2006 6/30/2008 421
16031323140325 1/1/2009 6/30/2011 421
16031323140325 10/1/2011 6/30/2014 421
160313244002 5/16/1994 68
16031325486/22/1995 23
1603132819 4/1/2013 4/30/2013 1300
1603132819 5/1/2013 1344
160313281901 5/26/1995 9/30/2005 24
160313281901 10/1/2005 10005
16031328190125 5/1/2003 6/30/2005 421
16031328190125 10/1/2005 6/30/2008 421
16031328190125 3/1/2012 6/30/2014 421
16031328190126 4/1/2009 6/30/2011 421
160313281902 5/26/1995 9/30/2005 24
160313281902 10/1/2005 10005
16031328190225 5/1/2003 6/30/2005 421
16031328190225 10/1/2005 6/30/2008 421
16031328190225 3/1/2012 6/30/2014 421
16031328190226 4/1/2009 6/30/2011 421
160313281903 5/26/1995 3/31/2013 24
16031328190325 5/1/2003 6/30/2005 421
16031328190325 10/1/2005 6/30/2008 421
16031328190325 3/1/2012 6/30/2014 421
16031328190326 4/1/2009 6/30/2011 421
160313392512/1/2010 6/30/2013 1065
1603133925 1/1/2011 549
1603133925 7/1/2013 1358
1603133932 2/1/2011 24
1603133932 4/1/2013 1302
16031339322525 2/1/2011 3/31/2011 29
1603133992 4/1/2013 1328
16031339922525 4/1/2013 29
16031339922525 4/1/2013 429
1603133993 4/1/2013 1331
16031339932525 4/1/2013 29
16031339932525 4/1/2013 429
1603133998 4/1/2013 1324
16031339982525 4/1/2013 29
16031339982525 4/1/2013 429
1604 9/1/2002 5012
1604 9/1/2002 5013
16040115135/16/1994 23
1604011513 1/1/1999 7/31/2005 226
1604011513 8/1/2005 227
160401169601 5/16/1994 24
160401169601 4/1/2013 6/30/2014 1303
160401169601 7/1/2014 14
160401169601 7/1/2014 1455
16040116960101 8/1/2004 6/30/2007 421
16040116960101 1/1/2014 29
16040116960101 1/1/2014 429
16040118815/18/1995 9/30/1999 163
160401188106 5/16/1994 9/30/1999 75
160401188125 5/16/1994 9/30/1999 76
16040118812502 11/1/2004 6/30/2007 421
16040118812502 1/1/2007 3/31/2010 29
16040118812502 10/1/2007 6/30/2010 421
16040118812502 12/1/2010 6/30/2013 421
160401188126 5/16/1994 9/30/1999 76
16040118812601 9/1/2004 6/30/2007 421
16040118812601 10/1/2007 6/30/2010 421
16040118812601 12/1/2010 6/30/2013 421
16040127095/16/1994 7/31/2010 23
1604012709 1/1/1999 7/31/2005 226
1604012709 8/1/2005 7/31/2010 227
1604012709 8/1/2010 5/31/2011 24
160401270901 6/1/2011 24
16040127090125 3/1/2006 6/30/2008 421
16040127090125 10/1/2008 6/30/2011 421
16040127090126 4/1/2012 6/30/2014 421
160401270902 6/1/2011 ######## 1132
160401270902 6/1/2011 6/30/2011 1133
160401270902 7/1/2011 ######## 1140
160401270902 12/1/2011 1172
160401270902 12/1/2011 1173
16040127090225 3/1/2006 6/30/2008 421
16040127090225 10/1/2008 6/30/2011 421
16040127090226 4/1/2012 6/30/2014 421
160401270903 6/1/2011 24
16040127090325 3/1/2007 6/30/2008 421
16040127090325 10/1/2008 6/30/2011 421
16040127090326 4/1/2012 6/30/2014 421
160401270925 8/1/2011 429
160401270925 8/1/2011 6/30/2013 1148
160401270925 7/1/2013 1359
16040128035/16/1994 7/31/2010 23
1604012803 1/1/1999 7/31/2005 226
1604012803 8/1/2005 7/31/2010 227
1604012803 8/1/2010 3/31/2013 24
160401280301 4/1/2013 4/30/2013 1339
160401280301 5/1/2013 1346
16040128030101 9/1/2007 6/30/2010 421
16040128030125 5/1/2011 6/30/2013 421
16040128030125 11/1/2013 6/30/2016 421
160401280325 4/1/2013 1322
16040128305/27/1995 8/31/2005 23
1604012830 1/1/1999 8/31/2005 226
1604012830 6/1/2012 522
160401283001 12/1/2011 10
16040128300126 12/1/2006 6/30/2008 421
16040128300126 10/1/2008 6/30/2011 421
16040128300127 2/1/2012 6/30/2014 421
160401397811/1/2012 1273
160401397827 11/1/2012 429
1604013989 1/1/2013 1285
161001128010/1/2003 522
16100120735/16/1994 8/31/1998 23
1610014002 4/1/2013 1326
16100140022525 4/1/2013 29
16100140022525 4/1/2013 429
161204207910/1/2003 522
161204207901 11/1/1997 370
16120420790104 12/1/2000 6/30/2003 421
16120420790104 10/1/2003 6/30/2006 421
16120420790104 10/1/2006 6/30/2009 421
161204207902 11/1/1997 370
16120420790205 12/1/2000 6/30/2003 421
16120420790205 10/1/2003 6/30/2006 421
16120420790205 10/1/2006 6/30/2009 421
16120420790205 1/1/2010 6/30/2012 421
161301182001 7/1/1996 10030
16130118200102 11/1/1999 6/30/2002 421
16130118200102 9/1/2004 6/30/2007 421
16130118200202 11/1/1999 6/30/2002 421
16130118200202 9/1/2004 6/30/2007 421
16130119060101 12/1/2001 6/30/2004 421
161601 5/16/1994 856
16160112095/16/1994 7/31/1997 24
Trial Version
Not all rows exported
Code Memoranda
6 Special Authority for Subsidy - Form SA0006Initial application from any medical practitioner. Approvals valid for 5 years where the patient is likely to benefit from treatment. Renewal from any medical practitioner. Approvals valid for 5 years where the treatment remains appropriate and the patient is benefiting from treatment.
9 In combination
10 Pharmaceutical with a standardised formula for compounding in Ora products
11 Special Authority for Subsidy - Form SA0011Initial application only from a relevant specialist. Approvals valid for 2 years where the patient has diabetes. Renewal only from a relevant specialist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
14 Pharmaceutical Cancer Treatment in respect of which DHB hospital pharmacies and other Contractors can claim Subsidies.
15 Pharmaceutical Cancer Treatment in respect of which only DHB hospital pharmacies can claim Subsidies.
21 Month Restriction
22 Only on a prescription
23 Hospital Pharmacy - Specialist
24 Retail Pharmacy - Specialist
25 Specialist
26 Maximum daily dose of 400 mg
27 a) Only on a prescription. b) Not as an effervescent or dispersible tab.
28 Special Authority for Subsidy - Form SA0028Initial application only from a relevant specialist. Approvals valid for 6 months for applications meeting the following criteria: Either: 1 All of the following: 1.1 Treatment with other lipid modifying medicines has been unsuccessful; and 1.2 6 months of dietary modification has been unsuccessful; and 1.3 Cholesterol level > 7.0 mmol/litre; and 1.4 Either: 1.4.1 Familial hypercholesterolaemia; or 1.4.2 Manifest coronary heart disease, which has been clinically proven, or previously treated by coronary artery surgery; or 2 Cholesterol level > 9.0 mmol/litre:.Renewal only from a general practitioner. Approvals valid for 6 months where the treatment remains appropriate and the patient is benefiting from treatment. NoteFamilial hypercholesterolaemia is defined as being hypercholesterolaemia in the presence of tendon xanthomas or in association with a family history of premature heart disease (before age 55) or consisten
29 Unapproved medication supplied under Section 29 of the Medicines Act 1981. Practitioners prescribing this medication should: (a) be aware of and comply with their obligations under Section 29 of the Medicines Act 1981 and otherwise under that Act and the Medicines Regulations 1984; (b) be aware of and comply with their obligations under the Health and Disability Commissioner's Code of Consumer Rights, including the requirement to obtain informed consent from the patient (PHARMAC recommends that Practitioners obtain written consent); and(c) exercise their own skill, judgment, expertise and discretion, and make their own prescribing decisions with respect to the use of an unapproved Pharmaceutical or a Pharmaceutical for an indication for which it is not approved.
30 Maximum daily dose of 150 mg
31 Special Authority for Subsidy - Form SA0031Initial application from any medical practitioner. Approvals valid for 2 years for applications meeting the following criteria: Any of the following: 1 Oesophageal stricture; or 2 Terminal care; or 3 Too young to swallow conventional tablets; or 4 Too old to swallow conventional tablets. Renewal from any medical practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
32 Maximum daily dose of 50 mg
33 a) When ordered by a medical practitioner on a practitioner's supply order for ventricular arrhythmias and the order is endorsed accordinglyb) When ordered for a dialysis patient or a child with rhumatic fever and the order is endorsed accordingly
34 Additional Subsidy by Special Authority available to fully fund to the level of the lowest priced TDDS brand within the medium dose oestrogens.
35 Special Authority for Manufacturers Price - Form SA0035Initial application from any medical practitioner. Approvals valid for 5 years for applications meeting the following criteria: Both: 1 Either: 1.1 Both: 1.1.1 Duodenal and gastric ulcers, reflux oesophagitis and Zollinger-Ellison syndrome; and 1.1.2 Other treatments have failed; or 1.2 Patients who are on a Social Welfare benefit or an income no greater than a benefit; and 2 Patients must have endoscopically demonstrated lesions prior to commencement of treatment.. Renewal from any medical practitioner. Approvals valid for 5 years where the treatment remains appropriate and the patient is benefiting from treatment.
36 restricted to children under seven years of age
37 Maximum daily dose of 400 mg
38 Only as tablets
39 Not more than 30 patches per month
40 Only as capsules
41 Special Authority for Subsidy - Form SA0041Initial application only from a relevant specialist. Approvals valid for 2 years where alternative antihypertensives have failed. Renewal only from a relevant specialist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
42 Maximum daily dose of 20 mg
43 Note: Danthron with poloxamer is only approved for the prevention or treatment of constipation in the terminally ill. Studies in rats have associated use of danthron with tumours.
44 Oral use only
45 Special Authority for Subsidy - Form SA0045Initial application from any medical practitioner. Approvals valid for 2 years for applications meeting the following criteria: All of the following: 1 Continuation of treatment commenced prior to 1 August 1990; and 2 Alternatives (salbutamol and terbutaline) have been tried; and 3 Either: 3.1 Asthma; or 3.2 Chronic obstructive airways disease (COAD); and 4 Applicants must provide details of dose. Renewal from any medical practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
46 Special Authority for Subsidy - Form SA0046Initial application only from a gastroenterologist. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 Functioning gall bladder; and 2 Either: 2.1 Uncalcified gallbladder stones with a maximum size of 20 mm; or 2.2 Adjunctive treatment after extra corporeal lithotrypsy. Renewal only from a gastroenterologist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
47 Special Authority for Subsidy - Form SA0047Initial application only from a paediatrician or respiratory specialist. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 Child under 2 years of age; or 2 Both: 2.1 Child with major physical or intellectual disabilities; and 2.2 Lacks the necessary coordination to use aerosols with a spacer device. NoteThe cost of nebuliser therapy greatly exceeds other inhaled forms. Steroid nebulising solution can cause cataract formation. Renewal only from a paediatrician or respiratory specialist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
48 Not in combination
49 For terminal care patients, usually those in a hospice. Diagnosis needs to be provided.
50 Special Authority for Subsidy - Form SA0050Initial application only from a relevant specialist. Approvals valid for 2 years where terminally ill patient. Renewal only from a relevant specialist. Approvals valid for 2 years where terminally ill patient.
51 Special Authority for Subsidy - Form SA0051Initial application from any medical practitioner. Approvals valid for 6 months where control of nausea in the treatment of malignant disease. Renewal from any medical practitioner. Approvals valid for 6 months where the treatment remains appropriate and the patient is benefiting from treatment.
53 Special Authority for Subsidy - Form SA0053Initial application only from a relevant specialist. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 RAST or skin test positive; and 2 Patient has had severe generalised reaction to the sensitising agent. Renewal only from a relevant specialist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
54 Only on a prescrition when prescribed for prophylaxis of asthma
55 Special Authority for Subsidy - Form SA0055Initial application only from a psychiatrist, geriatrician or respiratory specialist. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 For use only as an anxiolytic; and 2 Other agents are contraindicated or have failed. Renewal only from a psychiatrist, geriatrician or respiratory specialist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
56 Special Authority for Subsidy - Form SA0056Initial application only from a psychiatrist. Approvals valid for 5 years for applications meeting the following criteria: Both: 1 Long-standing delusional states; and 2 Other injectable anti-psychotics have proven to be ineffective or inappropriate. Renewal only from a psychiatrist. Approvals valid for 5 years where the treatment remains appropriate and the patient is benefiting from treatment.
57 Special Authority for Subsidy - Form SA0057Initial application only from a psychiatrist. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 Depression; and 2 Any of the following: 2.1 Both: 2.1.1 Failed trials with other antidepressants; and 2.1.2 Patient has been maintained on mianserin prior to December1993; or 2.2 Co-existent bladder neck obstruction; or 2.3 Cardiovascular disease. Renewal only from a psychiatrist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
58 Maximum of 1 patch per week.
59 In a quantity not exceeding 3 tablets per prescription
60 Not more than 6 tablets per month
61 Only on a PSO
62 Only on a prescription.
63 PSO must be endorsed 'not for anaesthetic procedures'.
64 Not more than 2 per dispensing
66 Precriber needs approval from the Minister of Health
67 Subsidised only if prescribed for dialysis or cystic fibrosis patient and the prescription is endorsed accordingly
68 Injections (both 500 mg and 1 g) subsidised: a) only if prescribed for a dialysis or cystic fibrosis patient; and b) the prescription is endorsed accordingly.
69 Special Authority for Subsidy - Form SA0069Initial application only from a general physician, nephrologist or neurologist. Approvals valid for 5 years where syndrome of inappropriate anti-diuretic hormone secretion (SIADH). Renewal only from a general physician, nephrologist or neurologist. Approvals valid for 5 years where the treatment remains appropriate and the patient is benefiting from treatment.
70 Special Authority for Manufacturers Price - Form SA0070Initial application only from a respiratory specialist or infectious disease specialist. Approvals valid for 2 years for applications meeting the following criteria: Any of the following: 1 Avium intracellular atypical mycobacterial infections; or 2 Multiple drug resistant tuberculosis; or 3 Atypical and drug-resistant mycobacterial infections in patients with AIDS. Renewal only from a respiratory specialist or infectious disease specialist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
71 Only if prescribed for a dialysis or cystic fibrosis patient or in the treatment of pseudo membranous colitis and the prescription is endorsed accordingly
73 Not exceeding 30 ml per person.
74 Not exceeding 6 tab per person.
75 a) Maximum of one pack per month of oral powder.
76 Maximum of 42 cap or tab per prescription.
77 a) Only granted after the patient has proven to be intolerant to zidovudine or whose health has significantly deteriorated while on zidovudine. It is impossible to have approvals for both AZT and DDI concurrently but it is not expected that both medicines would be consumed at the same time. Applications can be made without patients having had a preliminary trialb) Specialist must make application
78 a) Approvals granted as third line therapy after patient has developed intolerance or treatment failure to both zidovudine and DDI b) Specialist must make application
79 a) All patients with AIDS meeting the definition developed by the Centres for Disease Control in the USA (see Circular Letter to Medical Practitioners HP2/88)b) Patients with AIDS Related Complex (ARC)c) HIV infected patients with CD4 (T4) counts below 500 regardless of symptomatologyd) Prophylactically for persons following severe parenteral exposure from a known HIV positive sourcee) HIV infected persons with associated thrombocytopenia regardless of CD4 (T4) count f) Applications can only be made by appropriate specialists. Prescriptions for those patients approved to use these medicines can be written either by the specialist or general practitioner with an endorsement of the name of the recommending specialist. g) Prescriptions for these can be written for a period of three months' supply. However, medicine must be dispensed on a monthly basis.
80 NOTE: Evidence that a patient is on insulin therapy can be by way of either: a) insulin being on the same prescription ofb) by the word "insulin patient" be in written on the prescription by either the doctor or the contractor.
81 All non-disposible diabetic supplies are only eligible for subsidy if there is produced to the contractor a certificate the gives the nome, address, and age of the patient and that:1) is signed by a doctor and2) is dated less than two years propr to the date of supply; and that 3) states that the patient is receiving iusulin therapy.
82 Only on a WSO
83 Additional Subsidy by Special Authority available to fully fund to the level of the lowest priced TDDS brand within the low dose oestrogens.
84 Additional Subsidy by Special Authority available to fully fund to the level of the lowest priced TDDS brand within the medium dose oestrogens.
85 Special Authority for Subsidy - Form SA0085Initial application from any medical practitioner. Approvals valid for 5 years where the patient is likely to benefit from treatment. Renewal from any medical practitioner. Approvals valid for 5 years where the treatment remains appropriate and the patient is benefiting from treatment.
86 a) Males: Fertile eunuch syndrome, females: anovulatory infertilityb) A declaration is required from the applying doctor that these agents are not being used as part of an IVF programmec) Approvals are valid for 6 months with a revewal for a further 6 months if the patient has some response and the prescriber believes further treatment will be effectived) Specialist must make application - endocrinologists and gynaecologists only
87 Special Authority for Subsidy - Form SA0087Initial application only from an endocrinologist or gynaecologist. Approvals valid for 6 months where hypogonadotrophic hypogonadism (including anovulatory infertility and cryptochidism). Renewal only from an endocrinologist or gynaecologist. Approvals valid for 6 months where the treatment remains appropriate and the patient is benefiting from treatment.
88 Special Authority for Subsidy - Form SA0088Initial application only from an endocrinologist or gynaecologist. Approvals valid for 6 months for applications meeting the following criteria: Both: 1 Either: 1.1 Female with anovulatory infertility, males: hypogonadotrophic hypogonadism; or 1.2 Male with hypogonadotrophic hypogonadism; and 2 These agents are not being used as part of an IVF programme. Renewal only from an endocrinologist or gynaecologist. Approvals valid for 6 months where the treatment remains appropriate and the patient is benefiting from treatment.
89 Special Authority for Subsidy - Form SA0089Initial application - (Breast or prostatic cancer) only from an oncologist, urologist or endocrinologist. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 Breast cancer in pre menopausal women unwilling or unable to undergo surgical or radiation oophorectomy; or 2 Advanced prostatic cancer when orchidectomy is contraindicated. Initial application - (Endometriosis) only from a gynaecologist. Approvals valid for 6 months for applications meeting the following criteria: Both: 1 Endometriosis; and 2 Either: 2.1 6 months treatment with medroxyprogesterone acetate, danazol or dimetriose has proven ineffective; or 2.2 The patient has failed to tolerate the treatment with medroxyprogesterone acetate, danazol or dimetriose for 6 months. NoteThe maximum treatment period for a GnRH analogue is: 3 months to assess whether surgery is appropriate3 months for infertile patients after surgery6 months for
90 Special Authority for Subsidy - Form SA0090Initial application only from a relevant specialist. Approvals valid for 2 years where patient cannot use desmopressin nasal spray or nasal drops. Renewal only from a relevant specialist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
91 Special Authority for Subsidy - Form SA0091Initial application only from a relevant specialist. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 Paget's disease; or 2 Both: 2.1 Patients under hospice care; and 2.2 Either: 2.2.1 Tumour-induced hypercalcaemia; or 2.2.2 Tumour-induced osteolysis without hypercalcaemia. Renewal only from a relevant specialist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
92 Special Authority for Subsidy - Form SA0092Initial application only from a relevant specialist. Approvals valid for 5 years where treatment of refractory absorptive hypercalcaemia. Renewal only from a relevant specialist. Approvals valid for 5 years where the treatment remains appropriate and the patient is benefiting from treatment.
94 Special Authority for Subsidy - Form SA0094Initial application only from a relevant specialist (Only for Epsom Day Unit in Auckland). Approvals valid for 1 month where termination of advanced pregnancy i.e. beyond 12 weeks. Only for Epsom Day Unit in Auckland.
95 Only on a prescription.
96 Special Authority for Subsidy - Form SA0096Initial application - (Organ transplant, Bone marrow transplant or Graft v host disease) only from a relevant specialist. Approvals valid for 2 years for applications meeting the following criteria: Any of the following: 1 Organ transplant; or 2 Bone marrow transplant; or 3 Graft v host disease. Initial application - (Psoriasis) only from a dermatologist. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 Psoriasis; and 2 Other systemic and topical therapy has failed. Initial application - (Severe atopic dermatitis) only from a dermatologist. Approvals valid for 6 months for applications meeting the following criteria: Both: 1 Severe atopic dermatitis; and 2 Not resopnsive to topical therapy, oral antihistamines and other commonly used orthodox therapies. Initial application - (Nephrotic Syndrome) from any medical practitioner. Approvals valid for 2 years for applications meeting the following cri
97 Special Authority for Subsidy - Form SA0097Initial application - (Chronic hepatitis C) only from a relevant specialist. Approvals valid for 6 months where chronic hepatitis C. Initial application - (Indications other than Chronic hepatitis C) only from a relevant specialist. Approvals valid for 5 years for applications meeting the following criteria: Any of the following: 1 Chronic myelogenous leukaemia; or 2 Hairycell leukaemia; or 3 Cutaneous T cell lymphoma; or 4 Essential thrombocythaemia; or 5 AIDS related Kaposi's sarcoma; or 6 Multiple myeloma; or 7 Chronic active hepatitis B. Renewal - (Chronic hepatitis C) only from a relevant specialist. Approvals valid for 6 months where the treatment remains appropriate and the patient is benefiting from treatment. Renewal - (Indications other than Chronic hepatitis C) only from a relevant specialist. Approvals valid for 5 years where the treatment remains appropriate and the patient is benefiting from treatment.
98 a) Hairy cell leukaemia, Kaposi's sarcoma, chronic active hepatitis B, chronic hepatitis C (6 month approval only), chronic myelogenous leukaemia, multiple myelomab) Specialist must make applicationc) No further approvals for:Malignant melanoma, superficial and noduloulcerative basal cell carcinomaNote: Patients with existing approvals can continue to have therapy
99 Special Authority for Subsidy - Form SA0099Initial application only from a relevant specialist. Approvals valid for 5 years for applications meeting the following criteria: Any of the following: 1 Both: 1.1 Acromegaly; and 1.2 Patients who have failed surgery, radiotherapy, bromocriptine and other oral therapies; or 2 Both: 2.1 Either: 2.1.1 Vipomas; or 2.1.2 Glucagonomas; and 2.2 Patients who are seriously ill in order to improve their clinical state prior to definitive surgery; or 3 Both: 3.1 Gastrinoma; and 3.2 Either: 3.2.1 Patient has failed surgery; or 3.2.2 Patient is in metastatic disease after H2 antagonists (or omeprazole) have failed; or 4 Both: 4.1 Insulinomas; and 4.2 Surgery is contraindicated or where surgery has failed; or 5 Pre-operative control of hypoglycaemia; or 6 Maintenance therapy. NoteThe use of octreotide in patients with fistulae, oesophageal varices, miscellaneous diarrhoea and hypotension will
100 Special Authority for Subsidy - Form SA0100Initial application only from a relevant specialist. Approvals valid for 5 years for applications meeting the following criteria: All of the following: 1 Anaemia of end-stage renal failure (other treatable causes of anaemia being excluded); and 2 Been on haemodialysis or continuous ambulatory peritoneal dialysis (CAPD) for at least three months; and 3 Not under evaluation for, or awaiting, a live donor kidney transplant; and 4 Any of the following: 4.1 Anephric; or 4.2 Dependent on regular blood transfusion (1 unit each 4-8 weeks) to maintain haemoglobin > 60g/L; or 4.3 Cannot be transfused because of severe transfusion reactions; or 4.4 Transfusion induced haemosiderosis (clinical manifestations, serum ferritin >1500 ug/L); or 4.5 Haemoglobin < 70 g/L (mean of at least 4 haemoglobin concentrations over 4 months); or 4.6 Both: 4.6.1 Haemoglobin < 90 g/L; and 4.6.2 Either: 4.6.2.1 Heart failure (low card
101 Maximum of 2 patches per week.
102 Only in quantities of 50 ml or less per unit
103 a) Maximum of 50 mls per unit b) On a prescription or practitioner's supply order only when on the same form as an injection listed in the Pharmaceutical Schedule requiring a solvent or diluent c) On a bulk supply orderd) When used in the extemporaneous compounding of eye drops
104 Not exceeding a strength of 50 mg per dose.
105 Not exceeding a strength of 50 mg per dose.
106 Only on a prescription.
107 Maximum of 1 pack (10 patches and 12 tablets) per month.
108 Special Authority for Subsidy - Form SA0108Initial application only from a relevant specialist. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 Hairy cell leukaemia; or 2 Chronic active hepatitis B. Renewal only from a relevant specialist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
109 Only on a prescription.
110 Special Authority for Subsidy - Form SA0110Initial application only from a relevant specialist. Approvals valid for 5 years where biotinidase deficiency. Renewal only from a relevant specialist. Approvals valid for 5 years where the treatment remains appropriate and the patient is benefiting from treatment.
111 Not exceeding a strength of 50 mg per dose.
112 Maximum 4 tablets per day
113 Not exceeding a strength of 100 mg per dose.
114 Not exceeding a strength of 10 mg per dose.
115 Special Authority for Subsidy - Form SA0115Initial application - (Oesophageal stricture) only from a general practitioner or relevant specialist. Approvals valid for 2 years where patient with oesophageal stricture who is unable to take capsules. Initial application - (Indications other than oesophageal stricture) only from a paediatrician. Approvals valid for 2 years for applications meeting the following criteria: All of the following: 1 infant or child with liver disease or short gut syndrome; and 2 Requires vitamin supplementation; and 3 Unable to swallow capsules. Renewal only from a general practitioner, relevant specialist or paediatrician. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
116 Only on a prescription
117 Maximum of 30 capsules per month
118 If not more than 3 months supply is prescribed
119 Special Authority for Subsidy - Form SA0119Initial application only from a rheumatologist. Approvals valid for 5 years where ankylosing spondylitis. Renewal only from a rheumatologist. Approvals valid for 5 years where the treatment remains appropriate and the patient is benefiting from treatment.
120 Maximum of 1% strength
121 Special Authority for Subsidy - Form SA0121Initial application from any medical practitioner. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 Patient has to use an unpreserved solution due to an allergy to the preservative; or 2 Patient wears soft contact lenses. NoteMinims for a general practice are considered to be "tools of trade" and are not approved as special authority items. Renewal from any medical practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
122 Special Authority for Subsidy - Form SA0122Initial application only from a relevant specialist. Approvals valid for 2 years where filamentary keratitis. Renewal only from a relevant specialist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
123 Only on a prescription.
124 Retail Pharmacy - Specialist prescription
125 Special Authority for Subsidy - Form SA0125Initial application - (Chronic post-thrombotic venous stasis ulcers) from any medical practitioner. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 Chronic post-thrombotic venous stasis ulcers of more than 4 months duration; and 2 Other interventions have failed. Initial application - (Sudden hearing loss) only from an otolaryngologist. Approvals valid for 2 years where sudden hearing loss. Renewal from any medical practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
126 a) Subsidised only if prescribed for an amputee with an artificial limb, or for a paraplegic patient; andb) On a prescription endorsed accordingly.
127 When prescribed in a quantity not exceeding 15 g per prescription
128 Not when prescribed as a contraceptive
129 b) When prescribed in a quantity not exceeding 3.5 ml per prescription.
130 Only on a prescription.
131 a) With other pharmaceutical requirementsb) In extemporaneously compounded preparations.
132 Only on a prescription.
133 a) Should be strictly reserved for use as second line therapy in: - patients unable to tolerate the other medications, such as infants, young children and patients with allergies or eczema- cases of scabies which are resistent to gamma benzene hexachlorideb) Verification of drug resistance is dependent on the persistence of the condition after treatment. In order to establish whether there is drug resistance, the following criteria should be fulfilled: - a definite diagnosis of scabies should be made- it should be ascertained that the medication was administered properly- the possibility of reinfestation should have been excluded
134 Maximum of 100 g per prescription.
135 Only on a prescription.
136 Only on a prescription.
137 Maximum of 14 g per prescription.
138 Special Authority - Hospital pharmacya) Approvals granted only for children receiving chemotherapyb) Specialist must make application
139 Only on a prescription.
140 Special Authority for Subsidy - Form SA0140Initial application only from a relevant specialist. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 Pain management in the terminally ill; and 2 Standard therapy has failed. Renewal only from a relevant specialist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
141 Not on a bulk supply order
142 Maximum 3.5 ml per prescription.
143 Only on a prescription.
144 Only on a WSO. Distributed by the Asthma Foundation. Forward orders to: The Asthma Foundation, PO Box 1459, Wellington. Distributed by the Asthma Foundation. Also available to paediatricians employed by an HHS, on a wholesale supply order signed by the paediatrician. Orders via a hospital pharmacy.
145 Only available for children aged six years and under.
146 Only when dispensed as an ingredient in a preparation specified in the Pharmaceutical Schedule. Industrial - In combination
147 Only on a prescription.
148 Maximum of 100 ml per prescription.
149 Only on the prescription of a practitioner.
150 Approvals for a CHEM number to waive the premium in the following circumstances: 1. Patients with prosthetic heart valves - as an adjunct to oral anticoagulation for prophylaxis of thromboembolism (2 year approval with renewal, applications only from cardiothoracic surgeons, cardiologists and general physicians). 2. Patients after coronary artery vein bypass graft - as an adjunct to aspirin (1 year approval only, applications only from cardiothoracic surgeons, cardiologists and general physicians). 3. Patients who continue to have transient ischaemic episodes despite aspirin therapy. A course of up to six months in combination with aspirin. Applications only from neurologists, cardiologists, vascular surgeons and general physicians. Six month approval only. Reapplications only if there is demonstrated recurrence of symptoms when dipyridamole therapy is discontinued. Note: these transitional criteria are currently being reviewed.
151 Only on a WSO.
152 Only on a prescription.
153 a) Approvals to fund the manufacturer's surcharge in the following circumstances: - Patients with prosthetic heart valves - as an adjunct to oral anticoagulation for prophylaxis of thromboembolism (2 year approval with renewal, applications only from cardiothoracic surgeons, cardiologists and general physicians). - Patients after coronary artery vein bypass graft - as an adjunct to aspirin or as monotherapy for patients who are aspirin intolerant as defined below (1 year approval only, applications only from cardiothoracic surgeons, cardiologists and general physicians); or- Patients who continue to have transient ischaemic episodes despite aspirin therapy or have transient ischaemic episodes and are aspirin intolerant as defined below (2 year approval with renewal, applications only from neurologists, neurosurgeons, cardiologists, vascular surgeons and general physicians). b) Aspirin intolerant patients are defined as those with aspirin induced asthma, urticaria, or anaphylaxi, or those with significant
154 Only on a BSO.
155 Subsidised only for patients with ventricular arrhythmia and PSO is endorsed accordingly.
156 Maximum of 2 patches per week.
157 Special Authority for Manufacturers Price - Form SA0157Initial application from any medical practitioner. Approvals valid for 5 years for applications meeting the following criteria: Any of the following: 1 Liver disease; or 2 Past history of thromboembolism; or 3 Significant hypertension; or 4 Hypertension associated with oral oestrogen therapy. Renewal from any medical practitioner. Approvals valid for 5 years where the treatment remains appropriate and the patient is benefiting from treatment.
158 When ordered with a spermicide
159 Tablets only when prescribed for a dialysis patient
160 Only in 36 tab pack or packs
161 Only on a prescription.
162 Only as an injection
163 Not as a sterile powder
164 Maximum of 2 patches per week.
165 Only on a prescription.
166 Maximum of 500mls per month
167 Only for a dialysis patient
168 Note: Marevan and Coumadin are not interchangeable
169 Not in any topical form except where explicitly listed in the Pharmaceutical Schedule
170 Not in any topical preparation
171 Subsidy is paid on acyclovir tablets for treatment of herpes zoster and genital herpes. Prescriptions with doses: 1. exceeding 1,600 mg per day for a period of more than one week will not be subsidised; and2. up to 4,000 mg per day for a maximum period of one week will be subsidised.
172 a) Maximum of 6 tablets per prescription; orb) Retail Pharmacy - specialist
173 Not in topical applications
174 Only on a prescription.
175 Special Authority for Waiver of Rule - Form SA0175Initial application only from an obstetrician, endocrinologist or gynaecologist. Approvals valid for 2 years where pathological hyperprolactinemia. Renewal only from an obstetrician, endocrinologist or gynaecologist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
176 Only on a prescription.
177 Only for treatment of uncomplicated urethritis or cervicitis due to chlamydia trachomatis and these patients' sexual contacts. Prescription must be endorsed "certified condition" (typed or handwriten and initialised in the prescriber's own handwriting)
178 Special Authority for Manufacturers Price - Form SA0178Initial application from any medical practitioner. Approvals valid for 6 months where control of nausea and vomiting in the treatment of terminal care patients. Renewal from any medical practitioner. Approvals valid for 6 months where the treatment remains appropriate and the patient is benefiting from treatment.
179 Only on a prescription.
180 Only on a controlled drug form
181 Limited to one pack of 20 per order.
182 Only if prescribed for a dialysis patient and the prescription is endorsed accordingly.
183 Only in combination
184 Maximum of 100 mg per dose
185 Only as extemporaneously compounded mouthwash or shampoo.
186 Not if in any proprietary liquid oral form, unless it is separately specified in the Pharmaceutical Schedule
187 When prescribed (alone or in combination) for home renal dialysis
188 Not available on BSO or to rural doctors on PSO.
189 Only when extemporaneously compounded with idoxuridine
190 Not exceeding 10 ml per prescription
191 Only in extemporaneously compounded preparations, unles separately specified in the Pharmaceutical Schedule
192 only in ephedrine nasal drops BPC
193 - only in combination in oral mixtures
194 Maximum of 10 ml per prescription
195 Only if extemporaneously prepared
196 - only in phenol and hydrogen peroxide gargle
197 Max 2,000 ml per dispensing.
198 Only if prescribed for a dialysis patient and the prescription is endorsed accordingly.
199 Only on the prescription of a practioner, or maternity hospital
200 Maximum of 100 ml per bulk supply order.
201 Not more than 100 ml per prescription
202 - not in lozenges
203 Maximum of 100 ml per prescription.
204 Dietitian may prescribe
205 Maximum of 25 ml
206 Only on the prescription of a doctor
207 Maximum of 1 patch per week.
208 Maternity hospital only
209 Only on a prescription.
210 Restriction of two tablets per prescription.
211 Only on a prescription.
212 except proprietary oral drops
213 Not on a PSO.
214 Not on a Prescription.
215 The new anticonvulsant drugs are restricted to1. neurologists2. paediatric neurologists3. any other prescriber approved in writing by the relevant RHA budget holding manager. The HFA holds a budget for expenditure on the new anticonvulsant drugs. Unless otherwise specified, ultimate authority for approving prescriptions for subsidy lies with the HFA budget holding manager for the new anticonvulsant drugs. The regional divisions of the HFA will be in contact with hospital pharmacists and approved prescribers with more detail of the approval system. GUIDELINES FOR USE OF THE NEW ANTICONVULSANTS ARE AS FOLLOWS: A. Entry criteriaThe following patients are eligible for trial on the new anticonvulsant drugs (NADs)1. Patients who are under the supervision of an approved prescriber, and whose seizures are not adequately controlled with optimal conventional anticonvulsant drug treatment. 2. Patients, who are under the supervision of an approved prescriber, and whose seizures are only controlled adequatel
216 Not on a WSO.
217 Only available on a WSO.
218 Only available on a WSO.
219 Subsidised only if prescribed for patients with uncomplicated urethritis or cervicitis proven or presumed to be due to Chlamydia trachomatis and their sexual contacts and prescription is endorsed "certified condition".
220 Maximum of 3 capsules per dispensing.
221 Restricted to 10 PFMs per order form.
222 For a renal dialysis patient in the home of the patient concerned
223 Maximum of 4 g per prescription, inclusive of repeats.
224 Only if dispensed with a requirement specified in the Pharmaceutical Schedule
225 Available from hospital pharmacies providing an outpatient dispensing service, and selected retail pharmacies in the Northern, Western Bay of Plenty, Wellington, Christchurch or South Canterbury regions that have an exclusive contract to dispense 'Hospital Pharmacy' [HP1] pharmaceuticals.
226 Available from any retail pharmacy in the Southern region.
227 Available from hospital pharmacies providing an outpatient dispensing service, and any retail pharmacy in the Northern, Midland, Central (including Nelson and Blenheim) and South Canterbury regions, and selected retail pharmacies in the Christchurch region that have an exclusive contract to dispense 'Hospital Pharmacy' [HP3] pharmaceuticals.
228 Available from hospital pharmacies and retail pharmacies with a Funder contract to dispense particular medicines.
233 a) Maximum of 450mg (30 ml) per prescription; orb) Retail pharmacy - specialist.
234 a) Maximum of 750mg (1 injection) per prescription; orb) Hospital pharmacy [HP3] - specialist - Only if prescribed for a dialysis or cystic fibrosis patient; and- The prescription is endorsed accordingly.
235 Hospital pharmacy [HP3] - specialist - Only if prescribed for a dialysis or cystic fibrosis patient; and- The prescription is endorsed accordingly.
256 Special Authority for Subsidy - Form SA0256Initial application only from a cardiologist or general physician. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 Refractory angina; and 2 Patient is already on maximal anti-anginal therapy. Renewal only from a cardiologist or general physician. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
264 Special Authority for Subsidy - Form SA0264Initial application only from a paediatrician or respiratory specialist. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 Cystic fibrosis patient; or 2 Both: 2.1 Infant or child with liver disease or short gut syndrome; and 2.2 Requires vitamin supplementation. Renewal only from a paediatrician or respiratory specialist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
265 Special Authority for Manufacturers Price - Form SA0265Initial application from any medical practitioner. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 Social Welfare Benefiary; or 2 Income no greater than a Benefiary. Renewal from any medical practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
266 Special Authority for Subsidy - Form SA0266Initial application - (Chronic hepatitis C) only from a relevant specialist. Approvals valid for 6 months where chronic hepatitis C. NoteMaximum reimbursable dosage 15 million iu/weekInitial application - (Indications other than chronic hepatitis C) only from a dermatologist, plastic surgeon or radiation oncologist. Approvals valid for 5 years for applications meeting the following criteria: Any of the following: 1 Chronic myelogenous leukaemia; or 2 Hairycell leukaemia; or 3 Cutaneous T cell lymphoma; or 4 Essential thrombocythaemia; or 5 AIDS related Kaposi's sarcoma; or 6 Multiple myeloma; or 7 Chronic active hepatitis B; or 8 Basal cell carcinoma unable to be treated surgically or by radiotherapy. NoteMaximum reimbursable dosage 15 million iu/weekRenewal - (Chronic hepatitis C) only from a relevant specialist. Approvals valid for 6 months where the treatment remains appropriate and the patient is benefiting from trea
267 a) - hairy cell leukaemia - Kaposi's sarcoma - chronic active hepatitis B - chronic hepatitis C (6 month approval only) - chronic myelogenous leukaemia - multiple myeloma - basal cell carcinoma 1) Only for basal cell carcinoma unable to be treated surgically or by radiotherapy. 2) Applications only from radiation oncologists, plastic surgeons and dermatologists. Applications from dermatologists will only be accepted with evidence from either a plastic surgeon or oncologist that the patient was unsuitable for surgery. 3) Maximum reimbursable dosage 15 million iu/weekb) Specialist must make applicationc) No further approvals for: Malignant melanoma Note: Patients with existing approvals can continue to have therapy
269 Special Authority - Retail pharmacy: a) Existing patients only. b) Specialist must make application.
270 Lansoprazole is subsidised for patients who have one or more of the following conditions: 1. Duodenal ulcer proven by endoscopy or barium meal and after failure of: a)two alternative courses of H. pylori eradication therapy (if H. pylori positive); and b)H2 antagonist therapy for 8 weeks; and where a second endoscopy/barium meal has demonstrated non healing duodenal ulcer. 2. Gastric ulcer proven by endoscopy and after failure of: a)two alternative courses of H. pylori eradication therapy (if H. pylori positive); andb)H2 antagonist therapy for 12 weeks; and where a second endoscopy has demonstrated non healing gastric ulcer and excluded malignancy. 3. Gastro-oesophageal reflux disease (GORD) proven by endoscopy: i) Grade 0 GORD (normal endoscopy) after positive 24 hour pH monitoring test and failure of H2 antagonist therapy for one month with multiple daily dosing; orii) Grades 1 and 2 GORD after failure of H2 antagonist therapy for one month with multiple daily dosing; or
271 Special Authority for Manufacturers Price - Form SA0271Initial application from any medical practitioner. Approvals valid for 5 years for applications meeting the following criteria: Either: 1 Continuation of treatment commenced prior to 1 October 1995; or 2 Both: 2.1 Either: 2.1.1 Asthma; or 2.1.2 Chronic obstructive airways disease; and 2.2 Patient has tried alternatives and these are unsuitable. Renewal from any medical practitioner. Approvals valid for 5 years where the treatment remains appropriate and the patient is benefiting from treatment.
273 a) All patients with AIDS meeting the definition developed by the Centres for Disease Control in the USA (see Circular Letter to Medical Practitioners HP2/88)b) Patients with AIDS Related Complex (ARC)c) HIV infected patients with CD4 (T4) counts below 500 regardless of symptomatologyd) Prophylactically for persons following severe parenteral exposure from a known HIV positive sourcee) HIV infected persons with associated thrombocytopenia regardless of CD4 (T4) count f) For the prevention of maternal foetal transmission of HIVg) Applications can only be made by appropriate specialists. Prescriptions for those patients approved to use these medicines can be written either by the specialist or general practitioner with an endorsement of the name of the recommending specialist. h) Prescriptions for these can be written for a period of three months' supply. However, medicine must be dispensed on a monthly basis.
274 Special Authority for Subsidy - Form SA0274Initial application only from a relevant specialist. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 All of the following: 1.1 Treatment with other lipid modifying medicines has been unsuccessful; and 1.2 6 months of dietary modification has been unsuccessful; and 1.3 Cholesterol level > 7.0 mmol/litre:; and 1.4 Either: 1.4.1 Familial hypercholesterolaemia; or 1.4.2 Manifest coronary heart disease, which has been clinically proven, or previously treated by coronary artery surgery; or 2 Cholesterol level > 9.0 mmol/litre:.NoteFamilial hypercholesterolaemia is defined as being hypercholesterolaemia in the presence of tendon xanthomas or in association with a family history of premature heart disease (before age 55) or consistent with autosomal dominant inheritance. Simvastatin and Pravastatin may be considered for first line therapy in patients with familial hypercholesterolaemia or
275 Special Authority for Subsidy - Form SA0275Initial application - (Chronic hepatitis C) only from a relevant specialist. Approvals valid for 6 months where chronic hepatitis C. NoteMaximum reimbursable dosage 15 million iu/weekInitial application - (Indications other than chronic hepatitis C) only from a dermatologist, plastic surgeon or radiation oncologist. Approvals valid for 5 years for applications meeting the following criteria: Any of the following: 1 Chronic myelogenous leukaemia; or 2 Hairycell leukaemia; or 3 Cutaneous T cell lymphoma; or 4 Essential thrombocythaemia; or 5 Multiple myeloma; or 6 Chronic active hepatitis B; or 7 Basal cell carcinoma unable to be treated surgically or by radiotherapy. NoteMaximum reimbursable dosage 15 million iu/weekRenewal - (Chronic hepatitis C) only from a relevant specialist. Approvals valid for 6 months where the treatment remains appropriate and the patient is benefiting from treatment. Renewal - (Indications other tha
276 Special Authority for Subsidy - Form SA0276Initial application - (Chronic hepatitis C) only from a relevant specialist. Approvals valid for 6 months where chronic hepatitis C. NoteMaximum reimbursable dosage 15 million iu/weekInitial application - (Indications other than chronic hepatitis C) only from a dermatologist, plastic surgeon or radiation oncologist. Approvals valid for 5 years for applications meeting the following criteria: Any of the following: 1 Chronic myelogenous leukaemia; or 2 Hairycell leukaemia; or 3 Multiple myeloma; or 4 Chronic active hepatitis B; or 5 Basal cell carcinoma unable to be treated surgically or by radiotherapy. NoteMaximum reimbursable dosage 15 million iu/weekRenewal - (Chronic hepatitis C) only from a relevant specialist. Approvals valid for 6 months where the treatment remains appropriate and the patient is benefiting from treatment. Renewal - (Indications other than chronic hepatitis C) only from a dermatologist, plastic surgeon or radiat
278 Patients who have been on omeprazole and have not accessed therapy through Special Authority will continue to have subsidy for six months, by which time the necessary investigations should have been carried out to determine if ongoing therapy is warranted. For these patients the following conditions will apply: Omeprazole(a) Retail pharmacy specialist (b) month restriction
279 Maximum of 125 ml per bulk supply order.
280 Omeprazole is subsidised for patients who have one or more of the conditions numbered 1-4: 1. Duodenal ulcer proven by endoscopy or barium meal and after failure of: a)two alternative courses of H. pylori eradication therapy (if H. pylori positive); and b)H2 antagonist therapy for 8 weeks; and where a second endoscopy/barium meal has demonstrated non healing duodenal ulcer. 2. Gastric ulcer proven by endoscopy and after failure of: a)two alternative courses of H. pylori eradication therapy (if H. pylori positive); andb)H2 antagonist therapy for 12 weeks; and where a second endoscopy has demonstrated non healing gastric ulcer and excluded malignancy. 3. Gastro-oesophageal reflux disease (GORD) proven by endoscopy: i) Grade 0 GORD (normal endoscopy) after positive 24 hour pH monitoring test and failure of H2 antagonist therapy for one month with multiple daily dosing; orii) Grades 1 and 2 GORD after failure of H2 antagonist therapy for one month with multipl
281 Hospital Pharmacy - dermatologist
283 Retail Pharmacy - Specialist prescriptionPaediatricians and paediatric cardiologists may prescribe
284 maximum of 21 tablets per prescription
285 maximum of 15 tablets per prescription
286 Special Authority for Manufacturers Price - Form SA0286Initial application from any medical practitioner. Approvals valid for 5 years where patient is stabilised on aminophylline, theophylline, warfarin, or phenytoin..Renewal from any medical practitioner. Approvals valid for 5 years where the treatment remains appropriate and the patient is benefiting from treatment.
289 Retail pharmacy-Specialist Specialist must be a paediatrician or paediatric cardiologist.
290 Special Authority for Subsidy - Form SA0290Initial application only from a relevant specialist. Approvals valid for 5 years for applications meeting the following criteria: Any of the following: 1 AIDS meeting the definition developed by the Centers for Disease Control in the USA; or 2 AIDS Related Complex (ARC).; or 3 Both: 3.1 HIV infection regardless of symptomatology; and 3.2 CD4 (T4) counts < 500. NoteSee Circular Letter to Medical Practitioners HP2/88)Renewal only from a relevant specialist. Approvals valid for 5 years where the treatment remains appropriate and the patient is benefiting from treatment.
291 Special Authority for Manufacturers Price - Form SA0291Initial application from any medical practitioner. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 Inflammatory arthritis (including osteoarthritis with an inflammatory component); and 2 Stabilised and are well controlled on the particular NSAID medication. Renewal from any medical practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
293 No compounding fees will be paid when the prescribed strength of methadone is available in a proprietary solution
294 Extemporaneously compounded methadone will only be reimbursed at the rate of the cheapest form available (methadone powder, not methadone tablets)
295 Dispensing fee for commercially prepared methadone solutions is the Class A rate
298 Above local anesthetic strengths are: a) For a dialysis patient; orb) A child with rheumatic fever. c) Prescription must be endorsed accordingly.
300 Special Authority for Subsidy - Form SA0300Initial application - (Breast or prostatic cancer) only from an oncologist, urologist or endocrinologist. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 Breast cancer in pre menopausal women unwilling or unable to undergo surgical or radiation oophorectomy; or 2 Advanced prostatic cancer when orchidectomy is contraindicated. NoteNot in long term combination with an anti-androgenInitial application - (Endometriosis) only from a gynaecologist. Approvals valid for 6 months for applications meeting the following criteria: Both: 1 Endometriosis ; and 2 Either: 2.1 6 months treatment with medroxyprogesterone acetate, danazol or dimetriose has proven ineffective; or 2.2 The patient has failed to tolerate the treatment with medroxyprogesterone acetate, danazol or dimetriose for 6 months. NoteThe maximum treatment period for a GnRH analogue is: 3 months to assess whether surgery is appropriate3 m
301 Special Authority for Subsidy - Form SA0301Initial application only from a relevant specialist. Approvals valid for 2 years where type III dyslipidaemias. Renewal only from a relevant specialist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
303 Special Authority for Waiver of Rule - Form SA0303Initial application only from a paediatric surgeon or paediatrician. Approvals valid for 1 year where children post liver transplant. Renewal only from a paediatric surgeon or paediatrician. Approvals valid for 1 year where the treatment remains appropriate and the patient is benefiting from treatment.
304 Safety medicine; prescriber may determine dispensing frequency
309 Special Authority for Subsidy - Form SA0309Initial application only from a neurologist or physician for the elderly (FRACP). Approvals valid for 2 years for applications meeting the following criteria: All of the following: 1 Idiopathic Parkinson's disease; and 2 The patient does not have dementia and/or neuropsychiatric disorders; and 3 Has responded to L-dopa; and 4 Any of the following: 4.1 Has resistance to conventional treatment of severe motor fluctuations; or 4.2 Has severe "off" period disability; or 4.3 Has severe "off" period dystonic cramps. Renewal only from a neurologist or physician for the elderly (FRACP). Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
311 Special Authority for Subsidy - Form SA0311Initial application - (Breast or prostatic cancer) only from an oncologist, urologist or endocrinologist. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 Breast cancer in pre menopausal women unwilling or unable to undergo surgical or radiation oophorectomy; or 2 Advanced prostatic cancer when orchidectomy is contraindicated or where the patient srongly opposes orchidectomy. NoteNot to be prescribed with an anti-androgen except for a period of three weeks, if necessary, when GnRH analogue therapy is intiatedInitial application - (Endometriosis) only from a gynaecologist. Approvals valid for 6 months for applications meeting the following criteria: Both: 1 Endometriosis; and 2 Either: 2.1 6 months treatment with medroxyprogesterone acetate, danazol or dimetriose has proven ineffective; or 2.2 The patient has failed to tolerate the treatment with medroxyprogesterone acetate, danazol or dimetrio
312 Special Authority for Alternate Subsidy - Form SA0312Initial application only from an obstetrician, gynaecologist, general practitioner or general physician. Approvals valid for 5 years for applications meeting the following criteria: Any of the following: 1 acute or significant liver disease - a declaration must be provided from a gastroenterologist or general physician stating that oral oestrogens are contraindicated due to liver disease (Details to be attached to application); or 2 oestrogen induced hypertension requiring antihypertensive therapy - documented evidence must be provided that raised blood pressure levels or inability to control blood pressure adequately occurred post oral oestrogens (Details to be attached to application); or 3 hypertriglyceridaemia - documented evidence must be provided that triglyceride levels increased to at least 2 x normal triglyceride levels post oral oestrogens (Details to be attached to application). NotePrescriptions with a valid Special Authority (
313 Special Authority for Manufacturers Price - Form SA0313Initial application from any medical practitioner. Approvals valid for 5 years where the patient is likely to benefit from treatment. Renewal from any medical practitioner. Approvals valid for 5 years where the treatment remains appropriate and the patient is benefiting from treatment.
314 Additional subsidy by Special Authority available to fully fund to the level of the lowest priced TDDS brand within the medium dose oestrogens.
315 Additional Subsidy by Special Authority available to fully fund to the level of the lowest priced TDDS brand within the high dose oestrogens.
317 Special Authority for Subsidy - Form SA0317Initial application only from a renal physician. Approvals valid for 2 years for applications meeting the following criteria: All of the following: General Criteria: 1 Anaemia of end-stage renal failure (other treatable causes of anaemia being excluded); and 2 Been on haemodialysis or continuous ambulatory peritoneal dialysis (CAPD) for at least three months; and 3 Not under evaluation for, or awaiting, a live donor kidney transplant; and 4 Any of the following: Specific Criteria: 4.1 Anephric; or 4.2 Dependent on regular blood transfusion (1 unit each 4-8 weeks) to maintain haemoglobin > 60g/L; or 4.3 Cannot be transfused because of severe transfusion reactions; or 4.4 Transfusion induced haemosiderosis (clinical manifestations, serum ferritin >1500 ug/L); or 4.5 Haemoglobin < 70 g/L (mean of at least 4 haemoglobin concentrations over 4 months); or 4.6 Both: 4.6.1 Haemoglobin < 90 g/L; and 4.6.2 Either:
319 Neurologists or Physician for the Elderly (FRACP) must write prescription
320 a) All nucleosides will be subsidised for patients meeting any of the following criteria: - All patients with AIDS meeting the definition developed by the Centers for Disease Control in the USA (see Circular Letter to Medical Practitioners HP2/88); or- Patients with AIDS Related Complex (ARC); or- HIV infected patients with CD4 (T4) counts below 500 regardless of symptomatology. b) Zidovudine will also be subsidised for patients meeting any of the following criteria: - Prophylactically for persons following severe parenteral exposure from a known HIV positive source; or- HIV infected persons with associated thrombocytopenia regardless of CD4 (T4) count; or- For the prevention of maternal foetal transmission of HIV. c) Applications can only be made by appropriate specialists. d) Prescriptions for those patients approved to use these medications can be written by either the specialist or general practitioner with an endorsement of the name of the recommending specialist.
323 Special Authority for Subsidy - Form SA0323Initial application only from a relevant specialist. Approvals valid for 2 years where children receiving frequent parenteral injections (i.e. intradermal, subcutaneous, intravenous or intramuscular) requiring a 21 gauge or larger bore needle. Renewal only from a relevant specialist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
324 All oral Beta Adrenoceptor Blockers are exempted from monthly dispensing for patients with angina or arrhythmia.
325 Special Authority for Subsidy - Form SA0325Initial application from any medical practitioner. Approvals valid for 5 years where applicatons will be considered and approved subject to funding availability. NoteApplications to be made on the approved forms which are available from the co-ordinator for the Cystic Fibrosis DN'ase Advisory Panel: The Co-ordinatorCystic Fibrosis DN'ase Advisory PanelC/- Room 4-28, Building 13 Greenlane HospitalPrivate Bag, AUCKLANDPhone: 09 630 9871Facsimile: 09 631 0753
328 Special Authority for Subsidy - Form SA0328Initial application only from a general physician. Approvals valid for 2 years for applications meeting the following criteria: Any of the following: 1 Both: 1.1 CD4 count < 500 cells/mm3; and 1.2 Viral load > 50,000> copies per ml (or equivalent value on the Chiron test); or 2 All of the following: 2.1 CD4 count < 500 cells/mm3; and 2.2 Viral load > 50,000> copies per ml (or equivalent value on the Chiron test); and 2.3 At least 6 weeks of dual therapy with nucleoside agents; or 3 Both: 3.1 CD4 count < 500 cells/mm3; and 3.2 CD4 counts are declining rapidly (>120 cells over 12 months or >60 - 80 cells over six months). Renewal only from a general physician. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
338 Guidelines for use of cyclosporin A in rheumatoid arthritisMonitoring: All patients require frequent monitoring for creatinine levels and blood pressure:- fortnightly, in the first three months of therapy and then monthly, if results are stable; - if dose is increased or there is a rise in serum creatinine or blood pressure, then more frequent monitoring is required. Contraindications: Cyclosporin A is contraindicated in patients with the following conditions: - current or past malignancy; - uncontrolled hypertension; - renal dysfunction (abnormal serum creatinine for age and sex); - immunodeficiency and neutropenia; - abnormally low white blood cell count or platelet count; or- liver function tests more than twice the upper limit of normal. Caution in use: - age above 65 years; - controlled hypertension; - use of ant-epileptic medications; - use of NSAIDs; - use of ketoconazole, fluconazole, trimethoprim, erythromycin, verapamil, and diltiazem; - concurrent or previous use of al
341 Special Authority - Retail pharmacy (Salmeterol, eformoterol fumarate):a) Approvals are interchangeable between all presenations of salmeterol and eformoterol fumarate agents. b) Diagnosis of asthma confirmed. c) Inhaler/device technique checked. d) At least three months of >= 1500 ug daily of beclomethasone inhaled steroid (or equivalent) for adult, or >= 800 ug daily for child. e) Patient monitors PEFR regularly during exacerbations where appropriate. f) Evidence of poor control (at least one of the following): - short acting beta agonist used > 3-4 time daily - nocturnal awakenings >= 2 times per week. g) The first applicaton may be for six months and subsequent applications for two yars. The criteria for reapplication are: - compliant with medication - improved asthma symptom control. h) Appication for Special Authority to be made by general practitioners or appropriate specialist.
345 a) Should be strictly reserved for use as second line therapy in: - patients unable to tolerate the other medications, such as infants, young children and patients with allergies or eczema; - cases of scabies which are resistent to gamma benzene hexachloride and resistant to malathion. b) Verification of drug resistance is dependent on the persistence of the condition after treatment. In order to establish whether there is drug resistance, the following criteria should be fulfilled: - a definite diagnosis of scabies should be made; - it should be ascertained that the medication was administered properly; - the possibility of reinfestation should have been excluded.
348 a) Approvals will be granted for treating the following conditions: - avium intracellular atypical mycobacterial infections; and- multiple drug resistant tuberculosis; and- atypical and drug-resistant mycobacterial infections in patients with AIDS. b) Specialist must make application - respiratory physician/ infectious disease specialist. c) Approvals will be valid for two years.
349 Special Authority for Manufacturers Price - Form SA0349Initial application only from a respiratory specialist or infectious disease specialist. Approvals valid for 2 years for applications meeting the following criteria: Any of the following: 1 Avium intracellular atypical mycobacterial infections; or 2 Multiple drug resistant tuberculosis; or 3 Atypical and drug-resistant mycobacterial infections in patients with AIDS. Renewal only from a respiratory specialist or infectious disease specialist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
350 Omeprazole and pantoprazole is subsidised for patients who have one or more of the conditions a-d: a) Duodenal ulcer proven by endoscopy or barium meal and after failure of: - two alternative courses of H. pylori eradication therapy (if H. pylori positive); and - H2 antagonist therapy for 8 weeks; and where a second endoscopy/barium meal has demonstrated non healing duodenal ulcer. b) Gastric ulcer proven by endoscopy and after failure of: - two alternative courses of H. pylori eradication therapy (if H. pylori positive); and - H2 antagonist therapy for 12 weeks; and where a second endoscopy has demonstrated non healing gastric ulcer and excluded malignancy. c) Gastro-oesophageal reflux disease (GORD) proven by endoscopy: - Grade 0 GORD (normal endoscopy) after positive 24 hour pH monitoring test and failure of H2 antagonist therapy for four weeks with multiple daily dosing; or - Grades 1 and 2 GORD after failure of H2 antagonist therapy for
355 a) Not to exceed 3 capsules per prescriptionb) No more than one prescription per month.
357 a) Not to exceed 6 tablets per prescription; andb) No more than one prescription per month.
359 Subsidy is available for disposable diabetic syringes and needles: 1) When the prescription is written on the same prescription form as the one used for the supply of insulin vials; or2) When "insulin patient" has been written on the prescription by either the doctor or the contractor; and3) For no more than 50 plastic syringes with attached needles as a single supply in the case of a prescription for three months supply of insulin vials; or4) For no more than 4 plastic syringes with attached needles as a single supply for each week's supply in the case of a prescription for less than three months supply of insulin vials.
360 Subsidy is available for insulin pen needles: 1) When the prescription is written on the same prescription form as the one used for the supply of insulin cartridges; or2) When "insulin patient" has been written on the prescription by either the doctor or the contractor; and3) For no more than 30 insulin pen needles as a single supply in the case of a prescription for three months supply of insulin cartridges; or4) For no more than 2 insulin pen needles as a single supply for each week's supply in the case of a prescription for less than three months supply of insulin cartridges.
361 Special Authority for Subsidy - Form SA0361Initial application only from a geriatrician, neurologist or general physician. Approvals valid for 2 years for applications meeting the following criteria: All of the following: 1 Disabling orthostatic hypotension not due to drugs; and 2 Patient has tried fludrocortisone (unless contra-indicated) with unsatisfactory results; and 3 Patient has tried non pharmacological treatments such as support hose, increased salt intake, exercise, and elevation of head and trunk at night. NoteTreatment should be started with small doses and titrated upwards as necessary. Hypertesion should be avoided, and the usual target is a standing systolic blood pressure of 90 mm Hg. Renewal only from a geriatrician, neurologist or general physician. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
366 Special Authority for Subsidy - Form SA0366Initial application - (North Island patients) from any medical practitioner. Approvals valid for 5 years where the patient is likely to benefit from treatment. NoteFor details of the patient criteria, prescriber criteria, application and reporting forms contact the appointed clinician: Dr Richard FisherFertility Associates131 Remuera RoadAUCKLANDFax: 09 520 0499Appointed clinicians will distribute these agents to prescribers whose applications are approvedInitial application - (South Island patients) from any medical practitioner. Approvals valid for 5 years where the patient is likely to benefit from treatment. NoteFor details of the patient criteria, prescriber criteria, application and reporting forms contact the appointed clinician: Dr Peter BennyChristchurch Women's HospitalPrivate Bag 4711CHRISTCHURCHFax: 03 364 4634Appointed clinicians will distribute these agents to prescribers whose applications are approved
370 Child resistant closure (NZS 5825:1991) required and reimbursed when used to create an extemporaneously prepared oral solution.
375 Subsidy is available for disposable and non-disposable insulin syringes, needles, and pen needles if prescribed on the same form as the one used for the supply of insulin or when prescribed for an insulin patient and the prescription is endorsed accordingly.
378 Up to 50 plastic syringes with attached needles may be dispensed in the case of a prescription for three months supply of insulin vials; orUp to four plastic syringes with attached needles may be dispensed for each week's supply in the case of a prescription for less than three months supply of insulin vials.
380 Up to 30 pen needles may be dispensed in the case of a prescription for three months supply of insulin cartridges; orUp to two pen needles may be dispensed for each week's supply in the case of a prescription for less than three months supply of insulin cartridges.
382 Special Authority for Subsidy - Form SA0382Initial application only from a gastroenterologist, general surgeon or general physician. Approvals valid for 3 years for applications meeting the following criteria: Any of the following: 1 All of the following: 1.1 Duodenal ulcer proven by endoscopy or barium meal; and 1.2 Failure of two alternative courses of H. pylori eradication therapy (if H. pylori positive); and 1.3 Non healing duodenal ulcer proven by second barium meal; and 1.4 H2 antagonist therapy for 8 weeks; or 2 All of the following: 2.1 Gastric ulcer proven by endoscopy; and 2.2 Two alternative courses of H. pylori eradication therapy (if H. pylori positive); and 2.3 Non healing gastric ulcer and excluded malignancy demonstrated by a second endoscopy; and 2.4 H2 antagonist therapy for 12 weeks; or 3 All of the following: 3.1 Grade 0 GORD (normal endoscopy); and 3.2 Positive 24 hour pH monitoring test; and 3.3 Failure of H2 antagonist t
383 n) Further approvals to fund the manufacturer's surcharge on either pravastatin or simvastatin (if applicable) may be granted to patients who are unable to continue treatment with fluvastatin due to adverse effects. Either general practitioners or specialist may make the application. To obtain a new Special Authority number, the application must include the following information: - the amount of time the patient has been treated with fluvastatin; and- the adverse effects experienced by the patient. o) Further approvals to fund the manufacturer's surcharge on simvastatin may be granted to patients with familial hypercholesterolaemia (FH) or familial combined hypercholesterolaemia (FCH) if a specialist considers that the patient is not achieving sufficient benefit from the fully funded statin(s). Only specialists may make application. To obtain a new Special Authority number, the application must include the following information: - the cholesterol level before and after treatment with the fully funded sta
386 Subsidised only for treatment of prostate cancer
387 Special Authority for Subsidy - Form SA0387Initial application - (Breast or prostatic cancer) only from an oncologist, urologist or endocrinologist. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 Breast cancer in pre menopausal women unwilling or unable to undergo surgical or radiation oophorectomy; or 2 Advanced prostatic cancer when orchidectomy is contraindicated or where the patient srongly opposes orchidectomy. NoteNot to be prescribed with an anti-androgen except for a period of three weeks, if necessary, when GnRH analogue therapy is intiatedInitial application - (Endometriosis) only from a gynaecologist. Approvals valid for 6 months for applications meeting the following criteria: Both: 1 Endometriosis; and 2 Either: 2.1 6 months treatment with medroxyprogesterone acetate, danazol or dimetriose has proven ineffective; or 2.2 The patient has failed to tolerate the treatment with medroxyprogesterone acetate, danazol or dimetrio
388 Subsidised only for treatment of prostate cancer endometriosis and precocious puberty.
389 Retail Pharmacy - Specialist when used in the treatment of eye conditions.
391 Special Authority for Subsidy - Form SA0391Initial application only from a relevant specialist. Approvals valid for 5 years for applications meeting the following criteria: Either: 1 Liver transplant recipients; or 2 Renal transplant recipients - as rescue therapy only. Renewal only from a relevant specialist. Approvals valid for 5 years where the treatment remains appropriate and the patient is benefiting from treatment.
392 Only when prescribed in a quantity of 100 ml per prescription form
394 Special Authority for Manufacturers Price - Form SA0394Initial application - (Helicobacter pylori infections) only from a general practitioner or relevant specialist. Approvals valid for 6 months for applications meeting the following criteria: Both: 1 Eradication of Helicobacter pylori in patient with proven infection; and 2 Peptic ulcer disease proven by endoscopy. NoteMaximum of two prescriptions (two courses) per patient. Initial application - (Mycobacterial infections) only from a respiratory specialist or infectious disease specialist. Approvals valid for 2 years for applications meeting the following criteria: Any of the following: 1 Mycobacterium Avium Intracellulare Complex infections in patient with AIDS; or 2 Atypical and drug-resistant mycobacterial infection; or 3 All of the following: 3.1 Prophylaxis against disseminated Mycobacterium Avium Intracellulare Complex infection; and 3.2 HIV infection; and 3.3 CD4 count <= 50 cells/mm3. Renewal - (Mycobacteri
396 a) Cyproterone acetate with ethinyloestradiol is available from retail pharmacy to patients as indicated. b) Prescribers may code prescriptions "contraceptive" (code "O") when used as indicated for contraception. The period of supply and prescription charge will be as per other contraceptives, as follows: - $3.00 prescription charge (patient co-payment) will apply; - Prescription may be written for up to 6 months supply; and- Pharmacists may dispense up to 3 month supply. c) Prescriptions coded in any other way are subject to the non-contraceptive prescription charges, and the non-contraceptive period of supply. Eg. Prescriptons may be written for up to 3 months supply, and dispensed monthly. d) The Special Authority number for hormonal contraceptive agents (combined and progesterone-only) does not apply, and is not interchangeable. e) Health Benefits Limited will return any claims unpaid as follows: - any uncoded prescription; - any prescription that does not have a period of supply or the quantity
400 Preferred Supplier
401 Special Authority for Subsidy - Form SA0401Initial application - (Basal cell carcinoma) only from a dermatologist, plastic surgeon or radiation oncologist. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 Basal cell carcinoma unable to be treated surgically or by radiotherapy; and 2 Unsuitability for surgery confirmed by a Plastic Surgeon or Oncologist. NoteMaximum reimbursable dosage 15 million iu/weekInitial application - (Chronic hepatitis C) only from a relevant specialist. Approvals valid for 12 months where chronic hepatitis C. Initial application - (Indications other than Basal cell carcinoma and Chronic hepatitis C) only from a relevant specialist, plastic surgeon or radiation oncologist. Approvals valid for 2 years for applications meeting the following criteria: Any of the following: 1 Chronic myelogenous leukaemia; or 2 Hairy cell leukaemia; or 3 Cutaneous T cell lymphoma; or 4 Essential thrombocythaemia; or 5 Multiple myelo
402 Special Authority for Subsidy - Form SA0402Initial application - (Patients aged 74 and under) only from a general practitioner. Approvals valid for 2 years for applications meeting the following criteria: All of the following: 1 Patients aged 74 and under; and 2 The patient has been offered 3-6 months of counselling and an opportunity to modify lifestyle; and 3 Any of the following: 3.1 Both: 3.1.1 NHF A1:1 - Clinically proven ischaemic heart disease; and 3.1.2 total cholesterol > 6.0; or 3.2 Both: 3.2.1 NHF A1:2 - Post coronary artery bypass graft (CABG); and 3.2.2 total cholesterol > 5.5; or 3.3 Both: 3.3.1 NHF B:Patients with > 20% 5-year cardiovascular disease risk; and 3.3.2 total cholesterol > 9.0; or 3.4 Both: 3.4.1 NHF C:15-20% 5-year cardiovascular disease risk; and 3.4.2 total cholesterol > 9.0; or 3.5 Both: 3.5.1 NHF D:10-15% 5-year cardiovascular disease risk; and 3.5.2 total cholesterol > 9.0; or 3.6
403 Special Authority for Subsidy - Form SA0403Initial application only from a nephrologist or transplant surgeon. Approvals valid for 12 months where renal transplant recipient. Renewal only from a nephrologist or transplant surgeon. Approvals valid for 12 months where re-graft patient.
404 Special Authority for Subsidy - Form SA0404Initial application only from an ophthalmologist. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 Primary open-angle glaucoma; and 2 Either: 2.1 Other subsidised glaucoma medical therapy is contraindicated; or 2.2 Both: 2.2.1 intra-ocular pressure > 26 mmHg (average from consecutive measurements); and 2.2.2 Unable to be controlled using other subsidised medical therapy. Renewal only from an ophthalmologist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
410 Special Authority for Manufacturers Price - Form SA0410Initial application from any medical practitioner. Approvals valid for 2 years for applications meeting the following criteria: Any of the following: 1 Polycystic ovarian syndrome; or 2 Hirsutism; or 3 Androngenic alopecia. Renewal from any medical practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
411 Special Authority for Manufacturers Price - Form SA0411Renewal from any medical practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
420 Funding of manufacturers surcharge for existing patients taking ACE inhibitors for Congestive Heart Failure.a) Patients taking any ACE inhibitor for the treatment of congestive heart failure prior to 1 June 1998 can continue to have their ACE inhibitor treatment fully subsidised; b) Prescribers must endorse the prescription 'Congestive Heart Failure'. The endorsement can be typed (this includes computer generated prescriptions) or handwritten; c) The endorsement must be initialled in the prescriber's own handwriting. Definition of Congestive Heart FailureAt the request of some prescribers the PTAC Cardiovascular subcommittee has provided a definition of congestive heart failure for the purposes of the funding of the manufacturer's surcharge: "Clinicians should use their clinical judgement. Existing patients would be eligible for the funding of the surcharge if the patient shows signs and symptoms of congestive heart failure, and requires or has in the past required concomitant treatment with a
421 Sole Supply
423 Special Authority for Subsidy - Form SA0423Initial application only from a gastroenterologist, general surgeon or general physician. Approvals valid for 3 years for applications meeting the following criteria: Any of the following: 1 All of the following: Duodenal Ulcer: 1.1 Duodenal ulcer proven by endoscopy or barium meal; and 1.2 Non healing duodenal ulcer proven by second barium meal; and 1.3 After failure of two alternative courses of H. pylori eradication therapy (if H. pylori positive); and 1.4 After H2 antagonist therapy for 8 weeks; or 2 All of the following: Gastric Ulcer: 2.1 Gastric ulcer proven by endoscopy; and 2.2 Non healing gastric ulcer and excluded malignancy demonstrated by a second endoscopy; and 2.3 After two alternative courses of H. pylori eradication therapy (if H. pylori positive); and 2.4 After H2 antagonist therapy for 12 weeks; or 3 All of the following: GORD: 3.1 Grade 0 GORD (normal endoscopy); and 3.2 Positive 24
424 Special Authority for Subsidy - Form SA0424Initial application - (Confirmed HIV/AIDS) only from a general physician. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 Confirmed HIV/AIDS; and 2 Any of the following: 2.1 Symptomatic patients aged 6 years and over with HIV/AIDS; or 2.2 Both: 2.2.1 Asymptomatic patients aged 6 years and over; and 2.2.2 CD4 counts < 500 cells/mm3; or 2.3 Both: 2.3.1 Asymptomatic patients aged 6 years and over; and 2.3.2 Viral load counts > 10,000 copies per ml; or 2.4 Symptomatic patients aged under 6 with HIV/AIDS ; or 2.5 Asymptomatic patients aged 12 months and under; or 2.6 Both: 2.6.1 Asymptomatic patients aged 1 to 5 years; and 2.6.2 CD4 counts < 1,000 cells/mm3; or 2.7 Both: 2.7.1 Asymptomatic patients aged 1 to 5 years; and 2.7.2 CD4 counts < 0.25 x total white cell count; or 2.8 Both: 2.8.1 Asymptomatic patients aged under 6 years; and
429 If a Community Pharmaceutical is the liquid oral form of an antibiotic to which a diluent must be added by the Contractor at the time of dispensing and it is prescribed or ordered by a Practittioner in an amount that does not coincide with the amount contained in one or more standard packs of that Community Pharmaceutical, Subsidy will only be made for the amount prescribed or ordered by the Practitioner in accordance with either Clause 3.1 or Clause 3.3 of the Schedule, unless the Contractor satisfies the Funder that he or she has not been able to dispense the balance of the pack or packs from which the Community Pharmaceutical has been dispensed. In such cases all of that pack or those packs is eligible for Subsidy.
430 Special Authority for Subsidy - Form SA0430Initial application - (National Heart Foundation risk groups A1:1, A1:2, B, C, D or E) only from a relevant specialist or general practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria: Both: 1 The patient has been offered 3-6 months of counselling and an opportunity to modify lifestyle; and 2 Any of the following: 2.1 Both: 2.1.1 NHF A1:1 - Clinically proven ischaemic heart disease; and 2.1.2 total cholesterol * > 5.5; or 2.2 Both: 2.2.1 NHF A1:2 - Post coronary artery bypass graft (CABG) or angioplasty; and 2.2.2 total cholesterol * > 4.5; or 2.3 Post heart transplant (regardless of cholesterol level); or 2.4 Both: 2.4.1 NHF B:Patients with > 20% 5-year cardiovascular disease risk; and 2.4.2 total cholesterol * > 9.0; or 2.5 Both: 2.5.1 NHF C:15-20% 5-year cardiovascular disease risk; and 2.5.2 total cholesterol * > 9
432 Maximum 15 g per prescription.
434 Special Authority for Manufacturers Price - Form SA0434Initial application only from a general practitioner, general physician, geriatrician or neurologist. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 Patients with swallowing difficulties; and 2 Applicant is a specialist or specialist has authorised treatment. Renewal only from a general practitioner, general physician, geriatrician or neurologist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
435 Special Authority for Manufacturers Price - Form SA0435Initial application from any medical practitioner. Approvals valid for 6 months where control of nausea and vomiting in the treatment of terminal care patients. Renewal from any medical practitioner. Approvals valid for 6 months where the treatment remains appropriate and the patient is benefiting from treatment.
436 Special Authority for Manufacturers Price - Form SA0436Initial application - (Patient with prosthetic heart valves) only from a cardiothoracic surgeon, cardiologist or general physician. Approvals valid for 2 years where patient with prosthetic heart valves - as an adjunct to oral anticoagulation for prophylaxis of thromboembolism. Initial application - (Following coronary artery vein bypass graft) only from a cardiothoracic surgeon, cardiologist or general physician. Approvals valid for 1 year where patients after coronary artery vein bypass graft - as an adjunct to aspirin or as monotherapy for patients who are aspirin intolerant as defined below. Initial application - (Transient ischaemic episodes) only from a neurologist, neuro surgeon, cardiologist, vascular surgeon or general physician. Approvals valid for 2 years where patients who continue to have transient ischaemic episodes despite aspirin therapy or have transient ischaemic episodes and are aspirin intolerant as defined below. Renewal - (Fo
443 Special Authority for Subsidy - Form SA0443Initial application - (Helicobacter pylori infections) only from a general practitioner or relevant specialist. Approvals valid for 6 months for applications meeting the following criteria: Both: 1 Eradication of Helicobacter pylori in patient with proven infection; and 2 Peptic ulcer disease proven by endoscopy. NoteMaximum of two prescriptions (two courses) per patient. Initial application - (Mycobacterial infections) only from a respiratory specialist or infectious disease specialist. Approvals valid for 2 years for applications meeting the following criteria: Any of the following: 1 Mycobacterium Avium Intracellulare Complex infections in patient with AIDS; or 2 Atypical and drug-resistant mycobacterial infection; or 3 All of the following: 3.1 Prophylaxis against disseminated Mycobacterium Avium Intracellulare Complex infection; and 3.2 HIV infection; and 3.3 CD4 count <= 50 cells/mm3. Renewal - (Mycobacterial infection
445 Special Authority for Subsidy - Form SA0445Initial application only from a relevant specialist. Approvals valid for 5 years for applications meeting the following criteria: Any of the following: 1 Both: 1.1 Acromegaly; and 1.2 Patient has failed surgery, radiotherapy, bromocriptine or other oral therapies; or 2 VIPomas and Glucagonomas - for patients who are seriously ill in order to improve their clinical state prior to definitive surgery.; or 3 Both: 3.1 Gastrinoma; and 3.2 Patient has failed surgery, or metastatic disease after H2 antagoists (or proton pump inhibitors) have failed; or 4 Both: 4.1 Insulinomas; and 4.2 Surgery is contraindicated or has failed; or 5 For pre-operative control of hypoglycaemia and for maintenance therapy; or 6 Both: 6.1 Carcinoidsyndrome (diagnosed by tissue pathology and/or urinary 5HIAA analysis); and 6.2 Disabling symptoms not controlled by maximal medical therapy. NoteThe use of octretide in patients with fis
446 Maximum one pack (two 500 mg tablets) per prescription.
447 Retail Pharmacy - Specialist prescriptionSpecialist must be either a neurologist, geriatrician or general physician
450 Special Authority for Subsidy - Form SA0450Initial application only from a psychiatrist. Approvals valid for 12 months for applications meeting the following criteria: Both: 1 Patients suffering from schizophrenia and related psychoses; and 2 Either: 2.1 Failed to respond to full trials (duration of at least 6 weeks each) of effective doses of at least two classes of anti-psychotic agents (refer to guidelines below); or 2.2 Demonstrated intolerance to other neuroleptic agents. NoteClinicians must confirm that informed consent and a satisfactory White Bloodcell Count (WBC) result has been obtained. Diagnosis: Treatment resistant schizophrenia and related psychoses when positive symptoms (delusions, hallucinations and thought disorder) are prominent and/or disabling or when both positive symptoms and negative symptoms (flattened affect, emotional and social withdrawal and poverty of speech) are present. Treatment: Trial therapy undertaken before initiating treatment with clozapine could
451 Special Authority for Manufacturers Price - Form SA0451Initial application only from a relevant specialist. Approvals valid for 3 years for applications meeting the following criteria: Both: 1 Patients being treated for advanced breast cancer who are refractory to tamoxifen; and 2 Any of the following: 2.1 Unable to tolerate aminoglutethimide; or 2.2 Unable to tolerate megestrol acetate; or 2.3 Unable to tolerate medroxyprogesterone acetate.Renewal only from a relevant specialist. Approvals valid for 3 years where the treatment remains appropriate and the patient is benefiting from treatment.
452 Special Authority for Manufacturers Price - Form SA0452Initial application only from a relevant specialist. Approvals valid for 3 years for applications meeting the following criteria: Both: 1 Patients being treated for advanced breast cancer who are refractory to tamoxifen; and 2 Any of the following: 2.1 Unable to tolerate aminoglutethimide; or 2.2 Unable to tolerate megestrol acetate; or 2.3 Unable to tolerate medroxyprogesterone acetate.Renewal only from a relevant specialist. Approvals valid for 3 years where the treatment remains appropriate and the patient is benefiting from treatment.
454 Guidelines for the use of atypical anti-psychotic agents Diagnosis: Schizophrenia and related psychoses when positive symptoms (delusions, hallucinations and thought disorder) are prominent and/or disabling or when both positive symptoms and negative symptoms (flattened affect, emotional and social withdrawal and poverty of speech) are present. Treatment: Before initiating atypical anti-psychotic therapy, physicians should consider whether the patient is likely to respond to and/or tolerate conventional anti-psychotic therapy and, where appropriate, trial one or more conventional agent prior to use of an atypical agent.
455 Maximum 100 ml per prescription.
456 Special Authority for Subsidy - Form SA0456Initial application only from a psychiatrist. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 Patients suffering from schizophrenia and related psychoses who are likely to benefit from anti-psychotic treatment; and 2 Any of the following: 2.1 Effective dose of risperidone has been discontinued because of recurrent acute dystonias; or 2.2 Effective dose of risperidone has been discontinued because of excessive Parkinson-like symptoms; or 2.3 Effective dose of risperidone has been discontinued after 6 weeks because of inadequate clinical response. Renewal only from a psychiatrist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
458 Special Authority for Subsidy - Form SA0458Initial application only from a gastroenterologist. Approvals valid for 6 months for applications meeting the following criteria: Both: 1 Primary biliary cirrhosis confirmed by antimitochondrial antibody titre (AMA) > 1:80, and raised cholestatic liver enzymes with or without raised serum IgM or, if AMA is negative, by liver biopsy; and 2 Patient not requiring a liver transplant (bilirubin > 170umol/l; decompensated cirrhosis). NoteLiver biopsy is not usually required for diagnosis but is helpful to stage the diseaseRenewal only from a gastroenterologist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment. NoteActigall is not an appropriate therapy for patients requiring a liver transplant (bilirubin > 170 micromol/l; decompensated cirrhosis). These patients should be referred to an appropriate transplant centreTreatment failure - doubling of serum bilirubin levels, absence of a signi
459 Special Authority for Subsidy - Form SA0459Initial application only from a gastroenterologist or general physician. Approvals valid for 3 months for applications meeting the following criteria: Both: 1 Mild to moderate ileal, ileocaecal or proximal Crohn's disease; and 2 Any of the following: 2.1 Diabetes; or 2.2 Cushingoid habitus; or 2.3 Osteoporosis where there is significant risk of fracture; or 2.4 Both: 2.4.1 Severe acne; and 2.4.2 Treatment with conventional corticosteroid therapy. Renewal only from a gastroenterologist or general physician. Approvals valid for 3 months where the treatment remains appropriate and the patient is benefiting from treatment.
460 Special Authority for Manufacturers Price - Form SA0460Initial application - (Patient with prosthetic heart valves) only from a cardiothoracic surgeon, cardiologist or general physician. Approvals valid for 2 years where patient with prosthetic heart valves - as an adjunct to oral anticoagulation for prophylaxis of thromboembolism. Initial application - (Following coronary artery vein bypass graft) only from a cardiothoracic surgeon, cardiologist or general physician. Approvals valid for 1 year where patients after coronary artery vein bypass graft - as an adjunct to aspirin or as monotherapy for patients who are aspirin intolerant as defined below. Initial application - (Transient ischaemic episodes) only from a neurologist, neuro surgeon, cardiologist, vascular surgeon or general physician. Approvals valid for 2 years where patients who continue to have transient ischaemic episodes despite aspirin therapy or have transient ischaemic episodes and are aspirin intolerant as defined below. Renewal - (Fo
461 Special Authority for Subsidy - Form SA0461Initial application - (Basal cell carcinoma) only from a dermatologist, plastic surgeon or radiation oncologist. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 Basal cell carcinoma unable to be treated surgically or by radiotherapy; and 2 Unsuitablity for surgery confirmed by a Plastic Surgeon or Radiation Oncologist. NoteThe maximum reimbursable dosage is 15 million iu per weekInitial application - (Chronic hepatitis C) only from a relevant specialist. Approvals valid for 12 months where chronic hepatitis C. Initial application - (Indications other than Basal cell carcinoma and Chronic hepatitis C) only from a relevant specialist. Approvals valid for 2 years for applications meeting the following criteria: Any of the following: 1 Chronic myelogenous leukaemia; or 2 Hairy cell leukaemia; or 3 Multiple myeloma; or 4 Chronic active hepatitis B. Renewal - (Basal cell carcinoma) only from a dermato
462 Hospital pharmacy - Specialist prescription. Note: Prescribing and dispensing of clozapine is subject to Ministry of Health restrictions including the requirement for blood monitoring.
464 Special Authority for Subsidy - Form SA0464Initial application only from a diabetologist, general physician or paediatrician. Approvals valid without further renewal unless notified for applications meeting the following criteria: Any of the following: 1 Both: 1.1 Use alone (monotherapy); and 1.2 The patient is unable to use any other insulins including those on insulin pump treatment; or 2 Both: 2.1 Use with Humulin 70/30 or Humulin 80/20; and 2.2 A reasonable trial of Humulin N has been undertaken and it is not effective or not well tolerated; or 3 Both: 3.1 Use with insulins (aside from insulin zinc suspension) other than Humulin 70/30, Humulin 80/20, or Humulin N; and 3.2 A reasonable trial of one or more of these Humulin insulins has been undertaken and it is/are ineffective or not well tolerated; or 4 Both: 4.1 Use with Humulin L or Humulin U; and 4.2 Use with Humulin N is not appropriate; or 5 Both: 5.1 Use with other insulin zinc suspensio
465 Maximum 500ml per month.
466 Special Authority for Alternate Subsidy - Form SA0466Initial application only from a relevant specialist or general practitioner. Approvals valid for 5 years for applications meeting the following criteria: Any of the following: 1 Angina that is not controlled by other anginal medications; or 2 Continuation of treatment commenced prior to 1 June 1999; or 3 Receiving maximal antihypertensive therapy, requires a DHP CCB, and cannot tolerate felodipine. Renewal only from a relevant specialist or general practitioner. Approvals valid for 5 years where the treatment remains appropriate and the patient is benefiting from treatment.
467 Special Authority for Subsidy - Form SA0467Initial application only from a relevant specialist. Approvals valid for 6 months for applications meeting the following criteria: Both: 1 Paget's disease; and 2 Any of the following: 2.1 Bone or articular pain; or 2.2 Bone deformity; or 2.3 Bone, articular or neurological complications; or 2.4 Asymptomatic disease, but risk of complications due to site (base of skull, spine, long bones of lower limbs); or 2.5 Preparation for orthopaedic surgery. Renewal only from a relevant specialist. Approvals valid for 6 months where the treatment remains appropriate and the patient is benefiting from treatment.
468 Retail Pharmacy-Specialist Prescriptiona) Specialist must be an ophthalmologist. b) For treatment of bacterial keratitis or severe bacterial conjunctivitis resistant to chloramphenicol.
469 a) On a prescription or practitioner's supply order only when on the same form as an injection listed in the Pharmaceutical Schedule requiring a solvent or diluent b) On a bulk supply orderc) When used in the extemporaneous compounding of eye drops
470 Special Authority for Subsidy - Form SA0470Initial application - (Organ transplant) only from a relevant specialist. Approvals valid without further renewal unless notified where organ transplant. Initial application - (Bone marrow transplant or Graft v host disease) only from a relevant specialist. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 Bone marrow transplant; or 2 Graft v host disease. Initial application - (Psoriasis) only from a dermatologist. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 Psoriasis; and 2 Applicant must state which systemic and topical therapies have failed. Initial application - (Severe atopic dermatitis) only from a dermatologist. Approvals valid for 6 months for applications meeting the following criteria: Both: 1 Severe atopic dermatitis; and 2 Not responsive to topical therapy, oral antihistamines and other commonly used orthodox therapies. Initial application - (N
471 Special Authority for Subsidy - Form SA0471Initial application - (Breast cancer) from any medical practitioner. Approvals valid for 1 year where breast cancer in pre menopausal women unwilling or unable to undergo surgical or radiation oophorectomy. Initial application - (Prostate cancer) only from an oncologist, urologist or endocrinologist. Approvals valid for 1 year where advanced prostatic cancer when orchidectomy is contraindicated or where the patient strongly opposes orchidectomy. NoteNot to be prescribed with an anti-androgen except for a period of three weeks, if necessary, when GnRH analogue therapy is intiatedInitial application - (Endometriosis) only from a gynaecologist. Approvals valid for 3 months for applications meeting the following criteria: Both: 1 Endometriosis ; and 2 Either: 2.1 6 months treatment with medroxyprogesterone acetate, danazol or dimetriose has proven ineffective; or 2.2 The patient has failed to tolerate the treatment with medroxyprogesterone
472 Special Authority for Subsidy - Form SA0472Initial application only from a cardiologist. Approvals valid for 2 years for applications meeting the following criteria: Any of the following: 1 Both: 1.1 Congestive heart failure; and 1.2 Cannot tolerate currently fully subsidised ACE inhibitors due to persistent cough that resolves on cessation and recurs on re-challenge with ACE inhibitor; or 2 Patients who have experienced angioedema on an ACE inhibitor at any time in the past; or 3 Patients who have experienced angioedema (even if not using an ACE inhibitor) in the last 2 years. Renewal only from a cardiologist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
473 Special Authority for Subsidy - Form SA0473Initial application from any medical practitioner. Approvals valid for 1 year where the patient is likely to benefit from treatment. Note Applications to be made on the approved forms which are available from: The Co-ordinatorGaucher's Treatment PanelPhone: (04) 460 4990 PHARMAC, PO Box 10 254 WellingtonFacsimile: (04) 916 7571Email: erin.murphy@pharmac.govt.nzPrescriptions for patients approved for treatment must be written by respiratory physicians or paediatricians who have experience and expertise in treating cystic fibrosis.
474 Maximum 500 ml per prescription.
478 Maximum 200 ml per prescription.
479 Max 6,000 ml per prescription.
480 a) When prescribed (alone or in combination) for renal dialysis in the home of the patient concerned.b) Only maternity hospital, or on the prescription of a practitioner. c) Obstetric cream only in a quantity not exceeding 500 ml per prescription or on a bulk supply order. d) Solution 5% in quantity not exceeding 100 ml per prescription or on a bulk supply order.
481 a) Up to 10 %;b) Only in combination with a dermatological base or proprietary Topical Corticosteriod - Plain; c) With or without other dermatological galenicals.
482 a) Up to 2 %; b) Only in combination with a dermatological base or proprietary Topical Corticosteriod - Plain; c) With or without other dermatological galenicals.
483 a) Up to 5 %; b) In a dermatological base (not proprietary Topical Corticosteriod - Plain);c) With or without other dermatological galenicals.
484 a) Only in combination with aqueous cream, 10 % urea cream, wool fat with mineral oil lotion, 1% hydrocortisone with wool fat and mineral oil lotion, and glycerol, paraffin and cetyl alcohol lotion; b) With or without phenol liquefied.
485 a) Only in combination with aqueous cream, 10 % urea cream, wool fat with mineral oil lotion, 1% hydrocortisone with wool fat and mineral oil lotion, and glycerol, paraffin and cetyl alcohol lotion; b) With or without menthol crystals.
486 a) In a dermatological base or proprietary Topical Corticosteroid - Plain; b) With or without other dermatological galenicals. c) In a 'standard formula'.
487 a) Only in combination with a dermatological base or proprietary Topical Corticosteriod - Plain; c) With or without other dermatological galenicals.
488 Special Authority for Subsidy - Form SA0488Initial application only from a gastroenterologist, general surgeon or general physician. Approvals valid for 3 months for applications meeting the following criteria: Both: 1 Mild to moderate ileal, ileocaecal or proximal Crohn's disease; and 2 Any of the following: 2.1 Diabetes; or 2.2 Cushingoid habitus; or 2.3 Osteoporosis where there is significant risk of fracture; or 2.4 Both: 2.4.1 Severe acne; and 2.4.2 Treatment with conventional corticosteroid therapy. Renewal only from a gastroenterologist, general surgeon or general physician. Approvals valid for 3 months where the treatment remains appropriate and the patient is benefiting from treatment.
489 Special Authority for Manufacturers Price - Form SA0489Initial application - (Conditions other than transient ischaemic episodes) only from a cardiothoracic surgeon, cardiologist or general physician. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 Patients with prosthetic heart valves - as an adjunct to oral anticoagulation for prophylaxis of thromboembolism; or 2 Both: 2.1 Patients after coronary artery vein bypass graft; and 2.2 Any of the following: 2.2.1 aspirin induced asthma; or 2.2.2 aspirin induced anaphylaxi; or 2.2.3 significant aspirin induced bleeding excluding bruising. Initial application - (Transient ischaemic episodes) only from a neurologist, neuro surgeon, cardiologist, vascular surgeon or general physician. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 Patients who continue to have transient ischaemic episodes despite aspirin therapy; or 2 Both: 2.1 Patients wh
490 Special Authority for Subsidy - Form SA0490Initial application only from a relevant specialist. Approvals valid for 2 years for applications meeting the following criteria: Any of the following: 1 Requires but is not able to tolerate metformin therapy; or 2 Requires metformin but metformin is contraindicated; or 3 Has not responded to or tolerated the maximum appropriate dose of metformin. Renewal only from a relevant specialist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
491 a) only if prescribed for prohylaxis of endocarditis and the prescription is endorsed accordingly.
493 Maximum of 500ml per month.
494 Special Authority for Subsidy - Form SA0494Initial application only from an ophthalmologist. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 Both: 1.1 Primary open-angle glaucoma; and 1.2 Any of the following: 1.2.1 Patient cannot tolerate Beta-blockers, or Beta-blockers are contraindicated; or 1.2.2 Patient cannot tolerate Pilocarpine, or Pilocarpine is contraindicated; or 1.2.3 Patient cannot tolerate Dorzolamide, or Dorzolamide is contraindicated; or 1.2.4 A reduction in intraocular pressure of 15% or more is not achieved or maintained using dorzolamide either alone or in combination with a beta-blocker; or 2 There is progressive visual field loss and/or optic nerve damage persists after treatment with dorzolamide either alone or in combination with a beta-blocker. NoteSubsidised as monotherapy onlyRenewal only from an ophthalmologist. Approvals valid for 2 years where the treatment remains appropriate and the patient
495 a) Maximum of 50 plastic syringes with attached needles per prescription.
496 a) Maximum of 30 pen needles per prescription.
497 a) All transdermal patches are only on prescription.
498 a) Not more than 6 per prescription.
499 b) Not more than 6 per dispensing.
500 Special Authority for Alternate Subsidy - Form SA0500Initial application from any medical practitioner. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 Either: 1.1 Patient is on a Social Welfare benefit; or 1.2 Patient has an income no greater than the benefit; and 2 Has tried at least one of the fully funded options and has been unable to tolerate it. Renewal from any medical practitioner. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 Patient is on a Social Welfare benefit; or 2 Patient has an income no greater than the benefit. NoteThe approval numbers of Special Authorities approved after 1 November 1999 are interchangeable between Mercilon and Marvelon. The additional subsidy will fund Mercilon and Marvelon up to the manufacturer's price for each of these products as identified on the Schedule at 1 November 1999Special Authorities approved before 1 November 1999 remain valid until the expiry d
502 a) Hospital pharmacy [HP3] - Maximum of 750mg (3 injections) per prescription; orb) Hospital pharmacy [HP3] - specialist - Only if prescribed for a dialysis or cystic fibrosis patient; and- The prescription is endorsed accordingly.
503 a) Maximum of 500mg per prescription; orb) More than 500mg per prescription - Special Authority available
504 a) Maximum of 450mg (3 capsules) per prescription; orb) Retail pharmacy - specialist.
505 a) Only if prescribed for a dialysis or cystic fibrosis patient or for prophylaxis of endocarditis and; b) the prescription is endorsed accordingly.
506 a) Only if prescribed for a dialysis or cystic fibrosis patient or in the treatment of pseudo membranous colitis or for prophylaxis of endocarditis; and b) The prescription is endorsed accordingly.
508 Special Authority for Subsidy - Form SA0508Initial application only from a relevant specialist or general practitioner. Approvals valid for 2 years for applications meeting the following criteria: All of the following: 1 Patient with raised blood pressure; and 2 A beta blocker or diuretic is contraindicated; or not well tolerated; or insufficient to control blood pressure adequately at appropriate doses; and 3 An ACE inhibitor is contraindicated; or not well tolerated; or insufficient to control blood pressure adequately at appropriate doses. Renewal only from a relevant specialist or general practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
509 Special Authority for Subsidy - Form SA0509Initial application only from a psychiatrist. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 Patient with first episode schizophrenia or related psychoses; or 2 Both: 2.1 Patient suffering from schizophrenia and related psychoses who is likely to benefit from anti-psychotic treatment; and 2.2 Both: 2.2.1 An effective dose of risperidone had been trialled and has been discontinued either because of; and 2.2.2 Any of the following: 2.2.2.1 Patient has recurrent acute dystonias; or 2.2.2.2 Patient has excessive Parkinson-like symptoms; or 2.2.2.3 Patient has hyperprolactinaemia; or 2.2.2.4 Patient has inadequate clinical response after four weeks. NoteDiscontinued treatment should be notified to HealthPAC if possibleRenewal only from a psychiatrist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
510 Special Authority for Alternate Subsidy - Form SA0510Initial application only from a relevant specialist or general practitioner. Approvals valid for 2 years for applications meeting the following criteria: Any of the following: 1 Angina that is not controlled by other anginal medications (including felodipine); or 2 Patient was taking Adalat Oros for the treatment of angina prior to 1 June 1999; or 3 Receiving maximal antihypertensive therapy, requires a DHP CCB, and cannot tolerate felodipine. Renewal only from a relevant specialist or general practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
511 Special Authority for Subsidy - Form SA0511Initial application only from a geriatrician, rheumatologist, endocrinologist, gynaecologist or general physician. Approvals valid for 2 years for applications meeting the following criteria: All of the following: 1 Severe osteoporosis; and 2 History of two previous significant osteoporotic fractures demonstrated radiologically; and 3 T-Score <= -3.0 (bone mass density (BMD) >= 3.0 standard deviations below the mean normal value in young adults). NoteIn line with the Australian guidelines for funding alendronate, a vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral bodyRenewal only from a geriatrician, rheumatologist, endocrinologist, gynaecologist or general physician. Approvals valid for 2 years where the tr
512 Special Authority for Subsidy - Form SA0512Initial application only from a gastroenterologist, general surgeon or general physician. Approvals valid for 3 months for applications meeting the following criteria: Both: 1 Mild to moderate ileal, ileocaecal or proximal Crohn's disease; and 2 Either: 2.1 Diabetes; or 2.2 Both: 2.2.1 Treatment with conventional corticosteroid therapy; and 2.2.2 Any of the following: 2.2.2.1 Cushingoid habitus; or 2.2.2.2 Osteoporosis where there is significant risk of fracture; or 2.2.2.3 Severe acne. Renewal only from a gastroenterologist, general surgeon or general physician. Approvals valid for 3 months where the patient has had no more than 1 prior approval in the last 12 months. The patient must have had no more than 1 prior approval in the last year. NoteClinical trials for Entocort CIR use beyond three months demonstrated no improvement in relapse rate
513 Special Authority for Subsidy - Form SA0513Initial application - (Narcolepsy) only from a neurologist. Approvals valid for 24 months where narcolepsy. Initial application - (ADHD in patients aged 5 years or over) only from a paediatrician or psychiatrist. Approvals valid for 24 months for applications meeting the following criteria: Both: 1 ADHD (Attention Deficient and Hyperactivity Disorder) patients aged 5 years or over; and 2 Diagnosed according to DSM-IV or ICD 10 criteria. Initial application - (ADHD in patients under 5 years of age) only from a paediatrician or psychiatrist. Approvals valid for 12 months for applications meeting the following criteria: Both: 1 ADHD (Attention Deficient and Hyperactivity Disorder) patients under 5 years of age; and 2 Diagnosed according to DSM-IV or ICD 10 criteria. Renewal - (Narcolepsy or ADHD in patients under 5 years of age) only from a neurologist, paediatrician or psychiatrist. Approvals valid for 24 months where the treatment remains appr
514 Hospital Pharmacy - Specialist prescription
515 Additional Subsidy by Special Authority available to fully fund to the level of the lowest priced TDDS brand within the highdose oestrogens.
516 Special Authority for Subsidy - Form SA0516Initial application from any medical practitioner. Approvals valid for 2 years where the patient is likely to benefit from treatment. Note Applications to be made on the approved forms which are available from: Prof. Wayne CutfieldNational Co-ordinatorNew Zealand Growth Hormone CommitteeC/- Department of PaediatricsUniversity of AucklandPrivate Bag 92019AUCKLAND
518 Injection 500 mg subsidised: a) only if prescribed for a dialysis or cystic fibrosis patient; and b) the prescription is endorsed accordingly.
519 (Only in aspirin and chloroform application)
521 (Only in extemporaneously compounded methadone mixture, codeine linctus diabetic or codeine linctus paediatric)
522 Must be dispensed in one lot
523 Special Authority for Subsidy - Form SA0523Initial application only from a relevant specialist or general practitioner. Approvals valid for 6 months for applications meeting the following criteria: All of the following: 1 Diagnosis of asthma confirmed; and 2 Inhaler/device technique checked; and 3 Patient monitors PEFR regularly during exacerbations where appropriate; and 4 Any of the following: 4.1 At least three months of 1500 ug or more daily of inhaled beclomethasone or budesonide for adult; or 4.2 At least three months of 750 ug or more daily of inhaled fluticasone) for adult; or 4.3 At least three months of 800 ug or more daily inhaled beclomethasone or budesonide for child; or 4.4 At least three months of 400 ug or more daily inhaled fluticasone) for child; and 5 Either: 5.1 Short acting beta agonist used at least 3-4 times daily; or 5.2 Nocturnal awakenings at least twice a week. Renewal only from a relevant specialist or general practitioner. Appro
524 Maximum of 35 tablets per prescription
525 Maximum of 25 tablets per prescription
526 Maximum of one pack (21 tabs) per prescription
527 Maximum of one pack (42 tabs) per prescription
528 Special Authority for Subsidy - Form SA0528Initial application - (Narcolepsy) only from a neurologist or respiratory specialist. Approvals valid for 24 months where narcolepsy. Initial application - (ADHD in patients 5 or over) only from a paediatrician, psychiatrist or general practitioner. Approvals valid for 24 months for applications meeting the following criteria: All of the following: 1 ADHD (Attention Deficient and Hyperactivity Disorder) patients aged 5 years or over; and 2 Diagnosed according to DSM-IV or ICD 10 criteria; and 3 Applicant is a specialist or specialist has recommended treatment. Initial application - (ADHD in patients under 5) only from a paediatrician or psychiatrist. Approvals valid for 12 months for applications meeting the following criteria: Both: 1 ADHD (Attention Deficient and Hyperactivity Disorder) patients under 5 years of age; and 2 Diagnosed according to DSM-IV or ICD 10 criteria. Renewal - (Narcolepsy) only from a neurologist or respiratory spec
530 Safety cap reimbursed
532 Oral contraceptive
533 Exempt from monthly dispensing
535 ACE inhibitors will be funded to the level of the ex-manufacturer price listed in the Schedule for patients who were taking an ACE inhibitor for the treatment of congestive heart failure prior to 1 June 1998. The prescription must be endorsed accordingly. We recommend that the words used to indicate eligibility are "certified condition" or an appropriate description of the patient such as "congestive heart failure", "CHF", "congestive cardiac failure" or "CCF". Additional subsidy for lisinopril is available only up to the price of the least expensive brand listed in the Schedule. Definition of Congestive Heart FailureAt the request of some prescribers the PTAC Cardiovascular subcommittee has provided adefinition of congestive heart failure for the purposes of the funding of the manufacturer'ssurcharge: "Clinicians should use their clinical judgement. Existing patients would be eligible for thefunding of the surcharge if the patient shows signs and symptoms of congestive heart failure, and requir
536 Additional subsidy by endorsement for:Moclobemide tab 150 mg x 100 (Aurorix) up to $47.00Moclobemide tab 300 mg x 60 (Aurorix) up to $56.40Nefazadone tab 100 mg x 56 (Serzone) up to $20.16Nefazadone tab 200 mg x 56 (Serzone) up to $40.32Citalopram tab 20 mg x 28 (Cipramil) up to $27.00is available for patients who: * are taking moclobemide or nefazodone on 1 December 1999 or citalopram on 1 February2000; * have previously responded to treatment with moclobemide or nefazodone or citalopram; * have had a trial of fluoxetine and have to discontinue due to: - inability to tolerate the drug due to side effects OR - failed to respond to an adequate dose and duration of treatment; * have contraindications to fluoxetine (eg pre-existing significant levels of nausea, breastfeeding, potential drug interactions); The prescription must be endorsed accordingly. We recommend that the words used to indicate eligibility are "certified condition" however these particular words are not a requirement.
537 Maximum of 12 tablets per prescription.
538 Special Authority for Subsidy - Form SA0538Initial application only from a gastroenterologist, infectious disease specialist, paediatrician or general physician. Approvals valid for 1 year for applications meeting the following criteria: Both: 1 Any of the following: 1.1 All of the following: 1.1.1 HBsAg positive for more than 6 months; and 1.1.2 HBeAg positive or HBV DNA positive defined as >0.6 pg/ml by quantitative PCR at reference laboratory; and 1.1.3 ALT greater than twice upper limit of normal or stage 3 or 4 fibrosis on liver histology clinical/radiological evidence of cirrhosis; or 1.2 HBV DNA positive cirrhosis prior to liver transplantation; or 1.3 HBsAg positive and have had a liver, kidney, heart, lung or bone marrow transplant; and 2 All of the following: 2.1 No continuing alcohol abuse or intravenous drug use; and 2.2 Not coinfected with HCV, HDV, or HIV; and 2.3 Neither ALT nor AST greater than 10 times upper limit of normal; and 2.4
539 Special Authority for Subsidy - Form SA0539Initial application from any medical practitioner. Approvals valid for 5 years where the patient is likely to benefit from treatment. NoteApplications to be made on the approved forms which are available from: The Co-ordinatorPhone: 09 580 9176Multiple Sclerosis Treatment CommitteeFacsimile: 09 580 9205Level 3, Unisys HouseEmail: murray@ppc.govt.nz650 Great South Road, PenrosePrivate Bag, AUCKLANDBudget managed by appointed clinicians on the Multiple Sclerosis Treatment Assessments Committee (MSTAC). Applications will be considered by MSTAC at its regular meetings and approved subject to eligibility according to the Entry and Stopping criteria (below). Completed application forms must be sent to the co-ordinator for MSTAC and will be considered by MSTAC at the next practicable opportunity. Notification of MSTAC's decision will be sent to the patient, the applying clinician and the patient's GP (if specified). These agents will N
540 Only if prescribed for a dialysis patient and the prescription is endorsed accordingly.
541 Only if prescribed for renal dialysis, maternity or post-natal care in the home of the patient and the prescription is endorsed accordingly.
542 Only when prescribed in a quantity not exceeding 15 g per prescription form.
543 Not on a WSO.
544 Oral liq prescriptions: a) Must be written by a Paediatrician or Paediatric Cardiologist; orb) On the recommendation of a Paediatrician or Paediatric Cardiologist.
545 Restricted to children under 12 years of age.
546 Additional subsidy by endorsement for:Moclobemide tab 150 mg x 100 (Aurorix) up to $47.00Moclobemide tab 300 mg x 60 (Aurorix) up to $56.40Nefazadone tab 100 mg x 56 (Serzone) up to $20.16Nefazadone tab 200 mg x 56 (Serzone) up to $40.32Citalopram tab 20 mg x 28 (Cipramil) up to $27.00is available for patients who: * were taking moclobemide or nefazodone on 1 December 1999 or citalopram on 1 February 2000; or* have previously responded to treatment with moclobemide, nefazodone or citalopram; or* have had a trial of fluoxetine and have to discontinue due to: - inability to tolerate the drug due to side effects; or - failed to respond to an adequate dose and duration of treatment; or* have contraindications to fluoxetine (eg pre-existing significant levels of nausea, breastfeeding, potential drug interactions); The prescription must be endorsed accordingly. We recommend that the words used to indicate eligibility are "certified condition" however these words are not a requirement.
547 Alphagan is subsidised for use as either monotherapy or as an adjunctive agent for the treatment of glaucoma. Alphagan should not be prescribed for a person in whom less expensive first line agents for the treatment of glaucoma are not contraindicated unless: (a) that person has previously trialled all other such subsidised agents (except dorzolamide hydrochloride); and(b) those trials have indicated that that person does not respond adequately to or does not tolerate treatment with those other agents.
548 a) Maximum of 4 tablets per prescription
549 No user copayment payable
550 Maximum user copayment of $3
551 Special Authority for Subsidy - Form SA0551Initial application only from a paediatrician, neurologist or general physician. Approvals valid for 15 months for applications meeting the following criteria: Any of the following: 1 Was on NAED therapy before 1 September 2000; or 2 Seizures are not adequately controlled with optimal older anti-epilepsy drug treatment; or 3 Seizures are controlled adequately but who experience unacceptable side effects from older anti-epilepsy drug treatment. NoteApproval entitles patients to a subsidy for one NAED. Dual NAED therapy will be subsidised for patients who were already stabilised on two NAEDs on or before 31 July 2000 or, for whom a second NAED has been added to therapy with one NAED provided an attempt to withdraw one NAED has been made and was unsuccessful. "Optimal older anti-epilepsy drug therapy" is defined as treatment with those older anti-epilepsy drugs which are indicated and clinically appropriate for the patient, given singly and in combin
552 Nicotine patches and gum: a) are only available /subsidised on presentation of a Quitline exchange card.b) for reimbursement refer to the Claiming Procedures for the Subsidised Nicotine Patches and Gum Programme. c) have a maximum patient co-payment (contribution) of $10 per exchange card.
554 Special Authority for Subsidy - Form SA0554Initial application only from a relevant specialist. Approvals valid without further renewal unless notified for applications meeting the following criteria: Either: 1 Liver transplant recipients; or 2 Renal transplant recipients - as rescue therapy only. Renewal only from a relevant specialist. Approvals valid without further renewal unless notified where the treatment remains appropriate and the patient is benefiting from treatment.
555 a) Fluoxetine hydrochloride tab dispersible 20 mg restricted to a maximum daily dose of 10 mg. b) Tablets can be combined with capsules to facilitate incremental 10 mg doses.
556 Special Authority for Subsidy - Form SA0556Initial application - (Confirmed HIV/AIDS) only from a named general physician. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 Confirmed HIV/AIDS; and 2 Any of the following: 2.1 Symptomatic patient; or 2.2 Both: 2.2.1 Asymptomatic patient; and 2.2.2 Patient aged 12 months and under; or 2.3 Both: 2.3.1 Asymptomatic patient; and 2.3.2 Patient has viral load counts > 10,000 copies per ml or equivalent value on the Chiron test; or 2.4 All of the following: 2.4.1 Asymptomatic patient; and 2.4.2 Patient aged 1 to 5 years; and 2.4.3 CD4 counts < 1,000 cells/mm3; or 2.5 All of the following: 2.5.1 Asymptomatic patient; and 2.5.2 Patient aged 1 to 5 years; and 2.5.3 CD4 counts < 0.25 x total white cell count; or 2.6 All of the following: 2.6.1 Asymptomatic patient; and 2.6.2 Patient aged 6 years and over; and 2.6.3 CD4 counts
557 Special Authority for Subsidy - Form SA0557Initial application - (Single NAED Therapy) only from a paediatrician, neurologist or general physician. Approvals valid for 15 months for applications meeting the following criteria: Any of the following: 1 Was on NAED therapy before 1 September 2000; or 2 Seizures are not adequately controlled with optimal older anti-epilepsy drug treatment; or 3 Seizures are controlled adequately but who experience unacceptable side effects from older anti-epilepsy drug treatment. Note"Optimal older anti-epilepsy drug therapy" is defined as treatment with those older anti-epilepsy drugs which are indicated and clinically appropriate for the patient, given singly and in combination in adequate doses for the patient's age, weight, and other features affecting the pharmacokinetics of the drug with good evidence of complianceAs a guideline, clinical trials have referred to a notional 50% reduction in seizure frequency as an indicator of success with anti-convulsan
558 Additional subsidy by endorsement for:Moclobemide tab 150mg x 100 (Aurorix) up to $32.90Moclobemide tab 300mg x 60 (Aurorix) up to $39.48Nefazodone tab 100mg x 56 (Serzone) up to $20.16Nefazodone tab 200mg x 56 (Serzone) up to $40.32Citalopram tab 20mg x 28 (Cipramil) up to $27.00is available for patients who: * were taking moclobemide or nefazodone on 1 December 1999 or citalopram on 1 February 2000; or* have previously responded to treatment with moclobemide, nefazodone or citalopram; or* have had a trial of fluoxetine and have had to discontinue due to - inability to tolerate the drug due to side effects; or - failed to respond to an adequate dose and duration of treatment; or* have contraindications to fluoxetine (eg pre-existing significant levels of nausea, breastfeeding, potential drug interactions). The prescription must be endorsed accordingly. We recommend that the words used to indicate eligibility are "certified condition" however these words are not a requirement.
560 Additional subsidy by endorsement for:Moclobemide tab 150mg x 100 (Aurorix) up to $32.90Moclobemide tab 300mg x 60 (Aurorix) up to $39.48Nefazodone tab 100mg x 56 (Serzone) up to $20.16Nefazodone tab 200mg x 56 (Serzone) up to $40.32Citalopram tab 20mg x 28 (Cipramil and Celapram) up to $10.00Paroxetine hydrochloride tab 20 mg x 30 (Aropax) up to $35.02is available for patients who: * were taking moclobemide or nefazodone on 1 December 1999 or citalopram on 1 February 2000; or paroxetine hydrochloride on Februrary 2001; or * have previously responded to treatment with moclobemide or nefazodone or citalopram or paroxetine hydrochloride; or* have had a trial of fluoxetine and have had to discontinue due to - inability to tolerate the drug due to side effects; or - failed to respond to an adequate dose and duration of treatment; or* have contraindications to fluoxetine (eg pre-existing significant levels of nausea, breastfeeding, potential drug interactions). The prescription must be e
561 Not on a BSO.
563 Special Authority for Subsidy - Form SA0563Initial application only from a relevant specialist. Approvals valid for 2 years for applications meeting the following criteria: Any of the following: 1 Both: 1.1 Acromegaly; and 1.2 Patient has failed surgery, radiotherapy, bromocriptine and other oral therapies; or 2 VIPomas and Glucagonomas - for patients who are seriously ill in order to improve their clinical state prior to definitive surgery.; or 3 Both: 3.1 Gastrinoma; and 3.2 Either: 3.2.1 Patient has failed surgery; or 3.2.2 Patient in metastatic disease after H2 antagonists (or proton pump inhibitors) have failed; or 4 Both: 4.1 Insulinomas; and 4.2 Surgery is contraindicated or has failed; or 5 For pre-operative control of hypoglycaemia and for maintenance therapy; or 6 Both: 6.1 Carcinoid syndrome (diagnosed by tissue pathology and/or urinary 5HIAA analysis); and 6.2 Disabling symptoms not controlled by maximal medical therapy. No
564 Only if prescribed on a prescription for for renal dialysis, maternity or post-natal care in the home of the patient, or on a PSO for emergency use.
566 Trandolapril will be funded to the level of the ex-manufacturer price listed in the Schedule for patients who were taking these ACE inhibitors for the treatment of congestive heart failure prior to 1 June 1998. The prescription must be endorsed accordingly. We recommend that the words used to indicate eligibility are "certified condition" or an appropriate description of the patient such as "congestive heart failure", "CHF", "congestive cardiac failure" or "CCF". Definition of Congestive Heart Failure At the request of some prescribers the PTAC Cardiovascular subcommittee has provided a definition of congestive heart failure for the purposes of the funding of the manufacturer's surcharge: "Clinicians should use their clinical judgement. Existing patients would be eligible for the funding of the surcharge if the patient shows signs and symptoms of congestive heart failure, and requires or has in the past required concomitant treatment with a diuretic. The definition could also be considered to include pat
567 Additional subsidy by endorsement for dispersible tablets
568 Perindopril will be funded to the level of the ex-manufacturer price listed in the Schedule for patients who were taking these ACE inhibitors for the treatment of congestive heart failure prior to 1 June 1998. The prescription must be endorsed accordingly. We recommend that the words used to indicate eligibility are "certified condition" or an appropriate description of the patient such as "congestive heart failure", "CHF", "congestive cardiac failure" or "CCF". Definition of Congestive Heart Failure At the request of some prescribers the PTAC Cardiovascular subcommittee has provided a definition of congestive heart failure for the purposes of the funding of the manufacturer's surcharge: "Clinicians should use their clinical judgement. Existing patients would be eligible for the funding of the surcharge if the patient shows signs and symptoms of congestive heart failure, and requires or has in the past required concomitant treatment with a diuretic. The definition could also be considered to include pati
569 Special Authority for Subsidy - Form SA0569Initial application only from a geriatrician, rheumatologist, endocrinologist, gynaecologist or general physician. Approvals valid for 2 years for applications meeting the following criteria: All of the following: 1 Severe osteoporosis; and 2 History of one previous significant osteoporotic fractures demonstrated radiologically; and 3 T-Score <= -3.0 (bone mass density (BMD) >= 3.0 standard deviations below the mean normal value in young adults). NoteIn line with the Australian guidelines for funding alendronate, a vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body. Renewal only from a geriatrician, rheumatologist, endocrinologist, gynaecologist or general physician. Approvals valid for 2 years where the t
570 Not on a Prescription.
571 a) Only if prescribed on prescription for a dialysis patient or child with rheumatic fever or on a PSO for emergency use.
572 Special Authority for Subsidy - Form SA0572Initial application only from a psychiatrist. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 Patient presenting with first episode schizophrenia or related psychoses; or 2 Both: 2.1 Patients suffers from schizophrenia or related psychoses ; and 2.2 Either: 2.2.1 A trial of risperidone has been discontinued because of unacceptable side effects; or 2.2.2 A trial of risperidone has been discontinued because of inadequate response. Renewal only from a psychiatrist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
574 Subsidy is available for patients with poorly controlled asthma where: a) at least three months of 750 mcg or more daily of inhaled beclomethasone or budesonide(or 400 mcg of fluticasone) for adults has been used; orb) at least three months of 400 mcg or more daily of inhaled beclomethasone or budesonide (or 200mcg of fluticasone) for children 12 years or older has been used; The prescription must be endorsed accordingly. We recommend that the words used to indicateeligibility are "poor control with ICS" or "certified condition".
575 Special Authority for Subsidy - Form SA0575Initial application - (Confirmed HIV/AIDS) only from a named general physician. Approvals valid without further renewal unless notified for applications meeting the following criteria: Both: 1 Confirmed HIV/AIDS; and 2 Any of the following: 2.1 Symptomatic patient; or 2.2 Both: 2.2.1 Asymptomatic patient; and 2.2.2 Patient aged 12 months and under; or 2.3 Both: 2.3.1 Asymptomatic patient; and 2.3.2 Patient has viral load counts > 10,000 copies per ml or equivalent value on the Chiron test; or 2.4 All of the following: 2.4.1 Asymptomatic patient; and 2.4.2 Patient aged 1 to 5 years; and 2.4.3 CD4 counts < 1,000 cells/mm3; or 2.5 All of the following: 2.5.1 Asymptomatic patient; and 2.5.2 Patient aged 1 to 5 years; and 2.5.3 CD4 counts < 0.25 x total white cell count; or 2.6 All of the following: 2.6.1 Asymptomatic patient; and 2.6.2 Patient aged 6 years and over
577 Dispersible tablets are subsidised only for patients who are unable to swallow tablets and the prescription is endorsed accordingly.
579 Special Authority for Subsidy - Form SA0579Initial application - (Cystic fibrosis or renal failure) only from a relevant specialist. Approvals valid for 3 years for applications meeting the following criteria: Either: 1 cystic fibrosis; or 2 chronic renal failure or continuous ambulatory peritoneal dialysis (CAPD) patient. Initial application - (Indications other than cystic fibrosis or renal failure) only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria: Any of the following: 1 cancer in children; or 2 cancers affecting alimentary tract where there are malabsorption problems in patients over the age of 20 years; or 3 failure to thrive; or 4 growth deficiency; or 5 bronchopulmonary dysplasia; or 6 premature and post premature infant. Renewal - (Cystic fibrosis or renal failure) only from a relevant specialist or general practitioner on the recommendation of such a specialist. Approvals valid for 3 years for applicatio
580 Special Authority for Subsidy - Form SA0580Initial application - (Inborn errors of metabolism) only from a relevant specialist. Approvals valid for 3 years where inborn errors of metabolism. Initial application - (Indications other than inborn errors of metabolism) only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria: Any of the following: 1 failure to thrive ; or 2 growth deficiency; or 3 bronchopulmonary dysplasia ; or 4 fat malabsorption ; or 5 lymphangiectasia; or 6 short bowel syndrome ; or 7 infants with necrotising enterocolitis; or 8 biliary atresia. Renewal - (Inborn errors of metabolism) only from a relevant specialist or general practitioner on the recommendation of such a specialist. Approvals valid for 3 years for applications meeting the following criteria: Both: 1 The treatment remains appropriate and the patient is benefiting from treatment; and 2 General Practitioners must include the name of
581 Special Authority for Subsidy - Form SA0581Initial application - (Cystic fibrosis) only from a relevant specialist. Approvals valid for 3 years for applications meeting the following criteria: Both: 1 infant aged four years or under; and 2 cystic fibrosis. Initial application - (Indications other than cystic fibrosis) only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria: Both: 1 infant aged four years or under; and 2 Any of the following: 2.1 cancer in children; or 2.2 failure to thrive; or 2.3 growth deficiency; or 2.4 bronchopulmonary dysplasia; or 2.5 premature and post premature infants. Renewal - (Cystic fibrosis) only from a relevant specialist or general practitioner on the recommendation of such a specialist. Approvals valid for 3 years for applications meeting the following criteria: Both: 1 The treatment remains appropriate and the patient is benefiting from treatment; and 2 General Practiti
582 Special Authority for Subsidy - Form SA0582Initial application only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria: Either: 1 protein losing enteropathy; or 2 high protein needs (eg burns). Renewal only from a relevant specialist or general practitioner on the recommendation of such a specialist. Approvals valid for 1 year for applications meeting the following criteria: Both: 1 The treatment remains appropriate and the patient is benefiting from treatment; and 2 General Practitioners must include the name of the specialist and date contacted.
585 Special Authority for Subsidy - Form SA0585Initial application - (Cystic fibrosis) only from a relevant specialist. Approvals valid for 3 years for applications meeting the following criteria: All of the following: 1 Cystic fibrosis; and 2 other lower calorie products have been tried; and 3 patient has substantially increased metabolic requirements; and 4 Either: 4.1 The product is to be used as a supplement; or 4.2 The product is to be used as a complete diet.Initial application - (Indications other than cystic fibrosis) only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria: All of the following: 1 Any of the following: 1.1 any condition causing malabsorption ; or 1.2 failure to thrive ; or 1.3 increased nutritional requirements.; and 2 other lower calorie products have been tried; and 3 patient has substantially increased metabolic requirements; and 4 Either: 4.1 The product is to be used a
587 Special Authority for Subsidy - Form SA0587Initial application only from a relevant specialist. Approvals valid for 3 years for applications meeting the following criteria: Both: 1 acute or chronic renal failure; and 2 Either: 2.1 The product is to be used as a supplement (maximum 500 ml per day); or 2.2 The product is to be used as a complete diet.Renewal only from a relevant specialist or general practitioner on the recommendation of such a specialist. Approvals valid for 3 years for applications meeting the following criteria: All of the following: 1 The treatment remains appropriate and the patient is benefiting from treatment; and 2 Either: 2.1 The product is to be used as a supplement (maximum 500 ml per day); or 2.2 The product is to be used as a complete diet; and 3 General Practitioners must include the name of the specialist and date contacted.
588 Special Authority for Subsidy - Form SA0588Initial application only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria: Both: 1 CORD patients who have hypercapnia; and 2 Either: 2.1 The product is to be used as a supplement (maximum 500 ml per day); or 2.2 The product is to be used as a complete diet.Renewal only from a relevant specialist or general practitioner on the recommendation of such a specialist. Approvals valid for 1 year for applications meeting the following criteria: All of the following: 1 The treatment remains appropriate and the patient is benefiting from treatment; and 2 Either: 2.1 The product is to be used as a supplement (maximum 500 ml per day); or 2.2 The product is to be used as a complete diet; and 3 General Practitioners must include the name of the specialist and date contacted.
589 Special Authority for Subsidy - Form SA0589Initial application only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria: All of the following: 1 Anorexia and weight loss; and 2 Either: 2.1 decompensating liver disease without encephalopathy ; or 2.2 protein losing gastro-enteropathy; and 3 Either: 3.1 The product is to be used as a supplement (maximum 500 ml per day); or 3.2 The product is to be used as a complete diet.Renewal only from a relevant specialist or general practitioner on the recommendation of such a specialist. Approvals valid for 1 year for applications meeting the following criteria: All of the following: 1 The treatment remains appropriate and the patient is benefiting from treatment; and 2 Either: 2.1 The product is to be used as a supplement (maximum 500 ml per day); or 2.2 The product is to be used as a complete diet; and 3 General Practitioners must include the name of the specialis
590 Special Authority for Subsidy - Form SA0590Initial application only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria: All of the following: 1 infant aged one to six years; and 2 Any of the following: 2.1 any condition causing malabsorption ; or 2.2 failure to thrive; or 2.3 increased nutritional requirements; and 3 Either: 3.1 The product is to be used as a supplement (maximum 500 ml per day); or 3.2 The product is to be used as a complete diet.Renewal only from a relevant specialist or general practitioner on the recommendation of such a specialist. Approvals valid for 1 year for applications meeting the following criteria: All of the following: 1 The treatment remains appropriate and the patient is benefiting from treatment; and 2 Either: 2.1 The product is to be used as a supplement (maximum 500 ml per day); or 2.2 The product is to be used as a complete diet; and 3 General Practitioners must
591 Special Authority for Subsidy - Form SA0591Initial application only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria: Both: 1 Any of the following: 1.1 enteral feeding; or 1.2 nasogastric; or 1.3 nasoduodenal ; or 1.4 nasojejunal; or 1.5 gastrostomy/jejunostomy; and 2 Either: 2.1 The product is to be used as a supplement; or 2.2 The product is to be used as a complete diet.Renewal only from a general practitioner or relevant specialist. Approvals valid for 1 year for applications meeting the following criteria: All of the following: 1 The treatment remains appropriate and the patient is benefiting from treatment; and 2 Either: 2.1 The product is to be used as a supplement; or 2.2 The product is to be used as a complete diet; and 3 General Practitioners must include the name of the specialist and date contacted.
592 Special Authority for Subsidy - Form SA0592Initial application only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria: Both: 1 Any of the following: 1.1 malabsorption ; or 1.2 short bowel syndrome; or 1.3 enterocutaneous fistulas ; or 1.4 pancreatitis; and 2 Either: 2.1 The product is to be used as a supplement (maximum 500 ml per day); or 2.2 The product is to be used as a complete diet.NoteEach of these products is highly specialised and would be prescribed only by an expert for a specific disorder. The alternative is hospitalisation. Elemental 028 Extra is more expensive than other products listed in this section and should only be used where the alternatives have been tried first and/or are unsuitable. Renewal only from a relevant specialist or general practitioner on the recommendation of such a specialist. Approvals valid for 1 year for applications meeting the following criteria: All of the following:
594 Special Authority for Subsidy - Form SA0594Initial application only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria: Both: 1 Type I and II diabetics who require nutritional supplementation.; and 2 Either: 2.1 The product is to be used as a supplement (maximum 500 ml per day); or 2.2 The product is to be used as a complete diet.Renewal only from a relevant specialist or general practitioner on the recommendation of such a specialist. Approvals valid for 1 year for applications meeting the following criteria: All of the following: 1 The treatment remains appropriate and the patient is benefiting from treatment; and 2 Either: 2.1 The product is to be used as a supplement (maximum 500 ml per day); or 2.2 The product is to be used as a complete diet; and 3 General Practitioners must include the name of the specialist and date contacted.
595 Special Authority for Subsidy - Form SA0595Initial application only from a relevant specialist. Approvals valid for 1 year where patient has motor neurone disease with swallowing disorder. Renewal only from a relevant specialist or general practitioner on the recommendation of such a specialist. Approvals valid for 1 year for applications meeting the following criteria: Both: 1 The treatment remains appropriate and the patient is benefiting from treatment; and 2 General Practitioners must include the name of the specialist and date contacted.
596 Special Authority for Subsidy - Form SA0596Initial application only from a relevant specialist. Approvals valid for 3 years for applications meeting the following criteria: Either: 1 gluten enteropathy has been diagnosed by biopsy; or 2 dermatitis herpetiformis. NoteA premium may be payable if the subsidy does not match the price charged by the manufacturer. The subsidy for these products reflects the philosophy that the patient incurs no additional financial burden for purchasing specialised more expensive products. Renewal only from a relevant specialist or general practitioner on the recommendation of such a specialist. Approvals valid for 3 years for applications meeting the following criteria: Both: 1 The treatment remains appropriate and the patient is benefiting from treatment; and 2 General Practitioners must include the name of the specialist and date contacted.
597 Special Authority for Subsidy - Form SA0597Initial application - (PKU Patient aged over 16) only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria: Both: 1 PKU; and 2 blood phenylalanine level < 900 mmol/litre (average of tests over last 12 months). Initial application - (Patient aged over 16) only from a relevant specialist. Approvals valid for 3 years for applications meeting the following criteria: Any of the following: 1 dietary management of homocystinuria; or 2 inborn errors of metabolism other than PKU; or 3 dietary management of maple syrup urine disease..Initial application - (Patient aged 16 or under) only from a relevant specialist. Approvals valid for 3 years for applications meeting the following criteria: Any of the following: 1 dietary management of homocystinuria; or 2 PKU and other inborn errors of metabolism; or 3 dietary management of maple syrup urine disease..Renewal - (PKU Patient aged over 16
599 NoteLofenalac when used with Ketovite is considerably cheaper than Maxamaid or Maxamum.
600 Special Authority for Subsidy - Form SA0600Initial application only from a relevant specialist. Approvals valid for 3 years where inborn errors of metabolism. Renewal only from a relevant specialist or general practitioner on the recommendation of such a specialist. Approvals valid for 3 years for applications meeting the following criteria: Both: 1 The treatment remains appropriate and the patient is benefiting from treatment; and 2 General Practitioners must include the name of the specialist and date contacted.
601 Special Authority for Subsidy - Form SA0601Initial application only from a relevant specialist. Approvals valid for 1 year where Infant suffering from Williams Syndrome and associated hypercalcaemia. Renewal only from a relevant specialist or general practitioner on the recommendation of such a specialist. Approvals valid for 1 year for applications meeting the following criteria: Both: 1 The treatment remains appropriate and the patient is benefiting from treatment; and 2 General Practitioners must include the name of the specialist and date contacted.
602 Special Authority for Subsidy - Form SA0602Initial application only from a relevant specialist. Approvals valid for 6 months where infant weighing less than 1.5 kg at birth.
603 Special Authority for Subsidy - Form SA0603Initial application only from a relevant specialist. Approvals valid for 1 year where infant suffering from malabsorption and other gastrointestinal problems. Renewal only from a relevant specialist or general practitioner on the recommendation of such a specialist. Approvals valid for 1 year for applications meeting the following criteria: Both: 1 The treatment remains appropriate and the patient is benefiting from treatment; and 2 General Practitioners must include the name of the specialist and date contacted.
604 Special Authority for Subsidy - Form SA0604Initial application - (Lactase deficiency or disaccharide intolerance) only from a relevant specialist. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 Patient is less than 3 years of age; and 2 Either: 2.1 diagnosed as suffering from congenital lactase deficiency; or 2.2 suffering from disaccharide intolerance. NoteSecondary lactose intolerance in children is usually short lasting, and can be controlled by dietary measures and by giving sufficient calories to regenerate digestive enzymes. The subsidy for these products reflects the philosophy that the patient incurs no additional financial burden for purchasing specialised more expensive products. Initial application - (Infant with intolerance to cows' milk) only from a relevant specialist. Approvals valid for 6 months for applications meeting the following criteria: Both: 1 intolerant to cows' milk; and 2 patient is less than 3 years of age. No
605 Special Authority for Subsidy - Form SA0605Initial application - (Cystic fibrosis or renal disorder) only from a relevant specialist. Approvals valid for 3 years for applications meeting the following criteria: Both: 1 Either: 1.1 cystic fibrosis; or 1.2 renal disorder; and 2 Either: 2.1 The product is to be used as a supplement; or 2.2 The product is to be used as a complete diet.Initial application - (Indications other than cystic fibrosis or renal disorder) only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria: Both: 1 Any of the following: 1.1 any condition causing malabsorption; or 1.2 failure to thrive; or 1.3 increased nutritional requirements; and 2 Either: 2.1 The product is to be used as a supplement; or 2.2 The product is to be used as a complete diet.Renewal - (Cystic fibrosis or renal disorder) only from a relevant specialist or general practitioner. Approvals valid for 3 years
606 Special Authority for Subsidy - Form SA0606Initial application only from a paediatrician. Approvals valid for 3 years for applications meeting the following criteria: Both: 1 child (up to 18 years) with chronic renal failure.; and 2 Either: 2.1 The product is to be used as a supplement; or 2.2 The product is to be used as a complete diet.Renewal only from a paediatrician. Approvals valid for 3 years for applications meeting the following criteria: Both: 1 The treatment remains appropriate and the patient is benefiting from treatment; and 2 Either: 2.1 The product is to be used as a supplement; or 2.2 The product is to be used as a complete diet.
607 Special Authority for Subsidy - Form SA0607Initial application only from a paediatrician. Approvals valid for 3 years for applications meeting the following criteria: Both: 1 Child (up to 18 years) who is awaiting liver transplant; and 2 Either: 2.1 The product is to be used as a supplement (maximum 500 ml per day); or 2.2 The product is to be used as a complete diet.Renewal only from a paediatrician. Approvals valid for 3 years for applications meeting the following criteria: Both: 1 The treatment remains appropriate and the patient is benefiting from treatment; and 2 Either: 2.1 The product is to be used as a supplement (maximum 500 ml per day); or 2.2 The product is to be used as a complete diet.
609 Special Authority for Subsidy - Form SA0609Initial application - (Serevent MDI, Serevent Accuhaler Foradil, Oxis Turbuhaler 12 mcg, Symbicort Turbuhaler) only from a relevant specialist or general practitioner. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 Both: 1.1 Child under the age of 12 with poorly controlled asthma; and 1.2 Either: 1.2.1 Required at least three months of 400 mcg or more daily inhaled beclomethasone or budesonide; or 1.2.2 Required at least three months of 200 mcg or more of fluticasone; or 2 Both: 2.1 Adult with poorly controlled asthma; and 2.2 Either: 2.2.1 Required at least three months of 1500 mcg or more daily inhaled beclomethasone or budesonide; or 2.2.2 Required at least three months of 750 mcg or more of fluticasone. NotePatients are to be reviewed at least at six months to assess compliance and effectiveness of therapy. Special Authority approvals are interchangeable among all prese
610 Special Authority for Subsidy - Form SA0610Initial application from any specialist. Approvals valid without further renewal unless notified for applications meeting the following criteria: All of the following: 1 Quantity used by patient on a weekly volume intraveneously (Details to be attached to application); and 2 Amount of nutrition patient is able to receive orally (Details to be attached to application); and 3 Exact formula of TPN (Details to be attached to application); and 4 Who has paid for TPN so far (Details to be attached to application); and 5 Place of manufacture (Details to be attached to application); and 6 Complete medical history of patient including details of previous therapies. (Details to be attached to application). Renewal - (Previous approval has expired) from any specialist. Approvals valid without further renewal unless notified where the treatment remains appropriate and the patient is benefiting from treatment.
611 Special Authority for Subsidy - Form SA0611Initial application from any medical practitioner. Approvals valid for 1 year where applicaton approved by the Cystic Fibrosis DN'ase Advisory Panel. NoteApplications to be made on the approved forms which are available from: The Co-ordinatorCystic Fibrosis DN'ase Advisory PanelPhone: (04) 460 4990 PHARMAC, PO Box 10 254 WellingtonFacsimile: (04) 916 7571Email: erin.murphy@pharmac.govt.nzPrescriptions for patients approved for treatment must be written by respiratory physicians or paediatricians who have experience and expertise in treating cystic fibrosis.
612 Special Authority for Manufacturers Price - Form SA0612Renewal from any medical practitioner. Approvals valid for 2 years where patient recieved Special Authority prior to 1 June 1998.
613 Special Authority for Alternate Subsidy - Form SA0613Initial application from any medical practitioner. Approvals valid for 2 years for applications meeting the following criteria: Any of the following: 1 Polycystic ovarian syndrome; or 2 Hirsutism; or 3 Androngenic alopecia. Renewal from any medical practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
614 Special Authority for Subsidy - Form SA0614Initial application only from a geriatrician, rheumatologist, endocrinologist, gynaecologist or general physician. Approvals valid for 2 years for applications meeting the following criteria: All of the following: 1 Severe osteoporosis; and 2 History of one previous significant osteoporotic fractures demonstrated radiologically; and 3 T-Score <= -3.0 (bone mass density (BMD) >= 3.0 standard deviations below the mean normal value in young adults). NoteIn line with the Australian guidelines for funding alendronate, a vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral bodyRenewal only from a geriatrician, rheumatologist, endocrinologist, gynaecologist or general physician. Approvals valid for 2 years where the tr
615 Special Authority for Subsidy - Form SA0615Initial application only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria: Both: 1 The product is to be used as a complete diet; and 2 Either: 2.1 Patient has metabolic disorders of fat metabolism; or 2.2 Patient has chylothorax. Renewal only from a relevant specialist or general practitioner on the recommendation of such a specialist. Approvals valid for 1 year for applications meeting the following criteria: Both: 1 The treatment remains appropriate and the patient is benefiting from treatment; and 2 General Practitioners must include the name of the specialist and date contacted.
616 Special Authority for Manufacturers Price - Form SA0616Initial application - (Conditions other than transient ischaemic episodes) only from a cardiothoracic surgeon, cardiologist or general physician. Approvals valid without further renewal unless notified for applications meeting the following criteria: Either: 1 Patients with prosthetic heart valves - as an adjunct to oral anticoagulation for prophylaxis of thromboembolism; or 2 Patients after coronary artery vein bypass graft - as an adjunct to aspirin or as monotherapy for patients who are aspirin intolerant. NoteAspirin intolerant patients are defined as those with aspirin induced asthma, urticaria, or anaphylaxi, or those with significant aspirin induced bleeding, excluding bruisingInitial application - (Transient ischaemic episodes) only from a neurologist, neuro surgeon, cardiologist, vascular surgeon or general physician. Approvals valid without further renewal unless notified where patients who continue to have transient ischaemic
617 Nicotine patches and gum are only available /subsidised on presentation of a Quitline exchange card.
618 Special Authority - Retail pharmacy
619 Special Authority - Hospital pharmacy
620 a) Prescribers may code prescriptions "contraceptive" (code "O") when used as indicated for contraception. The period of supply and prescription charge will be as per other contraceptives, as follows: - $3.00 prescription charge (patient co-payment) will apply; - prescription may be written for up to six months supply; and- pharmacists may dispense up to three months supply. b) Prescriptions coded in any other way are subject to the non-contraceptive prescription charges, and the non-contraceptive period of supply. ie. Prescriptions may be written for up to three months supply, and dispensed monthly
621 Special Authority for Subsidy - Form SA0621Initial application only from a relevant specialist. Approvals valid for 5 years where the patient is likely to benefit from treatment. Renewal only from a relevant specialist. Approvals valid for 5 years where the treatment remains appropriate and the patient is benefiting from treatment.
622 Special Authority for Subsidy - Form SA0622Initial application only from a geriatrician, rheumatologist, endocrinologist, gynaecologist or general physician. Approvals valid without further renewal unless notified for applications meeting the following criteria: All of the following: 1 Severe osteoporosis; and 2 History of one previous significant osteoporotic fractures demonstrated radiologically; and 3 T-Score <= -3.0 (bone mass density (BMD) >= 3.0 standard deviations below the mean normal value in young adults). NoteIn line with the Australian guidelines for funding alendronate, a vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral bodyRenewal only from a geriatrician, rheumatologist, endocrinologist, gynaecologist or general physician. Approvals va
623 Special Authority for Subsidy - Form SA0623Initial application from any medical practitioner. Approvals valid for 1 year for applications meeting the following criteria: All of the following: 1 The patient is not predisposed to heart arrhythmias; and 2 The patient does not have a pre-existing QT-prolongation or hepatic failure; and 3 The patient is not using other medications which either inhibit the cytochrome P450 3A4 enzyme system or prolong the QT interval; and 4 Any of the following: 4.1 Both: 4.1.1 The patient is an adult with severe reflux oesophagitis; and 4.1.2 other treatment, including acid suppression with proton pump inhibitors, has failed; or 4.2 gastroparesis; or 4.3 malignancy of GI tract causing gastroparesis (or gastric outlet obstruction); or 4.4 The patient is a child (not including infants from 0 to 3 months of age who were born prematurely) with severe gastro-oesophageal reflux; and 5 Diagnosis has been made or confirmed by a general p
624 Subsidy by endorsement Oral liquid is subsidised only for patients: - with oesophageal stricture, or- in terminal care, or- who are either too young or too old to swallow conventional tablets and the prescription is endorsed accordingly. Note: the cost of treatment with ranitidine oral liquid is more than 10 times higher than that of ranitidine tablets. Following the derestriction of access PHARMAC will be monitoring expenditure on ranitidine oral liquid more closely and may, subject to consultation and PHARMAC Board approval, restrict access again if the expenditure was to grow substantially.
625 Maximum of 20 per WSO.
626 Special Authority for Subsidy - Form SA0626Initial application only from a renal physician. Approvals valid for 2 years for applications meeting the following criteria: All of the following: General Criteria: 1 Anaemia of end-stage renal failure (other treatable causes of anaemia being excluded); and 2 Been on haemodialysis or continuous ambulatory peritoneal dialysis (CAPD) for at least three months; and 3 Not under evaluation for, or awaiting, a live donor kidney transplant; and 4 Any of the following: Specific Criteria: 4.1 Anephric; or 4.2 Dependent on regular blood transfusion (1 unit each 4-8 weeks) to maintain haemoglobin > 60g/L; or 4.3 Dependent on regular blood transfusion but cannot be transfused because of severe transfusion reactions; or 4.4 Transfusion induced haemosiderosis (clinical manifestations, serum ferritin >1500 ug/L); or 4.5 Haemoglobin < 70 g/L (mean of at least 4 haemoglobin concentrations over 4 months); or 4.6 Both: 4.6.1 Haemo
627 Prescribing GuidelineTreatment with HMG CoA Reductase Inhibitors (Statins) is recommended for patients withdyslipidaemia and an absolute 5 year cardiovascular risk of 15% or greater. New Zealand Cardiovascular Guideline Group statement. "The 1996 Heart Foundation guidelines for the Assessment and Management of Dyslipidaemia are currently being revised. An evidence-based guideline on the Assessment and Management of Cardiovascular Risk will be developed in 2002. The Cardiovascular Guideline Group has written an interim consensus statement for themanagement of dyslipidaemia. The Heart Foundation cardiovascular risk tables should be used to determine risk. Certain groups are classified to be at very high risk (>20%) and should be treated as such: - Patients who have had a previous cardiovascular event (angina, MI, angioplasty, coronary artery bypass grafts, TIA, ischaemic stroke and peripheral vascular disease)- Patients with genetic lipid disorders- Patients with diabetes and associated microa
628 Special Authority for Subsidy - Form SA0628Initial application only from a cardiologist. Approvals valid without further renewal unless notified for applications meeting the following criteria: Any of the following: 1 Both: 1.1 Congestive heart failure; and 1.2 Cannot tolerate two ACE inhibitors due to persistent cough that resolves on cessation and recurs on re-challenge with ACE inhibitor; or 2 Patients who have experienced angioedema on an ACE inhibitor at any time in the past; or 3 Patients who have experienced angioedema (even if not using an ACE inhibitor) in the last 2 years. Renewal - ((2 year approvals granted before April 2002)) only from a cardiologist. Approvals valid without further renewal unless notified where the treatment remains appropriate and the patient is benefiting from treatment.
631 Special Authority for Subsidy - Form SA0631Initial application only from an ophthalmologist. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 Both: 1.1 Primary open-angle glaucoma; and 1.2 Any of the following: 1.2.1 Patient cannot tolerate Beta-blockers, or Beta-blockers are contraindicated; or 1.2.2 Patient cannot tolerate Pilocarpine, or Pilocarpine is contraindicated; or 1.2.3 Patient cannot tolerate Dorzolamide, or Dorzolamide is contraindicated; or 1.2.4 A reduction in intraocular pressure of 15% or more is not achieved or maintained using dorzolamide either alone or in combination with a beta-blocker; or 2 There is progressive visual field loss and/or optic nerve damage persists after treatment with dorzolamide either alone or in combination with a beta-blocker. NoteSubsidised also for adjunctive use for the treatment of patients who have met the initial application criteria, and in whom latanoprost monotherapy has bee
633 Special Authority for Subsidy - Form SA0633Initial application only from a general practitioner or relevant specialist. Approvals valid without further renewal unless notified for applications meeting the following criteria: Both: 1 Patient is already on an ACE inhibitor or Angiotensin II Antagonist; and 2 Any of the following: 2.1 Both: 2.1.1 Symptomatic heart failure NYHA functional class II-III; and 2.1.2 Patient has been treated with metoprolol and is intolerant to metoprolol or has demonstrated a sub-optimal response to metoprolol; or 2.2 Symptomatic heart failure NYHA functional class III-IV; or 2.3 Patient has left ventricular systolic dysfunction with an ejection fraction of less than 35%.NoteWhere possible treatment should be initiated by or on the recommendation of a specialist.
634 a) Oral liquid restricted to children under 12 years of age.
635 Special Authority for Subsidy - Form SA0635Initial application only from a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria: All of the following: 1 Rheumatoid arthritis; and 2 Patient is not a pregnant woman, or a woman of child-bearing age without adequate contraception; and 3 Patient has been unable to tolerate or has a contraindication to or has had an inadequate response to sulphasalazine and methotrexate (individually or in combination). Renewal only from a rheumatologist. Approvals valid without further renewal unless notified for applications meeting the following criteria: Both: 1 Compliance (prescriber determined) with medication; and 2 Improved rheumatoid arthritis symptom control. NotePatient should have full blood count and liver function tests regularly monitored.
636 Retail pharmacy - subsidy by endorsement a) Subsidised for:i) patients presenting with first episode schizophrenia or related psychoses; andii) patients suffering from schizophrenia or related psychoses after a trial of an effective dose of risperidone that has been discontinued because of unacceptable side effects or inadequate response. b) Initial prescription must be written by a relevant specialist. c) Subsequent prescriptions may be written by a general practitioner. d) The prescription must be endorsed "certified condition".
637 Special Authority for Subsidy - Form SA0637Initial application - (National Heart Foundation risk groups A1:1, A1:2, B, C, D or E) only from a relevant specialist or general practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria: All of the following: 1 The patient has been offered 3-6 months of counseling and an opportunity to modify lifestyle; and 2 Any of the following: 2.1 Both: 2.1.1 NHF A1:1 - Clinically proven ischaemic heart disease; and 2.1.2 total cholesterol > 5.5; or 2.2 Both: 2.2.1 NHF A1:2 - Post coronary artery bypass graft (CABG) or angioplasty; and 2.2.2 total cholesterol > 4.5; or 2.3 Post heart transplant (regardless of cholesterol level); or 2.4 Both: 2.4.1 NHF B: Patients with > 20% 5-year cardiovascular disease risk; and 2.4.2 total cholesterol > 9.0; or 2.5 Both: 2.5.1 NHF C: 15-20% 5-year cardiovascular disease risk; and 2.5.2 total cholesterol >
638 Note: only one multidose cartridge starter pack to be prescribed and dispensed per patient per approval.
639 Special Authority for Subsidy - Form SA0639Initial application - (No previous use) only from a relevant specialist or general practitioner. Approvals valid for 3 months for applications meeting the following criteria: All of the following: 1 The patient has a clinical diagnosis of heavy menstrual bleeding; and 2 The patient has failed to respond to or is unable to tolerate other appropriate pharmaceutical therapies as per the Heavy Menstrual Bleeding Guidelines; and 3 Either: 3.1 serum ferritin level < 16 mg/l (within the last 12 months); or 3.2 haemoglobin level < 120 g/l . NoteApplications are not to be made for use in patients as contraception except where they meet the above criteriaInitial application - (Previous use before 1 October 2002) only from a relevant specialist or general practitioner. Approvals valid for 3 months for applications meeting the following criteria: All of the following: 1 The patient had a clinical diagnosis of heavy menstrual bleeding; and 2
640 Special Authority for Manufacturers Price - Form SA0640Initial application only from a relevant specialist. Approvals valid for 3 years where patients being treated for advanced breast cancer who are refractory to tamoxifen. Renewal only from a relevant specialist. Approvals valid for 3 years where the treatment remains appropriate and the patient is benefiting from treatment.
641 Special Authority for Waiver of Rule - Form SA0641Initial application only from a diabetologist, general physician or paediatrician. Approvals valid without further renewal unless notified for applications meeting the following criteria: Either: 1 Both: 1.1 Use alone (monotherapy); and 1.2 The patient is unable to use any other insulins including those on insulin pump treatment; or 2 Both: 2.1 Use with insulin other than insulin isophane (including ready-mixed preparations); and 2.2 A reasonable trial of insulin isophane has been undertaken and it is not effective or not well tolerated. Note"Reasonable trial", "unable to use", "not effective", "not well tolerated", and "not well tolerated" are not defined and we ask clinicians to use their clinical judgement in interpreting these terms.
642 Restricted to 20 PFMs per order form.
643 Special Authority for Subsidy - Form SA0643Initial application - (CML) only from an oncologist or relevant specialist. Approvals valid for 7 months where approved by the The Glivec Co-ordinator. Initial application - (GIST) only from an oncologist. Approvals valid for 1 year where approved by the The Glivec Co-ordinator. Renewal - (CML) only from an oncologist or relevant specialist. Approvals valid for 6 months where approved by the The Glivec Co-ordinator. Initial application - (GIST) only from an oncologist. Approvals valid for 1 year where approved by the The Glivec Co-ordinator. NoteApplication forms are available from, and prescriptions should be sent to: The Glivec Co-ordinatorPhone: 09 580 9176Level 3, Unisys HouseFacsimile: 09 580 9205650 Great South Road, PenroseEmail: murray@ppc.govt.nzPrivate Bag, AUCKLANDSpecial Authority criteria for CML - access by applicationFunded for patients with diagnosis (confirmed by a haematologist) of a chronic myeloid leukaemia (CML) i
645 Special Authority for Subsidy - Form SA0645Initial application only from a renal physician. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 Both: 1.1 patient in chronic renal failure; and 1.2 Haemoglobin <= 100 g/L; and 2 Either: 2.1 Both: 2.1.1 patient is not diabetic; and 2.1.2 glomerular filtration rate <= 30 ml/min; or 2.2 Both: 2.2.1 patient is diabetic; and 2.2.2 glomerular filtration rate <= 45 ml/min. Renewal only from a renal physician. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment. NoteErythropoietin beta is indicated in the treatment of anaemia associated with chronic renal failure (CRF) where no cause for anaemia other than CRF is detected and there is adequate monitoring of iron stores and iron replacement therapy. The Cockroft-Gault Formula may be used to estimate glomerular filtration rate (GFR) in persons 18 years and over:GFR (male)
646 Special Authority for Subsidy - Form SA0646Initial application only from a renal physician. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 Both: 1.1 patient in chronic renal failure; and 1.2 Haemoglobin <= 100 g/L; and 2 Any of the following: 2.1 Both: 2.1.1 patient is not diabetic; and 2.1.2 glomerular filtration rate <= 30 ml/min; or 2.2 Both: 2.2.1 patient is diabetic; and 2.2.2 glomerular filtration rate <= 45 ml/min; or 2.3 patient is on haemodialysis or peritoneal dialysis. Renewal only from a renal physician. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment. NoteErythropoietin beta is indicated in the treatment of anaemia associated with chronic renal failure (CRF) where no cause for anaemia other than CRF is detected and there is adequate monitoring of iron stores and iron replacement therapy. The Cockroft-Gault Formula may be used to estim
648 Special Authority for Manufacturers Price - Form SA0648Initial application - (Conditions other than transient ischaemic episodes) only from a cardiothoracic surgeon, cardiologist or general physician. Approvals valid without further renewal unless notified for applications meeting the following criteria: Either: 1 Patients with prosthetic heart valves - as an adjunct to oral anticoagulation for prophylaxis of thromboembolism; or 2 Patients after coronary artery vein bypass graft - as an adjunct to aspirin or as monotherapy for patients who are aspirin intolerant. NoteAspirin intolerant patients are defined as those with aspirin induced asthma, urticaria, or anaphylaxi, or those with significant aspirin induced bleeding, excluding bruisingInitial application - (Transient ischaemic episodes) only from a neurologist, neuro surgeon, cardiologist, vascular surgeon or general physician. Approvals valid without further renewal unless notified where patients who continue to have transient ischaemic
649 Special Authority for Subsidy - Form SA0649Initial application - (Conditions other than transient ischaemic episodes) only from a cardiothoracic surgeon, cardiologist or general physician. Approvals valid without further renewal unless notified for applications meeting the following criteria: Either: 1 Patients with prosthetic heart valves - as an adjunct to oral anticoagulation for prophylaxis of thromboembolism; or 2 Patients after coronary artery vein bypass graft - as an adjunct to aspirin or as monotherapy for patients who are aspirin intolerant. NoteAspirin intolerant patients are defined as those with aspirin induced asthma, urticaria, or anaphylaxi, or those with significant aspirin induced bleeding, excluding bruisingInitial application - (Transient ischaemic episodes) only from a neurologist, neuro surgeon, cardiologist, vascular surgeon or general physician. Approvals valid without further renewal unless notified where patients who continue to have transient ischaemic episodes des
650 Etidronate for osteoporosis should be prescribed for 14 days (400 mg in the morning) and repeated every three months. It should not be taken at the same time of the day as any calcium supplementation (minimum dose - 500 mg per day of elemental calcium). Etidronate should be taken at least 2 hours before or after any food or fluid, except water
652 Special Authority for Subsidy - Form SA0652Initial application - (Single NAED Therapy) only from a paediatrician, neurologist or general physician. Approvals valid for 15 months for applications meeting the following criteria: Any of the following: 1 Was on NAED therapy before 1 September 2000; or 2 Seizures are not adequately controlled with optimal older anti-epilepsy drug treatment; or 3 Seizures are controlled adequately but who experience unacceptable side effects from older anti-epilepsy drug treatment. Note"Optimal older anti-epilepsy drug therapy" is defined as treatment with those older anti-epilepsy drugs which are indicated and clinically appropriate for the patient, given singly and in combination in adequate doses for the patient's age, weight, and other features affecting the pharmacokinetics of the drug with good evidence of complianceInitial application - (Dual NAED Therapy) only from a paediatrician, neurologist or general physician. Approvals valid for 18 months for app
656 Additional subsidy by endorsement for:Calcium carbonate tablets x 1,000 (Titralac) up to $35.10 is available for pregnant women. The prescription must be endorsed accordingly. We recommend that the words used to indicate eligibility are "certified condition" however these particular words are not a requirement.
657 Special Authority for Subsidy - Form SA0657Initial application - (Helicobacter pylori infections) only from a general practitioner or relevant specialist. Approvals valid for 6 months for applications meeting the following criteria: Both: 1 Eradication of Helicobacter pylori in patient with proven infection; and 2 Peptic ulcer disease proven by endoscopy. NoteMaximum of two prescriptions (two courses) per patient. Initial application - (Mycobacterial infections) only from a respiratory specialist, infectious disease specialist or paediatrician. Approvals valid for 2 years for applications meeting the following criteria: Any of the following: 1 Mycobacterium Avium Intracellulare Complex infections in patient with AIDS; or 2 Atypical and drug-resistant mycobacterial infection; or 3 All of the following: 3.1 Prophylaxis against disseminated Mycobacterium Avium Intracellulare Complex infection; and 3.2 HIV infection; and 3.3 CD4 count <= 50 cells/mm3. Renewal - (Mycobact
658 Additional subsidy by endorsement for:Moclobemide tab 150 mg x 500 (Apo-Moclobemide) up to $46.00Moclobemide tab 150 mg x 100 (Aurorix) up to $32.90Moclobemide tab 300 mg x 100 (Apo-Moclobemide) up to $26.11Moclobemide tab 300 mg x 60 (Aurorix) up to $39.48Nefazodone tab 100 mg x 56 (Serzone) up to $20.16Nefazodone tab 200 mg x 56 (Serzone) up to $40.32Citalopram tab 20 mg x 28 (Celapram) up to $4.00Citalopram tab 20 mg x 28 (Cipramil) up to $10.00Paroxetine hydrochloride tab 20 mg x 30 (Aropax) up to $35.02is available for patients who: - were taking moclobemide or nefazodone on 1 December 1999 or citalopram on 1 February 2000; or paroxetine hydrochloride on February 2001; or- have previously responded to treatment with moclobemide or nefazodone or citalopram or paroxetine hydrochloride; or- have had a trial of fluoxetine and have had to discontinue due to- inability to tolerate the drug due to side effects; or- failed to respond to an adequate dose and duration of treatment; or
661 Special Authority for Subsidy - Form SA0661Initial application only from a psychiatrist. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 The patient has "treatment resistant" depression; and 2 Either: 2.1 The patient must have had a trial of two different antidepressants and failed to respond to an adequate dose over an adequate period of time (usually at least four weeks); or 2.2 Both: 2.2.1 The patient is currently a hospital in-patient as a result of an acute depressive episode; and 2.2.2 The patient must have had a trial of one other antidepressant and failed to respond to an adequate dose over an adequate period of time. Renewal from any medical practitioner. Approvals valid for 2 years where patient has a high risk of relapse (prescriber determined)..NoteFirst prescription can be written by a psychiatrist or psychiatric registrar. Subsequent prescriptions may be written by a General Practitioner
663 a) Injection subsidised only if not more than 10 injections per prescription.
665 Prescribing GuidelinesBoth Trusopt and Cosopt are subsidised for use as either monotherapy or as an adjunctive agent for the treatment of glaucoma. Trusopt and Cosopt should not be prescribed for a person in whom less expensive first line agents for the treatment of glaucoma are not contraindicated unless: i) that person has previously trialled all other such subsidised agents (except brimonidine tartrate); andii) those trials have indicated that that person does not respond adequately to treatment with those other agents.
666 a) Spacer devices and masks also available to paediatricians employed by a DHB on a wholesalesupply order signed by the paediatrician. Limited to one pack of 20 per order. Orders via ahospital pharmacy. b) Only available for children aged six years and under. c) For Space Chamber and Foremount Child's Silicone Mask wholesale supply order must indicate clearly if either the spacer device, the mask, or both are required. d) Distributed by Airflow Products. Forward orders to: Airflow ProductsPO Box 1485 Telephone: 04 499 1240 or 0800 AIR FLOWWellington Facsimile: 04 499 1245 or 0800 323 270
667 Special Authority for Subsidy - Form SA0667Initial application only from a named specialist. Approvals valid for 4 months for applications meeting the following criteria: All of the following: 1 To be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and 2 Patient is less than 18 years of age at commencement of treatment; and 3 Patient has had severe active polyarticular course Juvenile Idiopathic Arthritis (JIA) for 6 months duration or longer; and 4 Patient has tried and not responded to at least three months of oral or parenteral methotrexate at a dose of 10-20mg/m2 weekly in combination with oral corticosteroids (prednisone 0.25 mg/kg); and 5 Patient has tried and not responded to at least three months of oral or parenteral methotrexate (at a dose of 10-15mg/m2 weekly) in combination with one other disease-modifying agent; and 6 Both: 6.1 Either: 6.1.1 Patient has persistent symptoms of poorly-cont
668 Note: Due to uncertainty around the long term effects of Selegiline it is not recommended as a first line agent.
669 Special Authority for Subsidy - Form SA0669Initial application only from a relevant specialist. Approvals valid without further renewal unless notified where organ transplant recipients. NoteSubsidy applies for either primary or rescue therapy
670 Special Authority available.
671 Note: There is a significant cost differential between moclobemide and fluoxetine (moclobemide being about three times more expensive). For depressive syndromes it is therefore more cost-effective to start treatment with fluoxetine first before considering prescribing moclobemide.
672 Additional subsidy by endorsement for:Nefazodone tab 100 mg x 56 (Serzone) up to $20.16Nefazodone tab 200 mg x 56 (Serzone) up to $40.32Citalopram tab 20 mg x 28 (Celapram) up to $4.00Citalopram tab 20 mg x 28 (Cipramil) up to $10.00Paroxetine hydrochloride tab 20 mg x 30 (Aropax) up to $35.02is available for patients who: -were taking nefazodone on 1 December 1999 or citalopram on 1 February 2000; or paroxetine hydrochloride on February 2001; or- have previously responded to treatment with nefazodone or citalopram or paroxetinehydrochloride; or- have had a trial of fluoxetine and have had to discontinue due to- inability to tolerate the drug due to side effects; or- failed to respond to an adequate dose and duration of treatment; or- have contraindications to fluoxetine (eg pre-existing significant levels of nausea, breastfeeding, potential drug interactions). The prescription must be endorsed accordingly.
673 Special Authority for Manufacturers Price - Form SA0673Initial application from any medical practitioner. Approvals valid for 3 months for applications meeting the following criteria: Both: 1 Patient considered unsafe to switch to m-Eslon; and 2 Patient was stabilised and well controlled on Kapanol, MST or LA-Morph before 1 December 2003. NoteSpecial Authority effective from 1 February 2004 to 31 July 2004
674 Note: Combivir counts as two anti-retroviral medications for the purposes of the anti-retroviral Special Authority
675 Tablets can be combined with capsules to facilitate incremental 10 mg doses.
676 Only in extemporaneously compounded methyl hydroxybenzoate 10% solution
677 Only in extemporaneously compounded codeine linctus diabetic or codeine linctus paediatric
679 Only in extemporaneously compounded oral mixtures
681 Only a prescription for a female patient
683 Special Authority available.
684 Rapid acting insulin analogues are subsidised when: 1) prescribed with insulin isophane or insulin glargine but are on a different prescription and the prescription is endorsed accordingly; or prescribed on the same prescription as insulin isophane or insulin glargine in which case the prescription is deemed to be endorsed; or2) a Special Authority has been approved. For 1and 2 first prescription to be written by a specialist (diabetologist, general physician or paediatrician). Any medical practitioner can writte subsequent prescriptions.
685 Not more than one prescription per month.
686 Additional subsidy by Special Authority - Retail Pharmacy - for: - Nifedipine tab long-acting 30mg x 30 (Adalat Oros) up to $19.90 - Nifedipine tab long-acting 60mg x 30 (Adalat Oros) up to $29.50
687 Additional subsidy by Special Authority - Retail Pharmacy - for: - Amlodipine 5mg x 30 (Norvasc) up to $19.90 - Amlodipine 10mg x 30 (Norvasc) up to $29.50
688 Only in combination with a dermatological galenical or as a diluent for a proprietary Topical Corticosteroid - Plain.
692 Special Authority for Subsidy - Form SA0692Initial application from any specialist. Approvals valid for 11 months where patient has chronic, genotype 1 hepatitis C.
693 Special Authority for Subsidy - Form SA0693Initial application only from a relevant specialist or vocationally registered general practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria: All of the following: 1 Severe osteoporosis; and 2 History of one previous significant osteoporotic fracture demonstrated radiologically; and 3 T-Score <= -3.0 (bone mass density (BMD) >= 3.0 standard deviations below the mean normal value in young adults). NoteIn line with the Australian guidelines for funding alendronate, a vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral bodyRenewal - ((2 year approvals granted before February 2002)) only from a geriatrician, rheumatologist, endocrinologist, gynaecologis
694 Subsidy is available for patients with poorly controlled asthma where: a) at least three months of 750 mcg or more daily of inhaled beclomethasone or budesonide (or 400 mcg or fluticasone) for adults has been used; orb) at least three months of 400 mcg or more daily inhaled beclomethasone or budesonide (or 200 mcg or fluticasone) for children has been used; The prescription must be endorsed accordingly. We recommend that the words used to indicate eligibility are "poor control with ICS" or "certified exemption".
696 Special Authority for Subsidy - Form SA0696Initial application - (Narcolepsy) only from a neurologist or respiratory specialist. Approvals valid for 24 months where narcolepsy. Initial application - (ADHD in patients 5 or over) only from a paediatrician, psychiatrist or general practitioner on the recommendation of such a specialist. Approvals valid for 24 months for applications meeting the following criteria: All of the following: 1 ADHD (Attention Deficit and Hyperactivity Disorder) patients aged 5 years or over; and 2 Diagnosed according to DSM-IV or ICD 10 criteria; and 3 Either: 3.1 Applicant is a specialist; or 3.2 Both: 3.2.1 Applicant is a GP and a specialist has recommended treatment; and 3.2.2 Provide name of specialist (Details to be attached to application). Initial application - (ADHD in patients under 5) only from a paediatrician or psychiatrist. Approvals valid for 12 months for applications meeting the following criteria: Both: 1 ADHD (Attention Defi
698 Special Authority for Subsidy - Form SA0698Initial application only from a gastroenterologist, general surgeon or general physician. Approvals valid for 3 months for applications meeting the following criteria: Both: 1 Mild to moderate ileal, ileocaecal or proximal Crohn's disease; and 2 Any of the following: 2.1 Diabetes; or 2.2 Cushingoid habitus; or 2.3 Osteoporosis where there is significant risk of fracture; or 2.4 Severe acne following treatment with conventional corticosteroid therapy. Renewal only from a gastroenterologist, general surgeon or general physician. Approvals valid for 3 months where the treatment remains appropriate and the patient is benefiting from treatment. The patient must have had no more than 1 prior approval in the last year. NoteClinical trials for Entocort CIR use beyond three months demonstrated no improvement in relapse rate.
699 Special Authority for Subsidy - Form SA0699Initial application from any medical practitioner. Approvals valid for 1 year for applications meeting the following criteria: All of the following: 1 The patient is not predisposed to heart arrhythmias; and 2 The patient does not have a pre-existing QT-prolongation or hepatic failure; and 3 The patient is not using other medications which either inhibit the cytochrome P450 3A4 enzyme system or prolong the QT interval; and 4 Any of the following: 4.1 Both: 4.1.1 adult with severe reflux oesophagitis; and 4.1.2 other treatment, including acid suppression with proton pump inhibitors, has failed; or 4.2 gastroparesis; or 4.3 malignancy of GI tract causing gastroparesis (or gastric outlet obstruction); or 4.4 child (not including infants from 0 to 3 months of age who were born prematurely) with severe gastro-oesophageal reflux; and 5 Diagnosis has been made or confirmed by a general physician, gastroenterologist, or ge
700 Special Authority for Subsidy - Form SA0700Initial application only from an ophthalmologist. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 Both: 1.1 Monotherapy in primary open-angle glaucoma; and 1.2 Any of the following: 1.2.1 Patient cannot tolerate Beta-blockers, Pilocarpine and Dorzolamide; or 1.2.2 Beta-blockers, Pilocarpine and Dorzolamide are contraindicated; or 1.2.3 A reduction in intraocular pressure of 15% or more is not achieved or maintained using dorzolamide either alone or in combination with a beta-blocker; or 1.2.4 There is progressive visual field loss and/or optic nerve damage persists after treatment with dorzolamide either alone or in combination with a beta-blocker; or 2 Adjunctive use for the treatment of patients who have met the initial application criteria, and in whom latanoprost monotherapy has been ineffective in controlling intraocular pressure.Note An adjunctive agent may be added without a
701 Prescriptions can be written either by specialist or general practitioner.
702 Special Authority for Subsidy - Form SA0702Initial application - (Oral feed for cystic fibrosis patient) only from a relevant specialist. Approvals valid for 3 years for applications meeting the following criteria: Both: 1 Cystic fibrosis; and 2 Either: 2.1 The product is to be used as a supplement; or 2.2 The product is to be used as a complete diet.Initial application - (Oral feed for indications other than cystic fibrosis) only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria: Both: 1 Any of the following: 1.1 any condition causing malabsorption; or 1.2 failure to thrive; or 1.3 increased nutritional requirements; and 2 Either: 2.1 The product is to be used as a supplement; or 2.2 The product is to be used as a complete diet.Renewal - (Oral feed cystic fibrosis patient) only from a relevant specialist or general practitioner on the recommendation of such a specialist. Approvals valid for 3 years f
703 Special Authority for Subsidy - Form SA0703Initial application only from a relevant specialist or general practitioner. Approvals valid for 2 years for applications meeting the following criteria: All of the following: 1 Patient has raised blood pressure; and 2 The use of fully funded beta blockers is contraindicated, or not well tolerated; or where use of fully funded beta blockers and diuretics are insufficient to control blood pressure adequately at appropriate doses; and 3 Either: 3.1 Has been treated with, and cannot tolerate two ACE inhibitors, due to persistent cough; or 3.2 Has experienced angioedema on an ACE inhibitor at any time in the past or who have experienced angioedema (even if not using an ACE inhibitor) in the last 2 years. Renewal only from a relevant specialist or general practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
705 Only in infants under two years
706 Special Authority for Subsidy - Form SA0706Initial application only from a relevant specialist or general practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria: Either: 1 Both: 1.1 Patient with congestive heart failure; and 1.2 Either: 1.2.1 Has been treated with, and cannot tolerate, two ACE inhibitors, due to persistent cough; or 1.2.2 Has experienced angioedema on an ACE inhibitor at any time in the past or who have experienced angioedema (even if not using an ACE inhibitor) in the last 2 years; or 2 All of the following: 2.1 Patient with raised blood pressure; and 2.2 Use of fully funded beta blockers or diuretics are contraindicated; or not well tolerated; or insufficient to control blood pressure adequately at appropriate doses; and 2.3 Either: 2.3.1 Has been treated with, and cannot tolerate, two ACE inhibitors, due to persistent cough; or 2.3.2 Has experienced angioedema on an ACE in
708 Effective, consistent management of herpes from prescribing to these guidelines will improve patient outcomes. The guidelines on the following four pages are for the prescribing of aciclovir. The guidelines aim to: - improve patient care and clinical outcome through faster, more accessible treatment - protect patients' wider wellbeing by reinforcing the psychosocial aspects of treatment - improve the consistency and breadth of medical management of genital herpes in New Zealand. The guidelines are: - integral to ensuring a consistent, effective treatment regimen- the result of consultation with clinicians and patient representatives- set out in line with the recommended international algorithm format for treatment. The guidelines are endorsed by the Herpes Foundation's professional advisory board whose members represent venereology, NZDS, RNZCGP, RNZCOG, psychotherapy and nursing. Herpes Foundation Helpline: Toll free 0508 11 12 13Auckland Branch Herpes Foundation: 09 360 1966
709 Guidelines for the use of interferon in the treatment of hepatitis C: Physicians considering treatment of patients with hepatitis C should discuss cases with a gastroenterologist or aninfectious disease physician. All subjects undergoing treatment require careful monitoring for side effects. Patients should be otherwise fit. Hepatocellular carcinoma should be excluded by ultrasound examination and alpha-fetoprotein level. Criteria for Treatment a) Diagnosis- Anti-HCV positive on at least two occasions with a positive PCR for HCV-RNA and preferably confirmed by asupplementary RIBA test; or- PCR-RNA positive for HCV on at least 2 occasions if antibody negative; or- Anti-HCV positive on at least two occasions with a positive supplementary RIBA test with a negative PCR forHCV RNA but with a liver biopsy consistent with 2(b) following. b) Establishing Active Chronic Liver Disease- Confirmed HCV infection and serum ALT/AST levels measured on at least three occasions over six monthsaveraging >
710 Special Authority for Subsidy - Form SA0710Initial application only from an ophthalmologist. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 Either: 1.1 Monotherapy in primary open-angle glaucoma; or 1.2 Adjunctive use for the treatment of open-angle glaucoma in a patient who has met the initial application criteria, and in whom prostaglandin analogue monotherapy has been ineffective in controlling intraocular pressure; and 2 Any of the following: 2.1 Patient cannot tolerate beta-blockers, pilocarpine, and carbonic anhydrase inhibitors; or 2.2 Beta-blockers, pilocarpine and carbonic anhydrase inhibitors are contraindicated; or 2.3 A reduction in intraocular pressure of 15% or more is not achieved or maintained using carbonic anhydrase inhibitor either alone or in combination with a beta blocker; or 2.4 There is progressive visual field loss and/or optic nerve damage persists after treatment with carbonic anhydrase inhibitor either alo
713 Special Authority for Subsidy - Form SA0713Initial application from any specialist. Approvals valid for 11 months for applications meeting the following criteria: Either: 1 Patient has chronic hepatitis C, genotype 1, 4, 5 or 6 infection; or 2 Patient has chronic hepatitis C, genotype 2 or 3 infection with bridging fibrosis or cirrhosis (Metavir stage 3 or 4, or equivalent).
714 Special Authority for Subsidy - Form SA0714Initial application from any medical practitioner. Approvals valid for 3 months for applications meeting the following criteria: All of the following: 1 Patient is currently enrolled in a recognised comprehensive treatment programme for alcohol dependence in a service accredited against the New Zealand Alcohol and Other Drug Sector Standard or the National Mental Health Sector Standard; and 2 Applicant works in an Alcohol & Drug Service; and 3 Applicant must include the address of the service (Details to be attached to application). Renewal from any medical practitioner. Approvals valid for 3 months for applications meeting the following criteria: Both: 1 Compliance with the medication (prescriber determined); and 2 Any of the following: 2.1 Patient is still unstable and requires further treatment; or 2.2 Patient achieved significant improvement but requires further treatment; or 2.3 Patient is well controlled but requires maint
715 Prescribing GuidelinesTrusopt, Cosopt and Azopt are subsidised for use as either monotherapy or as an adjunctive agent for the treatment of glaucoma. Trusopt, Cosopt and Azopt should not be prescribed for a person in whom less expensive first line agents for the treatment of glaucoma are not contraindicated unless: a) that person has previously trialled all other such subsidised agents (except brimonidine tartrate); andb) those trials have indicated that that person does not respond adequately to treatment with those other agents.
716 Prescribing GuidelineTreatment with HMG CoA Reductase Inhibitors (statins) is recommended for patients with dyslipidaemia and an absolute 5 year cardiovascular risk of 15% or greater.
717 Special Authority for Manufacturers Price - Form SA0717Initial application only from a relevant specialist or general practitioner. Approvals valid for 12 weeks for applications meeting the following criteria: Both: 1 Patient has a calculated absolute risk of cardiovascular disease of at least 15% over 5 years; and 2 Either: 2.1 Patient has severe documented intolerance to simvastatin; or 2.2 Both: 2.2.1 Patient has been compliant with a dose of simvastatin of 80 mg per day for at least 2 months; and 2.2.2 Either: 2.2.2.1 All of the following: 2.2.2.1.1 Patient has venous CABG; and 2.2.2.1.2 LDL cholesterol test 1 >= 2.0 mmol/litre; and 2.2.2.1.3 LDL cholesterol test 2 >= 2.0 mmol/litre (at least 1 week after test 1); or 2.2.2.2 All of the following: 2.2.2.2.1 Patient does not have venous CABG; and 2.2.2.2.2 LDL cholesterol test 1 >= 2.5 mmol/litre; and 2.2.2.2.3 LDL cholesterol test 2 >= 2.5 mmol/litre (at least 1 w
718 No more than 1 tab per day
719 Repeat dispensings fully subsidised where initial dispensing was before 1 June 2004.
720 Maximum of 108 g available on PSO
721 Special Authority for Subsidy - Form SA0721Initial application only from a named specialist. Approvals valid without further renewal unless notified for applications meeting the following criteria: All of the following: 1 The patient already has a Special Authority approval for anti-retroviral therapy (Details to be attached to application); and 2 Kaletra is to be used as a salvage therapy in place of one protease inhibitor; and 3 The patient must have trialed for at least six months and have failed on currently funded NNRTI based regimens or triple NRTI regimens; and 4 The patient must have trialed for at least six months and have failed on currently funded PI based regimens. NoteFailure is defined as: a) not achieving HIV RNA < 400 copies/ml after 24 weeks of a regimen, orb) an increase of HIV RNA to > 400 copies/ml on two separate occasions not less than one month apart, after suppression to < 400 copies/ml in a patient taking the regimen.
722 Special Authority for Subsidy - Form SA0722Initial application only from a relevant specialist. Approvals valid without further renewal unless notified for applications meeting the following criteria: Either: 1 Gluten enteropathy has been diagnosed by biopsy; or 2 Patient suffers from dermatitis herpetiformis.
723 Special Authority for Subsidy - Form SA0723Initial application only from a relevant specialist. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 All of the following: 1.1 Patient has a calculated absolute risk of cardiovascular disease >20% over 5 years; and 1.2 Patient cannot tolerate statin therapy at a dose of 40 mg per day; and 1.3 Either: 1.3.1 All of the following: 1.3.1.1 Patient has venous CABG; and 1.3.1.2 LDL cholesterol >= 2.0 mmol/litre (see note); and 1.3.1.3 LDL cholesterol >= 2.0 mmol/litre (at least 1 week after test 1 - see note); or 1.3.2 All of the following: 1.3.2.1 Patient does not have venous CABG; and 1.3.2.2 LDL cholesterol >= 2.5 mmol/litre (see note); and 1.3.2.3 LDL cholesterol >= 2.5 mmol/litre (at least 1 week after test 1 - see note); or 2 All of the following: 2.1 Patient has homozygous familial hypercholesterolemia, or heterozygous familial hypercholesterol
724 Special Authority for Manufacturers Price - Form SA0724Initial application only from a relevant specialist or general practitioner. Approvals valid for 12 weeks for applications meeting the following criteria: Both: 1 Patient has a calculated absolute risk of cardiovascular disease of at least 15% over 5 years; and 2 Either: 2.1 Patient has severe documented intolerance to simvastatin (blood tests are not required); or 2.2 Both: 2.2.1 Patient has been compliant with a dose of simvastatin of 80 mg per day for at least 2 months; and 2.2.2 Either: 2.2.2.1 All of the following: 2.2.2.1.1 Patient has venous CABG; and 2.2.2.1.2 LDL cholesterol test 1 >= 2.0 mmol/litre; and 2.2.2.1.3 LDL cholesterol test 2 >= 2.0 mmol/litre (at least 1 week after test 1); or 2.2.2.2 All of the following: 2.2.2.2.1 Patient does not have venous CABG; and 2.2.2.2.2 LDL cholesterol test 1 >= 2.5 mmol/litre; and 2.2.2.2.3 LDL cholesterol test 2 >
725 Special Authority for Subsidy - Form SA0725Initial application only from a relevant specialist or general practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria: All of the following: 1 Patient with raised blood pressure; and 2 Use of fully funded beta blockers and diuretics are contraindicated; or not well tolerated; or insufficient to control blood pressure adequately at appropriate doses; and 3 Either: 3.1 Has been treated with, and cannot tolerate, two ACE inhibitors, due to persistent cough; or 3.2 Has experienced angioedema on an ACE inhibitor at any time in the past or who have experienced angioedema (even if not using an ACE inhibitor) in the last 2 years. Renewal - (Previous approval has expired) only from a relevant specialist or general practitioner. Approvals valid without further renewal unless notified where the treatment remains appropriate and the patient is benefiting from treatment.
726 Maximum one pack (two 500mg tablets) per prescription.
727 Special Authority for Subsidy - Form SA0727Initial application from any medical practitioner. Approvals valid for 1 year for applications meeting the following criteria: All of the following: 1 Control of intractable nausea, vomiting, or inability to swallow saliva in the treatment of malignancy or chronic disease; and 2 Patient cannot tolerate or does not adequately respond to oral anti-nausea agents; and 3 The applicant must specify the underlying malignancy or chronic disease (Details to be attached to application). Renewal from any medical practitioner. Approvals valid for 1 year where the treatment remains appropriate and the patient is benefiting from treatment.
728 Retail pharmacy - subsidy by endorsement a) Subsidised for:(i) patients presenting with first episode schizophrenia or related psychoses, or manic episodes associated with bipolar disorder; and(ii) patients suffering from schizophrenia or related psychoses, or manic episodes associated with bipolar disorder, after a trial of an effective dose of risperidone that has been discontinued because of unacceptable side effects or inadequate response. b) Initial prescription must be written by a relevant specialist. c) Subsequent prescriptions may be written by a general practitioner. d) The prescription must be endorsed "certified condition".
729 Only in extemporaneously compounded methadone mixture, codeine linctus diabetic or codeine linctus paediatric or phenobarbitone oral liquid
730 No more than 1.5 tabs per day
731 No more than 1 tab per day
732 Special Authority for Subsidy - Form SA0732Initial application only from a relevant specialist. Approvals valid for 3 years for applications meeting the following criteria: Either: 1 dietary management of homocystinuria; or 2 dietary management of maple syrup urine disease. Renewal only from a relevant specialist or general practitioner on the recommendation of such a specialist. Approvals valid for 1 year for applications meeting the following criteria: Both: 1 The treatment remains appropriate and the patient is benefiting from treatment; and 2 General Practitioners must include the name of the specialist and date contacted.
733 Special Authority for Subsidy - Form SA0733Initial application - (Patient aged over 16) only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria: Both: 1 dietary management of PKU; and 2 blood phenylalanine level < 900 mmol/litre (average of tests over last 12 months). Initial application - (Patient aged 16 or under) only from a relevant specialist. Approvals valid for 3 years where dietary management of PKU.Renewal - (Patient aged over 16) only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria: blood phenylalanine level < 900 mmol/litre (average of tests over last 12 months). Renewal - (Patient aged 16 or under) only from a relevant specialist or general practitioner on the recommendation of such a specialist. Approvals valid for 3 years for applications meeting the following criteria: Both: 1 The treatment remains appropriate and the patient is benefiting from treatment; and 2
734 GuidelinesIt can cost up to $70,000 a year to keep an adult on protein supplements. Because protein substitutes are so expensive and because they are only effective in controlling PKU if a restricted diet is followed, adults with PKU will be required to demonstrate they are following the prescribed diet by regular blood testing. The requirement for testing applies to those aged over 16 years. Failure to follow an appropriate diet results in high blood phenylalanine levels. Those consistently testing above 15 mg (900 micromol) over a twelve month period will not be able to claim these products as a Special Authority. Specialists will be required to renew applications for their PKU patients every year and, when they do so, will have to submit the results of two blood tests.
735 Neocate should be used only as a last resort when the infant is unable to absorb any of the above formulae. The objective with each of thees formulae prescribed is to get the infant off them as soon as possible. This may take six months, it may take three years. Because of this, variation on age limit is not regarded as appropriate.These formulae will be available only from a hospital pharmacy. Vivonex Pediatric may be a suitable and less expensive alternative for many children that would otherwise be eligible for a subsidy for Neocate and should, therefore, be tried first in these cases. The subsidy for these products reflects the philosophy that the patient incurs no additional financial burden for purchasing specialised more expensive products.
738 Special Authority for Subsidy - Form SA0738Initial application only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria: Either: 1 All of the following: 1.1 To be used as monotherapy for patients with type 2 diabetes who after six months of diet and lifestyle changes do not have adequate glycaemic control (inadequate control defined as HbA1c > 8.0% in tests carried out at least two months apart); and 1.2 Metformin is not tolerated or contraindicated. Intolerance and contraindications as defined in the notes below, a minimum of a four week trial period of metformin is required; and 1.3 Sulphonylurea is not tolerated or contraindicated. Overweight patients are only eligible under the criteria of contraindication to sulphonylureas if their body mass index (BMI) exceeds 35; or 2 Both: 2.1 For use in combination with a sulphonylurea when diet and lifestyle changes and a twelve month trial of sulphonylurea results in inadequate glycaem
740 Prescribing GuidelineHRT should be taken at the lowest dose for the shortest period of time necessary to control symptoms. Patients should be reviewed 6 monthly in line with the updated NZGG "Evidence-based Best Practice Guideline on Hormone Replacement Therapy March 2004".
741 Special Authority for Subsidy - Form SA0741Initial application only from a psychiatrist. Approvals valid for 2 years for applications meeting the following criteria: Any of the following: 1 Patient with first episode schizophrenia or related psychoses; or 2 Both: 2.1 Patient suffering from schizophrenia and related psychoses; or acute mania in bipolar disorder who is likely to benefit from anti-psychotic treatment; and 2.2 Either: 2.2.1 An effective dose of risperidone had been trialled and has been discontinued because of unacceptable side effects; or 2.2.2 An effective dose of risperidone had been trialled and has been discontinued because of inadequate clinical response after 4 weeks; or 3 The patient has suffered from an acute episode of schizophrenia or bipolar mania and has been treated with olanzapine short-acting intra-muscular injection. Renewal only from a psychiatrist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefit
742 Special Authority for Subsidy - Form SA0742Initial application - (genotype 1, 4, 5 or 6 infection) from any specialist. Approvals valid for 11 months where patient has chronic hepatitis C, genotype 1, 4, 5 or 6 infection. Initial application - (genotype 2 or 3 infection) from any specialist. Approvals valid for 6 months for applications meeting the following criteria: Both: 1 Patient has chronic hepatitis C, genotype 2 or 3 infection; and 2 Patient has bridging fibrosis or cirrhosis (Metavir stage 3 or 4 or equivalent).
743 Special Authority for Subsidy - Form SA0743Initial application only from a relevant specialist. Approvals valid for 3 months for applications meeting the following criteria: Both: 1 Patient is terminally ill and is opioid-responsive; and 2 Either: 2.1 is unable to take oral medication; or 2.2 is intolerant to morphine, or morphine is contraindicated..Renewal only from a relevant specialist or general practitioner. Approvals valid for 3 months where the treatment remains appropriate and the patient is benefiting from treatment.
745 Only in extemporaneously compounded omeprazole suspension
746 Maximum of 6 capsules per prescription.
749 Additional subsidy by endorsement for:Citalopram tab 20 mg x 28 (Celapram) up to $4.00Citalopram tab 20 mg x 28 (Cipramil) up to $10.00Paroxetine hydrochloride tab 20 mg x 30 (Aropax) up to $35.02is available for patients who: -were taking citalopram on 1 February 2000; or paroxetine hydrochloride on February 2001; or- have previously responded to treatment with citalopram or paroxetinehydrochloride; or- have had a trial of fluoxetine and have had to discontinue due to- inability to tolerate the drug due to side effects; or- failed to respond to an adequate dose and duration of treatment; or- have contraindications to fluoxetine (eg pre-existing significant levels of nausea, breastfeeding, potential drug interactions). The prescription must be endorsed accordingly.
750 Special Authority for Subsidy - Form SA0750Initial application only from a relevant specialist. Approvals valid without further renewal unless notified where continuation of previous therapy.
751 Special Authority for Subsidy - Form SA0751Initial application only from an ophthalmologist. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 Either: 1.1 Monotherapy in primary open-angle glaucoma; or 1.2 Adjunctive use for the treatment of open-angle glaucoma in a patient who has met the initial application criteria, and in whom prostaglandin analogue monotherapy has been ineffective in controlling intraocular pressure; and 2 Any of the following: 2.1 Patient cannot tolerate beta-blockers, pilocarpine, and carbonic anhydrase inhibitors; or 2.2 Beta-blockers, pilocarpine and carbonic anhydrase inhibitors are contraindicated; or 2.3 A reduction in intraocular pressure of 15% or more is not achieved or maintained using carbonic anhydrase inhibitor either alone or in combination with a beta blocker; or 2.4 There is progressive visual field loss and/or optic nerve damage persists after treatment with carbonic anhydrase inhibitor either alo
752 (a) Subsidy is available between 1 March and 30 June of each year for patients who meet the following criteria, as set by the Ministry of Health: a) all people 65 years of age and over; b) people under 65 years of age with: i) the following cardiovascular disease: 1) ischaemic heart disease, 2) congestive heart disease, 3) rheumatic heart disease, 4) congenital heart disease, or 5) cerebo-vascular disease; ii) the following chronic respiratory disease: 1) asthma, if on a regular preventative therapy, or 2) other chronic respiratory disease with impaired lung function; iii) diabetes; iv) chronic renal disease; v) any cancer, excluding basal and squamous skin cancers if not invasive; vi) the following other conditions: 1) autoimmune disease, 2) immune suppression, 3) HIV, 4) transplant recipients, 5) neuromuscular and CNS diseases, 6) haemoglobinopathies, or 7) children on long term aspirin. The following conditions are excluded from funding: i) asthma not requiri
753 Special Authority for Manufacturers Price - Form SA0753Initial application only from a relevant specialist. Approvals valid for 3 years for applications meeting the following criteria: Both: 1 Patient is a postmenopausal women; and 2 Patient has hormone receptor positive advanced breast cancer (Stage IIIb, or metastatic Stage IV). Renewal only from a relevant specialist. Approvals valid for 3 years where the treatment remains appropriate and the patient is benefiting from treatment.
754 Special Authority for Subsidy - Form SA0754Initial application only from a named specialist. Approvals valid without further renewal unless notified for applications meeting the following criteria: All of the following: 1 The patient already has a Special Authority approval for anti-retroviral therapy (Details to be attached to application); and 2 Kaletra is to be used as a salvage therapy in place of one protease inhibitor; and 3 The patient must have trialed for at least six months and have failed on currently funded NNRTI based regimens or triple NRTI regimens; and 4 The patient must have trialed for at least six months and have failed on currently funded PI based regimens. NoteFailure is defined as: a) not achieving HIV RNA < 400 copies/ml after 24 weeks of a regimen, orb) an increase of HIV RNA to > 400 copies/ml on two separate occasions not less than one month apart, after suppression to < 400 copies/ml in a patient taking the regimen.
755 Special Authority for Subsidy - Form SA0755Initial application from any medical practitioner. Approvals valid for 2 years where the patient is likely to benefit from treatment. Note Applications to be made on the approved forms which are available from: Prof. Wayne CutfieldNational Co-ordinatorNew Zealand Growth Hormone CommitteeC/- Department of PaediatricsUniversity of AucklandPrivate Bag 92019AUCKLAND
756 Pharmacies cannot claim subsidy because PHARMAC has made alternative distribution arrangements.
757 Special Authority for Subsidy - Form SA0757Initial application only from a relevant specialist. Approvals valid for 6 months for applications meeting the following criteria: All of the following: 1 The patient is less than 2 years of age; and 2 Intolerant to cows' milk; and 3 Diagnosed as suffering from congenital lactase deficiency. Renewal only from a relevant specialist. Approvals valid for 6 months where the treatment remains appropriate and the patient is benefiting from treatment.
758 Special Authority for Subsidy - Form SA0758Initial application only from a general practitioner or relevant specialist. Approvals valid for 2 years for applications meeting the following criteria: All of the following: 1 To be used for the long-term maintenance treatment of bronchospasm and dyspnoea associated with COPD; and 2 In addition to standard treatment, the patient has trialled a dose of at least 40 mcg ipratropium q.i.d; and 3 The patient's breathlessness >= grade 4 according to the Medical Research Council dyspnoea scale (see note); and 4 FEV1 (litres) < 0.4 x predicted (litres); and 5 Either: 5.1 Patient is not a smoker (for reporting purposes only); or 5.2 Patient is a smoker and been offered smoking cessation councilling; and 6 The patient has been offered annual influenza immunisation. Renewal only from a general practitioner or relevant specialist. Approvals valid for 2 years for applications meeting the following criteria: All of the following: 1
759 Prescriptions must be written by a gastroenterologist.
760 a) Prescribers may code prescriptions "contraceptive" (code "O") when used as indicated for contraception. The period of supply and prescription charge will be as per other contraceptives, as follows: - $3.00 prescription charge (patient co-payment) will apply; - prescription may be written for up to six months supply. b) Prescriptions coded in any other way are subject to the non-contraceptive prescription charges, and the non-contraceptive period of supply. ie. Prescriptions may be written for up to three months supply.
761 Only in children up to 12 years
763 Maximum of 100 plastic syringes with attached needles per prescription.
764 Maximum 100 pen needles per prescription.
765 Subject to budgetary cap. Applications will be considered and approved subject to funding availability.
766 A diagnostic blood glucose test meter is subsidised for patients who begin insulin or sulphonylurea therapy after 1 March 2005. Only one meter per patient. No further prescriptions will be subsidised. The prescription must be endorsed accordingly.
767 Retail pharmacy - specialist prescriptionPrescriptions must be written by a gastroenterologist
768 Hospital pharmacy - specialist prescriptionSpecialist must be a psychiatrist
770 (a) Subsidy is available between 1 March and 30 June of each year for patients who meet the following criteria, as set by the Ministry of Health: a) all people 65 years of age and over; b) people under 65 years of age with: i) the following cardiovascular disease: 1) ischaemic heart disease, 2) congestive heart disease, 3) rheumatic heart disease, 4) congenital heart disease, or 5) cerebo-vascular disease; ii) the following chronic respiratory disease: 1) asthma, if on a regular preventative therapy, or 2) other chronic respiratory disease with impaired lung function; iii) diabetes; iv) chronic renal disease; v) any cancer, excluding basal and squamous skin cancers if not invasive; vi) the following other conditions: 1) autoimmune disease, 2) immune suppression, 3) HIV, 4) transplant recipients, 5) neuromuscular and CNS diseases, 6) haemoglobinopathies, or 7) children on long term aspirin. The following conditions are excluded from funding: i) asthma not requiri
771 The number of test strips available on a prescription is restricted to 50 unless: a) Prescribed with insulin or a sulphonylurea but are on a different prescription and the prescription is endorsed accordingly; orb) Prescribed on the same prescription as insulin or a sulphonylurea in which case the prescription is deemed to be endorsed; orc) Prescribed for a pregnant woman with diabetes and endorsed accordingly.
772 Special Authority for Subsidy - Form SA0772Initial application only from a gastroenterologist, infectious disease specialist, paediatrician or general physician. Approvals valid for 1 year for applications meeting the following criteria: Both: 1 Any of the following: 1.1 All of the following: 1.1.1 HBsAg positive for more than 6 months; and 1.1.2 HBeAg positive or HBV DNA positive defined as >0.6 pg/ml by quantitative PCR at reference laboratory; and 1.1.3 ALT greater than twice upper limit of normal or stage 3 or 4 fibrosis on liver histology clinical/radiological evidence of cirrhosis; or 1.2 HBV DNA positive cirrhosis prior to liver transplantation; or 1.3 HBsAg positive and have had a liver, kidney, heart, lung or bone marrow transplant; or 1.4 Hepatitis B surface antigen positive (HbsAg) patient who is receiving chemotherapy for a malignancy, or who has received such treatment within the previous two months; and 2 All of the following: 2.1 No continuing
773 Additional subsidy by endorsement for:Paroxetine hydrochloride tab 20 mg x 30 (Aropax) up to $35.02is available for patients who: -were taking paroxetine hydrochloride on February 2001; or- have previously responded to treatment with paroxetinehydrochloride; or- have had a trial of fluoxetine and have had to discontinue due to- inability to tolerate the drug due to side effects; or- failed to respond to an adequate dose and duration of treatment; or- have contraindications to fluoxetine (eg pre-existing significant levels of nausea, breastfeeding, potential drug interactions). The prescription must be endorsed accordingly.
774 Special Authority for Subsidy - Form SA0774Initial application only from a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Any of the following: 1 The patient has advanced gastrointestinal malignancy; or 2 The patient has metastatic breast cancer*; or 3 Both: 3.1 The patient has poor venous access or needle phobia*; and 3.2 The patient requires a substitute for single agent fluoropyrimidine*. Renewal only from a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Either: 1 The patient requires continued therapy; or 2 The tumour has relapsed and requires re-treatment. Noteindications marked with * are unapproved indications.
775 Special Authority for Subsidy - Form SA0775Initial application only from a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Both: 1 The patient has metastatic colorectal cancer; and 2 Either: 2.1 To be used for first or second line use as part of a combination chemotherapy regimen; or 2.2 As single agent chemotherapy in fluropyrimidine-relapsed disease. Renewal only from a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Either: 1 The patient requires continued therapy; or 2 The tumour has relapsed and requires re-treatment.
776 Special Authority for Subsidy - Form SA0776Initial application only from a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Any of the following: 1 Both: 1.1 The patient has ovarian, fallopian* or primary peritoneal cancer*; and 1.2 Either: 1.2.1 Has not received prior chemotherapy; or 1.2.2 Has received prior chemotherapy but has not previously been treated with taxanes; or 2 The patient has metastatic breast cancer; or 3 Both: 3.1 The patient has non-small cell lung cancer; and 3.2 Either: 3.2.1 The patient has advanced disease (stage IIIa or above); or 3.2.2 The patient is receiving combined chemotherapy and radiotherapy; or 4 Both: 4.1 The patient has small-cell lung cancer*; and 4.2 Paclitaxel is to be used as second-line therapy. Renewal only from a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Both: 1 The patient has metastati
777 Special Authority for Subsidy - Form SA0777Initial application - (Post-transplant) only from a relevant specialist. Approvals valid for 6 months where the patient has B-cell post-transplant lymphoproliferative disorder*. NoteFor no more than 8 treatment cycles. Initial application - (Low-grade lymphomas) only from a relevant specialist. Approvals valid for 6 months where the patient has low grade NHL - relapsed disease following prior chemotherapy. NoteFor no more than 4 treatment cycles. Initial application - (Large cell lymphomas) only from a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Both: 1 The patient has treatment naive large B-cell NHL; and 2 To be used with CHOP (or alternative anthracycline containing multi-agent chemotherapy regime given with curative intent).NoteFor no more than 8 treatment cycles. Renewal - (Low-grade lymphomas) only from a relevant specialist. Approvals valid for 6 months for applications meeting
779 Special Authority for Subsidy - Form SA0779Initial application - (Confirmed HIV/AIDS) only from a named specialist. Approvals valid without further renewal unless notified for applications meeting the following criteria: Both: 1 Confirmed HIV infection; and 2 Any of the following: 2.1 Symptomatic patient; or 2.2 Patient aged 12 months and under; or 2.3 Both: 2.3.1 Patient aged 1 to 5 years; and 2.3.2 Any of the following: 2.3.2.1 CD4 counts < 1,000 cells/mm3; or 2.3.2.2 CD4 counts < 0.25 x total lymphocyte count; or 2.3.2.3 Viral load counts > 100,000 copies per ml; or 2.4 Both: 2.4.1 Patient aged 6 years and over; and 2.4.2 CD4 counts < 350 cells/mm3. NoteTenofovir disoproxil fumarate prescribed under endorsement for HIV/AIDS is included in the count of up to 3 subsidised antiretrovirals. Subsidies for a combination of up to three anti-retroviral medications, including a maximum of two protease inhibitors. Combinations including r
780 Special Authority for Subsidy - Form SA0780Initial application - (Single NAED Therapy) only from a paediatrician, neurologist or general physician. Approvals valid for 15 months for applications meeting the following criteria: Any of the following: 1 Was on NAED therapy before 1 September 2000; or 2 Seizures are not adequately controlled with optimal older anti-epilepsy drug treatment; or 3 Seizures are controlled adequately but who experience unacceptable side effects from older anti-epilepsy drug treatment. Note"Optimal older anti-epilepsy drug therapy" is defined as treatment with those older anti-epilepsy drugs which are indicated and clinically appropriate for the patient, given singly and in combination in adequate doses for the patient's age, weight, and other features affecting the pharmacokinetics of the drug with good evidence of complianceInitial application - (Dual NAED Therapy) only from a paediatrician, neurologist or general physician. Approvals valid for 18 months for app
781 Special Authority for Subsidy - Form: SA0781Initial application only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria: Any of the following: Monotherapy1 All of the following: 1.1 To be used as monotherapy for patients with type 2 diabetes who after six months of diet and lifestyle changes do not have adequate glycaemic control (inadequate control defined as HbA1c > 7.0% in tests carried out at least two months apart); and 1.2 Metformin is not tolerated or contraindicated. Intolerance and contraindications as defined in the notes below, a minimum of a four week trial period of metformin is required; and 1.3 Sulphonylurea is not tolerated or contraindicated. Obesity is only eligible under the criteria of contraindication to sulphonylureas if the patient's body mass index (BMI) exceeds 33 , intolerance as defined in the notes below; orIn combination with sulphonylurea2 Both: 2.1 For use in combination with a sulphonylure
782 Special Authority for Subsidy - Form SA0782Initial application - (No previous use) only from a relevant specialist or general practitioner. Approvals valid for 6 months for applications meeting the following criteria: All of the following: 1 The patient has a clinical diagnosis of heavy menstrual bleeding; and 2 The patient has failed to respond to or is unable to tolerate other appropriate pharmaceutical therapies as per the Heavy Menstrual Bleeding Guidelines; and 3 Either: 3.1 serum ferritin level < 16 mg/l (within the last 12 months); or 3.2 haemoglobin level < 120 g/l . NoteApplications are not to be made for use in patients as contraception except where they meet the above criteriaInitial application - (Previous use before 1 October 2002) only from a relevant specialist or general practitioner. Approvals valid for 6 months for applications meeting the following criteria: All of the following: 1 The patient had a clinical diagnosis of heavy menstrual bleeding; and 2
783 Special Authority for Manufacturers Price - Form: SA0783Initial application only from a relevant specialist. Approvals valid for 5 years for applications meeting the following criteria: All of the following: 1 Patient is a postmenopausal women; and2 Patient has hormone receptor positive advanced breast cancer; and3 Any of the following: 3.1 The cancer is advanced (Stage IIIb, or metastatic Stage IV); or 3.2 The patient has a very clear history of intolerance to tamoxifen; or 3.3 The use of tamoxifen is contraindicated due to a history of thromboembolic disease. Renewal only from a relevant specialist. Approvals valid without further renewal unless notified where the treatment remains appropriate and the patient is benefiting from treatment.
784 Special Authority for Subsidy - Form: SA0784Initial application from any specialist. Approvals valid for 12 months where patient has chronic hepatitis C (all genotypes).
785 Not exceeding a strength of 250 mg per dose.
786 Prescribing GuidelinePrescribers should note that oxycodone is significantly more expensive than long-acting morphine sulphate and clinical advice suggests that it is reasonable to consider this as a second-line agent to be used after morphine.
788 Special Authority for Manufacturers Price - Form SA0788Initial application only from a relevant specialist or general practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria: Both: 1 Patient has a calculated absolute risk of cardiovascular disease of at least 15% over 5 years; and 2 Either: 2.1 Patient has severe documented intolerance to simvastatin (blood tests are not required); or 2.2 Both: 2.2.1 Patient has been compliant with a dose of simvastatin of 80 mg per day for at least 2 months; and 2.2.2 Either: 2.2.2.1 All of the following: 2.2.2.1.1 Patient has venous CABG; and 2.2.2.1.2 LDL cholesterol test 1 >= 2.0 mmol/litre; and 2.2.2.1.3 LDL cholesterol test 2 >= 2.0 mmol/litre (at least 1 week after test 1); or 2.2.2.2 All of the following: 2.2.2.2.1 Patient does not have venous CABG; and 2.2.2.2.2 LDL cholesterol test 1 >= 2.5 mmol/litre; and 2.2.2.2.
789 Special Authority for Subsidy - Form SA0789Initial application only from a relevant specialist or vocationally registered general practitioner. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 The patient has "treatment resistant" depression; and 2 Either: 2.1 The patient must have had a trial of two different antidepressants and failed to respond to an adequate dose over an adequate period of time (usually at least four weeks); or 2.2 Both: 2.2.1 The patient is currently a hospital in-patient as a result of an acute depressive episode; and 2.2.2 The patient must have had a trial of one other antidepressant and failed to respond to an adequate dose over an adequate period of time. Renewal from any medical practitioner. Approvals valid for 2 years where patient has a high risk of relapse (prescriber determined).
790 Prescribing GuidelineBimatoprost, lantanoprost and travoprost are subsidised for use in the treatment of glaucoma as either monotherapy or as an adjunctive agent for patients in whom prostaglandin analogue monotherapy has been ineffective in controlling intraocular pressure.Bimatoprost, lantanoprost and travoprost should not be prescribed for a person in whom less expensive first line agents for the treatment of glaucoma are not contraindicated unless: 1 That person has previously trialled all other such subsidised agents (beta-blockers, pilocarpine, carbonic anhydrase inhibitors); and2 Those trials have indicated that that person does not respond adequately to treatment with those other agents.
791 Mycophenolate powder for oral liquid is subsidised only for patients unable to swallow tablets and capsules, and when the prescription is endorsed accordingly.
792 Special Authority for Subsidy - Form: SA0792Initial application only from a psychiatrist. Approvals valid for 6 months for applications meeting the following criteria: All of the following: 1 The patient has schizophrenia or other psychotic disorder; and2 Has tried but failed to comply with treatment using oral atypical anti-psychotic agents; and3 Has been admitted to hospital or treated in respite care, or intensive outpatient or home-based treatment for 30 days or more in last 12 months. Renewal only from a psychiatrist. Approvals valid for 12 months for applications meeting the following criteria: Either: 4 Both: 4.1 The patient has had less than 12 months treatment with risperidone microspheres; and 4.2 There is no clinical reason to discontinue treatment; or5 The initiation of risperidone microspheres has been associated with fewer days of intensive intervention than was the case during a corresponding period of time prior to the initiation of risperidone microspheres. NoteRisp
793 a) Subsidised only if prescribed for a dialysis or cystic fibrosis patient; orb) for the treatment of confirmed ciprofloxacin-resistant gonorrhoea; orc) for the treatment of suspected meningitis in patients who have a known allergy to penicillin; andd) the prescription is endorsed accordingly
795 Maximum of 4 available on PSO
796 Special Authority for Subsidy - Form: SA0796Initial application only from a relevant specialist. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 Either: 1.1 ezetimibe is to be used in combination with simvastatin; or 1.2 ezetimibe is to be used without a statin; and2 Either: 2.1 All of the following: 2.1.1 Patient has a calculated absolute risk of cardiovascular disease >20% over 5 years; and 2.1.2 Patient cannot tolerate statin therapy at a dose of 40 mg per day; and 2.1.3 Either: 2.1.3.1 All of the following: 2.1.3.1.1 Patient has venous CABG; and 2.1.3.1.2 LDL cholesterol >= 2.0 mmol/litre (see note); and 2.1.3.1.3 LDL cholesterol >= 2.0 mmol/litre (at least 1 week after test 1 - see note); or 2.1.3.2 All of the following: 2.1.3.2.1 Patient does not have venous CABG; and 2.1.3.2.2 LDL cholesterol >= 2.5 mmol/litre (see note); and 2.1.3.2.3 LDL cholest
797 Special Authority for Subsidy - Form: SA0797Initial application - (Underlying cause - Osteoporosis) only from a relevant specialist or vocationally registered general practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria: Any of the following: 1 History of one significant osteoporotic fracture demonstrated radiologically and documented bone mass density (BMD) >= 2.5 standard deviations below the mean normal value in young adults (i.e. T-Score <= -2.5); or2 History of one significant osteoporotic fracture demonstrated radiologically and the patient is either over 75 years of age or is too frail* to undergo a bone mass density scan; or3 History of two significant osteoporotic fractures demonstrated radiologically; or4 Documented T-Score <= -3.0. Note*The patient may be considered to be frail if it is expected that there is significant risk of further fracture or other negative health outcome if the patient were to undergo a BMD s
798 Special Authority for Subsidy - Form: SA0798Initial application only from a relevant specialist. Approvals valid without further renewal unless notified for applications meeting the following criteria: Either: 1 Renal transplant recipient; or2 Heart transplant recipient. or; 3 Patient has an organ transplant and has severe tophaceous gout making azathioprine unsuitableRenewal only from a relevant specialist. Approvals valid without further renewal unless notified where patient had a previous Special Authority approval and was receiving mycophenolate prior to 1 October 2005
799 Special Authority for Subsidy - Form: SA0799Initial application only from a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Either: 1 The patient has metastatic breast cancer; or2 The patient has non-small cell lung cancer (stage IIIa, or above).Renewal only from a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Either: 3 The patient requires continued therapy; or4 The tumour has relapsed and requires re-treatment.
801 Special Authority for Subsidy - Form SA0801Initial application - (Serevent Accuhaler, Foradil, Symbicort Turbuhaler) only from a relevant specialist or general practitioner. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 Both: 1.1 Child under the age of 12 with poorly controlled asthma; and 1.2 Either: 1.2.1 Required at least three months of 400 mcg or more daily inhaled beclomethasone or budesonide; or 1.2.2 Required at least three months of 200 mcg or more of fluticasone; or 2 Both: 2.1 Adult with poorly controlled asthma; and 2.2 Either: 2.2.1 Required at least three months of 1500 mcg or more daily inhaled beclomethasone or budesonide; or 2.2.2 Required at least three months of 750 mcg or more of fluticasone. NotePatients are to be reviewed at least at six months to assess compliance and effectiveness of therapy. Special Authority approvals are interchangeable among all presentations of inhaled long-acting beta
802 Special Authority for Subsidy - Form SA0802Initial application - (genotype 1, 4, 5 or 6 infection or co-infection with HIV) from any specialist. Approvals valid for 11 months for applications meeting the following criteria: 1. Patient has chronic hepatitis C, genotype 1, 4, 5 or 6 infection; or2. Patient has chronic hepatitis C and is co-infected with HIV. Note: consider stopping treatment if there is absence of a virological response (defined as at least a 2-log reduction in viral load) following 12 weeks of treatment since this is predictive of treatment failure.Initial application - (genotype 2 or 3 infection without co-infection with HIV) from any specialist. Approvals valid for 6 months for applications meeting the following criteria: 3. Patient has chronic hepatitis C, genotype 2 or 3 infection; andEither: 3.1 Patient has bridging fibrosis or cirrhosis (Metavir stage 3 or 4 or equivalent); or 3.2 is unsuitable for liver biopsy due to coagulopathy.
803 Special Authority for Subsidy - Form SA0803Initial application from any specialist. Approvals valid for 11 months for applications meeting the following criteria: either: 1 Patient has chronic hepatitis C, genotype 1, 4, 5 or 6 infection; or2 Patient has chronic hepatitis C, genotype 2 or 3 infection; and 2.1 With has bridging fibrosis or cirrhosis (Metavir stage 3 or 4, or equivalent). 2.2 is unsuitable for liver biopsy due to coagulopathy. Note: consider stopping treatment if there is absence of a virological response (defined as at least a 2-log reduction in viral load) following 12 weeks of treatment since this is predictive of treatment failure.
804 Prescribing Guideline for Inhaled Long-Acting Beta-Adrenoceptor AgonistsThe addition of inhaled long-acting beta-adrenoceptor agonists (LABAs) to inhaled corticosteroids is recommended: - For younger children (aged under 12 years) where asthma is poorly controlled despite using inhaled corticosteroids for at least three months at total daily doses of 200 mcg beclomethasone or budesonide (or 100 mcg fluticasone).- For adults and older children (aged 12 years and over) where asthma is poorly controlled despite using inhaled corticosteroids for at least three months at total daily doses of 400 mcg beclomethasone or budesonide (or 200 mcg fluticasone).Note: Further information on the place of inhaled corticosteroids and inhaled LABAs in the management of asthma can be found in the New Zealand guidelines for asthma in adults (www.nzgg.org.nz) and in the New Zealand guidelines for asthma in children aged 1-15 (www.paediatrics.org.nz).
805 Access by applicationa) Budget managed by appointed clinicians on the Multiple Sclerosis Treatment Assessments Committee (MSTAC). b) Applications will be considered by MSTAC at its regular meetings and approved subject to eligibility according to the Entry and Stopping criteria (below). c) Applications to be made on the approved forms which are available from the co-ordinator for MSTAC:The Co-ordinator Phone: (04) 460 4990Multiple Sclerosis Treatment Assessments Committee Facsimile: (04) 916 7571PHARMAC, PO Box 10 254 E mail: silvia.valsenti@pharmac.govt.nzWellingtond) Completed application forms must be sent to the co-ordinator for MSTAC and will be considered by MSTAC at the next practicable opportunity. e) Notification of MSTAC's decision will be sent to the patient, the applying clinician and the patient's GP (if specified). f) These agents will not be subsidised if dispensed from a community or hospital pharmacy. Regular supplies will be distributed to all approved patients or their c
806 a) Subsidised only if prescribed for a dialysis or cystic fibrosis patient; orb) for the treatment of confirmed ciprofloxacin-resistant gonorrhoea; orc) for the treatment of suspected meningitis in patients who have a known allergy to penicillin; andd) the prescription or PSO is endorsed accordingly
807 subsidised only if prescribed for patients with uncomplicated urethritis or cervicitis proven or presumed to be due to Chlamydia trachomatis and their sexual contacts and prescription or PSO is endorsed accordingly.
808 Special Authority for Subsidy Initial application only from a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: 1 The patient has metastatic colorectal cancer; and2 To be used for first or second line use as part of a combination chemotherapy regimen. Renewal only from a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: 3 The patient requires continued therapy; or4 The tumour has relapsed and requires re-treatment.
809 Special Authority for Subsidy - Form: SA0809Initial application only from a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Any of the following: 1 Both: 1.1 The patient has ovarian*, fallopian* or primary peritoneal cancer*; and 1.2 Either: 1.2.1 Has not received prior chemotherapy; or 1.2.2 Has received prior chemotherapy but has not previously been treated with taxanes; or2 The patient has metastatic breast cancer; or3 Both: 3.1 The patient has non small-cell lung cancer; and 3.2 Either: 3.2.1 Has advanced disease (stage IIIa or above); or 3.2.2 Is receiving combined chemotherapy and radiotherapy; or4 Both: 4.1 The patient has small-cell lung cancer*; and 4.2 Docetaxel is to be used as second-line therapy. Renewal only from a relevant specialist. Approvals valid for 12 months for applications meeting the followingcriteria: 5. The patient has metastatic breast cancer, non small-cell lung cancer,
810 Special Authority for Alternate SubsidyInitial application only from a relevant specialist. Approvals valid for 5 years for applications meeting the following criteria: All of the following: 1 Patient is a postmenopausal women; and2 Patient has hormone receptor positive breast cancer; and3 Any of the following: 3.1 The cancer is advanced (Stage IIIb, or metastatic Stage IV); or 3.2 The patient has a very clear history of intolerance to tamoxifen; or 3.3 The use of tamoxifen is contraindicated due to a history of thromboembolic disease. Renewal only from a relevant specialist. Approvals valid without further renewal unless notified where the treatment remains appropriate and the patient is benefiting from treatment.
811 Special Authority for Alternate SubsidyInitial application only from a relevant specialist. Approvals valid for 5 years for applications meeting the following criteria: All of the following: 1 Patient is a postmenopausal women; and2 Patient has hormone receptor positive breast cancer; and3 Any of the following: 3.1 The cancer is advanced (Stage IIIb, or metastatic Stage IV); or 3.2 The patient has a very clear history of intolerance to tamoxifen; or 3.3 The use of tamoxifen is contraindicated due to a history of thromboembolic disease. Renewal only from a relevant specialist. Approvals valid without further renewal unless notified where the treatment remains appropriate and the patient is benefiting from treatment.
812 Special Authority for SubsidyInitial application only from a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria: All of the following1 Patient is an adult who has had severe and active erosive Rheumatoid Arthritis for six months duration or longer; and2 Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and3 Patient has tried and not responded to at least three months of oral or parenteral methotrexate at a dose of at least 20 mg weekly or a maximum tolerated dose; and4 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with at least two of the following (triple therapy): sulphasalazine, prednisone at a dose of at least 7.5 mg per day, azathioprine, intramuscular gold, or hydroxychloroquine sulphate (at maximum tolerated doses); and5 Patient has tried and not responded to at least three months therapy at th
813 Special Authority for Subsidy Initial application only from a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Any of the following: 1 The patient has non small cell lung carcinoma (stage IIIa, or above); or2 The patient has advanced malignant mesothelioma*; or3 The patient has advanced pancreatic carcinoma; or4 The patient has ovarian, fallopian tube* or primary peritoneal carcinoma*. Renewal only from a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Both: 5 The patient requires continued therapy; or6 The tumour has relapsed and requires re-treatment. Note indications marked with a * are unapproved indications.
814 Special Authority for Subsidy Initial application only from a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Both: 1 The patient has primary thrombocythaemia; and2 Either 2.1 is at high risk (previous thromboembolic disease, bleeding or platelet count >1500/ml); or 2.2 is intolerant or refractory to hydroxyurea or interferon. Renewal only from a relevant specialist. Approvals valid for 12 months where the treatment remains appropriate and the patient is benefiting from treatment. NoteIt is recommended that treatment with anagrelide be initiated only on the recommendation of a haematologist.
817 Special Authority for Subsidy Initial application - (for new patients) only from a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Both: 1 The patient has refractory, progressive or relapsed multiple myeloma; and2 The patient has received prior chemotherapy. Initial application - (for patients receiving thalidomide prior to 1 January 2006) only from a relevant specialist. Approvals valid without further renewal where the patient was receiving treatment with thalidomide for multiple myeloma on or before 31 December 2005. Renewal only from a relevant specialist. Approvals valid without further renewal where the patient has obtained a response from treatment during the initial approval period. Note: Prescription must be written by registered prescriber in the thalidomide risk management programme operated by the supplier. Maximum dose of 400 mg daily as monotherapy or in a combination therapy regimen.
819 Special Authority for Subsidy Initial application for patients with type 2 diabetes only from a relevant specialist. Approvals valid for one year for applications meeting the following criteria: Any of the following: Monotherapy1 All of the following: 1.1 To be used as monotherapy for patients who after six months of diet and lifestyle changes have inadequate glycaemic control (defined as HbA1c > 7.0% in tests carried out at least two months apart); and 1.2 Metformin is contraindicated or not tolerated after a minimum of a four week trial period; and 1.3 Sulphonylurea is contraindicated or not tolerated or the patient's body mass index (BMI) exceeds 33 kg/m2; orIn combination with sulphonylurea2 Both: 2.1 For use in combination with a sulphonylurea for patients who after diet and lifestyle changes and a six-month trial of sulphonylurea have poor glycaemic control (defined as HbA1c > 8.0% measured within the last month of the six month period); and 2.2 Metformin is contrain
822 Subsidised only for treatment of prostate cancer and breast cancer
824 Prescribing GuidelineCombigan is subsidised for use as either monotherapy or as an adjunctive agent for the treatment of glaucoma. Combigan should only be prescribed when: a) less expensive first line agents for the treatment of glaucoma are contraindicated; orb) the response to such subsidised agents is inadequate; orc) the patient cannot tolerate such subsidised agents.
825 Perindopril and trandolapril will be funded to the level of the ex-manufacturer price listed in the Schedule for patients who were taking these ACE inhibitors for the treatment of congestive heart failure prior to 1 June 1998. The prescription must be endorsed accordingly. We recommend that the words used to indicate eligibility are "certified condition" or an appropriate description of the patient such as "congestive heart failure", "CHF", "congestive cardiac failure" or "CCF". Definition of Congestive Heart Failure At the request of some prescribers the PTAC Cardiovascular subcommittee has provided a definition of congestive heart failure for the purposes of the funding of the manufacturer's surcharge: "Clinicians should use their clinical judgement. Existing patients would be eligible for the funding of the surcharge if the patient shows signs and symptoms of congestive heart failure, and requires or has in the past required concomitant treatment with a diuretic. The definition could also be considere
826 Special Authority for Subsidy - Form: SA0826Initial application only from a relevant specialist. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 All of the following: 1.1 Patient has a calculated absolute risk of cardiovascular disease >20% over 5 years; and 1.2 Patient cannot tolerate statin therapy at a dose of >= 40 mg per day; and 1.3 Either: 1.3.1 All of the following: 1.3.1.1 Patient has venous CABG; and 1.3.1.2 LDL cholesterol >= 2.0 mmol/litre (see note); and 1.3.1.3 LDL cholesterol >= 2.0 mmol/litre (at least 1 week after test 1 - see note); or 1.3.2 All of the following: 1.3.2.1 Patient does not have venous CABG; and 1.3.2.2 LDL cholesterol >= 2.5 mmol/litre (see note); and 1.3.2.3 LDL cholesterol >= 2.5 mmol/litre (at least 1 week after test 1 - see note); or2 All of the following: 2.1 Patient has homozygous familial hypercholesterolemia, or heterozygous familial hypercholest
827 Subsidy by endorsement: a. Only if prescribed for post-herpetic neuralgia or diabetic peripheral neuropathy; andb. The prescription is endorsed accordingly.
829 Special Authority for Subsidy - Retail Pharmacy - Form SA0829Initial Application only from gastroenterologist or infectious disease specialist. Approvals valid for 1 year for applications meeting the following criteria: All of the following: 1. Patient has confirmed Hepatitis B infection (HBsAg+); andDocumented resistance to lamivudine, defined as: 2. patient has raised serum ALT (> 1 x ULN); and3. patient has HBV DNA greater than 100,000 copies per mL, or viral load ? 10 fold over nadir; and4. detection of M204I or M204V mutation; and5. Either5.1. Both5.1.1. patient is cirrhotic; and5.1.2. adefovir dipivoxil to be used in combination with lamivudine; or5.2. Both5.2.1. patient is not cirrhotic; and5.2.2. adefovir dipivoxil to be used as monotherapyRenewal only from a gastroenterologist or infectious disease specialist. Approvals valid for 2 years for applications where in the opinion of the treating physician, treatment remains appropriate and patient is benefiting from treatmen
831 Special Authority for Subsidy - Form: SA0831Application only from a relevant specialist. Approvals valid for 10 months for applications meeting the following criteria: 1. Patient has newly diagnosed glioblastoma multiforme; and2. Temozolomide is to be (or has been) given concomitantly with radiotherapy; and3. Following concomitant treatment temozolomide is to be used for a maximum of six cycles of 5 days treatment, at a maximum dose of 200 mg/m2. Note: Temozolomide is not subsidised for the treatment of relapsed glioblastoma multiforme. Studies of temozolomide show that its benefit is predominantly in those patients with a good performance status (WHO grade 0 or 1 or Karnofsky score >80), and in patients who have had at least a partial resection of the tumour.
832 Special Authority for Subsidy - Form: SA0832Initial application only from a gastroenterologist, infectious disease specialist, paediatrician or general physician. Approvals valid for 1 year for applications meeting the following criteria: Both: 1 Any of the following: 1.1 All of the following: 1.1.1 HBsAg positive for more than 6 months; and1.1.2 HBeAg positive or HBV DNA positive defined as > 100,000 copies per ml by quantitative PCR at a reference laboratory; and1.1.3 ALT greater than twice upper limit of normal or bridging fibrosis or cirrhosis (Metavir stage 3 or 4 or equivalent) on liver histology or clinical/radiological evidence of cirrhosis; or 1.2 HBV DNA positive cirrhosis prior to liver transplantation; or1.3 HBsAg positive and have had a liver, kidney, heart, lung or bone marrow transplant; or1.4 Hepatitis B surface antigen positive (HbsAg) patient who is receiving chemotherapy for a malignancy, or who has received such treatment within the previous two months;
833 Special Authority for Subsidy - Form SA0833Initial application only from a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Any of the following: 1 The patient has non small cell lung carcinoma (stage IIIa, or above); or2 The patient has advanced malignant mesothelioma*; or3 The patient has advanced pancreatic carcinoma; or4 The patient has ovarian, fallopian tube* or primary peritoneal carcinoma*; or5 The patient has advanced transitional cell carcinoma of the urothelial tract (locally advanced or metastatic). Renewal only from a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Both: 6 The patient requires continued therapy; or7 The tumour has relapsed and requires re-treatment. Note indications marked with a * are unapproved indications.
834 Special Authority for Subsidy - Form: SA0834Initial application only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria: Either: 1 Both: 1.1 Patient has type 1 diabetes and has received an intensive regimen (injections at least three times a day) of an intermediate acting insulin in combination with a rapid acting insulin analogue for at least three months; and1.2 Either: 1.2.1 Patient has experienced more than one unexplained severe hypoglycaemic episode in the previous 12 months (severe defined as requiring the assistance of another person); or1.2.2 Patient has experienced unexplained symptomatic nocturnal hypoglycaemia, biochemically documented at <3.0 mmol/L, more than once a month despite optimal management; or2 Patient has documented severe, or continuing, systemic or local allergic reaction to existing insulins. Note this does not include hypoglycaemic episodes. Renewal only from a relevant specialist or general practitioner. Approv
835 Special Authority for Subsidy - Form SA0835Initial application - (Breast cancer) from any medical practitioner. Approvals valid for 1 year: where the patient is a premenopausal woman with breast cancer. Initial application - (Prostate cancer) only from an oncologist, urologist or endocrinologist. Approvals valid for 1 year for applications meeting the following criteria: Advanced prostatic cancer;. Note Not to be prescribed with an anti-androgen except for a period of three weeks, if necessary, when GnRH analogue therapy is initiated. Initial application - (Endometriosis) only from a gynaecologist. Approvals valid for 3 months for applications meeting the following criteria: Both: 1 Endometriosis; and2 Either: 2.1 6 months treatment with medroxyprogesterone acetate, danazol or dimetriose has proven ineffective; or2.2 The patient has failed to tolerate the treatment with medroxyprogesterone acetate, danazol or dimetriose for 6 months. Note The maximum treatment period for a GnRH analogue is:
836 Special Authority for Subsidy - Form SA0836Initial application - (Breast cancer) from any medical practitioner. Approvals valid for 1 year where the patient is a premenopausal woman with breast cancer. Initial application - (Prostate cancer) only from an oncologist, urologist or endocrinologist. Approvals valid for 1 year for applications meeting the following criteria: Either: 1 Advanced prostatic cancer; or. 2 Locally advanced prostatic cancer. Note Not to be prescribed with an anti-androgen except for a period of three weeks, if necessary, when GnRH analogue therapy is initiated. Initial application - (Endometriosis) only from a gynaecologist. Approvals valid for 3 months for applications meeting the following criteria: Both: 3 Endometriosis; and4 Either: 4.1 6 months treatment with medroxyprogesterone acetate, danazol or dimetriose has proven ineffective; or4.2 The patient has failed to tolerate the treatment with medroxyprogesterone acetate, danazol or dimetriose for 6 months. Note
837 Special Authority for Subsidy - Form SA0837Initial application - (Breast cancer) from any medical practitioner. Approvals valid for 1 year where the patient is a premenopausal woman with breast cancer. Initial application - (Prostate cancer) only from an oncologist, urologist or endocrinologist. Approvals valid for 1 year where the patient has: Advanced prostatic cancer;. Note Not to be prescribed with an anti-androgen except for a period of three weeks, if necessary, when GnRH analogue therapy is initiated. Initial application - (Endometriosis) only from a gynaecologist. Approvals valid for 3 months for applications meeting the following criteria: Both: 1 Endometriosis; and2 Either: 2.1 6 months treatment with medroxyprogesterone acetate, danazol or dimetriose has proven ineffective; or2.2 The patient has failed to tolerate the treatment with medroxyprogesterone acetate, danazol or dimetriose for 6 months. Note The maximum treatment period for a GnRH analogue is: - 3 months to assess whet
838 Special Authority for Subsidy - Form: SA0838Initial Application only from a relevant specialist or General Practitioner. Approvals valid for 2 years forapplications meeting the following criteria: Either: 1 All of the following: 1.1 Patient is a child under the age of 12; and1.2 All of the following: Has, for 3 months or more, been treated with:1.2.1 An inhaled long-acting beta adrenoceptor agonist; and1.2.2 Inhaled corticosteroids at a dose of at least 400 mcg per day beclomethasone or budesonide, or200 mcg per day fluticasone; and1.3 The prescriber considers that the patient would receive additional clinical benefit from switching to acombination product; or2 All of the following: 2 .1 Patient is over the age of 12; and2 .2 All of the following: Has, for 3 months or more, been treated with:2 .2.1 An inhaled long-acting beta adrenoceptor agonist; and2 .2.2 Inhaled corticosteroids at a dose of at least 800 mcg per day beclomethasone or budesonide, or500 mcg per day fluticasone;
839 Special Authority for Subsidy - Form SA0839Initial application - (Breast cancer) from any medical practitioner. Approvals valid for 1 year where the patient is a premenopausal woman with breast cancer. Initial application - (Prostate cancer) only from an oncologist, urologist or endocrinologist. Approvals valid for 1 year for applications meeting the following criteria: Either: 1 Advanced prostatic cancer; or. 2 Neoadjuvant or adjuvant treatment of locally advanced prostatic cancer. Note Not to be prescribed with an anti-androgen except for a period of three weeks, if necessary, when GnRH analogue therapy is initiated. Initial application - (Endometriosis) only from a gynaecologist. Approvals valid for 3 months for applications meeting the following criteria: Both: 3 Endometriosis; and4 Either: 4.1 6 months treatment with medroxyprogesterone acetate, danazol or dimetriose has proven ineffective; or4.2 The patient has failed to tolerate the treatment with medroxyprogesterone acetate, danazo
840 Maximum of 2 inhalations per day
841 Special Authority for Subsidy - form: SA0841Initial application only from a gastroenterologist or general physician. Approvals valid for 6 months for applications meeting the following criteria: Both: 1 Primary biliary cirrhosis confirmed by antimitochondrial antibody titre (AMA) > 1:80, and raised cholestatic liver enzymes with or without raised serum IgM or, if AMA is negative, by liver biopsy; and2 Patient not requiring a liver transplant (bilirubin > 170umol/l; decompensated cirrhosis). NoteLiver biopsy is not usually required for diagnosis but is helpful to stage the diseaseRenewal only from a gastroenterologist or general physician. Approvals valid for 2 years for applications meeting the following criteria: The treatment remains appropriate and the patient is benefiting from treatment. NoteActigall is not an appropriate therapy for patients requiring a liver transplant (bilirubin > 170 micromol/l; decompensated cirrhosis). These patients should be referred to an appropriate transp
842 Special Authority for Subsidy - Form: SA842Initial application only from a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Any of the following: 1 Both: 1.1 The patient has ovarian, fallopian* or primary peritoneal cancer*; and 1.2 Either: 1.2.1 Has not received prior chemotherapy; or 1.2.2 Has received prior chemotherapy but have not previously been treated with taxanes; or2 The patient has metastatic breast cancer; or3 The patient has node-positive early breast cancer; or4 Both 4.1 The patient has non small-cell lung cancer; and 4.2 Either: 4.2.1 Has advancing disease (stage IIIa or above); or 4.2.2 Is receiving combined chemotherapy and radiotherapy; or5 Both: 5.1 The patient has small-cell lung cancer*; and 5.2 Paclitaxel is to be used as second-line therapy. Renewal only from a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: 6 The patient has metasta
843 Only one multidose cartridge starter pack to be prescribed and dispensed per patient.
Trial Version
Not all rows exported
Special Authority for Subsidy - Form SA0006Initial application from any medical practitioner. Approvals valid for 5 years where the patient is likely to benefit from treatment. Renewal from any medical practitioner. Approvals valid for 5 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0011Initial application only from a relevant specialist. Approvals valid for 2 years where the patient has diabetes. Renewal only from a relevant specialist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
Pharmaceutical Cancer Treatment in respect of which DHB hospital pharmacies and other Contractors can claim Subsidies.
Pharmaceutical Cancer Treatment in respect of which only DHB hospital pharmacies can claim Subsidies.
Special Authority for Subsidy - Form SA0028Initial application only from a relevant specialist. Approvals valid for 6 months for applications meeting the following criteria: Either: 1 All of the following: 1.1 Treatment with other lipid modifying medicines has been unsuccessful; and 1.2 6 months of dietary modification has been unsuccessful; and 1.3 Cholesterol level > 7.0 mmol/litre; and 1.4 Either: 1.4.1 Familial hypercholesterolaemia; or 1.4.2 Manifest coronary heart disease, which has been clinically proven, or previously treated by coronary artery surgery; or 2 Cholesterol level > 9.0 mmol/litre:.Renewal only from a general practitioner. Approvals valid for 6 months where the treatment remains appropriate and the patient is benefiting from treatment. NoteFamilial hypercholesterolaemia is defined as being hypercholesterolaemia in the presence of tendon xanthomas or in association with a family history of premature heart disease (before age 55) or consisten
Unapproved medication supplied under Section 29 of the Medicines Act 1981. Practitioners prescribing this medication should: (a) be aware of and comply with their obligations under Section 29 of the Medicines Act 1981 and otherwise under that Act and the Medicines Regulations 1984; (b) be aware of and comply with their obligations under the Health and Disability Commissioner's Code of Consumer Rights, including the requirement to obtain informed consent from the patient (PHARMAC recommends that Practitioners obtain written consent); and(c) exercise their own skill, judgment, expertise and discretion, and make their own prescribing decisions with respect to the use of an unapproved Pharmaceutical or a Pharmaceutical for an indication for which it is not approved.
Special Authority for Subsidy - Form SA0031Initial application from any medical practitioner. Approvals valid for 2 years for applications meeting the following criteria: Any of the following: 1 Oesophageal stricture; or 2 Terminal care; or 3 Too young to swallow conventional tablets; or 4 Too old to swallow conventional tablets. Renewal from any medical practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
a) When ordered by a medical practitioner on a practitioner's supply order for ventricular arrhythmias and the order is endorsed accordinglyb) When ordered for a dialysis patient or a child with rhumatic fever and the order is endorsed accordingly
Additional Subsidy by Special Authority available to fully fund to the level of the lowest priced TDDS brand within the medium dose oestrogens.
Special Authority for Manufacturers Price - Form SA0035Initial application from any medical practitioner. Approvals valid for 5 years for applications meeting the following criteria: Both: 1 Either: 1.1 Both: 1.1.1 Duodenal and gastric ulcers, reflux oesophagitis and Zollinger-Ellison syndrome; and 1.1.2 Other treatments have failed; or 1.2 Patients who are on a Social Welfare benefit or an income no greater than a benefit; and 2 Patients must have endoscopically demonstrated lesions prior to commencement of treatment.. Renewal from any medical practitioner. Approvals valid for 5 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0041Initial application only from a relevant specialist. Approvals valid for 2 years where alternative antihypertensives have failed. Renewal only from a relevant specialist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
Note: Danthron with poloxamer is only approved for the prevention or treatment of constipation in the terminally ill. Studies in rats have associated use of danthron with tumours.
Special Authority for Subsidy - Form SA0045Initial application from any medical practitioner. Approvals valid for 2 years for applications meeting the following criteria: All of the following: 1 Continuation of treatment commenced prior to 1 August 1990; and 2 Alternatives (salbutamol and terbutaline) have been tried; and 3 Either: 3.1 Asthma; or 3.2 Chronic obstructive airways disease (COAD); and 4 Applicants must provide details of dose. Renewal from any medical practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0046Initial application only from a gastroenterologist. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 Functioning gall bladder; and 2 Either: 2.1 Uncalcified gallbladder stones with a maximum size of 20 mm; or 2.2 Adjunctive treatment after extra corporeal lithotrypsy. Renewal only from a gastroenterologist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0047Initial application only from a paediatrician or respiratory specialist. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 Child under 2 years of age; or 2 Both: 2.1 Child with major physical or intellectual disabilities; and 2.2 Lacks the necessary coordination to use aerosols with a spacer device. NoteThe cost of nebuliser therapy greatly exceeds other inhaled forms. Steroid nebulising solution can cause cataract formation. Renewal only from a paediatrician or respiratory specialist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0050Initial application only from a relevant specialist. Approvals valid for 2 years where terminally ill patient. Renewal only from a relevant specialist. Approvals valid for 2 years where terminally ill patient.
Special Authority for Subsidy - Form SA0051Initial application from any medical practitioner. Approvals valid for 6 months where control of nausea in the treatment of malignant disease. Renewal from any medical practitioner. Approvals valid for 6 months where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0053Initial application only from a relevant specialist. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 RAST or skin test positive; and 2 Patient has had severe generalised reaction to the sensitising agent. Renewal only from a relevant specialist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0055Initial application only from a psychiatrist, geriatrician or respiratory specialist. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 For use only as an anxiolytic; and 2 Other agents are contraindicated or have failed. Renewal only from a psychiatrist, geriatrician or respiratory specialist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0056Initial application only from a psychiatrist. Approvals valid for 5 years for applications meeting the following criteria: Both: 1 Long-standing delusional states; and 2 Other injectable anti-psychotics have proven to be ineffective or inappropriate. Renewal only from a psychiatrist. Approvals valid for 5 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0057Initial application only from a psychiatrist. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 Depression; and 2 Any of the following: 2.1 Both: 2.1.1 Failed trials with other antidepressants; and 2.1.2 Patient has been maintained on mianserin prior to December1993; or 2.2 Co-existent bladder neck obstruction; or 2.3 Cardiovascular disease. Renewal only from a psychiatrist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
Subsidised only if prescribed for dialysis or cystic fibrosis patient and the prescription is endorsed accordingly
Injections (both 500 mg and 1 g) subsidised: a) only if prescribed for a dialysis or cystic fibrosis patient; and b) the prescription is endorsed accordingly.
Special Authority for Subsidy - Form SA0069Initial application only from a general physician, nephrologist or neurologist. Approvals valid for 5 years where syndrome of inappropriate anti-diuretic hormone secretion (SIADH). Renewal only from a general physician, nephrologist or neurologist. Approvals valid for 5 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Manufacturers Price - Form SA0070Initial application only from a respiratory specialist or infectious disease specialist. Approvals valid for 2 years for applications meeting the following criteria: Any of the following: 1 Avium intracellular atypical mycobacterial infections; or 2 Multiple drug resistant tuberculosis; or 3 Atypical and drug-resistant mycobacterial infections in patients with AIDS. Renewal only from a respiratory specialist or infectious disease specialist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
Only if prescribed for a dialysis or cystic fibrosis patient or in the treatment of pseudo membranous colitis and the prescription is endorsed accordingly
a) Only granted after the patient has proven to be intolerant to zidovudine or whose health has significantly deteriorated while on zidovudine. It is impossible to have approvals for both AZT and DDI concurrently but it is not expected that both medicines would be consumed at the same time. Applications can be made without patients having had a preliminary trialb) Specialist must make application
a) Approvals granted as third line therapy after patient has developed intolerance or treatment failure to both zidovudine and DDI b) Specialist must make application
a) All patients with AIDS meeting the definition developed by the Centres for Disease Control in the USA (see Circular Letter to Medical Practitioners HP2/88)b) Patients with AIDS Related Complex (ARC)c) HIV infected patients with CD4 (T4) counts below 500 regardless of symptomatologyd) Prophylactically for persons following severe parenteral exposure from a known HIV positive sourcee) HIV infected persons with associated thrombocytopenia regardless of CD4 (T4) count f) Applications can only be made by appropriate specialists. Prescriptions for those patients approved to use these medicines can be written either by the specialist or general practitioner with an endorsement of the name of the recommending specialist. g) Prescriptions for these can be written for a period of three months' supply. However, medicine must be dispensed on a monthly basis.
NOTE: Evidence that a patient is on insulin therapy can be by way of either: a) insulin being on the same prescription ofb) by the word "insulin patient" be in written on the prescription by either the doctor or the contractor.
All non-disposible diabetic supplies are only eligible for subsidy if there is produced to the contractor a certificate the gives the nome, address, and age of the patient and that:1) is signed by a doctor and2) is dated less than two years propr to the date of supply; and that 3) states that the patient is receiving iusulin therapy.
Additional Subsidy by Special Authority available to fully fund to the level of the lowest priced TDDS brand within the low dose oestrogens.
Additional Subsidy by Special Authority available to fully fund to the level of the lowest priced TDDS brand within the medium dose oestrogens.
Special Authority for Subsidy - Form SA0085Initial application from any medical practitioner. Approvals valid for 5 years where the patient is likely to benefit from treatment. Renewal from any medical practitioner. Approvals valid for 5 years where the treatment remains appropriate and the patient is benefiting from treatment.
a) Males: Fertile eunuch syndrome, females: anovulatory infertilityb) A declaration is required from the applying doctor that these agents are not being used as part of an IVF programmec) Approvals are valid for 6 months with a revewal for a further 6 months if the patient has some response and the prescriber believes further treatment will be effectived) Specialist must make application - endocrinologists and gynaecologists only
Special Authority for Subsidy - Form SA0087Initial application only from an endocrinologist or gynaecologist. Approvals valid for 6 months where hypogonadotrophic hypogonadism (including anovulatory infertility and cryptochidism). Renewal only from an endocrinologist or gynaecologist. Approvals valid for 6 months where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0088Initial application only from an endocrinologist or gynaecologist. Approvals valid for 6 months for applications meeting the following criteria: Both: 1 Either: 1.1 Female with anovulatory infertility, males: hypogonadotrophic hypogonadism; or 1.2 Male with hypogonadotrophic hypogonadism; and 2 These agents are not being used as part of an IVF programme. Renewal only from an endocrinologist or gynaecologist. Approvals valid for 6 months where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0089Initial application - (Breast or prostatic cancer) only from an oncologist, urologist or endocrinologist. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 Breast cancer in pre menopausal women unwilling or unable to undergo surgical or radiation oophorectomy; or 2 Advanced prostatic cancer when orchidectomy is contraindicated. Initial application - (Endometriosis) only from a gynaecologist. Approvals valid for 6 months for applications meeting the following criteria: Both: 1 Endometriosis; and 2 Either: 2.1 6 months treatment with medroxyprogesterone acetate, danazol or dimetriose has proven ineffective; or 2.2 The patient has failed to tolerate the treatment with medroxyprogesterone acetate, danazol or dimetriose for 6 months. NoteThe maximum treatment period for a GnRH analogue is: 3 months to assess whether surgery is appropriate3 months for infertile patients after surgery6 months for
Special Authority for Subsidy - Form SA0090Initial application only from a relevant specialist. Approvals valid for 2 years where patient cannot use desmopressin nasal spray or nasal drops. Renewal only from a relevant specialist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0091Initial application only from a relevant specialist. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 Paget's disease; or 2 Both: 2.1 Patients under hospice care; and 2.2 Either: 2.2.1 Tumour-induced hypercalcaemia; or 2.2.2 Tumour-induced osteolysis without hypercalcaemia. Renewal only from a relevant specialist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0092Initial application only from a relevant specialist. Approvals valid for 5 years where treatment of refractory absorptive hypercalcaemia. Renewal only from a relevant specialist. Approvals valid for 5 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0094Initial application only from a relevant specialist (Only for Epsom Day Unit in Auckland). Approvals valid for 1 month where termination of advanced pregnancy i.e. beyond 12 weeks. Only for Epsom Day Unit in Auckland.
Special Authority for Subsidy - Form SA0096Initial application - (Organ transplant, Bone marrow transplant or Graft v host disease) only from a relevant specialist. Approvals valid for 2 years for applications meeting the following criteria: Any of the following: 1 Organ transplant; or 2 Bone marrow transplant; or 3 Graft v host disease. Initial application - (Psoriasis) only from a dermatologist. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 Psoriasis; and 2 Other systemic and topical therapy has failed. Initial application - (Severe atopic dermatitis) only from a dermatologist. Approvals valid for 6 months for applications meeting the following criteria: Both: 1 Severe atopic dermatitis; and 2 Not resopnsive to topical therapy, oral antihistamines and other commonly used orthodox therapies. Initial application - (Nephrotic Syndrome) from any medical practitioner. Approvals valid for 2 years for applications meeting the following cri
Special Authority for Subsidy - Form SA0097Initial application - (Chronic hepatitis C) only from a relevant specialist. Approvals valid for 6 months where chronic hepatitis C. Initial application - (Indications other than Chronic hepatitis C) only from a relevant specialist. Approvals valid for 5 years for applications meeting the following criteria: Any of the following: 1 Chronic myelogenous leukaemia; or 2 Hairycell leukaemia; or 3 Cutaneous T cell lymphoma; or 4 Essential thrombocythaemia; or 5 AIDS related Kaposi's sarcoma; or 6 Multiple myeloma; or 7 Chronic active hepatitis B. Renewal - (Chronic hepatitis C) only from a relevant specialist. Approvals valid for 6 months where the treatment remains appropriate and the patient is benefiting from treatment. Renewal - (Indications other than Chronic hepatitis C) only from a relevant specialist. Approvals valid for 5 years where the treatment remains appropriate and the patient is benefiting from treatment.
a) Hairy cell leukaemia, Kaposi's sarcoma, chronic active hepatitis B, chronic hepatitis C (6 month approval only), chronic myelogenous leukaemia, multiple myelomab) Specialist must make applicationc) No further approvals for:Malignant melanoma, superficial and noduloulcerative basal cell carcinomaNote: Patients with existing approvals can continue to have therapy
Special Authority for Subsidy - Form SA0099Initial application only from a relevant specialist. Approvals valid for 5 years for applications meeting the following criteria: Any of the following: 1 Both: 1.1 Acromegaly; and 1.2 Patients who have failed surgery, radiotherapy, bromocriptine and other oral therapies; or 2 Both: 2.1 Either: 2.1.1 Vipomas; or 2.1.2 Glucagonomas; and 2.2 Patients who are seriously ill in order to improve their clinical state prior to definitive surgery; or 3 Both: 3.1 Gastrinoma; and 3.2 Either: 3.2.1 Patient has failed surgery; or 3.2.2 Patient is in metastatic disease after H2 antagonists (or omeprazole) have failed; or 4 Both: 4.1 Insulinomas; and 4.2 Surgery is contraindicated or where surgery has failed; or 5 Pre-operative control of hypoglycaemia; or 6 Maintenance therapy. NoteThe use of octreotide in patients with fistulae, oesophageal varices, miscellaneous diarrhoea and hypotension will
Special Authority for Subsidy - Form SA0100Initial application only from a relevant specialist. Approvals valid for 5 years for applications meeting the following criteria: All of the following: 1 Anaemia of end-stage renal failure (other treatable causes of anaemia being excluded); and 2 Been on haemodialysis or continuous ambulatory peritoneal dialysis (CAPD) for at least three months; and 3 Not under evaluation for, or awaiting, a live donor kidney transplant; and 4 Any of the following: 4.1 Anephric; or 4.2 Dependent on regular blood transfusion (1 unit each 4-8 weeks) to maintain haemoglobin > 60g/L; or 4.3 Cannot be transfused because of severe transfusion reactions; or 4.4 Transfusion induced haemosiderosis (clinical manifestations, serum ferritin >1500 ug/L); or 4.5 Haemoglobin < 70 g/L (mean of at least 4 haemoglobin concentrations over 4 months); or 4.6 Both: 4.6.1 Haemoglobin < 90 g/L; and 4.6.2 Either: 4.6.2.1 Heart failure (low card
a) Maximum of 50 mls per unit b) On a prescription or practitioner's supply order only when on the same form as an injection listed in the Pharmaceutical Schedule requiring a solvent or diluent c) On a bulk supply orderd) When used in the extemporaneous compounding of eye drops
Special Authority for Subsidy - Form SA0108Initial application only from a relevant specialist. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 Hairy cell leukaemia; or 2 Chronic active hepatitis B. Renewal only from a relevant specialist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0110Initial application only from a relevant specialist. Approvals valid for 5 years where biotinidase deficiency. Renewal only from a relevant specialist. Approvals valid for 5 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0115Initial application - (Oesophageal stricture) only from a general practitioner or relevant specialist. Approvals valid for 2 years where patient with oesophageal stricture who is unable to take capsules. Initial application - (Indications other than oesophageal stricture) only from a paediatrician. Approvals valid for 2 years for applications meeting the following criteria: All of the following: 1 infant or child with liver disease or short gut syndrome; and 2 Requires vitamin supplementation; and 3 Unable to swallow capsules. Renewal only from a general practitioner, relevant specialist or paediatrician. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0119Initial application only from a rheumatologist. Approvals valid for 5 years where ankylosing spondylitis. Renewal only from a rheumatologist. Approvals valid for 5 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0121Initial application from any medical practitioner. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 Patient has to use an unpreserved solution due to an allergy to the preservative; or 2 Patient wears soft contact lenses. NoteMinims for a general practice are considered to be "tools of trade" and are not approved as special authority items. Renewal from any medical practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0122Initial application only from a relevant specialist. Approvals valid for 2 years where filamentary keratitis. Renewal only from a relevant specialist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0125Initial application - (Chronic post-thrombotic venous stasis ulcers) from any medical practitioner. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 Chronic post-thrombotic venous stasis ulcers of more than 4 months duration; and 2 Other interventions have failed. Initial application - (Sudden hearing loss) only from an otolaryngologist. Approvals valid for 2 years where sudden hearing loss. Renewal from any medical practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
a) Subsidised only if prescribed for an amputee with an artificial limb, or for a paraplegic patient; andb) On a prescription endorsed accordingly.
a) With other pharmaceutical requirementsb) In extemporaneously compounded preparations.
a) Should be strictly reserved for use as second line therapy in: - patients unable to tolerate the other medications, such as infants, young children and patients with allergies or eczema- cases of scabies which are resistent to gamma benzene hexachlorideb) Verification of drug resistance is dependent on the persistence of the condition after treatment. In order to establish whether there is drug resistance, the following criteria should be fulfilled: - a definite diagnosis of scabies should be made- it should be ascertained that the medication was administered properly- the possibility of reinfestation should have been excluded
Special Authority - Hospital pharmacya) Approvals granted only for children receiving chemotherapyb) Specialist must make application
Special Authority for Subsidy - Form SA0140Initial application only from a relevant specialist. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 Pain management in the terminally ill; and 2 Standard therapy has failed. Renewal only from a relevant specialist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
Only on a WSO. Distributed by the Asthma Foundation. Forward orders to: The Asthma Foundation, PO Box 1459, Wellington. Distributed by the Asthma Foundation. Also available to paediatricians employed by an HHS, on a wholesale supply order signed by the paediatrician. Orders via a hospital pharmacy.
Only when dispensed as an ingredient in a preparation specified in the Pharmaceutical Schedule. Industrial - In combination
Approvals for a CHEM number to waive the premium in the following circumstances: 1. Patients with prosthetic heart valves - as an adjunct to oral anticoagulation for prophylaxis of thromboembolism (2 year approval with renewal, applications only from cardiothoracic surgeons, cardiologists and general physicians). 2. Patients after coronary artery vein bypass graft - as an adjunct to aspirin (1 year approval only, applications only from cardiothoracic surgeons, cardiologists and general physicians). 3. Patients who continue to have transient ischaemic episodes despite aspirin therapy. A course of up to six months in combination with aspirin. Applications only from neurologists, cardiologists, vascular surgeons and general physicians. Six month approval only. Reapplications only if there is demonstrated recurrence of symptoms when dipyridamole therapy is discontinued. Note: these transitional criteria are currently being reviewed.
a) Approvals to fund the manufacturer's surcharge in the following circumstances: - Patients with prosthetic heart valves - as an adjunct to oral anticoagulation for prophylaxis of thromboembolism (2 year approval with renewal, applications only from cardiothoracic surgeons, cardiologists and general physicians). - Patients after coronary artery vein bypass graft - as an adjunct to aspirin or as monotherapy for patients who are aspirin intolerant as defined below (1 year approval only, applications only from cardiothoracic surgeons, cardiologists and general physicians); or- Patients who continue to have transient ischaemic episodes despite aspirin therapy or have transient ischaemic episodes and are aspirin intolerant as defined below (2 year approval with renewal, applications only from neurologists, neurosurgeons, cardiologists, vascular surgeons and general physicians). b) Aspirin intolerant patients are defined as those with aspirin induced asthma, urticaria, or anaphylaxi, or those with significant
Special Authority for Manufacturers Price - Form SA0157Initial application from any medical practitioner. Approvals valid for 5 years for applications meeting the following criteria: Any of the following: 1 Liver disease; or 2 Past history of thromboembolism; or 3 Significant hypertension; or 4 Hypertension associated with oral oestrogen therapy. Renewal from any medical practitioner. Approvals valid for 5 years where the treatment remains appropriate and the patient is benefiting from treatment.
Subsidy is paid on acyclovir tablets for treatment of herpes zoster and genital herpes. Prescriptions with doses: 1. exceeding 1,600 mg per day for a period of more than one week will not be subsidised; and2. up to 4,000 mg per day for a maximum period of one week will be subsidised.
Special Authority for Waiver of Rule - Form SA0175Initial application only from an obstetrician, endocrinologist or gynaecologist. Approvals valid for 2 years where pathological hyperprolactinemia. Renewal only from an obstetrician, endocrinologist or gynaecologist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
Only for treatment of uncomplicated urethritis or cervicitis due to chlamydia trachomatis and these patients' sexual contacts. Prescription must be endorsed "certified condition" (typed or handwriten and initialised in the prescriber's own handwriting)
Special Authority for Manufacturers Price - Form SA0178Initial application from any medical practitioner. Approvals valid for 6 months where control of nausea and vomiting in the treatment of terminal care patients. Renewal from any medical practitioner. Approvals valid for 6 months where the treatment remains appropriate and the patient is benefiting from treatment.
Not if in any proprietary liquid oral form, unless it is separately specified in the Pharmaceutical Schedule
Only in extemporaneously compounded preparations, unles separately specified in the Pharmaceutical Schedule
The new anticonvulsant drugs are restricted to1. neurologists2. paediatric neurologists3. any other prescriber approved in writing by the relevant RHA budget holding manager. The HFA holds a budget for expenditure on the new anticonvulsant drugs. Unless otherwise specified, ultimate authority for approving prescriptions for subsidy lies with the HFA budget holding manager for the new anticonvulsant drugs. The regional divisions of the HFA will be in contact with hospital pharmacists and approved prescribers with more detail of the approval system. GUIDELINES FOR USE OF THE NEW ANTICONVULSANTS ARE AS FOLLOWS: A. Entry criteriaThe following patients are eligible for trial on the new anticonvulsant drugs (NADs)1. Patients who are under the supervision of an approved prescriber, and whose seizures are not adequately controlled with optimal conventional anticonvulsant drug treatment. 2. Patients, who are under the supervision of an approved prescriber, and whose seizures are only controlled adequatel
Subsidised only if prescribed for patients with uncomplicated urethritis or cervicitis proven or presumed to be due to Chlamydia trachomatis and their sexual contacts and prescription is endorsed "certified condition".
Available from hospital pharmacies providing an outpatient dispensing service, and selected retail pharmacies in the Northern, Western Bay of Plenty, Wellington, Christchurch or South Canterbury regions that have an exclusive contract to dispense 'Hospital Pharmacy' [HP1] pharmaceuticals.
Available from hospital pharmacies providing an outpatient dispensing service, and any retail pharmacy in the Northern, Midland, Central (including Nelson and Blenheim) and South Canterbury regions, and selected retail pharmacies in the Christchurch region that have an exclusive contract to dispense 'Hospital Pharmacy' [HP3] pharmaceuticals.
Available from hospital pharmacies and retail pharmacies with a Funder contract to dispense particular medicines.
a) Maximum of 750mg (1 injection) per prescription; orb) Hospital pharmacy [HP3] - specialist - Only if prescribed for a dialysis or cystic fibrosis patient; and- The prescription is endorsed accordingly.
Hospital pharmacy [HP3] - specialist - Only if prescribed for a dialysis or cystic fibrosis patient; and- The prescription is endorsed accordingly.
Special Authority for Subsidy - Form SA0256Initial application only from a cardiologist or general physician. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 Refractory angina; and 2 Patient is already on maximal anti-anginal therapy. Renewal only from a cardiologist or general physician. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0264Initial application only from a paediatrician or respiratory specialist. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 Cystic fibrosis patient; or 2 Both: 2.1 Infant or child with liver disease or short gut syndrome; and 2.2 Requires vitamin supplementation. Renewal only from a paediatrician or respiratory specialist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Manufacturers Price - Form SA0265Initial application from any medical practitioner. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 Social Welfare Benefiary; or 2 Income no greater than a Benefiary. Renewal from any medical practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0266Initial application - (Chronic hepatitis C) only from a relevant specialist. Approvals valid for 6 months where chronic hepatitis C. NoteMaximum reimbursable dosage 15 million iu/weekInitial application - (Indications other than chronic hepatitis C) only from a dermatologist, plastic surgeon or radiation oncologist. Approvals valid for 5 years for applications meeting the following criteria: Any of the following: 1 Chronic myelogenous leukaemia; or 2 Hairycell leukaemia; or 3 Cutaneous T cell lymphoma; or 4 Essential thrombocythaemia; or 5 AIDS related Kaposi's sarcoma; or 6 Multiple myeloma; or 7 Chronic active hepatitis B; or 8 Basal cell carcinoma unable to be treated surgically or by radiotherapy. NoteMaximum reimbursable dosage 15 million iu/weekRenewal - (Chronic hepatitis C) only from a relevant specialist. Approvals valid for 6 months where the treatment remains appropriate and the patient is benefiting from trea
a) - hairy cell leukaemia - Kaposi's sarcoma - chronic active hepatitis B - chronic hepatitis C (6 month approval only) - chronic myelogenous leukaemia - multiple myeloma - basal cell carcinoma 1) Only for basal cell carcinoma unable to be treated surgically or by radiotherapy. 2) Applications only from radiation oncologists, plastic surgeons and dermatologists. Applications from dermatologists will only be accepted with evidence from either a plastic surgeon or oncologist that the patient was unsuitable for surgery. 3) Maximum reimbursable dosage 15 million iu/weekb) Specialist must make applicationc) No further approvals for: Malignant melanoma Note: Patients with existing approvals can continue to have therapy
Special Authority - Retail pharmacy: a) Existing patients only. b) Specialist must make application.
Lansoprazole is subsidised for patients who have one or more of the following conditions: 1. Duodenal ulcer proven by endoscopy or barium meal and after failure of: a)two alternative courses of H. pylori eradication therapy (if H. pylori positive); and b)H2 antagonist therapy for 8 weeks; and where a second endoscopy/barium meal has demonstrated non healing duodenal ulcer. 2. Gastric ulcer proven by endoscopy and after failure of: a)two alternative courses of H. pylori eradication therapy (if H. pylori positive); andb)H2 antagonist therapy for 12 weeks; and where a second endoscopy has demonstrated non healing gastric ulcer and excluded malignancy. 3. Gastro-oesophageal reflux disease (GORD) proven by endoscopy: i) Grade 0 GORD (normal endoscopy) after positive 24 hour pH monitoring test and failure of H2 antagonist therapy for one month with multiple daily dosing; orii) Grades 1 and 2 GORD after failure of H2 antagonist therapy for one month with multiple daily dosing; or
Special Authority for Manufacturers Price - Form SA0271Initial application from any medical practitioner. Approvals valid for 5 years for applications meeting the following criteria: Either: 1 Continuation of treatment commenced prior to 1 October 1995; or 2 Both: 2.1 Either: 2.1.1 Asthma; or 2.1.2 Chronic obstructive airways disease; and 2.2 Patient has tried alternatives and these are unsuitable. Renewal from any medical practitioner. Approvals valid for 5 years where the treatment remains appropriate and the patient is benefiting from treatment.
a) All patients with AIDS meeting the definition developed by the Centres for Disease Control in the USA (see Circular Letter to Medical Practitioners HP2/88)b) Patients with AIDS Related Complex (ARC)c) HIV infected patients with CD4 (T4) counts below 500 regardless of symptomatologyd) Prophylactically for persons following severe parenteral exposure from a known HIV positive sourcee) HIV infected persons with associated thrombocytopenia regardless of CD4 (T4) count f) For the prevention of maternal foetal transmission of HIVg) Applications can only be made by appropriate specialists. Prescriptions for those patients approved to use these medicines can be written either by the specialist or general practitioner with an endorsement of the name of the recommending specialist. h) Prescriptions for these can be written for a period of three months' supply. However, medicine must be dispensed on a monthly basis.
Special Authority for Subsidy - Form SA0274Initial application only from a relevant specialist. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 All of the following: 1.1 Treatment with other lipid modifying medicines has been unsuccessful; and 1.2 6 months of dietary modification has been unsuccessful; and 1.3 Cholesterol level > 7.0 mmol/litre:; and 1.4 Either: 1.4.1 Familial hypercholesterolaemia; or 1.4.2 Manifest coronary heart disease, which has been clinically proven, or previously treated by coronary artery surgery; or 2 Cholesterol level > 9.0 mmol/litre:.NoteFamilial hypercholesterolaemia is defined as being hypercholesterolaemia in the presence of tendon xanthomas or in association with a family history of premature heart disease (before age 55) or consistent with autosomal dominant inheritance. Simvastatin and Pravastatin may be considered for first line therapy in patients with familial hypercholesterolaemia or
Special Authority for Subsidy - Form SA0275Initial application - (Chronic hepatitis C) only from a relevant specialist. Approvals valid for 6 months where chronic hepatitis C. NoteMaximum reimbursable dosage 15 million iu/weekInitial application - (Indications other than chronic hepatitis C) only from a dermatologist, plastic surgeon or radiation oncologist. Approvals valid for 5 years for applications meeting the following criteria: Any of the following: 1 Chronic myelogenous leukaemia; or 2 Hairycell leukaemia; or 3 Cutaneous T cell lymphoma; or 4 Essential thrombocythaemia; or 5 Multiple myeloma; or 6 Chronic active hepatitis B; or 7 Basal cell carcinoma unable to be treated surgically or by radiotherapy. NoteMaximum reimbursable dosage 15 million iu/weekRenewal - (Chronic hepatitis C) only from a relevant specialist. Approvals valid for 6 months where the treatment remains appropriate and the patient is benefiting from treatment. Renewal - (Indications other tha
Special Authority for Subsidy - Form SA0276Initial application - (Chronic hepatitis C) only from a relevant specialist. Approvals valid for 6 months where chronic hepatitis C. NoteMaximum reimbursable dosage 15 million iu/weekInitial application - (Indications other than chronic hepatitis C) only from a dermatologist, plastic surgeon or radiation oncologist. Approvals valid for 5 years for applications meeting the following criteria: Any of the following: 1 Chronic myelogenous leukaemia; or 2 Hairycell leukaemia; or 3 Multiple myeloma; or 4 Chronic active hepatitis B; or 5 Basal cell carcinoma unable to be treated surgically or by radiotherapy. NoteMaximum reimbursable dosage 15 million iu/weekRenewal - (Chronic hepatitis C) only from a relevant specialist. Approvals valid for 6 months where the treatment remains appropriate and the patient is benefiting from treatment. Renewal - (Indications other than chronic hepatitis C) only from a dermatologist, plastic surgeon or radiat
Patients who have been on omeprazole and have not accessed therapy through Special Authority will continue to have subsidy for six months, by which time the necessary investigations should have been carried out to determine if ongoing therapy is warranted. For these patients the following conditions will apply: Omeprazole(a) Retail pharmacy specialist (b) month restriction
Omeprazole is subsidised for patients who have one or more of the conditions numbered 1-4: 1. Duodenal ulcer proven by endoscopy or barium meal and after failure of: a)two alternative courses of H. pylori eradication therapy (if H. pylori positive); and b)H2 antagonist therapy for 8 weeks; and where a second endoscopy/barium meal has demonstrated non healing duodenal ulcer. 2. Gastric ulcer proven by endoscopy and after failure of: a)two alternative courses of H. pylori eradication therapy (if H. pylori positive); andb)H2 antagonist therapy for 12 weeks; and where a second endoscopy has demonstrated non healing gastric ulcer and excluded malignancy. 3. Gastro-oesophageal reflux disease (GORD) proven by endoscopy: i) Grade 0 GORD (normal endoscopy) after positive 24 hour pH monitoring test and failure of H2 antagonist therapy for one month with multiple daily dosing; orii) Grades 1 and 2 GORD after failure of H2 antagonist therapy for one month with multipl
Retail Pharmacy - Specialist prescriptionPaediatricians and paediatric cardiologists may prescribe
Special Authority for Manufacturers Price - Form SA0286Initial application from any medical practitioner. Approvals valid for 5 years where patient is stabilised on aminophylline, theophylline, warfarin, or phenytoin..Renewal from any medical practitioner. Approvals valid for 5 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0290Initial application only from a relevant specialist. Approvals valid for 5 years for applications meeting the following criteria: Any of the following: 1 AIDS meeting the definition developed by the Centers for Disease Control in the USA; or 2 AIDS Related Complex (ARC).; or 3 Both: 3.1 HIV infection regardless of symptomatology; and 3.2 CD4 (T4) counts < 500. NoteSee Circular Letter to Medical Practitioners HP2/88)Renewal only from a relevant specialist. Approvals valid for 5 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Manufacturers Price - Form SA0291Initial application from any medical practitioner. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 Inflammatory arthritis (including osteoarthritis with an inflammatory component); and 2 Stabilised and are well controlled on the particular NSAID medication. Renewal from any medical practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
No compounding fees will be paid when the prescribed strength of methadone is available in a proprietary solution
Extemporaneously compounded methadone will only be reimbursed at the rate of the cheapest form available (methadone powder, not methadone tablets)
Above local anesthetic strengths are: a) For a dialysis patient; orb) A child with rheumatic fever. c) Prescription must be endorsed accordingly.
Special Authority for Subsidy - Form SA0300Initial application - (Breast or prostatic cancer) only from an oncologist, urologist or endocrinologist. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 Breast cancer in pre menopausal women unwilling or unable to undergo surgical or radiation oophorectomy; or 2 Advanced prostatic cancer when orchidectomy is contraindicated. NoteNot in long term combination with an anti-androgenInitial application - (Endometriosis) only from a gynaecologist. Approvals valid for 6 months for applications meeting the following criteria: Both: 1 Endometriosis ; and 2 Either: 2.1 6 months treatment with medroxyprogesterone acetate, danazol or dimetriose has proven ineffective; or 2.2 The patient has failed to tolerate the treatment with medroxyprogesterone acetate, danazol or dimetriose for 6 months. NoteThe maximum treatment period for a GnRH analogue is: 3 months to assess whether surgery is appropriate3 m
Special Authority for Subsidy - Form SA0301Initial application only from a relevant specialist. Approvals valid for 2 years where type III dyslipidaemias. Renewal only from a relevant specialist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Waiver of Rule - Form SA0303Initial application only from a paediatric surgeon or paediatrician. Approvals valid for 1 year where children post liver transplant. Renewal only from a paediatric surgeon or paediatrician. Approvals valid for 1 year where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0309Initial application only from a neurologist or physician for the elderly (FRACP). Approvals valid for 2 years for applications meeting the following criteria: All of the following: 1 Idiopathic Parkinson's disease; and 2 The patient does not have dementia and/or neuropsychiatric disorders; and 3 Has responded to L-dopa; and 4 Any of the following: 4.1 Has resistance to conventional treatment of severe motor fluctuations; or 4.2 Has severe "off" period disability; or 4.3 Has severe "off" period dystonic cramps. Renewal only from a neurologist or physician for the elderly (FRACP). Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0311Initial application - (Breast or prostatic cancer) only from an oncologist, urologist or endocrinologist. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 Breast cancer in pre menopausal women unwilling or unable to undergo surgical or radiation oophorectomy; or 2 Advanced prostatic cancer when orchidectomy is contraindicated or where the patient srongly opposes orchidectomy. NoteNot to be prescribed with an anti-androgen except for a period of three weeks, if necessary, when GnRH analogue therapy is intiatedInitial application - (Endometriosis) only from a gynaecologist. Approvals valid for 6 months for applications meeting the following criteria: Both: 1 Endometriosis; and 2 Either: 2.1 6 months treatment with medroxyprogesterone acetate, danazol or dimetriose has proven ineffective; or 2.2 The patient has failed to tolerate the treatment with medroxyprogesterone acetate, danazol or dimetrio
Special Authority for Alternate Subsidy - Form SA0312Initial application only from an obstetrician, gynaecologist, general practitioner or general physician. Approvals valid for 5 years for applications meeting the following criteria: Any of the following: 1 acute or significant liver disease - a declaration must be provided from a gastroenterologist or general physician stating that oral oestrogens are contraindicated due to liver disease (Details to be attached to application); or 2 oestrogen induced hypertension requiring antihypertensive therapy - documented evidence must be provided that raised blood pressure levels or inability to control blood pressure adequately occurred post oral oestrogens (Details to be attached to application); or 3 hypertriglyceridaemia - documented evidence must be provided that triglyceride levels increased to at least 2 x normal triglyceride levels post oral oestrogens (Details to be attached to application). NotePrescriptions with a valid Special Authority (
Special Authority for Manufacturers Price - Form SA0313Initial application from any medical practitioner. Approvals valid for 5 years where the patient is likely to benefit from treatment. Renewal from any medical practitioner. Approvals valid for 5 years where the treatment remains appropriate and the patient is benefiting from treatment.
Additional subsidy by Special Authority available to fully fund to the level of the lowest priced TDDS brand within the medium dose oestrogens.
Additional Subsidy by Special Authority available to fully fund to the level of the lowest priced TDDS brand within the high dose oestrogens.
Special Authority for Subsidy - Form SA0317Initial application only from a renal physician. Approvals valid for 2 years for applications meeting the following criteria: All of the following: General Criteria: 1 Anaemia of end-stage renal failure (other treatable causes of anaemia being excluded); and 2 Been on haemodialysis or continuous ambulatory peritoneal dialysis (CAPD) for at least three months; and 3 Not under evaluation for, or awaiting, a live donor kidney transplant; and 4 Any of the following: Specific Criteria: 4.1 Anephric; or 4.2 Dependent on regular blood transfusion (1 unit each 4-8 weeks) to maintain haemoglobin > 60g/L; or 4.3 Cannot be transfused because of severe transfusion reactions; or 4.4 Transfusion induced haemosiderosis (clinical manifestations, serum ferritin >1500 ug/L); or 4.5 Haemoglobin < 70 g/L (mean of at least 4 haemoglobin concentrations over 4 months); or 4.6 Both: 4.6.1 Haemoglobin < 90 g/L; and 4.6.2 Either:
a) All nucleosides will be subsidised for patients meeting any of the following criteria: - All patients with AIDS meeting the definition developed by the Centers for Disease Control in the USA (see Circular Letter to Medical Practitioners HP2/88); or- Patients with AIDS Related Complex (ARC); or- HIV infected patients with CD4 (T4) counts below 500 regardless of symptomatology. b) Zidovudine will also be subsidised for patients meeting any of the following criteria: - Prophylactically for persons following severe parenteral exposure from a known HIV positive source; or- HIV infected persons with associated thrombocytopenia regardless of CD4 (T4) count; or- For the prevention of maternal foetal transmission of HIV. c) Applications can only be made by appropriate specialists. d) Prescriptions for those patients approved to use these medications can be written by either the specialist or general practitioner with an endorsement of the name of the recommending specialist.
Special Authority for Subsidy - Form SA0323Initial application only from a relevant specialist. Approvals valid for 2 years where children receiving frequent parenteral injections (i.e. intradermal, subcutaneous, intravenous or intramuscular) requiring a 21 gauge or larger bore needle. Renewal only from a relevant specialist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
All oral Beta Adrenoceptor Blockers are exempted from monthly dispensing for patients with angina or arrhythmia.
Special Authority for Subsidy - Form SA0325Initial application from any medical practitioner. Approvals valid for 5 years where applicatons will be considered and approved subject to funding availability. NoteApplications to be made on the approved forms which are available from the co-ordinator for the Cystic Fibrosis DN'ase Advisory Panel: The Co-ordinatorCystic Fibrosis DN'ase Advisory PanelC/- Room 4-28, Building 13 Greenlane HospitalPrivate Bag, AUCKLANDPhone: 09 630 9871Facsimile: 09 631 0753
Special Authority for Subsidy - Form SA0328Initial application only from a general physician. Approvals valid for 2 years for applications meeting the following criteria: Any of the following: 1 Both: 1.1 CD4 count < 500 cells/mm3; and 1.2 Viral load > 50,000> copies per ml (or equivalent value on the Chiron test); or 2 All of the following: 2.1 CD4 count < 500 cells/mm3; and 2.2 Viral load > 50,000> copies per ml (or equivalent value on the Chiron test); and 2.3 At least 6 weeks of dual therapy with nucleoside agents; or 3 Both: 3.1 CD4 count < 500 cells/mm3; and 3.2 CD4 counts are declining rapidly (>120 cells over 12 months or >60 - 80 cells over six months). Renewal only from a general physician. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
Guidelines for use of cyclosporin A in rheumatoid arthritisMonitoring: All patients require frequent monitoring for creatinine levels and blood pressure:- fortnightly, in the first three months of therapy and then monthly, if results are stable; - if dose is increased or there is a rise in serum creatinine or blood pressure, then more frequent monitoring is required. Contraindications: Cyclosporin A is contraindicated in patients with the following conditions: - current or past malignancy; - uncontrolled hypertension; - renal dysfunction (abnormal serum creatinine for age and sex); - immunodeficiency and neutropenia; - abnormally low white blood cell count or platelet count; or- liver function tests more than twice the upper limit of normal. Caution in use: - age above 65 years; - controlled hypertension; - use of ant-epileptic medications; - use of NSAIDs; - use of ketoconazole, fluconazole, trimethoprim, erythromycin, verapamil, and diltiazem; - concurrent or previous use of al
Special Authority - Retail pharmacy (Salmeterol, eformoterol fumarate):a) Approvals are interchangeable between all presenations of salmeterol and eformoterol fumarate agents. b) Diagnosis of asthma confirmed. c) Inhaler/device technique checked. d) At least three months of >= 1500 ug daily of beclomethasone inhaled steroid (or equivalent) for adult, or >= 800 ug daily for child. e) Patient monitors PEFR regularly during exacerbations where appropriate. f) Evidence of poor control (at least one of the following): - short acting beta agonist used > 3-4 time daily - nocturnal awakenings >= 2 times per week. g) The first applicaton may be for six months and subsequent applications for two yars. The criteria for reapplication are: - compliant with medication - improved asthma symptom control. h) Appication for Special Authority to be made by general practitioners or appropriate specialist.
a) Should be strictly reserved for use as second line therapy in: - patients unable to tolerate the other medications, such as infants, young children and patients with allergies or eczema; - cases of scabies which are resistent to gamma benzene hexachloride and resistant to malathion. b) Verification of drug resistance is dependent on the persistence of the condition after treatment. In order to establish whether there is drug resistance, the following criteria should be fulfilled: - a definite diagnosis of scabies should be made; - it should be ascertained that the medication was administered properly; - the possibility of reinfestation should have been excluded.
a) Approvals will be granted for treating the following conditions: - avium intracellular atypical mycobacterial infections; and- multiple drug resistant tuberculosis; and- atypical and drug-resistant mycobacterial infections in patients with AIDS. b) Specialist must make application - respiratory physician/ infectious disease specialist. c) Approvals will be valid for two years.
Special Authority for Manufacturers Price - Form SA0349Initial application only from a respiratory specialist or infectious disease specialist. Approvals valid for 2 years for applications meeting the following criteria: Any of the following: 1 Avium intracellular atypical mycobacterial infections; or 2 Multiple drug resistant tuberculosis; or 3 Atypical and drug-resistant mycobacterial infections in patients with AIDS. Renewal only from a respiratory specialist or infectious disease specialist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
Omeprazole and pantoprazole is subsidised for patients who have one or more of the conditions a-d: a) Duodenal ulcer proven by endoscopy or barium meal and after failure of: - two alternative courses of H. pylori eradication therapy (if H. pylori positive); and - H2 antagonist therapy for 8 weeks; and where a second endoscopy/barium meal has demonstrated non healing duodenal ulcer. b) Gastric ulcer proven by endoscopy and after failure of: - two alternative courses of H. pylori eradication therapy (if H. pylori positive); and - H2 antagonist therapy for 12 weeks; and where a second endoscopy has demonstrated non healing gastric ulcer and excluded malignancy. c) Gastro-oesophageal reflux disease (GORD) proven by endoscopy: - Grade 0 GORD (normal endoscopy) after positive 24 hour pH monitoring test and failure of H2 antagonist therapy for four weeks with multiple daily dosing; or - Grades 1 and 2 GORD after failure of H2 antagonist therapy for
a) Not to exceed 3 capsules per prescriptionb) No more than one prescription per month.
a) Not to exceed 6 tablets per prescription; andb) No more than one prescription per month.
Subsidy is available for disposable diabetic syringes and needles: 1) When the prescription is written on the same prescription form as the one used for the supply of insulin vials; or2) When "insulin patient" has been written on the prescription by either the doctor or the contractor; and3) For no more than 50 plastic syringes with attached needles as a single supply in the case of a prescription for three months supply of insulin vials; or4) For no more than 4 plastic syringes with attached needles as a single supply for each week's supply in the case of a prescription for less than three months supply of insulin vials.
Subsidy is available for insulin pen needles: 1) When the prescription is written on the same prescription form as the one used for the supply of insulin cartridges; or2) When "insulin patient" has been written on the prescription by either the doctor or the contractor; and3) For no more than 30 insulin pen needles as a single supply in the case of a prescription for three months supply of insulin cartridges; or4) For no more than 2 insulin pen needles as a single supply for each week's supply in the case of a prescription for less than three months supply of insulin cartridges.
Special Authority for Subsidy - Form SA0361Initial application only from a geriatrician, neurologist or general physician. Approvals valid for 2 years for applications meeting the following criteria: All of the following: 1 Disabling orthostatic hypotension not due to drugs; and 2 Patient has tried fludrocortisone (unless contra-indicated) with unsatisfactory results; and 3 Patient has tried non pharmacological treatments such as support hose, increased salt intake, exercise, and elevation of head and trunk at night. NoteTreatment should be started with small doses and titrated upwards as necessary. Hypertesion should be avoided, and the usual target is a standing systolic blood pressure of 90 mm Hg. Renewal only from a geriatrician, neurologist or general physician. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0366Initial application - (North Island patients) from any medical practitioner. Approvals valid for 5 years where the patient is likely to benefit from treatment. NoteFor details of the patient criteria, prescriber criteria, application and reporting forms contact the appointed clinician: Dr Richard FisherFertility Associates131 Remuera RoadAUCKLANDFax: 09 520 0499Appointed clinicians will distribute these agents to prescribers whose applications are approvedInitial application - (South Island patients) from any medical practitioner. Approvals valid for 5 years where the patient is likely to benefit from treatment. NoteFor details of the patient criteria, prescriber criteria, application and reporting forms contact the appointed clinician: Dr Peter BennyChristchurch Women's HospitalPrivate Bag 4711CHRISTCHURCHFax: 03 364 4634Appointed clinicians will distribute these agents to prescribers whose applications are approved
Child resistant closure (NZS 5825:1991) required and reimbursed when used to create an extemporaneously prepared oral solution.
Subsidy is available for disposable and non-disposable insulin syringes, needles, and pen needles if prescribed on the same form as the one used for the supply of insulin or when prescribed for an insulin patient and the prescription is endorsed accordingly.
Up to 50 plastic syringes with attached needles may be dispensed in the case of a prescription for three months supply of insulin vials; orUp to four plastic syringes with attached needles may be dispensed for each week's supply in the case of a prescription for less than three months supply of insulin vials.
Up to 30 pen needles may be dispensed in the case of a prescription for three months supply of insulin cartridges; orUp to two pen needles may be dispensed for each week's supply in the case of a prescription for less than three months supply of insulin cartridges.
Special Authority for Subsidy - Form SA0382Initial application only from a gastroenterologist, general surgeon or general physician. Approvals valid for 3 years for applications meeting the following criteria: Any of the following: 1 All of the following: 1.1 Duodenal ulcer proven by endoscopy or barium meal; and 1.2 Failure of two alternative courses of H. pylori eradication therapy (if H. pylori positive); and 1.3 Non healing duodenal ulcer proven by second barium meal; and 1.4 H2 antagonist therapy for 8 weeks; or 2 All of the following: 2.1 Gastric ulcer proven by endoscopy; and 2.2 Two alternative courses of H. pylori eradication therapy (if H. pylori positive); and 2.3 Non healing gastric ulcer and excluded malignancy demonstrated by a second endoscopy; and 2.4 H2 antagonist therapy for 12 weeks; or 3 All of the following: 3.1 Grade 0 GORD (normal endoscopy); and 3.2 Positive 24 hour pH monitoring test; and 3.3 Failure of H2 antagonist t
n) Further approvals to fund the manufacturer's surcharge on either pravastatin or simvastatin (if applicable) may be granted to patients who are unable to continue treatment with fluvastatin due to adverse effects. Either general practitioners or specialist may make the application. To obtain a new Special Authority number, the application must include the following information: - the amount of time the patient has been treated with fluvastatin; and- the adverse effects experienced by the patient. o) Further approvals to fund the manufacturer's surcharge on simvastatin may be granted to patients with familial hypercholesterolaemia (FH) or familial combined hypercholesterolaemia (FCH) if a specialist considers that the patient is not achieving sufficient benefit from the fully funded statin(s). Only specialists may make application. To obtain a new Special Authority number, the application must include the following information: - the cholesterol level before and after treatment with the fully funded sta
Special Authority for Subsidy - Form SA0387Initial application - (Breast or prostatic cancer) only from an oncologist, urologist or endocrinologist. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 Breast cancer in pre menopausal women unwilling or unable to undergo surgical or radiation oophorectomy; or 2 Advanced prostatic cancer when orchidectomy is contraindicated or where the patient srongly opposes orchidectomy. NoteNot to be prescribed with an anti-androgen except for a period of three weeks, if necessary, when GnRH analogue therapy is intiatedInitial application - (Endometriosis) only from a gynaecologist. Approvals valid for 6 months for applications meeting the following criteria: Both: 1 Endometriosis; and 2 Either: 2.1 6 months treatment with medroxyprogesterone acetate, danazol or dimetriose has proven ineffective; or 2.2 The patient has failed to tolerate the treatment with medroxyprogesterone acetate, danazol or dimetrio
Special Authority for Subsidy - Form SA0391Initial application only from a relevant specialist. Approvals valid for 5 years for applications meeting the following criteria: Either: 1 Liver transplant recipients; or 2 Renal transplant recipients - as rescue therapy only. Renewal only from a relevant specialist. Approvals valid for 5 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Manufacturers Price - Form SA0394Initial application - (Helicobacter pylori infections) only from a general practitioner or relevant specialist. Approvals valid for 6 months for applications meeting the following criteria: Both: 1 Eradication of Helicobacter pylori in patient with proven infection; and 2 Peptic ulcer disease proven by endoscopy. NoteMaximum of two prescriptions (two courses) per patient. Initial application - (Mycobacterial infections) only from a respiratory specialist or infectious disease specialist. Approvals valid for 2 years for applications meeting the following criteria: Any of the following: 1 Mycobacterium Avium Intracellulare Complex infections in patient with AIDS; or 2 Atypical and drug-resistant mycobacterial infection; or 3 All of the following: 3.1 Prophylaxis against disseminated Mycobacterium Avium Intracellulare Complex infection; and 3.2 HIV infection; and 3.3 CD4 count <= 50 cells/mm3. Renewal - (Mycobacteri
a) Cyproterone acetate with ethinyloestradiol is available from retail pharmacy to patients as indicated. b) Prescribers may code prescriptions "contraceptive" (code "O") when used as indicated for contraception. The period of supply and prescription charge will be as per other contraceptives, as follows: - $3.00 prescription charge (patient co-payment) will apply; - Prescription may be written for up to 6 months supply; and- Pharmacists may dispense up to 3 month supply. c) Prescriptions coded in any other way are subject to the non-contraceptive prescription charges, and the non-contraceptive period of supply. Eg. Prescriptons may be written for up to 3 months supply, and dispensed monthly. d) The Special Authority number for hormonal contraceptive agents (combined and progesterone-only) does not apply, and is not interchangeable. e) Health Benefits Limited will return any claims unpaid as follows: - any uncoded prescription; - any prescription that does not have a period of supply or the quantity
Special Authority for Subsidy - Form SA0401Initial application - (Basal cell carcinoma) only from a dermatologist, plastic surgeon or radiation oncologist. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 Basal cell carcinoma unable to be treated surgically or by radiotherapy; and 2 Unsuitability for surgery confirmed by a Plastic Surgeon or Oncologist. NoteMaximum reimbursable dosage 15 million iu/weekInitial application - (Chronic hepatitis C) only from a relevant specialist. Approvals valid for 12 months where chronic hepatitis C. Initial application - (Indications other than Basal cell carcinoma and Chronic hepatitis C) only from a relevant specialist, plastic surgeon or radiation oncologist. Approvals valid for 2 years for applications meeting the following criteria: Any of the following: 1 Chronic myelogenous leukaemia; or 2 Hairy cell leukaemia; or 3 Cutaneous T cell lymphoma; or 4 Essential thrombocythaemia; or 5 Multiple myelo
Special Authority for Subsidy - Form SA0402Initial application - (Patients aged 74 and under) only from a general practitioner. Approvals valid for 2 years for applications meeting the following criteria: All of the following: 1 Patients aged 74 and under; and 2 The patient has been offered 3-6 months of counselling and an opportunity to modify lifestyle; and 3 Any of the following: 3.1 Both: 3.1.1 NHF A1:1 - Clinically proven ischaemic heart disease; and 3.1.2 total cholesterol > 6.0; or 3.2 Both: 3.2.1 NHF A1:2 - Post coronary artery bypass graft (CABG); and 3.2.2 total cholesterol > 5.5; or 3.3 Both: 3.3.1 NHF B:Patients with > 20% 5-year cardiovascular disease risk; and 3.3.2 total cholesterol > 9.0; or 3.4 Both: 3.4.1 NHF C:15-20% 5-year cardiovascular disease risk; and 3.4.2 total cholesterol > 9.0; or 3.5 Both: 3.5.1 NHF D:10-15% 5-year cardiovascular disease risk; and 3.5.2 total cholesterol > 9.0; or 3.6
Special Authority for Subsidy - Form SA0403Initial application only from a nephrologist or transplant surgeon. Approvals valid for 12 months where renal transplant recipient. Renewal only from a nephrologist or transplant surgeon. Approvals valid for 12 months where re-graft patient.
Special Authority for Subsidy - Form SA0404Initial application only from an ophthalmologist. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 Primary open-angle glaucoma; and 2 Either: 2.1 Other subsidised glaucoma medical therapy is contraindicated; or 2.2 Both: 2.2.1 intra-ocular pressure > 26 mmHg (average from consecutive measurements); and 2.2.2 Unable to be controlled using other subsidised medical therapy. Renewal only from an ophthalmologist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Manufacturers Price - Form SA0410Initial application from any medical practitioner. Approvals valid for 2 years for applications meeting the following criteria: Any of the following: 1 Polycystic ovarian syndrome; or 2 Hirsutism; or 3 Androngenic alopecia. Renewal from any medical practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Manufacturers Price - Form SA0411Renewal from any medical practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
Funding of manufacturers surcharge for existing patients taking ACE inhibitors for Congestive Heart Failure.a) Patients taking any ACE inhibitor for the treatment of congestive heart failure prior to 1 June 1998 can continue to have their ACE inhibitor treatment fully subsidised; b) Prescribers must endorse the prescription 'Congestive Heart Failure'. The endorsement can be typed (this includes computer generated prescriptions) or handwritten; c) The endorsement must be initialled in the prescriber's own handwriting. Definition of Congestive Heart FailureAt the request of some prescribers the PTAC Cardiovascular subcommittee has provided a definition of congestive heart failure for the purposes of the funding of the manufacturer's surcharge: "Clinicians should use their clinical judgement. Existing patients would be eligible for the funding of the surcharge if the patient shows signs and symptoms of congestive heart failure, and requires or has in the past required concomitant treatment with a
Special Authority for Subsidy - Form SA0423Initial application only from a gastroenterologist, general surgeon or general physician. Approvals valid for 3 years for applications meeting the following criteria: Any of the following: 1 All of the following: Duodenal Ulcer: 1.1 Duodenal ulcer proven by endoscopy or barium meal; and 1.2 Non healing duodenal ulcer proven by second barium meal; and 1.3 After failure of two alternative courses of H. pylori eradication therapy (if H. pylori positive); and 1.4 After H2 antagonist therapy for 8 weeks; or 2 All of the following: Gastric Ulcer: 2.1 Gastric ulcer proven by endoscopy; and 2.2 Non healing gastric ulcer and excluded malignancy demonstrated by a second endoscopy; and 2.3 After two alternative courses of H. pylori eradication therapy (if H. pylori positive); and 2.4 After H2 antagonist therapy for 12 weeks; or 3 All of the following: GORD: 3.1 Grade 0 GORD (normal endoscopy); and 3.2 Positive 24
Special Authority for Subsidy - Form SA0424Initial application - (Confirmed HIV/AIDS) only from a general physician. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 Confirmed HIV/AIDS; and 2 Any of the following: 2.1 Symptomatic patients aged 6 years and over with HIV/AIDS; or 2.2 Both: 2.2.1 Asymptomatic patients aged 6 years and over; and 2.2.2 CD4 counts < 500 cells/mm3; or 2.3 Both: 2.3.1 Asymptomatic patients aged 6 years and over; and 2.3.2 Viral load counts > 10,000 copies per ml; or 2.4 Symptomatic patients aged under 6 with HIV/AIDS ; or 2.5 Asymptomatic patients aged 12 months and under; or 2.6 Both: 2.6.1 Asymptomatic patients aged 1 to 5 years; and 2.6.2 CD4 counts < 1,000 cells/mm3; or 2.7 Both: 2.7.1 Asymptomatic patients aged 1 to 5 years; and 2.7.2 CD4 counts < 0.25 x total white cell count; or 2.8 Both: 2.8.1 Asymptomatic patients aged under 6 years; and
If a Community Pharmaceutical is the liquid oral form of an antibiotic to which a diluent must be added by the Contractor at the time of dispensing and it is prescribed or ordered by a Practittioner in an amount that does not coincide with the amount contained in one or more standard packs of that Community Pharmaceutical, Subsidy will only be made for the amount prescribed or ordered by the Practitioner in accordance with either Clause 3.1 or Clause 3.3 of the Schedule, unless the Contractor satisfies the Funder that he or she has not been able to dispense the balance of the pack or packs from which the Community Pharmaceutical has been dispensed. In such cases all of that pack or those packs is eligible for Subsidy.
Special Authority for Subsidy - Form SA0430Initial application - (National Heart Foundation risk groups A1:1, A1:2, B, C, D or E) only from a relevant specialist or general practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria: Both: 1 The patient has been offered 3-6 months of counselling and an opportunity to modify lifestyle; and 2 Any of the following: 2.1 Both: 2.1.1 NHF A1:1 - Clinically proven ischaemic heart disease; and 2.1.2 total cholesterol * > 5.5; or 2.2 Both: 2.2.1 NHF A1:2 - Post coronary artery bypass graft (CABG) or angioplasty; and 2.2.2 total cholesterol * > 4.5; or 2.3 Post heart transplant (regardless of cholesterol level); or 2.4 Both: 2.4.1 NHF B:Patients with > 20% 5-year cardiovascular disease risk; and 2.4.2 total cholesterol * > 9.0; or 2.5 Both: 2.5.1 NHF C:15-20% 5-year cardiovascular disease risk; and 2.5.2 total cholesterol * > 9
Special Authority for Manufacturers Price - Form SA0434Initial application only from a general practitioner, general physician, geriatrician or neurologist. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 Patients with swallowing difficulties; and 2 Applicant is a specialist or specialist has authorised treatment. Renewal only from a general practitioner, general physician, geriatrician or neurologist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Manufacturers Price - Form SA0435Initial application from any medical practitioner. Approvals valid for 6 months where control of nausea and vomiting in the treatment of terminal care patients. Renewal from any medical practitioner. Approvals valid for 6 months where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Manufacturers Price - Form SA0436Initial application - (Patient with prosthetic heart valves) only from a cardiothoracic surgeon, cardiologist or general physician. Approvals valid for 2 years where patient with prosthetic heart valves - as an adjunct to oral anticoagulation for prophylaxis of thromboembolism. Initial application - (Following coronary artery vein bypass graft) only from a cardiothoracic surgeon, cardiologist or general physician. Approvals valid for 1 year where patients after coronary artery vein bypass graft - as an adjunct to aspirin or as monotherapy for patients who are aspirin intolerant as defined below. Initial application - (Transient ischaemic episodes) only from a neurologist, neuro surgeon, cardiologist, vascular surgeon or general physician. Approvals valid for 2 years where patients who continue to have transient ischaemic episodes despite aspirin therapy or have transient ischaemic episodes and are aspirin intolerant as defined below. Renewal - (Fo
Special Authority for Subsidy - Form SA0443Initial application - (Helicobacter pylori infections) only from a general practitioner or relevant specialist. Approvals valid for 6 months for applications meeting the following criteria: Both: 1 Eradication of Helicobacter pylori in patient with proven infection; and 2 Peptic ulcer disease proven by endoscopy. NoteMaximum of two prescriptions (two courses) per patient. Initial application - (Mycobacterial infections) only from a respiratory specialist or infectious disease specialist. Approvals valid for 2 years for applications meeting the following criteria: Any of the following: 1 Mycobacterium Avium Intracellulare Complex infections in patient with AIDS; or 2 Atypical and drug-resistant mycobacterial infection; or 3 All of the following: 3.1 Prophylaxis against disseminated Mycobacterium Avium Intracellulare Complex infection; and 3.2 HIV infection; and 3.3 CD4 count <= 50 cells/mm3. Renewal - (Mycobacterial infection
Special Authority for Subsidy - Form SA0445Initial application only from a relevant specialist. Approvals valid for 5 years for applications meeting the following criteria: Any of the following: 1 Both: 1.1 Acromegaly; and 1.2 Patient has failed surgery, radiotherapy, bromocriptine or other oral therapies; or 2 VIPomas and Glucagonomas - for patients who are seriously ill in order to improve their clinical state prior to definitive surgery.; or 3 Both: 3.1 Gastrinoma; and 3.2 Patient has failed surgery, or metastatic disease after H2 antagoists (or proton pump inhibitors) have failed; or 4 Both: 4.1 Insulinomas; and 4.2 Surgery is contraindicated or has failed; or 5 For pre-operative control of hypoglycaemia and for maintenance therapy; or 6 Both: 6.1 Carcinoidsyndrome (diagnosed by tissue pathology and/or urinary 5HIAA analysis); and 6.2 Disabling symptoms not controlled by maximal medical therapy. NoteThe use of octretide in patients with fis
Retail Pharmacy - Specialist prescriptionSpecialist must be either a neurologist, geriatrician or general physician
Special Authority for Subsidy - Form SA0450Initial application only from a psychiatrist. Approvals valid for 12 months for applications meeting the following criteria: Both: 1 Patients suffering from schizophrenia and related psychoses; and 2 Either: 2.1 Failed to respond to full trials (duration of at least 6 weeks each) of effective doses of at least two classes of anti-psychotic agents (refer to guidelines below); or 2.2 Demonstrated intolerance to other neuroleptic agents. NoteClinicians must confirm that informed consent and a satisfactory White Bloodcell Count (WBC) result has been obtained. Diagnosis: Treatment resistant schizophrenia and related psychoses when positive symptoms (delusions, hallucinations and thought disorder) are prominent and/or disabling or when both positive symptoms and negative symptoms (flattened affect, emotional and social withdrawal and poverty of speech) are present. Treatment: Trial therapy undertaken before initiating treatment with clozapine could
Special Authority for Manufacturers Price - Form SA0451Initial application only from a relevant specialist. Approvals valid for 3 years for applications meeting the following criteria: Both: 1 Patients being treated for advanced breast cancer who are refractory to tamoxifen; and 2 Any of the following: 2.1 Unable to tolerate aminoglutethimide; or 2.2 Unable to tolerate megestrol acetate; or 2.3 Unable to tolerate medroxyprogesterone acetate.Renewal only from a relevant specialist. Approvals valid for 3 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Manufacturers Price - Form SA0452Initial application only from a relevant specialist. Approvals valid for 3 years for applications meeting the following criteria: Both: 1 Patients being treated for advanced breast cancer who are refractory to tamoxifen; and 2 Any of the following: 2.1 Unable to tolerate aminoglutethimide; or 2.2 Unable to tolerate megestrol acetate; or 2.3 Unable to tolerate medroxyprogesterone acetate.Renewal only from a relevant specialist. Approvals valid for 3 years where the treatment remains appropriate and the patient is benefiting from treatment.
Guidelines for the use of atypical anti-psychotic agents Diagnosis: Schizophrenia and related psychoses when positive symptoms (delusions, hallucinations and thought disorder) are prominent and/or disabling or when both positive symptoms and negative symptoms (flattened affect, emotional and social withdrawal and poverty of speech) are present. Treatment: Before initiating atypical anti-psychotic therapy, physicians should consider whether the patient is likely to respond to and/or tolerate conventional anti-psychotic therapy and, where appropriate, trial one or more conventional agent prior to use of an atypical agent.
Special Authority for Subsidy - Form SA0456Initial application only from a psychiatrist. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 Patients suffering from schizophrenia and related psychoses who are likely to benefit from anti-psychotic treatment; and 2 Any of the following: 2.1 Effective dose of risperidone has been discontinued because of recurrent acute dystonias; or 2.2 Effective dose of risperidone has been discontinued because of excessive Parkinson-like symptoms; or 2.3 Effective dose of risperidone has been discontinued after 6 weeks because of inadequate clinical response. Renewal only from a psychiatrist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0458Initial application only from a gastroenterologist. Approvals valid for 6 months for applications meeting the following criteria: Both: 1 Primary biliary cirrhosis confirmed by antimitochondrial antibody titre (AMA) > 1:80, and raised cholestatic liver enzymes with or without raised serum IgM or, if AMA is negative, by liver biopsy; and 2 Patient not requiring a liver transplant (bilirubin > 170umol/l; decompensated cirrhosis). NoteLiver biopsy is not usually required for diagnosis but is helpful to stage the diseaseRenewal only from a gastroenterologist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment. NoteActigall is not an appropriate therapy for patients requiring a liver transplant (bilirubin > 170 micromol/l; decompensated cirrhosis). These patients should be referred to an appropriate transplant centreTreatment failure - doubling of serum bilirubin levels, absence of a signi
Special Authority for Subsidy - Form SA0459Initial application only from a gastroenterologist or general physician. Approvals valid for 3 months for applications meeting the following criteria: Both: 1 Mild to moderate ileal, ileocaecal or proximal Crohn's disease; and 2 Any of the following: 2.1 Diabetes; or 2.2 Cushingoid habitus; or 2.3 Osteoporosis where there is significant risk of fracture; or 2.4 Both: 2.4.1 Severe acne; and 2.4.2 Treatment with conventional corticosteroid therapy. Renewal only from a gastroenterologist or general physician. Approvals valid for 3 months where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Manufacturers Price - Form SA0460Initial application - (Patient with prosthetic heart valves) only from a cardiothoracic surgeon, cardiologist or general physician. Approvals valid for 2 years where patient with prosthetic heart valves - as an adjunct to oral anticoagulation for prophylaxis of thromboembolism. Initial application - (Following coronary artery vein bypass graft) only from a cardiothoracic surgeon, cardiologist or general physician. Approvals valid for 1 year where patients after coronary artery vein bypass graft - as an adjunct to aspirin or as monotherapy for patients who are aspirin intolerant as defined below. Initial application - (Transient ischaemic episodes) only from a neurologist, neuro surgeon, cardiologist, vascular surgeon or general physician. Approvals valid for 2 years where patients who continue to have transient ischaemic episodes despite aspirin therapy or have transient ischaemic episodes and are aspirin intolerant as defined below. Renewal - (Fo
Special Authority for Subsidy - Form SA0461Initial application - (Basal cell carcinoma) only from a dermatologist, plastic surgeon or radiation oncologist. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 Basal cell carcinoma unable to be treated surgically or by radiotherapy; and 2 Unsuitablity for surgery confirmed by a Plastic Surgeon or Radiation Oncologist. NoteThe maximum reimbursable dosage is 15 million iu per weekInitial application - (Chronic hepatitis C) only from a relevant specialist. Approvals valid for 12 months where chronic hepatitis C. Initial application - (Indications other than Basal cell carcinoma and Chronic hepatitis C) only from a relevant specialist. Approvals valid for 2 years for applications meeting the following criteria: Any of the following: 1 Chronic myelogenous leukaemia; or 2 Hairy cell leukaemia; or 3 Multiple myeloma; or 4 Chronic active hepatitis B. Renewal - (Basal cell carcinoma) only from a dermato
Hospital pharmacy - Specialist prescription. Note: Prescribing and dispensing of clozapine is subject to Ministry of Health restrictions including the requirement for blood monitoring.
Special Authority for Subsidy - Form SA0464Initial application only from a diabetologist, general physician or paediatrician. Approvals valid without further renewal unless notified for applications meeting the following criteria: Any of the following: 1 Both: 1.1 Use alone (monotherapy); and 1.2 The patient is unable to use any other insulins including those on insulin pump treatment; or 2 Both: 2.1 Use with Humulin 70/30 or Humulin 80/20; and 2.2 A reasonable trial of Humulin N has been undertaken and it is not effective or not well tolerated; or 3 Both: 3.1 Use with insulins (aside from insulin zinc suspension) other than Humulin 70/30, Humulin 80/20, or Humulin N; and 3.2 A reasonable trial of one or more of these Humulin insulins has been undertaken and it is/are ineffective or not well tolerated; or 4 Both: 4.1 Use with Humulin L or Humulin U; and 4.2 Use with Humulin N is not appropriate; or 5 Both: 5.1 Use with other insulin zinc suspensio
Special Authority for Alternate Subsidy - Form SA0466Initial application only from a relevant specialist or general practitioner. Approvals valid for 5 years for applications meeting the following criteria: Any of the following: 1 Angina that is not controlled by other anginal medications; or 2 Continuation of treatment commenced prior to 1 June 1999; or 3 Receiving maximal antihypertensive therapy, requires a DHP CCB, and cannot tolerate felodipine. Renewal only from a relevant specialist or general practitioner. Approvals valid for 5 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0467Initial application only from a relevant specialist. Approvals valid for 6 months for applications meeting the following criteria: Both: 1 Paget's disease; and 2 Any of the following: 2.1 Bone or articular pain; or 2.2 Bone deformity; or 2.3 Bone, articular or neurological complications; or 2.4 Asymptomatic disease, but risk of complications due to site (base of skull, spine, long bones of lower limbs); or 2.5 Preparation for orthopaedic surgery. Renewal only from a relevant specialist. Approvals valid for 6 months where the treatment remains appropriate and the patient is benefiting from treatment.
Retail Pharmacy-Specialist Prescriptiona) Specialist must be an ophthalmologist. b) For treatment of bacterial keratitis or severe bacterial conjunctivitis resistant to chloramphenicol.
a) On a prescription or practitioner's supply order only when on the same form as an injection listed in the Pharmaceutical Schedule requiring a solvent or diluent b) On a bulk supply orderc) When used in the extemporaneous compounding of eye drops
Special Authority for Subsidy - Form SA0470Initial application - (Organ transplant) only from a relevant specialist. Approvals valid without further renewal unless notified where organ transplant. Initial application - (Bone marrow transplant or Graft v host disease) only from a relevant specialist. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 Bone marrow transplant; or 2 Graft v host disease. Initial application - (Psoriasis) only from a dermatologist. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 Psoriasis; and 2 Applicant must state which systemic and topical therapies have failed. Initial application - (Severe atopic dermatitis) only from a dermatologist. Approvals valid for 6 months for applications meeting the following criteria: Both: 1 Severe atopic dermatitis; and 2 Not responsive to topical therapy, oral antihistamines and other commonly used orthodox therapies. Initial application - (N
Special Authority for Subsidy - Form SA0471Initial application - (Breast cancer) from any medical practitioner. Approvals valid for 1 year where breast cancer in pre menopausal women unwilling or unable to undergo surgical or radiation oophorectomy. Initial application - (Prostate cancer) only from an oncologist, urologist or endocrinologist. Approvals valid for 1 year where advanced prostatic cancer when orchidectomy is contraindicated or where the patient strongly opposes orchidectomy. NoteNot to be prescribed with an anti-androgen except for a period of three weeks, if necessary, when GnRH analogue therapy is intiatedInitial application - (Endometriosis) only from a gynaecologist. Approvals valid for 3 months for applications meeting the following criteria: Both: 1 Endometriosis ; and 2 Either: 2.1 6 months treatment with medroxyprogesterone acetate, danazol or dimetriose has proven ineffective; or 2.2 The patient has failed to tolerate the treatment with medroxyprogesterone
Special Authority for Subsidy - Form SA0472Initial application only from a cardiologist. Approvals valid for 2 years for applications meeting the following criteria: Any of the following: 1 Both: 1.1 Congestive heart failure; and 1.2 Cannot tolerate currently fully subsidised ACE inhibitors due to persistent cough that resolves on cessation and recurs on re-challenge with ACE inhibitor; or 2 Patients who have experienced angioedema on an ACE inhibitor at any time in the past; or 3 Patients who have experienced angioedema (even if not using an ACE inhibitor) in the last 2 years. Renewal only from a cardiologist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0473Initial application from any medical practitioner. Approvals valid for 1 year where the patient is likely to benefit from treatment. Note Applications to be made on the approved forms which are available from: The Co-ordinatorGaucher's Treatment PanelPhone: (04) 460 4990 PHARMAC, PO Box 10 254 WellingtonFacsimile: (04) 916 7571Email: erin.murphy@pharmac.govt.nzPrescriptions for patients approved for treatment must be written by respiratory physicians or paediatricians who have experience and expertise in treating cystic fibrosis.
a) When prescribed (alone or in combination) for renal dialysis in the home of the patient concerned.b) Only maternity hospital, or on the prescription of a practitioner. c) Obstetric cream only in a quantity not exceeding 500 ml per prescription or on a bulk supply order. d) Solution 5% in quantity not exceeding 100 ml per prescription or on a bulk supply order.
a) Up to 10 %;b) Only in combination with a dermatological base or proprietary Topical Corticosteriod - Plain; c) With or without other dermatological galenicals.
a) Up to 2 %; b) Only in combination with a dermatological base or proprietary Topical Corticosteriod - Plain; c) With or without other dermatological galenicals.
a) Up to 5 %; b) In a dermatological base (not proprietary Topical Corticosteriod - Plain);c) With or without other dermatological galenicals.
a) Only in combination with aqueous cream, 10 % urea cream, wool fat with mineral oil lotion, 1% hydrocortisone with wool fat and mineral oil lotion, and glycerol, paraffin and cetyl alcohol lotion; b) With or without phenol liquefied.
a) Only in combination with aqueous cream, 10 % urea cream, wool fat with mineral oil lotion, 1% hydrocortisone with wool fat and mineral oil lotion, and glycerol, paraffin and cetyl alcohol lotion; b) With or without menthol crystals.
a) In a dermatological base or proprietary Topical Corticosteroid - Plain; b) With or without other dermatological galenicals. c) In a 'standard formula'.
a) Only in combination with a dermatological base or proprietary Topical Corticosteriod - Plain; c) With or without other dermatological galenicals.
Special Authority for Subsidy - Form SA0488Initial application only from a gastroenterologist, general surgeon or general physician. Approvals valid for 3 months for applications meeting the following criteria: Both: 1 Mild to moderate ileal, ileocaecal or proximal Crohn's disease; and 2 Any of the following: 2.1 Diabetes; or 2.2 Cushingoid habitus; or 2.3 Osteoporosis where there is significant risk of fracture; or 2.4 Both: 2.4.1 Severe acne; and 2.4.2 Treatment with conventional corticosteroid therapy. Renewal only from a gastroenterologist, general surgeon or general physician. Approvals valid for 3 months where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Manufacturers Price - Form SA0489Initial application - (Conditions other than transient ischaemic episodes) only from a cardiothoracic surgeon, cardiologist or general physician. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 Patients with prosthetic heart valves - as an adjunct to oral anticoagulation for prophylaxis of thromboembolism; or 2 Both: 2.1 Patients after coronary artery vein bypass graft; and 2.2 Any of the following: 2.2.1 aspirin induced asthma; or 2.2.2 aspirin induced anaphylaxi; or 2.2.3 significant aspirin induced bleeding excluding bruising. Initial application - (Transient ischaemic episodes) only from a neurologist, neuro surgeon, cardiologist, vascular surgeon or general physician. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 Patients who continue to have transient ischaemic episodes despite aspirin therapy; or 2 Both: 2.1 Patients wh
Special Authority for Subsidy - Form SA0490Initial application only from a relevant specialist. Approvals valid for 2 years for applications meeting the following criteria: Any of the following: 1 Requires but is not able to tolerate metformin therapy; or 2 Requires metformin but metformin is contraindicated; or 3 Has not responded to or tolerated the maximum appropriate dose of metformin. Renewal only from a relevant specialist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
a) only if prescribed for prohylaxis of endocarditis and the prescription is endorsed accordingly.
Special Authority for Subsidy - Form SA0494Initial application only from an ophthalmologist. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 Both: 1.1 Primary open-angle glaucoma; and 1.2 Any of the following: 1.2.1 Patient cannot tolerate Beta-blockers, or Beta-blockers are contraindicated; or 1.2.2 Patient cannot tolerate Pilocarpine, or Pilocarpine is contraindicated; or 1.2.3 Patient cannot tolerate Dorzolamide, or Dorzolamide is contraindicated; or 1.2.4 A reduction in intraocular pressure of 15% or more is not achieved or maintained using dorzolamide either alone or in combination with a beta-blocker; or 2 There is progressive visual field loss and/or optic nerve damage persists after treatment with dorzolamide either alone or in combination with a beta-blocker. NoteSubsidised as monotherapy onlyRenewal only from an ophthalmologist. Approvals valid for 2 years where the treatment remains appropriate and the patient
Special Authority for Alternate Subsidy - Form SA0500Initial application from any medical practitioner. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 Either: 1.1 Patient is on a Social Welfare benefit; or 1.2 Patient has an income no greater than the benefit; and 2 Has tried at least one of the fully funded options and has been unable to tolerate it. Renewal from any medical practitioner. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 Patient is on a Social Welfare benefit; or 2 Patient has an income no greater than the benefit. NoteThe approval numbers of Special Authorities approved after 1 November 1999 are interchangeable between Mercilon and Marvelon. The additional subsidy will fund Mercilon and Marvelon up to the manufacturer's price for each of these products as identified on the Schedule at 1 November 1999Special Authorities approved before 1 November 1999 remain valid until the expiry d
a) Hospital pharmacy [HP3] - Maximum of 750mg (3 injections) per prescription; orb) Hospital pharmacy [HP3] - specialist - Only if prescribed for a dialysis or cystic fibrosis patient; and- The prescription is endorsed accordingly.
a) Maximum of 500mg per prescription; orb) More than 500mg per prescription - Special Authority available
a) Only if prescribed for a dialysis or cystic fibrosis patient or for prophylaxis of endocarditis and; b) the prescription is endorsed accordingly.
a) Only if prescribed for a dialysis or cystic fibrosis patient or in the treatment of pseudo membranous colitis or for prophylaxis of endocarditis; and b) The prescription is endorsed accordingly.
Special Authority for Subsidy - Form SA0508Initial application only from a relevant specialist or general practitioner. Approvals valid for 2 years for applications meeting the following criteria: All of the following: 1 Patient with raised blood pressure; and 2 A beta blocker or diuretic is contraindicated; or not well tolerated; or insufficient to control blood pressure adequately at appropriate doses; and 3 An ACE inhibitor is contraindicated; or not well tolerated; or insufficient to control blood pressure adequately at appropriate doses. Renewal only from a relevant specialist or general practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0509Initial application only from a psychiatrist. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 Patient with first episode schizophrenia or related psychoses; or 2 Both: 2.1 Patient suffering from schizophrenia and related psychoses who is likely to benefit from anti-psychotic treatment; and 2.2 Both: 2.2.1 An effective dose of risperidone had been trialled and has been discontinued either because of; and 2.2.2 Any of the following: 2.2.2.1 Patient has recurrent acute dystonias; or 2.2.2.2 Patient has excessive Parkinson-like symptoms; or 2.2.2.3 Patient has hyperprolactinaemia; or 2.2.2.4 Patient has inadequate clinical response after four weeks. NoteDiscontinued treatment should be notified to HealthPAC if possibleRenewal only from a psychiatrist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Alternate Subsidy - Form SA0510Initial application only from a relevant specialist or general practitioner. Approvals valid for 2 years for applications meeting the following criteria: Any of the following: 1 Angina that is not controlled by other anginal medications (including felodipine); or 2 Patient was taking Adalat Oros for the treatment of angina prior to 1 June 1999; or 3 Receiving maximal antihypertensive therapy, requires a DHP CCB, and cannot tolerate felodipine. Renewal only from a relevant specialist or general practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0511Initial application only from a geriatrician, rheumatologist, endocrinologist, gynaecologist or general physician. Approvals valid for 2 years for applications meeting the following criteria: All of the following: 1 Severe osteoporosis; and 2 History of two previous significant osteoporotic fractures demonstrated radiologically; and 3 T-Score <= -3.0 (bone mass density (BMD) >= 3.0 standard deviations below the mean normal value in young adults). NoteIn line with the Australian guidelines for funding alendronate, a vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral bodyRenewal only from a geriatrician, rheumatologist, endocrinologist, gynaecologist or general physician. Approvals valid for 2 years where the tr
Special Authority for Subsidy - Form SA0512Initial application only from a gastroenterologist, general surgeon or general physician. Approvals valid for 3 months for applications meeting the following criteria: Both: 1 Mild to moderate ileal, ileocaecal or proximal Crohn's disease; and 2 Either: 2.1 Diabetes; or 2.2 Both: 2.2.1 Treatment with conventional corticosteroid therapy; and 2.2.2 Any of the following: 2.2.2.1 Cushingoid habitus; or 2.2.2.2 Osteoporosis where there is significant risk of fracture; or 2.2.2.3 Severe acne. Renewal only from a gastroenterologist, general surgeon or general physician. Approvals valid for 3 months where the patient has had no more than 1 prior approval in the last 12 months. The patient must have had no more than 1 prior approval in the last year. NoteClinical trials for Entocort CIR use beyond three months demonstrated no improvement in relapse rate
Special Authority for Subsidy - Form SA0513Initial application - (Narcolepsy) only from a neurologist. Approvals valid for 24 months where narcolepsy. Initial application - (ADHD in patients aged 5 years or over) only from a paediatrician or psychiatrist. Approvals valid for 24 months for applications meeting the following criteria: Both: 1 ADHD (Attention Deficient and Hyperactivity Disorder) patients aged 5 years or over; and 2 Diagnosed according to DSM-IV or ICD 10 criteria. Initial application - (ADHD in patients under 5 years of age) only from a paediatrician or psychiatrist. Approvals valid for 12 months for applications meeting the following criteria: Both: 1 ADHD (Attention Deficient and Hyperactivity Disorder) patients under 5 years of age; and 2 Diagnosed according to DSM-IV or ICD 10 criteria. Renewal - (Narcolepsy or ADHD in patients under 5 years of age) only from a neurologist, paediatrician or psychiatrist. Approvals valid for 24 months where the treatment remains appr
Additional Subsidy by Special Authority available to fully fund to the level of the lowest priced TDDS brand within the highdose oestrogens.
Special Authority for Subsidy - Form SA0516Initial application from any medical practitioner. Approvals valid for 2 years where the patient is likely to benefit from treatment. Note Applications to be made on the approved forms which are available from: Prof. Wayne CutfieldNational Co-ordinatorNew Zealand Growth Hormone CommitteeC/- Department of PaediatricsUniversity of AucklandPrivate Bag 92019AUCKLAND
Injection 500 mg subsidised: a) only if prescribed for a dialysis or cystic fibrosis patient; and b) the prescription is endorsed accordingly.
(Only in extemporaneously compounded methadone mixture, codeine linctus diabetic or codeine linctus paediatric)
Special Authority for Subsidy - Form SA0523Initial application only from a relevant specialist or general practitioner. Approvals valid for 6 months for applications meeting the following criteria: All of the following: 1 Diagnosis of asthma confirmed; and 2 Inhaler/device technique checked; and 3 Patient monitors PEFR regularly during exacerbations where appropriate; and 4 Any of the following: 4.1 At least three months of 1500 ug or more daily of inhaled beclomethasone or budesonide for adult; or 4.2 At least three months of 750 ug or more daily of inhaled fluticasone) for adult; or 4.3 At least three months of 800 ug or more daily inhaled beclomethasone or budesonide for child; or 4.4 At least three months of 400 ug or more daily inhaled fluticasone) for child; and 5 Either: 5.1 Short acting beta agonist used at least 3-4 times daily; or 5.2 Nocturnal awakenings at least twice a week. Renewal only from a relevant specialist or general practitioner. Appro
Special Authority for Subsidy - Form SA0528Initial application - (Narcolepsy) only from a neurologist or respiratory specialist. Approvals valid for 24 months where narcolepsy. Initial application - (ADHD in patients 5 or over) only from a paediatrician, psychiatrist or general practitioner. Approvals valid for 24 months for applications meeting the following criteria: All of the following: 1 ADHD (Attention Deficient and Hyperactivity Disorder) patients aged 5 years or over; and 2 Diagnosed according to DSM-IV or ICD 10 criteria; and 3 Applicant is a specialist or specialist has recommended treatment. Initial application - (ADHD in patients under 5) only from a paediatrician or psychiatrist. Approvals valid for 12 months for applications meeting the following criteria: Both: 1 ADHD (Attention Deficient and Hyperactivity Disorder) patients under 5 years of age; and 2 Diagnosed according to DSM-IV or ICD 10 criteria. Renewal - (Narcolepsy) only from a neurologist or respiratory spec
ACE inhibitors will be funded to the level of the ex-manufacturer price listed in the Schedule for patients who were taking an ACE inhibitor for the treatment of congestive heart failure prior to 1 June 1998. The prescription must be endorsed accordingly. We recommend that the words used to indicate eligibility are "certified condition" or an appropriate description of the patient such as "congestive heart failure", "CHF", "congestive cardiac failure" or "CCF". Additional subsidy for lisinopril is available only up to the price of the least expensive brand listed in the Schedule. Definition of Congestive Heart FailureAt the request of some prescribers the PTAC Cardiovascular subcommittee has provided adefinition of congestive heart failure for the purposes of the funding of the manufacturer'ssurcharge: "Clinicians should use their clinical judgement. Existing patients would be eligible for thefunding of the surcharge if the patient shows signs and symptoms of congestive heart failure, and requir
Additional subsidy by endorsement for:Moclobemide tab 150 mg x 100 (Aurorix) up to $47.00Moclobemide tab 300 mg x 60 (Aurorix) up to $56.40Nefazadone tab 100 mg x 56 (Serzone) up to $20.16Nefazadone tab 200 mg x 56 (Serzone) up to $40.32Citalopram tab 20 mg x 28 (Cipramil) up to $27.00is available for patients who: * are taking moclobemide or nefazodone on 1 December 1999 or citalopram on 1 February2000; * have previously responded to treatment with moclobemide or nefazodone or citalopram; * have had a trial of fluoxetine and have to discontinue due to: - inability to tolerate the drug due to side effects OR - failed to respond to an adequate dose and duration of treatment; * have contraindications to fluoxetine (eg pre-existing significant levels of nausea, breastfeeding, potential drug interactions); The prescription must be endorsed accordingly. We recommend that the words used to indicate eligibility are "certified condition" however these particular words are not a requirement.
Special Authority for Subsidy - Form SA0538Initial application only from a gastroenterologist, infectious disease specialist, paediatrician or general physician. Approvals valid for 1 year for applications meeting the following criteria: Both: 1 Any of the following: 1.1 All of the following: 1.1.1 HBsAg positive for more than 6 months; and 1.1.2 HBeAg positive or HBV DNA positive defined as >0.6 pg/ml by quantitative PCR at reference laboratory; and 1.1.3 ALT greater than twice upper limit of normal or stage 3 or 4 fibrosis on liver histology clinical/radiological evidence of cirrhosis; or 1.2 HBV DNA positive cirrhosis prior to liver transplantation; or 1.3 HBsAg positive and have had a liver, kidney, heart, lung or bone marrow transplant; and 2 All of the following: 2.1 No continuing alcohol abuse or intravenous drug use; and 2.2 Not coinfected with HCV, HDV, or HIV; and 2.3 Neither ALT nor AST greater than 10 times upper limit of normal; and 2.4
Special Authority for Subsidy - Form SA0539Initial application from any medical practitioner. Approvals valid for 5 years where the patient is likely to benefit from treatment. NoteApplications to be made on the approved forms which are available from: The Co-ordinatorPhone: 09 580 9176Multiple Sclerosis Treatment CommitteeFacsimile: 09 580 9205Level 3, Unisys HouseEmail: murray@ppc.govt.nz650 Great South Road, PenrosePrivate Bag, AUCKLANDBudget managed by appointed clinicians on the Multiple Sclerosis Treatment Assessments Committee (MSTAC). Applications will be considered by MSTAC at its regular meetings and approved subject to eligibility according to the Entry and Stopping criteria (below). Completed application forms must be sent to the co-ordinator for MSTAC and will be considered by MSTAC at the next practicable opportunity. Notification of MSTAC's decision will be sent to the patient, the applying clinician and the patient's GP (if specified). These agents will N
Only if prescribed for renal dialysis, maternity or post-natal care in the home of the patient and the prescription is endorsed accordingly.
Oral liq prescriptions: a) Must be written by a Paediatrician or Paediatric Cardiologist; orb) On the recommendation of a Paediatrician or Paediatric Cardiologist.
Additional subsidy by endorsement for:Moclobemide tab 150 mg x 100 (Aurorix) up to $47.00Moclobemide tab 300 mg x 60 (Aurorix) up to $56.40Nefazadone tab 100 mg x 56 (Serzone) up to $20.16Nefazadone tab 200 mg x 56 (Serzone) up to $40.32Citalopram tab 20 mg x 28 (Cipramil) up to $27.00is available for patients who: * were taking moclobemide or nefazodone on 1 December 1999 or citalopram on 1 February 2000; or* have previously responded to treatment with moclobemide, nefazodone or citalopram; or* have had a trial of fluoxetine and have to discontinue due to: - inability to tolerate the drug due to side effects; or - failed to respond to an adequate dose and duration of treatment; or* have contraindications to fluoxetine (eg pre-existing significant levels of nausea, breastfeeding, potential drug interactions); The prescription must be endorsed accordingly. We recommend that the words used to indicate eligibility are "certified condition" however these words are not a requirement.
Alphagan is subsidised for use as either monotherapy or as an adjunctive agent for the treatment of glaucoma. Alphagan should not be prescribed for a person in whom less expensive first line agents for the treatment of glaucoma are not contraindicated unless: (a) that person has previously trialled all other such subsidised agents (except dorzolamide hydrochloride); and(b) those trials have indicated that that person does not respond adequately to or does not tolerate treatment with those other agents.
Special Authority for Subsidy - Form SA0551Initial application only from a paediatrician, neurologist or general physician. Approvals valid for 15 months for applications meeting the following criteria: Any of the following: 1 Was on NAED therapy before 1 September 2000; or 2 Seizures are not adequately controlled with optimal older anti-epilepsy drug treatment; or 3 Seizures are controlled adequately but who experience unacceptable side effects from older anti-epilepsy drug treatment. NoteApproval entitles patients to a subsidy for one NAED. Dual NAED therapy will be subsidised for patients who were already stabilised on two NAEDs on or before 31 July 2000 or, for whom a second NAED has been added to therapy with one NAED provided an attempt to withdraw one NAED has been made and was unsuccessful. "Optimal older anti-epilepsy drug therapy" is defined as treatment with those older anti-epilepsy drugs which are indicated and clinically appropriate for the patient, given singly and in combin
Nicotine patches and gum: a) are only available /subsidised on presentation of a Quitline exchange card.b) for reimbursement refer to the Claiming Procedures for the Subsidised Nicotine Patches and Gum Programme. c) have a maximum patient co-payment (contribution) of $10 per exchange card.
Special Authority for Subsidy - Form SA0554Initial application only from a relevant specialist. Approvals valid without further renewal unless notified for applications meeting the following criteria: Either: 1 Liver transplant recipients; or 2 Renal transplant recipients - as rescue therapy only. Renewal only from a relevant specialist. Approvals valid without further renewal unless notified where the treatment remains appropriate and the patient is benefiting from treatment.
a) Fluoxetine hydrochloride tab dispersible 20 mg restricted to a maximum daily dose of 10 mg. b) Tablets can be combined with capsules to facilitate incremental 10 mg doses.
Special Authority for Subsidy - Form SA0556Initial application - (Confirmed HIV/AIDS) only from a named general physician. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 Confirmed HIV/AIDS; and 2 Any of the following: 2.1 Symptomatic patient; or 2.2 Both: 2.2.1 Asymptomatic patient; and 2.2.2 Patient aged 12 months and under; or 2.3 Both: 2.3.1 Asymptomatic patient; and 2.3.2 Patient has viral load counts > 10,000 copies per ml or equivalent value on the Chiron test; or 2.4 All of the following: 2.4.1 Asymptomatic patient; and 2.4.2 Patient aged 1 to 5 years; and 2.4.3 CD4 counts < 1,000 cells/mm3; or 2.5 All of the following: 2.5.1 Asymptomatic patient; and 2.5.2 Patient aged 1 to 5 years; and 2.5.3 CD4 counts < 0.25 x total white cell count; or 2.6 All of the following: 2.6.1 Asymptomatic patient; and 2.6.2 Patient aged 6 years and over; and 2.6.3 CD4 counts
Special Authority for Subsidy - Form SA0557Initial application - (Single NAED Therapy) only from a paediatrician, neurologist or general physician. Approvals valid for 15 months for applications meeting the following criteria: Any of the following: 1 Was on NAED therapy before 1 September 2000; or 2 Seizures are not adequately controlled with optimal older anti-epilepsy drug treatment; or 3 Seizures are controlled adequately but who experience unacceptable side effects from older anti-epilepsy drug treatment. Note"Optimal older anti-epilepsy drug therapy" is defined as treatment with those older anti-epilepsy drugs which are indicated and clinically appropriate for the patient, given singly and in combination in adequate doses for the patient's age, weight, and other features affecting the pharmacokinetics of the drug with good evidence of complianceAs a guideline, clinical trials have referred to a notional 50% reduction in seizure frequency as an indicator of success with anti-convulsan
Additional subsidy by endorsement for:Moclobemide tab 150mg x 100 (Aurorix) up to $32.90Moclobemide tab 300mg x 60 (Aurorix) up to $39.48Nefazodone tab 100mg x 56 (Serzone) up to $20.16Nefazodone tab 200mg x 56 (Serzone) up to $40.32Citalopram tab 20mg x 28 (Cipramil) up to $27.00is available for patients who: * were taking moclobemide or nefazodone on 1 December 1999 or citalopram on 1 February 2000; or* have previously responded to treatment with moclobemide, nefazodone or citalopram; or* have had a trial of fluoxetine and have had to discontinue due to - inability to tolerate the drug due to side effects; or - failed to respond to an adequate dose and duration of treatment; or* have contraindications to fluoxetine (eg pre-existing significant levels of nausea, breastfeeding, potential drug interactions). The prescription must be endorsed accordingly. We recommend that the words used to indicate eligibility are "certified condition" however these words are not a requirement.
Additional subsidy by endorsement for:Moclobemide tab 150mg x 100 (Aurorix) up to $32.90Moclobemide tab 300mg x 60 (Aurorix) up to $39.48Nefazodone tab 100mg x 56 (Serzone) up to $20.16Nefazodone tab 200mg x 56 (Serzone) up to $40.32Citalopram tab 20mg x 28 (Cipramil and Celapram) up to $10.00Paroxetine hydrochloride tab 20 mg x 30 (Aropax) up to $35.02is available for patients who: * were taking moclobemide or nefazodone on 1 December 1999 or citalopram on 1 February 2000; or paroxetine hydrochloride on Februrary 2001; or * have previously responded to treatment with moclobemide or nefazodone or citalopram or paroxetine hydrochloride; or* have had a trial of fluoxetine and have had to discontinue due to - inability to tolerate the drug due to side effects; or - failed to respond to an adequate dose and duration of treatment; or* have contraindications to fluoxetine (eg pre-existing significant levels of nausea, breastfeeding, potential drug interactions). The prescription must be e
Special Authority for Subsidy - Form SA0563Initial application only from a relevant specialist. Approvals valid for 2 years for applications meeting the following criteria: Any of the following: 1 Both: 1.1 Acromegaly; and 1.2 Patient has failed surgery, radiotherapy, bromocriptine and other oral therapies; or 2 VIPomas and Glucagonomas - for patients who are seriously ill in order to improve their clinical state prior to definitive surgery.; or 3 Both: 3.1 Gastrinoma; and 3.2 Either: 3.2.1 Patient has failed surgery; or 3.2.2 Patient in metastatic disease after H2 antagonists (or proton pump inhibitors) have failed; or 4 Both: 4.1 Insulinomas; and 4.2 Surgery is contraindicated or has failed; or 5 For pre-operative control of hypoglycaemia and for maintenance therapy; or 6 Both: 6.1 Carcinoid syndrome (diagnosed by tissue pathology and/or urinary 5HIAA analysis); and 6.2 Disabling symptoms not controlled by maximal medical therapy. No
Only if prescribed on a prescription for for renal dialysis, maternity or post-natal care in the home of the patient, or on a PSO for emergency use.
Trandolapril will be funded to the level of the ex-manufacturer price listed in the Schedule for patients who were taking these ACE inhibitors for the treatment of congestive heart failure prior to 1 June 1998. The prescription must be endorsed accordingly. We recommend that the words used to indicate eligibility are "certified condition" or an appropriate description of the patient such as "congestive heart failure", "CHF", "congestive cardiac failure" or "CCF". Definition of Congestive Heart Failure At the request of some prescribers the PTAC Cardiovascular subcommittee has provided a definition of congestive heart failure for the purposes of the funding of the manufacturer's surcharge: "Clinicians should use their clinical judgement. Existing patients would be eligible for the funding of the surcharge if the patient shows signs and symptoms of congestive heart failure, and requires or has in the past required concomitant treatment with a diuretic. The definition could also be considered to include pat
Perindopril will be funded to the level of the ex-manufacturer price listed in the Schedule for patients who were taking these ACE inhibitors for the treatment of congestive heart failure prior to 1 June 1998. The prescription must be endorsed accordingly. We recommend that the words used to indicate eligibility are "certified condition" or an appropriate description of the patient such as "congestive heart failure", "CHF", "congestive cardiac failure" or "CCF". Definition of Congestive Heart Failure At the request of some prescribers the PTAC Cardiovascular subcommittee has provided a definition of congestive heart failure for the purposes of the funding of the manufacturer's surcharge: "Clinicians should use their clinical judgement. Existing patients would be eligible for the funding of the surcharge if the patient shows signs and symptoms of congestive heart failure, and requires or has in the past required concomitant treatment with a diuretic. The definition could also be considered to include pati
Special Authority for Subsidy - Form SA0569Initial application only from a geriatrician, rheumatologist, endocrinologist, gynaecologist or general physician. Approvals valid for 2 years for applications meeting the following criteria: All of the following: 1 Severe osteoporosis; and 2 History of one previous significant osteoporotic fractures demonstrated radiologically; and 3 T-Score <= -3.0 (bone mass density (BMD) >= 3.0 standard deviations below the mean normal value in young adults). NoteIn line with the Australian guidelines for funding alendronate, a vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body. Renewal only from a geriatrician, rheumatologist, endocrinologist, gynaecologist or general physician. Approvals valid for 2 years where the t
a) Only if prescribed on prescription for a dialysis patient or child with rheumatic fever or on a PSO for emergency use.
Special Authority for Subsidy - Form SA0572Initial application only from a psychiatrist. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 Patient presenting with first episode schizophrenia or related psychoses; or 2 Both: 2.1 Patients suffers from schizophrenia or related psychoses ; and 2.2 Either: 2.2.1 A trial of risperidone has been discontinued because of unacceptable side effects; or 2.2.2 A trial of risperidone has been discontinued because of inadequate response. Renewal only from a psychiatrist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
Subsidy is available for patients with poorly controlled asthma where: a) at least three months of 750 mcg or more daily of inhaled beclomethasone or budesonide(or 400 mcg of fluticasone) for adults has been used; orb) at least three months of 400 mcg or more daily of inhaled beclomethasone or budesonide (or 200mcg of fluticasone) for children 12 years or older has been used; The prescription must be endorsed accordingly. We recommend that the words used to indicateeligibility are "poor control with ICS" or "certified condition".
Special Authority for Subsidy - Form SA0575Initial application - (Confirmed HIV/AIDS) only from a named general physician. Approvals valid without further renewal unless notified for applications meeting the following criteria: Both: 1 Confirmed HIV/AIDS; and 2 Any of the following: 2.1 Symptomatic patient; or 2.2 Both: 2.2.1 Asymptomatic patient; and 2.2.2 Patient aged 12 months and under; or 2.3 Both: 2.3.1 Asymptomatic patient; and 2.3.2 Patient has viral load counts > 10,000 copies per ml or equivalent value on the Chiron test; or 2.4 All of the following: 2.4.1 Asymptomatic patient; and 2.4.2 Patient aged 1 to 5 years; and 2.4.3 CD4 counts < 1,000 cells/mm3; or 2.5 All of the following: 2.5.1 Asymptomatic patient; and 2.5.2 Patient aged 1 to 5 years; and 2.5.3 CD4 counts < 0.25 x total white cell count; or 2.6 All of the following: 2.6.1 Asymptomatic patient; and 2.6.2 Patient aged 6 years and over
Dispersible tablets are subsidised only for patients who are unable to swallow tablets and the prescription is endorsed accordingly.
Special Authority for Subsidy - Form SA0579Initial application - (Cystic fibrosis or renal failure) only from a relevant specialist. Approvals valid for 3 years for applications meeting the following criteria: Either: 1 cystic fibrosis; or 2 chronic renal failure or continuous ambulatory peritoneal dialysis (CAPD) patient. Initial application - (Indications other than cystic fibrosis or renal failure) only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria: Any of the following: 1 cancer in children; or 2 cancers affecting alimentary tract where there are malabsorption problems in patients over the age of 20 years; or 3 failure to thrive; or 4 growth deficiency; or 5 bronchopulmonary dysplasia; or 6 premature and post premature infant. Renewal - (Cystic fibrosis or renal failure) only from a relevant specialist or general practitioner on the recommendation of such a specialist. Approvals valid for 3 years for applicatio
Special Authority for Subsidy - Form SA0580Initial application - (Inborn errors of metabolism) only from a relevant specialist. Approvals valid for 3 years where inborn errors of metabolism. Initial application - (Indications other than inborn errors of metabolism) only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria: Any of the following: 1 failure to thrive ; or 2 growth deficiency; or 3 bronchopulmonary dysplasia ; or 4 fat malabsorption ; or 5 lymphangiectasia; or 6 short bowel syndrome ; or 7 infants with necrotising enterocolitis; or 8 biliary atresia. Renewal - (Inborn errors of metabolism) only from a relevant specialist or general practitioner on the recommendation of such a specialist. Approvals valid for 3 years for applications meeting the following criteria: Both: 1 The treatment remains appropriate and the patient is benefiting from treatment; and 2 General Practitioners must include the name of
Special Authority for Subsidy - Form SA0581Initial application - (Cystic fibrosis) only from a relevant specialist. Approvals valid for 3 years for applications meeting the following criteria: Both: 1 infant aged four years or under; and 2 cystic fibrosis. Initial application - (Indications other than cystic fibrosis) only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria: Both: 1 infant aged four years or under; and 2 Any of the following: 2.1 cancer in children; or 2.2 failure to thrive; or 2.3 growth deficiency; or 2.4 bronchopulmonary dysplasia; or 2.5 premature and post premature infants. Renewal - (Cystic fibrosis) only from a relevant specialist or general practitioner on the recommendation of such a specialist. Approvals valid for 3 years for applications meeting the following criteria: Both: 1 The treatment remains appropriate and the patient is benefiting from treatment; and 2 General Practiti
Special Authority for Subsidy - Form SA0582Initial application only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria: Either: 1 protein losing enteropathy; or 2 high protein needs (eg burns). Renewal only from a relevant specialist or general practitioner on the recommendation of such a specialist. Approvals valid for 1 year for applications meeting the following criteria: Both: 1 The treatment remains appropriate and the patient is benefiting from treatment; and 2 General Practitioners must include the name of the specialist and date contacted.
Special Authority for Subsidy - Form SA0585Initial application - (Cystic fibrosis) only from a relevant specialist. Approvals valid for 3 years for applications meeting the following criteria: All of the following: 1 Cystic fibrosis; and 2 other lower calorie products have been tried; and 3 patient has substantially increased metabolic requirements; and 4 Either: 4.1 The product is to be used as a supplement; or 4.2 The product is to be used as a complete diet.Initial application - (Indications other than cystic fibrosis) only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria: All of the following: 1 Any of the following: 1.1 any condition causing malabsorption ; or 1.2 failure to thrive ; or 1.3 increased nutritional requirements.; and 2 other lower calorie products have been tried; and 3 patient has substantially increased metabolic requirements; and 4 Either: 4.1 The product is to be used a
Special Authority for Subsidy - Form SA0587Initial application only from a relevant specialist. Approvals valid for 3 years for applications meeting the following criteria: Both: 1 acute or chronic renal failure; and 2 Either: 2.1 The product is to be used as a supplement (maximum 500 ml per day); or 2.2 The product is to be used as a complete diet.Renewal only from a relevant specialist or general practitioner on the recommendation of such a specialist. Approvals valid for 3 years for applications meeting the following criteria: All of the following: 1 The treatment remains appropriate and the patient is benefiting from treatment; and 2 Either: 2.1 The product is to be used as a supplement (maximum 500 ml per day); or 2.2 The product is to be used as a complete diet; and 3 General Practitioners must include the name of the specialist and date contacted.
Special Authority for Subsidy - Form SA0588Initial application only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria: Both: 1 CORD patients who have hypercapnia; and 2 Either: 2.1 The product is to be used as a supplement (maximum 500 ml per day); or 2.2 The product is to be used as a complete diet.Renewal only from a relevant specialist or general practitioner on the recommendation of such a specialist. Approvals valid for 1 year for applications meeting the following criteria: All of the following: 1 The treatment remains appropriate and the patient is benefiting from treatment; and 2 Either: 2.1 The product is to be used as a supplement (maximum 500 ml per day); or 2.2 The product is to be used as a complete diet; and 3 General Practitioners must include the name of the specialist and date contacted.
Special Authority for Subsidy - Form SA0589Initial application only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria: All of the following: 1 Anorexia and weight loss; and 2 Either: 2.1 decompensating liver disease without encephalopathy ; or 2.2 protein losing gastro-enteropathy; and 3 Either: 3.1 The product is to be used as a supplement (maximum 500 ml per day); or 3.2 The product is to be used as a complete diet.Renewal only from a relevant specialist or general practitioner on the recommendation of such a specialist. Approvals valid for 1 year for applications meeting the following criteria: All of the following: 1 The treatment remains appropriate and the patient is benefiting from treatment; and 2 Either: 2.1 The product is to be used as a supplement (maximum 500 ml per day); or 2.2 The product is to be used as a complete diet; and 3 General Practitioners must include the name of the specialis
Special Authority for Subsidy - Form SA0590Initial application only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria: All of the following: 1 infant aged one to six years; and 2 Any of the following: 2.1 any condition causing malabsorption ; or 2.2 failure to thrive; or 2.3 increased nutritional requirements; and 3 Either: 3.1 The product is to be used as a supplement (maximum 500 ml per day); or 3.2 The product is to be used as a complete diet.Renewal only from a relevant specialist or general practitioner on the recommendation of such a specialist. Approvals valid for 1 year for applications meeting the following criteria: All of the following: 1 The treatment remains appropriate and the patient is benefiting from treatment; and 2 Either: 2.1 The product is to be used as a supplement (maximum 500 ml per day); or 2.2 The product is to be used as a complete diet; and 3 General Practitioners must
Special Authority for Subsidy - Form SA0591Initial application only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria: Both: 1 Any of the following: 1.1 enteral feeding; or 1.2 nasogastric; or 1.3 nasoduodenal ; or 1.4 nasojejunal; or 1.5 gastrostomy/jejunostomy; and 2 Either: 2.1 The product is to be used as a supplement; or 2.2 The product is to be used as a complete diet.Renewal only from a general practitioner or relevant specialist. Approvals valid for 1 year for applications meeting the following criteria: All of the following: 1 The treatment remains appropriate and the patient is benefiting from treatment; and 2 Either: 2.1 The product is to be used as a supplement; or 2.2 The product is to be used as a complete diet; and 3 General Practitioners must include the name of the specialist and date contacted.
Special Authority for Subsidy - Form SA0592Initial application only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria: Both: 1 Any of the following: 1.1 malabsorption ; or 1.2 short bowel syndrome; or 1.3 enterocutaneous fistulas ; or 1.4 pancreatitis; and 2 Either: 2.1 The product is to be used as a supplement (maximum 500 ml per day); or 2.2 The product is to be used as a complete diet.NoteEach of these products is highly specialised and would be prescribed only by an expert for a specific disorder. The alternative is hospitalisation. Elemental 028 Extra is more expensive than other products listed in this section and should only be used where the alternatives have been tried first and/or are unsuitable. Renewal only from a relevant specialist or general practitioner on the recommendation of such a specialist. Approvals valid for 1 year for applications meeting the following criteria: All of the following:
Special Authority for Subsidy - Form SA0594Initial application only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria: Both: 1 Type I and II diabetics who require nutritional supplementation.; and 2 Either: 2.1 The product is to be used as a supplement (maximum 500 ml per day); or 2.2 The product is to be used as a complete diet.Renewal only from a relevant specialist or general practitioner on the recommendation of such a specialist. Approvals valid for 1 year for applications meeting the following criteria: All of the following: 1 The treatment remains appropriate and the patient is benefiting from treatment; and 2 Either: 2.1 The product is to be used as a supplement (maximum 500 ml per day); or 2.2 The product is to be used as a complete diet; and 3 General Practitioners must include the name of the specialist and date contacted.
Special Authority for Subsidy - Form SA0595Initial application only from a relevant specialist. Approvals valid for 1 year where patient has motor neurone disease with swallowing disorder. Renewal only from a relevant specialist or general practitioner on the recommendation of such a specialist. Approvals valid for 1 year for applications meeting the following criteria: Both: 1 The treatment remains appropriate and the patient is benefiting from treatment; and 2 General Practitioners must include the name of the specialist and date contacted.
Special Authority for Subsidy - Form SA0596Initial application only from a relevant specialist. Approvals valid for 3 years for applications meeting the following criteria: Either: 1 gluten enteropathy has been diagnosed by biopsy; or 2 dermatitis herpetiformis. NoteA premium may be payable if the subsidy does not match the price charged by the manufacturer. The subsidy for these products reflects the philosophy that the patient incurs no additional financial burden for purchasing specialised more expensive products. Renewal only from a relevant specialist or general practitioner on the recommendation of such a specialist. Approvals valid for 3 years for applications meeting the following criteria: Both: 1 The treatment remains appropriate and the patient is benefiting from treatment; and 2 General Practitioners must include the name of the specialist and date contacted.
Special Authority for Subsidy - Form SA0597Initial application - (PKU Patient aged over 16) only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria: Both: 1 PKU; and 2 blood phenylalanine level < 900 mmol/litre (average of tests over last 12 months). Initial application - (Patient aged over 16) only from a relevant specialist. Approvals valid for 3 years for applications meeting the following criteria: Any of the following: 1 dietary management of homocystinuria; or 2 inborn errors of metabolism other than PKU; or 3 dietary management of maple syrup urine disease..Initial application - (Patient aged 16 or under) only from a relevant specialist. Approvals valid for 3 years for applications meeting the following criteria: Any of the following: 1 dietary management of homocystinuria; or 2 PKU and other inborn errors of metabolism; or 3 dietary management of maple syrup urine disease..Renewal - (PKU Patient aged over 16
NoteLofenalac when used with Ketovite is considerably cheaper than Maxamaid or Maxamum.
Special Authority for Subsidy - Form SA0600Initial application only from a relevant specialist. Approvals valid for 3 years where inborn errors of metabolism. Renewal only from a relevant specialist or general practitioner on the recommendation of such a specialist. Approvals valid for 3 years for applications meeting the following criteria: Both: 1 The treatment remains appropriate and the patient is benefiting from treatment; and 2 General Practitioners must include the name of the specialist and date contacted.
Special Authority for Subsidy - Form SA0601Initial application only from a relevant specialist. Approvals valid for 1 year where Infant suffering from Williams Syndrome and associated hypercalcaemia. Renewal only from a relevant specialist or general practitioner on the recommendation of such a specialist. Approvals valid for 1 year for applications meeting the following criteria: Both: 1 The treatment remains appropriate and the patient is benefiting from treatment; and 2 General Practitioners must include the name of the specialist and date contacted.
Special Authority for Subsidy - Form SA0602Initial application only from a relevant specialist. Approvals valid for 6 months where infant weighing less than 1.5 kg at birth.
Special Authority for Subsidy - Form SA0603Initial application only from a relevant specialist. Approvals valid for 1 year where infant suffering from malabsorption and other gastrointestinal problems. Renewal only from a relevant specialist or general practitioner on the recommendation of such a specialist. Approvals valid for 1 year for applications meeting the following criteria: Both: 1 The treatment remains appropriate and the patient is benefiting from treatment; and 2 General Practitioners must include the name of the specialist and date contacted.
Special Authority for Subsidy - Form SA0604Initial application - (Lactase deficiency or disaccharide intolerance) only from a relevant specialist. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 Patient is less than 3 years of age; and 2 Either: 2.1 diagnosed as suffering from congenital lactase deficiency; or 2.2 suffering from disaccharide intolerance. NoteSecondary lactose intolerance in children is usually short lasting, and can be controlled by dietary measures and by giving sufficient calories to regenerate digestive enzymes. The subsidy for these products reflects the philosophy that the patient incurs no additional financial burden for purchasing specialised more expensive products. Initial application - (Infant with intolerance to cows' milk) only from a relevant specialist. Approvals valid for 6 months for applications meeting the following criteria: Both: 1 intolerant to cows' milk; and 2 patient is less than 3 years of age. No
Special Authority for Subsidy - Form SA0605Initial application - (Cystic fibrosis or renal disorder) only from a relevant specialist. Approvals valid for 3 years for applications meeting the following criteria: Both: 1 Either: 1.1 cystic fibrosis; or 1.2 renal disorder; and 2 Either: 2.1 The product is to be used as a supplement; or 2.2 The product is to be used as a complete diet.Initial application - (Indications other than cystic fibrosis or renal disorder) only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria: Both: 1 Any of the following: 1.1 any condition causing malabsorption; or 1.2 failure to thrive; or 1.3 increased nutritional requirements; and 2 Either: 2.1 The product is to be used as a supplement; or 2.2 The product is to be used as a complete diet.Renewal - (Cystic fibrosis or renal disorder) only from a relevant specialist or general practitioner. Approvals valid for 3 years
Special Authority for Subsidy - Form SA0606Initial application only from a paediatrician. Approvals valid for 3 years for applications meeting the following criteria: Both: 1 child (up to 18 years) with chronic renal failure.; and 2 Either: 2.1 The product is to be used as a supplement; or 2.2 The product is to be used as a complete diet.Renewal only from a paediatrician. Approvals valid for 3 years for applications meeting the following criteria: Both: 1 The treatment remains appropriate and the patient is benefiting from treatment; and 2 Either: 2.1 The product is to be used as a supplement; or 2.2 The product is to be used as a complete diet.
Special Authority for Subsidy - Form SA0607Initial application only from a paediatrician. Approvals valid for 3 years for applications meeting the following criteria: Both: 1 Child (up to 18 years) who is awaiting liver transplant; and 2 Either: 2.1 The product is to be used as a supplement (maximum 500 ml per day); or 2.2 The product is to be used as a complete diet.Renewal only from a paediatrician. Approvals valid for 3 years for applications meeting the following criteria: Both: 1 The treatment remains appropriate and the patient is benefiting from treatment; and 2 Either: 2.1 The product is to be used as a supplement (maximum 500 ml per day); or 2.2 The product is to be used as a complete diet.
Special Authority for Subsidy - Form SA0609Initial application - (Serevent MDI, Serevent Accuhaler Foradil, Oxis Turbuhaler 12 mcg, Symbicort Turbuhaler) only from a relevant specialist or general practitioner. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 Both: 1.1 Child under the age of 12 with poorly controlled asthma; and 1.2 Either: 1.2.1 Required at least three months of 400 mcg or more daily inhaled beclomethasone or budesonide; or 1.2.2 Required at least three months of 200 mcg or more of fluticasone; or 2 Both: 2.1 Adult with poorly controlled asthma; and 2.2 Either: 2.2.1 Required at least three months of 1500 mcg or more daily inhaled beclomethasone or budesonide; or 2.2.2 Required at least three months of 750 mcg or more of fluticasone. NotePatients are to be reviewed at least at six months to assess compliance and effectiveness of therapy. Special Authority approvals are interchangeable among all prese
Special Authority for Subsidy - Form SA0610Initial application from any specialist. Approvals valid without further renewal unless notified for applications meeting the following criteria: All of the following: 1 Quantity used by patient on a weekly volume intraveneously (Details to be attached to application); and 2 Amount of nutrition patient is able to receive orally (Details to be attached to application); and 3 Exact formula of TPN (Details to be attached to application); and 4 Who has paid for TPN so far (Details to be attached to application); and 5 Place of manufacture (Details to be attached to application); and 6 Complete medical history of patient including details of previous therapies. (Details to be attached to application). Renewal - (Previous approval has expired) from any specialist. Approvals valid without further renewal unless notified where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0611Initial application from any medical practitioner. Approvals valid for 1 year where applicaton approved by the Cystic Fibrosis DN'ase Advisory Panel. NoteApplications to be made on the approved forms which are available from: The Co-ordinatorCystic Fibrosis DN'ase Advisory PanelPhone: (04) 460 4990 PHARMAC, PO Box 10 254 WellingtonFacsimile: (04) 916 7571Email: erin.murphy@pharmac.govt.nzPrescriptions for patients approved for treatment must be written by respiratory physicians or paediatricians who have experience and expertise in treating cystic fibrosis.
Special Authority for Manufacturers Price - Form SA0612Renewal from any medical practitioner. Approvals valid for 2 years where patient recieved Special Authority prior to 1 June 1998.
Special Authority for Alternate Subsidy - Form SA0613Initial application from any medical practitioner. Approvals valid for 2 years for applications meeting the following criteria: Any of the following: 1 Polycystic ovarian syndrome; or 2 Hirsutism; or 3 Androngenic alopecia. Renewal from any medical practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0614Initial application only from a geriatrician, rheumatologist, endocrinologist, gynaecologist or general physician. Approvals valid for 2 years for applications meeting the following criteria: All of the following: 1 Severe osteoporosis; and 2 History of one previous significant osteoporotic fractures demonstrated radiologically; and 3 T-Score <= -3.0 (bone mass density (BMD) >= 3.0 standard deviations below the mean normal value in young adults). NoteIn line with the Australian guidelines for funding alendronate, a vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral bodyRenewal only from a geriatrician, rheumatologist, endocrinologist, gynaecologist or general physician. Approvals valid for 2 years where the tr
Special Authority for Subsidy - Form SA0615Initial application only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria: Both: 1 The product is to be used as a complete diet; and 2 Either: 2.1 Patient has metabolic disorders of fat metabolism; or 2.2 Patient has chylothorax. Renewal only from a relevant specialist or general practitioner on the recommendation of such a specialist. Approvals valid for 1 year for applications meeting the following criteria: Both: 1 The treatment remains appropriate and the patient is benefiting from treatment; and 2 General Practitioners must include the name of the specialist and date contacted.
Special Authority for Manufacturers Price - Form SA0616Initial application - (Conditions other than transient ischaemic episodes) only from a cardiothoracic surgeon, cardiologist or general physician. Approvals valid without further renewal unless notified for applications meeting the following criteria: Either: 1 Patients with prosthetic heart valves - as an adjunct to oral anticoagulation for prophylaxis of thromboembolism; or 2 Patients after coronary artery vein bypass graft - as an adjunct to aspirin or as monotherapy for patients who are aspirin intolerant. NoteAspirin intolerant patients are defined as those with aspirin induced asthma, urticaria, or anaphylaxi, or those with significant aspirin induced bleeding, excluding bruisingInitial application - (Transient ischaemic episodes) only from a neurologist, neuro surgeon, cardiologist, vascular surgeon or general physician. Approvals valid without further renewal unless notified where patients who continue to have transient ischaemic
Nicotine patches and gum are only available /subsidised on presentation of a Quitline exchange card.
a) Prescribers may code prescriptions "contraceptive" (code "O") when used as indicated for contraception. The period of supply and prescription charge will be as per other contraceptives, as follows: - $3.00 prescription charge (patient co-payment) will apply; - prescription may be written for up to six months supply; and- pharmacists may dispense up to three months supply. b) Prescriptions coded in any other way are subject to the non-contraceptive prescription charges, and the non-contraceptive period of supply. ie. Prescriptions may be written for up to three months supply, and dispensed monthly
Special Authority for Subsidy - Form SA0621Initial application only from a relevant specialist. Approvals valid for 5 years where the patient is likely to benefit from treatment. Renewal only from a relevant specialist. Approvals valid for 5 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0622Initial application only from a geriatrician, rheumatologist, endocrinologist, gynaecologist or general physician. Approvals valid without further renewal unless notified for applications meeting the following criteria: All of the following: 1 Severe osteoporosis; and 2 History of one previous significant osteoporotic fractures demonstrated radiologically; and 3 T-Score <= -3.0 (bone mass density (BMD) >= 3.0 standard deviations below the mean normal value in young adults). NoteIn line with the Australian guidelines for funding alendronate, a vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral bodyRenewal only from a geriatrician, rheumatologist, endocrinologist, gynaecologist or general physician. Approvals va
Special Authority for Subsidy - Form SA0623Initial application from any medical practitioner. Approvals valid for 1 year for applications meeting the following criteria: All of the following: 1 The patient is not predisposed to heart arrhythmias; and 2 The patient does not have a pre-existing QT-prolongation or hepatic failure; and 3 The patient is not using other medications which either inhibit the cytochrome P450 3A4 enzyme system or prolong the QT interval; and 4 Any of the following: 4.1 Both: 4.1.1 The patient is an adult with severe reflux oesophagitis; and 4.1.2 other treatment, including acid suppression with proton pump inhibitors, has failed; or 4.2 gastroparesis; or 4.3 malignancy of GI tract causing gastroparesis (or gastric outlet obstruction); or 4.4 The patient is a child (not including infants from 0 to 3 months of age who were born prematurely) with severe gastro-oesophageal reflux; and 5 Diagnosis has been made or confirmed by a general p
Subsidy by endorsement Oral liquid is subsidised only for patients: - with oesophageal stricture, or- in terminal care, or- who are either too young or too old to swallow conventional tablets and the prescription is endorsed accordingly. Note: the cost of treatment with ranitidine oral liquid is more than 10 times higher than that of ranitidine tablets. Following the derestriction of access PHARMAC will be monitoring expenditure on ranitidine oral liquid more closely and may, subject to consultation and PHARMAC Board approval, restrict access again if the expenditure was to grow substantially.
Special Authority for Subsidy - Form SA0626Initial application only from a renal physician. Approvals valid for 2 years for applications meeting the following criteria: All of the following: General Criteria: 1 Anaemia of end-stage renal failure (other treatable causes of anaemia being excluded); and 2 Been on haemodialysis or continuous ambulatory peritoneal dialysis (CAPD) for at least three months; and 3 Not under evaluation for, or awaiting, a live donor kidney transplant; and 4 Any of the following: Specific Criteria: 4.1 Anephric; or 4.2 Dependent on regular blood transfusion (1 unit each 4-8 weeks) to maintain haemoglobin > 60g/L; or 4.3 Dependent on regular blood transfusion but cannot be transfused because of severe transfusion reactions; or 4.4 Transfusion induced haemosiderosis (clinical manifestations, serum ferritin >1500 ug/L); or 4.5 Haemoglobin < 70 g/L (mean of at least 4 haemoglobin concentrations over 4 months); or 4.6 Both: 4.6.1 Haemo
Prescribing GuidelineTreatment with HMG CoA Reductase Inhibitors (Statins) is recommended for patients withdyslipidaemia and an absolute 5 year cardiovascular risk of 15% or greater. New Zealand Cardiovascular Guideline Group statement. "The 1996 Heart Foundation guidelines for the Assessment and Management of Dyslipidaemia are currently being revised. An evidence-based guideline on the Assessment and Management of Cardiovascular Risk will be developed in 2002. The Cardiovascular Guideline Group has written an interim consensus statement for themanagement of dyslipidaemia. The Heart Foundation cardiovascular risk tables should be used to determine risk. Certain groups are classified to be at very high risk (>20%) and should be treated as such: - Patients who have had a previous cardiovascular event (angina, MI, angioplasty, coronary artery bypass grafts, TIA, ischaemic stroke and peripheral vascular disease)- Patients with genetic lipid disorders- Patients with diabetes and associated microa
Special Authority for Subsidy - Form SA0628Initial application only from a cardiologist. Approvals valid without further renewal unless notified for applications meeting the following criteria: Any of the following: 1 Both: 1.1 Congestive heart failure; and 1.2 Cannot tolerate two ACE inhibitors due to persistent cough that resolves on cessation and recurs on re-challenge with ACE inhibitor; or 2 Patients who have experienced angioedema on an ACE inhibitor at any time in the past; or 3 Patients who have experienced angioedema (even if not using an ACE inhibitor) in the last 2 years. Renewal - ((2 year approvals granted before April 2002)) only from a cardiologist. Approvals valid without further renewal unless notified where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0631Initial application only from an ophthalmologist. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 Both: 1.1 Primary open-angle glaucoma; and 1.2 Any of the following: 1.2.1 Patient cannot tolerate Beta-blockers, or Beta-blockers are contraindicated; or 1.2.2 Patient cannot tolerate Pilocarpine, or Pilocarpine is contraindicated; or 1.2.3 Patient cannot tolerate Dorzolamide, or Dorzolamide is contraindicated; or 1.2.4 A reduction in intraocular pressure of 15% or more is not achieved or maintained using dorzolamide either alone or in combination with a beta-blocker; or 2 There is progressive visual field loss and/or optic nerve damage persists after treatment with dorzolamide either alone or in combination with a beta-blocker. NoteSubsidised also for adjunctive use for the treatment of patients who have met the initial application criteria, and in whom latanoprost monotherapy has bee
Special Authority for Subsidy - Form SA0633Initial application only from a general practitioner or relevant specialist. Approvals valid without further renewal unless notified for applications meeting the following criteria: Both: 1 Patient is already on an ACE inhibitor or Angiotensin II Antagonist; and 2 Any of the following: 2.1 Both: 2.1.1 Symptomatic heart failure NYHA functional class II-III; and 2.1.2 Patient has been treated with metoprolol and is intolerant to metoprolol or has demonstrated a sub-optimal response to metoprolol; or 2.2 Symptomatic heart failure NYHA functional class III-IV; or 2.3 Patient has left ventricular systolic dysfunction with an ejection fraction of less than 35%.NoteWhere possible treatment should be initiated by or on the recommendation of a specialist.
Special Authority for Subsidy - Form SA0635Initial application only from a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria: All of the following: 1 Rheumatoid arthritis; and 2 Patient is not a pregnant woman, or a woman of child-bearing age without adequate contraception; and 3 Patient has been unable to tolerate or has a contraindication to or has had an inadequate response to sulphasalazine and methotrexate (individually or in combination). Renewal only from a rheumatologist. Approvals valid without further renewal unless notified for applications meeting the following criteria: Both: 1 Compliance (prescriber determined) with medication; and 2 Improved rheumatoid arthritis symptom control. NotePatient should have full blood count and liver function tests regularly monitored.
Retail pharmacy - subsidy by endorsement a) Subsidised for:i) patients presenting with first episode schizophrenia or related psychoses; andii) patients suffering from schizophrenia or related psychoses after a trial of an effective dose of risperidone that has been discontinued because of unacceptable side effects or inadequate response. b) Initial prescription must be written by a relevant specialist. c) Subsequent prescriptions may be written by a general practitioner. d) The prescription must be endorsed "certified condition".
Special Authority for Subsidy - Form SA0637Initial application - (National Heart Foundation risk groups A1:1, A1:2, B, C, D or E) only from a relevant specialist or general practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria: All of the following: 1 The patient has been offered 3-6 months of counseling and an opportunity to modify lifestyle; and 2 Any of the following: 2.1 Both: 2.1.1 NHF A1:1 - Clinically proven ischaemic heart disease; and 2.1.2 total cholesterol > 5.5; or 2.2 Both: 2.2.1 NHF A1:2 - Post coronary artery bypass graft (CABG) or angioplasty; and 2.2.2 total cholesterol > 4.5; or 2.3 Post heart transplant (regardless of cholesterol level); or 2.4 Both: 2.4.1 NHF B: Patients with > 20% 5-year cardiovascular disease risk; and 2.4.2 total cholesterol > 9.0; or 2.5 Both: 2.5.1 NHF C: 15-20% 5-year cardiovascular disease risk; and 2.5.2 total cholesterol >
Note: only one multidose cartridge starter pack to be prescribed and dispensed per patient per approval.
Special Authority for Subsidy - Form SA0639Initial application - (No previous use) only from a relevant specialist or general practitioner. Approvals valid for 3 months for applications meeting the following criteria: All of the following: 1 The patient has a clinical diagnosis of heavy menstrual bleeding; and 2 The patient has failed to respond to or is unable to tolerate other appropriate pharmaceutical therapies as per the Heavy Menstrual Bleeding Guidelines; and 3 Either: 3.1 serum ferritin level < 16 mg/l (within the last 12 months); or 3.2 haemoglobin level < 120 g/l . NoteApplications are not to be made for use in patients as contraception except where they meet the above criteriaInitial application - (Previous use before 1 October 2002) only from a relevant specialist or general practitioner. Approvals valid for 3 months for applications meeting the following criteria: All of the following: 1 The patient had a clinical diagnosis of heavy menstrual bleeding; and 2
Special Authority for Manufacturers Price - Form SA0640Initial application only from a relevant specialist. Approvals valid for 3 years where patients being treated for advanced breast cancer who are refractory to tamoxifen. Renewal only from a relevant specialist. Approvals valid for 3 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Waiver of Rule - Form SA0641Initial application only from a diabetologist, general physician or paediatrician. Approvals valid without further renewal unless notified for applications meeting the following criteria: Either: 1 Both: 1.1 Use alone (monotherapy); and 1.2 The patient is unable to use any other insulins including those on insulin pump treatment; or 2 Both: 2.1 Use with insulin other than insulin isophane (including ready-mixed preparations); and 2.2 A reasonable trial of insulin isophane has been undertaken and it is not effective or not well tolerated. Note"Reasonable trial", "unable to use", "not effective", "not well tolerated", and "not well tolerated" are not defined and we ask clinicians to use their clinical judgement in interpreting these terms.
Special Authority for Subsidy - Form SA0643Initial application - (CML) only from an oncologist or relevant specialist. Approvals valid for 7 months where approved by the The Glivec Co-ordinator. Initial application - (GIST) only from an oncologist. Approvals valid for 1 year where approved by the The Glivec Co-ordinator. Renewal - (CML) only from an oncologist or relevant specialist. Approvals valid for 6 months where approved by the The Glivec Co-ordinator. Initial application - (GIST) only from an oncologist. Approvals valid for 1 year where approved by the The Glivec Co-ordinator. NoteApplication forms are available from, and prescriptions should be sent to: The Glivec Co-ordinatorPhone: 09 580 9176Level 3, Unisys HouseFacsimile: 09 580 9205650 Great South Road, PenroseEmail: murray@ppc.govt.nzPrivate Bag, AUCKLANDSpecial Authority criteria for CML - access by applicationFunded for patients with diagnosis (confirmed by a haematologist) of a chronic myeloid leukaemia (CML) i
Special Authority for Subsidy - Form SA0645Initial application only from a renal physician. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 Both: 1.1 patient in chronic renal failure; and 1.2 Haemoglobin <= 100 g/L; and 2 Either: 2.1 Both: 2.1.1 patient is not diabetic; and 2.1.2 glomerular filtration rate <= 30 ml/min; or 2.2 Both: 2.2.1 patient is diabetic; and 2.2.2 glomerular filtration rate <= 45 ml/min. Renewal only from a renal physician. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment. NoteErythropoietin beta is indicated in the treatment of anaemia associated with chronic renal failure (CRF) where no cause for anaemia other than CRF is detected and there is adequate monitoring of iron stores and iron replacement therapy. The Cockroft-Gault Formula may be used to estimate glomerular filtration rate (GFR) in persons 18 years and over:GFR (male)
Special Authority for Subsidy - Form SA0646Initial application only from a renal physician. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 Both: 1.1 patient in chronic renal failure; and 1.2 Haemoglobin <= 100 g/L; and 2 Any of the following: 2.1 Both: 2.1.1 patient is not diabetic; and 2.1.2 glomerular filtration rate <= 30 ml/min; or 2.2 Both: 2.2.1 patient is diabetic; and 2.2.2 glomerular filtration rate <= 45 ml/min; or 2.3 patient is on haemodialysis or peritoneal dialysis. Renewal only from a renal physician. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment. NoteErythropoietin beta is indicated in the treatment of anaemia associated with chronic renal failure (CRF) where no cause for anaemia other than CRF is detected and there is adequate monitoring of iron stores and iron replacement therapy. The Cockroft-Gault Formula may be used to estim
Special Authority for Manufacturers Price - Form SA0648Initial application - (Conditions other than transient ischaemic episodes) only from a cardiothoracic surgeon, cardiologist or general physician. Approvals valid without further renewal unless notified for applications meeting the following criteria: Either: 1 Patients with prosthetic heart valves - as an adjunct to oral anticoagulation for prophylaxis of thromboembolism; or 2 Patients after coronary artery vein bypass graft - as an adjunct to aspirin or as monotherapy for patients who are aspirin intolerant. NoteAspirin intolerant patients are defined as those with aspirin induced asthma, urticaria, or anaphylaxi, or those with significant aspirin induced bleeding, excluding bruisingInitial application - (Transient ischaemic episodes) only from a neurologist, neuro surgeon, cardiologist, vascular surgeon or general physician. Approvals valid without further renewal unless notified where patients who continue to have transient ischaemic
Special Authority for Subsidy - Form SA0649Initial application - (Conditions other than transient ischaemic episodes) only from a cardiothoracic surgeon, cardiologist or general physician. Approvals valid without further renewal unless notified for applications meeting the following criteria: Either: 1 Patients with prosthetic heart valves - as an adjunct to oral anticoagulation for prophylaxis of thromboembolism; or 2 Patients after coronary artery vein bypass graft - as an adjunct to aspirin or as monotherapy for patients who are aspirin intolerant. NoteAspirin intolerant patients are defined as those with aspirin induced asthma, urticaria, or anaphylaxi, or those with significant aspirin induced bleeding, excluding bruisingInitial application - (Transient ischaemic episodes) only from a neurologist, neuro surgeon, cardiologist, vascular surgeon or general physician. Approvals valid without further renewal unless notified where patients who continue to have transient ischaemic episodes des
Etidronate for osteoporosis should be prescribed for 14 days (400 mg in the morning) and repeated every three months. It should not be taken at the same time of the day as any calcium supplementation (minimum dose - 500 mg per day of elemental calcium). Etidronate should be taken at least 2 hours before or after any food or fluid, except water
Special Authority for Subsidy - Form SA0652Initial application - (Single NAED Therapy) only from a paediatrician, neurologist or general physician. Approvals valid for 15 months for applications meeting the following criteria: Any of the following: 1 Was on NAED therapy before 1 September 2000; or 2 Seizures are not adequately controlled with optimal older anti-epilepsy drug treatment; or 3 Seizures are controlled adequately but who experience unacceptable side effects from older anti-epilepsy drug treatment. Note"Optimal older anti-epilepsy drug therapy" is defined as treatment with those older anti-epilepsy drugs which are indicated and clinically appropriate for the patient, given singly and in combination in adequate doses for the patient's age, weight, and other features affecting the pharmacokinetics of the drug with good evidence of complianceInitial application - (Dual NAED Therapy) only from a paediatrician, neurologist or general physician. Approvals valid for 18 months for app
Additional subsidy by endorsement for:Calcium carbonate tablets x 1,000 (Titralac) up to $35.10 is available for pregnant women. The prescription must be endorsed accordingly. We recommend that the words used to indicate eligibility are "certified condition" however these particular words are not a requirement.
Special Authority for Subsidy - Form SA0657Initial application - (Helicobacter pylori infections) only from a general practitioner or relevant specialist. Approvals valid for 6 months for applications meeting the following criteria: Both: 1 Eradication of Helicobacter pylori in patient with proven infection; and 2 Peptic ulcer disease proven by endoscopy. NoteMaximum of two prescriptions (two courses) per patient. Initial application - (Mycobacterial infections) only from a respiratory specialist, infectious disease specialist or paediatrician. Approvals valid for 2 years for applications meeting the following criteria: Any of the following: 1 Mycobacterium Avium Intracellulare Complex infections in patient with AIDS; or 2 Atypical and drug-resistant mycobacterial infection; or 3 All of the following: 3.1 Prophylaxis against disseminated Mycobacterium Avium Intracellulare Complex infection; and 3.2 HIV infection; and 3.3 CD4 count <= 50 cells/mm3. Renewal - (Mycobact
Additional subsidy by endorsement for:Moclobemide tab 150 mg x 500 (Apo-Moclobemide) up to $46.00Moclobemide tab 150 mg x 100 (Aurorix) up to $32.90Moclobemide tab 300 mg x 100 (Apo-Moclobemide) up to $26.11Moclobemide tab 300 mg x 60 (Aurorix) up to $39.48Nefazodone tab 100 mg x 56 (Serzone) up to $20.16Nefazodone tab 200 mg x 56 (Serzone) up to $40.32Citalopram tab 20 mg x 28 (Celapram) up to $4.00Citalopram tab 20 mg x 28 (Cipramil) up to $10.00Paroxetine hydrochloride tab 20 mg x 30 (Aropax) up to $35.02is available for patients who: - were taking moclobemide or nefazodone on 1 December 1999 or citalopram on 1 February 2000; or paroxetine hydrochloride on February 2001; or- have previously responded to treatment with moclobemide or nefazodone or citalopram or paroxetine hydrochloride; or- have had a trial of fluoxetine and have had to discontinue due to- inability to tolerate the drug due to side effects; or- failed to respond to an adequate dose and duration of treatment; or
Special Authority for Subsidy - Form SA0661Initial application only from a psychiatrist. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 The patient has "treatment resistant" depression; and 2 Either: 2.1 The patient must have had a trial of two different antidepressants and failed to respond to an adequate dose over an adequate period of time (usually at least four weeks); or 2.2 Both: 2.2.1 The patient is currently a hospital in-patient as a result of an acute depressive episode; and 2.2.2 The patient must have had a trial of one other antidepressant and failed to respond to an adequate dose over an adequate period of time. Renewal from any medical practitioner. Approvals valid for 2 years where patient has a high risk of relapse (prescriber determined)..NoteFirst prescription can be written by a psychiatrist or psychiatric registrar. Subsequent prescriptions may be written by a General Practitioner
Prescribing GuidelinesBoth Trusopt and Cosopt are subsidised for use as either monotherapy or as an adjunctive agent for the treatment of glaucoma. Trusopt and Cosopt should not be prescribed for a person in whom less expensive first line agents for the treatment of glaucoma are not contraindicated unless: i) that person has previously trialled all other such subsidised agents (except brimonidine tartrate); andii) those trials have indicated that that person does not respond adequately to treatment with those other agents.
a) Spacer devices and masks also available to paediatricians employed by a DHB on a wholesalesupply order signed by the paediatrician. Limited to one pack of 20 per order. Orders via ahospital pharmacy. b) Only available for children aged six years and under. c) For Space Chamber and Foremount Child's Silicone Mask wholesale supply order must indicate clearly if either the spacer device, the mask, or both are required. d) Distributed by Airflow Products. Forward orders to: Airflow ProductsPO Box 1485 Telephone: 04 499 1240 or 0800 AIR FLOWWellington Facsimile: 04 499 1245 or 0800 323 270
Special Authority for Subsidy - Form SA0667Initial application only from a named specialist. Approvals valid for 4 months for applications meeting the following criteria: All of the following: 1 To be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and 2 Patient is less than 18 years of age at commencement of treatment; and 3 Patient has had severe active polyarticular course Juvenile Idiopathic Arthritis (JIA) for 6 months duration or longer; and 4 Patient has tried and not responded to at least three months of oral or parenteral methotrexate at a dose of 10-20mg/m2 weekly in combination with oral corticosteroids (prednisone 0.25 mg/kg); and 5 Patient has tried and not responded to at least three months of oral or parenteral methotrexate (at a dose of 10-15mg/m2 weekly) in combination with one other disease-modifying agent; and 6 Both: 6.1 Either: 6.1.1 Patient has persistent symptoms of poorly-cont
Note: Due to uncertainty around the long term effects of Selegiline it is not recommended as a first line agent.
Special Authority for Subsidy - Form SA0669Initial application only from a relevant specialist. Approvals valid without further renewal unless notified where organ transplant recipients. NoteSubsidy applies for either primary or rescue therapy
Note: There is a significant cost differential between moclobemide and fluoxetine (moclobemide being about three times more expensive). For depressive syndromes it is therefore more cost-effective to start treatment with fluoxetine first before considering prescribing moclobemide.
Additional subsidy by endorsement for:Nefazodone tab 100 mg x 56 (Serzone) up to $20.16Nefazodone tab 200 mg x 56 (Serzone) up to $40.32Citalopram tab 20 mg x 28 (Celapram) up to $4.00Citalopram tab 20 mg x 28 (Cipramil) up to $10.00Paroxetine hydrochloride tab 20 mg x 30 (Aropax) up to $35.02is available for patients who: -were taking nefazodone on 1 December 1999 or citalopram on 1 February 2000; or paroxetine hydrochloride on February 2001; or- have previously responded to treatment with nefazodone or citalopram or paroxetinehydrochloride; or- have had a trial of fluoxetine and have had to discontinue due to- inability to tolerate the drug due to side effects; or- failed to respond to an adequate dose and duration of treatment; or- have contraindications to fluoxetine (eg pre-existing significant levels of nausea, breastfeeding, potential drug interactions). The prescription must be endorsed accordingly.
Special Authority for Manufacturers Price - Form SA0673Initial application from any medical practitioner. Approvals valid for 3 months for applications meeting the following criteria: Both: 1 Patient considered unsafe to switch to m-Eslon; and 2 Patient was stabilised and well controlled on Kapanol, MST or LA-Morph before 1 December 2003. NoteSpecial Authority effective from 1 February 2004 to 31 July 2004
Note: Combivir counts as two anti-retroviral medications for the purposes of the anti-retroviral Special Authority
Only in extemporaneously compounded codeine linctus diabetic or codeine linctus paediatric
Rapid acting insulin analogues are subsidised when: 1) prescribed with insulin isophane or insulin glargine but are on a different prescription and the prescription is endorsed accordingly; or prescribed on the same prescription as insulin isophane or insulin glargine in which case the prescription is deemed to be endorsed; or2) a Special Authority has been approved. For 1and 2 first prescription to be written by a specialist (diabetologist, general physician or paediatrician). Any medical practitioner can writte subsequent prescriptions.
Additional subsidy by Special Authority - Retail Pharmacy - for: - Nifedipine tab long-acting 30mg x 30 (Adalat Oros) up to $19.90 - Nifedipine tab long-acting 60mg x 30 (Adalat Oros) up to $29.50
Additional subsidy by Special Authority - Retail Pharmacy - for: - Amlodipine 5mg x 30 (Norvasc) up to $19.90 - Amlodipine 10mg x 30 (Norvasc) up to $29.50
Only in combination with a dermatological galenical or as a diluent for a proprietary Topical Corticosteroid - Plain.
Special Authority for Subsidy - Form SA0692Initial application from any specialist. Approvals valid for 11 months where patient has chronic, genotype 1 hepatitis C.
Special Authority for Subsidy - Form SA0693Initial application only from a relevant specialist or vocationally registered general practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria: All of the following: 1 Severe osteoporosis; and 2 History of one previous significant osteoporotic fracture demonstrated radiologically; and 3 T-Score <= -3.0 (bone mass density (BMD) >= 3.0 standard deviations below the mean normal value in young adults). NoteIn line with the Australian guidelines for funding alendronate, a vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral bodyRenewal - ((2 year approvals granted before February 2002)) only from a geriatrician, rheumatologist, endocrinologist, gynaecologis
Subsidy is available for patients with poorly controlled asthma where: a) at least three months of 750 mcg or more daily of inhaled beclomethasone or budesonide (or 400 mcg or fluticasone) for adults has been used; orb) at least three months of 400 mcg or more daily inhaled beclomethasone or budesonide (or 200 mcg or fluticasone) for children has been used; The prescription must be endorsed accordingly. We recommend that the words used to indicate eligibility are "poor control with ICS" or "certified exemption".
Special Authority for Subsidy - Form SA0696Initial application - (Narcolepsy) only from a neurologist or respiratory specialist. Approvals valid for 24 months where narcolepsy. Initial application - (ADHD in patients 5 or over) only from a paediatrician, psychiatrist or general practitioner on the recommendation of such a specialist. Approvals valid for 24 months for applications meeting the following criteria: All of the following: 1 ADHD (Attention Deficit and Hyperactivity Disorder) patients aged 5 years or over; and 2 Diagnosed according to DSM-IV or ICD 10 criteria; and 3 Either: 3.1 Applicant is a specialist; or 3.2 Both: 3.2.1 Applicant is a GP and a specialist has recommended treatment; and 3.2.2 Provide name of specialist (Details to be attached to application). Initial application - (ADHD in patients under 5) only from a paediatrician or psychiatrist. Approvals valid for 12 months for applications meeting the following criteria: Both: 1 ADHD (Attention Defi
Special Authority for Subsidy - Form SA0698Initial application only from a gastroenterologist, general surgeon or general physician. Approvals valid for 3 months for applications meeting the following criteria: Both: 1 Mild to moderate ileal, ileocaecal or proximal Crohn's disease; and 2 Any of the following: 2.1 Diabetes; or 2.2 Cushingoid habitus; or 2.3 Osteoporosis where there is significant risk of fracture; or 2.4 Severe acne following treatment with conventional corticosteroid therapy. Renewal only from a gastroenterologist, general surgeon or general physician. Approvals valid for 3 months where the treatment remains appropriate and the patient is benefiting from treatment. The patient must have had no more than 1 prior approval in the last year. NoteClinical trials for Entocort CIR use beyond three months demonstrated no improvement in relapse rate.
Special Authority for Subsidy - Form SA0699Initial application from any medical practitioner. Approvals valid for 1 year for applications meeting the following criteria: All of the following: 1 The patient is not predisposed to heart arrhythmias; and 2 The patient does not have a pre-existing QT-prolongation or hepatic failure; and 3 The patient is not using other medications which either inhibit the cytochrome P450 3A4 enzyme system or prolong the QT interval; and 4 Any of the following: 4.1 Both: 4.1.1 adult with severe reflux oesophagitis; and 4.1.2 other treatment, including acid suppression with proton pump inhibitors, has failed; or 4.2 gastroparesis; or 4.3 malignancy of GI tract causing gastroparesis (or gastric outlet obstruction); or 4.4 child (not including infants from 0 to 3 months of age who were born prematurely) with severe gastro-oesophageal reflux; and 5 Diagnosis has been made or confirmed by a general physician, gastroenterologist, or ge
Special Authority for Subsidy - Form SA0700Initial application only from an ophthalmologist. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 Both: 1.1 Monotherapy in primary open-angle glaucoma; and 1.2 Any of the following: 1.2.1 Patient cannot tolerate Beta-blockers, Pilocarpine and Dorzolamide; or 1.2.2 Beta-blockers, Pilocarpine and Dorzolamide are contraindicated; or 1.2.3 A reduction in intraocular pressure of 15% or more is not achieved or maintained using dorzolamide either alone or in combination with a beta-blocker; or 1.2.4 There is progressive visual field loss and/or optic nerve damage persists after treatment with dorzolamide either alone or in combination with a beta-blocker; or 2 Adjunctive use for the treatment of patients who have met the initial application criteria, and in whom latanoprost monotherapy has been ineffective in controlling intraocular pressure.Note An adjunctive agent may be added without a
Special Authority for Subsidy - Form SA0702Initial application - (Oral feed for cystic fibrosis patient) only from a relevant specialist. Approvals valid for 3 years for applications meeting the following criteria: Both: 1 Cystic fibrosis; and 2 Either: 2.1 The product is to be used as a supplement; or 2.2 The product is to be used as a complete diet.Initial application - (Oral feed for indications other than cystic fibrosis) only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria: Both: 1 Any of the following: 1.1 any condition causing malabsorption; or 1.2 failure to thrive; or 1.3 increased nutritional requirements; and 2 Either: 2.1 The product is to be used as a supplement; or 2.2 The product is to be used as a complete diet.Renewal - (Oral feed cystic fibrosis patient) only from a relevant specialist or general practitioner on the recommendation of such a specialist. Approvals valid for 3 years f
Special Authority for Subsidy - Form SA0703Initial application only from a relevant specialist or general practitioner. Approvals valid for 2 years for applications meeting the following criteria: All of the following: 1 Patient has raised blood pressure; and 2 The use of fully funded beta blockers is contraindicated, or not well tolerated; or where use of fully funded beta blockers and diuretics are insufficient to control blood pressure adequately at appropriate doses; and 3 Either: 3.1 Has been treated with, and cannot tolerate two ACE inhibitors, due to persistent cough; or 3.2 Has experienced angioedema on an ACE inhibitor at any time in the past or who have experienced angioedema (even if not using an ACE inhibitor) in the last 2 years. Renewal only from a relevant specialist or general practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0706Initial application only from a relevant specialist or general practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria: Either: 1 Both: 1.1 Patient with congestive heart failure; and 1.2 Either: 1.2.1 Has been treated with, and cannot tolerate, two ACE inhibitors, due to persistent cough; or 1.2.2 Has experienced angioedema on an ACE inhibitor at any time in the past or who have experienced angioedema (even if not using an ACE inhibitor) in the last 2 years; or 2 All of the following: 2.1 Patient with raised blood pressure; and 2.2 Use of fully funded beta blockers or diuretics are contraindicated; or not well tolerated; or insufficient to control blood pressure adequately at appropriate doses; and 2.3 Either: 2.3.1 Has been treated with, and cannot tolerate, two ACE inhibitors, due to persistent cough; or 2.3.2 Has experienced angioedema on an ACE in
Effective, consistent management of herpes from prescribing to these guidelines will improve patient outcomes. The guidelines on the following four pages are for the prescribing of aciclovir. The guidelines aim to: - improve patient care and clinical outcome through faster, more accessible treatment - protect patients' wider wellbeing by reinforcing the psychosocial aspects of treatment - improve the consistency and breadth of medical management of genital herpes in New Zealand. The guidelines are: - integral to ensuring a consistent, effective treatment regimen- the result of consultation with clinicians and patient representatives- set out in line with the recommended international algorithm format for treatment. The guidelines are endorsed by the Herpes Foundation's professional advisory board whose members represent venereology, NZDS, RNZCGP, RNZCOG, psychotherapy and nursing. Herpes Foundation Helpline: Toll free 0508 11 12 13Auckland Branch Herpes Foundation: 09 360 1966
Guidelines for the use of interferon in the treatment of hepatitis C: Physicians considering treatment of patients with hepatitis C should discuss cases with a gastroenterologist or aninfectious disease physician. All subjects undergoing treatment require careful monitoring for side effects. Patients should be otherwise fit. Hepatocellular carcinoma should be excluded by ultrasound examination and alpha-fetoprotein level. Criteria for Treatment a) Diagnosis- Anti-HCV positive on at least two occasions with a positive PCR for HCV-RNA and preferably confirmed by asupplementary RIBA test; or- PCR-RNA positive for HCV on at least 2 occasions if antibody negative; or- Anti-HCV positive on at least two occasions with a positive supplementary RIBA test with a negative PCR forHCV RNA but with a liver biopsy consistent with 2(b) following. b) Establishing Active Chronic Liver Disease- Confirmed HCV infection and serum ALT/AST levels measured on at least three occasions over six monthsaveraging >
Special Authority for Subsidy - Form SA0710Initial application only from an ophthalmologist. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 Either: 1.1 Monotherapy in primary open-angle glaucoma; or 1.2 Adjunctive use for the treatment of open-angle glaucoma in a patient who has met the initial application criteria, and in whom prostaglandin analogue monotherapy has been ineffective in controlling intraocular pressure; and 2 Any of the following: 2.1 Patient cannot tolerate beta-blockers, pilocarpine, and carbonic anhydrase inhibitors; or 2.2 Beta-blockers, pilocarpine and carbonic anhydrase inhibitors are contraindicated; or 2.3 A reduction in intraocular pressure of 15% or more is not achieved or maintained using carbonic anhydrase inhibitor either alone or in combination with a beta blocker; or 2.4 There is progressive visual field loss and/or optic nerve damage persists after treatment with carbonic anhydrase inhibitor either alo
Special Authority for Subsidy - Form SA0713Initial application from any specialist. Approvals valid for 11 months for applications meeting the following criteria: Either: 1 Patient has chronic hepatitis C, genotype 1, 4, 5 or 6 infection; or 2 Patient has chronic hepatitis C, genotype 2 or 3 infection with bridging fibrosis or cirrhosis (Metavir stage 3 or 4, or equivalent).
Special Authority for Subsidy - Form SA0714Initial application from any medical practitioner. Approvals valid for 3 months for applications meeting the following criteria: All of the following: 1 Patient is currently enrolled in a recognised comprehensive treatment programme for alcohol dependence in a service accredited against the New Zealand Alcohol and Other Drug Sector Standard or the National Mental Health Sector Standard; and 2 Applicant works in an Alcohol & Drug Service; and 3 Applicant must include the address of the service (Details to be attached to application). Renewal from any medical practitioner. Approvals valid for 3 months for applications meeting the following criteria: Both: 1 Compliance with the medication (prescriber determined); and 2 Any of the following: 2.1 Patient is still unstable and requires further treatment; or 2.2 Patient achieved significant improvement but requires further treatment; or 2.3 Patient is well controlled but requires maint
Prescribing GuidelinesTrusopt, Cosopt and Azopt are subsidised for use as either monotherapy or as an adjunctive agent for the treatment of glaucoma. Trusopt, Cosopt and Azopt should not be prescribed for a person in whom less expensive first line agents for the treatment of glaucoma are not contraindicated unless: a) that person has previously trialled all other such subsidised agents (except brimonidine tartrate); andb) those trials have indicated that that person does not respond adequately to treatment with those other agents.
Prescribing GuidelineTreatment with HMG CoA Reductase Inhibitors (statins) is recommended for patients with dyslipidaemia and an absolute 5 year cardiovascular risk of 15% or greater.
Special Authority for Manufacturers Price - Form SA0717Initial application only from a relevant specialist or general practitioner. Approvals valid for 12 weeks for applications meeting the following criteria: Both: 1 Patient has a calculated absolute risk of cardiovascular disease of at least 15% over 5 years; and 2 Either: 2.1 Patient has severe documented intolerance to simvastatin; or 2.2 Both: 2.2.1 Patient has been compliant with a dose of simvastatin of 80 mg per day for at least 2 months; and 2.2.2 Either: 2.2.2.1 All of the following: 2.2.2.1.1 Patient has venous CABG; and 2.2.2.1.2 LDL cholesterol test 1 >= 2.0 mmol/litre; and 2.2.2.1.3 LDL cholesterol test 2 >= 2.0 mmol/litre (at least 1 week after test 1); or 2.2.2.2 All of the following: 2.2.2.2.1 Patient does not have venous CABG; and 2.2.2.2.2 LDL cholesterol test 1 >= 2.5 mmol/litre; and 2.2.2.2.3 LDL cholesterol test 2 >= 2.5 mmol/litre (at least 1 w
Special Authority for Subsidy - Form SA0721Initial application only from a named specialist. Approvals valid without further renewal unless notified for applications meeting the following criteria: All of the following: 1 The patient already has a Special Authority approval for anti-retroviral therapy (Details to be attached to application); and 2 Kaletra is to be used as a salvage therapy in place of one protease inhibitor; and 3 The patient must have trialed for at least six months and have failed on currently funded NNRTI based regimens or triple NRTI regimens; and 4 The patient must have trialed for at least six months and have failed on currently funded PI based regimens. NoteFailure is defined as: a) not achieving HIV RNA < 400 copies/ml after 24 weeks of a regimen, orb) an increase of HIV RNA to > 400 copies/ml on two separate occasions not less than one month apart, after suppression to < 400 copies/ml in a patient taking the regimen.
Special Authority for Subsidy - Form SA0722Initial application only from a relevant specialist. Approvals valid without further renewal unless notified for applications meeting the following criteria: Either: 1 Gluten enteropathy has been diagnosed by biopsy; or 2 Patient suffers from dermatitis herpetiformis.
Special Authority for Subsidy - Form SA0723Initial application only from a relevant specialist. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 All of the following: 1.1 Patient has a calculated absolute risk of cardiovascular disease >20% over 5 years; and 1.2 Patient cannot tolerate statin therapy at a dose of 40 mg per day; and 1.3 Either: 1.3.1 All of the following: 1.3.1.1 Patient has venous CABG; and 1.3.1.2 LDL cholesterol >= 2.0 mmol/litre (see note); and 1.3.1.3 LDL cholesterol >= 2.0 mmol/litre (at least 1 week after test 1 - see note); or 1.3.2 All of the following: 1.3.2.1 Patient does not have venous CABG; and 1.3.2.2 LDL cholesterol >= 2.5 mmol/litre (see note); and 1.3.2.3 LDL cholesterol >= 2.5 mmol/litre (at least 1 week after test 1 - see note); or 2 All of the following: 2.1 Patient has homozygous familial hypercholesterolemia, or heterozygous familial hypercholesterol
Special Authority for Manufacturers Price - Form SA0724Initial application only from a relevant specialist or general practitioner. Approvals valid for 12 weeks for applications meeting the following criteria: Both: 1 Patient has a calculated absolute risk of cardiovascular disease of at least 15% over 5 years; and 2 Either: 2.1 Patient has severe documented intolerance to simvastatin (blood tests are not required); or 2.2 Both: 2.2.1 Patient has been compliant with a dose of simvastatin of 80 mg per day for at least 2 months; and 2.2.2 Either: 2.2.2.1 All of the following: 2.2.2.1.1 Patient has venous CABG; and 2.2.2.1.2 LDL cholesterol test 1 >= 2.0 mmol/litre; and 2.2.2.1.3 LDL cholesterol test 2 >= 2.0 mmol/litre (at least 1 week after test 1); or 2.2.2.2 All of the following: 2.2.2.2.1 Patient does not have venous CABG; and 2.2.2.2.2 LDL cholesterol test 1 >= 2.5 mmol/litre; and 2.2.2.2.3 LDL cholesterol test 2 >
Special Authority for Subsidy - Form SA0725Initial application only from a relevant specialist or general practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria: All of the following: 1 Patient with raised blood pressure; and 2 Use of fully funded beta blockers and diuretics are contraindicated; or not well tolerated; or insufficient to control blood pressure adequately at appropriate doses; and 3 Either: 3.1 Has been treated with, and cannot tolerate, two ACE inhibitors, due to persistent cough; or 3.2 Has experienced angioedema on an ACE inhibitor at any time in the past or who have experienced angioedema (even if not using an ACE inhibitor) in the last 2 years. Renewal - (Previous approval has expired) only from a relevant specialist or general practitioner. Approvals valid without further renewal unless notified where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0727Initial application from any medical practitioner. Approvals valid for 1 year for applications meeting the following criteria: All of the following: 1 Control of intractable nausea, vomiting, or inability to swallow saliva in the treatment of malignancy or chronic disease; and 2 Patient cannot tolerate or does not adequately respond to oral anti-nausea agents; and 3 The applicant must specify the underlying malignancy or chronic disease (Details to be attached to application). Renewal from any medical practitioner. Approvals valid for 1 year where the treatment remains appropriate and the patient is benefiting from treatment.
Retail pharmacy - subsidy by endorsement a) Subsidised for:(i) patients presenting with first episode schizophrenia or related psychoses, or manic episodes associated with bipolar disorder; and(ii) patients suffering from schizophrenia or related psychoses, or manic episodes associated with bipolar disorder, after a trial of an effective dose of risperidone that has been discontinued because of unacceptable side effects or inadequate response. b) Initial prescription must be written by a relevant specialist. c) Subsequent prescriptions may be written by a general practitioner. d) The prescription must be endorsed "certified condition".
Only in extemporaneously compounded methadone mixture, codeine linctus diabetic or codeine linctus paediatric or phenobarbitone oral liquid
Special Authority for Subsidy - Form SA0732Initial application only from a relevant specialist. Approvals valid for 3 years for applications meeting the following criteria: Either: 1 dietary management of homocystinuria; or 2 dietary management of maple syrup urine disease. Renewal only from a relevant specialist or general practitioner on the recommendation of such a specialist. Approvals valid for 1 year for applications meeting the following criteria: Both: 1 The treatment remains appropriate and the patient is benefiting from treatment; and 2 General Practitioners must include the name of the specialist and date contacted.
Special Authority for Subsidy - Form SA0733Initial application - (Patient aged over 16) only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria: Both: 1 dietary management of PKU; and 2 blood phenylalanine level < 900 mmol/litre (average of tests over last 12 months). Initial application - (Patient aged 16 or under) only from a relevant specialist. Approvals valid for 3 years where dietary management of PKU.Renewal - (Patient aged over 16) only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria: blood phenylalanine level < 900 mmol/litre (average of tests over last 12 months). Renewal - (Patient aged 16 or under) only from a relevant specialist or general practitioner on the recommendation of such a specialist. Approvals valid for 3 years for applications meeting the following criteria: Both: 1 The treatment remains appropriate and the patient is benefiting from treatment; and 2
GuidelinesIt can cost up to $70,000 a year to keep an adult on protein supplements. Because protein substitutes are so expensive and because they are only effective in controlling PKU if a restricted diet is followed, adults with PKU will be required to demonstrate they are following the prescribed diet by regular blood testing. The requirement for testing applies to those aged over 16 years. Failure to follow an appropriate diet results in high blood phenylalanine levels. Those consistently testing above 15 mg (900 micromol) over a twelve month period will not be able to claim these products as a Special Authority. Specialists will be required to renew applications for their PKU patients every year and, when they do so, will have to submit the results of two blood tests.
Neocate should be used only as a last resort when the infant is unable to absorb any of the above formulae. The objective with each of thees formulae prescribed is to get the infant off them as soon as possible. This may take six months, it may take three years. Because of this, variation on age limit is not regarded as appropriate.These formulae will be available only from a hospital pharmacy. Vivonex Pediatric may be a suitable and less expensive alternative for many children that would otherwise be eligible for a subsidy for Neocate and should, therefore, be tried first in these cases. The subsidy for these products reflects the philosophy that the patient incurs no additional financial burden for purchasing specialised more expensive products.
Special Authority for Subsidy - Form SA0738Initial application only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria: Either: 1 All of the following: 1.1 To be used as monotherapy for patients with type 2 diabetes who after six months of diet and lifestyle changes do not have adequate glycaemic control (inadequate control defined as HbA1c > 8.0% in tests carried out at least two months apart); and 1.2 Metformin is not tolerated or contraindicated. Intolerance and contraindications as defined in the notes below, a minimum of a four week trial period of metformin is required; and 1.3 Sulphonylurea is not tolerated or contraindicated. Overweight patients are only eligible under the criteria of contraindication to sulphonylureas if their body mass index (BMI) exceeds 35; or 2 Both: 2.1 For use in combination with a sulphonylurea when diet and lifestyle changes and a twelve month trial of sulphonylurea results in inadequate glycaem
Prescribing GuidelineHRT should be taken at the lowest dose for the shortest period of time necessary to control symptoms. Patients should be reviewed 6 monthly in line with the updated NZGG "Evidence-based Best Practice Guideline on Hormone Replacement Therapy March 2004".
Special Authority for Subsidy - Form SA0741Initial application only from a psychiatrist. Approvals valid for 2 years for applications meeting the following criteria: Any of the following: 1 Patient with first episode schizophrenia or related psychoses; or 2 Both: 2.1 Patient suffering from schizophrenia and related psychoses; or acute mania in bipolar disorder who is likely to benefit from anti-psychotic treatment; and 2.2 Either: 2.2.1 An effective dose of risperidone had been trialled and has been discontinued because of unacceptable side effects; or 2.2.2 An effective dose of risperidone had been trialled and has been discontinued because of inadequate clinical response after 4 weeks; or 3 The patient has suffered from an acute episode of schizophrenia or bipolar mania and has been treated with olanzapine short-acting intra-muscular injection. Renewal only from a psychiatrist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefit
Special Authority for Subsidy - Form SA0742Initial application - (genotype 1, 4, 5 or 6 infection) from any specialist. Approvals valid for 11 months where patient has chronic hepatitis C, genotype 1, 4, 5 or 6 infection. Initial application - (genotype 2 or 3 infection) from any specialist. Approvals valid for 6 months for applications meeting the following criteria: Both: 1 Patient has chronic hepatitis C, genotype 2 or 3 infection; and 2 Patient has bridging fibrosis or cirrhosis (Metavir stage 3 or 4 or equivalent).
Special Authority for Subsidy - Form SA0743Initial application only from a relevant specialist. Approvals valid for 3 months for applications meeting the following criteria: Both: 1 Patient is terminally ill and is opioid-responsive; and 2 Either: 2.1 is unable to take oral medication; or 2.2 is intolerant to morphine, or morphine is contraindicated..Renewal only from a relevant specialist or general practitioner. Approvals valid for 3 months where the treatment remains appropriate and the patient is benefiting from treatment.
Additional subsidy by endorsement for:Citalopram tab 20 mg x 28 (Celapram) up to $4.00Citalopram tab 20 mg x 28 (Cipramil) up to $10.00Paroxetine hydrochloride tab 20 mg x 30 (Aropax) up to $35.02is available for patients who: -were taking citalopram on 1 February 2000; or paroxetine hydrochloride on February 2001; or- have previously responded to treatment with citalopram or paroxetinehydrochloride; or- have had a trial of fluoxetine and have had to discontinue due to- inability to tolerate the drug due to side effects; or- failed to respond to an adequate dose and duration of treatment; or- have contraindications to fluoxetine (eg pre-existing significant levels of nausea, breastfeeding, potential drug interactions). The prescription must be endorsed accordingly.
Special Authority for Subsidy - Form SA0750Initial application only from a relevant specialist. Approvals valid without further renewal unless notified where continuation of previous therapy.
Special Authority for Subsidy - Form SA0751Initial application only from an ophthalmologist. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 Either: 1.1 Monotherapy in primary open-angle glaucoma; or 1.2 Adjunctive use for the treatment of open-angle glaucoma in a patient who has met the initial application criteria, and in whom prostaglandin analogue monotherapy has been ineffective in controlling intraocular pressure; and 2 Any of the following: 2.1 Patient cannot tolerate beta-blockers, pilocarpine, and carbonic anhydrase inhibitors; or 2.2 Beta-blockers, pilocarpine and carbonic anhydrase inhibitors are contraindicated; or 2.3 A reduction in intraocular pressure of 15% or more is not achieved or maintained using carbonic anhydrase inhibitor either alone or in combination with a beta blocker; or 2.4 There is progressive visual field loss and/or optic nerve damage persists after treatment with carbonic anhydrase inhibitor either alo
(a) Subsidy is available between 1 March and 30 June of each year for patients who meet the following criteria, as set by the Ministry of Health: a) all people 65 years of age and over; b) people under 65 years of age with: i) the following cardiovascular disease: 1) ischaemic heart disease, 2) congestive heart disease, 3) rheumatic heart disease, 4) congenital heart disease, or 5) cerebo-vascular disease; ii) the following chronic respiratory disease: 1) asthma, if on a regular preventative therapy, or 2) other chronic respiratory disease with impaired lung function; iii) diabetes; iv) chronic renal disease; v) any cancer, excluding basal and squamous skin cancers if not invasive; vi) the following other conditions: 1) autoimmune disease, 2) immune suppression, 3) HIV, 4) transplant recipients, 5) neuromuscular and CNS diseases, 6) haemoglobinopathies, or 7) children on long term aspirin. The following conditions are excluded from funding: i) asthma not requiri
Special Authority for Manufacturers Price - Form SA0753Initial application only from a relevant specialist. Approvals valid for 3 years for applications meeting the following criteria: Both: 1 Patient is a postmenopausal women; and 2 Patient has hormone receptor positive advanced breast cancer (Stage IIIb, or metastatic Stage IV). Renewal only from a relevant specialist. Approvals valid for 3 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0754Initial application only from a named specialist. Approvals valid without further renewal unless notified for applications meeting the following criteria: All of the following: 1 The patient already has a Special Authority approval for anti-retroviral therapy (Details to be attached to application); and 2 Kaletra is to be used as a salvage therapy in place of one protease inhibitor; and 3 The patient must have trialed for at least six months and have failed on currently funded NNRTI based regimens or triple NRTI regimens; and 4 The patient must have trialed for at least six months and have failed on currently funded PI based regimens. NoteFailure is defined as: a) not achieving HIV RNA < 400 copies/ml after 24 weeks of a regimen, orb) an increase of HIV RNA to > 400 copies/ml on two separate occasions not less than one month apart, after suppression to < 400 copies/ml in a patient taking the regimen.
Special Authority for Subsidy - Form SA0755Initial application from any medical practitioner. Approvals valid for 2 years where the patient is likely to benefit from treatment. Note Applications to be made on the approved forms which are available from: Prof. Wayne CutfieldNational Co-ordinatorNew Zealand Growth Hormone CommitteeC/- Department of PaediatricsUniversity of AucklandPrivate Bag 92019AUCKLAND
Pharmacies cannot claim subsidy because PHARMAC has made alternative distribution arrangements.
Special Authority for Subsidy - Form SA0757Initial application only from a relevant specialist. Approvals valid for 6 months for applications meeting the following criteria: All of the following: 1 The patient is less than 2 years of age; and 2 Intolerant to cows' milk; and 3 Diagnosed as suffering from congenital lactase deficiency. Renewal only from a relevant specialist. Approvals valid for 6 months where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0758Initial application only from a general practitioner or relevant specialist. Approvals valid for 2 years for applications meeting the following criteria: All of the following: 1 To be used for the long-term maintenance treatment of bronchospasm and dyspnoea associated with COPD; and 2 In addition to standard treatment, the patient has trialled a dose of at least 40 mcg ipratropium q.i.d; and 3 The patient's breathlessness >= grade 4 according to the Medical Research Council dyspnoea scale (see note); and 4 FEV1 (litres) < 0.4 x predicted (litres); and 5 Either: 5.1 Patient is not a smoker (for reporting purposes only); or 5.2 Patient is a smoker and been offered smoking cessation councilling; and 6 The patient has been offered annual influenza immunisation. Renewal only from a general practitioner or relevant specialist. Approvals valid for 2 years for applications meeting the following criteria: All of the following: 1
a) Prescribers may code prescriptions "contraceptive" (code "O") when used as indicated for contraception. The period of supply and prescription charge will be as per other contraceptives, as follows: - $3.00 prescription charge (patient co-payment) will apply; - prescription may be written for up to six months supply. b) Prescriptions coded in any other way are subject to the non-contraceptive prescription charges, and the non-contraceptive period of supply. ie. Prescriptions may be written for up to three months supply.
Subject to budgetary cap. Applications will be considered and approved subject to funding availability.
A diagnostic blood glucose test meter is subsidised for patients who begin insulin or sulphonylurea therapy after 1 March 2005. Only one meter per patient. No further prescriptions will be subsidised. The prescription must be endorsed accordingly.
Retail pharmacy - specialist prescriptionPrescriptions must be written by a gastroenterologist
(a) Subsidy is available between 1 March and 30 June of each year for patients who meet the following criteria, as set by the Ministry of Health: a) all people 65 years of age and over; b) people under 65 years of age with: i) the following cardiovascular disease: 1) ischaemic heart disease, 2) congestive heart disease, 3) rheumatic heart disease, 4) congenital heart disease, or 5) cerebo-vascular disease; ii) the following chronic respiratory disease: 1) asthma, if on a regular preventative therapy, or 2) other chronic respiratory disease with impaired lung function; iii) diabetes; iv) chronic renal disease; v) any cancer, excluding basal and squamous skin cancers if not invasive; vi) the following other conditions: 1) autoimmune disease, 2) immune suppression, 3) HIV, 4) transplant recipients, 5) neuromuscular and CNS diseases, 6) haemoglobinopathies, or 7) children on long term aspirin. The following conditions are excluded from funding: i) asthma not requiri
The number of test strips available on a prescription is restricted to 50 unless: a) Prescribed with insulin or a sulphonylurea but are on a different prescription and the prescription is endorsed accordingly; orb) Prescribed on the same prescription as insulin or a sulphonylurea in which case the prescription is deemed to be endorsed; orc) Prescribed for a pregnant woman with diabetes and endorsed accordingly.
Special Authority for Subsidy - Form SA0772Initial application only from a gastroenterologist, infectious disease specialist, paediatrician or general physician. Approvals valid for 1 year for applications meeting the following criteria: Both: 1 Any of the following: 1.1 All of the following: 1.1.1 HBsAg positive for more than 6 months; and 1.1.2 HBeAg positive or HBV DNA positive defined as >0.6 pg/ml by quantitative PCR at reference laboratory; and 1.1.3 ALT greater than twice upper limit of normal or stage 3 or 4 fibrosis on liver histology clinical/radiological evidence of cirrhosis; or 1.2 HBV DNA positive cirrhosis prior to liver transplantation; or 1.3 HBsAg positive and have had a liver, kidney, heart, lung or bone marrow transplant; or 1.4 Hepatitis B surface antigen positive (HbsAg) patient who is receiving chemotherapy for a malignancy, or who has received such treatment within the previous two months; and 2 All of the following: 2.1 No continuing
Additional subsidy by endorsement for:Paroxetine hydrochloride tab 20 mg x 30 (Aropax) up to $35.02is available for patients who: -were taking paroxetine hydrochloride on February 2001; or- have previously responded to treatment with paroxetinehydrochloride; or- have had a trial of fluoxetine and have had to discontinue due to- inability to tolerate the drug due to side effects; or- failed to respond to an adequate dose and duration of treatment; or- have contraindications to fluoxetine (eg pre-existing significant levels of nausea, breastfeeding, potential drug interactions). The prescription must be endorsed accordingly.
Special Authority for Subsidy - Form SA0774Initial application only from a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Any of the following: 1 The patient has advanced gastrointestinal malignancy; or 2 The patient has metastatic breast cancer*; or 3 Both: 3.1 The patient has poor venous access or needle phobia*; and 3.2 The patient requires a substitute for single agent fluoropyrimidine*. Renewal only from a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Either: 1 The patient requires continued therapy; or 2 The tumour has relapsed and requires re-treatment. Noteindications marked with * are unapproved indications.
Special Authority for Subsidy - Form SA0775Initial application only from a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Both: 1 The patient has metastatic colorectal cancer; and 2 Either: 2.1 To be used for first or second line use as part of a combination chemotherapy regimen; or 2.2 As single agent chemotherapy in fluropyrimidine-relapsed disease. Renewal only from a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Either: 1 The patient requires continued therapy; or 2 The tumour has relapsed and requires re-treatment.
Special Authority for Subsidy - Form SA0776Initial application only from a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Any of the following: 1 Both: 1.1 The patient has ovarian, fallopian* or primary peritoneal cancer*; and 1.2 Either: 1.2.1 Has not received prior chemotherapy; or 1.2.2 Has received prior chemotherapy but has not previously been treated with taxanes; or 2 The patient has metastatic breast cancer; or 3 Both: 3.1 The patient has non-small cell lung cancer; and 3.2 Either: 3.2.1 The patient has advanced disease (stage IIIa or above); or 3.2.2 The patient is receiving combined chemotherapy and radiotherapy; or 4 Both: 4.1 The patient has small-cell lung cancer*; and 4.2 Paclitaxel is to be used as second-line therapy. Renewal only from a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Both: 1 The patient has metastati
Special Authority for Subsidy - Form SA0777Initial application - (Post-transplant) only from a relevant specialist. Approvals valid for 6 months where the patient has B-cell post-transplant lymphoproliferative disorder*. NoteFor no more than 8 treatment cycles. Initial application - (Low-grade lymphomas) only from a relevant specialist. Approvals valid for 6 months where the patient has low grade NHL - relapsed disease following prior chemotherapy. NoteFor no more than 4 treatment cycles. Initial application - (Large cell lymphomas) only from a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Both: 1 The patient has treatment naive large B-cell NHL; and 2 To be used with CHOP (or alternative anthracycline containing multi-agent chemotherapy regime given with curative intent).NoteFor no more than 8 treatment cycles. Renewal - (Low-grade lymphomas) only from a relevant specialist. Approvals valid for 6 months for applications meeting
Special Authority for Subsidy - Form SA0779Initial application - (Confirmed HIV/AIDS) only from a named specialist. Approvals valid without further renewal unless notified for applications meeting the following criteria: Both: 1 Confirmed HIV infection; and 2 Any of the following: 2.1 Symptomatic patient; or 2.2 Patient aged 12 months and under; or 2.3 Both: 2.3.1 Patient aged 1 to 5 years; and 2.3.2 Any of the following: 2.3.2.1 CD4 counts < 1,000 cells/mm3; or 2.3.2.2 CD4 counts < 0.25 x total lymphocyte count; or 2.3.2.3 Viral load counts > 100,000 copies per ml; or 2.4 Both: 2.4.1 Patient aged 6 years and over; and 2.4.2 CD4 counts < 350 cells/mm3. NoteTenofovir disoproxil fumarate prescribed under endorsement for HIV/AIDS is included in the count of up to 3 subsidised antiretrovirals. Subsidies for a combination of up to three anti-retroviral medications, including a maximum of two protease inhibitors. Combinations including r
Special Authority for Subsidy - Form SA0780Initial application - (Single NAED Therapy) only from a paediatrician, neurologist or general physician. Approvals valid for 15 months for applications meeting the following criteria: Any of the following: 1 Was on NAED therapy before 1 September 2000; or 2 Seizures are not adequately controlled with optimal older anti-epilepsy drug treatment; or 3 Seizures are controlled adequately but who experience unacceptable side effects from older anti-epilepsy drug treatment. Note"Optimal older anti-epilepsy drug therapy" is defined as treatment with those older anti-epilepsy drugs which are indicated and clinically appropriate for the patient, given singly and in combination in adequate doses for the patient's age, weight, and other features affecting the pharmacokinetics of the drug with good evidence of complianceInitial application - (Dual NAED Therapy) only from a paediatrician, neurologist or general physician. Approvals valid for 18 months for app
Special Authority for Subsidy - Form: SA0781Initial application only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria: Any of the following: Monotherapy1 All of the following: 1.1 To be used as monotherapy for patients with type 2 diabetes who after six months of diet and lifestyle changes do not have adequate glycaemic control (inadequate control defined as HbA1c > 7.0% in tests carried out at least two months apart); and 1.2 Metformin is not tolerated or contraindicated. Intolerance and contraindications as defined in the notes below, a minimum of a four week trial period of metformin is required; and 1.3 Sulphonylurea is not tolerated or contraindicated. Obesity is only eligible under the criteria of contraindication to sulphonylureas if the patient's body mass index (BMI) exceeds 33 , intolerance as defined in the notes below; orIn combination with sulphonylurea2 Both: 2.1 For use in combination with a sulphonylure
Special Authority for Subsidy - Form SA0782Initial application - (No previous use) only from a relevant specialist or general practitioner. Approvals valid for 6 months for applications meeting the following criteria: All of the following: 1 The patient has a clinical diagnosis of heavy menstrual bleeding; and 2 The patient has failed to respond to or is unable to tolerate other appropriate pharmaceutical therapies as per the Heavy Menstrual Bleeding Guidelines; and 3 Either: 3.1 serum ferritin level < 16 mg/l (within the last 12 months); or 3.2 haemoglobin level < 120 g/l . NoteApplications are not to be made for use in patients as contraception except where they meet the above criteriaInitial application - (Previous use before 1 October 2002) only from a relevant specialist or general practitioner. Approvals valid for 6 months for applications meeting the following criteria: All of the following: 1 The patient had a clinical diagnosis of heavy menstrual bleeding; and 2
Special Authority for Manufacturers Price - Form: SA0783Initial application only from a relevant specialist. Approvals valid for 5 years for applications meeting the following criteria: All of the following: 1 Patient is a postmenopausal women; and2 Patient has hormone receptor positive advanced breast cancer; and3 Any of the following: 3.1 The cancer is advanced (Stage IIIb, or metastatic Stage IV); or 3.2 The patient has a very clear history of intolerance to tamoxifen; or 3.3 The use of tamoxifen is contraindicated due to a history of thromboembolic disease. Renewal only from a relevant specialist. Approvals valid without further renewal unless notified where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form: SA0784Initial application from any specialist. Approvals valid for 12 months where patient has chronic hepatitis C (all genotypes).
Prescribing GuidelinePrescribers should note that oxycodone is significantly more expensive than long-acting morphine sulphate and clinical advice suggests that it is reasonable to consider this as a second-line agent to be used after morphine.
Special Authority for Manufacturers Price - Form SA0788Initial application only from a relevant specialist or general practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria: Both: 1 Patient has a calculated absolute risk of cardiovascular disease of at least 15% over 5 years; and 2 Either: 2.1 Patient has severe documented intolerance to simvastatin (blood tests are not required); or 2.2 Both: 2.2.1 Patient has been compliant with a dose of simvastatin of 80 mg per day for at least 2 months; and 2.2.2 Either: 2.2.2.1 All of the following: 2.2.2.1.1 Patient has venous CABG; and 2.2.2.1.2 LDL cholesterol test 1 >= 2.0 mmol/litre; and 2.2.2.1.3 LDL cholesterol test 2 >= 2.0 mmol/litre (at least 1 week after test 1); or 2.2.2.2 All of the following: 2.2.2.2.1 Patient does not have venous CABG; and 2.2.2.2.2 LDL cholesterol test 1 >= 2.5 mmol/litre; and 2.2.2.2.
Special Authority for Subsidy - Form SA0789Initial application only from a relevant specialist or vocationally registered general practitioner. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 The patient has "treatment resistant" depression; and 2 Either: 2.1 The patient must have had a trial of two different antidepressants and failed to respond to an adequate dose over an adequate period of time (usually at least four weeks); or 2.2 Both: 2.2.1 The patient is currently a hospital in-patient as a result of an acute depressive episode; and 2.2.2 The patient must have had a trial of one other antidepressant and failed to respond to an adequate dose over an adequate period of time. Renewal from any medical practitioner. Approvals valid for 2 years where patient has a high risk of relapse (prescriber determined).
Prescribing GuidelineBimatoprost, lantanoprost and travoprost are subsidised for use in the treatment of glaucoma as either monotherapy or as an adjunctive agent for patients in whom prostaglandin analogue monotherapy has been ineffective in controlling intraocular pressure.Bimatoprost, lantanoprost and travoprost should not be prescribed for a person in whom less expensive first line agents for the treatment of glaucoma are not contraindicated unless: 1 That person has previously trialled all other such subsidised agents (beta-blockers, pilocarpine, carbonic anhydrase inhibitors); and2 Those trials have indicated that that person does not respond adequately to treatment with those other agents.
Mycophenolate powder for oral liquid is subsidised only for patients unable to swallow tablets and capsules, and when the prescription is endorsed accordingly.
Special Authority for Subsidy - Form: SA0792Initial application only from a psychiatrist. Approvals valid for 6 months for applications meeting the following criteria: All of the following: 1 The patient has schizophrenia or other psychotic disorder; and2 Has tried but failed to comply with treatment using oral atypical anti-psychotic agents; and3 Has been admitted to hospital or treated in respite care, or intensive outpatient or home-based treatment for 30 days or more in last 12 months. Renewal only from a psychiatrist. Approvals valid for 12 months for applications meeting the following criteria: Either: 4 Both: 4.1 The patient has had less than 12 months treatment with risperidone microspheres; and 4.2 There is no clinical reason to discontinue treatment; or5 The initiation of risperidone microspheres has been associated with fewer days of intensive intervention than was the case during a corresponding period of time prior to the initiation of risperidone microspheres. NoteRisp
a) Subsidised only if prescribed for a dialysis or cystic fibrosis patient; orb) for the treatment of confirmed ciprofloxacin-resistant gonorrhoea; orc) for the treatment of suspected meningitis in patients who have a known allergy to penicillin; andd) the prescription is endorsed accordingly
Special Authority for Subsidy - Form: SA0796Initial application only from a relevant specialist. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 Either: 1.1 ezetimibe is to be used in combination with simvastatin; or 1.2 ezetimibe is to be used without a statin; and2 Either: 2.1 All of the following: 2.1.1 Patient has a calculated absolute risk of cardiovascular disease >20% over 5 years; and 2.1.2 Patient cannot tolerate statin therapy at a dose of 40 mg per day; and 2.1.3 Either: 2.1.3.1 All of the following: 2.1.3.1.1 Patient has venous CABG; and 2.1.3.1.2 LDL cholesterol >= 2.0 mmol/litre (see note); and 2.1.3.1.3 LDL cholesterol >= 2.0 mmol/litre (at least 1 week after test 1 - see note); or 2.1.3.2 All of the following: 2.1.3.2.1 Patient does not have venous CABG; and 2.1.3.2.2 LDL cholesterol >= 2.5 mmol/litre (see note); and 2.1.3.2.3 LDL cholest
Special Authority for Subsidy - Form: SA0797Initial application - (Underlying cause - Osteoporosis) only from a relevant specialist or vocationally registered general practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria: Any of the following: 1 History of one significant osteoporotic fracture demonstrated radiologically and documented bone mass density (BMD) >= 2.5 standard deviations below the mean normal value in young adults (i.e. T-Score <= -2.5); or2 History of one significant osteoporotic fracture demonstrated radiologically and the patient is either over 75 years of age or is too frail* to undergo a bone mass density scan; or3 History of two significant osteoporotic fractures demonstrated radiologically; or4 Documented T-Score <= -3.0. Note*The patient may be considered to be frail if it is expected that there is significant risk of further fracture or other negative health outcome if the patient were to undergo a BMD s
Special Authority for Subsidy - Form: SA0798Initial application only from a relevant specialist. Approvals valid without further renewal unless notified for applications meeting the following criteria: Either: 1 Renal transplant recipient; or2 Heart transplant recipient. or; 3 Patient has an organ transplant and has severe tophaceous gout making azathioprine unsuitableRenewal only from a relevant specialist. Approvals valid without further renewal unless notified where patient had a previous Special Authority approval and was receiving mycophenolate prior to 1 October 2005
Special Authority for Subsidy - Form: SA0799Initial application only from a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Either: 1 The patient has metastatic breast cancer; or2 The patient has non-small cell lung cancer (stage IIIa, or above).Renewal only from a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Either: 3 The patient requires continued therapy; or4 The tumour has relapsed and requires re-treatment.
Special Authority for Subsidy - Form SA0801Initial application - (Serevent Accuhaler, Foradil, Symbicort Turbuhaler) only from a relevant specialist or general practitioner. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 Both: 1.1 Child under the age of 12 with poorly controlled asthma; and 1.2 Either: 1.2.1 Required at least three months of 400 mcg or more daily inhaled beclomethasone or budesonide; or 1.2.2 Required at least three months of 200 mcg or more of fluticasone; or 2 Both: 2.1 Adult with poorly controlled asthma; and 2.2 Either: 2.2.1 Required at least three months of 1500 mcg or more daily inhaled beclomethasone or budesonide; or 2.2.2 Required at least three months of 750 mcg or more of fluticasone. NotePatients are to be reviewed at least at six months to assess compliance and effectiveness of therapy. Special Authority approvals are interchangeable among all presentations of inhaled long-acting beta
Special Authority for Subsidy - Form SA0802Initial application - (genotype 1, 4, 5 or 6 infection or co-infection with HIV) from any specialist. Approvals valid for 11 months for applications meeting the following criteria: 1. Patient has chronic hepatitis C, genotype 1, 4, 5 or 6 infection; or2. Patient has chronic hepatitis C and is co-infected with HIV. Note: consider stopping treatment if there is absence of a virological response (defined as at least a 2-log reduction in viral load) following 12 weeks of treatment since this is predictive of treatment failure.Initial application - (genotype 2 or 3 infection without co-infection with HIV) from any specialist. Approvals valid for 6 months for applications meeting the following criteria: 3. Patient has chronic hepatitis C, genotype 2 or 3 infection; andEither: 3.1 Patient has bridging fibrosis or cirrhosis (Metavir stage 3 or 4 or equivalent); or 3.2 is unsuitable for liver biopsy due to coagulopathy.
Special Authority for Subsidy - Form SA0803Initial application from any specialist. Approvals valid for 11 months for applications meeting the following criteria: either: 1 Patient has chronic hepatitis C, genotype 1, 4, 5 or 6 infection; or2 Patient has chronic hepatitis C, genotype 2 or 3 infection; and 2.1 With has bridging fibrosis or cirrhosis (Metavir stage 3 or 4, or equivalent). 2.2 is unsuitable for liver biopsy due to coagulopathy. Note: consider stopping treatment if there is absence of a virological response (defined as at least a 2-log reduction in viral load) following 12 weeks of treatment since this is predictive of treatment failure.
Prescribing Guideline for Inhaled Long-Acting Beta-Adrenoceptor AgonistsThe addition of inhaled long-acting beta-adrenoceptor agonists (LABAs) to inhaled corticosteroids is recommended: - For younger children (aged under 12 years) where asthma is poorly controlled despite using inhaled corticosteroids for at least three months at total daily doses of 200 mcg beclomethasone or budesonide (or 100 mcg fluticasone).- For adults and older children (aged 12 years and over) where asthma is poorly controlled despite using inhaled corticosteroids for at least three months at total daily doses of 400 mcg beclomethasone or budesonide (or 200 mcg fluticasone).Note: Further information on the place of inhaled corticosteroids and inhaled LABAs in the management of asthma can be found in the New Zealand guidelines for asthma in adults (www.nzgg.org.nz) and in the New Zealand guidelines for asthma in children aged 1-15 (www.paediatrics.org.nz).
Access by applicationa) Budget managed by appointed clinicians on the Multiple Sclerosis Treatment Assessments Committee (MSTAC). b) Applications will be considered by MSTAC at its regular meetings and approved subject to eligibility according to the Entry and Stopping criteria (below). c) Applications to be made on the approved forms which are available from the co-ordinator for MSTAC:The Co-ordinator Phone: (04) 460 4990Multiple Sclerosis Treatment Assessments Committee Facsimile: (04) 916 7571PHARMAC, PO Box 10 254 E mail: silvia.valsenti@pharmac.govt.nzWellingtond) Completed application forms must be sent to the co-ordinator for MSTAC and will be considered by MSTAC at the next practicable opportunity. e) Notification of MSTAC's decision will be sent to the patient, the applying clinician and the patient's GP (if specified). f) These agents will not be subsidised if dispensed from a community or hospital pharmacy. Regular supplies will be distributed to all approved patients or their c
a) Subsidised only if prescribed for a dialysis or cystic fibrosis patient; orb) for the treatment of confirmed ciprofloxacin-resistant gonorrhoea; orc) for the treatment of suspected meningitis in patients who have a known allergy to penicillin; andd) the prescription or PSO is endorsed accordingly
subsidised only if prescribed for patients with uncomplicated urethritis or cervicitis proven or presumed to be due to Chlamydia trachomatis and their sexual contacts and prescription or PSO is endorsed accordingly.
Special Authority for Subsidy Initial application only from a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: 1 The patient has metastatic colorectal cancer; and2 To be used for first or second line use as part of a combination chemotherapy regimen. Renewal only from a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: 3 The patient requires continued therapy; or4 The tumour has relapsed and requires re-treatment.
Special Authority for Subsidy - Form: SA0809Initial application only from a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Any of the following: 1 Both: 1.1 The patient has ovarian*, fallopian* or primary peritoneal cancer*; and 1.2 Either: 1.2.1 Has not received prior chemotherapy; or 1.2.2 Has received prior chemotherapy but has not previously been treated with taxanes; or2 The patient has metastatic breast cancer; or3 Both: 3.1 The patient has non small-cell lung cancer; and 3.2 Either: 3.2.1 Has advanced disease (stage IIIa or above); or 3.2.2 Is receiving combined chemotherapy and radiotherapy; or4 Both: 4.1 The patient has small-cell lung cancer*; and 4.2 Docetaxel is to be used as second-line therapy. Renewal only from a relevant specialist. Approvals valid for 12 months for applications meeting the followingcriteria: 5. The patient has metastatic breast cancer, non small-cell lung cancer,
Special Authority for Alternate SubsidyInitial application only from a relevant specialist. Approvals valid for 5 years for applications meeting the following criteria: All of the following: 1 Patient is a postmenopausal women; and2 Patient has hormone receptor positive breast cancer; and3 Any of the following: 3.1 The cancer is advanced (Stage IIIb, or metastatic Stage IV); or 3.2 The patient has a very clear history of intolerance to tamoxifen; or 3.3 The use of tamoxifen is contraindicated due to a history of thromboembolic disease. Renewal only from a relevant specialist. Approvals valid without further renewal unless notified where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Alternate SubsidyInitial application only from a relevant specialist. Approvals valid for 5 years for applications meeting the following criteria: All of the following: 1 Patient is a postmenopausal women; and2 Patient has hormone receptor positive breast cancer; and3 Any of the following: 3.1 The cancer is advanced (Stage IIIb, or metastatic Stage IV); or 3.2 The patient has a very clear history of intolerance to tamoxifen; or 3.3 The use of tamoxifen is contraindicated due to a history of thromboembolic disease. Renewal only from a relevant specialist. Approvals valid without further renewal unless notified where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for SubsidyInitial application only from a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria: All of the following1 Patient is an adult who has had severe and active erosive Rheumatoid Arthritis for six months duration or longer; and2 Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and3 Patient has tried and not responded to at least three months of oral or parenteral methotrexate at a dose of at least 20 mg weekly or a maximum tolerated dose; and4 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with at least two of the following (triple therapy): sulphasalazine, prednisone at a dose of at least 7.5 mg per day, azathioprine, intramuscular gold, or hydroxychloroquine sulphate (at maximum tolerated doses); and5 Patient has tried and not responded to at least three months therapy at th
Special Authority for Subsidy Initial application only from a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Any of the following: 1 The patient has non small cell lung carcinoma (stage IIIa, or above); or2 The patient has advanced malignant mesothelioma*; or3 The patient has advanced pancreatic carcinoma; or4 The patient has ovarian, fallopian tube* or primary peritoneal carcinoma*. Renewal only from a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Both: 5 The patient requires continued therapy; or6 The tumour has relapsed and requires re-treatment. Note indications marked with a * are unapproved indications.
Special Authority for Subsidy Initial application only from a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Both: 1 The patient has primary thrombocythaemia; and2 Either 2.1 is at high risk (previous thromboembolic disease, bleeding or platelet count >1500/ml); or 2.2 is intolerant or refractory to hydroxyurea or interferon. Renewal only from a relevant specialist. Approvals valid for 12 months where the treatment remains appropriate and the patient is benefiting from treatment. NoteIt is recommended that treatment with anagrelide be initiated only on the recommendation of a haematologist.
Special Authority for Subsidy Initial application - (for new patients) only from a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Both: 1 The patient has refractory, progressive or relapsed multiple myeloma; and2 The patient has received prior chemotherapy. Initial application - (for patients receiving thalidomide prior to 1 January 2006) only from a relevant specialist. Approvals valid without further renewal where the patient was receiving treatment with thalidomide for multiple myeloma on or before 31 December 2005. Renewal only from a relevant specialist. Approvals valid without further renewal where the patient has obtained a response from treatment during the initial approval period. Note: Prescription must be written by registered prescriber in the thalidomide risk management programme operated by the supplier. Maximum dose of 400 mg daily as monotherapy or in a combination therapy regimen.
Special Authority for Subsidy Initial application for patients with type 2 diabetes only from a relevant specialist. Approvals valid for one year for applications meeting the following criteria: Any of the following: Monotherapy1 All of the following: 1.1 To be used as monotherapy for patients who after six months of diet and lifestyle changes have inadequate glycaemic control (defined as HbA1c > 7.0% in tests carried out at least two months apart); and 1.2 Metformin is contraindicated or not tolerated after a minimum of a four week trial period; and 1.3 Sulphonylurea is contraindicated or not tolerated or the patient's body mass index (BMI) exceeds 33 kg/m2; orIn combination with sulphonylurea2 Both: 2.1 For use in combination with a sulphonylurea for patients who after diet and lifestyle changes and a six-month trial of sulphonylurea have poor glycaemic control (defined as HbA1c > 8.0% measured within the last month of the six month period); and 2.2 Metformin is contrain
Prescribing GuidelineCombigan is subsidised for use as either monotherapy or as an adjunctive agent for the treatment of glaucoma. Combigan should only be prescribed when: a) less expensive first line agents for the treatment of glaucoma are contraindicated; orb) the response to such subsidised agents is inadequate; orc) the patient cannot tolerate such subsidised agents.
Perindopril and trandolapril will be funded to the level of the ex-manufacturer price listed in the Schedule for patients who were taking these ACE inhibitors for the treatment of congestive heart failure prior to 1 June 1998. The prescription must be endorsed accordingly. We recommend that the words used to indicate eligibility are "certified condition" or an appropriate description of the patient such as "congestive heart failure", "CHF", "congestive cardiac failure" or "CCF". Definition of Congestive Heart Failure At the request of some prescribers the PTAC Cardiovascular subcommittee has provided a definition of congestive heart failure for the purposes of the funding of the manufacturer's surcharge: "Clinicians should use their clinical judgement. Existing patients would be eligible for the funding of the surcharge if the patient shows signs and symptoms of congestive heart failure, and requires or has in the past required concomitant treatment with a diuretic. The definition could also be considere
Special Authority for Subsidy - Form: SA0826Initial application only from a relevant specialist. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 All of the following: 1.1 Patient has a calculated absolute risk of cardiovascular disease >20% over 5 years; and 1.2 Patient cannot tolerate statin therapy at a dose of >= 40 mg per day; and 1.3 Either: 1.3.1 All of the following: 1.3.1.1 Patient has venous CABG; and 1.3.1.2 LDL cholesterol >= 2.0 mmol/litre (see note); and 1.3.1.3 LDL cholesterol >= 2.0 mmol/litre (at least 1 week after test 1 - see note); or 1.3.2 All of the following: 1.3.2.1 Patient does not have venous CABG; and 1.3.2.2 LDL cholesterol >= 2.5 mmol/litre (see note); and 1.3.2.3 LDL cholesterol >= 2.5 mmol/litre (at least 1 week after test 1 - see note); or2 All of the following: 2.1 Patient has homozygous familial hypercholesterolemia, or heterozygous familial hypercholest
Subsidy by endorsement: a. Only if prescribed for post-herpetic neuralgia or diabetic peripheral neuropathy; andb. The prescription is endorsed accordingly.
Special Authority for Subsidy - Retail Pharmacy - Form SA0829Initial Application only from gastroenterologist or infectious disease specialist. Approvals valid for 1 year for applications meeting the following criteria: All of the following: 1. Patient has confirmed Hepatitis B infection (HBsAg+); andDocumented resistance to lamivudine, defined as: 2. patient has raised serum ALT (> 1 x ULN); and3. patient has HBV DNA greater than 100,000 copies per mL, or viral load ? 10 fold over nadir; and4. detection of M204I or M204V mutation; and5. Either 5.1. Both5.1.1. patient is cirrhotic; and5.1.2. adefovir dipivoxil to be used in combination with lamivudine; or5.2. Both5.2.1. patient is not cirrhotic; and5.2.2. adefovir dipivoxil to be used as monotherapyRenewal only from a gastroenterologist or infectious disease specialist. Approvals valid for 2 years for applications where in the opinion of the treating physician, treatment remains appropriate and patient is benefiting from treatmen
Special Authority for Subsidy - Form: SA0831Application only from a relevant specialist. Approvals valid for 10 months for applications meeting the following criteria: 1. Patient has newly diagnosed glioblastoma multiforme; and2. Temozolomide is to be (or has been) given concomitantly with radiotherapy; and3. Following concomitant treatment temozolomide is to be used for a maximum of six cycles of 5 days treatment, at a maximum dose of 200 mg/m2. Note: Temozolomide is not subsidised for the treatment of relapsed glioblastoma multiforme. Studies of temozolomide show that its benefit is predominantly in those patients with a good performance status (WHO grade 0 or 1 or Karnofsky score >80), and in patients who have had at least a partial resection of the tumour.
Special Authority for Subsidy - Form: SA0832Initial application only from a gastroenterologist, infectious disease specialist, paediatrician or general physician. Approvals valid for 1 year for applications meeting the following criteria: Both: 1 Any of the following: 1.1 All of the following: 1.1.1 HBsAg positive for more than 6 months; and1.1.2 HBeAg positive or HBV DNA positive defined as > 100,000 copies per ml by quantitative PCR at a reference laboratory; and1.1.3 ALT greater than twice upper limit of normal or bridging fibrosis or cirrhosis (Metavir stage 3 or 4 or equivalent) on liver histology or clinical/radiological evidence of cirrhosis; or 1.2 HBV DNA positive cirrhosis prior to liver transplantation; or1.3 HBsAg positive and have had a liver, kidney, heart, lung or bone marrow transplant; or1.4 Hepatitis B surface antigen positive (HbsAg) patient who is receiving chemotherapy for a malignancy, or who has received such treatment within the previous two months;
Special Authority for Subsidy - Form SA0833Initial application only from a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Any of the following: 1 The patient has non small cell lung carcinoma (stage IIIa, or above); or2 The patient has advanced malignant mesothelioma*; or3 The patient has advanced pancreatic carcinoma; or4 The patient has ovarian, fallopian tube* or primary peritoneal carcinoma*; or5 The patient has advanced transitional cell carcinoma of the urothelial tract (locally advanced or metastatic). Renewal only from a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Both: 6 The patient requires continued therapy; or7 The tumour has relapsed and requires re-treatment. Note indications marked with a * are unapproved indications.
Special Authority for Subsidy - Form: SA0834Initial application only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria: Either: 1 Both: 1.1 Patient has type 1 diabetes and has received an intensive regimen (injections at least three times a day) of an intermediate acting insulin in combination with a rapid acting insulin analogue for at least three months; and1.2 Either: 1.2.1 Patient has experienced more than one unexplained severe hypoglycaemic episode in the previous 12 months (severe defined as requiring the assistance of another person); or1.2.2 Patient has experienced unexplained symptomatic nocturnal hypoglycaemia, biochemically documented at <3.0 mmol/L, more than once a month despite optimal management; or2 Patient has documented severe, or continuing, systemic or local allergic reaction to existing insulins. Note this does not include hypoglycaemic episodes. Renewal only from a relevant specialist or general practitioner. Approv
Special Authority for Subsidy - Form SA0835Initial application - (Breast cancer) from any medical practitioner. Approvals valid for 1 year: where the patient is a premenopausal woman with breast cancer. Initial application - (Prostate cancer) only from an oncologist, urologist or endocrinologist. Approvals valid for 1 year for applications meeting the following criteria: Advanced prostatic cancer;. Note Not to be prescribed with an anti-androgen except for a period of three weeks, if necessary, when GnRH analogue therapy is initiated. Initial application - (Endometriosis) only from a gynaecologist. Approvals valid for 3 months for applications meeting the following criteria: Both: 1 Endometriosis; and2 Either: 2.1 6 months treatment with medroxyprogesterone acetate, danazol or dimetriose has proven ineffective; or2.2 The patient has failed to tolerate the treatment with medroxyprogesterone acetate, danazol or dimetriose for 6 months. Note The maximum treatment period for a GnRH analogue is:
Special Authority for Subsidy - Form SA0836Initial application - (Breast cancer) from any medical practitioner. Approvals valid for 1 year where the patient is a premenopausal woman with breast cancer. Initial application - (Prostate cancer) only from an oncologist, urologist or endocrinologist. Approvals valid for 1 year for applications meeting the following criteria: Either: 1 Advanced prostatic cancer; or. 2 Locally advanced prostatic cancer. Note Not to be prescribed with an anti-androgen except for a period of three weeks, if necessary, when GnRH analogue therapy is initiated. Initial application - (Endometriosis) only from a gynaecologist. Approvals valid for 3 months for applications meeting the following criteria: Both: 3 Endometriosis; and4 Either: 4.1 6 months treatment with medroxyprogesterone acetate, danazol or dimetriose has proven ineffective; or4.2 The patient has failed to tolerate the treatment with medroxyprogesterone acetate, danazol or dimetriose for 6 months. Note
Special Authority for Subsidy - Form SA0837Initial application - (Breast cancer) from any medical practitioner. Approvals valid for 1 year where the patient is a premenopausal woman with breast cancer. Initial application - (Prostate cancer) only from an oncologist, urologist or endocrinologist. Approvals valid for 1 year where the patient has: Advanced prostatic cancer;. Note Not to be prescribed with an anti-androgen except for a period of three weeks, if necessary, when GnRH analogue therapy is initiated. Initial application - (Endometriosis) only from a gynaecologist. Approvals valid for 3 months for applications meeting the following criteria: Both: 1 Endometriosis; and2 Either: 2.1 6 months treatment with medroxyprogesterone acetate, danazol or dimetriose has proven ineffective; or2.2 The patient has failed to tolerate the treatment with medroxyprogesterone acetate, danazol or dimetriose for 6 months. Note The maximum treatment period for a GnRH analogue is: - 3 months to assess whet
Special Authority for Subsidy - Form: SA0838Initial Application only from a relevant specialist or General Practitioner. Approvals valid for 2 years forapplications meeting the following criteria: Either: 1 All of the following: 1.1 Patient is a child under the age of 12; and1.2 All of the following: Has, for 3 months or more, been treated with:1.2.1 An inhaled long-acting beta adrenoceptor agonist; and1.2.2 Inhaled corticosteroids at a dose of at least 400 mcg per day beclomethasone or budesonide, or200 mcg per day fluticasone; and1.3 The prescriber considers that the patient would receive additional clinical benefit from switching to acombination product; or2 All of the following: 2 .1 Patient is over the age of 12; and2 .2 All of the following: Has, for 3 months or more, been treated with:2 .2.1 An inhaled long-acting beta adrenoceptor agonist; and2 .2.2 Inhaled corticosteroids at a dose of at least 800 mcg per day beclomethasone or budesonide, or500 mcg per day fluticasone;
Special Authority for Subsidy - Form SA0839Initial application - (Breast cancer) from any medical practitioner. Approvals valid for 1 year where the patient is a premenopausal woman with breast cancer. Initial application - (Prostate cancer) only from an oncologist, urologist or endocrinologist. Approvals valid for 1 year for applications meeting the following criteria: Either: 1 Advanced prostatic cancer; or. 2 Neoadjuvant or adjuvant treatment of locally advanced prostatic cancer. Note Not to be prescribed with an anti-androgen except for a period of three weeks, if necessary, when GnRH analogue therapy is initiated. Initial application - (Endometriosis) only from a gynaecologist. Approvals valid for 3 months for applications meeting the following criteria: Both: 3 Endometriosis; and4 Either: 4.1 6 months treatment with medroxyprogesterone acetate, danazol or dimetriose has proven ineffective; or4.2 The patient has failed to tolerate the treatment with medroxyprogesterone acetate, danazo
Special Authority for Subsidy - form: SA0841Initial application only from a gastroenterologist or general physician. Approvals valid for 6 months for applications meeting the following criteria: Both: 1 Primary biliary cirrhosis confirmed by antimitochondrial antibody titre (AMA) > 1:80, and raised cholestatic liver enzymes with or without raised serum IgM or, if AMA is negative, by liver biopsy; and2 Patient not requiring a liver transplant (bilirubin > 170umol/l; decompensated cirrhosis). NoteLiver biopsy is not usually required for diagnosis but is helpful to stage the diseaseRenewal only from a gastroenterologist or general physician. Approvals valid for 2 years for applications meeting the following criteria: The treatment remains appropriate and the patient is benefiting from treatment. NoteActigall is not an appropriate therapy for patients requiring a liver transplant (bilirubin > 170 micromol/l; decompensated cirrhosis). These patients should be referred to an appropriate transp
Special Authority for Subsidy - Form: SA842Initial application only from a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Any of the following: 1 Both: 1.1 The patient has ovarian, fallopian* or primary peritoneal cancer*; and 1.2 Either: 1.2.1 Has not received prior chemotherapy; or 1.2.2 Has received prior chemotherapy but have not previously been treated with taxanes; or2 The patient has metastatic breast cancer; or3 The patient has node-positive early breast cancer; or4 Both 4.1 The patient has non small-cell lung cancer; and 4.2 Either: 4.2.1 Has advancing disease (stage IIIa or above); or 4.2.2 Is receiving combined chemotherapy and radiotherapy; or5 Both: 5.1 The patient has small-cell lung cancer*; and 5.2 Paclitaxel is to be used as second-line therapy. Renewal only from a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: 6 The patient has metasta
Special Authority for Subsidy - Form SA0006Initial application from any medical practitioner. Approvals valid for 5 years where the patient is likely to benefit from treatment. Renewal from any medical practitioner. Approvals valid for 5 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0011Initial application only from a relevant specialist. Approvals valid for 2 years where the patient has diabetes. Renewal only from a relevant specialist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0028Initial application only from a relevant specialist. Approvals valid for 6 months for applications meeting the following criteria: Either: 1 All of the following: 1.1 Treatment with other lipid modifying medicines has been unsuccessful; and 1.2 6 months of dietary modification has been unsuccessful; and 1.3 Cholesterol level > 7.0 mmol/litre; and 1.4 Either: 1.4.1 Familial hypercholesterolaemia; or 1.4.2 Manifest coronary heart disease, which has been clinically proven, or previously treated by coronary artery surgery; or 2 Cholesterol level > 9.0 mmol/litre:.Renewal only from a general practitioner. Approvals valid for 6 months where the treatment remains appropriate and the patient is benefiting from treatment. NoteFamilial hypercholesterolaemia is defined as being hypercholesterolaemia in the presence of tendon xanthomas or in association with a family history of premature heart disease (before age 55) or consisten
Unapproved medication supplied under Section 29 of the Medicines Act 1981. Practitioners prescribing this medication should: (a) be aware of and comply with their obligations under Section 29 of the Medicines Act 1981 and otherwise under that Act and the Medicines Regulations 1984; (b) be aware of and comply with their obligations under the Health and Disability Commissioner's Code of Consumer Rights, including the requirement to obtain informed consent from the patient (PHARMAC recommends that Practitioners obtain written consent); and(c) exercise their own skill, judgment, expertise and discretion, and make their own prescribing decisions with respect to the use of an unapproved Pharmaceutical or a Pharmaceutical for an indication for which it is not approved.
Special Authority for Subsidy - Form SA0031Initial application from any medical practitioner. Approvals valid for 2 years for applications meeting the following criteria: Any of the following: 1 Oesophageal stricture; or 2 Terminal care; or 3 Too young to swallow conventional tablets; or 4 Too old to swallow conventional tablets. Renewal from any medical practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
a) When ordered by a medical practitioner on a practitioner's supply order for ventricular arrhythmias and the order is endorsed accordinglyb) When ordered for a dialysis patient or a child with rhumatic fever and the order is endorsed accordingly
Special Authority for Manufacturers Price - Form SA0035Initial application from any medical practitioner. Approvals valid for 5 years for applications meeting the following criteria: Both: 1 Either: 1.1 Both: 1.1.1 Duodenal and gastric ulcers, reflux oesophagitis and Zollinger-Ellison syndrome; and 1.1.2 Other treatments have failed; or 1.2 Patients who are on a Social Welfare benefit or an income no greater than a benefit; and 2 Patients must have endoscopically demonstrated lesions prior to commencement of treatment.. Renewal from any medical practitioner. Approvals valid for 5 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0041Initial application only from a relevant specialist. Approvals valid for 2 years where alternative antihypertensives have failed. Renewal only from a relevant specialist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0045Initial application from any medical practitioner. Approvals valid for 2 years for applications meeting the following criteria: All of the following: 1 Continuation of treatment commenced prior to 1 August 1990; and 2 Alternatives (salbutamol and terbutaline) have been tried; and 3 Either: 3.1 Asthma; or 3.2 Chronic obstructive airways disease (COAD); and 4 Applicants must provide details of dose. Renewal from any medical practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0046Initial application only from a gastroenterologist. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 Functioning gall bladder; and 2 Either: 2.1 Uncalcified gallbladder stones with a maximum size of 20 mm; or 2.2 Adjunctive treatment after extra corporeal lithotrypsy. Renewal only from a gastroenterologist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0047Initial application only from a paediatrician or respiratory specialist. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 Child under 2 years of age; or 2 Both: 2.1 Child with major physical or intellectual disabilities; and 2.2 Lacks the necessary coordination to use aerosols with a spacer device. NoteThe cost of nebuliser therapy greatly exceeds other inhaled forms. Steroid nebulising solution can cause cataract formation. Renewal only from a paediatrician or respiratory specialist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0050Initial application only from a relevant specialist. Approvals valid for 2 years where terminally ill patient. Renewal only from a relevant specialist. Approvals valid for 2 years where terminally ill patient.
Special Authority for Subsidy - Form SA0051Initial application from any medical practitioner. Approvals valid for 6 months where control of nausea in the treatment of malignant disease. Renewal from any medical practitioner. Approvals valid for 6 months where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0053Initial application only from a relevant specialist. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 RAST or skin test positive; and 2 Patient has had severe generalised reaction to the sensitising agent. Renewal only from a relevant specialist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0055Initial application only from a psychiatrist, geriatrician or respiratory specialist. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 For use only as an anxiolytic; and 2 Other agents are contraindicated or have failed. Renewal only from a psychiatrist, geriatrician or respiratory specialist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0056Initial application only from a psychiatrist. Approvals valid for 5 years for applications meeting the following criteria: Both: 1 Long-standing delusional states; and 2 Other injectable anti-psychotics have proven to be ineffective or inappropriate. Renewal only from a psychiatrist. Approvals valid for 5 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0057Initial application only from a psychiatrist. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 Depression; and 2 Any of the following: 2.1 Both: 2.1.1 Failed trials with other antidepressants; and 2.1.2 Patient has been maintained on mianserin prior to December1993; or 2.2 Co-existent bladder neck obstruction; or 2.3 Cardiovascular disease. Renewal only from a psychiatrist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0069Initial application only from a general physician, nephrologist or neurologist. Approvals valid for 5 years where syndrome of inappropriate anti-diuretic hormone secretion (SIADH). Renewal only from a general physician, nephrologist or neurologist. Approvals valid for 5 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Manufacturers Price - Form SA0070Initial application only from a respiratory specialist or infectious disease specialist. Approvals valid for 2 years for applications meeting the following criteria: Any of the following: 1 Avium intracellular atypical mycobacterial infections; or 2 Multiple drug resistant tuberculosis; or 3 Atypical and drug-resistant mycobacterial infections in patients with AIDS. Renewal only from a respiratory specialist or infectious disease specialist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
a) Only granted after the patient has proven to be intolerant to zidovudine or whose health has significantly deteriorated while on zidovudine. It is impossible to have approvals for both AZT and DDI concurrently but it is not expected that both medicines would be consumed at the same time. Applications can be made without patients having had a preliminary trialb) Specialist must make application
a) All patients with AIDS meeting the definition developed by the Centres for Disease Control in the USA (see Circular Letter to Medical Practitioners HP2/88)b) Patients with AIDS Related Complex (ARC)c) HIV infected patients with CD4 (T4) counts below 500 regardless of symptomatologyd) Prophylactically for persons following severe parenteral exposure from a known HIV positive sourcee) HIV infected persons with associated thrombocytopenia regardless of CD4 (T4) count f) Applications can only be made by appropriate specialists. Prescriptions for those patients approved to use these medicines can be written either by the specialist or general practitioner with an endorsement of the name of the recommending specialist. g) Prescriptions for these can be written for a period of three months' supply. However, medicine must be dispensed on a monthly basis.
NOTE: Evidence that a patient is on insulin therapy can be by way of either: a) insulin being on the same prescription ofb) by the word "insulin patient" be in written on the prescription by either the doctor or the contractor.
All non-disposible diabetic supplies are only eligible for subsidy if there is produced to the contractor a certificate the gives the nome, address, and age of the patient and that:1) is signed by a doctor and2) is dated less than two years propr to the date of supply; and that 3) states that the patient is receiving iusulin therapy.
Special Authority for Subsidy - Form SA0085Initial application from any medical practitioner. Approvals valid for 5 years where the patient is likely to benefit from treatment. Renewal from any medical practitioner. Approvals valid for 5 years where the treatment remains appropriate and the patient is benefiting from treatment.
a) Males: Fertile eunuch syndrome, females: anovulatory infertilityb) A declaration is required from the applying doctor that these agents are not being used as part of an IVF programmec) Approvals are valid for 6 months with a revewal for a further 6 months if the patient has some response and the prescriber believes further treatment will be effectived) Specialist must make application - endocrinologists and gynaecologists only
Special Authority for Subsidy - Form SA0087Initial application only from an endocrinologist or gynaecologist. Approvals valid for 6 months where hypogonadotrophic hypogonadism (including anovulatory infertility and cryptochidism). Renewal only from an endocrinologist or gynaecologist. Approvals valid for 6 months where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0088Initial application only from an endocrinologist or gynaecologist. Approvals valid for 6 months for applications meeting the following criteria: Both: 1 Either: 1.1 Female with anovulatory infertility, males: hypogonadotrophic hypogonadism; or 1.2 Male with hypogonadotrophic hypogonadism; and 2 These agents are not being used as part of an IVF programme. Renewal only from an endocrinologist or gynaecologist. Approvals valid for 6 months where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0089Initial application - (Breast or prostatic cancer) only from an oncologist, urologist or endocrinologist. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 Breast cancer in pre menopausal women unwilling or unable to undergo surgical or radiation oophorectomy; or 2 Advanced prostatic cancer when orchidectomy is contraindicated. Initial application - (Endometriosis) only from a gynaecologist. Approvals valid for 6 months for applications meeting the following criteria: Both: 1 Endometriosis; and 2 Either: 2.1 6 months treatment with medroxyprogesterone acetate, danazol or dimetriose has proven ineffective; or 2.2 The patient has failed to tolerate the treatment with medroxyprogesterone acetate, danazol or dimetriose for 6 months. NoteThe maximum treatment period for a GnRH analogue is: 3 months to assess whether surgery is appropriate3 months for infertile patients after surgery6 months for
Special Authority for Subsidy - Form SA0090Initial application only from a relevant specialist. Approvals valid for 2 years where patient cannot use desmopressin nasal spray or nasal drops. Renewal only from a relevant specialist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0091Initial application only from a relevant specialist. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 Paget's disease; or 2 Both: 2.1 Patients under hospice care; and 2.2 Either: 2.2.1 Tumour-induced hypercalcaemia; or 2.2.2 Tumour-induced osteolysis without hypercalcaemia. Renewal only from a relevant specialist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0092Initial application only from a relevant specialist. Approvals valid for 5 years where treatment of refractory absorptive hypercalcaemia. Renewal only from a relevant specialist. Approvals valid for 5 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0094Initial application only from a relevant specialist (Only for Epsom Day Unit in Auckland). Approvals valid for 1 month where termination of advanced pregnancy i.e. beyond 12 weeks. Only for Epsom Day Unit in Auckland.
Special Authority for Subsidy - Form SA0096Initial application - (Organ transplant, Bone marrow transplant or Graft v host disease) only from a relevant specialist. Approvals valid for 2 years for applications meeting the following criteria: Any of the following: 1 Organ transplant; or 2 Bone marrow transplant; or 3 Graft v host disease. Initial application - (Psoriasis) only from a dermatologist. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 Psoriasis; and 2 Other systemic and topical therapy has failed. Initial application - (Severe atopic dermatitis) only from a dermatologist. Approvals valid for 6 months for applications meeting the following criteria: Both: 1 Severe atopic dermatitis; and 2 Not resopnsive to topical therapy, oral antihistamines and other commonly used orthodox therapies. Initial application - (Nephrotic Syndrome) from any medical practitioner. Approvals valid for 2 years for applications meeting the following cri
Special Authority for Subsidy - Form SA0097Initial application - (Chronic hepatitis C) only from a relevant specialist. Approvals valid for 6 months where chronic hepatitis C. Initial application - (Indications other than Chronic hepatitis C) only from a relevant specialist. Approvals valid for 5 years for applications meeting the following criteria: Any of the following: 1 Chronic myelogenous leukaemia; or 2 Hairycell leukaemia; or 3 Cutaneous T cell lymphoma; or 4 Essential thrombocythaemia; or 5 AIDS related Kaposi's sarcoma; or 6 Multiple myeloma; or 7 Chronic active hepatitis B. Renewal - (Chronic hepatitis C) only from a relevant specialist. Approvals valid for 6 months where the treatment remains appropriate and the patient is benefiting from treatment. Renewal - (Indications other than Chronic hepatitis C) only from a relevant specialist. Approvals valid for 5 years where the treatment remains appropriate and the patient is benefiting from treatment.
a) Hairy cell leukaemia, Kaposi's sarcoma, chronic active hepatitis B, chronic hepatitis C (6 month approval only), chronic myelogenous leukaemia, multiple myelomab) Specialist must make applicationc) No further approvals for:Malignant melanoma, superficial and noduloulcerative basal cell carcinomaNote: Patients with existing approvals can continue to have therapy
Special Authority for Subsidy - Form SA0099Initial application only from a relevant specialist. Approvals valid for 5 years for applications meeting the following criteria: Any of the following: 1 Both: 1.1 Acromegaly; and 1.2 Patients who have failed surgery, radiotherapy, bromocriptine and other oral therapies; or 2 Both: 2.1 Either: 2.1.1 Vipomas; or 2.1.2 Glucagonomas; and 2.2 Patients who are seriously ill in order to improve their clinical state prior to definitive surgery; or 3 Both: 3.1 Gastrinoma; and 3.2 Either: 3.2.1 Patient has failed surgery; or 3.2.2 Patient is in metastatic disease after H2 antagonists (or omeprazole) have failed; or 4 Both: 4.1 Insulinomas; and 4.2 Surgery is contraindicated or where surgery has failed; or 5 Pre-operative control of hypoglycaemia; or 6 Maintenance therapy. NoteThe use of octreotide in patients with fistulae, oesophageal varices, miscellaneous diarrhoea and hypotension will
Special Authority for Subsidy - Form SA0100Initial application only from a relevant specialist. Approvals valid for 5 years for applications meeting the following criteria: All of the following: 1 Anaemia of end-stage renal failure (other treatable causes of anaemia being excluded); and 2 Been on haemodialysis or continuous ambulatory peritoneal dialysis (CAPD) for at least three months; and 3 Not under evaluation for, or awaiting, a live donor kidney transplant; and 4 Any of the following: 4.1 Anephric; or 4.2 Dependent on regular blood transfusion (1 unit each 4-8 weeks) to maintain haemoglobin > 60g/L; or 4.3 Cannot be transfused because of severe transfusion reactions; or 4.4 Transfusion induced haemosiderosis (clinical manifestations, serum ferritin >1500 ug/L); or 4.5 Haemoglobin < 70 g/L (mean of at least 4 haemoglobin concentrations over 4 months); or 4.6 Both: 4.6.1 Haemoglobin < 90 g/L; and 4.6.2 Either: 4.6.2.1 Heart failure (low card
a) Maximum of 50 mls per unit b) On a prescription or practitioner's supply order only when on the same form as an injection listed in the Pharmaceutical Schedule requiring a solvent or diluent c) On a bulk supply orderd) When used in the extemporaneous compounding of eye drops
Special Authority for Subsidy - Form SA0108Initial application only from a relevant specialist. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 Hairy cell leukaemia; or 2 Chronic active hepatitis B. Renewal only from a relevant specialist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0110Initial application only from a relevant specialist. Approvals valid for 5 years where biotinidase deficiency. Renewal only from a relevant specialist. Approvals valid for 5 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0115Initial application - (Oesophageal stricture) only from a general practitioner or relevant specialist. Approvals valid for 2 years where patient with oesophageal stricture who is unable to take capsules. Initial application - (Indications other than oesophageal stricture) only from a paediatrician. Approvals valid for 2 years for applications meeting the following criteria: All of the following: 1 infant or child with liver disease or short gut syndrome; and 2 Requires vitamin supplementation; and 3 Unable to swallow capsules. Renewal only from a general practitioner, relevant specialist or paediatrician. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0119Initial application only from a rheumatologist. Approvals valid for 5 years where ankylosing spondylitis. Renewal only from a rheumatologist. Approvals valid for 5 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0121Initial application from any medical practitioner. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 Patient has to use an unpreserved solution due to an allergy to the preservative; or 2 Patient wears soft contact lenses. NoteMinims for a general practice are considered to be "tools of trade" and are not approved as special authority items. Renewal from any medical practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0122Initial application only from a relevant specialist. Approvals valid for 2 years where filamentary keratitis. Renewal only from a relevant specialist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0125Initial application - (Chronic post-thrombotic venous stasis ulcers) from any medical practitioner. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 Chronic post-thrombotic venous stasis ulcers of more than 4 months duration; and 2 Other interventions have failed. Initial application - (Sudden hearing loss) only from an otolaryngologist. Approvals valid for 2 years where sudden hearing loss. Renewal from any medical practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
a) Should be strictly reserved for use as second line therapy in: - patients unable to tolerate the other medications, such as infants, young children and patients with allergies or eczema- cases of scabies which are resistent to gamma benzene hexachlorideb) Verification of drug resistance is dependent on the persistence of the condition after treatment. In order to establish whether there is drug resistance, the following criteria should be fulfilled: - a definite diagnosis of scabies should be made- it should be ascertained that the medication was administered properly- the possibility of reinfestation should have been excluded
Special Authority for Subsidy - Form SA0140Initial application only from a relevant specialist. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 Pain management in the terminally ill; and 2 Standard therapy has failed. Renewal only from a relevant specialist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
Only on a WSO. Distributed by the Asthma Foundation. Forward orders to: The Asthma Foundation, PO Box 1459, Wellington. Distributed by the Asthma Foundation. Also available to paediatricians employed by an HHS, on a wholesale supply order signed by the paediatrician. Orders via a hospital pharmacy.
Approvals for a CHEM number to waive the premium in the following circumstances: 1. Patients with prosthetic heart valves - as an adjunct to oral anticoagulation for prophylaxis of thromboembolism (2 year approval with renewal, applications only from cardiothoracic surgeons, cardiologists and general physicians). 2. Patients after coronary artery vein bypass graft - as an adjunct to aspirin (1 year approval only, applications only from cardiothoracic surgeons, cardiologists and general physicians). 3. Patients who continue to have transient ischaemic episodes despite aspirin therapy. A course of up to six months in combination with aspirin. Applications only from neurologists, cardiologists, vascular surgeons and general physicians. Six month approval only. Reapplications only if there is demonstrated recurrence of symptoms when dipyridamole therapy is discontinued. Note: these transitional criteria are currently being reviewed.
a) Approvals to fund the manufacturer's surcharge in the following circumstances: - Patients with prosthetic heart valves - as an adjunct to oral anticoagulation for prophylaxis of thromboembolism (2 year approval with renewal, applications only from cardiothoracic surgeons, cardiologists and general physicians). - Patients after coronary artery vein bypass graft - as an adjunct to aspirin or as monotherapy for patients who are aspirin intolerant as defined below (1 year approval only, applications only from cardiothoracic surgeons, cardiologists and general physicians); or- Patients who continue to have transient ischaemic episodes despite aspirin therapy or have transient ischaemic episodes and are aspirin intolerant as defined below (2 year approval with renewal, applications only from neurologists, neurosurgeons, cardiologists, vascular surgeons and general physicians). b) Aspirin intolerant patients are defined as those with aspirin induced asthma, urticaria, or anaphylaxi, or those with significant
Special Authority for Manufacturers Price - Form SA0157Initial application from any medical practitioner. Approvals valid for 5 years for applications meeting the following criteria: Any of the following: 1 Liver disease; or 2 Past history of thromboembolism; or 3 Significant hypertension; or 4 Hypertension associated with oral oestrogen therapy. Renewal from any medical practitioner. Approvals valid for 5 years where the treatment remains appropriate and the patient is benefiting from treatment.
Subsidy is paid on acyclovir tablets for treatment of herpes zoster and genital herpes. Prescriptions with doses: 1. exceeding 1,600 mg per day for a period of more than one week will not be subsidised; and2. up to 4,000 mg per day for a maximum period of one week will be subsidised.
Special Authority for Waiver of Rule - Form SA0175Initial application only from an obstetrician, endocrinologist or gynaecologist. Approvals valid for 2 years where pathological hyperprolactinemia. Renewal only from an obstetrician, endocrinologist or gynaecologist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
Only for treatment of uncomplicated urethritis or cervicitis due to chlamydia trachomatis and these patients' sexual contacts. Prescription must be endorsed "certified condition" (typed or handwriten and initialised in the prescriber's own handwriting)
Special Authority for Manufacturers Price - Form SA0178Initial application from any medical practitioner. Approvals valid for 6 months where control of nausea and vomiting in the treatment of terminal care patients. Renewal from any medical practitioner. Approvals valid for 6 months where the treatment remains appropriate and the patient is benefiting from treatment.
The new anticonvulsant drugs are restricted to1. neurologists2. paediatric neurologists3. any other prescriber approved in writing by the relevant RHA budget holding manager. The HFA holds a budget for expenditure on the new anticonvulsant drugs. Unless otherwise specified, ultimate authority for approving prescriptions for subsidy lies with the HFA budget holding manager for the new anticonvulsant drugs. The regional divisions of the HFA will be in contact with hospital pharmacists and approved prescribers with more detail of the approval system. GUIDELINES FOR USE OF THE NEW ANTICONVULSANTS ARE AS FOLLOWS: A. Entry criteriaThe following patients are eligible for trial on the new anticonvulsant drugs (NADs)1. Patients who are under the supervision of an approved prescriber, and whose seizures are not adequately controlled with optimal conventional anticonvulsant drug treatment. 2. Patients, who are under the supervision of an approved prescriber, and whose seizures are only controlled adequatel
Subsidised only if prescribed for patients with uncomplicated urethritis or cervicitis proven or presumed to be due to Chlamydia trachomatis and their sexual contacts and prescription is endorsed "certified condition".
Available from hospital pharmacies providing an outpatient dispensing service, and selected retail pharmacies in the Northern, Western Bay of Plenty, Wellington, Christchurch or South Canterbury regions that have an exclusive contract to dispense 'Hospital Pharmacy' [HP1] pharmaceuticals.
Available from hospital pharmacies providing an outpatient dispensing service, and any retail pharmacy in the Northern, Midland, Central (including Nelson and Blenheim) and South Canterbury regions, and selected retail pharmacies in the Christchurch region that have an exclusive contract to dispense 'Hospital Pharmacy' [HP3] pharmaceuticals.
a) Maximum of 750mg (1 injection) per prescription; orb) Hospital pharmacy [HP3] - specialist - Only if prescribed for a dialysis or cystic fibrosis patient; and- The prescription is endorsed accordingly.
Special Authority for Subsidy - Form SA0256Initial application only from a cardiologist or general physician. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 Refractory angina; and 2 Patient is already on maximal anti-anginal therapy. Renewal only from a cardiologist or general physician. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0264Initial application only from a paediatrician or respiratory specialist. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 Cystic fibrosis patient; or 2 Both: 2.1 Infant or child with liver disease or short gut syndrome; and 2.2 Requires vitamin supplementation. Renewal only from a paediatrician or respiratory specialist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Manufacturers Price - Form SA0265Initial application from any medical practitioner. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 Social Welfare Benefiary; or 2 Income no greater than a Benefiary. Renewal from any medical practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0266Initial application - (Chronic hepatitis C) only from a relevant specialist. Approvals valid for 6 months where chronic hepatitis C. NoteMaximum reimbursable dosage 15 million iu/weekInitial application - (Indications other than chronic hepatitis C) only from a dermatologist, plastic surgeon or radiation oncologist. Approvals valid for 5 years for applications meeting the following criteria: Any of the following: 1 Chronic myelogenous leukaemia; or 2 Hairycell leukaemia; or 3 Cutaneous T cell lymphoma; or 4 Essential thrombocythaemia; or 5 AIDS related Kaposi's sarcoma; or 6 Multiple myeloma; or 7 Chronic active hepatitis B; or 8 Basal cell carcinoma unable to be treated surgically or by radiotherapy. NoteMaximum reimbursable dosage 15 million iu/weekRenewal - (Chronic hepatitis C) only from a relevant specialist. Approvals valid for 6 months where the treatment remains appropriate and the patient is benefiting from trea
a) - hairy cell leukaemia - Kaposi's sarcoma - chronic active hepatitis B - chronic hepatitis C (6 month approval only) - chronic myelogenous leukaemia - multiple myeloma - basal cell carcinoma 1) Only for basal cell carcinoma unable to be treated surgically or by radiotherapy. 2) Applications only from radiation oncologists, plastic surgeons and dermatologists. Applications from dermatologists will only be accepted with evidence from either a plastic surgeon or oncologist that the patient was unsuitable for surgery. 3) Maximum reimbursable dosage 15 million iu/weekb) Specialist must make applicationc) No further approvals for: Malignant melanoma Note: Patients with existing approvals can continue to have therapy
Lansoprazole is subsidised for patients who have one or more of the following conditions: 1. Duodenal ulcer proven by endoscopy or barium meal and after failure of: a)two alternative courses of H. pylori eradication therapy (if H. pylori positive); and b)H2 antagonist therapy for 8 weeks; and where a second endoscopy/barium meal has demonstrated non healing duodenal ulcer. 2. Gastric ulcer proven by endoscopy and after failure of: a)two alternative courses of H. pylori eradication therapy (if H. pylori positive); andb)H2 antagonist therapy for 12 weeks; and where a second endoscopy has demonstrated non healing gastric ulcer and excluded malignancy. 3. Gastro-oesophageal reflux disease (GORD) proven by endoscopy: i) Grade 0 GORD (normal endoscopy) after positive 24 hour pH monitoring test and failure of H2 antagonist therapy for one month with multiple daily dosing; orii) Grades 1 and 2 GORD after failure of H2 antagonist therapy for one month with multiple daily dosing; or
Special Authority for Manufacturers Price - Form SA0271Initial application from any medical practitioner. Approvals valid for 5 years for applications meeting the following criteria: Either: 1 Continuation of treatment commenced prior to 1 October 1995; or 2 Both: 2.1 Either: 2.1.1 Asthma; or 2.1.2 Chronic obstructive airways disease; and 2.2 Patient has tried alternatives and these are unsuitable. Renewal from any medical practitioner. Approvals valid for 5 years where the treatment remains appropriate and the patient is benefiting from treatment.
a) All patients with AIDS meeting the definition developed by the Centres for Disease Control in the USA (see Circular Letter to Medical Practitioners HP2/88)b) Patients with AIDS Related Complex (ARC)c) HIV infected patients with CD4 (T4) counts below 500 regardless of symptomatologyd) Prophylactically for persons following severe parenteral exposure from a known HIV positive sourcee) HIV infected persons with associated thrombocytopenia regardless of CD4 (T4) count f) For the prevention of maternal foetal transmission of HIVg) Applications can only be made by appropriate specialists. Prescriptions for those patients approved to use these medicines can be written either by the specialist or general practitioner with an endorsement of the name of the recommending specialist. h) Prescriptions for these can be written for a period of three months' supply. However, medicine must be dispensed on a monthly basis.
Special Authority for Subsidy - Form SA0274Initial application only from a relevant specialist. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 All of the following: 1.1 Treatment with other lipid modifying medicines has been unsuccessful; and 1.2 6 months of dietary modification has been unsuccessful; and 1.3 Cholesterol level > 7.0 mmol/litre:; and 1.4 Either: 1.4.1 Familial hypercholesterolaemia; or 1.4.2 Manifest coronary heart disease, which has been clinically proven, or previously treated by coronary artery surgery; or 2 Cholesterol level > 9.0 mmol/litre:.NoteFamilial hypercholesterolaemia is defined as being hypercholesterolaemia in the presence of tendon xanthomas or in association with a family history of premature heart disease (before age 55) or consistent with autosomal dominant inheritance. Simvastatin and Pravastatin may be considered for first line therapy in patients with familial hypercholesterolaemia or
Special Authority for Subsidy - Form SA0275Initial application - (Chronic hepatitis C) only from a relevant specialist. Approvals valid for 6 months where chronic hepatitis C. NoteMaximum reimbursable dosage 15 million iu/weekInitial application - (Indications other than chronic hepatitis C) only from a dermatologist, plastic surgeon or radiation oncologist. Approvals valid for 5 years for applications meeting the following criteria: Any of the following: 1 Chronic myelogenous leukaemia; or 2 Hairycell leukaemia; or 3 Cutaneous T cell lymphoma; or 4 Essential thrombocythaemia; or 5 Multiple myeloma; or 6 Chronic active hepatitis B; or 7 Basal cell carcinoma unable to be treated surgically or by radiotherapy. NoteMaximum reimbursable dosage 15 million iu/weekRenewal - (Chronic hepatitis C) only from a relevant specialist. Approvals valid for 6 months where the treatment remains appropriate and the patient is benefiting from treatment. Renewal - (Indications other tha
Special Authority for Subsidy - Form SA0276Initial application - (Chronic hepatitis C) only from a relevant specialist. Approvals valid for 6 months where chronic hepatitis C. NoteMaximum reimbursable dosage 15 million iu/weekInitial application - (Indications other than chronic hepatitis C) only from a dermatologist, plastic surgeon or radiation oncologist. Approvals valid for 5 years for applications meeting the following criteria: Any of the following: 1 Chronic myelogenous leukaemia; or 2 Hairycell leukaemia; or 3 Multiple myeloma; or 4 Chronic active hepatitis B; or 5 Basal cell carcinoma unable to be treated surgically or by radiotherapy. NoteMaximum reimbursable dosage 15 million iu/weekRenewal - (Chronic hepatitis C) only from a relevant specialist. Approvals valid for 6 months where the treatment remains appropriate and the patient is benefiting from treatment. Renewal - (Indications other than chronic hepatitis C) only from a dermatologist, plastic surgeon or radiat
Patients who have been on omeprazole and have not accessed therapy through Special Authority will continue to have subsidy for six months, by which time the necessary investigations should have been carried out to determine if ongoing therapy is warranted. For these patients the following conditions will apply: Omeprazole(a) Retail pharmacy specialist (b) month restriction
Omeprazole is subsidised for patients who have one or more of the conditions numbered 1-4: 1. Duodenal ulcer proven by endoscopy or barium meal and after failure of: a)two alternative courses of H. pylori eradication therapy (if H. pylori positive); and b)H2 antagonist therapy for 8 weeks; and where a second endoscopy/barium meal has demonstrated non healing duodenal ulcer. 2. Gastric ulcer proven by endoscopy and after failure of: a)two alternative courses of H. pylori eradication therapy (if H. pylori positive); andb)H2 antagonist therapy for 12 weeks; and where a second endoscopy has demonstrated non healing gastric ulcer and excluded malignancy. 3. Gastro-oesophageal reflux disease (GORD) proven by endoscopy: i) Grade 0 GORD (normal endoscopy) after positive 24 hour pH monitoring test and failure of H2 antagonist therapy for one month with multiple daily dosing; orii) Grades 1 and 2 GORD after failure of H2 antagonist therapy for one month with multipl
Special Authority for Manufacturers Price - Form SA0286Initial application from any medical practitioner. Approvals valid for 5 years where patient is stabilised on aminophylline, theophylline, warfarin, or phenytoin..Renewal from any medical practitioner. Approvals valid for 5 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0290Initial application only from a relevant specialist. Approvals valid for 5 years for applications meeting the following criteria: Any of the following: 1 AIDS meeting the definition developed by the Centers for Disease Control in the USA; or 2 AIDS Related Complex (ARC).; or 3 Both: 3.1 HIV infection regardless of symptomatology; and 3.2 CD4 (T4) counts < 500. NoteSee Circular Letter to Medical Practitioners HP2/88)Renewal only from a relevant specialist. Approvals valid for 5 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Manufacturers Price - Form SA0291Initial application from any medical practitioner. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 Inflammatory arthritis (including osteoarthritis with an inflammatory component); and 2 Stabilised and are well controlled on the particular NSAID medication. Renewal from any medical practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0300Initial application - (Breast or prostatic cancer) only from an oncologist, urologist or endocrinologist. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 Breast cancer in pre menopausal women unwilling or unable to undergo surgical or radiation oophorectomy; or 2 Advanced prostatic cancer when orchidectomy is contraindicated. NoteNot in long term combination with an anti-androgenInitial application - (Endometriosis) only from a gynaecologist. Approvals valid for 6 months for applications meeting the following criteria: Both: 1 Endometriosis ; and 2 Either: 2.1 6 months treatment with medroxyprogesterone acetate, danazol or dimetriose has proven ineffective; or 2.2 The patient has failed to tolerate the treatment with medroxyprogesterone acetate, danazol or dimetriose for 6 months. NoteThe maximum treatment period for a GnRH analogue is: 3 months to assess whether surgery is appropriate3 m
Special Authority for Subsidy - Form SA0301Initial application only from a relevant specialist. Approvals valid for 2 years where type III dyslipidaemias. Renewal only from a relevant specialist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Waiver of Rule - Form SA0303Initial application only from a paediatric surgeon or paediatrician. Approvals valid for 1 year where children post liver transplant. Renewal only from a paediatric surgeon or paediatrician. Approvals valid for 1 year where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0309Initial application only from a neurologist or physician for the elderly (FRACP). Approvals valid for 2 years for applications meeting the following criteria: All of the following: 1 Idiopathic Parkinson's disease; and 2 The patient does not have dementia and/or neuropsychiatric disorders; and 3 Has responded to L-dopa; and 4 Any of the following: 4.1 Has resistance to conventional treatment of severe motor fluctuations; or 4.2 Has severe "off" period disability; or 4.3 Has severe "off" period dystonic cramps. Renewal only from a neurologist or physician for the elderly (FRACP). Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0311Initial application - (Breast or prostatic cancer) only from an oncologist, urologist or endocrinologist. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 Breast cancer in pre menopausal women unwilling or unable to undergo surgical or radiation oophorectomy; or 2 Advanced prostatic cancer when orchidectomy is contraindicated or where the patient srongly opposes orchidectomy. NoteNot to be prescribed with an anti-androgen except for a period of three weeks, if necessary, when GnRH analogue therapy is intiatedInitial application - (Endometriosis) only from a gynaecologist. Approvals valid for 6 months for applications meeting the following criteria: Both: 1 Endometriosis; and 2 Either: 2.1 6 months treatment with medroxyprogesterone acetate, danazol or dimetriose has proven ineffective; or 2.2 The patient has failed to tolerate the treatment with medroxyprogesterone acetate, danazol or dimetrio
Special Authority for Alternate Subsidy - Form SA0312Initial application only from an obstetrician, gynaecologist, general practitioner or general physician. Approvals valid for 5 years for applications meeting the following criteria: Any of the following: 1 acute or significant liver disease - a declaration must be provided from a gastroenterologist or general physician stating that oral oestrogens are contraindicated due to liver disease (Details to be attached to application); or 2 oestrogen induced hypertension requiring antihypertensive therapy - documented evidence must be provided that raised blood pressure levels or inability to control blood pressure adequately occurred post oral oestrogens (Details to be attached to application); or 3 hypertriglyceridaemia - documented evidence must be provided that triglyceride levels increased to at least 2 x normal triglyceride levels post oral oestrogens (Details to be attached to application). NotePrescriptions with a valid Special Authority (
Special Authority for Manufacturers Price - Form SA0313Initial application from any medical practitioner. Approvals valid for 5 years where the patient is likely to benefit from treatment. Renewal from any medical practitioner. Approvals valid for 5 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0317Initial application only from a renal physician. Approvals valid for 2 years for applications meeting the following criteria: All of the following: General Criteria: 1 Anaemia of end-stage renal failure (other treatable causes of anaemia being excluded); and 2 Been on haemodialysis or continuous ambulatory peritoneal dialysis (CAPD) for at least three months; and 3 Not under evaluation for, or awaiting, a live donor kidney transplant; and 4 Any of the following: Specific Criteria: 4.1 Anephric; or 4.2 Dependent on regular blood transfusion (1 unit each 4-8 weeks) to maintain haemoglobin > 60g/L; or 4.3 Cannot be transfused because of severe transfusion reactions; or 4.4 Transfusion induced haemosiderosis (clinical manifestations, serum ferritin >1500 ug/L); or 4.5 Haemoglobin < 70 g/L (mean of at least 4 haemoglobin concentrations over 4 months); or 4.6 Both: 4.6.1 Haemoglobin < 90 g/L; and 4.6.2 Either:
a) All nucleosides will be subsidised for patients meeting any of the following criteria: - All patients with AIDS meeting the definition developed by the Centers for Disease Control in the USA (see Circular Letter to Medical Practitioners HP2/88); or- Patients with AIDS Related Complex (ARC); or- HIV infected patients with CD4 (T4) counts below 500 regardless of symptomatology. b) Zidovudine will also be subsidised for patients meeting any of the following criteria: - Prophylactically for persons following severe parenteral exposure from a known HIV positive source; or- HIV infected persons with associated thrombocytopenia regardless of CD4 (T4) count; or- For the prevention of maternal foetal transmission of HIV. c) Applications can only be made by appropriate specialists. d) Prescriptions for those patients approved to use these medications can be written by either the specialist or general practitioner with an endorsement of the name of the recommending specialist.
Special Authority for Subsidy - Form SA0323Initial application only from a relevant specialist. Approvals valid for 2 years where children receiving frequent parenteral injections (i.e. intradermal, subcutaneous, intravenous or intramuscular) requiring a 21 gauge or larger bore needle. Renewal only from a relevant specialist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0325Initial application from any medical practitioner. Approvals valid for 5 years where applicatons will be considered and approved subject to funding availability. NoteApplications to be made on the approved forms which are available from the co-ordinator for the Cystic Fibrosis DN'ase Advisory Panel: The Co-ordinatorCystic Fibrosis DN'ase Advisory PanelC/- Room 4-28, Building 13 Greenlane HospitalPrivate Bag, AUCKLANDPhone: 09 630 9871Facsimile: 09 631 0753
Special Authority for Subsidy - Form SA0328Initial application only from a general physician. Approvals valid for 2 years for applications meeting the following criteria: Any of the following: 1 Both: 1.1 CD4 count < 500 cells/mm3; and 1.2 Viral load > 50,000> copies per ml (or equivalent value on the Chiron test); or 2 All of the following: 2.1 CD4 count < 500 cells/mm3; and 2.2 Viral load > 50,000> copies per ml (or equivalent value on the Chiron test); and 2.3 At least 6 weeks of dual therapy with nucleoside agents; or 3 Both: 3.1 CD4 count < 500 cells/mm3; and 3.2 CD4 counts are declining rapidly (>120 cells over 12 months or >60 - 80 cells over six months). Renewal only from a general physician. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
Guidelines for use of cyclosporin A in rheumatoid arthritisMonitoring: All patients require frequent monitoring for creatinine levels and blood pressure:- fortnightly, in the first three months of therapy and then monthly, if results are stable; - if dose is increased or there is a rise in serum creatinine or blood pressure, then more frequent monitoring is required. Contraindications: Cyclosporin A is contraindicated in patients with the following conditions: - current or past malignancy; - uncontrolled hypertension; - renal dysfunction (abnormal serum creatinine for age and sex); - immunodeficiency and neutropenia; - abnormally low white blood cell count or platelet count; or- liver function tests more than twice the upper limit of normal. Caution in use: - age above 65 years; - controlled hypertension; - use of ant-epileptic medications; - use of NSAIDs; - use of ketoconazole, fluconazole, trimethoprim, erythromycin, verapamil, and diltiazem; - concurrent or previous use of al
Special Authority - Retail pharmacy (Salmeterol, eformoterol fumarate):a) Approvals are interchangeable between all presenations of salmeterol and eformoterol fumarate agents. b) Diagnosis of asthma confirmed. c) Inhaler/device technique checked. d) At least three months of >= 1500 ug daily of beclomethasone inhaled steroid (or equivalent) for adult, or >= 800 ug daily for child. e) Patient monitors PEFR regularly during exacerbations where appropriate. f) Evidence of poor control (at least one of the following): - short acting beta agonist used > 3-4 time daily - nocturnal awakenings >= 2 times per week. g) The first applicaton may be for six months and subsequent applications for two yars. The criteria for reapplication are: - compliant with medication - improved asthma symptom control. h) Appication for Special Authority to be made by general practitioners or appropriate specialist.
a) Should be strictly reserved for use as second line therapy in: - patients unable to tolerate the other medications, such as infants, young children and patients with allergies or eczema; - cases of scabies which are resistent to gamma benzene hexachloride and resistant to malathion. b) Verification of drug resistance is dependent on the persistence of the condition after treatment. In order to establish whether there is drug resistance, the following criteria should be fulfilled: - a definite diagnosis of scabies should be made; - it should be ascertained that the medication was administered properly; - the possibility of reinfestation should have been excluded.
a) Approvals will be granted for treating the following conditions: - avium intracellular atypical mycobacterial infections; and- multiple drug resistant tuberculosis; and- atypical and drug-resistant mycobacterial infections in patients with AIDS. b) Specialist must make application - respiratory physician/ infectious disease specialist. c) Approvals will be valid for two years.
Special Authority for Manufacturers Price - Form SA0349Initial application only from a respiratory specialist or infectious disease specialist. Approvals valid for 2 years for applications meeting the following criteria: Any of the following: 1 Avium intracellular atypical mycobacterial infections; or 2 Multiple drug resistant tuberculosis; or 3 Atypical and drug-resistant mycobacterial infections in patients with AIDS. Renewal only from a respiratory specialist or infectious disease specialist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
Omeprazole and pantoprazole is subsidised for patients who have one or more of the conditions a-d: a) Duodenal ulcer proven by endoscopy or barium meal and after failure of: - two alternative courses of H. pylori eradication therapy (if H. pylori positive); and - H2 antagonist therapy for 8 weeks; and where a second endoscopy/barium meal has demonstrated non healing duodenal ulcer. b) Gastric ulcer proven by endoscopy and after failure of: - two alternative courses of H. pylori eradication therapy (if H. pylori positive); and - H2 antagonist therapy for 12 weeks; and where a second endoscopy has demonstrated non healing gastric ulcer and excluded malignancy. c) Gastro-oesophageal reflux disease (GORD) proven by endoscopy: - Grade 0 GORD (normal endoscopy) after positive 24 hour pH monitoring test and failure of H2 antagonist therapy for four weeks with multiple daily dosing; or - Grades 1 and 2 GORD after failure of H2 antagonist therapy for
Subsidy is available for disposable diabetic syringes and needles: 1) When the prescription is written on the same prescription form as the one used for the supply of insulin vials; or2) When "insulin patient" has been written on the prescription by either the doctor or the contractor; and3) For no more than 50 plastic syringes with attached needles as a single supply in the case of a prescription for three months supply of insulin vials; or4) For no more than 4 plastic syringes with attached needles as a single supply for each week's supply in the case of a prescription for less than three months supply of insulin vials.
Subsidy is available for insulin pen needles: 1) When the prescription is written on the same prescription form as the one used for the supply of insulin cartridges; or2) When "insulin patient" has been written on the prescription by either the doctor or the contractor; and3) For no more than 30 insulin pen needles as a single supply in the case of a prescription for three months supply of insulin cartridges; or4) For no more than 2 insulin pen needles as a single supply for each week's supply in the case of a prescription for less than three months supply of insulin cartridges.
Special Authority for Subsidy - Form SA0361Initial application only from a geriatrician, neurologist or general physician. Approvals valid for 2 years for applications meeting the following criteria: All of the following: 1 Disabling orthostatic hypotension not due to drugs; and 2 Patient has tried fludrocortisone (unless contra-indicated) with unsatisfactory results; and 3 Patient has tried non pharmacological treatments such as support hose, increased salt intake, exercise, and elevation of head and trunk at night. NoteTreatment should be started with small doses and titrated upwards as necessary. Hypertesion should be avoided, and the usual target is a standing systolic blood pressure of 90 mm Hg. Renewal only from a geriatrician, neurologist or general physician. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0366Initial application - (North Island patients) from any medical practitioner. Approvals valid for 5 years where the patient is likely to benefit from treatment. NoteFor details of the patient criteria, prescriber criteria, application and reporting forms contact the appointed clinician: Dr Richard FisherFertility Associates131 Remuera RoadAUCKLANDFax: 09 520 0499Appointed clinicians will distribute these agents to prescribers whose applications are approvedInitial application - (South Island patients) from any medical practitioner. Approvals valid for 5 years where the patient is likely to benefit from treatment. NoteFor details of the patient criteria, prescriber criteria, application and reporting forms contact the appointed clinician: Dr Peter BennyChristchurch Women's HospitalPrivate Bag 4711CHRISTCHURCHFax: 03 364 4634Appointed clinicians will distribute these agents to prescribers whose applications are approved
Subsidy is available for disposable and non-disposable insulin syringes, needles, and pen needles if prescribed on the same form as the one used for the supply of insulin or when prescribed for an insulin patient and the prescription is endorsed accordingly.
Up to 50 plastic syringes with attached needles may be dispensed in the case of a prescription for three months supply of insulin vials; orUp to four plastic syringes with attached needles may be dispensed for each week's supply in the case of a prescription for less than three months supply of insulin vials.
Up to 30 pen needles may be dispensed in the case of a prescription for three months supply of insulin cartridges; orUp to two pen needles may be dispensed for each week's supply in the case of a prescription for less than three months supply of insulin cartridges.
Special Authority for Subsidy - Form SA0382Initial application only from a gastroenterologist, general surgeon or general physician. Approvals valid for 3 years for applications meeting the following criteria: Any of the following: 1 All of the following: 1.1 Duodenal ulcer proven by endoscopy or barium meal; and 1.2 Failure of two alternative courses of H. pylori eradication therapy (if H. pylori positive); and 1.3 Non healing duodenal ulcer proven by second barium meal; and 1.4 H2 antagonist therapy for 8 weeks; or 2 All of the following: 2.1 Gastric ulcer proven by endoscopy; and 2.2 Two alternative courses of H. pylori eradication therapy (if H. pylori positive); and 2.3 Non healing gastric ulcer and excluded malignancy demonstrated by a second endoscopy; and 2.4 H2 antagonist therapy for 12 weeks; or 3 All of the following: 3.1 Grade 0 GORD (normal endoscopy); and 3.2 Positive 24 hour pH monitoring test; and 3.3 Failure of H2 antagonist t
n) Further approvals to fund the manufacturer's surcharge on either pravastatin or simvastatin (if applicable) may be granted to patients who are unable to continue treatment with fluvastatin due to adverse effects. Either general practitioners or specialist may make the application. To obtain a new Special Authority number, the application must include the following information: - the amount of time the patient has been treated with fluvastatin; and- the adverse effects experienced by the patient. o) Further approvals to fund the manufacturer's surcharge on simvastatin may be granted to patients with familial hypercholesterolaemia (FH) or familial combined hypercholesterolaemia (FCH) if a specialist considers that the patient is not achieving sufficient benefit from the fully funded statin(s). Only specialists may make application. To obtain a new Special Authority number, the application must include the following information: - the cholesterol level before and after treatment with the fully funded sta
Special Authority for Subsidy - Form SA0387Initial application - (Breast or prostatic cancer) only from an oncologist, urologist or endocrinologist. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 Breast cancer in pre menopausal women unwilling or unable to undergo surgical or radiation oophorectomy; or 2 Advanced prostatic cancer when orchidectomy is contraindicated or where the patient srongly opposes orchidectomy. NoteNot to be prescribed with an anti-androgen except for a period of three weeks, if necessary, when GnRH analogue therapy is intiatedInitial application - (Endometriosis) only from a gynaecologist. Approvals valid for 6 months for applications meeting the following criteria: Both: 1 Endometriosis; and 2 Either: 2.1 6 months treatment with medroxyprogesterone acetate, danazol or dimetriose has proven ineffective; or 2.2 The patient has failed to tolerate the treatment with medroxyprogesterone acetate, danazol or dimetrio
Special Authority for Subsidy - Form SA0391Initial application only from a relevant specialist. Approvals valid for 5 years for applications meeting the following criteria: Either: 1 Liver transplant recipients; or 2 Renal transplant recipients - as rescue therapy only. Renewal only from a relevant specialist. Approvals valid for 5 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Manufacturers Price - Form SA0394Initial application - (Helicobacter pylori infections) only from a general practitioner or relevant specialist. Approvals valid for 6 months for applications meeting the following criteria: Both: 1 Eradication of Helicobacter pylori in patient with proven infection; and 2 Peptic ulcer disease proven by endoscopy. NoteMaximum of two prescriptions (two courses) per patient. Initial application - (Mycobacterial infections) only from a respiratory specialist or infectious disease specialist. Approvals valid for 2 years for applications meeting the following criteria: Any of the following: 1 Mycobacterium Avium Intracellulare Complex infections in patient with AIDS; or 2 Atypical and drug-resistant mycobacterial infection; or 3 All of the following: 3.1 Prophylaxis against disseminated Mycobacterium Avium Intracellulare Complex infection; and 3.2 HIV infection; and 3.3 CD4 count <= 50 cells/mm3. Renewal - (Mycobacteri
a) Cyproterone acetate with ethinyloestradiol is available from retail pharmacy to patients as indicated. b) Prescribers may code prescriptions "contraceptive" (code "O") when used as indicated for contraception. The period of supply and prescription charge will be as per other contraceptives, as follows: - $3.00 prescription charge (patient co-payment) will apply; - Prescription may be written for up to 6 months supply; and- Pharmacists may dispense up to 3 month supply. c) Prescriptions coded in any other way are subject to the non-contraceptive prescription charges, and the non-contraceptive period of supply. Eg. Prescriptons may be written for up to 3 months supply, and dispensed monthly. d) The Special Authority number for hormonal contraceptive agents (combined and progesterone-only) does not apply, and is not interchangeable. e) Health Benefits Limited will return any claims unpaid as follows: - any uncoded prescription; - any prescription that does not have a period of supply or the quantity
Special Authority for Subsidy - Form SA0401Initial application - (Basal cell carcinoma) only from a dermatologist, plastic surgeon or radiation oncologist. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 Basal cell carcinoma unable to be treated surgically or by radiotherapy; and 2 Unsuitability for surgery confirmed by a Plastic Surgeon or Oncologist. NoteMaximum reimbursable dosage 15 million iu/weekInitial application - (Chronic hepatitis C) only from a relevant specialist. Approvals valid for 12 months where chronic hepatitis C. Initial application - (Indications other than Basal cell carcinoma and Chronic hepatitis C) only from a relevant specialist, plastic surgeon or radiation oncologist. Approvals valid for 2 years for applications meeting the following criteria: Any of the following: 1 Chronic myelogenous leukaemia; or 2 Hairy cell leukaemia; or 3 Cutaneous T cell lymphoma; or 4 Essential thrombocythaemia; or 5 Multiple myelo
Special Authority for Subsidy - Form SA0402Initial application - (Patients aged 74 and under) only from a general practitioner. Approvals valid for 2 years for applications meeting the following criteria: All of the following: 1 Patients aged 74 and under; and 2 The patient has been offered 3-6 months of counselling and an opportunity to modify lifestyle; and 3 Any of the following: 3.1 Both: 3.1.1 NHF A1:1 - Clinically proven ischaemic heart disease; and 3.1.2 total cholesterol > 6.0; or 3.2 Both: 3.2.1 NHF A1:2 - Post coronary artery bypass graft (CABG); and 3.2.2 total cholesterol > 5.5; or 3.3 Both: 3.3.1 NHF B:Patients with > 20% 5-year cardiovascular disease risk; and 3.3.2 total cholesterol > 9.0; or 3.4 Both: 3.4.1 NHF C:15-20% 5-year cardiovascular disease risk; and 3.4.2 total cholesterol > 9.0; or 3.5 Both: 3.5.1 NHF D:10-15% 5-year cardiovascular disease risk; and 3.5.2 total cholesterol > 9.0; or 3.6
Special Authority for Subsidy - Form SA0403Initial application only from a nephrologist or transplant surgeon. Approvals valid for 12 months where renal transplant recipient. Renewal only from a nephrologist or transplant surgeon. Approvals valid for 12 months where re-graft patient.
Special Authority for Subsidy - Form SA0404Initial application only from an ophthalmologist. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 Primary open-angle glaucoma; and 2 Either: 2.1 Other subsidised glaucoma medical therapy is contraindicated; or 2.2 Both: 2.2.1 intra-ocular pressure > 26 mmHg (average from consecutive measurements); and 2.2.2 Unable to be controlled using other subsidised medical therapy. Renewal only from an ophthalmologist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Manufacturers Price - Form SA0410Initial application from any medical practitioner. Approvals valid for 2 years for applications meeting the following criteria: Any of the following: 1 Polycystic ovarian syndrome; or 2 Hirsutism; or 3 Androngenic alopecia. Renewal from any medical practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Manufacturers Price - Form SA0411Renewal from any medical practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
Funding of manufacturers surcharge for existing patients taking ACE inhibitors for Congestive Heart Failure.a) Patients taking any ACE inhibitor for the treatment of congestive heart failure prior to 1 June 1998 can continue to have their ACE inhibitor treatment fully subsidised; b) Prescribers must endorse the prescription 'Congestive Heart Failure'. The endorsement can be typed (this includes computer generated prescriptions) or handwritten; c) The endorsement must be initialled in the prescriber's own handwriting. Definition of Congestive Heart FailureAt the request of some prescribers the PTAC Cardiovascular subcommittee has provided a definition of congestive heart failure for the purposes of the funding of the manufacturer's surcharge: "Clinicians should use their clinical judgement. Existing patients would be eligible for the funding of the surcharge if the patient shows signs and symptoms of congestive heart failure, and requires or has in the past required concomitant treatment with a
Special Authority for Subsidy - Form SA0423Initial application only from a gastroenterologist, general surgeon or general physician. Approvals valid for 3 years for applications meeting the following criteria: Any of the following: 1 All of the following: Duodenal Ulcer: 1.1 Duodenal ulcer proven by endoscopy or barium meal; and 1.2 Non healing duodenal ulcer proven by second barium meal; and 1.3 After failure of two alternative courses of H. pylori eradication therapy (if H. pylori positive); and 1.4 After H2 antagonist therapy for 8 weeks; or 2 All of the following: Gastric Ulcer: 2.1 Gastric ulcer proven by endoscopy; and 2.2 Non healing gastric ulcer and excluded malignancy demonstrated by a second endoscopy; and 2.3 After two alternative courses of H. pylori eradication therapy (if H. pylori positive); and 2.4 After H2 antagonist therapy for 12 weeks; or 3 All of the following: GORD: 3.1 Grade 0 GORD (normal endoscopy); and 3.2 Positive 24
Special Authority for Subsidy - Form SA0424Initial application - (Confirmed HIV/AIDS) only from a general physician. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 Confirmed HIV/AIDS; and 2 Any of the following: 2.1 Symptomatic patients aged 6 years and over with HIV/AIDS; or 2.2 Both: 2.2.1 Asymptomatic patients aged 6 years and over; and 2.2.2 CD4 counts < 500 cells/mm3; or 2.3 Both: 2.3.1 Asymptomatic patients aged 6 years and over; and 2.3.2 Viral load counts > 10,000 copies per ml; or 2.4 Symptomatic patients aged under 6 with HIV/AIDS ; or 2.5 Asymptomatic patients aged 12 months and under; or 2.6 Both: 2.6.1 Asymptomatic patients aged 1 to 5 years; and 2.6.2 CD4 counts < 1,000 cells/mm3; or 2.7 Both: 2.7.1 Asymptomatic patients aged 1 to 5 years; and 2.7.2 CD4 counts < 0.25 x total white cell count; or 2.8 Both: 2.8.1 Asymptomatic patients aged under 6 years; and
If a Community Pharmaceutical is the liquid oral form of an antibiotic to which a diluent must be added by the Contractor at the time of dispensing and it is prescribed or ordered by a Practittioner in an amount that does not coincide with the amount contained in one or more standard packs of that Community Pharmaceutical, Subsidy will only be made for the amount prescribed or ordered by the Practitioner in accordance with either Clause 3.1 or Clause 3.3 of the Schedule, unless the Contractor satisfies the Funder that he or she has not been able to dispense the balance of the pack or packs from which the Community Pharmaceutical has been dispensed. In such cases all of that pack or those packs is eligible for Subsidy.
Special Authority for Subsidy - Form SA0430Initial application - (National Heart Foundation risk groups A1:1, A1:2, B, C, D or E) only from a relevant specialist or general practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria: Both: 1 The patient has been offered 3-6 months of counselling and an opportunity to modify lifestyle; and 2 Any of the following: 2.1 Both: 2.1.1 NHF A1:1 - Clinically proven ischaemic heart disease; and 2.1.2 total cholesterol * > 5.5; or 2.2 Both: 2.2.1 NHF A1:2 - Post coronary artery bypass graft (CABG) or angioplasty; and 2.2.2 total cholesterol * > 4.5; or 2.3 Post heart transplant (regardless of cholesterol level); or 2.4 Both: 2.4.1 NHF B:Patients with > 20% 5-year cardiovascular disease risk; and 2.4.2 total cholesterol * > 9.0; or 2.5 Both: 2.5.1 NHF C:15-20% 5-year cardiovascular disease risk; and 2.5.2 total cholesterol * > 9
Special Authority for Manufacturers Price - Form SA0434Initial application only from a general practitioner, general physician, geriatrician or neurologist. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 Patients with swallowing difficulties; and 2 Applicant is a specialist or specialist has authorised treatment. Renewal only from a general practitioner, general physician, geriatrician or neurologist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Manufacturers Price - Form SA0435Initial application from any medical practitioner. Approvals valid for 6 months where control of nausea and vomiting in the treatment of terminal care patients. Renewal from any medical practitioner. Approvals valid for 6 months where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Manufacturers Price - Form SA0436Initial application - (Patient with prosthetic heart valves) only from a cardiothoracic surgeon, cardiologist or general physician. Approvals valid for 2 years where patient with prosthetic heart valves - as an adjunct to oral anticoagulation for prophylaxis of thromboembolism. Initial application - (Following coronary artery vein bypass graft) only from a cardiothoracic surgeon, cardiologist or general physician. Approvals valid for 1 year where patients after coronary artery vein bypass graft - as an adjunct to aspirin or as monotherapy for patients who are aspirin intolerant as defined below. Initial application - (Transient ischaemic episodes) only from a neurologist, neuro surgeon, cardiologist, vascular surgeon or general physician. Approvals valid for 2 years where patients who continue to have transient ischaemic episodes despite aspirin therapy or have transient ischaemic episodes and are aspirin intolerant as defined below. Renewal - (Fo
Special Authority for Subsidy - Form SA0443Initial application - (Helicobacter pylori infections) only from a general practitioner or relevant specialist. Approvals valid for 6 months for applications meeting the following criteria: Both: 1 Eradication of Helicobacter pylori in patient with proven infection; and 2 Peptic ulcer disease proven by endoscopy. NoteMaximum of two prescriptions (two courses) per patient. Initial application - (Mycobacterial infections) only from a respiratory specialist or infectious disease specialist. Approvals valid for 2 years for applications meeting the following criteria: Any of the following: 1 Mycobacterium Avium Intracellulare Complex infections in patient with AIDS; or 2 Atypical and drug-resistant mycobacterial infection; or 3 All of the following: 3.1 Prophylaxis against disseminated Mycobacterium Avium Intracellulare Complex infection; and 3.2 HIV infection; and 3.3 CD4 count <= 50 cells/mm3. Renewal - (Mycobacterial infection
Special Authority for Subsidy - Form SA0445Initial application only from a relevant specialist. Approvals valid for 5 years for applications meeting the following criteria: Any of the following: 1 Both: 1.1 Acromegaly; and 1.2 Patient has failed surgery, radiotherapy, bromocriptine or other oral therapies; or 2 VIPomas and Glucagonomas - for patients who are seriously ill in order to improve their clinical state prior to definitive surgery.; or 3 Both: 3.1 Gastrinoma; and 3.2 Patient has failed surgery, or metastatic disease after H2 antagoists (or proton pump inhibitors) have failed; or 4 Both: 4.1 Insulinomas; and 4.2 Surgery is contraindicated or has failed; or 5 For pre-operative control of hypoglycaemia and for maintenance therapy; or 6 Both: 6.1 Carcinoidsyndrome (diagnosed by tissue pathology and/or urinary 5HIAA analysis); and 6.2 Disabling symptoms not controlled by maximal medical therapy. NoteThe use of octretide in patients with fis
Special Authority for Subsidy - Form SA0450Initial application only from a psychiatrist. Approvals valid for 12 months for applications meeting the following criteria: Both: 1 Patients suffering from schizophrenia and related psychoses; and 2 Either: 2.1 Failed to respond to full trials (duration of at least 6 weeks each) of effective doses of at least two classes of anti-psychotic agents (refer to guidelines below); or 2.2 Demonstrated intolerance to other neuroleptic agents. NoteClinicians must confirm that informed consent and a satisfactory White Bloodcell Count (WBC) result has been obtained. Diagnosis: Treatment resistant schizophrenia and related psychoses when positive symptoms (delusions, hallucinations and thought disorder) are prominent and/or disabling or when both positive symptoms and negative symptoms (flattened affect, emotional and social withdrawal and poverty of speech) are present. Treatment: Trial therapy undertaken before initiating treatment with clozapine could
Special Authority for Manufacturers Price - Form SA0451Initial application only from a relevant specialist. Approvals valid for 3 years for applications meeting the following criteria: Both: 1 Patients being treated for advanced breast cancer who are refractory to tamoxifen; and 2 Any of the following: 2.1 Unable to tolerate aminoglutethimide; or 2.2 Unable to tolerate megestrol acetate; or 2.3 Unable to tolerate medroxyprogesterone acetate.Renewal only from a relevant specialist. Approvals valid for 3 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Manufacturers Price - Form SA0452Initial application only from a relevant specialist. Approvals valid for 3 years for applications meeting the following criteria: Both: 1 Patients being treated for advanced breast cancer who are refractory to tamoxifen; and 2 Any of the following: 2.1 Unable to tolerate aminoglutethimide; or 2.2 Unable to tolerate megestrol acetate; or 2.3 Unable to tolerate medroxyprogesterone acetate.Renewal only from a relevant specialist. Approvals valid for 3 years where the treatment remains appropriate and the patient is benefiting from treatment.
Guidelines for the use of atypical anti-psychotic agents Diagnosis: Schizophrenia and related psychoses when positive symptoms (delusions, hallucinations and thought disorder) are prominent and/or disabling or when both positive symptoms and negative symptoms (flattened affect, emotional and social withdrawal and poverty of speech) are present. Treatment: Before initiating atypical anti-psychotic therapy, physicians should consider whether the patient is likely to respond to and/or tolerate conventional anti-psychotic therapy and, where appropriate, trial one or more conventional agent prior to use of an atypical agent.
Special Authority for Subsidy - Form SA0456Initial application only from a psychiatrist. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 Patients suffering from schizophrenia and related psychoses who are likely to benefit from anti-psychotic treatment; and 2 Any of the following: 2.1 Effective dose of risperidone has been discontinued because of recurrent acute dystonias; or 2.2 Effective dose of risperidone has been discontinued because of excessive Parkinson-like symptoms; or 2.3 Effective dose of risperidone has been discontinued after 6 weeks because of inadequate clinical response. Renewal only from a psychiatrist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0458Initial application only from a gastroenterologist. Approvals valid for 6 months for applications meeting the following criteria: Both: 1 Primary biliary cirrhosis confirmed by antimitochondrial antibody titre (AMA) > 1:80, and raised cholestatic liver enzymes with or without raised serum IgM or, if AMA is negative, by liver biopsy; and 2 Patient not requiring a liver transplant (bilirubin > 170umol/l; decompensated cirrhosis). NoteLiver biopsy is not usually required for diagnosis but is helpful to stage the diseaseRenewal only from a gastroenterologist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment. NoteActigall is not an appropriate therapy for patients requiring a liver transplant (bilirubin > 170 micromol/l; decompensated cirrhosis). These patients should be referred to an appropriate transplant centreTreatment failure - doubling of serum bilirubin levels, absence of a signi
Special Authority for Subsidy - Form SA0459Initial application only from a gastroenterologist or general physician. Approvals valid for 3 months for applications meeting the following criteria: Both: 1 Mild to moderate ileal, ileocaecal or proximal Crohn's disease; and 2 Any of the following: 2.1 Diabetes; or 2.2 Cushingoid habitus; or 2.3 Osteoporosis where there is significant risk of fracture; or 2.4 Both: 2.4.1 Severe acne; and 2.4.2 Treatment with conventional corticosteroid therapy. Renewal only from a gastroenterologist or general physician. Approvals valid for 3 months where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Manufacturers Price - Form SA0460Initial application - (Patient with prosthetic heart valves) only from a cardiothoracic surgeon, cardiologist or general physician. Approvals valid for 2 years where patient with prosthetic heart valves - as an adjunct to oral anticoagulation for prophylaxis of thromboembolism. Initial application - (Following coronary artery vein bypass graft) only from a cardiothoracic surgeon, cardiologist or general physician. Approvals valid for 1 year where patients after coronary artery vein bypass graft - as an adjunct to aspirin or as monotherapy for patients who are aspirin intolerant as defined below. Initial application - (Transient ischaemic episodes) only from a neurologist, neuro surgeon, cardiologist, vascular surgeon or general physician. Approvals valid for 2 years where patients who continue to have transient ischaemic episodes despite aspirin therapy or have transient ischaemic episodes and are aspirin intolerant as defined below. Renewal - (Fo
Special Authority for Subsidy - Form SA0461Initial application - (Basal cell carcinoma) only from a dermatologist, plastic surgeon or radiation oncologist. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 Basal cell carcinoma unable to be treated surgically or by radiotherapy; and 2 Unsuitablity for surgery confirmed by a Plastic Surgeon or Radiation Oncologist. NoteThe maximum reimbursable dosage is 15 million iu per weekInitial application - (Chronic hepatitis C) only from a relevant specialist. Approvals valid for 12 months where chronic hepatitis C. Initial application - (Indications other than Basal cell carcinoma and Chronic hepatitis C) only from a relevant specialist. Approvals valid for 2 years for applications meeting the following criteria: Any of the following: 1 Chronic myelogenous leukaemia; or 2 Hairy cell leukaemia; or 3 Multiple myeloma; or 4 Chronic active hepatitis B. Renewal - (Basal cell carcinoma) only from a dermato
Special Authority for Subsidy - Form SA0464Initial application only from a diabetologist, general physician or paediatrician. Approvals valid without further renewal unless notified for applications meeting the following criteria: Any of the following: 1 Both: 1.1 Use alone (monotherapy); and 1.2 The patient is unable to use any other insulins including those on insulin pump treatment; or 2 Both: 2.1 Use with Humulin 70/30 or Humulin 80/20; and 2.2 A reasonable trial of Humulin N has been undertaken and it is not effective or not well tolerated; or 3 Both: 3.1 Use with insulins (aside from insulin zinc suspension) other than Humulin 70/30, Humulin 80/20, or Humulin N; and 3.2 A reasonable trial of one or more of these Humulin insulins has been undertaken and it is/are ineffective or not well tolerated; or 4 Both: 4.1 Use with Humulin L or Humulin U; and 4.2 Use with Humulin N is not appropriate; or 5 Both: 5.1 Use with other insulin zinc suspensio
Special Authority for Alternate Subsidy - Form SA0466Initial application only from a relevant specialist or general practitioner. Approvals valid for 5 years for applications meeting the following criteria: Any of the following: 1 Angina that is not controlled by other anginal medications; or 2 Continuation of treatment commenced prior to 1 June 1999; or 3 Receiving maximal antihypertensive therapy, requires a DHP CCB, and cannot tolerate felodipine. Renewal only from a relevant specialist or general practitioner. Approvals valid for 5 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0467Initial application only from a relevant specialist. Approvals valid for 6 months for applications meeting the following criteria: Both: 1 Paget's disease; and 2 Any of the following: 2.1 Bone or articular pain; or 2.2 Bone deformity; or 2.3 Bone, articular or neurological complications; or 2.4 Asymptomatic disease, but risk of complications due to site (base of skull, spine, long bones of lower limbs); or 2.5 Preparation for orthopaedic surgery. Renewal only from a relevant specialist. Approvals valid for 6 months where the treatment remains appropriate and the patient is benefiting from treatment.
a) On a prescription or practitioner's supply order only when on the same form as an injection listed in the Pharmaceutical Schedule requiring a solvent or diluent b) On a bulk supply orderc) When used in the extemporaneous compounding of eye drops
Special Authority for Subsidy - Form SA0470Initial application - (Organ transplant) only from a relevant specialist. Approvals valid without further renewal unless notified where organ transplant. Initial application - (Bone marrow transplant or Graft v host disease) only from a relevant specialist. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 Bone marrow transplant; or 2 Graft v host disease. Initial application - (Psoriasis) only from a dermatologist. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 Psoriasis; and 2 Applicant must state which systemic and topical therapies have failed. Initial application - (Severe atopic dermatitis) only from a dermatologist. Approvals valid for 6 months for applications meeting the following criteria: Both: 1 Severe atopic dermatitis; and 2 Not responsive to topical therapy, oral antihistamines and other commonly used orthodox therapies. Initial application - (N
Special Authority for Subsidy - Form SA0471Initial application - (Breast cancer) from any medical practitioner. Approvals valid for 1 year where breast cancer in pre menopausal women unwilling or unable to undergo surgical or radiation oophorectomy. Initial application - (Prostate cancer) only from an oncologist, urologist or endocrinologist. Approvals valid for 1 year where advanced prostatic cancer when orchidectomy is contraindicated or where the patient strongly opposes orchidectomy. NoteNot to be prescribed with an anti-androgen except for a period of three weeks, if necessary, when GnRH analogue therapy is intiatedInitial application - (Endometriosis) only from a gynaecologist. Approvals valid for 3 months for applications meeting the following criteria: Both: 1 Endometriosis ; and 2 Either: 2.1 6 months treatment with medroxyprogesterone acetate, danazol or dimetriose has proven ineffective; or 2.2 The patient has failed to tolerate the treatment with medroxyprogesterone
Special Authority for Subsidy - Form SA0472Initial application only from a cardiologist. Approvals valid for 2 years for applications meeting the following criteria: Any of the following: 1 Both: 1.1 Congestive heart failure; and 1.2 Cannot tolerate currently fully subsidised ACE inhibitors due to persistent cough that resolves on cessation and recurs on re-challenge with ACE inhibitor; or 2 Patients who have experienced angioedema on an ACE inhibitor at any time in the past; or 3 Patients who have experienced angioedema (even if not using an ACE inhibitor) in the last 2 years. Renewal only from a cardiologist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0473Initial application from any medical practitioner. Approvals valid for 1 year where the patient is likely to benefit from treatment. Note Applications to be made on the approved forms which are available from: The Co-ordinatorGaucher's Treatment PanelPhone: (04) 460 4990 PHARMAC, PO Box 10 254 WellingtonFacsimile: (04) 916 7571Email: erin.murphy@pharmac.govt.nzPrescriptions for patients approved for treatment must be written by respiratory physicians or paediatricians who have experience and expertise in treating cystic fibrosis.
a) When prescribed (alone or in combination) for renal dialysis in the home of the patient concerned.b) Only maternity hospital, or on the prescription of a practitioner. c) Obstetric cream only in a quantity not exceeding 500 ml per prescription or on a bulk supply order. d) Solution 5% in quantity not exceeding 100 ml per prescription or on a bulk supply order.
a) Only in combination with aqueous cream, 10 % urea cream, wool fat with mineral oil lotion, 1% hydrocortisone with wool fat and mineral oil lotion, and glycerol, paraffin and cetyl alcohol lotion; b) With or without phenol liquefied.
a) Only in combination with aqueous cream, 10 % urea cream, wool fat with mineral oil lotion, 1% hydrocortisone with wool fat and mineral oil lotion, and glycerol, paraffin and cetyl alcohol lotion; b) With or without menthol crystals.
Special Authority for Subsidy - Form SA0488Initial application only from a gastroenterologist, general surgeon or general physician. Approvals valid for 3 months for applications meeting the following criteria: Both: 1 Mild to moderate ileal, ileocaecal or proximal Crohn's disease; and 2 Any of the following: 2.1 Diabetes; or 2.2 Cushingoid habitus; or 2.3 Osteoporosis where there is significant risk of fracture; or 2.4 Both: 2.4.1 Severe acne; and 2.4.2 Treatment with conventional corticosteroid therapy. Renewal only from a gastroenterologist, general surgeon or general physician. Approvals valid for 3 months where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Manufacturers Price - Form SA0489Initial application - (Conditions other than transient ischaemic episodes) only from a cardiothoracic surgeon, cardiologist or general physician. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 Patients with prosthetic heart valves - as an adjunct to oral anticoagulation for prophylaxis of thromboembolism; or 2 Both: 2.1 Patients after coronary artery vein bypass graft; and 2.2 Any of the following: 2.2.1 aspirin induced asthma; or 2.2.2 aspirin induced anaphylaxi; or 2.2.3 significant aspirin induced bleeding excluding bruising. Initial application - (Transient ischaemic episodes) only from a neurologist, neuro surgeon, cardiologist, vascular surgeon or general physician. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 Patients who continue to have transient ischaemic episodes despite aspirin therapy; or 2 Both: 2.1 Patients wh
Special Authority for Subsidy - Form SA0490Initial application only from a relevant specialist. Approvals valid for 2 years for applications meeting the following criteria: Any of the following: 1 Requires but is not able to tolerate metformin therapy; or 2 Requires metformin but metformin is contraindicated; or 3 Has not responded to or tolerated the maximum appropriate dose of metformin. Renewal only from a relevant specialist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0494Initial application only from an ophthalmologist. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 Both: 1.1 Primary open-angle glaucoma; and 1.2 Any of the following: 1.2.1 Patient cannot tolerate Beta-blockers, or Beta-blockers are contraindicated; or 1.2.2 Patient cannot tolerate Pilocarpine, or Pilocarpine is contraindicated; or 1.2.3 Patient cannot tolerate Dorzolamide, or Dorzolamide is contraindicated; or 1.2.4 A reduction in intraocular pressure of 15% or more is not achieved or maintained using dorzolamide either alone or in combination with a beta-blocker; or 2 There is progressive visual field loss and/or optic nerve damage persists after treatment with dorzolamide either alone or in combination with a beta-blocker. NoteSubsidised as monotherapy onlyRenewal only from an ophthalmologist. Approvals valid for 2 years where the treatment remains appropriate and the patient
Special Authority for Alternate Subsidy - Form SA0500Initial application from any medical practitioner. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 Either: 1.1 Patient is on a Social Welfare benefit; or 1.2 Patient has an income no greater than the benefit; and 2 Has tried at least one of the fully funded options and has been unable to tolerate it. Renewal from any medical practitioner. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 Patient is on a Social Welfare benefit; or 2 Patient has an income no greater than the benefit. NoteThe approval numbers of Special Authorities approved after 1 November 1999 are interchangeable between Mercilon and Marvelon. The additional subsidy will fund Mercilon and Marvelon up to the manufacturer's price for each of these products as identified on the Schedule at 1 November 1999Special Authorities approved before 1 November 1999 remain valid until the expiry d
a) Hospital pharmacy [HP3] - Maximum of 750mg (3 injections) per prescription; orb) Hospital pharmacy [HP3] - specialist - Only if prescribed for a dialysis or cystic fibrosis patient; and- The prescription is endorsed accordingly.
a) Only if prescribed for a dialysis or cystic fibrosis patient or in the treatment of pseudo membranous colitis or for prophylaxis of endocarditis; and b) The prescription is endorsed accordingly.
Special Authority for Subsidy - Form SA0508Initial application only from a relevant specialist or general practitioner. Approvals valid for 2 years for applications meeting the following criteria: All of the following: 1 Patient with raised blood pressure; and 2 A beta blocker or diuretic is contraindicated; or not well tolerated; or insufficient to control blood pressure adequately at appropriate doses; and 3 An ACE inhibitor is contraindicated; or not well tolerated; or insufficient to control blood pressure adequately at appropriate doses. Renewal only from a relevant specialist or general practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0509Initial application only from a psychiatrist. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 Patient with first episode schizophrenia or related psychoses; or 2 Both: 2.1 Patient suffering from schizophrenia and related psychoses who is likely to benefit from anti-psychotic treatment; and 2.2 Both: 2.2.1 An effective dose of risperidone had been trialled and has been discontinued either because of; and 2.2.2 Any of the following: 2.2.2.1 Patient has recurrent acute dystonias; or 2.2.2.2 Patient has excessive Parkinson-like symptoms; or 2.2.2.3 Patient has hyperprolactinaemia; or 2.2.2.4 Patient has inadequate clinical response after four weeks. NoteDiscontinued treatment should be notified to HealthPAC if possibleRenewal only from a psychiatrist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Alternate Subsidy - Form SA0510Initial application only from a relevant specialist or general practitioner. Approvals valid for 2 years for applications meeting the following criteria: Any of the following: 1 Angina that is not controlled by other anginal medications (including felodipine); or 2 Patient was taking Adalat Oros for the treatment of angina prior to 1 June 1999; or 3 Receiving maximal antihypertensive therapy, requires a DHP CCB, and cannot tolerate felodipine. Renewal only from a relevant specialist or general practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0511Initial application only from a geriatrician, rheumatologist, endocrinologist, gynaecologist or general physician. Approvals valid for 2 years for applications meeting the following criteria: All of the following: 1 Severe osteoporosis; and 2 History of two previous significant osteoporotic fractures demonstrated radiologically; and 3 T-Score <= -3.0 (bone mass density (BMD) >= 3.0 standard deviations below the mean normal value in young adults). NoteIn line with the Australian guidelines for funding alendronate, a vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral bodyRenewal only from a geriatrician, rheumatologist, endocrinologist, gynaecologist or general physician. Approvals valid for 2 years where the tr
Special Authority for Subsidy - Form SA0512Initial application only from a gastroenterologist, general surgeon or general physician. Approvals valid for 3 months for applications meeting the following criteria: Both: 1 Mild to moderate ileal, ileocaecal or proximal Crohn's disease; and 2 Either: 2.1 Diabetes; or 2.2 Both: 2.2.1 Treatment with conventional corticosteroid therapy; and 2.2.2 Any of the following: 2.2.2.1 Cushingoid habitus; or 2.2.2.2 Osteoporosis where there is significant risk of fracture; or 2.2.2.3 Severe acne. Renewal only from a gastroenterologist, general surgeon or general physician. Approvals valid for 3 months where the patient has had no more than 1 prior approval in the last 12 months. The patient must have had no more than 1 prior approval in the last year. NoteClinical trials for Entocort CIR use beyond three months demonstrated no improvement in relapse rate
Special Authority for Subsidy - Form SA0513Initial application - (Narcolepsy) only from a neurologist. Approvals valid for 24 months where narcolepsy. Initial application - (ADHD in patients aged 5 years or over) only from a paediatrician or psychiatrist. Approvals valid for 24 months for applications meeting the following criteria: Both: 1 ADHD (Attention Deficient and Hyperactivity Disorder) patients aged 5 years or over; and 2 Diagnosed according to DSM-IV or ICD 10 criteria. Initial application - (ADHD in patients under 5 years of age) only from a paediatrician or psychiatrist. Approvals valid for 12 months for applications meeting the following criteria: Both: 1 ADHD (Attention Deficient and Hyperactivity Disorder) patients under 5 years of age; and 2 Diagnosed according to DSM-IV or ICD 10 criteria. Renewal - (Narcolepsy or ADHD in patients under 5 years of age) only from a neurologist, paediatrician or psychiatrist. Approvals valid for 24 months where the treatment remains appr
Special Authority for Subsidy - Form SA0516Initial application from any medical practitioner. Approvals valid for 2 years where the patient is likely to benefit from treatment. Note Applications to be made on the approved forms which are available from: Prof. Wayne CutfieldNational Co-ordinatorNew Zealand Growth Hormone CommitteeC/- Department of PaediatricsUniversity of AucklandPrivate Bag 92019AUCKLAND
Special Authority for Subsidy - Form SA0523Initial application only from a relevant specialist or general practitioner. Approvals valid for 6 months for applications meeting the following criteria: All of the following: 1 Diagnosis of asthma confirmed; and 2 Inhaler/device technique checked; and 3 Patient monitors PEFR regularly during exacerbations where appropriate; and 4 Any of the following: 4.1 At least three months of 1500 ug or more daily of inhaled beclomethasone or budesonide for adult; or 4.2 At least three months of 750 ug or more daily of inhaled fluticasone) for adult; or 4.3 At least three months of 800 ug or more daily inhaled beclomethasone or budesonide for child; or 4.4 At least three months of 400 ug or more daily inhaled fluticasone) for child; and 5 Either: 5.1 Short acting beta agonist used at least 3-4 times daily; or 5.2 Nocturnal awakenings at least twice a week. Renewal only from a relevant specialist or general practitioner. Appro
Special Authority for Subsidy - Form SA0528Initial application - (Narcolepsy) only from a neurologist or respiratory specialist. Approvals valid for 24 months where narcolepsy. Initial application - (ADHD in patients 5 or over) only from a paediatrician, psychiatrist or general practitioner. Approvals valid for 24 months for applications meeting the following criteria: All of the following: 1 ADHD (Attention Deficient and Hyperactivity Disorder) patients aged 5 years or over; and 2 Diagnosed according to DSM-IV or ICD 10 criteria; and 3 Applicant is a specialist or specialist has recommended treatment. Initial application - (ADHD in patients under 5) only from a paediatrician or psychiatrist. Approvals valid for 12 months for applications meeting the following criteria: Both: 1 ADHD (Attention Deficient and Hyperactivity Disorder) patients under 5 years of age; and 2 Diagnosed according to DSM-IV or ICD 10 criteria. Renewal - (Narcolepsy) only from a neurologist or respiratory spec
ACE inhibitors will be funded to the level of the ex-manufacturer price listed in the Schedule for patients who were taking an ACE inhibitor for the treatment of congestive heart failure prior to 1 June 1998. The prescription must be endorsed accordingly. We recommend that the words used to indicate eligibility are "certified condition" or an appropriate description of the patient such as "congestive heart failure", "CHF", "congestive cardiac failure" or "CCF". Additional subsidy for lisinopril is available only up to the price of the least expensive brand listed in the Schedule. Definition of Congestive Heart FailureAt the request of some prescribers the PTAC Cardiovascular subcommittee has provided adefinition of congestive heart failure for the purposes of the funding of the manufacturer'ssurcharge: "Clinicians should use their clinical judgement. Existing patients would be eligible for thefunding of the surcharge if the patient shows signs and symptoms of congestive heart failure, and requir
Additional subsidy by endorsement for:Moclobemide tab 150 mg x 100 (Aurorix) up to $47.00Moclobemide tab 300 mg x 60 (Aurorix) up to $56.40Nefazadone tab 100 mg x 56 (Serzone) up to $20.16Nefazadone tab 200 mg x 56 (Serzone) up to $40.32Citalopram tab 20 mg x 28 (Cipramil) up to $27.00is available for patients who: * are taking moclobemide or nefazodone on 1 December 1999 or citalopram on 1 February2000; * have previously responded to treatment with moclobemide or nefazodone or citalopram; * have had a trial of fluoxetine and have to discontinue due to: - inability to tolerate the drug due to side effects OR - failed to respond to an adequate dose and duration of treatment; * have contraindications to fluoxetine (eg pre-existing significant levels of nausea, breastfeeding, potential drug interactions); The prescription must be endorsed accordingly. We recommend that the words used to indicate eligibility are "certified condition" however these particular words are not a requirement.
Special Authority for Subsidy - Form SA0538Initial application only from a gastroenterologist, infectious disease specialist, paediatrician or general physician. Approvals valid for 1 year for applications meeting the following criteria: Both: 1 Any of the following: 1.1 All of the following: 1.1.1 HBsAg positive for more than 6 months; and 1.1.2 HBeAg positive or HBV DNA positive defined as >0.6 pg/ml by quantitative PCR at reference laboratory; and 1.1.3 ALT greater than twice upper limit of normal or stage 3 or 4 fibrosis on liver histology clinical/radiological evidence of cirrhosis; or 1.2 HBV DNA positive cirrhosis prior to liver transplantation; or 1.3 HBsAg positive and have had a liver, kidney, heart, lung or bone marrow transplant; and 2 All of the following: 2.1 No continuing alcohol abuse or intravenous drug use; and 2.2 Not coinfected with HCV, HDV, or HIV; and 2.3 Neither ALT nor AST greater than 10 times upper limit of normal; and 2.4
Special Authority for Subsidy - Form SA0539Initial application from any medical practitioner. Approvals valid for 5 years where the patient is likely to benefit from treatment. NoteApplications to be made on the approved forms which are available from: The Co-ordinatorPhone: 09 580 9176Multiple Sclerosis Treatment CommitteeFacsimile: 09 580 9205Level 3, Unisys HouseEmail: murray@ppc.govt.nz650 Great South Road, PenrosePrivate Bag, AUCKLANDBudget managed by appointed clinicians on the Multiple Sclerosis Treatment Assessments Committee (MSTAC). Applications will be considered by MSTAC at its regular meetings and approved subject to eligibility according to the Entry and Stopping criteria (below). Completed application forms must be sent to the co-ordinator for MSTAC and will be considered by MSTAC at the next practicable opportunity. Notification of MSTAC's decision will be sent to the patient, the applying clinician and the patient's GP (if specified). These agents will N
Additional subsidy by endorsement for:Moclobemide tab 150 mg x 100 (Aurorix) up to $47.00Moclobemide tab 300 mg x 60 (Aurorix) up to $56.40Nefazadone tab 100 mg x 56 (Serzone) up to $20.16Nefazadone tab 200 mg x 56 (Serzone) up to $40.32Citalopram tab 20 mg x 28 (Cipramil) up to $27.00is available for patients who: * were taking moclobemide or nefazodone on 1 December 1999 or citalopram on 1 February 2000; or* have previously responded to treatment with moclobemide, nefazodone or citalopram; or* have had a trial of fluoxetine and have to discontinue due to: - inability to tolerate the drug due to side effects; or - failed to respond to an adequate dose and duration of treatment; or* have contraindications to fluoxetine (eg pre-existing significant levels of nausea, breastfeeding, potential drug interactions); The prescription must be endorsed accordingly. We recommend that the words used to indicate eligibility are "certified condition" however these words are not a requirement.
Alphagan is subsidised for use as either monotherapy or as an adjunctive agent for the treatment of glaucoma. Alphagan should not be prescribed for a person in whom less expensive first line agents for the treatment of glaucoma are not contraindicated unless: (a) that person has previously trialled all other such subsidised agents (except dorzolamide hydrochloride); and(b) those trials have indicated that that person does not respond adequately to or does not tolerate treatment with those other agents.
Special Authority for Subsidy - Form SA0551Initial application only from a paediatrician, neurologist or general physician. Approvals valid for 15 months for applications meeting the following criteria: Any of the following: 1 Was on NAED therapy before 1 September 2000; or 2 Seizures are not adequately controlled with optimal older anti-epilepsy drug treatment; or 3 Seizures are controlled adequately but who experience unacceptable side effects from older anti-epilepsy drug treatment. NoteApproval entitles patients to a subsidy for one NAED. Dual NAED therapy will be subsidised for patients who were already stabilised on two NAEDs on or before 31 July 2000 or, for whom a second NAED has been added to therapy with one NAED provided an attempt to withdraw one NAED has been made and was unsuccessful. "Optimal older anti-epilepsy drug therapy" is defined as treatment with those older anti-epilepsy drugs which are indicated and clinically appropriate for the patient, given singly and in combin
Nicotine patches and gum: a) are only available /subsidised on presentation of a Quitline exchange card.b) for reimbursement refer to the Claiming Procedures for the Subsidised Nicotine Patches and Gum Programme. c) have a maximum patient co-payment (contribution) of $10 per exchange card.
Special Authority for Subsidy - Form SA0554Initial application only from a relevant specialist. Approvals valid without further renewal unless notified for applications meeting the following criteria: Either: 1 Liver transplant recipients; or 2 Renal transplant recipients - as rescue therapy only. Renewal only from a relevant specialist. Approvals valid without further renewal unless notified where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0556Initial application - (Confirmed HIV/AIDS) only from a named general physician. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 Confirmed HIV/AIDS; and 2 Any of the following: 2.1 Symptomatic patient; or 2.2 Both: 2.2.1 Asymptomatic patient; and 2.2.2 Patient aged 12 months and under; or 2.3 Both: 2.3.1 Asymptomatic patient; and 2.3.2 Patient has viral load counts > 10,000 copies per ml or equivalent value on the Chiron test; or 2.4 All of the following: 2.4.1 Asymptomatic patient; and 2.4.2 Patient aged 1 to 5 years; and 2.4.3 CD4 counts < 1,000 cells/mm3; or 2.5 All of the following: 2.5.1 Asymptomatic patient; and 2.5.2 Patient aged 1 to 5 years; and 2.5.3 CD4 counts < 0.25 x total white cell count; or 2.6 All of the following: 2.6.1 Asymptomatic patient; and 2.6.2 Patient aged 6 years and over; and 2.6.3 CD4 counts
Special Authority for Subsidy - Form SA0557Initial application - (Single NAED Therapy) only from a paediatrician, neurologist or general physician. Approvals valid for 15 months for applications meeting the following criteria: Any of the following: 1 Was on NAED therapy before 1 September 2000; or 2 Seizures are not adequately controlled with optimal older anti-epilepsy drug treatment; or 3 Seizures are controlled adequately but who experience unacceptable side effects from older anti-epilepsy drug treatment. Note"Optimal older anti-epilepsy drug therapy" is defined as treatment with those older anti-epilepsy drugs which are indicated and clinically appropriate for the patient, given singly and in combination in adequate doses for the patient's age, weight, and other features affecting the pharmacokinetics of the drug with good evidence of complianceAs a guideline, clinical trials have referred to a notional 50% reduction in seizure frequency as an indicator of success with anti-convulsan
Additional subsidy by endorsement for:Moclobemide tab 150mg x 100 (Aurorix) up to $32.90Moclobemide tab 300mg x 60 (Aurorix) up to $39.48Nefazodone tab 100mg x 56 (Serzone) up to $20.16Nefazodone tab 200mg x 56 (Serzone) up to $40.32Citalopram tab 20mg x 28 (Cipramil) up to $27.00is available for patients who: * were taking moclobemide or nefazodone on 1 December 1999 or citalopram on 1 February 2000; or* have previously responded to treatment with moclobemide, nefazodone or citalopram; or* have had a trial of fluoxetine and have had to discontinue due to - inability to tolerate the drug due to side effects; or - failed to respond to an adequate dose and duration of treatment; or* have contraindications to fluoxetine (eg pre-existing significant levels of nausea, breastfeeding, potential drug interactions). The prescription must be endorsed accordingly. We recommend that the words used to indicate eligibility are "certified condition" however these words are not a requirement.
Additional subsidy by endorsement for:Moclobemide tab 150mg x 100 (Aurorix) up to $32.90Moclobemide tab 300mg x 60 (Aurorix) up to $39.48Nefazodone tab 100mg x 56 (Serzone) up to $20.16Nefazodone tab 200mg x 56 (Serzone) up to $40.32Citalopram tab 20mg x 28 (Cipramil and Celapram) up to $10.00Paroxetine hydrochloride tab 20 mg x 30 (Aropax) up to $35.02is available for patients who: * were taking moclobemide or nefazodone on 1 December 1999 or citalopram on 1 February 2000; or paroxetine hydrochloride on Februrary 2001; or * have previously responded to treatment with moclobemide or nefazodone or citalopram or paroxetine hydrochloride; or* have had a trial of fluoxetine and have had to discontinue due to - inability to tolerate the drug due to side effects; or - failed to respond to an adequate dose and duration of treatment; or* have contraindications to fluoxetine (eg pre-existing significant levels of nausea, breastfeeding, potential drug interactions). The prescription must be e
Special Authority for Subsidy - Form SA0563Initial application only from a relevant specialist. Approvals valid for 2 years for applications meeting the following criteria: Any of the following: 1 Both: 1.1 Acromegaly; and 1.2 Patient has failed surgery, radiotherapy, bromocriptine and other oral therapies; or 2 VIPomas and Glucagonomas - for patients who are seriously ill in order to improve their clinical state prior to definitive surgery.; or 3 Both: 3.1 Gastrinoma; and 3.2 Either: 3.2.1 Patient has failed surgery; or 3.2.2 Patient in metastatic disease after H2 antagonists (or proton pump inhibitors) have failed; or 4 Both: 4.1 Insulinomas; and 4.2 Surgery is contraindicated or has failed; or 5 For pre-operative control of hypoglycaemia and for maintenance therapy; or 6 Both: 6.1 Carcinoid syndrome (diagnosed by tissue pathology and/or urinary 5HIAA analysis); and 6.2 Disabling symptoms not controlled by maximal medical therapy. No
Trandolapril will be funded to the level of the ex-manufacturer price listed in the Schedule for patients who were taking these ACE inhibitors for the treatment of congestive heart failure prior to 1 June 1998. The prescription must be endorsed accordingly. We recommend that the words used to indicate eligibility are "certified condition" or an appropriate description of the patient such as "congestive heart failure", "CHF", "congestive cardiac failure" or "CCF". Definition of Congestive Heart Failure At the request of some prescribers the PTAC Cardiovascular subcommittee has provided a definition of congestive heart failure for the purposes of the funding of the manufacturer's surcharge: "Clinicians should use their clinical judgement. Existing patients would be eligible for the funding of the surcharge if the patient shows signs and symptoms of congestive heart failure, and requires or has in the past required concomitant treatment with a diuretic. The definition could also be considered to include pat
Perindopril will be funded to the level of the ex-manufacturer price listed in the Schedule for patients who were taking these ACE inhibitors for the treatment of congestive heart failure prior to 1 June 1998. The prescription must be endorsed accordingly. We recommend that the words used to indicate eligibility are "certified condition" or an appropriate description of the patient such as "congestive heart failure", "CHF", "congestive cardiac failure" or "CCF". Definition of Congestive Heart Failure At the request of some prescribers the PTAC Cardiovascular subcommittee has provided a definition of congestive heart failure for the purposes of the funding of the manufacturer's surcharge: "Clinicians should use their clinical judgement. Existing patients would be eligible for the funding of the surcharge if the patient shows signs and symptoms of congestive heart failure, and requires or has in the past required concomitant treatment with a diuretic. The definition could also be considered to include pati
Special Authority for Subsidy - Form SA0569Initial application only from a geriatrician, rheumatologist, endocrinologist, gynaecologist or general physician. Approvals valid for 2 years for applications meeting the following criteria: All of the following: 1 Severe osteoporosis; and 2 History of one previous significant osteoporotic fractures demonstrated radiologically; and 3 T-Score <= -3.0 (bone mass density (BMD) >= 3.0 standard deviations below the mean normal value in young adults). NoteIn line with the Australian guidelines for funding alendronate, a vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body. Renewal only from a geriatrician, rheumatologist, endocrinologist, gynaecologist or general physician. Approvals valid for 2 years where the t
Special Authority for Subsidy - Form SA0572Initial application only from a psychiatrist. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 Patient presenting with first episode schizophrenia or related psychoses; or 2 Both: 2.1 Patients suffers from schizophrenia or related psychoses ; and 2.2 Either: 2.2.1 A trial of risperidone has been discontinued because of unacceptable side effects; or 2.2.2 A trial of risperidone has been discontinued because of inadequate response. Renewal only from a psychiatrist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
Subsidy is available for patients with poorly controlled asthma where: a) at least three months of 750 mcg or more daily of inhaled beclomethasone or budesonide(or 400 mcg of fluticasone) for adults has been used; orb) at least three months of 400 mcg or more daily of inhaled beclomethasone or budesonide (or 200mcg of fluticasone) for children 12 years or older has been used; The prescription must be endorsed accordingly. We recommend that the words used to indicateeligibility are "poor control with ICS" or "certified condition".
Special Authority for Subsidy - Form SA0575Initial application - (Confirmed HIV/AIDS) only from a named general physician. Approvals valid without further renewal unless notified for applications meeting the following criteria: Both: 1 Confirmed HIV/AIDS; and 2 Any of the following: 2.1 Symptomatic patient; or 2.2 Both: 2.2.1 Asymptomatic patient; and 2.2.2 Patient aged 12 months and under; or 2.3 Both: 2.3.1 Asymptomatic patient; and 2.3.2 Patient has viral load counts > 10,000 copies per ml or equivalent value on the Chiron test; or 2.4 All of the following: 2.4.1 Asymptomatic patient; and 2.4.2 Patient aged 1 to 5 years; and 2.4.3 CD4 counts < 1,000 cells/mm3; or 2.5 All of the following: 2.5.1 Asymptomatic patient; and 2.5.2 Patient aged 1 to 5 years; and 2.5.3 CD4 counts < 0.25 x total white cell count; or 2.6 All of the following: 2.6.1 Asymptomatic patient; and 2.6.2 Patient aged 6 years and over
Special Authority for Subsidy - Form SA0579Initial application - (Cystic fibrosis or renal failure) only from a relevant specialist. Approvals valid for 3 years for applications meeting the following criteria: Either: 1 cystic fibrosis; or 2 chronic renal failure or continuous ambulatory peritoneal dialysis (CAPD) patient. Initial application - (Indications other than cystic fibrosis or renal failure) only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria: Any of the following: 1 cancer in children; or 2 cancers affecting alimentary tract where there are malabsorption problems in patients over the age of 20 years; or 3 failure to thrive; or 4 growth deficiency; or 5 bronchopulmonary dysplasia; or 6 premature and post premature infant. Renewal - (Cystic fibrosis or renal failure) only from a relevant specialist or general practitioner on the recommendation of such a specialist. Approvals valid for 3 years for applicatio
Special Authority for Subsidy - Form SA0580Initial application - (Inborn errors of metabolism) only from a relevant specialist. Approvals valid for 3 years where inborn errors of metabolism. Initial application - (Indications other than inborn errors of metabolism) only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria: Any of the following: 1 failure to thrive ; or 2 growth deficiency; or 3 bronchopulmonary dysplasia ; or 4 fat malabsorption ; or 5 lymphangiectasia; or 6 short bowel syndrome ; or 7 infants with necrotising enterocolitis; or 8 biliary atresia. Renewal - (Inborn errors of metabolism) only from a relevant specialist or general practitioner on the recommendation of such a specialist. Approvals valid for 3 years for applications meeting the following criteria: Both: 1 The treatment remains appropriate and the patient is benefiting from treatment; and 2 General Practitioners must include the name of
Special Authority for Subsidy - Form SA0581Initial application - (Cystic fibrosis) only from a relevant specialist. Approvals valid for 3 years for applications meeting the following criteria: Both: 1 infant aged four years or under; and 2 cystic fibrosis. Initial application - (Indications other than cystic fibrosis) only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria: Both: 1 infant aged four years or under; and 2 Any of the following: 2.1 cancer in children; or 2.2 failure to thrive; or 2.3 growth deficiency; or 2.4 bronchopulmonary dysplasia; or 2.5 premature and post premature infants. Renewal - (Cystic fibrosis) only from a relevant specialist or general practitioner on the recommendation of such a specialist. Approvals valid for 3 years for applications meeting the following criteria: Both: 1 The treatment remains appropriate and the patient is benefiting from treatment; and 2 General Practiti
Special Authority for Subsidy - Form SA0582Initial application only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria: Either: 1 protein losing enteropathy; or 2 high protein needs (eg burns). Renewal only from a relevant specialist or general practitioner on the recommendation of such a specialist. Approvals valid for 1 year for applications meeting the following criteria: Both: 1 The treatment remains appropriate and the patient is benefiting from treatment; and 2 General Practitioners must include the name of the specialist and date contacted.
Special Authority for Subsidy - Form SA0585Initial application - (Cystic fibrosis) only from a relevant specialist. Approvals valid for 3 years for applications meeting the following criteria: All of the following: 1 Cystic fibrosis; and 2 other lower calorie products have been tried; and 3 patient has substantially increased metabolic requirements; and 4 Either: 4.1 The product is to be used as a supplement; or 4.2 The product is to be used as a complete diet.Initial application - (Indications other than cystic fibrosis) only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria: All of the following: 1 Any of the following: 1.1 any condition causing malabsorption ; or 1.2 failure to thrive ; or 1.3 increased nutritional requirements.; and 2 other lower calorie products have been tried; and 3 patient has substantially increased metabolic requirements; and 4 Either: 4.1 The product is to be used a
Special Authority for Subsidy - Form SA0587Initial application only from a relevant specialist. Approvals valid for 3 years for applications meeting the following criteria: Both: 1 acute or chronic renal failure; and 2 Either: 2.1 The product is to be used as a supplement (maximum 500 ml per day); or 2.2 The product is to be used as a complete diet.Renewal only from a relevant specialist or general practitioner on the recommendation of such a specialist. Approvals valid for 3 years for applications meeting the following criteria: All of the following: 1 The treatment remains appropriate and the patient is benefiting from treatment; and 2 Either: 2.1 The product is to be used as a supplement (maximum 500 ml per day); or 2.2 The product is to be used as a complete diet; and 3 General Practitioners must include the name of the specialist and date contacted.
Special Authority for Subsidy - Form SA0588Initial application only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria: Both: 1 CORD patients who have hypercapnia; and 2 Either: 2.1 The product is to be used as a supplement (maximum 500 ml per day); or 2.2 The product is to be used as a complete diet.Renewal only from a relevant specialist or general practitioner on the recommendation of such a specialist. Approvals valid for 1 year for applications meeting the following criteria: All of the following: 1 The treatment remains appropriate and the patient is benefiting from treatment; and 2 Either: 2.1 The product is to be used as a supplement (maximum 500 ml per day); or 2.2 The product is to be used as a complete diet; and 3 General Practitioners must include the name of the specialist and date contacted.
Special Authority for Subsidy - Form SA0589Initial application only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria: All of the following: 1 Anorexia and weight loss; and 2 Either: 2.1 decompensating liver disease without encephalopathy ; or 2.2 protein losing gastro-enteropathy; and 3 Either: 3.1 The product is to be used as a supplement (maximum 500 ml per day); or 3.2 The product is to be used as a complete diet.Renewal only from a relevant specialist or general practitioner on the recommendation of such a specialist. Approvals valid for 1 year for applications meeting the following criteria: All of the following: 1 The treatment remains appropriate and the patient is benefiting from treatment; and 2 Either: 2.1 The product is to be used as a supplement (maximum 500 ml per day); or 2.2 The product is to be used as a complete diet; and 3 General Practitioners must include the name of the specialis
Special Authority for Subsidy - Form SA0590Initial application only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria: All of the following: 1 infant aged one to six years; and 2 Any of the following: 2.1 any condition causing malabsorption ; or 2.2 failure to thrive; or 2.3 increased nutritional requirements; and 3 Either: 3.1 The product is to be used as a supplement (maximum 500 ml per day); or 3.2 The product is to be used as a complete diet.Renewal only from a relevant specialist or general practitioner on the recommendation of such a specialist. Approvals valid for 1 year for applications meeting the following criteria: All of the following: 1 The treatment remains appropriate and the patient is benefiting from treatment; and 2 Either: 2.1 The product is to be used as a supplement (maximum 500 ml per day); or 2.2 The product is to be used as a complete diet; and 3 General Practitioners must
Special Authority for Subsidy - Form SA0591Initial application only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria: Both: 1 Any of the following: 1.1 enteral feeding; or 1.2 nasogastric; or 1.3 nasoduodenal ; or 1.4 nasojejunal; or 1.5 gastrostomy/jejunostomy; and 2 Either: 2.1 The product is to be used as a supplement; or 2.2 The product is to be used as a complete diet.Renewal only from a general practitioner or relevant specialist. Approvals valid for 1 year for applications meeting the following criteria: All of the following: 1 The treatment remains appropriate and the patient is benefiting from treatment; and 2 Either: 2.1 The product is to be used as a supplement; or 2.2 The product is to be used as a complete diet; and 3 General Practitioners must include the name of the specialist and date contacted.
Special Authority for Subsidy - Form SA0592Initial application only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria: Both: 1 Any of the following: 1.1 malabsorption ; or 1.2 short bowel syndrome; or 1.3 enterocutaneous fistulas ; or 1.4 pancreatitis; and 2 Either: 2.1 The product is to be used as a supplement (maximum 500 ml per day); or 2.2 The product is to be used as a complete diet.NoteEach of these products is highly specialised and would be prescribed only by an expert for a specific disorder. The alternative is hospitalisation. Elemental 028 Extra is more expensive than other products listed in this section and should only be used where the alternatives have been tried first and/or are unsuitable. Renewal only from a relevant specialist or general practitioner on the recommendation of such a specialist. Approvals valid for 1 year for applications meeting the following criteria: All of the following:
Special Authority for Subsidy - Form SA0594Initial application only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria: Both: 1 Type I and II diabetics who require nutritional supplementation.; and 2 Either: 2.1 The product is to be used as a supplement (maximum 500 ml per day); or 2.2 The product is to be used as a complete diet.Renewal only from a relevant specialist or general practitioner on the recommendation of such a specialist. Approvals valid for 1 year for applications meeting the following criteria: All of the following: 1 The treatment remains appropriate and the patient is benefiting from treatment; and 2 Either: 2.1 The product is to be used as a supplement (maximum 500 ml per day); or 2.2 The product is to be used as a complete diet; and 3 General Practitioners must include the name of the specialist and date contacted.
Special Authority for Subsidy - Form SA0595Initial application only from a relevant specialist. Approvals valid for 1 year where patient has motor neurone disease with swallowing disorder. Renewal only from a relevant specialist or general practitioner on the recommendation of such a specialist. Approvals valid for 1 year for applications meeting the following criteria: Both: 1 The treatment remains appropriate and the patient is benefiting from treatment; and 2 General Practitioners must include the name of the specialist and date contacted.
Special Authority for Subsidy - Form SA0596Initial application only from a relevant specialist. Approvals valid for 3 years for applications meeting the following criteria: Either: 1 gluten enteropathy has been diagnosed by biopsy; or 2 dermatitis herpetiformis. NoteA premium may be payable if the subsidy does not match the price charged by the manufacturer. The subsidy for these products reflects the philosophy that the patient incurs no additional financial burden for purchasing specialised more expensive products. Renewal only from a relevant specialist or general practitioner on the recommendation of such a specialist. Approvals valid for 3 years for applications meeting the following criteria: Both: 1 The treatment remains appropriate and the patient is benefiting from treatment; and 2 General Practitioners must include the name of the specialist and date contacted.
Special Authority for Subsidy - Form SA0597Initial application - (PKU Patient aged over 16) only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria: Both: 1 PKU; and 2 blood phenylalanine level < 900 mmol/litre (average of tests over last 12 months). Initial application - (Patient aged over 16) only from a relevant specialist. Approvals valid for 3 years for applications meeting the following criteria: Any of the following: 1 dietary management of homocystinuria; or 2 inborn errors of metabolism other than PKU; or 3 dietary management of maple syrup urine disease..Initial application - (Patient aged 16 or under) only from a relevant specialist. Approvals valid for 3 years for applications meeting the following criteria: Any of the following: 1 dietary management of homocystinuria; or 2 PKU and other inborn errors of metabolism; or 3 dietary management of maple syrup urine disease..Renewal - (PKU Patient aged over 16
Special Authority for Subsidy - Form SA0600Initial application only from a relevant specialist. Approvals valid for 3 years where inborn errors of metabolism. Renewal only from a relevant specialist or general practitioner on the recommendation of such a specialist. Approvals valid for 3 years for applications meeting the following criteria: Both: 1 The treatment remains appropriate and the patient is benefiting from treatment; and 2 General Practitioners must include the name of the specialist and date contacted.
Special Authority for Subsidy - Form SA0601Initial application only from a relevant specialist. Approvals valid for 1 year where Infant suffering from Williams Syndrome and associated hypercalcaemia. Renewal only from a relevant specialist or general practitioner on the recommendation of such a specialist. Approvals valid for 1 year for applications meeting the following criteria: Both: 1 The treatment remains appropriate and the patient is benefiting from treatment; and 2 General Practitioners must include the name of the specialist and date contacted.
Special Authority for Subsidy - Form SA0603Initial application only from a relevant specialist. Approvals valid for 1 year where infant suffering from malabsorption and other gastrointestinal problems. Renewal only from a relevant specialist or general practitioner on the recommendation of such a specialist. Approvals valid for 1 year for applications meeting the following criteria: Both: 1 The treatment remains appropriate and the patient is benefiting from treatment; and 2 General Practitioners must include the name of the specialist and date contacted.
Special Authority for Subsidy - Form SA0604Initial application - (Lactase deficiency or disaccharide intolerance) only from a relevant specialist. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 Patient is less than 3 years of age; and 2 Either: 2.1 diagnosed as suffering from congenital lactase deficiency; or 2.2 suffering from disaccharide intolerance. NoteSecondary lactose intolerance in children is usually short lasting, and can be controlled by dietary measures and by giving sufficient calories to regenerate digestive enzymes. The subsidy for these products reflects the philosophy that the patient incurs no additional financial burden for purchasing specialised more expensive products. Initial application - (Infant with intolerance to cows' milk) only from a relevant specialist. Approvals valid for 6 months for applications meeting the following criteria: Both: 1 intolerant to cows' milk; and 2 patient is less than 3 years of age. No
Special Authority for Subsidy - Form SA0605Initial application - (Cystic fibrosis or renal disorder) only from a relevant specialist. Approvals valid for 3 years for applications meeting the following criteria: Both: 1 Either: 1.1 cystic fibrosis; or 1.2 renal disorder; and 2 Either: 2.1 The product is to be used as a supplement; or 2.2 The product is to be used as a complete diet.Initial application - (Indications other than cystic fibrosis or renal disorder) only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria: Both: 1 Any of the following: 1.1 any condition causing malabsorption; or 1.2 failure to thrive; or 1.3 increased nutritional requirements; and 2 Either: 2.1 The product is to be used as a supplement; or 2.2 The product is to be used as a complete diet.Renewal - (Cystic fibrosis or renal disorder) only from a relevant specialist or general practitioner. Approvals valid for 3 years
Special Authority for Subsidy - Form SA0606Initial application only from a paediatrician. Approvals valid for 3 years for applications meeting the following criteria: Both: 1 child (up to 18 years) with chronic renal failure.; and 2 Either: 2.1 The product is to be used as a supplement; or 2.2 The product is to be used as a complete diet.Renewal only from a paediatrician. Approvals valid for 3 years for applications meeting the following criteria: Both: 1 The treatment remains appropriate and the patient is benefiting from treatment; and 2 Either: 2.1 The product is to be used as a supplement; or 2.2 The product is to be used as a complete diet.
Special Authority for Subsidy - Form SA0607Initial application only from a paediatrician. Approvals valid for 3 years for applications meeting the following criteria: Both: 1 Child (up to 18 years) who is awaiting liver transplant; and 2 Either: 2.1 The product is to be used as a supplement (maximum 500 ml per day); or 2.2 The product is to be used as a complete diet.Renewal only from a paediatrician. Approvals valid for 3 years for applications meeting the following criteria: Both: 1 The treatment remains appropriate and the patient is benefiting from treatment; and 2 Either: 2.1 The product is to be used as a supplement (maximum 500 ml per day); or 2.2 The product is to be used as a complete diet.
Special Authority for Subsidy - Form SA0609Initial application - (Serevent MDI, Serevent Accuhaler Foradil, Oxis Turbuhaler 12 mcg, Symbicort Turbuhaler) only from a relevant specialist or general practitioner. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 Both: 1.1 Child under the age of 12 with poorly controlled asthma; and 1.2 Either: 1.2.1 Required at least three months of 400 mcg or more daily inhaled beclomethasone or budesonide; or 1.2.2 Required at least three months of 200 mcg or more of fluticasone; or 2 Both: 2.1 Adult with poorly controlled asthma; and 2.2 Either: 2.2.1 Required at least three months of 1500 mcg or more daily inhaled beclomethasone or budesonide; or 2.2.2 Required at least three months of 750 mcg or more of fluticasone. NotePatients are to be reviewed at least at six months to assess compliance and effectiveness of therapy. Special Authority approvals are interchangeable among all prese
Special Authority for Subsidy - Form SA0610Initial application from any specialist. Approvals valid without further renewal unless notified for applications meeting the following criteria: All of the following: 1 Quantity used by patient on a weekly volume intraveneously (Details to be attached to application); and 2 Amount of nutrition patient is able to receive orally (Details to be attached to application); and 3 Exact formula of TPN (Details to be attached to application); and 4 Who has paid for TPN so far (Details to be attached to application); and 5 Place of manufacture (Details to be attached to application); and 6 Complete medical history of patient including details of previous therapies. (Details to be attached to application). Renewal - (Previous approval has expired) from any specialist. Approvals valid without further renewal unless notified where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0611Initial application from any medical practitioner. Approvals valid for 1 year where applicaton approved by the Cystic Fibrosis DN'ase Advisory Panel. NoteApplications to be made on the approved forms which are available from: The Co-ordinatorCystic Fibrosis DN'ase Advisory PanelPhone: (04) 460 4990 PHARMAC, PO Box 10 254 WellingtonFacsimile: (04) 916 7571Email: erin.murphy@pharmac.govt.nzPrescriptions for patients approved for treatment must be written by respiratory physicians or paediatricians who have experience and expertise in treating cystic fibrosis.
Special Authority for Alternate Subsidy - Form SA0613Initial application from any medical practitioner. Approvals valid for 2 years for applications meeting the following criteria: Any of the following: 1 Polycystic ovarian syndrome; or 2 Hirsutism; or 3 Androngenic alopecia. Renewal from any medical practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0614Initial application only from a geriatrician, rheumatologist, endocrinologist, gynaecologist or general physician. Approvals valid for 2 years for applications meeting the following criteria: All of the following: 1 Severe osteoporosis; and 2 History of one previous significant osteoporotic fractures demonstrated radiologically; and 3 T-Score <= -3.0 (bone mass density (BMD) >= 3.0 standard deviations below the mean normal value in young adults). NoteIn line with the Australian guidelines for funding alendronate, a vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral bodyRenewal only from a geriatrician, rheumatologist, endocrinologist, gynaecologist or general physician. Approvals valid for 2 years where the tr
Special Authority for Subsidy - Form SA0615Initial application only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria: Both: 1 The product is to be used as a complete diet; and 2 Either: 2.1 Patient has metabolic disorders of fat metabolism; or 2.2 Patient has chylothorax. Renewal only from a relevant specialist or general practitioner on the recommendation of such a specialist. Approvals valid for 1 year for applications meeting the following criteria: Both: 1 The treatment remains appropriate and the patient is benefiting from treatment; and 2 General Practitioners must include the name of the specialist and date contacted.
Special Authority for Manufacturers Price - Form SA0616Initial application - (Conditions other than transient ischaemic episodes) only from a cardiothoracic surgeon, cardiologist or general physician. Approvals valid without further renewal unless notified for applications meeting the following criteria: Either: 1 Patients with prosthetic heart valves - as an adjunct to oral anticoagulation for prophylaxis of thromboembolism; or 2 Patients after coronary artery vein bypass graft - as an adjunct to aspirin or as monotherapy for patients who are aspirin intolerant. NoteAspirin intolerant patients are defined as those with aspirin induced asthma, urticaria, or anaphylaxi, or those with significant aspirin induced bleeding, excluding bruisingInitial application - (Transient ischaemic episodes) only from a neurologist, neuro surgeon, cardiologist, vascular surgeon or general physician. Approvals valid without further renewal unless notified where patients who continue to have transient ischaemic
a) Prescribers may code prescriptions "contraceptive" (code "O") when used as indicated for contraception. The period of supply and prescription charge will be as per other contraceptives, as follows: - $3.00 prescription charge (patient co-payment) will apply; - prescription may be written for up to six months supply; and- pharmacists may dispense up to three months supply. b) Prescriptions coded in any other way are subject to the non-contraceptive prescription charges, and the non-contraceptive period of supply. ie. Prescriptions may be written for up to three months supply, and dispensed monthly
Special Authority for Subsidy - Form SA0621Initial application only from a relevant specialist. Approvals valid for 5 years where the patient is likely to benefit from treatment. Renewal only from a relevant specialist. Approvals valid for 5 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0622Initial application only from a geriatrician, rheumatologist, endocrinologist, gynaecologist or general physician. Approvals valid without further renewal unless notified for applications meeting the following criteria: All of the following: 1 Severe osteoporosis; and 2 History of one previous significant osteoporotic fractures demonstrated radiologically; and 3 T-Score <= -3.0 (bone mass density (BMD) >= 3.0 standard deviations below the mean normal value in young adults). NoteIn line with the Australian guidelines for funding alendronate, a vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral bodyRenewal only from a geriatrician, rheumatologist, endocrinologist, gynaecologist or general physician. Approvals va
Special Authority for Subsidy - Form SA0623Initial application from any medical practitioner. Approvals valid for 1 year for applications meeting the following criteria: All of the following: 1 The patient is not predisposed to heart arrhythmias; and 2 The patient does not have a pre-existing QT-prolongation or hepatic failure; and 3 The patient is not using other medications which either inhibit the cytochrome P450 3A4 enzyme system or prolong the QT interval; and 4 Any of the following: 4.1 Both: 4.1.1 The patient is an adult with severe reflux oesophagitis; and 4.1.2 other treatment, including acid suppression with proton pump inhibitors, has failed; or 4.2 gastroparesis; or 4.3 malignancy of GI tract causing gastroparesis (or gastric outlet obstruction); or 4.4 The patient is a child (not including infants from 0 to 3 months of age who were born prematurely) with severe gastro-oesophageal reflux; and 5 Diagnosis has been made or confirmed by a general p
Subsidy by endorsement Oral liquid is subsidised only for patients: - with oesophageal stricture, or- in terminal care, or- who are either too young or too old to swallow conventional tablets and the prescription is endorsed accordingly. Note: the cost of treatment with ranitidine oral liquid is more than 10 times higher than that of ranitidine tablets. Following the derestriction of access PHARMAC will be monitoring expenditure on ranitidine oral liquid more closely and may, subject to consultation and PHARMAC Board approval, restrict access again if the expenditure was to grow substantially.
Special Authority for Subsidy - Form SA0626Initial application only from a renal physician. Approvals valid for 2 years for applications meeting the following criteria: All of the following: General Criteria: 1 Anaemia of end-stage renal failure (other treatable causes of anaemia being excluded); and 2 Been on haemodialysis or continuous ambulatory peritoneal dialysis (CAPD) for at least three months; and 3 Not under evaluation for, or awaiting, a live donor kidney transplant; and 4 Any of the following: Specific Criteria: 4.1 Anephric; or 4.2 Dependent on regular blood transfusion (1 unit each 4-8 weeks) to maintain haemoglobin > 60g/L; or 4.3 Dependent on regular blood transfusion but cannot be transfused because of severe transfusion reactions; or 4.4 Transfusion induced haemosiderosis (clinical manifestations, serum ferritin >1500 ug/L); or 4.5 Haemoglobin < 70 g/L (mean of at least 4 haemoglobin concentrations over 4 months); or 4.6 Both: 4.6.1 Haemo
Prescribing GuidelineTreatment with HMG CoA Reductase Inhibitors (Statins) is recommended for patients withdyslipidaemia and an absolute 5 year cardiovascular risk of 15% or greater. New Zealand Cardiovascular Guideline Group statement. "The 1996 Heart Foundation guidelines for the Assessment and Management of Dyslipidaemia are currently being revised. An evidence-based guideline on the Assessment and Management of Cardiovascular Risk will be developed in 2002. The Cardiovascular Guideline Group has written an interim consensus statement for themanagement of dyslipidaemia. The Heart Foundation cardiovascular risk tables should be used to determine risk. Certain groups are classified to be at very high risk (>20%) and should be treated as such: - Patients who have had a previous cardiovascular event (angina, MI, angioplasty, coronary artery bypass grafts, TIA, ischaemic stroke and peripheral vascular disease)- Patients with genetic lipid disorders- Patients with diabetes and associated microa
Special Authority for Subsidy - Form SA0628Initial application only from a cardiologist. Approvals valid without further renewal unless notified for applications meeting the following criteria: Any of the following: 1 Both: 1.1 Congestive heart failure; and 1.2 Cannot tolerate two ACE inhibitors due to persistent cough that resolves on cessation and recurs on re-challenge with ACE inhibitor; or 2 Patients who have experienced angioedema on an ACE inhibitor at any time in the past; or 3 Patients who have experienced angioedema (even if not using an ACE inhibitor) in the last 2 years. Renewal - ((2 year approvals granted before April 2002)) only from a cardiologist. Approvals valid without further renewal unless notified where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0631Initial application only from an ophthalmologist. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 Both: 1.1 Primary open-angle glaucoma; and 1.2 Any of the following: 1.2.1 Patient cannot tolerate Beta-blockers, or Beta-blockers are contraindicated; or 1.2.2 Patient cannot tolerate Pilocarpine, or Pilocarpine is contraindicated; or 1.2.3 Patient cannot tolerate Dorzolamide, or Dorzolamide is contraindicated; or 1.2.4 A reduction in intraocular pressure of 15% or more is not achieved or maintained using dorzolamide either alone or in combination with a beta-blocker; or 2 There is progressive visual field loss and/or optic nerve damage persists after treatment with dorzolamide either alone or in combination with a beta-blocker. NoteSubsidised also for adjunctive use for the treatment of patients who have met the initial application criteria, and in whom latanoprost monotherapy has bee
Special Authority for Subsidy - Form SA0633Initial application only from a general practitioner or relevant specialist. Approvals valid without further renewal unless notified for applications meeting the following criteria: Both: 1 Patient is already on an ACE inhibitor or Angiotensin II Antagonist; and 2 Any of the following: 2.1 Both: 2.1.1 Symptomatic heart failure NYHA functional class II-III; and 2.1.2 Patient has been treated with metoprolol and is intolerant to metoprolol or has demonstrated a sub-optimal response to metoprolol; or 2.2 Symptomatic heart failure NYHA functional class III-IV; or 2.3 Patient has left ventricular systolic dysfunction with an ejection fraction of less than 35%.NoteWhere possible treatment should be initiated by or on the recommendation of a specialist.
Special Authority for Subsidy - Form SA0635Initial application only from a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria: All of the following: 1 Rheumatoid arthritis; and 2 Patient is not a pregnant woman, or a woman of child-bearing age without adequate contraception; and 3 Patient has been unable to tolerate or has a contraindication to or has had an inadequate response to sulphasalazine and methotrexate (individually or in combination). Renewal only from a rheumatologist. Approvals valid without further renewal unless notified for applications meeting the following criteria: Both: 1 Compliance (prescriber determined) with medication; and 2 Improved rheumatoid arthritis symptom control. NotePatient should have full blood count and liver function tests regularly monitored.
Retail pharmacy - subsidy by endorsement a) Subsidised for:i) patients presenting with first episode schizophrenia or related psychoses; andii) patients suffering from schizophrenia or related psychoses after a trial of an effective dose of risperidone that has been discontinued because of unacceptable side effects or inadequate response. b) Initial prescription must be written by a relevant specialist. c) Subsequent prescriptions may be written by a general practitioner. d) The prescription must be endorsed "certified condition".
Special Authority for Subsidy - Form SA0637Initial application - (National Heart Foundation risk groups A1:1, A1:2, B, C, D or E) only from a relevant specialist or general practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria: All of the following: 1 The patient has been offered 3-6 months of counseling and an opportunity to modify lifestyle; and 2 Any of the following: 2.1 Both: 2.1.1 NHF A1:1 - Clinically proven ischaemic heart disease; and 2.1.2 total cholesterol > 5.5; or 2.2 Both: 2.2.1 NHF A1:2 - Post coronary artery bypass graft (CABG) or angioplasty; and 2.2.2 total cholesterol > 4.5; or 2.3 Post heart transplant (regardless of cholesterol level); or 2.4 Both: 2.4.1 NHF B: Patients with > 20% 5-year cardiovascular disease risk; and 2.4.2 total cholesterol > 9.0; or 2.5 Both: 2.5.1 NHF C: 15-20% 5-year cardiovascular disease risk; and 2.5.2 total cholesterol >
Special Authority for Subsidy - Form SA0639Initial application - (No previous use) only from a relevant specialist or general practitioner. Approvals valid for 3 months for applications meeting the following criteria: All of the following: 1 The patient has a clinical diagnosis of heavy menstrual bleeding; and 2 The patient has failed to respond to or is unable to tolerate other appropriate pharmaceutical therapies as per the Heavy Menstrual Bleeding Guidelines; and 3 Either: 3.1 serum ferritin level < 16 mg/l (within the last 12 months); or 3.2 haemoglobin level < 120 g/l . NoteApplications are not to be made for use in patients as contraception except where they meet the above criteriaInitial application - (Previous use before 1 October 2002) only from a relevant specialist or general practitioner. Approvals valid for 3 months for applications meeting the following criteria: All of the following: 1 The patient had a clinical diagnosis of heavy menstrual bleeding; and 2
Special Authority for Manufacturers Price - Form SA0640Initial application only from a relevant specialist. Approvals valid for 3 years where patients being treated for advanced breast cancer who are refractory to tamoxifen. Renewal only from a relevant specialist. Approvals valid for 3 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Waiver of Rule - Form SA0641Initial application only from a diabetologist, general physician or paediatrician. Approvals valid without further renewal unless notified for applications meeting the following criteria: Either: 1 Both: 1.1 Use alone (monotherapy); and 1.2 The patient is unable to use any other insulins including those on insulin pump treatment; or 2 Both: 2.1 Use with insulin other than insulin isophane (including ready-mixed preparations); and 2.2 A reasonable trial of insulin isophane has been undertaken and it is not effective or not well tolerated. Note"Reasonable trial", "unable to use", "not effective", "not well tolerated", and "not well tolerated" are not defined and we ask clinicians to use their clinical judgement in interpreting these terms.
Special Authority for Subsidy - Form SA0643Initial application - (CML) only from an oncologist or relevant specialist. Approvals valid for 7 months where approved by the The Glivec Co-ordinator. Initial application - (GIST) only from an oncologist. Approvals valid for 1 year where approved by the The Glivec Co-ordinator. Renewal - (CML) only from an oncologist or relevant specialist. Approvals valid for 6 months where approved by the The Glivec Co-ordinator. Initial application - (GIST) only from an oncologist. Approvals valid for 1 year where approved by the The Glivec Co-ordinator. NoteApplication forms are available from, and prescriptions should be sent to: The Glivec Co-ordinatorPhone: 09 580 9176Level 3, Unisys HouseFacsimile: 09 580 9205650 Great South Road, PenroseEmail: murray@ppc.govt.nzPrivate Bag, AUCKLANDSpecial Authority criteria for CML - access by applicationFunded for patients with diagnosis (confirmed by a haematologist) of a chronic myeloid leukaemia (CML) i
Special Authority for Subsidy - Form SA0645Initial application only from a renal physician. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 Both: 1.1 patient in chronic renal failure; and 1.2 Haemoglobin <= 100 g/L; and 2 Either: 2.1 Both: 2.1.1 patient is not diabetic; and 2.1.2 glomerular filtration rate <= 30 ml/min; or 2.2 Both: 2.2.1 patient is diabetic; and 2.2.2 glomerular filtration rate <= 45 ml/min. Renewal only from a renal physician. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment. NoteErythropoietin beta is indicated in the treatment of anaemia associated with chronic renal failure (CRF) where no cause for anaemia other than CRF is detected and there is adequate monitoring of iron stores and iron replacement therapy. The Cockroft-Gault Formula may be used to estimate glomerular filtration rate (GFR) in persons 18 years and over:GFR (male)
Special Authority for Subsidy - Form SA0646Initial application only from a renal physician. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 Both: 1.1 patient in chronic renal failure; and 1.2 Haemoglobin <= 100 g/L; and 2 Any of the following: 2.1 Both: 2.1.1 patient is not diabetic; and 2.1.2 glomerular filtration rate <= 30 ml/min; or 2.2 Both: 2.2.1 patient is diabetic; and 2.2.2 glomerular filtration rate <= 45 ml/min; or 2.3 patient is on haemodialysis or peritoneal dialysis. Renewal only from a renal physician. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment. NoteErythropoietin beta is indicated in the treatment of anaemia associated with chronic renal failure (CRF) where no cause for anaemia other than CRF is detected and there is adequate monitoring of iron stores and iron replacement therapy. The Cockroft-Gault Formula may be used to estim
Special Authority for Manufacturers Price - Form SA0648Initial application - (Conditions other than transient ischaemic episodes) only from a cardiothoracic surgeon, cardiologist or general physician. Approvals valid without further renewal unless notified for applications meeting the following criteria: Either: 1 Patients with prosthetic heart valves - as an adjunct to oral anticoagulation for prophylaxis of thromboembolism; or 2 Patients after coronary artery vein bypass graft - as an adjunct to aspirin or as monotherapy for patients who are aspirin intolerant. NoteAspirin intolerant patients are defined as those with aspirin induced asthma, urticaria, or anaphylaxi, or those with significant aspirin induced bleeding, excluding bruisingInitial application - (Transient ischaemic episodes) only from a neurologist, neuro surgeon, cardiologist, vascular surgeon or general physician. Approvals valid without further renewal unless notified where patients who continue to have transient ischaemic
Special Authority for Subsidy - Form SA0649Initial application - (Conditions other than transient ischaemic episodes) only from a cardiothoracic surgeon, cardiologist or general physician. Approvals valid without further renewal unless notified for applications meeting the following criteria: Either: 1 Patients with prosthetic heart valves - as an adjunct to oral anticoagulation for prophylaxis of thromboembolism; or 2 Patients after coronary artery vein bypass graft - as an adjunct to aspirin or as monotherapy for patients who are aspirin intolerant. NoteAspirin intolerant patients are defined as those with aspirin induced asthma, urticaria, or anaphylaxi, or those with significant aspirin induced bleeding, excluding bruisingInitial application - (Transient ischaemic episodes) only from a neurologist, neuro surgeon, cardiologist, vascular surgeon or general physician. Approvals valid without further renewal unless notified where patients who continue to have transient ischaemic episodes des
Etidronate for osteoporosis should be prescribed for 14 days (400 mg in the morning) and repeated every three months. It should not be taken at the same time of the day as any calcium supplementation (minimum dose - 500 mg per day of elemental calcium). Etidronate should be taken at least 2 hours before or after any food or fluid, except water
Special Authority for Subsidy - Form SA0652Initial application - (Single NAED Therapy) only from a paediatrician, neurologist or general physician. Approvals valid for 15 months for applications meeting the following criteria: Any of the following: 1 Was on NAED therapy before 1 September 2000; or 2 Seizures are not adequately controlled with optimal older anti-epilepsy drug treatment; or 3 Seizures are controlled adequately but who experience unacceptable side effects from older anti-epilepsy drug treatment. Note"Optimal older anti-epilepsy drug therapy" is defined as treatment with those older anti-epilepsy drugs which are indicated and clinically appropriate for the patient, given singly and in combination in adequate doses for the patient's age, weight, and other features affecting the pharmacokinetics of the drug with good evidence of complianceInitial application - (Dual NAED Therapy) only from a paediatrician, neurologist or general physician. Approvals valid for 18 months for app
Additional subsidy by endorsement for:Calcium carbonate tablets x 1,000 (Titralac) up to $35.10 is available for pregnant women. The prescription must be endorsed accordingly. We recommend that the words used to indicate eligibility are "certified condition" however these particular words are not a requirement.
Special Authority for Subsidy - Form SA0657Initial application - (Helicobacter pylori infections) only from a general practitioner or relevant specialist. Approvals valid for 6 months for applications meeting the following criteria: Both: 1 Eradication of Helicobacter pylori in patient with proven infection; and 2 Peptic ulcer disease proven by endoscopy. NoteMaximum of two prescriptions (two courses) per patient. Initial application - (Mycobacterial infections) only from a respiratory specialist, infectious disease specialist or paediatrician. Approvals valid for 2 years for applications meeting the following criteria: Any of the following: 1 Mycobacterium Avium Intracellulare Complex infections in patient with AIDS; or 2 Atypical and drug-resistant mycobacterial infection; or 3 All of the following: 3.1 Prophylaxis against disseminated Mycobacterium Avium Intracellulare Complex infection; and 3.2 HIV infection; and 3.3 CD4 count <= 50 cells/mm3. Renewal - (Mycobact
Additional subsidy by endorsement for:Moclobemide tab 150 mg x 500 (Apo-Moclobemide) up to $46.00Moclobemide tab 150 mg x 100 (Aurorix) up to $32.90Moclobemide tab 300 mg x 100 (Apo-Moclobemide) up to $26.11Moclobemide tab 300 mg x 60 (Aurorix) up to $39.48Nefazodone tab 100 mg x 56 (Serzone) up to $20.16Nefazodone tab 200 mg x 56 (Serzone) up to $40.32Citalopram tab 20 mg x 28 (Celapram) up to $4.00Citalopram tab 20 mg x 28 (Cipramil) up to $10.00Paroxetine hydrochloride tab 20 mg x 30 (Aropax) up to $35.02is available for patients who: - were taking moclobemide or nefazodone on 1 December 1999 or citalopram on 1 February 2000; or paroxetine hydrochloride on February 2001; or- have previously responded to treatment with moclobemide or nefazodone or citalopram or paroxetine hydrochloride; or- have had a trial of fluoxetine and have had to discontinue due to- inability to tolerate the drug due to side effects; or- failed to respond to an adequate dose and duration of treatment; or
Special Authority for Subsidy - Form SA0661Initial application only from a psychiatrist. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 The patient has "treatment resistant" depression; and 2 Either: 2.1 The patient must have had a trial of two different antidepressants and failed to respond to an adequate dose over an adequate period of time (usually at least four weeks); or 2.2 Both: 2.2.1 The patient is currently a hospital in-patient as a result of an acute depressive episode; and 2.2.2 The patient must have had a trial of one other antidepressant and failed to respond to an adequate dose over an adequate period of time. Renewal from any medical practitioner. Approvals valid for 2 years where patient has a high risk of relapse (prescriber determined)..NoteFirst prescription can be written by a psychiatrist or psychiatric registrar. Subsequent prescriptions may be written by a General Practitioner
Prescribing GuidelinesBoth Trusopt and Cosopt are subsidised for use as either monotherapy or as an adjunctive agent for the treatment of glaucoma. Trusopt and Cosopt should not be prescribed for a person in whom less expensive first line agents for the treatment of glaucoma are not contraindicated unless: i) that person has previously trialled all other such subsidised agents (except brimonidine tartrate); andii) those trials have indicated that that person does not respond adequately to treatment with those other agents.
a) Spacer devices and masks also available to paediatricians employed by a DHB on a wholesalesupply order signed by the paediatrician. Limited to one pack of 20 per order. Orders via ahospital pharmacy. b) Only available for children aged six years and under. c) For Space Chamber and Foremount Child's Silicone Mask wholesale supply order must indicate clearly if either the spacer device, the mask, or both are required. d) Distributed by Airflow Products. Forward orders to: Airflow ProductsPO Box 1485 Telephone: 04 499 1240 or 0800 AIR FLOWWellington Facsimile: 04 499 1245 or 0800 323 270
Special Authority for Subsidy - Form SA0667Initial application only from a named specialist. Approvals valid for 4 months for applications meeting the following criteria: All of the following: 1 To be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and 2 Patient is less than 18 years of age at commencement of treatment; and 3 Patient has had severe active polyarticular course Juvenile Idiopathic Arthritis (JIA) for 6 months duration or longer; and 4 Patient has tried and not responded to at least three months of oral or parenteral methotrexate at a dose of 10-20mg/m2 weekly in combination with oral corticosteroids (prednisone 0.25 mg/kg); and 5 Patient has tried and not responded to at least three months of oral or parenteral methotrexate (at a dose of 10-15mg/m2 weekly) in combination with one other disease-modifying agent; and 6 Both: 6.1 Either: 6.1.1 Patient has persistent symptoms of poorly-cont
Special Authority for Subsidy - Form SA0669Initial application only from a relevant specialist. Approvals valid without further renewal unless notified where organ transplant recipients. NoteSubsidy applies for either primary or rescue therapy
Note: There is a significant cost differential between moclobemide and fluoxetine (moclobemide being about three times more expensive). For depressive syndromes it is therefore more cost-effective to start treatment with fluoxetine first before considering prescribing moclobemide.
Additional subsidy by endorsement for:Nefazodone tab 100 mg x 56 (Serzone) up to $20.16Nefazodone tab 200 mg x 56 (Serzone) up to $40.32Citalopram tab 20 mg x 28 (Celapram) up to $4.00Citalopram tab 20 mg x 28 (Cipramil) up to $10.00Paroxetine hydrochloride tab 20 mg x 30 (Aropax) up to $35.02is available for patients who: -were taking nefazodone on 1 December 1999 or citalopram on 1 February 2000; or paroxetine hydrochloride on February 2001; or- have previously responded to treatment with nefazodone or citalopram or paroxetinehydrochloride; or- have had a trial of fluoxetine and have had to discontinue due to- inability to tolerate the drug due to side effects; or- failed to respond to an adequate dose and duration of treatment; or- have contraindications to fluoxetine (eg pre-existing significant levels of nausea, breastfeeding, potential drug interactions). The prescription must be endorsed accordingly.
Special Authority for Manufacturers Price - Form SA0673Initial application from any medical practitioner. Approvals valid for 3 months for applications meeting the following criteria: Both: 1 Patient considered unsafe to switch to m-Eslon; and 2 Patient was stabilised and well controlled on Kapanol, MST or LA-Morph before 1 December 2003. NoteSpecial Authority effective from 1 February 2004 to 31 July 2004
Rapid acting insulin analogues are subsidised when: 1) prescribed with insulin isophane or insulin glargine but are on a different prescription and the prescription is endorsed accordingly; or prescribed on the same prescription as insulin isophane or insulin glargine in which case the prescription is deemed to be endorsed; or2) a Special Authority has been approved. For 1and 2 first prescription to be written by a specialist (diabetologist, general physician or paediatrician). Any medical practitioner can writte subsequent prescriptions.
Additional subsidy by Special Authority - Retail Pharmacy - for: - Nifedipine tab long-acting 30mg x 30 (Adalat Oros) up to $19.90 - Nifedipine tab long-acting 60mg x 30 (Adalat Oros) up to $29.50
Special Authority for Subsidy - Form SA0693Initial application only from a relevant specialist or vocationally registered general practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria: All of the following: 1 Severe osteoporosis; and 2 History of one previous significant osteoporotic fracture demonstrated radiologically; and 3 T-Score <= -3.0 (bone mass density (BMD) >= 3.0 standard deviations below the mean normal value in young adults). NoteIn line with the Australian guidelines for funding alendronate, a vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral bodyRenewal - ((2 year approvals granted before February 2002)) only from a geriatrician, rheumatologist, endocrinologist, gynaecologis
Subsidy is available for patients with poorly controlled asthma where: a) at least three months of 750 mcg or more daily of inhaled beclomethasone or budesonide (or 400 mcg or fluticasone) for adults has been used; orb) at least three months of 400 mcg or more daily inhaled beclomethasone or budesonide (or 200 mcg or fluticasone) for children has been used; The prescription must be endorsed accordingly. We recommend that the words used to indicate eligibility are "poor control with ICS" or "certified exemption".
Special Authority for Subsidy - Form SA0696Initial application - (Narcolepsy) only from a neurologist or respiratory specialist. Approvals valid for 24 months where narcolepsy. Initial application - (ADHD in patients 5 or over) only from a paediatrician, psychiatrist or general practitioner on the recommendation of such a specialist. Approvals valid for 24 months for applications meeting the following criteria: All of the following: 1 ADHD (Attention Deficit and Hyperactivity Disorder) patients aged 5 years or over; and 2 Diagnosed according to DSM-IV or ICD 10 criteria; and 3 Either: 3.1 Applicant is a specialist; or 3.2 Both: 3.2.1 Applicant is a GP and a specialist has recommended treatment; and 3.2.2 Provide name of specialist (Details to be attached to application). Initial application - (ADHD in patients under 5) only from a paediatrician or psychiatrist. Approvals valid for 12 months for applications meeting the following criteria: Both: 1 ADHD (Attention Defi
Special Authority for Subsidy - Form SA0698Initial application only from a gastroenterologist, general surgeon or general physician. Approvals valid for 3 months for applications meeting the following criteria: Both: 1 Mild to moderate ileal, ileocaecal or proximal Crohn's disease; and 2 Any of the following: 2.1 Diabetes; or 2.2 Cushingoid habitus; or 2.3 Osteoporosis where there is significant risk of fracture; or 2.4 Severe acne following treatment with conventional corticosteroid therapy. Renewal only from a gastroenterologist, general surgeon or general physician. Approvals valid for 3 months where the treatment remains appropriate and the patient is benefiting from treatment. The patient must have had no more than 1 prior approval in the last year. NoteClinical trials for Entocort CIR use beyond three months demonstrated no improvement in relapse rate.
Special Authority for Subsidy - Form SA0699Initial application from any medical practitioner. Approvals valid for 1 year for applications meeting the following criteria: All of the following: 1 The patient is not predisposed to heart arrhythmias; and 2 The patient does not have a pre-existing QT-prolongation or hepatic failure; and 3 The patient is not using other medications which either inhibit the cytochrome P450 3A4 enzyme system or prolong the QT interval; and 4 Any of the following: 4.1 Both: 4.1.1 adult with severe reflux oesophagitis; and 4.1.2 other treatment, including acid suppression with proton pump inhibitors, has failed; or 4.2 gastroparesis; or 4.3 malignancy of GI tract causing gastroparesis (or gastric outlet obstruction); or 4.4 child (not including infants from 0 to 3 months of age who were born prematurely) with severe gastro-oesophageal reflux; and 5 Diagnosis has been made or confirmed by a general physician, gastroenterologist, or ge
Special Authority for Subsidy - Form SA0700Initial application only from an ophthalmologist. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 Both: 1.1 Monotherapy in primary open-angle glaucoma; and 1.2 Any of the following: 1.2.1 Patient cannot tolerate Beta-blockers, Pilocarpine and Dorzolamide; or 1.2.2 Beta-blockers, Pilocarpine and Dorzolamide are contraindicated; or 1.2.3 A reduction in intraocular pressure of 15% or more is not achieved or maintained using dorzolamide either alone or in combination with a beta-blocker; or 1.2.4 There is progressive visual field loss and/or optic nerve damage persists after treatment with dorzolamide either alone or in combination with a beta-blocker; or 2 Adjunctive use for the treatment of patients who have met the initial application criteria, and in whom latanoprost monotherapy has been ineffective in controlling intraocular pressure.Note An adjunctive agent may be added without a
Special Authority for Subsidy - Form SA0702Initial application - (Oral feed for cystic fibrosis patient) only from a relevant specialist. Approvals valid for 3 years for applications meeting the following criteria: Both: 1 Cystic fibrosis; and 2 Either: 2.1 The product is to be used as a supplement; or 2.2 The product is to be used as a complete diet.Initial application - (Oral feed for indications other than cystic fibrosis) only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria: Both: 1 Any of the following: 1.1 any condition causing malabsorption; or 1.2 failure to thrive; or 1.3 increased nutritional requirements; and 2 Either: 2.1 The product is to be used as a supplement; or 2.2 The product is to be used as a complete diet.Renewal - (Oral feed cystic fibrosis patient) only from a relevant specialist or general practitioner on the recommendation of such a specialist. Approvals valid for 3 years f
Special Authority for Subsidy - Form SA0703Initial application only from a relevant specialist or general practitioner. Approvals valid for 2 years for applications meeting the following criteria: All of the following: 1 Patient has raised blood pressure; and 2 The use of fully funded beta blockers is contraindicated, or not well tolerated; or where use of fully funded beta blockers and diuretics are insufficient to control blood pressure adequately at appropriate doses; and 3 Either: 3.1 Has been treated with, and cannot tolerate two ACE inhibitors, due to persistent cough; or 3.2 Has experienced angioedema on an ACE inhibitor at any time in the past or who have experienced angioedema (even if not using an ACE inhibitor) in the last 2 years. Renewal only from a relevant specialist or general practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0706Initial application only from a relevant specialist or general practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria: Either: 1 Both: 1.1 Patient with congestive heart failure; and 1.2 Either: 1.2.1 Has been treated with, and cannot tolerate, two ACE inhibitors, due to persistent cough; or 1.2.2 Has experienced angioedema on an ACE inhibitor at any time in the past or who have experienced angioedema (even if not using an ACE inhibitor) in the last 2 years; or 2 All of the following: 2.1 Patient with raised blood pressure; and 2.2 Use of fully funded beta blockers or diuretics are contraindicated; or not well tolerated; or insufficient to control blood pressure adequately at appropriate doses; and 2.3 Either: 2.3.1 Has been treated with, and cannot tolerate, two ACE inhibitors, due to persistent cough; or 2.3.2 Has experienced angioedema on an ACE in
Effective, consistent management of herpes from prescribing to these guidelines will improve patient outcomes. The guidelines on the following four pages are for the prescribing of aciclovir. The guidelines aim to: - improve patient care and clinical outcome through faster, more accessible treatment - protect patients' wider wellbeing by reinforcing the psychosocial aspects of treatment - improve the consistency and breadth of medical management of genital herpes in New Zealand. The guidelines are: - integral to ensuring a consistent, effective treatment regimen- the result of consultation with clinicians and patient representatives- set out in line with the recommended international algorithm format for treatment. The guidelines are endorsed by the Herpes Foundation's professional advisory board whose members represent venereology, NZDS, RNZCGP, RNZCOG, psychotherapy and nursing. Herpes Foundation Helpline: Toll free 0508 11 12 13Auckland Branch Herpes Foundation: 09 360 1966
Guidelines for the use of interferon in the treatment of hepatitis C: Physicians considering treatment of patients with hepatitis C should discuss cases with a gastroenterologist or aninfectious disease physician. All subjects undergoing treatment require careful monitoring for side effects. Patients should be otherwise fit. Hepatocellular carcinoma should be excluded by ultrasound examination and alpha-fetoprotein level. Criteria for Treatment a) Diagnosis- Anti-HCV positive on at least two occasions with a positive PCR for HCV-RNA and preferably confirmed by asupplementary RIBA test; or- PCR-RNA positive for HCV on at least 2 occasions if antibody negative; or- Anti-HCV positive on at least two occasions with a positive supplementary RIBA test with a negative PCR forHCV RNA but with a liver biopsy consistent with 2(b) following. b) Establishing Active Chronic Liver Disease- Confirmed HCV infection and serum ALT/AST levels measured on at least three occasions over six monthsaveraging >
Special Authority for Subsidy - Form SA0710Initial application only from an ophthalmologist. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 Either: 1.1 Monotherapy in primary open-angle glaucoma; or 1.2 Adjunctive use for the treatment of open-angle glaucoma in a patient who has met the initial application criteria, and in whom prostaglandin analogue monotherapy has been ineffective in controlling intraocular pressure; and 2 Any of the following: 2.1 Patient cannot tolerate beta-blockers, pilocarpine, and carbonic anhydrase inhibitors; or 2.2 Beta-blockers, pilocarpine and carbonic anhydrase inhibitors are contraindicated; or 2.3 A reduction in intraocular pressure of 15% or more is not achieved or maintained using carbonic anhydrase inhibitor either alone or in combination with a beta blocker; or 2.4 There is progressive visual field loss and/or optic nerve damage persists after treatment with carbonic anhydrase inhibitor either alo
Special Authority for Subsidy - Form SA0713Initial application from any specialist. Approvals valid for 11 months for applications meeting the following criteria: Either: 1 Patient has chronic hepatitis C, genotype 1, 4, 5 or 6 infection; or 2 Patient has chronic hepatitis C, genotype 2 or 3 infection with bridging fibrosis or cirrhosis (Metavir stage 3 or 4, or equivalent).
Special Authority for Subsidy - Form SA0714Initial application from any medical practitioner. Approvals valid for 3 months for applications meeting the following criteria: All of the following: 1 Patient is currently enrolled in a recognised comprehensive treatment programme for alcohol dependence in a service accredited against the New Zealand Alcohol and Other Drug Sector Standard or the National Mental Health Sector Standard; and 2 Applicant works in an Alcohol & Drug Service; and 3 Applicant must include the address of the service (Details to be attached to application). Renewal from any medical practitioner. Approvals valid for 3 months for applications meeting the following criteria: Both: 1 Compliance with the medication (prescriber determined); and 2 Any of the following: 2.1 Patient is still unstable and requires further treatment; or 2.2 Patient achieved significant improvement but requires further treatment; or 2.3 Patient is well controlled but requires maint
Prescribing GuidelinesTrusopt, Cosopt and Azopt are subsidised for use as either monotherapy or as an adjunctive agent for the treatment of glaucoma. Trusopt, Cosopt and Azopt should not be prescribed for a person in whom less expensive first line agents for the treatment of glaucoma are not contraindicated unless: a) that person has previously trialled all other such subsidised agents (except brimonidine tartrate); andb) those trials have indicated that that person does not respond adequately to treatment with those other agents.
Special Authority for Manufacturers Price - Form SA0717Initial application only from a relevant specialist or general practitioner. Approvals valid for 12 weeks for applications meeting the following criteria: Both: 1 Patient has a calculated absolute risk of cardiovascular disease of at least 15% over 5 years; and 2 Either: 2.1 Patient has severe documented intolerance to simvastatin; or 2.2 Both: 2.2.1 Patient has been compliant with a dose of simvastatin of 80 mg per day for at least 2 months; and 2.2.2 Either: 2.2.2.1 All of the following: 2.2.2.1.1 Patient has venous CABG; and 2.2.2.1.2 LDL cholesterol test 1 >= 2.0 mmol/litre; and 2.2.2.1.3 LDL cholesterol test 2 >= 2.0 mmol/litre (at least 1 week after test 1); or 2.2.2.2 All of the following: 2.2.2.2.1 Patient does not have venous CABG; and 2.2.2.2.2 LDL cholesterol test 1 >= 2.5 mmol/litre; and 2.2.2.2.3 LDL cholesterol test 2 >= 2.5 mmol/litre (at least 1 w
Special Authority for Subsidy - Form SA0721Initial application only from a named specialist. Approvals valid without further renewal unless notified for applications meeting the following criteria: All of the following: 1 The patient already has a Special Authority approval for anti-retroviral therapy (Details to be attached to application); and 2 Kaletra is to be used as a salvage therapy in place of one protease inhibitor; and 3 The patient must have trialed for at least six months and have failed on currently funded NNRTI based regimens or triple NRTI regimens; and 4 The patient must have trialed for at least six months and have failed on currently funded PI based regimens. NoteFailure is defined as: a) not achieving HIV RNA < 400 copies/ml after 24 weeks of a regimen, orb) an increase of HIV RNA to > 400 copies/ml on two separate occasions not less than one month apart, after suppression to < 400 copies/ml in a patient taking the regimen.
Special Authority for Subsidy - Form SA0722Initial application only from a relevant specialist. Approvals valid without further renewal unless notified for applications meeting the following criteria: Either: 1 Gluten enteropathy has been diagnosed by biopsy; or 2 Patient suffers from dermatitis herpetiformis.
Special Authority for Subsidy - Form SA0723Initial application only from a relevant specialist. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 All of the following: 1.1 Patient has a calculated absolute risk of cardiovascular disease >20% over 5 years; and 1.2 Patient cannot tolerate statin therapy at a dose of 40 mg per day; and 1.3 Either: 1.3.1 All of the following: 1.3.1.1 Patient has venous CABG; and 1.3.1.2 LDL cholesterol >= 2.0 mmol/litre (see note); and 1.3.1.3 LDL cholesterol >= 2.0 mmol/litre (at least 1 week after test 1 - see note); or 1.3.2 All of the following: 1.3.2.1 Patient does not have venous CABG; and 1.3.2.2 LDL cholesterol >= 2.5 mmol/litre (see note); and 1.3.2.3 LDL cholesterol >= 2.5 mmol/litre (at least 1 week after test 1 - see note); or 2 All of the following: 2.1 Patient has homozygous familial hypercholesterolemia, or heterozygous familial hypercholesterol
Special Authority for Manufacturers Price - Form SA0724Initial application only from a relevant specialist or general practitioner. Approvals valid for 12 weeks for applications meeting the following criteria: Both: 1 Patient has a calculated absolute risk of cardiovascular disease of at least 15% over 5 years; and 2 Either: 2.1 Patient has severe documented intolerance to simvastatin (blood tests are not required); or 2.2 Both: 2.2.1 Patient has been compliant with a dose of simvastatin of 80 mg per day for at least 2 months; and 2.2.2 Either: 2.2.2.1 All of the following: 2.2.2.1.1 Patient has venous CABG; and 2.2.2.1.2 LDL cholesterol test 1 >= 2.0 mmol/litre; and 2.2.2.1.3 LDL cholesterol test 2 >= 2.0 mmol/litre (at least 1 week after test 1); or 2.2.2.2 All of the following: 2.2.2.2.1 Patient does not have venous CABG; and 2.2.2.2.2 LDL cholesterol test 1 >= 2.5 mmol/litre; and 2.2.2.2.3 LDL cholesterol test 2 >
Special Authority for Subsidy - Form SA0725Initial application only from a relevant specialist or general practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria: All of the following: 1 Patient with raised blood pressure; and 2 Use of fully funded beta blockers and diuretics are contraindicated; or not well tolerated; or insufficient to control blood pressure adequately at appropriate doses; and 3 Either: 3.1 Has been treated with, and cannot tolerate, two ACE inhibitors, due to persistent cough; or 3.2 Has experienced angioedema on an ACE inhibitor at any time in the past or who have experienced angioedema (even if not using an ACE inhibitor) in the last 2 years. Renewal - (Previous approval has expired) only from a relevant specialist or general practitioner. Approvals valid without further renewal unless notified where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0727Initial application from any medical practitioner. Approvals valid for 1 year for applications meeting the following criteria: All of the following: 1 Control of intractable nausea, vomiting, or inability to swallow saliva in the treatment of malignancy or chronic disease; and 2 Patient cannot tolerate or does not adequately respond to oral anti-nausea agents; and 3 The applicant must specify the underlying malignancy or chronic disease (Details to be attached to application). Renewal from any medical practitioner. Approvals valid for 1 year where the treatment remains appropriate and the patient is benefiting from treatment.
Retail pharmacy - subsidy by endorsement a) Subsidised for:(i) patients presenting with first episode schizophrenia or related psychoses, or manic episodes associated with bipolar disorder; and(ii) patients suffering from schizophrenia or related psychoses, or manic episodes associated with bipolar disorder, after a trial of an effective dose of risperidone that has been discontinued because of unacceptable side effects or inadequate response. b) Initial prescription must be written by a relevant specialist. c) Subsequent prescriptions may be written by a general practitioner. d) The prescription must be endorsed "certified condition".
Special Authority for Subsidy - Form SA0732Initial application only from a relevant specialist. Approvals valid for 3 years for applications meeting the following criteria: Either: 1 dietary management of homocystinuria; or 2 dietary management of maple syrup urine disease. Renewal only from a relevant specialist or general practitioner on the recommendation of such a specialist. Approvals valid for 1 year for applications meeting the following criteria: Both: 1 The treatment remains appropriate and the patient is benefiting from treatment; and 2 General Practitioners must include the name of the specialist and date contacted.
Special Authority for Subsidy - Form SA0733Initial application - (Patient aged over 16) only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria: Both: 1 dietary management of PKU; and 2 blood phenylalanine level < 900 mmol/litre (average of tests over last 12 months). Initial application - (Patient aged 16 or under) only from a relevant specialist. Approvals valid for 3 years where dietary management of PKU.Renewal - (Patient aged over 16) only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria: blood phenylalanine level < 900 mmol/litre (average of tests over last 12 months). Renewal - (Patient aged 16 or under) only from a relevant specialist or general practitioner on the recommendation of such a specialist. Approvals valid for 3 years for applications meeting the following criteria: Both: 1 The treatment remains appropriate and the patient is benefiting from treatment; and 2
GuidelinesIt can cost up to $70,000 a year to keep an adult on protein supplements. Because protein substitutes are so expensive and because they are only effective in controlling PKU if a restricted diet is followed, adults with PKU will be required to demonstrate they are following the prescribed diet by regular blood testing. The requirement for testing applies to those aged over 16 years. Failure to follow an appropriate diet results in high blood phenylalanine levels. Those consistently testing above 15 mg (900 micromol) over a twelve month period will not be able to claim these products as a Special Authority. Specialists will be required to renew applications for their PKU patients every year and, when they do so, will have to submit the results of two blood tests.
Neocate should be used only as a last resort when the infant is unable to absorb any of the above formulae. The objective with each of thees formulae prescribed is to get the infant off them as soon as possible. This may take six months, it may take three years. Because of this, variation on age limit is not regarded as appropriate.These formulae will be available only from a hospital pharmacy. Vivonex Pediatric may be a suitable and less expensive alternative for many children that would otherwise be eligible for a subsidy for Neocate and should, therefore, be tried first in these cases. The subsidy for these products reflects the philosophy that the patient incurs no additional financial burden for purchasing specialised more expensive products.
Special Authority for Subsidy - Form SA0738Initial application only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria: Either: 1 All of the following: 1.1 To be used as monotherapy for patients with type 2 diabetes who after six months of diet and lifestyle changes do not have adequate glycaemic control (inadequate control defined as HbA1c > 8.0% in tests carried out at least two months apart); and 1.2 Metformin is not tolerated or contraindicated. Intolerance and contraindications as defined in the notes below, a minimum of a four week trial period of metformin is required; and 1.3 Sulphonylurea is not tolerated or contraindicated. Overweight patients are only eligible under the criteria of contraindication to sulphonylureas if their body mass index (BMI) exceeds 35; or 2 Both: 2.1 For use in combination with a sulphonylurea when diet and lifestyle changes and a twelve month trial of sulphonylurea results in inadequate glycaem
Prescribing GuidelineHRT should be taken at the lowest dose for the shortest period of time necessary to control symptoms. Patients should be reviewed 6 monthly in line with the updated NZGG "Evidence-based Best Practice Guideline on Hormone Replacement Therapy March 2004".
Special Authority for Subsidy - Form SA0741Initial application only from a psychiatrist. Approvals valid for 2 years for applications meeting the following criteria: Any of the following: 1 Patient with first episode schizophrenia or related psychoses; or 2 Both: 2.1 Patient suffering from schizophrenia and related psychoses; or acute mania in bipolar disorder who is likely to benefit from anti-psychotic treatment; and 2.2 Either: 2.2.1 An effective dose of risperidone had been trialled and has been discontinued because of unacceptable side effects; or 2.2.2 An effective dose of risperidone had been trialled and has been discontinued because of inadequate clinical response after 4 weeks; or 3 The patient has suffered from an acute episode of schizophrenia or bipolar mania and has been treated with olanzapine short-acting intra-muscular injection. Renewal only from a psychiatrist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefit
Special Authority for Subsidy - Form SA0742Initial application - (genotype 1, 4, 5 or 6 infection) from any specialist. Approvals valid for 11 months where patient has chronic hepatitis C, genotype 1, 4, 5 or 6 infection. Initial application - (genotype 2 or 3 infection) from any specialist. Approvals valid for 6 months for applications meeting the following criteria: Both: 1 Patient has chronic hepatitis C, genotype 2 or 3 infection; and 2 Patient has bridging fibrosis or cirrhosis (Metavir stage 3 or 4 or equivalent).
Special Authority for Subsidy - Form SA0743Initial application only from a relevant specialist. Approvals valid for 3 months for applications meeting the following criteria: Both: 1 Patient is terminally ill and is opioid-responsive; and 2 Either: 2.1 is unable to take oral medication; or 2.2 is intolerant to morphine, or morphine is contraindicated..Renewal only from a relevant specialist or general practitioner. Approvals valid for 3 months where the treatment remains appropriate and the patient is benefiting from treatment.
Additional subsidy by endorsement for:Citalopram tab 20 mg x 28 (Celapram) up to $4.00Citalopram tab 20 mg x 28 (Cipramil) up to $10.00Paroxetine hydrochloride tab 20 mg x 30 (Aropax) up to $35.02is available for patients who: -were taking citalopram on 1 February 2000; or paroxetine hydrochloride on February 2001; or- have previously responded to treatment with citalopram or paroxetinehydrochloride; or- have had a trial of fluoxetine and have had to discontinue due to- inability to tolerate the drug due to side effects; or- failed to respond to an adequate dose and duration of treatment; or- have contraindications to fluoxetine (eg pre-existing significant levels of nausea, breastfeeding, potential drug interactions). The prescription must be endorsed accordingly.
Special Authority for Subsidy - Form SA0751Initial application only from an ophthalmologist. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 Either: 1.1 Monotherapy in primary open-angle glaucoma; or 1.2 Adjunctive use for the treatment of open-angle glaucoma in a patient who has met the initial application criteria, and in whom prostaglandin analogue monotherapy has been ineffective in controlling intraocular pressure; and 2 Any of the following: 2.1 Patient cannot tolerate beta-blockers, pilocarpine, and carbonic anhydrase inhibitors; or 2.2 Beta-blockers, pilocarpine and carbonic anhydrase inhibitors are contraindicated; or 2.3 A reduction in intraocular pressure of 15% or more is not achieved or maintained using carbonic anhydrase inhibitor either alone or in combination with a beta blocker; or 2.4 There is progressive visual field loss and/or optic nerve damage persists after treatment with carbonic anhydrase inhibitor either alo
(a) Subsidy is available between 1 March and 30 June of each year for patients who meet the following criteria, as set by the Ministry of Health: a) all people 65 years of age and over; b) people under 65 years of age with: i) the following cardiovascular disease: 1) ischaemic heart disease, 2) congestive heart disease, 3) rheumatic heart disease, 4) congenital heart disease, or 5) cerebo-vascular disease; ii) the following chronic respiratory disease: 1) asthma, if on a regular preventative therapy, or 2) other chronic respiratory disease with impaired lung function; iii) diabetes; iv) chronic renal disease; v) any cancer, excluding basal and squamous skin cancers if not invasive; vi) the following other conditions: 1) autoimmune disease, 2) immune suppression, 3) HIV, 4) transplant recipients, 5) neuromuscular and CNS diseases, 6) haemoglobinopathies, or 7) children on long term aspirin. The following conditions are excluded from funding: i) asthma not requiri
Special Authority for Manufacturers Price - Form SA0753Initial application only from a relevant specialist. Approvals valid for 3 years for applications meeting the following criteria: Both: 1 Patient is a postmenopausal women; and 2 Patient has hormone receptor positive advanced breast cancer (Stage IIIb, or metastatic Stage IV). Renewal only from a relevant specialist. Approvals valid for 3 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0754Initial application only from a named specialist. Approvals valid without further renewal unless notified for applications meeting the following criteria: All of the following: 1 The patient already has a Special Authority approval for anti-retroviral therapy (Details to be attached to application); and 2 Kaletra is to be used as a salvage therapy in place of one protease inhibitor; and 3 The patient must have trialed for at least six months and have failed on currently funded NNRTI based regimens or triple NRTI regimens; and 4 The patient must have trialed for at least six months and have failed on currently funded PI based regimens. NoteFailure is defined as: a) not achieving HIV RNA < 400 copies/ml after 24 weeks of a regimen, orb) an increase of HIV RNA to > 400 copies/ml on two separate occasions not less than one month apart, after suppression to < 400 copies/ml in a patient taking the regimen.
Special Authority for Subsidy - Form SA0755Initial application from any medical practitioner. Approvals valid for 2 years where the patient is likely to benefit from treatment. Note Applications to be made on the approved forms which are available from: Prof. Wayne CutfieldNational Co-ordinatorNew Zealand Growth Hormone CommitteeC/- Department of PaediatricsUniversity of AucklandPrivate Bag 92019AUCKLAND
Special Authority for Subsidy - Form SA0757Initial application only from a relevant specialist. Approvals valid for 6 months for applications meeting the following criteria: All of the following: 1 The patient is less than 2 years of age; and 2 Intolerant to cows' milk; and 3 Diagnosed as suffering from congenital lactase deficiency. Renewal only from a relevant specialist. Approvals valid for 6 months where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0758Initial application only from a general practitioner or relevant specialist. Approvals valid for 2 years for applications meeting the following criteria: All of the following: 1 To be used for the long-term maintenance treatment of bronchospasm and dyspnoea associated with COPD; and 2 In addition to standard treatment, the patient has trialled a dose of at least 40 mcg ipratropium q.i.d; and 3 The patient's breathlessness >= grade 4 according to the Medical Research Council dyspnoea scale (see note); and 4 FEV1 (litres) < 0.4 x predicted (litres); and 5 Either: 5.1 Patient is not a smoker (for reporting purposes only); or 5.2 Patient is a smoker and been offered smoking cessation councilling; and 6 The patient has been offered annual influenza immunisation. Renewal only from a general practitioner or relevant specialist. Approvals valid for 2 years for applications meeting the following criteria: All of the following: 1
a) Prescribers may code prescriptions "contraceptive" (code "O") when used as indicated for contraception. The period of supply and prescription charge will be as per other contraceptives, as follows: - $3.00 prescription charge (patient co-payment) will apply; - prescription may be written for up to six months supply. b) Prescriptions coded in any other way are subject to the non-contraceptive prescription charges, and the non-contraceptive period of supply. ie. Prescriptions may be written for up to three months supply.
A diagnostic blood glucose test meter is subsidised for patients who begin insulin or sulphonylurea therapy after 1 March 2005. Only one meter per patient. No further prescriptions will be subsidised. The prescription must be endorsed accordingly.
(a) Subsidy is available between 1 March and 30 June of each year for patients who meet the following criteria, as set by the Ministry of Health: a) all people 65 years of age and over; b) people under 65 years of age with: i) the following cardiovascular disease: 1) ischaemic heart disease, 2) congestive heart disease, 3) rheumatic heart disease, 4) congenital heart disease, or 5) cerebo-vascular disease; ii) the following chronic respiratory disease: 1) asthma, if on a regular preventative therapy, or 2) other chronic respiratory disease with impaired lung function; iii) diabetes; iv) chronic renal disease; v) any cancer, excluding basal and squamous skin cancers if not invasive; vi) the following other conditions: 1) autoimmune disease, 2) immune suppression, 3) HIV, 4) transplant recipients, 5) neuromuscular and CNS diseases, 6) haemoglobinopathies, or 7) children on long term aspirin. The following conditions are excluded from funding: i) asthma not requiri
The number of test strips available on a prescription is restricted to 50 unless: a) Prescribed with insulin or a sulphonylurea but are on a different prescription and the prescription is endorsed accordingly; orb) Prescribed on the same prescription as insulin or a sulphonylurea in which case the prescription is deemed to be endorsed; orc) Prescribed for a pregnant woman with diabetes and endorsed accordingly.
Special Authority for Subsidy - Form SA0772Initial application only from a gastroenterologist, infectious disease specialist, paediatrician or general physician. Approvals valid for 1 year for applications meeting the following criteria: Both: 1 Any of the following: 1.1 All of the following: 1.1.1 HBsAg positive for more than 6 months; and 1.1.2 HBeAg positive or HBV DNA positive defined as >0.6 pg/ml by quantitative PCR at reference laboratory; and 1.1.3 ALT greater than twice upper limit of normal or stage 3 or 4 fibrosis on liver histology clinical/radiological evidence of cirrhosis; or 1.2 HBV DNA positive cirrhosis prior to liver transplantation; or 1.3 HBsAg positive and have had a liver, kidney, heart, lung or bone marrow transplant; or 1.4 Hepatitis B surface antigen positive (HbsAg) patient who is receiving chemotherapy for a malignancy, or who has received such treatment within the previous two months; and 2 All of the following: 2.1 No continuing
Additional subsidy by endorsement for:Paroxetine hydrochloride tab 20 mg x 30 (Aropax) up to $35.02is available for patients who: -were taking paroxetine hydrochloride on February 2001; or- have previously responded to treatment with paroxetinehydrochloride; or- have had a trial of fluoxetine and have had to discontinue due to- inability to tolerate the drug due to side effects; or- failed to respond to an adequate dose and duration of treatment; or- have contraindications to fluoxetine (eg pre-existing significant levels of nausea, breastfeeding, potential drug interactions). The prescription must be endorsed accordingly.
Special Authority for Subsidy - Form SA0774Initial application only from a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Any of the following: 1 The patient has advanced gastrointestinal malignancy; or 2 The patient has metastatic breast cancer*; or 3 Both: 3.1 The patient has poor venous access or needle phobia*; and 3.2 The patient requires a substitute for single agent fluoropyrimidine*. Renewal only from a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Either: 1 The patient requires continued therapy; or 2 The tumour has relapsed and requires re-treatment. Noteindications marked with * are unapproved indications.
Special Authority for Subsidy - Form SA0775Initial application only from a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Both: 1 The patient has metastatic colorectal cancer; and 2 Either: 2.1 To be used for first or second line use as part of a combination chemotherapy regimen; or 2.2 As single agent chemotherapy in fluropyrimidine-relapsed disease. Renewal only from a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Either: 1 The patient requires continued therapy; or 2 The tumour has relapsed and requires re-treatment.
Special Authority for Subsidy - Form SA0776Initial application only from a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Any of the following: 1 Both: 1.1 The patient has ovarian, fallopian* or primary peritoneal cancer*; and 1.2 Either: 1.2.1 Has not received prior chemotherapy; or 1.2.2 Has received prior chemotherapy but has not previously been treated with taxanes; or 2 The patient has metastatic breast cancer; or 3 Both: 3.1 The patient has non-small cell lung cancer; and 3.2 Either: 3.2.1 The patient has advanced disease (stage IIIa or above); or 3.2.2 The patient is receiving combined chemotherapy and radiotherapy; or 4 Both: 4.1 The patient has small-cell lung cancer*; and 4.2 Paclitaxel is to be used as second-line therapy. Renewal only from a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Both: 1 The patient has metastati
Special Authority for Subsidy - Form SA0777Initial application - (Post-transplant) only from a relevant specialist. Approvals valid for 6 months where the patient has B-cell post-transplant lymphoproliferative disorder*. NoteFor no more than 8 treatment cycles. Initial application - (Low-grade lymphomas) only from a relevant specialist. Approvals valid for 6 months where the patient has low grade NHL - relapsed disease following prior chemotherapy. NoteFor no more than 4 treatment cycles. Initial application - (Large cell lymphomas) only from a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Both: 1 The patient has treatment naive large B-cell NHL; and 2 To be used with CHOP (or alternative anthracycline containing multi-agent chemotherapy regime given with curative intent).NoteFor no more than 8 treatment cycles. Renewal - (Low-grade lymphomas) only from a relevant specialist. Approvals valid for 6 months for applications meeting
Special Authority for Subsidy - Form SA0779Initial application - (Confirmed HIV/AIDS) only from a named specialist. Approvals valid without further renewal unless notified for applications meeting the following criteria: Both: 1 Confirmed HIV infection; and 2 Any of the following: 2.1 Symptomatic patient; or 2.2 Patient aged 12 months and under; or 2.3 Both: 2.3.1 Patient aged 1 to 5 years; and 2.3.2 Any of the following: 2.3.2.1 CD4 counts < 1,000 cells/mm3; or 2.3.2.2 CD4 counts < 0.25 x total lymphocyte count; or 2.3.2.3 Viral load counts > 100,000 copies per ml; or 2.4 Both: 2.4.1 Patient aged 6 years and over; and 2.4.2 CD4 counts < 350 cells/mm3. NoteTenofovir disoproxil fumarate prescribed under endorsement for HIV/AIDS is included in the count of up to 3 subsidised antiretrovirals. Subsidies for a combination of up to three anti-retroviral medications, including a maximum of two protease inhibitors. Combinations including r
Special Authority for Subsidy - Form SA0780Initial application - (Single NAED Therapy) only from a paediatrician, neurologist or general physician. Approvals valid for 15 months for applications meeting the following criteria: Any of the following: 1 Was on NAED therapy before 1 September 2000; or 2 Seizures are not adequately controlled with optimal older anti-epilepsy drug treatment; or 3 Seizures are controlled adequately but who experience unacceptable side effects from older anti-epilepsy drug treatment. Note"Optimal older anti-epilepsy drug therapy" is defined as treatment with those older anti-epilepsy drugs which are indicated and clinically appropriate for the patient, given singly and in combination in adequate doses for the patient's age, weight, and other features affecting the pharmacokinetics of the drug with good evidence of complianceInitial application - (Dual NAED Therapy) only from a paediatrician, neurologist or general physician. Approvals valid for 18 months for app
Special Authority for Subsidy - Form: SA0781Initial application only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria: Any of the following: Monotherapy1 All of the following: 1.1 To be used as monotherapy for patients with type 2 diabetes who after six months of diet and lifestyle changes do not have adequate glycaemic control (inadequate control defined as HbA1c > 7.0% in tests carried out at least two months apart); and 1.2 Metformin is not tolerated or contraindicated. Intolerance and contraindications as defined in the notes below, a minimum of a four week trial period of metformin is required; and 1.3 Sulphonylurea is not tolerated or contraindicated. Obesity is only eligible under the criteria of contraindication to sulphonylureas if the patient's body mass index (BMI) exceeds 33 , intolerance as defined in the notes below; orIn combination with sulphonylurea2 Both: 2.1 For use in combination with a sulphonylure
Special Authority for Subsidy - Form SA0782Initial application - (No previous use) only from a relevant specialist or general practitioner. Approvals valid for 6 months for applications meeting the following criteria: All of the following: 1 The patient has a clinical diagnosis of heavy menstrual bleeding; and 2 The patient has failed to respond to or is unable to tolerate other appropriate pharmaceutical therapies as per the Heavy Menstrual Bleeding Guidelines; and 3 Either: 3.1 serum ferritin level < 16 mg/l (within the last 12 months); or 3.2 haemoglobin level < 120 g/l . NoteApplications are not to be made for use in patients as contraception except where they meet the above criteriaInitial application - (Previous use before 1 October 2002) only from a relevant specialist or general practitioner. Approvals valid for 6 months for applications meeting the following criteria: All of the following: 1 The patient had a clinical diagnosis of heavy menstrual bleeding; and 2
Special Authority for Manufacturers Price - Form: SA0783Initial application only from a relevant specialist. Approvals valid for 5 years for applications meeting the following criteria: All of the following: 1 Patient is a postmenopausal women; and2 Patient has hormone receptor positive advanced breast cancer; and3 Any of the following: 3.1 The cancer is advanced (Stage IIIb, or metastatic Stage IV); or 3.2 The patient has a very clear history of intolerance to tamoxifen; or 3.3 The use of tamoxifen is contraindicated due to a history of thromboembolic disease. Renewal only from a relevant specialist. Approvals valid without further renewal unless notified where the treatment remains appropriate and the patient is benefiting from treatment.
Prescribing GuidelinePrescribers should note that oxycodone is significantly more expensive than long-acting morphine sulphate and clinical advice suggests that it is reasonable to consider this as a second-line agent to be used after morphine.
Special Authority for Manufacturers Price - Form SA0788Initial application only from a relevant specialist or general practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria: Both: 1 Patient has a calculated absolute risk of cardiovascular disease of at least 15% over 5 years; and 2 Either: 2.1 Patient has severe documented intolerance to simvastatin (blood tests are not required); or 2.2 Both: 2.2.1 Patient has been compliant with a dose of simvastatin of 80 mg per day for at least 2 months; and 2.2.2 Either: 2.2.2.1 All of the following: 2.2.2.1.1 Patient has venous CABG; and 2.2.2.1.2 LDL cholesterol test 1 >= 2.0 mmol/litre; and 2.2.2.1.3 LDL cholesterol test 2 >= 2.0 mmol/litre (at least 1 week after test 1); or 2.2.2.2 All of the following: 2.2.2.2.1 Patient does not have venous CABG; and 2.2.2.2.2 LDL cholesterol test 1 >= 2.5 mmol/litre; and 2.2.2.2.
Special Authority for Subsidy - Form SA0789Initial application only from a relevant specialist or vocationally registered general practitioner. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 The patient has "treatment resistant" depression; and 2 Either: 2.1 The patient must have had a trial of two different antidepressants and failed to respond to an adequate dose over an adequate period of time (usually at least four weeks); or 2.2 Both: 2.2.1 The patient is currently a hospital in-patient as a result of an acute depressive episode; and 2.2.2 The patient must have had a trial of one other antidepressant and failed to respond to an adequate dose over an adequate period of time. Renewal from any medical practitioner. Approvals valid for 2 years where patient has a high risk of relapse (prescriber determined).
Prescribing GuidelineBimatoprost, lantanoprost and travoprost are subsidised for use in the treatment of glaucoma as either monotherapy or as an adjunctive agent for patients in whom prostaglandin analogue monotherapy has been ineffective in controlling intraocular pressure.Bimatoprost, lantanoprost and travoprost should not be prescribed for a person in whom less expensive first line agents for the treatment of glaucoma are not contraindicated unless: 1 That person has previously trialled all other such subsidised agents (beta-blockers, pilocarpine, carbonic anhydrase inhibitors); and2 Those trials have indicated that that person does not respond adequately to treatment with those other agents.
Special Authority for Subsidy - Form: SA0792Initial application only from a psychiatrist. Approvals valid for 6 months for applications meeting the following criteria: All of the following: 1 The patient has schizophrenia or other psychotic disorder; and2 Has tried but failed to comply with treatment using oral atypical anti-psychotic agents; and3 Has been admitted to hospital or treated in respite care, or intensive outpatient or home-based treatment for 30 days or more in last 12 months. Renewal only from a psychiatrist. Approvals valid for 12 months for applications meeting the following criteria: Either: 4 Both: 4.1 The patient has had less than 12 months treatment with risperidone microspheres; and 4.2 There is no clinical reason to discontinue treatment; or5 The initiation of risperidone microspheres has been associated with fewer days of intensive intervention than was the case during a corresponding period of time prior to the initiation of risperidone microspheres. NoteRisp
a) Subsidised only if prescribed for a dialysis or cystic fibrosis patient; orb) for the treatment of confirmed ciprofloxacin-resistant gonorrhoea; orc) for the treatment of suspected meningitis in patients who have a known allergy to penicillin; andd) the prescription is endorsed accordingly
Special Authority for Subsidy - Form: SA0796Initial application only from a relevant specialist. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 Either: 1.1 ezetimibe is to be used in combination with simvastatin; or 1.2 ezetimibe is to be used without a statin; and2 Either: 2.1 All of the following: 2.1.1 Patient has a calculated absolute risk of cardiovascular disease >20% over 5 years; and 2.1.2 Patient cannot tolerate statin therapy at a dose of 40 mg per day; and 2.1.3 Either: 2.1.3.1 All of the following: 2.1.3.1.1 Patient has venous CABG; and 2.1.3.1.2 LDL cholesterol >= 2.0 mmol/litre (see note); and 2.1.3.1.3 LDL cholesterol >= 2.0 mmol/litre (at least 1 week after test 1 - see note); or 2.1.3.2 All of the following: 2.1.3.2.1 Patient does not have venous CABG; and 2.1.3.2.2 LDL cholesterol >= 2.5 mmol/litre (see note); and 2.1.3.2.3 LDL cholest
Special Authority for Subsidy - Form: SA0797Initial application - (Underlying cause - Osteoporosis) only from a relevant specialist or vocationally registered general practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria: Any of the following: 1 History of one significant osteoporotic fracture demonstrated radiologically and documented bone mass density (BMD) >= 2.5 standard deviations below the mean normal value in young adults (i.e. T-Score <= -2.5); or2 History of one significant osteoporotic fracture demonstrated radiologically and the patient is either over 75 years of age or is too frail* to undergo a bone mass density scan; or3 History of two significant osteoporotic fractures demonstrated radiologically; or4 Documented T-Score <= -3.0. Note*The patient may be considered to be frail if it is expected that there is significant risk of further fracture or other negative health outcome if the patient were to undergo a BMD s
Special Authority for Subsidy - Form: SA0798Initial application only from a relevant specialist. Approvals valid without further renewal unless notified for applications meeting the following criteria: Either: 1 Renal transplant recipient; or2 Heart transplant recipient. or; 3 Patient has an organ transplant and has severe tophaceous gout making azathioprine unsuitableRenewal only from a relevant specialist. Approvals valid without further renewal unless notified where patient had a previous Special Authority approval and was receiving mycophenolate prior to 1 October 2005
Special Authority for Subsidy - Form: SA0799Initial application only from a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Either: 1 The patient has metastatic breast cancer; or2 The patient has non-small cell lung cancer (stage IIIa, or above).Renewal only from a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Either: 3 The patient requires continued therapy; or4 The tumour has relapsed and requires re-treatment.
Special Authority for Subsidy - Form SA0801Initial application - (Serevent Accuhaler, Foradil, Symbicort Turbuhaler) only from a relevant specialist or general practitioner. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 Both: 1.1 Child under the age of 12 with poorly controlled asthma; and 1.2 Either: 1.2.1 Required at least three months of 400 mcg or more daily inhaled beclomethasone or budesonide; or 1.2.2 Required at least three months of 200 mcg or more of fluticasone; or 2 Both: 2.1 Adult with poorly controlled asthma; and 2.2 Either: 2.2.1 Required at least three months of 1500 mcg or more daily inhaled beclomethasone or budesonide; or 2.2.2 Required at least three months of 750 mcg or more of fluticasone. NotePatients are to be reviewed at least at six months to assess compliance and effectiveness of therapy. Special Authority approvals are interchangeable among all presentations of inhaled long-acting beta
Special Authority for Subsidy - Form SA0802Initial application - (genotype 1, 4, 5 or 6 infection or co-infection with HIV) from any specialist. Approvals valid for 11 months for applications meeting the following criteria: 1. Patient has chronic hepatitis C, genotype 1, 4, 5 or 6 infection; or2. Patient has chronic hepatitis C and is co-infected with HIV. Note: consider stopping treatment if there is absence of a virological response (defined as at least a 2-log reduction in viral load) following 12 weeks of treatment since this is predictive of treatment failure.Initial application - (genotype 2 or 3 infection without co-infection with HIV) from any specialist. Approvals valid for 6 months for applications meeting the following criteria: 3. Patient has chronic hepatitis C, genotype 2 or 3 infection; andEither: 3.1 Patient has bridging fibrosis or cirrhosis (Metavir stage 3 or 4 or equivalent); or 3.2 is unsuitable for liver biopsy due to coagulopathy.
Special Authority for Subsidy - Form SA0803Initial application from any specialist. Approvals valid for 11 months for applications meeting the following criteria: either: 1 Patient has chronic hepatitis C, genotype 1, 4, 5 or 6 infection; or2 Patient has chronic hepatitis C, genotype 2 or 3 infection; and 2.1 With has bridging fibrosis or cirrhosis (Metavir stage 3 or 4, or equivalent). 2.2 is unsuitable for liver biopsy due to coagulopathy. Note: consider stopping treatment if there is absence of a virological response (defined as at least a 2-log reduction in viral load) following 12 weeks of treatment since this is predictive of treatment failure.
Prescribing Guideline for Inhaled Long-Acting Beta-Adrenoceptor AgonistsThe addition of inhaled long-acting beta-adrenoceptor agonists (LABAs) to inhaled corticosteroids is recommended: - For younger children (aged under 12 years) where asthma is poorly controlled despite using inhaled corticosteroids for at least three months at total daily doses of 200 mcg beclomethasone or budesonide (or 100 mcg fluticasone).- For adults and older children (aged 12 years and over) where asthma is poorly controlled despite using inhaled corticosteroids for at least three months at total daily doses of 400 mcg beclomethasone or budesonide (or 200 mcg fluticasone).Note: Further information on the place of inhaled corticosteroids and inhaled LABAs in the management of asthma can be found in the New Zealand guidelines for asthma in adults (www.nzgg.org.nz) and in the New Zealand guidelines for asthma in children aged 1-15 (www.paediatrics.org.nz).
Access by applicationa) Budget managed by appointed clinicians on the Multiple Sclerosis Treatment Assessments Committee (MSTAC). b) Applications will be considered by MSTAC at its regular meetings and approved subject to eligibility according to the Entry and Stopping criteria (below). c) Applications to be made on the approved forms which are available from the co-ordinator for MSTAC:The Co-ordinator Phone: (04) 460 4990Multiple Sclerosis Treatment Assessments Committee Facsimile: (04) 916 7571PHARMAC, PO Box 10 254 E mail: silvia.valsenti@pharmac.govt.nzWellingtond) Completed application forms must be sent to the co-ordinator for MSTAC and will be considered by MSTAC at the next practicable opportunity. e) Notification of MSTAC's decision will be sent to the patient, the applying clinician and the patient's GP (if specified). f) These agents will not be subsidised if dispensed from a community or hospital pharmacy. Regular supplies will be distributed to all approved patients or their c
a) Subsidised only if prescribed for a dialysis or cystic fibrosis patient; orb) for the treatment of confirmed ciprofloxacin-resistant gonorrhoea; orc) for the treatment of suspected meningitis in patients who have a known allergy to penicillin; andd) the prescription or PSO is endorsed accordingly
subsidised only if prescribed for patients with uncomplicated urethritis or cervicitis proven or presumed to be due to Chlamydia trachomatis and their sexual contacts and prescription or PSO is endorsed accordingly.
Special Authority for Subsidy Initial application only from a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: 1 The patient has metastatic colorectal cancer; and2 To be used for first or second line use as part of a combination chemotherapy regimen. Renewal only from a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: 3 The patient requires continued therapy; or4 The tumour has relapsed and requires re-treatment.
Special Authority for Subsidy - Form: SA0809Initial application only from a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Any of the following: 1 Both: 1.1 The patient has ovarian*, fallopian* or primary peritoneal cancer*; and 1.2 Either: 1.2.1 Has not received prior chemotherapy; or 1.2.2 Has received prior chemotherapy but has not previously been treated with taxanes; or2 The patient has metastatic breast cancer; or3 Both: 3.1 The patient has non small-cell lung cancer; and 3.2 Either: 3.2.1 Has advanced disease (stage IIIa or above); or 3.2.2 Is receiving combined chemotherapy and radiotherapy; or4 Both: 4.1 The patient has small-cell lung cancer*; and 4.2 Docetaxel is to be used as second-line therapy. Renewal only from a relevant specialist. Approvals valid for 12 months for applications meeting the followingcriteria: 5. The patient has metastatic breast cancer, non small-cell lung cancer,
Special Authority for Alternate SubsidyInitial application only from a relevant specialist. Approvals valid for 5 years for applications meeting the following criteria: All of the following: 1 Patient is a postmenopausal women; and2 Patient has hormone receptor positive breast cancer; and3 Any of the following: 3.1 The cancer is advanced (Stage IIIb, or metastatic Stage IV); or 3.2 The patient has a very clear history of intolerance to tamoxifen; or 3.3 The use of tamoxifen is contraindicated due to a history of thromboembolic disease. Renewal only from a relevant specialist. Approvals valid without further renewal unless notified where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Alternate SubsidyInitial application only from a relevant specialist. Approvals valid for 5 years for applications meeting the following criteria: All of the following: 1 Patient is a postmenopausal women; and2 Patient has hormone receptor positive breast cancer; and3 Any of the following: 3.1 The cancer is advanced (Stage IIIb, or metastatic Stage IV); or 3.2 The patient has a very clear history of intolerance to tamoxifen; or 3.3 The use of tamoxifen is contraindicated due to a history of thromboembolic disease. Renewal only from a relevant specialist. Approvals valid without further renewal unless notified where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for SubsidyInitial application only from a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria: All of the following1 Patient is an adult who has had severe and active erosive Rheumatoid Arthritis for six months duration or longer; and2 Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and3 Patient has tried and not responded to at least three months of oral or parenteral methotrexate at a dose of at least 20 mg weekly or a maximum tolerated dose; and4 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with at least two of the following (triple therapy): sulphasalazine, prednisone at a dose of at least 7.5 mg per day, azathioprine, intramuscular gold, or hydroxychloroquine sulphate (at maximum tolerated doses); and5 Patient has tried and not responded to at least three months therapy at th
Special Authority for Subsidy Initial application only from a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Any of the following: 1 The patient has non small cell lung carcinoma (stage IIIa, or above); or2 The patient has advanced malignant mesothelioma*; or3 The patient has advanced pancreatic carcinoma; or4 The patient has ovarian, fallopian tube* or primary peritoneal carcinoma*. Renewal only from a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Both: 5 The patient requires continued therapy; or6 The tumour has relapsed and requires re-treatment. Note indications marked with a * are unapproved indications.
Special Authority for Subsidy Initial application only from a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Both: 1 The patient has primary thrombocythaemia; and2 Either 2.1 is at high risk (previous thromboembolic disease, bleeding or platelet count >1500/ml); or 2.2 is intolerant or refractory to hydroxyurea or interferon. Renewal only from a relevant specialist. Approvals valid for 12 months where the treatment remains appropriate and the patient is benefiting from treatment. NoteIt is recommended that treatment with anagrelide be initiated only on the recommendation of a haematologist.
Special Authority for Subsidy Initial application - (for new patients) only from a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Both: 1 The patient has refractory, progressive or relapsed multiple myeloma; and2 The patient has received prior chemotherapy. Initial application - (for patients receiving thalidomide prior to 1 January 2006) only from a relevant specialist. Approvals valid without further renewal where the patient was receiving treatment with thalidomide for multiple myeloma on or before 31 December 2005. Renewal only from a relevant specialist. Approvals valid without further renewal where the patient has obtained a response from treatment during the initial approval period. Note: Prescription must be written by registered prescriber in the thalidomide risk management programme operated by the supplier. Maximum dose of 400 mg daily as monotherapy or in a combination therapy regimen.
Special Authority for Subsidy Initial application for patients with type 2 diabetes only from a relevant specialist. Approvals valid for one year for applications meeting the following criteria: Any of the following: Monotherapy1 All of the following: 1.1 To be used as monotherapy for patients who after six months of diet and lifestyle changes have inadequate glycaemic control (defined as HbA1c > 7.0% in tests carried out at least two months apart); and 1.2 Metformin is contraindicated or not tolerated after a minimum of a four week trial period; and 1.3 Sulphonylurea is contraindicated or not tolerated or the patient's body mass index (BMI) exceeds 33 kg/m2; orIn combination with sulphonylurea2 Both: 2.1 For use in combination with a sulphonylurea for patients who after diet and lifestyle changes and a six-month trial of sulphonylurea have poor glycaemic control (defined as HbA1c > 8.0% measured within the last month of the six month period); and 2.2 Metformin is contrain
Prescribing GuidelineCombigan is subsidised for use as either monotherapy or as an adjunctive agent for the treatment of glaucoma. Combigan should only be prescribed when: a) less expensive first line agents for the treatment of glaucoma are contraindicated; orb) the response to such subsidised agents is inadequate; orc) the patient cannot tolerate such subsidised agents.
Perindopril and trandolapril will be funded to the level of the ex-manufacturer price listed in the Schedule for patients who were taking these ACE inhibitors for the treatment of congestive heart failure prior to 1 June 1998. The prescription must be endorsed accordingly. We recommend that the words used to indicate eligibility are "certified condition" or an appropriate description of the patient such as "congestive heart failure", "CHF", "congestive cardiac failure" or "CCF". Definition of Congestive Heart Failure At the request of some prescribers the PTAC Cardiovascular subcommittee has provided a definition of congestive heart failure for the purposes of the funding of the manufacturer's surcharge: "Clinicians should use their clinical judgement. Existing patients would be eligible for the funding of the surcharge if the patient shows signs and symptoms of congestive heart failure, and requires or has in the past required concomitant treatment with a diuretic. The definition could also be considere
Special Authority for Subsidy - Form: SA0826Initial application only from a relevant specialist. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 All of the following: 1.1 Patient has a calculated absolute risk of cardiovascular disease >20% over 5 years; and 1.2 Patient cannot tolerate statin therapy at a dose of >= 40 mg per day; and 1.3 Either: 1.3.1 All of the following: 1.3.1.1 Patient has venous CABG; and 1.3.1.2 LDL cholesterol >= 2.0 mmol/litre (see note); and 1.3.1.3 LDL cholesterol >= 2.0 mmol/litre (at least 1 week after test 1 - see note); or 1.3.2 All of the following: 1.3.2.1 Patient does not have venous CABG; and 1.3.2.2 LDL cholesterol >= 2.5 mmol/litre (see note); and 1.3.2.3 LDL cholesterol >= 2.5 mmol/litre (at least 1 week after test 1 - see note); or2 All of the following: 2.1 Patient has homozygous familial hypercholesterolemia, or heterozygous familial hypercholest
Special Authority for Subsidy - Retail Pharmacy - Form SA0829Initial Application only from gastroenterologist or infectious disease specialist. Approvals valid for 1 year for applications meeting the following criteria: All of the following: 1. Patient has confirmed Hepatitis B infection (HBsAg+); andDocumented resistance to lamivudine, defined as: 2. patient has raised serum ALT (> 1 x ULN); and3. patient has HBV DNA greater than 100,000 copies per mL, or viral load ? 10 fold over nadir; and4. detection of M204I or M204V mutation; and5. Either5.1. Both5.1.1. patient is cirrhotic; and5.1.2. adefovir dipivoxil to be used in combination with lamivudine; or5.2. Both5.2.1. patient is not cirrhotic; and5.2.2. adefovir dipivoxil to be used as monotherapyRenewal only from a gastroenterologist or infectious disease specialist. Approvals valid for 2 years for applications where in the opinion of the treating physician, treatment remains appropriate and patient is benefiting from treatmen
Special Authority for Subsidy - Form: SA0831Application only from a relevant specialist. Approvals valid for 10 months for applications meeting the following criteria: 1. Patient has newly diagnosed glioblastoma multiforme; and2. Temozolomide is to be (or has been) given concomitantly with radiotherapy; and3. Following concomitant treatment temozolomide is to be used for a maximum of six cycles of 5 days treatment, at a maximum dose of 200 mg/m2. Note: Temozolomide is not subsidised for the treatment of relapsed glioblastoma multiforme. Studies of temozolomide show that its benefit is predominantly in those patients with a good performance status (WHO grade 0 or 1 or Karnofsky score >80), and in patients who have had at least a partial resection of the tumour.
Special Authority for Subsidy - Form: SA0832Initial application only from a gastroenterologist, infectious disease specialist, paediatrician or general physician. Approvals valid for 1 year for applications meeting the following criteria: Both: 1 Any of the following: 1.1 All of the following: 1.1.1 HBsAg positive for more than 6 months; and1.1.2 HBeAg positive or HBV DNA positive defined as > 100,000 copies per ml by quantitative PCR at a reference laboratory; and1.1.3 ALT greater than twice upper limit of normal or bridging fibrosis or cirrhosis (Metavir stage 3 or 4 or equivalent) on liver histology or clinical/radiological evidence of cirrhosis; or 1.2 HBV DNA positive cirrhosis prior to liver transplantation; or1.3 HBsAg positive and have had a liver, kidney, heart, lung or bone marrow transplant; or1.4 Hepatitis B surface antigen positive (HbsAg) patient who is receiving chemotherapy for a malignancy, or who has received such treatment within the previous two months;
Special Authority for Subsidy - Form SA0833Initial application only from a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Any of the following: 1 The patient has non small cell lung carcinoma (stage IIIa, or above); or2 The patient has advanced malignant mesothelioma*; or3 The patient has advanced pancreatic carcinoma; or4 The patient has ovarian, fallopian tube* or primary peritoneal carcinoma*; or5 The patient has advanced transitional cell carcinoma of the urothelial tract (locally advanced or metastatic). Renewal only from a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Both: 6 The patient requires continued therapy; or7 The tumour has relapsed and requires re-treatment. Note indications marked with a * are unapproved indications.
Special Authority for Subsidy - Form: SA0834Initial application only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria: Either: 1 Both: 1.1 Patient has type 1 diabetes and has received an intensive regimen (injections at least three times a day) of an intermediate acting insulin in combination with a rapid acting insulin analogue for at least three months; and1.2 Either: 1.2.1 Patient has experienced more than one unexplained severe hypoglycaemic episode in the previous 12 months (severe defined as requiring the assistance of another person); or1.2.2 Patient has experienced unexplained symptomatic nocturnal hypoglycaemia, biochemically documented at <3.0 mmol/L, more than once a month despite optimal management; or2 Patient has documented severe, or continuing, systemic or local allergic reaction to existing insulins. Note this does not include hypoglycaemic episodes. Renewal only from a relevant specialist or general practitioner. Approv
Special Authority for Subsidy - Form SA0835Initial application - (Breast cancer) from any medical practitioner. Approvals valid for 1 year: where the patient is a premenopausal woman with breast cancer. Initial application - (Prostate cancer) only from an oncologist, urologist or endocrinologist. Approvals valid for 1 year for applications meeting the following criteria: Advanced prostatic cancer;. Note Not to be prescribed with an anti-androgen except for a period of three weeks, if necessary, when GnRH analogue therapy is initiated. Initial application - (Endometriosis) only from a gynaecologist. Approvals valid for 3 months for applications meeting the following criteria: Both: 1 Endometriosis; and2 Either: 2.1 6 months treatment with medroxyprogesterone acetate, danazol or dimetriose has proven ineffective; or2.2 The patient has failed to tolerate the treatment with medroxyprogesterone acetate, danazol or dimetriose for 6 months. Note The maximum treatment period for a GnRH analogue is:
Special Authority for Subsidy - Form SA0836Initial application - (Breast cancer) from any medical practitioner. Approvals valid for 1 year where the patient is a premenopausal woman with breast cancer. Initial application - (Prostate cancer) only from an oncologist, urologist or endocrinologist. Approvals valid for 1 year for applications meeting the following criteria: Either: 1 Advanced prostatic cancer; or. 2 Locally advanced prostatic cancer. Note Not to be prescribed with an anti-androgen except for a period of three weeks, if necessary, when GnRH analogue therapy is initiated. Initial application - (Endometriosis) only from a gynaecologist. Approvals valid for 3 months for applications meeting the following criteria: Both: 3 Endometriosis; and4 Either: 4.1 6 months treatment with medroxyprogesterone acetate, danazol or dimetriose has proven ineffective; or4.2 The patient has failed to tolerate the treatment with medroxyprogesterone acetate, danazol or dimetriose for 6 months. Note
Special Authority for Subsidy - Form SA0837Initial application - (Breast cancer) from any medical practitioner. Approvals valid for 1 year where the patient is a premenopausal woman with breast cancer. Initial application - (Prostate cancer) only from an oncologist, urologist or endocrinologist. Approvals valid for 1 year where the patient has: Advanced prostatic cancer;. Note Not to be prescribed with an anti-androgen except for a period of three weeks, if necessary, when GnRH analogue therapy is initiated. Initial application - (Endometriosis) only from a gynaecologist. Approvals valid for 3 months for applications meeting the following criteria: Both: 1 Endometriosis; and2 Either: 2.1 6 months treatment with medroxyprogesterone acetate, danazol or dimetriose has proven ineffective; or2.2 The patient has failed to tolerate the treatment with medroxyprogesterone acetate, danazol or dimetriose for 6 months. Note The maximum treatment period for a GnRH analogue is: - 3 months to assess whet
Special Authority for Subsidy - Form: SA0838Initial Application only from a relevant specialist or General Practitioner. Approvals valid for 2 years forapplications meeting the following criteria: Either: 1 All of the following: 1.1 Patient is a child under the age of 12; and1.2 All of the following: Has, for 3 months or more, been treated with:1.2.1 An inhaled long-acting beta adrenoceptor agonist; and1.2.2 Inhaled corticosteroids at a dose of at least 400 mcg per day beclomethasone or budesonide, or200 mcg per day fluticasone; and1.3 The prescriber considers that the patient would receive additional clinical benefit from switching to acombination product; or2 All of the following: 2 .1 Patient is over the age of 12; and2 .2 All of the following: Has, for 3 months or more, been treated with:2 .2.1 An inhaled long-acting beta adrenoceptor agonist; and2 .2.2 Inhaled corticosteroids at a dose of at least 800 mcg per day beclomethasone or budesonide, or500 mcg per day fluticasone;
Special Authority for Subsidy - Form SA0839Initial application - (Breast cancer) from any medical practitioner. Approvals valid for 1 year where the patient is a premenopausal woman with breast cancer. Initial application - (Prostate cancer) only from an oncologist, urologist or endocrinologist. Approvals valid for 1 year for applications meeting the following criteria: Either: 1 Advanced prostatic cancer; or. 2 Neoadjuvant or adjuvant treatment of locally advanced prostatic cancer. Note Not to be prescribed with an anti-androgen except for a period of three weeks, if necessary, when GnRH analogue therapy is initiated. Initial application - (Endometriosis) only from a gynaecologist. Approvals valid for 3 months for applications meeting the following criteria: Both: 3 Endometriosis; and4 Either: 4.1 6 months treatment with medroxyprogesterone acetate, danazol or dimetriose has proven ineffective; or4.2 The patient has failed to tolerate the treatment with medroxyprogesterone acetate, danazo
Special Authority for Subsidy - form: SA0841Initial application only from a gastroenterologist or general physician. Approvals valid for 6 months for applications meeting the following criteria: Both: 1 Primary biliary cirrhosis confirmed by antimitochondrial antibody titre (AMA) > 1:80, and raised cholestatic liver enzymes with or without raised serum IgM or, if AMA is negative, by liver biopsy; and2 Patient not requiring a liver transplant (bilirubin > 170umol/l; decompensated cirrhosis). NoteLiver biopsy is not usually required for diagnosis but is helpful to stage the diseaseRenewal only from a gastroenterologist or general physician. Approvals valid for 2 years for applications meeting the following criteria: The treatment remains appropriate and the patient is benefiting from treatment. NoteActigall is not an appropriate therapy for patients requiring a liver transplant (bilirubin > 170 micromol/l; decompensated cirrhosis). These patients should be referred to an appropriate transp
Special Authority for Subsidy - Form: SA842Initial application only from a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Any of the following: 1 Both: 1.1 The patient has ovarian, fallopian* or primary peritoneal cancer*; and 1.2 Either: 1.2.1 Has not received prior chemotherapy; or 1.2.2 Has received prior chemotherapy but have not previously been treated with taxanes; or2 The patient has metastatic breast cancer; or3 The patient has node-positive early breast cancer; or4 Both 4.1 The patient has non small-cell lung cancer; and 4.2 Either: 4.2.1 Has advancing disease (stage IIIa or above); or 4.2.2 Is receiving combined chemotherapy and radiotherapy; or5 Both: 5.1 The patient has small-cell lung cancer*; and 5.2 Paclitaxel is to be used as second-line therapy. Renewal only from a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: 6 The patient has metasta
Special Authority for Subsidy - Form SA0006Initial application from any medical practitioner. Approvals valid for 5 years where the patient is likely to benefit from treatment. Renewal from any medical practitioner. Approvals valid for 5 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0011Initial application only from a relevant specialist. Approvals valid for 2 years where the patient has diabetes. Renewal only from a relevant specialist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0028Initial application only from a relevant specialist. Approvals valid for 6 months for applications meeting the following criteria: Either: 1 All of the following: 1.1 Treatment with other lipid modifying medicines has been unsuccessful; and 1.2 6 months of dietary modification has been unsuccessful; and 1.3 Cholesterol level > 7.0 mmol/litre; and 1.4 Either: 1.4.1 Familial hypercholesterolaemia; or 1.4.2 Manifest coronary heart disease, which has been clinically proven, or previously treated by coronary artery surgery; or 2 Cholesterol level > 9.0 mmol/litre:.Renewal only from a general practitioner. Approvals valid for 6 months where the treatment remains appropriate and the patient is benefiting from treatment. NoteFamilial hypercholesterolaemia is defined as being hypercholesterolaemia in the presence of tendon xanthomas or in association with a family history of premature heart disease (before age 55) or consisten
Unapproved medication supplied under Section 29 of the Medicines Act 1981. Practitioners prescribing this medication should: (a) be aware of and comply with their obligations under Section 29 of the Medicines Act 1981 and otherwise under that Act and the Medicines Regulations 1984; (b) be aware of and comply with their obligations under the Health and Disability Commissioner's Code of Consumer Rights, including the requirement to obtain informed consent from the patient (PHARMAC recommends that Practitioners obtain written consent); and(c) exercise their own skill, judgment, expertise and discretion, and make their own prescribing decisions with respect to the use of an unapproved Pharmaceutical or a Pharmaceutical for an indication for which it is not approved.
Special Authority for Subsidy - Form SA0031Initial application from any medical practitioner. Approvals valid for 2 years for applications meeting the following criteria: Any of the following: 1 Oesophageal stricture; or 2 Terminal care; or 3 Too young to swallow conventional tablets; or 4 Too old to swallow conventional tablets. Renewal from any medical practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Manufacturers Price - Form SA0035Initial application from any medical practitioner. Approvals valid for 5 years for applications meeting the following criteria: Both: 1 Either: 1.1 Both: 1.1.1 Duodenal and gastric ulcers, reflux oesophagitis and Zollinger-Ellison syndrome; and 1.1.2 Other treatments have failed; or 1.2 Patients who are on a Social Welfare benefit or an income no greater than a benefit; and 2 Patients must have endoscopically demonstrated lesions prior to commencement of treatment.. Renewal from any medical practitioner. Approvals valid for 5 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0041Initial application only from a relevant specialist. Approvals valid for 2 years where alternative antihypertensives have failed. Renewal only from a relevant specialist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0045Initial application from any medical practitioner. Approvals valid for 2 years for applications meeting the following criteria: All of the following: 1 Continuation of treatment commenced prior to 1 August 1990; and 2 Alternatives (salbutamol and terbutaline) have been tried; and 3 Either: 3.1 Asthma; or 3.2 Chronic obstructive airways disease (COAD); and 4 Applicants must provide details of dose. Renewal from any medical practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0046Initial application only from a gastroenterologist. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 Functioning gall bladder; and 2 Either: 2.1 Uncalcified gallbladder stones with a maximum size of 20 mm; or 2.2 Adjunctive treatment after extra corporeal lithotrypsy. Renewal only from a gastroenterologist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0047Initial application only from a paediatrician or respiratory specialist. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 Child under 2 years of age; or 2 Both: 2.1 Child with major physical or intellectual disabilities; and 2.2 Lacks the necessary coordination to use aerosols with a spacer device. NoteThe cost of nebuliser therapy greatly exceeds other inhaled forms. Steroid nebulising solution can cause cataract formation. Renewal only from a paediatrician or respiratory specialist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0051Initial application from any medical practitioner. Approvals valid for 6 months where control of nausea in the treatment of malignant disease. Renewal from any medical practitioner. Approvals valid for 6 months where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0053Initial application only from a relevant specialist. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 RAST or skin test positive; and 2 Patient has had severe generalised reaction to the sensitising agent. Renewal only from a relevant specialist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0055Initial application only from a psychiatrist, geriatrician or respiratory specialist. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 For use only as an anxiolytic; and 2 Other agents are contraindicated or have failed. Renewal only from a psychiatrist, geriatrician or respiratory specialist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0056Initial application only from a psychiatrist. Approvals valid for 5 years for applications meeting the following criteria: Both: 1 Long-standing delusional states; and 2 Other injectable anti-psychotics have proven to be ineffective or inappropriate. Renewal only from a psychiatrist. Approvals valid for 5 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0057Initial application only from a psychiatrist. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 Depression; and 2 Any of the following: 2.1 Both: 2.1.1 Failed trials with other antidepressants; and 2.1.2 Patient has been maintained on mianserin prior to December1993; or 2.2 Co-existent bladder neck obstruction; or 2.3 Cardiovascular disease. Renewal only from a psychiatrist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0069Initial application only from a general physician, nephrologist or neurologist. Approvals valid for 5 years where syndrome of inappropriate anti-diuretic hormone secretion (SIADH). Renewal only from a general physician, nephrologist or neurologist. Approvals valid for 5 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Manufacturers Price - Form SA0070Initial application only from a respiratory specialist or infectious disease specialist. Approvals valid for 2 years for applications meeting the following criteria: Any of the following: 1 Avium intracellular atypical mycobacterial infections; or 2 Multiple drug resistant tuberculosis; or 3 Atypical and drug-resistant mycobacterial infections in patients with AIDS. Renewal only from a respiratory specialist or infectious disease specialist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
a) Only granted after the patient has proven to be intolerant to zidovudine or whose health has significantly deteriorated while on zidovudine. It is impossible to have approvals for both AZT and DDI concurrently but it is not expected that both medicines would be consumed at the same time. Applications can be made without patients having had a preliminary trialb) Specialist must make application
a) All patients with AIDS meeting the definition developed by the Centres for Disease Control in the USA (see Circular Letter to Medical Practitioners HP2/88)b) Patients with AIDS Related Complex (ARC)c) HIV infected patients with CD4 (T4) counts below 500 regardless of symptomatologyd) Prophylactically for persons following severe parenteral exposure from a known HIV positive sourcee) HIV infected persons with associated thrombocytopenia regardless of CD4 (T4) count f) Applications can only be made by appropriate specialists. Prescriptions for those patients approved to use these medicines can be written either by the specialist or general practitioner with an endorsement of the name of the recommending specialist. g) Prescriptions for these can be written for a period of three months' supply. However, medicine must be dispensed on a monthly basis.
All non-disposible diabetic supplies are only eligible for subsidy if there is produced to the contractor a certificate the gives the nome, address, and age of the patient and that:1) is signed by a doctor and2) is dated less than two years propr to the date of supply; and that 3) states that the patient is receiving iusulin therapy.
Special Authority for Subsidy - Form SA0085Initial application from any medical practitioner. Approvals valid for 5 years where the patient is likely to benefit from treatment. Renewal from any medical practitioner. Approvals valid for 5 years where the treatment remains appropriate and the patient is benefiting from treatment.
a) Males: Fertile eunuch syndrome, females: anovulatory infertilityb) A declaration is required from the applying doctor that these agents are not being used as part of an IVF programmec) Approvals are valid for 6 months with a revewal for a further 6 months if the patient has some response and the prescriber believes further treatment will be effectived) Specialist must make application - endocrinologists and gynaecologists only
Special Authority for Subsidy - Form SA0087Initial application only from an endocrinologist or gynaecologist. Approvals valid for 6 months where hypogonadotrophic hypogonadism (including anovulatory infertility and cryptochidism). Renewal only from an endocrinologist or gynaecologist. Approvals valid for 6 months where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0088Initial application only from an endocrinologist or gynaecologist. Approvals valid for 6 months for applications meeting the following criteria: Both: 1 Either: 1.1 Female with anovulatory infertility, males: hypogonadotrophic hypogonadism; or 1.2 Male with hypogonadotrophic hypogonadism; and 2 These agents are not being used as part of an IVF programme. Renewal only from an endocrinologist or gynaecologist. Approvals valid for 6 months where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0089Initial application - (Breast or prostatic cancer) only from an oncologist, urologist or endocrinologist. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 Breast cancer in pre menopausal women unwilling or unable to undergo surgical or radiation oophorectomy; or 2 Advanced prostatic cancer when orchidectomy is contraindicated. Initial application - (Endometriosis) only from a gynaecologist. Approvals valid for 6 months for applications meeting the following criteria: Both: 1 Endometriosis; and 2 Either: 2.1 6 months treatment with medroxyprogesterone acetate, danazol or dimetriose has proven ineffective; or 2.2 The patient has failed to tolerate the treatment with medroxyprogesterone acetate, danazol or dimetriose for 6 months. NoteThe maximum treatment period for a GnRH analogue is: 3 months to assess whether surgery is appropriate3 months for infertile patients after surgery6 months for
Special Authority for Subsidy - Form SA0090Initial application only from a relevant specialist. Approvals valid for 2 years where patient cannot use desmopressin nasal spray or nasal drops. Renewal only from a relevant specialist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0091Initial application only from a relevant specialist. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 Paget's disease; or 2 Both: 2.1 Patients under hospice care; and 2.2 Either: 2.2.1 Tumour-induced hypercalcaemia; or 2.2.2 Tumour-induced osteolysis without hypercalcaemia. Renewal only from a relevant specialist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0092Initial application only from a relevant specialist. Approvals valid for 5 years where treatment of refractory absorptive hypercalcaemia. Renewal only from a relevant specialist. Approvals valid for 5 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0096Initial application - (Organ transplant, Bone marrow transplant or Graft v host disease) only from a relevant specialist. Approvals valid for 2 years for applications meeting the following criteria: Any of the following: 1 Organ transplant; or 2 Bone marrow transplant; or 3 Graft v host disease. Initial application - (Psoriasis) only from a dermatologist. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 Psoriasis; and 2 Other systemic and topical therapy has failed. Initial application - (Severe atopic dermatitis) only from a dermatologist. Approvals valid for 6 months for applications meeting the following criteria: Both: 1 Severe atopic dermatitis; and 2 Not resopnsive to topical therapy, oral antihistamines and other commonly used orthodox therapies. Initial application - (Nephrotic Syndrome) from any medical practitioner. Approvals valid for 2 years for applications meeting the following cri
Special Authority for Subsidy - Form SA0097Initial application - (Chronic hepatitis C) only from a relevant specialist. Approvals valid for 6 months where chronic hepatitis C. Initial application - (Indications other than Chronic hepatitis C) only from a relevant specialist. Approvals valid for 5 years for applications meeting the following criteria: Any of the following: 1 Chronic myelogenous leukaemia; or 2 Hairycell leukaemia; or 3 Cutaneous T cell lymphoma; or 4 Essential thrombocythaemia; or 5 AIDS related Kaposi's sarcoma; or 6 Multiple myeloma; or 7 Chronic active hepatitis B. Renewal - (Chronic hepatitis C) only from a relevant specialist. Approvals valid for 6 months where the treatment remains appropriate and the patient is benefiting from treatment. Renewal - (Indications other than Chronic hepatitis C) only from a relevant specialist. Approvals valid for 5 years where the treatment remains appropriate and the patient is benefiting from treatment.
a) Hairy cell leukaemia, Kaposi's sarcoma, chronic active hepatitis B, chronic hepatitis C (6 month approval only), chronic myelogenous leukaemia, multiple myelomab) Specialist must make applicationc) No further approvals for:Malignant melanoma, superficial and noduloulcerative basal cell carcinomaNote: Patients with existing approvals can continue to have therapy
Special Authority for Subsidy - Form SA0099Initial application only from a relevant specialist. Approvals valid for 5 years for applications meeting the following criteria: Any of the following: 1 Both: 1.1 Acromegaly; and 1.2 Patients who have failed surgery, radiotherapy, bromocriptine and other oral therapies; or 2 Both: 2.1 Either: 2.1.1 Vipomas; or 2.1.2 Glucagonomas; and 2.2 Patients who are seriously ill in order to improve their clinical state prior to definitive surgery; or 3 Both: 3.1 Gastrinoma; and 3.2 Either: 3.2.1 Patient has failed surgery; or 3.2.2 Patient is in metastatic disease after H2 antagonists (or omeprazole) have failed; or 4 Both: 4.1 Insulinomas; and 4.2 Surgery is contraindicated or where surgery has failed; or 5 Pre-operative control of hypoglycaemia; or 6 Maintenance therapy. NoteThe use of octreotide in patients with fistulae, oesophageal varices, miscellaneous diarrhoea and hypotension will
Special Authority for Subsidy - Form SA0100Initial application only from a relevant specialist. Approvals valid for 5 years for applications meeting the following criteria: All of the following: 1 Anaemia of end-stage renal failure (other treatable causes of anaemia being excluded); and 2 Been on haemodialysis or continuous ambulatory peritoneal dialysis (CAPD) for at least three months; and 3 Not under evaluation for, or awaiting, a live donor kidney transplant; and 4 Any of the following: 4.1 Anephric; or 4.2 Dependent on regular blood transfusion (1 unit each 4-8 weeks) to maintain haemoglobin > 60g/L; or 4.3 Cannot be transfused because of severe transfusion reactions; or 4.4 Transfusion induced haemosiderosis (clinical manifestations, serum ferritin >1500 ug/L); or 4.5 Haemoglobin < 70 g/L (mean of at least 4 haemoglobin concentrations over 4 months); or 4.6 Both: 4.6.1 Haemoglobin < 90 g/L; and 4.6.2 Either: 4.6.2.1 Heart failure (low card
Special Authority for Subsidy - Form SA0108Initial application only from a relevant specialist. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 Hairy cell leukaemia; or 2 Chronic active hepatitis B. Renewal only from a relevant specialist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0110Initial application only from a relevant specialist. Approvals valid for 5 years where biotinidase deficiency. Renewal only from a relevant specialist. Approvals valid for 5 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0115Initial application - (Oesophageal stricture) only from a general practitioner or relevant specialist. Approvals valid for 2 years where patient with oesophageal stricture who is unable to take capsules. Initial application - (Indications other than oesophageal stricture) only from a paediatrician. Approvals valid for 2 years for applications meeting the following criteria: All of the following: 1 infant or child with liver disease or short gut syndrome; and 2 Requires vitamin supplementation; and 3 Unable to swallow capsules. Renewal only from a general practitioner, relevant specialist or paediatrician. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0119Initial application only from a rheumatologist. Approvals valid for 5 years where ankylosing spondylitis. Renewal only from a rheumatologist. Approvals valid for 5 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0121Initial application from any medical practitioner. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 Patient has to use an unpreserved solution due to an allergy to the preservative; or 2 Patient wears soft contact lenses. NoteMinims for a general practice are considered to be "tools of trade" and are not approved as special authority items. Renewal from any medical practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0122Initial application only from a relevant specialist. Approvals valid for 2 years where filamentary keratitis. Renewal only from a relevant specialist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0125Initial application - (Chronic post-thrombotic venous stasis ulcers) from any medical practitioner. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 Chronic post-thrombotic venous stasis ulcers of more than 4 months duration; and 2 Other interventions have failed. Initial application - (Sudden hearing loss) only from an otolaryngologist. Approvals valid for 2 years where sudden hearing loss. Renewal from any medical practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
a) Should be strictly reserved for use as second line therapy in: - patients unable to tolerate the other medications, such as infants, young children and patients with allergies or eczema- cases of scabies which are resistent to gamma benzene hexachlorideb) Verification of drug resistance is dependent on the persistence of the condition after treatment. In order to establish whether there is drug resistance, the following criteria should be fulfilled: - a definite diagnosis of scabies should be made- it should be ascertained that the medication was administered properly- the possibility of reinfestation should have been excluded
Special Authority for Subsidy - Form SA0140Initial application only from a relevant specialist. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 Pain management in the terminally ill; and 2 Standard therapy has failed. Renewal only from a relevant specialist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
Only on a WSO. Distributed by the Asthma Foundation. Forward orders to: The Asthma Foundation, PO Box 1459, Wellington. Distributed by the Asthma Foundation. Also available to paediatricians employed by an HHS, on a wholesale supply order signed by the paediatrician. Orders via a hospital pharmacy.
Approvals for a CHEM number to waive the premium in the following circumstances: 1. Patients with prosthetic heart valves - as an adjunct to oral anticoagulation for prophylaxis of thromboembolism (2 year approval with renewal, applications only from cardiothoracic surgeons, cardiologists and general physicians). 2. Patients after coronary artery vein bypass graft - as an adjunct to aspirin (1 year approval only, applications only from cardiothoracic surgeons, cardiologists and general physicians). 3. Patients who continue to have transient ischaemic episodes despite aspirin therapy. A course of up to six months in combination with aspirin. Applications only from neurologists, cardiologists, vascular surgeons and general physicians. Six month approval only. Reapplications only if there is demonstrated recurrence of symptoms when dipyridamole therapy is discontinued. Note: these transitional criteria are currently being reviewed.
a) Approvals to fund the manufacturer's surcharge in the following circumstances: - Patients with prosthetic heart valves - as an adjunct to oral anticoagulation for prophylaxis of thromboembolism (2 year approval with renewal, applications only from cardiothoracic surgeons, cardiologists and general physicians). - Patients after coronary artery vein bypass graft - as an adjunct to aspirin or as monotherapy for patients who are aspirin intolerant as defined below (1 year approval only, applications only from cardiothoracic surgeons, cardiologists and general physicians); or- Patients who continue to have transient ischaemic episodes despite aspirin therapy or have transient ischaemic episodes and are aspirin intolerant as defined below (2 year approval with renewal, applications only from neurologists, neurosurgeons, cardiologists, vascular surgeons and general physicians). b) Aspirin intolerant patients are defined as those with aspirin induced asthma, urticaria, or anaphylaxi, or those with significant
Special Authority for Manufacturers Price - Form SA0157Initial application from any medical practitioner. Approvals valid for 5 years for applications meeting the following criteria: Any of the following: 1 Liver disease; or 2 Past history of thromboembolism; or 3 Significant hypertension; or 4 Hypertension associated with oral oestrogen therapy. Renewal from any medical practitioner. Approvals valid for 5 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Waiver of Rule - Form SA0175Initial application only from an obstetrician, endocrinologist or gynaecologist. Approvals valid for 2 years where pathological hyperprolactinemia. Renewal only from an obstetrician, endocrinologist or gynaecologist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Manufacturers Price - Form SA0178Initial application from any medical practitioner. Approvals valid for 6 months where control of nausea and vomiting in the treatment of terminal care patients. Renewal from any medical practitioner. Approvals valid for 6 months where the treatment remains appropriate and the patient is benefiting from treatment.
The new anticonvulsant drugs are restricted to1. neurologists2. paediatric neurologists3. any other prescriber approved in writing by the relevant RHA budget holding manager. The HFA holds a budget for expenditure on the new anticonvulsant drugs. Unless otherwise specified, ultimate authority for approving prescriptions for subsidy lies with the HFA budget holding manager for the new anticonvulsant drugs. The regional divisions of the HFA will be in contact with hospital pharmacists and approved prescribers with more detail of the approval system. GUIDELINES FOR USE OF THE NEW ANTICONVULSANTS ARE AS FOLLOWS: A. Entry criteriaThe following patients are eligible for trial on the new anticonvulsant drugs (NADs)1. Patients who are under the supervision of an approved prescriber, and whose seizures are not adequately controlled with optimal conventional anticonvulsant drug treatment. 2. Patients, who are under the supervision of an approved prescriber, and whose seizures are only controlled adequatel
Available from hospital pharmacies providing an outpatient dispensing service, and any retail pharmacy in the Northern, Midland, Central (including Nelson and Blenheim) and South Canterbury regions, and selected retail pharmacies in the Christchurch region that have an exclusive contract to dispense 'Hospital Pharmacy' [HP3] pharmaceuticals.
Special Authority for Subsidy - Form SA0256Initial application only from a cardiologist or general physician. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 Refractory angina; and 2 Patient is already on maximal anti-anginal therapy. Renewal only from a cardiologist or general physician. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0264Initial application only from a paediatrician or respiratory specialist. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 Cystic fibrosis patient; or 2 Both: 2.1 Infant or child with liver disease or short gut syndrome; and 2.2 Requires vitamin supplementation. Renewal only from a paediatrician or respiratory specialist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Manufacturers Price - Form SA0265Initial application from any medical practitioner. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 Social Welfare Benefiary; or 2 Income no greater than a Benefiary. Renewal from any medical practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0266Initial application - (Chronic hepatitis C) only from a relevant specialist. Approvals valid for 6 months where chronic hepatitis C. NoteMaximum reimbursable dosage 15 million iu/weekInitial application - (Indications other than chronic hepatitis C) only from a dermatologist, plastic surgeon or radiation oncologist. Approvals valid for 5 years for applications meeting the following criteria: Any of the following: 1 Chronic myelogenous leukaemia; or 2 Hairycell leukaemia; or 3 Cutaneous T cell lymphoma; or 4 Essential thrombocythaemia; or 5 AIDS related Kaposi's sarcoma; or 6 Multiple myeloma; or 7 Chronic active hepatitis B; or 8 Basal cell carcinoma unable to be treated surgically or by radiotherapy. NoteMaximum reimbursable dosage 15 million iu/weekRenewal - (Chronic hepatitis C) only from a relevant specialist. Approvals valid for 6 months where the treatment remains appropriate and the patient is benefiting from trea
a) - hairy cell leukaemia - Kaposi's sarcoma - chronic active hepatitis B - chronic hepatitis C (6 month approval only) - chronic myelogenous leukaemia - multiple myeloma - basal cell carcinoma 1) Only for basal cell carcinoma unable to be treated surgically or by radiotherapy. 2) Applications only from radiation oncologists, plastic surgeons and dermatologists. Applications from dermatologists will only be accepted with evidence from either a plastic surgeon or oncologist that the patient was unsuitable for surgery. 3) Maximum reimbursable dosage 15 million iu/weekb) Specialist must make applicationc) No further approvals for: Malignant melanoma Note: Patients with existing approvals can continue to have therapy
Lansoprazole is subsidised for patients who have one or more of the following conditions: 1. Duodenal ulcer proven by endoscopy or barium meal and after failure of: a)two alternative courses of H. pylori eradication therapy (if H. pylori positive); and b)H2 antagonist therapy for 8 weeks; and where a second endoscopy/barium meal has demonstrated non healing duodenal ulcer. 2. Gastric ulcer proven by endoscopy and after failure of: a)two alternative courses of H. pylori eradication therapy (if H. pylori positive); andb)H2 antagonist therapy for 12 weeks; and where a second endoscopy has demonstrated non healing gastric ulcer and excluded malignancy. 3. Gastro-oesophageal reflux disease (GORD) proven by endoscopy: i) Grade 0 GORD (normal endoscopy) after positive 24 hour pH monitoring test and failure of H2 antagonist therapy for one month with multiple daily dosing; orii) Grades 1 and 2 GORD after failure of H2 antagonist therapy for one month with multiple daily dosing; or
Special Authority for Manufacturers Price - Form SA0271Initial application from any medical practitioner. Approvals valid for 5 years for applications meeting the following criteria: Either: 1 Continuation of treatment commenced prior to 1 October 1995; or 2 Both: 2.1 Either: 2.1.1 Asthma; or 2.1.2 Chronic obstructive airways disease; and 2.2 Patient has tried alternatives and these are unsuitable. Renewal from any medical practitioner. Approvals valid for 5 years where the treatment remains appropriate and the patient is benefiting from treatment.
a) All patients with AIDS meeting the definition developed by the Centres for Disease Control in the USA (see Circular Letter to Medical Practitioners HP2/88)b) Patients with AIDS Related Complex (ARC)c) HIV infected patients with CD4 (T4) counts below 500 regardless of symptomatologyd) Prophylactically for persons following severe parenteral exposure from a known HIV positive sourcee) HIV infected persons with associated thrombocytopenia regardless of CD4 (T4) count f) For the prevention of maternal foetal transmission of HIVg) Applications can only be made by appropriate specialists. Prescriptions for those patients approved to use these medicines can be written either by the specialist or general practitioner with an endorsement of the name of the recommending specialist. h) Prescriptions for these can be written for a period of three months' supply. However, medicine must be dispensed on a monthly basis.
Special Authority for Subsidy - Form SA0274Initial application only from a relevant specialist. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 All of the following: 1.1 Treatment with other lipid modifying medicines has been unsuccessful; and 1.2 6 months of dietary modification has been unsuccessful; and 1.3 Cholesterol level > 7.0 mmol/litre:; and 1.4 Either: 1.4.1 Familial hypercholesterolaemia; or 1.4.2 Manifest coronary heart disease, which has been clinically proven, or previously treated by coronary artery surgery; or 2 Cholesterol level > 9.0 mmol/litre:.NoteFamilial hypercholesterolaemia is defined as being hypercholesterolaemia in the presence of tendon xanthomas or in association with a family history of premature heart disease (before age 55) or consistent with autosomal dominant inheritance. Simvastatin and Pravastatin may be considered for first line therapy in patients with familial hypercholesterolaemia or
Special Authority for Subsidy - Form SA0275Initial application - (Chronic hepatitis C) only from a relevant specialist. Approvals valid for 6 months where chronic hepatitis C. NoteMaximum reimbursable dosage 15 million iu/weekInitial application - (Indications other than chronic hepatitis C) only from a dermatologist, plastic surgeon or radiation oncologist. Approvals valid for 5 years for applications meeting the following criteria: Any of the following: 1 Chronic myelogenous leukaemia; or 2 Hairycell leukaemia; or 3 Cutaneous T cell lymphoma; or 4 Essential thrombocythaemia; or 5 Multiple myeloma; or 6 Chronic active hepatitis B; or 7 Basal cell carcinoma unable to be treated surgically or by radiotherapy. NoteMaximum reimbursable dosage 15 million iu/weekRenewal - (Chronic hepatitis C) only from a relevant specialist. Approvals valid for 6 months where the treatment remains appropriate and the patient is benefiting from treatment. Renewal - (Indications other tha
Special Authority for Subsidy - Form SA0276Initial application - (Chronic hepatitis C) only from a relevant specialist. Approvals valid for 6 months where chronic hepatitis C. NoteMaximum reimbursable dosage 15 million iu/weekInitial application - (Indications other than chronic hepatitis C) only from a dermatologist, plastic surgeon or radiation oncologist. Approvals valid for 5 years for applications meeting the following criteria: Any of the following: 1 Chronic myelogenous leukaemia; or 2 Hairycell leukaemia; or 3 Multiple myeloma; or 4 Chronic active hepatitis B; or 5 Basal cell carcinoma unable to be treated surgically or by radiotherapy. NoteMaximum reimbursable dosage 15 million iu/weekRenewal - (Chronic hepatitis C) only from a relevant specialist. Approvals valid for 6 months where the treatment remains appropriate and the patient is benefiting from treatment. Renewal - (Indications other than chronic hepatitis C) only from a dermatologist, plastic surgeon or radiat
Patients who have been on omeprazole and have not accessed therapy through Special Authority will continue to have subsidy for six months, by which time the necessary investigations should have been carried out to determine if ongoing therapy is warranted. For these patients the following conditions will apply: Omeprazole(a) Retail pharmacy specialist (b) month restriction
Omeprazole is subsidised for patients who have one or more of the conditions numbered 1-4: 1. Duodenal ulcer proven by endoscopy or barium meal and after failure of: a)two alternative courses of H. pylori eradication therapy (if H. pylori positive); and b)H2 antagonist therapy for 8 weeks; and where a second endoscopy/barium meal has demonstrated non healing duodenal ulcer. 2. Gastric ulcer proven by endoscopy and after failure of: a)two alternative courses of H. pylori eradication therapy (if H. pylori positive); andb)H2 antagonist therapy for 12 weeks; and where a second endoscopy has demonstrated non healing gastric ulcer and excluded malignancy. 3. Gastro-oesophageal reflux disease (GORD) proven by endoscopy: i) Grade 0 GORD (normal endoscopy) after positive 24 hour pH monitoring test and failure of H2 antagonist therapy for one month with multiple daily dosing; orii) Grades 1 and 2 GORD after failure of H2 antagonist therapy for one month with multipl
Special Authority for Manufacturers Price - Form SA0286Initial application from any medical practitioner. Approvals valid for 5 years where patient is stabilised on aminophylline, theophylline, warfarin, or phenytoin..Renewal from any medical practitioner. Approvals valid for 5 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0290Initial application only from a relevant specialist. Approvals valid for 5 years for applications meeting the following criteria: Any of the following: 1 AIDS meeting the definition developed by the Centers for Disease Control in the USA; or 2 AIDS Related Complex (ARC).; or 3 Both: 3.1 HIV infection regardless of symptomatology; and 3.2 CD4 (T4) counts < 500. NoteSee Circular Letter to Medical Practitioners HP2/88)Renewal only from a relevant specialist. Approvals valid for 5 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Manufacturers Price - Form SA0291Initial application from any medical practitioner. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 Inflammatory arthritis (including osteoarthritis with an inflammatory component); and 2 Stabilised and are well controlled on the particular NSAID medication. Renewal from any medical practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0300Initial application - (Breast or prostatic cancer) only from an oncologist, urologist or endocrinologist. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 Breast cancer in pre menopausal women unwilling or unable to undergo surgical or radiation oophorectomy; or 2 Advanced prostatic cancer when orchidectomy is contraindicated. NoteNot in long term combination with an anti-androgenInitial application - (Endometriosis) only from a gynaecologist. Approvals valid for 6 months for applications meeting the following criteria: Both: 1 Endometriosis ; and 2 Either: 2.1 6 months treatment with medroxyprogesterone acetate, danazol or dimetriose has proven ineffective; or 2.2 The patient has failed to tolerate the treatment with medroxyprogesterone acetate, danazol or dimetriose for 6 months. NoteThe maximum treatment period for a GnRH analogue is: 3 months to assess whether surgery is appropriate3 m
Special Authority for Subsidy - Form SA0301Initial application only from a relevant specialist. Approvals valid for 2 years where type III dyslipidaemias. Renewal only from a relevant specialist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Waiver of Rule - Form SA0303Initial application only from a paediatric surgeon or paediatrician. Approvals valid for 1 year where children post liver transplant. Renewal only from a paediatric surgeon or paediatrician. Approvals valid for 1 year where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0309Initial application only from a neurologist or physician for the elderly (FRACP). Approvals valid for 2 years for applications meeting the following criteria: All of the following: 1 Idiopathic Parkinson's disease; and 2 The patient does not have dementia and/or neuropsychiatric disorders; and 3 Has responded to L-dopa; and 4 Any of the following: 4.1 Has resistance to conventional treatment of severe motor fluctuations; or 4.2 Has severe "off" period disability; or 4.3 Has severe "off" period dystonic cramps. Renewal only from a neurologist or physician for the elderly (FRACP). Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0311Initial application - (Breast or prostatic cancer) only from an oncologist, urologist or endocrinologist. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 Breast cancer in pre menopausal women unwilling or unable to undergo surgical or radiation oophorectomy; or 2 Advanced prostatic cancer when orchidectomy is contraindicated or where the patient srongly opposes orchidectomy. NoteNot to be prescribed with an anti-androgen except for a period of three weeks, if necessary, when GnRH analogue therapy is intiatedInitial application - (Endometriosis) only from a gynaecologist. Approvals valid for 6 months for applications meeting the following criteria: Both: 1 Endometriosis; and 2 Either: 2.1 6 months treatment with medroxyprogesterone acetate, danazol or dimetriose has proven ineffective; or 2.2 The patient has failed to tolerate the treatment with medroxyprogesterone acetate, danazol or dimetrio
Special Authority for Alternate Subsidy - Form SA0312Initial application only from an obstetrician, gynaecologist, general practitioner or general physician. Approvals valid for 5 years for applications meeting the following criteria: Any of the following: 1 acute or significant liver disease - a declaration must be provided from a gastroenterologist or general physician stating that oral oestrogens are contraindicated due to liver disease (Details to be attached to application); or 2 oestrogen induced hypertension requiring antihypertensive therapy - documented evidence must be provided that raised blood pressure levels or inability to control blood pressure adequately occurred post oral oestrogens (Details to be attached to application); or 3 hypertriglyceridaemia - documented evidence must be provided that triglyceride levels increased to at least 2 x normal triglyceride levels post oral oestrogens (Details to be attached to application). NotePrescriptions with a valid Special Authority (
Special Authority for Manufacturers Price - Form SA0313Initial application from any medical practitioner. Approvals valid for 5 years where the patient is likely to benefit from treatment. Renewal from any medical practitioner. Approvals valid for 5 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0317Initial application only from a renal physician. Approvals valid for 2 years for applications meeting the following criteria: All of the following: General Criteria: 1 Anaemia of end-stage renal failure (other treatable causes of anaemia being excluded); and 2 Been on haemodialysis or continuous ambulatory peritoneal dialysis (CAPD) for at least three months; and 3 Not under evaluation for, or awaiting, a live donor kidney transplant; and 4 Any of the following: Specific Criteria: 4.1 Anephric; or 4.2 Dependent on regular blood transfusion (1 unit each 4-8 weeks) to maintain haemoglobin > 60g/L; or 4.3 Cannot be transfused because of severe transfusion reactions; or 4.4 Transfusion induced haemosiderosis (clinical manifestations, serum ferritin >1500 ug/L); or 4.5 Haemoglobin < 70 g/L (mean of at least 4 haemoglobin concentrations over 4 months); or 4.6 Both: 4.6.1 Haemoglobin < 90 g/L; and 4.6.2 Either:
a) All nucleosides will be subsidised for patients meeting any of the following criteria: - All patients with AIDS meeting the definition developed by the Centers for Disease Control in the USA (see Circular Letter to Medical Practitioners HP2/88); or- Patients with AIDS Related Complex (ARC); or- HIV infected patients with CD4 (T4) counts below 500 regardless of symptomatology. b) Zidovudine will also be subsidised for patients meeting any of the following criteria: - Prophylactically for persons following severe parenteral exposure from a known HIV positive source; or- HIV infected persons with associated thrombocytopenia regardless of CD4 (T4) count; or- For the prevention of maternal foetal transmission of HIV. c) Applications can only be made by appropriate specialists. d) Prescriptions for those patients approved to use these medications can be written by either the specialist or general practitioner with an endorsement of the name of the recommending specialist.
Special Authority for Subsidy - Form SA0323Initial application only from a relevant specialist. Approvals valid for 2 years where children receiving frequent parenteral injections (i.e. intradermal, subcutaneous, intravenous or intramuscular) requiring a 21 gauge or larger bore needle. Renewal only from a relevant specialist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0325Initial application from any medical practitioner. Approvals valid for 5 years where applicatons will be considered and approved subject to funding availability. NoteApplications to be made on the approved forms which are available from the co-ordinator for the Cystic Fibrosis DN'ase Advisory Panel: The Co-ordinatorCystic Fibrosis DN'ase Advisory PanelC/- Room 4-28, Building 13 Greenlane HospitalPrivate Bag, AUCKLANDPhone: 09 630 9871Facsimile: 09 631 0753
Special Authority for Subsidy - Form SA0328Initial application only from a general physician. Approvals valid for 2 years for applications meeting the following criteria: Any of the following: 1 Both: 1.1 CD4 count < 500 cells/mm3; and 1.2 Viral load > 50,000> copies per ml (or equivalent value on the Chiron test); or 2 All of the following: 2.1 CD4 count < 500 cells/mm3; and 2.2 Viral load > 50,000> copies per ml (or equivalent value on the Chiron test); and 2.3 At least 6 weeks of dual therapy with nucleoside agents; or 3 Both: 3.1 CD4 count < 500 cells/mm3; and 3.2 CD4 counts are declining rapidly (>120 cells over 12 months or >60 - 80 cells over six months). Renewal only from a general physician. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
Guidelines for use of cyclosporin A in rheumatoid arthritisMonitoring: All patients require frequent monitoring for creatinine levels and blood pressure:- fortnightly, in the first three months of therapy and then monthly, if results are stable; - if dose is increased or there is a rise in serum creatinine or blood pressure, then more frequent monitoring is required. Contraindications: Cyclosporin A is contraindicated in patients with the following conditions: - current or past malignancy; - uncontrolled hypertension; - renal dysfunction (abnormal serum creatinine for age and sex); - immunodeficiency and neutropenia; - abnormally low white blood cell count or platelet count; or- liver function tests more than twice the upper limit of normal. Caution in use: - age above 65 years; - controlled hypertension; - use of ant-epileptic medications; - use of NSAIDs; - use of ketoconazole, fluconazole, trimethoprim, erythromycin, verapamil, and diltiazem; - concurrent or previous use of al
Special Authority - Retail pharmacy (Salmeterol, eformoterol fumarate):a) Approvals are interchangeable between all presenations of salmeterol and eformoterol fumarate agents. b) Diagnosis of asthma confirmed. c) Inhaler/device technique checked. d) At least three months of >= 1500 ug daily of beclomethasone inhaled steroid (or equivalent) for adult, or >= 800 ug daily for child. e) Patient monitors PEFR regularly during exacerbations where appropriate. f) Evidence of poor control (at least one of the following): - short acting beta agonist used > 3-4 time daily - nocturnal awakenings >= 2 times per week. g) The first applicaton may be for six months and subsequent applications for two yars. The criteria for reapplication are: - compliant with medication - improved asthma symptom control. h) Appication for Special Authority to be made by general practitioners or appropriate specialist.
a) Should be strictly reserved for use as second line therapy in: - patients unable to tolerate the other medications, such as infants, young children and patients with allergies or eczema; - cases of scabies which are resistent to gamma benzene hexachloride and resistant to malathion. b) Verification of drug resistance is dependent on the persistence of the condition after treatment. In order to establish whether there is drug resistance, the following criteria should be fulfilled: - a definite diagnosis of scabies should be made; - it should be ascertained that the medication was administered properly; - the possibility of reinfestation should have been excluded.
a) Approvals will be granted for treating the following conditions: - avium intracellular atypical mycobacterial infections; and- multiple drug resistant tuberculosis; and- atypical and drug-resistant mycobacterial infections in patients with AIDS. b) Specialist must make application - respiratory physician/ infectious disease specialist. c) Approvals will be valid for two years.
Special Authority for Manufacturers Price - Form SA0349Initial application only from a respiratory specialist or infectious disease specialist. Approvals valid for 2 years for applications meeting the following criteria: Any of the following: 1 Avium intracellular atypical mycobacterial infections; or 2 Multiple drug resistant tuberculosis; or 3 Atypical and drug-resistant mycobacterial infections in patients with AIDS. Renewal only from a respiratory specialist or infectious disease specialist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
Omeprazole and pantoprazole is subsidised for patients who have one or more of the conditions a-d: a) Duodenal ulcer proven by endoscopy or barium meal and after failure of: - two alternative courses of H. pylori eradication therapy (if H. pylori positive); and - H2 antagonist therapy for 8 weeks; and where a second endoscopy/barium meal has demonstrated non healing duodenal ulcer. b) Gastric ulcer proven by endoscopy and after failure of: - two alternative courses of H. pylori eradication therapy (if H. pylori positive); and - H2 antagonist therapy for 12 weeks; and where a second endoscopy has demonstrated non healing gastric ulcer and excluded malignancy. c) Gastro-oesophageal reflux disease (GORD) proven by endoscopy: - Grade 0 GORD (normal endoscopy) after positive 24 hour pH monitoring test and failure of H2 antagonist therapy for four weeks with multiple daily dosing; or - Grades 1 and 2 GORD after failure of H2 antagonist therapy for
Subsidy is available for disposable diabetic syringes and needles: 1) When the prescription is written on the same prescription form as the one used for the supply of insulin vials; or2) When "insulin patient" has been written on the prescription by either the doctor or the contractor; and3) For no more than 50 plastic syringes with attached needles as a single supply in the case of a prescription for three months supply of insulin vials; or4) For no more than 4 plastic syringes with attached needles as a single supply for each week's supply in the case of a prescription for less than three months supply of insulin vials.
Subsidy is available for insulin pen needles: 1) When the prescription is written on the same prescription form as the one used for the supply of insulin cartridges; or2) When "insulin patient" has been written on the prescription by either the doctor or the contractor; and3) For no more than 30 insulin pen needles as a single supply in the case of a prescription for three months supply of insulin cartridges; or4) For no more than 2 insulin pen needles as a single supply for each week's supply in the case of a prescription for less than three months supply of insulin cartridges.
Special Authority for Subsidy - Form SA0361Initial application only from a geriatrician, neurologist or general physician. Approvals valid for 2 years for applications meeting the following criteria: All of the following: 1 Disabling orthostatic hypotension not due to drugs; and 2 Patient has tried fludrocortisone (unless contra-indicated) with unsatisfactory results; and 3 Patient has tried non pharmacological treatments such as support hose, increased salt intake, exercise, and elevation of head and trunk at night. NoteTreatment should be started with small doses and titrated upwards as necessary. Hypertesion should be avoided, and the usual target is a standing systolic blood pressure of 90 mm Hg. Renewal only from a geriatrician, neurologist or general physician. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0366Initial application - (North Island patients) from any medical practitioner. Approvals valid for 5 years where the patient is likely to benefit from treatment. NoteFor details of the patient criteria, prescriber criteria, application and reporting forms contact the appointed clinician: Dr Richard FisherFertility Associates131 Remuera RoadAUCKLANDFax: 09 520 0499Appointed clinicians will distribute these agents to prescribers whose applications are approvedInitial application - (South Island patients) from any medical practitioner. Approvals valid for 5 years where the patient is likely to benefit from treatment. NoteFor details of the patient criteria, prescriber criteria, application and reporting forms contact the appointed clinician: Dr Peter BennyChristchurch Women's HospitalPrivate Bag 4711CHRISTCHURCHFax: 03 364 4634Appointed clinicians will distribute these agents to prescribers whose applications are approved
Up to 50 plastic syringes with attached needles may be dispensed in the case of a prescription for three months supply of insulin vials; orUp to four plastic syringes with attached needles may be dispensed for each week's supply in the case of a prescription for less than three months supply of insulin vials.
Special Authority for Subsidy - Form SA0382Initial application only from a gastroenterologist, general surgeon or general physician. Approvals valid for 3 years for applications meeting the following criteria: Any of the following: 1 All of the following: 1.1 Duodenal ulcer proven by endoscopy or barium meal; and 1.2 Failure of two alternative courses of H. pylori eradication therapy (if H. pylori positive); and 1.3 Non healing duodenal ulcer proven by second barium meal; and 1.4 H2 antagonist therapy for 8 weeks; or 2 All of the following: 2.1 Gastric ulcer proven by endoscopy; and 2.2 Two alternative courses of H. pylori eradication therapy (if H. pylori positive); and 2.3 Non healing gastric ulcer and excluded malignancy demonstrated by a second endoscopy; and 2.4 H2 antagonist therapy for 12 weeks; or 3 All of the following: 3.1 Grade 0 GORD (normal endoscopy); and 3.2 Positive 24 hour pH monitoring test; and 3.3 Failure of H2 antagonist t
n) Further approvals to fund the manufacturer's surcharge on either pravastatin or simvastatin (if applicable) may be granted to patients who are unable to continue treatment with fluvastatin due to adverse effects. Either general practitioners or specialist may make the application. To obtain a new Special Authority number, the application must include the following information: - the amount of time the patient has been treated with fluvastatin; and- the adverse effects experienced by the patient. o) Further approvals to fund the manufacturer's surcharge on simvastatin may be granted to patients with familial hypercholesterolaemia (FH) or familial combined hypercholesterolaemia (FCH) if a specialist considers that the patient is not achieving sufficient benefit from the fully funded statin(s). Only specialists may make application. To obtain a new Special Authority number, the application must include the following information: - the cholesterol level before and after treatment with the fully funded sta
Special Authority for Subsidy - Form SA0387Initial application - (Breast or prostatic cancer) only from an oncologist, urologist or endocrinologist. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 Breast cancer in pre menopausal women unwilling or unable to undergo surgical or radiation oophorectomy; or 2 Advanced prostatic cancer when orchidectomy is contraindicated or where the patient srongly opposes orchidectomy. NoteNot to be prescribed with an anti-androgen except for a period of three weeks, if necessary, when GnRH analogue therapy is intiatedInitial application - (Endometriosis) only from a gynaecologist. Approvals valid for 6 months for applications meeting the following criteria: Both: 1 Endometriosis; and 2 Either: 2.1 6 months treatment with medroxyprogesterone acetate, danazol or dimetriose has proven ineffective; or 2.2 The patient has failed to tolerate the treatment with medroxyprogesterone acetate, danazol or dimetrio
Special Authority for Subsidy - Form SA0391Initial application only from a relevant specialist. Approvals valid for 5 years for applications meeting the following criteria: Either: 1 Liver transplant recipients; or 2 Renal transplant recipients - as rescue therapy only. Renewal only from a relevant specialist. Approvals valid for 5 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Manufacturers Price - Form SA0394Initial application - (Helicobacter pylori infections) only from a general practitioner or relevant specialist. Approvals valid for 6 months for applications meeting the following criteria: Both: 1 Eradication of Helicobacter pylori in patient with proven infection; and 2 Peptic ulcer disease proven by endoscopy. NoteMaximum of two prescriptions (two courses) per patient. Initial application - (Mycobacterial infections) only from a respiratory specialist or infectious disease specialist. Approvals valid for 2 years for applications meeting the following criteria: Any of the following: 1 Mycobacterium Avium Intracellulare Complex infections in patient with AIDS; or 2 Atypical and drug-resistant mycobacterial infection; or 3 All of the following: 3.1 Prophylaxis against disseminated Mycobacterium Avium Intracellulare Complex infection; and 3.2 HIV infection; and 3.3 CD4 count <= 50 cells/mm3. Renewal - (Mycobacteri
a) Cyproterone acetate with ethinyloestradiol is available from retail pharmacy to patients as indicated. b) Prescribers may code prescriptions "contraceptive" (code "O") when used as indicated for contraception. The period of supply and prescription charge will be as per other contraceptives, as follows: - $3.00 prescription charge (patient co-payment) will apply; - Prescription may be written for up to 6 months supply; and- Pharmacists may dispense up to 3 month supply. c) Prescriptions coded in any other way are subject to the non-contraceptive prescription charges, and the non-contraceptive period of supply. Eg. Prescriptons may be written for up to 3 months supply, and dispensed monthly. d) The Special Authority number for hormonal contraceptive agents (combined and progesterone-only) does not apply, and is not interchangeable. e) Health Benefits Limited will return any claims unpaid as follows: - any uncoded prescription; - any prescription that does not have a period of supply or the quantity
Special Authority for Subsidy - Form SA0401Initial application - (Basal cell carcinoma) only from a dermatologist, plastic surgeon or radiation oncologist. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 Basal cell carcinoma unable to be treated surgically or by radiotherapy; and 2 Unsuitability for surgery confirmed by a Plastic Surgeon or Oncologist. NoteMaximum reimbursable dosage 15 million iu/weekInitial application - (Chronic hepatitis C) only from a relevant specialist. Approvals valid for 12 months where chronic hepatitis C. Initial application - (Indications other than Basal cell carcinoma and Chronic hepatitis C) only from a relevant specialist, plastic surgeon or radiation oncologist. Approvals valid for 2 years for applications meeting the following criteria: Any of the following: 1 Chronic myelogenous leukaemia; or 2 Hairy cell leukaemia; or 3 Cutaneous T cell lymphoma; or 4 Essential thrombocythaemia; or 5 Multiple myelo
Special Authority for Subsidy - Form SA0402Initial application - (Patients aged 74 and under) only from a general practitioner. Approvals valid for 2 years for applications meeting the following criteria: All of the following: 1 Patients aged 74 and under; and 2 The patient has been offered 3-6 months of counselling and an opportunity to modify lifestyle; and 3 Any of the following: 3.1 Both: 3.1.1 NHF A1:1 - Clinically proven ischaemic heart disease; and 3.1.2 total cholesterol > 6.0; or 3.2 Both: 3.2.1 NHF A1:2 - Post coronary artery bypass graft (CABG); and 3.2.2 total cholesterol > 5.5; or 3.3 Both: 3.3.1 NHF B:Patients with > 20% 5-year cardiovascular disease risk; and 3.3.2 total cholesterol > 9.0; or 3.4 Both: 3.4.1 NHF C:15-20% 5-year cardiovascular disease risk; and 3.4.2 total cholesterol > 9.0; or 3.5 Both: 3.5.1 NHF D:10-15% 5-year cardiovascular disease risk; and 3.5.2 total cholesterol > 9.0; or 3.6
Special Authority for Subsidy - Form SA0404Initial application only from an ophthalmologist. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 Primary open-angle glaucoma; and 2 Either: 2.1 Other subsidised glaucoma medical therapy is contraindicated; or 2.2 Both: 2.2.1 intra-ocular pressure > 26 mmHg (average from consecutive measurements); and 2.2.2 Unable to be controlled using other subsidised medical therapy. Renewal only from an ophthalmologist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Manufacturers Price - Form SA0410Initial application from any medical practitioner. Approvals valid for 2 years for applications meeting the following criteria: Any of the following: 1 Polycystic ovarian syndrome; or 2 Hirsutism; or 3 Androngenic alopecia. Renewal from any medical practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
Funding of manufacturers surcharge for existing patients taking ACE inhibitors for Congestive Heart Failure.a) Patients taking any ACE inhibitor for the treatment of congestive heart failure prior to 1 June 1998 can continue to have their ACE inhibitor treatment fully subsidised; b) Prescribers must endorse the prescription 'Congestive Heart Failure'. The endorsement can be typed (this includes computer generated prescriptions) or handwritten; c) The endorsement must be initialled in the prescriber's own handwriting. Definition of Congestive Heart FailureAt the request of some prescribers the PTAC Cardiovascular subcommittee has provided a definition of congestive heart failure for the purposes of the funding of the manufacturer's surcharge: "Clinicians should use their clinical judgement. Existing patients would be eligible for the funding of the surcharge if the patient shows signs and symptoms of congestive heart failure, and requires or has in the past required concomitant treatment with a
Special Authority for Subsidy - Form SA0423Initial application only from a gastroenterologist, general surgeon or general physician. Approvals valid for 3 years for applications meeting the following criteria: Any of the following: 1 All of the following: Duodenal Ulcer: 1.1 Duodenal ulcer proven by endoscopy or barium meal; and 1.2 Non healing duodenal ulcer proven by second barium meal; and 1.3 After failure of two alternative courses of H. pylori eradication therapy (if H. pylori positive); and 1.4 After H2 antagonist therapy for 8 weeks; or 2 All of the following: Gastric Ulcer: 2.1 Gastric ulcer proven by endoscopy; and 2.2 Non healing gastric ulcer and excluded malignancy demonstrated by a second endoscopy; and 2.3 After two alternative courses of H. pylori eradication therapy (if H. pylori positive); and 2.4 After H2 antagonist therapy for 12 weeks; or 3 All of the following: GORD: 3.1 Grade 0 GORD (normal endoscopy); and 3.2 Positive 24
Special Authority for Subsidy - Form SA0424Initial application - (Confirmed HIV/AIDS) only from a general physician. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 Confirmed HIV/AIDS; and 2 Any of the following: 2.1 Symptomatic patients aged 6 years and over with HIV/AIDS; or 2.2 Both: 2.2.1 Asymptomatic patients aged 6 years and over; and 2.2.2 CD4 counts < 500 cells/mm3; or 2.3 Both: 2.3.1 Asymptomatic patients aged 6 years and over; and 2.3.2 Viral load counts > 10,000 copies per ml; or 2.4 Symptomatic patients aged under 6 with HIV/AIDS ; or 2.5 Asymptomatic patients aged 12 months and under; or 2.6 Both: 2.6.1 Asymptomatic patients aged 1 to 5 years; and 2.6.2 CD4 counts < 1,000 cells/mm3; or 2.7 Both: 2.7.1 Asymptomatic patients aged 1 to 5 years; and 2.7.2 CD4 counts < 0.25 x total white cell count; or 2.8 Both: 2.8.1 Asymptomatic patients aged under 6 years; and
If a Community Pharmaceutical is the liquid oral form of an antibiotic to which a diluent must be added by the Contractor at the time of dispensing and it is prescribed or ordered by a Practittioner in an amount that does not coincide with the amount contained in one or more standard packs of that Community Pharmaceutical, Subsidy will only be made for the amount prescribed or ordered by the Practitioner in accordance with either Clause 3.1 or Clause 3.3 of the Schedule, unless the Contractor satisfies the Funder that he or she has not been able to dispense the balance of the pack or packs from which the Community Pharmaceutical has been dispensed. In such cases all of that pack or those packs is eligible for Subsidy.
Special Authority for Subsidy - Form SA0430Initial application - (National Heart Foundation risk groups A1:1, A1:2, B, C, D or E) only from a relevant specialist or general practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria: Both: 1 The patient has been offered 3-6 months of counselling and an opportunity to modify lifestyle; and 2 Any of the following: 2.1 Both: 2.1.1 NHF A1:1 - Clinically proven ischaemic heart disease; and 2.1.2 total cholesterol * > 5.5; or 2.2 Both: 2.2.1 NHF A1:2 - Post coronary artery bypass graft (CABG) or angioplasty; and 2.2.2 total cholesterol * > 4.5; or 2.3 Post heart transplant (regardless of cholesterol level); or 2.4 Both: 2.4.1 NHF B:Patients with > 20% 5-year cardiovascular disease risk; and 2.4.2 total cholesterol * > 9.0; or 2.5 Both: 2.5.1 NHF C:15-20% 5-year cardiovascular disease risk; and 2.5.2 total cholesterol * > 9
Special Authority for Manufacturers Price - Form SA0434Initial application only from a general practitioner, general physician, geriatrician or neurologist. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 Patients with swallowing difficulties; and 2 Applicant is a specialist or specialist has authorised treatment. Renewal only from a general practitioner, general physician, geriatrician or neurologist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Manufacturers Price - Form SA0435Initial application from any medical practitioner. Approvals valid for 6 months where control of nausea and vomiting in the treatment of terminal care patients. Renewal from any medical practitioner. Approvals valid for 6 months where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Manufacturers Price - Form SA0436Initial application - (Patient with prosthetic heart valves) only from a cardiothoracic surgeon, cardiologist or general physician. Approvals valid for 2 years where patient with prosthetic heart valves - as an adjunct to oral anticoagulation for prophylaxis of thromboembolism. Initial application - (Following coronary artery vein bypass graft) only from a cardiothoracic surgeon, cardiologist or general physician. Approvals valid for 1 year where patients after coronary artery vein bypass graft - as an adjunct to aspirin or as monotherapy for patients who are aspirin intolerant as defined below. Initial application - (Transient ischaemic episodes) only from a neurologist, neuro surgeon, cardiologist, vascular surgeon or general physician. Approvals valid for 2 years where patients who continue to have transient ischaemic episodes despite aspirin therapy or have transient ischaemic episodes and are aspirin intolerant as defined below. Renewal - (Fo
Special Authority for Subsidy - Form SA0443Initial application - (Helicobacter pylori infections) only from a general practitioner or relevant specialist. Approvals valid for 6 months for applications meeting the following criteria: Both: 1 Eradication of Helicobacter pylori in patient with proven infection; and 2 Peptic ulcer disease proven by endoscopy. NoteMaximum of two prescriptions (two courses) per patient. Initial application - (Mycobacterial infections) only from a respiratory specialist or infectious disease specialist. Approvals valid for 2 years for applications meeting the following criteria: Any of the following: 1 Mycobacterium Avium Intracellulare Complex infections in patient with AIDS; or 2 Atypical and drug-resistant mycobacterial infection; or 3 All of the following: 3.1 Prophylaxis against disseminated Mycobacterium Avium Intracellulare Complex infection; and 3.2 HIV infection; and 3.3 CD4 count <= 50 cells/mm3. Renewal - (Mycobacterial infection
Special Authority for Subsidy - Form SA0445Initial application only from a relevant specialist. Approvals valid for 5 years for applications meeting the following criteria: Any of the following: 1 Both: 1.1 Acromegaly; and 1.2 Patient has failed surgery, radiotherapy, bromocriptine or other oral therapies; or 2 VIPomas and Glucagonomas - for patients who are seriously ill in order to improve their clinical state prior to definitive surgery.; or 3 Both: 3.1 Gastrinoma; and 3.2 Patient has failed surgery, or metastatic disease after H2 antagoists (or proton pump inhibitors) have failed; or 4 Both: 4.1 Insulinomas; and 4.2 Surgery is contraindicated or has failed; or 5 For pre-operative control of hypoglycaemia and for maintenance therapy; or 6 Both: 6.1 Carcinoidsyndrome (diagnosed by tissue pathology and/or urinary 5HIAA analysis); and 6.2 Disabling symptoms not controlled by maximal medical therapy. NoteThe use of octretide in patients with fis
Special Authority for Subsidy - Form SA0450Initial application only from a psychiatrist. Approvals valid for 12 months for applications meeting the following criteria: Both: 1 Patients suffering from schizophrenia and related psychoses; and 2 Either: 2.1 Failed to respond to full trials (duration of at least 6 weeks each) of effective doses of at least two classes of anti-psychotic agents (refer to guidelines below); or 2.2 Demonstrated intolerance to other neuroleptic agents. NoteClinicians must confirm that informed consent and a satisfactory White Bloodcell Count (WBC) result has been obtained. Diagnosis: Treatment resistant schizophrenia and related psychoses when positive symptoms (delusions, hallucinations and thought disorder) are prominent and/or disabling or when both positive symptoms and negative symptoms (flattened affect, emotional and social withdrawal and poverty of speech) are present. Treatment: Trial therapy undertaken before initiating treatment with clozapine could
Special Authority for Manufacturers Price - Form SA0451Initial application only from a relevant specialist. Approvals valid for 3 years for applications meeting the following criteria: Both: 1 Patients being treated for advanced breast cancer who are refractory to tamoxifen; and 2 Any of the following: 2.1 Unable to tolerate aminoglutethimide; or 2.2 Unable to tolerate megestrol acetate; or 2.3 Unable to tolerate medroxyprogesterone acetate.Renewal only from a relevant specialist. Approvals valid for 3 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Manufacturers Price - Form SA0452Initial application only from a relevant specialist. Approvals valid for 3 years for applications meeting the following criteria: Both: 1 Patients being treated for advanced breast cancer who are refractory to tamoxifen; and 2 Any of the following: 2.1 Unable to tolerate aminoglutethimide; or 2.2 Unable to tolerate megestrol acetate; or 2.3 Unable to tolerate medroxyprogesterone acetate.Renewal only from a relevant specialist. Approvals valid for 3 years where the treatment remains appropriate and the patient is benefiting from treatment.
Guidelines for the use of atypical anti-psychotic agents Diagnosis: Schizophrenia and related psychoses when positive symptoms (delusions, hallucinations and thought disorder) are prominent and/or disabling or when both positive symptoms and negative symptoms (flattened affect, emotional and social withdrawal and poverty of speech) are present. Treatment: Before initiating atypical anti-psychotic therapy, physicians should consider whether the patient is likely to respond to and/or tolerate conventional anti-psychotic therapy and, where appropriate, trial one or more conventional agent prior to use of an atypical agent.
Special Authority for Subsidy - Form SA0456Initial application only from a psychiatrist. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 Patients suffering from schizophrenia and related psychoses who are likely to benefit from anti-psychotic treatment; and 2 Any of the following: 2.1 Effective dose of risperidone has been discontinued because of recurrent acute dystonias; or 2.2 Effective dose of risperidone has been discontinued because of excessive Parkinson-like symptoms; or 2.3 Effective dose of risperidone has been discontinued after 6 weeks because of inadequate clinical response. Renewal only from a psychiatrist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0458Initial application only from a gastroenterologist. Approvals valid for 6 months for applications meeting the following criteria: Both: 1 Primary biliary cirrhosis confirmed by antimitochondrial antibody titre (AMA) > 1:80, and raised cholestatic liver enzymes with or without raised serum IgM or, if AMA is negative, by liver biopsy; and 2 Patient not requiring a liver transplant (bilirubin > 170umol/l; decompensated cirrhosis). NoteLiver biopsy is not usually required for diagnosis but is helpful to stage the diseaseRenewal only from a gastroenterologist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment. NoteActigall is not an appropriate therapy for patients requiring a liver transplant (bilirubin > 170 micromol/l; decompensated cirrhosis). These patients should be referred to an appropriate transplant centreTreatment failure - doubling of serum bilirubin levels, absence of a signi
Special Authority for Subsidy - Form SA0459Initial application only from a gastroenterologist or general physician. Approvals valid for 3 months for applications meeting the following criteria: Both: 1 Mild to moderate ileal, ileocaecal or proximal Crohn's disease; and 2 Any of the following: 2.1 Diabetes; or 2.2 Cushingoid habitus; or 2.3 Osteoporosis where there is significant risk of fracture; or 2.4 Both: 2.4.1 Severe acne; and 2.4.2 Treatment with conventional corticosteroid therapy. Renewal only from a gastroenterologist or general physician. Approvals valid for 3 months where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Manufacturers Price - Form SA0460Initial application - (Patient with prosthetic heart valves) only from a cardiothoracic surgeon, cardiologist or general physician. Approvals valid for 2 years where patient with prosthetic heart valves - as an adjunct to oral anticoagulation for prophylaxis of thromboembolism. Initial application - (Following coronary artery vein bypass graft) only from a cardiothoracic surgeon, cardiologist or general physician. Approvals valid for 1 year where patients after coronary artery vein bypass graft - as an adjunct to aspirin or as monotherapy for patients who are aspirin intolerant as defined below. Initial application - (Transient ischaemic episodes) only from a neurologist, neuro surgeon, cardiologist, vascular surgeon or general physician. Approvals valid for 2 years where patients who continue to have transient ischaemic episodes despite aspirin therapy or have transient ischaemic episodes and are aspirin intolerant as defined below. Renewal - (Fo
Special Authority for Subsidy - Form SA0461Initial application - (Basal cell carcinoma) only from a dermatologist, plastic surgeon or radiation oncologist. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 Basal cell carcinoma unable to be treated surgically or by radiotherapy; and 2 Unsuitablity for surgery confirmed by a Plastic Surgeon or Radiation Oncologist. NoteThe maximum reimbursable dosage is 15 million iu per weekInitial application - (Chronic hepatitis C) only from a relevant specialist. Approvals valid for 12 months where chronic hepatitis C. Initial application - (Indications other than Basal cell carcinoma and Chronic hepatitis C) only from a relevant specialist. Approvals valid for 2 years for applications meeting the following criteria: Any of the following: 1 Chronic myelogenous leukaemia; or 2 Hairy cell leukaemia; or 3 Multiple myeloma; or 4 Chronic active hepatitis B. Renewal - (Basal cell carcinoma) only from a dermato
Special Authority for Subsidy - Form SA0464Initial application only from a diabetologist, general physician or paediatrician. Approvals valid without further renewal unless notified for applications meeting the following criteria: Any of the following: 1 Both: 1.1 Use alone (monotherapy); and 1.2 The patient is unable to use any other insulins including those on insulin pump treatment; or 2 Both: 2.1 Use with Humulin 70/30 or Humulin 80/20; and 2.2 A reasonable trial of Humulin N has been undertaken and it is not effective or not well tolerated; or 3 Both: 3.1 Use with insulins (aside from insulin zinc suspension) other than Humulin 70/30, Humulin 80/20, or Humulin N; and 3.2 A reasonable trial of one or more of these Humulin insulins has been undertaken and it is/are ineffective or not well tolerated; or 4 Both: 4.1 Use with Humulin L or Humulin U; and 4.2 Use with Humulin N is not appropriate; or 5 Both: 5.1 Use with other insulin zinc suspensio
Special Authority for Alternate Subsidy - Form SA0466Initial application only from a relevant specialist or general practitioner. Approvals valid for 5 years for applications meeting the following criteria: Any of the following: 1 Angina that is not controlled by other anginal medications; or 2 Continuation of treatment commenced prior to 1 June 1999; or 3 Receiving maximal antihypertensive therapy, requires a DHP CCB, and cannot tolerate felodipine. Renewal only from a relevant specialist or general practitioner. Approvals valid for 5 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0467Initial application only from a relevant specialist. Approvals valid for 6 months for applications meeting the following criteria: Both: 1 Paget's disease; and 2 Any of the following: 2.1 Bone or articular pain; or 2.2 Bone deformity; or 2.3 Bone, articular or neurological complications; or 2.4 Asymptomatic disease, but risk of complications due to site (base of skull, spine, long bones of lower limbs); or 2.5 Preparation for orthopaedic surgery. Renewal only from a relevant specialist. Approvals valid for 6 months where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0470Initial application - (Organ transplant) only from a relevant specialist. Approvals valid without further renewal unless notified where organ transplant. Initial application - (Bone marrow transplant or Graft v host disease) only from a relevant specialist. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 Bone marrow transplant; or 2 Graft v host disease. Initial application - (Psoriasis) only from a dermatologist. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 Psoriasis; and 2 Applicant must state which systemic and topical therapies have failed. Initial application - (Severe atopic dermatitis) only from a dermatologist. Approvals valid for 6 months for applications meeting the following criteria: Both: 1 Severe atopic dermatitis; and 2 Not responsive to topical therapy, oral antihistamines and other commonly used orthodox therapies. Initial application - (N
Special Authority for Subsidy - Form SA0471Initial application - (Breast cancer) from any medical practitioner. Approvals valid for 1 year where breast cancer in pre menopausal women unwilling or unable to undergo surgical or radiation oophorectomy. Initial application - (Prostate cancer) only from an oncologist, urologist or endocrinologist. Approvals valid for 1 year where advanced prostatic cancer when orchidectomy is contraindicated or where the patient strongly opposes orchidectomy. NoteNot to be prescribed with an anti-androgen except for a period of three weeks, if necessary, when GnRH analogue therapy is intiatedInitial application - (Endometriosis) only from a gynaecologist. Approvals valid for 3 months for applications meeting the following criteria: Both: 1 Endometriosis ; and 2 Either: 2.1 6 months treatment with medroxyprogesterone acetate, danazol or dimetriose has proven ineffective; or 2.2 The patient has failed to tolerate the treatment with medroxyprogesterone
Special Authority for Subsidy - Form SA0472Initial application only from a cardiologist. Approvals valid for 2 years for applications meeting the following criteria: Any of the following: 1 Both: 1.1 Congestive heart failure; and 1.2 Cannot tolerate currently fully subsidised ACE inhibitors due to persistent cough that resolves on cessation and recurs on re-challenge with ACE inhibitor; or 2 Patients who have experienced angioedema on an ACE inhibitor at any time in the past; or 3 Patients who have experienced angioedema (even if not using an ACE inhibitor) in the last 2 years. Renewal only from a cardiologist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0473Initial application from any medical practitioner. Approvals valid for 1 year where the patient is likely to benefit from treatment. Note Applications to be made on the approved forms which are available from: The Co-ordinatorGaucher's Treatment PanelPhone: (04) 460 4990 PHARMAC, PO Box 10 254 WellingtonFacsimile: (04) 916 7571Email: erin.murphy@pharmac.govt.nzPrescriptions for patients approved for treatment must be written by respiratory physicians or paediatricians who have experience and expertise in treating cystic fibrosis.
a) When prescribed (alone or in combination) for renal dialysis in the home of the patient concerned.b) Only maternity hospital, or on the prescription of a practitioner. c) Obstetric cream only in a quantity not exceeding 500 ml per prescription or on a bulk supply order. d) Solution 5% in quantity not exceeding 100 ml per prescription or on a bulk supply order.
Special Authority for Subsidy - Form SA0488Initial application only from a gastroenterologist, general surgeon or general physician. Approvals valid for 3 months for applications meeting the following criteria: Both: 1 Mild to moderate ileal, ileocaecal or proximal Crohn's disease; and 2 Any of the following: 2.1 Diabetes; or 2.2 Cushingoid habitus; or 2.3 Osteoporosis where there is significant risk of fracture; or 2.4 Both: 2.4.1 Severe acne; and 2.4.2 Treatment with conventional corticosteroid therapy. Renewal only from a gastroenterologist, general surgeon or general physician. Approvals valid for 3 months where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Manufacturers Price - Form SA0489Initial application - (Conditions other than transient ischaemic episodes) only from a cardiothoracic surgeon, cardiologist or general physician. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 Patients with prosthetic heart valves - as an adjunct to oral anticoagulation for prophylaxis of thromboembolism; or 2 Both: 2.1 Patients after coronary artery vein bypass graft; and 2.2 Any of the following: 2.2.1 aspirin induced asthma; or 2.2.2 aspirin induced anaphylaxi; or 2.2.3 significant aspirin induced bleeding excluding bruising. Initial application - (Transient ischaemic episodes) only from a neurologist, neuro surgeon, cardiologist, vascular surgeon or general physician. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 Patients who continue to have transient ischaemic episodes despite aspirin therapy; or 2 Both: 2.1 Patients wh
Special Authority for Subsidy - Form SA0490Initial application only from a relevant specialist. Approvals valid for 2 years for applications meeting the following criteria: Any of the following: 1 Requires but is not able to tolerate metformin therapy; or 2 Requires metformin but metformin is contraindicated; or 3 Has not responded to or tolerated the maximum appropriate dose of metformin. Renewal only from a relevant specialist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0494Initial application only from an ophthalmologist. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 Both: 1.1 Primary open-angle glaucoma; and 1.2 Any of the following: 1.2.1 Patient cannot tolerate Beta-blockers, or Beta-blockers are contraindicated; or 1.2.2 Patient cannot tolerate Pilocarpine, or Pilocarpine is contraindicated; or 1.2.3 Patient cannot tolerate Dorzolamide, or Dorzolamide is contraindicated; or 1.2.4 A reduction in intraocular pressure of 15% or more is not achieved or maintained using dorzolamide either alone or in combination with a beta-blocker; or 2 There is progressive visual field loss and/or optic nerve damage persists after treatment with dorzolamide either alone or in combination with a beta-blocker. NoteSubsidised as monotherapy onlyRenewal only from an ophthalmologist. Approvals valid for 2 years where the treatment remains appropriate and the patient
Special Authority for Alternate Subsidy - Form SA0500Initial application from any medical practitioner. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 Either: 1.1 Patient is on a Social Welfare benefit; or 1.2 Patient has an income no greater than the benefit; and 2 Has tried at least one of the fully funded options and has been unable to tolerate it. Renewal from any medical practitioner. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 Patient is on a Social Welfare benefit; or 2 Patient has an income no greater than the benefit. NoteThe approval numbers of Special Authorities approved after 1 November 1999 are interchangeable between Mercilon and Marvelon. The additional subsidy will fund Mercilon and Marvelon up to the manufacturer's price for each of these products as identified on the Schedule at 1 November 1999Special Authorities approved before 1 November 1999 remain valid until the expiry d
Special Authority for Subsidy - Form SA0508Initial application only from a relevant specialist or general practitioner. Approvals valid for 2 years for applications meeting the following criteria: All of the following: 1 Patient with raised blood pressure; and 2 A beta blocker or diuretic is contraindicated; or not well tolerated; or insufficient to control blood pressure adequately at appropriate doses; and 3 An ACE inhibitor is contraindicated; or not well tolerated; or insufficient to control blood pressure adequately at appropriate doses. Renewal only from a relevant specialist or general practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0509Initial application only from a psychiatrist. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 Patient with first episode schizophrenia or related psychoses; or 2 Both: 2.1 Patient suffering from schizophrenia and related psychoses who is likely to benefit from anti-psychotic treatment; and 2.2 Both: 2.2.1 An effective dose of risperidone had been trialled and has been discontinued either because of; and 2.2.2 Any of the following: 2.2.2.1 Patient has recurrent acute dystonias; or 2.2.2.2 Patient has excessive Parkinson-like symptoms; or 2.2.2.3 Patient has hyperprolactinaemia; or 2.2.2.4 Patient has inadequate clinical response after four weeks. NoteDiscontinued treatment should be notified to HealthPAC if possibleRenewal only from a psychiatrist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Alternate Subsidy - Form SA0510Initial application only from a relevant specialist or general practitioner. Approvals valid for 2 years for applications meeting the following criteria: Any of the following: 1 Angina that is not controlled by other anginal medications (including felodipine); or 2 Patient was taking Adalat Oros for the treatment of angina prior to 1 June 1999; or 3 Receiving maximal antihypertensive therapy, requires a DHP CCB, and cannot tolerate felodipine. Renewal only from a relevant specialist or general practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0511Initial application only from a geriatrician, rheumatologist, endocrinologist, gynaecologist or general physician. Approvals valid for 2 years for applications meeting the following criteria: All of the following: 1 Severe osteoporosis; and 2 History of two previous significant osteoporotic fractures demonstrated radiologically; and 3 T-Score <= -3.0 (bone mass density (BMD) >= 3.0 standard deviations below the mean normal value in young adults). NoteIn line with the Australian guidelines for funding alendronate, a vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral bodyRenewal only from a geriatrician, rheumatologist, endocrinologist, gynaecologist or general physician. Approvals valid for 2 years where the tr
Special Authority for Subsidy - Form SA0512Initial application only from a gastroenterologist, general surgeon or general physician. Approvals valid for 3 months for applications meeting the following criteria: Both: 1 Mild to moderate ileal, ileocaecal or proximal Crohn's disease; and 2 Either: 2.1 Diabetes; or 2.2 Both: 2.2.1 Treatment with conventional corticosteroid therapy; and 2.2.2 Any of the following: 2.2.2.1 Cushingoid habitus; or 2.2.2.2 Osteoporosis where there is significant risk of fracture; or 2.2.2.3 Severe acne. Renewal only from a gastroenterologist, general surgeon or general physician. Approvals valid for 3 months where the patient has had no more than 1 prior approval in the last 12 months. The patient must have had no more than 1 prior approval in the last year. NoteClinical trials for Entocort CIR use beyond three months demonstrated no improvement in relapse rate
Special Authority for Subsidy - Form SA0513Initial application - (Narcolepsy) only from a neurologist. Approvals valid for 24 months where narcolepsy. Initial application - (ADHD in patients aged 5 years or over) only from a paediatrician or psychiatrist. Approvals valid for 24 months for applications meeting the following criteria: Both: 1 ADHD (Attention Deficient and Hyperactivity Disorder) patients aged 5 years or over; and 2 Diagnosed according to DSM-IV or ICD 10 criteria. Initial application - (ADHD in patients under 5 years of age) only from a paediatrician or psychiatrist. Approvals valid for 12 months for applications meeting the following criteria: Both: 1 ADHD (Attention Deficient and Hyperactivity Disorder) patients under 5 years of age; and 2 Diagnosed according to DSM-IV or ICD 10 criteria. Renewal - (Narcolepsy or ADHD in patients under 5 years of age) only from a neurologist, paediatrician or psychiatrist. Approvals valid for 24 months where the treatment remains appr
Special Authority for Subsidy - Form SA0516Initial application from any medical practitioner. Approvals valid for 2 years where the patient is likely to benefit from treatment. Note Applications to be made on the approved forms which are available from: Prof. Wayne CutfieldNational Co-ordinatorNew Zealand Growth Hormone CommitteeC/- Department of PaediatricsUniversity of AucklandPrivate Bag 92019AUCKLAND
Special Authority for Subsidy - Form SA0523Initial application only from a relevant specialist or general practitioner. Approvals valid for 6 months for applications meeting the following criteria: All of the following: 1 Diagnosis of asthma confirmed; and 2 Inhaler/device technique checked; and 3 Patient monitors PEFR regularly during exacerbations where appropriate; and 4 Any of the following: 4.1 At least three months of 1500 ug or more daily of inhaled beclomethasone or budesonide for adult; or 4.2 At least three months of 750 ug or more daily of inhaled fluticasone) for adult; or 4.3 At least three months of 800 ug or more daily inhaled beclomethasone or budesonide for child; or 4.4 At least three months of 400 ug or more daily inhaled fluticasone) for child; and 5 Either: 5.1 Short acting beta agonist used at least 3-4 times daily; or 5.2 Nocturnal awakenings at least twice a week. Renewal only from a relevant specialist or general practitioner. Appro
Special Authority for Subsidy - Form SA0528Initial application - (Narcolepsy) only from a neurologist or respiratory specialist. Approvals valid for 24 months where narcolepsy. Initial application - (ADHD in patients 5 or over) only from a paediatrician, psychiatrist or general practitioner. Approvals valid for 24 months for applications meeting the following criteria: All of the following: 1 ADHD (Attention Deficient and Hyperactivity Disorder) patients aged 5 years or over; and 2 Diagnosed according to DSM-IV or ICD 10 criteria; and 3 Applicant is a specialist or specialist has recommended treatment. Initial application - (ADHD in patients under 5) only from a paediatrician or psychiatrist. Approvals valid for 12 months for applications meeting the following criteria: Both: 1 ADHD (Attention Deficient and Hyperactivity Disorder) patients under 5 years of age; and 2 Diagnosed according to DSM-IV or ICD 10 criteria. Renewal - (Narcolepsy) only from a neurologist or respiratory spec
ACE inhibitors will be funded to the level of the ex-manufacturer price listed in the Schedule for patients who were taking an ACE inhibitor for the treatment of congestive heart failure prior to 1 June 1998. The prescription must be endorsed accordingly. We recommend that the words used to indicate eligibility are "certified condition" or an appropriate description of the patient such as "congestive heart failure", "CHF", "congestive cardiac failure" or "CCF". Additional subsidy for lisinopril is available only up to the price of the least expensive brand listed in the Schedule. Definition of Congestive Heart FailureAt the request of some prescribers the PTAC Cardiovascular subcommittee has provided adefinition of congestive heart failure for the purposes of the funding of the manufacturer'ssurcharge: "Clinicians should use their clinical judgement. Existing patients would be eligible for thefunding of the surcharge if the patient shows signs and symptoms of congestive heart failure, and requir
Additional subsidy by endorsement for:Moclobemide tab 150 mg x 100 (Aurorix) up to $47.00Moclobemide tab 300 mg x 60 (Aurorix) up to $56.40Nefazadone tab 100 mg x 56 (Serzone) up to $20.16Nefazadone tab 200 mg x 56 (Serzone) up to $40.32Citalopram tab 20 mg x 28 (Cipramil) up to $27.00is available for patients who: * are taking moclobemide or nefazodone on 1 December 1999 or citalopram on 1 February2000; * have previously responded to treatment with moclobemide or nefazodone or citalopram; * have had a trial of fluoxetine and have to discontinue due to: - inability to tolerate the drug due to side effects OR - failed to respond to an adequate dose and duration of treatment; * have contraindications to fluoxetine (eg pre-existing significant levels of nausea, breastfeeding, potential drug interactions); The prescription must be endorsed accordingly. We recommend that the words used to indicate eligibility are "certified condition" however these particular words are not a requirement.
Special Authority for Subsidy - Form SA0538Initial application only from a gastroenterologist, infectious disease specialist, paediatrician or general physician. Approvals valid for 1 year for applications meeting the following criteria: Both: 1 Any of the following: 1.1 All of the following: 1.1.1 HBsAg positive for more than 6 months; and 1.1.2 HBeAg positive or HBV DNA positive defined as >0.6 pg/ml by quantitative PCR at reference laboratory; and 1.1.3 ALT greater than twice upper limit of normal or stage 3 or 4 fibrosis on liver histology clinical/radiological evidence of cirrhosis; or 1.2 HBV DNA positive cirrhosis prior to liver transplantation; or 1.3 HBsAg positive and have had a liver, kidney, heart, lung or bone marrow transplant; and 2 All of the following: 2.1 No continuing alcohol abuse or intravenous drug use; and 2.2 Not coinfected with HCV, HDV, or HIV; and 2.3 Neither ALT nor AST greater than 10 times upper limit of normal; and 2.4
Special Authority for Subsidy - Form SA0539Initial application from any medical practitioner. Approvals valid for 5 years where the patient is likely to benefit from treatment. NoteApplications to be made on the approved forms which are available from: The Co-ordinatorPhone: 09 580 9176Multiple Sclerosis Treatment CommitteeFacsimile: 09 580 9205Level 3, Unisys HouseEmail: murray@ppc.govt.nz650 Great South Road, PenrosePrivate Bag, AUCKLANDBudget managed by appointed clinicians on the Multiple Sclerosis Treatment Assessments Committee (MSTAC). Applications will be considered by MSTAC at its regular meetings and approved subject to eligibility according to the Entry and Stopping criteria (below). Completed application forms must be sent to the co-ordinator for MSTAC and will be considered by MSTAC at the next practicable opportunity. Notification of MSTAC's decision will be sent to the patient, the applying clinician and the patient's GP (if specified). These agents will N
Additional subsidy by endorsement for:Moclobemide tab 150 mg x 100 (Aurorix) up to $47.00Moclobemide tab 300 mg x 60 (Aurorix) up to $56.40Nefazadone tab 100 mg x 56 (Serzone) up to $20.16Nefazadone tab 200 mg x 56 (Serzone) up to $40.32Citalopram tab 20 mg x 28 (Cipramil) up to $27.00is available for patients who: * were taking moclobemide or nefazodone on 1 December 1999 or citalopram on 1 February 2000; or* have previously responded to treatment with moclobemide, nefazodone or citalopram; or* have had a trial of fluoxetine and have to discontinue due to: - inability to tolerate the drug due to side effects; or - failed to respond to an adequate dose and duration of treatment; or* have contraindications to fluoxetine (eg pre-existing significant levels of nausea, breastfeeding, potential drug interactions); The prescription must be endorsed accordingly. We recommend that the words used to indicate eligibility are "certified condition" however these words are not a requirement.
Alphagan is subsidised for use as either monotherapy or as an adjunctive agent for the treatment of glaucoma. Alphagan should not be prescribed for a person in whom less expensive first line agents for the treatment of glaucoma are not contraindicated unless: (a) that person has previously trialled all other such subsidised agents (except dorzolamide hydrochloride); and(b) those trials have indicated that that person does not respond adequately to or does not tolerate treatment with those other agents.
Special Authority for Subsidy - Form SA0551Initial application only from a paediatrician, neurologist or general physician. Approvals valid for 15 months for applications meeting the following criteria: Any of the following: 1 Was on NAED therapy before 1 September 2000; or 2 Seizures are not adequately controlled with optimal older anti-epilepsy drug treatment; or 3 Seizures are controlled adequately but who experience unacceptable side effects from older anti-epilepsy drug treatment. NoteApproval entitles patients to a subsidy for one NAED. Dual NAED therapy will be subsidised for patients who were already stabilised on two NAEDs on or before 31 July 2000 or, for whom a second NAED has been added to therapy with one NAED provided an attempt to withdraw one NAED has been made and was unsuccessful. "Optimal older anti-epilepsy drug therapy" is defined as treatment with those older anti-epilepsy drugs which are indicated and clinically appropriate for the patient, given singly and in combin
Nicotine patches and gum: a) are only available /subsidised on presentation of a Quitline exchange card.b) for reimbursement refer to the Claiming Procedures for the Subsidised Nicotine Patches and Gum Programme. c) have a maximum patient co-payment (contribution) of $10 per exchange card.
Special Authority for Subsidy - Form SA0554Initial application only from a relevant specialist. Approvals valid without further renewal unless notified for applications meeting the following criteria: Either: 1 Liver transplant recipients; or 2 Renal transplant recipients - as rescue therapy only. Renewal only from a relevant specialist. Approvals valid without further renewal unless notified where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0556Initial application - (Confirmed HIV/AIDS) only from a named general physician. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 Confirmed HIV/AIDS; and 2 Any of the following: 2.1 Symptomatic patient; or 2.2 Both: 2.2.1 Asymptomatic patient; and 2.2.2 Patient aged 12 months and under; or 2.3 Both: 2.3.1 Asymptomatic patient; and 2.3.2 Patient has viral load counts > 10,000 copies per ml or equivalent value on the Chiron test; or 2.4 All of the following: 2.4.1 Asymptomatic patient; and 2.4.2 Patient aged 1 to 5 years; and 2.4.3 CD4 counts < 1,000 cells/mm3; or 2.5 All of the following: 2.5.1 Asymptomatic patient; and 2.5.2 Patient aged 1 to 5 years; and 2.5.3 CD4 counts < 0.25 x total white cell count; or 2.6 All of the following: 2.6.1 Asymptomatic patient; and 2.6.2 Patient aged 6 years and over; and 2.6.3 CD4 counts
Special Authority for Subsidy - Form SA0557Initial application - (Single NAED Therapy) only from a paediatrician, neurologist or general physician. Approvals valid for 15 months for applications meeting the following criteria: Any of the following: 1 Was on NAED therapy before 1 September 2000; or 2 Seizures are not adequately controlled with optimal older anti-epilepsy drug treatment; or 3 Seizures are controlled adequately but who experience unacceptable side effects from older anti-epilepsy drug treatment. Note"Optimal older anti-epilepsy drug therapy" is defined as treatment with those older anti-epilepsy drugs which are indicated and clinically appropriate for the patient, given singly and in combination in adequate doses for the patient's age, weight, and other features affecting the pharmacokinetics of the drug with good evidence of complianceAs a guideline, clinical trials have referred to a notional 50% reduction in seizure frequency as an indicator of success with anti-convulsan
Additional subsidy by endorsement for:Moclobemide tab 150mg x 100 (Aurorix) up to $32.90Moclobemide tab 300mg x 60 (Aurorix) up to $39.48Nefazodone tab 100mg x 56 (Serzone) up to $20.16Nefazodone tab 200mg x 56 (Serzone) up to $40.32Citalopram tab 20mg x 28 (Cipramil) up to $27.00is available for patients who: * were taking moclobemide or nefazodone on 1 December 1999 or citalopram on 1 February 2000; or* have previously responded to treatment with moclobemide, nefazodone or citalopram; or* have had a trial of fluoxetine and have had to discontinue due to - inability to tolerate the drug due to side effects; or - failed to respond to an adequate dose and duration of treatment; or* have contraindications to fluoxetine (eg pre-existing significant levels of nausea, breastfeeding, potential drug interactions). The prescription must be endorsed accordingly. We recommend that the words used to indicate eligibility are "certified condition" however these words are not a requirement.
Additional subsidy by endorsement for:Moclobemide tab 150mg x 100 (Aurorix) up to $32.90Moclobemide tab 300mg x 60 (Aurorix) up to $39.48Nefazodone tab 100mg x 56 (Serzone) up to $20.16Nefazodone tab 200mg x 56 (Serzone) up to $40.32Citalopram tab 20mg x 28 (Cipramil and Celapram) up to $10.00Paroxetine hydrochloride tab 20 mg x 30 (Aropax) up to $35.02is available for patients who: * were taking moclobemide or nefazodone on 1 December 1999 or citalopram on 1 February 2000; or paroxetine hydrochloride on Februrary 2001; or * have previously responded to treatment with moclobemide or nefazodone or citalopram or paroxetine hydrochloride; or* have had a trial of fluoxetine and have had to discontinue due to - inability to tolerate the drug due to side effects; or - failed to respond to an adequate dose and duration of treatment; or* have contraindications to fluoxetine (eg pre-existing significant levels of nausea, breastfeeding, potential drug interactions). The prescription must be e
Special Authority for Subsidy - Form SA0563Initial application only from a relevant specialist. Approvals valid for 2 years for applications meeting the following criteria: Any of the following: 1 Both: 1.1 Acromegaly; and 1.2 Patient has failed surgery, radiotherapy, bromocriptine and other oral therapies; or 2 VIPomas and Glucagonomas - for patients who are seriously ill in order to improve their clinical state prior to definitive surgery.; or 3 Both: 3.1 Gastrinoma; and 3.2 Either: 3.2.1 Patient has failed surgery; or 3.2.2 Patient in metastatic disease after H2 antagonists (or proton pump inhibitors) have failed; or 4 Both: 4.1 Insulinomas; and 4.2 Surgery is contraindicated or has failed; or 5 For pre-operative control of hypoglycaemia and for maintenance therapy; or 6 Both: 6.1 Carcinoid syndrome (diagnosed by tissue pathology and/or urinary 5HIAA analysis); and 6.2 Disabling symptoms not controlled by maximal medical therapy. No
Trandolapril will be funded to the level of the ex-manufacturer price listed in the Schedule for patients who were taking these ACE inhibitors for the treatment of congestive heart failure prior to 1 June 1998. The prescription must be endorsed accordingly. We recommend that the words used to indicate eligibility are "certified condition" or an appropriate description of the patient such as "congestive heart failure", "CHF", "congestive cardiac failure" or "CCF". Definition of Congestive Heart Failure At the request of some prescribers the PTAC Cardiovascular subcommittee has provided a definition of congestive heart failure for the purposes of the funding of the manufacturer's surcharge: "Clinicians should use their clinical judgement. Existing patients would be eligible for the funding of the surcharge if the patient shows signs and symptoms of congestive heart failure, and requires or has in the past required concomitant treatment with a diuretic. The definition could also be considered to include pat
Perindopril will be funded to the level of the ex-manufacturer price listed in the Schedule for patients who were taking these ACE inhibitors for the treatment of congestive heart failure prior to 1 June 1998. The prescription must be endorsed accordingly. We recommend that the words used to indicate eligibility are "certified condition" or an appropriate description of the patient such as "congestive heart failure", "CHF", "congestive cardiac failure" or "CCF". Definition of Congestive Heart Failure At the request of some prescribers the PTAC Cardiovascular subcommittee has provided a definition of congestive heart failure for the purposes of the funding of the manufacturer's surcharge: "Clinicians should use their clinical judgement. Existing patients would be eligible for the funding of the surcharge if the patient shows signs and symptoms of congestive heart failure, and requires or has in the past required concomitant treatment with a diuretic. The definition could also be considered to include pati
Special Authority for Subsidy - Form SA0569Initial application only from a geriatrician, rheumatologist, endocrinologist, gynaecologist or general physician. Approvals valid for 2 years for applications meeting the following criteria: All of the following: 1 Severe osteoporosis; and 2 History of one previous significant osteoporotic fractures demonstrated radiologically; and 3 T-Score <= -3.0 (bone mass density (BMD) >= 3.0 standard deviations below the mean normal value in young adults). NoteIn line with the Australian guidelines for funding alendronate, a vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body. Renewal only from a geriatrician, rheumatologist, endocrinologist, gynaecologist or general physician. Approvals valid for 2 years where the t
Special Authority for Subsidy - Form SA0572Initial application only from a psychiatrist. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 Patient presenting with first episode schizophrenia or related psychoses; or 2 Both: 2.1 Patients suffers from schizophrenia or related psychoses ; and 2.2 Either: 2.2.1 A trial of risperidone has been discontinued because of unacceptable side effects; or 2.2.2 A trial of risperidone has been discontinued because of inadequate response. Renewal only from a psychiatrist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
Subsidy is available for patients with poorly controlled asthma where: a) at least three months of 750 mcg or more daily of inhaled beclomethasone or budesonide(or 400 mcg of fluticasone) for adults has been used; orb) at least three months of 400 mcg or more daily of inhaled beclomethasone or budesonide (or 200mcg of fluticasone) for children 12 years or older has been used; The prescription must be endorsed accordingly. We recommend that the words used to indicateeligibility are "poor control with ICS" or "certified condition".
Special Authority for Subsidy - Form SA0575Initial application - (Confirmed HIV/AIDS) only from a named general physician. Approvals valid without further renewal unless notified for applications meeting the following criteria: Both: 1 Confirmed HIV/AIDS; and 2 Any of the following: 2.1 Symptomatic patient; or 2.2 Both: 2.2.1 Asymptomatic patient; and 2.2.2 Patient aged 12 months and under; or 2.3 Both: 2.3.1 Asymptomatic patient; and 2.3.2 Patient has viral load counts > 10,000 copies per ml or equivalent value on the Chiron test; or 2.4 All of the following: 2.4.1 Asymptomatic patient; and 2.4.2 Patient aged 1 to 5 years; and 2.4.3 CD4 counts < 1,000 cells/mm3; or 2.5 All of the following: 2.5.1 Asymptomatic patient; and 2.5.2 Patient aged 1 to 5 years; and 2.5.3 CD4 counts < 0.25 x total white cell count; or 2.6 All of the following: 2.6.1 Asymptomatic patient; and 2.6.2 Patient aged 6 years and over
Special Authority for Subsidy - Form SA0579Initial application - (Cystic fibrosis or renal failure) only from a relevant specialist. Approvals valid for 3 years for applications meeting the following criteria: Either: 1 cystic fibrosis; or 2 chronic renal failure or continuous ambulatory peritoneal dialysis (CAPD) patient. Initial application - (Indications other than cystic fibrosis or renal failure) only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria: Any of the following: 1 cancer in children; or 2 cancers affecting alimentary tract where there are malabsorption problems in patients over the age of 20 years; or 3 failure to thrive; or 4 growth deficiency; or 5 bronchopulmonary dysplasia; or 6 premature and post premature infant. Renewal - (Cystic fibrosis or renal failure) only from a relevant specialist or general practitioner on the recommendation of such a specialist. Approvals valid for 3 years for applicatio
Special Authority for Subsidy - Form SA0580Initial application - (Inborn errors of metabolism) only from a relevant specialist. Approvals valid for 3 years where inborn errors of metabolism. Initial application - (Indications other than inborn errors of metabolism) only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria: Any of the following: 1 failure to thrive ; or 2 growth deficiency; or 3 bronchopulmonary dysplasia ; or 4 fat malabsorption ; or 5 lymphangiectasia; or 6 short bowel syndrome ; or 7 infants with necrotising enterocolitis; or 8 biliary atresia. Renewal - (Inborn errors of metabolism) only from a relevant specialist or general practitioner on the recommendation of such a specialist. Approvals valid for 3 years for applications meeting the following criteria: Both: 1 The treatment remains appropriate and the patient is benefiting from treatment; and 2 General Practitioners must include the name of
Special Authority for Subsidy - Form SA0581Initial application - (Cystic fibrosis) only from a relevant specialist. Approvals valid for 3 years for applications meeting the following criteria: Both: 1 infant aged four years or under; and 2 cystic fibrosis. Initial application - (Indications other than cystic fibrosis) only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria: Both: 1 infant aged four years or under; and 2 Any of the following: 2.1 cancer in children; or 2.2 failure to thrive; or 2.3 growth deficiency; or 2.4 bronchopulmonary dysplasia; or 2.5 premature and post premature infants. Renewal - (Cystic fibrosis) only from a relevant specialist or general practitioner on the recommendation of such a specialist. Approvals valid for 3 years for applications meeting the following criteria: Both: 1 The treatment remains appropriate and the patient is benefiting from treatment; and 2 General Practiti
Special Authority for Subsidy - Form SA0582Initial application only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria: Either: 1 protein losing enteropathy; or 2 high protein needs (eg burns). Renewal only from a relevant specialist or general practitioner on the recommendation of such a specialist. Approvals valid for 1 year for applications meeting the following criteria: Both: 1 The treatment remains appropriate and the patient is benefiting from treatment; and 2 General Practitioners must include the name of the specialist and date contacted.
Special Authority for Subsidy - Form SA0585Initial application - (Cystic fibrosis) only from a relevant specialist. Approvals valid for 3 years for applications meeting the following criteria: All of the following: 1 Cystic fibrosis; and 2 other lower calorie products have been tried; and 3 patient has substantially increased metabolic requirements; and 4 Either: 4.1 The product is to be used as a supplement; or 4.2 The product is to be used as a complete diet.Initial application - (Indications other than cystic fibrosis) only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria: All of the following: 1 Any of the following: 1.1 any condition causing malabsorption ; or 1.2 failure to thrive ; or 1.3 increased nutritional requirements.; and 2 other lower calorie products have been tried; and 3 patient has substantially increased metabolic requirements; and 4 Either: 4.1 The product is to be used a
Special Authority for Subsidy - Form SA0587Initial application only from a relevant specialist. Approvals valid for 3 years for applications meeting the following criteria: Both: 1 acute or chronic renal failure; and 2 Either: 2.1 The product is to be used as a supplement (maximum 500 ml per day); or 2.2 The product is to be used as a complete diet.Renewal only from a relevant specialist or general practitioner on the recommendation of such a specialist. Approvals valid for 3 years for applications meeting the following criteria: All of the following: 1 The treatment remains appropriate and the patient is benefiting from treatment; and 2 Either: 2.1 The product is to be used as a supplement (maximum 500 ml per day); or 2.2 The product is to be used as a complete diet; and 3 General Practitioners must include the name of the specialist and date contacted.
Special Authority for Subsidy - Form SA0588Initial application only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria: Both: 1 CORD patients who have hypercapnia; and 2 Either: 2.1 The product is to be used as a supplement (maximum 500 ml per day); or 2.2 The product is to be used as a complete diet.Renewal only from a relevant specialist or general practitioner on the recommendation of such a specialist. Approvals valid for 1 year for applications meeting the following criteria: All of the following: 1 The treatment remains appropriate and the patient is benefiting from treatment; and 2 Either: 2.1 The product is to be used as a supplement (maximum 500 ml per day); or 2.2 The product is to be used as a complete diet; and 3 General Practitioners must include the name of the specialist and date contacted.
Special Authority for Subsidy - Form SA0589Initial application only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria: All of the following: 1 Anorexia and weight loss; and 2 Either: 2.1 decompensating liver disease without encephalopathy ; or 2.2 protein losing gastro-enteropathy; and 3 Either: 3.1 The product is to be used as a supplement (maximum 500 ml per day); or 3.2 The product is to be used as a complete diet.Renewal only from a relevant specialist or general practitioner on the recommendation of such a specialist. Approvals valid for 1 year for applications meeting the following criteria: All of the following: 1 The treatment remains appropriate and the patient is benefiting from treatment; and 2 Either: 2.1 The product is to be used as a supplement (maximum 500 ml per day); or 2.2 The product is to be used as a complete diet; and 3 General Practitioners must include the name of the specialis
Special Authority for Subsidy - Form SA0590Initial application only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria: All of the following: 1 infant aged one to six years; and 2 Any of the following: 2.1 any condition causing malabsorption ; or 2.2 failure to thrive; or 2.3 increased nutritional requirements; and 3 Either: 3.1 The product is to be used as a supplement (maximum 500 ml per day); or 3.2 The product is to be used as a complete diet.Renewal only from a relevant specialist or general practitioner on the recommendation of such a specialist. Approvals valid for 1 year for applications meeting the following criteria: All of the following: 1 The treatment remains appropriate and the patient is benefiting from treatment; and 2 Either: 2.1 The product is to be used as a supplement (maximum 500 ml per day); or 2.2 The product is to be used as a complete diet; and 3 General Practitioners must
Special Authority for Subsidy - Form SA0591Initial application only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria: Both: 1 Any of the following: 1.1 enteral feeding; or 1.2 nasogastric; or 1.3 nasoduodenal ; or 1.4 nasojejunal; or 1.5 gastrostomy/jejunostomy; and 2 Either: 2.1 The product is to be used as a supplement; or 2.2 The product is to be used as a complete diet.Renewal only from a general practitioner or relevant specialist. Approvals valid for 1 year for applications meeting the following criteria: All of the following: 1 The treatment remains appropriate and the patient is benefiting from treatment; and 2 Either: 2.1 The product is to be used as a supplement; or 2.2 The product is to be used as a complete diet; and 3 General Practitioners must include the name of the specialist and date contacted.
Special Authority for Subsidy - Form SA0592Initial application only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria: Both: 1 Any of the following: 1.1 malabsorption ; or 1.2 short bowel syndrome; or 1.3 enterocutaneous fistulas ; or 1.4 pancreatitis; and 2 Either: 2.1 The product is to be used as a supplement (maximum 500 ml per day); or 2.2 The product is to be used as a complete diet.NoteEach of these products is highly specialised and would be prescribed only by an expert for a specific disorder. The alternative is hospitalisation. Elemental 028 Extra is more expensive than other products listed in this section and should only be used where the alternatives have been tried first and/or are unsuitable. Renewal only from a relevant specialist or general practitioner on the recommendation of such a specialist. Approvals valid for 1 year for applications meeting the following criteria: All of the following:
Special Authority for Subsidy - Form SA0594Initial application only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria: Both: 1 Type I and II diabetics who require nutritional supplementation.; and 2 Either: 2.1 The product is to be used as a supplement (maximum 500 ml per day); or 2.2 The product is to be used as a complete diet.Renewal only from a relevant specialist or general practitioner on the recommendation of such a specialist. Approvals valid for 1 year for applications meeting the following criteria: All of the following: 1 The treatment remains appropriate and the patient is benefiting from treatment; and 2 Either: 2.1 The product is to be used as a supplement (maximum 500 ml per day); or 2.2 The product is to be used as a complete diet; and 3 General Practitioners must include the name of the specialist and date contacted.
Special Authority for Subsidy - Form SA0595Initial application only from a relevant specialist. Approvals valid for 1 year where patient has motor neurone disease with swallowing disorder. Renewal only from a relevant specialist or general practitioner on the recommendation of such a specialist. Approvals valid for 1 year for applications meeting the following criteria: Both: 1 The treatment remains appropriate and the patient is benefiting from treatment; and 2 General Practitioners must include the name of the specialist and date contacted.
Special Authority for Subsidy - Form SA0596Initial application only from a relevant specialist. Approvals valid for 3 years for applications meeting the following criteria: Either: 1 gluten enteropathy has been diagnosed by biopsy; or 2 dermatitis herpetiformis. NoteA premium may be payable if the subsidy does not match the price charged by the manufacturer. The subsidy for these products reflects the philosophy that the patient incurs no additional financial burden for purchasing specialised more expensive products. Renewal only from a relevant specialist or general practitioner on the recommendation of such a specialist. Approvals valid for 3 years for applications meeting the following criteria: Both: 1 The treatment remains appropriate and the patient is benefiting from treatment; and 2 General Practitioners must include the name of the specialist and date contacted.
Special Authority for Subsidy - Form SA0597Initial application - (PKU Patient aged over 16) only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria: Both: 1 PKU; and 2 blood phenylalanine level < 900 mmol/litre (average of tests over last 12 months). Initial application - (Patient aged over 16) only from a relevant specialist. Approvals valid for 3 years for applications meeting the following criteria: Any of the following: 1 dietary management of homocystinuria; or 2 inborn errors of metabolism other than PKU; or 3 dietary management of maple syrup urine disease..Initial application - (Patient aged 16 or under) only from a relevant specialist. Approvals valid for 3 years for applications meeting the following criteria: Any of the following: 1 dietary management of homocystinuria; or 2 PKU and other inborn errors of metabolism; or 3 dietary management of maple syrup urine disease..Renewal - (PKU Patient aged over 16
Special Authority for Subsidy - Form SA0600Initial application only from a relevant specialist. Approvals valid for 3 years where inborn errors of metabolism. Renewal only from a relevant specialist or general practitioner on the recommendation of such a specialist. Approvals valid for 3 years for applications meeting the following criteria: Both: 1 The treatment remains appropriate and the patient is benefiting from treatment; and 2 General Practitioners must include the name of the specialist and date contacted.
Special Authority for Subsidy - Form SA0601Initial application only from a relevant specialist. Approvals valid for 1 year where Infant suffering from Williams Syndrome and associated hypercalcaemia. Renewal only from a relevant specialist or general practitioner on the recommendation of such a specialist. Approvals valid for 1 year for applications meeting the following criteria: Both: 1 The treatment remains appropriate and the patient is benefiting from treatment; and 2 General Practitioners must include the name of the specialist and date contacted.
Special Authority for Subsidy - Form SA0603Initial application only from a relevant specialist. Approvals valid for 1 year where infant suffering from malabsorption and other gastrointestinal problems. Renewal only from a relevant specialist or general practitioner on the recommendation of such a specialist. Approvals valid for 1 year for applications meeting the following criteria: Both: 1 The treatment remains appropriate and the patient is benefiting from treatment; and 2 General Practitioners must include the name of the specialist and date contacted.
Special Authority for Subsidy - Form SA0604Initial application - (Lactase deficiency or disaccharide intolerance) only from a relevant specialist. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 Patient is less than 3 years of age; and 2 Either: 2.1 diagnosed as suffering from congenital lactase deficiency; or 2.2 suffering from disaccharide intolerance. NoteSecondary lactose intolerance in children is usually short lasting, and can be controlled by dietary measures and by giving sufficient calories to regenerate digestive enzymes. The subsidy for these products reflects the philosophy that the patient incurs no additional financial burden for purchasing specialised more expensive products. Initial application - (Infant with intolerance to cows' milk) only from a relevant specialist. Approvals valid for 6 months for applications meeting the following criteria: Both: 1 intolerant to cows' milk; and 2 patient is less than 3 years of age. No
Special Authority for Subsidy - Form SA0605Initial application - (Cystic fibrosis or renal disorder) only from a relevant specialist. Approvals valid for 3 years for applications meeting the following criteria: Both: 1 Either: 1.1 cystic fibrosis; or 1.2 renal disorder; and 2 Either: 2.1 The product is to be used as a supplement; or 2.2 The product is to be used as a complete diet.Initial application - (Indications other than cystic fibrosis or renal disorder) only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria: Both: 1 Any of the following: 1.1 any condition causing malabsorption; or 1.2 failure to thrive; or 1.3 increased nutritional requirements; and 2 Either: 2.1 The product is to be used as a supplement; or 2.2 The product is to be used as a complete diet.Renewal - (Cystic fibrosis or renal disorder) only from a relevant specialist or general practitioner. Approvals valid for 3 years
Special Authority for Subsidy - Form SA0606Initial application only from a paediatrician. Approvals valid for 3 years for applications meeting the following criteria: Both: 1 child (up to 18 years) with chronic renal failure.; and 2 Either: 2.1 The product is to be used as a supplement; or 2.2 The product is to be used as a complete diet.Renewal only from a paediatrician. Approvals valid for 3 years for applications meeting the following criteria: Both: 1 The treatment remains appropriate and the patient is benefiting from treatment; and 2 Either: 2.1 The product is to be used as a supplement; or 2.2 The product is to be used as a complete diet.
Special Authority for Subsidy - Form SA0607Initial application only from a paediatrician. Approvals valid for 3 years for applications meeting the following criteria: Both: 1 Child (up to 18 years) who is awaiting liver transplant; and 2 Either: 2.1 The product is to be used as a supplement (maximum 500 ml per day); or 2.2 The product is to be used as a complete diet.Renewal only from a paediatrician. Approvals valid for 3 years for applications meeting the following criteria: Both: 1 The treatment remains appropriate and the patient is benefiting from treatment; and 2 Either: 2.1 The product is to be used as a supplement (maximum 500 ml per day); or 2.2 The product is to be used as a complete diet.
Special Authority for Subsidy - Form SA0609Initial application - (Serevent MDI, Serevent Accuhaler Foradil, Oxis Turbuhaler 12 mcg, Symbicort Turbuhaler) only from a relevant specialist or general practitioner. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 Both: 1.1 Child under the age of 12 with poorly controlled asthma; and 1.2 Either: 1.2.1 Required at least three months of 400 mcg or more daily inhaled beclomethasone or budesonide; or 1.2.2 Required at least three months of 200 mcg or more of fluticasone; or 2 Both: 2.1 Adult with poorly controlled asthma; and 2.2 Either: 2.2.1 Required at least three months of 1500 mcg or more daily inhaled beclomethasone or budesonide; or 2.2.2 Required at least three months of 750 mcg or more of fluticasone. NotePatients are to be reviewed at least at six months to assess compliance and effectiveness of therapy. Special Authority approvals are interchangeable among all prese
Special Authority for Subsidy - Form SA0610Initial application from any specialist. Approvals valid without further renewal unless notified for applications meeting the following criteria: All of the following: 1 Quantity used by patient on a weekly volume intraveneously (Details to be attached to application); and 2 Amount of nutrition patient is able to receive orally (Details to be attached to application); and 3 Exact formula of TPN (Details to be attached to application); and 4 Who has paid for TPN so far (Details to be attached to application); and 5 Place of manufacture (Details to be attached to application); and 6 Complete medical history of patient including details of previous therapies. (Details to be attached to application). Renewal - (Previous approval has expired) from any specialist. Approvals valid without further renewal unless notified where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0611Initial application from any medical practitioner. Approvals valid for 1 year where applicaton approved by the Cystic Fibrosis DN'ase Advisory Panel. NoteApplications to be made on the approved forms which are available from: The Co-ordinatorCystic Fibrosis DN'ase Advisory PanelPhone: (04) 460 4990 PHARMAC, PO Box 10 254 WellingtonFacsimile: (04) 916 7571Email: erin.murphy@pharmac.govt.nzPrescriptions for patients approved for treatment must be written by respiratory physicians or paediatricians who have experience and expertise in treating cystic fibrosis.
Special Authority for Alternate Subsidy - Form SA0613Initial application from any medical practitioner. Approvals valid for 2 years for applications meeting the following criteria: Any of the following: 1 Polycystic ovarian syndrome; or 2 Hirsutism; or 3 Androngenic alopecia. Renewal from any medical practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0614Initial application only from a geriatrician, rheumatologist, endocrinologist, gynaecologist or general physician. Approvals valid for 2 years for applications meeting the following criteria: All of the following: 1 Severe osteoporosis; and 2 History of one previous significant osteoporotic fractures demonstrated radiologically; and 3 T-Score <= -3.0 (bone mass density (BMD) >= 3.0 standard deviations below the mean normal value in young adults). NoteIn line with the Australian guidelines for funding alendronate, a vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral bodyRenewal only from a geriatrician, rheumatologist, endocrinologist, gynaecologist or general physician. Approvals valid for 2 years where the tr
Special Authority for Subsidy - Form SA0615Initial application only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria: Both: 1 The product is to be used as a complete diet; and 2 Either: 2.1 Patient has metabolic disorders of fat metabolism; or 2.2 Patient has chylothorax. Renewal only from a relevant specialist or general practitioner on the recommendation of such a specialist. Approvals valid for 1 year for applications meeting the following criteria: Both: 1 The treatment remains appropriate and the patient is benefiting from treatment; and 2 General Practitioners must include the name of the specialist and date contacted.
Special Authority for Manufacturers Price - Form SA0616Initial application - (Conditions other than transient ischaemic episodes) only from a cardiothoracic surgeon, cardiologist or general physician. Approvals valid without further renewal unless notified for applications meeting the following criteria: Either: 1 Patients with prosthetic heart valves - as an adjunct to oral anticoagulation for prophylaxis of thromboembolism; or 2 Patients after coronary artery vein bypass graft - as an adjunct to aspirin or as monotherapy for patients who are aspirin intolerant. NoteAspirin intolerant patients are defined as those with aspirin induced asthma, urticaria, or anaphylaxi, or those with significant aspirin induced bleeding, excluding bruisingInitial application - (Transient ischaemic episodes) only from a neurologist, neuro surgeon, cardiologist, vascular surgeon or general physician. Approvals valid without further renewal unless notified where patients who continue to have transient ischaemic
a) Prescribers may code prescriptions "contraceptive" (code "O") when used as indicated for contraception. The period of supply and prescription charge will be as per other contraceptives, as follows: - $3.00 prescription charge (patient co-payment) will apply; - prescription may be written for up to six months supply; and- pharmacists may dispense up to three months supply. b) Prescriptions coded in any other way are subject to the non-contraceptive prescription charges, and the non-contraceptive period of supply. ie. Prescriptions may be written for up to three months supply, and dispensed monthly
Special Authority for Subsidy - Form SA0621Initial application only from a relevant specialist. Approvals valid for 5 years where the patient is likely to benefit from treatment. Renewal only from a relevant specialist. Approvals valid for 5 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0622Initial application only from a geriatrician, rheumatologist, endocrinologist, gynaecologist or general physician. Approvals valid without further renewal unless notified for applications meeting the following criteria: All of the following: 1 Severe osteoporosis; and 2 History of one previous significant osteoporotic fractures demonstrated radiologically; and 3 T-Score <= -3.0 (bone mass density (BMD) >= 3.0 standard deviations below the mean normal value in young adults). NoteIn line with the Australian guidelines for funding alendronate, a vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral bodyRenewal only from a geriatrician, rheumatologist, endocrinologist, gynaecologist or general physician. Approvals va
Special Authority for Subsidy - Form SA0623Initial application from any medical practitioner. Approvals valid for 1 year for applications meeting the following criteria: All of the following: 1 The patient is not predisposed to heart arrhythmias; and 2 The patient does not have a pre-existing QT-prolongation or hepatic failure; and 3 The patient is not using other medications which either inhibit the cytochrome P450 3A4 enzyme system or prolong the QT interval; and 4 Any of the following: 4.1 Both: 4.1.1 The patient is an adult with severe reflux oesophagitis; and 4.1.2 other treatment, including acid suppression with proton pump inhibitors, has failed; or 4.2 gastroparesis; or 4.3 malignancy of GI tract causing gastroparesis (or gastric outlet obstruction); or 4.4 The patient is a child (not including infants from 0 to 3 months of age who were born prematurely) with severe gastro-oesophageal reflux; and 5 Diagnosis has been made or confirmed by a general p
Subsidy by endorsement Oral liquid is subsidised only for patients: - with oesophageal stricture, or- in terminal care, or- who are either too young or too old to swallow conventional tablets and the prescription is endorsed accordingly. Note: the cost of treatment with ranitidine oral liquid is more than 10 times higher than that of ranitidine tablets. Following the derestriction of access PHARMAC will be monitoring expenditure on ranitidine oral liquid more closely and may, subject to consultation and PHARMAC Board approval, restrict access again if the expenditure was to grow substantially.
Special Authority for Subsidy - Form SA0626Initial application only from a renal physician. Approvals valid for 2 years for applications meeting the following criteria: All of the following: General Criteria: 1 Anaemia of end-stage renal failure (other treatable causes of anaemia being excluded); and 2 Been on haemodialysis or continuous ambulatory peritoneal dialysis (CAPD) for at least three months; and 3 Not under evaluation for, or awaiting, a live donor kidney transplant; and 4 Any of the following: Specific Criteria: 4.1 Anephric; or 4.2 Dependent on regular blood transfusion (1 unit each 4-8 weeks) to maintain haemoglobin > 60g/L; or 4.3 Dependent on regular blood transfusion but cannot be transfused because of severe transfusion reactions; or 4.4 Transfusion induced haemosiderosis (clinical manifestations, serum ferritin >1500 ug/L); or 4.5 Haemoglobin < 70 g/L (mean of at least 4 haemoglobin concentrations over 4 months); or 4.6 Both: 4.6.1 Haemo
Prescribing GuidelineTreatment with HMG CoA Reductase Inhibitors (Statins) is recommended for patients withdyslipidaemia and an absolute 5 year cardiovascular risk of 15% or greater. New Zealand Cardiovascular Guideline Group statement. "The 1996 Heart Foundation guidelines for the Assessment and Management of Dyslipidaemia are currently being revised. An evidence-based guideline on the Assessment and Management of Cardiovascular Risk will be developed in 2002. The Cardiovascular Guideline Group has written an interim consensus statement for themanagement of dyslipidaemia. The Heart Foundation cardiovascular risk tables should be used to determine risk. Certain groups are classified to be at very high risk (>20%) and should be treated as such: - Patients who have had a previous cardiovascular event (angina, MI, angioplasty, coronary artery bypass grafts, TIA, ischaemic stroke and peripheral vascular disease)- Patients with genetic lipid disorders- Patients with diabetes and associated microa
Special Authority for Subsidy - Form SA0628Initial application only from a cardiologist. Approvals valid without further renewal unless notified for applications meeting the following criteria: Any of the following: 1 Both: 1.1 Congestive heart failure; and 1.2 Cannot tolerate two ACE inhibitors due to persistent cough that resolves on cessation and recurs on re-challenge with ACE inhibitor; or 2 Patients who have experienced angioedema on an ACE inhibitor at any time in the past; or 3 Patients who have experienced angioedema (even if not using an ACE inhibitor) in the last 2 years. Renewal - ((2 year approvals granted before April 2002)) only from a cardiologist. Approvals valid without further renewal unless notified where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0631Initial application only from an ophthalmologist. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 Both: 1.1 Primary open-angle glaucoma; and 1.2 Any of the following: 1.2.1 Patient cannot tolerate Beta-blockers, or Beta-blockers are contraindicated; or 1.2.2 Patient cannot tolerate Pilocarpine, or Pilocarpine is contraindicated; or 1.2.3 Patient cannot tolerate Dorzolamide, or Dorzolamide is contraindicated; or 1.2.4 A reduction in intraocular pressure of 15% or more is not achieved or maintained using dorzolamide either alone or in combination with a beta-blocker; or 2 There is progressive visual field loss and/or optic nerve damage persists after treatment with dorzolamide either alone or in combination with a beta-blocker. NoteSubsidised also for adjunctive use for the treatment of patients who have met the initial application criteria, and in whom latanoprost monotherapy has bee
Special Authority for Subsidy - Form SA0633Initial application only from a general practitioner or relevant specialist. Approvals valid without further renewal unless notified for applications meeting the following criteria: Both: 1 Patient is already on an ACE inhibitor or Angiotensin II Antagonist; and 2 Any of the following: 2.1 Both: 2.1.1 Symptomatic heart failure NYHA functional class II-III; and 2.1.2 Patient has been treated with metoprolol and is intolerant to metoprolol or has demonstrated a sub-optimal response to metoprolol; or 2.2 Symptomatic heart failure NYHA functional class III-IV; or 2.3 Patient has left ventricular systolic dysfunction with an ejection fraction of less than 35%.NoteWhere possible treatment should be initiated by or on the recommendation of a specialist.
Special Authority for Subsidy - Form SA0635Initial application only from a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria: All of the following: 1 Rheumatoid arthritis; and 2 Patient is not a pregnant woman, or a woman of child-bearing age without adequate contraception; and 3 Patient has been unable to tolerate or has a contraindication to or has had an inadequate response to sulphasalazine and methotrexate (individually or in combination). Renewal only from a rheumatologist. Approvals valid without further renewal unless notified for applications meeting the following criteria: Both: 1 Compliance (prescriber determined) with medication; and 2 Improved rheumatoid arthritis symptom control. NotePatient should have full blood count and liver function tests regularly monitored.
Retail pharmacy - subsidy by endorsement a) Subsidised for:i) patients presenting with first episode schizophrenia or related psychoses; andii) patients suffering from schizophrenia or related psychoses after a trial of an effective dose of risperidone that has been discontinued because of unacceptable side effects or inadequate response. b) Initial prescription must be written by a relevant specialist. c) Subsequent prescriptions may be written by a general practitioner. d) The prescription must be endorsed "certified condition".
Special Authority for Subsidy - Form SA0637Initial application - (National Heart Foundation risk groups A1:1, A1:2, B, C, D or E) only from a relevant specialist or general practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria: All of the following: 1 The patient has been offered 3-6 months of counseling and an opportunity to modify lifestyle; and 2 Any of the following: 2.1 Both: 2.1.1 NHF A1:1 - Clinically proven ischaemic heart disease; and 2.1.2 total cholesterol > 5.5; or 2.2 Both: 2.2.1 NHF A1:2 - Post coronary artery bypass graft (CABG) or angioplasty; and 2.2.2 total cholesterol > 4.5; or 2.3 Post heart transplant (regardless of cholesterol level); or 2.4 Both: 2.4.1 NHF B: Patients with > 20% 5-year cardiovascular disease risk; and 2.4.2 total cholesterol > 9.0; or 2.5 Both: 2.5.1 NHF C: 15-20% 5-year cardiovascular disease risk; and 2.5.2 total cholesterol >
Special Authority for Subsidy - Form SA0639Initial application - (No previous use) only from a relevant specialist or general practitioner. Approvals valid for 3 months for applications meeting the following criteria: All of the following: 1 The patient has a clinical diagnosis of heavy menstrual bleeding; and 2 The patient has failed to respond to or is unable to tolerate other appropriate pharmaceutical therapies as per the Heavy Menstrual Bleeding Guidelines; and 3 Either: 3.1 serum ferritin level < 16 mg/l (within the last 12 months); or 3.2 haemoglobin level < 120 g/l . NoteApplications are not to be made for use in patients as contraception except where they meet the above criteriaInitial application - (Previous use before 1 October 2002) only from a relevant specialist or general practitioner. Approvals valid for 3 months for applications meeting the following criteria: All of the following: 1 The patient had a clinical diagnosis of heavy menstrual bleeding; and 2
Special Authority for Manufacturers Price - Form SA0640Initial application only from a relevant specialist. Approvals valid for 3 years where patients being treated for advanced breast cancer who are refractory to tamoxifen. Renewal only from a relevant specialist. Approvals valid for 3 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Waiver of Rule - Form SA0641Initial application only from a diabetologist, general physician or paediatrician. Approvals valid without further renewal unless notified for applications meeting the following criteria: Either: 1 Both: 1.1 Use alone (monotherapy); and 1.2 The patient is unable to use any other insulins including those on insulin pump treatment; or 2 Both: 2.1 Use with insulin other than insulin isophane (including ready-mixed preparations); and 2.2 A reasonable trial of insulin isophane has been undertaken and it is not effective or not well tolerated. Note"Reasonable trial", "unable to use", "not effective", "not well tolerated", and "not well tolerated" are not defined and we ask clinicians to use their clinical judgement in interpreting these terms.
Special Authority for Subsidy - Form SA0643Initial application - (CML) only from an oncologist or relevant specialist. Approvals valid for 7 months where approved by the The Glivec Co-ordinator. Initial application - (GIST) only from an oncologist. Approvals valid for 1 year where approved by the The Glivec Co-ordinator. Renewal - (CML) only from an oncologist or relevant specialist. Approvals valid for 6 months where approved by the The Glivec Co-ordinator. Initial application - (GIST) only from an oncologist. Approvals valid for 1 year where approved by the The Glivec Co-ordinator. NoteApplication forms are available from, and prescriptions should be sent to: The Glivec Co-ordinatorPhone: 09 580 9176Level 3, Unisys HouseFacsimile: 09 580 9205650 Great South Road, PenroseEmail: murray@ppc.govt.nzPrivate Bag, AUCKLANDSpecial Authority criteria for CML - access by applicationFunded for patients with diagnosis (confirmed by a haematologist) of a chronic myeloid leukaemia (CML) i
Special Authority for Subsidy - Form SA0645Initial application only from a renal physician. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 Both: 1.1 patient in chronic renal failure; and 1.2 Haemoglobin <= 100 g/L; and 2 Either: 2.1 Both: 2.1.1 patient is not diabetic; and 2.1.2 glomerular filtration rate <= 30 ml/min; or 2.2 Both: 2.2.1 patient is diabetic; and 2.2.2 glomerular filtration rate <= 45 ml/min. Renewal only from a renal physician. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment. NoteErythropoietin beta is indicated in the treatment of anaemia associated with chronic renal failure (CRF) where no cause for anaemia other than CRF is detected and there is adequate monitoring of iron stores and iron replacement therapy. The Cockroft-Gault Formula may be used to estimate glomerular filtration rate (GFR) in persons 18 years and over:GFR (male)
Special Authority for Subsidy - Form SA0646Initial application only from a renal physician. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 Both: 1.1 patient in chronic renal failure; and 1.2 Haemoglobin <= 100 g/L; and 2 Any of the following: 2.1 Both: 2.1.1 patient is not diabetic; and 2.1.2 glomerular filtration rate <= 30 ml/min; or 2.2 Both: 2.2.1 patient is diabetic; and 2.2.2 glomerular filtration rate <= 45 ml/min; or 2.3 patient is on haemodialysis or peritoneal dialysis. Renewal only from a renal physician. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment. NoteErythropoietin beta is indicated in the treatment of anaemia associated with chronic renal failure (CRF) where no cause for anaemia other than CRF is detected and there is adequate monitoring of iron stores and iron replacement therapy. The Cockroft-Gault Formula may be used to estim
Special Authority for Manufacturers Price - Form SA0648Initial application - (Conditions other than transient ischaemic episodes) only from a cardiothoracic surgeon, cardiologist or general physician. Approvals valid without further renewal unless notified for applications meeting the following criteria: Either: 1 Patients with prosthetic heart valves - as an adjunct to oral anticoagulation for prophylaxis of thromboembolism; or 2 Patients after coronary artery vein bypass graft - as an adjunct to aspirin or as monotherapy for patients who are aspirin intolerant. NoteAspirin intolerant patients are defined as those with aspirin induced asthma, urticaria, or anaphylaxi, or those with significant aspirin induced bleeding, excluding bruisingInitial application - (Transient ischaemic episodes) only from a neurologist, neuro surgeon, cardiologist, vascular surgeon or general physician. Approvals valid without further renewal unless notified where patients who continue to have transient ischaemic
Special Authority for Subsidy - Form SA0649Initial application - (Conditions other than transient ischaemic episodes) only from a cardiothoracic surgeon, cardiologist or general physician. Approvals valid without further renewal unless notified for applications meeting the following criteria: Either: 1 Patients with prosthetic heart valves - as an adjunct to oral anticoagulation for prophylaxis of thromboembolism; or 2 Patients after coronary artery vein bypass graft - as an adjunct to aspirin or as monotherapy for patients who are aspirin intolerant. NoteAspirin intolerant patients are defined as those with aspirin induced asthma, urticaria, or anaphylaxi, or those with significant aspirin induced bleeding, excluding bruisingInitial application - (Transient ischaemic episodes) only from a neurologist, neuro surgeon, cardiologist, vascular surgeon or general physician. Approvals valid without further renewal unless notified where patients who continue to have transient ischaemic episodes des
Etidronate for osteoporosis should be prescribed for 14 days (400 mg in the morning) and repeated every three months. It should not be taken at the same time of the day as any calcium supplementation (minimum dose - 500 mg per day of elemental calcium). Etidronate should be taken at least 2 hours before or after any food or fluid, except water
Special Authority for Subsidy - Form SA0652Initial application - (Single NAED Therapy) only from a paediatrician, neurologist or general physician. Approvals valid for 15 months for applications meeting the following criteria: Any of the following: 1 Was on NAED therapy before 1 September 2000; or 2 Seizures are not adequately controlled with optimal older anti-epilepsy drug treatment; or 3 Seizures are controlled adequately but who experience unacceptable side effects from older anti-epilepsy drug treatment. Note"Optimal older anti-epilepsy drug therapy" is defined as treatment with those older anti-epilepsy drugs which are indicated and clinically appropriate for the patient, given singly and in combination in adequate doses for the patient's age, weight, and other features affecting the pharmacokinetics of the drug with good evidence of complianceInitial application - (Dual NAED Therapy) only from a paediatrician, neurologist or general physician. Approvals valid for 18 months for app
Additional subsidy by endorsement for:Calcium carbonate tablets x 1,000 (Titralac) up to $35.10 is available for pregnant women. The prescription must be endorsed accordingly. We recommend that the words used to indicate eligibility are "certified condition" however these particular words are not a requirement.
Special Authority for Subsidy - Form SA0657Initial application - (Helicobacter pylori infections) only from a general practitioner or relevant specialist. Approvals valid for 6 months for applications meeting the following criteria: Both: 1 Eradication of Helicobacter pylori in patient with proven infection; and 2 Peptic ulcer disease proven by endoscopy. NoteMaximum of two prescriptions (two courses) per patient. Initial application - (Mycobacterial infections) only from a respiratory specialist, infectious disease specialist or paediatrician. Approvals valid for 2 years for applications meeting the following criteria: Any of the following: 1 Mycobacterium Avium Intracellulare Complex infections in patient with AIDS; or 2 Atypical and drug-resistant mycobacterial infection; or 3 All of the following: 3.1 Prophylaxis against disseminated Mycobacterium Avium Intracellulare Complex infection; and 3.2 HIV infection; and 3.3 CD4 count <= 50 cells/mm3. Renewal - (Mycobact
Additional subsidy by endorsement for:Moclobemide tab 150 mg x 500 (Apo-Moclobemide) up to $46.00Moclobemide tab 150 mg x 100 (Aurorix) up to $32.90Moclobemide tab 300 mg x 100 (Apo-Moclobemide) up to $26.11Moclobemide tab 300 mg x 60 (Aurorix) up to $39.48Nefazodone tab 100 mg x 56 (Serzone) up to $20.16Nefazodone tab 200 mg x 56 (Serzone) up to $40.32Citalopram tab 20 mg x 28 (Celapram) up to $4.00Citalopram tab 20 mg x 28 (Cipramil) up to $10.00Paroxetine hydrochloride tab 20 mg x 30 (Aropax) up to $35.02is available for patients who: - were taking moclobemide or nefazodone on 1 December 1999 or citalopram on 1 February 2000; or paroxetine hydrochloride on February 2001; or- have previously responded to treatment with moclobemide or nefazodone or citalopram or paroxetine hydrochloride; or- have had a trial of fluoxetine and have had to discontinue due to- inability to tolerate the drug due to side effects; or- failed to respond to an adequate dose and duration of treatment; or
Special Authority for Subsidy - Form SA0661Initial application only from a psychiatrist. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 The patient has "treatment resistant" depression; and 2 Either: 2.1 The patient must have had a trial of two different antidepressants and failed to respond to an adequate dose over an adequate period of time (usually at least four weeks); or 2.2 Both: 2.2.1 The patient is currently a hospital in-patient as a result of an acute depressive episode; and 2.2.2 The patient must have had a trial of one other antidepressant and failed to respond to an adequate dose over an adequate period of time. Renewal from any medical practitioner. Approvals valid for 2 years where patient has a high risk of relapse (prescriber determined)..NoteFirst prescription can be written by a psychiatrist or psychiatric registrar. Subsequent prescriptions may be written by a General Practitioner
Prescribing GuidelinesBoth Trusopt and Cosopt are subsidised for use as either monotherapy or as an adjunctive agent for the treatment of glaucoma. Trusopt and Cosopt should not be prescribed for a person in whom less expensive first line agents for the treatment of glaucoma are not contraindicated unless: i) that person has previously trialled all other such subsidised agents (except brimonidine tartrate); andii) those trials have indicated that that person does not respond adequately to treatment with those other agents.
a) Spacer devices and masks also available to paediatricians employed by a DHB on a wholesalesupply order signed by the paediatrician. Limited to one pack of 20 per order. Orders via ahospital pharmacy. b) Only available for children aged six years and under. c) For Space Chamber and Foremount Child's Silicone Mask wholesale supply order must indicate clearly if either the spacer device, the mask, or both are required. d) Distributed by Airflow Products. Forward orders to: Airflow ProductsPO Box 1485 Telephone: 04 499 1240 or 0800 AIR FLOWWellington Facsimile: 04 499 1245 or 0800 323 270
Special Authority for Subsidy - Form SA0667Initial application only from a named specialist. Approvals valid for 4 months for applications meeting the following criteria: All of the following: 1 To be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and 2 Patient is less than 18 years of age at commencement of treatment; and 3 Patient has had severe active polyarticular course Juvenile Idiopathic Arthritis (JIA) for 6 months duration or longer; and 4 Patient has tried and not responded to at least three months of oral or parenteral methotrexate at a dose of 10-20mg/m2 weekly in combination with oral corticosteroids (prednisone 0.25 mg/kg); and 5 Patient has tried and not responded to at least three months of oral or parenteral methotrexate (at a dose of 10-15mg/m2 weekly) in combination with one other disease-modifying agent; and 6 Both: 6.1 Either: 6.1.1 Patient has persistent symptoms of poorly-cont
Additional subsidy by endorsement for:Nefazodone tab 100 mg x 56 (Serzone) up to $20.16Nefazodone tab 200 mg x 56 (Serzone) up to $40.32Citalopram tab 20 mg x 28 (Celapram) up to $4.00Citalopram tab 20 mg x 28 (Cipramil) up to $10.00Paroxetine hydrochloride tab 20 mg x 30 (Aropax) up to $35.02is available for patients who: -were taking nefazodone on 1 December 1999 or citalopram on 1 February 2000; or paroxetine hydrochloride on February 2001; or- have previously responded to treatment with nefazodone or citalopram or paroxetinehydrochloride; or- have had a trial of fluoxetine and have had to discontinue due to- inability to tolerate the drug due to side effects; or- failed to respond to an adequate dose and duration of treatment; or- have contraindications to fluoxetine (eg pre-existing significant levels of nausea, breastfeeding, potential drug interactions). The prescription must be endorsed accordingly.
Special Authority for Manufacturers Price - Form SA0673Initial application from any medical practitioner. Approvals valid for 3 months for applications meeting the following criteria: Both: 1 Patient considered unsafe to switch to m-Eslon; and 2 Patient was stabilised and well controlled on Kapanol, MST or LA-Morph before 1 December 2003. NoteSpecial Authority effective from 1 February 2004 to 31 July 2004
Rapid acting insulin analogues are subsidised when: 1) prescribed with insulin isophane or insulin glargine but are on a different prescription and the prescription is endorsed accordingly; or prescribed on the same prescription as insulin isophane or insulin glargine in which case the prescription is deemed to be endorsed; or2) a Special Authority has been approved. For 1and 2 first prescription to be written by a specialist (diabetologist, general physician or paediatrician). Any medical practitioner can writte subsequent prescriptions.
Special Authority for Subsidy - Form SA0693Initial application only from a relevant specialist or vocationally registered general practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria: All of the following: 1 Severe osteoporosis; and 2 History of one previous significant osteoporotic fracture demonstrated radiologically; and 3 T-Score <= -3.0 (bone mass density (BMD) >= 3.0 standard deviations below the mean normal value in young adults). NoteIn line with the Australian guidelines for funding alendronate, a vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral bodyRenewal - ((2 year approvals granted before February 2002)) only from a geriatrician, rheumatologist, endocrinologist, gynaecologis
Subsidy is available for patients with poorly controlled asthma where: a) at least three months of 750 mcg or more daily of inhaled beclomethasone or budesonide (or 400 mcg or fluticasone) for adults has been used; orb) at least three months of 400 mcg or more daily inhaled beclomethasone or budesonide (or 200 mcg or fluticasone) for children has been used; The prescription must be endorsed accordingly. We recommend that the words used to indicate eligibility are "poor control with ICS" or "certified exemption".
Special Authority for Subsidy - Form SA0696Initial application - (Narcolepsy) only from a neurologist or respiratory specialist. Approvals valid for 24 months where narcolepsy. Initial application - (ADHD in patients 5 or over) only from a paediatrician, psychiatrist or general practitioner on the recommendation of such a specialist. Approvals valid for 24 months for applications meeting the following criteria: All of the following: 1 ADHD (Attention Deficit and Hyperactivity Disorder) patients aged 5 years or over; and 2 Diagnosed according to DSM-IV or ICD 10 criteria; and 3 Either: 3.1 Applicant is a specialist; or 3.2 Both: 3.2.1 Applicant is a GP and a specialist has recommended treatment; and 3.2.2 Provide name of specialist (Details to be attached to application). Initial application - (ADHD in patients under 5) only from a paediatrician or psychiatrist. Approvals valid for 12 months for applications meeting the following criteria: Both: 1 ADHD (Attention Defi
Special Authority for Subsidy - Form SA0698Initial application only from a gastroenterologist, general surgeon or general physician. Approvals valid for 3 months for applications meeting the following criteria: Both: 1 Mild to moderate ileal, ileocaecal or proximal Crohn's disease; and 2 Any of the following: 2.1 Diabetes; or 2.2 Cushingoid habitus; or 2.3 Osteoporosis where there is significant risk of fracture; or 2.4 Severe acne following treatment with conventional corticosteroid therapy. Renewal only from a gastroenterologist, general surgeon or general physician. Approvals valid for 3 months where the treatment remains appropriate and the patient is benefiting from treatment. The patient must have had no more than 1 prior approval in the last year. NoteClinical trials for Entocort CIR use beyond three months demonstrated no improvement in relapse rate.
Special Authority for Subsidy - Form SA0699Initial application from any medical practitioner. Approvals valid for 1 year for applications meeting the following criteria: All of the following: 1 The patient is not predisposed to heart arrhythmias; and 2 The patient does not have a pre-existing QT-prolongation or hepatic failure; and 3 The patient is not using other medications which either inhibit the cytochrome P450 3A4 enzyme system or prolong the QT interval; and 4 Any of the following: 4.1 Both: 4.1.1 adult with severe reflux oesophagitis; and 4.1.2 other treatment, including acid suppression with proton pump inhibitors, has failed; or 4.2 gastroparesis; or 4.3 malignancy of GI tract causing gastroparesis (or gastric outlet obstruction); or 4.4 child (not including infants from 0 to 3 months of age who were born prematurely) with severe gastro-oesophageal reflux; and 5 Diagnosis has been made or confirmed by a general physician, gastroenterologist, or ge
Special Authority for Subsidy - Form SA0700Initial application only from an ophthalmologist. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 Both: 1.1 Monotherapy in primary open-angle glaucoma; and 1.2 Any of the following: 1.2.1 Patient cannot tolerate Beta-blockers, Pilocarpine and Dorzolamide; or 1.2.2 Beta-blockers, Pilocarpine and Dorzolamide are contraindicated; or 1.2.3 A reduction in intraocular pressure of 15% or more is not achieved or maintained using dorzolamide either alone or in combination with a beta-blocker; or 1.2.4 There is progressive visual field loss and/or optic nerve damage persists after treatment with dorzolamide either alone or in combination with a beta-blocker; or 2 Adjunctive use for the treatment of patients who have met the initial application criteria, and in whom latanoprost monotherapy has been ineffective in controlling intraocular pressure.Note An adjunctive agent may be added without a
Special Authority for Subsidy - Form SA0702Initial application - (Oral feed for cystic fibrosis patient) only from a relevant specialist. Approvals valid for 3 years for applications meeting the following criteria: Both: 1 Cystic fibrosis; and 2 Either: 2.1 The product is to be used as a supplement; or 2.2 The product is to be used as a complete diet.Initial application - (Oral feed for indications other than cystic fibrosis) only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria: Both: 1 Any of the following: 1.1 any condition causing malabsorption; or 1.2 failure to thrive; or 1.3 increased nutritional requirements; and 2 Either: 2.1 The product is to be used as a supplement; or 2.2 The product is to be used as a complete diet.Renewal - (Oral feed cystic fibrosis patient) only from a relevant specialist or general practitioner on the recommendation of such a specialist. Approvals valid for 3 years f
Special Authority for Subsidy - Form SA0703Initial application only from a relevant specialist or general practitioner. Approvals valid for 2 years for applications meeting the following criteria: All of the following: 1 Patient has raised blood pressure; and 2 The use of fully funded beta blockers is contraindicated, or not well tolerated; or where use of fully funded beta blockers and diuretics are insufficient to control blood pressure adequately at appropriate doses; and 3 Either: 3.1 Has been treated with, and cannot tolerate two ACE inhibitors, due to persistent cough; or 3.2 Has experienced angioedema on an ACE inhibitor at any time in the past or who have experienced angioedema (even if not using an ACE inhibitor) in the last 2 years. Renewal only from a relevant specialist or general practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0706Initial application only from a relevant specialist or general practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria: Either: 1 Both: 1.1 Patient with congestive heart failure; and 1.2 Either: 1.2.1 Has been treated with, and cannot tolerate, two ACE inhibitors, due to persistent cough; or 1.2.2 Has experienced angioedema on an ACE inhibitor at any time in the past or who have experienced angioedema (even if not using an ACE inhibitor) in the last 2 years; or 2 All of the following: 2.1 Patient with raised blood pressure; and 2.2 Use of fully funded beta blockers or diuretics are contraindicated; or not well tolerated; or insufficient to control blood pressure adequately at appropriate doses; and 2.3 Either: 2.3.1 Has been treated with, and cannot tolerate, two ACE inhibitors, due to persistent cough; or 2.3.2 Has experienced angioedema on an ACE in
Effective, consistent management of herpes from prescribing to these guidelines will improve patient outcomes. The guidelines on the following four pages are for the prescribing of aciclovir. The guidelines aim to: - improve patient care and clinical outcome through faster, more accessible treatment - protect patients' wider wellbeing by reinforcing the psychosocial aspects of treatment - improve the consistency and breadth of medical management of genital herpes in New Zealand. The guidelines are: - integral to ensuring a consistent, effective treatment regimen- the result of consultation with clinicians and patient representatives- set out in line with the recommended international algorithm format for treatment. The guidelines are endorsed by the Herpes Foundation's professional advisory board whose members represent venereology, NZDS, RNZCGP, RNZCOG, psychotherapy and nursing. Herpes Foundation Helpline: Toll free 0508 11 12 13Auckland Branch Herpes Foundation: 09 360 1966
Guidelines for the use of interferon in the treatment of hepatitis C: Physicians considering treatment of patients with hepatitis C should discuss cases with a gastroenterologist or aninfectious disease physician. All subjects undergoing treatment require careful monitoring for side effects. Patients should be otherwise fit. Hepatocellular carcinoma should be excluded by ultrasound examination and alpha-fetoprotein level. Criteria for Treatment a) Diagnosis- Anti-HCV positive on at least two occasions with a positive PCR for HCV-RNA and preferably confirmed by asupplementary RIBA test; or- PCR-RNA positive for HCV on at least 2 occasions if antibody negative; or- Anti-HCV positive on at least two occasions with a positive supplementary RIBA test with a negative PCR forHCV RNA but with a liver biopsy consistent with 2(b) following. b) Establishing Active Chronic Liver Disease- Confirmed HCV infection and serum ALT/AST levels measured on at least three occasions over six monthsaveraging >
Special Authority for Subsidy - Form SA0710Initial application only from an ophthalmologist. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 Either: 1.1 Monotherapy in primary open-angle glaucoma; or 1.2 Adjunctive use for the treatment of open-angle glaucoma in a patient who has met the initial application criteria, and in whom prostaglandin analogue monotherapy has been ineffective in controlling intraocular pressure; and 2 Any of the following: 2.1 Patient cannot tolerate beta-blockers, pilocarpine, and carbonic anhydrase inhibitors; or 2.2 Beta-blockers, pilocarpine and carbonic anhydrase inhibitors are contraindicated; or 2.3 A reduction in intraocular pressure of 15% or more is not achieved or maintained using carbonic anhydrase inhibitor either alone or in combination with a beta blocker; or 2.4 There is progressive visual field loss and/or optic nerve damage persists after treatment with carbonic anhydrase inhibitor either alo
Special Authority for Subsidy - Form SA0713Initial application from any specialist. Approvals valid for 11 months for applications meeting the following criteria: Either: 1 Patient has chronic hepatitis C, genotype 1, 4, 5 or 6 infection; or 2 Patient has chronic hepatitis C, genotype 2 or 3 infection with bridging fibrosis or cirrhosis (Metavir stage 3 or 4, or equivalent).
Special Authority for Subsidy - Form SA0714Initial application from any medical practitioner. Approvals valid for 3 months for applications meeting the following criteria: All of the following: 1 Patient is currently enrolled in a recognised comprehensive treatment programme for alcohol dependence in a service accredited against the New Zealand Alcohol and Other Drug Sector Standard or the National Mental Health Sector Standard; and 2 Applicant works in an Alcohol & Drug Service; and 3 Applicant must include the address of the service (Details to be attached to application). Renewal from any medical practitioner. Approvals valid for 3 months for applications meeting the following criteria: Both: 1 Compliance with the medication (prescriber determined); and 2 Any of the following: 2.1 Patient is still unstable and requires further treatment; or 2.2 Patient achieved significant improvement but requires further treatment; or 2.3 Patient is well controlled but requires maint
Prescribing GuidelinesTrusopt, Cosopt and Azopt are subsidised for use as either monotherapy or as an adjunctive agent for the treatment of glaucoma. Trusopt, Cosopt and Azopt should not be prescribed for a person in whom less expensive first line agents for the treatment of glaucoma are not contraindicated unless: a) that person has previously trialled all other such subsidised agents (except brimonidine tartrate); andb) those trials have indicated that that person does not respond adequately to treatment with those other agents.
Special Authority for Manufacturers Price - Form SA0717Initial application only from a relevant specialist or general practitioner. Approvals valid for 12 weeks for applications meeting the following criteria: Both: 1 Patient has a calculated absolute risk of cardiovascular disease of at least 15% over 5 years; and 2 Either: 2.1 Patient has severe documented intolerance to simvastatin; or 2.2 Both: 2.2.1 Patient has been compliant with a dose of simvastatin of 80 mg per day for at least 2 months; and 2.2.2 Either: 2.2.2.1 All of the following: 2.2.2.1.1 Patient has venous CABG; and 2.2.2.1.2 LDL cholesterol test 1 >= 2.0 mmol/litre; and 2.2.2.1.3 LDL cholesterol test 2 >= 2.0 mmol/litre (at least 1 week after test 1); or 2.2.2.2 All of the following: 2.2.2.2.1 Patient does not have venous CABG; and 2.2.2.2.2 LDL cholesterol test 1 >= 2.5 mmol/litre; and 2.2.2.2.3 LDL cholesterol test 2 >= 2.5 mmol/litre (at least 1 w
Special Authority for Subsidy - Form SA0721Initial application only from a named specialist. Approvals valid without further renewal unless notified for applications meeting the following criteria: All of the following: 1 The patient already has a Special Authority approval for anti-retroviral therapy (Details to be attached to application); and 2 Kaletra is to be used as a salvage therapy in place of one protease inhibitor; and 3 The patient must have trialed for at least six months and have failed on currently funded NNRTI based regimens or triple NRTI regimens; and 4 The patient must have trialed for at least six months and have failed on currently funded PI based regimens. NoteFailure is defined as: a) not achieving HIV RNA < 400 copies/ml after 24 weeks of a regimen, orb) an increase of HIV RNA to > 400 copies/ml on two separate occasions not less than one month apart, after suppression to < 400 copies/ml in a patient taking the regimen.
Special Authority for Subsidy - Form SA0722Initial application only from a relevant specialist. Approvals valid without further renewal unless notified for applications meeting the following criteria: Either: 1 Gluten enteropathy has been diagnosed by biopsy; or 2 Patient suffers from dermatitis herpetiformis.
Special Authority for Subsidy - Form SA0723Initial application only from a relevant specialist. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 All of the following: 1.1 Patient has a calculated absolute risk of cardiovascular disease >20% over 5 years; and 1.2 Patient cannot tolerate statin therapy at a dose of 40 mg per day; and 1.3 Either: 1.3.1 All of the following: 1.3.1.1 Patient has venous CABG; and 1.3.1.2 LDL cholesterol >= 2.0 mmol/litre (see note); and 1.3.1.3 LDL cholesterol >= 2.0 mmol/litre (at least 1 week after test 1 - see note); or 1.3.2 All of the following: 1.3.2.1 Patient does not have venous CABG; and 1.3.2.2 LDL cholesterol >= 2.5 mmol/litre (see note); and 1.3.2.3 LDL cholesterol >= 2.5 mmol/litre (at least 1 week after test 1 - see note); or 2 All of the following: 2.1 Patient has homozygous familial hypercholesterolemia, or heterozygous familial hypercholesterol
Special Authority for Manufacturers Price - Form SA0724Initial application only from a relevant specialist or general practitioner. Approvals valid for 12 weeks for applications meeting the following criteria: Both: 1 Patient has a calculated absolute risk of cardiovascular disease of at least 15% over 5 years; and 2 Either: 2.1 Patient has severe documented intolerance to simvastatin (blood tests are not required); or 2.2 Both: 2.2.1 Patient has been compliant with a dose of simvastatin of 80 mg per day for at least 2 months; and 2.2.2 Either: 2.2.2.1 All of the following: 2.2.2.1.1 Patient has venous CABG; and 2.2.2.1.2 LDL cholesterol test 1 >= 2.0 mmol/litre; and 2.2.2.1.3 LDL cholesterol test 2 >= 2.0 mmol/litre (at least 1 week after test 1); or 2.2.2.2 All of the following: 2.2.2.2.1 Patient does not have venous CABG; and 2.2.2.2.2 LDL cholesterol test 1 >= 2.5 mmol/litre; and 2.2.2.2.3 LDL cholesterol test 2 >
Special Authority for Subsidy - Form SA0725Initial application only from a relevant specialist or general practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria: All of the following: 1 Patient with raised blood pressure; and 2 Use of fully funded beta blockers and diuretics are contraindicated; or not well tolerated; or insufficient to control blood pressure adequately at appropriate doses; and 3 Either: 3.1 Has been treated with, and cannot tolerate, two ACE inhibitors, due to persistent cough; or 3.2 Has experienced angioedema on an ACE inhibitor at any time in the past or who have experienced angioedema (even if not using an ACE inhibitor) in the last 2 years. Renewal - (Previous approval has expired) only from a relevant specialist or general practitioner. Approvals valid without further renewal unless notified where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0727Initial application from any medical practitioner. Approvals valid for 1 year for applications meeting the following criteria: All of the following: 1 Control of intractable nausea, vomiting, or inability to swallow saliva in the treatment of malignancy or chronic disease; and 2 Patient cannot tolerate or does not adequately respond to oral anti-nausea agents; and 3 The applicant must specify the underlying malignancy or chronic disease (Details to be attached to application). Renewal from any medical practitioner. Approvals valid for 1 year where the treatment remains appropriate and the patient is benefiting from treatment.
Retail pharmacy - subsidy by endorsement a) Subsidised for:(i) patients presenting with first episode schizophrenia or related psychoses, or manic episodes associated with bipolar disorder; and(ii) patients suffering from schizophrenia or related psychoses, or manic episodes associated with bipolar disorder, after a trial of an effective dose of risperidone that has been discontinued because of unacceptable side effects or inadequate response. b) Initial prescription must be written by a relevant specialist. c) Subsequent prescriptions may be written by a general practitioner. d) The prescription must be endorsed "certified condition".
Special Authority for Subsidy - Form SA0732Initial application only from a relevant specialist. Approvals valid for 3 years for applications meeting the following criteria: Either: 1 dietary management of homocystinuria; or 2 dietary management of maple syrup urine disease. Renewal only from a relevant specialist or general practitioner on the recommendation of such a specialist. Approvals valid for 1 year for applications meeting the following criteria: Both: 1 The treatment remains appropriate and the patient is benefiting from treatment; and 2 General Practitioners must include the name of the specialist and date contacted.
Special Authority for Subsidy - Form SA0733Initial application - (Patient aged over 16) only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria: Both: 1 dietary management of PKU; and 2 blood phenylalanine level < 900 mmol/litre (average of tests over last 12 months). Initial application - (Patient aged 16 or under) only from a relevant specialist. Approvals valid for 3 years where dietary management of PKU.Renewal - (Patient aged over 16) only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria: blood phenylalanine level < 900 mmol/litre (average of tests over last 12 months). Renewal - (Patient aged 16 or under) only from a relevant specialist or general practitioner on the recommendation of such a specialist. Approvals valid for 3 years for applications meeting the following criteria: Both: 1 The treatment remains appropriate and the patient is benefiting from treatment; and 2
GuidelinesIt can cost up to $70,000 a year to keep an adult on protein supplements. Because protein substitutes are so expensive and because they are only effective in controlling PKU if a restricted diet is followed, adults with PKU will be required to demonstrate they are following the prescribed diet by regular blood testing. The requirement for testing applies to those aged over 16 years. Failure to follow an appropriate diet results in high blood phenylalanine levels. Those consistently testing above 15 mg (900 micromol) over a twelve month period will not be able to claim these products as a Special Authority. Specialists will be required to renew applications for their PKU patients every year and, when they do so, will have to submit the results of two blood tests.
Neocate should be used only as a last resort when the infant is unable to absorb any of the above formulae. The objective with each of thees formulae prescribed is to get the infant off them as soon as possible. This may take six months, it may take three years. Because of this, variation on age limit is not regarded as appropriate.These formulae will be available only from a hospital pharmacy. Vivonex Pediatric may be a suitable and less expensive alternative for many children that would otherwise be eligible for a subsidy for Neocate and should, therefore, be tried first in these cases. The subsidy for these products reflects the philosophy that the patient incurs no additional financial burden for purchasing specialised more expensive products.
Special Authority for Subsidy - Form SA0738Initial application only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria: Either: 1 All of the following: 1.1 To be used as monotherapy for patients with type 2 diabetes who after six months of diet and lifestyle changes do not have adequate glycaemic control (inadequate control defined as HbA1c > 8.0% in tests carried out at least two months apart); and 1.2 Metformin is not tolerated or contraindicated. Intolerance and contraindications as defined in the notes below, a minimum of a four week trial period of metformin is required; and 1.3 Sulphonylurea is not tolerated or contraindicated. Overweight patients are only eligible under the criteria of contraindication to sulphonylureas if their body mass index (BMI) exceeds 35; or 2 Both: 2.1 For use in combination with a sulphonylurea when diet and lifestyle changes and a twelve month trial of sulphonylurea results in inadequate glycaem
Special Authority for Subsidy - Form SA0741Initial application only from a psychiatrist. Approvals valid for 2 years for applications meeting the following criteria: Any of the following: 1 Patient with first episode schizophrenia or related psychoses; or 2 Both: 2.1 Patient suffering from schizophrenia and related psychoses; or acute mania in bipolar disorder who is likely to benefit from anti-psychotic treatment; and 2.2 Either: 2.2.1 An effective dose of risperidone had been trialled and has been discontinued because of unacceptable side effects; or 2.2.2 An effective dose of risperidone had been trialled and has been discontinued because of inadequate clinical response after 4 weeks; or 3 The patient has suffered from an acute episode of schizophrenia or bipolar mania and has been treated with olanzapine short-acting intra-muscular injection. Renewal only from a psychiatrist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefit
Special Authority for Subsidy - Form SA0742Initial application - (genotype 1, 4, 5 or 6 infection) from any specialist. Approvals valid for 11 months where patient has chronic hepatitis C, genotype 1, 4, 5 or 6 infection. Initial application - (genotype 2 or 3 infection) from any specialist. Approvals valid for 6 months for applications meeting the following criteria: Both: 1 Patient has chronic hepatitis C, genotype 2 or 3 infection; and 2 Patient has bridging fibrosis or cirrhosis (Metavir stage 3 or 4 or equivalent).
Special Authority for Subsidy - Form SA0743Initial application only from a relevant specialist. Approvals valid for 3 months for applications meeting the following criteria: Both: 1 Patient is terminally ill and is opioid-responsive; and 2 Either: 2.1 is unable to take oral medication; or 2.2 is intolerant to morphine, or morphine is contraindicated..Renewal only from a relevant specialist or general practitioner. Approvals valid for 3 months where the treatment remains appropriate and the patient is benefiting from treatment.
Additional subsidy by endorsement for:Citalopram tab 20 mg x 28 (Celapram) up to $4.00Citalopram tab 20 mg x 28 (Cipramil) up to $10.00Paroxetine hydrochloride tab 20 mg x 30 (Aropax) up to $35.02is available for patients who: -were taking citalopram on 1 February 2000; or paroxetine hydrochloride on February 2001; or- have previously responded to treatment with citalopram or paroxetinehydrochloride; or- have had a trial of fluoxetine and have had to discontinue due to- inability to tolerate the drug due to side effects; or- failed to respond to an adequate dose and duration of treatment; or- have contraindications to fluoxetine (eg pre-existing significant levels of nausea, breastfeeding, potential drug interactions). The prescription must be endorsed accordingly.
Special Authority for Subsidy - Form SA0751Initial application only from an ophthalmologist. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 Either: 1.1 Monotherapy in primary open-angle glaucoma; or 1.2 Adjunctive use for the treatment of open-angle glaucoma in a patient who has met the initial application criteria, and in whom prostaglandin analogue monotherapy has been ineffective in controlling intraocular pressure; and 2 Any of the following: 2.1 Patient cannot tolerate beta-blockers, pilocarpine, and carbonic anhydrase inhibitors; or 2.2 Beta-blockers, pilocarpine and carbonic anhydrase inhibitors are contraindicated; or 2.3 A reduction in intraocular pressure of 15% or more is not achieved or maintained using carbonic anhydrase inhibitor either alone or in combination with a beta blocker; or 2.4 There is progressive visual field loss and/or optic nerve damage persists after treatment with carbonic anhydrase inhibitor either alo
(a) Subsidy is available between 1 March and 30 June of each year for patients who meet the following criteria, as set by the Ministry of Health: a) all people 65 years of age and over; b) people under 65 years of age with: i) the following cardiovascular disease: 1) ischaemic heart disease, 2) congestive heart disease, 3) rheumatic heart disease, 4) congenital heart disease, or 5) cerebo-vascular disease; ii) the following chronic respiratory disease: 1) asthma, if on a regular preventative therapy, or 2) other chronic respiratory disease with impaired lung function; iii) diabetes; iv) chronic renal disease; v) any cancer, excluding basal and squamous skin cancers if not invasive; vi) the following other conditions: 1) autoimmune disease, 2) immune suppression, 3) HIV, 4) transplant recipients, 5) neuromuscular and CNS diseases, 6) haemoglobinopathies, or 7) children on long term aspirin. The following conditions are excluded from funding: i) asthma not requiri
Special Authority for Manufacturers Price - Form SA0753Initial application only from a relevant specialist. Approvals valid for 3 years for applications meeting the following criteria: Both: 1 Patient is a postmenopausal women; and 2 Patient has hormone receptor positive advanced breast cancer (Stage IIIb, or metastatic Stage IV). Renewal only from a relevant specialist. Approvals valid for 3 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0754Initial application only from a named specialist. Approvals valid without further renewal unless notified for applications meeting the following criteria: All of the following: 1 The patient already has a Special Authority approval for anti-retroviral therapy (Details to be attached to application); and 2 Kaletra is to be used as a salvage therapy in place of one protease inhibitor; and 3 The patient must have trialed for at least six months and have failed on currently funded NNRTI based regimens or triple NRTI regimens; and 4 The patient must have trialed for at least six months and have failed on currently funded PI based regimens. NoteFailure is defined as: a) not achieving HIV RNA < 400 copies/ml after 24 weeks of a regimen, orb) an increase of HIV RNA to > 400 copies/ml on two separate occasions not less than one month apart, after suppression to < 400 copies/ml in a patient taking the regimen.
Special Authority for Subsidy - Form SA0755Initial application from any medical practitioner. Approvals valid for 2 years where the patient is likely to benefit from treatment. Note Applications to be made on the approved forms which are available from: Prof. Wayne CutfieldNational Co-ordinatorNew Zealand Growth Hormone CommitteeC/- Department of PaediatricsUniversity of AucklandPrivate Bag 92019AUCKLAND
Special Authority for Subsidy - Form SA0757Initial application only from a relevant specialist. Approvals valid for 6 months for applications meeting the following criteria: All of the following: 1 The patient is less than 2 years of age; and 2 Intolerant to cows' milk; and 3 Diagnosed as suffering from congenital lactase deficiency. Renewal only from a relevant specialist. Approvals valid for 6 months where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0758Initial application only from a general practitioner or relevant specialist. Approvals valid for 2 years for applications meeting the following criteria: All of the following: 1 To be used for the long-term maintenance treatment of bronchospasm and dyspnoea associated with COPD; and 2 In addition to standard treatment, the patient has trialled a dose of at least 40 mcg ipratropium q.i.d; and 3 The patient's breathlessness >= grade 4 according to the Medical Research Council dyspnoea scale (see note); and 4 FEV1 (litres) < 0.4 x predicted (litres); and 5 Either: 5.1 Patient is not a smoker (for reporting purposes only); or 5.2 Patient is a smoker and been offered smoking cessation councilling; and 6 The patient has been offered annual influenza immunisation. Renewal only from a general practitioner or relevant specialist. Approvals valid for 2 years for applications meeting the following criteria: All of the following: 1
a) Prescribers may code prescriptions "contraceptive" (code "O") when used as indicated for contraception. The period of supply and prescription charge will be as per other contraceptives, as follows: - $3.00 prescription charge (patient co-payment) will apply; - prescription may be written for up to six months supply. b) Prescriptions coded in any other way are subject to the non-contraceptive prescription charges, and the non-contraceptive period of supply. ie. Prescriptions may be written for up to three months supply.
(a) Subsidy is available between 1 March and 30 June of each year for patients who meet the following criteria, as set by the Ministry of Health: a) all people 65 years of age and over; b) people under 65 years of age with: i) the following cardiovascular disease: 1) ischaemic heart disease, 2) congestive heart disease, 3) rheumatic heart disease, 4) congenital heart disease, or 5) cerebo-vascular disease; ii) the following chronic respiratory disease: 1) asthma, if on a regular preventative therapy, or 2) other chronic respiratory disease with impaired lung function; iii) diabetes; iv) chronic renal disease; v) any cancer, excluding basal and squamous skin cancers if not invasive; vi) the following other conditions: 1) autoimmune disease, 2) immune suppression, 3) HIV, 4) transplant recipients, 5) neuromuscular and CNS diseases, 6) haemoglobinopathies, or 7) children on long term aspirin. The following conditions are excluded from funding: i) asthma not requiri
The number of test strips available on a prescription is restricted to 50 unless: a) Prescribed with insulin or a sulphonylurea but are on a different prescription and the prescription is endorsed accordingly; orb) Prescribed on the same prescription as insulin or a sulphonylurea in which case the prescription is deemed to be endorsed; orc) Prescribed for a pregnant woman with diabetes and endorsed accordingly.
Special Authority for Subsidy - Form SA0772Initial application only from a gastroenterologist, infectious disease specialist, paediatrician or general physician. Approvals valid for 1 year for applications meeting the following criteria: Both: 1 Any of the following: 1.1 All of the following: 1.1.1 HBsAg positive for more than 6 months; and 1.1.2 HBeAg positive or HBV DNA positive defined as >0.6 pg/ml by quantitative PCR at reference laboratory; and 1.1.3 ALT greater than twice upper limit of normal or stage 3 or 4 fibrosis on liver histology clinical/radiological evidence of cirrhosis; or 1.2 HBV DNA positive cirrhosis prior to liver transplantation; or 1.3 HBsAg positive and have had a liver, kidney, heart, lung or bone marrow transplant; or 1.4 Hepatitis B surface antigen positive (HbsAg) patient who is receiving chemotherapy for a malignancy, or who has received such treatment within the previous two months; and 2 All of the following: 2.1 No continuing
Additional subsidy by endorsement for:Paroxetine hydrochloride tab 20 mg x 30 (Aropax) up to $35.02is available for patients who: -were taking paroxetine hydrochloride on February 2001; or- have previously responded to treatment with paroxetinehydrochloride; or- have had a trial of fluoxetine and have had to discontinue due to- inability to tolerate the drug due to side effects; or- failed to respond to an adequate dose and duration of treatment; or- have contraindications to fluoxetine (eg pre-existing significant levels of nausea, breastfeeding, potential drug interactions). The prescription must be endorsed accordingly.
Special Authority for Subsidy - Form SA0774Initial application only from a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Any of the following: 1 The patient has advanced gastrointestinal malignancy; or 2 The patient has metastatic breast cancer*; or 3 Both: 3.1 The patient has poor venous access or needle phobia*; and 3.2 The patient requires a substitute for single agent fluoropyrimidine*. Renewal only from a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Either: 1 The patient requires continued therapy; or 2 The tumour has relapsed and requires re-treatment. Noteindications marked with * are unapproved indications.
Special Authority for Subsidy - Form SA0775Initial application only from a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Both: 1 The patient has metastatic colorectal cancer; and 2 Either: 2.1 To be used for first or second line use as part of a combination chemotherapy regimen; or 2.2 As single agent chemotherapy in fluropyrimidine-relapsed disease. Renewal only from a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Either: 1 The patient requires continued therapy; or 2 The tumour has relapsed and requires re-treatment.
Special Authority for Subsidy - Form SA0776Initial application only from a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Any of the following: 1 Both: 1.1 The patient has ovarian, fallopian* or primary peritoneal cancer*; and 1.2 Either: 1.2.1 Has not received prior chemotherapy; or 1.2.2 Has received prior chemotherapy but has not previously been treated with taxanes; or 2 The patient has metastatic breast cancer; or 3 Both: 3.1 The patient has non-small cell lung cancer; and 3.2 Either: 3.2.1 The patient has advanced disease (stage IIIa or above); or 3.2.2 The patient is receiving combined chemotherapy and radiotherapy; or 4 Both: 4.1 The patient has small-cell lung cancer*; and 4.2 Paclitaxel is to be used as second-line therapy. Renewal only from a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Both: 1 The patient has metastati
Special Authority for Subsidy - Form SA0777Initial application - (Post-transplant) only from a relevant specialist. Approvals valid for 6 months where the patient has B-cell post-transplant lymphoproliferative disorder*. NoteFor no more than 8 treatment cycles. Initial application - (Low-grade lymphomas) only from a relevant specialist. Approvals valid for 6 months where the patient has low grade NHL - relapsed disease following prior chemotherapy. NoteFor no more than 4 treatment cycles. Initial application - (Large cell lymphomas) only from a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Both: 1 The patient has treatment naive large B-cell NHL; and 2 To be used with CHOP (or alternative anthracycline containing multi-agent chemotherapy regime given with curative intent).NoteFor no more than 8 treatment cycles. Renewal - (Low-grade lymphomas) only from a relevant specialist. Approvals valid for 6 months for applications meeting
Special Authority for Subsidy - Form SA0779Initial application - (Confirmed HIV/AIDS) only from a named specialist. Approvals valid without further renewal unless notified for applications meeting the following criteria: Both: 1 Confirmed HIV infection; and 2 Any of the following: 2.1 Symptomatic patient; or 2.2 Patient aged 12 months and under; or 2.3 Both: 2.3.1 Patient aged 1 to 5 years; and 2.3.2 Any of the following: 2.3.2.1 CD4 counts < 1,000 cells/mm3; or 2.3.2.2 CD4 counts < 0.25 x total lymphocyte count; or 2.3.2.3 Viral load counts > 100,000 copies per ml; or 2.4 Both: 2.4.1 Patient aged 6 years and over; and 2.4.2 CD4 counts < 350 cells/mm3. NoteTenofovir disoproxil fumarate prescribed under endorsement for HIV/AIDS is included in the count of up to 3 subsidised antiretrovirals. Subsidies for a combination of up to three anti-retroviral medications, including a maximum of two protease inhibitors. Combinations including r
Special Authority for Subsidy - Form SA0780Initial application - (Single NAED Therapy) only from a paediatrician, neurologist or general physician. Approvals valid for 15 months for applications meeting the following criteria: Any of the following: 1 Was on NAED therapy before 1 September 2000; or 2 Seizures are not adequately controlled with optimal older anti-epilepsy drug treatment; or 3 Seizures are controlled adequately but who experience unacceptable side effects from older anti-epilepsy drug treatment. Note"Optimal older anti-epilepsy drug therapy" is defined as treatment with those older anti-epilepsy drugs which are indicated and clinically appropriate for the patient, given singly and in combination in adequate doses for the patient's age, weight, and other features affecting the pharmacokinetics of the drug with good evidence of complianceInitial application - (Dual NAED Therapy) only from a paediatrician, neurologist or general physician. Approvals valid for 18 months for app
Special Authority for Subsidy - Form: SA0781Initial application only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria: Any of the following: Monotherapy1 All of the following: 1.1 To be used as monotherapy for patients with type 2 diabetes who after six months of diet and lifestyle changes do not have adequate glycaemic control (inadequate control defined as HbA1c > 7.0% in tests carried out at least two months apart); and 1.2 Metformin is not tolerated or contraindicated. Intolerance and contraindications as defined in the notes below, a minimum of a four week trial period of metformin is required; and 1.3 Sulphonylurea is not tolerated or contraindicated. Obesity is only eligible under the criteria of contraindication to sulphonylureas if the patient's body mass index (BMI) exceeds 33 , intolerance as defined in the notes below; orIn combination with sulphonylurea2 Both: 2.1 For use in combination with a sulphonylure
Special Authority for Subsidy - Form SA0782Initial application - (No previous use) only from a relevant specialist or general practitioner. Approvals valid for 6 months for applications meeting the following criteria: All of the following: 1 The patient has a clinical diagnosis of heavy menstrual bleeding; and 2 The patient has failed to respond to or is unable to tolerate other appropriate pharmaceutical therapies as per the Heavy Menstrual Bleeding Guidelines; and 3 Either: 3.1 serum ferritin level < 16 mg/l (within the last 12 months); or 3.2 haemoglobin level < 120 g/l . NoteApplications are not to be made for use in patients as contraception except where they meet the above criteriaInitial application - (Previous use before 1 October 2002) only from a relevant specialist or general practitioner. Approvals valid for 6 months for applications meeting the following criteria: All of the following: 1 The patient had a clinical diagnosis of heavy menstrual bleeding; and 2
Special Authority for Manufacturers Price - Form: SA0783Initial application only from a relevant specialist. Approvals valid for 5 years for applications meeting the following criteria: All of the following: 1 Patient is a postmenopausal women; and2 Patient has hormone receptor positive advanced breast cancer; and3 Any of the following: 3.1 The cancer is advanced (Stage IIIb, or metastatic Stage IV); or 3.2 The patient has a very clear history of intolerance to tamoxifen; or 3.3 The use of tamoxifen is contraindicated due to a history of thromboembolic disease. Renewal only from a relevant specialist. Approvals valid without further renewal unless notified where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Manufacturers Price - Form SA0788Initial application only from a relevant specialist or general practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria: Both: 1 Patient has a calculated absolute risk of cardiovascular disease of at least 15% over 5 years; and 2 Either: 2.1 Patient has severe documented intolerance to simvastatin (blood tests are not required); or 2.2 Both: 2.2.1 Patient has been compliant with a dose of simvastatin of 80 mg per day for at least 2 months; and 2.2.2 Either: 2.2.2.1 All of the following: 2.2.2.1.1 Patient has venous CABG; and 2.2.2.1.2 LDL cholesterol test 1 >= 2.0 mmol/litre; and 2.2.2.1.3 LDL cholesterol test 2 >= 2.0 mmol/litre (at least 1 week after test 1); or 2.2.2.2 All of the following: 2.2.2.2.1 Patient does not have venous CABG; and 2.2.2.2.2 LDL cholesterol test 1 >= 2.5 mmol/litre; and 2.2.2.2.
Special Authority for Subsidy - Form SA0789Initial application only from a relevant specialist or vocationally registered general practitioner. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 The patient has "treatment resistant" depression; and 2 Either: 2.1 The patient must have had a trial of two different antidepressants and failed to respond to an adequate dose over an adequate period of time (usually at least four weeks); or 2.2 Both: 2.2.1 The patient is currently a hospital in-patient as a result of an acute depressive episode; and 2.2.2 The patient must have had a trial of one other antidepressant and failed to respond to an adequate dose over an adequate period of time. Renewal from any medical practitioner. Approvals valid for 2 years where patient has a high risk of relapse (prescriber determined).
Prescribing GuidelineBimatoprost, lantanoprost and travoprost are subsidised for use in the treatment of glaucoma as either monotherapy or as an adjunctive agent for patients in whom prostaglandin analogue monotherapy has been ineffective in controlling intraocular pressure.Bimatoprost, lantanoprost and travoprost should not be prescribed for a person in whom less expensive first line agents for the treatment of glaucoma are not contraindicated unless: 1 That person has previously trialled all other such subsidised agents (beta-blockers, pilocarpine, carbonic anhydrase inhibitors); and2 Those trials have indicated that that person does not respond adequately to treatment with those other agents.
Special Authority for Subsidy - Form: SA0792Initial application only from a psychiatrist. Approvals valid for 6 months for applications meeting the following criteria: All of the following: 1 The patient has schizophrenia or other psychotic disorder; and2 Has tried but failed to comply with treatment using oral atypical anti-psychotic agents; and3 Has been admitted to hospital or treated in respite care, or intensive outpatient or home-based treatment for 30 days or more in last 12 months. Renewal only from a psychiatrist. Approvals valid for 12 months for applications meeting the following criteria: Either: 4 Both: 4.1 The patient has had less than 12 months treatment with risperidone microspheres; and 4.2 There is no clinical reason to discontinue treatment; or5 The initiation of risperidone microspheres has been associated with fewer days of intensive intervention than was the case during a corresponding period of time prior to the initiation of risperidone microspheres. NoteRisp
Special Authority for Subsidy - Form: SA0796Initial application only from a relevant specialist. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 Either: 1.1 ezetimibe is to be used in combination with simvastatin; or 1.2 ezetimibe is to be used without a statin; and2 Either: 2.1 All of the following: 2.1.1 Patient has a calculated absolute risk of cardiovascular disease >20% over 5 years; and 2.1.2 Patient cannot tolerate statin therapy at a dose of 40 mg per day; and 2.1.3 Either: 2.1.3.1 All of the following: 2.1.3.1.1 Patient has venous CABG; and 2.1.3.1.2 LDL cholesterol >= 2.0 mmol/litre (see note); and 2.1.3.1.3 LDL cholesterol >= 2.0 mmol/litre (at least 1 week after test 1 - see note); or 2.1.3.2 All of the following: 2.1.3.2.1 Patient does not have venous CABG; and 2.1.3.2.2 LDL cholesterol >= 2.5 mmol/litre (see note); and 2.1.3.2.3 LDL cholest
Special Authority for Subsidy - Form: SA0797Initial application - (Underlying cause - Osteoporosis) only from a relevant specialist or vocationally registered general practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria: Any of the following: 1 History of one significant osteoporotic fracture demonstrated radiologically and documented bone mass density (BMD) >= 2.5 standard deviations below the mean normal value in young adults (i.e. T-Score <= -2.5); or2 History of one significant osteoporotic fracture demonstrated radiologically and the patient is either over 75 years of age or is too frail* to undergo a bone mass density scan; or3 History of two significant osteoporotic fractures demonstrated radiologically; or4 Documented T-Score <= -3.0. Note*The patient may be considered to be frail if it is expected that there is significant risk of further fracture or other negative health outcome if the patient were to undergo a BMD s
Special Authority for Subsidy - Form: SA0798Initial application only from a relevant specialist. Approvals valid without further renewal unless notified for applications meeting the following criteria: Either: 1 Renal transplant recipient; or2 Heart transplant recipient. or; 3 Patient has an organ transplant and has severe tophaceous gout making azathioprine unsuitableRenewal only from a relevant specialist. Approvals valid without further renewal unless notified where patient had a previous Special Authority approval and was receiving mycophenolate prior to 1 October 2005
Special Authority for Subsidy - Form: SA0799Initial application only from a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Either: 1 The patient has metastatic breast cancer; or2 The patient has non-small cell lung cancer (stage IIIa, or above).Renewal only from a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Either: 3 The patient requires continued therapy; or4 The tumour has relapsed and requires re-treatment.
Special Authority for Subsidy - Form SA0801Initial application - (Serevent Accuhaler, Foradil, Symbicort Turbuhaler) only from a relevant specialist or general practitioner. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 Both: 1.1 Child under the age of 12 with poorly controlled asthma; and 1.2 Either: 1.2.1 Required at least three months of 400 mcg or more daily inhaled beclomethasone or budesonide; or 1.2.2 Required at least three months of 200 mcg or more of fluticasone; or 2 Both: 2.1 Adult with poorly controlled asthma; and 2.2 Either: 2.2.1 Required at least three months of 1500 mcg or more daily inhaled beclomethasone or budesonide; or 2.2.2 Required at least three months of 750 mcg or more of fluticasone. NotePatients are to be reviewed at least at six months to assess compliance and effectiveness of therapy. Special Authority approvals are interchangeable among all presentations of inhaled long-acting beta
Special Authority for Subsidy - Form SA0802Initial application - (genotype 1, 4, 5 or 6 infection or co-infection with HIV) from any specialist. Approvals valid for 11 months for applications meeting the following criteria: 1. Patient has chronic hepatitis C, genotype 1, 4, 5 or 6 infection; or2. Patient has chronic hepatitis C and is co-infected with HIV. Note: consider stopping treatment if there is absence of a virological response (defined as at least a 2-log reduction in viral load) following 12 weeks of treatment since this is predictive of treatment failure.Initial application - (genotype 2 or 3 infection without co-infection with HIV) from any specialist. Approvals valid for 6 months for applications meeting the following criteria: 3. Patient has chronic hepatitis C, genotype 2 or 3 infection; andEither: 3.1 Patient has bridging fibrosis or cirrhosis (Metavir stage 3 or 4 or equivalent); or 3.2 is unsuitable for liver biopsy due to coagulopathy.
Special Authority for Subsidy - Form SA0803Initial application from any specialist. Approvals valid for 11 months for applications meeting the following criteria: either: 1 Patient has chronic hepatitis C, genotype 1, 4, 5 or 6 infection; or2 Patient has chronic hepatitis C, genotype 2 or 3 infection; and 2.1 With has bridging fibrosis or cirrhosis (Metavir stage 3 or 4, or equivalent). 2.2 is unsuitable for liver biopsy due to coagulopathy. Note: consider stopping treatment if there is absence of a virological response (defined as at least a 2-log reduction in viral load) following 12 weeks of treatment since this is predictive of treatment failure.
Prescribing Guideline for Inhaled Long-Acting Beta-Adrenoceptor AgonistsThe addition of inhaled long-acting beta-adrenoceptor agonists (LABAs) to inhaled corticosteroids is recommended: - For younger children (aged under 12 years) where asthma is poorly controlled despite using inhaled corticosteroids for at least three months at total daily doses of 200 mcg beclomethasone or budesonide (or 100 mcg fluticasone).- For adults and older children (aged 12 years and over) where asthma is poorly controlled despite using inhaled corticosteroids for at least three months at total daily doses of 400 mcg beclomethasone or budesonide (or 200 mcg fluticasone).Note: Further information on the place of inhaled corticosteroids and inhaled LABAs in the management of asthma can be found in the New Zealand guidelines for asthma in adults (www.nzgg.org.nz) and in the New Zealand guidelines for asthma in children aged 1-15 (www.paediatrics.org.nz).
Access by applicationa) Budget managed by appointed clinicians on the Multiple Sclerosis Treatment Assessments Committee (MSTAC). b) Applications will be considered by MSTAC at its regular meetings and approved subject to eligibility according to the Entry and Stopping criteria (below). c) Applications to be made on the approved forms which are available from the co-ordinator for MSTAC:The Co-ordinator Phone: (04) 460 4990Multiple Sclerosis Treatment Assessments Committee Facsimile: (04) 916 7571PHARMAC, PO Box 10 254 E mail: silvia.valsenti@pharmac.govt.nzWellingtond) Completed application forms must be sent to the co-ordinator for MSTAC and will be considered by MSTAC at the next practicable opportunity. e) Notification of MSTAC's decision will be sent to the patient, the applying clinician and the patient's GP (if specified). f) These agents will not be subsidised if dispensed from a community or hospital pharmacy. Regular supplies will be distributed to all approved patients or their c
a) Subsidised only if prescribed for a dialysis or cystic fibrosis patient; orb) for the treatment of confirmed ciprofloxacin-resistant gonorrhoea; orc) for the treatment of suspected meningitis in patients who have a known allergy to penicillin; andd) the prescription or PSO is endorsed accordingly
Special Authority for Subsidy Initial application only from a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: 1 The patient has metastatic colorectal cancer; and2 To be used for first or second line use as part of a combination chemotherapy regimen. Renewal only from a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: 3 The patient requires continued therapy; or4 The tumour has relapsed and requires re-treatment.
Special Authority for Subsidy - Form: SA0809Initial application only from a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Any of the following: 1 Both: 1.1 The patient has ovarian*, fallopian* or primary peritoneal cancer*; and 1.2 Either: 1.2.1 Has not received prior chemotherapy; or 1.2.2 Has received prior chemotherapy but has not previously been treated with taxanes; or2 The patient has metastatic breast cancer; or3 Both: 3.1 The patient has non small-cell lung cancer; and 3.2 Either: 3.2.1 Has advanced disease (stage IIIa or above); or 3.2.2 Is receiving combined chemotherapy and radiotherapy; or4 Both: 4.1 The patient has small-cell lung cancer*; and 4.2 Docetaxel is to be used as second-line therapy. Renewal only from a relevant specialist. Approvals valid for 12 months for applications meeting the followingcriteria: 5. The patient has metastatic breast cancer, non small-cell lung cancer,
Special Authority for Alternate SubsidyInitial application only from a relevant specialist. Approvals valid for 5 years for applications meeting the following criteria: All of the following: 1 Patient is a postmenopausal women; and2 Patient has hormone receptor positive breast cancer; and3 Any of the following: 3.1 The cancer is advanced (Stage IIIb, or metastatic Stage IV); or 3.2 The patient has a very clear history of intolerance to tamoxifen; or 3.3 The use of tamoxifen is contraindicated due to a history of thromboembolic disease. Renewal only from a relevant specialist. Approvals valid without further renewal unless notified where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Alternate SubsidyInitial application only from a relevant specialist. Approvals valid for 5 years for applications meeting the following criteria: All of the following: 1 Patient is a postmenopausal women; and2 Patient has hormone receptor positive breast cancer; and3 Any of the following: 3.1 The cancer is advanced (Stage IIIb, or metastatic Stage IV); or 3.2 The patient has a very clear history of intolerance to tamoxifen; or 3.3 The use of tamoxifen is contraindicated due to a history of thromboembolic disease. Renewal only from a relevant specialist. Approvals valid without further renewal unless notified where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for SubsidyInitial application only from a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria: All of the following1 Patient is an adult who has had severe and active erosive Rheumatoid Arthritis for six months duration or longer; and2 Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and3 Patient has tried and not responded to at least three months of oral or parenteral methotrexate at a dose of at least 20 mg weekly or a maximum tolerated dose; and4 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with at least two of the following (triple therapy): sulphasalazine, prednisone at a dose of at least 7.5 mg per day, azathioprine, intramuscular gold, or hydroxychloroquine sulphate (at maximum tolerated doses); and5 Patient has tried and not responded to at least three months therapy at th
Special Authority for Subsidy Initial application only from a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Any of the following: 1 The patient has non small cell lung carcinoma (stage IIIa, or above); or2 The patient has advanced malignant mesothelioma*; or3 The patient has advanced pancreatic carcinoma; or4 The patient has ovarian, fallopian tube* or primary peritoneal carcinoma*. Renewal only from a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Both: 5 The patient requires continued therapy; or6 The tumour has relapsed and requires re-treatment. Note indications marked with a * are unapproved indications.
Special Authority for Subsidy Initial application only from a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Both: 1 The patient has primary thrombocythaemia; and2 Either 2.1 is at high risk (previous thromboembolic disease, bleeding or platelet count >1500/ml); or 2.2 is intolerant or refractory to hydroxyurea or interferon. Renewal only from a relevant specialist. Approvals valid for 12 months where the treatment remains appropriate and the patient is benefiting from treatment. NoteIt is recommended that treatment with anagrelide be initiated only on the recommendation of a haematologist.
Special Authority for Subsidy Initial application - (for new patients) only from a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Both: 1 The patient has refractory, progressive or relapsed multiple myeloma; and2 The patient has received prior chemotherapy. Initial application - (for patients receiving thalidomide prior to 1 January 2006) only from a relevant specialist. Approvals valid without further renewal where the patient was receiving treatment with thalidomide for multiple myeloma on or before 31 December 2005. Renewal only from a relevant specialist. Approvals valid without further renewal where the patient has obtained a response from treatment during the initial approval period. Note: Prescription must be written by registered prescriber in the thalidomide risk management programme operated by the supplier. Maximum dose of 400 mg daily as monotherapy or in a combination therapy regimen.
Special Authority for Subsidy Initial application for patients with type 2 diabetes only from a relevant specialist. Approvals valid for one year for applications meeting the following criteria: Any of the following: Monotherapy1 All of the following: 1.1 To be used as monotherapy for patients who after six months of diet and lifestyle changes have inadequate glycaemic control (defined as HbA1c > 7.0% in tests carried out at least two months apart); and 1.2 Metformin is contraindicated or not tolerated after a minimum of a four week trial period; and 1.3 Sulphonylurea is contraindicated or not tolerated or the patient's body mass index (BMI) exceeds 33 kg/m2; orIn combination with sulphonylurea2 Both: 2.1 For use in combination with a sulphonylurea for patients who after diet and lifestyle changes and a six-month trial of sulphonylurea have poor glycaemic control (defined as HbA1c > 8.0% measured within the last month of the six month period); and 2.2 Metformin is contrain
Prescribing GuidelineCombigan is subsidised for use as either monotherapy or as an adjunctive agent for the treatment of glaucoma. Combigan should only be prescribed when: a) less expensive first line agents for the treatment of glaucoma are contraindicated; orb) the response to such subsidised agents is inadequate; orc) the patient cannot tolerate such subsidised agents.
Perindopril and trandolapril will be funded to the level of the ex-manufacturer price listed in the Schedule for patients who were taking these ACE inhibitors for the treatment of congestive heart failure prior to 1 June 1998. The prescription must be endorsed accordingly. We recommend that the words used to indicate eligibility are "certified condition" or an appropriate description of the patient such as "congestive heart failure", "CHF", "congestive cardiac failure" or "CCF". Definition of Congestive Heart Failure At the request of some prescribers the PTAC Cardiovascular subcommittee has provided a definition of congestive heart failure for the purposes of the funding of the manufacturer's surcharge: "Clinicians should use their clinical judgement. Existing patients would be eligible for the funding of the surcharge if the patient shows signs and symptoms of congestive heart failure, and requires or has in the past required concomitant treatment with a diuretic. The definition could also be considere
Special Authority for Subsidy - Form: SA0826Initial application only from a relevant specialist. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 All of the following: 1.1 Patient has a calculated absolute risk of cardiovascular disease >20% over 5 years; and 1.2 Patient cannot tolerate statin therapy at a dose of >= 40 mg per day; and 1.3 Either: 1.3.1 All of the following: 1.3.1.1 Patient has venous CABG; and 1.3.1.2 LDL cholesterol >= 2.0 mmol/litre (see note); and 1.3.1.3 LDL cholesterol >= 2.0 mmol/litre (at least 1 week after test 1 - see note); or 1.3.2 All of the following: 1.3.2.1 Patient does not have venous CABG; and 1.3.2.2 LDL cholesterol >= 2.5 mmol/litre (see note); and 1.3.2.3 LDL cholesterol >= 2.5 mmol/litre (at least 1 week after test 1 - see note); or2 All of the following: 2.1 Patient has homozygous familial hypercholesterolemia, or heterozygous familial hypercholest
Special Authority for Subsidy - Retail Pharmacy - Form SA0829Initial Application only from gastroenterologist or infectious disease specialist. Approvals valid for 1 year for applications meeting the following criteria: All of the following: 1. Patient has confirmed Hepatitis B infection (HBsAg+); andDocumented resistance to lamivudine, defined as: 2. patient has raised serum ALT (> 1 x ULN); and3. patient has HBV DNA greater than 100,000 copies per mL, or viral load ? 10 fold over nadir; and4. detection of M204I or M204V mutation; and5. Either5.1. Both5.1.1. patient is cirrhotic; and5.1.2. adefovir dipivoxil to be used in combination with lamivudine; or5.2. Both5.2.1. patient is not cirrhotic; and5.2.2. adefovir dipivoxil to be used as monotherapyRenewal only from a gastroenterologist or infectious disease specialist. Approvals valid for 2 years for applications where in the opinion of the treating physician, treatment remains appropriate and patient is benefiting from treatmen
Special Authority for Subsidy - Form: SA0831Application only from a relevant specialist. Approvals valid for 10 months for applications meeting the following criteria: 1. Patient has newly diagnosed glioblastoma multiforme; and2. Temozolomide is to be (or has been) given concomitantly with radiotherapy; and3. Following concomitant treatment temozolomide is to be used for a maximum of six cycles of 5 days treatment, at a maximum dose of 200 mg/m2. Note: Temozolomide is not subsidised for the treatment of relapsed glioblastoma multiforme. Studies of temozolomide show that its benefit is predominantly in those patients with a good performance status (WHO grade 0 or 1 or Karnofsky score >80), and in patients who have had at least a partial resection of the tumour.
Special Authority for Subsidy - Form: SA0832Initial application only from a gastroenterologist, infectious disease specialist, paediatrician or general physician. Approvals valid for 1 year for applications meeting the following criteria: Both: 1 Any of the following: 1.1 All of the following: 1.1.1 HBsAg positive for more than 6 months; and1.1.2 HBeAg positive or HBV DNA positive defined as > 100,000 copies per ml by quantitative PCR at a reference laboratory; and1.1.3 ALT greater than twice upper limit of normal or bridging fibrosis or cirrhosis (Metavir stage 3 or 4 or equivalent) on liver histology or clinical/radiological evidence of cirrhosis; or 1.2 HBV DNA positive cirrhosis prior to liver transplantation; or1.3 HBsAg positive and have had a liver, kidney, heart, lung or bone marrow transplant; or1.4 Hepatitis B surface antigen positive (HbsAg) patient who is receiving chemotherapy for a malignancy, or who has received such treatment within the previous two months;
Special Authority for Subsidy - Form SA0833Initial application only from a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Any of the following: 1 The patient has non small cell lung carcinoma (stage IIIa, or above); or2 The patient has advanced malignant mesothelioma*; or3 The patient has advanced pancreatic carcinoma; or4 The patient has ovarian, fallopian tube* or primary peritoneal carcinoma*; or5 The patient has advanced transitional cell carcinoma of the urothelial tract (locally advanced or metastatic). Renewal only from a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Both: 6 The patient requires continued therapy; or7 The tumour has relapsed and requires re-treatment. Note indications marked with a * are unapproved indications.
Special Authority for Subsidy - Form: SA0834Initial application only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria: Either: 1 Both: 1.1 Patient has type 1 diabetes and has received an intensive regimen (injections at least three times a day) of an intermediate acting insulin in combination with a rapid acting insulin analogue for at least three months; and1.2 Either: 1.2.1 Patient has experienced more than one unexplained severe hypoglycaemic episode in the previous 12 months (severe defined as requiring the assistance of another person); or1.2.2 Patient has experienced unexplained symptomatic nocturnal hypoglycaemia, biochemically documented at <3.0 mmol/L, more than once a month despite optimal management; or2 Patient has documented severe, or continuing, systemic or local allergic reaction to existing insulins. Note this does not include hypoglycaemic episodes. Renewal only from a relevant specialist or general practitioner. Approv
Special Authority for Subsidy - Form SA0835Initial application - (Breast cancer) from any medical practitioner. Approvals valid for 1 year: where the patient is a premenopausal woman with breast cancer. Initial application - (Prostate cancer) only from an oncologist, urologist or endocrinologist. Approvals valid for 1 year for applications meeting the following criteria: Advanced prostatic cancer;. Note Not to be prescribed with an anti-androgen except for a period of three weeks, if necessary, when GnRH analogue therapy is initiated. Initial application - (Endometriosis) only from a gynaecologist. Approvals valid for 3 months for applications meeting the following criteria: Both: 1 Endometriosis; and2 Either: 2.1 6 months treatment with medroxyprogesterone acetate, danazol or dimetriose has proven ineffective; or2.2 The patient has failed to tolerate the treatment with medroxyprogesterone acetate, danazol or dimetriose for 6 months. Note The maximum treatment period for a GnRH analogue is:
Special Authority for Subsidy - Form SA0836Initial application - (Breast cancer) from any medical practitioner. Approvals valid for 1 year where the patient is a premenopausal woman with breast cancer. Initial application - (Prostate cancer) only from an oncologist, urologist or endocrinologist. Approvals valid for 1 year for applications meeting the following criteria: Either: 1 Advanced prostatic cancer; or. 2 Locally advanced prostatic cancer. Note Not to be prescribed with an anti-androgen except for a period of three weeks, if necessary, when GnRH analogue therapy is initiated. Initial application - (Endometriosis) only from a gynaecologist. Approvals valid for 3 months for applications meeting the following criteria: Both: 3 Endometriosis; and4 Either: 4.1 6 months treatment with medroxyprogesterone acetate, danazol or dimetriose has proven ineffective; or4.2 The patient has failed to tolerate the treatment with medroxyprogesterone acetate, danazol or dimetriose for 6 months. Note
Special Authority for Subsidy - Form SA0837Initial application - (Breast cancer) from any medical practitioner. Approvals valid for 1 year where the patient is a premenopausal woman with breast cancer. Initial application - (Prostate cancer) only from an oncologist, urologist or endocrinologist. Approvals valid for 1 year where the patient has: Advanced prostatic cancer;. Note Not to be prescribed with an anti-androgen except for a period of three weeks, if necessary, when GnRH analogue therapy is initiated. Initial application - (Endometriosis) only from a gynaecologist. Approvals valid for 3 months for applications meeting the following criteria: Both: 1 Endometriosis; and2 Either: 2.1 6 months treatment with medroxyprogesterone acetate, danazol or dimetriose has proven ineffective; or2.2 The patient has failed to tolerate the treatment with medroxyprogesterone acetate, danazol or dimetriose for 6 months. Note The maximum treatment period for a GnRH analogue is: - 3 months to assess whet
Special Authority for Subsidy - Form: SA0838Initial Application only from a relevant specialist or General Practitioner. Approvals valid for 2 years forapplications meeting the following criteria: Either: 1 All of the following: 1.1 Patient is a child under the age of 12; and1.2 All of the following: Has, for 3 months or more, been treated with:1.2.1 An inhaled long-acting beta adrenoceptor agonist; and1.2.2 Inhaled corticosteroids at a dose of at least 400 mcg per day beclomethasone or budesonide, or200 mcg per day fluticasone; and1.3 The prescriber considers that the patient would receive additional clinical benefit from switching to acombination product; or2 All of the following: 2 .1 Patient is over the age of 12; and2 .2 All of the following: Has, for 3 months or more, been treated with:2 .2.1 An inhaled long-acting beta adrenoceptor agonist; and2 .2.2 Inhaled corticosteroids at a dose of at least 800 mcg per day beclomethasone or budesonide, or500 mcg per day fluticasone;
Special Authority for Subsidy - Form SA0839Initial application - (Breast cancer) from any medical practitioner. Approvals valid for 1 year where the patient is a premenopausal woman with breast cancer. Initial application - (Prostate cancer) only from an oncologist, urologist or endocrinologist. Approvals valid for 1 year for applications meeting the following criteria: Either: 1 Advanced prostatic cancer; or. 2 Neoadjuvant or adjuvant treatment of locally advanced prostatic cancer. Note Not to be prescribed with an anti-androgen except for a period of three weeks, if necessary, when GnRH analogue therapy is initiated. Initial application - (Endometriosis) only from a gynaecologist. Approvals valid for 3 months for applications meeting the following criteria: Both: 3 Endometriosis; and4 Either: 4.1 6 months treatment with medroxyprogesterone acetate, danazol or dimetriose has proven ineffective; or4.2 The patient has failed to tolerate the treatment with medroxyprogesterone acetate, danazo
Special Authority for Subsidy - form: SA0841Initial application only from a gastroenterologist or general physician. Approvals valid for 6 months for applications meeting the following criteria: Both: 1 Primary biliary cirrhosis confirmed by antimitochondrial antibody titre (AMA) > 1:80, and raised cholestatic liver enzymes with or without raised serum IgM or, if AMA is negative, by liver biopsy; and2 Patient not requiring a liver transplant (bilirubin > 170umol/l; decompensated cirrhosis). NoteLiver biopsy is not usually required for diagnosis but is helpful to stage the diseaseRenewal only from a gastroenterologist or general physician. Approvals valid for 2 years for applications meeting the following criteria: The treatment remains appropriate and the patient is benefiting from treatment. NoteActigall is not an appropriate therapy for patients requiring a liver transplant (bilirubin > 170 micromol/l; decompensated cirrhosis). These patients should be referred to an appropriate transp
Special Authority for Subsidy - Form: SA842Initial application only from a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Any of the following: 1 Both: 1.1 The patient has ovarian, fallopian* or primary peritoneal cancer*; and 1.2 Either: 1.2.1 Has not received prior chemotherapy; or 1.2.2 Has received prior chemotherapy but have not previously been treated with taxanes; or2 The patient has metastatic breast cancer; or3 The patient has node-positive early breast cancer; or4 Both 4.1 The patient has non small-cell lung cancer; and 4.2 Either: 4.2.1 Has advancing disease (stage IIIa or above); or 4.2.2 Is receiving combined chemotherapy and radiotherapy; or5 Both: 5.1 The patient has small-cell lung cancer*; and 5.2 Paclitaxel is to be used as second-line therapy. Renewal only from a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: 6 The patient has metasta
Special Authority for Subsidy - Form SA0028Initial application only from a relevant specialist. Approvals valid for 6 months for applications meeting the following criteria: Either: 1 All of the following: 1.1 Treatment with other lipid modifying medicines has been unsuccessful; and 1.2 6 months of dietary modification has been unsuccessful; and 1.3 Cholesterol level > 7.0 mmol/litre; and 1.4 Either: 1.4.1 Familial hypercholesterolaemia; or 1.4.2 Manifest coronary heart disease, which has been clinically proven, or previously treated by coronary artery surgery; or 2 Cholesterol level > 9.0 mmol/litre:.Renewal only from a general practitioner. Approvals valid for 6 months where the treatment remains appropriate and the patient is benefiting from treatment. NoteFamilial hypercholesterolaemia is defined as being hypercholesterolaemia in the presence of tendon xanthomas or in association with a family history of premature heart disease (before age 55) or consisten
Unapproved medication supplied under Section 29 of the Medicines Act 1981. Practitioners prescribing this medication should: (a) be aware of and comply with their obligations under Section 29 of the Medicines Act 1981 and otherwise under that Act and the Medicines Regulations 1984; (b) be aware of and comply with their obligations under the Health and Disability Commissioner's Code of Consumer Rights, including the requirement to obtain informed consent from the patient (PHARMAC recommends that Practitioners obtain written consent); and(c) exercise their own skill, judgment, expertise and discretion, and make their own prescribing decisions with respect to the use of an unapproved Pharmaceutical or a Pharmaceutical for an indication for which it is not approved.
Special Authority for Subsidy - Form SA0031Initial application from any medical practitioner. Approvals valid for 2 years for applications meeting the following criteria: Any of the following: 1 Oesophageal stricture; or 2 Terminal care; or 3 Too young to swallow conventional tablets; or 4 Too old to swallow conventional tablets. Renewal from any medical practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Manufacturers Price - Form SA0035Initial application from any medical practitioner. Approvals valid for 5 years for applications meeting the following criteria: Both: 1 Either: 1.1 Both: 1.1.1 Duodenal and gastric ulcers, reflux oesophagitis and Zollinger-Ellison syndrome; and 1.1.2 Other treatments have failed; or 1.2 Patients who are on a Social Welfare benefit or an income no greater than a benefit; and 2 Patients must have endoscopically demonstrated lesions prior to commencement of treatment.. Renewal from any medical practitioner. Approvals valid for 5 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0045Initial application from any medical practitioner. Approvals valid for 2 years for applications meeting the following criteria: All of the following: 1 Continuation of treatment commenced prior to 1 August 1990; and 2 Alternatives (salbutamol and terbutaline) have been tried; and 3 Either: 3.1 Asthma; or 3.2 Chronic obstructive airways disease (COAD); and 4 Applicants must provide details of dose. Renewal from any medical practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0046Initial application only from a gastroenterologist. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 Functioning gall bladder; and 2 Either: 2.1 Uncalcified gallbladder stones with a maximum size of 20 mm; or 2.2 Adjunctive treatment after extra corporeal lithotrypsy. Renewal only from a gastroenterologist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0047Initial application only from a paediatrician or respiratory specialist. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 Child under 2 years of age; or 2 Both: 2.1 Child with major physical or intellectual disabilities; and 2.2 Lacks the necessary coordination to use aerosols with a spacer device. NoteThe cost of nebuliser therapy greatly exceeds other inhaled forms. Steroid nebulising solution can cause cataract formation. Renewal only from a paediatrician or respiratory specialist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0053Initial application only from a relevant specialist. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 RAST or skin test positive; and 2 Patient has had severe generalised reaction to the sensitising agent. Renewal only from a relevant specialist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0055Initial application only from a psychiatrist, geriatrician or respiratory specialist. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 For use only as an anxiolytic; and 2 Other agents are contraindicated or have failed. Renewal only from a psychiatrist, geriatrician or respiratory specialist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0056Initial application only from a psychiatrist. Approvals valid for 5 years for applications meeting the following criteria: Both: 1 Long-standing delusional states; and 2 Other injectable anti-psychotics have proven to be ineffective or inappropriate. Renewal only from a psychiatrist. Approvals valid for 5 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0057Initial application only from a psychiatrist. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 Depression; and 2 Any of the following: 2.1 Both: 2.1.1 Failed trials with other antidepressants; and 2.1.2 Patient has been maintained on mianserin prior to December1993; or 2.2 Co-existent bladder neck obstruction; or 2.3 Cardiovascular disease. Renewal only from a psychiatrist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0069Initial application only from a general physician, nephrologist or neurologist. Approvals valid for 5 years where syndrome of inappropriate anti-diuretic hormone secretion (SIADH). Renewal only from a general physician, nephrologist or neurologist. Approvals valid for 5 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Manufacturers Price - Form SA0070Initial application only from a respiratory specialist or infectious disease specialist. Approvals valid for 2 years for applications meeting the following criteria: Any of the following: 1 Avium intracellular atypical mycobacterial infections; or 2 Multiple drug resistant tuberculosis; or 3 Atypical and drug-resistant mycobacterial infections in patients with AIDS. Renewal only from a respiratory specialist or infectious disease specialist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
a) All patients with AIDS meeting the definition developed by the Centres for Disease Control in the USA (see Circular Letter to Medical Practitioners HP2/88)b) Patients with AIDS Related Complex (ARC)c) HIV infected patients with CD4 (T4) counts below 500 regardless of symptomatologyd) Prophylactically for persons following severe parenteral exposure from a known HIV positive sourcee) HIV infected persons with associated thrombocytopenia regardless of CD4 (T4) count f) Applications can only be made by appropriate specialists. Prescriptions for those patients approved to use these medicines can be written either by the specialist or general practitioner with an endorsement of the name of the recommending specialist. g) Prescriptions for these can be written for a period of three months' supply. However, medicine must be dispensed on a monthly basis.
a) Males: Fertile eunuch syndrome, females: anovulatory infertilityb) A declaration is required from the applying doctor that these agents are not being used as part of an IVF programmec) Approvals are valid for 6 months with a revewal for a further 6 months if the patient has some response and the prescriber believes further treatment will be effectived) Specialist must make application - endocrinologists and gynaecologists only
Special Authority for Subsidy - Form SA0087Initial application only from an endocrinologist or gynaecologist. Approvals valid for 6 months where hypogonadotrophic hypogonadism (including anovulatory infertility and cryptochidism). Renewal only from an endocrinologist or gynaecologist. Approvals valid for 6 months where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0088Initial application only from an endocrinologist or gynaecologist. Approvals valid for 6 months for applications meeting the following criteria: Both: 1 Either: 1.1 Female with anovulatory infertility, males: hypogonadotrophic hypogonadism; or 1.2 Male with hypogonadotrophic hypogonadism; and 2 These agents are not being used as part of an IVF programme. Renewal only from an endocrinologist or gynaecologist. Approvals valid for 6 months where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0089Initial application - (Breast or prostatic cancer) only from an oncologist, urologist or endocrinologist. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 Breast cancer in pre menopausal women unwilling or unable to undergo surgical or radiation oophorectomy; or 2 Advanced prostatic cancer when orchidectomy is contraindicated. Initial application - (Endometriosis) only from a gynaecologist. Approvals valid for 6 months for applications meeting the following criteria: Both: 1 Endometriosis; and 2 Either: 2.1 6 months treatment with medroxyprogesterone acetate, danazol or dimetriose has proven ineffective; or 2.2 The patient has failed to tolerate the treatment with medroxyprogesterone acetate, danazol or dimetriose for 6 months. NoteThe maximum treatment period for a GnRH analogue is: 3 months to assess whether surgery is appropriate3 months for infertile patients after surgery6 months for
Special Authority for Subsidy - Form SA0091Initial application only from a relevant specialist. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 Paget's disease; or 2 Both: 2.1 Patients under hospice care; and 2.2 Either: 2.2.1 Tumour-induced hypercalcaemia; or 2.2.2 Tumour-induced osteolysis without hypercalcaemia. Renewal only from a relevant specialist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0096Initial application - (Organ transplant, Bone marrow transplant or Graft v host disease) only from a relevant specialist. Approvals valid for 2 years for applications meeting the following criteria: Any of the following: 1 Organ transplant; or 2 Bone marrow transplant; or 3 Graft v host disease. Initial application - (Psoriasis) only from a dermatologist. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 Psoriasis; and 2 Other systemic and topical therapy has failed. Initial application - (Severe atopic dermatitis) only from a dermatologist. Approvals valid for 6 months for applications meeting the following criteria: Both: 1 Severe atopic dermatitis; and 2 Not resopnsive to topical therapy, oral antihistamines and other commonly used orthodox therapies. Initial application - (Nephrotic Syndrome) from any medical practitioner. Approvals valid for 2 years for applications meeting the following cri
Special Authority for Subsidy - Form SA0097Initial application - (Chronic hepatitis C) only from a relevant specialist. Approvals valid for 6 months where chronic hepatitis C. Initial application - (Indications other than Chronic hepatitis C) only from a relevant specialist. Approvals valid for 5 years for applications meeting the following criteria: Any of the following: 1 Chronic myelogenous leukaemia; or 2 Hairycell leukaemia; or 3 Cutaneous T cell lymphoma; or 4 Essential thrombocythaemia; or 5 AIDS related Kaposi's sarcoma; or 6 Multiple myeloma; or 7 Chronic active hepatitis B. Renewal - (Chronic hepatitis C) only from a relevant specialist. Approvals valid for 6 months where the treatment remains appropriate and the patient is benefiting from treatment. Renewal - (Indications other than Chronic hepatitis C) only from a relevant specialist. Approvals valid for 5 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0099Initial application only from a relevant specialist. Approvals valid for 5 years for applications meeting the following criteria: Any of the following: 1 Both: 1.1 Acromegaly; and 1.2 Patients who have failed surgery, radiotherapy, bromocriptine and other oral therapies; or 2 Both: 2.1 Either: 2.1.1 Vipomas; or 2.1.2 Glucagonomas; and 2.2 Patients who are seriously ill in order to improve their clinical state prior to definitive surgery; or 3 Both: 3.1 Gastrinoma; and 3.2 Either: 3.2.1 Patient has failed surgery; or 3.2.2 Patient is in metastatic disease after H2 antagonists (or omeprazole) have failed; or 4 Both: 4.1 Insulinomas; and 4.2 Surgery is contraindicated or where surgery has failed; or 5 Pre-operative control of hypoglycaemia; or 6 Maintenance therapy. NoteThe use of octreotide in patients with fistulae, oesophageal varices, miscellaneous diarrhoea and hypotension will
Special Authority for Subsidy - Form SA0100Initial application only from a relevant specialist. Approvals valid for 5 years for applications meeting the following criteria: All of the following: 1 Anaemia of end-stage renal failure (other treatable causes of anaemia being excluded); and 2 Been on haemodialysis or continuous ambulatory peritoneal dialysis (CAPD) for at least three months; and 3 Not under evaluation for, or awaiting, a live donor kidney transplant; and 4 Any of the following: 4.1 Anephric; or 4.2 Dependent on regular blood transfusion (1 unit each 4-8 weeks) to maintain haemoglobin > 60g/L; or 4.3 Cannot be transfused because of severe transfusion reactions; or 4.4 Transfusion induced haemosiderosis (clinical manifestations, serum ferritin >1500 ug/L); or 4.5 Haemoglobin < 70 g/L (mean of at least 4 haemoglobin concentrations over 4 months); or 4.6 Both: 4.6.1 Haemoglobin < 90 g/L; and 4.6.2 Either: 4.6.2.1 Heart failure (low card
Special Authority for Subsidy - Form SA0108Initial application only from a relevant specialist. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 Hairy cell leukaemia; or 2 Chronic active hepatitis B. Renewal only from a relevant specialist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0115Initial application - (Oesophageal stricture) only from a general practitioner or relevant specialist. Approvals valid for 2 years where patient with oesophageal stricture who is unable to take capsules. Initial application - (Indications other than oesophageal stricture) only from a paediatrician. Approvals valid for 2 years for applications meeting the following criteria: All of the following: 1 infant or child with liver disease or short gut syndrome; and 2 Requires vitamin supplementation; and 3 Unable to swallow capsules. Renewal only from a general practitioner, relevant specialist or paediatrician. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0121Initial application from any medical practitioner. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 Patient has to use an unpreserved solution due to an allergy to the preservative; or 2 Patient wears soft contact lenses. NoteMinims for a general practice are considered to be "tools of trade" and are not approved as special authority items. Renewal from any medical practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0125Initial application - (Chronic post-thrombotic venous stasis ulcers) from any medical practitioner. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 Chronic post-thrombotic venous stasis ulcers of more than 4 months duration; and 2 Other interventions have failed. Initial application - (Sudden hearing loss) only from an otolaryngologist. Approvals valid for 2 years where sudden hearing loss. Renewal from any medical practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
a) Should be strictly reserved for use as second line therapy in: - patients unable to tolerate the other medications, such as infants, young children and patients with allergies or eczema- cases of scabies which are resistent to gamma benzene hexachlorideb) Verification of drug resistance is dependent on the persistence of the condition after treatment. In order to establish whether there is drug resistance, the following criteria should be fulfilled: - a definite diagnosis of scabies should be made- it should be ascertained that the medication was administered properly- the possibility of reinfestation should have been excluded
Special Authority for Subsidy - Form SA0140Initial application only from a relevant specialist. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 Pain management in the terminally ill; and 2 Standard therapy has failed. Renewal only from a relevant specialist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
Approvals for a CHEM number to waive the premium in the following circumstances: 1. Patients with prosthetic heart valves - as an adjunct to oral anticoagulation for prophylaxis of thromboembolism (2 year approval with renewal, applications only from cardiothoracic surgeons, cardiologists and general physicians). 2. Patients after coronary artery vein bypass graft - as an adjunct to aspirin (1 year approval only, applications only from cardiothoracic surgeons, cardiologists and general physicians). 3. Patients who continue to have transient ischaemic episodes despite aspirin therapy. A course of up to six months in combination with aspirin. Applications only from neurologists, cardiologists, vascular surgeons and general physicians. Six month approval only. Reapplications only if there is demonstrated recurrence of symptoms when dipyridamole therapy is discontinued. Note: these transitional criteria are currently being reviewed.
a) Approvals to fund the manufacturer's surcharge in the following circumstances: - Patients with prosthetic heart valves - as an adjunct to oral anticoagulation for prophylaxis of thromboembolism (2 year approval with renewal, applications only from cardiothoracic surgeons, cardiologists and general physicians). - Patients after coronary artery vein bypass graft - as an adjunct to aspirin or as monotherapy for patients who are aspirin intolerant as defined below (1 year approval only, applications only from cardiothoracic surgeons, cardiologists and general physicians); or- Patients who continue to have transient ischaemic episodes despite aspirin therapy or have transient ischaemic episodes and are aspirin intolerant as defined below (2 year approval with renewal, applications only from neurologists, neurosurgeons, cardiologists, vascular surgeons and general physicians). b) Aspirin intolerant patients are defined as those with aspirin induced asthma, urticaria, or anaphylaxi, or those with significant
Special Authority for Manufacturers Price - Form SA0157Initial application from any medical practitioner. Approvals valid for 5 years for applications meeting the following criteria: Any of the following: 1 Liver disease; or 2 Past history of thromboembolism; or 3 Significant hypertension; or 4 Hypertension associated with oral oestrogen therapy. Renewal from any medical practitioner. Approvals valid for 5 years where the treatment remains appropriate and the patient is benefiting from treatment.
The new anticonvulsant drugs are restricted to1. neurologists2. paediatric neurologists3. any other prescriber approved in writing by the relevant RHA budget holding manager. The HFA holds a budget for expenditure on the new anticonvulsant drugs. Unless otherwise specified, ultimate authority for approving prescriptions for subsidy lies with the HFA budget holding manager for the new anticonvulsant drugs. The regional divisions of the HFA will be in contact with hospital pharmacists and approved prescribers with more detail of the approval system. GUIDELINES FOR USE OF THE NEW ANTICONVULSANTS ARE AS FOLLOWS: A. Entry criteriaThe following patients are eligible for trial on the new anticonvulsant drugs (NADs)1. Patients who are under the supervision of an approved prescriber, and whose seizures are not adequately controlled with optimal conventional anticonvulsant drug treatment. 2. Patients, who are under the supervision of an approved prescriber, and whose seizures are only controlled adequatel
Special Authority for Subsidy - Form SA0256Initial application only from a cardiologist or general physician. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 Refractory angina; and 2 Patient is already on maximal anti-anginal therapy. Renewal only from a cardiologist or general physician. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0264Initial application only from a paediatrician or respiratory specialist. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 Cystic fibrosis patient; or 2 Both: 2.1 Infant or child with liver disease or short gut syndrome; and 2.2 Requires vitamin supplementation. Renewal only from a paediatrician or respiratory specialist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Manufacturers Price - Form SA0265Initial application from any medical practitioner. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 Social Welfare Benefiary; or 2 Income no greater than a Benefiary. Renewal from any medical practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0266Initial application - (Chronic hepatitis C) only from a relevant specialist. Approvals valid for 6 months where chronic hepatitis C. NoteMaximum reimbursable dosage 15 million iu/weekInitial application - (Indications other than chronic hepatitis C) only from a dermatologist, plastic surgeon or radiation oncologist. Approvals valid for 5 years for applications meeting the following criteria: Any of the following: 1 Chronic myelogenous leukaemia; or 2 Hairycell leukaemia; or 3 Cutaneous T cell lymphoma; or 4 Essential thrombocythaemia; or 5 AIDS related Kaposi's sarcoma; or 6 Multiple myeloma; or 7 Chronic active hepatitis B; or 8 Basal cell carcinoma unable to be treated surgically or by radiotherapy. NoteMaximum reimbursable dosage 15 million iu/weekRenewal - (Chronic hepatitis C) only from a relevant specialist. Approvals valid for 6 months where the treatment remains appropriate and the patient is benefiting from trea
a) - hairy cell leukaemia - Kaposi's sarcoma - chronic active hepatitis B - chronic hepatitis C (6 month approval only) - chronic myelogenous leukaemia - multiple myeloma - basal cell carcinoma 1) Only for basal cell carcinoma unable to be treated surgically or by radiotherapy. 2) Applications only from radiation oncologists, plastic surgeons and dermatologists. Applications from dermatologists will only be accepted with evidence from either a plastic surgeon or oncologist that the patient was unsuitable for surgery. 3) Maximum reimbursable dosage 15 million iu/weekb) Specialist must make applicationc) No further approvals for: Malignant melanoma Note: Patients with existing approvals can continue to have therapy
Lansoprazole is subsidised for patients who have one or more of the following conditions: 1. Duodenal ulcer proven by endoscopy or barium meal and after failure of: a)two alternative courses of H. pylori eradication therapy (if H. pylori positive); and b)H2 antagonist therapy for 8 weeks; and where a second endoscopy/barium meal has demonstrated non healing duodenal ulcer. 2. Gastric ulcer proven by endoscopy and after failure of: a)two alternative courses of H. pylori eradication therapy (if H. pylori positive); andb)H2 antagonist therapy for 12 weeks; and where a second endoscopy has demonstrated non healing gastric ulcer and excluded malignancy. 3. Gastro-oesophageal reflux disease (GORD) proven by endoscopy: i) Grade 0 GORD (normal endoscopy) after positive 24 hour pH monitoring test and failure of H2 antagonist therapy for one month with multiple daily dosing; orii) Grades 1 and 2 GORD after failure of H2 antagonist therapy for one month with multiple daily dosing; or
Special Authority for Manufacturers Price - Form SA0271Initial application from any medical practitioner. Approvals valid for 5 years for applications meeting the following criteria: Either: 1 Continuation of treatment commenced prior to 1 October 1995; or 2 Both: 2.1 Either: 2.1.1 Asthma; or 2.1.2 Chronic obstructive airways disease; and 2.2 Patient has tried alternatives and these are unsuitable. Renewal from any medical practitioner. Approvals valid for 5 years where the treatment remains appropriate and the patient is benefiting from treatment.
a) All patients with AIDS meeting the definition developed by the Centres for Disease Control in the USA (see Circular Letter to Medical Practitioners HP2/88)b) Patients with AIDS Related Complex (ARC)c) HIV infected patients with CD4 (T4) counts below 500 regardless of symptomatologyd) Prophylactically for persons following severe parenteral exposure from a known HIV positive sourcee) HIV infected persons with associated thrombocytopenia regardless of CD4 (T4) count f) For the prevention of maternal foetal transmission of HIVg) Applications can only be made by appropriate specialists. Prescriptions for those patients approved to use these medicines can be written either by the specialist or general practitioner with an endorsement of the name of the recommending specialist. h) Prescriptions for these can be written for a period of three months' supply. However, medicine must be dispensed on a monthly basis.
Special Authority for Subsidy - Form SA0274Initial application only from a relevant specialist. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 All of the following: 1.1 Treatment with other lipid modifying medicines has been unsuccessful; and 1.2 6 months of dietary modification has been unsuccessful; and 1.3 Cholesterol level > 7.0 mmol/litre:; and 1.4 Either: 1.4.1 Familial hypercholesterolaemia; or 1.4.2 Manifest coronary heart disease, which has been clinically proven, or previously treated by coronary artery surgery; or 2 Cholesterol level > 9.0 mmol/litre:.NoteFamilial hypercholesterolaemia is defined as being hypercholesterolaemia in the presence of tendon xanthomas or in association with a family history of premature heart disease (before age 55) or consistent with autosomal dominant inheritance. Simvastatin and Pravastatin may be considered for first line therapy in patients with familial hypercholesterolaemia or
Special Authority for Subsidy - Form SA0275Initial application - (Chronic hepatitis C) only from a relevant specialist. Approvals valid for 6 months where chronic hepatitis C. NoteMaximum reimbursable dosage 15 million iu/weekInitial application - (Indications other than chronic hepatitis C) only from a dermatologist, plastic surgeon or radiation oncologist. Approvals valid for 5 years for applications meeting the following criteria: Any of the following: 1 Chronic myelogenous leukaemia; or 2 Hairycell leukaemia; or 3 Cutaneous T cell lymphoma; or 4 Essential thrombocythaemia; or 5 Multiple myeloma; or 6 Chronic active hepatitis B; or 7 Basal cell carcinoma unable to be treated surgically or by radiotherapy. NoteMaximum reimbursable dosage 15 million iu/weekRenewal - (Chronic hepatitis C) only from a relevant specialist. Approvals valid for 6 months where the treatment remains appropriate and the patient is benefiting from treatment. Renewal - (Indications other tha
Special Authority for Subsidy - Form SA0276Initial application - (Chronic hepatitis C) only from a relevant specialist. Approvals valid for 6 months where chronic hepatitis C. NoteMaximum reimbursable dosage 15 million iu/weekInitial application - (Indications other than chronic hepatitis C) only from a dermatologist, plastic surgeon or radiation oncologist. Approvals valid for 5 years for applications meeting the following criteria: Any of the following: 1 Chronic myelogenous leukaemia; or 2 Hairycell leukaemia; or 3 Multiple myeloma; or 4 Chronic active hepatitis B; or 5 Basal cell carcinoma unable to be treated surgically or by radiotherapy. NoteMaximum reimbursable dosage 15 million iu/weekRenewal - (Chronic hepatitis C) only from a relevant specialist. Approvals valid for 6 months where the treatment remains appropriate and the patient is benefiting from treatment. Renewal - (Indications other than chronic hepatitis C) only from a dermatologist, plastic surgeon or radiat
Omeprazole is subsidised for patients who have one or more of the conditions numbered 1-4: 1. Duodenal ulcer proven by endoscopy or barium meal and after failure of: a)two alternative courses of H. pylori eradication therapy (if H. pylori positive); and b)H2 antagonist therapy for 8 weeks; and where a second endoscopy/barium meal has demonstrated non healing duodenal ulcer. 2. Gastric ulcer proven by endoscopy and after failure of: a)two alternative courses of H. pylori eradication therapy (if H. pylori positive); andb)H2 antagonist therapy for 12 weeks; and where a second endoscopy has demonstrated non healing gastric ulcer and excluded malignancy. 3. Gastro-oesophageal reflux disease (GORD) proven by endoscopy: i) Grade 0 GORD (normal endoscopy) after positive 24 hour pH monitoring test and failure of H2 antagonist therapy for one month with multiple daily dosing; orii) Grades 1 and 2 GORD after failure of H2 antagonist therapy for one month with multipl
Special Authority for Subsidy - Form SA0290Initial application only from a relevant specialist. Approvals valid for 5 years for applications meeting the following criteria: Any of the following: 1 AIDS meeting the definition developed by the Centers for Disease Control in the USA; or 2 AIDS Related Complex (ARC).; or 3 Both: 3.1 HIV infection regardless of symptomatology; and 3.2 CD4 (T4) counts < 500. NoteSee Circular Letter to Medical Practitioners HP2/88)Renewal only from a relevant specialist. Approvals valid for 5 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Manufacturers Price - Form SA0291Initial application from any medical practitioner. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 Inflammatory arthritis (including osteoarthritis with an inflammatory component); and 2 Stabilised and are well controlled on the particular NSAID medication. Renewal from any medical practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0300Initial application - (Breast or prostatic cancer) only from an oncologist, urologist or endocrinologist. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 Breast cancer in pre menopausal women unwilling or unable to undergo surgical or radiation oophorectomy; or 2 Advanced prostatic cancer when orchidectomy is contraindicated. NoteNot in long term combination with an anti-androgenInitial application - (Endometriosis) only from a gynaecologist. Approvals valid for 6 months for applications meeting the following criteria: Both: 1 Endometriosis ; and 2 Either: 2.1 6 months treatment with medroxyprogesterone acetate, danazol or dimetriose has proven ineffective; or 2.2 The patient has failed to tolerate the treatment with medroxyprogesterone acetate, danazol or dimetriose for 6 months. NoteThe maximum treatment period for a GnRH analogue is: 3 months to assess whether surgery is appropriate3 m
Special Authority for Subsidy - Form SA0309Initial application only from a neurologist or physician for the elderly (FRACP). Approvals valid for 2 years for applications meeting the following criteria: All of the following: 1 Idiopathic Parkinson's disease; and 2 The patient does not have dementia and/or neuropsychiatric disorders; and 3 Has responded to L-dopa; and 4 Any of the following: 4.1 Has resistance to conventional treatment of severe motor fluctuations; or 4.2 Has severe "off" period disability; or 4.3 Has severe "off" period dystonic cramps. Renewal only from a neurologist or physician for the elderly (FRACP). Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0311Initial application - (Breast or prostatic cancer) only from an oncologist, urologist or endocrinologist. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 Breast cancer in pre menopausal women unwilling or unable to undergo surgical or radiation oophorectomy; or 2 Advanced prostatic cancer when orchidectomy is contraindicated or where the patient srongly opposes orchidectomy. NoteNot to be prescribed with an anti-androgen except for a period of three weeks, if necessary, when GnRH analogue therapy is intiatedInitial application - (Endometriosis) only from a gynaecologist. Approvals valid for 6 months for applications meeting the following criteria: Both: 1 Endometriosis; and 2 Either: 2.1 6 months treatment with medroxyprogesterone acetate, danazol or dimetriose has proven ineffective; or 2.2 The patient has failed to tolerate the treatment with medroxyprogesterone acetate, danazol or dimetrio
Special Authority for Alternate Subsidy - Form SA0312Initial application only from an obstetrician, gynaecologist, general practitioner or general physician. Approvals valid for 5 years for applications meeting the following criteria: Any of the following: 1 acute or significant liver disease - a declaration must be provided from a gastroenterologist or general physician stating that oral oestrogens are contraindicated due to liver disease (Details to be attached to application); or 2 oestrogen induced hypertension requiring antihypertensive therapy - documented evidence must be provided that raised blood pressure levels or inability to control blood pressure adequately occurred post oral oestrogens (Details to be attached to application); or 3 hypertriglyceridaemia - documented evidence must be provided that triglyceride levels increased to at least 2 x normal triglyceride levels post oral oestrogens (Details to be attached to application). NotePrescriptions with a valid Special Authority (
Special Authority for Subsidy - Form SA0317Initial application only from a renal physician. Approvals valid for 2 years for applications meeting the following criteria: All of the following: General Criteria: 1 Anaemia of end-stage renal failure (other treatable causes of anaemia being excluded); and 2 Been on haemodialysis or continuous ambulatory peritoneal dialysis (CAPD) for at least three months; and 3 Not under evaluation for, or awaiting, a live donor kidney transplant; and 4 Any of the following: Specific Criteria: 4.1 Anephric; or 4.2 Dependent on regular blood transfusion (1 unit each 4-8 weeks) to maintain haemoglobin > 60g/L; or 4.3 Cannot be transfused because of severe transfusion reactions; or 4.4 Transfusion induced haemosiderosis (clinical manifestations, serum ferritin >1500 ug/L); or 4.5 Haemoglobin < 70 g/L (mean of at least 4 haemoglobin concentrations over 4 months); or 4.6 Both: 4.6.1 Haemoglobin < 90 g/L; and 4.6.2 Either:
a) All nucleosides will be subsidised for patients meeting any of the following criteria: - All patients with AIDS meeting the definition developed by the Centers for Disease Control in the USA (see Circular Letter to Medical Practitioners HP2/88); or- Patients with AIDS Related Complex (ARC); or- HIV infected patients with CD4 (T4) counts below 500 regardless of symptomatology. b) Zidovudine will also be subsidised for patients meeting any of the following criteria: - Prophylactically for persons following severe parenteral exposure from a known HIV positive source; or- HIV infected persons with associated thrombocytopenia regardless of CD4 (T4) count; or- For the prevention of maternal foetal transmission of HIV. c) Applications can only be made by appropriate specialists. d) Prescriptions for those patients approved to use these medications can be written by either the specialist or general practitioner with an endorsement of the name of the recommending specialist.
Special Authority for Subsidy - Form SA0323Initial application only from a relevant specialist. Approvals valid for 2 years where children receiving frequent parenteral injections (i.e. intradermal, subcutaneous, intravenous or intramuscular) requiring a 21 gauge or larger bore needle. Renewal only from a relevant specialist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0325Initial application from any medical practitioner. Approvals valid for 5 years where applicatons will be considered and approved subject to funding availability. NoteApplications to be made on the approved forms which are available from the co-ordinator for the Cystic Fibrosis DN'ase Advisory Panel: The Co-ordinatorCystic Fibrosis DN'ase Advisory PanelC/- Room 4-28, Building 13 Greenlane HospitalPrivate Bag, AUCKLANDPhone: 09 630 9871Facsimile: 09 631 0753
Special Authority for Subsidy - Form SA0328Initial application only from a general physician. Approvals valid for 2 years for applications meeting the following criteria: Any of the following: 1 Both: 1.1 CD4 count < 500 cells/mm3; and 1.2 Viral load > 50,000> copies per ml (or equivalent value on the Chiron test); or 2 All of the following: 2.1 CD4 count < 500 cells/mm3; and 2.2 Viral load > 50,000> copies per ml (or equivalent value on the Chiron test); and 2.3 At least 6 weeks of dual therapy with nucleoside agents; or 3 Both: 3.1 CD4 count < 500 cells/mm3; and 3.2 CD4 counts are declining rapidly (>120 cells over 12 months or >60 - 80 cells over six months). Renewal only from a general physician. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
Guidelines for use of cyclosporin A in rheumatoid arthritisMonitoring: All patients require frequent monitoring for creatinine levels and blood pressure:- fortnightly, in the first three months of therapy and then monthly, if results are stable; - if dose is increased or there is a rise in serum creatinine or blood pressure, then more frequent monitoring is required. Contraindications: Cyclosporin A is contraindicated in patients with the following conditions: - current or past malignancy; - uncontrolled hypertension; - renal dysfunction (abnormal serum creatinine for age and sex); - immunodeficiency and neutropenia; - abnormally low white blood cell count or platelet count; or- liver function tests more than twice the upper limit of normal. Caution in use: - age above 65 years; - controlled hypertension; - use of ant-epileptic medications; - use of NSAIDs; - use of ketoconazole, fluconazole, trimethoprim, erythromycin, verapamil, and diltiazem; - concurrent or previous use of al
Special Authority - Retail pharmacy (Salmeterol, eformoterol fumarate):a) Approvals are interchangeable between all presenations of salmeterol and eformoterol fumarate agents. b) Diagnosis of asthma confirmed. c) Inhaler/device technique checked. d) At least three months of >= 1500 ug daily of beclomethasone inhaled steroid (or equivalent) for adult, or >= 800 ug daily for child. e) Patient monitors PEFR regularly during exacerbations where appropriate. f) Evidence of poor control (at least one of the following): - short acting beta agonist used > 3-4 time daily - nocturnal awakenings >= 2 times per week. g) The first applicaton may be for six months and subsequent applications for two yars. The criteria for reapplication are: - compliant with medication - improved asthma symptom control. h) Appication for Special Authority to be made by general practitioners or appropriate specialist.
a) Should be strictly reserved for use as second line therapy in: - patients unable to tolerate the other medications, such as infants, young children and patients with allergies or eczema; - cases of scabies which are resistent to gamma benzene hexachloride and resistant to malathion. b) Verification of drug resistance is dependent on the persistence of the condition after treatment. In order to establish whether there is drug resistance, the following criteria should be fulfilled: - a definite diagnosis of scabies should be made; - it should be ascertained that the medication was administered properly; - the possibility of reinfestation should have been excluded.
Special Authority for Manufacturers Price - Form SA0349Initial application only from a respiratory specialist or infectious disease specialist. Approvals valid for 2 years for applications meeting the following criteria: Any of the following: 1 Avium intracellular atypical mycobacterial infections; or 2 Multiple drug resistant tuberculosis; or 3 Atypical and drug-resistant mycobacterial infections in patients with AIDS. Renewal only from a respiratory specialist or infectious disease specialist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
Omeprazole and pantoprazole is subsidised for patients who have one or more of the conditions a-d: a) Duodenal ulcer proven by endoscopy or barium meal and after failure of: - two alternative courses of H. pylori eradication therapy (if H. pylori positive); and - H2 antagonist therapy for 8 weeks; and where a second endoscopy/barium meal has demonstrated non healing duodenal ulcer. b) Gastric ulcer proven by endoscopy and after failure of: - two alternative courses of H. pylori eradication therapy (if H. pylori positive); and - H2 antagonist therapy for 12 weeks; and where a second endoscopy has demonstrated non healing gastric ulcer and excluded malignancy. c) Gastro-oesophageal reflux disease (GORD) proven by endoscopy: - Grade 0 GORD (normal endoscopy) after positive 24 hour pH monitoring test and failure of H2 antagonist therapy for four weeks with multiple daily dosing; or - Grades 1 and 2 GORD after failure of H2 antagonist therapy for
Subsidy is available for disposable diabetic syringes and needles: 1) When the prescription is written on the same prescription form as the one used for the supply of insulin vials; or2) When "insulin patient" has been written on the prescription by either the doctor or the contractor; and3) For no more than 50 plastic syringes with attached needles as a single supply in the case of a prescription for three months supply of insulin vials; or4) For no more than 4 plastic syringes with attached needles as a single supply for each week's supply in the case of a prescription for less than three months supply of insulin vials.
Subsidy is available for insulin pen needles: 1) When the prescription is written on the same prescription form as the one used for the supply of insulin cartridges; or2) When "insulin patient" has been written on the prescription by either the doctor or the contractor; and3) For no more than 30 insulin pen needles as a single supply in the case of a prescription for three months supply of insulin cartridges; or4) For no more than 2 insulin pen needles as a single supply for each week's supply in the case of a prescription for less than three months supply of insulin cartridges.
Special Authority for Subsidy - Form SA0361Initial application only from a geriatrician, neurologist or general physician. Approvals valid for 2 years for applications meeting the following criteria: All of the following: 1 Disabling orthostatic hypotension not due to drugs; and 2 Patient has tried fludrocortisone (unless contra-indicated) with unsatisfactory results; and 3 Patient has tried non pharmacological treatments such as support hose, increased salt intake, exercise, and elevation of head and trunk at night. NoteTreatment should be started with small doses and titrated upwards as necessary. Hypertesion should be avoided, and the usual target is a standing systolic blood pressure of 90 mm Hg. Renewal only from a geriatrician, neurologist or general physician. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0366Initial application - (North Island patients) from any medical practitioner. Approvals valid for 5 years where the patient is likely to benefit from treatment. NoteFor details of the patient criteria, prescriber criteria, application and reporting forms contact the appointed clinician: Dr Richard FisherFertility Associates131 Remuera RoadAUCKLANDFax: 09 520 0499Appointed clinicians will distribute these agents to prescribers whose applications are approvedInitial application - (South Island patients) from any medical practitioner. Approvals valid for 5 years where the patient is likely to benefit from treatment. NoteFor details of the patient criteria, prescriber criteria, application and reporting forms contact the appointed clinician: Dr Peter BennyChristchurch Women's HospitalPrivate Bag 4711CHRISTCHURCHFax: 03 364 4634Appointed clinicians will distribute these agents to prescribers whose applications are approved
Special Authority for Subsidy - Form SA0382Initial application only from a gastroenterologist, general surgeon or general physician. Approvals valid for 3 years for applications meeting the following criteria: Any of the following: 1 All of the following: 1.1 Duodenal ulcer proven by endoscopy or barium meal; and 1.2 Failure of two alternative courses of H. pylori eradication therapy (if H. pylori positive); and 1.3 Non healing duodenal ulcer proven by second barium meal; and 1.4 H2 antagonist therapy for 8 weeks; or 2 All of the following: 2.1 Gastric ulcer proven by endoscopy; and 2.2 Two alternative courses of H. pylori eradication therapy (if H. pylori positive); and 2.3 Non healing gastric ulcer and excluded malignancy demonstrated by a second endoscopy; and 2.4 H2 antagonist therapy for 12 weeks; or 3 All of the following: 3.1 Grade 0 GORD (normal endoscopy); and 3.2 Positive 24 hour pH monitoring test; and 3.3 Failure of H2 antagonist t
n) Further approvals to fund the manufacturer's surcharge on either pravastatin or simvastatin (if applicable) may be granted to patients who are unable to continue treatment with fluvastatin due to adverse effects. Either general practitioners or specialist may make the application. To obtain a new Special Authority number, the application must include the following information: - the amount of time the patient has been treated with fluvastatin; and- the adverse effects experienced by the patient. o) Further approvals to fund the manufacturer's surcharge on simvastatin may be granted to patients with familial hypercholesterolaemia (FH) or familial combined hypercholesterolaemia (FCH) if a specialist considers that the patient is not achieving sufficient benefit from the fully funded statin(s). Only specialists may make application. To obtain a new Special Authority number, the application must include the following information: - the cholesterol level before and after treatment with the fully funded sta
Special Authority for Subsidy - Form SA0387Initial application - (Breast or prostatic cancer) only from an oncologist, urologist or endocrinologist. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 Breast cancer in pre menopausal women unwilling or unable to undergo surgical or radiation oophorectomy; or 2 Advanced prostatic cancer when orchidectomy is contraindicated or where the patient srongly opposes orchidectomy. NoteNot to be prescribed with an anti-androgen except for a period of three weeks, if necessary, when GnRH analogue therapy is intiatedInitial application - (Endometriosis) only from a gynaecologist. Approvals valid for 6 months for applications meeting the following criteria: Both: 1 Endometriosis; and 2 Either: 2.1 6 months treatment with medroxyprogesterone acetate, danazol or dimetriose has proven ineffective; or 2.2 The patient has failed to tolerate the treatment with medroxyprogesterone acetate, danazol or dimetrio
Special Authority for Subsidy - Form SA0391Initial application only from a relevant specialist. Approvals valid for 5 years for applications meeting the following criteria: Either: 1 Liver transplant recipients; or 2 Renal transplant recipients - as rescue therapy only. Renewal only from a relevant specialist. Approvals valid for 5 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Manufacturers Price - Form SA0394Initial application - (Helicobacter pylori infections) only from a general practitioner or relevant specialist. Approvals valid for 6 months for applications meeting the following criteria: Both: 1 Eradication of Helicobacter pylori in patient with proven infection; and 2 Peptic ulcer disease proven by endoscopy. NoteMaximum of two prescriptions (two courses) per patient. Initial application - (Mycobacterial infections) only from a respiratory specialist or infectious disease specialist. Approvals valid for 2 years for applications meeting the following criteria: Any of the following: 1 Mycobacterium Avium Intracellulare Complex infections in patient with AIDS; or 2 Atypical and drug-resistant mycobacterial infection; or 3 All of the following: 3.1 Prophylaxis against disseminated Mycobacterium Avium Intracellulare Complex infection; and 3.2 HIV infection; and 3.3 CD4 count <= 50 cells/mm3. Renewal - (Mycobacteri
a) Cyproterone acetate with ethinyloestradiol is available from retail pharmacy to patients as indicated. b) Prescribers may code prescriptions "contraceptive" (code "O") when used as indicated for contraception. The period of supply and prescription charge will be as per other contraceptives, as follows: - $3.00 prescription charge (patient co-payment) will apply; - Prescription may be written for up to 6 months supply; and- Pharmacists may dispense up to 3 month supply. c) Prescriptions coded in any other way are subject to the non-contraceptive prescription charges, and the non-contraceptive period of supply. Eg. Prescriptons may be written for up to 3 months supply, and dispensed monthly. d) The Special Authority number for hormonal contraceptive agents (combined and progesterone-only) does not apply, and is not interchangeable. e) Health Benefits Limited will return any claims unpaid as follows: - any uncoded prescription; - any prescription that does not have a period of supply or the quantity
Special Authority for Subsidy - Form SA0401Initial application - (Basal cell carcinoma) only from a dermatologist, plastic surgeon or radiation oncologist. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 Basal cell carcinoma unable to be treated surgically or by radiotherapy; and 2 Unsuitability for surgery confirmed by a Plastic Surgeon or Oncologist. NoteMaximum reimbursable dosage 15 million iu/weekInitial application - (Chronic hepatitis C) only from a relevant specialist. Approvals valid for 12 months where chronic hepatitis C. Initial application - (Indications other than Basal cell carcinoma and Chronic hepatitis C) only from a relevant specialist, plastic surgeon or radiation oncologist. Approvals valid for 2 years for applications meeting the following criteria: Any of the following: 1 Chronic myelogenous leukaemia; or 2 Hairy cell leukaemia; or 3 Cutaneous T cell lymphoma; or 4 Essential thrombocythaemia; or 5 Multiple myelo
Special Authority for Subsidy - Form SA0402Initial application - (Patients aged 74 and under) only from a general practitioner. Approvals valid for 2 years for applications meeting the following criteria: All of the following: 1 Patients aged 74 and under; and 2 The patient has been offered 3-6 months of counselling and an opportunity to modify lifestyle; and 3 Any of the following: 3.1 Both: 3.1.1 NHF A1:1 - Clinically proven ischaemic heart disease; and 3.1.2 total cholesterol > 6.0; or 3.2 Both: 3.2.1 NHF A1:2 - Post coronary artery bypass graft (CABG); and 3.2.2 total cholesterol > 5.5; or 3.3 Both: 3.3.1 NHF B:Patients with > 20% 5-year cardiovascular disease risk; and 3.3.2 total cholesterol > 9.0; or 3.4 Both: 3.4.1 NHF C:15-20% 5-year cardiovascular disease risk; and 3.4.2 total cholesterol > 9.0; or 3.5 Both: 3.5.1 NHF D:10-15% 5-year cardiovascular disease risk; and 3.5.2 total cholesterol > 9.0; or 3.6
Special Authority for Subsidy - Form SA0404Initial application only from an ophthalmologist. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 Primary open-angle glaucoma; and 2 Either: 2.1 Other subsidised glaucoma medical therapy is contraindicated; or 2.2 Both: 2.2.1 intra-ocular pressure > 26 mmHg (average from consecutive measurements); and 2.2.2 Unable to be controlled using other subsidised medical therapy. Renewal only from an ophthalmologist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Manufacturers Price - Form SA0410Initial application from any medical practitioner. Approvals valid for 2 years for applications meeting the following criteria: Any of the following: 1 Polycystic ovarian syndrome; or 2 Hirsutism; or 3 Androngenic alopecia. Renewal from any medical practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
Funding of manufacturers surcharge for existing patients taking ACE inhibitors for Congestive Heart Failure.a) Patients taking any ACE inhibitor for the treatment of congestive heart failure prior to 1 June 1998 can continue to have their ACE inhibitor treatment fully subsidised; b) Prescribers must endorse the prescription 'Congestive Heart Failure'. The endorsement can be typed (this includes computer generated prescriptions) or handwritten; c) The endorsement must be initialled in the prescriber's own handwriting. Definition of Congestive Heart FailureAt the request of some prescribers the PTAC Cardiovascular subcommittee has provided a definition of congestive heart failure for the purposes of the funding of the manufacturer's surcharge: "Clinicians should use their clinical judgement. Existing patients would be eligible for the funding of the surcharge if the patient shows signs and symptoms of congestive heart failure, and requires or has in the past required concomitant treatment with a
Special Authority for Subsidy - Form SA0423Initial application only from a gastroenterologist, general surgeon or general physician. Approvals valid for 3 years for applications meeting the following criteria: Any of the following: 1 All of the following: Duodenal Ulcer: 1.1 Duodenal ulcer proven by endoscopy or barium meal; and 1.2 Non healing duodenal ulcer proven by second barium meal; and 1.3 After failure of two alternative courses of H. pylori eradication therapy (if H. pylori positive); and 1.4 After H2 antagonist therapy for 8 weeks; or 2 All of the following: Gastric Ulcer: 2.1 Gastric ulcer proven by endoscopy; and 2.2 Non healing gastric ulcer and excluded malignancy demonstrated by a second endoscopy; and 2.3 After two alternative courses of H. pylori eradication therapy (if H. pylori positive); and 2.4 After H2 antagonist therapy for 12 weeks; or 3 All of the following: GORD: 3.1 Grade 0 GORD (normal endoscopy); and 3.2 Positive 24
Special Authority for Subsidy - Form SA0424Initial application - (Confirmed HIV/AIDS) only from a general physician. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 Confirmed HIV/AIDS; and 2 Any of the following: 2.1 Symptomatic patients aged 6 years and over with HIV/AIDS; or 2.2 Both: 2.2.1 Asymptomatic patients aged 6 years and over; and 2.2.2 CD4 counts < 500 cells/mm3; or 2.3 Both: 2.3.1 Asymptomatic patients aged 6 years and over; and 2.3.2 Viral load counts > 10,000 copies per ml; or 2.4 Symptomatic patients aged under 6 with HIV/AIDS ; or 2.5 Asymptomatic patients aged 12 months and under; or 2.6 Both: 2.6.1 Asymptomatic patients aged 1 to 5 years; and 2.6.2 CD4 counts < 1,000 cells/mm3; or 2.7 Both: 2.7.1 Asymptomatic patients aged 1 to 5 years; and 2.7.2 CD4 counts < 0.25 x total white cell count; or 2.8 Both: 2.8.1 Asymptomatic patients aged under 6 years; and
If a Community Pharmaceutical is the liquid oral form of an antibiotic to which a diluent must be added by the Contractor at the time of dispensing and it is prescribed or ordered by a Practittioner in an amount that does not coincide with the amount contained in one or more standard packs of that Community Pharmaceutical, Subsidy will only be made for the amount prescribed or ordered by the Practitioner in accordance with either Clause 3.1 or Clause 3.3 of the Schedule, unless the Contractor satisfies the Funder that he or she has not been able to dispense the balance of the pack or packs from which the Community Pharmaceutical has been dispensed. In such cases all of that pack or those packs is eligible for Subsidy.
Special Authority for Subsidy - Form SA0430Initial application - (National Heart Foundation risk groups A1:1, A1:2, B, C, D or E) only from a relevant specialist or general practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria: Both: 1 The patient has been offered 3-6 months of counselling and an opportunity to modify lifestyle; and 2 Any of the following: 2.1 Both: 2.1.1 NHF A1:1 - Clinically proven ischaemic heart disease; and 2.1.2 total cholesterol * > 5.5; or 2.2 Both: 2.2.1 NHF A1:2 - Post coronary artery bypass graft (CABG) or angioplasty; and 2.2.2 total cholesterol * > 4.5; or 2.3 Post heart transplant (regardless of cholesterol level); or 2.4 Both: 2.4.1 NHF B:Patients with > 20% 5-year cardiovascular disease risk; and 2.4.2 total cholesterol * > 9.0; or 2.5 Both: 2.5.1 NHF C:15-20% 5-year cardiovascular disease risk; and 2.5.2 total cholesterol * > 9
Special Authority for Manufacturers Price - Form SA0434Initial application only from a general practitioner, general physician, geriatrician or neurologist. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 Patients with swallowing difficulties; and 2 Applicant is a specialist or specialist has authorised treatment. Renewal only from a general practitioner, general physician, geriatrician or neurologist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Manufacturers Price - Form SA0436Initial application - (Patient with prosthetic heart valves) only from a cardiothoracic surgeon, cardiologist or general physician. Approvals valid for 2 years where patient with prosthetic heart valves - as an adjunct to oral anticoagulation for prophylaxis of thromboembolism. Initial application - (Following coronary artery vein bypass graft) only from a cardiothoracic surgeon, cardiologist or general physician. Approvals valid for 1 year where patients after coronary artery vein bypass graft - as an adjunct to aspirin or as monotherapy for patients who are aspirin intolerant as defined below. Initial application - (Transient ischaemic episodes) only from a neurologist, neuro surgeon, cardiologist, vascular surgeon or general physician. Approvals valid for 2 years where patients who continue to have transient ischaemic episodes despite aspirin therapy or have transient ischaemic episodes and are aspirin intolerant as defined below. Renewal - (Fo
Special Authority for Subsidy - Form SA0443Initial application - (Helicobacter pylori infections) only from a general practitioner or relevant specialist. Approvals valid for 6 months for applications meeting the following criteria: Both: 1 Eradication of Helicobacter pylori in patient with proven infection; and 2 Peptic ulcer disease proven by endoscopy. NoteMaximum of two prescriptions (two courses) per patient. Initial application - (Mycobacterial infections) only from a respiratory specialist or infectious disease specialist. Approvals valid for 2 years for applications meeting the following criteria: Any of the following: 1 Mycobacterium Avium Intracellulare Complex infections in patient with AIDS; or 2 Atypical and drug-resistant mycobacterial infection; or 3 All of the following: 3.1 Prophylaxis against disseminated Mycobacterium Avium Intracellulare Complex infection; and 3.2 HIV infection; and 3.3 CD4 count <= 50 cells/mm3. Renewal - (Mycobacterial infection
Special Authority for Subsidy - Form SA0445Initial application only from a relevant specialist. Approvals valid for 5 years for applications meeting the following criteria: Any of the following: 1 Both: 1.1 Acromegaly; and 1.2 Patient has failed surgery, radiotherapy, bromocriptine or other oral therapies; or 2 VIPomas and Glucagonomas - for patients who are seriously ill in order to improve their clinical state prior to definitive surgery.; or 3 Both: 3.1 Gastrinoma; and 3.2 Patient has failed surgery, or metastatic disease after H2 antagoists (or proton pump inhibitors) have failed; or 4 Both: 4.1 Insulinomas; and 4.2 Surgery is contraindicated or has failed; or 5 For pre-operative control of hypoglycaemia and for maintenance therapy; or 6 Both: 6.1 Carcinoidsyndrome (diagnosed by tissue pathology and/or urinary 5HIAA analysis); and 6.2 Disabling symptoms not controlled by maximal medical therapy. NoteThe use of octretide in patients with fis
Special Authority for Subsidy - Form SA0450Initial application only from a psychiatrist. Approvals valid for 12 months for applications meeting the following criteria: Both: 1 Patients suffering from schizophrenia and related psychoses; and 2 Either: 2.1 Failed to respond to full trials (duration of at least 6 weeks each) of effective doses of at least two classes of anti-psychotic agents (refer to guidelines below); or 2.2 Demonstrated intolerance to other neuroleptic agents. NoteClinicians must confirm that informed consent and a satisfactory White Bloodcell Count (WBC) result has been obtained. Diagnosis: Treatment resistant schizophrenia and related psychoses when positive symptoms (delusions, hallucinations and thought disorder) are prominent and/or disabling or when both positive symptoms and negative symptoms (flattened affect, emotional and social withdrawal and poverty of speech) are present. Treatment: Trial therapy undertaken before initiating treatment with clozapine could
Special Authority for Manufacturers Price - Form SA0451Initial application only from a relevant specialist. Approvals valid for 3 years for applications meeting the following criteria: Both: 1 Patients being treated for advanced breast cancer who are refractory to tamoxifen; and 2 Any of the following: 2.1 Unable to tolerate aminoglutethimide; or 2.2 Unable to tolerate megestrol acetate; or 2.3 Unable to tolerate medroxyprogesterone acetate.Renewal only from a relevant specialist. Approvals valid for 3 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Manufacturers Price - Form SA0452Initial application only from a relevant specialist. Approvals valid for 3 years for applications meeting the following criteria: Both: 1 Patients being treated for advanced breast cancer who are refractory to tamoxifen; and 2 Any of the following: 2.1 Unable to tolerate aminoglutethimide; or 2.2 Unable to tolerate megestrol acetate; or 2.3 Unable to tolerate medroxyprogesterone acetate.Renewal only from a relevant specialist. Approvals valid for 3 years where the treatment remains appropriate and the patient is benefiting from treatment.
Guidelines for the use of atypical anti-psychotic agents Diagnosis: Schizophrenia and related psychoses when positive symptoms (delusions, hallucinations and thought disorder) are prominent and/or disabling or when both positive symptoms and negative symptoms (flattened affect, emotional and social withdrawal and poverty of speech) are present. Treatment: Before initiating atypical anti-psychotic therapy, physicians should consider whether the patient is likely to respond to and/or tolerate conventional anti-psychotic therapy and, where appropriate, trial one or more conventional agent prior to use of an atypical agent.
Special Authority for Subsidy - Form SA0456Initial application only from a psychiatrist. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 Patients suffering from schizophrenia and related psychoses who are likely to benefit from anti-psychotic treatment; and 2 Any of the following: 2.1 Effective dose of risperidone has been discontinued because of recurrent acute dystonias; or 2.2 Effective dose of risperidone has been discontinued because of excessive Parkinson-like symptoms; or 2.3 Effective dose of risperidone has been discontinued after 6 weeks because of inadequate clinical response. Renewal only from a psychiatrist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0458Initial application only from a gastroenterologist. Approvals valid for 6 months for applications meeting the following criteria: Both: 1 Primary biliary cirrhosis confirmed by antimitochondrial antibody titre (AMA) > 1:80, and raised cholestatic liver enzymes with or without raised serum IgM or, if AMA is negative, by liver biopsy; and 2 Patient not requiring a liver transplant (bilirubin > 170umol/l; decompensated cirrhosis). NoteLiver biopsy is not usually required for diagnosis but is helpful to stage the diseaseRenewal only from a gastroenterologist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment. NoteActigall is not an appropriate therapy for patients requiring a liver transplant (bilirubin > 170 micromol/l; decompensated cirrhosis). These patients should be referred to an appropriate transplant centreTreatment failure - doubling of serum bilirubin levels, absence of a signi
Special Authority for Subsidy - Form SA0459Initial application only from a gastroenterologist or general physician. Approvals valid for 3 months for applications meeting the following criteria: Both: 1 Mild to moderate ileal, ileocaecal or proximal Crohn's disease; and 2 Any of the following: 2.1 Diabetes; or 2.2 Cushingoid habitus; or 2.3 Osteoporosis where there is significant risk of fracture; or 2.4 Both: 2.4.1 Severe acne; and 2.4.2 Treatment with conventional corticosteroid therapy. Renewal only from a gastroenterologist or general physician. Approvals valid for 3 months where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Manufacturers Price - Form SA0460Initial application - (Patient with prosthetic heart valves) only from a cardiothoracic surgeon, cardiologist or general physician. Approvals valid for 2 years where patient with prosthetic heart valves - as an adjunct to oral anticoagulation for prophylaxis of thromboembolism. Initial application - (Following coronary artery vein bypass graft) only from a cardiothoracic surgeon, cardiologist or general physician. Approvals valid for 1 year where patients after coronary artery vein bypass graft - as an adjunct to aspirin or as monotherapy for patients who are aspirin intolerant as defined below. Initial application - (Transient ischaemic episodes) only from a neurologist, neuro surgeon, cardiologist, vascular surgeon or general physician. Approvals valid for 2 years where patients who continue to have transient ischaemic episodes despite aspirin therapy or have transient ischaemic episodes and are aspirin intolerant as defined below. Renewal - (Fo
Special Authority for Subsidy - Form SA0461Initial application - (Basal cell carcinoma) only from a dermatologist, plastic surgeon or radiation oncologist. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 Basal cell carcinoma unable to be treated surgically or by radiotherapy; and 2 Unsuitablity for surgery confirmed by a Plastic Surgeon or Radiation Oncologist. NoteThe maximum reimbursable dosage is 15 million iu per weekInitial application - (Chronic hepatitis C) only from a relevant specialist. Approvals valid for 12 months where chronic hepatitis C. Initial application - (Indications other than Basal cell carcinoma and Chronic hepatitis C) only from a relevant specialist. Approvals valid for 2 years for applications meeting the following criteria: Any of the following: 1 Chronic myelogenous leukaemia; or 2 Hairy cell leukaemia; or 3 Multiple myeloma; or 4 Chronic active hepatitis B. Renewal - (Basal cell carcinoma) only from a dermato
Special Authority for Subsidy - Form SA0464Initial application only from a diabetologist, general physician or paediatrician. Approvals valid without further renewal unless notified for applications meeting the following criteria: Any of the following: 1 Both: 1.1 Use alone (monotherapy); and 1.2 The patient is unable to use any other insulins including those on insulin pump treatment; or 2 Both: 2.1 Use with Humulin 70/30 or Humulin 80/20; and 2.2 A reasonable trial of Humulin N has been undertaken and it is not effective or not well tolerated; or 3 Both: 3.1 Use with insulins (aside from insulin zinc suspension) other than Humulin 70/30, Humulin 80/20, or Humulin N; and 3.2 A reasonable trial of one or more of these Humulin insulins has been undertaken and it is/are ineffective or not well tolerated; or 4 Both: 4.1 Use with Humulin L or Humulin U; and 4.2 Use with Humulin N is not appropriate; or 5 Both: 5.1 Use with other insulin zinc suspensio
Special Authority for Alternate Subsidy - Form SA0466Initial application only from a relevant specialist or general practitioner. Approvals valid for 5 years for applications meeting the following criteria: Any of the following: 1 Angina that is not controlled by other anginal medications; or 2 Continuation of treatment commenced prior to 1 June 1999; or 3 Receiving maximal antihypertensive therapy, requires a DHP CCB, and cannot tolerate felodipine. Renewal only from a relevant specialist or general practitioner. Approvals valid for 5 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0467Initial application only from a relevant specialist. Approvals valid for 6 months for applications meeting the following criteria: Both: 1 Paget's disease; and 2 Any of the following: 2.1 Bone or articular pain; or 2.2 Bone deformity; or 2.3 Bone, articular or neurological complications; or 2.4 Asymptomatic disease, but risk of complications due to site (base of skull, spine, long bones of lower limbs); or 2.5 Preparation for orthopaedic surgery. Renewal only from a relevant specialist. Approvals valid for 6 months where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0470Initial application - (Organ transplant) only from a relevant specialist. Approvals valid without further renewal unless notified where organ transplant. Initial application - (Bone marrow transplant or Graft v host disease) only from a relevant specialist. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 Bone marrow transplant; or 2 Graft v host disease. Initial application - (Psoriasis) only from a dermatologist. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 Psoriasis; and 2 Applicant must state which systemic and topical therapies have failed. Initial application - (Severe atopic dermatitis) only from a dermatologist. Approvals valid for 6 months for applications meeting the following criteria: Both: 1 Severe atopic dermatitis; and 2 Not responsive to topical therapy, oral antihistamines and other commonly used orthodox therapies. Initial application - (N
Special Authority for Subsidy - Form SA0471Initial application - (Breast cancer) from any medical practitioner. Approvals valid for 1 year where breast cancer in pre menopausal women unwilling or unable to undergo surgical or radiation oophorectomy. Initial application - (Prostate cancer) only from an oncologist, urologist or endocrinologist. Approvals valid for 1 year where advanced prostatic cancer when orchidectomy is contraindicated or where the patient strongly opposes orchidectomy. NoteNot to be prescribed with an anti-androgen except for a period of three weeks, if necessary, when GnRH analogue therapy is intiatedInitial application - (Endometriosis) only from a gynaecologist. Approvals valid for 3 months for applications meeting the following criteria: Both: 1 Endometriosis ; and 2 Either: 2.1 6 months treatment with medroxyprogesterone acetate, danazol or dimetriose has proven ineffective; or 2.2 The patient has failed to tolerate the treatment with medroxyprogesterone
Special Authority for Subsidy - Form SA0472Initial application only from a cardiologist. Approvals valid for 2 years for applications meeting the following criteria: Any of the following: 1 Both: 1.1 Congestive heart failure; and 1.2 Cannot tolerate currently fully subsidised ACE inhibitors due to persistent cough that resolves on cessation and recurs on re-challenge with ACE inhibitor; or 2 Patients who have experienced angioedema on an ACE inhibitor at any time in the past; or 3 Patients who have experienced angioedema (even if not using an ACE inhibitor) in the last 2 years. Renewal only from a cardiologist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0473Initial application from any medical practitioner. Approvals valid for 1 year where the patient is likely to benefit from treatment. Note Applications to be made on the approved forms which are available from: The Co-ordinatorGaucher's Treatment PanelPhone: (04) 460 4990 PHARMAC, PO Box 10 254 WellingtonFacsimile: (04) 916 7571Email: erin.murphy@pharmac.govt.nzPrescriptions for patients approved for treatment must be written by respiratory physicians or paediatricians who have experience and expertise in treating cystic fibrosis.
Special Authority for Subsidy - Form SA0488Initial application only from a gastroenterologist, general surgeon or general physician. Approvals valid for 3 months for applications meeting the following criteria: Both: 1 Mild to moderate ileal, ileocaecal or proximal Crohn's disease; and 2 Any of the following: 2.1 Diabetes; or 2.2 Cushingoid habitus; or 2.3 Osteoporosis where there is significant risk of fracture; or 2.4 Both: 2.4.1 Severe acne; and 2.4.2 Treatment with conventional corticosteroid therapy. Renewal only from a gastroenterologist, general surgeon or general physician. Approvals valid for 3 months where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Manufacturers Price - Form SA0489Initial application - (Conditions other than transient ischaemic episodes) only from a cardiothoracic surgeon, cardiologist or general physician. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 Patients with prosthetic heart valves - as an adjunct to oral anticoagulation for prophylaxis of thromboembolism; or 2 Both: 2.1 Patients after coronary artery vein bypass graft; and 2.2 Any of the following: 2.2.1 aspirin induced asthma; or 2.2.2 aspirin induced anaphylaxi; or 2.2.3 significant aspirin induced bleeding excluding bruising. Initial application - (Transient ischaemic episodes) only from a neurologist, neuro surgeon, cardiologist, vascular surgeon or general physician. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 Patients who continue to have transient ischaemic episodes despite aspirin therapy; or 2 Both: 2.1 Patients wh
Special Authority for Subsidy - Form SA0490Initial application only from a relevant specialist. Approvals valid for 2 years for applications meeting the following criteria: Any of the following: 1 Requires but is not able to tolerate metformin therapy; or 2 Requires metformin but metformin is contraindicated; or 3 Has not responded to or tolerated the maximum appropriate dose of metformin. Renewal only from a relevant specialist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0494Initial application only from an ophthalmologist. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 Both: 1.1 Primary open-angle glaucoma; and 1.2 Any of the following: 1.2.1 Patient cannot tolerate Beta-blockers, or Beta-blockers are contraindicated; or 1.2.2 Patient cannot tolerate Pilocarpine, or Pilocarpine is contraindicated; or 1.2.3 Patient cannot tolerate Dorzolamide, or Dorzolamide is contraindicated; or 1.2.4 A reduction in intraocular pressure of 15% or more is not achieved or maintained using dorzolamide either alone or in combination with a beta-blocker; or 2 There is progressive visual field loss and/or optic nerve damage persists after treatment with dorzolamide either alone or in combination with a beta-blocker. NoteSubsidised as monotherapy onlyRenewal only from an ophthalmologist. Approvals valid for 2 years where the treatment remains appropriate and the patient
Special Authority for Alternate Subsidy - Form SA0500Initial application from any medical practitioner. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 Either: 1.1 Patient is on a Social Welfare benefit; or 1.2 Patient has an income no greater than the benefit; and 2 Has tried at least one of the fully funded options and has been unable to tolerate it. Renewal from any medical practitioner. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 Patient is on a Social Welfare benefit; or 2 Patient has an income no greater than the benefit. NoteThe approval numbers of Special Authorities approved after 1 November 1999 are interchangeable between Mercilon and Marvelon. The additional subsidy will fund Mercilon and Marvelon up to the manufacturer's price for each of these products as identified on the Schedule at 1 November 1999Special Authorities approved before 1 November 1999 remain valid until the expiry d
Special Authority for Subsidy - Form SA0508Initial application only from a relevant specialist or general practitioner. Approvals valid for 2 years for applications meeting the following criteria: All of the following: 1 Patient with raised blood pressure; and 2 A beta blocker or diuretic is contraindicated; or not well tolerated; or insufficient to control blood pressure adequately at appropriate doses; and 3 An ACE inhibitor is contraindicated; or not well tolerated; or insufficient to control blood pressure adequately at appropriate doses. Renewal only from a relevant specialist or general practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0509Initial application only from a psychiatrist. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 Patient with first episode schizophrenia or related psychoses; or 2 Both: 2.1 Patient suffering from schizophrenia and related psychoses who is likely to benefit from anti-psychotic treatment; and 2.2 Both: 2.2.1 An effective dose of risperidone had been trialled and has been discontinued either because of; and 2.2.2 Any of the following: 2.2.2.1 Patient has recurrent acute dystonias; or 2.2.2.2 Patient has excessive Parkinson-like symptoms; or 2.2.2.3 Patient has hyperprolactinaemia; or 2.2.2.4 Patient has inadequate clinical response after four weeks. NoteDiscontinued treatment should be notified to HealthPAC if possibleRenewal only from a psychiatrist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Alternate Subsidy - Form SA0510Initial application only from a relevant specialist or general practitioner. Approvals valid for 2 years for applications meeting the following criteria: Any of the following: 1 Angina that is not controlled by other anginal medications (including felodipine); or 2 Patient was taking Adalat Oros for the treatment of angina prior to 1 June 1999; or 3 Receiving maximal antihypertensive therapy, requires a DHP CCB, and cannot tolerate felodipine. Renewal only from a relevant specialist or general practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0511Initial application only from a geriatrician, rheumatologist, endocrinologist, gynaecologist or general physician. Approvals valid for 2 years for applications meeting the following criteria: All of the following: 1 Severe osteoporosis; and 2 History of two previous significant osteoporotic fractures demonstrated radiologically; and 3 T-Score <= -3.0 (bone mass density (BMD) >= 3.0 standard deviations below the mean normal value in young adults). NoteIn line with the Australian guidelines for funding alendronate, a vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral bodyRenewal only from a geriatrician, rheumatologist, endocrinologist, gynaecologist or general physician. Approvals valid for 2 years where the tr
Special Authority for Subsidy - Form SA0512Initial application only from a gastroenterologist, general surgeon or general physician. Approvals valid for 3 months for applications meeting the following criteria: Both: 1 Mild to moderate ileal, ileocaecal or proximal Crohn's disease; and 2 Either: 2.1 Diabetes; or 2.2 Both: 2.2.1 Treatment with conventional corticosteroid therapy; and 2.2.2 Any of the following: 2.2.2.1 Cushingoid habitus; or 2.2.2.2 Osteoporosis where there is significant risk of fracture; or 2.2.2.3 Severe acne. Renewal only from a gastroenterologist, general surgeon or general physician. Approvals valid for 3 months where the patient has had no more than 1 prior approval in the last 12 months. The patient must have had no more than 1 prior approval in the last year. NoteClinical trials for Entocort CIR use beyond three months demonstrated no improvement in relapse rate
Special Authority for Subsidy - Form SA0513Initial application - (Narcolepsy) only from a neurologist. Approvals valid for 24 months where narcolepsy. Initial application - (ADHD in patients aged 5 years or over) only from a paediatrician or psychiatrist. Approvals valid for 24 months for applications meeting the following criteria: Both: 1 ADHD (Attention Deficient and Hyperactivity Disorder) patients aged 5 years or over; and 2 Diagnosed according to DSM-IV or ICD 10 criteria. Initial application - (ADHD in patients under 5 years of age) only from a paediatrician or psychiatrist. Approvals valid for 12 months for applications meeting the following criteria: Both: 1 ADHD (Attention Deficient and Hyperactivity Disorder) patients under 5 years of age; and 2 Diagnosed according to DSM-IV or ICD 10 criteria. Renewal - (Narcolepsy or ADHD in patients under 5 years of age) only from a neurologist, paediatrician or psychiatrist. Approvals valid for 24 months where the treatment remains appr
Special Authority for Subsidy - Form SA0516Initial application from any medical practitioner. Approvals valid for 2 years where the patient is likely to benefit from treatment. Note Applications to be made on the approved forms which are available from: Prof. Wayne CutfieldNational Co-ordinatorNew Zealand Growth Hormone CommitteeC/- Department of PaediatricsUniversity of AucklandPrivate Bag 92019AUCKLAND
Special Authority for Subsidy - Form SA0523Initial application only from a relevant specialist or general practitioner. Approvals valid for 6 months for applications meeting the following criteria: All of the following: 1 Diagnosis of asthma confirmed; and 2 Inhaler/device technique checked; and 3 Patient monitors PEFR regularly during exacerbations where appropriate; and 4 Any of the following: 4.1 At least three months of 1500 ug or more daily of inhaled beclomethasone or budesonide for adult; or 4.2 At least three months of 750 ug or more daily of inhaled fluticasone) for adult; or 4.3 At least three months of 800 ug or more daily inhaled beclomethasone or budesonide for child; or 4.4 At least three months of 400 ug or more daily inhaled fluticasone) for child; and 5 Either: 5.1 Short acting beta agonist used at least 3-4 times daily; or 5.2 Nocturnal awakenings at least twice a week. Renewal only from a relevant specialist or general practitioner. Appro
Special Authority for Subsidy - Form SA0528Initial application - (Narcolepsy) only from a neurologist or respiratory specialist. Approvals valid for 24 months where narcolepsy. Initial application - (ADHD in patients 5 or over) only from a paediatrician, psychiatrist or general practitioner. Approvals valid for 24 months for applications meeting the following criteria: All of the following: 1 ADHD (Attention Deficient and Hyperactivity Disorder) patients aged 5 years or over; and 2 Diagnosed according to DSM-IV or ICD 10 criteria; and 3 Applicant is a specialist or specialist has recommended treatment. Initial application - (ADHD in patients under 5) only from a paediatrician or psychiatrist. Approvals valid for 12 months for applications meeting the following criteria: Both: 1 ADHD (Attention Deficient and Hyperactivity Disorder) patients under 5 years of age; and 2 Diagnosed according to DSM-IV or ICD 10 criteria. Renewal - (Narcolepsy) only from a neurologist or respiratory spec
ACE inhibitors will be funded to the level of the ex-manufacturer price listed in the Schedule for patients who were taking an ACE inhibitor for the treatment of congestive heart failure prior to 1 June 1998. The prescription must be endorsed accordingly. We recommend that the words used to indicate eligibility are "certified condition" or an appropriate description of the patient such as "congestive heart failure", "CHF", "congestive cardiac failure" or "CCF". Additional subsidy for lisinopril is available only up to the price of the least expensive brand listed in the Schedule. Definition of Congestive Heart FailureAt the request of some prescribers the PTAC Cardiovascular subcommittee has provided adefinition of congestive heart failure for the purposes of the funding of the manufacturer'ssurcharge: "Clinicians should use their clinical judgement. Existing patients would be eligible for thefunding of the surcharge if the patient shows signs and symptoms of congestive heart failure, and requir
Additional subsidy by endorsement for:Moclobemide tab 150 mg x 100 (Aurorix) up to $47.00Moclobemide tab 300 mg x 60 (Aurorix) up to $56.40Nefazadone tab 100 mg x 56 (Serzone) up to $20.16Nefazadone tab 200 mg x 56 (Serzone) up to $40.32Citalopram tab 20 mg x 28 (Cipramil) up to $27.00is available for patients who: * are taking moclobemide or nefazodone on 1 December 1999 or citalopram on 1 February2000; * have previously responded to treatment with moclobemide or nefazodone or citalopram; * have had a trial of fluoxetine and have to discontinue due to: - inability to tolerate the drug due to side effects OR - failed to respond to an adequate dose and duration of treatment; * have contraindications to fluoxetine (eg pre-existing significant levels of nausea, breastfeeding, potential drug interactions); The prescription must be endorsed accordingly. We recommend that the words used to indicate eligibility are "certified condition" however these particular words are not a requirement.
Special Authority for Subsidy - Form SA0538Initial application only from a gastroenterologist, infectious disease specialist, paediatrician or general physician. Approvals valid for 1 year for applications meeting the following criteria: Both: 1 Any of the following: 1.1 All of the following: 1.1.1 HBsAg positive for more than 6 months; and 1.1.2 HBeAg positive or HBV DNA positive defined as >0.6 pg/ml by quantitative PCR at reference laboratory; and 1.1.3 ALT greater than twice upper limit of normal or stage 3 or 4 fibrosis on liver histology clinical/radiological evidence of cirrhosis; or 1.2 HBV DNA positive cirrhosis prior to liver transplantation; or 1.3 HBsAg positive and have had a liver, kidney, heart, lung or bone marrow transplant; and 2 All of the following: 2.1 No continuing alcohol abuse or intravenous drug use; and 2.2 Not coinfected with HCV, HDV, or HIV; and 2.3 Neither ALT nor AST greater than 10 times upper limit of normal; and 2.4
Special Authority for Subsidy - Form SA0539Initial application from any medical practitioner. Approvals valid for 5 years where the patient is likely to benefit from treatment. NoteApplications to be made on the approved forms which are available from: The Co-ordinatorPhone: 09 580 9176Multiple Sclerosis Treatment CommitteeFacsimile: 09 580 9205Level 3, Unisys HouseEmail: murray@ppc.govt.nz650 Great South Road, PenrosePrivate Bag, AUCKLANDBudget managed by appointed clinicians on the Multiple Sclerosis Treatment Assessments Committee (MSTAC). Applications will be considered by MSTAC at its regular meetings and approved subject to eligibility according to the Entry and Stopping criteria (below). Completed application forms must be sent to the co-ordinator for MSTAC and will be considered by MSTAC at the next practicable opportunity. Notification of MSTAC's decision will be sent to the patient, the applying clinician and the patient's GP (if specified). These agents will N
Additional subsidy by endorsement for:Moclobemide tab 150 mg x 100 (Aurorix) up to $47.00Moclobemide tab 300 mg x 60 (Aurorix) up to $56.40Nefazadone tab 100 mg x 56 (Serzone) up to $20.16Nefazadone tab 200 mg x 56 (Serzone) up to $40.32Citalopram tab 20 mg x 28 (Cipramil) up to $27.00is available for patients who: * were taking moclobemide or nefazodone on 1 December 1999 or citalopram on 1 February 2000; or* have previously responded to treatment with moclobemide, nefazodone or citalopram; or* have had a trial of fluoxetine and have to discontinue due to: - inability to tolerate the drug due to side effects; or - failed to respond to an adequate dose and duration of treatment; or* have contraindications to fluoxetine (eg pre-existing significant levels of nausea, breastfeeding, potential drug interactions); The prescription must be endorsed accordingly. We recommend that the words used to indicate eligibility are "certified condition" however these words are not a requirement.
Alphagan is subsidised for use as either monotherapy or as an adjunctive agent for the treatment of glaucoma. Alphagan should not be prescribed for a person in whom less expensive first line agents for the treatment of glaucoma are not contraindicated unless: (a) that person has previously trialled all other such subsidised agents (except dorzolamide hydrochloride); and(b) those trials have indicated that that person does not respond adequately to or does not tolerate treatment with those other agents.
Special Authority for Subsidy - Form SA0551Initial application only from a paediatrician, neurologist or general physician. Approvals valid for 15 months for applications meeting the following criteria: Any of the following: 1 Was on NAED therapy before 1 September 2000; or 2 Seizures are not adequately controlled with optimal older anti-epilepsy drug treatment; or 3 Seizures are controlled adequately but who experience unacceptable side effects from older anti-epilepsy drug treatment. NoteApproval entitles patients to a subsidy for one NAED. Dual NAED therapy will be subsidised for patients who were already stabilised on two NAEDs on or before 31 July 2000 or, for whom a second NAED has been added to therapy with one NAED provided an attempt to withdraw one NAED has been made and was unsuccessful. "Optimal older anti-epilepsy drug therapy" is defined as treatment with those older anti-epilepsy drugs which are indicated and clinically appropriate for the patient, given singly and in combin
Special Authority for Subsidy - Form SA0554Initial application only from a relevant specialist. Approvals valid without further renewal unless notified for applications meeting the following criteria: Either: 1 Liver transplant recipients; or 2 Renal transplant recipients - as rescue therapy only. Renewal only from a relevant specialist. Approvals valid without further renewal unless notified where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0556Initial application - (Confirmed HIV/AIDS) only from a named general physician. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 Confirmed HIV/AIDS; and 2 Any of the following: 2.1 Symptomatic patient; or 2.2 Both: 2.2.1 Asymptomatic patient; and 2.2.2 Patient aged 12 months and under; or 2.3 Both: 2.3.1 Asymptomatic patient; and 2.3.2 Patient has viral load counts > 10,000 copies per ml or equivalent value on the Chiron test; or 2.4 All of the following: 2.4.1 Asymptomatic patient; and 2.4.2 Patient aged 1 to 5 years; and 2.4.3 CD4 counts < 1,000 cells/mm3; or 2.5 All of the following: 2.5.1 Asymptomatic patient; and 2.5.2 Patient aged 1 to 5 years; and 2.5.3 CD4 counts < 0.25 x total white cell count; or 2.6 All of the following: 2.6.1 Asymptomatic patient; and 2.6.2 Patient aged 6 years and over; and 2.6.3 CD4 counts
Special Authority for Subsidy - Form SA0557Initial application - (Single NAED Therapy) only from a paediatrician, neurologist or general physician. Approvals valid for 15 months for applications meeting the following criteria: Any of the following: 1 Was on NAED therapy before 1 September 2000; or 2 Seizures are not adequately controlled with optimal older anti-epilepsy drug treatment; or 3 Seizures are controlled adequately but who experience unacceptable side effects from older anti-epilepsy drug treatment. Note"Optimal older anti-epilepsy drug therapy" is defined as treatment with those older anti-epilepsy drugs which are indicated and clinically appropriate for the patient, given singly and in combination in adequate doses for the patient's age, weight, and other features affecting the pharmacokinetics of the drug with good evidence of complianceAs a guideline, clinical trials have referred to a notional 50% reduction in seizure frequency as an indicator of success with anti-convulsan
Additional subsidy by endorsement for:Moclobemide tab 150mg x 100 (Aurorix) up to $32.90Moclobemide tab 300mg x 60 (Aurorix) up to $39.48Nefazodone tab 100mg x 56 (Serzone) up to $20.16Nefazodone tab 200mg x 56 (Serzone) up to $40.32Citalopram tab 20mg x 28 (Cipramil) up to $27.00is available for patients who: * were taking moclobemide or nefazodone on 1 December 1999 or citalopram on 1 February 2000; or* have previously responded to treatment with moclobemide, nefazodone or citalopram; or* have had a trial of fluoxetine and have had to discontinue due to - inability to tolerate the drug due to side effects; or - failed to respond to an adequate dose and duration of treatment; or* have contraindications to fluoxetine (eg pre-existing significant levels of nausea, breastfeeding, potential drug interactions). The prescription must be endorsed accordingly. We recommend that the words used to indicate eligibility are "certified condition" however these words are not a requirement.
Additional subsidy by endorsement for:Moclobemide tab 150mg x 100 (Aurorix) up to $32.90Moclobemide tab 300mg x 60 (Aurorix) up to $39.48Nefazodone tab 100mg x 56 (Serzone) up to $20.16Nefazodone tab 200mg x 56 (Serzone) up to $40.32Citalopram tab 20mg x 28 (Cipramil and Celapram) up to $10.00Paroxetine hydrochloride tab 20 mg x 30 (Aropax) up to $35.02is available for patients who: * were taking moclobemide or nefazodone on 1 December 1999 or citalopram on 1 February 2000; or paroxetine hydrochloride on Februrary 2001; or * have previously responded to treatment with moclobemide or nefazodone or citalopram or paroxetine hydrochloride; or* have had a trial of fluoxetine and have had to discontinue due to - inability to tolerate the drug due to side effects; or - failed to respond to an adequate dose and duration of treatment; or* have contraindications to fluoxetine (eg pre-existing significant levels of nausea, breastfeeding, potential drug interactions). The prescription must be e
Special Authority for Subsidy - Form SA0563Initial application only from a relevant specialist. Approvals valid for 2 years for applications meeting the following criteria: Any of the following: 1 Both: 1.1 Acromegaly; and 1.2 Patient has failed surgery, radiotherapy, bromocriptine and other oral therapies; or 2 VIPomas and Glucagonomas - for patients who are seriously ill in order to improve their clinical state prior to definitive surgery.; or 3 Both: 3.1 Gastrinoma; and 3.2 Either: 3.2.1 Patient has failed surgery; or 3.2.2 Patient in metastatic disease after H2 antagonists (or proton pump inhibitors) have failed; or 4 Both: 4.1 Insulinomas; and 4.2 Surgery is contraindicated or has failed; or 5 For pre-operative control of hypoglycaemia and for maintenance therapy; or 6 Both: 6.1 Carcinoid syndrome (diagnosed by tissue pathology and/or urinary 5HIAA analysis); and 6.2 Disabling symptoms not controlled by maximal medical therapy. No
Trandolapril will be funded to the level of the ex-manufacturer price listed in the Schedule for patients who were taking these ACE inhibitors for the treatment of congestive heart failure prior to 1 June 1998. The prescription must be endorsed accordingly. We recommend that the words used to indicate eligibility are "certified condition" or an appropriate description of the patient such as "congestive heart failure", "CHF", "congestive cardiac failure" or "CCF". Definition of Congestive Heart Failure At the request of some prescribers the PTAC Cardiovascular subcommittee has provided a definition of congestive heart failure for the purposes of the funding of the manufacturer's surcharge: "Clinicians should use their clinical judgement. Existing patients would be eligible for the funding of the surcharge if the patient shows signs and symptoms of congestive heart failure, and requires or has in the past required concomitant treatment with a diuretic. The definition could also be considered to include pat
Perindopril will be funded to the level of the ex-manufacturer price listed in the Schedule for patients who were taking these ACE inhibitors for the treatment of congestive heart failure prior to 1 June 1998. The prescription must be endorsed accordingly. We recommend that the words used to indicate eligibility are "certified condition" or an appropriate description of the patient such as "congestive heart failure", "CHF", "congestive cardiac failure" or "CCF". Definition of Congestive Heart Failure At the request of some prescribers the PTAC Cardiovascular subcommittee has provided a definition of congestive heart failure for the purposes of the funding of the manufacturer's surcharge: "Clinicians should use their clinical judgement. Existing patients would be eligible for the funding of the surcharge if the patient shows signs and symptoms of congestive heart failure, and requires or has in the past required concomitant treatment with a diuretic. The definition could also be considered to include pati
Special Authority for Subsidy - Form SA0569Initial application only from a geriatrician, rheumatologist, endocrinologist, gynaecologist or general physician. Approvals valid for 2 years for applications meeting the following criteria: All of the following: 1 Severe osteoporosis; and 2 History of one previous significant osteoporotic fractures demonstrated radiologically; and 3 T-Score <= -3.0 (bone mass density (BMD) >= 3.0 standard deviations below the mean normal value in young adults). NoteIn line with the Australian guidelines for funding alendronate, a vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body. Renewal only from a geriatrician, rheumatologist, endocrinologist, gynaecologist or general physician. Approvals valid for 2 years where the t
Special Authority for Subsidy - Form SA0572Initial application only from a psychiatrist. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 Patient presenting with first episode schizophrenia or related psychoses; or 2 Both: 2.1 Patients suffers from schizophrenia or related psychoses ; and 2.2 Either: 2.2.1 A trial of risperidone has been discontinued because of unacceptable side effects; or 2.2.2 A trial of risperidone has been discontinued because of inadequate response. Renewal only from a psychiatrist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
Subsidy is available for patients with poorly controlled asthma where: a) at least three months of 750 mcg or more daily of inhaled beclomethasone or budesonide(or 400 mcg of fluticasone) for adults has been used; orb) at least three months of 400 mcg or more daily of inhaled beclomethasone or budesonide (or 200mcg of fluticasone) for children 12 years or older has been used; The prescription must be endorsed accordingly. We recommend that the words used to indicateeligibility are "poor control with ICS" or "certified condition".
Special Authority for Subsidy - Form SA0575Initial application - (Confirmed HIV/AIDS) only from a named general physician. Approvals valid without further renewal unless notified for applications meeting the following criteria: Both: 1 Confirmed HIV/AIDS; and 2 Any of the following: 2.1 Symptomatic patient; or 2.2 Both: 2.2.1 Asymptomatic patient; and 2.2.2 Patient aged 12 months and under; or 2.3 Both: 2.3.1 Asymptomatic patient; and 2.3.2 Patient has viral load counts > 10,000 copies per ml or equivalent value on the Chiron test; or 2.4 All of the following: 2.4.1 Asymptomatic patient; and 2.4.2 Patient aged 1 to 5 years; and 2.4.3 CD4 counts < 1,000 cells/mm3; or 2.5 All of the following: 2.5.1 Asymptomatic patient; and 2.5.2 Patient aged 1 to 5 years; and 2.5.3 CD4 counts < 0.25 x total white cell count; or 2.6 All of the following: 2.6.1 Asymptomatic patient; and 2.6.2 Patient aged 6 years and over
Special Authority for Subsidy - Form SA0579Initial application - (Cystic fibrosis or renal failure) only from a relevant specialist. Approvals valid for 3 years for applications meeting the following criteria: Either: 1 cystic fibrosis; or 2 chronic renal failure or continuous ambulatory peritoneal dialysis (CAPD) patient. Initial application - (Indications other than cystic fibrosis or renal failure) only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria: Any of the following: 1 cancer in children; or 2 cancers affecting alimentary tract where there are malabsorption problems in patients over the age of 20 years; or 3 failure to thrive; or 4 growth deficiency; or 5 bronchopulmonary dysplasia; or 6 premature and post premature infant. Renewal - (Cystic fibrosis or renal failure) only from a relevant specialist or general practitioner on the recommendation of such a specialist. Approvals valid for 3 years for applicatio
Special Authority for Subsidy - Form SA0580Initial application - (Inborn errors of metabolism) only from a relevant specialist. Approvals valid for 3 years where inborn errors of metabolism. Initial application - (Indications other than inborn errors of metabolism) only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria: Any of the following: 1 failure to thrive ; or 2 growth deficiency; or 3 bronchopulmonary dysplasia ; or 4 fat malabsorption ; or 5 lymphangiectasia; or 6 short bowel syndrome ; or 7 infants with necrotising enterocolitis; or 8 biliary atresia. Renewal - (Inborn errors of metabolism) only from a relevant specialist or general practitioner on the recommendation of such a specialist. Approvals valid for 3 years for applications meeting the following criteria: Both: 1 The treatment remains appropriate and the patient is benefiting from treatment; and 2 General Practitioners must include the name of
Special Authority for Subsidy - Form SA0581Initial application - (Cystic fibrosis) only from a relevant specialist. Approvals valid for 3 years for applications meeting the following criteria: Both: 1 infant aged four years or under; and 2 cystic fibrosis. Initial application - (Indications other than cystic fibrosis) only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria: Both: 1 infant aged four years or under; and 2 Any of the following: 2.1 cancer in children; or 2.2 failure to thrive; or 2.3 growth deficiency; or 2.4 bronchopulmonary dysplasia; or 2.5 premature and post premature infants. Renewal - (Cystic fibrosis) only from a relevant specialist or general practitioner on the recommendation of such a specialist. Approvals valid for 3 years for applications meeting the following criteria: Both: 1 The treatment remains appropriate and the patient is benefiting from treatment; and 2 General Practiti
Special Authority for Subsidy - Form SA0582Initial application only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria: Either: 1 protein losing enteropathy; or 2 high protein needs (eg burns). Renewal only from a relevant specialist or general practitioner on the recommendation of such a specialist. Approvals valid for 1 year for applications meeting the following criteria: Both: 1 The treatment remains appropriate and the patient is benefiting from treatment; and 2 General Practitioners must include the name of the specialist and date contacted.
Special Authority for Subsidy - Form SA0585Initial application - (Cystic fibrosis) only from a relevant specialist. Approvals valid for 3 years for applications meeting the following criteria: All of the following: 1 Cystic fibrosis; and 2 other lower calorie products have been tried; and 3 patient has substantially increased metabolic requirements; and 4 Either: 4.1 The product is to be used as a supplement; or 4.2 The product is to be used as a complete diet.Initial application - (Indications other than cystic fibrosis) only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria: All of the following: 1 Any of the following: 1.1 any condition causing malabsorption ; or 1.2 failure to thrive ; or 1.3 increased nutritional requirements.; and 2 other lower calorie products have been tried; and 3 patient has substantially increased metabolic requirements; and 4 Either: 4.1 The product is to be used a
Special Authority for Subsidy - Form SA0587Initial application only from a relevant specialist. Approvals valid for 3 years for applications meeting the following criteria: Both: 1 acute or chronic renal failure; and 2 Either: 2.1 The product is to be used as a supplement (maximum 500 ml per day); or 2.2 The product is to be used as a complete diet.Renewal only from a relevant specialist or general practitioner on the recommendation of such a specialist. Approvals valid for 3 years for applications meeting the following criteria: All of the following: 1 The treatment remains appropriate and the patient is benefiting from treatment; and 2 Either: 2.1 The product is to be used as a supplement (maximum 500 ml per day); or 2.2 The product is to be used as a complete diet; and 3 General Practitioners must include the name of the specialist and date contacted.
Special Authority for Subsidy - Form SA0588Initial application only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria: Both: 1 CORD patients who have hypercapnia; and 2 Either: 2.1 The product is to be used as a supplement (maximum 500 ml per day); or 2.2 The product is to be used as a complete diet.Renewal only from a relevant specialist or general practitioner on the recommendation of such a specialist. Approvals valid for 1 year for applications meeting the following criteria: All of the following: 1 The treatment remains appropriate and the patient is benefiting from treatment; and 2 Either: 2.1 The product is to be used as a supplement (maximum 500 ml per day); or 2.2 The product is to be used as a complete diet; and 3 General Practitioners must include the name of the specialist and date contacted.
Special Authority for Subsidy - Form SA0589Initial application only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria: All of the following: 1 Anorexia and weight loss; and 2 Either: 2.1 decompensating liver disease without encephalopathy ; or 2.2 protein losing gastro-enteropathy; and 3 Either: 3.1 The product is to be used as a supplement (maximum 500 ml per day); or 3.2 The product is to be used as a complete diet.Renewal only from a relevant specialist or general practitioner on the recommendation of such a specialist. Approvals valid for 1 year for applications meeting the following criteria: All of the following: 1 The treatment remains appropriate and the patient is benefiting from treatment; and 2 Either: 2.1 The product is to be used as a supplement (maximum 500 ml per day); or 2.2 The product is to be used as a complete diet; and 3 General Practitioners must include the name of the specialis
Special Authority for Subsidy - Form SA0590Initial application only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria: All of the following: 1 infant aged one to six years; and 2 Any of the following: 2.1 any condition causing malabsorption ; or 2.2 failure to thrive; or 2.3 increased nutritional requirements; and 3 Either: 3.1 The product is to be used as a supplement (maximum 500 ml per day); or 3.2 The product is to be used as a complete diet.Renewal only from a relevant specialist or general practitioner on the recommendation of such a specialist. Approvals valid for 1 year for applications meeting the following criteria: All of the following: 1 The treatment remains appropriate and the patient is benefiting from treatment; and 2 Either: 2.1 The product is to be used as a supplement (maximum 500 ml per day); or 2.2 The product is to be used as a complete diet; and 3 General Practitioners must
Special Authority for Subsidy - Form SA0591Initial application only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria: Both: 1 Any of the following: 1.1 enteral feeding; or 1.2 nasogastric; or 1.3 nasoduodenal ; or 1.4 nasojejunal; or 1.5 gastrostomy/jejunostomy; and 2 Either: 2.1 The product is to be used as a supplement; or 2.2 The product is to be used as a complete diet.Renewal only from a general practitioner or relevant specialist. Approvals valid for 1 year for applications meeting the following criteria: All of the following: 1 The treatment remains appropriate and the patient is benefiting from treatment; and 2 Either: 2.1 The product is to be used as a supplement; or 2.2 The product is to be used as a complete diet; and 3 General Practitioners must include the name of the specialist and date contacted.
Special Authority for Subsidy - Form SA0592Initial application only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria: Both: 1 Any of the following: 1.1 malabsorption ; or 1.2 short bowel syndrome; or 1.3 enterocutaneous fistulas ; or 1.4 pancreatitis; and 2 Either: 2.1 The product is to be used as a supplement (maximum 500 ml per day); or 2.2 The product is to be used as a complete diet.NoteEach of these products is highly specialised and would be prescribed only by an expert for a specific disorder. The alternative is hospitalisation. Elemental 028 Extra is more expensive than other products listed in this section and should only be used where the alternatives have been tried first and/or are unsuitable. Renewal only from a relevant specialist or general practitioner on the recommendation of such a specialist. Approvals valid for 1 year for applications meeting the following criteria: All of the following:
Special Authority for Subsidy - Form SA0594Initial application only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria: Both: 1 Type I and II diabetics who require nutritional supplementation.; and 2 Either: 2.1 The product is to be used as a supplement (maximum 500 ml per day); or 2.2 The product is to be used as a complete diet.Renewal only from a relevant specialist or general practitioner on the recommendation of such a specialist. Approvals valid for 1 year for applications meeting the following criteria: All of the following: 1 The treatment remains appropriate and the patient is benefiting from treatment; and 2 Either: 2.1 The product is to be used as a supplement (maximum 500 ml per day); or 2.2 The product is to be used as a complete diet; and 3 General Practitioners must include the name of the specialist and date contacted.
Special Authority for Subsidy - Form SA0595Initial application only from a relevant specialist. Approvals valid for 1 year where patient has motor neurone disease with swallowing disorder. Renewal only from a relevant specialist or general practitioner on the recommendation of such a specialist. Approvals valid for 1 year for applications meeting the following criteria: Both: 1 The treatment remains appropriate and the patient is benefiting from treatment; and 2 General Practitioners must include the name of the specialist and date contacted.
Special Authority for Subsidy - Form SA0596Initial application only from a relevant specialist. Approvals valid for 3 years for applications meeting the following criteria: Either: 1 gluten enteropathy has been diagnosed by biopsy; or 2 dermatitis herpetiformis. NoteA premium may be payable if the subsidy does not match the price charged by the manufacturer. The subsidy for these products reflects the philosophy that the patient incurs no additional financial burden for purchasing specialised more expensive products. Renewal only from a relevant specialist or general practitioner on the recommendation of such a specialist. Approvals valid for 3 years for applications meeting the following criteria: Both: 1 The treatment remains appropriate and the patient is benefiting from treatment; and 2 General Practitioners must include the name of the specialist and date contacted.
Special Authority for Subsidy - Form SA0597Initial application - (PKU Patient aged over 16) only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria: Both: 1 PKU; and 2 blood phenylalanine level < 900 mmol/litre (average of tests over last 12 months). Initial application - (Patient aged over 16) only from a relevant specialist. Approvals valid for 3 years for applications meeting the following criteria: Any of the following: 1 dietary management of homocystinuria; or 2 inborn errors of metabolism other than PKU; or 3 dietary management of maple syrup urine disease..Initial application - (Patient aged 16 or under) only from a relevant specialist. Approvals valid for 3 years for applications meeting the following criteria: Any of the following: 1 dietary management of homocystinuria; or 2 PKU and other inborn errors of metabolism; or 3 dietary management of maple syrup urine disease..Renewal - (PKU Patient aged over 16
Special Authority for Subsidy - Form SA0600Initial application only from a relevant specialist. Approvals valid for 3 years where inborn errors of metabolism. Renewal only from a relevant specialist or general practitioner on the recommendation of such a specialist. Approvals valid for 3 years for applications meeting the following criteria: Both: 1 The treatment remains appropriate and the patient is benefiting from treatment; and 2 General Practitioners must include the name of the specialist and date contacted.
Special Authority for Subsidy - Form SA0601Initial application only from a relevant specialist. Approvals valid for 1 year where Infant suffering from Williams Syndrome and associated hypercalcaemia. Renewal only from a relevant specialist or general practitioner on the recommendation of such a specialist. Approvals valid for 1 year for applications meeting the following criteria: Both: 1 The treatment remains appropriate and the patient is benefiting from treatment; and 2 General Practitioners must include the name of the specialist and date contacted.
Special Authority for Subsidy - Form SA0603Initial application only from a relevant specialist. Approvals valid for 1 year where infant suffering from malabsorption and other gastrointestinal problems. Renewal only from a relevant specialist or general practitioner on the recommendation of such a specialist. Approvals valid for 1 year for applications meeting the following criteria: Both: 1 The treatment remains appropriate and the patient is benefiting from treatment; and 2 General Practitioners must include the name of the specialist and date contacted.
Special Authority for Subsidy - Form SA0604Initial application - (Lactase deficiency or disaccharide intolerance) only from a relevant specialist. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 Patient is less than 3 years of age; and 2 Either: 2.1 diagnosed as suffering from congenital lactase deficiency; or 2.2 suffering from disaccharide intolerance. NoteSecondary lactose intolerance in children is usually short lasting, and can be controlled by dietary measures and by giving sufficient calories to regenerate digestive enzymes. The subsidy for these products reflects the philosophy that the patient incurs no additional financial burden for purchasing specialised more expensive products. Initial application - (Infant with intolerance to cows' milk) only from a relevant specialist. Approvals valid for 6 months for applications meeting the following criteria: Both: 1 intolerant to cows' milk; and 2 patient is less than 3 years of age. No
Special Authority for Subsidy - Form SA0605Initial application - (Cystic fibrosis or renal disorder) only from a relevant specialist. Approvals valid for 3 years for applications meeting the following criteria: Both: 1 Either: 1.1 cystic fibrosis; or 1.2 renal disorder; and 2 Either: 2.1 The product is to be used as a supplement; or 2.2 The product is to be used as a complete diet.Initial application - (Indications other than cystic fibrosis or renal disorder) only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria: Both: 1 Any of the following: 1.1 any condition causing malabsorption; or 1.2 failure to thrive; or 1.3 increased nutritional requirements; and 2 Either: 2.1 The product is to be used as a supplement; or 2.2 The product is to be used as a complete diet.Renewal - (Cystic fibrosis or renal disorder) only from a relevant specialist or general practitioner. Approvals valid for 3 years
Special Authority for Subsidy - Form SA0606Initial application only from a paediatrician. Approvals valid for 3 years for applications meeting the following criteria: Both: 1 child (up to 18 years) with chronic renal failure.; and 2 Either: 2.1 The product is to be used as a supplement; or 2.2 The product is to be used as a complete diet.Renewal only from a paediatrician. Approvals valid for 3 years for applications meeting the following criteria: Both: 1 The treatment remains appropriate and the patient is benefiting from treatment; and 2 Either: 2.1 The product is to be used as a supplement; or 2.2 The product is to be used as a complete diet.
Special Authority for Subsidy - Form SA0607Initial application only from a paediatrician. Approvals valid for 3 years for applications meeting the following criteria: Both: 1 Child (up to 18 years) who is awaiting liver transplant; and 2 Either: 2.1 The product is to be used as a supplement (maximum 500 ml per day); or 2.2 The product is to be used as a complete diet.Renewal only from a paediatrician. Approvals valid for 3 years for applications meeting the following criteria: Both: 1 The treatment remains appropriate and the patient is benefiting from treatment; and 2 Either: 2.1 The product is to be used as a supplement (maximum 500 ml per day); or 2.2 The product is to be used as a complete diet.
Special Authority for Subsidy - Form SA0609Initial application - (Serevent MDI, Serevent Accuhaler Foradil, Oxis Turbuhaler 12 mcg, Symbicort Turbuhaler) only from a relevant specialist or general practitioner. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 Both: 1.1 Child under the age of 12 with poorly controlled asthma; and 1.2 Either: 1.2.1 Required at least three months of 400 mcg or more daily inhaled beclomethasone or budesonide; or 1.2.2 Required at least three months of 200 mcg or more of fluticasone; or 2 Both: 2.1 Adult with poorly controlled asthma; and 2.2 Either: 2.2.1 Required at least three months of 1500 mcg or more daily inhaled beclomethasone or budesonide; or 2.2.2 Required at least three months of 750 mcg or more of fluticasone. NotePatients are to be reviewed at least at six months to assess compliance and effectiveness of therapy. Special Authority approvals are interchangeable among all prese
Special Authority for Subsidy - Form SA0610Initial application from any specialist. Approvals valid without further renewal unless notified for applications meeting the following criteria: All of the following: 1 Quantity used by patient on a weekly volume intraveneously (Details to be attached to application); and 2 Amount of nutrition patient is able to receive orally (Details to be attached to application); and 3 Exact formula of TPN (Details to be attached to application); and 4 Who has paid for TPN so far (Details to be attached to application); and 5 Place of manufacture (Details to be attached to application); and 6 Complete medical history of patient including details of previous therapies. (Details to be attached to application). Renewal - (Previous approval has expired) from any specialist. Approvals valid without further renewal unless notified where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0611Initial application from any medical practitioner. Approvals valid for 1 year where applicaton approved by the Cystic Fibrosis DN'ase Advisory Panel. NoteApplications to be made on the approved forms which are available from: The Co-ordinatorCystic Fibrosis DN'ase Advisory PanelPhone: (04) 460 4990 PHARMAC, PO Box 10 254 WellingtonFacsimile: (04) 916 7571Email: erin.murphy@pharmac.govt.nzPrescriptions for patients approved for treatment must be written by respiratory physicians or paediatricians who have experience and expertise in treating cystic fibrosis.
Special Authority for Alternate Subsidy - Form SA0613Initial application from any medical practitioner. Approvals valid for 2 years for applications meeting the following criteria: Any of the following: 1 Polycystic ovarian syndrome; or 2 Hirsutism; or 3 Androngenic alopecia. Renewal from any medical practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0614Initial application only from a geriatrician, rheumatologist, endocrinologist, gynaecologist or general physician. Approvals valid for 2 years for applications meeting the following criteria: All of the following: 1 Severe osteoporosis; and 2 History of one previous significant osteoporotic fractures demonstrated radiologically; and 3 T-Score <= -3.0 (bone mass density (BMD) >= 3.0 standard deviations below the mean normal value in young adults). NoteIn line with the Australian guidelines for funding alendronate, a vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral bodyRenewal only from a geriatrician, rheumatologist, endocrinologist, gynaecologist or general physician. Approvals valid for 2 years where the tr
Special Authority for Subsidy - Form SA0615Initial application only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria: Both: 1 The product is to be used as a complete diet; and 2 Either: 2.1 Patient has metabolic disorders of fat metabolism; or 2.2 Patient has chylothorax. Renewal only from a relevant specialist or general practitioner on the recommendation of such a specialist. Approvals valid for 1 year for applications meeting the following criteria: Both: 1 The treatment remains appropriate and the patient is benefiting from treatment; and 2 General Practitioners must include the name of the specialist and date contacted.
Special Authority for Manufacturers Price - Form SA0616Initial application - (Conditions other than transient ischaemic episodes) only from a cardiothoracic surgeon, cardiologist or general physician. Approvals valid without further renewal unless notified for applications meeting the following criteria: Either: 1 Patients with prosthetic heart valves - as an adjunct to oral anticoagulation for prophylaxis of thromboembolism; or 2 Patients after coronary artery vein bypass graft - as an adjunct to aspirin or as monotherapy for patients who are aspirin intolerant. NoteAspirin intolerant patients are defined as those with aspirin induced asthma, urticaria, or anaphylaxi, or those with significant aspirin induced bleeding, excluding bruisingInitial application - (Transient ischaemic episodes) only from a neurologist, neuro surgeon, cardiologist, vascular surgeon or general physician. Approvals valid without further renewal unless notified where patients who continue to have transient ischaemic
a) Prescribers may code prescriptions "contraceptive" (code "O") when used as indicated for contraception. The period of supply and prescription charge will be as per other contraceptives, as follows: - $3.00 prescription charge (patient co-payment) will apply; - prescription may be written for up to six months supply; and- pharmacists may dispense up to three months supply. b) Prescriptions coded in any other way are subject to the non-contraceptive prescription charges, and the non-contraceptive period of supply. ie. Prescriptions may be written for up to three months supply, and dispensed monthly
Special Authority for Subsidy - Form SA0622Initial application only from a geriatrician, rheumatologist, endocrinologist, gynaecologist or general physician. Approvals valid without further renewal unless notified for applications meeting the following criteria: All of the following: 1 Severe osteoporosis; and 2 History of one previous significant osteoporotic fractures demonstrated radiologically; and 3 T-Score <= -3.0 (bone mass density (BMD) >= 3.0 standard deviations below the mean normal value in young adults). NoteIn line with the Australian guidelines for funding alendronate, a vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral bodyRenewal only from a geriatrician, rheumatologist, endocrinologist, gynaecologist or general physician. Approvals va
Special Authority for Subsidy - Form SA0623Initial application from any medical practitioner. Approvals valid for 1 year for applications meeting the following criteria: All of the following: 1 The patient is not predisposed to heart arrhythmias; and 2 The patient does not have a pre-existing QT-prolongation or hepatic failure; and 3 The patient is not using other medications which either inhibit the cytochrome P450 3A4 enzyme system or prolong the QT interval; and 4 Any of the following: 4.1 Both: 4.1.1 The patient is an adult with severe reflux oesophagitis; and 4.1.2 other treatment, including acid suppression with proton pump inhibitors, has failed; or 4.2 gastroparesis; or 4.3 malignancy of GI tract causing gastroparesis (or gastric outlet obstruction); or 4.4 The patient is a child (not including infants from 0 to 3 months of age who were born prematurely) with severe gastro-oesophageal reflux; and 5 Diagnosis has been made or confirmed by a general p
Subsidy by endorsement Oral liquid is subsidised only for patients: - with oesophageal stricture, or- in terminal care, or- who are either too young or too old to swallow conventional tablets and the prescription is endorsed accordingly. Note: the cost of treatment with ranitidine oral liquid is more than 10 times higher than that of ranitidine tablets. Following the derestriction of access PHARMAC will be monitoring expenditure on ranitidine oral liquid more closely and may, subject to consultation and PHARMAC Board approval, restrict access again if the expenditure was to grow substantially.
Special Authority for Subsidy - Form SA0626Initial application only from a renal physician. Approvals valid for 2 years for applications meeting the following criteria: All of the following: General Criteria: 1 Anaemia of end-stage renal failure (other treatable causes of anaemia being excluded); and 2 Been on haemodialysis or continuous ambulatory peritoneal dialysis (CAPD) for at least three months; and 3 Not under evaluation for, or awaiting, a live donor kidney transplant; and 4 Any of the following: Specific Criteria: 4.1 Anephric; or 4.2 Dependent on regular blood transfusion (1 unit each 4-8 weeks) to maintain haemoglobin > 60g/L; or 4.3 Dependent on regular blood transfusion but cannot be transfused because of severe transfusion reactions; or 4.4 Transfusion induced haemosiderosis (clinical manifestations, serum ferritin >1500 ug/L); or 4.5 Haemoglobin < 70 g/L (mean of at least 4 haemoglobin concentrations over 4 months); or 4.6 Both: 4.6.1 Haemo
Prescribing GuidelineTreatment with HMG CoA Reductase Inhibitors (Statins) is recommended for patients withdyslipidaemia and an absolute 5 year cardiovascular risk of 15% or greater. New Zealand Cardiovascular Guideline Group statement. "The 1996 Heart Foundation guidelines for the Assessment and Management of Dyslipidaemia are currently being revised. An evidence-based guideline on the Assessment and Management of Cardiovascular Risk will be developed in 2002. The Cardiovascular Guideline Group has written an interim consensus statement for themanagement of dyslipidaemia. The Heart Foundation cardiovascular risk tables should be used to determine risk. Certain groups are classified to be at very high risk (>20%) and should be treated as such: - Patients who have had a previous cardiovascular event (angina, MI, angioplasty, coronary artery bypass grafts, TIA, ischaemic stroke and peripheral vascular disease)- Patients with genetic lipid disorders- Patients with diabetes and associated microa
Special Authority for Subsidy - Form SA0628Initial application only from a cardiologist. Approvals valid without further renewal unless notified for applications meeting the following criteria: Any of the following: 1 Both: 1.1 Congestive heart failure; and 1.2 Cannot tolerate two ACE inhibitors due to persistent cough that resolves on cessation and recurs on re-challenge with ACE inhibitor; or 2 Patients who have experienced angioedema on an ACE inhibitor at any time in the past; or 3 Patients who have experienced angioedema (even if not using an ACE inhibitor) in the last 2 years. Renewal - ((2 year approvals granted before April 2002)) only from a cardiologist. Approvals valid without further renewal unless notified where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0631Initial application only from an ophthalmologist. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 Both: 1.1 Primary open-angle glaucoma; and 1.2 Any of the following: 1.2.1 Patient cannot tolerate Beta-blockers, or Beta-blockers are contraindicated; or 1.2.2 Patient cannot tolerate Pilocarpine, or Pilocarpine is contraindicated; or 1.2.3 Patient cannot tolerate Dorzolamide, or Dorzolamide is contraindicated; or 1.2.4 A reduction in intraocular pressure of 15% or more is not achieved or maintained using dorzolamide either alone or in combination with a beta-blocker; or 2 There is progressive visual field loss and/or optic nerve damage persists after treatment with dorzolamide either alone or in combination with a beta-blocker. NoteSubsidised also for adjunctive use for the treatment of patients who have met the initial application criteria, and in whom latanoprost monotherapy has bee
Special Authority for Subsidy - Form SA0633Initial application only from a general practitioner or relevant specialist. Approvals valid without further renewal unless notified for applications meeting the following criteria: Both: 1 Patient is already on an ACE inhibitor or Angiotensin II Antagonist; and 2 Any of the following: 2.1 Both: 2.1.1 Symptomatic heart failure NYHA functional class II-III; and 2.1.2 Patient has been treated with metoprolol and is intolerant to metoprolol or has demonstrated a sub-optimal response to metoprolol; or 2.2 Symptomatic heart failure NYHA functional class III-IV; or 2.3 Patient has left ventricular systolic dysfunction with an ejection fraction of less than 35%.NoteWhere possible treatment should be initiated by or on the recommendation of a specialist.
Special Authority for Subsidy - Form SA0635Initial application only from a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria: All of the following: 1 Rheumatoid arthritis; and 2 Patient is not a pregnant woman, or a woman of child-bearing age without adequate contraception; and 3 Patient has been unable to tolerate or has a contraindication to or has had an inadequate response to sulphasalazine and methotrexate (individually or in combination). Renewal only from a rheumatologist. Approvals valid without further renewal unless notified for applications meeting the following criteria: Both: 1 Compliance (prescriber determined) with medication; and 2 Improved rheumatoid arthritis symptom control. NotePatient should have full blood count and liver function tests regularly monitored.
Retail pharmacy - subsidy by endorsement a) Subsidised for:i) patients presenting with first episode schizophrenia or related psychoses; andii) patients suffering from schizophrenia or related psychoses after a trial of an effective dose of risperidone that has been discontinued because of unacceptable side effects or inadequate response. b) Initial prescription must be written by a relevant specialist. c) Subsequent prescriptions may be written by a general practitioner. d) The prescription must be endorsed "certified condition".
Special Authority for Subsidy - Form SA0637Initial application - (National Heart Foundation risk groups A1:1, A1:2, B, C, D or E) only from a relevant specialist or general practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria: All of the following: 1 The patient has been offered 3-6 months of counseling and an opportunity to modify lifestyle; and 2 Any of the following: 2.1 Both: 2.1.1 NHF A1:1 - Clinically proven ischaemic heart disease; and 2.1.2 total cholesterol > 5.5; or 2.2 Both: 2.2.1 NHF A1:2 - Post coronary artery bypass graft (CABG) or angioplasty; and 2.2.2 total cholesterol > 4.5; or 2.3 Post heart transplant (regardless of cholesterol level); or 2.4 Both: 2.4.1 NHF B: Patients with > 20% 5-year cardiovascular disease risk; and 2.4.2 total cholesterol > 9.0; or 2.5 Both: 2.5.1 NHF C: 15-20% 5-year cardiovascular disease risk; and 2.5.2 total cholesterol >
Special Authority for Subsidy - Form SA0639Initial application - (No previous use) only from a relevant specialist or general practitioner. Approvals valid for 3 months for applications meeting the following criteria: All of the following: 1 The patient has a clinical diagnosis of heavy menstrual bleeding; and 2 The patient has failed to respond to or is unable to tolerate other appropriate pharmaceutical therapies as per the Heavy Menstrual Bleeding Guidelines; and 3 Either: 3.1 serum ferritin level < 16 mg/l (within the last 12 months); or 3.2 haemoglobin level < 120 g/l . NoteApplications are not to be made for use in patients as contraception except where they meet the above criteriaInitial application - (Previous use before 1 October 2002) only from a relevant specialist or general practitioner. Approvals valid for 3 months for applications meeting the following criteria: All of the following: 1 The patient had a clinical diagnosis of heavy menstrual bleeding; and 2
Special Authority for Waiver of Rule - Form SA0641Initial application only from a diabetologist, general physician or paediatrician. Approvals valid without further renewal unless notified for applications meeting the following criteria: Either: 1 Both: 1.1 Use alone (monotherapy); and 1.2 The patient is unable to use any other insulins including those on insulin pump treatment; or 2 Both: 2.1 Use with insulin other than insulin isophane (including ready-mixed preparations); and 2.2 A reasonable trial of insulin isophane has been undertaken and it is not effective or not well tolerated. Note"Reasonable trial", "unable to use", "not effective", "not well tolerated", and "not well tolerated" are not defined and we ask clinicians to use their clinical judgement in interpreting these terms.
Special Authority for Subsidy - Form SA0643Initial application - (CML) only from an oncologist or relevant specialist. Approvals valid for 7 months where approved by the The Glivec Co-ordinator. Initial application - (GIST) only from an oncologist. Approvals valid for 1 year where approved by the The Glivec Co-ordinator. Renewal - (CML) only from an oncologist or relevant specialist. Approvals valid for 6 months where approved by the The Glivec Co-ordinator. Initial application - (GIST) only from an oncologist. Approvals valid for 1 year where approved by the The Glivec Co-ordinator. NoteApplication forms are available from, and prescriptions should be sent to: The Glivec Co-ordinatorPhone: 09 580 9176Level 3, Unisys HouseFacsimile: 09 580 9205650 Great South Road, PenroseEmail: murray@ppc.govt.nzPrivate Bag, AUCKLANDSpecial Authority criteria for CML - access by applicationFunded for patients with diagnosis (confirmed by a haematologist) of a chronic myeloid leukaemia (CML) i
Special Authority for Subsidy - Form SA0645Initial application only from a renal physician. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 Both: 1.1 patient in chronic renal failure; and 1.2 Haemoglobin <= 100 g/L; and 2 Either: 2.1 Both: 2.1.1 patient is not diabetic; and 2.1.2 glomerular filtration rate <= 30 ml/min; or 2.2 Both: 2.2.1 patient is diabetic; and 2.2.2 glomerular filtration rate <= 45 ml/min. Renewal only from a renal physician. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment. NoteErythropoietin beta is indicated in the treatment of anaemia associated with chronic renal failure (CRF) where no cause for anaemia other than CRF is detected and there is adequate monitoring of iron stores and iron replacement therapy. The Cockroft-Gault Formula may be used to estimate glomerular filtration rate (GFR) in persons 18 years and over:GFR (male)
Special Authority for Subsidy - Form SA0646Initial application only from a renal physician. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 Both: 1.1 patient in chronic renal failure; and 1.2 Haemoglobin <= 100 g/L; and 2 Any of the following: 2.1 Both: 2.1.1 patient is not diabetic; and 2.1.2 glomerular filtration rate <= 30 ml/min; or 2.2 Both: 2.2.1 patient is diabetic; and 2.2.2 glomerular filtration rate <= 45 ml/min; or 2.3 patient is on haemodialysis or peritoneal dialysis. Renewal only from a renal physician. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment. NoteErythropoietin beta is indicated in the treatment of anaemia associated with chronic renal failure (CRF) where no cause for anaemia other than CRF is detected and there is adequate monitoring of iron stores and iron replacement therapy. The Cockroft-Gault Formula may be used to estim
Special Authority for Manufacturers Price - Form SA0648Initial application - (Conditions other than transient ischaemic episodes) only from a cardiothoracic surgeon, cardiologist or general physician. Approvals valid without further renewal unless notified for applications meeting the following criteria: Either: 1 Patients with prosthetic heart valves - as an adjunct to oral anticoagulation for prophylaxis of thromboembolism; or 2 Patients after coronary artery vein bypass graft - as an adjunct to aspirin or as monotherapy for patients who are aspirin intolerant. NoteAspirin intolerant patients are defined as those with aspirin induced asthma, urticaria, or anaphylaxi, or those with significant aspirin induced bleeding, excluding bruisingInitial application - (Transient ischaemic episodes) only from a neurologist, neuro surgeon, cardiologist, vascular surgeon or general physician. Approvals valid without further renewal unless notified where patients who continue to have transient ischaemic
Special Authority for Subsidy - Form SA0649Initial application - (Conditions other than transient ischaemic episodes) only from a cardiothoracic surgeon, cardiologist or general physician. Approvals valid without further renewal unless notified for applications meeting the following criteria: Either: 1 Patients with prosthetic heart valves - as an adjunct to oral anticoagulation for prophylaxis of thromboembolism; or 2 Patients after coronary artery vein bypass graft - as an adjunct to aspirin or as monotherapy for patients who are aspirin intolerant. NoteAspirin intolerant patients are defined as those with aspirin induced asthma, urticaria, or anaphylaxi, or those with significant aspirin induced bleeding, excluding bruisingInitial application - (Transient ischaemic episodes) only from a neurologist, neuro surgeon, cardiologist, vascular surgeon or general physician. Approvals valid without further renewal unless notified where patients who continue to have transient ischaemic episodes des
Special Authority for Subsidy - Form SA0652Initial application - (Single NAED Therapy) only from a paediatrician, neurologist or general physician. Approvals valid for 15 months for applications meeting the following criteria: Any of the following: 1 Was on NAED therapy before 1 September 2000; or 2 Seizures are not adequately controlled with optimal older anti-epilepsy drug treatment; or 3 Seizures are controlled adequately but who experience unacceptable side effects from older anti-epilepsy drug treatment. Note"Optimal older anti-epilepsy drug therapy" is defined as treatment with those older anti-epilepsy drugs which are indicated and clinically appropriate for the patient, given singly and in combination in adequate doses for the patient's age, weight, and other features affecting the pharmacokinetics of the drug with good evidence of complianceInitial application - (Dual NAED Therapy) only from a paediatrician, neurologist or general physician. Approvals valid for 18 months for app
Special Authority for Subsidy - Form SA0657Initial application - (Helicobacter pylori infections) only from a general practitioner or relevant specialist. Approvals valid for 6 months for applications meeting the following criteria: Both: 1 Eradication of Helicobacter pylori in patient with proven infection; and 2 Peptic ulcer disease proven by endoscopy. NoteMaximum of two prescriptions (two courses) per patient. Initial application - (Mycobacterial infections) only from a respiratory specialist, infectious disease specialist or paediatrician. Approvals valid for 2 years for applications meeting the following criteria: Any of the following: 1 Mycobacterium Avium Intracellulare Complex infections in patient with AIDS; or 2 Atypical and drug-resistant mycobacterial infection; or 3 All of the following: 3.1 Prophylaxis against disseminated Mycobacterium Avium Intracellulare Complex infection; and 3.2 HIV infection; and 3.3 CD4 count <= 50 cells/mm3. Renewal - (Mycobact
Additional subsidy by endorsement for:Moclobemide tab 150 mg x 500 (Apo-Moclobemide) up to $46.00Moclobemide tab 150 mg x 100 (Aurorix) up to $32.90Moclobemide tab 300 mg x 100 (Apo-Moclobemide) up to $26.11Moclobemide tab 300 mg x 60 (Aurorix) up to $39.48Nefazodone tab 100 mg x 56 (Serzone) up to $20.16Nefazodone tab 200 mg x 56 (Serzone) up to $40.32Citalopram tab 20 mg x 28 (Celapram) up to $4.00Citalopram tab 20 mg x 28 (Cipramil) up to $10.00Paroxetine hydrochloride tab 20 mg x 30 (Aropax) up to $35.02is available for patients who: - were taking moclobemide or nefazodone on 1 December 1999 or citalopram on 1 February 2000; or paroxetine hydrochloride on February 2001; or- have previously responded to treatment with moclobemide or nefazodone or citalopram or paroxetine hydrochloride; or- have had a trial of fluoxetine and have had to discontinue due to- inability to tolerate the drug due to side effects; or- failed to respond to an adequate dose and duration of treatment; or
Special Authority for Subsidy - Form SA0661Initial application only from a psychiatrist. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 The patient has "treatment resistant" depression; and 2 Either: 2.1 The patient must have had a trial of two different antidepressants and failed to respond to an adequate dose over an adequate period of time (usually at least four weeks); or 2.2 Both: 2.2.1 The patient is currently a hospital in-patient as a result of an acute depressive episode; and 2.2.2 The patient must have had a trial of one other antidepressant and failed to respond to an adequate dose over an adequate period of time. Renewal from any medical practitioner. Approvals valid for 2 years where patient has a high risk of relapse (prescriber determined)..NoteFirst prescription can be written by a psychiatrist or psychiatric registrar. Subsequent prescriptions may be written by a General Practitioner
Prescribing GuidelinesBoth Trusopt and Cosopt are subsidised for use as either monotherapy or as an adjunctive agent for the treatment of glaucoma. Trusopt and Cosopt should not be prescribed for a person in whom less expensive first line agents for the treatment of glaucoma are not contraindicated unless: i) that person has previously trialled all other such subsidised agents (except brimonidine tartrate); andii) those trials have indicated that that person does not respond adequately to treatment with those other agents.
a) Spacer devices and masks also available to paediatricians employed by a DHB on a wholesalesupply order signed by the paediatrician. Limited to one pack of 20 per order. Orders via ahospital pharmacy. b) Only available for children aged six years and under. c) For Space Chamber and Foremount Child's Silicone Mask wholesale supply order must indicate clearly if either the spacer device, the mask, or both are required. d) Distributed by Airflow Products. Forward orders to: Airflow ProductsPO Box 1485 Telephone: 04 499 1240 or 0800 AIR FLOWWellington Facsimile: 04 499 1245 or 0800 323 270
Special Authority for Subsidy - Form SA0667Initial application only from a named specialist. Approvals valid for 4 months for applications meeting the following criteria: All of the following: 1 To be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and 2 Patient is less than 18 years of age at commencement of treatment; and 3 Patient has had severe active polyarticular course Juvenile Idiopathic Arthritis (JIA) for 6 months duration or longer; and 4 Patient has tried and not responded to at least three months of oral or parenteral methotrexate at a dose of 10-20mg/m2 weekly in combination with oral corticosteroids (prednisone 0.25 mg/kg); and 5 Patient has tried and not responded to at least three months of oral or parenteral methotrexate (at a dose of 10-15mg/m2 weekly) in combination with one other disease-modifying agent; and 6 Both: 6.1 Either: 6.1.1 Patient has persistent symptoms of poorly-cont
Additional subsidy by endorsement for:Nefazodone tab 100 mg x 56 (Serzone) up to $20.16Nefazodone tab 200 mg x 56 (Serzone) up to $40.32Citalopram tab 20 mg x 28 (Celapram) up to $4.00Citalopram tab 20 mg x 28 (Cipramil) up to $10.00Paroxetine hydrochloride tab 20 mg x 30 (Aropax) up to $35.02is available for patients who: -were taking nefazodone on 1 December 1999 or citalopram on 1 February 2000; or paroxetine hydrochloride on February 2001; or- have previously responded to treatment with nefazodone or citalopram or paroxetinehydrochloride; or- have had a trial of fluoxetine and have had to discontinue due to- inability to tolerate the drug due to side effects; or- failed to respond to an adequate dose and duration of treatment; or- have contraindications to fluoxetine (eg pre-existing significant levels of nausea, breastfeeding, potential drug interactions). The prescription must be endorsed accordingly.
Special Authority for Manufacturers Price - Form SA0673Initial application from any medical practitioner. Approvals valid for 3 months for applications meeting the following criteria: Both: 1 Patient considered unsafe to switch to m-Eslon; and 2 Patient was stabilised and well controlled on Kapanol, MST or LA-Morph before 1 December 2003. NoteSpecial Authority effective from 1 February 2004 to 31 July 2004
Rapid acting insulin analogues are subsidised when: 1) prescribed with insulin isophane or insulin glargine but are on a different prescription and the prescription is endorsed accordingly; or prescribed on the same prescription as insulin isophane or insulin glargine in which case the prescription is deemed to be endorsed; or2) a Special Authority has been approved. For 1and 2 first prescription to be written by a specialist (diabetologist, general physician or paediatrician). Any medical practitioner can writte subsequent prescriptions.
Special Authority for Subsidy - Form SA0693Initial application only from a relevant specialist or vocationally registered general practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria: All of the following: 1 Severe osteoporosis; and 2 History of one previous significant osteoporotic fracture demonstrated radiologically; and 3 T-Score <= -3.0 (bone mass density (BMD) >= 3.0 standard deviations below the mean normal value in young adults). NoteIn line with the Australian guidelines for funding alendronate, a vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral bodyRenewal - ((2 year approvals granted before February 2002)) only from a geriatrician, rheumatologist, endocrinologist, gynaecologis
Subsidy is available for patients with poorly controlled asthma where: a) at least three months of 750 mcg or more daily of inhaled beclomethasone or budesonide (or 400 mcg or fluticasone) for adults has been used; orb) at least three months of 400 mcg or more daily inhaled beclomethasone or budesonide (or 200 mcg or fluticasone) for children has been used; The prescription must be endorsed accordingly. We recommend that the words used to indicate eligibility are "poor control with ICS" or "certified exemption".
Special Authority for Subsidy - Form SA0696Initial application - (Narcolepsy) only from a neurologist or respiratory specialist. Approvals valid for 24 months where narcolepsy. Initial application - (ADHD in patients 5 or over) only from a paediatrician, psychiatrist or general practitioner on the recommendation of such a specialist. Approvals valid for 24 months for applications meeting the following criteria: All of the following: 1 ADHD (Attention Deficit and Hyperactivity Disorder) patients aged 5 years or over; and 2 Diagnosed according to DSM-IV or ICD 10 criteria; and 3 Either: 3.1 Applicant is a specialist; or 3.2 Both: 3.2.1 Applicant is a GP and a specialist has recommended treatment; and 3.2.2 Provide name of specialist (Details to be attached to application). Initial application - (ADHD in patients under 5) only from a paediatrician or psychiatrist. Approvals valid for 12 months for applications meeting the following criteria: Both: 1 ADHD (Attention Defi
Special Authority for Subsidy - Form SA0698Initial application only from a gastroenterologist, general surgeon or general physician. Approvals valid for 3 months for applications meeting the following criteria: Both: 1 Mild to moderate ileal, ileocaecal or proximal Crohn's disease; and 2 Any of the following: 2.1 Diabetes; or 2.2 Cushingoid habitus; or 2.3 Osteoporosis where there is significant risk of fracture; or 2.4 Severe acne following treatment with conventional corticosteroid therapy. Renewal only from a gastroenterologist, general surgeon or general physician. Approvals valid for 3 months where the treatment remains appropriate and the patient is benefiting from treatment. The patient must have had no more than 1 prior approval in the last year. NoteClinical trials for Entocort CIR use beyond three months demonstrated no improvement in relapse rate.
Special Authority for Subsidy - Form SA0699Initial application from any medical practitioner. Approvals valid for 1 year for applications meeting the following criteria: All of the following: 1 The patient is not predisposed to heart arrhythmias; and 2 The patient does not have a pre-existing QT-prolongation or hepatic failure; and 3 The patient is not using other medications which either inhibit the cytochrome P450 3A4 enzyme system or prolong the QT interval; and 4 Any of the following: 4.1 Both: 4.1.1 adult with severe reflux oesophagitis; and 4.1.2 other treatment, including acid suppression with proton pump inhibitors, has failed; or 4.2 gastroparesis; or 4.3 malignancy of GI tract causing gastroparesis (or gastric outlet obstruction); or 4.4 child (not including infants from 0 to 3 months of age who were born prematurely) with severe gastro-oesophageal reflux; and 5 Diagnosis has been made or confirmed by a general physician, gastroenterologist, or ge
Special Authority for Subsidy - Form SA0700Initial application only from an ophthalmologist. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 Both: 1.1 Monotherapy in primary open-angle glaucoma; and 1.2 Any of the following: 1.2.1 Patient cannot tolerate Beta-blockers, Pilocarpine and Dorzolamide; or 1.2.2 Beta-blockers, Pilocarpine and Dorzolamide are contraindicated; or 1.2.3 A reduction in intraocular pressure of 15% or more is not achieved or maintained using dorzolamide either alone or in combination with a beta-blocker; or 1.2.4 There is progressive visual field loss and/or optic nerve damage persists after treatment with dorzolamide either alone or in combination with a beta-blocker; or 2 Adjunctive use for the treatment of patients who have met the initial application criteria, and in whom latanoprost monotherapy has been ineffective in controlling intraocular pressure.Note An adjunctive agent may be added without a
Special Authority for Subsidy - Form SA0702Initial application - (Oral feed for cystic fibrosis patient) only from a relevant specialist. Approvals valid for 3 years for applications meeting the following criteria: Both: 1 Cystic fibrosis; and 2 Either: 2.1 The product is to be used as a supplement; or 2.2 The product is to be used as a complete diet.Initial application - (Oral feed for indications other than cystic fibrosis) only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria: Both: 1 Any of the following: 1.1 any condition causing malabsorption; or 1.2 failure to thrive; or 1.3 increased nutritional requirements; and 2 Either: 2.1 The product is to be used as a supplement; or 2.2 The product is to be used as a complete diet.Renewal - (Oral feed cystic fibrosis patient) only from a relevant specialist or general practitioner on the recommendation of such a specialist. Approvals valid for 3 years f
Special Authority for Subsidy - Form SA0703Initial application only from a relevant specialist or general practitioner. Approvals valid for 2 years for applications meeting the following criteria: All of the following: 1 Patient has raised blood pressure; and 2 The use of fully funded beta blockers is contraindicated, or not well tolerated; or where use of fully funded beta blockers and diuretics are insufficient to control blood pressure adequately at appropriate doses; and 3 Either: 3.1 Has been treated with, and cannot tolerate two ACE inhibitors, due to persistent cough; or 3.2 Has experienced angioedema on an ACE inhibitor at any time in the past or who have experienced angioedema (even if not using an ACE inhibitor) in the last 2 years. Renewal only from a relevant specialist or general practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0706Initial application only from a relevant specialist or general practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria: Either: 1 Both: 1.1 Patient with congestive heart failure; and 1.2 Either: 1.2.1 Has been treated with, and cannot tolerate, two ACE inhibitors, due to persistent cough; or 1.2.2 Has experienced angioedema on an ACE inhibitor at any time in the past or who have experienced angioedema (even if not using an ACE inhibitor) in the last 2 years; or 2 All of the following: 2.1 Patient with raised blood pressure; and 2.2 Use of fully funded beta blockers or diuretics are contraindicated; or not well tolerated; or insufficient to control blood pressure adequately at appropriate doses; and 2.3 Either: 2.3.1 Has been treated with, and cannot tolerate, two ACE inhibitors, due to persistent cough; or 2.3.2 Has experienced angioedema on an ACE in
Effective, consistent management of herpes from prescribing to these guidelines will improve patient outcomes. The guidelines on the following four pages are for the prescribing of aciclovir. The guidelines aim to: - improve patient care and clinical outcome through faster, more accessible treatment - protect patients' wider wellbeing by reinforcing the psychosocial aspects of treatment - improve the consistency and breadth of medical management of genital herpes in New Zealand. The guidelines are: - integral to ensuring a consistent, effective treatment regimen- the result of consultation with clinicians and patient representatives- set out in line with the recommended international algorithm format for treatment. The guidelines are endorsed by the Herpes Foundation's professional advisory board whose members represent venereology, NZDS, RNZCGP, RNZCOG, psychotherapy and nursing. Herpes Foundation Helpline: Toll free 0508 11 12 13Auckland Branch Herpes Foundation: 09 360 1966
Guidelines for the use of interferon in the treatment of hepatitis C: Physicians considering treatment of patients with hepatitis C should discuss cases with a gastroenterologist or aninfectious disease physician. All subjects undergoing treatment require careful monitoring for side effects. Patients should be otherwise fit. Hepatocellular carcinoma should be excluded by ultrasound examination and alpha-fetoprotein level. Criteria for Treatment a) Diagnosis- Anti-HCV positive on at least two occasions with a positive PCR for HCV-RNA and preferably confirmed by asupplementary RIBA test; or- PCR-RNA positive for HCV on at least 2 occasions if antibody negative; or- Anti-HCV positive on at least two occasions with a positive supplementary RIBA test with a negative PCR forHCV RNA but with a liver biopsy consistent with 2(b) following. b) Establishing Active Chronic Liver Disease- Confirmed HCV infection and serum ALT/AST levels measured on at least three occasions over six monthsaveraging >
Special Authority for Subsidy - Form SA0710Initial application only from an ophthalmologist. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 Either: 1.1 Monotherapy in primary open-angle glaucoma; or 1.2 Adjunctive use for the treatment of open-angle glaucoma in a patient who has met the initial application criteria, and in whom prostaglandin analogue monotherapy has been ineffective in controlling intraocular pressure; and 2 Any of the following: 2.1 Patient cannot tolerate beta-blockers, pilocarpine, and carbonic anhydrase inhibitors; or 2.2 Beta-blockers, pilocarpine and carbonic anhydrase inhibitors are contraindicated; or 2.3 A reduction in intraocular pressure of 15% or more is not achieved or maintained using carbonic anhydrase inhibitor either alone or in combination with a beta blocker; or 2.4 There is progressive visual field loss and/or optic nerve damage persists after treatment with carbonic anhydrase inhibitor either alo
Special Authority for Subsidy - Form SA0714Initial application from any medical practitioner. Approvals valid for 3 months for applications meeting the following criteria: All of the following: 1 Patient is currently enrolled in a recognised comprehensive treatment programme for alcohol dependence in a service accredited against the New Zealand Alcohol and Other Drug Sector Standard or the National Mental Health Sector Standard; and 2 Applicant works in an Alcohol & Drug Service; and 3 Applicant must include the address of the service (Details to be attached to application). Renewal from any medical practitioner. Approvals valid for 3 months for applications meeting the following criteria: Both: 1 Compliance with the medication (prescriber determined); and 2 Any of the following: 2.1 Patient is still unstable and requires further treatment; or 2.2 Patient achieved significant improvement but requires further treatment; or 2.3 Patient is well controlled but requires maint
Prescribing GuidelinesTrusopt, Cosopt and Azopt are subsidised for use as either monotherapy or as an adjunctive agent for the treatment of glaucoma. Trusopt, Cosopt and Azopt should not be prescribed for a person in whom less expensive first line agents for the treatment of glaucoma are not contraindicated unless: a) that person has previously trialled all other such subsidised agents (except brimonidine tartrate); andb) those trials have indicated that that person does not respond adequately to treatment with those other agents.
Special Authority for Manufacturers Price - Form SA0717Initial application only from a relevant specialist or general practitioner. Approvals valid for 12 weeks for applications meeting the following criteria: Both: 1 Patient has a calculated absolute risk of cardiovascular disease of at least 15% over 5 years; and 2 Either: 2.1 Patient has severe documented intolerance to simvastatin; or 2.2 Both: 2.2.1 Patient has been compliant with a dose of simvastatin of 80 mg per day for at least 2 months; and 2.2.2 Either: 2.2.2.1 All of the following: 2.2.2.1.1 Patient has venous CABG; and 2.2.2.1.2 LDL cholesterol test 1 >= 2.0 mmol/litre; and 2.2.2.1.3 LDL cholesterol test 2 >= 2.0 mmol/litre (at least 1 week after test 1); or 2.2.2.2 All of the following: 2.2.2.2.1 Patient does not have venous CABG; and 2.2.2.2.2 LDL cholesterol test 1 >= 2.5 mmol/litre; and 2.2.2.2.3 LDL cholesterol test 2 >= 2.5 mmol/litre (at least 1 w
Special Authority for Subsidy - Form SA0721Initial application only from a named specialist. Approvals valid without further renewal unless notified for applications meeting the following criteria: All of the following: 1 The patient already has a Special Authority approval for anti-retroviral therapy (Details to be attached to application); and 2 Kaletra is to be used as a salvage therapy in place of one protease inhibitor; and 3 The patient must have trialed for at least six months and have failed on currently funded NNRTI based regimens or triple NRTI regimens; and 4 The patient must have trialed for at least six months and have failed on currently funded PI based regimens. NoteFailure is defined as: a) not achieving HIV RNA < 400 copies/ml after 24 weeks of a regimen, orb) an increase of HIV RNA to > 400 copies/ml on two separate occasions not less than one month apart, after suppression to < 400 copies/ml in a patient taking the regimen.
Special Authority for Subsidy - Form SA0723Initial application only from a relevant specialist. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 All of the following: 1.1 Patient has a calculated absolute risk of cardiovascular disease >20% over 5 years; and 1.2 Patient cannot tolerate statin therapy at a dose of 40 mg per day; and 1.3 Either: 1.3.1 All of the following: 1.3.1.1 Patient has venous CABG; and 1.3.1.2 LDL cholesterol >= 2.0 mmol/litre (see note); and 1.3.1.3 LDL cholesterol >= 2.0 mmol/litre (at least 1 week after test 1 - see note); or 1.3.2 All of the following: 1.3.2.1 Patient does not have venous CABG; and 1.3.2.2 LDL cholesterol >= 2.5 mmol/litre (see note); and 1.3.2.3 LDL cholesterol >= 2.5 mmol/litre (at least 1 week after test 1 - see note); or 2 All of the following: 2.1 Patient has homozygous familial hypercholesterolemia, or heterozygous familial hypercholesterol
Special Authority for Manufacturers Price - Form SA0724Initial application only from a relevant specialist or general practitioner. Approvals valid for 12 weeks for applications meeting the following criteria: Both: 1 Patient has a calculated absolute risk of cardiovascular disease of at least 15% over 5 years; and 2 Either: 2.1 Patient has severe documented intolerance to simvastatin (blood tests are not required); or 2.2 Both: 2.2.1 Patient has been compliant with a dose of simvastatin of 80 mg per day for at least 2 months; and 2.2.2 Either: 2.2.2.1 All of the following: 2.2.2.1.1 Patient has venous CABG; and 2.2.2.1.2 LDL cholesterol test 1 >= 2.0 mmol/litre; and 2.2.2.1.3 LDL cholesterol test 2 >= 2.0 mmol/litre (at least 1 week after test 1); or 2.2.2.2 All of the following: 2.2.2.2.1 Patient does not have venous CABG; and 2.2.2.2.2 LDL cholesterol test 1 >= 2.5 mmol/litre; and 2.2.2.2.3 LDL cholesterol test 2 >
Special Authority for Subsidy - Form SA0725Initial application only from a relevant specialist or general practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria: All of the following: 1 Patient with raised blood pressure; and 2 Use of fully funded beta blockers and diuretics are contraindicated; or not well tolerated; or insufficient to control blood pressure adequately at appropriate doses; and 3 Either: 3.1 Has been treated with, and cannot tolerate, two ACE inhibitors, due to persistent cough; or 3.2 Has experienced angioedema on an ACE inhibitor at any time in the past or who have experienced angioedema (even if not using an ACE inhibitor) in the last 2 years. Renewal - (Previous approval has expired) only from a relevant specialist or general practitioner. Approvals valid without further renewal unless notified where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0727Initial application from any medical practitioner. Approvals valid for 1 year for applications meeting the following criteria: All of the following: 1 Control of intractable nausea, vomiting, or inability to swallow saliva in the treatment of malignancy or chronic disease; and 2 Patient cannot tolerate or does not adequately respond to oral anti-nausea agents; and 3 The applicant must specify the underlying malignancy or chronic disease (Details to be attached to application). Renewal from any medical practitioner. Approvals valid for 1 year where the treatment remains appropriate and the patient is benefiting from treatment.
Retail pharmacy - subsidy by endorsement a) Subsidised for:(i) patients presenting with first episode schizophrenia or related psychoses, or manic episodes associated with bipolar disorder; and(ii) patients suffering from schizophrenia or related psychoses, or manic episodes associated with bipolar disorder, after a trial of an effective dose of risperidone that has been discontinued because of unacceptable side effects or inadequate response. b) Initial prescription must be written by a relevant specialist. c) Subsequent prescriptions may be written by a general practitioner. d) The prescription must be endorsed "certified condition".
Special Authority for Subsidy - Form SA0732Initial application only from a relevant specialist. Approvals valid for 3 years for applications meeting the following criteria: Either: 1 dietary management of homocystinuria; or 2 dietary management of maple syrup urine disease. Renewal only from a relevant specialist or general practitioner on the recommendation of such a specialist. Approvals valid for 1 year for applications meeting the following criteria: Both: 1 The treatment remains appropriate and the patient is benefiting from treatment; and 2 General Practitioners must include the name of the specialist and date contacted.
Special Authority for Subsidy - Form SA0733Initial application - (Patient aged over 16) only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria: Both: 1 dietary management of PKU; and 2 blood phenylalanine level < 900 mmol/litre (average of tests over last 12 months). Initial application - (Patient aged 16 or under) only from a relevant specialist. Approvals valid for 3 years where dietary management of PKU.Renewal - (Patient aged over 16) only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria: blood phenylalanine level < 900 mmol/litre (average of tests over last 12 months). Renewal - (Patient aged 16 or under) only from a relevant specialist or general practitioner on the recommendation of such a specialist. Approvals valid for 3 years for applications meeting the following criteria: Both: 1 The treatment remains appropriate and the patient is benefiting from treatment; and 2
GuidelinesIt can cost up to $70,000 a year to keep an adult on protein supplements. Because protein substitutes are so expensive and because they are only effective in controlling PKU if a restricted diet is followed, adults with PKU will be required to demonstrate they are following the prescribed diet by regular blood testing. The requirement for testing applies to those aged over 16 years. Failure to follow an appropriate diet results in high blood phenylalanine levels. Those consistently testing above 15 mg (900 micromol) over a twelve month period will not be able to claim these products as a Special Authority. Specialists will be required to renew applications for their PKU patients every year and, when they do so, will have to submit the results of two blood tests.
Neocate should be used only as a last resort when the infant is unable to absorb any of the above formulae. The objective with each of thees formulae prescribed is to get the infant off them as soon as possible. This may take six months, it may take three years. Because of this, variation on age limit is not regarded as appropriate.These formulae will be available only from a hospital pharmacy. Vivonex Pediatric may be a suitable and less expensive alternative for many children that would otherwise be eligible for a subsidy for Neocate and should, therefore, be tried first in these cases. The subsidy for these products reflects the philosophy that the patient incurs no additional financial burden for purchasing specialised more expensive products.
Special Authority for Subsidy - Form SA0738Initial application only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria: Either: 1 All of the following: 1.1 To be used as monotherapy for patients with type 2 diabetes who after six months of diet and lifestyle changes do not have adequate glycaemic control (inadequate control defined as HbA1c > 8.0% in tests carried out at least two months apart); and 1.2 Metformin is not tolerated or contraindicated. Intolerance and contraindications as defined in the notes below, a minimum of a four week trial period of metformin is required; and 1.3 Sulphonylurea is not tolerated or contraindicated. Overweight patients are only eligible under the criteria of contraindication to sulphonylureas if their body mass index (BMI) exceeds 35; or 2 Both: 2.1 For use in combination with a sulphonylurea when diet and lifestyle changes and a twelve month trial of sulphonylurea results in inadequate glycaem
Special Authority for Subsidy - Form SA0741Initial application only from a psychiatrist. Approvals valid for 2 years for applications meeting the following criteria: Any of the following: 1 Patient with first episode schizophrenia or related psychoses; or 2 Both: 2.1 Patient suffering from schizophrenia and related psychoses; or acute mania in bipolar disorder who is likely to benefit from anti-psychotic treatment; and 2.2 Either: 2.2.1 An effective dose of risperidone had been trialled and has been discontinued because of unacceptable side effects; or 2.2.2 An effective dose of risperidone had been trialled and has been discontinued because of inadequate clinical response after 4 weeks; or 3 The patient has suffered from an acute episode of schizophrenia or bipolar mania and has been treated with olanzapine short-acting intra-muscular injection. Renewal only from a psychiatrist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefit
Special Authority for Subsidy - Form SA0742Initial application - (genotype 1, 4, 5 or 6 infection) from any specialist. Approvals valid for 11 months where patient has chronic hepatitis C, genotype 1, 4, 5 or 6 infection. Initial application - (genotype 2 or 3 infection) from any specialist. Approvals valid for 6 months for applications meeting the following criteria: Both: 1 Patient has chronic hepatitis C, genotype 2 or 3 infection; and 2 Patient has bridging fibrosis or cirrhosis (Metavir stage 3 or 4 or equivalent).
Special Authority for Subsidy - Form SA0743Initial application only from a relevant specialist. Approvals valid for 3 months for applications meeting the following criteria: Both: 1 Patient is terminally ill and is opioid-responsive; and 2 Either: 2.1 is unable to take oral medication; or 2.2 is intolerant to morphine, or morphine is contraindicated..Renewal only from a relevant specialist or general practitioner. Approvals valid for 3 months where the treatment remains appropriate and the patient is benefiting from treatment.
Additional subsidy by endorsement for:Citalopram tab 20 mg x 28 (Celapram) up to $4.00Citalopram tab 20 mg x 28 (Cipramil) up to $10.00Paroxetine hydrochloride tab 20 mg x 30 (Aropax) up to $35.02is available for patients who: -were taking citalopram on 1 February 2000; or paroxetine hydrochloride on February 2001; or- have previously responded to treatment with citalopram or paroxetinehydrochloride; or- have had a trial of fluoxetine and have had to discontinue due to- inability to tolerate the drug due to side effects; or- failed to respond to an adequate dose and duration of treatment; or- have contraindications to fluoxetine (eg pre-existing significant levels of nausea, breastfeeding, potential drug interactions). The prescription must be endorsed accordingly.
Special Authority for Subsidy - Form SA0751Initial application only from an ophthalmologist. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 Either: 1.1 Monotherapy in primary open-angle glaucoma; or 1.2 Adjunctive use for the treatment of open-angle glaucoma in a patient who has met the initial application criteria, and in whom prostaglandin analogue monotherapy has been ineffective in controlling intraocular pressure; and 2 Any of the following: 2.1 Patient cannot tolerate beta-blockers, pilocarpine, and carbonic anhydrase inhibitors; or 2.2 Beta-blockers, pilocarpine and carbonic anhydrase inhibitors are contraindicated; or 2.3 A reduction in intraocular pressure of 15% or more is not achieved or maintained using carbonic anhydrase inhibitor either alone or in combination with a beta blocker; or 2.4 There is progressive visual field loss and/or optic nerve damage persists after treatment with carbonic anhydrase inhibitor either alo
(a) Subsidy is available between 1 March and 30 June of each year for patients who meet the following criteria, as set by the Ministry of Health: a) all people 65 years of age and over; b) people under 65 years of age with: i) the following cardiovascular disease: 1) ischaemic heart disease, 2) congestive heart disease, 3) rheumatic heart disease, 4) congenital heart disease, or 5) cerebo-vascular disease; ii) the following chronic respiratory disease: 1) asthma, if on a regular preventative therapy, or 2) other chronic respiratory disease with impaired lung function; iii) diabetes; iv) chronic renal disease; v) any cancer, excluding basal and squamous skin cancers if not invasive; vi) the following other conditions: 1) autoimmune disease, 2) immune suppression, 3) HIV, 4) transplant recipients, 5) neuromuscular and CNS diseases, 6) haemoglobinopathies, or 7) children on long term aspirin. The following conditions are excluded from funding: i) asthma not requiri
Special Authority for Manufacturers Price - Form SA0753Initial application only from a relevant specialist. Approvals valid for 3 years for applications meeting the following criteria: Both: 1 Patient is a postmenopausal women; and 2 Patient has hormone receptor positive advanced breast cancer (Stage IIIb, or metastatic Stage IV). Renewal only from a relevant specialist. Approvals valid for 3 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0754Initial application only from a named specialist. Approvals valid without further renewal unless notified for applications meeting the following criteria: All of the following: 1 The patient already has a Special Authority approval for anti-retroviral therapy (Details to be attached to application); and 2 Kaletra is to be used as a salvage therapy in place of one protease inhibitor; and 3 The patient must have trialed for at least six months and have failed on currently funded NNRTI based regimens or triple NRTI regimens; and 4 The patient must have trialed for at least six months and have failed on currently funded PI based regimens. NoteFailure is defined as: a) not achieving HIV RNA < 400 copies/ml after 24 weeks of a regimen, orb) an increase of HIV RNA to > 400 copies/ml on two separate occasions not less than one month apart, after suppression to < 400 copies/ml in a patient taking the regimen.
Special Authority for Subsidy - Form SA0755Initial application from any medical practitioner. Approvals valid for 2 years where the patient is likely to benefit from treatment. Note Applications to be made on the approved forms which are available from: Prof. Wayne CutfieldNational Co-ordinatorNew Zealand Growth Hormone CommitteeC/- Department of PaediatricsUniversity of AucklandPrivate Bag 92019AUCKLAND
Special Authority for Subsidy - Form SA0757Initial application only from a relevant specialist. Approvals valid for 6 months for applications meeting the following criteria: All of the following: 1 The patient is less than 2 years of age; and 2 Intolerant to cows' milk; and 3 Diagnosed as suffering from congenital lactase deficiency. Renewal only from a relevant specialist. Approvals valid for 6 months where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0758Initial application only from a general practitioner or relevant specialist. Approvals valid for 2 years for applications meeting the following criteria: All of the following: 1 To be used for the long-term maintenance treatment of bronchospasm and dyspnoea associated with COPD; and 2 In addition to standard treatment, the patient has trialled a dose of at least 40 mcg ipratropium q.i.d; and 3 The patient's breathlessness >= grade 4 according to the Medical Research Council dyspnoea scale (see note); and 4 FEV1 (litres) < 0.4 x predicted (litres); and 5 Either: 5.1 Patient is not a smoker (for reporting purposes only); or 5.2 Patient is a smoker and been offered smoking cessation councilling; and 6 The patient has been offered annual influenza immunisation. Renewal only from a general practitioner or relevant specialist. Approvals valid for 2 years for applications meeting the following criteria: All of the following: 1
a) Prescribers may code prescriptions "contraceptive" (code "O") when used as indicated for contraception. The period of supply and prescription charge will be as per other contraceptives, as follows: - $3.00 prescription charge (patient co-payment) will apply; - prescription may be written for up to six months supply. b) Prescriptions coded in any other way are subject to the non-contraceptive prescription charges, and the non-contraceptive period of supply. ie. Prescriptions may be written for up to three months supply.
(a) Subsidy is available between 1 March and 30 June of each year for patients who meet the following criteria, as set by the Ministry of Health: a) all people 65 years of age and over; b) people under 65 years of age with: i) the following cardiovascular disease: 1) ischaemic heart disease, 2) congestive heart disease, 3) rheumatic heart disease, 4) congenital heart disease, or 5) cerebo-vascular disease; ii) the following chronic respiratory disease: 1) asthma, if on a regular preventative therapy, or 2) other chronic respiratory disease with impaired lung function; iii) diabetes; iv) chronic renal disease; v) any cancer, excluding basal and squamous skin cancers if not invasive; vi) the following other conditions: 1) autoimmune disease, 2) immune suppression, 3) HIV, 4) transplant recipients, 5) neuromuscular and CNS diseases, 6) haemoglobinopathies, or 7) children on long term aspirin. The following conditions are excluded from funding: i) asthma not requiri
The number of test strips available on a prescription is restricted to 50 unless: a) Prescribed with insulin or a sulphonylurea but are on a different prescription and the prescription is endorsed accordingly; orb) Prescribed on the same prescription as insulin or a sulphonylurea in which case the prescription is deemed to be endorsed; orc) Prescribed for a pregnant woman with diabetes and endorsed accordingly.
Special Authority for Subsidy - Form SA0772Initial application only from a gastroenterologist, infectious disease specialist, paediatrician or general physician. Approvals valid for 1 year for applications meeting the following criteria: Both: 1 Any of the following: 1.1 All of the following: 1.1.1 HBsAg positive for more than 6 months; and 1.1.2 HBeAg positive or HBV DNA positive defined as >0.6 pg/ml by quantitative PCR at reference laboratory; and 1.1.3 ALT greater than twice upper limit of normal or stage 3 or 4 fibrosis on liver histology clinical/radiological evidence of cirrhosis; or 1.2 HBV DNA positive cirrhosis prior to liver transplantation; or 1.3 HBsAg positive and have had a liver, kidney, heart, lung or bone marrow transplant; or 1.4 Hepatitis B surface antigen positive (HbsAg) patient who is receiving chemotherapy for a malignancy, or who has received such treatment within the previous two months; and 2 All of the following: 2.1 No continuing
Additional subsidy by endorsement for:Paroxetine hydrochloride tab 20 mg x 30 (Aropax) up to $35.02is available for patients who: -were taking paroxetine hydrochloride on February 2001; or- have previously responded to treatment with paroxetinehydrochloride; or- have had a trial of fluoxetine and have had to discontinue due to- inability to tolerate the drug due to side effects; or- failed to respond to an adequate dose and duration of treatment; or- have contraindications to fluoxetine (eg pre-existing significant levels of nausea, breastfeeding, potential drug interactions). The prescription must be endorsed accordingly.
Special Authority for Subsidy - Form SA0774Initial application only from a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Any of the following: 1 The patient has advanced gastrointestinal malignancy; or 2 The patient has metastatic breast cancer*; or 3 Both: 3.1 The patient has poor venous access or needle phobia*; and 3.2 The patient requires a substitute for single agent fluoropyrimidine*. Renewal only from a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Either: 1 The patient requires continued therapy; or 2 The tumour has relapsed and requires re-treatment. Noteindications marked with * are unapproved indications.
Special Authority for Subsidy - Form SA0775Initial application only from a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Both: 1 The patient has metastatic colorectal cancer; and 2 Either: 2.1 To be used for first or second line use as part of a combination chemotherapy regimen; or 2.2 As single agent chemotherapy in fluropyrimidine-relapsed disease. Renewal only from a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Either: 1 The patient requires continued therapy; or 2 The tumour has relapsed and requires re-treatment.
Special Authority for Subsidy - Form SA0776Initial application only from a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Any of the following: 1 Both: 1.1 The patient has ovarian, fallopian* or primary peritoneal cancer*; and 1.2 Either: 1.2.1 Has not received prior chemotherapy; or 1.2.2 Has received prior chemotherapy but has not previously been treated with taxanes; or 2 The patient has metastatic breast cancer; or 3 Both: 3.1 The patient has non-small cell lung cancer; and 3.2 Either: 3.2.1 The patient has advanced disease (stage IIIa or above); or 3.2.2 The patient is receiving combined chemotherapy and radiotherapy; or 4 Both: 4.1 The patient has small-cell lung cancer*; and 4.2 Paclitaxel is to be used as second-line therapy. Renewal only from a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Both: 1 The patient has metastati
Special Authority for Subsidy - Form SA0777Initial application - (Post-transplant) only from a relevant specialist. Approvals valid for 6 months where the patient has B-cell post-transplant lymphoproliferative disorder*. NoteFor no more than 8 treatment cycles. Initial application - (Low-grade lymphomas) only from a relevant specialist. Approvals valid for 6 months where the patient has low grade NHL - relapsed disease following prior chemotherapy. NoteFor no more than 4 treatment cycles. Initial application - (Large cell lymphomas) only from a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Both: 1 The patient has treatment naive large B-cell NHL; and 2 To be used with CHOP (or alternative anthracycline containing multi-agent chemotherapy regime given with curative intent).NoteFor no more than 8 treatment cycles. Renewal - (Low-grade lymphomas) only from a relevant specialist. Approvals valid for 6 months for applications meeting
Special Authority for Subsidy - Form SA0779Initial application - (Confirmed HIV/AIDS) only from a named specialist. Approvals valid without further renewal unless notified for applications meeting the following criteria: Both: 1 Confirmed HIV infection; and 2 Any of the following: 2.1 Symptomatic patient; or 2.2 Patient aged 12 months and under; or 2.3 Both: 2.3.1 Patient aged 1 to 5 years; and 2.3.2 Any of the following: 2.3.2.1 CD4 counts < 1,000 cells/mm3; or 2.3.2.2 CD4 counts < 0.25 x total lymphocyte count; or 2.3.2.3 Viral load counts > 100,000 copies per ml; or 2.4 Both: 2.4.1 Patient aged 6 years and over; and 2.4.2 CD4 counts < 350 cells/mm3. NoteTenofovir disoproxil fumarate prescribed under endorsement for HIV/AIDS is included in the count of up to 3 subsidised antiretrovirals. Subsidies for a combination of up to three anti-retroviral medications, including a maximum of two protease inhibitors. Combinations including r
Special Authority for Subsidy - Form SA0780Initial application - (Single NAED Therapy) only from a paediatrician, neurologist or general physician. Approvals valid for 15 months for applications meeting the following criteria: Any of the following: 1 Was on NAED therapy before 1 September 2000; or 2 Seizures are not adequately controlled with optimal older anti-epilepsy drug treatment; or 3 Seizures are controlled adequately but who experience unacceptable side effects from older anti-epilepsy drug treatment. Note"Optimal older anti-epilepsy drug therapy" is defined as treatment with those older anti-epilepsy drugs which are indicated and clinically appropriate for the patient, given singly and in combination in adequate doses for the patient's age, weight, and other features affecting the pharmacokinetics of the drug with good evidence of complianceInitial application - (Dual NAED Therapy) only from a paediatrician, neurologist or general physician. Approvals valid for 18 months for app
Special Authority for Subsidy - Form: SA0781Initial application only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria: Any of the following: Monotherapy1 All of the following: 1.1 To be used as monotherapy for patients with type 2 diabetes who after six months of diet and lifestyle changes do not have adequate glycaemic control (inadequate control defined as HbA1c > 7.0% in tests carried out at least two months apart); and 1.2 Metformin is not tolerated or contraindicated. Intolerance and contraindications as defined in the notes below, a minimum of a four week trial period of metformin is required; and 1.3 Sulphonylurea is not tolerated or contraindicated. Obesity is only eligible under the criteria of contraindication to sulphonylureas if the patient's body mass index (BMI) exceeds 33 , intolerance as defined in the notes below; orIn combination with sulphonylurea2 Both: 2.1 For use in combination with a sulphonylure
Special Authority for Subsidy - Form SA0782Initial application - (No previous use) only from a relevant specialist or general practitioner. Approvals valid for 6 months for applications meeting the following criteria: All of the following: 1 The patient has a clinical diagnosis of heavy menstrual bleeding; and 2 The patient has failed to respond to or is unable to tolerate other appropriate pharmaceutical therapies as per the Heavy Menstrual Bleeding Guidelines; and 3 Either: 3.1 serum ferritin level < 16 mg/l (within the last 12 months); or 3.2 haemoglobin level < 120 g/l . NoteApplications are not to be made for use in patients as contraception except where they meet the above criteriaInitial application - (Previous use before 1 October 2002) only from a relevant specialist or general practitioner. Approvals valid for 6 months for applications meeting the following criteria: All of the following: 1 The patient had a clinical diagnosis of heavy menstrual bleeding; and 2
Special Authority for Manufacturers Price - Form: SA0783Initial application only from a relevant specialist. Approvals valid for 5 years for applications meeting the following criteria: All of the following: 1 Patient is a postmenopausal women; and2 Patient has hormone receptor positive advanced breast cancer; and3 Any of the following: 3.1 The cancer is advanced (Stage IIIb, or metastatic Stage IV); or 3.2 The patient has a very clear history of intolerance to tamoxifen; or 3.3 The use of tamoxifen is contraindicated due to a history of thromboembolic disease. Renewal only from a relevant specialist. Approvals valid without further renewal unless notified where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Manufacturers Price - Form SA0788Initial application only from a relevant specialist or general practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria: Both: 1 Patient has a calculated absolute risk of cardiovascular disease of at least 15% over 5 years; and 2 Either: 2.1 Patient has severe documented intolerance to simvastatin (blood tests are not required); or 2.2 Both: 2.2.1 Patient has been compliant with a dose of simvastatin of 80 mg per day for at least 2 months; and 2.2.2 Either: 2.2.2.1 All of the following: 2.2.2.1.1 Patient has venous CABG; and 2.2.2.1.2 LDL cholesterol test 1 >= 2.0 mmol/litre; and 2.2.2.1.3 LDL cholesterol test 2 >= 2.0 mmol/litre (at least 1 week after test 1); or 2.2.2.2 All of the following: 2.2.2.2.1 Patient does not have venous CABG; and 2.2.2.2.2 LDL cholesterol test 1 >= 2.5 mmol/litre; and 2.2.2.2.
Special Authority for Subsidy - Form SA0789Initial application only from a relevant specialist or vocationally registered general practitioner. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 The patient has "treatment resistant" depression; and 2 Either: 2.1 The patient must have had a trial of two different antidepressants and failed to respond to an adequate dose over an adequate period of time (usually at least four weeks); or 2.2 Both: 2.2.1 The patient is currently a hospital in-patient as a result of an acute depressive episode; and 2.2.2 The patient must have had a trial of one other antidepressant and failed to respond to an adequate dose over an adequate period of time. Renewal from any medical practitioner. Approvals valid for 2 years where patient has a high risk of relapse (prescriber determined).
Prescribing GuidelineBimatoprost, lantanoprost and travoprost are subsidised for use in the treatment of glaucoma as either monotherapy or as an adjunctive agent for patients in whom prostaglandin analogue monotherapy has been ineffective in controlling intraocular pressure.Bimatoprost, lantanoprost and travoprost should not be prescribed for a person in whom less expensive first line agents for the treatment of glaucoma are not contraindicated unless: 1 That person has previously trialled all other such subsidised agents (beta-blockers, pilocarpine, carbonic anhydrase inhibitors); and2 Those trials have indicated that that person does not respond adequately to treatment with those other agents.
Special Authority for Subsidy - Form: SA0792Initial application only from a psychiatrist. Approvals valid for 6 months for applications meeting the following criteria: All of the following: 1 The patient has schizophrenia or other psychotic disorder; and2 Has tried but failed to comply with treatment using oral atypical anti-psychotic agents; and3 Has been admitted to hospital or treated in respite care, or intensive outpatient or home-based treatment for 30 days or more in last 12 months. Renewal only from a psychiatrist. Approvals valid for 12 months for applications meeting the following criteria: Either: 4 Both: 4.1 The patient has had less than 12 months treatment with risperidone microspheres; and 4.2 There is no clinical reason to discontinue treatment; or5 The initiation of risperidone microspheres has been associated with fewer days of intensive intervention than was the case during a corresponding period of time prior to the initiation of risperidone microspheres. NoteRisp
Special Authority for Subsidy - Form: SA0796Initial application only from a relevant specialist. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 Either: 1.1 ezetimibe is to be used in combination with simvastatin; or 1.2 ezetimibe is to be used without a statin; and2 Either: 2.1 All of the following: 2.1.1 Patient has a calculated absolute risk of cardiovascular disease >20% over 5 years; and 2.1.2 Patient cannot tolerate statin therapy at a dose of 40 mg per day; and 2.1.3 Either: 2.1.3.1 All of the following: 2.1.3.1.1 Patient has venous CABG; and 2.1.3.1.2 LDL cholesterol >= 2.0 mmol/litre (see note); and 2.1.3.1.3 LDL cholesterol >= 2.0 mmol/litre (at least 1 week after test 1 - see note); or 2.1.3.2 All of the following: 2.1.3.2.1 Patient does not have venous CABG; and 2.1.3.2.2 LDL cholesterol >= 2.5 mmol/litre (see note); and 2.1.3.2.3 LDL cholest
Special Authority for Subsidy - Form: SA0797Initial application - (Underlying cause - Osteoporosis) only from a relevant specialist or vocationally registered general practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria: Any of the following: 1 History of one significant osteoporotic fracture demonstrated radiologically and documented bone mass density (BMD) >= 2.5 standard deviations below the mean normal value in young adults (i.e. T-Score <= -2.5); or2 History of one significant osteoporotic fracture demonstrated radiologically and the patient is either over 75 years of age or is too frail* to undergo a bone mass density scan; or3 History of two significant osteoporotic fractures demonstrated radiologically; or4 Documented T-Score <= -3.0. Note*The patient may be considered to be frail if it is expected that there is significant risk of further fracture or other negative health outcome if the patient were to undergo a BMD s
Special Authority for Subsidy - Form: SA0798Initial application only from a relevant specialist. Approvals valid without further renewal unless notified for applications meeting the following criteria: Either: 1 Renal transplant recipient; or2 Heart transplant recipient. or; 3 Patient has an organ transplant and has severe tophaceous gout making azathioprine unsuitableRenewal only from a relevant specialist. Approvals valid without further renewal unless notified where patient had a previous Special Authority approval and was receiving mycophenolate prior to 1 October 2005
Special Authority for Subsidy - Form: SA0799Initial application only from a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Either: 1 The patient has metastatic breast cancer; or2 The patient has non-small cell lung cancer (stage IIIa, or above).Renewal only from a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Either: 3 The patient requires continued therapy; or4 The tumour has relapsed and requires re-treatment.
Special Authority for Subsidy - Form SA0801Initial application - (Serevent Accuhaler, Foradil, Symbicort Turbuhaler) only from a relevant specialist or general practitioner. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 Both: 1.1 Child under the age of 12 with poorly controlled asthma; and 1.2 Either: 1.2.1 Required at least three months of 400 mcg or more daily inhaled beclomethasone or budesonide; or 1.2.2 Required at least three months of 200 mcg or more of fluticasone; or 2 Both: 2.1 Adult with poorly controlled asthma; and 2.2 Either: 2.2.1 Required at least three months of 1500 mcg or more daily inhaled beclomethasone or budesonide; or 2.2.2 Required at least three months of 750 mcg or more of fluticasone. NotePatients are to be reviewed at least at six months to assess compliance and effectiveness of therapy. Special Authority approvals are interchangeable among all presentations of inhaled long-acting beta
Special Authority for Subsidy - Form SA0802Initial application - (genotype 1, 4, 5 or 6 infection or co-infection with HIV) from any specialist. Approvals valid for 11 months for applications meeting the following criteria: 1. Patient has chronic hepatitis C, genotype 1, 4, 5 or 6 infection; or2. Patient has chronic hepatitis C and is co-infected with HIV. Note: consider stopping treatment if there is absence of a virological response (defined as at least a 2-log reduction in viral load) following 12 weeks of treatment since this is predictive of treatment failure.Initial application - (genotype 2 or 3 infection without co-infection with HIV) from any specialist. Approvals valid for 6 months for applications meeting the following criteria: 3. Patient has chronic hepatitis C, genotype 2 or 3 infection; andEither: 3.1 Patient has bridging fibrosis or cirrhosis (Metavir stage 3 or 4 or equivalent); or 3.2 is unsuitable for liver biopsy due to coagulopathy.
Special Authority for Subsidy - Form SA0803Initial application from any specialist. Approvals valid for 11 months for applications meeting the following criteria: either: 1 Patient has chronic hepatitis C, genotype 1, 4, 5 or 6 infection; or2 Patient has chronic hepatitis C, genotype 2 or 3 infection; and 2.1 With has bridging fibrosis or cirrhosis (Metavir stage 3 or 4, or equivalent). 2.2 is unsuitable for liver biopsy due to coagulopathy. Note: consider stopping treatment if there is absence of a virological response (defined as at least a 2-log reduction in viral load) following 12 weeks of treatment since this is predictive of treatment failure.
Prescribing Guideline for Inhaled Long-Acting Beta-Adrenoceptor AgonistsThe addition of inhaled long-acting beta-adrenoceptor agonists (LABAs) to inhaled corticosteroids is recommended: - For younger children (aged under 12 years) where asthma is poorly controlled despite using inhaled corticosteroids for at least three months at total daily doses of 200 mcg beclomethasone or budesonide (or 100 mcg fluticasone).- For adults and older children (aged 12 years and over) where asthma is poorly controlled despite using inhaled corticosteroids for at least three months at total daily doses of 400 mcg beclomethasone or budesonide (or 200 mcg fluticasone).Note: Further information on the place of inhaled corticosteroids and inhaled LABAs in the management of asthma can be found in the New Zealand guidelines for asthma in adults (www.nzgg.org.nz) and in the New Zealand guidelines for asthma in children aged 1-15 (www.paediatrics.org.nz).
Access by applicationa) Budget managed by appointed clinicians on the Multiple Sclerosis Treatment Assessments Committee (MSTAC). b) Applications will be considered by MSTAC at its regular meetings and approved subject to eligibility according to the Entry and Stopping criteria (below). c) Applications to be made on the approved forms which are available from the co-ordinator for MSTAC:The Co-ordinator Phone: (04) 460 4990Multiple Sclerosis Treatment Assessments Committee Facsimile: (04) 916 7571PHARMAC, PO Box 10 254 E mail: silvia.valsenti@pharmac.govt.nzWellingtond) Completed application forms must be sent to the co-ordinator for MSTAC and will be considered by MSTAC at the next practicable opportunity. e) Notification of MSTAC's decision will be sent to the patient, the applying clinician and the patient's GP (if specified). f) These agents will not be subsidised if dispensed from a community or hospital pharmacy. Regular supplies will be distributed to all approved patients or their c
Special Authority for Subsidy Initial application only from a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: 1 The patient has metastatic colorectal cancer; and2 To be used for first or second line use as part of a combination chemotherapy regimen. Renewal only from a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: 3 The patient requires continued therapy; or4 The tumour has relapsed and requires re-treatment.
Special Authority for Subsidy - Form: SA0809Initial application only from a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Any of the following: 1 Both: 1.1 The patient has ovarian*, fallopian* or primary peritoneal cancer*; and 1.2 Either: 1.2.1 Has not received prior chemotherapy; or 1.2.2 Has received prior chemotherapy but has not previously been treated with taxanes; or2 The patient has metastatic breast cancer; or3 Both: 3.1 The patient has non small-cell lung cancer; and 3.2 Either: 3.2.1 Has advanced disease (stage IIIa or above); or 3.2.2 Is receiving combined chemotherapy and radiotherapy; or4 Both: 4.1 The patient has small-cell lung cancer*; and 4.2 Docetaxel is to be used as second-line therapy. Renewal only from a relevant specialist. Approvals valid for 12 months for applications meeting the followingcriteria: 5. The patient has metastatic breast cancer, non small-cell lung cancer,
Special Authority for Alternate SubsidyInitial application only from a relevant specialist. Approvals valid for 5 years for applications meeting the following criteria: All of the following: 1 Patient is a postmenopausal women; and2 Patient has hormone receptor positive breast cancer; and3 Any of the following: 3.1 The cancer is advanced (Stage IIIb, or metastatic Stage IV); or 3.2 The patient has a very clear history of intolerance to tamoxifen; or 3.3 The use of tamoxifen is contraindicated due to a history of thromboembolic disease. Renewal only from a relevant specialist. Approvals valid without further renewal unless notified where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Alternate SubsidyInitial application only from a relevant specialist. Approvals valid for 5 years for applications meeting the following criteria: All of the following: 1 Patient is a postmenopausal women; and2 Patient has hormone receptor positive breast cancer; and3 Any of the following: 3.1 The cancer is advanced (Stage IIIb, or metastatic Stage IV); or 3.2 The patient has a very clear history of intolerance to tamoxifen; or 3.3 The use of tamoxifen is contraindicated due to a history of thromboembolic disease. Renewal only from a relevant specialist. Approvals valid without further renewal unless notified where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for SubsidyInitial application only from a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria: All of the following1 Patient is an adult who has had severe and active erosive Rheumatoid Arthritis for six months duration or longer; and2 Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and3 Patient has tried and not responded to at least three months of oral or parenteral methotrexate at a dose of at least 20 mg weekly or a maximum tolerated dose; and4 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with at least two of the following (triple therapy): sulphasalazine, prednisone at a dose of at least 7.5 mg per day, azathioprine, intramuscular gold, or hydroxychloroquine sulphate (at maximum tolerated doses); and5 Patient has tried and not responded to at least three months therapy at th
Special Authority for Subsidy Initial application only from a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Any of the following: 1 The patient has non small cell lung carcinoma (stage IIIa, or above); or2 The patient has advanced malignant mesothelioma*; or3 The patient has advanced pancreatic carcinoma; or4 The patient has ovarian, fallopian tube* or primary peritoneal carcinoma*. Renewal only from a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Both: 5 The patient requires continued therapy; or6 The tumour has relapsed and requires re-treatment. Note indications marked with a * are unapproved indications.
Special Authority for Subsidy Initial application only from a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Both: 1 The patient has primary thrombocythaemia; and2 Either 2.1 is at high risk (previous thromboembolic disease, bleeding or platelet count >1500/ml); or 2.2 is intolerant or refractory to hydroxyurea or interferon. Renewal only from a relevant specialist. Approvals valid for 12 months where the treatment remains appropriate and the patient is benefiting from treatment. NoteIt is recommended that treatment with anagrelide be initiated only on the recommendation of a haematologist.
Special Authority for Subsidy Initial application - (for new patients) only from a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Both: 1 The patient has refractory, progressive or relapsed multiple myeloma; and2 The patient has received prior chemotherapy. Initial application - (for patients receiving thalidomide prior to 1 January 2006) only from a relevant specialist. Approvals valid without further renewal where the patient was receiving treatment with thalidomide for multiple myeloma on or before 31 December 2005. Renewal only from a relevant specialist. Approvals valid without further renewal where the patient has obtained a response from treatment during the initial approval period. Note: Prescription must be written by registered prescriber in the thalidomide risk management programme operated by the supplier. Maximum dose of 400 mg daily as monotherapy or in a combination therapy regimen.
Special Authority for Subsidy Initial application for patients with type 2 diabetes only from a relevant specialist. Approvals valid for one year for applications meeting the following criteria: Any of the following: Monotherapy1 All of the following: 1.1 To be used as monotherapy for patients who after six months of diet and lifestyle changes have inadequate glycaemic control (defined as HbA1c > 7.0% in tests carried out at least two months apart); and 1.2 Metformin is contraindicated or not tolerated after a minimum of a four week trial period; and 1.3 Sulphonylurea is contraindicated or not tolerated or the patient's body mass index (BMI) exceeds 33 kg/m2; orIn combination with sulphonylurea2 Both: 2.1 For use in combination with a sulphonylurea for patients who after diet and lifestyle changes and a six-month trial of sulphonylurea have poor glycaemic control (defined as HbA1c > 8.0% measured within the last month of the six month period); and 2.2 Metformin is contrain
Perindopril and trandolapril will be funded to the level of the ex-manufacturer price listed in the Schedule for patients who were taking these ACE inhibitors for the treatment of congestive heart failure prior to 1 June 1998. The prescription must be endorsed accordingly. We recommend that the words used to indicate eligibility are "certified condition" or an appropriate description of the patient such as "congestive heart failure", "CHF", "congestive cardiac failure" or "CCF". Definition of Congestive Heart Failure At the request of some prescribers the PTAC Cardiovascular subcommittee has provided a definition of congestive heart failure for the purposes of the funding of the manufacturer's surcharge: "Clinicians should use their clinical judgement. Existing patients would be eligible for the funding of the surcharge if the patient shows signs and symptoms of congestive heart failure, and requires or has in the past required concomitant treatment with a diuretic. The definition could also be considere
Special Authority for Subsidy - Form: SA0826Initial application only from a relevant specialist. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 All of the following: 1.1 Patient has a calculated absolute risk of cardiovascular disease >20% over 5 years; and 1.2 Patient cannot tolerate statin therapy at a dose of >= 40 mg per day; and 1.3 Either: 1.3.1 All of the following: 1.3.1.1 Patient has venous CABG; and 1.3.1.2 LDL cholesterol >= 2.0 mmol/litre (see note); and 1.3.1.3 LDL cholesterol >= 2.0 mmol/litre (at least 1 week after test 1 - see note); or 1.3.2 All of the following: 1.3.2.1 Patient does not have venous CABG; and 1.3.2.2 LDL cholesterol >= 2.5 mmol/litre (see note); and 1.3.2.3 LDL cholesterol >= 2.5 mmol/litre (at least 1 week after test 1 - see note); or2 All of the following: 2.1 Patient has homozygous familial hypercholesterolemia, or heterozygous familial hypercholest
Special Authority for Subsidy - Retail Pharmacy - Form SA0829Initial Application only from gastroenterologist or infectious disease specialist. Approvals valid for 1 year for applications meeting the following criteria: All of the following: 1. Patient has confirmed Hepatitis B infection (HBsAg+); andDocumented resistance to lamivudine, defined as: 2. patient has raised serum ALT (> 1 x ULN); and3. patient has HBV DNA greater than 100,000 copies per mL, or viral load ? 10 fold over nadir; and4. detection of M204I or M204V mutation; and5. Either5.1. Both5.1.1. patient is cirrhotic; and5.1.2. adefovir dipivoxil to be used in combination with lamivudine; or5.2. Both5.2.1. patient is not cirrhotic; and5.2.2. adefovir dipivoxil to be used as monotherapyRenewal only from a gastroenterologist or infectious disease specialist. Approvals valid for 2 years for applications where in the opinion of the treating physician, treatment remains appropriate and patient is benefiting from treatmen
Special Authority for Subsidy - Form: SA0831Application only from a relevant specialist. Approvals valid for 10 months for applications meeting the following criteria: 1. Patient has newly diagnosed glioblastoma multiforme; and2. Temozolomide is to be (or has been) given concomitantly with radiotherapy; and3. Following concomitant treatment temozolomide is to be used for a maximum of six cycles of 5 days treatment, at a maximum dose of 200 mg/m2. Note: Temozolomide is not subsidised for the treatment of relapsed glioblastoma multiforme. Studies of temozolomide show that its benefit is predominantly in those patients with a good performance status (WHO grade 0 or 1 or Karnofsky score >80), and in patients who have had at least a partial resection of the tumour.
Special Authority for Subsidy - Form: SA0832Initial application only from a gastroenterologist, infectious disease specialist, paediatrician or general physician. Approvals valid for 1 year for applications meeting the following criteria: Both: 1 Any of the following: 1.1 All of the following: 1.1.1 HBsAg positive for more than 6 months; and1.1.2 HBeAg positive or HBV DNA positive defined as > 100,000 copies per ml by quantitative PCR at a reference laboratory; and1.1.3 ALT greater than twice upper limit of normal or bridging fibrosis or cirrhosis (Metavir stage 3 or 4 or equivalent) on liver histology or clinical/radiological evidence of cirrhosis; or 1.2 HBV DNA positive cirrhosis prior to liver transplantation; or1.3 HBsAg positive and have had a liver, kidney, heart, lung or bone marrow transplant; or1.4 Hepatitis B surface antigen positive (HbsAg) patient who is receiving chemotherapy for a malignancy, or who has received such treatment within the previous two months;
Special Authority for Subsidy - Form SA0833Initial application only from a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Any of the following: 1 The patient has non small cell lung carcinoma (stage IIIa, or above); or2 The patient has advanced malignant mesothelioma*; or3 The patient has advanced pancreatic carcinoma; or4 The patient has ovarian, fallopian tube* or primary peritoneal carcinoma*; or5 The patient has advanced transitional cell carcinoma of the urothelial tract (locally advanced or metastatic). Renewal only from a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Both: 6 The patient requires continued therapy; or7 The tumour has relapsed and requires re-treatment. Note indications marked with a * are unapproved indications.
Special Authority for Subsidy - Form: SA0834Initial application only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria: Either: 1 Both: 1.1 Patient has type 1 diabetes and has received an intensive regimen (injections at least three times a day) of an intermediate acting insulin in combination with a rapid acting insulin analogue for at least three months; and1.2 Either: 1.2.1 Patient has experienced more than one unexplained severe hypoglycaemic episode in the previous 12 months (severe defined as requiring the assistance of another person); or1.2.2 Patient has experienced unexplained symptomatic nocturnal hypoglycaemia, biochemically documented at <3.0 mmol/L, more than once a month despite optimal management; or2 Patient has documented severe, or continuing, systemic or local allergic reaction to existing insulins. Note this does not include hypoglycaemic episodes. Renewal only from a relevant specialist or general practitioner. Approv
Special Authority for Subsidy - Form SA0835Initial application - (Breast cancer) from any medical practitioner. Approvals valid for 1 year: where the patient is a premenopausal woman with breast cancer. Initial application - (Prostate cancer) only from an oncologist, urologist or endocrinologist. Approvals valid for 1 year for applications meeting the following criteria: Advanced prostatic cancer;. Note Not to be prescribed with an anti-androgen except for a period of three weeks, if necessary, when GnRH analogue therapy is initiated. Initial application - (Endometriosis) only from a gynaecologist. Approvals valid for 3 months for applications meeting the following criteria: Both: 1 Endometriosis; and2 Either: 2.1 6 months treatment with medroxyprogesterone acetate, danazol or dimetriose has proven ineffective; or2.2 The patient has failed to tolerate the treatment with medroxyprogesterone acetate, danazol or dimetriose for 6 months. Note The maximum treatment period for a GnRH analogue is:
Special Authority for Subsidy - Form SA0836Initial application - (Breast cancer) from any medical practitioner. Approvals valid for 1 year where the patient is a premenopausal woman with breast cancer. Initial application - (Prostate cancer) only from an oncologist, urologist or endocrinologist. Approvals valid for 1 year for applications meeting the following criteria: Either: 1 Advanced prostatic cancer; or. 2 Locally advanced prostatic cancer. Note Not to be prescribed with an anti-androgen except for a period of three weeks, if necessary, when GnRH analogue therapy is initiated. Initial application - (Endometriosis) only from a gynaecologist. Approvals valid for 3 months for applications meeting the following criteria: Both: 3 Endometriosis; and4 Either: 4.1 6 months treatment with medroxyprogesterone acetate, danazol or dimetriose has proven ineffective; or4.2 The patient has failed to tolerate the treatment with medroxyprogesterone acetate, danazol or dimetriose for 6 months. Note
Special Authority for Subsidy - Form SA0837Initial application - (Breast cancer) from any medical practitioner. Approvals valid for 1 year where the patient is a premenopausal woman with breast cancer. Initial application - (Prostate cancer) only from an oncologist, urologist or endocrinologist. Approvals valid for 1 year where the patient has: Advanced prostatic cancer;. Note Not to be prescribed with an anti-androgen except for a period of three weeks, if necessary, when GnRH analogue therapy is initiated. Initial application - (Endometriosis) only from a gynaecologist. Approvals valid for 3 months for applications meeting the following criteria: Both: 1 Endometriosis; and2 Either: 2.1 6 months treatment with medroxyprogesterone acetate, danazol or dimetriose has proven ineffective; or2.2 The patient has failed to tolerate the treatment with medroxyprogesterone acetate, danazol or dimetriose for 6 months. Note The maximum treatment period for a GnRH analogue is: - 3 months to assess whet
Special Authority for Subsidy - Form: SA0838Initial Application only from a relevant specialist or General Practitioner. Approvals valid for 2 years forapplications meeting the following criteria: Either: 1 All of the following: 1.1 Patient is a child under the age of 12; and1.2 All of the following: Has, for 3 months or more, been treated with:1.2.1 An inhaled long-acting beta adrenoceptor agonist; and1.2.2 Inhaled corticosteroids at a dose of at least 400 mcg per day beclomethasone or budesonide, or200 mcg per day fluticasone; and1.3 The prescriber considers that the patient would receive additional clinical benefit from switching to acombination product; or2 All of the following: 2 .1 Patient is over the age of 12; and2 .2 All of the following: Has, for 3 months or more, been treated with:2 .2.1 An inhaled long-acting beta adrenoceptor agonist; and2 .2.2 Inhaled corticosteroids at a dose of at least 800 mcg per day beclomethasone or budesonide, or500 mcg per day fluticasone;
Special Authority for Subsidy - Form SA0839Initial application - (Breast cancer) from any medical practitioner. Approvals valid for 1 year where the patient is a premenopausal woman with breast cancer. Initial application - (Prostate cancer) only from an oncologist, urologist or endocrinologist. Approvals valid for 1 year for applications meeting the following criteria: Either: 1 Advanced prostatic cancer; or. 2 Neoadjuvant or adjuvant treatment of locally advanced prostatic cancer. Note Not to be prescribed with an anti-androgen except for a period of three weeks, if necessary, when GnRH analogue therapy is initiated. Initial application - (Endometriosis) only from a gynaecologist. Approvals valid for 3 months for applications meeting the following criteria: Both: 3 Endometriosis; and4 Either: 4.1 6 months treatment with medroxyprogesterone acetate, danazol or dimetriose has proven ineffective; or4.2 The patient has failed to tolerate the treatment with medroxyprogesterone acetate, danazo
Special Authority for Subsidy - form: SA0841Initial application only from a gastroenterologist or general physician. Approvals valid for 6 months for applications meeting the following criteria: Both: 1 Primary biliary cirrhosis confirmed by antimitochondrial antibody titre (AMA) > 1:80, and raised cholestatic liver enzymes with or without raised serum IgM or, if AMA is negative, by liver biopsy; and2 Patient not requiring a liver transplant (bilirubin > 170umol/l; decompensated cirrhosis). NoteLiver biopsy is not usually required for diagnosis but is helpful to stage the diseaseRenewal only from a gastroenterologist or general physician. Approvals valid for 2 years for applications meeting the following criteria: The treatment remains appropriate and the patient is benefiting from treatment. NoteActigall is not an appropriate therapy for patients requiring a liver transplant (bilirubin > 170 micromol/l; decompensated cirrhosis). These patients should be referred to an appropriate transp
Special Authority for Subsidy - Form: SA842Initial application only from a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Any of the following: 1 Both: 1.1 The patient has ovarian, fallopian* or primary peritoneal cancer*; and 1.2 Either: 1.2.1 Has not received prior chemotherapy; or 1.2.2 Has received prior chemotherapy but have not previously been treated with taxanes; or2 The patient has metastatic breast cancer; or3 The patient has node-positive early breast cancer; or4 Both 4.1 The patient has non small-cell lung cancer; and 4.2 Either: 4.2.1 Has advancing disease (stage IIIa or above); or 4.2.2 Is receiving combined chemotherapy and radiotherapy; or5 Both: 5.1 The patient has small-cell lung cancer*; and 5.2 Paclitaxel is to be used as second-line therapy. Renewal only from a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: 6 The patient has metasta
Special Authority for Subsidy - Form SA0028Initial application only from a relevant specialist. Approvals valid for 6 months for applications meeting the following criteria: Either: 1 All of the following: 1.1 Treatment with other lipid modifying medicines has been unsuccessful; and 1.2 6 months of dietary modification has been unsuccessful; and 1.3 Cholesterol level > 7.0 mmol/litre; and 1.4 Either: 1.4.1 Familial hypercholesterolaemia; or 1.4.2 Manifest coronary heart disease, which has been clinically proven, or previously treated by coronary artery surgery; or 2 Cholesterol level > 9.0 mmol/litre:.Renewal only from a general practitioner. Approvals valid for 6 months where the treatment remains appropriate and the patient is benefiting from treatment. NoteFamilial hypercholesterolaemia is defined as being hypercholesterolaemia in the presence of tendon xanthomas or in association with a family history of premature heart disease (before age 55) or consisten
Unapproved medication supplied under Section 29 of the Medicines Act 1981. Practitioners prescribing this medication should: (a) be aware of and comply with their obligations under Section 29 of the Medicines Act 1981 and otherwise under that Act and the Medicines Regulations 1984; (b) be aware of and comply with their obligations under the Health and Disability Commissioner's Code of Consumer Rights, including the requirement to obtain informed consent from the patient (PHARMAC recommends that Practitioners obtain written consent); and(c) exercise their own skill, judgment, expertise and discretion, and make their own prescribing decisions with respect to the use of an unapproved Pharmaceutical or a Pharmaceutical for an indication for which it is not approved.
Special Authority for Subsidy - Form SA0031Initial application from any medical practitioner. Approvals valid for 2 years for applications meeting the following criteria: Any of the following: 1 Oesophageal stricture; or 2 Terminal care; or 3 Too young to swallow conventional tablets; or 4 Too old to swallow conventional tablets. Renewal from any medical practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Manufacturers Price - Form SA0035Initial application from any medical practitioner. Approvals valid for 5 years for applications meeting the following criteria: Both: 1 Either: 1.1 Both: 1.1.1 Duodenal and gastric ulcers, reflux oesophagitis and Zollinger-Ellison syndrome; and 1.1.2 Other treatments have failed; or 1.2 Patients who are on a Social Welfare benefit or an income no greater than a benefit; and 2 Patients must have endoscopically demonstrated lesions prior to commencement of treatment.. Renewal from any medical practitioner. Approvals valid for 5 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0045Initial application from any medical practitioner. Approvals valid for 2 years for applications meeting the following criteria: All of the following: 1 Continuation of treatment commenced prior to 1 August 1990; and 2 Alternatives (salbutamol and terbutaline) have been tried; and 3 Either: 3.1 Asthma; or 3.2 Chronic obstructive airways disease (COAD); and 4 Applicants must provide details of dose. Renewal from any medical practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0046Initial application only from a gastroenterologist. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 Functioning gall bladder; and 2 Either: 2.1 Uncalcified gallbladder stones with a maximum size of 20 mm; or 2.2 Adjunctive treatment after extra corporeal lithotrypsy. Renewal only from a gastroenterologist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0047Initial application only from a paediatrician or respiratory specialist. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 Child under 2 years of age; or 2 Both: 2.1 Child with major physical or intellectual disabilities; and 2.2 Lacks the necessary coordination to use aerosols with a spacer device. NoteThe cost of nebuliser therapy greatly exceeds other inhaled forms. Steroid nebulising solution can cause cataract formation. Renewal only from a paediatrician or respiratory specialist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0057Initial application only from a psychiatrist. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 Depression; and 2 Any of the following: 2.1 Both: 2.1.1 Failed trials with other antidepressants; and 2.1.2 Patient has been maintained on mianserin prior to December1993; or 2.2 Co-existent bladder neck obstruction; or 2.3 Cardiovascular disease. Renewal only from a psychiatrist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Manufacturers Price - Form SA0070Initial application only from a respiratory specialist or infectious disease specialist. Approvals valid for 2 years for applications meeting the following criteria: Any of the following: 1 Avium intracellular atypical mycobacterial infections; or 2 Multiple drug resistant tuberculosis; or 3 Atypical and drug-resistant mycobacterial infections in patients with AIDS. Renewal only from a respiratory specialist or infectious disease specialist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
a) All patients with AIDS meeting the definition developed by the Centres for Disease Control in the USA (see Circular Letter to Medical Practitioners HP2/88)b) Patients with AIDS Related Complex (ARC)c) HIV infected patients with CD4 (T4) counts below 500 regardless of symptomatologyd) Prophylactically for persons following severe parenteral exposure from a known HIV positive sourcee) HIV infected persons with associated thrombocytopenia regardless of CD4 (T4) count f) Applications can only be made by appropriate specialists. Prescriptions for those patients approved to use these medicines can be written either by the specialist or general practitioner with an endorsement of the name of the recommending specialist. g) Prescriptions for these can be written for a period of three months' supply. However, medicine must be dispensed on a monthly basis.
Special Authority for Subsidy - Form SA0088Initial application only from an endocrinologist or gynaecologist. Approvals valid for 6 months for applications meeting the following criteria: Both: 1 Either: 1.1 Female with anovulatory infertility, males: hypogonadotrophic hypogonadism; or 1.2 Male with hypogonadotrophic hypogonadism; and 2 These agents are not being used as part of an IVF programme. Renewal only from an endocrinologist or gynaecologist. Approvals valid for 6 months where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0089Initial application - (Breast or prostatic cancer) only from an oncologist, urologist or endocrinologist. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 Breast cancer in pre menopausal women unwilling or unable to undergo surgical or radiation oophorectomy; or 2 Advanced prostatic cancer when orchidectomy is contraindicated. Initial application - (Endometriosis) only from a gynaecologist. Approvals valid for 6 months for applications meeting the following criteria: Both: 1 Endometriosis; and 2 Either: 2.1 6 months treatment with medroxyprogesterone acetate, danazol or dimetriose has proven ineffective; or 2.2 The patient has failed to tolerate the treatment with medroxyprogesterone acetate, danazol or dimetriose for 6 months. NoteThe maximum treatment period for a GnRH analogue is: 3 months to assess whether surgery is appropriate3 months for infertile patients after surgery6 months for
Special Authority for Subsidy - Form SA0091Initial application only from a relevant specialist. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 Paget's disease; or 2 Both: 2.1 Patients under hospice care; and 2.2 Either: 2.2.1 Tumour-induced hypercalcaemia; or 2.2.2 Tumour-induced osteolysis without hypercalcaemia. Renewal only from a relevant specialist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0096Initial application - (Organ transplant, Bone marrow transplant or Graft v host disease) only from a relevant specialist. Approvals valid for 2 years for applications meeting the following criteria: Any of the following: 1 Organ transplant; or 2 Bone marrow transplant; or 3 Graft v host disease. Initial application - (Psoriasis) only from a dermatologist. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 Psoriasis; and 2 Other systemic and topical therapy has failed. Initial application - (Severe atopic dermatitis) only from a dermatologist. Approvals valid for 6 months for applications meeting the following criteria: Both: 1 Severe atopic dermatitis; and 2 Not resopnsive to topical therapy, oral antihistamines and other commonly used orthodox therapies. Initial application - (Nephrotic Syndrome) from any medical practitioner. Approvals valid for 2 years for applications meeting the following cri
Special Authority for Subsidy - Form SA0097Initial application - (Chronic hepatitis C) only from a relevant specialist. Approvals valid for 6 months where chronic hepatitis C. Initial application - (Indications other than Chronic hepatitis C) only from a relevant specialist. Approvals valid for 5 years for applications meeting the following criteria: Any of the following: 1 Chronic myelogenous leukaemia; or 2 Hairycell leukaemia; or 3 Cutaneous T cell lymphoma; or 4 Essential thrombocythaemia; or 5 AIDS related Kaposi's sarcoma; or 6 Multiple myeloma; or 7 Chronic active hepatitis B. Renewal - (Chronic hepatitis C) only from a relevant specialist. Approvals valid for 6 months where the treatment remains appropriate and the patient is benefiting from treatment. Renewal - (Indications other than Chronic hepatitis C) only from a relevant specialist. Approvals valid for 5 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0099Initial application only from a relevant specialist. Approvals valid for 5 years for applications meeting the following criteria: Any of the following: 1 Both: 1.1 Acromegaly; and 1.2 Patients who have failed surgery, radiotherapy, bromocriptine and other oral therapies; or 2 Both: 2.1 Either: 2.1.1 Vipomas; or 2.1.2 Glucagonomas; and 2.2 Patients who are seriously ill in order to improve their clinical state prior to definitive surgery; or 3 Both: 3.1 Gastrinoma; and 3.2 Either: 3.2.1 Patient has failed surgery; or 3.2.2 Patient is in metastatic disease after H2 antagonists (or omeprazole) have failed; or 4 Both: 4.1 Insulinomas; and 4.2 Surgery is contraindicated or where surgery has failed; or 5 Pre-operative control of hypoglycaemia; or 6 Maintenance therapy. NoteThe use of octreotide in patients with fistulae, oesophageal varices, miscellaneous diarrhoea and hypotension will
Special Authority for Subsidy - Form SA0100Initial application only from a relevant specialist. Approvals valid for 5 years for applications meeting the following criteria: All of the following: 1 Anaemia of end-stage renal failure (other treatable causes of anaemia being excluded); and 2 Been on haemodialysis or continuous ambulatory peritoneal dialysis (CAPD) for at least three months; and 3 Not under evaluation for, or awaiting, a live donor kidney transplant; and 4 Any of the following: 4.1 Anephric; or 4.2 Dependent on regular blood transfusion (1 unit each 4-8 weeks) to maintain haemoglobin > 60g/L; or 4.3 Cannot be transfused because of severe transfusion reactions; or 4.4 Transfusion induced haemosiderosis (clinical manifestations, serum ferritin >1500 ug/L); or 4.5 Haemoglobin < 70 g/L (mean of at least 4 haemoglobin concentrations over 4 months); or 4.6 Both: 4.6.1 Haemoglobin < 90 g/L; and 4.6.2 Either: 4.6.2.1 Heart failure (low card
Special Authority for Subsidy - Form SA0115Initial application - (Oesophageal stricture) only from a general practitioner or relevant specialist. Approvals valid for 2 years where patient with oesophageal stricture who is unable to take capsules. Initial application - (Indications other than oesophageal stricture) only from a paediatrician. Approvals valid for 2 years for applications meeting the following criteria: All of the following: 1 infant or child with liver disease or short gut syndrome; and 2 Requires vitamin supplementation; and 3 Unable to swallow capsules. Renewal only from a general practitioner, relevant specialist or paediatrician. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0121Initial application from any medical practitioner. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 Patient has to use an unpreserved solution due to an allergy to the preservative; or 2 Patient wears soft contact lenses. NoteMinims for a general practice are considered to be "tools of trade" and are not approved as special authority items. Renewal from any medical practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0125Initial application - (Chronic post-thrombotic venous stasis ulcers) from any medical practitioner. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 Chronic post-thrombotic venous stasis ulcers of more than 4 months duration; and 2 Other interventions have failed. Initial application - (Sudden hearing loss) only from an otolaryngologist. Approvals valid for 2 years where sudden hearing loss. Renewal from any medical practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
a) Should be strictly reserved for use as second line therapy in: - patients unable to tolerate the other medications, such as infants, young children and patients with allergies or eczema- cases of scabies which are resistent to gamma benzene hexachlorideb) Verification of drug resistance is dependent on the persistence of the condition after treatment. In order to establish whether there is drug resistance, the following criteria should be fulfilled: - a definite diagnosis of scabies should be made- it should be ascertained that the medication was administered properly- the possibility of reinfestation should have been excluded
Approvals for a CHEM number to waive the premium in the following circumstances: 1. Patients with prosthetic heart valves - as an adjunct to oral anticoagulation for prophylaxis of thromboembolism (2 year approval with renewal, applications only from cardiothoracic surgeons, cardiologists and general physicians). 2. Patients after coronary artery vein bypass graft - as an adjunct to aspirin (1 year approval only, applications only from cardiothoracic surgeons, cardiologists and general physicians). 3. Patients who continue to have transient ischaemic episodes despite aspirin therapy. A course of up to six months in combination with aspirin. Applications only from neurologists, cardiologists, vascular surgeons and general physicians. Six month approval only. Reapplications only if there is demonstrated recurrence of symptoms when dipyridamole therapy is discontinued. Note: these transitional criteria are currently being reviewed.
a) Approvals to fund the manufacturer's surcharge in the following circumstances: - Patients with prosthetic heart valves - as an adjunct to oral anticoagulation for prophylaxis of thromboembolism (2 year approval with renewal, applications only from cardiothoracic surgeons, cardiologists and general physicians). - Patients after coronary artery vein bypass graft - as an adjunct to aspirin or as monotherapy for patients who are aspirin intolerant as defined below (1 year approval only, applications only from cardiothoracic surgeons, cardiologists and general physicians); or- Patients who continue to have transient ischaemic episodes despite aspirin therapy or have transient ischaemic episodes and are aspirin intolerant as defined below (2 year approval with renewal, applications only from neurologists, neurosurgeons, cardiologists, vascular surgeons and general physicians). b) Aspirin intolerant patients are defined as those with aspirin induced asthma, urticaria, or anaphylaxi, or those with significant
Special Authority for Manufacturers Price - Form SA0157Initial application from any medical practitioner. Approvals valid for 5 years for applications meeting the following criteria: Any of the following: 1 Liver disease; or 2 Past history of thromboembolism; or 3 Significant hypertension; or 4 Hypertension associated with oral oestrogen therapy. Renewal from any medical practitioner. Approvals valid for 5 years where the treatment remains appropriate and the patient is benefiting from treatment.
The new anticonvulsant drugs are restricted to1. neurologists2. paediatric neurologists3. any other prescriber approved in writing by the relevant RHA budget holding manager. The HFA holds a budget for expenditure on the new anticonvulsant drugs. Unless otherwise specified, ultimate authority for approving prescriptions for subsidy lies with the HFA budget holding manager for the new anticonvulsant drugs. The regional divisions of the HFA will be in contact with hospital pharmacists and approved prescribers with more detail of the approval system. GUIDELINES FOR USE OF THE NEW ANTICONVULSANTS ARE AS FOLLOWS: A. Entry criteriaThe following patients are eligible for trial on the new anticonvulsant drugs (NADs)1. Patients who are under the supervision of an approved prescriber, and whose seizures are not adequately controlled with optimal conventional anticonvulsant drug treatment. 2. Patients, who are under the supervision of an approved prescriber, and whose seizures are only controlled adequatel
Special Authority for Subsidy - Form SA0264Initial application only from a paediatrician or respiratory specialist. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 Cystic fibrosis patient; or 2 Both: 2.1 Infant or child with liver disease or short gut syndrome; and 2.2 Requires vitamin supplementation. Renewal only from a paediatrician or respiratory specialist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0266Initial application - (Chronic hepatitis C) only from a relevant specialist. Approvals valid for 6 months where chronic hepatitis C. NoteMaximum reimbursable dosage 15 million iu/weekInitial application - (Indications other than chronic hepatitis C) only from a dermatologist, plastic surgeon or radiation oncologist. Approvals valid for 5 years for applications meeting the following criteria: Any of the following: 1 Chronic myelogenous leukaemia; or 2 Hairycell leukaemia; or 3 Cutaneous T cell lymphoma; or 4 Essential thrombocythaemia; or 5 AIDS related Kaposi's sarcoma; or 6 Multiple myeloma; or 7 Chronic active hepatitis B; or 8 Basal cell carcinoma unable to be treated surgically or by radiotherapy. NoteMaximum reimbursable dosage 15 million iu/weekRenewal - (Chronic hepatitis C) only from a relevant specialist. Approvals valid for 6 months where the treatment remains appropriate and the patient is benefiting from trea
a) - hairy cell leukaemia - Kaposi's sarcoma - chronic active hepatitis B - chronic hepatitis C (6 month approval only) - chronic myelogenous leukaemia - multiple myeloma - basal cell carcinoma 1) Only for basal cell carcinoma unable to be treated surgically or by radiotherapy. 2) Applications only from radiation oncologists, plastic surgeons and dermatologists. Applications from dermatologists will only be accepted with evidence from either a plastic surgeon or oncologist that the patient was unsuitable for surgery. 3) Maximum reimbursable dosage 15 million iu/weekb) Specialist must make applicationc) No further approvals for: Malignant melanoma Note: Patients with existing approvals can continue to have therapy
Lansoprazole is subsidised for patients who have one or more of the following conditions: 1. Duodenal ulcer proven by endoscopy or barium meal and after failure of: a)two alternative courses of H. pylori eradication therapy (if H. pylori positive); and b)H2 antagonist therapy for 8 weeks; and where a second endoscopy/barium meal has demonstrated non healing duodenal ulcer. 2. Gastric ulcer proven by endoscopy and after failure of: a)two alternative courses of H. pylori eradication therapy (if H. pylori positive); andb)H2 antagonist therapy for 12 weeks; and where a second endoscopy has demonstrated non healing gastric ulcer and excluded malignancy. 3. Gastro-oesophageal reflux disease (GORD) proven by endoscopy: i) Grade 0 GORD (normal endoscopy) after positive 24 hour pH monitoring test and failure of H2 antagonist therapy for one month with multiple daily dosing; orii) Grades 1 and 2 GORD after failure of H2 antagonist therapy for one month with multiple daily dosing; or
Special Authority for Manufacturers Price - Form SA0271Initial application from any medical practitioner. Approvals valid for 5 years for applications meeting the following criteria: Either: 1 Continuation of treatment commenced prior to 1 October 1995; or 2 Both: 2.1 Either: 2.1.1 Asthma; or 2.1.2 Chronic obstructive airways disease; and 2.2 Patient has tried alternatives and these are unsuitable. Renewal from any medical practitioner. Approvals valid for 5 years where the treatment remains appropriate and the patient is benefiting from treatment.
a) All patients with AIDS meeting the definition developed by the Centres for Disease Control in the USA (see Circular Letter to Medical Practitioners HP2/88)b) Patients with AIDS Related Complex (ARC)c) HIV infected patients with CD4 (T4) counts below 500 regardless of symptomatologyd) Prophylactically for persons following severe parenteral exposure from a known HIV positive sourcee) HIV infected persons with associated thrombocytopenia regardless of CD4 (T4) count f) For the prevention of maternal foetal transmission of HIVg) Applications can only be made by appropriate specialists. Prescriptions for those patients approved to use these medicines can be written either by the specialist or general practitioner with an endorsement of the name of the recommending specialist. h) Prescriptions for these can be written for a period of three months' supply. However, medicine must be dispensed on a monthly basis.
Special Authority for Subsidy - Form SA0274Initial application only from a relevant specialist. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 All of the following: 1.1 Treatment with other lipid modifying medicines has been unsuccessful; and 1.2 6 months of dietary modification has been unsuccessful; and 1.3 Cholesterol level > 7.0 mmol/litre:; and 1.4 Either: 1.4.1 Familial hypercholesterolaemia; or 1.4.2 Manifest coronary heart disease, which has been clinically proven, or previously treated by coronary artery surgery; or 2 Cholesterol level > 9.0 mmol/litre:.NoteFamilial hypercholesterolaemia is defined as being hypercholesterolaemia in the presence of tendon xanthomas or in association with a family history of premature heart disease (before age 55) or consistent with autosomal dominant inheritance. Simvastatin and Pravastatin may be considered for first line therapy in patients with familial hypercholesterolaemia or
Special Authority for Subsidy - Form SA0275Initial application - (Chronic hepatitis C) only from a relevant specialist. Approvals valid for 6 months where chronic hepatitis C. NoteMaximum reimbursable dosage 15 million iu/weekInitial application - (Indications other than chronic hepatitis C) only from a dermatologist, plastic surgeon or radiation oncologist. Approvals valid for 5 years for applications meeting the following criteria: Any of the following: 1 Chronic myelogenous leukaemia; or 2 Hairycell leukaemia; or 3 Cutaneous T cell lymphoma; or 4 Essential thrombocythaemia; or 5 Multiple myeloma; or 6 Chronic active hepatitis B; or 7 Basal cell carcinoma unable to be treated surgically or by radiotherapy. NoteMaximum reimbursable dosage 15 million iu/weekRenewal - (Chronic hepatitis C) only from a relevant specialist. Approvals valid for 6 months where the treatment remains appropriate and the patient is benefiting from treatment. Renewal - (Indications other tha
Special Authority for Subsidy - Form SA0276Initial application - (Chronic hepatitis C) only from a relevant specialist. Approvals valid for 6 months where chronic hepatitis C. NoteMaximum reimbursable dosage 15 million iu/weekInitial application - (Indications other than chronic hepatitis C) only from a dermatologist, plastic surgeon or radiation oncologist. Approvals valid for 5 years for applications meeting the following criteria: Any of the following: 1 Chronic myelogenous leukaemia; or 2 Hairycell leukaemia; or 3 Multiple myeloma; or 4 Chronic active hepatitis B; or 5 Basal cell carcinoma unable to be treated surgically or by radiotherapy. NoteMaximum reimbursable dosage 15 million iu/weekRenewal - (Chronic hepatitis C) only from a relevant specialist. Approvals valid for 6 months where the treatment remains appropriate and the patient is benefiting from treatment. Renewal - (Indications other than chronic hepatitis C) only from a dermatologist, plastic surgeon or radiat
Omeprazole is subsidised for patients who have one or more of the conditions numbered 1-4: 1. Duodenal ulcer proven by endoscopy or barium meal and after failure of: a)two alternative courses of H. pylori eradication therapy (if H. pylori positive); and b)H2 antagonist therapy for 8 weeks; and where a second endoscopy/barium meal has demonstrated non healing duodenal ulcer. 2. Gastric ulcer proven by endoscopy and after failure of: a)two alternative courses of H. pylori eradication therapy (if H. pylori positive); andb)H2 antagonist therapy for 12 weeks; and where a second endoscopy has demonstrated non healing gastric ulcer and excluded malignancy. 3. Gastro-oesophageal reflux disease (GORD) proven by endoscopy: i) Grade 0 GORD (normal endoscopy) after positive 24 hour pH monitoring test and failure of H2 antagonist therapy for one month with multiple daily dosing; orii) Grades 1 and 2 GORD after failure of H2 antagonist therapy for one month with multipl
Special Authority for Subsidy - Form SA0290Initial application only from a relevant specialist. Approvals valid for 5 years for applications meeting the following criteria: Any of the following: 1 AIDS meeting the definition developed by the Centers for Disease Control in the USA; or 2 AIDS Related Complex (ARC).; or 3 Both: 3.1 HIV infection regardless of symptomatology; and 3.2 CD4 (T4) counts < 500. NoteSee Circular Letter to Medical Practitioners HP2/88)Renewal only from a relevant specialist. Approvals valid for 5 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Manufacturers Price - Form SA0291Initial application from any medical practitioner. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 Inflammatory arthritis (including osteoarthritis with an inflammatory component); and 2 Stabilised and are well controlled on the particular NSAID medication. Renewal from any medical practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0300Initial application - (Breast or prostatic cancer) only from an oncologist, urologist or endocrinologist. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 Breast cancer in pre menopausal women unwilling or unable to undergo surgical or radiation oophorectomy; or 2 Advanced prostatic cancer when orchidectomy is contraindicated. NoteNot in long term combination with an anti-androgenInitial application - (Endometriosis) only from a gynaecologist. Approvals valid for 6 months for applications meeting the following criteria: Both: 1 Endometriosis ; and 2 Either: 2.1 6 months treatment with medroxyprogesterone acetate, danazol or dimetriose has proven ineffective; or 2.2 The patient has failed to tolerate the treatment with medroxyprogesterone acetate, danazol or dimetriose for 6 months. NoteThe maximum treatment period for a GnRH analogue is: 3 months to assess whether surgery is appropriate3 m
Special Authority for Subsidy - Form SA0309Initial application only from a neurologist or physician for the elderly (FRACP). Approvals valid for 2 years for applications meeting the following criteria: All of the following: 1 Idiopathic Parkinson's disease; and 2 The patient does not have dementia and/or neuropsychiatric disorders; and 3 Has responded to L-dopa; and 4 Any of the following: 4.1 Has resistance to conventional treatment of severe motor fluctuations; or 4.2 Has severe "off" period disability; or 4.3 Has severe "off" period dystonic cramps. Renewal only from a neurologist or physician for the elderly (FRACP). Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0311Initial application - (Breast or prostatic cancer) only from an oncologist, urologist or endocrinologist. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 Breast cancer in pre menopausal women unwilling or unable to undergo surgical or radiation oophorectomy; or 2 Advanced prostatic cancer when orchidectomy is contraindicated or where the patient srongly opposes orchidectomy. NoteNot to be prescribed with an anti-androgen except for a period of three weeks, if necessary, when GnRH analogue therapy is intiatedInitial application - (Endometriosis) only from a gynaecologist. Approvals valid for 6 months for applications meeting the following criteria: Both: 1 Endometriosis; and 2 Either: 2.1 6 months treatment with medroxyprogesterone acetate, danazol or dimetriose has proven ineffective; or 2.2 The patient has failed to tolerate the treatment with medroxyprogesterone acetate, danazol or dimetrio
Special Authority for Alternate Subsidy - Form SA0312Initial application only from an obstetrician, gynaecologist, general practitioner or general physician. Approvals valid for 5 years for applications meeting the following criteria: Any of the following: 1 acute or significant liver disease - a declaration must be provided from a gastroenterologist or general physician stating that oral oestrogens are contraindicated due to liver disease (Details to be attached to application); or 2 oestrogen induced hypertension requiring antihypertensive therapy - documented evidence must be provided that raised blood pressure levels or inability to control blood pressure adequately occurred post oral oestrogens (Details to be attached to application); or 3 hypertriglyceridaemia - documented evidence must be provided that triglyceride levels increased to at least 2 x normal triglyceride levels post oral oestrogens (Details to be attached to application). NotePrescriptions with a valid Special Authority (
Special Authority for Subsidy - Form SA0317Initial application only from a renal physician. Approvals valid for 2 years for applications meeting the following criteria: All of the following: General Criteria: 1 Anaemia of end-stage renal failure (other treatable causes of anaemia being excluded); and 2 Been on haemodialysis or continuous ambulatory peritoneal dialysis (CAPD) for at least three months; and 3 Not under evaluation for, or awaiting, a live donor kidney transplant; and 4 Any of the following: Specific Criteria: 4.1 Anephric; or 4.2 Dependent on regular blood transfusion (1 unit each 4-8 weeks) to maintain haemoglobin > 60g/L; or 4.3 Cannot be transfused because of severe transfusion reactions; or 4.4 Transfusion induced haemosiderosis (clinical manifestations, serum ferritin >1500 ug/L); or 4.5 Haemoglobin < 70 g/L (mean of at least 4 haemoglobin concentrations over 4 months); or 4.6 Both: 4.6.1 Haemoglobin < 90 g/L; and 4.6.2 Either:
a) All nucleosides will be subsidised for patients meeting any of the following criteria: - All patients with AIDS meeting the definition developed by the Centers for Disease Control in the USA (see Circular Letter to Medical Practitioners HP2/88); or- Patients with AIDS Related Complex (ARC); or- HIV infected patients with CD4 (T4) counts below 500 regardless of symptomatology. b) Zidovudine will also be subsidised for patients meeting any of the following criteria: - Prophylactically for persons following severe parenteral exposure from a known HIV positive source; or- HIV infected persons with associated thrombocytopenia regardless of CD4 (T4) count; or- For the prevention of maternal foetal transmission of HIV. c) Applications can only be made by appropriate specialists. d) Prescriptions for those patients approved to use these medications can be written by either the specialist or general practitioner with an endorsement of the name of the recommending specialist.
Special Authority for Subsidy - Form SA0325Initial application from any medical practitioner. Approvals valid for 5 years where applicatons will be considered and approved subject to funding availability. NoteApplications to be made on the approved forms which are available from the co-ordinator for the Cystic Fibrosis DN'ase Advisory Panel: The Co-ordinatorCystic Fibrosis DN'ase Advisory PanelC/- Room 4-28, Building 13 Greenlane HospitalPrivate Bag, AUCKLANDPhone: 09 630 9871Facsimile: 09 631 0753
Special Authority for Subsidy - Form SA0328Initial application only from a general physician. Approvals valid for 2 years for applications meeting the following criteria: Any of the following: 1 Both: 1.1 CD4 count < 500 cells/mm3; and 1.2 Viral load > 50,000> copies per ml (or equivalent value on the Chiron test); or 2 All of the following: 2.1 CD4 count < 500 cells/mm3; and 2.2 Viral load > 50,000> copies per ml (or equivalent value on the Chiron test); and 2.3 At least 6 weeks of dual therapy with nucleoside agents; or 3 Both: 3.1 CD4 count < 500 cells/mm3; and 3.2 CD4 counts are declining rapidly (>120 cells over 12 months or >60 - 80 cells over six months). Renewal only from a general physician. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
Guidelines for use of cyclosporin A in rheumatoid arthritisMonitoring: All patients require frequent monitoring for creatinine levels and blood pressure:- fortnightly, in the first three months of therapy and then monthly, if results are stable; - if dose is increased or there is a rise in serum creatinine or blood pressure, then more frequent monitoring is required. Contraindications: Cyclosporin A is contraindicated in patients with the following conditions: - current or past malignancy; - uncontrolled hypertension; - renal dysfunction (abnormal serum creatinine for age and sex); - immunodeficiency and neutropenia; - abnormally low white blood cell count or platelet count; or- liver function tests more than twice the upper limit of normal. Caution in use: - age above 65 years; - controlled hypertension; - use of ant-epileptic medications; - use of NSAIDs; - use of ketoconazole, fluconazole, trimethoprim, erythromycin, verapamil, and diltiazem; - concurrent or previous use of al
Special Authority - Retail pharmacy (Salmeterol, eformoterol fumarate):a) Approvals are interchangeable between all presenations of salmeterol and eformoterol fumarate agents. b) Diagnosis of asthma confirmed. c) Inhaler/device technique checked. d) At least three months of >= 1500 ug daily of beclomethasone inhaled steroid (or equivalent) for adult, or >= 800 ug daily for child. e) Patient monitors PEFR regularly during exacerbations where appropriate. f) Evidence of poor control (at least one of the following): - short acting beta agonist used > 3-4 time daily - nocturnal awakenings >= 2 times per week. g) The first applicaton may be for six months and subsequent applications for two yars. The criteria for reapplication are: - compliant with medication - improved asthma symptom control. h) Appication for Special Authority to be made by general practitioners or appropriate specialist.
a) Should be strictly reserved for use as second line therapy in: - patients unable to tolerate the other medications, such as infants, young children and patients with allergies or eczema; - cases of scabies which are resistent to gamma benzene hexachloride and resistant to malathion. b) Verification of drug resistance is dependent on the persistence of the condition after treatment. In order to establish whether there is drug resistance, the following criteria should be fulfilled: - a definite diagnosis of scabies should be made; - it should be ascertained that the medication was administered properly; - the possibility of reinfestation should have been excluded.
Special Authority for Manufacturers Price - Form SA0349Initial application only from a respiratory specialist or infectious disease specialist. Approvals valid for 2 years for applications meeting the following criteria: Any of the following: 1 Avium intracellular atypical mycobacterial infections; or 2 Multiple drug resistant tuberculosis; or 3 Atypical and drug-resistant mycobacterial infections in patients with AIDS. Renewal only from a respiratory specialist or infectious disease specialist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
Omeprazole and pantoprazole is subsidised for patients who have one or more of the conditions a-d: a) Duodenal ulcer proven by endoscopy or barium meal and after failure of: - two alternative courses of H. pylori eradication therapy (if H. pylori positive); and - H2 antagonist therapy for 8 weeks; and where a second endoscopy/barium meal has demonstrated non healing duodenal ulcer. b) Gastric ulcer proven by endoscopy and after failure of: - two alternative courses of H. pylori eradication therapy (if H. pylori positive); and - H2 antagonist therapy for 12 weeks; and where a second endoscopy has demonstrated non healing gastric ulcer and excluded malignancy. c) Gastro-oesophageal reflux disease (GORD) proven by endoscopy: - Grade 0 GORD (normal endoscopy) after positive 24 hour pH monitoring test and failure of H2 antagonist therapy for four weeks with multiple daily dosing; or - Grades 1 and 2 GORD after failure of H2 antagonist therapy for
Subsidy is available for disposable diabetic syringes and needles: 1) When the prescription is written on the same prescription form as the one used for the supply of insulin vials; or2) When "insulin patient" has been written on the prescription by either the doctor or the contractor; and3) For no more than 50 plastic syringes with attached needles as a single supply in the case of a prescription for three months supply of insulin vials; or4) For no more than 4 plastic syringes with attached needles as a single supply for each week's supply in the case of a prescription for less than three months supply of insulin vials.
Subsidy is available for insulin pen needles: 1) When the prescription is written on the same prescription form as the one used for the supply of insulin cartridges; or2) When "insulin patient" has been written on the prescription by either the doctor or the contractor; and3) For no more than 30 insulin pen needles as a single supply in the case of a prescription for three months supply of insulin cartridges; or4) For no more than 2 insulin pen needles as a single supply for each week's supply in the case of a prescription for less than three months supply of insulin cartridges.
Special Authority for Subsidy - Form SA0361Initial application only from a geriatrician, neurologist or general physician. Approvals valid for 2 years for applications meeting the following criteria: All of the following: 1 Disabling orthostatic hypotension not due to drugs; and 2 Patient has tried fludrocortisone (unless contra-indicated) with unsatisfactory results; and 3 Patient has tried non pharmacological treatments such as support hose, increased salt intake, exercise, and elevation of head and trunk at night. NoteTreatment should be started with small doses and titrated upwards as necessary. Hypertesion should be avoided, and the usual target is a standing systolic blood pressure of 90 mm Hg. Renewal only from a geriatrician, neurologist or general physician. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0366Initial application - (North Island patients) from any medical practitioner. Approvals valid for 5 years where the patient is likely to benefit from treatment. NoteFor details of the patient criteria, prescriber criteria, application and reporting forms contact the appointed clinician: Dr Richard FisherFertility Associates131 Remuera RoadAUCKLANDFax: 09 520 0499Appointed clinicians will distribute these agents to prescribers whose applications are approvedInitial application - (South Island patients) from any medical practitioner. Approvals valid for 5 years where the patient is likely to benefit from treatment. NoteFor details of the patient criteria, prescriber criteria, application and reporting forms contact the appointed clinician: Dr Peter BennyChristchurch Women's HospitalPrivate Bag 4711CHRISTCHURCHFax: 03 364 4634Appointed clinicians will distribute these agents to prescribers whose applications are approved
Special Authority for Subsidy - Form SA0382Initial application only from a gastroenterologist, general surgeon or general physician. Approvals valid for 3 years for applications meeting the following criteria: Any of the following: 1 All of the following: 1.1 Duodenal ulcer proven by endoscopy or barium meal; and 1.2 Failure of two alternative courses of H. pylori eradication therapy (if H. pylori positive); and 1.3 Non healing duodenal ulcer proven by second barium meal; and 1.4 H2 antagonist therapy for 8 weeks; or 2 All of the following: 2.1 Gastric ulcer proven by endoscopy; and 2.2 Two alternative courses of H. pylori eradication therapy (if H. pylori positive); and 2.3 Non healing gastric ulcer and excluded malignancy demonstrated by a second endoscopy; and 2.4 H2 antagonist therapy for 12 weeks; or 3 All of the following: 3.1 Grade 0 GORD (normal endoscopy); and 3.2 Positive 24 hour pH monitoring test; and 3.3 Failure of H2 antagonist t
n) Further approvals to fund the manufacturer's surcharge on either pravastatin or simvastatin (if applicable) may be granted to patients who are unable to continue treatment with fluvastatin due to adverse effects. Either general practitioners or specialist may make the application. To obtain a new Special Authority number, the application must include the following information: - the amount of time the patient has been treated with fluvastatin; and- the adverse effects experienced by the patient. o) Further approvals to fund the manufacturer's surcharge on simvastatin may be granted to patients with familial hypercholesterolaemia (FH) or familial combined hypercholesterolaemia (FCH) if a specialist considers that the patient is not achieving sufficient benefit from the fully funded statin(s). Only specialists may make application. To obtain a new Special Authority number, the application must include the following information: - the cholesterol level before and after treatment with the fully funded sta
Special Authority for Subsidy - Form SA0387Initial application - (Breast or prostatic cancer) only from an oncologist, urologist or endocrinologist. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 Breast cancer in pre menopausal women unwilling or unable to undergo surgical or radiation oophorectomy; or 2 Advanced prostatic cancer when orchidectomy is contraindicated or where the patient srongly opposes orchidectomy. NoteNot to be prescribed with an anti-androgen except for a period of three weeks, if necessary, when GnRH analogue therapy is intiatedInitial application - (Endometriosis) only from a gynaecologist. Approvals valid for 6 months for applications meeting the following criteria: Both: 1 Endometriosis; and 2 Either: 2.1 6 months treatment with medroxyprogesterone acetate, danazol or dimetriose has proven ineffective; or 2.2 The patient has failed to tolerate the treatment with medroxyprogesterone acetate, danazol or dimetrio
Special Authority for Manufacturers Price - Form SA0394Initial application - (Helicobacter pylori infections) only from a general practitioner or relevant specialist. Approvals valid for 6 months for applications meeting the following criteria: Both: 1 Eradication of Helicobacter pylori in patient with proven infection; and 2 Peptic ulcer disease proven by endoscopy. NoteMaximum of two prescriptions (two courses) per patient. Initial application - (Mycobacterial infections) only from a respiratory specialist or infectious disease specialist. Approvals valid for 2 years for applications meeting the following criteria: Any of the following: 1 Mycobacterium Avium Intracellulare Complex infections in patient with AIDS; or 2 Atypical and drug-resistant mycobacterial infection; or 3 All of the following: 3.1 Prophylaxis against disseminated Mycobacterium Avium Intracellulare Complex infection; and 3.2 HIV infection; and 3.3 CD4 count <= 50 cells/mm3. Renewal - (Mycobacteri
a) Cyproterone acetate with ethinyloestradiol is available from retail pharmacy to patients as indicated. b) Prescribers may code prescriptions "contraceptive" (code "O") when used as indicated for contraception. The period of supply and prescription charge will be as per other contraceptives, as follows: - $3.00 prescription charge (patient co-payment) will apply; - Prescription may be written for up to 6 months supply; and- Pharmacists may dispense up to 3 month supply. c) Prescriptions coded in any other way are subject to the non-contraceptive prescription charges, and the non-contraceptive period of supply. Eg. Prescriptons may be written for up to 3 months supply, and dispensed monthly. d) The Special Authority number for hormonal contraceptive agents (combined and progesterone-only) does not apply, and is not interchangeable. e) Health Benefits Limited will return any claims unpaid as follows: - any uncoded prescription; - any prescription that does not have a period of supply or the quantity
Special Authority for Subsidy - Form SA0401Initial application - (Basal cell carcinoma) only from a dermatologist, plastic surgeon or radiation oncologist. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 Basal cell carcinoma unable to be treated surgically or by radiotherapy; and 2 Unsuitability for surgery confirmed by a Plastic Surgeon or Oncologist. NoteMaximum reimbursable dosage 15 million iu/weekInitial application - (Chronic hepatitis C) only from a relevant specialist. Approvals valid for 12 months where chronic hepatitis C. Initial application - (Indications other than Basal cell carcinoma and Chronic hepatitis C) only from a relevant specialist, plastic surgeon or radiation oncologist. Approvals valid for 2 years for applications meeting the following criteria: Any of the following: 1 Chronic myelogenous leukaemia; or 2 Hairy cell leukaemia; or 3 Cutaneous T cell lymphoma; or 4 Essential thrombocythaemia; or 5 Multiple myelo
Special Authority for Subsidy - Form SA0402Initial application - (Patients aged 74 and under) only from a general practitioner. Approvals valid for 2 years for applications meeting the following criteria: All of the following: 1 Patients aged 74 and under; and 2 The patient has been offered 3-6 months of counselling and an opportunity to modify lifestyle; and 3 Any of the following: 3.1 Both: 3.1.1 NHF A1:1 - Clinically proven ischaemic heart disease; and 3.1.2 total cholesterol > 6.0; or 3.2 Both: 3.2.1 NHF A1:2 - Post coronary artery bypass graft (CABG); and 3.2.2 total cholesterol > 5.5; or 3.3 Both: 3.3.1 NHF B:Patients with > 20% 5-year cardiovascular disease risk; and 3.3.2 total cholesterol > 9.0; or 3.4 Both: 3.4.1 NHF C:15-20% 5-year cardiovascular disease risk; and 3.4.2 total cholesterol > 9.0; or 3.5 Both: 3.5.1 NHF D:10-15% 5-year cardiovascular disease risk; and 3.5.2 total cholesterol > 9.0; or 3.6
Special Authority for Subsidy - Form SA0404Initial application only from an ophthalmologist. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 Primary open-angle glaucoma; and 2 Either: 2.1 Other subsidised glaucoma medical therapy is contraindicated; or 2.2 Both: 2.2.1 intra-ocular pressure > 26 mmHg (average from consecutive measurements); and 2.2.2 Unable to be controlled using other subsidised medical therapy. Renewal only from an ophthalmologist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
Funding of manufacturers surcharge for existing patients taking ACE inhibitors for Congestive Heart Failure.a) Patients taking any ACE inhibitor for the treatment of congestive heart failure prior to 1 June 1998 can continue to have their ACE inhibitor treatment fully subsidised; b) Prescribers must endorse the prescription 'Congestive Heart Failure'. The endorsement can be typed (this includes computer generated prescriptions) or handwritten; c) The endorsement must be initialled in the prescriber's own handwriting. Definition of Congestive Heart FailureAt the request of some prescribers the PTAC Cardiovascular subcommittee has provided a definition of congestive heart failure for the purposes of the funding of the manufacturer's surcharge: "Clinicians should use their clinical judgement. Existing patients would be eligible for the funding of the surcharge if the patient shows signs and symptoms of congestive heart failure, and requires or has in the past required concomitant treatment with a
Special Authority for Subsidy - Form SA0423Initial application only from a gastroenterologist, general surgeon or general physician. Approvals valid for 3 years for applications meeting the following criteria: Any of the following: 1 All of the following: Duodenal Ulcer: 1.1 Duodenal ulcer proven by endoscopy or barium meal; and 1.2 Non healing duodenal ulcer proven by second barium meal; and 1.3 After failure of two alternative courses of H. pylori eradication therapy (if H. pylori positive); and 1.4 After H2 antagonist therapy for 8 weeks; or 2 All of the following: Gastric Ulcer: 2.1 Gastric ulcer proven by endoscopy; and 2.2 Non healing gastric ulcer and excluded malignancy demonstrated by a second endoscopy; and 2.3 After two alternative courses of H. pylori eradication therapy (if H. pylori positive); and 2.4 After H2 antagonist therapy for 12 weeks; or 3 All of the following: GORD: 3.1 Grade 0 GORD (normal endoscopy); and 3.2 Positive 24
Special Authority for Subsidy - Form SA0424Initial application - (Confirmed HIV/AIDS) only from a general physician. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 Confirmed HIV/AIDS; and 2 Any of the following: 2.1 Symptomatic patients aged 6 years and over with HIV/AIDS; or 2.2 Both: 2.2.1 Asymptomatic patients aged 6 years and over; and 2.2.2 CD4 counts < 500 cells/mm3; or 2.3 Both: 2.3.1 Asymptomatic patients aged 6 years and over; and 2.3.2 Viral load counts > 10,000 copies per ml; or 2.4 Symptomatic patients aged under 6 with HIV/AIDS ; or 2.5 Asymptomatic patients aged 12 months and under; or 2.6 Both: 2.6.1 Asymptomatic patients aged 1 to 5 years; and 2.6.2 CD4 counts < 1,000 cells/mm3; or 2.7 Both: 2.7.1 Asymptomatic patients aged 1 to 5 years; and 2.7.2 CD4 counts < 0.25 x total white cell count; or 2.8 Both: 2.8.1 Asymptomatic patients aged under 6 years; and
If a Community Pharmaceutical is the liquid oral form of an antibiotic to which a diluent must be added by the Contractor at the time of dispensing and it is prescribed or ordered by a Practittioner in an amount that does not coincide with the amount contained in one or more standard packs of that Community Pharmaceutical, Subsidy will only be made for the amount prescribed or ordered by the Practitioner in accordance with either Clause 3.1 or Clause 3.3 of the Schedule, unless the Contractor satisfies the Funder that he or she has not been able to dispense the balance of the pack or packs from which the Community Pharmaceutical has been dispensed. In such cases all of that pack or those packs is eligible for Subsidy.
Special Authority for Subsidy - Form SA0430Initial application - (National Heart Foundation risk groups A1:1, A1:2, B, C, D or E) only from a relevant specialist or general practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria: Both: 1 The patient has been offered 3-6 months of counselling and an opportunity to modify lifestyle; and 2 Any of the following: 2.1 Both: 2.1.1 NHF A1:1 - Clinically proven ischaemic heart disease; and 2.1.2 total cholesterol * > 5.5; or 2.2 Both: 2.2.1 NHF A1:2 - Post coronary artery bypass graft (CABG) or angioplasty; and 2.2.2 total cholesterol * > 4.5; or 2.3 Post heart transplant (regardless of cholesterol level); or 2.4 Both: 2.4.1 NHF B:Patients with > 20% 5-year cardiovascular disease risk; and 2.4.2 total cholesterol * > 9.0; or 2.5 Both: 2.5.1 NHF C:15-20% 5-year cardiovascular disease risk; and 2.5.2 total cholesterol * > 9
Special Authority for Manufacturers Price - Form SA0434Initial application only from a general practitioner, general physician, geriatrician or neurologist. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 Patients with swallowing difficulties; and 2 Applicant is a specialist or specialist has authorised treatment. Renewal only from a general practitioner, general physician, geriatrician or neurologist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Manufacturers Price - Form SA0436Initial application - (Patient with prosthetic heart valves) only from a cardiothoracic surgeon, cardiologist or general physician. Approvals valid for 2 years where patient with prosthetic heart valves - as an adjunct to oral anticoagulation for prophylaxis of thromboembolism. Initial application - (Following coronary artery vein bypass graft) only from a cardiothoracic surgeon, cardiologist or general physician. Approvals valid for 1 year where patients after coronary artery vein bypass graft - as an adjunct to aspirin or as monotherapy for patients who are aspirin intolerant as defined below. Initial application - (Transient ischaemic episodes) only from a neurologist, neuro surgeon, cardiologist, vascular surgeon or general physician. Approvals valid for 2 years where patients who continue to have transient ischaemic episodes despite aspirin therapy or have transient ischaemic episodes and are aspirin intolerant as defined below. Renewal - (Fo
Special Authority for Subsidy - Form SA0443Initial application - (Helicobacter pylori infections) only from a general practitioner or relevant specialist. Approvals valid for 6 months for applications meeting the following criteria: Both: 1 Eradication of Helicobacter pylori in patient with proven infection; and 2 Peptic ulcer disease proven by endoscopy. NoteMaximum of two prescriptions (two courses) per patient. Initial application - (Mycobacterial infections) only from a respiratory specialist or infectious disease specialist. Approvals valid for 2 years for applications meeting the following criteria: Any of the following: 1 Mycobacterium Avium Intracellulare Complex infections in patient with AIDS; or 2 Atypical and drug-resistant mycobacterial infection; or 3 All of the following: 3.1 Prophylaxis against disseminated Mycobacterium Avium Intracellulare Complex infection; and 3.2 HIV infection; and 3.3 CD4 count <= 50 cells/mm3. Renewal - (Mycobacterial infection
Special Authority for Subsidy - Form SA0445Initial application only from a relevant specialist. Approvals valid for 5 years for applications meeting the following criteria: Any of the following: 1 Both: 1.1 Acromegaly; and 1.2 Patient has failed surgery, radiotherapy, bromocriptine or other oral therapies; or 2 VIPomas and Glucagonomas - for patients who are seriously ill in order to improve their clinical state prior to definitive surgery.; or 3 Both: 3.1 Gastrinoma; and 3.2 Patient has failed surgery, or metastatic disease after H2 antagoists (or proton pump inhibitors) have failed; or 4 Both: 4.1 Insulinomas; and 4.2 Surgery is contraindicated or has failed; or 5 For pre-operative control of hypoglycaemia and for maintenance therapy; or 6 Both: 6.1 Carcinoidsyndrome (diagnosed by tissue pathology and/or urinary 5HIAA analysis); and 6.2 Disabling symptoms not controlled by maximal medical therapy. NoteThe use of octretide in patients with fis
Special Authority for Subsidy - Form SA0450Initial application only from a psychiatrist. Approvals valid for 12 months for applications meeting the following criteria: Both: 1 Patients suffering from schizophrenia and related psychoses; and 2 Either: 2.1 Failed to respond to full trials (duration of at least 6 weeks each) of effective doses of at least two classes of anti-psychotic agents (refer to guidelines below); or 2.2 Demonstrated intolerance to other neuroleptic agents. NoteClinicians must confirm that informed consent and a satisfactory White Bloodcell Count (WBC) result has been obtained. Diagnosis: Treatment resistant schizophrenia and related psychoses when positive symptoms (delusions, hallucinations and thought disorder) are prominent and/or disabling or when both positive symptoms and negative symptoms (flattened affect, emotional and social withdrawal and poverty of speech) are present. Treatment: Trial therapy undertaken before initiating treatment with clozapine could
Special Authority for Manufacturers Price - Form SA0451Initial application only from a relevant specialist. Approvals valid for 3 years for applications meeting the following criteria: Both: 1 Patients being treated for advanced breast cancer who are refractory to tamoxifen; and 2 Any of the following: 2.1 Unable to tolerate aminoglutethimide; or 2.2 Unable to tolerate megestrol acetate; or 2.3 Unable to tolerate medroxyprogesterone acetate.Renewal only from a relevant specialist. Approvals valid for 3 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Manufacturers Price - Form SA0452Initial application only from a relevant specialist. Approvals valid for 3 years for applications meeting the following criteria: Both: 1 Patients being treated for advanced breast cancer who are refractory to tamoxifen; and 2 Any of the following: 2.1 Unable to tolerate aminoglutethimide; or 2.2 Unable to tolerate megestrol acetate; or 2.3 Unable to tolerate medroxyprogesterone acetate.Renewal only from a relevant specialist. Approvals valid for 3 years where the treatment remains appropriate and the patient is benefiting from treatment.
Guidelines for the use of atypical anti-psychotic agents Diagnosis: Schizophrenia and related psychoses when positive symptoms (delusions, hallucinations and thought disorder) are prominent and/or disabling or when both positive symptoms and negative symptoms (flattened affect, emotional and social withdrawal and poverty of speech) are present. Treatment: Before initiating atypical anti-psychotic therapy, physicians should consider whether the patient is likely to respond to and/or tolerate conventional anti-psychotic therapy and, where appropriate, trial one or more conventional agent prior to use of an atypical agent.
Special Authority for Subsidy - Form SA0456Initial application only from a psychiatrist. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 Patients suffering from schizophrenia and related psychoses who are likely to benefit from anti-psychotic treatment; and 2 Any of the following: 2.1 Effective dose of risperidone has been discontinued because of recurrent acute dystonias; or 2.2 Effective dose of risperidone has been discontinued because of excessive Parkinson-like symptoms; or 2.3 Effective dose of risperidone has been discontinued after 6 weeks because of inadequate clinical response. Renewal only from a psychiatrist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0458Initial application only from a gastroenterologist. Approvals valid for 6 months for applications meeting the following criteria: Both: 1 Primary biliary cirrhosis confirmed by antimitochondrial antibody titre (AMA) > 1:80, and raised cholestatic liver enzymes with or without raised serum IgM or, if AMA is negative, by liver biopsy; and 2 Patient not requiring a liver transplant (bilirubin > 170umol/l; decompensated cirrhosis). NoteLiver biopsy is not usually required for diagnosis but is helpful to stage the diseaseRenewal only from a gastroenterologist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment. NoteActigall is not an appropriate therapy for patients requiring a liver transplant (bilirubin > 170 micromol/l; decompensated cirrhosis). These patients should be referred to an appropriate transplant centreTreatment failure - doubling of serum bilirubin levels, absence of a signi
Special Authority for Subsidy - Form SA0459Initial application only from a gastroenterologist or general physician. Approvals valid for 3 months for applications meeting the following criteria: Both: 1 Mild to moderate ileal, ileocaecal or proximal Crohn's disease; and 2 Any of the following: 2.1 Diabetes; or 2.2 Cushingoid habitus; or 2.3 Osteoporosis where there is significant risk of fracture; or 2.4 Both: 2.4.1 Severe acne; and 2.4.2 Treatment with conventional corticosteroid therapy. Renewal only from a gastroenterologist or general physician. Approvals valid for 3 months where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Manufacturers Price - Form SA0460Initial application - (Patient with prosthetic heart valves) only from a cardiothoracic surgeon, cardiologist or general physician. Approvals valid for 2 years where patient with prosthetic heart valves - as an adjunct to oral anticoagulation for prophylaxis of thromboembolism. Initial application - (Following coronary artery vein bypass graft) only from a cardiothoracic surgeon, cardiologist or general physician. Approvals valid for 1 year where patients after coronary artery vein bypass graft - as an adjunct to aspirin or as monotherapy for patients who are aspirin intolerant as defined below. Initial application - (Transient ischaemic episodes) only from a neurologist, neuro surgeon, cardiologist, vascular surgeon or general physician. Approvals valid for 2 years where patients who continue to have transient ischaemic episodes despite aspirin therapy or have transient ischaemic episodes and are aspirin intolerant as defined below. Renewal - (Fo
Special Authority for Subsidy - Form SA0461Initial application - (Basal cell carcinoma) only from a dermatologist, plastic surgeon or radiation oncologist. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 Basal cell carcinoma unable to be treated surgically or by radiotherapy; and 2 Unsuitablity for surgery confirmed by a Plastic Surgeon or Radiation Oncologist. NoteThe maximum reimbursable dosage is 15 million iu per weekInitial application - (Chronic hepatitis C) only from a relevant specialist. Approvals valid for 12 months where chronic hepatitis C. Initial application - (Indications other than Basal cell carcinoma and Chronic hepatitis C) only from a relevant specialist. Approvals valid for 2 years for applications meeting the following criteria: Any of the following: 1 Chronic myelogenous leukaemia; or 2 Hairy cell leukaemia; or 3 Multiple myeloma; or 4 Chronic active hepatitis B. Renewal - (Basal cell carcinoma) only from a dermato
Special Authority for Subsidy - Form SA0464Initial application only from a diabetologist, general physician or paediatrician. Approvals valid without further renewal unless notified for applications meeting the following criteria: Any of the following: 1 Both: 1.1 Use alone (monotherapy); and 1.2 The patient is unable to use any other insulins including those on insulin pump treatment; or 2 Both: 2.1 Use with Humulin 70/30 or Humulin 80/20; and 2.2 A reasonable trial of Humulin N has been undertaken and it is not effective or not well tolerated; or 3 Both: 3.1 Use with insulins (aside from insulin zinc suspension) other than Humulin 70/30, Humulin 80/20, or Humulin N; and 3.2 A reasonable trial of one or more of these Humulin insulins has been undertaken and it is/are ineffective or not well tolerated; or 4 Both: 4.1 Use with Humulin L or Humulin U; and 4.2 Use with Humulin N is not appropriate; or 5 Both: 5.1 Use with other insulin zinc suspensio
Special Authority for Alternate Subsidy - Form SA0466Initial application only from a relevant specialist or general practitioner. Approvals valid for 5 years for applications meeting the following criteria: Any of the following: 1 Angina that is not controlled by other anginal medications; or 2 Continuation of treatment commenced prior to 1 June 1999; or 3 Receiving maximal antihypertensive therapy, requires a DHP CCB, and cannot tolerate felodipine. Renewal only from a relevant specialist or general practitioner. Approvals valid for 5 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0467Initial application only from a relevant specialist. Approvals valid for 6 months for applications meeting the following criteria: Both: 1 Paget's disease; and 2 Any of the following: 2.1 Bone or articular pain; or 2.2 Bone deformity; or 2.3 Bone, articular or neurological complications; or 2.4 Asymptomatic disease, but risk of complications due to site (base of skull, spine, long bones of lower limbs); or 2.5 Preparation for orthopaedic surgery. Renewal only from a relevant specialist. Approvals valid for 6 months where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0470Initial application - (Organ transplant) only from a relevant specialist. Approvals valid without further renewal unless notified where organ transplant. Initial application - (Bone marrow transplant or Graft v host disease) only from a relevant specialist. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 Bone marrow transplant; or 2 Graft v host disease. Initial application - (Psoriasis) only from a dermatologist. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 Psoriasis; and 2 Applicant must state which systemic and topical therapies have failed. Initial application - (Severe atopic dermatitis) only from a dermatologist. Approvals valid for 6 months for applications meeting the following criteria: Both: 1 Severe atopic dermatitis; and 2 Not responsive to topical therapy, oral antihistamines and other commonly used orthodox therapies. Initial application - (N
Special Authority for Subsidy - Form SA0471Initial application - (Breast cancer) from any medical practitioner. Approvals valid for 1 year where breast cancer in pre menopausal women unwilling or unable to undergo surgical or radiation oophorectomy. Initial application - (Prostate cancer) only from an oncologist, urologist or endocrinologist. Approvals valid for 1 year where advanced prostatic cancer when orchidectomy is contraindicated or where the patient strongly opposes orchidectomy. NoteNot to be prescribed with an anti-androgen except for a period of three weeks, if necessary, when GnRH analogue therapy is intiatedInitial application - (Endometriosis) only from a gynaecologist. Approvals valid for 3 months for applications meeting the following criteria: Both: 1 Endometriosis ; and 2 Either: 2.1 6 months treatment with medroxyprogesterone acetate, danazol or dimetriose has proven ineffective; or 2.2 The patient has failed to tolerate the treatment with medroxyprogesterone
Special Authority for Subsidy - Form SA0472Initial application only from a cardiologist. Approvals valid for 2 years for applications meeting the following criteria: Any of the following: 1 Both: 1.1 Congestive heart failure; and 1.2 Cannot tolerate currently fully subsidised ACE inhibitors due to persistent cough that resolves on cessation and recurs on re-challenge with ACE inhibitor; or 2 Patients who have experienced angioedema on an ACE inhibitor at any time in the past; or 3 Patients who have experienced angioedema (even if not using an ACE inhibitor) in the last 2 years. Renewal only from a cardiologist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0473Initial application from any medical practitioner. Approvals valid for 1 year where the patient is likely to benefit from treatment. Note Applications to be made on the approved forms which are available from: The Co-ordinatorGaucher's Treatment PanelPhone: (04) 460 4990 PHARMAC, PO Box 10 254 WellingtonFacsimile: (04) 916 7571Email: erin.murphy@pharmac.govt.nzPrescriptions for patients approved for treatment must be written by respiratory physicians or paediatricians who have experience and expertise in treating cystic fibrosis.
Special Authority for Subsidy - Form SA0488Initial application only from a gastroenterologist, general surgeon or general physician. Approvals valid for 3 months for applications meeting the following criteria: Both: 1 Mild to moderate ileal, ileocaecal or proximal Crohn's disease; and 2 Any of the following: 2.1 Diabetes; or 2.2 Cushingoid habitus; or 2.3 Osteoporosis where there is significant risk of fracture; or 2.4 Both: 2.4.1 Severe acne; and 2.4.2 Treatment with conventional corticosteroid therapy. Renewal only from a gastroenterologist, general surgeon or general physician. Approvals valid for 3 months where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Manufacturers Price - Form SA0489Initial application - (Conditions other than transient ischaemic episodes) only from a cardiothoracic surgeon, cardiologist or general physician. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 Patients with prosthetic heart valves - as an adjunct to oral anticoagulation for prophylaxis of thromboembolism; or 2 Both: 2.1 Patients after coronary artery vein bypass graft; and 2.2 Any of the following: 2.2.1 aspirin induced asthma; or 2.2.2 aspirin induced anaphylaxi; or 2.2.3 significant aspirin induced bleeding excluding bruising. Initial application - (Transient ischaemic episodes) only from a neurologist, neuro surgeon, cardiologist, vascular surgeon or general physician. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 Patients who continue to have transient ischaemic episodes despite aspirin therapy; or 2 Both: 2.1 Patients wh
Special Authority for Subsidy - Form SA0490Initial application only from a relevant specialist. Approvals valid for 2 years for applications meeting the following criteria: Any of the following: 1 Requires but is not able to tolerate metformin therapy; or 2 Requires metformin but metformin is contraindicated; or 3 Has not responded to or tolerated the maximum appropriate dose of metformin. Renewal only from a relevant specialist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0494Initial application only from an ophthalmologist. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 Both: 1.1 Primary open-angle glaucoma; and 1.2 Any of the following: 1.2.1 Patient cannot tolerate Beta-blockers, or Beta-blockers are contraindicated; or 1.2.2 Patient cannot tolerate Pilocarpine, or Pilocarpine is contraindicated; or 1.2.3 Patient cannot tolerate Dorzolamide, or Dorzolamide is contraindicated; or 1.2.4 A reduction in intraocular pressure of 15% or more is not achieved or maintained using dorzolamide either alone or in combination with a beta-blocker; or 2 There is progressive visual field loss and/or optic nerve damage persists after treatment with dorzolamide either alone or in combination with a beta-blocker. NoteSubsidised as monotherapy onlyRenewal only from an ophthalmologist. Approvals valid for 2 years where the treatment remains appropriate and the patient
Special Authority for Alternate Subsidy - Form SA0500Initial application from any medical practitioner. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 Either: 1.1 Patient is on a Social Welfare benefit; or 1.2 Patient has an income no greater than the benefit; and 2 Has tried at least one of the fully funded options and has been unable to tolerate it. Renewal from any medical practitioner. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 Patient is on a Social Welfare benefit; or 2 Patient has an income no greater than the benefit. NoteThe approval numbers of Special Authorities approved after 1 November 1999 are interchangeable between Mercilon and Marvelon. The additional subsidy will fund Mercilon and Marvelon up to the manufacturer's price for each of these products as identified on the Schedule at 1 November 1999Special Authorities approved before 1 November 1999 remain valid until the expiry d
Special Authority for Subsidy - Form SA0508Initial application only from a relevant specialist or general practitioner. Approvals valid for 2 years for applications meeting the following criteria: All of the following: 1 Patient with raised blood pressure; and 2 A beta blocker or diuretic is contraindicated; or not well tolerated; or insufficient to control blood pressure adequately at appropriate doses; and 3 An ACE inhibitor is contraindicated; or not well tolerated; or insufficient to control blood pressure adequately at appropriate doses. Renewal only from a relevant specialist or general practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0509Initial application only from a psychiatrist. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 Patient with first episode schizophrenia or related psychoses; or 2 Both: 2.1 Patient suffering from schizophrenia and related psychoses who is likely to benefit from anti-psychotic treatment; and 2.2 Both: 2.2.1 An effective dose of risperidone had been trialled and has been discontinued either because of; and 2.2.2 Any of the following: 2.2.2.1 Patient has recurrent acute dystonias; or 2.2.2.2 Patient has excessive Parkinson-like symptoms; or 2.2.2.3 Patient has hyperprolactinaemia; or 2.2.2.4 Patient has inadequate clinical response after four weeks. NoteDiscontinued treatment should be notified to HealthPAC if possibleRenewal only from a psychiatrist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Alternate Subsidy - Form SA0510Initial application only from a relevant specialist or general practitioner. Approvals valid for 2 years for applications meeting the following criteria: Any of the following: 1 Angina that is not controlled by other anginal medications (including felodipine); or 2 Patient was taking Adalat Oros for the treatment of angina prior to 1 June 1999; or 3 Receiving maximal antihypertensive therapy, requires a DHP CCB, and cannot tolerate felodipine. Renewal only from a relevant specialist or general practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0511Initial application only from a geriatrician, rheumatologist, endocrinologist, gynaecologist or general physician. Approvals valid for 2 years for applications meeting the following criteria: All of the following: 1 Severe osteoporosis; and 2 History of two previous significant osteoporotic fractures demonstrated radiologically; and 3 T-Score <= -3.0 (bone mass density (BMD) >= 3.0 standard deviations below the mean normal value in young adults). NoteIn line with the Australian guidelines for funding alendronate, a vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral bodyRenewal only from a geriatrician, rheumatologist, endocrinologist, gynaecologist or general physician. Approvals valid for 2 years where the tr
Special Authority for Subsidy - Form SA0512Initial application only from a gastroenterologist, general surgeon or general physician. Approvals valid for 3 months for applications meeting the following criteria: Both: 1 Mild to moderate ileal, ileocaecal or proximal Crohn's disease; and 2 Either: 2.1 Diabetes; or 2.2 Both: 2.2.1 Treatment with conventional corticosteroid therapy; and 2.2.2 Any of the following: 2.2.2.1 Cushingoid habitus; or 2.2.2.2 Osteoporosis where there is significant risk of fracture; or 2.2.2.3 Severe acne. Renewal only from a gastroenterologist, general surgeon or general physician. Approvals valid for 3 months where the patient has had no more than 1 prior approval in the last 12 months. The patient must have had no more than 1 prior approval in the last year. NoteClinical trials for Entocort CIR use beyond three months demonstrated no improvement in relapse rate
Special Authority for Subsidy - Form SA0513Initial application - (Narcolepsy) only from a neurologist. Approvals valid for 24 months where narcolepsy. Initial application - (ADHD in patients aged 5 years or over) only from a paediatrician or psychiatrist. Approvals valid for 24 months for applications meeting the following criteria: Both: 1 ADHD (Attention Deficient and Hyperactivity Disorder) patients aged 5 years or over; and 2 Diagnosed according to DSM-IV or ICD 10 criteria. Initial application - (ADHD in patients under 5 years of age) only from a paediatrician or psychiatrist. Approvals valid for 12 months for applications meeting the following criteria: Both: 1 ADHD (Attention Deficient and Hyperactivity Disorder) patients under 5 years of age; and 2 Diagnosed according to DSM-IV or ICD 10 criteria. Renewal - (Narcolepsy or ADHD in patients under 5 years of age) only from a neurologist, paediatrician or psychiatrist. Approvals valid for 24 months where the treatment remains appr
Special Authority for Subsidy - Form SA0523Initial application only from a relevant specialist or general practitioner. Approvals valid for 6 months for applications meeting the following criteria: All of the following: 1 Diagnosis of asthma confirmed; and 2 Inhaler/device technique checked; and 3 Patient monitors PEFR regularly during exacerbations where appropriate; and 4 Any of the following: 4.1 At least three months of 1500 ug or more daily of inhaled beclomethasone or budesonide for adult; or 4.2 At least three months of 750 ug or more daily of inhaled fluticasone) for adult; or 4.3 At least three months of 800 ug or more daily inhaled beclomethasone or budesonide for child; or 4.4 At least three months of 400 ug or more daily inhaled fluticasone) for child; and 5 Either: 5.1 Short acting beta agonist used at least 3-4 times daily; or 5.2 Nocturnal awakenings at least twice a week. Renewal only from a relevant specialist or general practitioner. Appro
Special Authority for Subsidy - Form SA0528Initial application - (Narcolepsy) only from a neurologist or respiratory specialist. Approvals valid for 24 months where narcolepsy. Initial application - (ADHD in patients 5 or over) only from a paediatrician, psychiatrist or general practitioner. Approvals valid for 24 months for applications meeting the following criteria: All of the following: 1 ADHD (Attention Deficient and Hyperactivity Disorder) patients aged 5 years or over; and 2 Diagnosed according to DSM-IV or ICD 10 criteria; and 3 Applicant is a specialist or specialist has recommended treatment. Initial application - (ADHD in patients under 5) only from a paediatrician or psychiatrist. Approvals valid for 12 months for applications meeting the following criteria: Both: 1 ADHD (Attention Deficient and Hyperactivity Disorder) patients under 5 years of age; and 2 Diagnosed according to DSM-IV or ICD 10 criteria. Renewal - (Narcolepsy) only from a neurologist or respiratory spec
ACE inhibitors will be funded to the level of the ex-manufacturer price listed in the Schedule for patients who were taking an ACE inhibitor for the treatment of congestive heart failure prior to 1 June 1998. The prescription must be endorsed accordingly. We recommend that the words used to indicate eligibility are "certified condition" or an appropriate description of the patient such as "congestive heart failure", "CHF", "congestive cardiac failure" or "CCF". Additional subsidy for lisinopril is available only up to the price of the least expensive brand listed in the Schedule. Definition of Congestive Heart FailureAt the request of some prescribers the PTAC Cardiovascular subcommittee has provided adefinition of congestive heart failure for the purposes of the funding of the manufacturer'ssurcharge: "Clinicians should use their clinical judgement. Existing patients would be eligible for thefunding of the surcharge if the patient shows signs and symptoms of congestive heart failure, and requir
Additional subsidy by endorsement for:Moclobemide tab 150 mg x 100 (Aurorix) up to $47.00Moclobemide tab 300 mg x 60 (Aurorix) up to $56.40Nefazadone tab 100 mg x 56 (Serzone) up to $20.16Nefazadone tab 200 mg x 56 (Serzone) up to $40.32Citalopram tab 20 mg x 28 (Cipramil) up to $27.00is available for patients who: * are taking moclobemide or nefazodone on 1 December 1999 or citalopram on 1 February2000; * have previously responded to treatment with moclobemide or nefazodone or citalopram; * have had a trial of fluoxetine and have to discontinue due to: - inability to tolerate the drug due to side effects OR - failed to respond to an adequate dose and duration of treatment; * have contraindications to fluoxetine (eg pre-existing significant levels of nausea, breastfeeding, potential drug interactions); The prescription must be endorsed accordingly. We recommend that the words used to indicate eligibility are "certified condition" however these particular words are not a requirement.
Special Authority for Subsidy - Form SA0538Initial application only from a gastroenterologist, infectious disease specialist, paediatrician or general physician. Approvals valid for 1 year for applications meeting the following criteria: Both: 1 Any of the following: 1.1 All of the following: 1.1.1 HBsAg positive for more than 6 months; and 1.1.2 HBeAg positive or HBV DNA positive defined as >0.6 pg/ml by quantitative PCR at reference laboratory; and 1.1.3 ALT greater than twice upper limit of normal or stage 3 or 4 fibrosis on liver histology clinical/radiological evidence of cirrhosis; or 1.2 HBV DNA positive cirrhosis prior to liver transplantation; or 1.3 HBsAg positive and have had a liver, kidney, heart, lung or bone marrow transplant; and 2 All of the following: 2.1 No continuing alcohol abuse or intravenous drug use; and 2.2 Not coinfected with HCV, HDV, or HIV; and 2.3 Neither ALT nor AST greater than 10 times upper limit of normal; and 2.4
Special Authority for Subsidy - Form SA0539Initial application from any medical practitioner. Approvals valid for 5 years where the patient is likely to benefit from treatment. NoteApplications to be made on the approved forms which are available from: The Co-ordinatorPhone: 09 580 9176Multiple Sclerosis Treatment CommitteeFacsimile: 09 580 9205Level 3, Unisys HouseEmail: murray@ppc.govt.nz650 Great South Road, PenrosePrivate Bag, AUCKLANDBudget managed by appointed clinicians on the Multiple Sclerosis Treatment Assessments Committee (MSTAC). Applications will be considered by MSTAC at its regular meetings and approved subject to eligibility according to the Entry and Stopping criteria (below). Completed application forms must be sent to the co-ordinator for MSTAC and will be considered by MSTAC at the next practicable opportunity. Notification of MSTAC's decision will be sent to the patient, the applying clinician and the patient's GP (if specified). These agents will N
Additional subsidy by endorsement for:Moclobemide tab 150 mg x 100 (Aurorix) up to $47.00Moclobemide tab 300 mg x 60 (Aurorix) up to $56.40Nefazadone tab 100 mg x 56 (Serzone) up to $20.16Nefazadone tab 200 mg x 56 (Serzone) up to $40.32Citalopram tab 20 mg x 28 (Cipramil) up to $27.00is available for patients who: * were taking moclobemide or nefazodone on 1 December 1999 or citalopram on 1 February 2000; or* have previously responded to treatment with moclobemide, nefazodone or citalopram; or* have had a trial of fluoxetine and have to discontinue due to: - inability to tolerate the drug due to side effects; or - failed to respond to an adequate dose and duration of treatment; or* have contraindications to fluoxetine (eg pre-existing significant levels of nausea, breastfeeding, potential drug interactions); The prescription must be endorsed accordingly. We recommend that the words used to indicate eligibility are "certified condition" however these words are not a requirement.
Alphagan is subsidised for use as either monotherapy or as an adjunctive agent for the treatment of glaucoma. Alphagan should not be prescribed for a person in whom less expensive first line agents for the treatment of glaucoma are not contraindicated unless: (a) that person has previously trialled all other such subsidised agents (except dorzolamide hydrochloride); and(b) those trials have indicated that that person does not respond adequately to or does not tolerate treatment with those other agents.
Special Authority for Subsidy - Form SA0551Initial application only from a paediatrician, neurologist or general physician. Approvals valid for 15 months for applications meeting the following criteria: Any of the following: 1 Was on NAED therapy before 1 September 2000; or 2 Seizures are not adequately controlled with optimal older anti-epilepsy drug treatment; or 3 Seizures are controlled adequately but who experience unacceptable side effects from older anti-epilepsy drug treatment. NoteApproval entitles patients to a subsidy for one NAED. Dual NAED therapy will be subsidised for patients who were already stabilised on two NAEDs on or before 31 July 2000 or, for whom a second NAED has been added to therapy with one NAED provided an attempt to withdraw one NAED has been made and was unsuccessful. "Optimal older anti-epilepsy drug therapy" is defined as treatment with those older anti-epilepsy drugs which are indicated and clinically appropriate for the patient, given singly and in combin
Special Authority for Subsidy - Form SA0556Initial application - (Confirmed HIV/AIDS) only from a named general physician. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 Confirmed HIV/AIDS; and 2 Any of the following: 2.1 Symptomatic patient; or 2.2 Both: 2.2.1 Asymptomatic patient; and 2.2.2 Patient aged 12 months and under; or 2.3 Both: 2.3.1 Asymptomatic patient; and 2.3.2 Patient has viral load counts > 10,000 copies per ml or equivalent value on the Chiron test; or 2.4 All of the following: 2.4.1 Asymptomatic patient; and 2.4.2 Patient aged 1 to 5 years; and 2.4.3 CD4 counts < 1,000 cells/mm3; or 2.5 All of the following: 2.5.1 Asymptomatic patient; and 2.5.2 Patient aged 1 to 5 years; and 2.5.3 CD4 counts < 0.25 x total white cell count; or 2.6 All of the following: 2.6.1 Asymptomatic patient; and 2.6.2 Patient aged 6 years and over; and 2.6.3 CD4 counts
Special Authority for Subsidy - Form SA0557Initial application - (Single NAED Therapy) only from a paediatrician, neurologist or general physician. Approvals valid for 15 months for applications meeting the following criteria: Any of the following: 1 Was on NAED therapy before 1 September 2000; or 2 Seizures are not adequately controlled with optimal older anti-epilepsy drug treatment; or 3 Seizures are controlled adequately but who experience unacceptable side effects from older anti-epilepsy drug treatment. Note"Optimal older anti-epilepsy drug therapy" is defined as treatment with those older anti-epilepsy drugs which are indicated and clinically appropriate for the patient, given singly and in combination in adequate doses for the patient's age, weight, and other features affecting the pharmacokinetics of the drug with good evidence of complianceAs a guideline, clinical trials have referred to a notional 50% reduction in seizure frequency as an indicator of success with anti-convulsan
Additional subsidy by endorsement for:Moclobemide tab 150mg x 100 (Aurorix) up to $32.90Moclobemide tab 300mg x 60 (Aurorix) up to $39.48Nefazodone tab 100mg x 56 (Serzone) up to $20.16Nefazodone tab 200mg x 56 (Serzone) up to $40.32Citalopram tab 20mg x 28 (Cipramil) up to $27.00is available for patients who: * were taking moclobemide or nefazodone on 1 December 1999 or citalopram on 1 February 2000; or* have previously responded to treatment with moclobemide, nefazodone or citalopram; or* have had a trial of fluoxetine and have had to discontinue due to - inability to tolerate the drug due to side effects; or - failed to respond to an adequate dose and duration of treatment; or* have contraindications to fluoxetine (eg pre-existing significant levels of nausea, breastfeeding, potential drug interactions). The prescription must be endorsed accordingly. We recommend that the words used to indicate eligibility are "certified condition" however these words are not a requirement.
Additional subsidy by endorsement for:Moclobemide tab 150mg x 100 (Aurorix) up to $32.90Moclobemide tab 300mg x 60 (Aurorix) up to $39.48Nefazodone tab 100mg x 56 (Serzone) up to $20.16Nefazodone tab 200mg x 56 (Serzone) up to $40.32Citalopram tab 20mg x 28 (Cipramil and Celapram) up to $10.00Paroxetine hydrochloride tab 20 mg x 30 (Aropax) up to $35.02is available for patients who: * were taking moclobemide or nefazodone on 1 December 1999 or citalopram on 1 February 2000; or paroxetine hydrochloride on Februrary 2001; or * have previously responded to treatment with moclobemide or nefazodone or citalopram or paroxetine hydrochloride; or* have had a trial of fluoxetine and have had to discontinue due to - inability to tolerate the drug due to side effects; or - failed to respond to an adequate dose and duration of treatment; or* have contraindications to fluoxetine (eg pre-existing significant levels of nausea, breastfeeding, potential drug interactions). The prescription must be e
Special Authority for Subsidy - Form SA0563Initial application only from a relevant specialist. Approvals valid for 2 years for applications meeting the following criteria: Any of the following: 1 Both: 1.1 Acromegaly; and 1.2 Patient has failed surgery, radiotherapy, bromocriptine and other oral therapies; or 2 VIPomas and Glucagonomas - for patients who are seriously ill in order to improve their clinical state prior to definitive surgery.; or 3 Both: 3.1 Gastrinoma; and 3.2 Either: 3.2.1 Patient has failed surgery; or 3.2.2 Patient in metastatic disease after H2 antagonists (or proton pump inhibitors) have failed; or 4 Both: 4.1 Insulinomas; and 4.2 Surgery is contraindicated or has failed; or 5 For pre-operative control of hypoglycaemia and for maintenance therapy; or 6 Both: 6.1 Carcinoid syndrome (diagnosed by tissue pathology and/or urinary 5HIAA analysis); and 6.2 Disabling symptoms not controlled by maximal medical therapy. No
Trandolapril will be funded to the level of the ex-manufacturer price listed in the Schedule for patients who were taking these ACE inhibitors for the treatment of congestive heart failure prior to 1 June 1998. The prescription must be endorsed accordingly. We recommend that the words used to indicate eligibility are "certified condition" or an appropriate description of the patient such as "congestive heart failure", "CHF", "congestive cardiac failure" or "CCF". Definition of Congestive Heart Failure At the request of some prescribers the PTAC Cardiovascular subcommittee has provided a definition of congestive heart failure for the purposes of the funding of the manufacturer's surcharge: "Clinicians should use their clinical judgement. Existing patients would be eligible for the funding of the surcharge if the patient shows signs and symptoms of congestive heart failure, and requires or has in the past required concomitant treatment with a diuretic. The definition could also be considered to include pat
Perindopril will be funded to the level of the ex-manufacturer price listed in the Schedule for patients who were taking these ACE inhibitors for the treatment of congestive heart failure prior to 1 June 1998. The prescription must be endorsed accordingly. We recommend that the words used to indicate eligibility are "certified condition" or an appropriate description of the patient such as "congestive heart failure", "CHF", "congestive cardiac failure" or "CCF". Definition of Congestive Heart Failure At the request of some prescribers the PTAC Cardiovascular subcommittee has provided a definition of congestive heart failure for the purposes of the funding of the manufacturer's surcharge: "Clinicians should use their clinical judgement. Existing patients would be eligible for the funding of the surcharge if the patient shows signs and symptoms of congestive heart failure, and requires or has in the past required concomitant treatment with a diuretic. The definition could also be considered to include pati
Special Authority for Subsidy - Form SA0569Initial application only from a geriatrician, rheumatologist, endocrinologist, gynaecologist or general physician. Approvals valid for 2 years for applications meeting the following criteria: All of the following: 1 Severe osteoporosis; and 2 History of one previous significant osteoporotic fractures demonstrated radiologically; and 3 T-Score <= -3.0 (bone mass density (BMD) >= 3.0 standard deviations below the mean normal value in young adults). NoteIn line with the Australian guidelines for funding alendronate, a vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body. Renewal only from a geriatrician, rheumatologist, endocrinologist, gynaecologist or general physician. Approvals valid for 2 years where the t
Special Authority for Subsidy - Form SA0572Initial application only from a psychiatrist. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 Patient presenting with first episode schizophrenia or related psychoses; or 2 Both: 2.1 Patients suffers from schizophrenia or related psychoses ; and 2.2 Either: 2.2.1 A trial of risperidone has been discontinued because of unacceptable side effects; or 2.2.2 A trial of risperidone has been discontinued because of inadequate response. Renewal only from a psychiatrist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
Subsidy is available for patients with poorly controlled asthma where: a) at least three months of 750 mcg or more daily of inhaled beclomethasone or budesonide(or 400 mcg of fluticasone) for adults has been used; orb) at least three months of 400 mcg or more daily of inhaled beclomethasone or budesonide (or 200mcg of fluticasone) for children 12 years or older has been used; The prescription must be endorsed accordingly. We recommend that the words used to indicateeligibility are "poor control with ICS" or "certified condition".
Special Authority for Subsidy - Form SA0575Initial application - (Confirmed HIV/AIDS) only from a named general physician. Approvals valid without further renewal unless notified for applications meeting the following criteria: Both: 1 Confirmed HIV/AIDS; and 2 Any of the following: 2.1 Symptomatic patient; or 2.2 Both: 2.2.1 Asymptomatic patient; and 2.2.2 Patient aged 12 months and under; or 2.3 Both: 2.3.1 Asymptomatic patient; and 2.3.2 Patient has viral load counts > 10,000 copies per ml or equivalent value on the Chiron test; or 2.4 All of the following: 2.4.1 Asymptomatic patient; and 2.4.2 Patient aged 1 to 5 years; and 2.4.3 CD4 counts < 1,000 cells/mm3; or 2.5 All of the following: 2.5.1 Asymptomatic patient; and 2.5.2 Patient aged 1 to 5 years; and 2.5.3 CD4 counts < 0.25 x total white cell count; or 2.6 All of the following: 2.6.1 Asymptomatic patient; and 2.6.2 Patient aged 6 years and over
Special Authority for Subsidy - Form SA0579Initial application - (Cystic fibrosis or renal failure) only from a relevant specialist. Approvals valid for 3 years for applications meeting the following criteria: Either: 1 cystic fibrosis; or 2 chronic renal failure or continuous ambulatory peritoneal dialysis (CAPD) patient. Initial application - (Indications other than cystic fibrosis or renal failure) only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria: Any of the following: 1 cancer in children; or 2 cancers affecting alimentary tract where there are malabsorption problems in patients over the age of 20 years; or 3 failure to thrive; or 4 growth deficiency; or 5 bronchopulmonary dysplasia; or 6 premature and post premature infant. Renewal - (Cystic fibrosis or renal failure) only from a relevant specialist or general practitioner on the recommendation of such a specialist. Approvals valid for 3 years for applicatio
Special Authority for Subsidy - Form SA0580Initial application - (Inborn errors of metabolism) only from a relevant specialist. Approvals valid for 3 years where inborn errors of metabolism. Initial application - (Indications other than inborn errors of metabolism) only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria: Any of the following: 1 failure to thrive ; or 2 growth deficiency; or 3 bronchopulmonary dysplasia ; or 4 fat malabsorption ; or 5 lymphangiectasia; or 6 short bowel syndrome ; or 7 infants with necrotising enterocolitis; or 8 biliary atresia. Renewal - (Inborn errors of metabolism) only from a relevant specialist or general practitioner on the recommendation of such a specialist. Approvals valid for 3 years for applications meeting the following criteria: Both: 1 The treatment remains appropriate and the patient is benefiting from treatment; and 2 General Practitioners must include the name of
Special Authority for Subsidy - Form SA0581Initial application - (Cystic fibrosis) only from a relevant specialist. Approvals valid for 3 years for applications meeting the following criteria: Both: 1 infant aged four years or under; and 2 cystic fibrosis. Initial application - (Indications other than cystic fibrosis) only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria: Both: 1 infant aged four years or under; and 2 Any of the following: 2.1 cancer in children; or 2.2 failure to thrive; or 2.3 growth deficiency; or 2.4 bronchopulmonary dysplasia; or 2.5 premature and post premature infants. Renewal - (Cystic fibrosis) only from a relevant specialist or general practitioner on the recommendation of such a specialist. Approvals valid for 3 years for applications meeting the following criteria: Both: 1 The treatment remains appropriate and the patient is benefiting from treatment; and 2 General Practiti
Special Authority for Subsidy - Form SA0582Initial application only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria: Either: 1 protein losing enteropathy; or 2 high protein needs (eg burns). Renewal only from a relevant specialist or general practitioner on the recommendation of such a specialist. Approvals valid for 1 year for applications meeting the following criteria: Both: 1 The treatment remains appropriate and the patient is benefiting from treatment; and 2 General Practitioners must include the name of the specialist and date contacted.
Special Authority for Subsidy - Form SA0585Initial application - (Cystic fibrosis) only from a relevant specialist. Approvals valid for 3 years for applications meeting the following criteria: All of the following: 1 Cystic fibrosis; and 2 other lower calorie products have been tried; and 3 patient has substantially increased metabolic requirements; and 4 Either: 4.1 The product is to be used as a supplement; or 4.2 The product is to be used as a complete diet.Initial application - (Indications other than cystic fibrosis) only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria: All of the following: 1 Any of the following: 1.1 any condition causing malabsorption ; or 1.2 failure to thrive ; or 1.3 increased nutritional requirements.; and 2 other lower calorie products have been tried; and 3 patient has substantially increased metabolic requirements; and 4 Either: 4.1 The product is to be used a
Special Authority for Subsidy - Form SA0587Initial application only from a relevant specialist. Approvals valid for 3 years for applications meeting the following criteria: Both: 1 acute or chronic renal failure; and 2 Either: 2.1 The product is to be used as a supplement (maximum 500 ml per day); or 2.2 The product is to be used as a complete diet.Renewal only from a relevant specialist or general practitioner on the recommendation of such a specialist. Approvals valid for 3 years for applications meeting the following criteria: All of the following: 1 The treatment remains appropriate and the patient is benefiting from treatment; and 2 Either: 2.1 The product is to be used as a supplement (maximum 500 ml per day); or 2.2 The product is to be used as a complete diet; and 3 General Practitioners must include the name of the specialist and date contacted.
Special Authority for Subsidy - Form SA0588Initial application only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria: Both: 1 CORD patients who have hypercapnia; and 2 Either: 2.1 The product is to be used as a supplement (maximum 500 ml per day); or 2.2 The product is to be used as a complete diet.Renewal only from a relevant specialist or general practitioner on the recommendation of such a specialist. Approvals valid for 1 year for applications meeting the following criteria: All of the following: 1 The treatment remains appropriate and the patient is benefiting from treatment; and 2 Either: 2.1 The product is to be used as a supplement (maximum 500 ml per day); or 2.2 The product is to be used as a complete diet; and 3 General Practitioners must include the name of the specialist and date contacted.
Special Authority for Subsidy - Form SA0589Initial application only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria: All of the following: 1 Anorexia and weight loss; and 2 Either: 2.1 decompensating liver disease without encephalopathy ; or 2.2 protein losing gastro-enteropathy; and 3 Either: 3.1 The product is to be used as a supplement (maximum 500 ml per day); or 3.2 The product is to be used as a complete diet.Renewal only from a relevant specialist or general practitioner on the recommendation of such a specialist. Approvals valid for 1 year for applications meeting the following criteria: All of the following: 1 The treatment remains appropriate and the patient is benefiting from treatment; and 2 Either: 2.1 The product is to be used as a supplement (maximum 500 ml per day); or 2.2 The product is to be used as a complete diet; and 3 General Practitioners must include the name of the specialis
Special Authority for Subsidy - Form SA0590Initial application only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria: All of the following: 1 infant aged one to six years; and 2 Any of the following: 2.1 any condition causing malabsorption ; or 2.2 failure to thrive; or 2.3 increased nutritional requirements; and 3 Either: 3.1 The product is to be used as a supplement (maximum 500 ml per day); or 3.2 The product is to be used as a complete diet.Renewal only from a relevant specialist or general practitioner on the recommendation of such a specialist. Approvals valid for 1 year for applications meeting the following criteria: All of the following: 1 The treatment remains appropriate and the patient is benefiting from treatment; and 2 Either: 2.1 The product is to be used as a supplement (maximum 500 ml per day); or 2.2 The product is to be used as a complete diet; and 3 General Practitioners must
Special Authority for Subsidy - Form SA0591Initial application only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria: Both: 1 Any of the following: 1.1 enteral feeding; or 1.2 nasogastric; or 1.3 nasoduodenal ; or 1.4 nasojejunal; or 1.5 gastrostomy/jejunostomy; and 2 Either: 2.1 The product is to be used as a supplement; or 2.2 The product is to be used as a complete diet.Renewal only from a general practitioner or relevant specialist. Approvals valid for 1 year for applications meeting the following criteria: All of the following: 1 The treatment remains appropriate and the patient is benefiting from treatment; and 2 Either: 2.1 The product is to be used as a supplement; or 2.2 The product is to be used as a complete diet; and 3 General Practitioners must include the name of the specialist and date contacted.
Special Authority for Subsidy - Form SA0592Initial application only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria: Both: 1 Any of the following: 1.1 malabsorption ; or 1.2 short bowel syndrome; or 1.3 enterocutaneous fistulas ; or 1.4 pancreatitis; and 2 Either: 2.1 The product is to be used as a supplement (maximum 500 ml per day); or 2.2 The product is to be used as a complete diet.NoteEach of these products is highly specialised and would be prescribed only by an expert for a specific disorder. The alternative is hospitalisation. Elemental 028 Extra is more expensive than other products listed in this section and should only be used where the alternatives have been tried first and/or are unsuitable. Renewal only from a relevant specialist or general practitioner on the recommendation of such a specialist. Approvals valid for 1 year for applications meeting the following criteria: All of the following:
Special Authority for Subsidy - Form SA0594Initial application only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria: Both: 1 Type I and II diabetics who require nutritional supplementation.; and 2 Either: 2.1 The product is to be used as a supplement (maximum 500 ml per day); or 2.2 The product is to be used as a complete diet.Renewal only from a relevant specialist or general practitioner on the recommendation of such a specialist. Approvals valid for 1 year for applications meeting the following criteria: All of the following: 1 The treatment remains appropriate and the patient is benefiting from treatment; and 2 Either: 2.1 The product is to be used as a supplement (maximum 500 ml per day); or 2.2 The product is to be used as a complete diet; and 3 General Practitioners must include the name of the specialist and date contacted.
Special Authority for Subsidy - Form SA0595Initial application only from a relevant specialist. Approvals valid for 1 year where patient has motor neurone disease with swallowing disorder. Renewal only from a relevant specialist or general practitioner on the recommendation of such a specialist. Approvals valid for 1 year for applications meeting the following criteria: Both: 1 The treatment remains appropriate and the patient is benefiting from treatment; and 2 General Practitioners must include the name of the specialist and date contacted.
Special Authority for Subsidy - Form SA0596Initial application only from a relevant specialist. Approvals valid for 3 years for applications meeting the following criteria: Either: 1 gluten enteropathy has been diagnosed by biopsy; or 2 dermatitis herpetiformis. NoteA premium may be payable if the subsidy does not match the price charged by the manufacturer. The subsidy for these products reflects the philosophy that the patient incurs no additional financial burden for purchasing specialised more expensive products. Renewal only from a relevant specialist or general practitioner on the recommendation of such a specialist. Approvals valid for 3 years for applications meeting the following criteria: Both: 1 The treatment remains appropriate and the patient is benefiting from treatment; and 2 General Practitioners must include the name of the specialist and date contacted.
Special Authority for Subsidy - Form SA0597Initial application - (PKU Patient aged over 16) only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria: Both: 1 PKU; and 2 blood phenylalanine level < 900 mmol/litre (average of tests over last 12 months). Initial application - (Patient aged over 16) only from a relevant specialist. Approvals valid for 3 years for applications meeting the following criteria: Any of the following: 1 dietary management of homocystinuria; or 2 inborn errors of metabolism other than PKU; or 3 dietary management of maple syrup urine disease..Initial application - (Patient aged 16 or under) only from a relevant specialist. Approvals valid for 3 years for applications meeting the following criteria: Any of the following: 1 dietary management of homocystinuria; or 2 PKU and other inborn errors of metabolism; or 3 dietary management of maple syrup urine disease..Renewal - (PKU Patient aged over 16
Special Authority for Subsidy - Form SA0600Initial application only from a relevant specialist. Approvals valid for 3 years where inborn errors of metabolism. Renewal only from a relevant specialist or general practitioner on the recommendation of such a specialist. Approvals valid for 3 years for applications meeting the following criteria: Both: 1 The treatment remains appropriate and the patient is benefiting from treatment; and 2 General Practitioners must include the name of the specialist and date contacted.
Special Authority for Subsidy - Form SA0601Initial application only from a relevant specialist. Approvals valid for 1 year where Infant suffering from Williams Syndrome and associated hypercalcaemia. Renewal only from a relevant specialist or general practitioner on the recommendation of such a specialist. Approvals valid for 1 year for applications meeting the following criteria: Both: 1 The treatment remains appropriate and the patient is benefiting from treatment; and 2 General Practitioners must include the name of the specialist and date contacted.
Special Authority for Subsidy - Form SA0603Initial application only from a relevant specialist. Approvals valid for 1 year where infant suffering from malabsorption and other gastrointestinal problems. Renewal only from a relevant specialist or general practitioner on the recommendation of such a specialist. Approvals valid for 1 year for applications meeting the following criteria: Both: 1 The treatment remains appropriate and the patient is benefiting from treatment; and 2 General Practitioners must include the name of the specialist and date contacted.
Special Authority for Subsidy - Form SA0604Initial application - (Lactase deficiency or disaccharide intolerance) only from a relevant specialist. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 Patient is less than 3 years of age; and 2 Either: 2.1 diagnosed as suffering from congenital lactase deficiency; or 2.2 suffering from disaccharide intolerance. NoteSecondary lactose intolerance in children is usually short lasting, and can be controlled by dietary measures and by giving sufficient calories to regenerate digestive enzymes. The subsidy for these products reflects the philosophy that the patient incurs no additional financial burden for purchasing specialised more expensive products. Initial application - (Infant with intolerance to cows' milk) only from a relevant specialist. Approvals valid for 6 months for applications meeting the following criteria: Both: 1 intolerant to cows' milk; and 2 patient is less than 3 years of age. No
Special Authority for Subsidy - Form SA0605Initial application - (Cystic fibrosis or renal disorder) only from a relevant specialist. Approvals valid for 3 years for applications meeting the following criteria: Both: 1 Either: 1.1 cystic fibrosis; or 1.2 renal disorder; and 2 Either: 2.1 The product is to be used as a supplement; or 2.2 The product is to be used as a complete diet.Initial application - (Indications other than cystic fibrosis or renal disorder) only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria: Both: 1 Any of the following: 1.1 any condition causing malabsorption; or 1.2 failure to thrive; or 1.3 increased nutritional requirements; and 2 Either: 2.1 The product is to be used as a supplement; or 2.2 The product is to be used as a complete diet.Renewal - (Cystic fibrosis or renal disorder) only from a relevant specialist or general practitioner. Approvals valid for 3 years
Special Authority for Subsidy - Form SA0606Initial application only from a paediatrician. Approvals valid for 3 years for applications meeting the following criteria: Both: 1 child (up to 18 years) with chronic renal failure.; and 2 Either: 2.1 The product is to be used as a supplement; or 2.2 The product is to be used as a complete diet.Renewal only from a paediatrician. Approvals valid for 3 years for applications meeting the following criteria: Both: 1 The treatment remains appropriate and the patient is benefiting from treatment; and 2 Either: 2.1 The product is to be used as a supplement; or 2.2 The product is to be used as a complete diet.
Special Authority for Subsidy - Form SA0607Initial application only from a paediatrician. Approvals valid for 3 years for applications meeting the following criteria: Both: 1 Child (up to 18 years) who is awaiting liver transplant; and 2 Either: 2.1 The product is to be used as a supplement (maximum 500 ml per day); or 2.2 The product is to be used as a complete diet.Renewal only from a paediatrician. Approvals valid for 3 years for applications meeting the following criteria: Both: 1 The treatment remains appropriate and the patient is benefiting from treatment; and 2 Either: 2.1 The product is to be used as a supplement (maximum 500 ml per day); or 2.2 The product is to be used as a complete diet.
Special Authority for Subsidy - Form SA0609Initial application - (Serevent MDI, Serevent Accuhaler Foradil, Oxis Turbuhaler 12 mcg, Symbicort Turbuhaler) only from a relevant specialist or general practitioner. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 Both: 1.1 Child under the age of 12 with poorly controlled asthma; and 1.2 Either: 1.2.1 Required at least three months of 400 mcg or more daily inhaled beclomethasone or budesonide; or 1.2.2 Required at least three months of 200 mcg or more of fluticasone; or 2 Both: 2.1 Adult with poorly controlled asthma; and 2.2 Either: 2.2.1 Required at least three months of 1500 mcg or more daily inhaled beclomethasone or budesonide; or 2.2.2 Required at least three months of 750 mcg or more of fluticasone. NotePatients are to be reviewed at least at six months to assess compliance and effectiveness of therapy. Special Authority approvals are interchangeable among all prese
Special Authority for Subsidy - Form SA0610Initial application from any specialist. Approvals valid without further renewal unless notified for applications meeting the following criteria: All of the following: 1 Quantity used by patient on a weekly volume intraveneously (Details to be attached to application); and 2 Amount of nutrition patient is able to receive orally (Details to be attached to application); and 3 Exact formula of TPN (Details to be attached to application); and 4 Who has paid for TPN so far (Details to be attached to application); and 5 Place of manufacture (Details to be attached to application); and 6 Complete medical history of patient including details of previous therapies. (Details to be attached to application). Renewal - (Previous approval has expired) from any specialist. Approvals valid without further renewal unless notified where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0611Initial application from any medical practitioner. Approvals valid for 1 year where applicaton approved by the Cystic Fibrosis DN'ase Advisory Panel. NoteApplications to be made on the approved forms which are available from: The Co-ordinatorCystic Fibrosis DN'ase Advisory PanelPhone: (04) 460 4990 PHARMAC, PO Box 10 254 WellingtonFacsimile: (04) 916 7571Email: erin.murphy@pharmac.govt.nzPrescriptions for patients approved for treatment must be written by respiratory physicians or paediatricians who have experience and expertise in treating cystic fibrosis.
Special Authority for Subsidy - Form SA0614Initial application only from a geriatrician, rheumatologist, endocrinologist, gynaecologist or general physician. Approvals valid for 2 years for applications meeting the following criteria: All of the following: 1 Severe osteoporosis; and 2 History of one previous significant osteoporotic fractures demonstrated radiologically; and 3 T-Score <= -3.0 (bone mass density (BMD) >= 3.0 standard deviations below the mean normal value in young adults). NoteIn line with the Australian guidelines for funding alendronate, a vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral bodyRenewal only from a geriatrician, rheumatologist, endocrinologist, gynaecologist or general physician. Approvals valid for 2 years where the tr
Special Authority for Subsidy - Form SA0615Initial application only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria: Both: 1 The product is to be used as a complete diet; and 2 Either: 2.1 Patient has metabolic disorders of fat metabolism; or 2.2 Patient has chylothorax. Renewal only from a relevant specialist or general practitioner on the recommendation of such a specialist. Approvals valid for 1 year for applications meeting the following criteria: Both: 1 The treatment remains appropriate and the patient is benefiting from treatment; and 2 General Practitioners must include the name of the specialist and date contacted.
Special Authority for Manufacturers Price - Form SA0616Initial application - (Conditions other than transient ischaemic episodes) only from a cardiothoracic surgeon, cardiologist or general physician. Approvals valid without further renewal unless notified for applications meeting the following criteria: Either: 1 Patients with prosthetic heart valves - as an adjunct to oral anticoagulation for prophylaxis of thromboembolism; or 2 Patients after coronary artery vein bypass graft - as an adjunct to aspirin or as monotherapy for patients who are aspirin intolerant. NoteAspirin intolerant patients are defined as those with aspirin induced asthma, urticaria, or anaphylaxi, or those with significant aspirin induced bleeding, excluding bruisingInitial application - (Transient ischaemic episodes) only from a neurologist, neuro surgeon, cardiologist, vascular surgeon or general physician. Approvals valid without further renewal unless notified where patients who continue to have transient ischaemic
a) Prescribers may code prescriptions "contraceptive" (code "O") when used as indicated for contraception. The period of supply and prescription charge will be as per other contraceptives, as follows: - $3.00 prescription charge (patient co-payment) will apply; - prescription may be written for up to six months supply; and- pharmacists may dispense up to three months supply. b) Prescriptions coded in any other way are subject to the non-contraceptive prescription charges, and the non-contraceptive period of supply. ie. Prescriptions may be written for up to three months supply, and dispensed monthly
Special Authority for Subsidy - Form SA0622Initial application only from a geriatrician, rheumatologist, endocrinologist, gynaecologist or general physician. Approvals valid without further renewal unless notified for applications meeting the following criteria: All of the following: 1 Severe osteoporosis; and 2 History of one previous significant osteoporotic fractures demonstrated radiologically; and 3 T-Score <= -3.0 (bone mass density (BMD) >= 3.0 standard deviations below the mean normal value in young adults). NoteIn line with the Australian guidelines for funding alendronate, a vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral bodyRenewal only from a geriatrician, rheumatologist, endocrinologist, gynaecologist or general physician. Approvals va
Special Authority for Subsidy - Form SA0623Initial application from any medical practitioner. Approvals valid for 1 year for applications meeting the following criteria: All of the following: 1 The patient is not predisposed to heart arrhythmias; and 2 The patient does not have a pre-existing QT-prolongation or hepatic failure; and 3 The patient is not using other medications which either inhibit the cytochrome P450 3A4 enzyme system or prolong the QT interval; and 4 Any of the following: 4.1 Both: 4.1.1 The patient is an adult with severe reflux oesophagitis; and 4.1.2 other treatment, including acid suppression with proton pump inhibitors, has failed; or 4.2 gastroparesis; or 4.3 malignancy of GI tract causing gastroparesis (or gastric outlet obstruction); or 4.4 The patient is a child (not including infants from 0 to 3 months of age who were born prematurely) with severe gastro-oesophageal reflux; and 5 Diagnosis has been made or confirmed by a general p
Subsidy by endorsement Oral liquid is subsidised only for patients: - with oesophageal stricture, or- in terminal care, or- who are either too young or too old to swallow conventional tablets and the prescription is endorsed accordingly. Note: the cost of treatment with ranitidine oral liquid is more than 10 times higher than that of ranitidine tablets. Following the derestriction of access PHARMAC will be monitoring expenditure on ranitidine oral liquid more closely and may, subject to consultation and PHARMAC Board approval, restrict access again if the expenditure was to grow substantially.
Special Authority for Subsidy - Form SA0626Initial application only from a renal physician. Approvals valid for 2 years for applications meeting the following criteria: All of the following: General Criteria: 1 Anaemia of end-stage renal failure (other treatable causes of anaemia being excluded); and 2 Been on haemodialysis or continuous ambulatory peritoneal dialysis (CAPD) for at least three months; and 3 Not under evaluation for, or awaiting, a live donor kidney transplant; and 4 Any of the following: Specific Criteria: 4.1 Anephric; or 4.2 Dependent on regular blood transfusion (1 unit each 4-8 weeks) to maintain haemoglobin > 60g/L; or 4.3 Dependent on regular blood transfusion but cannot be transfused because of severe transfusion reactions; or 4.4 Transfusion induced haemosiderosis (clinical manifestations, serum ferritin >1500 ug/L); or 4.5 Haemoglobin < 70 g/L (mean of at least 4 haemoglobin concentrations over 4 months); or 4.6 Both: 4.6.1 Haemo
Prescribing GuidelineTreatment with HMG CoA Reductase Inhibitors (Statins) is recommended for patients withdyslipidaemia and an absolute 5 year cardiovascular risk of 15% or greater. New Zealand Cardiovascular Guideline Group statement. "The 1996 Heart Foundation guidelines for the Assessment and Management of Dyslipidaemia are currently being revised. An evidence-based guideline on the Assessment and Management of Cardiovascular Risk will be developed in 2002. The Cardiovascular Guideline Group has written an interim consensus statement for themanagement of dyslipidaemia. The Heart Foundation cardiovascular risk tables should be used to determine risk. Certain groups are classified to be at very high risk (>20%) and should be treated as such: - Patients who have had a previous cardiovascular event (angina, MI, angioplasty, coronary artery bypass grafts, TIA, ischaemic stroke and peripheral vascular disease)- Patients with genetic lipid disorders- Patients with diabetes and associated microa
Special Authority for Subsidy - Form SA0628Initial application only from a cardiologist. Approvals valid without further renewal unless notified for applications meeting the following criteria: Any of the following: 1 Both: 1.1 Congestive heart failure; and 1.2 Cannot tolerate two ACE inhibitors due to persistent cough that resolves on cessation and recurs on re-challenge with ACE inhibitor; or 2 Patients who have experienced angioedema on an ACE inhibitor at any time in the past; or 3 Patients who have experienced angioedema (even if not using an ACE inhibitor) in the last 2 years. Renewal - ((2 year approvals granted before April 2002)) only from a cardiologist. Approvals valid without further renewal unless notified where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0631Initial application only from an ophthalmologist. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 Both: 1.1 Primary open-angle glaucoma; and 1.2 Any of the following: 1.2.1 Patient cannot tolerate Beta-blockers, or Beta-blockers are contraindicated; or 1.2.2 Patient cannot tolerate Pilocarpine, or Pilocarpine is contraindicated; or 1.2.3 Patient cannot tolerate Dorzolamide, or Dorzolamide is contraindicated; or 1.2.4 A reduction in intraocular pressure of 15% or more is not achieved or maintained using dorzolamide either alone or in combination with a beta-blocker; or 2 There is progressive visual field loss and/or optic nerve damage persists after treatment with dorzolamide either alone or in combination with a beta-blocker. NoteSubsidised also for adjunctive use for the treatment of patients who have met the initial application criteria, and in whom latanoprost monotherapy has bee
Special Authority for Subsidy - Form SA0633Initial application only from a general practitioner or relevant specialist. Approvals valid without further renewal unless notified for applications meeting the following criteria: Both: 1 Patient is already on an ACE inhibitor or Angiotensin II Antagonist; and 2 Any of the following: 2.1 Both: 2.1.1 Symptomatic heart failure NYHA functional class II-III; and 2.1.2 Patient has been treated with metoprolol and is intolerant to metoprolol or has demonstrated a sub-optimal response to metoprolol; or 2.2 Symptomatic heart failure NYHA functional class III-IV; or 2.3 Patient has left ventricular systolic dysfunction with an ejection fraction of less than 35%.NoteWhere possible treatment should be initiated by or on the recommendation of a specialist.
Special Authority for Subsidy - Form SA0635Initial application only from a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria: All of the following: 1 Rheumatoid arthritis; and 2 Patient is not a pregnant woman, or a woman of child-bearing age without adequate contraception; and 3 Patient has been unable to tolerate or has a contraindication to or has had an inadequate response to sulphasalazine and methotrexate (individually or in combination). Renewal only from a rheumatologist. Approvals valid without further renewal unless notified for applications meeting the following criteria: Both: 1 Compliance (prescriber determined) with medication; and 2 Improved rheumatoid arthritis symptom control. NotePatient should have full blood count and liver function tests regularly monitored.
Retail pharmacy - subsidy by endorsement a) Subsidised for:i) patients presenting with first episode schizophrenia or related psychoses; andii) patients suffering from schizophrenia or related psychoses after a trial of an effective dose of risperidone that has been discontinued because of unacceptable side effects or inadequate response. b) Initial prescription must be written by a relevant specialist. c) Subsequent prescriptions may be written by a general practitioner. d) The prescription must be endorsed "certified condition".
Special Authority for Subsidy - Form SA0637Initial application - (National Heart Foundation risk groups A1:1, A1:2, B, C, D or E) only from a relevant specialist or general practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria: All of the following: 1 The patient has been offered 3-6 months of counseling and an opportunity to modify lifestyle; and 2 Any of the following: 2.1 Both: 2.1.1 NHF A1:1 - Clinically proven ischaemic heart disease; and 2.1.2 total cholesterol > 5.5; or 2.2 Both: 2.2.1 NHF A1:2 - Post coronary artery bypass graft (CABG) or angioplasty; and 2.2.2 total cholesterol > 4.5; or 2.3 Post heart transplant (regardless of cholesterol level); or 2.4 Both: 2.4.1 NHF B: Patients with > 20% 5-year cardiovascular disease risk; and 2.4.2 total cholesterol > 9.0; or 2.5 Both: 2.5.1 NHF C: 15-20% 5-year cardiovascular disease risk; and 2.5.2 total cholesterol >
Special Authority for Subsidy - Form SA0639Initial application - (No previous use) only from a relevant specialist or general practitioner. Approvals valid for 3 months for applications meeting the following criteria: All of the following: 1 The patient has a clinical diagnosis of heavy menstrual bleeding; and 2 The patient has failed to respond to or is unable to tolerate other appropriate pharmaceutical therapies as per the Heavy Menstrual Bleeding Guidelines; and 3 Either: 3.1 serum ferritin level < 16 mg/l (within the last 12 months); or 3.2 haemoglobin level < 120 g/l . NoteApplications are not to be made for use in patients as contraception except where they meet the above criteriaInitial application - (Previous use before 1 October 2002) only from a relevant specialist or general practitioner. Approvals valid for 3 months for applications meeting the following criteria: All of the following: 1 The patient had a clinical diagnosis of heavy menstrual bleeding; and 2
Special Authority for Waiver of Rule - Form SA0641Initial application only from a diabetologist, general physician or paediatrician. Approvals valid without further renewal unless notified for applications meeting the following criteria: Either: 1 Both: 1.1 Use alone (monotherapy); and 1.2 The patient is unable to use any other insulins including those on insulin pump treatment; or 2 Both: 2.1 Use with insulin other than insulin isophane (including ready-mixed preparations); and 2.2 A reasonable trial of insulin isophane has been undertaken and it is not effective or not well tolerated. Note"Reasonable trial", "unable to use", "not effective", "not well tolerated", and "not well tolerated" are not defined and we ask clinicians to use their clinical judgement in interpreting these terms.
Special Authority for Subsidy - Form SA0643Initial application - (CML) only from an oncologist or relevant specialist. Approvals valid for 7 months where approved by the The Glivec Co-ordinator. Initial application - (GIST) only from an oncologist. Approvals valid for 1 year where approved by the The Glivec Co-ordinator. Renewal - (CML) only from an oncologist or relevant specialist. Approvals valid for 6 months where approved by the The Glivec Co-ordinator. Initial application - (GIST) only from an oncologist. Approvals valid for 1 year where approved by the The Glivec Co-ordinator. NoteApplication forms are available from, and prescriptions should be sent to: The Glivec Co-ordinatorPhone: 09 580 9176Level 3, Unisys HouseFacsimile: 09 580 9205650 Great South Road, PenroseEmail: murray@ppc.govt.nzPrivate Bag, AUCKLANDSpecial Authority criteria for CML - access by applicationFunded for patients with diagnosis (confirmed by a haematologist) of a chronic myeloid leukaemia (CML) i
Special Authority for Subsidy - Form SA0645Initial application only from a renal physician. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 Both: 1.1 patient in chronic renal failure; and 1.2 Haemoglobin <= 100 g/L; and 2 Either: 2.1 Both: 2.1.1 patient is not diabetic; and 2.1.2 glomerular filtration rate <= 30 ml/min; or 2.2 Both: 2.2.1 patient is diabetic; and 2.2.2 glomerular filtration rate <= 45 ml/min. Renewal only from a renal physician. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment. NoteErythropoietin beta is indicated in the treatment of anaemia associated with chronic renal failure (CRF) where no cause for anaemia other than CRF is detected and there is adequate monitoring of iron stores and iron replacement therapy. The Cockroft-Gault Formula may be used to estimate glomerular filtration rate (GFR) in persons 18 years and over:GFR (male)
Special Authority for Subsidy - Form SA0646Initial application only from a renal physician. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 Both: 1.1 patient in chronic renal failure; and 1.2 Haemoglobin <= 100 g/L; and 2 Any of the following: 2.1 Both: 2.1.1 patient is not diabetic; and 2.1.2 glomerular filtration rate <= 30 ml/min; or 2.2 Both: 2.2.1 patient is diabetic; and 2.2.2 glomerular filtration rate <= 45 ml/min; or 2.3 patient is on haemodialysis or peritoneal dialysis. Renewal only from a renal physician. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment. NoteErythropoietin beta is indicated in the treatment of anaemia associated with chronic renal failure (CRF) where no cause for anaemia other than CRF is detected and there is adequate monitoring of iron stores and iron replacement therapy. The Cockroft-Gault Formula may be used to estim
Special Authority for Manufacturers Price - Form SA0648Initial application - (Conditions other than transient ischaemic episodes) only from a cardiothoracic surgeon, cardiologist or general physician. Approvals valid without further renewal unless notified for applications meeting the following criteria: Either: 1 Patients with prosthetic heart valves - as an adjunct to oral anticoagulation for prophylaxis of thromboembolism; or 2 Patients after coronary artery vein bypass graft - as an adjunct to aspirin or as monotherapy for patients who are aspirin intolerant. NoteAspirin intolerant patients are defined as those with aspirin induced asthma, urticaria, or anaphylaxi, or those with significant aspirin induced bleeding, excluding bruisingInitial application - (Transient ischaemic episodes) only from a neurologist, neuro surgeon, cardiologist, vascular surgeon or general physician. Approvals valid without further renewal unless notified where patients who continue to have transient ischaemic
Special Authority for Subsidy - Form SA0649Initial application - (Conditions other than transient ischaemic episodes) only from a cardiothoracic surgeon, cardiologist or general physician. Approvals valid without further renewal unless notified for applications meeting the following criteria: Either: 1 Patients with prosthetic heart valves - as an adjunct to oral anticoagulation for prophylaxis of thromboembolism; or 2 Patients after coronary artery vein bypass graft - as an adjunct to aspirin or as monotherapy for patients who are aspirin intolerant. NoteAspirin intolerant patients are defined as those with aspirin induced asthma, urticaria, or anaphylaxi, or those with significant aspirin induced bleeding, excluding bruisingInitial application - (Transient ischaemic episodes) only from a neurologist, neuro surgeon, cardiologist, vascular surgeon or general physician. Approvals valid without further renewal unless notified where patients who continue to have transient ischaemic episodes des
Special Authority for Subsidy - Form SA0652Initial application - (Single NAED Therapy) only from a paediatrician, neurologist or general physician. Approvals valid for 15 months for applications meeting the following criteria: Any of the following: 1 Was on NAED therapy before 1 September 2000; or 2 Seizures are not adequately controlled with optimal older anti-epilepsy drug treatment; or 3 Seizures are controlled adequately but who experience unacceptable side effects from older anti-epilepsy drug treatment. Note"Optimal older anti-epilepsy drug therapy" is defined as treatment with those older anti-epilepsy drugs which are indicated and clinically appropriate for the patient, given singly and in combination in adequate doses for the patient's age, weight, and other features affecting the pharmacokinetics of the drug with good evidence of complianceInitial application - (Dual NAED Therapy) only from a paediatrician, neurologist or general physician. Approvals valid for 18 months for app
Special Authority for Subsidy - Form SA0657Initial application - (Helicobacter pylori infections) only from a general practitioner or relevant specialist. Approvals valid for 6 months for applications meeting the following criteria: Both: 1 Eradication of Helicobacter pylori in patient with proven infection; and 2 Peptic ulcer disease proven by endoscopy. NoteMaximum of two prescriptions (two courses) per patient. Initial application - (Mycobacterial infections) only from a respiratory specialist, infectious disease specialist or paediatrician. Approvals valid for 2 years for applications meeting the following criteria: Any of the following: 1 Mycobacterium Avium Intracellulare Complex infections in patient with AIDS; or 2 Atypical and drug-resistant mycobacterial infection; or 3 All of the following: 3.1 Prophylaxis against disseminated Mycobacterium Avium Intracellulare Complex infection; and 3.2 HIV infection; and 3.3 CD4 count <= 50 cells/mm3. Renewal - (Mycobact
Additional subsidy by endorsement for:Moclobemide tab 150 mg x 500 (Apo-Moclobemide) up to $46.00Moclobemide tab 150 mg x 100 (Aurorix) up to $32.90Moclobemide tab 300 mg x 100 (Apo-Moclobemide) up to $26.11Moclobemide tab 300 mg x 60 (Aurorix) up to $39.48Nefazodone tab 100 mg x 56 (Serzone) up to $20.16Nefazodone tab 200 mg x 56 (Serzone) up to $40.32Citalopram tab 20 mg x 28 (Celapram) up to $4.00Citalopram tab 20 mg x 28 (Cipramil) up to $10.00Paroxetine hydrochloride tab 20 mg x 30 (Aropax) up to $35.02is available for patients who: - were taking moclobemide or nefazodone on 1 December 1999 or citalopram on 1 February 2000; or paroxetine hydrochloride on February 2001; or- have previously responded to treatment with moclobemide or nefazodone or citalopram or paroxetine hydrochloride; or- have had a trial of fluoxetine and have had to discontinue due to- inability to tolerate the drug due to side effects; or- failed to respond to an adequate dose and duration of treatment; or
Special Authority for Subsidy - Form SA0661Initial application only from a psychiatrist. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 The patient has "treatment resistant" depression; and 2 Either: 2.1 The patient must have had a trial of two different antidepressants and failed to respond to an adequate dose over an adequate period of time (usually at least four weeks); or 2.2 Both: 2.2.1 The patient is currently a hospital in-patient as a result of an acute depressive episode; and 2.2.2 The patient must have had a trial of one other antidepressant and failed to respond to an adequate dose over an adequate period of time. Renewal from any medical practitioner. Approvals valid for 2 years where patient has a high risk of relapse (prescriber determined)..NoteFirst prescription can be written by a psychiatrist or psychiatric registrar. Subsequent prescriptions may be written by a General Practitioner
Prescribing GuidelinesBoth Trusopt and Cosopt are subsidised for use as either monotherapy or as an adjunctive agent for the treatment of glaucoma. Trusopt and Cosopt should not be prescribed for a person in whom less expensive first line agents for the treatment of glaucoma are not contraindicated unless: i) that person has previously trialled all other such subsidised agents (except brimonidine tartrate); andii) those trials have indicated that that person does not respond adequately to treatment with those other agents.
a) Spacer devices and masks also available to paediatricians employed by a DHB on a wholesalesupply order signed by the paediatrician. Limited to one pack of 20 per order. Orders via ahospital pharmacy. b) Only available for children aged six years and under. c) For Space Chamber and Foremount Child's Silicone Mask wholesale supply order must indicate clearly if either the spacer device, the mask, or both are required. d) Distributed by Airflow Products. Forward orders to: Airflow ProductsPO Box 1485 Telephone: 04 499 1240 or 0800 AIR FLOWWellington Facsimile: 04 499 1245 or 0800 323 270
Special Authority for Subsidy - Form SA0667Initial application only from a named specialist. Approvals valid for 4 months for applications meeting the following criteria: All of the following: 1 To be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and 2 Patient is less than 18 years of age at commencement of treatment; and 3 Patient has had severe active polyarticular course Juvenile Idiopathic Arthritis (JIA) for 6 months duration or longer; and 4 Patient has tried and not responded to at least three months of oral or parenteral methotrexate at a dose of 10-20mg/m2 weekly in combination with oral corticosteroids (prednisone 0.25 mg/kg); and 5 Patient has tried and not responded to at least three months of oral or parenteral methotrexate (at a dose of 10-15mg/m2 weekly) in combination with one other disease-modifying agent; and 6 Both: 6.1 Either: 6.1.1 Patient has persistent symptoms of poorly-cont
Additional subsidy by endorsement for:Nefazodone tab 100 mg x 56 (Serzone) up to $20.16Nefazodone tab 200 mg x 56 (Serzone) up to $40.32Citalopram tab 20 mg x 28 (Celapram) up to $4.00Citalopram tab 20 mg x 28 (Cipramil) up to $10.00Paroxetine hydrochloride tab 20 mg x 30 (Aropax) up to $35.02is available for patients who: -were taking nefazodone on 1 December 1999 or citalopram on 1 February 2000; or paroxetine hydrochloride on February 2001; or- have previously responded to treatment with nefazodone or citalopram or paroxetinehydrochloride; or- have had a trial of fluoxetine and have had to discontinue due to- inability to tolerate the drug due to side effects; or- failed to respond to an adequate dose and duration of treatment; or- have contraindications to fluoxetine (eg pre-existing significant levels of nausea, breastfeeding, potential drug interactions). The prescription must be endorsed accordingly.
Rapid acting insulin analogues are subsidised when: 1) prescribed with insulin isophane or insulin glargine but are on a different prescription and the prescription is endorsed accordingly; or prescribed on the same prescription as insulin isophane or insulin glargine in which case the prescription is deemed to be endorsed; or2) a Special Authority has been approved. For 1and 2 first prescription to be written by a specialist (diabetologist, general physician or paediatrician). Any medical practitioner can writte subsequent prescriptions.
Special Authority for Subsidy - Form SA0693Initial application only from a relevant specialist or vocationally registered general practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria: All of the following: 1 Severe osteoporosis; and 2 History of one previous significant osteoporotic fracture demonstrated radiologically; and 3 T-Score <= -3.0 (bone mass density (BMD) >= 3.0 standard deviations below the mean normal value in young adults). NoteIn line with the Australian guidelines for funding alendronate, a vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral bodyRenewal - ((2 year approvals granted before February 2002)) only from a geriatrician, rheumatologist, endocrinologist, gynaecologis
Subsidy is available for patients with poorly controlled asthma where: a) at least three months of 750 mcg or more daily of inhaled beclomethasone or budesonide (or 400 mcg or fluticasone) for adults has been used; orb) at least three months of 400 mcg or more daily inhaled beclomethasone or budesonide (or 200 mcg or fluticasone) for children has been used; The prescription must be endorsed accordingly. We recommend that the words used to indicate eligibility are "poor control with ICS" or "certified exemption".
Special Authority for Subsidy - Form SA0696Initial application - (Narcolepsy) only from a neurologist or respiratory specialist. Approvals valid for 24 months where narcolepsy. Initial application - (ADHD in patients 5 or over) only from a paediatrician, psychiatrist or general practitioner on the recommendation of such a specialist. Approvals valid for 24 months for applications meeting the following criteria: All of the following: 1 ADHD (Attention Deficit and Hyperactivity Disorder) patients aged 5 years or over; and 2 Diagnosed according to DSM-IV or ICD 10 criteria; and 3 Either: 3.1 Applicant is a specialist; or 3.2 Both: 3.2.1 Applicant is a GP and a specialist has recommended treatment; and 3.2.2 Provide name of specialist (Details to be attached to application). Initial application - (ADHD in patients under 5) only from a paediatrician or psychiatrist. Approvals valid for 12 months for applications meeting the following criteria: Both: 1 ADHD (Attention Defi
Special Authority for Subsidy - Form SA0698Initial application only from a gastroenterologist, general surgeon or general physician. Approvals valid for 3 months for applications meeting the following criteria: Both: 1 Mild to moderate ileal, ileocaecal or proximal Crohn's disease; and 2 Any of the following: 2.1 Diabetes; or 2.2 Cushingoid habitus; or 2.3 Osteoporosis where there is significant risk of fracture; or 2.4 Severe acne following treatment with conventional corticosteroid therapy. Renewal only from a gastroenterologist, general surgeon or general physician. Approvals valid for 3 months where the treatment remains appropriate and the patient is benefiting from treatment. The patient must have had no more than 1 prior approval in the last year. NoteClinical trials for Entocort CIR use beyond three months demonstrated no improvement in relapse rate.
Special Authority for Subsidy - Form SA0699Initial application from any medical practitioner. Approvals valid for 1 year for applications meeting the following criteria: All of the following: 1 The patient is not predisposed to heart arrhythmias; and 2 The patient does not have a pre-existing QT-prolongation or hepatic failure; and 3 The patient is not using other medications which either inhibit the cytochrome P450 3A4 enzyme system or prolong the QT interval; and 4 Any of the following: 4.1 Both: 4.1.1 adult with severe reflux oesophagitis; and 4.1.2 other treatment, including acid suppression with proton pump inhibitors, has failed; or 4.2 gastroparesis; or 4.3 malignancy of GI tract causing gastroparesis (or gastric outlet obstruction); or 4.4 child (not including infants from 0 to 3 months of age who were born prematurely) with severe gastro-oesophageal reflux; and 5 Diagnosis has been made or confirmed by a general physician, gastroenterologist, or ge
Special Authority for Subsidy - Form SA0700Initial application only from an ophthalmologist. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 Both: 1.1 Monotherapy in primary open-angle glaucoma; and 1.2 Any of the following: 1.2.1 Patient cannot tolerate Beta-blockers, Pilocarpine and Dorzolamide; or 1.2.2 Beta-blockers, Pilocarpine and Dorzolamide are contraindicated; or 1.2.3 A reduction in intraocular pressure of 15% or more is not achieved or maintained using dorzolamide either alone or in combination with a beta-blocker; or 1.2.4 There is progressive visual field loss and/or optic nerve damage persists after treatment with dorzolamide either alone or in combination with a beta-blocker; or 2 Adjunctive use for the treatment of patients who have met the initial application criteria, and in whom latanoprost monotherapy has been ineffective in controlling intraocular pressure.Note An adjunctive agent may be added without a
Special Authority for Subsidy - Form SA0702Initial application - (Oral feed for cystic fibrosis patient) only from a relevant specialist. Approvals valid for 3 years for applications meeting the following criteria: Both: 1 Cystic fibrosis; and 2 Either: 2.1 The product is to be used as a supplement; or 2.2 The product is to be used as a complete diet.Initial application - (Oral feed for indications other than cystic fibrosis) only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria: Both: 1 Any of the following: 1.1 any condition causing malabsorption; or 1.2 failure to thrive; or 1.3 increased nutritional requirements; and 2 Either: 2.1 The product is to be used as a supplement; or 2.2 The product is to be used as a complete diet.Renewal - (Oral feed cystic fibrosis patient) only from a relevant specialist or general practitioner on the recommendation of such a specialist. Approvals valid for 3 years f
Special Authority for Subsidy - Form SA0703Initial application only from a relevant specialist or general practitioner. Approvals valid for 2 years for applications meeting the following criteria: All of the following: 1 Patient has raised blood pressure; and 2 The use of fully funded beta blockers is contraindicated, or not well tolerated; or where use of fully funded beta blockers and diuretics are insufficient to control blood pressure adequately at appropriate doses; and 3 Either: 3.1 Has been treated with, and cannot tolerate two ACE inhibitors, due to persistent cough; or 3.2 Has experienced angioedema on an ACE inhibitor at any time in the past or who have experienced angioedema (even if not using an ACE inhibitor) in the last 2 years. Renewal only from a relevant specialist or general practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0706Initial application only from a relevant specialist or general practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria: Either: 1 Both: 1.1 Patient with congestive heart failure; and 1.2 Either: 1.2.1 Has been treated with, and cannot tolerate, two ACE inhibitors, due to persistent cough; or 1.2.2 Has experienced angioedema on an ACE inhibitor at any time in the past or who have experienced angioedema (even if not using an ACE inhibitor) in the last 2 years; or 2 All of the following: 2.1 Patient with raised blood pressure; and 2.2 Use of fully funded beta blockers or diuretics are contraindicated; or not well tolerated; or insufficient to control blood pressure adequately at appropriate doses; and 2.3 Either: 2.3.1 Has been treated with, and cannot tolerate, two ACE inhibitors, due to persistent cough; or 2.3.2 Has experienced angioedema on an ACE in
Effective, consistent management of herpes from prescribing to these guidelines will improve patient outcomes. The guidelines on the following four pages are for the prescribing of aciclovir. The guidelines aim to: - improve patient care and clinical outcome through faster, more accessible treatment - protect patients' wider wellbeing by reinforcing the psychosocial aspects of treatment - improve the consistency and breadth of medical management of genital herpes in New Zealand. The guidelines are: - integral to ensuring a consistent, effective treatment regimen- the result of consultation with clinicians and patient representatives- set out in line with the recommended international algorithm format for treatment. The guidelines are endorsed by the Herpes Foundation's professional advisory board whose members represent venereology, NZDS, RNZCGP, RNZCOG, psychotherapy and nursing. Herpes Foundation Helpline: Toll free 0508 11 12 13Auckland Branch Herpes Foundation: 09 360 1966
Guidelines for the use of interferon in the treatment of hepatitis C: Physicians considering treatment of patients with hepatitis C should discuss cases with a gastroenterologist or aninfectious disease physician. All subjects undergoing treatment require careful monitoring for side effects. Patients should be otherwise fit. Hepatocellular carcinoma should be excluded by ultrasound examination and alpha-fetoprotein level. Criteria for Treatment a) Diagnosis- Anti-HCV positive on at least two occasions with a positive PCR for HCV-RNA and preferably confirmed by asupplementary RIBA test; or- PCR-RNA positive for HCV on at least 2 occasions if antibody negative; or- Anti-HCV positive on at least two occasions with a positive supplementary RIBA test with a negative PCR forHCV RNA but with a liver biopsy consistent with 2(b) following. b) Establishing Active Chronic Liver Disease- Confirmed HCV infection and serum ALT/AST levels measured on at least three occasions over six monthsaveraging >
Special Authority for Subsidy - Form SA0710Initial application only from an ophthalmologist. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 Either: 1.1 Monotherapy in primary open-angle glaucoma; or 1.2 Adjunctive use for the treatment of open-angle glaucoma in a patient who has met the initial application criteria, and in whom prostaglandin analogue monotherapy has been ineffective in controlling intraocular pressure; and 2 Any of the following: 2.1 Patient cannot tolerate beta-blockers, pilocarpine, and carbonic anhydrase inhibitors; or 2.2 Beta-blockers, pilocarpine and carbonic anhydrase inhibitors are contraindicated; or 2.3 A reduction in intraocular pressure of 15% or more is not achieved or maintained using carbonic anhydrase inhibitor either alone or in combination with a beta blocker; or 2.4 There is progressive visual field loss and/or optic nerve damage persists after treatment with carbonic anhydrase inhibitor either alo
Special Authority for Subsidy - Form SA0714Initial application from any medical practitioner. Approvals valid for 3 months for applications meeting the following criteria: All of the following: 1 Patient is currently enrolled in a recognised comprehensive treatment programme for alcohol dependence in a service accredited against the New Zealand Alcohol and Other Drug Sector Standard or the National Mental Health Sector Standard; and 2 Applicant works in an Alcohol & Drug Service; and 3 Applicant must include the address of the service (Details to be attached to application). Renewal from any medical practitioner. Approvals valid for 3 months for applications meeting the following criteria: Both: 1 Compliance with the medication (prescriber determined); and 2 Any of the following: 2.1 Patient is still unstable and requires further treatment; or 2.2 Patient achieved significant improvement but requires further treatment; or 2.3 Patient is well controlled but requires maint
Prescribing GuidelinesTrusopt, Cosopt and Azopt are subsidised for use as either monotherapy or as an adjunctive agent for the treatment of glaucoma. Trusopt, Cosopt and Azopt should not be prescribed for a person in whom less expensive first line agents for the treatment of glaucoma are not contraindicated unless: a) that person has previously trialled all other such subsidised agents (except brimonidine tartrate); andb) those trials have indicated that that person does not respond adequately to treatment with those other agents.
Special Authority for Manufacturers Price - Form SA0717Initial application only from a relevant specialist or general practitioner. Approvals valid for 12 weeks for applications meeting the following criteria: Both: 1 Patient has a calculated absolute risk of cardiovascular disease of at least 15% over 5 years; and 2 Either: 2.1 Patient has severe documented intolerance to simvastatin; or 2.2 Both: 2.2.1 Patient has been compliant with a dose of simvastatin of 80 mg per day for at least 2 months; and 2.2.2 Either: 2.2.2.1 All of the following: 2.2.2.1.1 Patient has venous CABG; and 2.2.2.1.2 LDL cholesterol test 1 >= 2.0 mmol/litre; and 2.2.2.1.3 LDL cholesterol test 2 >= 2.0 mmol/litre (at least 1 week after test 1); or 2.2.2.2 All of the following: 2.2.2.2.1 Patient does not have venous CABG; and 2.2.2.2.2 LDL cholesterol test 1 >= 2.5 mmol/litre; and 2.2.2.2.3 LDL cholesterol test 2 >= 2.5 mmol/litre (at least 1 w
Special Authority for Subsidy - Form SA0721Initial application only from a named specialist. Approvals valid without further renewal unless notified for applications meeting the following criteria: All of the following: 1 The patient already has a Special Authority approval for anti-retroviral therapy (Details to be attached to application); and 2 Kaletra is to be used as a salvage therapy in place of one protease inhibitor; and 3 The patient must have trialed for at least six months and have failed on currently funded NNRTI based regimens or triple NRTI regimens; and 4 The patient must have trialed for at least six months and have failed on currently funded PI based regimens. NoteFailure is defined as: a) not achieving HIV RNA < 400 copies/ml after 24 weeks of a regimen, orb) an increase of HIV RNA to > 400 copies/ml on two separate occasions not less than one month apart, after suppression to < 400 copies/ml in a patient taking the regimen.
Special Authority for Subsidy - Form SA0723Initial application only from a relevant specialist. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 All of the following: 1.1 Patient has a calculated absolute risk of cardiovascular disease >20% over 5 years; and 1.2 Patient cannot tolerate statin therapy at a dose of 40 mg per day; and 1.3 Either: 1.3.1 All of the following: 1.3.1.1 Patient has venous CABG; and 1.3.1.2 LDL cholesterol >= 2.0 mmol/litre (see note); and 1.3.1.3 LDL cholesterol >= 2.0 mmol/litre (at least 1 week after test 1 - see note); or 1.3.2 All of the following: 1.3.2.1 Patient does not have venous CABG; and 1.3.2.2 LDL cholesterol >= 2.5 mmol/litre (see note); and 1.3.2.3 LDL cholesterol >= 2.5 mmol/litre (at least 1 week after test 1 - see note); or 2 All of the following: 2.1 Patient has homozygous familial hypercholesterolemia, or heterozygous familial hypercholesterol
Special Authority for Manufacturers Price - Form SA0724Initial application only from a relevant specialist or general practitioner. Approvals valid for 12 weeks for applications meeting the following criteria: Both: 1 Patient has a calculated absolute risk of cardiovascular disease of at least 15% over 5 years; and 2 Either: 2.1 Patient has severe documented intolerance to simvastatin (blood tests are not required); or 2.2 Both: 2.2.1 Patient has been compliant with a dose of simvastatin of 80 mg per day for at least 2 months; and 2.2.2 Either: 2.2.2.1 All of the following: 2.2.2.1.1 Patient has venous CABG; and 2.2.2.1.2 LDL cholesterol test 1 >= 2.0 mmol/litre; and 2.2.2.1.3 LDL cholesterol test 2 >= 2.0 mmol/litre (at least 1 week after test 1); or 2.2.2.2 All of the following: 2.2.2.2.1 Patient does not have venous CABG; and 2.2.2.2.2 LDL cholesterol test 1 >= 2.5 mmol/litre; and 2.2.2.2.3 LDL cholesterol test 2 >
Special Authority for Subsidy - Form SA0725Initial application only from a relevant specialist or general practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria: All of the following: 1 Patient with raised blood pressure; and 2 Use of fully funded beta blockers and diuretics are contraindicated; or not well tolerated; or insufficient to control blood pressure adequately at appropriate doses; and 3 Either: 3.1 Has been treated with, and cannot tolerate, two ACE inhibitors, due to persistent cough; or 3.2 Has experienced angioedema on an ACE inhibitor at any time in the past or who have experienced angioedema (even if not using an ACE inhibitor) in the last 2 years. Renewal - (Previous approval has expired) only from a relevant specialist or general practitioner. Approvals valid without further renewal unless notified where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0727Initial application from any medical practitioner. Approvals valid for 1 year for applications meeting the following criteria: All of the following: 1 Control of intractable nausea, vomiting, or inability to swallow saliva in the treatment of malignancy or chronic disease; and 2 Patient cannot tolerate or does not adequately respond to oral anti-nausea agents; and 3 The applicant must specify the underlying malignancy or chronic disease (Details to be attached to application). Renewal from any medical practitioner. Approvals valid for 1 year where the treatment remains appropriate and the patient is benefiting from treatment.
Retail pharmacy - subsidy by endorsement a) Subsidised for:(i) patients presenting with first episode schizophrenia or related psychoses, or manic episodes associated with bipolar disorder; and(ii) patients suffering from schizophrenia or related psychoses, or manic episodes associated with bipolar disorder, after a trial of an effective dose of risperidone that has been discontinued because of unacceptable side effects or inadequate response. b) Initial prescription must be written by a relevant specialist. c) Subsequent prescriptions may be written by a general practitioner. d) The prescription must be endorsed "certified condition".
Special Authority for Subsidy - Form SA0732Initial application only from a relevant specialist. Approvals valid for 3 years for applications meeting the following criteria: Either: 1 dietary management of homocystinuria; or 2 dietary management of maple syrup urine disease. Renewal only from a relevant specialist or general practitioner on the recommendation of such a specialist. Approvals valid for 1 year for applications meeting the following criteria: Both: 1 The treatment remains appropriate and the patient is benefiting from treatment; and 2 General Practitioners must include the name of the specialist and date contacted.
Special Authority for Subsidy - Form SA0733Initial application - (Patient aged over 16) only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria: Both: 1 dietary management of PKU; and 2 blood phenylalanine level < 900 mmol/litre (average of tests over last 12 months). Initial application - (Patient aged 16 or under) only from a relevant specialist. Approvals valid for 3 years where dietary management of PKU.Renewal - (Patient aged over 16) only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria: blood phenylalanine level < 900 mmol/litre (average of tests over last 12 months). Renewal - (Patient aged 16 or under) only from a relevant specialist or general practitioner on the recommendation of such a specialist. Approvals valid for 3 years for applications meeting the following criteria: Both: 1 The treatment remains appropriate and the patient is benefiting from treatment; and 2
GuidelinesIt can cost up to $70,000 a year to keep an adult on protein supplements. Because protein substitutes are so expensive and because they are only effective in controlling PKU if a restricted diet is followed, adults with PKU will be required to demonstrate they are following the prescribed diet by regular blood testing. The requirement for testing applies to those aged over 16 years. Failure to follow an appropriate diet results in high blood phenylalanine levels. Those consistently testing above 15 mg (900 micromol) over a twelve month period will not be able to claim these products as a Special Authority. Specialists will be required to renew applications for their PKU patients every year and, when they do so, will have to submit the results of two blood tests.
Neocate should be used only as a last resort when the infant is unable to absorb any of the above formulae. The objective with each of thees formulae prescribed is to get the infant off them as soon as possible. This may take six months, it may take three years. Because of this, variation on age limit is not regarded as appropriate.These formulae will be available only from a hospital pharmacy. Vivonex Pediatric may be a suitable and less expensive alternative for many children that would otherwise be eligible for a subsidy for Neocate and should, therefore, be tried first in these cases. The subsidy for these products reflects the philosophy that the patient incurs no additional financial burden for purchasing specialised more expensive products.
Special Authority for Subsidy - Form SA0738Initial application only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria: Either: 1 All of the following: 1.1 To be used as monotherapy for patients with type 2 diabetes who after six months of diet and lifestyle changes do not have adequate glycaemic control (inadequate control defined as HbA1c > 8.0% in tests carried out at least two months apart); and 1.2 Metformin is not tolerated or contraindicated. Intolerance and contraindications as defined in the notes below, a minimum of a four week trial period of metformin is required; and 1.3 Sulphonylurea is not tolerated or contraindicated. Overweight patients are only eligible under the criteria of contraindication to sulphonylureas if their body mass index (BMI) exceeds 35; or 2 Both: 2.1 For use in combination with a sulphonylurea when diet and lifestyle changes and a twelve month trial of sulphonylurea results in inadequate glycaem
Special Authority for Subsidy - Form SA0741Initial application only from a psychiatrist. Approvals valid for 2 years for applications meeting the following criteria: Any of the following: 1 Patient with first episode schizophrenia or related psychoses; or 2 Both: 2.1 Patient suffering from schizophrenia and related psychoses; or acute mania in bipolar disorder who is likely to benefit from anti-psychotic treatment; and 2.2 Either: 2.2.1 An effective dose of risperidone had been trialled and has been discontinued because of unacceptable side effects; or 2.2.2 An effective dose of risperidone had been trialled and has been discontinued because of inadequate clinical response after 4 weeks; or 3 The patient has suffered from an acute episode of schizophrenia or bipolar mania and has been treated with olanzapine short-acting intra-muscular injection. Renewal only from a psychiatrist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefit
Special Authority for Subsidy - Form SA0742Initial application - (genotype 1, 4, 5 or 6 infection) from any specialist. Approvals valid for 11 months where patient has chronic hepatitis C, genotype 1, 4, 5 or 6 infection. Initial application - (genotype 2 or 3 infection) from any specialist. Approvals valid for 6 months for applications meeting the following criteria: Both: 1 Patient has chronic hepatitis C, genotype 2 or 3 infection; and 2 Patient has bridging fibrosis or cirrhosis (Metavir stage 3 or 4 or equivalent).
Special Authority for Subsidy - Form SA0743Initial application only from a relevant specialist. Approvals valid for 3 months for applications meeting the following criteria: Both: 1 Patient is terminally ill and is opioid-responsive; and 2 Either: 2.1 is unable to take oral medication; or 2.2 is intolerant to morphine, or morphine is contraindicated..Renewal only from a relevant specialist or general practitioner. Approvals valid for 3 months where the treatment remains appropriate and the patient is benefiting from treatment.
Additional subsidy by endorsement for:Citalopram tab 20 mg x 28 (Celapram) up to $4.00Citalopram tab 20 mg x 28 (Cipramil) up to $10.00Paroxetine hydrochloride tab 20 mg x 30 (Aropax) up to $35.02is available for patients who: -were taking citalopram on 1 February 2000; or paroxetine hydrochloride on February 2001; or- have previously responded to treatment with citalopram or paroxetinehydrochloride; or- have had a trial of fluoxetine and have had to discontinue due to- inability to tolerate the drug due to side effects; or- failed to respond to an adequate dose and duration of treatment; or- have contraindications to fluoxetine (eg pre-existing significant levels of nausea, breastfeeding, potential drug interactions). The prescription must be endorsed accordingly.
Special Authority for Subsidy - Form SA0751Initial application only from an ophthalmologist. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 Either: 1.1 Monotherapy in primary open-angle glaucoma; or 1.2 Adjunctive use for the treatment of open-angle glaucoma in a patient who has met the initial application criteria, and in whom prostaglandin analogue monotherapy has been ineffective in controlling intraocular pressure; and 2 Any of the following: 2.1 Patient cannot tolerate beta-blockers, pilocarpine, and carbonic anhydrase inhibitors; or 2.2 Beta-blockers, pilocarpine and carbonic anhydrase inhibitors are contraindicated; or 2.3 A reduction in intraocular pressure of 15% or more is not achieved or maintained using carbonic anhydrase inhibitor either alone or in combination with a beta blocker; or 2.4 There is progressive visual field loss and/or optic nerve damage persists after treatment with carbonic anhydrase inhibitor either alo
(a) Subsidy is available between 1 March and 30 June of each year for patients who meet the following criteria, as set by the Ministry of Health: a) all people 65 years of age and over; b) people under 65 years of age with: i) the following cardiovascular disease: 1) ischaemic heart disease, 2) congestive heart disease, 3) rheumatic heart disease, 4) congenital heart disease, or 5) cerebo-vascular disease; ii) the following chronic respiratory disease: 1) asthma, if on a regular preventative therapy, or 2) other chronic respiratory disease with impaired lung function; iii) diabetes; iv) chronic renal disease; v) any cancer, excluding basal and squamous skin cancers if not invasive; vi) the following other conditions: 1) autoimmune disease, 2) immune suppression, 3) HIV, 4) transplant recipients, 5) neuromuscular and CNS diseases, 6) haemoglobinopathies, or 7) children on long term aspirin. The following conditions are excluded from funding: i) asthma not requiri
Special Authority for Subsidy - Form SA0754Initial application only from a named specialist. Approvals valid without further renewal unless notified for applications meeting the following criteria: All of the following: 1 The patient already has a Special Authority approval for anti-retroviral therapy (Details to be attached to application); and 2 Kaletra is to be used as a salvage therapy in place of one protease inhibitor; and 3 The patient must have trialed for at least six months and have failed on currently funded NNRTI based regimens or triple NRTI regimens; and 4 The patient must have trialed for at least six months and have failed on currently funded PI based regimens. NoteFailure is defined as: a) not achieving HIV RNA < 400 copies/ml after 24 weeks of a regimen, orb) an increase of HIV RNA to > 400 copies/ml on two separate occasions not less than one month apart, after suppression to < 400 copies/ml in a patient taking the regimen.
Special Authority for Subsidy - Form SA0757Initial application only from a relevant specialist. Approvals valid for 6 months for applications meeting the following criteria: All of the following: 1 The patient is less than 2 years of age; and 2 Intolerant to cows' milk; and 3 Diagnosed as suffering from congenital lactase deficiency. Renewal only from a relevant specialist. Approvals valid for 6 months where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0758Initial application only from a general practitioner or relevant specialist. Approvals valid for 2 years for applications meeting the following criteria: All of the following: 1 To be used for the long-term maintenance treatment of bronchospasm and dyspnoea associated with COPD; and 2 In addition to standard treatment, the patient has trialled a dose of at least 40 mcg ipratropium q.i.d; and 3 The patient's breathlessness >= grade 4 according to the Medical Research Council dyspnoea scale (see note); and 4 FEV1 (litres) < 0.4 x predicted (litres); and 5 Either: 5.1 Patient is not a smoker (for reporting purposes only); or 5.2 Patient is a smoker and been offered smoking cessation councilling; and 6 The patient has been offered annual influenza immunisation. Renewal only from a general practitioner or relevant specialist. Approvals valid for 2 years for applications meeting the following criteria: All of the following: 1
a) Prescribers may code prescriptions "contraceptive" (code "O") when used as indicated for contraception. The period of supply and prescription charge will be as per other contraceptives, as follows: - $3.00 prescription charge (patient co-payment) will apply; - prescription may be written for up to six months supply. b) Prescriptions coded in any other way are subject to the non-contraceptive prescription charges, and the non-contraceptive period of supply. ie. Prescriptions may be written for up to three months supply.
(a) Subsidy is available between 1 March and 30 June of each year for patients who meet the following criteria, as set by the Ministry of Health: a) all people 65 years of age and over; b) people under 65 years of age with: i) the following cardiovascular disease: 1) ischaemic heart disease, 2) congestive heart disease, 3) rheumatic heart disease, 4) congenital heart disease, or 5) cerebo-vascular disease; ii) the following chronic respiratory disease: 1) asthma, if on a regular preventative therapy, or 2) other chronic respiratory disease with impaired lung function; iii) diabetes; iv) chronic renal disease; v) any cancer, excluding basal and squamous skin cancers if not invasive; vi) the following other conditions: 1) autoimmune disease, 2) immune suppression, 3) HIV, 4) transplant recipients, 5) neuromuscular and CNS diseases, 6) haemoglobinopathies, or 7) children on long term aspirin. The following conditions are excluded from funding: i) asthma not requiri
Special Authority for Subsidy - Form SA0772Initial application only from a gastroenterologist, infectious disease specialist, paediatrician or general physician. Approvals valid for 1 year for applications meeting the following criteria: Both: 1 Any of the following: 1.1 All of the following: 1.1.1 HBsAg positive for more than 6 months; and 1.1.2 HBeAg positive or HBV DNA positive defined as >0.6 pg/ml by quantitative PCR at reference laboratory; and 1.1.3 ALT greater than twice upper limit of normal or stage 3 or 4 fibrosis on liver histology clinical/radiological evidence of cirrhosis; or 1.2 HBV DNA positive cirrhosis prior to liver transplantation; or 1.3 HBsAg positive and have had a liver, kidney, heart, lung or bone marrow transplant; or 1.4 Hepatitis B surface antigen positive (HbsAg) patient who is receiving chemotherapy for a malignancy, or who has received such treatment within the previous two months; and 2 All of the following: 2.1 No continuing
Additional subsidy by endorsement for:Paroxetine hydrochloride tab 20 mg x 30 (Aropax) up to $35.02is available for patients who: -were taking paroxetine hydrochloride on February 2001; or- have previously responded to treatment with paroxetinehydrochloride; or- have had a trial of fluoxetine and have had to discontinue due to- inability to tolerate the drug due to side effects; or- failed to respond to an adequate dose and duration of treatment; or- have contraindications to fluoxetine (eg pre-existing significant levels of nausea, breastfeeding, potential drug interactions). The prescription must be endorsed accordingly.
Special Authority for Subsidy - Form SA0774Initial application only from a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Any of the following: 1 The patient has advanced gastrointestinal malignancy; or 2 The patient has metastatic breast cancer*; or 3 Both: 3.1 The patient has poor venous access or needle phobia*; and 3.2 The patient requires a substitute for single agent fluoropyrimidine*. Renewal only from a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Either: 1 The patient requires continued therapy; or 2 The tumour has relapsed and requires re-treatment. Noteindications marked with * are unapproved indications.
Special Authority for Subsidy - Form SA0775Initial application only from a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Both: 1 The patient has metastatic colorectal cancer; and 2 Either: 2.1 To be used for first or second line use as part of a combination chemotherapy regimen; or 2.2 As single agent chemotherapy in fluropyrimidine-relapsed disease. Renewal only from a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Either: 1 The patient requires continued therapy; or 2 The tumour has relapsed and requires re-treatment.
Special Authority for Subsidy - Form SA0776Initial application only from a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Any of the following: 1 Both: 1.1 The patient has ovarian, fallopian* or primary peritoneal cancer*; and 1.2 Either: 1.2.1 Has not received prior chemotherapy; or 1.2.2 Has received prior chemotherapy but has not previously been treated with taxanes; or 2 The patient has metastatic breast cancer; or 3 Both: 3.1 The patient has non-small cell lung cancer; and 3.2 Either: 3.2.1 The patient has advanced disease (stage IIIa or above); or 3.2.2 The patient is receiving combined chemotherapy and radiotherapy; or 4 Both: 4.1 The patient has small-cell lung cancer*; and 4.2 Paclitaxel is to be used as second-line therapy. Renewal only from a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Both: 1 The patient has metastati
Special Authority for Subsidy - Form SA0777Initial application - (Post-transplant) only from a relevant specialist. Approvals valid for 6 months where the patient has B-cell post-transplant lymphoproliferative disorder*. NoteFor no more than 8 treatment cycles. Initial application - (Low-grade lymphomas) only from a relevant specialist. Approvals valid for 6 months where the patient has low grade NHL - relapsed disease following prior chemotherapy. NoteFor no more than 4 treatment cycles. Initial application - (Large cell lymphomas) only from a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Both: 1 The patient has treatment naive large B-cell NHL; and 2 To be used with CHOP (or alternative anthracycline containing multi-agent chemotherapy regime given with curative intent).NoteFor no more than 8 treatment cycles. Renewal - (Low-grade lymphomas) only from a relevant specialist. Approvals valid for 6 months for applications meeting
Special Authority for Subsidy - Form SA0779Initial application - (Confirmed HIV/AIDS) only from a named specialist. Approvals valid without further renewal unless notified for applications meeting the following criteria: Both: 1 Confirmed HIV infection; and 2 Any of the following: 2.1 Symptomatic patient; or 2.2 Patient aged 12 months and under; or 2.3 Both: 2.3.1 Patient aged 1 to 5 years; and 2.3.2 Any of the following: 2.3.2.1 CD4 counts < 1,000 cells/mm3; or 2.3.2.2 CD4 counts < 0.25 x total lymphocyte count; or 2.3.2.3 Viral load counts > 100,000 copies per ml; or 2.4 Both: 2.4.1 Patient aged 6 years and over; and 2.4.2 CD4 counts < 350 cells/mm3. NoteTenofovir disoproxil fumarate prescribed under endorsement for HIV/AIDS is included in the count of up to 3 subsidised antiretrovirals. Subsidies for a combination of up to three anti-retroviral medications, including a maximum of two protease inhibitors. Combinations including r
Special Authority for Subsidy - Form SA0780Initial application - (Single NAED Therapy) only from a paediatrician, neurologist or general physician. Approvals valid for 15 months for applications meeting the following criteria: Any of the following: 1 Was on NAED therapy before 1 September 2000; or 2 Seizures are not adequately controlled with optimal older anti-epilepsy drug treatment; or 3 Seizures are controlled adequately but who experience unacceptable side effects from older anti-epilepsy drug treatment. Note"Optimal older anti-epilepsy drug therapy" is defined as treatment with those older anti-epilepsy drugs which are indicated and clinically appropriate for the patient, given singly and in combination in adequate doses for the patient's age, weight, and other features affecting the pharmacokinetics of the drug with good evidence of complianceInitial application - (Dual NAED Therapy) only from a paediatrician, neurologist or general physician. Approvals valid for 18 months for app
Special Authority for Subsidy - Form: SA0781Initial application only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria: Any of the following: Monotherapy1 All of the following: 1.1 To be used as monotherapy for patients with type 2 diabetes who after six months of diet and lifestyle changes do not have adequate glycaemic control (inadequate control defined as HbA1c > 7.0% in tests carried out at least two months apart); and 1.2 Metformin is not tolerated or contraindicated. Intolerance and contraindications as defined in the notes below, a minimum of a four week trial period of metformin is required; and 1.3 Sulphonylurea is not tolerated or contraindicated. Obesity is only eligible under the criteria of contraindication to sulphonylureas if the patient's body mass index (BMI) exceeds 33 , intolerance as defined in the notes below; orIn combination with sulphonylurea2 Both: 2.1 For use in combination with a sulphonylure
Special Authority for Subsidy - Form SA0782Initial application - (No previous use) only from a relevant specialist or general practitioner. Approvals valid for 6 months for applications meeting the following criteria: All of the following: 1 The patient has a clinical diagnosis of heavy menstrual bleeding; and 2 The patient has failed to respond to or is unable to tolerate other appropriate pharmaceutical therapies as per the Heavy Menstrual Bleeding Guidelines; and 3 Either: 3.1 serum ferritin level < 16 mg/l (within the last 12 months); or 3.2 haemoglobin level < 120 g/l . NoteApplications are not to be made for use in patients as contraception except where they meet the above criteriaInitial application - (Previous use before 1 October 2002) only from a relevant specialist or general practitioner. Approvals valid for 6 months for applications meeting the following criteria: All of the following: 1 The patient had a clinical diagnosis of heavy menstrual bleeding; and 2
Special Authority for Manufacturers Price - Form: SA0783Initial application only from a relevant specialist. Approvals valid for 5 years for applications meeting the following criteria: All of the following: 1 Patient is a postmenopausal women; and2 Patient has hormone receptor positive advanced breast cancer; and3 Any of the following: 3.1 The cancer is advanced (Stage IIIb, or metastatic Stage IV); or 3.2 The patient has a very clear history of intolerance to tamoxifen; or 3.3 The use of tamoxifen is contraindicated due to a history of thromboembolic disease. Renewal only from a relevant specialist. Approvals valid without further renewal unless notified where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Manufacturers Price - Form SA0788Initial application only from a relevant specialist or general practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria: Both: 1 Patient has a calculated absolute risk of cardiovascular disease of at least 15% over 5 years; and 2 Either: 2.1 Patient has severe documented intolerance to simvastatin (blood tests are not required); or 2.2 Both: 2.2.1 Patient has been compliant with a dose of simvastatin of 80 mg per day for at least 2 months; and 2.2.2 Either: 2.2.2.1 All of the following: 2.2.2.1.1 Patient has venous CABG; and 2.2.2.1.2 LDL cholesterol test 1 >= 2.0 mmol/litre; and 2.2.2.1.3 LDL cholesterol test 2 >= 2.0 mmol/litre (at least 1 week after test 1); or 2.2.2.2 All of the following: 2.2.2.2.1 Patient does not have venous CABG; and 2.2.2.2.2 LDL cholesterol test 1 >= 2.5 mmol/litre; and 2.2.2.2.
Special Authority for Subsidy - Form SA0789Initial application only from a relevant specialist or vocationally registered general practitioner. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 The patient has "treatment resistant" depression; and 2 Either: 2.1 The patient must have had a trial of two different antidepressants and failed to respond to an adequate dose over an adequate period of time (usually at least four weeks); or 2.2 Both: 2.2.1 The patient is currently a hospital in-patient as a result of an acute depressive episode; and 2.2.2 The patient must have had a trial of one other antidepressant and failed to respond to an adequate dose over an adequate period of time. Renewal from any medical practitioner. Approvals valid for 2 years where patient has a high risk of relapse (prescriber determined).
Prescribing GuidelineBimatoprost, lantanoprost and travoprost are subsidised for use in the treatment of glaucoma as either monotherapy or as an adjunctive agent for patients in whom prostaglandin analogue monotherapy has been ineffective in controlling intraocular pressure.Bimatoprost, lantanoprost and travoprost should not be prescribed for a person in whom less expensive first line agents for the treatment of glaucoma are not contraindicated unless: 1 That person has previously trialled all other such subsidised agents (beta-blockers, pilocarpine, carbonic anhydrase inhibitors); and2 Those trials have indicated that that person does not respond adequately to treatment with those other agents.
Special Authority for Subsidy - Form: SA0792Initial application only from a psychiatrist. Approvals valid for 6 months for applications meeting the following criteria: All of the following: 1 The patient has schizophrenia or other psychotic disorder; and2 Has tried but failed to comply with treatment using oral atypical anti-psychotic agents; and3 Has been admitted to hospital or treated in respite care, or intensive outpatient or home-based treatment for 30 days or more in last 12 months. Renewal only from a psychiatrist. Approvals valid for 12 months for applications meeting the following criteria: Either: 4 Both: 4.1 The patient has had less than 12 months treatment with risperidone microspheres; and 4.2 There is no clinical reason to discontinue treatment; or5 The initiation of risperidone microspheres has been associated with fewer days of intensive intervention than was the case during a corresponding period of time prior to the initiation of risperidone microspheres. NoteRisp
Special Authority for Subsidy - Form: SA0796Initial application only from a relevant specialist. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 Either: 1.1 ezetimibe is to be used in combination with simvastatin; or 1.2 ezetimibe is to be used without a statin; and2 Either: 2.1 All of the following: 2.1.1 Patient has a calculated absolute risk of cardiovascular disease >20% over 5 years; and 2.1.2 Patient cannot tolerate statin therapy at a dose of 40 mg per day; and 2.1.3 Either: 2.1.3.1 All of the following: 2.1.3.1.1 Patient has venous CABG; and 2.1.3.1.2 LDL cholesterol >= 2.0 mmol/litre (see note); and 2.1.3.1.3 LDL cholesterol >= 2.0 mmol/litre (at least 1 week after test 1 - see note); or 2.1.3.2 All of the following: 2.1.3.2.1 Patient does not have venous CABG; and 2.1.3.2.2 LDL cholesterol >= 2.5 mmol/litre (see note); and 2.1.3.2.3 LDL cholest
Special Authority for Subsidy - Form: SA0797Initial application - (Underlying cause - Osteoporosis) only from a relevant specialist or vocationally registered general practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria: Any of the following: 1 History of one significant osteoporotic fracture demonstrated radiologically and documented bone mass density (BMD) >= 2.5 standard deviations below the mean normal value in young adults (i.e. T-Score <= -2.5); or2 History of one significant osteoporotic fracture demonstrated radiologically and the patient is either over 75 years of age or is too frail* to undergo a bone mass density scan; or3 History of two significant osteoporotic fractures demonstrated radiologically; or4 Documented T-Score <= -3.0. Note*The patient may be considered to be frail if it is expected that there is significant risk of further fracture or other negative health outcome if the patient were to undergo a BMD s
Special Authority for Subsidy - Form: SA0798Initial application only from a relevant specialist. Approvals valid without further renewal unless notified for applications meeting the following criteria: Either: 1 Renal transplant recipient; or2 Heart transplant recipient. or; 3 Patient has an organ transplant and has severe tophaceous gout making azathioprine unsuitableRenewal only from a relevant specialist. Approvals valid without further renewal unless notified where patient had a previous Special Authority approval and was receiving mycophenolate prior to 1 October 2005
Special Authority for Subsidy - Form: SA0799Initial application only from a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Either: 1 The patient has metastatic breast cancer; or2 The patient has non-small cell lung cancer (stage IIIa, or above).Renewal only from a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Either: 3 The patient requires continued therapy; or4 The tumour has relapsed and requires re-treatment.
Special Authority for Subsidy - Form SA0801Initial application - (Serevent Accuhaler, Foradil, Symbicort Turbuhaler) only from a relevant specialist or general practitioner. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 Both: 1.1 Child under the age of 12 with poorly controlled asthma; and 1.2 Either: 1.2.1 Required at least three months of 400 mcg or more daily inhaled beclomethasone or budesonide; or 1.2.2 Required at least three months of 200 mcg or more of fluticasone; or 2 Both: 2.1 Adult with poorly controlled asthma; and 2.2 Either: 2.2.1 Required at least three months of 1500 mcg or more daily inhaled beclomethasone or budesonide; or 2.2.2 Required at least three months of 750 mcg or more of fluticasone. NotePatients are to be reviewed at least at six months to assess compliance and effectiveness of therapy. Special Authority approvals are interchangeable among all presentations of inhaled long-acting beta
Special Authority for Subsidy - Form SA0802Initial application - (genotype 1, 4, 5 or 6 infection or co-infection with HIV) from any specialist. Approvals valid for 11 months for applications meeting the following criteria: 1. Patient has chronic hepatitis C, genotype 1, 4, 5 or 6 infection; or2. Patient has chronic hepatitis C and is co-infected with HIV. Note: consider stopping treatment if there is absence of a virological response (defined as at least a 2-log reduction in viral load) following 12 weeks of treatment since this is predictive of treatment failure.Initial application - (genotype 2 or 3 infection without co-infection with HIV) from any specialist. Approvals valid for 6 months for applications meeting the following criteria: 3. Patient has chronic hepatitis C, genotype 2 or 3 infection; andEither: 3.1 Patient has bridging fibrosis or cirrhosis (Metavir stage 3 or 4 or equivalent); or 3.2 is unsuitable for liver biopsy due to coagulopathy.
Special Authority for Subsidy - Form SA0803Initial application from any specialist. Approvals valid for 11 months for applications meeting the following criteria: either: 1 Patient has chronic hepatitis C, genotype 1, 4, 5 or 6 infection; or2 Patient has chronic hepatitis C, genotype 2 or 3 infection; and 2.1 With has bridging fibrosis or cirrhosis (Metavir stage 3 or 4, or equivalent). 2.2 is unsuitable for liver biopsy due to coagulopathy. Note: consider stopping treatment if there is absence of a virological response (defined as at least a 2-log reduction in viral load) following 12 weeks of treatment since this is predictive of treatment failure.
Prescribing Guideline for Inhaled Long-Acting Beta-Adrenoceptor AgonistsThe addition of inhaled long-acting beta-adrenoceptor agonists (LABAs) to inhaled corticosteroids is recommended: - For younger children (aged under 12 years) where asthma is poorly controlled despite using inhaled corticosteroids for at least three months at total daily doses of 200 mcg beclomethasone or budesonide (or 100 mcg fluticasone).- For adults and older children (aged 12 years and over) where asthma is poorly controlled despite using inhaled corticosteroids for at least three months at total daily doses of 400 mcg beclomethasone or budesonide (or 200 mcg fluticasone).Note: Further information on the place of inhaled corticosteroids and inhaled LABAs in the management of asthma can be found in the New Zealand guidelines for asthma in adults (www.nzgg.org.nz) and in the New Zealand guidelines for asthma in children aged 1-15 (www.paediatrics.org.nz).
Access by applicationa) Budget managed by appointed clinicians on the Multiple Sclerosis Treatment Assessments Committee (MSTAC). b) Applications will be considered by MSTAC at its regular meetings and approved subject to eligibility according to the Entry and Stopping criteria (below). c) Applications to be made on the approved forms which are available from the co-ordinator for MSTAC:The Co-ordinator Phone: (04) 460 4990Multiple Sclerosis Treatment Assessments Committee Facsimile: (04) 916 7571PHARMAC, PO Box 10 254 E mail: silvia.valsenti@pharmac.govt.nzWellingtond) Completed application forms must be sent to the co-ordinator for MSTAC and will be considered by MSTAC at the next practicable opportunity. e) Notification of MSTAC's decision will be sent to the patient, the applying clinician and the patient's GP (if specified). f) These agents will not be subsidised if dispensed from a community or hospital pharmacy. Regular supplies will be distributed to all approved patients or their c
Special Authority for Subsidy Initial application only from a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: 1 The patient has metastatic colorectal cancer; and2 To be used for first or second line use as part of a combination chemotherapy regimen. Renewal only from a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: 3 The patient requires continued therapy; or4 The tumour has relapsed and requires re-treatment.
Special Authority for Subsidy - Form: SA0809Initial application only from a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Any of the following: 1 Both: 1.1 The patient has ovarian*, fallopian* or primary peritoneal cancer*; and 1.2 Either: 1.2.1 Has not received prior chemotherapy; or 1.2.2 Has received prior chemotherapy but has not previously been treated with taxanes; or2 The patient has metastatic breast cancer; or3 Both: 3.1 The patient has non small-cell lung cancer; and 3.2 Either: 3.2.1 Has advanced disease (stage IIIa or above); or 3.2.2 Is receiving combined chemotherapy and radiotherapy; or4 Both: 4.1 The patient has small-cell lung cancer*; and 4.2 Docetaxel is to be used as second-line therapy. Renewal only from a relevant specialist. Approvals valid for 12 months for applications meeting the followingcriteria: 5. The patient has metastatic breast cancer, non small-cell lung cancer,
Special Authority for Alternate SubsidyInitial application only from a relevant specialist. Approvals valid for 5 years for applications meeting the following criteria: All of the following: 1 Patient is a postmenopausal women; and2 Patient has hormone receptor positive breast cancer; and3 Any of the following: 3.1 The cancer is advanced (Stage IIIb, or metastatic Stage IV); or 3.2 The patient has a very clear history of intolerance to tamoxifen; or 3.3 The use of tamoxifen is contraindicated due to a history of thromboembolic disease. Renewal only from a relevant specialist. Approvals valid without further renewal unless notified where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Alternate SubsidyInitial application only from a relevant specialist. Approvals valid for 5 years for applications meeting the following criteria: All of the following: 1 Patient is a postmenopausal women; and2 Patient has hormone receptor positive breast cancer; and3 Any of the following: 3.1 The cancer is advanced (Stage IIIb, or metastatic Stage IV); or 3.2 The patient has a very clear history of intolerance to tamoxifen; or 3.3 The use of tamoxifen is contraindicated due to a history of thromboembolic disease. Renewal only from a relevant specialist. Approvals valid without further renewal unless notified where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for SubsidyInitial application only from a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria: All of the following1 Patient is an adult who has had severe and active erosive Rheumatoid Arthritis for six months duration or longer; and2 Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and3 Patient has tried and not responded to at least three months of oral or parenteral methotrexate at a dose of at least 20 mg weekly or a maximum tolerated dose; and4 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with at least two of the following (triple therapy): sulphasalazine, prednisone at a dose of at least 7.5 mg per day, azathioprine, intramuscular gold, or hydroxychloroquine sulphate (at maximum tolerated doses); and5 Patient has tried and not responded to at least three months therapy at th
Special Authority for Subsidy Initial application only from a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Any of the following: 1 The patient has non small cell lung carcinoma (stage IIIa, or above); or2 The patient has advanced malignant mesothelioma*; or3 The patient has advanced pancreatic carcinoma; or4 The patient has ovarian, fallopian tube* or primary peritoneal carcinoma*. Renewal only from a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Both: 5 The patient requires continued therapy; or6 The tumour has relapsed and requires re-treatment. Note indications marked with a * are unapproved indications.
Special Authority for Subsidy Initial application only from a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Both: 1 The patient has primary thrombocythaemia; and2 Either 2.1 is at high risk (previous thromboembolic disease, bleeding or platelet count >1500/ml); or 2.2 is intolerant or refractory to hydroxyurea or interferon. Renewal only from a relevant specialist. Approvals valid for 12 months where the treatment remains appropriate and the patient is benefiting from treatment. NoteIt is recommended that treatment with anagrelide be initiated only on the recommendation of a haematologist.
Special Authority for Subsidy Initial application - (for new patients) only from a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Both: 1 The patient has refractory, progressive or relapsed multiple myeloma; and2 The patient has received prior chemotherapy. Initial application - (for patients receiving thalidomide prior to 1 January 2006) only from a relevant specialist. Approvals valid without further renewal where the patient was receiving treatment with thalidomide for multiple myeloma on or before 31 December 2005. Renewal only from a relevant specialist. Approvals valid without further renewal where the patient has obtained a response from treatment during the initial approval period. Note: Prescription must be written by registered prescriber in the thalidomide risk management programme operated by the supplier. Maximum dose of 400 mg daily as monotherapy or in a combination therapy regimen.
Special Authority for Subsidy Initial application for patients with type 2 diabetes only from a relevant specialist. Approvals valid for one year for applications meeting the following criteria: Any of the following: Monotherapy1 All of the following: 1.1 To be used as monotherapy for patients who after six months of diet and lifestyle changes have inadequate glycaemic control (defined as HbA1c > 7.0% in tests carried out at least two months apart); and 1.2 Metformin is contraindicated or not tolerated after a minimum of a four week trial period; and 1.3 Sulphonylurea is contraindicated or not tolerated or the patient's body mass index (BMI) exceeds 33 kg/m2; orIn combination with sulphonylurea2 Both: 2.1 For use in combination with a sulphonylurea for patients who after diet and lifestyle changes and a six-month trial of sulphonylurea have poor glycaemic control (defined as HbA1c > 8.0% measured within the last month of the six month period); and 2.2 Metformin is contrain
Perindopril and trandolapril will be funded to the level of the ex-manufacturer price listed in the Schedule for patients who were taking these ACE inhibitors for the treatment of congestive heart failure prior to 1 June 1998. The prescription must be endorsed accordingly. We recommend that the words used to indicate eligibility are "certified condition" or an appropriate description of the patient such as "congestive heart failure", "CHF", "congestive cardiac failure" or "CCF". Definition of Congestive Heart Failure At the request of some prescribers the PTAC Cardiovascular subcommittee has provided a definition of congestive heart failure for the purposes of the funding of the manufacturer's surcharge: "Clinicians should use their clinical judgement. Existing patients would be eligible for the funding of the surcharge if the patient shows signs and symptoms of congestive heart failure, and requires or has in the past required concomitant treatment with a diuretic. The definition could also be considere
Special Authority for Subsidy - Form: SA0826Initial application only from a relevant specialist. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 All of the following: 1.1 Patient has a calculated absolute risk of cardiovascular disease >20% over 5 years; and 1.2 Patient cannot tolerate statin therapy at a dose of >= 40 mg per day; and 1.3 Either: 1.3.1 All of the following: 1.3.1.1 Patient has venous CABG; and 1.3.1.2 LDL cholesterol >= 2.0 mmol/litre (see note); and 1.3.1.3 LDL cholesterol >= 2.0 mmol/litre (at least 1 week after test 1 - see note); or 1.3.2 All of the following: 1.3.2.1 Patient does not have venous CABG; and 1.3.2.2 LDL cholesterol >= 2.5 mmol/litre (see note); and 1.3.2.3 LDL cholesterol >= 2.5 mmol/litre (at least 1 week after test 1 - see note); or2 All of the following: 2.1 Patient has homozygous familial hypercholesterolemia, or heterozygous familial hypercholest
Special Authority for Subsidy - Retail Pharmacy - Form SA0829Initial Application only from gastroenterologist or infectious disease specialist. Approvals valid for 1 year for applications meeting the following criteria: All of the following: 1. Patient has confirmed Hepatitis B infection (HBsAg+); andDocumented resistance to lamivudine, defined as: 2. patient has raised serum ALT (> 1 x ULN); and3. patient has HBV DNA greater than 100,000 copies per mL, or viral load ? 10 fold over nadir; and4. detection of M204I or M204V mutation; and5. Either5.1. Both5.1.1. patient is cirrhotic; and5.1.2. adefovir dipivoxil to be used in combination with lamivudine; or5.2. Both5.2.1. patient is not cirrhotic; and5.2.2. adefovir dipivoxil to be used as monotherapyRenewal only from a gastroenterologist or infectious disease specialist. Approvals valid for 2 years for applications where in the opinion of the treating physician, treatment remains appropriate and patient is benefiting from treatmen
Special Authority for Subsidy - Form: SA0831Application only from a relevant specialist. Approvals valid for 10 months for applications meeting the following criteria: 1. Patient has newly diagnosed glioblastoma multiforme; and2. Temozolomide is to be (or has been) given concomitantly with radiotherapy; and3. Following concomitant treatment temozolomide is to be used for a maximum of six cycles of 5 days treatment, at a maximum dose of 200 mg/m2. Note: Temozolomide is not subsidised for the treatment of relapsed glioblastoma multiforme. Studies of temozolomide show that its benefit is predominantly in those patients with a good performance status (WHO grade 0 or 1 or Karnofsky score >80), and in patients who have had at least a partial resection of the tumour.
Special Authority for Subsidy - Form: SA0832Initial application only from a gastroenterologist, infectious disease specialist, paediatrician or general physician. Approvals valid for 1 year for applications meeting the following criteria: Both: 1 Any of the following: 1.1 All of the following: 1.1.1 HBsAg positive for more than 6 months; and1.1.2 HBeAg positive or HBV DNA positive defined as > 100,000 copies per ml by quantitative PCR at a reference laboratory; and1.1.3 ALT greater than twice upper limit of normal or bridging fibrosis or cirrhosis (Metavir stage 3 or 4 or equivalent) on liver histology or clinical/radiological evidence of cirrhosis; or 1.2 HBV DNA positive cirrhosis prior to liver transplantation; or1.3 HBsAg positive and have had a liver, kidney, heart, lung or bone marrow transplant; or1.4 Hepatitis B surface antigen positive (HbsAg) patient who is receiving chemotherapy for a malignancy, or who has received such treatment within the previous two months;
Special Authority for Subsidy - Form SA0833Initial application only from a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Any of the following: 1 The patient has non small cell lung carcinoma (stage IIIa, or above); or2 The patient has advanced malignant mesothelioma*; or3 The patient has advanced pancreatic carcinoma; or4 The patient has ovarian, fallopian tube* or primary peritoneal carcinoma*; or5 The patient has advanced transitional cell carcinoma of the urothelial tract (locally advanced or metastatic). Renewal only from a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Both: 6 The patient requires continued therapy; or 7 The tumour has relapsed and requires re-treatment. Note indications marked with a * are unapproved indications.
Special Authority for Subsidy - Form: SA0834Initial application only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria: Either: 1 Both: 1.1 Patient has type 1 diabetes and has received an intensive regimen (injections at least three times a day) of an intermediate acting insulin in combination with a rapid acting insulin analogue for at least three months; and1.2 Either: 1.2.1 Patient has experienced more than one unexplained severe hypoglycaemic episode in the previous 12 months (severe defined as requiring the assistance of another person); or1.2.2 Patient has experienced unexplained symptomatic nocturnal hypoglycaemia, biochemically documented at <3.0 mmol/L, more than once a month despite optimal management; or2 Patient has documented severe, or continuing, systemic or local allergic reaction to existing insulins. Note this does not include hypoglycaemic episodes. Renewal only from a relevant specialist or general practitioner. Approv
Special Authority for Subsidy - Form SA0835Initial application - (Breast cancer) from any medical practitioner. Approvals valid for 1 year: where the patient is a premenopausal woman with breast cancer. Initial application - (Prostate cancer) only from an oncologist, urologist or endocrinologist. Approvals valid for 1 year for applications meeting the following criteria: Advanced prostatic cancer;. Note Not to be prescribed with an anti-androgen except for a period of three weeks, if necessary, when GnRH analogue therapy is initiated. Initial application - (Endometriosis) only from a gynaecologist. Approvals valid for 3 months for applications meeting the following criteria: Both: 1 Endometriosis; and2 Either: 2.1 6 months treatment with medroxyprogesterone acetate, danazol or dimetriose has proven ineffective; or2.2 The patient has failed to tolerate the treatment with medroxyprogesterone acetate, danazol or dimetriose for 6 months. Note The maximum treatment period for a GnRH analogue is:
Special Authority for Subsidy - Form SA0836Initial application - (Breast cancer) from any medical practitioner. Approvals valid for 1 year where the patient is a premenopausal woman with breast cancer. Initial application - (Prostate cancer) only from an oncologist, urologist or endocrinologist. Approvals valid for 1 year for applications meeting the following criteria: Either: 1 Advanced prostatic cancer; or. 2 Locally advanced prostatic cancer. Note Not to be prescribed with an anti-androgen except for a period of three weeks, if necessary, when GnRH analogue therapy is initiated. Initial application - (Endometriosis) only from a gynaecologist. Approvals valid for 3 months for applications meeting the following criteria: Both: 3 Endometriosis; and4 Either: 4.1 6 months treatment with medroxyprogesterone acetate, danazol or dimetriose has proven ineffective; or4.2 The patient has failed to tolerate the treatment with medroxyprogesterone acetate, danazol or dimetriose for 6 months. Note
Special Authority for Subsidy - Form SA0837Initial application - (Breast cancer) from any medical practitioner. Approvals valid for 1 year where the patient is a premenopausal woman with breast cancer. Initial application - (Prostate cancer) only from an oncologist, urologist or endocrinologist. Approvals valid for 1 year where the patient has: Advanced prostatic cancer;. Note Not to be prescribed with an anti-androgen except for a period of three weeks, if necessary, when GnRH analogue therapy is initiated. Initial application - (Endometriosis) only from a gynaecologist. Approvals valid for 3 months for applications meeting the following criteria: Both: 1 Endometriosis; and2 Either: 2.1 6 months treatment with medroxyprogesterone acetate, danazol or dimetriose has proven ineffective; or2.2 The patient has failed to tolerate the treatment with medroxyprogesterone acetate, danazol or dimetriose for 6 months. Note The maximum treatment period for a GnRH analogue is: - 3 months to assess whet
Special Authority for Subsidy - Form: SA0838Initial Application only from a relevant specialist or General Practitioner. Approvals valid for 2 years forapplications meeting the following criteria: Either: 1 All of the following: 1.1 Patient is a child under the age of 12; and1.2 All of the following: Has, for 3 months or more, been treated with:1.2.1 An inhaled long-acting beta adrenoceptor agonist; and1.2.2 Inhaled corticosteroids at a dose of at least 400 mcg per day beclomethasone or budesonide, or200 mcg per day fluticasone; and1.3 The prescriber considers that the patient would receive additional clinical benefit from switching to acombination product; or2 All of the following: 2 .1 Patient is over the age of 12; and2 .2 All of the following: Has, for 3 months or more, been treated with:2 .2.1 An inhaled long-acting beta adrenoceptor agonist; and2 .2.2 Inhaled corticosteroids at a dose of at least 800 mcg per day beclomethasone or budesonide, or500 mcg per day fluticasone;
Special Authority for Subsidy - Form SA0839Initial application - (Breast cancer) from any medical practitioner. Approvals valid for 1 year where the patient is a premenopausal woman with breast cancer. Initial application - (Prostate cancer) only from an oncologist, urologist or endocrinologist. Approvals valid for 1 year for applications meeting the following criteria: Either: 1 Advanced prostatic cancer; or. 2 Neoadjuvant or adjuvant treatment of locally advanced prostatic cancer. Note Not to be prescribed with an anti-androgen except for a period of three weeks, if necessary, when GnRH analogue therapy is initiated. Initial application - (Endometriosis) only from a gynaecologist. Approvals valid for 3 months for applications meeting the following criteria: Both: 3 Endometriosis; and4 Either: 4.1 6 months treatment with medroxyprogesterone acetate, danazol or dimetriose has proven ineffective; or4.2 The patient has failed to tolerate the treatment with medroxyprogesterone acetate, danazo
Special Authority for Subsidy - form: SA0841Initial application only from a gastroenterologist or general physician. Approvals valid for 6 months for applications meeting the following criteria: Both: 1 Primary biliary cirrhosis confirmed by antimitochondrial antibody titre (AMA) > 1:80, and raised cholestatic liver enzymes with or without raised serum IgM or, if AMA is negative, by liver biopsy; and2 Patient not requiring a liver transplant (bilirubin > 170umol/l; decompensated cirrhosis). NoteLiver biopsy is not usually required for diagnosis but is helpful to stage the diseaseRenewal only from a gastroenterologist or general physician. Approvals valid for 2 years for applications meeting the following criteria: The treatment remains appropriate and the patient is benefiting from treatment. NoteActigall is not an appropriate therapy for patients requiring a liver transplant (bilirubin > 170 micromol/l; decompensated cirrhosis). These patients should be referred to an appropriate transp
Special Authority for Subsidy - Form: SA842Initial application only from a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Any of the following: 1 Both: 1.1 The patient has ovarian, fallopian* or primary peritoneal cancer*; and 1.2 Either: 1.2.1 Has not received prior chemotherapy; or 1.2.2 Has received prior chemotherapy but have not previously been treated with taxanes; or2 The patient has metastatic breast cancer; or3 The patient has node-positive early breast cancer; or4 Both 4.1 The patient has non small-cell lung cancer; and 4.2 Either: 4.2.1 Has advancing disease (stage IIIa or above); or 4.2.2 Is receiving combined chemotherapy and radiotherapy; or5 Both: 5.1 The patient has small-cell lung cancer*; and 5.2 Paclitaxel is to be used as second-line therapy. Renewal only from a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: 6 The patient has metasta
Special Authority for Subsidy - Form SA0028Initial application only from a relevant specialist. Approvals valid for 6 months for applications meeting the following criteria: Either: 1 All of the following: 1.1 Treatment with other lipid modifying medicines has been unsuccessful; and 1.2 6 months of dietary modification has been unsuccessful; and 1.3 Cholesterol level > 7.0 mmol/litre; and 1.4 Either: 1.4.1 Familial hypercholesterolaemia; or 1.4.2 Manifest coronary heart disease, which has been clinically proven, or previously treated by coronary artery surgery; or 2 Cholesterol level > 9.0 mmol/litre:.Renewal only from a general practitioner. Approvals valid for 6 months where the treatment remains appropriate and the patient is benefiting from treatment. NoteFamilial hypercholesterolaemia is defined as being hypercholesterolaemia in the presence of tendon xanthomas or in association with a family history of premature heart disease (before age 55) or consisten
Unapproved medication supplied under Section 29 of the Medicines Act 1981. Practitioners prescribing this medication should: (a) be aware of and comply with their obligations under Section 29 of the Medicines Act 1981 and otherwise under that Act and the Medicines Regulations 1984; (b) be aware of and comply with their obligations under the Health and Disability Commissioner's Code of Consumer Rights, including the requirement to obtain informed consent from the patient (PHARMAC recommends that Practitioners obtain written consent); and(c) exercise their own skill, judgment, expertise and discretion, and make their own prescribing decisions with respect to the use of an unapproved Pharmaceutical or a Pharmaceutical for an indication for which it is not approved.
Special Authority for Manufacturers Price - Form SA0035Initial application from any medical practitioner. Approvals valid for 5 years for applications meeting the following criteria: Both: 1 Either: 1.1 Both: 1.1.1 Duodenal and gastric ulcers, reflux oesophagitis and Zollinger-Ellison syndrome; and 1.1.2 Other treatments have failed; or 1.2 Patients who are on a Social Welfare benefit or an income no greater than a benefit; and 2 Patients must have endoscopically demonstrated lesions prior to commencement of treatment.. Renewal from any medical practitioner. Approvals valid for 5 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0045Initial application from any medical practitioner. Approvals valid for 2 years for applications meeting the following criteria: All of the following: 1 Continuation of treatment commenced prior to 1 August 1990; and 2 Alternatives (salbutamol and terbutaline) have been tried; and 3 Either: 3.1 Asthma; or 3.2 Chronic obstructive airways disease (COAD); and 4 Applicants must provide details of dose. Renewal from any medical practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0047Initial application only from a paediatrician or respiratory specialist. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 Child under 2 years of age; or 2 Both: 2.1 Child with major physical or intellectual disabilities; and 2.2 Lacks the necessary coordination to use aerosols with a spacer device. NoteThe cost of nebuliser therapy greatly exceeds other inhaled forms. Steroid nebulising solution can cause cataract formation. Renewal only from a paediatrician or respiratory specialist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0057Initial application only from a psychiatrist. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 Depression; and 2 Any of the following: 2.1 Both: 2.1.1 Failed trials with other antidepressants; and 2.1.2 Patient has been maintained on mianserin prior to December1993; or 2.2 Co-existent bladder neck obstruction; or 2.3 Cardiovascular disease. Renewal only from a psychiatrist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Manufacturers Price - Form SA0070Initial application only from a respiratory specialist or infectious disease specialist. Approvals valid for 2 years for applications meeting the following criteria: Any of the following: 1 Avium intracellular atypical mycobacterial infections; or 2 Multiple drug resistant tuberculosis; or 3 Atypical and drug-resistant mycobacterial infections in patients with AIDS. Renewal only from a respiratory specialist or infectious disease specialist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
a) All patients with AIDS meeting the definition developed by the Centres for Disease Control in the USA (see Circular Letter to Medical Practitioners HP2/88)b) Patients with AIDS Related Complex (ARC)c) HIV infected patients with CD4 (T4) counts below 500 regardless of symptomatologyd) Prophylactically for persons following severe parenteral exposure from a known HIV positive sourcee) HIV infected persons with associated thrombocytopenia regardless of CD4 (T4) count f) Applications can only be made by appropriate specialists. Prescriptions for those patients approved to use these medicines can be written either by the specialist or general practitioner with an endorsement of the name of the recommending specialist. g) Prescriptions for these can be written for a period of three months' supply. However, medicine must be dispensed on a monthly basis.
Special Authority for Subsidy - Form SA0089Initial application - (Breast or prostatic cancer) only from an oncologist, urologist or endocrinologist. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 Breast cancer in pre menopausal women unwilling or unable to undergo surgical or radiation oophorectomy; or 2 Advanced prostatic cancer when orchidectomy is contraindicated. Initial application - (Endometriosis) only from a gynaecologist. Approvals valid for 6 months for applications meeting the following criteria: Both: 1 Endometriosis; and 2 Either: 2.1 6 months treatment with medroxyprogesterone acetate, danazol or dimetriose has proven ineffective; or 2.2 The patient has failed to tolerate the treatment with medroxyprogesterone acetate, danazol or dimetriose for 6 months. NoteThe maximum treatment period for a GnRH analogue is: 3 months to assess whether surgery is appropriate3 months for infertile patients after surgery6 months for
Special Authority for Subsidy - Form SA0096Initial application - (Organ transplant, Bone marrow transplant or Graft v host disease) only from a relevant specialist. Approvals valid for 2 years for applications meeting the following criteria: Any of the following: 1 Organ transplant; or 2 Bone marrow transplant; or 3 Graft v host disease. Initial application - (Psoriasis) only from a dermatologist. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 Psoriasis; and 2 Other systemic and topical therapy has failed. Initial application - (Severe atopic dermatitis) only from a dermatologist. Approvals valid for 6 months for applications meeting the following criteria: Both: 1 Severe atopic dermatitis; and 2 Not resopnsive to topical therapy, oral antihistamines and other commonly used orthodox therapies. Initial application - (Nephrotic Syndrome) from any medical practitioner. Approvals valid for 2 years for applications meeting the following cri
Special Authority for Subsidy - Form SA0097Initial application - (Chronic hepatitis C) only from a relevant specialist. Approvals valid for 6 months where chronic hepatitis C. Initial application - (Indications other than Chronic hepatitis C) only from a relevant specialist. Approvals valid for 5 years for applications meeting the following criteria: Any of the following: 1 Chronic myelogenous leukaemia; or 2 Hairycell leukaemia; or 3 Cutaneous T cell lymphoma; or 4 Essential thrombocythaemia; or 5 AIDS related Kaposi's sarcoma; or 6 Multiple myeloma; or 7 Chronic active hepatitis B. Renewal - (Chronic hepatitis C) only from a relevant specialist. Approvals valid for 6 months where the treatment remains appropriate and the patient is benefiting from treatment. Renewal - (Indications other than Chronic hepatitis C) only from a relevant specialist. Approvals valid for 5 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0099Initial application only from a relevant specialist. Approvals valid for 5 years for applications meeting the following criteria: Any of the following: 1 Both: 1.1 Acromegaly; and 1.2 Patients who have failed surgery, radiotherapy, bromocriptine and other oral therapies; or 2 Both: 2.1 Either: 2.1.1 Vipomas; or 2.1.2 Glucagonomas; and 2.2 Patients who are seriously ill in order to improve their clinical state prior to definitive surgery; or 3 Both: 3.1 Gastrinoma; and 3.2 Either: 3.2.1 Patient has failed surgery; or 3.2.2 Patient is in metastatic disease after H2 antagonists (or omeprazole) have failed; or 4 Both: 4.1 Insulinomas; and 4.2 Surgery is contraindicated or where surgery has failed; or 5 Pre-operative control of hypoglycaemia; or 6 Maintenance therapy. NoteThe use of octreotide in patients with fistulae, oesophageal varices, miscellaneous diarrhoea and hypotension will
Special Authority for Subsidy - Form SA0100Initial application only from a relevant specialist. Approvals valid for 5 years for applications meeting the following criteria: All of the following: 1 Anaemia of end-stage renal failure (other treatable causes of anaemia being excluded); and 2 Been on haemodialysis or continuous ambulatory peritoneal dialysis (CAPD) for at least three months; and 3 Not under evaluation for, or awaiting, a live donor kidney transplant; and 4 Any of the following: 4.1 Anephric; or 4.2 Dependent on regular blood transfusion (1 unit each 4-8 weeks) to maintain haemoglobin > 60g/L; or 4.3 Cannot be transfused because of severe transfusion reactions; or 4.4 Transfusion induced haemosiderosis (clinical manifestations, serum ferritin >1500 ug/L); or 4.5 Haemoglobin < 70 g/L (mean of at least 4 haemoglobin concentrations over 4 months); or 4.6 Both: 4.6.1 Haemoglobin < 90 g/L; and 4.6.2 Either: 4.6.2.1 Heart failure (low card
Special Authority for Subsidy - Form SA0115Initial application - (Oesophageal stricture) only from a general practitioner or relevant specialist. Approvals valid for 2 years where patient with oesophageal stricture who is unable to take capsules. Initial application - (Indications other than oesophageal stricture) only from a paediatrician. Approvals valid for 2 years for applications meeting the following criteria: All of the following: 1 infant or child with liver disease or short gut syndrome; and 2 Requires vitamin supplementation; and 3 Unable to swallow capsules. Renewal only from a general practitioner, relevant specialist or paediatrician. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0125Initial application - (Chronic post-thrombotic venous stasis ulcers) from any medical practitioner. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 Chronic post-thrombotic venous stasis ulcers of more than 4 months duration; and 2 Other interventions have failed. Initial application - (Sudden hearing loss) only from an otolaryngologist. Approvals valid for 2 years where sudden hearing loss. Renewal from any medical practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
a) Should be strictly reserved for use as second line therapy in: - patients unable to tolerate the other medications, such as infants, young children and patients with allergies or eczema- cases of scabies which are resistent to gamma benzene hexachlorideb) Verification of drug resistance is dependent on the persistence of the condition after treatment. In order to establish whether there is drug resistance, the following criteria should be fulfilled: - a definite diagnosis of scabies should be made- it should be ascertained that the medication was administered properly- the possibility of reinfestation should have been excluded
Approvals for a CHEM number to waive the premium in the following circumstances: 1. Patients with prosthetic heart valves - as an adjunct to oral anticoagulation for prophylaxis of thromboembolism (2 year approval with renewal, applications only from cardiothoracic surgeons, cardiologists and general physicians). 2. Patients after coronary artery vein bypass graft - as an adjunct to aspirin (1 year approval only, applications only from cardiothoracic surgeons, cardiologists and general physicians). 3. Patients who continue to have transient ischaemic episodes despite aspirin therapy. A course of up to six months in combination with aspirin. Applications only from neurologists, cardiologists, vascular surgeons and general physicians. Six month approval only. Reapplications only if there is demonstrated recurrence of symptoms when dipyridamole therapy is discontinued. Note: these transitional criteria are currently being reviewed.
a) Approvals to fund the manufacturer's surcharge in the following circumstances: - Patients with prosthetic heart valves - as an adjunct to oral anticoagulation for prophylaxis of thromboembolism (2 year approval with renewal, applications only from cardiothoracic surgeons, cardiologists and general physicians). - Patients after coronary artery vein bypass graft - as an adjunct to aspirin or as monotherapy for patients who are aspirin intolerant as defined below (1 year approval only, applications only from cardiothoracic surgeons, cardiologists and general physicians); or- Patients who continue to have transient ischaemic episodes despite aspirin therapy or have transient ischaemic episodes and are aspirin intolerant as defined below (2 year approval with renewal, applications only from neurologists, neurosurgeons, cardiologists, vascular surgeons and general physicians). b) Aspirin intolerant patients are defined as those with aspirin induced asthma, urticaria, or anaphylaxi, or those with significant
The new anticonvulsant drugs are restricted to1. neurologists2. paediatric neurologists3. any other prescriber approved in writing by the relevant RHA budget holding manager. The HFA holds a budget for expenditure on the new anticonvulsant drugs. Unless otherwise specified, ultimate authority for approving prescriptions for subsidy lies with the HFA budget holding manager for the new anticonvulsant drugs. The regional divisions of the HFA will be in contact with hospital pharmacists and approved prescribers with more detail of the approval system. GUIDELINES FOR USE OF THE NEW ANTICONVULSANTS ARE AS FOLLOWS: A. Entry criteriaThe following patients are eligible for trial on the new anticonvulsant drugs (NADs)1. Patients who are under the supervision of an approved prescriber, and whose seizures are not adequately controlled with optimal conventional anticonvulsant drug treatment. 2. Patients, who are under the supervision of an approved prescriber, and whose seizures are only controlled adequatel
Special Authority for Subsidy - Form SA0266Initial application - (Chronic hepatitis C) only from a relevant specialist. Approvals valid for 6 months where chronic hepatitis C. NoteMaximum reimbursable dosage 15 million iu/weekInitial application - (Indications other than chronic hepatitis C) only from a dermatologist, plastic surgeon or radiation oncologist. Approvals valid for 5 years for applications meeting the following criteria: Any of the following: 1 Chronic myelogenous leukaemia; or 2 Hairycell leukaemia; or 3 Cutaneous T cell lymphoma; or 4 Essential thrombocythaemia; or 5 AIDS related Kaposi's sarcoma; or 6 Multiple myeloma; or 7 Chronic active hepatitis B; or 8 Basal cell carcinoma unable to be treated surgically or by radiotherapy. NoteMaximum reimbursable dosage 15 million iu/weekRenewal - (Chronic hepatitis C) only from a relevant specialist. Approvals valid for 6 months where the treatment remains appropriate and the patient is benefiting from trea
a) - hairy cell leukaemia - Kaposi's sarcoma - chronic active hepatitis B - chronic hepatitis C (6 month approval only) - chronic myelogenous leukaemia - multiple myeloma - basal cell carcinoma 1) Only for basal cell carcinoma unable to be treated surgically or by radiotherapy. 2) Applications only from radiation oncologists, plastic surgeons and dermatologists. Applications from dermatologists will only be accepted with evidence from either a plastic surgeon or oncologist that the patient was unsuitable for surgery. 3) Maximum reimbursable dosage 15 million iu/weekb) Specialist must make applicationc) No further approvals for: Malignant melanoma Note: Patients with existing approvals can continue to have therapy
Lansoprazole is subsidised for patients who have one or more of the following conditions: 1. Duodenal ulcer proven by endoscopy or barium meal and after failure of: a)two alternative courses of H. pylori eradication therapy (if H. pylori positive); and b)H2 antagonist therapy for 8 weeks; and where a second endoscopy/barium meal has demonstrated non healing duodenal ulcer. 2. Gastric ulcer proven by endoscopy and after failure of: a)two alternative courses of H. pylori eradication therapy (if H. pylori positive); andb)H2 antagonist therapy for 12 weeks; and where a second endoscopy has demonstrated non healing gastric ulcer and excluded malignancy. 3. Gastro-oesophageal reflux disease (GORD) proven by endoscopy: i) Grade 0 GORD (normal endoscopy) after positive 24 hour pH monitoring test and failure of H2 antagonist therapy for one month with multiple daily dosing; orii) Grades 1 and 2 GORD after failure of H2 antagonist therapy for one month with multiple daily dosing; or
a) All patients with AIDS meeting the definition developed by the Centres for Disease Control in the USA (see Circular Letter to Medical Practitioners HP2/88)b) Patients with AIDS Related Complex (ARC)c) HIV infected patients with CD4 (T4) counts below 500 regardless of symptomatologyd) Prophylactically for persons following severe parenteral exposure from a known HIV positive sourcee) HIV infected persons with associated thrombocytopenia regardless of CD4 (T4) count f) For the prevention of maternal foetal transmission of HIVg) Applications can only be made by appropriate specialists. Prescriptions for those patients approved to use these medicines can be written either by the specialist or general practitioner with an endorsement of the name of the recommending specialist. h) Prescriptions for these can be written for a period of three months' supply. However, medicine must be dispensed on a monthly basis.
Special Authority for Subsidy - Form SA0274Initial application only from a relevant specialist. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 All of the following: 1.1 Treatment with other lipid modifying medicines has been unsuccessful; and 1.2 6 months of dietary modification has been unsuccessful; and 1.3 Cholesterol level > 7.0 mmol/litre:; and 1.4 Either: 1.4.1 Familial hypercholesterolaemia; or 1.4.2 Manifest coronary heart disease, which has been clinically proven, or previously treated by coronary artery surgery; or 2 Cholesterol level > 9.0 mmol/litre:.NoteFamilial hypercholesterolaemia is defined as being hypercholesterolaemia in the presence of tendon xanthomas or in association with a family history of premature heart disease (before age 55) or consistent with autosomal dominant inheritance. Simvastatin and Pravastatin may be considered for first line therapy in patients with familial hypercholesterolaemia or
Special Authority for Subsidy - Form SA0275Initial application - (Chronic hepatitis C) only from a relevant specialist. Approvals valid for 6 months where chronic hepatitis C. NoteMaximum reimbursable dosage 15 million iu/weekInitial application - (Indications other than chronic hepatitis C) only from a dermatologist, plastic surgeon or radiation oncologist. Approvals valid for 5 years for applications meeting the following criteria: Any of the following: 1 Chronic myelogenous leukaemia; or 2 Hairycell leukaemia; or 3 Cutaneous T cell lymphoma; or 4 Essential thrombocythaemia; or 5 Multiple myeloma; or 6 Chronic active hepatitis B; or 7 Basal cell carcinoma unable to be treated surgically or by radiotherapy. NoteMaximum reimbursable dosage 15 million iu/weekRenewal - (Chronic hepatitis C) only from a relevant specialist. Approvals valid for 6 months where the treatment remains appropriate and the patient is benefiting from treatment. Renewal - (Indications other tha
Special Authority for Subsidy - Form SA0276Initial application - (Chronic hepatitis C) only from a relevant specialist. Approvals valid for 6 months where chronic hepatitis C. NoteMaximum reimbursable dosage 15 million iu/weekInitial application - (Indications other than chronic hepatitis C) only from a dermatologist, plastic surgeon or radiation oncologist. Approvals valid for 5 years for applications meeting the following criteria: Any of the following: 1 Chronic myelogenous leukaemia; or 2 Hairycell leukaemia; or 3 Multiple myeloma; or 4 Chronic active hepatitis B; or 5 Basal cell carcinoma unable to be treated surgically or by radiotherapy. NoteMaximum reimbursable dosage 15 million iu/weekRenewal - (Chronic hepatitis C) only from a relevant specialist. Approvals valid for 6 months where the treatment remains appropriate and the patient is benefiting from treatment. Renewal - (Indications other than chronic hepatitis C) only from a dermatologist, plastic surgeon or radiat
Omeprazole is subsidised for patients who have one or more of the conditions numbered 1-4: 1. Duodenal ulcer proven by endoscopy or barium meal and after failure of: a)two alternative courses of H. pylori eradication therapy (if H. pylori positive); and b)H2 antagonist therapy for 8 weeks; and where a second endoscopy/barium meal has demonstrated non healing duodenal ulcer. 2. Gastric ulcer proven by endoscopy and after failure of: a)two alternative courses of H. pylori eradication therapy (if H. pylori positive); andb)H2 antagonist therapy for 12 weeks; and where a second endoscopy has demonstrated non healing gastric ulcer and excluded malignancy. 3. Gastro-oesophageal reflux disease (GORD) proven by endoscopy: i) Grade 0 GORD (normal endoscopy) after positive 24 hour pH monitoring test and failure of H2 antagonist therapy for one month with multiple daily dosing; orii) Grades 1 and 2 GORD after failure of H2 antagonist therapy for one month with multipl
Special Authority for Subsidy - Form SA0290Initial application only from a relevant specialist. Approvals valid for 5 years for applications meeting the following criteria: Any of the following: 1 AIDS meeting the definition developed by the Centers for Disease Control in the USA; or 2 AIDS Related Complex (ARC).; or 3 Both: 3.1 HIV infection regardless of symptomatology; and 3.2 CD4 (T4) counts < 500. NoteSee Circular Letter to Medical Practitioners HP2/88)Renewal only from a relevant specialist. Approvals valid for 5 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0300Initial application - (Breast or prostatic cancer) only from an oncologist, urologist or endocrinologist. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 Breast cancer in pre menopausal women unwilling or unable to undergo surgical or radiation oophorectomy; or 2 Advanced prostatic cancer when orchidectomy is contraindicated. NoteNot in long term combination with an anti-androgenInitial application - (Endometriosis) only from a gynaecologist. Approvals valid for 6 months for applications meeting the following criteria: Both: 1 Endometriosis ; and 2 Either: 2.1 6 months treatment with medroxyprogesterone acetate, danazol or dimetriose has proven ineffective; or 2.2 The patient has failed to tolerate the treatment with medroxyprogesterone acetate, danazol or dimetriose for 6 months. NoteThe maximum treatment period for a GnRH analogue is: 3 months to assess whether surgery is appropriate3 m
Special Authority for Subsidy - Form SA0309Initial application only from a neurologist or physician for the elderly (FRACP). Approvals valid for 2 years for applications meeting the following criteria: All of the following: 1 Idiopathic Parkinson's disease; and 2 The patient does not have dementia and/or neuropsychiatric disorders; and 3 Has responded to L-dopa; and 4 Any of the following: 4.1 Has resistance to conventional treatment of severe motor fluctuations; or 4.2 Has severe "off" period disability; or 4.3 Has severe "off" period dystonic cramps. Renewal only from a neurologist or physician for the elderly (FRACP). Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0311Initial application - (Breast or prostatic cancer) only from an oncologist, urologist or endocrinologist. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 Breast cancer in pre menopausal women unwilling or unable to undergo surgical or radiation oophorectomy; or 2 Advanced prostatic cancer when orchidectomy is contraindicated or where the patient srongly opposes orchidectomy. NoteNot to be prescribed with an anti-androgen except for a period of three weeks, if necessary, when GnRH analogue therapy is intiatedInitial application - (Endometriosis) only from a gynaecologist. Approvals valid for 6 months for applications meeting the following criteria: Both: 1 Endometriosis; and 2 Either: 2.1 6 months treatment with medroxyprogesterone acetate, danazol or dimetriose has proven ineffective; or 2.2 The patient has failed to tolerate the treatment with medroxyprogesterone acetate, danazol or dimetrio
Special Authority for Alternate Subsidy - Form SA0312Initial application only from an obstetrician, gynaecologist, general practitioner or general physician. Approvals valid for 5 years for applications meeting the following criteria: Any of the following: 1 acute or significant liver disease - a declaration must be provided from a gastroenterologist or general physician stating that oral oestrogens are contraindicated due to liver disease (Details to be attached to application); or 2 oestrogen induced hypertension requiring antihypertensive therapy - documented evidence must be provided that raised blood pressure levels or inability to control blood pressure adequately occurred post oral oestrogens (Details to be attached to application); or 3 hypertriglyceridaemia - documented evidence must be provided that triglyceride levels increased to at least 2 x normal triglyceride levels post oral oestrogens (Details to be attached to application). NotePrescriptions with a valid Special Authority (
Special Authority for Subsidy - Form SA0317Initial application only from a renal physician. Approvals valid for 2 years for applications meeting the following criteria: All of the following: General Criteria: 1 Anaemia of end-stage renal failure (other treatable causes of anaemia being excluded); and 2 Been on haemodialysis or continuous ambulatory peritoneal dialysis (CAPD) for at least three months; and 3 Not under evaluation for, or awaiting, a live donor kidney transplant; and 4 Any of the following: Specific Criteria: 4.1 Anephric; or 4.2 Dependent on regular blood transfusion (1 unit each 4-8 weeks) to maintain haemoglobin > 60g/L; or 4.3 Cannot be transfused because of severe transfusion reactions; or 4.4 Transfusion induced haemosiderosis (clinical manifestations, serum ferritin >1500 ug/L); or 4.5 Haemoglobin < 70 g/L (mean of at least 4 haemoglobin concentrations over 4 months); or 4.6 Both: 4.6.1 Haemoglobin < 90 g/L; and 4.6.2 Either:
a) All nucleosides will be subsidised for patients meeting any of the following criteria: - All patients with AIDS meeting the definition developed by the Centers for Disease Control in the USA (see Circular Letter to Medical Practitioners HP2/88); or- Patients with AIDS Related Complex (ARC); or- HIV infected patients with CD4 (T4) counts below 500 regardless of symptomatology. b) Zidovudine will also be subsidised for patients meeting any of the following criteria: - Prophylactically for persons following severe parenteral exposure from a known HIV positive source; or- HIV infected persons with associated thrombocytopenia regardless of CD4 (T4) count; or- For the prevention of maternal foetal transmission of HIV. c) Applications can only be made by appropriate specialists. d) Prescriptions for those patients approved to use these medications can be written by either the specialist or general practitioner with an endorsement of the name of the recommending specialist.
Special Authority for Subsidy - Form SA0328Initial application only from a general physician. Approvals valid for 2 years for applications meeting the following criteria: Any of the following: 1 Both: 1.1 CD4 count < 500 cells/mm3; and 1.2 Viral load > 50,000> copies per ml (or equivalent value on the Chiron test); or 2 All of the following: 2.1 CD4 count < 500 cells/mm3; and 2.2 Viral load > 50,000> copies per ml (or equivalent value on the Chiron test); and 2.3 At least 6 weeks of dual therapy with nucleoside agents; or 3 Both: 3.1 CD4 count < 500 cells/mm3; and 3.2 CD4 counts are declining rapidly (>120 cells over 12 months or >60 - 80 cells over six months). Renewal only from a general physician. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
Guidelines for use of cyclosporin A in rheumatoid arthritisMonitoring: All patients require frequent monitoring for creatinine levels and blood pressure:- fortnightly, in the first three months of therapy and then monthly, if results are stable; - if dose is increased or there is a rise in serum creatinine or blood pressure, then more frequent monitoring is required. Contraindications: Cyclosporin A is contraindicated in patients with the following conditions: - current or past malignancy; - uncontrolled hypertension; - renal dysfunction (abnormal serum creatinine for age and sex); - immunodeficiency and neutropenia; - abnormally low white blood cell count or platelet count; or- liver function tests more than twice the upper limit of normal. Caution in use: - age above 65 years; - controlled hypertension; - use of ant-epileptic medications; - use of NSAIDs; - use of ketoconazole, fluconazole, trimethoprim, erythromycin, verapamil, and diltiazem; - concurrent or previous use of al
Special Authority - Retail pharmacy (Salmeterol, eformoterol fumarate):a) Approvals are interchangeable between all presenations of salmeterol and eformoterol fumarate agents. b) Diagnosis of asthma confirmed. c) Inhaler/device technique checked. d) At least three months of >= 1500 ug daily of beclomethasone inhaled steroid (or equivalent) for adult, or >= 800 ug daily for child. e) Patient monitors PEFR regularly during exacerbations where appropriate. f) Evidence of poor control (at least one of the following): - short acting beta agonist used > 3-4 time daily - nocturnal awakenings >= 2 times per week. g) The first applicaton may be for six months and subsequent applications for two yars. The criteria for reapplication are: - compliant with medication - improved asthma symptom control. h) Appication for Special Authority to be made by general practitioners or appropriate specialist.
a) Should be strictly reserved for use as second line therapy in: - patients unable to tolerate the other medications, such as infants, young children and patients with allergies or eczema; - cases of scabies which are resistent to gamma benzene hexachloride and resistant to malathion. b) Verification of drug resistance is dependent on the persistence of the condition after treatment. In order to establish whether there is drug resistance, the following criteria should be fulfilled: - a definite diagnosis of scabies should be made; - it should be ascertained that the medication was administered properly; - the possibility of reinfestation should have been excluded.
Special Authority for Manufacturers Price - Form SA0349Initial application only from a respiratory specialist or infectious disease specialist. Approvals valid for 2 years for applications meeting the following criteria: Any of the following: 1 Avium intracellular atypical mycobacterial infections; or 2 Multiple drug resistant tuberculosis; or 3 Atypical and drug-resistant mycobacterial infections in patients with AIDS. Renewal only from a respiratory specialist or infectious disease specialist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
Omeprazole and pantoprazole is subsidised for patients who have one or more of the conditions a-d: a) Duodenal ulcer proven by endoscopy or barium meal and after failure of: - two alternative courses of H. pylori eradication therapy (if H. pylori positive); and - H2 antagonist therapy for 8 weeks; and where a second endoscopy/barium meal has demonstrated non healing duodenal ulcer. b) Gastric ulcer proven by endoscopy and after failure of: - two alternative courses of H. pylori eradication therapy (if H. pylori positive); and - H2 antagonist therapy for 12 weeks; and where a second endoscopy has demonstrated non healing gastric ulcer and excluded malignancy. c) Gastro-oesophageal reflux disease (GORD) proven by endoscopy: - Grade 0 GORD (normal endoscopy) after positive 24 hour pH monitoring test and failure of H2 antagonist therapy for four weeks with multiple daily dosing; or - Grades 1 and 2 GORD after failure of H2 antagonist therapy for
Subsidy is available for disposable diabetic syringes and needles: 1) When the prescription is written on the same prescription form as the one used for the supply of insulin vials; or2) When "insulin patient" has been written on the prescription by either the doctor or the contractor; and3) For no more than 50 plastic syringes with attached needles as a single supply in the case of a prescription for three months supply of insulin vials; or4) For no more than 4 plastic syringes with attached needles as a single supply for each week's supply in the case of a prescription for less than three months supply of insulin vials.
Special Authority for Subsidy - Form SA0361Initial application only from a geriatrician, neurologist or general physician. Approvals valid for 2 years for applications meeting the following criteria: All of the following: 1 Disabling orthostatic hypotension not due to drugs; and 2 Patient has tried fludrocortisone (unless contra-indicated) with unsatisfactory results; and 3 Patient has tried non pharmacological treatments such as support hose, increased salt intake, exercise, and elevation of head and trunk at night. NoteTreatment should be started with small doses and titrated upwards as necessary. Hypertesion should be avoided, and the usual target is a standing systolic blood pressure of 90 mm Hg. Renewal only from a geriatrician, neurologist or general physician. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0366Initial application - (North Island patients) from any medical practitioner. Approvals valid for 5 years where the patient is likely to benefit from treatment. NoteFor details of the patient criteria, prescriber criteria, application and reporting forms contact the appointed clinician: Dr Richard FisherFertility Associates131 Remuera RoadAUCKLANDFax: 09 520 0499Appointed clinicians will distribute these agents to prescribers whose applications are approvedInitial application - (South Island patients) from any medical practitioner. Approvals valid for 5 years where the patient is likely to benefit from treatment. NoteFor details of the patient criteria, prescriber criteria, application and reporting forms contact the appointed clinician: Dr Peter BennyChristchurch Women's HospitalPrivate Bag 4711CHRISTCHURCHFax: 03 364 4634Appointed clinicians will distribute these agents to prescribers whose applications are approved
Special Authority for Subsidy - Form SA0382Initial application only from a gastroenterologist, general surgeon or general physician. Approvals valid for 3 years for applications meeting the following criteria: Any of the following: 1 All of the following: 1.1 Duodenal ulcer proven by endoscopy or barium meal; and 1.2 Failure of two alternative courses of H. pylori eradication therapy (if H. pylori positive); and 1.3 Non healing duodenal ulcer proven by second barium meal; and 1.4 H2 antagonist therapy for 8 weeks; or 2 All of the following: 2.1 Gastric ulcer proven by endoscopy; and 2.2 Two alternative courses of H. pylori eradication therapy (if H. pylori positive); and 2.3 Non healing gastric ulcer and excluded malignancy demonstrated by a second endoscopy; and 2.4 H2 antagonist therapy for 12 weeks; or 3 All of the following: 3.1 Grade 0 GORD (normal endoscopy); and 3.2 Positive 24 hour pH monitoring test; and 3.3 Failure of H2 antagonist t
n) Further approvals to fund the manufacturer's surcharge on either pravastatin or simvastatin (if applicable) may be granted to patients who are unable to continue treatment with fluvastatin due to adverse effects. Either general practitioners or specialist may make the application. To obtain a new Special Authority number, the application must include the following information: - the amount of time the patient has been treated with fluvastatin; and- the adverse effects experienced by the patient. o) Further approvals to fund the manufacturer's surcharge on simvastatin may be granted to patients with familial hypercholesterolaemia (FH) or familial combined hypercholesterolaemia (FCH) if a specialist considers that the patient is not achieving sufficient benefit from the fully funded statin(s). Only specialists may make application. To obtain a new Special Authority number, the application must include the following information: - the cholesterol level before and after treatment with the fully funded sta
Special Authority for Subsidy - Form SA0387Initial application - (Breast or prostatic cancer) only from an oncologist, urologist or endocrinologist. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 Breast cancer in pre menopausal women unwilling or unable to undergo surgical or radiation oophorectomy; or 2 Advanced prostatic cancer when orchidectomy is contraindicated or where the patient srongly opposes orchidectomy. NoteNot to be prescribed with an anti-androgen except for a period of three weeks, if necessary, when GnRH analogue therapy is intiatedInitial application - (Endometriosis) only from a gynaecologist. Approvals valid for 6 months for applications meeting the following criteria: Both: 1 Endometriosis; and 2 Either: 2.1 6 months treatment with medroxyprogesterone acetate, danazol or dimetriose has proven ineffective; or 2.2 The patient has failed to tolerate the treatment with medroxyprogesterone acetate, danazol or dimetrio
Special Authority for Manufacturers Price - Form SA0394Initial application - (Helicobacter pylori infections) only from a general practitioner or relevant specialist. Approvals valid for 6 months for applications meeting the following criteria: Both: 1 Eradication of Helicobacter pylori in patient with proven infection; and 2 Peptic ulcer disease proven by endoscopy. NoteMaximum of two prescriptions (two courses) per patient. Initial application - (Mycobacterial infections) only from a respiratory specialist or infectious disease specialist. Approvals valid for 2 years for applications meeting the following criteria: Any of the following: 1 Mycobacterium Avium Intracellulare Complex infections in patient with AIDS; or 2 Atypical and drug-resistant mycobacterial infection; or 3 All of the following: 3.1 Prophylaxis against disseminated Mycobacterium Avium Intracellulare Complex infection; and 3.2 HIV infection; and 3.3 CD4 count <= 50 cells/mm3. Renewal - (Mycobacteri
a) Cyproterone acetate with ethinyloestradiol is available from retail pharmacy to patients as indicated. b) Prescribers may code prescriptions "contraceptive" (code "O") when used as indicated for contraception. The period of supply and prescription charge will be as per other contraceptives, as follows: - $3.00 prescription charge (patient co-payment) will apply; - Prescription may be written for up to 6 months supply; and- Pharmacists may dispense up to 3 month supply. c) Prescriptions coded in any other way are subject to the non-contraceptive prescription charges, and the non-contraceptive period of supply. Eg. Prescriptons may be written for up to 3 months supply, and dispensed monthly. d) The Special Authority number for hormonal contraceptive agents (combined and progesterone-only) does not apply, and is not interchangeable. e) Health Benefits Limited will return any claims unpaid as follows: - any uncoded prescription; - any prescription that does not have a period of supply or the quantity
Special Authority for Subsidy - Form SA0401Initial application - (Basal cell carcinoma) only from a dermatologist, plastic surgeon or radiation oncologist. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 Basal cell carcinoma unable to be treated surgically or by radiotherapy; and 2 Unsuitability for surgery confirmed by a Plastic Surgeon or Oncologist. NoteMaximum reimbursable dosage 15 million iu/weekInitial application - (Chronic hepatitis C) only from a relevant specialist. Approvals valid for 12 months where chronic hepatitis C. Initial application - (Indications other than Basal cell carcinoma and Chronic hepatitis C) only from a relevant specialist, plastic surgeon or radiation oncologist. Approvals valid for 2 years for applications meeting the following criteria: Any of the following: 1 Chronic myelogenous leukaemia; or 2 Hairy cell leukaemia; or 3 Cutaneous T cell lymphoma; or 4 Essential thrombocythaemia; or 5 Multiple myelo
Special Authority for Subsidy - Form SA0402Initial application - (Patients aged 74 and under) only from a general practitioner. Approvals valid for 2 years for applications meeting the following criteria: All of the following: 1 Patients aged 74 and under; and 2 The patient has been offered 3-6 months of counselling and an opportunity to modify lifestyle; and 3 Any of the following: 3.1 Both: 3.1.1 NHF A1:1 - Clinically proven ischaemic heart disease; and 3.1.2 total cholesterol > 6.0; or 3.2 Both: 3.2.1 NHF A1:2 - Post coronary artery bypass graft (CABG); and 3.2.2 total cholesterol > 5.5; or 3.3 Both: 3.3.1 NHF B:Patients with > 20% 5-year cardiovascular disease risk; and 3.3.2 total cholesterol > 9.0; or 3.4 Both: 3.4.1 NHF C:15-20% 5-year cardiovascular disease risk; and 3.4.2 total cholesterol > 9.0; or 3.5 Both: 3.5.1 NHF D:10-15% 5-year cardiovascular disease risk; and 3.5.2 total cholesterol > 9.0; or 3.6
Special Authority for Subsidy - Form SA0404Initial application only from an ophthalmologist. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 Primary open-angle glaucoma; and 2 Either: 2.1 Other subsidised glaucoma medical therapy is contraindicated; or 2.2 Both: 2.2.1 intra-ocular pressure > 26 mmHg (average from consecutive measurements); and 2.2.2 Unable to be controlled using other subsidised medical therapy. Renewal only from an ophthalmologist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
Funding of manufacturers surcharge for existing patients taking ACE inhibitors for Congestive Heart Failure.a) Patients taking any ACE inhibitor for the treatment of congestive heart failure prior to 1 June 1998 can continue to have their ACE inhibitor treatment fully subsidised; b) Prescribers must endorse the prescription 'Congestive Heart Failure'. The endorsement can be typed (this includes computer generated prescriptions) or handwritten; c) The endorsement must be initialled in the prescriber's own handwriting. Definition of Congestive Heart FailureAt the request of some prescribers the PTAC Cardiovascular subcommittee has provided a definition of congestive heart failure for the purposes of the funding of the manufacturer's surcharge: "Clinicians should use their clinical judgement. Existing patients would be eligible for the funding of the surcharge if the patient shows signs and symptoms of congestive heart failure, and requires or has in the past required concomitant treatment with a
Special Authority for Subsidy - Form SA0423Initial application only from a gastroenterologist, general surgeon or general physician. Approvals valid for 3 years for applications meeting the following criteria: Any of the following: 1 All of the following: Duodenal Ulcer: 1.1 Duodenal ulcer proven by endoscopy or barium meal; and 1.2 Non healing duodenal ulcer proven by second barium meal; and 1.3 After failure of two alternative courses of H. pylori eradication therapy (if H. pylori positive); and 1.4 After H2 antagonist therapy for 8 weeks; or 2 All of the following: Gastric Ulcer: 2.1 Gastric ulcer proven by endoscopy; and 2.2 Non healing gastric ulcer and excluded malignancy demonstrated by a second endoscopy; and 2.3 After two alternative courses of H. pylori eradication therapy (if H. pylori positive); and 2.4 After H2 antagonist therapy for 12 weeks; or 3 All of the following: GORD: 3.1 Grade 0 GORD (normal endoscopy); and 3.2 Positive 24
Special Authority for Subsidy - Form SA0424Initial application - (Confirmed HIV/AIDS) only from a general physician. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 Confirmed HIV/AIDS; and 2 Any of the following: 2.1 Symptomatic patients aged 6 years and over with HIV/AIDS; or 2.2 Both: 2.2.1 Asymptomatic patients aged 6 years and over; and 2.2.2 CD4 counts < 500 cells/mm3; or 2.3 Both: 2.3.1 Asymptomatic patients aged 6 years and over; and 2.3.2 Viral load counts > 10,000 copies per ml; or 2.4 Symptomatic patients aged under 6 with HIV/AIDS ; or 2.5 Asymptomatic patients aged 12 months and under; or 2.6 Both: 2.6.1 Asymptomatic patients aged 1 to 5 years; and 2.6.2 CD4 counts < 1,000 cells/mm3; or 2.7 Both: 2.7.1 Asymptomatic patients aged 1 to 5 years; and 2.7.2 CD4 counts < 0.25 x total white cell count; or 2.8 Both: 2.8.1 Asymptomatic patients aged under 6 years; and
If a Community Pharmaceutical is the liquid oral form of an antibiotic to which a diluent must be added by the Contractor at the time of dispensing and it is prescribed or ordered by a Practittioner in an amount that does not coincide with the amount contained in one or more standard packs of that Community Pharmaceutical, Subsidy will only be made for the amount prescribed or ordered by the Practitioner in accordance with either Clause 3.1 or Clause 3.3 of the Schedule, unless the Contractor satisfies the Funder that he or she has not been able to dispense the balance of the pack or packs from which the Community Pharmaceutical has been dispensed. In such cases all of that pack or those packs is eligible for Subsidy.
Special Authority for Subsidy - Form SA0430Initial application - (National Heart Foundation risk groups A1:1, A1:2, B, C, D or E) only from a relevant specialist or general practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria: Both: 1 The patient has been offered 3-6 months of counselling and an opportunity to modify lifestyle; and 2 Any of the following: 2.1 Both: 2.1.1 NHF A1:1 - Clinically proven ischaemic heart disease; and 2.1.2 total cholesterol * > 5.5; or 2.2 Both: 2.2.1 NHF A1:2 - Post coronary artery bypass graft (CABG) or angioplasty; and 2.2.2 total cholesterol * > 4.5; or 2.3 Post heart transplant (regardless of cholesterol level); or 2.4 Both: 2.4.1 NHF B:Patients with > 20% 5-year cardiovascular disease risk; and 2.4.2 total cholesterol * > 9.0; or 2.5 Both: 2.5.1 NHF C:15-20% 5-year cardiovascular disease risk; and 2.5.2 total cholesterol * > 9
Special Authority for Manufacturers Price - Form SA0436Initial application - (Patient with prosthetic heart valves) only from a cardiothoracic surgeon, cardiologist or general physician. Approvals valid for 2 years where patient with prosthetic heart valves - as an adjunct to oral anticoagulation for prophylaxis of thromboembolism. Initial application - (Following coronary artery vein bypass graft) only from a cardiothoracic surgeon, cardiologist or general physician. Approvals valid for 1 year where patients after coronary artery vein bypass graft - as an adjunct to aspirin or as monotherapy for patients who are aspirin intolerant as defined below. Initial application - (Transient ischaemic episodes) only from a neurologist, neuro surgeon, cardiologist, vascular surgeon or general physician. Approvals valid for 2 years where patients who continue to have transient ischaemic episodes despite aspirin therapy or have transient ischaemic episodes and are aspirin intolerant as defined below. Renewal - (Fo
Special Authority for Subsidy - Form SA0443Initial application - (Helicobacter pylori infections) only from a general practitioner or relevant specialist. Approvals valid for 6 months for applications meeting the following criteria: Both: 1 Eradication of Helicobacter pylori in patient with proven infection; and 2 Peptic ulcer disease proven by endoscopy. NoteMaximum of two prescriptions (two courses) per patient. Initial application - (Mycobacterial infections) only from a respiratory specialist or infectious disease specialist. Approvals valid for 2 years for applications meeting the following criteria: Any of the following: 1 Mycobacterium Avium Intracellulare Complex infections in patient with AIDS; or 2 Atypical and drug-resistant mycobacterial infection; or 3 All of the following: 3.1 Prophylaxis against disseminated Mycobacterium Avium Intracellulare Complex infection; and 3.2 HIV infection; and 3.3 CD4 count <= 50 cells/mm3. Renewal - (Mycobacterial infection
Special Authority for Subsidy - Form SA0445Initial application only from a relevant specialist. Approvals valid for 5 years for applications meeting the following criteria: Any of the following: 1 Both: 1.1 Acromegaly; and 1.2 Patient has failed surgery, radiotherapy, bromocriptine or other oral therapies; or 2 VIPomas and Glucagonomas - for patients who are seriously ill in order to improve their clinical state prior to definitive surgery.; or 3 Both: 3.1 Gastrinoma; and 3.2 Patient has failed surgery, or metastatic disease after H2 antagoists (or proton pump inhibitors) have failed; or 4 Both: 4.1 Insulinomas; and 4.2 Surgery is contraindicated or has failed; or 5 For pre-operative control of hypoglycaemia and for maintenance therapy; or 6 Both: 6.1 Carcinoidsyndrome (diagnosed by tissue pathology and/or urinary 5HIAA analysis); and 6.2 Disabling symptoms not controlled by maximal medical therapy. NoteThe use of octretide in patients with fis
Special Authority for Subsidy - Form SA0450Initial application only from a psychiatrist. Approvals valid for 12 months for applications meeting the following criteria: Both: 1 Patients suffering from schizophrenia and related psychoses; and 2 Either: 2.1 Failed to respond to full trials (duration of at least 6 weeks each) of effective doses of at least two classes of anti-psychotic agents (refer to guidelines below); or 2.2 Demonstrated intolerance to other neuroleptic agents. NoteClinicians must confirm that informed consent and a satisfactory White Bloodcell Count (WBC) result has been obtained. Diagnosis: Treatment resistant schizophrenia and related psychoses when positive symptoms (delusions, hallucinations and thought disorder) are prominent and/or disabling or when both positive symptoms and negative symptoms (flattened affect, emotional and social withdrawal and poverty of speech) are present. Treatment: Trial therapy undertaken before initiating treatment with clozapine could
Special Authority for Manufacturers Price - Form SA0451Initial application only from a relevant specialist. Approvals valid for 3 years for applications meeting the following criteria: Both: 1 Patients being treated for advanced breast cancer who are refractory to tamoxifen; and 2 Any of the following: 2.1 Unable to tolerate aminoglutethimide; or 2.2 Unable to tolerate megestrol acetate; or 2.3 Unable to tolerate medroxyprogesterone acetate.Renewal only from a relevant specialist. Approvals valid for 3 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Manufacturers Price - Form SA0452Initial application only from a relevant specialist. Approvals valid for 3 years for applications meeting the following criteria: Both: 1 Patients being treated for advanced breast cancer who are refractory to tamoxifen; and 2 Any of the following: 2.1 Unable to tolerate aminoglutethimide; or 2.2 Unable to tolerate megestrol acetate; or 2.3 Unable to tolerate medroxyprogesterone acetate.Renewal only from a relevant specialist. Approvals valid for 3 years where the treatment remains appropriate and the patient is benefiting from treatment.
Guidelines for the use of atypical anti-psychotic agents Diagnosis: Schizophrenia and related psychoses when positive symptoms (delusions, hallucinations and thought disorder) are prominent and/or disabling or when both positive symptoms and negative symptoms (flattened affect, emotional and social withdrawal and poverty of speech) are present. Treatment: Before initiating atypical anti-psychotic therapy, physicians should consider whether the patient is likely to respond to and/or tolerate conventional anti-psychotic therapy and, where appropriate, trial one or more conventional agent prior to use of an atypical agent.
Special Authority for Subsidy - Form SA0456Initial application only from a psychiatrist. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 Patients suffering from schizophrenia and related psychoses who are likely to benefit from anti-psychotic treatment; and 2 Any of the following: 2.1 Effective dose of risperidone has been discontinued because of recurrent acute dystonias; or 2.2 Effective dose of risperidone has been discontinued because of excessive Parkinson-like symptoms; or 2.3 Effective dose of risperidone has been discontinued after 6 weeks because of inadequate clinical response. Renewal only from a psychiatrist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0458Initial application only from a gastroenterologist. Approvals valid for 6 months for applications meeting the following criteria: Both: 1 Primary biliary cirrhosis confirmed by antimitochondrial antibody titre (AMA) > 1:80, and raised cholestatic liver enzymes with or without raised serum IgM or, if AMA is negative, by liver biopsy; and 2 Patient not requiring a liver transplant (bilirubin > 170umol/l; decompensated cirrhosis). NoteLiver biopsy is not usually required for diagnosis but is helpful to stage the diseaseRenewal only from a gastroenterologist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment. NoteActigall is not an appropriate therapy for patients requiring a liver transplant (bilirubin > 170 micromol/l; decompensated cirrhosis). These patients should be referred to an appropriate transplant centreTreatment failure - doubling of serum bilirubin levels, absence of a signi
Special Authority for Subsidy - Form SA0459Initial application only from a gastroenterologist or general physician. Approvals valid for 3 months for applications meeting the following criteria: Both: 1 Mild to moderate ileal, ileocaecal or proximal Crohn's disease; and 2 Any of the following: 2.1 Diabetes; or 2.2 Cushingoid habitus; or 2.3 Osteoporosis where there is significant risk of fracture; or 2.4 Both: 2.4.1 Severe acne; and 2.4.2 Treatment with conventional corticosteroid therapy. Renewal only from a gastroenterologist or general physician. Approvals valid for 3 months where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Manufacturers Price - Form SA0460Initial application - (Patient with prosthetic heart valves) only from a cardiothoracic surgeon, cardiologist or general physician. Approvals valid for 2 years where patient with prosthetic heart valves - as an adjunct to oral anticoagulation for prophylaxis of thromboembolism. Initial application - (Following coronary artery vein bypass graft) only from a cardiothoracic surgeon, cardiologist or general physician. Approvals valid for 1 year where patients after coronary artery vein bypass graft - as an adjunct to aspirin or as monotherapy for patients who are aspirin intolerant as defined below. Initial application - (Transient ischaemic episodes) only from a neurologist, neuro surgeon, cardiologist, vascular surgeon or general physician. Approvals valid for 2 years where patients who continue to have transient ischaemic episodes despite aspirin therapy or have transient ischaemic episodes and are aspirin intolerant as defined below. Renewal - (Fo
Special Authority for Subsidy - Form SA0461Initial application - (Basal cell carcinoma) only from a dermatologist, plastic surgeon or radiation oncologist. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 Basal cell carcinoma unable to be treated surgically or by radiotherapy; and 2 Unsuitablity for surgery confirmed by a Plastic Surgeon or Radiation Oncologist. NoteThe maximum reimbursable dosage is 15 million iu per weekInitial application - (Chronic hepatitis C) only from a relevant specialist. Approvals valid for 12 months where chronic hepatitis C. Initial application - (Indications other than Basal cell carcinoma and Chronic hepatitis C) only from a relevant specialist. Approvals valid for 2 years for applications meeting the following criteria: Any of the following: 1 Chronic myelogenous leukaemia; or 2 Hairy cell leukaemia; or 3 Multiple myeloma; or 4 Chronic active hepatitis B. Renewal - (Basal cell carcinoma) only from a dermato
Special Authority for Subsidy - Form SA0464Initial application only from a diabetologist, general physician or paediatrician. Approvals valid without further renewal unless notified for applications meeting the following criteria: Any of the following: 1 Both: 1.1 Use alone (monotherapy); and 1.2 The patient is unable to use any other insulins including those on insulin pump treatment; or 2 Both: 2.1 Use with Humulin 70/30 or Humulin 80/20; and 2.2 A reasonable trial of Humulin N has been undertaken and it is not effective or not well tolerated; or 3 Both: 3.1 Use with insulins (aside from insulin zinc suspension) other than Humulin 70/30, Humulin 80/20, or Humulin N; and 3.2 A reasonable trial of one or more of these Humulin insulins has been undertaken and it is/are ineffective or not well tolerated; or 4 Both: 4.1 Use with Humulin L or Humulin U; and 4.2 Use with Humulin N is not appropriate; or 5 Both: 5.1 Use with other insulin zinc suspensio
Special Authority for Alternate Subsidy - Form SA0466Initial application only from a relevant specialist or general practitioner. Approvals valid for 5 years for applications meeting the following criteria: Any of the following: 1 Angina that is not controlled by other anginal medications; or 2 Continuation of treatment commenced prior to 1 June 1999; or 3 Receiving maximal antihypertensive therapy, requires a DHP CCB, and cannot tolerate felodipine. Renewal only from a relevant specialist or general practitioner. Approvals valid for 5 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0467Initial application only from a relevant specialist. Approvals valid for 6 months for applications meeting the following criteria: Both: 1 Paget's disease; and 2 Any of the following: 2.1 Bone or articular pain; or 2.2 Bone deformity; or 2.3 Bone, articular or neurological complications; or 2.4 Asymptomatic disease, but risk of complications due to site (base of skull, spine, long bones of lower limbs); or 2.5 Preparation for orthopaedic surgery. Renewal only from a relevant specialist. Approvals valid for 6 months where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0470Initial application - (Organ transplant) only from a relevant specialist. Approvals valid without further renewal unless notified where organ transplant. Initial application - (Bone marrow transplant or Graft v host disease) only from a relevant specialist. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 Bone marrow transplant; or 2 Graft v host disease. Initial application - (Psoriasis) only from a dermatologist. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 Psoriasis; and 2 Applicant must state which systemic and topical therapies have failed. Initial application - (Severe atopic dermatitis) only from a dermatologist. Approvals valid for 6 months for applications meeting the following criteria: Both: 1 Severe atopic dermatitis; and 2 Not responsive to topical therapy, oral antihistamines and other commonly used orthodox therapies. Initial application - (N
Special Authority for Subsidy - Form SA0471Initial application - (Breast cancer) from any medical practitioner. Approvals valid for 1 year where breast cancer in pre menopausal women unwilling or unable to undergo surgical or radiation oophorectomy. Initial application - (Prostate cancer) only from an oncologist, urologist or endocrinologist. Approvals valid for 1 year where advanced prostatic cancer when orchidectomy is contraindicated or where the patient strongly opposes orchidectomy. NoteNot to be prescribed with an anti-androgen except for a period of three weeks, if necessary, when GnRH analogue therapy is intiatedInitial application - (Endometriosis) only from a gynaecologist. Approvals valid for 3 months for applications meeting the following criteria: Both: 1 Endometriosis ; and 2 Either: 2.1 6 months treatment with medroxyprogesterone acetate, danazol or dimetriose has proven ineffective; or 2.2 The patient has failed to tolerate the treatment with medroxyprogesterone
Special Authority for Subsidy - Form SA0472Initial application only from a cardiologist. Approvals valid for 2 years for applications meeting the following criteria: Any of the following: 1 Both: 1.1 Congestive heart failure; and 1.2 Cannot tolerate currently fully subsidised ACE inhibitors due to persistent cough that resolves on cessation and recurs on re-challenge with ACE inhibitor; or 2 Patients who have experienced angioedema on an ACE inhibitor at any time in the past; or 3 Patients who have experienced angioedema (even if not using an ACE inhibitor) in the last 2 years. Renewal only from a cardiologist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0473Initial application from any medical practitioner. Approvals valid for 1 year where the patient is likely to benefit from treatment. Note Applications to be made on the approved forms which are available from: The Co-ordinatorGaucher's Treatment PanelPhone: (04) 460 4990 PHARMAC, PO Box 10 254 WellingtonFacsimile: (04) 916 7571Email: erin.murphy@pharmac.govt.nzPrescriptions for patients approved for treatment must be written by respiratory physicians or paediatricians who have experience and expertise in treating cystic fibrosis.
Special Authority for Subsidy - Form SA0488Initial application only from a gastroenterologist, general surgeon or general physician. Approvals valid for 3 months for applications meeting the following criteria: Both: 1 Mild to moderate ileal, ileocaecal or proximal Crohn's disease; and 2 Any of the following: 2.1 Diabetes; or 2.2 Cushingoid habitus; or 2.3 Osteoporosis where there is significant risk of fracture; or 2.4 Both: 2.4.1 Severe acne; and 2.4.2 Treatment with conventional corticosteroid therapy. Renewal only from a gastroenterologist, general surgeon or general physician. Approvals valid for 3 months where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Manufacturers Price - Form SA0489Initial application - (Conditions other than transient ischaemic episodes) only from a cardiothoracic surgeon, cardiologist or general physician. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 Patients with prosthetic heart valves - as an adjunct to oral anticoagulation for prophylaxis of thromboembolism; or 2 Both: 2.1 Patients after coronary artery vein bypass graft; and 2.2 Any of the following: 2.2.1 aspirin induced asthma; or 2.2.2 aspirin induced anaphylaxi; or 2.2.3 significant aspirin induced bleeding excluding bruising. Initial application - (Transient ischaemic episodes) only from a neurologist, neuro surgeon, cardiologist, vascular surgeon or general physician. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 Patients who continue to have transient ischaemic episodes despite aspirin therapy; or 2 Both: 2.1 Patients wh
Special Authority for Subsidy - Form SA0494Initial application only from an ophthalmologist. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 Both: 1.1 Primary open-angle glaucoma; and 1.2 Any of the following: 1.2.1 Patient cannot tolerate Beta-blockers, or Beta-blockers are contraindicated; or 1.2.2 Patient cannot tolerate Pilocarpine, or Pilocarpine is contraindicated; or 1.2.3 Patient cannot tolerate Dorzolamide, or Dorzolamide is contraindicated; or 1.2.4 A reduction in intraocular pressure of 15% or more is not achieved or maintained using dorzolamide either alone or in combination with a beta-blocker; or 2 There is progressive visual field loss and/or optic nerve damage persists after treatment with dorzolamide either alone or in combination with a beta-blocker. NoteSubsidised as monotherapy onlyRenewal only from an ophthalmologist. Approvals valid for 2 years where the treatment remains appropriate and the patient
Special Authority for Alternate Subsidy - Form SA0500Initial application from any medical practitioner. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 Either: 1.1 Patient is on a Social Welfare benefit; or 1.2 Patient has an income no greater than the benefit; and 2 Has tried at least one of the fully funded options and has been unable to tolerate it. Renewal from any medical practitioner. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 Patient is on a Social Welfare benefit; or 2 Patient has an income no greater than the benefit. NoteThe approval numbers of Special Authorities approved after 1 November 1999 are interchangeable between Mercilon and Marvelon. The additional subsidy will fund Mercilon and Marvelon up to the manufacturer's price for each of these products as identified on the Schedule at 1 November 1999Special Authorities approved before 1 November 1999 remain valid until the expiry d
Special Authority for Subsidy - Form SA0508Initial application only from a relevant specialist or general practitioner. Approvals valid for 2 years for applications meeting the following criteria: All of the following: 1 Patient with raised blood pressure; and 2 A beta blocker or diuretic is contraindicated; or not well tolerated; or insufficient to control blood pressure adequately at appropriate doses; and 3 An ACE inhibitor is contraindicated; or not well tolerated; or insufficient to control blood pressure adequately at appropriate doses. Renewal only from a relevant specialist or general practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0509Initial application only from a psychiatrist. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 Patient with first episode schizophrenia or related psychoses; or 2 Both: 2.1 Patient suffering from schizophrenia and related psychoses who is likely to benefit from anti-psychotic treatment; and 2.2 Both: 2.2.1 An effective dose of risperidone had been trialled and has been discontinued either because of; and 2.2.2 Any of the following: 2.2.2.1 Patient has recurrent acute dystonias; or 2.2.2.2 Patient has excessive Parkinson-like symptoms; or 2.2.2.3 Patient has hyperprolactinaemia; or 2.2.2.4 Patient has inadequate clinical response after four weeks. NoteDiscontinued treatment should be notified to HealthPAC if possibleRenewal only from a psychiatrist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Alternate Subsidy - Form SA0510Initial application only from a relevant specialist or general practitioner. Approvals valid for 2 years for applications meeting the following criteria: Any of the following: 1 Angina that is not controlled by other anginal medications (including felodipine); or 2 Patient was taking Adalat Oros for the treatment of angina prior to 1 June 1999; or 3 Receiving maximal antihypertensive therapy, requires a DHP CCB, and cannot tolerate felodipine. Renewal only from a relevant specialist or general practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0511Initial application only from a geriatrician, rheumatologist, endocrinologist, gynaecologist or general physician. Approvals valid for 2 years for applications meeting the following criteria: All of the following: 1 Severe osteoporosis; and 2 History of two previous significant osteoporotic fractures demonstrated radiologically; and 3 T-Score <= -3.0 (bone mass density (BMD) >= 3.0 standard deviations below the mean normal value in young adults). NoteIn line with the Australian guidelines for funding alendronate, a vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral bodyRenewal only from a geriatrician, rheumatologist, endocrinologist, gynaecologist or general physician. Approvals valid for 2 years where the tr
Special Authority for Subsidy - Form SA0512Initial application only from a gastroenterologist, general surgeon or general physician. Approvals valid for 3 months for applications meeting the following criteria: Both: 1 Mild to moderate ileal, ileocaecal or proximal Crohn's disease; and 2 Either: 2.1 Diabetes; or 2.2 Both: 2.2.1 Treatment with conventional corticosteroid therapy; and 2.2.2 Any of the following: 2.2.2.1 Cushingoid habitus; or 2.2.2.2 Osteoporosis where there is significant risk of fracture; or 2.2.2.3 Severe acne. Renewal only from a gastroenterologist, general surgeon or general physician. Approvals valid for 3 months where the patient has had no more than 1 prior approval in the last 12 months. The patient must have had no more than 1 prior approval in the last year. NoteClinical trials for Entocort CIR use beyond three months demonstrated no improvement in relapse rate
Special Authority for Subsidy - Form SA0513Initial application - (Narcolepsy) only from a neurologist. Approvals valid for 24 months where narcolepsy. Initial application - (ADHD in patients aged 5 years or over) only from a paediatrician or psychiatrist. Approvals valid for 24 months for applications meeting the following criteria: Both: 1 ADHD (Attention Deficient and Hyperactivity Disorder) patients aged 5 years or over; and 2 Diagnosed according to DSM-IV or ICD 10 criteria. Initial application - (ADHD in patients under 5 years of age) only from a paediatrician or psychiatrist. Approvals valid for 12 months for applications meeting the following criteria: Both: 1 ADHD (Attention Deficient and Hyperactivity Disorder) patients under 5 years of age; and 2 Diagnosed according to DSM-IV or ICD 10 criteria. Renewal - (Narcolepsy or ADHD in patients under 5 years of age) only from a neurologist, paediatrician or psychiatrist. Approvals valid for 24 months where the treatment remains appr
Special Authority for Subsidy - Form SA0523Initial application only from a relevant specialist or general practitioner. Approvals valid for 6 months for applications meeting the following criteria: All of the following: 1 Diagnosis of asthma confirmed; and 2 Inhaler/device technique checked; and 3 Patient monitors PEFR regularly during exacerbations where appropriate; and 4 Any of the following: 4.1 At least three months of 1500 ug or more daily of inhaled beclomethasone or budesonide for adult; or 4.2 At least three months of 750 ug or more daily of inhaled fluticasone) for adult; or 4.3 At least three months of 800 ug or more daily inhaled beclomethasone or budesonide for child; or 4.4 At least three months of 400 ug or more daily inhaled fluticasone) for child; and 5 Either: 5.1 Short acting beta agonist used at least 3-4 times daily; or 5.2 Nocturnal awakenings at least twice a week. Renewal only from a relevant specialist or general practitioner. Appro
Special Authority for Subsidy - Form SA0528Initial application - (Narcolepsy) only from a neurologist or respiratory specialist. Approvals valid for 24 months where narcolepsy. Initial application - (ADHD in patients 5 or over) only from a paediatrician, psychiatrist or general practitioner. Approvals valid for 24 months for applications meeting the following criteria: All of the following: 1 ADHD (Attention Deficient and Hyperactivity Disorder) patients aged 5 years or over; and 2 Diagnosed according to DSM-IV or ICD 10 criteria; and 3 Applicant is a specialist or specialist has recommended treatment. Initial application - (ADHD in patients under 5) only from a paediatrician or psychiatrist. Approvals valid for 12 months for applications meeting the following criteria: Both: 1 ADHD (Attention Deficient and Hyperactivity Disorder) patients under 5 years of age; and 2 Diagnosed according to DSM-IV or ICD 10 criteria. Renewal - (Narcolepsy) only from a neurologist or respiratory spec
ACE inhibitors will be funded to the level of the ex-manufacturer price listed in the Schedule for patients who were taking an ACE inhibitor for the treatment of congestive heart failure prior to 1 June 1998. The prescription must be endorsed accordingly. We recommend that the words used to indicate eligibility are "certified condition" or an appropriate description of the patient such as "congestive heart failure", "CHF", "congestive cardiac failure" or "CCF". Additional subsidy for lisinopril is available only up to the price of the least expensive brand listed in the Schedule. Definition of Congestive Heart FailureAt the request of some prescribers the PTAC Cardiovascular subcommittee has provided adefinition of congestive heart failure for the purposes of the funding of the manufacturer'ssurcharge: "Clinicians should use their clinical judgement. Existing patients would be eligible for thefunding of the surcharge if the patient shows signs and symptoms of congestive heart failure, and requir
Additional subsidy by endorsement for:Moclobemide tab 150 mg x 100 (Aurorix) up to $47.00Moclobemide tab 300 mg x 60 (Aurorix) up to $56.40Nefazadone tab 100 mg x 56 (Serzone) up to $20.16Nefazadone tab 200 mg x 56 (Serzone) up to $40.32Citalopram tab 20 mg x 28 (Cipramil) up to $27.00is available for patients who: * are taking moclobemide or nefazodone on 1 December 1999 or citalopram on 1 February2000; * have previously responded to treatment with moclobemide or nefazodone or citalopram; * have had a trial of fluoxetine and have to discontinue due to: - inability to tolerate the drug due to side effects OR - failed to respond to an adequate dose and duration of treatment; * have contraindications to fluoxetine (eg pre-existing significant levels of nausea, breastfeeding, potential drug interactions); The prescription must be endorsed accordingly. We recommend that the words used to indicate eligibility are "certified condition" however these particular words are not a requirement.
Special Authority for Subsidy - Form SA0538Initial application only from a gastroenterologist, infectious disease specialist, paediatrician or general physician. Approvals valid for 1 year for applications meeting the following criteria: Both: 1 Any of the following: 1.1 All of the following: 1.1.1 HBsAg positive for more than 6 months; and 1.1.2 HBeAg positive or HBV DNA positive defined as >0.6 pg/ml by quantitative PCR at reference laboratory; and 1.1.3 ALT greater than twice upper limit of normal or stage 3 or 4 fibrosis on liver histology clinical/radiological evidence of cirrhosis; or 1.2 HBV DNA positive cirrhosis prior to liver transplantation; or 1.3 HBsAg positive and have had a liver, kidney, heart, lung or bone marrow transplant; and 2 All of the following: 2.1 No continuing alcohol abuse or intravenous drug use; and 2.2 Not coinfected with HCV, HDV, or HIV; and 2.3 Neither ALT nor AST greater than 10 times upper limit of normal; and 2.4
Special Authority for Subsidy - Form SA0539Initial application from any medical practitioner. Approvals valid for 5 years where the patient is likely to benefit from treatment. NoteApplications to be made on the approved forms which are available from: The Co-ordinatorPhone: 09 580 9176Multiple Sclerosis Treatment CommitteeFacsimile: 09 580 9205Level 3, Unisys HouseEmail: murray@ppc.govt.nz650 Great South Road, PenrosePrivate Bag, AUCKLANDBudget managed by appointed clinicians on the Multiple Sclerosis Treatment Assessments Committee (MSTAC). Applications will be considered by MSTAC at its regular meetings and approved subject to eligibility according to the Entry and Stopping criteria (below). Completed application forms must be sent to the co-ordinator for MSTAC and will be considered by MSTAC at the next practicable opportunity. Notification of MSTAC's decision will be sent to the patient, the applying clinician and the patient's GP (if specified). These agents will N
Additional subsidy by endorsement for:Moclobemide tab 150 mg x 100 (Aurorix) up to $47.00Moclobemide tab 300 mg x 60 (Aurorix) up to $56.40Nefazadone tab 100 mg x 56 (Serzone) up to $20.16Nefazadone tab 200 mg x 56 (Serzone) up to $40.32Citalopram tab 20 mg x 28 (Cipramil) up to $27.00is available for patients who: * were taking moclobemide or nefazodone on 1 December 1999 or citalopram on 1 February 2000; or* have previously responded to treatment with moclobemide, nefazodone or citalopram; or* have had a trial of fluoxetine and have to discontinue due to: - inability to tolerate the drug due to side effects; or - failed to respond to an adequate dose and duration of treatment; or* have contraindications to fluoxetine (eg pre-existing significant levels of nausea, breastfeeding, potential drug interactions); The prescription must be endorsed accordingly. We recommend that the words used to indicate eligibility are "certified condition" however these words are not a requirement.
Special Authority for Subsidy - Form SA0551Initial application only from a paediatrician, neurologist or general physician. Approvals valid for 15 months for applications meeting the following criteria: Any of the following: 1 Was on NAED therapy before 1 September 2000; or 2 Seizures are not adequately controlled with optimal older anti-epilepsy drug treatment; or 3 Seizures are controlled adequately but who experience unacceptable side effects from older anti-epilepsy drug treatment. NoteApproval entitles patients to a subsidy for one NAED. Dual NAED therapy will be subsidised for patients who were already stabilised on two NAEDs on or before 31 July 2000 or, for whom a second NAED has been added to therapy with one NAED provided an attempt to withdraw one NAED has been made and was unsuccessful. "Optimal older anti-epilepsy drug therapy" is defined as treatment with those older anti-epilepsy drugs which are indicated and clinically appropriate for the patient, given singly and in combin
Special Authority for Subsidy - Form SA0556Initial application - (Confirmed HIV/AIDS) only from a named general physician. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 Confirmed HIV/AIDS; and 2 Any of the following: 2.1 Symptomatic patient; or 2.2 Both: 2.2.1 Asymptomatic patient; and 2.2.2 Patient aged 12 months and under; or 2.3 Both: 2.3.1 Asymptomatic patient; and 2.3.2 Patient has viral load counts > 10,000 copies per ml or equivalent value on the Chiron test; or 2.4 All of the following: 2.4.1 Asymptomatic patient; and 2.4.2 Patient aged 1 to 5 years; and 2.4.3 CD4 counts < 1,000 cells/mm3; or 2.5 All of the following: 2.5.1 Asymptomatic patient; and 2.5.2 Patient aged 1 to 5 years; and 2.5.3 CD4 counts < 0.25 x total white cell count; or 2.6 All of the following: 2.6.1 Asymptomatic patient; and 2.6.2 Patient aged 6 years and over; and 2.6.3 CD4 counts
Special Authority for Subsidy - Form SA0557Initial application - (Single NAED Therapy) only from a paediatrician, neurologist or general physician. Approvals valid for 15 months for applications meeting the following criteria: Any of the following: 1 Was on NAED therapy before 1 September 2000; or 2 Seizures are not adequately controlled with optimal older anti-epilepsy drug treatment; or 3 Seizures are controlled adequately but who experience unacceptable side effects from older anti-epilepsy drug treatment. Note"Optimal older anti-epilepsy drug therapy" is defined as treatment with those older anti-epilepsy drugs which are indicated and clinically appropriate for the patient, given singly and in combination in adequate doses for the patient's age, weight, and other features affecting the pharmacokinetics of the drug with good evidence of complianceAs a guideline, clinical trials have referred to a notional 50% reduction in seizure frequency as an indicator of success with anti-convulsan
Additional subsidy by endorsement for:Moclobemide tab 150mg x 100 (Aurorix) up to $32.90Moclobemide tab 300mg x 60 (Aurorix) up to $39.48Nefazodone tab 100mg x 56 (Serzone) up to $20.16Nefazodone tab 200mg x 56 (Serzone) up to $40.32Citalopram tab 20mg x 28 (Cipramil) up to $27.00is available for patients who: * were taking moclobemide or nefazodone on 1 December 1999 or citalopram on 1 February 2000; or* have previously responded to treatment with moclobemide, nefazodone or citalopram; or* have had a trial of fluoxetine and have had to discontinue due to - inability to tolerate the drug due to side effects; or - failed to respond to an adequate dose and duration of treatment; or* have contraindications to fluoxetine (eg pre-existing significant levels of nausea, breastfeeding, potential drug interactions). The prescription must be endorsed accordingly. We recommend that the words used to indicate eligibility are "certified condition" however these words are not a requirement.
Additional subsidy by endorsement for:Moclobemide tab 150mg x 100 (Aurorix) up to $32.90Moclobemide tab 300mg x 60 (Aurorix) up to $39.48Nefazodone tab 100mg x 56 (Serzone) up to $20.16Nefazodone tab 200mg x 56 (Serzone) up to $40.32Citalopram tab 20mg x 28 (Cipramil and Celapram) up to $10.00Paroxetine hydrochloride tab 20 mg x 30 (Aropax) up to $35.02is available for patients who: * were taking moclobemide or nefazodone on 1 December 1999 or citalopram on 1 February 2000; or paroxetine hydrochloride on Februrary 2001; or * have previously responded to treatment with moclobemide or nefazodone or citalopram or paroxetine hydrochloride; or* have had a trial of fluoxetine and have had to discontinue due to - inability to tolerate the drug due to side effects; or - failed to respond to an adequate dose and duration of treatment; or* have contraindications to fluoxetine (eg pre-existing significant levels of nausea, breastfeeding, potential drug interactions). The prescription must be e
Special Authority for Subsidy - Form SA0563Initial application only from a relevant specialist. Approvals valid for 2 years for applications meeting the following criteria: Any of the following: 1 Both: 1.1 Acromegaly; and 1.2 Patient has failed surgery, radiotherapy, bromocriptine and other oral therapies; or 2 VIPomas and Glucagonomas - for patients who are seriously ill in order to improve their clinical state prior to definitive surgery.; or 3 Both: 3.1 Gastrinoma; and 3.2 Either: 3.2.1 Patient has failed surgery; or 3.2.2 Patient in metastatic disease after H2 antagonists (or proton pump inhibitors) have failed; or 4 Both: 4.1 Insulinomas; and 4.2 Surgery is contraindicated or has failed; or 5 For pre-operative control of hypoglycaemia and for maintenance therapy; or 6 Both: 6.1 Carcinoid syndrome (diagnosed by tissue pathology and/or urinary 5HIAA analysis); and 6.2 Disabling symptoms not controlled by maximal medical therapy. No
Trandolapril will be funded to the level of the ex-manufacturer price listed in the Schedule for patients who were taking these ACE inhibitors for the treatment of congestive heart failure prior to 1 June 1998. The prescription must be endorsed accordingly. We recommend that the words used to indicate eligibility are "certified condition" or an appropriate description of the patient such as "congestive heart failure", "CHF", "congestive cardiac failure" or "CCF". Definition of Congestive Heart Failure At the request of some prescribers the PTAC Cardiovascular subcommittee has provided a definition of congestive heart failure for the purposes of the funding of the manufacturer's surcharge: "Clinicians should use their clinical judgement. Existing patients would be eligible for the funding of the surcharge if the patient shows signs and symptoms of congestive heart failure, and requires or has in the past required concomitant treatment with a diuretic. The definition could also be considered to include pat
Perindopril will be funded to the level of the ex-manufacturer price listed in the Schedule for patients who were taking these ACE inhibitors for the treatment of congestive heart failure prior to 1 June 1998. The prescription must be endorsed accordingly. We recommend that the words used to indicate eligibility are "certified condition" or an appropriate description of the patient such as "congestive heart failure", "CHF", "congestive cardiac failure" or "CCF". Definition of Congestive Heart Failure At the request of some prescribers the PTAC Cardiovascular subcommittee has provided a definition of congestive heart failure for the purposes of the funding of the manufacturer's surcharge: "Clinicians should use their clinical judgement. Existing patients would be eligible for the funding of the surcharge if the patient shows signs and symptoms of congestive heart failure, and requires or has in the past required concomitant treatment with a diuretic. The definition could also be considered to include pati
Special Authority for Subsidy - Form SA0569Initial application only from a geriatrician, rheumatologist, endocrinologist, gynaecologist or general physician. Approvals valid for 2 years for applications meeting the following criteria: All of the following: 1 Severe osteoporosis; and 2 History of one previous significant osteoporotic fractures demonstrated radiologically; and 3 T-Score <= -3.0 (bone mass density (BMD) >= 3.0 standard deviations below the mean normal value in young adults). NoteIn line with the Australian guidelines for funding alendronate, a vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body. Renewal only from a geriatrician, rheumatologist, endocrinologist, gynaecologist or general physician. Approvals valid for 2 years where the t
Special Authority for Subsidy - Form SA0572Initial application only from a psychiatrist. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 Patient presenting with first episode schizophrenia or related psychoses; or 2 Both: 2.1 Patients suffers from schizophrenia or related psychoses ; and 2.2 Either: 2.2.1 A trial of risperidone has been discontinued because of unacceptable side effects; or 2.2.2 A trial of risperidone has been discontinued because of inadequate response. Renewal only from a psychiatrist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0575Initial application - (Confirmed HIV/AIDS) only from a named general physician. Approvals valid without further renewal unless notified for applications meeting the following criteria: Both: 1 Confirmed HIV/AIDS; and 2 Any of the following: 2.1 Symptomatic patient; or 2.2 Both: 2.2.1 Asymptomatic patient; and 2.2.2 Patient aged 12 months and under; or 2.3 Both: 2.3.1 Asymptomatic patient; and 2.3.2 Patient has viral load counts > 10,000 copies per ml or equivalent value on the Chiron test; or 2.4 All of the following: 2.4.1 Asymptomatic patient; and 2.4.2 Patient aged 1 to 5 years; and 2.4.3 CD4 counts < 1,000 cells/mm3; or 2.5 All of the following: 2.5.1 Asymptomatic patient; and 2.5.2 Patient aged 1 to 5 years; and 2.5.3 CD4 counts < 0.25 x total white cell count; or 2.6 All of the following: 2.6.1 Asymptomatic patient; and 2.6.2 Patient aged 6 years and over
Special Authority for Subsidy - Form SA0579Initial application - (Cystic fibrosis or renal failure) only from a relevant specialist. Approvals valid for 3 years for applications meeting the following criteria: Either: 1 cystic fibrosis; or 2 chronic renal failure or continuous ambulatory peritoneal dialysis (CAPD) patient. Initial application - (Indications other than cystic fibrosis or renal failure) only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria: Any of the following: 1 cancer in children; or 2 cancers affecting alimentary tract where there are malabsorption problems in patients over the age of 20 years; or 3 failure to thrive; or 4 growth deficiency; or 5 bronchopulmonary dysplasia; or 6 premature and post premature infant. Renewal - (Cystic fibrosis or renal failure) only from a relevant specialist or general practitioner on the recommendation of such a specialist. Approvals valid for 3 years for applicatio
Special Authority for Subsidy - Form SA0580Initial application - (Inborn errors of metabolism) only from a relevant specialist. Approvals valid for 3 years where inborn errors of metabolism. Initial application - (Indications other than inborn errors of metabolism) only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria: Any of the following: 1 failure to thrive ; or 2 growth deficiency; or 3 bronchopulmonary dysplasia ; or 4 fat malabsorption ; or 5 lymphangiectasia; or 6 short bowel syndrome ; or 7 infants with necrotising enterocolitis; or 8 biliary atresia. Renewal - (Inborn errors of metabolism) only from a relevant specialist or general practitioner on the recommendation of such a specialist. Approvals valid for 3 years for applications meeting the following criteria: Both: 1 The treatment remains appropriate and the patient is benefiting from treatment; and 2 General Practitioners must include the name of
Special Authority for Subsidy - Form SA0581Initial application - (Cystic fibrosis) only from a relevant specialist. Approvals valid for 3 years for applications meeting the following criteria: Both: 1 infant aged four years or under; and 2 cystic fibrosis. Initial application - (Indications other than cystic fibrosis) only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria: Both: 1 infant aged four years or under; and 2 Any of the following: 2.1 cancer in children; or 2.2 failure to thrive; or 2.3 growth deficiency; or 2.4 bronchopulmonary dysplasia; or 2.5 premature and post premature infants. Renewal - (Cystic fibrosis) only from a relevant specialist or general practitioner on the recommendation of such a specialist. Approvals valid for 3 years for applications meeting the following criteria: Both: 1 The treatment remains appropriate and the patient is benefiting from treatment; and 2 General Practiti
Special Authority for Subsidy - Form SA0582Initial application only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria: Either: 1 protein losing enteropathy; or 2 high protein needs (eg burns). Renewal only from a relevant specialist or general practitioner on the recommendation of such a specialist. Approvals valid for 1 year for applications meeting the following criteria: Both: 1 The treatment remains appropriate and the patient is benefiting from treatment; and 2 General Practitioners must include the name of the specialist and date contacted.
Special Authority for Subsidy - Form SA0585Initial application - (Cystic fibrosis) only from a relevant specialist. Approvals valid for 3 years for applications meeting the following criteria: All of the following: 1 Cystic fibrosis; and 2 other lower calorie products have been tried; and 3 patient has substantially increased metabolic requirements; and 4 Either: 4.1 The product is to be used as a supplement; or 4.2 The product is to be used as a complete diet.Initial application - (Indications other than cystic fibrosis) only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria: All of the following: 1 Any of the following: 1.1 any condition causing malabsorption ; or 1.2 failure to thrive ; or 1.3 increased nutritional requirements.; and 2 other lower calorie products have been tried; and 3 patient has substantially increased metabolic requirements; and 4 Either: 4.1 The product is to be used a
Special Authority for Subsidy - Form SA0587Initial application only from a relevant specialist. Approvals valid for 3 years for applications meeting the following criteria: Both: 1 acute or chronic renal failure; and 2 Either: 2.1 The product is to be used as a supplement (maximum 500 ml per day); or 2.2 The product is to be used as a complete diet.Renewal only from a relevant specialist or general practitioner on the recommendation of such a specialist. Approvals valid for 3 years for applications meeting the following criteria: All of the following: 1 The treatment remains appropriate and the patient is benefiting from treatment; and 2 Either: 2.1 The product is to be used as a supplement (maximum 500 ml per day); or 2.2 The product is to be used as a complete diet; and 3 General Practitioners must include the name of the specialist and date contacted.
Special Authority for Subsidy - Form SA0588Initial application only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria: Both: 1 CORD patients who have hypercapnia; and 2 Either: 2.1 The product is to be used as a supplement (maximum 500 ml per day); or 2.2 The product is to be used as a complete diet.Renewal only from a relevant specialist or general practitioner on the recommendation of such a specialist. Approvals valid for 1 year for applications meeting the following criteria: All of the following: 1 The treatment remains appropriate and the patient is benefiting from treatment; and 2 Either: 2.1 The product is to be used as a supplement (maximum 500 ml per day); or 2.2 The product is to be used as a complete diet; and 3 General Practitioners must include the name of the specialist and date contacted.
Special Authority for Subsidy - Form SA0589Initial application only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria: All of the following: 1 Anorexia and weight loss; and 2 Either: 2.1 decompensating liver disease without encephalopathy ; or 2.2 protein losing gastro-enteropathy; and 3 Either: 3.1 The product is to be used as a supplement (maximum 500 ml per day); or 3.2 The product is to be used as a complete diet.Renewal only from a relevant specialist or general practitioner on the recommendation of such a specialist. Approvals valid for 1 year for applications meeting the following criteria: All of the following: 1 The treatment remains appropriate and the patient is benefiting from treatment; and 2 Either: 2.1 The product is to be used as a supplement (maximum 500 ml per day); or 2.2 The product is to be used as a complete diet; and 3 General Practitioners must include the name of the specialis
Special Authority for Subsidy - Form SA0590Initial application only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria: All of the following: 1 infant aged one to six years; and 2 Any of the following: 2.1 any condition causing malabsorption ; or 2.2 failure to thrive; or 2.3 increased nutritional requirements; and 3 Either: 3.1 The product is to be used as a supplement (maximum 500 ml per day); or 3.2 The product is to be used as a complete diet.Renewal only from a relevant specialist or general practitioner on the recommendation of such a specialist. Approvals valid for 1 year for applications meeting the following criteria: All of the following: 1 The treatment remains appropriate and the patient is benefiting from treatment; and 2 Either: 2.1 The product is to be used as a supplement (maximum 500 ml per day); or 2.2 The product is to be used as a complete diet; and 3 General Practitioners must
Special Authority for Subsidy - Form SA0591Initial application only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria: Both: 1 Any of the following: 1.1 enteral feeding; or 1.2 nasogastric; or 1.3 nasoduodenal ; or 1.4 nasojejunal; or 1.5 gastrostomy/jejunostomy; and 2 Either: 2.1 The product is to be used as a supplement; or 2.2 The product is to be used as a complete diet.Renewal only from a general practitioner or relevant specialist. Approvals valid for 1 year for applications meeting the following criteria: All of the following: 1 The treatment remains appropriate and the patient is benefiting from treatment; and 2 Either: 2.1 The product is to be used as a supplement; or 2.2 The product is to be used as a complete diet; and 3 General Practitioners must include the name of the specialist and date contacted.
Special Authority for Subsidy - Form SA0592Initial application only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria: Both: 1 Any of the following: 1.1 malabsorption ; or 1.2 short bowel syndrome; or 1.3 enterocutaneous fistulas ; or 1.4 pancreatitis; and 2 Either: 2.1 The product is to be used as a supplement (maximum 500 ml per day); or 2.2 The product is to be used as a complete diet.NoteEach of these products is highly specialised and would be prescribed only by an expert for a specific disorder. The alternative is hospitalisation. Elemental 028 Extra is more expensive than other products listed in this section and should only be used where the alternatives have been tried first and/or are unsuitable. Renewal only from a relevant specialist or general practitioner on the recommendation of such a specialist. Approvals valid for 1 year for applications meeting the following criteria: All of the following:
Special Authority for Subsidy - Form SA0594Initial application only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria: Both: 1 Type I and II diabetics who require nutritional supplementation.; and 2 Either: 2.1 The product is to be used as a supplement (maximum 500 ml per day); or 2.2 The product is to be used as a complete diet.Renewal only from a relevant specialist or general practitioner on the recommendation of such a specialist. Approvals valid for 1 year for applications meeting the following criteria: All of the following: 1 The treatment remains appropriate and the patient is benefiting from treatment; and 2 Either: 2.1 The product is to be used as a supplement (maximum 500 ml per day); or 2.2 The product is to be used as a complete diet; and 3 General Practitioners must include the name of the specialist and date contacted.
Special Authority for Subsidy - Form SA0596Initial application only from a relevant specialist. Approvals valid for 3 years for applications meeting the following criteria: Either: 1 gluten enteropathy has been diagnosed by biopsy; or 2 dermatitis herpetiformis. NoteA premium may be payable if the subsidy does not match the price charged by the manufacturer. The subsidy for these products reflects the philosophy that the patient incurs no additional financial burden for purchasing specialised more expensive products. Renewal only from a relevant specialist or general practitioner on the recommendation of such a specialist. Approvals valid for 3 years for applications meeting the following criteria: Both: 1 The treatment remains appropriate and the patient is benefiting from treatment; and 2 General Practitioners must include the name of the specialist and date contacted.
Special Authority for Subsidy - Form SA0597Initial application - (PKU Patient aged over 16) only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria: Both: 1 PKU; and 2 blood phenylalanine level < 900 mmol/litre (average of tests over last 12 months). Initial application - (Patient aged over 16) only from a relevant specialist. Approvals valid for 3 years for applications meeting the following criteria: Any of the following: 1 dietary management of homocystinuria; or 2 inborn errors of metabolism other than PKU; or 3 dietary management of maple syrup urine disease..Initial application - (Patient aged 16 or under) only from a relevant specialist. Approvals valid for 3 years for applications meeting the following criteria: Any of the following: 1 dietary management of homocystinuria; or 2 PKU and other inborn errors of metabolism; or 3 dietary management of maple syrup urine disease..Renewal - (PKU Patient aged over 16
Special Authority for Subsidy - Form SA0604Initial application - (Lactase deficiency or disaccharide intolerance) only from a relevant specialist. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 Patient is less than 3 years of age; and 2 Either: 2.1 diagnosed as suffering from congenital lactase deficiency; or 2.2 suffering from disaccharide intolerance. NoteSecondary lactose intolerance in children is usually short lasting, and can be controlled by dietary measures and by giving sufficient calories to regenerate digestive enzymes. The subsidy for these products reflects the philosophy that the patient incurs no additional financial burden for purchasing specialised more expensive products. Initial application - (Infant with intolerance to cows' milk) only from a relevant specialist. Approvals valid for 6 months for applications meeting the following criteria: Both: 1 intolerant to cows' milk; and 2 patient is less than 3 years of age. No
Special Authority for Subsidy - Form SA0605Initial application - (Cystic fibrosis or renal disorder) only from a relevant specialist. Approvals valid for 3 years for applications meeting the following criteria: Both: 1 Either: 1.1 cystic fibrosis; or 1.2 renal disorder; and 2 Either: 2.1 The product is to be used as a supplement; or 2.2 The product is to be used as a complete diet.Initial application - (Indications other than cystic fibrosis or renal disorder) only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria: Both: 1 Any of the following: 1.1 any condition causing malabsorption; or 1.2 failure to thrive; or 1.3 increased nutritional requirements; and 2 Either: 2.1 The product is to be used as a supplement; or 2.2 The product is to be used as a complete diet.Renewal - (Cystic fibrosis or renal disorder) only from a relevant specialist or general practitioner. Approvals valid for 3 years
Special Authority for Subsidy - Form SA0606Initial application only from a paediatrician. Approvals valid for 3 years for applications meeting the following criteria: Both: 1 child (up to 18 years) with chronic renal failure.; and 2 Either: 2.1 The product is to be used as a supplement; or 2.2 The product is to be used as a complete diet.Renewal only from a paediatrician. Approvals valid for 3 years for applications meeting the following criteria: Both: 1 The treatment remains appropriate and the patient is benefiting from treatment; and 2 Either: 2.1 The product is to be used as a supplement; or 2.2 The product is to be used as a complete diet.
Special Authority for Subsidy - Form SA0607Initial application only from a paediatrician. Approvals valid for 3 years for applications meeting the following criteria: Both: 1 Child (up to 18 years) who is awaiting liver transplant; and 2 Either: 2.1 The product is to be used as a supplement (maximum 500 ml per day); or 2.2 The product is to be used as a complete diet.Renewal only from a paediatrician. Approvals valid for 3 years for applications meeting the following criteria: Both: 1 The treatment remains appropriate and the patient is benefiting from treatment; and 2 Either: 2.1 The product is to be used as a supplement (maximum 500 ml per day); or 2.2 The product is to be used as a complete diet.
Special Authority for Subsidy - Form SA0609Initial application - (Serevent MDI, Serevent Accuhaler Foradil, Oxis Turbuhaler 12 mcg, Symbicort Turbuhaler) only from a relevant specialist or general practitioner. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 Both: 1.1 Child under the age of 12 with poorly controlled asthma; and 1.2 Either: 1.2.1 Required at least three months of 400 mcg or more daily inhaled beclomethasone or budesonide; or 1.2.2 Required at least three months of 200 mcg or more of fluticasone; or 2 Both: 2.1 Adult with poorly controlled asthma; and 2.2 Either: 2.2.1 Required at least three months of 1500 mcg or more daily inhaled beclomethasone or budesonide; or 2.2.2 Required at least three months of 750 mcg or more of fluticasone. NotePatients are to be reviewed at least at six months to assess compliance and effectiveness of therapy. Special Authority approvals are interchangeable among all prese
Special Authority for Subsidy - Form SA0610Initial application from any specialist. Approvals valid without further renewal unless notified for applications meeting the following criteria: All of the following: 1 Quantity used by patient on a weekly volume intraveneously (Details to be attached to application); and 2 Amount of nutrition patient is able to receive orally (Details to be attached to application); and 3 Exact formula of TPN (Details to be attached to application); and 4 Who has paid for TPN so far (Details to be attached to application); and 5 Place of manufacture (Details to be attached to application); and 6 Complete medical history of patient including details of previous therapies. (Details to be attached to application). Renewal - (Previous approval has expired) from any specialist. Approvals valid without further renewal unless notified where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0611Initial application from any medical practitioner. Approvals valid for 1 year where applicaton approved by the Cystic Fibrosis DN'ase Advisory Panel. NoteApplications to be made on the approved forms which are available from: The Co-ordinatorCystic Fibrosis DN'ase Advisory PanelPhone: (04) 460 4990 PHARMAC, PO Box 10 254 WellingtonFacsimile: (04) 916 7571Email: erin.murphy@pharmac.govt.nzPrescriptions for patients approved for treatment must be written by respiratory physicians or paediatricians who have experience and expertise in treating cystic fibrosis.
Special Authority for Subsidy - Form SA0614Initial application only from a geriatrician, rheumatologist, endocrinologist, gynaecologist or general physician. Approvals valid for 2 years for applications meeting the following criteria: All of the following: 1 Severe osteoporosis; and 2 History of one previous significant osteoporotic fractures demonstrated radiologically; and 3 T-Score <= -3.0 (bone mass density (BMD) >= 3.0 standard deviations below the mean normal value in young adults). NoteIn line with the Australian guidelines for funding alendronate, a vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral bodyRenewal only from a geriatrician, rheumatologist, endocrinologist, gynaecologist or general physician. Approvals valid for 2 years where the tr
Special Authority for Subsidy - Form SA0615Initial application only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria: Both: 1 The product is to be used as a complete diet; and 2 Either: 2.1 Patient has metabolic disorders of fat metabolism; or 2.2 Patient has chylothorax. Renewal only from a relevant specialist or general practitioner on the recommendation of such a specialist. Approvals valid for 1 year for applications meeting the following criteria: Both: 1 The treatment remains appropriate and the patient is benefiting from treatment; and 2 General Practitioners must include the name of the specialist and date contacted.
Special Authority for Manufacturers Price - Form SA0616Initial application - (Conditions other than transient ischaemic episodes) only from a cardiothoracic surgeon, cardiologist or general physician. Approvals valid without further renewal unless notified for applications meeting the following criteria: Either: 1 Patients with prosthetic heart valves - as an adjunct to oral anticoagulation for prophylaxis of thromboembolism; or 2 Patients after coronary artery vein bypass graft - as an adjunct to aspirin or as monotherapy for patients who are aspirin intolerant. NoteAspirin intolerant patients are defined as those with aspirin induced asthma, urticaria, or anaphylaxi, or those with significant aspirin induced bleeding, excluding bruisingInitial application - (Transient ischaemic episodes) only from a neurologist, neuro surgeon, cardiologist, vascular surgeon or general physician. Approvals valid without further renewal unless notified where patients who continue to have transient ischaemic
a) Prescribers may code prescriptions "contraceptive" (code "O") when used as indicated for contraception. The period of supply and prescription charge will be as per other contraceptives, as follows: - $3.00 prescription charge (patient co-payment) will apply; - prescription may be written for up to six months supply; and- pharmacists may dispense up to three months supply. b) Prescriptions coded in any other way are subject to the non-contraceptive prescription charges, and the non-contraceptive period of supply. ie. Prescriptions may be written for up to three months supply, and dispensed monthly
Special Authority for Subsidy - Form SA0622Initial application only from a geriatrician, rheumatologist, endocrinologist, gynaecologist or general physician. Approvals valid without further renewal unless notified for applications meeting the following criteria: All of the following: 1 Severe osteoporosis; and 2 History of one previous significant osteoporotic fractures demonstrated radiologically; and 3 T-Score <= -3.0 (bone mass density (BMD) >= 3.0 standard deviations below the mean normal value in young adults). NoteIn line with the Australian guidelines for funding alendronate, a vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral bodyRenewal only from a geriatrician, rheumatologist, endocrinologist, gynaecologist or general physician. Approvals va
Special Authority for Subsidy - Form SA0623Initial application from any medical practitioner. Approvals valid for 1 year for applications meeting the following criteria: All of the following: 1 The patient is not predisposed to heart arrhythmias; and 2 The patient does not have a pre-existing QT-prolongation or hepatic failure; and 3 The patient is not using other medications which either inhibit the cytochrome P450 3A4 enzyme system or prolong the QT interval; and 4 Any of the following: 4.1 Both: 4.1.1 The patient is an adult with severe reflux oesophagitis; and 4.1.2 other treatment, including acid suppression with proton pump inhibitors, has failed; or 4.2 gastroparesis; or 4.3 malignancy of GI tract causing gastroparesis (or gastric outlet obstruction); or 4.4 The patient is a child (not including infants from 0 to 3 months of age who were born prematurely) with severe gastro-oesophageal reflux; and 5 Diagnosis has been made or confirmed by a general p
Special Authority for Subsidy - Form SA0626Initial application only from a renal physician. Approvals valid for 2 years for applications meeting the following criteria: All of the following: General Criteria: 1 Anaemia of end-stage renal failure (other treatable causes of anaemia being excluded); and 2 Been on haemodialysis or continuous ambulatory peritoneal dialysis (CAPD) for at least three months; and 3 Not under evaluation for, or awaiting, a live donor kidney transplant; and 4 Any of the following: Specific Criteria: 4.1 Anephric; or 4.2 Dependent on regular blood transfusion (1 unit each 4-8 weeks) to maintain haemoglobin > 60g/L; or 4.3 Dependent on regular blood transfusion but cannot be transfused because of severe transfusion reactions; or 4.4 Transfusion induced haemosiderosis (clinical manifestations, serum ferritin >1500 ug/L); or 4.5 Haemoglobin < 70 g/L (mean of at least 4 haemoglobin concentrations over 4 months); or 4.6 Both: 4.6.1 Haemo
Prescribing GuidelineTreatment with HMG CoA Reductase Inhibitors (Statins) is recommended for patients withdyslipidaemia and an absolute 5 year cardiovascular risk of 15% or greater. New Zealand Cardiovascular Guideline Group statement. "The 1996 Heart Foundation guidelines for the Assessment and Management of Dyslipidaemia are currently being revised. An evidence-based guideline on the Assessment and Management of Cardiovascular Risk will be developed in 2002. The Cardiovascular Guideline Group has written an interim consensus statement for themanagement of dyslipidaemia. The Heart Foundation cardiovascular risk tables should be used to determine risk. Certain groups are classified to be at very high risk (>20%) and should be treated as such: - Patients who have had a previous cardiovascular event (angina, MI, angioplasty, coronary artery bypass grafts, TIA, ischaemic stroke and peripheral vascular disease)- Patients with genetic lipid disorders- Patients with diabetes and associated microa
Special Authority for Subsidy - Form SA0628Initial application only from a cardiologist. Approvals valid without further renewal unless notified for applications meeting the following criteria: Any of the following: 1 Both: 1.1 Congestive heart failure; and 1.2 Cannot tolerate two ACE inhibitors due to persistent cough that resolves on cessation and recurs on re-challenge with ACE inhibitor; or 2 Patients who have experienced angioedema on an ACE inhibitor at any time in the past; or 3 Patients who have experienced angioedema (even if not using an ACE inhibitor) in the last 2 years. Renewal - ((2 year approvals granted before April 2002)) only from a cardiologist. Approvals valid without further renewal unless notified where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0631Initial application only from an ophthalmologist. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 Both: 1.1 Primary open-angle glaucoma; and 1.2 Any of the following: 1.2.1 Patient cannot tolerate Beta-blockers, or Beta-blockers are contraindicated; or 1.2.2 Patient cannot tolerate Pilocarpine, or Pilocarpine is contraindicated; or 1.2.3 Patient cannot tolerate Dorzolamide, or Dorzolamide is contraindicated; or 1.2.4 A reduction in intraocular pressure of 15% or more is not achieved or maintained using dorzolamide either alone or in combination with a beta-blocker; or 2 There is progressive visual field loss and/or optic nerve damage persists after treatment with dorzolamide either alone or in combination with a beta-blocker. NoteSubsidised also for adjunctive use for the treatment of patients who have met the initial application criteria, and in whom latanoprost monotherapy has bee
Special Authority for Subsidy - Form SA0633Initial application only from a general practitioner or relevant specialist. Approvals valid without further renewal unless notified for applications meeting the following criteria: Both: 1 Patient is already on an ACE inhibitor or Angiotensin II Antagonist; and 2 Any of the following: 2.1 Both: 2.1.1 Symptomatic heart failure NYHA functional class II-III; and 2.1.2 Patient has been treated with metoprolol and is intolerant to metoprolol or has demonstrated a sub-optimal response to metoprolol; or 2.2 Symptomatic heart failure NYHA functional class III-IV; or 2.3 Patient has left ventricular systolic dysfunction with an ejection fraction of less than 35%.NoteWhere possible treatment should be initiated by or on the recommendation of a specialist.
Special Authority for Subsidy - Form SA0635Initial application only from a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria: All of the following: 1 Rheumatoid arthritis; and 2 Patient is not a pregnant woman, or a woman of child-bearing age without adequate contraception; and 3 Patient has been unable to tolerate or has a contraindication to or has had an inadequate response to sulphasalazine and methotrexate (individually or in combination). Renewal only from a rheumatologist. Approvals valid without further renewal unless notified for applications meeting the following criteria: Both: 1 Compliance (prescriber determined) with medication; and 2 Improved rheumatoid arthritis symptom control. NotePatient should have full blood count and liver function tests regularly monitored.
Special Authority for Subsidy - Form SA0637Initial application - (National Heart Foundation risk groups A1:1, A1:2, B, C, D or E) only from a relevant specialist or general practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria: All of the following: 1 The patient has been offered 3-6 months of counseling and an opportunity to modify lifestyle; and 2 Any of the following: 2.1 Both: 2.1.1 NHF A1:1 - Clinically proven ischaemic heart disease; and 2.1.2 total cholesterol > 5.5; or 2.2 Both: 2.2.1 NHF A1:2 - Post coronary artery bypass graft (CABG) or angioplasty; and 2.2.2 total cholesterol > 4.5; or 2.3 Post heart transplant (regardless of cholesterol level); or 2.4 Both: 2.4.1 NHF B: Patients with > 20% 5-year cardiovascular disease risk; and 2.4.2 total cholesterol > 9.0; or 2.5 Both: 2.5.1 NHF C: 15-20% 5-year cardiovascular disease risk; and 2.5.2 total cholesterol >
Special Authority for Subsidy - Form SA0639Initial application - (No previous use) only from a relevant specialist or general practitioner. Approvals valid for 3 months for applications meeting the following criteria: All of the following: 1 The patient has a clinical diagnosis of heavy menstrual bleeding; and 2 The patient has failed to respond to or is unable to tolerate other appropriate pharmaceutical therapies as per the Heavy Menstrual Bleeding Guidelines; and 3 Either: 3.1 serum ferritin level < 16 mg/l (within the last 12 months); or 3.2 haemoglobin level < 120 g/l . NoteApplications are not to be made for use in patients as contraception except where they meet the above criteriaInitial application - (Previous use before 1 October 2002) only from a relevant specialist or general practitioner. Approvals valid for 3 months for applications meeting the following criteria: All of the following: 1 The patient had a clinical diagnosis of heavy menstrual bleeding; and 2
Special Authority for Waiver of Rule - Form SA0641Initial application only from a diabetologist, general physician or paediatrician. Approvals valid without further renewal unless notified for applications meeting the following criteria: Either: 1 Both: 1.1 Use alone (monotherapy); and 1.2 The patient is unable to use any other insulins including those on insulin pump treatment; or 2 Both: 2.1 Use with insulin other than insulin isophane (including ready-mixed preparations); and 2.2 A reasonable trial of insulin isophane has been undertaken and it is not effective or not well tolerated. Note"Reasonable trial", "unable to use", "not effective", "not well tolerated", and "not well tolerated" are not defined and we ask clinicians to use their clinical judgement in interpreting these terms.
Special Authority for Subsidy - Form SA0643Initial application - (CML) only from an oncologist or relevant specialist. Approvals valid for 7 months where approved by the The Glivec Co-ordinator. Initial application - (GIST) only from an oncologist. Approvals valid for 1 year where approved by the The Glivec Co-ordinator. Renewal - (CML) only from an oncologist or relevant specialist. Approvals valid for 6 months where approved by the The Glivec Co-ordinator. Initial application - (GIST) only from an oncologist. Approvals valid for 1 year where approved by the The Glivec Co-ordinator. NoteApplication forms are available from, and prescriptions should be sent to: The Glivec Co-ordinatorPhone: 09 580 9176Level 3, Unisys HouseFacsimile: 09 580 9205650 Great South Road, PenroseEmail: murray@ppc.govt.nzPrivate Bag, AUCKLANDSpecial Authority criteria for CML - access by applicationFunded for patients with diagnosis (confirmed by a haematologist) of a chronic myeloid leukaemia (CML) i
Special Authority for Subsidy - Form SA0645Initial application only from a renal physician. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 Both: 1.1 patient in chronic renal failure; and 1.2 Haemoglobin <= 100 g/L; and 2 Either: 2.1 Both: 2.1.1 patient is not diabetic; and 2.1.2 glomerular filtration rate <= 30 ml/min; or 2.2 Both: 2.2.1 patient is diabetic; and 2.2.2 glomerular filtration rate <= 45 ml/min. Renewal only from a renal physician. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment. NoteErythropoietin beta is indicated in the treatment of anaemia associated with chronic renal failure (CRF) where no cause for anaemia other than CRF is detected and there is adequate monitoring of iron stores and iron replacement therapy. The Cockroft-Gault Formula may be used to estimate glomerular filtration rate (GFR) in persons 18 years and over:GFR (male)
Special Authority for Subsidy - Form SA0646Initial application only from a renal physician. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 Both: 1.1 patient in chronic renal failure; and 1.2 Haemoglobin <= 100 g/L; and 2 Any of the following: 2.1 Both: 2.1.1 patient is not diabetic; and 2.1.2 glomerular filtration rate <= 30 ml/min; or 2.2 Both: 2.2.1 patient is diabetic; and 2.2.2 glomerular filtration rate <= 45 ml/min; or 2.3 patient is on haemodialysis or peritoneal dialysis. Renewal only from a renal physician. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment. NoteErythropoietin beta is indicated in the treatment of anaemia associated with chronic renal failure (CRF) where no cause for anaemia other than CRF is detected and there is adequate monitoring of iron stores and iron replacement therapy. The Cockroft-Gault Formula may be used to estim
Special Authority for Manufacturers Price - Form SA0648Initial application - (Conditions other than transient ischaemic episodes) only from a cardiothoracic surgeon, cardiologist or general physician. Approvals valid without further renewal unless notified for applications meeting the following criteria: Either: 1 Patients with prosthetic heart valves - as an adjunct to oral anticoagulation for prophylaxis of thromboembolism; or 2 Patients after coronary artery vein bypass graft - as an adjunct to aspirin or as monotherapy for patients who are aspirin intolerant. NoteAspirin intolerant patients are defined as those with aspirin induced asthma, urticaria, or anaphylaxi, or those with significant aspirin induced bleeding, excluding bruisingInitial application - (Transient ischaemic episodes) only from a neurologist, neuro surgeon, cardiologist, vascular surgeon or general physician. Approvals valid without further renewal unless notified where patients who continue to have transient ischaemic
Special Authority for Subsidy - Form SA0649Initial application - (Conditions other than transient ischaemic episodes) only from a cardiothoracic surgeon, cardiologist or general physician. Approvals valid without further renewal unless notified for applications meeting the following criteria: Either: 1 Patients with prosthetic heart valves - as an adjunct to oral anticoagulation for prophylaxis of thromboembolism; or 2 Patients after coronary artery vein bypass graft - as an adjunct to aspirin or as monotherapy for patients who are aspirin intolerant. NoteAspirin intolerant patients are defined as those with aspirin induced asthma, urticaria, or anaphylaxi, or those with significant aspirin induced bleeding, excluding bruisingInitial application - (Transient ischaemic episodes) only from a neurologist, neuro surgeon, cardiologist, vascular surgeon or general physician. Approvals valid without further renewal unless notified where patients who continue to have transient ischaemic episodes des
Special Authority for Subsidy - Form SA0652Initial application - (Single NAED Therapy) only from a paediatrician, neurologist or general physician. Approvals valid for 15 months for applications meeting the following criteria: Any of the following: 1 Was on NAED therapy before 1 September 2000; or 2 Seizures are not adequately controlled with optimal older anti-epilepsy drug treatment; or 3 Seizures are controlled adequately but who experience unacceptable side effects from older anti-epilepsy drug treatment. Note"Optimal older anti-epilepsy drug therapy" is defined as treatment with those older anti-epilepsy drugs which are indicated and clinically appropriate for the patient, given singly and in combination in adequate doses for the patient's age, weight, and other features affecting the pharmacokinetics of the drug with good evidence of complianceInitial application - (Dual NAED Therapy) only from a paediatrician, neurologist or general physician. Approvals valid for 18 months for app
Special Authority for Subsidy - Form SA0657Initial application - (Helicobacter pylori infections) only from a general practitioner or relevant specialist. Approvals valid for 6 months for applications meeting the following criteria: Both: 1 Eradication of Helicobacter pylori in patient with proven infection; and 2 Peptic ulcer disease proven by endoscopy. NoteMaximum of two prescriptions (two courses) per patient. Initial application - (Mycobacterial infections) only from a respiratory specialist, infectious disease specialist or paediatrician. Approvals valid for 2 years for applications meeting the following criteria: Any of the following: 1 Mycobacterium Avium Intracellulare Complex infections in patient with AIDS; or 2 Atypical and drug-resistant mycobacterial infection; or 3 All of the following: 3.1 Prophylaxis against disseminated Mycobacterium Avium Intracellulare Complex infection; and 3.2 HIV infection; and 3.3 CD4 count <= 50 cells/mm3. Renewal - (Mycobact
Additional subsidy by endorsement for:Moclobemide tab 150 mg x 500 (Apo-Moclobemide) up to $46.00Moclobemide tab 150 mg x 100 (Aurorix) up to $32.90Moclobemide tab 300 mg x 100 (Apo-Moclobemide) up to $26.11Moclobemide tab 300 mg x 60 (Aurorix) up to $39.48Nefazodone tab 100 mg x 56 (Serzone) up to $20.16Nefazodone tab 200 mg x 56 (Serzone) up to $40.32Citalopram tab 20 mg x 28 (Celapram) up to $4.00Citalopram tab 20 mg x 28 (Cipramil) up to $10.00Paroxetine hydrochloride tab 20 mg x 30 (Aropax) up to $35.02is available for patients who: - were taking moclobemide or nefazodone on 1 December 1999 or citalopram on 1 February 2000; or paroxetine hydrochloride on February 2001; or- have previously responded to treatment with moclobemide or nefazodone or citalopram or paroxetine hydrochloride; or- have had a trial of fluoxetine and have had to discontinue due to- inability to tolerate the drug due to side effects; or- failed to respond to an adequate dose and duration of treatment; or
Special Authority for Subsidy - Form SA0661Initial application only from a psychiatrist. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 The patient has "treatment resistant" depression; and 2 Either: 2.1 The patient must have had a trial of two different antidepressants and failed to respond to an adequate dose over an adequate period of time (usually at least four weeks); or 2.2 Both: 2.2.1 The patient is currently a hospital in-patient as a result of an acute depressive episode; and 2.2.2 The patient must have had a trial of one other antidepressant and failed to respond to an adequate dose over an adequate period of time. Renewal from any medical practitioner. Approvals valid for 2 years where patient has a high risk of relapse (prescriber determined)..NoteFirst prescription can be written by a psychiatrist or psychiatric registrar. Subsequent prescriptions may be written by a General Practitioner
a) Spacer devices and masks also available to paediatricians employed by a DHB on a wholesalesupply order signed by the paediatrician. Limited to one pack of 20 per order. Orders via ahospital pharmacy. b) Only available for children aged six years and under. c) For Space Chamber and Foremount Child's Silicone Mask wholesale supply order must indicate clearly if either the spacer device, the mask, or both are required. d) Distributed by Airflow Products. Forward orders to: Airflow ProductsPO Box 1485 Telephone: 04 499 1240 or 0800 AIR FLOWWellington Facsimile: 04 499 1245 or 0800 323 270
Special Authority for Subsidy - Form SA0667Initial application only from a named specialist. Approvals valid for 4 months for applications meeting the following criteria: All of the following: 1 To be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and 2 Patient is less than 18 years of age at commencement of treatment; and 3 Patient has had severe active polyarticular course Juvenile Idiopathic Arthritis (JIA) for 6 months duration or longer; and 4 Patient has tried and not responded to at least three months of oral or parenteral methotrexate at a dose of 10-20mg/m2 weekly in combination with oral corticosteroids (prednisone 0.25 mg/kg); and 5 Patient has tried and not responded to at least three months of oral or parenteral methotrexate (at a dose of 10-15mg/m2 weekly) in combination with one other disease-modifying agent; and 6 Both: 6.1 Either: 6.1.1 Patient has persistent symptoms of poorly-cont
Additional subsidy by endorsement for:Nefazodone tab 100 mg x 56 (Serzone) up to $20.16Nefazodone tab 200 mg x 56 (Serzone) up to $40.32Citalopram tab 20 mg x 28 (Celapram) up to $4.00Citalopram tab 20 mg x 28 (Cipramil) up to $10.00Paroxetine hydrochloride tab 20 mg x 30 (Aropax) up to $35.02is available for patients who: -were taking nefazodone on 1 December 1999 or citalopram on 1 February 2000; or paroxetine hydrochloride on February 2001; or- have previously responded to treatment with nefazodone or citalopram or paroxetinehydrochloride; or- have had a trial of fluoxetine and have had to discontinue due to- inability to tolerate the drug due to side effects; or- failed to respond to an adequate dose and duration of treatment; or- have contraindications to fluoxetine (eg pre-existing significant levels of nausea, breastfeeding, potential drug interactions). The prescription must be endorsed accordingly.
Special Authority for Subsidy - Form SA0693Initial application only from a relevant specialist or vocationally registered general practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria: All of the following: 1 Severe osteoporosis; and 2 History of one previous significant osteoporotic fracture demonstrated radiologically; and 3 T-Score <= -3.0 (bone mass density (BMD) >= 3.0 standard deviations below the mean normal value in young adults). NoteIn line with the Australian guidelines for funding alendronate, a vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral bodyRenewal - ((2 year approvals granted before February 2002)) only from a geriatrician, rheumatologist, endocrinologist, gynaecologis
Special Authority for Subsidy - Form SA0696Initial application - (Narcolepsy) only from a neurologist or respiratory specialist. Approvals valid for 24 months where narcolepsy. Initial application - (ADHD in patients 5 or over) only from a paediatrician, psychiatrist or general practitioner on the recommendation of such a specialist. Approvals valid for 24 months for applications meeting the following criteria: All of the following: 1 ADHD (Attention Deficit and Hyperactivity Disorder) patients aged 5 years or over; and 2 Diagnosed according to DSM-IV or ICD 10 criteria; and 3 Either: 3.1 Applicant is a specialist; or 3.2 Both: 3.2.1 Applicant is a GP and a specialist has recommended treatment; and 3.2.2 Provide name of specialist (Details to be attached to application). Initial application - (ADHD in patients under 5) only from a paediatrician or psychiatrist. Approvals valid for 12 months for applications meeting the following criteria: Both: 1 ADHD (Attention Defi
Special Authority for Subsidy - Form SA0698Initial application only from a gastroenterologist, general surgeon or general physician. Approvals valid for 3 months for applications meeting the following criteria: Both: 1 Mild to moderate ileal, ileocaecal or proximal Crohn's disease; and 2 Any of the following: 2.1 Diabetes; or 2.2 Cushingoid habitus; or 2.3 Osteoporosis where there is significant risk of fracture; or 2.4 Severe acne following treatment with conventional corticosteroid therapy. Renewal only from a gastroenterologist, general surgeon or general physician. Approvals valid for 3 months where the treatment remains appropriate and the patient is benefiting from treatment. The patient must have had no more than 1 prior approval in the last year. NoteClinical trials for Entocort CIR use beyond three months demonstrated no improvement in relapse rate.
Special Authority for Subsidy - Form SA0699Initial application from any medical practitioner. Approvals valid for 1 year for applications meeting the following criteria: All of the following: 1 The patient is not predisposed to heart arrhythmias; and 2 The patient does not have a pre-existing QT-prolongation or hepatic failure; and 3 The patient is not using other medications which either inhibit the cytochrome P450 3A4 enzyme system or prolong the QT interval; and 4 Any of the following: 4.1 Both: 4.1.1 adult with severe reflux oesophagitis; and 4.1.2 other treatment, including acid suppression with proton pump inhibitors, has failed; or 4.2 gastroparesis; or 4.3 malignancy of GI tract causing gastroparesis (or gastric outlet obstruction); or 4.4 child (not including infants from 0 to 3 months of age who were born prematurely) with severe gastro-oesophageal reflux; and 5 Diagnosis has been made or confirmed by a general physician, gastroenterologist, or ge
Special Authority for Subsidy - Form SA0700Initial application only from an ophthalmologist. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 Both: 1.1 Monotherapy in primary open-angle glaucoma; and 1.2 Any of the following: 1.2.1 Patient cannot tolerate Beta-blockers, Pilocarpine and Dorzolamide; or 1.2.2 Beta-blockers, Pilocarpine and Dorzolamide are contraindicated; or 1.2.3 A reduction in intraocular pressure of 15% or more is not achieved or maintained using dorzolamide either alone or in combination with a beta-blocker; or 1.2.4 There is progressive visual field loss and/or optic nerve damage persists after treatment with dorzolamide either alone or in combination with a beta-blocker; or 2 Adjunctive use for the treatment of patients who have met the initial application criteria, and in whom latanoprost monotherapy has been ineffective in controlling intraocular pressure.Note An adjunctive agent may be added without a
Special Authority for Subsidy - Form SA0702Initial application - (Oral feed for cystic fibrosis patient) only from a relevant specialist. Approvals valid for 3 years for applications meeting the following criteria: Both: 1 Cystic fibrosis; and 2 Either: 2.1 The product is to be used as a supplement; or 2.2 The product is to be used as a complete diet.Initial application - (Oral feed for indications other than cystic fibrosis) only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria: Both: 1 Any of the following: 1.1 any condition causing malabsorption; or 1.2 failure to thrive; or 1.3 increased nutritional requirements; and 2 Either: 2.1 The product is to be used as a supplement; or 2.2 The product is to be used as a complete diet.Renewal - (Oral feed cystic fibrosis patient) only from a relevant specialist or general practitioner on the recommendation of such a specialist. Approvals valid for 3 years f
Special Authority for Subsidy - Form SA0703Initial application only from a relevant specialist or general practitioner. Approvals valid for 2 years for applications meeting the following criteria: All of the following: 1 Patient has raised blood pressure; and 2 The use of fully funded beta blockers is contraindicated, or not well tolerated; or where use of fully funded beta blockers and diuretics are insufficient to control blood pressure adequately at appropriate doses; and 3 Either: 3.1 Has been treated with, and cannot tolerate two ACE inhibitors, due to persistent cough; or 3.2 Has experienced angioedema on an ACE inhibitor at any time in the past or who have experienced angioedema (even if not using an ACE inhibitor) in the last 2 years. Renewal only from a relevant specialist or general practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0706Initial application only from a relevant specialist or general practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria: Either: 1 Both: 1.1 Patient with congestive heart failure; and 1.2 Either: 1.2.1 Has been treated with, and cannot tolerate, two ACE inhibitors, due to persistent cough; or 1.2.2 Has experienced angioedema on an ACE inhibitor at any time in the past or who have experienced angioedema (even if not using an ACE inhibitor) in the last 2 years; or 2 All of the following: 2.1 Patient with raised blood pressure; and 2.2 Use of fully funded beta blockers or diuretics are contraindicated; or not well tolerated; or insufficient to control blood pressure adequately at appropriate doses; and 2.3 Either: 2.3.1 Has been treated with, and cannot tolerate, two ACE inhibitors, due to persistent cough; or 2.3.2 Has experienced angioedema on an ACE in
Effective, consistent management of herpes from prescribing to these guidelines will improve patient outcomes. The guidelines on the following four pages are for the prescribing of aciclovir. The guidelines aim to: - improve patient care and clinical outcome through faster, more accessible treatment - protect patients' wider wellbeing by reinforcing the psychosocial aspects of treatment - improve the consistency and breadth of medical management of genital herpes in New Zealand. The guidelines are: - integral to ensuring a consistent, effective treatment regimen- the result of consultation with clinicians and patient representatives- set out in line with the recommended international algorithm format for treatment. The guidelines are endorsed by the Herpes Foundation's professional advisory board whose members represent venereology, NZDS, RNZCGP, RNZCOG, psychotherapy and nursing. Herpes Foundation Helpline: Toll free 0508 11 12 13Auckland Branch Herpes Foundation: 09 360 1966
Guidelines for the use of interferon in the treatment of hepatitis C: Physicians considering treatment of patients with hepatitis C should discuss cases with a gastroenterologist or aninfectious disease physician. All subjects undergoing treatment require careful monitoring for side effects. Patients should be otherwise fit. Hepatocellular carcinoma should be excluded by ultrasound examination and alpha-fetoprotein level. Criteria for Treatment a) Diagnosis- Anti-HCV positive on at least two occasions with a positive PCR for HCV-RNA and preferably confirmed by asupplementary RIBA test; or- PCR-RNA positive for HCV on at least 2 occasions if antibody negative; or- Anti-HCV positive on at least two occasions with a positive supplementary RIBA test with a negative PCR forHCV RNA but with a liver biopsy consistent with 2(b) following. b) Establishing Active Chronic Liver Disease- Confirmed HCV infection and serum ALT/AST levels measured on at least three occasions over six monthsaveraging >
Special Authority for Subsidy - Form SA0710Initial application only from an ophthalmologist. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 Either: 1.1 Monotherapy in primary open-angle glaucoma; or 1.2 Adjunctive use for the treatment of open-angle glaucoma in a patient who has met the initial application criteria, and in whom prostaglandin analogue monotherapy has been ineffective in controlling intraocular pressure; and 2 Any of the following: 2.1 Patient cannot tolerate beta-blockers, pilocarpine, and carbonic anhydrase inhibitors; or 2.2 Beta-blockers, pilocarpine and carbonic anhydrase inhibitors are contraindicated; or 2.3 A reduction in intraocular pressure of 15% or more is not achieved or maintained using carbonic anhydrase inhibitor either alone or in combination with a beta blocker; or 2.4 There is progressive visual field loss and/or optic nerve damage persists after treatment with carbonic anhydrase inhibitor either alo
Special Authority for Subsidy - Form SA0714Initial application from any medical practitioner. Approvals valid for 3 months for applications meeting the following criteria: All of the following: 1 Patient is currently enrolled in a recognised comprehensive treatment programme for alcohol dependence in a service accredited against the New Zealand Alcohol and Other Drug Sector Standard or the National Mental Health Sector Standard; and 2 Applicant works in an Alcohol & Drug Service; and 3 Applicant must include the address of the service (Details to be attached to application). Renewal from any medical practitioner. Approvals valid for 3 months for applications meeting the following criteria: Both: 1 Compliance with the medication (prescriber determined); and 2 Any of the following: 2.1 Patient is still unstable and requires further treatment; or 2.2 Patient achieved significant improvement but requires further treatment; or 2.3 Patient is well controlled but requires maint
Special Authority for Manufacturers Price - Form SA0717Initial application only from a relevant specialist or general practitioner. Approvals valid for 12 weeks for applications meeting the following criteria: Both: 1 Patient has a calculated absolute risk of cardiovascular disease of at least 15% over 5 years; and 2 Either: 2.1 Patient has severe documented intolerance to simvastatin; or 2.2 Both: 2.2.1 Patient has been compliant with a dose of simvastatin of 80 mg per day for at least 2 months; and 2.2.2 Either: 2.2.2.1 All of the following: 2.2.2.1.1 Patient has venous CABG; and 2.2.2.1.2 LDL cholesterol test 1 >= 2.0 mmol/litre; and 2.2.2.1.3 LDL cholesterol test 2 >= 2.0 mmol/litre (at least 1 week after test 1); or 2.2.2.2 All of the following: 2.2.2.2.1 Patient does not have venous CABG; and 2.2.2.2.2 LDL cholesterol test 1 >= 2.5 mmol/litre; and 2.2.2.2.3 LDL cholesterol test 2 >= 2.5 mmol/litre (at least 1 w
Special Authority for Subsidy - Form SA0721Initial application only from a named specialist. Approvals valid without further renewal unless notified for applications meeting the following criteria: All of the following: 1 The patient already has a Special Authority approval for anti-retroviral therapy (Details to be attached to application); and 2 Kaletra is to be used as a salvage therapy in place of one protease inhibitor; and 3 The patient must have trialed for at least six months and have failed on currently funded NNRTI based regimens or triple NRTI regimens; and 4 The patient must have trialed for at least six months and have failed on currently funded PI based regimens. NoteFailure is defined as: a) not achieving HIV RNA < 400 copies/ml after 24 weeks of a regimen, orb) an increase of HIV RNA to > 400 copies/ml on two separate occasions not less than one month apart, after suppression to < 400 copies/ml in a patient taking the regimen.
Special Authority for Subsidy - Form SA0723Initial application only from a relevant specialist. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 All of the following: 1.1 Patient has a calculated absolute risk of cardiovascular disease >20% over 5 years; and 1.2 Patient cannot tolerate statin therapy at a dose of 40 mg per day; and 1.3 Either: 1.3.1 All of the following: 1.3.1.1 Patient has venous CABG; and 1.3.1.2 LDL cholesterol >= 2.0 mmol/litre (see note); and 1.3.1.3 LDL cholesterol >= 2.0 mmol/litre (at least 1 week after test 1 - see note); or 1.3.2 All of the following: 1.3.2.1 Patient does not have venous CABG; and 1.3.2.2 LDL cholesterol >= 2.5 mmol/litre (see note); and 1.3.2.3 LDL cholesterol >= 2.5 mmol/litre (at least 1 week after test 1 - see note); or 2 All of the following: 2.1 Patient has homozygous familial hypercholesterolemia, or heterozygous familial hypercholesterol
Special Authority for Manufacturers Price - Form SA0724Initial application only from a relevant specialist or general practitioner. Approvals valid for 12 weeks for applications meeting the following criteria: Both: 1 Patient has a calculated absolute risk of cardiovascular disease of at least 15% over 5 years; and 2 Either: 2.1 Patient has severe documented intolerance to simvastatin (blood tests are not required); or 2.2 Both: 2.2.1 Patient has been compliant with a dose of simvastatin of 80 mg per day for at least 2 months; and 2.2.2 Either: 2.2.2.1 All of the following: 2.2.2.1.1 Patient has venous CABG; and 2.2.2.1.2 LDL cholesterol test 1 >= 2.0 mmol/litre; and 2.2.2.1.3 LDL cholesterol test 2 >= 2.0 mmol/litre (at least 1 week after test 1); or 2.2.2.2 All of the following: 2.2.2.2.1 Patient does not have venous CABG; and 2.2.2.2.2 LDL cholesterol test 1 >= 2.5 mmol/litre; and 2.2.2.2.3 LDL cholesterol test 2 >
Special Authority for Subsidy - Form SA0725Initial application only from a relevant specialist or general practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria: All of the following: 1 Patient with raised blood pressure; and 2 Use of fully funded beta blockers and diuretics are contraindicated; or not well tolerated; or insufficient to control blood pressure adequately at appropriate doses; and 3 Either: 3.1 Has been treated with, and cannot tolerate, two ACE inhibitors, due to persistent cough; or 3.2 Has experienced angioedema on an ACE inhibitor at any time in the past or who have experienced angioedema (even if not using an ACE inhibitor) in the last 2 years. Renewal - (Previous approval has expired) only from a relevant specialist or general practitioner. Approvals valid without further renewal unless notified where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0727Initial application from any medical practitioner. Approvals valid for 1 year for applications meeting the following criteria: All of the following: 1 Control of intractable nausea, vomiting, or inability to swallow saliva in the treatment of malignancy or chronic disease; and 2 Patient cannot tolerate or does not adequately respond to oral anti-nausea agents; and 3 The applicant must specify the underlying malignancy or chronic disease (Details to be attached to application). Renewal from any medical practitioner. Approvals valid for 1 year where the treatment remains appropriate and the patient is benefiting from treatment.
Retail pharmacy - subsidy by endorsement a) Subsidised for:(i) patients presenting with first episode schizophrenia or related psychoses, or manic episodes associated with bipolar disorder; and(ii) patients suffering from schizophrenia or related psychoses, or manic episodes associated with bipolar disorder, after a trial of an effective dose of risperidone that has been discontinued because of unacceptable side effects or inadequate response. b) Initial prescription must be written by a relevant specialist. c) Subsequent prescriptions may be written by a general practitioner. d) The prescription must be endorsed "certified condition".
Special Authority for Subsidy - Form SA0732Initial application only from a relevant specialist. Approvals valid for 3 years for applications meeting the following criteria: Either: 1 dietary management of homocystinuria; or 2 dietary management of maple syrup urine disease. Renewal only from a relevant specialist or general practitioner on the recommendation of such a specialist. Approvals valid for 1 year for applications meeting the following criteria: Both: 1 The treatment remains appropriate and the patient is benefiting from treatment; and 2 General Practitioners must include the name of the specialist and date contacted.
Special Authority for Subsidy - Form SA0733Initial application - (Patient aged over 16) only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria: Both: 1 dietary management of PKU; and 2 blood phenylalanine level < 900 mmol/litre (average of tests over last 12 months). Initial application - (Patient aged 16 or under) only from a relevant specialist. Approvals valid for 3 years where dietary management of PKU.Renewal - (Patient aged over 16) only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria: blood phenylalanine level < 900 mmol/litre (average of tests over last 12 months). Renewal - (Patient aged 16 or under) only from a relevant specialist or general practitioner on the recommendation of such a specialist. Approvals valid for 3 years for applications meeting the following criteria: Both: 1 The treatment remains appropriate and the patient is benefiting from treatment; and 2
GuidelinesIt can cost up to $70,000 a year to keep an adult on protein supplements. Because protein substitutes are so expensive and because they are only effective in controlling PKU if a restricted diet is followed, adults with PKU will be required to demonstrate they are following the prescribed diet by regular blood testing. The requirement for testing applies to those aged over 16 years. Failure to follow an appropriate diet results in high blood phenylalanine levels. Those consistently testing above 15 mg (900 micromol) over a twelve month period will not be able to claim these products as a Special Authority. Specialists will be required to renew applications for their PKU patients every year and, when they do so, will have to submit the results of two blood tests.
Neocate should be used only as a last resort when the infant is unable to absorb any of the above formulae. The objective with each of thees formulae prescribed is to get the infant off them as soon as possible. This may take six months, it may take three years. Because of this, variation on age limit is not regarded as appropriate.These formulae will be available only from a hospital pharmacy. Vivonex Pediatric may be a suitable and less expensive alternative for many children that would otherwise be eligible for a subsidy for Neocate and should, therefore, be tried first in these cases. The subsidy for these products reflects the philosophy that the patient incurs no additional financial burden for purchasing specialised more expensive products.
Special Authority for Subsidy - Form SA0738Initial application only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria: Either: 1 All of the following: 1.1 To be used as monotherapy for patients with type 2 diabetes who after six months of diet and lifestyle changes do not have adequate glycaemic control (inadequate control defined as HbA1c > 8.0% in tests carried out at least two months apart); and 1.2 Metformin is not tolerated or contraindicated. Intolerance and contraindications as defined in the notes below, a minimum of a four week trial period of metformin is required; and 1.3 Sulphonylurea is not tolerated or contraindicated. Overweight patients are only eligible under the criteria of contraindication to sulphonylureas if their body mass index (BMI) exceeds 35; or 2 Both: 2.1 For use in combination with a sulphonylurea when diet and lifestyle changes and a twelve month trial of sulphonylurea results in inadequate glycaem
Special Authority for Subsidy - Form SA0741Initial application only from a psychiatrist. Approvals valid for 2 years for applications meeting the following criteria: Any of the following: 1 Patient with first episode schizophrenia or related psychoses; or 2 Both: 2.1 Patient suffering from schizophrenia and related psychoses; or acute mania in bipolar disorder who is likely to benefit from anti-psychotic treatment; and 2.2 Either: 2.2.1 An effective dose of risperidone had been trialled and has been discontinued because of unacceptable side effects; or 2.2.2 An effective dose of risperidone had been trialled and has been discontinued because of inadequate clinical response after 4 weeks; or 3 The patient has suffered from an acute episode of schizophrenia or bipolar mania and has been treated with olanzapine short-acting intra-muscular injection. Renewal only from a psychiatrist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefit
Additional subsidy by endorsement for:Citalopram tab 20 mg x 28 (Celapram) up to $4.00Citalopram tab 20 mg x 28 (Cipramil) up to $10.00Paroxetine hydrochloride tab 20 mg x 30 (Aropax) up to $35.02is available for patients who: -were taking citalopram on 1 February 2000; or paroxetine hydrochloride on February 2001; or- have previously responded to treatment with citalopram or paroxetinehydrochloride; or- have had a trial of fluoxetine and have had to discontinue due to- inability to tolerate the drug due to side effects; or- failed to respond to an adequate dose and duration of treatment; or- have contraindications to fluoxetine (eg pre-existing significant levels of nausea, breastfeeding, potential drug interactions). The prescription must be endorsed accordingly.
Special Authority for Subsidy - Form SA0751Initial application only from an ophthalmologist. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 Either: 1.1 Monotherapy in primary open-angle glaucoma; or 1.2 Adjunctive use for the treatment of open-angle glaucoma in a patient who has met the initial application criteria, and in whom prostaglandin analogue monotherapy has been ineffective in controlling intraocular pressure; and 2 Any of the following: 2.1 Patient cannot tolerate beta-blockers, pilocarpine, and carbonic anhydrase inhibitors; or 2.2 Beta-blockers, pilocarpine and carbonic anhydrase inhibitors are contraindicated; or 2.3 A reduction in intraocular pressure of 15% or more is not achieved or maintained using carbonic anhydrase inhibitor either alone or in combination with a beta blocker; or 2.4 There is progressive visual field loss and/or optic nerve damage persists after treatment with carbonic anhydrase inhibitor either alo
(a) Subsidy is available between 1 March and 30 June of each year for patients who meet the following criteria, as set by the Ministry of Health: a) all people 65 years of age and over; b) people under 65 years of age with: i) the following cardiovascular disease: 1) ischaemic heart disease, 2) congestive heart disease, 3) rheumatic heart disease, 4) congenital heart disease, or 5) cerebo-vascular disease; ii) the following chronic respiratory disease: 1) asthma, if on a regular preventative therapy, or 2) other chronic respiratory disease with impaired lung function; iii) diabetes; iv) chronic renal disease; v) any cancer, excluding basal and squamous skin cancers if not invasive; vi) the following other conditions: 1) autoimmune disease, 2) immune suppression, 3) HIV, 4) transplant recipients, 5) neuromuscular and CNS diseases, 6) haemoglobinopathies, or 7) children on long term aspirin. The following conditions are excluded from funding: i) asthma not requiri
Special Authority for Subsidy - Form SA0754Initial application only from a named specialist. Approvals valid without further renewal unless notified for applications meeting the following criteria: All of the following: 1 The patient already has a Special Authority approval for anti-retroviral therapy (Details to be attached to application); and 2 Kaletra is to be used as a salvage therapy in place of one protease inhibitor; and 3 The patient must have trialed for at least six months and have failed on currently funded NNRTI based regimens or triple NRTI regimens; and 4 The patient must have trialed for at least six months and have failed on currently funded PI based regimens. NoteFailure is defined as: a) not achieving HIV RNA < 400 copies/ml after 24 weeks of a regimen, orb) an increase of HIV RNA to > 400 copies/ml on two separate occasions not less than one month apart, after suppression to < 400 copies/ml in a patient taking the regimen.
Special Authority for Subsidy - Form SA0758Initial application only from a general practitioner or relevant specialist. Approvals valid for 2 years for applications meeting the following criteria: All of the following: 1 To be used for the long-term maintenance treatment of bronchospasm and dyspnoea associated with COPD; and 2 In addition to standard treatment, the patient has trialled a dose of at least 40 mcg ipratropium q.i.d; and 3 The patient's breathlessness >= grade 4 according to the Medical Research Council dyspnoea scale (see note); and 4 FEV1 (litres) < 0.4 x predicted (litres); and 5 Either: 5.1 Patient is not a smoker (for reporting purposes only); or 5.2 Patient is a smoker and been offered smoking cessation councilling; and 6 The patient has been offered annual influenza immunisation. Renewal only from a general practitioner or relevant specialist. Approvals valid for 2 years for applications meeting the following criteria: All of the following: 1
(a) Subsidy is available between 1 March and 30 June of each year for patients who meet the following criteria, as set by the Ministry of Health: a) all people 65 years of age and over; b) people under 65 years of age with: i) the following cardiovascular disease: 1) ischaemic heart disease, 2) congestive heart disease, 3) rheumatic heart disease, 4) congenital heart disease, or 5) cerebo-vascular disease; ii) the following chronic respiratory disease: 1) asthma, if on a regular preventative therapy, or 2) other chronic respiratory disease with impaired lung function; iii) diabetes; iv) chronic renal disease; v) any cancer, excluding basal and squamous skin cancers if not invasive; vi) the following other conditions: 1) autoimmune disease, 2) immune suppression, 3) HIV, 4) transplant recipients, 5) neuromuscular and CNS diseases, 6) haemoglobinopathies, or 7) children on long term aspirin. The following conditions are excluded from funding: i) asthma not requiri
Special Authority for Subsidy - Form SA0772Initial application only from a gastroenterologist, infectious disease specialist, paediatrician or general physician. Approvals valid for 1 year for applications meeting the following criteria: Both: 1 Any of the following: 1.1 All of the following: 1.1.1 HBsAg positive for more than 6 months; and 1.1.2 HBeAg positive or HBV DNA positive defined as >0.6 pg/ml by quantitative PCR at reference laboratory; and 1.1.3 ALT greater than twice upper limit of normal or stage 3 or 4 fibrosis on liver histology clinical/radiological evidence of cirrhosis; or 1.2 HBV DNA positive cirrhosis prior to liver transplantation; or 1.3 HBsAg positive and have had a liver, kidney, heart, lung or bone marrow transplant; or 1.4 Hepatitis B surface antigen positive (HbsAg) patient who is receiving chemotherapy for a malignancy, or who has received such treatment within the previous two months; and 2 All of the following: 2.1 No continuing
Additional subsidy by endorsement for:Paroxetine hydrochloride tab 20 mg x 30 (Aropax) up to $35.02is available for patients who: -were taking paroxetine hydrochloride on February 2001; or- have previously responded to treatment with paroxetinehydrochloride; or- have had a trial of fluoxetine and have had to discontinue due to- inability to tolerate the drug due to side effects; or- failed to respond to an adequate dose and duration of treatment; or- have contraindications to fluoxetine (eg pre-existing significant levels of nausea, breastfeeding, potential drug interactions). The prescription must be endorsed accordingly.
Special Authority for Subsidy - Form SA0774Initial application only from a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Any of the following: 1 The patient has advanced gastrointestinal malignancy; or 2 The patient has metastatic breast cancer*; or 3 Both: 3.1 The patient has poor venous access or needle phobia*; and 3.2 The patient requires a substitute for single agent fluoropyrimidine*. Renewal only from a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Either: 1 The patient requires continued therapy; or 2 The tumour has relapsed and requires re-treatment. Noteindications marked with * are unapproved indications.
Special Authority for Subsidy - Form SA0775Initial application only from a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Both: 1 The patient has metastatic colorectal cancer; and 2 Either: 2.1 To be used for first or second line use as part of a combination chemotherapy regimen; or 2.2 As single agent chemotherapy in fluropyrimidine-relapsed disease. Renewal only from a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Either: 1 The patient requires continued therapy; or 2 The tumour has relapsed and requires re-treatment.
Special Authority for Subsidy - Form SA0776Initial application only from a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Any of the following: 1 Both: 1.1 The patient has ovarian, fallopian* or primary peritoneal cancer*; and 1.2 Either: 1.2.1 Has not received prior chemotherapy; or 1.2.2 Has received prior chemotherapy but has not previously been treated with taxanes; or 2 The patient has metastatic breast cancer; or 3 Both: 3.1 The patient has non-small cell lung cancer; and 3.2 Either: 3.2.1 The patient has advanced disease (stage IIIa or above); or 3.2.2 The patient is receiving combined chemotherapy and radiotherapy; or 4 Both: 4.1 The patient has small-cell lung cancer*; and 4.2 Paclitaxel is to be used as second-line therapy. Renewal only from a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Both: 1 The patient has metastati
Special Authority for Subsidy - Form SA0777Initial application - (Post-transplant) only from a relevant specialist. Approvals valid for 6 months where the patient has B-cell post-transplant lymphoproliferative disorder*. NoteFor no more than 8 treatment cycles. Initial application - (Low-grade lymphomas) only from a relevant specialist. Approvals valid for 6 months where the patient has low grade NHL - relapsed disease following prior chemotherapy. NoteFor no more than 4 treatment cycles. Initial application - (Large cell lymphomas) only from a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Both: 1 The patient has treatment naive large B-cell NHL; and 2 To be used with CHOP (or alternative anthracycline containing multi-agent chemotherapy regime given with curative intent).NoteFor no more than 8 treatment cycles. Renewal - (Low-grade lymphomas) only from a relevant specialist. Approvals valid for 6 months for applications meeting
Special Authority for Subsidy - Form SA0779Initial application - (Confirmed HIV/AIDS) only from a named specialist. Approvals valid without further renewal unless notified for applications meeting the following criteria: Both: 1 Confirmed HIV infection; and 2 Any of the following: 2.1 Symptomatic patient; or 2.2 Patient aged 12 months and under; or 2.3 Both: 2.3.1 Patient aged 1 to 5 years; and 2.3.2 Any of the following: 2.3.2.1 CD4 counts < 1,000 cells/mm3; or 2.3.2.2 CD4 counts < 0.25 x total lymphocyte count; or 2.3.2.3 Viral load counts > 100,000 copies per ml; or 2.4 Both: 2.4.1 Patient aged 6 years and over; and 2.4.2 CD4 counts < 350 cells/mm3. NoteTenofovir disoproxil fumarate prescribed under endorsement for HIV/AIDS is included in the count of up to 3 subsidised antiretrovirals. Subsidies for a combination of up to three anti-retroviral medications, including a maximum of two protease inhibitors. Combinations including r
Special Authority for Subsidy - Form SA0780Initial application - (Single NAED Therapy) only from a paediatrician, neurologist or general physician. Approvals valid for 15 months for applications meeting the following criteria: Any of the following: 1 Was on NAED therapy before 1 September 2000; or 2 Seizures are not adequately controlled with optimal older anti-epilepsy drug treatment; or 3 Seizures are controlled adequately but who experience unacceptable side effects from older anti-epilepsy drug treatment. Note"Optimal older anti-epilepsy drug therapy" is defined as treatment with those older anti-epilepsy drugs which are indicated and clinically appropriate for the patient, given singly and in combination in adequate doses for the patient's age, weight, and other features affecting the pharmacokinetics of the drug with good evidence of complianceInitial application - (Dual NAED Therapy) only from a paediatrician, neurologist or general physician. Approvals valid for 18 months for app
Special Authority for Subsidy - Form: SA0781Initial application only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria: Any of the following: Monotherapy1 All of the following: 1.1 To be used as monotherapy for patients with type 2 diabetes who after six months of diet and lifestyle changes do not have adequate glycaemic control (inadequate control defined as HbA1c > 7.0% in tests carried out at least two months apart); and 1.2 Metformin is not tolerated or contraindicated. Intolerance and contraindications as defined in the notes below, a minimum of a four week trial period of metformin is required; and 1.3 Sulphonylurea is not tolerated or contraindicated. Obesity is only eligible under the criteria of contraindication to sulphonylureas if the patient's body mass index (BMI) exceeds 33 , intolerance as defined in the notes below; orIn combination with sulphonylurea2 Both: 2.1 For use in combination with a sulphonylure
Special Authority for Subsidy - Form SA0782Initial application - (No previous use) only from a relevant specialist or general practitioner. Approvals valid for 6 months for applications meeting the following criteria: All of the following: 1 The patient has a clinical diagnosis of heavy menstrual bleeding; and 2 The patient has failed to respond to or is unable to tolerate other appropriate pharmaceutical therapies as per the Heavy Menstrual Bleeding Guidelines; and 3 Either: 3.1 serum ferritin level < 16 mg/l (within the last 12 months); or 3.2 haemoglobin level < 120 g/l . NoteApplications are not to be made for use in patients as contraception except where they meet the above criteriaInitial application - (Previous use before 1 October 2002) only from a relevant specialist or general practitioner. Approvals valid for 6 months for applications meeting the following criteria: All of the following: 1 The patient had a clinical diagnosis of heavy menstrual bleeding; and 2
Special Authority for Manufacturers Price - Form: SA0783Initial application only from a relevant specialist. Approvals valid for 5 years for applications meeting the following criteria: All of the following: 1 Patient is a postmenopausal women; and2 Patient has hormone receptor positive advanced breast cancer; and3 Any of the following: 3.1 The cancer is advanced (Stage IIIb, or metastatic Stage IV); or 3.2 The patient has a very clear history of intolerance to tamoxifen; or 3.3 The use of tamoxifen is contraindicated due to a history of thromboembolic disease. Renewal only from a relevant specialist. Approvals valid without further renewal unless notified where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Manufacturers Price - Form SA0788Initial application only from a relevant specialist or general practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria: Both: 1 Patient has a calculated absolute risk of cardiovascular disease of at least 15% over 5 years; and 2 Either: 2.1 Patient has severe documented intolerance to simvastatin (blood tests are not required); or 2.2 Both: 2.2.1 Patient has been compliant with a dose of simvastatin of 80 mg per day for at least 2 months; and 2.2.2 Either: 2.2.2.1 All of the following: 2.2.2.1.1 Patient has venous CABG; and 2.2.2.1.2 LDL cholesterol test 1 >= 2.0 mmol/litre; and 2.2.2.1.3 LDL cholesterol test 2 >= 2.0 mmol/litre (at least 1 week after test 1); or 2.2.2.2 All of the following: 2.2.2.2.1 Patient does not have venous CABG; and 2.2.2.2.2 LDL cholesterol test 1 >= 2.5 mmol/litre; and 2.2.2.2.
Special Authority for Subsidy - Form SA0789Initial application only from a relevant specialist or vocationally registered general practitioner. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 The patient has "treatment resistant" depression; and 2 Either: 2.1 The patient must have had a trial of two different antidepressants and failed to respond to an adequate dose over an adequate period of time (usually at least four weeks); or 2.2 Both: 2.2.1 The patient is currently a hospital in-patient as a result of an acute depressive episode; and 2.2.2 The patient must have had a trial of one other antidepressant and failed to respond to an adequate dose over an adequate period of time. Renewal from any medical practitioner. Approvals valid for 2 years where patient has a high risk of relapse (prescriber determined).
Prescribing GuidelineBimatoprost, lantanoprost and travoprost are subsidised for use in the treatment of glaucoma as either monotherapy or as an adjunctive agent for patients in whom prostaglandin analogue monotherapy has been ineffective in controlling intraocular pressure.Bimatoprost, lantanoprost and travoprost should not be prescribed for a person in whom less expensive first line agents for the treatment of glaucoma are not contraindicated unless: 1 That person has previously trialled all other such subsidised agents (beta-blockers, pilocarpine, carbonic anhydrase inhibitors); and2 Those trials have indicated that that person does not respond adequately to treatment with those other agents.
Special Authority for Subsidy - Form: SA0792Initial application only from a psychiatrist. Approvals valid for 6 months for applications meeting the following criteria: All of the following: 1 The patient has schizophrenia or other psychotic disorder; and2 Has tried but failed to comply with treatment using oral atypical anti-psychotic agents; and3 Has been admitted to hospital or treated in respite care, or intensive outpatient or home-based treatment for 30 days or more in last 12 months. Renewal only from a psychiatrist. Approvals valid for 12 months for applications meeting the following criteria: Either: 4 Both: 4.1 The patient has had less than 12 months treatment with risperidone microspheres; and 4.2 There is no clinical reason to discontinue treatment; or5 The initiation of risperidone microspheres has been associated with fewer days of intensive intervention than was the case during a corresponding period of time prior to the initiation of risperidone microspheres. NoteRisp
Special Authority for Subsidy - Form: SA0796Initial application only from a relevant specialist. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 Either: 1.1 ezetimibe is to be used in combination with simvastatin; or 1.2 ezetimibe is to be used without a statin; and2 Either: 2.1 All of the following: 2.1.1 Patient has a calculated absolute risk of cardiovascular disease >20% over 5 years; and 2.1.2 Patient cannot tolerate statin therapy at a dose of 40 mg per day; and 2.1.3 Either: 2.1.3.1 All of the following: 2.1.3.1.1 Patient has venous CABG; and 2.1.3.1.2 LDL cholesterol >= 2.0 mmol/litre (see note); and 2.1.3.1.3 LDL cholesterol >= 2.0 mmol/litre (at least 1 week after test 1 - see note); or 2.1.3.2 All of the following: 2.1.3.2.1 Patient does not have venous CABG; and 2.1.3.2.2 LDL cholesterol >= 2.5 mmol/litre (see note); and 2.1.3.2.3 LDL cholest
Special Authority for Subsidy - Form: SA0797Initial application - (Underlying cause - Osteoporosis) only from a relevant specialist or vocationally registered general practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria: Any of the following: 1 History of one significant osteoporotic fracture demonstrated radiologically and documented bone mass density (BMD) >= 2.5 standard deviations below the mean normal value in young adults (i.e. T-Score <= -2.5); or2 History of one significant osteoporotic fracture demonstrated radiologically and the patient is either over 75 years of age or is too frail* to undergo a bone mass density scan; or3 History of two significant osteoporotic fractures demonstrated radiologically; or4 Documented T-Score <= -3.0. Note*The patient may be considered to be frail if it is expected that there is significant risk of further fracture or other negative health outcome if the patient were to undergo a BMD s
Special Authority for Subsidy - Form SA0801Initial application - (Serevent Accuhaler, Foradil, Symbicort Turbuhaler) only from a relevant specialist or general practitioner. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 Both: 1.1 Child under the age of 12 with poorly controlled asthma; and 1.2 Either: 1.2.1 Required at least three months of 400 mcg or more daily inhaled beclomethasone or budesonide; or 1.2.2 Required at least three months of 200 mcg or more of fluticasone; or 2 Both: 2.1 Adult with poorly controlled asthma; and 2.2 Either: 2.2.1 Required at least three months of 1500 mcg or more daily inhaled beclomethasone or budesonide; or 2.2.2 Required at least three months of 750 mcg or more of fluticasone. NotePatients are to be reviewed at least at six months to assess compliance and effectiveness of therapy. Special Authority approvals are interchangeable among all presentations of inhaled long-acting beta
Special Authority for Subsidy - Form SA0802Initial application - (genotype 1, 4, 5 or 6 infection or co-infection with HIV) from any specialist. Approvals valid for 11 months for applications meeting the following criteria: 1. Patient has chronic hepatitis C, genotype 1, 4, 5 or 6 infection; or2. Patient has chronic hepatitis C and is co-infected with HIV. Note: consider stopping treatment if there is absence of a virological response (defined as at least a 2-log reduction in viral load) following 12 weeks of treatment since this is predictive of treatment failure.Initial application - (genotype 2 or 3 infection without co-infection with HIV) from any specialist. Approvals valid for 6 months for applications meeting the following criteria: 3. Patient has chronic hepatitis C, genotype 2 or 3 infection; andEither: 3.1 Patient has bridging fibrosis or cirrhosis (Metavir stage 3 or 4 or equivalent); or 3.2 is unsuitable for liver biopsy due to coagulopathy.
Special Authority for Subsidy - Form SA0803Initial application from any specialist. Approvals valid for 11 months for applications meeting the following criteria: either: 1 Patient has chronic hepatitis C, genotype 1, 4, 5 or 6 infection; or2 Patient has chronic hepatitis C, genotype 2 or 3 infection; and 2.1 With has bridging fibrosis or cirrhosis (Metavir stage 3 or 4, or equivalent). 2.2 is unsuitable for liver biopsy due to coagulopathy. Note: consider stopping treatment if there is absence of a virological response (defined as at least a 2-log reduction in viral load) following 12 weeks of treatment since this is predictive of treatment failure.
Prescribing Guideline for Inhaled Long-Acting Beta-Adrenoceptor AgonistsThe addition of inhaled long-acting beta-adrenoceptor agonists (LABAs) to inhaled corticosteroids is recommended: - For younger children (aged under 12 years) where asthma is poorly controlled despite using inhaled corticosteroids for at least three months at total daily doses of 200 mcg beclomethasone or budesonide (or 100 mcg fluticasone).- For adults and older children (aged 12 years and over) where asthma is poorly controlled despite using inhaled corticosteroids for at least three months at total daily doses of 400 mcg beclomethasone or budesonide (or 200 mcg fluticasone).Note: Further information on the place of inhaled corticosteroids and inhaled LABAs in the management of asthma can be found in the New Zealand guidelines for asthma in adults (www.nzgg.org.nz) and in the New Zealand guidelines for asthma in children aged 1-15 (www.paediatrics.org.nz).
Access by applicationa) Budget managed by appointed clinicians on the Multiple Sclerosis Treatment Assessments Committee (MSTAC). b) Applications will be considered by MSTAC at its regular meetings and approved subject to eligibility according to the Entry and Stopping criteria (below). c) Applications to be made on the approved forms which are available from the co-ordinator for MSTAC:The Co-ordinator Phone: (04) 460 4990Multiple Sclerosis Treatment Assessments Committee Facsimile: (04) 916 7571PHARMAC, PO Box 10 254 E mail: silvia.valsenti@pharmac.govt.nzWellingtond) Completed application forms must be sent to the co-ordinator for MSTAC and will be considered by MSTAC at the next practicable opportunity. e) Notification of MSTAC's decision will be sent to the patient, the applying clinician and the patient's GP (if specified). f) These agents will not be subsidised if dispensed from a community or hospital pharmacy. Regular supplies will be distributed to all approved patients or their c
Special Authority for Subsidy - Form: SA0809Initial application only from a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Any of the following: 1 Both: 1.1 The patient has ovarian*, fallopian* or primary peritoneal cancer*; and 1.2 Either: 1.2.1 Has not received prior chemotherapy; or 1.2.2 Has received prior chemotherapy but has not previously been treated with taxanes; or2 The patient has metastatic breast cancer; or3 Both: 3.1 The patient has non small-cell lung cancer; and 3.2 Either: 3.2.1 Has advanced disease (stage IIIa or above); or 3.2.2 Is receiving combined chemotherapy and radiotherapy; or4 Both: 4.1 The patient has small-cell lung cancer*; and 4.2 Docetaxel is to be used as second-line therapy. Renewal only from a relevant specialist. Approvals valid for 12 months for applications meeting the followingcriteria: 5. The patient has metastatic breast cancer, non small-cell lung cancer,
Special Authority for Alternate SubsidyInitial application only from a relevant specialist. Approvals valid for 5 years for applications meeting the following criteria: All of the following: 1 Patient is a postmenopausal women; and2 Patient has hormone receptor positive breast cancer; and3 Any of the following: 3.1 The cancer is advanced (Stage IIIb, or metastatic Stage IV); or 3.2 The patient has a very clear history of intolerance to tamoxifen; or 3.3 The use of tamoxifen is contraindicated due to a history of thromboembolic disease. Renewal only from a relevant specialist. Approvals valid without further renewal unless notified where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Alternate SubsidyInitial application only from a relevant specialist. Approvals valid for 5 years for applications meeting the following criteria: All of the following: 1 Patient is a postmenopausal women; and2 Patient has hormone receptor positive breast cancer; and3 Any of the following: 3.1 The cancer is advanced (Stage IIIb, or metastatic Stage IV); or 3.2 The patient has a very clear history of intolerance to tamoxifen; or 3.3 The use of tamoxifen is contraindicated due to a history of thromboembolic disease. Renewal only from a relevant specialist. Approvals valid without further renewal unless notified where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for SubsidyInitial application only from a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria: All of the following1 Patient is an adult who has had severe and active erosive Rheumatoid Arthritis for six months duration or longer; and2 Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and3 Patient has tried and not responded to at least three months of oral or parenteral methotrexate at a dose of at least 20 mg weekly or a maximum tolerated dose; and4 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with at least two of the following (triple therapy): sulphasalazine, prednisone at a dose of at least 7.5 mg per day, azathioprine, intramuscular gold, or hydroxychloroquine sulphate (at maximum tolerated doses); and5 Patient has tried and not responded to at least three months therapy at th
Special Authority for Subsidy Initial application only from a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Any of the following: 1 The patient has non small cell lung carcinoma (stage IIIa, or above); or2 The patient has advanced malignant mesothelioma*; or3 The patient has advanced pancreatic carcinoma; or4 The patient has ovarian, fallopian tube* or primary peritoneal carcinoma*. Renewal only from a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Both: 5 The patient requires continued therapy; or6 The tumour has relapsed and requires re-treatment. Note indications marked with a * are unapproved indications.
Special Authority for Subsidy Initial application only from a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Both: 1 The patient has primary thrombocythaemia; and2 Either 2.1 is at high risk (previous thromboembolic disease, bleeding or platelet count >1500/ml); or 2.2 is intolerant or refractory to hydroxyurea or interferon. Renewal only from a relevant specialist. Approvals valid for 12 months where the treatment remains appropriate and the patient is benefiting from treatment. NoteIt is recommended that treatment with anagrelide be initiated only on the recommendation of a haematologist.
Special Authority for Subsidy Initial application - (for new patients) only from a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Both: 1 The patient has refractory, progressive or relapsed multiple myeloma; and2 The patient has received prior chemotherapy. Initial application - (for patients receiving thalidomide prior to 1 January 2006) only from a relevant specialist. Approvals valid without further renewal where the patient was receiving treatment with thalidomide for multiple myeloma on or before 31 December 2005. Renewal only from a relevant specialist. Approvals valid without further renewal where the patient has obtained a response from treatment during the initial approval period. Note: Prescription must be written by registered prescriber in the thalidomide risk management programme operated by the supplier. Maximum dose of 400 mg daily as monotherapy or in a combination therapy regimen.
Special Authority for Subsidy Initial application for patients with type 2 diabetes only from a relevant specialist. Approvals valid for one year for applications meeting the following criteria: Any of the following: Monotherapy1 All of the following: 1.1 To be used as monotherapy for patients who after six months of diet and lifestyle changes have inadequate glycaemic control (defined as HbA1c > 7.0% in tests carried out at least two months apart); and 1.2 Metformin is contraindicated or not tolerated after a minimum of a four week trial period; and 1.3 Sulphonylurea is contraindicated or not tolerated or the patient's body mass index (BMI) exceeds 33 kg/m2; orIn combination with sulphonylurea2 Both: 2.1 For use in combination with a sulphonylurea for patients who after diet and lifestyle changes and a six-month trial of sulphonylurea have poor glycaemic control (defined as HbA1c > 8.0% measured within the last month of the six month period); and 2.2 Metformin is contrain
Perindopril and trandolapril will be funded to the level of the ex-manufacturer price listed in the Schedule for patients who were taking these ACE inhibitors for the treatment of congestive heart failure prior to 1 June 1998. The prescription must be endorsed accordingly. We recommend that the words used to indicate eligibility are "certified condition" or an appropriate description of the patient such as "congestive heart failure", "CHF", "congestive cardiac failure" or "CCF". Definition of Congestive Heart Failure At the request of some prescribers the PTAC Cardiovascular subcommittee has provided a definition of congestive heart failure for the purposes of the funding of the manufacturer's surcharge: "Clinicians should use their clinical judgement. Existing patients would be eligible for the funding of the surcharge if the patient shows signs and symptoms of congestive heart failure, and requires or has in the past required concomitant treatment with a diuretic. The definition could also be considere
Special Authority for Subsidy - Form: SA0826Initial application only from a relevant specialist. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 All of the following: 1.1 Patient has a calculated absolute risk of cardiovascular disease >20% over 5 years; and 1.2 Patient cannot tolerate statin therapy at a dose of >= 40 mg per day; and 1.3 Either: 1.3.1 All of the following: 1.3.1.1 Patient has venous CABG; and 1.3.1.2 LDL cholesterol >= 2.0 mmol/litre (see note); and 1.3.1.3 LDL cholesterol >= 2.0 mmol/litre (at least 1 week after test 1 - see note); or 1.3.2 All of the following: 1.3.2.1 Patient does not have venous CABG; and 1.3.2.2 LDL cholesterol >= 2.5 mmol/litre (see note); and 1.3.2.3 LDL cholesterol >= 2.5 mmol/litre (at least 1 week after test 1 - see note); or2 All of the following: 2.1 Patient has homozygous familial hypercholesterolemia, or heterozygous familial hypercholest
Special Authority for Subsidy - Retail Pharmacy - Form SA0829Initial Application only from gastroenterologist or infectious disease specialist. Approvals valid for 1 year for applications meeting the following criteria: All of the following: 1. Patient has confirmed Hepatitis B infection (HBsAg+); andDocumented resistance to lamivudine, defined as: 2. patient has raised serum ALT (> 1 x ULN); and3. patient has HBV DNA greater than 100,000 copies per mL, or viral load ? 10 fold over nadir; and4. detection of M204I or M204V mutation; and5. Either5.1. Both5.1.1. patient is cirrhotic; and5.1.2. adefovir dipivoxil to be used in combination with lamivudine; or5.2. Both5.2.1. patient is not cirrhotic; and5.2.2. adefovir dipivoxil to be used as monotherapyRenewal only from a gastroenterologist or infectious disease specialist. Approvals valid for 2 years for applications where in the opinion of the treating physician, treatment remains appropriate and patient is benefiting from treatmen
Special Authority for Subsidy - Form: SA0831Application only from a relevant specialist. Approvals valid for 10 months for applications meeting the following criteria: 1. Patient has newly diagnosed glioblastoma multiforme; and2. Temozolomide is to be (or has been) given concomitantly with radiotherapy; and3. Following concomitant treatment temozolomide is to be used for a maximum of six cycles of 5 days treatment, at a maximum dose of 200 mg/m2. Note: Temozolomide is not subsidised for the treatment of relapsed glioblastoma multiforme. Studies of temozolomide show that its benefit is predominantly in those patients with a good performance status (WHO grade 0 or 1 or Karnofsky score >80), and in patients who have had at least a partial resection of the tumour.
Special Authority for Subsidy - Form: SA0832Initial application only from a gastroenterologist, infectious disease specialist, paediatrician or general physician. Approvals valid for 1 year for applications meeting the following criteria: Both: 1 Any of the following: 1.1 All of the following: 1.1.1 HBsAg positive for more than 6 months; and1.1.2 HBeAg positive or HBV DNA positive defined as > 100,000 copies per ml by quantitative PCR at a reference laboratory; and1.1.3 ALT greater than twice upper limit of normal or bridging fibrosis or cirrhosis (Metavir stage 3 or 4 or equivalent) on liver histology or clinical/radiological evidence of cirrhosis; or 1.2 HBV DNA positive cirrhosis prior to liver transplantation; or1.3 HBsAg positive and have had a liver, kidney, heart, lung or bone marrow transplant; or1.4 Hepatitis B surface antigen positive (HbsAg) patient who is receiving chemotherapy for a malignancy, or who has received such treatment within the previous two months;
Special Authority for Subsidy - Form SA0833Initial application only from a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Any of the following: 1 The patient has non small cell lung carcinoma (stage IIIa, or above); or2 The patient has advanced malignant mesothelioma*; or3 The patient has advanced pancreatic carcinoma; or4 The patient has ovarian, fallopian tube* or primary peritoneal carcinoma*; or5 The patient has advanced transitional cell carcinoma of the urothelial tract (locally advanced or metastatic). Renewal only from a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Both: 6 The patient requires continued therapy; or7 The tumour has relapsed and requires re-treatment. Note indications marked with a * are unapproved indications.
Special Authority for Subsidy - Form: SA0834Initial application only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria: Either: 1 Both: 1.1 Patient has type 1 diabetes and has received an intensive regimen (injections at least three times a day) of an intermediate acting insulin in combination with a rapid acting insulin analogue for at least three months; and1.2 Either: 1.2.1 Patient has experienced more than one unexplained severe hypoglycaemic episode in the previous 12 months (severe defined as requiring the assistance of another person); or1.2.2 Patient has experienced unexplained symptomatic nocturnal hypoglycaemia, biochemically documented at <3.0 mmol/L, more than once a month despite optimal management; or2 Patient has documented severe, or continuing, systemic or local allergic reaction to existing insulins. Note this does not include hypoglycaemic episodes. Renewal only from a relevant specialist or general practitioner. Approv
Special Authority for Subsidy - Form SA0835Initial application - (Breast cancer) from any medical practitioner. Approvals valid for 1 year: where the patient is a premenopausal woman with breast cancer. Initial application - (Prostate cancer) only from an oncologist, urologist or endocrinologist. Approvals valid for 1 year for applications meeting the following criteria: Advanced prostatic cancer;. Note Not to be prescribed with an anti-androgen except for a period of three weeks, if necessary, when GnRH analogue therapy is initiated. Initial application - (Endometriosis) only from a gynaecologist. Approvals valid for 3 months for applications meeting the following criteria: Both: 1 Endometriosis; and2 Either: 2.1 6 months treatment with medroxyprogesterone acetate, danazol or dimetriose has proven ineffective; or2.2 The patient has failed to tolerate the treatment with medroxyprogesterone acetate, danazol or dimetriose for 6 months. Note The maximum treatment period for a GnRH analogue is:
Special Authority for Subsidy - Form SA0836Initial application - (Breast cancer) from any medical practitioner. Approvals valid for 1 year where the patient is a premenopausal woman with breast cancer. Initial application - (Prostate cancer) only from an oncologist, urologist or endocrinologist. Approvals valid for 1 year for applications meeting the following criteria: Either: 1 Advanced prostatic cancer; or. 2 Locally advanced prostatic cancer. Note Not to be prescribed with an anti-androgen except for a period of three weeks, if necessary, when GnRH analogue therapy is initiated. Initial application - (Endometriosis) only from a gynaecologist. Approvals valid for 3 months for applications meeting the following criteria: Both: 3 Endometriosis; and4 Either: 4.1 6 months treatment with medroxyprogesterone acetate, danazol or dimetriose has proven ineffective; or4.2 The patient has failed to tolerate the treatment with medroxyprogesterone acetate, danazol or dimetriose for 6 months. Note
Special Authority for Subsidy - Form SA0837Initial application - (Breast cancer) from any medical practitioner. Approvals valid for 1 year where the patient is a premenopausal woman with breast cancer. Initial application - (Prostate cancer) only from an oncologist, urologist or endocrinologist. Approvals valid for 1 year where the patient has: Advanced prostatic cancer;. Note Not to be prescribed with an anti-androgen except for a period of three weeks, if necessary, when GnRH analogue therapy is initiated. Initial application - (Endometriosis) only from a gynaecologist. Approvals valid for 3 months for applications meeting the following criteria: Both: 1 Endometriosis; and2 Either: 2.1 6 months treatment with medroxyprogesterone acetate, danazol or dimetriose has proven ineffective; or2.2 The patient has failed to tolerate the treatment with medroxyprogesterone acetate, danazol or dimetriose for 6 months. Note The maximum treatment period for a GnRH analogue is: - 3 months to assess whet
Special Authority for Subsidy - Form: SA0838Initial Application only from a relevant specialist or General Practitioner. Approvals valid for 2 years forapplications meeting the following criteria: Either: 1 All of the following: 1.1 Patient is a child under the age of 12; and1.2 All of the following: Has, for 3 months or more, been treated with:1.2.1 An inhaled long-acting beta adrenoceptor agonist; and1.2.2 Inhaled corticosteroids at a dose of at least 400 mcg per day beclomethasone or budesonide, or200 mcg per day fluticasone; and1.3 The prescriber considers that the patient would receive additional clinical benefit from switching to acombination product; or2 All of the following: 2 .1 Patient is over the age of 12; and2 .2 All of the following: Has, for 3 months or more, been treated with:2 .2.1 An inhaled long-acting beta adrenoceptor agonist; and2 .2.2 Inhaled corticosteroids at a dose of at least 800 mcg per day beclomethasone or budesonide, or500 mcg per day fluticasone;
Special Authority for Subsidy - Form SA0839Initial application - (Breast cancer) from any medical practitioner. Approvals valid for 1 year where the patient is a premenopausal woman with breast cancer. Initial application - (Prostate cancer) only from an oncologist, urologist or endocrinologist. Approvals valid for 1 year for applications meeting the following criteria: Either: 1 Advanced prostatic cancer; or. 2 Neoadjuvant or adjuvant treatment of locally advanced prostatic cancer. Note Not to be prescribed with an anti-androgen except for a period of three weeks, if necessary, when GnRH analogue therapy is initiated. Initial application - (Endometriosis) only from a gynaecologist. Approvals valid for 3 months for applications meeting the following criteria: Both: 3 Endometriosis; and4 Either: 4.1 6 months treatment with medroxyprogesterone acetate, danazol or dimetriose has proven ineffective; or4.2 The patient has failed to tolerate the treatment with medroxyprogesterone acetate, danazo
Special Authority for Subsidy - form: SA0841Initial application only from a gastroenterologist or general physician. Approvals valid for 6 months for applications meeting the following criteria: Both: 1 Primary biliary cirrhosis confirmed by antimitochondrial antibody titre (AMA) > 1:80, and raised cholestatic liver enzymes with or without raised serum IgM or, if AMA is negative, by liver biopsy; and2 Patient not requiring a liver transplant (bilirubin > 170umol/l; decompensated cirrhosis). NoteLiver biopsy is not usually required for diagnosis but is helpful to stage the diseaseRenewal only from a gastroenterologist or general physician. Approvals valid for 2 years for applications meeting the following criteria: The treatment remains appropriate and the patient is benefiting from treatment. NoteActigall is not an appropriate therapy for patients requiring a liver transplant (bilirubin > 170 micromol/l; decompensated cirrhosis). These patients should be referred to an appropriate transp
Special Authority for Subsidy - Form: SA842Initial application only from a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Any of the following: 1 Both: 1.1 The patient has ovarian, fallopian* or primary peritoneal cancer*; and 1.2 Either: 1.2.1 Has not received prior chemotherapy; or 1.2.2 Has received prior chemotherapy but have not previously been treated with taxanes; or2 The patient has metastatic breast cancer; or3 The patient has node-positive early breast cancer; or4 Both 4.1 The patient has non small-cell lung cancer; and 4.2 Either: 4.2.1 Has advancing disease (stage IIIa or above); or 4.2.2 Is receiving combined chemotherapy and radiotherapy; or5 Both: 5.1 The patient has small-cell lung cancer*; and 5.2 Paclitaxel is to be used as second-line therapy. Renewal only from a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: 6 The patient has metasta
Special Authority for Subsidy - Form SA0028Initial application only from a relevant specialist. Approvals valid for 6 months for applications meeting the following criteria: Either: 1 All of the following: 1.1 Treatment with other lipid modifying medicines has been unsuccessful; and 1.2 6 months of dietary modification has been unsuccessful; and 1.3 Cholesterol level > 7.0 mmol/litre; and 1.4 Either: 1.4.1 Familial hypercholesterolaemia; or 1.4.2 Manifest coronary heart disease, which has been clinically proven, or previously treated by coronary artery surgery; or 2 Cholesterol level > 9.0 mmol/litre:.Renewal only from a general practitioner. Approvals valid for 6 months where the treatment remains appropriate and the patient is benefiting from treatment. NoteFamilial hypercholesterolaemia is defined as being hypercholesterolaemia in the presence of tendon xanthomas or in association with a family history of premature heart disease (before age 55) or consisten
Unapproved medication supplied under Section 29 of the Medicines Act 1981. Practitioners prescribing this medication should: (a) be aware of and comply with their obligations under Section 29 of the Medicines Act 1981 and otherwise under that Act and the Medicines Regulations 1984; (b) be aware of and comply with their obligations under the Health and Disability Commissioner's Code of Consumer Rights, including the requirement to obtain informed consent from the patient (PHARMAC recommends that Practitioners obtain written consent); and(c) exercise their own skill, judgment, expertise and discretion, and make their own prescribing decisions with respect to the use of an unapproved Pharmaceutical or a Pharmaceutical for an indication for which it is not approved.
Special Authority for Manufacturers Price - Form SA0035Initial application from any medical practitioner. Approvals valid for 5 years for applications meeting the following criteria: Both: 1 Either: 1.1 Both: 1.1.1 Duodenal and gastric ulcers, reflux oesophagitis and Zollinger-Ellison syndrome; and 1.1.2 Other treatments have failed; or 1.2 Patients who are on a Social Welfare benefit or an income no greater than a benefit; and 2 Patients must have endoscopically demonstrated lesions prior to commencement of treatment.. Renewal from any medical practitioner. Approvals valid for 5 years where the treatment remains appropriate and the patient is benefiting from treatment.
a) All patients with AIDS meeting the definition developed by the Centres for Disease Control in the USA (see Circular Letter to Medical Practitioners HP2/88)b) Patients with AIDS Related Complex (ARC)c) HIV infected patients with CD4 (T4) counts below 500 regardless of symptomatologyd) Prophylactically for persons following severe parenteral exposure from a known HIV positive sourcee) HIV infected persons with associated thrombocytopenia regardless of CD4 (T4) count f) Applications can only be made by appropriate specialists. Prescriptions for those patients approved to use these medicines can be written either by the specialist or general practitioner with an endorsement of the name of the recommending specialist. g) Prescriptions for these can be written for a period of three months' supply. However, medicine must be dispensed on a monthly basis.
Special Authority for Subsidy - Form SA0089Initial application - (Breast or prostatic cancer) only from an oncologist, urologist or endocrinologist. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 Breast cancer in pre menopausal women unwilling or unable to undergo surgical or radiation oophorectomy; or 2 Advanced prostatic cancer when orchidectomy is contraindicated. Initial application - (Endometriosis) only from a gynaecologist. Approvals valid for 6 months for applications meeting the following criteria: Both: 1 Endometriosis; and 2 Either: 2.1 6 months treatment with medroxyprogesterone acetate, danazol or dimetriose has proven ineffective; or 2.2 The patient has failed to tolerate the treatment with medroxyprogesterone acetate, danazol or dimetriose for 6 months. NoteThe maximum treatment period for a GnRH analogue is: 3 months to assess whether surgery is appropriate3 months for infertile patients after surgery6 months for
Special Authority for Subsidy - Form SA0096Initial application - (Organ transplant, Bone marrow transplant or Graft v host disease) only from a relevant specialist. Approvals valid for 2 years for applications meeting the following criteria: Any of the following: 1 Organ transplant; or 2 Bone marrow transplant; or 3 Graft v host disease. Initial application - (Psoriasis) only from a dermatologist. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 Psoriasis; and 2 Other systemic and topical therapy has failed. Initial application - (Severe atopic dermatitis) only from a dermatologist. Approvals valid for 6 months for applications meeting the following criteria: Both: 1 Severe atopic dermatitis; and 2 Not resopnsive to topical therapy, oral antihistamines and other commonly used orthodox therapies. Initial application - (Nephrotic Syndrome) from any medical practitioner. Approvals valid for 2 years for applications meeting the following cri
Special Authority for Subsidy - Form SA0097Initial application - (Chronic hepatitis C) only from a relevant specialist. Approvals valid for 6 months where chronic hepatitis C. Initial application - (Indications other than Chronic hepatitis C) only from a relevant specialist. Approvals valid for 5 years for applications meeting the following criteria: Any of the following: 1 Chronic myelogenous leukaemia; or 2 Hairycell leukaemia; or 3 Cutaneous T cell lymphoma; or 4 Essential thrombocythaemia; or 5 AIDS related Kaposi's sarcoma; or 6 Multiple myeloma; or 7 Chronic active hepatitis B. Renewal - (Chronic hepatitis C) only from a relevant specialist. Approvals valid for 6 months where the treatment remains appropriate and the patient is benefiting from treatment. Renewal - (Indications other than Chronic hepatitis C) only from a relevant specialist. Approvals valid for 5 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0099Initial application only from a relevant specialist. Approvals valid for 5 years for applications meeting the following criteria: Any of the following: 1 Both: 1.1 Acromegaly; and 1.2 Patients who have failed surgery, radiotherapy, bromocriptine and other oral therapies; or 2 Both: 2.1 Either: 2.1.1 Vipomas; or 2.1.2 Glucagonomas; and 2.2 Patients who are seriously ill in order to improve their clinical state prior to definitive surgery; or 3 Both: 3.1 Gastrinoma; and 3.2 Either: 3.2.1 Patient has failed surgery; or 3.2.2 Patient is in metastatic disease after H2 antagonists (or omeprazole) have failed; or 4 Both: 4.1 Insulinomas; and 4.2 Surgery is contraindicated or where surgery has failed; or 5 Pre-operative control of hypoglycaemia; or 6 Maintenance therapy. NoteThe use of octreotide in patients with fistulae, oesophageal varices, miscellaneous diarrhoea and hypotension will
Special Authority for Subsidy - Form SA0100Initial application only from a relevant specialist. Approvals valid for 5 years for applications meeting the following criteria: All of the following: 1 Anaemia of end-stage renal failure (other treatable causes of anaemia being excluded); and 2 Been on haemodialysis or continuous ambulatory peritoneal dialysis (CAPD) for at least three months; and 3 Not under evaluation for, or awaiting, a live donor kidney transplant; and 4 Any of the following: 4.1 Anephric; or 4.2 Dependent on regular blood transfusion (1 unit each 4-8 weeks) to maintain haemoglobin > 60g/L; or 4.3 Cannot be transfused because of severe transfusion reactions; or 4.4 Transfusion induced haemosiderosis (clinical manifestations, serum ferritin >1500 ug/L); or 4.5 Haemoglobin < 70 g/L (mean of at least 4 haemoglobin concentrations over 4 months); or 4.6 Both: 4.6.1 Haemoglobin < 90 g/L; and 4.6.2 Either: 4.6.2.1 Heart failure (low card
Special Authority for Subsidy - Form SA0115Initial application - (Oesophageal stricture) only from a general practitioner or relevant specialist. Approvals valid for 2 years where patient with oesophageal stricture who is unable to take capsules. Initial application - (Indications other than oesophageal stricture) only from a paediatrician. Approvals valid for 2 years for applications meeting the following criteria: All of the following: 1 infant or child with liver disease or short gut syndrome; and 2 Requires vitamin supplementation; and 3 Unable to swallow capsules. Renewal only from a general practitioner, relevant specialist or paediatrician. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
Approvals for a CHEM number to waive the premium in the following circumstances: 1. Patients with prosthetic heart valves - as an adjunct to oral anticoagulation for prophylaxis of thromboembolism (2 year approval with renewal, applications only from cardiothoracic surgeons, cardiologists and general physicians). 2. Patients after coronary artery vein bypass graft - as an adjunct to aspirin (1 year approval only, applications only from cardiothoracic surgeons, cardiologists and general physicians). 3. Patients who continue to have transient ischaemic episodes despite aspirin therapy. A course of up to six months in combination with aspirin. Applications only from neurologists, cardiologists, vascular surgeons and general physicians. Six month approval only. Reapplications only if there is demonstrated recurrence of symptoms when dipyridamole therapy is discontinued. Note: these transitional criteria are currently being reviewed.
a) Approvals to fund the manufacturer's surcharge in the following circumstances: - Patients with prosthetic heart valves - as an adjunct to oral anticoagulation for prophylaxis of thromboembolism (2 year approval with renewal, applications only from cardiothoracic surgeons, cardiologists and general physicians). - Patients after coronary artery vein bypass graft - as an adjunct to aspirin or as monotherapy for patients who are aspirin intolerant as defined below (1 year approval only, applications only from cardiothoracic surgeons, cardiologists and general physicians); or- Patients who continue to have transient ischaemic episodes despite aspirin therapy or have transient ischaemic episodes and are aspirin intolerant as defined below (2 year approval with renewal, applications only from neurologists, neurosurgeons, cardiologists, vascular surgeons and general physicians). b) Aspirin intolerant patients are defined as those with aspirin induced asthma, urticaria, or anaphylaxi, or those with significant
The new anticonvulsant drugs are restricted to1. neurologists2. paediatric neurologists3. any other prescriber approved in writing by the relevant RHA budget holding manager. The HFA holds a budget for expenditure on the new anticonvulsant drugs. Unless otherwise specified, ultimate authority for approving prescriptions for subsidy lies with the HFA budget holding manager for the new anticonvulsant drugs. The regional divisions of the HFA will be in contact with hospital pharmacists and approved prescribers with more detail of the approval system. GUIDELINES FOR USE OF THE NEW ANTICONVULSANTS ARE AS FOLLOWS: A. Entry criteriaThe following patients are eligible for trial on the new anticonvulsant drugs (NADs)1. Patients who are under the supervision of an approved prescriber, and whose seizures are not adequately controlled with optimal conventional anticonvulsant drug treatment. 2. Patients, who are under the supervision of an approved prescriber, and whose seizures are only controlled adequatel
Special Authority for Subsidy - Form SA0266Initial application - (Chronic hepatitis C) only from a relevant specialist. Approvals valid for 6 months where chronic hepatitis C. NoteMaximum reimbursable dosage 15 million iu/weekInitial application - (Indications other than chronic hepatitis C) only from a dermatologist, plastic surgeon or radiation oncologist. Approvals valid for 5 years for applications meeting the following criteria: Any of the following: 1 Chronic myelogenous leukaemia; or 2 Hairycell leukaemia; or 3 Cutaneous T cell lymphoma; or 4 Essential thrombocythaemia; or 5 AIDS related Kaposi's sarcoma; or 6 Multiple myeloma; or 7 Chronic active hepatitis B; or 8 Basal cell carcinoma unable to be treated surgically or by radiotherapy. NoteMaximum reimbursable dosage 15 million iu/weekRenewal - (Chronic hepatitis C) only from a relevant specialist. Approvals valid for 6 months where the treatment remains appropriate and the patient is benefiting from trea
a) - hairy cell leukaemia - Kaposi's sarcoma - chronic active hepatitis B - chronic hepatitis C (6 month approval only) - chronic myelogenous leukaemia - multiple myeloma - basal cell carcinoma 1) Only for basal cell carcinoma unable to be treated surgically or by radiotherapy. 2) Applications only from radiation oncologists, plastic surgeons and dermatologists. Applications from dermatologists will only be accepted with evidence from either a plastic surgeon or oncologist that the patient was unsuitable for surgery. 3) Maximum reimbursable dosage 15 million iu/weekb) Specialist must make applicationc) No further approvals for: Malignant melanoma Note: Patients with existing approvals can continue to have therapy
Lansoprazole is subsidised for patients who have one or more of the following conditions: 1. Duodenal ulcer proven by endoscopy or barium meal and after failure of: a)two alternative courses of H. pylori eradication therapy (if H. pylori positive); and b)H2 antagonist therapy for 8 weeks; and where a second endoscopy/barium meal has demonstrated non healing duodenal ulcer. 2. Gastric ulcer proven by endoscopy and after failure of: a)two alternative courses of H. pylori eradication therapy (if H. pylori positive); andb)H2 antagonist therapy for 12 weeks; and where a second endoscopy has demonstrated non healing gastric ulcer and excluded malignancy. 3. Gastro-oesophageal reflux disease (GORD) proven by endoscopy: i) Grade 0 GORD (normal endoscopy) after positive 24 hour pH monitoring test and failure of H2 antagonist therapy for one month with multiple daily dosing; orii) Grades 1 and 2 GORD after failure of H2 antagonist therapy for one month with multiple daily dosing; or
a) All patients with AIDS meeting the definition developed by the Centres for Disease Control in the USA (see Circular Letter to Medical Practitioners HP2/88)b) Patients with AIDS Related Complex (ARC)c) HIV infected patients with CD4 (T4) counts below 500 regardless of symptomatologyd) Prophylactically for persons following severe parenteral exposure from a known HIV positive sourcee) HIV infected persons with associated thrombocytopenia regardless of CD4 (T4) count f) For the prevention of maternal foetal transmission of HIVg) Applications can only be made by appropriate specialists. Prescriptions for those patients approved to use these medicines can be written either by the specialist or general practitioner with an endorsement of the name of the recommending specialist. h) Prescriptions for these can be written for a period of three months' supply. However, medicine must be dispensed on a monthly basis.
Special Authority for Subsidy - Form SA0274Initial application only from a relevant specialist. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 All of the following: 1.1 Treatment with other lipid modifying medicines has been unsuccessful; and 1.2 6 months of dietary modification has been unsuccessful; and 1.3 Cholesterol level > 7.0 mmol/litre:; and 1.4 Either: 1.4.1 Familial hypercholesterolaemia; or 1.4.2 Manifest coronary heart disease, which has been clinically proven, or previously treated by coronary artery surgery; or 2 Cholesterol level > 9.0 mmol/litre:.NoteFamilial hypercholesterolaemia is defined as being hypercholesterolaemia in the presence of tendon xanthomas or in association with a family history of premature heart disease (before age 55) or consistent with autosomal dominant inheritance. Simvastatin and Pravastatin may be considered for first line therapy in patients with familial hypercholesterolaemia or
Special Authority for Subsidy - Form SA0275Initial application - (Chronic hepatitis C) only from a relevant specialist. Approvals valid for 6 months where chronic hepatitis C. NoteMaximum reimbursable dosage 15 million iu/weekInitial application - (Indications other than chronic hepatitis C) only from a dermatologist, plastic surgeon or radiation oncologist. Approvals valid for 5 years for applications meeting the following criteria: Any of the following: 1 Chronic myelogenous leukaemia; or 2 Hairycell leukaemia; or 3 Cutaneous T cell lymphoma; or 4 Essential thrombocythaemia; or 5 Multiple myeloma; or 6 Chronic active hepatitis B; or 7 Basal cell carcinoma unable to be treated surgically or by radiotherapy. NoteMaximum reimbursable dosage 15 million iu/weekRenewal - (Chronic hepatitis C) only from a relevant specialist. Approvals valid for 6 months where the treatment remains appropriate and the patient is benefiting from treatment. Renewal - (Indications other tha
Special Authority for Subsidy - Form SA0276Initial application - (Chronic hepatitis C) only from a relevant specialist. Approvals valid for 6 months where chronic hepatitis C. NoteMaximum reimbursable dosage 15 million iu/weekInitial application - (Indications other than chronic hepatitis C) only from a dermatologist, plastic surgeon or radiation oncologist. Approvals valid for 5 years for applications meeting the following criteria: Any of the following: 1 Chronic myelogenous leukaemia; or 2 Hairycell leukaemia; or 3 Multiple myeloma; or 4 Chronic active hepatitis B; or 5 Basal cell carcinoma unable to be treated surgically or by radiotherapy. NoteMaximum reimbursable dosage 15 million iu/weekRenewal - (Chronic hepatitis C) only from a relevant specialist. Approvals valid for 6 months where the treatment remains appropriate and the patient is benefiting from treatment. Renewal - (Indications other than chronic hepatitis C) only from a dermatologist, plastic surgeon or radiat
Omeprazole is subsidised for patients who have one or more of the conditions numbered 1-4: 1. Duodenal ulcer proven by endoscopy or barium meal and after failure of: a)two alternative courses of H. pylori eradication therapy (if H. pylori positive); and b)H2 antagonist therapy for 8 weeks; and where a second endoscopy/barium meal has demonstrated non healing duodenal ulcer. 2. Gastric ulcer proven by endoscopy and after failure of: a)two alternative courses of H. pylori eradication therapy (if H. pylori positive); andb)H2 antagonist therapy for 12 weeks; and where a second endoscopy has demonstrated non healing gastric ulcer and excluded malignancy. 3. Gastro-oesophageal reflux disease (GORD) proven by endoscopy: i) Grade 0 GORD (normal endoscopy) after positive 24 hour pH monitoring test and failure of H2 antagonist therapy for one month with multiple daily dosing; orii) Grades 1 and 2 GORD after failure of H2 antagonist therapy for one month with multipl
Special Authority for Subsidy - Form SA0300Initial application - (Breast or prostatic cancer) only from an oncologist, urologist or endocrinologist. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 Breast cancer in pre menopausal women unwilling or unable to undergo surgical or radiation oophorectomy; or 2 Advanced prostatic cancer when orchidectomy is contraindicated. NoteNot in long term combination with an anti-androgenInitial application - (Endometriosis) only from a gynaecologist. Approvals valid for 6 months for applications meeting the following criteria: Both: 1 Endometriosis ; and 2 Either: 2.1 6 months treatment with medroxyprogesterone acetate, danazol or dimetriose has proven ineffective; or 2.2 The patient has failed to tolerate the treatment with medroxyprogesterone acetate, danazol or dimetriose for 6 months. NoteThe maximum treatment period for a GnRH analogue is: 3 months to assess whether surgery is appropriate3 m
Special Authority for Subsidy - Form SA0309Initial application only from a neurologist or physician for the elderly (FRACP). Approvals valid for 2 years for applications meeting the following criteria: All of the following: 1 Idiopathic Parkinson's disease; and 2 The patient does not have dementia and/or neuropsychiatric disorders; and 3 Has responded to L-dopa; and 4 Any of the following: 4.1 Has resistance to conventional treatment of severe motor fluctuations; or 4.2 Has severe "off" period disability; or 4.3 Has severe "off" period dystonic cramps. Renewal only from a neurologist or physician for the elderly (FRACP). Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0311Initial application - (Breast or prostatic cancer) only from an oncologist, urologist or endocrinologist. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 Breast cancer in pre menopausal women unwilling or unable to undergo surgical or radiation oophorectomy; or 2 Advanced prostatic cancer when orchidectomy is contraindicated or where the patient srongly opposes orchidectomy. NoteNot to be prescribed with an anti-androgen except for a period of three weeks, if necessary, when GnRH analogue therapy is intiatedInitial application - (Endometriosis) only from a gynaecologist. Approvals valid for 6 months for applications meeting the following criteria: Both: 1 Endometriosis; and 2 Either: 2.1 6 months treatment with medroxyprogesterone acetate, danazol or dimetriose has proven ineffective; or 2.2 The patient has failed to tolerate the treatment with medroxyprogesterone acetate, danazol or dimetrio
Special Authority for Alternate Subsidy - Form SA0312Initial application only from an obstetrician, gynaecologist, general practitioner or general physician. Approvals valid for 5 years for applications meeting the following criteria: Any of the following: 1 acute or significant liver disease - a declaration must be provided from a gastroenterologist or general physician stating that oral oestrogens are contraindicated due to liver disease (Details to be attached to application); or 2 oestrogen induced hypertension requiring antihypertensive therapy - documented evidence must be provided that raised blood pressure levels or inability to control blood pressure adequately occurred post oral oestrogens (Details to be attached to application); or 3 hypertriglyceridaemia - documented evidence must be provided that triglyceride levels increased to at least 2 x normal triglyceride levels post oral oestrogens (Details to be attached to application). NotePrescriptions with a valid Special Authority (
Special Authority for Subsidy - Form SA0317Initial application only from a renal physician. Approvals valid for 2 years for applications meeting the following criteria: All of the following: General Criteria: 1 Anaemia of end-stage renal failure (other treatable causes of anaemia being excluded); and 2 Been on haemodialysis or continuous ambulatory peritoneal dialysis (CAPD) for at least three months; and 3 Not under evaluation for, or awaiting, a live donor kidney transplant; and 4 Any of the following: Specific Criteria: 4.1 Anephric; or 4.2 Dependent on regular blood transfusion (1 unit each 4-8 weeks) to maintain haemoglobin > 60g/L; or 4.3 Cannot be transfused because of severe transfusion reactions; or 4.4 Transfusion induced haemosiderosis (clinical manifestations, serum ferritin >1500 ug/L); or 4.5 Haemoglobin < 70 g/L (mean of at least 4 haemoglobin concentrations over 4 months); or 4.6 Both: 4.6.1 Haemoglobin < 90 g/L; and 4.6.2 Either:
a) All nucleosides will be subsidised for patients meeting any of the following criteria: - All patients with AIDS meeting the definition developed by the Centers for Disease Control in the USA (see Circular Letter to Medical Practitioners HP2/88); or- Patients with AIDS Related Complex (ARC); or- HIV infected patients with CD4 (T4) counts below 500 regardless of symptomatology. b) Zidovudine will also be subsidised for patients meeting any of the following criteria: - Prophylactically for persons following severe parenteral exposure from a known HIV positive source; or- HIV infected persons with associated thrombocytopenia regardless of CD4 (T4) count; or- For the prevention of maternal foetal transmission of HIV. c) Applications can only be made by appropriate specialists. d) Prescriptions for those patients approved to use these medications can be written by either the specialist or general practitioner with an endorsement of the name of the recommending specialist.
Special Authority for Subsidy - Form SA0328Initial application only from a general physician. Approvals valid for 2 years for applications meeting the following criteria: Any of the following: 1 Both: 1.1 CD4 count < 500 cells/mm3; and 1.2 Viral load > 50,000> copies per ml (or equivalent value on the Chiron test); or 2 All of the following: 2.1 CD4 count < 500 cells/mm3; and 2.2 Viral load > 50,000> copies per ml (or equivalent value on the Chiron test); and 2.3 At least 6 weeks of dual therapy with nucleoside agents; or 3 Both: 3.1 CD4 count < 500 cells/mm3; and 3.2 CD4 counts are declining rapidly (>120 cells over 12 months or >60 - 80 cells over six months). Renewal only from a general physician. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
Guidelines for use of cyclosporin A in rheumatoid arthritisMonitoring: All patients require frequent monitoring for creatinine levels and blood pressure:- fortnightly, in the first three months of therapy and then monthly, if results are stable; - if dose is increased or there is a rise in serum creatinine or blood pressure, then more frequent monitoring is required. Contraindications: Cyclosporin A is contraindicated in patients with the following conditions: - current or past malignancy; - uncontrolled hypertension; - renal dysfunction (abnormal serum creatinine for age and sex); - immunodeficiency and neutropenia; - abnormally low white blood cell count or platelet count; or- liver function tests more than twice the upper limit of normal. Caution in use: - age above 65 years; - controlled hypertension; - use of ant-epileptic medications; - use of NSAIDs; - use of ketoconazole, fluconazole, trimethoprim, erythromycin, verapamil, and diltiazem; - concurrent or previous use of al
Special Authority - Retail pharmacy (Salmeterol, eformoterol fumarate):a) Approvals are interchangeable between all presenations of salmeterol and eformoterol fumarate agents. b) Diagnosis of asthma confirmed. c) Inhaler/device technique checked. d) At least three months of >= 1500 ug daily of beclomethasone inhaled steroid (or equivalent) for adult, or >= 800 ug daily for child. e) Patient monitors PEFR regularly during exacerbations where appropriate. f) Evidence of poor control (at least one of the following): - short acting beta agonist used > 3-4 time daily - nocturnal awakenings >= 2 times per week. g) The first applicaton may be for six months and subsequent applications for two yars. The criteria for reapplication are: - compliant with medication - improved asthma symptom control. h) Appication for Special Authority to be made by general practitioners or appropriate specialist.
Omeprazole and pantoprazole is subsidised for patients who have one or more of the conditions a-d: a) Duodenal ulcer proven by endoscopy or barium meal and after failure of: - two alternative courses of H. pylori eradication therapy (if H. pylori positive); and - H2 antagonist therapy for 8 weeks; and where a second endoscopy/barium meal has demonstrated non healing duodenal ulcer. b) Gastric ulcer proven by endoscopy and after failure of: - two alternative courses of H. pylori eradication therapy (if H. pylori positive); and - H2 antagonist therapy for 12 weeks; and where a second endoscopy has demonstrated non healing gastric ulcer and excluded malignancy. c) Gastro-oesophageal reflux disease (GORD) proven by endoscopy: - Grade 0 GORD (normal endoscopy) after positive 24 hour pH monitoring test and failure of H2 antagonist therapy for four weeks with multiple daily dosing; or - Grades 1 and 2 GORD after failure of H2 antagonist therapy for
Special Authority for Subsidy - Form SA0361Initial application only from a geriatrician, neurologist or general physician. Approvals valid for 2 years for applications meeting the following criteria: All of the following: 1 Disabling orthostatic hypotension not due to drugs; and 2 Patient has tried fludrocortisone (unless contra-indicated) with unsatisfactory results; and 3 Patient has tried non pharmacological treatments such as support hose, increased salt intake, exercise, and elevation of head and trunk at night. NoteTreatment should be started with small doses and titrated upwards as necessary. Hypertesion should be avoided, and the usual target is a standing systolic blood pressure of 90 mm Hg. Renewal only from a geriatrician, neurologist or general physician. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0366Initial application - (North Island patients) from any medical practitioner. Approvals valid for 5 years where the patient is likely to benefit from treatment. NoteFor details of the patient criteria, prescriber criteria, application and reporting forms contact the appointed clinician: Dr Richard FisherFertility Associates131 Remuera RoadAUCKLANDFax: 09 520 0499Appointed clinicians will distribute these agents to prescribers whose applications are approvedInitial application - (South Island patients) from any medical practitioner. Approvals valid for 5 years where the patient is likely to benefit from treatment. NoteFor details of the patient criteria, prescriber criteria, application and reporting forms contact the appointed clinician: Dr Peter BennyChristchurch Women's HospitalPrivate Bag 4711CHRISTCHURCHFax: 03 364 4634Appointed clinicians will distribute these agents to prescribers whose applications are approved
Special Authority for Subsidy - Form SA0382Initial application only from a gastroenterologist, general surgeon or general physician. Approvals valid for 3 years for applications meeting the following criteria: Any of the following: 1 All of the following: 1.1 Duodenal ulcer proven by endoscopy or barium meal; and 1.2 Failure of two alternative courses of H. pylori eradication therapy (if H. pylori positive); and 1.3 Non healing duodenal ulcer proven by second barium meal; and 1.4 H2 antagonist therapy for 8 weeks; or 2 All of the following: 2.1 Gastric ulcer proven by endoscopy; and 2.2 Two alternative courses of H. pylori eradication therapy (if H. pylori positive); and 2.3 Non healing gastric ulcer and excluded malignancy demonstrated by a second endoscopy; and 2.4 H2 antagonist therapy for 12 weeks; or 3 All of the following: 3.1 Grade 0 GORD (normal endoscopy); and 3.2 Positive 24 hour pH monitoring test; and 3.3 Failure of H2 antagonist t
n) Further approvals to fund the manufacturer's surcharge on either pravastatin or simvastatin (if applicable) may be granted to patients who are unable to continue treatment with fluvastatin due to adverse effects. Either general practitioners or specialist may make the application. To obtain a new Special Authority number, the application must include the following information: - the amount of time the patient has been treated with fluvastatin; and- the adverse effects experienced by the patient. o) Further approvals to fund the manufacturer's surcharge on simvastatin may be granted to patients with familial hypercholesterolaemia (FH) or familial combined hypercholesterolaemia (FCH) if a specialist considers that the patient is not achieving sufficient benefit from the fully funded statin(s). Only specialists may make application. To obtain a new Special Authority number, the application must include the following information: - the cholesterol level before and after treatment with the fully funded sta
Special Authority for Subsidy - Form SA0387Initial application - (Breast or prostatic cancer) only from an oncologist, urologist or endocrinologist. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 Breast cancer in pre menopausal women unwilling or unable to undergo surgical or radiation oophorectomy; or 2 Advanced prostatic cancer when orchidectomy is contraindicated or where the patient srongly opposes orchidectomy. NoteNot to be prescribed with an anti-androgen except for a period of three weeks, if necessary, when GnRH analogue therapy is intiatedInitial application - (Endometriosis) only from a gynaecologist. Approvals valid for 6 months for applications meeting the following criteria: Both: 1 Endometriosis; and 2 Either: 2.1 6 months treatment with medroxyprogesterone acetate, danazol or dimetriose has proven ineffective; or 2.2 The patient has failed to tolerate the treatment with medroxyprogesterone acetate, danazol or dimetrio
Special Authority for Manufacturers Price - Form SA0394Initial application - (Helicobacter pylori infections) only from a general practitioner or relevant specialist. Approvals valid for 6 months for applications meeting the following criteria: Both: 1 Eradication of Helicobacter pylori in patient with proven infection; and 2 Peptic ulcer disease proven by endoscopy. NoteMaximum of two prescriptions (two courses) per patient. Initial application - (Mycobacterial infections) only from a respiratory specialist or infectious disease specialist. Approvals valid for 2 years for applications meeting the following criteria: Any of the following: 1 Mycobacterium Avium Intracellulare Complex infections in patient with AIDS; or 2 Atypical and drug-resistant mycobacterial infection; or 3 All of the following: 3.1 Prophylaxis against disseminated Mycobacterium Avium Intracellulare Complex infection; and 3.2 HIV infection; and 3.3 CD4 count <= 50 cells/mm3. Renewal - (Mycobacteri
a) Cyproterone acetate with ethinyloestradiol is available from retail pharmacy to patients as indicated. b) Prescribers may code prescriptions "contraceptive" (code "O") when used as indicated for contraception. The period of supply and prescription charge will be as per other contraceptives, as follows: - $3.00 prescription charge (patient co-payment) will apply; - Prescription may be written for up to 6 months supply; and- Pharmacists may dispense up to 3 month supply. c) Prescriptions coded in any other way are subject to the non-contraceptive prescription charges, and the non-contraceptive period of supply. Eg. Prescriptons may be written for up to 3 months supply, and dispensed monthly. d) The Special Authority number for hormonal contraceptive agents (combined and progesterone-only) does not apply, and is not interchangeable. e) Health Benefits Limited will return any claims unpaid as follows: - any uncoded prescription; - any prescription that does not have a period of supply or the quantity
Special Authority for Subsidy - Form SA0401Initial application - (Basal cell carcinoma) only from a dermatologist, plastic surgeon or radiation oncologist. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 Basal cell carcinoma unable to be treated surgically or by radiotherapy; and 2 Unsuitability for surgery confirmed by a Plastic Surgeon or Oncologist. NoteMaximum reimbursable dosage 15 million iu/weekInitial application - (Chronic hepatitis C) only from a relevant specialist. Approvals valid for 12 months where chronic hepatitis C. Initial application - (Indications other than Basal cell carcinoma and Chronic hepatitis C) only from a relevant specialist, plastic surgeon or radiation oncologist. Approvals valid for 2 years for applications meeting the following criteria: Any of the following: 1 Chronic myelogenous leukaemia; or 2 Hairy cell leukaemia; or 3 Cutaneous T cell lymphoma; or 4 Essential thrombocythaemia; or 5 Multiple myelo
Special Authority for Subsidy - Form SA0402Initial application - (Patients aged 74 and under) only from a general practitioner. Approvals valid for 2 years for applications meeting the following criteria: All of the following: 1 Patients aged 74 and under; and 2 The patient has been offered 3-6 months of counselling and an opportunity to modify lifestyle; and 3 Any of the following: 3.1 Both: 3.1.1 NHF A1:1 - Clinically proven ischaemic heart disease; and 3.1.2 total cholesterol > 6.0; or 3.2 Both: 3.2.1 NHF A1:2 - Post coronary artery bypass graft (CABG); and 3.2.2 total cholesterol > 5.5; or 3.3 Both: 3.3.1 NHF B:Patients with > 20% 5-year cardiovascular disease risk; and 3.3.2 total cholesterol > 9.0; or 3.4 Both: 3.4.1 NHF C:15-20% 5-year cardiovascular disease risk; and 3.4.2 total cholesterol > 9.0; or 3.5 Both: 3.5.1 NHF D:10-15% 5-year cardiovascular disease risk; and 3.5.2 total cholesterol > 9.0; or 3.6
Funding of manufacturers surcharge for existing patients taking ACE inhibitors for Congestive Heart Failure.a) Patients taking any ACE inhibitor for the treatment of congestive heart failure prior to 1 June 1998 can continue to have their ACE inhibitor treatment fully subsidised; b) Prescribers must endorse the prescription 'Congestive Heart Failure'. The endorsement can be typed (this includes computer generated prescriptions) or handwritten; c) The endorsement must be initialled in the prescriber's own handwriting. Definition of Congestive Heart FailureAt the request of some prescribers the PTAC Cardiovascular subcommittee has provided a definition of congestive heart failure for the purposes of the funding of the manufacturer's surcharge: "Clinicians should use their clinical judgement. Existing patients would be eligible for the funding of the surcharge if the patient shows signs and symptoms of congestive heart failure, and requires or has in the past required concomitant treatment with a
Special Authority for Subsidy - Form SA0423Initial application only from a gastroenterologist, general surgeon or general physician. Approvals valid for 3 years for applications meeting the following criteria: Any of the following: 1 All of the following: Duodenal Ulcer: 1.1 Duodenal ulcer proven by endoscopy or barium meal; and 1.2 Non healing duodenal ulcer proven by second barium meal; and 1.3 After failure of two alternative courses of H. pylori eradication therapy (if H. pylori positive); and 1.4 After H2 antagonist therapy for 8 weeks; or 2 All of the following: Gastric Ulcer: 2.1 Gastric ulcer proven by endoscopy; and 2.2 Non healing gastric ulcer and excluded malignancy demonstrated by a second endoscopy; and 2.3 After two alternative courses of H. pylori eradication therapy (if H. pylori positive); and 2.4 After H2 antagonist therapy for 12 weeks; or 3 All of the following: GORD: 3.1 Grade 0 GORD (normal endoscopy); and 3.2 Positive 24
Special Authority for Subsidy - Form SA0424Initial application - (Confirmed HIV/AIDS) only from a general physician. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 Confirmed HIV/AIDS; and 2 Any of the following: 2.1 Symptomatic patients aged 6 years and over with HIV/AIDS; or 2.2 Both: 2.2.1 Asymptomatic patients aged 6 years and over; and 2.2.2 CD4 counts < 500 cells/mm3; or 2.3 Both: 2.3.1 Asymptomatic patients aged 6 years and over; and 2.3.2 Viral load counts > 10,000 copies per ml; or 2.4 Symptomatic patients aged under 6 with HIV/AIDS ; or 2.5 Asymptomatic patients aged 12 months and under; or 2.6 Both: 2.6.1 Asymptomatic patients aged 1 to 5 years; and 2.6.2 CD4 counts < 1,000 cells/mm3; or 2.7 Both: 2.7.1 Asymptomatic patients aged 1 to 5 years; and 2.7.2 CD4 counts < 0.25 x total white cell count; or 2.8 Both: 2.8.1 Asymptomatic patients aged under 6 years; and
If a Community Pharmaceutical is the liquid oral form of an antibiotic to which a diluent must be added by the Contractor at the time of dispensing and it is prescribed or ordered by a Practittioner in an amount that does not coincide with the amount contained in one or more standard packs of that Community Pharmaceutical, Subsidy will only be made for the amount prescribed or ordered by the Practitioner in accordance with either Clause 3.1 or Clause 3.3 of the Schedule, unless the Contractor satisfies the Funder that he or she has not been able to dispense the balance of the pack or packs from which the Community Pharmaceutical has been dispensed. In such cases all of that pack or those packs is eligible for Subsidy.
Special Authority for Subsidy - Form SA0430Initial application - (National Heart Foundation risk groups A1:1, A1:2, B, C, D or E) only from a relevant specialist or general practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria: Both: 1 The patient has been offered 3-6 months of counselling and an opportunity to modify lifestyle; and 2 Any of the following: 2.1 Both: 2.1.1 NHF A1:1 - Clinically proven ischaemic heart disease; and 2.1.2 total cholesterol * > 5.5; or 2.2 Both: 2.2.1 NHF A1:2 - Post coronary artery bypass graft (CABG) or angioplasty; and 2.2.2 total cholesterol * > 4.5; or 2.3 Post heart transplant (regardless of cholesterol level); or 2.4 Both: 2.4.1 NHF B:Patients with > 20% 5-year cardiovascular disease risk; and 2.4.2 total cholesterol * > 9.0; or 2.5 Both: 2.5.1 NHF C:15-20% 5-year cardiovascular disease risk; and 2.5.2 total cholesterol * > 9
Special Authority for Manufacturers Price - Form SA0436Initial application - (Patient with prosthetic heart valves) only from a cardiothoracic surgeon, cardiologist or general physician. Approvals valid for 2 years where patient with prosthetic heart valves - as an adjunct to oral anticoagulation for prophylaxis of thromboembolism. Initial application - (Following coronary artery vein bypass graft) only from a cardiothoracic surgeon, cardiologist or general physician. Approvals valid for 1 year where patients after coronary artery vein bypass graft - as an adjunct to aspirin or as monotherapy for patients who are aspirin intolerant as defined below. Initial application - (Transient ischaemic episodes) only from a neurologist, neuro surgeon, cardiologist, vascular surgeon or general physician. Approvals valid for 2 years where patients who continue to have transient ischaemic episodes despite aspirin therapy or have transient ischaemic episodes and are aspirin intolerant as defined below. Renewal - (Fo
Special Authority for Subsidy - Form SA0443Initial application - (Helicobacter pylori infections) only from a general practitioner or relevant specialist. Approvals valid for 6 months for applications meeting the following criteria: Both: 1 Eradication of Helicobacter pylori in patient with proven infection; and 2 Peptic ulcer disease proven by endoscopy. NoteMaximum of two prescriptions (two courses) per patient. Initial application - (Mycobacterial infections) only from a respiratory specialist or infectious disease specialist. Approvals valid for 2 years for applications meeting the following criteria: Any of the following: 1 Mycobacterium Avium Intracellulare Complex infections in patient with AIDS; or 2 Atypical and drug-resistant mycobacterial infection; or 3 All of the following: 3.1 Prophylaxis against disseminated Mycobacterium Avium Intracellulare Complex infection; and 3.2 HIV infection; and 3.3 CD4 count <= 50 cells/mm3. Renewal - (Mycobacterial infection
Special Authority for Subsidy - Form SA0445Initial application only from a relevant specialist. Approvals valid for 5 years for applications meeting the following criteria: Any of the following: 1 Both: 1.1 Acromegaly; and 1.2 Patient has failed surgery, radiotherapy, bromocriptine or other oral therapies; or 2 VIPomas and Glucagonomas - for patients who are seriously ill in order to improve their clinical state prior to definitive surgery.; or 3 Both: 3.1 Gastrinoma; and 3.2 Patient has failed surgery, or metastatic disease after H2 antagoists (or proton pump inhibitors) have failed; or 4 Both: 4.1 Insulinomas; and 4.2 Surgery is contraindicated or has failed; or 5 For pre-operative control of hypoglycaemia and for maintenance therapy; or 6 Both: 6.1 Carcinoidsyndrome (diagnosed by tissue pathology and/or urinary 5HIAA analysis); and 6.2 Disabling symptoms not controlled by maximal medical therapy. NoteThe use of octretide in patients with fis
Special Authority for Subsidy - Form SA0450Initial application only from a psychiatrist. Approvals valid for 12 months for applications meeting the following criteria: Both: 1 Patients suffering from schizophrenia and related psychoses; and 2 Either: 2.1 Failed to respond to full trials (duration of at least 6 weeks each) of effective doses of at least two classes of anti-psychotic agents (refer to guidelines below); or 2.2 Demonstrated intolerance to other neuroleptic agents. NoteClinicians must confirm that informed consent and a satisfactory White Bloodcell Count (WBC) result has been obtained. Diagnosis: Treatment resistant schizophrenia and related psychoses when positive symptoms (delusions, hallucinations and thought disorder) are prominent and/or disabling or when both positive symptoms and negative symptoms (flattened affect, emotional and social withdrawal and poverty of speech) are present. Treatment: Trial therapy undertaken before initiating treatment with clozapine could
Special Authority for Subsidy - Form SA0456Initial application only from a psychiatrist. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 Patients suffering from schizophrenia and related psychoses who are likely to benefit from anti-psychotic treatment; and 2 Any of the following: 2.1 Effective dose of risperidone has been discontinued because of recurrent acute dystonias; or 2.2 Effective dose of risperidone has been discontinued because of excessive Parkinson-like symptoms; or 2.3 Effective dose of risperidone has been discontinued after 6 weeks because of inadequate clinical response. Renewal only from a psychiatrist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0458Initial application only from a gastroenterologist. Approvals valid for 6 months for applications meeting the following criteria: Both: 1 Primary biliary cirrhosis confirmed by antimitochondrial antibody titre (AMA) > 1:80, and raised cholestatic liver enzymes with or without raised serum IgM or, if AMA is negative, by liver biopsy; and 2 Patient not requiring a liver transplant (bilirubin > 170umol/l; decompensated cirrhosis). NoteLiver biopsy is not usually required for diagnosis but is helpful to stage the diseaseRenewal only from a gastroenterologist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment. NoteActigall is not an appropriate therapy for patients requiring a liver transplant (bilirubin > 170 micromol/l; decompensated cirrhosis). These patients should be referred to an appropriate transplant centreTreatment failure - doubling of serum bilirubin levels, absence of a signi
Special Authority for Subsidy - Form SA0459Initial application only from a gastroenterologist or general physician. Approvals valid for 3 months for applications meeting the following criteria: Both: 1 Mild to moderate ileal, ileocaecal or proximal Crohn's disease; and 2 Any of the following: 2.1 Diabetes; or 2.2 Cushingoid habitus; or 2.3 Osteoporosis where there is significant risk of fracture; or 2.4 Both: 2.4.1 Severe acne; and 2.4.2 Treatment with conventional corticosteroid therapy. Renewal only from a gastroenterologist or general physician. Approvals valid for 3 months where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Manufacturers Price - Form SA0460Initial application - (Patient with prosthetic heart valves) only from a cardiothoracic surgeon, cardiologist or general physician. Approvals valid for 2 years where patient with prosthetic heart valves - as an adjunct to oral anticoagulation for prophylaxis of thromboembolism. Initial application - (Following coronary artery vein bypass graft) only from a cardiothoracic surgeon, cardiologist or general physician. Approvals valid for 1 year where patients after coronary artery vein bypass graft - as an adjunct to aspirin or as monotherapy for patients who are aspirin intolerant as defined below. Initial application - (Transient ischaemic episodes) only from a neurologist, neuro surgeon, cardiologist, vascular surgeon or general physician. Approvals valid for 2 years where patients who continue to have transient ischaemic episodes despite aspirin therapy or have transient ischaemic episodes and are aspirin intolerant as defined below. Renewal - (Fo
Special Authority for Subsidy - Form SA0461Initial application - (Basal cell carcinoma) only from a dermatologist, plastic surgeon or radiation oncologist. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 Basal cell carcinoma unable to be treated surgically or by radiotherapy; and 2 Unsuitablity for surgery confirmed by a Plastic Surgeon or Radiation Oncologist. NoteThe maximum reimbursable dosage is 15 million iu per weekInitial application - (Chronic hepatitis C) only from a relevant specialist. Approvals valid for 12 months where chronic hepatitis C. Initial application - (Indications other than Basal cell carcinoma and Chronic hepatitis C) only from a relevant specialist. Approvals valid for 2 years for applications meeting the following criteria: Any of the following: 1 Chronic myelogenous leukaemia; or 2 Hairy cell leukaemia; or 3 Multiple myeloma; or 4 Chronic active hepatitis B. Renewal - (Basal cell carcinoma) only from a dermato
Special Authority for Subsidy - Form SA0464Initial application only from a diabetologist, general physician or paediatrician. Approvals valid without further renewal unless notified for applications meeting the following criteria: Any of the following: 1 Both: 1.1 Use alone (monotherapy); and 1.2 The patient is unable to use any other insulins including those on insulin pump treatment; or 2 Both: 2.1 Use with Humulin 70/30 or Humulin 80/20; and 2.2 A reasonable trial of Humulin N has been undertaken and it is not effective or not well tolerated; or 3 Both: 3.1 Use with insulins (aside from insulin zinc suspension) other than Humulin 70/30, Humulin 80/20, or Humulin N; and 3.2 A reasonable trial of one or more of these Humulin insulins has been undertaken and it is/are ineffective or not well tolerated; or 4 Both: 4.1 Use with Humulin L or Humulin U; and 4.2 Use with Humulin N is not appropriate; or 5 Both: 5.1 Use with other insulin zinc suspensio
Special Authority for Subsidy - Form SA0470Initial application - (Organ transplant) only from a relevant specialist. Approvals valid without further renewal unless notified where organ transplant. Initial application - (Bone marrow transplant or Graft v host disease) only from a relevant specialist. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 Bone marrow transplant; or 2 Graft v host disease. Initial application - (Psoriasis) only from a dermatologist. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 Psoriasis; and 2 Applicant must state which systemic and topical therapies have failed. Initial application - (Severe atopic dermatitis) only from a dermatologist. Approvals valid for 6 months for applications meeting the following criteria: Both: 1 Severe atopic dermatitis; and 2 Not responsive to topical therapy, oral antihistamines and other commonly used orthodox therapies. Initial application - (N
Special Authority for Subsidy - Form SA0471Initial application - (Breast cancer) from any medical practitioner. Approvals valid for 1 year where breast cancer in pre menopausal women unwilling or unable to undergo surgical or radiation oophorectomy. Initial application - (Prostate cancer) only from an oncologist, urologist or endocrinologist. Approvals valid for 1 year where advanced prostatic cancer when orchidectomy is contraindicated or where the patient strongly opposes orchidectomy. NoteNot to be prescribed with an anti-androgen except for a period of three weeks, if necessary, when GnRH analogue therapy is intiatedInitial application - (Endometriosis) only from a gynaecologist. Approvals valid for 3 months for applications meeting the following criteria: Both: 1 Endometriosis ; and 2 Either: 2.1 6 months treatment with medroxyprogesterone acetate, danazol or dimetriose has proven ineffective; or 2.2 The patient has failed to tolerate the treatment with medroxyprogesterone
Special Authority for Subsidy - Form SA0472Initial application only from a cardiologist. Approvals valid for 2 years for applications meeting the following criteria: Any of the following: 1 Both: 1.1 Congestive heart failure; and 1.2 Cannot tolerate currently fully subsidised ACE inhibitors due to persistent cough that resolves on cessation and recurs on re-challenge with ACE inhibitor; or 2 Patients who have experienced angioedema on an ACE inhibitor at any time in the past; or 3 Patients who have experienced angioedema (even if not using an ACE inhibitor) in the last 2 years. Renewal only from a cardiologist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0488Initial application only from a gastroenterologist, general surgeon or general physician. Approvals valid for 3 months for applications meeting the following criteria: Both: 1 Mild to moderate ileal, ileocaecal or proximal Crohn's disease; and 2 Any of the following: 2.1 Diabetes; or 2.2 Cushingoid habitus; or 2.3 Osteoporosis where there is significant risk of fracture; or 2.4 Both: 2.4.1 Severe acne; and 2.4.2 Treatment with conventional corticosteroid therapy. Renewal only from a gastroenterologist, general surgeon or general physician. Approvals valid for 3 months where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Manufacturers Price - Form SA0489Initial application - (Conditions other than transient ischaemic episodes) only from a cardiothoracic surgeon, cardiologist or general physician. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 Patients with prosthetic heart valves - as an adjunct to oral anticoagulation for prophylaxis of thromboembolism; or 2 Both: 2.1 Patients after coronary artery vein bypass graft; and 2.2 Any of the following: 2.2.1 aspirin induced asthma; or 2.2.2 aspirin induced anaphylaxi; or 2.2.3 significant aspirin induced bleeding excluding bruising. Initial application - (Transient ischaemic episodes) only from a neurologist, neuro surgeon, cardiologist, vascular surgeon or general physician. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 Patients who continue to have transient ischaemic episodes despite aspirin therapy; or 2 Both: 2.1 Patients wh
Special Authority for Subsidy - Form SA0494Initial application only from an ophthalmologist. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 Both: 1.1 Primary open-angle glaucoma; and 1.2 Any of the following: 1.2.1 Patient cannot tolerate Beta-blockers, or Beta-blockers are contraindicated; or 1.2.2 Patient cannot tolerate Pilocarpine, or Pilocarpine is contraindicated; or 1.2.3 Patient cannot tolerate Dorzolamide, or Dorzolamide is contraindicated; or 1.2.4 A reduction in intraocular pressure of 15% or more is not achieved or maintained using dorzolamide either alone or in combination with a beta-blocker; or 2 There is progressive visual field loss and/or optic nerve damage persists after treatment with dorzolamide either alone or in combination with a beta-blocker. NoteSubsidised as monotherapy onlyRenewal only from an ophthalmologist. Approvals valid for 2 years where the treatment remains appropriate and the patient
Special Authority for Alternate Subsidy - Form SA0500Initial application from any medical practitioner. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 Either: 1.1 Patient is on a Social Welfare benefit; or 1.2 Patient has an income no greater than the benefit; and 2 Has tried at least one of the fully funded options and has been unable to tolerate it. Renewal from any medical practitioner. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 Patient is on a Social Welfare benefit; or 2 Patient has an income no greater than the benefit. NoteThe approval numbers of Special Authorities approved after 1 November 1999 are interchangeable between Mercilon and Marvelon. The additional subsidy will fund Mercilon and Marvelon up to the manufacturer's price for each of these products as identified on the Schedule at 1 November 1999Special Authorities approved before 1 November 1999 remain valid until the expiry d
Special Authority for Subsidy - Form SA0508Initial application only from a relevant specialist or general practitioner. Approvals valid for 2 years for applications meeting the following criteria: All of the following: 1 Patient with raised blood pressure; and 2 A beta blocker or diuretic is contraindicated; or not well tolerated; or insufficient to control blood pressure adequately at appropriate doses; and 3 An ACE inhibitor is contraindicated; or not well tolerated; or insufficient to control blood pressure adequately at appropriate doses. Renewal only from a relevant specialist or general practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0509Initial application only from a psychiatrist. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 Patient with first episode schizophrenia or related psychoses; or 2 Both: 2.1 Patient suffering from schizophrenia and related psychoses who is likely to benefit from anti-psychotic treatment; and 2.2 Both: 2.2.1 An effective dose of risperidone had been trialled and has been discontinued either because of; and 2.2.2 Any of the following: 2.2.2.1 Patient has recurrent acute dystonias; or 2.2.2.2 Patient has excessive Parkinson-like symptoms; or 2.2.2.3 Patient has hyperprolactinaemia; or 2.2.2.4 Patient has inadequate clinical response after four weeks. NoteDiscontinued treatment should be notified to HealthPAC if possibleRenewal only from a psychiatrist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0511Initial application only from a geriatrician, rheumatologist, endocrinologist, gynaecologist or general physician. Approvals valid for 2 years for applications meeting the following criteria: All of the following: 1 Severe osteoporosis; and 2 History of two previous significant osteoporotic fractures demonstrated radiologically; and 3 T-Score <= -3.0 (bone mass density (BMD) >= 3.0 standard deviations below the mean normal value in young adults). NoteIn line with the Australian guidelines for funding alendronate, a vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral bodyRenewal only from a geriatrician, rheumatologist, endocrinologist, gynaecologist or general physician. Approvals valid for 2 years where the tr
Special Authority for Subsidy - Form SA0512Initial application only from a gastroenterologist, general surgeon or general physician. Approvals valid for 3 months for applications meeting the following criteria: Both: 1 Mild to moderate ileal, ileocaecal or proximal Crohn's disease; and 2 Either: 2.1 Diabetes; or 2.2 Both: 2.2.1 Treatment with conventional corticosteroid therapy; and 2.2.2 Any of the following: 2.2.2.1 Cushingoid habitus; or 2.2.2.2 Osteoporosis where there is significant risk of fracture; or 2.2.2.3 Severe acne. Renewal only from a gastroenterologist, general surgeon or general physician. Approvals valid for 3 months where the patient has had no more than 1 prior approval in the last 12 months. The patient must have had no more than 1 prior approval in the last year. NoteClinical trials for Entocort CIR use beyond three months demonstrated no improvement in relapse rate
Special Authority for Subsidy - Form SA0513Initial application - (Narcolepsy) only from a neurologist. Approvals valid for 24 months where narcolepsy. Initial application - (ADHD in patients aged 5 years or over) only from a paediatrician or psychiatrist. Approvals valid for 24 months for applications meeting the following criteria: Both: 1 ADHD (Attention Deficient and Hyperactivity Disorder) patients aged 5 years or over; and 2 Diagnosed according to DSM-IV or ICD 10 criteria. Initial application - (ADHD in patients under 5 years of age) only from a paediatrician or psychiatrist. Approvals valid for 12 months for applications meeting the following criteria: Both: 1 ADHD (Attention Deficient and Hyperactivity Disorder) patients under 5 years of age; and 2 Diagnosed according to DSM-IV or ICD 10 criteria. Renewal - (Narcolepsy or ADHD in patients under 5 years of age) only from a neurologist, paediatrician or psychiatrist. Approvals valid for 24 months where the treatment remains appr
Special Authority for Subsidy - Form SA0523Initial application only from a relevant specialist or general practitioner. Approvals valid for 6 months for applications meeting the following criteria: All of the following: 1 Diagnosis of asthma confirmed; and 2 Inhaler/device technique checked; and 3 Patient monitors PEFR regularly during exacerbations where appropriate; and 4 Any of the following: 4.1 At least three months of 1500 ug or more daily of inhaled beclomethasone or budesonide for adult; or 4.2 At least three months of 750 ug or more daily of inhaled fluticasone) for adult; or 4.3 At least three months of 800 ug or more daily inhaled beclomethasone or budesonide for child; or 4.4 At least three months of 400 ug or more daily inhaled fluticasone) for child; and 5 Either: 5.1 Short acting beta agonist used at least 3-4 times daily; or 5.2 Nocturnal awakenings at least twice a week. Renewal only from a relevant specialist or general practitioner. Appro
Special Authority for Subsidy - Form SA0528Initial application - (Narcolepsy) only from a neurologist or respiratory specialist. Approvals valid for 24 months where narcolepsy. Initial application - (ADHD in patients 5 or over) only from a paediatrician, psychiatrist or general practitioner. Approvals valid for 24 months for applications meeting the following criteria: All of the following: 1 ADHD (Attention Deficient and Hyperactivity Disorder) patients aged 5 years or over; and 2 Diagnosed according to DSM-IV or ICD 10 criteria; and 3 Applicant is a specialist or specialist has recommended treatment. Initial application - (ADHD in patients under 5) only from a paediatrician or psychiatrist. Approvals valid for 12 months for applications meeting the following criteria: Both: 1 ADHD (Attention Deficient and Hyperactivity Disorder) patients under 5 years of age; and 2 Diagnosed according to DSM-IV or ICD 10 criteria. Renewal - (Narcolepsy) only from a neurologist or respiratory spec
ACE inhibitors will be funded to the level of the ex-manufacturer price listed in the Schedule for patients who were taking an ACE inhibitor for the treatment of congestive heart failure prior to 1 June 1998. The prescription must be endorsed accordingly. We recommend that the words used to indicate eligibility are "certified condition" or an appropriate description of the patient such as "congestive heart failure", "CHF", "congestive cardiac failure" or "CCF". Additional subsidy for lisinopril is available only up to the price of the least expensive brand listed in the Schedule. Definition of Congestive Heart FailureAt the request of some prescribers the PTAC Cardiovascular subcommittee has provided adefinition of congestive heart failure for the purposes of the funding of the manufacturer'ssurcharge: "Clinicians should use their clinical judgement. Existing patients would be eligible for thefunding of the surcharge if the patient shows signs and symptoms of congestive heart failure, and requir
Additional subsidy by endorsement for:Moclobemide tab 150 mg x 100 (Aurorix) up to $47.00Moclobemide tab 300 mg x 60 (Aurorix) up to $56.40Nefazadone tab 100 mg x 56 (Serzone) up to $20.16Nefazadone tab 200 mg x 56 (Serzone) up to $40.32Citalopram tab 20 mg x 28 (Cipramil) up to $27.00is available for patients who: * are taking moclobemide or nefazodone on 1 December 1999 or citalopram on 1 February2000; * have previously responded to treatment with moclobemide or nefazodone or citalopram; * have had a trial of fluoxetine and have to discontinue due to: - inability to tolerate the drug due to side effects OR - failed to respond to an adequate dose and duration of treatment; * have contraindications to fluoxetine (eg pre-existing significant levels of nausea, breastfeeding, potential drug interactions); The prescription must be endorsed accordingly. We recommend that the words used to indicate eligibility are "certified condition" however these particular words are not a requirement.
Special Authority for Subsidy - Form SA0538Initial application only from a gastroenterologist, infectious disease specialist, paediatrician or general physician. Approvals valid for 1 year for applications meeting the following criteria: Both: 1 Any of the following: 1.1 All of the following: 1.1.1 HBsAg positive for more than 6 months; and 1.1.2 HBeAg positive or HBV DNA positive defined as >0.6 pg/ml by quantitative PCR at reference laboratory; and 1.1.3 ALT greater than twice upper limit of normal or stage 3 or 4 fibrosis on liver histology clinical/radiological evidence of cirrhosis; or 1.2 HBV DNA positive cirrhosis prior to liver transplantation; or 1.3 HBsAg positive and have had a liver, kidney, heart, lung or bone marrow transplant; and 2 All of the following: 2.1 No continuing alcohol abuse or intravenous drug use; and 2.2 Not coinfected with HCV, HDV, or HIV; and 2.3 Neither ALT nor AST greater than 10 times upper limit of normal; and 2.4
Special Authority for Subsidy - Form SA0539Initial application from any medical practitioner. Approvals valid for 5 years where the patient is likely to benefit from treatment. NoteApplications to be made on the approved forms which are available from: The Co-ordinatorPhone: 09 580 9176Multiple Sclerosis Treatment CommitteeFacsimile: 09 580 9205Level 3, Unisys HouseEmail: murray@ppc.govt.nz650 Great South Road, PenrosePrivate Bag, AUCKLANDBudget managed by appointed clinicians on the Multiple Sclerosis Treatment Assessments Committee (MSTAC). Applications will be considered by MSTAC at its regular meetings and approved subject to eligibility according to the Entry and Stopping criteria (below). Completed application forms must be sent to the co-ordinator for MSTAC and will be considered by MSTAC at the next practicable opportunity. Notification of MSTAC's decision will be sent to the patient, the applying clinician and the patient's GP (if specified). These agents will N
Additional subsidy by endorsement for:Moclobemide tab 150 mg x 100 (Aurorix) up to $47.00Moclobemide tab 300 mg x 60 (Aurorix) up to $56.40Nefazadone tab 100 mg x 56 (Serzone) up to $20.16Nefazadone tab 200 mg x 56 (Serzone) up to $40.32Citalopram tab 20 mg x 28 (Cipramil) up to $27.00is available for patients who: * were taking moclobemide or nefazodone on 1 December 1999 or citalopram on 1 February 2000; or* have previously responded to treatment with moclobemide, nefazodone or citalopram; or* have had a trial of fluoxetine and have to discontinue due to: - inability to tolerate the drug due to side effects; or - failed to respond to an adequate dose and duration of treatment; or* have contraindications to fluoxetine (eg pre-existing significant levels of nausea, breastfeeding, potential drug interactions); The prescription must be endorsed accordingly. We recommend that the words used to indicate eligibility are "certified condition" however these words are not a requirement.
Special Authority for Subsidy - Form SA0551Initial application only from a paediatrician, neurologist or general physician. Approvals valid for 15 months for applications meeting the following criteria: Any of the following: 1 Was on NAED therapy before 1 September 2000; or 2 Seizures are not adequately controlled with optimal older anti-epilepsy drug treatment; or 3 Seizures are controlled adequately but who experience unacceptable side effects from older anti-epilepsy drug treatment. NoteApproval entitles patients to a subsidy for one NAED. Dual NAED therapy will be subsidised for patients who were already stabilised on two NAEDs on or before 31 July 2000 or, for whom a second NAED has been added to therapy with one NAED provided an attempt to withdraw one NAED has been made and was unsuccessful. "Optimal older anti-epilepsy drug therapy" is defined as treatment with those older anti-epilepsy drugs which are indicated and clinically appropriate for the patient, given singly and in combin
Special Authority for Subsidy - Form SA0556Initial application - (Confirmed HIV/AIDS) only from a named general physician. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 Confirmed HIV/AIDS; and 2 Any of the following: 2.1 Symptomatic patient; or 2.2 Both: 2.2.1 Asymptomatic patient; and 2.2.2 Patient aged 12 months and under; or 2.3 Both: 2.3.1 Asymptomatic patient; and 2.3.2 Patient has viral load counts > 10,000 copies per ml or equivalent value on the Chiron test; or 2.4 All of the following: 2.4.1 Asymptomatic patient; and 2.4.2 Patient aged 1 to 5 years; and 2.4.3 CD4 counts < 1,000 cells/mm3; or 2.5 All of the following: 2.5.1 Asymptomatic patient; and 2.5.2 Patient aged 1 to 5 years; and 2.5.3 CD4 counts < 0.25 x total white cell count; or 2.6 All of the following: 2.6.1 Asymptomatic patient; and 2.6.2 Patient aged 6 years and over; and 2.6.3 CD4 counts
Special Authority for Subsidy - Form SA0557Initial application - (Single NAED Therapy) only from a paediatrician, neurologist or general physician. Approvals valid for 15 months for applications meeting the following criteria: Any of the following: 1 Was on NAED therapy before 1 September 2000; or 2 Seizures are not adequately controlled with optimal older anti-epilepsy drug treatment; or 3 Seizures are controlled adequately but who experience unacceptable side effects from older anti-epilepsy drug treatment. Note"Optimal older anti-epilepsy drug therapy" is defined as treatment with those older anti-epilepsy drugs which are indicated and clinically appropriate for the patient, given singly and in combination in adequate doses for the patient's age, weight, and other features affecting the pharmacokinetics of the drug with good evidence of complianceAs a guideline, clinical trials have referred to a notional 50% reduction in seizure frequency as an indicator of success with anti-convulsan
Additional subsidy by endorsement for:Moclobemide tab 150mg x 100 (Aurorix) up to $32.90Moclobemide tab 300mg x 60 (Aurorix) up to $39.48Nefazodone tab 100mg x 56 (Serzone) up to $20.16Nefazodone tab 200mg x 56 (Serzone) up to $40.32Citalopram tab 20mg x 28 (Cipramil) up to $27.00is available for patients who: * were taking moclobemide or nefazodone on 1 December 1999 or citalopram on 1 February 2000; or* have previously responded to treatment with moclobemide, nefazodone or citalopram; or* have had a trial of fluoxetine and have had to discontinue due to - inability to tolerate the drug due to side effects; or - failed to respond to an adequate dose and duration of treatment; or* have contraindications to fluoxetine (eg pre-existing significant levels of nausea, breastfeeding, potential drug interactions). The prescription must be endorsed accordingly. We recommend that the words used to indicate eligibility are "certified condition" however these words are not a requirement.
Additional subsidy by endorsement for:Moclobemide tab 150mg x 100 (Aurorix) up to $32.90Moclobemide tab 300mg x 60 (Aurorix) up to $39.48Nefazodone tab 100mg x 56 (Serzone) up to $20.16Nefazodone tab 200mg x 56 (Serzone) up to $40.32Citalopram tab 20mg x 28 (Cipramil and Celapram) up to $10.00Paroxetine hydrochloride tab 20 mg x 30 (Aropax) up to $35.02is available for patients who: * were taking moclobemide or nefazodone on 1 December 1999 or citalopram on 1 February 2000; or paroxetine hydrochloride on Februrary 2001; or * have previously responded to treatment with moclobemide or nefazodone or citalopram or paroxetine hydrochloride; or* have had a trial of fluoxetine and have had to discontinue due to - inability to tolerate the drug due to side effects; or - failed to respond to an adequate dose and duration of treatment; or* have contraindications to fluoxetine (eg pre-existing significant levels of nausea, breastfeeding, potential drug interactions). The prescription must be e
Special Authority for Subsidy - Form SA0563Initial application only from a relevant specialist. Approvals valid for 2 years for applications meeting the following criteria: Any of the following: 1 Both: 1.1 Acromegaly; and 1.2 Patient has failed surgery, radiotherapy, bromocriptine and other oral therapies; or 2 VIPomas and Glucagonomas - for patients who are seriously ill in order to improve their clinical state prior to definitive surgery.; or 3 Both: 3.1 Gastrinoma; and 3.2 Either: 3.2.1 Patient has failed surgery; or 3.2.2 Patient in metastatic disease after H2 antagonists (or proton pump inhibitors) have failed; or 4 Both: 4.1 Insulinomas; and 4.2 Surgery is contraindicated or has failed; or 5 For pre-operative control of hypoglycaemia and for maintenance therapy; or 6 Both: 6.1 Carcinoid syndrome (diagnosed by tissue pathology and/or urinary 5HIAA analysis); and 6.2 Disabling symptoms not controlled by maximal medical therapy. No
Trandolapril will be funded to the level of the ex-manufacturer price listed in the Schedule for patients who were taking these ACE inhibitors for the treatment of congestive heart failure prior to 1 June 1998. The prescription must be endorsed accordingly. We recommend that the words used to indicate eligibility are "certified condition" or an appropriate description of the patient such as "congestive heart failure", "CHF", "congestive cardiac failure" or "CCF". Definition of Congestive Heart Failure At the request of some prescribers the PTAC Cardiovascular subcommittee has provided a definition of congestive heart failure for the purposes of the funding of the manufacturer's surcharge: "Clinicians should use their clinical judgement. Existing patients would be eligible for the funding of the surcharge if the patient shows signs and symptoms of congestive heart failure, and requires or has in the past required concomitant treatment with a diuretic. The definition could also be considered to include pat
Perindopril will be funded to the level of the ex-manufacturer price listed in the Schedule for patients who were taking these ACE inhibitors for the treatment of congestive heart failure prior to 1 June 1998. The prescription must be endorsed accordingly. We recommend that the words used to indicate eligibility are "certified condition" or an appropriate description of the patient such as "congestive heart failure", "CHF", "congestive cardiac failure" or "CCF". Definition of Congestive Heart Failure At the request of some prescribers the PTAC Cardiovascular subcommittee has provided a definition of congestive heart failure for the purposes of the funding of the manufacturer's surcharge: "Clinicians should use their clinical judgement. Existing patients would be eligible for the funding of the surcharge if the patient shows signs and symptoms of congestive heart failure, and requires or has in the past required concomitant treatment with a diuretic. The definition could also be considered to include pati
Special Authority for Subsidy - Form SA0569Initial application only from a geriatrician, rheumatologist, endocrinologist, gynaecologist or general physician. Approvals valid for 2 years for applications meeting the following criteria: All of the following: 1 Severe osteoporosis; and 2 History of one previous significant osteoporotic fractures demonstrated radiologically; and 3 T-Score <= -3.0 (bone mass density (BMD) >= 3.0 standard deviations below the mean normal value in young adults). NoteIn line with the Australian guidelines for funding alendronate, a vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body. Renewal only from a geriatrician, rheumatologist, endocrinologist, gynaecologist or general physician. Approvals valid for 2 years where the t
Special Authority for Subsidy - Form SA0575Initial application - (Confirmed HIV/AIDS) only from a named general physician. Approvals valid without further renewal unless notified for applications meeting the following criteria: Both: 1 Confirmed HIV/AIDS; and 2 Any of the following: 2.1 Symptomatic patient; or 2.2 Both: 2.2.1 Asymptomatic patient; and 2.2.2 Patient aged 12 months and under; or 2.3 Both: 2.3.1 Asymptomatic patient; and 2.3.2 Patient has viral load counts > 10,000 copies per ml or equivalent value on the Chiron test; or 2.4 All of the following: 2.4.1 Asymptomatic patient; and 2.4.2 Patient aged 1 to 5 years; and 2.4.3 CD4 counts < 1,000 cells/mm3; or 2.5 All of the following: 2.5.1 Asymptomatic patient; and 2.5.2 Patient aged 1 to 5 years; and 2.5.3 CD4 counts < 0.25 x total white cell count; or 2.6 All of the following: 2.6.1 Asymptomatic patient; and 2.6.2 Patient aged 6 years and over
Special Authority for Subsidy - Form SA0579Initial application - (Cystic fibrosis or renal failure) only from a relevant specialist. Approvals valid for 3 years for applications meeting the following criteria: Either: 1 cystic fibrosis; or 2 chronic renal failure or continuous ambulatory peritoneal dialysis (CAPD) patient. Initial application - (Indications other than cystic fibrosis or renal failure) only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria: Any of the following: 1 cancer in children; or 2 cancers affecting alimentary tract where there are malabsorption problems in patients over the age of 20 years; or 3 failure to thrive; or 4 growth deficiency; or 5 bronchopulmonary dysplasia; or 6 premature and post premature infant. Renewal - (Cystic fibrosis or renal failure) only from a relevant specialist or general practitioner on the recommendation of such a specialist. Approvals valid for 3 years for applicatio
Special Authority for Subsidy - Form SA0580Initial application - (Inborn errors of metabolism) only from a relevant specialist. Approvals valid for 3 years where inborn errors of metabolism. Initial application - (Indications other than inborn errors of metabolism) only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria: Any of the following: 1 failure to thrive ; or 2 growth deficiency; or 3 bronchopulmonary dysplasia ; or 4 fat malabsorption ; or 5 lymphangiectasia; or 6 short bowel syndrome ; or 7 infants with necrotising enterocolitis; or 8 biliary atresia. Renewal - (Inborn errors of metabolism) only from a relevant specialist or general practitioner on the recommendation of such a specialist. Approvals valid for 3 years for applications meeting the following criteria: Both: 1 The treatment remains appropriate and the patient is benefiting from treatment; and 2 General Practitioners must include the name of
Special Authority for Subsidy - Form SA0581Initial application - (Cystic fibrosis) only from a relevant specialist. Approvals valid for 3 years for applications meeting the following criteria: Both: 1 infant aged four years or under; and 2 cystic fibrosis. Initial application - (Indications other than cystic fibrosis) only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria: Both: 1 infant aged four years or under; and 2 Any of the following: 2.1 cancer in children; or 2.2 failure to thrive; or 2.3 growth deficiency; or 2.4 bronchopulmonary dysplasia; or 2.5 premature and post premature infants. Renewal - (Cystic fibrosis) only from a relevant specialist or general practitioner on the recommendation of such a specialist. Approvals valid for 3 years for applications meeting the following criteria: Both: 1 The treatment remains appropriate and the patient is benefiting from treatment; and 2 General Practiti
Special Authority for Subsidy - Form SA0585Initial application - (Cystic fibrosis) only from a relevant specialist. Approvals valid for 3 years for applications meeting the following criteria: All of the following: 1 Cystic fibrosis; and 2 other lower calorie products have been tried; and 3 patient has substantially increased metabolic requirements; and 4 Either: 4.1 The product is to be used as a supplement; or 4.2 The product is to be used as a complete diet.Initial application - (Indications other than cystic fibrosis) only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria: All of the following: 1 Any of the following: 1.1 any condition causing malabsorption ; or 1.2 failure to thrive ; or 1.3 increased nutritional requirements.; and 2 other lower calorie products have been tried; and 3 patient has substantially increased metabolic requirements; and 4 Either: 4.1 The product is to be used a
Special Authority for Subsidy - Form SA0587Initial application only from a relevant specialist. Approvals valid for 3 years for applications meeting the following criteria: Both: 1 acute or chronic renal failure; and 2 Either: 2.1 The product is to be used as a supplement (maximum 500 ml per day); or 2.2 The product is to be used as a complete diet.Renewal only from a relevant specialist or general practitioner on the recommendation of such a specialist. Approvals valid for 3 years for applications meeting the following criteria: All of the following: 1 The treatment remains appropriate and the patient is benefiting from treatment; and 2 Either: 2.1 The product is to be used as a supplement (maximum 500 ml per day); or 2.2 The product is to be used as a complete diet; and 3 General Practitioners must include the name of the specialist and date contacted.
Special Authority for Subsidy - Form SA0588Initial application only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria: Both: 1 CORD patients who have hypercapnia; and 2 Either: 2.1 The product is to be used as a supplement (maximum 500 ml per day); or 2.2 The product is to be used as a complete diet.Renewal only from a relevant specialist or general practitioner on the recommendation of such a specialist. Approvals valid for 1 year for applications meeting the following criteria: All of the following: 1 The treatment remains appropriate and the patient is benefiting from treatment; and 2 Either: 2.1 The product is to be used as a supplement (maximum 500 ml per day); or 2.2 The product is to be used as a complete diet; and 3 General Practitioners must include the name of the specialist and date contacted.
Special Authority for Subsidy - Form SA0589Initial application only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria: All of the following: 1 Anorexia and weight loss; and 2 Either: 2.1 decompensating liver disease without encephalopathy ; or 2.2 protein losing gastro-enteropathy; and 3 Either: 3.1 The product is to be used as a supplement (maximum 500 ml per day); or 3.2 The product is to be used as a complete diet.Renewal only from a relevant specialist or general practitioner on the recommendation of such a specialist. Approvals valid for 1 year for applications meeting the following criteria: All of the following: 1 The treatment remains appropriate and the patient is benefiting from treatment; and 2 Either: 2.1 The product is to be used as a supplement (maximum 500 ml per day); or 2.2 The product is to be used as a complete diet; and 3 General Practitioners must include the name of the specialis
Special Authority for Subsidy - Form SA0590Initial application only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria: All of the following: 1 infant aged one to six years; and 2 Any of the following: 2.1 any condition causing malabsorption ; or 2.2 failure to thrive; or 2.3 increased nutritional requirements; and 3 Either: 3.1 The product is to be used as a supplement (maximum 500 ml per day); or 3.2 The product is to be used as a complete diet.Renewal only from a relevant specialist or general practitioner on the recommendation of such a specialist. Approvals valid for 1 year for applications meeting the following criteria: All of the following: 1 The treatment remains appropriate and the patient is benefiting from treatment; and 2 Either: 2.1 The product is to be used as a supplement (maximum 500 ml per day); or 2.2 The product is to be used as a complete diet; and 3 General Practitioners must
Special Authority for Subsidy - Form SA0591Initial application only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria: Both: 1 Any of the following: 1.1 enteral feeding; or 1.2 nasogastric; or 1.3 nasoduodenal ; or 1.4 nasojejunal; or 1.5 gastrostomy/jejunostomy; and 2 Either: 2.1 The product is to be used as a supplement; or 2.2 The product is to be used as a complete diet.Renewal only from a general practitioner or relevant specialist. Approvals valid for 1 year for applications meeting the following criteria: All of the following: 1 The treatment remains appropriate and the patient is benefiting from treatment; and 2 Either: 2.1 The product is to be used as a supplement; or 2.2 The product is to be used as a complete diet; and 3 General Practitioners must include the name of the specialist and date contacted.
Special Authority for Subsidy - Form SA0592Initial application only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria: Both: 1 Any of the following: 1.1 malabsorption ; or 1.2 short bowel syndrome; or 1.3 enterocutaneous fistulas ; or 1.4 pancreatitis; and 2 Either: 2.1 The product is to be used as a supplement (maximum 500 ml per day); or 2.2 The product is to be used as a complete diet.NoteEach of these products is highly specialised and would be prescribed only by an expert for a specific disorder. The alternative is hospitalisation. Elemental 028 Extra is more expensive than other products listed in this section and should only be used where the alternatives have been tried first and/or are unsuitable. Renewal only from a relevant specialist or general practitioner on the recommendation of such a specialist. Approvals valid for 1 year for applications meeting the following criteria: All of the following:
Special Authority for Subsidy - Form SA0594Initial application only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria: Both: 1 Type I and II diabetics who require nutritional supplementation.; and 2 Either: 2.1 The product is to be used as a supplement (maximum 500 ml per day); or 2.2 The product is to be used as a complete diet.Renewal only from a relevant specialist or general practitioner on the recommendation of such a specialist. Approvals valid for 1 year for applications meeting the following criteria: All of the following: 1 The treatment remains appropriate and the patient is benefiting from treatment; and 2 Either: 2.1 The product is to be used as a supplement (maximum 500 ml per day); or 2.2 The product is to be used as a complete diet; and 3 General Practitioners must include the name of the specialist and date contacted.
Special Authority for Subsidy - Form SA0596Initial application only from a relevant specialist. Approvals valid for 3 years for applications meeting the following criteria: Either: 1 gluten enteropathy has been diagnosed by biopsy; or 2 dermatitis herpetiformis. NoteA premium may be payable if the subsidy does not match the price charged by the manufacturer. The subsidy for these products reflects the philosophy that the patient incurs no additional financial burden for purchasing specialised more expensive products. Renewal only from a relevant specialist or general practitioner on the recommendation of such a specialist. Approvals valid for 3 years for applications meeting the following criteria: Both: 1 The treatment remains appropriate and the patient is benefiting from treatment; and 2 General Practitioners must include the name of the specialist and date contacted.
Special Authority for Subsidy - Form SA0597Initial application - (PKU Patient aged over 16) only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria: Both: 1 PKU; and 2 blood phenylalanine level < 900 mmol/litre (average of tests over last 12 months). Initial application - (Patient aged over 16) only from a relevant specialist. Approvals valid for 3 years for applications meeting the following criteria: Any of the following: 1 dietary management of homocystinuria; or 2 inborn errors of metabolism other than PKU; or 3 dietary management of maple syrup urine disease..Initial application - (Patient aged 16 or under) only from a relevant specialist. Approvals valid for 3 years for applications meeting the following criteria: Any of the following: 1 dietary management of homocystinuria; or 2 PKU and other inborn errors of metabolism; or 3 dietary management of maple syrup urine disease..Renewal - (PKU Patient aged over 16
Special Authority for Subsidy - Form SA0604Initial application - (Lactase deficiency or disaccharide intolerance) only from a relevant specialist. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 Patient is less than 3 years of age; and 2 Either: 2.1 diagnosed as suffering from congenital lactase deficiency; or 2.2 suffering from disaccharide intolerance. NoteSecondary lactose intolerance in children is usually short lasting, and can be controlled by dietary measures and by giving sufficient calories to regenerate digestive enzymes. The subsidy for these products reflects the philosophy that the patient incurs no additional financial burden for purchasing specialised more expensive products. Initial application - (Infant with intolerance to cows' milk) only from a relevant specialist. Approvals valid for 6 months for applications meeting the following criteria: Both: 1 intolerant to cows' milk; and 2 patient is less than 3 years of age. No
Special Authority for Subsidy - Form SA0605Initial application - (Cystic fibrosis or renal disorder) only from a relevant specialist. Approvals valid for 3 years for applications meeting the following criteria: Both: 1 Either: 1.1 cystic fibrosis; or 1.2 renal disorder; and 2 Either: 2.1 The product is to be used as a supplement; or 2.2 The product is to be used as a complete diet.Initial application - (Indications other than cystic fibrosis or renal disorder) only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria: Both: 1 Any of the following: 1.1 any condition causing malabsorption; or 1.2 failure to thrive; or 1.3 increased nutritional requirements; and 2 Either: 2.1 The product is to be used as a supplement; or 2.2 The product is to be used as a complete diet.Renewal - (Cystic fibrosis or renal disorder) only from a relevant specialist or general practitioner. Approvals valid for 3 years
Special Authority for Subsidy - Form SA0607Initial application only from a paediatrician. Approvals valid for 3 years for applications meeting the following criteria: Both: 1 Child (up to 18 years) who is awaiting liver transplant; and 2 Either: 2.1 The product is to be used as a supplement (maximum 500 ml per day); or 2.2 The product is to be used as a complete diet.Renewal only from a paediatrician. Approvals valid for 3 years for applications meeting the following criteria: Both: 1 The treatment remains appropriate and the patient is benefiting from treatment; and 2 Either: 2.1 The product is to be used as a supplement (maximum 500 ml per day); or 2.2 The product is to be used as a complete diet.
Special Authority for Subsidy - Form SA0609Initial application - (Serevent MDI, Serevent Accuhaler Foradil, Oxis Turbuhaler 12 mcg, Symbicort Turbuhaler) only from a relevant specialist or general practitioner. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 Both: 1.1 Child under the age of 12 with poorly controlled asthma; and 1.2 Either: 1.2.1 Required at least three months of 400 mcg or more daily inhaled beclomethasone or budesonide; or 1.2.2 Required at least three months of 200 mcg or more of fluticasone; or 2 Both: 2.1 Adult with poorly controlled asthma; and 2.2 Either: 2.2.1 Required at least three months of 1500 mcg or more daily inhaled beclomethasone or budesonide; or 2.2.2 Required at least three months of 750 mcg or more of fluticasone. NotePatients are to be reviewed at least at six months to assess compliance and effectiveness of therapy. Special Authority approvals are interchangeable among all prese
Special Authority for Subsidy - Form SA0610Initial application from any specialist. Approvals valid without further renewal unless notified for applications meeting the following criteria: All of the following: 1 Quantity used by patient on a weekly volume intraveneously (Details to be attached to application); and 2 Amount of nutrition patient is able to receive orally (Details to be attached to application); and 3 Exact formula of TPN (Details to be attached to application); and 4 Who has paid for TPN so far (Details to be attached to application); and 5 Place of manufacture (Details to be attached to application); and 6 Complete medical history of patient including details of previous therapies. (Details to be attached to application). Renewal - (Previous approval has expired) from any specialist. Approvals valid without further renewal unless notified where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0614Initial application only from a geriatrician, rheumatologist, endocrinologist, gynaecologist or general physician. Approvals valid for 2 years for applications meeting the following criteria: All of the following: 1 Severe osteoporosis; and 2 History of one previous significant osteoporotic fractures demonstrated radiologically; and 3 T-Score <= -3.0 (bone mass density (BMD) >= 3.0 standard deviations below the mean normal value in young adults). NoteIn line with the Australian guidelines for funding alendronate, a vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral bodyRenewal only from a geriatrician, rheumatologist, endocrinologist, gynaecologist or general physician. Approvals valid for 2 years where the tr
Special Authority for Subsidy - Form SA0615Initial application only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria: Both: 1 The product is to be used as a complete diet; and 2 Either: 2.1 Patient has metabolic disorders of fat metabolism; or 2.2 Patient has chylothorax. Renewal only from a relevant specialist or general practitioner on the recommendation of such a specialist. Approvals valid for 1 year for applications meeting the following criteria: Both: 1 The treatment remains appropriate and the patient is benefiting from treatment; and 2 General Practitioners must include the name of the specialist and date contacted.
Special Authority for Manufacturers Price - Form SA0616Initial application - (Conditions other than transient ischaemic episodes) only from a cardiothoracic surgeon, cardiologist or general physician. Approvals valid without further renewal unless notified for applications meeting the following criteria: Either: 1 Patients with prosthetic heart valves - as an adjunct to oral anticoagulation for prophylaxis of thromboembolism; or 2 Patients after coronary artery vein bypass graft - as an adjunct to aspirin or as monotherapy for patients who are aspirin intolerant. NoteAspirin intolerant patients are defined as those with aspirin induced asthma, urticaria, or anaphylaxi, or those with significant aspirin induced bleeding, excluding bruisingInitial application - (Transient ischaemic episodes) only from a neurologist, neuro surgeon, cardiologist, vascular surgeon or general physician. Approvals valid without further renewal unless notified where patients who continue to have transient ischaemic
Special Authority for Subsidy - Form SA0622Initial application only from a geriatrician, rheumatologist, endocrinologist, gynaecologist or general physician. Approvals valid without further renewal unless notified for applications meeting the following criteria: All of the following: 1 Severe osteoporosis; and 2 History of one previous significant osteoporotic fractures demonstrated radiologically; and 3 T-Score <= -3.0 (bone mass density (BMD) >= 3.0 standard deviations below the mean normal value in young adults). NoteIn line with the Australian guidelines for funding alendronate, a vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral bodyRenewal only from a geriatrician, rheumatologist, endocrinologist, gynaecologist or general physician. Approvals va
Special Authority for Subsidy - Form SA0623Initial application from any medical practitioner. Approvals valid for 1 year for applications meeting the following criteria: All of the following: 1 The patient is not predisposed to heart arrhythmias; and 2 The patient does not have a pre-existing QT-prolongation or hepatic failure; and 3 The patient is not using other medications which either inhibit the cytochrome P450 3A4 enzyme system or prolong the QT interval; and 4 Any of the following: 4.1 Both: 4.1.1 The patient is an adult with severe reflux oesophagitis; and 4.1.2 other treatment, including acid suppression with proton pump inhibitors, has failed; or 4.2 gastroparesis; or 4.3 malignancy of GI tract causing gastroparesis (or gastric outlet obstruction); or 4.4 The patient is a child (not including infants from 0 to 3 months of age who were born prematurely) with severe gastro-oesophageal reflux; and 5 Diagnosis has been made or confirmed by a general p
Special Authority for Subsidy - Form SA0626Initial application only from a renal physician. Approvals valid for 2 years for applications meeting the following criteria: All of the following: General Criteria: 1 Anaemia of end-stage renal failure (other treatable causes of anaemia being excluded); and 2 Been on haemodialysis or continuous ambulatory peritoneal dialysis (CAPD) for at least three months; and 3 Not under evaluation for, or awaiting, a live donor kidney transplant; and 4 Any of the following: Specific Criteria: 4.1 Anephric; or 4.2 Dependent on regular blood transfusion (1 unit each 4-8 weeks) to maintain haemoglobin > 60g/L; or 4.3 Dependent on regular blood transfusion but cannot be transfused because of severe transfusion reactions; or 4.4 Transfusion induced haemosiderosis (clinical manifestations, serum ferritin >1500 ug/L); or 4.5 Haemoglobin < 70 g/L (mean of at least 4 haemoglobin concentrations over 4 months); or 4.6 Both: 4.6.1 Haemo
Prescribing GuidelineTreatment with HMG CoA Reductase Inhibitors (Statins) is recommended for patients withdyslipidaemia and an absolute 5 year cardiovascular risk of 15% or greater. New Zealand Cardiovascular Guideline Group statement. "The 1996 Heart Foundation guidelines for the Assessment and Management of Dyslipidaemia are currently being revised. An evidence-based guideline on the Assessment and Management of Cardiovascular Risk will be developed in 2002. The Cardiovascular Guideline Group has written an interim consensus statement for themanagement of dyslipidaemia. The Heart Foundation cardiovascular risk tables should be used to determine risk. Certain groups are classified to be at very high risk (>20%) and should be treated as such: - Patients who have had a previous cardiovascular event (angina, MI, angioplasty, coronary artery bypass grafts, TIA, ischaemic stroke and peripheral vascular disease)- Patients with genetic lipid disorders- Patients with diabetes and associated microa
Special Authority for Subsidy - Form SA0628Initial application only from a cardiologist. Approvals valid without further renewal unless notified for applications meeting the following criteria: Any of the following: 1 Both: 1.1 Congestive heart failure; and 1.2 Cannot tolerate two ACE inhibitors due to persistent cough that resolves on cessation and recurs on re-challenge with ACE inhibitor; or 2 Patients who have experienced angioedema on an ACE inhibitor at any time in the past; or 3 Patients who have experienced angioedema (even if not using an ACE inhibitor) in the last 2 years. Renewal - ((2 year approvals granted before April 2002)) only from a cardiologist. Approvals valid without further renewal unless notified where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0631Initial application only from an ophthalmologist. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 Both: 1.1 Primary open-angle glaucoma; and 1.2 Any of the following: 1.2.1 Patient cannot tolerate Beta-blockers, or Beta-blockers are contraindicated; or 1.2.2 Patient cannot tolerate Pilocarpine, or Pilocarpine is contraindicated; or 1.2.3 Patient cannot tolerate Dorzolamide, or Dorzolamide is contraindicated; or 1.2.4 A reduction in intraocular pressure of 15% or more is not achieved or maintained using dorzolamide either alone or in combination with a beta-blocker; or 2 There is progressive visual field loss and/or optic nerve damage persists after treatment with dorzolamide either alone or in combination with a beta-blocker. NoteSubsidised also for adjunctive use for the treatment of patients who have met the initial application criteria, and in whom latanoprost monotherapy has bee
Special Authority for Subsidy - Form SA0633Initial application only from a general practitioner or relevant specialist. Approvals valid without further renewal unless notified for applications meeting the following criteria: Both: 1 Patient is already on an ACE inhibitor or Angiotensin II Antagonist; and 2 Any of the following: 2.1 Both: 2.1.1 Symptomatic heart failure NYHA functional class II-III; and 2.1.2 Patient has been treated with metoprolol and is intolerant to metoprolol or has demonstrated a sub-optimal response to metoprolol; or 2.2 Symptomatic heart failure NYHA functional class III-IV; or 2.3 Patient has left ventricular systolic dysfunction with an ejection fraction of less than 35%.NoteWhere possible treatment should be initiated by or on the recommendation of a specialist.
Special Authority for Subsidy - Form SA0635Initial application only from a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria: All of the following: 1 Rheumatoid arthritis; and 2 Patient is not a pregnant woman, or a woman of child-bearing age without adequate contraception; and 3 Patient has been unable to tolerate or has a contraindication to or has had an inadequate response to sulphasalazine and methotrexate (individually or in combination). Renewal only from a rheumatologist. Approvals valid without further renewal unless notified for applications meeting the following criteria: Both: 1 Compliance (prescriber determined) with medication; and 2 Improved rheumatoid arthritis symptom control. NotePatient should have full blood count and liver function tests regularly monitored.
Special Authority for Subsidy - Form SA0637Initial application - (National Heart Foundation risk groups A1:1, A1:2, B, C, D or E) only from a relevant specialist or general practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria: All of the following: 1 The patient has been offered 3-6 months of counseling and an opportunity to modify lifestyle; and 2 Any of the following: 2.1 Both: 2.1.1 NHF A1:1 - Clinically proven ischaemic heart disease; and 2.1.2 total cholesterol > 5.5; or 2.2 Both: 2.2.1 NHF A1:2 - Post coronary artery bypass graft (CABG) or angioplasty; and 2.2.2 total cholesterol > 4.5; or 2.3 Post heart transplant (regardless of cholesterol level); or 2.4 Both: 2.4.1 NHF B: Patients with > 20% 5-year cardiovascular disease risk; and 2.4.2 total cholesterol > 9.0; or 2.5 Both: 2.5.1 NHF C: 15-20% 5-year cardiovascular disease risk; and 2.5.2 total cholesterol >
Special Authority for Subsidy - Form SA0639Initial application - (No previous use) only from a relevant specialist or general practitioner. Approvals valid for 3 months for applications meeting the following criteria: All of the following: 1 The patient has a clinical diagnosis of heavy menstrual bleeding; and 2 The patient has failed to respond to or is unable to tolerate other appropriate pharmaceutical therapies as per the Heavy Menstrual Bleeding Guidelines; and 3 Either: 3.1 serum ferritin level < 16 mg/l (within the last 12 months); or 3.2 haemoglobin level < 120 g/l . NoteApplications are not to be made for use in patients as contraception except where they meet the above criteriaInitial application - (Previous use before 1 October 2002) only from a relevant specialist or general practitioner. Approvals valid for 3 months for applications meeting the following criteria: All of the following: 1 The patient had a clinical diagnosis of heavy menstrual bleeding; and 2
Special Authority for Waiver of Rule - Form SA0641Initial application only from a diabetologist, general physician or paediatrician. Approvals valid without further renewal unless notified for applications meeting the following criteria: Either: 1 Both: 1.1 Use alone (monotherapy); and 1.2 The patient is unable to use any other insulins including those on insulin pump treatment; or 2 Both: 2.1 Use with insulin other than insulin isophane (including ready-mixed preparations); and 2.2 A reasonable trial of insulin isophane has been undertaken and it is not effective or not well tolerated. Note"Reasonable trial", "unable to use", "not effective", "not well tolerated", and "not well tolerated" are not defined and we ask clinicians to use their clinical judgement in interpreting these terms.
Special Authority for Subsidy - Form SA0643Initial application - (CML) only from an oncologist or relevant specialist. Approvals valid for 7 months where approved by the The Glivec Co-ordinator. Initial application - (GIST) only from an oncologist. Approvals valid for 1 year where approved by the The Glivec Co-ordinator. Renewal - (CML) only from an oncologist or relevant specialist. Approvals valid for 6 months where approved by the The Glivec Co-ordinator. Initial application - (GIST) only from an oncologist. Approvals valid for 1 year where approved by the The Glivec Co-ordinator. NoteApplication forms are available from, and prescriptions should be sent to: The Glivec Co-ordinatorPhone: 09 580 9176Level 3, Unisys HouseFacsimile: 09 580 9205650 Great South Road, PenroseEmail: murray@ppc.govt.nzPrivate Bag, AUCKLANDSpecial Authority criteria for CML - access by applicationFunded for patients with diagnosis (confirmed by a haematologist) of a chronic myeloid leukaemia (CML) i
Special Authority for Subsidy - Form SA0645Initial application only from a renal physician. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 Both: 1.1 patient in chronic renal failure; and 1.2 Haemoglobin <= 100 g/L; and 2 Either: 2.1 Both: 2.1.1 patient is not diabetic; and 2.1.2 glomerular filtration rate <= 30 ml/min; or 2.2 Both: 2.2.1 patient is diabetic; and 2.2.2 glomerular filtration rate <= 45 ml/min. Renewal only from a renal physician. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment. NoteErythropoietin beta is indicated in the treatment of anaemia associated with chronic renal failure (CRF) where no cause for anaemia other than CRF is detected and there is adequate monitoring of iron stores and iron replacement therapy. The Cockroft-Gault Formula may be used to estimate glomerular filtration rate (GFR) in persons 18 years and over:GFR (male)
Special Authority for Subsidy - Form SA0646Initial application only from a renal physician. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 Both: 1.1 patient in chronic renal failure; and 1.2 Haemoglobin <= 100 g/L; and 2 Any of the following: 2.1 Both: 2.1.1 patient is not diabetic; and 2.1.2 glomerular filtration rate <= 30 ml/min; or 2.2 Both: 2.2.1 patient is diabetic; and 2.2.2 glomerular filtration rate <= 45 ml/min; or 2.3 patient is on haemodialysis or peritoneal dialysis. Renewal only from a renal physician. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment. NoteErythropoietin beta is indicated in the treatment of anaemia associated with chronic renal failure (CRF) where no cause for anaemia other than CRF is detected and there is adequate monitoring of iron stores and iron replacement therapy. The Cockroft-Gault Formula may be used to estim
Special Authority for Manufacturers Price - Form SA0648Initial application - (Conditions other than transient ischaemic episodes) only from a cardiothoracic surgeon, cardiologist or general physician. Approvals valid without further renewal unless notified for applications meeting the following criteria: Either: 1 Patients with prosthetic heart valves - as an adjunct to oral anticoagulation for prophylaxis of thromboembolism; or 2 Patients after coronary artery vein bypass graft - as an adjunct to aspirin or as monotherapy for patients who are aspirin intolerant. NoteAspirin intolerant patients are defined as those with aspirin induced asthma, urticaria, or anaphylaxi, or those with significant aspirin induced bleeding, excluding bruisingInitial application - (Transient ischaemic episodes) only from a neurologist, neuro surgeon, cardiologist, vascular surgeon or general physician. Approvals valid without further renewal unless notified where patients who continue to have transient ischaemic
Special Authority for Subsidy - Form SA0649Initial application - (Conditions other than transient ischaemic episodes) only from a cardiothoracic surgeon, cardiologist or general physician. Approvals valid without further renewal unless notified for applications meeting the following criteria: Either: 1 Patients with prosthetic heart valves - as an adjunct to oral anticoagulation for prophylaxis of thromboembolism; or 2 Patients after coronary artery vein bypass graft - as an adjunct to aspirin or as monotherapy for patients who are aspirin intolerant. NoteAspirin intolerant patients are defined as those with aspirin induced asthma, urticaria, or anaphylaxi, or those with significant aspirin induced bleeding, excluding bruisingInitial application - (Transient ischaemic episodes) only from a neurologist, neuro surgeon, cardiologist, vascular surgeon or general physician. Approvals valid without further renewal unless notified where patients who continue to have transient ischaemic episodes des
Special Authority for Subsidy - Form SA0652Initial application - (Single NAED Therapy) only from a paediatrician, neurologist or general physician. Approvals valid for 15 months for applications meeting the following criteria: Any of the following: 1 Was on NAED therapy before 1 September 2000; or 2 Seizures are not adequately controlled with optimal older anti-epilepsy drug treatment; or 3 Seizures are controlled adequately but who experience unacceptable side effects from older anti-epilepsy drug treatment. Note"Optimal older anti-epilepsy drug therapy" is defined as treatment with those older anti-epilepsy drugs which are indicated and clinically appropriate for the patient, given singly and in combination in adequate doses for the patient's age, weight, and other features affecting the pharmacokinetics of the drug with good evidence of complianceInitial application - (Dual NAED Therapy) only from a paediatrician, neurologist or general physician. Approvals valid for 18 months for app
Special Authority for Subsidy - Form SA0657Initial application - (Helicobacter pylori infections) only from a general practitioner or relevant specialist. Approvals valid for 6 months for applications meeting the following criteria: Both: 1 Eradication of Helicobacter pylori in patient with proven infection; and 2 Peptic ulcer disease proven by endoscopy. NoteMaximum of two prescriptions (two courses) per patient. Initial application - (Mycobacterial infections) only from a respiratory specialist, infectious disease specialist or paediatrician. Approvals valid for 2 years for applications meeting the following criteria: Any of the following: 1 Mycobacterium Avium Intracellulare Complex infections in patient with AIDS; or 2 Atypical and drug-resistant mycobacterial infection; or 3 All of the following: 3.1 Prophylaxis against disseminated Mycobacterium Avium Intracellulare Complex infection; and 3.2 HIV infection; and 3.3 CD4 count <= 50 cells/mm3. Renewal - (Mycobact
Additional subsidy by endorsement for:Moclobemide tab 150 mg x 500 (Apo-Moclobemide) up to $46.00Moclobemide tab 150 mg x 100 (Aurorix) up to $32.90Moclobemide tab 300 mg x 100 (Apo-Moclobemide) up to $26.11Moclobemide tab 300 mg x 60 (Aurorix) up to $39.48Nefazodone tab 100 mg x 56 (Serzone) up to $20.16Nefazodone tab 200 mg x 56 (Serzone) up to $40.32Citalopram tab 20 mg x 28 (Celapram) up to $4.00Citalopram tab 20 mg x 28 (Cipramil) up to $10.00Paroxetine hydrochloride tab 20 mg x 30 (Aropax) up to $35.02is available for patients who: - were taking moclobemide or nefazodone on 1 December 1999 or citalopram on 1 February 2000; or paroxetine hydrochloride on February 2001; or- have previously responded to treatment with moclobemide or nefazodone or citalopram or paroxetine hydrochloride; or- have had a trial of fluoxetine and have had to discontinue due to- inability to tolerate the drug due to side effects; or- failed to respond to an adequate dose and duration of treatment; or
Special Authority for Subsidy - Form SA0661Initial application only from a psychiatrist. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 The patient has "treatment resistant" depression; and 2 Either: 2.1 The patient must have had a trial of two different antidepressants and failed to respond to an adequate dose over an adequate period of time (usually at least four weeks); or 2.2 Both: 2.2.1 The patient is currently a hospital in-patient as a result of an acute depressive episode; and 2.2.2 The patient must have had a trial of one other antidepressant and failed to respond to an adequate dose over an adequate period of time. Renewal from any medical practitioner. Approvals valid for 2 years where patient has a high risk of relapse (prescriber determined)..NoteFirst prescription can be written by a psychiatrist or psychiatric registrar. Subsequent prescriptions may be written by a General Practitioner
Special Authority for Subsidy - Form SA0667Initial application only from a named specialist. Approvals valid for 4 months for applications meeting the following criteria: All of the following: 1 To be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and 2 Patient is less than 18 years of age at commencement of treatment; and 3 Patient has had severe active polyarticular course Juvenile Idiopathic Arthritis (JIA) for 6 months duration or longer; and 4 Patient has tried and not responded to at least three months of oral or parenteral methotrexate at a dose of 10-20mg/m2 weekly in combination with oral corticosteroids (prednisone 0.25 mg/kg); and 5 Patient has tried and not responded to at least three months of oral or parenteral methotrexate (at a dose of 10-15mg/m2 weekly) in combination with one other disease-modifying agent; and 6 Both: 6.1 Either: 6.1.1 Patient has persistent symptoms of poorly-cont
Additional subsidy by endorsement for:Nefazodone tab 100 mg x 56 (Serzone) up to $20.16Nefazodone tab 200 mg x 56 (Serzone) up to $40.32Citalopram tab 20 mg x 28 (Celapram) up to $4.00Citalopram tab 20 mg x 28 (Cipramil) up to $10.00Paroxetine hydrochloride tab 20 mg x 30 (Aropax) up to $35.02is available for patients who: -were taking nefazodone on 1 December 1999 or citalopram on 1 February 2000; or paroxetine hydrochloride on February 2001; or- have previously responded to treatment with nefazodone or citalopram or paroxetinehydrochloride; or- have had a trial of fluoxetine and have had to discontinue due to- inability to tolerate the drug due to side effects; or- failed to respond to an adequate dose and duration of treatment; or- have contraindications to fluoxetine (eg pre-existing significant levels of nausea, breastfeeding, potential drug interactions). The prescription must be endorsed accordingly.
Special Authority for Subsidy - Form SA0693Initial application only from a relevant specialist or vocationally registered general practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria: All of the following: 1 Severe osteoporosis; and 2 History of one previous significant osteoporotic fracture demonstrated radiologically; and 3 T-Score <= -3.0 (bone mass density (BMD) >= 3.0 standard deviations below the mean normal value in young adults). NoteIn line with the Australian guidelines for funding alendronate, a vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral bodyRenewal - ((2 year approvals granted before February 2002)) only from a geriatrician, rheumatologist, endocrinologist, gynaecologis
Special Authority for Subsidy - Form SA0696Initial application - (Narcolepsy) only from a neurologist or respiratory specialist. Approvals valid for 24 months where narcolepsy. Initial application - (ADHD in patients 5 or over) only from a paediatrician, psychiatrist or general practitioner on the recommendation of such a specialist. Approvals valid for 24 months for applications meeting the following criteria: All of the following: 1 ADHD (Attention Deficit and Hyperactivity Disorder) patients aged 5 years or over; and 2 Diagnosed according to DSM-IV or ICD 10 criteria; and 3 Either: 3.1 Applicant is a specialist; or 3.2 Both: 3.2.1 Applicant is a GP and a specialist has recommended treatment; and 3.2.2 Provide name of specialist (Details to be attached to application). Initial application - (ADHD in patients under 5) only from a paediatrician or psychiatrist. Approvals valid for 12 months for applications meeting the following criteria: Both: 1 ADHD (Attention Defi
Special Authority for Subsidy - Form SA0698Initial application only from a gastroenterologist, general surgeon or general physician. Approvals valid for 3 months for applications meeting the following criteria: Both: 1 Mild to moderate ileal, ileocaecal or proximal Crohn's disease; and 2 Any of the following: 2.1 Diabetes; or 2.2 Cushingoid habitus; or 2.3 Osteoporosis where there is significant risk of fracture; or 2.4 Severe acne following treatment with conventional corticosteroid therapy. Renewal only from a gastroenterologist, general surgeon or general physician. Approvals valid for 3 months where the treatment remains appropriate and the patient is benefiting from treatment. The patient must have had no more than 1 prior approval in the last year. NoteClinical trials for Entocort CIR use beyond three months demonstrated no improvement in relapse rate.
Special Authority for Subsidy - Form SA0699Initial application from any medical practitioner. Approvals valid for 1 year for applications meeting the following criteria: All of the following: 1 The patient is not predisposed to heart arrhythmias; and 2 The patient does not have a pre-existing QT-prolongation or hepatic failure; and 3 The patient is not using other medications which either inhibit the cytochrome P450 3A4 enzyme system or prolong the QT interval; and 4 Any of the following: 4.1 Both: 4.1.1 adult with severe reflux oesophagitis; and 4.1.2 other treatment, including acid suppression with proton pump inhibitors, has failed; or 4.2 gastroparesis; or 4.3 malignancy of GI tract causing gastroparesis (or gastric outlet obstruction); or 4.4 child (not including infants from 0 to 3 months of age who were born prematurely) with severe gastro-oesophageal reflux; and 5 Diagnosis has been made or confirmed by a general physician, gastroenterologist, or ge
Special Authority for Subsidy - Form SA0700Initial application only from an ophthalmologist. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 Both: 1.1 Monotherapy in primary open-angle glaucoma; and 1.2 Any of the following: 1.2.1 Patient cannot tolerate Beta-blockers, Pilocarpine and Dorzolamide; or 1.2.2 Beta-blockers, Pilocarpine and Dorzolamide are contraindicated; or 1.2.3 A reduction in intraocular pressure of 15% or more is not achieved or maintained using dorzolamide either alone or in combination with a beta-blocker; or 1.2.4 There is progressive visual field loss and/or optic nerve damage persists after treatment with dorzolamide either alone or in combination with a beta-blocker; or 2 Adjunctive use for the treatment of patients who have met the initial application criteria, and in whom latanoprost monotherapy has been ineffective in controlling intraocular pressure. Note An adjunctive agent may be added without a
Special Authority for Subsidy - Form SA0702Initial application - (Oral feed for cystic fibrosis patient) only from a relevant specialist. Approvals valid for 3 years for applications meeting the following criteria: Both: 1 Cystic fibrosis; and 2 Either: 2.1 The product is to be used as a supplement; or 2.2 The product is to be used as a complete diet.Initial application - (Oral feed for indications other than cystic fibrosis) only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria: Both: 1 Any of the following: 1.1 any condition causing malabsorption; or 1.2 failure to thrive; or 1.3 increased nutritional requirements; and 2 Either: 2.1 The product is to be used as a supplement; or 2.2 The product is to be used as a complete diet.Renewal - (Oral feed cystic fibrosis patient) only from a relevant specialist or general practitioner on the recommendation of such a specialist. Approvals valid for 3 years f
Special Authority for Subsidy - Form SA0703Initial application only from a relevant specialist or general practitioner. Approvals valid for 2 years for applications meeting the following criteria: All of the following: 1 Patient has raised blood pressure; and 2 The use of fully funded beta blockers is contraindicated, or not well tolerated; or where use of fully funded beta blockers and diuretics are insufficient to control blood pressure adequately at appropriate doses; and 3 Either: 3.1 Has been treated with, and cannot tolerate two ACE inhibitors, due to persistent cough; or 3.2 Has experienced angioedema on an ACE inhibitor at any time in the past or who have experienced angioedema (even if not using an ACE inhibitor) in the last 2 years. Renewal only from a relevant specialist or general practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0706Initial application only from a relevant specialist or general practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria: Either: 1 Both: 1.1 Patient with congestive heart failure; and 1.2 Either: 1.2.1 Has been treated with, and cannot tolerate, two ACE inhibitors, due to persistent cough; or 1.2.2 Has experienced angioedema on an ACE inhibitor at any time in the past or who have experienced angioedema (even if not using an ACE inhibitor) in the last 2 years; or 2 All of the following: 2.1 Patient with raised blood pressure; and 2.2 Use of fully funded beta blockers or diuretics are contraindicated; or not well tolerated; or insufficient to control blood pressure adequately at appropriate doses; and 2.3 Either: 2.3.1 Has been treated with, and cannot tolerate, two ACE inhibitors, due to persistent cough; or 2.3.2 Has experienced angioedema on an ACE in
Effective, consistent management of herpes from prescribing to these guidelines will improve patient outcomes. The guidelines on the following four pages are for the prescribing of aciclovir. The guidelines aim to: - improve patient care and clinical outcome through faster, more accessible treatment - protect patients' wider wellbeing by reinforcing the psychosocial aspects of treatment - improve the consistency and breadth of medical management of genital herpes in New Zealand. The guidelines are: - integral to ensuring a consistent, effective treatment regimen- the result of consultation with clinicians and patient representatives- set out in line with the recommended international algorithm format for treatment. The guidelines are endorsed by the Herpes Foundation's professional advisory board whose members represent venereology, NZDS, RNZCGP, RNZCOG, psychotherapy and nursing. Herpes Foundation Helpline: Toll free 0508 11 12 13Auckland Branch Herpes Foundation: 09 360 1966
Guidelines for the use of interferon in the treatment of hepatitis C: Physicians considering treatment of patients with hepatitis C should discuss cases with a gastroenterologist or aninfectious disease physician. All subjects undergoing treatment require careful monitoring for side effects. Patients should be otherwise fit. Hepatocellular carcinoma should be excluded by ultrasound examination and alpha-fetoprotein level. Criteria for Treatment a) Diagnosis- Anti-HCV positive on at least two occasions with a positive PCR for HCV-RNA and preferably confirmed by asupplementary RIBA test; or- PCR-RNA positive for HCV on at least 2 occasions if antibody negative; or- Anti-HCV positive on at least two occasions with a positive supplementary RIBA test with a negative PCR forHCV RNA but with a liver biopsy consistent with 2(b) following. b) Establishing Active Chronic Liver Disease- Confirmed HCV infection and serum ALT/AST levels measured on at least three occasions over six monthsaveraging >
Special Authority for Subsidy - Form SA0710Initial application only from an ophthalmologist. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 Either: 1.1 Monotherapy in primary open-angle glaucoma; or 1.2 Adjunctive use for the treatment of open-angle glaucoma in a patient who has met the initial application criteria, and in whom prostaglandin analogue monotherapy has been ineffective in controlling intraocular pressure; and 2 Any of the following: 2.1 Patient cannot tolerate beta-blockers, pilocarpine, and carbonic anhydrase inhibitors; or 2.2 Beta-blockers, pilocarpine and carbonic anhydrase inhibitors are contraindicated; or 2.3 A reduction in intraocular pressure of 15% or more is not achieved or maintained using carbonic anhydrase inhibitor either alone or in combination with a beta blocker; or 2.4 There is progressive visual field loss and/or optic nerve damage persists after treatment with carbonic anhydrase inhibitor either alo
Special Authority for Subsidy - Form SA0714Initial application from any medical practitioner. Approvals valid for 3 months for applications meeting the following criteria: All of the following: 1 Patient is currently enrolled in a recognised comprehensive treatment programme for alcohol dependence in a service accredited against the New Zealand Alcohol and Other Drug Sector Standard or the National Mental Health Sector Standard; and 2 Applicant works in an Alcohol & Drug Service; and 3 Applicant must include the address of the service (Details to be attached to application). Renewal from any medical practitioner. Approvals valid for 3 months for applications meeting the following criteria: Both: 1 Compliance with the medication (prescriber determined); and 2 Any of the following: 2.1 Patient is still unstable and requires further treatment; or 2.2 Patient achieved significant improvement but requires further treatment; or 2.3 Patient is well controlled but requires maint
Special Authority for Manufacturers Price - Form SA0717Initial application only from a relevant specialist or general practitioner. Approvals valid for 12 weeks for applications meeting the following criteria: Both: 1 Patient has a calculated absolute risk of cardiovascular disease of at least 15% over 5 years; and 2 Either: 2.1 Patient has severe documented intolerance to simvastatin; or 2.2 Both: 2.2.1 Patient has been compliant with a dose of simvastatin of 80 mg per day for at least 2 months; and 2.2.2 Either: 2.2.2.1 All of the following: 2.2.2.1.1 Patient has venous CABG; and 2.2.2.1.2 LDL cholesterol test 1 >= 2.0 mmol/litre; and 2.2.2.1.3 LDL cholesterol test 2 >= 2.0 mmol/litre (at least 1 week after test 1); or 2.2.2.2 All of the following: 2.2.2.2.1 Patient does not have venous CABG; and 2.2.2.2.2 LDL cholesterol test 1 >= 2.5 mmol/litre; and 2.2.2.2.3 LDL cholesterol test 2 >= 2.5 mmol/litre (at least 1 w
Special Authority for Subsidy - Form SA0721Initial application only from a named specialist. Approvals valid without further renewal unless notified for applications meeting the following criteria: All of the following: 1 The patient already has a Special Authority approval for anti-retroviral therapy (Details to be attached to application); and 2 Kaletra is to be used as a salvage therapy in place of one protease inhibitor; and 3 The patient must have trialed for at least six months and have failed on currently funded NNRTI based regimens or triple NRTI regimens; and 4 The patient must have trialed for at least six months and have failed on currently funded PI based regimens. NoteFailure is defined as: a) not achieving HIV RNA < 400 copies/ml after 24 weeks of a regimen, orb) an increase of HIV RNA to > 400 copies/ml on two separate occasions not less than one month apart, after suppression to < 400 copies/ml in a patient taking the regimen.
Special Authority for Subsidy - Form SA0723Initial application only from a relevant specialist. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 All of the following: 1.1 Patient has a calculated absolute risk of cardiovascular disease >20% over 5 years; and 1.2 Patient cannot tolerate statin therapy at a dose of 40 mg per day; and 1.3 Either: 1.3.1 All of the following: 1.3.1.1 Patient has venous CABG; and 1.3.1.2 LDL cholesterol >= 2.0 mmol/litre (see note); and 1.3.1.3 LDL cholesterol >= 2.0 mmol/litre (at least 1 week after test 1 - see note); or 1.3.2 All of the following: 1.3.2.1 Patient does not have venous CABG; and 1.3.2.2 LDL cholesterol >= 2.5 mmol/litre (see note); and 1.3.2.3 LDL cholesterol >= 2.5 mmol/litre (at least 1 week after test 1 - see note); or 2 All of the following: 2.1 Patient has homozygous familial hypercholesterolemia, or heterozygous familial hypercholesterol
Special Authority for Manufacturers Price - Form SA0724Initial application only from a relevant specialist or general practitioner. Approvals valid for 12 weeks for applications meeting the following criteria: Both: 1 Patient has a calculated absolute risk of cardiovascular disease of at least 15% over 5 years; and 2 Either: 2.1 Patient has severe documented intolerance to simvastatin (blood tests are not required); or 2.2 Both: 2.2.1 Patient has been compliant with a dose of simvastatin of 80 mg per day for at least 2 months; and 2.2.2 Either: 2.2.2.1 All of the following: 2.2.2.1.1 Patient has venous CABG; and 2.2.2.1.2 LDL cholesterol test 1 >= 2.0 mmol/litre; and 2.2.2.1.3 LDL cholesterol test 2 >= 2.0 mmol/litre (at least 1 week after test 1); or 2.2.2.2 All of the following: 2.2.2.2.1 Patient does not have venous CABG; and 2.2.2.2.2 LDL cholesterol test 1 >= 2.5 mmol/litre; and 2.2.2.2.3 LDL cholesterol test 2 >
Special Authority for Subsidy - Form SA0725Initial application only from a relevant specialist or general practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria: All of the following: 1 Patient with raised blood pressure; and 2 Use of fully funded beta blockers and diuretics are contraindicated; or not well tolerated; or insufficient to control blood pressure adequately at appropriate doses; and 3 Either: 3.1 Has been treated with, and cannot tolerate, two ACE inhibitors, due to persistent cough; or 3.2 Has experienced angioedema on an ACE inhibitor at any time in the past or who have experienced angioedema (even if not using an ACE inhibitor) in the last 2 years. Renewal - (Previous approval has expired) only from a relevant specialist or general practitioner. Approvals valid without further renewal unless notified where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0733Initial application - (Patient aged over 16) only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria: Both: 1 dietary management of PKU; and 2 blood phenylalanine level < 900 mmol/litre (average of tests over last 12 months). Initial application - (Patient aged 16 or under) only from a relevant specialist. Approvals valid for 3 years where dietary management of PKU.Renewal - (Patient aged over 16) only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria: blood phenylalanine level < 900 mmol/litre (average of tests over last 12 months). Renewal - (Patient aged 16 or under) only from a relevant specialist or general practitioner on the recommendation of such a specialist. Approvals valid for 3 years for applications meeting the following criteria: Both: 1 The treatment remains appropriate and the patient is benefiting from treatment; and 2
GuidelinesIt can cost up to $70,000 a year to keep an adult on protein supplements. Because protein substitutes are so expensive and because they are only effective in controlling PKU if a restricted diet is followed, adults with PKU will be required to demonstrate they are following the prescribed diet by regular blood testing. The requirement for testing applies to those aged over 16 years. Failure to follow an appropriate diet results in high blood phenylalanine levels. Those consistently testing above 15 mg (900 micromol) over a twelve month period will not be able to claim these products as a Special Authority. Specialists will be required to renew applications for their PKU patients every year and, when they do so, will have to submit the results of two blood tests.
Neocate should be used only as a last resort when the infant is unable to absorb any of the above formulae. The objective with each of thees formulae prescribed is to get the infant off them as soon as possible. This may take six months, it may take three years. Because of this, variation on age limit is not regarded as appropriate.These formulae will be available only from a hospital pharmacy. Vivonex Pediatric may be a suitable and less expensive alternative for many children that would otherwise be eligible for a subsidy for Neocate and should, therefore, be tried first in these cases. The subsidy for these products reflects the philosophy that the patient incurs no additional financial burden for purchasing specialised more expensive products.
Special Authority for Subsidy - Form SA0738Initial application only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria: Either: 1 All of the following: 1.1 To be used as monotherapy for patients with type 2 diabetes who after six months of diet and lifestyle changes do not have adequate glycaemic control (inadequate control defined as HbA1c > 8.0% in tests carried out at least two months apart); and 1.2 Metformin is not tolerated or contraindicated. Intolerance and contraindications as defined in the notes below, a minimum of a four week trial period of metformin is required; and 1.3 Sulphonylurea is not tolerated or contraindicated. Overweight patients are only eligible under the criteria of contraindication to sulphonylureas if their body mass index (BMI) exceeds 35; or 2 Both: 2.1 For use in combination with a sulphonylurea when diet and lifestyle changes and a twelve month trial of sulphonylurea results in inadequate glycaem
Special Authority for Subsidy - Form SA0741Initial application only from a psychiatrist. Approvals valid for 2 years for applications meeting the following criteria: Any of the following: 1 Patient with first episode schizophrenia or related psychoses; or 2 Both: 2.1 Patient suffering from schizophrenia and related psychoses; or acute mania in bipolar disorder who is likely to benefit from anti-psychotic treatment; and 2.2 Either: 2.2.1 An effective dose of risperidone had been trialled and has been discontinued because of unacceptable side effects; or 2.2.2 An effective dose of risperidone had been trialled and has been discontinued because of inadequate clinical response after 4 weeks; or 3 The patient has suffered from an acute episode of schizophrenia or bipolar mania and has been treated with olanzapine short-acting intra-muscular injection. Renewal only from a psychiatrist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefit
Additional subsidy by endorsement for:Citalopram tab 20 mg x 28 (Celapram) up to $4.00Citalopram tab 20 mg x 28 (Cipramil) up to $10.00Paroxetine hydrochloride tab 20 mg x 30 (Aropax) up to $35.02is available for patients who: -were taking citalopram on 1 February 2000; or paroxetine hydrochloride on February 2001; or- have previously responded to treatment with citalopram or paroxetinehydrochloride; or- have had a trial of fluoxetine and have had to discontinue due to- inability to tolerate the drug due to side effects; or- failed to respond to an adequate dose and duration of treatment; or- have contraindications to fluoxetine (eg pre-existing significant levels of nausea, breastfeeding, potential drug interactions). The prescription must be endorsed accordingly.
Special Authority for Subsidy - Form SA0751Initial application only from an ophthalmologist. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 Either: 1.1 Monotherapy in primary open-angle glaucoma; or 1.2 Adjunctive use for the treatment of open-angle glaucoma in a patient who has met the initial application criteria, and in whom prostaglandin analogue monotherapy has been ineffective in controlling intraocular pressure; and 2 Any of the following: 2.1 Patient cannot tolerate beta-blockers, pilocarpine, and carbonic anhydrase inhibitors; or 2.2 Beta-blockers, pilocarpine and carbonic anhydrase inhibitors are contraindicated; or 2.3 A reduction in intraocular pressure of 15% or more is not achieved or maintained using carbonic anhydrase inhibitor either alone or in combination with a beta blocker; or 2.4 There is progressive visual field loss and/or optic nerve damage persists after treatment with carbonic anhydrase inhibitor either alo
(a) Subsidy is available between 1 March and 30 June of each year for patients who meet the following criteria, as set by the Ministry of Health: a) all people 65 years of age and over; b) people under 65 years of age with: i) the following cardiovascular disease: 1) ischaemic heart disease, 2) congestive heart disease, 3) rheumatic heart disease, 4) congenital heart disease, or 5) cerebo-vascular disease; ii) the following chronic respiratory disease: 1) asthma, if on a regular preventative therapy, or 2) other chronic respiratory disease with impaired lung function; iii) diabetes; iv) chronic renal disease; v) any cancer, excluding basal and squamous skin cancers if not invasive; vi) the following other conditions: 1) autoimmune disease, 2) immune suppression, 3) HIV, 4) transplant recipients, 5) neuromuscular and CNS diseases, 6) haemoglobinopathies, or 7) children on long term aspirin. The following conditions are excluded from funding: i) asthma not requiri
Special Authority for Subsidy - Form SA0754Initial application only from a named specialist. Approvals valid without further renewal unless notified for applications meeting the following criteria: All of the following: 1 The patient already has a Special Authority approval for anti-retroviral therapy (Details to be attached to application); and 2 Kaletra is to be used as a salvage therapy in place of one protease inhibitor; and 3 The patient must have trialed for at least six months and have failed on currently funded NNRTI based regimens or triple NRTI regimens; and 4 The patient must have trialed for at least six months and have failed on currently funded PI based regimens. NoteFailure is defined as: a) not achieving HIV RNA < 400 copies/ml after 24 weeks of a regimen, orb) an increase of HIV RNA to > 400 copies/ml on two separate occasions not less than one month apart, after suppression to < 400 copies/ml in a patient taking the regimen.
Special Authority for Subsidy - Form SA0758Initial application only from a general practitioner or relevant specialist. Approvals valid for 2 years for applications meeting the following criteria: All of the following: 1 To be used for the long-term maintenance treatment of bronchospasm and dyspnoea associated with COPD; and 2 In addition to standard treatment, the patient has trialled a dose of at least 40 mcg ipratropium q.i.d; and 3 The patient's breathlessness >= grade 4 according to the Medical Research Council dyspnoea scale (see note); and 4 FEV1 (litres) < 0.4 x predicted (litres); and 5 Either: 5.1 Patient is not a smoker (for reporting purposes only); or 5.2 Patient is a smoker and been offered smoking cessation councilling; and 6 The patient has been offered annual influenza immunisation. Renewal only from a general practitioner or relevant specialist. Approvals valid for 2 years for applications meeting the following criteria: All of the following: 1
(a) Subsidy is available between 1 March and 30 June of each year for patients who meet the following criteria, as set by the Ministry of Health: a) all people 65 years of age and over; b) people under 65 years of age with: i) the following cardiovascular disease: 1) ischaemic heart disease, 2) congestive heart disease, 3) rheumatic heart disease, 4) congenital heart disease, or 5) cerebo-vascular disease; ii) the following chronic respiratory disease: 1) asthma, if on a regular preventative therapy, or 2) other chronic respiratory disease with impaired lung function; iii) diabetes; iv) chronic renal disease; v) any cancer, excluding basal and squamous skin cancers if not invasive; vi) the following other conditions: 1) autoimmune disease, 2) immune suppression, 3) HIV, 4) transplant recipients, 5) neuromuscular and CNS diseases, 6) haemoglobinopathies, or 7) children on long term aspirin. The following conditions are excluded from funding: i) asthma not requiri
Special Authority for Subsidy - Form SA0772Initial application only from a gastroenterologist, infectious disease specialist, paediatrician or general physician. Approvals valid for 1 year for applications meeting the following criteria: Both: 1 Any of the following: 1.1 All of the following: 1.1.1 HBsAg positive for more than 6 months; and 1.1.2 HBeAg positive or HBV DNA positive defined as >0.6 pg/ml by quantitative PCR at reference laboratory; and 1.1.3 ALT greater than twice upper limit of normal or stage 3 or 4 fibrosis on liver histology clinical/radiological evidence of cirrhosis; or 1.2 HBV DNA positive cirrhosis prior to liver transplantation; or 1.3 HBsAg positive and have had a liver, kidney, heart, lung or bone marrow transplant; or 1.4 Hepatitis B surface antigen positive (HbsAg) patient who is receiving chemotherapy for a malignancy, or who has received such treatment within the previous two months; and 2 All of the following: 2.1 No continuing
Special Authority for Subsidy - Form SA0774Initial application only from a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Any of the following: 1 The patient has advanced gastrointestinal malignancy; or 2 The patient has metastatic breast cancer*; or 3 Both: 3.1 The patient has poor venous access or needle phobia*; and 3.2 The patient requires a substitute for single agent fluoropyrimidine*. Renewal only from a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Either: 1 The patient requires continued therapy; or 2 The tumour has relapsed and requires re-treatment. Noteindications marked with * are unapproved indications.
Special Authority for Subsidy - Form SA0776Initial application only from a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Any of the following: 1 Both: 1.1 The patient has ovarian, fallopian* or primary peritoneal cancer*; and 1.2 Either: 1.2.1 Has not received prior chemotherapy; or 1.2.2 Has received prior chemotherapy but has not previously been treated with taxanes; or 2 The patient has metastatic breast cancer; or 3 Both: 3.1 The patient has non-small cell lung cancer; and 3.2 Either: 3.2.1 The patient has advanced disease (stage IIIa or above); or 3.2.2 The patient is receiving combined chemotherapy and radiotherapy; or 4 Both: 4.1 The patient has small-cell lung cancer*; and 4.2 Paclitaxel is to be used as second-line therapy. Renewal only from a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Both: 1 The patient has metastati
Special Authority for Subsidy - Form SA0777Initial application - (Post-transplant) only from a relevant specialist. Approvals valid for 6 months where the patient has B-cell post-transplant lymphoproliferative disorder*. NoteFor no more than 8 treatment cycles. Initial application - (Low-grade lymphomas) only from a relevant specialist. Approvals valid for 6 months where the patient has low grade NHL - relapsed disease following prior chemotherapy. NoteFor no more than 4 treatment cycles. Initial application - (Large cell lymphomas) only from a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Both: 1 The patient has treatment naive large B-cell NHL; and 2 To be used with CHOP (or alternative anthracycline containing multi-agent chemotherapy regime given with curative intent).NoteFor no more than 8 treatment cycles. Renewal - (Low-grade lymphomas) only from a relevant specialist. Approvals valid for 6 months for applications meeting
Special Authority for Subsidy - Form SA0779Initial application - (Confirmed HIV/AIDS) only from a named specialist. Approvals valid without further renewal unless notified for applications meeting the following criteria: Both: 1 Confirmed HIV infection; and 2 Any of the following: 2.1 Symptomatic patient; or 2.2 Patient aged 12 months and under; or 2.3 Both: 2.3.1 Patient aged 1 to 5 years; and 2.3.2 Any of the following: 2.3.2.1 CD4 counts < 1,000 cells/mm3; or 2.3.2.2 CD4 counts < 0.25 x total lymphocyte count; or 2.3.2.3 Viral load counts > 100,000 copies per ml; or 2.4 Both: 2.4.1 Patient aged 6 years and over; and 2.4.2 CD4 counts < 350 cells/mm3. NoteTenofovir disoproxil fumarate prescribed under endorsement for HIV/AIDS is included in the count of up to 3 subsidised antiretrovirals. Subsidies for a combination of up to three anti-retroviral medications, including a maximum of two protease inhibitors. Combinations including r
Special Authority for Subsidy - Form SA0780Initial application - (Single NAED Therapy) only from a paediatrician, neurologist or general physician. Approvals valid for 15 months for applications meeting the following criteria: Any of the following: 1 Was on NAED therapy before 1 September 2000; or 2 Seizures are not adequately controlled with optimal older anti-epilepsy drug treatment; or 3 Seizures are controlled adequately but who experience unacceptable side effects from older anti-epilepsy drug treatment. Note"Optimal older anti-epilepsy drug therapy" is defined as treatment with those older anti-epilepsy drugs which are indicated and clinically appropriate for the patient, given singly and in combination in adequate doses for the patient's age, weight, and other features affecting the pharmacokinetics of the drug with good evidence of complianceInitial application - (Dual NAED Therapy) only from a paediatrician, neurologist or general physician. Approvals valid for 18 months for app
Special Authority for Subsidy - Form: SA0781Initial application only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria: Any of the following: Monotherapy1 All of the following: 1.1 To be used as monotherapy for patients with type 2 diabetes who after six months of diet and lifestyle changes do not have adequate glycaemic control (inadequate control defined as HbA1c > 7.0% in tests carried out at least two months apart); and 1.2 Metformin is not tolerated or contraindicated. Intolerance and contraindications as defined in the notes below, a minimum of a four week trial period of metformin is required; and 1.3 Sulphonylurea is not tolerated or contraindicated. Obesity is only eligible under the criteria of contraindication to sulphonylureas if the patient's body mass index (BMI) exceeds 33 , intolerance as defined in the notes below; orIn combination with sulphonylurea2 Both: 2.1 For use in combination with a sulphonylure
Special Authority for Subsidy - Form SA0782Initial application - (No previous use) only from a relevant specialist or general practitioner. Approvals valid for 6 months for applications meeting the following criteria: All of the following: 1 The patient has a clinical diagnosis of heavy menstrual bleeding; and 2 The patient has failed to respond to or is unable to tolerate other appropriate pharmaceutical therapies as per the Heavy Menstrual Bleeding Guidelines; and 3 Either: 3.1 serum ferritin level < 16 mg/l (within the last 12 months); or 3.2 haemoglobin level < 120 g/l . NoteApplications are not to be made for use in patients as contraception except where they meet the above criteriaInitial application - (Previous use before 1 October 2002) only from a relevant specialist or general practitioner. Approvals valid for 6 months for applications meeting the following criteria: All of the following: 1 The patient had a clinical diagnosis of heavy menstrual bleeding; and 2
Special Authority for Manufacturers Price - Form: SA0783Initial application only from a relevant specialist. Approvals valid for 5 years for applications meeting the following criteria: All of the following: 1 Patient is a postmenopausal women; and2 Patient has hormone receptor positive advanced breast cancer; and3 Any of the following: 3.1 The cancer is advanced (Stage IIIb, or metastatic Stage IV); or 3.2 The patient has a very clear history of intolerance to tamoxifen; or 3.3 The use of tamoxifen is contraindicated due to a history of thromboembolic disease. Renewal only from a relevant specialist. Approvals valid without further renewal unless notified where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Manufacturers Price - Form SA0788Initial application only from a relevant specialist or general practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria: Both: 1 Patient has a calculated absolute risk of cardiovascular disease of at least 15% over 5 years; and 2 Either: 2.1 Patient has severe documented intolerance to simvastatin (blood tests are not required); or 2.2 Both: 2.2.1 Patient has been compliant with a dose of simvastatin of 80 mg per day for at least 2 months; and 2.2.2 Either: 2.2.2.1 All of the following: 2.2.2.1.1 Patient has venous CABG; and 2.2.2.1.2 LDL cholesterol test 1 >= 2.0 mmol/litre; and 2.2.2.1.3 LDL cholesterol test 2 >= 2.0 mmol/litre (at least 1 week after test 1); or 2.2.2.2 All of the following: 2.2.2.2.1 Patient does not have venous CABG; and 2.2.2.2.2 LDL cholesterol test 1 >= 2.5 mmol/litre; and 2.2.2.2.
Special Authority for Subsidy - Form SA0789Initial application only from a relevant specialist or vocationally registered general practitioner. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 The patient has "treatment resistant" depression; and 2 Either: 2.1 The patient must have had a trial of two different antidepressants and failed to respond to an adequate dose over an adequate period of time (usually at least four weeks); or 2.2 Both: 2.2.1 The patient is currently a hospital in-patient as a result of an acute depressive episode; and 2.2.2 The patient must have had a trial of one other antidepressant and failed to respond to an adequate dose over an adequate period of time. Renewal from any medical practitioner. Approvals valid for 2 years where patient has a high risk of relapse (prescriber determined).
Prescribing GuidelineBimatoprost, lantanoprost and travoprost are subsidised for use in the treatment of glaucoma as either monotherapy or as an adjunctive agent for patients in whom prostaglandin analogue monotherapy has been ineffective in controlling intraocular pressure.Bimatoprost, lantanoprost and travoprost should not be prescribed for a person in whom less expensive first line agents for the treatment of glaucoma are not contraindicated unless: 1 That person has previously trialled all other such subsidised agents (beta-blockers, pilocarpine, carbonic anhydrase inhibitors); and2 Those trials have indicated that that person does not respond adequately to treatment with those other agents.
Special Authority for Subsidy - Form: SA0792Initial application only from a psychiatrist. Approvals valid for 6 months for applications meeting the following criteria: All of the following: 1 The patient has schizophrenia or other psychotic disorder; and2 Has tried but failed to comply with treatment using oral atypical anti-psychotic agents; and3 Has been admitted to hospital or treated in respite care, or intensive outpatient or home-based treatment for 30 days or more in last 12 months. Renewal only from a psychiatrist. Approvals valid for 12 months for applications meeting the following criteria: Either: 4 Both: 4.1 The patient has had less than 12 months treatment with risperidone microspheres; and 4.2 There is no clinical reason to discontinue treatment; or5 The initiation of risperidone microspheres has been associated with fewer days of intensive intervention than was the case during a corresponding period of time prior to the initiation of risperidone microspheres. NoteRisp
Special Authority for Subsidy - Form: SA0796Initial application only from a relevant specialist. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 Either: 1.1 ezetimibe is to be used in combination with simvastatin; or 1.2 ezetimibe is to be used without a statin; and2 Either: 2.1 All of the following: 2.1.1 Patient has a calculated absolute risk of cardiovascular disease >20% over 5 years; and 2.1.2 Patient cannot tolerate statin therapy at a dose of 40 mg per day; and 2.1.3 Either: 2.1.3.1 All of the following: 2.1.3.1.1 Patient has venous CABG; and 2.1.3.1.2 LDL cholesterol >= 2.0 mmol/litre (see note); and 2.1.3.1.3 LDL cholesterol >= 2.0 mmol/litre (at least 1 week after test 1 - see note); or 2.1.3.2 All of the following: 2.1.3.2.1 Patient does not have venous CABG; and 2.1.3.2.2 LDL cholesterol >= 2.5 mmol/litre (see note); and 2.1.3.2.3 LDL cholest
Special Authority for Subsidy - Form: SA0797Initial application - (Underlying cause - Osteoporosis) only from a relevant specialist or vocationally registered general practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria: Any of the following: 1 History of one significant osteoporotic fracture demonstrated radiologically and documented bone mass density (BMD) >= 2.5 standard deviations below the mean normal value in young adults (i.e. T-Score <= -2.5); or2 History of one significant osteoporotic fracture demonstrated radiologically and the patient is either over 75 years of age or is too frail* to undergo a bone mass density scan; or3 History of two significant osteoporotic fractures demonstrated radiologically; or4 Documented T-Score <= -3.0. Note*The patient may be considered to be frail if it is expected that there is significant risk of further fracture or other negative health outcome if the patient were to undergo a BMD s
Special Authority for Subsidy - Form SA0801Initial application - (Serevent Accuhaler, Foradil, Symbicort Turbuhaler) only from a relevant specialist or general practitioner. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 Both: 1.1 Child under the age of 12 with poorly controlled asthma; and 1.2 Either: 1.2.1 Required at least three months of 400 mcg or more daily inhaled beclomethasone or budesonide; or 1.2.2 Required at least three months of 200 mcg or more of fluticasone; or 2 Both: 2.1 Adult with poorly controlled asthma; and 2.2 Either: 2.2.1 Required at least three months of 1500 mcg or more daily inhaled beclomethasone or budesonide; or 2.2.2 Required at least three months of 750 mcg or more of fluticasone. NotePatients are to be reviewed at least at six months to assess compliance and effectiveness of therapy. Special Authority approvals are interchangeable among all presentations of inhaled long-acting beta
Special Authority for Subsidy - Form SA0802Initial application - (genotype 1, 4, 5 or 6 infection or co-infection with HIV) from any specialist. Approvals valid for 11 months for applications meeting the following criteria: 1. Patient has chronic hepatitis C, genotype 1, 4, 5 or 6 infection; or2. Patient has chronic hepatitis C and is co-infected with HIV. Note: consider stopping treatment if there is absence of a virological response (defined as at least a 2-log reduction in viral load) following 12 weeks of treatment since this is predictive of treatment failure.Initial application - (genotype 2 or 3 infection without co-infection with HIV) from any specialist. Approvals valid for 6 months for applications meeting the following criteria: 3. Patient has chronic hepatitis C, genotype 2 or 3 infection; andEither: 3.1 Patient has bridging fibrosis or cirrhosis (Metavir stage 3 or 4 or equivalent); or 3.2 is unsuitable for liver biopsy due to coagulopathy.
Prescribing Guideline for Inhaled Long-Acting Beta-Adrenoceptor AgonistsThe addition of inhaled long-acting beta-adrenoceptor agonists (LABAs) to inhaled corticosteroids is recommended: - For younger children (aged under 12 years) where asthma is poorly controlled despite using inhaled corticosteroids for at least three months at total daily doses of 200 mcg beclomethasone or budesonide (or 100 mcg fluticasone).- For adults and older children (aged 12 years and over) where asthma is poorly controlled despite using inhaled corticosteroids for at least three months at total daily doses of 400 mcg beclomethasone or budesonide (or 200 mcg fluticasone).Note: Further information on the place of inhaled corticosteroids and inhaled LABAs in the management of asthma can be found in the New Zealand guidelines for asthma in adults (www.nzgg.org.nz) and in the New Zealand guidelines for asthma in children aged 1-15 (www.paediatrics.org.nz).
Access by applicationa) Budget managed by appointed clinicians on the Multiple Sclerosis Treatment Assessments Committee (MSTAC). b) Applications will be considered by MSTAC at its regular meetings and approved subject to eligibility according to the Entry and Stopping criteria (below). c) Applications to be made on the approved forms which are available from the co-ordinator for MSTAC:The Co-ordinator Phone: (04) 460 4990Multiple Sclerosis Treatment Assessments Committee Facsimile: (04) 916 7571PHARMAC, PO Box 10 254 E mail: silvia.valsenti@pharmac.govt.nzWellingtond) Completed application forms must be sent to the co-ordinator for MSTAC and will be considered by MSTAC at the next practicable opportunity. e) Notification of MSTAC's decision will be sent to the patient, the applying clinician and the patient's GP (if specified). f) These agents will not be subsidised if dispensed from a community or hospital pharmacy. Regular supplies will be distributed to all approved patients or their c
Special Authority for Subsidy - Form: SA0809Initial application only from a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Any of the following: 1 Both: 1.1 The patient has ovarian*, fallopian* or primary peritoneal cancer*; and 1.2 Either: 1.2.1 Has not received prior chemotherapy; or 1.2.2 Has received prior chemotherapy but has not previously been treated with taxanes; or2 The patient has metastatic breast cancer; or3 Both: 3.1 The patient has non small-cell lung cancer; and 3.2 Either: 3.2.1 Has advanced disease (stage IIIa or above); or 3.2.2 Is receiving combined chemotherapy and radiotherapy; or4 Both: 4.1 The patient has small-cell lung cancer*; and 4.2 Docetaxel is to be used as second-line therapy. Renewal only from a relevant specialist. Approvals valid for 12 months for applications meeting the followingcriteria: 5. The patient has metastatic breast cancer, non small-cell lung cancer,
Special Authority for Alternate SubsidyInitial application only from a relevant specialist. Approvals valid for 5 years for applications meeting the following criteria: All of the following: 1 Patient is a postmenopausal women; and2 Patient has hormone receptor positive breast cancer; and3 Any of the following: 3.1 The cancer is advanced (Stage IIIb, or metastatic Stage IV); or 3.2 The patient has a very clear history of intolerance to tamoxifen; or 3.3 The use of tamoxifen is contraindicated due to a history of thromboembolic disease. Renewal only from a relevant specialist. Approvals valid without further renewal unless notified where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Alternate SubsidyInitial application only from a relevant specialist. Approvals valid for 5 years for applications meeting the following criteria: All of the following: 1 Patient is a postmenopausal women; and2 Patient has hormone receptor positive breast cancer; and3 Any of the following: 3.1 The cancer is advanced (Stage IIIb, or metastatic Stage IV); or 3.2 The patient has a very clear history of intolerance to tamoxifen; or 3.3 The use of tamoxifen is contraindicated due to a history of thromboembolic disease. Renewal only from a relevant specialist. Approvals valid without further renewal unless notified where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for SubsidyInitial application only from a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria: All of the following1 Patient is an adult who has had severe and active erosive Rheumatoid Arthritis for six months duration or longer; and2 Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and3 Patient has tried and not responded to at least three months of oral or parenteral methotrexate at a dose of at least 20 mg weekly or a maximum tolerated dose; and4 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with at least two of the following (triple therapy): sulphasalazine, prednisone at a dose of at least 7.5 mg per day, azathioprine, intramuscular gold, or hydroxychloroquine sulphate (at maximum tolerated doses); and5 Patient has tried and not responded to at least three months therapy at th
Special Authority for Subsidy Initial application only from a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Any of the following: 1 The patient has non small cell lung carcinoma (stage IIIa, or above); or2 The patient has advanced malignant mesothelioma*; or3 The patient has advanced pancreatic carcinoma; or4 The patient has ovarian, fallopian tube* or primary peritoneal carcinoma*. Renewal only from a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Both: 5 The patient requires continued therapy; or6 The tumour has relapsed and requires re-treatment. Note indications marked with a * are unapproved indications.
Special Authority for Subsidy Initial application - (for new patients) only from a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Both: 1 The patient has refractory, progressive or relapsed multiple myeloma; and2 The patient has received prior chemotherapy. Initial application - (for patients receiving thalidomide prior to 1 January 2006) only from a relevant specialist. Approvals valid without further renewal where the patient was receiving treatment with thalidomide for multiple myeloma on or before 31 December 2005. Renewal only from a relevant specialist. Approvals valid without further renewal where the patient has obtained a response from treatment during the initial approval period. Note: Prescription must be written by registered prescriber in the thalidomide risk management programme operated by the supplier. Maximum dose of 400 mg daily as monotherapy or in a combination therapy regimen.
Special Authority for Subsidy Initial application for patients with type 2 diabetes only from a relevant specialist. Approvals valid for one year for applications meeting the following criteria: Any of the following: Monotherapy1 All of the following: 1.1 To be used as monotherapy for patients who after six months of diet and lifestyle changes have inadequate glycaemic control (defined as HbA1c > 7.0% in tests carried out at least two months apart); and 1.2 Metformin is contraindicated or not tolerated after a minimum of a four week trial period; and 1.3 Sulphonylurea is contraindicated or not tolerated or the patient's body mass index (BMI) exceeds 33 kg/m2; orIn combination with sulphonylurea2 Both: 2.1 For use in combination with a sulphonylurea for patients who after diet and lifestyle changes and a six-month trial of sulphonylurea have poor glycaemic control (defined as HbA1c > 8.0% measured within the last month of the six month period); and 2.2 Metformin is contrain
Perindopril and trandolapril will be funded to the level of the ex-manufacturer price listed in the Schedule for patients who were taking these ACE inhibitors for the treatment of congestive heart failure prior to 1 June 1998. The prescription must be endorsed accordingly. We recommend that the words used to indicate eligibility are "certified condition" or an appropriate description of the patient such as "congestive heart failure", "CHF", "congestive cardiac failure" or "CCF". Definition of Congestive Heart Failure At the request of some prescribers the PTAC Cardiovascular subcommittee has provided a definition of congestive heart failure for the purposes of the funding of the manufacturer's surcharge: "Clinicians should use their clinical judgement. Existing patients would be eligible for the funding of the surcharge if the patient shows signs and symptoms of congestive heart failure, and requires or has in the past required concomitant treatment with a diuretic. The definition could also be considere
Special Authority for Subsidy - Form: SA0826Initial application only from a relevant specialist. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 All of the following: 1.1 Patient has a calculated absolute risk of cardiovascular disease >20% over 5 years; and 1.2 Patient cannot tolerate statin therapy at a dose of >= 40 mg per day; and 1.3 Either: 1.3.1 All of the following: 1.3.1.1 Patient has venous CABG; and 1.3.1.2 LDL cholesterol >= 2.0 mmol/litre (see note); and 1.3.1.3 LDL cholesterol >= 2.0 mmol/litre (at least 1 week after test 1 - see note); or 1.3.2 All of the following: 1.3.2.1 Patient does not have venous CABG; and 1.3.2.2 LDL cholesterol >= 2.5 mmol/litre (see note); and 1.3.2.3 LDL cholesterol >= 2.5 mmol/litre (at least 1 week after test 1 - see note); or2 All of the following: 2.1 Patient has homozygous familial hypercholesterolemia, or heterozygous familial hypercholest
Special Authority for Subsidy - Retail Pharmacy - Form SA0829Initial Application only from gastroenterologist or infectious disease specialist. Approvals valid for 1 year for applications meeting the following criteria: All of the following: 1. Patient has confirmed Hepatitis B infection (HBsAg+); andDocumented resistance to lamivudine, defined as: 2. patient has raised serum ALT (> 1 x ULN); and3. patient has HBV DNA greater than 100,000 copies per mL, or viral load ? 10 fold over nadir; and4. detection of M204I or M204V mutation; and5. Either5.1. Both5.1.1. patient is cirrhotic; and5.1.2. adefovir dipivoxil to be used in combination with lamivudine; or5.2. Both5.2.1. patient is not cirrhotic; and5.2.2. adefovir dipivoxil to be used as monotherapyRenewal only from a gastroenterologist or infectious disease specialist. Approvals valid for 2 years for applications where in the opinion of the treating physician, treatment remains appropriate and patient is benefiting from treatmen
Special Authority for Subsidy - Form: SA0831Application only from a relevant specialist. Approvals valid for 10 months for applications meeting the following criteria: 1. Patient has newly diagnosed glioblastoma multiforme; and2. Temozolomide is to be (or has been) given concomitantly with radiotherapy; and3. Following concomitant treatment temozolomide is to be used for a maximum of six cycles of 5 days treatment, at a maximum dose of 200 mg/m2. Note: Temozolomide is not subsidised for the treatment of relapsed glioblastoma multiforme. Studies of temozolomide show that its benefit is predominantly in those patients with a good performance status (WHO grade 0 or 1 or Karnofsky score >80), and in patients who have had at least a partial resection of the tumour.
Special Authority for Subsidy - Form: SA0832Initial application only from a gastroenterologist, infectious disease specialist, paediatrician or general physician. Approvals valid for 1 year for applications meeting the following criteria: Both: 1 Any of the following: 1.1 All of the following: 1.1.1 HBsAg positive for more than 6 months; and1.1.2 HBeAg positive or HBV DNA positive defined as > 100,000 copies per ml by quantitative PCR at a reference laboratory; and1.1.3 ALT greater than twice upper limit of normal or bridging fibrosis or cirrhosis (Metavir stage 3 or 4 or equivalent) on liver histology or clinical/radiological evidence of cirrhosis; or 1.2 HBV DNA positive cirrhosis prior to liver transplantation; or1.3 HBsAg positive and have had a liver, kidney, heart, lung or bone marrow transplant; or1.4 Hepatitis B surface antigen positive (HbsAg) patient who is receiving chemotherapy for a malignancy, or who has received such treatment within the previous two months;
Special Authority for Subsidy - Form SA0833Initial application only from a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Any of the following: 1 The patient has non small cell lung carcinoma (stage IIIa, or above); or2 The patient has advanced malignant mesothelioma*; or3 The patient has advanced pancreatic carcinoma; or4 The patient has ovarian, fallopian tube* or primary peritoneal carcinoma*; or5 The patient has advanced transitional cell carcinoma of the urothelial tract (locally advanced or metastatic). Renewal only from a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Both: 6 The patient requires continued therapy; or7 The tumour has relapsed and requires re-treatment. Note indications marked with a * are unapproved indications.
Special Authority for Subsidy - Form: SA0834Initial application only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria: Either: 1 Both: 1.1 Patient has type 1 diabetes and has received an intensive regimen (injections at least three times a day) of an intermediate acting insulin in combination with a rapid acting insulin analogue for at least three months; and1.2 Either: 1.2.1 Patient has experienced more than one unexplained severe hypoglycaemic episode in the previous 12 months (severe defined as requiring the assistance of another person); or1.2.2 Patient has experienced unexplained symptomatic nocturnal hypoglycaemia, biochemically documented at <3.0 mmol/L, more than once a month despite optimal management; or2 Patient has documented severe, or continuing, systemic or local allergic reaction to existing insulins. Note this does not include hypoglycaemic episodes. Renewal only from a relevant specialist or general practitioner. Approv
Special Authority for Subsidy - Form SA0835Initial application - (Breast cancer) from any medical practitioner. Approvals valid for 1 year: where the patient is a premenopausal woman with breast cancer. Initial application - (Prostate cancer) only from an oncologist, urologist or endocrinologist. Approvals valid for 1 year for applications meeting the following criteria: Advanced prostatic cancer;. Note Not to be prescribed with an anti-androgen except for a period of three weeks, if necessary, when GnRH analogue therapy is initiated. Initial application - (Endometriosis) only from a gynaecologist. Approvals valid for 3 months for applications meeting the following criteria: Both: 1 Endometriosis; and2 Either: 2.1 6 months treatment with medroxyprogesterone acetate, danazol or dimetriose has proven ineffective; or2.2 The patient has failed to tolerate the treatment with medroxyprogesterone acetate, danazol or dimetriose for 6 months. Note The maximum treatment period for a GnRH analogue is:
Special Authority for Subsidy - Form SA0836Initial application - (Breast cancer) from any medical practitioner. Approvals valid for 1 year where the patient is a premenopausal woman with breast cancer. Initial application - (Prostate cancer) only from an oncologist, urologist or endocrinologist. Approvals valid for 1 year for applications meeting the following criteria: Either: 1 Advanced prostatic cancer; or. 2 Locally advanced prostatic cancer. Note Not to be prescribed with an anti-androgen except for a period of three weeks, if necessary, when GnRH analogue therapy is initiated. Initial application - (Endometriosis) only from a gynaecologist. Approvals valid for 3 months for applications meeting the following criteria: Both: 3 Endometriosis; and4 Either: 4.1 6 months treatment with medroxyprogesterone acetate, danazol or dimetriose has proven ineffective; or4.2 The patient has failed to tolerate the treatment with medroxyprogesterone acetate, danazol or dimetriose for 6 months. Note
Special Authority for Subsidy - Form SA0837Initial application - (Breast cancer) from any medical practitioner. Approvals valid for 1 year where the patient is a premenopausal woman with breast cancer. Initial application - (Prostate cancer) only from an oncologist, urologist or endocrinologist. Approvals valid for 1 year where the patient has: Advanced prostatic cancer;. Note Not to be prescribed with an anti-androgen except for a period of three weeks, if necessary, when GnRH analogue therapy is initiated. Initial application - (Endometriosis) only from a gynaecologist. Approvals valid for 3 months for applications meeting the following criteria: Both: 1 Endometriosis; and2 Either: 2.1 6 months treatment with medroxyprogesterone acetate, danazol or dimetriose has proven ineffective; or2.2 The patient has failed to tolerate the treatment with medroxyprogesterone acetate, danazol or dimetriose for 6 months. Note The maximum treatment period for a GnRH analogue is: - 3 months to assess whet
Special Authority for Subsidy - Form: SA0838Initial Application only from a relevant specialist or General Practitioner. Approvals valid for 2 years forapplications meeting the following criteria: Either: 1 All of the following: 1.1 Patient is a child under the age of 12; and1.2 All of the following: Has, for 3 months or more, been treated with:1.2.1 An inhaled long-acting beta adrenoceptor agonist; and1.2.2 Inhaled corticosteroids at a dose of at least 400 mcg per day beclomethasone or budesonide, or200 mcg per day fluticasone; and1.3 The prescriber considers that the patient would receive additional clinical benefit from switching to acombination product; or2 All of the following: 2 .1 Patient is over the age of 12; and2 .2 All of the following: Has, for 3 months or more, been treated with:2 .2.1 An inhaled long-acting beta adrenoceptor agonist; and2 .2.2 Inhaled corticosteroids at a dose of at least 800 mcg per day beclomethasone or budesonide, or500 mcg per day fluticasone;
Special Authority for Subsidy - Form SA0839Initial application - (Breast cancer) from any medical practitioner. Approvals valid for 1 year where the patient is a premenopausal woman with breast cancer. Initial application - (Prostate cancer) only from an oncologist, urologist or endocrinologist. Approvals valid for 1 year for applications meeting the following criteria: Either: 1 Advanced prostatic cancer; or. 2 Neoadjuvant or adjuvant treatment of locally advanced prostatic cancer. Note Not to be prescribed with an anti-androgen except for a period of three weeks, if necessary, when GnRH analogue therapy is initiated. Initial application - (Endometriosis) only from a gynaecologist. Approvals valid for 3 months for applications meeting the following criteria: Both: 3 Endometriosis; and4 Either: 4.1 6 months treatment with medroxyprogesterone acetate, danazol or dimetriose has proven ineffective; or4.2 The patient has failed to tolerate the treatment with medroxyprogesterone acetate, danazo
Special Authority for Subsidy - form: SA0841Initial application only from a gastroenterologist or general physician. Approvals valid for 6 months for applications meeting the following criteria: Both: 1 Primary biliary cirrhosis confirmed by antimitochondrial antibody titre (AMA) > 1:80, and raised cholestatic liver enzymes with or without raised serum IgM or, if AMA is negative, by liver biopsy; and2 Patient not requiring a liver transplant (bilirubin > 170umol/l; decompensated cirrhosis). NoteLiver biopsy is not usually required for diagnosis but is helpful to stage the diseaseRenewal only from a gastroenterologist or general physician. Approvals valid for 2 years for applications meeting the following criteria: The treatment remains appropriate and the patient is benefiting from treatment. NoteActigall is not an appropriate therapy for patients requiring a liver transplant (bilirubin > 170 micromol/l; decompensated cirrhosis). These patients should be referred to an appropriate transp
Special Authority for Subsidy - Form: SA842Initial application only from a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Any of the following: 1 Both: 1.1 The patient has ovarian, fallopian* or primary peritoneal cancer*; and 1.2 Either: 1.2.1 Has not received prior chemotherapy; or 1.2.2 Has received prior chemotherapy but have not previously been treated with taxanes; or2 The patient has metastatic breast cancer; or3 The patient has node-positive early breast cancer; or4 Both 4.1 The patient has non small-cell lung cancer; and 4.2 Either: 4.2.1 Has advancing disease (stage IIIa or above); or 4.2.2 Is receiving combined chemotherapy and radiotherapy; or5 Both: 5.1 The patient has small-cell lung cancer*; and 5.2 Paclitaxel is to be used as second-line therapy. Renewal only from a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: 6 The patient has metasta
Special Authority for Subsidy - Form SA0028Initial application only from a relevant specialist. Approvals valid for 6 months for applications meeting the following criteria: Either: 1 All of the following: 1.1 Treatment with other lipid modifying medicines has been unsuccessful; and 1.2 6 months of dietary modification has been unsuccessful; and 1.3 Cholesterol level > 7.0 mmol/litre; and 1.4 Either: 1.4.1 Familial hypercholesterolaemia; or 1.4.2 Manifest coronary heart disease, which has been clinically proven, or previously treated by coronary artery surgery; or 2 Cholesterol level > 9.0 mmol/litre:.Renewal only from a general practitioner. Approvals valid for 6 months where the treatment remains appropriate and the patient is benefiting from treatment. NoteFamilial hypercholesterolaemia is defined as being hypercholesterolaemia in the presence of tendon xanthomas or in association with a family history of premature heart disease (before age 55) or consisten
a) All patients with AIDS meeting the definition developed by the Centres for Disease Control in the USA (see Circular Letter to Medical Practitioners HP2/88)b) Patients with AIDS Related Complex (ARC)c) HIV infected patients with CD4 (T4) counts below 500 regardless of symptomatologyd) Prophylactically for persons following severe parenteral exposure from a known HIV positive sourcee) HIV infected persons with associated thrombocytopenia regardless of CD4 (T4) count f) Applications can only be made by appropriate specialists. Prescriptions for those patients approved to use these medicines can be written either by the specialist or general practitioner with an endorsement of the name of the recommending specialist. g) Prescriptions for these can be written for a period of three months' supply. However, medicine must be dispensed on a monthly basis.
Special Authority for Subsidy - Form SA0089Initial application - (Breast or prostatic cancer) only from an oncologist, urologist or endocrinologist. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 Breast cancer in pre menopausal women unwilling or unable to undergo surgical or radiation oophorectomy; or 2 Advanced prostatic cancer when orchidectomy is contraindicated. Initial application - (Endometriosis) only from a gynaecologist. Approvals valid for 6 months for applications meeting the following criteria: Both: 1 Endometriosis; and 2 Either: 2.1 6 months treatment with medroxyprogesterone acetate, danazol or dimetriose has proven ineffective; or 2.2 The patient has failed to tolerate the treatment with medroxyprogesterone acetate, danazol or dimetriose for 6 months. NoteThe maximum treatment period for a GnRH analogue is: 3 months to assess whether surgery is appropriate3 months for infertile patients after surgery6 months for
Special Authority for Subsidy - Form SA0096Initial application - (Organ transplant, Bone marrow transplant or Graft v host disease) only from a relevant specialist. Approvals valid for 2 years for applications meeting the following criteria: Any of the following: 1 Organ transplant; or 2 Bone marrow transplant; or 3 Graft v host disease. Initial application - (Psoriasis) only from a dermatologist. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 Psoriasis; and 2 Other systemic and topical therapy has failed. Initial application - (Severe atopic dermatitis) only from a dermatologist. Approvals valid for 6 months for applications meeting the following criteria: Both: 1 Severe atopic dermatitis; and 2 Not resopnsive to topical therapy, oral antihistamines and other commonly used orthodox therapies. Initial application - (Nephrotic Syndrome) from any medical practitioner. Approvals valid for 2 years for applications meeting the following cri
Special Authority for Subsidy - Form SA0097Initial application - (Chronic hepatitis C) only from a relevant specialist. Approvals valid for 6 months where chronic hepatitis C. Initial application - (Indications other than Chronic hepatitis C) only from a relevant specialist. Approvals valid for 5 years for applications meeting the following criteria: Any of the following: 1 Chronic myelogenous leukaemia; or 2 Hairycell leukaemia; or 3 Cutaneous T cell lymphoma; or 4 Essential thrombocythaemia; or 5 AIDS related Kaposi's sarcoma; or 6 Multiple myeloma; or 7 Chronic active hepatitis B. Renewal - (Chronic hepatitis C) only from a relevant specialist. Approvals valid for 6 months where the treatment remains appropriate and the patient is benefiting from treatment. Renewal - (Indications other than Chronic hepatitis C) only from a relevant specialist. Approvals valid for 5 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0099Initial application only from a relevant specialist. Approvals valid for 5 years for applications meeting the following criteria: Any of the following: 1 Both: 1.1 Acromegaly; and 1.2 Patients who have failed surgery, radiotherapy, bromocriptine and other oral therapies; or 2 Both: 2.1 Either: 2.1.1 Vipomas; or 2.1.2 Glucagonomas; and 2.2 Patients who are seriously ill in order to improve their clinical state prior to definitive surgery; or 3 Both: 3.1 Gastrinoma; and 3.2 Either: 3.2.1 Patient has failed surgery; or 3.2.2 Patient is in metastatic disease after H2 antagonists (or omeprazole) have failed; or 4 Both: 4.1 Insulinomas; and 4.2 Surgery is contraindicated or where surgery has failed; or 5 Pre-operative control of hypoglycaemia; or 6 Maintenance therapy. NoteThe use of octreotide in patients with fistulae, oesophageal varices, miscellaneous diarrhoea and hypotension will
Special Authority for Subsidy - Form SA0100Initial application only from a relevant specialist. Approvals valid for 5 years for applications meeting the following criteria: All of the following: 1 Anaemia of end-stage renal failure (other treatable causes of anaemia being excluded); and 2 Been on haemodialysis or continuous ambulatory peritoneal dialysis (CAPD) for at least three months; and 3 Not under evaluation for, or awaiting, a live donor kidney transplant; and 4 Any of the following: 4.1 Anephric; or 4.2 Dependent on regular blood transfusion (1 unit each 4-8 weeks) to maintain haemoglobin > 60g/L; or 4.3 Cannot be transfused because of severe transfusion reactions; or 4.4 Transfusion induced haemosiderosis (clinical manifestations, serum ferritin >1500 ug/L); or 4.5 Haemoglobin < 70 g/L (mean of at least 4 haemoglobin concentrations over 4 months); or 4.6 Both: 4.6.1 Haemoglobin < 90 g/L; and 4.6.2 Either: 4.6.2.1 Heart failure (low card
Approvals for a CHEM number to waive the premium in the following circumstances: 1. Patients with prosthetic heart valves - as an adjunct to oral anticoagulation for prophylaxis of thromboembolism (2 year approval with renewal, applications only from cardiothoracic surgeons, cardiologists and general physicians). 2. Patients after coronary artery vein bypass graft - as an adjunct to aspirin (1 year approval only, applications only from cardiothoracic surgeons, cardiologists and general physicians). 3. Patients who continue to have transient ischaemic episodes despite aspirin therapy. A course of up to six months in combination with aspirin. Applications only from neurologists, cardiologists, vascular surgeons and general physicians. Six month approval only. Reapplications only if there is demonstrated recurrence of symptoms when dipyridamole therapy is discontinued. Note: these transitional criteria are currently being reviewed.
a) Approvals to fund the manufacturer's surcharge in the following circumstances: - Patients with prosthetic heart valves - as an adjunct to oral anticoagulation for prophylaxis of thromboembolism (2 year approval with renewal, applications only from cardiothoracic surgeons, cardiologists and general physicians). - Patients after coronary artery vein bypass graft - as an adjunct to aspirin or as monotherapy for patients who are aspirin intolerant as defined below (1 year approval only, applications only from cardiothoracic surgeons, cardiologists and general physicians); or- Patients who continue to have transient ischaemic episodes despite aspirin therapy or have transient ischaemic episodes and are aspirin intolerant as defined below (2 year approval with renewal, applications only from neurologists, neurosurgeons, cardiologists, vascular surgeons and general physicians). b) Aspirin intolerant patients are defined as those with aspirin induced asthma, urticaria, or anaphylaxi, or those with significant
The new anticonvulsant drugs are restricted to1. neurologists2. paediatric neurologists3. any other prescriber approved in writing by the relevant RHA budget holding manager. The HFA holds a budget for expenditure on the new anticonvulsant drugs. Unless otherwise specified, ultimate authority for approving prescriptions for subsidy lies with the HFA budget holding manager for the new anticonvulsant drugs. The regional divisions of the HFA will be in contact with hospital pharmacists and approved prescribers with more detail of the approval system. GUIDELINES FOR USE OF THE NEW ANTICONVULSANTS ARE AS FOLLOWS: A. Entry criteriaThe following patients are eligible for trial on the new anticonvulsant drugs (NADs)1. Patients who are under the supervision of an approved prescriber, and whose seizures are not adequately controlled with optimal conventional anticonvulsant drug treatment. 2. Patients, who are under the supervision of an approved prescriber, and whose seizures are only controlled adequatel
Special Authority for Subsidy - Form SA0266Initial application - (Chronic hepatitis C) only from a relevant specialist. Approvals valid for 6 months where chronic hepatitis C. NoteMaximum reimbursable dosage 15 million iu/weekInitial application - (Indications other than chronic hepatitis C) only from a dermatologist, plastic surgeon or radiation oncologist. Approvals valid for 5 years for applications meeting the following criteria: Any of the following: 1 Chronic myelogenous leukaemia; or 2 Hairycell leukaemia; or 3 Cutaneous T cell lymphoma; or 4 Essential thrombocythaemia; or 5 AIDS related Kaposi's sarcoma; or 6 Multiple myeloma; or 7 Chronic active hepatitis B; or 8 Basal cell carcinoma unable to be treated surgically or by radiotherapy. NoteMaximum reimbursable dosage 15 million iu/weekRenewal - (Chronic hepatitis C) only from a relevant specialist. Approvals valid for 6 months where the treatment remains appropriate and the patient is benefiting from trea
Lansoprazole is subsidised for patients who have one or more of the following conditions: 1. Duodenal ulcer proven by endoscopy or barium meal and after failure of: a)two alternative courses of H. pylori eradication therapy (if H. pylori positive); and b)H2 antagonist therapy for 8 weeks; and where a second endoscopy/barium meal has demonstrated non healing duodenal ulcer. 2. Gastric ulcer proven by endoscopy and after failure of: a)two alternative courses of H. pylori eradication therapy (if H. pylori positive); andb)H2 antagonist therapy for 12 weeks; and where a second endoscopy has demonstrated non healing gastric ulcer and excluded malignancy. 3. Gastro-oesophageal reflux disease (GORD) proven by endoscopy: i) Grade 0 GORD (normal endoscopy) after positive 24 hour pH monitoring test and failure of H2 antagonist therapy for one month with multiple daily dosing; orii) Grades 1 and 2 GORD after failure of H2 antagonist therapy for one month with multiple daily dosing; or
a) All patients with AIDS meeting the definition developed by the Centres for Disease Control in the USA (see Circular Letter to Medical Practitioners HP2/88)b) Patients with AIDS Related Complex (ARC)c) HIV infected patients with CD4 (T4) counts below 500 regardless of symptomatologyd) Prophylactically for persons following severe parenteral exposure from a known HIV positive sourcee) HIV infected persons with associated thrombocytopenia regardless of CD4 (T4) count f) For the prevention of maternal foetal transmission of HIVg) Applications can only be made by appropriate specialists. Prescriptions for those patients approved to use these medicines can be written either by the specialist or general practitioner with an endorsement of the name of the recommending specialist. h) Prescriptions for these can be written for a period of three months' supply. However, medicine must be dispensed on a monthly basis.
Special Authority for Subsidy - Form SA0274Initial application only from a relevant specialist. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 All of the following: 1.1 Treatment with other lipid modifying medicines has been unsuccessful; and 1.2 6 months of dietary modification has been unsuccessful; and 1.3 Cholesterol level > 7.0 mmol/litre:; and 1.4 Either: 1.4.1 Familial hypercholesterolaemia; or 1.4.2 Manifest coronary heart disease, which has been clinically proven, or previously treated by coronary artery surgery; or 2 Cholesterol level > 9.0 mmol/litre:.NoteFamilial hypercholesterolaemia is defined as being hypercholesterolaemia in the presence of tendon xanthomas or in association with a family history of premature heart disease (before age 55) or consistent with autosomal dominant inheritance. Simvastatin and Pravastatin may be considered for first line therapy in patients with familial hypercholesterolaemia or
Special Authority for Subsidy - Form SA0275Initial application - (Chronic hepatitis C) only from a relevant specialist. Approvals valid for 6 months where chronic hepatitis C. NoteMaximum reimbursable dosage 15 million iu/weekInitial application - (Indications other than chronic hepatitis C) only from a dermatologist, plastic surgeon or radiation oncologist. Approvals valid for 5 years for applications meeting the following criteria: Any of the following: 1 Chronic myelogenous leukaemia; or 2 Hairycell leukaemia; or 3 Cutaneous T cell lymphoma; or 4 Essential thrombocythaemia; or 5 Multiple myeloma; or 6 Chronic active hepatitis B; or 7 Basal cell carcinoma unable to be treated surgically or by radiotherapy. NoteMaximum reimbursable dosage 15 million iu/weekRenewal - (Chronic hepatitis C) only from a relevant specialist. Approvals valid for 6 months where the treatment remains appropriate and the patient is benefiting from treatment. Renewal - (Indications other tha
Special Authority for Subsidy - Form SA0276Initial application - (Chronic hepatitis C) only from a relevant specialist. Approvals valid for 6 months where chronic hepatitis C. NoteMaximum reimbursable dosage 15 million iu/weekInitial application - (Indications other than chronic hepatitis C) only from a dermatologist, plastic surgeon or radiation oncologist. Approvals valid for 5 years for applications meeting the following criteria: Any of the following: 1 Chronic myelogenous leukaemia; or 2 Hairycell leukaemia; or 3 Multiple myeloma; or 4 Chronic active hepatitis B; or 5 Basal cell carcinoma unable to be treated surgically or by radiotherapy. NoteMaximum reimbursable dosage 15 million iu/weekRenewal - (Chronic hepatitis C) only from a relevant specialist. Approvals valid for 6 months where the treatment remains appropriate and the patient is benefiting from treatment. Renewal - (Indications other than chronic hepatitis C) only from a dermatologist, plastic surgeon or radiat
Omeprazole is subsidised for patients who have one or more of the conditions numbered 1-4: 1. Duodenal ulcer proven by endoscopy or barium meal and after failure of: a)two alternative courses of H. pylori eradication therapy (if H. pylori positive); and b)H2 antagonist therapy for 8 weeks; and where a second endoscopy/barium meal has demonstrated non healing duodenal ulcer. 2. Gastric ulcer proven by endoscopy and after failure of: a)two alternative courses of H. pylori eradication therapy (if H. pylori positive); andb)H2 antagonist therapy for 12 weeks; and where a second endoscopy has demonstrated non healing gastric ulcer and excluded malignancy. 3. Gastro-oesophageal reflux disease (GORD) proven by endoscopy: i) Grade 0 GORD (normal endoscopy) after positive 24 hour pH monitoring test and failure of H2 antagonist therapy for one month with multiple daily dosing; orii) Grades 1 and 2 GORD after failure of H2 antagonist therapy for one month with multipl
Special Authority for Subsidy - Form SA0300Initial application - (Breast or prostatic cancer) only from an oncologist, urologist or endocrinologist. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 Breast cancer in pre menopausal women unwilling or unable to undergo surgical or radiation oophorectomy; or 2 Advanced prostatic cancer when orchidectomy is contraindicated. NoteNot in long term combination with an anti-androgenInitial application - (Endometriosis) only from a gynaecologist. Approvals valid for 6 months for applications meeting the following criteria: Both: 1 Endometriosis ; and 2 Either: 2.1 6 months treatment with medroxyprogesterone acetate, danazol or dimetriose has proven ineffective; or 2.2 The patient has failed to tolerate the treatment with medroxyprogesterone acetate, danazol or dimetriose for 6 months. NoteThe maximum treatment period for a GnRH analogue is: 3 months to assess whether surgery is appropriate3 m
Special Authority for Subsidy - Form SA0311Initial application - (Breast or prostatic cancer) only from an oncologist, urologist or endocrinologist. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 Breast cancer in pre menopausal women unwilling or unable to undergo surgical or radiation oophorectomy; or 2 Advanced prostatic cancer when orchidectomy is contraindicated or where the patient srongly opposes orchidectomy. NoteNot to be prescribed with an anti-androgen except for a period of three weeks, if necessary, when GnRH analogue therapy is intiatedInitial application - (Endometriosis) only from a gynaecologist. Approvals valid for 6 months for applications meeting the following criteria: Both: 1 Endometriosis; and 2 Either: 2.1 6 months treatment with medroxyprogesterone acetate, danazol or dimetriose has proven ineffective; or 2.2 The patient has failed to tolerate the treatment with medroxyprogesterone acetate, danazol or dimetrio
Special Authority for Alternate Subsidy - Form SA0312Initial application only from an obstetrician, gynaecologist, general practitioner or general physician. Approvals valid for 5 years for applications meeting the following criteria: Any of the following: 1 acute or significant liver disease - a declaration must be provided from a gastroenterologist or general physician stating that oral oestrogens are contraindicated due to liver disease (Details to be attached to application); or 2 oestrogen induced hypertension requiring antihypertensive therapy - documented evidence must be provided that raised blood pressure levels or inability to control blood pressure adequately occurred post oral oestrogens (Details to be attached to application); or 3 hypertriglyceridaemia - documented evidence must be provided that triglyceride levels increased to at least 2 x normal triglyceride levels post oral oestrogens (Details to be attached to application). NotePrescriptions with a valid Special Authority (
Special Authority for Subsidy - Form SA0317Initial application only from a renal physician. Approvals valid for 2 years for applications meeting the following criteria: All of the following: General Criteria: 1 Anaemia of end-stage renal failure (other treatable causes of anaemia being excluded); and 2 Been on haemodialysis or continuous ambulatory peritoneal dialysis (CAPD) for at least three months; and 3 Not under evaluation for, or awaiting, a live donor kidney transplant; and 4 Any of the following: Specific Criteria: 4.1 Anephric; or 4.2 Dependent on regular blood transfusion (1 unit each 4-8 weeks) to maintain haemoglobin > 60g/L; or 4.3 Cannot be transfused because of severe transfusion reactions; or 4.4 Transfusion induced haemosiderosis (clinical manifestations, serum ferritin >1500 ug/L); or 4.5 Haemoglobin < 70 g/L (mean of at least 4 haemoglobin concentrations over 4 months); or 4.6 Both: 4.6.1 Haemoglobin < 90 g/L; and 4.6.2 Either:
a) All nucleosides will be subsidised for patients meeting any of the following criteria: - All patients with AIDS meeting the definition developed by the Centers for Disease Control in the USA (see Circular Letter to Medical Practitioners HP2/88); or- Patients with AIDS Related Complex (ARC); or- HIV infected patients with CD4 (T4) counts below 500 regardless of symptomatology. b) Zidovudine will also be subsidised for patients meeting any of the following criteria: - Prophylactically for persons following severe parenteral exposure from a known HIV positive source; or- HIV infected persons with associated thrombocytopenia regardless of CD4 (T4) count; or- For the prevention of maternal foetal transmission of HIV. c) Applications can only be made by appropriate specialists. d) Prescriptions for those patients approved to use these medications can be written by either the specialist or general practitioner with an endorsement of the name of the recommending specialist.
Special Authority for Subsidy - Form SA0328Initial application only from a general physician. Approvals valid for 2 years for applications meeting the following criteria: Any of the following: 1 Both: 1.1 CD4 count < 500 cells/mm3; and 1.2 Viral load > 50,000> copies per ml (or equivalent value on the Chiron test); or 2 All of the following: 2.1 CD4 count < 500 cells/mm3; and 2.2 Viral load > 50,000> copies per ml (or equivalent value on the Chiron test); and 2.3 At least 6 weeks of dual therapy with nucleoside agents; or 3 Both: 3.1 CD4 count < 500 cells/mm3; and 3.2 CD4 counts are declining rapidly (>120 cells over 12 months or >60 - 80 cells over six months). Renewal only from a general physician. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
Guidelines for use of cyclosporin A in rheumatoid arthritisMonitoring: All patients require frequent monitoring for creatinine levels and blood pressure:- fortnightly, in the first three months of therapy and then monthly, if results are stable; - if dose is increased or there is a rise in serum creatinine or blood pressure, then more frequent monitoring is required. Contraindications: Cyclosporin A is contraindicated in patients with the following conditions: - current or past malignancy; - uncontrolled hypertension; - renal dysfunction (abnormal serum creatinine for age and sex); - immunodeficiency and neutropenia; - abnormally low white blood cell count or platelet count; or- liver function tests more than twice the upper limit of normal. Caution in use: - age above 65 years; - controlled hypertension; - use of ant-epileptic medications; - use of NSAIDs; - use of ketoconazole, fluconazole, trimethoprim, erythromycin, verapamil, and diltiazem; - concurrent or previous use of al
Special Authority - Retail pharmacy (Salmeterol, eformoterol fumarate):a) Approvals are interchangeable between all presenations of salmeterol and eformoterol fumarate agents. b) Diagnosis of asthma confirmed. c) Inhaler/device technique checked. d) At least three months of >= 1500 ug daily of beclomethasone inhaled steroid (or equivalent) for adult, or >= 800 ug daily for child. e) Patient monitors PEFR regularly during exacerbations where appropriate. f) Evidence of poor control (at least one of the following): - short acting beta agonist used > 3-4 time daily - nocturnal awakenings >= 2 times per week. g) The first applicaton may be for six months and subsequent applications for two yars. The criteria for reapplication are: - compliant with medication - improved asthma symptom control. h) Appication for Special Authority to be made by general practitioners or appropriate specialist.
Omeprazole and pantoprazole is subsidised for patients who have one or more of the conditions a-d: a) Duodenal ulcer proven by endoscopy or barium meal and after failure of: - two alternative courses of H. pylori eradication therapy (if H. pylori positive); and - H2 antagonist therapy for 8 weeks; and where a second endoscopy/barium meal has demonstrated non healing duodenal ulcer. b) Gastric ulcer proven by endoscopy and after failure of: - two alternative courses of H. pylori eradication therapy (if H. pylori positive); and - H2 antagonist therapy for 12 weeks; and where a second endoscopy has demonstrated non healing gastric ulcer and excluded malignancy. c) Gastro-oesophageal reflux disease (GORD) proven by endoscopy: - Grade 0 GORD (normal endoscopy) after positive 24 hour pH monitoring test and failure of H2 antagonist therapy for four weeks with multiple daily dosing; or - Grades 1 and 2 GORD after failure of H2 antagonist therapy for
Special Authority for Subsidy - Form SA0361Initial application only from a geriatrician, neurologist or general physician. Approvals valid for 2 years for applications meeting the following criteria: All of the following: 1 Disabling orthostatic hypotension not due to drugs; and 2 Patient has tried fludrocortisone (unless contra-indicated) with unsatisfactory results; and 3 Patient has tried non pharmacological treatments such as support hose, increased salt intake, exercise, and elevation of head and trunk at night. NoteTreatment should be started with small doses and titrated upwards as necessary. Hypertesion should be avoided, and the usual target is a standing systolic blood pressure of 90 mm Hg. Renewal only from a geriatrician, neurologist or general physician. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0366Initial application - (North Island patients) from any medical practitioner. Approvals valid for 5 years where the patient is likely to benefit from treatment. NoteFor details of the patient criteria, prescriber criteria, application and reporting forms contact the appointed clinician: Dr Richard FisherFertility Associates131 Remuera RoadAUCKLANDFax: 09 520 0499Appointed clinicians will distribute these agents to prescribers whose applications are approvedInitial application - (South Island patients) from any medical practitioner. Approvals valid for 5 years where the patient is likely to benefit from treatment. NoteFor details of the patient criteria, prescriber criteria, application and reporting forms contact the appointed clinician: Dr Peter BennyChristchurch Women's HospitalPrivate Bag 4711CHRISTCHURCHFax: 03 364 4634Appointed clinicians will distribute these agents to prescribers whose applications are approved
Special Authority for Subsidy - Form SA0382Initial application only from a gastroenterologist, general surgeon or general physician. Approvals valid for 3 years for applications meeting the following criteria: Any of the following: 1 All of the following: 1.1 Duodenal ulcer proven by endoscopy or barium meal; and 1.2 Failure of two alternative courses of H. pylori eradication therapy (if H. pylori positive); and 1.3 Non healing duodenal ulcer proven by second barium meal; and 1.4 H2 antagonist therapy for 8 weeks; or 2 All of the following: 2.1 Gastric ulcer proven by endoscopy; and 2.2 Two alternative courses of H. pylori eradication therapy (if H. pylori positive); and 2.3 Non healing gastric ulcer and excluded malignancy demonstrated by a second endoscopy; and 2.4 H2 antagonist therapy for 12 weeks; or 3 All of the following: 3.1 Grade 0 GORD (normal endoscopy); and 3.2 Positive 24 hour pH monitoring test; and 3.3 Failure of H2 antagonist t
n) Further approvals to fund the manufacturer's surcharge on either pravastatin or simvastatin (if applicable) may be granted to patients who are unable to continue treatment with fluvastatin due to adverse effects. Either general practitioners or specialist may make the application. To obtain a new Special Authority number, the application must include the following information: - the amount of time the patient has been treated with fluvastatin; and- the adverse effects experienced by the patient. o) Further approvals to fund the manufacturer's surcharge on simvastatin may be granted to patients with familial hypercholesterolaemia (FH) or familial combined hypercholesterolaemia (FCH) if a specialist considers that the patient is not achieving sufficient benefit from the fully funded statin(s). Only specialists may make application. To obtain a new Special Authority number, the application must include the following information: - the cholesterol level before and after treatment with the fully funded sta
Special Authority for Subsidy - Form SA0387Initial application - (Breast or prostatic cancer) only from an oncologist, urologist or endocrinologist. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 Breast cancer in pre menopausal women unwilling or unable to undergo surgical or radiation oophorectomy; or 2 Advanced prostatic cancer when orchidectomy is contraindicated or where the patient srongly opposes orchidectomy. NoteNot to be prescribed with an anti-androgen except for a period of three weeks, if necessary, when GnRH analogue therapy is intiatedInitial application - (Endometriosis) only from a gynaecologist. Approvals valid for 6 months for applications meeting the following criteria: Both: 1 Endometriosis; and 2 Either: 2.1 6 months treatment with medroxyprogesterone acetate, danazol or dimetriose has proven ineffective; or 2.2 The patient has failed to tolerate the treatment with medroxyprogesterone acetate, danazol or dimetrio
Special Authority for Manufacturers Price - Form SA0394Initial application - (Helicobacter pylori infections) only from a general practitioner or relevant specialist. Approvals valid for 6 months for applications meeting the following criteria: Both: 1 Eradication of Helicobacter pylori in patient with proven infection; and 2 Peptic ulcer disease proven by endoscopy. NoteMaximum of two prescriptions (two courses) per patient. Initial application - (Mycobacterial infections) only from a respiratory specialist or infectious disease specialist. Approvals valid for 2 years for applications meeting the following criteria: Any of the following: 1 Mycobacterium Avium Intracellulare Complex infections in patient with AIDS; or 2 Atypical and drug-resistant mycobacterial infection; or 3 All of the following: 3.1 Prophylaxis against disseminated Mycobacterium Avium Intracellulare Complex infection; and 3.2 HIV infection; and 3.3 CD4 count <= 50 cells/mm3. Renewal - (Mycobacteri
a) Cyproterone acetate with ethinyloestradiol is available from retail pharmacy to patients as indicated. b) Prescribers may code prescriptions "contraceptive" (code "O") when used as indicated for contraception. The period of supply and prescription charge will be as per other contraceptives, as follows: - $3.00 prescription charge (patient co-payment) will apply; - Prescription may be written for up to 6 months supply; and- Pharmacists may dispense up to 3 month supply. c) Prescriptions coded in any other way are subject to the non-contraceptive prescription charges, and the non-contraceptive period of supply. Eg. Prescriptons may be written for up to 3 months supply, and dispensed monthly. d) The Special Authority number for hormonal contraceptive agents (combined and progesterone-only) does not apply, and is not interchangeable. e) Health Benefits Limited will return any claims unpaid as follows: - any uncoded prescription; - any prescription that does not have a period of supply or the quantity
Special Authority for Subsidy - Form SA0401Initial application - (Basal cell carcinoma) only from a dermatologist, plastic surgeon or radiation oncologist. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 Basal cell carcinoma unable to be treated surgically or by radiotherapy; and 2 Unsuitability for surgery confirmed by a Plastic Surgeon or Oncologist. NoteMaximum reimbursable dosage 15 million iu/weekInitial application - (Chronic hepatitis C) only from a relevant specialist. Approvals valid for 12 months where chronic hepatitis C. Initial application - (Indications other than Basal cell carcinoma and Chronic hepatitis C) only from a relevant specialist, plastic surgeon or radiation oncologist. Approvals valid for 2 years for applications meeting the following criteria: Any of the following: 1 Chronic myelogenous leukaemia; or 2 Hairy cell leukaemia; or 3 Cutaneous T cell lymphoma; or 4 Essential thrombocythaemia; or 5 Multiple myelo
Special Authority for Subsidy - Form SA0402Initial application - (Patients aged 74 and under) only from a general practitioner. Approvals valid for 2 years for applications meeting the following criteria: All of the following: 1 Patients aged 74 and under; and 2 The patient has been offered 3-6 months of counselling and an opportunity to modify lifestyle; and 3 Any of the following: 3.1 Both: 3.1.1 NHF A1:1 - Clinically proven ischaemic heart disease; and 3.1.2 total cholesterol > 6.0; or 3.2 Both: 3.2.1 NHF A1:2 - Post coronary artery bypass graft (CABG); and 3.2.2 total cholesterol > 5.5; or 3.3 Both: 3.3.1 NHF B:Patients with > 20% 5-year cardiovascular disease risk; and 3.3.2 total cholesterol > 9.0; or 3.4 Both: 3.4.1 NHF C:15-20% 5-year cardiovascular disease risk; and 3.4.2 total cholesterol > 9.0; or 3.5 Both: 3.5.1 NHF D:10-15% 5-year cardiovascular disease risk; and 3.5.2 total cholesterol > 9.0; or 3.6
Funding of manufacturers surcharge for existing patients taking ACE inhibitors for Congestive Heart Failure.a) Patients taking any ACE inhibitor for the treatment of congestive heart failure prior to 1 June 1998 can continue to have their ACE inhibitor treatment fully subsidised; b) Prescribers must endorse the prescription 'Congestive Heart Failure'. The endorsement can be typed (this includes computer generated prescriptions) or handwritten; c) The endorsement must be initialled in the prescriber's own handwriting. Definition of Congestive Heart FailureAt the request of some prescribers the PTAC Cardiovascular subcommittee has provided a definition of congestive heart failure for the purposes of the funding of the manufacturer's surcharge: "Clinicians should use their clinical judgement. Existing patients would be eligible for the funding of the surcharge if the patient shows signs and symptoms of congestive heart failure, and requires or has in the past required concomitant treatment with a
Special Authority for Subsidy - Form SA0423Initial application only from a gastroenterologist, general surgeon or general physician. Approvals valid for 3 years for applications meeting the following criteria: Any of the following: 1 All of the following: Duodenal Ulcer: 1.1 Duodenal ulcer proven by endoscopy or barium meal; and 1.2 Non healing duodenal ulcer proven by second barium meal; and 1.3 After failure of two alternative courses of H. pylori eradication therapy (if H. pylori positive); and 1.4 After H2 antagonist therapy for 8 weeks; or 2 All of the following: Gastric Ulcer: 2.1 Gastric ulcer proven by endoscopy; and 2.2 Non healing gastric ulcer and excluded malignancy demonstrated by a second endoscopy; and 2.3 After two alternative courses of H. pylori eradication therapy (if H. pylori positive); and 2.4 After H2 antagonist therapy for 12 weeks; or 3 All of the following: GORD: 3.1 Grade 0 GORD (normal endoscopy); and 3.2 Positive 24
Special Authority for Subsidy - Form SA0424Initial application - (Confirmed HIV/AIDS) only from a general physician. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 Confirmed HIV/AIDS; and 2 Any of the following: 2.1 Symptomatic patients aged 6 years and over with HIV/AIDS; or 2.2 Both: 2.2.1 Asymptomatic patients aged 6 years and over; and 2.2.2 CD4 counts < 500 cells/mm3; or 2.3 Both: 2.3.1 Asymptomatic patients aged 6 years and over; and 2.3.2 Viral load counts > 10,000 copies per ml; or 2.4 Symptomatic patients aged under 6 with HIV/AIDS ; or 2.5 Asymptomatic patients aged 12 months and under; or 2.6 Both: 2.6.1 Asymptomatic patients aged 1 to 5 years; and 2.6.2 CD4 counts < 1,000 cells/mm3; or 2.7 Both: 2.7.1 Asymptomatic patients aged 1 to 5 years; and 2.7.2 CD4 counts < 0.25 x total white cell count; or 2.8 Both: 2.8.1 Asymptomatic patients aged under 6 years; and
Special Authority for Subsidy - Form SA0430Initial application - (National Heart Foundation risk groups A1:1, A1:2, B, C, D or E) only from a relevant specialist or general practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria: Both: 1 The patient has been offered 3-6 months of counselling and an opportunity to modify lifestyle; and 2 Any of the following: 2.1 Both: 2.1.1 NHF A1:1 - Clinically proven ischaemic heart disease; and 2.1.2 total cholesterol * > 5.5; or 2.2 Both: 2.2.1 NHF A1:2 - Post coronary artery bypass graft (CABG) or angioplasty; and 2.2.2 total cholesterol * > 4.5; or 2.3 Post heart transplant (regardless of cholesterol level); or 2.4 Both: 2.4.1 NHF B:Patients with > 20% 5-year cardiovascular disease risk; and 2.4.2 total cholesterol * > 9.0; or 2.5 Both: 2.5.1 NHF C:15-20% 5-year cardiovascular disease risk; and 2.5.2 total cholesterol * > 9
Special Authority for Manufacturers Price - Form SA0436Initial application - (Patient with prosthetic heart valves) only from a cardiothoracic surgeon, cardiologist or general physician. Approvals valid for 2 years where patient with prosthetic heart valves - as an adjunct to oral anticoagulation for prophylaxis of thromboembolism. Initial application - (Following coronary artery vein bypass graft) only from a cardiothoracic surgeon, cardiologist or general physician. Approvals valid for 1 year where patients after coronary artery vein bypass graft - as an adjunct to aspirin or as monotherapy for patients who are aspirin intolerant as defined below. Initial application - (Transient ischaemic episodes) only from a neurologist, neuro surgeon, cardiologist, vascular surgeon or general physician. Approvals valid for 2 years where patients who continue to have transient ischaemic episodes despite aspirin therapy or have transient ischaemic episodes and are aspirin intolerant as defined below. Renewal - (Fo
Special Authority for Subsidy - Form SA0443Initial application - (Helicobacter pylori infections) only from a general practitioner or relevant specialist. Approvals valid for 6 months for applications meeting the following criteria: Both: 1 Eradication of Helicobacter pylori in patient with proven infection; and 2 Peptic ulcer disease proven by endoscopy. NoteMaximum of two prescriptions (two courses) per patient. Initial application - (Mycobacterial infections) only from a respiratory specialist or infectious disease specialist. Approvals valid for 2 years for applications meeting the following criteria: Any of the following: 1 Mycobacterium Avium Intracellulare Complex infections in patient with AIDS; or 2 Atypical and drug-resistant mycobacterial infection; or 3 All of the following: 3.1 Prophylaxis against disseminated Mycobacterium Avium Intracellulare Complex infection; and 3.2 HIV infection; and 3.3 CD4 count <= 50 cells/mm3. Renewal - (Mycobacterial infection
Special Authority for Subsidy - Form SA0445Initial application only from a relevant specialist. Approvals valid for 5 years for applications meeting the following criteria: Any of the following: 1 Both: 1.1 Acromegaly; and 1.2 Patient has failed surgery, radiotherapy, bromocriptine or other oral therapies; or 2 VIPomas and Glucagonomas - for patients who are seriously ill in order to improve their clinical state prior to definitive surgery.; or 3 Both: 3.1 Gastrinoma; and 3.2 Patient has failed surgery, or metastatic disease after H2 antagoists (or proton pump inhibitors) have failed; or 4 Both: 4.1 Insulinomas; and 4.2 Surgery is contraindicated or has failed; or 5 For pre-operative control of hypoglycaemia and for maintenance therapy; or 6 Both: 6.1 Carcinoidsyndrome (diagnosed by tissue pathology and/or urinary 5HIAA analysis); and 6.2 Disabling symptoms not controlled by maximal medical therapy. NoteThe use of octretide in patients with fis
Special Authority for Subsidy - Form SA0450Initial application only from a psychiatrist. Approvals valid for 12 months for applications meeting the following criteria: Both: 1 Patients suffering from schizophrenia and related psychoses; and 2 Either: 2.1 Failed to respond to full trials (duration of at least 6 weeks each) of effective doses of at least two classes of anti-psychotic agents (refer to guidelines below); or 2.2 Demonstrated intolerance to other neuroleptic agents. NoteClinicians must confirm that informed consent and a satisfactory White Bloodcell Count (WBC) result has been obtained. Diagnosis: Treatment resistant schizophrenia and related psychoses when positive symptoms (delusions, hallucinations and thought disorder) are prominent and/or disabling or when both positive symptoms and negative symptoms (flattened affect, emotional and social withdrawal and poverty of speech) are present. Treatment: Trial therapy undertaken before initiating treatment with clozapine could
Special Authority for Subsidy - Form SA0458Initial application only from a gastroenterologist. Approvals valid for 6 months for applications meeting the following criteria: Both: 1 Primary biliary cirrhosis confirmed by antimitochondrial antibody titre (AMA) > 1:80, and raised cholestatic liver enzymes with or without raised serum IgM or, if AMA is negative, by liver biopsy; and 2 Patient not requiring a liver transplant (bilirubin > 170umol/l; decompensated cirrhosis). NoteLiver biopsy is not usually required for diagnosis but is helpful to stage the diseaseRenewal only from a gastroenterologist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment. NoteActigall is not an appropriate therapy for patients requiring a liver transplant (bilirubin > 170 micromol/l; decompensated cirrhosis). These patients should be referred to an appropriate transplant centreTreatment failure - doubling of serum bilirubin levels, absence of a signi
Special Authority for Manufacturers Price - Form SA0460Initial application - (Patient with prosthetic heart valves) only from a cardiothoracic surgeon, cardiologist or general physician. Approvals valid for 2 years where patient with prosthetic heart valves - as an adjunct to oral anticoagulation for prophylaxis of thromboembolism. Initial application - (Following coronary artery vein bypass graft) only from a cardiothoracic surgeon, cardiologist or general physician. Approvals valid for 1 year where patients after coronary artery vein bypass graft - as an adjunct to aspirin or as monotherapy for patients who are aspirin intolerant as defined below. Initial application - (Transient ischaemic episodes) only from a neurologist, neuro surgeon, cardiologist, vascular surgeon or general physician. Approvals valid for 2 years where patients who continue to have transient ischaemic episodes despite aspirin therapy or have transient ischaemic episodes and are aspirin intolerant as defined below. Renewal - (Fo
Special Authority for Subsidy - Form SA0461Initial application - (Basal cell carcinoma) only from a dermatologist, plastic surgeon or radiation oncologist. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 Basal cell carcinoma unable to be treated surgically or by radiotherapy; and 2 Unsuitablity for surgery confirmed by a Plastic Surgeon or Radiation Oncologist. NoteThe maximum reimbursable dosage is 15 million iu per weekInitial application - (Chronic hepatitis C) only from a relevant specialist. Approvals valid for 12 months where chronic hepatitis C. Initial application - (Indications other than Basal cell carcinoma and Chronic hepatitis C) only from a relevant specialist. Approvals valid for 2 years for applications meeting the following criteria: Any of the following: 1 Chronic myelogenous leukaemia; or 2 Hairy cell leukaemia; or 3 Multiple myeloma; or 4 Chronic active hepatitis B. Renewal - (Basal cell carcinoma) only from a dermato
Special Authority for Subsidy - Form SA0464Initial application only from a diabetologist, general physician or paediatrician. Approvals valid without further renewal unless notified for applications meeting the following criteria: Any of the following: 1 Both: 1.1 Use alone (monotherapy); and 1.2 The patient is unable to use any other insulins including those on insulin pump treatment; or 2 Both: 2.1 Use with Humulin 70/30 or Humulin 80/20; and 2.2 A reasonable trial of Humulin N has been undertaken and it is not effective or not well tolerated; or 3 Both: 3.1 Use with insulins (aside from insulin zinc suspension) other than Humulin 70/30, Humulin 80/20, or Humulin N; and 3.2 A reasonable trial of one or more of these Humulin insulins has been undertaken and it is/are ineffective or not well tolerated; or 4 Both: 4.1 Use with Humulin L or Humulin U; and 4.2 Use with Humulin N is not appropriate; or 5 Both: 5.1 Use with other insulin zinc suspensio
Special Authority for Subsidy - Form SA0470Initial application - (Organ transplant) only from a relevant specialist. Approvals valid without further renewal unless notified where organ transplant. Initial application - (Bone marrow transplant or Graft v host disease) only from a relevant specialist. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 Bone marrow transplant; or 2 Graft v host disease. Initial application - (Psoriasis) only from a dermatologist. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 Psoriasis; and 2 Applicant must state which systemic and topical therapies have failed. Initial application - (Severe atopic dermatitis) only from a dermatologist. Approvals valid for 6 months for applications meeting the following criteria: Both: 1 Severe atopic dermatitis; and 2 Not responsive to topical therapy, oral antihistamines and other commonly used orthodox therapies. Initial application - (N
Special Authority for Subsidy - Form SA0471Initial application - (Breast cancer) from any medical practitioner. Approvals valid for 1 year where breast cancer in pre menopausal women unwilling or unable to undergo surgical or radiation oophorectomy. Initial application - (Prostate cancer) only from an oncologist, urologist or endocrinologist. Approvals valid for 1 year where advanced prostatic cancer when orchidectomy is contraindicated or where the patient strongly opposes orchidectomy. NoteNot to be prescribed with an anti-androgen except for a period of three weeks, if necessary, when GnRH analogue therapy is intiatedInitial application - (Endometriosis) only from a gynaecologist. Approvals valid for 3 months for applications meeting the following criteria: Both: 1 Endometriosis ; and 2 Either: 2.1 6 months treatment with medroxyprogesterone acetate, danazol or dimetriose has proven ineffective; or 2.2 The patient has failed to tolerate the treatment with medroxyprogesterone
Special Authority for Manufacturers Price - Form SA0489Initial application - (Conditions other than transient ischaemic episodes) only from a cardiothoracic surgeon, cardiologist or general physician. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 Patients with prosthetic heart valves - as an adjunct to oral anticoagulation for prophylaxis of thromboembolism; or 2 Both: 2.1 Patients after coronary artery vein bypass graft; and 2.2 Any of the following: 2.2.1 aspirin induced asthma; or 2.2.2 aspirin induced anaphylaxi; or 2.2.3 significant aspirin induced bleeding excluding bruising. Initial application - (Transient ischaemic episodes) only from a neurologist, neuro surgeon, cardiologist, vascular surgeon or general physician. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 Patients who continue to have transient ischaemic episodes despite aspirin therapy; or 2 Both: 2.1 Patients wh
Special Authority for Subsidy - Form SA0494Initial application only from an ophthalmologist. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 Both: 1.1 Primary open-angle glaucoma; and 1.2 Any of the following: 1.2.1 Patient cannot tolerate Beta-blockers, or Beta-blockers are contraindicated; or 1.2.2 Patient cannot tolerate Pilocarpine, or Pilocarpine is contraindicated; or 1.2.3 Patient cannot tolerate Dorzolamide, or Dorzolamide is contraindicated; or 1.2.4 A reduction in intraocular pressure of 15% or more is not achieved or maintained using dorzolamide either alone or in combination with a beta-blocker; or 2 There is progressive visual field loss and/or optic nerve damage persists after treatment with dorzolamide either alone or in combination with a beta-blocker. NoteSubsidised as monotherapy onlyRenewal only from an ophthalmologist. Approvals valid for 2 years where the treatment remains appropriate and the patient
Special Authority for Alternate Subsidy - Form SA0500Initial application from any medical practitioner. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 Either: 1.1 Patient is on a Social Welfare benefit; or 1.2 Patient has an income no greater than the benefit; and 2 Has tried at least one of the fully funded options and has been unable to tolerate it. Renewal from any medical practitioner. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 Patient is on a Social Welfare benefit; or 2 Patient has an income no greater than the benefit. NoteThe approval numbers of Special Authorities approved after 1 November 1999 are interchangeable between Mercilon and Marvelon. The additional subsidy will fund Mercilon and Marvelon up to the manufacturer's price for each of these products as identified on the Schedule at 1 November 1999Special Authorities approved before 1 November 1999 remain valid until the expiry d
Special Authority for Subsidy - Form SA0509Initial application only from a psychiatrist. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 Patient with first episode schizophrenia or related psychoses; or 2 Both: 2.1 Patient suffering from schizophrenia and related psychoses who is likely to benefit from anti-psychotic treatment; and 2.2 Both: 2.2.1 An effective dose of risperidone had been trialled and has been discontinued either because of; and 2.2.2 Any of the following: 2.2.2.1 Patient has recurrent acute dystonias; or 2.2.2.2 Patient has excessive Parkinson-like symptoms; or 2.2.2.3 Patient has hyperprolactinaemia; or 2.2.2.4 Patient has inadequate clinical response after four weeks. NoteDiscontinued treatment should be notified to HealthPAC if possibleRenewal only from a psychiatrist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0511Initial application only from a geriatrician, rheumatologist, endocrinologist, gynaecologist or general physician. Approvals valid for 2 years for applications meeting the following criteria: All of the following: 1 Severe osteoporosis; and 2 History of two previous significant osteoporotic fractures demonstrated radiologically; and 3 T-Score <= -3.0 (bone mass density (BMD) >= 3.0 standard deviations below the mean normal value in young adults). NoteIn line with the Australian guidelines for funding alendronate, a vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral bodyRenewal only from a geriatrician, rheumatologist, endocrinologist, gynaecologist or general physician. Approvals valid for 2 years where the tr
Special Authority for Subsidy - Form SA0512Initial application only from a gastroenterologist, general surgeon or general physician. Approvals valid for 3 months for applications meeting the following criteria: Both: 1 Mild to moderate ileal, ileocaecal or proximal Crohn's disease; and 2 Either: 2.1 Diabetes; or 2.2 Both: 2.2.1 Treatment with conventional corticosteroid therapy; and 2.2.2 Any of the following: 2.2.2.1 Cushingoid habitus; or 2.2.2.2 Osteoporosis where there is significant risk of fracture; or 2.2.2.3 Severe acne. Renewal only from a gastroenterologist, general surgeon or general physician. Approvals valid for 3 months where the patient has had no more than 1 prior approval in the last 12 months. The patient must have had no more than 1 prior approval in the last year. NoteClinical trials for Entocort CIR use beyond three months demonstrated no improvement in relapse rate
Special Authority for Subsidy - Form SA0513Initial application - (Narcolepsy) only from a neurologist. Approvals valid for 24 months where narcolepsy. Initial application - (ADHD in patients aged 5 years or over) only from a paediatrician or psychiatrist. Approvals valid for 24 months for applications meeting the following criteria: Both: 1 ADHD (Attention Deficient and Hyperactivity Disorder) patients aged 5 years or over; and 2 Diagnosed according to DSM-IV or ICD 10 criteria. Initial application - (ADHD in patients under 5 years of age) only from a paediatrician or psychiatrist. Approvals valid for 12 months for applications meeting the following criteria: Both: 1 ADHD (Attention Deficient and Hyperactivity Disorder) patients under 5 years of age; and 2 Diagnosed according to DSM-IV or ICD 10 criteria. Renewal - (Narcolepsy or ADHD in patients under 5 years of age) only from a neurologist, paediatrician or psychiatrist. Approvals valid for 24 months where the treatment remains appr
Special Authority for Subsidy - Form SA0523Initial application only from a relevant specialist or general practitioner. Approvals valid for 6 months for applications meeting the following criteria: All of the following: 1 Diagnosis of asthma confirmed; and 2 Inhaler/device technique checked; and 3 Patient monitors PEFR regularly during exacerbations where appropriate; and 4 Any of the following: 4.1 At least three months of 1500 ug or more daily of inhaled beclomethasone or budesonide for adult; or 4.2 At least three months of 750 ug or more daily of inhaled fluticasone) for adult; or 4.3 At least three months of 800 ug or more daily inhaled beclomethasone or budesonide for child; or 4.4 At least three months of 400 ug or more daily inhaled fluticasone) for child; and 5 Either: 5.1 Short acting beta agonist used at least 3-4 times daily; or 5.2 Nocturnal awakenings at least twice a week. Renewal only from a relevant specialist or general practitioner. Appro
Special Authority for Subsidy - Form SA0528Initial application - (Narcolepsy) only from a neurologist or respiratory specialist. Approvals valid for 24 months where narcolepsy. Initial application - (ADHD in patients 5 or over) only from a paediatrician, psychiatrist or general practitioner. Approvals valid for 24 months for applications meeting the following criteria: All of the following: 1 ADHD (Attention Deficient and Hyperactivity Disorder) patients aged 5 years or over; and 2 Diagnosed according to DSM-IV or ICD 10 criteria; and 3 Applicant is a specialist or specialist has recommended treatment. Initial application - (ADHD in patients under 5) only from a paediatrician or psychiatrist. Approvals valid for 12 months for applications meeting the following criteria: Both: 1 ADHD (Attention Deficient and Hyperactivity Disorder) patients under 5 years of age; and 2 Diagnosed according to DSM-IV or ICD 10 criteria. Renewal - (Narcolepsy) only from a neurologist or respiratory spec
ACE inhibitors will be funded to the level of the ex-manufacturer price listed in the Schedule for patients who were taking an ACE inhibitor for the treatment of congestive heart failure prior to 1 June 1998. The prescription must be endorsed accordingly. We recommend that the words used to indicate eligibility are "certified condition" or an appropriate description of the patient such as "congestive heart failure", "CHF", "congestive cardiac failure" or "CCF". Additional subsidy for lisinopril is available only up to the price of the least expensive brand listed in the Schedule. Definition of Congestive Heart FailureAt the request of some prescribers the PTAC Cardiovascular subcommittee has provided adefinition of congestive heart failure for the purposes of the funding of the manufacturer'ssurcharge: "Clinicians should use their clinical judgement. Existing patients would be eligible for thefunding of the surcharge if the patient shows signs and symptoms of congestive heart failure, and requir
Additional subsidy by endorsement for:Moclobemide tab 150 mg x 100 (Aurorix) up to $47.00Moclobemide tab 300 mg x 60 (Aurorix) up to $56.40Nefazadone tab 100 mg x 56 (Serzone) up to $20.16Nefazadone tab 200 mg x 56 (Serzone) up to $40.32Citalopram tab 20 mg x 28 (Cipramil) up to $27.00is available for patients who: * are taking moclobemide or nefazodone on 1 December 1999 or citalopram on 1 February2000; * have previously responded to treatment with moclobemide or nefazodone or citalopram; * have had a trial of fluoxetine and have to discontinue due to: - inability to tolerate the drug due to side effects OR - failed to respond to an adequate dose and duration of treatment; * have contraindications to fluoxetine (eg pre-existing significant levels of nausea, breastfeeding, potential drug interactions); The prescription must be endorsed accordingly. We recommend that the words used to indicate eligibility are "certified condition" however these particular words are not a requirement.
Special Authority for Subsidy - Form SA0538Initial application only from a gastroenterologist, infectious disease specialist, paediatrician or general physician. Approvals valid for 1 year for applications meeting the following criteria: Both: 1 Any of the following: 1.1 All of the following: 1.1.1 HBsAg positive for more than 6 months; and 1.1.2 HBeAg positive or HBV DNA positive defined as >0.6 pg/ml by quantitative PCR at reference laboratory; and 1.1.3 ALT greater than twice upper limit of normal or stage 3 or 4 fibrosis on liver histology clinical/radiological evidence of cirrhosis; or 1.2 HBV DNA positive cirrhosis prior to liver transplantation; or 1.3 HBsAg positive and have had a liver, kidney, heart, lung or bone marrow transplant; and 2 All of the following: 2.1 No continuing alcohol abuse or intravenous drug use; and 2.2 Not coinfected with HCV, HDV, or HIV; and 2.3 Neither ALT nor AST greater than 10 times upper limit of normal; and 2.4
Special Authority for Subsidy - Form SA0539Initial application from any medical practitioner. Approvals valid for 5 years where the patient is likely to benefit from treatment. NoteApplications to be made on the approved forms which are available from: The Co-ordinatorPhone: 09 580 9176Multiple Sclerosis Treatment CommitteeFacsimile: 09 580 9205Level 3, Unisys HouseEmail: murray@ppc.govt.nz650 Great South Road, PenrosePrivate Bag, AUCKLANDBudget managed by appointed clinicians on the Multiple Sclerosis Treatment Assessments Committee (MSTAC). Applications will be considered by MSTAC at its regular meetings and approved subject to eligibility according to the Entry and Stopping criteria (below). Completed application forms must be sent to the co-ordinator for MSTAC and will be considered by MSTAC at the next practicable opportunity. Notification of MSTAC's decision will be sent to the patient, the applying clinician and the patient's GP (if specified). These agents will N
Additional subsidy by endorsement for:Moclobemide tab 150 mg x 100 (Aurorix) up to $47.00Moclobemide tab 300 mg x 60 (Aurorix) up to $56.40Nefazadone tab 100 mg x 56 (Serzone) up to $20.16Nefazadone tab 200 mg x 56 (Serzone) up to $40.32Citalopram tab 20 mg x 28 (Cipramil) up to $27.00is available for patients who: * were taking moclobemide or nefazodone on 1 December 1999 or citalopram on 1 February 2000; or* have previously responded to treatment with moclobemide, nefazodone or citalopram; or* have had a trial of fluoxetine and have to discontinue due to: - inability to tolerate the drug due to side effects; or - failed to respond to an adequate dose and duration of treatment; or* have contraindications to fluoxetine (eg pre-existing significant levels of nausea, breastfeeding, potential drug interactions); The prescription must be endorsed accordingly. We recommend that the words used to indicate eligibility are "certified condition" however these words are not a requirement.
Special Authority for Subsidy - Form SA0551Initial application only from a paediatrician, neurologist or general physician. Approvals valid for 15 months for applications meeting the following criteria: Any of the following: 1 Was on NAED therapy before 1 September 2000; or 2 Seizures are not adequately controlled with optimal older anti-epilepsy drug treatment; or 3 Seizures are controlled adequately but who experience unacceptable side effects from older anti-epilepsy drug treatment. NoteApproval entitles patients to a subsidy for one NAED. Dual NAED therapy will be subsidised for patients who were already stabilised on two NAEDs on or before 31 July 2000 or, for whom a second NAED has been added to therapy with one NAED provided an attempt to withdraw one NAED has been made and was unsuccessful. "Optimal older anti-epilepsy drug therapy" is defined as treatment with those older anti-epilepsy drugs which are indicated and clinically appropriate for the patient, given singly and in combin
Special Authority for Subsidy - Form SA0556Initial application - (Confirmed HIV/AIDS) only from a named general physician. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 Confirmed HIV/AIDS; and 2 Any of the following: 2.1 Symptomatic patient; or 2.2 Both: 2.2.1 Asymptomatic patient; and 2.2.2 Patient aged 12 months and under; or 2.3 Both: 2.3.1 Asymptomatic patient; and 2.3.2 Patient has viral load counts > 10,000 copies per ml or equivalent value on the Chiron test; or 2.4 All of the following: 2.4.1 Asymptomatic patient; and 2.4.2 Patient aged 1 to 5 years; and 2.4.3 CD4 counts < 1,000 cells/mm3; or 2.5 All of the following: 2.5.1 Asymptomatic patient; and 2.5.2 Patient aged 1 to 5 years; and 2.5.3 CD4 counts < 0.25 x total white cell count; or 2.6 All of the following: 2.6.1 Asymptomatic patient; and 2.6.2 Patient aged 6 years and over; and 2.6.3 CD4 counts
Special Authority for Subsidy - Form SA0557Initial application - (Single NAED Therapy) only from a paediatrician, neurologist or general physician. Approvals valid for 15 months for applications meeting the following criteria: Any of the following: 1 Was on NAED therapy before 1 September 2000; or 2 Seizures are not adequately controlled with optimal older anti-epilepsy drug treatment; or 3 Seizures are controlled adequately but who experience unacceptable side effects from older anti-epilepsy drug treatment. Note"Optimal older anti-epilepsy drug therapy" is defined as treatment with those older anti-epilepsy drugs which are indicated and clinically appropriate for the patient, given singly and in combination in adequate doses for the patient's age, weight, and other features affecting the pharmacokinetics of the drug with good evidence of complianceAs a guideline, clinical trials have referred to a notional 50% reduction in seizure frequency as an indicator of success with anti-convulsan
Additional subsidy by endorsement for:Moclobemide tab 150mg x 100 (Aurorix) up to $32.90Moclobemide tab 300mg x 60 (Aurorix) up to $39.48Nefazodone tab 100mg x 56 (Serzone) up to $20.16Nefazodone tab 200mg x 56 (Serzone) up to $40.32Citalopram tab 20mg x 28 (Cipramil) up to $27.00is available for patients who: * were taking moclobemide or nefazodone on 1 December 1999 or citalopram on 1 February 2000; or* have previously responded to treatment with moclobemide, nefazodone or citalopram; or* have had a trial of fluoxetine and have had to discontinue due to - inability to tolerate the drug due to side effects; or - failed to respond to an adequate dose and duration of treatment; or* have contraindications to fluoxetine (eg pre-existing significant levels of nausea, breastfeeding, potential drug interactions). The prescription must be endorsed accordingly. We recommend that the words used to indicate eligibility are "certified condition" however these words are not a requirement.
Additional subsidy by endorsement for:Moclobemide tab 150mg x 100 (Aurorix) up to $32.90Moclobemide tab 300mg x 60 (Aurorix) up to $39.48Nefazodone tab 100mg x 56 (Serzone) up to $20.16Nefazodone tab 200mg x 56 (Serzone) up to $40.32Citalopram tab 20mg x 28 (Cipramil and Celapram) up to $10.00Paroxetine hydrochloride tab 20 mg x 30 (Aropax) up to $35.02is available for patients who: * were taking moclobemide or nefazodone on 1 December 1999 or citalopram on 1 February 2000; or paroxetine hydrochloride on Februrary 2001; or * have previously responded to treatment with moclobemide or nefazodone or citalopram or paroxetine hydrochloride; or* have had a trial of fluoxetine and have had to discontinue due to - inability to tolerate the drug due to side effects; or - failed to respond to an adequate dose and duration of treatment; or* have contraindications to fluoxetine (eg pre-existing significant levels of nausea, breastfeeding, potential drug interactions). The prescription must be e
Special Authority for Subsidy - Form SA0563Initial application only from a relevant specialist. Approvals valid for 2 years for applications meeting the following criteria: Any of the following: 1 Both: 1.1 Acromegaly; and 1.2 Patient has failed surgery, radiotherapy, bromocriptine and other oral therapies; or 2 VIPomas and Glucagonomas - for patients who are seriously ill in order to improve their clinical state prior to definitive surgery.; or 3 Both: 3.1 Gastrinoma; and 3.2 Either: 3.2.1 Patient has failed surgery; or 3.2.2 Patient in metastatic disease after H2 antagonists (or proton pump inhibitors) have failed; or 4 Both: 4.1 Insulinomas; and 4.2 Surgery is contraindicated or has failed; or 5 For pre-operative control of hypoglycaemia and for maintenance therapy; or 6 Both: 6.1 Carcinoid syndrome (diagnosed by tissue pathology and/or urinary 5HIAA analysis); and 6.2 Disabling symptoms not controlled by maximal medical therapy. No
Trandolapril will be funded to the level of the ex-manufacturer price listed in the Schedule for patients who were taking these ACE inhibitors for the treatment of congestive heart failure prior to 1 June 1998. The prescription must be endorsed accordingly. We recommend that the words used to indicate eligibility are "certified condition" or an appropriate description of the patient such as "congestive heart failure", "CHF", "congestive cardiac failure" or "CCF". Definition of Congestive Heart Failure At the request of some prescribers the PTAC Cardiovascular subcommittee has provided a definition of congestive heart failure for the purposes of the funding of the manufacturer's surcharge: "Clinicians should use their clinical judgement. Existing patients would be eligible for the funding of the surcharge if the patient shows signs and symptoms of congestive heart failure, and requires or has in the past required concomitant treatment with a diuretic. The definition could also be considered to include pat
Perindopril will be funded to the level of the ex-manufacturer price listed in the Schedule for patients who were taking these ACE inhibitors for the treatment of congestive heart failure prior to 1 June 1998. The prescription must be endorsed accordingly. We recommend that the words used to indicate eligibility are "certified condition" or an appropriate description of the patient such as "congestive heart failure", "CHF", "congestive cardiac failure" or "CCF". Definition of Congestive Heart Failure At the request of some prescribers the PTAC Cardiovascular subcommittee has provided a definition of congestive heart failure for the purposes of the funding of the manufacturer's surcharge: "Clinicians should use their clinical judgement. Existing patients would be eligible for the funding of the surcharge if the patient shows signs and symptoms of congestive heart failure, and requires or has in the past required concomitant treatment with a diuretic. The definition could also be considered to include pati
Special Authority for Subsidy - Form SA0569Initial application only from a geriatrician, rheumatologist, endocrinologist, gynaecologist or general physician. Approvals valid for 2 years for applications meeting the following criteria: All of the following: 1 Severe osteoporosis; and 2 History of one previous significant osteoporotic fractures demonstrated radiologically; and 3 T-Score <= -3.0 (bone mass density (BMD) >= 3.0 standard deviations below the mean normal value in young adults). NoteIn line with the Australian guidelines for funding alendronate, a vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body. Renewal only from a geriatrician, rheumatologist, endocrinologist, gynaecologist or general physician. Approvals valid for 2 years where the t
Special Authority for Subsidy - Form SA0575Initial application - (Confirmed HIV/AIDS) only from a named general physician. Approvals valid without further renewal unless notified for applications meeting the following criteria: Both: 1 Confirmed HIV/AIDS; and 2 Any of the following: 2.1 Symptomatic patient; or 2.2 Both: 2.2.1 Asymptomatic patient; and 2.2.2 Patient aged 12 months and under; or 2.3 Both: 2.3.1 Asymptomatic patient; and 2.3.2 Patient has viral load counts > 10,000 copies per ml or equivalent value on the Chiron test; or 2.4 All of the following: 2.4.1 Asymptomatic patient; and 2.4.2 Patient aged 1 to 5 years; and 2.4.3 CD4 counts < 1,000 cells/mm3; or 2.5 All of the following: 2.5.1 Asymptomatic patient; and 2.5.2 Patient aged 1 to 5 years; and 2.5.3 CD4 counts < 0.25 x total white cell count; or 2.6 All of the following: 2.6.1 Asymptomatic patient; and 2.6.2 Patient aged 6 years and over
Special Authority for Subsidy - Form SA0579Initial application - (Cystic fibrosis or renal failure) only from a relevant specialist. Approvals valid for 3 years for applications meeting the following criteria: Either: 1 cystic fibrosis; or 2 chronic renal failure or continuous ambulatory peritoneal dialysis (CAPD) patient. Initial application - (Indications other than cystic fibrosis or renal failure) only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria: Any of the following: 1 cancer in children; or 2 cancers affecting alimentary tract where there are malabsorption problems in patients over the age of 20 years; or 3 failure to thrive; or 4 growth deficiency; or 5 bronchopulmonary dysplasia; or 6 premature and post premature infant. Renewal - (Cystic fibrosis or renal failure) only from a relevant specialist or general practitioner on the recommendation of such a specialist. Approvals valid for 3 years for applicatio
Special Authority for Subsidy - Form SA0580Initial application - (Inborn errors of metabolism) only from a relevant specialist. Approvals valid for 3 years where inborn errors of metabolism. Initial application - (Indications other than inborn errors of metabolism) only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria: Any of the following: 1 failure to thrive ; or 2 growth deficiency; or 3 bronchopulmonary dysplasia ; or 4 fat malabsorption ; or 5 lymphangiectasia; or 6 short bowel syndrome ; or 7 infants with necrotising enterocolitis; or 8 biliary atresia. Renewal - (Inborn errors of metabolism) only from a relevant specialist or general practitioner on the recommendation of such a specialist. Approvals valid for 3 years for applications meeting the following criteria: Both: 1 The treatment remains appropriate and the patient is benefiting from treatment; and 2 General Practitioners must include the name of
Special Authority for Subsidy - Form SA0581Initial application - (Cystic fibrosis) only from a relevant specialist. Approvals valid for 3 years for applications meeting the following criteria: Both: 1 infant aged four years or under; and 2 cystic fibrosis. Initial application - (Indications other than cystic fibrosis) only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria: Both: 1 infant aged four years or under; and 2 Any of the following: 2.1 cancer in children; or 2.2 failure to thrive; or 2.3 growth deficiency; or 2.4 bronchopulmonary dysplasia; or 2.5 premature and post premature infants. Renewal - (Cystic fibrosis) only from a relevant specialist or general practitioner on the recommendation of such a specialist. Approvals valid for 3 years for applications meeting the following criteria: Both: 1 The treatment remains appropriate and the patient is benefiting from treatment; and 2 General Practiti
Special Authority for Subsidy - Form SA0585Initial application - (Cystic fibrosis) only from a relevant specialist. Approvals valid for 3 years for applications meeting the following criteria: All of the following: 1 Cystic fibrosis; and 2 other lower calorie products have been tried; and 3 patient has substantially increased metabolic requirements; and 4 Either: 4.1 The product is to be used as a supplement; or 4.2 The product is to be used as a complete diet.Initial application - (Indications other than cystic fibrosis) only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria: All of the following: 1 Any of the following: 1.1 any condition causing malabsorption ; or 1.2 failure to thrive ; or 1.3 increased nutritional requirements.; and 2 other lower calorie products have been tried; and 3 patient has substantially increased metabolic requirements; and 4 Either: 4.1 The product is to be used a
Special Authority for Subsidy - Form SA0587Initial application only from a relevant specialist. Approvals valid for 3 years for applications meeting the following criteria: Both: 1 acute or chronic renal failure; and 2 Either: 2.1 The product is to be used as a supplement (maximum 500 ml per day); or 2.2 The product is to be used as a complete diet.Renewal only from a relevant specialist or general practitioner on the recommendation of such a specialist. Approvals valid for 3 years for applications meeting the following criteria: All of the following: 1 The treatment remains appropriate and the patient is benefiting from treatment; and 2 Either: 2.1 The product is to be used as a supplement (maximum 500 ml per day); or 2.2 The product is to be used as a complete diet; and 3 General Practitioners must include the name of the specialist and date contacted.
Special Authority for Subsidy - Form SA0588Initial application only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria: Both: 1 CORD patients who have hypercapnia; and 2 Either: 2.1 The product is to be used as a supplement (maximum 500 ml per day); or 2.2 The product is to be used as a complete diet.Renewal only from a relevant specialist or general practitioner on the recommendation of such a specialist. Approvals valid for 1 year for applications meeting the following criteria: All of the following: 1 The treatment remains appropriate and the patient is benefiting from treatment; and 2 Either: 2.1 The product is to be used as a supplement (maximum 500 ml per day); or 2.2 The product is to be used as a complete diet; and 3 General Practitioners must include the name of the specialist and date contacted.
Special Authority for Subsidy - Form SA0589Initial application only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria: All of the following: 1 Anorexia and weight loss; and 2 Either: 2.1 decompensating liver disease without encephalopathy ; or 2.2 protein losing gastro-enteropathy; and 3 Either: 3.1 The product is to be used as a supplement (maximum 500 ml per day); or 3.2 The product is to be used as a complete diet.Renewal only from a relevant specialist or general practitioner on the recommendation of such a specialist. Approvals valid for 1 year for applications meeting the following criteria: All of the following: 1 The treatment remains appropriate and the patient is benefiting from treatment; and 2 Either: 2.1 The product is to be used as a supplement (maximum 500 ml per day); or 2.2 The product is to be used as a complete diet; and 3 General Practitioners must include the name of the specialis
Special Authority for Subsidy - Form SA0590Initial application only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria: All of the following: 1 infant aged one to six years; and 2 Any of the following: 2.1 any condition causing malabsorption ; or 2.2 failure to thrive; or 2.3 increased nutritional requirements; and 3 Either: 3.1 The product is to be used as a supplement (maximum 500 ml per day); or 3.2 The product is to be used as a complete diet.Renewal only from a relevant specialist or general practitioner on the recommendation of such a specialist. Approvals valid for 1 year for applications meeting the following criteria: All of the following: 1 The treatment remains appropriate and the patient is benefiting from treatment; and 2 Either: 2.1 The product is to be used as a supplement (maximum 500 ml per day); or 2.2 The product is to be used as a complete diet; and 3 General Practitioners must
Special Authority for Subsidy - Form SA0591Initial application only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria: Both: 1 Any of the following: 1.1 enteral feeding; or 1.2 nasogastric; or 1.3 nasoduodenal ; or 1.4 nasojejunal; or 1.5 gastrostomy/jejunostomy; and 2 Either: 2.1 The product is to be used as a supplement; or 2.2 The product is to be used as a complete diet.Renewal only from a general practitioner or relevant specialist. Approvals valid for 1 year for applications meeting the following criteria: All of the following: 1 The treatment remains appropriate and the patient is benefiting from treatment; and 2 Either: 2.1 The product is to be used as a supplement; or 2.2 The product is to be used as a complete diet; and 3 General Practitioners must include the name of the specialist and date contacted.
Special Authority for Subsidy - Form SA0592Initial application only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria: Both: 1 Any of the following: 1.1 malabsorption ; or 1.2 short bowel syndrome; or 1.3 enterocutaneous fistulas ; or 1.4 pancreatitis; and 2 Either: 2.1 The product is to be used as a supplement (maximum 500 ml per day); or 2.2 The product is to be used as a complete diet.NoteEach of these products is highly specialised and would be prescribed only by an expert for a specific disorder. The alternative is hospitalisation. Elemental 028 Extra is more expensive than other products listed in this section and should only be used where the alternatives have been tried first and/or are unsuitable. Renewal only from a relevant specialist or general practitioner on the recommendation of such a specialist. Approvals valid for 1 year for applications meeting the following criteria: All of the following:
Special Authority for Subsidy - Form SA0594Initial application only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria: Both: 1 Type I and II diabetics who require nutritional supplementation.; and 2 Either: 2.1 The product is to be used as a supplement (maximum 500 ml per day); or 2.2 The product is to be used as a complete diet.Renewal only from a relevant specialist or general practitioner on the recommendation of such a specialist. Approvals valid for 1 year for applications meeting the following criteria: All of the following: 1 The treatment remains appropriate and the patient is benefiting from treatment; and 2 Either: 2.1 The product is to be used as a supplement (maximum 500 ml per day); or 2.2 The product is to be used as a complete diet; and 3 General Practitioners must include the name of the specialist and date contacted.
Special Authority for Subsidy - Form SA0596Initial application only from a relevant specialist. Approvals valid for 3 years for applications meeting the following criteria: Either: 1 gluten enteropathy has been diagnosed by biopsy; or 2 dermatitis herpetiformis. NoteA premium may be payable if the subsidy does not match the price charged by the manufacturer. The subsidy for these products reflects the philosophy that the patient incurs no additional financial burden for purchasing specialised more expensive products. Renewal only from a relevant specialist or general practitioner on the recommendation of such a specialist. Approvals valid for 3 years for applications meeting the following criteria: Both: 1 The treatment remains appropriate and the patient is benefiting from treatment; and 2 General Practitioners must include the name of the specialist and date contacted.
Special Authority for Subsidy - Form SA0597Initial application - (PKU Patient aged over 16) only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria: Both: 1 PKU; and 2 blood phenylalanine level < 900 mmol/litre (average of tests over last 12 months). Initial application - (Patient aged over 16) only from a relevant specialist. Approvals valid for 3 years for applications meeting the following criteria: Any of the following: 1 dietary management of homocystinuria; or 2 inborn errors of metabolism other than PKU; or 3 dietary management of maple syrup urine disease..Initial application - (Patient aged 16 or under) only from a relevant specialist. Approvals valid for 3 years for applications meeting the following criteria: Any of the following: 1 dietary management of homocystinuria; or 2 PKU and other inborn errors of metabolism; or 3 dietary management of maple syrup urine disease..Renewal - (PKU Patient aged over 16
Special Authority for Subsidy - Form SA0604Initial application - (Lactase deficiency or disaccharide intolerance) only from a relevant specialist. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 Patient is less than 3 years of age; and 2 Either: 2.1 diagnosed as suffering from congenital lactase deficiency; or 2.2 suffering from disaccharide intolerance. NoteSecondary lactose intolerance in children is usually short lasting, and can be controlled by dietary measures and by giving sufficient calories to regenerate digestive enzymes. The subsidy for these products reflects the philosophy that the patient incurs no additional financial burden for purchasing specialised more expensive products. Initial application - (Infant with intolerance to cows' milk) only from a relevant specialist. Approvals valid for 6 months for applications meeting the following criteria: Both: 1 intolerant to cows' milk; and 2 patient is less than 3 years of age. No
Special Authority for Subsidy - Form SA0605Initial application - (Cystic fibrosis or renal disorder) only from a relevant specialist. Approvals valid for 3 years for applications meeting the following criteria: Both: 1 Either: 1.1 cystic fibrosis; or 1.2 renal disorder; and 2 Either: 2.1 The product is to be used as a supplement; or 2.2 The product is to be used as a complete diet.Initial application - (Indications other than cystic fibrosis or renal disorder) only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria: Both: 1 Any of the following: 1.1 any condition causing malabsorption; or 1.2 failure to thrive; or 1.3 increased nutritional requirements; and 2 Either: 2.1 The product is to be used as a supplement; or 2.2 The product is to be used as a complete diet.Renewal - (Cystic fibrosis or renal disorder) only from a relevant specialist or general practitioner. Approvals valid for 3 years
Special Authority for Subsidy - Form SA0609Initial application - (Serevent MDI, Serevent Accuhaler Foradil, Oxis Turbuhaler 12 mcg, Symbicort Turbuhaler) only from a relevant specialist or general practitioner. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 Both: 1.1 Child under the age of 12 with poorly controlled asthma; and 1.2 Either: 1.2.1 Required at least three months of 400 mcg or more daily inhaled beclomethasone or budesonide; or 1.2.2 Required at least three months of 200 mcg or more of fluticasone; or 2 Both: 2.1 Adult with poorly controlled asthma; and 2.2 Either: 2.2.1 Required at least three months of 1500 mcg or more daily inhaled beclomethasone or budesonide; or 2.2.2 Required at least three months of 750 mcg or more of fluticasone. NotePatients are to be reviewed at least at six months to assess compliance and effectiveness of therapy. Special Authority approvals are interchangeable among all prese
Special Authority for Subsidy - Form SA0610Initial application from any specialist. Approvals valid without further renewal unless notified for applications meeting the following criteria: All of the following: 1 Quantity used by patient on a weekly volume intraveneously (Details to be attached to application); and 2 Amount of nutrition patient is able to receive orally (Details to be attached to application); and 3 Exact formula of TPN (Details to be attached to application); and 4 Who has paid for TPN so far (Details to be attached to application); and 5 Place of manufacture (Details to be attached to application); and 6 Complete medical history of patient including details of previous therapies. (Details to be attached to application). Renewal - (Previous approval has expired) from any specialist. Approvals valid without further renewal unless notified where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0614Initial application only from a geriatrician, rheumatologist, endocrinologist, gynaecologist or general physician. Approvals valid for 2 years for applications meeting the following criteria: All of the following: 1 Severe osteoporosis; and 2 History of one previous significant osteoporotic fractures demonstrated radiologically; and 3 T-Score <= -3.0 (bone mass density (BMD) >= 3.0 standard deviations below the mean normal value in young adults). NoteIn line with the Australian guidelines for funding alendronate, a vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral bodyRenewal only from a geriatrician, rheumatologist, endocrinologist, gynaecologist or general physician. Approvals valid for 2 years where the tr
Special Authority for Manufacturers Price - Form SA0616Initial application - (Conditions other than transient ischaemic episodes) only from a cardiothoracic surgeon, cardiologist or general physician. Approvals valid without further renewal unless notified for applications meeting the following criteria: Either: 1 Patients with prosthetic heart valves - as an adjunct to oral anticoagulation for prophylaxis of thromboembolism; or 2 Patients after coronary artery vein bypass graft - as an adjunct to aspirin or as monotherapy for patients who are aspirin intolerant. NoteAspirin intolerant patients are defined as those with aspirin induced asthma, urticaria, or anaphylaxi, or those with significant aspirin induced bleeding, excluding bruisingInitial application - (Transient ischaemic episodes) only from a neurologist, neuro surgeon, cardiologist, vascular surgeon or general physician. Approvals valid without further renewal unless notified where patients who continue to have transient ischaemic
Special Authority for Subsidy - Form SA0622Initial application only from a geriatrician, rheumatologist, endocrinologist, gynaecologist or general physician. Approvals valid without further renewal unless notified for applications meeting the following criteria: All of the following: 1 Severe osteoporosis; and 2 History of one previous significant osteoporotic fractures demonstrated radiologically; and 3 T-Score <= -3.0 (bone mass density (BMD) >= 3.0 standard deviations below the mean normal value in young adults). NoteIn line with the Australian guidelines for funding alendronate, a vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral bodyRenewal only from a geriatrician, rheumatologist, endocrinologist, gynaecologist or general physician. Approvals va
Special Authority for Subsidy - Form SA0623Initial application from any medical practitioner. Approvals valid for 1 year for applications meeting the following criteria: All of the following: 1 The patient is not predisposed to heart arrhythmias; and 2 The patient does not have a pre-existing QT-prolongation or hepatic failure; and 3 The patient is not using other medications which either inhibit the cytochrome P450 3A4 enzyme system or prolong the QT interval; and 4 Any of the following: 4.1 Both: 4.1.1 The patient is an adult with severe reflux oesophagitis; and 4.1.2 other treatment, including acid suppression with proton pump inhibitors, has failed; or 4.2 gastroparesis; or 4.3 malignancy of GI tract causing gastroparesis (or gastric outlet obstruction); or 4.4 The patient is a child (not including infants from 0 to 3 months of age who were born prematurely) with severe gastro-oesophageal reflux; and 5 Diagnosis has been made or confirmed by a general p
Special Authority for Subsidy - Form SA0626Initial application only from a renal physician. Approvals valid for 2 years for applications meeting the following criteria: All of the following: General Criteria: 1 Anaemia of end-stage renal failure (other treatable causes of anaemia being excluded); and 2 Been on haemodialysis or continuous ambulatory peritoneal dialysis (CAPD) for at least three months; and 3 Not under evaluation for, or awaiting, a live donor kidney transplant; and 4 Any of the following: Specific Criteria: 4.1 Anephric; or 4.2 Dependent on regular blood transfusion (1 unit each 4-8 weeks) to maintain haemoglobin > 60g/L; or 4.3 Dependent on regular blood transfusion but cannot be transfused because of severe transfusion reactions; or 4.4 Transfusion induced haemosiderosis (clinical manifestations, serum ferritin >1500 ug/L); or 4.5 Haemoglobin < 70 g/L (mean of at least 4 haemoglobin concentrations over 4 months); or 4.6 Both: 4.6.1 Haemo
Prescribing GuidelineTreatment with HMG CoA Reductase Inhibitors (Statins) is recommended for patients withdyslipidaemia and an absolute 5 year cardiovascular risk of 15% or greater. New Zealand Cardiovascular Guideline Group statement. "The 1996 Heart Foundation guidelines for the Assessment and Management of Dyslipidaemia are currently being revised. An evidence-based guideline on the Assessment and Management of Cardiovascular Risk will be developed in 2002. The Cardiovascular Guideline Group has written an interim consensus statement for themanagement of dyslipidaemia. The Heart Foundation cardiovascular risk tables should be used to determine risk. Certain groups are classified to be at very high risk (>20%) and should be treated as such: - Patients who have had a previous cardiovascular event (angina, MI, angioplasty, coronary artery bypass grafts, TIA, ischaemic stroke and peripheral vascular disease)- Patients with genetic lipid disorders- Patients with diabetes and associated microa
Special Authority for Subsidy - Form SA0628Initial application only from a cardiologist. Approvals valid without further renewal unless notified for applications meeting the following criteria: Any of the following: 1 Both: 1.1 Congestive heart failure; and 1.2 Cannot tolerate two ACE inhibitors due to persistent cough that resolves on cessation and recurs on re-challenge with ACE inhibitor; or 2 Patients who have experienced angioedema on an ACE inhibitor at any time in the past; or 3 Patients who have experienced angioedema (even if not using an ACE inhibitor) in the last 2 years. Renewal - ((2 year approvals granted before April 2002)) only from a cardiologist. Approvals valid without further renewal unless notified where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0631Initial application only from an ophthalmologist. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 Both: 1.1 Primary open-angle glaucoma; and 1.2 Any of the following: 1.2.1 Patient cannot tolerate Beta-blockers, or Beta-blockers are contraindicated; or 1.2.2 Patient cannot tolerate Pilocarpine, or Pilocarpine is contraindicated; or 1.2.3 Patient cannot tolerate Dorzolamide, or Dorzolamide is contraindicated; or 1.2.4 A reduction in intraocular pressure of 15% or more is not achieved or maintained using dorzolamide either alone or in combination with a beta-blocker; or 2 There is progressive visual field loss and/or optic nerve damage persists after treatment with dorzolamide either alone or in combination with a beta-blocker. NoteSubsidised also for adjunctive use for the treatment of patients who have met the initial application criteria, and in whom latanoprost monotherapy has bee
Special Authority for Subsidy - Form SA0633Initial application only from a general practitioner or relevant specialist. Approvals valid without further renewal unless notified for applications meeting the following criteria: Both: 1 Patient is already on an ACE inhibitor or Angiotensin II Antagonist; and 2 Any of the following: 2.1 Both: 2.1.1 Symptomatic heart failure NYHA functional class II-III; and 2.1.2 Patient has been treated with metoprolol and is intolerant to metoprolol or has demonstrated a sub-optimal response to metoprolol; or 2.2 Symptomatic heart failure NYHA functional class III-IV; or 2.3 Patient has left ventricular systolic dysfunction with an ejection fraction of less than 35%.NoteWhere possible treatment should be initiated by or on the recommendation of a specialist.
Special Authority for Subsidy - Form SA0635Initial application only from a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria: All of the following: 1 Rheumatoid arthritis; and 2 Patient is not a pregnant woman, or a woman of child-bearing age without adequate contraception; and 3 Patient has been unable to tolerate or has a contraindication to or has had an inadequate response to sulphasalazine and methotrexate (individually or in combination). Renewal only from a rheumatologist. Approvals valid without further renewal unless notified for applications meeting the following criteria: Both: 1 Compliance (prescriber determined) with medication; and 2 Improved rheumatoid arthritis symptom control. NotePatient should have full blood count and liver function tests regularly monitored.
Special Authority for Subsidy - Form SA0637Initial application - (National Heart Foundation risk groups A1:1, A1:2, B, C, D or E) only from a relevant specialist or general practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria: All of the following: 1 The patient has been offered 3-6 months of counseling and an opportunity to modify lifestyle; and 2 Any of the following: 2.1 Both: 2.1.1 NHF A1:1 - Clinically proven ischaemic heart disease; and 2.1.2 total cholesterol > 5.5; or 2.2 Both: 2.2.1 NHF A1:2 - Post coronary artery bypass graft (CABG) or angioplasty; and 2.2.2 total cholesterol > 4.5; or 2.3 Post heart transplant (regardless of cholesterol level); or 2.4 Both: 2.4.1 NHF B: Patients with > 20% 5-year cardiovascular disease risk; and 2.4.2 total cholesterol > 9.0; or 2.5 Both: 2.5.1 NHF C: 15-20% 5-year cardiovascular disease risk; and 2.5.2 total cholesterol >
Special Authority for Subsidy - Form SA0639Initial application - (No previous use) only from a relevant specialist or general practitioner. Approvals valid for 3 months for applications meeting the following criteria: All of the following: 1 The patient has a clinical diagnosis of heavy menstrual bleeding; and 2 The patient has failed to respond to or is unable to tolerate other appropriate pharmaceutical therapies as per the Heavy Menstrual Bleeding Guidelines; and 3 Either: 3.1 serum ferritin level < 16 mg/l (within the last 12 months); or 3.2 haemoglobin level < 120 g/l . NoteApplications are not to be made for use in patients as contraception except where they meet the above criteriaInitial application - (Previous use before 1 October 2002) only from a relevant specialist or general practitioner. Approvals valid for 3 months for applications meeting the following criteria: All of the following: 1 The patient had a clinical diagnosis of heavy menstrual bleeding; and 2
Special Authority for Waiver of Rule - Form SA0641Initial application only from a diabetologist, general physician or paediatrician. Approvals valid without further renewal unless notified for applications meeting the following criteria: Either: 1 Both: 1.1 Use alone (monotherapy); and 1.2 The patient is unable to use any other insulins including those on insulin pump treatment; or 2 Both: 2.1 Use with insulin other than insulin isophane (including ready-mixed preparations); and 2.2 A reasonable trial of insulin isophane has been undertaken and it is not effective or not well tolerated. Note"Reasonable trial", "unable to use", "not effective", "not well tolerated", and "not well tolerated" are not defined and we ask clinicians to use their clinical judgement in interpreting these terms.
Special Authority for Subsidy - Form SA0643Initial application - (CML) only from an oncologist or relevant specialist. Approvals valid for 7 months where approved by the The Glivec Co-ordinator. Initial application - (GIST) only from an oncologist. Approvals valid for 1 year where approved by the The Glivec Co-ordinator. Renewal - (CML) only from an oncologist or relevant specialist. Approvals valid for 6 months where approved by the The Glivec Co-ordinator. Initial application - (GIST) only from an oncologist. Approvals valid for 1 year where approved by the The Glivec Co-ordinator. NoteApplication forms are available from, and prescriptions should be sent to: The Glivec Co-ordinatorPhone: 09 580 9176Level 3, Unisys HouseFacsimile: 09 580 9205650 Great South Road, PenroseEmail: murray@ppc.govt.nzPrivate Bag, AUCKLANDSpecial Authority criteria for CML - access by applicationFunded for patients with diagnosis (confirmed by a haematologist) of a chronic myeloid leukaemia (CML) i
Special Authority for Subsidy - Form SA0645Initial application only from a renal physician. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 Both: 1.1 patient in chronic renal failure; and 1.2 Haemoglobin <= 100 g/L; and 2 Either: 2.1 Both: 2.1.1 patient is not diabetic; and 2.1.2 glomerular filtration rate <= 30 ml/min; or 2.2 Both: 2.2.1 patient is diabetic; and 2.2.2 glomerular filtration rate <= 45 ml/min. Renewal only from a renal physician. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment. NoteErythropoietin beta is indicated in the treatment of anaemia associated with chronic renal failure (CRF) where no cause for anaemia other than CRF is detected and there is adequate monitoring of iron stores and iron replacement therapy. The Cockroft-Gault Formula may be used to estimate glomerular filtration rate (GFR) in persons 18 years and over:GFR (male)
Special Authority for Subsidy - Form SA0646Initial application only from a renal physician. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 Both: 1.1 patient in chronic renal failure; and 1.2 Haemoglobin <= 100 g/L; and 2 Any of the following: 2.1 Both: 2.1.1 patient is not diabetic; and 2.1.2 glomerular filtration rate <= 30 ml/min; or 2.2 Both: 2.2.1 patient is diabetic; and 2.2.2 glomerular filtration rate <= 45 ml/min; or 2.3 patient is on haemodialysis or peritoneal dialysis. Renewal only from a renal physician. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment. NoteErythropoietin beta is indicated in the treatment of anaemia associated with chronic renal failure (CRF) where no cause for anaemia other than CRF is detected and there is adequate monitoring of iron stores and iron replacement therapy. The Cockroft-Gault Formula may be used to estim
Special Authority for Manufacturers Price - Form SA0648Initial application - (Conditions other than transient ischaemic episodes) only from a cardiothoracic surgeon, cardiologist or general physician. Approvals valid without further renewal unless notified for applications meeting the following criteria: Either: 1 Patients with prosthetic heart valves - as an adjunct to oral anticoagulation for prophylaxis of thromboembolism; or 2 Patients after coronary artery vein bypass graft - as an adjunct to aspirin or as monotherapy for patients who are aspirin intolerant. NoteAspirin intolerant patients are defined as those with aspirin induced asthma, urticaria, or anaphylaxi, or those with significant aspirin induced bleeding, excluding bruisingInitial application - (Transient ischaemic episodes) only from a neurologist, neuro surgeon, cardiologist, vascular surgeon or general physician. Approvals valid without further renewal unless notified where patients who continue to have transient ischaemic
Special Authority for Subsidy - Form SA0649Initial application - (Conditions other than transient ischaemic episodes) only from a cardiothoracic surgeon, cardiologist or general physician. Approvals valid without further renewal unless notified for applications meeting the following criteria: Either: 1 Patients with prosthetic heart valves - as an adjunct to oral anticoagulation for prophylaxis of thromboembolism; or 2 Patients after coronary artery vein bypass graft - as an adjunct to aspirin or as monotherapy for patients who are aspirin intolerant. NoteAspirin intolerant patients are defined as those with aspirin induced asthma, urticaria, or anaphylaxi, or those with significant aspirin induced bleeding, excluding bruisingInitial application - (Transient ischaemic episodes) only from a neurologist, neuro surgeon, cardiologist, vascular surgeon or general physician. Approvals valid without further renewal unless notified where patients who continue to have transient ischaemic episodes des
Special Authority for Subsidy - Form SA0652Initial application - (Single NAED Therapy) only from a paediatrician, neurologist or general physician. Approvals valid for 15 months for applications meeting the following criteria: Any of the following: 1 Was on NAED therapy before 1 September 2000; or 2 Seizures are not adequately controlled with optimal older anti-epilepsy drug treatment; or 3 Seizures are controlled adequately but who experience unacceptable side effects from older anti-epilepsy drug treatment. Note"Optimal older anti-epilepsy drug therapy" is defined as treatment with those older anti-epilepsy drugs which are indicated and clinically appropriate for the patient, given singly and in combination in adequate doses for the patient's age, weight, and other features affecting the pharmacokinetics of the drug with good evidence of complianceInitial application - (Dual NAED Therapy) only from a paediatrician, neurologist or general physician. Approvals valid for 18 months for app
Special Authority for Subsidy - Form SA0657Initial application - (Helicobacter pylori infections) only from a general practitioner or relevant specialist. Approvals valid for 6 months for applications meeting the following criteria: Both: 1 Eradication of Helicobacter pylori in patient with proven infection; and 2 Peptic ulcer disease proven by endoscopy. NoteMaximum of two prescriptions (two courses) per patient. Initial application - (Mycobacterial infections) only from a respiratory specialist, infectious disease specialist or paediatrician. Approvals valid for 2 years for applications meeting the following criteria: Any of the following: 1 Mycobacterium Avium Intracellulare Complex infections in patient with AIDS; or 2 Atypical and drug-resistant mycobacterial infection; or 3 All of the following: 3.1 Prophylaxis against disseminated Mycobacterium Avium Intracellulare Complex infection; and 3.2 HIV infection; and 3.3 CD4 count <= 50 cells/mm3. Renewal - (Mycobact
Additional subsidy by endorsement for:Moclobemide tab 150 mg x 500 (Apo-Moclobemide) up to $46.00Moclobemide tab 150 mg x 100 (Aurorix) up to $32.90Moclobemide tab 300 mg x 100 (Apo-Moclobemide) up to $26.11Moclobemide tab 300 mg x 60 (Aurorix) up to $39.48Nefazodone tab 100 mg x 56 (Serzone) up to $20.16Nefazodone tab 200 mg x 56 (Serzone) up to $40.32Citalopram tab 20 mg x 28 (Celapram) up to $4.00Citalopram tab 20 mg x 28 (Cipramil) up to $10.00Paroxetine hydrochloride tab 20 mg x 30 (Aropax) up to $35.02is available for patients who: - were taking moclobemide or nefazodone on 1 December 1999 or citalopram on 1 February 2000; or paroxetine hydrochloride on February 2001; or- have previously responded to treatment with moclobemide or nefazodone or citalopram or paroxetine hydrochloride; or- have had a trial of fluoxetine and have had to discontinue due to- inability to tolerate the drug due to side effects; or- failed to respond to an adequate dose and duration of treatment; or
Special Authority for Subsidy - Form SA0661Initial application only from a psychiatrist. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 The patient has "treatment resistant" depression; and 2 Either: 2.1 The patient must have had a trial of two different antidepressants and failed to respond to an adequate dose over an adequate period of time (usually at least four weeks); or 2.2 Both: 2.2.1 The patient is currently a hospital in-patient as a result of an acute depressive episode; and 2.2.2 The patient must have had a trial of one other antidepressant and failed to respond to an adequate dose over an adequate period of time. Renewal from any medical practitioner. Approvals valid for 2 years where patient has a high risk of relapse (prescriber determined)..NoteFirst prescription can be written by a psychiatrist or psychiatric registrar. Subsequent prescriptions may be written by a General Practitioner
Special Authority for Subsidy - Form SA0667Initial application only from a named specialist. Approvals valid for 4 months for applications meeting the following criteria: All of the following: 1 To be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and 2 Patient is less than 18 years of age at commencement of treatment; and 3 Patient has had severe active polyarticular course Juvenile Idiopathic Arthritis (JIA) for 6 months duration or longer; and 4 Patient has tried and not responded to at least three months of oral or parenteral methotrexate at a dose of 10-20mg/m2 weekly in combination with oral corticosteroids (prednisone 0.25 mg/kg); and 5 Patient has tried and not responded to at least three months of oral or parenteral methotrexate (at a dose of 10-15mg/m2 weekly) in combination with one other disease-modifying agent; and 6 Both: 6.1 Either: 6.1.1 Patient has persistent symptoms of poorly-cont
Additional subsidy by endorsement for:Nefazodone tab 100 mg x 56 (Serzone) up to $20.16Nefazodone tab 200 mg x 56 (Serzone) up to $40.32Citalopram tab 20 mg x 28 (Celapram) up to $4.00Citalopram tab 20 mg x 28 (Cipramil) up to $10.00Paroxetine hydrochloride tab 20 mg x 30 (Aropax) up to $35.02is available for patients who: -were taking nefazodone on 1 December 1999 or citalopram on 1 February 2000; or paroxetine hydrochloride on February 2001; or- have previously responded to treatment with nefazodone or citalopram or paroxetinehydrochloride; or- have had a trial of fluoxetine and have had to discontinue due to- inability to tolerate the drug due to side effects; or- failed to respond to an adequate dose and duration of treatment; or- have contraindications to fluoxetine (eg pre-existing significant levels of nausea, breastfeeding, potential drug interactions). The prescription must be endorsed accordingly.
Special Authority for Subsidy - Form SA0693Initial application only from a relevant specialist or vocationally registered general practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria: All of the following: 1 Severe osteoporosis; and 2 History of one previous significant osteoporotic fracture demonstrated radiologically; and 3 T-Score <= -3.0 (bone mass density (BMD) >= 3.0 standard deviations below the mean normal value in young adults). NoteIn line with the Australian guidelines for funding alendronate, a vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral bodyRenewal - ((2 year approvals granted before February 2002)) only from a geriatrician, rheumatologist, endocrinologist, gynaecologis
Special Authority for Subsidy - Form SA0696Initial application - (Narcolepsy) only from a neurologist or respiratory specialist. Approvals valid for 24 months where narcolepsy. Initial application - (ADHD in patients 5 or over) only from a paediatrician, psychiatrist or general practitioner on the recommendation of such a specialist. Approvals valid for 24 months for applications meeting the following criteria: All of the following: 1 ADHD (Attention Deficit and Hyperactivity Disorder) patients aged 5 years or over; and 2 Diagnosed according to DSM-IV or ICD 10 criteria; and 3 Either: 3.1 Applicant is a specialist; or 3.2 Both: 3.2.1 Applicant is a GP and a specialist has recommended treatment; and 3.2.2 Provide name of specialist (Details to be attached to application). Initial application - (ADHD in patients under 5) only from a paediatrician or psychiatrist. Approvals valid for 12 months for applications meeting the following criteria: Both: 1 ADHD (Attention Defi
Special Authority for Subsidy - Form SA0698Initial application only from a gastroenterologist, general surgeon or general physician. Approvals valid for 3 months for applications meeting the following criteria: Both: 1 Mild to moderate ileal, ileocaecal or proximal Crohn's disease; and 2 Any of the following: 2.1 Diabetes; or 2.2 Cushingoid habitus; or 2.3 Osteoporosis where there is significant risk of fracture; or 2.4 Severe acne following treatment with conventional corticosteroid therapy. Renewal only from a gastroenterologist, general surgeon or general physician. Approvals valid for 3 months where the treatment remains appropriate and the patient is benefiting from treatment. The patient must have had no more than 1 prior approval in the last year. NoteClinical trials for Entocort CIR use beyond three months demonstrated no improvement in relapse rate.
Special Authority for Subsidy - Form SA0699Initial application from any medical practitioner. Approvals valid for 1 year for applications meeting the following criteria: All of the following: 1 The patient is not predisposed to heart arrhythmias; and 2 The patient does not have a pre-existing QT-prolongation or hepatic failure; and 3 The patient is not using other medications which either inhibit the cytochrome P450 3A4 enzyme system or prolong the QT interval; and 4 Any of the following: 4.1 Both: 4.1.1 adult with severe reflux oesophagitis; and 4.1.2 other treatment, including acid suppression with proton pump inhibitors, has failed; or 4.2 gastroparesis; or 4.3 malignancy of GI tract causing gastroparesis (or gastric outlet obstruction); or 4.4 child (not including infants from 0 to 3 months of age who were born prematurely) with severe gastro-oesophageal reflux; and 5 Diagnosis has been made or confirmed by a general physician, gastroenterologist, or ge
Special Authority for Subsidy - Form SA0700Initial application only from an ophthalmologist. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 Both: 1.1 Monotherapy in primary open-angle glaucoma; and 1.2 Any of the following: 1.2.1 Patient cannot tolerate Beta-blockers, Pilocarpine and Dorzolamide; or 1.2.2 Beta-blockers, Pilocarpine and Dorzolamide are contraindicated; or 1.2.3 A reduction in intraocular pressure of 15% or more is not achieved or maintained using dorzolamide either alone or in combination with a beta-blocker; or 1.2.4 There is progressive visual field loss and/or optic nerve damage persists after treatment with dorzolamide either alone or in combination with a beta-blocker; or 2 Adjunctive use for the treatment of patients who have met the initial application criteria, and in whom latanoprost monotherapy has been ineffective in controlling intraocular pressure.Note An adjunctive agent may be added without a
Special Authority for Subsidy - Form SA0702Initial application - (Oral feed for cystic fibrosis patient) only from a relevant specialist. Approvals valid for 3 years for applications meeting the following criteria: Both: 1 Cystic fibrosis; and 2 Either: 2.1 The product is to be used as a supplement; or 2.2 The product is to be used as a complete diet.Initial application - (Oral feed for indications other than cystic fibrosis) only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria: Both: 1 Any of the following: 1.1 any condition causing malabsorption; or 1.2 failure to thrive; or 1.3 increased nutritional requirements; and 2 Either: 2.1 The product is to be used as a supplement; or 2.2 The product is to be used as a complete diet.Renewal - (Oral feed cystic fibrosis patient) only from a relevant specialist or general practitioner on the recommendation of such a specialist. Approvals valid for 3 years f
Special Authority for Subsidy - Form SA0703Initial application only from a relevant specialist or general practitioner. Approvals valid for 2 years for applications meeting the following criteria: All of the following: 1 Patient has raised blood pressure; and 2 The use of fully funded beta blockers is contraindicated, or not well tolerated; or where use of fully funded beta blockers and diuretics are insufficient to control blood pressure adequately at appropriate doses; and 3 Either: 3.1 Has been treated with, and cannot tolerate two ACE inhibitors, due to persistent cough; or 3.2 Has experienced angioedema on an ACE inhibitor at any time in the past or who have experienced angioedema (even if not using an ACE inhibitor) in the last 2 years. Renewal only from a relevant specialist or general practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0706Initial application only from a relevant specialist or general practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria: Either: 1 Both: 1.1 Patient with congestive heart failure; and 1.2 Either: 1.2.1 Has been treated with, and cannot tolerate, two ACE inhibitors, due to persistent cough; or 1.2.2 Has experienced angioedema on an ACE inhibitor at any time in the past or who have experienced angioedema (even if not using an ACE inhibitor) in the last 2 years; or 2 All of the following: 2.1 Patient with raised blood pressure; and 2.2 Use of fully funded beta blockers or diuretics are contraindicated; or not well tolerated; or insufficient to control blood pressure adequately at appropriate doses; and 2.3 Either: 2.3.1 Has been treated with, and cannot tolerate, two ACE inhibitors, due to persistent cough; or 2.3.2 Has experienced angioedema on an ACE in
Effective, consistent management of herpes from prescribing to these guidelines will improve patient outcomes. The guidelines on the following four pages are for the prescribing of aciclovir. The guidelines aim to: - improve patient care and clinical outcome through faster, more accessible treatment - protect patients' wider wellbeing by reinforcing the psychosocial aspects of treatment - improve the consistency and breadth of medical management of genital herpes in New Zealand. The guidelines are: - integral to ensuring a consistent, effective treatment regimen- the result of consultation with clinicians and patient representatives- set out in line with the recommended international algorithm format for treatment. The guidelines are endorsed by the Herpes Foundation's professional advisory board whose members represent venereology, NZDS, RNZCGP, RNZCOG, psychotherapy and nursing. Herpes Foundation Helpline: Toll free 0508 11 12 13Auckland Branch Herpes Foundation: 09 360 1966
Guidelines for the use of interferon in the treatment of hepatitis C: Physicians considering treatment of patients with hepatitis C should discuss cases with a gastroenterologist or aninfectious disease physician. All subjects undergoing treatment require careful monitoring for side effects. Patients should be otherwise fit. Hepatocellular carcinoma should be excluded by ultrasound examination and alpha-fetoprotein level. Criteria for Treatment a) Diagnosis- Anti-HCV positive on at least two occasions with a positive PCR for HCV-RNA and preferably confirmed by asupplementary RIBA test; or- PCR-RNA positive for HCV on at least 2 occasions if antibody negative; or- Anti-HCV positive on at least two occasions with a positive supplementary RIBA test with a negative PCR forHCV RNA but with a liver biopsy consistent with 2(b) following. b) Establishing Active Chronic Liver Disease- Confirmed HCV infection and serum ALT/AST levels measured on at least three occasions over six monthsaveraging >
Special Authority for Subsidy - Form SA0710Initial application only from an ophthalmologist. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 Either: 1.1 Monotherapy in primary open-angle glaucoma; or 1.2 Adjunctive use for the treatment of open-angle glaucoma in a patient who has met the initial application criteria, and in whom prostaglandin analogue monotherapy has been ineffective in controlling intraocular pressure; and 2 Any of the following: 2.1 Patient cannot tolerate beta-blockers, pilocarpine, and carbonic anhydrase inhibitors; or 2.2 Beta-blockers, pilocarpine and carbonic anhydrase inhibitors are contraindicated; or 2.3 A reduction in intraocular pressure of 15% or more is not achieved or maintained using carbonic anhydrase inhibitor either alone or in combination with a beta blocker; or 2.4 There is progressive visual field loss and/or optic nerve damage persists after treatment with carbonic anhydrase inhibitor either alo
Special Authority for Subsidy - Form SA0714Initial application from any medical practitioner. Approvals valid for 3 months for applications meeting the following criteria: All of the following: 1 Patient is currently enrolled in a recognised comprehensive treatment programme for alcohol dependence in a service accredited against the New Zealand Alcohol and Other Drug Sector Standard or the National Mental Health Sector Standard; and 2 Applicant works in an Alcohol & Drug Service; and 3 Applicant must include the address of the service (Details to be attached to application). Renewal from any medical practitioner. Approvals valid for 3 months for applications meeting the following criteria: Both: 1 Compliance with the medication (prescriber determined); and 2 Any of the following: 2.1 Patient is still unstable and requires further treatment; or 2.2 Patient achieved significant improvement but requires further treatment; or 2.3 Patient is well controlled but requires maint
Special Authority for Manufacturers Price - Form SA0717Initial application only from a relevant specialist or general practitioner. Approvals valid for 12 weeks for applications meeting the following criteria: Both: 1 Patient has a calculated absolute risk of cardiovascular disease of at least 15% over 5 years; and 2 Either: 2.1 Patient has severe documented intolerance to simvastatin; or 2.2 Both: 2.2.1 Patient has been compliant with a dose of simvastatin of 80 mg per day for at least 2 months; and 2.2.2 Either: 2.2.2.1 All of the following: 2.2.2.1.1 Patient has venous CABG; and 2.2.2.1.2 LDL cholesterol test 1 >= 2.0 mmol/litre; and 2.2.2.1.3 LDL cholesterol test 2 >= 2.0 mmol/litre (at least 1 week after test 1); or 2.2.2.2 All of the following: 2.2.2.2.1 Patient does not have venous CABG; and 2.2.2.2.2 LDL cholesterol test 1 >= 2.5 mmol/litre; and 2.2.2.2.3 LDL cholesterol test 2 >= 2.5 mmol/litre (at least 1 w
Special Authority for Subsidy - Form SA0721Initial application only from a named specialist. Approvals valid without further renewal unless notified for applications meeting the following criteria: All of the following: 1 The patient already has a Special Authority approval for anti-retroviral therapy (Details to be attached to application); and 2 Kaletra is to be used as a salvage therapy in place of one protease inhibitor; and 3 The patient must have trialed for at least six months and have failed on currently funded NNRTI based regimens or triple NRTI regimens; and 4 The patient must have trialed for at least six months and have failed on currently funded PI based regimens. NoteFailure is defined as: a) not achieving HIV RNA < 400 copies/ml after 24 weeks of a regimen, orb) an increase of HIV RNA to > 400 copies/ml on two separate occasions not less than one month apart, after suppression to < 400 copies/ml in a patient taking the regimen.
Special Authority for Subsidy - Form SA0723Initial application only from a relevant specialist. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 All of the following: 1.1 Patient has a calculated absolute risk of cardiovascular disease >20% over 5 years; and 1.2 Patient cannot tolerate statin therapy at a dose of 40 mg per day; and 1.3 Either: 1.3.1 All of the following: 1.3.1.1 Patient has venous CABG; and 1.3.1.2 LDL cholesterol >= 2.0 mmol/litre (see note); and 1.3.1.3 LDL cholesterol >= 2.0 mmol/litre (at least 1 week after test 1 - see note); or 1.3.2 All of the following: 1.3.2.1 Patient does not have venous CABG; and 1.3.2.2 LDL cholesterol >= 2.5 mmol/litre (see note); and 1.3.2.3 LDL cholesterol >= 2.5 mmol/litre (at least 1 week after test 1 - see note); or 2 All of the following: 2.1 Patient has homozygous familial hypercholesterolemia, or heterozygous familial hypercholesterol
Special Authority for Manufacturers Price - Form SA0724Initial application only from a relevant specialist or general practitioner. Approvals valid for 12 weeks for applications meeting the following criteria: Both: 1 Patient has a calculated absolute risk of cardiovascular disease of at least 15% over 5 years; and 2 Either: 2.1 Patient has severe documented intolerance to simvastatin (blood tests are not required); or 2.2 Both: 2.2.1 Patient has been compliant with a dose of simvastatin of 80 mg per day for at least 2 months; and 2.2.2 Either: 2.2.2.1 All of the following: 2.2.2.1.1 Patient has venous CABG; and 2.2.2.1.2 LDL cholesterol test 1 >= 2.0 mmol/litre; and 2.2.2.1.3 LDL cholesterol test 2 >= 2.0 mmol/litre (at least 1 week after test 1); or 2.2.2.2 All of the following: 2.2.2.2.1 Patient does not have venous CABG; and 2.2.2.2.2 LDL cholesterol test 1 >= 2.5 mmol/litre; and 2.2.2.2.3 LDL cholesterol test 2 >
Special Authority for Subsidy - Form SA0725Initial application only from a relevant specialist or general practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria: All of the following: 1 Patient with raised blood pressure; and 2 Use of fully funded beta blockers and diuretics are contraindicated; or not well tolerated; or insufficient to control blood pressure adequately at appropriate doses; and 3 Either: 3.1 Has been treated with, and cannot tolerate, two ACE inhibitors, due to persistent cough; or 3.2 Has experienced angioedema on an ACE inhibitor at any time in the past or who have experienced angioedema (even if not using an ACE inhibitor) in the last 2 years. Renewal - (Previous approval has expired) only from a relevant specialist or general practitioner. Approvals valid without further renewal unless notified where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0733Initial application - (Patient aged over 16) only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria: Both: 1 dietary management of PKU; and 2 blood phenylalanine level < 900 mmol/litre (average of tests over last 12 months). Initial application - (Patient aged 16 or under) only from a relevant specialist. Approvals valid for 3 years where dietary management of PKU.Renewal - (Patient aged over 16) only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria: blood phenylalanine level < 900 mmol/litre (average of tests over last 12 months). Renewal - (Patient aged 16 or under) only from a relevant specialist or general practitioner on the recommendation of such a specialist. Approvals valid for 3 years for applications meeting the following criteria: Both: 1 The treatment remains appropriate and the patient is benefiting from treatment; and 2
Special Authority for Subsidy - Form SA0738Initial application only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria: Either: 1 All of the following: 1.1 To be used as monotherapy for patients with type 2 diabetes who after six months of diet and lifestyle changes do not have adequate glycaemic control (inadequate control defined as HbA1c > 8.0% in tests carried out at least two months apart); and 1.2 Metformin is not tolerated or contraindicated. Intolerance and contraindications as defined in the notes below, a minimum of a four week trial period of metformin is required; and 1.3 Sulphonylurea is not tolerated or contraindicated. Overweight patients are only eligible under the criteria of contraindication to sulphonylureas if their body mass index (BMI) exceeds 35; or 2 Both: 2.1 For use in combination with a sulphonylurea when diet and lifestyle changes and a twelve month trial of sulphonylurea results in inadequate glycaem
Special Authority for Subsidy - Form SA0741Initial application only from a psychiatrist. Approvals valid for 2 years for applications meeting the following criteria: Any of the following: 1 Patient with first episode schizophrenia or related psychoses; or 2 Both: 2.1 Patient suffering from schizophrenia and related psychoses; or acute mania in bipolar disorder who is likely to benefit from anti-psychotic treatment; and 2.2 Either: 2.2.1 An effective dose of risperidone had been trialled and has been discontinued because of unacceptable side effects; or 2.2.2 An effective dose of risperidone had been trialled and has been discontinued because of inadequate clinical response after 4 weeks; or 3 The patient has suffered from an acute episode of schizophrenia or bipolar mania and has been treated with olanzapine short-acting intra-muscular injection. Renewal only from a psychiatrist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefit
Special Authority for Subsidy - Form SA0751Initial application only from an ophthalmologist. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 Either: 1.1 Monotherapy in primary open-angle glaucoma; or 1.2 Adjunctive use for the treatment of open-angle glaucoma in a patient who has met the initial application criteria, and in whom prostaglandin analogue monotherapy has been ineffective in controlling intraocular pressure; and 2 Any of the following: 2.1 Patient cannot tolerate beta-blockers, pilocarpine, and carbonic anhydrase inhibitors; or 2.2 Beta-blockers, pilocarpine and carbonic anhydrase inhibitors are contraindicated; or 2.3 A reduction in intraocular pressure of 15% or more is not achieved or maintained using carbonic anhydrase inhibitor either alone or in combination with a beta blocker; or 2.4 There is progressive visual field loss and/or optic nerve damage persists after treatment with carbonic anhydrase inhibitor either alo
(a) Subsidy is available between 1 March and 30 June of each year for patients who meet the following criteria, as set by the Ministry of Health: a) all people 65 years of age and over; b) people under 65 years of age with: i) the following cardiovascular disease: 1) ischaemic heart disease, 2) congestive heart disease, 3) rheumatic heart disease, 4) congenital heart disease, or 5) cerebo-vascular disease; ii) the following chronic respiratory disease: 1) asthma, if on a regular preventative therapy, or 2) other chronic respiratory disease with impaired lung function; iii) diabetes; iv) chronic renal disease; v) any cancer, excluding basal and squamous skin cancers if not invasive; vi) the following other conditions: 1) autoimmune disease, 2) immune suppression, 3) HIV, 4) transplant recipients, 5) neuromuscular and CNS diseases, 6) haemoglobinopathies, or 7) children on long term aspirin. The following conditions are excluded from funding: i) asthma not requiri
Special Authority for Subsidy - Form SA0754Initial application only from a named specialist. Approvals valid without further renewal unless notified for applications meeting the following criteria: All of the following: 1 The patient already has a Special Authority approval for anti-retroviral therapy (Details to be attached to application); and 2 Kaletra is to be used as a salvage therapy in place of one protease inhibitor; and 3 The patient must have trialed for at least six months and have failed on currently funded NNRTI based regimens or triple NRTI regimens; and 4 The patient must have trialed for at least six months and have failed on currently funded PI based regimens. NoteFailure is defined as: a) not achieving HIV RNA < 400 copies/ml after 24 weeks of a regimen, orb) an increase of HIV RNA to > 400 copies/ml on two separate occasions not less than one month apart, after suppression to < 400 copies/ml in a patient taking the regimen.
Special Authority for Subsidy - Form SA0758Initial application only from a general practitioner or relevant specialist. Approvals valid for 2 years for applications meeting the following criteria: All of the following: 1 To be used for the long-term maintenance treatment of bronchospasm and dyspnoea associated with COPD; and 2 In addition to standard treatment, the patient has trialled a dose of at least 40 mcg ipratropium q.i.d; and 3 The patient's breathlessness >= grade 4 according to the Medical Research Council dyspnoea scale (see note); and 4 FEV1 (litres) < 0.4 x predicted (litres); and 5 Either: 5.1 Patient is not a smoker (for reporting purposes only); or 5.2 Patient is a smoker and been offered smoking cessation councilling; and 6 The patient has been offered annual influenza immunisation. Renewal only from a general practitioner or relevant specialist. Approvals valid for 2 years for applications meeting the following criteria: All of the following: 1
(a) Subsidy is available between 1 March and 30 June of each year for patients who meet the following criteria, as set by the Ministry of Health: a) all people 65 years of age and over; b) people under 65 years of age with: i) the following cardiovascular disease: 1) ischaemic heart disease, 2) congestive heart disease, 3) rheumatic heart disease, 4) congenital heart disease, or 5) cerebo-vascular disease; ii) the following chronic respiratory disease: 1) asthma, if on a regular preventative therapy, or 2) other chronic respiratory disease with impaired lung function; iii) diabetes; iv) chronic renal disease; v) any cancer, excluding basal and squamous skin cancers if not invasive; vi) the following other conditions: 1) autoimmune disease, 2) immune suppression, 3) HIV, 4) transplant recipients, 5) neuromuscular and CNS diseases, 6) haemoglobinopathies, or 7) children on long term aspirin. The following conditions are excluded from funding: i) asthma not requiri
Special Authority for Subsidy - Form SA0772Initial application only from a gastroenterologist, infectious disease specialist, paediatrician or general physician. Approvals valid for 1 year for applications meeting the following criteria: Both: 1 Any of the following: 1.1 All of the following: 1.1.1 HBsAg positive for more than 6 months; and 1.1.2 HBeAg positive or HBV DNA positive defined as >0.6 pg/ml by quantitative PCR at reference laboratory; and 1.1.3 ALT greater than twice upper limit of normal or stage 3 or 4 fibrosis on liver histology clinical/radiological evidence of cirrhosis; or 1.2 HBV DNA positive cirrhosis prior to liver transplantation; or 1.3 HBsAg positive and have had a liver, kidney, heart, lung or bone marrow transplant; or 1.4 Hepatitis B surface antigen positive (HbsAg) patient who is receiving chemotherapy for a malignancy, or who has received such treatment within the previous two months; and 2 All of the following: 2.1 No continuing
Special Authority for Subsidy - Form SA0776Initial application only from a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Any of the following: 1 Both: 1.1 The patient has ovarian, fallopian* or primary peritoneal cancer*; and 1.2 Either: 1.2.1 Has not received prior chemotherapy; or 1.2.2 Has received prior chemotherapy but has not previously been treated with taxanes; or 2 The patient has metastatic breast cancer; or 3 Both: 3.1 The patient has non-small cell lung cancer; and 3.2 Either: 3.2.1 The patient has advanced disease (stage IIIa or above); or 3.2.2 The patient is receiving combined chemotherapy and radiotherapy; or 4 Both: 4.1 The patient has small-cell lung cancer*; and 4.2 Paclitaxel is to be used as second-line therapy. Renewal only from a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Both: 1 The patient has metastati
Special Authority for Subsidy - Form SA0777Initial application - (Post-transplant) only from a relevant specialist. Approvals valid for 6 months where the patient has B-cell post-transplant lymphoproliferative disorder*. NoteFor no more than 8 treatment cycles. Initial application - (Low-grade lymphomas) only from a relevant specialist. Approvals valid for 6 months where the patient has low grade NHL - relapsed disease following prior chemotherapy. NoteFor no more than 4 treatment cycles. Initial application - (Large cell lymphomas) only from a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Both: 1 The patient has treatment naive large B-cell NHL; and 2 To be used with CHOP (or alternative anthracycline containing multi-agent chemotherapy regime given with curative intent).NoteFor no more than 8 treatment cycles. Renewal - (Low-grade lymphomas) only from a relevant specialist. Approvals valid for 6 months for applications meeting
Special Authority for Subsidy - Form SA0779Initial application - (Confirmed HIV/AIDS) only from a named specialist. Approvals valid without further renewal unless notified for applications meeting the following criteria: Both: 1 Confirmed HIV infection; and 2 Any of the following: 2.1 Symptomatic patient; or 2.2 Patient aged 12 months and under; or 2.3 Both: 2.3.1 Patient aged 1 to 5 years; and 2.3.2 Any of the following: 2.3.2.1 CD4 counts < 1,000 cells/mm3; or 2.3.2.2 CD4 counts < 0.25 x total lymphocyte count; or 2.3.2.3 Viral load counts > 100,000 copies per ml; or 2.4 Both: 2.4.1 Patient aged 6 years and over; and 2.4.2 CD4 counts < 350 cells/mm3. NoteTenofovir disoproxil fumarate prescribed under endorsement for HIV/AIDS is included in the count of up to 3 subsidised antiretrovirals. Subsidies for a combination of up to three anti-retroviral medications, including a maximum of two protease inhibitors. Combinations including r
Special Authority for Subsidy - Form SA0780Initial application - (Single NAED Therapy) only from a paediatrician, neurologist or general physician. Approvals valid for 15 months for applications meeting the following criteria: Any of the following: 1 Was on NAED therapy before 1 September 2000; or 2 Seizures are not adequately controlled with optimal older anti-epilepsy drug treatment; or 3 Seizures are controlled adequately but who experience unacceptable side effects from older anti-epilepsy drug treatment. Note"Optimal older anti-epilepsy drug therapy" is defined as treatment with those older anti-epilepsy drugs which are indicated and clinically appropriate for the patient, given singly and in combination in adequate doses for the patient's age, weight, and other features affecting the pharmacokinetics of the drug with good evidence of complianceInitial application - (Dual NAED Therapy) only from a paediatrician, neurologist or general physician. Approvals valid for 18 months for app
Special Authority for Subsidy - Form: SA0781Initial application only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria: Any of the following: Monotherapy1 All of the following: 1.1 To be used as monotherapy for patients with type 2 diabetes who after six months of diet and lifestyle changes do not have adequate glycaemic control (inadequate control defined as HbA1c > 7.0% in tests carried out at least two months apart); and 1.2 Metformin is not tolerated or contraindicated. Intolerance and contraindications as defined in the notes below, a minimum of a four week trial period of metformin is required; and 1.3 Sulphonylurea is not tolerated or contraindicated. Obesity is only eligible under the criteria of contraindication to sulphonylureas if the patient's body mass index (BMI) exceeds 33 , intolerance as defined in the notes below; orIn combination with sulphonylurea2 Both: 2.1 For use in combination with a sulphonylure
Special Authority for Subsidy - Form SA0782Initial application - (No previous use) only from a relevant specialist or general practitioner. Approvals valid for 6 months for applications meeting the following criteria: All of the following: 1 The patient has a clinical diagnosis of heavy menstrual bleeding; and 2 The patient has failed to respond to or is unable to tolerate other appropriate pharmaceutical therapies as per the Heavy Menstrual Bleeding Guidelines; and 3 Either: 3.1 serum ferritin level < 16 mg/l (within the last 12 months); or 3.2 haemoglobin level < 120 g/l . NoteApplications are not to be made for use in patients as contraception except where they meet the above criteriaInitial application - (Previous use before 1 October 2002) only from a relevant specialist or general practitioner. Approvals valid for 6 months for applications meeting the following criteria: All of the following: 1 The patient had a clinical diagnosis of heavy menstrual bleeding; and 2
Special Authority for Manufacturers Price - Form SA0788Initial application only from a relevant specialist or general practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria: Both: 1 Patient has a calculated absolute risk of cardiovascular disease of at least 15% over 5 years; and 2 Either: 2.1 Patient has severe documented intolerance to simvastatin (blood tests are not required); or 2.2 Both: 2.2.1 Patient has been compliant with a dose of simvastatin of 80 mg per day for at least 2 months; and 2.2.2 Either: 2.2.2.1 All of the following: 2.2.2.1.1 Patient has venous CABG; and 2.2.2.1.2 LDL cholesterol test 1 >= 2.0 mmol/litre; and 2.2.2.1.3 LDL cholesterol test 2 >= 2.0 mmol/litre (at least 1 week after test 1); or 2.2.2.2 All of the following: 2.2.2.2.1 Patient does not have venous CABG; and 2.2.2.2.2 LDL cholesterol test 1 >= 2.5 mmol/litre; and 2.2.2.2.
Special Authority for Subsidy - Form SA0789Initial application only from a relevant specialist or vocationally registered general practitioner. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 The patient has "treatment resistant" depression; and 2 Either: 2.1 The patient must have had a trial of two different antidepressants and failed to respond to an adequate dose over an adequate period of time (usually at least four weeks); or 2.2 Both: 2.2.1 The patient is currently a hospital in-patient as a result of an acute depressive episode; and 2.2.2 The patient must have had a trial of one other antidepressant and failed to respond to an adequate dose over an adequate period of time. Renewal from any medical practitioner. Approvals valid for 2 years where patient has a high risk of relapse (prescriber determined).
Special Authority for Subsidy - Form: SA0792Initial application only from a psychiatrist. Approvals valid for 6 months for applications meeting the following criteria: All of the following: 1 The patient has schizophrenia or other psychotic disorder; and2 Has tried but failed to comply with treatment using oral atypical anti-psychotic agents; and3 Has been admitted to hospital or treated in respite care, or intensive outpatient or home-based treatment for 30 days or more in last 12 months. Renewal only from a psychiatrist. Approvals valid for 12 months for applications meeting the following criteria: Either: 4 Both: 4.1 The patient has had less than 12 months treatment with risperidone microspheres; and 4.2 There is no clinical reason to discontinue treatment; or5 The initiation of risperidone microspheres has been associated with fewer days of intensive intervention than was the case during a corresponding period of time prior to the initiation of risperidone microspheres. NoteRisp
Special Authority for Subsidy - Form: SA0796Initial application only from a relevant specialist. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 Either: 1.1 ezetimibe is to be used in combination with simvastatin; or 1.2 ezetimibe is to be used without a statin; and2 Either: 2.1 All of the following: 2.1.1 Patient has a calculated absolute risk of cardiovascular disease >20% over 5 years; and 2.1.2 Patient cannot tolerate statin therapy at a dose of 40 mg per day; and 2.1.3 Either: 2.1.3.1 All of the following: 2.1.3.1.1 Patient has venous CABG; and 2.1.3.1.2 LDL cholesterol >= 2.0 mmol/litre (see note); and 2.1.3.1.3 LDL cholesterol >= 2.0 mmol/litre (at least 1 week after test 1 - see note); or 2.1.3.2 All of the following: 2.1.3.2.1 Patient does not have venous CABG; and 2.1.3.2.2 LDL cholesterol >= 2.5 mmol/litre (see note); and 2.1.3.2.3 LDL cholest
Special Authority for Subsidy - Form: SA0797Initial application - (Underlying cause - Osteoporosis) only from a relevant specialist or vocationally registered general practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria: Any of the following: 1 History of one significant osteoporotic fracture demonstrated radiologically and documented bone mass density (BMD) >= 2.5 standard deviations below the mean normal value in young adults (i.e. T-Score <= -2.5); or2 History of one significant osteoporotic fracture demonstrated radiologically and the patient is either over 75 years of age or is too frail* to undergo a bone mass density scan; or3 History of two significant osteoporotic fractures demonstrated radiologically; or4 Documented T-Score <= -3.0. Note*The patient may be considered to be frail if it is expected that there is significant risk of further fracture or other negative health outcome if the patient were to undergo a BMD s
Special Authority for Subsidy - Form SA0801Initial application - (Serevent Accuhaler, Foradil, Symbicort Turbuhaler) only from a relevant specialist or general practitioner. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 Both: 1.1 Child under the age of 12 with poorly controlled asthma; and 1.2 Either: 1.2.1 Required at least three months of 400 mcg or more daily inhaled beclomethasone or budesonide; or 1.2.2 Required at least three months of 200 mcg or more of fluticasone; or 2 Both: 2.1 Adult with poorly controlled asthma; and 2.2 Either: 2.2.1 Required at least three months of 1500 mcg or more daily inhaled beclomethasone or budesonide; or 2.2.2 Required at least three months of 750 mcg or more of fluticasone. NotePatients are to be reviewed at least at six months to assess compliance and effectiveness of therapy. Special Authority approvals are interchangeable among all presentations of inhaled long-acting beta
Special Authority for Subsidy - Form SA0802Initial application - (genotype 1, 4, 5 or 6 infection or co-infection with HIV) from any specialist. Approvals valid for 11 months for applications meeting the following criteria: 1. Patient has chronic hepatitis C, genotype 1, 4, 5 or 6 infection; or2. Patient has chronic hepatitis C and is co-infected with HIV. Note: consider stopping treatment if there is absence of a virological response (defined as at least a 2-log reduction in viral load) following 12 weeks of treatment since this is predictive of treatment failure.Initial application - (genotype 2 or 3 infection without co-infection with HIV) from any specialist. Approvals valid for 6 months for applications meeting the following criteria: 3. Patient has chronic hepatitis C, genotype 2 or 3 infection; andEither: 3.1 Patient has bridging fibrosis or cirrhosis (Metavir stage 3 or 4 or equivalent); or 3.2 is unsuitable for liver biopsy due to coagulopathy.
Prescribing Guideline for Inhaled Long-Acting Beta-Adrenoceptor AgonistsThe addition of inhaled long-acting beta-adrenoceptor agonists (LABAs) to inhaled corticosteroids is recommended: - For younger children (aged under 12 years) where asthma is poorly controlled despite using inhaled corticosteroids for at least three months at total daily doses of 200 mcg beclomethasone or budesonide (or 100 mcg fluticasone).- For adults and older children (aged 12 years and over) where asthma is poorly controlled despite using inhaled corticosteroids for at least three months at total daily doses of 400 mcg beclomethasone or budesonide (or 200 mcg fluticasone).Note: Further information on the place of inhaled corticosteroids and inhaled LABAs in the management of asthma can be found in the New Zealand guidelines for asthma in adults (www.nzgg.org.nz) and in the New Zealand guidelines for asthma in children aged 1-15 (www.paediatrics.org.nz).
Access by applicationa) Budget managed by appointed clinicians on the Multiple Sclerosis Treatment Assessments Committee (MSTAC). b) Applications will be considered by MSTAC at its regular meetings and approved subject to eligibility according to the Entry and Stopping criteria (below). c) Applications to be made on the approved forms which are available from the co-ordinator for MSTAC:The Co-ordinator Phone: (04) 460 4990Multiple Sclerosis Treatment Assessments Committee Facsimile: (04) 916 7571PHARMAC, PO Box 10 254 E mail: silvia.valsenti@pharmac.govt.nzWellingtond) Completed application forms must be sent to the co-ordinator for MSTAC and will be considered by MSTAC at the next practicable opportunity. e) Notification of MSTAC's decision will be sent to the patient, the applying clinician and the patient's GP (if specified). f) These agents will not be subsidised if dispensed from a community or hospital pharmacy. Regular supplies will be distributed to all approved patients or their c
Special Authority for Subsidy - Form: SA0809Initial application only from a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Any of the following: 1 Both: 1.1 The patient has ovarian*, fallopian* or primary peritoneal cancer*; and 1.2 Either: 1.2.1 Has not received prior chemotherapy; or 1.2.2 Has received prior chemotherapy but has not previously been treated with taxanes; or2 The patient has metastatic breast cancer; or3 Both: 3.1 The patient has non small-cell lung cancer; and 3.2 Either: 3.2.1 Has advanced disease (stage IIIa or above); or 3.2.2 Is receiving combined chemotherapy and radiotherapy; or4 Both: 4.1 The patient has small-cell lung cancer*; and 4.2 Docetaxel is to be used as second-line therapy. Renewal only from a relevant specialist. Approvals valid for 12 months for applications meeting the followingcriteria: 5. The patient has metastatic breast cancer, non small-cell lung cancer,
Special Authority for SubsidyInitial application only from a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria: All of the following1 Patient is an adult who has had severe and active erosive Rheumatoid Arthritis for six months duration or longer; and2 Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and3 Patient has tried and not responded to at least three months of oral or parenteral methotrexate at a dose of at least 20 mg weekly or a maximum tolerated dose; and4 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with at least two of the following (triple therapy): sulphasalazine, prednisone at a dose of at least 7.5 mg per day, azathioprine, intramuscular gold, or hydroxychloroquine sulphate (at maximum tolerated doses); and5 Patient has tried and not responded to at least three months therapy at th
Special Authority for Subsidy Initial application - (for new patients) only from a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Both: 1 The patient has refractory, progressive or relapsed multiple myeloma; and2 The patient has received prior chemotherapy. Initial application - (for patients receiving thalidomide prior to 1 January 2006) only from a relevant specialist. Approvals valid without further renewal where the patient was receiving treatment with thalidomide for multiple myeloma on or before 31 December 2005. Renewal only from a relevant specialist. Approvals valid without further renewal where the patient has obtained a response from treatment during the initial approval period. Note: Prescription must be written by registered prescriber in the thalidomide risk management programme operated by the supplier. Maximum dose of 400 mg daily as monotherapy or in a combination therapy regimen.
Special Authority for Subsidy Initial application for patients with type 2 diabetes only from a relevant specialist. Approvals valid for one year for applications meeting the following criteria: Any of the following: Monotherapy1 All of the following: 1.1 To be used as monotherapy for patients who after six months of diet and lifestyle changes have inadequate glycaemic control (defined as HbA1c > 7.0% in tests carried out at least two months apart); and 1.2 Metformin is contraindicated or not tolerated after a minimum of a four week trial period; and 1.3 Sulphonylurea is contraindicated or not tolerated or the patient's body mass index (BMI) exceeds 33 kg/m2; orIn combination with sulphonylurea2 Both: 2.1 For use in combination with a sulphonylurea for patients who after diet and lifestyle changes and a six-month trial of sulphonylurea have poor glycaemic control (defined as HbA1c > 8.0% measured within the last month of the six month period); and 2.2 Metformin is contrain
Perindopril and trandolapril will be funded to the level of the ex-manufacturer price listed in the Schedule for patients who were taking these ACE inhibitors for the treatment of congestive heart failure prior to 1 June 1998. The prescription must be endorsed accordingly. We recommend that the words used to indicate eligibility are "certified condition" or an appropriate description of the patient such as "congestive heart failure", "CHF", "congestive cardiac failure" or "CCF". Definition of Congestive Heart Failure At the request of some prescribers the PTAC Cardiovascular subcommittee has provided a definition of congestive heart failure for the purposes of the funding of the manufacturer's surcharge: "Clinicians should use their clinical judgement. Existing patients would be eligible for the funding of the surcharge if the patient shows signs and symptoms of congestive heart failure, and requires or has in the past required concomitant treatment with a diuretic. The definition could also be considere
Special Authority for Subsidy - Form: SA0826Initial application only from a relevant specialist. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 All of the following: 1.1 Patient has a calculated absolute risk of cardiovascular disease >20% over 5 years; and 1.2 Patient cannot tolerate statin therapy at a dose of >= 40 mg per day; and 1.3 Either: 1.3.1 All of the following: 1.3.1.1 Patient has venous CABG; and 1.3.1.2 LDL cholesterol >= 2.0 mmol/litre (see note); and 1.3.1.3 LDL cholesterol >= 2.0 mmol/litre (at least 1 week after test 1 - see note); or 1.3.2 All of the following: 1.3.2.1 Patient does not have venous CABG; and 1.3.2.2 LDL cholesterol >= 2.5 mmol/litre (see note); and 1.3.2.3 LDL cholesterol >= 2.5 mmol/litre (at least 1 week after test 1 - see note); or2 All of the following: 2.1 Patient has homozygous familial hypercholesterolemia, or heterozygous familial hypercholest
Special Authority for Subsidy - Retail Pharmacy - Form SA0829Initial Application only from gastroenterologist or infectious disease specialist. Approvals valid for 1 year for applications meeting the following criteria: All of the following: 1. Patient has confirmed Hepatitis B infection (HBsAg+); andDocumented resistance to lamivudine, defined as: 2. patient has raised serum ALT (> 1 x ULN); and3. patient has HBV DNA greater than 100,000 copies per mL, or viral load ? 10 fold over nadir; and4. detection of M204I or M204V mutation; and5. Either5.1. Both5.1.1. patient is cirrhotic; and5.1.2. adefovir dipivoxil to be used in combination with lamivudine; or5.2. Both5.2.1. patient is not cirrhotic; and5.2.2. adefovir dipivoxil to be used as monotherapyRenewal only from a gastroenterologist or infectious disease specialist. Approvals valid for 2 years for applications where in the opinion of the treating physician, treatment remains appropriate and patient is benefiting from treatmen
Special Authority for Subsidy - Form: SA0832Initial application only from a gastroenterologist, infectious disease specialist, paediatrician or general physician. Approvals valid for 1 year for applications meeting the following criteria: Both: 1 Any of the following: 1.1 All of the following: 1.1.1 HBsAg positive for more than 6 months; and1.1.2 HBeAg positive or HBV DNA positive defined as > 100,000 copies per ml by quantitative PCR at a reference laboratory; and1.1.3 ALT greater than twice upper limit of normal or bridging fibrosis or cirrhosis (Metavir stage 3 or 4 or equivalent) on liver histology or clinical/radiological evidence of cirrhosis; or 1.2 HBV DNA positive cirrhosis prior to liver transplantation; or1.3 HBsAg positive and have had a liver, kidney, heart, lung or bone marrow transplant; or1.4 Hepatitis B surface antigen positive (HbsAg) patient who is receiving chemotherapy for a malignancy, or who has received such treatment within the previous two months;
Special Authority for Subsidy - Form SA0833Initial application only from a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Any of the following: 1 The patient has non small cell lung carcinoma (stage IIIa, or above); or2 The patient has advanced malignant mesothelioma*; or3 The patient has advanced pancreatic carcinoma; or4 The patient has ovarian, fallopian tube* or primary peritoneal carcinoma*; or5 The patient has advanced transitional cell carcinoma of the urothelial tract (locally advanced or metastatic). Renewal only from a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Both: 6 The patient requires continued therapy; or7 The tumour has relapsed and requires re-treatment. Note indications marked with a * are unapproved indications.
Special Authority for Subsidy - Form: SA0834Initial application only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria: Either: 1 Both: 1.1 Patient has type 1 diabetes and has received an intensive regimen (injections at least three times a day) of an intermediate acting insulin in combination with a rapid acting insulin analogue for at least three months; and1.2 Either: 1.2.1 Patient has experienced more than one unexplained severe hypoglycaemic episode in the previous 12 months (severe defined as requiring the assistance of another person); or1.2.2 Patient has experienced unexplained symptomatic nocturnal hypoglycaemia, biochemically documented at <3.0 mmol/L, more than once a month despite optimal management; or2 Patient has documented severe, or continuing, systemic or local allergic reaction to existing insulins. Note this does not include hypoglycaemic episodes. Renewal only from a relevant specialist or general practitioner. Approv
Special Authority for Subsidy - Form SA0835Initial application - (Breast cancer) from any medical practitioner. Approvals valid for 1 year: where the patient is a premenopausal woman with breast cancer. Initial application - (Prostate cancer) only from an oncologist, urologist or endocrinologist. Approvals valid for 1 year for applications meeting the following criteria: Advanced prostatic cancer;. Note Not to be prescribed with an anti-androgen except for a period of three weeks, if necessary, when GnRH analogue therapy is initiated. Initial application - (Endometriosis) only from a gynaecologist. Approvals valid for 3 months for applications meeting the following criteria: Both: 1 Endometriosis; and2 Either: 2.1 6 months treatment with medroxyprogesterone acetate, danazol or dimetriose has proven ineffective; or2.2 The patient has failed to tolerate the treatment with medroxyprogesterone acetate, danazol or dimetriose for 6 months. Note The maximum treatment period for a GnRH analogue is:
Special Authority for Subsidy - Form SA0836Initial application - (Breast cancer) from any medical practitioner. Approvals valid for 1 year where the patient is a premenopausal woman with breast cancer. Initial application - (Prostate cancer) only from an oncologist, urologist or endocrinologist. Approvals valid for 1 year for applications meeting the following criteria: Either: 1 Advanced prostatic cancer; or. 2 Locally advanced prostatic cancer. Note Not to be prescribed with an anti-androgen except for a period of three weeks, if necessary, when GnRH analogue therapy is initiated. Initial application - (Endometriosis) only from a gynaecologist. Approvals valid for 3 months for applications meeting the following criteria: Both: 3 Endometriosis; and4 Either: 4.1 6 months treatment with medroxyprogesterone acetate, danazol or dimetriose has proven ineffective; or4.2 The patient has failed to tolerate the treatment with medroxyprogesterone acetate, danazol or dimetriose for 6 months. Note
Special Authority for Subsidy - Form SA0837Initial application - (Breast cancer) from any medical practitioner. Approvals valid for 1 year where the patient is a premenopausal woman with breast cancer. Initial application - (Prostate cancer) only from an oncologist, urologist or endocrinologist. Approvals valid for 1 year where the patient has: Advanced prostatic cancer;. Note Not to be prescribed with an anti-androgen except for a period of three weeks, if necessary, when GnRH analogue therapy is initiated. Initial application - (Endometriosis) only from a gynaecologist. Approvals valid for 3 months for applications meeting the following criteria: Both: 1 Endometriosis; and2 Either: 2.1 6 months treatment with medroxyprogesterone acetate, danazol or dimetriose has proven ineffective; or2.2 The patient has failed to tolerate the treatment with medroxyprogesterone acetate, danazol or dimetriose for 6 months. Note The maximum treatment period for a GnRH analogue is: - 3 months to assess whet
Special Authority for Subsidy - Form: SA0838Initial Application only from a relevant specialist or General Practitioner. Approvals valid for 2 years forapplications meeting the following criteria: Either: 1 All of the following: 1.1 Patient is a child under the age of 12; and1.2 All of the following: Has, for 3 months or more, been treated with:1.2.1 An inhaled long-acting beta adrenoceptor agonist; and1.2.2 Inhaled corticosteroids at a dose of at least 400 mcg per day beclomethasone or budesonide, or200 mcg per day fluticasone; and1.3 The prescriber considers that the patient would receive additional clinical benefit from switching to acombination product; or2 All of the following: 2 .1 Patient is over the age of 12; and2 .2 All of the following: Has, for 3 months or more, been treated with:2 .2.1 An inhaled long-acting beta adrenoceptor agonist; and2 .2.2 Inhaled corticosteroids at a dose of at least 800 mcg per day beclomethasone or budesonide, or500 mcg per day fluticasone;
Special Authority for Subsidy - Form SA0839Initial application - (Breast cancer) from any medical practitioner. Approvals valid for 1 year where the patient is a premenopausal woman with breast cancer. Initial application - (Prostate cancer) only from an oncologist, urologist or endocrinologist. Approvals valid for 1 year for applications meeting the following criteria: Either: 1 Advanced prostatic cancer; or. 2 Neoadjuvant or adjuvant treatment of locally advanced prostatic cancer. Note Not to be prescribed with an anti-androgen except for a period of three weeks, if necessary, when GnRH analogue therapy is initiated. Initial application - (Endometriosis) only from a gynaecologist. Approvals valid for 3 months for applications meeting the following criteria: Both: 3 Endometriosis; and4 Either: 4.1 6 months treatment with medroxyprogesterone acetate, danazol or dimetriose has proven ineffective; or4.2 The patient has failed to tolerate the treatment with medroxyprogesterone acetate, danazo
Special Authority for Subsidy - form: SA0841Initial application only from a gastroenterologist or general physician. Approvals valid for 6 months for applications meeting the following criteria: Both: 1 Primary biliary cirrhosis confirmed by antimitochondrial antibody titre (AMA) > 1:80, and raised cholestatic liver enzymes with or without raised serum IgM or, if AMA is negative, by liver biopsy; and2 Patient not requiring a liver transplant (bilirubin > 170umol/l; decompensated cirrhosis). NoteLiver biopsy is not usually required for diagnosis but is helpful to stage the diseaseRenewal only from a gastroenterologist or general physician. Approvals valid for 2 years for applications meeting the following criteria: The treatment remains appropriate and the patient is benefiting from treatment. NoteActigall is not an appropriate therapy for patients requiring a liver transplant (bilirubin > 170 micromol/l; decompensated cirrhosis). These patients should be referred to an appropriate transp
Special Authority for Subsidy - Form: SA842Initial application only from a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Any of the following: 1 Both: 1.1 The patient has ovarian, fallopian* or primary peritoneal cancer*; and 1.2 Either: 1.2.1 Has not received prior chemotherapy; or 1.2.2 Has received prior chemotherapy but have not previously been treated with taxanes; or2 The patient has metastatic breast cancer; or3 The patient has node-positive early breast cancer; or4 Both 4.1 The patient has non small-cell lung cancer; and 4.2 Either: 4.2.1 Has advancing disease (stage IIIa or above); or 4.2.2 Is receiving combined chemotherapy and radiotherapy; or5 Both: 5.1 The patient has small-cell lung cancer*; and 5.2 Paclitaxel is to be used as second-line therapy. Renewal only from a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: 6 The patient has metasta
Special Authority for Subsidy - Form SA0028Initial application only from a relevant specialist. Approvals valid for 6 months for applications meeting the following criteria: Either: 1 All of the following: 1.1 Treatment with other lipid modifying medicines has been unsuccessful; and 1.2 6 months of dietary modification has been unsuccessful; and 1.3 Cholesterol level > 7.0 mmol/litre; and 1.4 Either: 1.4.1 Familial hypercholesterolaemia; or 1.4.2 Manifest coronary heart disease, which has been clinically proven, or previously treated by coronary artery surgery; or 2 Cholesterol level > 9.0 mmol/litre:.Renewal only from a general practitioner. Approvals valid for 6 months where the treatment remains appropriate and the patient is benefiting from treatment. NoteFamilial hypercholesterolaemia is defined as being hypercholesterolaemia in the presence of tendon xanthomas or in association with a family history of premature heart disease (before age 55) or consisten
Special Authority for Subsidy - Form SA0089Initial application - (Breast or prostatic cancer) only from an oncologist, urologist or endocrinologist. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 Breast cancer in pre menopausal women unwilling or unable to undergo surgical or radiation oophorectomy; or 2 Advanced prostatic cancer when orchidectomy is contraindicated. Initial application - (Endometriosis) only from a gynaecologist. Approvals valid for 6 months for applications meeting the following criteria: Both: 1 Endometriosis; and 2 Either: 2.1 6 months treatment with medroxyprogesterone acetate, danazol or dimetriose has proven ineffective; or 2.2 The patient has failed to tolerate the treatment with medroxyprogesterone acetate, danazol or dimetriose for 6 months. NoteThe maximum treatment period for a GnRH analogue is: 3 months to assess whether surgery is appropriate3 months for infertile patients after surgery6 months for
Special Authority for Subsidy - Form SA0096Initial application - (Organ transplant, Bone marrow transplant or Graft v host disease) only from a relevant specialist. Approvals valid for 2 years for applications meeting the following criteria: Any of the following: 1 Organ transplant; or 2 Bone marrow transplant; or 3 Graft v host disease. Initial application - (Psoriasis) only from a dermatologist. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 Psoriasis; and 2 Other systemic and topical therapy has failed. Initial application - (Severe atopic dermatitis) only from a dermatologist. Approvals valid for 6 months for applications meeting the following criteria: Both: 1 Severe atopic dermatitis; and 2 Not resopnsive to topical therapy, oral antihistamines and other commonly used orthodox therapies. Initial application - (Nephrotic Syndrome) from any medical practitioner. Approvals valid for 2 years for applications meeting the following cri
Special Authority for Subsidy - Form SA0097Initial application - (Chronic hepatitis C) only from a relevant specialist. Approvals valid for 6 months where chronic hepatitis C. Initial application - (Indications other than Chronic hepatitis C) only from a relevant specialist. Approvals valid for 5 years for applications meeting the following criteria: Any of the following: 1 Chronic myelogenous leukaemia; or 2 Hairycell leukaemia; or 3 Cutaneous T cell lymphoma; or 4 Essential thrombocythaemia; or 5 AIDS related Kaposi's sarcoma; or 6 Multiple myeloma; or 7 Chronic active hepatitis B. Renewal - (Chronic hepatitis C) only from a relevant specialist. Approvals valid for 6 months where the treatment remains appropriate and the patient is benefiting from treatment. Renewal - (Indications other than Chronic hepatitis C) only from a relevant specialist. Approvals valid for 5 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0099Initial application only from a relevant specialist. Approvals valid for 5 years for applications meeting the following criteria: Any of the following: 1 Both: 1.1 Acromegaly; and 1.2 Patients who have failed surgery, radiotherapy, bromocriptine and other oral therapies; or 2 Both: 2.1 Either: 2.1.1 Vipomas; or 2.1.2 Glucagonomas; and 2.2 Patients who are seriously ill in order to improve their clinical state prior to definitive surgery; or 3 Both: 3.1 Gastrinoma; and 3.2 Either: 3.2.1 Patient has failed surgery; or 3.2.2 Patient is in metastatic disease after H2 antagonists (or omeprazole) have failed; or 4 Both: 4.1 Insulinomas; and 4.2 Surgery is contraindicated or where surgery has failed; or 5 Pre-operative control of hypoglycaemia; or 6 Maintenance therapy. NoteThe use of octreotide in patients with fistulae, oesophageal varices, miscellaneous diarrhoea and hypotension will
Special Authority for Subsidy - Form SA0100Initial application only from a relevant specialist. Approvals valid for 5 years for applications meeting the following criteria: All of the following: 1 Anaemia of end-stage renal failure (other treatable causes of anaemia being excluded); and 2 Been on haemodialysis or continuous ambulatory peritoneal dialysis (CAPD) for at least three months; and 3 Not under evaluation for, or awaiting, a live donor kidney transplant; and 4 Any of the following: 4.1 Anephric; or 4.2 Dependent on regular blood transfusion (1 unit each 4-8 weeks) to maintain haemoglobin > 60g/L; or 4.3 Cannot be transfused because of severe transfusion reactions; or 4.4 Transfusion induced haemosiderosis (clinical manifestations, serum ferritin >1500 ug/L); or 4.5 Haemoglobin < 70 g/L (mean of at least 4 haemoglobin concentrations over 4 months); or 4.6 Both: 4.6.1 Haemoglobin < 90 g/L; and 4.6.2 Either: 4.6.2.1 Heart failure (low card
Approvals for a CHEM number to waive the premium in the following circumstances: 1. Patients with prosthetic heart valves - as an adjunct to oral anticoagulation for prophylaxis of thromboembolism (2 year approval with renewal, applications only from cardiothoracic surgeons, cardiologists and general physicians). 2. Patients after coronary artery vein bypass graft - as an adjunct to aspirin (1 year approval only, applications only from cardiothoracic surgeons, cardiologists and general physicians). 3. Patients who continue to have transient ischaemic episodes despite aspirin therapy. A course of up to six months in combination with aspirin. Applications only from neurologists, cardiologists, vascular surgeons and general physicians. Six month approval only. Reapplications only if there is demonstrated recurrence of symptoms when dipyridamole therapy is discontinued. Note: these transitional criteria are currently being reviewed.
a) Approvals to fund the manufacturer's surcharge in the following circumstances: - Patients with prosthetic heart valves - as an adjunct to oral anticoagulation for prophylaxis of thromboembolism (2 year approval with renewal, applications only from cardiothoracic surgeons, cardiologists and general physicians). - Patients after coronary artery vein bypass graft - as an adjunct to aspirin or as monotherapy for patients who are aspirin intolerant as defined below (1 year approval only, applications only from cardiothoracic surgeons, cardiologists and general physicians); or- Patients who continue to have transient ischaemic episodes despite aspirin therapy or have transient ischaemic episodes and are aspirin intolerant as defined below (2 year approval with renewal, applications only from neurologists, neurosurgeons, cardiologists, vascular surgeons and general physicians). b) Aspirin intolerant patients are defined as those with aspirin induced asthma, urticaria, or anaphylaxi, or those with significant
The new anticonvulsant drugs are restricted to1. neurologists2. paediatric neurologists3. any other prescriber approved in writing by the relevant RHA budget holding manager. The HFA holds a budget for expenditure on the new anticonvulsant drugs. Unless otherwise specified, ultimate authority for approving prescriptions for subsidy lies with the HFA budget holding manager for the new anticonvulsant drugs. The regional divisions of the HFA will be in contact with hospital pharmacists and approved prescribers with more detail of the approval system. GUIDELINES FOR USE OF THE NEW ANTICONVULSANTS ARE AS FOLLOWS: A. Entry criteriaThe following patients are eligible for trial on the new anticonvulsant drugs (NADs)1. Patients who are under the supervision of an approved prescriber, and whose seizures are not adequately controlled with optimal conventional anticonvulsant drug treatment. 2. Patients, who are under the supervision of an approved prescriber, and whose seizures are only controlled adequatel
Special Authority for Subsidy - Form SA0266Initial application - (Chronic hepatitis C) only from a relevant specialist. Approvals valid for 6 months where chronic hepatitis C. NoteMaximum reimbursable dosage 15 million iu/weekInitial application - (Indications other than chronic hepatitis C) only from a dermatologist, plastic surgeon or radiation oncologist. Approvals valid for 5 years for applications meeting the following criteria: Any of the following: 1 Chronic myelogenous leukaemia; or 2 Hairycell leukaemia; or 3 Cutaneous T cell lymphoma; or 4 Essential thrombocythaemia; or 5 AIDS related Kaposi's sarcoma; or 6 Multiple myeloma; or 7 Chronic active hepatitis B; or 8 Basal cell carcinoma unable to be treated surgically or by radiotherapy. NoteMaximum reimbursable dosage 15 million iu/weekRenewal - (Chronic hepatitis C) only from a relevant specialist. Approvals valid for 6 months where the treatment remains appropriate and the patient is benefiting from trea
Lansoprazole is subsidised for patients who have one or more of the following conditions: 1. Duodenal ulcer proven by endoscopy or barium meal and after failure of: a)two alternative courses of H. pylori eradication therapy (if H. pylori positive); and b)H2 antagonist therapy for 8 weeks; and where a second endoscopy/barium meal has demonstrated non healing duodenal ulcer. 2. Gastric ulcer proven by endoscopy and after failure of: a)two alternative courses of H. pylori eradication therapy (if H. pylori positive); andb)H2 antagonist therapy for 12 weeks; and where a second endoscopy has demonstrated non healing gastric ulcer and excluded malignancy. 3. Gastro-oesophageal reflux disease (GORD) proven by endoscopy: i) Grade 0 GORD (normal endoscopy) after positive 24 hour pH monitoring test and failure of H2 antagonist therapy for one month with multiple daily dosing; orii) Grades 1 and 2 GORD after failure of H2 antagonist therapy for one month with multiple daily dosing; or
a) All patients with AIDS meeting the definition developed by the Centres for Disease Control in the USA (see Circular Letter to Medical Practitioners HP2/88)b) Patients with AIDS Related Complex (ARC)c) HIV infected patients with CD4 (T4) counts below 500 regardless of symptomatologyd) Prophylactically for persons following severe parenteral exposure from a known HIV positive sourcee) HIV infected persons with associated thrombocytopenia regardless of CD4 (T4) count f) For the prevention of maternal foetal transmission of HIVg) Applications can only be made by appropriate specialists. Prescriptions for those patients approved to use these medicines can be written either by the specialist or general practitioner with an endorsement of the name of the recommending specialist. h) Prescriptions for these can be written for a period of three months' supply. However, medicine must be dispensed on a monthly basis.
Special Authority for Subsidy - Form SA0274Initial application only from a relevant specialist. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 All of the following: 1.1 Treatment with other lipid modifying medicines has been unsuccessful; and 1.2 6 months of dietary modification has been unsuccessful; and 1.3 Cholesterol level > 7.0 mmol/litre:; and 1.4 Either: 1.4.1 Familial hypercholesterolaemia; or 1.4.2 Manifest coronary heart disease, which has been clinically proven, or previously treated by coronary artery surgery; or 2 Cholesterol level > 9.0 mmol/litre:.NoteFamilial hypercholesterolaemia is defined as being hypercholesterolaemia in the presence of tendon xanthomas or in association with a family history of premature heart disease (before age 55) or consistent with autosomal dominant inheritance. Simvastatin and Pravastatin may be considered for first line therapy in patients with familial hypercholesterolaemia or
Special Authority for Subsidy - Form SA0275Initial application - (Chronic hepatitis C) only from a relevant specialist. Approvals valid for 6 months where chronic hepatitis C. NoteMaximum reimbursable dosage 15 million iu/weekInitial application - (Indications other than chronic hepatitis C) only from a dermatologist, plastic surgeon or radiation oncologist. Approvals valid for 5 years for applications meeting the following criteria: Any of the following: 1 Chronic myelogenous leukaemia; or 2 Hairycell leukaemia; or 3 Cutaneous T cell lymphoma; or 4 Essential thrombocythaemia; or 5 Multiple myeloma; or 6 Chronic active hepatitis B; or 7 Basal cell carcinoma unable to be treated surgically or by radiotherapy. NoteMaximum reimbursable dosage 15 million iu/weekRenewal - (Chronic hepatitis C) only from a relevant specialist. Approvals valid for 6 months where the treatment remains appropriate and the patient is benefiting from treatment. Renewal - (Indications other tha
Special Authority for Subsidy - Form SA0276Initial application - (Chronic hepatitis C) only from a relevant specialist. Approvals valid for 6 months where chronic hepatitis C. NoteMaximum reimbursable dosage 15 million iu/weekInitial application - (Indications other than chronic hepatitis C) only from a dermatologist, plastic surgeon or radiation oncologist. Approvals valid for 5 years for applications meeting the following criteria: Any of the following: 1 Chronic myelogenous leukaemia; or 2 Hairycell leukaemia; or 3 Multiple myeloma; or 4 Chronic active hepatitis B; or 5 Basal cell carcinoma unable to be treated surgically or by radiotherapy. NoteMaximum reimbursable dosage 15 million iu/weekRenewal - (Chronic hepatitis C) only from a relevant specialist. Approvals valid for 6 months where the treatment remains appropriate and the patient is benefiting from treatment. Renewal - (Indications other than chronic hepatitis C) only from a dermatologist, plastic surgeon or radiat
Omeprazole is subsidised for patients who have one or more of the conditions numbered 1-4: 1. Duodenal ulcer proven by endoscopy or barium meal and after failure of: a)two alternative courses of H. pylori eradication therapy (if H. pylori positive); and b)H2 antagonist therapy for 8 weeks; and where a second endoscopy/barium meal has demonstrated non healing duodenal ulcer. 2. Gastric ulcer proven by endoscopy and after failure of: a)two alternative courses of H. pylori eradication therapy (if H. pylori positive); andb)H2 antagonist therapy for 12 weeks; and where a second endoscopy has demonstrated non healing gastric ulcer and excluded malignancy. 3. Gastro-oesophageal reflux disease (GORD) proven by endoscopy: i) Grade 0 GORD (normal endoscopy) after positive 24 hour pH monitoring test and failure of H2 antagonist therapy for one month with multiple daily dosing; orii) Grades 1 and 2 GORD after failure of H2 antagonist therapy for one month with multipl
Special Authority for Subsidy - Form SA0300Initial application - (Breast or prostatic cancer) only from an oncologist, urologist or endocrinologist. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 Breast cancer in pre menopausal women unwilling or unable to undergo surgical or radiation oophorectomy; or 2 Advanced prostatic cancer when orchidectomy is contraindicated. NoteNot in long term combination with an anti-androgenInitial application - (Endometriosis) only from a gynaecologist. Approvals valid for 6 months for applications meeting the following criteria: Both: 1 Endometriosis ; and 2 Either: 2.1 6 months treatment with medroxyprogesterone acetate, danazol or dimetriose has proven ineffective; or 2.2 The patient has failed to tolerate the treatment with medroxyprogesterone acetate, danazol or dimetriose for 6 months. NoteThe maximum treatment period for a GnRH analogue is: 3 months to assess whether surgery is appropriate3 m
Special Authority for Subsidy - Form SA0311Initial application - (Breast or prostatic cancer) only from an oncologist, urologist or endocrinologist. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 Breast cancer in pre menopausal women unwilling or unable to undergo surgical or radiation oophorectomy; or 2 Advanced prostatic cancer when orchidectomy is contraindicated or where the patient srongly opposes orchidectomy. NoteNot to be prescribed with an anti-androgen except for a period of three weeks, if necessary, when GnRH analogue therapy is intiatedInitial application - (Endometriosis) only from a gynaecologist. Approvals valid for 6 months for applications meeting the following criteria: Both: 1 Endometriosis; and 2 Either: 2.1 6 months treatment with medroxyprogesterone acetate, danazol or dimetriose has proven ineffective; or 2.2 The patient has failed to tolerate the treatment with medroxyprogesterone acetate, danazol or dimetrio
Special Authority for Alternate Subsidy - Form SA0312Initial application only from an obstetrician, gynaecologist, general practitioner or general physician. Approvals valid for 5 years for applications meeting the following criteria: Any of the following: 1 acute or significant liver disease - a declaration must be provided from a gastroenterologist or general physician stating that oral oestrogens are contraindicated due to liver disease (Details to be attached to application); or 2 oestrogen induced hypertension requiring antihypertensive therapy - documented evidence must be provided that raised blood pressure levels or inability to control blood pressure adequately occurred post oral oestrogens (Details to be attached to application); or 3 hypertriglyceridaemia - documented evidence must be provided that triglyceride levels increased to at least 2 x normal triglyceride levels post oral oestrogens (Details to be attached to application). NotePrescriptions with a valid Special Authority (
Special Authority for Subsidy - Form SA0317Initial application only from a renal physician. Approvals valid for 2 years for applications meeting the following criteria: All of the following: General Criteria: 1 Anaemia of end-stage renal failure (other treatable causes of anaemia being excluded); and 2 Been on haemodialysis or continuous ambulatory peritoneal dialysis (CAPD) for at least three months; and 3 Not under evaluation for, or awaiting, a live donor kidney transplant; and 4 Any of the following: Specific Criteria: 4.1 Anephric; or 4.2 Dependent on regular blood transfusion (1 unit each 4-8 weeks) to maintain haemoglobin > 60g/L; or 4.3 Cannot be transfused because of severe transfusion reactions; or 4.4 Transfusion induced haemosiderosis (clinical manifestations, serum ferritin >1500 ug/L); or 4.5 Haemoglobin < 70 g/L (mean of at least 4 haemoglobin concentrations over 4 months); or 4.6 Both: 4.6.1 Haemoglobin < 90 g/L; and 4.6.2 Either:
a) All nucleosides will be subsidised for patients meeting any of the following criteria: - All patients with AIDS meeting the definition developed by the Centers for Disease Control in the USA (see Circular Letter to Medical Practitioners HP2/88); or- Patients with AIDS Related Complex (ARC); or- HIV infected patients with CD4 (T4) counts below 500 regardless of symptomatology. b) Zidovudine will also be subsidised for patients meeting any of the following criteria: - Prophylactically for persons following severe parenteral exposure from a known HIV positive source; or- HIV infected persons with associated thrombocytopenia regardless of CD4 (T4) count; or- For the prevention of maternal foetal transmission of HIV. c) Applications can only be made by appropriate specialists. d) Prescriptions for those patients approved to use these medications can be written by either the specialist or general practitioner with an endorsement of the name of the recommending specialist.
Guidelines for use of cyclosporin A in rheumatoid arthritisMonitoring: All patients require frequent monitoring for creatinine levels and blood pressure:- fortnightly, in the first three months of therapy and then monthly, if results are stable; - if dose is increased or there is a rise in serum creatinine or blood pressure, then more frequent monitoring is required. Contraindications: Cyclosporin A is contraindicated in patients with the following conditions: - current or past malignancy; - uncontrolled hypertension; - renal dysfunction (abnormal serum creatinine for age and sex); - immunodeficiency and neutropenia; - abnormally low white blood cell count or platelet count; or- liver function tests more than twice the upper limit of normal. Caution in use: - age above 65 years; - controlled hypertension; - use of ant-epileptic medications; - use of NSAIDs; - use of ketoconazole, fluconazole, trimethoprim, erythromycin, verapamil, and diltiazem; - concurrent or previous use of al
Special Authority - Retail pharmacy (Salmeterol, eformoterol fumarate):a) Approvals are interchangeable between all presenations of salmeterol and eformoterol fumarate agents. b) Diagnosis of asthma confirmed. c) Inhaler/device technique checked. d) At least three months of >= 1500 ug daily of beclomethasone inhaled steroid (or equivalent) for adult, or >= 800 ug daily for child. e) Patient monitors PEFR regularly during exacerbations where appropriate. f) Evidence of poor control (at least one of the following): - short acting beta agonist used > 3-4 time daily - nocturnal awakenings >= 2 times per week. g) The first applicaton may be for six months and subsequent applications for two yars. The criteria for reapplication are: - compliant with medication - improved asthma symptom control. h) Appication for Special Authority to be made by general practitioners or appropriate specialist.
Omeprazole and pantoprazole is subsidised for patients who have one or more of the conditions a-d: a) Duodenal ulcer proven by endoscopy or barium meal and after failure of: - two alternative courses of H. pylori eradication therapy (if H. pylori positive); and - H2 antagonist therapy for 8 weeks; and where a second endoscopy/barium meal has demonstrated non healing duodenal ulcer. b) Gastric ulcer proven by endoscopy and after failure of: - two alternative courses of H. pylori eradication therapy (if H. pylori positive); and - H2 antagonist therapy for 12 weeks; and where a second endoscopy has demonstrated non healing gastric ulcer and excluded malignancy. c) Gastro-oesophageal reflux disease (GORD) proven by endoscopy: - Grade 0 GORD (normal endoscopy) after positive 24 hour pH monitoring test and failure of H2 antagonist therapy for four weeks with multiple daily dosing; or - Grades 1 and 2 GORD after failure of H2 antagonist therapy for
Special Authority for Subsidy - Form SA0366Initial application - (North Island patients) from any medical practitioner. Approvals valid for 5 years where the patient is likely to benefit from treatment. NoteFor details of the patient criteria, prescriber criteria, application and reporting forms contact the appointed clinician: Dr Richard FisherFertility Associates131 Remuera RoadAUCKLANDFax: 09 520 0499Appointed clinicians will distribute these agents to prescribers whose applications are approvedInitial application - (South Island patients) from any medical practitioner. Approvals valid for 5 years where the patient is likely to benefit from treatment. NoteFor details of the patient criteria, prescriber criteria, application and reporting forms contact the appointed clinician: Dr Peter BennyChristchurch Women's HospitalPrivate Bag 4711CHRISTCHURCHFax: 03 364 4634Appointed clinicians will distribute these agents to prescribers whose applications are approved
Special Authority for Subsidy - Form SA0382Initial application only from a gastroenterologist, general surgeon or general physician. Approvals valid for 3 years for applications meeting the following criteria: Any of the following: 1 All of the following: 1.1 Duodenal ulcer proven by endoscopy or barium meal; and 1.2 Failure of two alternative courses of H. pylori eradication therapy (if H. pylori positive); and 1.3 Non healing duodenal ulcer proven by second barium meal; and 1.4 H2 antagonist therapy for 8 weeks; or 2 All of the following: 2.1 Gastric ulcer proven by endoscopy; and 2.2 Two alternative courses of H. pylori eradication therapy (if H. pylori positive); and 2.3 Non healing gastric ulcer and excluded malignancy demonstrated by a second endoscopy; and 2.4 H2 antagonist therapy for 12 weeks; or 3 All of the following: 3.1 Grade 0 GORD (normal endoscopy); and 3.2 Positive 24 hour pH monitoring test; and 3.3 Failure of H2 antagonist t
n) Further approvals to fund the manufacturer's surcharge on either pravastatin or simvastatin (if applicable) may be granted to patients who are unable to continue treatment with fluvastatin due to adverse effects. Either general practitioners or specialist may make the application. To obtain a new Special Authority number, the application must include the following information: - the amount of time the patient has been treated with fluvastatin; and- the adverse effects experienced by the patient. o) Further approvals to fund the manufacturer's surcharge on simvastatin may be granted to patients with familial hypercholesterolaemia (FH) or familial combined hypercholesterolaemia (FCH) if a specialist considers that the patient is not achieving sufficient benefit from the fully funded statin(s). Only specialists may make application. To obtain a new Special Authority number, the application must include the following information: - the cholesterol level before and after treatment with the fully funded sta
Special Authority for Subsidy - Form SA0387Initial application - (Breast or prostatic cancer) only from an oncologist, urologist or endocrinologist. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 Breast cancer in pre menopausal women unwilling or unable to undergo surgical or radiation oophorectomy; or 2 Advanced prostatic cancer when orchidectomy is contraindicated or where the patient srongly opposes orchidectomy. NoteNot to be prescribed with an anti-androgen except for a period of three weeks, if necessary, when GnRH analogue therapy is intiatedInitial application - (Endometriosis) only from a gynaecologist. Approvals valid for 6 months for applications meeting the following criteria: Both: 1 Endometriosis; and 2 Either: 2.1 6 months treatment with medroxyprogesterone acetate, danazol or dimetriose has proven ineffective; or 2.2 The patient has failed to tolerate the treatment with medroxyprogesterone acetate, danazol or dimetrio
Special Authority for Manufacturers Price - Form SA0394Initial application - (Helicobacter pylori infections) only from a general practitioner or relevant specialist. Approvals valid for 6 months for applications meeting the following criteria: Both: 1 Eradication of Helicobacter pylori in patient with proven infection; and 2 Peptic ulcer disease proven by endoscopy. NoteMaximum of two prescriptions (two courses) per patient. Initial application - (Mycobacterial infections) only from a respiratory specialist or infectious disease specialist. Approvals valid for 2 years for applications meeting the following criteria: Any of the following: 1 Mycobacterium Avium Intracellulare Complex infections in patient with AIDS; or 2 Atypical and drug-resistant mycobacterial infection; or 3 All of the following: 3.1 Prophylaxis against disseminated Mycobacterium Avium Intracellulare Complex infection; and 3.2 HIV infection; and 3.3 CD4 count <= 50 cells/mm3. Renewal - (Mycobacteri
a) Cyproterone acetate with ethinyloestradiol is available from retail pharmacy to patients as indicated. b) Prescribers may code prescriptions "contraceptive" (code "O") when used as indicated for contraception. The period of supply and prescription charge will be as per other contraceptives, as follows: - $3.00 prescription charge (patient co-payment) will apply; - Prescription may be written for up to 6 months supply; and- Pharmacists may dispense up to 3 month supply. c) Prescriptions coded in any other way are subject to the non-contraceptive prescription charges, and the non-contraceptive period of supply. Eg. Prescriptons may be written for up to 3 months supply, and dispensed monthly. d) The Special Authority number for hormonal contraceptive agents (combined and progesterone-only) does not apply, and is not interchangeable. e) Health Benefits Limited will return any claims unpaid as follows: - any uncoded prescription; - any prescription that does not have a period of supply or the quantity
Special Authority for Subsidy - Form SA0401Initial application - (Basal cell carcinoma) only from a dermatologist, plastic surgeon or radiation oncologist. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 Basal cell carcinoma unable to be treated surgically or by radiotherapy; and 2 Unsuitability for surgery confirmed by a Plastic Surgeon or Oncologist. NoteMaximum reimbursable dosage 15 million iu/weekInitial application - (Chronic hepatitis C) only from a relevant specialist. Approvals valid for 12 months where chronic hepatitis C. Initial application - (Indications other than Basal cell carcinoma and Chronic hepatitis C) only from a relevant specialist, plastic surgeon or radiation oncologist. Approvals valid for 2 years for applications meeting the following criteria: Any of the following: 1 Chronic myelogenous leukaemia; or 2 Hairy cell leukaemia; or 3 Cutaneous T cell lymphoma; or 4 Essential thrombocythaemia; or 5 Multiple myelo
Special Authority for Subsidy - Form SA0402Initial application - (Patients aged 74 and under) only from a general practitioner. Approvals valid for 2 years for applications meeting the following criteria: All of the following: 1 Patients aged 74 and under; and 2 The patient has been offered 3-6 months of counselling and an opportunity to modify lifestyle; and 3 Any of the following: 3.1 Both: 3.1.1 NHF A1:1 - Clinically proven ischaemic heart disease; and 3.1.2 total cholesterol > 6.0; or 3.2 Both: 3.2.1 NHF A1:2 - Post coronary artery bypass graft (CABG); and 3.2.2 total cholesterol > 5.5; or 3.3 Both: 3.3.1 NHF B:Patients with > 20% 5-year cardiovascular disease risk; and 3.3.2 total cholesterol > 9.0; or 3.4 Both: 3.4.1 NHF C:15-20% 5-year cardiovascular disease risk; and 3.4.2 total cholesterol > 9.0; or 3.5 Both: 3.5.1 NHF D:10-15% 5-year cardiovascular disease risk; and 3.5.2 total cholesterol > 9.0; or 3.6
Funding of manufacturers surcharge for existing patients taking ACE inhibitors for Congestive Heart Failure.a) Patients taking any ACE inhibitor for the treatment of congestive heart failure prior to 1 June 1998 can continue to have their ACE inhibitor treatment fully subsidised; b) Prescribers must endorse the prescription 'Congestive Heart Failure'. The endorsement can be typed (this includes computer generated prescriptions) or handwritten; c) The endorsement must be initialled in the prescriber's own handwriting. Definition of Congestive Heart FailureAt the request of some prescribers the PTAC Cardiovascular subcommittee has provided a definition of congestive heart failure for the purposes of the funding of the manufacturer's surcharge: "Clinicians should use their clinical judgement. Existing patients would be eligible for the funding of the surcharge if the patient shows signs and symptoms of congestive heart failure, and requires or has in the past required concomitant treatment with a
Special Authority for Subsidy - Form SA0423Initial application only from a gastroenterologist, general surgeon or general physician. Approvals valid for 3 years for applications meeting the following criteria: Any of the following: 1 All of the following: Duodenal Ulcer: 1.1 Duodenal ulcer proven by endoscopy or barium meal; and 1.2 Non healing duodenal ulcer proven by second barium meal; and 1.3 After failure of two alternative courses of H. pylori eradication therapy (if H. pylori positive); and 1.4 After H2 antagonist therapy for 8 weeks; or 2 All of the following: Gastric Ulcer: 2.1 Gastric ulcer proven by endoscopy; and 2.2 Non healing gastric ulcer and excluded malignancy demonstrated by a second endoscopy; and 2.3 After two alternative courses of H. pylori eradication therapy (if H. pylori positive); and 2.4 After H2 antagonist therapy for 12 weeks; or 3 All of the following: GORD: 3.1 Grade 0 GORD (normal endoscopy); and 3.2 Positive 24
Special Authority for Subsidy - Form SA0424Initial application - (Confirmed HIV/AIDS) only from a general physician. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 Confirmed HIV/AIDS; and 2 Any of the following: 2.1 Symptomatic patients aged 6 years and over with HIV/AIDS; or 2.2 Both: 2.2.1 Asymptomatic patients aged 6 years and over; and 2.2.2 CD4 counts < 500 cells/mm3; or 2.3 Both: 2.3.1 Asymptomatic patients aged 6 years and over; and 2.3.2 Viral load counts > 10,000 copies per ml; or 2.4 Symptomatic patients aged under 6 with HIV/AIDS ; or 2.5 Asymptomatic patients aged 12 months and under; or 2.6 Both: 2.6.1 Asymptomatic patients aged 1 to 5 years; and 2.6.2 CD4 counts < 1,000 cells/mm3; or 2.7 Both: 2.7.1 Asymptomatic patients aged 1 to 5 years; and 2.7.2 CD4 counts < 0.25 x total white cell count; or 2.8 Both: 2.8.1 Asymptomatic patients aged under 6 years; and
Special Authority for Subsidy - Form SA0430Initial application - (National Heart Foundation risk groups A1:1, A1:2, B, C, D or E) only from a relevant specialist or general practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria: Both: 1 The patient has been offered 3-6 months of counselling and an opportunity to modify lifestyle; and 2 Any of the following: 2.1 Both: 2.1.1 NHF A1:1 - Clinically proven ischaemic heart disease; and 2.1.2 total cholesterol * > 5.5; or 2.2 Both: 2.2.1 NHF A1:2 - Post coronary artery bypass graft (CABG) or angioplasty; and 2.2.2 total cholesterol * > 4.5; or 2.3 Post heart transplant (regardless of cholesterol level); or 2.4 Both: 2.4.1 NHF B:Patients with > 20% 5-year cardiovascular disease risk; and 2.4.2 total cholesterol * > 9.0; or 2.5 Both: 2.5.1 NHF C:15-20% 5-year cardiovascular disease risk; and 2.5.2 total cholesterol * > 9
Special Authority for Manufacturers Price - Form SA0436Initial application - (Patient with prosthetic heart valves) only from a cardiothoracic surgeon, cardiologist or general physician. Approvals valid for 2 years where patient with prosthetic heart valves - as an adjunct to oral anticoagulation for prophylaxis of thromboembolism. Initial application - (Following coronary artery vein bypass graft) only from a cardiothoracic surgeon, cardiologist or general physician. Approvals valid for 1 year where patients after coronary artery vein bypass graft - as an adjunct to aspirin or as monotherapy for patients who are aspirin intolerant as defined below. Initial application - (Transient ischaemic episodes) only from a neurologist, neuro surgeon, cardiologist, vascular surgeon or general physician. Approvals valid for 2 years where patients who continue to have transient ischaemic episodes despite aspirin therapy or have transient ischaemic episodes and are aspirin intolerant as defined below. Renewal - (Fo
Special Authority for Subsidy - Form SA0443Initial application - (Helicobacter pylori infections) only from a general practitioner or relevant specialist. Approvals valid for 6 months for applications meeting the following criteria: Both: 1 Eradication of Helicobacter pylori in patient with proven infection; and 2 Peptic ulcer disease proven by endoscopy. NoteMaximum of two prescriptions (two courses) per patient. Initial application - (Mycobacterial infections) only from a respiratory specialist or infectious disease specialist. Approvals valid for 2 years for applications meeting the following criteria: Any of the following: 1 Mycobacterium Avium Intracellulare Complex infections in patient with AIDS; or 2 Atypical and drug-resistant mycobacterial infection; or 3 All of the following: 3.1 Prophylaxis against disseminated Mycobacterium Avium Intracellulare Complex infection; and 3.2 HIV infection; and 3.3 CD4 count <= 50 cells/mm3. Renewal - (Mycobacterial infection
Special Authority for Subsidy - Form SA0445Initial application only from a relevant specialist. Approvals valid for 5 years for applications meeting the following criteria: Any of the following: 1 Both: 1.1 Acromegaly; and 1.2 Patient has failed surgery, radiotherapy, bromocriptine or other oral therapies; or 2 VIPomas and Glucagonomas - for patients who are seriously ill in order to improve their clinical state prior to definitive surgery.; or 3 Both: 3.1 Gastrinoma; and 3.2 Patient has failed surgery, or metastatic disease after H2 antagoists (or proton pump inhibitors) have failed; or 4 Both: 4.1 Insulinomas; and 4.2 Surgery is contraindicated or has failed; or 5 For pre-operative control of hypoglycaemia and for maintenance therapy; or 6 Both: 6.1 Carcinoidsyndrome (diagnosed by tissue pathology and/or urinary 5HIAA analysis); and 6.2 Disabling symptoms not controlled by maximal medical therapy. NoteThe use of octretide in patients with fis
Special Authority for Subsidy - Form SA0450Initial application only from a psychiatrist. Approvals valid for 12 months for applications meeting the following criteria: Both: 1 Patients suffering from schizophrenia and related psychoses; and 2 Either: 2.1 Failed to respond to full trials (duration of at least 6 weeks each) of effective doses of at least two classes of anti-psychotic agents (refer to guidelines below); or 2.2 Demonstrated intolerance to other neuroleptic agents. NoteClinicians must confirm that informed consent and a satisfactory White Bloodcell Count (WBC) result has been obtained. Diagnosis: Treatment resistant schizophrenia and related psychoses when positive symptoms (delusions, hallucinations and thought disorder) are prominent and/or disabling or when both positive symptoms and negative symptoms (flattened affect, emotional and social withdrawal and poverty of speech) are present. Treatment: Trial therapy undertaken before initiating treatment with clozapine could
Special Authority for Subsidy - Form SA0458Initial application only from a gastroenterologist. Approvals valid for 6 months for applications meeting the following criteria: Both: 1 Primary biliary cirrhosis confirmed by antimitochondrial antibody titre (AMA) > 1:80, and raised cholestatic liver enzymes with or without raised serum IgM or, if AMA is negative, by liver biopsy; and 2 Patient not requiring a liver transplant (bilirubin > 170umol/l; decompensated cirrhosis). NoteLiver biopsy is not usually required for diagnosis but is helpful to stage the diseaseRenewal only from a gastroenterologist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment. NoteActigall is not an appropriate therapy for patients requiring a liver transplant (bilirubin > 170 micromol/l; decompensated cirrhosis). These patients should be referred to an appropriate transplant centreTreatment failure - doubling of serum bilirubin levels, absence of a signi
Special Authority for Manufacturers Price - Form SA0460Initial application - (Patient with prosthetic heart valves) only from a cardiothoracic surgeon, cardiologist or general physician. Approvals valid for 2 years where patient with prosthetic heart valves - as an adjunct to oral anticoagulation for prophylaxis of thromboembolism. Initial application - (Following coronary artery vein bypass graft) only from a cardiothoracic surgeon, cardiologist or general physician. Approvals valid for 1 year where patients after coronary artery vein bypass graft - as an adjunct to aspirin or as monotherapy for patients who are aspirin intolerant as defined below. Initial application - (Transient ischaemic episodes) only from a neurologist, neuro surgeon, cardiologist, vascular surgeon or general physician. Approvals valid for 2 years where patients who continue to have transient ischaemic episodes despite aspirin therapy or have transient ischaemic episodes and are aspirin intolerant as defined below. Renewal - (Fo
Special Authority for Subsidy - Form SA0461Initial application - (Basal cell carcinoma) only from a dermatologist, plastic surgeon or radiation oncologist. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 Basal cell carcinoma unable to be treated surgically or by radiotherapy; and 2 Unsuitablity for surgery confirmed by a Plastic Surgeon or Radiation Oncologist. NoteThe maximum reimbursable dosage is 15 million iu per weekInitial application - (Chronic hepatitis C) only from a relevant specialist. Approvals valid for 12 months where chronic hepatitis C. Initial application - (Indications other than Basal cell carcinoma and Chronic hepatitis C) only from a relevant specialist. Approvals valid for 2 years for applications meeting the following criteria: Any of the following: 1 Chronic myelogenous leukaemia; or 2 Hairy cell leukaemia; or 3 Multiple myeloma; or 4 Chronic active hepatitis B. Renewal - (Basal cell carcinoma) only from a dermato
Special Authority for Subsidy - Form SA0464Initial application only from a diabetologist, general physician or paediatrician. Approvals valid without further renewal unless notified for applications meeting the following criteria: Any of the following: 1 Both: 1.1 Use alone (monotherapy); and 1.2 The patient is unable to use any other insulins including those on insulin pump treatment; or 2 Both: 2.1 Use with Humulin 70/30 or Humulin 80/20; and 2.2 A reasonable trial of Humulin N has been undertaken and it is not effective or not well tolerated; or 3 Both: 3.1 Use with insulins (aside from insulin zinc suspension) other than Humulin 70/30, Humulin 80/20, or Humulin N; and 3.2 A reasonable trial of one or more of these Humulin insulins has been undertaken and it is/are ineffective or not well tolerated; or 4 Both: 4.1 Use with Humulin L or Humulin U; and 4.2 Use with Humulin N is not appropriate; or 5 Both: 5.1 Use with other insulin zinc suspensio
Special Authority for Subsidy - Form SA0470Initial application - (Organ transplant) only from a relevant specialist. Approvals valid without further renewal unless notified where organ transplant. Initial application - (Bone marrow transplant or Graft v host disease) only from a relevant specialist. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 Bone marrow transplant; or 2 Graft v host disease. Initial application - (Psoriasis) only from a dermatologist. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 Psoriasis; and 2 Applicant must state which systemic and topical therapies have failed. Initial application - (Severe atopic dermatitis) only from a dermatologist. Approvals valid for 6 months for applications meeting the following criteria: Both: 1 Severe atopic dermatitis; and 2 Not responsive to topical therapy, oral antihistamines and other commonly used orthodox therapies. Initial application - (N
Special Authority for Subsidy - Form SA0471Initial application - (Breast cancer) from any medical practitioner. Approvals valid for 1 year where breast cancer in pre menopausal women unwilling or unable to undergo surgical or radiation oophorectomy. Initial application - (Prostate cancer) only from an oncologist, urologist or endocrinologist. Approvals valid for 1 year where advanced prostatic cancer when orchidectomy is contraindicated or where the patient strongly opposes orchidectomy. NoteNot to be prescribed with an anti-androgen except for a period of three weeks, if necessary, when GnRH analogue therapy is intiatedInitial application - (Endometriosis) only from a gynaecologist. Approvals valid for 3 months for applications meeting the following criteria: Both: 1 Endometriosis ; and 2 Either: 2.1 6 months treatment with medroxyprogesterone acetate, danazol or dimetriose has proven ineffective; or 2.2 The patient has failed to tolerate the treatment with medroxyprogesterone
Special Authority for Manufacturers Price - Form SA0489Initial application - (Conditions other than transient ischaemic episodes) only from a cardiothoracic surgeon, cardiologist or general physician. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 Patients with prosthetic heart valves - as an adjunct to oral anticoagulation for prophylaxis of thromboembolism; or 2 Both: 2.1 Patients after coronary artery vein bypass graft; and 2.2 Any of the following: 2.2.1 aspirin induced asthma; or 2.2.2 aspirin induced anaphylaxi; or 2.2.3 significant aspirin induced bleeding excluding bruising. Initial application - (Transient ischaemic episodes) only from a neurologist, neuro surgeon, cardiologist, vascular surgeon or general physician. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 Patients who continue to have transient ischaemic episodes despite aspirin therapy; or 2 Both: 2.1 Patients wh
Special Authority for Subsidy - Form SA0494Initial application only from an ophthalmologist. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 Both: 1.1 Primary open-angle glaucoma; and 1.2 Any of the following: 1.2.1 Patient cannot tolerate Beta-blockers, or Beta-blockers are contraindicated; or 1.2.2 Patient cannot tolerate Pilocarpine, or Pilocarpine is contraindicated; or 1.2.3 Patient cannot tolerate Dorzolamide, or Dorzolamide is contraindicated; or 1.2.4 A reduction in intraocular pressure of 15% or more is not achieved or maintained using dorzolamide either alone or in combination with a beta-blocker; or 2 There is progressive visual field loss and/or optic nerve damage persists after treatment with dorzolamide either alone or in combination with a beta-blocker. NoteSubsidised as monotherapy onlyRenewal only from an ophthalmologist. Approvals valid for 2 years where the treatment remains appropriate and the patient
Special Authority for Alternate Subsidy - Form SA0500Initial application from any medical practitioner. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 Either: 1.1 Patient is on a Social Welfare benefit; or 1.2 Patient has an income no greater than the benefit; and 2 Has tried at least one of the fully funded options and has been unable to tolerate it. Renewal from any medical practitioner. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 Patient is on a Social Welfare benefit; or 2 Patient has an income no greater than the benefit. NoteThe approval numbers of Special Authorities approved after 1 November 1999 are interchangeable between Mercilon and Marvelon. The additional subsidy will fund Mercilon and Marvelon up to the manufacturer's price for each of these products as identified on the Schedule at 1 November 1999Special Authorities approved before 1 November 1999 remain valid until the expiry d
Special Authority for Subsidy - Form SA0509Initial application only from a psychiatrist. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 Patient with first episode schizophrenia or related psychoses; or 2 Both: 2.1 Patient suffering from schizophrenia and related psychoses who is likely to benefit from anti-psychotic treatment; and 2.2 Both: 2.2.1 An effective dose of risperidone had been trialled and has been discontinued either because of; and 2.2.2 Any of the following: 2.2.2.1 Patient has recurrent acute dystonias; or 2.2.2.2 Patient has excessive Parkinson-like symptoms; or 2.2.2.3 Patient has hyperprolactinaemia; or 2.2.2.4 Patient has inadequate clinical response after four weeks. NoteDiscontinued treatment should be notified to HealthPAC if possibleRenewal only from a psychiatrist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0511Initial application only from a geriatrician, rheumatologist, endocrinologist, gynaecologist or general physician. Approvals valid for 2 years for applications meeting the following criteria: All of the following: 1 Severe osteoporosis; and 2 History of two previous significant osteoporotic fractures demonstrated radiologically; and 3 T-Score <= -3.0 (bone mass density (BMD) >= 3.0 standard deviations below the mean normal value in young adults). NoteIn line with the Australian guidelines for funding alendronate, a vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral bodyRenewal only from a geriatrician, rheumatologist, endocrinologist, gynaecologist or general physician. Approvals valid for 2 years where the tr
Special Authority for Subsidy - Form SA0512Initial application only from a gastroenterologist, general surgeon or general physician. Approvals valid for 3 months for applications meeting the following criteria: Both: 1 Mild to moderate ileal, ileocaecal or proximal Crohn's disease; and 2 Either: 2.1 Diabetes; or 2.2 Both: 2.2.1 Treatment with conventional corticosteroid therapy; and 2.2.2 Any of the following: 2.2.2.1 Cushingoid habitus; or 2.2.2.2 Osteoporosis where there is significant risk of fracture; or 2.2.2.3 Severe acne. Renewal only from a gastroenterologist, general surgeon or general physician. Approvals valid for 3 months where the patient has had no more than 1 prior approval in the last 12 months. The patient must have had no more than 1 prior approval in the last year. NoteClinical trials for Entocort CIR use beyond three months demonstrated no improvement in relapse rate
Special Authority for Subsidy - Form SA0513Initial application - (Narcolepsy) only from a neurologist. Approvals valid for 24 months where narcolepsy. Initial application - (ADHD in patients aged 5 years or over) only from a paediatrician or psychiatrist. Approvals valid for 24 months for applications meeting the following criteria: Both: 1 ADHD (Attention Deficient and Hyperactivity Disorder) patients aged 5 years or over; and 2 Diagnosed according to DSM-IV or ICD 10 criteria. Initial application - (ADHD in patients under 5 years of age) only from a paediatrician or psychiatrist. Approvals valid for 12 months for applications meeting the following criteria: Both: 1 ADHD (Attention Deficient and Hyperactivity Disorder) patients under 5 years of age; and 2 Diagnosed according to DSM-IV or ICD 10 criteria. Renewal - (Narcolepsy or ADHD in patients under 5 years of age) only from a neurologist, paediatrician or psychiatrist. Approvals valid for 24 months where the treatment remains appr
Special Authority for Subsidy - Form SA0523Initial application only from a relevant specialist or general practitioner. Approvals valid for 6 months for applications meeting the following criteria: All of the following: 1 Diagnosis of asthma confirmed; and 2 Inhaler/device technique checked; and 3 Patient monitors PEFR regularly during exacerbations where appropriate; and 4 Any of the following: 4.1 At least three months of 1500 ug or more daily of inhaled beclomethasone or budesonide for adult; or 4.2 At least three months of 750 ug or more daily of inhaled fluticasone) for adult; or 4.3 At least three months of 800 ug or more daily inhaled beclomethasone or budesonide for child; or 4.4 At least three months of 400 ug or more daily inhaled fluticasone) for child; and 5 Either: 5.1 Short acting beta agonist used at least 3-4 times daily; or 5.2 Nocturnal awakenings at least twice a week. Renewal only from a relevant specialist or general practitioner. Appro
Special Authority for Subsidy - Form SA0528Initial application - (Narcolepsy) only from a neurologist or respiratory specialist. Approvals valid for 24 months where narcolepsy. Initial application - (ADHD in patients 5 or over) only from a paediatrician, psychiatrist or general practitioner. Approvals valid for 24 months for applications meeting the following criteria: All of the following: 1 ADHD (Attention Deficient and Hyperactivity Disorder) patients aged 5 years or over; and 2 Diagnosed according to DSM-IV or ICD 10 criteria; and 3 Applicant is a specialist or specialist has recommended treatment. Initial application - (ADHD in patients under 5) only from a paediatrician or psychiatrist. Approvals valid for 12 months for applications meeting the following criteria: Both: 1 ADHD (Attention Deficient and Hyperactivity Disorder) patients under 5 years of age; and 2 Diagnosed according to DSM-IV or ICD 10 criteria. Renewal - (Narcolepsy) only from a neurologist or respiratory spec
ACE inhibitors will be funded to the level of the ex-manufacturer price listed in the Schedule for patients who were taking an ACE inhibitor for the treatment of congestive heart failure prior to 1 June 1998. The prescription must be endorsed accordingly. We recommend that the words used to indicate eligibility are "certified condition" or an appropriate description of the patient such as "congestive heart failure", "CHF", "congestive cardiac failure" or "CCF". Additional subsidy for lisinopril is available only up to the price of the least expensive brand listed in the Schedule. Definition of Congestive Heart FailureAt the request of some prescribers the PTAC Cardiovascular subcommittee has provided adefinition of congestive heart failure for the purposes of the funding of the manufacturer'ssurcharge: "Clinicians should use their clinical judgement. Existing patients would be eligible for thefunding of the surcharge if the patient shows signs and symptoms of congestive heart failure, and requir
Additional subsidy by endorsement for:Moclobemide tab 150 mg x 100 (Aurorix) up to $47.00Moclobemide tab 300 mg x 60 (Aurorix) up to $56.40Nefazadone tab 100 mg x 56 (Serzone) up to $20.16Nefazadone tab 200 mg x 56 (Serzone) up to $40.32Citalopram tab 20 mg x 28 (Cipramil) up to $27.00is available for patients who: * are taking moclobemide or nefazodone on 1 December 1999 or citalopram on 1 February2000; * have previously responded to treatment with moclobemide or nefazodone or citalopram; * have had a trial of fluoxetine and have to discontinue due to: - inability to tolerate the drug due to side effects OR - failed to respond to an adequate dose and duration of treatment; * have contraindications to fluoxetine (eg pre-existing significant levels of nausea, breastfeeding, potential drug interactions); The prescription must be endorsed accordingly. We recommend that the words used to indicate eligibility are "certified condition" however these particular words are not a requirement.
Special Authority for Subsidy - Form SA0538Initial application only from a gastroenterologist, infectious disease specialist, paediatrician or general physician. Approvals valid for 1 year for applications meeting the following criteria: Both: 1 Any of the following: 1.1 All of the following: 1.1.1 HBsAg positive for more than 6 months; and 1.1.2 HBeAg positive or HBV DNA positive defined as >0.6 pg/ml by quantitative PCR at reference laboratory; and 1.1.3 ALT greater than twice upper limit of normal or stage 3 or 4 fibrosis on liver histology clinical/radiological evidence of cirrhosis; or 1.2 HBV DNA positive cirrhosis prior to liver transplantation; or 1.3 HBsAg positive and have had a liver, kidney, heart, lung or bone marrow transplant; and 2 All of the following: 2.1 No continuing alcohol abuse or intravenous drug use; and 2.2 Not coinfected with HCV, HDV, or HIV; and 2.3 Neither ALT nor AST greater than 10 times upper limit of normal; and 2.4
Special Authority for Subsidy - Form SA0539Initial application from any medical practitioner. Approvals valid for 5 years where the patient is likely to benefit from treatment. NoteApplications to be made on the approved forms which are available from: The Co-ordinatorPhone: 09 580 9176Multiple Sclerosis Treatment CommitteeFacsimile: 09 580 9205Level 3, Unisys HouseEmail: murray@ppc.govt.nz650 Great South Road, PenrosePrivate Bag, AUCKLANDBudget managed by appointed clinicians on the Multiple Sclerosis Treatment Assessments Committee (MSTAC). Applications will be considered by MSTAC at its regular meetings and approved subject to eligibility according to the Entry and Stopping criteria (below). Completed application forms must be sent to the co-ordinator for MSTAC and will be considered by MSTAC at the next practicable opportunity. Notification of MSTAC's decision will be sent to the patient, the applying clinician and the patient's GP (if specified). These agents will N
Additional subsidy by endorsement for:Moclobemide tab 150 mg x 100 (Aurorix) up to $47.00Moclobemide tab 300 mg x 60 (Aurorix) up to $56.40Nefazadone tab 100 mg x 56 (Serzone) up to $20.16Nefazadone tab 200 mg x 56 (Serzone) up to $40.32Citalopram tab 20 mg x 28 (Cipramil) up to $27.00is available for patients who: * were taking moclobemide or nefazodone on 1 December 1999 or citalopram on 1 February 2000; or* have previously responded to treatment with moclobemide, nefazodone or citalopram; or* have had a trial of fluoxetine and have to discontinue due to: - inability to tolerate the drug due to side effects; or - failed to respond to an adequate dose and duration of treatment; or* have contraindications to fluoxetine (eg pre-existing significant levels of nausea, breastfeeding, potential drug interactions); The prescription must be endorsed accordingly. We recommend that the words used to indicate eligibility are "certified condition" however these words are not a requirement.
Special Authority for Subsidy - Form SA0551Initial application only from a paediatrician, neurologist or general physician. Approvals valid for 15 months for applications meeting the following criteria: Any of the following: 1 Was on NAED therapy before 1 September 2000; or 2 Seizures are not adequately controlled with optimal older anti-epilepsy drug treatment; or 3 Seizures are controlled adequately but who experience unacceptable side effects from older anti-epilepsy drug treatment. NoteApproval entitles patients to a subsidy for one NAED. Dual NAED therapy will be subsidised for patients who were already stabilised on two NAEDs on or before 31 July 2000 or, for whom a second NAED has been added to therapy with one NAED provided an attempt to withdraw one NAED has been made and was unsuccessful. "Optimal older anti-epilepsy drug therapy" is defined as treatment with those older anti-epilepsy drugs which are indicated and clinically appropriate for the patient, given singly and in combin
Special Authority for Subsidy - Form SA0556Initial application - (Confirmed HIV/AIDS) only from a named general physician. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 Confirmed HIV/AIDS; and 2 Any of the following: 2.1 Symptomatic patient; or 2.2 Both: 2.2.1 Asymptomatic patient; and 2.2.2 Patient aged 12 months and under; or 2.3 Both: 2.3.1 Asymptomatic patient; and 2.3.2 Patient has viral load counts > 10,000 copies per ml or equivalent value on the Chiron test; or 2.4 All of the following: 2.4.1 Asymptomatic patient; and 2.4.2 Patient aged 1 to 5 years; and 2.4.3 CD4 counts < 1,000 cells/mm3; or 2.5 All of the following: 2.5.1 Asymptomatic patient; and 2.5.2 Patient aged 1 to 5 years; and 2.5.3 CD4 counts < 0.25 x total white cell count; or 2.6 All of the following: 2.6.1 Asymptomatic patient; and 2.6.2 Patient aged 6 years and over; and 2.6.3 CD4 counts
Special Authority for Subsidy - Form SA0557Initial application - (Single NAED Therapy) only from a paediatrician, neurologist or general physician. Approvals valid for 15 months for applications meeting the following criteria: Any of the following: 1 Was on NAED therapy before 1 September 2000; or 2 Seizures are not adequately controlled with optimal older anti-epilepsy drug treatment; or 3 Seizures are controlled adequately but who experience unacceptable side effects from older anti-epilepsy drug treatment. Note"Optimal older anti-epilepsy drug therapy" is defined as treatment with those older anti-epilepsy drugs which are indicated and clinically appropriate for the patient, given singly and in combination in adequate doses for the patient's age, weight, and other features affecting the pharmacokinetics of the drug with good evidence of complianceAs a guideline, clinical trials have referred to a notional 50% reduction in seizure frequency as an indicator of success with anti-convulsan
Additional subsidy by endorsement for:Moclobemide tab 150mg x 100 (Aurorix) up to $32.90Moclobemide tab 300mg x 60 (Aurorix) up to $39.48Nefazodone tab 100mg x 56 (Serzone) up to $20.16Nefazodone tab 200mg x 56 (Serzone) up to $40.32Citalopram tab 20mg x 28 (Cipramil) up to $27.00is available for patients who: * were taking moclobemide or nefazodone on 1 December 1999 or citalopram on 1 February 2000; or* have previously responded to treatment with moclobemide, nefazodone or citalopram; or* have had a trial of fluoxetine and have had to discontinue due to - inability to tolerate the drug due to side effects; or - failed to respond to an adequate dose and duration of treatment; or* have contraindications to fluoxetine (eg pre-existing significant levels of nausea, breastfeeding, potential drug interactions). The prescription must be endorsed accordingly. We recommend that the words used to indicate eligibility are "certified condition" however these words are not a requirement.
Additional subsidy by endorsement for:Moclobemide tab 150mg x 100 (Aurorix) up to $32.90Moclobemide tab 300mg x 60 (Aurorix) up to $39.48Nefazodone tab 100mg x 56 (Serzone) up to $20.16Nefazodone tab 200mg x 56 (Serzone) up to $40.32Citalopram tab 20mg x 28 (Cipramil and Celapram) up to $10.00Paroxetine hydrochloride tab 20 mg x 30 (Aropax) up to $35.02is available for patients who: * were taking moclobemide or nefazodone on 1 December 1999 or citalopram on 1 February 2000; or paroxetine hydrochloride on Februrary 2001; or * have previously responded to treatment with moclobemide or nefazodone or citalopram or paroxetine hydrochloride; or* have had a trial of fluoxetine and have had to discontinue due to - inability to tolerate the drug due to side effects; or - failed to respond to an adequate dose and duration of treatment; or* have contraindications to fluoxetine (eg pre-existing significant levels of nausea, breastfeeding, potential drug interactions). The prescription must be e
Special Authority for Subsidy - Form SA0563Initial application only from a relevant specialist. Approvals valid for 2 years for applications meeting the following criteria: Any of the following: 1 Both: 1.1 Acromegaly; and 1.2 Patient has failed surgery, radiotherapy, bromocriptine and other oral therapies; or 2 VIPomas and Glucagonomas - for patients who are seriously ill in order to improve their clinical state prior to definitive surgery.; or 3 Both: 3.1 Gastrinoma; and 3.2 Either: 3.2.1 Patient has failed surgery; or 3.2.2 Patient in metastatic disease after H2 antagonists (or proton pump inhibitors) have failed; or 4 Both: 4.1 Insulinomas; and 4.2 Surgery is contraindicated or has failed; or 5 For pre-operative control of hypoglycaemia and for maintenance therapy; or 6 Both: 6.1 Carcinoid syndrome (diagnosed by tissue pathology and/or urinary 5HIAA analysis); and 6.2 Disabling symptoms not controlled by maximal medical therapy. No
Trandolapril will be funded to the level of the ex-manufacturer price listed in the Schedule for patients who were taking these ACE inhibitors for the treatment of congestive heart failure prior to 1 June 1998. The prescription must be endorsed accordingly. We recommend that the words used to indicate eligibility are "certified condition" or an appropriate description of the patient such as "congestive heart failure", "CHF", "congestive cardiac failure" or "CCF". Definition of Congestive Heart Failure At the request of some prescribers the PTAC Cardiovascular subcommittee has provided a definition of congestive heart failure for the purposes of the funding of the manufacturer's surcharge: "Clinicians should use their clinical judgement. Existing patients would be eligible for the funding of the surcharge if the patient shows signs and symptoms of congestive heart failure, and requires or has in the past required concomitant treatment with a diuretic. The definition could also be considered to include pat
Perindopril will be funded to the level of the ex-manufacturer price listed in the Schedule for patients who were taking these ACE inhibitors for the treatment of congestive heart failure prior to 1 June 1998. The prescription must be endorsed accordingly. We recommend that the words used to indicate eligibility are "certified condition" or an appropriate description of the patient such as "congestive heart failure", "CHF", "congestive cardiac failure" or "CCF". Definition of Congestive Heart Failure At the request of some prescribers the PTAC Cardiovascular subcommittee has provided a definition of congestive heart failure for the purposes of the funding of the manufacturer's surcharge: "Clinicians should use their clinical judgement. Existing patients would be eligible for the funding of the surcharge if the patient shows signs and symptoms of congestive heart failure, and requires or has in the past required concomitant treatment with a diuretic. The definition could also be considered to include pati
Special Authority for Subsidy - Form SA0569Initial application only from a geriatrician, rheumatologist, endocrinologist, gynaecologist or general physician. Approvals valid for 2 years for applications meeting the following criteria: All of the following: 1 Severe osteoporosis; and 2 History of one previous significant osteoporotic fractures demonstrated radiologically; and 3 T-Score <= -3.0 (bone mass density (BMD) >= 3.0 standard deviations below the mean normal value in young adults). NoteIn line with the Australian guidelines for funding alendronate, a vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body. Renewal only from a geriatrician, rheumatologist, endocrinologist, gynaecologist or general physician. Approvals valid for 2 years where the t
Special Authority for Subsidy - Form SA0575Initial application - (Confirmed HIV/AIDS) only from a named general physician. Approvals valid without further renewal unless notified for applications meeting the following criteria: Both: 1 Confirmed HIV/AIDS; and 2 Any of the following: 2.1 Symptomatic patient; or 2.2 Both: 2.2.1 Asymptomatic patient; and 2.2.2 Patient aged 12 months and under; or 2.3 Both: 2.3.1 Asymptomatic patient; and 2.3.2 Patient has viral load counts > 10,000 copies per ml or equivalent value on the Chiron test; or 2.4 All of the following: 2.4.1 Asymptomatic patient; and 2.4.2 Patient aged 1 to 5 years; and 2.4.3 CD4 counts < 1,000 cells/mm3; or 2.5 All of the following: 2.5.1 Asymptomatic patient; and 2.5.2 Patient aged 1 to 5 years; and 2.5.3 CD4 counts < 0.25 x total white cell count; or 2.6 All of the following: 2.6.1 Asymptomatic patient; and 2.6.2 Patient aged 6 years and over
Special Authority for Subsidy - Form SA0579Initial application - (Cystic fibrosis or renal failure) only from a relevant specialist. Approvals valid for 3 years for applications meeting the following criteria: Either: 1 cystic fibrosis; or 2 chronic renal failure or continuous ambulatory peritoneal dialysis (CAPD) patient. Initial application - (Indications other than cystic fibrosis or renal failure) only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria: Any of the following: 1 cancer in children; or 2 cancers affecting alimentary tract where there are malabsorption problems in patients over the age of 20 years; or 3 failure to thrive; or 4 growth deficiency; or 5 bronchopulmonary dysplasia; or 6 premature and post premature infant. Renewal - (Cystic fibrosis or renal failure) only from a relevant specialist or general practitioner on the recommendation of such a specialist. Approvals valid for 3 years for applicatio
Special Authority for Subsidy - Form SA0580Initial application - (Inborn errors of metabolism) only from a relevant specialist. Approvals valid for 3 years where inborn errors of metabolism. Initial application - (Indications other than inborn errors of metabolism) only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria: Any of the following: 1 failure to thrive ; or 2 growth deficiency; or 3 bronchopulmonary dysplasia ; or 4 fat malabsorption ; or 5 lymphangiectasia; or 6 short bowel syndrome ; or 7 infants with necrotising enterocolitis; or 8 biliary atresia. Renewal - (Inborn errors of metabolism) only from a relevant specialist or general practitioner on the recommendation of such a specialist. Approvals valid for 3 years for applications meeting the following criteria: Both: 1 The treatment remains appropriate and the patient is benefiting from treatment; and 2 General Practitioners must include the name of
Special Authority for Subsidy - Form SA0581Initial application - (Cystic fibrosis) only from a relevant specialist. Approvals valid for 3 years for applications meeting the following criteria: Both: 1 infant aged four years or under; and 2 cystic fibrosis. Initial application - (Indications other than cystic fibrosis) only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria: Both: 1 infant aged four years or under; and 2 Any of the following: 2.1 cancer in children; or 2.2 failure to thrive; or 2.3 growth deficiency; or 2.4 bronchopulmonary dysplasia; or 2.5 premature and post premature infants. Renewal - (Cystic fibrosis) only from a relevant specialist or general practitioner on the recommendation of such a specialist. Approvals valid for 3 years for applications meeting the following criteria: Both: 1 The treatment remains appropriate and the patient is benefiting from treatment; and 2 General Practiti
Special Authority for Subsidy - Form SA0585Initial application - (Cystic fibrosis) only from a relevant specialist. Approvals valid for 3 years for applications meeting the following criteria: All of the following: 1 Cystic fibrosis; and 2 other lower calorie products have been tried; and 3 patient has substantially increased metabolic requirements; and 4 Either: 4.1 The product is to be used as a supplement; or 4.2 The product is to be used as a complete diet.Initial application - (Indications other than cystic fibrosis) only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria: All of the following: 1 Any of the following: 1.1 any condition causing malabsorption ; or 1.2 failure to thrive ; or 1.3 increased nutritional requirements.; and 2 other lower calorie products have been tried; and 3 patient has substantially increased metabolic requirements; and 4 Either: 4.1 The product is to be used a
Special Authority for Subsidy - Form SA0588Initial application only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria: Both: 1 CORD patients who have hypercapnia; and 2 Either: 2.1 The product is to be used as a supplement (maximum 500 ml per day); or 2.2 The product is to be used as a complete diet.Renewal only from a relevant specialist or general practitioner on the recommendation of such a specialist. Approvals valid for 1 year for applications meeting the following criteria: All of the following: 1 The treatment remains appropriate and the patient is benefiting from treatment; and 2 Either: 2.1 The product is to be used as a supplement (maximum 500 ml per day); or 2.2 The product is to be used as a complete diet; and 3 General Practitioners must include the name of the specialist and date contacted.
Special Authority for Subsidy - Form SA0589Initial application only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria: All of the following: 1 Anorexia and weight loss; and 2 Either: 2.1 decompensating liver disease without encephalopathy ; or 2.2 protein losing gastro-enteropathy; and 3 Either: 3.1 The product is to be used as a supplement (maximum 500 ml per day); or 3.2 The product is to be used as a complete diet.Renewal only from a relevant specialist or general practitioner on the recommendation of such a specialist. Approvals valid for 1 year for applications meeting the following criteria: All of the following: 1 The treatment remains appropriate and the patient is benefiting from treatment; and 2 Either: 2.1 The product is to be used as a supplement (maximum 500 ml per day); or 2.2 The product is to be used as a complete diet; and 3 General Practitioners must include the name of the specialis
Special Authority for Subsidy - Form SA0590Initial application only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria: All of the following: 1 infant aged one to six years; and 2 Any of the following: 2.1 any condition causing malabsorption ; or 2.2 failure to thrive; or 2.3 increased nutritional requirements; and 3 Either: 3.1 The product is to be used as a supplement (maximum 500 ml per day); or 3.2 The product is to be used as a complete diet.Renewal only from a relevant specialist or general practitioner on the recommendation of such a specialist. Approvals valid for 1 year for applications meeting the following criteria: All of the following: 1 The treatment remains appropriate and the patient is benefiting from treatment; and 2 Either: 2.1 The product is to be used as a supplement (maximum 500 ml per day); or 2.2 The product is to be used as a complete diet; and 3 General Practitioners must
Special Authority for Subsidy - Form SA0591Initial application only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria: Both: 1 Any of the following: 1.1 enteral feeding; or 1.2 nasogastric; or 1.3 nasoduodenal ; or 1.4 nasojejunal; or 1.5 gastrostomy/jejunostomy; and 2 Either: 2.1 The product is to be used as a supplement; or 2.2 The product is to be used as a complete diet.Renewal only from a general practitioner or relevant specialist. Approvals valid for 1 year for applications meeting the following criteria: All of the following: 1 The treatment remains appropriate and the patient is benefiting from treatment; and 2 Either: 2.1 The product is to be used as a supplement; or 2.2 The product is to be used as a complete diet; and 3 General Practitioners must include the name of the specialist and date contacted.
Special Authority for Subsidy - Form SA0592Initial application only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria: Both: 1 Any of the following: 1.1 malabsorption ; or 1.2 short bowel syndrome; or 1.3 enterocutaneous fistulas ; or 1.4 pancreatitis; and 2 Either: 2.1 The product is to be used as a supplement (maximum 500 ml per day); or 2.2 The product is to be used as a complete diet.NoteEach of these products is highly specialised and would be prescribed only by an expert for a specific disorder. The alternative is hospitalisation. Elemental 028 Extra is more expensive than other products listed in this section and should only be used where the alternatives have been tried first and/or are unsuitable. Renewal only from a relevant specialist or general practitioner on the recommendation of such a specialist. Approvals valid for 1 year for applications meeting the following criteria: All of the following:
Special Authority for Subsidy - Form SA0594Initial application only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria: Both: 1 Type I and II diabetics who require nutritional supplementation.; and 2 Either: 2.1 The product is to be used as a supplement (maximum 500 ml per day); or 2.2 The product is to be used as a complete diet.Renewal only from a relevant specialist or general practitioner on the recommendation of such a specialist. Approvals valid for 1 year for applications meeting the following criteria: All of the following: 1 The treatment remains appropriate and the patient is benefiting from treatment; and 2 Either: 2.1 The product is to be used as a supplement (maximum 500 ml per day); or 2.2 The product is to be used as a complete diet; and 3 General Practitioners must include the name of the specialist and date contacted.
Special Authority for Subsidy - Form SA0597Initial application - (PKU Patient aged over 16) only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria: Both: 1 PKU; and 2 blood phenylalanine level < 900 mmol/litre (average of tests over last 12 months). Initial application - (Patient aged over 16) only from a relevant specialist. Approvals valid for 3 years for applications meeting the following criteria: Any of the following: 1 dietary management of homocystinuria; or 2 inborn errors of metabolism other than PKU; or 3 dietary management of maple syrup urine disease..Initial application - (Patient aged 16 or under) only from a relevant specialist. Approvals valid for 3 years for applications meeting the following criteria: Any of the following: 1 dietary management of homocystinuria; or 2 PKU and other inborn errors of metabolism; or 3 dietary management of maple syrup urine disease..Renewal - (PKU Patient aged over 16
Special Authority for Subsidy - Form SA0604Initial application - (Lactase deficiency or disaccharide intolerance) only from a relevant specialist. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 Patient is less than 3 years of age; and 2 Either: 2.1 diagnosed as suffering from congenital lactase deficiency; or 2.2 suffering from disaccharide intolerance. NoteSecondary lactose intolerance in children is usually short lasting, and can be controlled by dietary measures and by giving sufficient calories to regenerate digestive enzymes. The subsidy for these products reflects the philosophy that the patient incurs no additional financial burden for purchasing specialised more expensive products. Initial application - (Infant with intolerance to cows' milk) only from a relevant specialist. Approvals valid for 6 months for applications meeting the following criteria: Both: 1 intolerant to cows' milk; and 2 patient is less than 3 years of age. No
Special Authority for Subsidy - Form SA0605Initial application - (Cystic fibrosis or renal disorder) only from a relevant specialist. Approvals valid for 3 years for applications meeting the following criteria: Both: 1 Either: 1.1 cystic fibrosis; or 1.2 renal disorder; and 2 Either: 2.1 The product is to be used as a supplement; or 2.2 The product is to be used as a complete diet.Initial application - (Indications other than cystic fibrosis or renal disorder) only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria: Both: 1 Any of the following: 1.1 any condition causing malabsorption; or 1.2 failure to thrive; or 1.3 increased nutritional requirements; and 2 Either: 2.1 The product is to be used as a supplement; or 2.2 The product is to be used as a complete diet.Renewal - (Cystic fibrosis or renal disorder) only from a relevant specialist or general practitioner. Approvals valid for 3 years
Special Authority for Subsidy - Form SA0609Initial application - (Serevent MDI, Serevent Accuhaler Foradil, Oxis Turbuhaler 12 mcg, Symbicort Turbuhaler) only from a relevant specialist or general practitioner. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 Both: 1.1 Child under the age of 12 with poorly controlled asthma; and 1.2 Either: 1.2.1 Required at least three months of 400 mcg or more daily inhaled beclomethasone or budesonide; or 1.2.2 Required at least three months of 200 mcg or more of fluticasone; or 2 Both: 2.1 Adult with poorly controlled asthma; and 2.2 Either: 2.2.1 Required at least three months of 1500 mcg or more daily inhaled beclomethasone or budesonide; or 2.2.2 Required at least three months of 750 mcg or more of fluticasone. NotePatients are to be reviewed at least at six months to assess compliance and effectiveness of therapy. Special Authority approvals are interchangeable among all prese
Special Authority for Subsidy - Form SA0610Initial application from any specialist. Approvals valid without further renewal unless notified for applications meeting the following criteria: All of the following: 1 Quantity used by patient on a weekly volume intraveneously (Details to be attached to application); and 2 Amount of nutrition patient is able to receive orally (Details to be attached to application); and 3 Exact formula of TPN (Details to be attached to application); and 4 Who has paid for TPN so far (Details to be attached to application); and 5 Place of manufacture (Details to be attached to application); and 6 Complete medical history of patient including details of previous therapies. (Details to be attached to application). Renewal - (Previous approval has expired) from any specialist. Approvals valid without further renewal unless notified where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0614Initial application only from a geriatrician, rheumatologist, endocrinologist, gynaecologist or general physician. Approvals valid for 2 years for applications meeting the following criteria: All of the following: 1 Severe osteoporosis; and 2 History of one previous significant osteoporotic fractures demonstrated radiologically; and 3 T-Score <= -3.0 (bone mass density (BMD) >= 3.0 standard deviations below the mean normal value in young adults). NoteIn line with the Australian guidelines for funding alendronate, a vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral bodyRenewal only from a geriatrician, rheumatologist, endocrinologist, gynaecologist or general physician. Approvals valid for 2 years where the tr
Special Authority for Manufacturers Price - Form SA0616Initial application - (Conditions other than transient ischaemic episodes) only from a cardiothoracic surgeon, cardiologist or general physician. Approvals valid without further renewal unless notified for applications meeting the following criteria: Either: 1 Patients with prosthetic heart valves - as an adjunct to oral anticoagulation for prophylaxis of thromboembolism; or 2 Patients after coronary artery vein bypass graft - as an adjunct to aspirin or as monotherapy for patients who are aspirin intolerant. NoteAspirin intolerant patients are defined as those with aspirin induced asthma, urticaria, or anaphylaxi, or those with significant aspirin induced bleeding, excluding bruisingInitial application - (Transient ischaemic episodes) only from a neurologist, neuro surgeon, cardiologist, vascular surgeon or general physician. Approvals valid without further renewal unless notified where patients who continue to have transient ischaemic
Special Authority for Subsidy - Form SA0622Initial application only from a geriatrician, rheumatologist, endocrinologist, gynaecologist or general physician. Approvals valid without further renewal unless notified for applications meeting the following criteria: All of the following: 1 Severe osteoporosis; and 2 History of one previous significant osteoporotic fractures demonstrated radiologically; and 3 T-Score <= -3.0 (bone mass density (BMD) >= 3.0 standard deviations below the mean normal value in young adults). NoteIn line with the Australian guidelines for funding alendronate, a vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral bodyRenewal only from a geriatrician, rheumatologist, endocrinologist, gynaecologist or general physician. Approvals va
Special Authority for Subsidy - Form SA0623Initial application from any medical practitioner. Approvals valid for 1 year for applications meeting the following criteria: All of the following: 1 The patient is not predisposed to heart arrhythmias; and 2 The patient does not have a pre-existing QT-prolongation or hepatic failure; and 3 The patient is not using other medications which either inhibit the cytochrome P450 3A4 enzyme system or prolong the QT interval; and 4 Any of the following: 4.1 Both: 4.1.1 The patient is an adult with severe reflux oesophagitis; and 4.1.2 other treatment, including acid suppression with proton pump inhibitors, has failed; or 4.2 gastroparesis; or 4.3 malignancy of GI tract causing gastroparesis (or gastric outlet obstruction); or 4.4 The patient is a child (not including infants from 0 to 3 months of age who were born prematurely) with severe gastro-oesophageal reflux; and 5 Diagnosis has been made or confirmed by a general p
Special Authority for Subsidy - Form SA0626Initial application only from a renal physician. Approvals valid for 2 years for applications meeting the following criteria: All of the following: General Criteria: 1 Anaemia of end-stage renal failure (other treatable causes of anaemia being excluded); and 2 Been on haemodialysis or continuous ambulatory peritoneal dialysis (CAPD) for at least three months; and 3 Not under evaluation for, or awaiting, a live donor kidney transplant; and 4 Any of the following: Specific Criteria: 4.1 Anephric; or 4.2 Dependent on regular blood transfusion (1 unit each 4-8 weeks) to maintain haemoglobin > 60g/L; or 4.3 Dependent on regular blood transfusion but cannot be transfused because of severe transfusion reactions; or 4.4 Transfusion induced haemosiderosis (clinical manifestations, serum ferritin >1500 ug/L); or 4.5 Haemoglobin < 70 g/L (mean of at least 4 haemoglobin concentrations over 4 months); or 4.6 Both: 4.6.1 Haemo
Prescribing GuidelineTreatment with HMG CoA Reductase Inhibitors (Statins) is recommended for patients withdyslipidaemia and an absolute 5 year cardiovascular risk of 15% or greater. New Zealand Cardiovascular Guideline Group statement. "The 1996 Heart Foundation guidelines for the Assessment and Management of Dyslipidaemia are currently being revised. An evidence-based guideline on the Assessment and Management of Cardiovascular Risk will be developed in 2002. The Cardiovascular Guideline Group has written an interim consensus statement for themanagement of dyslipidaemia. The Heart Foundation cardiovascular risk tables should be used to determine risk. Certain groups are classified to be at very high risk (>20%) and should be treated as such: - Patients who have had a previous cardiovascular event (angina, MI, angioplasty, coronary artery bypass grafts, TIA, ischaemic stroke and peripheral vascular disease)- Patients with genetic lipid disorders- Patients with diabetes and associated microa
Special Authority for Subsidy - Form SA0631Initial application only from an ophthalmologist. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 Both: 1.1 Primary open-angle glaucoma; and 1.2 Any of the following: 1.2.1 Patient cannot tolerate Beta-blockers, or Beta-blockers are contraindicated; or 1.2.2 Patient cannot tolerate Pilocarpine, or Pilocarpine is contraindicated; or 1.2.3 Patient cannot tolerate Dorzolamide, or Dorzolamide is contraindicated; or 1.2.4 A reduction in intraocular pressure of 15% or more is not achieved or maintained using dorzolamide either alone or in combination with a beta-blocker; or 2 There is progressive visual field loss and/or optic nerve damage persists after treatment with dorzolamide either alone or in combination with a beta-blocker. NoteSubsidised also for adjunctive use for the treatment of patients who have met the initial application criteria, and in whom latanoprost monotherapy has bee
Special Authority for Subsidy - Form SA0637Initial application - (National Heart Foundation risk groups A1:1, A1:2, B, C, D or E) only from a relevant specialist or general practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria: All of the following: 1 The patient has been offered 3-6 months of counseling and an opportunity to modify lifestyle; and 2 Any of the following: 2.1 Both: 2.1.1 NHF A1:1 - Clinically proven ischaemic heart disease; and 2.1.2 total cholesterol > 5.5; or 2.2 Both: 2.2.1 NHF A1:2 - Post coronary artery bypass graft (CABG) or angioplasty; and 2.2.2 total cholesterol > 4.5; or 2.3 Post heart transplant (regardless of cholesterol level); or 2.4 Both: 2.4.1 NHF B: Patients with > 20% 5-year cardiovascular disease risk; and 2.4.2 total cholesterol > 9.0; or 2.5 Both: 2.5.1 NHF C: 15-20% 5-year cardiovascular disease risk; and 2.5.2 total cholesterol >
Special Authority for Subsidy - Form SA0639Initial application - (No previous use) only from a relevant specialist or general practitioner. Approvals valid for 3 months for applications meeting the following criteria: All of the following: 1 The patient has a clinical diagnosis of heavy menstrual bleeding; and 2 The patient has failed to respond to or is unable to tolerate other appropriate pharmaceutical therapies as per the Heavy Menstrual Bleeding Guidelines; and 3 Either: 3.1 serum ferritin level < 16 mg/l (within the last 12 months); or 3.2 haemoglobin level < 120 g/l . NoteApplications are not to be made for use in patients as contraception except where they meet the above criteriaInitial application - (Previous use before 1 October 2002) only from a relevant specialist or general practitioner. Approvals valid for 3 months for applications meeting the following criteria: All of the following: 1 The patient had a clinical diagnosis of heavy menstrual bleeding; and 2
Special Authority for Subsidy - Form SA0643Initial application - (CML) only from an oncologist or relevant specialist. Approvals valid for 7 months where approved by the The Glivec Co-ordinator. Initial application - (GIST) only from an oncologist. Approvals valid for 1 year where approved by the The Glivec Co-ordinator. Renewal - (CML) only from an oncologist or relevant specialist. Approvals valid for 6 months where approved by the The Glivec Co-ordinator. Initial application - (GIST) only from an oncologist. Approvals valid for 1 year where approved by the The Glivec Co-ordinator. NoteApplication forms are available from, and prescriptions should be sent to: The Glivec Co-ordinatorPhone: 09 580 9176Level 3, Unisys HouseFacsimile: 09 580 9205650 Great South Road, PenroseEmail: murray@ppc.govt.nzPrivate Bag, AUCKLANDSpecial Authority criteria for CML - access by applicationFunded for patients with diagnosis (confirmed by a haematologist) of a chronic myeloid leukaemia (CML) i
Special Authority for Subsidy - Form SA0645Initial application only from a renal physician. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 Both: 1.1 patient in chronic renal failure; and 1.2 Haemoglobin <= 100 g/L; and 2 Either: 2.1 Both: 2.1.1 patient is not diabetic; and 2.1.2 glomerular filtration rate <= 30 ml/min; or 2.2 Both: 2.2.1 patient is diabetic; and 2.2.2 glomerular filtration rate <= 45 ml/min. Renewal only from a renal physician. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment. NoteErythropoietin beta is indicated in the treatment of anaemia associated with chronic renal failure (CRF) where no cause for anaemia other than CRF is detected and there is adequate monitoring of iron stores and iron replacement therapy. The Cockroft-Gault Formula may be used to estimate glomerular filtration rate (GFR) in persons 18 years and over:GFR (male)
Special Authority for Subsidy - Form SA0646Initial application only from a renal physician. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 Both: 1.1 patient in chronic renal failure; and 1.2 Haemoglobin <= 100 g/L; and 2 Any of the following: 2.1 Both: 2.1.1 patient is not diabetic; and 2.1.2 glomerular filtration rate <= 30 ml/min; or 2.2 Both: 2.2.1 patient is diabetic; and 2.2.2 glomerular filtration rate <= 45 ml/min; or 2.3 patient is on haemodialysis or peritoneal dialysis. Renewal only from a renal physician. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment. NoteErythropoietin beta is indicated in the treatment of anaemia associated with chronic renal failure (CRF) where no cause for anaemia other than CRF is detected and there is adequate monitoring of iron stores and iron replacement therapy. The Cockroft-Gault Formula may be used to estim
Special Authority for Manufacturers Price - Form SA0648Initial application - (Conditions other than transient ischaemic episodes) only from a cardiothoracic surgeon, cardiologist or general physician. Approvals valid without further renewal unless notified for applications meeting the following criteria: Either: 1 Patients with prosthetic heart valves - as an adjunct to oral anticoagulation for prophylaxis of thromboembolism; or 2 Patients after coronary artery vein bypass graft - as an adjunct to aspirin or as monotherapy for patients who are aspirin intolerant. NoteAspirin intolerant patients are defined as those with aspirin induced asthma, urticaria, or anaphylaxi, or those with significant aspirin induced bleeding, excluding bruisingInitial application - (Transient ischaemic episodes) only from a neurologist, neuro surgeon, cardiologist, vascular surgeon or general physician. Approvals valid without further renewal unless notified where patients who continue to have transient ischaemic
Special Authority for Subsidy - Form SA0649Initial application - (Conditions other than transient ischaemic episodes) only from a cardiothoracic surgeon, cardiologist or general physician. Approvals valid without further renewal unless notified for applications meeting the following criteria: Either: 1 Patients with prosthetic heart valves - as an adjunct to oral anticoagulation for prophylaxis of thromboembolism; or 2 Patients after coronary artery vein bypass graft - as an adjunct to aspirin or as monotherapy for patients who are aspirin intolerant. NoteAspirin intolerant patients are defined as those with aspirin induced asthma, urticaria, or anaphylaxi, or those with significant aspirin induced bleeding, excluding bruisingInitial application - (Transient ischaemic episodes) only from a neurologist, neuro surgeon, cardiologist, vascular surgeon or general physician. Approvals valid without further renewal unless notified where patients who continue to have transient ischaemic episodes des
Special Authority for Subsidy - Form SA0652Initial application - (Single NAED Therapy) only from a paediatrician, neurologist or general physician. Approvals valid for 15 months for applications meeting the following criteria: Any of the following: 1 Was on NAED therapy before 1 September 2000; or 2 Seizures are not adequately controlled with optimal older anti-epilepsy drug treatment; or 3 Seizures are controlled adequately but who experience unacceptable side effects from older anti-epilepsy drug treatment. Note"Optimal older anti-epilepsy drug therapy" is defined as treatment with those older anti-epilepsy drugs which are indicated and clinically appropriate for the patient, given singly and in combination in adequate doses for the patient's age, weight, and other features affecting the pharmacokinetics of the drug with good evidence of complianceInitial application - (Dual NAED Therapy) only from a paediatrician, neurologist or general physician. Approvals valid for 18 months for app
Special Authority for Subsidy - Form SA0657Initial application - (Helicobacter pylori infections) only from a general practitioner or relevant specialist. Approvals valid for 6 months for applications meeting the following criteria: Both: 1 Eradication of Helicobacter pylori in patient with proven infection; and 2 Peptic ulcer disease proven by endoscopy. NoteMaximum of two prescriptions (two courses) per patient. Initial application - (Mycobacterial infections) only from a respiratory specialist, infectious disease specialist or paediatrician. Approvals valid for 2 years for applications meeting the following criteria: Any of the following: 1 Mycobacterium Avium Intracellulare Complex infections in patient with AIDS; or 2 Atypical and drug-resistant mycobacterial infection; or 3 All of the following: 3.1 Prophylaxis against disseminated Mycobacterium Avium Intracellulare Complex infection; and 3.2 HIV infection; and 3.3 CD4 count <= 50 cells/mm3. Renewal - (Mycobact
Additional subsidy by endorsement for:Moclobemide tab 150 mg x 500 (Apo-Moclobemide) up to $46.00Moclobemide tab 150 mg x 100 (Aurorix) up to $32.90Moclobemide tab 300 mg x 100 (Apo-Moclobemide) up to $26.11Moclobemide tab 300 mg x 60 (Aurorix) up to $39.48Nefazodone tab 100 mg x 56 (Serzone) up to $20.16Nefazodone tab 200 mg x 56 (Serzone) up to $40.32Citalopram tab 20 mg x 28 (Celapram) up to $4.00Citalopram tab 20 mg x 28 (Cipramil) up to $10.00Paroxetine hydrochloride tab 20 mg x 30 (Aropax) up to $35.02is available for patients who: - were taking moclobemide or nefazodone on 1 December 1999 or citalopram on 1 February 2000; or paroxetine hydrochloride on February 2001; or- have previously responded to treatment with moclobemide or nefazodone or citalopram or paroxetine hydrochloride; or- have had a trial of fluoxetine and have had to discontinue due to- inability to tolerate the drug due to side effects; or- failed to respond to an adequate dose and duration of treatment; or
Special Authority for Subsidy - Form SA0661Initial application only from a psychiatrist. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 The patient has "treatment resistant" depression; and 2 Either: 2.1 The patient must have had a trial of two different antidepressants and failed to respond to an adequate dose over an adequate period of time (usually at least four weeks); or 2.2 Both: 2.2.1 The patient is currently a hospital in-patient as a result of an acute depressive episode; and 2.2.2 The patient must have had a trial of one other antidepressant and failed to respond to an adequate dose over an adequate period of time. Renewal from any medical practitioner. Approvals valid for 2 years where patient has a high risk of relapse (prescriber determined)..NoteFirst prescription can be written by a psychiatrist or psychiatric registrar. Subsequent prescriptions may be written by a General Practitioner
Special Authority for Subsidy - Form SA0667Initial application only from a named specialist. Approvals valid for 4 months for applications meeting the following criteria: All of the following: 1 To be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and 2 Patient is less than 18 years of age at commencement of treatment; and 3 Patient has had severe active polyarticular course Juvenile Idiopathic Arthritis (JIA) for 6 months duration or longer; and 4 Patient has tried and not responded to at least three months of oral or parenteral methotrexate at a dose of 10-20mg/m2 weekly in combination with oral corticosteroids (prednisone 0.25 mg/kg); and 5 Patient has tried and not responded to at least three months of oral or parenteral methotrexate (at a dose of 10-15mg/m2 weekly) in combination with one other disease-modifying agent; and 6 Both: 6.1 Either: 6.1.1 Patient has persistent symptoms of poorly-cont
Additional subsidy by endorsement for:Nefazodone tab 100 mg x 56 (Serzone) up to $20.16Nefazodone tab 200 mg x 56 (Serzone) up to $40.32Citalopram tab 20 mg x 28 (Celapram) up to $4.00Citalopram tab 20 mg x 28 (Cipramil) up to $10.00Paroxetine hydrochloride tab 20 mg x 30 (Aropax) up to $35.02is available for patients who: -were taking nefazodone on 1 December 1999 or citalopram on 1 February 2000; or paroxetine hydrochloride on February 2001; or- have previously responded to treatment with nefazodone or citalopram or paroxetinehydrochloride; or- have had a trial of fluoxetine and have had to discontinue due to- inability to tolerate the drug due to side effects; or- failed to respond to an adequate dose and duration of treatment; or- have contraindications to fluoxetine (eg pre-existing significant levels of nausea, breastfeeding, potential drug interactions). The prescription must be endorsed accordingly.
Special Authority for Subsidy - Form SA0693Initial application only from a relevant specialist or vocationally registered general practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria: All of the following: 1 Severe osteoporosis; and 2 History of one previous significant osteoporotic fracture demonstrated radiologically; and 3 T-Score <= -3.0 (bone mass density (BMD) >= 3.0 standard deviations below the mean normal value in young adults). NoteIn line with the Australian guidelines for funding alendronate, a vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral bodyRenewal - ((2 year approvals granted before February 2002)) only from a geriatrician, rheumatologist, endocrinologist, gynaecologis
Special Authority for Subsidy - Form SA0696Initial application - (Narcolepsy) only from a neurologist or respiratory specialist. Approvals valid for 24 months where narcolepsy. Initial application - (ADHD in patients 5 or over) only from a paediatrician, psychiatrist or general practitioner on the recommendation of such a specialist. Approvals valid for 24 months for applications meeting the following criteria: All of the following: 1 ADHD (Attention Deficit and Hyperactivity Disorder) patients aged 5 years or over; and 2 Diagnosed according to DSM-IV or ICD 10 criteria; and 3 Either: 3.1 Applicant is a specialist; or 3.2 Both: 3.2.1 Applicant is a GP and a specialist has recommended treatment; and 3.2.2 Provide name of specialist (Details to be attached to application). Initial application - (ADHD in patients under 5) only from a paediatrician or psychiatrist. Approvals valid for 12 months for applications meeting the following criteria: Both: 1 ADHD (Attention Defi
Special Authority for Subsidy - Form SA0699Initial application from any medical practitioner. Approvals valid for 1 year for applications meeting the following criteria: All of the following: 1 The patient is not predisposed to heart arrhythmias; and 2 The patient does not have a pre-existing QT-prolongation or hepatic failure; and 3 The patient is not using other medications which either inhibit the cytochrome P450 3A4 enzyme system or prolong the QT interval; and 4 Any of the following: 4.1 Both: 4.1.1 adult with severe reflux oesophagitis; and 4.1.2 other treatment, including acid suppression with proton pump inhibitors, has failed; or 4.2 gastroparesis; or 4.3 malignancy of GI tract causing gastroparesis (or gastric outlet obstruction); or 4.4 child (not including infants from 0 to 3 months of age who were born prematurely) with severe gastro-oesophageal reflux; and 5 Diagnosis has been made or confirmed by a general physician, gastroenterologist, or ge
Special Authority for Subsidy - Form SA0700Initial application only from an ophthalmologist. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 Both: 1.1 Monotherapy in primary open-angle glaucoma; and 1.2 Any of the following: 1.2.1 Patient cannot tolerate Beta-blockers, Pilocarpine and Dorzolamide; or 1.2.2 Beta-blockers, Pilocarpine and Dorzolamide are contraindicated; or 1.2.3 A reduction in intraocular pressure of 15% or more is not achieved or maintained using dorzolamide either alone or in combination with a beta-blocker; or 1.2.4 There is progressive visual field loss and/or optic nerve damage persists after treatment with dorzolamide either alone or in combination with a beta-blocker; or 2 Adjunctive use for the treatment of patients who have met the initial application criteria, and in whom latanoprost monotherapy has been ineffective in controlling intraocular pressure.Note An adjunctive agent may be added without a
Special Authority for Subsidy - Form SA0702Initial application - (Oral feed for cystic fibrosis patient) only from a relevant specialist. Approvals valid for 3 years for applications meeting the following criteria: Both: 1 Cystic fibrosis; and 2 Either: 2.1 The product is to be used as a supplement; or 2.2 The product is to be used as a complete diet.Initial application - (Oral feed for indications other than cystic fibrosis) only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria: Both: 1 Any of the following: 1.1 any condition causing malabsorption; or 1.2 failure to thrive; or 1.3 increased nutritional requirements; and 2 Either: 2.1 The product is to be used as a supplement; or 2.2 The product is to be used as a complete diet.Renewal - (Oral feed cystic fibrosis patient) only from a relevant specialist or general practitioner on the recommendation of such a specialist. Approvals valid for 3 years f
Special Authority for Subsidy - Form SA0703Initial application only from a relevant specialist or general practitioner. Approvals valid for 2 years for applications meeting the following criteria: All of the following: 1 Patient has raised blood pressure; and 2 The use of fully funded beta blockers is contraindicated, or not well tolerated; or where use of fully funded beta blockers and diuretics are insufficient to control blood pressure adequately at appropriate doses; and 3 Either: 3.1 Has been treated with, and cannot tolerate two ACE inhibitors, due to persistent cough; or 3.2 Has experienced angioedema on an ACE inhibitor at any time in the past or who have experienced angioedema (even if not using an ACE inhibitor) in the last 2 years. Renewal only from a relevant specialist or general practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0706Initial application only from a relevant specialist or general practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria: Either: 1 Both: 1.1 Patient with congestive heart failure; and 1.2 Either: 1.2.1 Has been treated with, and cannot tolerate, two ACE inhibitors, due to persistent cough; or 1.2.2 Has experienced angioedema on an ACE inhibitor at any time in the past or who have experienced angioedema (even if not using an ACE inhibitor) in the last 2 years; or 2 All of the following: 2.1 Patient with raised blood pressure; and 2.2 Use of fully funded beta blockers or diuretics are contraindicated; or not well tolerated; or insufficient to control blood pressure adequately at appropriate doses; and 2.3 Either: 2.3.1 Has been treated with, and cannot tolerate, two ACE inhibitors, due to persistent cough; or 2.3.2 Has experienced angioedema on an ACE in
Effective, consistent management of herpes from prescribing to these guidelines will improve patient outcomes. The guidelines on the following four pages are for the prescribing of aciclovir. The guidelines aim to: - improve patient care and clinical outcome through faster, more accessible treatment - protect patients' wider wellbeing by reinforcing the psychosocial aspects of treatment - improve the consistency and breadth of medical management of genital herpes in New Zealand. The guidelines are: - integral to ensuring a consistent, effective treatment regimen- the result of consultation with clinicians and patient representatives- set out in line with the recommended international algorithm format for treatment. The guidelines are endorsed by the Herpes Foundation's professional advisory board whose members represent venereology, NZDS, RNZCGP, RNZCOG, psychotherapy and nursing. Herpes Foundation Helpline: Toll free 0508 11 12 13Auckland Branch Herpes Foundation: 09 360 1966
Guidelines for the use of interferon in the treatment of hepatitis C: Physicians considering treatment of patients with hepatitis C should discuss cases with a gastroenterologist or aninfectious disease physician. All subjects undergoing treatment require careful monitoring for side effects. Patients should be otherwise fit. Hepatocellular carcinoma should be excluded by ultrasound examination and alpha-fetoprotein level. Criteria for Treatment a) Diagnosis- Anti-HCV positive on at least two occasions with a positive PCR for HCV-RNA and preferably confirmed by asupplementary RIBA test; or- PCR-RNA positive for HCV on at least 2 occasions if antibody negative; or- Anti-HCV positive on at least two occasions with a positive supplementary RIBA test with a negative PCR forHCV RNA but with a liver biopsy consistent with 2(b) following. b) Establishing Active Chronic Liver Disease- Confirmed HCV infection and serum ALT/AST levels measured on at least three occasions over six monthsaveraging >
Special Authority for Subsidy - Form SA0710Initial application only from an ophthalmologist. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 Either: 1.1 Monotherapy in primary open-angle glaucoma; or 1.2 Adjunctive use for the treatment of open-angle glaucoma in a patient who has met the initial application criteria, and in whom prostaglandin analogue monotherapy has been ineffective in controlling intraocular pressure; and 2 Any of the following: 2.1 Patient cannot tolerate beta-blockers, pilocarpine, and carbonic anhydrase inhibitors; or 2.2 Beta-blockers, pilocarpine and carbonic anhydrase inhibitors are contraindicated; or 2.3 A reduction in intraocular pressure of 15% or more is not achieved or maintained using carbonic anhydrase inhibitor either alone or in combination with a beta blocker; or 2.4 There is progressive visual field loss and/or optic nerve damage persists after treatment with carbonic anhydrase inhibitor either alo
Special Authority for Subsidy - Form SA0714Initial application from any medical practitioner. Approvals valid for 3 months for applications meeting the following criteria: All of the following: 1 Patient is currently enrolled in a recognised comprehensive treatment programme for alcohol dependence in a service accredited against the New Zealand Alcohol and Other Drug Sector Standard or the National Mental Health Sector Standard; and 2 Applicant works in an Alcohol & Drug Service; and 3 Applicant must include the address of the service (Details to be attached to application). Renewal from any medical practitioner. Approvals valid for 3 months for applications meeting the following criteria: Both: 1 Compliance with the medication (prescriber determined); and 2 Any of the following: 2.1 Patient is still unstable and requires further treatment; or 2.2 Patient achieved significant improvement but requires further treatment; or 2.3 Patient is well controlled but requires maint
Special Authority for Manufacturers Price - Form SA0717Initial application only from a relevant specialist or general practitioner. Approvals valid for 12 weeks for applications meeting the following criteria: Both: 1 Patient has a calculated absolute risk of cardiovascular disease of at least 15% over 5 years; and 2 Either: 2.1 Patient has severe documented intolerance to simvastatin; or 2.2 Both: 2.2.1 Patient has been compliant with a dose of simvastatin of 80 mg per day for at least 2 months; and 2.2.2 Either: 2.2.2.1 All of the following: 2.2.2.1.1 Patient has venous CABG; and 2.2.2.1.2 LDL cholesterol test 1 >= 2.0 mmol/litre; and 2.2.2.1.3 LDL cholesterol test 2 >= 2.0 mmol/litre (at least 1 week after test 1); or 2.2.2.2 All of the following: 2.2.2.2.1 Patient does not have venous CABG; and 2.2.2.2.2 LDL cholesterol test 1 >= 2.5 mmol/litre; and 2.2.2.2.3 LDL cholesterol test 2 >= 2.5 mmol/litre (at least 1 w
Special Authority for Subsidy - Form SA0721Initial application only from a named specialist. Approvals valid without further renewal unless notified for applications meeting the following criteria: All of the following: 1 The patient already has a Special Authority approval for anti-retroviral therapy (Details to be attached to application); and 2 Kaletra is to be used as a salvage therapy in place of one protease inhibitor; and 3 The patient must have trialed for at least six months and have failed on currently funded NNRTI based regimens or triple NRTI regimens; and 4 The patient must have trialed for at least six months and have failed on currently funded PI based regimens. NoteFailure is defined as: a) not achieving HIV RNA < 400 copies/ml after 24 weeks of a regimen, orb) an increase of HIV RNA to > 400 copies/ml on two separate occasions not less than one month apart, after suppression to < 400 copies/ml in a patient taking the regimen.
Special Authority for Subsidy - Form SA0723Initial application only from a relevant specialist. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 All of the following: 1.1 Patient has a calculated absolute risk of cardiovascular disease >20% over 5 years; and 1.2 Patient cannot tolerate statin therapy at a dose of 40 mg per day; and 1.3 Either: 1.3.1 All of the following: 1.3.1.1 Patient has venous CABG; and 1.3.1.2 LDL cholesterol >= 2.0 mmol/litre (see note); and 1.3.1.3 LDL cholesterol >= 2.0 mmol/litre (at least 1 week after test 1 - see note); or 1.3.2 All of the following: 1.3.2.1 Patient does not have venous CABG; and 1.3.2.2 LDL cholesterol >= 2.5 mmol/litre (see note); and 1.3.2.3 LDL cholesterol >= 2.5 mmol/litre (at least 1 week after test 1 - see note); or 2 All of the following: 2.1 Patient has homozygous familial hypercholesterolemia, or heterozygous familial hypercholesterol
Special Authority for Manufacturers Price - Form SA0724Initial application only from a relevant specialist or general practitioner. Approvals valid for 12 weeks for applications meeting the following criteria: Both: 1 Patient has a calculated absolute risk of cardiovascular disease of at least 15% over 5 years; and 2 Either: 2.1 Patient has severe documented intolerance to simvastatin (blood tests are not required); or 2.2 Both: 2.2.1 Patient has been compliant with a dose of simvastatin of 80 mg per day for at least 2 months; and 2.2.2 Either: 2.2.2.1 All of the following: 2.2.2.1.1 Patient has venous CABG; and 2.2.2.1.2 LDL cholesterol test 1 >= 2.0 mmol/litre; and 2.2.2.1.3 LDL cholesterol test 2 >= 2.0 mmol/litre (at least 1 week after test 1); or 2.2.2.2 All of the following: 2.2.2.2.1 Patient does not have venous CABG; and 2.2.2.2.2 LDL cholesterol test 1 >= 2.5 mmol/litre; and 2.2.2.2.3 LDL cholesterol test 2 >
Special Authority for Subsidy - Form SA0725Initial application only from a relevant specialist or general practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria: All of the following: 1 Patient with raised blood pressure; and 2 Use of fully funded beta blockers and diuretics are contraindicated; or not well tolerated; or insufficient to control blood pressure adequately at appropriate doses; and 3 Either: 3.1 Has been treated with, and cannot tolerate, two ACE inhibitors, due to persistent cough; or 3.2 Has experienced angioedema on an ACE inhibitor at any time in the past or who have experienced angioedema (even if not using an ACE inhibitor) in the last 2 years. Renewal - (Previous approval has expired) only from a relevant specialist or general practitioner. Approvals valid without further renewal unless notified where the treatment remains appropriate and the patient is benefiting from treatment.
Special Authority for Subsidy - Form SA0733Initial application - (Patient aged over 16) only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria: Both: 1 dietary management of PKU; and 2 blood phenylalanine level < 900 mmol/litre (average of tests over last 12 months). Initial application - (Patient aged 16 or under) only from a relevant specialist. Approvals valid for 3 years where dietary management of PKU.Renewal - (Patient aged over 16) only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria: blood phenylalanine level < 900 mmol/litre (average of tests over last 12 months). Renewal - (Patient aged 16 or under) only from a relevant specialist or general practitioner on the recommendation of such a specialist. Approvals valid for 3 years for applications meeting the following criteria: Both: 1 The treatment remains appropriate and the patient is benefiting from treatment; and 2
Special Authority for Subsidy - Form SA0738Initial application only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria: Either: 1 All of the following: 1.1 To be used as monotherapy for patients with type 2 diabetes who after six months of diet and lifestyle changes do not have adequate glycaemic control (inadequate control defined as HbA1c > 8.0% in tests carried out at least two months apart); and 1.2 Metformin is not tolerated or contraindicated. Intolerance and contraindications as defined in the notes below, a minimum of a four week trial period of metformin is required; and 1.3 Sulphonylurea is not tolerated or contraindicated. Overweight patients are only eligible under the criteria of contraindication to sulphonylureas if their body mass index (BMI) exceeds 35; or 2 Both: 2.1 For use in combination with a sulphonylurea when diet and lifestyle changes and a twelve month trial of sulphonylurea results in inadequate glycaem
Special Authority for Subsidy - Form SA0741Initial application only from a psychiatrist. Approvals valid for 2 years for applications meeting the following criteria: Any of the following: 1 Patient with first episode schizophrenia or related psychoses; or 2 Both: 2.1 Patient suffering from schizophrenia and related psychoses; or acute mania in bipolar disorder who is likely to benefit from anti-psychotic treatment; and 2.2 Either: 2.2.1 An effective dose of risperidone had been trialled and has been discontinued because of unacceptable side effects; or 2.2.2 An effective dose of risperidone had been trialled and has been discontinued because of inadequate clinical response after 4 weeks; or 3 The patient has suffered from an acute episode of schizophrenia or bipolar mania and has been treated with olanzapine short-acting intra-muscular injection. Renewal only from a psychiatrist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefit
Special Authority for Subsidy - Form SA0751Initial application only from an ophthalmologist. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 Either: 1.1 Monotherapy in primary open-angle glaucoma; or 1.2 Adjunctive use for the treatment of open-angle glaucoma in a patient who has met the initial application criteria, and in whom prostaglandin analogue monotherapy has been ineffective in controlling intraocular pressure; and 2 Any of the following: 2.1 Patient cannot tolerate beta-blockers, pilocarpine, and carbonic anhydrase inhibitors; or 2.2 Beta-blockers, pilocarpine and carbonic anhydrase inhibitors are contraindicated; or 2.3 A reduction in intraocular pressure of 15% or more is not achieved or maintained using carbonic anhydrase inhibitor either alone or in combination with a beta blocker; or 2.4 There is progressive visual field loss and/or optic nerve damage persists after treatment with carbonic anhydrase inhibitor either alo
(a) Subsidy is available between 1 March and 30 June of each year for patients who meet the following criteria, as set by the Ministry of Health: a) all people 65 years of age and over; b) people under 65 years of age with: i) the following cardiovascular disease: 1) ischaemic heart disease, 2) congestive heart disease, 3) rheumatic heart disease, 4) congenital heart disease, or 5) cerebo-vascular disease; ii) the following chronic respiratory disease: 1) asthma, if on a regular preventative therapy, or 2) other chronic respiratory disease with impaired lung function; iii) diabetes; iv) chronic renal disease; v) any cancer, excluding basal and squamous skin cancers if not invasive; vi) the following other conditions: 1) autoimmune disease, 2) immune suppression, 3) HIV, 4) transplant recipients, 5) neuromuscular and CNS diseases, 6) haemoglobinopathies, or 7) children on long term aspirin. The following conditions are excluded from funding: i) asthma not requiri
Special Authority for Subsidy - Form SA0754Initial application only from a named specialist. Approvals valid without further renewal unless notified for applications meeting the following criteria: All of the following: 1 The patient already has a Special Authority approval for anti-retroviral therapy (Details to be attached to application); and 2 Kaletra is to be used as a salvage therapy in place of one protease inhibitor; and 3 The patient must have trialed for at least six months and have failed on currently funded NNRTI based regimens or triple NRTI regimens; and 4 The patient must have trialed for at least six months and have failed on currently funded PI based regimens. NoteFailure is defined as: a) not achieving HIV RNA < 400 copies/ml after 24 weeks of a regimen, orb) an increase of HIV RNA to > 400 copies/ml on two separate occasions not less than one month apart, after suppression to < 400 copies/ml in a patient taking the regimen.
Special Authority for Subsidy - Form SA0758Initial application only from a general practitioner or relevant specialist. Approvals valid for 2 years for applications meeting the following criteria: All of the following: 1 To be used for the long-term maintenance treatment of bronchospasm and dyspnoea associated with COPD; and 2 In addition to standard treatment, the patient has trialled a dose of at least 40 mcg ipratropium q.i.d; and 3 The patient's breathlessness >= grade 4 according to the Medical Research Council dyspnoea scale (see note); and 4 FEV1 (litres) < 0.4 x predicted (litres); and 5 Either: 5.1 Patient is not a smoker (for reporting purposes only); or 5.2 Patient is a smoker and been offered smoking cessation councilling; and 6 The patient has been offered annual influenza immunisation. Renewal only from a general practitioner or relevant specialist. Approvals valid for 2 years for applications meeting the following criteria: All of the following: 1
(a) Subsidy is available between 1 March and 30 June of each year for patients who meet the following criteria, as set by the Ministry of Health: a) all people 65 years of age and over; b) people under 65 years of age with: i) the following cardiovascular disease: 1) ischaemic heart disease, 2) congestive heart disease, 3) rheumatic heart disease, 4) congenital heart disease, or 5) cerebo-vascular disease; ii) the following chronic respiratory disease: 1) asthma, if on a regular preventative therapy, or 2) other chronic respiratory disease with impaired lung function; iii) diabetes; iv) chronic renal disease; v) any cancer, excluding basal and squamous skin cancers if not invasive; vi) the following other conditions: 1) autoimmune disease, 2) immune suppression, 3) HIV, 4) transplant recipients, 5) neuromuscular and CNS diseases, 6) haemoglobinopathies, or 7) children on long term aspirin. The following conditions are excluded from funding: i) asthma not requiri
Special Authority for Subsidy - Form SA0772Initial application only from a gastroenterologist, infectious disease specialist, paediatrician or general physician. Approvals valid for 1 year for applications meeting the following criteria: Both: 1 Any of the following: 1.1 All of the following: 1.1.1 HBsAg positive for more than 6 months; and 1.1.2 HBeAg positive or HBV DNA positive defined as >0.6 pg/ml by quantitative PCR at reference laboratory; and 1.1.3 ALT greater than twice upper limit of normal or stage 3 or 4 fibrosis on liver histology clinical/radiological evidence of cirrhosis; or 1.2 HBV DNA positive cirrhosis prior to liver transplantation; or 1.3 HBsAg positive and have had a liver, kidney, heart, lung or bone marrow transplant; or 1.4 Hepatitis B surface antigen positive (HbsAg) patient who is receiving chemotherapy for a malignancy, or who has received such treatment within the previous two months; and 2 All of the following: 2.1 No continuing
Special Authority for Subsidy - Form SA0776Initial application only from a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Any of the following: 1 Both: 1.1 The patient has ovarian, fallopian* or primary peritoneal cancer*; and 1.2 Either: 1.2.1 Has not received prior chemotherapy; or 1.2.2 Has received prior chemotherapy but has not previously been treated with taxanes; or 2 The patient has metastatic breast cancer; or 3 Both: 3.1 The patient has non-small cell lung cancer; and 3.2 Either: 3.2.1 The patient has advanced disease (stage IIIa or above); or 3.2.2 The patient is receiving combined chemotherapy and radiotherapy; or 4 Both: 4.1 The patient has small-cell lung cancer*; and 4.2 Paclitaxel is to be used as second-line therapy. Renewal only from a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Both: 1 The patient has metastati
Special Authority for Subsidy - Form SA0777Initial application - (Post-transplant) only from a relevant specialist. Approvals valid for 6 months where the patient has B-cell post-transplant lymphoproliferative disorder*. NoteFor no more than 8 treatment cycles. Initial application - (Low-grade lymphomas) only from a relevant specialist. Approvals valid for 6 months where the patient has low grade NHL - relapsed disease following prior chemotherapy. NoteFor no more than 4 treatment cycles. Initial application - (Large cell lymphomas) only from a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Both: 1 The patient has treatment naive large B-cell NHL; and 2 To be used with CHOP (or alternative anthracycline containing multi-agent chemotherapy regime given with curative intent).NoteFor no more than 8 treatment cycles. Renewal - (Low-grade lymphomas) only from a relevant specialist. Approvals valid for 6 months for applications meeting
Special Authority for Subsidy - Form SA0779Initial application - (Confirmed HIV/AIDS) only from a named specialist. Approvals valid without further renewal unless notified for applications meeting the following criteria: Both: 1 Confirmed HIV infection; and 2 Any of the following: 2.1 Symptomatic patient; or 2.2 Patient aged 12 months and under; or 2.3 Both: 2.3.1 Patient aged 1 to 5 years; and 2.3.2 Any of the following: 2.3.2.1 CD4 counts < 1,000 cells/mm3; or 2.3.2.2 CD4 counts < 0.25 x total lymphocyte count; or 2.3.2.3 Viral load counts > 100,000 copies per ml; or 2.4 Both: 2.4.1 Patient aged 6 years and over; and 2.4.2 CD4 counts < 350 cells/mm3. NoteTenofovir disoproxil fumarate prescribed under endorsement for HIV/AIDS is included in the count of up to 3 subsidised antiretrovirals. Subsidies for a combination of up to three anti-retroviral medications, including a maximum of two protease inhibitors. Combinations including r
Special Authority for Subsidy - Form SA0780Initial application - (Single NAED Therapy) only from a paediatrician, neurologist or general physician. Approvals valid for 15 months for applications meeting the following criteria: Any of the following: 1 Was on NAED therapy before 1 September 2000; or 2 Seizures are not adequately controlled with optimal older anti-epilepsy drug treatment; or 3 Seizures are controlled adequately but who experience unacceptable side effects from older anti-epilepsy drug treatment. Note"Optimal older anti-epilepsy drug therapy" is defined as treatment with those older anti-epilepsy drugs which are indicated and clinically appropriate for the patient, given singly and in combination in adequate doses for the patient's age, weight, and other features affecting the pharmacokinetics of the drug with good evidence of complianceInitial application - (Dual NAED Therapy) only from a paediatrician, neurologist or general physician. Approvals valid for 18 months for app
Special Authority for Subsidy - Form: SA0781Initial application only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria: Any of the following: Monotherapy1 All of the following: 1.1 To be used as monotherapy for patients with type 2 diabetes who after six months of diet and lifestyle changes do not have adequate glycaemic control (inadequate control defined as HbA1c > 7.0% in tests carried out at least two months apart); and 1.2 Metformin is not tolerated or contraindicated. Intolerance and contraindications as defined in the notes below, a minimum of a four week trial period of metformin is required; and 1.3 Sulphonylurea is not tolerated or contraindicated. Obesity is only eligible under the criteria of contraindication to sulphonylureas if the patient's body mass index (BMI) exceeds 33 , intolerance as defined in the notes below; orIn combination with sulphonylurea2 Both: 2.1 For use in combination with a sulphonylure
Special Authority for Subsidy - Form SA0782Initial application - (No previous use) only from a relevant specialist or general practitioner. Approvals valid for 6 months for applications meeting the following criteria: All of the following: 1 The patient has a clinical diagnosis of heavy menstrual bleeding; and 2 The patient has failed to respond to or is unable to tolerate other appropriate pharmaceutical therapies as per the Heavy Menstrual Bleeding Guidelines; and 3 Either: 3.1 serum ferritin level < 16 mg/l (within the last 12 months); or 3.2 haemoglobin level < 120 g/l . NoteApplications are not to be made for use in patients as contraception except where they meet the above criteriaInitial application - (Previous use before 1 October 2002) only from a relevant specialist or general practitioner. Approvals valid for 6 months for applications meeting the following criteria: All of the following: 1 The patient had a clinical diagnosis of heavy menstrual bleeding; and 2
Special Authority for Manufacturers Price - Form SA0788Initial application only from a relevant specialist or general practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria: Both: 1 Patient has a calculated absolute risk of cardiovascular disease of at least 15% over 5 years; and 2 Either: 2.1 Patient has severe documented intolerance to simvastatin (blood tests are not required); or 2.2 Both: 2.2.1 Patient has been compliant with a dose of simvastatin of 80 mg per day for at least 2 months; and 2.2.2 Either: 2.2.2.1 All of the following: 2.2.2.1.1 Patient has venous CABG; and 2.2.2.1.2 LDL cholesterol test 1 >= 2.0 mmol/litre; and 2.2.2.1.3 LDL cholesterol test 2 >= 2.0 mmol/litre (at least 1 week after test 1); or 2.2.2.2 All of the following: 2.2.2.2.1 Patient does not have venous CABG; and 2.2.2.2.2 LDL cholesterol test 1 >= 2.5 mmol/litre; and 2.2.2.2.
Special Authority for Subsidy - Form: SA0792Initial application only from a psychiatrist. Approvals valid for 6 months for applications meeting the following criteria: All of the following: 1 The patient has schizophrenia or other psychotic disorder; and2 Has tried but failed to comply with treatment using oral atypical anti-psychotic agents; and3 Has been admitted to hospital or treated in respite care, or intensive outpatient or home-based treatment for 30 days or more in last 12 months. Renewal only from a psychiatrist. Approvals valid for 12 months for applications meeting the following criteria: Either: 4 Both: 4.1 The patient has had less than 12 months treatment with risperidone microspheres; and 4.2 There is no clinical reason to discontinue treatment; or5 The initiation of risperidone microspheres has been associated with fewer days of intensive intervention than was the case during a corresponding period of time prior to the initiation of risperidone microspheres. NoteRisp
Special Authority for Subsidy - Form: SA0796Initial application only from a relevant specialist. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 Either: 1.1 ezetimibe is to be used in combination with simvastatin; or 1.2 ezetimibe is to be used without a statin; and2 Either: 2.1 All of the following: 2.1.1 Patient has a calculated absolute risk of cardiovascular disease >20% over 5 years; and 2.1.2 Patient cannot tolerate statin therapy at a dose of 40 mg per day; and 2.1.3 Either: 2.1.3.1 All of the following: 2.1.3.1.1 Patient has venous CABG; and 2.1.3.1.2 LDL cholesterol >= 2.0 mmol/litre (see note); and 2.1.3.1.3 LDL cholesterol >= 2.0 mmol/litre (at least 1 week after test 1 - see note); or 2.1.3.2 All of the following: 2.1.3.2.1 Patient does not have venous CABG; and 2.1.3.2.2 LDL cholesterol >= 2.5 mmol/litre (see note); and 2.1.3.2.3 LDL cholest
Special Authority for Subsidy - Form: SA0797Initial application - (Underlying cause - Osteoporosis) only from a relevant specialist or vocationally registered general practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria: Any of the following: 1 History of one significant osteoporotic fracture demonstrated radiologically and documented bone mass density (BMD) >= 2.5 standard deviations below the mean normal value in young adults (i.e. T-Score <= -2.5); or2 History of one significant osteoporotic fracture demonstrated radiologically and the patient is either over 75 years of age or is too frail* to undergo a bone mass density scan; or3 History of two significant osteoporotic fractures demonstrated radiologically; or4 Documented T-Score <= -3.0. Note*The patient may be considered to be frail if it is expected that there is significant risk of further fracture or other negative health outcome if the patient were to undergo a BMD s
Special Authority for Subsidy - Form SA0801Initial application - (Serevent Accuhaler, Foradil, Symbicort Turbuhaler) only from a relevant specialist or general practitioner. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 Both: 1.1 Child under the age of 12 with poorly controlled asthma; and 1.2 Either: 1.2.1 Required at least three months of 400 mcg or more daily inhaled beclomethasone or budesonide; or 1.2.2 Required at least three months of 200 mcg or more of fluticasone; or 2 Both: 2.1 Adult with poorly controlled asthma; and 2.2 Either: 2.2.1 Required at least three months of 1500 mcg or more daily inhaled beclomethasone or budesonide; or 2.2.2 Required at least three months of 750 mcg or more of fluticasone. NotePatients are to be reviewed at least at six months to assess compliance and effectiveness of therapy. Special Authority approvals are interchangeable among all presentations of inhaled long-acting beta
Special Authority for Subsidy - Form SA0802Initial application - (genotype 1, 4, 5 or 6 infection or co-infection with HIV) from any specialist. Approvals valid for 11 months for applications meeting the following criteria: 1. Patient has chronic hepatitis C, genotype 1, 4, 5 or 6 infection; or2. Patient has chronic hepatitis C and is co-infected with HIV. Note: consider stopping treatment if there is absence of a virological response (defined as at least a 2-log reduction in viral load) following 12 weeks of treatment since this is predictive of treatment failure.Initial application - (genotype 2 or 3 infection without co-infection with HIV) from any specialist. Approvals valid for 6 months for applications meeting the following criteria: 3. Patient has chronic hepatitis C, genotype 2 or 3 infection; andEither: 3.1 Patient has bridging fibrosis or cirrhosis (Metavir stage 3 or 4 or equivalent); or 3.2 is unsuitable for liver biopsy due to coagulopathy.
Prescribing Guideline for Inhaled Long-Acting Beta-Adrenoceptor AgonistsThe addition of inhaled long-acting beta-adrenoceptor agonists (LABAs) to inhaled corticosteroids is recommended: - For younger children (aged under 12 years) where asthma is poorly controlled despite using inhaled corticosteroids for at least three months at total daily doses of 200 mcg beclomethasone or budesonide (or 100 mcg fluticasone).- For adults and older children (aged 12 years and over) where asthma is poorly controlled despite using inhaled corticosteroids for at least three months at total daily doses of 400 mcg beclomethasone or budesonide (or 200 mcg fluticasone).Note: Further information on the place of inhaled corticosteroids and inhaled LABAs in the management of asthma can be found in the New Zealand guidelines for asthma in adults (www.nzgg.org.nz) and in the New Zealand guidelines for asthma in children aged 1-15 (www.paediatrics.org.nz).
Access by applicationa) Budget managed by appointed clinicians on the Multiple Sclerosis Treatment Assessments Committee (MSTAC). b) Applications will be considered by MSTAC at its regular meetings and approved subject to eligibility according to the Entry and Stopping criteria (below). c) Applications to be made on the approved forms which are available from the co-ordinator for MSTAC:The Co-ordinator Phone: (04) 460 4990Multiple Sclerosis Treatment Assessments Committee Facsimile: (04) 916 7571PHARMAC, PO Box 10 254 E mail: silvia.valsenti@pharmac.govt.nzWellingtond) Completed application forms must be sent to the co-ordinator for MSTAC and will be considered by MSTAC at the next practicable opportunity. e) Notification of MSTAC's decision will be sent to the patient, the applying clinician and the patient's GP (if specified). f) These agents will not be subsidised if dispensed from a community or hospital pharmacy. Regular supplies will be distributed to all approved patients or their c
Special Authority for Subsidy - Form: SA0809Initial application only from a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Any of the following: 1 Both: 1.1 The patient has ovarian*, fallopian* or primary peritoneal cancer*; and 1.2 Either: 1.2.1 Has not received prior chemotherapy; or 1.2.2 Has received prior chemotherapy but has not previously been treated with taxanes; or2 The patient has metastatic breast cancer; or3 Both: 3.1 The patient has non small-cell lung cancer; and 3.2 Either: 3.2.1 Has advanced disease (stage IIIa or above); or 3.2.2 Is receiving combined chemotherapy and radiotherapy; or4 Both: 4.1 The patient has small-cell lung cancer*; and 4.2 Docetaxel is to be used as second-line therapy. Renewal only from a relevant specialist. Approvals valid for 12 months for applications meeting the followingcriteria: 5. The patient has metastatic breast cancer, non small-cell lung cancer,
Special Authority for SubsidyInitial application only from a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria: All of the following1 Patient is an adult who has had severe and active erosive Rheumatoid Arthritis for six months duration or longer; and2 Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and3 Patient has tried and not responded to at least three months of oral or parenteral methotrexate at a dose of at least 20 mg weekly or a maximum tolerated dose; and4 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with at least two of the following (triple therapy): sulphasalazine, prednisone at a dose of at least 7.5 mg per day, azathioprine, intramuscular gold, or hydroxychloroquine sulphate (at maximum tolerated doses); and5 Patient has tried and not responded to at least three months therapy at th
Special Authority for Subsidy Initial application - (for new patients) only from a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Both: 1 The patient has refractory, progressive or relapsed multiple myeloma; and2 The patient has received prior chemotherapy. Initial application - (for patients receiving thalidomide prior to 1 January 2006) only from a relevant specialist. Approvals valid without further renewal where the patient was receiving treatment with thalidomide for multiple myeloma on or before 31 December 2005. Renewal only from a relevant specialist. Approvals valid without further renewal where the patient has obtained a response from treatment during the initial approval period. Note: Prescription must be written by registered prescriber in the thalidomide risk management programme operated by the supplier. Maximum dose of 400 mg daily as monotherapy or in a combination therapy regimen.
Special Authority for Subsidy Initial application for patients with type 2 diabetes only from a relevant specialist. Approvals valid for one year for applications meeting the following criteria: Any of the following: Monotherapy1 All of the following: 1.1 To be used as monotherapy for patients who after six months of diet and lifestyle changes have inadequate glycaemic control (defined as HbA1c > 7.0% in tests carried out at least two months apart); and 1.2 Metformin is contraindicated or not tolerated after a minimum of a four week trial period; and 1.3 Sulphonylurea is contraindicated or not tolerated or the patient's body mass index (BMI) exceeds 33 kg/m2; orIn combination with sulphonylurea2 Both: 2.1 For use in combination with a sulphonylurea for patients who after diet and lifestyle changes and a six-month trial of sulphonylurea have poor glycaemic control (defined as HbA1c > 8.0% measured within the last month of the six month period); and 2.2 Metformin is contrain
Perindopril and trandolapril will be funded to the level of the ex-manufacturer price listed in the Schedule for patients who were taking these ACE inhibitors for the treatment of congestive heart failure prior to 1 June 1998. The prescription must be endorsed accordingly. We recommend that the words used to indicate eligibility are "certified condition" or an appropriate description of the patient such as "congestive heart failure", "CHF", "congestive cardiac failure" or "CCF". Definition of Congestive Heart Failure At the request of some prescribers the PTAC Cardiovascular subcommittee has provided a definition of congestive heart failure for the purposes of the funding of the manufacturer's surcharge: "Clinicians should use their clinical judgement. Existing patients would be eligible for the funding of the surcharge if the patient shows signs and symptoms of congestive heart failure, and requires or has in the past required concomitant treatment with a diuretic. The definition could also be considere
Special Authority for Subsidy - Form: SA0826Initial application only from a relevant specialist. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 All of the following: 1.1 Patient has a calculated absolute risk of cardiovascular disease >20% over 5 years; and 1.2 Patient cannot tolerate statin therapy at a dose of >= 40 mg per day; and 1.3 Either: 1.3.1 All of the following: 1.3.1.1 Patient has venous CABG; and 1.3.1.2 LDL cholesterol >= 2.0 mmol/litre (see note); and 1.3.1.3 LDL cholesterol >= 2.0 mmol/litre (at least 1 week after test 1 - see note); or 1.3.2 All of the following: 1.3.2.1 Patient does not have venous CABG; and 1.3.2.2 LDL cholesterol >= 2.5 mmol/litre (see note); and 1.3.2.3 LDL cholesterol >= 2.5 mmol/litre (at least 1 week after test 1 - see note); or2 All of the following: 2.1 Patient has homozygous familial hypercholesterolemia, or heterozygous familial hypercholest
Special Authority for Subsidy - Retail Pharmacy - Form SA0829Initial Application only from gastroenterologist or infectious disease specialist. Approvals valid for 1 year for applications meeting the following criteria: All of the following: 1. Patient has confirmed Hepatitis B infection (HBsAg+); andDocumented resistance to lamivudine, defined as: 2. patient has raised serum ALT (> 1 x ULN); and3. patient has HBV DNA greater than 100,000 copies per mL, or viral load ? 10 fold over nadir; and4. detection of M204I or M204V mutation; and5. Either5.1. Both5.1.1. patient is cirrhotic; and5.1.2. adefovir dipivoxil to be used in combination with lamivudine; or5.2. Both5.2.1. patient is not cirrhotic; and5.2.2. adefovir dipivoxil to be used as monotherapyRenewal only from a gastroenterologist or infectious disease specialist. Approvals valid for 2 years for applications where in the opinion of the treating physician, treatment remains appropriate and patient is benefiting from treatmen
Special Authority for Subsidy - Form: SA0832Initial application only from a gastroenterologist, infectious disease specialist, paediatrician or general physician. Approvals valid for 1 year for applications meeting the following criteria: Both: 1 Any of the following: 1.1 All of the following: 1.1.1 HBsAg positive for more than 6 months; and1.1.2 HBeAg positive or HBV DNA positive defined as > 100,000 copies per ml by quantitative PCR at a reference laboratory; and1.1.3 ALT greater than twice upper limit of normal or bridging fibrosis or cirrhosis (Metavir stage 3 or 4 or equivalent) on liver histology or clinical/radiological evidence of cirrhosis; or 1.2 HBV DNA positive cirrhosis prior to liver transplantation; or1.3 HBsAg positive and have had a liver, kidney, heart, lung or bone marrow transplant; or1.4 Hepatitis B surface antigen positive (HbsAg) patient who is receiving chemotherapy for a malignancy, or who has received such treatment within the previous two months;
Special Authority for Subsidy - Form: SA0834Initial application only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria: Either: 1 Both: 1.1 Patient has type 1 diabetes and has received an intensive regimen (injections at least three times a day) of an intermediate acting insulin in combination with a rapid acting insulin analogue for at least three months; and1.2 Either: 1.2.1 Patient has experienced more than one unexplained severe hypoglycaemic episode in the previous 12 months (severe defined as requiring the assistance of another person); or1.2.2 Patient has experienced unexplained symptomatic nocturnal hypoglycaemia, biochemically documented at <3.0 mmol/L, more than once a month despite optimal management; or2 Patient has documented severe, or continuing, systemic or local allergic reaction to existing insulins. Note this does not include hypoglycaemic episodes. Renewal only from a relevant specialist or general practitioner. Approv
Special Authority for Subsidy - Form SA0835Initial application - (Breast cancer) from any medical practitioner. Approvals valid for 1 year: where the patient is a premenopausal woman with breast cancer. Initial application - (Prostate cancer) only from an oncologist, urologist or endocrinologist. Approvals valid for 1 year for applications meeting the following criteria: Advanced prostatic cancer;. Note Not to be prescribed with an anti-androgen except for a period of three weeks, if necessary, when GnRH analogue therapy is initiated. Initial application - (Endometriosis) only from a gynaecologist. Approvals valid for 3 months for applications meeting the following criteria: Both: 1 Endometriosis; and2 Either: 2.1 6 months treatment with medroxyprogesterone acetate, danazol or dimetriose has proven ineffective; or2.2 The patient has failed to tolerate the treatment with medroxyprogesterone acetate, danazol or dimetriose for 6 months. Note The maximum treatment period for a GnRH analogue is:
Special Authority for Subsidy - Form SA0836Initial application - (Breast cancer) from any medical practitioner. Approvals valid for 1 year where the patient is a premenopausal woman with breast cancer. Initial application - (Prostate cancer) only from an oncologist, urologist or endocrinologist. Approvals valid for 1 year for applications meeting the following criteria: Either: 1 Advanced prostatic cancer; or. 2 Locally advanced prostatic cancer. Note Not to be prescribed with an anti-androgen except for a period of three weeks, if necessary, when GnRH analogue therapy is initiated. Initial application - (Endometriosis) only from a gynaecologist. Approvals valid for 3 months for applications meeting the following criteria: Both: 3 Endometriosis; and4 Either: 4.1 6 months treatment with medroxyprogesterone acetate, danazol or dimetriose has proven ineffective; or4.2 The patient has failed to tolerate the treatment with medroxyprogesterone acetate, danazol or dimetriose for 6 months. Note
Special Authority for Subsidy - Form SA0837Initial application - (Breast cancer) from any medical practitioner. Approvals valid for 1 year where the patient is a premenopausal woman with breast cancer. Initial application - (Prostate cancer) only from an oncologist, urologist or endocrinologist. Approvals valid for 1 year where the patient has: Advanced prostatic cancer;. Note Not to be prescribed with an anti-androgen except for a period of three weeks, if necessary, when GnRH analogue therapy is initiated. Initial application - (Endometriosis) only from a gynaecologist. Approvals valid for 3 months for applications meeting the following criteria: Both: 1 Endometriosis; and2 Either: 2.1 6 months treatment with medroxyprogesterone acetate, danazol or dimetriose has proven ineffective; or2.2 The patient has failed to tolerate the treatment with medroxyprogesterone acetate, danazol or dimetriose for 6 months. Note The maximum treatment period for a GnRH analogue is: - 3 months to assess whet
Special Authority for Subsidy - Form: SA0838Initial Application only from a relevant specialist or General Practitioner. Approvals valid for 2 years forapplications meeting the following criteria: Either: 1 All of the following: 1.1 Patient is a child under the age of 12; and1.2 All of the following: Has, for 3 months or more, been treated with:1.2.1 An inhaled long-acting beta adrenoceptor agonist; and1.2.2 Inhaled corticosteroids at a dose of at least 400 mcg per day beclomethasone or budesonide, or200 mcg per day fluticasone; and1.3 The prescriber considers that the patient would receive additional clinical benefit from switching to acombination product; or2 All of the following: 2 .1 Patient is over the age of 12; and2 .2 All of the following: Has, for 3 months or more, been treated with:2 .2.1 An inhaled long-acting beta adrenoceptor agonist; and2 .2.2 Inhaled corticosteroids at a dose of at least 800 mcg per day beclomethasone or budesonide, or500 mcg per day fluticasone;
Special Authority for Subsidy - Form SA0839Initial application - (Breast cancer) from any medical practitioner. Approvals valid for 1 year where the patient is a premenopausal woman with breast cancer. Initial application - (Prostate cancer) only from an oncologist, urologist or endocrinologist. Approvals valid for 1 year for applications meeting the following criteria: Either: 1 Advanced prostatic cancer; or. 2 Neoadjuvant or adjuvant treatment of locally advanced prostatic cancer. Note Not to be prescribed with an anti-androgen except for a period of three weeks, if necessary, when GnRH analogue therapy is initiated. Initial application - (Endometriosis) only from a gynaecologist. Approvals valid for 3 months for applications meeting the following criteria: Both: 3 Endometriosis; and4 Either: 4.1 6 months treatment with medroxyprogesterone acetate, danazol or dimetriose has proven ineffective; or4.2 The patient has failed to tolerate the treatment with medroxyprogesterone acetate, danazo
Special Authority for Subsidy - form: SA0841Initial application only from a gastroenterologist or general physician. Approvals valid for 6 months for applications meeting the following criteria: Both: 1 Primary biliary cirrhosis confirmed by antimitochondrial antibody titre (AMA) > 1:80, and raised cholestatic liver enzymes with or without raised serum IgM or, if AMA is negative, by liver biopsy; and2 Patient not requiring a liver transplant (bilirubin > 170umol/l; decompensated cirrhosis). NoteLiver biopsy is not usually required for diagnosis but is helpful to stage the diseaseRenewal only from a gastroenterologist or general physician. Approvals valid for 2 years for applications meeting the following criteria: The treatment remains appropriate and the patient is benefiting from treatment. NoteActigall is not an appropriate therapy for patients requiring a liver transplant (bilirubin > 170 micromol/l; decompensated cirrhosis). These patients should be referred to an appropriate transp
Special Authority for Subsidy - Form: SA842Initial application only from a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Any of the following: 1 Both: 1.1 The patient has ovarian, fallopian* or primary peritoneal cancer*; and 1.2 Either: 1.2.1 Has not received prior chemotherapy; or 1.2.2 Has received prior chemotherapy but have not previously been treated with taxanes; or2 The patient has metastatic breast cancer; or3 The patient has node-positive early breast cancer; or4 Both 4.1 The patient has non small-cell lung cancer; and 4.2 Either: 4.2.1 Has advancing disease (stage IIIa or above); or 4.2.2 Is receiving combined chemotherapy and radiotherapy; or5 Both: 5.1 The patient has small-cell lung cancer*; and 5.2 Paclitaxel is to be used as second-line therapy. Renewal only from a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: 6 The patient has metasta
Special Authority for Subsidy - Form SA0089Initial application - (Breast or prostatic cancer) only from an oncologist, urologist or endocrinologist. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 Breast cancer in pre menopausal women unwilling or unable to undergo surgical or radiation oophorectomy; or 2 Advanced prostatic cancer when orchidectomy is contraindicated. Initial application - (Endometriosis) only from a gynaecologist. Approvals valid for 6 months for applications meeting the following criteria: Both: 1 Endometriosis; and 2 Either: 2.1 6 months treatment with medroxyprogesterone acetate, danazol or dimetriose has proven ineffective; or 2.2 The patient has failed to tolerate the treatment with medroxyprogesterone acetate, danazol or dimetriose for 6 months. NoteThe maximum treatment period for a GnRH analogue is: 3 months to assess whether surgery is appropriate3 months for infertile patients after surgery6 months for
Special Authority for Subsidy - Form SA0100Initial application only from a relevant specialist. Approvals valid for 5 years for applications meeting the following criteria: All of the following: 1 Anaemia of end-stage renal failure (other treatable causes of anaemia being excluded); and 2 Been on haemodialysis or continuous ambulatory peritoneal dialysis (CAPD) for at least three months; and 3 Not under evaluation for, or awaiting, a live donor kidney transplant; and 4 Any of the following: 4.1 Anephric; or 4.2 Dependent on regular blood transfusion (1 unit each 4-8 weeks) to maintain haemoglobin > 60g/L; or 4.3 Cannot be transfused because of severe transfusion reactions; or 4.4 Transfusion induced haemosiderosis (clinical manifestations, serum ferritin >1500 ug/L); or 4.5 Haemoglobin < 70 g/L (mean of at least 4 haemoglobin concentrations over 4 months); or 4.6 Both: 4.6.1 Haemoglobin < 90 g/L; and 4.6.2 Either: 4.6.2.1 Heart failure (low card
The new anticonvulsant drugs are restricted to1. neurologists2. paediatric neurologists3. any other prescriber approved in writing by the relevant RHA budget holding manager. The HFA holds a budget for expenditure on the new anticonvulsant drugs. Unless otherwise specified, ultimate authority for approving prescriptions for subsidy lies with the HFA budget holding manager for the new anticonvulsant drugs. The regional divisions of the HFA will be in contact with hospital pharmacists and approved prescribers with more detail of the approval system. GUIDELINES FOR USE OF THE NEW ANTICONVULSANTS ARE AS FOLLOWS: A. Entry criteriaThe following patients are eligible for trial on the new anticonvulsant drugs (NADs)1. Patients who are under the supervision of an approved prescriber, and whose seizures are not adequately controlled with optimal conventional anticonvulsant drug treatment. 2. Patients, who are under the supervision of an approved prescriber, and whose seizures are only controlled adequatel
Special Authority for Subsidy - Form SA0266Initial application - (Chronic hepatitis C) only from a relevant specialist. Approvals valid for 6 months where chronic hepatitis C. NoteMaximum reimbursable dosage 15 million iu/weekInitial application - (Indications other than chronic hepatitis C) only from a dermatologist, plastic surgeon or radiation oncologist. Approvals valid for 5 years for applications meeting the following criteria: Any of the following: 1 Chronic myelogenous leukaemia; or 2 Hairycell leukaemia; or 3 Cutaneous T cell lymphoma; or 4 Essential thrombocythaemia; or 5 AIDS related Kaposi's sarcoma; or 6 Multiple myeloma; or 7 Chronic active hepatitis B; or 8 Basal cell carcinoma unable to be treated surgically or by radiotherapy. NoteMaximum reimbursable dosage 15 million iu/weekRenewal - (Chronic hepatitis C) only from a relevant specialist. Approvals valid for 6 months where the treatment remains appropriate and the patient is benefiting from trea
Lansoprazole is subsidised for patients who have one or more of the following conditions: 1. Duodenal ulcer proven by endoscopy or barium meal and after failure of: a)two alternative courses of H. pylori eradication therapy (if H. pylori positive); and b)H2 antagonist therapy for 8 weeks; and where a second endoscopy/barium meal has demonstrated non healing duodenal ulcer. 2. Gastric ulcer proven by endoscopy and after failure of: a)two alternative courses of H. pylori eradication therapy (if H. pylori positive); andb)H2 antagonist therapy for 12 weeks; and where a second endoscopy has demonstrated non healing gastric ulcer and excluded malignancy. 3. Gastro-oesophageal reflux disease (GORD) proven by endoscopy: i) Grade 0 GORD (normal endoscopy) after positive 24 hour pH monitoring test and failure of H2 antagonist therapy for one month with multiple daily dosing; orii) Grades 1 and 2 GORD after failure of H2 antagonist therapy for one month with multiple daily dosing; or
Special Authority for Subsidy - Form SA0275Initial application - (Chronic hepatitis C) only from a relevant specialist. Approvals valid for 6 months where chronic hepatitis C. NoteMaximum reimbursable dosage 15 million iu/weekInitial application - (Indications other than chronic hepatitis C) only from a dermatologist, plastic surgeon or radiation oncologist. Approvals valid for 5 years for applications meeting the following criteria: Any of the following: 1 Chronic myelogenous leukaemia; or 2 Hairycell leukaemia; or 3 Cutaneous T cell lymphoma; or 4 Essential thrombocythaemia; or 5 Multiple myeloma; or 6 Chronic active hepatitis B; or 7 Basal cell carcinoma unable to be treated surgically or by radiotherapy. NoteMaximum reimbursable dosage 15 million iu/weekRenewal - (Chronic hepatitis C) only from a relevant specialist. Approvals valid for 6 months where the treatment remains appropriate and the patient is benefiting from treatment. Renewal - (Indications other tha
Special Authority for Subsidy - Form SA0276Initial application - (Chronic hepatitis C) only from a relevant specialist. Approvals valid for 6 months where chronic hepatitis C. NoteMaximum reimbursable dosage 15 million iu/weekInitial application - (Indications other than chronic hepatitis C) only from a dermatologist, plastic surgeon or radiation oncologist. Approvals valid for 5 years for applications meeting the following criteria: Any of the following: 1 Chronic myelogenous leukaemia; or 2 Hairycell leukaemia; or 3 Multiple myeloma; or 4 Chronic active hepatitis B; or 5 Basal cell carcinoma unable to be treated surgically or by radiotherapy. NoteMaximum reimbursable dosage 15 million iu/weekRenewal - (Chronic hepatitis C) only from a relevant specialist. Approvals valid for 6 months where the treatment remains appropriate and the patient is benefiting from treatment. Renewal - (Indications other than chronic hepatitis C) only from a dermatologist, plastic surgeon or radiat
Omeprazole is subsidised for patients who have one or more of the conditions numbered 1-4: 1. Duodenal ulcer proven by endoscopy or barium meal and after failure of: a)two alternative courses of H. pylori eradication therapy (if H. pylori positive); and b)H2 antagonist therapy for 8 weeks; and where a second endoscopy/barium meal has demonstrated non healing duodenal ulcer. 2. Gastric ulcer proven by endoscopy and after failure of: a)two alternative courses of H. pylori eradication therapy (if H. pylori positive); andb)H2 antagonist therapy for 12 weeks; and where a second endoscopy has demonstrated non healing gastric ulcer and excluded malignancy. 3. Gastro-oesophageal reflux disease (GORD) proven by endoscopy: i) Grade 0 GORD (normal endoscopy) after positive 24 hour pH monitoring test and failure of H2 antagonist therapy for one month with multiple daily dosing; orii) Grades 1 and 2 GORD after failure of H2 antagonist therapy for one month with multipl
Special Authority for Subsidy - Form SA0300Initial application - (Breast or prostatic cancer) only from an oncologist, urologist or endocrinologist. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 Breast cancer in pre menopausal women unwilling or unable to undergo surgical or radiation oophorectomy; or 2 Advanced prostatic cancer when orchidectomy is contraindicated. NoteNot in long term combination with an anti-androgenInitial application - (Endometriosis) only from a gynaecologist. Approvals valid for 6 months for applications meeting the following criteria: Both: 1 Endometriosis ; and 2 Either: 2.1 6 months treatment with medroxyprogesterone acetate, danazol or dimetriose has proven ineffective; or 2.2 The patient has failed to tolerate the treatment with medroxyprogesterone acetate, danazol or dimetriose for 6 months. NoteThe maximum treatment period for a GnRH analogue is: 3 months to assess whether surgery is appropriate3 m
Special Authority for Subsidy - Form SA0311Initial application - (Breast or prostatic cancer) only from an oncologist, urologist or endocrinologist. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 Breast cancer in pre menopausal women unwilling or unable to undergo surgical or radiation oophorectomy; or 2 Advanced prostatic cancer when orchidectomy is contraindicated or where the patient srongly opposes orchidectomy. NoteNot to be prescribed with an anti-androgen except for a period of three weeks, if necessary, when GnRH analogue therapy is intiatedInitial application - (Endometriosis) only from a gynaecologist. Approvals valid for 6 months for applications meeting the following criteria: Both: 1 Endometriosis; and 2 Either: 2.1 6 months treatment with medroxyprogesterone acetate, danazol or dimetriose has proven ineffective; or 2.2 The patient has failed to tolerate the treatment with medroxyprogesterone acetate, danazol or dimetrio
Special Authority for Subsidy - Form SA0317Initial application only from a renal physician. Approvals valid for 2 years for applications meeting the following criteria: All of the following: General Criteria: 1 Anaemia of end-stage renal failure (other treatable causes of anaemia being excluded); and 2 Been on haemodialysis or continuous ambulatory peritoneal dialysis (CAPD) for at least three months; and 3 Not under evaluation for, or awaiting, a live donor kidney transplant; and 4 Any of the following: Specific Criteria: 4.1 Anephric; or 4.2 Dependent on regular blood transfusion (1 unit each 4-8 weeks) to maintain haemoglobin > 60g/L; or 4.3 Cannot be transfused because of severe transfusion reactions; or 4.4 Transfusion induced haemosiderosis (clinical manifestations, serum ferritin >1500 ug/L); or 4.5 Haemoglobin < 70 g/L (mean of at least 4 haemoglobin concentrations over 4 months); or 4.6 Both: 4.6.1 Haemoglobin < 90 g/L; and 4.6.2 Either:
Guidelines for use of cyclosporin A in rheumatoid arthritisMonitoring: All patients require frequent monitoring for creatinine levels and blood pressure:- fortnightly, in the first three months of therapy and then monthly, if results are stable; - if dose is increased or there is a rise in serum creatinine or blood pressure, then more frequent monitoring is required. Contraindications: Cyclosporin A is contraindicated in patients with the following conditions: - current or past malignancy; - uncontrolled hypertension; - renal dysfunction (abnormal serum creatinine for age and sex); - immunodeficiency and neutropenia; - abnormally low white blood cell count or platelet count; or- liver function tests more than twice the upper limit of normal. Caution in use: - age above 65 years; - controlled hypertension; - use of ant-epileptic medications; - use of NSAIDs; - use of ketoconazole, fluconazole, trimethoprim, erythromycin, verapamil, and diltiazem; - concurrent or previous use of al
Omeprazole and pantoprazole is subsidised for patients who have one or more of the conditions a-d: a) Duodenal ulcer proven by endoscopy or barium meal and after failure of: - two alternative courses of H. pylori eradication therapy (if H. pylori positive); and - H2 antagonist therapy for 8 weeks; and where a second endoscopy/barium meal has demonstrated non healing duodenal ulcer. b) Gastric ulcer proven by endoscopy and after failure of: - two alternative courses of H. pylori eradication therapy (if H. pylori positive); and - H2 antagonist therapy for 12 weeks; and where a second endoscopy has demonstrated non healing gastric ulcer and excluded malignancy. c) Gastro-oesophageal reflux disease (GORD) proven by endoscopy: - Grade 0 GORD (normal endoscopy) after positive 24 hour pH monitoring test and failure of H2 antagonist therapy for four weeks with multiple daily dosing; or - Grades 1 and 2 GORD after failure of H2 antagonist therapy for
Special Authority for Subsidy - Form SA0366Initial application - (North Island patients) from any medical practitioner. Approvals valid for 5 years where the patient is likely to benefit from treatment. NoteFor details of the patient criteria, prescriber criteria, application and reporting forms contact the appointed clinician: Dr Richard FisherFertility Associates131 Remuera RoadAUCKLANDFax: 09 520 0499Appointed clinicians will distribute these agents to prescribers whose applications are approvedInitial application - (South Island patients) from any medical practitioner. Approvals valid for 5 years where the patient is likely to benefit from treatment. NoteFor details of the patient criteria, prescriber criteria, application and reporting forms contact the appointed clinician: Dr Peter BennyChristchurch Women's HospitalPrivate Bag 4711CHRISTCHURCHFax: 03 364 4634Appointed clinicians will distribute these agents to prescribers whose applications are approved
Special Authority for Subsidy - Form SA0382Initial application only from a gastroenterologist, general surgeon or general physician. Approvals valid for 3 years for applications meeting the following criteria: Any of the following: 1 All of the following: 1.1 Duodenal ulcer proven by endoscopy or barium meal; and 1.2 Failure of two alternative courses of H. pylori eradication therapy (if H. pylori positive); and 1.3 Non healing duodenal ulcer proven by second barium meal; and 1.4 H2 antagonist therapy for 8 weeks; or 2 All of the following: 2.1 Gastric ulcer proven by endoscopy; and 2.2 Two alternative courses of H. pylori eradication therapy (if H. pylori positive); and 2.3 Non healing gastric ulcer and excluded malignancy demonstrated by a second endoscopy; and 2.4 H2 antagonist therapy for 12 weeks; or 3 All of the following: 3.1 Grade 0 GORD (normal endoscopy); and 3.2 Positive 24 hour pH monitoring test; and 3.3 Failure of H2 antagonist t
Special Authority for Subsidy - Form SA0387Initial application - (Breast or prostatic cancer) only from an oncologist, urologist or endocrinologist. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 Breast cancer in pre menopausal women unwilling or unable to undergo surgical or radiation oophorectomy; or 2 Advanced prostatic cancer when orchidectomy is contraindicated or where the patient srongly opposes orchidectomy. NoteNot to be prescribed with an anti-androgen except for a period of three weeks, if necessary, when GnRH analogue therapy is intiatedInitial application - (Endometriosis) only from a gynaecologist. Approvals valid for 6 months for applications meeting the following criteria: Both: 1 Endometriosis; and 2 Either: 2.1 6 months treatment with medroxyprogesterone acetate, danazol or dimetriose has proven ineffective; or 2.2 The patient has failed to tolerate the treatment with medroxyprogesterone acetate, danazol or dimetrio
a) Cyproterone acetate with ethinyloestradiol is available from retail pharmacy to patients as indicated. b) Prescribers may code prescriptions "contraceptive" (code "O") when used as indicated for contraception. The period of supply and prescription charge will be as per other contraceptives, as follows: - $3.00 prescription charge (patient co-payment) will apply; - Prescription may be written for up to 6 months supply; and- Pharmacists may dispense up to 3 month supply. c) Prescriptions coded in any other way are subject to the non-contraceptive prescription charges, and the non-contraceptive period of supply. Eg. Prescriptons may be written for up to 3 months supply, and dispensed monthly. d) The Special Authority number for hormonal contraceptive agents (combined and progesterone-only) does not apply, and is not interchangeable. e) Health Benefits Limited will return any claims unpaid as follows: - any uncoded prescription; - any prescription that does not have a period of supply or the quantity
Funding of manufacturers surcharge for existing patients taking ACE inhibitors for Congestive Heart Failure.a) Patients taking any ACE inhibitor for the treatment of congestive heart failure prior to 1 June 1998 can continue to have their ACE inhibitor treatment fully subsidised; b) Prescribers must endorse the prescription 'Congestive Heart Failure'. The endorsement can be typed (this includes computer generated prescriptions) or handwritten; c) The endorsement must be initialled in the prescriber's own handwriting. Definition of Congestive Heart FailureAt the request of some prescribers the PTAC Cardiovascular subcommittee has provided a definition of congestive heart failure for the purposes of the funding of the manufacturer's surcharge: "Clinicians should use their clinical judgement. Existing patients would be eligible for the funding of the surcharge if the patient shows signs and symptoms of congestive heart failure, and requires or has in the past required concomitant treatment with a
Special Authority for Subsidy - Form SA0423Initial application only from a gastroenterologist, general surgeon or general physician. Approvals valid for 3 years for applications meeting the following criteria: Any of the following: 1 All of the following: Duodenal Ulcer: 1.1 Duodenal ulcer proven by endoscopy or barium meal; and 1.2 Non healing duodenal ulcer proven by second barium meal; and 1.3 After failure of two alternative courses of H. pylori eradication therapy (if H. pylori positive); and 1.4 After H2 antagonist therapy for 8 weeks; or 2 All of the following: Gastric Ulcer: 2.1 Gastric ulcer proven by endoscopy; and 2.2 Non healing gastric ulcer and excluded malignancy demonstrated by a second endoscopy; and 2.3 After two alternative courses of H. pylori eradication therapy (if H. pylori positive); and 2.4 After H2 antagonist therapy for 12 weeks; or 3 All of the following: GORD: 3.1 Grade 0 GORD (normal endoscopy); and 3.2 Positive 24
Special Authority for Subsidy - Form SA0424Initial application - (Confirmed HIV/AIDS) only from a general physician. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 Confirmed HIV/AIDS; and 2 Any of the following: 2.1 Symptomatic patients aged 6 years and over with HIV/AIDS; or 2.2 Both: 2.2.1 Asymptomatic patients aged 6 years and over; and 2.2.2 CD4 counts < 500 cells/mm3; or 2.3 Both: 2.3.1 Asymptomatic patients aged 6 years and over; and 2.3.2 Viral load counts > 10,000 copies per ml; or 2.4 Symptomatic patients aged under 6 with HIV/AIDS ; or 2.5 Asymptomatic patients aged 12 months and under; or 2.6 Both: 2.6.1 Asymptomatic patients aged 1 to 5 years; and 2.6.2 CD4 counts < 1,000 cells/mm3; or 2.7 Both: 2.7.1 Asymptomatic patients aged 1 to 5 years; and 2.7.2 CD4 counts < 0.25 x total white cell count; or 2.8 Both: 2.8.1 Asymptomatic patients aged under 6 years; and
Special Authority for Subsidy - Form SA0450Initial application only from a psychiatrist. Approvals valid for 12 months for applications meeting the following criteria: Both: 1 Patients suffering from schizophrenia and related psychoses; and 2 Either: 2.1 Failed to respond to full trials (duration of at least 6 weeks each) of effective doses of at least two classes of anti-psychotic agents (refer to guidelines below); or 2.2 Demonstrated intolerance to other neuroleptic agents. NoteClinicians must confirm that informed consent and a satisfactory White Bloodcell Count (WBC) result has been obtained. Diagnosis: Treatment resistant schizophrenia and related psychoses when positive symptoms (delusions, hallucinations and thought disorder) are prominent and/or disabling or when both positive symptoms and negative symptoms (flattened affect, emotional and social withdrawal and poverty of speech) are present. Treatment: Trial therapy undertaken before initiating treatment with clozapine could
Special Authority for Subsidy - Form SA0471Initial application - (Breast cancer) from any medical practitioner. Approvals valid for 1 year where breast cancer in pre menopausal women unwilling or unable to undergo surgical or radiation oophorectomy. Initial application - (Prostate cancer) only from an oncologist, urologist or endocrinologist. Approvals valid for 1 year where advanced prostatic cancer when orchidectomy is contraindicated or where the patient strongly opposes orchidectomy. NoteNot to be prescribed with an anti-androgen except for a period of three weeks, if necessary, when GnRH analogue therapy is intiatedInitial application - (Endometriosis) only from a gynaecologist. Approvals valid for 3 months for applications meeting the following criteria: Both: 1 Endometriosis ; and 2 Either: 2.1 6 months treatment with medroxyprogesterone acetate, danazol or dimetriose has proven ineffective; or 2.2 The patient has failed to tolerate the treatment with medroxyprogesterone
Special Authority for Subsidy - Form SA0494Initial application only from an ophthalmologist. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 Both: 1.1 Primary open-angle glaucoma; and 1.2 Any of the following: 1.2.1 Patient cannot tolerate Beta-blockers, or Beta-blockers are contraindicated; or 1.2.2 Patient cannot tolerate Pilocarpine, or Pilocarpine is contraindicated; or 1.2.3 Patient cannot tolerate Dorzolamide, or Dorzolamide is contraindicated; or 1.2.4 A reduction in intraocular pressure of 15% or more is not achieved or maintained using dorzolamide either alone or in combination with a beta-blocker; or 2 There is progressive visual field loss and/or optic nerve damage persists after treatment with dorzolamide either alone or in combination with a beta-blocker. NoteSubsidised as monotherapy onlyRenewal only from an ophthalmologist. Approvals valid for 2 years where the treatment remains appropriate and the patient
Special Authority for Alternate Subsidy - Form SA0500Initial application from any medical practitioner. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 Either: 1.1 Patient is on a Social Welfare benefit; or 1.2 Patient has an income no greater than the benefit; and 2 Has tried at least one of the fully funded options and has been unable to tolerate it. Renewal from any medical practitioner. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 Patient is on a Social Welfare benefit; or 2 Patient has an income no greater than the benefit. NoteThe approval numbers of Special Authorities approved after 1 November 1999 are interchangeable between Mercilon and Marvelon. The additional subsidy will fund Mercilon and Marvelon up to the manufacturer's price for each of these products as identified on the Schedule at 1 November 1999Special Authorities approved before 1 November 1999 remain valid until the expiry d
Special Authority for Subsidy - Form SA0513Initial application - (Narcolepsy) only from a neurologist. Approvals valid for 24 months where narcolepsy. Initial application - (ADHD in patients aged 5 years or over) only from a paediatrician or psychiatrist. Approvals valid for 24 months for applications meeting the following criteria: Both: 1 ADHD (Attention Deficient and Hyperactivity Disorder) patients aged 5 years or over; and 2 Diagnosed according to DSM-IV or ICD 10 criteria. Initial application - (ADHD in patients under 5 years of age) only from a paediatrician or psychiatrist. Approvals valid for 12 months for applications meeting the following criteria: Both: 1 ADHD (Attention Deficient and Hyperactivity Disorder) patients under 5 years of age; and 2 Diagnosed according to DSM-IV or ICD 10 criteria. Renewal - (Narcolepsy or ADHD in patients under 5 years of age) only from a neurologist, paediatrician or psychiatrist. Approvals valid for 24 months where the treatment remains appr
Additional subsidy by endorsement for:Moclobemide tab 150 mg x 100 (Aurorix) up to $47.00Moclobemide tab 300 mg x 60 (Aurorix) up to $56.40Nefazadone tab 100 mg x 56 (Serzone) up to $20.16Nefazadone tab 200 mg x 56 (Serzone) up to $40.32Citalopram tab 20 mg x 28 (Cipramil) up to $27.00is available for patients who: * are taking moclobemide or nefazodone on 1 December 1999 or citalopram on 1 February2000; * have previously responded to treatment with moclobemide or nefazodone or citalopram; * have had a trial of fluoxetine and have to discontinue due to: - inability to tolerate the drug due to side effects OR - failed to respond to an adequate dose and duration of treatment; * have contraindications to fluoxetine (eg pre-existing significant levels of nausea, breastfeeding, potential drug interactions); The prescription must be endorsed accordingly. We recommend that the words used to indicate eligibility are "certified condition" however these particular words are not a requirement.
Special Authority for Subsidy - Form SA0539Initial application from any medical practitioner. Approvals valid for 5 years where the patient is likely to benefit from treatment. NoteApplications to be made on the approved forms which are available from: The Co-ordinatorPhone: 09 580 9176Multiple Sclerosis Treatment CommitteeFacsimile: 09 580 9205Level 3, Unisys HouseEmail: murray@ppc.govt.nz650 Great South Road, PenrosePrivate Bag, AUCKLANDBudget managed by appointed clinicians on the Multiple Sclerosis Treatment Assessments Committee (MSTAC). Applications will be considered by MSTAC at its regular meetings and approved subject to eligibility according to the Entry and Stopping criteria (below). Completed application forms must be sent to the co-ordinator for MSTAC and will be considered by MSTAC at the next practicable opportunity. Notification of MSTAC's decision will be sent to the patient, the applying clinician and the patient's GP (if specified). These agents will N
Additional subsidy by endorsement for:Moclobemide tab 150 mg x 100 (Aurorix) up to $47.00Moclobemide tab 300 mg x 60 (Aurorix) up to $56.40Nefazadone tab 100 mg x 56 (Serzone) up to $20.16Nefazadone tab 200 mg x 56 (Serzone) up to $40.32Citalopram tab 20 mg x 28 (Cipramil) up to $27.00is available for patients who: * were taking moclobemide or nefazodone on 1 December 1999 or citalopram on 1 February 2000; or* have previously responded to treatment with moclobemide, nefazodone or citalopram; or* have had a trial of fluoxetine and have to discontinue due to: - inability to tolerate the drug due to side effects; or - failed to respond to an adequate dose and duration of treatment; or* have contraindications to fluoxetine (eg pre-existing significant levels of nausea, breastfeeding, potential drug interactions); The prescription must be endorsed accordingly. We recommend that the words used to indicate eligibility are "certified condition" however these words are not a requirement.
Special Authority for Subsidy - Form SA0551Initial application only from a paediatrician, neurologist or general physician. Approvals valid for 15 months for applications meeting the following criteria: Any of the following: 1 Was on NAED therapy before 1 September 2000; or 2 Seizures are not adequately controlled with optimal older anti-epilepsy drug treatment; or 3 Seizures are controlled adequately but who experience unacceptable side effects from older anti-epilepsy drug treatment. NoteApproval entitles patients to a subsidy for one NAED. Dual NAED therapy will be subsidised for patients who were already stabilised on two NAEDs on or before 31 July 2000 or, for whom a second NAED has been added to therapy with one NAED provided an attempt to withdraw one NAED has been made and was unsuccessful. "Optimal older anti-epilepsy drug therapy" is defined as treatment with those older anti-epilepsy drugs which are indicated and clinically appropriate for the patient, given singly and in combin
Special Authority for Subsidy - Form SA0556Initial application - (Confirmed HIV/AIDS) only from a named general physician. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 Confirmed HIV/AIDS; and 2 Any of the following: 2.1 Symptomatic patient; or 2.2 Both: 2.2.1 Asymptomatic patient; and 2.2.2 Patient aged 12 months and under; or 2.3 Both: 2.3.1 Asymptomatic patient; and 2.3.2 Patient has viral load counts > 10,000 copies per ml or equivalent value on the Chiron test; or 2.4 All of the following: 2.4.1 Asymptomatic patient; and 2.4.2 Patient aged 1 to 5 years; and 2.4.3 CD4 counts < 1,000 cells/mm3; or 2.5 All of the following: 2.5.1 Asymptomatic patient; and 2.5.2 Patient aged 1 to 5 years; and 2.5.3 CD4 counts < 0.25 x total white cell count; or 2.6 All of the following: 2.6.1 Asymptomatic patient; and 2.6.2 Patient aged 6 years and over; and 2.6.3 CD4 counts
Special Authority for Subsidy - Form SA0557Initial application - (Single NAED Therapy) only from a paediatrician, neurologist or general physician. Approvals valid for 15 months for applications meeting the following criteria: Any of the following: 1 Was on NAED therapy before 1 September 2000; or 2 Seizures are not adequately controlled with optimal older anti-epilepsy drug treatment; or 3 Seizures are controlled adequately but who experience unacceptable side effects from older anti-epilepsy drug treatment. Note"Optimal older anti-epilepsy drug therapy" is defined as treatment with those older anti-epilepsy drugs which are indicated and clinically appropriate for the patient, given singly and in combination in adequate doses for the patient's age, weight, and other features affecting the pharmacokinetics of the drug with good evidence of complianceAs a guideline, clinical trials have referred to a notional 50% reduction in seizure frequency as an indicator of success with anti-convulsan
Additional subsidy by endorsement for:Moclobemide tab 150mg x 100 (Aurorix) up to $32.90Moclobemide tab 300mg x 60 (Aurorix) up to $39.48Nefazodone tab 100mg x 56 (Serzone) up to $20.16Nefazodone tab 200mg x 56 (Serzone) up to $40.32Citalopram tab 20mg x 28 (Cipramil) up to $27.00is available for patients who: * were taking moclobemide or nefazodone on 1 December 1999 or citalopram on 1 February 2000; or* have previously responded to treatment with moclobemide, nefazodone or citalopram; or* have had a trial of fluoxetine and have had to discontinue due to - inability to tolerate the drug due to side effects; or - failed to respond to an adequate dose and duration of treatment; or* have contraindications to fluoxetine (eg pre-existing significant levels of nausea, breastfeeding, potential drug interactions). The prescription must be endorsed accordingly. We recommend that the words used to indicate eligibility are "certified condition" however these words are not a requirement.
Additional subsidy by endorsement for:Moclobemide tab 150mg x 100 (Aurorix) up to $32.90Moclobemide tab 300mg x 60 (Aurorix) up to $39.48Nefazodone tab 100mg x 56 (Serzone) up to $20.16Nefazodone tab 200mg x 56 (Serzone) up to $40.32Citalopram tab 20mg x 28 (Cipramil and Celapram) up to $10.00Paroxetine hydrochloride tab 20 mg x 30 (Aropax) up to $35.02is available for patients who: * were taking moclobemide or nefazodone on 1 December 1999 or citalopram on 1 February 2000; or paroxetine hydrochloride on Februrary 2001; or * have previously responded to treatment with moclobemide or nefazodone or citalopram or paroxetine hydrochloride; or* have had a trial of fluoxetine and have had to discontinue due to - inability to tolerate the drug due to side effects; or - failed to respond to an adequate dose and duration of treatment; or* have contraindications to fluoxetine (eg pre-existing significant levels of nausea, breastfeeding, potential drug interactions). The prescription must be e
Special Authority for Subsidy - Form SA0589Initial application only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria: All of the following: 1 Anorexia and weight loss; and 2 Either: 2.1 decompensating liver disease without encephalopathy ; or 2.2 protein losing gastro-enteropathy; and 3 Either: 3.1 The product is to be used as a supplement (maximum 500 ml per day); or 3.2 The product is to be used as a complete diet.Renewal only from a relevant specialist or general practitioner on the recommendation of such a specialist. Approvals valid for 1 year for applications meeting the following criteria: All of the following: 1 The treatment remains appropriate and the patient is benefiting from treatment; and 2 Either: 2.1 The product is to be used as a supplement (maximum 500 ml per day); or 2.2 The product is to be used as a complete diet; and 3 General Practitioners must include the name of the specialis
Special Authority for Subsidy - Form SA0597Initial application - (PKU Patient aged over 16) only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria: Both: 1 PKU; and 2 blood phenylalanine level < 900 mmol/litre (average of tests over last 12 months). Initial application - (Patient aged over 16) only from a relevant specialist. Approvals valid for 3 years for applications meeting the following criteria: Any of the following: 1 dietary management of homocystinuria; or 2 inborn errors of metabolism other than PKU; or 3 dietary management of maple syrup urine disease..Initial application - (Patient aged 16 or under) only from a relevant specialist. Approvals valid for 3 years for applications meeting the following criteria: Any of the following: 1 dietary management of homocystinuria; or 2 PKU and other inborn errors of metabolism; or 3 dietary management of maple syrup urine disease..Renewal - (PKU Patient aged over 16
Special Authority for Subsidy - Form SA0609Initial application - (Serevent MDI, Serevent Accuhaler Foradil, Oxis Turbuhaler 12 mcg, Symbicort Turbuhaler) only from a relevant specialist or general practitioner. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 Both: 1.1 Child under the age of 12 with poorly controlled asthma; and 1.2 Either: 1.2.1 Required at least three months of 400 mcg or more daily inhaled beclomethasone or budesonide; or 1.2.2 Required at least three months of 200 mcg or more of fluticasone; or 2 Both: 2.1 Adult with poorly controlled asthma; and 2.2 Either: 2.2.1 Required at least three months of 1500 mcg or more daily inhaled beclomethasone or budesonide; or 2.2.2 Required at least three months of 750 mcg or more of fluticasone. NotePatients are to be reviewed at least at six months to assess compliance and effectiveness of therapy. Special Authority approvals are interchangeable among all prese
Special Authority for Subsidy - Form SA0626Initial application only from a renal physician. Approvals valid for 2 years for applications meeting the following criteria: All of the following: General Criteria: 1 Anaemia of end-stage renal failure (other treatable causes of anaemia being excluded); and 2 Been on haemodialysis or continuous ambulatory peritoneal dialysis (CAPD) for at least three months; and 3 Not under evaluation for, or awaiting, a live donor kidney transplant; and 4 Any of the following: Specific Criteria: 4.1 Anephric; or 4.2 Dependent on regular blood transfusion (1 unit each 4-8 weeks) to maintain haemoglobin > 60g/L; or 4.3 Dependent on regular blood transfusion but cannot be transfused because of severe transfusion reactions; or 4.4 Transfusion induced haemosiderosis (clinical manifestations, serum ferritin >1500 ug/L); or 4.5 Haemoglobin < 70 g/L (mean of at least 4 haemoglobin concentrations over 4 months); or 4.6 Both: 4.6.1 Haemo
Prescribing GuidelineTreatment with HMG CoA Reductase Inhibitors (Statins) is recommended for patients withdyslipidaemia and an absolute 5 year cardiovascular risk of 15% or greater. New Zealand Cardiovascular Guideline Group statement. "The 1996 Heart Foundation guidelines for the Assessment and Management of Dyslipidaemia are currently being revised. An evidence-based guideline on the Assessment and Management of Cardiovascular Risk will be developed in 2002. The Cardiovascular Guideline Group has written an interim consensus statement for themanagement of dyslipidaemia. The Heart Foundation cardiovascular risk tables should be used to determine risk. Certain groups are classified to be at very high risk (>20%) and should be treated as such: - Patients who have had a previous cardiovascular event (angina, MI, angioplasty, coronary artery bypass grafts, TIA, ischaemic stroke and peripheral vascular disease)- Patients with genetic lipid disorders- Patients with diabetes and associated microa
Special Authority for Subsidy - Form SA0643Initial application - (CML) only from an oncologist or relevant specialist. Approvals valid for 7 months where approved by the The Glivec Co-ordinator. Initial application - (GIST) only from an oncologist. Approvals valid for 1 year where approved by the The Glivec Co-ordinator. Renewal - (CML) only from an oncologist or relevant specialist. Approvals valid for 6 months where approved by the The Glivec Co-ordinator. Initial application - (GIST) only from an oncologist. Approvals valid for 1 year where approved by the The Glivec Co-ordinator. NoteApplication forms are available from, and prescriptions should be sent to: The Glivec Co-ordinatorPhone: 09 580 9176Level 3, Unisys HouseFacsimile: 09 580 9205650 Great South Road, PenroseEmail: murray@ppc.govt.nzPrivate Bag, AUCKLANDSpecial Authority criteria for CML - access by applicationFunded for patients with diagnosis (confirmed by a haematologist) of a chronic myeloid leukaemia (CML) i
Special Authority for Subsidy - Form SA0645Initial application only from a renal physician. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 Both: 1.1 patient in chronic renal failure; and 1.2 Haemoglobin <= 100 g/L; and 2 Either: 2.1 Both: 2.1.1 patient is not diabetic; and 2.1.2 glomerular filtration rate <= 30 ml/min; or 2.2 Both: 2.2.1 patient is diabetic; and 2.2.2 glomerular filtration rate <= 45 ml/min. Renewal only from a renal physician. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment. NoteErythropoietin beta is indicated in the treatment of anaemia associated with chronic renal failure (CRF) where no cause for anaemia other than CRF is detected and there is adequate monitoring of iron stores and iron replacement therapy. The Cockroft-Gault Formula may be used to estimate glomerular filtration rate (GFR) in persons 18 years and over:GFR (male)
Special Authority for Subsidy - Form SA0652Initial application - (Single NAED Therapy) only from a paediatrician, neurologist or general physician. Approvals valid for 15 months for applications meeting the following criteria: Any of the following: 1 Was on NAED therapy before 1 September 2000; or 2 Seizures are not adequately controlled with optimal older anti-epilepsy drug treatment; or 3 Seizures are controlled adequately but who experience unacceptable side effects from older anti-epilepsy drug treatment. Note"Optimal older anti-epilepsy drug therapy" is defined as treatment with those older anti-epilepsy drugs which are indicated and clinically appropriate for the patient, given singly and in combination in adequate doses for the patient's age, weight, and other features affecting the pharmacokinetics of the drug with good evidence of complianceInitial application - (Dual NAED Therapy) only from a paediatrician, neurologist or general physician. Approvals valid for 18 months for app
Additional subsidy by endorsement for:Moclobemide tab 150 mg x 500 (Apo-Moclobemide) up to $46.00Moclobemide tab 150 mg x 100 (Aurorix) up to $32.90Moclobemide tab 300 mg x 100 (Apo-Moclobemide) up to $26.11Moclobemide tab 300 mg x 60 (Aurorix) up to $39.48Nefazodone tab 100 mg x 56 (Serzone) up to $20.16Nefazodone tab 200 mg x 56 (Serzone) up to $40.32Citalopram tab 20 mg x 28 (Celapram) up to $4.00Citalopram tab 20 mg x 28 (Cipramil) up to $10.00Paroxetine hydrochloride tab 20 mg x 30 (Aropax) up to $35.02is available for patients who: - were taking moclobemide or nefazodone on 1 December 1999 or citalopram on 1 February 2000; or paroxetine hydrochloride on February 2001; or- have previously responded to treatment with moclobemide or nefazodone or citalopram or paroxetine hydrochloride; or- have had a trial of fluoxetine and have had to discontinue due to- inability to tolerate the drug due to side effects; or- failed to respond to an adequate dose and duration of treatment; or
Special Authority for Subsidy - Form SA0667Initial application only from a named specialist. Approvals valid for 4 months for applications meeting the following criteria: All of the following: 1 To be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and 2 Patient is less than 18 years of age at commencement of treatment; and 3 Patient has had severe active polyarticular course Juvenile Idiopathic Arthritis (JIA) for 6 months duration or longer; and 4 Patient has tried and not responded to at least three months of oral or parenteral methotrexate at a dose of 10-20mg/m2 weekly in combination with oral corticosteroids (prednisone 0.25 mg/kg); and 5 Patient has tried and not responded to at least three months of oral or parenteral methotrexate (at a dose of 10-15mg/m2 weekly) in combination with one other disease-modifying agent; and 6 Both: 6.1 Either: 6.1.1 Patient has persistent symptoms of poorly-cont
Special Authority for Subsidy - Form SA0700Initial application only from an ophthalmologist. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 Both: 1.1 Monotherapy in primary open-angle glaucoma; and 1.2 Any of the following: 1.2.1 Patient cannot tolerate Beta-blockers, Pilocarpine and Dorzolamide; or 1.2.2 Beta-blockers, Pilocarpine and Dorzolamide are contraindicated; or 1.2.3 A reduction in intraocular pressure of 15% or more is not achieved or maintained using dorzolamide either alone or in combination with a beta-blocker; or 1.2.4 There is progressive visual field loss and/or optic nerve damage persists after treatment with dorzolamide either alone or in combination with a beta-blocker; or 2 Adjunctive use for the treatment of patients who have met the initial application criteria, and in whom latanoprost monotherapy has been ineffective in controlling intraocular pressure.Note An adjunctive agent may be added without a
Effective, consistent management of herpes from prescribing to these guidelines will improve patient outcomes. The guidelines on the following four pages are for the prescribing of aciclovir. The guidelines aim to: - improve patient care and clinical outcome through faster, more accessible treatment - protect patients' wider wellbeing by reinforcing the psychosocial aspects of treatment - improve the consistency and breadth of medical management of genital herpes in New Zealand. The guidelines are: - integral to ensuring a consistent, effective treatment regimen- the result of consultation with clinicians and patient representatives- set out in line with the recommended international algorithm format for treatment. The guidelines are endorsed by the Herpes Foundation's professional advisory board whose members represent venereology, NZDS, RNZCGP, RNZCOG, psychotherapy and nursing. Herpes Foundation Helpline: Toll free 0508 11 12 13Auckland Branch Herpes Foundation: 09 360 1966
Guidelines for the use of interferon in the treatment of hepatitis C: Physicians considering treatment of patients with hepatitis C should discuss cases with a gastroenterologist or aninfectious disease physician. All subjects undergoing treatment require careful monitoring for side effects. Patients should be otherwise fit. Hepatocellular carcinoma should be excluded by ultrasound examination and alpha-fetoprotein level. Criteria for Treatment a) Diagnosis- Anti-HCV positive on at least two occasions with a positive PCR for HCV-RNA and preferably confirmed by asupplementary RIBA test; or- PCR-RNA positive for HCV on at least 2 occasions if antibody negative; or- Anti-HCV positive on at least two occasions with a positive supplementary RIBA test with a negative PCR forHCV RNA but with a liver biopsy consistent with 2(b) following. b) Establishing Active Chronic Liver Disease- Confirmed HCV infection and serum ALT/AST levels measured on at least three occasions over six monthsaveraging >
Special Authority for Subsidy - Form SA0714Initial application from any medical practitioner. Approvals valid for 3 months for applications meeting the following criteria: All of the following: 1 Patient is currently enrolled in a recognised comprehensive treatment programme for alcohol dependence in a service accredited against the New Zealand Alcohol and Other Drug Sector Standard or the National Mental Health Sector Standard; and 2 Applicant works in an Alcohol & Drug Service; and 3 Applicant must include the address of the service (Details to be attached to application). Renewal from any medical practitioner. Approvals valid for 3 months for applications meeting the following criteria: Both: 1 Compliance with the medication (prescriber determined); and 2 Any of the following: 2.1 Patient is still unstable and requires further treatment; or 2.2 Patient achieved significant improvement but requires further treatment; or 2.3 Patient is well controlled but requires maint
(a) Subsidy is available between 1 March and 30 June of each year for patients who meet the following criteria, as set by the Ministry of Health: a) all people 65 years of age and over; b) people under 65 years of age with: i) the following cardiovascular disease: 1) ischaemic heart disease, 2) congestive heart disease, 3) rheumatic heart disease, 4) congenital heart disease, or 5) cerebo-vascular disease; ii) the following chronic respiratory disease: 1) asthma, if on a regular preventative therapy, or 2) other chronic respiratory disease with impaired lung function; iii) diabetes; iv) chronic renal disease; v) any cancer, excluding basal and squamous skin cancers if not invasive; vi) the following other conditions: 1) autoimmune disease, 2) immune suppression, 3) HIV, 4) transplant recipients, 5) neuromuscular and CNS diseases, 6) haemoglobinopathies, or 7) children on long term aspirin. The following conditions are excluded from funding: i) asthma not requiri
(a) Subsidy is available between 1 March and 30 June of each year for patients who meet the following criteria, as set by the Ministry of Health: a) all people 65 years of age and over; b) people under 65 years of age with: i) the following cardiovascular disease: 1) ischaemic heart disease, 2) congestive heart disease, 3) rheumatic heart disease, 4) congenital heart disease, or 5) cerebo-vascular disease; ii) the following chronic respiratory disease: 1) asthma, if on a regular preventative therapy, or 2) other chronic respiratory disease with impaired lung function; iii) diabetes; iv) chronic renal disease; v) any cancer, excluding basal and squamous skin cancers if not invasive; vi) the following other conditions: 1) autoimmune disease, 2) immune suppression, 3) HIV, 4) transplant recipients, 5) neuromuscular and CNS diseases, 6) haemoglobinopathies, or 7) children on long term aspirin. The following conditions are excluded from funding: i) asthma not requiri
Special Authority for Subsidy - Form SA0776Initial application only from a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Any of the following: 1 Both: 1.1 The patient has ovarian, fallopian* or primary peritoneal cancer*; and 1.2 Either: 1.2.1 Has not received prior chemotherapy; or 1.2.2 Has received prior chemotherapy but has not previously been treated with taxanes; or 2 The patient has metastatic breast cancer; or 3 Both: 3.1 The patient has non-small cell lung cancer; and 3.2 Either: 3.2.1 The patient has advanced disease (stage IIIa or above); or 3.2.2 The patient is receiving combined chemotherapy and radiotherapy; or 4 Both: 4.1 The patient has small-cell lung cancer*; and 4.2 Paclitaxel is to be used as second-line therapy. Renewal only from a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Both: 1 The patient has metastati
Special Authority for Subsidy - Form SA0777Initial application - (Post-transplant) only from a relevant specialist. Approvals valid for 6 months where the patient has B-cell post-transplant lymphoproliferative disorder*. NoteFor no more than 8 treatment cycles. Initial application - (Low-grade lymphomas) only from a relevant specialist. Approvals valid for 6 months where the patient has low grade NHL - relapsed disease following prior chemotherapy. NoteFor no more than 4 treatment cycles. Initial application - (Large cell lymphomas) only from a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Both: 1 The patient has treatment naive large B-cell NHL; and 2 To be used with CHOP (or alternative anthracycline containing multi-agent chemotherapy regime given with curative intent).NoteFor no more than 8 treatment cycles. Renewal - (Low-grade lymphomas) only from a relevant specialist. Approvals valid for 6 months for applications meeting
Special Authority for Subsidy - Form SA0779Initial application - (Confirmed HIV/AIDS) only from a named specialist. Approvals valid without further renewal unless notified for applications meeting the following criteria: Both: 1 Confirmed HIV infection; and 2 Any of the following: 2.1 Symptomatic patient; or 2.2 Patient aged 12 months and under; or 2.3 Both: 2.3.1 Patient aged 1 to 5 years; and 2.3.2 Any of the following: 2.3.2.1 CD4 counts < 1,000 cells/mm3; or 2.3.2.2 CD4 counts < 0.25 x total lymphocyte count; or 2.3.2.3 Viral load counts > 100,000 copies per ml; or 2.4 Both: 2.4.1 Patient aged 6 years and over; and 2.4.2 CD4 counts < 350 cells/mm3. NoteTenofovir disoproxil fumarate prescribed under endorsement for HIV/AIDS is included in the count of up to 3 subsidised antiretrovirals. Subsidies for a combination of up to three anti-retroviral medications, including a maximum of two protease inhibitors. Combinations including r
Special Authority for Subsidy - Form SA0780Initial application - (Single NAED Therapy) only from a paediatrician, neurologist or general physician. Approvals valid for 15 months for applications meeting the following criteria: Any of the following: 1 Was on NAED therapy before 1 September 2000; or 2 Seizures are not adequately controlled with optimal older anti-epilepsy drug treatment; or 3 Seizures are controlled adequately but who experience unacceptable side effects from older anti-epilepsy drug treatment. Note"Optimal older anti-epilepsy drug therapy" is defined as treatment with those older anti-epilepsy drugs which are indicated and clinically appropriate for the patient, given singly and in combination in adequate doses for the patient's age, weight, and other features affecting the pharmacokinetics of the drug with good evidence of complianceInitial application - (Dual NAED Therapy) only from a paediatrician, neurologist or general physician. Approvals valid for 18 months for app
Special Authority for Subsidy - Form: SA0792Initial application only from a psychiatrist. Approvals valid for 6 months for applications meeting the following criteria: All of the following: 1 The patient has schizophrenia or other psychotic disorder; and2 Has tried but failed to comply with treatment using oral atypical anti-psychotic agents; and3 Has been admitted to hospital or treated in respite care, or intensive outpatient or home-based treatment for 30 days or more in last 12 months. Renewal only from a psychiatrist. Approvals valid for 12 months for applications meeting the following criteria: Either: 4 Both: 4.1 The patient has had less than 12 months treatment with risperidone microspheres; and 4.2 There is no clinical reason to discontinue treatment; or5 The initiation of risperidone microspheres has been associated with fewer days of intensive intervention than was the case during a corresponding period of time prior to the initiation of risperidone microspheres. NoteRisp
Special Authority for Subsidy - Form SA0801Initial application - (Serevent Accuhaler, Foradil, Symbicort Turbuhaler) only from a relevant specialist or general practitioner. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 Both: 1.1 Child under the age of 12 with poorly controlled asthma; and 1.2 Either: 1.2.1 Required at least three months of 400 mcg or more daily inhaled beclomethasone or budesonide; or 1.2.2 Required at least three months of 200 mcg or more of fluticasone; or 2 Both: 2.1 Adult with poorly controlled asthma; and 2.2 Either: 2.2.1 Required at least three months of 1500 mcg or more daily inhaled beclomethasone or budesonide; or 2.2.2 Required at least three months of 750 mcg or more of fluticasone. NotePatients are to be reviewed at least at six months to assess compliance and effectiveness of therapy. Special Authority approvals are interchangeable among all presentations of inhaled long-acting beta
Access by applicationa) Budget managed by appointed clinicians on the Multiple Sclerosis Treatment Assessments Committee (MSTAC). b) Applications will be considered by MSTAC at its regular meetings and approved subject to eligibility according to the Entry and Stopping criteria (below). c) Applications to be made on the approved forms which are available from the co-ordinator for MSTAC:The Co-ordinator Phone: (04) 460 4990Multiple Sclerosis Treatment Assessments Committee Facsimile: (04) 916 7571PHARMAC, PO Box 10 254 E mail: silvia.valsenti@pharmac.govt.nzWellingtond) Completed application forms must be sent to the co-ordinator for MSTAC and will be considered by MSTAC at the next practicable opportunity. e) Notification of MSTAC's decision will be sent to the patient, the applying clinician and the patient's GP (if specified). f) These agents will not be subsidised if dispensed from a community or hospital pharmacy. Regular supplies will be distributed to all approved patients or their c
Special Authority for Subsidy - Form: SA0809Initial application only from a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Any of the following: 1 Both: 1.1 The patient has ovarian*, fallopian* or primary peritoneal cancer*; and 1.2 Either: 1.2.1 Has not received prior chemotherapy; or 1.2.2 Has received prior chemotherapy but has not previously been treated with taxanes; or2 The patient has metastatic breast cancer; or3 Both: 3.1 The patient has non small-cell lung cancer; and 3.2 Either: 3.2.1 Has advanced disease (stage IIIa or above); or 3.2.2 Is receiving combined chemotherapy and radiotherapy; or4 Both: 4.1 The patient has small-cell lung cancer*; and 4.2 Docetaxel is to be used as second-line therapy. Renewal only from a relevant specialist. Approvals valid for 12 months for applications meeting the followingcriteria: 5. The patient has metastatic breast cancer, non small-cell lung cancer,
Special Authority for SubsidyInitial application only from a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria: All of the following1 Patient is an adult who has had severe and active erosive Rheumatoid Arthritis for six months duration or longer; and2 Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and3 Patient has tried and not responded to at least three months of oral or parenteral methotrexate at a dose of at least 20 mg weekly or a maximum tolerated dose; and4 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with at least two of the following (triple therapy): sulphasalazine, prednisone at a dose of at least 7.5 mg per day, azathioprine, intramuscular gold, or hydroxychloroquine sulphate (at maximum tolerated doses); and5 Patient has tried and not responded to at least three months therapy at th
Special Authority for Subsidy Initial application for patients with type 2 diabetes only from a relevant specialist. Approvals valid for one year for applications meeting the following criteria: Any of the following: Monotherapy1 All of the following: 1.1 To be used as monotherapy for patients who after six months of diet and lifestyle changes have inadequate glycaemic control (defined as HbA1c > 7.0% in tests carried out at least two months apart); and 1.2 Metformin is contraindicated or not tolerated after a minimum of a four week trial period; and 1.3 Sulphonylurea is contraindicated or not tolerated or the patient's body mass index (BMI) exceeds 33 kg/m2; orIn combination with sulphonylurea2 Both: 2.1 For use in combination with a sulphonylurea for patients who after diet and lifestyle changes and a six-month trial of sulphonylurea have poor glycaemic control (defined as HbA1c > 8.0% measured within the last month of the six month period); and 2.2 Metformin is contrain
Special Authority for Subsidy - Retail Pharmacy - Form SA0829Initial Application only from gastroenterologist or infectious disease specialist. Approvals valid for 1 year for applications meeting the following criteria: All of the following: 1. Patient has confirmed Hepatitis B infection (HBsAg+); andDocumented resistance to lamivudine, defined as: 2. patient has raised serum ALT (> 1 x ULN); and3. patient has HBV DNA greater than 100,000 copies per mL, or viral load ? 10 fold over nadir; and4. detection of M204I or M204V mutation; and5. Either5.1. Both5.1.1. patient is cirrhotic; and5.1.2. adefovir dipivoxil to be used in combination with lamivudine; or5.2. Both5.2.1. patient is not cirrhotic; and5.2.2. adefovir dipivoxil to be used as monotherapyRenewal only from a gastroenterologist or infectious disease specialist. Approvals valid for 2 years for applications where in the opinion of the treating physician, treatment remains appropriate and patient is benefiting from treatmen
Special Authority for Subsidy - Form: SA0834Initial application only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria: Either: 1 Both: 1.1 Patient has type 1 diabetes and has received an intensive regimen (injections at least three times a day) of an intermediate acting insulin in combination with a rapid acting insulin analogue for at least three months; and1.2 Either: 1.2.1 Patient has experienced more than one unexplained severe hypoglycaemic episode in the previous 12 months (severe defined as requiring the assistance of another person); or1.2.2 Patient has experienced unexplained symptomatic nocturnal hypoglycaemia, biochemically documented at <3.0 mmol/L, more than once a month despite optimal management; or2 Patient has documented severe, or continuing, systemic or local allergic reaction to existing insulins. Note this does not include hypoglycaemic episodes. Renewal only from a relevant specialist or general practitioner. Approv
Special Authority for Subsidy - Form SA0835Initial application - (Breast cancer) from any medical practitioner. Approvals valid for 1 year: where the patient is a premenopausal woman with breast cancer. Initial application - (Prostate cancer) only from an oncologist, urologist or endocrinologist. Approvals valid for 1 year for applications meeting the following criteria: Advanced prostatic cancer;. Note Not to be prescribed with an anti-androgen except for a period of three weeks, if necessary, when GnRH analogue therapy is initiated. Initial application - (Endometriosis) only from a gynaecologist. Approvals valid for 3 months for applications meeting the following criteria: Both: 1 Endometriosis; and2 Either: 2.1 6 months treatment with medroxyprogesterone acetate, danazol or dimetriose has proven ineffective; or2.2 The patient has failed to tolerate the treatment with medroxyprogesterone acetate, danazol or dimetriose for 6 months. Note The maximum treatment period for a GnRH analogue is:
Special Authority for Subsidy - Form SA0836Initial application - (Breast cancer) from any medical practitioner. Approvals valid for 1 year where the patient is a premenopausal woman with breast cancer. Initial application - (Prostate cancer) only from an oncologist, urologist or endocrinologist. Approvals valid for 1 year for applications meeting the following criteria: Either: 1 Advanced prostatic cancer; or. 2 Locally advanced prostatic cancer. Note Not to be prescribed with an anti-androgen except for a period of three weeks, if necessary, when GnRH analogue therapy is initiated. Initial application - (Endometriosis) only from a gynaecologist. Approvals valid for 3 months for applications meeting the following criteria: Both: 3 Endometriosis; and4 Either: 4.1 6 months treatment with medroxyprogesterone acetate, danazol or dimetriose has proven ineffective; or4.2 The patient has failed to tolerate the treatment with medroxyprogesterone acetate, danazol or dimetriose for 6 months. Note
Special Authority for Subsidy - Form SA0837Initial application - (Breast cancer) from any medical practitioner. Approvals valid for 1 year where the patient is a premenopausal woman with breast cancer. Initial application - (Prostate cancer) only from an oncologist, urologist or endocrinologist. Approvals valid for 1 year where the patient has: Advanced prostatic cancer;. Note Not to be prescribed with an anti-androgen except for a period of three weeks, if necessary, when GnRH analogue therapy is initiated. Initial application - (Endometriosis) only from a gynaecologist. Approvals valid for 3 months for applications meeting the following criteria: Both: 1 Endometriosis; and2 Either: 2.1 6 months treatment with medroxyprogesterone acetate, danazol or dimetriose has proven ineffective; or2.2 The patient has failed to tolerate the treatment with medroxyprogesterone acetate, danazol or dimetriose for 6 months. Note The maximum treatment period for a GnRH analogue is: - 3 months to assess whet
Special Authority for Subsidy - Form: SA0838Initial Application only from a relevant specialist or General Practitioner. Approvals valid for 2 years forapplications meeting the following criteria: Either: 1 All of the following: 1.1 Patient is a child under the age of 12; and1.2 All of the following: Has, for 3 months or more, been treated with:1.2.1 An inhaled long-acting beta adrenoceptor agonist; and1.2.2 Inhaled corticosteroids at a dose of at least 400 mcg per day beclomethasone or budesonide, or200 mcg per day fluticasone; and1.3 The prescriber considers that the patient would receive additional clinical benefit from switching to acombination product; or2 All of the following: 2 .1 Patient is over the age of 12; and2 .2 All of the following: Has, for 3 months or more, been treated with:2 .2.1 An inhaled long-acting beta adrenoceptor agonist; and2 .2.2 Inhaled corticosteroids at a dose of at least 800 mcg per day beclomethasone or budesonide, or500 mcg per day fluticasone;
Special Authority for Subsidy - Form SA0839Initial application - (Breast cancer) from any medical practitioner. Approvals valid for 1 year where the patient is a premenopausal woman with breast cancer. Initial application - (Prostate cancer) only from an oncologist, urologist or endocrinologist. Approvals valid for 1 year for applications meeting the following criteria: Either: 1 Advanced prostatic cancer; or. 2 Neoadjuvant or adjuvant treatment of locally advanced prostatic cancer. Note Not to be prescribed with an anti-androgen except for a period of three weeks, if necessary, when GnRH analogue therapy is initiated. Initial application - (Endometriosis) only from a gynaecologist. Approvals valid for 3 months for applications meeting the following criteria: Both: 3 Endometriosis; and4 Either: 4.1 6 months treatment with medroxyprogesterone acetate, danazol or dimetriose has proven ineffective; or4.2 The patient has failed to tolerate the treatment with medroxyprogesterone acetate, danazo
Special Authority for Subsidy - Form: SA842Initial application only from a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Any of the following: 1 Both: 1.1 The patient has ovarian, fallopian* or primary peritoneal cancer*; and 1.2 Either: 1.2.1 Has not received prior chemotherapy; or 1.2.2 Has received prior chemotherapy but have not previously been treated with taxanes; or2 The patient has metastatic breast cancer; or3 The patient has node-positive early breast cancer; or4 Both 4.1 The patient has non small-cell lung cancer; and 4.2 Either: 4.2.1 Has advancing disease (stage IIIa or above); or 4.2.2 Is receiving combined chemotherapy and radiotherapy; or5 Both: 5.1 The patient has small-cell lung cancer*; and 5.2 Paclitaxel is to be used as second-line therapy. Renewal only from a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: 6 The patient has metasta
RestrictionCode Type Value Attribute Waiver
129 FormMax 3 Rx
14 PCT
131 Combined
133 NO RULE
134 FormMax 100 Rx
136 FormReqd Rx
137 FormMax 14 Rx
139 FormReqd Rx
138 NO RULE
140 Special
141 FormBan BSO
142 FormMax 3.5 Rx
143 FormReqd Rx
146 Combined
153 SpecialWav
479 FormMax 6000 Rx
197 MaxQtyDisp 2000
447 SpecOnly Retail
157 SpecialWav
158 NO RULE
159 NO RULE
160 NO RULE
162 NO RULE
163 NO RULE
166 DoseMMax 500
167 NO RULE
168 NO RULE
169 NO RULE
170 NO RULE
171 NO RULE
172 FormMax 6 Rx SpecEnd
688 Combined
173 NO RULE
175 Application
15 PCT only
178 SpecialWav
615 Special
180 Controlled
781 Special
788 SpecialWav
183 Combined
184 DoseSMax 100
185 Combined
147 FormReqd Rx
186 NO RULE
187 NO RULE
189 Combined
190 FormMax 10 Rx
789 Special
191 NO RULE
192 Combined
193 Combined
194 FormMax 10 Rx
791 SubRxF
195 Combined
196 Combined
199 ProvReqd M
148 FormMax 100 Rx
201 FormMax 100 Rx
849 Special
202 NO RULE
203 FormMax 100 Rx
149 FormReqd Rx
205 MaxQtyDisp 25
756 Dispensary Xpharm
206 ProvReqd M
208 NO RULE
210 FormMax 2 Rx Special
693 Application
212 NO RULE
215 NO RULE
280 Special
150 SpecialWav
221 FormMax 10 WSO
151 FormReqd WSO
222 NO RULE
223 FormMax 4 Rx
152 FormReqd Rx
224 NO RULE
809 Special
810 AltSubSA
850 SubRxF
233 FormMax 30 Rx SpecEnd
234 FormMax 1 Rx SubRxF
824 NO RULE Guideline
643 Special
609 Application
256 Special
826 Special
929 Special
25 SpecEnd Hospital
543 FormBan WSO
545 NO RULE
396 NO RULE
400 Preferred
401 Special
402 Special
403 Special
404 Special
936 Special
410 SpecialWav
411 SpecialWav
420 AltSubRxF
421 SoleSupply
423 Special
424 Special SpecEnd
429 Wastage
430 Special
432 FormMax 15 Rx
176 FormReqd Rx
434 SpecialWav
435 SpecialWav
436 SpecialWav
443 Special
445 Special
446 FormMax 2 Rx
708 NO RULE Guideline
709 NO RULE Guideline
450 Special
451 SpecialWav
452 SpecialWav
454 NO RULE
455 FormMax 100 Rx
179 FormReqd Rx
456 Special
458 Special
459 Special
460 SpecialWav
461 Special
710 Special
462 SpecOnly Hospital
464 Application
465 DoseMMax 500
5026 Xref A1904
466 AltSubSA
467 Application
827 SubRxF
468 SpecOnly Retail
469 NO RULE
470 Special
471 Special
472 Special
473 Special
474 FormMax 500 Rx
5027 Xref A0716
478 FormMax 200 Rx
701 ProvReqd M
188 FormReqd Rx
480 FormMax 100 Rx
481 Combined
482 Combined
483 Combined
484 Combined
485 Combined
486 Combined
487 Combined
488 Special
489 SpecialWav
490 Special
5028 Xref A1017
493 DoseMMax 500
702 Special
494 Special
495 FormMax 50 Rx
705 NO RULE
496 FormMax 30 Rx
706 Special
497 FormReqd Rx
498 FormMax 6 Rx
829 Special
499 MaxQtyDisp 6
500 AltSubSA
738 Special
502 FormMax 3 Rx SubRxF
740 NO RULE Guideline
833 Special
503 FormWt 500 Rx Special
504 FormMax 3 Rx SpecEnd
834 Special
835 Special
29 S29
508 Special
509 Special
510 Application
511 Special
512 Special
939 Special
513 Special
838 Special
514 SpecOnly Hospital
515 AltSubSA Claim only
207 DoseWMax 1
209 FormReqd Rx
516 Special
840 DoseDMax 2
519 Combined
521 Combined
610 Special
523 Special
524 FormMax 35 Rx
525 FormMax 25 Rx Special
526 FormMax 21 Rx
841 Special
527 FormMax 42 Rx
528 Special
530 Safety Uncompounded
532 Contraceptive
533 Statim May
941 Special
535 AltSubRxF
536 AltSubRxF
537 FormMax 12 Rx
942 AltSubSA
538 Application
539 Special
943 AltSubSA
563 Special
542 FormMax 15 Rx
211 FormReqd Rx
213 FormBan PSO
944 FormMax 4 Rx SpecEnd
1022 NO RULE
946 Special
947 Special
948 Special
949 Special
950 NO RULE
951 Special
952 Special
953 Special
973 Special
957 Special
967 Special
968 Special
969 Special
970 NO RULE
12000 FormMax 2000 PSO
974 Special
264 Special
265 SpecialWav
266 Special
267 NO RULE
269 Special
270 Special
271 SpecialWav
273 NO RULE
274 Special
275 Special
276 Special
975 Special
278 NO RULE
279 FormMax 125 BSO
154 FormReqd BSO
281 SpecOnly Hospital
283 SpecOnly Retail
284 FormMax 21 Rx
844 Repeat
285 FormMax 15 Rx
845 Special
286 SpecialWav
611 Special
618 Special Claim only
717 SpecialWav
289 SpecEnd Retail
290 Special
291 Application
293 NO RULE
294 NO RULE
295 NO RULE
1006 NO RULE
214 FormBan Rx
300 Special
301 Special
303 Application
612 SpecialWav
1007 NO RULE
979 MaxQtyDisp 384
309 Special
980 MaxQtyDisp 216
311 Special
312 Application
313 SpecialWav
314 AltSubSA Claim only
156 DoseWMax 2
161 FormReqd Rx
315 AltSubSA Claim only
164 DoseWMax 2
165 FormReqd Rx
981 MaxQtyDisp 28
317 Special
719 Repeat
319 SpecOnly Retail
320 NO RULE
323 Special
324 NO RULE
325 Special
328 Special
338 NO RULE Guideline
620 NO RULE Guideline
621 Special
341 Special
622 Application
217 FormReqd WSO
720 FormMax 108 PSO
982 FormMax 768 Rx
348 NO RULE
349 Special
983 FormMax 432 Rx
613 AltSubSA
627 NO RULE Guideline
633 Special
355 FormMax 3 Rx
721 Special
357 FormMax 6 Rx
219 SubRxF
359 NO RULE
360 NO RULE
361 Special
366 Special
634 NO RULE
370 Safety Compounded
636 SubRxF
37 DoseDMax 1
638 NO RULE
727 Special
378 NO RULE
639 Special
380 NO RULE
5004 Xref A310301
382 Special
383 NO RULE
640 SpecialWav
386 NO RULE
387 Special
388 NO RULE
389 NO RULE
391 Special
392 FormMax 100 Rx
174 FormReqd Rx
394 SpecialWav
225 Dispensary HP1
984 FormMax 56 Rx
6 Special
9 Combined
11 Special
21 TreatMax 30
22 FormReqd Rx
23 SpecEnd Hospital
24 SpecEnd Retail
26 DoseDMax 2
27 FormReqd Rx
28 Special
730 DoseDMax 1.5
30 DoseDMax 1
31 Special
32 DoseDMax 1
33 FormReqd PSO
34 AltSubSA Claim only
58 DoseWMax 1
62 FormReqd Rx
35 SpecialWav
36 NO RULE
732 Special
38 NotCombined
39 DoseMMax 30
40 NotCombined
41 Special
43 NO RULE
44 NO RULE
45 Special
46 Special
47 Special
48 NotCombined
49 NO RULE
50 Application
51 Special
53 Special
54 FormReqd Rx
55 Special
56 Special
57 Special
59 FormMax 3 Rx
847 Special
60 DoseMMax 6
61 FormReqd PSO
64 MaxQtyDisp 2
1008 NO RULE
66 NO RULE
733 Special
848 Combined
69 Special
70 SpecialWav
71 FormReqd Rx
5015 Xref StdFormulae
73 FormMax 30 Rx
986 SubRxF
74 FormMax 6 Rx
95 FormReqd Rx
75 DoseMMax 1
76 FormMax 42 Rx
987 Special
77 NO RULE
78 NO RULE
79 NO RULE
80 NO RULE
81 NO RULE
82 FormReqd WSO
83 AltSubSA Claim only
101 DoseWMax 2
106 FormReqd Rx
84 AltSubSA Claim only
107 DoseMMax 1
109 FormReqd Rx
85 Special
86 NO RULE
87 Special
88 Special
89 Special
90 Special
91 Special
92 Special
94 Special
96 Special
97 Special
98 NO RULE
99 Special
100 Special
102 NO RULE
103 NO RULE
108 Special
110 Special
111 DoseSMax 5
130 FormReqd Rx
112 DoseDMax 4
113 DoseSWt 100
132 FormReqd Rx
114 DoseSMax 1
135 FormReqd Rx
115 Special
117 DoseMMax 30
118 TreatMax 90
119 Special
120 NO RULE
121 Special
122 Special
124 SpecOnly Retail
125 Special
127 FormMax 15 Rx
128 NO RULE
544 NO RULE
546 AltSubRxF
547 NO RULE Guideline
63 SubRxF
551 Special
552 FormReqd QEC
555 DoseDWt 10
556 Special
568 AltSubRxF
572 Special
575 Application
577 SubRxF
579 Special
548 FormMax 4 Rx
624 SubRxF
606 Special
625 FormMax 20 WSO
637 Special
104 DoseSMax 1
116 FormReqd Rx
642 FormMax 20 WSO
645 Special
226 Dispensary HP2&3
227 Dispensary HP3
228 Dispensary HP4
774 Special
648 SpecialWav
649 Special
775 Special
776 Special
650 NO RULE Guideline
652 Application
851 Special
522 Statim Must
6001 Graphic cardiovascular.txg
696 Special
5002 Xref A220101
656 AltSubRxF
931 NO RULE
657 Application
658 AltSubRxF
661 Special
793 SubRxF
663 FormMax 10 Rx
5003 Xref A1622
345 NO RULE
666 NO RULE
667 Special
671 NO RULE
672 AltSubRxF
673 Application
676 NO RULE
677 Combined
679 Combined
681 NO RULE
683 SpecialWav Claim only
684 SubRxF Special
692 Special
700 Special
703 Special
792 Special
713 Special
716 NO RULE Guideline
725 Special
726 FormMax 2 Rx Special
734 NO RULE Guideline
735 NO RULE
934 Special
743 Special
220 MaxQtyDisp 3
746 FormMax 6 Rx
757 Special
795 FormMax 4 PSO
749 AltSubRxF
750 Special
752 NO RULE
753 SpecialWav
754 Special
755 Special
758 Special
760 NO RULE Guideline
761 NO RULE
1023 FormMax 20 Rx
765 NO RULE
766 SubRxF
767 SpecOnly Retail
768 SpecOnly Hospital
770 NO RULE
772 Application
773 AltSubRxF
796 Special
798 Special
799 Special
804 NO RULE Guideline
822 NO RULE
825 NO RULE
836 Special
832 Special
839 Special
846 Special
5016 Xref StdFormulae
5017 Xref StdFormulae
5018 Xref StdFormulae
5019 Xref StdFormulae
5020 Xref StdFormulae
5021 Xref StdFormulae
5022 Xref A310301
857 NO RULE
5024 Xref StdFormulae
5025 Xref A1019
1026 Special
5007 Xref A1603
852 NO RULE
938 SpecialWav
855 Special
858 NO RULE
859 Special
958 Special
861 NO RULE
5029 Xref A1004
862 Special
863 Special
864 Special
873 Special
867 Special
868 Special
869 Special
870 Special
871 Special
875 Special
878 Special
879 Special
884 Special
886 AltSubRxF
887 Application
891 Special
892 FormMax 60 Rx
894 NO RULE
895 Special
897 AltSubRxF
898 Repeat
899 Special
900 Special
901 Special
903 AltSubRxF
904 Combined
905 SubRxF
906 Special
909 Special
910 NO RULE
911 Special
912 Special
913 Special
914 Special
918 SubRxF
976 Special
920 Special
921 Special
923 Special
925 Special
926 Special
928 Special
10001 FormMax 1 PSO
10005 FormMax 5 PSO
10006 FormMax 6 PSO
985 NO RULE
10010 FormMax 10 PSO
10012 FormMax 12 PSO
10015 FormMax 15 PSO
10020 FormMax 20 PSO
10030 FormMax 30 PSO
10040 FormMax 40 PSO
10063 FormMax 63 PSO
10072 FormMax 72 PSO
10075 FormMax 75 PSO
10084 FormMax 84 PSO
Trial Version
Not all rows exported
BrandCodeExtent Effective Expiry Type Value Attribute Waiver XML
10090101 ATC3 7/1/1999 6/30/2006 Special
10090101 Brand 11/1/2004 6/30/2007 SoleSupply
10090101 ATC3 9/1/1996 ######## Special
10090201 ATC3 9/1/1996 ######## Special
10090201 Brand 11/1/2004 6/30/2007 SoleSupply
10090201 ATC3 7/1/1999 6/30/2006 Special
10090201 ATC3 2/1/1998 6/30/1999 Special
10090201 Chemical 7/1/2006 7/31/2009 Special
10090201 Chemical 1/1/1999 7/31/2010 Dispensary HP3
10090201 ATC3 12/1/1996 1/31/1998 Special
10090201 ATC3 5/16/1994 8/31/1996 Special
10092525 ATC3 5/16/1994 8/31/1996 Special
10092525 ATC3 12/1/1996 1/31/1998 Special
10092525 Chemical 1/1/1999 7/31/2010 Dispensary HP3
10092525 Chemical 7/1/2006 7/31/2009 Special
10092525 ATC3 2/1/1998 6/30/1999 Special
10092525 ATC3 7/1/1999 6/30/2006 Special
10092525 ATC3 9/1/1996 ######## Special
10092625 ATC3 9/1/1996 ######## Special
10092625 ATC3 2/1/1998 6/30/1999 Special
10092625 ATC3 7/1/1999 6/30/2006 Special
10092625 Chemical 7/1/2006 7/31/2009 Special
10092625 Chemical 1/1/1999 7/31/2010 Dispensary HP3
10092625 ATC3 12/1/1996 1/31/1998 Special
10092625 ATC3 5/16/1994 8/31/1996 Special
10092725 ATC3 5/16/1994 8/31/1996 Special
10092725 ATC3 12/1/1996 1/31/1998 Special
10092725 Chemical 1/1/1999 7/31/2010 Dispensary HP3
10092725 Chemical 7/1/2006 7/31/2009 Special
10092725 ATC3 7/1/1999 6/30/2006 Special
10092725 ATC3 2/1/1998 6/30/1999 Special
10092725 ATC3 9/1/1996 ######## Special
10092825 ATC3 9/1/1996 ######## Special
10092825 ATC3 2/1/1998 6/30/1999 Special
10092825 ATC3 7/1/1999 6/30/2006 Special
10092825 Chemical 7/1/2006 7/31/2009 Special
10092825 Chemical 1/1/1999 7/31/2010 Dispensary HP3
10092825 ATC3 12/1/1996 1/31/1998 Special
10092825 ATC3 5/16/1994 8/31/1996 Special
10092925 ATC3 5/16/1994 8/31/1996 Special
10092925 ATC3 12/1/1996 1/31/1998 Special
10092925 Chemical 1/1/1999 7/31/2010 Dispensary HP3
10092925 Chemical 7/1/2006 7/31/2009 Special
10092925 ATC3 7/1/1999 6/30/2006 Special
10092925 ATC3 2/1/1998 6/30/1999 Special
10092925 ATC3 9/1/1996 ######## Special
10093025 ATC3 9/1/1996 ######## Special
10093025 ATC3 2/1/1998 6/30/1999 Special
10093025 ATC3 7/1/1999 6/30/2006 Special
10093025 Chemical 7/1/2006 7/31/2009 Special
10093025 Chemical 1/1/1999 7/31/2010 Dispensary HP3
10093025 ATC3 12/1/1996 1/31/1998 Special
10093025 ATC3 5/16/1994 8/31/1996 Special
10093125 ATC3 5/16/1994 8/31/1996 Special
10093125 ATC3 12/1/1996 1/31/1998 Special
10093125 Chemical 1/1/1999 7/31/2010 Dispensary HP3
10093125 Chemical 7/1/2006 7/31/2009 Special
10093125 ATC3 7/1/1999 6/30/2006 Special
10093125 ATC3 2/1/1998 6/30/1999 Special
10093125 ATC3 9/1/1996 ######## Special
10100101 Chemical 8/1/2000 Special
10100101 Chemical 4/1/1997 7/31/2000 Special
10100101 Chemical 1/1/1999 7/31/2010 Dispensary HP1
10110101 Chemical 2/1/1999 8/31/2008 SpecEnd Retail
10110101 Chemical 9/1/2008 Application
10110101 Chemical 8/1/2012 SafetyListMedicine
10110125 Chemical 8/1/2012 SafetyListMedicine
10110125 Chemical 9/1/2008 Application
10110125 Chemical 2/1/1999 8/31/2008 SpecEnd Retail
10110126 Chemical 2/1/1999 8/31/2008 SpecEnd Retail
10110126 Chemical 9/1/2008 Application
10110126 Chemical 8/1/2012 SafetyListMedicine
10110127 Chemical 8/1/2012 SafetyListMedicine
10110127 Chemical 9/1/2008 Application
10110127 Chemical 2/1/1999 8/31/2008 SpecEnd Retail
10110201 Chemical 2/1/1999 8/31/2008 SpecEnd Retail
10110201 Chemical 9/1/2008 Application
10110201 Chemical 8/1/2012 SafetyListMedicine
10110225 Chemical 8/1/2012 SafetyListMedicine
10110225 Chemical 9/1/2008 Application
10110225 Chemical 2/1/1999 8/31/2008 SpecEnd Retail
10110226 Chemical 2/1/1999 8/31/2008 SpecEnd Retail
10110226 Chemical 9/1/2008 Application
10110226 Chemical 8/1/2012 SafetyListMedicine
10110227 Chemical 8/1/2012 SafetyListMedicine
10110227 Chemical 9/1/2008 Application
10110227 Chemical 2/1/1999 8/31/2008 SpecEnd Retail
10110301 Chemical 2/1/1999 8/31/2008 SpecEnd Retail
10110301 Chemical 9/1/2008 Application
10110301 Chemical 8/1/2012 SafetyListMedicine
10110325 Chemical 8/1/2012 SafetyListMedicine
10110325 Chemical 9/1/2008 Application
10110325 Chemical 2/1/1999 8/31/2008 SpecEnd Retail
10110326 Chemical 2/1/1999 8/31/2008 SpecEnd Retail
10110326 Chemical 9/1/2008 Application
10110326 Chemical 8/1/2012 SafetyListMedicine
10110327 Chemical 8/1/2012 SafetyListMedicine
10110327 Chemical 2/1/1999 8/31/2008 SpecEnd Retail
10110327 Chemical 9/1/2008 Application
10110401 Chemical 9/1/2008 Application
10110401 Chemical 2/1/1999 8/31/2008 SpecEnd Retail
10110401 Chemical 8/1/2012 SafetyListMedicine
10110425 Chemical 8/1/2012 SafetyListMedicine
10110425 Chemical 2/1/1999 8/31/2008 SpecEnd Retail
10110425 Chemical 9/1/2008 Application
10110426 Chemical 9/1/2008 Application
10110426 Chemical 2/1/1999 8/31/2008 SpecEnd Retail
10110426 Chemical 8/1/2012 SafetyListMedicine
10110427 Chemical 8/1/2012 SafetyListMedicine
10110427 Chemical 2/1/1999 8/31/2008 SpecEnd Retail
10110427 Chemical 9/1/2008 Application
10110501 Chemical 9/1/2008 Application
10110501 Chemical 2/1/1999 8/31/2008 SpecEnd Retail
10110501 Chemical 8/1/2012 SafetyListMedicine
10110525 Chemical 8/1/2012 SafetyListMedicine
10110525 Chemical 2/1/1999 8/31/2008 SpecEnd Retail
10110525 Chemical 9/1/2008 Application
10110526 Chemical 9/1/2008 Application
10110526 Chemical 2/1/1999 8/31/2008 SpecEnd Retail
10110526 Chemical 8/1/2012 SafetyListMedicine
10112525 Chemical 8/1/2012 SafetyListMedicine
10112525 Chemical 9/1/2008 Application
10112525 Chemical 2/1/1999 8/31/2008 SpecEnd Retail
10112526 Chemical 2/1/1999 8/31/2008 SpecEnd Retail
10112526 Chemical 9/1/2008 Application
10112526 Chemical 8/1/2012 SafetyListMedicine
10112527 Chemical 8/1/2012 SafetyListMedicine
10112527 Chemical 9/1/2008 Application
10260226 Brand 4/1/2013 Wastage
10270201 Chemical 10/1/2003 Statim Must
10270201 Brand 10/1/2003 6/30/2006 SoleSupply
10290101 Formulation 7/1/1996 Statim May
10310101 Chemical 4/1/2001 4/30/2013 AltSubRxF
10310101 ATC3 5/1/2000 3/31/2001 AltSubRxF
10310101 Chemical 10/1/2003 Statim Must
10310101 ATC3 6/1/1998 4/30/2000 AltSubRxF
10310101 Chemical 5/1/2013 AltSubRxF
10310102 Chemical 5/1/2013 AltSubRxF
10310102 ATC3 6/1/1998 4/30/2000 AltSubRxF
10310102 Chemical 10/1/2003 Statim Must
10310102 ATC3 5/1/2000 3/31/2001 AltSubRxF
10310102 Chemical 4/1/2001 4/30/2013 AltSubRxF
10310201 Chemical 4/1/2001 4/30/2013 AltSubRxF
10310201 ATC3 5/1/2000 3/31/2001 AltSubRxF
10310201 Chemical 10/1/2003 Statim Must
10310201 ATC3 6/1/1998 4/30/2000 AltSubRxF
10310201 Chemical 5/1/2013 AltSubRxF
10310202 Chemical 5/1/2013 AltSubRxF
10310202 ATC3 6/1/1998 4/30/2000 AltSubRxF
10310202 Chemical 10/1/2003 Statim Must
10310202 ATC3 5/1/2000 3/31/2001 AltSubRxF
10310202 Chemical 4/1/2001 4/30/2013 AltSubRxF
10310301 Chemical 4/1/2001 4/30/2013 AltSubRxF
10310301 ATC3 5/1/2000 3/31/2001 AltSubRxF
10310301 Chemical 10/1/2003 Statim Must
10310301 ATC3 6/1/1998 4/30/2000 AltSubRxF
10310301 Chemical 5/1/2013 AltSubRxF
10310302 Chemical 5/1/2013 AltSubRxF
10310302 ATC3 6/1/1998 4/30/2000 AltSubRxF
10310302 Chemical 10/1/2003 Statim Must
10310302 ATC3 5/1/2000 3/31/2001 AltSubRxF
10310302 Chemical 4/1/2001 4/30/2013 AltSubRxF
10320101 Chemical 7/1/1996 Statim May
10320101 Brand 1/1/2003 6/30/2005 SoleSupply
10320101 Brand 7/1/2006 6/30/2008 SoleSupply
10320101 Brand 10/1/2008 6/30/2011 SoleSupply
10320101 Brand 10/1/2011 6/30/2014 SoleSupply
10320101 Chemical 9/1/1995 ######## SpecEnd Retail
10320201 Chemical 9/1/1995 ######## SpecEnd Retail
10320201 Brand 1/1/2003 6/30/2005 SoleSupply
10320201 Brand 7/1/2006 6/30/2008 SoleSupply
10320201 Brand 10/1/2008 6/30/2011 SoleSupply
10320201 Brand 10/1/2011 6/30/2014 SoleSupply
10320201 Chemical 7/1/1996 Statim May
10340101 Formulation 2/1/2014 4/30/2014 Brandswitch 2452189 BSF Cellcept
10340101 Brand 2/1/2014 6/30/2016 SoleSupply
10340101 Chemical 6/1/1998 9/30/2005 Special
10340101 Chemical 10/1/2005 9/30/2007 Special
10340101 Chemical 10/1/2007 6/30/2009 Special
10340101 Chemical 7/1/2009 9/30/2010 Special
10340101 Chemical 10/1/2010 Special
10340101 Chemical 1/1/1999 7/31/2010 Dispensary HP3
10340125 Chemical 1/1/1999 7/31/2010 Dispensary HP3
10340125 Chemical 7/1/2009 9/30/2010 Special
10340125 Chemical 10/1/2010 Special
10340125 Chemical 10/1/2007 6/30/2009 Special
10340125 Chemical 10/1/2005 9/30/2007 Special
10340125 Chemical 6/1/1998 9/30/2005 Special
10340125 Formulation 2/1/2014 4/30/2014 Brandswitch 2452189 BSF Cellcept
10340126 Formulation 2/1/2014 4/30/2014 Brandswitch 2452189 BSF Cellcept
10340126 Chemical 6/1/1998 9/30/2005 Special
10340126 Chemical 10/1/2005 9/30/2007 Special
10340126 Chemical 10/1/2007 6/30/2009 Special
10340126 Chemical 7/1/2009 9/30/2010 Special
10340126 Chemical 10/1/2010 Special
10340126 Chemical 1/1/1999 7/31/2010 Dispensary HP3
10342625 Chemical 1/1/1999 7/31/2010 Dispensary HP3
10342625 Chemical 10/1/2010 Special
10342625 Chemical 7/1/2009 9/30/2010 Special
10342625 Chemical 10/1/2007 6/30/2009 Special
10342625 Chemical 10/1/2005 9/30/2007 Special
10342625 Chemical 6/1/1998 9/30/2005 Special
10342625 Brand 2/1/2014 6/30/2016 SoleSupply
10342625 Formulation 2/1/2014 4/30/2014 Brandswitch 2452189 BSF Cellcept
10342626 Formulation 2/1/2014 4/30/2014 Brandswitch 2452189 BSF Cellcept
10342626 Chemical 6/1/1998 9/30/2005 Special
10342626 Chemical 10/1/2005 9/30/2007 Special
10342626 Chemical 10/1/2007 6/30/2009 Special
10342626 Chemical 10/1/2010 Special
10342626 Chemical 7/1/2009 9/30/2010 Special
10342626 Chemical 1/1/1999 7/31/2010 Dispensary HP3
10342627 Chemical 1/1/1999 7/31/2010 Dispensary HP3
10342627 Chemical 7/1/2009 9/30/2010 Special
10342627 Chemical 10/1/2007 6/30/2009 Special
10342627 Chemical 10/1/2010 Special
10342627 Chemical 10/1/2005 9/30/2007 Special
10342627 Chemical 6/1/1998 9/30/2005 Special
10342627 Formulation 2/1/2014 4/30/2014 Brandswitch 2452189 BSF Cellcept
10342725 Chemical 10/1/2005 9/30/2007 Special
10342725 Chemical 6/1/1998 9/30/2005 Special
10342725 Chemical 7/1/2009 9/30/2010 Special
10342725 Chemical 10/1/2007 6/30/2009 Special
10342725 Chemical 10/1/2010 Special
10342725 Formulation10/1/2005 SubRxF
10342725 Chemical 1/1/1999 7/31/2010 Dispensary HP3
10370101 Chemical 6/1/2012 Statim Must
10370101 ATC3 10/1/2005 2/28/2009 Application
10370101 ATC3 10/1/2009 8/31/2010 Special
10370101 ATC3 2/1/2000 3/31/2001 Special
10370101 ATC3 2/1/2002 2/29/2004 Application
10370101 ATC3 3/1/2004 9/30/2005 Application
10370101 ATC3 3/1/2009 9/30/2009 Special
10370101 ATC3 4/1/2001 9/30/2001 Special
10370101 ATC3 10/1/2001 1/31/2002 Special
10370101 ATC3 9/1/2010 Special
10370101 Chemical 7/1/1999 2/28/2009 Special Claim only
10370201 ATC3 7/1/1999 2/28/2009 Application
10370201 ATC3 3/1/2009 Special
10370201 Chemical 7/1/1999 2/28/2009 Special Claim only
10370201 Chemical 6/1/2012 Statim Must
10372525 Chemical 6/1/2012 Statim Must
10372525 ATC3 2/1/2002 2/29/2004 Application
10372525 ATC3 2/1/2000 3/31/2001 Special
10372525 ATC3 10/1/2009 8/31/2010 Special
10372525 ATC3 10/1/2005 2/28/2009 Application
10372525 ATC3 3/1/2004 9/30/2005 Application
10372525 Chemical 7/1/1999 2/28/2009 Special Claim only
10372525 ATC3 9/1/2010 Special
10372525 ATC3 10/1/2001 1/31/2002 Special
10372525 ATC3 4/1/2001 9/30/2001 Special
10372525 ATC3 3/1/2009 9/30/2009 Special
10380201 Chemical 6/1/2012 Statim Must
10380401 Chemical 6/1/2012 Statim Must
10400101 Chemical 10/1/2003 Statim Must
10400201 Chemical 10/1/2003 Statim Must
10400225 Chemical 10/1/2003 Statim Must
10400301 Chemical 10/1/2003 Statim Must
10410101 Chemical 10/1/2003 Statim Must
10610201 Chemical 3/1/2012 5/31/2012 Brandswitch 2397153 BSF Arrow-losartan & H...
10610201 Chemical 5/1/2004 4/30/2007 Special
10610201 Chemical 6/1/2008 ######## Special
10610201 Chemical 8/1/1999 3/31/2002 Special
10610201 Formulation10/1/2003 Statim Must
10610225 Formulation10/1/2003 Statim Must
10610225 Chemical 8/1/1999 3/31/2002 Special
10610225 Chemical 6/1/2008 ######## Special
10610225 Chemical 5/1/2004 4/30/2007 Special
10610225 Chemical 3/1/2012 5/31/2012 Brandswitch 2397153 BSF Arrow-losartan & H...
10610225 Brand 3/1/2012 6/30/2014 SoleSupply
10610225 Formulation 5/1/2007 5/31/2008 Special
10610225 Chemical 4/1/2002 4/30/2004 Special
10612525 Chemical 4/1/2002 4/30/2004 Special
10612525 Formulation 5/1/2007 5/31/2008 Special
10612525 Chemical 3/1/2012 5/31/2012 Brandswitch 2397153 BSF Arrow-losartan & H...
10612525 Chemical 6/1/2008 ######## Special
10612525 Chemical 5/1/2004 4/30/2007 Special
10612525 Chemical 8/1/1999 3/31/2002 Special
10612525 Formulation10/1/2003 Statim Must
10612526 Formulation10/1/2003 Statim Must
10612526 Chemical 8/1/1999 3/31/2002 Special
10612526 Chemical 5/1/2004 4/30/2007 Special
10612526 Chemical 6/1/2008 ######## Special
10612526 Chemical 3/1/2012 5/31/2012 Brandswitch 2397153 BSF Arrow-losartan & H...
10612526 Formulation 5/1/2007 5/31/2008 Special
10612526 Brand 3/1/2012 6/30/2014 SoleSupply
10612526 Chemical 4/1/2002 4/30/2004 Special
10612625 Chemical 4/1/2002 4/30/2004 Special
10612625 Chemical 3/1/2012 5/31/2012 Brandswitch 2397153 BSF Arrow-losartan & H...
10612625 Chemical 6/1/2008 ######## Special
10612625 Chemical 8/1/1999 3/31/2002 Special
10612625 Chemical 5/1/2004 4/30/2007 Special
10612625 Formulation 6/1/2008 Statim Must
10612626 Formulation 6/1/2008 Statim Must
10612626 Chemical 8/1/1999 3/31/2002 Special
10612626 Chemical 5/1/2004 4/30/2007 Special
10612626 Chemical 6/1/2008 ######## Special
10612626 Chemical 3/1/2012 5/31/2012 Brandswitch 2397153 BSF Arrow-losartan & H...
10612626 Chemical 4/1/2002 4/30/2004 Special
10612626 Brand 3/1/2012 6/30/2014 SoleSupply
10620125 Chemical 8/1/2007 ######## Special
10620125 Chemical 1/1/2011 Special
10620125 ATC3 7/1/2005 7/31/2007 Application
10620125 Brand 8/1/2009 7/31/2012 SoleSupply
10620125 Formulation12/1/2011 OraProduct
10620125 Chemical 4/1/2001 Statim May
10620125 Chemical 8/1/2003 7/31/2007 Special Claim only
10620125 Chemical 11/1/2008 3/31/2010 Special
10620125 ATC3 8/1/2003 6/30/2005 Application
10620125 Chemical 4/1/2010 ######## Special
10620126 Chemical 4/1/2010 ######## Special
10620126 ATC3 8/1/2003 6/30/2005 Application
10620126 Chemical 11/1/2008 3/31/2010 Special
10620126 Chemical 4/1/2001 Statim May
10620126 Chemical 8/1/2003 7/31/2007 Special Claim only
10620126 Formulation12/1/2011 OraProduct
10620126 ATC3 7/1/2005 7/31/2007 Application
10620126 Chemical 8/1/2007 ######## Special
10620126 Chemical 1/1/2011 Special
10620225 Chemical 1/1/2011 Special
10620225 Chemical 8/1/2007 ######## Special
10620225 Brand 8/1/2009 7/31/2012 SoleSupply
10620225 ATC3 7/1/2005 7/31/2007 Application
10620225 Chemical 4/1/2001 Statim May
10620225 Chemical 8/1/2003 7/31/2007 Special Claim only
10620225 Chemical 11/1/2008 3/31/2010 Special
10620225 ATC3 8/1/2003 6/30/2005 Application
10620225 Chemical 4/1/2010 ######## Special
10620226 Chemical 4/1/2010 ######## Special
10620226 ATC3 8/1/2003 6/30/2005 Application
10620226 Chemical 11/1/2008 3/31/2010 Special
10620226 Chemical 4/1/2001 Statim May
10620226 Chemical 8/1/2003 7/31/2007 Special Claim only
10620226 ATC3 7/1/2005 7/31/2007 Application
10620226 Chemical 8/1/2007 ######## Special
10620226 Chemical 1/1/2011 Special
10622526 Chemical 1/1/2011 Special
10622526 Chemical 8/1/2007 ######## Special
10622526 Brand 8/1/2009 7/31/2012 SoleSupply
10622526 ATC3 7/1/2005 7/31/2007 Application
10622526 Chemical 8/1/2003 7/31/2007 Special Claim only
10622526 Chemical 4/1/2001 Statim May
10622526 Chemical 11/1/2008 3/31/2010 Special
10622526 ATC3 8/1/2003 6/30/2005 Application
10622526 Chemical 4/1/2010 ######## Special
10622527 Chemical 4/1/2010 ######## Special
10622527 ATC3 8/1/2003 6/30/2005 Application
10622527 Chemical 11/1/2008 3/31/2010 Special
10622527 Chemical 4/1/2001 Statim May
10622527 Chemical 8/1/2003 7/31/2007 Special Claim only
10622527 ATC3 7/1/2005 7/31/2007 Application
10622527 Chemical 8/1/2007 ######## Special
10622527 Chemical 1/1/2011 Special
10630101 ATC3 12/1/1998 3/31/2002 Special
10630101 ATC3 5/16/1994 ######## Special
10630101 ATC3 11/1/1997 ######## Special
10630101 ATC3 12/1/1995 ######## Special
10630102 ATC3 12/1/1995 ######## Special
10630102 ATC3 11/1/1997 ######## Special
10630102 ATC3 5/16/1994 ######## Special
10630102 ATC3 12/1/1998 3/31/2002 Special
10630202 ATC3 12/1/1998 3/31/2002 Special
10630202 ATC3 5/16/1994 ######## Special
10630202 ATC3 11/1/1997 ######## Special
10630202 ATC3 12/1/1995 ######## Special
10630203 ATC3 12/1/1995 ######## Special
10630203 ATC3 11/1/1997 ######## Special
10630203 ATC3 5/16/1994 ######## Special
10630203 ATC3 12/1/1998 3/31/2002 Special
10640101 Brand 10/1/2011 6/30/2014 SoleSupply
10640101 Chemical 10/1/2003 Statim Must
10640101 Chemical 5/16/1994 9/30/2007 SpecEnd Retail
10640201 Chemical 5/16/1994 9/30/2007 SpecEnd Retail
10640201 Chemical 10/1/2003 Statim Must
10640201 Brand 10/1/2011 6/30/2014 SoleSupply
10660101 Chemical 8/1/2001 ######## Special Claim only
10660101 ATC2 11/1/2005 7/31/2006 Application
10660101 ATC2 3/1/2000 7/31/2001 Special
10660101 ATC2 8/1/2001 ######## Application
10660101 ATC2 12/1/1996 2/29/2000 Special
10660201 ATC2 12/1/1996 2/29/2000 Special
10660201 ATC2 8/1/2001 ######## Application
10660201 ATC2 3/1/2000 7/31/2001 Special
10660201 Formulation 6/1/1997 ######## Special
10660201 ATC2 11/1/2005 7/31/2006 Application
10660201 Chemical 8/1/2001 ######## Special Claim only
10660301 Chemical 8/1/2001 ######## Special Claim only
10660301 ATC2 11/1/2005 7/31/2006 Application
10720801 Brand 4/1/2009 6/30/2011 SoleSupply
10720801 Brand 12/1/2011 6/30/2014 SoleSupply
10720901 Brand 1/1/2003 6/30/2005 SoleSupply
10720901 Brand 8/1/2006 6/30/2008 SoleSupply
10720901 Brand 4/1/2009 6/30/2011 SoleSupply
10720901 Brand 12/1/2011 6/30/2014 SoleSupply
10720901 Formulation5/26/1995 2/28/2001 FormMax 5 PSO
10721001 Formulation 7/1/1996 2/28/2001 FormMax 5 PSO
10721001 Brand 1/1/2003 6/30/2005 SoleSupply
10721001 Brand 8/1/2006 6/30/2008 SoleSupply
10721001 Brand 4/1/2009 6/30/2011 SoleSupply
10721001 Brand 12/1/2011 6/30/2014 SoleSupply
10740101 Brand 10/1/2003 6/30/2006 SoleSupply
10760101 Formulation 7/1/1998 9/30/2003 Statim May
10760101 Chemical 7/1/1998 3/31/2002 Special
10760101 Chemical 10/1/2003 Statim Must
10760101 Chemical 4/1/2002 9/30/2007 SpecEnd Retail
10770101 ATC2 10/1/1998 ######## Special SpecEnd
10770101 ATC2 1/1/1999 7/31/2010 Dispensary HP1
10770101 ATC2 1/1/2001 5/31/2001 Special
10770101 ATC2 6/1/2001 6/30/2005 Application
10770101 ATC2 8/1/2010 6/30/2013 Application
10770101 ATC2 7/1/2005 6/30/2010 Application
10770101 Chemical 8/1/2010 Special Claim only
10770101 Chemical 6/1/2001 7/31/2010 Special Claim only
10770101 ATC2 4/1/1997 9/30/1998 Special
10770101 ATC2 7/1/2010 7/31/2010 Application
10770101 ATC2 7/1/2013 Application
10770125 ATC2 7/1/2013 Application
10770125 ATC2 7/1/2010 7/31/2010 Application
10770125 ATC2 4/1/1997 9/30/1998 Special
10770125 Chemical 6/1/2001 7/31/2010 Special Claim only
10770125 Chemical 8/1/2010 Special Claim only
10770125 ATC2 7/1/2005 6/30/2010 Application
10770125 ATC2 8/1/2010 6/30/2013 Application
10770125 ATC2 6/1/2001 6/30/2005 Application
10770125 ATC2 1/1/2001 5/31/2001 Special
10770125 ATC2 1/1/1999 7/31/2010 Dispensary HP1
10770125 ATC2 10/1/1998 ######## Special SpecEnd
10772525 ATC2 10/1/1998 ######## Special SpecEnd
10772525 ATC2 1/1/1999 7/31/2010 Dispensary HP1
10772525 ATC2 1/1/2001 5/31/2001 Special
10772525 ATC2 6/1/2001 6/30/2005 Application
10772525 ATC2 8/1/2010 6/30/2013 Application
10772525 ATC2 7/1/2005 6/30/2010 Application
10772525 Chemical 8/1/2010 Special Claim only
10772525 Chemical 6/1/2001 7/31/2010 Special Claim only
10772525 ATC2 4/1/1997 9/30/1998 Special
10772525 ATC2 7/1/2010 7/31/2010 Application
10772525 ATC2 7/1/2013 Application
10780101 Chemical 1/1/1999 Dispensary HP4
10780101 Chemical 4/1/1999 ######## SpecOnly Hospital
10780101 Chemical 2/1/1999 3/31/1999 Special
10780101 Chemical 8/1/2012 SafetyListMedicine
10780125 Chemical 8/1/2012 SafetyListMedicine
10780125 Chemical 2/1/1999 3/31/1999 Special
10780125 Chemical 1/1/1999 Dispensary HP4
10780125 Chemical 4/1/1999 ######## SpecOnly Hospital
10780201 Chemical 1/1/1999 Dispensary HP4
10780201 Chemical 4/1/1999 ######## SpecOnly Hospital
10780201 Chemical 2/1/1999 3/31/1999 Special
10780201 Chemical 8/1/2012 SafetyListMedicine
10780225 Chemical 8/1/2012 SafetyListMedicine
10780225 Chemical 2/1/1999 3/31/1999 Special
10780225 Chemical 1/1/1999 Dispensary HP4
10780225 Chemical 4/1/1999 ######## SpecOnly Hospital
10782525 Chemical 1/1/1999 Dispensary HP4
10782525 Chemical 4/1/1999 ######## SpecOnly Hospital
10782525 Chemical 2/1/1999 3/31/1999 Special
10782525 Chemical 8/1/2012 SafetyListMedicine
10782625 Chemical 8/1/2012 SafetyListMedicine
10782625 Chemical 2/1/1999 3/31/1999 Special
10782625 Chemical 4/1/1999 ######## SpecOnly Hospital
10782625 Chemical 1/1/1999 Dispensary HP4
10782725 Chemical 1/1/1999 Dispensary HP4
10782725 Chemical 4/1/1999 ######## SpecOnly Hospital
10782725 Chemical 2/1/1999 3/31/1999 Special
10782725 Chemical 8/1/2012 SafetyListMedicine
10800101 Chemical 5/16/1994 TreatMax 30
10800101 Chemical 5/16/1994 MaxCoPayment 0
10800101 Chemical 6/1/1995 Controlled
10810201 Chemical 10/1/1999 SubRxF
10820101 Brand 12/1/2003 6/30/2006 SoleSupply
10820101 Brand 10/1/2006 6/30/2009 SoleSupply
10820201 Brand 12/1/2003 6/30/2006 SoleSupply
10820201 Brand 10/1/2006 6/30/2009 SoleSupply
10830101 Chemical 2/1/2012 7/31/2012 Repeat
10830101 Formulation 8/1/2001 7/31/2006 Special Claim only
10830101 ATC2 11/1/2005 7/31/2006 Application
10830101 ATC2 3/1/2000 7/31/2001 Special
10830101 ATC2 8/1/2001 ######## Application
10830101 ATC2 12/1/1996 2/29/2000 Special
10830101 Chemical 7/1/2011 1/31/2012 AltSubRxF
10830201 Chemical 7/1/2011 1/31/2012 AltSubRxF
10830201 ATC2 12/1/1996 2/29/2000 Special
10830201 ATC2 8/1/2001 ######## Application
10830201 ATC2 3/1/2000 7/31/2001 Special
10830201 ATC2 11/1/2005 7/31/2006 Application
10830201 Formulation 8/1/2001 7/31/2006 Special Claim only
10830201 Chemical 2/1/2012 7/31/2012 Repeat
10830301 Chemical 2/1/2012 7/31/2012 Repeat
10830301 Formulation 3/1/2004 7/31/2006 SubRxF
10830301 ATC2 11/1/2005 7/31/2006 Application
10830301 ATC2 3/1/2000 7/31/2001 Special
10830301 ATC2 8/1/2001 ######## Application
10830301 Formulation 5/1/2001 2/29/2004 SubRxF
10830301 ATC2 12/1/1996 2/29/2000 Special
10830301 Chemical 7/1/2011 1/31/2012 AltSubRxF
10840101 Chemical 10/1/2003 Statim Must
10840101 Formulation 8/1/2010 ProvAllow Dietitian
10840101 Chemical 5/16/1994 7/31/2005 DoseSWt 100
10840101 Chemical 5/16/1994 FormReqd Rx
10840101 Chemical 8/1/2005 7/31/2006 DoseSWt 250
10840101 Chemical 8/1/2006 DoseSWt 100
10840102 Chemical 8/1/2006 DoseSWt 100
10840102 Chemical 8/1/2005 7/31/2006 DoseSWt 250
10840102 Chemical 5/16/1994 FormReqd Rx
10840102 Chemical 5/16/1994 7/31/2005 DoseSWt 100
10840102 Formulation 8/1/2010 ProvAllow Dietitian
10840102 Chemical 10/1/2003 Statim Must
10840103 Chemical 10/1/2003 Statim Must
10840103 Formulation 8/1/2010 ProvAllow Dietitian
10840103 Chemical 5/16/1994 7/31/2005 DoseSWt 100
10840103 Chemical 5/16/1994 FormReqd Rx
10840103 Chemical 8/1/2005 7/31/2006 DoseSWt 250
10840103 Chemical 8/1/2006 DoseSWt 100
10840103 Brand 2/1/2007 6/30/2009 SoleSupply
10940102 Formulation 7/1/1996 9/30/2003 Statim May
10940102 Brand 3/1/2001 6/30/2003 SoleSupply
10940102 Brand 10/1/2003 6/30/2006 SoleSupply
10940102 Brand 10/1/2006 6/30/2009 SoleSupply
10940102 Chemical 10/1/2003 Statim Must
10940103 Chemical 10/1/2003 Statim Must
10940103 Formulation 7/1/1996 9/30/2003 Statim May
10940104 Formulation 7/1/1996 9/30/2003 Statim May
10940104 Chemical 10/1/2003 Statim Must
10940105 Chemical 10/1/2003 Statim Must
10940105 Formulation 7/1/1996 9/30/2003 Statim May
10940105 Brand 11/1/1998 Preferred
10940125 Formulation 7/1/1996 9/30/2003 Statim May
10940125 Brand 9/1/2008 6/9/2009 SoleSupply
10940125 Brand 11/1/2009 5/27/2010 SoleSupply
10940125 Brand 11/1/2012 6/30/2015 SoleSupply
10940125 Chemical 10/1/2003 Statim Must
10940126 Chemical 10/1/2003 Statim Must
10940126 Brand 12/1/2008 S29
10940126 Brand 4/1/2013 Wastage
10940126 Formulation 7/1/1996 9/30/2003 Statim May
10940127 Formulation 7/1/1996 9/30/2003 Statim May
10940127 Brand 5/28/2010 6/30/2012 SoleSupply
10940127 Chemical 10/1/2003 Statim Must
10940201 Chemical 10/1/2003 Statim Must
10940201 Formulation 7/1/1996 9/30/2003 Statim May
10940202 Formulation 7/1/1996 9/30/2003 Statim May
10940202 Brand 3/1/2001 6/30/2003 SoleSupply
10940202 Brand 10/1/2003 6/30/2006 SoleSupply
10940202 Brand 10/1/2006 6/30/2009 SoleSupply
10940202 Chemical 10/1/2003 Statim Must
10940203 Chemical 10/1/2003 Statim Must
10940203 Formulation 7/1/1996 9/30/2003 Statim May
10940204 Formulation 7/1/1996 9/30/2003 Statim May
10940204 Chemical 10/1/2003 Statim Must
10940205 Chemical 10/1/2003 Statim Must
10940205 Formulation 7/1/1996 9/30/2003 Statim May
10940205 Brand 11/1/1998 Preferred
10940225 Formulation 7/1/1996 9/30/2003 Statim May
10940225 Brand 9/1/2008 6/30/2009 SoleSupply
10940225 Brand 11/1/2009 5/27/2010 SoleSupply
10940225 Brand 11/1/2012 6/30/2015 SoleSupply
10940225 Chemical 10/1/2003 Statim Must
10940226 Chemical 10/1/2003 Statim Must
10940226 Brand 5/28/2010 6/30/2012 SoleSupply
10940226 Formulation 7/1/1996 9/30/2003 Statim May
10940301 Chemical 10/1/2003 Statim Must
10942525 Chemical 10/1/2003 Statim Must
10942525 Brand 2/1/2013 5/31/2014 S29
10942525 Brand 4/1/2013 5/31/2014 Wastage
10970101 Chemical 10/1/2003 Statim Must
10970202 Chemical 10/1/2003 Statim Must
10970202 Formulation5/16/1994 FormMax 5 PSO
10970202 Brand 12/1/2002 6/30/2005 SoleSupply
10970301 Brand 12/1/2002 6/30/2005 SoleSupply
10970301 Brand 1/1/2007 6/30/2009 SoleSupply
10970301 Brand 1/1/2010 6/30/2012 SoleSupply
10970301 Brand 2/1/2013 6/30/2015 SoleSupply
10970301 Formulation5/16/1994 FormMax 5 PSO
10970301 Chemical 10/1/2003 Statim Must
10970302 Chemical 10/1/2003 Statim Must
10970302 Formulation5/16/1994 FormMax 5 PSO
10970401 Formulation5/16/1994 FormMax 5 PSO
10970401 Chemical 10/1/2003 Statim Must
10970401 Brand 12/1/2002 6/30/2005 SoleSupply
10970401 Brand 1/1/2007 6/30/2009 SoleSupply
10970501 Brand 12/1/2002 6/30/2005 SoleSupply
10970501 Chemical 10/1/2003 Statim Must
10970601 Chemical 10/1/2003 Statim Must
10970601 Brand 12/1/2002 6/30/2005 SoleSupply
10970601 Brand 10/1/2005 6/30/2008 SoleSupply
10970601 Brand 1/1/2009 ######## SoleSupply
10970601 Brand 8/1/2014 6/30/2017 SoleSupply
10980101 Chemical 7/1/1997 8/31/1998 Special
10980101 Chemical 10/1/2003 Statim Must
10980125 Chemical 10/1/2003 Statim Must
10980125 Chemical 7/1/1997 8/31/1998 Special
10980125 Brand 6/1/2008 6/30/2010 SoleSupply
10980125 Brand 10/1/2010 6/30/2013 SoleSupply
10980126 Brand 8/1/2014 6/30/2016 SoleSupply
10980126 Chemical 7/1/1997 8/31/1998 Special
10980126 Chemical 10/1/2003 Statim Must
10980201 Chemical 10/1/2003 Statim Must
10980201 Chemical 7/1/1997 8/31/1998 Special
10980225 Chemical 7/1/1997 8/31/1998 Special
10980225 Brand 6/1/2008 6/30/2010 SoleSupply
10980225 Brand 10/1/2010 6/30/2013 SoleSupply
10980225 Chemical 10/1/2003 Statim Must
10980226 Chemical 10/1/2003 Statim Must
10980226 Brand 8/1/2014 6/30/2016 SoleSupply
10980226 Chemical 7/1/1997 8/31/1998 Special
10982525 Chemical 7/1/1997 8/31/1998 Special
10982525 Brand 5/1/2009 6/30/2010 SoleSupply
10982525 Brand 10/1/2011 6/30/2014 SoleSupply
10982525 Chemical 10/1/2003 Statim Must
10990101 Chemical 5/16/1994 2/28/2009 SpecEnd Retail
10990125 Chemical 5/16/1994 2/28/2009 SpecEnd Retail
10990125 Brand 6/1/2012 S29
10990125 Brand 4/1/2013 Wastage
11000101 Chemical 10/1/2003 Statim Must
11000101 Chemical 5/16/1994 SpecEnd Retail
11000101 Formulation12/1/2011 OraProduct
11000101 Formulation 1/1/2011 3/31/2011 Brandswitch 2377829 BSF Imuprine
11000102 Formulation 1/1/2011 3/31/2011 Brandswitch 2377829 BSF Imuprine
11000102 Formulation12/1/2011 OraProduct
11000102 Chemical 5/16/1994 SpecEnd Retail
11000102 Chemical 10/1/2003 Statim Must
11000103 Chemical 10/1/2003 Statim Must
11000103 Chemical 5/16/1994 SpecEnd Retail
11000103 Formulation12/1/2011 OraProduct
11000103 Formulation 1/1/2011 3/31/2011 Brandswitch 2377829 BSF Imuprine
11000103 Brand 11/1/1999 6/30/2001 Preferred
11000125 Formulation12/1/2011 OraProduct
11000125 Formulation 1/1/2011 3/31/2011 Brandswitch 2377829 BSF Imuprine
11000125 Brand 1/1/2011 6/30/2013 SoleSupply
11000125 Chemical 5/16/1994 SpecEnd Retail
11000125 Chemical 10/1/2003 Statim Must
11000201 Chemical 10/1/2003 Statim Must
11000201 Chemical 5/16/1994 SpecEnd Retail
11000201 Brand 11/1/2010 6/30/2013 SoleSupply
11010101 Brand 12/1/2007 6/30/2010 SoleSupply
11010125 Brand 3/1/2005 6/30/2007 SoleSupply
11010125 Brand 1/1/2011 6/30/2013 SoleSupply
11012525 Brand 9/1/2005 6/30/2007 SoleSupply
11012525 Brand 10/1/2007 6/30/2010 SoleSupply
11012525 Brand 10/1/2010 6/30/2013 SoleSupply
11020101 ATC2 7/1/2010 7/31/2010 Application
11100126 Chemical 10/1/1999 2/28/2005 FormMax 30 Rx
11100126 Chemical 3/1/2005 FormMax 100 Rx
11100201 Chemical 3/1/2005 FormMax 100 Rx
11100201 Chemical 10/1/1999 2/28/2005 FormMax 30 Rx
11100201 Formulation10/1/1999 9/30/2003 Statim May
11100201 ATC3 3/1/2014 SubRxF
11100201 Chemical 10/1/2003 Statim Must
11100201 ATC3 12/1/1997 2/28/2014 SubRxF
11100226 ATC3 12/1/1997 2/28/2014 SubRxF
11100226 Chemical 10/1/2003 Statim Must
11100226 Formulation10/1/1999 9/30/2003 Statim May
11100226 ATC3 3/1/2014 SubRxF
11100226 Chemical 3/1/2005 FormMax 100 Rx
11100226 Chemical 10/1/1999 2/28/2005 FormMax 30 Rx
11100227 Chemical 10/1/1999 2/28/2005 FormMax 30 Rx
11100227 Chemical 3/1/2005 FormMax 100 Rx
11100227 Formulation10/1/1999 9/30/2003 Statim May
11100227 ATC3 3/1/2014 SubRxF
11100227 Chemical 10/1/2003 Statim Must
11100227 ATC3 12/1/1997 2/28/2014 SubRxF
11102525 ATC3 12/1/1997 2/28/2014 SubRxF
11102525 Chemical 10/1/2003 Statim Must
11102525 ATC3 3/1/2014 SubRxF
11102525 Chemical 10/1/1999 2/28/2005 FormMax 30 Rx
11102525 Chemical 3/1/2005 FormMax 100 Rx
11102526 Chemical 10/1/1999 2/28/2005 FormMax 30 Rx
11102526 Chemical 3/1/2005 FormMax 100 Rx
11102526 ATC3 3/1/2014 SubRxF
11102526 Chemical 10/1/2003 Statim Must
11102526 ATC3 12/1/1997 2/28/2014 SubRxF
11102625 ATC3 12/1/1997 2/28/2014 SubRxF
11102625 Chemical 10/1/2003 Statim Must
11102625 ATC3 3/1/2014 SubRxF
11102625 Chemical 3/1/2005 FormMax 100 Rx
11102625 Chemical 10/1/1999 2/28/2005 FormMax 30 Rx
11102626 Chemical 10/1/1999 2/28/2005 FormMax 30 Rx
11102626 Chemical 3/1/2005 FormMax 100 Rx
11102626 ATC3 3/1/2014 SubRxF
11102626 Chemical 10/1/2003 Statim Must
11102626 ATC3 12/1/1997 2/28/2014 SubRxF
11102627 ATC3 12/1/1997 2/28/2014 SubRxF
11102627 Chemical 10/1/2003 Statim Must
11102627 ATC3 3/1/2014 SubRxF
11102627 Chemical 3/1/2005 FormMax 100 Rx
11102627 Chemical 10/1/1999 2/28/2005 FormMax 30 Rx
11102725 Chemical 3/1/2005 FormMax 100 Rx
11102725 Chemical 10/1/1999 2/28/2005 FormMax 30 Rx
11102725 ATC3 3/1/2014 SubRxF
11102725 Chemical 10/1/2003 Statim Must
11102725 ATC3 12/1/1997 2/28/2014 SubRxF
11120101 ATC3 7/1/2013 Special
11160101 Formulation 6/1/1998 FormMax 150 PSO
11160101 Chemical 10/1/2003 Statim Must
11160125 Chemical 10/1/2003 Statim Must
11160125 Formulation 6/1/1998 FormMax 150 PSO
11160125 Brand 10/1/2010 6/30/2011 SoleSupply
11160125 Brand 10/1/2011 6/30/2014 SoleSupply
11160201 Chemical 10/1/2003 Statim Must
11160225 Chemical 10/1/2003 Statim Must
11160225 Brand 10/1/2010 6/30/2011 SoleSupply
11160225 Brand 10/1/2011 6/30/2014 SoleSupply
11200201 Formulation5/16/1994 FormMax 5 PSO
11200202 Formulation5/16/1994 FormMax 5 PSO
11200225 Formulation5/16/1994 FormMax 5 PSO
11200225 Brand 10/1/2012 6/30/2015 SoleSupply
11202525 Formulation11/1/2006 FormMax 5 PSO
11240101 Formulation 1/1/1998 2/28/2001 FormMax 30 PSO
11240301 Formulation 1/1/1998 Wastage
11240401 Formulation 1/1/1998 Wastage
11240501 Formulation 1/1/1998 2/28/2001 FormMax 5 PSO
11240601 Formulation 1/1/1998 2/28/2001 FormMax 5 PSO
11250101 Chemical 5/1/2000 6/30/2000 AltSubRxF
11250101 Chemical 2/1/2004 ######## AltSubRxF
11250101 Chemical 1/1/1998 SpecEnd Retail
11250101 Chemical 1/1/2001 1/31/2001 AltSubRxF
11250101 Chemical 12/1/2003 1/31/2004 AltSubRxF
11250101 Chemical 7/1/2000 ######## AltSubRxF
11250101 Chemical 2/1/2001 ######## AltSubRxF
11250201 Chemical 2/1/2001 ######## AltSubRxF
11250201 Chemical 7/1/2000 ######## AltSubRxF
11250201 Chemical 12/1/2003 1/31/2004 AltSubRxF
11250201 Chemical 1/1/2001 1/31/2001 AltSubRxF
11250201 Chemical 1/1/1998 SpecEnd Retail
11250201 Chemical 2/1/2004 ######## AltSubRxF
11250201 Chemical 5/1/2000 6/30/2000 AltSubRxF
11260101 Chemical 3/1/2012 6/30/2013 Special
11260101 Chemical 8/1/2012 ######## Brandswitch 2405857 BSF Ursosan
11260101 Chemical 3/1/1999 8/31/2006 Special
11260101 Chemical 9/1/2006 6/30/2008 Special
11260101 Chemical 3/1/2005 3/31/2005 SpecOnly Retail
11260101 Formulation 3/1/1999 2/28/2005 SpecOnly Retail
11260101 Chemical 7/1/2008 2/28/2010 Special
11260101 Chemical 3/1/2010 2/29/2012 Special
11260101 Formulation12/1/2011 OraProduct
11260101 Brand 1/1/2006 6/30/2008 SoleSupply
11260101 Brand 10/1/2008 6/30/2011 SoleSupply
11260101 Chemical 7/1/2013 Special
11260101 Chemical 4/1/2005 8/31/2006 SpecOnly Retail
11262525 Chemical 7/1/2013 Special
11262525 Chemical 4/1/2005 8/31/2006 SpecOnly Retail
11262525 Formulation 3/1/2012 OraProduct
11262525 Brand 8/1/2012 6/30/2014 SoleSupply
11262525 Chemical 3/1/2010 2/29/2012 Special
11262525 Chemical 7/1/2008 2/28/2010 Special
11262525 Chemical 9/1/2006 6/30/2008 Special
11262525 Chemical 3/1/2005 3/31/2005 SpecOnly Retail
11262525 Chemical 3/1/1999 8/31/2006 Special
11262525 Chemical 8/1/2012 ######## Brandswitch 2405857 BSF Ursosan
11262525 Chemical 3/1/2012 6/30/2013 Special
11270101 Chemical 10/1/2003 Statim Must
11270101 Formulation 6/1/2014 8/31/2014 Brandswitch 2459299 Apo-Cilazapril
11270101 Brand 11/1/2010 6/30/2013 SoleSupply
11270125 Brand 6/1/2014 6/30/2016 SoleSupply
11270125 Formulation 6/1/2014 8/31/2014 Brandswitch 2459299 Apo-Cilazapril
11270125 Chemical 10/1/2003 Statim Must
11300125 Brand 9/1/2003 6/30/2004 S29
11300201 Formulation5/16/1994 ######## FormReqd PSO
11300201 Formulation5/16/1994 FormMax 5 PSO
11300201 Formulation######## FormReqd PSO
11320101 Chemical 1/1/1996 6/30/2008 SpecOnly Retail
11330101 Chemical 1/1/2001 7/31/2003 Special
11330101 Chemical 8/1/2007 8/31/2008 Special
11330101 ATC3 8/1/2003 6/30/2005 Application
11330101 ATC3 7/1/2005 7/31/2007 Application
11330101 Chemical 11/1/1997 Statim May
11330101 Chemical 9/1/2000 ######## Special
11330101 Chemical 8/1/2003 7/31/2007 Special Claim only
11330125 Chemical 11/1/1997 Statim May
11370226 ATC3 12/1/1995 ######## Special
11370226 Chemical 7/1/2002 5/31/2004 Special
11370226 Chemical 6/1/2004 9/30/2004 Repeat
11370226 ATC3 5/16/1994 ######## Special
11370226 ATC3 12/1/1998 3/31/2002 Special
11370226 Chemical 6/1/2004 6/30/2004 SpecialWav
11370227 Chemical 6/1/2004 6/30/2004 SpecialWav
11370227 Brand 1/1/2013 6/30/2015 SoleSupply
11370227 ATC3 12/1/1998 3/31/2002 Special
11370227 ATC3 5/16/1994 ######## Special
11370227 Chemical 6/1/2004 9/30/2004 Repeat
11370227 Chemical 7/1/2002 5/31/2004 Special
11370227 Chemical 7/1/2004 8/31/2005 SpecialWav
11370227 ATC3 12/1/1995 ######## Special
11370227 Chemical 10/1/2003 Statim Must
11370227 Chemical 9/1/2005 8/31/2010 SpecialWav
11370227 ATC3 11/1/1997 ######## Special
11370301 ATC3 11/1/1997 ######## Special
11370301 Chemical 9/1/2005 8/31/2010 SpecialWav
11370301 Chemical 10/1/2003 Statim Must
11370301 ATC3 12/1/1995 ######## Special
11370301 Chemical 7/1/2004 8/31/2005 SpecialWav
11370301 Chemical 7/1/2002 5/31/2004 Special
11370301 Chemical 6/1/2004 9/30/2004 Repeat
11370301 ATC3 12/1/1998 3/31/2002 Special
11370301 ATC3 5/16/1994 ######## Special
14790202 ATC2 1/1/2013 MaxCoPayment 5
14790202 Formulation 7/1/1996 FormMax 84 PSO
14790202 Chemical 8/1/2004 Statim Must
14790301 Chemical 8/1/2004 Statim Must
14790301 Formulation 8/1/1999 FormMax 84 PSO
14790301 ATC2 1/1/2013 MaxCoPayment 5
14790301 Formulation 8/1/1999 Contraceptive
14790301 ATC2 5/16/1994 ######## MaxCoPayment 3
14790301 ATC3 8/1/1995 ######## SpecialWav
14790301 ATC3 11/1/1999 AltSubSA
14810101 Formulation 7/1/1996 9/30/2003 Statim May
14810101 ATC3 7/1/2005 7/31/2007 Application
14810101 Chemical 10/1/2003 Statim Must
14810101 ATC3 8/1/2003 6/30/2005 Application
14810201 ATC3 8/1/2003 6/30/2005 Application
14810201 Chemical 10/1/2003 Statim Must
14810201 ATC3 7/1/2005 7/31/2007 Application
14810201 Formulation 7/1/1996 Safety Uncompounded
14810201 Formulation 7/1/1996 9/30/2003 Statim May
14840101 ATC3 8/1/1995 ######## SpecialWav
14840101 ATC3 11/1/1999 AltSubSA
14840101 Formulation 7/1/1996 Contraceptive
14840101 ATC2 5/16/1994 ######## MaxCoPayment 3
14840101 ATC2 1/1/2013 MaxCoPayment 5
14840101 Brand 11/1/2002 6/30/2005 SoleSupply
14840101 Chemical 8/1/2004 Statim Must
14840101 Formulation 7/1/1996 FormMax 84 PSO
14870101 Chemical 5/16/1994 6/30/2003 SpecEnd Retail
14870101 Chemical 4/1/2004 Statim Must
14870125 Chemical 4/1/2004 Statim Must
14870125 Chemical 5/16/1994 6/30/2003 SpecEnd Retail
14870125 Brand 4/1/2001 6/30/2003 SoleSupply
14870125 Brand 10/1/2003 6/30/2006 SoleSupply
14870126 Brand 4/1/2010 6/30/2012 SoleSupply
14870126 Brand 10/1/2012 6/30/2015 SoleSupply
14870126 Chemical 5/16/1994 6/30/2003 SpecEnd Retail
14870126 Chemical 4/1/2004 Statim Must
14920301 Formulation 1/1/2011 3/31/2011 Brandswitch 2377845 BSF Univent
14920301 Formulation 7/1/1996 FormMax 40 PSO
14920302 Formulation 7/1/1996 FormMax 40 PSO
14920302 Brand 7/1/1999 6/30/2001 SoleSupply
15120701 Formulation 7/1/2014 FormMax 10 PSO
15120701 Formulation 7/1/1996 6/30/2014 FormMax 5 PSO
15120702 Formulation 7/1/1996 6/30/2014 FormMax 5 PSO
15120702 Formulation 7/1/2014 FormMax 10 PSO
15120702 Brand 12/1/2000 6/30/2003 SoleSupply
15120702 Brand 10/1/2003 6/30/2006 SoleSupply
15120702 Brand 3/1/2009 6/30/2011 SoleSupply
15120702 Brand 12/1/2011 6/30/2014 SoleSupply
15130101 Chemical 1/1/1999 7/31/2005 Dispensary HP2&3
15130101 Chemical 8/1/2005 Dispensary HP3
15130101 Chemical 5/16/1994 SpecEnd Hospital
15150101 Chemical 10/1/2003 Statim Must
15150101 Brand 10/1/2003 6/30/2006 SoleSupply
15150101 Formulation 7/1/1996 9/30/2003 Statim May
15210101 Brand 4/1/2005 6/30/2007 SoleSupply
15210101 Brand 10/1/2007 6/30/2010 SoleSupply
15210201 Brand 4/1/2005 6/30/2007 SoleSupply
15210201 Brand 10/1/2007 6/30/2010 SoleSupply
15270101 Brand 12/1/2009 6/30/2012 SoleSupply
15270101 Chemical 10/1/2003 Statim Must
15270101 Chemical 5/16/1994 9/30/2007 SpecEnd Retail
15270102 Chemical 5/16/1994 9/30/2007 SpecEnd Retail
15270102 Chemical 10/1/2003 Statim Must
15270102 Brand 3/1/2004 6/30/2006 SoleSupply
15270102 Brand 10/1/2006 6/30/2009 SoleSupply
15270102 Brand 3/1/2013 6/30/2015 SoleSupply
15290101 Brand 3/1/2013 6/30/2015 SoleSupply
15290101 Chemical 5/16/1994 ######## SpecEnd Retail
15290201 Formulation 7/1/2005 SpecEnd Retail
15290201 Formulation 7/1/2005 PCT
15290202 Formulation 7/1/2005 PCT
15290202 Formulation 7/1/2005 SpecEnd Retail
15290301 Formulation 7/1/2005 SpecEnd Retail
15290301 Formulation 7/1/2005 PCT
15290301 Brand 12/1/2001 6/30/2004 SoleSupply
15290302 Formulation 7/1/2005 PCT
15290302 Formulation 7/1/2005 SpecEnd Retail
15290401 Formulation 7/1/2005 SpecEnd Retail
15290401 Formulation 7/1/2005 PCT
15290402 Formulation 7/1/2005 PCT
15290402 Brand 12/1/2001 6/30/2004 SoleSupply
15290402 Formulation 7/1/2005 SpecEnd Retail
15292525 Formulation 7/1/2005 SpecEnd Hospital
15292525 Formulation 7/1/2005 PCT only
15292625 Formulation10/1/2005 PCT only
15292625 Formulation10/1/2005 SpecEnd Hospital
15292626 Formulation10/1/2005 SpecEnd Hospital
15292626 Formulation10/1/2005 PCT only
15292725 Formulation10/1/2005 PCT only
15292725 Formulation10/1/2005 SpecEnd Hospital
15292726 Formulation10/1/2005 SpecEnd Hospital
15292726 Formulation10/1/2005 PCT only
15292825 Formulation12/1/2005 PCT only
15292825 Formulation12/1/2005 SpecEnd Hospital
15292826 Formulation12/1/2005 SpecEnd Hospital
15292826 Formulation12/1/2005 PCT only
15292925 Formulation 1/1/2007 PCT only
15292925 Formulation 1/1/2007 SpecEnd Hospital
15293025 Formulation 1/1/2007 SpecEnd Hospital
15293025 Formulation 1/1/2007 PCT only
15320101 Chemical 5/16/1994 3/31/2008 SpecEnd Retail
15320101 Chemical 8/1/2012 SafetyListMedicine
15320101 Formulation 7/1/1996 FormMax 5 PSO
15320125 Formulation 7/1/1996 FormMax 5 PSO
15320125 Chemical 8/1/2012 SafetyListMedicine
15320125 Chemical 5/16/1994 3/31/2008 SpecEnd Retail
15320125 Brand 10/1/2003 6/30/2006 SoleSupply
15320201 Chemical 5/16/1994 3/31/2008 SpecEnd Retail
15320201 Chemical 8/1/2012 SafetyListMedicine
15320201 Formulation 7/1/1996 FormMax 5 PSO
15320225 Formulation 7/1/1996 FormMax 5 PSO
15320225 Chemical 8/1/2012 SafetyListMedicine
15320225 Chemical 5/16/1994 3/31/2008 SpecEnd Retail
15320225 Brand 10/1/2003 6/30/2006 SoleSupply
15320301 Chemical 5/16/1994 3/31/2008 SpecEnd Retail
15320301 Chemical 8/1/2012 SafetyListMedicine
15320301 Formulation 7/1/1996 FormMax 5 PSO
15320325 Formulation 7/1/1996 FormMax 5 PSO
15320325 Chemical 8/1/2012 SafetyListMedicine
15320325 Chemical 5/16/1994 3/31/2008 SpecEnd Retail
15320325 Brand 10/1/2003 6/30/2006 SoleSupply
15330101 Brand 6/1/2003 6/30/2005 SoleSupply
15330101 Brand 11/1/2005 6/30/2008 SoleSupply
15330101 Chemical 5/16/1994 3/31/2008 SpecEnd Retail
15330101 Chemical 8/1/2012 SafetyListMedicine
15330101 Formulation 7/1/1996 FormMax 5 PSO
15330102 Formulation 7/1/1996 FormMax 5 PSO
15330102 Chemical 8/1/2012 SafetyListMedicine
15330102 Chemical 5/16/1994 3/31/2008 SpecEnd Retail
15330102 Brand 3/1/2000 6/30/2002 SoleSupply
15330201 Brand 6/1/2003 6/30/2005 SoleSupply
15330201 Brand 11/1/2005 6/30/2008 SoleSupply
15330201 Chemical 5/16/1994 3/31/2008 SpecEnd Retail
15330201 Chemical 8/1/2012 SafetyListMedicine
15330201 Formulation 7/1/1996 FormMax 5 PSO
15330202 Formulation 7/1/1996 FormMax 5 PSO
15330202 Chemical 8/1/2012 SafetyListMedicine
15330202 Chemical 5/16/1994 3/31/2008 SpecEnd Retail
15330202 Brand 3/1/2000 6/30/2002 SoleSupply
15330301 Chemical 5/16/1994 3/31/2008 SpecEnd Retail
15330301 Chemical 8/1/2012 SafetyListMedicine
15330301 Formulation 7/1/1996 FormMax 5 PSO
15330401 Formulation 7/1/1996 FormMax 5 PSO
15330401 Chemical 8/1/2012 SafetyListMedicine
15330401 Chemical 5/16/1994 3/31/2008 SpecEnd Retail
15330401 Brand 8/1/2003 6/30/2005 SoleSupply
15330401 Brand 11/1/2005 6/30/2008 SoleSupply
15330402 Brand 3/1/2000 6/30/2002 SoleSupply
15330402 Chemical 5/16/1994 3/31/2008 SpecEnd Retail
15330402 Chemical 8/1/2012 SafetyListMedicine
15330402 Formulation 7/1/1996 FormMax 5 PSO
15360101 ATC3 9/1/2010 Application
15360101 ATC3 3/1/1996 8/31/2010 Application
15360201 ATC3 3/1/1996 8/31/2010 Application
15360201 ATC3 9/1/2010 Application
15360301 ATC3 9/1/2010 Application
15360301 ATC3 3/1/1996 8/31/2010 Application
15370101 Chemical 5/16/1994 7/31/2010 SpecEnd Hospital
15370101 Chemical 8/1/2010 SpecEnd Retail
15370101 Chemical 1/1/1999 7/31/2010 Dispensary HP3
15370102 Chemical 1/1/1999 7/31/2010 Dispensary HP3
15370102 Chemical 8/1/2010 SpecEnd Retail
15370102 Chemical 5/16/1994 7/31/2010 SpecEnd Hospital
15370103 Chemical 5/16/1994 7/31/2010 SpecEnd Hospital
15370103 Chemical 8/1/2010 SpecEnd Retail
15370103 Chemical 1/1/1999 7/31/2010 Dispensary HP3
15370103 Brand 8/1/1999 6/30/2001 SoleSupply
15370103 Brand 9/1/2003 6/30/2006 SoleSupply
15370103 Brand 12/1/2010 6/30/2013 SoleSupply
15370125 Chemical 1/1/1999 7/31/2010 Dispensary HP3
15370125 Brand 3/1/2013 S29
15370125 Brand 4/1/2013 Wastage
15370125 Chemical 8/1/2010 SpecEnd Retail
15370125 Chemical 5/16/1994 7/31/2010 SpecEnd Hospital
15420301 Formulation5/16/1994 FormReqd Rx
15420301 Formulation 6/1/2002 NotCombined
15422501 Formulation 6/1/2002 NotCombined
15422501 Formulation5/16/1994 FormReqd Rx
15440101 Chemical 10/1/2003 Statim Must
15440101 Formulation 2/1/2001 FormMax 30 PSO
15440102 Formulation 2/1/2001 FormMax 30 PSO
15440102 Chemical 10/1/2003 Statim Must
15440103 Chemical 10/1/2003 Statim Must
15440103 Formulation 2/1/2001 FormMax 30 PSO
15440103 Brand 12/1/2000 6/30/2003 SoleSupply
15440103 Brand 10/1/2003 6/30/2006 SoleSupply
15440103 Brand 8/1/2009 6/30/2012 SoleSupply
15440103 Brand 10/1/2012 6/30/2015 SoleSupply
15440105 Formulation 2/1/2001 FormMax 30 PSO
15440105 Chemical 10/1/2003 Statim Must
15440201 Chemical 10/1/2003 Statim Must
15440201 Formulation5/17/1995 ######## SpecEnd Retail
15440202 Formulation5/17/1995 ######## SpecEnd Retail
15440202 Chemical 10/1/2003 Statim Must
15440202 Brand 12/1/2000 6/30/2003 SoleSupply
15440202 Brand 10/1/2003 6/30/2006 SoleSupply
15440203 Chemical 10/1/2003 Statim Must
15440203 Formulation5/17/1995 ######## SpecEnd Retail
15440225 Formulation5/17/1995 ######## SpecEnd Retail
15440225 Chemical 10/1/2003 Statim Must
15440225 Brand 12/1/2009 7/31/2010 S29
15440225 Brand 3/1/2013 6/30/2015 SoleSupply
15440301 Formulation 7/1/1996 Safety Uncompounded
15440301 Chemical 10/1/2003 Statim Must
15440401 Chemical 10/1/2003 Statim Must
15440401 Formulation 7/1/1996 FormMax 5 PSO
15440401 Brand 11/1/2004 6/30/2007 SoleSupply
15440402 Formulation 7/1/1996 FormMax 5 PSO
15440402 Chemical 10/1/2003 Statim Must
15440403 Chemical 10/1/2003 Statim Must
15440403 Formulation 7/1/1996 FormMax 5 PSO
15440425 Formulation 7/1/1996 FormMax 5 PSO
15440425 Chemical 10/1/2003 Statim Must
15440425 Brand 2/1/2011 6/30/2013 SoleSupply
15440501 Chemical 10/1/2003 Statim Must
15440501 Formulation 7/1/1996 FormMax 5 PSO
15440601 Chemical 10/1/2003 Statim Must
15440601 Formulation5/17/1995 ######## SpecEnd Retail
15460101 Formulation5/26/1995 7/31/2010 SpecEnd Hospital
15460101 Formulation 8/1/2010 SpecEnd Retail
15460101 Formulation 1/1/1999 7/31/2010 Dispensary HP3
15460101 Brand 10/1/2003 6/30/2006 SoleSupply
15460201 Formulation 1/1/1999 Dispensary HP3
15460201 Formulation5/26/1995 SpecEnd Hospital
15460301 Formulation5/26/1995 7/31/2010 SpecEnd Hospital
15460301 Formulation 8/1/2010 SpecEnd Retail
15460301 Formulation 1/1/1999 7/31/2010 Dispensary HP3
15460301 Formulation5/26/1995 SubRxF
15460801 Formulation12/1/1998 FormMax 15 Rx
15460801 Formulation 6/1/2002 NotCombined
15460801 Formulation12/1/1998 FormReqd Rx
15460801 Formulation10/1/1997 ######## FormMax 15 Rx
15460825 Formulation10/1/1997 ######## FormMax 15 Rx
11370301 Chemical 6/1/2004 6/30/2004 SpecialWav
11370325 Chemical 6/1/2004 6/30/2004 SpecialWav
11370325 ATC3 5/16/1994 ######## Special
11370325 ATC3 12/1/1998 3/31/2002 Special
11370325 Chemical 6/1/2004 9/30/2004 Repeat
11370325 Chemical 7/1/2002 5/31/2004 Special
11370325 Chemical 7/1/2004 8/31/2005 SpecialWav
11370325 ATC3 12/1/1995 ######## Special
11370325 Chemical 10/1/2003 Statim Must
11370325 Chemical 9/1/2005 8/31/2010 SpecialWav
11370325 ATC3 11/1/1997 ######## Special
11370326 ATC3 11/1/1997 ######## Special
11370326 Chemical 9/1/2005 8/31/2010 SpecialWav
11370326 Chemical 10/1/2003 Statim Must
11370326 ATC3 12/1/1995 ######## Special
11370326 Chemical 7/1/2004 8/31/2005 SpecialWav
11370326 Chemical 6/1/2004 9/30/2004 Repeat
11370326 Chemical 7/1/2002 5/31/2004 Special
11370326 ATC3 12/1/1998 3/31/2002 Special
11370326 ATC3 5/16/1994 ######## Special
11370326 Chemical 6/1/2004 6/30/2004 SpecialWav
11370327 Chemical 6/1/2004 6/30/2004 SpecialWav
11370327 ATC3 5/16/1994 ######## Special
11370327 Brand 1/1/2013 6/30/2015 SoleSupply
11370327 ATC3 12/1/1998 3/31/2002 Special
11370327 Chemical 6/1/2004 9/30/2004 Repeat
11370327 Chemical 7/1/2002 5/31/2004 Special
11370327 Chemical 7/1/2004 8/31/2005 SpecialWav
11370327 ATC3 12/1/1995 ######## Special
11370327 Chemical 10/1/2003 Statim Must
11370327 Chemical 9/1/2005 8/31/2010 SpecialWav
11370327 ATC3 11/1/1997 ######## Special
11372525 ATC3 11/1/1997 ######## Special
11372525 Chemical 9/1/2005 8/31/2010 SpecialWav
11372525 Chemical 10/1/2003 Statim Must
11372525 ATC3 12/1/1995 ######## Special
11372525 Chemical 7/1/2004 8/31/2005 SpecialWav
11372525 Chemical 7/1/2002 5/31/2004 Special
11372525 Chemical 6/1/2004 9/30/2004 Repeat
11372525 ATC3 12/1/1998 3/31/2002 Special
11372525 ATC3 5/16/1994 ######## Special
11372525 Chemical 6/1/2004 6/30/2004 SpecialWav
11372526 Chemical 6/1/2004 6/30/2004 SpecialWav
11372526 ATC3 12/1/1998 3/31/2002 Special
11372526 ATC3 5/16/1994 ######## Special
11372526 Chemical 6/1/2004 9/30/2004 Repeat
11372526 Chemical 7/1/2002 5/31/2004 Special
11372526 Chemical 7/1/2004 8/31/2005 SpecialWav
11372526 ATC3 12/1/1995 ######## Special
11372526 Chemical 10/1/2003 Statim Must
11372526 Chemical 9/1/2005 8/31/2010 SpecialWav
11372526 ATC3 11/1/1997 ######## Special
11372527 ATC3 11/1/1997 ######## Special
11372527 Chemical 9/1/2005 8/31/2010 SpecialWav
11372527 Chemical 10/1/2003 Statim Must
11372527 ATC3 12/1/1995 ######## Special
11372527 Chemical 7/1/2004 8/31/2005 SpecialWav
11372527 Chemical 7/1/2002 5/31/2004 Special
11372527 Chemical 6/1/2004 9/30/2004 Repeat
11372527 ATC3 5/16/1994 ######## Special
11372527 ATC3 12/1/1998 3/31/2002 Special
11372527 Chemical 6/1/2004 6/30/2004 SpecialWav
11372528 Chemical 6/1/2004 6/30/2004 SpecialWav
11372528 ATC3 12/1/1998 3/31/2002 Special
11372528 Brand 1/1/2013 6/30/2015 SoleSupply
11372528 ATC3 5/16/1994 ######## Special
11372528 Chemical 6/1/2004 9/30/2004 Repeat
11372528 Chemical 7/1/2002 5/31/2004 Special
11372528 Chemical 7/1/2004 8/31/2005 SpecialWav
11372528 ATC3 12/1/1995 ######## Special
11372528 Chemical 9/1/2005 8/31/2010 SpecialWav
11372528 Chemical 10/1/2003 Statim Must
11372528 ATC3 11/1/1997 ######## Special
11380101 Chemical 7/1/1998 6/30/2010 SpecOnly Retail
11380101 Brand 10/1/2011 6/30/2014 SoleSupply
11380101 Chemical 7/1/1998 Statim May
11400101 Brand 6/1/2011 8/31/2011 Special Claim only
11400101 Chemical 8/1/2012 SafetyListMedicine
11400101 Chemical 2/1/1999 ######## Special
11400101 Chemical 12/1/1999 8/31/2004 Special
11400101 Chemical 9/1/2004 8/31/2011 Application
11400125 Chemical 9/1/2004 8/31/2011 Application
11400125 Chemical 12/1/1999 8/31/2004 Special
11400125 Chemical 2/1/1999 ######## Special
11400125 Chemical 8/1/2012 SafetyListMedicine
11400126 Chemical 8/1/2012 SafetyListMedicine
11400126 Chemical 12/1/1999 8/31/2004 Special
11400126 Chemical 2/1/1999 ######## Special
11400126 Chemical 9/1/2004 8/31/2011 Application
11400127 Chemical 9/1/2004 8/31/2011 Application
11400127 Chemical 2/1/1999 ######## Special
11400127 Chemical 12/1/1999 8/31/2004 Special
11400127 Chemical 8/1/2012 SafetyListMedicine
11400201 Chemical 8/1/2012 SafetyListMedicine
11400201 Chemical 12/1/1999 8/31/2004 Special
11400201 Chemical 2/1/1999 ######## Special
11400201 Chemical 9/1/2004 8/31/2011 Application
11400201 Brand 6/1/2011 8/31/2011 Special Claim only
11400225 Chemical 9/1/2004 8/31/2011 Application
11400225 Chemical 12/1/1999 8/31/2004 Special
11400225 Chemical 2/1/1999 ######## Special
11400225 Chemical 8/1/2012 SafetyListMedicine
11400226 Chemical 8/1/2012 SafetyListMedicine
11400226 Chemical 2/1/1999 ######## Special
11400226 Chemical 12/1/1999 8/31/2004 Special
11400226 Chemical 9/1/2004 8/31/2011 Application
11400227 Chemical 9/1/2004 8/31/2011 Application
11580126 Chemical 1/1/2006 ######## AltSubSA
11580126 Chemical 12/1/2008 1/31/2009 AltSubSA
11590101 Chemical 5/16/1994 6/30/1999 TreatMax 30
11590201 Chemical 5/16/1994 6/30/1999 TreatMax 30
11660101 Chemical 5/16/1994 ######## TreatMax 30
11660201 Chemical 5/16/1994 ######## TreatMax 30
11670101 Chemical 10/1/2003 Statim Must
11670101 Formulation10/1/1997 9/30/2003 Statim May
11670102 Formulation10/1/1997 9/30/2003 Statim May
11670102 Chemical 10/1/2003 Statim Must
11670103 Chemical 10/1/2003 Statim Must
11670103 Formulation10/1/1997 9/30/2003 Statim May
11670103 Brand 11/1/1999 6/30/2002 SoleSupply
11670103 Brand 11/1/2002 6/30/2005 SoleSupply
11670103 Brand 10/1/2005 6/30/2008 SoleSupply
11670301 Formulation10/1/1997 9/30/2003 Statim May
11670301 Chemical 10/1/2003 Statim Must
11670302 Chemical 10/1/2003 Statim Must
11670302 Formulation10/1/1997 9/30/2003 Statim May
11670302 Brand 11/1/1999 6/30/2002 SoleSupply
11670302 Brand 11/1/2002 6/30/2005 SoleSupply
11670302 Brand 10/1/2005 6/30/2008 SoleSupply
11670401 Formulation10/1/1997 9/30/2003 Statim May
11670401 Chemical 10/1/2003 Statim Must
11672525 Chemical 10/1/2003 Statim Must
11672525 Brand 9/1/2009 ######## S29
11680501 Formulation 1/1/1999 Dispensary HP3
11680501 Formulation5/16/1994 Special
11680703 Brand 11/1/2000 6/30/2003 SoleSupply
11680703 Brand 10/1/2003 6/30/2006 SoleSupply
11680803 Brand 11/1/2000 6/30/2003 SoleSupply
11680803 Brand 10/1/2003 6/30/2006 SoleSupply
11680901 Formulation 2/1/2000 4/30/2004 Special
11680901 Formulation 9/1/2011 Special
11680901 Formulation 5/1/2004 6/30/2008 Special
11680901 Formulation 9/1/1999 1/31/2000 Special
11680901 Formulation 7/1/2008 8/31/2011 Special
11680901 Formulation 3/1/1999 8/31/1999 Special
11700101 ATC2 8/1/2010 6/30/2013 Application
11700101 ATC2 6/1/2001 6/30/2005 Application
11700101 ATC2 1/1/1999 7/31/2010 Dispensary HP1
11700101 ATC2 1/1/2001 5/31/2001 Special
11700101 ATC2 10/1/1998 ######## Special SpecEnd
11700101 ATC2 7/1/2005 6/30/2010 Application
11700101 Chemical 8/1/2010 Special Claim only
11700101 Formulation 4/1/2013 Brandswitch 2433265 BSF Nevirapine Alphapharm
11700101 Chemical 6/1/2001 7/31/2010 Special Claim only
11700101 ATC2 4/1/1997 9/30/1998 Special
11700101 ATC2 7/1/2013 Application
11700101 Brand 11/1/2009 6/30/2012 SoleSupply
11700101 ATC2 7/1/2010 7/31/2010 Application
11700125 ATC2 7/1/2010 7/31/2010 Application
11700125 Brand 4/1/2013 6/30/2015 SoleSupply
11700125 ATC2 7/1/2013 Application
11700125 ATC2 4/1/1997 9/30/1998 Special
11700125 Chemical 6/1/2001 7/31/2010 Special Claim only
11700125 Formulation 4/1/2013 Brandswitch 2433265 BSF Nevirapine Alphapharm
11700125 Chemical 8/1/2010 Special Claim only
11700125 ATC2 7/1/2005 6/30/2010 Application
11700125 ATC2 10/1/1998 ######## Special SpecEnd
11700125 ATC2 1/1/2001 5/31/2001 Special
11700125 ATC2 1/1/1999 7/31/2010 Dispensary HP1
11700125 ATC2 6/1/2001 6/30/2005 Application
11700125 ATC2 8/1/2010 6/30/2013 Application
11702525 ATC2 8/1/2010 6/30/2013 Application
11702525 ATC2 6/1/2001 6/30/2005 Application
11702525 ATC2 1/1/1999 7/31/2010 Dispensary HP1
11702525 ATC2 1/1/2001 5/31/2001 Special
11702525 ATC2 10/1/1998 ######## Special SpecEnd
11702525 ATC2 7/1/2005 6/30/2010 Application
11702525 Chemical 8/1/2010 Special Claim only
11702525 Chemical 6/1/2001 7/31/2010 Special Claim only
11702525 ATC2 4/1/1997 9/30/1998 Special
11702525 Brand 12/1/2006 6/30/2009 SoleSupply
11702525 Brand 11/1/2009 6/30/2012 SoleSupply
11702525 ATC2 7/1/2013 Application
11702525 ATC2 7/1/2010 7/31/2010 Application
11710101 Chemical 10/1/2003 Statim Must
11710201 Chemical 10/1/2003 Statim Must
11720101 ATC2 7/1/2005 6/30/2010 Application
11720101 ATC2 10/1/1998 ######## Special SpecEnd
11720101 ATC2 1/1/2001 5/31/2001 Special
11720101 ATC2 1/1/1999 7/31/2010 Dispensary HP1
11720101 ATC2 6/1/2001 6/30/2005 Application
11720101 ATC2 8/1/2010 6/30/2013 Application
11720101 ATC2 7/1/2010 7/31/2010 Application
11720101 ATC2 7/1/2013 Application
11720101 ATC2 4/1/1997 9/30/1998 Special
11720101 Chemical 6/1/2001 7/31/2010 Special Claim only
11720101 Chemical 8/1/2010 Special Claim only
11720201 Chemical 8/1/2010 Special Claim only
11720201 Chemical 6/1/2001 7/31/2010 Special Claim only
11720201 ATC2 4/1/1997 9/30/1998 Special
11720201 ATC2 7/1/2013 Application
11720201 ATC2 7/1/2010 7/31/2010 Application
11720201 ATC2 8/1/2010 6/30/2013 Application
11720201 ATC2 6/1/2001 6/30/2005 Application
11720201 ATC2 1/1/1999 7/31/2010 Dispensary HP1
11720201 ATC2 1/1/2001 5/31/2001 Special
11720201 ATC2 10/1/1998 ######## Special SpecEnd
11720201 ATC2 7/1/2005 6/30/2010 Application
11730101 Chemical 5/16/1994 SpecEnd Retail
11730101 Chemical 7/1/2005 PCT
11740101 ATC3 7/1/2013 Special
11740101 Chemical 10/1/1998 6/30/2013 Special
11740101 Chemical 1/1/1999 7/31/2010 Dispensary HP3
11740201 Chemical 1/1/1999 7/31/2010 Dispensary HP3
11740201 Chemical 10/1/1998 6/30/2013 Special
11740201 ATC3 7/1/2013 Special
11780101 Chemical 7/1/2009 5/31/2011 Application
11780101 Chemical 9/1/2010 5/31/2012 FormMax 8 PSO
11780101 Chemical 6/1/2011 5/31/2012 Application
11780101 Formulation 1/1/1999 6/30/2004 FormMax 2 Rx
11780101 Formulation 7/1/2004 ######## SubRxF
11780101 Formulation 6/1/2012 FormMax 8 PSO
11780101 Formulation 6/1/2012 ######## Application
11780101 Chemical 10/1/2005 8/31/2010 FormMax 4 PSO
11780101 Formulation 1/1/1999 6/30/2004 SubRxF
11780101 Chemical 7/1/2004 5/31/2012 FormMax 2 Rx Special
11780101 Chemical 12/1/2005 5/31/2012 SubRxF Special
11780101 Chemical 3/1/2013 TreatMax 5 Rx SubRxF
11780101 Formulation 6/1/2012 ######## FormMax 2 Rx Special
11780101 Formulation 6/1/2012 ######## SubRxF Special
11780125 Formulation 6/1/2012 ######## FormMax 2 Rx Special
11780125 Formulation 6/1/2012 ######## SubRxF Special
11780125 Chemical 3/1/2013 TreatMax 5 Rx SubRxF
11830401 Chemical 8/1/2012 SafetyListMedicine
11830401 Chemical 6/1/2002 6/30/2004 SubRxF
11832525 Chemical 6/1/2002 6/30/2004 SubRxF
11832525 Chemical 8/1/2012 SafetyListMedicine
11832525 Chemical 5/1/2001 5/31/2002 Special
11832525 Chemical 7/1/2004 9/30/2007 SubRxF
11832526 Chemical 7/1/2004 9/30/2007 SubRxF
11832526 Chemical 5/1/2001 5/31/2002 Special
11832526 Chemical 8/1/2012 SafetyListMedicine
11832526 Chemical 6/1/2002 6/30/2004 SubRxF
11832527 Chemical 6/1/2002 6/30/2004 SubRxF
11832527 Chemical 8/1/2012 SafetyListMedicine
11832527 Chemical 5/1/2001 5/31/2002 Special
11832527 Chemical 7/1/2004 9/30/2007 SubRxF
11870101 Formulation 5/1/2000 FormMax 12 Rx
11870101 Chemical 10/1/2003 Statim Must
11870125 Chemical 10/1/2003 Statim Must
11870125 Brand 2/1/2006 6/30/2007 SoleSupply
11870125 Formulation 5/1/2000 FormMax 12 Rx
11880201 Brand 1/1/2009 6/30/2011 SoleSupply
11880201 Brand 10/1/2011 6/30/2014 SoleSupply
11880201 Chemical 1/1/1999 2/28/2009 Dispensary HP3
11880201 Chemical 10/1/2003 Statim Must
11880201 Chemical 5/16/1994 2/28/2009 SpecEnd Hospital
11880301 Chemical 5/16/1994 2/28/2009 SpecEnd Hospital
11880301 Chemical 10/1/2003 Statim Must
11880301 Chemical 1/1/1999 2/28/2009 Dispensary HP3
11880401 Chemical 1/1/1999 2/28/2009 Dispensary HP3
11880401 Chemical 10/1/2003 Statim Must
11880401 Chemical 5/16/1994 2/28/2009 SpecEnd Hospital
11890101 Chemical 5/1/2002 6/30/2008 SpecEnd Retail
11890101 Formulation5/16/1994 4/30/2002 SpecEnd Retail
11890101 Chemical 10/1/2003 Statim Must
11890125 Chemical 10/1/2003 Statim Must
11890125 Formulation5/16/1994 4/30/2002 SpecEnd Retail
11890125 Chemical 5/1/2002 6/30/2008 SpecEnd Retail
11890125 Brand 5/1/2007 6/30/2009 SoleSupply
11890126 Brand 5/1/2010 6/30/2012 SoleSupply
11890126 Chemical 5/1/2002 6/30/2008 SpecEnd Retail
11890126 Formulation5/16/1994 4/30/2002 SpecEnd Retail
11890126 Chemical 10/1/2003 Statim Must
11890201 Chemical 10/1/2003 Statim Must
11890201 Formulation5/16/1994 4/30/2002 SpecEnd Retail
11890201 Chemical 5/1/2002 6/30/2008 SpecEnd Retail
11890225 Chemical 5/1/2002 6/30/2008 SpecEnd Retail
11890225 Formulation5/16/1994 4/30/2002 SpecEnd Retail
11890225 Chemical 10/1/2003 Statim Must
11890225 Brand 5/1/2007 6/30/2009 SoleSupply
11890226 Brand 5/1/2010 6/30/2012 SoleSupply
11890226 Chemical 10/1/2003 Statim Must
11890226 Formulation5/16/1994 4/30/2002 SpecEnd Retail
11890226 Chemical 5/1/2002 6/30/2008 SpecEnd Retail
11890301 Chemical 5/1/2002 6/30/2008 SpecEnd Retail
11890301 Chemical 10/1/2003 Statim Must
11890301 Brand 10/1/2003 6/30/2006 SoleSupply
11890301 Formulation5/16/1994 4/30/2002 Special
11910201 Chemical 10/1/2003 Statim Must
11910201 Formulation 8/1/2010 ProvAllow Dietitian
11910202 Formulation 8/1/2010 ProvAllow Dietitian
11910202 Chemical 10/1/2003 Statim Must
11910203 Chemical 10/1/2003 Statim Must
11910203 Formulation 8/1/2010 ProvAllow Dietitian
11910204 Formulation 8/1/2010 ProvAllow Dietitian
11910204 Chemical 10/1/2003 Statim Must
11910205 Chemical 10/1/2003 Statim Must
11910205 Formulation 8/1/2010 ProvAllow Dietitian
11910205 Brand 5/1/1999 6/30/2001 SoleSupply
11910225 Brand 12/1/2006 6/30/2008 SoleSupply
11910225 Brand 11/1/2010 6/30/2011 SoleSupply
11910225 Formulation 8/1/2010 ProvAllow Dietitian
11910225 Chemical 10/1/2003 Statim Must
11910226 Chemical 10/1/2003 Statim Must
11910226 Formulation 8/1/2010 ProvAllow Dietitian
11910226 Brand 5/1/2012 6/30/2014 SoleSupply
11910301 Formulation 8/1/2010 4/30/2012 ProvAllow Dietitian
11910301 Chemical 10/1/2003 Statim Must
11910302 Chemical 10/1/2003 Statim Must
11910302 Formulation 8/1/2010 4/30/2012 ProvAllow Dietitian
11910302 Brand 5/1/1999 6/30/2001 SoleSupply
11910325 Brand 12/1/2006 6/30/2008 SoleSupply
11910325 Brand 11/1/2010 6/30/2011 SoleSupply
11910325 Formulation 8/1/2010 4/30/2012 ProvAllow Dietitian
11910325 Chemical 10/1/2003 Statim Must
11912525 Chemical 10/1/2003 Statim Must
11912525 Brand 1/1/2007 6/30/2008 SoleSupply
11912601 Chemical 10/1/2003 Statim Must
11912601 Formulation 8/1/2010 ProvAllow Dietitian
11912625 Formulation 8/1/2010 ProvAllow Dietitian
11912625 Chemical 10/1/2003 Statim Must
11912625 Brand 12/1/2008 6/30/2011 SoleSupply
11912625 Brand 12/1/2011 6/30/2014 SoleSupply
11912725 Formulation12/1/2012 SubRxF
11920101 ATC3 11/1/2002 8/31/2006 Application
11920101 Chemical 5/1/1999 ######## Application
11920101 Chemical 5/1/1999 Statim May
11920101 ATC3 4/1/2004 8/31/2006 SubRxF Special
11920201 ATC3 4/1/2004 8/31/2006 SubRxF Special
11920201 Chemical 5/1/1999 Statim May
11920201 Chemical 5/1/1999 ######## Application
11920201 ATC3 11/1/2002 8/31/2006 Application
11930101 Chemical 12/1/2003 1/31/2004 AltSubRxF
11930101 Chemical 5/1/2000 6/30/2000 AltSubRxF
11930101 Chemical 10/1/2003 Statim Must
11930101 Chemical 2/1/2004 ######## AltSubRxF
11930101 Brand 11/1/2004 AltSubRxF
11930101 Chemical 7/1/2000 1/31/2001 AltSubRxF
11930101 Chemical 2/1/2001 ######## AltSubRxF
11930125 Chemical 2/1/2001 ######## AltSubRxF
11930125 Chemical 7/1/2000 1/31/2001 AltSubRxF
11930125 Brand 11/1/2004 5/31/2005 AltSubRxF
11930125 Chemical 2/1/2004 ######## AltSubRxF
11930125 Chemical 10/1/2003 Statim Must
11930125 Chemical 5/1/2000 6/30/2000 AltSubRxF
11930125 Chemical 12/1/2003 1/31/2004 AltSubRxF
11930126 Chemical 12/1/2003 1/31/2004 AltSubRxF
11930126 Chemical 5/1/2000 6/30/2000 AltSubRxF
11930126 Chemical 10/1/2003 Statim Must
11930126 Chemical 2/1/2004 ######## AltSubRxF
11930126 Chemical 7/1/2000 1/31/2001 AltSubRxF
11930126 Chemical 2/1/2001 ######## AltSubRxF
11930126 Brand 6/1/2005 6/30/2006 SoleSupply
11930126 Brand 4/1/2009 6/30/2011 SoleSupply
11930126 Brand 10/1/2011 6/30/2014 SoleSupply
11930127 Chemical 7/1/2000 1/31/2001 AltSubRxF
12210125 Brand 1/1/2014 Wastage
12230101 ATC2 7/1/2005 6/30/2010 Application
12230101 ATC2 10/1/1998 ######## Special SpecEnd
12230101 ATC2 1/1/2001 5/31/2001 Special
12230101 ATC2 1/1/1999 7/31/2010 Dispensary HP1
12230101 ATC2 6/1/2001 6/30/2005 Application
12230101 ATC2 8/1/2010 6/30/2013 Application
12230101 ATC2 4/1/1997 9/30/1998 Special
12230101 ATC2 7/1/2010 7/31/2010 Application
12230101 ATC2 7/1/2013 Application
12230101 Formulation 3/1/2013 5/31/2013 Brandswitch 2433494 BSF Alphapharm
12230101 Chemical 6/1/2001 7/31/2010 Special Claim only
12230101 Chemical 8/1/2010 Special Claim only
12230125 Chemical 8/1/2010 Special Claim only
12230125 Chemical 6/1/2001 7/31/2010 Special Claim only
12230125 Formulation 3/1/2013 5/31/2013 Brandswitch 2433494 BSF Alphapharm
12230125 Brand 3/1/2013 6/30/2014 SoleSupply
12230125 ATC2 7/1/2013 Application
12230125 ATC2 7/1/2010 7/31/2010 Application
12230125 ATC2 4/1/1997 9/30/1998 Special
12230125 ATC2 8/1/2010 6/30/2013 Application
12230125 ATC2 6/1/2001 6/30/2005 Application
12230125 ATC2 1/1/2001 5/31/2001 Special
12230125 ATC2 1/1/1999 7/31/2010 Dispensary HP1
12230125 ATC2 10/1/1998 ######## Special SpecEnd
12230125 ATC2 7/1/2005 6/30/2010 Application
12280101 Brand 5/1/1998 6/30/2001 SoleSupply
12280125 Brand 3/1/2002 6/30/2004 SoleSupply
12280126 Brand 3/1/2005 6/30/2007 SoleSupply
12280126 Brand 10/1/2007 6/30/2010 SoleSupply
12280126 Brand 1/1/2014 6/30/2016 SoleSupply
12280201 Brand 5/1/1998 6/30/2001 SoleSupply
12280201 Formulation5/16/1994 Wastage
12280225 Formulation5/16/1994 Wastage
12280225 Brand 3/1/2002 6/30/2004 SoleSupply
12280226 Brand 3/1/2005 6/30/2007 SoleSupply
12280226 Brand 10/1/2007 6/30/2010 SoleSupply
12280226 Brand 10/1/2010 6/30/2013 SoleSupply
12280226 Brand 1/1/2014 6/30/2016 SoleSupply
12280226 Formulation5/16/1994 Wastage
12300101 Chemical 1/1/1999 Dispensary HP3
12300101 Chemical 5/16/1994 SpecEnd Hospital
12300101 Chemical 5/16/1994 SubRxF
12300202 Chemical 5/16/1994 SubRxF
12300202 Brand 12/1/2002 6/30/2005 SoleSupply
12300202 Chemical 5/16/1994 SpecEnd Hospital
12300202 Chemical 1/1/1999 Dispensary HP3
12300203 Chemical 1/1/1999 Dispensary HP3
12300203 Chemical 5/16/1994 SpecEnd Hospital
12300203 Chemical 5/16/1994 SubRxF
12310101 Chemical 5/16/1994 SubRxF
12310101 Chemical 5/16/1994 7/31/2010 SpecEnd Hospital
12310101 Chemical 8/1/2010 SpecEnd Retail
12310101 Chemical 1/1/1999 7/31/2010 Dispensary HP3
12310125 Chemical 1/1/1999 7/31/2010 Dispensary HP3
12310125 Chemical 8/1/2010 SpecEnd Retail
12310125 Chemical 5/16/1994 7/31/2010 SpecEnd Hospital
12310125 Chemical 5/16/1994 SubRxF
12320101 Chemical 5/16/1994 9/30/2005 SubRxF
12320101 Chemical 5/16/1994 9/30/2005 SpecEnd Hospital
12320101 Chemical 10/1/2005 ######## SubRxF
12320101 Chemical 1/1/1999 7/31/2010 Dispensary HP3
12320101 Chemical 10/1/2005 FormMax 5 PSO
12320101 Chemical 12/1/2005 6/30/2013 SubRxF
12320101 Chemical 7/1/2013 SubRxF
12320102 Chemical 7/1/2013 SubRxF
12320102 Chemical 12/1/2005 6/30/2013 SubRxF
12320102 Chemical 10/1/2005 FormMax 5 PSO
12320102 Chemical 1/1/1999 7/31/2010 Dispensary HP3
12320102 Chemical 10/1/2005 ######## SubRxF
12320102 Chemical 5/16/1994 9/30/2005 SpecEnd Hospital
12320102 Chemical 5/16/1994 9/30/2005 SubRxF
12320102 Brand 10/1/2003 6/30/2006 SoleSupply
12320201 Chemical 5/16/1994 9/30/2005 SubRxF
12320201 Chemical 5/16/1994 9/30/2005 SpecEnd Hospital
12320201 Chemical 10/1/2005 ######## SubRxF
12320201 Chemical 1/1/1999 7/31/2010 Dispensary HP3
12320201 Chemical 10/1/2005 FormMax 5 PSO
12320201 Chemical 12/1/2005 6/30/2013 SubRxF
12320201 Chemical 7/1/2013 SubRxF
12320225 Chemical 7/1/2013 SubRxF
12320225 Chemical 12/1/2005 6/30/2013 SubRxF
12320225 Chemical 10/1/2005 FormMax 5 PSO
12320225 Chemical 1/1/1999 7/31/2010 Dispensary HP3
12320225 Chemical 5/16/1994 9/30/2005 SpecEnd Hospital
12320225 Chemical 10/1/2005 ######## SubRxF
12320225 Chemical 5/16/1994 9/30/2005 SubRxF
12320225 Brand 12/1/2002 6/30/2005 SoleSupply
12320226 Brand 1/1/2007 6/30/2008 SoleSupply
12320226 Chemical 5/16/1994 9/30/2005 SubRxF
12320226 Chemical 10/1/2005 ######## SubRxF
12320226 Chemical 5/16/1994 9/30/2005 SpecEnd Hospital
12320226 Chemical 10/1/2005 FormMax 5 PSO
12320226 Chemical 12/1/2005 6/30/2013 SubRxF
12320226 Chemical 7/1/2013 SubRxF
12320226 Chemical 1/1/1999 7/31/2010 Dispensary HP3
12320227 Chemical 12/1/2005 6/30/2013 SubRxF
12320227 Chemical 10/1/2005 FormMax 5 PSO
12320227 Chemical 1/1/1999 7/31/2010 Dispensary HP3
12320227 Chemical 7/1/2013 SubRxF
12320227 Chemical 5/16/1994 9/30/2005 SpecEnd Hospital
12320227 Chemical 10/1/2005 ######## SubRxF
12320227 Chemical 5/16/1994 9/30/2005 SubRxF
12320227 Brand 2/1/2011 6/30/2013 SoleSupply
12320228 Brand 6/1/2014 6/30/2016 SoleSupply
12320228 Chemical 5/16/1994 9/30/2005 SubRxF
12320228 Chemical 10/1/2005 ######## SubRxF
12320228 Chemical 5/16/1994 9/30/2005 SpecEnd Hospital
12320228 Chemical 7/1/2013 SubRxF
12320228 Chemical 1/1/1999 7/31/2010 Dispensary HP3
12320228 Chemical 10/1/2005 FormMax 5 PSO
12320228 Chemical 12/1/2005 6/30/2013 SubRxF
12320301 Chemical 12/1/2005 6/30/2013 SubRxF
12320301 Chemical 1/1/1999 7/31/2010 Dispensary HP3
12320301 Chemical 10/1/2005 FormMax 5 PSO
12320301 Chemical 7/1/2013 SubRxF
12320301 Chemical 5/16/1994 9/30/2005 SpecEnd Hospital
12320301 Chemical 10/1/2005 ######## SubRxF
12320301 Chemical 5/16/1994 9/30/2005 SubRxF
12320325 Chemical 5/16/1994 9/30/2005 SubRxF
12320325 Brand 12/1/2002 6/30/2005 SoleSupply
12320325 Chemical 5/16/1994 9/30/2005 SpecEnd Hospital
12320325 Chemical 10/1/2005 ######## SubRxF
12320325 Chemical 7/1/2013 SubRxF
12320325 Chemical 1/1/1999 7/31/2010 Dispensary HP3
12320325 Chemical 12/1/2005 6/30/2013 SubRxF
12320325 Chemical 10/1/2005 FormMax 5 PSO
12320326 Chemical 12/1/2005 6/30/2013 SubRxF
12360226 Chemical 1/1/1999 7/31/2010 Dispensary HP3
12360226 Brand 12/1/2002 6/30/2005 SoleSupply
12360226 Chemical 5/16/1994 6/30/2013 SubRxF
12360226 Chemical 7/1/2013 SubRxF
12360227 Chemical 7/1/2013 SubRxF
12360227 Chemical 5/16/1994 6/30/2013 SubRxF
12360227 Brand 12/1/2006 6/30/2008 SoleSupply
12360227 Chemical 1/1/1999 7/31/2010 Dispensary HP3
12360228 Chemical 1/1/1999 7/31/2010 Dispensary HP3
12360228 Brand 6/1/2012 6/30/2014 SoleSupply
12360228 Chemical 5/16/1994 6/30/2013 SubRxF
12360228 Chemical 7/1/2013 SubRxF
12370101 Brand 10/1/2003 6/30/2006 SoleSupply
12370101 Chemical 1/1/1999 Dispensary HP3
12370201 Chemical 1/1/1999 Dispensary HP3
12370201 Brand 10/1/2003 6/30/2006 SoleSupply
12370301 Brand 10/1/2003 6/30/2006 SoleSupply
12370301 Chemical 1/1/1999 Dispensary HP3
12370301 Formulation5/16/1994 SubRxF
12370401 Formulation5/16/1994 SubRxF
12370401 Chemical 1/1/1999 Dispensary HP3
12370401 Brand 10/1/2003 6/30/2006 SoleSupply
12380101 Chemical 1/1/1999 5/31/2005 Dispensary HP4
12380101 Chemical 8/1/1999 Special
12380101 Chemical 6/1/2005 7/31/2010 Dispensary HP1
12382525 Chemical 6/1/2005 7/31/2010 Dispensary HP1
12382525 Chemical 8/1/1999 Special
12382525 Brand 10/1/2010 2/28/2011 S29
12382525 Chemical 1/1/1999 5/31/2005 Dispensary HP4
12390101 Chemical 8/1/1999 Combined
12390125 Chemical 8/1/1999 Combined
12440101 Chemical 10/1/2003 Statim Must
12440101 Chemical 2/1/2004 DoseMMax 500
12440101 Formulation5/18/1995 FormMax 100 Rx
12440101 Chemical 6/7/1995 7/31/1999 Combined
12440101 Formulation 6/7/1995 7/31/1999 DoseMMax 500
12440101 Chemical 6/7/1995 7/31/1999 FormReqd Rx
12440101 Chemical 2/1/2004 SubRxF
12440201 Chemical 2/1/2004 SubRxF
12440201 Formulation10/1/1999 1/31/2004 SubRxF
12440201 Chemical 6/7/1995 7/31/1999 FormReqd Rx
12440201 Formulation 6/7/1995 7/31/1999 DoseMMax 500
12440201 Chemical 6/7/1995 7/31/1999 Combined
12440201 Chemical 2/1/2004 DoseMMax 500
12440201 Formulation10/1/1999 1/31/2004 DoseMMax 500
12440201 Chemical 10/1/2003 Statim Must
12440225 Chemical 10/1/2003 Statim Must
12440225 Formulation10/1/1999 1/31/2004 DoseMMax 500
12440225 Chemical 2/1/2004 DoseMMax 500
12440225 Chemical 6/7/1995 7/31/1999 Combined
12440225 Brand 10/1/2005 6/30/2008 SoleSupply
12440225 Brand 11/1/2008 6/30/2011 SoleSupply
12440225 Brand 10/1/2011 6/30/2014 SoleSupply
12440225 Formulation 6/7/1995 7/31/1999 DoseMMax 500
12440225 Chemical 6/7/1995 7/31/1999 FormReqd Rx
12440225 Formulation10/1/1999 1/31/2004 SubRxF
12440225 Chemical 2/1/2004 SubRxF
12440301 Chemical 2/1/2004 SubRxF
12440301 Formulation 6/7/1995 7/31/1999 DoseMMax 500
12440301 Chemical 6/7/1995 7/31/1999 FormReqd Rx
12440301 Formulation5/18/1995 FormMax 100 Rx
12440301 Chemical 6/7/1995 7/31/1999 Combined
12440301 Chemical 2/1/2004 DoseMMax 500
12440301 Chemical 10/1/2003 Statim Must
12440401 Chemical 10/1/2003 Statim Must
12440401 Chemical 2/1/2004 DoseMMax 500
12440401 Formulation5/16/1994 5/18/1995 SpecEnd Hospital
12440401 Chemical 6/7/1995 7/31/1999 Combined
12440401 Formulation5/18/1995 FormMax 100 Rx
12440401 Chemical 6/7/1995 7/31/1999 FormReqd Rx
12440401 Formulation 6/7/1995 7/31/1999 DoseMMax 500
12440401 Chemical 2/1/2004 SubRxF
12440402 Chemical 2/1/2004 SubRxF
12440402 Formulation 6/7/1995 7/31/1999 DoseMMax 500
12440402 Chemical 6/7/1995 7/31/1999 FormReqd Rx
12440402 Formulation5/18/1995 FormMax 100 Rx
12440402 Chemical 6/7/1995 7/31/1999 Combined
12440402 Formulation5/16/1994 5/18/1995 SpecEnd Hospital
12440402 Chemical 2/1/2004 DoseMMax 500
12440402 Chemical 10/1/2003 Statim Must
12440601 Chemical 10/1/2003 Statim Must
12440601 Chemical 2/1/2004 DoseMMax 500
12440601 Chemical 6/7/1995 7/31/1999 Combined
12440601 Chemical 6/7/1995 7/31/1999 FormReqd Rx
12440601 Formulation 6/7/1995 7/31/1999 DoseMMax 500
12440601 Formulation 5/1/1999 1/31/2004 SubRxF
12440601 Formulation 5/1/1999 1/31/2004 DoseMMax 500
12440601 Chemical 2/1/2004 SubRxF
12442525 Chemical 2/1/2004 SubRxF
12442525 Chemical 6/7/1995 7/31/1999 FormReqd Rx
12442525 Chemical 6/7/1995 7/31/1999 Combined
12442525 Brand 12/1/2006 6/30/2009 SoleSupply
12442525 Chemical 2/1/2004 DoseMMax 500
12442525 Chemical 10/1/2003 Statim Must
12442526 Chemical 10/1/2003 Statim Must
12442526 Chemical 2/1/2004 DoseMMax 500
12442526 Brand 8/1/2010 6/30/2012 SoleSupply
12442526 Brand 1/1/2013 6/30/2015 SoleSupply
12442526 Chemical 6/7/1995 7/31/1999 Combined
12442526 Chemical 6/7/1995 7/31/1999 FormReqd Rx
12442526 Chemical 2/1/2004 SubRxF
12442601 Brand 12/1/2006 6/30/2009 SoleSupply
12442625 Brand 3/1/2013 6/30/2015 SoleSupply
12470101 Chemical 3/1/2013 5/31/2013 Brandswitch 2433486 BSF Accarb
12470101 Brand 8/1/2009 6/30/2012 SoleSupply
12470101 Chemical 9/1/1999 8/31/2008 Special
12470101 Chemical 9/1/2008 8/31/2010 Special
12470101 Chemical 10/1/2003 Statim Must
12470125 Chemical 10/1/2003 Statim Must
12470125 Chemical 9/1/2008 8/31/2010 Special
12470125 Chemical 9/1/1999 8/31/2008 Special
12470125 Brand 3/1/2013 5/30/2015 SoleSupply
12470125 Chemical 3/1/2013 5/31/2013 Brandswitch 2433486 BSF Accarb
12470201 Chemical 3/1/2013 5/31/2013 Brandswitch 2433486 BSF Accarb
12470201 Brand 8/1/2009 6/30/2012 SoleSupply
12470201 Chemical 9/1/1999 8/31/2008 Special
12470201 Chemical 9/1/2008 8/31/2010 Special
12470201 Chemical 10/1/2003 Statim Must
12470225 Chemical 10/1/2003 Statim Must
12470225 Chemical 9/1/2008 8/31/2010 Special
12470225 Chemical 9/1/1999 8/31/2008 Special
12470225 Brand 3/1/2013 6/30/2015 SoleSupply
12470225 Chemical 3/1/2013 5/31/2013 Brandswitch 2433486 BSF Accarb
12480101 ATC3 3/1/2007 ######## Special
12480101 ATC3 12/1/2010 Special
12480101 ATC3 12/1/2005 2/28/2007 Special
12480101 ATC3 6/1/2000 ######## Special
12480101 ATC3 2/1/2005 Dispensary Xpharm
12800201 Chemical 10/1/2003 Statim Must
12800301 Chemical 10/1/2003 Statim Must
12820101 Chemical 10/1/2003 ######## Statim Must
12820201 Chemical 10/1/2003 ######## Statim Must
12820201 Formulation 3/1/1996 3/31/1996 SpecOnly Retail
12820201 Formulation 4/1/1996 ######## SpecEnd Retail
12820201 Formulation 7/1/1996 Safety Uncompounded
12820201 Brand 1/1/2003 ######## SoleSupply
12830101 Chemical 8/1/2012 SafetyListMedicine
12830101 Formulation5/16/1994 FormMax 30 PSO
12830201 Formulation5/16/1994 FormMax 30 PSO
12830201 Chemical 8/1/2012 SafetyListMedicine
12830301 Chemical 8/1/2012 SafetyListMedicine
12830301 Formulation 7/1/1996 FormMax 30 PSO
12830401 Formulation5/15/1994 FormMax 30 PSO
12830401 Chemical 8/1/2012 SafetyListMedicine
12830501 Chemical 8/1/2012 SafetyListMedicine
12830501 Formulation 2/1/2001 FormMax 200 PSO
12830501 Formulation 7/1/1996 Safety Uncompounded
12830601 Chemical 8/1/2012 SafetyListMedicine
12830601 Formulation5/16/1994 FormMax 5 PSO
12880101 Chemical 5/16/1994 FormReqd Rx
12880101 Formulation 6/1/2002 NotCombined
12900101 Brand 12/1/2006 6/30/2009 SoleSupply
12900101 Chemical 10/1/2003 Statim Must
12900125 Chemical 10/1/2003 Statim Must
12900125 Brand 9/1/2012 S29
12900125 Brand 4/1/2013 Wastage
12910101 ATC3 5/16/1994 9/30/1997 SpecEnd Retail
12910125 ATC3 5/16/1994 9/30/1997 SpecEnd Retail
12920101 Formulation 7/1/1996 Safety Uncompounded
12970101 Formulation5/16/1994 ######## DoseDMax 2
12970101 Chemical 5/16/1994 ######## TreatMax 30
12970101 Chemical 5/1/2005 FormReqd Rx
12970101 Chemical 5/16/1994 4/30/2005 FormReqd Rx
12970101 Chemical 10/1/2003 Statim Must
12970101 ATC3 3/1/1996 3/31/1996 SpecialWav
12970102 ATC3 3/1/1996 3/31/1996 SpecialWav
12970102 Chemical 10/1/2003 Statim Must
12970102 Chemical 5/16/1994 4/30/2005 FormReqd Rx
12970102 Chemical 5/1/2005 FormReqd Rx
12970102 Chemical 5/16/1994 ######## TreatMax 30
12970102 Formulation5/16/1994 ######## DoseDMax 2
12970103 Formulation5/16/1994 ######## DoseDMax 2
12970103 Chemical 5/16/1994 ######## TreatMax 30
12970103 Chemical 5/1/2005 FormReqd Rx
12970103 Chemical 5/16/1994 4/30/2005 FormReqd Rx
12970103 Chemical 10/1/2003 Statim Must
12970103 ATC3 3/1/1996 3/31/1996 SpecialWav
12970104 ATC3 3/1/1996 3/31/1996 SpecialWav
12970104 Chemical 10/1/2003 Statim Must
12970104 Chemical 5/16/1994 4/30/2005 FormReqd Rx
12970104 Chemical 5/1/2005 FormReqd Rx
12970104 Chemical 5/16/1994 ######## TreatMax 30
12970104 Formulation5/16/1994 ######## DoseDMax 2
12970104 Brand 9/1/1998 8/31/2001 Preferred
12970201 Formulation5/16/1994 ######## DoseDMax 1
12970201 Chemical 5/16/1994 ######## TreatMax 30
12970201 Chemical 5/1/2005 FormReqd Rx
12970201 Chemical 5/16/1994 4/30/2005 FormReqd Rx
12970201 Chemical 10/1/2003 Statim Must
12970201 ATC3 3/1/1996 3/31/1996 SpecialWav
12970202 ATC3 3/1/1996 3/31/1996 SpecialWav
12970202 Chemical 10/1/2003 Statim Must
12970202 Chemical 5/16/1994 4/30/2005 FormReqd Rx
12970202 Chemical 5/1/2005 FormReqd Rx
12970202 Chemical 5/16/1994 ######## TreatMax 30
12970202 Formulation5/16/1994 ######## DoseDMax 1
12970203 Formulation5/16/1994 ######## DoseDMax 1
12970203 Chemical 5/16/1994 ######## TreatMax 30
12970203 Chemical 5/1/2005 FormReqd Rx
12970203 Chemical 5/16/1994 4/30/2005 FormReqd Rx
12970203 Chemical 10/1/2003 Statim Must
12970203 ATC3 3/1/1996 3/31/1996 SpecialWav
12970204 ATC3 3/1/1996 3/31/1996 SpecialWav
12970204 Chemical 10/1/2003 Statim Must
12970204 Chemical 5/16/1994 4/30/2005 FormReqd Rx
12970204 Chemical 5/1/2005 FormReqd Rx
12970204 Chemical 5/16/1994 ######## TreatMax 30
12970204 Formulation5/16/1994 ######## DoseDMax 1
12970204 Brand 9/1/1998 8/31/2001 Preferred
12970301 Chemical 5/16/1994 ######## TreatMax 30
12970301 Chemical 5/1/2005 FormReqd Rx
12970301 Chemical 5/16/1994 4/30/2005 FormReqd Rx
12970301 Chemical 10/1/2003 Statim Must
12970301 ATC3 3/1/1996 3/31/1996 SpecialWav
12970302 ATC3 3/1/1996 3/31/1996 SpecialWav
12970302 Chemical 10/1/2003 Statim Must
12970302 Chemical 5/16/1994 4/30/2005 FormReqd Rx
12970302 Chemical 5/1/2005 FormReqd Rx
12970302 Chemical 5/16/1994 ######## TreatMax 30
12970304 Chemical 5/16/1994 ######## TreatMax 30
12970304 Chemical 5/1/2005 FormReqd Rx
12970304 Chemical 5/16/1994 4/30/2005 FormReqd Rx
12970304 Chemical 10/1/2003 Statim Must
12970304 ATC3 3/1/1996 3/31/1996 SpecialWav
12970304 Brand 9/1/1998 8/31/2001 Preferred
12970401 Formulation5/16/1994 ######## DoseDMax 2
12970401 ATC3 3/1/1996 3/31/1996 SpecialWav
12970401 Chemical 10/1/2003 Statim Must
12970401 Chemical 5/16/1994 4/30/2005 FormReqd Rx
12970401 Chemical 5/1/2005 FormReqd Rx
12970401 Chemical 5/16/1994 ######## TreatMax 30
13030101 Chemical 5/16/1994 ######## SpecEnd Retail
13030101 Formulation12/1/2008 FormMax 4 Rx SpecEnd
13030101 Formulation11/1/1999 ######## FormMax 3 Rx SpecEnd
13030101 Brand 1/1/2003 6/30/2005 SoleSupply
13030101 Brand 10/1/2005 6/30/2008 SoleSupply
13030125 Brand 8/1/2012 6/30/2013 SoleSupply
13030125 Brand 11/1/2013 6/30/2016 SoleSupply
13030125 Formulation11/1/1999 ######## FormMax 3 Rx SpecEnd
13030125 Formulation12/1/2008 FormMax 4 Rx SpecEnd
13030125 Chemical 5/16/1994 ######## SpecEnd Retail
13030201 Chemical 5/16/1994 ######## SpecEnd Retail
13030201 Formulation 5/1/1994 Wastage
13030201 Formulation11/1/1999 FormMax 30 Rx SpecEnd
13030301 Brand 1/1/2003 6/30/2005 SoleSupply
13030301 Brand 10/1/2005 6/30/2008 SoleSupply
13030301 Brand 10/1/2013 6/30/2016 SoleSupply
13030301 Chemical 5/16/1994 ######## SpecEnd Retail
13030301 Formulation11/1/1999 SpecEnd Retail
13080101 Chemical 5/16/1994 7/31/2007 SpecEnd Retail
13080101 Chemical 8/1/2012 SafetyListMedicine
13080101 ATC3 8/1/2003 6/30/2005 Application
13200325 Brand 4/1/2005 6/30/2007 SoleSupply
13200325 Brand 10/1/2007 6/30/2010 SoleSupply
13200325 Brand 10/1/2010 6/30/2013 SoleSupply
13200325 Brand 1/1/2014 6/30/2016 SoleSupply
13200401 Chemical 10/1/2003 Statim Must
13200402 Chemical 10/1/2003 Statim Must
13200402 Brand 12/1/2001 6/30/2004 SoleSupply
13200402 Brand 10/1/2004 6/30/2007 SoleSupply
13200425 Brand 4/1/2009 6/30/2010 SoleSupply
13200425 Brand 10/1/2010 6/30/2013 SoleSupply
13200425 Brand 1/1/2014 6/30/2016 SoleSupply
13200425 Chemical 10/1/2003 Statim Must
13200601 Chemical 10/1/2003 Statim Must
13200601 Formulation 6/1/2002 FormReqd Rx
13200601 Formulation 6/1/2002 NotCombined
13200701 Formulation 6/1/2002 NotCombined
13200701 Formulation 6/1/2002 FormReqd Rx
13200701 Chemical 10/1/2003 Statim Must
13200702 Chemical 10/1/2003 Statim Must
13200702 Formulation 6/1/2002 FormReqd Rx
13200702 Formulation 6/1/2002 NotCombined
13200702 Brand 12/1/2002 6/30/2005 SoleSupply
13200704 Formulation 6/1/2002 NotCombined
13200704 Formulation 6/1/2002 FormReqd Rx
13200704 Chemical 10/1/2003 Statim Must
13200705 Chemical 10/1/2003 Statim Must
13200705 Formulation 6/1/2002 FormReqd Rx
13200705 Formulation 6/1/2002 NotCombined
13200725 Formulation 6/1/2002 NotCombined
13200725 Brand 4/1/2006 6/30/2008 SoleSupply
13200725 Brand 10/1/2008 6/30/2011 SoleSupply
13200725 Brand 12/1/2011 6/30/2014 SoleSupply
13200725 Formulation 6/1/2002 FormReqd Rx
13200725 Chemical 10/1/2003 Statim Must
13320101 Chemical 8/1/2012 SafetyListMedicine
13320102 Chemical 8/1/2012 SafetyListMedicine
13320102 Brand 11/1/2004 6/30/2007 SoleSupply
13320102 Brand 4/1/2008 ######## SoleSupply
13320102 Brand 8/1/2013 6/30/2016 SoleSupply
13320102 Brand 6/1/1998 6/30/1999 Preferred
13320103 Chemical 8/1/2012 SafetyListMedicine
13320201 Chemical 8/1/2012 SafetyListMedicine
13320202 Chemical 8/1/2012 SafetyListMedicine
13320202 Brand 6/1/1998 6/30/1999 Preferred
13320202 Brand 11/1/2004 6/30/2007 SoleSupply
13320202 Brand 4/1/2008 ######## SoleSupply
13320202 Brand 8/1/2013 6/30/2016 SoleSupply
13320203 Chemical 8/1/2012 SafetyListMedicine
13320301 Chemical 8/1/2012 SafetyListMedicine
13320302 Chemical 8/1/2012 SafetyListMedicine
13320302 Brand 11/1/2004 6/30/2007 SoleSupply
13320302 Brand 4/1/2008 ######## SoleSupply
13320302 Brand 8/1/2013 6/30/2016 SoleSupply
13320302 Brand 6/1/1998 6/30/1999 Preferred
13320303 Chemical 8/1/2012 SafetyListMedicine
13320401 Chemical 8/1/2012 SafetyListMedicine
13320401 Formulation 7/1/1996 Safety Uncompounded
13320501 Chemical 8/1/2012 SafetyListMedicine
13320501 Formulation######## Safety Compounded
13320501 Formulation######## Combined
13320602 Chemical 8/1/2012 SafetyListMedicine
13320602 Formulation 7/1/1996 Safety Uncompounded
13410101 Chemical 10/1/2003 Statim Must
13412525 Chemical 10/1/2003 Statim Must
13412525 Brand 10/1/2007 6/30/2010 SoleSupply
13412525 Brand 10/1/2010 6/30/2013 SoleSupply
13412525 Brand 11/1/2013 6/30/2016 SoleSupply
13450101 Brand 12/1/2001 6/30/2004 SoleSupply
13450101 Brand 1/1/2008 6/30/2010 SoleSupply
13450101 ATC3 5/16/1994 9/30/1997 SpecEnd Retail
13460101 Chemical 5/16/1994 7/31/2010 SpecEnd Hospital
13460101 Chemical 8/1/2010 SpecEnd Retail
13460101 Chemical 1/1/1999 7/31/2010 Dispensary HP3
13460101 Chemical 5/16/1994 SubRxF
13460125 Chemical 5/16/1994 SubRxF
13460125 Brand 1/1/2008 6/30/2010 SoleSupply
13460125 Chemical 1/1/1999 7/31/2010 Dispensary HP3
13460125 Chemical 8/1/2010 SpecEnd Retail
13460125 Chemical 5/16/1994 7/31/2010 SpecEnd Hospital
13570101 Formulation5/16/1994 FormBan BSO
13570101 Chemical 10/1/2003 Statim Must
13600101 Chemical 10/1/2003 Statim Must
13600101 Formulation 7/1/1996 9/30/2003 Statim May
13600201 Formulation 7/1/1996 9/30/2003 Statim May
13600201 Chemical 10/1/2003 Statim Must
13610101 Chemical 10/1/2003 Statim Must
13610101 Formulation5/16/1994 FormMax 200 PSO
13610102 Formulation5/16/1994 FormMax 200 PSO
13610102 Chemical 10/1/2003 Statim Must
13610103 Chemical 10/1/2003 Statim Must
13610103 Formulation5/16/1994 FormMax 200 PSO
13610125 Formulation5/16/1994 FormMax 200 PSO
13610125 Chemical 10/1/2003 Statim Must
13610201 Chemical 10/1/2003 Statim Must
13610201 Formulation5/16/1994 FormMax 30 PSO
13610201 Brand 2/1/2003 6/30/2005 SoleSupply
13610201 Brand 10/1/2005 6/30/2008 SoleSupply
13610203 Formulation5/16/1994 FormMax 30 PSO
13610203 Chemical 10/1/2003 Statim Must
13610204 Chemical 10/1/2003 Statim Must
13610204 Formulation5/16/1994 FormMax 30 PSO
13610205 Formulation5/16/1994 FormMax 30 PSO
13610205 Chemical 10/1/2003 Statim Must
13610206 Chemical 10/1/2003 Statim Must
13610206 Formulation5/16/1994 FormMax 30 PSO
13610206 Brand 11/1/1999 6/30/2002 SoleSupply
13610301 Chemical 10/1/2003 Statim Must
13610401 Chemical 10/1/2003 Statim Must
13610401 Formulation 1/1/1999 FormMax 200 PSO
13610401 Brand 11/1/1999 6/30/2002 SoleSupply
13610401 Brand 12/1/2002 6/30/2005 SoleSupply
13610401 Brand 10/1/2005 6/30/2008 SoleSupply
13630101 Chemical 6/1/2002 NotCombined
13630101 Chemical 6/1/2002 FormReqd Rx
13630125 Chemical 6/1/2002 FormReqd Rx
13630125 Chemical 6/1/2002 NotCombined
13630125 Brand 8/1/2010 6/30/2012 SoleSupply
13630125 Brand 10/1/2012 6/30/2015 SoleSupply
13630201 Chemical 6/1/2002 NotCombined
13630201 Chemical 6/1/2002 FormReqd Rx
13670101 Chemical 10/1/2003 Statim Must
13670102 Chemical 10/1/2003 Statim Must
13690101 Formulation10/1/2013 Wastage
13690101 Chemical 5/16/1994 2/28/2007 SpecEnd Retail
13830301 Formulation 1/1/2005 Statim Must
13830301 Brand 10/1/2010 6/30/2013 SoleSupply
13830501 Brand 1/1/2003 ######## SoleSupply
13830501 Formulation 3/1/1996 3/31/1996 SpecOnly Retail
13830501 Chemical 10/1/2003 ######## Statim Must
13830501 Chemical 6/29/1995 9/30/2007 SpecEnd Retail
13830501 Formulation10/1/2007 SpecEnd Retail
13830601 Chemical 6/29/1995 9/30/2007 SpecEnd Retail
13830601 Chemical 10/1/2003 ######## Statim Must
13830601 Formulation 1/1/2005 Statim Must
13830601 Brand 10/1/2011 6/30/2014 SoleSupply
13850101 Brand 9/1/2006 6/30/2009 SoleSupply
13850101 Brand 9/1/2010 6/30/2013 SoleSupply
13850101 Chemical 5/16/1994 1/31/2001 FormReqd WSO
13850101 Chemical 2/1/2001 2/28/2001 FormBan Rx
13850101 Chemical 4/1/2001 6/30/2001 FormBan WSO
13850101 Chemical 2/1/2001 2/28/2001 FormBan BSO
13850101 Chemical 3/1/2001 3/31/2001 FormReqd PSO
13850101 Chemical 4/1/2001 6/30/2001 FormBan Rx
13850101 Chemical 7/1/2001 9/30/2006 FormMax 5 PSO
13850101 Chemical 4/1/2004 Statim Must
13850101 Formulation 2/1/2001 FormMax 5 PSO
13850125 Formulation 2/1/2001 FormMax 5 PSO
13850125 Chemical 4/1/2001 6/30/2001 FormBan Rx
13850125 Chemical 7/1/2001 9/30/2006 FormMax 5 PSO
13850125 Chemical 2/1/2001 2/28/2001 FormBan BSO
13850125 Chemical 3/1/2001 3/31/2001 FormReqd PSO
13850125 Chemical 4/1/2004 Statim Must
13850125 Chemical 2/1/2001 2/28/2001 FormBan Rx
13850125 Chemical 4/1/2001 6/30/2001 FormBan WSO
13850125 Chemical 5/16/1994 1/31/2001 FormReqd WSO
13850125 Brand 7/1/2014 6/30/2016 SoleSupply
13850201 Brand 9/1/2006 6/30/2009 SoleSupply
13850201 Brand 9/1/2010 3/30/2013 SoleSupply
13850201 Chemical 2/1/2001 2/28/2001 FormBan Rx
13850201 Chemical 5/16/1994 1/31/2001 FormReqd WSO
13850201 Chemical 4/1/2001 6/30/2001 FormBan WSO
13850201 Chemical 3/1/2001 3/31/2001 FormReqd PSO
13850201 Chemical 4/1/2001 6/30/2001 FormBan Rx
13850201 Chemical 4/1/2004 Statim Must
13850201 Chemical 7/1/2001 9/30/2006 FormMax 5 PSO
13850201 Chemical 2/1/2001 2/28/2001 FormBan BSO
13850201 Formulation 2/1/2001 FormMax 5 PSO
13850225 Formulation 2/1/2001 FormMax 5 PSO
13850225 Chemical 3/1/2001 3/31/2001 FormReqd PSO
13850225 Chemical 2/1/2001 2/28/2001 FormBan BSO
13850225 Chemical 4/1/2004 Statim Must
13850225 Chemical 7/1/2001 9/30/2006 FormMax 5 PSO
13850225 Chemical 4/1/2001 6/30/2001 FormBan Rx
13850225 Chemical 2/1/2001 2/28/2001 FormBan Rx
13850225 Chemical 4/1/2001 6/30/2001 FormBan WSO
13850225 Chemical 5/16/1994 1/31/2001 FormReqd WSO
13850225 Brand 7/1/2014 6/30/2016 SoleSupply
13890101 Chemical 4/1/2000 2/29/2004 Special
13890101 Chemical 3/1/2004 3/31/2008 Special
13890101 Chemical 1/1/2011 7/31/2011 Special
13890101 Brand 5/1/2008 ######## SoleSupply
13890101 Brand 4/1/2013 6/30/2015 SoleSupply
13890101 Chemical 8/1/2011 Special
13890101 Chemical 6/23/1995 Controlled
13890101 Chemical 3/1/1999 3/31/2000 Special
13890101 Chemical 8/1/2012 SafetyListMedicine
13890101 Chemical 4/1/2008 ######## Special
13890101 Chemical 5/16/1994 2/28/1999 SpecEnd Hospital
13890125 Chemical 4/1/2008 ######## Special
13890125 Chemical 5/16/1994 2/28/1999 SpecEnd Hospital
13890125 Chemical 8/1/2012 SafetyListMedicine
13890125 Chemical 3/1/1999 3/31/2000 Special
13890125 Brand 7/1/2014 S29
13890125 Brand 7/1/2014 Wastage
13890125 Chemical 8/1/2011 Special
13890125 Chemical 6/23/1995 Controlled
13890125 Chemical 1/1/2011 7/31/2011 Special
13890125 Chemical 3/1/2004 3/31/2008 Special
13890125 Chemical 4/1/2000 2/29/2004 Special
13900101 Chemical 5/16/1994 MaxCoPayment 0
13900101 Chemical 5/30/1995 Controlled
13920203 Brand 3/1/1999 6/30/2001 SoleSupply
13930101 Chemical 6/7/1995 9/30/1998 Combined
13930101 Chemical 10/1/2003 Statim Must
13930101 Formulation 7/1/1996 FormMax 5 PSO
13930125 Chemical 10/1/2003 Statim Must
13930125 Formulation 7/1/1996 FormMax 5 PSO
13930125 Chemical 6/7/1995 9/30/1998 Combined
13930125 Brand 8/1/2008 6/30/2011 SoleSupply
13930125 Brand 10/1/2011 6/30/2014 SoleSupply
13930201 Chemical 6/7/1995 9/30/1998 Combined
13930201 Chemical 10/1/2003 Statim Must
13932525 Chemical 10/1/2003 Statim Must
13932525 Formulation 2/1/2007 FormMax 5 PSO
13932525 Chemical 6/7/1995 9/30/1998 Combined
13940101 Formulation 8/1/2010 ProvAllow Dietitian
13940102 Formulation 8/1/2010 ProvAllow Dietitian
13940103 Formulation 8/1/2010 ProvAllow Dietitian
13940103 Brand 1/1/2008 6/30/2010 SoleSupply
13940103 Brand 10/1/2010 6/30/2013 SoleSupply
13940125 Brand 1/1/2008 6/30/2010 SoleSupply
13940125 Brand 10/1/2010 6/30/2013 SoleSupply
13940125 Brand 12/1/2013 6/30/2016 SoleSupply
13940125 Formulation 8/1/2010 ProvAllow Dietitian
13940126 Formulation 8/1/2010 ProvAllow Dietitian
13940126 Brand 1/1/2008 6/30/2010 SoleSupply
13940126 Brand 10/1/2010 6/30/2013 SoleSupply
13970103 Formulation11/1/1997 Safety Compounded
13970103 Chemical 8/1/2012 SafetyListMedicine
13970103 Formulation5/16/1994 8/31/2010 TreatMax 30
13970104 Formulation5/16/1994 8/31/2010 TreatMax 30
13970104 Chemical 8/1/2012 SafetyListMedicine
13970104 Formulation11/1/1997 Safety Compounded
13970125 Formulation11/1/1997 Safety Compounded
13970125 Chemical 8/1/2012 SafetyListMedicine
13970125 Formulation5/16/1994 8/31/2010 TreatMax 30
13970201 Formulation5/16/1994 8/31/2010 TreatMax 30
13970201 Chemical 8/1/2012 SafetyListMedicine
13970201 Formulation11/1/1997 Safety Compounded
13970201 Brand 1/1/2001 6/30/2003 SoleSupply
13970203 Formulation11/1/1997 Safety Compounded
13970203 Chemical 8/1/2012 SafetyListMedicine
13970203 Formulation5/16/1994 8/31/2010 TreatMax 30
13970225 Formulation5/16/1994 8/31/2010 TreatMax 30
13970225 Chemical 8/1/2012 SafetyListMedicine
13970225 Formulation11/1/1997 Safety Compounded
13970302 Formulation11/1/1997 Safety Compounded
13970302 Chemical 8/1/2012 SafetyListMedicine
14010801 ATC3 9/1/2010 Application
14010801 Chemical 4/1/2004 Statim Must
14010901 Chemical 4/1/2004 Statim Must
14010901 ATC3 9/1/2010 Application
14010901 ATC3 3/1/1996 8/31/2010 Application
14010901 Formulation 3/1/1996 SpecialWav Claim only
14010901 Brand 11/1/2003 6/30/2006 SoleSupply
14010901 Brand 10/1/2008 6/30/2011 SoleSupply
14010901 Brand 10/1/2011 6/30/2014 SoleSupply
14011001 Brand 11/1/2003 6/30/2006 SoleSupply
14011001 Brand 10/1/2008 6/30/2011 SoleSupply
14011001 Brand 10/1/2011 6/30/2014 SoleSupply
14011001 Formulation5/16/1994 9/30/2007 SpecEnd Retail
14011001 Chemical 4/1/2004 Statim Must
14011101 Chemical 4/1/2004 Statim Must
14011101 ATC3 9/1/2010 Application
14011101 ATC3 3/1/1996 8/31/2010 Application
14011101 Formulation 3/1/1996 SpecialWav Claim only
14011201 Formulation 3/1/1996 SpecialWav Claim only
14011201 Brand 1/1/2013 6/30/2015 SoleSupply
14011201 ATC3 3/1/1996 8/31/2010 Application
14011201 ATC3 9/1/2010 Application
14011201 Chemical 4/1/2004 Statim Must
14011202 Chemical 4/1/2004 Statim Must
14011202 ATC3 9/1/2010 Application
14011202 ATC3 3/1/1996 8/31/2010 Application
14011202 Formulation 3/1/1996 SpecialWav Claim only
14011203 Formulation 3/1/1996 SpecialWav Claim only
14011203 Brand 4/1/2004 6/30/2006 SoleSupply
14011203 Brand 10/1/2006 6/30/2009 SoleSupply
14011203 ATC3 3/1/1996 8/31/2010 Application
14011203 ATC3 9/1/2010 Application
14011203 Chemical 4/1/2004 Statim Must
14011204 Chemical 4/1/2004 Statim Must
14011204 ATC3 9/1/2010 Application
14011204 ATC3 3/1/1996 8/31/2010 Application
14011204 Formulation 3/1/1996 SpecialWav Claim only
14011301 Formulation 3/1/1996 SpecialWav Claim only
14011301 ATC3 3/1/1996 8/31/2010 Application
14011301 ATC3 9/1/2010 Application
14011301 Chemical 4/1/2004 Statim Must
14050101 Chemical 10/1/2003 Statim Must
14050101 Formulation 7/1/1996 FormMax 30 PSO
14050101 Brand 12/1/2002 6/30/2005 SoleSupply
14050201 Chemical 10/1/2003 Statim Must
14050301 Chemical 10/1/2003 Statim Must
14100101 Chemical 5/16/1994 FormReqd Rx
14110101 ATC3 3/1/1996 8/31/2010 Application
14110101 ATC3 9/1/2010 Application
14110201 ATC3 9/1/2010 Application
14110201 ATC3 3/1/1996 8/31/2010 Application
14110202 ATC3 3/1/1996 8/31/2010 Application
14110202 ATC3 9/1/2010 Application
14120101 Chemical 10/1/2003 Statim Must
14120101 Formulation 7/1/1996 FormMax 30 PSO
14120201 Formulation 7/1/1996 FormMax 30 PSO
14120201 Chemical 10/1/2003 Statim Must
14120301 Chemical 10/1/2003 Statim Must
14120301 Formulation 7/1/1996 Safety Uncompounded
14120401 Chemical 10/1/2003 Statim Must
14120401 Formulation 7/1/1996 2/28/2001 FormMax 5 PSO
14120501 Formulation 7/1/1996 2/28/2001 FormMax 5 PSO
14120501 Chemical 10/1/2003 Statim Must
14180101 Chemical 10/1/2003 Statim Must
14200101 Chemical 2/1/2014 Statim Must
14200102 Chemical 2/1/2014 Statim Must
14200201 Chemical 2/1/2014 Statim Must
14200202 Chemical 2/1/2014 Statim Must
14200301 Chemical 2/1/2014 Statim Must
14200401 Chemical 2/1/2014 Statim Must
14202525 Chemical 2/1/2014 Statim Must
14202525 Brand 7/1/2014 6/30/2016 SoleSupply
14230101 Chemical 5/16/1994 SubRxF
14240101 Chemical 10/1/2003 Statim Must
14240101 Formulation5/16/1994 7/31/1999 NotCombined
14240102 Formulation5/16/1994 7/31/1999 NotCombined
14240102 Chemical 10/1/2003 Statim Must
14240102 Brand 10/1/2008 ######## S29
14240102 Brand 12/1/2002 6/30/2005 SoleSupply
14240102 Brand 10/1/2005 6/30/2008 SoleSupply
14250101 Brand 5/1/2004 6/30/2006 SoleSupply
14250101 Chemical 11/1/1997 Statim May
14250101 Chemical 5/16/1994 SpecEnd Retail
14250103 Chemical 5/16/1994 SpecEnd Retail
14250103 Chemical 11/1/1997 Statim May
14250103 Brand 4/1/2000 6/30/2002 SoleSupply
14270101 Formulation 6/1/1997 ######## SpecialWav
14270101 Formulation 3/1/1999 8/31/1999 SpecialWav
14270101 Formulation11/1/2008 6/30/2009 SpecialWav
14270101 Formulation12/1/2011 OraProduct
14270101 Chemical 11/1/2001 4/30/2003 SpecialWav
14270101 Formulation 5/1/1995 5/31/1997 SpecialWav
14270101 Formulation 5/1/2003 ######## SpecialWav
14270101 Chemical 5/16/1994 ######## SpecEnd Retail
14270101 Chemical 9/1/1999 ######## SpecialWav
14270101 Formulation12/1/1998 2/28/1999 SpecialWav
14270101 Chemical 4/1/2004 Statim Must
14270301 Chemical 4/1/2004 Statim Must
14270301 Chemical 9/1/1999 ######## SpecialWav
14270301 Chemical 5/16/1994 ######## SpecEnd Retail
14270301 Chemical 11/1/2001 4/30/2003 SpecialWav
14270401 Chemical 11/1/2001 4/30/2003 SpecialWav
14270401 Formulation 5/1/2003 ######## Special
14270401 Formulation 5/1/1995 5/31/1997 SpecialWav
14270401 Formulation 6/1/1997 ######## SpecialWav
14270401 Formulation 3/1/1999 8/31/1999 SpecialWav
14270401 Brand 7/1/2003 6/30/2005 SoleSupply
14270401 Brand 11/1/2005 6/30/2008 SoleSupply
14270401 Brand 11/1/2008 6/30/2011 SoleSupply
14270401 Brand 11/1/2011 6/30/2014 SoleSupply
14270401 Chemical 5/16/1994 ######## SpecEnd Retail
14270401 Chemical 9/1/1999 ######## SpecialWav
14270401 Chemical 4/1/2004 Statim Must
14270401 Formulation12/1/1998 2/28/1999 SpecialWav
14270401 Formulation11/1/2008 6/30/2009 Special
14270501 Formulation12/1/1998 2/28/1999 SpecialWav
14270501 Chemical 4/1/2004 Statim Must
14270501 Chemical 9/1/1999 ######## SpecialWav
14270501 Chemical 5/16/1994 ######## SpecEnd Retail
14270501 Formulation 6/1/1997 ######## SpecialWav
14270501 Formulation 3/1/1999 8/31/1999 SpecialWav
14270501 Formulation 5/1/1995 5/31/1997 SpecialWav
14270501 Formulation 5/1/2003 Special
14270501 Chemical 11/1/2001 4/30/2003 SpecialWav
14280101 Chemical 10/1/2001 Statim May
14751001 ATC2 5/16/1994 ######## MaxCoPayment 3
14751001 ATC2 1/1/2013 MaxCoPayment 5
14751101 ATC2 1/1/2013 MaxCoPayment 5
14751101 Formulation 7/1/1996 FormMax 63 PSO
14751101 Brand 9/1/2007 6/30/2010 SoleSupply
14751101 ATC2 5/16/1994 ######## MaxCoPayment 3
14751101 ATC3 8/1/1995 ######## SpecialWav
14751101 ATC3 11/1/1999 AltSubSA
14751101 Formulation 7/1/1996 Contraceptive
14751101 Chemical 8/1/2004 Statim Must
14751201 Chemical 8/1/2004 Statim Must
14751201 Formulation 7/1/1996 FormMax 84 PSO
14751201 Formulation 7/1/1996 Contraceptive
14751201 ATC3 11/1/1999 AltSubSA
14751201 ATC3 8/1/1995 ######## SpecialWav
14751201 ATC2 5/16/1994 ######## MaxCoPayment 3
14751201 Brand 9/1/2007 6/30/2010 SoleSupply
14751201 ATC2 1/1/2013 MaxCoPayment 5
14760101 ATC2 1/1/2013 MaxCoPayment 5
14760101 Formulation 7/1/1996 4/30/1998 FormMax 63 PSO
14760101 ATC2 5/16/1994 ######## MaxCoPayment 3
14760101 ATC3 8/1/1995 ######## SpecialWav
14760101 ATC3 11/1/1999 AltSubSA
14760101 Formulation 7/1/1996 Contraceptive
14760201 Formulation 7/1/1996 Contraceptive
14760201 ATC3 11/1/1999 AltSubSA
14760201 ATC3 8/1/1995 ######## SpecialWav
14760201 ATC2 5/16/1994 ######## MaxCoPayment 3
14760201 Formulation 7/1/1996 4/30/1998 FormMax 63 PSO
14760201 ATC2 1/1/2013 MaxCoPayment 5
14770101 ATC2 1/1/2013 MaxCoPayment 5
14770101 Formulation 7/1/1996 FormMax 63 PSO
14770101 ATC2 5/16/1994 ######## MaxCoPayment 3
14770101 ATC3 8/1/1995 ######## SpecialWav
14770101 ATC3 11/1/1999 AltSubSA
14770101 Formulation 7/1/1996 Contraceptive
14770101 Chemical 8/1/2004 Statim Must
14770201 Chemical 8/1/2004 Statim Must
14770201 Formulation 7/1/1996 FormMax 84 PSO
14770201 ATC3 11/1/1999 AltSubSA
14770201 ATC3 8/1/1995 ######## SpecialWav
14770201 ATC2 5/16/1994 ######## MaxCoPayment 3
14770201 Formulation 7/1/1996 Contraceptive
14770201 ATC2 1/1/2013 MaxCoPayment 5
14770301 ATC2 1/1/2013 MaxCoPayment 5
14770301 Formulation 7/1/1996 FormMax 63 PSO
14770301 Formulation 7/1/1996 Contraceptive
14770301 ATC2 5/16/1994 ######## MaxCoPayment 3
14770301 ATC3 8/1/1995 ######## SpecialWav
14770301 ATC3 11/1/1999 AltSubSA
14770301 Chemical 8/1/2004 Statim Must
14770401 Chemical 8/1/2004 Statim Must
14770401 Formulation 7/1/1996 FormMax 84 PSO
14770401 ATC3 11/1/1999 AltSubSA
14770401 ATC3 8/1/1995 ######## SpecialWav
14770401 ATC2 5/16/1994 ######## MaxCoPayment 3
14770401 Formulation 7/1/1996 Contraceptive
14770401 ATC2 1/1/2013 MaxCoPayment 5
14780101 Brand 12/1/2006 6/30/2009 SoleSupply
14780101 Brand 10/1/2009 6/30/2012 SoleSupply
14780101 Brand 11/1/2012 6/30/2015 SoleSupply
14780101 Chemical 10/1/2003 Statim Must
14790101 Chemical 8/1/2004 Statim Must
14790101 Formulation 7/1/1996 FormMax 63 PSO
14790101 ATC2 1/1/2013 MaxCoPayment 5
14790101 Formulation 7/1/1996 Contraceptive
14790101 ATC2 5/16/1994 ######## MaxCoPayment 3
14790101 ATC3 8/1/1995 ######## SpecialWav
14790101 ATC3 11/1/1999 AltSubSA
14790102 ATC3 11/1/1999 AltSubSA
14790102 ATC3 8/1/1995 ######## SpecialWav
14790102 ATC2 5/16/1994 ######## MaxCoPayment 3
14790102 Formulation 7/1/1996 Contraceptive
14790102 ATC2 1/1/2013 MaxCoPayment 5
14790102 Formulation 7/1/1996 FormMax 63 PSO
14790102 Chemical 8/1/2004 Statim Must
14790201 Chemical 8/1/2004 Statim Must
14790201 Formulation 7/1/1996 FormMax 84 PSO
14790201 ATC2 1/1/2013 MaxCoPayment 5
14790201 Formulation 7/1/1996 Contraceptive
14790201 ATC2 5/16/1994 ######## MaxCoPayment 3
14790201 ATC3 8/1/1995 ######## SpecialWav
14790201 ATC3 11/1/1999 AltSubSA
14790202 ATC3 11/1/1999 AltSubSA
14790202 ATC3 8/1/1995 ######## SpecialWav
14790202 ATC2 5/16/1994 ######## MaxCoPayment 3
14790202 Formulation 7/1/1996 Contraceptive
15460825 Formulation12/1/1998 FormReqd Rx
15460825 Brand 11/1/2005 6/30/2007 SoleSupply
15460825 Brand 10/1/2007 6/30/2010 SoleSupply
15460825 Brand 10/1/2010 6/30/2013 SoleSupply
15460825 Formulation 6/1/2002 NotCombined
15460825 Formulation12/1/1998 FormMax 15 Rx
15460901 Formulation12/1/1998 FormMax 15 Rx
15460901 Formulation 6/1/2002 NotCombined
15460901 Formulation12/1/1998 FormReqd Rx
15460901 Formulation10/1/1997 ######## FormMax 15 Rx
15460925 Formulation10/1/1997 ######## FormMax 15 Rx
15460925 Brand 11/1/2005 6/30/2007 SoleSupply
15460925 Brand 10/1/2007 6/30/2010 SoleSupply
15460925 Brand 10/1/2010 6/30/2013 SoleSupply
15460925 Brand 10/1/2013 6/30/2016 SoleSupply
15460925 Formulation12/1/1998 FormReqd Rx
15460925 Formulation 6/1/2002 NotCombined
15460925 Formulation12/1/1998 FormMax 15 Rx
15461001 Formulation12/1/1998 FormMax 15 Rx
15461001 Formulation 6/1/2002 NotCombined
15461001 Formulation12/1/1998 FormReqd Rx
15461001 Formulation10/1/1997 ######## FormMax 15 Rx
15530101 Chemical 6/1/2012 Statim Must
15530101 ATC3 6/14/1995 9/30/1997 SpecEnd Retail
15530102 ATC3 6/14/1995 9/30/1997 SpecEnd Retail
15530102 Chemical 6/1/2012 Statim Must
15530103 Chemical 6/1/2012 Statim Must
15530103 ATC3 6/14/1995 9/30/1997 SpecEnd Retail
15530103 Brand 3/1/2000 6/30/2002 SoleSupply
15532525 Brand 3/1/2011 6/30/2013 SoleSupply
15532525 Brand 12/1/2013 6/30/2016 SoleSupply
15532525 ATC3 6/14/1995 9/30/1997 SpecEnd Retail
15532525 Chemical 6/1/2012 Statim Must
15540101 Formulation 1/1/1999 7/31/2010 Dispensary HP3
15540101 Formulation 7/1/2013 SubRxF
15540101 Formulation5/16/1994 ######## SubRxF
15540101 Formulation11/1/1999 6/30/2013 SubRxF
15540201 Formulation5/16/1994 ######## SubRxF
15540201 Formulation11/1/1999 6/30/2013 SubRxF
15540201 Formulation 7/1/2013 SubRxF
15540201 Formulation 1/1/1999 7/31/2010 Dispensary HP3
15540202 Formulation 1/1/1999 7/31/2010 Dispensary HP3
15540202 Formulation 7/1/2013 SubRxF
15540202 Formulation11/1/1999 6/30/2013 SubRxF
15540202 Formulation5/16/1994 ######## SubRxF
15540225 Formulation11/1/1999 6/30/2013 SubRxF
15540225 Formulation5/16/1994 ######## SubRxF
15540225 Brand 3/1/2013 S29
15540225 Brand 4/1/2013 Wastage
15540225 Formulation 7/1/2013 SubRxF
15540225 Formulation 1/1/1999 7/31/2010 Dispensary HP3
15540301 Formulation 1/1/1999 7/31/2010 Dispensary HP3
15540301 Formulation 7/1/2013 SubRxF
15540301 Brand 1/1/2003 6/30/2005 SoleSupply
15540301 Brand 9/1/2006 6/30/2009 SoleSupply
15540301 Brand 1/1/2010 6/30/2012 SoleSupply
15540301 Brand 10/1/2012 6/30/2015 SoleSupply
15540301 Formulation5/16/1994 ######## SubRxF
15540301 Formulation11/1/1999 6/30/2013 SubRxF
15540302 Formulation11/1/1999 6/30/2013 SubRxF
15540302 Formulation5/16/1994 ######## SubRxF
15540302 Formulation 7/1/2013 SubRxF
15540302 Formulation 1/1/1999 7/31/2010 Dispensary HP3
15540303 Formulation 1/1/1999 7/31/2010 Dispensary HP3
15540303 Formulation 7/1/2013 SubRxF
15540303 Formulation5/16/1994 ######## SubRxF
15540303 Formulation11/1/1999 6/30/2013 SubRxF
15540501 Brand 9/1/2003 6/30/2006 SoleSupply
15540501 Formulation5/16/1994 9/30/2007 SpecEnd Retail
15540701 Formulation 6/1/2002 FormReqd Rx
15540701 Formulation 6/1/2002 NotCombined
15540801 Formulation 6/1/2002 NotCombined
15540801 Formulation 6/1/2002 FormReqd Rx
15670101 Chemical 10/1/2003 Statim Must
15670102 Chemical 10/1/2003 Statim Must
15670104 Chemical 10/1/2003 Statim Must
15670104 Brand 11/1/1999 6/30/2002 SoleSupply
15670104 Brand 11/1/2002 6/30/2005 SoleSupply
15670201 Brand 11/1/1999 6/30/2002 SoleSupply
15670201 Brand 11/1/2002 6/30/2005 SoleSupply
15670201 Chemical 10/1/2003 Statim Must
15670202 Chemical 10/1/2003 Statim Must
15670204 Chemical 10/1/2003 Statim Must
15680101 Chemical 10/1/2003 Statim Must
15680125 Chemical 10/1/2003 Statim Must
15680125 Brand 5/1/2003 6/30/2005 SoleSupply
15680125 Brand 2/1/2006 6/30/2008 SoleSupply
15680125 Brand 10/1/2008 6/30/2011 SoleSupply
15680125 Brand 10/1/2011 6/30/2014 SoleSupply
15680126 Chemical 10/1/2003 Statim Must
15690101 Chemical 10/1/2003 Statim Must
15690102 Chemical 10/1/2003 Statim Must
15690102 Brand 4/1/2003 6/30/2005 SoleSupply
15690102 Brand 10/1/2005 6/30/2008 SoleSupply
15690102 Brand 10/1/2008 6/30/2011 SoleSupply
15690102 Brand 1/1/2013 6/30/2015 SoleSupply
15700101 Formulation 7/1/1996 FormMax 5 PSO
15700301 Formulation 7/1/1996 1/31/1997 FormMax 5 PSO
15700401 Formulation 3/1/1997 FormMax 5 PSO
15700402 Formulation 3/1/1997 FormMax 5 PSO
15720101 Formulation5/16/1994 FormBan BSO
15720102 Formulation5/16/1994 FormBan BSO
15720201 Formulation5/16/1994 FormBan BSO
15720202 Formulation5/16/1994 FormBan BSO
15720401 Formulation5/16/1994 FormBan BSO
15721001 Formulation5/16/1994 FormBan BSO
15740101 Formulation9/16/1994 FormReqd Rx
15740101 Chemical 10/1/2003 Statim Must
15740201 Chemical 10/1/2003 Statim Must
15740201 Formulation9/16/1994 FormReqd Rx
15740301 Formulation9/16/1994 FormReqd Rx
15740301 Chemical 10/1/2003 Statim Must
15740301 Brand 11/1/2004 6/30/2007 SoleSupply
15740301 Brand 2/1/2013 6/30/2015 SoleSupply
15740401 Chemical 10/1/2003 Statim Must
15740401 Formulation9/16/1994 FormReqd Rx
15740501 Formulation9/16/1994 FormReqd Rx
15740501 Chemical 10/1/2003 Statim Must
15740601 Chemical 10/1/2003 Statim Must
15740601 Formulation 7/1/2004 1/31/2007 Combined
15740601 Formulation 2/1/2007 Combined
15740601 Formulation 8/1/1999 6/30/2004 Combined
15740602 Formulation 8/1/1999 6/30/2004 Combined
15740602 Formulation 2/1/2007 Combined
15740602 Formulation 7/1/2004 1/31/2007 Combined
15740602 Chemical 10/1/2003 Statim Must
15740625 Chemical 10/1/2003 Statim Must
15740625 Formulation 7/1/2004 1/31/2007 Combined
15740625 Formulation 2/1/2007 Combined
15740625 Formulation 8/1/1999 6/30/2004 Combined
15740626 Formulation 8/1/1999 6/30/2004 Combined
15740626 Formulation 7/1/2004 1/31/2007 Combined
15740626 Formulation 2/1/2007 Combined
15740626 Chemical 10/1/2003 Statim Must
15740627 Chemical 10/1/2003 Statim Must
15740627 Formulation 2/1/2007 Combined
15740627 Formulation 7/1/2004 1/31/2007 Combined
15740627 Formulation 8/1/1999 6/30/2004 Combined
15740627 Brand 12/1/2010 6/30/2013 SoleSupply
15740701 Chemical 10/1/2003 Statim Must
15740701 Formulation9/16/1994 FormReqd Rx
15740801 Formulation9/16/1994 FormReqd Rx
15740801 Chemical 10/1/2003 Statim Must
15750101 Chemical 10/1/2003 Statim Must
15750101 Chemical 6/16/1995 2/28/2007 ProvReqd M
15750101 Chemical 3/1/2007 FormReqd Rx
15770102 Formulation 7/1/1996 9/30/1999 DoseMMax 30
15770102 Chemical 10/1/2003 Statim Must
15770102 Formulation 7/1/1996 9/30/2003 Statim May
15770103 Formulation 7/1/1996 9/30/2003 Statim May
15770103 Brand 2/1/2002 6/30/2004 SoleSupply
15770103 Brand 2/1/2005 6/30/2007 SoleSupply
15770103 Brand 8/1/2008 6/30/2011 SoleSupply
15770103 Brand 10/1/2011 6/30/2014 SoleSupply
15770103 Chemical 10/1/2003 Statim Must
15770103 Formulation 7/1/1996 9/30/1999 DoseMMax 30
15770104 Formulation 7/1/1996 9/30/1999 DoseMMax 30
15770104 Chemical 10/1/2003 Statim Must
15770104 Formulation 7/1/1996 9/30/2003 Statim May
15770105 Formulation 7/1/1996 9/30/2003 Statim May
15770105 Brand 8/1/1998 6/30/2001 SoleSupply
15770105 Chemical 10/1/2003 Statim Must
15770105 Formulation 7/1/1996 9/30/1999 DoseMMax 30
15770201 Formulation 7/1/1996 FormMax 100 PSO
15770201 Chemical 10/1/2003 Statim Must
15770201 Formulation 7/1/1996 9/30/2003 Statim May
15770225 Formulation 7/1/1996 9/30/2003 Statim May
15770225 Brand 3/1/2009 6/30/2011 SoleSupply
15770225 Brand 10/1/2011 6/30/2014 SoleSupply
15770225 Chemical 10/1/2003 Statim Must
15770225 Brand 8/1/2008 2/28/2009 S29
15770225 Formulation 7/1/1996 FormMax 100 PSO
15770301 Chemical 10/1/2003 Statim Must
15770301 Formulation 7/1/1996 9/30/2003 Statim May
15770401 Formulation 7/1/1996 6/30/1998 Statim May
15770401 Chemical 10/1/2003 Statim Must
15770502 Chemical 10/1/2003 Statim Must
15770502 Formulation 7/1/1996 9/30/2003 Statim May
15770502 Brand 2/1/2002 6/30/2004 SoleSupply
15770502 Brand 2/1/2005 6/30/2007 SoleSupply
15770502 Brand 8/1/2008 6/30/2011 SoleSupply
15770502 Brand 10/1/2011 6/30/2014 SoleSupply
15770503 Formulation 7/1/1996 9/30/2003 Statim May
15770503 Chemical 10/1/2003 Statim Must
15770504 Chemical 10/1/2003 Statim Must
15770504 Formulation 7/1/1996 9/30/2003 Statim May
15770505 Formulation 7/1/1996 9/30/2003 Statim May
15770505 Brand 8/1/1998 6/30/2001 SoleSupply
15770505 Chemical 10/1/2003 Statim Must
15770601 Chemical 10/1/2003 Statim Must
15770601 Formulation11/1/2003 FormMax 250 PSO
15770601 Brand 1/1/2005 6/30/2007 SoleSupply
15770601 Brand 11/1/2008 6/30/2011 SoleSupply
15770601 Formulation 7/1/1997 9/30/2003 Statim May
15772525 Formulation 6/1/2002 9/30/2003 Statim May
15772525 Brand 6/1/2012 6/30/2014 SoleSupply
15772525 Formulation11/1/2003 ######## FormMax 200 PSO
15772525 Formulation 1/1/2012 FormMax 250 PSO
15772525 Chemical 10/1/2003 Statim Must
15772625 Chemical 10/1/2003 Statim Must
15772625 Chemical 4/1/2013 Special
15800101 Chemical 10/1/2003 Statim Must
15800301 Chemical 10/1/2003 Statim Must
15800401 Chemical 10/1/2003 Statim Must
15800501 Chemical 10/1/2003 Statim Must
15800502 Chemical 10/1/2003 Statim Must
15800601 Chemical 10/1/2003 Statim Must
15800701 Chemical 10/1/2003 Statim Must
15800702 Chemical 10/1/2003 Statim Must
15800801 Chemical 10/1/2003 Statim Must
15800901 Chemical 10/1/2003 Statim Must
15801101 Chemical 10/1/2003 Statim Must
15801201 Chemical 10/1/2003 Statim Must
15801202 Chemical 10/1/2003 Statim Must
15801301 Chemical 10/1/2003 Statim Must
15801302 Chemical 10/1/2003 Statim Must
15801401 Chemical 10/1/2003 Statim Must
15801501 Chemical 10/1/2003 Statim Must
15801501 Formulation 7/1/1996 Safety Uncompounded
15830101 Brand 10/1/2003 6/30/2006 SoleSupply
15830101 Brand 10/1/2007 6/30/2010 SoleSupply
15830101 Brand 12/1/2010 6/30/2013 SoleSupply
15830101 Brand 11/1/2013 6/30/2016 SoleSupply
15830101 Chemical 8/1/2012 SafetyListMedicine
15830101 Formulation 7/1/1996 FormMax 30 PSO
15830201 Formulation 7/1/1996 FormMax 30 PSO
15830201 Chemical 8/1/2012 SafetyListMedicine
15830201 Brand 10/1/2003 6/30/2006 SoleSupply
15830201 Brand 10/1/2007 6/30/2010 SoleSupply
15830201 Brand 12/1/2010 6/30/2013 SoleSupply
15830201 Brand 11/1/2013 6/30/2016 SoleSupply
15830301 Brand 10/1/2003 6/30/2006 SoleSupply
15830301 Brand 10/1/2007 6/30/2010 SoleSupply
15830301 Brand 12/1/2010 6/30/2013 SoleSupply
15830301 Brand 11/1/2013 6/30/2016 SoleSupply
15830301 Chemical 8/1/2012 SafetyListMedicine
15830301 Formulation 7/1/1996 FormMax 30 PSO
15830401 Chemical 8/1/2012 SafetyListMedicine
15830401 Formulation 2/1/2001 FormMax 200 PSO
15830401 Brand 10/1/2003 6/30/2006 SoleSupply
15830401 Brand 10/1/2007 6/30/2010 SoleSupply
15830401 Brand 12/1/2010 6/30/2013 SoleSupply
15830401 Brand 11/1/2013 6/30/2016 SoleSupply
15830601 Brand 10/1/2003 6/30/2006 SoleSupply
15830601 Brand 1/1/2007 6/30/2009 SoleSupply
15830601 Brand 12/1/2010 6/30/2013 SoleSupply
15830601 Brand 11/1/2013 6/30/2016 SoleSupply
15830601 Chemical 8/1/2012 SafetyListMedicine
15830601 Formulation 2/1/2001 FormMax 5 PSO
15890601 Formulation 1/1/1999 ######## Dispensary HP3
15890601 Formulation6/27/1995 ######## SpecEnd Hospital
15890602 Formulation6/27/1995 ######## SpecEnd Hospital
15890602 Formulation 1/1/1999 ######## Dispensary HP3
15890603 Formulation 1/1/1999 ######## Dispensary HP3
15890603 Formulation6/27/1995 ######## SpecEnd Hospital
15890701 Formulation6/27/1995 SpecEnd Hospital
15890701 Formulation 1/1/1999 Dispensary HP3
15890702 Formulation 1/1/1999 Dispensary HP3
15890702 Formulation6/27/1995 SpecEnd Hospital
15940101 Chemical 10/1/2003 Statim Must
15980201 Formulation######## SpecialWav
15980301 Formulation######## SpecialWav
16000101 Chemical 10/1/2003 Statim Must
16000201 Chemical 10/1/2003 Statim Must
16040101 Chemical 10/1/2003 Statim Must
16040101 Formulation 4/1/2013 Special
16040102 Formulation 4/1/2013 Special
16040102 Chemical 10/1/2003 Statim Must
16040125 Chemical 10/1/2003 Statim Must
16040125 Formulation 4/1/2013 Special
16040126 Formulation 4/1/2013 Special
16040126 Chemical 10/1/2003 Statim Must
16040126 Brand 5/1/2013 S29
16040126 Brand 8/1/2013 Wastage
16040201 Chemical 10/1/2003 Statim Must
16040301 Chemical 10/1/2003 Statim Must
16040301 Brand 10/1/2013 ######## Wastage
16060201 Brand 1/1/2007 6/30/2009 SoleSupply
16060201 Brand 1/1/2010 6/30/2012 SoleSupply
16060201 Brand 2/1/2013 6/30/2015 SoleSupply
16110101 Brand 11/1/2001 6/30/2004 SoleSupply
16110101 Brand 5/1/2005 6/30/2007 SoleSupply
16110101 Brand 10/1/2010 6/30/2013 SoleSupply
16110101 Chemical 10/1/2003 Statim Must
16110101 Chemical 6/16/1995 FormReqd Rx
16110102 Chemical 6/16/1995 FormReqd Rx
16110102 Chemical 10/1/2003 Statim Must
16120201 Chemical 6/16/1995 FormReqd Rx
16120301 Chemical 6/16/1995 FormReqd Rx
16130101 Chemical 6/16/1995 2/28/2007 ProvReqd M
16130101 Formulation 3/1/2007 FormReqd Rx
16130101 Brand 1/1/2001 6/30/2003 SoleSupply
16130101 Brand 1/1/2006 6/30/2008 SoleSupply
16130101 Brand 10/1/2008 6/30/2011 SoleSupply
16130101 Brand 10/1/2011 6/30/2014 SoleSupply
16130102 Formulation 3/1/2007 FormReqd Rx
16130102 Chemical 6/16/1995 2/28/2007 ProvReqd M
16140101 Brand 4/1/2013 6/30/2015 SoleSupply
16140601 Brand 12/1/2007 6/30/2010 SoleSupply
16140601 Brand 4/1/2013 6/30/2015 SoleSupply
16140701 Brand 4/1/2013 6/30/2015 SoleSupply
16142525 Brand 4/1/2013 6/30/2015 SoleSupply
16150201 Chemical 6/16/1995 FormReqd Rx
16170101 Chemical 10/1/2003 Statim Must
17950425 Chemical 6/22/1995 Controlled
17950425 Brand 7/1/2004 6/30/2006 SoleSupply
17950425 Brand 10/1/2006 6/30/2009 SoleSupply
17950425 Chemical 8/1/2012 SafetyListMedicine
17950425 Formulation######## Safety Compounded
17950501 Chemical 8/1/2012 SafetyListMedicine
17950501 Formulation 7/1/1996 Safety Uncompounded
17950501 Brand 8/1/2009 6/30/2012 SoleSupply
17950501 Brand 10/1/2012 6/30/2015 SoleSupply
17950501 Chemical 6/22/1995 Controlled
17950501 Chemical 5/16/1994 MaxCoPayment 0
17950502 Chemical 5/16/1994 MaxCoPayment 0
17950502 Chemical 6/22/1995 Controlled
17950502 Formulation 7/1/1996 Safety Uncompounded
17950502 Chemical 8/1/2012 SafetyListMedicine
17950525 Chemical 8/1/2012 SafetyListMedicine
17950525 Formulation 7/1/1996 Safety Uncompounded
17950525 Chemical 6/22/1995 Controlled
17950525 Chemical 5/16/1994 MaxCoPayment 0
17950601 Chemical 5/16/1994 MaxCoPayment 0
17950601 Chemical 6/22/1995 Controlled
17950601 Formulation10/1/1996 Safety Uncompounded
17950601 Chemical 8/1/2012 SafetyListMedicine
17950602 Chemical 8/1/2012 SafetyListMedicine
17950602 Formulation10/1/1996 Safety Uncompounded
17950602 Brand 8/1/2009 6/30/2012 SoleSupply
17950602 Brand 10/1/2012 6/30/2015 SoleSupply
17950602 Chemical 6/22/1995 Controlled
17950602 Chemical 5/16/1994 MaxCoPayment 0
17950625 Chemical 5/16/1994 MaxCoPayment 0
17950625 Chemical 6/22/1995 Controlled
17950625 Formulation10/1/1996 Safety Uncompounded
17950625 Chemical 8/1/2012 SafetyListMedicine
17950701 Chemical 8/1/2012 SafetyListMedicine
17950701 Brand 8/1/2009 6/30/2012 SoleSupply
17950701 Brand 10/1/2012 6/30/2015 SoleSupply
17950701 Formulation 6/1/1997 Safety Uncompounded
17950701 Chemical 6/22/1995 Controlled
17950701 Chemical 5/16/1994 MaxCoPayment 0
17950725 Chemical 5/16/1994 MaxCoPayment 0
17950725 Chemical 6/22/1995 Controlled
17950725 Formulation 6/1/1997 Safety Uncompounded
17950725 Chemical 8/1/2012 SafetyListMedicine
17970101 Chemical 10/1/2003 Statim Must
17970101 Formulation 1/1/1999 7/31/2010 Dispensary HP3
17970101 Formulation 8/1/2010 SpecEnd Retail
17970101 Formulation5/16/1994 7/31/2010 SpecEnd Hospital
17970101 Chemical 7/1/2005 ######## PCT
17970101 Formulation12/1/2005 PCT
17970102 Formulation12/1/2005 PCT
17970102 Chemical 7/1/2005 ######## PCT
17970102 Formulation5/16/1994 7/31/2010 SpecEnd Hospital
17970102 Formulation 8/1/2010 SpecEnd Retail
17970102 Formulation 1/1/1999 7/31/2010 Dispensary HP3
17970102 Chemical 10/1/2003 Statim Must
17970103 Chemical 10/1/2003 Statim Must
17970103 Formulation 1/1/1999 7/31/2010 Dispensary HP3
17970103 Formulation 8/1/2010 SpecEnd Retail
17970103 Formulation5/16/1994 7/31/2010 SpecEnd Hospital
17970103 Chemical 7/1/2005 ######## PCT
17970103 Formulation12/1/2005 PCT
17970103 Brand 12/1/2002 6/30/2005 SoleSupply
17970103 Brand 10/1/2006 6/30/2009 SoleSupply
17970103 Brand 10/1/2009 6/30/2012 SoleSupply
17970125 Formulation12/1/2005 PCT
17970125 Chemical 7/1/2005 ######## PCT
17970125 Formulation 8/1/2010 SpecEnd Retail
17970125 Formulation5/16/1994 7/31/2010 SpecEnd Hospital
17970125 Formulation 1/1/1999 7/31/2010 Dispensary HP3
17970125 Chemical 10/1/2003 Statim Must
17970201 Chemical 10/1/2003 Statim Must
17970201 Formulation 1/1/1999 7/31/2010 Dispensary HP3
17970201 Formulation 8/1/2010 SpecEnd Retail
17970201 Formulation5/16/1994 7/31/2010 SpecEnd Hospital
17970201 Chemical 7/1/2005 ######## PCT
17970201 Formulation12/1/2005 PCT
17970201 Brand 12/1/2002 6/30/2005 SoleSupply
17970201 Brand 10/1/2006 6/30/2009 SoleSupply
17970201 Brand 10/1/2009 6/30/2012 SoleSupply
17970225 Formulation12/1/2005 PCT
17970225 Chemical 7/1/2005 ######## PCT
17970225 Formulation5/16/1994 7/31/2010 SpecEnd Hospital
17970225 Formulation 8/1/2010 SpecEnd Retail
17970225 Formulation 1/1/1999 7/31/2010 Dispensary HP3
17970225 Chemical 10/1/2003 Statim Must
17970401 Chemical 10/1/2003 Statim Must
17970401 Formulation5/16/1994 7/31/2010 SpecEnd Hospital
17970401 Formulation 1/1/1999 7/31/2010 Dispensary HP1
17970401 Formulation 8/1/2010 SpecEnd Retail
17970401 Chemical 7/1/2005 ######## PCT
17970401 Formulation12/1/2005 PCT
17970401 Brand 12/1/2001 6/30/2004 SoleSupply
17970501 Brand 12/1/2001 6/30/2004 SoleSupply
17970501 Formulation12/1/2005 PCT
17970501 Chemical 7/1/2005 ######## PCT
17970501 Formulation5/16/1994 SpecEnd Hospital
17970501 Formulation 1/1/1999 Dispensary HP1
17970501 Chemical 10/1/2003 Statim Must
17970701 Chemical 10/1/2003 Statim Must
17970701 Formulation5/16/1994 7/31/2010 SpecEnd Hospital
17970701 Formulation 1/1/1999 7/31/2010 Dispensary HP1
17970701 Formulation 8/1/2010 SpecEnd Retail
17970701 Chemical 7/1/2005 ######## PCT
17970701 Formulation12/1/2005 PCT
17970701 Brand 12/1/2001 6/30/2004 SoleSupply
17970701 Brand 12/1/2010 6/30/2013 SoleSupply
17970701 Brand 10/1/2013 6/30/2016 SoleSupply
17970703 Formulation12/1/2005 PCT
17970703 Chemical 7/1/2005 ######## PCT
17970703 Formulation 8/1/2010 SpecEnd Retail
17970703 Formulation 1/1/1999 7/31/2010 Dispensary HP1
17970703 Formulation5/16/1994 7/31/2010 SpecEnd Hospital
17970703 Chemical 10/1/2003 Statim Must
17970901 Chemical 10/1/2003 Statim Must
17970901 Formulation5/16/1994 SpecEnd Hospital
17970901 Formulation 1/1/1999 Dispensary HP1
17970901 Chemical 7/1/2005 ######## PCT
17970901 Formulation12/1/2005 PCT
17970901 Brand 12/1/2001 6/30/2004 SoleSupply
17971001 Brand 12/1/2010 6/30/2013 SoleSupply
17971001 Brand 10/1/2013 6/30/2016 SoleSupply
17971001 Formulation12/1/2005 PCT
17971001 Chemical 7/1/2005 ######## PCT
18760125 Brand 1/1/2009 6/30/2011 SoleSupply
18760125 Brand 7/1/2013 6/30/2016 SoleSupply
18760201 Chemical 8/1/2012 SafetyListMedicine
18760202 Chemical 8/1/2012 SafetyListMedicine
18760202 Brand 12/1/2002 6/30/2005 SoleSupply
18760202 Brand 1/1/2006 6/30/2008 SoleSupply
18760202 Brand 1/1/2009 6/30/2011 SoleSupply
18760202 Brand 7/1/2013 6/30/2016 SoleSupply
18760301 Formulation 7/1/1996 Safety Uncompounded
18760301 Chemical 8/1/2012 SafetyListMedicine
18810201 Formulation 6/1/2002 FormReqd Rx
18810201 Formulation 6/1/2002 NotCombined
18810301 Formulation 6/1/2002 NotCombined
18810301 Formulation 6/1/2002 FormReqd Rx
18810501 Brand 12/1/2002 6/30/2005 SoleSupply
18810502 Brand 12/1/2005 6/30/2008 SoleSupply
18810502 Brand 1/1/2009 6/30/2011 SoleSupply
18810502 Brand 10/1/2011 6/30/2014 SoleSupply
18810601 Formulation5/16/1994 9/30/1999 DoseMMax 1
18810901 Brand 12/1/2006 6/30/2009 SoleSupply
18811301 Formulation 6/1/2002 NotCombined
18811301 Formulation 6/1/2002 FormReqd Rx
18811302 Formulation 6/1/2002 FormReqd Rx
18811302 Formulation 6/1/2002 NotCombined
18811401 Formulation 6/1/2002 NotCombined
18811401 Formulation 6/1/2002 FormReqd Rx
18811402 Formulation 6/1/2002 FormReqd Rx
18811402 Formulation 6/1/2002 NotCombined
18812501 Formulation5/16/1994 9/30/1999 FormMax 42 Rx
18812502 Formulation5/16/1994 9/30/1999 FormMax 42 Rx
18812502 Brand 11/1/2004 6/30/2007 SoleSupply
18812502 Brand 10/1/2007 6/30/2010 SoleSupply
18812502 Brand 12/1/2010 6/30/2013 SoleSupply
18812502 Brand 1/1/2007 3/31/2010 S29
18812601 Formulation5/16/1994 9/30/1999 FormMax 42 Rx
18812601 Brand 9/1/2004 6/30/2007 SoleSupply
18812601 Brand 10/1/2007 6/30/2010 SoleSupply
18812601 Brand 12/1/2010 6/30/2013 SoleSupply
18860101 Chemical 10/1/2003 Statim Must
18860201 Chemical 10/1/2003 Statim Must
18860501 Chemical 10/1/2003 Statim Must
18860501 Formulation12/1/1996 ######## SpecialWav
18860501 Formulation 3/1/1995 FormReqd Rx
18860501 Formulation 3/1/1995 ######## SpecialWav
18860501 Formulation6/17/1995 ######## SpecEnd Retail
18860501 ATC2 12/1/1996 6/30/2010 Application
18860501 Formulation 3/1/1995 DoseWMax 2
18860501 ATC2 7/1/2010 Application
18860501 Formulation 3/1/1995 AltSubSA Claim only
18860525 ATC2 7/1/2010 Application
18860525 Formulation 3/1/1995 AltSubSA Claim only
18860525 Formulation 3/1/1995 DoseWMax 2
18860525 ATC2 12/1/1996 6/30/2010 Application
18860525 Formulation6/17/1995 ######## SpecEnd Retail
18860525 Formulation 3/1/1995 ######## SpecialWav
18860525 Formulation 3/1/1995 FormReqd Rx
18860525 Formulation12/1/1996 ######## SpecialWav
18860525 Chemical 10/1/2003 Statim Must
18860601 Chemical 10/1/2003 Statim Must
18860601 Formulation12/1/1996 FormReqd Rx
18860601 Formulation12/1/1996 DoseWMax 2
18860601 Formulation6/17/1995 ######## SpecEnd Retail
18860601 ATC2 12/1/1996 6/30/2010 Application
18860601 Formulation12/1/1996 AltSubSA Claim only
18860601 ATC2 7/1/2010 Application
18860625 Formulation12/1/1996 AltSubSA Claim only
18860625 ATC2 7/1/2010 Application
18860625 ATC2 12/1/1996 6/30/2010 Application
18860625 Formulation12/1/1996 DoseWMax 2
18860625 Formulation6/17/1995 ######## SpecEnd Retail
18860625 Formulation12/1/1996 FormReqd Rx
18860625 Chemical 10/1/2003 Statim Must
18860701 Chemical 10/1/2003 Statim Must
18860701 Formulation6/17/1995 ######## SpecEnd Retail
18860701 ATC2 12/1/1996 6/30/2010 Application
18860701 Formulation12/1/1996 DoseWMax 2
18860701 ATC2 7/1/2010 Application
18860701 Formulation12/1/1996 FormReqd Rx
18860701 Formulation12/1/1996 AltSubSA Claim only
18860725 Formulation12/1/1996 AltSubSA Claim only
18860725 Formulation12/1/1996 FormReqd Rx
18860725 Formulation12/1/1996 DoseWMax 2
18860725 ATC2 7/1/2010 Application
18860725 ATC2 12/1/1996 6/30/2010 Application
18860725 Formulation6/17/1995 ######## SpecEnd Retail
18860725 Chemical 10/1/2003 Statim Must
18860801 Chemical 10/1/2003 Statim Must
18860801 Formulation 3/1/1995 AltSubSA Claim only
18860801 Formulation 3/1/1995 ######## SpecEnd Retail
18860801 Formulation 3/1/1995 DoseWMax 1
18860801 ATC2 12/1/1996 6/30/2010 Application
18860801 Formulation 3/1/1995 FormReqd Rx
18860801 ATC2 7/1/2010 Application
18860802 ATC2 7/1/2010 Application
18860802 Formulation 3/1/1995 FormReqd Rx
18860802 ATC2 12/1/1996 6/30/2010 Application
18860802 Formulation 3/1/1995 DoseWMax 1
18860802 Formulation 3/1/1995 ######## SpecEnd Retail
18860802 Formulation 3/1/1995 AltSubSA Claim only
18860802 Chemical 10/1/2003 Statim Must
18860803 Chemical 10/1/2003 Statim Must
18860803 Formulation 3/1/1995 AltSubSA Claim only
18860803 Formulation 3/1/1995 ######## SpecEnd Retail
18860803 Formulation 3/1/1995 DoseWMax 1
18860803 ATC2 12/1/1996 6/30/2010 Application
18860803 Formulation 3/1/1995 FormReqd Rx
18860803 ATC2 7/1/2010 Application
18860901 ATC2 7/1/2010 Application
18860901 Formulation 3/1/1995 AltSubSA Claim only
18860901 ATC2 12/1/1996 6/30/2010 Application
18860901 Formulation 3/1/1995 ######## SpecEnd Retail
18860901 Formulation 3/1/1995 DoseWMax 1
18860901 Formulation 3/1/1995 FormReqd Rx
18860901 Chemical 10/1/2003 Statim Must
18860902 Chemical 10/1/2003 Statim Must
18860902 Formulation 3/1/1995 FormReqd Rx
18860902 Formulation 3/1/1995 DoseWMax 1
18860902 Formulation 3/1/1995 ######## SpecEnd Retail
18860902 ATC2 12/1/1996 6/30/2010 Application
18860902 Formulation 3/1/1995 AltSubSA Claim only
18860902 ATC2 7/1/2010 Application
18860903 ATC2 7/1/2010 Application
18860903 Formulation 3/1/1995 AltSubSA Claim only
20880201 Chemical 5/16/1994 MaxCoPayment 0
20880301 Chemical 5/16/1994 MaxCoPayment 0
20880301 Chemical 4/1/2013 SubRxF SpecEnd
20880301 Chemical 5/16/1994 3/31/2013 SpecEnd Retail
20880301 Chemical 10/1/2003 Statim Must
20880401 Chemical 10/1/2003 Statim Must
20880401 Chemical 5/16/1994 3/31/2013 SpecEnd Retail
20880401 Chemical 4/1/2013 SubRxF SpecEnd
20880401 Chemical 5/16/1994 MaxCoPayment 0
20880501 Chemical 5/16/1994 MaxCoPayment 0
20880501 Chemical 4/1/2013 SubRxF SpecEnd
20880501 Chemical 5/16/1994 3/31/2013 SpecEnd Retail
20880501 Chemical 10/1/2003 Statim Must
20960301 Formulation 7/1/1996 Safety Uncompounded
20960301 Brand 4/1/2014 6/30/2016 SoleSupply
20960325 Brand 9/1/2005 6/30/2007 SoleSupply
20960325 Brand 10/1/2007 6/30/2010 SoleSupply
20960325 Brand 10/1/2010 3/31/2012 SoleSupply
20960325 Formulation 7/1/1996 Safety Uncompounded
20960326 Formulation 7/1/1996 Safety Uncompounded
20960326 Brand 8/1/2012 S29
20960326 Brand 4/1/2013 Wastage
20960401 Formulation 7/1/1996 FormMax 5 PSO
20960601 Formulation5/16/1994 FormMax 1000 PSO
20960602 Formulation5/16/1994 FormMax 1000 PSO
20960603 Formulation5/16/1994 FormMax 1000 PSO
20960604 Formulation5/16/1994 FormMax 1000 PSO
20960901 Brand 7/1/1996 FormMax 500 PSO
20960902 Brand 7/1/1996 FormMax 1000 PSO
20961101 Formulation5/16/1994 FormMax 2000 PSO
20961401 Formulation10/1/1999 FormMax 30 PSO
20961401 Formulation 7/1/1996 9/30/1999 FormMax 20 PSO
20961402 Formulation 7/1/1996 9/30/1999 FormMax 20 PSO
20961402 Brand 11/1/2001 6/30/2004 SoleSupply
20961402 Formulation10/1/1999 FormMax 30 PSO
20961403 Formulation10/1/1999 FormMax 30 PSO
20961403 Formulation 7/1/1996 9/30/1999 FormMax 20 PSO
20961425 Formulation 7/1/1996 9/30/1999 FormMax 20 PSO
20961425 Formulation10/1/1999 FormMax 30 PSO
20961426 Formulation10/1/1999 FormMax 30 PSO
20961426 Brand 10/1/2007 6/30/2009 SoleSupply
20961426 Brand 10/1/2009 6/30/2012 SoleSupply
20961426 Brand 12/1/2012 6/30/2015 SoleSupply
20961426 Formulation 7/1/1996 9/30/1999 FormMax 20 PSO
20961501 Formulation 7/1/1996 9/30/1999 FormMax 20 PSO
20961501 Formulation10/1/1999 FormMax 30 PSO
20961502 Formulation10/1/1999 FormMax 30 PSO
20961502 Formulation 7/1/1996 9/30/1999 FormMax 20 PSO
20961502 Brand 11/1/2001 6/30/2004 SoleSupply
20961503 Formulation 7/1/1996 9/30/1999 FormMax 20 PSO
20961503 Formulation10/1/1999 FormMax 30 PSO
20961525 Formulation10/1/1999 FormMax 30 PSO
20961525 Formulation 7/1/1996 9/30/1999 FormMax 20 PSO
20961526 Formulation 7/1/1996 9/30/1999 FormMax 20 PSO
20961526 Brand 10/1/2007 6/30/2009 SoleSupply
20961526 Brand 10/1/2009 6/30/2012 SoleSupply
20961526 Brand 12/1/2012 6/30/2015 SoleSupply
20961526 Formulation10/1/1999 FormMax 30 PSO
20961601 Formulation 7/1/1996 FormMax 1000 PSO
20961625 Formulation 7/1/1996 FormMax 1000 PSO
20961626 Formulation 7/1/1996 FormMax 1000 PSO
20961627 Formulation 7/1/1996 FormMax 1000 PSO
20961701 Formulation11/1/1998 FormMax 1000 PSO
21140101 Formulation5/16/1994 8/31/2004 FormReqd PSO
21140101 Formulation 7/1/1996 FormMax 500 PSO
21140101 Brand 11/1/2004 6/30/2007 SoleSupply
21140101 Formulation 6/1/2002 NotCombined
21142525 Formulation 1/1/2010 NotCombined
21142525 Formulation 1/1/2010 FormMax 250 PSO
21250101 Chemical 10/1/2003 Statim Must
21252525 Chemical 10/1/2003 Statim Must
21252625 Chemical 10/1/2003 Statim Must
21260101 Chemical 5/16/1994 2/28/2009 SpecEnd Retail
21260201 Chemical 5/16/1994 2/28/2009 SpecEnd Retail
21260301 Chemical 5/16/1994 2/28/2009 SpecEnd Retail
21280101 Formulation10/1/2004 NotCombined
21280102 Formulation10/1/2004 NotCombined
21280125 Formulation10/1/2004 NotCombined
21280125 Brand 4/1/2006 S29
21280125 Brand 4/1/2013 Wastage
21280201 Formulation 1/1/2007 FormMax 5 PSO
21280201 Formulation10/1/2004 NotCombined
21280225 Formulation10/1/2004 NotCombined
21280225 Formulation 1/1/2007 FormMax 5 PSO
21282525 Formulation 2/1/2012 Combined
21282525 Formulation10/1/2004 1/31/2012 Combined
21282526 Formulation 2/1/2012 Combined
21282526 Formulation10/1/2004 1/31/2012 Combined
21282527 Formulation10/1/2004 1/31/2012 Combined
21282527 Formulation 2/1/2012 Combined
21282528 Formulation 2/1/2012 Combined
21282528 Formulation10/1/2004 1/31/2012 Combined
21282625 Formulation 1/1/2007 FormMax 5 PSO
21282625 Formulation 1/1/2007 NotCombined
21320101 Chemical 10/1/2003 Statim Must
21350301 Formulation 2/1/2001 FormMax 5 PSO
21350301 Brand 12/1/2006 6/30/2009 SoleSupply
21350302 Brand 12/1/2001 6/30/2004 SoleSupply
21350302 Formulation 2/1/2001 FormMax 5 PSO
21350325 Formulation 2/1/2001 FormMax 5 PSO
21350401 Formulation 2/1/2001 FormMax 5 PSO
21350401 Brand 12/1/2001 6/30/2004 SoleSupply
21350402 Brand 12/1/2006 6/30/2009 SoleSupply
21350402 Formulation 2/1/2001 FormMax 5 PSO
21350425 Formulation 2/1/2001 FormMax 5 PSO
21350501 Formulation10/1/2010 ######## FormMax 5 PSO
21350501 Brand 12/1/2001 6/30/2004 SoleSupply
21350502 Formulation10/1/2010 ######## FormMax 5 PSO
21350503 Formulation10/1/2010 ######## FormMax 5 PSO
21350525 Formulation10/1/2010 ######## FormMax 5 PSO
21350901 Formulation 2/1/2001 FormMax 2000 PSO
21350901 Formulation10/3/1997 2/28/2001 SubRxF
21352525 Formulation 8/1/2012 ProvAllow Dietitian
21352525 Brand 12/1/2010 6/30/2013 SoleSupply
21352525 Brand 10/1/2013 6/30/2016 SoleSupply
21400101 Brand 11/1/1999 6/30/2002 SoleSupply
21400101 Brand 10/1/2003 6/30/2006 SoleSupply
21400101 Chemical 5/16/1994 FormReqd Rx
21400102 Chemical 5/16/1994 FormReqd Rx
21400125 Chemical 5/16/1994 FormReqd Rx
21400125 Brand 1/1/2011 6/30/2013 SoleSupply
21400125 Brand 10/1/2013 6/30/2016 SoleSupply
21420101 Chemical 10/1/2003 Statim Must
11930127 Chemical 2/1/2001 ######## AltSubRxF
11930127 Chemical 5/1/2000 6/30/2000 AltSubRxF
11930127 Chemical 10/1/2003 Statim Must
11930127 Chemical 2/1/2004 ######## AltSubRxF
11930127 Chemical 12/1/2003 1/31/2004 AltSubRxF
11940101 Chemical 4/1/2004 Statim Must
11940201 Chemical 4/1/2004 Statim Must
11940301 Chemical 4/1/2004 Statim Must
11950101 Chemical 10/1/2003 Statim Must
11950101 Chemical 6/1/1995 ######## SpecEnd Retail
11950125 Chemical 6/1/1995 ######## SpecEnd Retail
11950125 Chemical 10/1/2003 Statim Must
11950125 Brand 11/1/2001 6/30/2003 SoleSupply
11950125 Brand 10/1/2003 6/30/2006 SoleSupply
11950125 Brand 7/1/2014 6/30/2017 SoleSupply
11950201 Chemical 10/1/2003 Statim Must
11950201 Chemical 6/1/1995 ######## SpecEnd Retail
11970101 Chemical 10/1/2003 Statim Must
11980101 Formulation 1/1/1999 7/31/2010 Dispensary HP3
11980101 Formulation5/16/1994 7/31/2010 SpecEnd Hospital
11980101 Formulation 8/1/2010 SpecEnd Retail
11980101 Chemical 7/1/2005 9/30/2005 PCT
11980101 Formulation10/1/2005 PCT
11980102 Formulation10/1/2005 PCT
11980102 Chemical 7/1/2005 9/30/2005 PCT
11980102 Brand 12/1/2011 6/30/2014 SoleSupply
11980102 Formulation 8/1/2010 SpecEnd Retail
11980102 Formulation5/16/1994 7/31/2010 SpecEnd Hospital
11980102 Formulation 1/1/1999 7/31/2010 Dispensary HP3
11980103 Formulation 1/1/1999 7/31/2010 Dispensary HP3
11980103 Formulation5/16/1994 7/31/2010 SpecEnd Hospital
11980103 Formulation 8/1/2010 SpecEnd Retail
11980103 Chemical 7/1/2005 9/30/2005 PCT
11980103 Formulation10/1/2005 PCT
11980104 Formulation10/1/2005 PCT
11980104 Chemical 7/1/2005 9/30/2005 PCT
11980104 Formulation 8/1/2010 SpecEnd Retail
11980104 Formulation5/16/1994 7/31/2010 SpecEnd Hospital
11980104 Formulation 1/1/1999 7/31/2010 Dispensary HP3
11980201 Formulation5/16/1994 7/31/2010 SpecEnd Hospital
11980201 Formulation 1/1/1999 7/31/2010 Dispensary HP1
11980201 Formulation 8/1/2010 SpecEnd Retail
11980201 Chemical 7/1/2005 9/30/2005 PCT
11980201 Formulation10/1/2005 PCT
11980301 Formulation10/1/2005 PCT
11980301 Chemical 7/1/2005 9/30/2005 PCT
11980301 Formulation5/16/1994 SpecEnd Hospital
11980301 Formulation 1/1/1999 Dispensary HP1
11980401 Formulation5/16/1994 7/31/2010 SpecEnd Hospital
11980401 Formulation 1/1/1999 7/31/2010 Dispensary HP1
11980401 Formulation 8/1/2010 SpecEnd Retail
11980401 Chemical 7/1/2005 9/30/2005 PCT
11980401 Formulation10/1/2005 PCT
11980402 Formulation10/1/2005 PCT
11980402 Chemical 7/1/2005 9/30/2005 PCT
11980402 Formulation 8/1/2010 SpecEnd Retail
11980402 Formulation 1/1/1999 7/31/2010 Dispensary HP1
11980402 Formulation5/16/1994 7/31/2010 SpecEnd Hospital
11980425 Formulation 1/1/1999 7/31/2010 Dispensary HP1
11980425 Formulation 8/1/2010 SpecEnd Retail
11980425 Formulation5/16/1994 7/31/2010 SpecEnd Hospital
11980425 Chemical 7/1/2005 9/30/2005 PCT
11980425 Formulation10/1/2005 PCT
11980425 Brand 12/1/2006 6/30/2008 SoleSupply
11980425 Brand 10/1/2008 6/30/2011 SoleSupply
11982525 Formulation10/1/2005 PCT only
11982525 Chemical 7/1/2005 9/30/2005 PCT
11982525 Formulation10/1/2005 SpecEnd Hospital
11982526 Formulation10/1/2005 SpecEnd Hospital
11982526 Chemical 7/1/2005 9/30/2005 PCT
11982526 Formulation10/1/2005 PCT only
11982625 Formulation12/1/2005 PCT only
11982625 Chemical 7/1/2005 9/30/2005 PCT
11982625 Formulation12/1/2005 SpecEnd Hospital
11982626 Formulation12/1/2005 SpecEnd Hospital
11982626 Chemical 7/1/2005 9/30/2005 PCT
11982626 Formulation12/1/2005 PCT only
11982725 Formulation 7/1/2006 PCT only
11982725 Chemical 7/1/2005 9/30/2005 PCT
11982725 Formulation 7/1/2006 SpecEnd Hospital
11982825 Formulation 7/1/2006 SpecEnd Hospital
11982825 Chemical 7/1/2005 9/30/2005 PCT
11982825 Formulation 7/1/2006 PCT only
11990101 Chemical 10/1/2003 Statim Must
12050101 Chemical 5/16/1994 ######## SpecEnd Retail
12090101 Chemical 5/16/1994 7/31/1997 SpecEnd Retail
12090101 Chemical 5/16/1994 MaxCoPayment 0
12160101 Formulation11/1/1997 9/30/2003 Statim May
12160101 Chemical 5/16/1994 SpecEnd Retail
12160101 Chemical 10/1/2003 Statim Must
12160201 Chemical 10/1/2003 Statim Must
12160201 Chemical 5/16/1994 SpecEnd Retail
12160201 Formulation11/1/1997 9/30/2003 Statim May
12170301 Formulation 7/1/1996 9/30/2003 Statim May
12170301 Formulation 7/1/1996 Safety Uncompounded
12170301 ATC3 7/1/2005 7/31/2007 Application
12170301 Chemical 10/1/2003 Statim Must
12170301 ATC3 8/1/2003 6/30/2005 Application
12170401 ATC3 8/1/2003 6/30/2005 Application
12170401 Chemical 10/1/2003 Statim Must
12170401 ATC3 7/1/2005 7/31/2007 Application
12170401 Formulation10/4/1997 9/30/2003 Statim May
12170402 Formulation10/4/1997 9/30/2003 Statim May
12170402 ATC3 7/1/2005 7/31/2007 Application
12170402 Chemical 10/1/2003 Statim Must
12170402 ATC3 8/1/2003 6/30/2005 Application
12170501 ATC3 8/1/2003 6/30/2005 Application
12170501 Chemical 10/1/2003 Statim Must
12170501 ATC3 7/1/2005 7/31/2007 Application
12170501 Formulation10/4/1997 9/30/2003 Statim May
12170601 Formulation10/4/1997 9/30/2003 Statim May
12170601 ATC3 7/1/2005 7/31/2007 Application
12170601 Chemical 10/1/2003 Statim Must
12170601 ATC3 8/1/2003 6/30/2005 Application
12170602 ATC3 8/1/2003 6/30/2005 Application
12170602 Chemical 10/1/2003 Statim Must
12170602 ATC3 7/1/2005 7/31/2007 Application
12170602 Formulation10/4/1997 9/30/2003 Statim May
12170701 Formulation10/4/1997 9/30/2003 Statim May
12170701 ATC3 7/1/2005 7/31/2007 Application
12170701 Chemical 10/1/2003 Statim Must
12170701 ATC3 8/1/2003 6/30/2005 Application
12210101 Chemical 4/1/2004 ######## Statim Must
12210125 Chemical 4/1/2004 ######## Statim Must
12210125 Brand 1/1/2014 S29
24242525 Brand 10/1/2011 6/30/2014 SoleSupply
24242625 Chemical 9/1/2013 Application
24242625 Formulation 9/1/2013 Special Claim only
24242725 Formulation 9/1/2013 Special Claim only
24242725 Chemical 9/1/2013 Application
24270101 Brand 9/1/2005 6/30/2008 SoleSupply
24270101 Brand 7/1/2010 6/30/2013 SoleSupply
24270101 Brand 10/1/2013 6/30/2016 SoleSupply
24290101 Brand 3/1/2003 6/30/2005 SoleSupply
24290101 Brand 1/1/2006 6/30/2008 SoleSupply
24290101 Chemical 5/16/1994 FormReqd Rx
24290101 Chemical 10/1/2003 Statim Must
24290201 Chemical 10/1/2003 Statim Must
24290201 Chemical 5/16/1994 FormReqd Rx
24290201 Brand 3/1/2003 6/30/2005 SoleSupply
24290201 Brand 1/1/2006 6/30/2008 SoleSupply
24290325 Brand 9/1/2010 6/30/2011 SoleSupply
24290325 Brand 10/1/2011 6/30/2014 SoleSupply
24290325 Chemical 5/16/1994 FormReqd Rx
24290325 Chemical 10/1/2003 Statim Must
24290425 Chemical 10/1/2003 Statim Must
24290425 Chemical 5/16/1994 FormReqd Rx
24290425 Brand 9/1/2010 6/30/2011 SoleSupply
24290425 Brand 10/1/2011 6/30/2014 SoleSupply
24290601 Brand 3/1/2003 6/30/2005 SoleSupply
24290601 Chemical 5/16/1994 FormReqd Rx
24290601 Chemical 10/1/2003 Statim Must
24300401 Chemical 10/1/2003 Statim Must
24300401 Chemical 5/16/1994 FormReqd Rx
24300401 Brand 3/1/2003 6/30/2005 SoleSupply
24300401 Brand 10/1/2005 6/30/2008 SoleSupply
24300401 Brand 1/1/2009 6/30/2011 SoleSupply
24300401 Brand 10/1/2011 6/30/2014 SoleSupply
24330101 Brand 11/1/2001 6/30/2004 SoleSupply
24330101 Brand 10/1/2006 6/30/2009 SoleSupply
24330101 Chemical 7/1/2005 ######## PCT
24330101 Formulation12/1/2005 PCT
24330101 Formulation5/16/1994 7/31/2010 SpecEnd Hospital
24330101 Formulation 8/1/2010 SpecEnd Retail
24330101 Formulation 1/1/1999 7/31/2010 Dispensary HP3
24330201 Formulation 1/1/1999 7/31/2010 Dispensary HP3
24330201 Formulation5/16/1994 7/31/2010 SpecEnd Hospital
24330201 Formulation 8/1/2010 SpecEnd Retail
24330201 Formulation12/1/2005 PCT
24330201 Chemical 7/1/2005 ######## PCT
24330201 Brand 11/1/2001 6/30/2004 SoleSupply
24330201 Brand 10/1/2006 6/30/2009 SoleSupply
24330301 Chemical 7/1/2005 ######## PCT
24330301 Formulation12/1/2005 PCT
24330301 Formulation5/16/1994 7/31/2010 SpecEnd Hospital
24330301 Formulation 8/1/2010 SpecEnd Retail
24330301 Formulation 1/1/1999 7/31/2010 Dispensary HP1
24330302 Formulation 1/1/1999 7/31/2010 Dispensary HP1
24330302 Formulation 8/1/2010 SpecEnd Retail
24330302 Formulation5/16/1994 7/31/2010 SpecEnd Hospital
24330302 Formulation12/1/2005 PCT
24330302 Chemical 7/1/2005 ######## PCT
24332525 Chemical 7/1/2005 ######## PCT
24332525 Formulation12/1/2005 PCT only
24332525 Formulation12/1/2005 SpecEnd Hospital
24332526 Formulation12/1/2005 SpecEnd Hospital
24332526 Formulation12/1/2005 PCT only
24332526 Chemical 7/1/2005 ######## PCT
24400201 Formulation5/16/1994 SubRxF
24410101 Chemical 1/1/1999 Dispensary HP1
24410101 Chemical 5/16/1994 Special
24450101 Chemical 12/1/1995 2/28/1999 Special
24450101 Chemical 1/1/2006 PCT
24450101 Chemical 9/1/2006 7/31/2010 SpecEnd Hospital
24450101 Chemical 8/1/2010 SpecEnd Retail
24450101 Chemical 1/1/1999 7/31/2010 Dispensary HP3
24450101 Chemical 3/1/1999 8/31/2006 Special
24450201 Chemical 3/1/1999 8/31/2006 Special
24450201 Chemical 1/1/1999 7/31/2010 Dispensary HP3
24450201 Chemical 8/1/2010 SpecEnd Retail
24450201 Chemical 9/1/2006 7/31/2010 SpecEnd Hospital
24450201 Chemical 1/1/2006 PCT
24450201 Chemical 12/1/1995 2/28/1999 Special
24450301 Chemical 12/1/1995 2/28/1999 Special
24450301 Chemical 1/1/2006 PCT
24450301 Chemical 9/1/2006 7/31/2010 SpecEnd Hospital
24450301 Chemical 8/1/2010 SpecEnd Retail
24450301 Chemical 1/1/1999 7/31/2010 Dispensary HP3
24450301 Chemical 3/1/1999 8/31/2006 Special
24450401 Chemical 3/1/1999 8/31/2006 Special
24450401 Chemical 1/1/1999 7/31/2010 Dispensary HP3
24450401 Chemical 8/1/2010 SpecEnd Retail
24450401 Chemical 9/1/2006 7/31/2010 SpecEnd Hospital
24450401 Chemical 1/1/2006 PCT
24450401 Chemical 12/1/1995 2/28/1999 Special
24450601 Chemical 12/1/1995 2/28/1999 Special
24450601 Chemical 1/1/2006 PCT
24450601 Chemical 9/1/2006 7/31/2010 SpecEnd Hospital
24450601 Chemical 8/1/2010 SpecEnd Retail
24450601 Chemical 1/1/1999 7/31/2010 Dispensary HP3
24450601 Chemical 3/1/1999 8/31/2006 Special
24450701 Chemical 3/1/1999 8/31/2006 Special
24450701 Chemical 1/1/1999 7/31/2010 Dispensary HP3
24450701 Chemical 8/1/2010 SpecEnd Retail
24450701 Chemical 9/1/2006 7/31/2010 SpecEnd Hospital
24450701 Chemical 1/1/2006 PCT
24450701 Chemical 12/1/1995 2/28/1999 Special
24450901 Chemical 12/1/1995 2/28/1999 Special
24450901 Chemical 1/1/2006 PCT
24450901 Chemical 9/1/2006 7/31/2010 SpecEnd Hospital
24450901 Chemical 8/1/2010 SpecEnd Retail
24450901 Chemical 1/1/1999 7/31/2010 Dispensary HP3
24450901 Chemical 3/1/1999 8/31/2006 Special
24451001 Chemical 3/1/1999 8/31/2006 Special
24451001 Chemical 1/1/1999 7/31/2010 Dispensary HP3
24451001 Chemical 8/1/2010 SpecEnd Retail
24451001 Chemical 9/1/2006 7/31/2010 SpecEnd Hospital
24451001 Chemical 1/1/2006 PCT
24451001 Chemical 12/1/1995 2/28/1999 Special
24451101 Chemical 12/1/1995 2/28/1999 Special
24451101 Chemical 1/1/2006 PCT
24451101 Chemical 9/1/2006 7/31/2010 SpecEnd Hospital
24451101 Chemical 8/1/2010 SpecEnd Retail
24451101 Chemical 1/1/1999 7/31/2010 Dispensary HP3
24451101 Chemical 3/1/1999 8/31/2006 Special
24451201 Chemical 3/1/1999 8/31/2006 Special
24451201 Chemical 1/1/1999 7/31/2010 Dispensary HP3
24451201 Chemical 8/1/2010 SpecEnd Retail
24451201 Chemical 9/1/2006 7/31/2010 SpecEnd Hospital
24451201 Chemical 1/1/2006 PCT
24451201 Chemical 12/1/1995 2/28/1999 Special
24451301 Chemical 12/1/1995 2/28/1999 Special
16170101 Brand 7/1/1999 6/30/2002 SoleSupply
16170101 Brand 9/1/2003 6/30/2006 SoleSupply
16170101 Brand 1/1/2007 6/30/2009 SoleSupply
16170101 Brand 1/1/2010 6/30/2012 SoleSupply
16170101 Brand 12/1/2012 6/30/2015 SoleSupply
16170101 Formulation 7/1/1996 9/30/2003 Statim May
16170201 Formulation 7/1/1996 9/30/2003 Statim May
16170201 Formulation12/1/2011 OraProduct
16170201 Brand 7/1/1999 6/30/2002 SoleSupply
16170201 Brand 9/1/2003 6/30/2006 SoleSupply
16170201 Brand 1/1/2007 6/30/2009 SoleSupply
16170201 Brand 1/1/2010 6/30/2012 SoleSupply
16170201 Brand 12/1/2012 6/30/2015 SoleSupply
16170201 Chemical 10/1/2003 Statim Must
16170501 Chemical 10/1/2003 Statim Must
16170501 Formulation 5/1/1996 FormReqd Rx
16170502 Formulation 5/1/1996 FormReqd Rx
16170502 Chemical 10/1/2003 Statim Must
16170601 Chemical 10/1/2003 Statim Must
16170601 Formulation 8/1/1999 Combined
16170602 Formulation 8/1/1999 Combined
16170602 Chemical 10/1/2003 Statim Must
16170603 Chemical 10/1/2003 Statim Must
16170603 Formulation 8/1/1999 Combined
16170604 Formulation 8/1/1999 Combined
16170604 Chemical 10/1/2003 Statim Must
16170625 Chemical 10/1/2003 Statim Must
16170625 Formulation 8/1/1999 Combined
16170625 Brand 4/1/2003 6/30/2005 SoleSupply
16170625 Brand 10/1/2005 6/30/2008 SoleSupply
16170626 Brand 11/1/2009 6/30/2011 SoleSupply
16170626 Brand 12/1/2011 6/30/2014 SoleSupply
16170626 Formulation 8/1/1999 Combined
16170626 Chemical 10/1/2003 Statim Must
16171601 Chemical 10/1/2003 Statim Must
16171601 Formulation5/23/1995 FormReqd PSO
16171601 Formulation 7/1/1996 FormMax 5 PSO
16171601 Brand 1/1/2001 6/30/2003 SoleSupply
16171601 Brand 12/1/2010 6/30/2013 SoleSupply
16171601 Brand 11/1/2013 6/30/2016 SoleSupply
16171701 Brand 1/1/2001 ######## SoleSupply
16171701 Formulation5/23/1995 FormReqd PSO
16171701 Formulation 7/1/1996 FormMax 5 PSO
16171701 Chemical 10/1/2003 Statim Must
16171801 Chemical 10/1/2003 Statim Must
16171801 Formulation5/23/1995 FormReqd PSO
16171801 Formulation 7/1/1996 FormMax 5 PSO
16171801 Brand 1/1/2001 ######## SoleSupply
16171901 Chemical 10/1/2003 Statim Must
16171901 Formulation 5/1/1996 FormReqd Rx
16171902 Formulation 5/1/1996 FormReqd Rx
16171902 Chemical 10/1/2003 Statim Must
16171902 Brand 10/1/2008 6/30/2011 SoleSupply
16171903 Chemical 10/1/2003 Statim Must
16171903 Formulation 5/1/1996 FormReqd Rx
16171904 Formulation 5/1/1996 FormReqd Rx
16171904 Chemical 10/1/2003 Statim Must
16171925 Chemical 10/1/2003 Statim Must
16171925 Formulation 5/1/1996 FormReqd Rx
16171926 Formulation 5/1/1996 FormReqd Rx
16171926 Chemical 10/1/2003 Statim Must
16171926 Brand 12/1/2011 6/30/2014 SoleSupply
16200101 Formulation 6/1/2002 NotCombined
16200101 Chemical 10/1/2003 Statim Must
16200101 Formulation 6/1/2002 FormReqd Rx
16200201 Formulation 6/1/2002 FormReqd Rx
16200201 Chemical 10/1/2003 Statim Must
16200201 Formulation 6/1/2002 NotCombined
16200301 Formulation 6/1/2002 NotCombined
16200301 Chemical 10/1/2003 Statim Must
16200301 Formulation 6/1/2002 FormReqd Rx
16200302 Formulation 6/1/2002 FormReqd Rx
16200302 Chemical 10/1/2003 Statim Must
16200302 Formulation 6/1/2002 NotCombined
16200302 Brand 12/1/2002 6/30/2005 SoleSupply
16200303 Formulation 6/1/2002 NotCombined
16200303 Chemical 10/1/2003 Statim Must
16200303 Formulation 6/1/2002 FormReqd Rx
16200325 Formulation 6/1/2002 FormReqd Rx
16200325 Chemical 10/1/2003 Statim Must
16200325 Formulation 6/1/2002 NotCombined
16200325 Brand 4/1/2006 6/30/2008 SoleSupply
16200325 Brand 10/1/2008 6/30/2011 SoleSupply
16200325 Brand 12/1/2011 6/30/2014 SoleSupply
16200401 Formulation 6/1/2002 NotCombined
16200401 Chemical 10/1/2003 Statim Must
16200401 Formulation 6/1/2002 FormReqd Rx
16200501 Chemical 10/1/2003 Statim Must
16200601 Chemical 10/1/2003 Statim Must
16200602 Chemical 10/1/2003 Statim Must
16200603 Chemical 10/1/2003 Statim Must
16240101 Chemical 10/1/2003 Statim Must
16240101 Formulation 7/1/2008 FormMax 6 PSO
16240125 Formulation 7/1/2008 FormMax 6 PSO
16240125 Chemical 10/1/2003 Statim Must
16240125 Brand 3/1/2007 S29
16240125 Brand 4/1/2013 Wastage
16240126 Chemical 10/1/2003 Statim Must
16240126 Formulation 7/1/2008 FormMax 6 PSO
16240127 Formulation 7/1/2008 FormMax 6 PSO
16240127 Brand 7/1/2010 6/30/2012 SoleSupply
16240127 Brand 10/1/2012 6/30/2015 SoleSupply
16240127 Chemical 10/1/2003 Statim Must
16250101 Chemical 10/1/2003 Statim Must
16250101 Brand 8/1/2009 6/30/2012 SoleSupply
16250101 Brand 12/1/2012 6/30/2015 SoleSupply
16260101 Brand 11/1/2001 6/30/2004 SoleSupply
16260101 Chemical 7/1/2005 PCT
16260101 Chemical 5/16/1994 SpecEnd Retail
16290101 Formulation 1/1/1999 7/31/2010 Dispensary HP3
16290101 Formulation 7/1/2004 ######## Special
16290101 Formulation 7/1/2013 Special
16290101 Formulation5/16/1994 6/30/2004 Special
16290101 Formulation11/1/2008 6/30/2013 Special
16290101 Brand 1/1/2014 6/30/2016 SoleSupply
16290201 Formulation10/1/2003 Statim Must
16290301 Formulation10/1/2003 Statim Must
16300101 Chemical 8/1/2013 Statim Must
16300101 Brand 12/1/2002 6/30/2005 SoleSupply
16300101 Brand 10/1/2005 6/30/2008 SoleSupply
16310101 Brand 1/1/2009 6/30/2011 SoleSupply
16310101 Chemical 10/1/2003 Statim Must
16310125 Chemical 10/1/2003 Statim Must
16310125 Brand 9/1/2007 6/30/2008 SoleSupply
16310125 Brand 1/1/2009 6/30/2011 SoleSupply
16310125 Brand 10/1/2011 6/30/2014 SoleSupply
12320326 Chemical 10/1/2005 FormMax 5 PSO
12320326 Chemical 1/1/1999 7/31/2010 Dispensary HP3
12320326 Chemical 7/1/2013 SubRxF
12320326 Chemical 10/1/2005 ######## SubRxF
12320326 Chemical 5/16/1994 9/30/2005 SpecEnd Hospital
12320326 Chemical 5/16/1994 9/30/2005 SubRxF
12320327 Chemical 5/16/1994 9/30/2005 SubRxF
12320327 Brand 1/1/2007 6/30/2008 SoleSupply
12320327 Chemical 5/16/1994 9/30/2005 SpecEnd Hospital
12320327 Chemical 10/1/2005 ######## SubRxF
12320327 Chemical 10/1/2005 FormMax 5 PSO
12320327 Chemical 7/1/2013 SubRxF
12320327 Chemical 12/1/2005 6/30/2013 SubRxF
12320327 Chemical 1/1/1999 7/31/2010 Dispensary HP3
12320328 Chemical 1/1/1999 7/31/2010 Dispensary HP3
12320328 Chemical 12/1/2005 6/30/2013 SubRxF
12320328 Chemical 7/1/2013 SubRxF
12320328 Chemical 10/1/2005 FormMax 5 PSO
12320328 Chemical 10/1/2005 ######## SubRxF
12320328 Chemical 5/16/1994 9/30/2005 SpecEnd Hospital
12320328 Brand 1/1/2011 6/30/2013 SoleSupply
12320328 Chemical 5/16/1994 9/30/2005 SubRxF
12320329 Chemical 5/16/1994 9/30/2005 SubRxF
12320329 Brand 6/1/2014 6/30/2016 SoleSupply
12320329 Chemical 5/16/1994 9/30/2005 SpecEnd Hospital
12320329 Chemical 10/1/2005 ######## SubRxF
12320329 Chemical 1/1/1999 7/31/2010 Dispensary HP3
12320329 Chemical 12/1/2005 6/30/2013 SubRxF
12320329 Chemical 10/1/2005 FormMax 5 PSO
12320329 Chemical 7/1/2013 SubRxF
12330101 Chemical 1/1/1999 7/31/2010 Dispensary HP3
12330101 Formulation11/1/1999 FormMax 3 Rx SubRxF
12330101 Chemical 5/16/1994 ######## SpecEnd Hospital
12330101 Chemical 5/16/1994 ######## SubRxF
12330125 Chemical 5/16/1994 ######## SubRxF
12330125 Chemical 5/16/1994 ######## SpecEnd Hospital
12330125 Formulation11/1/1999 FormMax 3 Rx SubRxF
12330125 Chemical 1/1/1999 7/31/2010 Dispensary HP3
12330201 Chemical 1/1/1999 7/31/2010 Dispensary HP3
12330201 Formulation11/1/1999 FormMax 1 Rx SubRxF
12330201 Chemical 5/16/1994 ######## SpecEnd Hospital
12330201 Chemical 5/16/1994 ######## SubRxF
12330201 Brand 12/1/2002 6/30/2005 SoleSupply
12330201 Brand 11/1/2008 6/30/2011 SoleSupply
12330225 Chemical 5/16/1994 ######## SubRxF
12330225 Chemical 5/16/1994 ######## SpecEnd Hospital
12330225 Formulation11/1/1999 FormMax 1 Rx SubRxF
12330225 Chemical 1/1/1999 7/31/2010 Dispensary HP3
12330226 Chemical 1/1/1999 7/31/2010 Dispensary HP3
12330226 Formulation11/1/1999 FormMax 1 Rx SubRxF
12330226 Chemical 5/16/1994 ######## SpecEnd Hospital
12330226 Chemical 5/16/1994 ######## SubRxF
12330226 Brand 6/1/2012 6/30/2014 SoleSupply
12330301 Formulation11/1/1999 7/31/2010 SubRxF
12330301 Formulation 8/1/2010 SubRxF
12330301 Brand 11/1/2008 6/30/2011 SoleSupply
12330301 Chemical 5/16/1994 ######## SubRxF
12330301 Chemical 5/16/1994 ######## SpecEnd Hospital
12330301 Formulation11/1/1999 7/31/2010 SpecEnd Hospital
12330301 Formulation 8/1/2010 SpecEnd Retail
12330301 Chemical 1/1/1999 7/31/2010 Dispensary HP3
12330325 Chemical 1/1/1999 7/31/2010 Dispensary HP3
12330325 Formulation 8/1/2010 SpecEnd Retail
12330325 Formulation11/1/1999 7/31/2010 SpecEnd Hospital
12330325 Chemical 5/16/1994 ######## SpecEnd Hospital
12330325 Chemical 5/16/1994 ######## SubRxF
12330325 Formulation 8/1/2010 SubRxF
12330325 Formulation11/1/1999 7/31/2010 SubRxF
12330326 Formulation 8/1/2010 SubRxF
12330326 Formulation11/1/1999 7/31/2010 SubRxF
12330326 Chemical 5/16/1994 ######## SubRxF
12330326 Chemical 5/16/1994 ######## SpecEnd Hospital
12330326 Formulation 8/1/2010 SpecEnd Retail
12330326 Formulation11/1/1999 7/31/2010 SpecEnd Hospital
12330326 Chemical 1/1/1999 7/31/2010 Dispensary HP3
12340101 Chemical 1/1/1999 7/31/2010 Dispensary HP3
12340101 Brand 12/1/2002 6/30/2005 SoleSupply
12340201 Brand 12/1/2002 6/30/2005 SoleSupply
12340201 Chemical 1/1/1999 7/31/2010 Dispensary HP3
12340301 Chemical 1/1/1999 7/31/2010 Dispensary HP3
12340301 Formulation5/16/1994 Wastage
12340301 Brand 12/1/2002 6/30/2005 SoleSupply
12340325 Brand 3/1/2010 6/30/2012 SoleSupply
12340325 Brand 11/1/2013 6/30/2015 SoleSupply
12340325 Formulation5/16/1994 Wastage
12340325 Chemical 1/1/1999 7/31/2010 Dispensary HP3
12340401 Chemical 1/1/1999 7/31/2010 Dispensary HP3
12340401 Formulation5/16/1994 Wastage
12340401 Brand 12/1/2002 6/30/2005 SoleSupply
12340425 Brand 3/1/2010 6/30/2012 SoleSupply
12340425 Brand 11/1/2013 6/30/2015 SoleSupply
12340425 Formulation5/16/1994 Wastage
12340425 Chemical 1/1/1999 7/31/2010 Dispensary HP3
12342525 Chemical 1/1/1999 7/31/2010 Dispensary HP3
12342525 Brand 11/1/2013 6/30/2016 SoleSupply
12350101 Chemical 5/16/1994 SubRxF
12350101 Chemical 1/1/1999 Dispensary HP3
12360101 Chemical 1/1/1999 7/31/2010 Dispensary HP3
12360101 Chemical 5/16/1994 6/30/2013 SubRxF
12360101 Chemical 7/1/2013 SubRxF
12360125 Chemical 7/1/2013 SubRxF
12360125 Chemical 5/16/1994 6/30/2013 SubRxF
12360125 Chemical 1/1/1999 7/31/2010 Dispensary HP3
12360126 Chemical 1/1/1999 7/31/2010 Dispensary HP3
12360126 Chemical 5/16/1994 6/30/2013 SubRxF
12360126 Brand 12/1/2002 6/30/2005 SoleSupply
12360126 Chemical 7/1/2013 SubRxF
12360127 Chemical 7/1/2013 SubRxF
12360127 Brand 12/1/2006 6/30/2008 SoleSupply
12360127 Chemical 5/16/1994 6/30/2013 SubRxF
12360127 Chemical 1/1/1999 7/31/2010 Dispensary HP3
12360128 Chemical 1/1/1999 7/31/2010 Dispensary HP3
12360128 Chemical 5/16/1994 6/30/2013 SubRxF
12360128 Brand 3/1/2009 6/30/2011 SoleSupply
12360128 Chemical 7/1/2013 SubRxF
12360129 Chemical 7/1/2013 SubRxF
12360129 Brand 6/1/2012 6/30/2014 SoleSupply
12360129 Chemical 5/16/1994 6/30/2013 SubRxF
12360129 Chemical 1/1/1999 7/31/2010 Dispensary HP3
12360201 Chemical 1/1/1999 7/31/2010 Dispensary HP3
12360201 Chemical 5/16/1994 6/30/2013 SubRxF
12360201 Chemical 7/1/2013 SubRxF
12360225 Chemical 7/1/2013 SubRxF
12360225 Chemical 5/16/1994 6/30/2013 SubRxF
12360225 Brand 3/1/2009 6/30/2011 SoleSupply
12360225 Chemical 1/1/1999 7/31/2010 Dispensary HP3
16310201 Formulation 7/1/1996 3/31/2001 FormMax 6 PSO
16310201 Brand 1/1/2006 6/30/2008 SoleSupply
16310201 Brand 1/1/2009 6/30/2011 SoleSupply
16310201 Brand 12/1/2011 6/30/2014 SoleSupply
16310201 Chemical 10/1/2003 Statim Must
16310201 Formulation 4/1/2001 FormMax 5 PSO
16320101 Brand 12/1/2001 6/30/2004 SoleSupply
16320401 Brand 12/1/2001 6/30/2004 SoleSupply
16330101 Chemical 10/1/2003 Statim Must
16330202 Chemical 10/1/2003 Statim Must
16330203 Chemical 10/1/2003 Statim Must
16330203 Brand 1/1/2001 6/30/2003 SoleSupply
16330203 Brand 9/1/2005 6/30/2008 SoleSupply
16330203 Brand 4/1/2009 6/30/2011 SoleSupply
16330301 Brand 1/1/2001 6/30/2003 SoleSupply
16330301 Chemical 10/1/2003 Statim Must
16420101 Chemical 8/1/2012 SafetyListMedicine
16420125 Chemical 8/1/2012 SafetyListMedicine
16420125 Brand 9/1/2013 ######## Wastage
16420125 Brand 1/1/2007 6/30/2009 SoleSupply
16420201 Chemical 8/1/2012 SafetyListMedicine
16420225 Chemical 8/1/2012 SafetyListMedicine
16420225 Brand 1/1/2007 6/30/2009 SoleSupply
16430101 Chemical 10/1/2003 Statim Must
16430101 Chemical 1/1/2011 3/31/2011 Brandswitch 2377837 BSF Dapa-Tabs
16430102 Chemical 1/1/2011 3/31/2011 Brandswitch 2377837 BSF Dapa-Tabs
16430102 Chemical 10/1/2003 Statim Must
16430102 Brand 2/1/2004 6/30/2006 SoleSupply
16430102 Brand 1/1/2007 6/30/2009 SoleSupply
16430103 Brand 12/1/2000 6/30/2003 SoleSupply
16430103 Chemical 10/1/2003 Statim Must
16430103 Chemical 1/1/2011 3/31/2011 Brandswitch 2377837 BSF Dapa-Tabs
16430125 Chemical 1/1/2011 3/31/2011 Brandswitch 2377837 BSF Dapa-Tabs
16430125 Chemical 10/1/2003 Statim Must
16430125 Brand 1/1/2011 6/30/2013 SoleSupply
16430125 Brand 11/1/2013 6/30/2016 SoleSupply
16450102 Chemical 10/1/2003 Statim Must
16450103 Chemical 10/1/2003 Statim Must
16450103 Brand 11/1/1999 6/30/2002 SoleSupply
16450103 Brand 4/1/2003 6/30/2005 SoleSupply
16450103 Brand 1/1/2006 6/30/2008 SoleSupply
16450201 Brand 11/1/1999 6/30/2002 SoleSupply
16450201 Brand 4/1/2003 6/30/2005 SoleSupply
16450201 Brand 1/1/2006 6/30/2008 SoleSupply
16450201 Chemical 10/1/2003 Statim Must
16450202 Chemical 10/1/2003 Statim Must
16450301 Chemical 10/1/2003 Statim Must
16450302 Chemical 10/1/2003 Statim Must
16450302 Brand 4/1/2003 6/30/2005 SoleSupply
16450401 Chemical 10/1/2003 Statim Must
16450402 Chemical 10/1/2003 Statim Must
16450402 Brand 11/1/1999 6/30/2002 SoleSupply
16450402 Brand 4/1/2003 6/30/2005 SoleSupply
16480101 Chemical 7/1/1996 Statim May
16480102 Chemical 7/1/1996 Statim May
16480201 Chemical 7/1/1996 Statim May
16480202 Chemical 7/1/1996 Statim May
16480204 Chemical 7/1/1996 Statim May
16480301 Chemical 7/1/1996 Statim May
16480302 Chemical 7/1/1996 Statim May
16482501 Chemical 7/1/1996 Statim May
16482501 Formulation11/1/2004 8/31/2006 Special
16482501 Formulation 9/1/1995 9/30/1996 Special
16482501 Formulation10/1/1996 ######## Special
16482502 Formulation10/1/1996 ######## Special
16482502 Formulation 9/1/1995 9/30/1996 Special
16482502 Formulation11/1/2004 8/31/2006 Special
16482502 Chemical 7/1/1996 Statim May
16490201 Chemical 7/1/1996 Statim May
16490203 Chemical 7/1/1996 Statim May
16490301 Chemical 7/1/1996 Statim May
16490302 Chemical 7/1/1996 Statim May
16490325 Chemical 7/1/1996 Statim May
16490401 Chemical 7/1/1996 Statim May
16490402 Chemical 7/1/1996 Statim May
16490425 Chemical 7/1/1996 Statim May
16492501 Chemical 7/1/1996 Statim May
16492503 Chemical 7/1/1996 Statim May
16530101 Formulation 7/1/1996 Statim May
16530101 ATC3 3/1/2014 SubRxF
16530101 Chemical 12/1/1997 ProvReqd M
16530101 ATC3 12/1/1997 2/28/2014 SubRxF
16550101 Chemical 7/1/1996 Statim May
16550102 Chemical 7/1/1996 Statim May
16550201 Chemical 7/1/1996 Statim May
16550202 Chemical 7/1/1996 Statim May
16760101 Brand 12/1/2008 6/30/2011 SoleSupply
16760101 Brand 11/1/2011 6/30/2014 SoleSupply
16760101 Chemical 6/1/2012 Statim Must
16760125 Chemical 6/1/2012 Statim Must
16760125 Brand 3/1/2004 6/30/2006 SoleSupply
16790101 Brand 4/1/2013 6/30/2015 SoleSupply
16790101 Chemical 5/16/1994 MaxCoPayment 0
16790101 Chemical 10/1/2003 Statim Must
16790101 Chemical 5/16/1994 SpecEnd Retail
16790201 Chemical 5/16/1994 SpecEnd Retail
16790201 Chemical 10/1/2003 Statim Must
16790201 Chemical 5/16/1994 MaxCoPayment 0
16790301 Chemical 5/16/1994 MaxCoPayment 0
16790301 Chemical 10/1/2003 Statim Must
16790301 Chemical 5/16/1994 SpecEnd Retail
16820101 Chemical 10/1/2003 Statim Must
16860101 Chemical 6/16/1995 ######## ProvReqd M
16860201 Chemical 6/16/1995 ######## ProvReqd M
16860202 Chemical 6/16/1995 ######## ProvReqd M
16880101 Chemical 1/1/1999 2/28/2009 Dispensary HP3
16880101 Chemical 3/1/2009 3/31/2009 Special
16880101 Chemical 5/16/1994 2/28/2009 SpecOnly Hospital
16880101 Chemical 4/1/2009 Special
16880125 Chemical 4/1/2009 Special
16880125 Brand 2/1/2010 6/30/2012 SoleSupply
16880125 Brand 4/1/2013 6/30/2015 SoleSupply
16880125 Chemical 5/16/1994 2/28/2009 SpecOnly Hospital
16880125 Chemical 1/1/1999 2/28/2009 Dispensary HP3
16880125 Chemical 3/1/2009 3/31/2009 Special
16880126 Chemical 1/1/1999 2/28/2009 Dispensary HP3
16880126 Chemical 3/1/2009 3/31/2009 Special
16880126 Chemical 5/16/1994 2/28/2009 SpecOnly Hospital
16880126 Brand 5/1/2004 6/30/2006 SoleSupply
16880126 Brand 10/1/2006 6/30/2009 SoleSupply
16880126 Chemical 4/1/2009 Special
16880201 Chemical 4/1/2009 Special
16880201 Chemical 5/16/1994 2/28/2009 SpecOnly Hospital
16880201 Chemical 3/1/2009 3/31/2009 Special
16880201 Chemical 1/1/1999 2/28/2009 Dispensary HP3
16880202 Chemical 1/1/1999 2/28/2009 Dispensary HP3
12482525 ATC3 2/1/2005 Dispensary Xpharm
12482525 ATC3 6/1/2000 ######## Special
12482525 ATC3 12/1/2005 2/28/2007 Special
12482525 ATC3 3/1/2007 ######## Special
12482525 ATC3 12/1/2010 Special
12482625 ATC3 12/1/2010 Special
12482625 ATC3 3/1/2007 ######## Special
12482625 ATC3 12/1/2005 2/28/2007 Special
12482625 ATC3 6/1/2000 ######## Special
12482625 ATC3 2/1/2005 Dispensary Xpharm
12500101 Chemical 5/1/2012 Statim Must
12500101 ATC3 6/1/2004 ######## Special
12500101 Chemical 9/1/2005 ######## SpecEnd Retail
12500101 Formulation10/1/1999 3/31/2002 Special
12500101 ATC3 11/1/2004 8/31/2005 Special
12500101 Chemical 10/1/1999 4/30/2012 Statim May
12500101 Chemical 4/1/2002 4/30/2004 Special
12500101 Chemical 5/1/2004 5/31/2004 Special
12500125 Chemical 5/1/2004 5/31/2004 Special
12500125 Chemical 4/1/2002 4/30/2004 Special
12500125 Chemical 10/1/1999 4/30/2012 Statim May
12500125 ATC3 11/1/2004 8/31/2005 Special
12500125 Formulation10/1/1999 3/31/2002 Special
12500125 Brand 3/1/2010 6/30/2012 SoleSupply
12500125 Brand 10/1/2012 6/30/2015 SoleSupply
12500125 Chemical 9/1/2005 ######## SpecEnd Retail
12500125 ATC3 6/1/2004 ######## Special
12500125 Chemical 5/1/2012 Statim Must
12540101 Chemical 10/1/2003 Statim Must
12540101 Chemical 2/1/2005 4/30/2007 Special
12540101 Chemical 12/1/1999 6/30/2004 Special
12540101 Chemical 7/1/2004 1/31/2005 Special
12540101 Chemical 11/1/2012 1/31/2013 Brandswitch 2426781 BSF Candestar
12540101 Chemical 5/1/2007 ######## Special
12540101 Chemical 8/1/2012 Special
12540101 Formulation 7/1/2004 7/31/2012 DoseDMax 1.5
12540101 Chemical 11/1/2008 7/31/2012 Special
12540125 Chemical 11/1/2008 7/31/2012 Special
12540125 Brand 11/1/2012 6/30/2015 SoleSupply
12540125 Formulation 7/1/2004 7/31/2012 DoseDMax 1.5
12540125 Chemical 8/1/2012 Special
12540125 Chemical 5/1/2007 ######## Special
12540125 Chemical 11/1/2012 1/31/2013 Brandswitch 2426781 BSF Candestar
12540125 Chemical 7/1/2004 1/31/2005 Special
12540125 Chemical 12/1/1999 6/30/2004 Special
12540125 Chemical 10/1/2003 Statim Must
12540125 Chemical 2/1/2005 4/30/2007 Special
12540201 Chemical 10/1/2003 Statim Must
12540201 Chemical 2/1/2005 4/30/2007 Special
12540201 Chemical 12/1/1999 6/30/2004 Special
12540201 Chemical 7/1/2004 1/31/2005 Special
12540201 Chemical 11/1/2012 1/31/2013 Brandswitch 2426781 BSF Candestar
12540201 Chemical 5/1/2007 ######## Special
12540201 Chemical 8/1/2012 Special
12540201 Formulation 7/1/2004 7/31/2012 DoseDMax 1.5
12540201 Chemical 11/1/2008 7/31/2012 Special
12540225 Chemical 11/1/2008 7/31/2012 Special
12540225 Brand 11/1/2012 6/30/2015 SoleSupply
12540225 Formulation 7/1/2004 7/31/2012 DoseDMax 1.5
12540225 Chemical 8/1/2012 Special
12540225 Chemical 5/1/2007 ######## Special
12540225 Chemical 11/1/2012 1/31/2013 Brandswitch 2426781 BSF Candestar
12540225 Chemical 7/1/2004 1/31/2005 Special
12540225 Chemical 12/1/1999 6/30/2004 Special
12540225 Chemical 10/1/2003 Statim Must
12540225 Chemical 2/1/2005 4/30/2007 Special
12540301 Chemical 10/1/2003 Statim Must
12540301 Chemical 2/1/2005 4/30/2007 Special
12540301 Formulation 7/1/2004 7/31/2012 DoseDMax 1
12540301 Chemical 12/1/1999 6/30/2004 Special
12540301 Chemical 7/1/2004 1/31/2005 Special
12540301 Chemical 11/1/2012 1/31/2013 Brandswitch 2426781 BSF Candestar
12540301 Chemical 5/1/2007 ######## Special
12540301 Chemical 8/1/2012 Special
12540301 Chemical 11/1/2008 7/31/2012 Special
12540325 Chemical 11/1/2008 7/31/2012 Special
12540325 Chemical 8/1/2012 Special
12540325 Chemical 5/1/2007 ######## Special
12540325 Brand 11/1/2012 6/30/2015 SoleSupply
12540325 Chemical 11/1/2012 1/31/2013 Brandswitch 2426781 BSF Candestar
12540325 Chemical 7/1/2004 1/31/2005 Special
12540325 Chemical 12/1/1999 6/30/2004 Special
12540325 Formulation 7/1/2004 7/31/2012 DoseDMax 1
12540325 Chemical 2/1/2005 4/30/2007 Special
12540325 Chemical 10/1/2003 Statim Must
12542525 Chemical 10/1/2003 Statim Must
12542525 Chemical 2/1/2005 4/30/2007 Special
12542525 Formulation 8/1/2006 7/31/2012 DoseDMax 1
12542525 Chemical 7/1/2004 1/31/2005 Special
12542525 Chemical 11/1/2012 1/31/2013 Brandswitch 2426781 BSF Candestar
12542525 Chemical 12/1/1999 6/30/2004 Special
12542525 Chemical 8/1/2012 Special
12542525 Chemical 5/1/2007 ######## Special
12542525 Chemical 11/1/2008 7/31/2012 Special
12542526 Chemical 11/1/2008 7/31/2012 Special
12542526 Chemical 5/1/2007 ######## Special
12542526 Chemical 8/1/2012 Special
12542526 Brand 11/1/2012 6/30/2015 SoleSupply
12542526 Chemical 7/1/2004 1/31/2005 Special
12542526 Chemical 12/1/1999 6/30/2004 Special
12542526 Chemical 11/1/2012 1/31/2013 Brandswitch 2426781 BSF Candestar
12542526 Formulation 8/1/2006 7/31/2012 DoseDMax 1
12542526 Chemical 2/1/2005 4/30/2007 Special
12542526 Chemical 10/1/2003 Statim Must
12550101 Chemical 5/16/1994 SpecEnd Retail
12550101 Chemical 7/1/2005 PCT
12550125 Chemical 7/1/2005 PCT
12550125 Chemical 5/16/1994 SpecEnd Retail
12550201 Chemical 5/16/1994 SpecEnd Retail
12550201 Chemical 7/1/2005 PCT
12570101 Chemical 6/3/1995 SpecEnd Retail
12590102 Brand 12/1/2002 6/30/2005 SoleSupply
12590102 Brand 1/1/2007 6/30/2009 SoleSupply
12590105 Brand 4/1/2000 6/30/2002 SoleSupply
12590125 Brand 3/1/2011 6/30/2012 SoleSupply
12590125 Brand 10/1/2012 6/30/2015 SoleSupply
12590403 Brand 11/1/1999 6/30/2002 SoleSupply
12590403 Brand 12/1/2002 6/30/2005 SoleSupply
12590403 Brand 1/1/2007 6/30/2009 SoleSupply
12590403 Brand 10/1/2009 6/30/2012 SoleSupply
12590403 Brand 2/1/2013 6/30/2015 SoleSupply
12590601 Formulation 7/1/1996 SpecEnd Retail
12610101 Chemical 6/22/1995 SpecEnd Retail
12730101 Formulation 6/1/1995 TreatMax 30
12750101 Formulation10/1/2003 3/31/2007 AltSubRxF
12750101 Formulation 4/1/2007 AltSubRxF
12750101 Chemical 10/1/2003 Statim Must
12760101 Chemical 10/1/2003 Statim Must
12800101 Chemical 10/1/2003 Statim Must
16880202 Chemical 3/1/2009 3/31/2009 Special
16880202 Chemical 5/16/1994 2/28/2009 SpecOnly Hospital
16880202 Chemical 4/1/2009 Special
16880202 Brand 2/1/2010 6/30/2012 SoleSupply
16880202 Brand 4/1/2013 6/30/2015 SoleSupply
16880225 Brand 5/1/2004 6/30/2006 SoleSupply
16880225 Brand 10/1/2006 6/30/2009 SoleSupply
16880225 Chemical 4/1/2009 Special
16880225 Chemical 5/16/1994 2/28/2009 SpecOnly Hospital
16880225 Chemical 3/1/2009 3/31/2009 Special
16880225 Chemical 1/1/1999 2/28/2009 Dispensary HP3
16960101 Brand 1/1/2014 S29
16960101 Brand 1/1/2014 Wastage
16960101 Formulation5/16/1994 SpecEnd Retail
16960101 Formulation 7/1/2014 PCT
16960101 Formulation 7/1/2014 SubRxF
16960101 Brand 8/1/2004 6/30/2007 SoleSupply
16960201 Formulation 6/1/2002 NotCombined
16960201 Formulation 6/1/2002 FormReqd Rx
16960301 Formulation 3/1/1998 ######## FormReqd Rx
16960301 Formulation 3/1/1998 ######## FormMax 100 Rx
16960301 Formulation12/1/1998 FormReqd Rx
16960301 Formulation12/1/1998 FormMax 100 Rx
16960302 Formulation12/1/1998 FormMax 100 Rx
16960302 Brand 11/1/1999 6/30/2002 SoleSupply
16960302 Brand 1/1/2009 6/30/2011 SoleSupply
16960302 Brand 10/1/2011 6/30/2014 SoleSupply
16960302 Formulation12/1/1998 FormReqd Rx
16960302 Formulation 3/1/1998 ######## FormMax 100 Rx
16960302 Formulation 3/1/1998 ######## FormReqd Rx
16960325 Formulation 3/1/1998 ######## FormReqd Rx
16960325 Formulation 3/1/1998 ######## FormMax 100 Rx
16960325 Formulation12/1/1998 FormReqd Rx
16960325 Brand 6/1/2004 6/30/2005 SoleSupply
16960325 Brand 12/1/2005 6/30/2008 SoleSupply
16960325 Formulation12/1/1998 FormMax 100 Rx
16970101 Chemical 3/1/1996 SpecialWav Claim only
16970101 ATC3 9/1/2010 Application
16970101 Chemical 10/1/2003 Statim Must
16970101 ATC3 3/1/1996 8/31/2010 Application
16970302 ATC3 3/1/1996 8/31/2010 Application
16970302 Chemical 10/1/2003 Statim Must
16970302 ATC3 9/1/2010 Application
16970302 Chemical 3/1/1996 SpecialWav Claim only
16970303 Chemical 3/1/1996 SpecialWav Claim only
16970303 ATC3 9/1/2010 Application
16970303 Chemical 10/1/2003 Statim Must
16970303 ATC3 3/1/1996 8/31/2010 Application
16970505 ATC3 3/1/1996 8/31/2010 Application
16970505 Chemical 10/1/2003 Statim Must
16970505 ATC3 9/1/2010 Application
16970505 Chemical 3/1/1996 SpecialWav Claim only
16970601 Chemical 3/1/1996 SpecialWav Claim only
16970601 ATC3 9/1/2010 Application
16970601 Chemical 10/1/2003 Statim Must
16970601 ATC3 3/1/1996 8/31/2010 Application
16970701 ATC3 3/1/1996 8/31/2010 Application
16970701 Chemical 10/1/2003 Statim Must
16970701 ATC3 9/1/2010 Application
16970701 Chemical 3/1/1996 SpecialWav Claim only
16970801 Chemical 3/1/1996 SpecialWav Claim only
16970801 ATC3 9/1/2010 Application
16970801 Chemical 10/1/2003 Statim Must
16970801 ATC3 3/1/1996 8/31/2010 Application
16980101 Chemical 5/16/1994 6/30/1997 FormReqd Rx
16980101 Chemical 10/1/2003 Statim Must
16980101 Chemical 6/2/1995 7/31/1999 NotCombined
16980201 Chemical 6/2/1995 7/31/1999 NotCombined
16980201 Chemical 10/1/2003 Statim Must
16980201 Chemical 5/16/1994 6/30/1997 FormReqd Rx
16980202 Chemical 5/16/1994 6/30/1997 FormReqd Rx
16980202 Chemical 10/1/2003 Statim Must
16980202 Chemical 6/2/1995 7/31/1999 NotCombined
16980202 Brand 11/1/1999 6/30/2002 SoleSupply
16990101 Formulation 7/1/1996 9/30/2003 Statim May
16990101 Chemical 10/1/2003 Statim Must
16990102 Chemical 10/1/2003 Statim Must
16990102 Formulation 7/1/1996 9/30/2003 Statim May
16990102 Brand 8/1/1998 6/30/2001 SoleSupply
16990102 Brand 11/1/2003 6/30/2006 SoleSupply
16990201 Formulation12/1/2011 OraProduct
16990201 Formulation 7/1/1996 9/30/2003 Statim May
16990201 Chemical 10/1/2003 Statim Must
16990202 Chemical 10/1/2003 Statim Must
16990202 Formulation 7/1/1996 9/30/2003 Statim May
16990202 Formulation12/1/2011 OraProduct
16990202 Brand 8/1/1998 6/30/2001 SoleSupply
16990202 Brand 11/1/2003 6/30/2006 SoleSupply
16990301 Brand 8/1/1998 6/30/2001 SoleSupply
16990301 Brand 11/1/2003 6/30/2006 SoleSupply
16990301 Formulation 7/1/1996 9/30/2003 Statim May
16990301 Chemical 10/1/2003 Statim Must
16990302 Chemical 10/1/2003 Statim Must
16990302 Formulation 7/1/1996 9/30/2003 Statim May
16990303 Formulation 7/1/1996 9/30/2003 Statim May
16990303 Chemical 10/1/2003 Statim Must
16990401 Chemical 10/1/2003 Statim Must
16990401 Formulation 7/1/1996 9/30/2003 Statim May
16990402 Formulation 7/1/1996 9/30/2003 Statim May
16990402 Chemical 10/1/2003 Statim Must
16990403 Chemical 10/1/2003 Statim Must
16990403 Formulation 7/1/1996 9/30/2003 Statim May
16990403 Brand 5/1/1998 6/30/2001 SoleSupply
16990403 Brand 11/1/2003 6/30/2006 SoleSupply
16990501 Chemical 10/1/2003 Statim Must
16992525 Chemical 10/1/2003 Statim Must
16992525 Brand 10/1/2005 S29
16992525 Brand 4/1/2013 Wastage
17150101 Chemical 4/1/2008 Special
17150101 Chemical 1/1/1999 7/31/2010 Dispensary HP3
17150101 Chemical 3/1/1997 3/31/2008 Special
17150101 Brand 10/1/2004 6/30/2007 SoleSupply
17150101 Brand 10/1/2007 6/30/2010 SoleSupply
17150101 Brand 12/1/2010 6/30/2013 SoleSupply
17150201 Brand 10/1/2004 6/30/2007 SoleSupply
17150201 Brand 10/1/2007 6/30/2010 SoleSupply
17150201 Brand 12/1/2010 6/30/2013 SoleSupply
17150201 Chemical 3/1/1997 3/31/2008 Special
17150201 Chemical 1/1/1999 7/31/2010 Dispensary HP3
17150201 Chemical 4/1/2008 Special
17160101 Chemical 10/1/2003 Statim Must
17160101 Chemical 5/16/1994 9/30/2007 SpecEnd Retail
17160101 Brand 12/1/2003 6/30/2006 SoleSupply
17160101 Brand 9/1/2007 6/30/2010 SoleSupply
17160101 Formulation11/1/1997 9/30/2003 Statim May
17160201 Formulation11/1/1997 9/30/2003 Statim May
13080101 Formulation11/1/1997 Safety Compounded
13080101 ATC3 7/1/2005 7/31/2007 Application
13080101 Formulation 7/1/1996 9/30/2003 Statim May
13090201 Chemical 10/1/2003 Statim Must
13090202 Chemical 10/1/2003 Statim Must
13090202 Brand 11/1/1999 6/30/2002 SoleSupply
13090202 Brand 11/1/2002 6/30/2005 SoleSupply
13090202 Brand 1/1/2006 6/30/2008 SoleSupply
13090202 Brand 1/1/2010 6/30/2012 SoleSupply
13090301 Brand 12/1/2000 6/30/2003 SoleSupply
13090301 Brand 10/1/2003 6/30/2006 SoleSupply
13090301 Brand 1/1/2007 6/30/2009 SoleSupply
13090301 Brand 1/1/2010 6/30/2012 SoleSupply
13090301 Chemical 10/1/2003 Statim Must
13090302 Chemical 10/1/2003 Statim Must
13090401 Chemical 10/1/2003 Statim Must
13090401 Brand 12/1/2000 6/30/2003 SoleSupply
13090401 Brand 1/1/2006 6/30/2008 SoleSupply
13090401 Brand 1/1/2010 6/30/2012 SoleSupply
13090402 Chemical 10/1/2003 Statim Must
13120101 Chemical 10/1/2003 Statim Must
13120101 Chemical 4/1/2013 SpecEnd Retail
13120101 Brand 4/1/2013 S29
13120101 Brand 4/1/2013 Wastage
13120101 Chemical 5/16/1994 MaxCoPayment 0
13130101 Chemical 10/1/1996 Special
13130101 Chemical 6/1/1995 9/30/1996 SpecEnd Retail
13140101 Chemical 5/16/1994 6/30/2010 SpecEnd Retail
13140102 Chemical 5/16/1994 6/30/2010 SpecEnd Retail
13140102 Brand 11/1/1999 6/30/2002 SoleSupply
13140102 Brand 9/1/2003 6/30/2006 SoleSupply
13140103 Brand 10/1/2013 6/30/2016 SoleSupply
13140103 Chemical 5/16/1994 6/30/2010 SpecEnd Retail
13150101 Chemical 5/16/1994 3/31/2008 SpecEnd Retail
13150101 Chemical 8/1/2012 SafetyListMedicine
13150101 Brand 7/1/1999 6/30/2002 SoleSupply
13150125 Brand 2/1/2003 6/30/2005 SoleSupply
13150125 Chemical 8/1/2012 SafetyListMedicine
13150125 Chemical 5/16/1994 3/31/2008 SpecEnd Retail
13150126 Chemical 5/16/1994 3/31/2008 SpecEnd Retail
13150126 Chemical 8/1/2012 SafetyListMedicine
13150126 Brand 2/1/2013 6/30/2015 SoleSupply
13150201 Chemical 8/1/2012 SafetyListMedicine
13150201 Chemical 5/16/1994 3/31/2008 SpecEnd Retail
13150202 Chemical 5/16/1994 3/31/2008 SpecEnd Retail
13150202 Chemical 8/1/2012 SafetyListMedicine
13150202 Brand 12/1/2000 6/30/2003 SoleSupply
13150202 Brand 10/1/2003 6/30/2006 SoleSupply
13150225 Brand 2/1/2013 6/30/2015 SoleSupply
13150225 Chemical 8/1/2012 SafetyListMedicine
13150225 Chemical 5/16/1994 3/31/2008 SpecEnd Retail
13160101 Chemical 8/1/2012 SafetyListMedicine
13160101 Formulation 7/1/1996 9/30/2003 Statim May
13160125 Formulation 7/1/1996 9/30/2003 Statim May
13160125 Brand 6/1/2003 6/30/2005 SoleSupply
13160125 Brand 10/1/2005 6/30/2008 SoleSupply
13160125 Brand 1/1/2009 6/30/2011 SoleSupply
13160125 Chemical 8/1/2012 SafetyListMedicine
13160201 Chemical 8/1/2012 SafetyListMedicine
13160201 Formulation 7/1/1996 9/30/2003 Statim May
13160225 Formulation 7/1/1996 9/30/2003 Statim May
13160225 Brand 6/1/2003 6/30/2005 SoleSupply
13160225 Brand 10/1/2005 6/30/2008 SoleSupply
13160225 Brand 1/1/2009 6/30/2011 SoleSupply
13160225 Chemical 8/1/2012 SafetyListMedicine
13160301 Chemical 8/1/2012 SafetyListMedicine
13160301 ATC3 8/1/2003 6/30/2005 Application
13160301 Formulation 7/1/1996 Safety Uncompounded
13160301 ATC3 7/1/2005 7/31/2007 Application
13160301 Formulation 7/1/1996 9/30/2003 Statim May
13160401 Brand 10/1/2003 6/30/2006 SoleSupply
13160401 Chemical 8/1/2012 SafetyListMedicine
13170201 Chemical 10/1/2003 Statim Must
13170201 Formulation10/1/1999 FormReqd Rx
13170201 Formulation5/16/1994 9/30/1999 DoseWMax 1
13170201 Formulation5/16/1994 9/30/1999 FormReqd Rx
13170201 Brand 1/1/2006 6/30/2008 SoleSupply
13170201 Brand 1/1/2010 6/30/2012 SoleSupply
13170201 Brand 8/1/2014 6/30/2017 SoleSupply
13170301 Formulation5/16/1994 9/30/1999 FormReqd Rx
13170301 Brand 1/1/2006 6/30/2008 SoleSupply
13170301 Brand 1/1/2010 6/30/2012 SoleSupply
13170301 Brand 8/1/2014 6/30/2017 SoleSupply
13170301 Formulation5/16/1994 9/30/1999 DoseWMax 1
13170301 Formulation10/1/1999 FormReqd Rx
13170301 Chemical 10/1/2003 Statim Must
13170401 Chemical 10/1/2003 Statim Must
13170401 Formulation10/1/1999 FormReqd Rx
13170401 Formulation5/16/1994 9/30/1999 DoseWMax 1
13170401 Formulation5/16/1994 9/30/1999 FormReqd Rx
13170401 Brand 1/1/2006 6/30/2008 SoleSupply
13170401 Brand 1/1/2010 6/30/2012 SoleSupply
13170401 Brand 8/1/2014 6/30/2017 SoleSupply
13180101 Brand 11/1/2002 6/30/2005 SoleSupply
13180101 Brand 1/1/2006 6/30/2008 SoleSupply
13180101 Brand 1/1/2010 6/30/2012 SoleSupply
13180101 Brand 3/1/2013 6/30/2015 SoleSupply
13180101 Chemical 10/1/2003 Statim Must
13180501 Chemical 10/1/2003 Statim Must
13180501 Brand 1/1/2006 6/30/2008 SoleSupply
13180501 Brand 1/1/2010 6/30/2012 SoleSupply
13180501 Brand 12/1/2012 6/30/2015 SoleSupply
13180801 Brand 11/1/2002 6/30/2005 SoleSupply
13180801 Brand 1/1/2006 6/30/2008 SoleSupply
13180801 Brand 1/1/2010 6/30/2012 SoleSupply
13180801 Chemical 10/1/2003 Statim Must
13180825 Chemical 10/1/2003 Statim Must
13180825 Brand 10/1/2013 6/30/2015 SoleSupply
13200101 Chemical 10/1/2003 Statim Must
13200101 Formulation5/16/1994 2/28/2001 FormMax 12 PSO
13200102 Formulation5/16/1994 2/28/2001 FormMax 12 PSO
13200102 Chemical 10/1/2003 Statim Must
13200103 Chemical 10/1/2003 Statim Must
13200103 Formulation5/16/1994 2/28/2001 FormMax 12 PSO
13200125 Formulation5/16/1994 2/28/2001 FormMax 12 PSO
13200125 Chemical 10/1/2003 Statim Must
13200125 Brand 1/1/2002 6/30/2004 SoleSupply
13200201 Chemical 10/1/2003 Statim Must
13200225 Chemical 10/1/2003 Statim Must
13200225 Brand 1/1/2002 6/30/2004 SoleSupply
13200301 Chemical 10/1/2003 Statim Must
13200302 Chemical 10/1/2003 Statim Must
13200302 Brand 12/1/2001 6/30/2004 SoleSupply
13200303 Chemical 10/1/2003 Statim Must
13200304 Chemical 10/1/2003 Statim Must
13200325 Chemical 10/1/2003 Statim Must
17160201 Brand 5/1/2004 6/30/2006 SoleSupply
17160201 Brand 9/1/2007 6/30/2010 SoleSupply
17160201 Chemical 5/16/1994 9/30/2007 SpecEnd Retail
17160201 Chemical 10/1/2003 Statim Must
17160225 Chemical 10/1/2003 Statim Must
17160225 Chemical 5/16/1994 9/30/2007 SpecEnd Retail
17160225 Brand 2/1/2001 6/30/2002 SoleSupply
17160225 Formulation11/1/1997 9/30/2003 Statim May
17170201 Formulation 7/1/1996 9/30/2003 Statim May
17170201 Brand 10/1/2003 6/30/2006 SoleSupply
17170201 Brand 11/1/2006 6/30/2009 SoleSupply
17170201 Chemical 10/1/2003 Statim Must
17170601 Chemical 10/1/2003 Statim Must
17170601 Brand 10/1/2003 6/30/2006 SoleSupply
17170601 Brand 11/1/2006 6/30/2009 SoleSupply
17170601 Formulation 7/1/1996 9/30/2003 Statim May
17170701 Formulation 7/1/1996 9/30/2003 Statim May
17170701 Brand 10/1/2003 6/30/2006 SoleSupply
17170701 Brand 11/1/2006 6/30/2009 SoleSupply
17170701 Chemical 10/1/2003 Statim Must
17170701 Formulation 7/1/1996 3/31/2008 SpecEnd Retail
17170801 Chemical 10/1/2003 Statim Must
17170801 Brand 10/1/2003 6/30/2006 SoleSupply
17170801 Brand 11/1/2006 6/30/2009 SoleSupply
17170801 Formulation10/4/1997 9/30/2003 Statim May
17170901 Formulation10/4/1997 9/30/2003 Statim May
17170901 Brand 10/1/2003 6/30/2006 SoleSupply
17170901 Brand 11/1/2006 6/30/2009 SoleSupply
17170901 Chemical 10/1/2003 Statim Must
17180201 Chemical 8/1/2004 Statim Must
17180201 Formulation 7/1/1996 FormMax 63 PSO
17180201 ATC2 1/1/2013 MaxCoPayment 5
17180201 Formulation 7/1/1996 Contraceptive
17180201 ATC2 5/16/1994 ######## MaxCoPayment 3
17180201 ATC3 11/1/1999 AltSubSA
17180201 ATC3 8/1/1995 ######## SpecialWav
17180301 ATC3 8/1/1995 ######## SpecialWav
17180301 ATC3 11/1/1999 AltSubSA
17180301 ATC2 5/16/1994 ######## MaxCoPayment 3
17180301 Formulation 7/1/1996 Contraceptive
17180301 ATC2 1/1/2013 MaxCoPayment 5
17180301 Formulation 7/1/1996 5/31/1998 FormMax 63 PSO
17180301 Chemical 8/1/2004 Statim Must
17180401 Chemical 8/1/2004 Statim Must
17180401 Formulation 7/1/1996 FormMax 84 PSO
17180401 ATC2 1/1/2013 MaxCoPayment 5
17180401 Formulation 7/1/1996 Contraceptive
17180401 ATC2 5/16/1994 ######## MaxCoPayment 3
17180401 ATC3 11/1/1999 AltSubSA
17180401 ATC3 8/1/1995 ######## SpecialWav
17180501 ATC3 8/1/1995 ######## SpecialWav
17180501 ATC3 11/1/1999 AltSubSA
17180501 ATC2 5/16/1994 ######## MaxCoPayment 3
17180501 Formulation 7/1/1996 Contraceptive
17180501 ATC2 1/1/2013 MaxCoPayment 5
17180501 Formulation 7/1/1996 FormMax 84 PSO
17180501 Chemical 8/1/2004 Statim Must
17180502 Chemical 8/1/2004 Statim Must
17180502 Formulation 7/1/1996 FormMax 84 PSO
17180502 ATC2 1/1/2013 MaxCoPayment 5
17180502 Formulation 7/1/1996 Contraceptive
17180502 ATC2 5/16/1994 ######## MaxCoPayment 3
17180502 ATC3 11/1/1999 AltSubSA
17180502 ATC3 8/1/1995 ######## SpecialWav
17180503 ATC3 8/1/1995 ######## SpecialWav
17180503 ATC3 11/1/1999 AltSubSA
17180503 ATC2 5/16/1994 ######## MaxCoPayment 3
17180503 Formulation 7/1/1996 Contraceptive
17180503 ATC2 1/1/2013 MaxCoPayment 5
17180503 Formulation 7/1/1996 FormMax 84 PSO
17180503 Chemical 8/1/2004 Statim Must
17180601 Chemical 8/1/2004 Statim Must
17180601 ATC2 1/1/2013 MaxCoPayment 5
17180601 Formulation 7/1/1996 FormMax 63 PSO
17180601 Formulation 7/1/1996 Contraceptive
17180601 ATC2 5/16/1994 ######## MaxCoPayment 3
17180601 ATC3 11/1/1999 AltSubSA
17180601 ATC3 8/1/1995 ######## SpecialWav
17180701 ATC3 8/1/1995 ######## SpecialWav
17180701 ATC3 11/1/1999 AltSubSA
17180701 ATC2 5/16/1994 ######## MaxCoPayment 3
17180701 Formulation 7/1/1996 Contraceptive
17180701 ATC2 1/1/2013 MaxCoPayment 5
17180701 Chemical 8/1/2004 Statim Must
17180701 Formulation 7/1/1996 FormMax 84 PSO
17180801 Chemical 8/1/2004 Statim Must
17180801 ATC2 1/1/2013 MaxCoPayment 5
17180801 Formulation 7/1/1996 FormMax 63 PSO
17180801 Formulation 7/1/1996 Contraceptive
17180801 ATC2 5/16/1994 ######## MaxCoPayment 3
17180801 ATC3 11/1/1999 AltSubSA
17180801 ATC3 8/1/1995 ######## SpecialWav
17180802 ATC3 8/1/1995 ######## SpecialWav
17180802 ATC3 11/1/1999 AltSubSA
17180802 ATC2 5/16/1994 ######## MaxCoPayment 3
17180802 Formulation 7/1/1996 Contraceptive
17180802 Formulation 7/1/1996 FormMax 63 PSO
17180802 ATC2 1/1/2013 MaxCoPayment 5
17180802 Chemical 8/1/2004 Statim Must
17180901 Chemical 8/1/2004 Statim Must
17180901 Formulation 7/1/1996 FormMax 84 PSO
17180901 ATC2 1/1/2013 MaxCoPayment 5
17180901 Formulation 9/1/2012 2/28/2013 Brandswitch 2405865 BSF Ava 30 ED
17180901 Formulation 7/1/1996 Contraceptive
17180901 ATC2 5/16/1994 ######## MaxCoPayment 3
17180901 ATC3 11/1/1999 AltSubSA
17180901 ATC3 8/1/1995 ######## SpecialWav
17180902 ATC3 8/1/1995 ######## SpecialWav
17180902 ATC3 11/1/1999 AltSubSA
17180902 ATC2 5/16/1994 ######## MaxCoPayment 3
17180902 Formulation 7/1/1996 Contraceptive
17180902 Formulation 9/1/2012 2/28/2013 Brandswitch 2405865 BSF Ava 30 ED
17180902 ATC2 1/1/2013 MaxCoPayment 5
17180902 Formulation 7/1/1996 FormMax 84 PSO
17180902 Chemical 8/1/2004 Statim Must
17180903 Chemical 8/1/2004 Statim Must
17180903 Formulation 7/1/1996 FormMax 84 PSO
17180903 ATC2 1/1/2013 MaxCoPayment 5
17180903 Formulation 9/1/2012 2/28/2013 Brandswitch 2405865 BSF Ava 30 ED
17180903 Formulation 7/1/1996 Contraceptive
17180903 ATC2 5/16/1994 ######## MaxCoPayment 3
17180903 ATC3 11/1/1999 AltSubSA
17180903 ATC3 8/1/1995 ######## SpecialWav
17180904 ATC3 8/1/1995 ######## SpecialWav
17180904 ATC3 11/1/1999 AltSubSA
17180904 ATC2 5/16/1994 ######## MaxCoPayment 3
17180904 Formulation 7/1/1996 Contraceptive
10112527 Chemical 2/1/1999 8/31/2008 SpecEnd Retail
10112528 Chemical 2/1/1999 8/31/2008 SpecEnd Retail
10112528 Chemical 9/1/2008 Application
10112528 Chemical 8/1/2012 SafetyListMedicine
10112625 Chemical 8/1/2012 SafetyListMedicine
10112625 Chemical 10/1/2005 8/31/2008 Special
10112625 Chemical 9/1/2008 4/30/2014 Special
10112625 Chemical 5/1/2014 Special
10112725 Chemical 5/1/2014 Special
10112725 Chemical 9/1/2008 4/30/2014 Special
10112725 Chemical 10/1/2005 8/31/2008 Special
10112725 Chemical 8/1/2012 SafetyListMedicine
10112825 Chemical 8/1/2012 SafetyListMedicine
10112825 Chemical 10/1/2005 8/31/2008 Special
10112825 Chemical 9/1/2008 4/30/2014 Special
10112825 Chemical 5/1/2014 Special
10112925 Chemical 9/1/2008 Application
10112925 Chemical 2/1/1999 8/31/2008 SpecEnd Retail
10112925 Chemical 8/1/2012 SafetyListMedicine
10112925 Formulation 9/1/2013 Special Claim only
10113025 Formulation 9/1/2013 Special Claim only
10113025 Chemical 8/1/2012 SafetyListMedicine
10113025 Chemical 2/1/1999 8/31/2008 SpecEnd Retail
10113025 Chemical 9/1/2008 Application
10113125 Chemical 9/1/2008 Application
10113125 Chemical 2/1/1999 8/31/2008 SpecEnd Retail
10113125 Chemical 8/1/2012 SafetyListMedicine
10113125 Formulation 9/1/2013 Special Claim only
10120101 Chemical 11/1/2008 Special
10120101 Brand 10/1/2006 6/30/2009 SoleSupply
10120101 Chemical 1/1/1999 7/31/2010 Dispensary HP3
10120101 Chemical 10/1/1997 ######## Special
10120201 Chemical 10/1/1997 ######## Special
10120201 Chemical 1/1/1999 7/31/2010 Dispensary HP3
10120201 Brand 10/1/2006 6/30/2009 SoleSupply
10120201 Chemical 11/1/2008 Special
10130301 Chemical 10/1/2003 Statim Must
10150101 Formulation5/16/1994 FormMax 5 PSO
10150102 Formulation5/16/1994 FormMax 5 PSO
10150125 Formulation5/16/1994 FormMax 5 PSO
10150201 Formulation5/16/1994 FormMax 5 PSO
10150225 Formulation5/16/1994 FormMax 5 PSO
10150301 ATC3 7/1/2013 Special
10150301 Formulation5/16/1994 ######## Special
10160101 Chemical 6/3/1995 6/30/1997 SpecEnd Retail
10160201 Chemical 6/3/1995 6/30/1997 SpecEnd Retail
10170101 Chemical 5/16/1994 6/30/1999 SpecEnd Retail
10170101 Formulation11/1/1997 6/30/1999 Statim May
10200101 Brand 10/1/2003 6/30/2006 SoleSupply
10200101 Chemical 5/16/1994 6/30/2008 SpecEnd Retail
10200101 Chemical 6/1/2012 Statim Must
10200201 Chemical 6/1/2012 Statim Must
10200201 Chemical 5/16/1994 6/30/2008 SpecEnd Retail
10200201 Brand 10/1/2003 6/30/2006 SoleSupply
10200301 Brand 10/1/2003 6/30/2006 SoleSupply
10200301 Chemical 5/16/1994 6/30/2008 SpecEnd Retail
10200301 Chemical 6/1/2012 Statim Must
10220101 Chemical 10/1/1995 ######## Special
10220101 Chemical 10/1/2003 Statim Must
10220101 Chemical 9/1/1998 ######## Special
10220101 Chemical 1/1/1998 8/31/1998 Special
10220125 Chemical 1/1/1998 8/31/1998 Special
10220125 Brand 4/1/2013 6/30/2015 SoleSupply
10220125 Chemical 9/1/1998 ######## Special
10220125 Chemical 10/1/2003 Statim Must
10220125 Chemical 10/1/1995 ######## Special
10220126 Chemical 10/1/1995 ######## Special
10220126 Chemical 10/1/2003 Statim Must
10220126 Chemical 9/1/1998 ######## Special
10220126 Chemical 1/1/1998 8/31/1998 Special
10222525 Chemical 1/1/1998 8/31/1998 Special
10222525 Brand 4/1/2013 6/30/2015 SoleSupply
10222525 Chemical 9/1/1998 ######## Special
10222525 Chemical 10/1/1995 ######## Special
10222525 Chemical 10/1/2003 Statim Must
10222526 Chemical 10/1/2003 Statim Must
10222526 Chemical 10/1/1995 ######## Special
10222526 Chemical 9/1/1998 ######## Special
10222526 Chemical 1/1/1998 8/31/1998 Special
10240101 Chemical 11/1/1997 Statim May
10240101 Chemical 12/1/1996 8/31/2006 SpecOnly Retail
10240101 Brand 12/1/2002 6/30/2005 SoleSupply
10240101 Brand 11/1/2006 6/30/2009 SoleSupply
10240101 Chemical 12/1/1996 8/31/2006 Special
10240101 Chemical 9/1/2006 7/31/2007 SpecEnd Hospital
10240101 Chemical 1/1/1999 7/31/2007 Dispensary HP3
10242525 Chemical 1/1/1999 7/31/2007 Dispensary HP3
10242525 Brand 3/1/2008 S29
10242525 Brand 4/1/2013 Wastage
10242525 Chemical 9/1/2006 7/31/2007 SpecEnd Hospital
10242525 Chemical 12/1/1996 8/31/2006 Special
10242525 Chemical 12/1/1996 8/31/2006 SpecOnly Retail
10242525 Chemical 11/1/1997 Statim May
10242526 Chemical 11/1/1997 Statim May
10242526 Chemical 12/1/1996 8/31/2006 SpecOnly Retail
10242526 Chemical 12/1/1996 8/31/2006 Special
10242526 Chemical 9/1/2006 7/31/2007 SpecEnd Hospital
10242526 Chemical 1/1/1999 7/31/2007 Dispensary HP3
10260101 Chemical 10/1/2003 Statim Must
10260101 Brand 12/1/2000 6/30/2003 SoleSupply
10260101 Brand 3/1/2006 6/30/2008 SoleSupply
10260102 Chemical 10/1/2003 Statim Must
10260103 Chemical 10/1/2003 Statim Must
10260104 Chemical 10/1/2003 Statim Must
10260104 Brand 6/1/2009 6/30/2011 SoleSupply
10260104 Brand 3/1/2012 6/30/2014 SoleSupply
10260125 Brand 7/1/2004 ######## SoleSupply
10260125 Chemical 10/1/2003 Statim Must
10260201 Chemical 10/1/2003 Statim Must
10260201 Formulation12/1/2011 OraProduct
10260202 Formulation12/1/2011 OraProduct
10260202 Brand 6/1/2009 6/30/2011 SoleSupply
10260202 Brand 3/1/2012 6/30/2014 SoleSupply
10260202 Chemical 10/1/2003 Statim Must
10260203 Chemical 10/1/2003 Statim Must
10260203 Brand 12/1/2000 6/30/2003 SoleSupply
10260203 Brand 3/1/2006 6/30/2008 SoleSupply
10260203 Formulation12/1/2011 OraProduct
10260205 Formulation12/1/2011 OraProduct
10260205 Chemical 10/1/2003 Statim Must
10260225 Chemical 10/1/2003 Statim Must
10260225 Formulation12/1/2011 OraProduct
10260225 Brand 7/1/2004 6/30/2006 SoleSupply
10260226 Formulation12/1/2011 OraProduct
10260226 Chemical 10/1/2003 Statim Must
10260226 Brand 5/9/2011 S29
13690101 Formulation 3/1/2007 SpecEnd Retail
13690101 Formulation 7/1/2005 PCT
13690101 Brand 12/1/2002 6/30/2005 SoleSupply
13690101 Brand 9/1/2007 6/30/2010 SoleSupply
13690101 Brand 10/1/2010 6/30/2013 SoleSupply
13690125 Formulation 7/1/2005 PCT
13690125 Formulation 3/1/2007 SpecEnd Retail
13690125 Chemical 5/16/1994 2/28/2007 SpecEnd Retail
13690125 Brand 10/1/2013 S29
13690125 Formulation10/1/2013 Wastage
13690126 Formulation10/1/2013 Wastage
13690126 Brand 3/1/2014 S29
13690126 Chemical 5/16/1994 2/28/2007 SpecEnd Retail
13690126 Formulation 3/1/2007 SpecEnd Retail
13690126 Formulation 7/1/2005 PCT
13690201 Formulation 3/1/2007 PCT
13690201 Brand 7/1/2005 2/28/2007 PCT
13690201 Formulation 3/1/2007 SpecEnd Retail
13690201 Brand 7/1/2005 2/28/2007 SpecEnd Retail
13690201 Chemical 5/16/1994 2/28/2007 SpecEnd Retail
13690202 Chemical 5/16/1994 2/28/2007 SpecEnd Retail
13690202 Formulation 3/1/2007 SpecEnd Retail
13690202 Formulation 3/1/2007 PCT
13690225 Formulation 3/1/2007 PCT
13690225 Brand 7/1/2005 2/28/2007 PCT only
13690225 Formulation 3/1/2007 SpecEnd Retail
13690225 Brand 7/1/2005 2/28/2007 SpecEnd Hospital
13690225 Chemical 5/16/1994 2/28/2007 SpecEnd Retail
13690301 Chemical 5/16/1994 2/28/2007 SpecEnd Retail
13690401 Chemical 5/16/1994 2/28/2007 SpecEnd Retail
13690402 Chemical 5/16/1994 2/28/2007 SpecEnd Retail
13692525 Chemical 5/16/1994 2/28/2007 SpecEnd Retail
13692525 Formulation 7/1/2005 SpecEnd Hospital
13692525 Formulation 7/1/2005 PCT only
13692625 Formulation12/1/2005 PCT only
13692625 Formulation 3/1/2007 SpecEnd Hospital
13692625 Chemical 5/16/1994 2/28/2007 SpecEnd Retail
13692626 Chemical 5/16/1994 2/28/2007 SpecEnd Retail
13692626 Formulation 3/1/2007 SpecEnd Hospital
13692626 Formulation12/1/2005 PCT only
13700101 Chemical 10/1/2003 Statim Must
13710101 Formulation 7/1/2005 SpecEnd Retail
13710101 Formulation 7/1/2005 PCT
13710102 Formulation 7/1/2005 PCT
13710102 Formulation 7/1/2005 SpecEnd Retail
13710103 Formulation 7/1/2005 SpecEnd Retail
13710103 Formulation 7/1/2005 PCT
13710201 Formulation 7/1/2005 PCT
13710201 Formulation 7/1/2005 SpecEnd Retail
13710202 Formulation 7/1/2005 SpecEnd Retail
13710202 Formulation 7/1/2005 PCT
13710225 Formulation 7/1/2005 PCT
13710225 Formulation 7/1/2005 SpecEnd Retail
13710226 Formulation 7/1/2005 SpecEnd Retail
13710226 Formulation 7/1/2005 PCT
13710301 Formulation 7/1/2005 PCT
13710301 Formulation 7/1/2005 SpecEnd Retail
13710302 Formulation 7/1/2005 SpecEnd Retail
13710302 Formulation 7/1/2005 PCT
13710325 Formulation 7/1/2005 PCT
13710325 Formulation 7/1/2005 SpecEnd Retail
13710326 Formulation 7/1/2005 SpecEnd Retail
13710326 Formulation 7/1/2005 PCT
13710401 Formulation 7/1/2005 PCT
13710401 Formulation 7/1/2005 SpecEnd Retail
13710402 Formulation 7/1/2005 SpecEnd Retail
13710402 Formulation 7/1/2005 PCT
13710425 Formulation 7/1/2005 PCT
13710425 Formulation 7/1/2005 SpecEnd Retail
13712625 Formulation12/1/2005 SpecEnd Hospital
13712625 Formulation12/1/2005 PCT only
13712626 Formulation12/1/2005 PCT only
13712626 Formulation12/1/2005 SpecEnd Hospital
13712725 Formulation12/1/2005 SpecEnd Hospital
13712725 Formulation12/1/2005 PCT only
13712726 Formulation12/1/2005 PCT only
13712726 Formulation12/1/2005 SpecEnd Hospital
13720101 Chemical 5/16/1994 6/30/2013 SpecEnd Retail
13720102 Chemical 5/16/1994 6/30/2013 SpecEnd Retail
13720102 Brand 1/1/2003 6/30/2005 SoleSupply
13720125 Chemical 5/16/1994 6/30/2013 SpecEnd Retail
13720201 Chemical 5/16/1994 6/30/2013 SpecEnd Retail
13720202 Chemical 5/16/1994 6/30/2013 SpecEnd Retail
13720202 Brand 1/1/2003 6/30/2005 SoleSupply
13720225 Chemical 5/16/1994 6/30/2013 SpecEnd Retail
13730101 Chemical 5/16/1994 2/28/2009 SpecEnd Retail
13730101 Chemical 10/1/2003 Statim Must
13730101 Brand 10/1/2006 6/30/2009 SoleSupply
13730201 Brand 10/1/2006 6/30/2009 SoleSupply
13730201 Chemical 10/1/2003 Statim Must
13730201 Chemical 5/16/1994 2/28/2009 SpecEnd Retail
13740101 Brand 7/1/2010 ######## S29
13740101 Chemical 4/1/2013 SpecEnd Retail
13740101 Chemical 5/16/1994 MaxCoPayment 0
13742525 Chemical 5/16/1994 MaxCoPayment 0
13742525 Chemical 4/1/2013 SpecEnd Retail
13742525 Brand 7/1/2010 ######## S29
13780101 Chemical 1/1/1999 7/31/2010 Dispensary HP3
13780101 Chemical 10/1/2003 Statim Must
13780101 Brand 12/1/2001 6/30/2004 SoleSupply
13780102 Brand 12/1/2004 6/30/2007 SoleSupply
13780102 Brand 10/1/2007 6/30/2010 SoleSupply
13780102 Chemical 10/1/2003 Statim Must
13780102 Chemical 1/1/1999 7/31/2010 Dispensary HP3
13790101 Chemical 1/1/1999 Dispensary HP3
13810101 Formulation5/16/1994 1/31/1998 SpecEnd Retail
13810201 Formulation 6/3/1995 1/31/1998 SpecEnd Retail
13830101 Chemical 6/29/1995 9/30/2007 SpecEnd Retail
13830101 Formulation10/1/2007 SpecEnd Retail
13830101 Chemical 10/1/2003 ######## Statim Must
13830101 Formulation 2/1/2001 FormMax 30 PSO
13830101 Formulation 1/1/2005 Statim Must
13830101 Brand 9/1/2012 6/30/2015 SoleSupply
13830101 Formulation 2/1/2001 9/30/2003 Statim May
13830201 Formulation 2/1/2001 9/30/2003 Statim May
13830201 Brand 9/1/2012 6/30/2015 SoleSupply
13830201 Formulation 2/1/2001 FormMax 30 PSO
13830201 Formulation 1/1/2005 Statim Must
13830201 Chemical 10/1/2003 ######## Statim Must
13830201 Formulation10/1/2007 SpecEnd Retail
13830201 Chemical 6/29/1995 9/30/2007 SpecEnd Retail
13830301 Chemical 6/29/1995 9/30/2007 SpecEnd Retail
13830301 Chemical 10/1/2003 ######## Statim Must
10430101 Chemical 7/1/2013 Special
10430101 Formulation 7/1/1996 3/31/1999 FormMax 42 Rx
10430101 Brand 12/1/2006 2/28/2007 S29
10430101 Chemical 7/1/2009 6/30/2013 Special
10430101 ATC3 9/1/1996 ######## Application
10480101 Brand 10/1/2003 6/30/2006 SoleSupply
10480101 Brand 11/1/2008 6/30/2011 SoleSupply
10480101 Brand 10/1/2011 6/30/2014 SoleSupply
10480101 Chemical 7/1/1996 Statim May
10480101 Chemical 5/16/1994 7/31/2007 SpecEnd Retail
10500101 Formulation 7/1/2013 Statim Must
10500101 Chemical 10/1/2003 ######## Statim Must
10500125 Chemical 10/1/2003 ######## Statim Must
10500125 Formulation 7/1/2013 Statim Must
10500401 Chemical 10/1/2003 ######## Statim Must
10500401 Formulation 4/1/1996 ######## SpecEnd Retail
10500401 Formulation 3/1/1996 3/31/1996 SpecOnly Retail
10500401 Formulation 7/1/1996 Safety Uncompounded
10500401 Brand 1/1/2003 ######## SoleSupply
10510101 Chemical 10/1/2003 Statim Must
10530101 Chemical 10/1/2003 Statim Must
10530101 Brand 12/1/2000 6/30/2003 SoleSupply
10530101 Brand 10/1/2003 6/30/2006 SoleSupply
10530102 Chemical 10/1/2003 Statim Must
10530103 Chemical 10/1/2003 Statim Must
10530103 Brand 8/1/2010 8/31/2010 S29
10540101 Chemical 5/16/1994 7/31/1997 SpecEnd Hospital
10550101 Chemical 4/24/1995 SpecEnd Retail
10560101 Formulation5/16/1994 FormMax 5 PSO
10560101 Chemical 10/1/2003 Statim Must
10560101 Brand 12/1/2011 6/30/2014 SoleSupply
10560401 Formulation 7/1/1996 Safety Uncompounded
10560401 Formulation 3/1/1996 3/31/1996 SpecOnly Retail
10560401 Chemical 10/1/2003 Statim Must
10560401 Formulation 4/1/1996 SpecEnd Retail
10570101 Chemical 5/16/1994 4/30/2006 SpecEnd Retail
10570101 Formulation 5/1/2006 SpecEnd Retail
10570101 Formulation 7/1/1996 Statim May
10570102 Formulation 7/1/1996 Statim May
10570102 Formulation 5/1/2006 SpecEnd Retail
10570102 Chemical 5/16/1994 4/30/2006 SpecEnd Retail
10570201 Chemical 5/16/1994 4/30/2006 SpecEnd Retail
10570201 Formulation 5/1/2006 SpecEnd Retail
10570201 Formulation 7/1/1996 Statim May
10570202 Formulation 7/1/1996 Statim May
10570202 Formulation 5/1/2006 SpecEnd Retail
10570202 Chemical 5/16/1994 4/30/2006 SpecEnd Retail
10570301 Chemical 5/16/1994 4/30/2006 SpecEnd Retail
10570301 Formulation 5/1/2006 ######## FormMax 5 PSO
10570301 Formulation12/1/2012 FormMax 6 PSO
10570301 Brand 9/1/2013 6/30/2016 SoleSupply
10590101 Chemical 8/1/2012 SafetyListMedicine
10590103 Chemical 8/1/2012 SafetyListMedicine
10590103 Brand 11/1/1999 6/30/2002 SoleSupply
10590103 Brand 3/1/2003 6/30/2005 SoleSupply
10590103 Brand 1/1/2006 6/30/2008 SoleSupply
10590125 Chemical 8/1/2012 SafetyListMedicine
10590126 Chemical 8/1/2012 SafetyListMedicine
10590126 Brand 4/1/2013 6/30/2014 SoleSupply
10590201 Brand 11/1/1999 6/30/2002 SoleSupply
10590201 Brand 3/1/2003 6/30/2005 SoleSupply
10590201 Brand 1/1/2006 6/30/2008 SoleSupply
10590201 Brand 7/1/2011 6/30/2014 SoleSupply
10590201 Chemical 8/1/2012 SafetyListMedicine
10590203 Chemical 8/1/2012 SafetyListMedicine
10590301 Chemical 8/1/2012 SafetyListMedicine
10590301 Brand 11/1/1999 6/30/2002 SoleSupply
10590301 Brand 12/1/2002 6/30/2005 SoleSupply
10590301 Brand 1/1/2006 6/30/2008 SoleSupply
10590301 Brand 7/1/2011 6/30/2014 SoleSupply
10590303 Chemical 8/1/2012 SafetyListMedicine
10590401 Chemical 8/1/2012 SafetyListMedicine
10590501 Chemical 8/1/2012 SafetyListMedicine
10590501 Formulation 7/1/1996 Safety Uncompounded
10600101 ATC3 7/1/2005 7/31/2007 Application
10600101 Formulation12/1/2011 OraProduct
10600101 Chemical 8/1/2007 ######## Special
10600101 Chemical 8/1/2009 Special
10600101 Chemical 4/1/2001 Statim May
10600101 Chemical 8/1/2003 7/31/2007 Special Claim only
10600101 Chemical 11/1/2008 7/23/2009 Special
10600101 ATC3 8/1/2003 6/30/2005 Application
10600101 Chemical 1/1/2001 7/31/2003 Special
10600201 Chemical 1/1/2001 7/31/2003 Special
10600201 ATC3 8/1/2003 6/30/2005 Application
10600201 Chemical 11/1/2008 7/23/2009 Special
10600201 Chemical 8/1/2003 7/31/2007 Special Claim only
10600201 Chemical 4/1/2001 Statim May
10600201 Chemical 8/1/2009 Special
10600201 Chemical 8/1/2007 ######## Special
10600201 ATC3 7/1/2005 7/31/2007 Application
10602525 ATC3 7/1/2005 7/31/2007 Application
10602525 Chemical 8/1/2007 ######## Special
10602525 Chemical 8/1/2009 Special
10602525 Chemical 4/1/2001 Statim May
10602525 Chemical 8/1/2003 7/31/2007 Special Claim only
10602525 Chemical 11/1/2008 7/23/2009 Special
10602525 ATC3 8/1/2003 6/30/2005 Application
10602525 Chemical 1/1/2001 7/31/2003 Special
10602625 Chemical 1/1/2001 7/31/2003 Special
10602625 ATC3 8/1/2003 6/30/2005 Application
10602625 Chemical 11/1/2008 7/23/2009 Special
10602625 Chemical 8/1/2003 7/31/2007 Special Claim only
10602625 Chemical 4/1/2001 Statim May
10602625 Chemical 8/1/2009 Special
10602625 Chemical 8/1/2007 ######## Special
10602625 ATC3 7/1/2005 7/31/2007 Application
10610101 Chemical 4/1/2002 4/30/2004 Special
10610101 Formulation 5/1/2007 5/31/2008 Special
10610101 Chemical 3/1/2012 5/31/2012 Brandswitch 2397153 BSF Arrow-losartan & H...
10610101 Chemical 8/1/1999 3/31/2002 Special
10610101 Chemical 5/1/2004 4/30/2007 Special
10610101 Chemical 6/1/2008 ######## Special
10610101 Formulation10/1/2003 Statim Must
10610125 Formulation10/1/2003 Statim Must
10610125 Chemical 6/1/2008 ######## Special
10610125 Chemical 5/1/2004 4/30/2007 Special
10610125 Chemical 8/1/1999 3/31/2002 Special
10610125 Chemical 3/1/2012 5/31/2012 Brandswitch 2397153 BSF Arrow-losartan & H...
10610125 Brand 3/1/2012 6/30/2014 SoleSupply
10610125 Formulation 5/1/2007 5/31/2008 Special
10610125 Chemical 4/1/2002 4/30/2004 Special
10610201 Chemical 4/1/2002 4/30/2004 Special
10610201 Formulation 5/1/2007 5/31/2008 Special
17180904 Formulation 9/1/2012 2/28/2013 Brandswitch 2405865 BSF Ava 30 ED
17180904 ATC2 1/1/2013 MaxCoPayment 5
17180904 Formulation 7/1/1996 FormMax 84 PSO
17180904 Chemical 8/1/2004 Statim Must
17180925 Chemical 8/1/2004 Statim Must
17180925 Formulation 7/1/1996 FormMax 84 PSO
17180925 ATC2 1/1/2013 MaxCoPayment 5
17180925 Brand 9/1/2012 6/30/2014 SoleSupply
17180925 Formulation 9/1/2012 2/28/2013 Brandswitch 2405865 BSF Ava 30 ED
17180925 Formulation 7/1/1996 Contraceptive
17180925 ATC2 5/16/1994 ######## MaxCoPayment 3
17180925 ATC3 8/1/1995 ######## SpecialWav
17180925 ATC3 11/1/1999 AltSubSA
17181001 ATC2 5/16/1994 ######## MaxCoPayment 3
17181001 ATC3 11/1/1999 AltSubSA
17181001 ATC3 8/1/1995 ######## SpecialWav
17181001 Formulation 7/1/1996 Contraceptive
17181001 Formulation 7/1/1996 FormMax 63 PSO
17181001 ATC2 1/1/2013 MaxCoPayment 5
17181001 Chemical 8/1/2004 Statim Must
17181101 Chemical 8/1/2004 Statim Must
17181101 Formulation 7/1/1996 FormMax 84 PSO
17181101 ATC2 1/1/2013 MaxCoPayment 5
17181101 Formulation 7/1/1996 Contraceptive
17181101 ATC3 8/1/1995 ######## SpecialWav
17181101 ATC3 11/1/1999 AltSubSA
17181101 ATC2 5/16/1994 ######## MaxCoPayment 3
17181201 ATC2 5/16/1994 ######## MaxCoPayment 3
17181201 ATC3 11/1/1999 AltSubSA
17181201 ATC3 8/1/1995 ######## SpecialWav
17181201 Formulation10/1/1998 Contraceptive
17181201 ATC2 1/1/2013 MaxCoPayment 5
17181201 Formulation12/1/2012 5/30/2013 Brandswitch 2427958 BSF Ava 20 ED
17181201 Formulation10/1/1998 FormMax 84 PSO
17181201 Chemical 8/1/2004 Statim Must
17181202 Chemical 8/1/2004 Statim Must
17181202 Formulation10/1/1998 FormMax 84 PSO
17181202 Formulation12/1/2012 5/30/2013 Brandswitch 2427958 BSF Ava 20 ED
17181202 ATC2 1/1/2013 MaxCoPayment 5
17181202 Formulation10/1/1998 Contraceptive
17181202 ATC3 8/1/1995 ######## SpecialWav
17181202 ATC3 11/1/1999 AltSubSA
17181202 ATC2 5/16/1994 ######## MaxCoPayment 3
17181225 ATC3 11/1/1999 AltSubSA
17181225 ATC3 8/1/1995 ######## SpecialWav
17181225 ATC2 5/16/1994 ######## MaxCoPayment 3
17181225 Formulation10/1/1998 Contraceptive
17181225 ATC2 1/1/2013 MaxCoPayment 5
17181225 Brand 12/1/2012 6/30/2014 SoleSupply
17181225 Formulation12/1/2012 5/30/2013 Brandswitch 2427958 BSF Ava 20 ED
17181225 Formulation10/1/1998 FormMax 84 PSO
17181225 Chemical 8/1/2004 Statim Must
17190101 Formulation 7/1/1996 FormMax 5 PSO
17190101 Formulation 8/1/1996 FormReqd PSO
17190101 Formulation 8/1/1996 SubRxF
17190101 Chemical 5/16/1994 7/31/1996 FormReqd PSO
17190201 Chemical 5/16/1994 7/31/1996 FormReqd PSO
17190201 Formulation 4/1/2002 FormMax 6 PSO
17190201 Formulation 8/1/1996 SubRxF
17190201 Formulation 7/1/1996 3/31/2002 FormMax 5 PSO
17190201 Formulation 8/1/1996 FormReqd PSO
17190401 Formulation 7/1/1996 FormMax 5 PSO
17190401 Brand 11/1/2004 6/30/2007 SoleSupply
17190401 Brand 10/1/2007 6/30/2010 SoleSupply
17190401 Chemical 5/16/1994 7/31/1996 FormReqd PSO
17190401 Formulation 8/1/1996 3/31/2001 SubRxF
17190601 Formulation 8/1/1996 3/31/2001 SubRxF
17190601 Chemical 5/16/1994 7/31/1996 FormReqd PSO
17190601 Formulation 7/1/1996 FormMax 5 PSO
17190701 Formulation 7/1/1996 FormMax 5 PSO
17190701 Chemical 5/16/1994 7/31/1996 FormReqd PSO
17190701 Formulation 8/1/1996 3/31/2001 SubRxF
17190701 Brand 11/1/2004 6/30/2007 SoleSupply
17190701 Brand 10/1/2007 6/30/2010 SoleSupply
17190701 Brand 12/1/2010 6/30/2013 SoleSupply
17190725 Formulation 8/1/1996 3/31/2001 SubRxF
17190725 Chemical 5/16/1994 7/31/1996 FormReqd PSO
17190725 Formulation 7/1/1996 FormMax 5 PSO
17190801 Formulation 7/1/1996 FormMax 5 PSO
17190801 Chemical 5/16/1994 7/31/1996 FormReqd PSO
17190801 Formulation 8/1/1996 3/31/2001 SubRxF
17191001 Formulation 7/1/2013 FormMax 25 PSO
17191001 Chemical 5/16/1994 7/31/1996 FormReqd PSO
17191001 Brand 11/1/2004 6/30/2007 SoleSupply
17191001 Brand 10/1/2007 6/30/2010 SoleSupply
17191001 Brand 12/1/2010 6/30/2013 SoleSupply
17191001 Formulation11/1/2002 6/30/2013 FormMax 5 PSO
17191025 Formulation11/1/2002 6/30/2013 FormMax 5 PSO
17191025 Chemical 5/16/1994 7/31/1996 FormReqd PSO
17191025 Formulation 7/1/2013 FormMax 25 PSO
17192525 Chemical 5/16/1994 7/31/1996 FormReqd PSO
17192525 Formulation 9/1/2010 FormMax 5 PSO
17192526 Formulation 9/1/2010 FormMax 5 PSO
17192526 Chemical 5/16/1994 7/31/1996 FormReqd PSO
17192526 Brand 10/1/2013 6/30/2015 SoleSupply
17192625 Chemical 5/16/1994 7/31/1996 FormReqd PSO
17192625 Formulation 9/1/2010 FormMax 5 PSO
17192626 Formulation 9/1/2010 FormMax 5 PSO
17192626 Chemical 5/16/1994 7/31/1996 FormReqd PSO
17192626 Brand 10/1/2013 6/30/2015 SoleSupply
17192725 Brand 10/1/2011 6/30/2014 SoleSupply
17192725 Chemical 5/16/1994 7/31/1996 FormReqd PSO
17210101 Chemical 10/1/2003 Statim Must
17230101 Chemical 10/1/2003 Statim Must
17230101 Formulation 7/1/1996 9/30/2003 Statim May
17230101 Formulation12/1/2011 OraProduct
17230102 Formulation12/1/2011 OraProduct
17230102 Formulation 7/1/1996 9/30/2003 Statim May
17230102 Chemical 10/1/2003 Statim Must
17230201 Chemical 10/1/2003 Statim Must
17230201 Formulation 7/1/1996 9/30/2003 Statim May
17230301 Formulation 7/1/1996 9/30/2003 Statim May
17230301 Chemical 10/1/2003 Statim Must
17230301 Formulation 7/1/1996 9/30/2009 SpecEnd Retail
17240101 Formulation 7/1/1996 FormMax 84 PSO
17240101 Chemical 8/1/2004 Statim Must
17240101 Formulation 7/1/1996 Contraceptive
17240101 ATC3 11/1/1999 AltSubSA
17240101 ATC3 8/1/1995 ######## SpecialWav
17240101 ATC2 5/16/1994 ######## MaxCoPayment 3
17240101 ATC2 1/1/2013 MaxCoPayment 5
17240102 ATC2 1/1/2013 MaxCoPayment 5
17240102 ATC2 5/16/1994 ######## MaxCoPayment 3
17240102 ATC3 8/1/1995 ######## SpecialWav
17240102 ATC3 11/1/1999 AltSubSA
10660301 Formulation11/1/2005 7/31/2006 Special Claim only
10660301 ATC2 3/1/2000 7/31/2001 Special
10660301 ATC2 8/1/2001 ######## Application
10660301 ATC2 12/1/1996 2/29/2000 Special
10662525 ATC2 3/1/2000 7/31/2001 Special
10662525 ATC2 12/1/1996 2/29/2000 Special
10662525 ATC2 8/1/2001 ######## Application
10662525 ATC2 11/1/2005 7/31/2006 Application
10662525 Chemical 8/1/2001 ######## Special Claim only
10670101 Chemical 6/3/1995 SpecEnd Retail
10680525 Formulation 6/1/2008 6/30/2008 Statim Must
10680525 Formulation 5/1/2004 5/31/2008 Special
10680526 Formulation 5/1/2004 5/31/2008 Special
10680526 Formulation 6/1/2008 6/30/2008 Statim Must
10700101 Formulation5/16/1994 FormMax 30 PSO
10700101 Brand 6/1/2003 6/30/2005 SoleSupply
10700102 Formulation5/16/1994 FormMax 30 PSO
10700103 Formulation5/16/1994 FormMax 30 PSO
10700103 Brand 10/1/1999 6/30/2002 SoleSupply
10700103 Brand 8/1/2009 6/30/2011 SoleSupply
10700125 Brand 12/1/2012 6/30/2014 SoleSupply
10700125 Formulation5/16/1994 FormMax 30 PSO
10700201 Formulation 5/1/1994 Wastage
10700201 Formulation5/16/1994 FormMax 200 PSO
10700201 Brand 6/1/2003 6/30/2005 SoleSupply
10700201 Brand 2/1/2013 6/30/2015 SoleSupply
10700202 Formulation5/16/1994 FormMax 200 PSO
10700202 Formulation 5/1/1994 Wastage
10700203 Formulation 5/1/1994 Wastage
10700203 Formulation5/16/1994 FormMax 200 PSO
10700203 Brand 6/1/2000 6/30/2002 SoleSupply
10700225 Brand 4/1/2010 6/30/2012 SoleSupply
10700225 Formulation5/16/1994 FormMax 200 PSO
10700225 Formulation 5/1/1994 Wastage
10700301 Formulation 5/1/1994 Wastage
10700301 Formulation 2/1/2001 FormMax 200 PSO
10700301 Brand 6/1/2003 6/30/2005 SoleSupply
10700301 Brand 2/1/2013 6/30/2015 SoleSupply
10700302 Formulation 2/1/2001 FormMax 200 PSO
10700302 Formulation 5/1/1994 Wastage
10700303 Formulation 5/1/1994 Wastage
10700303 Formulation 2/1/2001 FormMax 200 PSO
10700303 Brand 6/1/2000 6/30/2002 SoleSupply
10700325 Brand 4/1/2010 6/30/2012 SoleSupply
10700325 Formulation 2/1/2001 FormMax 200 PSO
10700325 Formulation 5/1/1994 Wastage
10720201 Formulation5/16/1994 FormMax 30 PSO
10720201 Formulation12/1/2013 RFPP 10
10720202 Formulation12/1/2013 RFPP 10
10720202 Formulation5/16/1994 FormMax 30 PSO
10720204 Formulation5/16/1994 FormMax 30 PSO
10720204 Formulation12/1/2013 RFPP 10
10720205 Formulation12/1/2013 RFPP 10
10720205 Brand 2/1/2005 6/30/2007 SoleSupply
10720205 Brand 10/1/2007 6/30/2010 SoleSupply
10720205 Brand 6/1/2014 6/30/2016 SoleSupply
10720205 Formulation5/16/1994 FormMax 30 PSO
10720225 Formulation5/16/1994 FormMax 30 PSO
10720225 Brand 1/1/2001 6/30/2003 SoleSupply
10720225 Formulation12/1/2013 RFPP 10
10720226 Brand 3/1/2011 6/30/2013 SoleSupply
10720226 Formulation12/1/2013 RFPP 10
10720226 Formulation5/16/1994 FormMax 30 PSO
10720301 Formulation12/1/2013 FormMax 30 PSO
10720301 Formulation12/1/2013 RFPP 10
10720302 Formulation12/1/2013 RFPP 10
10720302 Formulation12/1/2013 FormMax 30 PSO
10720304 Formulation12/1/2013 FormMax 30 PSO
10720304 Formulation12/1/2013 RFPP 10
10720305 Formulation12/1/2013 RFPP 10
10720305 Brand 2/1/2005 6/30/2007 SoleSupply
10720305 Brand 10/1/2007 6/30/2010 SoleSupply
10720305 Formulation12/1/2013 FormMax 30 PSO
10720325 Formulation12/1/2013 FormMax 30 PSO
10720325 Brand 1/1/2001 6/30/2003 SoleSupply
10720325 Formulation12/1/2013 RFPP 10
10720326 Brand 3/1/2011 6/30/2013 SoleSupply
10720326 Formulation12/1/2013 RFPP 10
10720326 Formulation12/1/2013 FormMax 30 PSO
10720425 Brand 1/1/2003 6/30/2005 SoleSupply
10720425 Brand 4/1/2009 6/30/2011 SoleSupply
10720501 Formulation 5/1/1994 Wastage
10720501 Formulation5/16/1994 FormMax 200 PSO
10720502 Formulation5/16/1994 FormMax 200 PSO
10720502 Formulation 5/1/1994 Wastage
10720503 Formulation 5/1/1994 Wastage
10720503 Formulation5/16/1994 FormMax 200 PSO
10720525 Formulation5/16/1994 FormMax 200 PSO
10720525 Formulation 5/1/1994 Wastage
10720525 Brand 2/1/2001 6/30/2003 SoleSupply
10720525 Brand 12/1/2003 6/30/2006 SoleSupply
10720526 Brand 5/1/2007 6/30/2009 SoleSupply
10720526 Formulation 5/1/1994 Wastage
10720526 Formulation5/16/1994 FormMax 200 PSO
10720527 Formulation5/16/1994 FormMax 200 PSO
10720527 Formulation 5/1/1994 Wastage
10720601 Formulation 5/1/1994 Wastage
10720601 Formulation12/1/2013 FormMax 300 PSO
10720601 Formulation 2/1/2001 ######## FormMax 200 PSO
10720601 Formulation12/1/2013 RFPP 10
10720602 Formulation12/1/2013 RFPP 10
10720602 Formulation 2/1/2001 ######## FormMax 200 PSO
10720602 Formulation12/1/2013 FormMax 300 PSO
10720602 Formulation 5/1/1994 Wastage
10720603 Formulation 5/1/1994 Wastage
10720603 Formulation12/1/2013 FormMax 300 PSO
10720603 Formulation 2/1/2001 ######## FormMax 200 PSO
10720603 Formulation12/1/2013 RFPP 10
10720625 Formulation12/1/2013 RFPP 10
10720625 Brand 2/1/2001 6/30/2003 SoleSupply
10720625 Brand 12/1/2003 6/30/2006 SoleSupply
10720625 Brand 5/1/2010 6/30/2012 SoleSupply
10720625 Formulation 2/1/2001 ######## FormMax 200 PSO
10720625 Formulation12/1/2013 FormMax 300 PSO
10720625 Formulation 5/1/1994 Wastage
10720626 Formulation 5/1/1994 Wastage
10720626 Formulation 2/1/2001 ######## FormMax 200 PSO
10720626 Formulation12/1/2013 FormMax 300 PSO
10720626 Brand 5/1/2007 6/30/2009 SoleSupply
10720626 Formulation12/1/2013 RFPP 10
10720627 Formulation12/1/2013 RFPP 10
10720627 Formulation12/1/2013 FormMax 300 PSO
10720627 Formulation 2/1/2001 ######## FormMax 200 PSO
10720627 Formulation 5/1/1994 Wastage
10720801 Formulation5/26/1995 FormMax 5 PSO
10720801 Brand 1/1/2003 6/30/2005 SoleSupply
10720801 Brand 8/1/2006 6/30/2008 SoleSupply
13970302 Formulation5/16/1994 8/31/2010 TreatMax 30
13970303 Formulation5/16/1994 8/31/2010 TreatMax 30
13970303 Chemical 8/1/2012 SafetyListMedicine
13970303 Formulation11/1/1997 Safety Compounded
13970303 Brand 1/1/2001 6/30/2003 SoleSupply
13970401 Brand 10/1/2003 6/30/2006 SoleSupply
13970401 Chemical 8/1/2012 SafetyListMedicine
13970401 Formulation 7/1/1996 FormMax 5 PSO
13970501 Formulation 2/1/2001 FormMax 5 PSO
13970501 Chemical 8/1/2012 SafetyListMedicine
13970501 Brand 10/1/2003 6/30/2006 SoleSupply
13970601 Formulation5/30/1995 SubRxF
13970601 Chemical 8/1/2012 SafetyListMedicine
13970601 Formulation5/30/1995 FormReqd PSO
13970601 Formulation 7/1/1996 FormMax 5 PSO
13970602 Formulation 7/1/1996 FormMax 5 PSO
13970602 Formulation5/30/1995 FormReqd PSO
13970602 Chemical 8/1/2012 SafetyListMedicine
13970602 Formulation5/30/1995 SubRxF
14000101 Chemical 10/1/2003 Statim Must
14010101 Chemical 4/1/2004 Statim Must
14010101 ATC3 9/1/2010 Application
14010101 ATC3 3/1/1996 8/31/2010 Application
14010101 Formulation 3/1/1996 SpecialWav Claim only
14010102 Formulation 3/1/1996 SpecialWav Claim only
14010102 ATC3 3/1/1996 8/31/2010 Application
14010102 ATC3 9/1/2010 Application
14010102 Chemical 4/1/2004 Statim Must
14010103 Chemical 4/1/2004 Statim Must
14010103 ATC3 9/1/2010 Application
14010103 ATC3 3/1/1996 8/31/2010 Application
14010103 Formulation 3/1/1996 SpecialWav Claim only
14010103 Brand 4/1/2004 6/30/2006 SoleSupply
14010103 Brand 10/1/2006 6/30/2009 SoleSupply
14010103 Brand 6/1/2013 6/30/2015 SoleSupply
14010104 Formulation 3/1/1996 SpecialWav Claim only
14010104 ATC3 3/1/1996 8/31/2010 Application
14010104 ATC3 9/1/2010 Application
14010104 Chemical 4/1/2004 Statim Must
14010125 Chemical 4/1/2004 Statim Must
14010125 ATC3 9/1/2010 Application
14010125 ATC3 3/1/1996 8/31/2010 Application
14010125 Formulation 3/1/1996 SpecialWav Claim only
14010125 Brand 3/1/2010 5/4/2010 SoleSupply
14010126 Brand 5/5/2010 6/30/2012 SoleSupply
14010126 Formulation 3/1/1996 SpecialWav Claim only
14010126 ATC3 3/1/1996 8/31/2010 Application
14010126 ATC3 9/1/2010 Application
14010126 Chemical 4/1/2004 Statim Must
14010201 Chemical 4/1/2004 Statim Must
14010201 ATC3 9/1/2010 Application
14010201 ATC3 3/1/1996 8/31/2010 Application
14010201 Formulation 3/1/1996 SpecialWav Claim only
14010202 Formulation 3/1/1996 SpecialWav Claim only
14010202 ATC3 3/1/1996 8/31/2010 Application
14010202 ATC3 9/1/2010 Application
14010202 Chemical 4/1/2004 Statim Must
14010203 Chemical 4/1/2004 Statim Must
14010203 ATC3 9/1/2010 Application
14010203 ATC3 3/1/1996 8/31/2010 Application
14010203 Formulation 3/1/1996 SpecialWav Claim only
14010203 Brand 4/1/2004 6/30/2006 SoleSupply
14010203 Brand 10/1/2006 6/30/2009 SoleSupply
14010203 Brand 6/1/2013 6/30/2015 SoleSupply
14010204 Formulation 3/1/1996 SpecialWav Claim only
14010204 ATC3 3/1/1996 8/31/2010 Application
14010204 ATC3 9/1/2010 Application
14010204 Chemical 4/1/2004 Statim Must
14010225 Chemical 4/1/2004 Statim Must
14010225 ATC3 9/1/2010 Application
14010225 ATC3 3/1/1996 8/31/2010 Application
14010225 Formulation 3/1/1996 SpecialWav Claim only
14010225 Brand 3/1/2010 5/4/2010 SoleSupply
14010226 Brand 5/5/2010 6/30/2012 SoleSupply
14010226 Formulation 3/1/1996 SpecialWav Claim only
14010226 ATC3 3/1/1996 8/31/2010 Application
14010226 ATC3 9/1/2010 Application
14010226 Chemical 4/1/2004 Statim Must
14010301 Chemical 4/1/2004 Statim Must
14010301 ATC3 9/1/2010 Application
14010301 ATC3 3/1/1996 8/31/2010 Application
14010301 Formulation 3/1/1996 SpecialWav Claim only
14010301 Brand 1/1/2013 6/30/2015 SoleSupply
14010302 Formulation 3/1/1996 SpecialWav Claim only
14010302 ATC3 3/1/1996 8/31/2010 Application
14010302 ATC3 9/1/2010 Application
14010302 Chemical 4/1/2004 Statim Must
14010303 Chemical 4/1/2004 Statim Must
14010303 ATC3 9/1/2010 Application
14010303 ATC3 3/1/1996 8/31/2010 Application
14010303 Formulation 3/1/1996 SpecialWav Claim only
14010303 Brand 4/1/2004 6/30/2006 SoleSupply
14010303 Brand 10/1/2006 6/30/2009 SoleSupply
14010304 Formulation 3/1/1996 SpecialWav Claim only
14010304 ATC3 3/1/1996 8/31/2010 Application
14010304 ATC3 9/1/2010 Application
14010304 Chemical 4/1/2004 Statim Must
14010501 Chemical 4/1/2004 Statim Must
14010501 ATC3 9/1/2010 Application
14010501 Formulation 7/1/1996 FormMax 5 PSO
14010501 ATC3 3/1/1996 8/31/2010 Application
14010501 Formulation 3/1/1996 SpecialWav Claim only
14010501 Brand 10/1/2008 6/30/2011 SoleSupply
14010501 Brand 10/1/2011 6/30/2014 SoleSupply
14010601 Brand 11/1/2003 6/30/2006 SoleSupply
14010601 Brand 10/1/2008 6/30/2011 SoleSupply
14010601 Brand 10/1/2011 6/30/2014 SoleSupply
14010601 Formulation 3/1/1996 SpecialWav Claim only
14010601 ATC3 3/1/1996 8/31/2010 Application
14010601 ATC3 9/1/2010 Application
14010601 Chemical 4/1/2004 Statim Must
14010701 Chemical 4/1/2004 Statim Must
14010701 ATC3 9/1/2010 Application
14010701 ATC3 3/1/1996 8/31/2010 Application
14010701 Formulation 3/1/1996 SpecialWav Claim only
14010701 Brand 11/1/2003 6/30/2006 SoleSupply
14010701 Brand 10/1/2008 6/30/2011 SoleSupply
14010701 Brand 10/1/2011 6/30/2014 SoleSupply
14010801 Brand 11/1/2003 6/30/2006 SoleSupply
14010801 Brand 10/1/2008 6/30/2011 SoleSupply
14010801 Brand 10/1/2011 6/30/2014 SoleSupply
14010801 Formulation 3/1/1996 SpecialWav Claim only
14010801 Formulation 2/1/2001 FormMax 10 PSO
14010801 ATC3 3/1/1996 8/31/2010 Application
10840125 Chemical 8/1/2006 DoseSWt 100
10840125 Chemical 8/1/2005 7/31/2006 DoseSWt 250
10840125 Chemical 5/16/1994 FormReqd Rx
10840125 Chemical 5/16/1994 7/31/2005 DoseSWt 100
10840125 Formulation 8/1/2010 ProvAllow Dietitian
10840125 Chemical 10/1/2003 Statim Must
10840126 Chemical 10/1/2003 Statim Must
10840126 Formulation 8/1/2010 ProvAllow Dietitian
10840126 Chemical 5/16/1994 7/31/2005 DoseSWt 100
10840126 Chemical 5/16/1994 FormReqd Rx
10840126 Chemical 8/1/2005 7/31/2006 DoseSWt 250
10840126 Chemical 8/1/2006 DoseSWt 100
10840126 Brand 1/1/2011 6/30/2013 SoleSupply
10840127 Brand 1/1/2014 6/30/2016 SoleSupply
10840127 Chemical 8/1/2006 DoseSWt 100
10840127 Chemical 8/1/2005 7/31/2006 DoseSWt 250
10840127 Chemical 5/16/1994 FormReqd Rx
10840127 Chemical 5/16/1994 7/31/2005 DoseSWt 100
10840127 Formulation 8/1/2010 ProvAllow Dietitian
10840127 Chemical 10/1/2003 Statim Must
10840201 Chemical 10/1/2003 Statim Must
10840201 Chemical 5/16/1994 7/31/2005 DoseSWt 100
10840201 Chemical 5/16/1994 FormReqd Rx
10840201 Chemical 8/1/2005 7/31/2006 DoseSWt 250
10840201 Chemical 8/1/2006 DoseSWt 100
10840202 Chemical 8/1/2006 DoseSWt 100
10840202 Chemical 8/1/2005 7/31/2006 DoseSWt 250
10840202 Chemical 5/16/1994 FormReqd Rx
10840202 Chemical 5/16/1994 7/31/2005 DoseSWt 100
10840202 Chemical 10/1/2003 Statim Must
10840301 Chemical 10/1/2003 Statim Must
10840301 Chemical 5/16/1994 7/31/2005 DoseSWt 100
10840301 Chemical 5/16/1994 FormReqd Rx
10840301 Chemical 8/1/2005 7/31/2006 DoseSWt 250
10840301 Chemical 8/1/2006 DoseSWt 100
10842525 Chemical 8/1/2006 DoseSWt 100
10842525 Chemical 8/1/2005 7/31/2006 DoseSWt 250
10842525 Chemical 5/16/1994 FormReqd Rx
10842525 Chemical 5/16/1994 7/31/2005 DoseSWt 100
10842525 Chemical 10/1/2003 Statim Must
10850101 Chemical 10/1/2003 Statim Must
10850101 Chemical 1/1/1999 Dispensary HP3
10850101 Chemical 5/12/1995 SpecEnd Hospital
10860101 ATC2 8/1/2010 6/30/2013 Application
10860101 ATC2 6/1/2001 6/30/2005 Application
10860101 ATC2 1/1/2001 5/31/2001 Special
10860101 ATC2 1/1/1999 7/31/2010 Dispensary HP1
10860101 ATC2 10/1/1998 ######## Special SpecEnd
10860101 ATC2 7/1/2005 6/30/2010 Application
10860101 Chemical 8/1/2010 Special Claim only
10860101 Chemical 6/1/2001 7/31/2010 Special Claim only
10860101 ATC2 7/1/2013 Application
10860101 Brand 10/1/2003 6/30/2006 SoleSupply
10860101 ATC2 7/1/2010 7/31/2010 Application
10860101 ATC2 4/1/1997 9/30/1998 Special
10860201 ATC2 4/1/1997 9/30/1998 Special
10860201 ATC2 7/1/2010 7/31/2010 Application
10860201 ATC2 7/1/2013 Application
10860201 Chemical 6/1/2001 7/31/2010 Special Claim only
10860201 Chemical 8/1/2010 Special Claim only
10860201 ATC2 7/1/2005 6/30/2010 Application
10860201 ATC2 10/1/1998 ######## Special SpecEnd
10860201 ATC2 1/1/1999 7/31/2010 Dispensary HP1
10860201 ATC2 1/1/2001 5/31/2001 Special
10860201 ATC2 6/1/2001 6/30/2005 Application
10860201 ATC2 8/1/2010 6/30/2013 Application
10862525 ATC2 8/1/2010 6/30/2013 Application
10862525 ATC2 6/1/2001 6/30/2005 Application
10862525 ATC2 1/1/2001 5/31/2001 Special
10862525 ATC2 1/1/1999 7/31/2010 Dispensary HP1
10862525 ATC2 10/1/1998 ######## Special SpecEnd
10862525 ATC2 7/1/2005 6/30/2010 Application
10862525 Chemical 8/1/2010 Special Claim only
10862525 Chemical 6/1/2001 7/31/2010 Special Claim only
10862525 ATC2 7/1/2013 Application
10862525 Brand 11/1/2012 6/30/2015 SoleSupply
10862525 ATC2 4/1/1997 9/30/1998 Special
10862525 ATC2 7/1/2010 7/31/2010 Application
10870101 Chemical 10/1/2003 Statim Must
10870101 Formulation 4/1/2005 FormMax 30 PSO
10870102 Formulation 4/1/2005 FormMax 30 PSO
10870102 Chemical 10/1/2003 Statim Must
10870103 Chemical 10/1/2003 Statim Must
10870103 Formulation 4/1/2005 FormMax 30 PSO
10870125 Formulation 4/1/2005 FormMax 30 PSO
10870125 Chemical 10/1/2003 Statim Must
10870125 Brand 11/1/2006 6/30/2007 SoleSupply
10870125 Brand 9/1/2008 6/30/2010 SoleSupply
10870125 Brand 10/1/2010 6/30/2013 SoleSupply
10870125 Brand 4/1/2014 6/30/2016 SoleSupply
10870201 Chemical 10/1/2003 Statim Must
10870201 Formulation 2/1/2001 3/31/2005 FormMax 30 PSO
10870501 Chemical 10/1/2003 Statim Must
10870601 Chemical 10/1/2003 Statim Must
10870701 Chemical 10/1/2003 Statim Must
10872525 Chemical 10/1/2003 Statim Must
10872525 Brand 4/1/2008 6/30/2010 SoleSupply
10872525 Brand 10/1/2010 6/30/2013 SoleSupply
10872525 Brand 4/1/2014 6/30/2016 SoleSupply
10872526 Chemical 10/1/2003 Statim Must
10880101 Chemical 1/1/1999 7/31/2010 Dispensary HP3
10880101 Chemical 11/1/2000 1/31/2004 Special
10880101 Chemical 3/1/1998 ######## Special
10880101 Chemical 2/1/2004 Special
10880125 Chemical 2/1/2004 Special
10880125 Chemical 3/1/1998 ######## Special
10880125 Chemical 1/1/1999 7/31/2010 Dispensary HP3
10880125 Chemical 11/1/2000 1/31/2004 Special
10880201 Chemical 11/1/2000 1/31/2004 Special
10880201 Chemical 1/1/1999 7/31/2010 Dispensary HP3
10880201 Chemical 3/1/1998 ######## Special
10880201 Chemical 2/1/2004 Special
10880201 Formulation12/1/2011 OraProduct
10880225 Formulation12/1/2011 OraProduct
10880225 Chemical 2/1/2004 Special
10880225 Chemical 3/1/1998 ######## Special
10880225 Chemical 1/1/1999 7/31/2010 Dispensary HP3
10880225 Chemical 11/1/2000 1/31/2004 Special
10882525 Chemical 11/1/2000 1/31/2004 Special
10882525 Chemical 1/1/1999 7/31/2010 Dispensary HP3
10882525 Chemical 3/1/1998 ######## Special
10882525 Chemical 2/1/2004 Special
10882526 Chemical 2/1/2004 Special
10882526 Chemical 3/1/1998 ######## Special
10882526 Chemical 1/1/1999 7/31/2010 Dispensary HP3
10882526 Chemical 11/1/2000 1/31/2004 Special
10940101 Chemical 10/1/2003 Statim Must
10940101 Formulation 7/1/1996 9/30/2003 Statim May
17240102 Formulation 7/1/1996 Contraceptive
17240102 Chemical 8/1/2004 Statim Must
17240102 Formulation 7/1/1996 FormMax 84 PSO
17242525 Chemical 8/1/2004 Statim Must
17242525 Formulation 8/1/2000 ######## FormMax 4 Rx
17242525 Formulation 8/1/2000 ######## FormMax 10 PSO
17242525 ATC2 5/16/1994 ######## MaxCoPayment 3
17242525 ATC2 1/1/2013 MaxCoPayment 5
17242526 ATC2 1/1/2013 MaxCoPayment 5
17242526 ATC2 5/16/1994 ######## MaxCoPayment 3
17242526 Formulation 8/1/2000 ######## FormMax 10 PSO
17242526 Formulation 8/1/2000 ######## FormMax 4 Rx
17242526 Chemical 8/1/2004 Statim Must
17242625 Chemical 8/1/2004 Statim Must
17242625 Formulation 8/1/2005 Special
17242625 Formulation10/1/2002 7/31/2005 Special
17242725 Brand 10/1/2013 6/30/2016 SoleSupply
17242725 ATC2 1/1/2013 MaxCoPayment 5
17242725 Formulation 6/1/2008 6/30/2008 FormMax 1 Rx
17242725 Formulation 7/1/2008 FormMax 2 Rx
17242725 ATC2 5/16/1994 ######## MaxCoPayment 3
17242725 Chemical 8/1/2004 Statim Must
17242725 Formulation 6/1/2008 FormMax 5 PSO
17242825 Chemical 8/1/2004 Statim Must
17242825 ATC2 5/16/1994 ######## MaxCoPayment 3
17242825 ATC3 11/1/1999 AltSubSA
17242825 ATC3 8/1/1995 ######## SpecialWav
17242825 ATC2 1/1/2013 MaxCoPayment 5
17242825 Brand 8/1/2010 ######## SoleSupply
17280101 Chemical 7/1/1996 FormMax 30 PSO
17280101 Chemical 10/1/2003 Statim Must
17280101 Formulation5/16/1994 7/31/1999 NotCombined
17280102 Formulation5/16/1994 7/31/1999 NotCombined
17280102 Chemical 10/1/2003 Statim Must
17280102 Chemical 7/1/1996 FormMax 30 PSO
17280102 Brand 12/1/2001 6/30/2004 SoleSupply
17280102 Brand 11/1/1999 6/30/2001 Preferred
17280125 Brand 3/1/2011 6/30/2013 SoleSupply
17280125 Brand 8/1/2014 6/30/2016 SoleSupply
17280125 Chemical 7/1/1996 FormMax 30 PSO
17280125 Chemical 10/1/2003 Statim Must
17280125 Formulation5/16/1994 7/31/1999 NotCombined
17280201 Chemical 7/1/1996 FormMax 30 PSO
17280201 Chemical 10/1/2003 Statim Must
17280225 Chemical 10/1/2003 Statim Must
17280225 Chemical 7/1/1996 FormMax 30 PSO
17280225 Brand 6/1/2006 6/30/2007 SoleSupply
17280225 Brand 10/1/2007 6/30/2010 SoleSupply
17290101 Formulation11/1/1997 2/28/1998 Safety Compounded
17290101 Formulation5/16/1994 2/28/1998 TreatMax 30
17300101 Chemical 5/16/1994 8/31/2010 TreatMax 30
17300101 Formulation11/1/1997 Safety Compounded
17300101 Chemical 8/1/2012 SafetyListMedicine
17300201 Chemical 8/1/2012 SafetyListMedicine
17300201 Formulation11/1/1997 Safety Compounded
17300201 Chemical 5/16/1994 8/31/2010 TreatMax 30
17300201 Brand 12/1/2004 6/30/2006 SoleSupply
17300201 Brand 1/1/2007 6/30/2009 SoleSupply
17300201 Brand 1/1/2011 6/30/2013 SoleSupply
17300202 Brand 1/1/2001 6/30/2003 SoleSupply
17300202 Chemical 5/16/1994 8/31/2010 TreatMax 30
17300202 Formulation11/1/1997 Safety Compounded
17300202 Chemical 8/1/2012 SafetyListMedicine
17300401 Chemical 8/1/2012 SafetyListMedicine
17300401 Formulation11/1/1997 Safety Compounded
17300401 Chemical 5/16/1994 8/31/2010 TreatMax 30
17300401 Brand 1/1/2001 6/30/2003 SoleSupply
17300402 Chemical 5/16/1994 8/31/2010 TreatMax 30
17300402 Formulation11/1/1997 Safety Compounded
17300402 Chemical 8/1/2012 SafetyListMedicine
17300403 Chemical 8/1/2012 SafetyListMedicine
17300403 Formulation11/1/1997 Safety Compounded
17300403 Chemical 5/16/1994 8/31/2010 TreatMax 30
17300403 Brand 5/1/2004 6/30/2006 SoleSupply
17300403 Brand 1/1/2007 6/30/2009 SoleSupply
17300403 Brand 1/1/2011 6/30/2013 SoleSupply
17300501 Chemical 5/16/1994 8/31/2010 TreatMax 30
17300501 Chemical 8/1/2012 SafetyListMedicine
17310101 Chemical 8/1/2012 SafetyListMedicine
17310101 Formulation11/1/1997 Safety Compounded
17310101 Chemical 5/16/1994 8/31/2010 TreatMax 30
17320101 Chemical 5/16/1994 SpecEnd Retail
17320201 Chemical 5/16/1994 SpecEnd Retail
17320301 Chemical 5/16/1994 SpecEnd Retail
17600101 Chemical 5/16/1994 3/31/2008 SpecEnd Retail
17600101 Chemical 8/1/2012 SafetyListMedicine
17600101 Brand 9/1/2006 6/30/2009 SoleSupply
17600201 Brand 9/1/2006 6/30/2009 SoleSupply
17600201 Chemical 8/1/2012 SafetyListMedicine
17600201 Brand 10/1/2013 ######## Wastage
17600201 Chemical 5/16/1994 3/31/2008 SpecEnd Retail
17620101 Chemical 5/1/2000 FormReqd Rx
17620101 Formulation5/16/1994 4/30/2000 FormReqd Rx
17620101 Formulation5/16/1994 4/30/2000 FormMax 30 Rx
17620201 Formulation5/16/1994 4/30/2000 FormMax 6 Rx
17620201 Chemical 5/1/2000 FormReqd Rx
17620201 Formulation5/16/1994 4/30/2000 FormReqd Rx
17620202 Formulation5/16/1994 4/30/2000 FormReqd Rx
17620202 Chemical 5/1/2000 FormReqd Rx
17620202 Formulation5/16/1994 4/30/2000 FormMax 6 Rx
17620225 Formulation5/16/1994 4/30/2000 FormMax 6 Rx
17620225 Chemical 5/1/2000 FormReqd Rx
17620225 Formulation5/16/1994 4/30/2000 FormReqd Rx
17620225 Brand 8/1/2009 6/30/2011 SoleSupply
17620225 Brand 12/1/2011 6/30/2014 SoleSupply
17660101 Brand 12/1/2002 6/30/2005 SoleSupply
17660101 Brand 10/1/2007 6/30/2010 SoleSupply
17660101 Brand 10/1/2013 6/30/2016 SoleSupply
17660101 Chemical 10/1/2003 Statim Must
17660101 Formulation5/25/1995 SpecEnd Retail
17660102 Formulation5/25/1995 SpecEnd Retail
17660102 Chemical 10/1/2003 Statim Must
17660201 Chemical 10/1/2003 Statim Must
17660201 Formulation5/25/1995 SpecEnd Retail
17660201 Brand 10/1/2007 6/30/2010 SoleSupply
17660202 Formulation5/25/1995 SpecEnd Retail
17660202 Chemical 10/1/2003 Statim Must
17660301 Chemical 10/1/2003 Statim Must
17660301 Formulation5/25/1995 SpecEnd Retail
17660401 Formulation5/25/1995 SpecEnd Retail
17660401 Chemical 10/1/2003 Statim Must
17660501 Chemical 10/1/2003 Statim Must
17660501 Brand 9/1/2003 6/30/2006 SoleSupply
17660501 Brand 10/1/2007 6/30/2010 SoleSupply
11020101 ATC2 7/1/2013 Application
11020101 ATC2 4/1/1997 9/30/1998 Special
11020101 Chemical 6/1/2001 7/31/2010 Special Claim only
11020101 Chemical 8/1/2010 Special Claim only
11020101 ATC2 10/1/1998 ######## Special SpecEnd
11020101 ATC2 1/1/2001 5/31/2001 Special
11020101 ATC2 1/1/1999 7/31/2010 Dispensary HP1
11020101 ATC2 6/1/2001 6/30/2005 Application
11020101 ATC2 8/1/2010 6/30/2013 Application
11020101 ATC2 7/1/2005 6/30/2010 Application
11020201 ATC2 7/1/2005 6/30/2010 Application
11020201 ATC2 8/1/2010 6/30/2013 Application
11020201 ATC2 6/1/2001 6/30/2005 Application
11020201 ATC2 1/1/1999 7/31/2010 Dispensary HP1
11020201 ATC2 1/1/2001 5/31/2001 Special
11020201 ATC2 10/1/1998 ######## Special SpecEnd
11020201 Chemical 8/1/2010 Special Claim only
11020201 Chemical 6/1/2001 7/31/2010 Special Claim only
11020201 ATC2 4/1/1997 9/30/1998 Special
11020201 ATC2 7/1/2013 Application
11020201 ATC2 7/1/2010 7/31/2010 Application
11030101 Brand 10/1/2011 6/30/2014 SoleSupply
11050101 ATC2 1/1/2013 MaxCoPayment 5
11050101 Brand 2/1/2006 6/30/2008 SoleSupply
11050101 ATC2 5/16/1994 ######## MaxCoPayment 3
11050101 Formulation 9/1/2006 FormMax 1 PSO
11050101 Chemical 8/1/2004 Statim Must
11070101 Chemical 1/1/1999 7/31/2010 Dispensary HP3
11070101 Chemical 10/1/2004 MaxQtyDisp 3
11070101 Chemical 8/1/1997 7/31/2010 SpecEnd Hospital
11070101 Chemical 8/1/2010 8/31/2010 SpecEnd Retail
11070101 Chemical 10/1/2004 FormMax 6 Rx
11070101 Formulation 8/1/1997 9/30/2004 FormMax 3 Rx
11070101 Brand 10/1/2004 6/30/2007 SoleSupply
11070101 Brand 4/1/2010 6/30/2012 SoleSupply
11080101 Brand 10/1/1999 9/30/2002 Preferred
11080101 Formulation11/1/2002 1/31/2003 FormMax 1000 PSO
11080102 Formulation11/1/2002 1/31/2003 FormMax 1000 PSO
11080125 Formulation11/1/2002 1/31/2003 FormMax 1000 PSO
11080201 Formulation11/1/2002 1/31/2003 FormMax 1000 PSO
11080201 Brand 10/1/1999 9/30/2002 Preferred
11080202 Formulation11/1/2002 1/31/2003 FormMax 1000 PSO
11080203 Formulation11/1/2002 1/31/2003 FormMax 1000 PSO
11080225 Formulation11/1/2002 1/31/2003 FormMax 1000 PSO
11080301 Formulation11/1/2002 1/31/2003 FormMax 1000 PSO
11080301 Brand 10/1/1999 9/30/2002 Preferred
11080302 Formulation11/1/2002 1/31/2003 FormMax 1000 PSO
11080303 Formulation11/1/2002 1/31/2003 FormMax 1000 PSO
11080325 Formulation11/1/2002 1/31/2003 FormMax 1000 PSO
11080326 Formulation11/1/2002 1/31/2003 FormMax 1000 PSO
11081301 Brand 11/1/2000 6/30/2003 SoleSupply
11081301 Brand 10/1/2003 6/30/2006 SoleSupply
11081301 Brand 1/1/2007 6/30/2009 SoleSupply
11081401 Brand 11/1/2000 6/30/2003 SoleSupply
11081401 Brand 10/1/2003 6/30/2006 SoleSupply
11081401 Brand 1/1/2007 6/30/2009 SoleSupply
11090101 ATC2 7/1/2010 7/31/2010 Application
11090101 ATC2 7/1/2013 Application
11090101 ATC2 4/1/1997 9/30/1998 Special
11090101 Chemical 6/1/2001 7/31/2010 Special Claim only
11090101 Chemical 8/1/2010 Special Claim only
11090101 ATC2 7/1/2005 6/30/2010 Application
11090101 ATC2 10/1/1998 ######## Special SpecEnd
11090101 ATC2 1/1/2001 5/31/2001 Special
11090101 ATC2 1/1/1999 7/31/2010 Dispensary HP1
11090101 ATC2 6/1/2001 6/30/2005 Application
11090101 ATC2 8/1/2010 6/30/2013 Application
11090201 ATC2 8/1/2010 6/30/2013 Application
11090201 ATC2 6/1/2001 6/30/2005 Application
11090201 ATC2 1/1/1999 7/31/2010 Dispensary HP1
11090201 ATC2 1/1/2001 5/31/2001 Special
11090201 ATC2 10/1/1998 ######## Special SpecEnd
11090201 ATC2 7/1/2005 6/30/2010 Application
11090201 Chemical 8/1/2010 Special Claim only
11090201 Chemical 6/1/2001 7/31/2010 Special Claim only
11090201 ATC2 4/1/1997 9/30/1998 Special
11090201 ATC2 7/1/2013 Application
11090201 ATC2 7/1/2010 7/31/2010 Application
11090301 ATC2 7/1/2010 7/31/2010 Application
11090301 ATC2 7/1/2013 Application
11090301 ATC2 4/1/1997 9/30/1998 Special
11090301 Chemical 6/1/2001 7/31/2010 Special Claim only
11090301 Chemical 8/1/2010 Special Claim only
11090301 ATC2 7/1/2005 6/30/2010 Application
11090301 ATC2 10/1/1998 ######## Special SpecEnd
11090301 ATC2 1/1/2001 5/31/2001 Special
11090301 ATC2 1/1/1999 7/31/2010 Dispensary HP1
11090301 ATC2 6/1/2001 6/30/2005 Application
11090301 ATC2 8/1/2010 6/30/2013 Application
11090401 ATC2 8/1/2010 6/30/2013 Application
11090401 ATC2 6/1/2001 6/30/2005 Application
11090401 ATC2 1/1/1999 7/31/2010 Dispensary HP1
11090401 ATC2 1/1/2001 5/31/2001 Special
11090401 ATC2 10/1/1998 ######## Special SpecEnd
11090401 ATC2 7/1/2005 6/30/2010 Application
11090401 Chemical 8/1/2010 Special Claim only
11090401 Chemical 6/1/2001 7/31/2010 Special Claim only
11090401 ATC2 4/1/1997 9/30/1998 Special
11090401 ATC2 7/1/2013 Application
11090401 ATC2 7/1/2010 7/31/2010 Application
11090501 ATC2 7/1/2010 7/31/2010 Application
11090501 ATC2 7/1/2013 Application
11090501 ATC2 4/1/1997 9/30/1998 Special
11090501 Chemical 6/1/2001 7/31/2010 Special Claim only
11090501 Chemical 8/1/2010 Special Claim only
11090501 ATC2 7/1/2005 6/30/2010 Application
11090501 Brand 4/1/2013 S29
11090501 Brand 4/1/2013 Wastage
11090501 ATC2 10/1/1998 ######## Special SpecEnd
11090501 ATC2 1/1/2001 5/31/2001 Special
11090501 ATC2 1/1/1999 7/31/2010 Dispensary HP1
11090501 ATC2 6/1/2001 6/30/2005 Application
11090501 ATC2 8/1/2010 6/30/2013 Application
11100101 ATC3 12/1/1997 2/28/2014 SubRxF
11100101 Chemical 10/1/2003 Statim Must
11100101 ATC3 3/1/2014 SubRxF
11100101 Formulation10/1/1999 9/30/2003 Statim May
11100101 Chemical 10/1/1999 2/28/2005 FormMax 30 Rx
11100101 Chemical 3/1/2005 FormMax 100 Rx
11100125 Chemical 3/1/2005 FormMax 100 Rx
11100125 Chemical 10/1/1999 2/28/2005 FormMax 30 Rx
11100125 Formulation10/1/1999 9/30/2003 Statim May
11100125 ATC3 3/1/2014 SubRxF
11100125 Chemical 10/1/2003 Statim Must
11100125 ATC3 12/1/1997 2/28/2014 SubRxF
11100126 ATC3 12/1/1997 2/28/2014 SubRxF
11100126 Chemical 10/1/2003 Statim Must
11100126 ATC3 3/1/2014 SubRxF
11100126 Formulation10/1/1999 9/30/2003 Statim May
14280101 Formulation 7/1/1996 9/30/2001 Statim May
14280201 Formulation 7/1/1996 9/30/2001 Statim May
14280201 Chemical 10/1/2001 Statim May
14280202 Chemical 10/1/2001 Statim May
14280202 Formulation 7/1/1996 9/30/2001 Statim May
14280401 Chemical 10/1/2001 Statim May
14280401 Formulation5/16/1994 SpecEnd Retail
14280501 Chemical 10/1/2001 Statim May
14280501 Formulation9/18/1997 9/30/2001 Statim May
14280601 Chemical 10/1/2001 Statim May
14280601 Formulation9/18/1997 9/30/2001 Statim May
14310102 Formulation 7/1/1996 Statim May
14310102 Chemical 6/22/1995 SpecEnd Hospital
14310201 Chemical 6/22/1995 SpecEnd Hospital
14320101 Brand 10/1/2003 6/30/2006 SoleSupply
14360101 Formulation12/1/2011 OraProduct
14360101 Chemical 12/1/1998 ######## SpecialWav
14360101 Chemical 10/1/2003 Statim Must
14360101 Chemical 11/1/2008 6/30/2010 SpecialWav
14360125 Chemical 11/1/2008 6/30/2010 SpecialWav
14360125 Chemical 10/1/2003 Statim Must
14360125 Chemical 12/1/1998 ######## SpecialWav
14360125 Brand 6/1/2013 6/30/2015 SoleSupply
14360125 Formulation12/1/2011 OraProduct
14370101 Chemical 8/1/2012 SafetyListMedicine
14370102 Chemical 8/1/2012 SafetyListMedicine
14370102 Brand 11/1/1999 6/30/2002 SoleSupply
14370201 Chemical 8/1/2012 SafetyListMedicine
14370202 Chemical 8/1/2012 SafetyListMedicine
14370202 Brand 11/1/1999 6/30/2002 SoleSupply
14380101 Brand 11/1/1999 6/30/2002 SoleSupply
14380101 Chemical 8/1/2012 SafetyListMedicine
14380201 Chemical 8/1/2012 SafetyListMedicine
14380202 Chemical 8/1/2012 SafetyListMedicine
14380202 Brand 11/1/1999 6/30/2002 SoleSupply
14380301 Brand 11/1/1999 6/30/2002 SoleSupply
14380301 Chemical 8/1/2012 SafetyListMedicine
14380401 Chemical 8/1/2012 SafetyListMedicine
14380401 Brand 11/1/1999 6/30/2002 SoleSupply
14380402 Chemical 8/1/2012 SafetyListMedicine
14430601 Formulation 6/1/2002 FormReqd Rx
14430601 Formulation 6/1/2002 NotCombined
14430701 Formulation 6/1/2002 NotCombined
14430701 Formulation 6/1/2002 FormReqd Rx
14431002 Formulation 6/1/2002 FormReqd Rx
14431002 Formulation 6/1/2002 NotCombined
14431003 Formulation 6/1/2002 NotCombined
14431003 Formulation 6/1/2002 FormReqd Rx
14431004 Formulation 6/1/2002 FormReqd Rx
14431004 Formulation 6/1/2002 NotCombined
14431102 Formulation 6/1/2002 NotCombined
14431102 Formulation 6/1/2002 FormReqd Rx
14460101 Formulation 8/1/2010 ProvAllow Dietitian
14460101 Formulation5/16/1994 FormMax 10 PSO
14460102 Formulation5/16/1994 FormMax 10 PSO
14460102 Formulation 8/1/2010 ProvAllow Dietitian
14460103 Formulation 8/1/2010 ProvAllow Dietitian
14460103 Formulation5/16/1994 FormMax 10 PSO
14460125 Formulation5/16/1994 FormMax 10 PSO
14460125 Brand 12/1/2005 6/30/2007 SoleSupply
14460125 Brand 10/1/2007 6/30/2010 SoleSupply
14460125 Formulation 8/1/2010 ProvAllow Dietitian
14462525 Formulation 5/1/2011 ProvAllow Dietitian
14462525 Brand 10/1/2011 6/30/2013 SoleSupply
14462525 Formulation 5/1/2011 FormMax 10 PSO
14462526 Formulation 5/1/2011 FormMax 10 PSO
14462526 Brand 5/1/2014 6/30/2016 SoleSupply
14462526 Formulation 5/1/2011 ProvAllow Dietitian
14480101 Chemical 5/16/1994 SpecEnd Retail
14530301 Formulation6/24/1995 Combined
14560101 Formulation 7/1/1996 FormMax 5 PSO
14560101 Brand 1/1/2003 6/30/2005 SoleSupply
14560101 Brand 10/1/2006 6/30/2009 SoleSupply
14560101 Brand 12/1/2011 6/30/2014 SoleSupply
14620301 Brand 11/1/2003 6/30/2006 SoleSupply
14620301 Brand 10/1/2006 6/30/2009 SoleSupply
14650401 Formulation10/4/1997 FormMax 30 PSO
14650501 Formulation10/4/1997 FormMax 30 PSO
14660201 Brand 12/1/2001 ######## SoleSupply
14660301 Formulation 7/1/1996 FormMax 200 PSO
14660501 Formulation10/4/1997 7/31/1999 FormMax 30 PSO
14680101 Chemical 10/1/2003 Statim Must
14680101 Chemical 5/16/1994 SpecEnd Retail
14680101 Chemical 4/1/2013 SpecEnd Retail
14680101 Chemical 5/16/1994 MaxCoPayment 0
14680201 Chemical 5/16/1994 MaxCoPayment 0
14680201 Chemical 4/1/2013 SpecEnd Retail
14680201 Chemical 5/16/1994 SpecEnd Retail
14680201 Chemical 10/1/2003 Statim Must
14680202 Chemical 10/1/2003 Statim Must
14680202 Chemical 5/16/1994 SpecEnd Retail
14680202 Chemical 4/1/2013 SpecEnd Retail
14680202 Chemical 5/16/1994 MaxCoPayment 0
14680202 Brand 11/1/2005 6/30/2008 SoleSupply
14750801 ATC2 1/1/2013 MaxCoPayment 5
14750801 Formulation 7/1/1996 FormMax 63 PSO
14750801 Brand 9/1/2007 6/30/2010 SoleSupply
14750801 ATC2 5/16/1994 ######## MaxCoPayment 3
14750801 ATC3 8/1/1995 ######## SpecialWav
14750801 ATC3 11/1/1999 AltSubSA
14750801 Formulation 7/1/1996 Contraceptive
14750801 Chemical 8/1/2004 Statim Must
14750901 Chemical 8/1/2004 Statim Must
14750901 Formulation 7/1/1996 FormMax 84 PSO
14750901 Formulation 7/1/1996 Contraceptive
14750901 ATC3 11/1/1999 AltSubSA
14750901 ATC3 8/1/1995 ######## SpecialWav
14750901 ATC2 5/16/1994 ######## MaxCoPayment 3
14750901 ATC2 1/1/2013 MaxCoPayment 5
14750902 ATC2 1/1/2013 MaxCoPayment 5
14750902 Brand 7/1/2003 6/30/2005 SoleSupply
14750902 Brand 12/1/2005 6/30/2008 SoleSupply
14750902 ATC2 5/16/1994 ######## MaxCoPayment 3
14750902 ATC3 8/1/1995 ######## SpecialWav
14750902 ATC3 11/1/1999 AltSubSA
14750902 Formulation 7/1/1996 Contraceptive
14750902 Formulation 7/1/1996 FormMax 84 PSO
14750902 Chemical 8/1/2004 Statim Must
14751001 Chemical 8/1/2004 Statim Must
14751001 Formulation 7/1/1996 FormMax 84 PSO
14751001 Formulation 7/1/1996 Contraceptive
14751001 ATC3 11/1/1999 AltSubSA
14751001 ATC3 8/1/1995 ######## SpecialWav
11330125 Chemical 9/1/2000 ######## Special
11330125 Chemical 8/1/2003 7/31/2007 Special Claim only
11330125 ATC3 7/1/2005 7/31/2007 Application
11330125 ATC3 8/1/2003 6/30/2005 Application
11330125 Chemical 1/1/2001 7/31/2003 Special
11330125 Chemical 8/1/2007 8/31/2008 Special
11330201 Chemical 8/1/2007 8/31/2008 Special
11330201 Chemical 1/1/2001 7/31/2003 Special
11330201 ATC3 8/1/2003 6/30/2005 Application
11330201 ATC3 7/1/2005 7/31/2007 Application
11330201 Chemical 9/1/2000 ######## Special
11330201 Chemical 8/1/2003 7/31/2007 Special Claim only
11330201 Chemical 11/1/1997 Statim May
11330225 Chemical 9/1/2000 ######## Special
11330225 Chemical 11/1/1997 Statim May
11330225 Chemical 8/1/2003 7/31/2007 Special Claim only
11330225 ATC3 7/1/2005 7/31/2007 Application
11330225 ATC3 8/1/2003 6/30/2005 Application
11330225 Chemical 1/1/2001 7/31/2003 Special
11330225 Chemical 8/1/2007 8/31/2008 Special
11330301 Chemical 8/1/2007 8/31/2008 Special
11330301 Chemical 1/1/2001 7/31/2003 Special
11330301 ATC3 8/1/2003 6/30/2005 Application
11330301 ATC3 7/1/2005 7/31/2007 Application
11330301 Chemical 9/1/2000 ######## Special
11330301 Chemical 8/1/2003 7/31/2007 Special Claim only
11330301 Chemical 11/1/1997 Statim May
11330325 Chemical 9/1/2000 ######## Special
11330325 Chemical 11/1/1997 Statim May
11330325 Chemical 8/1/2003 7/31/2007 Special Claim only
11330325 ATC3 7/1/2005 7/31/2007 Application
11330325 ATC3 8/1/2003 6/30/2005 Application
11330325 Chemical 1/1/2001 7/31/2003 Special
11330325 Chemical 8/1/2007 8/31/2008 Special
11330401 Chemical 8/1/2007 8/31/2008 Special
11330401 Chemical 1/1/2001 7/31/2003 Special
11330401 ATC3 8/1/2003 6/30/2005 Application
11330401 ATC3 7/1/2005 7/31/2007 Application
11330401 Chemical 9/1/2000 ######## Special
11330401 Chemical 8/1/2003 7/31/2007 Special Claim only
11330401 Chemical 11/1/1997 Statim May
11330425 Chemical 9/1/2000 ######## Special
11330425 Chemical 11/1/1997 Statim May
11330425 Chemical 8/1/2003 7/31/2007 Special Claim only
11330425 ATC3 7/1/2005 7/31/2007 Application
11330425 ATC3 8/1/2003 6/30/2005 Application
11330425 Chemical 1/1/2001 7/31/2003 Special
11330425 Chemical 8/1/2007 8/31/2008 Special
11332525 Chemical 8/1/2007 8/31/2008 Special
11332525 Chemical 1/1/2001 7/31/2003 Special
11332525 ATC3 8/1/2003 6/30/2005 Application
11332525 ATC3 7/1/2005 7/31/2007 Application
11332525 Chemical 9/1/2000 ######## Special
11332525 Chemical 8/1/2003 7/31/2007 Special Claim only
11332525 Chemical 11/1/1997 Statim May
11332625 Chemical 11/1/1997 Statim May
11332625 Chemical 8/1/2003 7/31/2007 Special Claim only
11332625 Chemical 9/1/2000 ######## Special
11332625 ATC3 7/1/2005 7/31/2007 Application
11332625 ATC3 8/1/2003 6/30/2005 Application
11332625 Chemical 1/1/2001 7/31/2003 Special
11332625 Chemical 8/1/2007 8/31/2008 Special
11360101 Formulation5/16/1994 FormMax 5 PSO
11360101 Brand 3/1/2004 6/30/2006 SoleSupply
11360101 Brand 1/1/2009 6/30/2011 SoleSupply
11360101 Brand 12/1/2011 6/30/2014 SoleSupply
11360102 Formulation5/16/1994 FormMax 5 PSO
11370101 ATC3 11/1/1997 ######## Special
11370101 Chemical 10/1/2003 Statim Must
11370101 Chemical 9/1/2005 8/31/2010 SpecialWav
11370101 Chemical 7/1/2004 8/31/2005 SpecialWav
11370101 ATC3 12/1/1995 ######## Special
11370101 Chemical 7/1/2002 5/31/2004 Special
11370101 Chemical 6/1/2004 9/30/2004 Repeat
11370101 ATC3 5/16/1994 ######## Special
11370101 ATC3 12/1/1998 3/31/2002 Special
11370101 Chemical 6/1/2004 6/30/2004 SpecialWav
11370125 Chemical 6/1/2004 6/30/2004 SpecialWav
11370125 ATC3 12/1/1998 3/31/2002 Special
11370125 ATC3 5/16/1994 ######## Special
11370125 Chemical 6/1/2004 9/30/2004 Repeat
11370125 Chemical 7/1/2002 5/31/2004 Special
11370125 ATC3 12/1/1995 ######## Special
11370125 Chemical 7/1/2004 8/31/2005 SpecialWav
11370125 Chemical 9/1/2005 8/31/2010 SpecialWav
11370125 Chemical 10/1/2003 Statim Must
11370125 ATC3 11/1/1997 ######## Special
11370126 ATC3 11/1/1997 ######## Special
11370126 Chemical 10/1/2003 Statim Must
11370126 Chemical 9/1/2005 8/31/2010 SpecialWav
11370126 Chemical 7/1/2004 8/31/2005 SpecialWav
11370126 ATC3 12/1/1995 ######## Special
11370126 Chemical 7/1/2002 5/31/2004 Special
11370126 Chemical 6/1/2004 9/30/2004 Repeat
11370126 ATC3 5/16/1994 ######## Special
11370126 ATC3 12/1/1998 3/31/2002 Special
11370126 Chemical 6/1/2004 6/30/2004 SpecialWav
11370127 Chemical 6/1/2004 6/30/2004 SpecialWav
11370127 Brand 1/1/2013 6/30/2015 SoleSupply
11370127 ATC3 12/1/1998 3/31/2002 Special
11370127 ATC3 5/16/1994 ######## Special
11370127 Chemical 6/1/2004 9/30/2004 Repeat
11370127 Chemical 7/1/2002 5/31/2004 Special
11370127 Chemical 7/1/2004 8/31/2005 SpecialWav
11370127 ATC3 12/1/1995 ######## Special
11370127 Chemical 10/1/2003 Statim Must
11370127 Chemical 9/1/2005 8/31/2010 SpecialWav
11370127 ATC3 11/1/1997 ######## Special
11370201 ATC3 11/1/1997 ######## Special
11370201 Chemical 10/1/2003 Statim Must
11370201 Chemical 9/1/2005 8/31/2010 SpecialWav
11370201 Chemical 7/1/2004 8/31/2005 SpecialWav
11370201 ATC3 12/1/1995 ######## Special
11370201 Chemical 7/1/2002 5/31/2004 Special
11370201 Chemical 6/1/2004 9/30/2004 Repeat
11370201 ATC3 12/1/1998 3/31/2002 Special
11370201 ATC3 5/16/1994 ######## Special
11370201 Chemical 6/1/2004 6/30/2004 SpecialWav
11370225 Chemical 6/1/2004 6/30/2004 SpecialWav
11370225 ATC3 12/1/1998 3/31/2002 Special
11370225 ATC3 5/16/1994 ######## Special
11370225 Chemical 6/1/2004 9/30/2004 Repeat
11370225 Chemical 7/1/2002 5/31/2004 Special
11370225 ATC3 12/1/1995 ######## Special
11370225 Chemical 7/1/2004 8/31/2005 SpecialWav
11370225 Chemical 9/1/2005 8/31/2010 SpecialWav
11370225 Chemical 10/1/2003 Statim Must
11370225 ATC3 11/1/1997 ######## Special
11370226 ATC3 11/1/1997 ######## Special
11370226 Chemical 10/1/2003 Statim Must
11370226 Chemical 9/1/2005 8/31/2010 SpecialWav
11370226 Chemical 7/1/2004 8/31/2005 SpecialWav
17660501 Brand 10/1/2013 6/30/2016 SoleSupply
17660501 ATC2 12/1/1996 6/30/2010 Application
17660501 ATC2 7/1/2010 Application
17660601 ATC2 7/1/2010 Application
17660601 ATC2 12/1/1996 6/30/2010 Application
17660601 Brand 9/1/2003 6/30/2006 SoleSupply
17660601 Brand 10/1/2007 6/30/2010 SoleSupply
17660601 Brand 10/1/2013 6/30/2016 SoleSupply
17660601 Chemical 10/1/2003 Statim Must
17660701 Chemical 10/1/2003 Statim Must
17660701 Brand 9/1/2003 6/30/2006 SoleSupply
17660701 Brand 10/1/2007 6/30/2010 SoleSupply
17660701 Brand 10/1/2013 6/30/2016 SoleSupply
17660701 ATC2 12/1/1996 6/30/2010 Application
17660701 ATC2 7/1/2010 Application
17660801 ATC2 5/16/1994 ######## MaxCoPayment 3
17660801 Formulation 7/1/1996 Contraceptive
17660801 ATC3 11/1/1999 AltSubSA
17660801 ATC3 8/1/1995 ######## SpecialWav
17660801 ATC2 1/1/2013 MaxCoPayment 5
17660801 Brand 12/1/2001 6/30/2004 SoleSupply
17660801 Brand 12/1/2005 6/30/2007 SoleSupply
17660801 Brand 10/1/2013 6/30/2016 SoleSupply
17660801 Chemical 10/1/2003 Statim Must
17660801 Formulation 7/1/1996 FormMax 5 PSO
17662525 Formulation 3/1/2003 FormMax 5 PSO
17662525 Chemical 10/1/2003 Statim Must
17662525 ATC2 1/1/2013 MaxCoPayment 5
17662525 ATC3 11/1/1999 AltSubSA
17662525 ATC3 8/1/1995 ######## SpecialWav
17662525 ATC2 5/16/1994 ######## MaxCoPayment 3
17690101 Chemical 3/1/1996 SpecialWav Claim only
17690101 Formulation5/16/1994 2/29/1996 DoseMMax 30
17690101 Chemical 5/16/1994 2/29/1996 TreatMax 90
17690101 ATC3 9/1/2010 Application
17690101 Chemical 10/1/2003 Statim Must
17690101 ATC3 3/1/1996 8/31/2010 Application
17690102 ATC3 3/1/1996 8/31/2010 Application
17690102 Chemical 10/1/2003 Statim Must
17690102 ATC3 9/1/2010 Application
17690102 Chemical 5/16/1994 2/29/1996 TreatMax 90
17690102 Formulation5/16/1994 2/29/1996 DoseMMax 30
17690102 Chemical 3/1/1996 SpecialWav Claim only
17720101 Chemical 6/1/1995 SpecEnd Retail
17720125 Chemical 6/1/1995 SpecEnd Retail
17720125 Brand 12/1/2001 6/30/2004 SoleSupply
17720126 Brand 8/1/2010 6/30/2012 SoleSupply
17720126 Brand 4/1/2013 6/30/2015 SoleSupply
17720126 Chemical 6/1/1995 SpecEnd Retail
17730101 Chemical 5/16/1994 ######## SpecEnd Retail
17730101 Formulation 1/1/2006 SpecEnd Retail
17730101 Chemical 7/1/2005 ######## PCT
17730101 Formulation 1/1/2006 PCT
17730201 Chemical 7/1/2005 ######## PCT
17730201 Chemical 5/16/1994 ######## SpecEnd Retail
17732525 Chemical 5/16/1994 ######## SpecEnd Retail
17732525 Formulation 1/1/2006 SpecEnd Hospital
17732525 Chemical 7/1/2005 ######## PCT
17732525 Formulation 1/1/2006 PCT only
17810101 Chemical 7/1/2005 PCT
17810101 Chemical 6/1/1995 SpecEnd Retail
17810201 Chemical 6/1/1995 SpecEnd Retail
17810201 Chemical 7/1/2005 PCT
17810201 Brand 1/1/2011 6/30/2013 SoleSupply
17810201 Brand 11/1/2013 6/30/2016 SoleSupply
17920101 Chemical 5/16/1994 7/31/1997 SpecEnd Retail
17930101 Chemical 10/1/2003 Statim Must
17940101 Chemical 4/1/2004 Statim Must
17940103 Chemical 4/1/2004 Statim Must
17940103 Brand 11/1/2000 6/30/2003 SoleSupply
17940103 Brand 11/1/2003 6/30/2006 SoleSupply
17940104 Chemical 4/1/2004 Statim Must
17940105 Chemical 4/1/2004 Statim Must
17940105 Brand 1/1/2013 6/30/2015 SoleSupply
17940106 Chemical 4/1/2004 Statim Must
17940125 Chemical 4/1/2004 Statim Must
17940125 Brand 1/1/2008 6/30/2009 SoleSupply
17940126 Brand 5/1/2010 6/30/2012 SoleSupply
17940126 Brand 1/1/2013 6/30/2015 SoleSupply
17940126 Chemical 4/1/2004 Statim Must
17940201 Chemical 4/1/2004 Statim Must
17940203 Chemical 4/1/2004 Statim Must
17940203 Brand 11/1/2000 6/30/2003 SoleSupply
17940203 Brand 11/1/2003 6/30/2006 SoleSupply
17940204 Chemical 4/1/2004 Statim Must
17940205 Chemical 4/1/2004 Statim Must
17940205 Brand 1/1/2013 6/30/2015 SoleSupply
17940206 Chemical 4/1/2004 Statim Must
17940225 Chemical 4/1/2004 Statim Must
17940226 Chemical 4/1/2004 Statim Must
17940226 Brand 1/1/2008 6/30/2009 SoleSupply
17940227 Brand 5/1/2010 6/30/2012 SoleSupply
17940227 Brand 1/1/2013 6/30/2015 SoleSupply
17940227 Chemical 4/1/2004 Statim Must
17950101 Chemical 8/1/2012 SafetyListMedicine
17950101 Formulation 8/1/1996 7/31/1999 NotCombined
17950101 Brand 2/1/2008 6/30/2010 SoleSupply
17950101 Brand 11/1/2010 6/30/2013 SoleSupply
17950101 Chemical 5/16/1994 MaxCoPayment 0
17950101 Chemical 6/22/1995 Controlled
17950102 Chemical 6/22/1995 Controlled
17950102 Chemical 5/16/1994 MaxCoPayment 0
17950102 Brand 1/1/2005 6/30/2007 SoleSupply
17950102 Formulation 8/1/1996 7/31/1999 NotCombined
17950102 Chemical 8/1/2012 SafetyListMedicine
17950201 Chemical 8/1/2012 SafetyListMedicine
17950201 Brand 11/1/2007 9/30/2008 S29
17950201 Chemical 5/16/1994 MaxCoPayment 0
17950201 Chemical 6/22/1995 Controlled
17950225 Chemical 6/22/1995 Controlled
17950225 Chemical 5/16/1994 MaxCoPayment 0
17950225 Brand 10/1/2003 S29
17950225 Brand 4/1/2013 Wastage
17950225 Chemical 8/1/2012 SafetyListMedicine
17950301 Chemical 8/1/2012 SafetyListMedicine
17950301 Chemical 5/16/1994 MaxCoPayment 0
17950301 Chemical 6/22/1995 Controlled
17950301 Formulation 7/1/1996 Safety Uncompounded
17950401 Chemical 6/22/1995 Controlled
17950401 Chemical 5/16/1994 MaxCoPayment 0
17950401 Chemical 8/1/2012 SafetyListMedicine
17950401 Formulation######## Safety Compounded
17950402 Formulation######## Safety Compounded
17950402 Chemical 8/1/2012 SafetyListMedicine
17950402 Chemical 5/16/1994 MaxCoPayment 0
17950402 Chemical 6/22/1995 Controlled
17950425 Chemical 5/16/1994 MaxCoPayment 0
11400227 Chemical 12/1/1999 8/31/2004 Special
11400227 Chemical 2/1/1999 ######## Special
11400227 Chemical 8/1/2012 SafetyListMedicine
11400301 Chemical 8/1/2012 SafetyListMedicine
11400301 Chemical 2/1/1999 ######## Special
11400301 Chemical 12/1/1999 8/31/2004 Special
11400301 Chemical 9/1/2004 8/31/2011 Application
11400301 Brand 6/1/2011 8/31/2011 Special Claim only
11400325 Chemical 9/1/2004 8/31/2011 Application
11400325 Chemical 2/1/1999 ######## Special
11400325 Chemical 12/1/1999 8/31/2004 Special
11400325 Chemical 8/1/2012 SafetyListMedicine
11400326 Chemical 8/1/2012 SafetyListMedicine
11400326 Chemical 12/1/1999 8/31/2004 Special
11400326 Chemical 2/1/1999 ######## Special
11400326 Chemical 9/1/2004 8/31/2011 Application
11400327 Chemical 9/1/2004 8/31/2011 Application
11400327 Chemical 2/1/1999 ######## Special
11400327 Chemical 12/1/1999 8/31/2004 Special
11400327 Chemical 8/1/2012 SafetyListMedicine
11401525 Chemical 8/1/2012 SafetyListMedicine
11401525 Chemical 2/1/1999 ######## Special
11401525 Chemical 12/1/1999 8/31/2004 Special
11401525 Chemical 5/1/2014 Special
11401525 Chemical 7/1/2011 4/30/2014 Special
11401625 Chemical 7/1/2011 4/30/2014 Special
11401625 Chemical 5/1/2014 Special
11401625 Chemical 12/1/1999 8/31/2004 Special
11401625 Chemical 2/1/1999 ######## Special
11401625 Chemical 8/1/2012 SafetyListMedicine
11401725 Chemical 8/1/2012 SafetyListMedicine
11401725 Chemical 2/1/1999 ######## Special
11401725 Chemical 12/1/1999 8/31/2004 Special
11401725 Chemical 5/1/2014 Special
11401725 Chemical 7/1/2011 4/30/2014 Special
11402725 Chemical 9/1/2004 8/31/2011 Application
11402725 Chemical 12/1/1999 8/31/2004 Special
11402725 Chemical 2/1/1999 ######## Special
11402725 Chemical 8/1/2012 SafetyListMedicine
11402726 Chemical 8/1/2012 SafetyListMedicine
11402726 Chemical 2/1/1999 ######## Special
11402726 Chemical 12/1/1999 8/31/2004 Special
11402726 Chemical 9/1/2004 8/31/2011 Application
11402727 Chemical 9/1/2004 8/31/2011 Application
11402727 Chemical 12/1/1999 8/31/2004 Special
11402727 Chemical 2/1/1999 ######## Special
11402727 Chemical 8/1/2012 SafetyListMedicine
11402728 Chemical 8/1/2012 SafetyListMedicine
11402728 Chemical 2/1/1999 ######## Special
11402728 Chemical 12/1/1999 8/31/2004 Special
11402728 Chemical 9/1/2004 8/31/2011 Application
11402825 Chemical 9/1/2004 8/31/2011 Application
11402825 Chemical 2/1/1999 ######## Special
11402825 Chemical 12/1/1999 8/31/2004 Special
11402825 Chemical 8/1/2012 SafetyListMedicine
11402826 Chemical 8/1/2012 SafetyListMedicine
11402826 Chemical 12/1/1999 8/31/2004 Special
11402826 Chemical 2/1/1999 ######## Special
11402826 Chemical 9/1/2004 8/31/2011 Application
11402827 Chemical 9/1/2004 8/31/2011 Application
11402827 Chemical 12/1/1999 8/31/2004 Special
11402827 Chemical 2/1/1999 ######## Special
11402827 Chemical 8/1/2012 SafetyListMedicine
11402828 Chemical 8/1/2012 SafetyListMedicine
11402828 Chemical 2/1/1999 ######## Special
11402828 Chemical 12/1/1999 8/31/2004 Special
11402828 Chemical 9/1/2004 8/31/2011 Application
11440101 Formulation5/16/1994 FormMax 30 PSO
11440101 Formulation5/16/1994 Statim May
11450101 Chemical 6/1/2002 FormReqd Rx
11460201 Chemical 6/15/1995 FormReqd Rx
11460301 Chemical 6/15/1995 FormReqd Rx
11472501 Formulation6/15/1995 FormMax 15 Rx
11472501 Formulation6/15/1995 FormReqd Rx
11480101 Formulation6/15/1995 ######## FormMax 15 Rx
11480101 Formulation12/1/1998 FormMax 15 Rx
11480101 Formulation12/1/1998 FormReqd Rx
11490101 Brand 10/1/2004 6/30/2007 SoleSupply
11490101 Brand 10/1/2011 6/30/2014 SoleSupply
11490101 Formulation11/1/1997 9/30/2003 Statim May
11490101 Chemical 10/1/2003 Statim Must
11490101 Chemical 5/16/1994 9/30/2007 SpecEnd Retail
11490201 Chemical 5/16/1994 9/30/2007 SpecEnd Retail
11490201 Chemical 10/1/2003 Statim Must
11490201 Formulation11/1/1997 9/30/2003 Statim May
11490201 Brand 12/1/2004 6/30/2007 SoleSupply
11490201 Brand 10/1/2011 6/30/2014 SoleSupply
11490225 Brand 10/1/2002 6/30/2004 SoleSupply
11490225 Formulation11/1/1997 9/30/2003 Statim May
11490225 Chemical 10/1/2003 Statim Must
11490225 Chemical 5/16/1994 9/30/2007 SpecEnd Retail
11500101 Chemical 6/1/2002 FormReqd Rx
11500201 Chemical 6/1/2002 FormReqd Rx
11510101 ATC3 6/14/1995 9/30/1997 SpecEnd Retail
11510101 Chemical 10/1/2003 Statim Must
11510101 Brand 11/1/1999 6/30/2002 SoleSupply
11510101 Brand 6/1/2013 6/30/2015 SoleSupply
11510102 Brand 3/1/2003 6/30/2005 SoleSupply
11510102 Brand 1/1/2006 6/30/2008 SoleSupply
11510102 Brand 1/1/2009 6/30/2011 SoleSupply
11510102 Chemical 10/1/2003 Statim Must
11510102 ATC3 6/14/1995 9/30/1997 SpecEnd Retail
11510201 ATC3 6/14/1995 9/30/1997 SpecEnd Retail
11510201 Chemical 10/1/2003 Statim Must
11510201 Brand 11/1/2012 6/30/2015 SoleSupply
11560101 ATC2 12/1/1996 6/30/2010 Application
11560101 ATC2 7/1/2010 Application
11560101 Chemical 10/1/2003 Statim Must
11560201 Chemical 10/1/2003 Statim Must
11560201 ATC2 7/1/2010 Application
11560201 ATC2 12/1/1996 6/30/2010 Application
11580101 Chemical 2/1/1999 ######## SpecialWav
11580101 Chemical 8/1/2005 ######## SpecialWav
11580101 Chemical 6/1/2012 Statim Must
11580101 Chemical 12/1/2008 1/31/2009 AltSubSA
11580101 Chemical 11/1/2002 7/31/2005 SpecialWav
11580101 Chemical 1/1/2006 ######## AltSubSA
11580125 Chemical 12/1/2008 1/31/2009 AltSubSA
11580125 Chemical 1/1/2006 ######## AltSubSA
11580125 Chemical 11/1/2002 7/31/2005 SpecialWav
11580125 Chemical 6/1/2012 Statim Must
11580125 Chemical 8/1/2005 ######## SpecialWav
11580125 Chemical 2/1/1999 ######## SpecialWav
11580126 Chemical 2/1/1999 ######## SpecialWav
11580126 Chemical 8/1/2005 ######## SpecialWav
11580126 Chemical 6/1/2012 Statim Must
11580126 Chemical 11/1/2002 7/31/2005 SpecialWav
14920302 Brand 4/1/2005 6/30/2007 SoleSupply
14920302 Brand 10/1/2007 6/30/2010 SoleSupply
14920302 Formulation 1/1/2011 3/31/2011 Brandswitch 2377845 BSF Univent
14920325 Formulation 1/1/2011 3/31/2011 Brandswitch 2377845 BSF Univent
14920325 Brand 9/1/2002 6/30/2004 SoleSupply
14920325 Formulation 7/1/1996 FormMax 40 PSO
14920326 Formulation 7/1/1996 FormMax 40 PSO
14920326 Brand 1/1/2011 6/30/2013 SoleSupply
14920326 Brand 10/1/2013 6/30/2016 SoleSupply
14920326 Formulation 1/1/2011 3/31/2011 Brandswitch 2377845 BSF Univent
14920401 Formulation 7/1/1996 FormMax 40 PSO
14920601 Brand 11/1/2002 6/30/2005 SoleSupply
14920625 Brand 3/1/2008 6/30/2010 SoleSupply
14920626 Brand 9/1/2011 6/30/2013 SoleSupply
14920626 Brand 10/1/2013 6/30/2016 SoleSupply
14920701 Formulation 4/1/1999 FormMax 40 PSO
14920701 Brand 7/1/1999 6/30/2001 SoleSupply
14920701 Brand 4/1/2005 6/30/2007 SoleSupply
14920701 Brand 10/1/2007 6/30/2010 SoleSupply
14920701 Formulation 1/1/2011 3/31/2011 Brandswitch 2377845 BSF Univent
14920725 Formulation 1/1/2011 3/31/2011 Brandswitch 2377845 BSF Univent
14920725 Brand 9/1/2002 6/30/2004 SoleSupply
14920725 Formulation 4/1/1999 FormMax 40 PSO
14920726 Formulation 4/1/1999 FormMax 40 PSO
14920726 Brand 1/1/2011 6/30/2013 SoleSupply
14920726 Brand 10/1/2013 6/30/2016 SoleSupply
14920726 Formulation 1/1/2011 3/31/2011 Brandswitch 2377845 BSF Univent
14922525 Brand 1/1/2006 6/30/2008 SoleSupply
14980101 Chemical 10/1/2003 ######## Statim Must
14980101 Formulation 1/1/2005 Statim Must
14980102 Formulation 1/1/2005 Statim Must
14980102 Chemical 10/1/2003 ######## Statim Must
14980103 Chemical 10/1/2003 ######## Statim Must
14980103 Formulation 1/1/2005 Statim Must
14980103 Brand 2/1/2001 6/30/2003 SoleSupply
14980103 Brand 12/1/2003 6/30/2006 SoleSupply
14980103 Brand 10/1/2006 6/30/2009 SoleSupply
14980125 Formulation 1/1/2005 Statim Must
14980125 Chemical 10/1/2003 ######## Statim Must
14980201 Chemical 10/1/2003 ######## Statim Must
14980201 Formulation 1/1/2005 Statim Must
14980301 Chemical 10/1/2003 ######## Statim Must
14980301 Formulation 3/1/1996 ######## SpecEnd Retail
14980301 Brand 12/1/2002 ######## SoleSupply
14982525 Brand 12/1/2003 6/30/2006 SoleSupply
14982525 Brand 10/1/2006 6/30/2009 SoleSupply
14982525 Chemical 10/1/2003 ######## Statim Must
14982525 Formulation 1/1/2005 Statim Must
14982525 Formulation 8/1/2012 ProvAllow Dietitian
14982526 Formulation 8/1/2012 ProvAllow Dietitian
14982526 Brand 2/1/2006 S29
14982526 Brand 4/1/2013 Wastage
14982526 Formulation 1/1/2005 Statim Must
14982526 Chemical 10/1/2003 ######## Statim Must
14990201 Formulation 7/1/1996 Safety Uncompounded
15010101 Chemical 10/1/2003 Statim Must
15010101 Formulation 8/1/2010 ProvAllow Dietitian
15100102 Chemical 6/14/1995 SpecEnd Retail
15100102 Formulation 7/1/1996 Statim May
15100103 Formulation 7/1/1996 Statim May
15100103 Chemical 6/14/1995 SpecEnd Retail
15100202 Chemical 6/14/1995 SpecEnd Retail
15100202 Formulation 7/1/1996 Statim May
15100202 Formulation12/1/2011 OraProduct
15100203 Formulation12/1/2011 OraProduct
15100203 Formulation 7/1/1996 Statim May
15100203 Chemical 6/14/1995 SpecEnd Retail
15100301 Chemical 6/14/1995 SpecEnd Retail
15100401 Chemical 6/14/1995 SpecEnd Retail
15100401 Formulation 7/1/1996 Statim May
15100501 Formulation 7/1/1996 Statim May
15100501 Chemical 6/14/1995 SpecEnd Retail
15110101 Formulation 2/1/2001 FormMax 200 PSO
15110101 Formulation5/16/1994 Wastage
15110101 Brand 8/1/1999 6/30/2002 SoleSupply
15110201 Formulation5/16/1994 Wastage
15110201 Formulation 2/1/2001 FormMax 200 PSO
15120101 Formulation 7/1/1996 FormMax 30 PSO
15120102 Formulation 7/1/1996 FormMax 30 PSO
15120104 Formulation 7/1/1996 FormMax 30 PSO
15120104 Brand 12/1/2000 6/30/2003 SoleSupply
15120104 Brand 5/1/2004 6/30/2006 SoleSupply
15120104 Brand 10/1/2006 6/30/2009 SoleSupply
15120104 Brand 1/1/2013 6/30/2015 SoleSupply
15120105 Formulation 7/1/1996 FormMax 30 PSO
15120125 Formulation 7/1/1996 FormMax 30 PSO
15120125 Brand 6/1/2010 6/30/2012 SoleSupply
15120204 Brand 12/1/2000 6/30/2003 SoleSupply
15120204 Brand 5/1/2004 6/30/2006 SoleSupply
15120204 Brand 10/1/2006 6/30/2009 SoleSupply
15120204 Brand 1/1/2013 6/30/2015 SoleSupply
15120225 Brand 6/1/2010 6/30/2012 SoleSupply
15120301 Formulation 5/1/1994 Wastage
15120301 Formulation 2/1/2001 FormMax 200 PSO
15120302 Formulation 2/1/2001 FormMax 200 PSO
15120302 Formulation 5/1/1994 Wastage
15120325 Formulation 5/1/1994 Wastage
15120325 Formulation 2/1/2001 FormMax 200 PSO
15120325 Brand 4/1/2004 6/30/2006 SoleSupply
15120325 Brand 10/1/2006 6/30/2009 SoleSupply
15120325 Brand 1/1/2010 6/30/2012 SoleSupply
15120325 Brand 10/1/2012 6/30/2015 SoleSupply
15120401 Formulation 2/1/2001 FormMax 200 PSO
15120401 Formulation 5/1/1994 Wastage
15120402 Formulation 5/1/1994 Wastage
15120402 Formulation 2/1/2001 FormMax 200 PSO
15120425 Formulation 2/1/2001 FormMax 200 PSO
15120425 Formulation 5/1/1994 Wastage
15120425 Brand 4/1/2004 6/30/2006 SoleSupply
15120425 Brand 10/1/2006 6/30/2009 SoleSupply
15120425 Brand 1/1/2010 6/30/2012 SoleSupply
15120425 Brand 10/1/2012 6/30/2015 SoleSupply
15120501 Formulation 7/1/1996 2/28/2001 FormMax 5 PSO
15120502 Formulation 7/1/1996 2/28/2001 FormMax 5 PSO
15120502 Brand 12/1/2000 6/30/2003 SoleSupply
15120502 Brand 10/1/2003 6/30/2006 SoleSupply
15120502 Brand 3/1/2009 6/30/2011 SoleSupply
15120502 Brand 12/1/2011 6/30/2014 SoleSupply
15120601 Formulation 7/1/1996 2/28/2001 FormMax 5 PSO
15120602 Formulation 7/1/1996 2/28/2001 FormMax 5 PSO
15120602 Brand 12/1/2000 6/30/2003 SoleSupply
15120602 Brand 10/1/2003 6/30/2006 SoleSupply
15120602 Brand 3/1/2009 6/30/2011 SoleSupply
15120602 Brand 12/1/2011 6/30/2014 SoleSupply
11780125 Chemical 12/1/2005 5/31/2012 SubRxF Special
11780125 Chemical 7/1/2004 5/31/2012 FormMax 2 Rx Special
11780125 Formulation 1/1/1999 6/30/2004 SubRxF
11780125 Chemical 10/1/2005 8/31/2010 FormMax 4 PSO
11780125 Formulation 6/1/2012 FormMax 8 PSO
11780125 Formulation 6/1/2012 ######## Application
11780125 Formulation 1/1/1999 6/30/2004 FormMax 2 Rx
11780125 Formulation 7/1/2004 ######## SubRxF
11780125 Brand 2/1/2008 6/30/2009 SoleSupply
11780125 Brand 10/1/2009 6/30/2012 SoleSupply
11780125 Chemical 6/1/2011 5/31/2012 Application
11780125 Chemical 9/1/2010 5/31/2012 FormMax 8 PSO
11780125 Chemical 7/1/2009 5/31/2011 Application
11780126 Chemical 7/1/2009 5/31/2011 Application
11780126 Chemical 9/1/2010 5/31/2012 FormMax 8 PSO
11780126 Chemical 6/1/2011 5/31/2012 Application
11780126 Brand 5/1/2013 6/30/2015 SoleSupply
11780126 Formulation 1/1/1999 6/30/2004 FormMax 2 Rx
11780126 Formulation 6/1/2012 FormMax 8 PSO
11780126 Formulation 7/1/2004 ######## SubRxF
11780126 Formulation 6/1/2012 ######## Application
11780126 Chemical 10/1/2005 8/31/2010 FormMax 4 PSO
11780126 Formulation 1/1/1999 6/30/2004 SubRxF
11780126 Chemical 7/1/2004 5/31/2012 FormMax 2 Rx Special
11780126 Chemical 3/1/2013 TreatMax 5 Rx SubRxF
11780126 Chemical 12/1/2005 5/31/2012 SubRxF Special
11780126 Formulation 6/1/2012 ######## SubRxF Special
11780126 Formulation 6/1/2012 ######## FormMax 2 Rx Special
11782525 Chemical 12/1/2005 5/31/2012 SubRxF Special
11782525 Chemical 3/1/2013 TreatMax 5 Rx SubRxF
11782525 Chemical 7/1/2004 5/31/2012 FormMax 2 Rx Special
11782525 Formulation 6/1/2012 Wastage
11782525 Formulation 8/1/2012 ######## SubRxF
11782525 Chemical 10/1/2005 8/31/2010 FormMax 4 PSO
11782525 Chemical 6/1/2011 5/31/2012 Application
11782525 Chemical 7/1/2009 5/31/2011 Application
11782525 Chemical 9/1/2010 5/31/2012 FormMax 8 PSO
11782525 Formulation 6/1/2012 7/31/2012 SubRxF
11782625 Chemical 7/1/2009 5/31/2011 Application
11782625 Chemical 6/1/2011 5/31/2012 Application
11782625 Chemical 9/1/2010 5/31/2012 FormMax 8 PSO
11782625 Chemical 10/1/2005 8/31/2010 FormMax 4 PSO
11782625 Chemical 7/1/2004 5/31/2012 FormMax 2 Rx Special
11782625 Chemical 3/1/2013 TreatMax 5 Rx SubRxF
11782625 Chemical 12/1/2005 5/31/2012 SubRxF Special
11790101 Chemical 6/1/2002 FormReqd Rx
11790101 Chemical 6/1/2002 NotCombined
11790125 Chemical 6/1/2002 NotCombined
11790125 Brand 2/1/2007 6/30/2009 SoleSupply
11790125 Chemical 6/1/2002 FormReqd Rx
11790126 Chemical 6/1/2002 FormReqd Rx
11790126 Brand 1/1/2010 6/30/2012 SoleSupply
11790126 Chemical 6/1/2002 NotCombined
11790127 Chemical 6/1/2002 NotCombined
11790127 Chemical 6/1/2002 FormReqd Rx
11790128 Chemical 6/1/2002 FormReqd Rx
11790128 Chemical 6/1/2002 NotCombined
11790201 Chemical 6/1/2002 NotCombined
11790201 Brand 1/1/2010 6/30/2012 SoleSupply
11790201 Brand 12/1/2012 6/30/2015 SoleSupply
11790201 Chemical 6/1/2002 FormReqd Rx
11790225 Chemical 6/1/2002 FormReqd Rx
11790225 Brand 3/1/2007 6/30/2009 SoleSupply
11790225 Chemical 6/1/2002 NotCombined
11790301 Chemical 6/1/2002 NotCombined
11790301 Chemical 6/1/2002 FormReqd Rx
11790401 Chemical 6/1/2002 FormReqd Rx
11790401 Chemical 6/1/2002 NotCombined
11810101 Chemical 8/1/2005 ######## SpecialWav
11810101 Chemical 1/1/2005 7/31/2005 SpecialWav
11810101 Chemical 12/1/2008 ######## AltSubSA
11810101 Chemical 2/1/1999 ######## SpecialWav
11810101 Chemical 1/1/2006 ######## AltSubSA
11810101 Chemical 6/1/2012 Statim Must
11810125 Chemical 6/1/2012 Statim Must
11810125 Chemical 1/1/2006 ######## AltSubSA
11810125 Chemical 2/1/1999 ######## SpecialWav
11810125 Chemical 12/1/2008 ######## AltSubSA
11810125 Chemical 1/1/2005 7/31/2005 SpecialWav
11810125 Brand 7/1/2010 6/30/2012 SoleSupply
11810125 Chemical 8/1/2005 ######## SpecialWav
11810126 Chemical 8/1/2005 ######## SpecialWav
11810126 Brand 1/1/2013 6/30/2015 SoleSupply
11810126 Chemical 1/1/2005 7/31/2005 SpecialWav
11810126 Chemical 12/1/2008 ######## AltSubSA
11810126 Chemical 2/1/1999 ######## SpecialWav
11810126 Chemical 1/1/2006 ######## AltSubSA
11810126 Chemical 6/1/2012 Statim Must
11830101 Chemical 5/1/2001 5/31/2002 Special
11830101 Chemical 6/1/2002 6/30/2004 SubRxF
11830101 Chemical 8/1/2012 SafetyListMedicine
11830101 Chemical 7/1/2004 9/30/2007 SubRxF
11830125 Chemical 7/1/2004 9/30/2007 SubRxF
11830125 Chemical 6/1/2002 6/30/2004 SubRxF
11830125 Chemical 8/1/2012 SafetyListMedicine
11830125 Chemical 5/1/2001 5/31/2002 Special
11830126 Chemical 6/1/2002 6/30/2004 SubRxF
11830126 Chemical 8/1/2012 SafetyListMedicine
11830126 Chemical 5/1/2001 5/31/2002 Special
11830126 Chemical 7/1/2004 9/30/2007 SubRxF
11830201 Chemical 7/1/2004 9/30/2007 SubRxF
11830201 Chemical 5/1/2001 5/31/2002 Special
11830201 Chemical 8/1/2012 SafetyListMedicine
11830201 Chemical 6/1/2002 6/30/2004 SubRxF
11830225 Chemical 5/1/2001 5/31/2002 Special
11830225 Chemical 8/1/2012 SafetyListMedicine
11830225 Chemical 6/1/2002 6/30/2004 SubRxF
11830225 Chemical 7/1/2004 9/30/2007 SubRxF
11830226 Chemical 7/1/2004 9/30/2007 SubRxF
11830226 Chemical 6/1/2002 6/30/2004 SubRxF
11830226 Chemical 8/1/2012 SafetyListMedicine
11830226 Chemical 5/1/2001 5/31/2002 Special
11830301 Chemical 5/1/2001 5/31/2002 Special
11830301 Chemical 8/1/2012 SafetyListMedicine
11830301 Chemical 6/1/2002 6/30/2004 SubRxF
11830301 Chemical 7/1/2004 9/30/2007 SubRxF
11830325 Chemical 7/1/2004 9/30/2007 SubRxF
11830325 Chemical 8/1/2012 SafetyListMedicine
11830325 Chemical 6/1/2002 6/30/2004 SubRxF
11830325 Chemical 5/1/2001 5/31/2002 Special
11830326 Chemical 6/1/2002 6/30/2004 SubRxF
11830326 Chemical 8/1/2012 SafetyListMedicine
11830326 Chemical 5/1/2001 5/31/2002 Special
11830326 Chemical 7/1/2004 9/30/2007 SubRxF
11830401 Chemical 7/1/2004 9/30/2007 SubRxF
11830401 Chemical 5/1/2001 5/31/2002 Special
10010101 Chemical 10/1/2003 Statim Must
10010101 Formulation 7/1/1996 9/30/2003 Statim May
10010102 Formulation 7/1/1996 9/30/2003 Statim May
10010102 Brand 8/1/1998 6/30/2001 SoleSupply
10010102 Chemical 10/1/2003 Statim Must
10010201 Chemical 10/1/2003 Statim Must
10010201 Formulation 7/1/1996 9/30/2003 Statim May
10010202 Formulation 7/1/1996 9/30/2003 Statim May
10010202 Brand 8/1/1998 6/30/2001 SoleSupply
10010202 Chemical 10/1/2003 Statim Must
10010301 Chemical 10/1/2003 Statim Must
10010301 Formulation 7/1/1996 9/30/2003 Statim May
10010302 Formulation 7/1/1996 9/30/2003 Statim May
10010302 Brand 8/1/1998 6/30/2001 SoleSupply
10010302 Chemical 10/1/2003 Statim Must
10020101 ATC3 8/1/2003 6/30/2005 Application
10020101 Chemical 1/1/2001 7/31/2003 Special
10020101 ATC3 1/1/2001 7/31/2003 Special
10020101 ATC3 7/1/2005 7/31/2007 Application
10020101 Chemical 7/1/1996 Statim May
10020101 Chemical 8/1/2003 Special Claim only
10020101 Chemical 9/1/2000 ######## Special
10020201 Chemical 9/1/2000 ######## Special
10020201 Chemical 8/1/2003 Special Claim only
10020201 Chemical 7/1/1996 Statim May
10020201 ATC3 7/1/2005 7/31/2007 Application
10020201 ATC3 1/1/2001 7/31/2003 Special
10020201 Chemical 1/1/2001 7/31/2003 Special
10020201 ATC3 8/1/2003 6/30/2005 Application
10020301 ATC3 8/1/2003 6/30/2005 Application
10020301 Chemical 1/1/2001 7/31/2003 Special
10020301 ATC3 1/1/2001 7/31/2003 Special
10020301 ATC3 7/1/2005 7/31/2007 Application
10020301 Chemical 7/1/1996 Statim May
10020301 Chemical 8/1/2003 Special Claim only
10020301 Chemical 9/1/2000 ######## Special
10022501 Formulation 2/1/2007 Statim May
10022501 ATC3 7/1/2005 7/31/2007 Application
10022501 Chemical 1/1/2001 7/31/2003 Special
10022501 ATC3 8/1/2003 6/30/2005 Application
10022525 ATC3 8/1/2003 6/30/2005 Application
10022525 Chemical 1/1/2001 7/31/2003 Special
10022525 ATC3 7/1/2005 7/31/2007 Application
10022525 Formulation 2/1/2007 Statim May
10022601 Formulation 2/1/2007 Statim May
10022601 ATC3 7/1/2005 7/31/2007 Application
10022601 Chemical 1/1/2001 7/31/2003 Special
10022601 ATC3 8/1/2003 6/30/2005 Application
10022625 ATC3 8/1/2003 6/30/2005 Application
10022625 Chemical 1/1/2001 7/31/2003 Special
10022625 ATC3 7/1/2005 7/31/2007 Application
10022625 Formulation 2/1/2007 Statim May
10022626 Formulation 2/1/2007 Statim May
10022626 ATC3 7/1/2005 7/31/2007 Application
10022626 Chemical 1/1/2001 7/31/2003 Special
10022626 ATC3 8/1/2003 6/30/2005 Application
10022627 ATC3 8/1/2003 6/30/2005 Application
10022627 Chemical 1/1/2001 7/31/2003 Special
10022627 ATC3 7/1/2005 7/31/2007 Application
10022627 Formulation 2/1/2007 Statim May
10022701 Formulation 2/1/2007 Statim May
10022701 ATC3 7/1/2005 7/31/2007 Application
10022701 Chemical 1/1/2001 7/31/2003 Special
10022701 ATC3 8/1/2003 6/30/2005 Application
10022725 ATC3 8/1/2003 6/30/2005 Application
10022725 Chemical 1/1/2001 7/31/2003 Special
10022725 ATC3 7/1/2005 7/31/2007 Application
10022725 Formulation 2/1/2007 Statim May
10022726 Formulation 2/1/2007 Statim May
10022726 ATC3 7/1/2005 7/31/2007 Application
10022726 Chemical 1/1/2001 7/31/2003 Special
10022726 ATC3 8/1/2003 6/30/2005 Application
10022727 ATC3 8/1/2003 6/30/2005 Application
10022727 Chemical 1/1/2001 7/31/2003 Special
10022727 ATC3 7/1/2005 7/31/2007 Application
10022727 Formulation 2/1/2007 Statim May
10022801 Formulation 2/1/2007 Statim May
10022801 ATC3 7/1/2005 7/31/2007 Application
10022801 Chemical 1/1/2001 7/31/2003 Special
10022801 ATC3 8/1/2003 6/30/2005 Application
10022825 ATC3 8/1/2003 6/30/2005 Application
10022825 Chemical 1/1/2001 7/31/2003 Special
10022825 ATC3 7/1/2005 7/31/2007 Application
10022825 Formulation 2/1/2007 Statim May
10022826 Formulation 2/1/2007 Statim May
10022826 ATC3 7/1/2005 7/31/2007 Application
10022826 Chemical 1/1/2001 7/31/2003 Special
10022826 ATC3 8/1/2003 6/30/2005 Application
10022827 ATC3 8/1/2003 6/30/2005 Application
10022827 Chemical 1/1/2001 7/31/2003 Special
10022827 ATC3 7/1/2005 7/31/2007 Application
10022827 Formulation 2/1/2007 Statim May
10022925 Formulation 2/1/2007 Statim May
10022925 ATC3 7/1/2005 7/31/2007 Application
10022925 Chemical 1/1/2001 7/31/2003 Special
10022925 ATC3 8/1/2003 6/30/2005 Application
10022926 ATC3 8/1/2003 6/30/2005 Application
10022926 Chemical 1/1/2001 7/31/2003 Special
10022926 ATC3 7/1/2005 7/31/2007 Application
10022926 Formulation 2/1/2007 Statim May
10023025 Formulation 7/1/2007 Statim May
10023025 ATC3 7/1/2005 7/31/2007 Application
10023025 Chemical 1/1/2001 7/31/2003 Special
10023025 ATC3 8/1/2003 6/30/2005 Application
10030101 Chemical 10/1/2003 Statim Must
10030101 Brand 10/1/2005 6/30/2008 SoleSupply
10030101 Brand 1/1/2009 6/30/2011 SoleSupply
10030101 Brand 12/1/2011 6/30/2014 SoleSupply
10030101 Formulation12/1/2011 OraProduct
10030101 Formulation11/1/1997 9/30/2003 Statim May
10030102 Formulation11/1/1997 9/30/2003 Statim May
10030102 Formulation12/1/2011 OraProduct
10030102 Chemical 10/1/2003 Statim Must
10030201 Chemical 10/1/2003 Statim Must
10030201 Formulation11/1/1997 9/30/2003 Statim May
10040101 Chemical 7/1/1996 Statim May
10040101 Chemical 9/1/2000 ######## Special
10040101 Chemical 8/1/2003 7/31/2007 Special Claim only
10040101 ATC3 7/1/2005 7/31/2007 Application
10040101 Chemical 11/1/2008 3/31/2010 Special
10040101 Chemical 1/1/2011 Special
10040101 ATC3 8/1/2003 6/30/2005 Application
10040101 Chemical 1/1/2001 7/31/2003 Special
10040101 Chemical 8/1/2007 ######## Special
10040101 Chemical 4/1/2010 ######## Special
10090101 ATC3 5/16/1994 8/31/1996 Special
10090101 ATC3 12/1/1996 1/31/1998 Special
10090101 Chemical 1/1/1999 7/31/2010 Dispensary HP3
10090101 Chemical 7/1/2006 7/31/2009 Special
10090101 ATC3 2/1/1998 6/30/1999 Special
17971001 Formulation5/16/1994 7/31/2010 SpecEnd Hospital
17971001 Formulation 1/1/1999 7/31/2010 Dispensary HP1
17971001 Formulation 8/1/2010 SpecEnd Retail
17971001 Chemical 10/1/2003 Statim Must
17971002 Chemical 10/1/2003 Statim Must
17971002 Formulation 8/1/2010 SpecEnd Retail
17971002 Formulation 1/1/1999 7/31/2010 Dispensary HP1
17971002 Formulation5/16/1994 7/31/2010 SpecEnd Hospital
17971002 Chemical 7/1/2005 ######## PCT
17971002 Formulation12/1/2005 PCT
17971101 Formulation12/1/2005 PCT
17971101 Chemical 7/1/2005 ######## PCT
17971101 Formulation5/16/1994 7/31/2010 SpecEnd Hospital
17971101 Formulation 1/1/1999 7/31/2010 Dispensary HP1
17971101 Formulation 8/1/2010 SpecEnd Retail
17971101 Chemical 10/1/2003 Statim Must
17971125 Chemical 10/1/2003 Statim Must
17971125 Formulation 8/1/2010 SpecEnd Retail
17971125 Formulation 1/1/1999 7/31/2010 Dispensary HP1
17971125 Formulation5/16/1994 7/31/2010 SpecEnd Hospital
17971125 Chemical 7/1/2005 ######## PCT
17971125 Formulation12/1/2005 PCT
17971125 Brand 9/1/2006 6/30/2008 SoleSupply
17971125 Brand 12/1/2008 6/30/2011 SoleSupply
17971201 Formulation12/1/2005 PCT
17971201 Chemical 7/1/2005 ######## PCT
17971201 Formulation5/16/1994 7/31/2010 SpecEnd Hospital
17971201 Formulation 8/1/2010 SpecEnd Retail
17971201 Formulation 1/1/1999 7/31/2010 Dispensary HP1
17971201 Chemical 10/1/2003 Statim Must
17971202 Chemical 10/1/2003 Statim Must
17971202 Formulation 1/1/1999 7/31/2010 Dispensary HP1
17971202 Formulation 8/1/2010 SpecEnd Retail
17971202 Formulation5/16/1994 7/31/2010 SpecEnd Hospital
17971202 Chemical 7/1/2005 ######## PCT
17971202 Formulation12/1/2005 PCT
17971225 Formulation12/1/2005 PCT
17971225 Chemical 7/1/2005 ######## PCT
17971225 Brand 9/1/2006 6/30/2008 SoleSupply
17971225 Brand 12/1/2008 6/30/2011 SoleSupply
17971225 Formulation 1/1/1999 7/31/2010 Dispensary HP1
17971225 Formulation5/16/1994 7/31/2010 SpecEnd Hospital
17971225 Formulation 8/1/2010 SpecEnd Retail
17971225 Chemical 10/1/2003 Statim Must
17972525 Chemical 10/1/2003 Statim Must
17972525 Formulation12/1/2005 SpecEnd Hospital
17972525 Chemical 7/1/2005 ######## PCT
17972525 Formulation12/1/2005 PCT only
17972526 Formulation12/1/2005 PCT only
17972526 Chemical 7/1/2005 ######## PCT
17972526 Formulation12/1/2005 SpecEnd Hospital
17972526 Chemical 10/1/2003 Statim Must
17972625 Chemical 10/1/2003 Statim Must
17972625 Formulation12/1/2005 SpecEnd Hospital
17972625 Chemical 7/1/2005 ######## PCT
17972625 Formulation12/1/2005 PCT only
17972626 Formulation12/1/2005 PCT only
17972626 Chemical 7/1/2005 ######## PCT
17972626 Formulation12/1/2005 SpecEnd Hospital
17972626 Chemical 10/1/2003 Statim Must
17972725 Chemical 10/1/2003 Statim Must
17972725 Formulation 4/1/2006 SpecEnd Hospital
17972725 Formulation 4/1/2006 Dispensary HP1
17972725 Chemical 7/1/2005 ######## PCT
17972725 Formulation 4/1/2006 PCT
17972725 Brand 7/1/2006 6/30/2008 SoleSupply
17972825 Formulation 6/1/2011 PCT
17972825 Chemical 7/1/2005 ######## PCT
17972825 Formulation 6/1/2011 SpecEnd Retail
17972825 Chemical 10/1/2003 Statim Must
17972825 Brand 6/1/2011 S29
17972825 Brand 4/1/2013 Wastage
17972925 Chemical 10/1/2003 Statim Must
17972925 Chemical 7/1/2005 ######## PCT
17972925 Brand 2/1/2014 6/30/2016 SoleSupply
17973025 Brand 2/1/2014 6/30/2016 SoleSupply
17973025 Chemical 7/1/2005 ######## PCT
17973025 Chemical 10/1/2003 Statim Must
17973125 Chemical 10/1/2003 Statim Must
17973125 Chemical 7/1/2005 ######## PCT
17973125 Brand 2/1/2014 6/30/2016 SoleSupply
17973225 Brand 2/1/2014 6/30/2016 SoleSupply
17973225 Chemical 7/1/2005 ######## PCT
17973225 Chemical 10/1/2003 Statim Must
17973325 Chemical 10/1/2003 Statim Must
17973325 Chemical 7/1/2005 ######## PCT
17973325 Brand 2/1/2014 6/30/2016 SoleSupply
17973425 Brand 2/1/2014 6/30/2016 SoleSupply
17973425 Chemical 7/1/2005 ######## PCT
17973425 Chemical 10/1/2003 Statim Must
17990101 Chemical 8/1/2012 SafetyListMedicine
17990201 Chemical 8/1/2012 SafetyListMedicine
17990301 Chemical 8/1/2012 SafetyListMedicine
18000101 Chemical 5/16/1994 SpecEnd Retail
18050101 Chemical 10/1/2003 Statim Must
18060101 Chemical 10/1/2003 Statim Must
18060103 Chemical 10/1/2003 Statim Must
18060104 Chemical 10/1/2003 Statim Must
18060104 Brand 1/1/2001 6/30/2003 SoleSupply
18060104 Brand 1/1/2006 6/30/2008 SoleSupply
18060104 Brand 1/1/2009 6/30/2011 SoleSupply
18060201 Brand 1/1/2001 6/30/2003 SoleSupply
18060201 Brand 1/1/2006 6/30/2008 SoleSupply
18060201 Brand 1/1/2009 6/30/2011 SoleSupply
18060201 Chemical 10/1/2003 Statim Must
18060202 Chemical 10/1/2003 Statim Must
18060204 Chemical 10/1/2003 Statim Must
18060301 Chemical 10/1/2003 Statim Must
18060303 Chemical 10/1/2003 Statim Must
18060304 Chemical 10/1/2003 Statim Must
18060304 Brand 1/1/2001 6/30/2003 SoleSupply
18060304 Brand 1/1/2006 6/30/2008 SoleSupply
18060304 Brand 1/1/2009 6/30/2011 SoleSupply
18090101 Chemical 4/1/2000 2/29/2004 Special
18090101 Chemical 3/1/2004 3/31/2008 Special
18090101 Chemical 6/23/1995 Controlled
18090101 Chemical 8/1/2011 Special
18090101 Chemical 2/1/2000 3/31/2000 Special
18090101 Chemical 8/1/2012 SafetyListMedicine
18090101 Chemical 1/1/2011 7/31/2011 Special
18090101 Chemical 4/1/2008 ######## Special
18090125 Chemical 4/1/2008 ######## Special
18090125 Chemical 1/1/2011 7/31/2011 Special
18090125 Chemical 8/1/2012 SafetyListMedicine
18090125 Chemical 2/1/2000 3/31/2000 Special
18090125 Chemical 8/1/2011 Special
18090125 Chemical 6/23/1995 Controlled
18090125 Chemical 3/1/2004 3/31/2008 Special
18090125 Chemical 4/1/2000 2/29/2004 Special
18090125 Brand 1/1/2001 6/30/2003 SoleSupply
18090125 Brand 10/1/2003 6/30/2006 SoleSupply
18090125 Brand 11/1/2006 6/30/2009 SoleSupply
18092525 Chemical 4/1/2000 2/29/2004 Special
18092525 Chemical 3/1/2004 3/31/2008 Special
18092525 Chemical 6/23/1995 Controlled
18092525 Chemical 8/1/2011 Special
18092525 Chemical 2/1/2000 3/31/2000 Special
18092525 Chemical 8/1/2012 SafetyListMedicine
18092525 Chemical 1/1/2011 7/31/2011 Special
18092525 Chemical 4/1/2008 ######## Special
18092526 Chemical 4/1/2008 ######## Special
18092526 Chemical 1/1/2011 7/31/2011 Special
18092526 Chemical 2/1/2000 3/31/2000 Special
18092526 Chemical 8/1/2012 SafetyListMedicine
18092526 Chemical 6/23/1995 Controlled
18092526 Chemical 8/1/2011 Special
18092526 Chemical 3/1/2004 3/31/2008 Special
18092526 Chemical 4/1/2000 2/29/2004 Special
18092526 Brand 4/1/2007 6/30/2009 SoleSupply
18092625 Brand 2/1/2007 6/30/2009 SoleSupply
18092625 Chemical 4/1/2000 2/29/2004 Special
18092625 Chemical 3/1/2004 3/31/2008 Special
18092625 Chemical 8/1/2011 Special
18092625 Chemical 6/23/1995 Controlled
18092625 Chemical 8/1/2012 SafetyListMedicine
18092625 Chemical 2/1/2000 3/31/2000 Special
18092625 Chemical 1/1/2011 7/31/2011 Special
18092625 Chemical 4/1/2008 ######## Special
18092725 Chemical 1/1/2011 7/31/2011 Special
18092725 Chemical 4/1/2008 ######## Special
18092725 Chemical 2/1/2000 3/31/2000 Special
18092725 Chemical 8/1/2012 SafetyListMedicine
18092725 Chemical 6/23/1995 Controlled
18092725 Chemical 8/1/2011 Special
18092725 Chemical 3/1/2004 3/31/2008 Special
18092725 Chemical 4/1/2000 2/29/2004 Special
18092725 Brand 2/1/2007 6/30/2009 SoleSupply
18100501 Brand 1/1/2003 6/30/2005 SoleSupply
18100501 Brand 10/1/2005 6/30/2008 SoleSupply
18100501 Brand 10/1/2008 6/30/2011 SoleSupply
18100501 Brand 11/1/2012 6/30/2015 SoleSupply
18110101 Brand 1/1/2003 6/30/2005 SoleSupply
18110101 Brand 10/1/2006 6/30/2009 SoleSupply
18110101 Brand 10/1/2009 6/30/2012 SoleSupply
18110101 Brand 11/1/2012 6/30/2015 SoleSupply
18110101 Formulation 7/1/1996 9/30/2003 Statim May
18110101 Chemical 10/1/2003 Statim Must
18110101 Chemical 5/16/1994 SpecEnd Retail
18110201 Chemical 5/16/1994 SpecEnd Retail
18110201 Chemical 10/1/2003 Statim Must
18110201 Formulation 7/1/1996 9/30/2003 Statim May
18110201 Brand 1/1/2003 6/30/2005 SoleSupply
18110201 Brand 10/1/2006 6/30/2009 SoleSupply
18110201 Brand 10/1/2009 6/30/2012 SoleSupply
18110201 Brand 11/1/2012 6/30/2015 SoleSupply
18120101 Brand 1/1/2003 6/30/2005 SoleSupply
18120101 Brand 10/1/2006 6/30/2009 SoleSupply
18120101 Brand 1/1/2010 6/30/2012 SoleSupply
18120101 Brand 1/1/2013 6/30/2015 SoleSupply
18120101 Chemical 5/16/1994 SpecEnd Retail
18120201 Chemical 5/16/1994 SpecEnd Retail
18120201 Brand 1/1/2003 6/30/2005 SoleSupply
18120201 Brand 10/1/2006 6/30/2009 SoleSupply
18120201 Brand 1/1/2010 6/30/2012 SoleSupply
18120201 Brand 1/1/2013 6/30/2015 SoleSupply
18120301 Chemical 5/16/1994 SpecEnd Retail
18120401 Chemical 5/16/1994 SpecEnd Retail
18120401 Brand 1/1/2003 6/30/2005 SoleSupply
18120401 Brand 10/1/2006 6/30/2009 SoleSupply
18120401 Brand 1/1/2010 6/30/2012 SoleSupply
18120401 Brand 1/1/2013 6/30/2015 SoleSupply
18120402 Chemical 5/16/1994 SpecEnd Retail
18120501 Chemical 5/16/1994 SpecEnd Retail
18120501 Brand 1/1/2003 6/30/2005 SoleSupply
18120501 Brand 10/1/2006 6/30/2009 SoleSupply
18120501 Brand 1/1/2010 6/30/2012 SoleSupply
18120501 Brand 1/1/2013 6/30/2015 SoleSupply
18120502 Chemical 5/16/1994 SpecEnd Retail
18130101 Chemical 5/16/1994 SpecEnd Retail
18140101 Chemical 10/1/2003 Statim Must
18140101 Formulation 6/1/2013 OraProduct
18140102 Formulation 6/1/2013 OraProduct
18140102 Brand 7/1/2005 6/30/2007 SoleSupply
18140102 Brand 7/1/2011 6/30/2014 SoleSupply
18140102 Chemical 10/1/2003 Statim Must
18140201 Chemical 10/1/2003 Statim Must
18140201 Formulation 7/1/1996 Safety Uncompounded
18140301 Chemical 10/1/2003 Statim Must
18140301 Formulation 7/1/1996 FormMax 5 PSO
18140302 Formulation 7/1/1996 FormMax 5 PSO
18140302 Chemical 10/1/2003 Statim Must
18140302 Brand 2/1/2000 6/30/2002 SoleSupply
18140302 Brand 1/1/2006 6/30/2008 SoleSupply
18140302 Brand 10/1/2008 6/30/2011 SoleSupply
18140302 Brand 10/1/2011 6/30/2014 SoleSupply
18140325 Brand 3/1/2003 6/30/2005 SoleSupply
18140325 Chemical 10/1/2003 Statim Must
18140325 Formulation 7/1/1996 FormMax 5 PSO
18140501 Chemical 10/1/2003 Statim Must
18150101 Brand 8/1/1999 6/30/2002 SoleSupply
18150101 Brand 12/1/2002 6/30/2005 SoleSupply
18160601 Brand 1/1/2003 6/30/2005 SoleSupply
18160601 Brand 10/1/2005 6/30/2008 SoleSupply
18160601 Brand 10/1/2008 6/30/2011 SoleSupply
18160601 Brand 11/1/2012 6/30/2015 SoleSupply
18170101 Chemical 10/1/2007 3/31/2008 Repeat
18170101 Chemical 12/1/2007 8/31/2009 AltSubRxF
18170101 Formulation 7/1/1996 9/30/2003 Statim May
18170101 Chemical 10/1/2003 Statim Must
18170101 Chemical 10/1/2007 ######## AltSubRxF
18170101 Chemical 9/1/2012 ######## Brandswitch 2405873 BSF Metoprolol - AFT CR
18170125 Chemical 9/1/2012 ######## Brandswitch 2405873 BSF Metoprolol - AFT CR
18170125 Chemical 10/1/2003 Statim Must
18170125 Chemical 10/1/2007 ######## AltSubRxF
18170125 Formulation 7/1/1996 9/30/2003 Statim May
18170125 Chemical 12/1/2007 8/31/2009 AltSubRxF
18170125 Chemical 10/1/2007 3/31/2008 Repeat
18170125 Brand 9/1/2012 6/30/2015 SoleSupply
18170126 Chemical 12/1/2007 8/31/2009 AltSubRxF
18170126 Chemical 10/1/2007 3/31/2008 Repeat
18170126 Formulation 7/1/1996 9/30/2003 Statim May
18170126 Chemical 10/1/2003 Statim Must
18170126 Chemical 10/1/2007 ######## AltSubRxF
18170126 Chemical 9/1/2012 ######## Brandswitch 2405873 BSF Metoprolol - AFT CR
18170201 Chemical 10/1/2007 ######## AltSubRxF
18170201 Chemical 9/1/2012 ######## Brandswitch 2405873 BSF Metoprolol - AFT CR
18170201 Chemical 10/1/2003 Statim Must
18170201 Formulation 7/1/1996 9/30/2003 Statim May
18170201 Chemical 12/1/2007 8/31/2009 AltSubRxF
18170201 Chemical 10/1/2007 3/31/2008 Repeat
18170225 Chemical 10/1/2007 3/31/2008 Repeat
18170225 Chemical 12/1/2007 8/31/2009 AltSubRxF
18170225 Brand 9/1/2012 6/30/2015 SoleSupply
18170225 Formulation 7/1/1996 9/30/2003 Statim May
18170225 Chemical 9/1/2012 ######## Brandswitch 2405873 BSF Metoprolol - AFT CR
18170225 Chemical 10/1/2007 ######## AltSubRxF
18170225 Chemical 10/1/2003 Statim Must
18170226 Chemical 10/1/2003 Statim Must
18170226 Chemical 10/1/2007 ######## AltSubRxF
18170226 Chemical 9/1/2012 ######## Brandswitch 2405873 BSF Metoprolol - AFT CR
18170226 Formulation 7/1/1996 9/30/2003 Statim May
18170226 Chemical 10/1/2007 3/31/2008 Repeat
18170226 Chemical 12/1/2007 8/31/2009 AltSubRxF
18170301 Chemical 10/1/2007 3/31/2008 Repeat
18170301 Chemical 12/1/2007 8/31/2009 AltSubRxF
18170301 Formulation 7/1/1996 9/30/2003 Statim May
18170301 Chemical 10/1/2007 ######## AltSubRxF
18170301 Chemical 9/1/2012 ######## Brandswitch 2405873 BSF Metoprolol - AFT CR
18170301 Chemical 10/1/2003 Statim Must
18170325 Chemical 9/1/2012 ######## Brandswitch 2405873 BSF Metoprolol - AFT CR
18170325 Chemical 10/1/2003 Statim Must
18170325 Chemical 10/1/2007 ######## AltSubRxF
18170325 Formulation 7/1/1996 9/30/2003 Statim May
18170325 Chemical 12/1/2007 8/31/2009 AltSubRxF
18170325 Chemical 10/1/2007 3/31/2008 Repeat
18170325 Brand 9/1/2012 6/30/2015 SoleSupply
18170326 Chemical 12/1/2007 8/31/2009 AltSubRxF
18170326 Chemical 10/1/2007 3/31/2008 Repeat
18170326 Formulation 7/1/1996 9/30/2003 Statim May
18170326 Chemical 10/1/2003 Statim Must
18170326 Chemical 10/1/2007 ######## AltSubRxF
18170326 Chemical 9/1/2012 ######## Brandswitch 2405873 BSF Metoprolol - AFT CR
18172525 Chemical 10/1/2007 ######## AltSubRxF
18172525 Chemical 9/1/2012 ######## Brandswitch 2405873 BSF Metoprolol - AFT CR
18172525 Chemical 10/1/2003 Statim Must
18172525 Formulation 7/1/2001 9/30/2003 Statim May
18172525 Chemical 12/1/2007 8/31/2009 AltSubRxF
18172525 Chemical 10/1/2007 3/31/2008 Repeat
18172526 Chemical 10/1/2007 3/31/2008 Repeat
18172526 Chemical 12/1/2007 8/31/2009 AltSubRxF
18172526 Brand 9/1/2012 6/30/2015 SoleSupply
18172526 Formulation 7/1/2001 9/30/2003 Statim May
18172526 Chemical 10/1/2003 Statim Must
18172526 Chemical 9/1/2012 ######## Brandswitch 2405873 BSF Metoprolol - AFT CR
18172526 Chemical 10/1/2007 ######## AltSubRxF
18172527 Chemical 10/1/2007 ######## AltSubRxF
18172527 Chemical 9/1/2012 ######## Brandswitch 2405873 BSF Metoprolol - AFT CR
18172527 Chemical 10/1/2003 Statim Must
18172527 Formulation 7/1/2001 9/30/2003 Statim May
18172527 Chemical 12/1/2007 8/31/2009 AltSubRxF
18172527 Chemical 10/1/2007 3/31/2008 Repeat
18180101 Formulation12/1/2011 OraProduct
18180101 Brand 8/1/2012 6/30/2015 SoleSupply
18180101 Formulation 7/1/1996 9/30/2003 Statim May
18180101 Chemical 10/1/2003 Statim Must
18180102 Chemical 10/1/2003 Statim Must
18180102 Formulation 7/1/1996 9/30/2003 Statim May
18180102 Formulation12/1/2011 OraProduct
18180201 Brand 8/1/2012 6/30/2015 SoleSupply
18180201 Formulation 7/1/1996 9/30/2003 Statim May
18180201 Chemical 10/1/2003 Statim Must
18180202 Chemical 10/1/2003 Statim Must
18180202 Formulation 7/1/1996 9/30/2003 Statim May
18180301 Formulation 7/1/1996 9/30/2003 Statim May
18180301 Brand 10/1/2003 6/30/2006 SoleSupply
18180301 Brand 10/1/2006 6/30/2009 SoleSupply
18180301 Brand 8/1/2012 6/30/2015 SoleSupply
18180301 Chemical 10/1/2003 Statim Must
18180401 Chemical 10/1/2003 Statim Must
18180425 Chemical 10/1/2003 Statim Must
18180425 Brand 8/1/2012 6/30/2015 SoleSupply
18200102 Brand 11/1/1999 6/30/2002 SoleSupply
18200102 Brand 9/1/2004 6/30/2007 SoleSupply
18200102 Formulation 7/1/1996 FormMax 30 PSO
18200103 Formulation 7/1/1996 FormMax 30 PSO
18200202 Brand 11/1/1999 6/30/2002 SoleSupply
18200202 Brand 9/1/2004 6/30/2007 SoleSupply
18220101 Brand 10/1/2003 6/30/2006 SoleSupply
18220101 Brand 12/1/2006 6/30/2009 SoleSupply
18220101 Formulation 1/1/1999 7/31/2010 Dispensary HP3
18220101 Formulation5/16/1994 7/31/2010 SpecEnd Hospital
18220101 Formulation 8/1/2010 SpecEnd Retail
18230101 Brand 1/1/2006 6/30/2008 SoleSupply
18230101 Chemical 10/1/2012 Statim May
18230101 Chemical 7/1/1996 9/30/2012 Statim May
18230201 Chemical 7/1/1996 9/30/2012 Statim May
18230201 Chemical 10/1/2012 Statim May
18230201 Brand 1/1/2006 6/30/2008 SoleSupply
18230301 Chemical 10/1/2012 Statim May
18230301 Chemical 7/1/1996 9/30/2012 Statim May
18232525 Chemical 7/1/1996 9/30/2012 Statim May
18232525 Chemical 10/1/2012 Statim May
18232525 Brand 10/1/2012 S29
18232525 Brand 4/1/2013 Wastage
18232625 Brand 10/1/2012 S29
18232625 Brand 4/1/2013 Wastage
18232625 Chemical 10/1/2012 Statim May
18232625 Chemical 7/1/1996 9/30/2012 Statim May
18240101 Chemical 4/1/2005 5/31/2007 SpecOnly Hospital
18240101 Chemical 6/1/2007 9/30/2010 Special
18240101 Chemical 10/1/2010 7/31/2013 Special
18240101 Chemical 1/1/1999 5/31/2007 Dispensary HP3
18240101 Chemical 8/1/2013 SafetyListMedicine
18240101 Formulation 7/1/2014 SubRxF
18240101 Chemical 5/16/1994 5/31/2007 Special
18250102 Brand 12/1/2001 6/30/2004 SoleSupply
18250102 Brand 8/1/2004 6/30/2007 SoleSupply
18250125 Brand 5/1/2013 6/30/2015 SoleSupply
18260101 Formulation 6/2/1995 2/28/2002 FormReqd WSO
18260101 Chemical 3/1/2002 7/31/2010 FormReqd WSO
18260101 Formulation 8/1/2010 SubRxF
18260101 Formulation 6/2/1995 2/28/2002 FormMax 20 WSO
18260101 Chemical 3/1/2002 7/31/2010 FormMax 20 WSO
18260101 Chemical 8/1/2010 ######## FormMax 20 PSO
18260101 Chemical 8/1/2010 FormReqd PSO
18260101 Chemical 12/1/2011 FormMax 5 PSO
18260101 Formulation11/1/2008 7/31/2010 SubRxF
18260125 Formulation11/1/2008 7/31/2010 SubRxF
18260125 Chemical 12/1/2011 FormMax 5 PSO
18260125 Chemical 8/1/2010 FormReqd PSO
18260125 Chemical 8/1/2010 ######## FormMax 20 PSO
18260125 Chemical 3/1/2002 7/31/2010 FormMax 20 WSO
18260125 Formulation 6/2/1995 2/28/2002 FormMax 20 WSO
18260125 Formulation 8/1/2010 SubRxF
18260125 Chemical 3/1/2002 7/31/2010 FormReqd WSO
18260125 Formulation 6/2/1995 2/28/2002 FormReqd WSO
18260125 Brand 10/1/2008 9/30/2011 SoleSupply
18270101 Formulation6/27/1995 ######## FormReqd WSO
18270101 Formulation6/27/1995 ######## FormMax 10 WSO
18270101 Chemical 5/1/2003 7/31/2010 FormReqd WSO
18270101 Chemical 5/1/2003 7/31/2010 FormMax 10 WSO
18270101 Formulation11/1/2002 4/30/2003 FormMax 20 WSO
18270101 Chemical 8/1/2010 FormReqd PSO
18270101 Chemical 8/1/2010 FormMax 10 PSO
18270101 Formulation11/1/2002 4/30/2003 FormReqd WSO
18270103 Formulation11/1/2002 4/30/2003 FormReqd WSO
18270103 Chemical 8/1/2010 FormMax 10 PSO
18270103 Chemical 8/1/2010 FormReqd PSO
18270103 Formulation11/1/2002 4/30/2003 FormMax 20 WSO
18270103 Chemical 5/1/2003 7/31/2010 FormMax 10 WSO
18270103 Chemical 5/1/2003 7/31/2010 FormReqd WSO
18270103 Formulation6/27/1995 ######## FormMax 10 WSO
18270103 Formulation6/27/1995 ######## FormReqd WSO
18270104 Formulation6/27/1995 ######## FormReqd WSO
18270104 Formulation6/27/1995 ######## FormMax 10 WSO
18270104 Chemical 5/1/2003 7/31/2010 FormReqd WSO
18270104 Chemical 5/1/2003 7/31/2010 FormMax 10 WSO
18270104 Formulation11/1/2002 4/30/2003 FormMax 20 WSO
18270104 Chemical 8/1/2010 FormReqd PSO
18270104 Chemical 8/1/2010 FormMax 10 PSO
18270104 Formulation11/1/2002 4/30/2003 FormReqd WSO
18270108 Formulation11/1/2002 4/30/2003 FormReqd WSO
18270108 Chemical 8/1/2010 FormMax 10 PSO
18270108 Chemical 8/1/2010 FormReqd PSO
18270108 Formulation11/1/2002 4/30/2003 FormMax 20 WSO
18270108 Chemical 5/1/2003 7/31/2010 FormMax 10 WSO
18270108 Chemical 5/1/2003 7/31/2010 FormReqd WSO
18270108 Formulation6/27/1995 ######## FormMax 10 WSO
18270108 Formulation6/27/1995 ######## FormReqd WSO
18270108 Brand 5/1/2004 ######## SoleSupply
18270108 Brand 10/1/2008 9/30/2011 SoleSupply
18270108 Brand 12/1/2011 6/30/2015 SoleSupply
18270125 Formulation6/27/1995 ######## FormReqd WSO
18270125 Formulation6/27/1995 ######## FormMax 10 WSO
18270125 Chemical 5/1/2003 7/31/2010 FormReqd WSO
18270125 Chemical 5/1/2003 7/31/2010 FormMax 10 WSO
18270125 Formulation11/1/2002 4/30/2003 FormMax 20 WSO
18270125 Chemical 8/1/2010 FormReqd PSO
18270125 Chemical 8/1/2010 FormMax 10 PSO
18270125 Formulation11/1/2002 4/30/2003 FormReqd WSO
18270126 Formulation11/1/2002 4/30/2003 FormReqd WSO
18270126 Chemical 8/1/2010 FormMax 10 PSO
18270126 Chemical 8/1/2010 FormReqd PSO
18270126 Formulation11/1/2002 4/30/2003 FormMax 20 WSO
18270126 Chemical 5/1/2003 7/31/2010 FormMax 10 WSO
18270126 Chemical 5/1/2003 7/31/2010 FormReqd WSO
18270126 Formulation6/27/1995 ######## FormMax 10 WSO
18270126 Formulation6/27/1995 ######## FormReqd WSO
18270201 Formulation6/27/1995 ######## FormReqd WSO
18270201 Brand 10/1/2008 9/30/2011 SoleSupply
18270201 Brand 12/1/2011 6/30/2015 SoleSupply
18270201 Formulation6/27/1995 ######## FormMax 10 WSO
18270201 Chemical 5/1/2003 7/31/2010 FormReqd WSO
18270201 Chemical 5/1/2003 7/31/2010 FormMax 10 WSO
18270201 Formulation11/1/2002 4/30/2003 FormMax 20 WSO
18270201 Chemical 8/1/2010 FormReqd PSO
18270201 Chemical 8/1/2010 FormMax 10 PSO
18270201 Formulation11/1/2002 4/30/2003 FormReqd WSO
18270202 Formulation11/1/2002 4/30/2003 FormReqd WSO
18270202 Chemical 8/1/2010 FormMax 10 PSO
18270202 Chemical 8/1/2010 FormReqd PSO
18270202 Formulation11/1/2002 4/30/2003 FormMax 20 WSO
18270202 Chemical 5/1/2003 7/31/2010 FormMax 10 WSO
18270202 Chemical 5/1/2003 7/31/2010 FormReqd WSO
18270202 Formulation6/27/1995 ######## FormMax 10 WSO
18270202 Formulation6/27/1995 ######## FormReqd WSO
18270203 Formulation6/27/1995 ######## FormReqd WSO
18270203 Formulation6/27/1995 ######## FormMax 10 WSO
18270203 Chemical 5/1/2003 7/31/2010 FormReqd WSO
18270203 Chemical 5/1/2003 7/31/2010 FormMax 10 WSO
18270203 Formulation11/1/2002 4/30/2003 FormMax 20 WSO
18270203 Chemical 8/1/2010 FormReqd PSO
18270203 Chemical 8/1/2010 FormMax 10 PSO
18270203 Formulation11/1/2002 4/30/2003 FormReqd WSO
18270225 Formulation11/1/2002 4/30/2003 FormReqd WSO
18270225 Chemical 8/1/2010 FormMax 10 PSO
18270225 Chemical 8/1/2010 FormReqd PSO
18270225 Formulation11/1/2002 4/30/2003 FormMax 20 WSO
18270225 Chemical 5/1/2003 7/31/2010 FormMax 10 WSO
18270225 Chemical 5/1/2003 7/31/2010 FormReqd WSO
18270225 Formulation6/27/1995 ######## FormMax 10 WSO
18270225 Formulation6/27/1995 ######## FormReqd WSO
18270226 Formulation6/27/1995 ######## FormReqd WSO
18270226 Formulation6/27/1995 ######## FormMax 10 WSO
18270226 Chemical 5/1/2003 7/31/2010 FormReqd WSO
18270226 Chemical 5/1/2003 7/31/2010 FormMax 10 WSO
18270226 Formulation11/1/2002 4/30/2003 FormMax 20 WSO
18270226 Chemical 8/1/2010 FormReqd PSO
18270226 Chemical 8/1/2010 FormMax 10 PSO
18270226 Formulation11/1/2002 4/30/2003 FormReqd WSO
18280101 Chemical 10/1/2003 Statim Must
18280101 Formulation 7/1/2013 SpecialWav
18280201 Chemical 10/1/2003 Statim Must
18292525 Chemical 8/1/2010 FormReqd PSO
18292525 Chemical 3/1/2002 7/31/2010 FormMax 20 WSO
18292525 Chemical 8/1/2010 FormMax 20 PSO
18292525 Brand 10/1/2008 9/30/2011 SoleSupply
18292525 Chemical 3/1/2002 7/31/2010 FormReqd WSO
18292526 Chemical 3/1/2002 7/31/2010 FormReqd WSO
18292526 Brand 12/1/2011 6/30/2015 SoleSupply
18292526 Chemical 8/1/2010 FormMax 20 PSO
18292526 Chemical 3/1/2002 7/31/2010 FormMax 20 WSO
18292526 Chemical 8/1/2010 FormReqd PSO
18292625 Chemical 8/1/2010 FormReqd PSO
18292625 Chemical 8/1/2010 FormMax 20 PSO
18292625 Chemical 3/1/2002 7/31/2010 FormMax 20 WSO
18292625 Brand 12/1/2011 6/30/2015 SoleSupply
18292625 Chemical 3/1/2002 7/31/2010 FormReqd WSO
18300101 Chemical 5/16/1994 MaxCoPayment 0
18300101 Chemical 5/30/1995 Controlled
18300101 Formulation 7/1/1996 Safety Uncompounded
18300101 Brand 11/1/2002 6/30/2005 SoleSupply
18300101 Brand 12/1/2006 6/30/2009 SoleSupply
18300101 Brand 1/1/2010 6/30/2012 SoleSupply
18300101 Brand 11/1/2012 6/30/2015 SoleSupply
18300101 Chemical 8/1/2012 SafetyListMedicine
18300201 Chemical 8/1/2012 SafetyListMedicine
18300201 Formulation 7/1/1996 Safety Uncompounded
18300201 Brand 11/1/2002 6/30/2005 SoleSupply
18300201 Brand 12/1/2006 6/30/2009 SoleSupply
18300201 Brand 1/1/2010 6/30/2012 SoleSupply
18300201 Brand 11/1/2012 6/30/2015 SoleSupply
18300201 Chemical 5/30/1995 Controlled
18300201 Chemical 5/16/1994 MaxCoPayment 0
18300301 Chemical 5/16/1994 MaxCoPayment 0
18300301 Chemical 5/30/1995 Controlled
18300301 Formulation 7/1/1996 Safety Uncompounded
18300301 Brand 11/1/2002 6/30/2005 SoleSupply
18300301 Brand 12/1/2006 6/30/2009 SoleSupply
18300301 Brand 1/1/2010 6/30/2012 SoleSupply
18300301 Brand 11/1/2012 6/30/2015 SoleSupply
18300301 Chemical 8/1/2012 SafetyListMedicine
18300401 Chemical 8/1/2012 SafetyListMedicine
18300401 Formulation 7/1/1996 Safety Uncompounded
18300401 Brand 11/1/2002 6/30/2005 SoleSupply
18300401 Brand 12/1/2006 6/30/2009 SoleSupply
18300401 Brand 1/1/2010 6/30/2012 SoleSupply
18300401 Brand 11/1/2012 6/30/2015 SoleSupply
18300401 Chemical 5/30/1995 Controlled
18300401 Chemical 5/16/1994 MaxCoPayment 0
18300501 Chemical 5/16/1994 MaxCoPayment 0
18300501 Chemical 5/30/1995 Controlled
18300501 Chemical 8/1/2012 SafetyListMedicine
18300501 Formulation######## Safety Compounded
18300502 Formulation######## Safety Compounded
18300502 Chemical 8/1/2012 SafetyListMedicine
18300502 Chemical 5/30/1995 Controlled
18300502 Chemical 5/16/1994 MaxCoPayment 0
18310101 Chemical 5/16/1994 MaxCoPayment 0
18310101 Chemical 5/30/1995 Controlled
18310101 Formulation 8/1/2004 1/31/2005 Repeat
18310101 Chemical 8/1/2012 SafetyListMedicine
18310101 Formulation 2/1/2004 7/31/2004 SpecialWav Claim only
18310101 Chemical 2/1/2004 7/31/2004 Application
18310102 Chemical 2/1/2004 7/31/2004 Application
18310102 Formulation 2/1/2004 7/31/2004 SpecialWav Claim only
18310102 Chemical 8/1/2012 SafetyListMedicine
18310102 Formulation 8/1/2004 1/31/2005 Repeat
18310102 Chemical 5/30/1995 Controlled
18310102 Chemical 5/16/1994 MaxCoPayment 0
18310125 Chemical 5/16/1994 MaxCoPayment 0
18310125 Chemical 5/30/1995 Controlled
18310125 Formulation 8/1/2004 1/31/2005 Repeat
18310125 Brand 11/1/2011 6/30/2013 SoleSupply
18310125 Brand 10/1/2013 6/30/2016 SoleSupply
18310125 Chemical 8/1/2012 SafetyListMedicine
18310125 Formulation 2/1/2004 7/31/2004 SpecialWav Claim only
18310125 Chemical 2/1/2004 7/31/2004 Application
18310201 Chemical 2/1/2004 7/31/2004 Application
18310201 Formulation 2/1/2004 7/31/2004 SpecialWav Claim only
18310201 Chemical 8/1/2012 SafetyListMedicine
18310201 Formulation 8/1/2004 1/31/2005 Repeat
18310201 Chemical 5/30/1995 Controlled
18310201 Chemical 5/16/1994 MaxCoPayment 0
18310202 Chemical 5/16/1994 MaxCoPayment 0
18310202 Chemical 5/30/1995 Controlled
18310202 Formulation 8/1/2004 1/31/2005 Repeat
18310202 Chemical 8/1/2012 SafetyListMedicine
18310202 Formulation 2/1/2004 7/31/2004 SpecialWav Claim only
18310202 Chemical 2/1/2004 7/31/2004 Application
18310225 Chemical 2/1/2004 7/31/2004 Application
18310225 Formulation 2/1/2004 7/31/2004 SpecialWav Claim only
18310225 Chemical 8/1/2012 SafetyListMedicine
18310225 Formulation 8/1/2004 1/31/2005 Repeat
18310225 Brand 11/1/2011 6/30/2013 SoleSupply
18310225 Brand 10/1/2013 6/30/2016 SoleSupply
18310225 Chemical 5/30/1995 Controlled
18310225 Chemical 5/16/1994 MaxCoPayment 0
18310301 Chemical 5/30/1995 Controlled
18310301 Chemical 5/16/1994 MaxCoPayment 0
18310301 Formulation 8/1/2004 1/31/2005 Repeat
18310301 Chemical 8/1/2012 SafetyListMedicine
18310301 Formulation 2/1/2004 7/31/2004 SpecialWav Claim only
18310301 Chemical 2/1/2004 7/31/2004 Application
18310302 Chemical 2/1/2004 7/31/2004 Application
18310302 Formulation 2/1/2004 7/31/2004 SpecialWav Claim only
18310302 Chemical 8/1/2012 SafetyListMedicine
18310302 Formulation 8/1/2004 1/31/2005 Repeat
18310302 Chemical 5/16/1994 MaxCoPayment 0
18310302 Chemical 5/30/1995 Controlled
18310325 Chemical 5/30/1995 Controlled
18310325 Chemical 5/16/1994 MaxCoPayment 0
18310325 Brand 11/1/2011 6/30/2013 SoleSupply
18310325 Brand 10/1/2013 6/30/2016 SoleSupply
18310325 Formulation 8/1/2004 1/31/2005 Repeat
18310325 Chemical 8/1/2012 SafetyListMedicine
18310325 Formulation 2/1/2004 7/31/2004 SpecialWav Claim only
18310325 Chemical 2/1/2004 7/31/2004 Application
18310401 Chemical 2/1/2004 7/31/2004 Application
18310401 Formulation 2/1/2004 7/31/2004 SpecialWav Claim only
18310401 Chemical 8/1/2012 SafetyListMedicine
18310401 Formulation 8/1/2004 1/31/2005 Repeat
18310401 Chemical 5/16/1994 MaxCoPayment 0
18310401 Chemical 5/30/1995 Controlled
18310402 Chemical 5/30/1995 Controlled
18310402 Chemical 5/16/1994 MaxCoPayment 0
18310402 Formulation 8/1/2004 1/31/2005 Repeat
18310402 Chemical 8/1/2012 SafetyListMedicine
18310402 Formulation 2/1/2004 7/31/2004 SpecialWav Claim only
18310402 Chemical 2/1/2004 7/31/2004 Application
18310425 Chemical 2/1/2004 7/31/2004 Application
18310425 Formulation 2/1/2004 7/31/2004 SpecialWav Claim only
18310425 Chemical 8/1/2012 SafetyListMedicine
18310425 Formulation 8/1/2004 1/31/2005 Repeat
18310425 Brand 11/1/2011 6/30/2013 SoleSupply
18310425 Brand 10/1/2013 6/30/2016 SoleSupply
18310425 Chemical 5/16/1994 MaxCoPayment 0
18310425 Chemical 5/30/1995 Controlled
18310501 Chemical 5/30/1995 Controlled
18310501 Chemical 5/16/1994 MaxCoPayment 0
18310501 Formulation 8/1/2004 1/31/2005 Repeat
18310501 Chemical 8/1/2012 SafetyListMedicine
18310501 Formulation 2/1/2004 7/31/2004 SpecialWav Claim only
18310501 Chemical 2/1/2004 7/31/2004 Application
18310601 Chemical 2/1/2004 7/31/2004 Application
18310601 Formulation 7/1/1996 FormMax 5 PSO
18310601 Chemical 8/1/2012 SafetyListMedicine
18310601 Chemical 5/16/1994 MaxCoPayment 0
18310601 Chemical 5/30/1995 Controlled
18310701 Chemical 5/30/1995 Controlled
18310701 Chemical 5/16/1994 MaxCoPayment 0
18310701 Brand 11/1/2006 6/30/2009 SoleSupply
18310701 Brand 12/1/2011 6/30/2014 SoleSupply
18310701 Chemical 8/1/2012 SafetyListMedicine
18310701 Formulation 7/1/1996 FormMax 5 PSO
18310701 Chemical 2/1/2004 7/31/2004 Application
18310801 Chemical 2/1/2004 7/31/2004 Application
18310801 Formulation 7/1/1996 FormMax 5 PSO
18310801 Chemical 8/1/2012 SafetyListMedicine
18310801 Brand 9/1/2008 6/30/2011 SoleSupply
18310801 Brand 12/1/2011 6/30/2014 SoleSupply
18310801 Chemical 5/16/1994 MaxCoPayment 0
18310801 Chemical 5/30/1995 Controlled
18310802 Chemical 5/30/1995 Controlled
18310802 Chemical 5/16/1994 MaxCoPayment 0
18310802 Chemical 8/1/2012 SafetyListMedicine
18310802 Formulation 7/1/1996 FormMax 5 PSO
18310802 Chemical 2/1/2004 7/31/2004 Application
18310901 Chemical 2/1/2004 7/31/2004 Application
18310901 Formulation 7/1/1996 FormMax 5 PSO
18310901 Chemical 8/1/2012 SafetyListMedicine
18310901 Chemical 5/16/1994 MaxCoPayment 0
18310901 Chemical 5/30/1995 Controlled
18311001 Chemical 5/30/1995 Controlled
18311001 Chemical 5/16/1994 MaxCoPayment 0
18311001 Brand 11/1/2006 6/30/2009 SoleSupply
18311001 Brand 12/1/2011 6/30/2014 SoleSupply
18311001 Chemical 8/1/2012 SafetyListMedicine
18311001 Formulation 7/1/1996 FormMax 5 PSO
18311001 Chemical 2/1/2004 7/31/2004 Application
18311002 Chemical 2/1/2004 7/31/2004 Application
18311002 Formulation 7/1/1996 FormMax 5 PSO
18311002 Chemical 8/1/2012 SafetyListMedicine
18311002 Chemical 5/16/1994 MaxCoPayment 0
18311002 Chemical 5/30/1995 Controlled
18311101 Chemical 5/30/1995 Controlled
18311101 Chemical 5/16/1994 MaxCoPayment 0
18311101 Brand 9/1/2008 6/30/2011 SoleSupply
18311101 Brand 12/1/2011 6/30/2014 SoleSupply
18311101 Chemical 8/1/2012 SafetyListMedicine
18311101 Formulation 7/1/1996 FormMax 5 PSO
18311101 Chemical 2/1/2004 7/31/2004 Application
18311102 Chemical 2/1/2004 7/31/2004 Application
18311102 Formulation 7/1/1996 FormMax 5 PSO
18311102 Chemical 8/1/2012 SafetyListMedicine
18311102 Chemical 5/16/1994 MaxCoPayment 0
18311102 Chemical 5/30/1995 Controlled
18311201 Chemical 5/30/1995 Controlled
18311201 Chemical 5/16/1994 MaxCoPayment 0
18311201 Chemical 8/1/2012 SafetyListMedicine
18311201 Chemical 2/1/2004 7/31/2004 Application
18311301 Chemical 2/1/2004 7/31/2004 Application
18311301 Chemical 8/1/2012 SafetyListMedicine
18311301 Chemical 5/16/1994 MaxCoPayment 0
18311301 Chemical 5/30/1995 Controlled
18311325 Chemical 5/30/1995 Controlled
18311325 Chemical 5/16/1994 MaxCoPayment 0
18311325 Chemical 8/1/2012 SafetyListMedicine
18311325 Brand 4/1/2007 S29
18311325 Brand 4/1/2013 Wastage
18311325 Chemical 2/1/2004 7/31/2004 Application
18311401 Chemical 2/1/2004 7/31/2004 Application
18311401 Chemical 8/1/2012 SafetyListMedicine
18311401 Chemical 5/16/1994 MaxCoPayment 0
18311401 Chemical 5/30/1995 Controlled
18311425 Chemical 5/30/1995 Controlled
18311425 Chemical 5/16/1994 MaxCoPayment 0
18311425 Chemical 8/1/2012 SafetyListMedicine
18311425 Brand 3/1/2004 S29
18311425 Brand 4/1/2013 Wastage
18311425 Chemical 2/1/2004 7/31/2004 Application
18311501 Chemical 2/1/2004 7/31/2004 Application
18311501 Chemical 8/1/2012 SafetyListMedicine
18311501 Chemical 5/16/1994 MaxCoPayment 0
18311501 Chemical 5/30/1995 Controlled
18311525 Chemical 5/30/1995 Controlled
18311525 Chemical 5/16/1994 MaxCoPayment 0
18311525 Chemical 8/1/2012 SafetyListMedicine
18311525 Brand 3/1/2004 S29
18311525 Brand 4/1/2013 Wastage
18311525 Chemical 2/1/2004 7/31/2004 Application
18311601 Chemical 2/1/2004 7/31/2004 Application
18311601 Chemical 8/1/2012 SafetyListMedicine
18311601 Formulation11/1/1997 Safety Compounded
18311601 Chemical 5/16/1994 MaxCoPayment 0
18311601 Chemical 5/30/1995 Controlled
18311701 Chemical 5/30/1995 Controlled
18311701 Chemical 5/16/1994 MaxCoPayment 0
18311701 Formulation 8/1/2004 1/31/2005 Repeat
18311701 Chemical 8/1/2012 SafetyListMedicine
18311701 Formulation 2/1/2004 7/31/2004 SpecialWav Claim only
18311701 Chemical 2/1/2004 7/31/2004 Application
18311801 Chemical 2/1/2004 7/31/2004 Application
18311801 Formulation 2/1/2004 7/31/2004 SpecialWav Claim only
18311801 Chemical 8/1/2012 SafetyListMedicine
18311801 Chemical 5/16/1994 MaxCoPayment 0
18311801 Chemical 5/30/1995 Controlled
18311901 Chemical 5/30/1995 Controlled
18311901 Chemical 5/16/1994 MaxCoPayment 0
18311901 Chemical 8/1/2012 SafetyListMedicine
18311901 Formulation 2/1/2004 7/31/2004 SpecialWav Claim only
18311901 Chemical 2/1/2004 7/31/2004 Application
18311925 Chemical 2/1/2004 7/31/2004 Application
18311925 Formulation 2/1/2004 7/31/2004 SpecialWav Claim only
18311925 Chemical 8/1/2012 SafetyListMedicine
18311925 Chemical 5/16/1994 MaxCoPayment 0
18311925 Chemical 5/30/1995 Controlled
18311925 Brand 10/1/2006 6/30/2009 SoleSupply
18311925 Brand 12/1/2010 6/30/2013 SoleSupply
18311925 Brand 3/1/2014 6/30/2016 SoleSupply
18312001 Brand 11/1/2003 6/30/2006 SoleSupply
18312001 Brand 10/1/2006 6/30/2009 SoleSupply
18312001 Brand 1/1/2010 6/30/2012 SoleSupply
18312001 Chemical 5/30/1995 Controlled
18312001 Chemical 5/16/1994 MaxCoPayment 0
18312001 Chemical 8/1/2012 SafetyListMedicine
18312001 Chemical 2/1/2004 7/31/2004 Application
18312101 Chemical 2/1/2004 7/31/2004 Application
18312101 Chemical 8/1/2012 SafetyListMedicine
18312101 Chemical 5/16/1994 MaxCoPayment 0
18312101 Chemical 5/30/1995 Controlled
18312101 Brand 11/1/2003 6/30/2006 SoleSupply
18312101 Brand 10/1/2006 6/30/2009 SoleSupply
18312101 Brand 1/1/2010 6/30/2012 SoleSupply
18312201 Chemical 5/30/1995 Controlled
18312201 Chemical 5/16/1994 MaxCoPayment 0
18312201 Chemical 8/1/2012 SafetyListMedicine
18312201 Formulation 2/1/2004 7/31/2004 SpecialWav Claim only
18312201 Chemical 2/1/2004 7/31/2004 Application
18312225 Chemical 2/1/2004 7/31/2004 Application
18312225 Formulation 2/1/2004 7/31/2004 SpecialWav Claim only
18312225 Chemical 8/1/2012 SafetyListMedicine
18312225 Chemical 5/16/1994 MaxCoPayment 0
18312225 Chemical 5/30/1995 Controlled
18312225 Brand 10/1/2006 6/30/2009 SoleSupply
18312225 Brand 12/1/2010 6/30/2013 SoleSupply
18312225 Brand 3/1/2014 6/30/2016 SoleSupply
18312525 Brand 10/1/2006 6/30/2009 SoleSupply
18312525 Brand 3/1/2014 6/30/2016 SoleSupply
18312525 Chemical 5/30/1995 Controlled
18312525 Chemical 5/16/1994 MaxCoPayment 0
18312525 Chemical 8/1/2012 SafetyListMedicine
18312525 Chemical 2/1/2004 7/31/2004 Application
18312625 Chemical 2/1/2004 7/31/2004 Application
18312625 Chemical 8/1/2012 SafetyListMedicine
18312625 Chemical 5/16/1994 MaxCoPayment 0
18312625 Chemical 5/30/1995 Controlled
18312625 Brand 10/1/2006 6/30/2009 SoleSupply
18312625 Brand 12/1/2010 6/30/2013 SoleSupply
18312625 Brand 3/1/2014 6/30/2016 SoleSupply
18312725 Brand 10/1/2006 6/30/2009 SoleSupply
18312725 Brand 12/1/2010 6/30/2013 SoleSupply
18312725 Brand 3/1/2014 6/30/2016 SoleSupply
18312725 Chemical 5/30/1995 Controlled
18312725 Chemical 5/16/1994 MaxCoPayment 0
18312725 Chemical 8/1/2012 SafetyListMedicine
18312725 Chemical 2/1/2004 7/31/2004 Application
18320225 Chemical 3/1/2002 7/31/2010 FormMax 20 WSO
18320225 Chemical 8/1/2010 FormMax 20 PSO
18320225 Chemical 8/1/2010 FormReqd PSO
18320225 Chemical 3/1/2002 7/31/2010 FormReqd WSO
18320225 Formulation 6/2/1995 2/2/2002 FormMax 20 WSO
18320225 Formulation 6/2/1995 2/2/2002 FormReqd WSO
18320225 Brand 10/1/2008 9/30/2011 SoleSupply
18320225 Brand 12/1/2011 6/30/2015 SoleSupply
18350101 Formulation 6/1/2002 NotCombined
18350101 Formulation5/16/1994 FormReqd Rx
18380101 Chemical 10/1/2003 Statim Must
18380101 Formulation 7/1/1996 9/30/2003 Statim May
18380102 Formulation 7/1/1996 9/30/2003 Statim May
18380102 Brand 8/1/1998 6/30/2001 SoleSupply
18380102 Brand 12/1/2001 6/30/2004 SoleSupply
18380102 Brand 10/1/2004 6/30/2007 SoleSupply
18380102 Brand 10/1/2007 6/30/2010 SoleSupply
18380102 Brand 5/1/2013 6/30/2015 SoleSupply
18380102 Chemical 10/1/2003 Statim Must
18380201 Chemical 10/1/2003 Statim Must
18380201 Formulation 7/1/1996 9/30/2003 Statim May
18380202 Formulation 7/1/1996 9/30/2003 Statim May
18380202 Brand 8/1/1998 6/30/2001 SoleSupply
18380202 Brand 12/1/2001 6/30/2004 SoleSupply
18380202 Brand 10/1/2004 6/30/2007 SoleSupply
18380202 Brand 10/1/2007 6/30/2010 SoleSupply
18380202 Brand 5/1/2013 6/30/2015 SoleSupply
18380202 Chemical 10/1/2003 Statim Must
18410101 Chemical 5/16/1994 FormReqd PSO
18410101 Chemical 7/1/1996 FormMax 5 PSO
18410101 Chemical 10/1/2003 Statim Must
18410125 Chemical 10/1/2003 Statim Must
18410125 Chemical 5/16/1994 FormReqd PSO
18410125 Chemical 7/1/1996 FormMax 5 PSO
18410201 Chemical 10/1/2003 Statim Must
18410201 Chemical 7/1/1996 FormMax 5 PSO
18410201 Chemical 5/16/1994 FormReqd PSO
18410202 Chemical 5/16/1994 FormReqd PSO
18410202 Chemical 7/1/1996 FormMax 5 PSO
18410202 Chemical 10/1/2003 Statim Must
18410202 Brand 12/1/2003 6/30/2006 SoleSupply
18430101 Chemical 10/1/2003 Statim Must
18430102 Chemical 10/1/2003 Statim Must
18430102 Brand 12/1/2002 6/30/2005 SoleSupply
18430102 Brand 10/1/2005 6/30/2008 SoleSupply
18430102 Brand 10/1/2011 6/30/2014 SoleSupply
18490101 Formulation 7/1/1996 2/28/2001 FormMax 30 PSO
18490201 Formulation 7/1/1996 2/28/2001 FormMax 5 PSO
18520101 Chemical 1/1/1999 Dispensary HP3
18520102 Chemical 1/1/1999 Dispensary HP3
18530601 Formulation5/16/1994 1/31/1998 FormReqd Rx
18530601 Formulation5/16/1994 1/31/1998 Combined
18540101 Formulation 6/1/2002 NotCombined
18540101 Chemical 6/29/1995 6/30/1999 FormReqd Rx
18540101 Formulation 6/1/2002 FormReqd Rx
18570301 Brand 9/1/2004 6/30/2007 SoleSupply
18570301 Brand 10/1/2007 6/30/2010 SoleSupply
18570301 Brand 10/1/2011 6/30/2014 SoleSupply
18600101 Formulation5/16/1994 DoseDMax 4
18600101 Chemical 6/28/1995 FormReqd Rx
18600101 Formulation5/16/1994 9/30/1999 DoseSMax 2
18600101 Formulation5/16/1994 9/30/1999 FormReqd Rx
18600201 Chemical 6/28/1995 FormReqd Rx
18600201 Formulation5/16/1994 9/30/1999 DoseSMax 1
18600201 Formulation5/16/1994 DoseDMax 4
18600201 Formulation5/16/1994 9/30/1999 FormReqd Rx
18600301 Chemical 6/28/1995 FormReqd Rx
18610101 Chemical 10/1/2003 Statim Must
18610101 Brand 12/1/2001 6/30/2004 SoleSupply
18610102 Chemical 10/1/2003 Statim Must
18610201 Chemical 10/1/2003 Statim Must
18610201 Brand 12/1/2001 6/30/2004 SoleSupply
18610201 Brand 1/1/2007 6/30/2009 SoleSupply
18610201 Brand 10/1/2011 6/30/2014 SoleSupply
18610202 Chemical 10/1/2003 Statim Must
18610301 Chemical 10/1/2003 Statim Must
18610301 Brand 12/1/2001 6/30/2004 SoleSupply
18610302 Chemical 10/1/2003 Statim Must
18610401 Chemical 10/1/2003 Statim Must
18610402 Chemical 10/1/2003 Statim Must
18610402 Brand 12/1/2001 6/30/2004 SoleSupply
18610402 Brand 3/1/2007 6/30/2009 SoleSupply
18610402 Brand 10/1/2011 6/30/2014 SoleSupply
18610425 Chemical 10/1/2003 Statim Must
18610425 Brand 6/1/2004 S29
18610425 Brand 4/1/2013 Wastage
18630101 Chemical 10/1/2003 Statim Must
18630101 Chemical 12/1/1999 8/31/2006 Application
18630101 Chemical 6/1/1999 ######## AltSubSA
18630125 Chemical 6/1/1999 ######## AltSubSA
18630125 Chemical 12/1/1999 8/31/2006 Application
18630125 Chemical 10/1/2003 Statim Must
18630201 Chemical 10/1/2003 Statim Must
18630201 Chemical 12/1/1999 8/31/2006 Application
18630201 Chemical 6/1/1999 ######## AltSubSA
18630202 Chemical 6/1/1999 ######## AltSubSA
18630202 Chemical 12/1/1999 8/31/2006 Application
18630202 Chemical 10/1/2003 Statim Must
18630203 Chemical 10/1/2003 Statim Must
18630203 Chemical 12/1/1999 8/31/2006 Application
18630203 Brand 12/1/2000 6/30/2003 SoleSupply
18630203 Brand 10/1/2003 6/30/2006 SoleSupply
18630203 Brand 12/1/2006 6/30/2009 SoleSupply
18630203 Chemical 6/1/1999 ######## AltSubSA
18630204 Chemical 6/1/1999 ######## AltSubSA
18630204 Chemical 12/1/1999 8/31/2006 Application
18630204 Chemical 10/1/2003 Statim Must
18630301 Chemical 10/1/2003 Statim Must
18630301 Formulation12/1/1999 8/31/2006 AltSubSA Claim only
18630301 Chemical 12/1/1999 8/31/2006 Application
18630301 Formulation 9/1/2006 2/28/2007 Repeat
18630301 Chemical 6/1/1999 ######## AltSubSA
18630325 Chemical 6/1/1999 ######## AltSubSA
18630325 Formulation 9/1/2006 2/28/2007 Repeat
18630325 Chemical 12/1/1999 8/31/2006 Application
18630325 Formulation12/1/1999 8/31/2006 AltSubSA Claim only
18630325 Chemical 10/1/2003 Statim Must
18630326 Chemical 10/1/2003 Statim Must
18630326 Formulation12/1/1999 8/31/2006 AltSubSA Claim only
18630326 Chemical 12/1/1999 8/31/2006 Application
18630326 Formulation 9/1/2006 2/28/2007 Repeat
18630326 Chemical 6/1/1999 ######## AltSubSA
18630401 Chemical 6/1/1999 ######## AltSubSA
18630401 Formulation 9/1/2006 2/28/2007 Repeat
18630401 Chemical 12/1/1999 8/31/2006 Application
18630401 Formulation12/1/1999 8/31/2006 AltSubSA Claim only
18630401 Chemical 10/1/2003 Statim Must
18630425 Chemical 10/1/2003 Statim Must
18630425 Formulation12/1/1999 8/31/2006 AltSubSA Claim only
18630425 Chemical 12/1/1999 8/31/2006 Application
18630425 Formulation 9/1/2006 2/28/2007 Repeat
18630425 Chemical 6/1/1999 ######## AltSubSA
18630426 Chemical 6/1/1999 ######## AltSubSA
18630426 Formulation 9/1/2006 2/28/2007 Repeat
18630426 Chemical 12/1/1999 8/31/2006 Application
18630426 Formulation12/1/1999 8/31/2006 AltSubSA Claim only
18630426 Chemical 10/1/2003 Statim Must
18630501 Chemical 10/1/2003 Statim Must
18630501 Chemical 12/1/1999 8/31/2006 Application
18630501 Chemical 6/1/1999 ######## AltSubSA
18630601 Chemical 6/1/1999 ######## AltSubSA
18630601 Chemical 12/1/1999 8/31/2006 Application
18630601 Chemical 10/1/2003 Statim Must
18630601 Formulation 7/1/1996 ######## FormMax 30 PSO
18630602 Formulation 7/1/1996 ######## FormMax 30 PSO
18630602 Chemical 10/1/2003 Statim Must
18630602 Chemical 12/1/1999 8/31/2006 Application
18630602 Chemical 6/1/1999 ######## AltSubSA
18630603 Chemical 6/1/1999 ######## AltSubSA
18630603 Chemical 12/1/1999 8/31/2006 Application
18630603 Chemical 10/1/2003 Statim Must
18630603 Formulation 7/1/1996 ######## FormMax 30 PSO
18650102 Chemical 8/1/2012 SafetyListMedicine
18650102 Formulation11/1/1997 Safety Compounded
18650102 Chemical 5/16/1994 8/31/2010 TreatMax 30
18650104 Chemical 5/16/1994 8/31/2010 TreatMax 30
18650104 Formulation11/1/1997 Safety Compounded
18650104 Chemical 8/1/2012 SafetyListMedicine
18670101 Chemical 10/1/2003 Statim Must
18670101 Formulation12/1/2011 OraProduct
18670201 Chemical 10/1/2003 Statim Must
18670301 Chemical 10/1/2003 Statim Must
18710101 Chemical 8/1/2004 Statim Must
18710101 Formulation 7/1/1996 FormMax 84 PSO
18710101 Brand 2/1/2003 6/30/2005 SoleSupply
18710101 Brand 11/1/2006 6/30/2009 SoleSupply
18710101 Brand 10/1/2009 6/30/2012 SoleSupply
18710101 Brand 10/1/2012 6/30/2015 SoleSupply
18710101 ATC2 1/1/2013 MaxCoPayment 5
18710101 ATC2 5/16/1994 ######## MaxCoPayment 3
18710101 Formulation 7/1/1996 Contraceptive
18710101 ATC3 8/1/1995 ######## SpecialWav
18710101 ATC3 11/1/1999 AltSubSA
18710201 Brand 2/1/2003 6/30/2005 SoleSupply
18710201 Brand 11/1/2005 6/30/2008 SoleSupply
18710201 Brand 10/1/2008 6/30/2011 SoleSupply
18710201 Brand 12/1/2011 6/30/2014 SoleSupply
18710201 Chemical 8/1/2004 Statim Must
18710201 Formulation 7/1/1996 FormMax 30 PSO
18730101 Chemical 8/1/2004 Statim Must
18730101 Formulation 7/1/1996 FormMax 63 PSO
18730101 ATC2 1/1/2013 MaxCoPayment 5
18730101 Formulation 7/1/1996 Contraceptive
18730101 ATC2 5/16/1994 ######## MaxCoPayment 3
18730101 ATC3 11/1/1999 AltSubSA
18730101 ATC3 8/1/1995 ######## SpecialWav
18730201 ATC3 8/1/1995 ######## SpecialWav
18730201 ATC3 11/1/1999 AltSubSA
18730201 ATC2 5/16/1994 ######## MaxCoPayment 3
18730201 Formulation 7/1/1996 Contraceptive
18730201 ATC2 1/1/2013 MaxCoPayment 5
18730201 Chemical 8/1/2004 Statim Must
18730201 Formulation 7/1/1996 FormMax 84 PSO
18740101 Chemical 5/16/1994 5/26/1995 SpecEnd Retail
18740101 Formulation5/27/1995 6/30/2014 FormMax 6 Rx SpecEnd
18740101 Formulation 7/1/2014 SubRxF
18740101 Brand 3/1/2000 6/30/2002 SoleSupply
18740125 Brand 9/1/2006 6/30/2008 SoleSupply
18740125 Brand 10/1/2011 6/30/2014 SoleSupply
18740125 Formulation 7/1/2014 SubRxF
18740125 Formulation5/27/1995 6/30/2014 FormMax 6 Rx SpecEnd
18740125 Chemical 5/16/1994 5/26/1995 SpecEnd Retail
18750101 ATC2 1/1/2013 MaxCoPayment 5
18750101 Formulation 7/1/1996 FormMax 63 PSO
18750101 Formulation 7/1/1996 Contraceptive
18750101 ATC2 5/16/1994 ######## MaxCoPayment 3
18750101 ATC3 11/1/1999 AltSubSA
18750101 ATC3 8/1/1995 ######## SpecialWav
18760101 Chemical 8/1/2012 SafetyListMedicine
18760125 Chemical 8/1/2012 SafetyListMedicine
18760125 Brand 2/1/2003 6/30/2005 SoleSupply
18760125 Brand 1/1/2006 6/30/2008 SoleSupply
18860903 ATC2 12/1/1996 6/30/2010 Application
18860903 Formulation 3/1/1995 ######## SpecEnd Retail
18860903 Formulation 3/1/1995 DoseWMax 1
18860903 Formulation 3/1/1995 FormReqd Rx
18860903 Chemical 10/1/2003 Statim Must
18861001 Chemical 10/1/2003 Statim Must
18861001 ATC2 12/1/1996 6/30/2010 Application
18861001 ATC2 7/1/2010 Application
18861101 ATC2 7/1/2010 Application
18861101 ATC2 12/1/1996 6/30/2010 Application
18861101 Chemical 10/1/2003 Statim Must
18880102 Chemical 10/1/2003 Statim Must
18880102 ATC2 12/1/1996 6/30/2010 Application
18880102 ATC2 7/1/2010 Application
18880202 ATC2 7/1/2010 Application
18880202 ATC2 12/1/1996 6/30/2010 Application
18880202 Chemical 10/1/2003 Statim Must
18880302 Chemical 10/1/2003 Statim Must
18880302 ATC2 12/1/1996 6/30/2010 Application
18880302 ATC2 7/1/2010 Application
18880501 Chemical 10/1/2003 Statim Must
19060101 Brand 12/1/2001 6/30/2004 SoleSupply
19080101 Brand 7/1/1999 6/30/2002 SoleSupply
19100101 Chemical 10/1/2003 Statim Must
19110101 Chemical 8/1/2012 SafetyListMedicine
19110101 Formulation11/1/1997 Safety Compounded
19110101 Chemical 5/16/1994 8/31/2010 TreatMax 30
19110102 Chemical 5/16/1994 8/31/2010 TreatMax 30
19110102 Formulation11/1/1997 Safety Compounded
19110102 Chemical 8/1/2012 SafetyListMedicine
19110102 Brand 11/1/2011 6/30/2014 SoleSupply
19110103 Chemical 8/1/2012 SafetyListMedicine
19110103 Formulation11/1/1997 Safety Compounded
19110103 Chemical 5/16/1994 8/31/2010 TreatMax 30
19110201 Chemical 5/16/1994 8/31/2010 TreatMax 30
19110201 Formulation11/1/1997 Safety Compounded
19110201 Chemical 8/1/2012 SafetyListMedicine
19110202 Chemical 8/1/2012 SafetyListMedicine
19110202 Formulation11/1/1997 Safety Compounded
19110202 Chemical 5/16/1994 8/31/2010 TreatMax 30
19110202 Brand 11/1/2011 6/30/2014 SoleSupply
19110203 Chemical 5/16/1994 8/31/2010 TreatMax 30
19110203 Formulation11/1/1997 Safety Compounded
19110203 Chemical 8/1/2012 SafetyListMedicine
19110301 Chemical 8/1/2012 SafetyListMedicine
19110301 Formulation11/1/1997 Safety Compounded
19110301 Chemical 5/16/1994 8/31/2010 TreatMax 30
19110302 Chemical 5/16/1994 8/31/2010 TreatMax 30
19110302 Formulation11/1/1997 Safety Compounded
19110302 Chemical 8/1/2012 SafetyListMedicine
19110303 Chemical 8/1/2012 SafetyListMedicine
19110303 Formulation11/1/1997 Safety Compounded
19110303 Chemical 5/16/1994 8/31/2010 TreatMax 30
19120101 Chemical 10/1/2003 Statim Must
19120101 Brand 8/1/1998 6/30/2001 SoleSupply
19120101 Formulation 7/1/1996 9/30/2003 Statim May
19120102 Formulation 7/1/1996 9/30/2003 Statim May
19120102 Chemical 10/1/2003 Statim Must
19120201 Chemical 10/1/2003 Statim Must
19120201 Formulation 7/1/1996 9/30/2003 Statim May
19120201 Brand 8/1/1998 6/30/2001 SoleSupply
19120202 Formulation 7/1/1996 9/30/2003 Statim May
19120202 Chemical 10/1/2003 Statim Must
19120401 Chemical 10/1/2003 Statim Must
19120401 Formulation10/4/1997 9/30/2003 Statim May
19120402 Formulation10/4/1997 9/30/2003 Statim May
19120402 Chemical 10/1/2003 Statim Must
19140101 Chemical 10/1/2003 Statim Must
19140102 Chemical 10/1/2003 Statim Must
19140102 Brand 11/1/1999 6/30/2002 SoleSupply
19140102 Brand 10/1/2004 6/30/2007 SoleSupply
19140102 Brand 1/1/2008 6/30/2010 SoleSupply
19140102 Brand 7/1/2013 6/30/2016 SoleSupply
19140201 Chemical 10/1/2003 Statim Must
19140202 Chemical 10/1/2003 Statim Must
19140202 Brand 10/1/2004 6/30/2007 SoleSupply
19140202 Brand 1/1/2008 6/30/2010 SoleSupply
19140202 Brand 7/1/2013 6/30/2016 SoleSupply
19150101 Chemical 5/16/1994 MaxCoPayment 0
19150101 Chemical 5/30/1995 Controlled
19170101 Chemical 5/16/1994 1/31/1997 SpecEnd Retail
19220101 Chemical 7/1/1996 FormMax 5 PSO
19220101 Brand 10/1/2003 6/30/2006 SoleSupply
19220101 Brand 6/1/2007 6/30/2009 SoleSupply
19220101 Brand 1/1/2010 6/30/2012 SoleSupply
19220125 Brand 5/1/2014 6/30/2015 SoleSupply
19220125 Chemical 7/1/1996 FormMax 5 PSO
19220201 Chemical 7/1/1996 FormMax 5 PSO
19220201 Brand 10/1/2003 6/30/2006 SoleSupply
19220201 Brand 6/1/2007 6/30/2009 SoleSupply
19220201 Brand 1/1/2010 6/30/2012 SoleSupply
19220225 Brand 5/1/2014 6/30/2015 SoleSupply
19220225 Chemical 7/1/1996 FormMax 5 PSO
19220301 Chemical 7/1/1996 FormMax 5 PSO
19220301 Brand 10/1/2003 6/30/2006 SoleSupply
19220301 Brand 6/1/2007 6/30/2009 SoleSupply
19220301 Brand 1/1/2010 6/30/2012 SoleSupply
19220301 Brand 11/1/2012 6/30/2015 SoleSupply
19250101 Formulation5/10/1995 SpecEnd Retail
19250201 Formulation5/10/1995 SpecEnd Retail
19250301 Formulation5/10/1995 SpecEnd Retail
19250901 Formulation5/10/1995 SpecEnd Retail
19251001 Formulation5/10/1995 SpecEnd Retail
19251101 Formulation5/10/1995 5/31/2010 SpecEnd Retail
19251201 Formulation5/10/1995 SpecEnd Retail
19251301 Formulation5/10/1995 5/31/2010 SpecEnd Retail
19251325 Formulation5/10/1995 5/31/2010 SpecEnd Retail
19251401 Formulation5/10/1995 SpecEnd Retail
19251501 Formulation5/10/1995 5/31/2010 SpecEnd Retail
19252525 Formulation 5/1/2000 5/31/2010 SpecEnd Retail
19252525 Formulation 8/1/2012 ProvAllow Dietitian
19270101 Chemical 5/30/1995 MaxCoPayment 0
19270101 Chemical 6/22/1995 Controlled
19280101 Chemical 10/1/2003 Statim Must
19290201 Chemical 10/1/2003 Statim Must
19290201 Formulation 7/1/1996 FormMax 200 PSO
19290201 Formulation 6/1/2002 NotCombined
19290201 Formulation 7/1/1996 Safety Uncompounded
19290202 Formulation 7/1/1996 Safety Uncompounded
19290202 Formulation 6/1/2002 NotCombined
19290202 Brand 6/1/1998 5/31/2000 Preferred
19290202 Formulation 7/1/1996 FormMax 200 PSO
19290202 Chemical 10/1/2003 Statim Must
19290203 Chemical 10/1/2003 Statim Must
19290203 Formulation 7/1/1996 FormMax 200 PSO
19290203 Formulation 6/1/2002 NotCombined
19290203 Formulation 7/1/1996 Safety Uncompounded
19290204 Formulation 7/1/1996 Safety Uncompounded
19290204 Formulation 6/1/2002 NotCombined
19290204 Formulation 7/1/1996 FormMax 200 PSO
19290204 Chemical 10/1/2003 Statim Must
19290205 Chemical 10/1/2003 Statim Must
19290205 Formulation 7/1/1996 FormMax 200 PSO
19290205 Formulation 6/1/2002 NotCombined
19290205 Formulation 7/1/1996 Safety Uncompounded
19290206 Formulation 7/1/1996 Safety Uncompounded
19290206 Formulation 6/1/2002 NotCombined
19290206 Brand 6/1/1998 5/31/2000 Preferred
19290206 Formulation 7/1/1996 FormMax 200 PSO
19290206 Chemical 10/1/2003 Statim Must
19290207 Chemical 10/1/2003 Statim Must
19290207 Formulation 7/1/1996 FormMax 200 PSO
19290207 Brand 8/1/1999 5/31/2000 Preferred
19290207 Formulation 6/1/2002 NotCombined
19290207 Formulation 7/1/1996 Safety Uncompounded
19290207 Brand 12/1/2008 6/30/2011 SoleSupply
19290225 Brand 2/1/2004 6/30/2005 SoleSupply
19290225 Brand 12/1/2005 6/30/2008 SoleSupply
19290225 Formulation 7/1/1996 Safety Uncompounded
19290225 Formulation 6/1/2002 NotCombined
19290225 Formulation 7/1/1996 FormMax 200 PSO
19290225 Chemical 10/1/2003 Statim Must
19290226 Chemical 10/1/2003 Statim Must
19290226 Formulation 7/1/1996 FormMax 200 PSO
19290226 Formulation 6/1/2002 NotCombined
19290226 Brand 3/1/2012 6/30/2014 SoleSupply
19290226 Formulation 7/1/1996 Safety Uncompounded
19290301 Formulation 7/1/1996 Safety Uncompounded
19290301 Formulation 6/1/2002 NotCombined
19290301 Formulation 3/1/2005 FormMax 100 PSO
19290301 Chemical 10/1/2003 Statim Must
19290302 Chemical 10/1/2003 Statim Must
19290302 Formulation 3/1/2005 FormMax 100 PSO
19290302 Formulation 6/1/2002 NotCombined
19290302 Formulation 7/1/1996 Safety Uncompounded
19290303 Formulation 7/1/1996 Safety Uncompounded
19290303 Formulation 6/1/2002 NotCombined
19290303 Brand 6/1/1998 5/31/2000 Preferred
19290303 Formulation 3/1/2005 FormMax 100 PSO
19290303 Chemical 10/1/2003 Statim Must
19290304 Chemical 10/1/2003 Statim Must
19290304 Formulation 3/1/2005 FormMax 100 PSO
19290304 Formulation 6/1/2002 NotCombined
19290304 Formulation 7/1/1996 Safety Uncompounded
19290305 Formulation 7/1/1996 Safety Uncompounded
19290305 Brand 12/1/2008 6/30/2011 SoleSupply
19290305 Brand 10/1/2011 6/30/2014 SoleSupply
19290305 Formulation 6/1/2002 NotCombined
19290305 Brand 8/1/1999 5/31/2000 Preferred
19290305 Formulation 3/1/2005 FormMax 100 PSO
19290305 Chemical 10/1/2003 Statim Must
19290325 Chemical 10/1/2003 Statim Must
19290325 Formulation 3/1/2005 FormMax 100 PSO
19290325 Formulation 6/1/2002 NotCombined
19290325 Brand 2/1/2004 6/30/2005 SoleSupply
19290325 Brand 12/1/2005 6/30/2008 SoleSupply
19290325 Formulation 7/1/1996 Safety Uncompounded
19290401 Brand 12/1/2002 6/30/2005 SoleSupply
19290401 Brand 1/1/2006 6/30/2008 SoleSupply
19290401 Chemical 10/1/2003 Statim Must
19290501 Chemical 10/1/2003 Statim Must
19290501 Brand 12/1/2002 6/30/2005 SoleSupply
19290501 Brand 1/1/2006 6/30/2008 SoleSupply
19290601 Chemical 10/1/2003 Statim Must
19290625 Chemical 10/1/2003 Statim Must
19290625 Brand 2/1/2005 6/30/2007 SoleSupply
19290625 Brand 2/1/2013 6/30/2015 SoleSupply
19290701 Chemical 10/1/2003 Statim Must
19290701 Formulation######## Safety Compounded
19290801 Chemical 10/1/2003 Statim Must
19290801 Formulation11/1/1997 FormMax 30 PSO
19290802 Formulation11/1/1997 FormMax 30 PSO
19290802 Chemical 10/1/2003 Statim Must
19290802 Brand 8/1/1999 6/30/2002 SoleSupply
19290802 Brand 4/1/2006 6/30/2008 SoleSupply
19290803 Chemical 10/1/2003 Statim Must
19290803 Formulation11/1/1997 FormMax 30 PSO
19290804 Formulation11/1/1997 FormMax 30 PSO
19290804 Chemical 10/1/2003 Statim Must
19290805 Chemical 10/1/2003 Statim Must
19290805 Formulation11/1/1997 FormMax 30 PSO
19290825 Formulation11/1/1997 FormMax 30 PSO
19290825 Chemical 10/1/2003 Statim Must
19290825 Brand 3/1/2003 6/30/2005 SoleSupply
19290826 Brand 4/1/2009 6/30/2011 SoleSupply
19290826 Chemical 10/1/2003 Statim Must
19290826 Formulation11/1/1997 FormMax 30 PSO
19290827 Formulation11/1/1997 FormMax 30 PSO
19290827 Chemical 10/1/2003 Statim Must
19290827 Brand 4/1/2012 6/30/2014 SoleSupply
19310101 Brand 8/1/1999 6/30/2002 SoleSupply
19310101 Chemical 8/1/2012 SafetyListMedicine
19310101 Chemical 10/1/2003 Statim Must
19310102 Chemical 10/1/2003 Statim Must
19310102 Chemical 8/1/2012 SafetyListMedicine
19310103 Chemical 8/1/2012 SafetyListMedicine
19310103 Chemical 10/1/2003 Statim Must
19310105 Chemical 10/1/2003 Statim Must
19310105 Chemical 8/1/2012 SafetyListMedicine
19310125 Chemical 8/1/2012 SafetyListMedicine
19310125 Chemical 10/1/2003 Statim Must
19310125 Brand 2/1/2004 6/30/2005 SoleSupply
19310125 Brand 10/1/2005 6/30/2008 SoleSupply
19310126 Brand 6/1/2010 6/30/2011 SoleSupply
19310126 Chemical 8/1/2012 SafetyListMedicine
19310126 Chemical 10/1/2003 Statim Must
19310127 Chemical 10/1/2003 Statim Must
19310127 Chemical 8/1/2012 SafetyListMedicine
19310127 Brand 2/1/2012 6/30/2014 SoleSupply
19420301 Chemical 5/16/1994 2/28/2009 SpecEnd Retail
19420325 Chemical 5/16/1994 2/28/2009 SpecEnd Retail
19420401 Chemical 5/16/1994 2/28/2009 SpecEnd Retail
19420425 Chemical 5/16/1994 2/28/2009 SpecEnd Retail
19440101 Chemical 5/16/1994 FormReqd PSO
19440101 Formulation 7/1/1996 FormMax 30 PSO
19440201 Formulation 7/1/1996 FormMax 30 PSO
19440201 Chemical 5/16/1994 FormReqd PSO
19440301 Chemical 5/16/1994 FormReqd PSO
19440301 Formulation 7/1/1996 FormMax 5 PSO
19490102 Chemical 1/1/1999 7/31/2010 Dispensary HP3
19490102 Chemical 10/1/2003 Statim Must
19490102 Chemical 6/14/1995 6/30/1996 SpecEnd Retail
19490102 Chemical 7/1/1995 9/30/2012 Special
19490102 Chemical 10/1/2012 Special
19490102 Chemical 7/1/1995 ######## ProvReqd M
19490125 Chemical 7/1/1995 ######## ProvReqd M
19490125 Brand 10/1/2003 6/30/2006 SoleSupply
19490125 Brand 1/1/2007 6/30/2009 SoleSupply
19490125 Chemical 10/1/2012 Special
19490125 Chemical 7/1/1995 9/30/2012 Special
19490125 Chemical 6/14/1995 6/30/1996 SpecEnd Retail
19490125 Chemical 10/1/2003 Statim Must
19490125 Chemical 1/1/1999 7/31/2010 Dispensary HP3
19500101 Chemical 8/1/2012 SafetyListMedicine
19500201 Chemical 8/1/2012 SafetyListMedicine
19530101 Chemical 8/1/2012 SafetyListMedicine
19530101 Brand 1/1/2005 6/30/2007 SoleSupply
19530101 Brand 4/1/2013 6/30/2015 SoleSupply
19530101 Chemical 5/16/1994 MaxCoPayment 0
19530101 Chemical 5/30/1995 Controlled
19530101 Brand 6/1/1998 5/31/2000 Preferred
19530102 Chemical 5/30/1995 Controlled
19530102 Chemical 5/16/1994 MaxCoPayment 0
19530102 Chemical 8/1/2012 SafetyListMedicine
19530201 Chemical 8/1/2012 SafetyListMedicine
19530201 Chemical 5/16/1994 MaxCoPayment 0
19530201 Chemical 5/30/1995 Controlled
19530201 Brand 6/1/1998 5/31/2000 Preferred
19530201 Brand 1/1/2005 6/30/2007 SoleSupply
19530201 Brand 4/1/2013 6/30/2015 SoleSupply
19530202 Chemical 5/30/1995 Controlled
19530202 Chemical 5/16/1994 MaxCoPayment 0
19530202 Chemical 8/1/2012 SafetyListMedicine
19530301 Chemical 8/1/2012 SafetyListMedicine
19530301 Formulation 7/1/1996 FormMax 5 PSO
19530301 Chemical 5/16/1994 MaxCoPayment 0
19530301 Chemical 5/30/1995 Controlled
19530301 Brand 11/1/1999 6/30/2002 SoleSupply
19530301 Brand 12/1/2011 6/30/2014 SoleSupply
19530302 Chemical 5/30/1995 Controlled
19530302 Chemical 5/16/1994 MaxCoPayment 0
19530302 Formulation 7/1/1996 FormMax 5 PSO
19530302 Chemical 8/1/2012 SafetyListMedicine
19530401 Chemical 8/1/2012 SafetyListMedicine
19530401 Formulation 7/1/1996 FormMax 5 PSO
19530401 Chemical 5/16/1994 MaxCoPayment 0
19530401 Chemical 5/30/1995 Controlled
19530501 Chemical 5/30/1995 Controlled
19530501 Chemical 5/16/1994 MaxCoPayment 0
19530501 Brand 11/1/1999 6/30/2002 SoleSupply
19530501 Brand 12/1/2011 6/30/2014 SoleSupply
19530501 Formulation 7/1/1996 FormMax 5 PSO
19530501 Chemical 8/1/2012 SafetyListMedicine
19530502 Chemical 8/1/2012 SafetyListMedicine
19530502 Formulation 7/1/1996 FormMax 5 PSO
19530502 Chemical 5/16/1994 MaxCoPayment 0
19530502 Chemical 5/30/1995 Controlled
19550101 Chemical 6/1/2012 Statim Must
19560501 Formulation######## Safety Compounded
19560501 Formulation 7/1/2004 Combined
19560525 Formulation 7/1/2004 Combined
19560525 Formulation######## Safety Compounded
19562525 Brand 7/1/2013 S29
19562525 Brand 7/1/2013 Wastage
19562525 Chemical 7/1/2013 Special
19660101 Chemical 10/1/2003 Statim Must
19660101 Brand 3/1/2008 S29
19660101 Brand 4/1/2013 Wastage
19660125 Brand 5/1/2014 S29
19660125 Brand 5/1/2014 Wastage
19660125 Chemical 10/1/2003 Statim Must
19700101 Formulation 7/1/1996 FormMax 30 PSO
19700301 Formulation 7/1/1996 FormMax 200 PSO
19700301 Brand 2/1/2000 6/30/2001 Preferred
19700401 Brand 2/1/2000 6/30/2001 Preferred
19700401 Formulation 2/1/2001 FormMax 200 PSO
19702525 Formulation 6/1/2000 FormMax 30 PSO
19702525 Brand 11/1/2000 6/30/2002 SoleSupply
19702525 Brand 10/1/2003 6/30/2006 SoleSupply
19702525 Brand 10/1/2007 6/30/2010 SoleSupply
19702525 Brand 12/1/2010 6/30/2013 SoleSupply
19702625 Formulation12/1/2013 RFPP 2
19702625 Formulation12/1/2013 FormMax 20 PSO
19702625 Brand 11/1/2000 6/30/2002 SoleSupply
19702625 Brand 10/1/2003 6/30/2006 SoleSupply
19702625 Brand 10/1/2007 6/30/2010 SoleSupply
19702625 Brand 12/1/2010 6/30/2013 SoleSupply
19702725 Brand 3/1/2002 6/30/2004 SoleSupply
19702725 Brand 10/1/2004 6/30/2007 SoleSupply
19702725 Brand 1/1/2008 6/30/2010 SoleSupply
19702725 Brand 10/1/2010 6/30/2013 SoleSupply
19702725 Brand 5/1/2014 6/30/2016 SoleSupply
19702725 Formulation10/1/2001 Wastage
19702725 Formulation 7/1/1996 FormMax 200 PSO
19702825 Formulation 7/1/1996 ######## FormMax 200 PSO
19702825 Formulation12/1/2013 FormMax 300 PSO
19702825 Formulation10/1/2001 Wastage
19702825 Formulation12/1/2013 RFPP 2
19702825 Brand 3/1/2002 6/30/2004 SoleSupply
19702825 Brand 10/1/2004 6/30/2007 SoleSupply
19702825 Brand 1/1/2008 6/30/2010 SoleSupply
19702825 Brand 10/1/2010 6/30/2013 SoleSupply
19702825 Brand 5/1/2014 6/30/2016 SoleSupply
19710101 Chemical 10/1/2003 Statim Must
19720101 Chemical 10/1/2003 Statim Must
19720102 Chemical 10/1/2003 Statim Must
19720102 Brand 12/1/2007 6/30/2010 SoleSupply
19730101 Chemical 10/1/2003 Statim Must
19730102 Chemical 10/1/2003 Statim Must
19780101 Chemical 10/1/2003 Statim Must
19780101 ATC3 8/1/2003 6/30/2005 Application
19780101 ATC3 7/1/2005 7/31/2007 Application
19780101 Formulation 7/1/1996 9/30/2003 Statim May
19780201 Formulation 7/1/1996 9/30/2003 Statim May
19780201 ATC3 7/1/2005 7/31/2007 Application
19780201 ATC3 8/1/2003 6/30/2005 Application
19780201 Chemical 10/1/2003 Statim Must
19780301 Chemical 10/1/2003 Statim Must
19780301 ATC3 8/1/2003 6/30/2005 Application
19780301 ATC3 7/1/2005 7/31/2007 Application
19780301 Formulation 7/1/1996 9/30/2003 Statim May
19780401 Formulation 7/1/1996 9/30/2003 Statim May
19780401 ATC3 7/1/2005 7/31/2007 Application
19780401 Formulation 7/1/1996 Safety Uncompounded
19780401 ATC3 8/1/2003 6/30/2005 Application
19780401 Chemical 10/1/2003 Statim Must
19780501 Chemical 10/1/2003 Statim Must
19780501 ATC3 8/1/2003 6/30/2005 Application
19780501 Formulation 7/1/1996 Safety Uncompounded
19780501 ATC3 7/1/2005 7/31/2007 Application
19780501 Formulation 7/1/1996 9/30/2003 Statim May
19780601 Formulation 7/1/1996 3/31/1999 FormMax 5 PSO
19780601 Formulation 8/1/2000 FormMax 5 PSO
19780601 Chemical 10/1/2003 Statim Must
19780625 Chemical 10/1/2003 Statim Must
19780625 Formulation 8/1/2000 FormMax 5 PSO
19780625 Formulation 7/1/1996 3/31/1999 FormMax 5 PSO
19780701 Formulation 7/1/1996 ######## FormMax 5 PSO
19780701 Formulation 8/1/2000 FormMax 5 PSO
19780701 Chemical 10/1/2003 Statim Must
19780725 Chemical 10/1/2003 Statim Must
19780725 Formulation 8/1/2000 FormMax 5 PSO
19780725 Formulation 7/1/1996 ######## FormMax 5 PSO
19860101 Brand 10/1/2003 6/30/2006 SoleSupply
19860201 Formulation 7/1/1996 FormMax 5 PSO
19860302 Formulation 7/1/1996 FormMax 5 PSO
19860302 Brand 10/1/2003 6/30/2006 SoleSupply
19862525 Brand 10/1/2003 6/30/2006 SoleSupply
19862525 Formulation 6/1/2000 FormMax 5 PSO
19870101 Chemical 10/1/2003 Statim Must
19870101 Formulation11/1/1997 9/30/2003 Statim May
19870102 Formulation11/1/1997 9/30/2003 Statim May
19870102 Chemical 10/1/2003 Statim Must
19870103 Chemical 10/1/2003 Statim Must
19870103 Formulation11/1/1997 9/30/2003 Statim May
19870103 Brand 11/1/1999 6/30/2002 SoleSupply
19870103 Brand 1/1/2003 6/30/2005 SoleSupply
19870103 Brand 1/1/2006 6/30/2008 SoleSupply
19870201 Formulation11/1/1997 9/30/2003 Statim May
19870201 Chemical 10/1/2003 Statim Must
19870201 Brand 8/1/2009 ######## S29
19870202 Chemical 10/1/2003 Statim Must
19870202 Formulation11/1/1997 9/30/2003 Statim May
19870203 Formulation11/1/1997 9/30/2003 Statim May
19870203 Brand 11/1/1999 6/30/2002 SoleSupply
19870203 Brand 1/1/2003 6/30/2005 SoleSupply
19870203 Brand 1/1/2006 6/30/2008 SoleSupply
19870203 Chemical 10/1/2003 Statim Must
19870301 Chemical 10/1/2003 Statim Must
19870301 Brand 8/1/2009 ######## S29
19870301 Formulation11/1/1997 9/30/2003 Statim May
19870302 Formulation11/1/1997 9/30/2003 Statim May
19870302 Chemical 10/1/2003 Statim Must
19870303 Chemical 10/1/2003 Statim Must
19870303 Formulation11/1/1997 9/30/2003 Statim May
19870303 Brand 11/1/1999 6/30/2002 SoleSupply
19870303 Brand 1/1/2003 6/30/2005 SoleSupply
19870303 Brand 1/1/2006 6/30/2008 SoleSupply
19870401 Formulation11/1/1997 9/30/2003 Statim May
19870401 Chemical 10/1/2003 Statim Must
19870402 Chemical 10/1/2003 Statim Must
19870402 Formulation11/1/1997 9/30/2003 Statim May
19870403 Formulation11/1/1997 9/30/2003 Statim May
19870403 Brand 11/1/1999 6/30/2002 SoleSupply
19870403 Brand 1/1/2003 6/30/2005 SoleSupply
19870403 Brand 1/1/2006 9/30/2007 SoleSupply
19870403 Chemical 10/1/2003 Statim Must
19870501 Chemical 10/1/2003 Statim Must
19870501 Brand 8/1/2009 ######## S29
19870501 Formulation11/1/1997 9/30/2003 Statim May
19870502 Formulation11/1/1997 9/30/2003 Statim May
19870502 Chemical 10/1/2003 Statim Must
19870503 Chemical 10/1/2003 Statim Must
19870503 Formulation11/1/1997 9/30/2003 Statim May
19870503 Brand 11/1/1999 6/30/2002 SoleSupply
19870503 Brand 1/1/2003 6/30/2005 SoleSupply
19870503 Brand 1/1/2006 6/30/2008 SoleSupply
19870601 Formulation11/1/1997 9/30/2003 Statim May
19870601 Chemical 10/1/2003 Statim Must
19870602 Chemical 10/1/2003 Statim Must
19870602 Formulation11/1/1997 9/30/2003 Statim May
19870603 Formulation11/1/1997 9/30/2003 Statim May
19870603 Brand 11/1/1999 6/30/2002 SoleSupply
19870603 Brand 1/1/2003 6/30/2005 SoleSupply
19870603 Brand 1/1/2006 6/30/2008 SoleSupply
19870603 Chemical 10/1/2003 Statim Must
19870701 Chemical 10/1/2003 Statim Must
19870701 Formulation 1/1/1999 7/31/2010 Dispensary HP3
19870701 Formulation10/1/2007 Special
19870701 Formulation 1/1/1999 9/30/2007 Special
19870701 Formulation 1/1/1999 9/30/2003 Statim May
19870801 Formulation11/1/1997 9/30/2003 Statim May
19870801 Chemical 10/1/2003 Statim Must
19870801 Formulation11/1/1997 SpecEnd Retail
19900101 Chemical 5/16/1994 SpecEnd Retail
19900101 Brand 10/1/2005 1/31/2007 SoleSupply
19900201 Chemical 5/16/1994 SpecEnd Retail
19902525 Chemical 5/16/1994 SpecEnd Retail
19902525 Brand 2/1/2007 S29
19902525 Brand 4/1/2013 Wastage
19910401 Chemical 10/1/2003 Statim Must
19910401 Formulation 7/1/1996 9/30/2003 Statim May
19910402 Formulation 7/1/1996 9/30/2003 Statim May
19910402 Brand 12/1/2001 6/30/2004 SoleSupply
19910402 Brand 9/1/2004 6/30/2007 SoleSupply
19910402 Chemical 10/1/2003 Statim Must
19910403 Chemical 10/1/2003 Statim Must
19910403 Brand 8/1/1998 6/30/2001 SoleSupply
19910403 Brand 6/1/2010 6/30/2012 SoleSupply
19910403 Brand 12/1/2013 6/30/2016 SoleSupply
19910403 Formulation 7/1/1996 9/30/2003 Statim May
19910404 Formulation 7/1/1996 9/30/2003 Statim May
19910404 Chemical 10/1/2003 Statim Must
19910501 Chemical 10/1/2003 Statim Must
19910501 Formulation 7/1/1996 9/30/2003 Statim May
19910501 Brand 6/1/2010 6/30/2012 SoleSupply
19910501 Brand 12/1/2013 6/30/2016 SoleSupply
19910503 Brand 8/1/1998 6/30/2001 SoleSupply
19910503 Brand 11/1/2004 6/30/2007 SoleSupply
19910503 Formulation 7/1/1996 9/30/2003 Statim May
19910503 Chemical 10/1/2003 Statim Must
19910504 Chemical 10/1/2003 Statim Must
19910504 Formulation 7/1/1996 9/30/2003 Statim May
19910505 Formulation 7/1/1996 9/30/2003 Statim May
19910505 Chemical 10/1/2003 Statim Must
19910601 Chemical 10/1/2003 Statim Must
19910601 Formulation 7/1/1996 9/30/2003 Statim May
19910601 Brand 6/1/2010 6/30/2012 SoleSupply
19910601 Brand 12/1/2013 6/30/2016 SoleSupply
19910603 Brand 8/1/1998 6/30/2001 SoleSupply
19910603 Brand 11/1/2004 6/30/2007 SoleSupply
19910603 Formulation 7/1/1996 9/30/2003 Statim May
19910603 Chemical 10/1/2003 Statim Must
19910604 Chemical 10/1/2003 Statim Must
19910604 Formulation 7/1/1996 9/30/2003 Statim May
19940101 Chemical 8/1/2012 SafetyListMedicine
19940101 Formulation 7/1/1996 FormMax 5 PSO
19940101 Chemical 5/16/1994 3/31/2008 SpecEnd Retail
19940201 Chemical 5/16/1994 3/31/2008 SpecEnd Retail
19940201 Formulation 7/1/1996 FormMax 5 PSO
19940201 Chemical 8/1/2012 SafetyListMedicine
19950101 Chemical 5/16/1994 TreatMax 30
19950101 Chemical 5/16/1994 FormReqd Rx
19950101 Formulation5/16/1994 DoseDMax 1
19960301 Chemical 10/1/2003 Statim Must
19960401 Chemical 10/1/2003 Statim Must
19960402 Chemical 10/1/2003 Statim Must
19960402 Brand 12/1/2000 6/30/2003 SoleSupply
19960402 Brand 11/1/2003 6/30/2006 SoleSupply
19960501 Chemical 10/1/2003 Statim Must
19960601 Chemical 10/1/2003 Statim Must
19960602 Chemical 10/1/2003 Statim Must
19960602 Brand 12/1/2000 6/30/2003 SoleSupply
19960602 Brand 11/1/2003 6/30/2006 SoleSupply
19960701 Chemical 10/1/2003 Statim Must
19960702 Chemical 10/1/2003 Statim Must
20000101 Chemical 10/1/2003 Statim Must
20000101 Brand 5/1/2010 6/30/2012 SoleSupply
20000101 Brand 4/1/2013 6/30/2015 SoleSupply
20000201 Chemical 10/1/2003 Statim Must
20080101 Formulation 6/1/2002 FormReqd Rx
20080101 Formulation 6/1/2002 NotCombined
20100201 Brand 10/1/2003 6/30/2006 SoleSupply
20100201 Chemical 10/1/2003 Statim Must
20100225 Chemical 10/1/2003 Statim Must
20100225 Brand 2/1/2009 6/30/2011 SoleSupply
20100301 Brand 10/1/2003 6/30/2006 SoleSupply
20100301 Chemical 10/1/2003 Statim Must
20100325 Chemical 10/1/2003 Statim Must
20100325 Brand 2/1/2009 6/30/2011 SoleSupply
20130101 Formulation 8/1/2010 ProvAllow Dietitian
20130101 Chemical 5/16/1994 ######## SpecEnd Retail
20160101 Formulation 8/1/2010 ProvAllow Dietitian
20160101 Chemical 10/1/2003 Statim Must
20160201 Chemical 10/1/2003 Statim Must
20160201 Formulation 8/1/2010 ProvAllow Dietitian
20160202 Formulation 8/1/2010 ProvAllow Dietitian
20160202 Chemical 10/1/2003 Statim Must
20160203 Chemical 10/1/2003 Statim Must
20160203 Formulation 8/1/2010 ProvAllow Dietitian
20160203 Brand 7/1/2004 6/30/2006 SoleSupply
20160203 Brand 1/1/2007 6/30/2009 SoleSupply
20160203 Brand 1/1/2010 6/30/2012 SoleSupply
20160203 Brand 11/1/2012 6/30/2015 SoleSupply
20160301 Chemical 10/1/2003 Statim Must
20160302 Chemical 10/1/2003 Statim Must
20160302 Brand 12/1/2002 6/30/2005 SoleSupply
20160302 Brand 10/1/2005 6/30/2008 SoleSupply
20160401 Chemical 10/1/2003 Statim Must
20160402 Chemical 10/1/2003 Statim Must
20160402 Brand 12/1/2002 6/30/2005 SoleSupply
20160402 Brand 10/1/2005 6/30/2008 SoleSupply
20160501 Chemical 10/1/2003 Statim Must
20310101 Chemical 10/1/2003 Statim Must
20310201 Chemical 10/1/2003 Statim Must
20310201 Brand 12/1/2001 6/30/2004 SoleSupply
20310201 Brand 10/1/2004 6/30/2007 SoleSupply
20310202 Chemical 10/1/2003 Statim Must
20310203 Chemical 10/1/2003 Statim Must
20310203 Brand 8/1/1998 6/30/2001 SoleSupply
20310225 Brand 8/1/2008 6/30/2010 SoleSupply
20310225 Chemical 10/1/2003 Statim Must
20310226 Chemical 10/1/2003 Statim Must
20310301 Chemical 10/1/2003 Statim Must
20310301 Brand 8/1/1998 6/30/2001 SoleSupply
20310302 Chemical 10/1/2003 Statim Must
20310303 Chemical 10/1/2003 Statim Must
20310303 Brand 12/1/2001 6/30/2004 SoleSupply
20310303 Brand 10/1/2004 6/30/2007 SoleSupply
20310325 Brand 8/1/2008 6/30/2010 SoleSupply
20310325 Chemical 10/1/2003 Statim Must
20310326 Chemical 10/1/2003 Statim Must
20310401 Chemical 10/1/2003 Statim Must
20310401 Brand 12/1/2001 6/30/2004 SoleSupply
20310401 Brand 10/1/2004 6/30/2007 SoleSupply
20310402 Chemical 10/1/2003 Statim Must
20310403 Chemical 10/1/2003 Statim Must
20310403 Brand 8/1/1998 6/30/2001 SoleSupply
20310425 Brand 8/1/2008 6/30/2010 SoleSupply
20310425 Chemical 10/1/2003 Statim Must
20310426 Chemical 10/1/2003 Statim Must
20320101 Chemical 10/1/2003 Statim Must
20320101 Chemical 5/16/1994 9/30/2007 SpecEnd Retail
20320201 Chemical 5/16/1994 9/30/2007 SpecEnd Retail
20320201 Chemical 10/1/2003 Statim Must
20330101 Chemical 6/3/1995 SpecEnd Retail
20340101 Chemical 10/1/2003 Statim Must
20340201 Chemical 10/1/2003 Statim Must
20342525 Chemical 10/1/2003 Statim Must
20342525 Formulation 2/1/2001 FormMax 30 PSO
20342525 Brand 10/1/2004 6/30/2007 SoleSupply
20342525 Brand 10/1/2009 6/30/2012 SoleSupply
20350101 Chemical 6/3/1995 SpecEnd Retail
20360101 Formulation 7/1/1996 5/31/1999 Statim May
20380101 Formulation 7/1/1996 9/30/2003 Statim May
20380101 Formulation 8/1/2013 Statim Must
20380101 Chemical 10/1/2003 6/30/2013 Statim Must
20380102 Chemical 10/1/2003 6/30/2013 Statim Must
20380102 Formulation 8/1/2013 Statim Must
20380102 Formulation 7/1/1996 9/30/2003 Statim May
20380102 Brand 11/1/2002 6/30/2005 SoleSupply
20380102 Brand 10/1/2005 6/30/2008 SoleSupply
20380102 Brand 1/1/2009 6/30/2011 SoleSupply
20380103 Formulation 7/1/1996 9/30/2003 Statim May
20380103 Formulation 8/1/2013 Statim Must
20380103 Chemical 10/1/2003 6/30/2013 Statim Must
20380125 Brand 8/1/2013 S29
20380125 Brand 8/1/2013 Wastage
20380125 Formulation 8/1/2013 Statim Must
20380125 Chemical 10/1/2003 6/30/2013 Statim Must
20380125 Formulation 7/1/1996 9/30/2003 Statim May
20380202 Formulation 7/1/1996 9/30/2003 Statim May
20380202 Formulation 7/1/2013 Statim Must
20380202 Chemical 10/1/2003 6/30/2013 Statim Must
20380203 Chemical 10/1/2003 6/30/2013 Statim Must
20380203 Formulation 7/1/2013 Statim Must
20380203 Formulation 7/1/1996 9/30/2003 Statim May
20380203 Brand 11/1/2002 6/30/2005 SoleSupply
20380203 Brand 10/1/2005 6/30/2008 SoleSupply
20380203 Brand 1/1/2009 6/30/2011 SoleSupply
20380204 Formulation 7/1/1996 9/30/2003 Statim May
20380204 Formulation 7/1/2013 Statim Must
20380204 Chemical 10/1/2003 6/30/2013 Statim Must
20380301 Chemical 10/1/2003 6/30/2013 Statim Must
20380301 Formulation 7/1/1996 FormMax 30 PSO
20380301 Formulation 7/1/2013 Statim Must
20380301 Formulation 7/1/1996 9/30/2003 Statim May
20380302 Formulation 7/1/1996 9/30/2003 Statim May
20380302 Brand 11/1/2002 6/30/2005 SoleSupply
20380302 Brand 10/1/2005 6/30/2008 SoleSupply
20380302 Brand 1/1/2009 6/30/2011 SoleSupply
20380302 Formulation 7/1/2013 Statim Must
20380302 Formulation 7/1/1996 FormMax 30 PSO
20380302 Chemical 10/1/2003 6/30/2013 Statim Must
20380303 Chemical 10/1/2003 6/30/2013 Statim Must
20380303 Formulation 7/1/1996 FormMax 30 PSO
20380303 Formulation 7/1/2013 Statim Must
20380303 Formulation 7/1/1996 9/30/2003 Statim May
20380304 Formulation 7/1/1996 9/30/2003 Statim May
20380304 Formulation 7/1/2013 Statim Must
20380304 Formulation 7/1/1996 FormMax 30 PSO
20380304 Chemical 10/1/2003 6/30/2013 Statim Must
20380401 Chemical 10/1/2003 6/30/2013 Statim Must
20380401 Formulation 7/1/2013 Statim Must
20380401 Formulation 7/1/1996 9/30/2003 Statim May
20380402 Formulation 7/1/1996 9/30/2003 Statim May
20380402 Formulation 7/1/2013 Statim Must
20380402 Chemical 10/1/2003 6/30/2013 Statim Must
20380403 Chemical 10/1/2003 6/30/2013 Statim Must
20380403 Formulation 7/1/2013 Statim Must
20380403 Formulation 7/1/1996 9/30/2003 Statim May
20380403 Brand 11/1/2002 6/30/2005 SoleSupply
20380403 Brand 10/1/2005 6/30/2008 SoleSupply
20380403 Brand 1/1/2009 6/30/2011 SoleSupply
20380404 Formulation 7/1/1996 9/30/2003 Statim May
20380404 Formulation 7/1/2013 Statim Must
20380404 Chemical 10/1/2003 6/30/2013 Statim Must
20380501 Chemical 10/1/2003 6/30/2013 Statim Must
20380501 Formulation 7/1/1997 9/30/2003 Statim May
20380601 Formulation 7/1/1997 9/30/2003 Statim May
20380601 Chemical 10/1/2003 6/30/2013 Statim Must
20410101 Chemical 10/1/2003 Statim Must
20410101 ATC3 8/1/2003 6/30/2005 Application
20410101 Formulation 7/1/1996 9/30/2003 Statim May
20410101 ATC3 7/1/2005 7/31/2007 Application
20410125 ATC3 7/1/2005 7/31/2007 Application
20410125 Formulation 7/1/1996 9/30/2003 Statim May
20410125 ATC3 8/1/2003 6/30/2005 Application
20410125 Chemical 10/1/2003 Statim Must
20420101 Chemical 10/1/2003 Statim Must
20420101 Formulation 7/1/1996 2/28/2003 FormMax 30 PSO
20420125 Formulation 7/1/1996 2/28/2003 FormMax 30 PSO
20420125 Chemical 10/1/2003 Statim Must
20440101 Chemical 5/16/1994 1/31/1998 SpecEnd Retail
20440101 Formulation 7/1/1996 1/31/1998 Statim May
20450101 ATC2 7/1/2010 Application
20450101 ATC2 12/1/1996 6/30/2010 Application
20450101 Chemical 10/1/2003 Statim Must
20450201 Chemical 10/1/2003 Statim Must
20450201 ATC2 12/1/1996 6/30/2010 Application
20450201 ATC2 7/1/2010 Application
20460101 Formulation 7/1/1996 2/28/2001 FormMax 5 PSO
20460201 Formulation 7/1/1996 FormMax 5 PSO
20460201 Brand 12/1/2002 6/30/2005 SoleSupply
20460201 Brand 10/1/2005 6/30/2008 SoleSupply
20460201 Brand 1/1/2009 6/30/2011 SoleSupply
20460201 Brand 12/1/2011 6/30/2014 SoleSupply
20470101 Chemical 1/1/2006 2/28/2014 PCT only
20470101 Chemical 3/1/2014 PCT
20470101 Brand 1/1/2006 S29
20470101 Brand 4/1/2013 Wastage
20470101 Chemical 5/16/1994 3/31/2014 SpecEnd Hospital
20470101 Chemical 4/1/2014 SpecEnd Retail
20500201 Chemical 10/1/2003 Statim Must
20500201 ATC2 7/1/2010 Application
20500201 ATC2 12/1/1996 6/30/2010 Application
20500202 ATC2 12/1/1996 6/30/2010 Application
20500202 ATC2 7/1/2010 Application
20500202 Chemical 10/1/2003 Statim Must
20500301 Chemical 10/1/2003 Statim Must
20500301 ATC2 7/1/2010 Application
20500301 ATC2 12/1/1996 6/30/2010 Application
20500401 ATC2 12/1/1996 6/30/2010 Application
20500401 ATC2 7/1/2010 Application
20500401 Chemical 10/1/2003 Statim Must
20500411 Chemical 10/1/2003 Statim Must
20500411 ATC2 7/1/2010 Application
20500411 ATC2 12/1/1996 6/30/2010 Application
20500412 ATC2 12/1/1996 6/30/2010 Application
20500412 ATC2 7/1/2010 Application
20500412 Chemical 10/1/2003 Statim Must
20500501 Chemical 10/1/2003 Statim Must
20500501 ATC2 7/1/2010 Application
20500501 ATC2 12/1/1996 6/30/2010 Application
20522525 Formulation 8/1/2013 Special
20530101 Chemical 10/1/2003 Statim Must
20530101 ATC2 12/1/1996 6/30/2010 Application
20530101 ATC2 7/1/2010 Application
20540101 Chemical 10/1/2003 Statim Must
20560101 Chemical 10/1/2003 Statim Must
20560101 Formulation5/25/1995 AltSubSA Claim only
20560101 Formulation5/25/1995 FormReqd Rx
20560101 Formulation5/25/1995 DoseMMax 1
20560101 Formulation6/17/1995 ######## SpecEnd Retail
20560101 ATC2 7/1/2010 Application
20560101 ATC2 12/1/1996 6/30/2010 Application
20560201 ATC2 12/1/1996 6/30/2010 Application
20560201 ATC2 7/1/2010 Application
20560201 Chemical 10/1/2003 Statim Must
20560301 Chemical 10/1/2003 Statim Must
20560301 ATC2 7/1/2010 Application
20560301 ATC2 12/1/1996 6/30/2010 Application
20560325 ATC2 12/1/1996 6/30/2010 Application
20560325 ATC2 7/1/2010 Application
20560325 Chemical 10/1/2003 Statim Must
20560401 Chemical 10/1/2003 Statim Must
20560401 ATC2 7/1/2010 Application
20560401 ATC2 12/1/1996 6/30/2010 Application
20570101 Chemical 10/1/2003 Statim Must
20590101 Chemical 10/1/2003 Statim Must
20600101 Chemical 10/1/2003 2/29/2012 Statim Must
20600101 Formulation 4/1/2012 Statim Must
20600101 Formulation 7/1/1996 9/30/2003 Statim May
20600102 Formulation 7/1/1996 9/30/2003 Statim May
20600102 Formulation 4/1/2012 Statim Must
20600102 Chemical 10/1/2003 2/29/2012 Statim Must
20600103 Chemical 10/1/2003 2/29/2012 Statim Must
20600103 Formulation 4/1/2012 Statim Must
20600103 Formulation 7/1/1996 9/30/2003 Statim May
20600103 Brand 8/1/1998 6/30/2001 SoleSupply
20600103 Brand 10/1/2004 6/30/2007 SoleSupply
20600104 Formulation 7/1/1996 9/30/2003 Statim May
20600104 Formulation 4/1/2012 Statim Must
20600104 Brand 4/1/2012 S29
20600104 Brand 4/1/2013 Wastage
20600104 Chemical 10/1/2003 2/29/2012 Statim Must
20600201 Chemical 10/1/2003 2/29/2012 Statim Must
20600201 Formulation 4/1/2012 Statim Must
20600201 Formulation 7/1/1996 9/30/2003 Statim May
20600202 Formulation 7/1/1996 9/30/2003 Statim May
20600202 Formulation 4/1/2012 Statim Must
20600202 Chemical 10/1/2003 2/29/2012 Statim Must
20600203 Chemical 10/1/2003 2/29/2012 Statim Must
20600203 Formulation 4/1/2012 Statim Must
20600203 Brand 4/1/2012 S29
20600203 Brand 4/1/2013 Wastage
20600203 Formulation 7/1/1996 9/30/2003 Statim May
20600204 Formulation 7/1/1996 9/30/2003 Statim May
20600204 Brand 8/1/1998 6/30/2001 SoleSupply
20600204 Brand 10/1/2004 6/30/2007 SoleSupply
20600204 Formulation 4/1/2012 Statim Must
20600204 Chemical 10/1/2003 2/29/2012 Statim Must
20600401 Chemical 10/1/2003 2/29/2012 Statim Must
20600501 Chemical 10/1/2003 2/29/2012 Statim Must
20600501 Formulation 3/1/2012 Statim Must
20600501 Formulation10/4/1997 7/31/1998 Statim May
20600502 Formulation10/4/1997 7/31/1998 Statim May
20600502 Formulation 3/1/2012 Statim Must
20600502 Chemical 10/1/2003 2/29/2012 Statim Must
20600503 Chemical 10/1/2003 2/29/2012 Statim Must
20600503 Formulation 3/1/2012 Statim Must
20600503 Formulation10/4/1997 7/31/1998 Statim May
20600601 Formulation10/4/1997 9/30/2003 Statim May
20600601 Formulation 3/1/2012 Statim Must
20600601 Chemical 10/1/2003 2/29/2012 Statim Must
20600602 Chemical 10/1/2003 2/29/2012 Statim Must
20600602 Formulation 3/1/2012 Statim Must
20600602 Formulation10/4/1997 9/30/2003 Statim May
20600602 Brand 8/1/1998 6/30/2001 SoleSupply
20600602 Brand 10/1/2004 6/30/2007 SoleSupply
20600603 Formulation10/4/1997 9/30/2003 Statim May
20600603 Formulation 3/1/2012 Statim Must
20600603 Chemical 10/1/2003 2/29/2012 Statim Must
20602525 Chemical 10/1/2003 2/29/2012 Statim Must
20602525 Formulation 4/1/2013 Statim Must
20602525 Brand 4/1/2013 S29
20602525 Brand 8/1/2013 Wastage
20602525 Formulation 4/1/2013 Special
20620101 Chemical 5/1/2012 Special
20620125 Chemical 5/1/2012 Special
20620125 Brand 5/1/2012 S29
20620125 Brand 4/1/2013 Wastage
20630101 Chemical 10/1/2003 Statim Must
20630101 Brand 7/1/2013 S29
20630101 Brand 7/1/2013 Wastage
20660101 Chemical 5/16/1994 2/28/1998 NotCombined
20660202 Chemical 5/16/1994 2/28/1998 NotCombined
20690101 Chemical 5/16/1994 MaxCoPayment 0
20690101 Formulation12/1/2011 OraProduct
20690101 Chemical 10/1/2003 Statim Must
20690101 Chemical 5/16/1994 SpecEnd Retail
20690125 Chemical 5/16/1994 SpecEnd Retail
20690125 Chemical 10/1/2003 Statim Must
20690125 Brand 12/1/2003 4/30/2008 S29
20690125 Formulation12/1/2011 OraProduct
20690125 Chemical 5/16/1994 MaxCoPayment 0
20700101 Chemical 7/1/1996 Statim May
20700101 Brand 10/1/2011 6/30/2014 SoleSupply
20710101 Chemical 5/16/1994 DoseSWt 100
20710101 Chemical 5/16/1994 FormReqd Rx
20710101 Chemical 10/1/2003 Statim Must
20710201 Chemical 10/1/2003 Statim Must
20710201 Formulation 8/1/2010 ProvAllow Dietitian
20710201 Chemical 5/16/1994 FormReqd Rx
20710201 Chemical 5/16/1994 DoseSWt 100
20710201 Formulation 8/1/2005 MaxCoPayment 0
20710202 Formulation 8/1/2005 MaxCoPayment 0
20710202 Chemical 5/16/1994 DoseSWt 100
20710202 Chemical 5/16/1994 FormReqd Rx
20710202 Formulation 8/1/2010 ProvAllow Dietitian
20710202 Chemical 10/1/2003 Statim Must
20710225 Chemical 10/1/2003 Statim Must
20710225 Formulation 8/1/2010 ProvAllow Dietitian
20710225 Chemical 5/16/1994 FormReqd Rx
20710225 Chemical 5/16/1994 DoseSWt 100
20710225 Formulation 8/1/2005 MaxCoPayment 0
20710226 Formulation 8/1/2005 MaxCoPayment 0
20710226 Chemical 5/16/1994 FormReqd Rx
20710226 Chemical 5/16/1994 DoseSWt 100
20710226 Brand 10/1/2011 6/30/2014 SoleSupply
20710226 Formulation 8/1/2010 ProvAllow Dietitian
20710226 Chemical 10/1/2003 Statim Must
20710301 Chemical 10/1/2003 Statim Must
20710301 Formulation 8/1/2010 ProvAllow Dietitian
20710301 Chemical 5/16/1994 DoseSWt 100
20710301 Chemical 5/16/1994 FormReqd Rx
20710302 Chemical 5/16/1994 FormReqd Rx
20710302 Chemical 5/16/1994 DoseSWt 100
20710302 Brand 12/1/2006 6/30/2009 SoleSupply
20710302 Brand 10/1/2011 6/30/2014 SoleSupply
20710302 Formulation 8/1/2010 ProvAllow Dietitian
20710302 Chemical 10/1/2003 Statim Must
20710303 Chemical 10/1/2003 Statim Must
20710303 Formulation 8/1/2010 ProvAllow Dietitian
20710303 Chemical 5/16/1994 DoseSWt 100
20710303 Chemical 5/16/1994 FormReqd Rx
20710401 Chemical 5/16/1994 FormReqd Rx
20710401 Chemical 5/16/1994 DoseSWt 100
20710401 Chemical 10/1/2003 Statim Must
20710402 Chemical 10/1/2003 Statim Must
20710402 Chemical 5/16/1994 DoseSWt 100
20710402 Chemical 5/16/1994 FormReqd Rx
20710403 Chemical 5/16/1994 FormReqd Rx
20710403 Chemical 5/16/1994 DoseSWt 100
20710403 Chemical 10/1/2003 Statim Must
20710501 Chemical 10/1/2003 Statim Must
20710501 Formulation 6/8/1995 1/31/1998 DoseSMax 100
20710501 Formulation 6/8/1995 1/31/1998 FormReqd Rx
20710501 Chemical 5/16/1994 DoseSWt 100
20710501 Chemical 5/16/1994 FormReqd Rx
20730101 Chemical 5/16/1994 8/31/1998 SpecEnd Hospital
20770101 Formulation 7/1/1996 Statim May
20780101 Formulation 7/1/1996 Statim May
20780201 Formulation 7/1/1996 1/31/1998 Statim May
20790101 Chemical 10/1/2003 Statim Must
20790101 Formulation11/1/1997 Safety Compounded
20790102 Formulation11/1/1997 Safety Compounded
20790102 Chemical 10/1/2003 Statim Must
20790103 Chemical 10/1/2003 Statim Must
20790103 Formulation11/1/1997 Safety Compounded
20790104 Formulation11/1/1997 Safety Compounded
20790104 Chemical 10/1/2003 Statim Must
20790104 Brand 12/1/2000 6/30/2003 SoleSupply
20790104 Brand 10/1/2003 6/30/2006 SoleSupply
20790104 Brand 10/1/2006 6/30/2009 SoleSupply
20790202 Chemical 10/1/2003 Statim Must
20790202 Formulation11/1/1997 Safety Compounded
20790204 Formulation11/1/1997 Safety Compounded
20790204 Chemical 10/1/2003 Statim Must
20790205 Chemical 10/1/2003 Statim Must
20790205 Formulation11/1/1997 Safety Compounded
20790205 Brand 12/1/2000 6/30/2003 SoleSupply
20790205 Brand 10/1/2003 6/30/2006 SoleSupply
20790205 Brand 10/1/2006 6/30/2009 SoleSupply
20790205 Brand 1/1/2010 6/30/2012 SoleSupply
20790206 Formulation11/1/1997 Safety Compounded
20790206 Chemical 10/1/2003 Statim Must
20790207 Chemical 10/1/2003 Statim Must
20790207 Formulation11/1/1997 Safety Compounded
20800301 ATC3 3/1/1996 3/31/1996 SpecialWav
20800301 Chemical 10/1/2003 Statim Must
20800301 Chemical 5/16/1994 ######## TreatMax 30
20800301 Chemical 5/16/1994 FormReqd Rx
20800301 Formulation 3/1/2002 6/30/2008 SubRxF
20800301 Formulation5/16/1994 ######## DoseDMax 1
20800301 Formulation5/16/1994 2/28/2002 Special
20800325 Formulation5/16/1994 2/28/2002 Special
20800325 Formulation5/16/1994 ######## DoseDMax 1
20800325 Brand 4/1/2008 6/30/2010 SoleSupply
20800325 Brand 10/1/2011 6/30/2014 SoleSupply
20800325 Formulation 3/1/2002 6/30/2008 SubRxF
20800325 Chemical 5/16/1994 ######## TreatMax 30
20800325 Chemical 5/16/1994 FormReqd Rx
20800325 Chemical 10/1/2003 Statim Must
20800325 ATC3 3/1/1996 3/31/1996 SpecialWav
20800401 ATC3 3/1/1996 3/31/1996 SpecialWav
20800401 Chemical 10/1/2003 Statim Must
20800401 Chemical 5/16/1994 FormReqd Rx
20800401 Chemical 5/16/1994 ######## TreatMax 30
20800501 Chemical 5/16/1994 ######## TreatMax 30
20800501 Chemical 5/16/1994 FormReqd Rx
20800501 Chemical 10/1/2003 Statim Must
20800501 ATC3 3/1/1996 3/31/1996 SpecialWav
20800501 Formulation5/16/1994 ######## DoseDMax 1
20800502 Formulation5/16/1994 ######## DoseDMax 1
20800502 Brand 9/1/1998 8/31/2001 Preferred
20800502 ATC3 3/1/1996 3/31/1996 SpecialWav
20800502 Chemical 10/1/2003 Statim Must
20800502 Chemical 5/16/1994 FormReqd Rx
20800502 Chemical 5/16/1994 ######## TreatMax 30
20800503 Chemical 5/16/1994 ######## TreatMax 30
20800503 Chemical 5/16/1994 FormReqd Rx
20800503 Chemical 10/1/2003 Statim Must
20800503 ATC3 3/1/1996 3/31/1996 SpecialWav
20800503 Formulation5/16/1994 ######## DoseDMax 1
20800525 Formulation5/16/1994 ######## DoseDMax 1
20800525 Brand 1/1/2004 6/30/2005 SoleSupply
20800525 Brand 10/1/2005 6/30/2008 SoleSupply
20800525 Brand 10/1/2011 6/30/2014 SoleSupply
20800525 ATC3 3/1/1996 3/31/1996 SpecialWav
20800525 Chemical 10/1/2003 Statim Must
20800525 Chemical 5/16/1994 FormReqd Rx
20800525 Chemical 5/16/1994 ######## TreatMax 30
20800601 Chemical 5/16/1994 FormReqd Rx
20800601 Chemical 5/16/1994 ######## TreatMax 30
20800601 Chemical 10/1/2003 Statim Must
20800601 ATC3 3/1/1996 3/31/1996 SpecialWav
20800602 ATC3 3/1/1996 3/31/1996 SpecialWav
20800602 Chemical 10/1/2003 Statim Must
20800602 Chemical 5/16/1994 ######## TreatMax 30
20800602 Chemical 5/16/1994 FormReqd Rx
20800602 Brand 9/1/1998 8/31/2001 Preferred
20800603 Chemical 5/16/1994 FormReqd Rx
20800603 Chemical 5/16/1994 ######## TreatMax 30
20800603 Chemical 10/1/2003 Statim Must
20800603 ATC3 3/1/1996 3/31/1996 SpecialWav
20800625 ATC3 3/1/1996 3/31/1996 SpecialWav
20800625 Chemical 10/1/2003 Statim Must
20800625 Chemical 5/16/1994 ######## TreatMax 30
20800625 Chemical 5/16/1994 FormReqd Rx
20800625 Brand 1/1/2004 6/30/2005 SoleSupply
20800625 Brand 10/1/2005 6/30/2008 SoleSupply
20800625 Brand 10/1/2011 6/30/2014 SoleSupply
20802501 Formulation5/16/1994 ######## DoseDMax 1
20802501 Chemical 5/16/1994 ######## TreatMax 30
20802501 Chemical 5/16/1994 FormReqd Rx
20802501 Chemical 10/1/2003 Statim Must
20802501 ATC3 3/1/1996 3/31/1996 SpecialWav
20802502 ATC3 3/1/1996 3/31/1996 SpecialWav
20802502 Chemical 10/1/2003 Statim Must
20802502 Chemical 5/16/1994 FormReqd Rx
20802502 Chemical 5/16/1994 ######## TreatMax 30
20802502 Formulation5/16/1994 ######## DoseDMax 1
20802601 Chemical 5/16/1994 ######## TreatMax 30
20802601 Chemical 5/16/1994 FormReqd Rx
20802601 Chemical 10/1/2003 Statim Must
20802601 ATC3 3/1/1996 3/31/1996 SpecialWav
20802602 ATC3 3/1/1996 3/31/1996 SpecialWav
20802602 Chemical 10/1/2003 Statim Must
20802602 Chemical 5/16/1994 FormReqd Rx
20802602 Chemical 5/16/1994 ######## TreatMax 30
20870101 Formulation5/16/1994 DoseSMax 1
20870101 Formulation5/16/1994 FormReqd Rx
20880101 Chemical 5/16/1994 MaxCoPayment 0
20880101 Chemical 4/1/2013 SubRxF SpecEnd
20880101 Chemical 5/16/1994 3/31/2013 SpecEnd Retail
20880101 Chemical 10/1/2003 Statim Must
20880201 Chemical 10/1/2003 Statim Must
20880201 Chemical 5/16/1994 3/31/2013 SpecEnd Retail
20880201 Chemical 4/1/2013 SubRxF SpecEnd
21420102 Chemical 10/1/2003 Statim Must
21420102 Brand 11/1/2004 6/30/2007 SoleSupply
21420102 Brand 10/1/2007 6/30/2010 SoleSupply
21420102 Brand 12/1/2010 6/30/2013 SoleSupply
21440601 Formulation 1/1/1999 6/30/2008 Dispensary HP3
21440601 Formulation5/16/1994 6/30/2008 SpecEnd Hospital
21440725 Brand 11/1/2003 6/30/2005 SoleSupply
21440725 Brand 10/1/2005 4/30/2008 SoleSupply
21440726 Brand 2/1/2011 6/30/2013 SoleSupply
21441225 Brand 6/1/2007 6/30/2009 SoleSupply
21441225 Brand 1/1/2010 6/30/2012 SoleSupply
21490101 Formulation 8/1/2010 ProvAllow Dietitian
21490101 Chemical 6/1/2012 Statim Must
21490125 Chemical 6/1/2012 Statim Must
21490125 Formulation 8/1/2010 ProvAllow Dietitian
21490201 Chemical 6/1/2012 Statim Must
21490301 Chemical 6/1/2012 Statim Must
21580101 Chemical 10/1/2003 Statim Must
21580101 Formulation5/16/1994 FormBan BSO
21580101 Chemical 8/1/2010 ######## FormMax 20 Rx
21580101 Chemical 11/1/2011 FormMax 50 Rx
21580102 Chemical 11/1/2011 FormMax 50 Rx
21580102 Chemical 8/1/2010 ######## FormMax 20 Rx
21580102 Formulation5/16/1994 FormBan BSO
21580102 Chemical 10/1/2003 Statim Must
21582525 Chemical 10/1/2003 Statim Must
21582525 Formulation 8/1/2009 FormBan BSO
21582525 Chemical 8/1/2010 ######## FormMax 20 Rx
21582525 Chemical 11/1/2011 FormMax 50 Rx
21582526 Chemical 11/1/2011 FormMax 50 Rx
21582526 Chemical 8/1/2010 ######## FormMax 20 Rx
21582526 Formulation 8/1/2009 FormBan BSO
21582526 Chemical 10/1/2003 Statim Must
21600101 Chemical 5/16/1994 ######## SpecEnd Retail
21640101 Chemical 5/16/1994 ######## SpecEnd Retail
21640101 Chemical 10/1/2003 Statim Must
21640201 Chemical 10/1/2003 Statim Must
21640201 Chemical 5/16/1994 ######## SpecEnd Retail
21640301 Chemical 5/16/1994 ######## SpecEnd Retail
21640301 Chemical 10/1/2003 Statim Must
21640401 Chemical 10/1/2003 Statim Must
21640401 Chemical 5/16/1994 ######## SpecEnd Retail
21660101 Chemical 10/1/2003 Statim Must
21660101 ATC3 8/1/2003 6/30/2005 Application
21660101 ATC3 7/1/2005 7/31/2007 Application
21660101 Formulation 7/1/1996 9/30/2003 Statim May
21660201 Formulation 7/1/1996 9/30/2003 Statim May
21660201 ATC3 7/1/2005 7/31/2007 Application
21660201 ATC3 8/1/2003 6/30/2005 Application
21660201 Chemical 10/1/2003 Statim Must
21660202 Chemical 10/1/2003 Statim Must
21660202 ATC3 8/1/2003 6/30/2005 Application
21660202 ATC3 7/1/2005 7/31/2007 Application
21660202 Formulation 7/1/1996 9/30/2003 Statim May
21660301 Formulation 7/1/1996 9/30/2003 Statim May
21660301 ATC3 7/1/2005 7/31/2007 Application
21660301 ATC3 8/1/2003 6/30/2005 Application
21660301 Chemical 10/1/2003 Statim Must
21660302 Chemical 10/1/2003 Statim Must
21660302 ATC3 8/1/2003 6/30/2005 Application
21660302 ATC3 7/1/2005 7/31/2007 Application
21660302 Formulation 7/1/1996 9/30/2003 Statim May
21660401 Formulation 7/1/1996 9/30/2003 Statim May
21660401 ATC3 7/1/2005 7/31/2007 Application
21660401 Formulation 7/1/1996 Safety Uncompounded
21660401 ATC3 8/1/2003 6/30/2005 Application
21660401 Chemical 10/1/2003 Statim Must
21660402 Chemical 10/1/2003 Statim Must
21660402 ATC3 8/1/2003 6/30/2005 Application
21660402 Formulation 7/1/1996 Safety Uncompounded
21660402 ATC3 7/1/2005 7/31/2007 Application
21660402 Formulation 7/1/1996 9/30/2003 Statim May
21660501 ATC3 7/1/2005 7/31/2007 Application
21660501 ATC3 8/1/2003 6/30/2005 Application
21660501 Chemical 10/1/2003 Statim Must
21690101 Chemical 10/1/2003 Statim Must
21690101 Formulation12/1/2011 OraProduct
21690101 Formulation 7/1/1996 9/30/2003 Statim May
21690102 Formulation 7/1/1996 9/30/2003 Statim May
21690102 Formulation12/1/2011 OraProduct
21690102 Brand 1/1/2004 6/30/2006 SoleSupply
21690102 Brand 10/1/2009 6/30/2012 SoleSupply
21690102 Chemical 10/1/2003 Statim Must
21690125 Chemical 10/1/2003 Statim Must
21690125 Formulation12/1/2011 OraProduct
21690125 Formulation 7/1/1996 9/30/2003 Statim May
21690201 Formulation 7/1/1996 9/30/2003 Statim May
21690201 Chemical 10/1/2003 Statim Must
21690202 Chemical 10/1/2003 Statim Must
21690202 Formulation 7/1/1996 9/30/2003 Statim May
21690202 Brand 1/1/2004 6/30/2006 SoleSupply
21690202 Brand 10/1/2009 6/30/2012 SoleSupply
21690225 Formulation 7/1/1996 9/30/2003 Statim May
21690225 Chemical 10/1/2003 Statim Must
21690301 Chemical 10/1/2003 Statim Must
21710101 Formulation5/16/1994 ######## SpecEnd Retail
21760101 Chemical 10/1/2003 ######## Statim Must
21760101 Formulation 1/1/2005 Statim Must
21760101 Brand 7/1/2001 6/30/2003 SoleSupply
21760101 Brand 11/1/2003 6/30/2006 SoleSupply
21760101 Brand 10/1/2010 6/30/2013 SoleSupply
21760101 Brand 10/1/2013 1/31/2014 SoleSupply
21760102 Formulation 1/1/2005 Statim Must
21760102 Chemical 10/1/2003 ######## Statim Must
21760125 Chemical 10/1/2003 ######## Statim Must
21760125 Formulation 1/1/2005 Statim Must
21760125 Brand 2/1/2014 6/30/2016 SoleSupply
21760201 Brand 7/1/2001 6/30/2003 SoleSupply
21760201 Brand 11/1/2003 6/30/2006 SoleSupply
21760201 Brand 10/1/2010 6/30/2013 SoleSupply
21760201 Brand 10/1/2013 6/30/2016 SoleSupply
21760201 Formulation 1/1/2005 Statim Must
21760201 Chemical 10/1/2003 ######## Statim Must
21760203 Chemical 10/1/2003 ######## Statim Must
21760203 Formulation 1/1/2005 Statim Must
21760225 Formulation 1/1/2005 Statim Must
21760225 Chemical 10/1/2003 ######## Statim Must
21760225 Brand 10/1/2013 6/30/2016 SoleSupply
21760301 Formulation 7/1/1996 Safety Uncompounded
21760301 Brand 12/1/2002 ######## SoleSupply
21760301 Chemical 10/1/2003 ######## Statim Must
21760301 Formulation 3/1/1996 3/31/1996 SpecOnly Retail
21760301 Formulation 4/1/1996 ######## SpecEnd Retail
21910101 Formulation5/16/1994 6/30/1999 TreatMax 30
21930101 ATC3 3/1/1996 8/31/2010 Application
21930101 Chemical 10/1/2003 Statim Must
21930101 ATC3 9/1/2010 Application
21930101 Chemical 3/1/1996 SpecialWav Claim only
21930102 Chemical 3/1/1996 SpecialWav Claim only
21930102 ATC3 9/1/2010 Application
21930102 Chemical 10/1/2003 Statim Must
21930102 ATC3 3/1/1996 8/31/2010 Application
21930103 ATC3 3/1/1996 8/31/2010 Application
21930103 Chemical 10/1/2003 Statim Must
21930103 ATC3 9/1/2010 Application
21930103 Chemical 3/1/1996 SpecialWav Claim only
21930125 Chemical 3/1/1996 SpecialWav Claim only
21930125 ATC3 9/1/2010 Application
21930125 Chemical 10/1/2003 Statim Must
21930125 ATC3 3/1/1996 8/31/2010 Application
21930201 ATC3 3/1/1996 8/31/2010 Application
21930201 Chemical 10/1/2003 Statim Must
21930201 ATC3 9/1/2010 Application
21930201 Chemical 3/1/1996 SpecialWav Claim only
21930202 Chemical 3/1/1996 SpecialWav Claim only
21930202 ATC3 9/1/2010 Application
21930202 Chemical 10/1/2003 Statim Must
21930202 ATC3 3/1/1996 8/31/2010 Application
21930203 ATC3 3/1/1996 8/31/2010 Application
21930203 Chemical 10/1/2003 Statim Must
21930203 ATC3 9/1/2010 Application
21930203 Chemical 3/1/1996 SpecialWav Claim only
21930225 Chemical 3/1/1996 SpecialWav Claim only
21930225 ATC3 9/1/2010 Application
21930225 Chemical 10/1/2003 Statim Must
21930225 ATC3 3/1/1996 8/31/2010 Application
21940101 Chemical 4/1/2004 Statim Must
21940101 Brand 12/1/2002 6/30/2005 SoleSupply
21940102 Chemical 4/1/2004 Statim Must
21940201 Chemical 4/1/2004 Statim Must
22050101 Chemical 10/1/2003 Statim Must
22050101 Formulation12/1/2011 OraProduct
22050101 Brand 11/1/1999 6/30/2002 SoleSupply
22050101 Brand 11/1/2002 6/30/2005 SoleSupply
22050101 Brand 10/1/2006 6/30/2009 SoleSupply
22050101 Brand 11/1/2013 6/30/2016 SoleSupply
22050102 Formulation12/1/2011 OraProduct
22050102 Chemical 10/1/2003 Statim Must
22050201 Chemical 10/1/2003 Statim Must
22050201 Brand 11/1/1999 6/30/2002 SoleSupply
22050201 Brand 11/1/2002 6/30/2005 SoleSupply
22050201 Brand 10/1/2006 6/30/2009 SoleSupply
22050201 Brand 11/1/2013 6/30/2016 SoleSupply
22050202 Chemical 10/1/2003 Statim Must
22050301 Chemical 10/1/2003 Statim Must
22050401 Chemical 10/1/2003 Statim Must
22050401 Formulation6/13/1995 SpecEnd Retail
22120101 ATC3 8/1/2003 6/30/2005 Application
22120101 ATC3 7/1/2005 7/31/2007 Application
22120101 Formulation 7/1/1996 ######## Statim May
22120201 Formulation 7/1/1996 ######## Statim May
22120201 ATC3 7/1/2005 7/31/2007 Application
22120201 ATC3 8/1/2003 6/30/2005 Application
22130101 Chemical 5/16/1994 2/29/2008 SpecEnd Retail
22130101 Chemical 3/1/2008 SubRxF
22130201 Chemical 3/1/2008 SubRxF
22130201 Chemical 5/16/1994 2/29/2008 SpecEnd Retail
22130202 Chemical 5/16/1994 2/29/2008 SpecEnd Retail
22130202 Chemical 3/1/2008 SubRxF
22130203 Chemical 3/1/2008 SubRxF
22130203 Chemical 5/16/1994 2/29/2008 SpecEnd Retail
22130204 Chemical 5/16/1994 2/29/2008 SpecEnd Retail
22130204 Chemical 3/1/2008 SubRxF
22130205 Chemical 3/1/2008 SubRxF
22130205 Chemical 5/16/1994 2/29/2008 SpecEnd Retail
22130206 Chemical 5/16/1994 2/29/2008 SpecEnd Retail
22130206 Chemical 3/1/2008 SubRxF
22130225 Chemical 3/1/2008 SubRxF
22130225 Chemical 5/16/1994 2/29/2008 SpecEnd Retail
22130401 Chemical 5/16/1994 2/29/2008 SpecEnd Retail
22130401 Chemical 3/1/2008 SubRxF
22130402 Chemical 3/1/2008 SubRxF
22130402 Chemical 5/16/1994 2/29/2008 SpecEnd Retail
22130403 Chemical 5/16/1994 2/29/2008 SpecEnd Retail
22130403 Chemical 3/1/2008 SubRxF
22130404 Chemical 3/1/2008 SubRxF
22130404 Chemical 5/16/1994 2/29/2008 SpecEnd Retail
22130405 Chemical 5/16/1994 2/29/2008 SpecEnd Retail
22130405 Chemical 3/1/2008 SubRxF
22130406 Chemical 3/1/2008 SubRxF
22130406 Chemical 5/16/1994 2/29/2008 SpecEnd Retail
22130425 Chemical 5/16/1994 2/29/2008 SpecEnd Retail
22130425 Chemical 3/1/2008 SubRxF
22132526 Chemical 3/1/2008 SubRxF
22132526 Chemical 5/16/1994 2/29/2008 SpecEnd Retail
22180101 Chemical 10/1/2003 Statim Must
22180102 Chemical 10/1/2003 Statim Must
22180102 Brand 12/1/2000 6/30/2003 SoleSupply
22180102 Brand 1/1/2004 6/30/2006 SoleSupply
22180103 Chemical 10/1/2003 Statim Must
22180105 Chemical 10/1/2003 Statim Must
22180106 Chemical 10/1/2003 Statim Must
22180202 Chemical 10/1/2003 Statim Must
22180203 Chemical 10/1/2003 Statim Must
22180203 Brand 12/1/2000 6/30/2003 SoleSupply
22180203 Brand 1/1/2004 6/30/2006 SoleSupply
22180203 Brand 9/1/2011 6/30/2014 SoleSupply
22180204 Chemical 10/1/2003 Statim Must
22180205 Chemical 10/1/2003 Statim Must
22180206 Chemical 10/1/2003 Statim Must
22180225 Chemical 10/1/2003 Statim Must
22200201 Chemical 10/1/2003 Statim Must
22200201 Chemical 5/16/1994 2/28/2007 ProvReqd M
22200201 Chemical 3/1/2007 FormReqd Rx
22200201 Brand 8/1/1999 6/30/2002 SoleSupply
22200201 Brand 1/1/2003 6/30/2005 SoleSupply
22200201 Brand 1/1/2006 6/30/2008 SoleSupply
22200201 Brand 1/1/2009 6/30/2011 SoleSupply
22200201 Brand 12/1/2011 6/30/2014 SoleSupply
22200202 Chemical 3/1/2007 FormReqd Rx
22200202 Chemical 5/16/1994 2/28/2007 ProvReqd M
22200202 Chemical 10/1/2003 Statim Must
22200204 Chemical 10/1/2003 Statim Must
22200204 Chemical 5/16/1994 2/28/2007 ProvReqd M
22200204 Chemical 3/1/2007 FormReqd Rx
22240101 Chemical 5/16/1994 8/31/2010 TreatMax 30
22240101 Chemical 8/1/2012 SafetyListMedicine
22240101 Formulation11/1/1997 Safety Compounded
22240102 Formulation11/1/1997 Safety Compounded
22240102 Chemical 8/1/2012 SafetyListMedicine
22240102 Chemical 5/16/1994 8/31/2010 TreatMax 30
22240102 Brand 11/1/1999 6/30/2002 SoleSupply
22240102 Brand 1/1/2003 6/30/2005 SoleSupply
22240103 Chemical 5/16/1994 8/31/2010 TreatMax 30
22240103 Chemical 8/1/2012 SafetyListMedicine
22240103 Formulation11/1/1997 Safety Compounded
22240201 Formulation11/1/1997 Safety Compounded
22240201 Chemical 8/1/2012 SafetyListMedicine
22240201 Chemical 5/16/1994 8/31/2010 TreatMax 30
22240201 Brand 2/1/2003 6/30/2005 SoleSupply
22240202 Chemical 5/16/1994 8/31/2010 TreatMax 30
22240202 Chemical 8/1/2012 SafetyListMedicine
22240202 Formulation11/1/1997 Safety Compounded
22240203 Formulation11/1/1997 Safety Compounded
22240203 Chemical 8/1/2012 SafetyListMedicine
22240203 Chemical 5/16/1994 8/31/2010 TreatMax 30
22240203 Brand 11/1/1999 6/30/2002 SoleSupply
22242525 Brand 5/1/2006 6/30/2008 SoleSupply
22242525 Brand 1/1/2009 6/30/2011 SoleSupply
22242525 Brand 12/1/2011 6/30/2014 SoleSupply
22242525 Chemical 5/16/1994 8/31/2010 TreatMax 30
22242525 Chemical 8/1/2012 SafetyListMedicine
22242525 Formulation 5/1/2005 Safety Compounded
22242525 Brand 5/1/2006 ######## S29
22370126 Brand 8/1/2012 6/30/2013 SoleSupply
22370126 Brand 10/1/2013 6/30/2016 SoleSupply
22380101 Chemical 10/1/2003 Statim Must
22380102 Chemical 10/1/2003 Statim Must
22390101 Chemical 10/1/2003 Statim Must
22390101 Brand 10/1/2003 6/30/2006 SoleSupply
22390101 Brand 10/1/2008 6/30/2011 SoleSupply
22390101 Brand 10/1/2011 6/30/2014 SoleSupply
22390301 Brand 10/1/2003 6/30/2006 SoleSupply
22390301 Brand 10/1/2008 6/30/2011 SoleSupply
22390301 Brand 10/1/2011 6/30/2014 SoleSupply
22390301 Chemical 10/1/2003 Statim Must
22410101 Formulation 7/1/1996 2/28/2001 FormMax 30 PSO
22500101 Chemical 10/1/2003 Statim Must
22500101 Formulation5/16/1994 9/30/1999 DoseSMax 5
22500101 Chemical 10/1/1999 FormReqd Rx
22500101 Formulation5/16/1994 9/30/1999 FormReqd Rx
22500201 Chemical 10/1/1999 FormReqd Rx
22500201 Formulation5/16/1994 9/30/1999 DoseSMax 2
22500201 Formulation5/16/1994 9/30/1999 FormReqd Rx
22500201 Chemical 10/1/2003 Statim Must
22500301 Chemical 10/1/2003 Statim Must
22500301 Formulation5/16/1994 9/30/1999 DoseSMax 1
22500301 Formulation 8/1/2010 ProvAllow Dietitian
22500301 Chemical 10/1/1999 FormReqd Rx
22500301 Formulation5/16/1994 9/30/1999 FormReqd Rx
22500302 Formulation5/16/1994 9/30/1999 FormReqd Rx
22500302 Brand 1/1/2007 6/30/2009 SoleSupply
22500302 Chemical 10/1/1999 FormReqd Rx
22500302 Formulation 8/1/2010 ProvAllow Dietitian
22500302 Formulation5/16/1994 9/30/1999 DoseSMax 1
22500302 Chemical 10/1/2003 Statim Must
22500401 Chemical 10/1/2003 Statim Must
22500401 Chemical 10/1/1999 FormReqd Rx
22500401 Formulation 6/8/1995 1/31/1998 FormReqd Rx
22520101 Chemical 5/16/1994 7/31/2010 SpecEnd Hospital
22520101 Chemical 8/1/2010 SpecEnd Retail
22520101 Chemical 1/1/1999 7/31/2010 Dispensary HP3
22520101 Chemical 7/1/2005 PCT
22550102 Brand 10/1/2003 6/30/2006 SoleSupply
22550202 Brand 12/1/2003 6/30/2006 SoleSupply
22550302 Brand 12/1/2003 6/30/2006 SoleSupply
22550401 Brand 12/1/2003 6/30/2006 SoleSupply
22550601 Formulation 7/1/1996 Safety Uncompounded
22550701 Formulation 7/1/1996 Safety Uncompounded
22570101 Chemical 7/1/2005 7/31/2009 PCT
22570101 Chemical 8/1/2009 PCT only
22570101 Brand 3/1/2012 S29
22570101 Chemical 8/1/2009 SpecEnd Hospital
22570101 Chemical 5/16/1994 7/31/2009 SpecEnd Retail
22570125 Chemical 5/16/1994 7/31/2009 SpecEnd Retail
22570125 Chemical 8/1/2009 SpecEnd Hospital
22570125 Brand 8/1/2009 S29
22570125 Chemical 7/1/2005 7/31/2009 PCT
22570125 Chemical 8/1/2009 PCT only
22570126 Chemical 8/1/2009 PCT only
22570126 Chemical 7/1/2005 7/31/2009 PCT
22570126 Brand 9/1/2013 S29
22570126 Chemical 8/1/2009 SpecEnd Hospital
22570126 Chemical 5/16/1994 7/31/2009 SpecEnd Retail
22570201 Chemical 5/16/1994 7/31/2009 SpecEnd Retail
22570201 Chemical 8/1/2009 SpecEnd Hospital
22570201 Chemical 7/1/2005 7/31/2009 PCT
22570201 Chemical 8/1/2009 PCT only
22620101 Chemical 10/1/2003 Statim Must
22620201 Chemical 10/1/2003 Statim Must
22630101 Chemical 10/1/2003 Statim Must
22630101 Formulation11/1/1997 Safety Compounded
22630125 Formulation11/1/1997 Safety Compounded
22630125 Chemical 10/1/2003 Statim Must
22630126 Chemical 10/1/2003 Statim Must
22630126 Formulation11/1/1997 Safety Compounded
22630201 Formulation11/1/1997 Safety Compounded
22630201 Chemical 10/1/2003 Statim Must
22630225 Chemical 10/1/2003 Statim Must
22630225 Formulation11/1/1997 Safety Compounded
22630226 Formulation11/1/1997 Safety Compounded
22630226 Chemical 10/1/2003 Statim Must
22632525 Chemical 10/1/2003 Statim Must
22632525 Formulation 8/1/2009 Safety Compounded
22660101 Chemical 10/1/2003 Statim Must
22660101 Formulation 7/1/1996 9/30/2003 Statim May
22660102 Formulation 7/1/1996 9/30/2003 Statim May
22660102 Brand 8/1/1998 6/30/2001 SoleSupply
22660102 Chemical 10/1/2003 Statim Must
22660104 Chemical 10/1/2003 Statim Must
22660104 Brand 1/1/2004 6/30/2006 SoleSupply
22660104 Brand 10/1/2006 6/30/2009 SoleSupply
22660104 Brand 10/1/2009 6/30/2012 SoleSupply
22660104 Formulation 7/1/1996 9/30/2003 Statim May
22660105 Formulation 7/1/1996 9/30/2003 Statim May
22660105 Chemical 10/1/2003 Statim Must
22660202 Chemical 10/1/2003 Statim Must
22660202 Chemical 6/3/1995 9/30/2007 SpecEnd Retail
22660202 Formulation11/1/1997 9/30/2003 Statim May
22660204 Formulation11/1/1997 9/30/2003 Statim May
22660204 Brand 8/1/1998 7/31/2000 Preferred
22660204 Chemical 6/3/1995 9/30/2007 SpecEnd Retail
22660204 Chemical 10/1/2003 Statim Must
22660225 Chemical 10/1/2003 Statim Must
22660225 Chemical 6/3/1995 9/30/2007 SpecEnd Retail
22660225 Formulation11/1/1997 9/30/2003 Statim May
22660225 Brand 12/1/2001 6/30/2004 SoleSupply
22660225 Brand 10/1/2004 6/30/2007 SoleSupply
22660225 Brand 9/1/2008 6/30/2011 SoleSupply
22660226 Brand 4/1/2012 6/30/2014 SoleSupply
22660226 Formulation11/1/1997 9/30/2003 Statim May
22660226 Chemical 6/3/1995 9/30/2007 SpecEnd Retail
22660226 Chemical 10/1/2003 Statim Must
22660402 Chemical 10/1/2003 Statim Must
22660402 Chemical 6/3/1995 9/30/2007 SpecEnd Retail
22660402 Formulation11/1/1997 9/30/2003 Statim May
22660404 Formulation11/1/1997 9/30/2003 Statim May
22660404 Brand 8/1/1998 7/31/2000 Preferred
22660404 Chemical 6/3/1995 9/30/2007 SpecEnd Retail
22660404 Chemical 10/1/2003 Statim Must
22660425 Chemical 10/1/2003 Statim Must
22660425 Chemical 6/3/1995 9/30/2007 SpecEnd Retail
22660425 Formulation11/1/1997 9/30/2003 Statim May
22660425 Brand 12/1/2001 6/30/2004 SoleSupply
22660425 Brand 10/1/2004 6/30/2007 SoleSupply
22660425 Brand 9/1/2008 6/30/2011 SoleSupply
22660426 Brand 4/1/2012 6/30/2014 SoleSupply
22660426 Formulation11/1/1997 9/30/2003 Statim May
22660426 Chemical 6/3/1995 9/30/2007 SpecEnd Retail
22660426 Chemical 10/1/2003 Statim Must
22660501 Chemical 10/1/2003 Statim Must
22660501 Chemical 6/3/1995 9/30/2007 SpecEnd Retail
22660501 Formulation12/1/1997 9/30/2003 Statim May
22660501 Brand 4/1/2014 6/30/2016 SoleSupply
22660601 Brand 4/1/2014 6/30/2016 SoleSupply
22660601 Formulation12/1/1997 9/30/2003 Statim May
22660601 Chemical 6/3/1995 9/30/2007 SpecEnd Retail
22660601 Chemical 10/1/2003 Statim Must
22680101 Chemical 10/1/2003 Statim Must
22680101 Chemical 6/24/1995 SpecEnd Retail
22680101 Formulation11/1/1997 9/30/2003 Statim May
22680201 Formulation11/1/1997 9/30/2003 Statim May
22680201 Chemical 6/24/1995 SpecEnd Retail
22680201 Chemical 10/1/2003 Statim Must
22700301 Formulation 6/1/2002 FormReqd Rx
22700301 Formulation 6/1/2002 NotCombined
22700401 Formulation 6/1/2002 NotCombined
22700401 Formulation 6/1/2002 FormReqd Rx
22740101 Formulation5/16/1994 SubRxF
22740202 Formulation5/16/1994 SubRxF
22740202 Formulation 1/1/1999 7/31/2010 Dispensary HP3
22740203 Formulation 1/1/1999 7/31/2010 Dispensary HP3
22740203 Formulation5/16/1994 SubRxF
22740203 Brand 10/1/2011 6/30/2014 SoleSupply
22740401 Brand 10/1/2011 6/30/2014 SoleSupply
22740401 Formulation5/16/1994 9/30/2007 SpecEnd Retail
22740501 Formulation5/16/1994 9/30/2007 SpecEnd Retail
22740501 Brand 10/1/2011 6/30/2014 SoleSupply
22750101 Formulation 7/1/1996 Statim May
22750101 Chemical 5/16/1994 SpecEnd Retail
22770101 Chemical 10/1/2003 Statim Must
22770101 Brand 10/1/2003 6/30/2006 SoleSupply
22850101 Chemical 6/1/2012 Statim Must
22860101 Chemical 1/1/2006 6/30/2010 SpecEnd Hospital
22860101 Chemical 1/1/2006 6/30/2010 PCT only
22860201 Chemical 1/1/2006 6/30/2010 PCT only
22860201 Chemical 1/1/2006 6/30/2010 SpecEnd Hospital
22860301 Chemical 1/1/2006 6/30/2010 SpecEnd Hospital
22860301 Chemical 1/1/2006 6/30/2010 PCT only
22860401 Chemical 1/1/2006 6/30/2010 PCT only
22860401 Chemical 1/1/2006 6/30/2010 SpecEnd Hospital
22862525 Chemical 1/1/2006 6/30/2010 SpecEnd Hospital
22862525 Formulation 1/1/2011 SpecEnd Retail
22862525 Chemical 1/1/2006 6/30/2010 PCT only
22862525 Formulation 1/1/2011 PCT
22862625 Chemical 1/1/2006 6/30/2010 PCT only
22862625 Brand 10/1/2013 6/30/2016 SoleSupply
22862625 Chemical 1/1/2006 6/30/2010 SpecEnd Hospital
22862625 Formulation 7/1/2010 FormMax 50 Rx
22930101 Chemical 10/1/2003 Statim Must
22930102 Chemical 10/1/2003 Statim Must
22930102 Brand 1/1/2001 6/30/2003 SoleSupply
22930102 Brand 11/1/2003 6/30/2006 SoleSupply
22930103 Chemical 10/1/2003 Statim Must
22950101 Chemical 8/1/2012 SafetyListMedicine
22950101 Formulation11/1/1997 Safety Compounded
22950101 Chemical 5/16/1994 8/31/2010 TreatMax 30
22950101 Brand 11/1/1999 6/30/2002 SoleSupply
22950101 Brand 2/1/2003 6/30/2005 SoleSupply
22950102 Chemical 5/16/1994 8/31/2010 TreatMax 30
22950102 Formulation11/1/1997 Safety Compounded
22950102 Chemical 8/1/2012 SafetyListMedicine
22950103 Chemical 8/1/2012 SafetyListMedicine
22950103 Formulation11/1/1997 Safety Compounded
22950103 Chemical 5/16/1994 8/31/2010 TreatMax 30
22950104 Chemical 5/16/1994 8/31/2010 TreatMax 30
22950104 Formulation11/1/1997 Safety Compounded
22950104 Chemical 8/1/2012 SafetyListMedicine
22950104 Brand 9/1/2006 6/30/2008 SoleSupply
22950201 Brand 11/1/1999 6/30/2002 SoleSupply
22950201 Chemical 8/1/2012 SafetyListMedicine
22950201 Formulation11/1/1997 Safety Compounded
22950201 Chemical 5/16/1994 8/31/2010 TreatMax 30
22950202 Chemical 5/16/1994 8/31/2010 TreatMax 30
22950202 Formulation11/1/1997 Safety Compounded
22950202 Chemical 8/1/2012 SafetyListMedicine
22950203 Chemical 8/1/2012 SafetyListMedicine
22950203 Formulation11/1/1997 Safety Compounded
22950203 Chemical 5/16/1994 8/31/2010 TreatMax 30
22950204 Chemical 5/16/1994 8/31/2010 TreatMax 30
22950204 Formulation11/1/1997 Safety Compounded
22950204 Chemical 8/1/2012 SafetyListMedicine
22950204 Brand 7/1/2003 6/30/2005 SoleSupply
22950204 Brand 1/1/2006 6/30/2008 SoleSupply
22980101 Chemical 8/1/2012 SafetyListMedicine
22980101 Brand 1/1/2007 2/28/2010 S29
22980125 Brand 1/1/2006 S29
22980125 Brand 4/1/2013 Wastage
22980125 Chemical 8/1/2012 SafetyListMedicine
22980201 Chemical 8/1/2012 SafetyListMedicine
22980201 Brand 3/1/2007 2/28/2010 S29
22980301 Brand 3/1/2007 2/28/2010 S29
22980301 Chemical 8/1/2012 SafetyListMedicine
22980325 Chemical 8/1/2012 SafetyListMedicine
22980325 Brand 1/1/2006 S29
22980325 Brand 4/1/2013 Wastage
22980401 Chemical 8/1/2012 SafetyListMedicine
22980501 Chemical 8/1/2012 SafetyListMedicine
22980501 Formulation 7/1/1996 Safety Uncompounded
23000101 Chemical 10/1/2003 Statim Must
23000201 Chemical 10/1/2003 Statim Must
23000201 Formulation 7/1/1996 FormMax 30 PSO
23000202 Formulation 7/1/1996 FormMax 30 PSO
23000202 Chemical 10/1/2003 Statim Must
23000202 Brand 8/1/1999 6/30/2002 SoleSupply
23000202 Brand 12/1/2002 6/30/2005 SoleSupply
23000202 Brand 1/1/2006 6/30/2008 SoleSupply
23000202 Brand 1/1/2009 6/30/2011 SoleSupply
23010302 Brand 5/1/2003 6/30/2005 SoleSupply
23010302 Brand 10/1/2005 6/30/2008 SoleSupply
23010401 Brand 5/1/2003 6/30/2005 SoleSupply
23010401 Brand 10/1/2005 6/30/2008 SoleSupply
23020101 Chemical 5/19/1994 6/30/1998 SpecEnd Retail
23040101 Formulation5/16/1994 6/30/1999 TreatMax 30
23050101 Chemical 10/1/2003 Statim Must
23050101 Brand 10/1/2011 6/30/2014 SoleSupply
23050201 Brand 10/1/2011 6/30/2014 SoleSupply
23050201 Chemical 10/1/2003 Statim Must
23100101 Chemical 10/1/2003 Statim Must
23100101 Brand 10/1/2011 6/30/2014 SoleSupply
23120101 Chemical 10/1/2003 Statim Must
23120102 Chemical 10/1/2003 Statim Must
23120103 Chemical 10/1/2003 Statim Must
23120103 Brand 12/1/2002 6/30/2005 SoleSupply
23120103 Brand 12/1/2005 6/30/2008 SoleSupply
23120104 Chemical 10/1/2003 Statim Must
23120125 Chemical 10/1/2003 Statim Must
23120125 Brand 5/1/2014 6/30/2016 SoleSupply
23120202 Chemical 10/1/2003 Statim Must
23140101 Chemical 1/1/1999 7/31/2010 Dispensary HP3
23140101 Chemical 11/1/1999 6/30/2013 SubRxF
23140101 Chemical 7/1/2013 SubRxF
23140101 Chemical 5/16/1994 ######## FormReqd Rx
23140101 Brand 12/1/2001 6/30/2004 SoleSupply
23140201 Brand 12/1/2001 6/30/2004 SoleSupply
23140201 Chemical 5/16/1994 ######## FormReqd Rx
23140201 Chemical 7/1/2013 SubRxF
23140201 Chemical 11/1/1999 6/30/2013 SubRxF
23140201 Chemical 1/1/1999 7/31/2010 Dispensary HP3
23140301 Chemical 1/1/1999 7/31/2010 Dispensary HP3
23140301 Chemical 11/1/1999 6/30/2013 SubRxF
23140301 Chemical 7/1/2013 SubRxF
23140301 Chemical 5/16/1994 ######## FormReqd Rx
23140301 Brand 12/1/2001 6/30/2004 SoleSupply
23140302 Chemical 5/16/1994 ######## FormReqd Rx
23140302 Chemical 7/1/2013 SubRxF
23140302 Chemical 11/1/1999 6/30/2013 SubRxF
23140302 Chemical 1/1/1999 7/31/2010 Dispensary HP3
23140325 Chemical 1/1/1999 7/31/2010 Dispensary HP3
23140325 Chemical 11/1/1999 6/30/2013 SubRxF
23140325 Chemical 7/1/2013 SubRxF
23140325 Chemical 5/16/1994 ######## FormReqd Rx
23140325 Brand 7/1/2006 6/30/2008 SoleSupply
23140325 Brand 1/1/2009 6/30/2011 SoleSupply
23140325 Brand 10/1/2011 6/30/2014 SoleSupply
23170101 Brand 10/1/2011 6/30/2014 SoleSupply
23170101 Chemical 10/1/2003 Statim Must
23170102 Chemical 10/1/2003 Statim Must
23170104 Chemical 10/1/2003 Statim Must
23170104 Brand 12/1/2000 6/30/2003 SoleSupply
23170104 Brand 10/1/2003 6/30/2006 SoleSupply
23170201 Formulation12/1/2011 OraProduct
23170201 Chemical 10/1/2003 Statim Must
23170202 Chemical 10/1/2003 Statim Must
23170202 Formulation12/1/2011 OraProduct
23170202 Brand 12/1/2000 6/30/2003 SoleSupply
23170202 Brand 10/1/2003 6/30/2006 SoleSupply
23170203 Brand 10/1/2011 6/30/2014 SoleSupply
23170203 Formulation12/1/2011 OraProduct
23170203 Chemical 10/1/2003 Statim Must
23170301 Chemical 10/1/2003 Statim Must
23170302 Chemical 10/1/2003 Statim Must
23170701 Chemical 10/1/2003 Statim Must
23170701 Formulation 7/1/1996 FormMax 5 PSO
23170701 Brand 10/1/2003 6/30/2006 SoleSupply
23170801 Chemical 10/1/2003 Statim Must
23170901 Chemical 10/1/2003 Statim Must
23170902 Chemical 10/1/2003 Statim Must
23170902 Brand 1/1/2003 6/30/2005 SoleSupply
23170902 Brand 10/1/2005 6/30/2008 SoleSupply
23171001 Chemical 10/1/2003 Statim Must
23171101 Chemical 10/1/2003 Statim Must
23171102 Chemical 10/1/2003 Statim Must
23171102 Brand 12/1/2000 6/30/2003 SoleSupply
23171102 Brand 10/1/2003 6/30/2006 SoleSupply
23180101 Chemical 5/16/1994 SpecEnd Retail
23190101 Formulation5/16/1994 SpecEnd Retail
23190101 Chemical 7/1/2005 ######## PCT
23190101 Formulation12/1/2005 PCT
23190102 Formulation12/1/2005 PCT
23190102 Chemical 7/1/2005 ######## PCT
23190102 Formulation5/16/1994 SpecEnd Retail
23192525 Formulation12/1/2005 SpecEnd Hospital
23192525 Chemical 7/1/2005 ######## PCT
23192525 Formulation12/1/2005 PCT only
23192526 Chemical 7/1/2005 ######## PCT
23192526 Formulation12/1/2005 PCT only
23192526 Formulation12/1/2005 SpecEnd Hospital
23200101 Formulation5/16/1994 SpecEnd Retail
23200101 Chemical 7/1/2005 ######## PCT
23200101 Formulation12/1/2005 PCT
23200101 Brand 9/1/2006 6/30/2009 SoleSupply
23200201 Brand 9/1/2006 6/30/2009 SoleSupply
23200201 Formulation12/1/2005 PCT
23200201 Chemical 7/1/2005 ######## PCT
23200201 Formulation5/16/1994 SpecEnd Retail
23202525 Formulation12/1/2005 SpecEnd Hospital
23202525 Chemical 7/1/2005 ######## PCT
23202525 Formulation12/1/2005 PCT only
23202526 Formulation12/1/2005 PCT only
Trial Version
Not all rows exported
Stamp
Pharmacode Effective Expiry Subsidy Alternate Price CBS OP Change
201502 4/1/1996 3/1/1997 151.69 151.69 151.69 FALSE FALSE Change -Subsidy -Price -Alternate
201502 3/1/1997 7/1/1997 113.77 113.77 113.77 FALSE FALSE Change -Subsidy -Price -Alternate
201502 7/1/1997 2/1/2007 87.98 87.98 87.98 FALSE FALSE Change -Subsidy -Price -Alternate
201502 2/1/2007 5/1/2007 24.95 24.95 87.98 FALSE FALSE Change -Subsidy -Alternate
201502 5/1/2007 0 0 0 FALSE FALSE Delisted
201510 5/16/1994 10/1/2006 141.54 141.54 141.54 FALSE FALSE New Listing
201510 10/1/2006 169.85 169.85 169.85 FALSE TRUE Change +Subsidy +Price +Alternate +OP
201529 5/16/1994 6/1/1996 14.03 14.03 14.03 FALSE FALSE New Listing
201529 6/1/1996 8/1/1997 16.84 16.84 16.84 FALSE FALSE Change +Subsidy +Price +Alternate
201529 8/1/1997 0 0 0 FALSE FALSE Delisted
201588 10/4/1997 3/1/2001 29.06 29.06 30.24 FALSE FALSE New Listing
201588 3/1/2001 7/1/2001 29.06 29.06 33.28 FALSE FALSE Change +Price
201588 7/1/2001 1/1/2002 29.06 29.06 38.27 FALSE FALSE Change +Price
201588 1/1/2002 6/1/2009 29.06 29.06 29.06 FALSE FALSE Change -Price
201588 6/1/2009 0 0 0 FALSE FALSE Delisted
201642 6/3/1995 8/1/2000 8.6 8.6 8.6 FALSE TRUE New Listing
201642 8/1/2000 9/1/2002 8.6 8.6 9.14 FALSE TRUE Change +Price
201642 9/1/2002 0 0 0 FALSE FALSE Delisted
201669 5/25/1995 11/1/1997 8.13 8.13 8.13 FALSE FALSE New Listing
201669 11/1/1997 0 0 0 FALSE FALSE Delisted
201677 6/3/1995 12/1/1997 3.94 3.94 4.35 FALSE TRUE New Listing
201677 12/1/1997 0 0 0 FALSE FALSE Delisted
201685 6/3/1995 12/1/1997 3.94 3.94 4.35 FALSE TRUE New Listing
201685 12/1/1997 0 0 0 FALSE FALSE Delisted
201693 5/16/1994 12/1/1999 2.52 2.52 2.52 FALSE TRUE New Listing
201693 12/1/1999 4/1/2000 1.1 1.1 2.52 FALSE TRUE Change -Subsidy -Alternate
201693 4/1/2000 0 0 0 FALSE FALSE Delisted
201707 6/26/1995 11/1/1999 1.85 1.85 2.77 FALSE TRUE New Listing
201707 11/1/1999 0 0 0 FALSE FALSE Delisted
201715 6/3/1995 4/1/2001 4.74 4.74 4.74 FALSE TRUE New Listing
201715 4/1/2001 0 0 0 FALSE FALSE Delisted
201731 5/16/1994 4/1/2003 7.27 7.27 7.27 FALSE FALSE New Listing
201731 4/1/2003 0 0 0 FALSE FALSE Delisted
201758 5/16/1994 12/1/2003 5.6 5.6 5.6 FALSE FALSE New Listing
201758 12/1/2003 0 0 0 FALSE FALSE Delisted
201766 5/16/1994 8/1/1996 1.72 1.72 1.72 FALSE FALSE New Listing
201766 8/1/1996 1/1/1997 9.2 9.2 17.2 FALSE FALSE Change +Subsidy +Price +Alternate
201766 1/1/1997 2/1/1999 9.2 9.2 12 FALSE FALSE Change -Price
201766 2/1/1999 8/1/2001 10.31 10.31 10.31 FALSE FALSE Change +Subsidy -Price +Alternate
201766 8/1/2001 13.36 13.36 13.36 FALSE FALSE Change +Subsidy +Price +Alternate
201782 8/16/1994 6/1/1995 235.84 235.84 235.84 FALSE FALSE New Listing
201782 6/1/1995 1/1/2006 244.1 244.1 244.1 FALSE FALSE Change +Subsidy +Price +Alternate
201782 1/1/2006 0 0 0 FALSE FALSE Delisted
201804 5/16/1994 2/1/2002 4.38 4.38 5.26 FALSE FALSE New Listing
201804 2/1/2002 0 0 0 FALSE FALSE Delisted
201820 5/16/1994 8/16/1994 108.61 108.61 108.61 FALSE FALSE New Listing
201820 8/16/1994 4/19/1995 105.47 105.47 105.47 FALSE FALSE Change -Subsidy -Price -Alternate
201820 4/19/1995 8/1/2000 55.6 55.6 55.6 FALSE FALSE Change -Subsidy -Price -Alternate
201820 8/1/2000 0 0 0 FALSE FALSE Delisted
201839 6/1/1997 10/4/1997 2.96 2.96 5 FALSE TRUE New Listing
201839 10/4/1997 6/1/1998 2.96 2.96 4.46 FALSE TRUE Change -Price
201839 6/1/1998 2/1/1999 2.96 2.96 5 FALSE TRUE Change +Price
201839 2/1/1999 3/1/2000 2.96 2.96 5.75 FALSE TRUE Change +Price
201839 3/1/2000 5/1/2003 2.96 2.96 6.1 FALSE TRUE Change +Price
201839 5/1/2003 1/1/2007 2.96 2.96 6.28 FALSE TRUE Change +Price
201839 1/1/2007 8/1/2013 2.96 2.96 6.91 FALSE TRUE Change +Price
201839 8/1/2013 2.96 2.96 2.96 FALSE TRUE Change -Price
201847 5/16/1994 5/19/1995 12.29 12.29 12.29 FALSE TRUE New Listing
201847 5/19/1995 7/1/1997 12.29 12.29 12.66 FALSE TRUE Change +Price
201847 7/1/1997 6/1/1998 12.29 12.29 13.29 FALSE TRUE Change +Price
201847 6/1/1998 2/1/1999 12.29 12.29 14.88 FALSE TRUE Change +Price
201847 2/1/1999 5/1/2001 12.29 12.29 17.11 FALSE TRUE Change +Price
201847 5/1/2001 5/1/2003 12.29 12.29 22.24 FALSE TRUE Change +Price
201847 5/1/2003 7/1/2005 12.29 12.29 22.91 FALSE TRUE Change +Price
201847 7/1/2005 0 0 0 FALSE FALSE Delisted
201855 6/16/1995 6/27/1995 3.43 3.43 3.43 FALSE TRUE New Listing
201855 6/27/1995 1/1/2001 3.43 3.43 3.6 FALSE TRUE Change +Price
201855 1/1/2001 5/1/2004 3.43 3.43 3.95 FALSE TRUE Change +Price
201855 5/1/2004 3.43 3.43 4.35 FALSE TRUE Change +Price
201863 6/16/1995 8/1/1997 6.59 6.59 6.59 FALSE TRUE New Listing
201863 8/1/1997 1/1/2001 6.59 6.59 6.92 FALSE TRUE Change +Price
201863 1/1/2001 5/1/2004 6.59 6.59 7.62 FALSE TRUE Change +Price
201863 5/1/2004 6.59 6.59 8 FALSE TRUE Change +Price
201871 6/16/1995 8/1/1997 28.33 28.33 30.77 FALSE TRUE New Listing
201871 8/1/1997 1/1/2001 28.33 28.33 32.31 FALSE TRUE Change +Price
201871 1/1/2001 4/1/2002 28.33 28.33 33.93 FALSE TRUE Change +Price
201871 4/1/2002 0 0 0 FALSE FALSE Delisted
201928 6/3/1995 7/1/1997 7.6 7.6 7.6 FALSE TRUE New Listing
201928 7/1/1997 0 0 0 FALSE FALSE Delisted
201936 6/3/1995 7/1/1997 8.75 8.75 8.75 FALSE TRUE New Listing
201936 7/1/1997 0 0 0 FALSE FALSE Delisted
201960 5/16/1994 7/1/2003 4.51 4.51 5.86 FALSE FALSE New Listing
201960 7/1/2003 5.86 5.86 5.86 FALSE FALSE Change +Subsidy +Alternate
201979 5/16/1994 2/1/1999 4.29 4.29 5.9 FALSE TRUE New Listing
201979 2/1/1999 0 0 0 FALSE FALSE Delisted
202029 6/15/1995 8/1/1997 5.99 5.99 6.48 FALSE TRUE New Listing
202029 8/1/1997 0 0 0 FALSE FALSE Delisted
202045 8/16/1994 5/1/1999 7.12 7.12 8.39 FALSE FALSE New Listing
202045 5/1/1999 0 0 0 FALSE FALSE Delisted
202096 5/16/1994 3/1/1998 2.91 2.91 2.91 FALSE FALSE New Listing
202096 3/1/1998 0 0 0 FALSE FALSE Delisted
202118 5/16/1994 8/1/2010 46.33 46.33 47.72 FALSE FALSE New Listing
202118 8/1/2010 1/1/2014 60 60 60 FALSE FALSE Change +Subsidy +Price +Alternate
202118 1/1/2014 126 126 126 FALSE FALSE Change +Subsidy +Price +Alternate
202126 5/16/1994 7/1/1999 89.11 89.11 89.11 FALSE FALSE New Listing
202126 7/1/1999 10/1/2010 25 25 34.9 FALSE FALSE Change -Subsidy -Price -Alternate
202126 10/1/2010 1/1/2011 18.45 18.45 34.9 FALSE FALSE Change -Subsidy -Alternate
202126 1/1/2011 2/1/2013 0 0 0 FALSE FALSE Delisted
202126 2/1/2013 3/1/2014 18.45 18.45 18.45 FALSE FALSE New Listing
202126 3/1/2014 0 0 0 FALSE FALSE Delisted
202185 5/16/1994 2/1/1998 15.92 15.92 20.7 FALSE FALSE New Listing
202185 2/1/1998 0 0 0 FALSE FALSE Delisted
202193 5/16/1994 11/1/1997 4.46 4.46 4.46 FALSE FALSE New Listing
202193 11/1/1997 3/1/1998 4.46 4.46 5.35 FALSE FALSE Change +Price
202193 3/1/1998 0 0 0 FALSE FALSE Delisted
202215 5/16/1994 5/1/1997 3.33 3.33 3.33 FALSE TRUE New Listing
202215 5/1/1997 10/1/1998 3.33 3.33 4.14 FALSE TRUE Change +Price
202215 10/1/1998 11/1/1998 1.83 1.83 4.14 FALSE TRUE Change -Subsidy -Alternate
202215 11/1/1998 1/1/1999 1.83 1.83 4.35 FALSE TRUE Change +Price
202215 1/1/1999 5/1/2001 1 1 4.35 FALSE TRUE Change -Subsidy -Alternate
202215 5/1/2001 9/1/2002 1 1 4.6 FALSE TRUE Change +Price
202215 9/1/2002 12/1/2002 0.8 0.8 4.6 FALSE TRUE Change -Subsidy -Alternate
202215 12/1/2002 0 0 0 FALSE FALSE Delisted
202223 5/16/1994 5/17/1995 6.56 6.56 6.56 FALSE TRUE New Listing
202223 5/17/1995 5/1/1997 6.57 6.57 6.57 FALSE TRUE Change +Subsidy +Price +Alternate
202223 5/1/1997 3/1/1998 6.57 6.57 6.98 FALSE TRUE Change +Price
200034 5/16/1994 8/1/2000 3.5 3.5 3.5 FALSE TRUE New Listing
200034 8/1/2000 0 0 0 FALSE FALSE Delisted
200069 5/16/1994 12/1/1996 31.22 31.22 31.22 FALSE FALSE New Listing
200069 12/1/1996 0 0 0 FALSE FALSE Delisted
200131 5/16/1994 7/1/1997 11.11 11.11 11.11 FALSE TRUE New Listing
200131 7/1/1997 0 0 0 FALSE FALSE Delisted
200182 5/16/1994 3/1/2002 4.2 4.2 4.41 FALSE TRUE New Listing
200182 3/1/2002 9/1/2002 4.2 4.2 4.74 FALSE TRUE Change +Price
200182 9/1/2002 12/1/2002 4.15 4.15 4.74 FALSE TRUE Change -Subsidy -Alternate
200182 12/1/2002 0 0 0 FALSE FALSE Delisted
200190 5/16/1994 8/1/1998 7.02 7.02 7.02 FALSE TRUE New Listing
200190 8/1/1998 11/1/2000 7.02 7.02 8.42 FALSE TRUE Change +Price
200190 11/1/2000 1/1/2001 7.02 7.02 11.77 FALSE TRUE Change +Price
200190 1/1/2001 9/1/2001 7.02 7.02 12.95 FALSE TRUE Change +Price
200190 9/1/2001 7.02 7.02 13.92 FALSE TRUE Change +Price
200212 5/16/1994 2/1/1998 7.69 7.69 7.69 FALSE FALSE New Listing
200212 2/1/1998 9/1/2000 6.15 6.15 6.15 FALSE FALSE Change -Subsidy -Price -Alternate
200212 9/1/2000 7/1/2001 5.6 5.6 6.15 FALSE FALSE Change -Subsidy -Alternate
200212 7/1/2001 0 0 0 FALSE FALSE Delisted
200220 10/1/1994 2/1/1998 28.96 28.96 28.96 FALSE FALSE New Listing
200220 2/1/1998 9/1/2000 23.17 23.17 23.17 FALSE FALSE Change -Subsidy -Price -Alternate
200220 9/1/2000 7/1/2001 18.5 18.5 23.17 FALSE FALSE Change -Subsidy -Alternate
200220 7/1/2001 0 0 0 FALSE FALSE Delisted
200247 5/16/1994 5/18/1996 12.31 12.31 13.64 FALSE TRUE New Listing
200247 5/18/1996 3/1/1997 10.46 10.46 13.64 FALSE TRUE Change -Subsidy -Alternate
200247 3/1/1997 0 0 0 FALSE FALSE Delisted
200255 5/16/1994 11/1/1997 7.35 7.35 8.24 FALSE FALSE New Listing
200255 11/1/1997 4/1/2000 7.35 7.35 8.23 FALSE FALSE Change -Price
200255 4/1/2000 0 0 0 FALSE FALSE Delisted
200263 5/16/1994 9/1/2000 21 21 23.01 FALSE FALSE New Listing
200263 9/1/2000 1/1/2001 15.99 15.99 23.01 FALSE FALSE Change -Subsidy -Alternate
200263 1/1/2001 0 0 0 FALSE FALSE Delisted
200271 5/16/1994 31.31 31.31 31.31 FALSE FALSE New Listing
200298 5/16/1994 10/1/2002 50.7 50.7 50.7 FALSE FALSE New Listing
200298 10/1/2002 0 0 0 FALSE FALSE Delisted
200301 5/16/1994 9/1/2000 12.14 12.14 12.14 FALSE FALSE New Listing
200301 9/1/2000 0 0 0 FALSE FALSE Delisted
200328 5/16/1994 9/1/2001 12.01 12.01 12.01 FALSE FALSE New Listing
200328 9/1/2001 0 0 0 FALSE FALSE Delisted
200336 5/16/1994 9/1/2001 23.43 23.43 23.44 FALSE FALSE New Listing
200336 9/1/2001 0 0 0 FALSE FALSE Delisted
200379 5/16/1994 3/1/1998 9 9 9 FALSE TRUE New Listing
200379 3/1/1998 10/1/2001 6.57 6.57 6.57 FALSE TRUE Change -Subsidy -Price -Alternate
200379 10/1/2001 0 0 0 FALSE FALSE Delisted
200417 5/16/1994 12.56 12.56 12.56 FALSE FALSE New Listing
200506 1/1/1998 8/1/2000 27.2 27.2 27.2 FALSE FALSE New Listing
200506 8/1/2000 7/1/2003 11.95 11.95 11.95 FALSE FALSE Change -Subsidy -Price -Alternate
200506 7/1/2003 4/1/2011 13 13 13 FALSE FALSE Change +Subsidy +Price +Alternate
200506 4/1/2011 0 0 0 FALSE FALSE Delisted
200549 5/16/1994 8/1/1998 7.39 7.39 7.39 FALSE FALSE New Listing
200549 8/1/1998 0 0 0 FALSE FALSE Delisted
200573 5/16/1994 7/1/1999 25.56 25.56 25.56 FALSE FALSE New Listing
200573 7/1/1999 9/1/2002 17.5 17.5 17.5 FALSE FALSE Change -Subsidy -Price -Alternate
200573 9/1/2002 11/1/2002 17.5 17.5 14 FALSE FALSE Change -Price
200573 11/1/2002 12/1/2002 10 10 14 FALSE FALSE Change -Subsidy -Alternate
200573 12/1/2002 2/1/2003 10 10 10 FALSE FALSE Change -Price
200573 2/1/2003 0 0 0 FALSE FALSE Delisted
200581 5/16/1994 2/1/1998 42.2 42.2 42.45 FALSE FALSE New Listing
200581 2/1/1998 8/1/2000 25.32 25.32 25.32 FALSE FALSE Change -Subsidy -Price -Alternate
200581 8/1/2000 12/1/2000 5.5 5.5 25.32 FALSE FALSE Change -Subsidy -Alternate
200581 12/1/2000 0 0 0 FALSE FALSE Delisted
200603 5/16/1994 2/1/1997 134.54 134.54 134.54 FALSE FALSE New Listing
200603 2/1/1997 0 0 0 FALSE FALSE Delisted
200638 5/16/1994 9/1/2001 115.2 115.2 115.2 FALSE FALSE New Listing
200638 9/1/2001 1/1/2002 84.75 84.75 84.75 FALSE FALSE Change -Subsidy -Price -Alternate
200638 1/1/2002 0 0 0 FALSE FALSE Delisted
200689 5/16/1994 8/1/2005 3.27 3.27 3.27 FALSE FALSE New Listing
200689 8/1/2005 0 0 0 FALSE FALSE Delisted
200751 8/16/1994 9/1/2001 28 28 29.9 FALSE FALSE New Listing
200751 9/1/2001 0 0 0 FALSE FALSE Delisted
200891 5/16/1994 4/1/2007 4.02 4.02 4.02 FALSE TRUE New Listing
200891 4/1/2007 0 0 0 FALSE FALSE Delisted
200905 5/16/1994 7/1/2005 4.02 4.02 4.02 FALSE TRUE New Listing
200905 7/1/2005 10/1/2008 4.01 4.01 4.01 FALSE TRUE Change -Subsidy -Price -Alternate
200905 10/1/2008 12/1/2009 4.4 4.4 4.4 FALSE TRUE Change +Subsidy +Price +Alternate
200905 12/1/2009 17.36 17.36 17.36 FALSE TRUE Change +Subsidy +Price +Alternate
200980 5/16/1994 3/1/2001 17.61 17.61 17.61 FALSE FALSE New Listing
200980 3/1/2001 0 0 0 FALSE FALSE Delisted
200999 5/16/1994 2/1/1997 3.5 3.5 5.66 FALSE TRUE New Listing
200999 2/1/1997 7/1/1997 3.5 3.5 7.4 FALSE TRUE Change +Price
200999 7/1/1997 0 0 0 FALSE FALSE Delisted
201022 5/16/1994 6/1/2001 9.88 9.88 9.88 FALSE FALSE New Listing
201022 6/1/2001 0 0 0 FALSE FALSE Delisted
201030 5/16/1994 6/1/2001 12.26 12.26 12.26 FALSE FALSE New Listing
201030 6/1/2001 0 0 0 FALSE FALSE Delisted
201049 5/16/1994 9/1/2001 4.68 4.68 4.68 FALSE FALSE New Listing
201049 9/1/2001 0 0 0 FALSE FALSE Delisted
201103 5/16/1994 2/1/2003 15 15 18 FALSE TRUE New Listing
201103 2/1/2003 0 0 0 FALSE FALSE Delisted
201111 5/16/1994 3/1/1998 8 8 9.2 TRUE TRUE New Listing
201111 3/1/1998 0 0 0 FALSE FALSE Delisted
201200 6/16/1995 7/1/1999 4.2 4.2 5.3 FALSE TRUE New Listing
201200 7/1/1999 11/1/1999 3.25 3.25 3.25 FALSE TRUE Change -Subsidy -Price -Alternate
201200 11/1/1999 0 0 0 FALSE FALSE Delisted
201286 5/16/1994 5/1/1996 9.45 9.45 13.2 FALSE TRUE New Listing
201286 5/1/1996 4/1/2000 9.45 13.8 13.8 FALSE TRUE Change +Price +Alternate
201286 4/1/2000 2/1/2003 9.45 13.8 13.8 FALSE FALSE Change -OP
201286 2/1/2003 0 0 0 FALSE FALSE Delisted
201308 7/1/2005 6/1/2010 680 680 680 FALSE FALSE New listing
201308 6/1/2010 0 0 0 FALSE FALSE Delisted
201316 10/1/1997 2/1/1999 332.46 332.46 332.46 FALSE FALSE New Listing
201316 2/1/1999 7/1/1999 232.72 232.72 232.72 FALSE FALSE Change -Subsidy -Price -Alternate
201316 7/1/1999 11/1/1999 134.74 134.74 232.72 FALSE FALSE Change -Subsidy -Alternate
201316 11/1/1999 0 0 0 FALSE FALSE Delisted
201324 5/16/1994 5/23/1995 25.19 25.19 25.19 FALSE FALSE New Listing
201324 5/23/1995 2/1/1999 24.69 24.69 24.69 FALSE FALSE Change -Subsidy -Price -Alternate
201324 2/1/1999 7/1/1999 17.28 17.28 17.28 FALSE FALSE Change -Subsidy -Price -Alternate
201324 7/1/1999 11/1/1999 10.84 10.84 17.28 FALSE FALSE Change -Subsidy -Alternate
201324 11/1/1999 0 0 0 FALSE FALSE Delisted
201413 10/4/1997 6/1/1998 41.6 41.6 41.6 FALSE FALSE New Listing
201413 6/1/1998 1/1/2001 29.12 29.12 29.12 FALSE FALSE Change -Subsidy -Price -Alternate
201413 1/1/2001 3/1/2002 20 20 20 FALSE FALSE Change -Subsidy -Price -Alternate
201413 3/1/2002 3/1/2004 14 14 14 FALSE FALSE Change -Subsidy -Price -Alternate
201413 3/1/2004 8 8 8 FALSE FALSE Change -Subsidy -Price -Alternate
201421 5/16/1994 3/1/1995 75.66 75.66 75.66 FALSE FALSE New Listing
201421 3/1/1995 6/1/1998 75.67 75.67 75.67 FALSE FALSE Change +Subsidy +Price +Alternate
201421 6/1/1998 1/1/2001 52.97 52.97 52.97 FALSE FALSE Change -Subsidy -Price -Alternate
201421 1/1/2001 3/1/2002 36 36 36 FALSE FALSE Change -Subsidy -Price -Alternate
201421 3/1/2002 3/1/2004 25 25 25 FALSE FALSE Change -Subsidy -Price -Alternate
201421 3/1/2004 12.5 12.5 12.5 FALSE FALSE Change -Subsidy -Price -Alternate
201448 5/16/1994 6/1/1998 88.25 88.25 88.25 FALSE FALSE New Listing
201448 6/1/1998 1/1/2001 61.78 61.78 61.78 FALSE FALSE Change -Subsidy -Price -Alternate
201448 1/1/2001 3/1/2004 40 40 40 FALSE FALSE Change -Subsidy -Price -Alternate
201448 3/1/2004 25 25 25 FALSE FALSE Change -Subsidy -Price -Alternate
201472 5/16/1994 4/1/2011 47.89 47.89 47.89 FALSE FALSE New Listing
201472 4/1/2011 59.5 59.5 59.5 FALSE FALSE Change +Subsidy +Price +Alternate
201499 5/16/1994 4/1/1996 98.62 98.62 98.62 FALSE FALSE New Listing
201499 4/1/1996 3/1/1997 91.06 91.06 91.06 FALSE FALSE Change -Subsidy -Price -Alternate
201499 3/1/1997 7/1/1997 68.3 68.3 68.3 FALSE FALSE Change -Subsidy -Price -Alternate
201499 7/1/1997 2/1/2007 52.63 52.63 52.63 FALSE FALSE Change -Subsidy -Price -Alternate
201499 2/1/2007 5/1/2007 13.45 13.45 52.63 FALSE FALSE Change -Subsidy -Alternate
201499 5/1/2007 0 0 0 FALSE FALSE Delisted
201502 5/16/1994 4/1/1996 175.92 175.92 175.92 FALSE FALSE New Listing
202223 3/1/1998 5/1/2001 4.36 4.36 6.98 FALSE TRUE Change -Subsidy -Alternate
202223 5/1/2001 1/1/2005 4.36 4.36 7.35 FALSE TRUE Change +Price
202223 1/1/2005 4.36 4.36 7.55 FALSE TRUE Change +Price
202231 5/16/1994 5/1/1997 6.48 6.48 6.48 FALSE TRUE New Listing
202231 5/1/1997 12/1/1997 6.48 6.48 7.02 FALSE TRUE Change +Price
202231 12/1/1997 10/1/1998 6.16 6.16 7.02 FALSE TRUE Change -Subsidy -Alternate
202231 10/1/1998 1/1/1999 4.38 4.38 7.02 FALSE TRUE Change -Subsidy -Alternate
202231 1/1/1999 5/1/2001 2.75 2.75 7.02 FALSE TRUE Change -Subsidy -Alternate
202231 5/1/2001 9/1/2001 2.75 2.75 7.3 FALSE TRUE Change +Price
202231 9/1/2001 12/1/2001 1.89 1.89 7.3 FALSE TRUE Change -Subsidy -Alternate
202231 12/1/2001 0 0 0 FALSE FALSE Delisted
202258 5/16/1994 5/1/1997 6.42 6.42 6.42 FALSE FALSE New Listing
202258 5/1/1997 12/1/1997 6.42 6.42 6.48 FALSE FALSE Change +Price
202258 12/1/1997 10/1/1998 6.16 6.16 6.48 FALSE FALSE Change -Subsidy -Alternate
202258 10/1/1998 11/1/1998 4.38 4.38 6.48 FALSE FALSE Change -Subsidy -Alternate
202258 11/1/1998 1/1/1999 4.38 4.38 7.02 FALSE FALSE Change +Price
202258 1/1/1999 5/1/2001 2.75 2.75 7.02 FALSE FALSE Change -Subsidy -Alternate
202258 5/1/2001 10/1/2001 2.75 2.75 7.3 FALSE FALSE Change +Price
202258 10/1/2001 1/1/2002 1.93 1.93 7.3 FALSE FALSE Change -Subsidy -Alternate
202258 1/1/2002 0 0 0 FALSE FALSE Delisted
202266 5/16/1994 4/3/1995 8.34 8.34 13 FALSE FALSE New Listing
202266 4/3/1995 10/1/2005 13 13 13 FALSE FALSE Change +Subsidy +Alternate
202266 10/1/2005 10/1/2009 14 14 14 FALSE FALSE Change +Subsidy +Price +Alternate
202266 10/1/2009 9/1/2012 15.45 15.45 15.45 FALSE FALSE Change +Subsidy +Price +Alternate
202266 9/1/2012 16.07 16.07 16.07 FALSE FALSE Change +Subsidy +Price +Alternate
202274 5/16/1994 8/1/2002 31.48 31.48 31.48 FALSE FALSE New Listing
202274 8/1/2002 10/1/2005 29.33 29.33 29.33 FALSE FALSE Change -Subsidy -Price -Alternate
202274 10/1/2005 10/1/2009 30.33 30.33 30.33 FALSE FALSE Change +Subsidy +Price +Alternate
202274 10/1/2009 12/1/2012 33 33 33 FALSE FALSE Change +Subsidy +Price +Alternate
202274 12/1/2012 34.32 34.32 34.32 FALSE FALSE Change +Subsidy +Price +Alternate
202320 5/16/1994 11/1/1997 2.92 2.92 12.24 FALSE FALSE New Listing
202320 11/1/1997 10/1/2000 2.92 2.92 12.23 FALSE FALSE Change -Price
202320 10/1/2000 0 0 0 FALSE FALSE Delisted
202371 5/16/1994 7/1/1995 12.82 12.82 12.82 FALSE TRUE New Listing
202371 7/1/1995 8/1/1997 13.07 13.07 13.07 FALSE TRUE Change +Subsidy +Price +Alternate
202371 8/1/1997 8/1/2000 13.07 13.07 13.73 FALSE TRUE Change +Price
202371 8/1/2000 0 0 0 FALSE FALSE Delisted
202436 5/16/1994 2/1/1998 21.55 21.55 21.55 FALSE FALSE New Listing
202436 2/1/1998 8/1/2000 12.93 12.93 12.93 FALSE FALSE Change -Subsidy -Price -Alternate
202436 8/1/2000 12/1/2000 6.63 6.63 6.63 FALSE FALSE Change -Subsidy -Price -Alternate
202436 12/1/2000 1/1/2009 0 0 0 FALSE FALSE Delisted
202436 1/1/2009 12/1/2011 5.44 5.44 5.44 FALSE FALSE New Listing
202436 12/1/2011 3/1/2012 3.98 3.98 5.44 FALSE FALSE Change -Subsidy -Alternate
202436 3/1/2012 0 0 0 FALSE FALSE Delisted
202452 5/16/1994 8/1/2001 8.38 8.38 8.96 FALSE FALSE New Listing
202452 8/1/2001 3/1/2004 8.38 8.38 17.41 FALSE FALSE Change +Price
202452 3/1/2004 0 0 0 FALSE FALSE Delisted
202479 5/16/1994 8/1/2001 13.94 13.94 14.92 FALSE FALSE New Listing
202479 8/1/2001 9/1/2003 13.94 13.94 21.81 FALSE FALSE Change +Price
202479 9/1/2003 0 0 0 FALSE FALSE Delisted
202487 10/1/1997 2/1/1998 20.53 20.53 20.55 FALSE FALSE New Listing
202487 2/1/1998 8/1/2000 12.33 12.33 12.33 FALSE FALSE Change -Subsidy -Price -Alternate
202487 8/1/2000 12/1/2000 5.4 5.4 5.4 FALSE FALSE Change -Subsidy -Price -Alternate
202487 12/1/2000 1/1/2009 0 0 0 FALSE FALSE Delisted
202487 1/1/2009 12/1/2011 4.03 4.03 4.03 FALSE FALSE New Listing
202487 12/1/2011 3/1/2012 3.35 3.35 4.03 FALSE FALSE Change -Subsidy -Alternate
202487 3/1/2012 0 0 0 FALSE FALSE Delisted
202525 5/16/1994 3/1/1995 16.46 16.46 17.68 FALSE FALSE New Listing
202525 3/1/1995 7/1/1995 16.46 16.46 21.21 FALSE FALSE Change +Price
202525 7/1/1995 3/1/2001 21.21 21.21 21.21 FALSE FALSE Change +Subsidy +Alternate
202525 3/1/2001 7/1/2001 21.21 21.21 23.33 FALSE FALSE Change +Price
202525 7/1/2001 11/1/2004 23.33 23.33 23.33 FALSE FALSE Change +Subsidy +Alternate
202525 11/1/2004 25.66 25.66 25.66 FALSE FALSE Change +Subsidy +Price +Alternate
202576 5/16/1994 3/1/1995 8.92 8.92 9.36 FALSE FALSE New Listing
202576 3/1/1995 7/1/1995 8.92 8.92 10.76 FALSE FALSE Change +Price
202576 7/1/1995 3/1/2001 10.76 10.76 10.76 FALSE FALSE Change +Subsidy +Alternate
202576 3/1/2001 7/1/2001 10.76 10.76 11.84 FALSE FALSE Change +Price
202576 7/1/2001 11/1/2004 11.84 11.84 11.84 FALSE FALSE Change +Subsidy +Alternate
202576 11/1/2004 13.02 13.02 13.02 FALSE FALSE Change +Subsidy +Price +Alternate
202584 5/16/1994 3/1/1995 12.52 12.52 13.15 FALSE FALSE New Listing
202584 3/1/1995 7/1/1995 12.52 12.52 15.12 FALSE FALSE Change +Price
202584 7/1/1995 3/1/1997 15.12 15.12 15.12 FALSE FALSE Change +Subsidy +Alternate
202584 3/1/1997 0 0 0 FALSE FALSE Delisted
202592 5/16/1994 3/1/1995 20.96 20.96 22 FALSE FALSE New Listing
202592 3/1/1995 7/1/1995 20.96 20.96 25.3 FALSE FALSE Change +Price
202592 7/1/1995 3/1/2001 25.3 25.3 25.3 FALSE FALSE Change +Subsidy +Alternate
202592 3/1/2001 7/1/2001 25.3 25.3 27.83 FALSE FALSE Change +Price
202592 7/1/2001 11/1/2004 27.83 27.83 27.83 FALSE FALSE Change +Subsidy +Alternate
202592 11/1/2004 30.61 30.61 30.61 FALSE FALSE Change +Subsidy +Price +Alternate
202614 5/16/1994 8/1/2002 22.35 22.35 22.35 FALSE FALSE New Listing
202614 8/1/2002 0 0 0 FALSE FALSE Delisted
202622 5/16/1994 8/1/2002 33.18 33.18 33.18 FALSE FALSE New Listing
202622 8/1/2002 0 0 0 FALSE FALSE Delisted
202665 5/16/1994 2/1/1998 93.32 93.32 93.32 FALSE FALSE New Listing
202665 2/1/1998 7/1/2000 65.32 65.32 65.32 FALSE FALSE Change -Subsidy -Price -Alternate
202665 7/1/2000 8/1/2000 4.19 65.32 65.32 FALSE FALSE Change -Subsidy
202665 8/1/2000 11/1/2000 4.19 4.19 2 FALSE FALSE Change -Price -Alternate
202665 11/1/2000 0 0 0 FALSE FALSE Delisted
202681 ######## 8/1/2000 0 0 0 TRUE FALSE New Listing
202681 8/1/2000 5/1/2002 137.06 137.06 137.06 FALSE FALSE Change +Subsidy +Price +Alternate -CBS
202681 5/1/2002 5/1/2008 137.06 137.06 242.5 FALSE FALSE Change +Price
202681 5/1/2008 0 0 0 FALSE FALSE Delisted
202746 5/16/1994 12/1/1997 8.61 8.61 8.61 FALSE TRUE New Listing
202746 12/1/1997 0 0 0 FALSE FALSE Delisted
202770 5/16/1994 9/1/1995 28.38 28.38 39.6 FALSE FALSE New Listing
202770 9/1/1995 6/1/1996 28.38 28.38 41.4 FALSE FALSE Change +Price
202770 6/1/1996 8/1/2002 9.45 14.49 14.49 FALSE FALSE Change -Subsidy -Price -Alternate
202770 8/1/2002 1/1/2004 9.45 15 15 FALSE FALSE Change +Price +Alternate
202770 1/1/2004 6.62 15 16.5 FALSE FALSE Change -Subsidy +Price
202800 5/16/1994 6/1/1996 28.38 28.38 39.6 FALSE FALSE New Listing
202800 6/1/1996 3/1/2002 9.45 13.2 13.2 FALSE FALSE Change -Subsidy -Price -Alternate
202800 3/1/2002 0 0 0 FALSE FALSE Delisted
202827 5/16/1994 9/1/1995 9.45 9.45 13.2 FALSE TRUE New Listing
202827 9/1/1995 6/1/1996 9.45 9.45 13.8 FALSE TRUE Change +Price
202827 6/1/1996 8/1/1999 9.45 14.49 14.49 FALSE TRUE Change +Price +Alternate
202827 8/1/1999 4/1/2000 9.45 9.45 9.45 FALSE TRUE Change -Price -Alternate
202827 4/1/2000 9.45 9.45 9.45 FALSE FALSE Change -OP
202878 6/15/1995 1/1/1998 29.17 29.17 36.26 FALSE FALSE New Listing
202878 1/1/1998 8/1/2000 27.2 27.2 36.26 FALSE FALSE Change -Subsidy -Alternate
202878 8/1/2000 12/1/2000 11.95 11.95 21.01 FALSE FALSE Change -Subsidy -Price -Alternate
202878 12/1/2000 0 0 0 FALSE FALSE Delisted
202967 5/16/1994 2/1/1995 7.4 7.4 7.4 FALSE FALSE New Listing
202967 2/1/1995 2/1/2001 7.76 7.76 7.76 FALSE FALSE Change +Subsidy +Price +Alternate
202967 2/1/2001 7/1/2010 13.5 13.5 13.5 FALSE FALSE Change +Subsidy +Price +Alternate
202967 7/1/2010 10/1/2010 7.58 7.58 13.5 FALSE FALSE Change -Subsidy -Alternate
202967 10/1/2010 0 0 0 FALSE FALSE Delisted
202975 5/16/1994 3/1/1995 14.13 14.13 14.13 FALSE FALSE New Listing
202975 3/1/1995 2/1/2001 14.84 14.84 14.84 FALSE FALSE Change +Subsidy +Price +Alternate
202975 2/1/2001 7/1/2010 21.5 21.5 21.5 FALSE FALSE Change +Subsidy +Price +Alternate
202975 7/1/2010 10/1/2010 11.75 11.75 21.5 FALSE FALSE Change -Subsidy -Alternate
202975 10/1/2010 0 0 0 FALSE FALSE Delisted
203017 5/16/1994 5/1/1996 28.38 28.38 39.6 FALSE FALSE New Listing
203017 5/1/1996 6/1/1996 28.38 28.38 41.4 FALSE FALSE Change +Price
203017 6/1/1996 8/1/2000 9.45 13.8 13.8 FALSE FALSE Change -Subsidy -Price -Alternate
203017 8/1/2000 10/1/2002 9.45 14.49 14.49 FALSE FALSE Change +Price +Alternate
203017 10/1/2002 0 0 0 FALSE FALSE Delisted
203033 5/16/1994 5/1/1996 9.45 9.45 13.2 FALSE TRUE New Listing
203033 5/1/1996 4/1/2000 9.45 13.8 13.8 FALSE TRUE Change +Price +Alternate
203033 4/1/2000 8/1/2000 9.45 13.8 13.8 FALSE FALSE Change -OP
203033 8/1/2000 1/1/2004 9.45 14.49 14.49 FALSE FALSE Change +Price +Alternate
203033 1/1/2004 6/1/2012 6.62 14.49 14.49 FALSE FALSE Change -Subsidy
203033 6/1/2012 9/1/2012 2.45 2.45 14.49 FALSE FALSE Change -Subsidy -Alternate
203033 9/1/2012 0 0 0 FALSE FALSE Delisted
203041 5/16/1994 5/1/1996 28.38 28.38 39.6 FALSE FALSE New Listing
203041 5/1/1996 6/1/1996 28.38 28.38 41.4 FALSE FALSE Change +Price
203041 6/1/1996 1/1/2004 9.45 13.8 13.8 FALSE FALSE Change -Subsidy -Price -Alternate
203041 1/1/2004 6/1/2005 6.62 13.8 13.8 FALSE FALSE Change -Subsidy
203041 6/1/2005 0 0 0 FALSE FALSE Delisted
203068 5/16/1994 5/1/1996 9.45 9.45 13.2 FALSE TRUE New Listing
203068 5/1/1996 4/1/2000 9.45 13.8 13.8 FALSE TRUE Change +Price +Alternate
203068 4/1/2000 1/1/2004 9.45 13.8 13.8 FALSE FALSE Change -OP
203068 1/1/2004 2/1/2004 6.62 13.8 13.8 FALSE FALSE Change -Subsidy
203068 2/1/2004 0 0 0 FALSE FALSE Delisted
203084 5/16/1994 3/1/1997 45.53 45.53 45.53 FALSE FALSE New Listing
203084 3/1/1997 7/1/1997 34.15 34.15 34.15 FALSE FALSE Change -Subsidy -Price -Alternate
203084 7/1/1997 26.32 26.32 26.32 FALSE FALSE Change -Subsidy -Price -Alternate
203092 5/16/1994 3/1/1997 151.69 151.69 151.69 FALSE FALSE New Listing
203092 3/1/1997 7/1/1997 113.77 113.77 113.77 FALSE FALSE Change -Subsidy -Price -Alternate
203092 7/1/1997 87.98 87.98 87.98 FALSE FALSE Change -Subsidy -Price -Alternate
203106 5/16/1994 7/1/1999 13 13 13 FALSE FALSE New Listing
203106 7/1/1999 11/1/1999 2.75 2.75 13 FALSE FALSE Change -Subsidy -Alternate
203106 11/1/1999 6/1/2009 0 0 0 FALSE FALSE Delisted
203106 6/1/2009 5 5 5 FALSE FALSE New Listing
203122 10/4/1997 5/1/1998 74.08 74.08 74.08 FALSE FALSE New Listing
203122 5/1/1998 6/1/1998 29.18 29.18 74.08 FALSE FALSE Change -Subsidy -Alternate
203122 6/1/1998 8/1/1998 29.18 29.18 29.17 FALSE FALSE Change -Price
203122 8/1/1998 0 0 0 FALSE FALSE Delisted
203149 5/16/1994 7/1/1999 2.2 2.2 3.25 FALSE FALSE New Listing
203149 7/1/1999 11/1/1999 1.59 1.59 3.25 FALSE FALSE Change -Subsidy -Alternate
203149 11/1/1999 0 0 0 FALSE FALSE Delisted
203211 5/16/1994 5/1/1998 16.5 16.5 16.5 FALSE FALSE New Listing
203211 5/1/1998 7/1/2001 10.1 10.1 10.1 FALSE FALSE Change -Subsidy -Price -Alternate
203211 7/1/2001 1/1/2002 11.1 11.1 11.1 FALSE FALSE Change +Subsidy +Price +Alternate
203211 1/1/2002 0 0 0 FALSE FALSE Delisted
203238 10/4/1997 5/1/1998 14.82 14.82 14.82 FALSE FALSE New Listing
203238 5/1/1998 6/1/1998 5.84 5.84 14.82 FALSE FALSE Change -Subsidy -Alternate
203238 6/1/1998 8/1/1998 5.84 5.84 5.84 FALSE FALSE Change +Subsidy -Price +Alternate
203238 8/1/1998 0 0 0 FALSE FALSE Delisted
203270 5/16/1994 10/1/2001 51.23 51.23 51.23 FALSE FALSE New Listing
203270 10/1/2001 0 0 0 FALSE FALSE Delisted
203300 9/1/1996 9/1/1998 205.44 205.44 205.44 FALSE TRUE New Listing
203300 9/1/1998 10/1/1998 102.72 102.72 102.72 FALSE TRUE Change -Subsidy -Price -Alternate
203300 10/1/1998 11/1/1998 82.18 82.18 82.18 FALSE TRUE Change -Subsidy -Price -Alternate
203300 11/1/1998 10/1/1999 50 50 50 FALSE TRUE Change -Subsidy -Price -Alternate
203300 10/1/1999 9/1/2000 50 50 50 FALSE FALSE Change -OP
203300 9/1/2000 3/1/2001 45 45 45 FALSE FALSE Change -Subsidy -Price -Alternate
203300 3/1/2001 7/1/2001 9.9 28.5 28.5 FALSE FALSE Change -Subsidy -Price -Alternate
203300 7/1/2001 0 0 0 FALSE FALSE Delisted
203343 1/1/2006 13.52 13.52 13.52 FALSE FALSE New listing
203351 5/16/1994 8.76 8.76 8.76 FALSE TRUE New Listing
203386 5/16/1994 6/1/1999 16 16 16 FALSE FALSE New Listing
203386 6/1/1999 0 0 0 FALSE FALSE Delisted
203416 5/16/1994 12/1/1998 16.79 16.79 16.79 FALSE FALSE New Listing
203416 12/1/1998 3/1/2000 16.78 16.78 16.78 FALSE FALSE Change -Subsidy -Price -Alternate
203416 3/1/2000 0 0 0 FALSE FALSE Delisted
203432 9/1/1997 10/1/2002 116.17 116.17 116.17 FALSE FALSE New Listing
203432 10/1/2002 1/1/2003 86.67 86.67 116.17 FALSE FALSE Change -Subsidy -Alternate
203432 1/1/2003 0 0 0 FALSE FALSE Delisted
203483 7/1/1999 12/1/1999 55.98 55.98 55.98 FALSE FALSE New Listing
203483 12/1/1999 8/1/2002 32.47 32.47 32.47 FALSE FALSE Change -Subsidy -Price -Alternate
203483 8/1/2002 3/1/2003 37.42 37.42 37.42 FALSE FALSE Change +Subsidy +Price +Alternate
203483 3/1/2003 6/1/2003 32 32 37.42 FALSE FALSE Change -Subsidy -Alternate
203483 6/1/2003 3/1/2009 0 0 0 FALSE FALSE Delisted
203483 3/1/2009 7/1/2011 25.1 25.1 25.1 FALSE FALSE New Listing
203483 7/1/2011 12/1/2012 26 26 26 FALSE FALSE Change +Subsidy +Price +Alternate
203483 12/1/2012 0 0 0 FALSE FALSE Delisted
203505 5/16/1994 8/1/2002 17.26 17.26 17.26 FALSE FALSE New Listing
203505 8/1/2002 10/1/2005 15.53 15.53 15.53 FALSE FALSE Change -Subsidy -Price -Alternate
203505 10/1/2005 10/1/2009 17.53 17.53 17.53 FALSE FALSE Change +Subsidy +Price +Alternate
203505 10/1/2009 7/1/2013 19.25 19.25 19.25 FALSE FALSE Change +Subsidy +Price +Alternate
203505 7/1/2013 10/1/2013 13.47 13.47 13.47 FALSE FALSE Change -Subsidy -Price -Alternate
203505 10/1/2013 0 0 0 FALSE FALSE Delisted
203513 1/1/1999 7/1/1999 11 11 11 FALSE FALSE New Listing
203513 7/1/1999 9/1/2002 7.95 7.95 7.95 FALSE FALSE Change -Subsidy -Price -Alternate
203513 9/1/2002 7/1/2005 7.2 7.2 7.2 FALSE FALSE Change -Subsidy -Price -Alternate
203513 7/1/2005 1/1/2010 5.9 5.9 5.9 FALSE FALSE Change -Subsidy -Price -Alternate
203513 1/1/2010 0 0 0 FALSE FALSE Delisted
203610 5/16/1994 5/1/2001 2.99 2.99 2.99 FALSE FALSE New Listing
203610 5/1/2001 0 0 0 FALSE FALSE Delisted
203629 5/16/1994 5/1/2001 14.95 14.95 14.95 FALSE FALSE New Listing
203629 5/1/2001 0 0 0 FALSE FALSE Delisted
203637 5/16/1994 5/1/2001 6.64 6.64 6.64 FALSE FALSE New Listing
203637 5/1/2001 0 0 0 FALSE FALSE Delisted
203645 5/16/1994 5/1/2001 33.2 33.2 33.2 FALSE FALSE New Listing
203645 5/1/2001 0 0 0 FALSE FALSE Delisted
203696 10/1/1997 2/1/1998 6.25 6.25 6.25 FALSE FALSE New Listing
203696 2/1/1998 8/1/2000 4.37 4.37 4.37 FALSE FALSE Change -Subsidy -Price -Alternate
203696 8/1/2000 12/1/2000 2.75 2.75 4.37 FALSE FALSE Change -Subsidy -Alternate
203696 12/1/2000 0 0 0 FALSE FALSE Delisted
203718 5/16/1994 10/1/1997 27.76 27.76 27.76 FALSE FALSE New Listing
203718 10/1/1997 2/1/1998 24.98 24.98 24.98 FALSE FALSE Change -Subsidy -Price -Alternate
203718 2/1/1998 8/1/2000 17.49 17.49 17.49 FALSE FALSE Change -Subsidy -Price -Alternate
203718 8/1/2000 12/1/2000 10.99 10.99 17.49 FALSE FALSE Change -Subsidy -Alternate
203718 12/1/2000 0 0 0 FALSE FALSE Delisted
203726 5/16/1994 2/1/1998 41.73 41.73 41.73 FALSE FALSE New Listing
203726 2/1/1998 8/1/2000 29.21 29.21 29.21 FALSE FALSE Change -Subsidy -Price -Alternate
203726 8/1/2000 12/1/2000 5.6 5.6 29.21 FALSE FALSE Change -Subsidy -Alternate
203726 12/1/2000 0 0 0 FALSE FALSE Delisted
203734 10/1/1997 3/1/2004 6.6 6.6 6.6 FALSE TRUE New Listing
203734 3/1/2004 8/1/2005 6.6 6.6 9.26 FALSE TRUE Change +Price
203734 8/1/2005 11/1/2005 4.99 4.99 9.26 FALSE TRUE Change -Subsidy -Alternate
203734 11/1/2005 0 0 0 FALSE FALSE Delisted
203742 7/1/1996 12/1/2003 16.69 16.69 16.69 FALSE TRUE New Listing
203742 12/1/2003 0 0 0 FALSE FALSE Delisted
203882 6/1/1995 12/1/2003 16.69 16.69 16.69 FALSE TRUE New Listing
203882 12/1/2003 0 0 0 FALSE FALSE Delisted
203890 5/16/1994 12/1/1997 7.39 7.39 8.5 FALSE FALSE New Listing
203890 12/1/1997 10/1/1998 6.16 6.16 8.5 FALSE FALSE Change -Subsidy -Alternate
203890 10/1/1998 11/1/1998 4.38 4.38 8.5 FALSE FALSE Change -Subsidy -Alternate
203890 11/1/1998 1/1/1999 4.38 4.38 9.71 FALSE FALSE Change +Price
203890 1/1/1999 11/1/2003 2.75 2.75 9.71 FALSE FALSE Change -Subsidy -Alternate
203890 11/1/2003 0 0 0 FALSE FALSE Delisted
203912 5/16/1994 7/1/1999 5.52 5.52 6.85 FALSE FALSE New Listing
203912 7/1/1999 11/1/2002 2.76 2.76 2.76 FALSE FALSE Change -Subsidy -Price -Alternate
203912 11/1/2002 5/1/2006 1.93 1.93 1.93 FALSE FALSE Change -Subsidy -Price -Alternate
203912 5/1/2006 9/1/2006 3.5 3.5 3.5 FALSE FALSE Change +Subsidy +Price +Alternate
203912 9/1/2006 0 0 0 FALSE FALSE Delisted
203920 5/16/1994 7/1/1999 10.39 10.39 12.47 FALSE FALSE New Listing
203920 7/1/1999 4/1/2003 5.2 5.2 5.2 FALSE FALSE Change -Subsidy -Price -Alternate
203920 4/1/2003 7/1/2003 3.45 3.45 5.2 FALSE FALSE Change -Subsidy -Alternate
203920 7/1/2003 0 0 0 FALSE FALSE Delisted
203939 6/1/1995 10/1/2003 90.75 90.75 90.75 FALSE TRUE New Listing
203939 10/1/2003 0 0 0 FALSE FALSE Delisted
203947 5/16/1994 8/1/2001 48.06 48.06 48.06 FALSE FALSE New Listing
203947 8/1/2001 1/1/2004 38.5 38.5 38.5 FALSE FALSE Change -Subsidy -Price -Alternate
203947 1/1/2004 31.76 31.76 31.76 FALSE FALSE Change -Subsidy -Price -Alternate
203971 6/1/1995 5/1/1999 150.13 150.13 150.13 FALSE TRUE New Listing
203971 5/1/1999 6/1/2000 150.13 150.13 384.95 FALSE TRUE Change +Price
203971 6/1/2000 0 0 0 FALSE FALSE Delisted
203998 5/16/1994 4/1/2004 16.31 16.31 16.31 FALSE FALSE New Listing
203998 4/1/2004 9/1/2010 16.31 16.31 17.94 FALSE FALSE Change +Price
203998 9/1/2010 17.94 17.94 17.94 FALSE FALSE Change +Subsidy +Alternate
204102 12/1/2005 102.32 102.32 102.32 FALSE FALSE New listing
204129 5/16/1994 4/1/2000 5.36 5.36 5.36 FALSE FALSE New Listing
204129 4/1/2000 3/1/2007 3.6 3.6 4.3 FALSE FALSE Change -Subsidy -Price -Alternate
204129 3/1/2007 0 0 0 FALSE FALSE Delisted
204137 5/16/1994 4/1/2000 10.28 10.28 10.28 FALSE FALSE New Listing
204137 4/1/2000 9/1/2002 7.2 7.2 7.2 FALSE FALSE Change -Subsidy -Price -Alternate
204137 9/1/2002 3/1/2007 4.3 4.3 4.3 FALSE FALSE Change -Subsidy -Price -Alternate
204137 3/1/2007 0 0 0 FALSE FALSE Delisted
204153 6/1/1995 5/1/1999 2.56 2.56 2.56 FALSE TRUE New Listing
204153 5/1/1999 11/1/1999 2.56 2.56 5.14 FALSE TRUE Change +Price
204153 11/1/1999 0 0 0 FALSE FALSE Delisted
204188 5/16/1994 2/1/1997 3.5 3.5 6.8 FALSE TRUE New Listing
204188 2/1/1997 7/1/1997 3.5 3.5 8.03 FALSE TRUE Change +Price
204188 7/1/1997 0 0 0 FALSE FALSE Delisted
204218 1/1/1999 11/1/2007 15.53 15.53 15.53 FALSE TRUE New Listing
204218 11/1/2007 2/1/2008 9.9 9.9 15.53 FALSE TRUE Change -Subsidy -Alternate
204218 2/1/2008 0 0 0 FALSE FALSE Delisted
204277 6/3/1995 8/1/1998 13.95 13.95 18.13 FALSE TRUE New Listing
204277 8/1/1998 4/1/2002 13.95 13.95 14.47 FALSE TRUE Change -Price
204277 4/1/2002 2/1/2006 13.95 13.95 13.95 FALSE TRUE Change -Price
204277 2/1/2006 0 0 0 FALSE FALSE Delisted
204315 6/1/1999 7/1/1999 13.9 13.9 13.9 FALSE FALSE New Listing
204315 7/1/1999 9/1/2001 7.48 7.48 7.48 FALSE FALSE Change -Subsidy -Price -Alternate
204315 9/1/2001 12/1/2001 3 3 3 FALSE FALSE Change -Subsidy -Price -Alternate
204315 12/1/2001 0 0 0 FALSE FALSE Delisted
204331 6/3/1995 8/1/1998 13.95 13.95 20.08 FALSE TRUE New Listing
204331 8/1/1998 4/1/2002 13.95 13.95 15.9 FALSE TRUE Change -Price
204331 4/1/2002 2/1/2006 13.95 13.95 13.95 FALSE TRUE Change -Price
204331 2/1/2006 0 0 0 FALSE FALSE Delisted
204366 12/1/1997 8/1/1998 12.19 12.19 12.19 FALSE TRUE New Listing
204366 8/1/1998 8/1/1999 8.53 8.53 8.53 FALSE TRUE Change -Subsidy -Price -Alternate
204366 8/1/1999 10/1/1999 7.31 7.31 8.53 FALSE TRUE Change -Subsidy -Alternate
204366 10/1/1999 8/1/2000 6.58 6.58 8.53 FALSE TRUE Change -Subsidy -Alternate
204366 8/1/2000 9/1/2001 3.66 3.66 8.53 FALSE TRUE Change -Subsidy -Alternate
204366 9/1/2001 4/1/2002 2.93 2.93 8.3 FALSE TRUE Change -Subsidy -Price -Alternate
204366 4/1/2002 10/1/2006 8 8 8 FALSE TRUE Change +Subsidy -Price +Alternate
204366 10/1/2006 1/1/2008 5.3 5.3 5.3 FALSE TRUE Change -Subsidy -Price -Alternate
204366 1/1/2008 3.3 3.3 3.3 FALSE TRUE Change -Subsidy -Price -Alternate
204374 12/1/1997 8/1/1998 13.95 13.95 13.95 FALSE TRUE New Listing
204374 8/1/1998 8/1/1999 9.77 9.77 9.77 FALSE TRUE Change -Subsidy -Price -Alternate
204374 8/1/1999 10/1/1999 8.37 8.37 9.77 FALSE TRUE Change -Subsidy -Alternate
204374 10/1/1999 8/1/2000 7.53 7.53 9.77 FALSE TRUE Change -Subsidy -Alternate
204374 8/1/2000 9/1/2001 4.19 4.19 9.77 FALSE TRUE Change -Subsidy -Alternate
204374 9/1/2001 4/1/2002 3.14 3.14 8.51 FALSE TRUE Change -Subsidy -Price -Alternate
204374 4/1/2002 10/1/2006 8.5 8.5 8.5 FALSE TRUE Change +Subsidy -Price +Alternate
204374 10/1/2006 1/1/2008 5.78 5.78 5.78 FALSE TRUE Change -Subsidy -Price -Alternate
204374 1/1/2008 3.78 3.78 3.78 FALSE TRUE Change -Subsidy -Price -Alternate
204404 5/16/1994 5/17/1995 4.13 4.13 4.13 FALSE FALSE New Listing
204404 5/17/1995 5/18/1995 5.5 5.5 5.5 FALSE FALSE Change +Subsidy +Price +Alternate
204404 5/18/1995 6/15/1995 4.13 4.13 5.5 FALSE FALSE Change -Subsidy -Alternate
204404 6/15/1995 3/1/2001 4.13 4.13 4.13 FALSE FALSE Change -Price
204404 3/1/2001 5/1/2001 8.93 8.93 8.93 FALSE FALSE Change +Subsidy +Price +Alternate
204404 5/1/2001 0 0 0 FALSE FALSE Delisted
204412 6/15/1995 3/1/2001 20.65 20.65 20.65 FALSE FALSE New Listing
204412 3/1/2001 5/1/2001 44.64 44.64 44.64 FALSE FALSE Change +Subsidy +Price +Alternate
204412 5/1/2001 0 0 0 FALSE FALSE Delisted
204420 5/16/1995 2/1/2001 7.75 7.75 7.75 FALSE TRUE New Listing
204420 2/1/2001 3/1/2002 7.75 7.75 8.14 FALSE TRUE Change +Price
204420 3/1/2002 6/1/2003 7.75 7.75 8.71 FALSE TRUE Change +Price
204420 6/1/2003 0 0 0 FALSE FALSE Delisted
204471 5/16/1994 12/1/2008 9.36 9.36 9.36 FALSE FALSE New Listing
204471 12/1/2008 19 19 19 FALSE FALSE Change +Subsidy +Price +Alternate
204498 5/16/1994 7.38 7.38 7.38 FALSE TRUE New Listing
204501 5/16/1994 3/1/1995 12.29 12.29 12.29 FALSE FALSE New Listing
204501 3/1/1995 1/1/2001 12.28 12.28 12.28 FALSE FALSE Change -Subsidy -Price -Alternate
204501 1/1/2001 3/1/2003 9.85 9.85 9.85 FALSE FALSE Change -Subsidy -Price -Alternate
204501 3/1/2003 6/1/2003 6 6 6 FALSE FALSE Change -Subsidy -Price -Alternate
204501 6/1/2003 0 0 0 FALSE FALSE Delisted
204528 ######## 9/1/2000 2.43 2.43 2.43 FALSE FALSE New Listing
204528 9/1/2000 0 0 0 FALSE FALSE Delisted
204536 5/16/1994 3/1/1995 23.24 23.24 23.24 FALSE FALSE New Listing
204536 3/1/1995 1/1/2001 23.23 23.23 23.23 FALSE FALSE Change -Subsidy -Price -Alternate
204536 1/1/2001 3/1/2003 18.58 18.58 18.58 FALSE FALSE Change -Subsidy -Price -Alternate
204536 3/1/2003 6/1/2003 11 11 11 FALSE FALSE Change -Subsidy -Price -Alternate
204536 6/1/2003 0 0 0 FALSE FALSE Delisted
204544 10/1/2004 7/1/2007 55.23 55.23 55.23 FALSE FALSE New listing
204544 7/1/2007 0 0 0 FALSE FALSE Delisted
204595 5/16/1994 5/1/1998 19.5 19.5 19.5 FALSE FALSE New Listing
204595 5/1/1998 8/1/1998 8.64 8.64 19.5 FALSE FALSE Change -Subsidy -Alternate
204595 8/1/1998 0 0 0 FALSE FALSE Delisted
204617 5/16/1994 5/1/1998 38.96 38.96 38.96 FALSE FALSE New Listing
204617 5/1/1998 8/1/1998 14.49 14.49 38.96 FALSE FALSE Change -Subsidy -Alternate
204617 8/1/1998 0 0 0 FALSE FALSE Delisted
204625 5/16/1994 ######## 23.05 23.05 23.05 FALSE FALSE New Listing
204625 ######## 5/1/1998 23.05 23.05 23.04 FALSE FALSE Change -Price
204625 5/1/1998 8/1/1998 7.03 7.03 23.04 FALSE FALSE Change -Subsidy +Price -Alternate
204625 8/1/1998 0 0 0 FALSE FALSE Delisted
204641 5/16/1994 7/1/1999 2.2 2.2 2.94 FALSE FALSE New Listing
204641 7/1/1999 11/1/1999 1.59 1.59 2.7 FALSE FALSE Change -Subsidy -Price -Alternate
204641 11/1/1999 0 0 0 FALSE FALSE Delisted
204676 5/16/1994 7/1/1999 59.65 59.65 72.18 FALSE FALSE New Listing
204676 7/1/1999 11/1/1999 22.79 22.79 45 FALSE FALSE Change -Subsidy -Price -Alternate
204676 11/1/1999 0 0 0 FALSE FALSE Delisted
204706 6/1/1995 4/1/2001 86.25 86.25 86.25 FALSE FALSE New Listing
204706 4/1/2001 10/1/2009 57.5 57.5 57.5 FALSE FALSE Change -Subsidy -Price -Alternate
204706 10/1/2009 7/1/2013 40 40 40 FALSE FALSE Change -Subsidy -Price -Alternate
204706 7/1/2013 0 0 0 FALSE FALSE Delisted
204714 11/1/1997 2/1/2000 26.64 26.64 26.64 FALSE FALSE New Listing
204714 2/1/2000 6/1/2001 21.6 21.6 26.64 FALSE FALSE Change -Subsidy -Alternate
204714 6/1/2001 0 0 0 FALSE FALSE Delisted
204730 10/1/2004 7/1/2007 100.52 100.52 100.52 FALSE FALSE New listing
204730 7/1/2007 0 0 0 FALSE FALSE Delisted
204757 5/16/1994 12/1/1997 27.95 27.95 27.95 FALSE FALSE New Listing
204757 12/1/1997 0 0 0 FALSE FALSE Delisted
204781 5/16/1994 12/1/1997 42.07 42.07 42.07 FALSE FALSE New Listing
204781 12/1/1997 11/1/1998 25.24 25.24 25.24 FALSE FALSE Change -Subsidy -Price -Alternate
204781 11/1/1998 7/1/2000 6.17 6.17 25.24 FALSE FALSE Change -Subsidy -Alternate
204781 7/1/2000 0 0 0 FALSE FALSE Delisted
204803 10/1/2004 7/1/2007 139.18 139.18 139.18 FALSE FALSE New listing
204803 7/1/2007 0 0 0 FALSE FALSE Delisted
204838 5/16/1994 5/1/1996 9.45 9.45 13.2 FALSE FALSE New Listing
204838 5/1/1996 8/1/2000 9.45 13.8 13.8 FALSE FALSE Change +Price +Alternate
204838 8/1/2000 6/1/2002 9.45 14.49 14.49 FALSE FALSE Change +Price +Alternate
204838 6/1/2002 0 0 0 FALSE FALSE Delisted
204846 5/16/1994 9/1/1997 35 35 35 FALSE FALSE New Listing
204846 9/1/1997 0 0 0 FALSE FALSE Delisted
204854 5/16/1994 7/1/1999 3.46 3.46 5 FALSE FALSE New Listing
204854 7/1/1999 11/1/1999 2.49 2.49 5 FALSE FALSE Change -Subsidy -Alternate
204854 11/1/1999 0 0 0 FALSE FALSE Delisted
204870 5/16/1994 7/1/1999 5.31 5.31 8.17 FALSE FALSE New Listing
204870 7/1/1999 11/1/1999 2.59 2.59 8.17 FALSE FALSE Change -Subsidy -Alternate
204870 11/1/1999 0 0 0 FALSE FALSE Delisted
204889 10/1/2004 7/1/2007 171.22 171.22 171.22 FALSE FALSE New listing
204889 7/1/2007 0 0 0 FALSE FALSE Delisted
204897 5/16/1994 7/1/1999 12.93 12.93 13.83 FALSE FALSE New Listing
204897 7/1/1999 11/1/1999 6.98 6.98 13.83 FALSE FALSE Change -Subsidy -Alternate
204897 11/1/1999 0 0 0 FALSE FALSE Delisted
204919 6/1/1998 2/1/1999 11.35 11.35 33 FALSE FALSE New Listing
204919 2/1/1999 3/1/2000 11.35 11.35 42.9 FALSE FALSE Change +Price
204919 3/1/2000 2/1/2002 11.35 11.35 49 FALSE FALSE Change +Price
204919 2/1/2002 8/1/2002 11.35 11.35 51.45 FALSE FALSE Change +Price
204919 8/1/2002 0 0 0 FALSE FALSE Delisted
204927 7/1/1997 6/1/1998 13.88 13.88 18 FALSE FALSE New Listing
204927 6/1/1998 2/1/1999 13.88 13.88 20.16 FALSE FALSE Change +Price
204927 2/1/1999 3/1/2000 13.88 13.88 26.2 FALSE FALSE Change +Price
204927 3/1/2000 2/1/2002 13.88 13.88 29.8 FALSE FALSE Change +Price
204927 2/1/2002 8/1/2002 13.88 13.88 31.3 FALSE FALSE Change +Price
204927 8/1/2002 0 0 0 FALSE FALSE Delisted
204935 5/16/1994 2/1/1998 8.62 8.62 10.17 FALSE FALSE New Listing
204935 2/1/1998 8/1/2000 5.17 5.17 10.17 FALSE FALSE Change -Subsidy -Alternate
204935 8/1/2000 12/1/2000 2.65 2.65 2.65 FALSE FALSE Change -Subsidy -Price -Alternate
204935 12/1/2000 0 0 0 FALSE FALSE Delisted
204943 ######## 3/1/2003 5.96 5.96 5.96 FALSE FALSE New Listing
204943 3/1/2003 0 0 0 FALSE FALSE Delisted
204951 5/16/1994 4/1/2011 7.62 7.62 7.62 FALSE FALSE New Listing
204951 4/1/2011 14.32 14.32 14.32 FALSE FALSE Change +Subsidy +Price +Alternate
204986 ######## 9/1/2003 6.86 6.86 7.23 FALSE FALSE New Listing
204986 9/1/2003 12/1/2003 7.33 7.33 7.23 FALSE FALSE Change +Subsidy +Alternate
204986 12/1/2003 0 0 0 FALSE FALSE Delisted
204994 ######## 9/1/2003 9.48 9.48 9.98 FALSE FALSE New Listing
204994 9/1/2003 12/1/2003 9.95 9.95 9.98 FALSE FALSE Change +Subsidy -Price +Alternate
204994 12/1/2003 0 0 0 FALSE FALSE Delisted
205001 ######## 8/1/2000 15.53 15.53 17.28 FALSE FALSE New Listing
205001 8/1/2000 9/1/2003 15.53 15.53 20.57 FALSE FALSE Change -Subsidy +Price -Alternate
205001 9/1/2003 12/1/2003 16 16 20.57 FALSE FALSE Change +Subsidy +Price +Alternate
205001 12/1/2003 0 0 0 FALSE FALSE Delisted
205028 5/16/1994 9/1/2002 4.13 4.13 4.13 FALSE TRUE New Listing
205028 9/1/2002 5/1/2008 3.6 3.6 3.6 FALSE TRUE Change -Subsidy -Price -Alternate
205028 5/1/2008 0 0 0 FALSE FALSE Delisted
205044 5/16/1994 3/1/1998 3.47 3.47 5.05 FALSE TRUE New Listing
205044 3/1/1998 10/1/1998 3.33 3.33 5.05 FALSE TRUE Change -Subsidy -Alternate
205044 10/1/1998 1/1/1999 1.83 1.83 5.05 FALSE TRUE Change -Subsidy -Alternate
205044 1/1/1999 4/1/2002 1 1 5.05 FALSE TRUE Change -Subsidy -Alternate
205044 4/1/2002 0 0 0 FALSE FALSE Delisted
205052 5/16/1994 3/1/1998 6.67 6.67 8.4 FALSE TRUE New Listing
205052 3/1/1998 10/1/1998 3.33 3.33 8.4 FALSE TRUE Change -Subsidy -Alternate
205052 10/1/1998 1/1/1999 1.83 1.83 8.4 FALSE TRUE Change -Subsidy -Alternate
205052 1/1/1999 4/1/2001 1 1 8.4 FALSE TRUE Change -Subsidy -Alternate
205052 4/1/2001 0 0 0 FALSE FALSE Delisted
205095 5/16/1994 12/1/1997 7.39 7.39 8.5 FALSE FALSE New Listing
205095 12/1/1997 10/1/1998 6.16 6.16 8.5 FALSE FALSE Change -Subsidy -Alternate
205095 10/1/1998 1/1/1999 4.38 4.38 8.5 FALSE FALSE Change -Subsidy -Alternate
205095 1/1/1999 4/1/2002 2.75 2.75 8.5 FALSE FALSE Change -Subsidy -Alternate
205095 4/1/2002 0 0 0 FALSE FALSE Delisted
205133 5/16/1994 7/1/1995 4.48 4.48 6.09 FALSE FALSE New Listing
205133 7/1/1995 9/1/2000 4.48 4.48 10 FALSE TRUE Change +Price +OP
205133 9/1/2000 0 0 0 FALSE FALSE Delisted
205141 5/16/1994 2/1/1996 4.72 4.72 5.32 FALSE FALSE New Listing
205141 2/1/1996 4/1/1996 4.48 4.48 5.32 FALSE FALSE Change -Subsidy -Alternate
205141 4/1/1996 8/1/1999 4.48 4.48 5.53 FALSE FALSE Change +Price
205141 8/1/1999 12/1/1999 2.75 2.75 3.39 FALSE FALSE Change -Subsidy -Price -Alternate
205141 12/1/1999 0 0 0 FALSE FALSE Delisted
205168 5/16/1994 2/1/1996 7.08 7.08 8.8 FALSE FALSE New Listing
205168 2/1/1996 4/1/1996 6.72 6.72 8.8 FALSE FALSE Change -Subsidy -Alternate
205168 4/1/1996 8/1/1999 6.72 6.72 8.32 FALSE FALSE Change -Price
205168 8/1/1999 12/1/1999 4.13 4.13 5.11 FALSE FALSE Change -Subsidy -Price -Alternate
205168 12/1/1999 0 0 0 FALSE FALSE Delisted
205257 10/4/1997 8/1/1999 22.29 22.29 25.2 FALSE FALSE New Listing
205257 8/1/1999 8/1/2000 14.99 14.99 25.2 FALSE FALSE Change -Subsidy -Alternate
205257 8/1/2000 0 0 0 FALSE FALSE Delisted
205265 5/16/1994 3/1/1998 4.6 4.6 9 FALSE TRUE New Listing
205265 3/1/1998 10/1/1998 3.33 3.33 9 FALSE TRUE Change -Subsidy -Alternate
205265 10/1/1998 12/1/1998 1.83 1.83 9 FALSE TRUE Change -Subsidy -Alternate
205265 12/1/1998 0 0 0 FALSE FALSE Delisted
205273 10/4/1997 7/1/1998 22.29 22.29 25.2 FALSE FALSE New Listing
205273 7/1/1998 8/1/1999 22.29 22.29 22.29 FALSE FALSE Change -Price
205273 8/1/1999 10/1/2000 14.99 14.99 22.29 FALSE FALSE Change -Subsidy -Alternate
205273 10/1/2000 14.95 14.95 22.29 FALSE FALSE Change -Subsidy -Alternate
205311 5/16/1994 4/1/1996 47.06 47.06 47.06 FALSE FALSE New Listing
205311 4/1/1996 9/1/1996 44.58 44.58 47.06 FALSE FALSE Change -Subsidy -Alternate
205311 9/1/1996 7/1/1998 44.58 44.58 50.55 FALSE FALSE Change +Price
205311 7/1/1998 8/1/1999 44.58 44.58 44.58 FALSE FALSE Change -Price
205311 8/1/1999 10/1/2000 29.98 29.98 44.58 FALSE FALSE Change -Subsidy -Alternate
205311 10/1/2000 29.9 29.9 44.58 FALSE FALSE Change -Subsidy -Alternate
205346 5/16/1994 6/1/2002 9.91 9.91 9.91 FALSE FALSE New Listing
205346 6/1/2002 0 0 0 FALSE FALSE Delisted
205354 3/1/1995 7/1/2003 8.81 8.81 8.81 FALSE FALSE New Listing
205354 7/1/2003 0 0 0 FALSE FALSE Delisted
205370 6/17/1995 12/1/2002 23.29 23.29 23.29 FALSE FALSE New Listing
205370 12/1/2002 0 0 0 FALSE FALSE Delisted
205397 5/16/1994 7/1/1998 35.97 35.97 35.97 FALSE FALSE New Listing
205397 7/1/1998 9/1/2006 35.97 35.97 44.85 FALSE FALSE Change +Price
205397 9/1/2006 0 0 0 FALSE FALSE Delisted
205494 8/1/1996 9/1/1997 9.2 9.2 9.2 FALSE FALSE New Listing
205494 9/1/1997 1/1/1998 9.2 9.2 10.8 FALSE FALSE Change +Price
205494 1/1/1998 7/1/1998 9.2 9.2 12.42 FALSE FALSE Change +Price
205494 7/1/1998 2/1/1999 9.2 9.2 13.36 FALSE FALSE Change +Price
205494 2/1/1999 8/1/2001 10.31 10.31 13.36 FALSE FALSE Change +Subsidy +Alternate
205494 8/1/2001 2/1/2005 13.36 13.36 13.36 FALSE FALSE Change +Subsidy +Alternate
205494 2/1/2005 0 0 0 FALSE FALSE Delisted
205508 1/1/1998 7/1/1998 1.87 1.87 2.37 FALSE FALSE New Listing
205508 7/1/1998 2/1/1999 1.87 1.87 2.77 FALSE FALSE Change +Price
205508 2/1/1999 8/1/2001 2.48 2.48 2.77 FALSE FALSE Change +Subsidy +Alternate
205508 8/1/2001 1/1/2002 2.77 2.77 2.77 FALSE FALSE Change +Subsidy +Alternate
205508 1/1/2002 7/1/2002 2.77 2.77 3.07 FALSE FALSE Change -Subsidy +Price -Alternate
205508 7/1/2002 0 0 0 FALSE FALSE Delisted
205516 1/1/1998 5/1/2004 11.73 11.73 14.32 FALSE FALSE New Listing
205516 5/1/2004 0 0 0 FALSE FALSE Delisted
205524 1/1/1998 7/1/1998 0.92 0.92 1.24 FALSE FALSE New Listing
205524 7/1/1998 2/1/1999 0.92 0.92 1.34 FALSE FALSE Change +Price
205524 2/1/1999 8/1/2001 1.03 1.03 1.34 FALSE FALSE Change +Subsidy +Alternate
205524 8/1/2001 5/1/2004 1.34 1.34 1.34 FALSE FALSE Change +Subsidy +Alternate
205524 5/1/2004 0 0 0 FALSE FALSE Delisted
205567 10/1/1997 2/1/1999 1.87 1.87 2.95 FALSE FALSE New Listing
205567 2/1/1999 3/1/2001 2.48 2.48 2.95 FALSE FALSE Change +Subsidy +Alternate
205567 3/1/2001 0 0 0 FALSE FALSE Delisted
205575 5/16/1994 8/1/1996 1.52 1.52 1.52 FALSE FALSE New Listing
205575 8/1/1996 10/1/1997 11.73 11.73 15.17 FALSE FALSE Change +Subsidy +Price +Alternate
205575 10/1/1997 3/1/2001 11.73 11.73 15.16 FALSE FALSE Change -Price
205575 3/1/2001 0 0 0 FALSE FALSE Delisted
205621 5/16/1994 7/1/1999 9.82 9.82 9.82 FALSE FALSE New Listing
205621 7/1/1999 6/1/2003 8.83 8.83 8.83 FALSE FALSE Change -Subsidy -Price -Alternate
205621 6/1/2003 10/1/2009 7.95 7.95 7.95 FALSE FALSE Change -Subsidy -Price -Alternate
205621 10/1/2009 9/1/2012 8.35 8.35 8.35 FALSE FALSE Change +Subsidy +Price +Alternate
205621 9/1/2012 8.1 8.1 8.1 FALSE FALSE Change -Subsidy -Price -Alternate
205648 5/16/1994 7/1/1999 18.26 18.26 18.26 FALSE FALSE New Listing
205648 7/1/1999 6/1/2003 16.43 16.43 16.43 FALSE FALSE Change -Subsidy -Price -Alternate
205648 6/1/2003 10/1/2006 14.27 14.27 14.27 FALSE FALSE Change -Subsidy -Price -Alternate
205648 10/1/2006 10/1/2009 19.95 19.95 19.95 FALSE FALSE Change +Subsidy +Price +Alternate
205648 10/1/2009 9/1/2012 20.95 20.95 20.95 FALSE FALSE Change +Subsidy +Price +Alternate
205648 9/1/2012 20.32 20.32 20.32 FALSE FALSE Change -Subsidy -Price -Alternate
205664 10/4/1997 9/1/2000 4.33 4.33 4.33 FALSE FALSE New Listing
205664 9/1/2000 7/1/2001 1.64 1.64 1.64 FALSE FALSE Change -Subsidy -Price -Alternate
205664 7/1/2001 0 0 0 FALSE FALSE Delisted
205672 10/4/1997 9/1/2000 21.65 21.65 21.65 FALSE FALSE New Listing
205672 9/1/2000 5/1/2002 8.2 8.2 8.2 FALSE FALSE Change -Subsidy -Price -Alternate
205672 5/1/2002 0 0 0 FALSE FALSE Delisted
205680 5/16/1994 9/1/2000 9.97 9.97 9.97 FALSE FALSE New Listing
205680 9/1/2000 9/1/2004 4.2 4.2 4.2 FALSE FALSE Change -Subsidy -Price -Alternate
205680 9/1/2004 12/1/2004 3.92 3.92 4.2 FALSE FALSE Change -Subsidy -Alternate
205680 12/1/2004 0 0 0 FALSE FALSE Delisted
205737 5/16/1994 2/1/1999 29.81 29.81 29.81 FALSE FALSE New Listing
205737 2/1/1999 0 0 0 FALSE FALSE Delisted
205745 5/16/1994 4/1/2002 49.25 49.25 49.25 FALSE FALSE New Listing
205745 4/1/2002 0 0 0 FALSE FALSE Delisted
205893 5/16/1994 8/1/2000 4.4 4.4 4.4 FALSE FALSE New Listing
205893 8/1/2000 0 0 0 FALSE FALSE Delisted
205915 5/16/1994 8/1/2000 10.28 10.28 10.28 FALSE FALSE New Listing
205915 8/1/2000 0 0 0 FALSE FALSE Delisted
205966 5/16/1994 8/1/1997 40.08 40.08 40.08 FALSE FALSE New Listing
205966 8/1/1997 0 0 0 FALSE FALSE Delisted
205982 4/11/1995 6/27/1995 47.87 47.87 61.42 FALSE FALSE New Listing
205982 6/27/1995 10/1/2002 47.87 47.87 47.87 FALSE FALSE Change -Price
205982 10/1/2002 0 0 0 FALSE FALSE Delisted
205990 4/11/1995 1/1/2003 47.87 47.87 47.87 FALSE FALSE New Listing
205990 1/1/2003 4/1/2003 46.2 46.2 47.87 FALSE FALSE Change -Subsidy -Alternate
205990 4/1/2003 0 0 0 FALSE FALSE Delisted
206024 5/16/1994 11/1/1996 2.98 2.98 3.71 FALSE FALSE New Listing
206024 11/1/1996 4/1/2001 2.98 2.98 12.76 FALSE FALSE Change +Price
206024 4/1/2001 0 0 0 FALSE FALSE Delisted
206032 5/16/1994 4/3/1995 9.59 9.59 9.59 FALSE FALSE New Listing
206032 4/3/1995 1/1/1998 7.5 7.5 7.5 FALSE FALSE Change -Subsidy -Price -Alternate
206032 1/1/1998 0 0 0 FALSE FALSE Delisted
206040 6/10/1995 9/1/2002 3.48 3.48 6.56 FALSE TRUE New Listing
206040 9/1/2002 0 0 0 FALSE FALSE Delisted
206075 5/16/1994 4/1/2006 6.79 6.79 6.79 FALSE TRUE New Listing
206075 4/1/2006 0 0 0 FALSE FALSE Delisted
206083 5/16/1994 4/1/1997 2.97 2.97 3.65 FALSE TRUE New Listing
206083 4/1/1997 2/1/2000 2.97 2.97 4.65 FALSE TRUE Change +Price
206083 2/1/2000 3/1/2001 2.97 2.97 4.95 FALSE TRUE Change +Price
206083 3/1/2001 4/1/2002 2.97 2.97 5.45 FALSE TRUE Change +Price
206083 4/1/2002 4/1/2003 2.97 2.97 6 FALSE TRUE Change +Price
206083 4/1/2003 4/1/2004 2.97 2.97 6.6 FALSE TRUE Change +Price
206083 4/1/2004 7/1/2006 2.97 2.97 7.26 FALSE TRUE Change +Price
206083 7/1/2006 3/1/2009 2.97 2.97 7.99 FALSE TRUE Change +Price
206083 3/1/2009 0 0 0 FALSE FALSE Delisted
206105 3/1/1995 7/1/2001 24.2 24.2 24.2 FALSE FALSE New Listing
206105 7/1/2001 4/1/2002 24.2 24.2 29.04 FALSE FALSE Change +Price
206105 4/1/2002 8/1/2003 24.2 24.2 31 FALSE FALSE Change +Price
206105 8/1/2003 31 31 31 FALSE FALSE Change +Subsidy +Alternate
206180 5/16/1994 8/1/1995 4.85 4.85 4.85 FALSE FALSE New Listing
206180 8/1/1995 5/1/1998 4.84 4.84 4.84 FALSE FALSE Change -Subsidy -Price -Alternate
206180 5/1/1998 0 0 0 FALSE FALSE Delisted
206229 4/3/1995 9/1/2002 8.55 8.55 8.55 FALSE FALSE New Listing
206229 9/1/2002 0 0 0 FALSE FALSE Delisted
206245 4/3/1995 4/1/2002 9.91 9.91 9.91 FALSE FALSE New Listing
206245 4/1/2002 10/1/2007 9.96 9.96 9.96 FALSE FALSE Change +Subsidy +Price +Alternate
206245 10/1/2007 11/1/2011 15.13 15.13 15.13 FALSE FALSE Change +Subsidy +Price +Alternate
206245 11/1/2011 0 0 0 FALSE FALSE Delisted
206261 7/1/1996 6/1/1999 32.2 32.2 32.2 FALSE FALSE New Listing
206261 6/1/1999 0 0 0 FALSE FALSE Delisted
206318 7/1/1996 5/1/1999 7.55 7.55 7.55 FALSE FALSE New Listing
206318 5/1/1999 0 0 0 FALSE FALSE Delisted
206326 7/1/1996 5/1/1999 37.75 37.75 37.75 FALSE FALSE New Listing
206326 5/1/1999 0 0 0 FALSE FALSE Delisted
206377 10/1/1997 2/1/1999 9.37 9.37 14.76 FALSE FALSE New Listing
206377 2/1/1999 3/1/2001 12.4 12.4 14.76 FALSE FALSE Change +Subsidy +Alternate
206377 3/1/2001 0 0 0 FALSE FALSE Delisted
206474 10/1/1997 2/1/1998 17.97 17.97 17.97 FALSE FALSE New Listing
206474 2/1/1998 9/1/2000 13.48 13.48 13.48 FALSE FALSE Change -Subsidy -Price -Alternate
206474 9/1/2000 10/1/2000 3.85 3.85 13.48 FALSE FALSE Change -Subsidy -Alternate
206474 10/1/2000 1/1/2001 3.85 3.85 10.11 FALSE FALSE Change -Price
206474 1/1/2001 0 0 0 FALSE FALSE Delisted
206482 5/16/1994 5/26/1995 112.29 112.29 112.29 FALSE FALSE New Listing
206482 5/26/1995 10/1/1997 112.31 112.31 112.31 FALSE FALSE Change +Subsidy +Price +Alternate
206482 10/1/1997 2/1/1998 89.85 89.85 89.85 FALSE FALSE Change -Subsidy -Price -Alternate
206482 2/1/1998 9/1/2000 67.39 67.39 67.39 FALSE FALSE Change -Subsidy -Price -Alternate
206482 9/1/2000 10/1/2000 19.25 19.25 67.39 FALSE FALSE Change -Subsidy -Alternate
206482 10/1/2000 1/1/2001 19.25 19.25 50.55 FALSE FALSE Change -Price
206482 1/1/2001 0 0 0 FALSE FALSE Delisted
206504 5/16/1994 10/1/1997 43.63 43.63 43.63 FALSE FALSE New Listing
206504 10/1/1997 2/1/1998 34.9 34.9 34.9 FALSE FALSE Change -Subsidy -Price -Alternate
206504 2/1/1998 9/1/2000 26.17 26.17 26.17 FALSE FALSE Change -Subsidy -Price -Alternate
206504 9/1/2000 10/1/2000 6.3 6.3 26.17 FALSE FALSE Change -Subsidy -Alternate
206504 10/1/2000 1/1/2001 6.3 6.3 15.7 FALSE FALSE Change -Price
206504 1/1/2001 0 0 0 FALSE FALSE Delisted
206512 5/16/1994 8/1/2000 7.5 7.5 7.5 FALSE TRUE New Listing
206512 8/1/2000 2/1/2001 7.5 7.5 8.25 FALSE TRUE Change +Price
206512 2/1/2001 3/1/2002 7.5 7.5 9.08 FALSE TRUE Change +Price
206512 3/1/2002 1/1/2003 3.17 3.17 3.17 FALSE TRUE Change -Subsidy -Price -Alternate
206512 1/1/2003 8/1/2006 0 0 0 FALSE FALSE Delisted
206512 8/1/2006 1/1/2009 7.25 7.25 7.25 FALSE TRUE New Listing
206512 1/1/2009 4/1/2009 2.67 2.67 7.25 FALSE TRUE Change -Subsidy -Alternate
206512 4/1/2009 0 0 0 FALSE FALSE Delisted
206547 3/1/1999 2/1/2007 19 19 19 FALSE FALSE New Listing
206547 2/1/2007 2/1/2008 18 18 18 FALSE FALSE Change -Subsidy -Price -Alternate
206547 2/1/2008 1/1/2010 17 17 17 FALSE FALSE Change -Subsidy -Price -Alternate
206547 1/1/2010 16.5 16.5 16.5 FALSE FALSE Change -Subsidy -Price -Alternate
206563 5/30/1995 ######## 3.98 3.98 3.98 FALSE FALSE New Listing
206563 ######## 10/1/2000 3.98 3.98 4.38 FALSE FALSE Change +Price
206563 10/1/2000 8/1/2010 3.98 3.98 4.9 FALSE FALSE Change +Price
206563 8/1/2010 0 0 0 FALSE FALSE Delisted
206571 5/30/1995 7/1/1997 19.91 19.91 19.91 FALSE FALSE New Listing
206571 7/1/1997 3/1/2009 19.91 19.91 24.5 FALSE FALSE Change +Price
206571 3/1/2009 8/1/2010 19.91 19.91 33.14 FALSE FALSE Change +Price
206571 8/1/2010 0 0 0 FALSE FALSE Delisted
206660 5/16/1994 6/1/1998 10.52 10.52 10.52 FALSE FALSE New Listing
206660 6/1/1998 2/1/2000 7.6 7.6 7.6 FALSE FALSE Change -Subsidy -Price -Alternate
206660 2/1/2000 11/1/2000 6.58 6.58 7.6 FALSE FALSE Change -Subsidy -Alternate
206660 11/1/2000 1/1/2003 7.6 7.6 7.6 FALSE FALSE Change +Subsidy +Alternate
206660 1/1/2003 0 0 0 FALSE FALSE Delisted
206687 5/16/1994 6/1/1998 13.69 13.69 13.69 FALSE FALSE New Listing
206687 6/1/1998 2/1/2000 8.4 8.4 8.4 FALSE FALSE Change -Subsidy -Price -Alternate
206687 2/1/2000 11/1/2000 7.9 7.9 8.4 FALSE FALSE Change -Subsidy -Alternate
206687 11/1/2000 1/1/2003 10.6 10.6 10.6 FALSE FALSE Change +Subsidy +Price +Alternate
206687 1/1/2003 0 0 0 FALSE FALSE Delisted
206709 5/16/1994 6/1/1998 24.69 24.69 24.69 FALSE FALSE New Listing
206709 6/1/1998 2/1/2000 22 22 22 FALSE FALSE Change -Subsidy -Price -Alternate
206709 2/1/2000 1/1/2003 20.1 20.1 22 FALSE FALSE Change -Subsidy -Alternate
206709 1/1/2003 0 0 0 FALSE FALSE Delisted
206717 5/16/1994 6/1/1998 10.52 10.52 10.52 FALSE FALSE New Listing
206717 6/1/1998 2/1/2000 7.6 7.6 7.6 FALSE FALSE Change -Subsidy -Price -Alternate
206717 2/1/2000 11/1/2000 6.58 6.58 6.58 FALSE FALSE Change -Subsidy -Price -Alternate
206717 11/1/2000 12/1/2001 7.6 7.6 7.6 FALSE FALSE Change +Subsidy +Price +Alternate
206717 12/1/2001 7/1/2003 7.6 7.6 8.2 FALSE FALSE Change +Price
206717 7/1/2003 8/1/2004 8.2 8.2 8.2 FALSE FALSE Change +Subsidy +Alternate
206717 8/1/2004 7/1/2007 7 7 7 FALSE FALSE Change -Subsidy -Price -Alternate
206717 7/1/2007 1/1/2008 6.65 6.65 6.65 FALSE FALSE Change -Subsidy -Price -Alternate
206717 1/1/2008 1/1/2010 5.5 5.5 5.5 FALSE FALSE Change -Subsidy -Price -Alternate
206717 1/1/2010 5/1/2013 5.39 5.39 5.39 FALSE FALSE Change -Subsidy -Price -Alternate
206717 5/1/2013 4.75 4.75 4.75 FALSE FALSE Change -Subsidy -Price -Alternate
206725 5/16/1994 6/1/1998 52.6 52.6 42.87 FALSE FALSE New Listing
206725 6/1/1998 2/1/2000 38 38 38 FALSE FALSE Change -Subsidy -Price -Alternate
206725 2/1/2000 3/1/2001 32.9 32.9 32.9 FALSE FALSE Change -Subsidy -Price -Alternate
206725 3/1/2001 0 0 0 FALSE FALSE Delisted
206733 5/16/1994 6/1/1998 13.69 13.69 13.69 FALSE FALSE New Listing
206733 6/1/1998 2/1/2000 8.4 8.4 8.4 FALSE FALSE Change -Subsidy -Price -Alternate
206733 2/1/2000 11/1/2000 7.9 7.9 7.9 FALSE FALSE Change -Subsidy -Price -Alternate
206733 11/1/2000 12/1/2001 10.6 10.6 10.6 FALSE FALSE Change +Subsidy +Price +Alternate
206733 12/1/2001 7/1/2003 10.6 10.6 12.7 FALSE FALSE Change +Price
206733 7/1/2003 8/1/2004 12.7 12.7 12.7 FALSE FALSE Change +Subsidy +Alternate
206733 8/1/2004 7/1/2007 10 10 10 FALSE FALSE Change -Subsidy -Price -Alternate
206733 7/1/2007 1/1/2008 9.75 9.75 9.75 FALSE FALSE Change -Subsidy -Price -Alternate
206733 1/1/2008 1/1/2010 8.5 8.5 8.5 FALSE FALSE Change -Subsidy -Price -Alternate
206733 1/1/2010 5/1/2013 8.25 8.25 8.25 FALSE FALSE Change -Subsidy -Price -Alternate
206733 5/1/2013 5.8 5.8 5.8 FALSE FALSE Change -Subsidy -Price -Alternate
206741 5/16/1994 6/1/1998 68.45 68.45 68.45 FALSE FALSE New Listing
206741 6/1/1998 2/1/2000 42 42 42 FALSE FALSE Change -Subsidy -Price -Alternate
206741 2/1/2000 3/1/2001 39.5 39.5 39.5 FALSE FALSE Change -Subsidy -Price -Alternate
206741 3/1/2001 0 0 0 FALSE FALSE Delisted
206776 5/16/1994 6/1/1998 24.69 24.69 24.69 FALSE FALSE New Listing
206776 6/1/1998 2/1/2000 22 22 22 FALSE FALSE Change -Subsidy -Price -Alternate
206776 2/1/2000 12/1/2001 20.1 20.1 20.1 FALSE FALSE Change -Subsidy -Price -Alternate
206776 12/1/2001 7/1/2003 20.1 20.1 23.75 FALSE FALSE Change +Price
206776 7/1/2003 8/1/2004 23.75 23.75 23.75 FALSE FALSE Change +Subsidy +Alternate
206776 8/1/2004 7/1/2007 20 20 20 FALSE FALSE Change -Subsidy -Price -Alternate
206776 7/1/2007 1/1/2008 19.65 19.65 19.65 FALSE FALSE Change -Subsidy -Price -Alternate
206776 1/1/2008 1/1/2010 18.5 18.5 18.5 FALSE FALSE Change -Subsidy -Price -Alternate
206776 1/1/2010 5/1/2013 17.76 17.76 17.76 FALSE FALSE Change -Subsidy -Price -Alternate
206776 5/1/2013 12.5 12.5 12.5 FALSE FALSE Change -Subsidy -Price -Alternate
206830 5/16/1994 4/1/2002 8.09 8.09 8.09 FALSE FALSE New Listing
206830 4/1/2002 6/1/2006 8.09 8.09 12.65 FALSE FALSE Change +Price
206830 6/1/2006 0 0 0 FALSE FALSE Delisted
206857 5/16/1994 4/1/2002 18.68 18.68 18.68 FALSE FALSE New Listing
206857 4/1/2002 2/1/2006 18.68 18.68 25 FALSE FALSE Change +Price
206857 2/1/2006 0 0 0 FALSE FALSE Delisted
206865 5/16/1994 11/1/1999 6.97 6.97 9.49 FALSE FALSE New Listing
206865 11/1/1999 11/1/2000 6.97 6.97 6.97 FALSE FALSE Change -Price
206865 11/1/2000 0 0 0 FALSE FALSE Delisted
207012 5/16/1994 12/1/2001 8.69 8.69 8.69 FALSE TRUE New Listing
207012 12/1/2001 0 0 0 FALSE FALSE Delisted
207020 5/30/1995 6/1/1996 20.52 20.52 20.52 FALSE FALSE New Listing
207020 6/1/1996 8/1/1998 20.52 20.52 24.5 FALSE FALSE Change +Price
207020 8/1/1998 12/1/1998 20.52 20.52 26.95 FALSE FALSE Change +Price
207020 12/1/1998 3/1/1999 14.5 14.5 14.5 FALSE FALSE Change -Subsidy -Price -Alternate
207020 3/1/1999 0 0 0 FALSE FALSE Delisted
207152 5/16/1994 6/1/1996 8.96 8.96 8.96 FALSE FALSE New Listing
207152 6/1/1996 8/1/1998 8.96 8.96 10.75 FALSE FALSE Change +Price
207152 8/1/1998 12/1/2005 8.96 8.96 11.83 FALSE FALSE Change +Price
207152 12/1/2005 0 0 0 FALSE FALSE Delisted
207195 3/1/1995 6/1/2002 1.08 1.08 1.09 FALSE FALSE New Listing
207195 6/1/2002 0 0 0 FALSE FALSE Delisted
207209 5/16/1994 3/1/1995 5.42 5.42 19.8 FALSE FALSE New Listing
207209 3/1/1995 6/1/2002 5.42 5.42 5.42 FALSE FALSE Change -Price
207209 6/1/2002 0 0 0 FALSE FALSE Delisted
207217 5/16/1994 9/1/2000 2.42 2.42 2.42 FALSE FALSE New Listing
207217 9/1/2000 1/1/2001 1.6 1.6 2.42 FALSE FALSE Change -Subsidy -Alternate
207217 1/1/2001 0 0 0 FALSE FALSE Delisted
207225 5/16/1994 9/1/2000 12.09 12.09 12.09 FALSE FALSE New Listing
207225 9/1/2000 1/1/2001 7.98 7.98 12.09 FALSE FALSE Change -Subsidy -Alternate
207225 1/1/2001 0 0 0 FALSE FALSE Delisted
207233 5/16/1994 9/1/2000 4.34 4.34 4.34 FALSE FALSE New Listing
207233 9/1/2000 1/1/2001 2.5 2.5 4.34 FALSE FALSE Change -Subsidy -Alternate
207233 1/1/2001 0 0 0 FALSE FALSE Delisted
207276 5/16/1994 8/1/1995 5.86 5.86 5.86 FALSE FALSE New Listing
207276 8/1/1995 2/1/2002 5.85 5.85 5.85 FALSE FALSE Change -Subsidy -Price -Alternate
207276 2/1/2002 0 0 0 FALSE FALSE Delisted
207357 5/27/1995 10/1/1997 3.58 3.58 4.3 FALSE FALSE New Listing
207357 10/1/1997 0 0 0 FALSE FALSE Delisted
207373 5/16/1994 5.86 5.86 5.86 FALSE TRUE New Listing
207381 5/16/1994 8/16/1994 5.36 5.36 5.36 FALSE TRUE New Listing
207381 8/16/1994 5.39 5.39 5.39 FALSE TRUE Change +Subsidy +Price +Alternate
207403 5/16/1994 3/1/1995 13.28 13.28 13.28 FALSE TRUE New Listing
207403 3/1/1995 5/30/1995 13.28 13.28 13.3 FALSE TRUE Change +Price
207403 5/30/1995 6/22/1995 13.28 13.28 13.28 FALSE TRUE Change -Price
207403 6/22/1995 12/1/1997 13.3 13.3 13.3 FALSE TRUE Change +Subsidy +Price +Alternate
207403 12/1/1997 8/1/2000 13.3 13.3 15.3 FALSE TRUE Change +Price
207403 8/1/2000 0 0 0 FALSE FALSE Delisted
207411 5/16/1994 8/1/2000 12.68 12.68 12.68 FALSE FALSE New Listing
207411 8/1/2000 0 0 0 FALSE FALSE Delisted
207446 5/16/1994 8/16/1994 6.64 6.64 6.64 FALSE TRUE New Listing
207446 8/16/1994 5/1/1996 4.5 4.5 4.5 FALSE TRUE Change -Subsidy -Price -Alternate
207446 5/1/1996 6/1/2003 4.5 4.5 8.8 FALSE TRUE Change +Price
207446 6/1/2003 9/1/2004 4.5 4.5 9.68 FALSE TRUE Change +Price
207446 9/1/2004 4.5 4.5 4.5 FALSE TRUE Change -Price
207454 6/3/1995 4.5 4.5 4.5 FALSE TRUE New Listing
207462 5/16/1994 9/1/2000 2.86 2.86 4.1 FALSE TRUE New Listing
207462 9/1/2000 1/1/2009 1.79 1.79 1.79 FALSE TRUE Change -Subsidy -Price -Alternate
207462 1/1/2009 1/1/2012 2 2 2 FALSE TRUE Change +Subsidy +Price +Alternate
207462 1/1/2012 2 2 3.92 FALSE TRUE Change +Price
207470 3/1/1995 12/1/2000 29.47 29.47 29.47 FALSE FALSE New Listing
207470 12/1/2000 0 0 0 FALSE FALSE Delisted
207489 5/16/1994 39.03 39.03 39.03 FALSE TRUE New Listing
207519 5/16/1994 10/1/2002 20.8 20.8 20.8 FALSE FALSE New Listing
207519 10/1/2002 2/1/2005 25.75 25.75 25.75 FALSE FALSE Change +Subsidy +Price +Alternate
207519 2/1/2005 0 0 0 FALSE FALSE Delisted
207527 8/16/1994 11/1/2004 40.8 40.8 40.8 FALSE FALSE New Listing
207527 11/1/2004 6/1/2005 28 28 28 FALSE FALSE Change -Subsidy -Price -Alternate
207527 6/1/2005 8/1/2007 19.6 19.6 19.6 FALSE FALSE Change -Subsidy -Price -Alternate
207527 8/1/2007 0 0 0 FALSE FALSE Delisted
207578 5/20/1995 2/1/1998 38.2 38.2 38.2 FALSE FALSE New Listing
207578 2/1/1998 0 0 0 FALSE FALSE Delisted
207594 5/1/1996 11/1/1997 2.96 2.96 3.64 FALSE TRUE New Listing
207594 11/1/1997 0 0 0 FALSE FALSE Delisted
207608 10/1/1997 8/1/1999 8.97 8.97 10.46 FALSE TRUE New Listing
207608 8/1/1999 1/1/2002 8.97 8.97 11 FALSE TRUE Change +Price
207608 1/1/2002 10/1/2002 8.97 8.97 11.5 FALSE TRUE Change +Price
207608 10/1/2002 10/1/2003 8.97 8.97 12.04 FALSE TRUE Change +Price
207608 10/1/2003 7/1/2007 8.97 8.97 13.85 FALSE TRUE Change +Price
207608 7/1/2007 8/1/2009 8.97 8.97 15.23 FALSE TRUE Change +Price
207608 8/1/2009 8.97 8.97 15.86 FALSE TRUE Change +Price
207624 10/1/1997 8/1/1999 8.97 8.97 10.46 FALSE TRUE New Listing
207624 8/1/1999 1/1/2002 8.97 8.97 11 FALSE TRUE Change +Price
207624 1/1/2002 10/1/2002 8.97 8.97 11.5 FALSE TRUE Change +Price
207624 10/1/2002 10/1/2003 8.97 8.97 12.04 FALSE TRUE Change +Price
207624 10/1/2003 7/1/2007 8.97 8.97 13.85 FALSE TRUE Change +Price
207624 7/1/2007 8/1/2009 8.97 8.97 15.23 FALSE TRUE Change +Price
207624 8/1/2009 8.97 8.97 15.86 FALSE TRUE Change +Price
207632 6/1/1996 12/1/1996 2.96 2.96 3.64 FALSE TRUE New Listing
207632 12/1/1996 0 0 0 FALSE FALSE Delisted
207640 10/1/1997 8/1/1999 8.97 8.97 10.46 FALSE TRUE New Listing
207640 8/1/1999 1/1/2002 8.97 8.97 11 FALSE TRUE Change +Price
207640 1/1/2002 10/1/2002 8.97 8.97 11.5 FALSE TRUE Change +Price
207640 10/1/2002 10/1/2003 8.97 8.97 12.04 FALSE TRUE Change +Price
207640 10/1/2003 7/1/2007 8.97 8.97 13.85 FALSE TRUE Change +Price
207640 7/1/2007 1/1/2009 8.97 8.97 15.23 FALSE TRUE Change +Price
207640 1/1/2009 0 0 0 FALSE FALSE Delisted
207659 5/16/1994 10/1/2002 4.9 4.9 6.08 FALSE TRUE New Listing
207659 10/1/2002 10/1/2003 4.9 4.9 7.05 FALSE TRUE Change +Price
207659 10/1/2003 2/1/2004 4.9 4.9 8.11 FALSE TRUE Change +Price
207659 2/1/2004 8/1/2004 3.49 3.49 8.11 FALSE TRUE Change -Subsidy -Alternate
207659 8/1/2004 0 0 0 FALSE FALSE Delisted
207756 ######## 12/1/1997 1.79 1.79 2.37 FALSE FALSE New Listing
207756 12/1/1997 0 0 0 FALSE FALSE Delisted
207764 5/16/1994 12/1/1997 8.95 8.95 8.95 FALSE FALSE New Listing
207764 12/1/1997 0 0 0 FALSE FALSE Delisted
207780 5/16/1994 12/1/1997 8.76 8.76 8.76 FALSE FALSE New Listing
207780 12/1/1997 0 0 0 FALSE FALSE Delisted
207799 5/16/1994 7/1/1997 3.26 3.26 3.26 FALSE FALSE New Listing
207799 7/1/1997 12/1/1997 3.25 3.25 3.25 FALSE FALSE Change -Subsidy -Price -Alternate
207799 12/1/1997 0 0 0 FALSE FALSE Delisted
207829 5/16/1994 9/1/1997 29.45 29.45 29.45 FALSE FALSE New Listing
207829 9/1/1997 12/1/1997 60 60 60 FALSE FALSE Change +Subsidy +Price +Alternate
207829 12/1/1997 0 0 0 FALSE FALSE Delisted
207950 6/16/1995 5/1/1998 2.83 2.83 4 FALSE FALSE New Listing
207950 5/1/1998 0 0 0 FALSE FALSE Delisted
207977 6/16/1995 5/1/1998 2.83 2.83 4 FALSE FALSE New Listing
207977 5/1/1998 0 0 0 FALSE FALSE Delisted
208043 5/16/1994 1/11/1995 3.93 3.93 3.93 FALSE FALSE New Listing
208043 1/11/1995 3/1/2001 3.93 3.93 10 FALSE FALSE Change +Price
208043 3/1/2001 0 0 0 FALSE FALSE Delisted
208051 5/16/1994 1/11/1995 12.93 12.93 14.22 FALSE FALSE New Listing
208051 1/11/1995 3/1/1999 0.26 0.26 14.22 FALSE FALSE Change -Subsidy -Alternate
208051 3/1/1999 2/1/2000 0.26 9.95 9.95 FALSE FALSE Change -Price +Alternate
208051 2/1/2000 6/1/2006 0.21 9.95 9.95 FALSE FALSE Change -Subsidy
208051 6/1/2006 1/1/2008 0.19 9.95 9.95 FALSE FALSE Change -Subsidy
208051 1/1/2008 0 0 0 FALSE FALSE Delisted
208086 5/16/1994 3/1/1998 3.47 3.47 5.05 FALSE TRUE New Listing
208086 3/1/1998 10/1/1998 3.33 3.33 5.05 FALSE TRUE Change -Subsidy -Alternate
208086 10/1/1998 11/1/1998 1.83 1.83 5.05 FALSE TRUE Change -Subsidy -Alternate
208086 11/1/1998 1/1/1999 1.83 1.83 5.77 FALSE TRUE Change +Price
208086 1/1/1999 3/1/2005 1 1 5.77 FALSE TRUE Change -Subsidy -Alternate
208086 3/1/2005 0 0 0 FALSE FALSE Delisted
208094 5/16/1994 3/1/1998 6.67 6.67 8.4 FALSE TRUE New Listing
208094 3/1/1998 10/1/1998 3.33 3.33 8.4 FALSE TRUE Change -Subsidy -Alternate
208094 10/1/1998 11/1/1998 1.83 1.83 8.4 FALSE TRUE Change -Subsidy -Alternate
208094 11/1/1998 1/1/1999 1.83 1.83 9.6 FALSE TRUE Change +Price
208094 1/1/1999 2/1/2004 1 1 9.6 FALSE TRUE Change -Subsidy -Alternate
208094 2/1/2004 0 0 0 FALSE FALSE Delisted
208108 5/16/1994 3/1/1998 8.95 8.95 8.95 FALSE TRUE New Listing
208108 3/1/1998 0 0 0 FALSE FALSE Delisted
208116 5/16/1994 11/1/1998 4.36 4.36 4.36 FALSE TRUE New Listing
208116 11/1/1998 11/1/2000 4.36 4.36 4.98 FALSE TRUE Change +Price
208116 11/1/2000 2/1/2004 4.36 4.36 6.7 FALSE TRUE Change +Price
208116 2/1/2004 0 0 0 FALSE FALSE Delisted
208124 5/16/1994 3/1/1998 8.95 8.95 8.95 FALSE TRUE New Listing
208124 3/1/1998 11/1/1998 4.36 4.36 8.95 FALSE TRUE Change -Subsidy -Alternate
208124 11/1/1998 11/1/2004 4.36 4.36 10.22 FALSE TRUE Change +Price
208124 11/1/2004 0 0 0 FALSE FALSE Delisted
208159 5/16/1994 4/1/1995 12.68 12.68 12.68 FALSE FALSE New Listing
208159 4/1/1995 3/1/2001 12.68 12.68 15.21 FALSE FALSE Change +Price
208159 3/1/2001 4/1/2003 12.68 12.68 16.73 FALSE FALSE Change +Price
208159 4/1/2003 4/1/2004 12.68 12.68 18.4 FALSE FALSE Change +Price
208159 4/1/2004 1/1/2007 12.68 12.68 20.24 FALSE FALSE Change +Price
208159 1/1/2007 0 0 0 FALSE FALSE Delisted
208183 1/1/1996 7/1/1996 59.3 59.3 68.2 FALSE FALSE New Listing
208183 7/1/1996 0 0 0 FALSE FALSE Delisted
208205 1/1/1996 2/1/1996 118.5 118.5 136.25 FALSE FALSE New Listing
208205 2/1/1996 2/1/2000 23.7 23.7 34.35 FALSE FALSE Change -Subsidy -Price -Alternate
208205 2/1/2000 3/1/2001 23.7 23.7 39.5 FALSE FALSE Change +Price
208205 3/1/2001 9/1/2001 23.7 23.7 43.45 FALSE FALSE Change +Price
208205 9/1/2001 0 0 0 FALSE FALSE Delisted
208264 5/16/1994 10/1/2006 28.26 28.26 28.26 FALSE FALSE New Listing
208264 10/1/2006 5/1/2009 31.09 31.09 31.09 FALSE FALSE Change +Subsidy +Price +Alternate
208264 5/1/2009 9/1/2012 22.5 22.5 22.5 FALSE FALSE Change -Subsidy -Price -Alternate
208264 9/1/2012 18 18 18 FALSE FALSE Change -Subsidy -Price -Alternate
208272 5/16/1994 1/1/1995 8.86 8.86 17.08 FALSE FALSE New Listing
208272 1/1/1995 1/1/1996 8.86 8.86 17.42 FALSE FALSE Change +Price
208272 1/1/1996 3/1/2000 8.86 8.86 19.51 FALSE FALSE Change +Price
208272 3/1/2000 2/1/2002 8.86 8.86 44.5 FALSE FALSE Change +Price
208272 2/1/2002 8/1/2002 8.86 8.86 46.75 FALSE FALSE Change +Price
208272 8/1/2002 0 0 0 FALSE FALSE Delisted
208280 7/1/1997 6/1/1998 5.04 5.04 10.94 FALSE FALSE New Listing
208280 6/1/1998 2/1/1999 5.04 5.04 12.58 FALSE FALSE Change +Price
208280 2/1/1999 3/1/2000 5.04 5.04 15.1 FALSE FALSE Change +Price
208280 3/1/2000 2/1/2002 5.04 5.04 16.8 FALSE FALSE Change +Price
208280 2/1/2002 8/1/2002 5.04 5.04 17.64 FALSE FALSE Change +Price
208280 8/1/2002 0 0 0 FALSE FALSE Delisted
208329 5/16/1994 6/16/1995 6.81 6.81 7.49 FALSE TRUE New Listing
208329 6/16/1995 1/1/1996 6.81 6.81 7.86 FALSE TRUE Change +Price
208329 1/1/1996 7/1/1997 6.81 6.81 8.41 FALSE TRUE Change +Price
208329 7/1/1997 6/1/1998 6.81 6.81 8.83 FALSE TRUE Change +Price
208329 6/1/1998 2/1/1999 6.81 6.81 9.71 FALSE TRUE Change +Price
208329 2/1/1999 3/1/2000 6.81 6.81 10.2 FALSE TRUE Change +Price
208329 3/1/2000 5/1/2003 6.81 6.81 10.7 FALSE TRUE Change +Price
208329 5/1/2003 9/1/2006 6.81 6.81 11.77 FALSE TRUE Change +Price
208329 9/1/2006 1/1/2011 6.81 6.81 13.54 FALSE TRUE Change +Price
208329 1/1/2011 0 0 0 FALSE FALSE Delisted
208361 6/13/1995 9/1/2001 9 9 9 FALSE TRUE New Listing
208361 9/1/2001 12/1/2001 5.68 5.68 9 FALSE TRUE Change -Subsidy -Alternate
208361 12/1/2001 0 0 0 FALSE FALSE Delisted
208388 6/13/1995 3/1/2001 13.47 13.47 15.48 FALSE TRUE New Listing
208388 3/1/2001 9/1/2001 13.47 13.47 17.02 FALSE TRUE Change +Price
208388 9/1/2001 1/1/2005 8.51 8.51 8.51 FALSE TRUE Change -Subsidy -Price -Alternate
208388 1/1/2005 4/1/2005 7.05 7.05 8.51 FALSE TRUE Change -Subsidy -Alternate
208388 4/1/2005 8/1/2010 0 0 0 FALSE FALSE Delisted
208388 8/1/2010 15 15 15 FALSE TRUE New Listing
208396 6/13/1995 9/1/2001 6.85 6.85 6.85 FALSE FALSE New Listing
208396 9/1/2001 1/1/2005 3.77 3.77 3.77 FALSE FALSE Change -Subsidy -Price -Alternate
208396 1/1/2005 4/1/2005 2.95 2.95 3.77 FALSE FALSE Change -Subsidy -Alternate
208396 4/1/2005 8/1/2010 0 0 0 FALSE FALSE Delisted
208396 8/1/2010 9.9 9.9 9.9 FALSE FALSE New Listing
208469 5/16/1994 3/1/1996 34.1 34.1 36.85 FALSE FALSE New Listing
208469 3/1/1996 7/1/1999 34.1 34.1 40.55 FALSE FALSE Change +Price
208469 7/1/1999 11/1/1999 22.5 22.5 40.55 FALSE FALSE Change -Subsidy -Alternate
208469 11/1/1999 0 0 0 FALSE FALSE Delisted
208590 9/18/1997 3/1/2001 21.66 21.66 21.66 FALSE FALSE New Listing
208590 3/1/2001 7/1/2001 21.66 21.66 23.83 FALSE FALSE Change +Price
208590 7/1/2001 11/1/2004 23.83 23.83 23.83 FALSE FALSE Change +Subsidy +Alternate
208590 11/1/2004 26.21 26.21 26.21 FALSE FALSE Change +Subsidy +Price +Alternate
208604 5/16/1994 12/1/1995 14.12 14.12 16.3 FALSE FALSE New Listing
208604 12/1/1995 10/1/2001 14.12 14.12 16.95 FALSE FALSE Change +Price
208604 10/1/2001 0 0 0 FALSE FALSE Delisted
208663 5/16/1994 6/1/1997 4.49 4.49 8.4 FALSE FALSE New Listing
208663 6/1/1997 0 0 0 FALSE FALSE Delisted
208728 6/3/1995 3/1/2001 4.5 4.5 5.5 FALSE TRUE New Listing
208728 3/1/2001 4/1/2002 4.5 4.5 6.05 FALSE TRUE Change +Price
208728 4/1/2002 4/1/2003 4.5 4.5 6.66 FALSE TRUE Change +Price
208728 4/1/2003 4/1/2004 4.5 4.5 7.33 FALSE TRUE Change +Price
208728 4/1/2004 7/1/2006 4.5 4.5 8.06 FALSE TRUE Change +Price
208728 7/1/2006 4.5 4.5 9.27 FALSE TRUE Change +Price
208736 6/3/1995 3/1/2001 4.5 4.5 5.5 FALSE TRUE New Listing
208736 3/1/2001 4/1/2002 4.5 4.5 6.05 FALSE TRUE Change +Price
208736 4/1/2002 4/1/2003 4.5 4.5 6.66 FALSE TRUE Change +Price
208736 4/1/2003 4/1/2004 4.5 4.5 7.33 FALSE TRUE Change +Price
208736 4/1/2004 9/1/2005 4.5 4.5 8.06 FALSE TRUE Change +Price
208736 9/1/2005 0 0 0 FALSE FALSE Delisted
208752 5/16/1994 8/16/1994 2.86 2.86 3.25 FALSE TRUE New Listing
208752 8/16/1994 9/1/2000 2.86 2.86 2.86 FALSE TRUE Change -Price
208752 9/1/2000 1/1/2001 1.79 1.79 2.86 FALSE TRUE Change -Subsidy -Alternate
208752 1/1/2001 0 0 0 FALSE FALSE Delisted
208760 5/16/1994 9/1/2002 2.86 2.86 2.86 FALSE TRUE New Listing
208760 9/1/2002 12/1/2002 2.65 2.65 2.86 FALSE TRUE Change -Subsidy -Alternate
208760 12/1/2002 0 0 0 FALSE FALSE Delisted
208841 6/13/1995 9/1/2001 13.75 13.75 13.75 FALSE TRUE New Listing
208841 9/1/2001 12/1/2001 8.67 8.67 13.75 FALSE TRUE Change -Subsidy -Alternate
208841 12/1/2001 0 0 0 FALSE FALSE Delisted
208868 6/13/1995 9/1/2001 5.71 5.71 5.71 FALSE FALSE New Listing
208868 9/1/2001 12/1/2001 3.14 3.14 5.71 FALSE FALSE Change -Subsidy -Alternate
208868 12/1/2001 0 0 0 FALSE FALSE Delisted
208876 5/16/1994 32.9 32.9 32.9 FALSE FALSE New Listing
208884 5/16/1994 5/1/2003 14.95 14.95 14.95 FALSE FALSE New Listing
208884 5/1/2003 0 0 0 FALSE FALSE Delisted
208914 5/16/1994 12/1/1997 26.47 26.47 26.47 FALSE TRUE New Listing
208914 12/1/1997 0 0 0 FALSE FALSE Delisted
208965 5/16/1994 7/1/1999 10.08 10.08 10.57 FALSE TRUE New Listing
208965 7/1/1999 0 0 0 FALSE FALSE Delisted
209058 5/16/1994 11/1/1998 3.97 3.97 5.27 FALSE FALSE New Listing
209058 11/1/1998 4/1/2001 3.97 3.97 5.79 FALSE FALSE Change +Price
209058 4/1/2001 0 0 0 FALSE FALSE Delisted
209066 6/14/1995 4/1/1996 9.02 9.02 13.27 FALSE FALSE New Listing
209066 4/1/1996 4/1/1998 9.02 9.02 14 FALSE FALSE Change +Price
209066 4/1/1998 4/1/1999 9.02 9.02 14.98 FALSE FALSE Change +Price
209066 4/1/1999 3/1/2000 9.02 9.02 15.43 FALSE FALSE Change +Price
209066 3/1/2000 3/1/2001 9.02 9.02 15.75 FALSE FALSE Change +Price
209066 3/1/2001 2/1/2006 9.02 9.02 16.2 FALSE FALSE Change +Price
209066 2/1/2006 0 0 0 FALSE FALSE Delisted
209074 5/16/1994 4/1/1996 5.06 5.06 10.8 FALSE FALSE New Listing
209074 4/1/1996 4/1/1998 5.06 5.06 11.7 FALSE FALSE Change +Price
209074 4/1/1998 4/1/1999 5.06 5.06 12.52 FALSE FALSE Change +Price
209074 4/1/1999 3/1/2000 5.06 5.06 12.9 FALSE FALSE Change +Price
209074 3/1/2000 3/1/2001 5.06 5.06 13.15 FALSE FALSE Change +Price
209074 3/1/2001 8/1/2009 5.06 5.06 13.55 FALSE FALSE Change +Price
209074 8/1/2009 8/1/2014 5.06 5.06 15.58 FALSE FALSE Change +Price
209074 8/1/2014 0 0 0 FALSE FALSE Delisted
209082 5/16/1994 11/1/1996 8.33 8.33 8.33 FALSE FALSE New Listing
209082 11/1/1996 9/1/1999 8.33 8.33 15.25 FALSE FALSE Change +Price
209082 9/1/1999 12/1/2003 38.97 38.97 38.97 FALSE FALSE Change +Subsidy +Price +Alternate
209082 12/1/2003 3/1/2004 29.95 29.95 38.97 FALSE FALSE Change -Subsidy -Alternate
209082 3/1/2004 7/1/2008 0 0 0 FALSE FALSE Delisted
209082 7/1/2008 8/1/2011 20.95 20.95 20.95 FALSE FALSE New Listing
209082 8/1/2011 7/1/2014 19.9 19.9 19.9 FALSE FALSE Change -Subsidy -Price -Alternate
209082 7/1/2014 15.22 15.22 15.22 FALSE FALSE Change -Subsidy -Price -Alternate
209120 5/16/1994 5/1/1997 28.73 28.73 28.73 FALSE FALSE New Listing
209120 5/1/1997 9/1/1997 17.24 17.24 28.73 FALSE FALSE Change -Subsidy -Alternate
209120 9/1/1997 1/1/1998 28.73 28.73 28.73 FALSE FALSE Change +Subsidy +Alternate
209120 1/1/1998 2/1/1998 23 23 28.73 FALSE FALSE Change -Subsidy -Alternate
209120 2/1/1998 9/1/1998 17.24 17.24 17.24 FALSE FALSE Change -Subsidy -Price -Alternate
209120 9/1/1998 8/1/2000 16.73 16.73 16.73 FALSE FALSE Change -Subsidy -Price -Alternate
209120 8/1/2000 12/1/2000 10.29 10.29 10.29 FALSE FALSE Change -Subsidy -Price -Alternate
209120 12/1/2000 0 0 0 FALSE FALSE Delisted
209244 10/4/1997 12/1/1998 6.6 6.6 7.63 FALSE TRUE New Listing
209244 12/1/1998 0 0 0 FALSE FALSE Delisted
209317 10/4/1997 12/1/1998 6.6 6.6 7.63 FALSE TRUE New Listing
209317 12/1/1998 0 0 0 FALSE FALSE Delisted
209538 5/16/1994 6/27/1995 18.4 18.4 18.4 FALSE FALSE New Listing
209538 6/27/1995 7/1/2000 18.4 18.4 28.5 FALSE FALSE Change +Price
209538 7/1/2000 10/1/2001 18.4 18.4 29.93 FALSE FALSE Change +Price
209538 10/1/2001 1/1/2003 18.4 18.4 31.43 FALSE FALSE Change +Price
209538 1/1/2003 12/1/2004 18.4 18.4 34.57 FALSE FALSE Change +Price
209538 12/1/2004 4/1/2008 18.4 18.4 36.99 FALSE FALSE Change +Price
209538 4/1/2008 18.4 18.4 38.1 FALSE FALSE Change +Price
209546 5/16/1994 2/1/1999 7.18 7.18 7.18 FALSE TRUE New Listing
209546 2/1/1999 6/1/2003 7.18 7.18 9.17 FALSE TRUE Change +Price
209546 6/1/2003 9/1/2004 7.18 7.18 10.09 FALSE TRUE Change +Price
209546 9/1/2004 10/1/2013 7.18 7.18 7.18 FALSE TRUE Change -Price
209546 10/1/2013 0 0 0 FALSE FALSE Delisted
209554 5/16/1994 2/1/1999 8.73 8.73 8.73 FALSE TRUE New Listing
209554 2/1/1999 6/1/2003 8.73 8.73 10.73 FALSE TRUE Change +Price
209554 6/1/2003 9/1/2004 8.73 8.73 11.8 FALSE TRUE Change +Price
209554 9/1/2004 1/1/2007 8.73 8.73 8.73 FALSE TRUE Change -Price
209554 1/1/2007 0 0 0 FALSE FALSE Delisted
209570 5/16/1994 10/1/1996 4.5 4.5 7.18 FALSE TRUE New Listing
209570 10/1/1996 1/1/2003 4.5 4.5 4.5 FALSE TRUE Change -Price
209570 1/1/2003 0 0 0 FALSE FALSE Delisted
209597 5/16/1994 12/1/2000 18.96 18.96 31.59 FALSE FALSE New Listing
209597 12/1/2000 0 0 0 FALSE FALSE Delisted
209600 5/16/1994 4/1/2003 11.86 11.86 11.86 FALSE FALSE New Listing
209600 4/1/2003 0 0 0 FALSE FALSE Delisted
209635 6/3/1995 10/1/1996 4.5 4.5 7.18 FALSE TRUE New Listing
209635 10/1/1996 1/1/2003 4.5 4.5 4.5 FALSE TRUE Change -Price
209635 1/1/2003 0 0 0 FALSE FALSE Delisted
209686 5/16/1994 7/1/1999 27.92 27.92 35 FALSE FALSE New Listing
209686 7/1/1999 11/1/1999 19.9 19.9 35 FALSE FALSE Change -Subsidy -Alternate
209686 11/1/1999 0 0 0 FALSE FALSE Delisted
209694 5/16/1994 7/1/1999 9.97 9.97 11.58 FALSE FALSE New Listing
209694 7/1/1999 11/1/1999 6.5 6.5 11.58 FALSE FALSE Change -Subsidy -Alternate
209694 11/1/1999 0 0 0 FALSE FALSE Delisted
209708 5/16/1994 7/1/1999 8.87 8.87 10 FALSE FALSE New Listing
209708 7/1/1999 11/1/1999 6.49 6.49 10 FALSE FALSE Change -Subsidy -Alternate
209708 11/1/1999 0 0 0 FALSE FALSE Delisted
209716 5/16/1994 5/1/2001 10.3 10.3 12.17 FALSE FALSE New Listing
209716 5/1/2001 0 0 0 FALSE FALSE Delisted
209724 10/4/1997 2/1/2004 4.9 4.9 4.9 FALSE TRUE New Listing
209724 2/1/2004 1/1/2015 3.49 3.49 4.9 FALSE TRUE Change -Subsidy -Alternate
209724 1/1/2015 0 0 0 FALSE FALSE Delisted
209759 10/4/1997 2/1/2004 4.9 4.9 4.9 FALSE TRUE New Listing
209759 2/1/2004 3.49 3.49 4.9 FALSE TRUE Change -Subsidy -Alternate
209775 5/16/1994 11/1/1995 12 12 12 FALSE FALSE New Listing
209775 11/1/1995 5/1/1996 8.76 8.76 12 FALSE FALSE Change -Subsidy -Alternate
209775 5/1/1996 0 0 0 FALSE FALSE Delisted
209783 5/16/1994 11/1/1995 21.96 21.96 21.96 FALSE FALSE New Listing
209783 11/1/1995 5/1/1996 17.52 17.52 21.96 FALSE FALSE Change -Subsidy -Alternate
209783 5/1/1996 0 0 0 FALSE FALSE Delisted
209813 5/16/1994 5/1/1996 28.38 28.38 39.6 FALSE FALSE New Listing
209813 5/1/1996 6/1/1996 28.38 28.38 41.4 FALSE FALSE Change +Price
209813 6/1/1996 6/1/1998 9.45 9.45 14.4 FALSE FALSE Change -Subsidy -Price -Alternate
209813 6/1/1998 0 0 0 FALSE FALSE Delisted
209880 6/1/1995 7/1/1998 2.69 2.69 2.69 FALSE TRUE New Listing
209880 7/1/1998 5/1/1999 2.69 2.69 6.57 FALSE TRUE Change +Price
209880 5/1/1999 6/1/1999 2.69 2.69 6.89 FALSE TRUE Change +Price
209880 6/1/1999 3/1/2001 2.89 2.89 6.89 FALSE TRUE Change +Subsidy +Alternate
209880 3/1/2001 5/1/2003 2.89 2.89 7.2 FALSE TRUE Change +Price
209880 5/1/2003 0 0 0 FALSE FALSE Delisted
209910 6/13/1995 8/1/1998 9.06 9.06 9.06 FALSE TRUE New Listing
209910 8/1/1998 1/1/2001 9.06 9.06 9.97 FALSE TRUE Change +Price
209910 1/1/2001 9/1/2001 9.06 9.06 10.67 FALSE TRUE Change +Price
209910 9/1/2001 5/1/2005 9.06 9.06 11.47 FALSE TRUE Change +Price
209910 5/1/2005 11/1/2005 9.06 9.06 14.03 FALSE TRUE Change +Price
209910 11/1/2005 0 0 0 FALSE FALSE Delisted
209937 5/16/1994 3/1/2001 2.99 2.99 4 FALSE FALSE New Listing
209937 3/1/2001 8/1/2001 2.99 2.99 4.4 FALSE FALSE Change +Price
209937 8/1/2001 6/1/2003 3.65 3.65 4.4 FALSE FALSE Change +Subsidy +Alternate
209937 6/1/2003 0 0 0 FALSE FALSE Delisted
209945 5/16/1994 10/1/1997 8.81 8.81 8.81 FALSE FALSE New Listing
209945 10/1/1997 3/1/2001 8.81 8.81 8.81 FALSE TRUE Change +OP
209945 3/1/2001 7/1/2001 8.81 8.81 9.69 FALSE TRUE Change +Price
209945 7/1/2001 11/1/2004 9.69 9.69 9.69 FALSE TRUE Change +Subsidy +Alternate
209945 11/1/2004 10.66 10.66 10.66 FALSE TRUE Change +Subsidy +Price +Alternate
209953 2/1/1998 8/1/2000 4.37 4.37 14.16 FALSE FALSE New Listing
209953 8/1/2000 12/1/2000 2.75 2.75 14.16 FALSE FALSE Change -Subsidy -Alternate
209953 12/1/2000 0 0 0 FALSE FALSE Delisted
209961 5/16/1994 2/1/1998 41.73 41.73 44.29 FALSE FALSE New Listing
209961 2/1/1998 8/1/2000 29.21 29.21 44.29 FALSE FALSE Change -Subsidy -Alternate
209961 8/1/2000 12/1/2000 5.6 5.6 44.29 FALSE FALSE Change -Subsidy -Alternate
209961 12/1/2000 0 0 0 FALSE FALSE Delisted
210021 10/1/2002 12/1/2002 30 30 30 FALSE FALSE New listing
210021 12/1/2002 10/1/2005 26.5 26.5 26.5 FALSE FALSE Change -Subsidy -Price -Alternate
210021 10/1/2005 1/1/2006 25 25 25 FALSE FALSE Change -Subsidy -Price -Alternate
210021 1/1/2006 0 0 0 FALSE FALSE Delisted
210110 6/15/1995 10.05 10.05 10.05 FALSE TRUE New Listing
210188 5/16/1994 12/1/1998 79.68 79.68 83.66 FALSE FALSE New Listing
210188 12/1/1998 1/1/2002 79.68 79.68 90.41 FALSE FALSE Change +Price
210188 1/1/2002 0 0 0 FALSE FALSE Delisted
210218 5/16/1994 8/1/1999 5.58 5.58 5.58 FALSE FALSE New Listing
210218 8/1/1999 5/1/2000 5.58 5.58 6.42 FALSE FALSE Change +Price
210218 5/1/2000 1/1/2002 5.58 5.58 7.65 FALSE FALSE Change +Price
210218 1/1/2002 0 0 0 FALSE FALSE Delisted
210250 5/16/1994 10/2/1995 3.64 3.64 3.64 FALSE TRUE New Listing
210250 10/2/1995 0 0 0 FALSE FALSE Delisted
210269 5/16/1994 4/1/1996 6 6 6 FALSE TRUE New Listing
210269 4/1/1996 10/1/1997 5.91 5.91 6 FALSE TRUE Change -Subsidy -Alternate
210269 10/1/1997 1/1/1998 5.38 5.38 6 FALSE TRUE Change -Subsidy -Alternate
210269 1/1/1998 3/1/2001 5.38 5.38 5.38 FALSE TRUE Change -Price
210269 3/1/2001 5/1/2009 5 5 5 FALSE TRUE Change -Subsidy -Price -Alternate
210269 5/1/2009 0 0 0 FALSE FALSE Delisted
210277 5/16/1994 10/1/1997 18.33 18.33 18.33 FALSE TRUE New Listing
210277 10/1/1997 1/1/1998 16.13 16.13 18.33 FALSE TRUE Change -Subsidy -Alternate
210277 1/1/1998 3/1/2001 16.13 16.13 16.13 FALSE TRUE Change -Price
210277 3/1/2001 5/1/2009 15 15 15 FALSE TRUE Change -Subsidy -Price -Alternate
210277 5/1/2009 0 0 0 FALSE FALSE Delisted
210285 5/16/1994 10/1/1997 62.49 62.49 62.49 FALSE TRUE New Listing
210285 10/1/1997 4/1/2001 56.46 56.46 62.49 FALSE TRUE Change -Subsidy -Alternate
210285 4/1/2001 0 0 0 FALSE FALSE Delisted
210307 5/16/1994 3/1/2001 7.7 7.7 7.7 FALSE TRUE New Listing
210307 3/1/2001 9/1/2007 7.16 7.16 7.16 FALSE TRUE Change -Subsidy -Price -Alternate
210307 9/1/2007 1/1/2010 7.52 7.52 7.52 FALSE TRUE Change +Subsidy +Price +Alternate
210307 1/1/2010 3.65 3.65 3.65 FALSE TRUE Change -Subsidy -Price -Alternate
210323 5/16/1994 9/1/2004 13.63 13.63 13.63 FALSE FALSE New Listing
210323 9/1/2004 16.36 16.36 16.36 FALSE FALSE Change +Subsidy +Price +Alternate
210331 5/16/1994 3/1/2001 19.25 19.25 19.25 FALSE TRUE New Listing
210331 3/1/2001 1/1/2009 17.9 17.9 17.9 FALSE TRUE Change -Subsidy -Price -Alternate
210331 1/1/2009 0 0 0 FALSE FALSE Delisted
210374 5/16/1994 4/1/1996 6 6 6 FALSE TRUE New Listing
210374 4/1/1996 10/1/1997 5.91 5.91 6 FALSE TRUE Change -Subsidy -Alternate
210374 10/1/1997 1/1/1998 5.38 5.38 6 FALSE TRUE Change -Subsidy -Alternate
210374 1/1/1998 2/1/1999 5.38 5.38 5.38 FALSE TRUE Change -Price
210374 2/1/1999 0 0 0 FALSE FALSE Delisted
210382 5/16/1994 10/1/1997 18.33 18.33 18.33 FALSE TRUE New Listing
210382 10/1/1997 1/1/1998 16.13 16.13 18.33 FALSE TRUE Change -Subsidy -Alternate
210382 1/1/1998 3/1/2001 16.13 16.13 16.13 FALSE TRUE Change -Price
210382 3/1/2001 1/1/2010 15 15 15 FALSE TRUE Change -Subsidy -Price -Alternate
210382 1/1/2010 6.85 6.85 6.85 FALSE TRUE Change -Subsidy -Price -Alternate
210439 5/16/1994 8/1/1999 14.28 14.28 14.28 FALSE FALSE New Listing
210439 8/1/1999 5/1/2000 14.28 14.28 16.42 FALSE FALSE Change +Price
210439 5/1/2000 10/1/2002 14.28 14.28 21.1 FALSE FALSE Change +Price
210439 10/1/2002 1/1/2010 19.45 19.45 19.45 FALSE FALSE Change +Subsidy -Price +Alternate
210439 1/1/2010 1/1/2012 16 16 16 FALSE FALSE Change -Subsidy -Price -Alternate
210439 1/1/2012 0 0 0 FALSE FALSE Delisted
210463 5/16/1994 2/1/1999 6.82 6.82 6.82 FALSE TRUE New Listing
210463 2/1/1999 6/1/2003 6.82 6.82 8.83 FALSE TRUE Change +Price
210463 6/1/2003 9/1/2004 6.82 6.82 9.71 FALSE TRUE Change +Price
210463 9/1/2004 1/1/2007 6.82 6.82 6.82 FALSE TRUE Change -Price
210463 1/1/2007 0 0 0 FALSE FALSE Delisted
210471 5/16/1994 2/1/1999 6.99 6.99 6.99 FALSE TRUE New Listing
210471 2/1/1999 6/1/2003 6.99 6.99 8.99 FALSE TRUE Change +Price
210471 6/1/2003 9/1/2004 6.99 6.99 9.89 FALSE TRUE Change +Price
210471 9/1/2004 7/1/2007 6.99 6.99 6.99 FALSE TRUE Change -Price
210471 7/1/2007 0 0 0 FALSE FALSE Delisted
210536 5/16/1994 12/1/1999 2.52 2.52 2.52 FALSE TRUE New Listing
210536 12/1/1999 4/1/2000 1.1 1.1 2.52 FALSE TRUE Change -Subsidy -Alternate
210536 4/1/2000 0 0 0 FALSE FALSE Delisted
210544 5/16/1994 7/1/1999 2.77 2.77 2.77 FALSE TRUE New Listing
210544 7/1/1999 11/1/1999 1.85 1.85 2.77 FALSE TRUE Change -Subsidy -Alternate
210544 11/1/1999 0 0 0 FALSE FALSE Delisted
210552 5/25/1995 12/1/1997 5.36 5.36 5.36 FALSE FALSE New Listing
210552 12/1/1997 0 0 0 FALSE FALSE Delisted
210587 5/16/1994 8/1/2013 5.69 5.69 5.69 FALSE FALSE New Listing
210587 8/1/2013 6.86 6.86 6.86 FALSE FALSE Change +Subsidy +Price +Alternate
210595 5/16/1994 8/1/2013 8 8 8 FALSE FALSE New Listing
210595 8/1/2013 9.7 9.7 9.7 FALSE FALSE Change +Subsidy +Price +Alternate
210609 5/16/1994 8/1/2013 9.64 9.64 9.64 FALSE FALSE New Listing
210609 8/1/2013 11.75 11.75 11.75 FALSE FALSE Change +Subsidy +Price +Alternate
210625 5/16/1994 10/1/1999 7.4 7.4 7.4 FALSE FALSE New Listing
210625 10/1/1999 2/1/2000 6 6 7.4 FALSE FALSE Change -Subsidy -Alternate
210625 2/1/2000 0 0 0 FALSE FALSE Delisted
210633 5/16/1994 4/1/1997 3 3 3 FALSE FALSE New Listing
210633 4/1/1997 6/1/2003 3 3 5 FALSE FALSE Change +Price
210633 6/1/2003 4/1/2005 3.95 3.95 5 FALSE FALSE Change +Subsidy +Alternate
210633 4/1/2005 7/1/2005 3.95 3.95 6 FALSE FALSE Change +Price
210633 7/1/2005 0 0 0 FALSE FALSE Delisted
210641 4/1/1997 6/1/2002 15 15 25 FALSE FALSE New Listing
210641 6/1/2002 0 0 0 FALSE FALSE Delisted
210668 5/16/1994 10/1/2001 2.74 2.74 2.74 FALSE FALSE New Listing
210668 10/1/2001 6/1/2003 2.74 2.74 4.4 FALSE FALSE Change +Price
210668 6/1/2003 6/1/2007 2.74 2.74 5.2 FALSE FALSE Change +Price
210668 6/1/2007 0 0 0 FALSE FALSE Delisted
210692 5/16/1994 12/1/1998 48.56 48.56 48.56 FALSE FALSE New Listing
210692 12/1/1998 10/1/2002 48.55 48.55 48.55 FALSE FALSE Change -Subsidy -Price -Alternate
210692 10/1/2002 8/1/2012 48.57 48.57 48.57 FALSE FALSE Change +Subsidy +Price +Alternate
210692 8/1/2012 60 60 60 FALSE FALSE Change +Subsidy +Price +Alternate
210773 5/16/1994 6/15/1995 8.25 8.25 8.25 FALSE TRUE New Listing
210773 6/15/1995 10/4/1997 7.22 7.22 8.25 FALSE TRUE Change -Subsidy -Alternate
210773 10/4/1997 0 0 0 FALSE FALSE Delisted
210838 5/16/1994 10/1/2005 22.52 22.52 22.52 FALSE FALSE New Listing
210838 10/1/2005 8/1/2011 23.52 23.52 23.52 FALSE FALSE Change +Subsidy +Price +Alternate
210838 8/1/2011 0 0 0 FALSE FALSE Delisted
210846 5/16/1994 11/1/1997 13.96 13.96 13.96 FALSE FALSE New Listing
210846 11/1/1997 4/1/2006 13.95 13.95 13.95 FALSE FALSE Change -Subsidy -Price -Alternate
210846 4/1/2006 0 0 0 FALSE FALSE Delisted
210854 5/16/1994 1/1/2005 11 11 11 FALSE FALSE New Listing
210854 1/1/2005 0 0 0 FALSE FALSE Delisted
210870 5/1/1994 1/1/1995 10.32 10.32 10.32 FALSE TRUE New Listing
210870 1/1/1995 4/1/1996 10.32 10.32 11.16 FALSE TRUE Change +Price
210870 4/1/1996 7/1/1997 9.85 9.85 11.16 FALSE TRUE Change -Subsidy -Alternate
210870 7/1/1997 10/1/1997 9.85 9.85 11.72 FALSE TRUE Change +Price
210870 10/1/1997 6/1/1998 8.97 8.97 11.72 FALSE TRUE Change -Subsidy -Alternate
210870 6/1/1998 2/1/1999 8.97 8.97 13.13 FALSE TRUE Change +Price
210870 2/1/1999 3/1/2000 8.97 8.97 15.1 FALSE TRUE Change +Price
210870 3/1/2000 5/1/2003 8.97 8.97 16.2 FALSE TRUE Change +Price
210870 5/1/2003 9/1/2006 8.97 8.97 16.69 FALSE TRUE Change +Price
210870 9/1/2006 8/1/2013 8.97 8.97 18.36 FALSE TRUE Change +Price
210870 8/1/2013 8.97 8.97 8.97 FALSE TRUE Change -Price
210889 10/4/1997 6/1/1998 2.96 2.96 4.46 FALSE TRUE New Listing
210889 6/1/1998 2/1/1999 2.96 2.96 5 FALSE TRUE Change +Price
210889 2/1/1999 5/1/2003 2.96 2.96 5.75 FALSE TRUE Change +Price
210889 5/1/2003 9/1/2006 2.96 2.96 5.92 FALSE TRUE Change +Price
210889 9/1/2006 8/1/2013 2.96 2.96 6.51 FALSE TRUE Change +Price
210889 8/1/2013 2.96 2.96 2.96 FALSE TRUE Change -Price
210897 5/1/1994 1/1/1995 10.32 10.32 10.32 FALSE TRUE New Listing
210897 1/1/1995 4/1/1996 10.32 10.32 11.16 FALSE TRUE Change +Price
210897 4/1/1996 7/1/1997 9.85 9.85 11.16 FALSE TRUE Change -Subsidy -Alternate
210897 7/1/1997 10/1/1997 9.85 9.85 11.72 FALSE TRUE Change +Price
210897 10/1/1997 6/1/1998 8.97 8.97 11.72 FALSE TRUE Change -Subsidy -Alternate
210897 6/1/1998 2/1/1999 8.97 8.97 13.13 FALSE TRUE Change +Price
210897 2/1/1999 5/1/2003 8.97 8.97 15.1 FALSE TRUE Change +Price
210897 5/1/2003 9/1/2006 8.97 8.97 15.55 FALSE TRUE Change +Price
210897 9/1/2006 8/1/2013 8.97 8.97 17.11 FALSE TRUE Change +Price
210897 8/1/2013 8.97 8.97 8.97 FALSE TRUE Change -Price
210935 5/16/1994 11/1/1999 31.27 31.27 31.27 FALSE FALSE New Listing
210935 11/1/1999 3/1/2000 29 29 31.27 FALSE FALSE Change -Subsidy -Alternate
210935 3/1/2000 1/1/2003 0 0 0 FALSE FALSE Delisted
210935 1/1/2003 3/1/2003 29 29 29 FALSE FALSE New listing
210935 3/1/2003 17.6 17.6 17.6 FALSE FALSE Change -Subsidy -Price -Alternate
210943 5/16/1994 10/1/1995 56.11 56.11 56.11 FALSE FALSE New Listing
210943 10/1/1995 11/1/1995 56.11 56.11 56.12 FALSE FALSE Change +Price
210943 11/1/1995 11/1/1999 56.11 56.11 56.11 FALSE FALSE Change -Price
210943 11/1/1999 3/1/2000 48.75 48.75 56.11 FALSE FALSE Change -Subsidy -Alternate
210943 3/1/2000 1/1/2003 0 0 0 FALSE FALSE Delisted
210943 1/1/2003 3/1/2003 48.75 48.75 48.75 FALSE FALSE New Listing
210943 3/1/2003 27.9 27.9 27.9 FALSE FALSE Change -Subsidy -Price -Alternate
210951 5/16/1994 6/27/1995 208.73 208.73 208.73 FALSE FALSE New Listing
210951 6/27/1995 11/1/1999 208.73 208.73 208.76 FALSE FALSE Change +Price
210951 11/1/1999 3/1/2000 168 168 208.76 FALSE FALSE Change -Subsidy -Alternate
210951 3/1/2000 3/1/2003 0 0 0 FALSE FALSE Delisted
210951 3/1/2003 5/1/2003 168 168 168 FALSE FALSE New Listing
210951 5/1/2003 154.5 154.5 154.5 FALSE FALSE Change -Subsidy -Price -Alternate
211036 5/16/1994 5/17/1995 4.51 4.51 5.06 FALSE TRUE New Listing
211036 5/17/1995 9/1/1997 4.51 4.51 4.51 FALSE TRUE Change -Price
211036 9/1/1997 0 0 0 FALSE FALSE Delisted
211044 10/4/1997 3/1/1998 4.1 4.1 4.36 FALSE TRUE New Listing
211044 3/1/1998 10/1/1998 3.33 3.33 4.36 FALSE TRUE Change -Subsidy -Alternate
211044 10/1/1998 1/1/1999 1.83 1.83 4.64 FALSE TRUE Change -Subsidy +Price -Alternate
211044 1/1/1999 6/1/2006 1 1 4.64 FALSE TRUE Change -Subsidy -Alternate
211044 6/1/2006 10/1/2010 1 1 5.1 FALSE TRUE Change +Price
211044 10/1/2010 1 1 7.9 FALSE TRUE Change +Price
211060 10/4/1997 3/1/1998 4.1 4.1 4.36 FALSE TRUE New Listing
211060 3/1/1998 4/1/1998 3.33 3.33 4.36 FALSE TRUE Change -Subsidy -Alternate
211060 4/1/1998 10/1/1998 3.33 3.33 4.91 FALSE TRUE Change +Price
211060 10/1/1998 1/1/1999 1.83 1.83 4.91 FALSE TRUE Change -Subsidy -Alternate
211060 1/1/1999 2/1/2004 1 1 4.91 FALSE TRUE Change -Subsidy -Alternate
211060 2/1/2004 0 0 0 FALSE FALSE Delisted
211109 5/16/1994 5/17/1995 6.5 6.5 7.3 FALSE TRUE New Listing
211109 5/17/1995 3/1/1998 6.5 6.5 6.5 FALSE TRUE Change -Price
211109 3/1/1998 10/1/1998 3.33 3.33 7.3 FALSE TRUE Change -Subsidy +Price -Alternate
211109 10/1/1998 1/1/1999 1.83 1.83 7.3 FALSE TRUE Change -Subsidy -Alternate
211109 1/1/1999 2/1/2004 1 1 7.3 FALSE TRUE Change -Subsidy -Alternate
211109 2/1/2004 0 0 0 FALSE FALSE Delisted
211133 5/16/1994 9/1/2002 4.9 4.9 5.98 FALSE TRUE New Listing
211133 9/1/2002 9/1/2005 4.28 4.28 4.28 FALSE TRUE Change -Subsidy -Price -Alternate
211133 9/1/2005 12/1/2005 3.03 3.03 3.03 FALSE TRUE Change -Subsidy -Price -Alternate
211133 12/1/2005 0 0 0 FALSE FALSE Delisted
211168 5/16/1994 12/1/1997 4.66 4.66 5.74 FALSE TRUE New Listing
211168 12/1/1997 5/1/2000 4.4 4.4 5.74 FALSE TRUE Change -Subsidy -Alternate
211168 5/1/2000 0 0 0 FALSE FALSE Delisted
211176 5/16/1994 5/1/2000 4.4 4.4 5.21 FALSE FALSE New Listing
211176 5/1/2000 0 0 0 FALSE FALSE Delisted
211192 6/8/1995 5/1/1997 15 15 15.26 FALSE FALSE New Listing
211192 5/1/1997 2/1/2007 15 15 18.7 FALSE FALSE Change +Price
211192 2/1/2007 0 0 0 FALSE FALSE Delisted
211206 6/1/1997 1/1/1998 1.51 1.51 1.89 FALSE FALSE New Listing
211206 1/1/1998 12/1/2000 0.75 0.75 3.4 FALSE FALSE Change -Subsidy +Price -Alternate
211206 12/1/2000 3/1/2002 0.75 0.75 4.45 FALSE FALSE Change +Price
211206 3/1/2002 6/1/2002 0.75 0.75 4.32 FALSE FALSE Change -Price
211206 6/1/2002 4/1/2004 0.75 0.75 4.45 FALSE FALSE Change +Price
211206 4/1/2004 0 0 0 FALSE FALSE Delisted
211214 6/1/1997 1/1/1998 3.02 3.02 3.78 FALSE FALSE New Listing
211214 1/1/1998 12/1/2000 1.5 1.5 5.64 FALSE FALSE Change -Subsidy +Price -Alternate
211214 12/1/2000 3/1/2002 1.5 1.5 6.9 FALSE FALSE Change +Price
211214 3/1/2002 6/1/2002 1.5 1.5 6.69 FALSE FALSE Change -Price
211214 6/1/2002 8/1/2003 1.5 1.5 6.9 FALSE FALSE Change +Price
211214 8/1/2003 4/1/2004 1.5 1.5 7.25 FALSE FALSE Change +Price
211214 4/1/2004 0 0 0 FALSE FALSE Delisted
211265 5/16/1994 9/1/2002 4.2 4.2 4.41 FALSE TRUE New Listing
211265 9/1/2002 4.15 4.15 4.15 FALSE TRUE Change -Subsidy -Price -Alternate
211303 8/1/1997 5/1/1998 55.5 55.5 55.5 FALSE FALSE New Listing
211303 5/1/1998 1/1/2001 36.08 36.08 36.08 FALSE FALSE Change -Subsidy -Price -Alternate
211303 1/1/2001 2/1/2003 30 30 30 FALSE FALSE Change -Subsidy -Price -Alternate
211303 2/1/2003 0 0 0 FALSE FALSE Delisted
211354 5/16/1994 8/1/2001 118.81 118.81 118.81 FALSE FALSE New Listing
211354 8/1/2001 9/1/2003 59.9 59.9 59.9 FALSE FALSE Change -Subsidy -Price -Alternate
211354 9/1/2003 12/1/2003 54 54 59.9 FALSE FALSE Change -Subsidy -Alternate
211354 12/1/2003 0 0 0 FALSE FALSE Delisted
211362 5/16/1994 8/1/2001 86.24 86.24 86.24 FALSE FALSE New Listing
211362 8/1/2001 11/1/2004 59.9 59.9 59.9 FALSE FALSE Change -Subsidy -Price -Alternate
211362 11/1/2004 0 0 0 FALSE FALSE Delisted
211389 11/1/2006 95 95 95 FALSE FALSE New listing
211443 5/16/1994 8/1/2001 7.62 7.62 7.62 FALSE FALSE New Listing
211443 8/1/2001 4/1/2005 4.95 4.95 7.62 FALSE FALSE Change -Subsidy -Alternate
211443 4/1/2005 0 0 0 FALSE FALSE Delisted
211486 5/16/1994 2/1/2002 20.5 20.5 20.5 FALSE FALSE New Listing
211486 2/1/2002 0 0 0 FALSE FALSE Delisted
211559 5/16/1994 2/1/1999 20.58 20.58 23.82 FALSE FALSE New Listing
211559 2/1/1999 9/1/2000 20.58 20.58 41.6 FALSE FALSE Change +Price
211559 9/1/2000 0 0 0 FALSE FALSE Delisted
211575 5/16/1994 2/1/1998 35.6 35.6 35.6 FALSE TRUE New Listing
211575 2/1/1998 0 0 0 FALSE FALSE Delisted
211591 5/16/1994 2/1/1998 35.6 35.6 35.6 FALSE TRUE New Listing
211591 2/1/1998 0 0 0 FALSE FALSE Delisted
211648 5/20/1995 3/1/1998 4.42 4.42 4.42 FALSE TRUE New Listing
211648 3/1/1998 0 0 0 FALSE FALSE Delisted
211842 5/1/1997 6/1/1998 6.9 6.9 8.1 FALSE FALSE New Listing
211842 6/1/1998 12/1/2003 6.9 6.9 6.9 FALSE FALSE Change -Price
211842 12/1/2003 3/1/2004 3.5 3.5 3.5 FALSE FALSE Change -Subsidy -Price -Alternate
211842 3/1/2004 0 0 0 FALSE FALSE Delisted
211850 6/1/1995 7/1/1998 6.75 6.75 6.75 FALSE TRUE New Listing
211850 7/1/1998 6/1/1999 6.75 6.75 14.09 FALSE TRUE Change +Price
211850 6/1/1999 1/1/2001 9.03 9.03 14.09 FALSE TRUE Change +Subsidy +Alternate
211850 1/1/2001 4/1/2001 9.03 9.03 14.6 FALSE TRUE Change +Price
211850 4/1/2001 1/1/2002 9.03 9.03 16.21 FALSE TRUE Change +Price
211850 1/1/2002 6/1/2005 9.03 9.03 18.11 FALSE TRUE Change +Price
211850 6/1/2005 0 0 0 FALSE FALSE Delisted
211869 6/1/1995 10/1/1998 0.75 0.75 0.75 FALSE TRUE New Listing
211869 10/1/1998 0 0 0 FALSE FALSE Delisted
211877 10/4/1997 12/1/1997 40.51 40.51 40.51 FALSE FALSE New Listing
211877 12/1/1997 8/1/2000 30.38 30.38 30.38 FALSE FALSE Change -Subsidy -Price -Alternate
211877 8/1/2000 3/1/2001 7.08 7.08 7.08 FALSE FALSE Change -Subsidy -Price -Alternate
211877 3/1/2001 0 0 0 FALSE FALSE Delisted
212032 8/16/1994 4/1/1998 1.59 1.59 2.56 FALSE FALSE New Listing
212032 4/1/1998 0 0 0 FALSE FALSE Delisted
212040 5/16/1994 4/1/1998 3.56 3.56 7.28 FALSE FALSE New Listing
212040 4/1/1998 0 0 0 FALSE FALSE Delisted
212059 6/1/1995 12/1/1997 328.73 328.73 328.73 FALSE TRUE New Listing
212059 12/1/1997 10/1/2008 305 305 305 FALSE TRUE Change -Subsidy -Price -Alternate
212059 10/1/2008 320 320 320 FALSE TRUE Change +Subsidy +Price +Alternate
212156 10/1/1997 6/1/2000 550 550 550 FALSE FALSE New Listing
212156 6/1/2000 0 0 0 FALSE FALSE Delisted
212172 10/1/1997 6/1/2000 275 275 275 FALSE FALSE New Listing
212172 6/1/2000 0 0 0 FALSE FALSE Delisted
212180 5/16/1994 11/1/2002 2182.5 2182.5 2182.5 FALSE FALSE New Listing
212180 11/1/2002 6/1/2006 2000 2000 2000 FALSE FALSE Change -Subsidy -Price -Alternate
212180 6/1/2006 0 0 0 FALSE FALSE Delisted
212229 2/1/1998 11/1/2001 16.06 16.06 16.06 FALSE FALSE New Listing
212229 11/1/2001 2/1/2002 7.65 7.65 16.06 FALSE FALSE Change -Subsidy +Price -Alternate
212229 2/1/2002 0 0 0 FALSE FALSE Delisted
212415 5/16/1994 4/1/1997 1.2 1.2 2.22 FALSE FALSE New Listing
212415 4/1/1997 2/1/2000 1.2 1.2 3.6 FALSE FALSE Change +Price
212415 2/1/2000 3/1/2001 1.2 1.2 4.25 FALSE FALSE Change +Price
212415 3/1/2001 4/1/2002 1.2 1.2 4.68 FALSE FALSE Change +Price
212415 4/1/2002 4/1/2003 1.2 1.2 5.15 FALSE FALSE Change +Price
212415 4/1/2003 4/1/2004 1.2 1.2 5.67 FALSE FALSE Change +Price
212415 4/1/2004 1.2 1.2 6.24 FALSE FALSE Change +Price
212555 6/1/1995 11/1/1999 5.78 5.78 5.78 FALSE TRUE New Listing
212555 11/1/1999 0 0 0 FALSE FALSE Delisted
212741 5/16/1994 3/1/2008 2.88 2.88 2.88 FALSE TRUE New Listing
212741 3/1/2008 0 0 0 FALSE FALSE Delisted
213071 5/1/1999 8/1/2001 7.99 7.99 9.6 FALSE FALSE New Listing
213071 8/1/2001 11/1/2001 4.37 4.37 9.6 FALSE FALSE Change -Subsidy -Alternate
213071 11/1/2001 0 0 0 FALSE FALSE Delisted
213098 5/16/1994 3/1/1996 30 30 30 FALSE FALSE New Listing
213098 3/1/1996 4/1/1996 23.17 23.17 30 FALSE FALSE Change -Subsidy -Alternate
213098 4/1/1996 3/1/1999 23.17 23.17 23.17 FALSE FALSE Change -Price
213098 3/1/1999 6/1/1999 19.9 19.9 19.9 FALSE FALSE Change -Subsidy -Price -Alternate
213098 6/1/1999 12/1/1999 13.9 19.9 19.9 FALSE FALSE Change -Subsidy
213098 12/1/1999 8/1/2000 8.11 19.9 19.9 FALSE FALSE Change -Subsidy
213098 8/1/2000 3/1/2003 4.17 19.9 19.9 FALSE FALSE Change -Subsidy
213098 3/1/2003 12/1/2003 12.81 19.9 19.9 FALSE FALSE Change +Subsidy
213098 12/1/2003 9/1/2006 4.69 19.9 19.9 FALSE FALSE Change -Subsidy
213098 9/1/2006 5.5 5.5 19.9 FALSE FALSE Change +Subsidy -Alternate
213101 5/16/1994 3/1/1999 37.5 37.5 37.5 FALSE FALSE New Listing
213101 3/1/1999 6/1/1999 29.5 29.5 29.5 FALSE FALSE Change -Subsidy -Price -Alternate
213101 6/1/1999 12/1/1999 22.5 29.5 29.5 FALSE FALSE Change -Subsidy
213101 12/1/1999 9/1/2002 13.12 29.5 29.5 FALSE FALSE Change -Subsidy
213101 9/1/2002 3/1/2003 7.01 29.5 29.5 FALSE FALSE Change -Subsidy
213101 3/1/2003 12/1/2003 24.38 29.5 29.5 FALSE FALSE Change +Subsidy
213101 12/1/2003 9/1/2006 7.01 29.5 29.5 FALSE FALSE Change -Subsidy
213101 9/1/2006 8 8 29.5 FALSE FALSE Change +Subsidy -Alternate
213128 5/16/1994 3/1/1996 23.16 23.16 23.16 FALSE FALSE New Listing
213128 3/1/1996 6/1/1996 22 22 23.16 FALSE FALSE Change -Subsidy -Alternate
213128 6/1/1996 6/1/1999 15 15 23.16 FALSE FALSE Change -Subsidy -Alternate
213128 6/1/1999 12/1/1999 9.56 9.56 17.72 FALSE FALSE Change -Subsidy -Price -Alternate
213128 12/1/1999 9/1/2002 5.25 5.25 17.72 FALSE FALSE Change -Subsidy -Alternate
213128 9/1/2002 0 0 0 FALSE FALSE Delisted
214396 2/1/1998 8/1/2000 11.1 11.1 11.1 FALSE FALSE New Listing
214396 8/1/2000 12/1/2000 4.86 4.86 11.1 FALSE FALSE Change -Subsidy -Alternate
214396 12/1/2000 0 0 0 FALSE FALSE Delisted
214507 6/16/1995 6/1/2000 11.44 11.44 12 FALSE TRUE New Listing
214507 6/1/2000 0 0 0 FALSE FALSE Delisted
214515 6/16/1995 6/1/2000 9.22 9.22 9.22 FALSE TRUE New Listing
214515 6/1/2000 0 0 0 FALSE FALSE Delisted
214531 5/16/1994 9/1/1996 66.65 66.65 66.65 FALSE FALSE New Listing
214531 9/1/1996 3/1/1999 60 60 60 FALSE FALSE Change -Subsidy -Price -Alternate
214531 3/1/1999 3/1/2000 52.2 52.2 52.2 FALSE FALSE Change -Subsidy -Price -Alternate
214531 3/1/2000 0 0 0 FALSE FALSE Delisted
214558 5/16/1994 7/1/2004 13.18 13.18 13.18 FALSE TRUE New Listing
214558 7/1/2004 11.8 11.8 11.8 FALSE TRUE Change -Subsidy -Price -Alternate
214728 5/16/1994 4/1/2000 4.14 4.14 3.25 FALSE FALSE New Listing
214728 4/1/2000 0 0 0 FALSE FALSE Delisted
214736 5/16/1994 4/1/2000 8.28 8.28 4.93 FALSE FALSE New Listing
214736 4/1/2000 0 0 0 FALSE FALSE Delisted
214833 5/16/1994 7/1/2000 20 20 20 FALSE FALSE New Listing
214833 7/1/2000 4/1/2011 18 18 18 FALSE FALSE Change -Subsidy -Price -Alternate
214833 4/1/2011 17.1 17.1 17.1 FALSE FALSE Change -Subsidy -Price -Alternate
214949 5/11/1995 2/1/2000 0.64 0.64 2.07 FALSE FALSE New Listing
214949 2/1/2000 11/1/2000 0.52 0.52 1.29 FALSE FALSE Change -Subsidy -Price -Alternate
214949 11/1/2000 7/1/2001 0.52 0.52 2.35 FALSE FALSE Change +Price
214949 7/1/2001 3/1/2002 0.52 0.52 2.4 FALSE FALSE Change +Price
214949 3/1/2002 9/1/2002 0.52 0.52 2.5 FALSE FALSE Change +Price
214949 9/1/2002 12/1/2002 0.64 0.64 2.5 FALSE FALSE Change +Subsidy +Alternate
214949 12/1/2002 5/1/2006 0.64 0.64 2.43 FALSE FALSE Change -Price
214949 5/1/2006 8/1/2006 0.64 0.64 2.48 FALSE FALSE Change +Price
214949 8/1/2006 11/1/2006 0.54 0.54 2.48 FALSE FALSE Change -Subsidy -Alternate
214949 11/1/2006 0 0 0 FALSE FALSE Delisted
214965 5/11/1995 2/1/2000 1.28 1.28 3.44 FALSE FALSE New Listing
214965 2/1/2000 11/1/2000 1.04 1.04 2.58 FALSE FALSE Change -Subsidy -Price -Alternate
214965 11/1/2000 0 0 0 FALSE FALSE Delisted
215112 8/1/1995 5/1/2000 0.59 0.59 2.27 FALSE FALSE New Listing
215112 5/1/2000 4/1/2008 0.59 0.59 3.07 FALSE FALSE Change +Price
215112 4/1/2008 0 0 0 FALSE FALSE Delisted
215929 5/16/1994 2/1/2000 2.79 2.79 4.56 FALSE FALSE New Listing
215929 2/1/2000 3/1/2001 2.79 2.79 5.5 FALSE FALSE Change +Price
215929 3/1/2001 4/1/2002 2.79 2.79 6.05 FALSE FALSE Change +Price
215929 4/1/2002 4/1/2003 2.79 2.79 6.66 FALSE FALSE Change +Price
215929 4/1/2003 4/1/2004 2.79 2.79 7.33 FALSE FALSE Change +Price
215929 4/1/2004 9/1/2006 2.79 2.79 8.06 FALSE FALSE Change +Price
215929 9/1/2006 2.79 2.79 8.06 FALSE TRUE Change +OP
216518 7/1/2012 0 0 84.83 FALSE FALSE New listing
216836 5/16/1994 1/11/1995 6.46 6.46 6.46 FALSE FALSE New Listing
216836 1/11/1995 2/1/1998 6.16 6.16 6.16 FALSE FALSE Change -Subsidy -Price -Alternate
216836 2/1/1998 8/1/2000 3.7 3.7 3.7 FALSE FALSE Change -Subsidy -Price -Alternate
216836 8/1/2000 12/1/2000 1.62 1.62 3.7 FALSE FALSE Change -Subsidy -Alternate
216836 12/1/2000 0 0 0 FALSE FALSE Delisted
216879 2/1/1998 8/1/2000 0.52 0.52 0.52 FALSE FALSE New Listing
216879 8/1/2000 12/1/2000 0.33 0.33 0.52 FALSE FALSE Change -Subsidy -Alternate
216879 12/1/2000 0 0 0 FALSE FALSE Delisted
216909 8/1/2012 0 0 40 FALSE FALSE New listing
217050 7/1/1997 7/1/1999 1.31 1.31 2.5 FALSE FALSE New Listing
217050 7/1/1999 11/1/1999 0.73 0.73 0.73 FALSE FALSE Change -Subsidy -Price -Alternate
217050 11/1/1999 0 0 0 FALSE FALSE Delisted
217093 7/1/1997 7/1/1999 4.17 4.17 7.5 FALSE FALSE New Listing
217093 7/1/1999 11/1/1999 2.19 2.19 2.19 FALSE FALSE Change -Subsidy -Price -Alternate
217093 11/1/1999 0 0 0 FALSE FALSE Delisted
217107 10/1/1997 2/1/1998 5.39 5.39 5.39 FALSE FALSE New Listing
217107 2/1/1998 9/1/2000 4.04 4.04 4.04 FALSE FALSE Change -Subsidy -Price -Alternate
217107 9/1/2000 1/1/2001 1.16 1.16 4.04 FALSE FALSE Change -Subsidy -Alternate
217107 1/1/2001 0 0 0 FALSE FALSE Delisted
217158 10/1/1997 2/1/1998 10.47 10.47 10.47 FALSE FALSE New Listing
217158 2/1/1998 9/1/2000 7.85 7.85 7.85 FALSE FALSE Change -Subsidy -Price -Alternate
217158 9/1/2000 1/1/2001 1.89 1.89 7.85 FALSE FALSE Change -Subsidy -Alternate
217158 1/1/2001 0 0 0 FALSE FALSE Delisted
217379 5/16/1994 5/1/1997 8.62 8.62 8.62 FALSE FALSE New Listing
217379 5/1/1997 9/1/1997 5.17 5.17 8.62 FALSE FALSE Change -Subsidy -Alternate
217379 9/1/1997 1/1/1998 8.62 8.62 8.62 FALSE FALSE Change +Subsidy +Alternate
217379 1/1/1998 2/1/1998 6.9 6.9 6.9 FALSE FALSE Change -Subsidy -Price -Alternate
217379 2/1/1998 9/1/1998 5.17 5.17 5.17 FALSE FALSE Change -Subsidy -Price -Alternate
217379 9/1/1998 8/1/2000 5.02 5.02 5.02 FALSE FALSE Change -Subsidy -Price -Alternate
217379 8/1/2000 12/1/2000 3.09 3.09 5.02 FALSE FALSE Change -Subsidy -Alternate
217379 12/1/2000 0 0 0 FALSE FALSE Delisted
217387 5/16/1994 5/1/1997 17.16 17.16 17.16 FALSE FALSE New Listing
217387 5/1/1997 9/1/1997 10.3 10.3 17.16 FALSE FALSE Change -Subsidy -Alternate
217387 9/1/1997 1/1/1998 17.16 17.16 17.16 FALSE FALSE Change +Subsidy +Alternate
217387 1/1/1998 2/1/1998 12.9 12.9 12.9 FALSE FALSE Change -Subsidy -Price -Alternate
217387 2/1/1998 9/1/1998 10.3 10.3 10.3 FALSE FALSE Change -Subsidy -Price -Alternate
217387 9/1/1998 8/1/2000 10.04 10.04 10.04 FALSE FALSE Change -Subsidy -Price -Alternate
217387 8/1/2000 12/1/2000 4.79 4.79 10.04 FALSE FALSE Change -Subsidy -Alternate
217387 12/1/2000 0 0 0 FALSE FALSE Delisted
217867 3/1/1999 12/1/2001 161 161 161 FALSE FALSE New Listing
217867 12/1/2001 0 0 0 FALSE FALSE Delisted
217875 8/1/1998 9/1/2002 6.15 6.15 6.15 FALSE FALSE New Listing
217875 9/1/2002 7/1/2009 5.8 5.8 5.8 FALSE FALSE Change -Subsidy -Price -Alternate
217875 7/1/2009 6/1/2014 5.22 5.22 5.22 FALSE FALSE Change -Subsidy -Price -Alternate
217875 6/1/2014 9/1/2014 3.82 3.82 3.82 FALSE FALSE Change -Subsidy -Price -Alternate
217875 9/1/2014 0 0 0 FALSE FALSE Delisted
218235 8/1/1998 12/1/2002 10.6 10.6 10.6 FALSE FALSE New Listing
218235 12/1/2002 0 0 0 FALSE FALSE Delisted
218278 5/16/1994 12/1/1995 1.26 1.26 2.74 FALSE FALSE New Listing
218278 12/1/1995 11/1/1996 1.26 1.26 3.2 FALSE FALSE Change +Price
218278 11/1/1996 8/1/2000 1.26 3.3 3.3 FALSE FALSE Change +Price +Alternate
218278 8/1/2000 12/1/2000 1.26 3.64 3.64 FALSE FALSE Change +Price +Alternate
218278 12/1/2000 3/1/2001 1.26 3.75 3.75 FALSE FALSE Change +Price +Alternate
218278 3/1/2001 3/1/2002 1.26 3.95 3.95 FALSE FALSE Change +Price +Alternate
218278 3/1/2002 1/1/2007 1.26 4.05 4.05 FALSE FALSE Change +Price +Alternate
218278 1/1/2007 2/1/2007 1.26 4.2 4.2 FALSE FALSE Change +Price +Alternate
218278 2/1/2007 3/1/2007 1.26 1.99 4.2 FALSE FALSE Change -Alternate
218278 3/1/2007 5/1/2007 1.26 4.2 4.2 FALSE FALSE Change +Alternate
218278 5/1/2007 0 0 0 FALSE FALSE Delisted
218294 5/16/1994 6/1/1995 5.05 5.05 9.02 FALSE FALSE New Listing
218294 6/1/1995 7/1/1997 2.52 2.52 4.65 FALSE FALSE Change -Subsidy -Price -Alternate
218294 7/1/1997 6/1/1998 2.52 2.52 5.47 FALSE FALSE Change +Price
218294 6/1/1998 2/1/1999 2.52 2.52 6.29 FALSE FALSE Change +Price
218294 2/1/1999 3/1/2000 2.52 2.52 7.55 FALSE FALSE Change +Price
218294 3/1/2000 2/1/2002 2.52 2.52 8.4 FALSE FALSE Change +Price
218294 2/1/2002 5/1/2003 2.52 2.52 8.82 FALSE FALSE Change +Price
218294 5/1/2003 9/1/2006 2.52 2.52 9.08 FALSE FALSE Change +Price
218294 9/1/2006 5/1/2010 2.52 2.52 9.99 FALSE FALSE Change +Price
218294 5/1/2010 0 0 0 FALSE FALSE Delisted
218308 5/16/1994 1/1/1996 6.75 6.75 6.75 FALSE FALSE New Listing
218308 1/1/1996 7/1/1997 6.75 6.75 7.3 FALSE FALSE Change +Price
218308 7/1/1997 6/1/1998 6.75 6.75 8.59 FALSE FALSE Change +Price
218308 6/1/1998 2/1/1999 6.75 6.75 9.88 FALSE FALSE Change +Price
218308 2/1/1999 3/1/2000 6.75 6.75 11.86 FALSE FALSE Change +Price
218308 3/1/2000 2/1/2002 6.75 6.75 13.2 FALSE FALSE Change +Price
218308 2/1/2002 5/1/2003 6.75 6.75 13.86 FALSE FALSE Change +Price
218308 5/1/2003 6/1/2006 6.75 6.75 14.28 FALSE FALSE Change +Price
218308 6/1/2006 0 0 0 FALSE FALSE Delisted
218375 10/4/1997 6/1/2004 4.95 4.95 4.95 FALSE TRUE New Listing
218375 6/1/2004 1/1/2010 3.96 3.96 3.96 FALSE TRUE Change -Subsidy -Price -Alternate
218375 1/1/2010 4/1/2010 2.38 2.38 2.38 FALSE TRUE Change -Subsidy -Price -Alternate
218375 4/1/2010 0 0 0 FALSE FALSE Delisted
218383 10/4/1997 6/1/2004 4.95 4.95 4.95 FALSE TRUE New Listing
218383 6/1/2004 1/1/2010 3.96 3.96 3.96 FALSE TRUE Change -Subsidy -Price -Alternate
218383 1/1/2010 4/1/2010 2.38 2.38 2.38 FALSE TRUE Change -Subsidy -Price -Alternate
218383 4/1/2010 0 0 0 FALSE FALSE Delisted
218405 4/1/1996 9/1/1996 600 600 600 FALSE FALSE New Listing
218405 9/1/1996 3/1/1999 540 540 540 FALSE FALSE Change -Subsidy -Price -Alternate
218405 3/1/1999 3/1/2000 469.8 469.8 469.8 FALSE FALSE Change -Subsidy -Price -Alternate
218405 3/1/2000 0 0 0 FALSE FALSE Delisted
218448 3/1/1996 7/1/1999 3.41 3.41 4.06 FALSE FALSE New Listing
218448 7/1/1999 11/1/1999 2.25 2.25 4.06 FALSE FALSE Change -Subsidy -Price -Alternate
218448 11/1/1999 0 0 0 FALSE FALSE Delisted
218510 3/1/1999 11/1/2002 156.6 156.6 156.6 FALSE FALSE New Listing
218510 11/1/2002 0 0 0 FALSE FALSE Delisted
218529 3/1/1999 3/1/2000 522 522 522 FALSE FALSE New Listing
218529 3/1/2000 0 0 0 FALSE FALSE Delisted
218537 3/1/1999 11/1/2002 261 261 261 FALSE FALSE New Listing
218537 11/1/2002 0 0 0 FALSE FALSE Delisted
219584 9/1/1996 3/1/1999 300 300 300 FALSE FALSE New Listing
219584 3/1/1999 11/1/2002 261 261 261 FALSE FALSE Change -Subsidy -Price -Alternate
219584 11/1/2002 0 0 0 FALSE FALSE Delisted
219843 1/1/2006 6/1/2006 170 170 170 FALSE FALSE New listing
219843 6/1/2006 144.5 144.5 144.5 FALSE FALSE Change -Subsidy -Price -Alternate
219916 1/1/2006 6/1/2006 95 95 95 FALSE FALSE New listing
219916 6/1/2006 11/1/2009 80.75 80.75 80.75 FALSE FALSE Change -Subsidy -Price -Alternate
219916 11/1/2009 115 115 115 FALSE FALSE Change +Subsidy +Price +Alternate
219924 5/16/1994 10/1/2002 189.5 189.5 189.5 FALSE FALSE New Listing
219924 10/1/2002 213.19 213.19 213.19 FALSE FALSE Change +Subsidy +Price +Alternate
220086 5/16/1994 4/1/1996 47.62 47.62 47.62 FALSE FALSE New Listing
220086 4/1/1996 0 0 0 FALSE FALSE Delisted
220582 3/1/1995 10/1/1998 1.81 1.81 5.95 FALSE FALSE New Listing
220582 10/1/1998 8/1/1999 1.81 1.81 2.53 FALSE FALSE Change -Price
220582 8/1/1999 12/1/2001 1.7 1.7 1.7 FALSE FALSE Change -Subsidy -Price -Alternate
220582 12/1/2001 11/1/2002 1.7 1.7 6.96 FALSE FALSE Change +Price
220582 11/1/2002 11/1/2003 2.14 2.14 2.14 FALSE FALSE Change +Subsidy -Price +Alternate
220582 11/1/2003 2/1/2004 1.64 1.64 2.14 FALSE FALSE Change -Subsidy -Alternate
220582 2/1/2004 0 0 0 FALSE FALSE Delisted
220590 3/1/1995 10/1/1998 3.62 3.62 10.77 FALSE FALSE New Listing
220590 10/1/1998 8/1/1999 3.62 3.62 5.07 FALSE FALSE Change -Price
220590 8/1/1999 12/1/2001 3.4 3.4 3.4 FALSE FALSE Change -Subsidy -Price -Alternate
220590 12/1/2001 11/1/2002 3.4 3.4 12.57 FALSE FALSE Change +Price
220590 11/1/2002 11/1/2003 4.28 4.28 4.28 FALSE FALSE Change +Subsidy -Price +Alternate
220590 11/1/2003 2/1/2004 3.28 3.28 4.28 FALSE FALSE Change -Subsidy -Alternate
220590 2/1/2004 0 0 0 FALSE FALSE Delisted
220612 7/1/1999 8/1/1999 0.33 0.33 0.33 FALSE FALSE New Listing
220612 8/1/1999 12/1/2001 0.22 0.22 0.22 FALSE FALSE Change -Subsidy -Price -Alternate
220612 12/1/2001 12/1/2002 0.22 0.22 3.1 FALSE FALSE Change +Price
220612 12/1/2002 3/1/2003 0.2 0.2 3.1 FALSE FALSE Change -Subsidy -Alternate
220612 3/1/2003 0 0 0 FALSE FALSE Delisted
220620 7/1/1999 8/1/1999 0.83 0.83 0.83 FALSE FALSE New Listing
220620 8/1/1999 12/1/2001 0.55 0.55 0.55 FALSE FALSE Change -Subsidy -Price -Alternate
220620 12/1/2001 12/1/2002 0.55 0.55 4.95 FALSE FALSE Change +Price
220620 12/1/2002 3/1/2003 0.49 0.49 4.95 FALSE FALSE Change -Subsidy -Alternate
220620 3/1/2003 0 0 0 FALSE FALSE Delisted
220639 7/1/1999 8/1/1999 1.67 1.67 1.67 FALSE FALSE New Listing
220639 8/1/1999 12/1/2001 1.1 1.1 1.1 FALSE FALSE Change -Subsidy -Price -Alternate
220639 12/1/2001 12/1/2002 1.1 1.1 8.66 FALSE FALSE Change +Price
220639 12/1/2002 3/1/2003 0.98 0.98 8.66 FALSE FALSE Change -Subsidy -Alternate
220639 3/1/2003 0 0 0 FALSE FALSE Delisted
220922 4/8/1995 8/1/1999 1.9 1.9 2.4 FALSE FALSE New Listing
220922 8/1/1999 0 0 0 FALSE FALSE Delisted
220930 4/8/1995 11/1/1998 1.39 1.39 1.73 FALSE FALSE New Listing
220930 11/1/1998 8/1/1999 1.39 1.39 1.4 FALSE FALSE Change -Price
220930 8/1/1999 0 0 0 FALSE FALSE Delisted
221058 4/8/1995 10/1/1996 3.6 3.6 3.6 FALSE FALSE New Listing
221058 10/1/1996 11/1/1998 3.25 3.25 3.25 FALSE FALSE Change -Subsidy -Price -Alternate
221058 11/1/1998 8/1/1999 3.25 3.25 3.6 FALSE FALSE Change +Price
221058 8/1/1999 0 0 0 FALSE FALSE Delisted
221066 10/1/1996 11/1/1998 6.5 6.5 5.28 FALSE FALSE New Listing
221066 11/1/1998 8/1/1999 6.5 6.5 7.2 FALSE FALSE Change +Price
221066 8/1/1999 0 0 0 FALSE FALSE Delisted
221074 10/1/1996 11/1/1998 13 13 8.29 FALSE FALSE New Listing
221074 11/1/1998 8/1/1999 13 13 14.4 FALSE FALSE Change +Price
221074 8/1/1999 0 0 0 FALSE FALSE Delisted
221155 4/11/1995 11/1/1998 1.93 1.93 1.93 FALSE FALSE New Listing
221155 11/1/1998 8/1/1999 1.93 1.93 2.15 FALSE FALSE Change +Price
221155 8/1/1999 0 0 0 FALSE FALSE Delisted
221198 10/1/1996 11/1/1998 4 4 4 FALSE FALSE New Listing
221198 11/1/1998 8/1/1999 4 4 5 FALSE FALSE Change +Price
221198 8/1/1999 0 0 0 FALSE FALSE Delisted
221201 4/11/1995 10/1/1996 3.1 3.1 3.1 FALSE FALSE New Listing
221201 10/1/1996 11/1/1998 2.75 2.75 2.75 FALSE FALSE Change -Subsidy -Price -Alternate
221201 11/1/1998 8/1/1999 2.75 2.75 3 FALSE FALSE Change +Price
221201 8/1/1999 0 0 0 FALSE FALSE Delisted
221244 4/11/1995 8/1/1999 0.79 0.79 1.5 FALSE FALSE New Listing
221244 8/1/1999 0 0 0 FALSE FALSE Delisted
221252 4/11/1995 8/1/1999 1.58 1.58 2.2 FALSE FALSE New Listing
221252 8/1/1999 0 0 0 FALSE FALSE Delisted
221260 4/11/1995 8/1/1999 7.9 7.9 7.9 FALSE FALSE New Listing
221260 8/1/1999 0 0 0 FALSE FALSE Delisted
221368 2/1/1996 8/1/1999 0.88 0.88 1.95 FALSE FALSE New Listing
221368 8/1/1999 0 0 0 FALSE FALSE Delisted
221376 2/1/1996 8/1/1999 1.77 1.77 2.4 FALSE FALSE New Listing
221376 8/1/1999 0 0 0 FALSE FALSE Delisted
221392 10/1/1997 8/1/1999 2.22 2.22 3.95 FALSE FALSE New Listing
221392 8/1/1999 4/1/2000 2.44 2.44 4.1 FALSE FALSE Change +Subsidy +Price +Alternate
221392 4/1/2000 12/1/2003 2.44 2.44 4.4 FALSE FALSE Change +Price
221392 12/1/2003 1/1/2005 2.44 2.44 5 FALSE FALSE Change +Price
221392 1/1/2005 2.44 2.44 5.1 FALSE FALSE Change +Price
221503 4/11/1995 8/1/1999 1.65 1.65 1.7 FALSE FALSE New Listing
221503 8/1/1999 4/1/2000 1.45 1.45 1.65 FALSE FALSE Change -Subsidy -Price -Alternate
221503 4/1/2000 5/1/2001 1.45 1.45 1.95 FALSE FALSE Change +Price
221503 5/1/2001 5/1/2002 1.45 1.45 2.35 FALSE FALSE Change +Price
221503 5/1/2002 12/1/2003 1.33 1.33 2.35 FALSE FALSE Change -Subsidy -Alternate
221503 12/1/2003 5/1/2004 1.33 1.33 2.5 FALSE FALSE Change +Price
221503 5/1/2004 6/1/2004 1.24 1.24 2.5 FALSE FALSE Change -Subsidy -Alternate
221503 6/1/2004 1/1/2005 1.24 1.24 2.59 FALSE FALSE Change +Price
221503 1/1/2005 9/1/2010 1.24 1.24 3 FALSE FALSE Change +Price
221503 9/1/2010 12/1/2010 0.89 0.89 3 FALSE FALSE Change -Subsidy -Alternate
221503 12/1/2010 0 0 0 FALSE FALSE Delisted
221511 4/11/1995 8/1/1999 3.3 3.3 3.25 FALSE FALSE New Listing
221511 8/1/1999 1/1/2000 2.9 2.9 3.3 FALSE FALSE Change -Subsidy +Price -Alternate
221511 1/1/2000 5/1/2001 2.9 2.9 3.6 FALSE FALSE Change +Price
221511 5/1/2001 5/1/2002 2.9 2.9 4 FALSE FALSE Change +Price
221511 5/1/2002 12/1/2003 2.67 2.67 4 FALSE FALSE Change -Subsidy -Alternate
221511 12/1/2003 5/1/2004 2.67 2.67 4.25 FALSE FALSE Change +Price
221511 5/1/2004 6/1/2004 2.48 2.48 4.25 FALSE FALSE Change -Subsidy -Alternate
221511 6/1/2004 1/1/2005 2.48 2.48 4.4 FALSE FALSE Change +Price
221511 1/1/2005 9/1/2010 2.48 2.48 4.9 FALSE FALSE Change +Price
221511 9/1/2010 12/1/2010 1.79 1.79 4.9 FALSE FALSE Change -Subsidy -Alternate
221511 12/1/2010 0 0 0 FALSE FALSE Delisted
221554 12/1/1995 9/1/1999 2.89 2.89 3.35 FALSE FALSE New Listing
221554 9/1/1999 12/1/2000 2.89 2.89 3.32 FALSE FALSE Change -Price
221554 12/1/2000 6/1/2001 2.89 2.89 3.58 FALSE FALSE Change +Price
221554 6/1/2001 0 0 0 FALSE FALSE Delisted
221562 12/1/1995 9/1/1999 14.46 14.46 14.46 FALSE FALSE New Listing
221562 9/1/1999 12/1/2000 14.46 14.46 16.6 FALSE FALSE Change +Price
221562 12/1/2000 4/1/2004 14.46 14.46 17.9 FALSE FALSE Change +Price
221562 4/1/2004 0 0 0 FALSE FALSE Delisted
221570 6/10/1995 11/1/1998 0.67 0.67 0.9 FALSE FALSE New Listing
221570 11/1/1998 8/1/1999 0.67 0.67 0.8 FALSE FALSE Change -Price
221570 8/1/1999 12/1/2000 0.63 0.63 1.6 FALSE FALSE Change -Subsidy +Price -Alternate
221570 12/1/2000 5/1/2001 0.63 0.63 1.75 FALSE FALSE Change +Price
221570 5/1/2001 12/1/2003 0.63 0.63 1.95 FALSE FALSE Change +Price
221570 12/1/2003 6/1/2004 0.63 0.63 2.1 FALSE FALSE Change +Price
221570 6/1/2004 1/1/2005 0.63 0.63 2.15 FALSE FALSE Change +Price
221570 1/1/2005 1/1/2011 0.63 0.63 2.35 FALSE FALSE Change +Price
221570 1/1/2011 0 0 0 FALSE FALSE Delisted
221589 8/1/1997 8/1/1999 1.23 1.23 4.2 FALSE FALSE New Listing
221589 8/1/1999 0 0 0 FALSE FALSE Delisted
221619 6/1/1997 10/1/1998 0.75 0.75 0.87 FALSE FALSE New Listing
221619 10/1/1998 8/1/1999 0.75 0.75 0.99 FALSE FALSE Change +Price
221619 8/1/1999 6/1/2002 0.7 0.7 0.7 FALSE FALSE Change -Subsidy -Price -Alternate
221619 6/1/2002 0 0 0 FALSE FALSE Delisted
221686 4/11/1995 11/1/1998 1.01 1.01 1.52 FALSE FALSE New Listing
221686 11/1/1998 8/1/1999 1.01 1.01 1.1 FALSE FALSE Change -Price
221686 8/1/1999 0 0 0 FALSE FALSE Delisted
221694 4/11/1995 11/1/1998 2.02 2.02 2.02 FALSE FALSE New Listing
221694 11/1/1998 8/1/1999 2.02 2.02 2.2 FALSE FALSE Change +Price
221694 8/1/1999 0 0 0 FALSE FALSE Delisted
221708 4/11/1995 11/1/1998 4.04 4.04 2.91 FALSE FALSE New Listing
221708 11/1/1998 8/1/1999 4.04 4.04 4.4 FALSE FALSE Change +Price
221708 8/1/1999 0 0 0 FALSE FALSE Delisted
221740 4/11/1995 8/1/1999 2.37 2.37 2.85 FALSE FALSE New Listing
221740 8/1/1999 0 0 0 FALSE FALSE Delisted
221759 4/11/1995 8/1/1999 5.92 5.92 5.92 FALSE FALSE New Listing
221759 8/1/1999 0 0 0 FALSE FALSE Delisted
221775 5/16/1994 9/1/2000 36.8 36.8 36.8 FALSE FALSE New Listing
221775 9/1/2000 3/1/2001 36.8 36.8 130 FALSE FALSE Change +Price
221775 3/1/2001 36.8 36.8 135 FALSE FALSE Change +Price
221783 4/11/1995 8/1/1999 6.63 6.63 6.63 FALSE FALSE New Listing
221783 8/1/1999 5/1/2002 6.63 6.63 7.9 FALSE FALSE Change +Price
221783 5/1/2002 6/1/2004 3.58 3.58 7.9 FALSE FALSE Change -Subsidy -Alternate
221783 6/1/2004 3.58 3.58 8.69 FALSE FALSE Change +Price
221813 7/1/1997 8/1/1999 0.81 0.81 2.8 FALSE FALSE New Listing
221813 8/1/1999 9/1/1999 0.89 0.89 2.8 FALSE FALSE Change +Subsidy +Alternate
221813 9/1/1999 12/1/2000 0.89 0.89 3.1 FALSE FALSE Change +Subsidy +Price +Alternate
221813 12/1/2000 8/1/2004 0.89 0.89 3.45 FALSE FALSE Change +Price
221813 8/1/2004 0 0 0 FALSE FALSE Delisted
221856 5/10/1995 10/1/1997 4.56 4.56 7.45 FALSE FALSE New Listing
221856 10/1/1997 10/1/1998 4.1 4.1 7.45 FALSE FALSE Change -Subsidy -Alternate
221856 10/1/1998 3/1/2002 3.7 3.7 7.45 FALSE FALSE Change -Subsidy -Alternate
221856 3/1/2002 0 0 0 FALSE FALSE Delisted
221864 4/12/1995 7/1/1997 18.45 18.45 18.45 FALSE FALSE New Listing
221864 7/1/1997 5/1/1999 18.45 18.45 20.3 FALSE FALSE Change +Price
221864 5/1/1999 0 0 0 FALSE FALSE Delisted
221872 7/1/1997 8/1/1999 2.84 2.84 4.29 FALSE FALSE New Listing
221872 8/1/1999 0 0 0 FALSE FALSE Delisted
221880 5/10/1995 10/1/1997 4.56 4.56 7.45 FALSE FALSE New Listing
221880 10/1/1997 10/1/1998 4.1 4.1 7.45 FALSE FALSE Change -Subsidy -Alternate
221880 10/1/1998 3/1/2002 3.7 3.7 7.45 FALSE FALSE Change -Subsidy -Alternate
221880 3/1/2002 0 0 0 FALSE FALSE Delisted
221945 4/11/1995 8/1/1999 1.19 1.19 1.9 FALSE FALSE New Listing
221945 8/1/1999 0 0 0 FALSE FALSE Delisted
221953 4/11/1995 8/1/1999 2.38 2.38 2.85 FALSE FALSE New Listing
221953 8/1/1999 0 0 0 FALSE FALSE Delisted
221961 4/11/1995 8/1/1999 5.95 5.95 5.95 FALSE FALSE New Listing
221961 8/1/1999 0 0 0 FALSE FALSE Delisted
222011 8/1/2007 4/1/2013 0.75 0.75 0.75 FALSE TRUE New listing
222011 4/1/2013 0 0 0 FALSE FALSE Delisted
222240 5/11/1995 2/1/2000 0.64 0.64 2.38 FALSE FALSE New Listing
222240 2/1/2000 8/1/2001 0.52 0.52 2.38 FALSE FALSE Change -Subsidy -Alternate
222240 8/1/2001 9/1/2002 0.52 0.52 2.46 FALSE FALSE Change +Price
222240 9/1/2002 7/1/2004 0.64 0.64 2.46 FALSE FALSE Change +Subsidy +Alternate
222240 7/1/2004 8/1/2006 0.64 0.64 2.53 FALSE FALSE Change +Price
222240 8/1/2006 11/1/2006 0.54 0.54 2.53 FALSE FALSE Change -Subsidy -Alternate
222240 11/1/2006 0 0 0 FALSE FALSE Delisted
222445 5/16/1994 4/1/1997 4.16 4.16 4.16 FALSE FALSE New Listing
222445 4/1/1997 0 0 0 FALSE FALSE Delisted
222666 6/1/1999 12/1/1999 9.56 9.56 9.56 FALSE FALSE New Listing
222666 12/1/1999 4/1/2002 5.25 5.25 5.25 FALSE FALSE Change -Subsidy -Price -Alternate
222666 4/1/2002 0 0 0 FALSE FALSE Delisted
222976 1/9/1995 12/1/1995 24.05 24.05 24.05 FALSE FALSE New Listing
222976 12/1/1995 4/1/1998 25.26 25.26 25.26 FALSE TRUE Change +Subsidy +Price +Alternate +OP
222976 4/1/1998 0 0 0 FALSE FALSE Delisted
222992 1/9/1995 12/1/1995 24.05 24.05 24.05 FALSE FALSE New Listing
222992 12/1/1995 4/1/1998 25.26 25.26 25.26 FALSE TRUE Change +Subsidy +Price +Alternate +OP
222992 4/1/1998 0 0 0 FALSE FALSE Delisted
223018 1/9/1995 12/1/1995 20.32 20.32 20.32 FALSE FALSE New Listing
223018 12/1/1995 4/1/1998 21.34 21.34 21.34 FALSE FALSE Change +Subsidy +Price +Alternate
223018 4/1/1998 0 0 0 FALSE FALSE Delisted
223034 1/9/1995 12/1/1995 20.32 20.32 20.32 FALSE FALSE New Listing
223034 12/1/1995 4/1/1998 21.34 21.34 21.34 FALSE FALSE Change +Subsidy +Price +Alternate
223034 4/1/1998 0 0 0 FALSE FALSE Delisted
223042 1/9/1995 12/1/1995 24.05 24.05 24.05 FALSE FALSE New Listing
223042 12/1/1995 4/1/1998 25.26 25.26 25.26 FALSE TRUE Change +Subsidy +Price +Alternate +OP
223042 4/1/1998 0 0 0 FALSE FALSE Delisted
223166 4/1/1996 9/1/1998 9.83 9.83 9.83 FALSE FALSE New Listing
223166 9/1/1998 3/1/2001 3 3 3 FALSE FALSE Change -Subsidy -Price -Alternate
223166 3/1/2001 0 0 0 FALSE FALSE Delisted
223174 5/16/1994 3/1/1996 54.6 54.6 54.6 FALSE FALSE New Listing
223174 3/1/1996 4/1/1996 19.66 19.66 32.76 FALSE FALSE Change -Subsidy -Price -Alternate
223174 4/1/1996 9/1/1998 19.66 19.66 19.66 FALSE FALSE Change -Price
223174 9/1/1998 9/1/1999 6 6 6 FALSE FALSE Change -Subsidy -Price -Alternate
223174 9/1/1999 0 0 0 FALSE FALSE Delisted
223549 5/16/1994 1/1/1996 13.88 13.88 15 FALSE FALSE New Listing
223549 1/1/1996 7/1/1997 6.94 6.94 8.57 FALSE FALSE Change -Subsidy -Price -Alternate
223549 7/1/1997 6/1/1998 6.94 6.94 9 FALSE FALSE Change +Price
223549 6/1/1998 2/1/1999 6.94 6.94 10.08 FALSE FALSE Change +Price
223549 2/1/1999 3/1/2000 6.94 6.94 13.1 FALSE FALSE Change +Price
223549 3/1/2000 2/1/2002 6.94 6.94 14.9 FALSE FALSE Change +Price
223549 2/1/2002 5/1/2003 6.94 6.94 15.65 FALSE FALSE Change +Price
223549 5/1/2003 2/1/2010 6.94 6.94 16.9 FALSE FALSE Change +Price
223549 2/1/2010 0 0 0 FALSE FALSE Delisted
223689 5/16/1994 12/1/2002 13.5 13.5 13.5 FALSE FALSE New Listing
223689 12/1/2002 0 0 0 FALSE FALSE Delisted
224553 10/1/1997 6/1/1998 1.12 1.12 5.36 FALSE FALSE New Listing
224553 6/1/1998 6/1/2000 0.92 0.92 5.36 FALSE FALSE Change -Subsidy -Alternate
224553 6/1/2000 12/1/2000 0.81 0.81 5.36 FALSE FALSE Change -Subsidy -Alternate
224553 12/1/2000 3/1/2001 0.81 0.81 6.25 FALSE FALSE Change +Price
224553 3/1/2001 6/1/2002 0.81 0.81 6.45 FALSE FALSE Change +Price
224553 6/1/2002 7/1/2003 0.81 0.81 6.65 FALSE FALSE Change +Price
224553 7/1/2003 11/1/2003 0.89 0.89 6.65 FALSE FALSE Change +Subsidy +Alternate
224553 11/1/2003 2/1/2004 0.77 0.77 6.65 FALSE FALSE Change -Subsidy -Alternate
224553 2/1/2004 0 0 0 FALSE FALSE Delisted
224715 12/1/1995 4/1/2003 11.2 11.2 11.2 FALSE FALSE New Listing
224715 4/1/2003 11/1/2004 1.97 1.97 4.66 FALSE FALSE Change -Subsidy -Price -Alternate
224715 11/1/2004 8/1/2005 1.48 1.48 4.66 FALSE FALSE Change -Subsidy -Alternate
224715 8/1/2005 0 0 0 FALSE FALSE Delisted
224731 3/31/1995 4/1/2003 18.2 18.2 18.2 FALSE FALSE New Listing
224731 4/1/2003 11/1/2004 2.91 2.91 5.6 FALSE FALSE Change -Subsidy -Price -Alternate
224731 11/1/2004 8/1/2005 1.91 1.91 5.6 FALSE FALSE Change -Subsidy -Alternate
224731 8/1/2005 0 0 0 FALSE FALSE Delisted
225045 6/1/1995 5/1/1999 8.98 8.98 8.98 FALSE TRUE New Listing
225045 5/1/1999 7/1/2009 8.98 8.98 13.5 FALSE TRUE Change +Price
225045 7/1/2009 9/1/2010 13.5 13.5 13.5 FALSE TRUE Change +Subsidy +Alternate
225045 9/1/2010 0 0 0 FALSE FALSE Delisted
225053 5/16/1994 4/1/1997 27.45 27.45 27.45 FALSE FALSE New Listing
225053 4/1/1997 0 0 0 FALSE FALSE Delisted
225061 5/16/1994 4/1/1997 52.25 52.25 52.25 FALSE FALSE New Listing
225061 4/1/1997 0 0 0 FALSE FALSE Delisted
225088 8/1/1998 8/1/1999 8.53 8.53 8.53 FALSE TRUE New Listing
225088 8/1/1999 9/1/1999 7.31 7.31 7.31 FALSE TRUE Change -Subsidy -Price -Alternate
225088 9/1/1999 10/1/1999 7.31 7.31 6.58 FALSE TRUE Change -Price
225088 10/1/1999 8/1/2000 6.58 6.58 6.58 FALSE TRUE Change -Subsidy -Alternate
225088 8/1/2000 9/1/2001 3.66 3.66 3.66 FALSE TRUE Change -Subsidy -Price -Alternate
225088 9/1/2001 0 0 0 FALSE FALSE Delisted
225096 8/1/1998 8/1/1999 9.77 9.77 9.77 FALSE TRUE New Listing
225096 8/1/1999 9/1/1999 8.37 8.37 8.37 FALSE TRUE Change -Subsidy -Price -Alternate
225096 9/1/1999 10/1/1999 8.37 8.37 7.53 FALSE TRUE Change -Price
225096 10/1/1999 8/1/2000 7.53 7.53 7.53 FALSE TRUE Change -Subsidy -Alternate
225096 8/1/2000 7/1/2001 4.19 4.19 4.19 FALSE TRUE Change -Subsidy -Price -Alternate
225096 7/1/2001 0 0 0 FALSE FALSE Delisted
225118 9/1/1995 5/1/1998 10.27 10.27 10.27 FALSE FALSE New Listing
225118 5/1/1998 10/1/2003 6 6 6 FALSE FALSE Change -Subsidy -Price -Alternate
225118 10/1/2003 5/1/2004 3.12 3.12 3.12 FALSE FALSE Change -Subsidy -Price -Alternate
225118 5/1/2004 0 0 0 FALSE FALSE Delisted
225126 9/1/1995 5/1/1998 21.54 21.54 21.54 FALSE FALSE New Listing
225126 5/1/1998 10/1/2003 10.45 10.45 10.45 FALSE FALSE Change -Subsidy -Price -Alternate
225126 10/1/2003 10/1/2004 6 6 6 FALSE FALSE Change -Subsidy -Price -Alternate
225126 10/1/2004 0 0 0 FALSE FALSE Delisted
225134 1/9/1995 7/1/1999 12.67 12.67 12.67 FALSE FALSE New Listing
225134 7/1/1999 1/1/2003 5.49 5.49 5.49 FALSE FALSE Change -Subsidy -Price -Alternate
225134 1/1/2003 4/1/2003 3.29 3.29 5.49 FALSE FALSE Change -Subsidy -Alternate
225134 4/1/2003 0 0 0 FALSE FALSE Delisted
225142 5/16/1994 7/1/1997 19.6 19.6 19.6 FALSE FALSE New Listing
225142 7/1/1997 7/1/1999 5.55 5.55 5.55 FALSE FALSE Change -Subsidy -Price -Alternate
225142 7/1/1999 10/1/2003 3.99 3.99 3.99 FALSE FALSE Change -Subsidy -Price -Alternate
225142 10/1/2003 12/1/2004 4.9 4.9 4.9 FALSE FALSE Change +Subsidy +Price +Alternate
225142 12/1/2004 2/1/2009 4.9 4.9 5.9 FALSE FALSE Change +Price
225142 2/1/2009 0 0 0 FALSE FALSE Delisted
225231 10/1/1994 7/1/1999 11 11 11 FALSE FALSE New Listing
225231 7/1/1999 11/1/1999 7.95 7.95 11 FALSE FALSE Change -Subsidy -Alternate
225231 11/1/1999 0 0 0 FALSE FALSE Delisted
225665 5/16/1994 23.4 23.4 23.4 FALSE FALSE New Listing
225762 5/16/1994 4/1/1997 2.6 2.6 2.6 FALSE FALSE New Listing
225762 4/1/1997 0 0 0 FALSE FALSE Delisted
225770 5/16/1994 6/1/1999 2.6 2.6 2.6 FALSE FALSE New Listing
225770 6/1/1999 0 0 0 FALSE FALSE Delisted
226173 5/16/1994 9/1/2003 63.6 63.6 63.6 FALSE FALSE New Listing
226173 9/1/2003 4/1/2007 63.6 63.6 69.9 FALSE FALSE Change +Price
226173 4/1/2007 11/1/2008 63.6 63.6 73.4 FALSE FALSE Change +Price
226173 11/1/2008 0 0 0 FALSE FALSE Delisted
226203 1/9/1995 3/1/1996 27.3 27.3 27.3 FALSE FALSE New Listing
226203 3/1/1996 4/1/1996 19.66 19.66 32.76 FALSE FALSE Change -Subsidy +Price -Alternate
226203 4/1/1996 9/1/1998 19.66 19.66 19.66 FALSE FALSE Change -Price
226203 9/1/1998 7/1/2003 6 6 6 FALSE FALSE Change -Subsidy -Price -Alternate
226203 7/1/2003 0 0 0 FALSE FALSE Delisted
226211 1/9/1995 3/1/1996 54.6 54.6 54.6 FALSE FALSE New Listing
226211 3/1/1996 4/1/1996 19.66 19.66 32.76 FALSE FALSE Change -Subsidy -Price -Alternate
226211 4/1/1996 9/1/1998 19.66 19.66 19.66 FALSE FALSE Change -Price
226211 9/1/1998 7/1/2003 6 6 6 FALSE FALSE Change -Subsidy -Price -Alternate
226211 7/1/2003 0 0 0 FALSE FALSE Delisted
226238 1/9/1995 3/1/1996 32.76 32.76 32.76 FALSE FALSE New Listing
226238 3/1/1996 4/1/1996 19.66 19.66 32.76 FALSE FALSE Change -Subsidy -Alternate
226238 4/1/1996 9/1/1998 19.66 19.66 19.66 FALSE FALSE Change -Price
226238 9/1/1998 7/1/2003 6 6 6 FALSE FALSE Change -Subsidy -Price -Alternate
226238 7/1/2003 0 0 0 FALSE FALSE Delisted
226262 9/1/1999 2/1/2000 4.86 4.86 4.86 FALSE FALSE New Listing
226262 2/1/2000 11/1/2000 2.92 2.92 2.92 FALSE FALSE Change -Subsidy -Price -Alternate
226262 11/1/2000 3/1/2001 2.63 2.63 2.63 FALSE FALSE Change -Subsidy -Price -Alternate
226262 3/1/2001 9/1/2001 2.37 2.63 2.63 FALSE FALSE Change -Subsidy
226262 9/1/2001 3/1/2002 2.02 2.02 2.02 FALSE FALSE Change -Subsidy -Price -Alternate
226262 3/1/2002 0 0 0 FALSE FALSE Delisted
226297 6/1/1999 2/1/2000 7.48 7.48 7.48 FALSE FALSE New Listing
226297 2/1/2000 3/1/2001 4.99 4.99 4.99 FALSE FALSE Change -Subsidy -Price -Alternate
226297 3/1/2001 9/1/2001 4.49 4.99 4.99 FALSE FALSE Change -Subsidy
226297 9/1/2001 11/1/2002 3.01 3.01 3.01 FALSE FALSE Change -Subsidy -Price -Alternate
226297 11/1/2002 0 0 0 FALSE FALSE Delisted
226572 5/16/1994 2/1/2000 16.08 16.08 16.08 FALSE TRUE New Listing
226572 2/1/2000 3/1/2001 16.08 16.08 17.5 FALSE TRUE Change +Price
226572 3/1/2001 4/1/2002 16.08 16.08 19.25 FALSE TRUE Change +Price
226572 4/1/2002 4/1/2003 16.08 16.08 21.18 FALSE TRUE Change +Price
226572 4/1/2003 4/1/2004 16.08 16.08 23.3 FALSE TRUE Change +Price
226572 4/1/2004 7/1/2006 16.08 16.08 25.63 FALSE TRUE Change +Price
226572 7/1/2006 3/1/2007 16.08 16.08 28.19 FALSE TRUE Change +Price
226572 3/1/2007 6/1/2007 13.5 13.5 13.5 FALSE TRUE Change -Subsidy -Price -Alternate
226572 6/1/2007 0 0 0 FALSE FALSE Delisted
226610 6/14/1995 6/1/1997 12.63 12.63 12.63 FALSE FALSE New Listing
226610 6/1/1997 0 0 0 FALSE FALSE Delisted
226645 6/14/1995 6/1/1997 25.24 25.24 25.24 FALSE FALSE New Listing
226645 6/1/1997 0 0 0 FALSE FALSE Delisted
227048 6/1/1995 2/1/1998 33.11 33.11 33.11 FALSE FALSE New Listing
227048 2/1/1998 4/1/2001 14.9 14.9 14.9 FALSE FALSE Change -Subsidy -Price -Alternate
227048 4/1/2001 10 10 10 FALSE FALSE Change -Subsidy -Price -Alternate
228435 8/1/1995 12/1/1997 37.47 37.47 37.47 FALSE FALSE New Listing
228435 12/1/1997 0 0 0 FALSE FALSE Delisted
228443 8/1/1995 12/1/1997 66.18 66.18 66.18 FALSE FALSE New Listing
228443 12/1/1997 0 0 0 FALSE FALSE Delisted
229040 10/4/1997 2/1/1998 7.22 7.22 7.22 FALSE TRUE New Listing
229040 2/1/1998 8/1/2000 4.33 4.33 4.33 FALSE TRUE Change -Subsidy -Price -Alternate
229040 8/1/2000 10/1/2005 1.2 1.2 1.2 FALSE TRUE Change -Subsidy -Price -Alternate
229040 10/1/2005 10/1/2009 1.6 1.6 1.6 FALSE TRUE Change +Subsidy +Price +Alternate
229040 10/1/2009 3/1/2013 3.48 3.48 3.48 FALSE TRUE Change +Subsidy +Price +Alternate
229040 3/1/2013 3.68 3.68 3.68 FALSE TRUE Change +Subsidy +Price +Alternate
229059 10/4/1997 2/1/1998 7.22 7.22 7.22 FALSE TRUE New Listing
229059 2/1/1998 8/1/2000 4.33 4.33 4.33 FALSE TRUE Change -Subsidy -Price -Alternate
229059 8/1/2000 7/1/2003 1.2 1.2 1.2 FALSE TRUE Change -Subsidy -Price -Alternate
229059 7/1/2003 10/1/2006 1.4 1.4 1.4 FALSE TRUE Change +Subsidy +Price +Alternate
229059 10/1/2006 10/1/2009 2.35 2.35 2.35 FALSE TRUE Change +Subsidy +Price +Alternate
229059 10/1/2009 3/1/2013 3.48 3.48 3.48 FALSE TRUE Change +Subsidy +Price +Alternate
229059 3/1/2013 3.68 6.68 3.68 FALSE TRUE Change +Subsidy +Price +Alternate
229075 8/16/1994 9/1/2002 2.86 2.86 2.86 FALSE TRUE New Listing
229075 9/1/2002 7/1/2005 2.65 2.65 2.65 FALSE TRUE Change -Subsidy -Price -Alternate
229075 7/1/2005 8/1/2013 2.62 2.62 2.62 FALSE TRUE Change -Subsidy -Price -Alternate
229075 8/1/2013 2.3 2.3 2.3 FALSE TRUE Change -Subsidy -Price -Alternate
229253 6/1/1998 12/1/2000 162.9 162.9 162.9 FALSE FALSE New Listing
229253 12/1/2000 0 0 0 FALSE FALSE Delisted
229369 1/11/1995 9/1/2001 1322.82 1322.82 1322.82 FALSE FALSE New Listing
229369 9/1/2001 0 0 0 FALSE FALSE Delisted
229385 5/16/1994 4/1/2002 325.8 325.8 325.8 FALSE FALSE New Listing
229385 4/1/2002 0 0 0 FALSE FALSE Delisted
229504 5/16/1994 9/1/2001 572.4 572.4 572.4 FALSE FALSE New Listing
229504 9/1/2001 0 0 0 FALSE FALSE Delisted
229520 6/1/1998 4/1/2002 1322.82 1322.82 1322.82 FALSE FALSE New Listing
229520 4/1/2002 2/1/2006 760.2 760.2 1322.82 FALSE FALSE Change -Subsidy +Price -Alternate
229520 2/1/2006 5/1/2007 684.18 684.18 1322.82 FALSE FALSE Change -Subsidy -Alternate
229520 5/1/2007 9/1/2008 608.16 608.16 1322.82 FALSE FALSE Change -Subsidy -Alternate
229520 9/1/2008 3/1/2009 395.18 395.18 395.18 FALSE FALSE Change -Subsidy -Price -Alternate
229520 3/1/2009 0 0 0 FALSE FALSE Delisted
229644 5/16/1994 8/1/1995 9.16 9.16 9.16 FALSE FALSE New Listing
229644 8/1/1995 8/1/1996 18.32 18.32 49.5 FALSE FALSE Change +Subsidy +Price +Alternate
229644 8/1/1996 9/1/1997 18.32 18.32 51.95 FALSE FALSE Change +Price
229644 9/1/1997 1/1/1998 18.32 18.32 63.6 FALSE FALSE Change +Price
229644 1/1/1998 7/1/1998 18.32 18.32 73.14 FALSE FALSE Change +Price
229644 7/1/1998 10/1/2000 18.32 18.32 90.81 FALSE FALSE Change +Price
229644 10/1/2000 10/1/2003 18.32 18.32 104.45 FALSE FALSE Change +Price
229644 10/1/2003 11/1/2006 18.32 18.32 151.5 FALSE FALSE Change +Price
229644 11/1/2006 4/1/2009 18.32 18.32 194.4 FALSE FALSE Change +Price
229644 4/1/2009 3/1/2011 18.32 18.32 243.24 FALSE FALSE Change +Price
229644 3/1/2011 7/1/2011 18.32 18.32 254.92 FALSE FALSE Change +Price
229644 7/1/2011 0 0 0 FALSE FALSE Delisted
229652 5/20/1995 6/1/1997 22.25 22.25 22.25 FALSE FALSE New Listing
229652 6/1/1997 11/1/1997 21.87 21.87 21.87 FALSE FALSE Change -Subsidy -Price -Alternate
229652 11/1/1997 3/1/1998 19.47 19.47 21.87 FALSE FALSE Change -Subsidy -Alternate
229652 3/1/1998 11/1/1998 19.47 19.47 19.47 FALSE FALSE Change -Price
229652 11/1/1998 3/1/1999 15.58 15.58 19.47 FALSE FALSE Change -Subsidy -Alternate
229652 3/1/1999 4/1/1999 13.08 13.08 19.47 FALSE FALSE Change -Subsidy -Alternate
229652 4/1/1999 11/1/1999 13.08 13.08 13.08 FALSE FALSE Change -Price
229652 11/1/1999 3/1/2000 9.58 9.58 13.08 FALSE FALSE Change -Subsidy -Alternate
229652 3/1/2000 0 0 0 FALSE FALSE Delisted
229660 6/1/1998 4/1/2002 325.8 325.8 325.8 FALSE FALSE New Listing
229660 4/1/2002 2/1/2006 152.04 152.04 325.8 FALSE FALSE Change -Subsidy -Alternate
229660 2/1/2006 5/1/2007 136.84 136.84 325.8 FALSE FALSE Change -Subsidy -Alternate
229660 5/1/2007 9/1/2008 121.63 121.63 325.8 FALSE FALSE Change -Subsidy -Alternate
229660 9/1/2008 3/1/2009 120.18 120.18 120.18 FALSE FALSE Change -Subsidy -Price -Alternate
229660 3/1/2009 0 0 0 FALSE FALSE Delisted
229687 6/1/1998 4/1/2002 455.34 455.34 455.34 FALSE FALSE New Listing
229687 4/1/2002 2/1/2006 228.06 228.06 455.34 FALSE FALSE Change -Subsidy -Alternate
229687 2/1/2006 5/1/2007 205.25 205.25 455.34 FALSE FALSE Change -Subsidy -Alternate
229687 5/1/2007 9/1/2008 182.45 182.45 455.34 FALSE FALSE Change -Subsidy -Alternate
229687 9/1/2008 3/1/2009 166.87 166.87 166.87 FALSE FALSE Change -Subsidy -Price -Alternate
229687 3/1/2009 0 0 0 FALSE FALSE Delisted
229695 5/16/1994 12/1/2002 26.37 26.37 26.37 FALSE FALSE New Listing
229695 12/1/2002 0 0 0 FALSE FALSE Delisted
229709 6/1/1998 4/1/2002 572.4 572.4 572.4 FALSE FALSE New Listing
229709 4/1/2002 2/1/2006 304.08 304.08 572.4 FALSE FALSE Change -Subsidy -Alternate
229709 2/1/2006 5/1/2007 273.67 273.67 572.4 FALSE FALSE Change -Subsidy -Alternate
229709 5/1/2007 9/1/2008 243.67 243.67 572.4 FALSE FALSE Change -Subsidy -Alternate
229709 9/1/2008 3/1/2009 193.13 193.13 193.13 FALSE FALSE Change -Subsidy -Price -Alternate
229709 3/1/2009 0 0 0 FALSE FALSE Delisted
229717 6/27/1995 1/1/1996 135 135 135 FALSE FALSE New Listing
229717 1/1/1996 10/1/1997 121.5 121.5 121.5 FALSE FALSE Change -Subsidy -Price -Alternate
229717 10/1/1997 2/1/1998 100 100 100 FALSE FALSE Change -Subsidy -Price -Alternate
229717 2/1/1998 8/1/2000 50 50 50 FALSE FALSE Change -Subsidy -Price -Alternate
229717 8/1/2000 12/1/2000 8.9 8.9 8.9 FALSE FALSE Change -Subsidy -Price -Alternate
229717 12/1/2000 2/1/2004 0 0 0 FALSE FALSE Delisted
229717 2/1/2004 5/1/2004 22.1 22.1 22.1 FALSE FALSE New Listing
229717 5/1/2004 7/1/2006 16.91 16.91 16.91 FALSE FALSE Change -Subsidy -Price -Alternate
229717 7/1/2006 16.06 16.06 16.06 FALSE FALSE Change -Subsidy -Price -Alternate
230391 5/16/1994 8/1/2002 2.4 2.4 2.4 FALSE FALSE New Listing
230391 8/1/2002 11/1/2002 2.4 2.4 4.8 FALSE FALSE Change +Price
230391 11/1/2002 2/1/2003 2.25 2.25 4.8 FALSE FALSE Change -Subsidy -Alternate
230391 2/1/2003 0 0 0 FALSE FALSE Delisted
230413 5/16/1994 8/1/2002 4.7 4.7 4.7 FALSE FALSE New Listing
230413 8/1/2002 9/1/2002 4.69 4.69 9.4 FALSE FALSE Change -Subsidy +Price -Alternate
230413 9/1/2002 12/1/2002 3 3 9.4 FALSE FALSE Change -Subsidy -Alternate
230413 12/1/2002 0 0 0 FALSE FALSE Delisted
230707 3/1/1995 5/1/1996 90 90 90 FALSE FALSE New Listing
230707 5/1/1996 10/1/1996 30 30 30 FALSE FALSE Change -Subsidy -Price -Alternate
230707 10/1/1996 12/1/1996 30 30 33 FALSE FALSE Change +Price
230707 12/1/1996 3/1/1998 24.75 24.75 33 FALSE FALSE Change -Subsidy -Alternate
230707 3/1/1998 8/1/2000 23.25 23.25 33 FALSE FALSE Change -Subsidy -Alternate
230707 8/1/2000 12/1/2001 21 21 33 FALSE FALSE Change -Subsidy -Alternate
230707 12/1/2001 0 0 0 FALSE FALSE Delisted
230731 4/1/1996 9/1/1998 16.38 16.38 16.38 FALSE FALSE New Listing
230731 9/1/1998 7/1/2006 5 5 5 FALSE FALSE Change -Subsidy -Price -Alternate
230731 7/1/2006 5 5 7.5 FALSE FALSE Change +Price
230820 4/1/1996 9/1/1998 32.77 32.77 32.77 FALSE FALSE New Listing
230820 9/1/1998 7/1/2006 10 10 10 FALSE FALSE Change -Subsidy -Price -Alternate
230820 7/1/2006 10 10 12 FALSE FALSE Change +Price
230855 9/1/1998 3/1/2004 20 20 20 FALSE FALSE New Listing
230855 3/1/2004 0 0 0 FALSE FALSE Delisted
232165 5/16/1994 3/1/1996 6.83 6.83 6.83 FALSE FALSE New Listing
232165 3/1/1996 4/1/1996 4.92 4.92 8.19 FALSE FALSE Change -Subsidy +Price -Alternate
232165 4/1/1996 9/1/1998 4.92 4.92 4.91 FALSE FALSE Change -Price
232165 9/1/1998 5/1/2001 1.5 1.5 4.92 FALSE FALSE Change -Subsidy +Price -Alternate
232165 5/1/2001 0 0 0 FALSE FALSE Delisted
232246 5/16/1994 3/1/1996 27.3 27.3 27.3 FALSE FALSE New Listing
232246 3/1/1996 4/1/1996 9.83 9.83 16.38 FALSE FALSE Change -Subsidy -Price -Alternate
232246 4/1/1996 9/1/1998 9.83 9.83 9.83 FALSE FALSE Change -Price
232246 9/1/1998 10/1/2002 3 3 9.83 FALSE FALSE Change -Subsidy -Alternate
232246 10/1/2002 0 0 0 FALSE FALSE Delisted
234524 5/16/1994 10/1/2002 40.73 40.73 40.73 FALSE FALSE New Listing
234524 10/1/2002 0 0 0 FALSE FALSE Delisted
234532 8/16/1994 2/1/2010 42.82 42.82 42.82 FALSE FALSE New Listing
234532 2/1/2010 45.82 45.82 45.82 FALSE FALSE Change +Subsidy +Price +Alternate
234540 8/16/1994 2/1/2010 75.63 75.63 75.63 FALSE FALSE New Listing
234540 2/1/2010 80.92 80.92 80.92 FALSE FALSE Change +Subsidy +Price +Alternate
234672 6/1/1995 7/1/1997 1.8 1.8 1.8 FALSE TRUE New Listing
234672 7/1/1997 5/1/1999 1.36 1.36 1.8 FALSE TRUE Change -Subsidy -Alternate
234672 5/1/1999 6/1/1999 1.12 1.12 1.12 FALSE TRUE Change -Subsidy -Price -Alternate
234672 6/1/1999 4/1/2011 1.12 1.12 1.45 FALSE TRUE Change +Price
234672 4/1/2011 5/1/2011 0.72 1.12 1.45 FALSE TRUE Change -Subsidy
234672 5/1/2011 0.72 1.26 1.26 FALSE TRUE Change -Price +Alternate
234680 7/1/1997 5/1/1999 1.36 1.36 1.8 FALSE TRUE New Listing
234680 5/1/1999 6/1/1999 1.12 1.12 1.12 FALSE TRUE Change -Subsidy -Price -Alternate
234680 6/1/1999 4/1/2011 1.12 1.12 1.45 FALSE TRUE Change -Subsidy +Price -Alternate
234680 4/1/2011 5/1/2011 0.72 1.12 1.45 FALSE TRUE Change -Subsidy
234680 5/1/2011 0.72 1.26 1.26 FALSE TRUE Change -Price +Alternate
234788 6/1/1995 7/1/1996 1.8 1.8 1.8 FALSE TRUE New Listing
234788 7/1/1996 7/1/1997 1.52 1.52 1.52 FALSE TRUE Change -Subsidy -Price -Alternate
234788 7/1/1997 5/1/1999 1.36 1.36 1.8 FALSE TRUE Change -Subsidy +Price -Alternate
234788 5/1/1999 6/1/1999 1.12 1.12 1.12 FALSE TRUE Change -Subsidy -Price -Alternate
234788 6/1/1999 4/1/2011 1.12 1.12 1.45 FALSE TRUE Change +Price
234788 4/1/2011 5/1/2011 0.72 1.12 1.45 FALSE TRUE Change -Subsidy
234788 5/1/2011 0.72 1.26 1.26 FALSE TRUE Change -Price +Alternate
234885 7/1/1996 7/1/1997 1.8 1.8 1.8 FALSE TRUE New Listing
234885 7/1/1997 5/1/1999 1.36 1.36 1.8 FALSE TRUE Change -Subsidy -Alternate
234885 5/1/1999 6/1/1999 1.12 1.12 1.12 FALSE TRUE Change -Subsidy -Price -Alternate
234885 6/1/1999 4/1/2011 1.12 1.12 1.45 FALSE TRUE Change +Price
234885 4/1/2011 5/1/2011 0.72 1.12 1.45 FALSE TRUE Change -Subsidy
234885 5/1/2011 0.72 1.26 1.26 FALSE TRUE Change -Price +Alternate
234893 7/1/1996 7/1/1997 1.8 1.8 1.8 FALSE TRUE New Listing
234893 7/1/1997 5/1/1999 1.36 1.36 1.8 FALSE TRUE Change -Subsidy -Alternate
234893 5/1/1999 6/1/1999 1.12 1.12 1.12 FALSE TRUE Change -Subsidy -Price -Alternate
234893 6/1/1999 4/1/2011 1.12 1.12 1.45 FALSE TRUE Change +Price
234893 4/1/2011 5/1/2011 0.72 1.12 1.45 FALSE TRUE Change -Subsidy
234893 5/1/2011 0.72 1.26 1.26 FALSE TRUE Change -Price +Alternate
234907 8/1/2007 7/1/2010 6.66 6.66 6.66 FALSE TRUE New listing
234907 7/1/2010 9/1/2013 6.6 6.6 6.6 FALSE TRUE Change -Subsidy -Price -Alternate
234907 9/1/2013 6.55 6.55 6.55 FALSE TRUE Change -Subsidy -Price -Alternate
235075 2/1/2005 10/1/2006 0.79 0.79 0.79 FALSE FALSE New listing
235075 10/1/2006 0 0 0 FALSE FALSE Delisted
235229 1/1/2006 435.9 435.9 435.9 FALSE FALSE New listing
236586 10/1/2005 2/1/2012 99 99 99 FALSE FALSE New listing
236586 2/1/2012 0 0 0 FALSE FALSE Delisted
236616 5/1/1999 6/1/2003 7.35 7.35 7.35 FALSE TRUE New Listing
236616 6/1/2003 6/1/2008 8.7 8.7 8.7 FALSE TRUE Change +Subsidy +Price +Alternate
236616 6/1/2008 8/1/2014 9.5 9.5 9.5 FALSE TRUE Change +Subsidy +Price +Alternate
236616 8/1/2014 0 0 0 FALSE FALSE Delisted
236640 5/16/1994 6/1/1995 31.34 31.34 31.34 FALSE FALSE New Listing
236640 6/1/1995 9/1/2010 6.27 6.27 6.27 FALSE FALSE Change -Subsidy -Price -Alternate
236640 9/1/2010 0 0 0 FALSE FALSE Delisted
236667 5/1/1999 6/1/2003 7.35 7.35 7.35 FALSE TRUE New Listing
236667 6/1/2003 6/1/2008 8.7 8.7 8.7 FALSE TRUE Change +Subsidy +Price +Alternate
236667 6/1/2008 8/1/2014 9.5 9.5 9.5 FALSE TRUE Change +Subsidy +Price +Alternate
236667 8/1/2014 0 0 0 FALSE FALSE Delisted
236772 5/1/1999 6/1/2003 7.35 7.35 7.35 FALSE TRUE New Listing
236772 6/1/2003 6/1/2008 8.7 8.7 8.7 FALSE TRUE Change +Subsidy +Price +Alternate
236772 6/1/2008 8/1/2014 9.5 9.5 9.5 FALSE TRUE Change +Subsidy +Price +Alternate
236772 8/1/2014 0 0 0 FALSE FALSE Delisted
237523 7/1/2011 53.76 53.76 53.76 FALSE FALSE New listing
238007 1/1/2006 78 78 78 FALSE FALSE New listing
238058 1/1/2006 11/1/2006 349 349 349 FALSE FALSE New listing
238058 11/1/2006 349.2 349.2 349.2 FALSE FALSE Change +Subsidy +Price +Alternate
238074 4/1/1999 3/1/2003 55.7 55.7 55.7 FALSE TRUE New Listing
238074 3/1/2003 7/1/2005 53.9 53.9 55.7 FALSE TRUE Change -Subsidy -Alternate
238074 7/1/2005 10/1/2005 44 44 55.7 FALSE TRUE Change -Subsidy -Alternate
238074 10/1/2005 0 0 0 FALSE FALSE Delisted
238147 4/1/1999 6/1/2004 1.6 1.6 1.6 FALSE TRUE New Listing
238147 6/1/2004 1/1/2011 1.07 1.07 1.07 FALSE TRUE Change -Subsidy -Price -Alternate
238147 1/1/2011 0 0 0 FALSE FALSE Delisted
238481 5/16/1994 8/1/2000 26.4 26.4 26.4 FALSE FALSE New Listing
238481 8/1/2000 0 0 0 FALSE FALSE Delisted
238732 10/1/2013 400 400 400 FALSE FALSE New listing
239070 4/1/1997 5/1/2012 294.3 294.3 294.3 FALSE FALSE New Listing
239070 5/1/2012 250 250 250 FALSE FALSE Change -Subsidy -Price -Alternate
239852 5/16/1994 8/16/1994 3.63 3.63 6.48 FALSE FALSE New Listing
239852 8/16/1994 2/1/1996 2.18 2.18 6.4 FALSE FALSE Change -Subsidy -Price -Alternate
239852 2/1/1996 9/1/1998 2.18 2.18 6.52 FALSE FALSE Change +Price
239852 9/1/1998 2.18 2.18 7.17 FALSE FALSE Change +Price
240206 3/1/1996 9/1/1998 1.64 1.64 1.64 FALSE FALSE New Listing
240206 9/1/1998 4/1/1999 0.5 0.5 1.64 FALSE FALSE Change -Subsidy -Price -Alternate
240206 4/1/1999 0 0 0 FALSE FALSE Delisted
240311 5/16/1994 6/1/1995 14.97 14.97 15.95 FALSE FALSE New Listing
240311 6/1/1995 8/1/2001 3.74 3.74 3.99 FALSE FALSE Change -Subsidy -Price -Alternate
240311 8/1/2001 8/1/2009 3.74 3.74 7.26 FALSE FALSE Change +Price
240311 8/1/2009 8.06 8.06 8.06 FALSE FALSE Change +Subsidy +Price +Alternate
241113 7/1/1996 10/1/2007 68.4 68.4 68.4 FALSE FALSE New Listing
241113 10/1/2007 49.5 49.5 49.5 FALSE FALSE Change -Subsidy -Price -Alternate
241172 5/1/1996 9/1/2001 30.8 30.8 34.2 FALSE FALSE New Listing
241172 9/1/2001 12/1/2001 21.55 21.55 34.2 FALSE FALSE Change -Subsidy -Alternate
241172 12/1/2001 7/1/2006 0 0 0 FALSE FALSE Delisted
241172 7/1/2006 4/1/2011 11.5 11.5 11.5 FALSE FALSE New Listing
241172 4/1/2011 0 0 0 FALSE FALSE Delisted
241180 5/1/1996 9/1/2001 30.8 30.8 34.2 FALSE FALSE New Listing
241180 9/1/2001 12/1/2001 20 20 34.2 FALSE FALSE Change -Subsidy -Alternate
241180 12/1/2001 11/1/2004 0 0 0 FALSE FALSE Delisted
241180 11/1/2004 9/1/2007 13.95 13.95 13.95 FALSE FALSE New Listing
241180 9/1/2007 5/1/2008 10.38 10.38 10.38 FALSE FALSE Change -Subsidy -Price -Alternate
241180 5/1/2008 7/1/2009 0 0 0 FALSE FALSE Delisted
241180 7/1/2009 4/1/2011 11.32 11.32 11.32 FALSE FALSE New Listing
241180 4/1/2011 0 0 0 FALSE FALSE Delisted
241202 7/1/1996 1/1/2002 0 0 0 TRUE FALSE New Listing
241202 1/1/2002 0 0 0 FALSE FALSE Delisted
242675 10/1/1997 7/1/2000 3.21 3.21 3.21 FALSE FALSE New Listing
242675 7/1/2000 9/1/2000 3.21 3.21 4.82 FALSE FALSE Change +Price
242675 9/1/2000 8/1/2003 3.21 3.21 3.21 FALSE FALSE Change -Price
242675 8/1/2003 10/1/2009 2.64 2.64 2.64 FALSE FALSE Change -Subsidy -Price -Alternate
242675 10/1/2009 2.8 2.8 2.8 FALSE FALSE Change +Subsidy +Price +Alternate
242756 10/1/1997 7/1/2000 6.42 6.42 6.42 FALSE FALSE New Listing
242756 7/1/2000 9/1/2000 6.42 6.42 9.63 FALSE FALSE Change +Price
242756 9/1/2000 8/1/2003 6.42 6.42 6.42 FALSE FALSE Change -Price
242756 8/1/2003 10/1/2009 5.1 5.1 5.1 FALSE FALSE Change -Subsidy -Price -Alternate
242756 10/1/2009 5.52 5.52 5.52 FALSE FALSE Change +Subsidy +Price +Alternate
242993 10/1/1997 11/1/1998 62 62 62 FALSE FALSE New Listing
242993 11/1/1998 11/1/1999 57 57 57 FALSE FALSE Change -Subsidy -Price -Alternate
242993 11/1/1999 53 53 53 FALSE FALSE Change -Subsidy -Price -Alternate
243000 10/1/1997 11/1/1998 93 93 93 FALSE FALSE New Listing
243000 11/1/1998 11/1/1999 86 86 86 FALSE FALSE Change -Subsidy -Price -Alternate
243000 11/1/1999 79 79 79 FALSE FALSE Change -Subsidy -Price -Alternate
243078 2/1/1996 8/1/1999 4.48 4.48 4.48 FALSE FALSE New Listing
243078 8/1/1999 10/1/2005 2.75 2.75 2.75 FALSE FALSE Change -Subsidy -Price -Alternate
243078 10/1/2005 10/1/2008 3.75 3.75 3.75 FALSE FALSE Change +Subsidy +Price +Alternate
243078 10/1/2008 4.35 4.35 4.35 FALSE FALSE Change +Subsidy +Price +Alternate
243086 3/1/1996 8/1/1999 8.96 8.96 8.96 FALSE FALSE New Listing
243086 8/1/1999 10/1/2005 4.99 4.99 4.99 FALSE FALSE Change -Subsidy -Price -Alternate
243086 10/1/2005 10/1/2008 5.6 5.6 5.6 FALSE FALSE Change +Subsidy +Price +Alternate
243086 10/1/2008 5.85 5.85 5.85 FALSE FALSE Change +Subsidy +Price +Alternate
243094 2/1/1996 8/1/1999 22.29 22.29 22.29 FALSE FALSE New Listing
243094 8/1/1999 11/1/2006 14.99 14.99 14.99 FALSE FALSE Change -Subsidy -Price -Alternate
243094 11/1/2006 5/1/2009 18.95 18.95 18.95 FALSE FALSE Change +Subsidy +Price +Alternate
243094 5/1/2009 16.95 16.95 16.95 FALSE FALSE Change -Subsidy -Price -Alternate
243108 7/1/2005 8/1/2007 14.12 14.12 14.12 FALSE FALSE New listing
243108 8/1/2007 13.55 13.55 13.55 FALSE FALSE Change -Subsidy -Price -Alternate
244368 6/17/1995 23.12 23.12 23.12 FALSE FALSE New Listing
244457 7/1/1999 12.43 12.43 12.43 FALSE TRUE New Listing
244481 12/1/1996 3/1/1998 24.75 24.75 33 FALSE FALSE New Listing
244481 3/1/1998 8/1/2000 23.25 23.25 33 FALSE FALSE Change -Subsidy -Alternate
244481 8/1/2000 12/1/2000 21 21 33 FALSE FALSE Change -Subsidy -Alternate
244481 12/1/2000 0 0 0 FALSE FALSE Delisted
244651 6/1/1995 5/1/1999 5.61 5.61 5.61 FALSE TRUE New Listing
244651 5/1/1999 3/1/2000 5.61 5.61 7.5 FALSE TRUE Change +Price
244651 3/1/2000 0 0 0 FALSE FALSE Delisted
244805 4/1/1999 4/1/2002 8.13 8.13 8.13 FALSE FALSE New Listing
244805 4/1/2002 0 0 0 FALSE FALSE Delisted
244937 11/1/1998 11/1/2000 18.51 18.51 18.51 FALSE FALSE New Listing
244937 11/1/2000 3/1/2001 6.22 6.22 18.51 FALSE FALSE Change -Subsidy -Alternate
244937 3/1/2001 0 0 0 FALSE FALSE Delisted
245283 11/1/1998 11/1/2000 18.51 18.51 18.51 FALSE FALSE New Listing
245283 11/1/2000 3/1/2001 5.1 5.1 18.51 FALSE FALSE Change -Subsidy -Alternate
245283 3/1/2001 0 0 0 FALSE FALSE Delisted
245356 2/1/1999 4/1/2002 30.61 30.61 30.61 FALSE FALSE New Listing
245356 4/1/2002 0 0 0 FALSE FALSE Delisted
245364 2/1/1999 4/1/2006 91.84 91.84 91.84 FALSE FALSE New Listing
245364 4/1/2006 9/1/2008 61.53 61.53 61.53 FALSE FALSE Change -Subsidy -Price -Alternate
245364 9/1/2008 7/1/2012 30.77 30.77 30.77 FALSE FALSE Change -Subsidy -Price -Alternate
245364 7/1/2012 6 6 16.92 FALSE FALSE Change -Subsidy -Price -Alternate
245372 2/1/1999 4/1/2006 183.66 183.66 183.66 FALSE FALSE New Listing
245372 4/1/2006 9/1/2008 123.05 123.05 123.05 FALSE FALSE Change -Subsidy -Price -Alternate
245372 9/1/2008 7/1/2012 61.53 61.53 61.53 FALSE FALSE Change -Subsidy -Price -Alternate
245372 7/1/2012 11 11 33.84 FALSE FALSE Change -Subsidy -Price -Alternate
245380 2/1/1999 4/1/2006 275.56 275.56 275.56 FALSE FALSE New Listing
245380 4/1/2006 9/1/2008 184.63 184.63 184.63 FALSE FALSE Change -Subsidy -Price -Alternate
245380 9/1/2008 7/1/2012 92.32 92.32 92.32 FALSE FALSE Change -Subsidy -Price -Alternate
245380 7/1/2012 15 15 50.78 FALSE FALSE Change -Subsidy -Price -Alternate
245402 2/1/1999 4/1/2006 367.3 367.3 367.3 FALSE FALSE New Listing
245402 4/1/2006 9/1/2008 246.09 246.09 246.09 FALSE FALSE Change -Subsidy -Price -Alternate
245402 9/1/2008 7/1/2012 123.05 123.05 123.05 FALSE FALSE Change -Subsidy -Price -Alternate
245402 7/1/2012 20 20 67.68 FALSE FALSE Change -Subsidy -Price -Alternate
245410 10/1/1996 8/1/1999 15.6 15.6 17.94 FALSE FALSE New Listing
245410 8/1/1999 12/1/2000 17.16 17.16 17.94 FALSE FALSE Change +Subsidy +Alternate
245410 12/1/2000 5/1/2002 17.16 17.16 19.2 FALSE FALSE Change +Price
245410 5/1/2002 12/1/2003 14.76 14.76 19.2 FALSE FALSE Change -Subsidy -Alternate
245410 12/1/2003 6/1/2004 14.76 14.76 22 FALSE FALSE Change +Price
245410 6/1/2004 1/1/2005 14.76 14.76 21.12 FALSE FALSE Change -Price
245410 1/1/2005 2/1/2007 14.76 14.76 23 FALSE FALSE Change +Price
245410 2/1/2007 18.88 18.88 18.88 FALSE FALSE Change +Subsidy -Price +Alternate
247510 5/1/2006 3/1/2012 2100 2100 2100 FALSE FALSE New listing
247510 3/1/2012 6/1/2012 820 820 820 FALSE FALSE Change -Subsidy -Price -Alternate
247510 6/1/2012 0 0 0 FALSE FALSE Delisted
249033 5/1/2006 3/1/2012 170 170 170 FALSE FALSE New listing
249033 3/1/2012 6/1/2012 72 72 72 FALSE FALSE Change -Subsidy -Price -Alternate
249033 6/1/2012 0 0 0 FALSE FALSE Delisted
249068 12/1/1997 12/1/2004 23.62 23.62 23.62 FALSE TRUE New Listing
249068 12/1/2004 2/1/2008 22.44 22.44 22.44 FALSE TRUE Change -Subsidy -Price -Alternate
249068 2/1/2008 2/1/2010 20.76 20.76 20.76 FALSE TRUE Change -Subsidy -Price -Alternate
249068 2/1/2010 12/1/2011 20.2 20.2 20.2 FALSE TRUE Change -Subsidy -Price -Alternate
249068 12/1/2011 16 16 16 FALSE TRUE Change -Subsidy -Price -Alternate
249076 12/1/1997 12/1/2004 65.87 65.87 65.87 FALSE TRUE New Listing
249076 12/1/2004 2/1/2008 62.58 62.58 62.58 FALSE TRUE Change -Subsidy -Price -Alternate
249076 2/1/2008 2/1/2010 57.89 57.89 57.89 FALSE TRUE Change -Subsidy -Price -Alternate
249076 2/1/2010 12/1/2011 56.32 56.32 56.32 FALSE TRUE Change -Subsidy -Price -Alternate
249076 12/1/2011 45 45 45 FALSE TRUE Change -Subsidy -Price -Alternate
249572 5/1/2006 3/1/2012 840 840 840 FALSE FALSE New listing
249572 3/1/2012 6/1/2012 350 350 350 FALSE FALSE Change -Subsidy -Price -Alternate
249572 6/1/2012 0 0 0 FALSE FALSE Delisted
249890 5/16/1994 12/1/2000 21.3 21.3 21.3 FALSE FALSE New Listing
249890 12/1/2000 0 0 0 FALSE FALSE Delisted
249904 5/16/1994 3/26/1995 15.29 15.29 15.29 FALSE FALSE New Listing
249904 3/26/1995 3/1/1996 32.76 32.76 32.76 FALSE FALSE Change +Subsidy +Price +Alternate
249904 3/1/1996 9/1/1998 19.66 19.66 32.76 FALSE FALSE Change -Subsidy -Alternate
249904 9/1/1998 12/1/1998 10.2 10.2 10.2 FALSE FALSE Change -Subsidy -Price -Alternate
249904 12/1/1998 1/1/1999 10.2 10.2 19.66 FALSE FALSE Change +Price
249904 1/1/1999 2/1/2000 6 6 19.66 FALSE FALSE Change -Subsidy -Alternate
249904 2/1/2000 0 0 0 FALSE FALSE Delisted
249912 5/16/1994 3/26/1995 30.57 30.57 30.57 FALSE FALSE New Listing
249912 3/26/1995 3/1/1996 32.76 32.76 32.76 FALSE FALSE Change +Subsidy +Price +Alternate
249912 3/1/1996 9/1/1998 19.66 19.66 32.76 FALSE FALSE Change -Subsidy -Alternate
249912 9/1/1998 12/1/1998 10.2 10.2 10.2 FALSE FALSE Change -Subsidy -Price -Alternate
249912 12/1/1998 1/1/1999 10.2 10.2 19.66 FALSE FALSE Change +Price
249912 1/1/1999 2/1/2000 6 6 19.66 FALSE FALSE Change -Subsidy -Alternate
249912 2/1/2000 0 0 0 FALSE FALSE Delisted
249955 5/16/1994 8/1/2003 25.99 25.99 25.99 FALSE FALSE New Listing
249955 8/1/2003 0 0 0 FALSE FALSE Delisted
249998 6/1/1995 1/1/2009 45.06 45.06 45.06 FALSE TRUE New Listing
249998 1/1/2009 0 0 0 FALSE FALSE Delisted
250007 6/1/1995 1/1/2009 244.18 244.18 244.18 FALSE TRUE New Listing
250007 1/1/2009 0 0 0 FALSE FALSE Delisted
250023 5/16/1994 3/1/2002 2.96 2.96 2.96 FALSE TRUE New Listing
250023 3/1/2002 9/1/2002 2.96 2.96 3.09 FALSE TRUE Change +Price
250023 9/1/2002 12/1/2002 2.52 2.52 3.09 FALSE TRUE Change -Subsidy -Alternate
250023 12/1/2002 0 0 0 FALSE FALSE Delisted
250066 10/1/1997 7/1/2005 6.45 6.45 7.34 FALSE TRUE New Listing
250066 7/1/2005 10/1/2008 6.45 6.45 6.45 FALSE TRUE Change -Price
250066 10/1/2008 6.63 6.63 6.63 FALSE TRUE Change +Subsidy +Price +Alternate
250074 10/1/1997 8/1/1999 5.38 5.38 7.38 FALSE TRUE New Listing
250074 8/1/1999 0 0 0 FALSE FALSE Delisted
250082 10/1/1997 7/1/2005 6.45 6.45 7.34 FALSE TRUE New Listing
250082 7/1/2005 10/1/2008 6.45 6.45 6.45 FALSE TRUE Change -Price
250082 10/1/2008 6.69 6.69 6.69 FALSE TRUE Change +Subsidy +Price +Alternate
250090 10/1/1997 5/1/1999 5.38 5.38 7.38 FALSE FALSE New Listing
250090 5/1/1999 0 0 0 FALSE FALSE Delisted
250112 10/4/1997 11/1/1997 4.33 4.33 6.32 FALSE FALSE New Listing
250112 11/1/1997 9/1/2000 4.33 4.33 5.33 FALSE FALSE Change -Price
250112 9/1/2000 1/1/2001 1.64 1.64 5.33 FALSE FALSE Change -Subsidy -Alternate
250112 1/1/2001 0 0 0 FALSE FALSE Delisted
250120 5/16/1994 9/1/2000 9.97 9.97 11.1 FALSE FALSE New Listing
250120 9/1/2000 1/1/2001 4.2 4.2 11.1 FALSE FALSE Change -Subsidy -Alternate
250120 1/1/2001 7/1/2004 0 0 0 FALSE FALSE Delisted
250120 7/1/2004 9/1/2004 4.2 4.2 4.2 FALSE FALSE New Listing
250120 9/1/2004 10/1/2006 3.92 3.92 3.92 FALSE FALSE Change -Subsidy -Price -Alternate
250120 10/1/2006 3/1/2010 4.12 4.12 4.12 FALSE FALSE Change +Subsidy +Price +Alternate
250120 3/1/2010 1/1/2014 11.17 11.17 11.17 FALSE FALSE Change +Subsidy +Price +Alternate
250120 1/1/2014 13.49 13.49 13.49 FALSE FALSE Change +Subsidy +Price +Alternate
250139 5/16/1994 3/1/1998 4.2 4.2 4.2 FALSE FALSE New Listing
250139 3/1/1998 0 0 0 FALSE FALSE Delisted
250163 5/16/1994 2/1/2002 2.84 2.84 2.84 FALSE FALSE New Listing
250163 2/1/2002 0 0 0 FALSE FALSE Delisted
250201 5/16/1994 2/1/2005 13.5 13.5 13.5 FALSE TRUE New Listing
250201 2/1/2005 0 0 0 FALSE FALSE Delisted
250244 5/16/1994 5/1/1998 1.72 1.72 4.65 FALSE FALSE New Listing
250244 5/1/1998 12/1/2000 1.72 1.72 5.12 FALSE FALSE Change +Price
250244 12/1/2000 0 0 0 FALSE FALSE Delisted
250252 5/16/1994 5/1/1998 3.56 3.56 7.28 FALSE FALSE New Listing
250252 5/1/1998 2/1/2000 3.56 3.56 8 FALSE FALSE Change +Price
250252 2/1/2000 3/1/2001 3.56 3.56 8.75 FALSE FALSE Change +Price
250252 3/1/2001 4/1/2002 3.56 3.56 9.63 FALSE FALSE Change +Price
250252 4/1/2002 4/1/2003 3.56 3.56 10.59 FALSE FALSE Change +Price
250252 4/1/2003 4/1/2004 3.56 3.56 11.65 FALSE FALSE Change +Price
250252 4/1/2004 8/1/2005 3.56 3.56 12.82 FALSE FALSE Change +Price
250252 8/1/2005 0 0 0 FALSE FALSE Delisted
250260 8/16/1994 5/1/1998 1.63 1.63 4.65 FALSE FALSE New Listing
250260 5/1/1998 12/1/2000 1.63 1.63 5.12 FALSE FALSE Change +Price
250260 12/1/2000 0 0 0 FALSE FALSE Delisted
250287 5/16/1994 7/1/2000 22.8 22.8 22.8 FALSE FALSE New Listing
250287 7/1/2000 10/1/2007 34 34 34 FALSE FALSE Change +Subsidy +Price +Alternate
250287 10/1/2007 1/1/2008 48.14 48.14 48.14 FALSE FALSE Change +Subsidy +Price +Alternate
250287 1/1/2008 64.28 64.28 64.28 FALSE FALSE Change +Subsidy +Price +Alternate
250295 5/16/1994 7/1/2000 27.3 27.3 27.3 FALSE FALSE New Listing
250295 7/1/2000 10/1/2007 38 38 38 FALSE FALSE Change +Subsidy +Price +Alternate
250295 10/1/2007 1/1/2008 50.39 50.39 50.39 FALSE FALSE Change +Subsidy +Price +Alternate
250295 1/1/2008 66.78 66.78 66.78 FALSE FALSE Change +Subsidy +Price +Alternate
250309 5/16/1994 11/1/1997 10.26 10.26 11.28 FALSE FALSE New Listing
250309 11/1/1997 8/1/1998 10.26 10.26 11.29 FALSE FALSE Change +Price
250309 8/1/1998 2/1/2000 10.26 10.26 14 FALSE FALSE Change +Price
250309 2/1/2000 0 0 0 FALSE FALSE Delisted
250422 5/16/1994 3/1/1998 3.19 3.19 3.19 FALSE FALSE New Listing
250422 3/1/1998 0 0 0 FALSE FALSE Delisted
250511 5/16/1994 4/1/2004 20.23 20.23 20.23 FALSE FALSE New Listing
250511 4/1/2004 11/1/2004 20.23 20.23 22.25 FALSE FALSE Change +Price
250511 11/1/2004 10/1/2006 22.25 22.25 22.25 FALSE FALSE Change +Subsidy +Alternate
250511 10/1/2006 24.48 24.48 24.48 FALSE FALSE Change +Subsidy +Price +Alternate
250538 5/16/1994 4/1/2004 27.53 27.53 27.53 FALSE FALSE New Listing
250538 4/1/2004 11/1/2004 27.53 27.53 30.28 FALSE FALSE Change +Price
250538 11/1/2004 10/1/2006 30.28 30.28 30.28 FALSE FALSE Change +Subsidy +Alternate
250538 10/1/2006 2/1/2009 33.31 33.31 33.31 FALSE FALSE Change +Subsidy +Price +Alternate
250538 2/1/2009 0 0 0 FALSE FALSE Delisted
250554 5/16/1994 6/1/1997 18.7 18.7 20.99 FALSE FALSE New Listing
250554 6/1/1997 7/1/1999 18.7 18.7 18.7 FALSE FALSE Change -Price
250554 7/1/1999 11/1/1999 8.99 8.99 18.7 FALSE FALSE Change -Subsidy -Alternate
250554 11/1/1999 0 0 0 FALSE FALSE Delisted
250570 5/16/1994 6/1/1997 36.46 36.46 39.75 FALSE FALSE New Listing
250570 6/1/1997 7/1/1999 36.46 36.46 36.46 FALSE FALSE Change -Price
250570 7/1/1999 11/1/1999 16.99 16.99 36.46 FALSE FALSE Change -Subsidy -Alternate
250570 11/1/1999 0 0 0 FALSE FALSE Delisted
250678 5/16/1994 3/1/1995 13.6 13.6 14.49 FALSE FALSE New Listing
250678 3/1/1995 5/30/1995 6.5 6.5 14.49 FALSE FALSE Change -Subsidy -Alternate
250678 5/30/1995 8/1/2001 6.5 6.5 14.5 FALSE FALSE Change +Price
250678 8/1/2001 0 0 0 FALSE FALSE Delisted
250686 5/16/1994 3/1/1995 22.95 22.95 23.69 FALSE FALSE New Listing
250686 3/1/1995 8/1/2001 12.99 12.99 23.69 FALSE FALSE Change -Subsidy -Alternate
250686 8/1/2001 0 0 0 FALSE FALSE Delisted
250732 5/16/1994 5/1/2000 11 11 11 FALSE FALSE New Listing
250732 5/1/2000 1/1/2005 12.5 12.5 12.5 FALSE FALSE Change +Subsidy +Price +Alternate
250732 1/1/2005 0 0 0 FALSE FALSE Delisted
250767 5/16/1994 10/1/1997 17.22 17.22 17.22 FALSE FALSE New Listing
250767 10/1/1997 4/1/1998 13.77 13.77 13.77 FALSE FALSE Change -Subsidy -Price -Alternate
250767 4/1/1998 7/1/2000 12.05 12.05 12.05 FALSE FALSE Change -Subsidy -Price -Alternate
250767 7/1/2000 11/1/2000 2.78 12.05 12.05 FALSE FALSE Change -Subsidy
250767 11/1/2000 0 0 0 FALSE FALSE Delisted
250775 5/16/1994 10/1/1997 17.16 17.16 17.16 FALSE FALSE New Listing
250775 10/1/1997 4/1/1998 13.73 13.73 13.73 FALSE FALSE Change -Subsidy -Price -Alternate
250775 4/1/1998 7/1/2000 12.01 12.01 12.01 FALSE FALSE Change -Subsidy -Price -Alternate
250775 7/1/2000 11/1/2000 2.8 12.01 12.01 FALSE FALSE Change -Subsidy
250775 11/1/2000 0 0 0 FALSE FALSE Delisted
250821 8/16/1994 10/1/1997 5.43 5.43 8 FALSE TRUE New Listing
250821 10/1/1997 10/1/1998 4.88 4.88 8 FALSE TRUE Change -Subsidy -Alternate
250821 10/1/1998 6/1/2000 4.4 4.4 8 FALSE TRUE Change -Subsidy -Alternate
250821 6/1/2000 1/1/2002 4.4 4.4 8.5 FALSE TRUE Change +Price
250821 1/1/2002 10/1/2002 4.4 4.4 9 FALSE TRUE Change +Price
250821 10/1/2002 4/1/2004 4.4 4.4 9.52 FALSE TRUE Change +Price
250821 4/1/2004 1/1/2007 4.4 4.4 10.8 FALSE TRUE Change +Price
250821 1/1/2007 7/1/2008 4.4 4.4 12 FALSE TRUE Change +Price
250821 7/1/2008 0 0 0 FALSE FALSE Delisted
250848 5/16/1994 10/1/1998 6.16 6.16 7.2 FALSE TRUE New Listing
250848 10/1/1998 1/1/1999 4.38 4.38 7.2 FALSE TRUE Change -Subsidy -Alternate
250848 1/1/1999 3/1/2000 2.75 2.75 7.2 FALSE TRUE Change -Subsidy -Alternate
250848 3/1/2000 0 0 0 FALSE FALSE Delisted
250856 5/16/1994 12/1/1997 6.94 6.94 7.46 FALSE FALSE New Listing
250856 12/1/1997 10/1/1998 6.16 6.16 7.46 FALSE FALSE Change -Subsidy -Alternate
250856 10/1/1998 1/1/1999 4.38 4.38 7.46 FALSE FALSE Change -Subsidy -Alternate
250856 1/1/1999 3/1/2000 2.75 2.75 7.46 FALSE FALSE Change -Subsidy -Alternate
250856 3/1/2000 0 0 0 FALSE FALSE Delisted
250872 5/16/1994 8/1/1998 7.5 7.5 7.5 FALSE TRUE New Listing
250872 8/1/1998 7.5 7.5 8.25 FALSE TRUE Change +Price
250880 5/16/1994 1/1/1998 3.62 3.62 3.62 FALSE FALSE New Listing
250880 1/1/1998 0 0 0 FALSE FALSE Delisted
250929 5/16/1994 10/1/1999 17.08 17.08 17.08 FALSE TRUE New Listing
250929 10/1/1999 4/1/2003 8.54 8.54 8.54 FALSE TRUE Change -Subsidy -Price -Alternate
250929 4/1/2003 0 0 0 FALSE FALSE Delisted
250937 6/14/1995 7/1/2005 24.8 24.8 24.8 FALSE FALSE New Listing
250937 7/1/2005 0 0 0 FALSE FALSE Delisted
251003 5/16/1994 2/1/1996 8.34 8.34 10.8 FALSE FALSE New Listing
251003 2/1/1996 9/1/1998 8.34 8.34 11.23 FALSE FALSE Change +Price
251003 9/1/1998 7/1/1999 8.34 8.34 14.59 FALSE FALSE Change +Price
251003 7/1/1999 9/1/2001 4.49 4.49 14.59 FALSE FALSE Change -Subsidy -Alternate
251003 9/1/2001 12/1/2001 1.8 1.8 14.59 FALSE FALSE Change -Subsidy -Alternate
251003 12/1/2001 0 0 0 FALSE FALSE Delisted
251011 5/16/1994 10/1/2001 21.67 21.67 21.67 FALSE FALSE New Listing
251011 10/1/2001 11/1/2001 21.67 21.67 28.6 FALSE FALSE Change +Price
251011 11/1/2001 12/1/2005 28.6 28.6 28.6 FALSE FALSE Change +Subsidy +Alternate
251011 12/1/2005 4/1/2006 28.6 28.6 34.32 FALSE FALSE Change +Price
251011 4/1/2006 1/1/2009 34.32 34.32 34.32 FALSE FALSE Change +Subsidy +Alternate
251011 1/1/2009 7/1/2011 40.08 40.08 40.08 FALSE FALSE Change +Subsidy +Price +Alternate
251011 7/1/2011 38.9 38.9 38.9 FALSE FALSE Change -Subsidy -Price -Alternate
251089 5/16/1994 89.1 89.1 89.1 FALSE TRUE New Listing
251097 5/16/1994 1/1/1997 4.69 4.69 8.52 FALSE TRUE New Listing
251097 1/1/1997 7/1/1997 4.69 4.69 14.3 FALSE TRUE Change +Price
251097 7/1/1997 0 0 0 FALSE FALSE Delisted
251100 5/16/1994 1/1/1997 8.03 8.03 8.03 FALSE TRUE New Listing
251100 1/1/1997 7/1/1997 8.03 8.03 21.79 FALSE TRUE Change +Price
251100 7/1/1997 0 0 0 FALSE FALSE Delisted
251119 5/16/1994 1/1/1997 8.03 8.03 8.03 FALSE TRUE New Listing
251119 1/1/1997 7/1/1997 8.03 8.03 18.89 FALSE TRUE Change +Price
251119 7/1/1997 0 0 0 FALSE FALSE Delisted
251178 5/16/1994 6/23/1995 12.31 12.31 12.31 FALSE TRUE New Listing
251178 6/23/1995 4/1/1997 10.46 10.46 12.31 FALSE TRUE Change -Subsidy -Alternate
251178 4/1/1997 12/1/1997 8.37 8.37 8.37 FALSE TRUE Change -Subsidy -Price -Alternate
251178 12/1/1997 7/1/1999 5.44 5.44 5.44 FALSE TRUE Change -Subsidy -Price -Alternate
251178 7/1/1999 0 0 0 FALSE FALSE Delisted
251186 5/16/1994 58.66 58.66 58.66 FALSE FALSE New Listing
251194 5/16/1994 122.36 122.36 122.36 FALSE FALSE New Listing
251208 5/16/1994 12.66 12.66 12.66 FALSE FALSE New Listing
251216 5/16/1994 4/1/2001 85.74 85.74 85.74 FALSE FALSE New Listing
251216 4/1/2001 0 0 0 FALSE FALSE Delisted
251224 5/16/1994 114.4 114.4 114.4 FALSE FALSE New Listing
251232 5/16/1994 90.04 90.04 90.04 FALSE FALSE New Listing
251240 5/16/1994 179.57 179.57 179.57 FALSE FALSE New Listing
251321 5/16/1994 11/1/1998 8.43 8.43 9.17 FALSE FALSE New Listing
251321 11/1/1998 3/1/2002 8.43 8.43 23.77 FALSE FALSE Change -Subsidy +Price -Alternate
251321 3/1/2002 0 0 0 FALSE FALSE Delisted
251410 5/16/1994 8/1/1997 6.36 6.36 23.33 FALSE FALSE New Listing
251410 8/1/1997 0 0 0 FALSE FALSE Delisted
251461 5/16/1994 10/1/1997 5 5 5 FALSE TRUE New Listing
251461 10/1/1997 7/1/1998 5 5 6.5 FALSE TRUE Change +Price
251461 7/1/1998 6/1/2002 5 5 12 FALSE TRUE Change +Price
251461 6/1/2002 8/1/2007 5 5 15 FALSE TRUE Change +Price
251461 8/1/2007 0 0 0 FALSE FALSE Delisted
251534 5/16/1994 2/1/1998 10.96 10.96 10.96 FALSE TRUE New Listing
251534 2/1/1998 0 0 0 FALSE FALSE Delisted
251585 5/16/1994 7/1/1999 17.73 17.73 17.73 FALSE FALSE New Listing
251585 7/1/1999 8/1/2002 12.42 12.42 12.42 FALSE FALSE Change -Subsidy -Price -Alternate
251585 8/1/2002 7/1/2006 9.94 9.94 9.94 FALSE FALSE Change -Subsidy -Price -Alternate
251585 7/1/2006 3/1/2010 9.44 9.44 9.44 FALSE FALSE Change -Subsidy -Price -Alternate
251585 3/1/2010 12.89 12.89 12.89 FALSE FALSE Change +Subsidy +Price +Alternate
251593 5/16/1994 2/1/1999 7.36 7.36 7.36 FALSE FALSE New Listing
251593 2/1/1999 5/1/2000 6.99 6.99 6.99 FALSE FALSE Change -Subsidy -Price -Alternate
251593 5/1/2000 1/1/2003 6.99 6.99 7.5 FALSE FALSE Change +Price
251593 1/1/2003 0 0 0 FALSE FALSE Delisted
251615 5/16/1994 7/1/1999 15.83 15.83 15.83 FALSE FALSE New Listing
251615 7/1/1999 8/1/2002 11.1 11.1 11.1 FALSE FALSE Change -Subsidy -Price -Alternate
251615 8/1/2002 7/1/2006 8.86 8.86 8.86 FALSE FALSE Change -Subsidy -Price -Alternate
251615 7/1/2006 3/1/2010 8.42 8.42 8.42 FALSE FALSE Change -Subsidy -Price -Alternate
251615 3/1/2010 11.68 11.68 11.68 FALSE FALSE Change +Subsidy +Price +Alternate
251623 10/1/1994 7/1/1999 79.15 79.15 79.15 FALSE FALSE New Listing
251623 7/1/1999 2/1/2002 55.5 55.5 55.5 FALSE FALSE Change -Subsidy -Price -Alternate
251623 2/1/2002 0 0 0 FALSE FALSE Delisted
251666 5/16/1994 4/1/2002 21.1 21.1 21.1 FALSE FALSE New Listing
251666 4/1/2002 2/1/2010 21.1 21.1 24.1 FALSE FALSE Change +Price
251666 2/1/2010 1/1/2013 21.1 21.1 21.1 FALSE FALSE Change -Price
251666 1/1/2013 23.21 23.21 23.21 FALSE FALSE Change +Subsidy +Price +Alternate
251704 5/16/1994 12/1/1999 7.99 7.99 7.99 FALSE FALSE New Listing
251704 12/1/1999 0 0 0 FALSE FALSE Delisted
251763 2/1/1997 9/1/2000 46.4 46.4 48.7 FALSE FALSE New Listing
251763 9/1/2000 3/1/2001 46.4 46.4 103.32 FALSE FALSE Change +Price
251763 3/1/2001 0 0 0 FALSE FALSE Delisted
251771 2/1/1997 9/1/2000 47.4 47.4 49.8 FALSE FALSE New Listing
251771 9/1/2000 3/1/2001 47.4 47.4 52.32 FALSE FALSE Change +Price
251771 3/1/2001 0 0 0 FALSE FALSE Delisted
251801 2/1/1997 9/1/2000 70.4 70.4 73.9 FALSE FALSE New Listing
251801 9/1/2000 3/1/2001 70.4 70.4 77.6 FALSE FALSE Change +Price
251801 3/1/2001 0 0 0 FALSE FALSE Delisted
251917 5/16/1994 5/1/1996 9.45 9.45 13.2 FALSE TRUE New Listing
251917 5/1/1996 4/1/2000 9.45 13.8 13.8 FALSE TRUE Change +Price +Alternate
251917 4/1/2000 8/1/2000 9.45 13.8 13.8 FALSE FALSE Change -OP
251917 8/1/2000 1/1/2004 9.45 14.49 14.49 FALSE FALSE Change +Price +Alternate
251917 1/1/2004 9/1/2009 6.62 14.49 14.49 FALSE FALSE Change -Subsidy
251917 9/1/2009 0 0 0 FALSE FALSE Delisted
251933 5/16/1994 12/1/2003 256.15 256.15 256.15 FALSE FALSE New Listing
251933 12/1/2003 0 0 0 FALSE FALSE Delisted
251976 5/16/1994 7/1/2000 1.2 1.2 2.76 FALSE FALSE New Listing
251976 7/1/2000 11/1/2001 1.2 1.2 2.9 FALSE FALSE Change +Price
251976 11/1/2001 5/1/2003 1.2 1.2 3.05 FALSE FALSE Change +Price
251976 5/1/2003 0 0 0 FALSE FALSE Delisted
251984 5/16/1994 7/1/2000 3 3 5.19 FALSE FALSE New Listing
251984 7/1/2000 11/1/2001 3 3 5.45 FALSE FALSE Change +Price
251984 11/1/2001 3/1/2004 3 3 5.72 FALSE FALSE Change +Price
251984 3/1/2004 0 0 0 FALSE FALSE Delisted
252018 5/16/1994 7/1/2000 1.2 1.2 2.36 FALSE FALSE New Listing
252018 7/1/2000 11/1/2001 1.2 1.2 2.48 FALSE FALSE Change +Price
252018 11/1/2001 5/1/2003 1.2 1.2 2.6 FALSE FALSE Change +Price
252018 5/1/2003 0 0 0 FALSE FALSE Delisted
252026 5/16/1994 7/1/2000 3 3 4.32 FALSE FALSE New Listing
252026 7/1/2000 11/1/2001 3 3 4.54 FALSE FALSE Change +Price
252026 11/1/2001 1/1/2003 3 3 4.77 FALSE FALSE Change +Price
252026 1/1/2003 10/1/2003 3 3 5.72 FALSE FALSE Change +Price
252026 10/1/2003 1/1/2005 3 3.51 5.72 FALSE FALSE Change +Alternate
252026 1/1/2005 4/1/2006 3 3.51 6.12 FALSE FALSE Change +Price
252026 4/1/2006 4/1/2008 3 3.76 6.12 FALSE FALSE Change +Alternate
252026 4/1/2008 5/1/2009 3 3.87 6.3 FALSE FALSE Change +Price +Alternate
252026 5/1/2009 5/1/2013 3 6.3 6.3 FALSE FALSE Change +Alternate
252026 5/1/2013 0 0 0 FALSE FALSE Delisted
252050 5/16/1994 1/1/2003 30 30 30 FALSE FALSE New Listing
252050 1/1/2003 10/1/2003 30 30 35.1 FALSE FALSE Change +Price
252050 10/1/2003 12/1/2004 30 35.1 35.1 FALSE FALSE Change +Alternate
252050 12/1/2004 4/1/2006 30 35.1 37.6 FALSE FALSE Change +Price
252050 4/1/2006 4/1/2008 30 37.6 37.6 FALSE FALSE Change +Alternate
252050 4/1/2008 12/1/2009 30 38.73 38.73 FALSE FALSE Change +Price +Alternate
252050 12/1/2009 0 0 0 FALSE FALSE Delisted
252077 5/16/1994 3/1/2002 4.25 4.25 4.25 FALSE TRUE New Listing
252077 3/1/2002 0 0 0 FALSE FALSE Delisted
252115 5/16/1994 5/1/1998 31.26 31.26 34.08 FALSE FALSE New Listing
252115 5/1/1998 8/1/1998 10.2 10.2 34.08 FALSE FALSE Change -Subsidy -Alternate
252115 8/1/1998 0 0 0 FALSE FALSE Delisted
252204 5/16/1994 4/1/1997 2.97 2.97 3.65 FALSE TRUE New Listing
252204 4/1/1997 2/1/2000 2.97 2.97 4.65 FALSE TRUE Change +Price
252204 2/1/2000 3/1/2001 2.97 2.97 4.95 FALSE TRUE Change +Price
252204 3/1/2001 4/1/2002 2.97 2.97 5.45 FALSE TRUE Change +Price
252204 4/1/2002 4/1/2003 2.97 2.97 6 FALSE TRUE Change +Price
252204 4/1/2003 4/1/2004 2.97 2.97 6.6 FALSE TRUE Change +Price
252204 4/1/2004 7/1/2006 2.97 2.97 7.26 FALSE TRUE Change +Price
252204 7/1/2006 2.97 2.97 7.99 FALSE TRUE Change +Price
252212 5/16/1994 3/1/1996 42.21 42.21 42.21 FALSE FALSE New Listing
252212 3/1/1996 3/1/1999 18.5 38 38 FALSE FALSE Change -Subsidy -Price -Alternate
252212 3/1/1999 12/1/1999 14.8 38 38 FALSE FALSE Change -Subsidy
252212 12/1/1999 4/1/2000 14.5 38 38 FALSE FALSE Change -Subsidy
252212 4/1/2000 6/1/2000 0 0 0 FALSE FALSE Delisted
252212 6/1/2000 2/1/2001 14.5 14.5 14.5 FALSE FALSE New Listing
252212 2/1/2001 0 0 0 FALSE FALSE Delisted
252220 5/16/1994 4/13/1995 9.45 9.45 9.45 FALSE TRUE New Listing
252220 4/13/1995 9/1/1995 9.45 9.45 13.2 FALSE TRUE Change +Price
252220 9/1/1995 6/1/1996 9.45 9.45 13.8 FALSE TRUE Change +Price
252220 6/1/1996 4/1/2000 9.45 14.49 14.49 FALSE TRUE Change +Price +Alternate
252220 4/1/2000 8/1/2002 9.45 14.49 14.49 FALSE FALSE Change -OP
252220 8/1/2002 1/1/2004 9.45 15 15 FALSE FALSE Change +Price +Alternate
252220 1/1/2004 6/1/2012 6.62 15 16.5 FALSE FALSE Change -Subsidy +Price
252220 6/1/2012 9/1/2012 2.45 2.45 16.5 FALSE FALSE Change -Subsidy -Alternate
252220 9/1/2012 0 0 0 FALSE FALSE Delisted
252247 5/16/1994 3/1/1996 39.58 39.58 42.2 FALSE FALSE New Listing
252247 3/1/1996 3/1/1999 18.5 38 38 FALSE FALSE Change -Subsidy -Price -Alternate
252247 3/1/1999 2/1/2000 14.8 38 38 FALSE FALSE Change -Subsidy
252247 2/1/2000 9/1/2001 8.88 38 38 FALSE FALSE Change -Subsidy
252247 9/1/2001 0 0 0 FALSE FALSE Delisted
252263 5/16/1994 12/1/1995 12 12 12 FALSE TRUE New Listing
252263 12/1/1995 2/1/1998 8.76 8.76 8.76 FALSE TRUE Change -Subsidy -Price -Alternate
252263 2/1/1998 5/1/1998 7.44 7.44 8.76 FALSE TRUE Change -Subsidy -Alternate
252263 5/1/1998 11/1/2005 7.44 7.44 7.44 FALSE TRUE Change -Price
252263 11/1/2005 0 0 0 FALSE FALSE Delisted
252271 5/16/1994 12/1/1995 21.05 21.05 21.05 FALSE FALSE New Listing
252271 12/1/1995 2/1/1999 7.32 7.32 7.32 FALSE FALSE Change -Subsidy -Price -Alternate
252271 2/1/1999 3/1/2001 7.32 7.32 13.64 FALSE FALSE Change +Price
252271 3/1/2001 0 0 0 FALSE FALSE Delisted
252301 5/16/1994 7/1/2008 10.21 10.21 10.21 FALSE FALSE New Listing
252301 7/1/2008 0 0 0 FALSE FALSE Delisted
252328 5/16/1994 12/1/1995 6.83 6.83 10.85 FALSE FALSE New Listing
252328 12/1/1995 5/1/1998 6.83 6.83 6.83 FALSE FALSE Change -Price
252328 5/1/1998 6/1/2007 6.83 6.83 10.85 FALSE FALSE Change +Price
252328 6/1/2007 9/1/2007 6.65 6.65 10.85 FALSE FALSE Change -Subsidy -Alternate
252328 9/1/2007 0 0 0 FALSE FALSE Delisted
252336 5/16/1994 3/5/1997 16.02 16.02 17.23 FALSE TRUE New Listing
252336 3/5/1997 5/1/2005 16.02 16.02 16.02 FALSE TRUE Change -Price
252336 5/1/2005 0 0 0 FALSE FALSE Delisted
252344 5/16/1994 8/1/1997 7.67 7.67 7.67 FALSE FALSE New Listing
252344 8/1/1997 6/1/2000 7.66 7.66 7.66 FALSE FALSE Change -Subsidy -Price -Alternate
252344 6/1/2000 0 0 0 FALSE FALSE Delisted
252360 5/16/1994 8/1/1997 9.32 9.32 9.32 FALSE FALSE New Listing
252360 8/1/1997 2/1/1999 9.33 9.33 9.33 FALSE FALSE Change +Subsidy +Price +Alternate
252360 2/1/1999 6/1/2000 9.33 9.33 40.48 FALSE FALSE Change +Price
252360 6/1/2000 0 0 0 FALSE FALSE Delisted
252395 5/16/1994 12/1/1997 53.31 53.31 53.31 FALSE FALSE New Listing
252395 12/1/1997 5/1/2007 53.31 53.31 55.99 FALSE FALSE Change +Price
252395 5/1/2007 53.31 53.31 156.71 FALSE FALSE Change +Price
252409 5/16/1994 10/1/2002 32.96 32.96 32.96 FALSE FALSE New Listing
252409 10/1/2002 7/1/2006 32.96 32.96 37.08 FALSE FALSE Change +Price
252409 7/1/2006 5/1/2011 32.96 32.96 32.96 FALSE FALSE Change -Price
252409 5/1/2011 8/1/2013 32.96 32.96 65 FALSE FALSE Change +Price
252409 8/1/2013 65 65 65 FALSE FALSE Change +Subsidy +Alternate
252417 5/16/1994 10/1/2002 51.7 51.7 51.7 FALSE FALSE New Listing
252417 10/1/2002 7/1/2006 51.7 51.7 58.16 FALSE FALSE Change +Price
252417 7/1/2006 5/1/2011 51.7 51.7 51.7 FALSE FALSE Change -Price
252417 5/1/2011 8/1/2013 51.7 51.7 77 FALSE FALSE Change +Price
252417 8/1/2013 77 77 77 FALSE FALSE Change +Subsidy +Alternate
252433 5/16/1994 10/1/2006 10.52 10.52 10.52 FALSE FALSE New Listing
252433 10/1/2006 1/1/2007 7.47 7.47 7.47 FALSE FALSE Change -Subsidy -Price -Alternate
252433 1/1/2007 7/1/2008 0 0 0 FALSE FALSE Delisted
252433 7/1/2008 12/1/2008 6.54 6.54 6.54 FALSE FALSE New Listing
252433 12/1/2008 0 0 0 FALSE FALSE Delisted
252468 5/16/1994 11/1/2000 2.96 2.96 4.95 FALSE TRUE New Listing
252468 11/1/2000 2/1/2001 2.96 2.96 5.43 FALSE TRUE Change +Price
252468 2/1/2001 3/1/2002 2.96 2.96 5.7 FALSE TRUE Change +Price
252468 3/1/2002 9/1/2002 2.96 2.96 6.1 FALSE TRUE Change +Price
252468 9/1/2002 12/1/2002 2.52 2.52 6.1 FALSE TRUE Change -Subsidy -Alternate
252468 12/1/2002 0 0 0 FALSE FALSE Delisted
252492 5/16/1994 5/1/2002 103.5 103.5 103.5 FALSE FALSE New Listing
252492 5/1/2002 0 0 0 FALSE FALSE Delisted
252506 5/16/1994 7/1/1999 3.81 3.81 3.81 FALSE TRUE New Listing
252506 7/1/1999 11/1/1999 2.67 2.67 3.81 FALSE TRUE Change -Subsidy -Alternate
252506 11/1/1999 0 0 0 FALSE FALSE Delisted
252514 5/16/1994 7/1/1999 4.08 4.08 4.08 FALSE TRUE New Listing
252514 7/1/1999 11/1/1999 2.86 2.86 4.08 FALSE TRUE Change -Subsidy -Alternate
252514 11/1/1999 8/1/2009 0 0 0 FALSE FALSE Delisted
252514 8/1/2009 4.26 4.26 4.26 FALSE TRUE New Listing
252522 5/16/1994 7/1/1999 5.23 5.23 5.23 FALSE TRUE New Listing
252522 7/1/1999 11/1/1999 3.66 3.66 5.23 FALSE TRUE Change -Subsidy -Alternate
252522 11/1/1999 8/1/2009 0 0 0 FALSE FALSE Delisted
252522 8/1/2009 5.35 5.35 5.35 FALSE TRUE New Listing
252530 5/16/1994 7/1/1999 6.63 6.63 6.63 FALSE TRUE New Listing
252530 7/1/1999 11/1/1999 4.64 4.64 6.63 FALSE TRUE Change -Subsidy -Alternate
252530 11/1/1999 0 0 0 FALSE FALSE Delisted
252549 5/16/1994 7/1/1999 7.66 7.66 7.66 FALSE TRUE New Listing
252549 7/1/1999 11/1/1999 5.36 5.36 7.66 FALSE TRUE Change -Subsidy -Alternate
252549 11/1/1999 8/1/2009 0 0 0 FALSE FALSE Delisted
252549 8/1/2009 7.99 7.99 7.99 FALSE TRUE New Listing
252557 5/16/1994 7/1/1999 10.92 10.92 10.92 FALSE TRUE New Listing
252557 7/1/1999 11/1/1999 7.64 7.64 10.92 FALSE TRUE Change -Subsidy -Alternate
252557 11/1/1999 0 0 0 FALSE FALSE Delisted
252581 5/16/1994 5/1/1997 5.06 5.06 5.06 FALSE TRUE New Listing
252581 5/1/1997 0 0 0 FALSE FALSE Delisted
252654 5/16/1994 3/1/1996 54.6 54.6 54.6 FALSE FALSE New Listing
252654 3/1/1996 9/1/1998 19.66 19.66 19.66 FALSE FALSE Change -Subsidy -Price -Alternate
252654 9/1/1998 4/1/1999 6 6 19.66 FALSE FALSE Change -Subsidy -Alternate
252654 4/1/1999 12/1/2000 6 6 6 FALSE FALSE Change -Price
252654 12/1/2000 0 0 0 FALSE FALSE Delisted
252662 5/16/1994 6/1/1999 4.13 4.13 4.75 FALSE FALSE New Listing
252662 6/1/1999 0 0 0 FALSE FALSE Delisted
252670 8/16/1994 11/1/1997 11 11 11 FALSE FALSE New Listing
252670 11/1/1997 10/1/2001 11 11 12.3 FALSE FALSE Change +Price
252670 10/1/2001 0 0 0 FALSE FALSE Delisted
252700 5/16/1994 4/1/1998 8.2 8.2 8.2 FALSE FALSE New Listing
252700 4/1/1998 0 0 0 FALSE FALSE Delisted
252719 5/16/1994 1/1/1998 2.63 2.63 2.63 FALSE FALSE New Listing
252719 1/1/1998 2/1/2000 2.63 2.63 3.53 FALSE FALSE Change +Price
252719 2/1/2000 2/1/2001 2.63 2.63 4.45 FALSE FALSE Change +Price
252719 2/1/2001 0 0 0 FALSE FALSE Delisted
252727 5/16/1994 10/1/2001 46.8 46.8 46.8 FALSE FALSE New Listing
252727 10/1/2001 0 0 0 FALSE FALSE Delisted
252735 5/16/1994 10/1/2008 47.6 47.6 47.6 FALSE FALSE New Listing
252735 10/1/2008 9/1/2011 50.86 50.86 50.86 FALSE FALSE Change +Subsidy +Price +Alternate
252735 9/1/2011 123.5 123.5 123.5 FALSE FALSE Change +Subsidy +Price +Alternate
252751 12/1/1994 8/1/1998 8.26 8.26 8.26 FALSE TRUE New Listing
252751 8/1/1998 6/1/2005 8.26 8.26 9.09 FALSE TRUE Change +Price
252751 6/1/2005 12/1/2005 8.26 8.26 11.12 FALSE TRUE Change +Price
252751 12/1/2005 0 0 0 FALSE FALSE Delisted
252786 3/1/1996 3/1/1999 55.5 83.8 83.8 FALSE FALSE New Listing
252786 3/1/1999 2/1/2000 44.4 83.8 83.8 FALSE FALSE Change -Subsidy
252786 2/1/2000 4/1/2002 26.6 83.8 83.8 FALSE FALSE Change -Subsidy
252786 4/1/2002 0 0 0 FALSE FALSE Delisted
252808 5/16/1994 7/1/1995 6.46 6.46 6.46 FALSE FALSE New Listing
252808 7/1/1995 5/1/1996 6.85 6.85 6.85 FALSE FALSE Change +Subsidy +Price +Alternate
252808 5/1/1996 4/1/1998 6.85 6.85 7.15 FALSE FALSE Change +Price
252808 4/1/1998 4/1/1999 6.85 6.85 7.64 FALSE FALSE Change +Price
252808 4/1/1999 9/1/1999 6.85 6.85 8.1 FALSE FALSE Change +Price
252808 9/1/1999 3/1/2000 6.85 6.85 13.75 FALSE FALSE Change +Price
252808 3/1/2000 9/1/2000 6.85 6.85 14.5 FALSE FALSE Change +Price
252808 9/1/2000 3/1/2001 6.85 6.85 15.5 FALSE FALSE Change +Price
252808 3/1/2001 8/1/2002 6.85 6.85 16.5 FALSE FALSE Change +Price
252808 8/1/2002 5/1/2006 16.5 16.5 16.5 FALSE FALSE Change +Subsidy +Alternate
252808 5/1/2006 0 0 0 FALSE FALSE Delisted
252816 8/16/1994 12/1/2002 3.3 3.3 3.95 FALSE TRUE New Listing
252816 12/1/2002 7/1/2005 3.95 3.95 3.95 FALSE TRUE Change +Subsidy +Alternate
252816 7/1/2005 10/1/2008 3.93 3.93 3.93 FALSE TRUE Change -Subsidy -Price -Alternate
252816 10/1/2008 3.78 3.78 3.78 FALSE TRUE Change -Subsidy -Price -Alternate
252824 5/16/1994 12/1/2002 4.46 4.46 5.25 FALSE TRUE New Listing
252824 12/1/2002 5.4 5.4 5.4 FALSE TRUE Change +Subsidy +Price +Alternate
252832 5/16/1994 12/1/2002 3.22 3.22 4.25 FALSE FALSE New Listing
252832 12/1/2002 10/1/2005 4.25 4.25 4.25 FALSE FALSE Change +Subsidy +Alternate
252832 10/1/2005 9/1/2006 4.89 4.89 4.89 FALSE FALSE Change +Subsidy +Price +Alternate
252832 9/1/2006 11/1/2006 3.37 3.37 3.37 FALSE FALSE Change -Subsidy -Price -Alternate
252832 11/1/2006 6/1/2010 4.89 4.89 4.89 FALSE FALSE Change +Subsidy +Price +Alternate
252832 6/1/2010 9/1/2010 3.95 3.95 4.89 FALSE FALSE Change -Subsidy -Alternate
252832 9/1/2010 0 0 0 FALSE FALSE Delisted
252840 5/16/1994 1/1/2003 16.1 16.1 18.25 FALSE FALSE New Listing
252840 1/1/2003 2/1/2003 21.25 21.25 18.25 FALSE FALSE Change +Subsidy +Alternate
252840 2/1/2003 7/1/2007 21.25 21.25 21.25 FALSE FALSE Change +Price
252840 7/1/2007 0 0 0 FALSE FALSE Delisted
252859 5/16/1994 12/1/2002 3.95 3.95 4.8 FALSE FALSE New Listing
252859 12/1/2002 10/1/2005 4.8 4.8 4.8 FALSE FALSE Change +Subsidy +Alternate
252859 10/1/2005 6/1/2010 6.73 6.73 6.73 FALSE FALSE Change +Subsidy +Price +Alternate
252859 6/1/2010 9/1/2010 5.49 5.49 6.73 FALSE FALSE Change -Subsidy -Alternate
252859 9/1/2010 0 0 0 FALSE FALSE Delisted
252867 5/16/1994 2/1/2003 19.75 19.75 22.95 FALSE FALSE New Listing
252867 2/1/2003 9/1/2010 24 24 24 FALSE FALSE Change +Subsidy +Price +Alternate
252867 9/1/2010 0 0 0 FALSE FALSE Delisted
252891 12/1/1995 8/1/2000 1.77 1.77 2.86 FALSE FALSE New Listing
252891 8/1/2000 3/1/2001 1.77 1.77 3 FALSE FALSE Change +Price
252891 3/1/2001 3/1/2002 1.77 1.77 3.1 FALSE FALSE Change +Price
252891 3/1/2002 6/1/2007 1.77 1.77 3.2 FALSE FALSE Change +Price
252891 6/1/2007 0 0 0 FALSE FALSE Delisted
252905 5/16/1994 7/1/1995 5.31 5.31 6.08 FALSE FALSE New Listing
252905 7/1/1995 12/1/1995 5.31 5.31 6.45 FALSE FALSE Change +Price
252905 12/1/1995 2/1/2001 5.31 5.31 6.58 FALSE FALSE Change +Price
252905 2/1/2001 3/1/2001 5.31 5.31 6.78 FALSE FALSE Change +Price
252905 3/1/2001 3/1/2002 5.31 5.31 6.8 FALSE FALSE Change +Price
252905 3/1/2002 2/1/2009 5.31 5.31 7 FALSE FALSE Change +Price
252905 2/1/2009 0 0 0 FALSE FALSE Delisted
252913 5/16/1994 8/1/2000 3.76 3.76 4.43 FALSE FALSE New Listing
252913 8/1/2000 2/1/2001 3.76 3.76 4.63 FALSE FALSE Change +Price
252913 2/1/2001 3/1/2001 3.76 3.76 4.77 FALSE FALSE Change +Price
252913 3/1/2001 3/1/2002 3.76 3.76 4.8 FALSE FALSE Change +Price
252913 3/1/2002 2/1/2009 3.76 3.76 4.95 FALSE FALSE Change +Price
252913 2/1/2009 0 0 0 FALSE FALSE Delisted
252956 4/1/1998 5/1/1999 23.85 23.85 28.05 FALSE FALSE New Listing
252956 5/1/1999 11/1/2001 28.05 28.05 28.05 FALSE FALSE Change +Subsidy +Alternate
252956 11/1/2001 0 0 0 FALSE FALSE Delisted
252972 4/1/1998 5/1/1999 23.85 23.85 28.05 FALSE FALSE New Listing
252972 5/1/1999 11/1/2001 28.05 28.05 28.05 FALSE FALSE Change +Subsidy +Alternate
252972 11/1/2001 0 0 0 FALSE FALSE Delisted
253022 5/16/1994 6/27/1995 40.4 40.4 52.53 FALSE FALSE New Listing
253022 6/27/1995 5/1/1996 40.4 40.4 55.16 FALSE FALSE Change +Price
253022 5/1/1996 4/1/1998 40.4 40.4 57.4 FALSE FALSE Change +Price
253022 4/1/1998 5/1/1999 40.4 40.4 61.41 FALSE FALSE Change +Price
253022 5/1/1999 7/1/2000 61.41 61.41 61.41 FALSE FALSE Change +Subsidy +Alternate
253022 7/1/2000 11/1/2000 40.4 40.4 40.4 FALSE FALSE Change -Subsidy -Price -Alternate
253022 11/1/2000 0 0 0 FALSE FALSE Delisted
253049 5/16/1994 6/27/1995 17.3 17.3 20 FALSE FALSE New Listing
253049 6/27/1995 5/1/1996 17.3 17.3 21.64 FALSE FALSE Change +Price
253049 5/1/1996 4/1/1998 17.3 17.3 22.5 FALSE FALSE Change +Price
253049 4/1/1998 5/1/1999 17.3 17.3 24.07 FALSE FALSE Change +Price
253049 5/1/1999 7/1/2000 24.07 24.07 24.07 FALSE FALSE Change +Subsidy +Alternate
253049 7/1/2000 11/1/2000 15.56 15.56 15.56 FALSE FALSE Change -Subsidy -Price -Alternate
253049 11/1/2000 0 0 0 FALSE FALSE Delisted
253065 5/16/1994 6/1/1995 17.96 17.96 17.96 FALSE TRUE New Listing
253065 6/1/1995 12/1/2005 23.89 23.89 23.89 FALSE TRUE Change +Subsidy +Price +Alternate
253065 12/1/2005 1/1/2008 23.89 23.89 28.68 FALSE TRUE Change +Price
253065 1/1/2008 12/1/2008 23.89 23.89 32.71 FALSE TRUE Change +Price
253065 12/1/2008 12/1/2012 26.49 26.49 26.49 FALSE TRUE Change +Subsidy -Price +Alternate
253065 12/1/2012 25.16 25.16 25.16 FALSE TRUE Change -Subsidy -Price -Alternate
253073 7/1/1996 5/1/1999 7.5 7.5 7.5 FALSE TRUE New Listing
253073 5/1/1999 6/1/1999 7.5 7.5 8.3 FALSE TRUE Change +Price
253073 6/1/1999 9/1/1999 7.5 7.5 8.6 FALSE TRUE Change +Price
253073 9/1/1999 6/1/2004 6.13 6.13 8.6 FALSE TRUE Change -Subsidy -Alternate
253073 6/1/2004 10/1/2010 4.75 4.75 7.22 FALSE TRUE Change -Subsidy -Price -Alternate
253073 10/1/2010 3/1/2012 4.22 4.22 4.22 FALSE TRUE Change -Subsidy -Price -Alternate
253073 3/1/2012 0 0 0 FALSE FALSE Delisted
253081 5/16/1994 5/1/2013 8.63 8.63 8.63 FALSE TRUE New Listing
253081 5/1/2013 0 0 0 FALSE FALSE Delisted
253154 5/16/1994 6/1/2002 5.34 5.34 6.22 FALSE FALSE New Listing
253154 6/1/2002 0 0 0 FALSE FALSE Delisted
253162 8/16/1994 5/1/1996 10.57 10.57 12.03 FALSE FALSE New Listing
253162 5/1/1996 7/1/1998 10.57 10.57 12.6 FALSE FALSE Change +Price
253162 7/1/1998 1/1/2004 10.57 10.57 10.57 FALSE FALSE Change -Price
253162 1/1/2004 6/1/2008 6.5 6.5 6.5 FALSE FALSE Change -Subsidy -Price -Alternate
253162 6/1/2008 0 0 0 FALSE FALSE Delisted
253197 5/16/1994 9/1/1995 7.56 7.56 7.56 FALSE FALSE New Listing
253197 9/1/1995 7/1/2009 7.56 7.56 7.7 FALSE FALSE Change +Price
253197 7/1/2009 0 0 0 FALSE FALSE Delisted
253251 5/16/1994 2/1/1996 4.54 4.54 5.55 FALSE TRUE New Listing
253251 2/1/1996 3/1/1998 4.54 4.54 5.83 FALSE TRUE Change +Price
253251 3/1/1998 9/1/1998 3.33 3.33 5.83 FALSE TRUE Change -Subsidy -Alternate
253251 9/1/1998 10/1/1998 3.33 3.33 6.7 FALSE TRUE Change +Price
253251 10/1/1998 1/1/1999 1.83 1.83 6.7 FALSE TRUE Change -Subsidy -Alternate
253251 1/1/1999 12/1/2001 1 1 6.7 FALSE TRUE Change -Subsidy -Alternate
253251 12/1/2001 0 0 0 FALSE FALSE Delisted
253278 5/16/1994 2/1/1996 7.58 7.58 8.08 FALSE TRUE New Listing
253278 2/1/1996 3/1/1998 7.58 7.58 8.48 FALSE TRUE Change +Price
253278 3/1/1998 9/1/1998 4.36 4.36 8.48 FALSE TRUE Change -Subsidy -Alternate
253278 9/1/1998 2/1/2003 4.36 4.36 9.88 FALSE TRUE Change +Price
253278 2/1/2003 4/1/2009 4.36 4.36 10.32 FALSE TRUE Change +Price
253278 4/1/2009 4.36 4.36 10.03 FALSE TRUE Change -Price
253286 5/16/1994 2/1/1996 5.66 5.66 5.66 FALSE TRUE New Listing
253286 2/1/1996 3/1/1998 5.66 5.66 5.94 FALSE TRUE Change +Price
253286 3/1/1998 0 0 0 FALSE FALSE Delisted
253294 5/16/1994 2/1/1996 8.3 8.3 8.3 FALSE TRUE New Listing
253294 2/1/1996 3/1/1998 8.3 8.3 8.72 FALSE TRUE Change +Price
253294 3/1/1998 9/1/1998 4.36 4.36 8.72 FALSE TRUE Change -Subsidy -Alternate
253294 9/1/1998 2/1/2003 4.36 4.36 11.33 FALSE TRUE Change +Price
253294 2/1/2003 4/1/2009 4.36 4.36 12.46 FALSE TRUE Change +Price
253294 4/1/2009 4.36 4.36 12.1 FALSE TRUE Change -Price
253308 6/2/1995 4/1/1997 10.46 10.46 10.46 FALSE TRUE New Listing
253308 4/1/1997 5/1/1997 8.37 8.37 10.46 FALSE TRUE Change -Subsidy -Alternate
253308 5/1/1997 12/1/1997 8.37 8.37 8.37 FALSE TRUE Change -Price
253308 12/1/1997 7/1/2000 5.44 5.44 5.44 FALSE TRUE Change -Subsidy -Price -Alternate
253308 7/1/2000 7/1/2003 2.6 2.6 2.6 FALSE TRUE Change -Subsidy -Price -Alternate
253308 7/1/2003 6/1/2007 2.35 2.35 2.35 FALSE TRUE Change -Subsidy -Price -Alternate
253308 6/1/2007 9/1/2009 2.35 2.35 2.95 FALSE TRUE Change +Price
253308 9/1/2009 10/1/2012 2.35 2.35 4 FALSE TRUE Change +Price
253308 10/1/2012 2.35 2.35 4.85 FALSE TRUE Change +Price
253332 5/16/1994 9/1/1998 10.53 10.53 10.53 FALSE FALSE New Listing
253332 9/1/1998 0 0 0 FALSE FALSE Delisted
253367 6/2/1995 4/1/1997 18.62 18.62 18.62 FALSE TRUE New Listing
253367 4/1/1997 5/1/1997 16.74 16.74 18.62 FALSE TRUE Change -Subsidy -Alternate
253367 5/1/1997 12/1/1997 16.74 16.74 16.74 FALSE TRUE Change -Price
253367 12/1/1997 7/1/2000 10.88 10.88 10.88 FALSE TRUE Change -Subsidy -Price -Alternate
253367 7/1/2000 7/1/2003 2.95 2.95 2.95 FALSE TRUE Change -Subsidy -Price -Alternate
253367 7/1/2003 6/1/2007 2.61 2.61 2.61 FALSE TRUE Change -Subsidy -Price -Alternate
253367 6/1/2007 9/1/2009 2.61 2.61 3.3 FALSE TRUE Change +Price
253367 9/1/2009 10/1/2012 2.61 2.61 4.81 FALSE TRUE Change +Price
253367 10/1/2012 2.61 2.61 5.75 FALSE TRUE Change +Price
253375 5/16/1994 3/1/1995 19.33 19.33 22.23 FALSE FALSE New Listing
253375 3/1/1995 8/1/1997 19.33 19.33 26.67 FALSE FALSE Change +Price
253375 8/1/1997 3/1/2001 19.33 19.33 67.2 FALSE FALSE Change +Price
253375 3/1/2001 7/1/2001 19.33 19.33 73.92 FALSE FALSE Change +Price
253375 7/1/2001 8/1/2004 73.92 73.92 73.92 FALSE FALSE Change +Subsidy +Alternate
253375 8/1/2004 0 0 0 FALSE FALSE Delisted
253383 5/16/1994 2/1/2000 9.02 9.02 9.02 FALSE FALSE New Listing
253383 2/1/2000 0 0 0 FALSE FALSE Delisted
253464 5/16/1994 5/10/1995 3.26 3.26 3.91 FALSE TRUE New Listing
253464 5/10/1995 10/1/1997 3.26 3.26 4.75 FALSE TRUE Change +Price
253464 10/1/1997 10/1/1998 2.93 2.93 4.75 FALSE TRUE Change -Subsidy -Alternate
253464 10/1/1998 1/1/2003 2.64 2.64 4.75 FALSE TRUE Change -Subsidy -Alternate
253464 1/1/2003 0 0 0 FALSE FALSE Delisted
253480 5/16/1994 7/1/2003 7.55 7.55 7.55 FALSE FALSE New Listing
253480 7/1/2003 7.54 7.54 7.54 FALSE FALSE Change -Subsidy -Price -Alternate
253499 5/16/1994 3/1/1996 13.33 13.33 13.33 FALSE FALSE New Listing
253499 3/1/1996 12/1/1997 11.25 11.25 11.25 FALSE FALSE Change -Subsidy -Price -Alternate
253499 12/1/1997 8/1/2000 8.44 8.44 8.44 FALSE FALSE Change -Subsidy -Price -Alternate
253499 8/1/2000 12/1/2000 5 5 7.32 FALSE FALSE Change -Subsidy -Price -Alternate
253499 12/1/2000 3/1/2008 0 0 0 FALSE FALSE Delisted
253499 3/1/2008 7.01 7.01 7.01 FALSE FALSE New Listing
253502 5/16/1994 3/1/1996 23.75 23.75 23.75 FALSE FALSE New Listing
253502 3/1/1996 12/1/1997 22.51 22.51 22.51 FALSE FALSE Change -Subsidy -Price -Alternate
253502 12/1/1997 8/1/2000 16.88 16.88 16.88 FALSE FALSE Change -Subsidy -Price -Alternate
253502 8/1/2000 12/1/2000 6.5 6.5 12.26 FALSE FALSE Change -Subsidy -Price -Alternate
253502 12/1/2000 3/1/2008 0 0 0 FALSE FALSE Delisted
253502 3/1/2008 11.74 11.74 11.74 FALSE FALSE New Listing
253529 5/16/1994 3/1/1998 13.1 13.1 13.1 FALSE FALSE New Listing
253529 3/1/1998 0 0 0 FALSE FALSE Delisted
253545 5/16/1994 6/1/2004 25.99 25.99 25.99 FALSE FALSE New Listing
253545 6/1/2004 0 0 0 FALSE FALSE Delisted
253553 5/16/1994 6/1/2002 7.09 7.09 7.09 FALSE FALSE New Listing
253553 6/1/2002 0 0 0 FALSE FALSE Delisted
253588 5/16/1994 6/1/2002 8.17 8.17 8.61 FALSE FALSE New Listing
253588 6/1/2002 0 0 0 FALSE FALSE Delisted
253596 10/4/1997 3/1/1998 6.1 6.1 7.32 FALSE TRUE New Listing
253596 3/1/1998 4/1/1998 4.9 4.9 7.32 FALSE TRUE Change -Subsidy -Alternate
253596 4/1/1998 2/1/2003 4.9 4.9 6.09 FALSE TRUE Change -Price
253596 2/1/2003 5/1/2003 3.49 3.49 6.09 FALSE TRUE Change -Subsidy -Alternate
253596 5/1/2003 0 0 0 FALSE FALSE Delisted
253634 6/3/1995 6/1/2003 3.67 3.67 3.67 FALSE TRUE New Listing
253634 6/1/2003 12/1/2006 2.57 2.57 2.57 FALSE TRUE Change -Subsidy -Price -Alternate
253634 12/1/2006 4/1/2011 3.35 3.35 3.35 FALSE TRUE Change +Subsidy +Price +Alternate
253634 4/1/2011 5.16 5.16 5.16 FALSE TRUE Change +Subsidy +Price +Alternate
253642 5/16/1994 6/1/2002 11.29 11.29 11.88 FALSE FALSE New Listing
253642 6/1/2002 0 0 0 FALSE FALSE Delisted
253650 10/4/1997 3/1/1998 6.1 6.1 7.32 FALSE TRUE New Listing
253650 3/1/1998 4/1/1998 4.9 4.9 7.32 FALSE TRUE Change -Subsidy -Alternate
253650 4/1/1998 2/1/2003 4.9 4.9 6.09 FALSE TRUE Change -Price
253650 2/1/2003 5/1/2003 3.49 3.49 6.09 FALSE TRUE Change -Subsidy -Alternate
253650 5/1/2003 12/1/2005 0 0 0 FALSE FALSE Delisted
253650 12/1/2005 9/1/2009 3 3 3 FALSE TRUE New Listing
253650 9/1/2009 0 0 0 FALSE FALSE Delisted
253685 5/16/1994 8/1/2000 18.49 18.49 20.57 FALSE FALSE New Listing
253685 8/1/2000 6/1/2002 18.49 18.49 24.29 FALSE FALSE Change +Price
253685 6/1/2002 0 0 0 FALSE FALSE Delisted
253723 5/16/1994 8/1/2000 45 45 45 FALSE FALSE New Listing
253723 8/1/2000 10/1/2003 45 45 70 FALSE FALSE Change +Price
253723 10/1/2003 1/1/2006 45 45 45 FALSE FALSE Change -Price
253723 1/1/2006 0 0 0 FALSE FALSE Delisted
253731 5/16/1994 1/1/2004 12.5 12.5 12.5 FALSE FALSE New Listing
253731 1/1/2004 9/1/2009 10.31 10.31 10.31 FALSE FALSE Change -Subsidy -Price -Alternate
253731 9/1/2009 0 0 0 FALSE FALSE Delisted
253766 5/16/1994 1/1/2004 34.05 34.05 34.05 FALSE FALSE New Listing
253766 1/1/2004 1/1/2012 28.09 28.09 28.09 FALSE FALSE Change -Subsidy -Price -Alternate
253766 1/1/2012 4/1/2012 56.48 56.48 56.48 FALSE FALSE Change +Subsidy +Price +Alternate
253766 4/1/2012 53.79 53.79 53.79 FALSE FALSE Change -Subsidy -Price -Alternate
253774 5/16/1994 10/1/2001 43.34 43.34 43.34 FALSE FALSE New Listing
253774 10/1/2001 2/1/2004 43.34 43.34 57.2 FALSE FALSE Change +Price
253774 2/1/2004 0 0 0 FALSE FALSE Delisted
253782 5/16/1994 1/1/2004 28.41 28.41 28.41 FALSE FALSE New Listing
253782 1/1/2004 8/1/2004 23.44 23.44 23.44 FALSE FALSE Change -Subsidy -Price -Alternate
253782 8/1/2004 0 0 0 FALSE FALSE Delisted
253790 8/16/1994 8/1/1999 5.43 5.43 8.08 FALSE TRUE New Listing
253790 8/1/1999 10/1/2002 4.9 4.9 8.08 FALSE TRUE Change -Subsidy -Alternate
253790 10/1/2002 1/1/2003 4.66 4.66 8.08 FALSE TRUE Change -Subsidy -Alternate
253790 1/1/2003 0 0 0 FALSE FALSE Delisted
253804 6/13/1995 9/1/2001 13.47 13.47 15.48 FALSE TRUE New Listing
253804 9/1/2001 12/1/2001 8.51 8.51 15.48 FALSE TRUE Change -Subsidy -Alternate
253804 12/1/2001 0 0 0 FALSE FALSE Delisted
253820 5/16/1994 10/1/2005 53.05 53.05 53.05 FALSE FALSE New Listing
253820 10/1/2005 8/1/2011 55.05 55.05 55.05 FALSE FALSE Change +Subsidy +Price +Alternate
253820 8/1/2011 0 0 0 FALSE FALSE Delisted
253839 6/13/1995 8/1/1998 6.79 6.79 6.79 FALSE TRUE New Listing
253839 8/1/1998 1/1/2001 6.79 6.79 7.47 FALSE TRUE Change +Price
253839 1/1/2001 9/1/2001 6.79 6.79 7.84 FALSE TRUE Change +Price
253839 9/1/2001 5/1/2005 6.79 6.79 8.43 FALSE TRUE Change +Price
253839 5/1/2005 11/1/2005 6.79 6.79 10.32 FALSE TRUE Change +Price
253839 11/1/2005 0 0 0 FALSE FALSE Delisted
253847 12/1/1994 8/1/1998 3.39 3.39 3.39 FALSE TRUE New Listing
253847 8/1/1998 3/1/2002 3.39 3.39 5.5 FALSE TRUE Change +Price
253847 3/1/2002 12/1/2009 3.39 3.39 6 FALSE TRUE Change +Price
253847 12/1/2009 0 0 0 FALSE FALSE Delisted
253855 5/16/1994 11/1/1999 26.21 26.21 26.21 FALSE FALSE New Listing
253855 11/1/1999 6/1/2000 26.21 26.21 28.83 FALSE FALSE Change +Price
253855 6/1/2000 0 0 0 FALSE FALSE Delisted
253898 5/16/1994 2/1/1999 12.87 12.87 12.87 FALSE FALSE New Listing
253898 2/1/1999 7/1/1999 10.94 10.94 10.94 FALSE FALSE Change -Subsidy -Price -Alternate
253898 7/1/1999 7/1/2003 8.21 8.21 8.21 FALSE FALSE Change -Subsidy -Price -Alternate
253898 7/1/2003 10/1/2010 7.3 7.3 7.3 FALSE FALSE Change -Subsidy -Price -Alternate
253898 10/1/2010 1/1/2011 6 6 7.3 FALSE FALSE Change -Subsidy -Alternate
253898 1/1/2011 0 0 0 FALSE FALSE Delisted
253936 5/16/1994 8/1/1997 34.4 34.4 39.5 FALSE FALSE New Listing
253936 8/1/1997 0 0 0 FALSE FALSE Delisted
253952 5/16/1994 8/1/1997 12.2 12.2 13.1 FALSE FALSE New Listing
253952 8/1/1997 0 0 0 FALSE FALSE Delisted
253979 5/16/1994 8/1/1997 30.42 30.42 31.3 FALSE FALSE New Listing
253979 8/1/1997 0 0 0 FALSE FALSE Delisted
253987 5/16/1994 3/1/2014 3.63 3.63 3.63 FALSE TRUE New Listing
253987 3/1/2014 0 0 0 FALSE FALSE Delisted
253995 5/16/1994 7.15 7.15 7.15 FALSE TRUE New Listing
254002 5/16/1994 8.66 8.66 8.66 FALSE TRUE New Listing
254037 5/16/1994 2/1/2000 57.75 57.75 57.75 FALSE FALSE New Listing
254037 2/1/2000 3/1/2001 57.75 57.75 63.53 FALSE FALSE Change +Price
254037 3/1/2001 7/1/2001 57.75 57.75 69.88 FALSE FALSE Change +Price
254037 7/1/2001 11/1/2004 69.88 69.88 69.88 FALSE FALSE Change +Subsidy +Alternate
254037 11/1/2004 76.87 76.87 76.87 FALSE FALSE Change +Subsidy +Price +Alternate
254045 6/16/1995 3/1/1997 68.25 68.25 68.25 FALSE FALSE New Listing
254045 3/1/1997 8/1/1998 61.87 61.87 61.87 FALSE FALSE Change -Subsidy -Price -Alternate
254045 8/1/1998 5/1/1999 43.75 43.75 61.87 FALSE FALSE Change -Subsidy -Alternate
254045 5/1/1999 2/1/2000 43.75 43.75 43.75 FALSE FALSE Change -Price
254045 2/1/2000 6/1/2000 27.5 27.5 43.75 FALSE FALSE Change -Subsidy -Alternate
254045 6/1/2000 0 0 0 FALSE FALSE Delisted
254053 5/16/1994 2/1/2000 85.04 85.04 85.04 FALSE FALSE New Listing
254053 2/1/2000 3/1/2001 85.04 85.04 93.53 FALSE FALSE Change +Price
254053 3/1/2001 7/1/2001 85.04 85.04 102.88 FALSE FALSE Change +Price
254053 7/1/2001 11/1/2004 102.88 102.88 102.88 FALSE FALSE Change +Subsidy +Alternate
254053 11/1/2004 113.17 113.17 113.17 FALSE FALSE Change +Subsidy +Price +Alternate
254061 5/16/1994 2/1/2000 163.21 163.21 163.21 FALSE FALSE New Listing
254061 2/1/2000 3/1/2001 163.21 163.21 179.53 FALSE FALSE Change +Price
254061 3/1/2001 7/1/2001 163.21 163.21 197.48 FALSE FALSE Change +Price
254061 7/1/2001 11/1/2004 197.48 197.48 197.48 FALSE FALSE Change +Subsidy +Alternate
254061 11/1/2004 217.23 217.23 217.23 FALSE FALSE Change +Subsidy +Price +Alternate
254088 5/16/1994 11/1/2008 3.62 3.62 3.62 FALSE TRUE New Listing
254088 11/1/2008 2/1/2009 2.68 2.68 2.68 FALSE TRUE Change -Subsidy -Price -Alternate
254088 2/1/2009 0 0 0 FALSE FALSE Delisted
254126 6/17/1995 2/1/1999 24.69 24.69 24.69 FALSE FALSE New Listing
254126 2/1/1999 3/1/1999 17.28 17.28 24.69 FALSE FALSE Change -Subsidy -Alternate
254126 3/1/1999 7/1/1999 17.28 17.28 17.28 FALSE FALSE Change -Price
254126 7/1/1999 8/1/2002 10.84 10.84 10.84 FALSE FALSE Change -Subsidy -Price -Alternate
254126 8/1/2002 7/1/2003 9.97 9.97 9.97 FALSE FALSE Change -Subsidy -Price -Alternate
254126 7/1/2003 0 0 0 FALSE FALSE Delisted
254134 10/1/1997 2/1/1999 332.46 332.46 332.46 FALSE FALSE New Listing
254134 2/1/1999 3/1/1999 232.72 232.72 332.46 FALSE FALSE Change -Subsidy -Alternate
254134 3/1/1999 7/1/1999 232.72 232.72 232.72 FALSE FALSE Change -Price
254134 7/1/1999 8/1/2002 134.74 134.74 134.74 FALSE FALSE Change -Subsidy -Price -Alternate
254134 8/1/2002 7/1/2005 123.96 123.96 123.96 FALSE FALSE Change -Subsidy -Price -Alternate
254134 7/1/2005 3/1/2010 120.86 120.86 120.86 FALSE FALSE Change -Subsidy -Price -Alternate
254134 3/1/2010 0 0 0 FALSE FALSE Delisted
254142 5/1/1999 8/1/1999 11.8 11.8 18.3 FALSE FALSE New Listing
254142 8/1/1999 12/1/1999 12.98 12.98 18.3 FALSE FALSE Change +Subsidy +Alternate
254142 12/1/1999 1/1/2002 12.98 12.98 15.19 FALSE FALSE Change -Price
254142 1/1/2002 4/1/2002 12.98 12.98 18.3 FALSE FALSE Change +Price
254142 4/1/2002 9/1/2004 12.98 12.98 15.74 FALSE FALSE Change -Price
254142 9/1/2004 9/1/2010 12.98 12.98 16.2 FALSE FALSE Change +Price
254142 9/1/2010 12/1/2010 12.95 12.95 12.95 FALSE FALSE Change -Subsidy -Price -Alternate
254142 12/1/2010 0 0 0 FALSE FALSE Delisted
254169 5/16/1994 9/1/2002 6.68 6.68 9.79 FALSE FALSE New Listing
254169 9/1/2002 12/1/2002 6 6 6 FALSE FALSE Change -Subsidy -Price -Alternate
254169 12/1/2002 0 0 0 FALSE FALSE Delisted
254193 5/20/1995 6/1/1997 9.66 9.66 9.66 FALSE FALSE New Listing
254193 6/1/1997 2/1/1998 7 7 7 FALSE FALSE Change -Subsidy -Price -Alternate
254193 2/1/1998 8/1/2000 5.6 5.6 5.6 FALSE FALSE Change -Subsidy -Price -Alternate
254193 8/1/2000 12/1/2000 3.88 5.6 5.6 FALSE FALSE Change -Subsidy
254193 12/1/2000 0 0 0 FALSE FALSE Delisted
254215 4/20/1995 2/1/1998 25.12 25.12 25.12 FALSE FALSE New Listing
254215 2/1/1998 2/1/1999 12.56 12.56 12.56 FALSE FALSE Change -Subsidy -Price -Alternate
254215 2/1/1999 6/1/2000 6.28 6.28 6.28 FALSE FALSE Change -Subsidy -Price -Alternate
254215 6/1/2000 0 0 0 FALSE FALSE Delisted
254231 4/20/1995 2/1/1998 47.7 47.7 47.7 FALSE FALSE New Listing
254231 2/1/1998 2/1/1999 23.85 23.85 23.85 FALSE FALSE Change -Subsidy -Price -Alternate
254231 2/1/1999 6/1/2000 11.93 11.93 11.93 FALSE FALSE Change -Subsidy -Price -Alternate
254231 6/1/2000 0 0 0 FALSE FALSE Delisted
254258 5/16/1994 7/1/2003 14.58 14.58 14.58 FALSE FALSE New Listing
254258 7/1/2003 10/1/2006 14.82 14.82 14.82 FALSE FALSE Change +Subsidy +Price +Alternate
254258 10/1/2006 9/1/2010 17.04 17.04 17.04 FALSE FALSE Change +Subsidy +Price +Alternate
254258 9/1/2010 8/1/2013 18.74 18.74 18.74 FALSE FALSE Change +Subsidy +Price +Alternate
254258 8/1/2013 21.55 21.55 21.55 FALSE FALSE Change +Subsidy +Price +Alternate
254274 5/16/1994 6/1/2001 4.8 4.8 4.8 FALSE FALSE New Listing
254274 6/1/2001 0 0 0 FALSE FALSE Delisted
254290 5/16/1994 8/1/1995 17.86 17.86 17.86 FALSE FALSE New Listing
254290 8/1/1995 7/1/2003 17.85 17.85 17.85 FALSE FALSE Change -Subsidy -Price -Alternate
254290 7/1/2003 9/1/2010 18.06 18.06 18.06 FALSE FALSE Change +Subsidy +Price +Alternate
254290 9/1/2010 8/1/2013 19.87 19.87 19.87 FALSE FALSE Change +Subsidy +Price +Alternate
254290 8/1/2013 23.84 23.84 23.84 FALSE FALSE Change +Subsidy +Price +Alternate
254320 5/16/1994 7/1/2003 4.8 4.8 4.8 FALSE FALSE New Listing
254320 7/1/2003 9/1/2010 4.93 4.93 4.93 FALSE FALSE Change +Subsidy +Price +Alternate
254320 9/1/2010 8/1/2013 5.42 5.42 5.42 FALSE FALSE Change +Subsidy +Price +Alternate
254320 8/1/2013 6.23 6.23 6.23 FALSE FALSE Change +Subsidy +Price +Alternate
254339 5/16/1994 7/1/2003 3.76 3.76 3.76 FALSE FALSE New Listing
254339 7/1/2003 8/1/2004 3.73 3.73 3.73 FALSE FALSE Change -Subsidy -Price -Alternate
254339 8/1/2004 0 0 0 FALSE FALSE Delisted
254347 5/16/1994 7/1/2003 18.8 18.8 18.8 FALSE FALSE New Listing
254347 7/1/2003 11/1/2004 18.63 18.63 18.63 FALSE FALSE Change -Subsidy -Price -Alternate
254347 11/1/2004 0 0 0 FALSE FALSE Delisted
254355 5/16/1994 8/1/1995 23.87 23.87 23.87 FALSE FALSE New Listing
254355 8/1/1995 7/1/2003 23.88 23.88 23.88 FALSE FALSE Change +Subsidy +Price +Alternate
254355 7/1/2003 9/1/2010 23.49 23.49 23.49 FALSE FALSE Change -Subsidy -Price -Alternate
254355 9/1/2010 8/1/2013 25.84 25.84 25.84 FALSE FALSE Change +Subsidy +Price +Alternate
254355 8/1/2013 29.72 29.72 29.72 FALSE FALSE Change +Subsidy +Price +Alternate
254363 1/10/1995 2/1/1998 46.66 46.66 46.66 FALSE FALSE New Listing
254363 2/1/1998 7/1/2000 32.66 32.66 32.66 FALSE FALSE Change -Subsidy -Price -Alternate
254363 7/1/2000 11/1/2000 2.1 2.1 2.1 FALSE FALSE Change -Subsidy -Price -Alternate
254363 11/1/2000 0 0 0 FALSE FALSE Delisted
254371 5/16/1994 8/1/1998 1.98 1.98 5 FALSE FALSE New Listing
254371 8/1/1998 9/1/2000 1.98 1.98 3.6 FALSE FALSE Change -Price
254371 9/1/2000 0 0 0 FALSE FALSE Delisted
254398 3/1/2002 12/1/2002 88 88 88 FALSE FALSE New listing
254398 12/1/2002 9/1/2007 44 44 44 FALSE FALSE Change -Subsidy -Price -Alternate
254398 9/1/2007 0 0 0 FALSE FALSE Delisted
254401 5/16/1994 8/1/1998 9.88 9.88 14 FALSE FALSE New Listing
254401 8/1/1998 9/1/2000 9.88 9.88 18 FALSE FALSE Change +Price
254401 9/1/2000 0 0 0 FALSE FALSE Delisted
254428 5/16/1994 8/1/1998 2.45 2.45 5.5 FALSE FALSE New Listing
254428 8/1/1998 6/1/2001 2.45 2.45 4 FALSE FALSE Change -Price
254428 6/1/2001 0 0 0 FALSE FALSE Delisted
254444 5/16/1994 8/1/1998 12.26 12.26 16.5 FALSE FALSE New Listing
254444 8/1/1998 6/1/2001 12.26 12.26 20 FALSE FALSE Change +Price
254444 6/1/2001 0 0 0 FALSE FALSE Delisted
254452 3/1/2002 12/1/2002 216 216 216 FALSE FALSE New listing
254452 12/1/2002 9/1/2007 114 114 114 FALSE FALSE Change -Subsidy -Price -Alternate
254452 9/1/2007 0 0 0 FALSE FALSE Delisted
254460 5/16/1994 8/1/1998 4.68 4.68 8 FALSE FALSE New Listing
254460 8/1/1998 9/1/2000 4.68 4.68 10 FALSE FALSE Change +Price
254460 9/1/2000 0 0 0 FALSE FALSE Delisted
254509 10/1/1996 2/1/1998 233.3 233.3 233.3 FALSE FALSE New Listing
254509 2/1/1998 7/1/2000 163.3 163.3 163.3 FALSE FALSE Change -Subsidy -Price -Alternate
254509 7/1/2000 11/1/2000 10.48 10.48 10.48 FALSE FALSE Change -Subsidy -Price -Alternate
254509 11/1/2000 0 0 0 FALSE FALSE Delisted
254576 5/20/1995 12/6/1995 35.61 35.61 35.61 FALSE FALSE New Listing
254576 12/6/1995 3/1/1996 33.73 33.73 33.73 FALSE FALSE Change -Subsidy -Price -Alternate
254576 3/1/1996 4/1/1996 23.17 23.17 33.73 FALSE FALSE Change -Subsidy -Alternate
254576 4/1/1996 6/1/1999 23.17 23.17 23.17 FALSE FALSE Change -Price
254576 6/1/1999 12/1/1999 13.9 13.9 13.9 FALSE FALSE Change -Subsidy -Price -Alternate
254576 12/1/1999 8/1/2000 8.11 8.11 8.11 FALSE FALSE Change -Subsidy -Price -Alternate
254576 8/1/2000 12/1/2000 4.17 4.17 8.11 FALSE FALSE Change -Subsidy -Alternate
254576 12/1/2000 0 0 0 FALSE FALSE Delisted
254584 4/3/1995 6/14/1995 32.22 32.22 32.22 FALSE FALSE New Listing
254584 6/14/1995 2/1/1998 24.69 24.69 24.69 FALSE FALSE Change -Subsidy -Price -Alternate
254584 2/1/1998 2/1/2002 16.06 16.06 16.06 FALSE FALSE Change -Subsidy -Price -Alternate
254584 2/1/2002 12/1/2008 7.65 7.65 7.65 FALSE FALSE Change -Subsidy -Price -Alternate
254584 12/1/2008 6/1/2009 7.08 7.08 7.08 FALSE FALSE Change -Subsidy -Price -Alternate
254584 6/1/2009 2/1/2013 6.5 6.5 6.5 FALSE FALSE Change -Subsidy -Price -Alternate
254584 2/1/2013 5/1/2013 2.86 2.86 6.5 FALSE FALSE Change -Subsidy -Alternate
254584 5/1/2013 4/1/2014 0 0 0 FALSE FALSE Delisted
254584 4/1/2014 7.56 7.56 7.56 FALSE FALSE New Listing
254592 4/3/1995 6/14/1995 40.81 40.81 40.81 FALSE FALSE New Listing
254592 6/14/1995 2/1/1998 32.93 32.93 32.93 FALSE FALSE Change -Subsidy -Price -Alternate
254592 2/1/1998 2/1/2002 21.41 21.41 21.41 FALSE FALSE Change -Subsidy -Price -Alternate
254592 2/1/2002 12/1/2008 10.2 10.2 10.2 FALSE FALSE Change -Subsidy -Price -Alternate
254592 12/1/2008 6/1/2009 9.44 9.44 9.44 FALSE FALSE Change -Subsidy -Price -Alternate
254592 6/1/2009 2/1/2013 8.67 8.67 8.67 FALSE FALSE Change -Subsidy -Price -Alternate
254592 2/1/2013 5/1/2013 3.81 3.81 8.67 FALSE FALSE Change -Subsidy -Alternate
254592 5/1/2013 4/1/2014 0 0 0 FALSE FALSE Delisted
254592 4/1/2014 10.22 10.22 10.22 FALSE FALSE New Listing
254657 5/6/2013 6/1/2013 11.95 11.95 11.95 FALSE TRUE New listing
254657 6/1/2013 11.15 11.15 11.15 FALSE TRUE Change -Subsidy -Price -Alternate
254665 5/16/1994 3/1/1995 10.32 10.32 10.83 FALSE FALSE New Listing
254665 3/1/1995 7/1/1995 10.32 10.32 12.99 FALSE FALSE Change +Price
254665 7/1/1995 3/1/2001 10.32 10.32 10.32 FALSE FALSE Change -Price
254665 3/1/2001 7/1/2001 10.32 10.32 11.35 FALSE FALSE Change +Price
254665 7/1/2001 11/1/2004 11.35 11.35 11.35 FALSE FALSE Change +Subsidy +Alternate
254665 11/1/2004 12.49 12.49 12.49 FALSE FALSE Change +Subsidy +Price +Alternate
254673 5/16/1994 3/1/1995 36.74 36.74 38.56 FALSE FALSE New Listing
254673 3/1/1995 7/1/1995 36.74 36.74 42.41 FALSE FALSE Change +Price
254673 7/1/1995 3/1/2001 36.74 36.74 36.74 FALSE FALSE Change -Price
254673 3/1/2001 7/1/2001 36.74 36.74 40.41 FALSE FALSE Change +Price
254673 7/1/2001 11/1/2004 40.41 40.41 40.41 FALSE FALSE Change +Subsidy +Alternate
254673 11/1/2004 44.45 44.45 44.45 FALSE FALSE Change +Subsidy +Price +Alternate
254703 5/16/1994 6/14/1995 12.31 12.31 12.31 FALSE FALSE New Listing
254703 6/14/1995 7/1/2004 12.31 12.31 15.39 FALSE FALSE Change +Price
254703 7/1/2004 0 0 0 FALSE FALSE Delisted
254738 5/16/1994 3/1/1996 10.6 10.6 10.6 FALSE FALSE New Listing
254738 3/1/1996 8/1/1998 11.7 11.7 11.7 FALSE FALSE Change +Subsidy +Price +Alternate
254738 8/1/1998 7/1/2000 12.5 12.5 12.5 FALSE FALSE Change +Subsidy +Price +Alternate
254738 7/1/2000 7/1/2002 13.25 13.25 13.25 FALSE FALSE Change +Subsidy +Price +Alternate
254738 7/1/2002 9/1/2004 14.7 14.7 14.7 FALSE FALSE Change +Subsidy +Price +Alternate
254738 9/1/2004 9/1/2006 15.8 15.8 15.8 FALSE FALSE Change +Subsidy +Price +Alternate
254738 9/1/2006 9/1/2007 16.5 16.5 16.5 FALSE FALSE Change +Subsidy +Price +Alternate
254738 9/1/2007 9/1/2008 17.2 17.2 17.2 FALSE FALSE Change +Subsidy +Price +Alternate
254738 9/1/2008 10/1/2010 17.9 17.9 17.9 FALSE FALSE Change +Subsidy +Price +Alternate
254738 10/1/2010 22.2 22.2 22.2 FALSE FALSE Change +Subsidy +Price +Alternate
254754 5/16/1994 3/1/1996 17.75 17.75 17.75 FALSE FALSE New Listing
254754 3/1/1996 8/1/1998 19.45 19.45 19.45 FALSE FALSE Change +Subsidy +Price +Alternate
254754 8/1/1998 7/1/2000 22 22 22 FALSE FALSE Change +Subsidy +Price +Alternate
254754 7/1/2000 7/1/2002 23.15 23.15 23.15 FALSE FALSE Change +Subsidy +Price +Alternate
254754 7/1/2002 9/1/2004 25.7 25.7 25.7 FALSE FALSE Change +Subsidy +Price +Alternate
254754 9/1/2004 9/1/2006 27.7 27.7 27.7 FALSE FALSE Change +Subsidy +Price +Alternate
254754 9/1/2006 9/1/2007 28.55 28.55 28.55 FALSE FALSE Change +Subsidy +Price +Alternate
254754 9/1/2007 9/1/2008 29.4 29.4 29.4 FALSE FALSE Change +Subsidy +Price +Alternate
254754 9/1/2008 10/1/2010 30.25 30.25 30.25 FALSE FALSE Change +Subsidy +Price +Alternate
254754 10/1/2010 37.5 37.5 37.5 FALSE FALSE Change +Subsidy +Price +Alternate
254819 10/4/1997 3/1/1998 4.1 4.1 4.1 FALSE TRUE New Listing
254819 3/1/1998 10/1/1998 3.33 3.33 4.1 FALSE TRUE Change -Subsidy -Alternate
254819 10/1/1998 1/1/1999 1.83 1.83 4.1 FALSE TRUE Change -Subsidy -Alternate
254819 1/1/1999 12/1/2004 1 1 4.1 FALSE TRUE Change -Subsidy -Alternate
254819 12/1/2004 0 0 0 FALSE FALSE Delisted
254827 5/16/1994 10/4/1997 6.6 6.6 7.6 FALSE TRUE New Listing
254827 10/4/1997 0 0 0 FALSE FALSE Delisted
254835 10/4/1997 3/1/1998 4.1 4.1 4.1 FALSE TRUE New Listing
254835 3/1/1998 10/1/1998 3.33 3.33 4.1 FALSE TRUE Change -Subsidy -Alternate
254835 10/1/1998 1/1/1999 1.83 1.83 4.1 FALSE TRUE Change -Subsidy -Alternate
254835 1/1/1999 12/1/2004 1 1 4.1 FALSE TRUE Change -Subsidy -Alternate
254835 12/1/2004 0 0 0 FALSE FALSE Delisted
254843 10/4/1997 3/1/2001 6.6 6.6 7.6 FALSE TRUE New Listing
254843 3/1/2001 4/1/2002 6.6 6.6 8.36 FALSE TRUE Change +Price
254843 4/1/2002 4/1/2003 6.6 6.6 9.2 FALSE TRUE Change +Price
254843 4/1/2003 4/1/2004 6.6 6.6 10.12 FALSE TRUE Change +Price
254843 4/1/2004 3/1/2005 6.6 6.6 11.13 FALSE TRUE Change +Price
254843 3/1/2005 0 0 0 FALSE FALSE Delisted
254851 5/16/1994 9/1/2002 4.9 4.9 4.9 FALSE TRUE New Listing
254851 9/1/2002 12/1/2002 4.28 4.28 4.9 FALSE TRUE Change -Subsidy -Alternate
254851 12/1/2002 7/1/2005 0 0 0 FALSE FALSE Delisted
254851 7/1/2005 10/1/2008 3.03 3.03 3.03 FALSE TRUE New Listing
254851 10/1/2008 3.19 3.19 3.19 FALSE TRUE Change +Subsidy +Price +Alternate
254894 5/16/1994 3/1/2001 4.13 4.13 5.15 FALSE TRUE New Listing
254894 3/1/2001 4/1/2002 4.13 4.13 5.65 FALSE TRUE Change +Price
254894 4/1/2002 4/1/2003 4.13 4.13 6.22 FALSE TRUE Change +Price
254894 4/1/2003 4/1/2004 4.13 4.13 6.84 FALSE TRUE Change +Price
254894 4/1/2004 7/1/2006 4.13 4.13 7.52 FALSE TRUE Change +Price
254894 7/1/2006 4.13 4.13 8.65 FALSE TRUE Change +Price
254908 5/16/1994 12/1/1997 4.66 4.66 4.66 FALSE TRUE New Listing
254908 12/1/1997 9/1/2006 4.4 4.4 4.66 FALSE TRUE Change -Subsidy -Alternate
254908 9/1/2006 4.71 4.71 4.71 FALSE TRUE Change +Subsidy +Price +Alternate
254916 5/1/1996 9/1/1997 15.4 15.4 15.4 FALSE FALSE New Listing
254916 9/1/1997 6/1/1998 12.32 12.32 12.32 FALSE FALSE Change -Subsidy -Price -Alternate
254916 6/1/1998 6/1/2000 11 11 11 FALSE FALSE Change -Subsidy -Price -Alternate
254916 6/1/2000 11/1/2001 11 11 17 FALSE FALSE Change +Price
254916 11/1/2001 1/1/2003 11 11 22 FALSE FALSE Change +Price
254916 1/1/2003 0 0 0 FALSE FALSE Delisted
254924 5/1/1996 9/1/1997 18.6 18.6 18.6 FALSE FALSE New Listing
254924 9/1/1997 6/1/1998 14.88 14.88 14.88 FALSE FALSE Change -Subsidy -Price -Alternate
254924 6/1/1998 6/1/2000 13 13 13 FALSE FALSE Change -Subsidy -Price -Alternate
254924 6/1/2000 11/1/2001 13 13 21 FALSE FALSE Change +Price
254924 11/1/2001 1/1/2003 13 13 27.5 FALSE FALSE Change +Price
254924 1/1/2003 0 0 0 FALSE FALSE Delisted
254932 5/16/1994 3/1/1999 88.81 88.81 88.81 FALSE FALSE New Listing
254932 3/1/1999 12/1/2001 718.75 718.75 718.75 FALSE FALSE Change +Subsidy +Price +Alternate
254932 12/1/2001 0 0 0 FALSE FALSE Delisted
254940 5/16/1994 3/1/2001 3.65 3.65 4.66 FALSE TRUE New Listing
254940 3/1/2001 4/1/2002 3.65 3.65 5.13 FALSE TRUE Change +Price
254940 4/1/2002 4/1/2003 3.65 3.65 5.64 FALSE TRUE Change +Price
254940 4/1/2003 4/1/2004 3.65 3.65 6.2 FALSE TRUE Change +Price
254940 4/1/2004 2/1/2005 3.65 3.65 6.82 FALSE TRUE Change +Price
254940 2/1/2005 0 0 0 FALSE FALSE Delisted
254959 5/16/1994 4/1/2000 12.27 12.27 12.27 FALSE TRUE New Listing
254959 4/1/2000 0 0 0 FALSE FALSE Delisted
254967 6/27/1995 12/1/1997 7.45 7.45 7.45 FALSE FALSE New Listing
254967 12/1/1997 9/1/2002 6.55 6.55 6.55 FALSE FALSE Change -Subsidy -Price -Alternate
254967 9/1/2002 12/1/2002 6.2 6.2 6.55 FALSE FALSE Change -Subsidy -Alternate
254967 12/1/2002 0 0 0 FALSE FALSE Delisted
254975 5/16/1994 1/1/1999 98 98 98 FALSE FALSE New Listing
254975 1/1/1999 0 0 0 FALSE FALSE Delisted
254983 3/1/1996 9/1/1998 3.28 3.28 3.28 FALSE FALSE New Listing
254983 9/1/1998 4/1/1999 1 1 3.28 FALSE FALSE Change -Subsidy +Price -Alternate
254983 4/1/1999 0 0 0 FALSE FALSE Delisted
254991 5/16/1994 5/27/1995 7.05 7.05 7.05 FALSE FALSE New Listing
254991 5/27/1995 2/1/1999 9.6 9.6 9.6 FALSE FALSE Change +Subsidy +Price +Alternate
254991 2/1/1999 12/1/2008 9.6 9.6 20.5 FALSE FALSE Change +Price
254991 12/1/2008 0 0 0 FALSE FALSE Delisted
255009 5/16/1994 7/1/1999 23.17 23.17 23.17 FALSE FALSE New Listing
255009 7/1/1999 18.54 18.54 18.54 FALSE FALSE Change -Subsidy -Price -Alternate
255033 5/16/1994 6/1/1996 28.38 28.38 41.4 FALSE FALSE New Listing
255033 6/1/1996 1/1/2004 9.45 13.8 13.8 FALSE FALSE Change -Subsidy -Price -Alternate
255033 1/1/2004 12/1/2006 6.62 13.8 13.8 FALSE FALSE Change -Subsidy
255033 12/1/2006 0 0 0 FALSE FALSE Delisted
255092 5/16/1994 4/1/2002 4.06 4.06 4.06 FALSE FALSE New Listing
255092 4/1/2002 7/1/2003 4.06 4.06 7.83 FALSE FALSE Change +Price
255092 7/1/2003 9/1/2010 4.06 4.06 15.5 FALSE FALSE Change +Price
255092 9/1/2010 15.5 15.5 15.5 FALSE FALSE Change +Subsidy +Alternate
255114 5/16/1994 7/1/1998 10.1 10.1 10.1 FALSE FALSE New Listing
255114 7/1/1998 0 0 0 FALSE FALSE Delisted
255130 5/16/1994 6/1/2003 16.14 16.14 16.14 FALSE FALSE New Listing
255130 6/1/2003 0 0 0 FALSE FALSE Delisted
255149 5/16/1994 21.51 21.51 21.51 FALSE FALSE New Listing
255157 5/16/1994 9/1/2003 40.8 40.8 40.8 FALSE FALSE New Listing
255157 9/1/2003 0 0 0 FALSE FALSE Delisted
255165 5/16/1994 1/1/1998 12.31 12.31 12.31 FALSE FALSE New Listing
255165 1/1/1998 3/1/2001 12.31 12.31 15.39 FALSE FALSE Change +Price
255165 3/1/2001 11/1/2002 12.31 12.31 16.93 FALSE FALSE Change +Price
255165 11/1/2002 0 0 0 FALSE FALSE Delisted
255173 6/15/1995 7/1/1999 5.3 5.3 5.3 FALSE TRUE New Listing
255173 7/1/1999 0 0 0 FALSE FALSE Delisted
255246 5/16/1994 10/1/1997 7.48 7.48 7.48 FALSE FALSE New Listing
255246 10/1/1997 8/1/2000 7.48 7.48 14.96 FALSE FALSE Change +Price
255246 8/1/2000 0 0 0 FALSE FALSE Delisted
255254 5/16/1994 7/1/2008 74.8 74.8 74.8 FALSE FALSE New Listing
255254 7/1/2008 0 0 0 FALSE FALSE Delisted
255262 5/16/1994 10/1/1997 9.83 9.83 9.83 FALSE FALSE New Listing
255262 10/1/1997 5/1/2008 9.83 9.83 10.22 FALSE FALSE Change +Price
255262 5/1/2008 0 0 0 FALSE FALSE Delisted
255270 5/16/1994 10/1/1997 245.8 245.8 245.8 FALSE FALSE New Listing
255270 10/1/1997 5/1/2001 49.15 49.15 51.1 FALSE FALSE Change -Subsidy -Price -Alternate
255270 5/1/2001 0 0 0 FALSE FALSE Delisted
255289 5/16/1994 10/1/1997 13.63 13.63 13.63 FALSE FALSE New Listing
255289 10/1/1997 9/1/2007 13.63 13.63 15.61 FALSE FALSE Change +Price
255289 9/1/2007 0 0 0 FALSE FALSE Delisted
255297 10/1/1997 5/1/2001 68.15 68.15 78.05 FALSE FALSE New Listing
255297 5/1/2001 0 0 0 FALSE FALSE Delisted
255300 5/16/1994 10/1/1997 15.79 15.79 15.79 FALSE FALSE New Listing
255300 10/1/1997 9/1/2007 15.79 15.79 17.77 FALSE FALSE Change +Price
255300 9/1/2007 0 0 0 FALSE FALSE Delisted
255319 5/16/1994 10/1/1997 78.95 78.95 78.95 FALSE FALSE New Listing
255319 10/1/1997 0 0 0 FALSE FALSE Delisted
255327 5/16/1994 10/1/1997 33.05 33.05 33.05 FALSE FALSE New Listing
255327 10/1/1997 5/1/2005 33.05 33.05 35.03 FALSE FALSE Change +Price
255327 5/1/2005 0 0 0 FALSE FALSE Delisted
255335 5/16/1994 3/1/1995 14.91 14.91 14.91 FALSE FALSE New Listing
255335 3/1/1995 3/1/2001 14.91 14.91 16.03 FALSE FALSE Change +Price
255335 3/1/2001 4/1/2002 14.91 14.91 17.63 FALSE FALSE Change +Price
255335 4/1/2002 4/1/2003 14.91 14.91 19.39 FALSE FALSE Change +Price
255335 4/1/2003 4/1/2004 14.91 14.91 21.33 FALSE FALSE Change +Price
255335 4/1/2004 7/1/2006 14.91 14.91 23.46 FALSE FALSE Change +Price
255335 7/1/2006 12/1/2008 14.91 14.91 25.81 FALSE FALSE Change +Price
255335 12/1/2008 25.81 25.81 25.81 FALSE FALSE Change +Subsidy +Alternate
255408 5/16/1994 3/1/1995 5.46 5.46 6.19 FALSE FALSE New Listing
255408 3/1/1995 2/1/2001 5.46 5.46 6.81 FALSE FALSE Change +Price
255408 2/1/2001 0 0 0 FALSE FALSE Delisted
255416 5/16/1994 1/1/2002 29.59 29.59 29.59 FALSE FALSE New Listing
255416 1/1/2002 0 0 0 FALSE FALSE Delisted
255424 5/16/1994 9/1/2002 2.96 2.96 2.95 FALSE TRUE New Listing
255424 9/1/2002 2/1/2009 2.52 2.52 2.52 FALSE TRUE Change -Subsidy -Price -Alternate
255424 2/1/2009 10/1/2010 2.52 2.52 3.07 FALSE TRUE Change +Price
255424 10/1/2010 2/1/2014 3.07 3.07 3.07 FALSE TRUE Change +Subsidy +Alternate
255424 2/1/2014 5/1/2014 1.65 1.65 3.07 FALSE TRUE Change -Subsidy -Alternate
255424 5/1/2014 0 0 0 FALSE FALSE Delisted
255432 5/16/1994 11/1/2000 14.8 14.8 13.75 FALSE FALSE New Listing
255432 11/1/2000 2/1/2001 14.8 14.8 14.03 FALSE FALSE Change +Price
255432 2/1/2001 9/1/2002 14.8 14.8 14.73 FALSE FALSE Change +Price
255432 9/1/2002 12/1/2002 12.6 12.6 14.73 FALSE FALSE Change -Subsidy -Alternate
255432 12/1/2002 0 0 0 FALSE FALSE Delisted
255459 5/16/1994 4/1/2001 75.97 75.97 75.97 FALSE FALSE New Listing
255459 4/1/2001 3/1/2002 75.97 75.97 79.78 FALSE FALSE Change +Price
255459 3/1/2002 0 0 0 FALSE FALSE Delisted
255599 8/16/1994 10/1/1999 4.55 4.55 6.5 FALSE TRUE New Listing
255599 10/1/1999 2/1/2001 4.55 4.55 7.5 FALSE TRUE Change +Price
255599 2/1/2001 4.55 4.55 7.9 FALSE TRUE Change +Price
255629 8/16/1994 12/1/2005 21.81 21.81 25.9 FALSE TRUE New Listing
255629 12/1/2005 0 0 0 FALSE FALSE Delisted
255718 5/16/1994 8/1/2007 14.72 14.72 14.72 FALSE FALSE New Listing
255718 8/1/2007 0 0 0 FALSE FALSE Delisted
255742 5/16/1994 7/1/2001 147.2 147.2 147.2 FALSE FALSE New Listing
255742 7/1/2001 0 0 0 FALSE FALSE Delisted
255815 5/16/1994 2/1/2001 10.88 10.88 10.88 FALSE TRUE New Listing
255815 2/1/2001 0 0 0 FALSE FALSE Delisted
255831 5/16/1994 2/1/2001 10.88 10.88 10.88 FALSE TRUE New Listing
255831 2/1/2001 0 0 0 FALSE FALSE Delisted
255874 5/16/1994 3/1/1996 13.19 13.19 13.19 FALSE FALSE New Listing
255874 3/1/1996 1/1/1998 11.11 11.11 13.19 FALSE FALSE Change -Subsidy -Alternate
255874 1/1/1998 3/1/1999 11.11 15.9 15.9 FALSE FALSE Change +Price +Alternate
255874 3/1/1999 2/1/2000 8.89 8.89 8.89 FALSE FALSE Change -Subsidy -Price -Alternate
255874 2/1/2000 4/1/2002 5.32 8.89 8.89 FALSE FALSE Change -Subsidy
255874 4/1/2002 4/1/2003 5.32 9.78 9.78 FALSE FALSE Change +Price +Alternate
255874 4/1/2003 7/1/2004 5.32 10.76 10.76 FALSE FALSE Change +Price +Alternate
255874 7/1/2004 0 0 0 FALSE FALSE Delisted
255904 8/1/1997 1/1/1998 22.55 22.55 23.74 FALSE FALSE New Listing
255904 1/1/1998 8/1/1998 22.55 24.85 24.85 FALSE FALSE Change +Price +Alternate
255904 8/1/1998 3/1/1999 20.77 24.85 24.85 FALSE FALSE Change -Subsidy
255904 3/1/1999 2/1/2000 16.2 16.2 16.2 FALSE FALSE Change -Subsidy -Price -Alternate
255904 2/1/2000 11/1/2000 9.73 16.2 16.2 FALSE FALSE Change -Subsidy
255904 11/1/2000 3/1/2001 8.76 16.2 16.2 FALSE FALSE Change -Subsidy
255904 3/1/2001 9/1/2001 7.88 16.2 16.2 FALSE FALSE Change -Subsidy
255904 9/1/2001 4/1/2002 6.72 16.2 16.2 FALSE FALSE Change -Subsidy
255904 4/1/2002 4/1/2003 6.72 17.82 17.82 FALSE FALSE Change +Price +Alternate
255904 4/1/2003 7/1/2006 6.72 19.6 19.6 FALSE FALSE Change +Price +Alternate
255904 7/1/2006 0 0 0 FALSE FALSE Delisted
255939 5/16/1994 3/1/1995 12.62 12.62 12.62 FALSE FALSE New Listing
255939 3/1/1995 2/1/2000 12.63 12.63 12.63 FALSE FALSE Change +Subsidy +Price +Alternate
255939 2/1/2000 0 0 0 FALSE FALSE Delisted
255955 5/16/1994 2/1/2000 29.07 29.07 29.07 FALSE FALSE New Listing
255955 2/1/2000 0 0 0 FALSE FALSE Delisted
256021 5/1/1997 3/1/2001 15.84 15.84 19 FALSE FALSE New Listing
256021 3/1/2001 11/1/2001 15.84 15.84 20.9 FALSE FALSE Change +Price
256021 11/1/2001 0 0 0 FALSE FALSE Delisted
256048 5/16/1994 5/1/1998 3.6 3.6 7.71 FALSE FALSE New Listing
256048 5/1/1998 0 0 0 FALSE FALSE Delisted
256056 5/16/1994 6/2/1995 2.22 2.22 2.33 FALSE TRUE New Listing
256056 6/2/1995 12/1/1997 2.22 2.22 2.5 FALSE TRUE Change +Price
256056 12/1/1997 0 0 0 FALSE FALSE Delisted
256064 10/4/1997 3/1/2001 7.91 7.91 10.88 FALSE FALSE New Listing
256064 3/1/2001 11/1/2001 7.91 7.91 11.96 FALSE FALSE Change +Price
256064 11/1/2001 0 0 0 FALSE FALSE Delisted
256072 5/16/1994 7/1/2005 12.98 12.98 12.98 FALSE FALSE New Listing
256072 7/1/2005 0 0 0 FALSE FALSE Delisted
256080 8/1/1997 2/1/2003 107.5 107.5 107.5 FALSE FALSE New Listing
256080 2/1/2003 2/1/2005 86 86 86 FALSE FALSE Change -Subsidy -Price -Alternate
256080 2/1/2005 7/1/2005 64.5 64.5 64.5 FALSE FALSE Change -Subsidy -Price -Alternate
256080 7/1/2005 6/1/2007 32.25 32.25 32.25 FALSE FALSE Change -Subsidy -Price -Alternate
256080 6/1/2007 2/1/2011 17.18 17.18 17.18 FALSE FALSE Change -Subsidy -Price -Alternate
256080 2/1/2011 5/1/2011 1.7 1.7 17.18 FALSE FALSE Change -Subsidy -Alternate
256080 5/1/2011 0 0 0 FALSE FALSE Delisted
256099 1/1/1994 8/1/1997 519.93 519.93 519.93 FALSE FALSE New Listing
256099 8/1/1997 2/1/2003 309.6 309.6 309.6 FALSE FALSE Change -Subsidy -Price -Alternate
256099 2/1/2003 2/1/2005 247.6 247.6 247.6 FALSE FALSE Change -Subsidy -Price -Alternate
256099 2/1/2005 7/1/2005 185.7 185.7 185.7 FALSE FALSE Change -Subsidy -Price -Alternate
256099 7/1/2005 6/1/2007 92.85 92.85 92.85 FALSE FALSE Change -Subsidy -Price -Alternate
256099 6/1/2007 2/1/2011 33.89 33.89 33.89 FALSE FALSE Change -Subsidy -Price -Alternate
256099 2/1/2011 5/1/2011 3.4 3.4 33.89 FALSE FALSE Change -Subsidy -Alternate
256099 5/1/2011 0 0 0 FALSE FALSE Delisted
256110 10/1/1997 3/1/1998 8.97 8.97 8.97 FALSE TRUE New Listing
256110 3/1/1998 0 0 0 FALSE FALSE Delisted
256129 5/16/1994 10/1/2000 5.23 5.23 8.23 FALSE TRUE New Listing
256129 10/1/2000 2/1/2003 5.23 5.23 5.23 FALSE TRUE Change -Price
256129 2/1/2003 10/1/2004 5.23 5.23 7.95 FALSE TRUE Change +Price
256129 10/1/2004 0 0 0 FALSE FALSE Delisted
256161 10/1/1997 3/1/1998 8.97 8.97 8.97 FALSE TRUE New Listing
256161 3/1/1998 0 0 0 FALSE FALSE Delisted
256218 5/16/1994 11/1/1998 4 4 4 FALSE FALSE New Listing
256218 11/1/1998 12/1/2002 4 4 5.2 FALSE FALSE Change +Price
256218 12/1/2002 7/1/2003 4 4 4.94 FALSE FALSE Change -Price
256218 7/1/2003 1/1/2007 4.94 4.94 4.94 FALSE FALSE Change +Subsidy +Alternate
256218 1/1/2007 3/1/2007 9.88 9.88 9.88 FALSE FALSE Change +Subsidy +Price +Alternate
256218 3/1/2007 10/1/2009 5.4 5.4 5.4 FALSE FALSE Change -Subsidy -Price -Alternate
256218 10/1/2009 2/1/2014 5.94 5.94 5.94 FALSE FALSE Change +Subsidy +Price +Alternate
256218 2/1/2014 5/1/2014 4.75 4.75 4.75 FALSE FALSE Change -Subsidy -Price -Alternate
256218 5/1/2014 0 0 0 FALSE FALSE Delisted
256226 5/16/1994 11/1/2003 3.15 4.73 4.73 FALSE FALSE New Listing
256226 11/1/2003 0 0 0 FALSE FALSE Delisted
256234 5/16/1994 11/1/1998 5 5 5 FALSE FALSE New Listing
256234 11/1/1998 12/1/2002 5 5 6.5 FALSE FALSE Change +Price
256234 12/1/2002 7/1/2003 5 5 6.18 FALSE FALSE Change -Price
256234 7/1/2003 1/1/2007 6.18 6.18 6.18 FALSE FALSE Change +Subsidy +Alternate
256234 1/1/2007 3/1/2007 12.36 12.36 12.36 FALSE FALSE Change +Subsidy +Price +Alternate
256234 3/1/2007 10/1/2009 6.8 6.8 6.8 FALSE FALSE Change -Subsidy -Price -Alternate
256234 10/1/2009 2/1/2014 7.48 7.48 7.48 FALSE FALSE Change +Subsidy +Price +Alternate
256234 2/1/2014 5/1/2014 5.98 5.98 5.98 FALSE FALSE Change -Subsidy -Price -Alternate
256234 5/1/2014 0 0 0 FALSE FALSE Delisted
256250 8/1/1997 8/1/2000 1.98 1.98 2.51 FALSE FALSE New Listing
256250 8/1/2000 7/1/2001 1.98 1.98 3.89 FALSE FALSE Change +Price
256250 7/1/2001 7/1/2007 1.98 1.98 4.9 FALSE FALSE Change +Price
256250 7/1/2007 11/1/2009 1.98 1.98 5.5 FALSE FALSE Change +Price
256250 11/1/2009 8/1/2011 1.98 1.98 5.89 FALSE FALSE Change +Price
256250 8/1/2011 5.89 5.89 5.89 FALSE FALSE Change +Subsidy +Alternate
256269 5/16/1994 6/27/1995 4.8 4.8 4.8 FALSE FALSE New Listing
256269 6/27/1995 11/1/1998 6.8 6.8 6.8 FALSE FALSE Change +Subsidy +Price +Alternate
256269 11/1/1998 12/1/2002 6.8 6.8 8.84 FALSE FALSE Change +Price
256269 12/1/2002 7/1/2003 6.8 6.8 8.4 FALSE FALSE Change -Price
256269 7/1/2003 3/1/2007 8.4 8.4 8.4 FALSE FALSE Change +Subsidy +Alternate
256269 3/1/2007 10/1/2009 9.2 9.2 9.2 FALSE FALSE Change +Subsidy +Price +Alternate
256269 10/1/2009 8/1/2012 10.12 10.12 10.12 FALSE FALSE Change +Subsidy +Price +Alternate
256269 8/1/2012 11.13 11.13 11.13 FALSE FALSE Change +Subsidy +Price +Alternate
256285 5/16/1994 8/1/2000 2.45 2.45 2.45 FALSE FALSE New Listing
256285 8/1/2000 7/1/2001 2.45 2.45 4.38 FALSE FALSE Change +Price
256285 7/1/2001 7/1/2007 2.45 2.45 6.9 FALSE FALSE Change +Price
256285 7/1/2007 11/1/2009 2.45 2.45 7.6 FALSE FALSE Change +Price
256285 11/1/2009 8/1/2011 2.45 2.45 8.13 FALSE FALSE Change +Price
256285 8/1/2011 8.13 8.13 8.13 FALSE FALSE Change +Subsidy +Alternate
256323 5/16/1994 8/1/2000 4.68 4.68 4.68 FALSE FALSE New Listing
256323 8/1/2000 12/1/2001 4.68 4.68 7.48 FALSE FALSE Change +Price
256323 12/1/2001 0 0 0 FALSE FALSE Delisted
256366 5/16/1994 7/1/2008 11.66 11.66 11.66 FALSE FALSE New Listing
256366 7/1/2008 0 0 0 FALSE FALSE Delisted
256390 5/16/1994 3/1/1995 36.24 36.24 36.24 FALSE FALSE New Listing
256390 3/1/1995 10/1/1998 36.24 36.24 40.61 FALSE FALSE Change +Price
256390 10/1/1998 8/1/1999 36.24 36.24 50.66 FALSE FALSE Change +Price
256390 8/1/1999 6/1/2002 34 34 34 FALSE FALSE Change -Subsidy -Price -Alternate
256390 6/1/2002 0 0 0 FALSE FALSE Delisted
256412 7/1/1999 8/1/1999 16.67 16.67 16.67 FALSE FALSE New Listing
256412 8/1/1999 6/1/2002 11 11 11 FALSE FALSE Change -Subsidy -Price -Alternate
256412 6/1/2002 0 0 0 FALSE FALSE Delisted
256439 5/16/1994 4/1/1998 28.92 28.92 28.92 FALSE FALSE New Listing
256439 4/1/1998 0 0 0 FALSE FALSE Delisted
256498 5/16/1994 3/1/2004 30.77 30.77 30.77 FALSE FALSE New Listing
256498 3/1/2004 0 0 0 FALSE FALSE Delisted
256528 5/16/1994 4/1/1998 39.43 39.43 39.43 FALSE FALSE New Listing
256528 4/1/1998 0 0 0 FALSE FALSE Delisted
256552 5/16/1994 4/1/1998 3.6 3.6 3.6 FALSE FALSE New Listing
256552 4/1/1998 3/1/2001 10.82 10.82 10.82 FALSE FALSE Change +Subsidy +Price +Alternate
256552 3/1/2001 0 0 0 FALSE FALSE Delisted
256684 10/1/1997 6/1/1998 23.14 23.14 23.14 FALSE FALSE New Listing
256684 6/1/1998 6/1/2000 18.3 18.3 18.3 FALSE FALSE Change -Subsidy -Price -Alternate
256684 6/1/2000 7/1/2003 16.2 16.2 18.3 FALSE FALSE Change -Subsidy -Alternate
256684 7/1/2003 9/1/2003 17.5 17.5 18.3 FALSE FALSE Change +Subsidy +Alternate
256684 9/1/2003 0 0 0 FALSE FALSE Delisted
256692 10/1/1997 6/1/1998 22.4 22.4 22.4 FALSE FALSE New Listing
256692 6/1/1998 6/1/2000 18.3 18.3 18.3 FALSE FALSE Change -Subsidy -Price -Alternate
256692 6/1/2000 7/1/2003 16.2 16.2 18.3 FALSE FALSE Change -Subsidy -Alternate
256692 7/1/2003 9/1/2003 17.8 17.8 18.3 FALSE FALSE Change +Subsidy +Alternate
256692 9/1/2003 0 0 0 FALSE FALSE Delisted
256706 10/1/1997 10/1/2000 5.38 5.38 5.38 FALSE TRUE New Listing
256706 10/1/2000 6/1/2002 2.25 2.25 5.38 FALSE TRUE Change -Subsidy -Alternate
256706 6/1/2002 0 0 0 FALSE FALSE Delisted
256714 10/1/1997 10/1/2000 16.13 16.13 16.13 FALSE TRUE New Listing
256714 10/1/2000 2/1/2001 7.5 7.5 16.13 FALSE TRUE Change -Subsidy -Alternate
256714 2/1/2001 0 0 0 FALSE FALSE Delisted
256722 10/1/1997 10/1/2000 5.38 5.38 5.38 FALSE TRUE New Listing
256722 10/1/2000 10/1/2002 2.25 2.25 5.38 FALSE TRUE Change -Subsidy -Alternate
256722 10/1/2002 1/1/2003 1.2 1.2 5.38 FALSE TRUE Change -Subsidy -Alternate
256722 1/1/2003 0 0 0 FALSE FALSE Delisted
256749 10/1/1997 10/1/2000 16.13 16.13 16.13 FALSE TRUE New Listing
256749 10/1/2000 2/1/2001 7.5 7.5 16.13 FALSE TRUE Change -Subsidy -Alternate
256749 2/1/2001 0 0 0 FALSE FALSE Delisted
256811 5/16/1994 3/1/2006 14.65 14.65 14.65 FALSE FALSE New Listing
256811 3/1/2006 3/1/2012 0 0 0 FALSE FALSE Delisted
256811 3/1/2012 0 0 0 TRUE FALSE New Listing
256838 5/16/1994 1/16/1995 25.49 25.49 25.49 FALSE TRUE New Listing
256838 1/16/1995 2/1/1999 25.5 25.5 25.5 FALSE TRUE Change +Subsidy +Price +Alternate
256838 2/1/1999 0 0 0 FALSE FALSE Delisted
256846 6/3/1995 8/1/1998 12.19 12.19 12.19 FALSE TRUE New Listing
256846 8/1/1998 8/1/1999 8.53 8.53 8.53 FALSE TRUE Change -Subsidy -Price -Alternate
256846 8/1/1999 10/1/1999 7.31 7.31 7.31 FALSE TRUE Change -Subsidy -Price -Alternate
256846 10/1/1999 8/1/2000 6.58 6.58 6.58 FALSE TRUE Change -Subsidy -Price -Alternate
256846 8/1/2000 9/1/2001 3.66 3.66 6.58 FALSE TRUE Change -Subsidy -Alternate
256846 9/1/2001 12/1/2001 2.93 2.93 7.23 FALSE TRUE Change -Subsidy +Price -Alternate
256846 12/1/2001 1/1/2003 0 0 0 FALSE FALSE Delisted
256846 1/1/2003 6/1/2003 4.3 4.3 4.3 FALSE TRUE New Listing
256846 6/1/2003 0 0 0 FALSE FALSE Delisted
256854 6/3/1995 8/1/1998 13.95 13.95 13.95 FALSE TRUE New Listing
256854 8/1/1998 8/1/1999 9.77 9.77 9.77 FALSE TRUE Change -Subsidy -Price -Alternate
256854 8/1/1999 10/1/1999 8.37 8.37 8.37 FALSE TRUE Change -Subsidy -Price -Alternate
256854 10/1/1999 8/1/2000 7.53 7.53 7.53 FALSE TRUE Change -Subsidy -Price -Alternate
256854 8/1/2000 9/1/2001 4.19 4.19 7.53 FALSE TRUE Change -Subsidy -Alternate
256854 9/1/2001 12/1/2001 3.14 3.14 7.44 FALSE TRUE Change -Subsidy -Price -Alternate
256854 12/1/2001 1/1/2003 0 0 0 FALSE FALSE Delisted
256854 1/1/2003 6/1/2003 4.3 4.3 4.3 FALSE TRUE New Listing
256854 6/1/2003 0 0 0 FALSE FALSE Delisted
256862 5/16/1994 5/17/1995 4.71 4.71 5.47 FALSE TRUE New Listing
256862 5/17/1995 1/1/1996 4.71 4.71 5.58 FALSE TRUE Change +Price
256862 1/1/1996 7/1/1997 4.71 4.71 5.86 FALSE TRUE Change +Price
256862 7/1/1997 3/1/1998 4.71 4.71 6.15 FALSE TRUE Change +Price
256862 3/1/1998 6/1/1998 3.33 3.33 6.15 FALSE TRUE Change -Subsidy -Alternate
256862 6/1/1998 10/1/1998 3.33 3.33 6.89 FALSE TRUE Change +Price
256862 10/1/1998 1/1/1999 1.83 1.83 6.89 FALSE TRUE Change -Subsidy -Alternate
256862 1/1/1999 2/1/1999 1 1 6.89 FALSE TRUE Change -Subsidy -Alternate
256862 2/1/1999 3/1/2000 1 1 7.58 FALSE TRUE Change +Price
256862 3/1/2000 2/1/2002 1 1 7.95 FALSE TRUE Change +Price
256862 2/1/2002 5/1/2003 1 1 8.35 FALSE TRUE Change +Price
256862 5/1/2003 7/1/2005 1 1 8.6 FALSE TRUE Change +Price
256862 7/1/2005 0 0 0 FALSE FALSE Delisted
256870 5/16/1994 5/17/1995 4.76 4.76 5.48 FALSE TRUE New Listing
256870 5/17/1995 1/1/1996 4.76 4.76 5.69 FALSE TRUE Change +Price
256870 1/1/1996 7/1/1997 4.76 4.76 6.15 FALSE TRUE Change +Price
256870 7/1/1997 3/1/1998 4.76 4.76 6.46 FALSE TRUE Change +Price
256870 3/1/1998 0 0 0 FALSE FALSE Delisted
256889 5/16/1994 5/17/1995 3.33 3.33 4.28 FALSE TRUE New Listing
256889 5/17/1995 1/1/1996 3.33 3.33 4.46 FALSE TRUE Change +Price
256889 1/1/1996 7/1/1997 3.33 3.33 4.68 FALSE TRUE Change +Price
256889 7/1/1997 3/1/1998 3.33 3.33 4.91 FALSE TRUE Change +Price
256889 3/1/1998 6/1/1998 4.36 4.36 4.91 FALSE TRUE Change +Subsidy +Alternate
256889 6/1/1998 2/1/1999 4.36 4.36 5.5 FALSE TRUE Change +Price
256889 2/1/1999 3/1/2000 4.36 4.36 6.05 FALSE TRUE Change +Price
256889 3/1/2000 2/1/2002 4.36 4.36 6.35 FALSE TRUE Change +Price
256889 2/1/2002 5/1/2003 4.36 4.36 6.67 FALSE TRUE Change +Price
256889 5/1/2003 7/1/2005 4.36 4.36 6.87 FALSE TRUE Change +Price
256889 7/1/2005 0 0 0 FALSE FALSE Delisted
256900 5/16/1994 1/1/1997 41.67 41.67 42.75 FALSE FALSE New Listing
256900 1/1/1997 0 0 0 FALSE FALSE Delisted
256919 5/16/1994 10/1/2010 29.25 29.25 29.25 FALSE FALSE New Listing
256919 10/1/2010 24.86 24.86 24.86 FALSE FALSE Change -Subsidy -Price -Alternate
256951 5/16/1994 5/12/1995 56.1 56.1 56.1 FALSE FALSE New Listing
256951 5/12/1995 2/1/1999 59.06 59.06 59.06 FALSE FALSE Change +Subsidy +Price +Alternate
256951 2/1/1999 59.06 59.06 88.6 FALSE FALSE Change +Price
256978 5/16/1994 5/12/1995 52.06 52.06 52.06 FALSE FALSE New Listing
256978 5/12/1995 5/1/1998 52.06 52.06 53.11 FALSE FALSE Change +Price
256978 5/1/1998 8/1/1998 21.88 21.88 21.88 FALSE FALSE Change -Subsidy -Price -Alternate
256978 8/1/1998 0 0 0 FALSE FALSE Delisted
256986 5/16/1994 5/12/1995 95.28 95.28 95.28 FALSE FALSE New Listing
256986 5/12/1995 5/1/1998 95.28 95.28 97.22 FALSE FALSE Change -Subsidy +Price -Alternate
256986 5/1/1998 8/1/1998 38.18 38.18 38.18 FALSE FALSE Change -Subsidy -Price -Alternate
256986 8/1/1998 0 0 0 FALSE FALSE Delisted
257028 5/16/1994 9/1/1995 10.6 10.6 10.6 FALSE FALSE New Listing
257028 9/1/1995 5/1/1998 10.6 10.6 11.15 FALSE FALSE Change +Price
257028 5/1/1998 8/1/1998 5.41 5.41 11.15 FALSE FALSE Change -Subsidy -Alternate
257028 8/1/1998 0 0 0 FALSE FALSE Delisted
257036 8/16/1994 9/1/1995 15.3 15.3 15.3 FALSE FALSE New Listing
257036 9/1/1995 5/1/1998 15.3 15.3 16.13 FALSE FALSE Change +Price
257036 5/1/1998 8/1/1998 8.96 8.96 16.13 FALSE FALSE Change -Subsidy -Alternate
257036 8/1/1998 0 0 0 FALSE FALSE Delisted
257168 5/16/1994 7/1/1998 7.12 7.12 7.12 FALSE FALSE New Listing
257168 7/1/1998 0 0 0 FALSE FALSE Delisted
257222 5/16/1994 7/1/1999 29.4 29.4 29.4 FALSE FALSE New Listing
257222 7/1/1999 0 0 0 FALSE FALSE Delisted
257249 10/1/1996 10/1/2001 174.37 174.37 174.37 FALSE FALSE New Listing
257249 10/1/2001 0 0 0 FALSE FALSE Delisted
257362 9/1/1999 1/1/2001 105.87 105.87 105.87 FALSE FALSE New Listing
257362 1/1/2001 2/1/2004 57 57 57 FALSE FALSE Change -Subsidy -Price -Alternate
257362 2/1/2004 5/1/2004 36 36 57 FALSE FALSE Change -Subsidy -Alternate
257362 5/1/2004 0 0 0 FALSE FALSE Delisted
257443 5/16/1994 5/1/1997 5.36 5.36 6.09 FALSE TRUE New Listing
257443 5/1/1997 2/1/2000 5.36 5.36 6.4 FALSE TRUE Change +Price
257443 2/1/2000 0 0 0 FALSE FALSE Delisted
257451 5/16/1994 5/1/1997 13.47 13.47 15.48 FALSE TRUE New Listing
257451 5/1/1997 9/1/2001 13.47 13.47 15.95 FALSE TRUE Change +Price
257451 9/1/2001 12/1/2001 8.51 8.51 12 FALSE TRUE Change -Subsidy -Price -Alternate
257451 12/1/2001 11/1/2004 0 0 0 FALSE FALSE Delisted
257451 11/1/2004 7/1/2007 7.05 7.05 7.05 FALSE TRUE New Listing
257451 7/1/2007 6.35 6.35 6.35 FALSE TRUE Change -Subsidy -Price -Alternate
257478 5/16/1994 5/1/1997 6.85 6.85 6.85 FALSE FALSE New Listing
257478 5/1/1997 9/1/2001 6.85 6.85 7.35 FALSE FALSE Change +Price
257478 9/1/2001 12/1/2001 3.77 3.77 7.35 FALSE FALSE Change -Subsidy -Alternate
257478 12/1/2001 11/1/2004 0 0 0 FALSE FALSE Delisted
257478 11/1/2004 7/1/2007 2.95 2.95 2.95 FALSE FALSE New Listing
257478 7/1/2007 2.66 2.66 2.66 FALSE FALSE Change -Subsidy -Price -Alternate
257494 8/16/1994 7/1/1995 3.2 3.2 3.2 FALSE FALSE New Listing
257494 7/1/1995 4/1/1997 3.2 3.2 3.41 FALSE FALSE Change +Price
257494 4/1/1997 4/1/1998 3.2 3.2 3.8 FALSE FALSE Change +Price
257494 4/1/1998 4/1/1999 3.2 3.2 4.06 FALSE FALSE Change +Price
257494 4/1/1999 3/1/2000 3.2 3.2 4.19 FALSE FALSE Change +Price
257494 3/1/2000 10/1/2003 3.2 3.2 4.33 FALSE FALSE Change +Price
257494 10/1/2003 0 0 0 FALSE FALSE Delisted
257796 5/16/1994 7/1/1999 22.9 22.9 22.9 FALSE FALSE New Listing
257796 7/1/1999 0 0 0 FALSE FALSE Delisted
257826 5/16/1994 9/1/2000 27.68 27.68 27.68 FALSE FALSE New Listing
257826 9/1/2000 0 0 0 FALSE FALSE Delisted
257885 5/16/1994 8/1/2007 16.78 16.78 16.78 FALSE FALSE New Listing
257885 8/1/2007 0 0 0 FALSE FALSE Delisted
257893 5/16/1994 8/1/2007 31.59 31.59 31.59 FALSE FALSE New Listing
257893 8/1/2007 0 0 0 FALSE FALSE Delisted
257907 5/16/1994 6/2/1995 5.13 5.13 5.13 FALSE TRUE New Listing
257907 6/2/1995 6/27/1995 4.75 4.75 4.75 FALSE TRUE Change -Subsidy -Price -Alternate
257907 6/27/1995 2/1/1998 4.38 4.38 4.38 FALSE TRUE Change -Subsidy -Price -Alternate
257907 2/1/1998 12/1/2001 3.72 3.72 3.72 FALSE TRUE Change -Subsidy -Price -Alternate
257907 12/1/2001 0 0 0 FALSE FALSE Delisted
257915 5/16/1994 12.9 12.9 12.9 FALSE FALSE New Listing
257923 5/16/1994 12/1/1995 118.38 118.38 118.38 FALSE FALSE New Listing
257923 12/1/1995 118.38 118.38 130.21 FALSE FALSE Change +Price
258024 5/16/1994 3/1/1995 12.12 12.12 12.72 FALSE FALSE New Listing
258024 3/1/1995 7/1/1995 12.12 12.12 13.99 FALSE FALSE Change +Price
258024 7/1/1995 3/1/2001 13.99 13.99 13.99 FALSE FALSE Change +Subsidy +Alternate
258024 3/1/2001 7/1/2001 13.99 13.99 15.39 FALSE FALSE Change +Price
258024 7/1/2001 11/1/2004 15.39 15.39 15.39 FALSE FALSE Change +Subsidy +Alternate
258024 11/1/2004 16.93 16.93 16.93 FALSE FALSE Change +Subsidy +Price +Alternate
258032 5/16/1994 3/1/1995 31.48 31.48 33.03 FALSE FALSE New Listing
258032 3/1/1995 7/1/1995 31.48 31.48 36.33 FALSE FALSE Change +Price
258032 7/1/1995 3/1/2001 36.33 36.33 36.33 FALSE FALSE Change +Subsidy +Alternate
258032 3/1/2001 7/1/2001 36.33 36.33 39.96 FALSE FALSE Change +Price
258032 7/1/2001 11/1/2004 39.96 39.96 39.96 FALSE FALSE Change +Subsidy +Alternate
258032 11/1/2004 43.96 43.96 43.96 FALSE FALSE Change +Subsidy +Price +Alternate
258040 5/16/1994 8/16/1994 3.79 3.79 6.05 FALSE FALSE New Listing
258040 8/16/1994 2/1/1996 3.79 3.79 6.77 FALSE FALSE Change +Price
258040 2/1/1996 9/1/1998 3.79 3.79 6.9 FALSE FALSE Change +Price
258040 9/1/1998 8/1/2009 3.79 3.79 7.59 FALSE FALSE Change +Price
258040 8/1/2009 0 0 0 FALSE FALSE Delisted
258059 2/1/1996 9/1/1998 63.17 63.17 67.5 FALSE FALSE New Listing
258059 9/1/1998 4/1/2002 63.17 63.17 126.5 FALSE FALSE Change +Subsidy +Price +Alternate
258059 4/1/2002 0 0 0 FALSE FALSE Delisted
258067 5/16/1994 3/1/2001 63.95 63.95 63.95 FALSE TRUE New Listing
258067 3/1/2001 0 0 0 FALSE FALSE Delisted
258075 5/16/1994 3/1/2001 64.79 64.79 64.79 FALSE FALSE New Listing
258075 3/1/2001 0 0 0 FALSE FALSE Delisted
258083 5/16/1994 12/1/2001 54 54 54 FALSE FALSE New Listing
258083 12/1/2001 0 0 0 FALSE FALSE Delisted
258091 5/16/1994 10/1/2000 14.6 14.6 14.6 FALSE TRUE New Listing
258091 10/1/2000 0 0 0 FALSE FALSE Delisted
258156 5/16/1994 5/1/1998 19.38 19.38 19.38 FALSE FALSE New Listing
258156 5/1/1998 8/1/1998 5.62 5.62 8.91 FALSE FALSE Change -Subsidy -Price -Alternate
258156 8/1/1998 0 0 0 FALSE FALSE Delisted
258164 10/1/1994 5/1/1998 193.8 193.8 193.8 FALSE FALSE New Listing
258164 5/1/1998 8/1/1998 56.2 56.2 89.1 FALSE FALSE Change -Subsidy -Price -Alternate
258164 8/1/1998 0 0 0 FALSE FALSE Delisted
258199 5/16/1994 5/1/1998 65.29 65.29 65.29 FALSE FALSE New Listing
258199 5/1/1998 8/1/1998 12.5 12.5 35.25 FALSE FALSE Change -Subsidy -Price -Alternate
258199 8/1/1998 0 0 0 FALSE FALSE Delisted
258245 6/7/1995 2/1/1999 4.51 4.51 4.74 FALSE TRUE New Listing
258245 2/1/1999 9/1/2010 4.51 4.51 4.51 FALSE TRUE Change -Price
258245 9/1/2010 0 0 0 FALSE FALSE Delisted
258253 5/16/1994 1/1/1998 5.56 5.56 5.56 FALSE FALSE New Listing
258253 1/1/1998 2/1/2000 5.56 5.56 6.53 FALSE FALSE Change +Price
258253 2/1/2000 3/1/2001 5.56 5.56 7.75 FALSE FALSE Change +Price
258253 3/1/2001 4/1/2002 5.56 5.56 7.29 FALSE FALSE Change -Price
258253 4/1/2002 4/1/2003 5.56 5.56 8.02 FALSE FALSE Change +Price
258253 4/1/2003 10/1/2005 5.56 5.56 8.82 FALSE FALSE Change +Price
258253 10/1/2005 10/1/2008 9 9 9 FALSE FALSE Change +Subsidy +Price +Alternate
258253 10/1/2008 9/1/2011 10 10 10 FALSE FALSE Change +Subsidy +Price +Alternate
258253 9/1/2011 11 11 11 FALSE FALSE Change +Subsidy +Price +Alternate
258296 5/16/1994 1/1/1999 4.5 4.5 4.5 FALSE FALSE New Listing
258296 1/1/1999 0 0 0 FALSE FALSE Delisted
258318 5/16/1994 11/1/2002 8.5 8.5 8.5 FALSE FALSE New Listing
258318 11/1/2002 1/1/2006 8.5 8.5 15.3 FALSE FALSE Change +Price
258318 1/1/2006 0 0 0 FALSE FALSE Delisted
258326 5/16/1994 8/1/2000 11.06 11.06 11.06 FALSE FALSE New Listing
258326 8/1/2000 0 0 0 FALSE FALSE Delisted
258407 5/16/1994 3/1/2001 17.97 17.97 20.65 FALSE FALSE New Listing
258407 3/1/2001 11/1/2002 17.97 17.97 22.71 FALSE FALSE Change +Price
258407 11/1/2002 5/1/2004 17.97 17.97 23.86 FALSE FALSE Change +Price
258407 5/1/2004 0 0 0 FALSE FALSE Delisted
258490 5/16/1994 5/1/2000 99.8 99.8 99.8 FALSE FALSE New Listing
258490 5/1/2000 11/1/2000 25.88 25.88 25.88 FALSE FALSE Change -Subsidy -Price -Alternate
258490 11/1/2000 0 0 0 FALSE FALSE Delisted
258504 5/16/1994 5/1/2000 163.05 163.05 163.05 FALSE FALSE New Listing
258504 5/1/2000 11/1/2000 40.36 40.36 40.36 FALSE FALSE Change -Subsidy -Price -Alternate
258504 11/1/2000 0 0 0 FALSE FALSE Delisted
258512 5/16/1994 8/1/2000 44 44 44 FALSE FALSE New Listing
258512 8/1/2000 0 0 0 FALSE FALSE Delisted
258555 9/1/1997 8/1/1998 8.21 8.21 8.21 FALSE TRUE New Listing
258555 8/1/1998 1/1/2001 8.21 8.21 9.03 FALSE TRUE Change +Price
258555 1/1/2001 5/1/2005 8.21 8.21 9.66 FALSE TRUE Change +Price
258555 5/1/2005 9/1/2005 8.21 8.21 11.83 FALSE TRUE Change +Price
258555 9/1/2005 0 0 0 FALSE FALSE Delisted
258563 5/16/1994 11/1/2014 26.05 26.05 26.05 FALSE FALSE New Listing
258563 11/1/2014 0 0 0 FALSE FALSE Delisted
258571 5/16/1994 7/1/2010 15.5 15.5 15.5 FALSE FALSE New Listing
258571 7/1/2010 19.13 19.13 19.13 FALSE FALSE Change +Subsidy +Price +Alternate
258598 5/16/1994 7/1/2010 14.69 14.69 14.69 FALSE FALSE New Listing
258598 7/1/2010 17.21 17.21 17.21 FALSE FALSE Change +Subsidy +Price +Alternate
258601 5/1/1999 8/1/2009 4.12 4.12 6.5 FALSE TRUE New Listing
258601 8/1/2009 6/1/2014 4.12 4.12 10.55 FALSE TRUE Change +Price
258601 6/1/2014 4.12 4.12 11.1 FALSE TRUE Change +Price
258628 5/16/1994 7/1/2010 15.63 15.63 15.63 FALSE FALSE New Listing
258628 7/1/2010 42.09 42.09 42.09 FALSE FALSE Change +Subsidy +Price +Alternate
258636 5/16/1994 4/1/1999 13.71 13.71 13.71 FALSE FALSE New Listing
258636 4/1/1999 0 0 0 FALSE FALSE Delisted
258644 5/16/1994 2/1/2000 15.3 15.3 15.3 FALSE FALSE New Listing
258644 2/1/2000 0 0 0 FALSE FALSE Delisted
258652 5/16/1994 7/1/2010 11.19 11.19 11.19 FALSE FALSE New Listing
258652 7/1/2010 19.16 19.16 19.16 FALSE FALSE Change +Subsidy +Price +Alternate
258660 5/16/1994 7/1/2003 15.83 15.83 15.83 FALSE FALSE New Listing
258660 7/1/2003 0 0 0 FALSE FALSE Delisted
258679 5/16/1994 3/1/2012 31.93 31.93 31.93 FALSE FALSE New Listing
258679 3/1/2012 11/1/2014 35.15 35.15 35.15 FALSE FALSE Change +Subsidy +Price +Alternate
258679 11/1/2014 0 0 0 FALSE FALSE Delisted
258717 5/16/1994 6/1/1996 46.92 46.92 46.92 FALSE FALSE New Listing
258717 6/1/1996 8/1/1996 46.92 46.92 56.3 FALSE FALSE Change +Price
258717 8/1/1996 8/1/1998 56.3 56.3 56.3 FALSE FALSE Change +Subsidy +Alternate
258717 8/1/1998 2/1/2007 56.3 56.3 61.93 FALSE FALSE Change +Price
258717 2/1/2007 11/1/2007 61.93 61.93 61.93 FALSE FALSE Change +Subsidy +Alternate
258717 11/1/2007 0 0 0 FALSE FALSE Delisted
258725 5/16/1994 6/1/1996 74.98 74.98 74.98 FALSE FALSE New Listing
258725 6/1/1996 8/1/1996 74.98 74.98 89.98 FALSE FALSE Change +Price
258725 8/1/1996 8/1/1998 89.98 89.98 89.98 FALSE FALSE Change +Subsidy +Alternate
258725 8/1/1998 2/1/2007 89.98 89.98 98.98 FALSE FALSE Change +Price
258725 2/1/2007 11/1/2007 98.98 98.98 98.98 FALSE FALSE Change +Subsidy +Alternate
258725 11/1/2007 0 0 0 FALSE FALSE Delisted
258814 5/16/1994 6/2/1995 3.16 3.16 3.48 FALSE TRUE New Listing
258814 6/2/1995 12/1/1997 3.16 3.16 3.55 FALSE TRUE Change +Price
258814 12/1/1997 0 0 0 FALSE FALSE Delisted
258830 5/16/1994 6/2/1995 2.78 2.78 3.48 FALSE TRUE New Listing
258830 6/2/1995 1/1/1996 2.78 2.78 3.55 FALSE TRUE Change +Price
258830 1/1/1996 7/1/1997 2.78 2.78 3.73 FALSE TRUE Change +Price
258830 7/1/1997 12/1/1997 2.78 2.78 3.92 FALSE TRUE Change +Price
258830 12/1/1997 0 0 0 FALSE FALSE Delisted
258865 5/16/1994 6/2/1995 3.16 3.16 3.48 FALSE TRUE New Listing
258865 6/2/1995 7/1/1997 3.16 3.16 3.55 FALSE TRUE Change +Price
258865 7/1/1997 12/1/1997 3.16 3.16 3.92 FALSE TRUE Change +Price
258865 12/1/1997 0 0 0 FALSE FALSE Delisted
258954 5/16/1994 8/1/2001 11.56 11.56 11.56 FALSE FALSE New Listing
258954 8/1/2001 1/1/2005 9.25 9.25 11.56 FALSE FALSE Change -Subsidy -Alternate
258954 1/1/2005 0 0 0 FALSE FALSE Delisted
259012 5/16/1994 10/1/2008 100 100 100 FALSE FALSE New Listing
259012 10/1/2008 110 110 110 FALSE FALSE Change +Subsidy +Price +Alternate
259144 5/16/1994 3/1/1995 6.14 6.14 6.14 FALSE FALSE New Listing
259144 3/1/1995 8/1/1995 6.14 6.14 9.25 FALSE FALSE Change +Price
259144 8/1/1995 1/1/1997 6.14 6.14 9.48 FALSE FALSE Change +Price
259144 1/1/1997 11/1/1997 6.14 6.14 10.47 FALSE FALSE Change +Price
259144 11/1/1997 8/1/2001 6.14 6.14 11 FALSE FALSE Change +Price
259144 8/1/2001 8/1/2005 6 6 6 FALSE FALSE Change -Subsidy -Price -Alternate
259144 8/1/2005 6.66 6.66 6.66 FALSE FALSE Change +Subsidy +Price +Alternate
259160 5/16/1994 6/22/1995 9.98 9.98 9.98 FALSE FALSE New Listing
259160 6/22/1995 4/1/2001 9.95 9.95 9.95 FALSE FALSE Change -Subsidy -Price -Alternate
259160 4/1/2001 6/1/2001 0 0 0 FALSE FALSE Delisted
259160 6/1/2001 12/1/2001 9.95 9.95 9.95 FALSE FALSE New listing
259160 12/1/2001 0 0 0 FALSE FALSE Delisted
259179 5/16/1994 3/1/1996 17.68 17.68 18.18 FALSE FALSE New Listing
259179 3/1/1996 2/1/2002 17.1 17.1 25 FALSE FALSE Change -Subsidy +Price -Alternate
259179 2/1/2002 5/1/2002 15.6 15.6 25 FALSE FALSE Change -Subsidy -Alternate
259179 5/1/2002 0 0 0 FALSE FALSE Delisted
259276 5/16/1994 2/1/1999 3.25 3.25 3.4 FALSE TRUE New Listing
259276 2/1/1999 7/1/2007 3.25 3.25 3.25 FALSE TRUE Change -Price
259276 7/1/2007 0 0 0 FALSE FALSE Delisted
259292 5/16/1994 9/1/2000 7.36 7.36 7.36 FALSE FALSE New Listing
259292 9/1/2000 3/1/2001 7.36 7.36 26 FALSE FALSE Change +Price
259292 3/1/2001 3/1/2004 7.36 7.36 27 FALSE FALSE Change +Price
259292 3/1/2004 0 0 0 FALSE FALSE Delisted
259349 5/16/1994 4/1/2004 81.1 81.1 81.1 FALSE FALSE New Listing
259349 4/1/2004 11/1/2004 81.1 81.1 89.21 FALSE FALSE Change +Price
259349 11/1/2004 89.21 89.21 89.21 FALSE FALSE Change +Subsidy +Alternate
259403 5/16/1994 9/1/2002 34.57 34.57 34.57 FALSE FALSE New Listing
259403 9/1/2002 3/1/2003 30 30 30 FALSE FALSE Change -Subsidy -Price -Alternate
259403 3/1/2003 0 0 0 FALSE FALSE Delisted
259438 5/16/1994 11/1/1997 5.27 5.27 5.84 FALSE FALSE New Listing
259438 11/1/1997 7/1/1999 5.27 5.27 5.8 FALSE FALSE Change -Price
259438 7/1/1999 11/1/1999 3.16 3.16 5.8 FALSE FALSE Change -Subsidy -Alternate
259438 11/1/1999 0 0 0 FALSE FALSE Delisted
259446 5/16/1994 9/1/2002 8.24 8.24 8.24 FALSE FALSE New Listing
259446 9/1/2002 9/1/2006 7 7 7 FALSE FALSE Change -Subsidy -Price -Alternate
259446 9/1/2006 0 0 0 FALSE FALSE Delisted
259462 5/16/1994 9/1/2002 11.48 11.48 11.48 FALSE FALSE New Listing
259462 9/1/2002 9/1/2006 9.5 9.5 9.5 FALSE FALSE Change -Subsidy -Price -Alternate
259462 9/1/2006 0 0 0 FALSE FALSE Delisted
259470 5/16/1994 9/1/2002 68.14 68.14 68.14 FALSE FALSE New Listing
259470 9/1/2002 3/1/2003 54.5 54.5 54.5 FALSE FALSE Change -Subsidy -Price -Alternate
259470 3/1/2003 0 0 0 FALSE FALSE Delisted
259667 5/16/1994 8/1/2009 4.75 4.75 4.75 FALSE FALSE New Listing
259667 8/1/2009 0 0 0 FALSE FALSE Delisted
259705 5/16/1994 11/1/1998 114.68 114.68 114.68 FALSE FALSE New Listing
259705 11/1/1998 5/1/2001 114.7 114.7 114.7 FALSE FALSE Change +Subsidy +Price +Alternate
259705 5/1/2001 0 0 0 FALSE FALSE Delisted
259713 5/16/1994 97.16 97.16 97.16 FALSE FALSE New Listing
259772 5/1/1999 8/1/2000 7.75 7.75 11.45 FALSE TRUE New Listing
259772 8/1/2000 10/1/2002 7 7 11.45 FALSE TRUE Change -Subsidy -Alternate
259772 10/1/2002 8/1/2009 5.4 5.4 11.45 FALSE TRUE Change -Subsidy -Alternate
259772 8/1/2009 6/1/2014 5.4 5.4 14.52 FALSE TRUE Change +Price
259772 6/1/2014 5.4 5.4 18.1 FALSE TRUE Change +Price
259799 5/16/1994 6/3/1995 4.46 4.46 4.46 FALSE TRUE New Listing
259799 6/3/1995 2/1/2008 4.46 4.46 4.65 FALSE TRUE Change +Price
259799 2/1/2008 4.46 4.46 4.46 FALSE TRUE Change -Price
259896 7/10/1995 3/1/2001 39.85 39.85 39.85 FALSE FALSE New Listing
259896 3/1/2001 0 0 0 FALSE FALSE Delisted
259942 5/16/1994 12/1/1995 5.72 5.72 5.72 FALSE FALSE New Listing
259942 12/1/1995 6/1/1998 5.71 5.71 5.71 FALSE FALSE Change -Subsidy -Price -Alternate
259942 6/1/1998 8/1/2004 4.5 4.5 4.5 FALSE FALSE Change -Subsidy -Price -Alternate
259942 8/1/2004 7/1/2007 3.5 3.5 3.5 FALSE FALSE Change -Subsidy -Price -Alternate
259942 7/1/2007 1/1/2010 3 3 3 FALSE FALSE Change -Subsidy -Price -Alternate
259942 1/1/2010 1/1/2013 3.2 3.2 3.2 FALSE FALSE Change +Subsidy +Price +Alternate
259942 1/1/2013 3.95 3.95 3.95 FALSE FALSE Change +Subsidy +Price +Alternate
259950 5/16/1994 6/1/1998 7.95 7.95 7.95 FALSE FALSE New Listing
259950 6/1/1998 8/1/2004 6.5 6.5 6.5 FALSE FALSE Change -Subsidy -Price -Alternate
259950 8/1/2004 7/1/2007 4.35 4.35 4.35 FALSE FALSE Change -Subsidy -Price -Alternate
259950 7/1/2007 1/1/2010 4 4 4 FALSE FALSE Change -Subsidy -Price -Alternate
259950 1/1/2010 1/1/2013 4.2 4.2 4.2 FALSE FALSE Change +Subsidy +Price +Alternate
259950 1/1/2013 5.8 5.8 5.8 FALSE FALSE Change +Subsidy +Price +Alternate
259977 3/1/1996 7/1/1998 7.5 7.5 7.5 FALSE FALSE New Listing
259977 7/1/1998 0 0 0 FALSE FALSE Delisted
259985 5/1/1999 7/1/2001 95 95 95 FALSE FALSE New Listing
259985 7/1/2001 6/1/2003 69 69 69 FALSE FALSE Change -Subsidy -Price -Alternate
259985 6/1/2003 9/1/2009 39.5 39.5 39.5 FALSE FALSE Change -Subsidy -Price -Alternate
259985 9/1/2009 9/1/2010 48.3 48.3 48.3 FALSE FALSE Change +Subsidy +Price +Alternate
259985 9/1/2010 55 55 55 FALSE FALSE Change +Subsidy +Price +Alternate
259993 3/1/1996 1/1/1998 10.5 10.5 10.5 FALSE FALSE New Listing
259993 1/1/1998 0 0 0 FALSE FALSE Delisted
260002 5/16/1994 5/1/1997 37.8 37.8 37.8 FALSE FALSE New Listing
260002 5/1/1997 5/1/2001 24.6 24.6 24.6 FALSE FALSE Change -Subsidy -Price -Alternate
260002 5/1/2001 0 0 0 FALSE FALSE Delisted
260061 4/12/1995 4/1/1998 15.4 15.4 15.4 FALSE FALSE New Listing
260061 4/1/1998 6/1/1998 12.32 12.32 12.32 FALSE FALSE Change -Subsidy -Price -Alternate
260061 6/1/1998 5/1/2000 11 11 11 FALSE FALSE Change -Subsidy -Price -Alternate
260061 5/1/2000 10/1/2001 11 11 17 FALSE FALSE Change +Price
260061 10/1/2001 4/1/2002 11 11 22 FALSE FALSE Change +Price
260061 4/1/2002 0 0 0 FALSE FALSE Delisted
260088 4/12/1995 7/1/1997 18.6 18.6 18.6 FALSE FALSE New Listing
260088 7/1/1997 4/1/1998 14.88 14.88 18.6 FALSE FALSE Change -Subsidy -Alternate
260088 4/1/1998 6/1/1998 14.88 14.88 14.88 FALSE FALSE Change -Price
260088 6/1/1998 5/1/2000 13 13 13 FALSE FALSE Change -Subsidy -Price -Alternate
260088 5/1/2000 10/1/2001 13 13 21 FALSE FALSE Change +Price
260088 10/1/2001 4/1/2002 13 13 27.5 FALSE FALSE Change +Price
260088 4/1/2002 0 0 0 FALSE FALSE Delisted
260134 5/16/1994 7/1/1999 3.81 3.81 3.81 FALSE TRUE New Listing
260134 7/1/1999 10/1/2002 2.67 2.67 2.67 FALSE TRUE Change -Subsidy -Price -Alternate
260134 10/1/2002 10/1/2005 2.77 2.77 2.77 FALSE TRUE Change +Subsidy +Price +Alternate
260134 10/1/2005 12/1/2009 3.19 3.19 3.19 FALSE TRUE Change +Subsidy +Price +Alternate
260134 12/1/2009 0 0 0 FALSE FALSE Delisted
260142 5/16/1994 7/1/1999 4.08 4.08 4.08 FALSE TRUE New Listing
260142 7/1/1999 10/1/2002 2.86 2.86 2.86 FALSE TRUE Change -Subsidy -Price -Alternate
260142 10/1/2002 10/1/2005 2.95 2.95 2.95 FALSE TRUE Change +Subsidy +Price +Alternate
260142 10/1/2005 3/1/2010 3.24 3.24 3.24 FALSE TRUE Change +Subsidy +Price +Alternate
260142 3/1/2010 0 0 0 FALSE FALSE Delisted
260150 5/16/1994 7/1/1999 5.23 5.23 5.23 FALSE TRUE New Listing
260150 7/1/1999 10/1/2002 3.66 3.66 3.66 FALSE TRUE Change -Subsidy -Price -Alternate
260150 10/1/2002 10/1/2005 3.76 3.76 3.76 FALSE TRUE Change +Subsidy +Price +Alternate
260150 10/1/2005 1/1/2010 4.32 4.32 4.32 FALSE TRUE Change +Subsidy +Price +Alternate
260150 1/1/2010 0 0 0 FALSE FALSE Delisted
260169 5/16/1994 7/1/1999 6.63 6.63 6.63 FALSE TRUE New Listing
260169 7/1/1999 10/1/2002 4.64 4.64 4.64 FALSE TRUE Change -Subsidy -Price -Alternate
260169 10/1/2002 10/1/2005 4.75 4.75 4.75 FALSE TRUE Change +Subsidy +Price +Alternate
260169 10/1/2005 4/1/2008 6.41 6.41 6.41 FALSE TRUE Change +Subsidy +Price +Alternate
260169 4/1/2008 0 0 0 FALSE FALSE Delisted
260177 5/16/1994 7/1/1999 7.66 7.66 7.66 FALSE TRUE New Listing
260177 7/1/1999 10/1/2002 5.36 5.36 5.36 FALSE TRUE Change -Subsidy -Price -Alternate
260177 10/1/2002 10/1/2005 5.48 5.48 5.48 FALSE TRUE Change +Subsidy +Price +Alternate
260177 10/1/2005 4/1/2010 6.57 6.57 6.57 FALSE TRUE Change +Subsidy +Price +Alternate
260177 4/1/2010 0 0 0 FALSE FALSE Delisted
260185 5/16/1994 7/1/1999 10.92 10.92 10.92 FALSE TRUE New Listing
260185 7/1/1999 10/1/2002 7.64 7.64 7.64 FALSE TRUE Change -Subsidy -Price -Alternate
260185 10/1/2002 10/1/2005 7.78 7.78 7.78 FALSE TRUE Change +Subsidy +Price +Alternate
260185 10/1/2005 2/1/2010 8.56 8.56 8.56 FALSE TRUE Change +Subsidy +Price +Alternate
260185 2/1/2010 0 0 0 FALSE FALSE Delisted
260223 1/1/1999 7/1/1999 2.2 2.2 2.2 FALSE FALSE New Listing
260223 7/1/1999 9/1/2002 1.59 1.59 1.59 FALSE FALSE Change -Subsidy -Price -Alternate
260223 9/1/2002 7/1/2003 1.44 1.44 1.44 FALSE FALSE Change -Subsidy -Price -Alternate
260223 7/1/2003 0 0 0 FALSE FALSE Delisted
260266 10/4/1997 3/1/1998 6.09 6.09 6.09 FALSE TRUE New Listing
260266 3/1/1998 1/1/2004 4.9 4.9 6.09 FALSE TRUE Change -Subsidy -Alternate
260266 1/1/2004 2/1/2008 3.49 3.49 3.49 FALSE TRUE Change -Subsidy -Price -Alternate
260266 2/1/2008 1/1/2010 4.4 4.4 4.4 FALSE TRUE Change +Subsidy +Price +Alternate
260266 1/1/2010 2.79 2.79 2.79 FALSE TRUE Change -Subsidy -Price -Alternate
260282 10/4/1997 3/1/1998 6.09 6.09 6.09 FALSE TRUE New Listing
260282 3/1/1998 1/1/2004 4.9 4.9 6.09 FALSE TRUE Change -Subsidy -Alternate
260282 1/1/2004 2/1/2008 3.49 3.49 3.49 FALSE TRUE Change -Subsidy -Price -Alternate
260282 2/1/2008 1/1/2010 4.4 4.4 4.4 FALSE TRUE Change +Subsidy +Price +Alternate
260282 1/1/2010 2.79 2.79 2.79 FALSE TRUE Change -Subsidy -Price -Alternate
260304 5/16/1994 1/1/2001 2.3 2.3 2.3 FALSE TRUE New Listing
260304 1/1/2001 10/1/2002 2.3 2.3 2.42 FALSE TRUE Change +Price
260304 10/1/2002 1/1/2003 0.44 0.44 2.42 FALSE TRUE Change -Subsidy -Alternate
260304 1/1/2003 0 0 0 FALSE FALSE Delisted
260312 5/16/1994 1/1/2001 4.22 4.22 4.22 FALSE TRUE New Listing
260312 1/1/2001 10/1/2002 4.22 4.22 4.43 FALSE TRUE Change +Price
260312 10/1/2002 1/1/2003 0.88 0.88 4.43 FALSE TRUE Change -Subsidy -Alternate
260312 1/1/2003 0 0 0 FALSE FALSE Delisted
260320 5/16/1994 12/1/1995 7.69 7.69 7.95 FALSE TRUE New Listing
260320 12/1/1995 8/1/1999 7.69 7.69 7.69 FALSE TRUE Change -Price
260320 8/1/1999 12/1/2001 2.1 2.1 2.1 FALSE TRUE Change -Subsidy -Price -Alternate
260320 12/1/2001 10/1/2002 2.1 2.1 8.07 FALSE TRUE Change +Price
260320 10/1/2002 4/1/2003 2.2 2.2 8.07 FALSE TRUE Change +Subsidy +Alternate
260320 4/1/2003 0 0 0 FALSE FALSE Delisted
260347 5/16/1994 1/1/2001 4.22 4.22 4.22 FALSE TRUE New Listing
260347 1/1/2001 10/1/2002 4.22 4.22 4.43 FALSE TRUE Change +Price
260347 10/1/2002 1/1/2003 0.88 0.88 4.43 FALSE TRUE Change -Subsidy -Alternate
260347 1/1/2003 0 0 0 FALSE FALSE Delisted
260363 5/16/1994 9/1/2002 143.11 143.11 143.11 FALSE FALSE New Listing
260363 9/1/2002 0 0 0 FALSE FALSE Delisted
260479 11/1/1996 8/1/1998 9.9 21.67 21.67 FALSE FALSE New Listing
260479 8/1/1998 6/1/1999 6.93 21.67 21.67 FALSE FALSE Change -Subsidy -Price -Alternate
260479 6/1/1999 2/1/2000 6.23 16.66 16.66 FALSE FALSE Change -Subsidy -Price -Alternate
260479 2/1/2000 12/1/2000 4.17 16.67 16.67 FALSE FALSE Change -Subsidy +Price +Alternate
260479 12/1/2000 3/1/2001 4.17 18.33 18.33 FALSE FALSE Change +Price +Alternate
260479 3/1/2001 9/1/2001 3.73 18.33 18.33 FALSE FALSE Change -Subsidy
260479 9/1/2001 3/1/2012 2.5 18.33 18.33 FALSE FALSE Change -Subsidy
260479 3/1/2012 0 0 0 FALSE FALSE Delisted
260525 6/3/1995 6/27/1995 4.5 4.5 5.96 FALSE TRUE New Listing
260525 6/27/1995 8/1/2000 4.5 4.5 4.5 FALSE TRUE Change -Price
260525 8/1/2000 10/1/2001 4.5 4.5 5.04 FALSE TRUE Change +Price
260525 10/1/2001 0 0 0 FALSE FALSE Delisted
260533 5/16/1994 8/16/1994 8.99 8.99 8.99 FALSE TRUE New Listing
260533 8/16/1994 2/1/1996 4.5 4.5 4.5 FALSE TRUE Change -Subsidy -Price -Alternate
260533 2/1/1996 8/1/2000 4.5 4.5 8.99 FALSE TRUE Change +Price
260533 8/1/2000 4/1/2010 4.5 4.5 9.44 FALSE TRUE Change +Price
260533 4/1/2010 4.5 4.5 4.5 FALSE TRUE Change -Price
260541 5/16/1994 8/16/1994 7.17 7.17 7.17 FALSE TRUE New Listing
260541 8/16/1994 2/1/1996 4.5 4.5 4.5 FALSE TRUE Change -Subsidy -Price -Alternate
260541 2/1/1996 8/1/2000 4.5 4.5 7.17 FALSE TRUE Change +Price
260541 8/1/2000 4/1/2010 4.5 4.5 7.53 FALSE TRUE Change +Price
260541 4/1/2010 4.5 4.5 4.5 FALSE TRUE Change -Price
260614 5/16/1994 6/1/1999 56.4 56.4 56.4 FALSE FALSE New Listing
260614 6/1/1999 0 0 0 FALSE FALSE Delisted
260622 10/1/1994 7/1/1999 4.23 4.23 4.23 FALSE FALSE New Listing
260622 7/1/1999 11/1/1999 2.06 2.06 2.06 FALSE FALSE Change -Subsidy -Price -Alternate
260622 11/1/1999 0 0 0 FALSE FALSE Delisted
260630 10/1/1994 7/1/1999 21.15 21.15 21.15 FALSE FALSE New Listing
260630 7/1/1999 11/1/1999 10.3 10.3 10.3 FALSE FALSE Change -Subsidy -Price -Alternate
260630 11/1/1999 0 0 0 FALSE FALSE Delisted
260649 7/1/1997 7/1/1999 3.9 3.9 4.11 FALSE FALSE New Listing
260649 7/1/1999 11/1/1999 2.31 2.31 2.31 FALSE FALSE Change -Subsidy -Price -Alternate
260649 11/1/1999 0 0 0 FALSE FALSE Delisted
260665 7/1/1997 7/1/1999 4.35 4.35 4.57 FALSE FALSE New Listing
260665 7/1/1999 11/1/1999 2.44 2.44 2.44 FALSE FALSE Change -Subsidy -Price -Alternate
260665 11/1/1999 0 0 0 FALSE FALSE Delisted
260673 5/16/1994 7/1/1997 22.85 22.85 22.85 FALSE FALSE New Listing
260673 7/1/1997 7/1/1999 21.75 21.75 22.85 FALSE FALSE Change -Subsidy -Alternate
260673 7/1/1999 11/1/1999 12.22 12.22 12.22 FALSE FALSE Change -Subsidy -Price -Alternate
260673 11/1/1999 0 0 0 FALSE FALSE Delisted
260762 5/16/1994 11/1/2002 17.33 17.33 17.33 FALSE FALSE New Listing
260762 11/1/2002 0 0 0 FALSE FALSE Delisted
260770 6/7/1995 10/1/2001 4.51 4.51 4.74 FALSE TRUE New Listing
260770 10/1/2001 0 0 0 FALSE FALSE Delisted
260789 5/16/1994 5/1/1999 3.25 3.25 3.4 FALSE TRUE New Listing
260789 5/1/1999 0 0 0 FALSE FALSE Delisted
260800 6/1/1995 7/1/1998 19.47 19.47 19.47 FALSE TRUE New Listing
260800 7/1/1998 2/1/2002 19.47 19.47 23 FALSE TRUE Change +Price
260800 2/1/2002 0 0 0 FALSE FALSE Delisted
260819 12/1/1996 2/1/2002 10.75 10.75 10.75 FALSE FALSE New Listing
260819 2/1/2002 0 0 0 FALSE FALSE Delisted
260827 12/1/1996 2/1/2002 8.83 8.83 8.83 FALSE FALSE New Listing
260827 2/1/2002 0 0 0 FALSE FALSE Delisted
260835 12/1/1996 2/1/2002 15.11 15.11 15.11 FALSE FALSE New Listing
260835 2/1/2002 0 0 0 FALSE FALSE Delisted
260851 5/16/1994 7/1/2002 12.15 12.15 12.15 FALSE FALSE New Listing
260851 7/1/2002 9/1/2004 13.35 13.35 13.35 FALSE FALSE Change +Subsidy +Price +Alternate
260851 9/1/2004 9/1/2006 14.25 14.25 14.25 FALSE FALSE Change +Subsidy +Price +Alternate
260851 9/1/2006 9/1/2007 14.85 14.85 14.85 FALSE FALSE Change +Subsidy +Price +Alternate
260851 9/1/2007 9/1/2008 15.45 15.45 15.45 FALSE FALSE Change +Subsidy +Price +Alternate
260851 9/1/2008 3/1/2010 16.05 16.05 16.05 FALSE FALSE Change +Subsidy +Price +Alternate
260851 3/1/2010 3/1/2011 17.65 17.65 17.65 FALSE FALSE Change +Subsidy +Price +Alternate
260851 3/1/2011 4/1/2012 18.5 18.5 18.5 FALSE FALSE Change +Subsidy +Price +Alternate
260851 4/1/2012 19.2 19.2 19.2 FALSE FALSE Change +Subsidy +Price +Alternate
260886 6/16/1995 11/1/2002 27.5 27.5 27.5 FALSE FALSE New Listing
260886 11/1/2002 5/1/2009 25 25 25 FALSE FALSE Change -Subsidy -Price -Alternate
260886 5/1/2009 0 0 0 FALSE FALSE Delisted
260940 5/16/1994 1/1/1998 2.86 2.86 4 FALSE TRUE New Listing
260940 1/1/1998 1/1/1999 2.86 2.86 4.6 FALSE TRUE Change +Price
260940 1/1/1999 1/1/2002 2.86 2.86 4.83 FALSE TRUE Change +Price
260940 1/1/2002 9/1/2005 2.86 2.86 5.27 FALSE TRUE Change +Price
260940 9/1/2005 0 0 0 FALSE FALSE Delisted
260983 5/16/1994 2/1/1998 23.41 23.41 23.41 FALSE FALSE New Listing
260983 2/1/1998 0 0 0 FALSE FALSE Delisted
261017 5/16/1994 4/3/1995 21 21 23.01 FALSE FALSE New Listing
261017 4/3/1995 9/1/2000 21 21 21 FALSE FALSE Change -Price
261017 9/1/2000 10/1/2005 15.99 15.99 15.99 FALSE FALSE Change -Subsidy -Price -Alternate
261017 10/1/2005 10/1/2008 19.5 19.5 19.5 FALSE FALSE Change +Subsidy +Price +Alternate
261017 10/1/2008 1/1/2012 20.85 20.85 20.85 FALSE FALSE Change +Subsidy +Price +Alternate
261017 1/1/2012 23.15 23.15 23.15 FALSE FALSE Change +Subsidy +Price +Alternate
261130 5/16/1994 10/1/2002 27.49 27.49 27.49 FALSE FALSE New Listing
261130 10/1/2002 6/1/2003 27.49 27.49 30.93 FALSE FALSE Change +Price
261130 6/1/2003 1/1/2010 13.75 13.75 13.75 FALSE FALSE Change -Subsidy -Price -Alternate
261130 1/1/2010 13.06 13.06 13.06 FALSE FALSE Change -Subsidy -Price -Alternate
261149 5/16/1994 9/1/2002 130.33 130.33 130.33 FALSE FALSE New Listing
261149 9/1/2002 1/1/2010 104.26 104.26 104.26 FALSE FALSE Change -Subsidy -Price -Alternate
261149 1/1/2010 96.5 96.5 96.5 FALSE FALSE Change -Subsidy -Price -Alternate
261165 5/16/1994 8/1/1997 25.66 25.66 25.66 FALSE FALSE New Listing
261165 8/1/1997 0 0 0 FALSE FALSE Delisted
261270 8/16/1994 8/1/2013 47.06 47.06 47.06 FALSE FALSE New Listing
261270 8/1/2013 49.41 49.41 49.41 FALSE FALSE Change +Subsidy +Price +Alternate
261289 5/16/1994 10/1/1998 3.2 3.2 3.2 FALSE FALSE New Listing
261289 10/1/1998 0 0 0 FALSE FALSE Delisted
261297 5/16/1994 3/1/2001 3.7 3.7 3.7 FALSE FALSE New Listing
261297 3/1/2001 5/1/2001 3.4 3.4 3.7 FALSE FALSE Change -Subsidy -Alternate
261297 5/1/2001 0 0 0 FALSE FALSE Delisted
261319 10/1/1996 2/1/1998 2.52 2.52 4.03 FALSE FALSE New Listing
261319 2/1/1998 0 0 0 FALSE FALSE Delisted
261327 10/1/1996 2/1/1998 12.59 12.59 20.15 FALSE FALSE New Listing
261327 2/1/1998 0 0 0 FALSE FALSE Delisted
261335 5/10/1995 2/1/1998 5.38 5.38 7.55 FALSE FALSE New Listing
261335 2/1/1998 0 0 0 FALSE FALSE Delisted
261467 5/16/1994 5/1/2001 5.5 5.5 5.5 FALSE FALSE New Listing
261467 5/1/2001 0 0 0 FALSE FALSE Delisted
261475 5/16/1994 4/1/2001 16.2 16.2 16.2 FALSE FALSE New Listing
261475 4/1/2001 0 0 0 FALSE FALSE Delisted
261505 5/16/1994 2/1/1998 35.73 35.73 35.73 FALSE FALSE New Listing
261505 2/1/1998 0 0 0 FALSE FALSE Delisted
261556 6/22/1995 8/1/2000 8.36 8.36 8.36 FALSE FALSE New Listing
261556 8/1/2000 12/1/2000 6.2 6.2 8.36 FALSE FALSE Change -Subsidy -Alternate
261556 12/1/2000 0 0 0 FALSE FALSE Delisted
261564 ######## 8/1/2000 41.8 41.8 41.75 FALSE FALSE New Listing
261564 8/1/2000 12/1/2000 31 31 41.75 FALSE FALSE Change -Subsidy -Alternate
261564 12/1/2000 0 0 0 FALSE FALSE Delisted
261572 5/27/1995 8/1/2000 10.63 10.63 10.63 FALSE FALSE New Listing
261572 8/1/2000 12/1/2000 6.66 6.66 10.63 FALSE FALSE Change -Subsidy -Alternate
261572 12/1/2000 0 0 0 FALSE FALSE Delisted
261580 5/27/1995 8/1/2000 53.15 53.15 53.15 FALSE FALSE New Listing
261580 8/1/2000 12/1/2000 33.3 33.3 53.15 FALSE FALSE Change -Subsidy -Alternate
261580 12/1/2000 0 0 0 FALSE FALSE Delisted
261645 5/16/1994 6/23/1995 44.64 44.64 44.64 FALSE FALSE New Listing
261645 6/23/1995 8/1/1995 44.64 44.64 46.8 FALSE FALSE Change +Price
261645 8/1/1995 9/1/2000 46.8 46.8 46.8 FALSE FALSE Change +Subsidy +Alternate
261645 9/1/2000 1/1/2001 22.93 22.93 22.93 FALSE FALSE Change -Subsidy -Price -Alternate
261645 1/1/2001 0 0 0 FALSE FALSE Delisted
261769 5/16/1994 9/1/1997 257.89 257.89 257.89 FALSE FALSE New Listing
261769 9/1/1997 10/1/1998 232 232 232 FALSE FALSE Change -Subsidy -Price -Alternate
261769 10/1/1998 9/1/2001 185.6 185.6 185.6 FALSE FALSE Change -Subsidy -Price -Alternate
261769 9/1/2001 9/1/2004 130 130 130 FALSE FALSE Change -Subsidy -Price -Alternate
261769 9/1/2004 12/1/2004 99 99 130 FALSE FALSE Change -Subsidy -Alternate
261769 12/1/2004 0 0 0 FALSE FALSE Delisted
261777 10/4/1997 8/1/1999 22.29 22.29 22.29 FALSE FALSE New Listing
261777 8/1/1999 8/1/2000 14.99 14.99 14.99 FALSE FALSE Change -Subsidy -Price -Alternate
261777 8/1/2000 0 0 0 FALSE FALSE Delisted
261793 10/4/1997 8/1/1999 111.45 111.45 111.45 FALSE FALSE New Listing
261793 8/1/1999 8/1/2000 74.95 74.95 74.95 FALSE FALSE Change -Subsidy -Price -Alternate
261793 8/1/2000 0 0 0 FALSE FALSE Delisted
261890 5/16/1994 6/1/1997 9.66 9.66 10.7 FALSE FALSE New Listing
261890 6/1/1997 2/1/1998 7 7 8 FALSE FALSE Change -Subsidy -Price -Alternate
261890 2/1/1998 8/1/2000 5.6 5.6 6.6 FALSE FALSE Change -Subsidy -Price -Alternate
261890 8/1/2000 12/1/2000 3.88 5.6 6.6 FALSE FALSE Change -Subsidy
261890 12/1/2000 0 0 0 FALSE FALSE Delisted
261998 4/12/1995 5/1/2000 31.4 31.4 31.4 FALSE FALSE New Listing
261998 5/1/2000 2/1/2003 31.4 31.4 34.5 FALSE FALSE Change +Price
261998 2/1/2003 0 0 0 FALSE FALSE Delisted
262005 5/16/1994 7/1/1995 12.5 12.5 13.12 FALSE FALSE New Listing
262005 7/1/1995 4/1/1998 12.5 12.5 14.44 FALSE FALSE Change +Price
262005 4/1/1998 4/1/1999 12.5 12.5 17.55 FALSE FALSE Change +Price
262005 4/1/1999 9/1/2000 12.5 12.5 18.6 FALSE FALSE Change +Price
262005 9/1/2000 0 0 0 FALSE FALSE Delisted
262102 5/16/1994 11/1/1997 30.34 30.34 30.34 FALSE FALSE New Listing
262102 11/1/1997 7/1/2001 30.34 30.34 30.67 FALSE FALSE Change +Price
262102 7/1/2001 1/1/2003 30.34 30.34 30.34 FALSE FALSE Change -Price
262102 1/1/2003 8/1/2007 49.54 49.54 49.54 FALSE FALSE Change +Subsidy +Price +Alternate
262102 8/1/2007 0 0 0 FALSE FALSE Delisted
262307 5/16/1994 5/1/2000 2.3 2.3 2.3 FALSE FALSE New Listing
262307 5/1/2000 0 0 0 FALSE FALSE Delisted
262315 5/16/1994 5/1/2000 3.91 3.91 3.91 FALSE FALSE New Listing
262315 5/1/2000 0 0 0 FALSE FALSE Delisted
262382 5/16/1994 5/10/1995 7.79 7.79 7.79 FALSE FALSE New Listing
262382 5/10/1995 10/1/1996 5.5 5.5 5.5 FALSE FALSE Change -Subsidy -Price -Alternate
262382 10/1/1996 5/1/1999 5.5 5.5 6 FALSE FALSE Change +Price
262382 5/1/1999 0 0 0 FALSE FALSE Delisted
262390 5/16/1994 5/1/1999 2.25 2.25 3 FALSE FALSE New Listing
262390 5/1/1999 0 0 0 FALSE FALSE Delisted
262404 5/16/1994 5/1/1999 6.75 6.75 6.75 FALSE FALSE New Listing
262404 5/1/1999 0 0 0 FALSE FALSE Delisted
262412 10/1/1996 6/1/1998 3.5 3.5 5 FALSE FALSE New Listing
262412 6/1/1998 0 0 0 FALSE FALSE Delisted
262420 5/16/1994 10/1/1996 11.06 11.06 11.06 FALSE FALSE New Listing
262420 10/1/1996 6/1/1998 10.5 10.5 10.5 FALSE FALSE Change -Subsidy -Price -Alternate
262420 6/1/1998 0 0 0 FALSE FALSE Delisted
262439 10/1/1996 6/1/1998 21 21 18.3 FALSE FALSE New Listing
262439 6/1/1998 0 0 0 FALSE FALSE Delisted
262447 10/1/1996 6/1/1998 42 42 30 FALSE FALSE New Listing
262447 6/1/1998 0 0 0 FALSE FALSE Delisted
262463 10/4/1997 10/6/1997 22.29 22.29 22.29 FALSE FALSE New Listing
262463 10/6/1997 0 0 0 FALSE FALSE Delisted
262471 10/4/1997 10/6/1997 111.45 111.45 111.45 FALSE FALSE New Listing
262471 10/6/1997 0 0 0 FALSE FALSE Delisted
262544 5/16/1994 2/1/1996 23.61 23.61 23.61 FALSE FALSE New Listing
262544 2/1/1996 8/1/1999 22.4 22.4 22.4 FALSE FALSE Change -Subsidy -Price -Alternate
262544 8/1/1999 2/1/2000 13.75 13.75 22.4 FALSE FALSE Change -Subsidy -Alternate
262544 2/1/2000 0 0 0 FALSE FALSE Delisted
262552 5/16/1994 2/1/1996 48.73 48.73 48.73 FALSE FALSE New Listing
262552 2/1/1996 8/1/1999 44.8 44.8 44.8 FALSE FALSE Change -Subsidy -Price -Alternate
262552 8/1/1999 2/1/2000 24.95 24.95 44.8 FALSE FALSE Change -Subsidy -Alternate
262552 2/1/2000 0 0 0 FALSE FALSE Delisted
262579 2/1/1996 8/1/1999 4.46 4.46 4.46 FALSE FALSE New Listing
262579 8/1/1999 10/1/1999 3 3 4.46 FALSE FALSE Change -Subsidy -Alternate
262579 10/1/1999 10/1/2000 2.99 2.99 2.99 FALSE FALSE Change -Subsidy -Price -Alternate
262579 10/1/2000 1/1/2004 2.99 2.99 2.99 FALSE FALSE Change
262579 1/1/2004 0 0 0 FALSE FALSE Delisted
262587 5/16/1994 2/1/1996 47.05 47.05 47.05 FALSE FALSE New Listing
262587 2/1/1996 8/1/1999 44.58 44.58 44.58 FALSE FALSE Change -Subsidy -Price -Alternate
262587 8/1/1999 10/1/1999 29.98 29.98 44.58 FALSE FALSE Change -Subsidy -Alternate
262587 10/1/1999 10/1/2000 29.98 29.98 29.98 FALSE FALSE Change -Price
262587 10/1/2000 9/1/2001 29.9 29.9 29.98 FALSE FALSE Change -Subsidy -Alternate
262587 9/1/2001 1/1/2004 29.9 29.9 29.9 FALSE FALSE Change -Price
262587 1/1/2004 0 0 0 FALSE FALSE Delisted
262609 10/1/1994 9/1/2000 2.1 2.1 2.1 FALSE FALSE New Listing
262609 9/1/2000 1/1/2001 1.32 1.32 2.1 FALSE FALSE Change -Subsidy -Alternate
262609 1/1/2001 0 0 0 FALSE FALSE Delisted
262617 5/16/1994 9/1/2000 10.5 10.5 10.5 FALSE FALSE New Listing
262617 9/1/2000 1/1/2001 6.62 6.62 10.5 FALSE FALSE Change -Subsidy -Alternate
262617 1/1/2001 0 0 0 FALSE FALSE Delisted
262625 5/16/1994 10/4/1997 32.2 32.2 32.2 FALSE FALSE New Listing
262625 10/4/1997 0 0 0 FALSE FALSE Delisted
262641 10/4/1997 2/1/1998 32.2 32.2 32.2 FALSE FALSE New Listing
262641 2/1/1998 8/1/2000 19.32 19.32 19.32 FALSE FALSE Change -Subsidy -Price -Alternate
262641 8/1/2000 5/1/2001 3.47 3.47 3.47 FALSE FALSE Change -Subsidy -Price -Alternate
262641 5/1/2001 0 0 0 FALSE FALSE Delisted
262668 5/16/1994 7/1/1997 10.5 10.5 10.5 FALSE FALSE New Listing
262668 7/1/1997 10/1/1999 10.5 10.5 10.51 FALSE FALSE Change +Price
262668 10/1/1999 0 0 0 FALSE FALSE Delisted
262692 5/16/1994 3/1/1996 15.15 15.15 15.15 FALSE FALSE New Listing
262692 3/1/1996 3/1/1999 7.4 15.15 15.15 FALSE FALSE Change -Subsidy
262692 3/1/1999 2/1/2000 5.92 15.15 15.15 FALSE FALSE Change -Subsidy
262692 2/1/2000 10/1/2001 3.55 15.15 15.15 FALSE FALSE Change -Subsidy
262692 10/1/2001 0 0 0 FALSE FALSE Delisted
262706 5/16/1994 3/1/1996 30.29 30.29 30.29 FALSE FALSE New Listing
262706 3/1/1996 8/1/1998 19.78 30.29 30.29 FALSE FALSE Change -Subsidy
262706 8/1/1998 6/1/1999 13.85 30.29 30.29 FALSE FALSE Change -Subsidy
262706 6/1/1999 2/1/2000 12.46 30.29 30.29 FALSE FALSE Change -Subsidy
262706 2/1/2000 3/1/2001 8.31 30.29 30.29 FALSE FALSE Change -Subsidy
262706 3/1/2001 0 0 0 FALSE FALSE Delisted
262714 5/16/1994 7/1/1999 12.67 12.67 12.67 FALSE FALSE New Listing
262714 7/1/1999 6/1/2003 2.99 2.99 2.99 FALSE FALSE Change -Subsidy -Price -Alternate
262714 6/1/2003 2/1/2011 2.5 2.5 2.5 FALSE FALSE Change -Subsidy -Price -Alternate
262714 2/1/2011 0 0 0 FALSE FALSE Delisted
262749 5/16/1994 1/1/2003 4.77 4.77 5.35 FALSE FALSE New Listing
262749 1/1/2003 0 0 0 FALSE FALSE Delisted
262765 5/16/1994 3/1/1995 5.54 5.54 5.54 FALSE FALSE New Listing
262765 3/1/1995 8/1/1997 4.95 4.95 4.95 FALSE FALSE Change -Subsidy -Price -Alternate
262765 8/1/1997 1/1/2003 4.95 4.95 5.54 FALSE FALSE Change +Price
262765 1/1/2003 0 0 0 FALSE FALSE Delisted
262781 5/16/1994 9/1/2003 6.9 6.9 6.9 FALSE FALSE New Listing
262781 9/1/2003 0 0 0 FALSE FALSE Delisted
262803 5/16/1994 6/1/2001 23.75 23.75 19 FALSE FALSE New Listing
262803 6/1/2001 0 0 0 FALSE FALSE Delisted
262854 5/16/1994 8/16/1994 64.44 64.44 64.44 FALSE FALSE New Listing
262854 8/16/1994 1/18/1995 45.3 45.3 45.3 FALSE FALSE Change -Subsidy -Price -Alternate
262854 1/18/1995 1/19/1995 64.44 64.44 64.44 FALSE FALSE Change +Subsidy +Price +Alternate
262854 1/19/1995 8/1/2001 45.3 45.3 48.5 FALSE FALSE Change -Subsidy -Price -Alternate
262854 8/1/2001 8/1/2003 29.95 29.95 48.5 FALSE FALSE Change -Subsidy -Alternate
262854 8/1/2003 0 0 0 FALSE FALSE Delisted
262870 5/16/1994 8/16/1994 108.61 108.61 108.61 FALSE FALSE New Listing
262870 8/16/1994 4/19/1995 105.47 105.47 105.47 FALSE FALSE Change -Subsidy -Price -Alternate
262870 4/19/1995 8/1/2001 55.6 55.6 55.6 FALSE FALSE Change -Subsidy -Price -Alternate
262870 8/1/2001 9/1/2007 38.9 38.9 55.6 FALSE FALSE Change -Subsidy -Alternate
262870 9/1/2007 0 0 0 FALSE FALSE Delisted
262943 5/16/1994 9/1/1997 10.8 10.8 10.8 FALSE TRUE New Listing
262943 9/1/1997 10/1/1997 10.8 10.8 13.59 FALSE TRUE Change +Price
262943 10/1/1997 8/1/2000 10.8 10.8 12.64 FALSE TRUE Change -Price
262943 8/1/2000 3/1/2002 10.8 10.8 14.3 FALSE TRUE Change +Price
262943 3/1/2002 7/1/2003 10.8 10.8 14.64 FALSE TRUE Change +Price
262943 7/1/2003 7/1/2004 10.8 10.8 15.04 FALSE TRUE Change +Price
262943 7/1/2004 7/1/2010 15.04 15.04 15.04 FALSE TRUE Change +Subsidy +Alternate
262943 7/1/2010 0 0 0 FALSE FALSE Delisted
263338 7/1/1997 10/1/1998 3.63 3.63 3.63 FALSE FALSE New Listing
263338 10/1/1998 0 0 0 FALSE FALSE Delisted
263346 5/16/1994 7/1/1997 18.16 18.16 18.16 FALSE FALSE New Listing
263346 7/1/1997 10/1/1998 18.15 18.15 18.15 FALSE FALSE Change -Subsidy -Price -Alternate
263346 10/1/1998 0 0 0 FALSE FALSE Delisted
263478 5/16/1994 10/1/1999 4.1 4.1 5.83 FALSE TRUE New Listing
263478 10/1/1999 0 0 0 FALSE FALSE Delisted
263486 5/16/1994 3/1/1996 18.33 18.33 18.33 FALSE FALSE New Listing
263486 3/1/1996 8/1/1996 16 16 18.33 FALSE FALSE Change -Subsidy -Alternate
263486 8/1/1996 8/1/1998 16 16 16 FALSE FALSE Change -Price
263486 8/1/1998 12 12 12 FALSE FALSE Change -Subsidy -Price -Alternate
263605 5/16/1994 4/1/1997 5.2 5.2 5.2 FALSE FALSE New Listing
263605 4/1/1997 0 0 0 FALSE FALSE Delisted
263710 5/1/2001 3/1/2005 15.38 15.38 17.05 FALSE TRUE New listing
263710 3/1/2005 1/1/2007 15.38 15.38 15.38 FALSE TRUE Change -Price
263710 1/1/2007 0 0 0 FALSE FALSE Delisted
263907 5/16/1994 12/1/1997 14.52 14.52 14.52 FALSE FALSE New Listing
263907 12/1/1997 0 0 0 FALSE FALSE Delisted
263966 5/16/1994 8/1/1998 5.02 5.02 5.02 FALSE TRUE New Listing
263966 8/1/1998 1/1/2002 5.02 5.02 10.75 FALSE TRUE Change +Price
263966 1/1/2002 5/1/2005 0 0 0 FALSE FALSE Delisted
263966 5/1/2005 5/1/2009 5.02 5.02 30.25 FALSE TRUE New Listing
263966 5/1/2009 9/1/2010 5.02 5.02 31.8 FALSE TRUE Change +Price
263966 9/1/2010 0 0 0 FALSE FALSE Delisted
263974 5/16/1994 8/1/1998 5.02 5.02 5.02 FALSE TRUE New Listing
263974 8/1/1998 1/1/2002 5.02 5.02 10.75 FALSE TRUE Change +Price
263974 1/1/2002 0 0 0 FALSE FALSE Delisted
264032 6/17/1995 6/27/1995 90.72 90.72 99.01 FALSE FALSE New Listing
264032 6/27/1995 6/1/2000 90.72 90.72 163.37 FALSE FALSE Change +Price
264032 6/1/2000 0 0 0 FALSE FALSE Delisted
264067 5/16/1994 5/1/1998 37.59 37.59 37.59 FALSE FALSE New Listing
264067 5/1/1998 7/1/2001 12.65 12.65 12.65 FALSE FALSE Change -Subsidy -Price -Alternate
264067 7/1/2001 1/1/2002 13.9 13.9 13.9 FALSE FALSE Change +Subsidy +Price +Alternate
264067 1/1/2002 0 0 0 FALSE FALSE Delisted
264075 5/16/1994 8/1/2001 4.83 4.83 4.83 FALSE FALSE New Listing
264075 8/1/2001 9/1/2002 3.38 3.38 4.83 FALSE FALSE Change -Subsidy -Alternate
264075 9/1/2002 12/1/2002 2.03 2.03 4.83 FALSE FALSE Change -Subsidy -Alternate
264075 12/1/2002 0 0 0 FALSE FALSE Delisted
264083 5/16/1994 8/1/2001 9.91 9.91 9.91 FALSE FALSE New Listing
264083 8/1/2001 9/1/2002 6.94 6.94 9.91 FALSE FALSE Change -Subsidy -Alternate
264083 9/1/2002 12/1/2002 4.16 4.16 9.91 FALSE FALSE Change -Subsidy -Alternate
264083 12/1/2002 0 0 0 FALSE FALSE Delisted
264105 10/1/1994 7/1/1999 65 65 63 FALSE FALSE New Listing
264105 7/1/1999 11/1/1999 13.75 13.75 65 FALSE FALSE Change -Subsidy +Price -Alternate
264105 11/1/1999 0 0 0 FALSE FALSE Delisted
264121 5/16/1994 6/16/1995 21.16 21.16 21.16 FALSE FALSE New Listing
264121 6/16/1995 1/1/2013 21.15 21.15 21.15 FALSE FALSE Change -Subsidy -Price -Alternate
264121 1/1/2013 0 0 0 FALSE FALSE Delisted
264172 5/16/1994 5/1/2000 380 380 380 FALSE FALSE New Listing
264172 5/1/2000 11/1/2000 78.96 78.96 78.96 FALSE FALSE Change -Subsidy -Price -Alternate
264172 11/1/2000 0 0 0 FALSE FALSE Delisted
264180 5/27/1995 11/1/2000 2.98 2.98 2.98 FALSE FALSE New Listing
264180 11/1/2000 0 0 0 FALSE FALSE Delisted
264199 5/27/1995 8/1/1999 13.16 13.16 13.16 FALSE FALSE New Listing
264199 8/1/1999 0 0 0 FALSE FALSE Delisted
264210 5/27/1995 4/1/2002 30.69 30.69 30.69 FALSE FALSE New Listing
264210 4/1/2002 0 0 0 FALSE FALSE Delisted
264229 5/27/1995 8/1/2012 6.03 6.03 6.03 FALSE FALSE New Listing
264229 8/1/2012 7.5 7.5 7.5 FALSE FALSE Change +Subsidy +Price +Alternate
264318 6/16/1995 7/1/1998 16.52 16.52 16.52 FALSE FALSE New Listing
264318 7/1/1998 9/1/2006 16.52 16.52 17.6 FALSE FALSE Change +Price
264318 9/1/2006 17.6 17.6 17.6 FALSE FALSE Change +Subsidy +Alternate
264407 5/1/1999 8/1/2000 23.25 23.25 34.35 FALSE FALSE New Listing
264407 8/1/2000 0 0 0 FALSE FALSE Delisted
264415 8/16/1994 2/1/1996 4.5 4.5 4.5 FALSE TRUE New Listing
264415 2/1/1996 7/1/1997 4.5 4.5 8.6 FALSE TRUE Change +Price
264415 7/1/1997 12/1/2003 4.5 4.5 4.5 FALSE TRUE Change -Price
264415 12/1/2003 3/1/2004 4.39 4.39 4.5 FALSE TRUE Change -Subsidy -Alternate
264415 3/1/2004 7/1/2009 0 0 0 FALSE FALSE Delisted
264415 7/1/2009 12/1/2012 4.05 4.05 4.05 FALSE TRUE New Listing
264415 12/1/2012 3/1/2013 3.8 3.8 4.05 FALSE TRUE Change -Subsidy -Alternate
264415 3/1/2013 0 0 0 FALSE FALSE Delisted
264423 5/16/1994 4/1/1997 2.16 2.16 3.4 FALSE FALSE New Listing
264423 4/1/1997 0 0 0 FALSE FALSE Delisted
264512 5/16/1994 4/1/2001 20.75 20.75 20.75 FALSE FALSE New Listing
264512 4/1/2001 6/1/2001 0 0 0 FALSE FALSE Delisted
264512 6/1/2001 12/1/2001 20.75 20.75 20.75 FALSE FALSE New listing
264512 12/1/2001 0 0 0 FALSE FALSE Delisted
264539 5/16/1994 3/1/1995 8.52 8.52 8.95 FALSE FALSE New Listing
264539 3/1/1995 7/1/1995 8.52 8.52 10.22 FALSE FALSE Change +Price
264539 7/1/1995 3/1/2001 10.22 10.22 10.22 FALSE FALSE Change +Subsidy +Alternate
264539 3/1/2001 7/1/2001 10.22 10.22 11.24 FALSE FALSE Change +Price
264539 7/1/2001 11/1/2004 11.24 11.24 11.24 FALSE FALSE Change +Subsidy +Alternate
264539 11/1/2004 12.36 12.36 12.36 FALSE FALSE Change +Subsidy +Price +Alternate
264547 5/16/1994 3/1/2001 39.79 39.79 39.79 FALSE FALSE New Listing
264547 3/1/2001 7/1/2001 39.79 39.79 43.76 FALSE FALSE Change +Price
264547 7/1/2001 11/1/2004 43.76 43.76 43.76 FALSE FALSE Change +Subsidy +Alternate
264547 11/1/2004 48.14 48.14 48.14 FALSE FALSE Change +Subsidy +Price +Alternate
264598 5/16/1994 9/1/2003 13 13 13 FALSE FALSE New Listing
264598 9/1/2003 0 0 0 FALSE FALSE Delisted
264709 7/1/2001 3/1/2002 11.92 11.92 11.92 FALSE FALSE New listing
264709 3/1/2002 0 0 0 FALSE FALSE Delisted
264776 5/16/1994 7/1/1995 13.68 13.68 13.68 FALSE TRUE New Listing
264776 7/1/1995 8/1/1996 12.31 12.31 12.31 FALSE TRUE Change -Subsidy -Price -Alternate
264776 8/1/1996 7/1/1997 11.08 11.08 11.08 FALSE TRUE Change -Subsidy -Price -Alternate
264776 7/1/1997 8/1/1998 10.19 10.19 11.08 FALSE TRUE Change -Subsidy -Alternate
264776 8/1/1998 3/1/1999 9.17 9.17 9.17 FALSE TRUE Change -Subsidy -Price -Alternate
264776 3/1/1999 8/1/2003 8.71 8.71 8.71 FALSE TRUE Change -Subsidy -Price -Alternate
264776 8/1/2003 11/1/2003 4.99 4.99 4.99 FALSE TRUE Change -Subsidy -Price -Alternate
264776 11/1/2003 0 0 0 FALSE FALSE Delisted
264792 10/1/1997 11/1/1997 23.14 23.14 24.36 FALSE FALSE New Listing
264792 11/1/1997 6/1/1998 23.14 23.14 23.14 FALSE FALSE Change -Price
264792 6/1/1998 6/1/2000 18.3 18.3 18.3 FALSE FALSE Change -Subsidy -Price -Alternate
264792 6/1/2000 7/1/2000 16.2 16.2 18.3 FALSE FALSE Change -Subsidy -Alternate
264792 7/1/2000 12/1/2001 16.2 16.2 16.2 FALSE FALSE Change -Price
264792 12/1/2001 7/1/2003 16.2 16.2 18.3 FALSE FALSE Change +Price
264792 7/1/2003 8/1/2003 17.5 17.5 18.3 FALSE FALSE Change +Subsidy +Alternate
264792 8/1/2003 0 0 0 FALSE FALSE Delisted
264881 5/16/1994 11/1/1997 5.72 5.72 10.32 FALSE FALSE New Listing
264881 11/1/1997 0 0 0 FALSE FALSE Delisted
264903 7/1/1997 6/1/2002 7.28 7.28 9.4 FALSE TRUE New Listing
264903 6/1/2002 3/1/2003 6.99 6.99 9.05 FALSE TRUE Change -Subsidy -Price -Alternate
264903 3/1/2003 11/1/2003 6.99 6.99 6.99 FALSE TRUE Change -Price
264903 11/1/2003 0 0 0 FALSE FALSE Delisted
264911 5/20/1995 5/1/1998 5.4 5.4 5.4 FALSE FALSE New Listing
264911 5/1/1998 0 0 0 FALSE FALSE Delisted
264962 5/16/1994 7.4 7.4 7.4 FALSE FALSE New Listing
265020 5/16/1994 7/1/1999 3.81 3.81 3.81 FALSE TRUE New Listing
265020 7/1/1999 11/1/1999 2.67 2.67 3.81 FALSE TRUE Change -Subsidy -Alternate
265020 11/1/1999 0 0 0 FALSE FALSE Delisted
265039 5/16/1994 7/1/1999 4.08 4.08 4.08 FALSE TRUE New Listing
265039 7/1/1999 11/1/1999 2.86 2.86 4.08 FALSE TRUE Change -Subsidy -Alternate
265039 11/1/1999 0 0 0 FALSE FALSE Delisted
265055 5/16/1994 7/1/1999 5.23 5.23 5.23 FALSE TRUE New Listing
265055 7/1/1999 11/1/1999 3.66 3.66 5.23 FALSE TRUE Change -Subsidy -Alternate
265055 11/1/1999 0 0 0 FALSE FALSE Delisted
265071 5/16/1994 7/1/1999 6.63 6.63 6.63 FALSE TRUE New Listing
265071 7/1/1999 11/1/1999 4.64 4.64 6.63 FALSE TRUE Change -Subsidy -Alternate
265071 11/1/1999 0 0 0 FALSE FALSE Delisted
265128 5/16/1994 7/1/1999 7.66 7.66 7.66 FALSE TRUE New Listing
265128 7/1/1999 11/1/1999 5.36 5.36 7.66 FALSE TRUE Change -Subsidy -Alternate
265128 11/1/1999 0 0 0 FALSE FALSE Delisted
265136 5/16/1994 7/1/1999 10.92 10.92 10.92 FALSE TRUE New Listing
265136 7/1/1999 11/1/1999 7.64 7.64 10.92 FALSE TRUE Change -Subsidy -Alternate
265136 11/1/1999 0 0 0 FALSE FALSE Delisted
265233 6/1/1995 2/1/1998 66.22 66.22 66.22 FALSE FALSE New Listing
265233 2/1/1998 4/1/2001 29.8 29.8 29.8 FALSE FALSE Change -Subsidy -Price -Alternate
265233 4/1/2001 7/1/2013 20 20 20 FALSE FALSE Change -Subsidy -Price -Alternate
265233 7/1/2013 0 0 0 FALSE FALSE Delisted
265284 5/23/1995 2/1/1996 3.35 3.35 3.52 FALSE FALSE New Listing
265284 2/1/1996 9/1/2000 3.83 3.83 3.83 FALSE FALSE Change +Subsidy +Price +Alternate
265284 9/1/2000 9/1/2010 3.72 3.72 3.72 FALSE FALSE Change -Subsidy -Price -Alternate
265284 9/1/2010 8/1/2013 3.99 3.99 3.99 FALSE FALSE Change +Subsidy +Price +Alternate
265284 8/1/2013 4.99 4.99 4.99 FALSE FALSE Change +Subsidy +Price +Alternate
265292 5/23/1995 2/1/1996 7.06 7.06 7.42 FALSE FALSE New Listing
265292 2/1/1996 9/1/2000 8.1 8.1 8.1 FALSE FALSE Change +Subsidy +Price +Alternate
265292 9/1/2000 11/1/2002 7.85 7.85 7.85 FALSE FALSE Change -Subsidy -Price -Alternate
265292 11/1/2002 0 0 0 FALSE FALSE Delisted
265306 5/23/1995 2/1/1996 12.02 12.02 12.02 FALSE FALSE New Listing
265306 2/1/1996 9/1/2000 13.7 13.7 13.7 FALSE FALSE Change +Subsidy +Price +Alternate
265306 9/1/2000 11/1/2002 13.28 13.28 13.28 FALSE FALSE Change -Subsidy -Price -Alternate
265306 11/1/2002 0 0 0 FALSE FALSE Delisted
265322 5/16/1994 9/1/1996 5.89 5.89 5.89 FALSE FALSE New Listing
265322 9/1/1996 4/1/2002 6.4 6.4 6.4 FALSE FALSE Change +Subsidy +Price +Alternate
265322 4/1/2002 0 0 0 FALSE FALSE Delisted
265330 5/16/1994 9/1/1996 16.07 16.07 16.07 FALSE FALSE New Listing
265330 9/1/1996 4/1/2002 17.45 17.45 17.45 FALSE FALSE Change +Subsidy +Price +Alternate
265330 4/1/2002 0 0 0 FALSE FALSE Delisted
265349 5/16/1994 10/1/2002 45 45 45 FALSE FALSE New Listing
265349 10/1/2002 7/1/2006 39.16 39.16 39.16 FALSE FALSE Change -Subsidy -Price -Alternate
265349 7/1/2006 10/1/2009 16.45 16.45 16.45 FALSE FALSE Change -Subsidy -Price -Alternate
265349 10/1/2009 8/1/2012 20.8 20.8 20.8 FALSE FALSE Change +Subsidy +Price +Alternate
265349 8/1/2012 7/1/2013 18 18 18 FALSE FALSE Change -Subsidy -Price -Alternate
265349 7/1/2013 0 0 0 FALSE FALSE Delisted
265357 5/16/1994 10/1/2002 80 80 80 FALSE FALSE New Listing
265357 10/1/2002 7/1/2006 70.95 70.95 70.95 FALSE FALSE Change -Subsidy -Price -Alternate
265357 7/1/2006 8/1/2012 42.57 42.57 42.57 FALSE FALSE Change -Subsidy -Price -Alternate
265357 8/1/2012 37.5 37.5 37.5 FALSE FALSE Change -Subsidy -Price -Alternate
265373 5/16/1994 2/1/2001 13.13 13.13 13.13 FALSE FALSE New Listing
265373 2/1/2001 0 0 0 FALSE FALSE Delisted
265381 5/16/1994 2/1/2001 65.65 65.65 65.65 FALSE FALSE New Listing
265381 2/1/2001 0 0 0 FALSE FALSE Delisted
265438 5/16/1994 2/1/1999 20 20 20 FALSE FALSE New Listing
265438 2/1/1999 0 0 0 FALSE FALSE Delisted
265586 5/16/1994 5/11/1995 27.5 27.5 27.5 FALSE FALSE New Listing
265586 5/11/1995 6/27/1995 33 33 33 FALSE FALSE Change +Subsidy +Price +Alternate
265586 6/27/1995 9/1/1995 27.5 27.5 27.5 FALSE FALSE Change -Subsidy -Price -Alternate
265586 9/1/1995 9/1/2001 33 33 33 FALSE FALSE Change +Subsidy +Price +Alternate
265586 9/1/2001 3/1/2004 23.1 23.1 33 FALSE FALSE Change -Subsidy -Alternate
265586 3/1/2004 0 0 0 FALSE FALSE Delisted
265594 12/1/1994 6/1/1996 7.32 7.32 7.32 FALSE TRUE New Listing
265594 6/1/1996 8/1/1998 7.32 7.32 8.21 FALSE TRUE Change +Price
265594 8/1/1998 11/1/2000 7.32 7.32 9.44 FALSE TRUE Change +Price
265594 11/1/2000 0 0 0 FALSE FALSE Delisted
265659 5/16/1994 1/1/1999 14.46 14.46 14.46 FALSE FALSE New Listing
265659 1/1/1999 0 0 0 FALSE FALSE Delisted
266124 5/16/1994 2/1/1997 3.71 3.71 7.1 FALSE TRUE New Listing
266124 2/1/1997 7/1/1997 3.71 3.71 9.07 FALSE TRUE Change +Price
266124 7/1/1997 0 0 0 FALSE FALSE Delisted
266167 5/16/1994 1/9/1995 19.48 19.48 19.48 FALSE FALSE New Listing
266167 1/9/1995 4/1/1998 58.45 58.45 58.45 FALSE FALSE Change +Subsidy +Price +Alternate
266167 4/1/1998 12/1/2011 58.44 58.44 58.44 FALSE FALSE Change -Subsidy -Price -Alternate
266167 12/1/2011 0 0 0 FALSE FALSE Delisted
266175 5/16/1994 11/1/1997 52.5 52.5 59.08 FALSE FALSE New Listing
266175 11/1/1997 9/1/2000 52.5 52.5 59.07 FALSE FALSE Change -Price
266175 9/1/2000 1/1/2001 46.5 46.5 59.07 FALSE FALSE Change -Subsidy -Alternate
266175 1/1/2001 0 0 0 FALSE FALSE Delisted
266507 5/16/1994 12/1/1995 47 47 61.11 FALSE FALSE New Listing
266507 12/1/1995 10/1/2000 56.4 56.4 73.87 FALSE FALSE Change +Subsidy +Price +Alternate
266507 10/1/2000 0 0 0 FALSE FALSE Delisted
266949 12/1/1999 2/1/2000 5.04 5.04 5.04 FALSE FALSE New Listing
266949 2/1/2000 8/1/2002 2.92 2.92 2.92 FALSE FALSE Change -Subsidy -Price -Alternate
266949 8/1/2002 3/1/2003 3.43 3.43 3.43 FALSE FALSE Change +Subsidy +Price +Alternate
266949 3/1/2003 6/1/2003 2.75 2.75 3.43 FALSE FALSE Change -Subsidy -Alternate
266949 6/1/2003 0 0 0 FALSE FALSE Delisted
266973 5/16/1994 7/1/1997 4.1 4.1 4.1 FALSE FALSE New Listing
266973 7/1/1997 11/1/2005 4.1 4.1 4.34 FALSE FALSE Change +Price -OP
266973 11/1/2005 1/1/2011 4.34 4.34 4.34 FALSE FALSE Change +Subsidy +Alternate -OP
266973 1/1/2011 0 0 0 FALSE FALSE Delisted
267007 5/16/1994 6/27/1995 28 28 28 FALSE TRUE New Listing
267007 6/27/1995 1/1/1997 30.23 30.23 30.23 FALSE TRUE Change +Subsidy +Price +Alternate
267007 1/1/1997 9/1/2000 30.23 30.23 33.63 FALSE TRUE Change +Price
267007 9/1/2000 0 0 0 FALSE FALSE Delisted
267201 4/1/1998 3/1/1999 2.17 2.17 3.04 FALSE FALSE New Listing
267201 3/1/1999 12/1/1999 2.17 2.17 4.01 FALSE FALSE Change +Price
267201 12/1/1999 2/1/2000 2.17 2.17 5.2 FALSE FALSE Change +Price
267201 2/1/2000 10/1/2001 2.17 2.17 5.03 FALSE FALSE Change -Price
267201 10/1/2001 3/1/2002 2.17 2.17 5.23 FALSE FALSE Change +Price
267201 3/1/2002 11/1/2003 2.17 2.17 5.49 FALSE FALSE Change +Price
267201 11/1/2003 8/1/2007 2.17 2.17 6.04 FALSE FALSE Change +Price
267201 8/1/2007 2.17 2.17 6.16 FALSE FALSE Change +Price
267236 12/1/1999 2/1/2000 8.53 8.53 8.53 FALSE FALSE New Listing
267236 2/1/2000 8/1/2002 4.95 4.95 4.95 FALSE FALSE Change -Subsidy -Price -Alternate
267236 8/1/2002 3/1/2003 5.89 5.89 5.89 FALSE FALSE Change +Subsidy +Price +Alternate
267236 3/1/2003 6/1/2003 4.75 4.75 5.89 FALSE FALSE Change -Subsidy -Alternate
267236 6/1/2003 0 0 0 FALSE FALSE Delisted
267430 9/1/1995 11/1/1997 2.5 2.5 2.5 FALSE TRUE New Listing
267430 11/1/1997 9/1/2001 2.5 2.5 2.75 FALSE FALSE Change +Price -OP
267430 9/1/2001 2.5 2.5 2.5 FALSE FALSE Change -Price
267473 5/16/1994 4/1/1998 14.85 14.85 14.85 FALSE FALSE New Listing
267473 4/1/1998 5/1/1998 14.85 14.85 19.65 FALSE FALSE Change +Price
267473 5/1/1998 4/1/2000 19.65 19.65 19.65 FALSE FALSE Change +Subsidy +Alternate
267473 4/1/2000 5/1/2000 19.65 19.65 21 FALSE FALSE Change +Price
267473 5/1/2000 2/1/2007 21 21 21 FALSE FALSE Change +Subsidy +Alternate
267473 2/1/2007 1/1/2010 20.5 20.5 20.5 FALSE FALSE Change -Subsidy -Price -Alternate
267473 1/1/2010 20 20 20 FALSE FALSE Change -Subsidy -Price -Alternate
267538 6/17/1995 6/27/1995 75.6 75.6 82.51 FALSE FALSE New Listing
267538 6/27/1995 6/1/2000 75.6 75.6 136.14 FALSE FALSE Change +Price
267538 6/1/2000 0 0 0 FALSE FALSE Delisted
267570 5/16/1994 10/1/1998 5.2 5.2 5.2 FALSE FALSE New Listing
267570 10/1/1998 0 0 0 FALSE FALSE Delisted
267600 5/16/1994 1/1/2004 24.32 24.32 24.32 FALSE FALSE New Listing
267600 1/1/2004 0 0 0 FALSE FALSE Delisted
267961 5/16/1994 6/24/1995 3.51 3.51 3.51 FALSE TRUE New Listing
267961 6/24/1995 5/1/2001 3.51 3.51 8.36 FALSE TRUE Change +Price
267961 5/1/2001 0 0 0 FALSE FALSE Delisted
268003 5/16/1994 12/1/1997 10.57 10.57 11.5 FALSE FALSE New Listing
268003 12/1/1997 0 0 0 FALSE FALSE Delisted
268011 5/16/1994 12/1/1997 21.21 21.21 23 FALSE FALSE New Listing
268011 12/1/1997 0 0 0 FALSE FALSE Delisted
268070 5/16/1994 12/1/1997 27.59 27.59 27.59 FALSE FALSE New Listing
268070 12/1/1997 1/1/1998 8.7 8.7 30 FALSE FALSE Change -Subsidy +Price -Alternate
268070 1/1/1998 11/1/1999 8.7 8.7 18.43 FALSE FALSE Change -Price
268070 11/1/1999 4/1/2001 5.94 5.94 18.43 FALSE FALSE Change -Subsidy -Alternate
268070 4/1/2001 10/1/2009 5.6 5.6 18.43 FALSE FALSE Change -Subsidy -Alternate
268070 10/1/2009 5.6 5.6 20.53 FALSE FALSE Change +Price
268194 5/16/1994 8/1/1999 21.67 21.67 22.37 FALSE FALSE New Listing
268194 8/1/1999 12/1/1999 6.5 6.5 22.37 FALSE FALSE Change -Subsidy -Alternate
268194 12/1/1999 0 0 0 FALSE FALSE Delisted
268321 5/16/1994 5/19/1995 1.48 1.48 2.48 FALSE TRUE New Listing
268321 5/19/1995 12/1/1997 1.48 1.48 3.52 FALSE TRUE Change +Price
268321 12/1/1997 0 0 0 FALSE FALSE Delisted
268380 12/1/1994 9/1/1997 29 29 29.9 FALSE TRUE New Listing
268380 9/1/1997 9/1/1998 28.42 28.42 29.9 FALSE TRUE Change -Subsidy -Alternate
268380 9/1/1998 2/1/2000 27.85 27.85 29.9 FALSE TRUE Change -Subsidy -Alternate
268380 2/1/2000 0 0 0 FALSE FALSE Delisted
268887 8/16/1994 2/1/1997 6.4 6.4 6.4 FALSE FALSE New Listing
268887 2/1/1997 0 0 0 FALSE FALSE Delisted
268925 5/16/1994 2/1/1998 12.4 12.4 12.4 FALSE FALSE New Listing
268925 2/1/1998 0 0 0 FALSE FALSE Delisted
269026 5/16/1994 5/11/1995 0.53 0.53 0.55 FALSE FALSE New Listing
269026 5/11/1995 2/1/2000 0.53 0.53 1.99 FALSE FALSE Change +Price
269026 2/1/2000 8/1/2001 0.43 0.43 1.99 FALSE FALSE Change -Subsidy -Alternate
269026 8/1/2001 2/1/2002 0.43 0.43 2.05 FALSE FALSE Change +Price
269026 2/1/2002 0 0 0 FALSE FALSE Delisted
269328 5/16/1994 8/1/1996 22.4 22.4 22.4 FALSE FALSE New Listing
269328 8/1/1996 9/1/1997 22.4 22.4 24.5 FALSE FALSE Change +Price
269328 9/1/1997 1/1/1998 22.4 22.4 26.95 FALSE FALSE Change +Price
269328 1/1/1998 7/1/1998 22.4 22.4 31.05 FALSE FALSE Change +Price
269328 7/1/1998 10/1/2000 22.4 22.4 34.5 FALSE FALSE Change +Price
269328 10/1/2000 8/1/2004 22.4 22.4 39.7 FALSE FALSE Change +Price
269328 8/1/2004 7/1/2006 22.4 22.4 49.85 FALSE FALSE Change +Price
269328 7/1/2006 4/1/2009 22.4 22.4 76.25 FALSE FALSE Change +Price
269328 4/1/2009 9/1/2011 22.4 22.4 86.54 FALSE FALSE Change +Price
269328 9/1/2011 2/1/2013 22.4 22.4 95.87 FALSE FALSE Change +Price
269328 2/1/2013 22.4 22.4 101.61 FALSE FALSE Change +Price
269549 5/16/1994 12/1/1997 19.25 19.25 19.25 FALSE TRUE New Listing
269549 12/1/1997 0 0 0 FALSE FALSE Delisted
269557 5/16/1994 6/1/1999 32.22 32.22 32.22 FALSE TRUE New Listing
269557 6/1/1999 0 0 0 FALSE FALSE Delisted
269603 5/16/1994 10/1/2002 11.95 11.95 11.95 FALSE FALSE New Listing
269603 10/1/2002 0 0 0 FALSE FALSE Delisted
269689 5/16/1994 7/1/2000 2 2 2 FALSE FALSE New Listing
269689 7/1/2000 7/1/2007 2 2 4.05 FALSE FALSE Change +Price
269689 7/1/2007 11/1/2009 2 2 4.65 FALSE FALSE Change +Price
269689 11/1/2009 7/1/2013 2 2 4.98 FALSE FALSE Change +Price
269689 7/1/2013 4.98 4.98 4.98 FALSE FALSE Change +Subsidy +Alternate
269859 5/16/1994 8/1/2000 15 15 15 FALSE FALSE New Listing
269859 8/1/2000 0 0 0 FALSE FALSE Delisted
269905 1/11/1995 3/1/1996 4.8 4.8 4.8 FALSE FALSE New Listing
269905 3/1/1996 5/1/1996 3.96 3.96 4.8 FALSE FALSE Change -Subsidy -Alternate
269905 5/1/1996 8/1/1998 3.96 3.96 3.96 FALSE FALSE Change -Price
269905 8/1/1998 6/1/1999 2.77 2.77 2.77 FALSE FALSE Change -Subsidy -Price -Alternate
269905 6/1/1999 2/1/2000 2.49 2.49 2.77 FALSE FALSE Change -Subsidy -Alternate
269905 2/1/2000 12/1/2000 1.66 2.77 2.77 FALSE FALSE Change -Subsidy +Alternate
269905 12/1/2000 3/1/2001 1.66 3.5 3.5 FALSE FALSE Change +Price +Alternate
269905 3/1/2001 7/1/2001 1.5 3.5 3.5 FALSE FALSE Change -Subsidy
269905 7/1/2001 1/1/2007 1.5 3.67 3.67 FALSE FALSE Change +Price +Alternate
269905 1/1/2007 1.5 8 8 FALSE FALSE Change +Price +Alternate
270377 5/16/1994 4/1/2010 2.35 2.35 3 FALSE FALSE New Listing
270377 4/1/2010 3 3 3 FALSE FALSE Change +Subsidy +Alternate
270385 5/16/1994 9/1/2001 2.38 2.38 3.47 FALSE FALSE New Listing
270385 9/1/2001 12/1/2001 1.98 1.98 3.47 FALSE FALSE Change -Subsidy -Alternate
270385 12/1/2001 4/1/2010 0 0 0 FALSE FALSE Delisted
270385 4/1/2010 3 3 3 FALSE FALSE New Listing
270393 5/16/1994 9/1/2001 19.85 19.85 19.85 FALSE FALSE New Listing
270393 9/1/2001 12/1/2001 16.5 16.5 19.85 FALSE FALSE Change -Subsidy -Alternate
270393 12/1/2001 0 0 0 FALSE FALSE Delisted
270407 5/16/1994 5/1/2001 79.4 79.4 79.4 FALSE FALSE New Listing
270407 5/1/2001 0 0 0 FALSE FALSE Delisted
270415 5/16/1994 9/1/2003 1.32 1.32 1.32 FALSE FALSE New Listing
270415 9/1/2003 2/1/2005 1.32 1.32 3.31 FALSE FALSE Change +Price
270415 2/1/2005 0 0 0 FALSE FALSE Delisted
270423 5/16/1994 11/1/2000 4.41 4.41 4.41 FALSE FALSE New Listing
270423 11/1/2000 2/1/2005 4.41 4.41 7.14 FALSE FALSE Change +Price
270423 2/1/2005 0 0 0 FALSE FALSE Delisted
270555 8/31/1997 3/1/1998 21.66 21.66 21.66 FALSE FALSE New Listing
270555 3/1/1998 0 0 0 FALSE FALSE Delisted
270563 5/16/1994 9/1/2001 4.13 4.13 4.13 FALSE TRUE New Listing
270563 9/1/2001 9/1/2002 4.13 4.13 4.41 FALSE TRUE Change +Price
270563 9/1/2002 12/1/2002 3.6 3.6 4.41 FALSE TRUE Change -Subsidy -Alternate
270563 12/1/2002 9/1/2003 0 0 0 FALSE FALSE Delisted
270563 9/1/2003 11/1/2011 4.41 4.41 4.41 FALSE TRUE New Listing
270563 11/1/2011 0 0 0 FALSE FALSE Delisted
270598 5/16/1994 8/1/1998 3.7 3.7 3.7 FALSE FALSE New Listing
270598 8/1/1998 2/1/2002 3.7 3.7 5 FALSE FALSE Change +Price
270598 2/1/2002 0 0 0 FALSE FALSE Delisted
270687 6/24/1995 12/1/2002 2.2 2.2 2.82 FALSE FALSE New Listing
270687 12/1/2002 8/1/2006 2.95 2.95 2.95 FALSE FALSE Change +Subsidy +Price +Alternate
270687 8/1/2006 0 0 0 FALSE FALSE Delisted
270695 6/24/1995 8/1/2006 22 22 24.95 FALSE FALSE New Listing
270695 8/1/2006 0 0 0 FALSE FALSE Delisted
270849 4/12/1995 8/1/1999 0.07 0.07 0.07 TRUE FALSE New Listing
270849 8/1/1999 0 0 0 FALSE FALSE Delisted
270865 8/1/1999 12/1/1999 8.05 8.05 10.6 FALSE FALSE New Listing
270865 12/1/1999 12/1/2000 8.05 8.05 8.8 FALSE FALSE Change -Price
270865 12/1/2000 7/1/2003 8.05 8.05 10.6 FALSE FALSE Change +Price
270865 7/1/2003 0 0 0 FALSE FALSE Delisted
270903 4/12/1995 8/1/1999 0 0 0 TRUE FALSE New Listing
270903 8/1/1999 0 0 0 FALSE FALSE Delisted
270954 8/1/1999 12/1/1999 21.2 21.2 37 FALSE FALSE New Listing
270954 12/1/1999 11/1/2000 21.2 21.2 30.71 FALSE FALSE Change -Price
270954 11/1/2000 7/1/2003 21.2 21.2 37 FALSE FALSE Change +Price
270954 7/1/2003 0 0 0 FALSE FALSE Delisted
270989 8/1/1999 5/1/2002 34.32 34.32 34.32 FALSE FALSE New Listing
270989 5/1/2002 4/1/2003 29.52 29.52 29.52 FALSE FALSE Change -Subsidy -Price -Alternate
270989 4/1/2003 9/1/2004 29.52 29.52 37.95 FALSE FALSE Change +Price
270989 9/1/2004 7/1/2008 29.52 29.52 55.63 FALSE FALSE Change +Price
270989 7/1/2008 1/1/2009 15 15 55.63 FALSE FALSE Change -Subsidy -Alternate
270989 1/1/2009 0 0 0 FALSE FALSE Delisted
271004 5/16/1994 2/1/2000 9.59 9.59 9.59 FALSE FALSE New Listing
271004 2/1/2000 0 0 0 FALSE FALSE Delisted
271012 10/1/2004 1/1/2005 17.5 17.5 17.5 FALSE FALSE New listing
271012 1/1/2005 1/1/2008 11.99 11.99 17.5 FALSE FALSE Change -Subsidy -Alternate
271012 1/1/2008 7/1/2008 11.99 11.99 29.5 FALSE FALSE Change +Price
271012 7/1/2008 9.8 9.8 29.5 FALSE FALSE Change -Subsidy -Alternate
271020 5/16/1994 1/9/1995 90.7 90.7 90.7 FALSE FALSE New Listing
271020 1/9/1995 5/10/1995 90.7 90.7 95.44 FALSE FALSE Change +Price
271020 5/10/1995 2/1/1997 90.7 90.7 90.7 FALSE FALSE Change -Price
271020 2/1/1997 0 0 0 FALSE FALSE Delisted
271314 10/4/1997 5/1/1998 8.3 8.3 10.79 FALSE FALSE New Listing
271314 5/1/1998 8/1/1998 3.27 3.27 10.79 FALSE FALSE Change -Subsidy -Alternate
271314 8/1/1998 0 0 0 FALSE FALSE Delisted
271373 6/27/1995 7/1/2000 5.29 5.29 5.29 FALSE FALSE New Listing
271373 7/1/2000 1/1/2001 5.29 5.29 6.08 FALSE FALSE Change +Price
271373 1/1/2001 0 0 0 FALSE FALSE Delisted
271454 5/16/1994 8/1/1995 6.56 6.56 6.56 FALSE FALSE New Listing
271454 8/1/1995 1/1/1997 6.56 6.56 8.65 FALSE FALSE Change +Price
271454 1/1/1997 11/1/1997 6.56 6.56 9.55 FALSE FALSE Change +Price
271454 11/1/1997 8/1/2001 6.56 6.56 10.05 FALSE FALSE Change +Price
271454 8/1/2001 8/1/2005 18.95 18.95 18.95 FALSE FALSE Change +Subsidy +Price +Alternate
271454 8/1/2005 5/1/2008 26 26 26 FALSE FALSE Change +Subsidy +Price +Alternate
271454 5/1/2008 0 0 0 FALSE FALSE Delisted
271691 5/16/1994 5/1/2000 9.46 11.28 11.28 FALSE FALSE New Listing
271691 5/1/2000 9/1/2001 9.46 12.1 12.1 FALSE FALSE Change +Price +Alternate
271691 9/1/2001 9/1/2005 8.47 8.47 8.47 FALSE FALSE Change -Subsidy -Price -Alternate
271691 9/1/2005 1/1/2010 8.05 8.05 8.05 FALSE FALSE Change -Subsidy -Price -Alternate
271691 1/1/2010 7/1/2013 7.15 7.15 7.15 FALSE FALSE Change -Subsidy -Price -Alternate
271691 7/1/2013 7 7 7 FALSE FALSE Change -Subsidy -Price -Alternate
272175 5/16/1994 3/1/2001 71.6 71.6 71.6 FALSE FALSE New Listing
272175 3/1/2001 4/1/2002 71.6 71.6 78.76 FALSE FALSE Change +Price
272175 4/1/2002 11/1/2003 71.6 71.6 86.64 FALSE FALSE Change +Price
272175 11/1/2003 0 0 0 FALSE FALSE Delisted
272353 5/16/1994 2/1/1996 4.42 4.42 5.38 FALSE TRUE New Listing
272353 2/1/1996 3/1/1998 4.42 4.42 5.75 FALSE TRUE Change +Price
272353 3/1/1998 0 0 0 FALSE FALSE Delisted
272396 4/12/1995 8/1/1999 0 0 0 TRUE FALSE New Listing
272396 8/1/1999 0 0 0 FALSE FALSE Delisted
272426 4/12/1995 8/1/1999 0 0 0 TRUE FALSE New Listing
272426 8/1/1999 0 0 0 FALSE FALSE Delisted
273104 5/16/1994 7/1/1997 5.19 5.19 5.19 FALSE FALSE New Listing
273104 7/1/1997 3/1/1998 5.18 5.18 5.18 FALSE FALSE Change -Subsidy -Price -Alternate
273104 3/1/1998 0 0 0 FALSE FALSE Delisted
273147 9/1/1997 9/1/1998 56.84 56.84 58 FALSE TRUE New Listing
273147 9/1/1998 9/1/1999 55.7 55.7 58 FALSE TRUE Change -Subsidy -Alternate
273147 9/1/1999 0 0 0 FALSE FALSE Delisted
273155 4/11/1995 6/10/1995 47.87 47.87 61.42 FALSE FALSE New Listing
273155 6/10/1995 5/1/2001 47.87 47.87 47.87 FALSE FALSE Change -Price
273155 5/1/2001 1/1/2003 47.87 47.87 69 FALSE FALSE Change +Price
273155 1/1/2003 4/1/2003 46.2 46.2 69 FALSE FALSE Change -Subsidy -Alternate
273155 4/1/2003 0 0 0 FALSE FALSE Delisted
273503 5/16/1994 11/1/1998 5.38 5.38 5.38 FALSE FALSE New Listing
273503 11/1/1998 0 0 0 FALSE FALSE Delisted
273511 5/16/1994 4/1/2000 9.45 13.8 13.8 FALSE TRUE New Listing
273511 4/1/2000 1/1/2004 9.45 13.8 13.8 FALSE FALSE Change -OP
273511 1/1/2004 3/1/2014 6.62 13.8 13.8 FALSE FALSE Change -Subsidy
273511 3/1/2014 0 0 0 FALSE FALSE Delisted
273546 5/16/1994 7/1/1999 12.67 12.67 12.67 FALSE FALSE New Listing
273546 7/1/1999 11/1/1999 2.99 2.99 12.67 FALSE FALSE Change -Subsidy -Alternate
273546 11/1/1999 0 0 0 FALSE FALSE Delisted
273600 5/16/1994 8/1/1997 2.6 2.6 2.6 FALSE FALSE New Listing
273600 8/1/1997 0 0 0 FALSE FALSE Delisted
273996 1/1/1995 10/1/1998 2.7 2.7 4.5 FALSE FALSE New Listing
273996 10/1/1998 4/1/1999 1.83 1.83 4.5 FALSE FALSE Change -Subsidy -Price -Alternate
273996 4/1/1999 0 0 0 FALSE FALSE Delisted
274062 3/1/1997 4/1/1999 13.05 13.05 25.2 FALSE FALSE New Listing
274062 4/1/1999 10/1/2000 13.05 13.05 25.14 FALSE FALSE Change -Price
274062 10/1/2000 11/1/2002 13.05 13.05 26 FALSE FALSE Change +Price
274062 11/1/2002 2/1/2003 2.5 2.8 26 FALSE FALSE Change -Subsidy -Alternate
274062 2/1/2003 0 0 0 FALSE FALSE Delisted
274135 5/16/1994 6/27/1995 25.24 25.24 25.24 FALSE FALSE New Listing
274135 6/27/1995 10/1/2002 15.14 15.14 15.14 FALSE FALSE Change -Subsidy -Price -Alternate
274135 10/1/2002 6/1/2003 15.14 15.14 17.03 FALSE FALSE Change +Price
274135 6/1/2003 1/1/2010 7.57 7.57 7.57 FALSE FALSE Change -Subsidy -Price -Alternate
274135 1/1/2010 6.85 6.85 6.85 FALSE FALSE Change -Subsidy -Price -Alternate
274143 10/1/2012 27.95 27.95 27.95 FALSE FALSE New listing
274151 10/1/2012 33.28 33.28 33.28 FALSE FALSE New listing
274186 5/16/1994 6/27/1995 13.75 13.75 13.75 FALSE FALSE New Listing
274186 6/27/1995 10/1/2002 4.13 4.13 4.13 FALSE FALSE Change -Subsidy -Price -Alternate
274186 10/1/2002 6/1/2003 4.13 4.13 4.65 FALSE FALSE Change +Price
274186 6/1/2003 1/1/2010 2.07 2.07 2.07 FALSE FALSE Change -Subsidy -Price -Alternate
274186 1/1/2010 3.09 3.09 3.09 FALSE FALSE Change +Subsidy +Price +Alternate
274437 2/1/1996 5/1/2003 25 25 25 FALSE TRUE New Listing
274437 5/1/2003 0 0 0 FALSE FALSE Delisted
274445 2/1/1996 6/1/2003 45.33 45.33 45.33 FALSE TRUE New Listing
274445 6/1/2003 0 0 0 FALSE FALSE Delisted
274550 5/16/1994 6/15/1995 30.5 30.5 30.5 FALSE FALSE New Listing
274550 6/15/1995 11/1/1999 30.5 30.5 32 FALSE FALSE Change +Price
274550 11/1/1999 9/1/2006 30.5 30.5 42 FALSE FALSE Change +Price
274550 9/1/2006 25.9 25.9 25.9 FALSE FALSE Change -Subsidy -Price -Alternate
275182 5/17/1995 12/1/2000 1.08 1.08 2.1 FALSE FALSE New Listing
275182 12/1/2000 12/1/2003 1.08 1.08 2.25 FALSE FALSE Change +Price
275182 12/1/2003 6/1/2004 1.08 1.08 2.5 FALSE FALSE Change +Price
275182 6/1/2004 1/1/2005 1.08 1.08 2.48 FALSE FALSE Change -Price
275182 1/1/2005 12/1/2006 1.08 1.08 3 FALSE FALSE Change +Price
275182 12/1/2006 3/1/2007 0.97 0.97 3 FALSE FALSE Change -Subsidy -Alternate
275182 3/1/2007 0 0 0 FALSE FALSE Delisted
275190 5/17/1995 12/1/2000 2.16 2.16 3.15 FALSE FALSE New Listing
275190 12/1/2000 12/1/2003 2.16 2.16 3.45 FALSE FALSE Change +Price
275190 12/1/2003 6/1/2004 2.16 2.16 3.75 FALSE FALSE Change +Price
275190 6/1/2004 1/1/2005 2.16 2.16 3.8 FALSE FALSE Change +Price
275190 1/1/2005 12/1/2006 2.16 2.16 4.55 FALSE FALSE Change +Price
275190 12/1/2006 3/1/2007 1.94 1.94 4.55 FALSE FALSE Change -Subsidy -Alternate
275190 3/1/2007 0 0 0 FALSE FALSE Delisted
275298 5/16/1994 1/9/1995 10.84 10.84 14.02 FALSE TRUE New Listing
275298 1/9/1995 10/1/1997 10.86 10.86 14.9 FALSE TRUE Change +Subsidy +Price +Alternate
275298 10/1/1997 10/1/1998 9.75 9.75 14.9 FALSE TRUE Change -Subsidy -Alternate
275298 10/1/1998 9/1/2006 8.8 8.8 14.9 FALSE TRUE Change -Subsidy -Alternate
275298 9/1/2006 7/1/2009 8.8 8.8 15.27 FALSE TRUE Change +Price
275298 7/1/2009 11/1/2010 8.8 8.8 16.49 FALSE TRUE Change +Price
275298 11/1/2010 2/1/2011 6.02 6.02 16.49 FALSE TRUE Change -Subsidy -Alternate
275298 2/1/2011 0 0 0 FALSE FALSE Delisted
275301 8/16/1994 5/12/1995 4.35 4.35 7.15 FALSE TRUE New Listing
275301 5/12/1995 10/1/1997 4.35 4.35 7.5 FALSE TRUE Change +Price
275301 10/1/1997 10/1/1998 3.9 3.9 7.5 FALSE TRUE Change -Subsidy -Alternate
275301 10/1/1998 9/1/2006 3.52 3.52 7.5 FALSE TRUE Change -Subsidy -Alternate
275301 9/1/2006 11/1/2010 3.52 3.52 7.69 FALSE TRUE Change +Price
275301 11/1/2010 5/1/2011 2.41 2.41 7.69 FALSE TRUE Change -Subsidy -Alternate
275301 5/1/2011 2.41 2.41 8.72 FALSE TRUE Change +Price
275328 8/16/1994 12/1/1995 10.86 10.86 14.02 FALSE TRUE New Listing
275328 12/1/1995 10/1/1997 10.86 10.86 14.9 FALSE TRUE Change +Price
275328 10/1/1997 10/1/1998 9.75 9.75 14.9 FALSE TRUE Change -Subsidy -Alternate
275328 10/1/1998 9/1/2006 8.8 8.8 14.9 FALSE TRUE Change -Subsidy -Alternate
275328 9/1/2006 7/1/2009 8.8 8.8 15.27 FALSE TRUE Change +Price
275328 7/1/2009 11/1/2010 8.8 8.8 16.49 FALSE TRUE Change +Price
275328 11/1/2010 5/1/2011 6.02 6.02 16.49 FALSE TRUE Change -Subsidy -Alternate
275328 5/1/2011 6.02 6.02 17.32 FALSE TRUE Change +Price
275336 5/16/1994 7/1/1997 5.96 5.96 5.96 FALSE FALSE New Listing
275336 7/1/1997 3/1/1998 5.95 5.95 5.95 FALSE FALSE Change -Subsidy -Price -Alternate
275336 3/1/1998 0 0 0 FALSE FALSE Delisted
275654 5/16/1994 4/1/2000 8.8 8.8 8.8 FALSE FALSE New Listing
275654 4/1/2000 0 0 0 FALSE FALSE Delisted
275670 10/4/1997 2/1/1998 32.2 32.2 32.2 FALSE FALSE New Listing
275670 2/1/1998 8/1/2000 19.32 19.32 19.32 FALSE FALSE Change -Subsidy -Price -Alternate
275670 8/1/2000 12/1/2000 3.47 3.47 19.32 FALSE FALSE Change -Subsidy -Alternate
275670 12/1/2000 0 0 0 FALSE FALSE Delisted
275700 10/4/1997 2/1/1998 32.2 32.2 32.2 FALSE FALSE New Listing
275700 2/1/1998 8/1/2000 19.32 19.32 19.32 FALSE FALSE Change -Subsidy -Price -Alternate
275700 8/1/2000 12/1/2000 3.47 3.47 19.32 FALSE FALSE Change -Subsidy -Alternate
275700 12/1/2000 0 0 0 FALSE FALSE Delisted
275719 5/16/1994 10/4/1997 32.2 32.2 32.2 FALSE FALSE New Listing
275719 10/4/1997 0 0 0 FALSE FALSE Delisted
275743 5/16/1994 4/1/1997 2.6 2.6 2.6 FALSE FALSE New Listing
275743 4/1/1997 0 0 0 FALSE FALSE Delisted
275778 5/16/1994 6/1/1999 13 13 8.6 FALSE FALSE New Listing
275778 6/1/1999 0 0 0 FALSE FALSE Delisted
275808 5/16/1994 5/1/2001 13.5 13.5 13.5 FALSE TRUE New Listing
275808 5/1/2001 0 0 0 FALSE FALSE Delisted
275824 5/23/1995 10/1/2002 23.34 23.34 23.34 FALSE FALSE New Listing
275824 10/1/2002 3/1/2003 23.34 23.34 26.26 FALSE FALSE Change +Price
275824 3/1/2003 1/1/2010 26.26 26.26 26.26 FALSE FALSE Change +Subsidy +Alternate
275824 1/1/2010 7/1/2012 16.5 16.5 16.5 FALSE FALSE Change -Subsidy -Price -Alternate
275824 7/1/2012 6.25 6.25 6.25 FALSE FALSE Change -Subsidy -Price -Alternate
275840 5/23/1995 10/1/2002 93.36 93.36 93.36 FALSE FALSE New Listing
275840 10/1/2002 3/1/2003 93.36 93.36 105.03 FALSE FALSE Change +Price
275840 3/1/2003 1/1/2010 105.03 105.03 105.03 FALSE FALSE Change +Subsidy +Alternate
275840 1/1/2010 7/1/2012 66 66 66 FALSE FALSE Change -Subsidy -Price -Alternate
275840 7/1/2012 25 25 25 FALSE FALSE Change -Subsidy -Price -Alternate
275859 5/16/1994 11/1/2003 17.5 17.5 17.5 FALSE FALSE New Listing
275859 11/1/2003 0 0 0 FALSE FALSE Delisted
275867 5/16/1994 2/1/2003 26 26 26 FALSE FALSE New Listing
275867 2/1/2003 0 0 0 FALSE FALSE Delisted
275875 5/16/1994 3/1/2002 48.95 48.95 48.95 FALSE FALSE New Listing
275875 3/1/2002 0 0 0 FALSE FALSE Delisted
275921 10/4/1997 8/1/1998 4.33 4.33 6.32 FALSE FALSE New Listing
275921 8/1/1998 9/1/2000 4.33 4.33 11 FALSE FALSE Change +Price
275921 9/1/2000 0 0 0 FALSE FALSE Delisted
276170 5/16/1994 1/11/1995 6.46 6.46 6.46 FALSE FALSE New Listing
276170 1/11/1995 2/1/1998 6.16 6.16 6.16 FALSE FALSE Change -Subsidy -Price -Alternate
276170 2/1/1998 8/1/2000 3.7 3.7 6.16 FALSE FALSE Change -Subsidy -Alternate
276170 8/1/2000 12/1/2000 1.62 1.62 1.62 FALSE FALSE Change -Subsidy -Price -Alternate
276170 12/1/2000 0 0 0 FALSE FALSE Delisted
276332 5/16/1994 8/16/1994 15.15 15.15 15.15 FALSE FALSE New Listing
276332 8/16/1994 8/1/2001 14.98 14.98 14.98 FALSE FALSE Change -Subsidy -Price -Alternate
276332 8/1/2001 9/1/2001 10.49 10.49 10.49 FALSE FALSE Change -Subsidy -Price -Alternate
276332 9/1/2001 7/1/2002 10.49 10.49 13.5 FALSE FALSE Change +Price
276332 7/1/2002 0 0 0 FALSE FALSE Delisted
276340 5/16/1994 8/1/2001 44.05 44.05 44.05 FALSE FALSE New Listing
276340 8/1/2001 9/1/2002 30.84 30.84 30.84 FALSE FALSE Change -Subsidy -Price -Alternate
276340 9/1/2002 6/1/2008 24 24 24 FALSE FALSE Change -Subsidy -Price -Alternate
276340 6/1/2008 3/1/2012 10.71 10.71 10.71 FALSE FALSE Change -Subsidy -Price -Alternate
276340 3/1/2012 6/1/2012 6.96 6.96 10.71 FALSE FALSE Change -Subsidy -Alternate
276340 6/1/2012 0 0 0 FALSE FALSE Delisted
276359 5/16/1994 8/1/2001 17.65 17.65 17.65 FALSE FALSE New Listing
276359 8/1/2001 6/1/2008 12.36 12.36 12.36 FALSE FALSE Change -Subsidy -Price -Alternate
276359 6/1/2008 10/1/2013 4.04 4.04 4.04 FALSE FALSE Change -Subsidy -Price -Alternate
276359 10/1/2013 0 0 0 FALSE FALSE Delisted
276626 4/8/1995 8/1/1999 9.5 9.5 9.5 FALSE FALSE New Listing
276626 8/1/1999 0 0 0 FALSE FALSE Delisted
276634 4/8/1995 8/1/1999 38 38 38 FALSE FALSE New Listing
276634 8/1/1999 0 0 0 FALSE FALSE Delisted
276642 4/8/1995 11/1/1998 6.95 6.95 6.95 FALSE FALSE New Listing
276642 11/1/1998 8/1/1999 6.95 6.95 7 FALSE FALSE Change +Price
276642 8/1/1999 0 0 0 FALSE FALSE Delisted
276723 10/1/1996 11/1/1998 65 65 36.02 FALSE FALSE New Listing
276723 11/1/1998 8/1/1999 65 65 72 FALSE FALSE Change +Price
276723 8/1/1999 0 0 0 FALSE FALSE Delisted
276774 4/12/1995 6/27/1995 6.09 6.09 6.09 TRUE FALSE New Listing
276774 6/27/1995 7/1/1997 6.09 6.09 7.6 TRUE FALSE Change +Price
276774 7/1/1997 8/1/1999 6.09 6.09 8.3 TRUE FALSE Change +Price
276774 8/1/1999 0 0 0 FALSE FALSE Delisted
276847 7/1/1997 8/1/1999 60.9 60.9 40 TRUE FALSE New Listing
276847 8/1/1999 0 0 0 FALSE FALSE Delisted
276898 7/1/1997 11/1/1999 21.12 21.12 21.12 FALSE FALSE New Listing
276898 11/1/1999 0 0 0 FALSE FALSE Delisted
276928 5/16/1994 8/1/2000 8.8 8.8 8.8 FALSE FALSE New Listing
276928 8/1/2000 0 0 0 FALSE FALSE Delisted
276936 6/16/1995 39.5 39.5 39.5 FALSE FALSE New Listing
276944 5/16/1994 5/17/1995 4.13 4.13 4.37 FALSE FALSE New Listing
276944 5/17/1995 3/1/1996 4.13 4.13 5.5 FALSE FALSE Change +Price
276944 3/1/1996 11/1/1999 4.13 4.13 6.1 FALSE FALSE Change +Price
276944 11/1/1999 7/1/2000 4.13 4.13 7.86 FALSE FALSE Change +Price
276944 7/1/2000 8/1/2000 4.13 4.13 8.93 FALSE FALSE Change +Price
276944 8/1/2000 3/1/2001 4.13 4.13 8.86 FALSE FALSE Change -Price
276944 3/1/2001 9/1/2001 8.93 8.93 8.93 FALSE FALSE Change +Subsidy +Price +Alternate
276944 9/1/2001 0 0 0 FALSE FALSE Delisted
276960 4/11/1995 8/1/1999 8.25 8.25 8.25 FALSE FALSE New Listing
276960 8/1/1999 4/1/2000 7.25 7.25 8.25 FALSE FALSE Change -Subsidy -Alternate
276960 4/1/2000 5/1/2002 7.25 7.25 8.83 FALSE FALSE Change +Price
276960 5/1/2002 12/1/2003 6.67 6.67 8.83 FALSE FALSE Change -Subsidy -Alternate
276960 12/1/2003 5/1/2004 6.67 6.67 8.9 FALSE FALSE Change +Price
276960 5/1/2004 6/1/2004 6.19 6.19 8.9 FALSE FALSE Change -Subsidy -Alternate
276960 6/1/2004 1/1/2005 6.19 6.19 9.71 FALSE FALSE Change +Price
276960 1/1/2005 9/1/2010 6.19 6.19 10 FALSE FALSE Change +Price
276960 9/1/2010 12/1/2010 4.47 4.47 10 FALSE FALSE Change -Subsidy -Alternate
276960 12/1/2010 0 0 0 FALSE FALSE Delisted
276979 4/11/1995 8/1/1999 33 33 23.45 FALSE FALSE New Listing
276979 8/1/1999 4/1/2000 29 29 33 FALSE FALSE Change -Subsidy +Price -Alternate
276979 4/1/2000 5/1/2001 29 29 26.2 FALSE FALSE Change -Price
276979 5/1/2001 5/1/2002 29 29 29 FALSE FALSE Change +Price
276979 5/1/2002 12/1/2003 26.66 26.66 29 FALSE FALSE Change -Subsidy -Alternate
276979 12/1/2003 5/1/2004 26.66 26.66 30 FALSE FALSE Change +Price
276979 5/1/2004 6/1/2004 24.75 24.75 30 FALSE FALSE Change -Subsidy -Alternate
276979 6/1/2004 1/1/2005 24.75 24.75 31.9 FALSE FALSE Change +Price
276979 1/1/2005 2/1/2007 24.75 24.75 33 FALSE FALSE Change +Price
276979 2/1/2007 7/1/2010 24.75 24.75 24.75 FALSE FALSE Change -Price
276979 7/1/2010 12/1/2010 17.86 17.86 17.86 FALSE FALSE Change -Subsidy -Price -Alternate
276979 12/1/2010 0 0 0 FALSE FALSE Delisted
276995 4/12/1995 2/1/1998 17.15 17.15 17.15 FALSE FALSE New Listing
276995 2/1/1998 0 0 0 FALSE FALSE Delisted
277002 5/1/1996 2/1/2000 23.85 23.85 23.85 FALSE FALSE New Listing
277002 2/1/2000 4/1/2001 14.3 14.3 14.3 FALSE FALSE Change -Subsidy -Price -Alternate
277002 4/1/2001 7/1/2008 12.2 12.2 14.3 FALSE FALSE Change -Subsidy -Alternate
277002 7/1/2008 9/1/2011 12.2 12.2 12.2 FALSE FALSE Change -Price
277002 9/1/2011 14 14 14 FALSE FALSE Change +Subsidy +Price +Alternate
277010 5/1/1996 2/1/2000 95.4 95.4 83.47 FALSE FALSE New Listing
277010 2/1/2000 10/1/2000 57.2 57.2 57.2 FALSE FALSE Change -Subsidy -Price -Alternate
277010 10/1/2000 0 0 0 FALSE FALSE Delisted
277045 4/11/1995 6/10/1995 3.33 3.33 3.33 FALSE FALSE New Listing
277045 6/10/1995 11/1/1998 3.33 3.33 3.32 FALSE FALSE Change -Price
277045 11/1/1998 8/1/1999 3.33 3.33 4 FALSE FALSE Change +Price
277045 8/1/1999 12/1/2000 3.13 3.13 4 FALSE FALSE Change -Subsidy -Alternate
277045 12/1/2000 12/1/2003 3.13 3.13 4.8 FALSE FALSE Change +Price
277045 12/1/2003 6/1/2004 3.13 3.13 5.2 FALSE FALSE Change +Price
277045 6/1/2004 1/1/2005 3.13 3.13 5.28 FALSE FALSE Change +Price
277045 1/1/2005 1/1/2011 3.13 3.13 7 FALSE FALSE Change +Price
277045 1/1/2011 0 0 0 FALSE FALSE Delisted
277053 6/10/1995 11/1/1998 13.32 13.32 9.6 FALSE FALSE New Listing
277053 11/1/1998 8/1/1999 13.32 13.32 16 FALSE FALSE Change +Price
277053 8/1/1999 12/1/2000 12.52 12.52 12.6 FALSE FALSE Change -Subsidy -Price -Alternate
277053 12/1/2000 6/1/2004 12.52 12.52 13.2 FALSE FALSE Change +Price
277053 6/1/2004 0 0 0 FALSE FALSE Delisted
277088 4/11/1995 10/1/1996 30.65 30.65 30.65 FALSE FALSE New Listing
277088 10/1/1996 0 0 0 FALSE FALSE Delisted
277142 4/11/1995 7/1/1997 41.2 41.2 41.2 FALSE FALSE New Listing
277142 7/1/1997 11/1/2011 41.2 41.2 43.4 FALSE FALSE Change +Price
277142 11/1/2011 0 0 0 FALSE FALSE Delisted
277169 1/1/1999 8/1/1999 4.4 4.4 4.4 FALSE FALSE New Listing
277169 8/1/1999 0 0 0 FALSE FALSE Delisted
277177 1/1/1999 8/1/1999 17.6 17.6 17.6 FALSE FALSE New Listing
277177 8/1/1999 0 0 0 FALSE FALSE Delisted
277258 6/1/1995 7/1/1997 1.8 1.8 1.8 FALSE TRUE New Listing
277258 7/1/1997 5/1/1999 1.36 1.36 1.36 FALSE TRUE Change -Subsidy -Price -Alternate
277258 5/1/1999 12/1/2006 1.12 1.12 1.12 FALSE TRUE Change -Subsidy -Price -Alternate
277258 12/1/2006 0 0 0 FALSE FALSE Delisted
277282 4/11/1995 10/1/1996 3.95 3.95 3.95 FALSE FALSE New Listing
277282 10/1/1996 8/1/1999 3.7 3.7 3.7 FALSE FALSE Change -Subsidy -Price -Alternate
277282 8/1/1999 0 0 0 FALSE FALSE Delisted
277320 6/1/1995 7/1/1997 1.8 1.8 1.8 FALSE TRUE New Listing
277320 7/1/1997 5/1/1999 1.36 1.36 1.36 FALSE TRUE Change -Subsidy -Price -Alternate
277320 5/1/1999 12/1/2006 1.12 1.12 1.12 FALSE TRUE Change -Subsidy -Price -Alternate
277320 12/1/2006 0 0 0 FALSE FALSE Delisted
277339 6/1/1995 7/1/1997 1.8 1.8 1.8 FALSE TRUE New Listing
277339 7/1/1997 5/1/1999 1.36 1.36 1.36 FALSE TRUE Change -Subsidy -Price -Alternate
277339 5/1/1999 12/1/2006 1.12 1.12 1.12 FALSE TRUE Change -Subsidy -Price -Alternate
277339 12/1/2006 0 0 0 FALSE FALSE Delisted
277355 6/1/1995 7/1/1997 1.8 1.8 1.8 FALSE TRUE New Listing
277355 7/1/1997 5/1/1999 1.36 1.36 1.36 FALSE TRUE Change -Subsidy -Price -Alternate
277355 5/1/1999 12/1/2006 1.12 1.12 1.12 FALSE TRUE Change -Subsidy -Price -Alternate
277355 12/1/2006 0 0 0 FALSE FALSE Delisted
277428 4/11/1995 7/1/1997 19.8 19.8 19.8 FALSE FALSE New Listing
277428 7/1/1997 8/1/1999 19.8 19.8 21.2 FALSE FALSE Change +Price
277428 8/1/1999 0 0 0 FALSE FALSE Delisted
277436 4/11/1995 9/1/1999 18.6 18.6 18.6 FALSE FALSE New Listing
277436 9/1/1999 11/1/2001 18.6 18.6 22.1 FALSE FALSE Change +Price
277436 11/1/2001 0 0 0 FALSE FALSE Delisted
277452 5/16/1994 7/1/1997 24.1 24.1 24.1 FALSE FALSE New Listing
277452 7/1/1997 5/1/1999 24.1 24.1 25.9 FALSE FALSE Change +Price
277452 5/1/1999 0 0 0 FALSE FALSE Delisted
277479 4/11/1995 11/1/1998 7.33 7.33 7.33 FALSE FALSE New Listing
277479 11/1/1998 8/1/1999 7.33 7.33 8.05 FALSE FALSE Change +Price
277479 8/1/1999 12/1/2000 8.05 8.05 8.05 FALSE FALSE Change +Subsidy +Alternate
277479 12/1/2000 5/1/2001 8.05 8.05 8.65 FALSE FALSE Change +Price
277479 5/1/2001 5/1/2004 8.05 8.05 10.6 FALSE FALSE Change +Price
277479 5/1/2004 2/1/2007 7.4 7.4 10.6 FALSE FALSE Change -Subsidy -Alternate
277479 2/1/2007 12/1/2010 7.4 7.4 7.4 FALSE FALSE Change -Price
277479 12/1/2010 6.5 6.5 6.5 FALSE FALSE Change -Subsidy -Price -Alternate
277495 4/11/1995 11/1/1998 29.32 29.32 29.6 FALSE FALSE New Listing
277495 11/1/1998 8/1/1999 29.32 29.32 32.2 FALSE FALSE Change +Price
277495 8/1/1999 12/1/2000 32.2 32.2 32.2 FALSE FALSE Change +Subsidy +Alternate
277495 12/1/2000 12/1/2003 32.2 32.2 32.8 FALSE FALSE Change +Price
277495 12/1/2003 5/1/2004 32.2 32.2 35 FALSE FALSE Change +Price
277495 5/1/2004 6/1/2004 29.6 29.6 35 FALSE FALSE Change -Subsidy -Alternate
277495 6/1/2004 1/1/2005 29.6 29.6 36.08 FALSE FALSE Change +Price
277495 1/1/2005 7/1/2006 29.6 29.6 40 FALSE FALSE Change +Price
277495 7/1/2006 0 0 0 FALSE FALSE Delisted
277762 5/16/1994 10/1/2002 6.18 6.18 6.18 FALSE FALSE New Listing
277762 10/1/2002 0 0 0 FALSE FALSE Delisted
277878 5/16/1994 6/1/2012 61.89 61.89 61.89 FALSE FALSE New Listing
277878 6/1/2012 8.16 8.16 8.16 FALSE FALSE Change -Subsidy -Price -Alternate
277916 5/16/1994 1/18/1995 20.5 20.5 24.12 FALSE FALSE New Listing
277916 1/18/1995 8/1/1995 20.5 20.5 21 FALSE FALSE Change -Price
277916 8/1/1995 8/1/1998 21 21 21 FALSE FALSE Change +Subsidy +Alternate
277916 8/1/1998 6/1/1999 20.5 20.5 21 FALSE FALSE Change -Subsidy -Alternate
277916 6/1/1999 2/1/2002 20.5 20.5 26.67 FALSE FALSE Change +Price
277916 2/1/2002 0 0 0 FALSE FALSE Delisted
277932 5/16/1994 5/27/1995 16.89 16.89 16.89 FALSE FALSE New Listing
277932 5/27/1995 2/1/2000 4.75 4.75 4.75 FALSE FALSE Change -Subsidy -Price -Alternate
277932 2/1/2000 3/1/2001 4.75 4.75 5.75 FALSE FALSE Change +Price
277932 3/1/2001 4/1/2002 4.75 4.75 6.33 FALSE FALSE Change +Price
277932 4/1/2002 4/1/2003 4.75 4.75 6.96 FALSE FALSE Change +Price
277932 4/1/2003 10/1/2004 4.75 4.75 7.66 FALSE FALSE Change +Price
277932 10/1/2004 0 0 0 FALSE FALSE Delisted
277940 6/1/1995 11/1/1999 1.62 1.62 1.62 FALSE TRUE New Listing
277940 11/1/1999 0 0 0 FALSE FALSE Delisted
277983 5/16/1994 3/1/1996 54.6 54.6 54.6 FALSE FALSE New Listing
277983 3/1/1996 4/1/1996 32.77 32.77 54.6 FALSE FALSE Change -Subsidy -Alternate
277983 4/1/1996 9/1/1998 32.77 32.77 32.77 FALSE FALSE Change -Price
277983 9/1/1998 6/1/2001 10 10 10 FALSE FALSE Change -Subsidy -Price -Alternate
277983 6/1/2001 9/1/2001 7.5 7.5 7.5 FALSE FALSE Change -Subsidy -Price -Alternate
277983 9/1/2001 12/1/2001 5.63 5.63 4.5 FALSE FALSE Change -Subsidy -Price -Alternate
277983 12/1/2001 0 0 0 FALSE FALSE Delisted
277991 4/1/1996 9/1/1998 65.53 65.53 65.53 FALSE FALSE New Listing
277991 9/1/1998 6/1/2001 20 20 20 FALSE FALSE Change -Subsidy -Price -Alternate
277991 6/1/2001 12/1/2001 15 15 15 FALSE FALSE Change -Subsidy -Price -Alternate
277991 12/1/2001 0 0 0 FALSE FALSE Delisted
278017 8/1/1999 12/1/1999 4.35 4.35 21.12 FALSE FALSE New Listing
278017 12/1/1999 11/1/2000 4.35 4.35 17.53 FALSE FALSE Change -Price
278017 11/1/2000 12/1/2000 4.35 4.35 21.12 FALSE FALSE Change +Price
278017 12/1/2000 4/1/2001 4.35 4.35 18.16 FALSE FALSE Change -Price
278017 4/1/2001 4/1/2002 2.8 2.8 18.16 FALSE FALSE Change -Subsidy -Alternate
278017 4/1/2002 9/1/2004 2.8 2.8 9.96 FALSE FALSE Change -Price
278017 9/1/2004 1/1/2011 2.8 2.8 13.6 FALSE FALSE Change +Price
278017 1/1/2011 0 0 0 FALSE FALSE Delisted
278068 6/1/1995 11/1/1999 0.45 0.45 0.45 FALSE TRUE New Listing
278068 11/1/1999 0 0 0 FALSE FALSE Delisted
278114 6/1/1995 5/1/1999 50 50 50 FALSE TRUE New Listing
278114 5/1/1999 6/1/2001 50 50 72.06 FALSE TRUE Change +Price
278114 6/1/2001 0 0 0 FALSE FALSE Delisted
278254 4/11/1995 4/1/2000 2.98 2.98 3.8 FALSE FALSE New Listing
278254 4/1/2000 12/1/2003 2.98 2.98 4.1 FALSE FALSE Change +Subsidy +Price +Alternate
278254 12/1/2003 1/1/2005 2.98 2.98 4.5 FALSE FALSE Change +Price
278254 1/1/2005 1/1/2014 2.98 2.98 4.9 FALSE FALSE Change +Price
278254 1/1/2014 0 0 0 FALSE FALSE Delisted
278572 5/16/1994 12/1/1997 7.87 7.87 7.87 TRUE FALSE New Listing
278572 12/1/1997 0 0 0 FALSE FALSE Delisted
278661 12/1/1995 11/1/2001 12 12 12 FALSE FALSE New Listing
278661 11/1/2001 0 0 0 FALSE FALSE Delisted
278688 6/1/1995 11/1/1999 3.5 3.5 3.5 FALSE TRUE New Listing
278688 11/1/1999 0 0 0 FALSE FALSE Delisted
278696 6/1/1995 11/1/1999 3.5 3.5 3.5 FALSE TRUE New Listing
278696 11/1/1999 0 0 0 FALSE FALSE Delisted
278734 5/16/1994 12/1/1995 5.72 5.72 5.72 FALSE FALSE New Listing
278734 12/1/1995 6/1/1998 5.71 5.71 5.71 FALSE FALSE Change -Subsidy -Price -Alternate
278734 6/1/1998 10/1/2004 4.5 4.5 4.5 FALSE FALSE Change -Subsidy -Price -Alternate
278734 10/1/2004 1/1/2005 3.5 3.5 3.5 FALSE FALSE Change -Subsidy -Price -Alternate
278734 1/1/2005 0 0 0 FALSE FALSE Delisted
278742 5/16/1994 6/1/1998 7.95 7.95 7.95 FALSE FALSE New Listing
278742 6/1/1998 10/1/2004 6.5 6.5 6.5 FALSE FALSE Change -Subsidy -Price -Alternate
278742 10/1/2004 1/1/2005 4.35 4.35 4.35 FALSE FALSE Change -Subsidy -Price -Alternate
278742 1/1/2005 0 0 0 FALSE FALSE Delisted
278750 5/16/1994 5/1/1998 3.3 3.3 3.3 FALSE FALSE New Listing
278750 5/1/1998 8/1/1998 2.02 2.02 2.02 FALSE FALSE Change -Subsidy -Price -Alternate
278750 8/1/1998 0 0 0 FALSE FALSE Delisted
278769 5/16/1994 5/1/1998 16.5 16.5 16.5 FALSE FALSE New Listing
278769 5/1/1998 8/1/1998 10.1 10.1 10.1 FALSE FALSE Change -Subsidy -Price -Alternate
278769 8/1/1998 0 0 0 FALSE FALSE Delisted
278777 5/16/1994 5/1/1998 7.52 7.52 7.52 FALSE FALSE New Listing
278777 5/1/1998 8/1/1998 2.53 2.53 2.53 FALSE FALSE Change -Subsidy -Price -Alternate
278777 8/1/1998 0 0 0 FALSE FALSE Delisted
278785 5/16/1994 5/1/1998 37.59 37.59 37.59 FALSE FALSE New Listing
278785 5/1/1998 8/1/1998 12.65 12.65 12.65 FALSE FALSE Change -Subsidy -Price -Alternate
278785 8/1/1998 0 0 0 FALSE FALSE Delisted
278793 10/4/1997 5/1/1998 14.82 14.82 14.82 FALSE FALSE New Listing
278793 5/1/1998 8/1/1998 5.84 5.84 5.84 FALSE FALSE Change -Subsidy -Price -Alternate
278793 8/1/1998 0 0 0 FALSE FALSE Delisted
278807 10/4/1997 5/1/1998 74.08 74.08 74.08 FALSE FALSE New Listing
278807 5/1/1998 8/1/1998 29.18 29.18 29.18 FALSE FALSE Change -Subsidy -Price -Alternate
278807 8/1/1998 0 0 0 FALSE FALSE Delisted
278882 5/22/1995 10/1/1998 3 3 3 FALSE FALSE New Listing
278882 10/1/1998 0 0 0 FALSE FALSE Delisted
279269 6/1/1995 11/1/1999 10.53 10.53 10.53 FALSE TRUE New Listing
279269 11/1/1999 7.9 7.9 7.9 FALSE TRUE Change -Subsidy -Price -Alternate
279285 5/1/1999 6/1/2004 0.89 0.89 0.89 FALSE TRUE New Listing
279285 6/1/2004 12/1/2004 0.67 0.67 0.89 FALSE TRUE Change -Subsidy -Alternate
279285 12/1/2004 0 0 0 FALSE FALSE Delisted
279307 5/1/1999 6/1/2004 0.89 0.89 0.89 FALSE TRUE New Listing
279307 6/1/2004 12/1/2004 0.67 0.67 0.89 FALSE TRUE Change -Subsidy -Alternate
279307 12/1/2004 0 0 0 FALSE FALSE Delisted
279552 5/1/1999 6/1/2004 0.89 0.89 0.89 FALSE TRUE New Listing
279552 6/1/2004 12/1/2004 0.67 0.67 0.89 FALSE TRUE Change -Subsidy -Alternate
279552 12/1/2004 0 0 0 FALSE FALSE Delisted
279587 5/16/1994 6/1/2011 15.4 15.4 16.75 FALSE FALSE New Listing
279587 6/1/2011 0 0 0 FALSE FALSE Delisted
279625 5/1/1999 1/1/2011 1.33 1.33 1.33 FALSE TRUE New Listing
279625 1/1/2011 0 0 0 FALSE FALSE Delisted
279633 5/16/1994 3/1/1996 791.65 791.65 837.75 FALSE FALSE New Listing
279633 3/1/1996 8/1/1998 112.75 167.6 167.6 FALSE FALSE Change -Subsidy -Price -Alternate
279633 8/1/1998 3/1/1999 103.85 158.7 158.7 FALSE FALSE Change -Subsidy -Price -Alternate
279633 3/1/1999 2/1/2000 81 158.7 158.7 FALSE FALSE Change -Subsidy
279633 2/1/2000 11/1/2000 48.65 158.7 158.7 FALSE FALSE Change -Subsidy
279633 11/1/2000 3/1/2001 43.8 158.7 158.7 FALSE FALSE Change -Subsidy
279633 3/1/2001 9/1/2001 39.4 158.7 158.7 FALSE FALSE Change -Subsidy
279633 9/1/2001 12/1/2001 33.6 158.7 158.7 FALSE FALSE Change -Subsidy
279633 12/1/2001 0 0 0 FALSE FALSE Delisted
279668 5/16/1994 7/1/1995 8.45 8.45 8.45 FALSE FALSE New Listing
279668 7/1/1995 8/1/1997 8.82 8.82 8.82 FALSE FALSE Change +Subsidy +Price +Alternate
279668 8/1/1997 6/1/2000 8.82 8.82 9.26 FALSE FALSE Change +Price
279668 6/1/2000 12/1/2000 9.34 9.34 9.34 FALSE FALSE Change +Subsidy +Price +Alternate
279668 12/1/2000 0 0 0 FALSE FALSE Delisted
279676 8/1/1997 6/1/2000 88.2 88.2 92.6 FALSE FALSE New Listing
279676 6/1/2000 12/1/2000 93.4 93.4 93.4 FALSE FALSE Change +Subsidy +Price +Alternate
279676 12/1/2000 0 0 0 FALSE FALSE Delisted
279722 3/1/1995 12/1/1996 10.73 10.73 10.73 FALSE FALSE New Listing
279722 12/1/1996 9/1/2000 4.12 10.73 10.73 FALSE FALSE Change -Subsidy
279722 9/1/2000 0 0 0 FALSE FALSE Delisted
279730 5/1/1999 2/1/2011 1.33 1.33 1.33 FALSE TRUE New Listing
279730 2/1/2011 0 0 0 FALSE FALSE Delisted
279757 5/1/1999 12/1/2010 1.33 1.33 1.33 FALSE TRUE New Listing
279757 12/1/2010 0 0 0 FALSE FALSE Delisted
279781 3/1/1995 12/1/1996 13.53 13.53 13.53 FALSE FALSE New Listing
279781 12/1/1996 9/1/2000 7.05 13.53 13.53 FALSE FALSE Change -Subsidy
279781 9/1/2000 0 0 0 FALSE FALSE Delisted
279889 5/16/1994 8/1/2004 11.64 11.64 11.64 FALSE FALSE New Listing
279889 8/1/2004 11/1/2004 9.6 9.6 9.6 FALSE FALSE Change -Subsidy -Price -Alternate
279889 11/1/2004 0 0 0 FALSE FALSE Delisted
280089 5/16/1994 11/1/1995 7.38 7.38 7.38 FALSE TRUE New Listing
280089 11/1/1995 10/1/1997 9.02 9.02 9.02 FALSE TRUE Change +Subsidy +Price +Alternate
280089 10/1/1997 10/1/1998 5.36 5.36 7 FALSE TRUE Change -Subsidy -Price -Alternate
280089 10/1/1998 4/1/2003 4.84 4.84 7 FALSE TRUE Change -Subsidy -Alternate
280089 4/1/2003 11/1/2010 4.84 4.84 10.6 FALSE TRUE Change +Price
280089 11/1/2010 9/1/2012 3.31 3.31 10.6 FALSE TRUE Change -Subsidy -Alternate
280089 9/1/2012 0 0 0 FALSE FALSE Delisted
280542 5/16/1994 6/22/1995 78.44 78.44 78.44 FALSE FALSE New Listing
280542 6/22/1995 1/1/2006 156.88 156.88 156.88 FALSE FALSE Change +Subsidy +Price +Alternate
280542 1/1/2006 4/1/2006 14.5 14.5 156.88 FALSE FALSE Change -Subsidy -Alternate
280542 4/1/2006 0 0 0 FALSE FALSE Delisted
280690 6/1/1995 11/1/1999 2.25 2.25 2.25 FALSE TRUE New Listing
280690 11/1/1999 0 0 0 FALSE FALSE Delisted
280712 6/1/1995 11/1/1999 9.5 9.5 9.5 FALSE TRUE New Listing
280712 11/1/1999 0 0 0 FALSE FALSE Delisted
280739 6/1/1995 11/1/1999 9.5 9.5 9.5 FALSE TRUE New Listing
280739 11/1/1999 0 0 0 FALSE FALSE Delisted
280755 5/1/1999 6/1/2004 1.9 1.9 1.9 FALSE TRUE New Listing
280755 6/1/2004 7/1/2009 1.27 1.27 1.27 FALSE TRUE Change -Subsidy -Price -Alternate
280755 7/1/2009 0 0 0 FALSE FALSE Delisted
280771 5/1/1999 6/1/2002 1.9 1.9 1.9 FALSE TRUE New Listing
280771 6/1/2002 0 0 0 FALSE FALSE Delisted
281506 5/1/1999 6/1/2004 1.9 1.9 1.9 FALSE TRUE New Listing
281506 6/1/2004 7/1/2009 1.27 1.27 1.27 FALSE TRUE Change -Subsidy -Price -Alternate
281506 7/1/2009 0 0 0 FALSE FALSE Delisted
281522 5/16/1994 11/1/1995 7.38 7.38 7.38 FALSE TRUE New Listing
281522 11/1/1995 10/1/1997 6.51 6.51 6.51 FALSE TRUE Change -Subsidy -Price -Alternate
281522 10/1/1997 10/1/1998 5.85 5.85 5.85 FALSE TRUE Change -Subsidy -Price -Alternate
281522 10/1/1998 4/1/2003 5.28 5.28 5.28 FALSE TRUE Change -Subsidy -Price -Alternate
281522 4/1/2003 8/1/2006 5.28 5.28 8.18 FALSE TRUE Change +Price
281522 8/1/2006 3/1/2007 5.28 5.28 5.28 FALSE TRUE Change -Price
281522 3/1/2007 0 0 0 FALSE FALSE Delisted
281891 5/16/1994 4/2/1995 12.31 12.31 13.34 FALSE TRUE New Listing
281891 4/2/1995 5/18/1996 12.31 12.31 14 FALSE TRUE Change +Price
281891 5/18/1996 3/1/1997 10.46 10.46 14 FALSE TRUE Change -Subsidy -Alternate
281891 3/1/1997 0 0 0 FALSE FALSE Delisted
281956 5/1/1996 7/1/2003 22.4 22.4 22.4 FALSE FALSE New Listing
281956 7/1/2003 7/1/2011 26.88 26.88 26.88 FALSE FALSE Change +Subsidy +Price +Alternate
281956 7/1/2011 29.56 29.56 29.56 FALSE FALSE Change +Subsidy +Price +Alternate
281964 5/16/1994 7/1/1999 8.87 8.87 8.87 FALSE FALSE New Listing
281964 7/1/1999 1/1/2003 6.49 6.49 6.49 FALSE FALSE Change -Subsidy -Price -Alternate
281964 1/1/2003 7/1/2007 12 12 12 FALSE FALSE Change +Subsidy +Price +Alternate
281964 7/1/2007 12/1/2012 14.5 14.5 14.5 FALSE FALSE Change +Subsidy +Price +Alternate
281964 12/1/2012 0 0 0 FALSE FALSE Delisted
281972 4/11/1995 6/27/1995 23.6 23.6 23.6 FALSE FALSE New Listing
281972 6/27/1995 7/1/1997 4.72 4.72 11.2 FALSE FALSE Change -Subsidy -Price -Alternate
281972 7/1/1997 8/1/1999 4.72 4.72 12.32 FALSE FALSE Change +Price
281972 8/1/1999 0 0 0 FALSE FALSE Delisted
281980 5/16/1994 8/1/1998 3.2 3.2 3.2 FALSE FALSE New Listing
281980 8/1/1998 8/1/2004 3.2 3.2 3.9 FALSE FALSE Change +Price
281980 8/1/2004 11/1/2004 2.46 2.46 3.9 FALSE FALSE Change -Subsidy -Alternate
281980 11/1/2004 0 0 0 FALSE FALSE Delisted
281999 5/16/1994 9/1/2002 6.68 6.68 6.68 FALSE FALSE New Listing
281999 9/1/2002 7/1/2005 6 6 6 FALSE FALSE Change -Subsidy -Price -Alternate
281999 7/1/2005 2/1/2014 3.9 3.9 3.9 FALSE FALSE Change -Subsidy -Price -Alternate
281999 2/1/2014 0 0 0 FALSE FALSE Delisted
282014 8/1/2000 7/1/2003 10.99 10.99 10.99 FALSE FALSE New Listing
282014 7/1/2003 7/1/2006 10.15 10.15 10.15 FALSE FALSE Change -Subsidy -Price -Alternate
282014 7/1/2006 5/1/2009 11.5 11.5 11.5 FALSE FALSE Change +Subsidy +Price +Alternate
282014 5/1/2009 7/1/2012 10.75 10.75 10.75 FALSE FALSE Change -Subsidy -Price -Alternate
282014 7/1/2012 10.25 10.25 10.25 FALSE FALSE Change -Subsidy -Price -Alternate
282022 5/16/1994 9/1/1997 8.75 8.75 8.75 FALSE FALSE New Listing
282022 9/1/1997 0 0 0 FALSE FALSE Delisted
282030 5/16/1994 10/1/1997 2 2 2 FALSE FALSE New Listing
282030 10/1/1997 4/1/2002 2 2 2.29 FALSE FALSE Change +Price
282030 4/1/2002 6/1/2003 2 2 3.5 FALSE FALSE Change +Price
282030 6/1/2003 3/1/2009 2 2 3.9 FALSE FALSE Change +Price
282030 3/1/2009 0 0 0 FALSE FALSE Delisted
282049 10/1/1997 5/1/2002 5 5 5.73 FALSE FALSE New Listing
282049 5/1/2002 0 0 0 FALSE FALSE Delisted
282057 4/11/1995 6/27/1995 27.4 27.4 27.4 FALSE FALSE New Listing
282057 6/27/1995 7/1/1997 5.48 5.48 9.45 FALSE FALSE Change -Subsidy -Price -Alternate
282057 7/1/1997 8/1/1999 5.48 5.48 10.4 FALSE FALSE Change +Price
282057 8/1/1999 0 0 0 FALSE FALSE Delisted
282065 4/11/1995 6/27/1995 22.6 22.6 22.6 FALSE FALSE New Listing
282065 6/27/1995 7/1/1997 4.52 4.52 10.2 FALSE FALSE Change -Subsidy -Price -Alternate
282065 7/1/1997 8/1/1999 4.52 4.52 11.22 FALSE FALSE Change +Price
282065 8/1/1999 0 0 0 FALSE FALSE Delisted
282073 4/12/1995 6/27/1995 17.8 17.8 17.8 FALSE FALSE New Listing
282073 6/27/1995 7/1/1997 3.56 3.56 7.2 FALSE FALSE Change -Subsidy -Price -Alternate
282073 7/1/1997 8/1/1999 3.56 3.56 7.92 FALSE FALSE Change +Price
282073 8/1/1999 9/1/1999 7.92 7.92 7.92 FALSE FALSE Change +Subsidy +Alternate
282073 9/1/1999 12/1/2000 7.92 7.92 8.5 FALSE FALSE Change +Price
282073 12/1/2000 7/1/2008 7.92 7.92 9.25 FALSE FALSE Change +Price
282073 7/1/2008 11/1/2011 6.5 6.5 9.25 FALSE FALSE Change -Subsidy -Alternate
282073 11/1/2011 0 0 0 FALSE FALSE Delisted
282081 5/16/1994 6/1/2003 3 3 3 FALSE FALSE New Listing
282081 6/1/2003 2/1/2005 3.95 3.95 3.95 FALSE FALSE Change +Subsidy +Price +Alternate
282081 2/1/2005 4/1/2011 5.15 5.15 5.15 FALSE FALSE Change +Subsidy +Price +Alternate
282081 4/1/2011 7/1/2014 3.95 3.95 3.95 FALSE FALSE Change -Subsidy -Price -Alternate
282081 7/1/2014 1.82 1.82 1.82 FALSE FALSE Change -Subsidy -Price -Alternate
282103 4/11/1995 6/27/1995 32.25 32.25 32.25 FALSE FALSE New Listing
282103 6/27/1995 8/1/1999 6.45 6.45 14.6 FALSE FALSE Change -Subsidy -Price -Alternate
282103 8/1/1999 9/1/1999 14.6 14.6 14.6 FALSE FALSE Change +Subsidy +Alternate
282103 9/1/1999 12/1/2000 14.6 14.6 15.8 FALSE FALSE Change +Price
282103 12/1/2000 5/1/2001 14.6 14.6 17.2 FALSE FALSE Change +Price
282103 5/1/2001 12/1/2003 14.6 14.6 19.9 FALSE FALSE Change +Price
282103 12/1/2003 6/1/2004 14.6 14.6 21 FALSE FALSE Change +Price
282103 6/1/2004 1/1/2005 14.6 14.6 21.89 FALSE FALSE Change +Price
282103 1/1/2005 2/1/2007 14.6 14.6 24 FALSE FALSE Change +Price
282103 2/1/2007 19.3 19.3 19.3 FALSE FALSE Change +Subsidy -Price +Alternate
282111 5/16/1994 3/1/1995 5.42 5.42 19.8 FALSE FALSE New Listing
282111 3/1/1995 10/1/2003 5.42 5.42 5.42 FALSE FALSE Change -Price
282111 10/1/2003 12/1/2003 5.42 5.42 8.4 FALSE FALSE Change +Price
282111 12/1/2003 2/1/2010 8.4 8.4 8.4 FALSE FALSE Change +Subsidy +Alternate
282111 2/1/2010 0 0 0 FALSE FALSE Delisted
282138 5/16/1994 9/1/2000 12.09 12.09 12.09 FALSE FALSE New Listing
282138 9/1/2000 5/1/2002 7.98 7.98 7.98 FALSE FALSE Change -Subsidy -Price -Alternate
282138 5/1/2002 0 0 0 FALSE FALSE Delisted
282146 5/16/1994 9/1/2000 4.34 4.34 4.34 FALSE FALSE New Listing
282146 9/1/2000 10/1/2003 2.5 2.5 2.5 FALSE FALSE Change -Subsidy -Price -Alternate
282146 10/1/2003 12/1/2003 2.5 2.5 3.45 FALSE FALSE Change +Price
282146 12/1/2003 4/1/2010 3.45 3.45 3.45 FALSE FALSE Change +Subsidy +Alternate
282146 4/1/2010 0 0 0 FALSE FALSE Delisted
282154 4/12/1995 6/27/1995 24.1 24.1 24.1 FALSE FALSE New Listing
282154 6/27/1995 7/1/1997 4.82 4.82 9.6 FALSE FALSE Change -Subsidy -Price -Alternate
282154 7/1/1997 8/1/1999 4.82 4.82 10.56 FALSE FALSE Change +Price
282154 8/1/1999 0 0 0 FALSE FALSE Delisted
282162 10/1/1994 2/1/1998 8.62 8.62 8.62 FALSE FALSE New Listing
282162 2/1/1998 8/1/2000 5.17 5.17 5.17 FALSE FALSE Change -Subsidy -Price -Alternate
282162 8/1/2000 3/1/2001 2.65 2.65 2.65 FALSE FALSE Change -Subsidy -Price -Alternate
282162 3/1/2001 0 0 0 FALSE FALSE Delisted
282170 5/16/1994 2/1/1998 21.55 21.55 21.55 FALSE FALSE New Listing
282170 2/1/1998 8/1/2000 12.93 12.93 12.93 FALSE FALSE Change -Subsidy -Price -Alternate
282170 8/1/2000 4/1/2001 6.63 6.63 6.63 FALSE FALSE Change -Subsidy -Price -Alternate
282170 4/1/2001 0 0 0 FALSE FALSE Delisted
282189 5/16/1994 1/11/1995 6.46 6.46 6.46 FALSE FALSE New Listing
282189 1/11/1995 2/1/1998 6.16 6.16 6.16 FALSE FALSE Change -Subsidy -Price -Alternate
282189 2/1/1998 8/1/2000 3.7 3.7 3.7 FALSE FALSE Change -Subsidy -Price -Alternate
282189 8/1/2000 3/1/2001 1.62 1.62 1.62 FALSE FALSE Change -Subsidy -Price -Alternate
282189 3/1/2001 0 0 0 FALSE FALSE Delisted
282197 1/11/1995 2/1/1998 20.53 20.53 20.54 FALSE FALSE New Listing
282197 2/1/1998 8/1/2000 12.33 12.33 12.33 FALSE FALSE Change -Subsidy -Price -Alternate
282197 8/1/2000 3/1/2001 5.4 5.4 5.4 FALSE FALSE Change -Subsidy -Price -Alternate
282197 3/1/2001 0 0 0 FALSE FALSE Delisted
282200 5/16/1994 7/1/1999 13.96 13.96 13.96 FALSE FALSE New Listing
282200 7/1/1999 5/1/2002 9.95 9.95 9.95 FALSE FALSE Change -Subsidy -Price -Alternate
282200 5/1/2002 0 0 0 FALSE FALSE Delisted
282219 5/16/1994 7/1/1999 9.97 9.97 9.97 FALSE FALSE New Listing
282219 7/1/1999 10/1/2005 6.5 6.5 6.5 FALSE FALSE Change -Subsidy -Price -Alternate
282219 10/1/2005 10/1/2009 6.95 6.95 6.95 FALSE FALSE Change +Subsidy +Price +Alternate
282219 10/1/2009 0 0 0 FALSE FALSE Delisted
282235 4/11/1995 6/27/1995 27.2 27.2 27.2 FALSE FALSE New Listing
282235 6/27/1995 8/1/1999 5.44 5.44 9.6 FALSE FALSE Change -Subsidy -Price -Alternate
282235 8/1/1999 0 0 0 FALSE FALSE Delisted
282251 5/16/1994 7/1/1999 18.7 18.7 18.7 FALSE FALSE New Listing
282251 7/1/1999 6/1/2003 8.99 8.99 8.99 FALSE FALSE Change -Subsidy -Price -Alternate
282251 6/1/2003 6/1/2004 10.5 10.5 10.5 FALSE FALSE Change +Subsidy +Price +Alternate
282251 6/1/2004 1/1/2012 9.5 9.5 9.5 FALSE FALSE Change -Subsidy -Price -Alternate
282251 1/1/2012 10.45 10.45 10.45 FALSE FALSE Change +Subsidy +Price +Alternate
282405 5/16/1994 9/1/2001 5.46 5.46 5.46 FALSE FALSE New Listing
282405 9/1/2001 6/1/2002 2.7 2.7 2.7 FALSE FALSE Change -Subsidy -Price -Alternate
282405 6/1/2002 0 0 0 FALSE FALSE Delisted
282413 6/1/1995 7/1/1999 1.31 1.31 1.31 FALSE TRUE New Listing
282413 7/1/1999 11/1/1999 1.18 1.18 1.31 FALSE TRUE Change -Subsidy -Alternate
282413 11/1/1999 0 0 0 FALSE FALSE Delisted
282499 5/16/1994 1/1/2004 13.47 13.47 13.47 FALSE FALSE New Listing
282499 1/1/2004 1/1/2012 11.11 11.11 11.11 FALSE FALSE Change -Subsidy -Price -Alternate
282499 1/1/2012 4/1/2012 23 23 23 FALSE FALSE Change +Subsidy +Price +Alternate
282499 4/1/2012 21.9 21.9 21.9 FALSE FALSE Change -Subsidy -Price -Alternate
282561 6/27/1995 5/1/2006 112 112 112 FALSE FALSE New Listing
282561 5/1/2006 8/1/2006 0 0 0 FALSE FALSE Delisted
282561 8/1/2006 9/1/2008 160 160 160 FALSE FALSE New Listing
282561 9/1/2008 0 0 0 FALSE FALSE Delisted
282588 5/16/1994 11/1/1998 39.73 39.73 52.66 FALSE FALSE New Listing
282588 11/1/1998 4/1/2001 39.73 39.73 57.92 FALSE FALSE Change +Price
282588 4/1/2001 0 0 0 FALSE FALSE Delisted
282642 6/1/1995 7/1/1999 5.55 5.55 5.55 FALSE TRUE New Listing
282642 7/1/1999 11/1/1999 5.29 5.29 5.55 FALSE TRUE Change -Subsidy -Alternate
282642 11/1/1999 0 0 0 FALSE FALSE Delisted
282766 5/1/1997 10/1/2004 42.66 42.66 42.66 FALSE FALSE New Listing
282766 10/1/2004 0 0 0 FALSE FALSE Delisted
282790 5/1/1997 42.66 42.66 42.66 FALSE FALSE New Listing
282820 5/1/1997 5/1/1999 42.66 42.66 42.66 FALSE FALSE New Listing
282820 5/1/1999 2/1/2007 29.86 29.86 29.86 FALSE FALSE Change -Subsidy -Price -Alternate
282820 2/1/2007 0 0 0 FALSE FALSE Delisted
282855 5/1/1997 2/1/2007 42.66 42.66 42.66 FALSE FALSE New Listing
282855 2/1/2007 0 0 0 FALSE FALSE Delisted
282928 5/16/1994 9/1/1999 6.57 6.57 6.57 FALSE FALSE New Listing
282928 9/1/1999 0 0 0 FALSE FALSE Delisted
282936 5/16/1994 5/1/1998 10.6 10.6 10.6 FALSE FALSE New Listing
282936 5/1/1998 7/1/2001 5.41 5.41 5.41 FALSE FALSE Change -Subsidy -Price -Alternate
282936 7/1/2001 9/1/2004 5.95 5.95 5.95 FALSE FALSE Change +Subsidy +Price +Alternate
282936 9/1/2004 0 0 0 FALSE FALSE Delisted
282944 5/16/1994 5/1/1998 15.3 15.3 15.3 FALSE FALSE New Listing
282944 5/1/1998 7/1/2001 8.96 8.96 8.96 FALSE FALSE Change -Subsidy -Price -Alternate
282944 7/1/2001 5/1/2004 9.86 9.86 9.86 FALSE FALSE Change +Subsidy +Price +Alternate
282944 5/1/2004 0 0 0 FALSE FALSE Delisted
282952 5/16/1994 5/1/2002 33.92 33.92 33.92 FALSE FALSE New Listing
282952 5/1/2002 0 0 0 FALSE FALSE Delisted
282960 5/16/1994 9/1/2002 1.34 1.34 1.88 FALSE FALSE New Listing
282960 9/1/2002 12/1/2002 1.2 1.2 1.88 FALSE FALSE Change -Subsidy -Alternate
282960 12/1/2002 0 0 0 FALSE FALSE Delisted
283118 4/3/1995 10/1/2007 6.51 6.51 6.51 FALSE FALSE New Listing
283118 10/1/2007 9/1/2011 6.94 6.94 6.94 FALSE FALSE Change +Subsidy +Price +Alternate
283118 9/1/2011 0 0 0 FALSE FALSE Delisted
283169 5/16/1994 4/1/2002 12.87 12.87 12.87 FALSE FALSE New Listing
283169 4/1/2002 3/1/2007 12.87 12.87 16.95 FALSE FALSE Change +Price
283169 3/1/2007 10/1/2013 12.87 12.87 17.8 FALSE FALSE Change +Price
283169 10/1/2013 0 0 0 FALSE FALSE Delisted
283177 5/16/1994 7/1/2003 50.15 50.15 50.15 FALSE FALSE New Listing
283177 7/1/2003 0 0 0 FALSE FALSE Delisted
283185 5/16/1994 1/1/2001 29.32 29.32 33.7 FALSE FALSE New Listing
283185 1/1/2001 10/1/2002 29.32 29.32 37.05 FALSE FALSE Change +Price
283185 10/1/2002 0 0 0 FALSE FALSE Delisted
283207 5/1/1999 1.24 1.24 1.24 FALSE TRUE New Listing
283223 5/16/1994 5/1/1998 55.85 55.85 55.85 FALSE FALSE New Listing
283223 5/1/1998 12/1/2001 41.89 41.89 41.89 FALSE FALSE Change -Subsidy -Price -Alternate
283223 12/1/2001 3/1/2002 35.5 35.5 41.89 FALSE FALSE Change -Subsidy -Alternate
283223 3/1/2002 0 0 0 FALSE FALSE Delisted
283258 5/16/1994 5/1/1997 133.98 133.98 133.98 FALSE FALSE New Listing
283258 5/1/1997 7/1/1997 133.98 133.98 160.79 FALSE FALSE Change +Price
283258 7/1/1997 12/1/1998 133.98 133.98 147.5 FALSE FALSE Change -Price
283258 12/1/1998 3/1/2001 147.5 147.5 147.5 FALSE FALSE Change +Subsidy +Alternate
283258 3/1/2001 7/1/2001 147.5 147.5 162.25 FALSE FALSE Change +Price
283258 7/1/2001 11/1/2004 162.25 162.25 162.25 FALSE FALSE Change +Subsidy +Alternate
283258 11/1/2004 178.48 178.48 178.48 FALSE FALSE Change +Subsidy +Price +Alternate
283274 5/16/1994 5/1/1997 265.55 265.55 265.55 FALSE FALSE New Listing
283274 5/1/1997 7/1/1997 265.55 265.55 318.79 FALSE FALSE Change +Price
283274 7/1/1997 12/1/1998 265.55 265.55 292 FALSE FALSE Change -Price
283274 12/1/1998 3/1/2001 292 292 292 FALSE FALSE Change +Subsidy +Alternate
283274 3/1/2001 7/1/2001 292 292 321.2 FALSE FALSE Change +Price
283274 7/1/2001 11/1/2004 321.2 321.2 321.2 FALSE FALSE Change +Subsidy +Alternate
283274 11/1/2004 353.32 353.32 353.32 FALSE FALSE Change +Subsidy +Price +Alternate
283339 6/9/1995 2/1/1996 7.76 7.76 8.28 FALSE TRUE New Listing
283339 2/1/1996 9/1/1998 7.76 7.76 8.69 FALSE TRUE Change +Price
283339 9/1/1998 9/1/2001 7.76 7.76 9.94 FALSE TRUE Change +Price
283339 9/1/2001 3/1/2009 8.95 8.95 8.95 FALSE TRUE Change +Subsidy -Price +Alternate
283339 3/1/2009 2/1/2013 8.7 8.7 8.7 FALSE TRUE Change -Subsidy -Price -Alternate
283339 2/1/2013 5/1/2013 4.95 4.95 8.7 FALSE TRUE Change -Subsidy -Alternate
283339 5/1/2013 0 0 0 FALSE FALSE Delisted
283347 5/16/1994 7/1/2014 38.12 38.12 38.12 FALSE FALSE New Listing
283347 7/1/2014 0 0 0 TRUE FALSE Change -Subsidy -Price -Alternate +CBS
283363 5/16/1994 7/1/1999 59.65 59.65 59.65 FALSE FALSE New Listing
283363 7/1/1999 11/1/1999 22.79 22.79 22.79 FALSE FALSE Change -Subsidy -Price -Alternate
283363 11/1/1999 9/1/2002 0 0 0 FALSE FALSE Delisted
283363 9/1/2002 11/1/2002 22.79 22.79 22.79 FALSE FALSE New Listing
283363 11/1/2002 7/1/2005 20.8 20.8 20.8 FALSE FALSE Change -Subsidy -Price -Alternate
283363 7/1/2005 10/1/2011 17 17 17 FALSE FALSE Change -Subsidy -Price -Alternate
283363 10/1/2011 20.97 20.97 20.97 FALSE FALSE Change +Subsidy +Price +Alternate
283428 5/16/1994 12/1/1999 5 5 5 FALSE FALSE New Listing
283428 12/1/1999 0 0 0 FALSE FALSE Delisted
283436 5/16/1994 1/1/1999 10 10 10 FALSE FALSE New Listing
283436 1/1/1999 0 0 0 FALSE FALSE Delisted
283444 5/1/1999 5.29 5.29 5.29 FALSE TRUE New Listing
283533 5/16/1994 1/1/1997 11.22 11.22 11.22 FALSE FALSE New Listing
283533 1/1/1997 0 0 0 FALSE FALSE Delisted
283568 5/16/1994 1/1/1997 32.5 32.5 32.5 FALSE FALSE New Listing
283568 1/1/1997 0 0 0 FALSE FALSE Delisted
283584 5/16/1994 4/1/2000 82.8 82.8 26.17 FALSE FALSE New Listing
283584 4/1/2000 0 0 0 FALSE FALSE Delisted
283622 5/16/1994 30.52 30.52 30.52 FALSE FALSE New Listing
283649 5/16/1994 5/1/1997 28.73 28.73 28.73 FALSE FALSE New Listing
283649 5/1/1997 9/1/1997 17.24 17.24 28.73 FALSE FALSE Change -Subsidy -Alternate
283649 9/1/1997 1/1/1998 28.73 28.73 28.73 FALSE FALSE Change +Subsidy +Alternate
283649 1/1/1998 2/1/1998 23 23 23 FALSE FALSE Change -Subsidy -Price -Alternate
283649 2/1/1998 9/1/1998 17.24 17.24 17.24 FALSE FALSE Change -Subsidy -Price -Alternate
283649 9/1/1998 8/1/2000 16.73 16.73 16.73 FALSE FALSE Change -Subsidy -Price -Alternate
283649 8/1/2000 12/1/2000 10.29 10.29 16.73 FALSE FALSE Change -Subsidy -Alternate
283649 12/1/2000 0 0 0 FALSE FALSE Delisted
283657 5/16/1994 5/1/1997 28.6 28.6 28.6 FALSE FALSE New Listing
283657 5/1/1997 9/1/1997 17.16 17.16 28.6 FALSE FALSE Change -Subsidy -Alternate
283657 9/1/1997 1/1/1998 28.6 28.6 28.6 FALSE FALSE Change +Subsidy +Alternate
283657 1/1/1998 2/1/1998 21.5 21.5 21.5 FALSE FALSE Change -Subsidy -Price -Alternate
283657 2/1/1998 9/1/1998 17.16 17.16 17.16 FALSE FALSE Change -Subsidy -Price -Alternate
283657 9/1/1998 8/1/2000 16.73 16.73 16.73 FALSE FALSE Change -Subsidy -Price -Alternate
283657 8/1/2000 12/1/2000 7.98 7.98 16.73 FALSE FALSE Change -Subsidy -Alternate
283657 12/1/2000 0 0 0 FALSE FALSE Delisted
283711 6/1/1995 7/1/1999 1.31 1.31 1.31 FALSE TRUE New Listing
283711 7/1/1999 11/1/1999 1.18 1.18 1.31 FALSE TRUE Change -Subsidy -Alternate
283711 11/1/1999 0 0 0 FALSE FALSE Delisted
283770 6/1/1995 7/1/1999 5.55 5.55 5.55 FALSE TRUE New Listing
283770 7/1/1999 11/1/1999 5.29 5.29 5.55 FALSE TRUE Change -Subsidy -Alternate
283770 11/1/1999 0 0 0 FALSE FALSE Delisted
283827 5/1/1999 12/1/2009 1.24 1.24 1.24 FALSE TRUE New Listing
283827 12/1/2009 0 0 0 FALSE FALSE Delisted
283878 5/1/1999 12/1/2009 5.29 5.29 5.29 FALSE TRUE New Listing
283878 12/1/2009 0 0 0 FALSE FALSE Delisted
283886 6/3/1995 10/1/2001 7.17 7.17 7.17 FALSE TRUE New Listing
283886 10/1/2001 0 0 0 FALSE FALSE Delisted
283908 6/1/1995 11/1/1999 20.75 20.75 20.75 FALSE TRUE New Listing
283908 11/1/1999 0 0 0 FALSE FALSE Delisted
283916 4/11/1995 8/1/1999 7.31 7.31 7.31 FALSE FALSE New Listing
283916 8/1/1999 0 0 0 FALSE FALSE Delisted
283924 4/11/1995 8/1/1999 7.53 7.53 7.53 FALSE FALSE New Listing
283924 8/1/1999 0 0 0 FALSE FALSE Delisted
283940 5/16/1994 1/10/1995 28 28 29.9 FALSE FALSE New Listing
283940 1/10/1995 1/1/2002 28 28 28 FALSE FALSE Change -Price
283940 1/1/2002 0 0 0 FALSE FALSE Delisted
283967 5/16/1994 1/10/1995 49.23 49.23 56.99 FALSE FALSE New Listing
283967 1/10/1995 1/1/2002 49.23 49.23 49.23 FALSE FALSE Change -Price
283967 1/1/2002 0 0 0 FALSE FALSE Delisted
283975 5/1/1999 1/1/2002 6.02 6.02 6.02 FALSE TRUE New Listing
283975 1/1/2002 0 0 0 FALSE FALSE Delisted
284025 5/1/1999 1/1/2002 12.04 12.04 12.04 FALSE TRUE New Listing
284025 1/1/2002 0 0 0 FALSE FALSE Delisted
284041 5/1/1999 8/1/2004 4 4 4 FALSE TRUE New Listing
284041 8/1/2004 0 0 0 FALSE FALSE Delisted
284076 5/1/1999 8/1/2004 4 4 4 FALSE TRUE New Listing
284076 8/1/2004 0 0 0 FALSE FALSE Delisted
284157 5/1/1999 8/1/2004 4 4 4 FALSE TRUE New Listing
284157 8/1/2004 0 0 0 FALSE FALSE Delisted
284173 5/1/1999 8/1/2004 4 4 4 FALSE TRUE New Listing
284173 8/1/2004 0 0 0 FALSE FALSE Delisted
284211 5/1/1999 6/1/2004 2.3 2.3 2.3 FALSE TRUE New Listing
284211 6/1/2004 10/1/2005 2.06 2.06 2.06 FALSE TRUE Change -Subsidy -Price -Alternate
284211 10/1/2005 11/1/2005 1.78 1.78 2.06 FALSE TRUE Change -Subsidy -Alternate
284211 11/1/2005 8/1/2009 1.78 1.78 1.78 FALSE TRUE Change -Price
284211 8/1/2009 0 0 0 FALSE FALSE Delisted
284246 5/1/1999 6/1/2004 2.3 2.3 2.3 FALSE TRUE New Listing
284246 6/1/2004 10/1/2005 2.06 2.06 2.06 FALSE TRUE Change -Subsidy -Price -Alternate
284246 10/1/2005 11/1/2005 1.78 1.78 2.06 FALSE TRUE Change -Subsidy -Alternate
284246 11/1/2005 2/1/2011 1.78 1.78 1.78 FALSE TRUE Change -Price
284246 2/1/2011 0 0 0 FALSE FALSE Delisted
284262 5/1/1999 6/1/2004 2.3 2.3 2.3 FALSE TRUE New Listing
284262 6/1/2004 10/1/2005 2.06 2.06 2.06 FALSE TRUE Change -Subsidy -Price -Alternate
284262 10/1/2005 11/1/2005 1.78 1.78 2.06 FALSE TRUE Change -Subsidy -Alternate
284262 11/1/2005 7/1/2010 1.78 1.78 1.78 FALSE TRUE Change -Price
284262 7/1/2010 1.78 1.78 2.1 FALSE TRUE Change +Price
284270 5/16/1994 3/1/1995 9.52 9.52 9.52 FALSE FALSE New Listing
284270 3/1/1995 2/1/2000 9.52 9.52 10.23 FALSE FALSE Change +Price
284270 2/1/2000 3/1/2001 9.52 9.52 11.25 FALSE FALSE Change +Price
284270 3/1/2001 4/1/2002 9.52 9.52 12.38 FALSE FALSE Change +Price
284270 4/1/2002 4/1/2003 9.52 9.52 13.62 FALSE FALSE Change +Price
284270 4/1/2003 4/1/2004 9.52 9.52 14.98 FALSE FALSE Change +Price
284270 4/1/2004 7/1/2006 9.52 9.52 16.48 FALSE FALSE Change +Price
284270 7/1/2006 12/1/2008 9.52 9.52 18.13 FALSE FALSE Change +Price
284270 12/1/2008 0 0 0 FALSE FALSE Delisted
284424 3/1/1995 2/1/2000 12.54 12.54 13.48 FALSE FALSE New Listing
284424 2/1/2000 3/1/2001 12.54 12.54 14.83 FALSE FALSE Change +Price
284424 3/1/2001 4/1/2002 12.54 12.54 16.31 FALSE FALSE Change +Price
284424 4/1/2002 4/1/2003 12.54 12.54 17.94 FALSE FALSE Change +Price
284424 4/1/2003 4/1/2004 12.54 12.54 19.73 FALSE FALSE Change +Price
284424 4/1/2004 7/1/2006 12.54 12.54 21.7 FALSE FALSE Change +Price
284424 7/1/2006 12/1/2008 12.54 12.54 23.87 FALSE FALSE Change +Price
284424 12/1/2008 23.87 23.87 23.87 FALSE FALSE Change +Subsidy +Alternate
284459 5/1/1999 6/1/2004 9.7 9.7 9.7 FALSE TRUE New Listing
284459 6/1/2004 10/1/2005 8.7 8.7 8.7 FALSE TRUE Change -Subsidy -Price -Alternate
284459 10/1/2005 11/1/2005 7.5 7.5 8.7 FALSE TRUE Change -Subsidy -Alternate
284459 11/1/2005 2/1/2008 7.5 7.5 7.5 FALSE TRUE Change -Price
284459 2/1/2008 0 0 0 FALSE FALSE Delisted
284521 1/1/1998 12/1/2000 1.13 1.13 4.47 FALSE FALSE New Listing
284521 12/1/2000 4/1/2002 1.13 1.13 5.8 FALSE FALSE Change +Price
284521 4/1/2002 0 0 0 FALSE FALSE Delisted
284548 6/8/1995 11/1/1996 12.67 12.67 12.67 FALSE FALSE New Listing
284548 11/1/1996 1/1/1998 12.66 12.66 12.66 FALSE FALSE Change -Subsidy -Price -Alternate
284548 1/1/1998 12/1/2000 6 6 12.66 FALSE FALSE Change -Subsidy -Alternate
284548 12/1/2000 4/1/2002 6 6 13.95 FALSE FALSE Change +Price
284548 4/1/2002 0 0 0 FALSE FALSE Delisted
284610 5/16/1994 6/1/2003 30 30 37.1 FALSE FALSE New Listing
284610 6/1/2003 0 0 0 FALSE FALSE Delisted
284629 5/27/1995 8/1/2012 6.03 6.03 6.03 FALSE FALSE New Listing
284629 8/1/2012 6.7 6.7 6.7 FALSE FALSE Change +Subsidy +Price +Alternate
284661 3/1/1996 12/1/1997 13.5 13.5 13.5 FALSE TRUE New Listing
284661 12/1/1997 4/1/1999 12.83 12.83 12.83 FALSE TRUE Change -Subsidy -Price -Alternate
284661 4/1/1999 7/1/2008 12.19 12.19 12.19 FALSE TRUE Change -Subsidy -Price -Alternate
284661 7/1/2008 11/1/2011 13.5 13.5 13.5 FALSE TRUE Change +Subsidy +Price +Alternate
284661 11/1/2011 0 0 0 FALSE FALSE Delisted
284688 5/16/1994 7/1/1999 13 13 13 FALSE FALSE New Listing
284688 7/1/1999 8/1/2002 2.75 2.75 2.75 FALSE FALSE Change -Subsidy -Price -Alternate
284688 8/1/2002 4/1/2006 2.1 2.1 2.1 FALSE FALSE Change -Subsidy -Price -Alternate
284688 4/1/2006 2/1/2010 3.31 3.31 3.31 FALSE FALSE Change +Subsidy +Price +Alternate
284688 2/1/2010 0 0 0 FALSE FALSE Delisted
284726 8/1/1997 5/1/1998 56.38 56.38 56.38 FALSE FALSE New Listing
284726 5/1/1998 1/1/2001 36.65 36.65 36.65 FALSE FALSE Change -Subsidy -Price -Alternate
284726 1/1/2001 4/1/2002 30 30 30 FALSE FALSE Change -Subsidy -Price -Alternate
284726 4/1/2002 0 0 0 FALSE FALSE Delisted
284734 5/16/1994 9/1/2001 14 14 14 FALSE FALSE New Listing
284734 9/1/2001 9/1/2002 14 14 13.74 FALSE FALSE Change -Price
284734 9/1/2002 12/1/2002 12.6 12.6 13.74 FALSE FALSE Change -Subsidy -Alternate
284734 12/1/2002 0 0 0 FALSE FALSE Delisted
284823 3/1/1996 9/1/1998 211.48 211.48 211.48 TRUE TRUE New Listing
284823 9/1/1998 10/1/1998 105.74 105.74 211.48 TRUE TRUE Change -Subsidy -Alternate
284823 10/1/1998 11/1/1998 84.59 84.59 211.48 TRUE TRUE Change -Subsidy -Alternate
284823 11/1/1998 5/1/1999 60 60 211.48 TRUE TRUE Change -Subsidy -Alternate
284823 5/1/1999 0 0 0 FALSE FALSE Delisted
284866 7/1/1997 12/1/2003 4.5 4.5 4.5 FALSE TRUE New Listing
284866 12/1/2003 7/1/2006 4.39 4.39 4.39 FALSE TRUE Change -Subsidy -Price -Alternate
284866 7/1/2006 9/1/2009 4.3 4.3 4.3 FALSE TRUE Change -Subsidy -Price -Alternate
284866 9/1/2009 12/1/2009 4.05 4.05 4.3 FALSE TRUE Change -Subsidy -Alternate
284866 12/1/2009 10/1/2012 0 0 0 FALSE FALSE Delisted
284866 10/1/2012 3.8 3.8 3.8 FALSE TRUE New Listing
285048 5/16/1994 10/4/1997 32.2 32.2 32.2 FALSE FALSE New Listing
285048 10/4/1997 0 0 0 FALSE FALSE Delisted
285056 10/4/1997 2/1/1998 32.2 32.2 32.2 FALSE FALSE New Listing
285056 2/1/1998 8/1/2000 19.32 19.32 19.32 FALSE FALSE Change -Subsidy -Price -Alternate
285056 8/1/2000 5/1/2002 3.47 3.47 3.47 FALSE FALSE Change -Subsidy -Price -Alternate
285056 5/1/2002 0 0 0 FALSE FALSE Delisted
285153 10/3/1997 8/1/2000 0 0 0 TRUE FALSE New Listing
285153 8/1/2000 3.06 3.06 3.06 FALSE FALSE Change +Subsidy +Price +Alternate -CBS
285161 10/3/1997 8/1/2000 0 0 0 TRUE FALSE New Listing
285161 8/1/2000 4.06 4.06 4.06 FALSE FALSE Change +Subsidy +Price +Alternate -CBS
285196 4/12/1995 8/1/1999 0.43 0.43 0.43 TRUE FALSE New Listing
285196 8/1/1999 0 0 0 FALSE FALSE Delisted
285226 7/1/1998 7/1/2004 13.95 13.95 13.95 FALSE TRUE New Listing
285226 7/1/2004 9.77 9.77 13.95 FALSE TRUE Change -Subsidy -Alternate
285234 5/16/1994 4/1/1998 24.5 24.5 24.5 FALSE FALSE New Listing
285234 4/1/1998 0 0 0 FALSE FALSE Delisted
285242 8/16/1994 12/1/1997 14.52 14.52 14.52 FALSE FALSE New Listing
285242 12/1/1997 0 0 0 FALSE FALSE Delisted
285285 2/1/2000 7/1/2002 57 57 57 FALSE FALSE New Listing
285285 7/1/2002 4/1/2004 51.3 51.3 51.3 FALSE FALSE Change -Subsidy -Price -Alternate
285285 4/1/2004 7/1/2005 47.3 47.3 47.3 FALSE FALSE Change -Subsidy -Price -Alternate
285285 7/1/2005 10/1/2005 45 45 45 FALSE FALSE Change -Subsidy -Price -Alternate
285285 10/1/2005 4/1/2006 42.75 42.75 42.75 FALSE FALSE Change -Subsidy -Price -Alternate
285285 4/1/2006 0 0 0 FALSE FALSE Delisted
285293 ######## 3/1/2001 38.4 38.4 38.4 FALSE FALSE New Listing
285293 3/1/2001 7/1/2003 34.72 34.72 34.72 FALSE FALSE Change -Subsidy -Price -Alternate
285293 7/1/2003 6/1/2008 31.79 31.79 31.79 FALSE FALSE Change -Subsidy -Price -Alternate
285293 6/1/2008 12/1/2011 23.1 23.1 23.1 FALSE FALSE Change -Subsidy -Price -Alternate
285293 12/1/2011 3/1/2012 1.74 1.74 8.7 FALSE FALSE Change -Subsidy -Price -Alternate
285293 3/1/2012 0 0 0 FALSE FALSE Delisted
285382 6/24/1995 6/27/1995 10.3 10.3 10.3 FALSE FALSE New Listing
285382 6/27/1995 7/1/1997 10.3 10.3 12.1 FALSE FALSE Change +Price
285382 7/1/1997 8/1/1999 10.3 10.3 13.31 FALSE FALSE Change +Price
285382 8/1/1999 0 0 0 FALSE FALSE Delisted
285544 4/12/1995 2/1/1998 27.1 27.1 27.1 FALSE FALSE New Listing
285544 2/1/1998 0 0 0 FALSE FALSE Delisted
285595 4/8/1995 8/1/1999 24.1 24.1 24.1 FALSE FALSE New Listing
285595 8/1/1999 0 0 0 FALSE FALSE Delisted
285641 4/8/1995 11/1/1999 4.35 4.35 4.35 FALSE FALSE New Listing
285641 11/1/1999 3/1/2000 2.97 2.97 2.97 FALSE FALSE Change -Subsidy -Price -Alternate
285641 3/1/2000 0 0 0 FALSE FALSE Delisted
285668 4/8/1995 11/1/1999 17.4 17.4 15.6 FALSE FALSE New Listing
285668 11/1/1999 3/1/2000 11.88 11.88 11.88 FALSE FALSE Change -Subsidy -Price -Alternate
285668 3/1/2000 0 0 0 FALSE FALSE Delisted
285684 7/1/1997 8/1/1999 23.6 23.6 61.6 FALSE FALSE New Listing
285684 8/1/1999 0 0 0 FALSE FALSE Delisted
285730 5/16/1994 6/27/1995 2.86 2.86 2.86 FALSE TRUE New Listing
285730 6/27/1995 4/1/1998 3.2 3.2 3.2 FALSE TRUE Change +Subsidy +Price +Alternate
285730 4/1/1998 2/1/2007 3.2 3.2 4 FALSE TRUE Change +Price
285730 2/1/2007 3.5 3.5 3.5 FALSE TRUE Change +Subsidy -Price +Alternate
285811 4/11/1995 8/1/1999 10.4 10.4 22.1 FALSE FALSE New Listing
285811 8/1/1999 0 0 0 FALSE FALSE Delisted
285838 4/11/1995 8/1/1999 41.6 41.6 41.6 FALSE FALSE New Listing
285838 8/1/1999 0 0 0 FALSE FALSE Delisted
285889 4/11/1995 4/1/1997 75.5 75.5 75.5 FALSE FALSE New Listing
285889 4/1/1997 0 0 0 FALSE FALSE Delisted
285927 4/12/1995 8/1/1999 0.02 0.02 0.02 TRUE FALSE New Listing
285927 8/1/1999 0 0 0 FALSE FALSE Delisted
285986 5/16/1994 12/1/2000 17.1 17.1 17.1 FALSE FALSE New Listing
285986 12/1/2000 11/1/2006 17.1 17.1 21.75 FALSE FALSE Change +Price
285986 11/1/2006 2/1/2007 15.1 15.1 21.75 FALSE FALSE Change -Subsidy -Alternate
285986 2/1/2007 0 0 0 FALSE FALSE Delisted
285994 5/16/1994 5/17/1995 17.4 17.4 17.4 FALSE FALSE New Listing
285994 5/17/1995 4/1/2000 21.6 21.6 21.6 FALSE FALSE Change +Subsidy +Price +Alternate
285994 4/1/2000 12/1/2003 21.6 21.6 24.5 FALSE FALSE Change +Price
285994 12/1/2003 6/1/2005 21.6 21.6 27 FALSE FALSE Change +Price
285994 6/1/2005 12/1/2006 21.6 21.6 26.95 FALSE FALSE Change -Price
285994 12/1/2006 3/1/2007 19.44 19.44 26.95 FALSE FALSE Change -Subsidy -Alternate
285994 3/1/2007 8/1/2009 0 0 0 FALSE FALSE Delisted
285994 8/1/2009 9/1/2012 16.7 16.7 16.7 FALSE FALSE New Listing
285994 9/1/2012 13.45 13.45 13.45 FALSE FALSE Change -Subsidy -Price -Alternate
286001 5/16/1994 5/17/1995 16.18 16.18 16.18 FALSE FALSE New Listing
286001 5/17/1995 5/1/2001 21.1 21.1 21.1 FALSE FALSE Change +Subsidy +Price +Alternate
286001 5/1/2001 0 0 0 FALSE FALSE Delisted
286028 4/11/1995 7/1/1997 31.5 31.5 31.5 FALSE FALSE New Listing
286028 7/1/1997 10/1/1998 31.5 31.5 47.25 FALSE FALSE Change +Price
286028 10/1/1998 0 0 0 FALSE FALSE Delisted
286044 4/11/1995 8/1/1999 18.2 18.2 18.2 FALSE FALSE New Listing
286044 8/1/1999 0 0 0 FALSE FALSE Delisted
286060 5/16/1994 6/1/1995 10.39 10.39 21.41 FALSE FALSE New Listing
286060 6/1/1995 7/1/1996 3.12 3.12 6.42 FALSE FALSE Change -Subsidy -Price -Alternate
286060 7/1/1996 4/1/1997 3.12 3.12 7.1 FALSE FALSE Change +Price
286060 4/1/1997 10/1/1999 3.12 3.12 7.95 FALSE FALSE Change +Price
286060 10/1/1999 11/1/1999 3.12 3.12 4.2 FALSE FALSE Change -Price
286060 11/1/1999 3/1/2000 2.8 2.8 4.2 FALSE FALSE Change -Subsidy -Alternate
286060 3/1/2000 9/1/2002 0 0 0 FALSE FALSE Delisted
286060 9/1/2002 11/1/2002 2.8 2.8 2.8 FALSE FALSE New Listing
286060 11/1/2002 12/1/2005 2.25 2.25 2.25 FALSE FALSE Change -Subsidy -Price -Alternate
286060 12/1/2005 3/1/2006 1.33 1.33 2.25 FALSE FALSE Change -Subsidy -Alternate
286060 3/1/2006 0 0 0 FALSE FALSE Delisted
286168 4/11/1995 2/1/1998 24.55 24.55 24.55 FALSE FALSE New Listing
286168 2/1/1998 0 0 0 FALSE FALSE Delisted
286176 4/11/1995 2/1/1998 16.8 16.8 16.8 FALSE FALSE New Listing
286176 2/1/1998 0 0 0 FALSE FALSE Delisted
286249 4/11/1995 11/1/1998 38.6 38.6 24.2 FALSE FALSE New Listing
286249 11/1/1998 8/1/1999 38.6 38.6 43 FALSE FALSE Change +Price
286249 8/1/1999 0 0 0 FALSE FALSE Delisted
286257 4/11/1995 11/1/1998 9.65 9.65 8.1 FALSE FALSE New Listing
286257 11/1/1998 8/1/1999 9.65 9.65 10.75 FALSE FALSE Change +Price
286257 8/1/1999 0 0 0 FALSE FALSE Delisted
286311 4/11/1995 4/1/1997 34.6 34.6 34.6 FALSE FALSE New Listing
286311 4/1/1997 0 0 0 FALSE FALSE Delisted
286400 5/16/1994 8/1/1999 0.03 0.03 0.03 TRUE FALSE New Listing
286400 8/1/1999 0 0 0 FALSE FALSE Delisted
286435 4/11/1995 7/1/1997 21.4 21.4 21.4 FALSE FALSE New Listing
286435 7/1/1997 0 0 0 FALSE FALSE Delisted
286494 4/11/1995 10/1/1996 32.6 32.6 32.6 FALSE FALSE New Listing
286494 10/1/1996 0 0 0 FALSE FALSE Delisted
286575 4/11/1995 10/1/1996 28.36 28.36 28.36 FALSE FALSE New Listing
286575 10/1/1996 7/1/1997 28.35 28.35 28.35 FALSE FALSE Change -Subsidy -Price -Alternate
286575 7/1/1997 0 0 0 FALSE FALSE Delisted
286648 4/11/1995 4/1/1997 21.1 21.1 21.1 FALSE FALSE New Listing
286648 4/1/1997 0 0 0 FALSE FALSE Delisted
286664 4/11/1995 12/1/2000 21.3 21.3 21.3 FALSE FALSE New Listing
286664 12/1/2000 6/1/2004 21.3 21.3 23.35 FALSE FALSE Change +Price
286664 6/1/2004 1/1/2005 21.3 21.3 25.69 FALSE FALSE Change +Price
286664 1/1/2005 11/1/2006 21.3 21.3 30 FALSE FALSE Change +Price
286664 11/1/2006 2/1/2007 21.3 21.3 32 FALSE FALSE Change +Price
286664 2/1/2007 25.5 25.5 25.5 FALSE FALSE Change +Subsidy -Price +Alternate
286699 4/11/1995 10/1/1996 19.7 19.7 19.7 FALSE FALSE New Listing
286699 10/1/1996 0 0 0 FALSE FALSE Delisted
286710 4/11/1995 10/1/1996 21.6 21.6 21.6 FALSE FALSE New Listing
286710 10/1/1996 0 0 0 FALSE FALSE Delisted
286753 5/1/1996 8/1/1999 19.6 19.6 19.6 TRUE FALSE New Listing
286753 8/1/1999 0 0 0 FALSE FALSE Delisted
286826 5/16/1994 3/1/1996 24 24 24 FALSE FALSE New Listing
286826 3/1/1996 5/1/1996 19.78 19.78 24 FALSE FALSE Change -Subsidy -Alternate
286826 5/1/1996 8/1/1998 19.78 19.78 19.78 FALSE FALSE Change -Price
286826 8/1/1998 6/1/1999 13.85 13.85 13.85 FALSE FALSE Change -Subsidy -Price -Alternate
286826 6/1/1999 2/1/2000 12.46 12.46 13.85 FALSE FALSE Change -Subsidy -Alternate
286826 2/1/2000 3/1/2001 8.31 13.85 13.85 FALSE FALSE Change -Subsidy +Alternate
286826 3/1/2001 7/1/2001 7.48 13.85 13.85 FALSE FALSE Change -Subsidy
286826 7/1/2001 1/1/2004 7.48 14.54 14.54 FALSE FALSE Change +Price +Alternate
286826 1/1/2004 4/1/2004 5.46 14.54 14.54 FALSE FALSE Change -Subsidy
286826 4/1/2004 0 0 0 FALSE FALSE Delisted
287180 2/1/1998 2/1/2000 32.1 32.1 32.1 FALSE FALSE New Listing
287180 2/1/2000 0 0 0 FALSE FALSE Delisted
287199 6/1/1995 12/1/2007 0.98 0.98 0.98 FALSE TRUE New Listing
287199 12/1/2007 0 0 0 FALSE FALSE Delisted
287350 4/11/1995 7/1/1997 10.6 10.6 10.6 FALSE FALSE New Listing
287350 7/1/1997 8/1/1999 10.6 10.6 12 FALSE FALSE Change +Price
287350 8/1/1999 0 0 0 FALSE FALSE Delisted
287377 4/11/1995 7/1/1997 4.9 4.9 4.9 FALSE FALSE New Listing
287377 7/1/1997 10/1/1998 4.9 4.9 5.39 FALSE FALSE Change +Price
287377 10/1/1998 0 0 0 FALSE FALSE Delisted
287407 5/16/1994 6/27/1995 13.96 13.96 13.96 FALSE FALSE New Listing
287407 6/27/1995 12/1/1997 13.96 13.96 16.25 FALSE FALSE Change +Price
287407 12/1/1997 0 0 0 FALSE FALSE Delisted
287415 5/16/1994 6/27/1995 13.96 13.96 13.96 FALSE FALSE New Listing
287415 6/27/1995 12/1/1997 13.96 13.96 16.25 FALSE FALSE Change +Price
287415 12/1/1997 0 0 0 FALSE FALSE Delisted
287423 4/11/1995 2/1/1998 14.2 14.2 14.2 FALSE FALSE New Listing
287423 2/1/1998 0 0 0 FALSE FALSE Delisted
287504 4/11/1995 7/1/1997 88.22 88.22 88.22 FALSE FALSE New Listing
287504 7/1/1997 8/1/1999 88.22 88.22 95.5 FALSE FALSE Change +Price
287504 8/1/1999 3/1/2001 95.5 95.5 95.5 FALSE FALSE Change +Subsidy +Alternate
287504 3/1/2001 0 0 0 FALSE FALSE Delisted
287520 4/11/1995 11/1/1999 6.35 6.35 6.35 FALSE FALSE New Listing
287520 11/1/1999 3/1/2000 4.18 4.18 4.18 FALSE FALSE Change -Subsidy -Price -Alternate
287520 3/1/2000 0 0 0 FALSE FALSE Delisted
287539 4/11/1995 11/1/1999 12.7 12.7 12.7 FALSE FALSE New Listing
287539 11/1/1999 3/1/2000 8.36 8.36 8.36 FALSE FALSE Change -Subsidy -Price -Alternate
287539 3/1/2000 0 0 0 FALSE FALSE Delisted
287547 4/11/1995 11/1/1999 25.4 25.4 23 FALSE FALSE New Listing
287547 11/1/1999 3/1/2000 16.72 16.72 16.72 FALSE FALSE Change -Subsidy -Price -Alternate
287547 3/1/2000 0 0 0 FALSE FALSE Delisted
287555 4/11/1995 6/27/1995 22.6 22.6 22.6 FALSE FALSE New Listing
287555 6/27/1995 7/1/1997 4.52 4.52 10.2 FALSE FALSE Change -Subsidy -Price -Alternate
287555 7/1/1997 8/1/1999 4.52 4.52 11.22 FALSE FALSE Change +Price
287555 8/1/1999 0 0 0 FALSE FALSE Delisted
287563 4/11/1995 6/7/1995 21.4 21.4 21.4 FALSE FALSE New Listing
287563 6/7/1995 6/27/1995 24.2 24.2 24.2 FALSE FALSE Change +Subsidy +Price +Alternate
287563 6/27/1995 7/1/1997 4.84 4.84 9.45 FALSE FALSE Change -Subsidy -Price -Alternate
287563 7/1/1997 8/1/1999 4.84 4.84 10.39 FALSE FALSE Change +Price
287563 8/1/1999 0 0 0 FALSE FALSE Delisted
287598 4/11/1995 7/1/1997 28.4 28.4 28.4 FALSE FALSE New Listing
287598 7/1/1997 8/1/1999 28.4 28.4 31.24 FALSE FALSE Change +Price
287598 8/1/1999 0 0 0 FALSE FALSE Delisted
287636 4/11/1995 8/1/1999 26.4 26.4 26.4 FALSE FALSE New Listing
287636 8/1/1999 0 0 0 FALSE FALSE Delisted
287644 5/1/1999 7/1/2009 2 2 2.63 FALSE TRUE New Listing
287644 7/1/2009 0 0 0 FALSE FALSE Delisted
287652 4/11/1995 8/1/1999 26.4 26.4 26.4 FALSE FALSE New Listing
287652 8/1/1999 0 0 0 FALSE FALSE Delisted
287660 4/12/1995 12/1/1996 0 0 0 TRUE FALSE New Listing
287660 12/1/1996 8/1/1999 17.65 17.65 17.65 FALSE FALSE Change +Subsidy +Price +Alternate -CBS
287660 8/1/1999 0 0 0 FALSE FALSE Delisted
287733 5/1/1999 12/1/2004 2 2 2.63 FALSE TRUE New Listing
287733 12/1/2004 0 0 0 FALSE FALSE Delisted
287962 10/1/1994 7/1/1999 65 65 65 FALSE FALSE New Listing
287962 7/1/1999 5/1/2002 13.75 13.75 13.75 FALSE FALSE Change -Subsidy -Price -Alternate
287962 5/1/2002 0 0 0 FALSE FALSE Delisted
288012 5/16/1994 11/1/1999 26.7 26.7 26.7 FALSE FALSE New Listing
288012 11/1/1999 0 0 0 FALSE FALSE Delisted
288098 4/11/1995 7/1/1997 22.2 22.2 22.2 FALSE FALSE New Listing
288098 7/1/1997 8/1/1999 22.2 22.2 24.42 FALSE FALSE Change +Price
288098 8/1/1999 4/1/2000 24.42 24.42 24.42 FALSE FALSE Change +Subsidy +Alternate
288098 4/1/2000 5/1/2001 24.42 24.42 26.15 FALSE FALSE Change +Price
288098 5/1/2001 12/1/2003 24.42 24.42 32.72 FALSE FALSE Change +Price
288098 12/1/2003 6/1/2004 24.42 24.42 35 FALSE FALSE Change +Price
288098 6/1/2004 1/1/2005 24.42 24.42 35.99 FALSE FALSE Change +Price
288098 1/1/2005 24.42 24.42 38 FALSE FALSE Change +Price
288217 4/11/1995 2/1/1998 24.6 24.6 24.6 FALSE FALSE New Listing
288217 2/1/1998 0 0 0 FALSE FALSE Delisted
288233 4/11/1995 8/1/1999 2.54 2.54 2.54 FALSE FALSE New Listing
288233 8/1/1999 0 0 0 FALSE FALSE Delisted
288306 4/12/1995 8/1/1999 0 0 0 TRUE FALSE New Listing
288306 8/1/1999 0 0 0 FALSE FALSE Delisted
288357 12/1/1995 9/1/1999 28.92 28.92 28.92 FALSE FALSE New Listing
288357 9/1/1999 12/1/2000 28.92 28.92 33.2 FALSE FALSE Change +Price
288357 12/1/2000 6/1/2001 28.92 28.92 35.8 FALSE FALSE Change +Price
288357 6/1/2001 0 0 0 FALSE FALSE Delisted
288381 4/11/1995 11/1/1998 0.62 0.62 0.9 FALSE FALSE New Listing
288381 11/1/1998 8/1/1999 0.62 0.62 0.75 FALSE FALSE Change -Price
288381 8/1/1999 10/1/2001 0.75 0.75 1.3 FALSE FALSE Change +Subsidy +Price +Alternate
288381 10/1/2001 12/1/2003 0.75 0.75 1.4 FALSE FALSE Change +Price
288381 12/1/2003 6/1/2004 0.75 0.75 1.5 FALSE FALSE Change +Price
288381 6/1/2004 1/1/2005 0.75 0.75 1.54 FALSE FALSE Change +Price
288381 1/1/2005 2/1/2007 0.75 0.75 1.8 FALSE FALSE Change +Price
288381 2/1/2007 1.28 1.28 1.28 FALSE FALSE Change +Subsidy -Price +Alternate
288403 4/11/1995 11/1/1998 3.1 3.1 3.1 FALSE FALSE New Listing
288403 11/1/1998 8/1/1999 3.1 3.1 3.75 FALSE FALSE Change +Price
288403 8/1/1999 8/1/2003 3.75 3.75 3.75 FALSE FALSE Change +Subsidy +Alternate
288403 8/1/2003 0 0 0 FALSE FALSE Delisted
288640 5/16/1994 10/1/1999 41.34 41.34 41.34 FALSE FALSE New Listing
288640 10/1/1999 0 0 0 FALSE FALSE Delisted
288691 4/11/1995 7/1/1997 15.3 15.3 15.3 FALSE FALSE New Listing
288691 7/1/1997 8/1/1999 15.3 15.3 17.1 FALSE FALSE Change +Price
288691 8/1/1999 0 0 0 FALSE FALSE Delisted
288713 4/12/1995 7/1/1997 13.1 13.1 13.1 FALSE FALSE New Listing
288713 7/1/1997 8/1/1999 13.1 13.1 15.1 FALSE FALSE Change +Price
288713 8/1/1999 0 0 0 FALSE FALSE Delisted
288721 4/12/1995 2/1/1998 12.1 12.1 12.1 FALSE FALSE New Listing
288721 2/1/1998 0 0 0 FALSE FALSE Delisted
289159 5/1/1999 1/1/2009 2 2 2.63 FALSE TRUE New Listing
289159 1/1/2009 3/1/2010 2 2 2.92 FALSE TRUE Change +Price
289159 3/1/2010 0 0 0 FALSE FALSE Delisted
289175 5/1/1999 1/1/2009 2 2 2.63 FALSE TRUE New Listing
289175 1/1/2009 2 2 2.92 FALSE TRUE Change +Price
289191 5/1/1999 1/1/2009 2 2 2.63 FALSE TRUE New Listing
289191 1/1/2009 0 0 0 FALSE FALSE Delisted
289213 5/1/1999 1/1/2009 2 2 2.63 FALSE TRUE New Listing
289213 1/1/2009 2 2 3.11 FALSE TRUE Change +Price
289248 5/1/1999 10/1/2008 2 2 2.63 FALSE TRUE New Listing
289248 10/1/2008 0 0 0 FALSE FALSE Delisted
289256 9/1/1999 5/1/2009 22 22 22 FALSE FALSE New Listing
289256 5/1/2009 10/1/2012 16.5 16.5 16.5 FALSE FALSE Change -Subsidy -Price -Alternate
289256 10/1/2012 3/1/2013 9.82 9.82 9.82 FALSE FALSE Change -Subsidy -Price -Alternate
289256 3/1/2013 0 0 0 FALSE FALSE Delisted
289272 5/1/1999 12/1/2004 2 2 2.63 FALSE TRUE New Listing
289272 12/1/2004 0 0 0 FALSE FALSE Delisted
289353 5/1/1999 1/1/2009 2 2 2.85 FALSE TRUE New Listing
289353 1/1/2009 2 2 2.92 FALSE TRUE Change +Price
289647 9/1/1999 5/1/2009 31 31 31 FALSE FALSE New Listing
289647 5/1/2009 10/1/2012 26.7 26.7 26.7 FALSE FALSE Change -Subsidy -Price -Alternate
289647 10/1/2012 3/1/2013 15.83 15.83 15.83 FALSE FALSE Change -Subsidy -Price -Alternate
289647 3/1/2013 0 0 0 FALSE FALSE Delisted
289655 5/1/1999 12/1/2004 2 2 2.85 FALSE TRUE New Listing
289655 12/1/2004 0 0 0 FALSE FALSE Delisted
289752 5/16/1994 2/1/2003 11 11 12 FALSE FALSE New Listing
289752 2/1/2003 0 0 0 FALSE FALSE Delisted
289760 5/16/1994 7/1/2003 14.07 14.07 14.07 FALSE FALSE New Listing
289760 7/1/2003 0 0 0 FALSE FALSE Delisted
289825 5/16/1994 6/9/1995 4.35 4.35 4.35 FALSE TRUE New Listing
289825 6/9/1995 4/1/2003 4.34 4.34 4.34 FALSE TRUE Change -Subsidy -Price -Alternate
289825 4/1/2003 8/1/2005 0.74 0.74 0.74 FALSE TRUE Change -Subsidy -Price -Alternate
289825 8/1/2005 0 0 0 FALSE FALSE Delisted
290033 4/12/1995 6/27/1995 25.6 25.6 25.6 FALSE FALSE New Listing
290033 6/27/1995 7/1/1997 25.6 25.6 27.3 FALSE FALSE Change +Price
290033 7/1/1997 0 0 0 FALSE FALSE Delisted
290114 4/12/1995 10/1/1996 0 0 0 TRUE FALSE New Listing
290114 10/1/1996 1/1/1997 11.94 11.94 11.94 TRUE FALSE Change +Subsidy +Price +Alternate
290114 1/1/1997 8/1/1999 13.2 13.2 13.2 TRUE FALSE Change +Subsidy +Price +Alternate
290114 8/1/1999 0 0 0 FALSE FALSE Delisted
290122 10/1/1996 1/1/1997 29.85 29.85 28.6 TRUE FALSE New Listing
290122 1/1/1997 8/1/1999 33 33 33 TRUE FALSE Change +Subsidy +Price +Alternate
290122 8/1/1999 0 0 0 FALSE FALSE Delisted
290270 4/11/1995 4/1/1997 13.6 13.6 13.6 FALSE FALSE New Listing
290270 4/1/1997 0 0 0 FALSE FALSE Delisted
290319 5/1/1999 1/1/2009 2 2 2.85 FALSE TRUE New Listing
290319 1/1/2009 2 2 3.11 FALSE TRUE Change +Price
290483 4/11/1995 8/1/1999 19.2 19.2 19.2 FALSE FALSE New Listing
290483 8/1/1999 3/1/2000 4.35 4.35 19.2 FALSE FALSE Change -Subsidy -Alternate
290483 3/1/2000 4/1/2001 4.35 4.35 7.5 FALSE FALSE Change -Price
290483 4/1/2001 9/1/2001 2.8 2.8 7.5 FALSE FALSE Change -Subsidy -Alternate
290483 9/1/2001 6/1/2004 2.8 2.8 14 FALSE FALSE Change +Price
290483 6/1/2004 1/1/2011 2.8 2.8 15.4 FALSE FALSE Change +Price
290483 1/1/2011 0 0 0 FALSE FALSE Delisted
290513 9/1/2010 55 55 55 FALSE FALSE New listing
290548 4/11/1995 6/8/1995 10.98 10.98 10.98 FALSE FALSE New Listing
290548 6/8/1995 10/1/1996 10.98 10.98 13.2 FALSE FALSE Change +Price
290548 10/1/1996 7/1/1997 10.98 10.98 10.98 FALSE FALSE Change -Price
290548 7/1/1997 5/1/1999 10.98 10.98 13.08 FALSE FALSE Change +Price
290548 5/1/1999 0 0 0 FALSE FALSE Delisted
290599 4/11/1995 7/1/1997 17.2 17.2 17.2 FALSE FALSE New Listing
290599 7/1/1997 8/1/1999 17.2 17.2 18.92 FALSE FALSE Change +Price
290599 8/1/1999 0 0 0 FALSE FALSE Delisted
290610 4/11/1995 11/1/1998 40.4 40.4 28.82 FALSE FALSE New Listing
290610 11/1/1998 8/1/1999 40.4 40.4 44 FALSE FALSE Change +Price
290610 8/1/1999 0 0 0 FALSE FALSE Delisted
290645 4/8/1995 4/1/1997 32.6 32.6 32.6 FALSE FALSE New Listing
290645 4/1/1997 0 0 0 FALSE FALSE Delisted
290688 10/1/1997 6/1/1998 1.16 1.16 1.22 FALSE FALSE New Listing
290688 6/1/1998 6/1/2000 0.92 0.92 2.3 FALSE FALSE Change -Subsidy +Price -Alternate
290688 6/1/2000 7/1/2000 0.81 0.81 2.3 FALSE FALSE Change -Subsidy -Alternate
290688 7/1/2000 1/1/2001 0.81 0.81 0.81 FALSE FALSE Change -Price
290688 1/1/2001 0 0 0 FALSE FALSE Delisted
290750 4/12/1995 2/1/1998 36.4 36.4 36.4 FALSE FALSE New Listing
290750 2/1/1998 0 0 0 FALSE FALSE Delisted
290777 4/11/1995 8/1/1999 23.68 23.68 13.75 FALSE FALSE New Listing
290777 8/1/1999 0 0 0 FALSE FALSE Delisted
290785 2/1/1996 6/1/1998 18.92 18.92 18.92 FALSE FALSE New Listing
290785 6/1/1998 3/1/2001 7.2 7.2 7.2 FALSE FALSE Change -Subsidy -Price -Alternate
290785 3/1/2001 3/1/2009 0 0 0 FALSE FALSE Delisted
290785 3/1/2009 12/1/2010 4.1 4.1 4.1 FALSE FALSE New Listing
290785 12/1/2010 3/1/2011 1.92 1.92 4.1 FALSE FALSE Change -Subsidy -Alternate
290785 3/1/2011 0 0 0 FALSE FALSE Delisted
290807 2/1/1996 6/1/1998 31.52 31.52 31.52 FALSE FALSE New Listing
290807 6/1/1998 3/1/2001 11.99 11.99 11.99 FALSE FALSE Change -Subsidy -Price -Alternate
290807 3/1/2001 3/1/2009 0 0 0 FALSE FALSE Delisted
290807 3/1/2009 12/1/2010 6.01 6.01 6.01 FALSE FALSE New Listing
290807 12/1/2010 3/1/2011 3.06 3.06 6.01 FALSE FALSE Change -Subsidy -Alternate
290807 3/1/2011 0 0 0 FALSE FALSE Delisted
290815 4/11/1995 8/1/1999 13.55 13.55 13.55 FALSE FALSE New Listing
290815 8/1/1999 0 0 0 FALSE FALSE Delisted
290874 5/1/1996 6/1/1998 24.69 24.69 24.69 FALSE FALSE New Listing
290874 6/1/1998 2/1/2000 22 22 22 FALSE FALSE Change -Subsidy -Price -Alternate
290874 2/1/2000 6/1/2000 20.1 20.1 22 FALSE FALSE Change -Subsidy -Alternate
290874 6/1/2000 0 0 0 FALSE FALSE Delisted
290882 5/16/1994 10/1/1999 21.4 21.4 21.4 FALSE FALSE New Listing
290882 10/1/1999 12/1/2001 21.4 21.4 22.1 FALSE FALSE Change +Price
290882 12/1/2001 0 0 0 FALSE FALSE Delisted
290890 4/11/1995 2/1/1998 16.1 16.1 16.1 FALSE FALSE New Listing
290890 2/1/1998 0 0 0 FALSE FALSE Delisted
290912 4/11/1995 7/1/1997 18.1 18.1 18.1 FALSE FALSE New Listing
290912 7/1/1997 8/1/1999 18.1 18.1 19.91 FALSE FALSE Change +Price
290912 8/1/1999 0 0 0 FALSE FALSE Delisted
290939 4/11/1995 8/1/1999 4.01 4.01 4.01 FALSE FALSE New Listing
290939 8/1/1999 0 0 0 FALSE FALSE Delisted
290955 5/1/1996 6/1/1998 13.69 13.69 13.69 FALSE FALSE New Listing
290955 6/1/1998 2/1/2000 8.4 8.4 8.4 FALSE FALSE Change -Subsidy -Price -Alternate
290955 2/1/2000 6/1/2000 7.9 7.9 8.4 FALSE FALSE Change -Subsidy -Alternate
290955 6/1/2000 0 0 0 FALSE FALSE Delisted
291005 5/1/1996 6/1/1998 10.52 10.52 10.52 FALSE FALSE New Listing
291005 6/1/1998 2/1/2000 7.6 7.6 7.6 FALSE FALSE Change -Subsidy -Price -Alternate
291005 2/1/2000 6/1/2000 6.58 6.58 7.6 FALSE FALSE Change -Subsidy -Alternate
291005 6/1/2000 0 0 0 FALSE FALSE Delisted
291293 1/1/1998 8/1/2000 5.44 5.44 5.44 FALSE FALSE New Listing
291293 8/1/2000 5/1/2002 2.39 2.39 2.39 FALSE FALSE Change -Subsidy -Price -Alternate
291293 5/1/2002 0 0 0 FALSE FALSE Delisted
291315 5/16/1994 6/1/2001 1.98 1.98 1.98 FALSE FALSE New Listing
291315 6/1/2001 0 0 0 FALSE FALSE Delisted
291323 5/16/1994 6/1/2001 2.45 2.45 2.45 FALSE FALSE New Listing
291323 6/1/2001 0 0 0 FALSE FALSE Delisted
291331 5/16/1994 5/1/1998 3.3 3.3 3.48 FALSE FALSE New Listing
291331 5/1/1998 7/1/2001 2.02 2.02 2.02 FALSE FALSE Change -Subsidy -Price -Alternate
291331 7/1/2001 7/1/2004 2.22 2.22 2.22 FALSE FALSE Change +Subsidy +Price +Alternate
291331 7/1/2004 7/1/2007 2 2 2 FALSE FALSE Change -Subsidy -Price -Alternate
291331 7/1/2007 7/1/2013 3.55 3.55 3.55 FALSE FALSE Change +Subsidy +Price +Alternate
291331 7/1/2013 0 0 0 FALSE FALSE Delisted
291358 5/16/1994 5/1/1998 7.52 7.52 7.52 FALSE FALSE New Listing
291358 5/1/1998 7/1/2001 2.53 2.53 2.53 FALSE FALSE Change -Subsidy -Price -Alternate
291358 7/1/2001 7/1/2004 2.78 2.78 2.78 FALSE FALSE Change +Subsidy +Price +Alternate
291358 7/1/2004 7/1/2007 2.6 2.6 2.6 FALSE FALSE Change -Subsidy -Price -Alternate
291358 7/1/2007 12/1/2012 4.65 4.65 4.65 FALSE FALSE Change +Subsidy +Price +Alternate
291358 12/1/2012 0 0 0 FALSE FALSE Delisted
291366 3/1/1995 12/1/2002 1.08 1.08 1.08 FALSE FALSE New Listing
291366 12/1/2002 0 0 0 FALSE FALSE Delisted
291374 5/16/1994 9/1/2000 2.42 2.42 2.42 FALSE FALSE New Listing
291374 9/1/2000 4/1/2001 1.6 1.6 1.6 FALSE FALSE Change -Subsidy -Price -Alternate
291374 4/1/2001 0 0 0 FALSE FALSE Delisted
291528 11/1/1997 8/1/1999 0.33 0.33 0.33 FALSE FALSE New Listing
291528 8/1/1999 12/1/1999 0.22 0.22 0.33 FALSE FALSE Change -Subsidy -Alternate
291528 12/1/1999 0 0 0 FALSE FALSE Delisted
293660 4/11/1995 6/27/1995 32.55 32.55 32.55 FALSE FALSE New Listing
293660 6/27/1995 7/1/1997 6.51 6.51 15.3 FALSE FALSE Change -Subsidy -Price -Alternate
293660 7/1/1997 8/1/1999 6.51 6.51 16.83 FALSE FALSE Change +Price
293660 8/1/1999 9/1/2001 16.83 16.83 16.83 FALSE FALSE Change +Subsidy +Alternate
293660 9/1/2001 0 0 0 FALSE FALSE Delisted
293687 4/12/1995 8/1/1999 7.68 7.68 8.45 TRUE FALSE New Listing
293687 8/1/1999 0 0 0 FALSE FALSE Delisted
293695 5/16/1994 6/27/1995 3.11 3.11 4.67 FALSE FALSE New Listing
293695 6/27/1995 3/1/1998 2.9 2.9 4.36 FALSE FALSE Change -Subsidy -Price -Alternate
293695 3/1/1998 0 0 0 FALSE FALSE Delisted
293822 5/16/1994 9/1/1999 162.88 162.88 162.88 FALSE FALSE New Listing
293822 9/1/1999 3/1/2001 105.87 105.87 162.88 FALSE FALSE Change -Subsidy -Alternate
293822 3/1/2001 0 0 0 FALSE FALSE Delisted
296325 4/1/1998 11/1/2011 32.46 32.46 32.46 FALSE FALSE New Listing
296325 11/1/2011 0 0 0 FALSE FALSE Delisted
296333 5/16/1994 10/1/1997 35.1 35.1 35.1 FALSE FALSE New Listing
296333 10/1/1997 0 0 0 FALSE FALSE Delisted
296341 7/1/2012 0 0 35.26 FALSE FALSE New listing
296368 8/1/1999 6/1/2000 38.2 38.2 58 FALSE FALSE New Listing
296368 6/1/2000 0 0 0 FALSE FALSE Delisted
296791 8/1/1999 4/1/2000 9.45 9.45 18 FALSE TRUE New Listing
296791 4/1/2000 9/1/2003 9.45 9.45 18 FALSE FALSE Change -OP
296791 9/1/2003 0 0 0 FALSE FALSE Delisted
296899 8/1/1999 4/1/2000 3.15 3.15 5.5 FALSE TRUE New Listing
296899 4/1/2000 10/1/2003 3.15 3.15 5.5 FALSE FALSE Change -OP
296899 10/1/2003 0 0 0 FALSE FALSE Delisted
296910 8/1/1999 4/1/2000 12.6 12.6 12.6 FALSE TRUE New Listing
296910 4/1/2000 12/1/2000 12.6 12.6 12.6 FALSE FALSE Change -OP
296910 12/1/2000 1/1/2001 0 0 0 FALSE FALSE Delisted
296910 1/1/2001 10/1/2003 12.6 12.6 12.6 FALSE FALSE New Listing
296910 10/1/2003 0 0 0 FALSE FALSE Delisted
296937 8/1/1995 5/1/1997 7.92 7.92 7.92 FALSE FALSE New Listing
296937 5/1/1997 3/1/2001 7.92 7.92 9.5 FALSE FALSE Change +Price
296937 3/1/2001 4/1/2002 7.92 7.92 10.45 FALSE FALSE Change +Price
296937 4/1/2002 2/1/2003 7.92 7.92 11.5 FALSE FALSE Change +Price
296937 2/1/2003 5/1/2003 6 6 11.5 FALSE FALSE Change -Subsidy -Alternate
296937 5/1/2003 0 0 0 FALSE FALSE Delisted
297178 4/1/1996 2/1/1998 4.38 4.38 4.38 FALSE TRUE New Listing
297178 2/1/1998 11/1/1998 3.72 3.72 3.72 FALSE TRUE Change -Subsidy -Price -Alternate
297178 11/1/1998 7/1/2005 3.72 3.72 6 FALSE TRUE Change +Price
297178 7/1/2005 0 0 0 FALSE FALSE Delisted
297887 8/1/1999 3/1/2003 27.85 27.85 27.85 FALSE TRUE New Listing
297887 3/1/2003 4/1/2005 26.95 26.95 27.85 FALSE TRUE Change -Subsidy -Alternate
297887 4/1/2005 7/1/2008 22 22 22 FALSE TRUE Change -Subsidy -Price -Alternate
297887 7/1/2008 0 0 0 FALSE FALSE Delisted
298093 5/1/1999 7/1/1999 7.7 7.7 11.91 FALSE TRUE New Listing
298093 7/1/1999 4/1/2009 10.65 10.65 11.91 FALSE TRUE Change +Subsidy +Alternate
298093 4/1/2009 0 0 0 FALSE FALSE Delisted
298115 9/1/1999 11/1/1999 3.12 3.12 3.12 FALSE FALSE New Listing
298115 11/1/1999 11/1/2002 2.8 2.8 2.8 FALSE FALSE Change -Subsidy -Price -Alternate
298115 11/1/2002 2/1/2003 2.25 2.25 2.8 FALSE FALSE Change -Subsidy -Alternate
298115 2/1/2003 0 0 0 FALSE FALSE Delisted
298131 6/14/1995 9/1/2001 6.16 6.16 6.16 FALSE FALSE New Listing
298131 9/1/2001 0 0 0 FALSE FALSE Delisted
298158 6/14/1995 2/1/2001 11.2 11.2 11.2 FALSE FALSE New Listing
298158 2/1/2001 3/1/2001 6.72 6.72 11.2 FALSE FALSE Change -Subsidy -Alternate
298158 3/1/2001 8/1/2001 6.72 6.72 6.72 FALSE FALSE Change -Price
298158 8/1/2001 11/1/2001 1.97 1.97 6.72 FALSE FALSE Change -Subsidy -Alternate
298158 11/1/2001 0 0 0 FALSE FALSE Delisted
298166 6/14/1995 2/1/2001 18.2 18.2 18.2 FALSE FALSE New Listing
298166 2/1/2001 3/1/2001 10.92 10.92 18.2 FALSE FALSE Change -Subsidy -Alternate
298166 3/1/2001 8/1/2001 10.92 10.92 10.92 FALSE FALSE Change -Price
298166 8/1/2001 11/1/2001 2.9 2.9 10.92 FALSE FALSE Change -Subsidy -Alternate
298166 11/1/2001 0 0 0 FALSE FALSE Delisted
298204 11/1/1995 9.21 9.21 9.21 FALSE FALSE New Listing
298212 9/1/1999 11/1/1999 13.08 13.08 13.08 FALSE FALSE New Listing
298212 11/1/1999 8/1/2003 9.58 9.58 9.58 FALSE FALSE Change -Subsidy -Price -Alternate
298212 8/1/2003 0 0 0 FALSE FALSE Delisted
298638 4/1/1998 4/1/1999 3.2 3.2 4.06 FALSE FALSE New Listing
298638 4/1/1999 3/1/2000 3.58 3.58 4.69 FALSE FALSE Change +Subsidy +Price +Alternate
298638 3/1/2000 6/1/2004 3.58 3.58 4.85 FALSE FALSE Change +Price
298638 6/1/2004 9/1/2010 2.75 2.75 2.75 FALSE FALSE Change -Subsidy -Price -Alternate
298638 9/1/2010 1/1/2014 2.71 2.71 2.71 FALSE FALSE Change -Subsidy -Price -Alternate
298638 1/1/2014 3.93 3.93 3.93 FALSE FALSE Change +Subsidy +Price +Alternate
299022 7/1/1995 8/1/1998 27 27 27 FALSE FALSE New Listing
299022 8/1/1998 4/1/2001 10.62 27 27 FALSE FALSE Change -Subsidy
299022 4/1/2001 4/1/2003 4.43 27 27 FALSE FALSE Change -Subsidy
299022 4/1/2003 4/1/2004 4.43 29.7 29.7 FALSE FALSE Change +Price +Alternate
299022 4/1/2004 12/1/2005 4.43 32.67 32.67 FALSE FALSE Change +Price +Alternate
299022 12/1/2005 0 0 0 FALSE FALSE Delisted
299030 7/1/1995 8/1/1998 18.67 18.67 18.67 FALSE FALSE New Listing
299030 8/1/1998 4/1/2001 7.34 18.67 18.67 FALSE FALSE Change -Subsidy
299030 4/1/2001 4/1/2003 3.06 18.67 18.67 FALSE FALSE Change -Subsidy
299030 4/1/2003 4/1/2004 3.06 20.54 20.54 FALSE FALSE Change +Price +Alternate
299030 4/1/2004 11/1/2005 3.06 22.59 22.59 FALSE FALSE Change +Price +Alternate
299030 11/1/2005 0 0 0 FALSE FALSE Delisted
299057 7/1/1994 8/1/1998 11.43 11.43 11.43 FALSE FALSE New Listing
299057 8/1/1998 4/1/2001 4.49 11.43 11.43 FALSE FALSE Change -Subsidy
299057 4/1/2001 4/1/2003 1.87 11.43 11.43 FALSE FALSE Change -Subsidy
299057 4/1/2003 4/1/2004 1.87 12.57 12.57 FALSE FALSE Change +Price +Alternate
299057 4/1/2004 10/1/2005 1.87 13.83 13.83 FALSE FALSE Change +Price +Alternate
299057 10/1/2005 0 0 0 FALSE FALSE Delisted
299308 10/1/2005 6/1/2006 45.44 45.44 45.44 FALSE FALSE New listing
299308 6/1/2006 9/1/2010 43.86 43.86 43.86 FALSE FALSE Change -Subsidy -Price -Alternate
299308 9/1/2010 8/1/2013 48 48 48 FALSE FALSE Change +Subsidy +Price +Alternate
299308 8/1/2013 51.84 51.84 51.84 FALSE FALSE Change +Subsidy +Price +Alternate
299448 12/1/1996 10/1/2009 50.43 50.43 50.43 FALSE FALSE New Listing
299448 10/1/2009 0 0 0 FALSE FALSE Delisted
299456 8/1/2001 8/1/2005 46.25 46.25 46.25 FALSE FALSE New listing
299456 8/1/2005 12/1/2007 48.68 48.68 48.68 FALSE FALSE Change +Subsidy +Price +Alternate
299456 12/1/2007 7/1/2009 48.48 48.48 48.48 FALSE FALSE Change -Subsidy -Price -Alternate
299456 7/1/2009 10/1/2013 55 55 55 FALSE FALSE Change +Subsidy +Price +Alternate
299456 10/1/2013 0 0 0 FALSE FALSE Delisted
300411 5/16/1994 4/3/1995 40.59 40.59 40.59 FALSE FALSE New Listing
300411 4/3/1995 4/1/1997 40.59 40.59 41.32 FALSE FALSE Change +Price
300411 4/1/1997 11/1/2000 40.59 40.59 44.65 FALSE FALSE Change +Price
300411 11/1/2000 0 0 0 FALSE FALSE Delisted
300438 5/16/1994 4/3/1995 69.5 69.5 69.5 FALSE FALSE New Listing
300438 4/3/1995 4/4/1995 41.32 41.32 41.32 FALSE FALSE Change -Subsidy -Price -Alternate
300438 4/4/1995 4/1/1997 69.5 69.5 76.46 FALSE FALSE Change +Subsidy +Price +Alternate
300438 4/1/1997 9/1/2001 69.5 69.5 82.6 FALSE FALSE Change +Price
300438 9/1/2001 11/1/2012 0 0 0 FALSE FALSE Delisted
300438 11/1/2012 70 70 70 FALSE FALSE New Listing
300446 5/16/1994 6/1/2003 16.65 16.65 16.65 FALSE FALSE New Listing
300446 6/1/2003 0 0 0 FALSE FALSE Delisted
300454 5/16/1994 6/27/1995 14.18 14.18 27.12 FALSE FALSE New Listing
300454 6/27/1995 5/1/1997 3.55 3.55 6.78 FALSE FALSE Change -Subsidy -Price -Alternate
300454 5/1/1997 0 0 0 FALSE FALSE Delisted
300497 5/16/1994 5/1/1997 5.54 5.54 5.54 FALSE FALSE New Listing
300497 5/1/1997 12/1/1997 5.54 5.54 6.48 FALSE FALSE Change +Price
300497 12/1/1997 10/1/1998 6.16 6.16 6.48 FALSE FALSE Change +Subsidy +Alternate
300497 10/1/1998 11/1/1998 4.38 4.38 6.48 FALSE FALSE Change -Subsidy -Alternate
300497 11/1/1998 1/1/1999 4.38 4.38 7.02 FALSE FALSE Change +Price
300497 1/1/1999 5/1/2001 2.75 2.75 7.02 FALSE FALSE Change -Subsidy -Alternate
300497 5/1/2001 10/1/2001 2.75 2.75 7.3 FALSE FALSE Change +Price
300497 10/1/2001 1/1/2002 1.93 1.93 7.3 FALSE FALSE Change -Subsidy -Alternate
300497 1/1/2002 9/19/2003 0 0 0 FALSE FALSE Delisted
300497 9/19/2003 11/1/2003 7.7 7.7 7.7 FALSE FALSE New Listing
300497 11/1/2003 6/1/2004 0 0 0 FALSE FALSE Delisted
300497 6/1/2004 7/1/2004 7.7 7.7 7.7 FALSE FALSE New Listing
300497 7/1/2004 0 0 0 FALSE FALSE Delisted
300616 8/1/1997 8/1/1998 22.55 22.55 22.55 FALSE FALSE New Listing
300616 8/1/1998 3/1/1999 20.77 20.77 20.77 FALSE FALSE Change -Subsidy -Price -Alternate
300616 3/1/1999 2/1/2000 16.2 16.2 16.2 FALSE FALSE Change -Subsidy -Price -Alternate
300616 2/1/2000 11/1/2000 9.73 16.2 16.2 FALSE FALSE Change -Subsidy
300616 11/1/2000 3/1/2001 8.76 16.2 16.2 FALSE FALSE Change -Subsidy
300616 3/1/2001 9/1/2001 7.88 16.2 16.2 FALSE FALSE Change -Subsidy
300616 9/1/2001 4/1/2002 6.72 16.2 16.2 FALSE FALSE Change -Subsidy
300616 4/1/2002 4/1/2003 6.72 17.82 17.82 FALSE FALSE Change +Price +Alternate
300616 4/1/2003 4/1/2004 6.72 19.6 19.6 FALSE FALSE Change +Price +Alternate
300616 4/1/2004 7/1/2011 6.72 21.56 21.56 FALSE FALSE Change +Price +Alternate
300616 7/1/2011 9/1/2014 21.56 21.56 21.56 FALSE FALSE Change +Subsidy
300616 9/1/2014 0 0 0 FALSE FALSE Delisted
300632 5/16/1994 4/14/1995 3.21 3.21 3.21 FALSE TRUE New Listing
300632 4/14/1995 5/19/1995 3.21 3.21 4.39 FALSE TRUE Change +Price
300632 5/19/1995 12/1/1997 3.21 3.21 6.3 FALSE TRUE Change +Price
300632 12/1/1997 0 0 0 FALSE FALSE Delisted
300799 10/1/1994 5/1/1997 57.2 57.2 57.2 FALSE FALSE New Listing
300799 5/1/1997 9/1/1997 34.32 34.32 57.2 FALSE FALSE Change -Subsidy -Alternate
300799 9/1/1997 1/1/1998 57.2 57.2 57.2 FALSE FALSE Change +Subsidy +Alternate
300799 1/1/1998 2/1/1998 43 43 57.2 FALSE FALSE Change -Subsidy -Alternate
300799 2/1/1998 9/1/1998 34.32 34.32 34.32 FALSE FALSE Change -Subsidy -Price -Alternate
300799 9/1/1998 8/1/2000 33.46 33.46 33.46 FALSE FALSE Change -Subsidy -Price -Alternate
300799 8/1/2000 12/1/2000 15.96 15.96 15.96 FALSE FALSE Change -Subsidy -Price -Alternate
300799 12/1/2000 0 0 0 FALSE FALSE Delisted
300802 5/16/1994 5/26/1995 18.67 18.67 18.67 FALSE FALSE New Listing
300802 5/26/1995 2/1/1998 16.1 16.1 18.67 FALSE FALSE Change -Subsidy -Alternate
300802 2/1/1998 2/1/2002 9.66 9.66 18.67 FALSE FALSE Change -Subsidy -Alternate
300802 2/1/2002 0 0 0 FALSE FALSE Delisted
300926 4/12/1995 11/1/1996 17.2 17.2 17.2 FALSE FALSE New Listing
300926 11/1/1996 0 0 0 FALSE FALSE Delisted
300977 4/12/1995 7/1/1997 27.3 27.3 27.3 FALSE FALSE New Listing
300977 7/1/1997 8/1/1999 27.3 27.3 30.08 FALSE FALSE Change +Price
300977 8/1/1999 0 0 0 FALSE FALSE Delisted
301043 4/12/1995 7/1/1997 16.1 16.1 16.1 FALSE FALSE New Listing
301043 7/1/1997 8/1/1999 16.1 16.1 17.71 FALSE FALSE Change +Price
301043 8/1/1999 9/1/1999 17.71 17.71 17.71 FALSE FALSE Change +Subsidy +Alternate
301043 9/1/1999 4/1/2002 17.71 17.71 21.1 FALSE FALSE Change +Price
301043 4/1/2002 0 0 0 FALSE FALSE Delisted
301108 8/1/1999 9/1/1999 16.2 16.2 16.2 FALSE FALSE New Listing
301108 9/1/1999 12/1/2000 16.2 16.2 17.4 FALSE FALSE Change +Price
301108 12/1/2000 2/1/2007 16.2 16.2 19.2 FALSE FALSE Change +Price
301108 2/1/2007 12/1/2010 17.7 17.7 17.7 FALSE FALSE Change +Subsidy -Price +Alternate
301108 12/1/2010 10.5 10.5 10.5 FALSE FALSE Change -Subsidy -Price -Alternate
301140 4/12/1995 2/1/1998 32.65 32.65 32.65 FALSE FALSE New Listing
301140 2/1/1998 0 0 0 FALSE FALSE Delisted
301175 4/12/1995 10/1/1996 18.4 18.4 18.4 FALSE FALSE New Listing
301175 10/1/1996 0 0 0 FALSE FALSE Delisted
301213 4/12/1995 2/1/1998 23.5 23.5 23.5 FALSE FALSE New Listing
301213 2/1/1998 0 0 0 FALSE FALSE Delisted
301353 8/1/1995 10/1/1998 2.7 2.7 2.7 FALSE FALSE New Listing
301353 10/1/1998 6/1/2000 1.83 1.83 1.83 FALSE FALSE Change -Subsidy -Price -Alternate
301353 6/1/2000 3/1/2004 1.54 1.54 1.54 FALSE FALSE Change -Subsidy -Price -Alternate
301353 3/1/2004 7/1/2008 1.24 1.24 1.24 FALSE FALSE Change -Subsidy -Price -Alternate
301353 7/1/2008 8/1/2008 1.11 1.11 1.24 FALSE FALSE Change -Subsidy -Alternate
301353 8/1/2008 1.11 1.11 1.11 FALSE FALSE Change -Price
301361 4/12/1995 10/1/1996 31.2 31.2 31.2 FALSE FALSE New Listing
301361 10/1/1996 8/1/1999 31.2 31.2 35.88 FALSE FALSE Change +Price
301361 8/1/1999 12/1/2000 34.32 34.32 35.88 FALSE FALSE Change +Subsidy +Alternate
301361 12/1/2000 6/1/2001 34.32 34.32 38.4 FALSE FALSE Change +Price
301361 6/1/2001 0 0 0 FALSE FALSE Delisted
301426 8/1/1995 10/1/1998 3 3 3 FALSE FALSE New Listing
301426 10/1/1998 9/1/2001 2.8 2.8 2.8 FALSE FALSE Change -Subsidy -Price -Alternate
301426 9/1/2001 11/1/2003 2.38 2.38 2.38 FALSE FALSE Change -Subsidy -Price -Alternate
301426 11/1/2003 0 0 0 FALSE FALSE Delisted
301485 4/12/1995 7/1/1997 15.4 15.4 15.4 FALSE FALSE New Listing
301485 7/1/1997 8/1/1999 15.4 15.4 17 FALSE FALSE Change +Price
301485 8/1/1999 0 0 0 FALSE FALSE Delisted
301558 4/12/1995 7/1/1997 12.4 12.4 12.4 FALSE FALSE New Listing
301558 7/1/1997 8/1/1999 12.4 12.4 14.4 FALSE FALSE Change +Price
301558 8/1/1999 0 0 0 FALSE FALSE Delisted
301604 4/12/1995 2/1/1998 25.7 25.7 25.7 FALSE FALSE New Listing
301604 2/1/1998 0 0 0 FALSE FALSE Delisted
301620 4/12/1995 7/1/1997 14.4 14.4 14.4 FALSE FALSE New Listing
301620 7/1/1997 10/1/1998 14.4 14.4 15.84 FALSE FALSE Change +Price
301620 10/1/1998 0 0 0 FALSE FALSE Delisted
301701 4/12/1995 7/1/1997 16.2 16.2 16.2 FALSE FALSE New Listing
301701 7/1/1997 8/1/1999 16.2 16.2 17.82 FALSE FALSE Change +Price
301701 8/1/1999 0 0 0 FALSE FALSE Delisted
301787 3/1/1995 7/1/2004 22.5 22.5 22.5 FALSE FALSE New Listing
301787 7/1/2004 0 0 0 FALSE FALSE Delisted
301809 4/12/1995 4/1/1997 20.45 20.45 20.45 FALSE FALSE New Listing
301809 4/1/1997 0 0 0 FALSE FALSE Delisted
301817 4/12/1995 4/1/1997 20.45 20.45 20.45 FALSE FALSE New Listing
301817 4/1/1997 0 0 0 FALSE FALSE Delisted
301833 4/11/1995 7/1/1997 22.4 22.4 22.4 FALSE FALSE New Listing
301833 7/1/1997 0 0 0 FALSE FALSE Delisted
301906 4/12/1995 7/1/1997 8.6 8.6 8.6 FALSE FALSE New Listing
301906 7/1/1997 8/1/1999 8.6 8.6 9.8 FALSE FALSE Change +Price
301906 8/1/1999 0 0 0 FALSE FALSE Delisted
301922 5/26/1995 9/1/2001 27.5 27.5 27.5 FALSE FALSE New Listing
301922 9/1/2001 12/1/2001 7.2 7.2 27.5 FALSE FALSE Change -Subsidy -Alternate
301922 12/1/2001 0 0 0 FALSE FALSE Delisted
302031 4/1/1996 6/1/1996 665 665 665 FALSE FALSE New Listing
302031 6/1/1996 9/1/1996 666.5 666.5 666.5 FALSE FALSE Change +Subsidy +Price +Alternate
302031 9/1/1996 3/1/1999 600 600 600 FALSE FALSE Change -Subsidy -Price -Alternate
302031 3/1/1999 11/1/2002 522 522 522 FALSE FALSE Change -Subsidy -Price -Alternate
302031 11/1/2002 0 0 0 FALSE FALSE Delisted
302058 4/11/1995 11/1/1998 10.1 10.1 8.14 FALSE FALSE New Listing
302058 11/1/1998 8/1/1999 10.1 10.1 11 FALSE FALSE Change +Price
302058 8/1/1999 0 0 0 FALSE FALSE Delisted
302066 5/16/1994 7/1/1999 4.4 4.4 4.4 FALSE FALSE New Listing
302066 7/1/1999 0 0 0 FALSE FALSE Delisted
302074 5/16/1994 12/1/1996 32.64 32.64 32.64 FALSE TRUE New Listing
302074 12/1/1996 0 0 0 FALSE FALSE Delisted
302082 4/1/1996 9/1/1996 1666.25 1666.25 1666.25 FALSE FALSE New Listing
302082 9/1/1996 3/1/1999 1500 1500 1500 FALSE FALSE Change -Subsidy -Price -Alternate
302082 3/1/1999 11/1/2002 1305 1305 1305 FALSE FALSE Change -Subsidy -Price -Alternate
302082 11/1/2002 0 0 0 FALSE FALSE Delisted
302104 1/1/1999 6/1/2001 6 6 6 FALSE FALSE New Listing
302104 6/1/2001 12/1/2001 3.5 3.5 3.5 FALSE FALSE Change -Subsidy -Price -Alternate
302104 12/1/2001 0 0 0 FALSE FALSE Delisted
302112 1/1/1999 6/1/2001 6 6 6 FALSE FALSE New Listing
302112 6/1/2001 12/1/2001 3.5 3.5 3.5 FALSE FALSE Change -Subsidy -Price -Alternate
302112 12/1/2001 0 0 0 FALSE FALSE Delisted
302139 4/12/1995 10/1/1996 15.9 15.9 15.9 FALSE FALSE New Listing
302139 10/1/1996 0 0 0 FALSE FALSE Delisted
302244 7/1/1997 8/1/1999 17.8 17.8 39.6 FALSE FALSE New Listing
302244 8/1/1999 9/1/1999 39.6 39.6 39.6 FALSE FALSE Change +Subsidy +Alternate
302244 9/1/1999 12/1/2000 39.6 39.6 42.5 FALSE FALSE Change +Price
302244 12/1/2000 6/1/2001 39.6 39.6 46.25 FALSE FALSE Change +Price
302244 6/1/2001 0 0 0 FALSE FALSE Delisted
302252 4/12/1995 7/1/1997 14.2 14.2 14.2 FALSE FALSE New Listing
302252 7/1/1997 8/1/1999 14.2 14.2 15.62 FALSE FALSE Change +Price
302252 8/1/1999 0 0 0 FALSE FALSE Delisted
302295 4/12/1995 7/1/1997 7.85 7.85 7.85 FALSE FALSE New Listing
302295 7/1/1997 8/1/1999 7.85 7.85 8.95 FALSE FALSE Change +Price
302295 8/1/1999 0 0 0 FALSE FALSE Delisted
302325 4/12/1995 4/1/1997 41.6 41.6 41.6 FALSE FALSE New Listing
302325 4/1/1997 0 0 0 FALSE FALSE Delisted
302414 4/11/1995 7/1/1997 29.5 29.5 29.5 FALSE FALSE New Listing
302414 7/1/1997 8/1/1999 29.5 29.5 32.45 FALSE FALSE Change +Price
302414 8/1/1999 4/1/2000 32.45 32.45 32.45 FALSE FALSE Change +Subsidy +Alternate
302414 4/1/2000 12/1/2000 32.45 32.45 37.5 FALSE FALSE Change +Price
302414 12/1/2000 6/1/2004 32.45 32.45 45.95 FALSE FALSE Change +Price
302414 6/1/2004 2/1/2007 32.45 32.45 50.55 FALSE FALSE Change +Price
302414 2/1/2007 7/1/2010 36.48 36.48 36.48 FALSE FALSE Change +Subsidy -Price +Alternate
302414 7/1/2010 12/1/2010 32.37 32.37 32.37 FALSE FALSE Change -Subsidy -Price -Alternate
302414 12/1/2010 0 0 0 FALSE FALSE Delisted
302449 5/16/1994 7/1/1998 40.89 40.89 40.89 FALSE FALSE New Listing
302449 7/1/1998 0 0 0 FALSE FALSE Delisted
302457 5/16/1994 7/1/2006 50 50 50 FALSE FALSE New Listing
302457 7/1/2006 0 0 0 FALSE FALSE Delisted
302465 5/16/1994 5/1/1998 10.03 10.03 10.03 FALSE FALSE New Listing
302465 5/1/1998 8/1/1998 6.82 6.82 7.27 FALSE FALSE Change -Subsidy -Price -Alternate
302465 8/1/1998 0 0 0 FALSE FALSE Delisted
302481 5/16/1994 7/1/2010 60.71 60.71 60.71 FALSE FALSE New Listing
302481 7/1/2010 10/1/2010 47.95 47.95 60.71 FALSE FALSE Change -Subsidy -Alternate
302481 10/1/2010 0 0 0 FALSE FALSE Delisted
302716 4/11/1995 7/1/1997 32.1 32.1 32.1 FALSE FALSE New Listing
302716 7/1/1997 8/1/1999 32.1 32.1 35.31 FALSE FALSE Change +Price
302716 8/1/1999 0 0 0 FALSE FALSE Delisted
302775 4/11/1995 10/1/1998 17.45 17.45 17.45 FALSE FALSE New Listing
302775 10/1/1998 0 0 0 FALSE FALSE Delisted
302805 4/11/1995 10/1/1996 32.6 32.6 32.6 FALSE FALSE New Listing
302805 10/1/1996 7/1/1997 32.5 32.5 32.5 FALSE FALSE Change -Subsidy -Price -Alternate
302805 7/1/1997 8/1/1999 32.5 32.5 35.86 FALSE FALSE Change +Price
302805 8/1/1999 0 0 0 FALSE FALSE Delisted
302821 4/11/1995 6/27/1995 24.65 24.65 24.65 FALSE FALSE New Listing
302821 6/27/1995 8/1/1997 24.65 24.65 32.6 FALSE FALSE Change +Price
302821 8/1/1997 8/1/1999 24.65 24.65 36.5 FALSE FALSE Change +Price
302821 8/1/1999 0 0 0 FALSE FALSE Delisted
302899 5/16/1994 6/1/1999 13.33 13.33 13.33 FALSE TRUE New Listing
302899 6/1/1999 0 0 0 FALSE FALSE Delisted
303070 5/16/1994 9/1/2001 16.5 16.5 16.5 FALSE FALSE New Listing
303070 9/1/2001 5/1/2012 12.38 12.38 12.38 FALSE FALSE Change -Subsidy -Price -Alternate
303070 5/1/2012 0 0 0 FALSE FALSE Delisted
303127 8/1/1999 12/1/2002 15.84 15.84 15.84 FALSE FALSE New Listing
303127 12/1/2002 3/1/2003 14.11 14.11 15.84 FALSE FALSE Change -Subsidy -Alternate
303127 3/1/2003 7/1/2005 0 0 0 FALSE FALSE Delisted
303127 7/1/2005 5/1/2009 13.23 13.23 13.23 FALSE FALSE New Listing
303127 5/1/2009 0 0 0 FALSE FALSE Delisted
303488 5/16/1994 1/1/1997 2.96 2.96 2.96 FALSE TRUE New Listing
303488 1/1/1997 0 0 0 FALSE FALSE Delisted
303518 5/16/1994 6/1/1996 28.38 28.38 43.56 FALSE FALSE New Listing
303518 6/1/1996 1/1/2004 9.45 14.52 14.52 FALSE FALSE Change -Subsidy -Price -Alternate
303518 1/1/2004 6/1/2007 6.62 14.52 14.52 FALSE FALSE Change -Subsidy
303518 6/1/2007 6.62 6.62 6.62 FALSE FALSE Change -Price -Alternate
303542 5/16/1994 4/1/2000 9.45 14.52 14.52 FALSE TRUE New Listing
303542 4/1/2000 1/1/2004 9.45 14.52 14.52 FALSE FALSE Change -OP
303542 1/1/2004 6/1/2007 6.62 14.52 14.52 FALSE FALSE Change -Subsidy
303542 6/1/2007 6.62 6.62 6.62 FALSE FALSE Change -Price -Alternate
303550 5/16/1994 4/1/2000 9.45 14.52 14.52 FALSE TRUE New Listing
303550 4/1/2000 4/1/2003 9.45 14.52 14.52 FALSE FALSE Change -OP
303550 4/1/2003 7/1/2003 6.62 14.52 14.52 FALSE FALSE Change -Subsidy
303550 7/1/2003 0 0 0 FALSE FALSE Delisted
303569 5/16/1994 7/1/1999 7.38 7.38 7.38 FALSE FALSE New Listing
303569 7/1/1999 11/1/1999 2.2 2.2 7.38 FALSE FALSE Change -Subsidy -Alternate
303569 11/1/1999 0 0 0 FALSE FALSE Delisted
303623 5/16/1994 8/1/1999 9.02 9.02 9.02 FALSE FALSE New Listing
303623 8/1/1999 4/1/2002 9.02 9.02 10.5 FALSE FALSE Change +Price
303623 4/1/2002 0 0 0 FALSE FALSE Delisted
303631 5/16/1994 8/1/1999 45.1 45.1 45.1 FALSE FALSE New Listing
303631 8/1/1999 11/1/2000 45.1 45.1 52.5 FALSE FALSE Change +Price
303631 11/1/2000 0 0 0 FALSE FALSE Delisted
303666 5/16/1994 5/12/1995 34.98 34.98 34.98 FALSE FALSE New Listing
303666 5/12/1995 5/1/1998 34.98 34.98 35.69 FALSE FALSE Change +Price
303666 5/1/1998 8/1/1998 14.7 14.7 14.7 FALSE FALSE Change -Subsidy -Price -Alternate
303666 8/1/1998 0 0 0 FALSE FALSE Delisted
303674 5/16/1994 5/12/1995 64.03 64.03 64.03 FALSE FALSE New Listing
303674 5/12/1995 5/1/1998 64.03 64.03 65.33 FALSE FALSE Change +Price
303674 5/1/1998 8/1/1998 25.65 25.65 25.65 FALSE FALSE Change -Subsidy -Price -Alternate
303674 8/1/1998 0 0 0 FALSE FALSE Delisted
303690 5/16/1994 1/1/1998 10 10 11.32 FALSE FALSE New Listing
303690 1/1/1998 7/1/1998 10 10 13.02 FALSE FALSE Change +Price
303690 7/1/1998 8/1/1999 10 10 14.92 FALSE FALSE Change +Price
303690 8/1/1999 4/1/2000 10 10 10 FALSE FALSE Change -Price
303690 4/1/2000 8/1/2001 10 10 14.92 FALSE FALSE Change +Price
303690 8/1/2001 2/1/2005 15 15 15 FALSE FALSE Change +Subsidy +Price +Alternate
303690 2/1/2005 0 0 0 FALSE FALSE Delisted
303763 5/16/1994 4/3/1995 7.35 7.35 8.24 FALSE FALSE New Listing
303763 4/3/1995 9/1/2000 7.35 7.35 7.35 FALSE FALSE Change -Price
303763 9/1/2000 10/1/2005 6.39 6.39 6.39 FALSE FALSE Change -Subsidy -Price -Alternate
303763 10/1/2005 10/1/2008 9 9 9 FALSE FALSE Change +Subsidy +Price +Alternate
303763 10/1/2008 1/1/2012 12 12 12 FALSE FALSE Change +Subsidy +Price +Alternate
303763 1/1/2012 14.25 14.25 14.25 FALSE FALSE Change +Subsidy +Price +Alternate
303984 5/16/1994 8/1/2000 13 13 13 FALSE FALSE New Listing
303984 8/1/2000 7/1/2003 13 13 16.25 FALSE FALSE Change +Price
303984 7/1/2003 0 0 0 FALSE FALSE Delisted
303992 8/16/1994 8/1/2000 13 13 13 FALSE FALSE New Listing
303992 8/1/2000 9/1/2006 13 13 17.25 FALSE FALSE Change +Price
303992 9/1/2006 10/1/2010 17.25 17.25 17.25 FALSE FALSE Change +Subsidy +Alternate
303992 10/1/2010 1/1/2011 13.8 13.8 17.25 FALSE FALSE Change -Subsidy -Alternate
303992 1/1/2011 0 0 0 FALSE FALSE Delisted
304093 5/30/1995 7/1/1995 20.52 20.52 20.52 FALSE FALSE New Listing
304093 7/1/1995 1/1/1998 20.52 20.52 24.55 FALSE FALSE Change +Price
304093 1/1/1998 12/1/1998 20.52 20.52 41.04 FALSE FALSE Change +Price
304093 12/1/1998 3/1/1999 14.5 14.5 41.04 FALSE FALSE Change -Subsidy -Alternate
304093 3/1/1999 0 0 0 FALSE FALSE Delisted
304123 5/16/1994 3/1/2002 40.8 40.8 40.8 FALSE FALSE New Listing
304123 3/1/2002 8/1/2002 40.8 40.8 51.7 FALSE FALSE Change +Price
304123 8/1/2002 10/1/2004 40.8 40.8 40.8 FALSE FALSE Change -Price
304123 10/1/2004 8/1/2005 28 28 28 FALSE FALSE Change -Subsidy -Price -Alternate
304123 8/1/2005 11/1/2005 19.6 19.6 28 FALSE FALSE Change -Subsidy -Alternate
304123 11/1/2005 0 0 0 FALSE FALSE Delisted
304131 5/16/1994 9/1/2000 10.5 10.5 10.5 FALSE FALSE New Listing
304131 9/1/2000 9/1/2003 6.62 6.62 6.62 FALSE FALSE Change -Subsidy -Price -Alternate
304131 9/1/2003 1/1/2010 6.59 6.59 6.59 FALSE FALSE Change -Subsidy -Price -Alternate
304131 1/1/2010 10.21 10.21 10.21 FALSE FALSE Change +Subsidy +Price +Alternate
304166 5/16/1994 10/1/1997 27.76 27.76 27.76 FALSE FALSE New Listing
304166 10/1/1997 2/1/1998 24.98 24.98 24.98 FALSE FALSE Change -Subsidy -Price -Alternate
304166 2/1/1998 8/1/2000 17.49 17.49 17.49 FALSE FALSE Change -Subsidy -Price -Alternate
304166 8/1/2000 12/1/2000 10.99 10.99 10.99 FALSE FALSE Change -Subsidy -Price -Alternate
304166 12/1/2000 0 0 0 FALSE FALSE Delisted
304174 8/16/1994 5/1/1996 17.1 17.1 17.1 FALSE FALSE New Listing
304174 5/1/1996 1/1/1999 17.1 17.1 19.68 FALSE FALSE Change +Price
304174 1/1/1999 8/1/2000 17.1 17.1 17.1 FALSE FALSE Change -Price
304174 8/1/2000 10/1/2000 17.1 17.1 22.25 FALSE FALSE Change +Price
304174 10/1/2000 2/1/2002 17.1 17.1 25 FALSE FALSE Change +Price
304174 2/1/2002 5/1/2002 15.6 15.6 25 FALSE FALSE Change -Subsidy -Alternate
304174 5/1/2002 0 0 0 FALSE FALSE Delisted
304182 5/16/1994 9/1/1996 13.64 13.64 13.64 FALSE FALSE New Listing
304182 9/1/1996 11/1/1997 13.64 13.64 18.41 FALSE FALSE Change +Price
304182 11/1/1997 5/1/2001 13.64 13.64 21.45 FALSE FALSE Change +Price
304182 5/1/2001 0 0 0 FALSE FALSE Delisted
304190 11/1/1997 5/1/2001 3.58 3.58 9.43 FALSE FALSE New Listing
304190 5/1/2001 0 0 0 FALSE FALSE Delisted
304204 5/16/1994 7/1/1995 10.71 10.71 10.71 FALSE FALSE New Listing
304204 7/1/1995 9/1/1996 17.91 17.91 17.91 FALSE FALSE Change +Subsidy +Price +Alternate
304204 9/1/1996 11/1/1997 17.91 17.91 23.27 FALSE FALSE Change +Price
304204 11/1/1997 5/1/2001 17.91 17.91 27.11 FALSE FALSE Change +Price
304204 5/1/2001 0 0 0 FALSE FALSE Delisted
304239 5/16/1994 7/1/1995 8.95 8.95 8.95 FALSE FALSE New Listing
304239 7/1/1995 10/1/1997 8.95 8.95 9.86 FALSE FALSE Change +Price
304239 10/1/1997 8/1/2000 9.86 9.86 9.86 FALSE FALSE Change +Subsidy +Alternate
304239 8/1/2000 10/1/2000 9.86 9.86 11.34 FALSE FALSE Change +Price
304239 10/1/2000 9/1/2001 9.86 9.86 13.27 FALSE FALSE Change +Price
304239 9/1/2001 8/1/2006 13.27 13.27 13.27 FALSE FALSE Change +Subsidy +Alternate
304239 8/1/2006 0 0 0 FALSE FALSE Delisted
304247 10/1/1997 8/1/2000 2.47 2.47 2.47 FALSE FALSE New Listing
304247 8/1/2000 10/1/2000 2.47 2.47 4.09 FALSE FALSE Change +Price
304247 10/1/2000 9/1/2001 2.47 2.47 3.33 FALSE FALSE Change -Price
304247 9/1/2001 10/1/2006 4.79 4.79 4.79 FALSE FALSE Change +Subsidy +Price +Alternate
304247 10/1/2006 7/1/2011 5.08 5.08 5.08 FALSE FALSE Change +Subsidy +Price +Alternate
304247 7/1/2011 4.17 4.17 4.17 FALSE FALSE Change -Subsidy -Price -Alternate
304255 5/16/1994 7/1/1995 8.76 8.76 8.76 FALSE FALSE New Listing
304255 7/1/1995 10/1/1997 8.76 8.76 12.36 FALSE FALSE Change +Price
304255 10/1/1997 8/1/2000 12.36 12.36 12.36 FALSE FALSE Change +Subsidy +Alternate
304255 8/1/2000 10/1/2000 12.36 12.36 14.25 FALSE FALSE Change +Price
304255 10/1/2000 9/1/2001 12.36 12.36 16.67 FALSE FALSE Change +Price
304255 9/1/2001 3/1/2002 23.95 23.95 23.95 FALSE FALSE Change +Subsidy +Price +Alternate
304255 3/1/2002 0 0 0 FALSE FALSE Delisted
304263 5/16/1994 7/1/1995 3.26 3.26 3.26 FALSE FALSE New Listing
304263 7/1/1995 7/1/1997 3.26 3.26 5.18 FALSE FALSE Change +Price
304263 7/1/1997 10/1/1997 3.25 3.25 5.18 FALSE FALSE Change -Subsidy -Alternate
304263 10/1/1997 8/1/2000 5.18 5.18 5.18 FALSE FALSE Change +Subsidy +Alternate
304263 8/1/2000 10/1/2000 5.18 5.18 5.96 FALSE FALSE Change +Price
304263 10/1/2000 9/1/2001 5.18 5.18 6.97 FALSE FALSE Change +Price
304263 9/1/2001 8/1/2006 6.97 6.97 6.97 FALSE FALSE Change +Subsidy +Alternate
304263 8/1/2006 0 0 0 FALSE FALSE Delisted
304271 10/1/1997 8/1/2000 25.9 25.9 25.9 FALSE FALSE New Listing
304271 8/1/2000 10/1/2000 25.9 25.9 29.8 FALSE FALSE Change +Price
304271 10/1/2000 9/1/2001 25.9 25.9 34.85 FALSE FALSE Change +Price
304271 9/1/2001 3/1/2002 34.85 34.85 34.85 FALSE FALSE Change +Subsidy +Alternate
304271 3/1/2002 0 0 0 FALSE FALSE Delisted
304298 5/16/1994 11/1/1997 30 30 30 FALSE FALSE New Listing
304298 11/1/1997 0 0 0 FALSE FALSE Delisted
304301 5/16/1994 7/1/1995 36.24 36.24 40.62 FALSE FALSE New Listing
304301 7/1/1995 8/1/1999 36.24 36.24 46.73 FALSE FALSE Change +Price
304301 8/1/1999 12/1/1999 34 34 46.73 FALSE FALSE Change -Subsidy -Alternate
304301 12/1/1999 0 0 0 FALSE FALSE Delisted
304328 5/16/1994 7/1/1997 22.85 22.85 22.85 FALSE FALSE New Listing
304328 7/1/1997 7/1/1999 21.75 21.75 21.75 FALSE FALSE Change -Subsidy -Price -Alternate
304328 7/1/1999 8/1/2002 12.22 12.22 12.22 FALSE FALSE Change -Subsidy -Price -Alternate
304328 8/1/2002 7/1/2005 11.98 11.98 11.98 FALSE FALSE Change -Subsidy -Price -Alternate
304328 7/1/2005 11.09 11.09 11.09 FALSE FALSE Change -Subsidy -Price -Alternate
304336 8/1/1999 11/1/2002 48.96 48.96 48.96 FALSE FALSE New Listing
304336 11/1/2002 11/1/2003 61.64 61.64 61.64 FALSE FALSE Change +Subsidy +Price +Alternate
304336 11/1/2003 2/1/2004 47.23 47.23 61.64 FALSE FALSE Change -Subsidy -Alternate
304336 2/1/2004 0 0 0 FALSE FALSE Delisted
304344 5/16/1994 8/1/2000 3.7 3.7 3.7 FALSE FALSE New Listing
304344 8/1/2000 3/1/2001 3.7 3.7 5.18 FALSE FALSE Change +Price
304344 3/1/2001 8/1/2006 3.4 3.4 5.18 FALSE FALSE Change -Subsidy -Alternate
304344 8/1/2006 0 0 0 FALSE FALSE Delisted
304352 5/16/1994 8/1/2000 18.5 18.5 18.5 FALSE FALSE New Listing
304352 8/1/2000 3/1/2001 18.5 18.5 25.9 FALSE FALSE Change +Price
304352 3/1/2001 7/1/2003 17 17 25.9 FALSE FALSE Change -Subsidy -Alternate
304352 7/1/2003 0 0 0 FALSE FALSE Delisted
304360 5/16/1994 8/1/2000 2.52 2.52 4.55 FALSE FALSE New Listing
304360 8/1/2000 7/1/2005 2.52 2.52 6.37 FALSE FALSE Change +Price
304360 7/1/2005 0 0 0 FALSE FALSE Delisted
304379 5/16/1994 8/1/2000 12.59 12.59 12.59 FALSE FALSE New Listing
304379 8/1/2000 9/1/2006 12.59 12.59 17.63 FALSE FALSE Change +Price
304379 9/1/2006 7/1/2011 17.63 17.63 17.63 FALSE FALSE Change +Subsidy +Alternate
304379 7/1/2011 12.16 12.16 12.16 FALSE FALSE Change -Subsidy -Price -Alternate
304441 5/16/1994 7/1/1995 16.73 16.73 16.73 FALSE FALSE New Listing
304441 7/1/1995 2/1/2001 19.27 19.27 19.27 FALSE FALSE Change +Subsidy +Price +Alternate
304441 2/1/2001 0 0 0 FALSE FALSE Delisted
304468 10/1/1997 8/1/2000 4.18 4.18 4.05 FALSE FALSE New Listing
304468 8/1/2000 10/1/2000 4.18 4.18 5.02 FALSE FALSE Change +Price
304468 10/1/2000 10/1/2006 4.18 4.18 5.62 FALSE FALSE Change +Price
304468 10/1/2006 5.62 5.62 5.62 FALSE FALSE Change +Subsidy +Alternate
304476 5/16/1994 7/1/1995 18.16 18.16 18.16 FALSE FALSE New Listing
304476 7/1/1995 7/1/1997 18.16 18.16 20.91 FALSE FALSE Change +Price
304476 7/1/1997 10/1/1997 18.15 18.15 20.91 FALSE FALSE Change -Subsidy -Alternate
304476 10/1/1997 8/1/2000 20.91 20.91 20.91 FALSE FALSE Change +Subsidy +Alternate
304476 8/1/2000 2/1/2001 20.91 20.91 25.1 FALSE FALSE Change +Price
304476 2/1/2001 0 0 0 FALSE FALSE Delisted
304786 8/1/1999 6/1/2000 4.58 4.58 4.58 FALSE FALSE New Listing
304786 6/1/2000 7/1/2003 4.05 4.05 4.05 FALSE FALSE Change -Subsidy -Price -Alternate
304786 7/1/2003 8/1/2003 4.38 4.38 4.38 FALSE FALSE Change +Subsidy +Price +Alternate
304786 8/1/2003 0 0 0 FALSE FALSE Delisted
304859 4/11/1995 6/27/1995 48.4 48.4 48.4 FALSE FALSE New Listing
304859 6/27/1995 8/1/1999 48.4 48.4 51.2 FALSE FALSE Change +Price
304859 8/1/1999 0 0 0 FALSE FALSE Delisted
304905 8/1/1999 6/1/2000 9.15 9.15 9.15 FALSE FALSE New Listing
304905 6/1/2000 7/1/2003 8.1 8.1 8.1 FALSE FALSE Change -Subsidy -Price -Alternate
304905 7/1/2003 11/1/2003 8.75 8.75 8.75 FALSE FALSE Change +Subsidy +Price +Alternate
304905 11/1/2003 2/1/2004 7.29 7.29 7.29 FALSE FALSE Change -Subsidy -Price -Alternate
304905 2/1/2004 7/1/2008 0 0 0 FALSE FALSE Delisted
304905 7/1/2008 12/1/2011 6.8 6.8 6.8 FALSE FALSE New Listing
304905 12/1/2011 3/1/2012 4.42 4.42 4.42 FALSE FALSE Change -Subsidy -Price -Alternate
304905 3/1/2012 0 0 0 FALSE FALSE Delisted
304913 5/16/1994 11/1/1999 15.5 15.5 15.5 FALSE FALSE New Listing
304913 11/1/1999 2/1/2000 15.5 15.5 50 FALSE FALSE Change +Price
304913 2/1/2000 1/1/2002 50 50 50 FALSE FALSE Change +Subsidy +Alternate
304913 1/1/2002 9/1/2008 75 75 75 FALSE FALSE Change +Subsidy +Price +Alternate
304913 9/1/2008 10/1/2008 75 75 82.5 FALSE FALSE Change +Price
304913 10/1/2008 82.5 82.5 82.5 FALSE FALSE Change +Subsidy +Alternate
304948 6/26/1995 4/1/2011 1.87 1.87 1.87 FALSE TRUE New Listing
304948 4/1/2011 2/1/2014 2.2 2.2 2.2 FALSE TRUE Change +Subsidy +Price +Alternate
304948 2/1/2014 0 0 0 FALSE FALSE Delisted
305197 5/16/1994 6/27/1995 28 28 28 FALSE TRUE New Listing
305197 6/27/1995 1/1/1997 30.23 30.23 30.23 FALSE TRUE Change +Subsidy +Price +Alternate
305197 1/1/1997 9/1/2001 30.23 30.23 33.63 FALSE TRUE Change +Price
305197 9/1/2001 11/1/2002 30.23 30.23 42.9 FALSE TRUE Change +Price
305197 11/1/2002 4/1/2007 42.9 42.9 42.9 FALSE TRUE Change +Subsidy +Alternate
305197 4/1/2007 1/1/2011 42.9 42.9 42.9 FALSE FALSE Change -OP
305197 1/1/2011 0 0 0 FALSE FALSE Delisted
305200 5/16/1994 6/27/1995 28 28 28 FALSE TRUE New Listing
305200 6/27/1995 1/1/1997 30.23 30.23 30.23 FALSE TRUE Change +Subsidy +Price +Alternate
305200 1/1/1997 9/1/2001 30.23 30.23 33.63 FALSE TRUE Change +Price
305200 9/1/2001 11/1/2002 30.23 30.23 42.9 FALSE TRUE Change +Price
305200 11/1/2002 4/1/2007 42.9 42.9 42.9 FALSE TRUE Change +Subsidy +Alternate
305200 4/1/2007 1/1/2011 42.9 42.9 42.9 FALSE FALSE Change -OP
305200 1/1/2011 0 0 0 FALSE FALSE Delisted
305219 5/16/1994 7/1/1997 14.97 14.97 14.97 FALSE FALSE New Listing
305219 7/1/1997 7/1/1999 13.9 13.9 13.9 FALSE FALSE Change -Subsidy -Price -Alternate
305219 7/1/1999 11/1/1999 7.3 7.3 7.3 FALSE FALSE Change -Subsidy -Price -Alternate
305219 11/1/1999 0 0 0 FALSE FALSE Delisted
305316 5/16/1994 10/1/1998 23.53 23.53 23.53 FALSE FALSE New Listing
305316 10/1/1998 7/1/1999 20 20 20 FALSE FALSE Change -Subsidy -Price -Alternate
305316 7/1/1999 9/1/1999 9.38 9.38 20 FALSE FALSE Change -Subsidy -Alternate
305316 9/1/1999 11/1/1999 9.38 9.38 9.38 FALSE FALSE Change -Price
305316 11/1/1999 0 0 0 FALSE FALSE Delisted
305367 8/1/1999 6/1/2000 4.58 4.58 4.58 FALSE FALSE New Listing
305367 6/1/2000 7/1/2003 4.05 4.05 4.05 FALSE FALSE Change -Subsidy -Price -Alternate
305367 7/1/2003 8/1/2003 4.45 4.45 4.45 FALSE FALSE Change +Subsidy +Price +Alternate
305367 8/1/2003 0 0 0 FALSE FALSE Delisted
305375 6/2/1995 7/1/2000 12.62 12.62 13.95 FALSE FALSE New Listing
305375 7/1/2000 7/1/2007 12.62 12.62 23.15 FALSE FALSE Change +Price
305375 7/1/2007 12.62 12.62 25.46 FALSE FALSE Change +Price
305502 4/12/1995 7/1/1997 8.4 8.4 8.4 FALSE FALSE New Listing
305502 7/1/1997 8/1/1999 8.4 8.4 9 FALSE FALSE Change +Price
305502 8/1/1999 0 0 0 FALSE FALSE Delisted
305537 4/12/1995 8/1/1999 9.3 9.3 9.3 TRUE FALSE New Listing
305537 8/1/1999 0 0 0 FALSE FALSE Delisted
305545 4/12/1995 8/1/1999 0.09 0.09 0.09 TRUE FALSE New Listing
305545 8/1/1999 0 0 0 FALSE FALSE Delisted
305618 4/12/1995 8/1/1999 0.07 0.07 0.07 TRUE FALSE New Listing
305618 8/1/1999 0 0 0 FALSE FALSE Delisted
305634 4/12/1995 8/1/1999 29.2 29.2 29.2 FALSE FALSE New Listing
305634 8/1/1999 0 0 0 FALSE FALSE Delisted
305642 4/12/1995 2/1/1998 19.05 19.05 19.05 FALSE FALSE New Listing
305642 2/1/1998 0 0 0 FALSE FALSE Delisted
305707 4/12/1995 10/1/1996 49.5 49.5 49.5 FALSE FALSE New Listing
305707 10/1/1996 0 0 0 FALSE FALSE Delisted
305723 4/12/1995 7/1/1997 26.6 26.6 26.6 FALSE FALSE New Listing
305723 7/1/1997 8/1/1999 26.6 26.6 29.26 FALSE FALSE Change +Price
305723 8/1/1999 0 0 0 FALSE FALSE Delisted
305774 10/1/1996 7/1/1997 41.56 41.56 60.8 FALSE FALSE New Listing
305774 7/1/1997 8/1/1999 41.56 41.56 66.88 FALSE FALSE Change +Price
305774 8/1/1999 0 0 0 FALSE FALSE Delisted
305782 10/1/1996 7/1/1997 10.39 10.39 15.2 FALSE FALSE New Listing
305782 7/1/1997 8/1/1999 10.39 10.39 16.72 FALSE FALSE Change +Price
305782 8/1/1999 0 0 0 FALSE FALSE Delisted
305847 10/1/1996 7/1/1997 21.6 21.6 45.25 FALSE FALSE New Listing
305847 7/1/1997 8/1/1999 21.6 21.6 49.75 FALSE FALSE Change +Price
305847 8/1/1999 0 0 0 FALSE FALSE Delisted
305960 4/11/1995 6/27/1995 18.1 18.1 18.1 FALSE FALSE New Listing
305960 6/27/1995 8/1/1999 18.1 18.1 21.6 FALSE FALSE Change +Price
305960 8/1/1999 0 0 0 FALSE FALSE Delisted
305987 4/12/1995 7/1/1997 24.2 24.2 24.2 FALSE FALSE New Listing
305987 7/1/1997 8/1/1999 24.2 24.2 26.62 FALSE FALSE Change +Price
305987 8/1/1999 0 0 0 FALSE FALSE Delisted
306002 4/12/1995 12/1/1997 7.45 7.45 7.45 FALSE FALSE New Listing
306002 12/1/1997 9/1/2002 6.55 6.55 6.55 FALSE FALSE Change -Subsidy -Price -Alternate
306002 9/1/2002 12/1/2002 6.2 6.2 6.55 FALSE FALSE Change -Subsidy -Alternate
306002 12/1/2002 7/1/2008 0 0 0 FALSE FALSE Delisted
306002 7/1/2008 5/1/2012 5.11 5.11 5.11 FALSE FALSE New Listing
306002 5/1/2012 8/1/2012 3.83 3.83 5.11 FALSE FALSE Change -Subsidy -Alternate
306002 8/1/2012 0 0 0 FALSE FALSE Delisted
306010 4/12/1995 12/1/1997 7.5 7.5 7.5 FALSE FALSE New Listing
306010 12/1/1997 9/1/1999 6.55 6.55 6.55 FALSE FALSE Change -Subsidy -Price -Alternate
306010 9/1/1999 12/1/2000 6.55 6.55 8.2 FALSE FALSE Change +Price
306010 12/1/2000 6/1/2004 6.55 6.55 8.9 FALSE FALSE Change +Price
306010 6/1/2004 11/1/2009 6.55 6.55 9.79 FALSE FALSE Change +Price
306010 11/1/2009 1/1/2011 6.55 6.55 12 FALSE FALSE Change +Price
306010 1/1/2011 0 0 0 FALSE FALSE Delisted
306029 4/12/1995 9/1/1999 6.55 6.55 6.55 FALSE FALSE New Listing
306029 9/1/1999 12/1/2000 6.55 6.55 8.25 FALSE FALSE Change +Price
306029 12/1/2000 9/1/2003 6.55 6.55 8.9 FALSE FALSE Change +Price
306029 9/1/2003 0 0 0 FALSE FALSE Delisted
306088 8/1/1999 6/1/2000 9.15 9.15 9.15 FALSE FALSE New Listing
306088 6/1/2000 7/1/2003 8.1 8.1 8.1 FALSE FALSE Change -Subsidy -Price -Alternate
306088 7/1/2003 11/1/2003 8.9 8.9 8.9 FALSE FALSE Change +Subsidy +Price +Alternate
306088 11/1/2003 2/1/2004 7.7 7.7 7.7 FALSE FALSE Change -Subsidy -Price -Alternate
306088 2/1/2004 7/1/2008 0 0 0 FALSE FALSE Delisted
306088 7/1/2008 7/1/2011 7 7 7 FALSE FALSE New Listing
306088 7/1/2011 7/1/2014 6.7 6.7 6.7 FALSE FALSE Change -Subsidy -Price -Alternate
306088 7/1/2014 4.35 4.35 4.35 FALSE FALSE Change -Subsidy -Price -Alternate
306096 4/12/1995 7/1/1997 34.08 34.08 34.08 FALSE FALSE New Listing
306096 7/1/1997 8/1/1999 34.08 34.08 37.5 FALSE FALSE Change +Price
306096 8/1/1999 0 0 0 FALSE FALSE Delisted
306762 4/11/1995 8/1/1999 23.8 23.8 18.4 FALSE FALSE New Listing
306762 8/1/1999 0 0 0 FALSE FALSE Delisted
306770 5/16/1994 3/1/1996 20.05 20.05 21.68 FALSE FALSE New Listing
306770 3/1/1996 7/1/1999 20.05 20.05 23.85 FALSE FALSE Change +Price
306770 7/1/1999 11/1/1999 8.58 8.58 23.85 FALSE FALSE Change -Subsidy +Price -Alternate
306770 11/1/1999 0 0 0 FALSE FALSE Delisted
306797 5/16/1994 6/1/1999 67 67 67 FALSE FALSE New Listing
306797 6/1/1999 0 0 0 FALSE FALSE Delisted
306835 5/16/1994 3/1/1995 25.08 25.08 25.08 FALSE FALSE New Listing
306835 3/1/1995 2/1/2000 25.08 25.08 26.96 FALSE FALSE Change +Price
306835 2/1/2000 11/1/2000 25.08 25.08 29.66 FALSE FALSE Change +Price
306835 11/1/2000 0 0 0 FALSE FALSE Delisted
306843 5/1/2002 5/1/2007 176.7 176.7 176.7 FALSE FALSE New listing
306843 5/1/2007 10/1/2012 79.27 79.27 79.27 FALSE FALSE Change -Subsidy -Price -Alternate
306843 10/1/2012 55 55 55 FALSE FALSE Change -Subsidy -Price -Alternate
306851 5/16/1994 12/1/1994 41.11 41.11 41.11 FALSE FALSE New Listing
306851 12/1/1994 2/1/1996 41 41 41.11 FALSE FALSE Change -Subsidy -Alternate
306851 2/1/1996 8/1/1998 37.56 37.56 37.56 FALSE FALSE Change -Subsidy -Price -Alternate
306851 8/1/1998 12/1/2000 13.98 37.56 37.56 FALSE FALSE Change -Subsidy
306851 12/1/2000 0 0 0 FALSE FALSE Delisted
307068 5/16/1994 1/1/1998 6.13 6.13 6.96 FALSE FALSE New Listing
307068 1/1/1998 10/1/1998 1.8 1.8 6.96 FALSE FALSE Change -Subsidy -Alternate
307068 10/1/1998 3/1/2002 1.8 1.8 7.1 FALSE FALSE Change +Price
307068 3/1/2002 11/1/2006 1.8 1.8 7.81 FALSE FALSE Change +Price
307068 11/1/2006 0 0 0 FALSE FALSE Delisted
307084 9/1/1997 10/1/2002 70.37 70.37 70.37 FALSE FALSE New Listing
307084 10/1/2002 1/1/2003 60 60 70.37 FALSE FALSE Change -Subsidy -Alternate
307084 1/1/2003 0 0 0 FALSE FALSE Delisted
307173 10/4/1997 6/1/1999 10.33 10.33 11.33 FALSE FALSE New Listing
307173 6/1/1999 0 0 0 FALSE FALSE Delisted
307181 5/16/1994 7/1/1999 10.11 10.11 10.86 FALSE FALSE New Listing
307181 7/1/1999 11/1/1999 5.25 5.25 10.86 FALSE FALSE Change -Subsidy -Alternate
307181 11/1/1999 0 0 0 FALSE FALSE Delisted
307211 5/16/1994 3/1/1995 11.66 11.66 11.66 FALSE FALSE New Listing
307211 3/1/1995 10/1/2003 11.66 11.66 17.1 FALSE FALSE Change +Price
307211 10/1/2003 0 0 0 FALSE FALSE Delisted
307335 7/1/1996 8/1/2000 0 0 0 TRUE FALSE New Listing
307335 8/1/2000 3/1/2002 31.95 31.95 31.95 FALSE FALSE Change +Subsidy +Price +Alternate -CBS
307335 3/1/2002 31.95 31.95 32.72 FALSE FALSE Change +Price
307521 5/16/1994 11/1/2003 29.54 29.54 30.71 FALSE TRUE New Listing
307521 11/1/2003 2/1/2004 29.54 29.54 37.53 FALSE TRUE Change +Price
307521 2/1/2004 37.53 37.53 37.53 FALSE TRUE Change +Subsidy +Alternate
307548 5/16/1994 2/1/1998 47.7 47.7 47.7 FALSE FALSE New Listing
307548 2/1/1998 2/1/1999 23.85 23.85 23.85 FALSE FALSE Change -Subsidy -Price -Alternate
307548 2/1/1999 8/1/2000 11.93 11.93 11.93 FALSE FALSE Change -Subsidy -Price -Alternate
307548 8/1/2000 12/1/2000 2.99 2.99 11.93 FALSE FALSE Change -Subsidy -Alternate
307548 12/1/2000 0 0 0 FALSE FALSE Delisted
307645 6/1/2000 12/1/2012 143 143 143 FALSE FALSE New Listing
307645 12/1/2012 3/1/2013 32.5 32.5 143 FALSE FALSE Change -Subsidy -Alternate
307645 3/1/2013 0 0 0 FALSE FALSE Delisted
307661 12/1/1995 8/1/1999 7.69 7.69 7.69 FALSE FALSE New Listing
307661 8/1/1999 10/1/2002 2.1 2.1 2.1 FALSE FALSE Change -Subsidy -Price -Alternate
307661 10/1/2002 10/1/2005 2.2 2.2 2.2 FALSE FALSE Change +Subsidy +Price +Alternate
307661 10/1/2005 10/1/2008 2.3 2.3 2.3 FALSE FALSE Change +Subsidy +Price +Alternate
307661 10/1/2008 9/1/2011 2.9 2.9 2.9 FALSE FALSE Change +Subsidy +Price +Alternate
307661 9/1/2011 3.05 3.05 3.05 FALSE FALSE Change +Subsidy +Price +Alternate
307696 6/1/2000 90 90 90 FALSE FALSE New Listing
307769 5/16/1994 8/1/1999 14.63 14.63 14.63 FALSE FALSE New Listing
307769 8/1/1999 10/1/2002 4.2 4.2 4.2 FALSE FALSE Change -Subsidy -Price -Alternate
307769 10/1/2002 10/1/2005 4.4 4.4 4.4 FALSE FALSE Change +Subsidy +Price +Alternate
307769 10/1/2005 10/1/2008 4.6 4.6 4.6 FALSE FALSE Change +Subsidy +Price +Alternate
307769 10/1/2008 9/1/2011 5.54 5.54 5.54 FALSE FALSE Change +Subsidy +Price +Alternate
307769 9/1/2011 5.82 5.82 5.82 FALSE FALSE Change +Subsidy +Price +Alternate
307785 7/1/2005 8/1/2011 1195 1195 1195 FALSE FALSE New listing
307785 8/1/2011 1075.5 1075.5 1075.5 FALSE FALSE Change -Subsidy -Price -Alternate
307831 7/1/2005 8/1/2011 2987 2987 2987 FALSE FALSE New listing
307831 8/1/2011 2688.3 2688.3 2688.3 FALSE FALSE Change -Subsidy -Price -Alternate
307939 7/1/2000 4/1/2002 162.9 162.9 162.9 FALSE FALSE New Listing
307939 4/1/2002 2/1/2006 76.02 76.02 162.9 FALSE FALSE Change -Subsidy -Alternate
307939 2/1/2006 5/1/2007 68.42 68.42 162.9 FALSE FALSE Change -Subsidy -Alternate
307939 5/1/2007 9/1/2008 60.82 60.82 162.9 FALSE FALSE Change -Subsidy -Alternate
307939 9/1/2008 48.68 48.68 48.68 FALSE FALSE Change -Subsidy -Price -Alternate
307947 6/1/1999 9/1/2002 6.15 6.15 8 FALSE FALSE New Listing
307947 9/1/2002 12/1/2002 5.8 5.8 8 FALSE FALSE Change -Subsidy -Alternate
307947 12/1/2002 0 0 0 FALSE FALSE Delisted
307963 6/1/1999 12/1/2012 667.2 667.2 667.2 FALSE FALSE New Listing
307963 12/1/2012 3/1/2013 63.5 63.5 667.2 FALSE FALSE Change -Subsidy -Alternate
307963 3/1/2013 3/22/2013 0 0 0 FALSE FALSE Delisted
307963 3/22/2013 6/1/2014 667.2 667.2 667.2 FALSE FALSE New Listing
307963 6/1/2014 0 0 0 FALSE FALSE Delisted
308021 8/1/1996 12/1/2011 10.9 10.9 10.9 FALSE FALSE New Listing
308021 12/1/2011 0 0 0 FALSE FALSE Delisted
308218 9/1/1997 3/1/2005 4.91 4.91 4.91 FALSE FALSE New Listing
308218 3/1/2005 7/1/2009 3.93 3.93 3.93 FALSE FALSE Change -Subsidy -Price -Alternate
308218 7/1/2009 3.15 3.15 3.15 FALSE FALSE Change -Subsidy -Price -Alternate
308390 5/16/1994 11.48 11.48 11.48 FALSE TRUE New Listing
308455 6/1/1995 7/1/1997 2.13 2.13 2.13 FALSE TRUE New Listing
308455 7/1/1997 5/1/1999 1.62 1.62 2.13 FALSE TRUE Change -Subsidy -Alternate
308455 5/1/1999 4/1/2011 1.33 1.33 1.33 FALSE TRUE Change -Subsidy -Price -Alternate
308455 4/1/2011 0.85 1.33 1.33 FALSE TRUE Change -Subsidy
308633 4/11/1995 2/1/1998 9.06 9.06 9.06 FALSE FALSE New Listing
308633 2/1/1998 0 0 0 FALSE FALSE Delisted
308641 4/11/1995 2/1/1998 22.38 22.38 22.38 FALSE FALSE New Listing
308641 2/1/1998 0 0 0 FALSE FALSE Delisted
309281 5/16/1994 6/1/2002 6.49 6.49 6.49 FALSE TRUE New Listing
309281 6/1/2002 0 0 0 FALSE FALSE Delisted
309508 4/11/1995 7/1/2000 9.3 9.3 9.3 FALSE FALSE New Listing
309508 7/1/2000 11/1/2000 9.3 9.3 10.7 FALSE FALSE Change +Price
309508 11/1/2000 4/1/2004 10.7 10.7 10.7 FALSE FALSE Change +Subsidy +Alternate
309508 4/1/2004 7/1/2004 8.35 10.7 10.7 FALSE FALSE Change -Subsidy
309508 7/1/2004 0 0 0 FALSE FALSE Delisted
309540 10/1/1999 7/1/2004 58 58 58 FALSE TRUE New Listing
309540 7/1/2004 5/1/2005 55 55 55 FALSE TRUE Change -Subsidy -Price -Alternate
309540 5/1/2005 0 0 0 FALSE FALSE Delisted
309591 5/16/1994 4/1/2000 33.04 33.04 33.04 FALSE FALSE New Listing
309591 4/1/2000 0 0 0 FALSE FALSE Delisted
309729 10/4/1997 8/1/1999 22.29 22.29 22.29 FALSE FALSE New Listing
309729 8/1/1999 10/1/2000 14.99 14.99 22.29 FALSE FALSE Change -Subsidy -Alternate
309729 10/1/2000 3/1/2003 14.95 14.95 22.29 FALSE FALSE Change -Subsidy -Alternate
309729 3/1/2003 0 0 0 FALSE FALSE Delisted
309796 5/16/1994 2/1/1996 78.1 78.1 78.1 FALSE FALSE New Listing
309796 2/1/1996 7/1/1997 71.36 71.36 71.36 FALSE FALSE Change -Subsidy -Price -Alternate
309796 7/1/1997 8/1/1998 71.36 71.36 71.36 FALSE FALSE Change -Subsidy -Price -Alternate
309796 8/1/1998 12/1/2000 26.57 71.36 71.36 FALSE FALSE Change -Subsidy +Alternate
309796 12/1/2000 0 0 0 FALSE FALSE Delisted
309923 5/16/1994 7/1/1999 36.46 36.46 36.46 FALSE FALSE New Listing
309923 7/1/1999 6/1/2003 16.99 16.99 16.99 FALSE FALSE Change -Subsidy -Price -Alternate
309923 6/1/2003 6/1/2004 18.5 18.5 18.5 FALSE FALSE Change +Subsidy +Price +Alternate
309923 6/1/2004 1/1/2012 17.5 17.5 17.5 FALSE FALSE Change -Subsidy -Price -Alternate
309923 1/1/2012 18.15 18.15 18.15 FALSE FALSE Change +Subsidy +Price +Alternate
309931 6/16/1995 5/1/1997 39.5 39.5 39.95 FALSE TRUE New Listing
309931 5/1/1997 10/1/2002 39.5 39.5 39.5 FALSE TRUE Change -Price
309931 10/1/2002 5/1/2006 28 28 28 FALSE TRUE Change -Subsidy -Price -Alternate
309931 5/1/2006 0 0 0 FALSE FALSE Delisted
309958 5/16/1994 9/1/1995 3.11 3.11 4.83 FALSE FALSE New Listing
309958 9/1/1995 6/1/1996 3.11 3.11 5.31 FALSE FALSE Change +Price
309958 6/1/1996 1/1/2002 3.11 3.11 10.62 FALSE FALSE Change +Price
309958 1/1/2002 10/1/2002 3.11 3.11 11.37 FALSE FALSE Change +Price
309958 10/1/2002 4/1/2004 3.11 3.11 12 FALSE FALSE Change +Price
309958 4/1/2004 10/1/2006 3.11 3.11 19.5 FALSE FALSE Change +Price
309958 10/1/2006 3.11 3.11 23.5 FALSE FALSE Change +Price
310018 6/16/1995 6/1/1996 28.38 28.38 41.4 FALSE FALSE New Listing
310018 6/1/1996 1/1/2004 9.45 13.8 13.8 FALSE FALSE Change -Subsidy -Price -Alternate
310018 1/1/2004 10/1/2013 6.62 13.8 16.5 FALSE FALSE Change -Subsidy +Price
310018 10/1/2013 0 0 0 FALSE FALSE Delisted
310034 5/16/1994 8/1/1997 3.33 3.33 4.41 FALSE TRUE New Listing
310034 8/1/1997 0 0 0 FALSE FALSE Delisted
310042 9/1/1996 9/1/1998 211.48 211.48 211.48 FALSE TRUE New Listing
310042 9/1/1998 10/1/1998 105.74 105.74 105.74 FALSE TRUE Change -Subsidy -Price -Alternate
310042 10/1/1998 11/1/1998 84.59 84.59 84.59 FALSE TRUE Change -Subsidy -Price -Alternate
310042 11/1/1998 9/1/2000 60 60 60 FALSE TRUE Change -Subsidy -Price -Alternate
310042 9/1/2000 3/1/2001 54 54 54 FALSE TRUE Change -Subsidy -Price -Alternate
310042 3/1/2001 7/1/2001 12.24 29.5 29.5 FALSE FALSE Change -Subsidy -Price -Alternate -OP
310042 7/1/2001 0 0 0 FALSE FALSE Delisted
310050 5/16/1994 12/1/1997 6.42 6.42 7.2 FALSE FALSE New Listing
310050 12/1/1997 1/1/1998 6.16 6.16 7.2 FALSE FALSE Change -Subsidy -Alternate
310050 1/1/1998 0 0 0 FALSE FALSE Delisted
310069 5/16/1994 12/1/1997 6.48 6.48 7.5 FALSE TRUE New Listing
310069 12/1/1997 1/1/1998 6.16 6.16 7.5 FALSE TRUE Change -Subsidy -Alternate
310069 1/1/1998 0 0 0 FALSE FALSE Delisted
310077 5/16/1994 3/1/1995 5.27 5.27 5.84 FALSE FALSE New Listing
310077 3/1/1995 7/1/1999 5.27 5.27 5.27 FALSE FALSE Change -Price
310077 7/1/1999 1/1/2005 3.16 3.16 3.16 FALSE FALSE Change -Subsidy -Price -Alternate
310077 1/1/2005 12/1/2005 2.94 2.94 2.94 FALSE FALSE Change -Subsidy -Price -Alternate
310077 12/1/2005 0 0 0 FALSE FALSE Delisted
310085 5/16/1994 12/1/1995 10.11 10.11 10.86 FALSE FALSE New Listing
310085 12/1/1995 7/1/1999 10.11 10.11 10.11 FALSE FALSE Change -Price
310085 7/1/1999 11/1/1999 5.25 5.25 10.11 FALSE FALSE Change -Subsidy -Alternate
310085 11/1/1999 9/1/2002 0 0 0 FALSE FALSE Delisted
310085 9/1/2002 11/1/2002 5.25 5.25 5.25 FALSE FALSE New Listing
310085 11/1/2002 7/1/2005 5.5 5.5 5.5 FALSE FALSE Change +Subsidy +Price +Alternate
310085 7/1/2005 0 0 0 FALSE FALSE Delisted
310115 5/16/1994 6/2/1995 12.31 12.31 12.31 FALSE TRUE New Listing
310115 6/2/1995 6/27/1995 10.46 10.46 12.31 FALSE TRUE Change -Subsidy -Alternate
310115 6/27/1995 4/1/1997 10.46 10.46 10.46 FALSE TRUE Change -Price
310115 4/1/1997 5/1/1997 8.37 8.37 10.46 FALSE TRUE Change -Subsidy -Alternate
310115 5/1/1997 12/1/1997 8.37 8.37 8.37 FALSE TRUE Change -Price
310115 12/1/1997 7/1/2000 5.44 5.44 8.37 FALSE TRUE Change -Subsidy -Alternate
310115 7/1/2000 11/1/2000 2.4 8.37 8.37 FALSE TRUE Change -Subsidy +Alternate
310115 11/1/2000 0 0 0 FALSE FALSE Delisted
310190 6/23/1995 12/1/1997 3.94 3.94 4.35 FALSE TRUE New Listing
310190 12/1/1997 0 0 0 FALSE FALSE Delisted
310204 5/16/1994 7/1/1997 7.04 7.04 8.18 FALSE TRUE New Listing
310204 7/1/1997 0 0 0 FALSE FALSE Delisted
310786 3/1/1999 2/1/2000 2.96 7.6 7.6 FALSE FALSE New Listing
310786 2/1/2000 12/1/2002 1.78 7.6 7.6 FALSE FALSE Change -Subsidy
310786 12/1/2002 2/1/2003 7.6 7.6 7.6 FALSE FALSE Change +Subsidy
310786 2/1/2003 3/1/2006 1.78 7.6 7.6 FALSE FALSE Change -Subsidy
310786 3/1/2006 0 0 0 FALSE FALSE Delisted
311197 12/1/1995 8/1/2004 56.79 56.79 56.79 FALSE FALSE New Listing
311197 8/1/2004 7/1/2007 45 45 45 FALSE FALSE Change -Subsidy -Price -Alternate
311197 7/1/2007 7/1/2011 44.1 44.1 44.1 FALSE FALSE Change -Subsidy -Price -Alternate
311197 7/1/2011 0 0 0 FALSE FALSE Delisted
311219 11/1/2002 8/1/2004 47.4 47.4 47.4 FALSE FALSE New listing
311219 8/1/2004 9/1/2010 42 42 42 FALSE FALSE Change -Subsidy -Price -Alternate
311219 9/1/2010 9/1/2013 35 35 35 FALSE FALSE Change -Subsidy -Price -Alternate
311219 9/1/2013 17.5 17.5 35 FALSE FALSE Change -Subsidy -Alternate
311235 9/1/2010 7/1/2013 23 23 23 FALSE FALSE New listing
311235 7/1/2013 10/1/2013 13.8 13.8 13.8 FALSE FALSE Change -Subsidy -Price -Alternate
311235 10/1/2013 0 0 0 FALSE FALSE Delisted
311243 5/1/1996 4/1/2001 22.9 22.9 25.4 FALSE FALSE New Listing
311243 4/1/2001 9/1/2001 22.9 22.9 24.5 FALSE FALSE Change -Price
311243 9/1/2001 12/1/2001 15 15 24.5 FALSE FALSE Change -Subsidy -Alternate
311243 12/1/2001 11/1/2004 0 0 0 FALSE FALSE Delisted
311243 11/1/2004 9/1/2007 12.5 12.5 12.5 FALSE FALSE New Listing
311243 9/1/2007 5/1/2008 9.31 9.31 9.31 FALSE FALSE Change -Subsidy -Price -Alternate
311243 5/1/2008 7/1/2009 0 0 0 FALSE FALSE Delisted
311243 7/1/2009 4/1/2011 10.51 10.51 10.51 FALSE FALSE New Listing
311243 4/1/2011 0 0 0 FALSE FALSE Delisted
311251 5/1/1996 9/1/2001 22.9 22.9 25.41 FALSE FALSE New Listing
311251 9/1/2001 12/1/2001 16 16 25.4 FALSE FALSE Change -Subsidy -Price -Alternate
311251 12/1/2001 7/1/2006 0 0 0 FALSE FALSE Delisted
311251 7/1/2006 4/1/2011 11.5 11.5 11.5 FALSE FALSE New Listing
311251 4/1/2011 0 0 0 FALSE FALSE Delisted
311278 5/16/1994 4/1/2002 24.9 24.9 24.9 FALSE FALSE New Listing
311278 4/1/2002 0 0 0 FALSE FALSE Delisted
311286 8/1/1997 9/1/2002 34.8 34.8 34.8 FALSE FALSE New Listing
311286 9/1/2002 4/1/2007 29.95 29.95 29.95 FALSE FALSE Change -Subsidy -Price -Alternate
311286 4/1/2007 0 0 0 FALSE FALSE Delisted
311294 5/16/1994 9/1/2002 28.4 28.4 28.4 FALSE FALSE New Listing
311294 9/1/2002 10/1/2006 24 24 24 FALSE FALSE Change -Subsidy -Price -Alternate
311294 10/1/2006 10/1/2009 26 26 26 FALSE FALSE Change +Subsidy +Price +Alternate
311294 10/1/2009 11/1/2012 52 52 52 FALSE FALSE Change +Subsidy +Price +Alternate
311294 11/1/2012 71 71 71 FALSE FALSE Change +Subsidy +Price +Alternate
311308 5/16/1994 9/1/2002 34.3 34.3 34.25 FALSE FALSE New Listing
311308 9/1/2002 10/1/2006 29.95 29.95 29.95 FALSE FALSE Change -Subsidy -Price -Alternate
311308 10/1/2006 6/1/2010 32 32 32 FALSE FALSE Change +Subsidy +Price +Alternate
311308 6/1/2010 0 0 0 FALSE FALSE Delisted
311316 12/1/1998 6/1/2004 23.8 23.8 26.2 FALSE FALSE New Listing
311316 6/1/2004 7/1/2007 22.5 22.5 22.5 FALSE FALSE Change -Subsidy -Price -Alternate
311316 7/1/2007 3/1/2011 20.3 20.3 20.3 FALSE FALSE Change -Subsidy -Price -Alternate
311316 3/1/2011 7/1/2011 150 150 150 FALSE FALSE Change +Subsidy +Price +Alternate
311316 7/1/2011 7/1/2014 140 140 140 FALSE FALSE Change -Subsidy -Price -Alternate
311316 7/1/2014 98 98 98 FALSE FALSE Change -Subsidy -Price -Alternate
311324 5/11/1995 9/1/2002 23 23 24.23 FALSE FALSE New Listing
311324 9/1/2002 7/1/2006 20 20 20 FALSE FALSE Change -Subsidy -Price -Alternate
311324 7/1/2006 4/1/2010 18 18 18 FALSE FALSE Change -Subsidy -Price -Alternate
311324 4/1/2010 0 0 0 FALSE FALSE Delisted
311340 5/16/1994 5/11/1995 34.55 34.55 34.55 FALSE FALSE New Listing
311340 5/11/1995 9/1/2002 30.16 30.16 34.55 FALSE FALSE Change -Subsidy -Alternate
311340 9/1/2002 3/1/2011 26 26 26 FALSE FALSE Change -Subsidy -Price -Alternate
311340 3/1/2011 55 55 55 FALSE FALSE Change +Subsidy +Price +Alternate
311359 9/1/2002 6/1/2010 26 26 26 FALSE FALSE New listing
311359 6/1/2010 0 0 0 FALSE FALSE Delisted
311472 5/16/1994 3/1/1995 9.56 9.56 9.56 FALSE FALSE New Listing
311472 3/1/1995 12/1/1999 9.56 9.56 9.95 FALSE FALSE Change +Price
311472 12/1/1999 2/1/2002 9.56 9.56 10.65 FALSE FALSE Change +Price
311472 2/1/2002 1/1/2009 9.56 9.56 12.4 FALSE FALSE Change +Price
311472 1/1/2009 11.95 11.95 11.95 FALSE FALSE Change +Subsidy -Price +Alternate
311480 5/16/1994 7/1/1999 41 41 41 FALSE FALSE New Listing
311480 7/1/1999 11/1/1999 38 38 41 FALSE FALSE Change -Subsidy -Alternate
311480 11/1/1999 0 0 0 FALSE FALSE Delisted
311502 5/16/1994 7/1/1999 7.98 7.98 7.9 FALSE FALSE New Listing
311502 7/1/1999 11/1/1999 6.8 6.8 7.98 FALSE FALSE Change -Subsidy +Price -Alternate
311502 11/1/1999 0 0 0 FALSE FALSE Delisted
311529 5/16/1994 7/1/1999 39.9 39.9 39.9 FALSE FALSE New Listing
311529 7/1/1999 11/1/1999 34 34 39.9 FALSE FALSE Change -Subsidy -Alternate
311529 11/1/1999 0 0 0 FALSE FALSE Delisted
311545 5/16/1994 7/1/1999 8.2 8.2 8.2 FALSE FALSE New Listing
311545 7/1/1999 11/1/1999 7.6 7.6 8.2 FALSE FALSE Change -Subsidy -Alternate
311545 11/1/1999 0 0 0 FALSE FALSE Delisted
311669 7/1/1995 8/1/1998 11.43 11.43 11.43 FALSE FALSE New Listing
311669 8/1/1998 4/1/2001 4.49 11.43 11.43 FALSE FALSE Change -Subsidy
311669 4/1/2001 9/1/2003 1.87 11.43 11.43 FALSE FALSE Change -Subsidy
311669 9/1/2003 0 0 0 FALSE FALSE Delisted
311677 7/1/1995 8/1/1998 18.67 18.67 18.67 FALSE FALSE New Listing
311677 8/1/1998 4/1/2001 7.34 18.67 18.67 FALSE FALSE Change -Subsidy
311677 4/1/2001 3.06 18.67 18.67 FALSE FALSE Change -Subsidy
311685 5/16/1994 11/1/1997 30 30 37.7 FALSE FALSE New Listing
311685 11/1/1997 0 0 0 FALSE FALSE Delisted
311693 5/16/1994 6/27/1995 28 28 28 FALSE TRUE New Listing
311693 6/27/1995 1/1/1997 30.23 30.23 30.23 FALSE TRUE Change +Subsidy +Price +Alternate
311693 1/1/1997 9/1/2001 30.23 30.23 33.63 FALSE TRUE Change +Price
311693 9/1/2001 11/1/2002 30.23 30.23 42.9 FALSE TRUE Change +Price
311693 11/1/2002 4/1/2007 42.9 42.9 42.9 FALSE TRUE Change +Subsidy +Alternate
311693 4/1/2007 1/1/2011 42.9 42.9 42.9 FALSE FALSE Change -OP
311693 1/1/2011 0 0 0 FALSE FALSE Delisted
311707 5/16/1994 6/27/1995 28 28 28 FALSE TRUE New Listing
311707 6/27/1995 1/1/1997 30.23 30.23 30.23 FALSE TRUE Change +Subsidy +Price +Alternate
311707 1/1/1997 9/1/2001 30.23 30.23 33.63 FALSE TRUE Change +Price
311707 9/1/2001 11/1/2002 30.23 30.23 42.9 FALSE TRUE Change +Price
311707 11/1/2002 4/1/2007 42.9 42.9 42.9 FALSE TRUE Change +Subsidy +Alternate
311707 4/1/2007 1/1/2011 42.9 42.9 42.9 FALSE FALSE Change -OP
311707 1/1/2011 0 0 0 FALSE FALSE Delisted
311715 5/16/1994 6/27/1995 28 28 28 FALSE TRUE New Listing
311715 6/27/1995 1/1/1997 30.23 30.23 30.23 FALSE TRUE Change +Subsidy +Price +Alternate
311715 1/1/1997 9/1/2001 30.23 30.23 33.63 FALSE TRUE Change +Price
311715 9/1/2001 11/1/2002 30.23 30.23 42.9 FALSE TRUE Change +Price
311715 11/1/2002 4/1/2007 42.9 42.9 42.9 FALSE TRUE Change +Subsidy +Alternate
311715 4/1/2007 1/1/2011 42.9 42.9 42.9 FALSE FALSE Change -OP
311715 1/1/2011 0 0 0 FALSE FALSE Delisted
311723 5/16/1994 6/27/1995 28 28 28 FALSE TRUE New Listing
311723 6/27/1995 1/1/1997 30.23 30.23 30.23 FALSE TRUE Change +Subsidy +Price +Alternate
311723 1/1/1997 9/1/2001 30.23 30.23 33.63 FALSE TRUE Change +Price
311723 9/1/2001 11/1/2002 30.23 30.23 42.9 FALSE TRUE Change +Price
311723 11/1/2002 4/1/2007 42.9 42.9 42.9 FALSE TRUE Change +Subsidy +Alternate
311723 4/1/2007 1/1/2011 42.9 42.9 42.9 FALSE FALSE Change -OP
311723 1/1/2011 0 0 0 FALSE FALSE Delisted
311731 5/16/1994 6/27/1995 28 28 28 FALSE TRUE New Listing
311731 6/27/1995 1/1/1997 30.23 30.23 30.23 FALSE TRUE Change +Subsidy +Price +Alternate
311731 1/1/1997 9/1/2001 30.23 30.23 33.63 FALSE TRUE Change +Price
311731 9/1/2001 11/1/2002 30.23 30.23 42.9 FALSE TRUE Change +Price
311731 11/1/2002 4/1/2007 42.9 42.9 42.9 FALSE TRUE Change +Subsidy +Alternate
311731 4/1/2007 1/1/2011 42.9 42.9 42.9 FALSE FALSE Change -OP
311731 1/1/2011 0 0 0 FALSE FALSE Delisted
311758 5/16/1994 6/27/1995 28 28 28 FALSE TRUE New Listing
311758 6/27/1995 1/1/1997 30.23 30.23 30.23 FALSE TRUE Change +Subsidy +Price +Alternate
311758 1/1/1997 9/1/2001 30.23 30.23 33.63 FALSE TRUE Change +Price
311758 9/1/2001 11/1/2002 30.23 30.23 42.9 FALSE TRUE Change +Price
311758 11/1/2002 4/1/2007 42.9 42.9 42.9 FALSE TRUE Change +Subsidy +Alternate
311758 4/1/2007 1/1/2011 42.9 42.9 42.9 FALSE FALSE Change -OP
311758 1/1/2011 0 0 0 FALSE FALSE Delisted
311766 5/16/1994 6/27/1995 28 28 28 FALSE TRUE New Listing
311766 6/27/1995 1/1/1997 30.23 30.23 30.23 FALSE TRUE Change +Subsidy +Price +Alternate
311766 1/1/1997 9/1/2001 30.23 30.23 33.63 FALSE TRUE Change +Price
311766 9/1/2001 11/1/2002 30.23 30.23 42.9 FALSE TRUE Change +Price
311766 11/1/2002 4/1/2007 42.9 42.9 42.9 FALSE TRUE Change +Subsidy +Alternate
311766 4/1/2007 1/1/2011 42.9 42.9 42.9 FALSE FALSE Change -OP
311766 1/1/2011 0 0 0 FALSE FALSE Delisted
311774 7/1/1995 8/1/1998 27 27 27 FALSE FALSE New Listing
311774 8/1/1998 4/1/2001 10.62 27 27 FALSE FALSE Change -Subsidy
311774 4/1/2001 4.43 27 27 FALSE FALSE Change -Subsidy
311804 5/16/1994 6/27/1995 28 28 28 FALSE TRUE New Listing
311804 6/27/1995 1/1/1997 30.23 30.23 30.23 FALSE TRUE Change +Subsidy +Price +Alternate
311804 1/1/1997 9/1/2000 30.23 30.23 33.63 FALSE TRUE Change +Price
311804 9/1/2000 0 0 0 FALSE FALSE Delisted
311812 5/16/1994 6/27/1995 28 28 28 FALSE TRUE New Listing
311812 6/27/1995 1/1/1997 30.23 30.23 30.23 FALSE TRUE Change +Subsidy +Price +Alternate
311812 1/1/1997 9/1/2000 30.23 30.23 33.63 FALSE TRUE Change +Price
311812 9/1/2000 0 0 0 FALSE FALSE Delisted
311820 5/16/1994 6/27/1995 28 28 28 FALSE TRUE New Listing
311820 6/27/1995 1/1/1997 30.23 30.23 30.23 FALSE TRUE Change +Subsidy +Price +Alternate
311820 1/1/1997 9/1/2000 30.23 30.23 33.63 FALSE TRUE Change +Price
311820 9/1/2000 0 0 0 FALSE FALSE Delisted
311839 5/16/1994 6/27/1995 28 28 28 FALSE TRUE New Listing
311839 6/27/1995 1/1/1997 30.23 30.23 30.23 FALSE TRUE Change +Subsidy +Price +Alternate
311839 1/1/1997 9/1/2000 30.23 30.23 33.63 FALSE TRUE Change +Price
311839 9/1/2000 0 0 0 FALSE FALSE Delisted
311847 5/16/1994 6/27/1995 28 28 28 FALSE TRUE New Listing
311847 6/27/1995 1/1/1997 30.23 30.23 30.23 FALSE TRUE Change +Subsidy +Price +Alternate
311847 1/1/1997 9/1/2000 30.23 30.23 33.63 FALSE TRUE Change +Price
311847 9/1/2000 0 0 0 FALSE FALSE Delisted
311855 5/16/1994 6/27/1995 28 28 28 FALSE TRUE New Listing
311855 6/27/1995 1/1/1997 30.23 30.23 30.23 FALSE TRUE Change +Subsidy +Price +Alternate
311855 1/1/1997 9/1/2000 30.23 30.23 33.63 FALSE TRUE Change +Price
311855 9/1/2000 0 0 0 FALSE FALSE Delisted
311871 5/16/1994 6/27/1995 28 28 28 FALSE TRUE New Listing
311871 6/27/1995 1/1/1997 30.23 30.23 30.23 FALSE TRUE Change +Subsidy +Price +Alternate
311871 1/1/1997 9/1/2001 30.23 30.23 33.63 FALSE TRUE Change +Price
311871 9/1/2001 11/1/2002 30.23 30.23 42.9 FALSE TRUE Change +Price
311871 11/1/2002 4/1/2007 42.9 42.9 42.9 FALSE TRUE Change +Subsidy +Alternate
311871 4/1/2007 42.9 42.9 42.9 FALSE FALSE Change -OP
311898 5/16/1994 6/27/1995 28 28 28 FALSE TRUE New Listing
311898 6/27/1995 1/1/1997 30.23 30.23 30.23 FALSE TRUE Change +Subsidy +Price +Alternate
311898 1/1/1997 9/1/2001 30.23 30.23 33.63 FALSE TRUE Change +Price
311898 9/1/2001 11/1/2002 30.23 30.23 42.9 FALSE TRUE Change +Price
311898 11/1/2002 4/1/2007 42.9 42.9 42.9 FALSE TRUE Change +Subsidy +Alternate
311898 4/1/2007 42.9 42.9 42.9 FALSE FALSE Change -OP
311901 5/16/1994 6/27/1995 28 28 28 FALSE TRUE New Listing
311901 6/27/1995 1/1/1997 30.23 30.23 30.23 FALSE TRUE Change +Subsidy +Price +Alternate
311901 1/1/1997 9/1/2001 30.23 30.23 33.63 FALSE TRUE Change +Price
311901 9/1/2001 11/1/2002 30.23 30.23 42.9 FALSE TRUE Change +Price
311901 11/1/2002 4/1/2007 42.9 42.9 42.9 FALSE TRUE Change +Subsidy +Alternate
311901 4/1/2007 42.9 42.9 42.9 FALSE FALSE Change -OP
311928 5/16/1994 6/27/1995 28 28 28 FALSE TRUE New Listing
311928 6/27/1995 1/1/1997 30.23 30.23 30.23 FALSE TRUE Change +Subsidy +Price +Alternate
311928 1/1/1997 9/1/2001 30.23 30.23 33.63 FALSE TRUE Change +Price
311928 9/1/2001 11/1/2002 30.23 30.23 42.9 FALSE TRUE Change +Price
311928 11/1/2002 4/1/2007 42.9 42.9 42.9 FALSE TRUE Change +Subsidy +Alternate
311928 4/1/2007 42.9 42.9 42.9 FALSE FALSE Change -OP
311944 5/16/1994 6/27/1995 28 28 28 FALSE TRUE New Listing
311944 6/27/1995 1/1/1997 30.23 30.23 30.23 FALSE TRUE Change +Subsidy +Price +Alternate
311944 1/1/1997 9/1/2001 30.23 30.23 33.63 FALSE TRUE Change +Price
311944 9/1/2001 11/1/2002 30.23 30.23 42.9 FALSE TRUE Change +Price
311944 11/1/2002 4/1/2007 42.9 42.9 42.9 FALSE TRUE Change +Subsidy +Alternate
311944 4/1/2007 1/1/2011 42.9 42.9 42.9 FALSE FALSE Change -OP
311944 1/1/2011 0 0 0 FALSE FALSE Delisted
311952 5/16/1994 6/27/1995 28 28 28 FALSE TRUE New Listing
311952 6/27/1995 1/1/1997 30.23 30.23 30.23 FALSE TRUE Change +Subsidy +Price +Alternate
311952 1/1/1997 9/1/2001 30.23 30.23 33.63 FALSE TRUE Change +Price
311952 9/1/2001 11/1/2002 30.23 30.23 42.9 FALSE TRUE Change +Price
311952 11/1/2002 4/1/2007 42.9 42.9 42.9 FALSE TRUE Change +Subsidy +Alternate
311952 4/1/2007 1/1/2011 42.9 42.9 42.9 FALSE FALSE Change -OP
311952 1/1/2011 0 0 0 FALSE FALSE Delisted
312193 8/1/1997 2/1/1998 5.54 5.54 5.54 FALSE FALSE New Listing
312193 2/1/1998 8/1/2000 3.32 3.32 3.32 FALSE FALSE Change -Subsidy -Price -Alternate
312193 8/1/2000 12/1/2000 1.74 1.74 3.32 FALSE FALSE Change -Subsidy -Alternate
312193 12/1/2000 0 0 0 FALSE FALSE Delisted
312304 4/11/1995 9/1/2000 26.52 26.52 19.75 FALSE FALSE New Listing
312304 9/1/2000 0 0 0 FALSE FALSE Delisted
312355 4/12/1995 7/1/1997 19.6 19.6 19.6 FALSE FALSE New Listing
312355 7/1/1997 8/1/1999 19.6 19.6 21.2 FALSE FALSE Change +Price
312355 8/1/1999 9/1/1999 21.2 21.2 21.2 FALSE FALSE Change +Subsidy +Alternate
312355 9/1/1999 12/1/2000 21.2 21.2 23.6 FALSE FALSE Change +Price
312355 12/1/2000 8/1/2003 21.2 21.2 29.7 FALSE FALSE Change +Price
312355 8/1/2003 0 0 0 FALSE FALSE Delisted
312363 4/12/1995 8/1/1999 0.05 0.05 0.05 TRUE FALSE New Listing
312363 8/1/1999 0 0 0 FALSE FALSE Delisted
312495 5/30/1995 2/1/1998 32.4 32.4 32.4 FALSE FALSE New Listing
312495 2/1/1998 0 0 0 FALSE FALSE Delisted
312649 5/16/1994 6/13/1995 16.45 16.45 19.8 FALSE FALSE New Listing
312649 6/13/1995 7/1/1997 19.8 19.8 19.8 FALSE FALSE Change +Subsidy +Alternate
312649 7/1/1997 1/1/1998 19.8 19.8 22.4 FALSE FALSE Change +Price
312649 1/1/1998 7/1/1998 6 6 22.4 FALSE FALSE Change -Subsidy -Alternate
312649 7/1/1998 0 0 0 FALSE FALSE Delisted
312673 3/1/1996 10/1/1999 25 25 25 FALSE TRUE New Listing
312673 10/1/1999 6/1/2004 12.5 12.5 12.5 FALSE TRUE Change -Subsidy -Price -Alternate
312673 6/1/2004 0 0 0 FALSE FALSE Delisted
312681 3/1/1996 10/1/1999 45.33 45.33 45.33 FALSE TRUE New Listing
312681 10/1/1999 11/1/2000 22.67 22.67 22.67 FALSE TRUE Change -Subsidy -Price -Alternate
312681 11/1/2000 0 0 0 FALSE FALSE Delisted
312762 6/1/1997 9/1/1998 19.66 19.66 32.76 FALSE FALSE New Listing
312762 9/1/1998 1/1/1999 10.2 10.2 19.66 FALSE FALSE Change -Subsidy -Price -Alternate
312762 1/1/1999 4/1/2000 6 6 19.66 FALSE FALSE Change -Subsidy -Alternate
312762 4/1/2000 6/1/2001 6 6 6 FALSE FALSE Change -Price
312762 6/1/2001 10/1/2003 3.5 3.5 3.5 FALSE FALSE Change -Subsidy -Price -Alternate
312762 10/1/2003 1/1/2004 2.38 2.38 2.38 FALSE FALSE Change -Subsidy -Price -Alternate
312762 1/1/2004 0 0 0 FALSE FALSE Delisted
313130 10/4/1997 3/1/2001 3.96 3.96 5.44 FALSE FALSE New Listing
313130 3/1/2001 4/1/2002 3.96 3.96 5.98 FALSE FALSE Change +Price
313130 4/1/2002 2/1/2003 3.96 3.96 6.58 FALSE FALSE Change +Price
313130 2/1/2003 5/1/2003 3.19 3.19 6.58 FALSE FALSE Change -Subsidy -Alternate
313130 5/1/2003 0 0 0 FALSE FALSE Delisted
313165 4/11/1995 12/1/2000 4.26 4.26 5.3 FALSE FALSE New Listing
313165 12/1/2000 6/1/2001 4.26 4.26 4.67 FALSE FALSE Change -Price
313165 6/1/2001 0 0 0 FALSE FALSE Delisted
313181 4/11/1995 6/27/1995 13.4 13.4 13.4 FALSE FALSE New Listing
313181 6/27/1995 9/1/1995 13.4 13.4 19.8 FALSE FALSE Change +Price
313181 9/1/1995 8/1/1999 2.68 2.68 11.8 FALSE FALSE Change -Subsidy -Price -Alternate
313181 8/1/1999 0 0 0 FALSE FALSE Delisted
313653 5/16/1994 5/1/1998 13.26 13.26 13.26 FALSE FALSE New Listing
313653 5/1/1998 8/1/1998 2.55 2.55 7.56 FALSE FALSE Change -Subsidy -Price -Alternate
313653 8/1/1998 0 0 0 FALSE FALSE Delisted
313661 5/16/1994 7/1/1999 5.31 5.31 5.31 FALSE FALSE New Listing
313661 7/1/1999 12/1/2002 2.59 2.59 2.59 FALSE FALSE Change -Subsidy -Price -Alternate
313661 12/1/2002 10/1/2005 3.1 3.1 3.1 FALSE FALSE Change +Subsidy +Price +Alternate
313661 10/1/2005 4/1/2011 3.4 3.4 3.4 FALSE FALSE Change +Subsidy +Price +Alternate
313661 4/1/2011 1.85 1.85 1.85 FALSE FALSE Change -Subsidy -Price -Alternate
313688 5/16/1994 7/1/1999 26.55 26.55 26.55 FALSE FALSE New Listing
313688 7/1/1999 10/1/2000 12.95 12.95 12.95 FALSE FALSE Change -Subsidy -Price -Alternate
313688 10/1/2000 0 0 0 FALSE FALSE Delisted
313696 5/16/1994 7/1/1999 12.93 12.93 12.93 FALSE FALSE New Listing
313696 7/1/1999 9/1/2002 6.98 6.98 6.98 FALSE FALSE Change -Subsidy -Price -Alternate
313696 9/1/2002 10/1/2005 4.75 4.75 4.75 FALSE FALSE Change -Subsidy -Price -Alternate
313696 10/1/2005 4/1/2011 5.2 5.2 5.2 FALSE FALSE Change +Subsidy +Price +Alternate
313696 4/1/2011 3.6 3.6 3.6 FALSE FALSE Change -Subsidy -Price -Alternate
313939 7/1/1995 12/1/1996 288 288 288 FALSE FALSE New Listing
313939 12/1/1996 1/1/2006 277 277 277 FALSE FALSE Change -Subsidy -Price -Alternate
313939 1/1/2006 2/1/2014 221.6 221.6 221.6 FALSE FALSE Change -Subsidy -Price -Alternate
313939 2/1/2014 0 0 0 FALSE FALSE Delisted
314293 8/1/1995 3/1/1999 27.29 27.29 27.29 FALSE TRUE New Listing
314293 3/1/1999 12/1/1999 23.2 23.2 23.2 FALSE TRUE Change -Subsidy -Price -Alternate
314293 12/1/1999 0 0 0 FALSE FALSE Delisted
314722 5/16/1994 4/1/1997 1.01 1.01 1.01 FALSE FALSE New Listing
314722 4/1/1997 0 0 0 FALSE FALSE Delisted
314730 5/16/1994 4/1/1997 1.75 1.75 1.75 FALSE FALSE New Listing
314730 4/1/1997 0 0 0 FALSE FALSE Delisted
314773 5/16/1994 6/27/1995 55 55 55 FALSE TRUE New Listing
314773 6/27/1995 2/1/1996 49 49 49 FALSE TRUE Change -Subsidy -Price -Alternate
314773 2/1/1996 10/1/1999 45.33 45.33 45.33 FALSE TRUE Change -Subsidy -Price -Alternate
314773 10/1/1999 4/1/2003 22.67 22.67 22.67 FALSE TRUE Change -Subsidy -Price -Alternate
314773 4/1/2003 0 0 0 FALSE FALSE Delisted
314803 5/16/1994 4/1/1996 6.8 6.8 6.8 FALSE FALSE New Listing
314803 4/1/1996 8/1/2001 13.6 13.6 18 FALSE FALSE Change +Subsidy +Price +Alternate
314803 8/1/2001 0 0 0 FALSE FALSE Delisted
314846 5/16/1994 3/1/1996 13.33 13.33 13.33 FALSE FALSE New Listing
314846 3/1/1996 12/1/1997 11.25 11.25 11.25 FALSE FALSE Change -Subsidy -Price -Alternate
314846 12/1/1997 8/1/2000 8.44 8.44 8.44 FALSE FALSE Change -Subsidy -Price -Alternate
314846 8/1/2000 7/1/2003 5 5 5 FALSE FALSE Change -Subsidy -Price -Alternate
314846 7/1/2003 3/1/2009 4.75 4.75 4.75 FALSE FALSE Change -Subsidy -Price -Alternate
314846 3/1/2009 0 0 0 FALSE FALSE Delisted
314854 5/16/1994 3/1/1996 23.75 23.75 23.75 FALSE FALSE New Listing
314854 3/1/1996 12/1/1997 22.51 22.51 22.51 FALSE FALSE Change -Subsidy -Price -Alternate
314854 12/1/1997 8/1/2000 16.88 16.88 16.88 FALSE FALSE Change -Subsidy -Price -Alternate
314854 8/1/2000 7/1/2003 6.5 6.5 6.5 FALSE FALSE Change -Subsidy -Price -Alternate
314854 7/1/2003 11/1/2008 6 6 6 FALSE FALSE Change -Subsidy -Price -Alternate
314854 11/1/2008 0 0 0 FALSE FALSE Delisted
314935 4/12/1995 8/1/1999 19.2 19.2 21.12 TRUE FALSE New Listing
314935 8/1/1999 0 0 0 FALSE FALSE Delisted
315125 5/16/1994 3/1/1995 19.03 19.03 19.03 FALSE FALSE New Listing
315125 3/1/1995 2/1/2000 19.03 19.03 20.45 FALSE FALSE Change +Price
315125 2/1/2000 11/1/2000 19.03 19.03 22.5 FALSE FALSE Change +Price
315125 11/1/2000 0 0 0 FALSE FALSE Delisted
315508 5/16/1994 5/1/1997 24 24 24 FALSE FALSE New Listing
315508 5/1/1997 0 0 0 FALSE FALSE Delisted
315559 5/16/1994 9/1/2002 169.66 169.66 169.66 FALSE FALSE New Listing
315559 9/1/2002 12/1/2002 62.5 62.5 169.66 FALSE FALSE Change -Subsidy -Alternate
315559 12/1/2002 0 0 0 FALSE FALSE Delisted
315567 2/1/1996 2/1/2003 47.62 47.62 47.62 FALSE FALSE New Listing
315567 2/1/2003 3/1/2003 20 20 47.62 FALSE FALSE Change -Subsidy -Alternate
315567 3/1/2003 0 0 0 FALSE FALSE Delisted
315575 5/16/1994 9/1/2002 88.01 88.01 88.01 FALSE FALSE New Listing
315575 9/1/2002 12/1/2002 39.6 39.6 88.01 FALSE FALSE Change -Subsidy -Alternate
315575 12/1/2002 0 0 0 FALSE FALSE Delisted
315583 5/16/1994 9/1/2002 169.66 169.66 169.66 FALSE FALSE New Listing
315583 9/1/2002 12/1/2002 62.5 62.5 169.66 FALSE FALSE Change -Subsidy -Alternate
315583 12/1/2002 0 0 0 FALSE FALSE Delisted
315648 7/1/1997 10/1/1997 8.14 8.14 10.85 FALSE TRUE New Listing
315648 10/1/1997 2/1/1998 7.31 7.31 10.85 FALSE TRUE Change -Subsidy -Alternate
315648 2/1/1998 0 0 0 FALSE FALSE Delisted
315672 5/16/1994 2/1/1998 25.12 25.12 25.12 FALSE FALSE New Listing
315672 2/1/1998 2/1/1999 12.56 12.56 12.56 FALSE FALSE Change -Subsidy -Price -Alternate
315672 2/1/1999 8/1/2000 6.28 6.28 6.28 FALSE FALSE Change -Subsidy -Price -Alternate
315672 8/1/2000 12/1/2000 2.6 2.6 6.28 FALSE FALSE Change -Subsidy -Alternate
315672 12/1/2000 0 0 0 FALSE FALSE Delisted
315680 3/1/2005 10/1/2009 25 25 25 FALSE FALSE New listing
315680 10/1/2009 0 0 0 FALSE FALSE Delisted
315699 5/16/1994 10/1/2000 15 15 15 FALSE FALSE New Listing
315699 10/1/2000 3/1/2001 15 15 16.31 FALSE FALSE Change +Price
315699 3/1/2001 4/1/2002 15 15 17.94 FALSE FALSE Change +Price
315699 4/1/2002 4/1/2003 15 15 19.73 FALSE FALSE Change +Price
315699 4/1/2003 4/1/2004 15 15 21.7 FALSE FALSE Change +Price
315699 4/1/2004 15 15 23.87 FALSE FALSE Change +Price
315753 5/16/1994 4/13/1995 3.9 3.9 5.22 FALSE FALSE New Listing
315753 4/13/1995 5/22/1995 3.9 3.9 5.48 FALSE FALSE Change +Price
315753 5/22/1995 10/1/1998 3 3 3 FALSE FALSE Change -Subsidy -Price -Alternate
315753 10/1/1998 6/1/1999 2.8 2.8 3 FALSE FALSE Change -Subsidy -Alternate
315753 6/1/1999 9/1/2000 2.8 2.8 6.79 FALSE FALSE Change +Price
315753 9/1/2000 9/1/2001 2.8 2.8 7.52 FALSE FALSE Change +Price
315753 9/1/2001 8/1/2002 2.38 2.38 7.89 FALSE FALSE Change -Subsidy +Price -Alternate
315753 8/1/2002 0 0 0 FALSE FALSE Delisted
315761 5/16/1994 60.68 60.68 60.68 FALSE TRUE New Listing
316059 5/16/1994 1/1/2002 13.85 13.85 18.52 FALSE FALSE New Listing
316059 1/1/2002 0 0 0 FALSE FALSE Delisted
316091 5/16/1994 3/1/2004 39.07 39.07 39.07 FALSE FALSE New Listing
316091 3/1/2004 0 0 0 FALSE FALSE Delisted
316164 5/27/1995 7/1/1996 27.75 27.75 30 FALSE FALSE New Listing
316164 7/1/1996 5/1/1998 27.75 27.75 27.75 FALSE FALSE Change -Price
316164 5/1/1998 1/1/2001 18.05 18.05 18.05 FALSE FALSE Change -Subsidy -Price -Alternate
316164 1/1/2001 4/1/2002 16 16 16 FALSE FALSE Change -Subsidy -Price -Alternate
316164 4/1/2002 0 0 0 FALSE FALSE Delisted
316199 5/16/1994 12/1/1998 52.25 52.25 52.25 FALSE FALSE New Listing
316199 12/1/1998 52.24 52.24 52.24 FALSE FALSE Change -Subsidy -Price -Alternate
316318 5/16/1994 10/1/1997 2.78 2.78 5.66 FALSE FALSE New Listing
316318 10/1/1997 2/1/1998 2.5 2.5 5.66 FALSE FALSE Change -Subsidy -Alternate
316318 2/1/1998 8/1/2000 1.75 1.75 5.66 FALSE FALSE Change -Subsidy +Price -Alternate
316318 8/1/2000 12/1/2000 1.1 1.1 5.66 FALSE FALSE Change -Subsidy -Alternate
316318 12/1/2000 0 0 0 FALSE FALSE Delisted
316512 5/16/1994 8/1/2001 30.65 30.65 30.65 FALSE FALSE New Listing
316512 8/1/2001 9/1/2002 24.25 24.25 30.65 FALSE FALSE Change -Subsidy -Alternate
316512 9/1/2002 12/1/2002 16 16 16 FALSE FALSE Change -Subsidy -Price -Alternate
316512 12/1/2002 3/1/2009 14 14 14 FALSE FALSE Change -Subsidy -Price -Alternate
316512 3/1/2009 11.9 11.9 11.9 FALSE FALSE Change -Subsidy -Price -Alternate
316644 11/1/1995 4/1/2004 37.81 37.81 37.81 FALSE TRUE New Listing
316644 4/1/2004 7/1/2006 37.81 37.81 41.59 FALSE TRUE Change +Price
316644 7/1/2006 5/1/2009 37.81 37.81 42.84 FALSE TRUE Change +Price
316644 5/1/2009 10/1/2012 19.85 19.85 19.85 FALSE TRUE Change -Subsidy -Price -Alternate
316644 10/1/2012 0 0 0 FALSE FALSE Delisted
316652 11/1/1996 2/1/1998 3.44 3.44 7.3 FALSE FALSE New Listing
316652 2/1/1998 0 0 0 FALSE FALSE Delisted
316660 7/1/1997 6/1/1998 1.51 1.51 4.21 FALSE FALSE New Listing
316660 6/1/1998 3/1/2000 1.51 1.51 5.08 FALSE FALSE Change +Price
316660 3/1/2000 2/1/2002 1.51 1.51 6.4 FALSE FALSE Change +Price
316660 2/1/2002 5/1/2007 1.51 1.51 6.72 FALSE FALSE Change +Price
316660 5/1/2007 0 0 0 FALSE FALSE Delisted
316679 7/1/1997 6/1/1998 2.43 2.43 3.09 FALSE FALSE New Listing
316679 6/1/1998 2/1/1999 2.43 2.43 3.56 FALSE FALSE Change +Price
316679 2/1/1999 3/1/2000 2.43 2.43 4.27 FALSE FALSE Change +Price
316679 3/1/2000 2/1/2002 2.43 2.43 4.75 FALSE FALSE Change +Price
316679 2/1/2002 8/1/2002 2.43 2.43 4.99 FALSE FALSE Change +Price
316679 8/1/2002 0 0 0 FALSE FALSE Delisted
316687 10/1/1996 7/1/1997 1.77 1.77 5.51 FALSE FALSE New Listing
316687 7/1/1997 6/1/1998 1.77 1.77 5.79 FALSE FALSE Change +Price
316687 6/1/1998 2/1/1999 1.77 1.77 6.66 FALSE FALSE Change +Price
316687 2/1/1999 3/1/2000 1.77 1.77 7.99 FALSE FALSE Change +Price
316687 3/1/2000 2/1/2002 1.77 1.77 8.9 FALSE FALSE Change +Price
316687 2/1/2002 9/1/2006 1.77 1.77 9.35 FALSE FALSE Change +Price
316687 9/1/2006 1.77 1.77 10.29 FALSE FALSE Change +Price
316709 10/1/1996 7/1/1997 8.05 8.05 14.65 FALSE FALSE New Listing
316709 7/1/1997 8/1/1999 8.05 8.05 16.11 FALSE FALSE Change +Price
316709 8/1/1999 4/1/2000 16.11 16.11 16.11 FALSE FALSE Change +Subsidy +Alternate
316709 4/1/2000 5/1/2001 16.11 16.11 17.23 FALSE FALSE Change +Price
316709 5/1/2001 8/1/2003 16.11 16.11 19.59 FALSE FALSE Change +Price
316709 8/1/2003 0 0 0 FALSE FALSE Delisted
316717 10/1/1996 7/1/1997 5.42 5.42 11.25 FALSE FALSE New Listing
316717 7/1/1997 8/1/1999 5.42 5.42 12.37 FALSE FALSE Change +Price
316717 8/1/1999 0 0 0 FALSE FALSE Delisted
316725 5/16/1994 8.75 8.75 8.75 FALSE FALSE New Listing
316741 11/1/1998 4/1/2007 34 34 34 FALSE FALSE New Listing
316741 4/1/2007 2/1/2010 22 22 22 FALSE FALSE Change -Subsidy -Price -Alternate
316741 2/1/2010 5/1/2010 1.55 1.55 22 FALSE FALSE Change -Subsidy -Alternate
316741 5/1/2010 0 0 0 FALSE FALSE Delisted
316881 6/2/1995 7/1/2000 63.09 63.09 63.09 FALSE FALSE New Listing
316881 7/1/2000 7/1/2007 63.09 63.09 72.55 FALSE FALSE Change +Price
316881 7/1/2007 11/1/2009 63.09 63.09 84.2 FALSE FALSE Change +Price
316881 11/1/2009 63.09 63.09 90.09 FALSE FALSE Change +Price
316962 8/1/1999 5/1/2003 3.83 3.83 3.83 FALSE FALSE New Listing
316962 5/1/2003 9/1/2004 21.5 21.5 21.5 FALSE FALSE Change +Subsidy +Price +Alternate
316962 9/1/2004 34.18 34.18 34.18 FALSE FALSE Change +Subsidy +Price +Alternate
316970 5/16/1994 11/1/2010 27.5 27.5 29.9 FALSE FALSE New Listing
316970 11/1/2010 0 0 0 FALSE FALSE Delisted
316989 6/16/1995 5/1/1996 26.1 26.1 36 FALSE FALSE New Listing
316989 5/1/1996 6/1/1996 26.1 26.1 41.4 FALSE FALSE Change +Price
316989 6/1/1996 1/1/2004 8.7 13.8 13.8 FALSE FALSE Change -Subsidy -Price -Alternate
316989 1/1/2004 11/1/2004 6.62 13.8 13.8 FALSE FALSE Change -Subsidy
316989 11/1/2004 0 0 0 FALSE FALSE Delisted
317071 2/1/1998 9/1/2000 2.7 2.7 2.7 FALSE FALSE New Listing
317071 9/1/2000 10/1/2000 0.77 0.77 2.7 FALSE FALSE Change -Subsidy -Alternate
317071 10/1/2000 1/1/2001 0.77 0.77 2.02 FALSE FALSE Change -Price
317071 1/1/2001 0 0 0 FALSE FALSE Delisted
317160 10/1/1997 2/1/1999 9.37 9.37 14.76 FALSE FALSE New Listing
317160 2/1/1999 3/1/2001 12.4 12.4 14.76 FALSE FALSE Change +Subsidy +Alternate
317160 3/1/2001 0 0 0 FALSE FALSE Delisted
317365 2/1/1998 9/1/2000 5.23 5.23 5.23 FALSE FALSE New Listing
317365 9/1/2000 10/1/2000 1.26 1.26 5.23 FALSE FALSE Change -Subsidy -Alternate
317365 10/1/2000 1/1/2001 1.26 1.26 3.14 FALSE FALSE Change -Price
317365 1/1/2001 0 0 0 FALSE FALSE Delisted
317381 7/1/1999 2/1/2004 4 4 4 FALSE FALSE New Listing
317381 2/1/2004 8/1/2004 1.8 4 4 FALSE FALSE Change -Subsidy
317381 8/1/2004 0 0 0 FALSE FALSE Delisted
317535 5/16/1994 1/1/2003 10.3 10.3 10.3 FALSE FALSE New Listing
317535 1/1/2003 7/1/2007 12.5 12.5 12.5 FALSE FALSE Change +Subsidy +Price +Alternate
317535 7/1/2007 2/1/2011 13.3 13.3 13.3 FALSE FALSE Change +Subsidy +Price +Alternate
317535 2/1/2011 0 0 0 FALSE FALSE Delisted
317659 7/1/2000 1/1/2013 9.95 9.95 9.95 FALSE TRUE New Listing
317659 1/1/2013 10.45 10.45 10.45 FALSE TRUE Change +Subsidy +Price +Alternate
317756 8/1/1999 6/1/2001 1396 1396 1396 FALSE FALSE New Listing
317756 6/1/2001 8/1/2001 1480 1480 1480 FALSE FALSE Change +Subsidy +Price +Alternate
317756 8/1/2001 10/1/2003 1606 1606 1606 FALSE FALSE Change +Subsidy +Price +Alternate
317756 10/1/2003 11/1/2004 1432 1432 1432 FALSE FALSE Change -Subsidy -Price -Alternate
317756 11/1/2004 9/1/2005 1188.79 1188.79 1188.79 FALSE FALSE Change -Subsidy -Price -Alternate
317756 9/1/2005 8/1/2010 1072 1072 1072 FALSE FALSE Change -Subsidy -Price -Alternate
317756 8/1/2010 10/1/2010 0 0 0 TRUE FALSE Change -Subsidy -Price -Alternate +CBS
317756 10/1/2010 1072 1072 1072 FALSE FALSE Change +Subsidy +Price +Alternate -CBS
317764 12/1/1999 7/1/2000 5.9 5.9 5.9 FALSE FALSE New Listing
317764 7/1/2000 9/1/2000 5.9 5.9 5.45 FALSE FALSE Change -Price
317764 9/1/2000 1/1/2001 4.45 4.45 4.45 FALSE FALSE Change -Subsidy -Price -Alternate
317764 1/1/2001 9/1/2001 4.1 4.1 4.1 FALSE FALSE Change -Subsidy -Price -Alternate
317764 9/1/2001 4/1/2002 3.58 3.58 3.58 FALSE FALSE Change -Subsidy -Price -Alternate
317764 4/1/2002 0 0 0 FALSE FALSE Delisted
317845 6/1/1999 2/1/2000 33.6 33.6 33.6 FALSE FALSE New Listing
317845 2/1/2000 8/1/2000 13.44 13.44 33.6 FALSE FALSE Change -Subsidy -Alternate
317845 8/1/2000 9/1/2000 8.5 8.5 33.6 FALSE FALSE Change -Subsidy -Alternate
317845 9/1/2000 12/1/2000 7.5 7.5 33.6 FALSE FALSE Change -Subsidy -Alternate
317845 12/1/2000 11/1/2002 16.8 16.8 33.6 FALSE FALSE Change +Subsidy +Alternate
317845 11/1/2002 2/1/2003 4.9 4.9 33.6 FALSE FALSE Change -Subsidy -Alternate
317845 2/1/2003 0 0 0 FALSE FALSE Delisted
317918 6/1/1999 2/1/2000 33.6 33.6 33.6 FALSE FALSE New Listing
317918 2/1/2000 8/1/2000 13.44 13.44 33.6 FALSE FALSE Change -Subsidy -Alternate
317918 8/1/2000 9/1/2000 8.5 8.5 33.6 FALSE FALSE Change -Subsidy -Alternate
317918 9/1/2000 1/1/2001 7.5 7.5 33.6 FALSE FALSE Change -Subsidy -Alternate
317918 1/1/2001 9/1/2001 4.05 4.05 33.6 FALSE FALSE Change -Subsidy -Alternate
317918 9/1/2001 12/1/2001 1.75 1.75 33.6 FALSE FALSE Change -Subsidy -Alternate
317918 12/1/2001 0 0 0 FALSE FALSE Delisted
318094 6/1/1999 4/1/2004 23.2 23.2 23.2 FALSE TRUE New Listing
318094 4/1/2004 7/1/2006 23.2 23.2 25.52 FALSE TRUE Change +Price
318094 7/1/2006 9/1/2010 23.2 23.2 28.07 FALSE TRUE Change +Price
318094 9/1/2010 28.07 28.07 28.07 FALSE TRUE Change +Subsidy +Alternate
318116 6/1/1999 4/1/2004 23.2 23.2 23.2 FALSE TRUE New Listing
318116 4/1/2004 7/1/2006 23.2 23.2 25.52 FALSE TRUE Change +Price
318116 7/1/2006 9/1/2010 23.2 23.2 28.07 FALSE TRUE Change +Price
318116 9/1/2010 3/1/2013 28.07 28.07 28.07 FALSE TRUE Change +Subsidy +Alternate
318116 3/1/2013 0 0 0 FALSE FALSE Delisted
318515 5/16/1994 10/1/2001 44.94 44.94 44.94 FALSE FALSE New Listing
318515 10/1/2001 0 0 0 FALSE FALSE Delisted
318558 9/1/1995 4/1/2006 299 299 299 FALSE FALSE New Listing
318558 4/1/2006 7/1/2008 274 274 274 FALSE FALSE Change -Subsidy -Price -Alternate
318558 7/1/2008 9/1/2014 170 170 170 FALSE FALSE Change -Subsidy -Price -Alternate
318558 9/1/2014 0 0 0 FALSE FALSE Delisted
318566 9/1/1995 4/1/2006 74.75 74.75 74.75 FALSE FALSE New Listing
318566 4/1/2006 7/1/2008 71 71 71 FALSE FALSE Change -Subsidy -Price -Alternate
318566 7/1/2008 9/1/2014 48 48 48 FALSE FALSE Change -Subsidy -Price -Alternate
318566 9/1/2014 0 0 0 FALSE FALSE Delisted
318647 5/16/1994 8/2/1996 13.5 13.5 14 TRUE TRUE New Listing
318647 8/2/1996 0 0 0 FALSE FALSE Delisted
318663 9/1/1996 10/1/1998 63.48 63.48 63.48 FALSE TRUE New Listing
318663 10/1/1998 9/1/2000 25.39 25.39 25.39 FALSE TRUE Change -Subsidy -Price -Alternate
318663 9/1/2000 3/1/2001 22.85 22.85 22.85 FALSE TRUE Change -Subsidy -Price -Alternate
318663 3/1/2001 7/1/2001 3.86 12.5 12.5 FALSE FALSE Change -Subsidy -Price -Alternate -OP
318663 7/1/2001 0 0 0 FALSE FALSE Delisted
318752 7/1/1999 1/1/2001 4.77 4.77 6.95 FALSE TRUE New Listing
318752 1/1/2001 2/1/2001 4.77 4.77 7.23 FALSE TRUE Change +Price
318752 2/1/2001 5/1/2001 4.77 4.77 6.95 FALSE TRUE Change -Price
318752 5/1/2001 9/1/2006 4.77 4.77 7.23 FALSE TRUE Change +Price
318752 9/1/2006 0 0 0 FALSE FALSE Delisted
318809 5/16/1994 4/1/2002 28.46 28.46 28.46 FALSE FALSE New Listing
318809 4/1/2002 6/1/2006 28.46 28.46 32.76 FALSE FALSE Change +Price
318809 6/1/2006 21.01 21.01 21.01 FALSE FALSE Change -Subsidy -Price -Alternate
318817 5/16/1994 4/1/2002 33.88 33.88 33.88 FALSE FALSE New Listing
318817 4/1/2002 6/1/2006 33.88 33.88 38.18 FALSE FALSE Change +Price
318817 6/1/2006 25.06 25.06 25.06 FALSE FALSE Change -Subsidy -Price -Alternate
319228 10/1/2000 10/1/2002 2.25 2.25 2.25 FALSE TRUE New Listing
319228 10/1/2002 9/1/2005 1.2 1.2 1.2 FALSE TRUE Change -Subsidy -Price -Alternate
319228 9/1/2005 5/1/2006 1.02 1.02 1.02 FALSE TRUE Change -Subsidy -Price -Alternate
319228 5/1/2006 0 0 0 FALSE FALSE Delisted
319309 8/1/2000 10/1/2000 16.13 16.13 16.13 FALSE TRUE New Listing
319309 10/1/2000 10/1/2002 7.5 7.5 7.5 FALSE TRUE Change -Subsidy -Price -Alternate
319309 10/1/2002 9/1/2005 4 4 4 FALSE TRUE Change -Subsidy -Price -Alternate
319309 9/1/2005 5/1/2006 3.4 3.4 3.4 FALSE TRUE Change -Subsidy -Price -Alternate
319309 5/1/2006 0 0 0 FALSE FALSE Delisted
319325 5/16/1994 5/23/1995 104.58 104.58 104.58 FALSE FALSE New Listing
319325 5/23/1995 6/1/2000 104.59 104.59 104.59 FALSE FALSE Change +Subsidy +Price +Alternate
319325 6/1/2000 12/1/2000 116.4 116.4 116.4 FALSE FALSE Change +Subsidy +Price +Alternate
319325 12/1/2000 4/1/2001 66 66 116.4 FALSE FALSE Change -Subsidy -Alternate
319325 4/1/2001 12/1/2006 0 0 0 FALSE FALSE Delisted
319325 12/1/2006 1/1/2010 22.8 22.8 22.8 FALSE FALSE New Listing
319325 1/1/2010 4/1/2010 14.37 14.37 22.8 FALSE FALSE Change -Subsidy -Alternate
319325 4/1/2010 0 0 0 FALSE FALSE Delisted
319333 8/1/1997 5/1/1998 55.5 55.5 59.36 FALSE FALSE New Listing
319333 5/1/1998 1/1/2001 36.08 36.08 36.08 FALSE FALSE Change -Subsidy -Price -Alternate
319333 1/1/2001 5/1/2002 30 30 30 FALSE FALSE Change -Subsidy -Price -Alternate
319333 5/1/2002 10/1/2006 0 0 0 FALSE FALSE Delisted
319333 10/1/2006 10/1/2009 21 21 21 FALSE FALSE New Listing
319333 10/1/2009 11/1/2012 23.7 23.7 23.7 FALSE FALSE Change +Subsidy +Price +Alternate
319333 11/1/2012 21.25 21.25 21.25 FALSE FALSE Change -Subsidy -Price -Alternate
319406 5/16/1994 1/1/2001 159.68 159.68 159.68 FALSE FALSE New Listing
319406 1/1/2001 12/1/2002 140 140 140 FALSE FALSE Change -Subsidy -Price -Alternate
319406 12/1/2002 0 0 0 FALSE FALSE Delisted
319414 5/16/1994 9/1/1999 271.47 271.47 271.47 FALSE FALSE New Listing
319414 9/1/1999 1/1/2001 176.45 176.45 271.47 FALSE FALSE Change -Subsidy -Alternate
319414 1/1/2001 12/1/2002 220 220 220 FALSE FALSE Change +Subsidy -Price +Alternate
319414 12/1/2002 0 0 0 FALSE FALSE Delisted
319449 7/1/1996 10/2/1997 0 0 0 TRUE FALSE New Listing
319449 10/2/1997 0 0 0 FALSE FALSE Delisted
319457 7/1/1996 10/2/1997 0 0 0 TRUE FALSE New Listing
319457 10/2/1997 0 0 0 FALSE FALSE Delisted
319465 5/16/1994 4/1/1997 3 3 3 FALSE FALSE New Listing
319465 4/1/1997 0 0 0 FALSE FALSE Delisted
319473 5/16/1994 2/1/2000 5.04 5.04 5.04 FALSE FALSE New Listing
319473 2/1/2000 6/1/2000 2.92 2.92 5.04 FALSE FALSE Change -Subsidy -Alternate
319473 6/1/2000 ######## 0 0 0 FALSE FALSE Delisted
319473 ######## 3/1/2003 3.43 3.43 3.43 FALSE FALSE New listing
319473 3/1/2003 1/1/2010 2.75 2.75 2.75 FALSE FALSE Change -Subsidy -Price -Alternate
319473 1/1/2010 4/1/2010 2.2 2.2 2.75 FALSE FALSE Change -Subsidy -Alternate
319473 4/1/2010 9/1/2012 0 0 0 FALSE FALSE Delisted
319473 9/1/2012 1.61 1.61 1.61 FALSE FALSE New Listing
319481 5/16/1994 2/1/2000 8.53 8.53 8.53 FALSE FALSE New Listing
319481 2/1/2000 6/1/2000 4.95 4.95 8.53 FALSE FALSE Change -Subsidy -Alternate
319481 6/1/2000 ######## 0 0 0 FALSE FALSE Delisted
319481 ######## 3/1/2003 5.89 5.89 5.89 FALSE FALSE New listing
319481 3/1/2003 1/1/2010 4.75 4.75 4.75 FALSE FALSE Change -Subsidy -Price -Alternate
319481 1/1/2010 4/1/2010 3.85 3.85 4.75 FALSE FALSE Change -Subsidy -Alternate
319481 4/1/2010 9/1/2012 0 0 0 FALSE FALSE Delisted
319481 9/1/2012 2.19 2.19 2.19 FALSE FALSE New Listing
319503 5/16/1994 12/1/1999 55.98 55.98 55.98 FALSE FALSE New Listing
319503 12/1/1999 4/1/2000 32.47 32.47 55.98 FALSE FALSE Change -Subsidy -Alternate
319503 4/1/2000 0 0 0 FALSE FALSE Delisted
319546 9/18/1997 3/1/1999 0.96 0.96 31.99 FALSE FALSE New Listing
319546 3/1/1999 2/1/2000 0.96 22.39 22.39 FALSE FALSE Change -Price +Alternate
319546 2/1/2000 4/1/2003 0.78 22.39 22.39 FALSE FALSE Change -Subsidy
319546 4/1/2003 5/1/2003 11.95 22.39 22.39 FALSE FALSE Change +Subsidy
319546 5/1/2003 7/1/2003 11.95 11.95 22.39 FALSE FALSE Change -Alternate
319546 7/1/2003 0 0 0 FALSE FALSE Delisted
319562 5/16/1994 10/1/1997 68.99 68.99 68.99 FALSE FALSE New Listing
319562 10/1/1997 4/1/2009 68.99 68.99 70.97 FALSE FALSE Change +Price
319562 4/1/2009 2/1/2013 68.99 68.99 68.99 FALSE FALSE Change -Price
319562 2/1/2013 0 0 0 FALSE FALSE Delisted
319627 5/16/1994 5/17/1995 6.67 6.67 8.16 FALSE TRUE New Listing
319627 5/17/1995 3/1/1998 6.67 6.67 8.17 FALSE TRUE Change +Price
319627 3/1/1998 10/1/1998 3.33 3.33 8.17 FALSE TRUE Change -Subsidy -Alternate
319627 10/1/1998 1/1/1999 1.83 1.83 8.17 FALSE TRUE Change -Subsidy -Alternate
319627 1/1/1999 3/1/2001 1 1 8.17 FALSE TRUE Change -Subsidy -Alternate
319627 3/1/2001 7/1/2002 1 1 8.6 FALSE TRUE Change +Price
319627 7/1/2002 0 0 0 FALSE FALSE Delisted
319635 5/16/1994 12/1/1997 7.2 7.2 8.76 FALSE TRUE New Listing
319635 12/1/1997 10/1/1998 6.16 6.16 8.76 FALSE TRUE Change -Subsidy -Alternate
319635 10/1/1998 1/1/1999 4.38 4.38 8.76 FALSE TRUE Change -Subsidy -Alternate
319635 1/1/1999 2/1/2001 2.75 2.75 8.76 FALSE TRUE Change -Subsidy -Alternate
319635 2/1/2001 2/1/2004 2.75 2.75 9.2 FALSE TRUE Change +Price
319635 2/1/2004 0 0 0 FALSE FALSE Delisted
319643 5/16/1994 12/1/1997 8.12 8.12 9.2 FALSE FALSE New Listing
319643 12/1/1997 10/1/1998 6.16 6.16 9.2 FALSE FALSE Change -Subsidy -Alternate
319643 10/1/1998 1/1/1999 4.38 4.38 9.2 FALSE FALSE Change -Subsidy -Alternate
319643 1/1/1999 1/1/2003 2.75 2.75 9.2 FALSE FALSE Change -Subsidy -Alternate
319643 1/1/2003 0 0 0 FALSE FALSE Delisted
319783 10/1/1996 7/1/1997 3.16 3.16 6.32 FALSE FALSE New Listing
319783 7/1/1997 8/1/1999 3.16 3.16 6.95 FALSE FALSE Change +Price
319783 8/1/1999 0 0 0 FALSE FALSE Delisted
319880 10/1/1996 7/1/1997 3.64 3.64 7.75 FALSE FALSE New Listing
319880 7/1/1997 8/1/1999 3.64 3.64 8.52 FALSE FALSE Change +Price
319880 8/1/1999 0 0 0 FALSE FALSE Delisted
319899 10/1/1996 7/1/1997 12.26 12.26 13.25 FALSE FALSE New Listing
319899 7/1/1997 8/1/1999 12.26 12.26 14.57 FALSE FALSE Change +Price
319899 8/1/1999 0 0 0 FALSE FALSE Delisted
319902 11/1/1996 2/1/1998 9.45 9.45 9.45 FALSE FALSE New Listing
319902 2/1/1998 0 0 0 FALSE FALSE Delisted
319910 4/12/1995 8/1/1999 0.07 0.07 0.07 TRUE FALSE New Listing
319910 8/1/1999 0 0 0 FALSE FALSE Delisted
319953 4/12/1995 8/1/1999 0 0 0 TRUE FALSE New Listing
319953 8/1/1999 0 0 0 FALSE FALSE Delisted
320056 10/1/1996 8/1/1999 3.94 3.94 8.45 FALSE FALSE New Listing
320056 8/1/1999 0 0 0 FALSE FALSE Delisted
320064 10/1/1996 8/1/1999 4.6 4.6 8.95 FALSE FALSE New Listing
320064 8/1/1999 0 0 0 FALSE FALSE Delisted
320102 7/1/1997 8/1/1999 2.08 2.08 7.64 FALSE FALSE New Listing
320102 8/1/1999 0 0 0 FALSE FALSE Delisted
320137 10/1/1996 7/1/1997 4.32 4.32 9.05 FALSE FALSE New Listing
320137 7/1/1997 8/1/1999 4.32 4.32 9.95 FALSE FALSE Change +Price
320137 8/1/1999 0 0 0 FALSE FALSE Delisted
320161 10/1/1996 7/1/1997 3.18 3.18 6.75 FALSE FALSE New Listing
320161 7/1/1997 8/1/1999 3.18 3.18 7.42 FALSE FALSE Change +Price
320161 8/1/1999 0 0 0 FALSE FALSE Delisted
320625 10/1/1996 7/1/1997 4.82 4.82 11.6 FALSE FALSE New Listing
320625 7/1/1997 8/1/1999 4.82 4.82 12.76 FALSE FALSE Change +Price
320625 8/1/1999 0 0 0 FALSE FALSE Delisted
320684 7/1/1997 8/1/1999 5.9 5.9 6.49 FALSE FALSE New Listing
320684 8/1/1999 4/1/2000 6.49 6.49 6.49 FALSE FALSE Change +Subsidy +Alternate
320684 4/1/2000 10/1/2000 6.49 6.49 7.5 FALSE FALSE Change +Price
320684 10/1/2000 0 0 0 FALSE FALSE Delisted
320692 7/1/1997 8/1/1999 4.28 4.28 10.39 FALSE FALSE New Listing
320692 8/1/1999 0 0 0 FALSE FALSE Delisted
320706 10/1/1996 2/1/1998 6.52 6.52 13.2 FALSE FALSE New Listing
320706 2/1/1998 0 0 0 FALSE FALSE Delisted
321249 5/16/1994 11/1/1999 115 115 115.01 FALSE FALSE New Listing
321249 11/1/1999 6/1/2006 92 92 92 FALSE FALSE Change -Subsidy -Price -Alternate
321249 6/1/2006 7/1/2006 32.14 32.14 92 FALSE FALSE Change -Subsidy -Alternate
321249 7/1/2006 0 0 0 FALSE FALSE Delisted
321397 5/16/1994 12/1/1997 6.75 6.75 7.76 FALSE TRUE New Listing
321397 12/1/1997 10/1/1998 6.16 6.16 7.76 FALSE TRUE Change -Subsidy -Alternate
321397 10/1/1998 1/1/1999 4.38 4.38 7.76 FALSE TRUE Change -Subsidy -Alternate
321397 1/1/1999 4/1/1999 2.75 2.75 7.76 FALSE TRUE Change -Subsidy -Alternate
321397 4/1/1999 0 0 0 FALSE FALSE Delisted
321567 5/16/1994 1/1/2005 78.06 78.06 78.06 FALSE FALSE New Listing
321567 1/1/2005 7/1/2007 78.06 78.06 87.82 FALSE FALSE Change +Price
321567 7/1/2007 1/1/2010 78.06 78.06 78.06 FALSE FALSE Change -Price
321567 1/1/2010 70.5 70.5 70.5 FALSE FALSE Change -Subsidy -Price -Alternate
321869 7/1/1997 8/1/1999 6.42 6.42 14.96 FALSE FALSE New Listing
321869 8/1/1999 0 0 0 FALSE FALSE Delisted
321974 10/1/1996 7/1/1997 9.9 9.9 10.5 FALSE FALSE New Listing
321974 7/1/1997 5/1/1999 9.9 9.9 11.55 FALSE FALSE Change +Price
321974 5/1/1999 0 0 0 FALSE FALSE Delisted
322075 7/1/1997 8/1/1999 5.12 5.12 12.76 FALSE FALSE New Listing
322075 8/1/1999 0 0 0 FALSE FALSE Delisted
322083 10/1/1996 7/1/1997 4.26 4.26 9.45 FALSE FALSE New Listing
322083 7/1/1997 8/1/1999 4.26 4.26 10.4 FALSE FALSE Change +Price
322083 8/1/1999 0 0 0 FALSE FALSE Delisted
322113 10/1/1996 7/1/1997 4.32 4.32 9.85 FALSE FALSE New Listing
322113 7/1/1997 8/1/1999 4.32 4.32 10.83 FALSE FALSE Change +Price
322113 8/1/1999 0 0 0 FALSE FALSE Delisted
322156 10/1/2000 10/1/2002 2.25 2.25 2.25 FALSE TRUE New Listing
322156 10/1/2002 9/1/2005 1.2 1.2 1.2 FALSE TRUE Change -Subsidy -Price -Alternate
322156 9/1/2005 5/1/2006 1.02 1.02 1.02 FALSE TRUE Change -Subsidy -Price -Alternate
322156 5/1/2006 0 0 0 FALSE FALSE Delisted
323047 10/1/1997 3/1/2004 6.6 6.6 6.6 FALSE TRUE New Listing
323047 3/1/2004 8/1/2005 6.6 6.6 9.26 FALSE TRUE Change +Price
323047 8/1/2005 11/1/2005 4.99 4.99 9.26 FALSE TRUE Change -Subsidy -Alternate
323047 11/1/2005 0 0 0 FALSE FALSE Delisted
323071 8/1/1997 5/1/1998 56.38 56.38 59.36 FALSE FALSE New Listing
323071 5/1/1998 1/1/2001 36.65 36.65 36.65 FALSE FALSE Change -Subsidy -Price -Alternate
323071 1/1/2001 5/1/2002 30 30 30 FALSE FALSE Change -Subsidy -Price -Alternate
323071 5/1/2002 10/1/2006 0 0 0 FALSE FALSE Delisted
323071 10/1/2006 10/1/2009 17.95 17.95 17.95 FALSE FALSE New Listing
323071 10/1/2009 11/1/2012 24.88 24.88 24.88 FALSE FALSE Change +Subsidy +Price +Alternate
323071 11/1/2012 22.25 22.25 22.25 FALSE FALSE Change -Subsidy -Price -Alternate
323152 5/16/1994 8/1/2000 2.6 2.6 2.6 FALSE FALSE New Listing
323152 8/1/2000 5/1/2005 2.6 2.6 3.25 FALSE FALSE Change +Price
323152 5/1/2005 0 0 0 FALSE FALSE Delisted
323160 8/16/1994 8/1/2000 2.6 2.6 2.6 FALSE FALSE New Listing
323160 8/1/2000 2/1/2007 2.6 2.6 3.45 FALSE FALSE Change +Price
323160 2/1/2007 0 0 0 FALSE FALSE Delisted
323446 5/16/1994 5/11/1995 1.07 1.07 1.1 FALSE FALSE New Listing
323446 5/11/1995 2/1/2000 1.07 1.07 3.97 FALSE FALSE Change +Price
323446 2/1/2000 8/1/2001 0.86 0.86 3.97 FALSE FALSE Change -Subsidy -Alternate
323446 8/1/2001 9/1/2002 0.86 0.86 4.1 FALSE FALSE Change +Price
323446 9/1/2002 12/1/2004 1.06 1.06 4.1 FALSE FALSE Change +Subsidy +Alternate
323446 12/1/2004 0 0 0 FALSE FALSE Delisted
323454 4/11/1995 3/1/2002 47.87 47.87 47.87 FALSE FALSE New Listing
323454 3/1/2002 10/1/2002 47.87 47.87 59.23 FALSE FALSE Change +Price
323454 10/1/2002 1/1/2003 47.87 47.87 47.87 FALSE FALSE Change -Price
323454 1/1/2003 4/1/2003 46.2 46.2 46.2 FALSE FALSE Change -Subsidy -Price -Alternate
323454 4/1/2003 0 0 0 FALSE FALSE Delisted
323748 5/16/1994 9/1/1997 8.45 8.45 8.45 FALSE TRUE New Listing
323748 9/1/1997 10/1/1997 8.45 8.45 10.63 FALSE TRUE Change +Price
323748 10/1/1997 8/1/2000 8.45 8.45 9.88 FALSE TRUE Change -Price
323748 8/1/2000 3/1/2002 8.45 8.45 11.04 FALSE TRUE Change +Price
323748 3/1/2002 7/1/2003 8.45 8.45 11.3 FALSE TRUE Change +Price
323748 7/1/2003 5/1/2004 8.45 8.45 11.61 FALSE TRUE Change +Price
323748 5/1/2004 11/1/2004 8.45 8.45 11.64 FALSE TRUE Change +Price
323748 11/1/2004 0 0 0 FALSE FALSE Delisted
323756 5/16/1994 9/1/1997 32.4 32.4 32.4 FALSE TRUE New Listing
323756 9/1/1997 10/1/1997 32.4 32.4 42.49 FALSE TRUE Change +Price
323756 10/1/1997 8/1/2000 32.4 32.4 39.53 FALSE TRUE Change -Price
323756 8/1/2000 3/1/2002 32.4 32.4 44.8 FALSE TRUE Change +Price
323756 3/1/2002 7/1/2003 32.4 32.4 45.88 FALSE TRUE Change +Price
323756 7/1/2003 11/1/2004 32.4 32.4 47.12 FALSE TRUE Change +Price
323756 11/1/2004 0 0 0 FALSE FALSE Delisted
323950 5/16/1994 3/1/1996 27.3 27.3 27.3 FALSE FALSE New Listing
323950 3/1/1996 9/1/1998 19.66 19.66 19.66 FALSE FALSE Change -Subsidy -Price -Alternate
323950 9/1/1998 4/1/1999 6 6 19.66 FALSE FALSE Change -Subsidy -Alternate
323950 4/1/1999 4/1/2001 6 6 6 FALSE FALSE Change -Price
323950 4/1/2001 0 0 0 FALSE FALSE Delisted
323985 8/1/2000 10/1/2000 16.13 16.13 16.13 FALSE TRUE New Listing
323985 10/1/2000 10/1/2002 7.5 7.5 7.5 FALSE TRUE Change -Subsidy -Price -Alternate
323985 10/1/2002 9/1/2005 4 4 4 FALSE TRUE Change -Subsidy -Price -Alternate
323985 9/1/2005 5/1/2006 3.4 3.4 3.4 FALSE TRUE Change -Subsidy -Price -Alternate
323985 5/1/2006 0 0 0 FALSE FALSE Delisted
324760 10/1/1995 12/1/1997 75.88 75.88 75.88 FALSE FALSE New Listing
324760 12/1/1997 1/1/1998 68.04 68.04 68.04 FALSE FALSE Change -Subsidy -Price -Alternate
324760 1/1/1998 9/1/1998 52.64 52.64 52.64 FALSE FALSE Change -Subsidy -Price -Alternate
324760 9/1/1998 12/1/2000 34.11 34.11 52.64 FALSE FALSE Change -Subsidy -Alternate
324760 12/1/2000 0 0 0 FALSE FALSE Delisted
325155 1/1/1999 6/1/2001 6 6 6 FALSE FALSE New Listing
325155 6/1/2001 9/1/2002 3.5 3.5 3.5 FALSE FALSE Change -Subsidy -Price -Alternate
325155 9/1/2002 0 0 0 FALSE FALSE Delisted
325163 1/1/1999 6/1/2001 6 6 6 FALSE FALSE New Listing
325163 6/1/2001 9/1/2002 3.5 3.5 3.5 FALSE FALSE Change -Subsidy -Price -Alternate
325163 9/1/2002 0 0 0 FALSE FALSE Delisted
325244 5/16/1994 12/1/1997 3.11 3.11 3.8 FALSE TRUE New Listing
325244 12/1/1997 0 0 0 FALSE FALSE Delisted
325260 5/16/1994 12/1/1997 10.57 10.57 11.5 FALSE FALSE New Listing
325260 12/1/1997 0 0 0 FALSE FALSE Delisted
325295 5/16/1994 12/1/1997 6.89 6.89 7.5 FALSE TRUE New Listing
325295 12/1/1997 11/1/1999 2.18 2.18 6.25 FALSE TRUE Change -Subsidy -Price -Alternate
325295 11/1/1999 4/1/2001 1.49 1.49 2.18 FALSE TRUE Change -Subsidy -Price -Alternate
325295 4/1/2001 10/1/2001 1.4 1.4 2.18 FALSE TRUE Change -Subsidy -Alternate
325295 10/1/2001 1/1/2003 1.4 1.4 6.56 FALSE TRUE Change +Price
325295 1/1/2003 12/1/2004 1.4 1.4 7.22 FALSE TRUE Change +Price
325295 12/1/2004 1.4 1.4 7.73 FALSE TRUE Change +Price
325309 5/16/1994 12/1/1997 27.59 27.59 27.59 FALSE FALSE New Listing
325309 12/1/1997 11/1/1999 8.7 8.7 19.4 FALSE FALSE Change -Subsidy -Price -Alternate
325309 11/1/1999 4/1/2001 5.94 5.94 19.4 FALSE FALSE Change -Subsidy -Alternate
325309 4/1/2001 10/1/2001 5.6 5.6 19.4 FALSE FALSE Change -Subsidy -Alternate
325309 10/1/2001 1/1/2003 5.6 5.6 20.37 FALSE FALSE Change +Price
325309 1/1/2003 12/1/2004 5.6 5.6 22.35 FALSE FALSE Change +Price
325309 12/1/2004 5.6 5.6 23.91 FALSE FALSE Change +Price
325988 12/1/1994 8/1/1998 4.53 4.53 4.53 FALSE TRUE New Listing
325988 8/1/1998 3/1/2002 4.53 4.53 7.5 FALSE TRUE Change +Price
325988 3/1/2002 12/1/2009 4.53 4.53 8 FALSE TRUE Change +Price
325988 12/1/2009 0 0 0 FALSE FALSE Delisted
325996 9/1/1997 3/1/2002 4.11 4.11 8.36 FALSE TRUE New Listing
325996 3/1/2002 9/1/2010 4.11 4.11 7 FALSE TRUE Change -Price
325996 9/1/2010 0 0 0 FALSE FALSE Delisted
326038 5/16/1994 7/1/1999 2.2 2.2 2.2 FALSE FALSE New Listing
326038 7/1/1999 11/1/1999 1.59 1.59 2.2 FALSE FALSE Change -Subsidy -Alternate
326038 11/1/1999 0 0 0 FALSE FALSE Delisted
326062 10/4/1997 5/1/1998 8.89 8.89 8.89 FALSE FALSE New Listing
326062 5/1/1998 7/1/2001 3.5 3.5 3.5 FALSE FALSE Change -Subsidy -Price -Alternate
326062 7/1/2001 6/1/2004 3.85 3.85 3.85 FALSE FALSE Change +Subsidy +Price +Alternate
326062 6/1/2004 0 0 0 FALSE FALSE Delisted
326070 10/4/1997 5/1/1998 29.63 29.63 29.63 FALSE FALSE New Listing
326070 5/1/1998 7/1/2001 11.67 11.67 11.67 FALSE FALSE Change -Subsidy -Price -Alternate
326070 7/1/2001 7/1/2004 12.83 12.83 12.83 FALSE FALSE Change +Subsidy +Price +Alternate
326070 7/1/2004 7/1/2007 15.5 15.5 15.5 FALSE FALSE Change +Subsidy +Price +Alternate
326070 7/1/2007 12/1/2010 16.9 16.9 16.9 FALSE FALSE Change +Subsidy +Price +Alternate
326070 12/1/2010 16.06 16.06 16.06 FALSE FALSE Change -Subsidy -Price -Alternate
326747 6/1/1995 5/1/1999 7.5 7.5 7.5 FALSE TRUE New Listing
326747 5/1/1999 7/1/2001 7.5 7.5 8.6 FALSE TRUE Change +Price
326747 7/1/2001 7.5 7.5 7.5 FALSE TRUE Change -Price
326755 12/1/2000 3.8 3.8 3.8 FALSE TRUE New listing
326844 6/1/1997 5/1/2001 41.05 41.05 41.05 FALSE FALSE New Listing
326844 5/1/2001 2/1/2012 35.8 35.8 35.8 FALSE FALSE Change -Subsidy -Price -Alternate
326844 2/1/2012 7/1/2012 23.02 35.8 35.8 FALSE FALSE Change -Subsidy
326844 7/1/2012 20.64 35.8 35.8 FALSE FALSE Change -Subsidy
326852 4/1/1996 9/1/1998 32.77 32.77 32.76 FALSE FALSE New Listing
326852 9/1/1998 6/1/2001 10 10 10 FALSE FALSE Change -Subsidy -Price -Alternate
326852 6/1/2001 12/1/2001 7.5 7.5 7.5 FALSE FALSE Change -Subsidy -Price -Alternate
326852 12/1/2001 0 0 0 FALSE FALSE Delisted
326860 4/1/1996 9/1/1998 16.38 16.38 16.38 FALSE FALSE New Listing
326860 9/1/1998 6/1/2001 5 5 5 FALSE FALSE Change -Subsidy -Price -Alternate
326860 6/1/2001 12/1/2001 3.75 3.75 3.75 FALSE FALSE Change -Subsidy -Price -Alternate
326860 12/1/2001 0 0 0 FALSE FALSE Delisted
326887 5/16/1994 5/1/1998 6.88 6.88 6.88 FALSE FALSE New Listing
326887 5/1/1998 8/1/1998 3.51 3.51 3.51 FALSE FALSE Change -Subsidy -Price -Alternate
326887 8/1/1998 7/1/2001 0 0 0 FALSE FALSE Delisted
326887 7/1/2001 9/1/2001 3.51 3.51 3.51 FALSE FALSE New Listing
326887 9/1/2001 8/1/2008 2.99 2.99 2.99 FALSE FALSE Change -Subsidy -Price -Alternate
326887 8/1/2008 0 0 0 FALSE FALSE Delisted
326895 5/16/1994 5/1/1998 12.2 12.2 12.2 FALSE FALSE New Listing
326895 5/1/1998 8/1/1998 6.22 6.22 6.22 FALSE FALSE Change -Subsidy -Price -Alternate
326895 8/1/1998 7/1/2001 0 0 0 FALSE FALSE Delisted
326895 7/1/2001 9/1/2001 6.22 6.22 6.22 FALSE FALSE New Listing
326895 9/1/2001 7/1/2004 4.49 4.49 4.49 FALSE FALSE Change -Subsidy -Price -Alternate
326895 7/1/2004 8/1/2008 4 4 4 FALSE FALSE Change -Subsidy -Price -Alternate
326895 8/1/2008 0 0 0 FALSE FALSE Delisted
326909 5/16/1994 5/1/1998 30.42 30.42 30.42 FALSE FALSE New Listing
326909 5/1/1998 8/1/1998 15.51 15.51 15.51 FALSE FALSE Change -Subsidy -Price -Alternate
326909 8/1/1998 7/1/2001 0 0 0 FALSE FALSE Delisted
326909 7/1/2001 9/1/2001 15.51 15.51 15.51 FALSE FALSE New Listing
326909 9/1/2001 7/1/2004 7.49 7.49 7.49 FALSE FALSE Change -Subsidy -Price -Alternate
326909 7/1/2004 8/1/2008 6.5 6.5 6.5 FALSE FALSE Change -Subsidy -Price -Alternate
326909 8/1/2008 0 0 0 FALSE FALSE Delisted
326992 5/16/1994 12/1/1998 10 10 10 FALSE FALSE New Listing
326992 12/1/1998 5/1/1999 4.5 4.5 10 FALSE FALSE Change -Subsidy -Alternate
326992 5/1/1999 0 0 0 FALSE FALSE Delisted
327050 5/1/2008 1.11 1.11 1.11 FALSE FALSE New listing
327476 5/16/1994 2/1/1997 3.29 3.29 6.55 FALSE TRUE New Listing
327476 2/1/1997 7/1/1997 3.29 3.29 7.8 FALSE TRUE Change +Price
327476 7/1/1997 0 0 0 FALSE FALSE Delisted
327611 6/16/1995 4/1/2000 9.45 13.8 13.8 FALSE TRUE New Listing
327611 4/1/2000 1/1/2004 9.45 13.8 13.8 FALSE FALSE Change -OP
327611 1/1/2004 6.62 13.8 16.5 FALSE FALSE Change -Subsidy +Price
327670 5/16/1994 12/1/1995 14 14 14 FALSE FALSE New Listing
327670 12/1/1995 4/1/2010 5.6 5.6 5.6 FALSE FALSE Change -Subsidy -Price -Alternate
327670 4/1/2010 0 0 0 FALSE FALSE Delisted
327794 5/16/1994 5/19/1995 3.44 3.44 4.42 FALSE TRUE New Listing
327794 5/19/1995 12/1/1997 3.44 3.44 4.55 FALSE TRUE Change +Price
327794 12/1/1997 11/1/1999 1.09 1.09 4.55 FALSE TRUE Change -Subsidy -Alternate
327794 11/1/1999 4/1/2001 0.74 0.74 4.55 FALSE TRUE Change -Subsidy -Alternate
327794 4/1/2001 10/1/2001 0.7 0.7 4.55 FALSE TRUE Change -Subsidy -Alternate
327794 10/1/2001 1/1/2003 0.7 0.7 4.78 FALSE TRUE Change +Price
327794 1/1/2003 5/1/2004 0.7 0.7 5.01 FALSE TRUE Change +Price
327794 5/1/2004 0 0 0 FALSE FALSE Delisted
327816 5/16/1994 6/2/1995 2.56 2.56 2.56 FALSE TRUE New Listing
327816 6/2/1995 12/1/1997 2.56 2.56 2.88 FALSE TRUE Change +Price
327816 12/1/1997 0 0 0 FALSE FALSE Delisted
327832 5/16/1994 8/1/2000 5.38 5.38 7.82 FALSE FALSE New Listing
327832 8/1/2000 8/1/2006 5.38 5.38 11.35 FALSE FALSE Change +Price
327832 8/1/2006 0 0 0 FALSE FALSE Delisted
327859 2/1/1996 10/1/2002 7 7 7 FALSE TRUE New Listing
327859 10/1/2002 5/1/2008 5.4 5.4 7 FALSE TRUE Change -Subsidy -Alternate
327859 5/1/2008 8/1/2009 4.12 4.12 7 FALSE TRUE Change -Subsidy -Alternate
327859 8/1/2009 6/1/2014 4.12 4.12 10.55 FALSE TRUE Change +Price
327859 6/1/2014 4.12 4.12 11.1 FALSE TRUE Change +Price
327883 5/16/1994 10/1/2005 24.08 24.08 27.22 FALSE FALSE New Listing
327883 10/1/2005 5/1/2012 24.08 24.08 34 FALSE FALSE Change +Price
327883 5/1/2012 8/1/2012 24 24 34 FALSE FALSE Change -Subsidy -Alternate
327883 8/1/2012 0 0 0 FALSE FALSE Delisted
327948 5/16/1994 6/1/1997 465.95 465.95 465.95 FALSE FALSE New Listing
327948 6/1/1997 3/1/1998 419.31 419.31 419.31 FALSE FALSE Change -Subsidy -Price -Alternate
327948 3/1/1998 0 0 0 FALSE FALSE Delisted
328235 8/1/1997 8/1/1998 11.87 11.87 11.87 FALSE FALSE New Listing
328235 8/1/1998 6/1/1999 8.31 8.31 8.31 FALSE FALSE Change -Subsidy -Price -Alternate
328235 6/1/1999 2/1/2000 7.48 7.48 8.31 FALSE FALSE Change -Subsidy -Alternate
328235 2/1/2000 3/1/2001 4.99 8.31 8.31 FALSE FALSE Change -Subsidy +Alternate
328235 3/1/2001 7/1/2001 4.49 8.31 8.31 FALSE FALSE Change -Subsidy
328235 7/1/2001 1/1/2004 4.49 9.14 9.14 FALSE FALSE Change +Price +Alternate
328235 1/1/2004 4/1/2004 2.29 9.14 9.14 FALSE FALSE Change -Subsidy
328235 4/1/2004 0 0 0 FALSE FALSE Delisted
328286 6/10/1995 2/1/2001 4.8 4.8 6.04 FALSE TRUE New Listing
328286 2/1/2001 4/1/2004 4.8 4.8 7.68 FALSE TRUE Change +Price
328286 4/1/2004 0 0 0 FALSE FALSE Delisted
328421 4/11/1995 7/1/1997 19.45 19.45 19.45 FALSE FALSE New Listing
328421 7/1/1997 8/1/1999 19.45 19.45 21 FALSE FALSE Change +Price
328421 8/1/1999 0 0 0 FALSE FALSE Delisted
328448 4/11/1995 7/1/1997 19.45 19.45 19.45 FALSE FALSE New Listing
328448 7/1/1997 8/1/1999 19.45 19.45 21 FALSE FALSE Change +Price
328448 8/1/1999 0 0 0 FALSE FALSE Delisted
328456 4/11/1995 4/1/1997 19.45 19.45 19.45 FALSE FALSE New Listing
328456 4/1/1997 0 0 0 FALSE FALSE Delisted
328464 4/11/1995 2/1/1998 19.45 19.45 19.45 FALSE FALSE New Listing
328464 2/1/1998 0 0 0 FALSE FALSE Delisted
328626 5/16/1994 5/12/1995 20.46 20.46 20.46 FALSE FALSE New Listing
328626 5/12/1995 10/1/1997 20.46 20.46 20.88 FALSE FALSE Change +Price
328626 10/1/1997 0 0 0 FALSE FALSE Delisted
328634 5/16/1994 5/12/1995 75.73 75.73 75.73 FALSE FALSE New Listing
328634 5/12/1995 5/1/1998 75.73 75.73 77.28 FALSE FALSE Change +Price
328634 5/1/1998 8/1/1998 28.46 28.46 28.46 FALSE FALSE Change -Subsidy -Price -Alternate
328634 8/1/1998 0 0 0 FALSE FALSE Delisted
328685 5/16/1994 4/1/1997 3.5 3.5 3.5 FALSE TRUE New Listing
328685 4/1/1997 3/1/2001 3.5 3.5 4.85 FALSE TRUE Change +Price
328685 3/1/2001 4/1/2002 3.5 3.5 5.34 FALSE TRUE Change +Price
328685 4/1/2002 4/1/2003 3.5 3.5 5.87 FALSE TRUE Change +Price
328685 4/1/2003 12/1/2005 3.5 3.5 6.46 FALSE TRUE Change +Price
328685 12/1/2005 0 0 0 FALSE FALSE Delisted
328898 9/1/1996 3/1/1997 360 360 360 FALSE FALSE New Listing
328898 3/1/1997 0 0 0 FALSE FALSE Delisted
329134 5/16/1994 2/1/1999 5.46 5.46 8.19 FALSE FALSE New Listing
329134 2/1/1999 3/1/2004 5.46 5.46 30.4 FALSE FALSE Change +Price
329134 3/1/2004 0 0 0 FALSE FALSE Delisted
329150 5/16/1994 7/1/1995 9.46 9.46 9.46 FALSE TRUE New Listing
329150 7/1/1995 8/1/1997 8.99 8.99 8.99 FALSE TRUE Change -Subsidy -Price -Alternate
329150 8/1/1997 10/1/1999 8.99 8.99 9.43 FALSE TRUE Change +Price
329150 10/1/1999 0 0 0 FALSE FALSE Delisted
329223 5/16/1994 12/1/1996 6.81 6.81 6.81 FALSE FALSE New Listing
329223 12/1/1996 2/1/2004 4 4 4 FALSE FALSE Change -Subsidy -Price -Alternate
329223 2/1/2004 8/1/2004 1.8 4 4 FALSE FALSE Change -Subsidy
329223 8/1/2004 10/1/2005 1.8 1.8 4 FALSE FALSE Change -Alternate
329223 10/1/2005 0 0 0 FALSE FALSE Delisted
329231 5/16/1994 12/1/1996 15.43 15.43 15.43 FALSE FALSE New Listing
329231 12/1/1996 2/1/2004 12 12 12 FALSE FALSE Change -Subsidy -Price -Alternate
329231 2/1/2004 8/1/2004 3.6 12 12 FALSE FALSE Change -Subsidy
329231 8/1/2004 10/1/2005 3.6 3.6 12 FALSE FALSE Change -Alternate
329231 10/1/2005 0 0 0 FALSE FALSE Delisted
329258 5/16/1994 12/1/1996 23.93 23.93 23.93 FALSE FALSE New Listing
329258 12/1/1996 2/1/2004 16.75 16.75 16.75 FALSE FALSE Change -Subsidy -Price -Alternate
329258 2/1/2004 8/1/2004 7.2 16.75 16.75 FALSE FALSE Change -Subsidy
329258 8/1/2004 10/1/2005 7.2 7.2 16.75 FALSE FALSE Change -Alternate
329258 10/1/2005 0 0 0 FALSE FALSE Delisted
329266 5/16/1994 12/1/1996 29.04 29.04 29.04 FALSE FALSE New Listing
329266 12/1/1996 2/1/2004 25.5 25.5 25.5 FALSE FALSE Change -Subsidy -Price -Alternate
329266 2/1/2004 8/1/2004 8.5 25.5 25.5 FALSE FALSE Change -Subsidy
329266 8/1/2004 10/1/2004 8.5 8.5 25.5 FALSE FALSE Change -Alternate
329266 10/1/2004 0 0 0 FALSE FALSE Delisted
329320 8/1/2005 2/1/2006 32 32 32 FALSE FALSE New listing
329320 2/1/2006 0 0 0 FALSE FALSE Delisted
329401 5/16/1994 7/1/1997 14.18 14.18 14.18 FALSE FALSE New Listing
329401 7/1/1997 12/1/2000 14.18 14.18 15.6 FALSE FALSE Change +Price
329401 12/1/2000 0 0 0 FALSE FALSE Delisted
329428 5/16/1994 2/1/1996 9.76 9.76 9.76 FALSE FALSE New Listing
329428 2/1/1996 4/1/1996 8.96 8.96 9.76 FALSE FALSE Change -Subsidy -Alternate
329428 4/1/1996 8/1/1999 8.96 8.96 9.75 FALSE FALSE Change -Price
329428 8/1/1999 12/1/1999 4.99 4.99 7 FALSE FALSE Change -Subsidy -Price -Alternate
329428 12/1/1999 0 0 0 FALSE FALSE Delisted
329436 5/16/1994 2/1/1999 14.97 14.97 14.97 FALSE FALSE New Listing
329436 2/1/1999 12/1/1999 14.97 14.97 29.85 FALSE FALSE Change +Price
329436 12/1/1999 5/1/2001 14.97 14.97 14.97 FALSE FALSE Change -Price
329436 5/1/2001 0 0 0 FALSE FALSE Delisted
329444 5/16/1994 4/3/1995 7.28 7.28 8.37 FALSE TRUE New Listing
329444 4/3/1995 7/1/1998 7.28 7.28 9.4 FALSE TRUE Change +Price
329444 7/1/1998 0 0 0 FALSE FALSE Delisted
329622 5/16/1994 9/1/2000 2.86 2.86 4.56 FALSE TRUE New Listing
329622 9/1/2000 1/1/2007 1.91 1.91 1.91 FALSE TRUE Change -Subsidy -Price -Alternate
329622 1/1/2007 0 0 0 FALSE FALSE Delisted
329983 5/16/1994 8/1/2000 2.14 2.14 3.55 FALSE FALSE New Listing
329983 8/1/2000 3/1/2001 0 0 0 FALSE FALSE Delisted
329983 3/1/2001 3/1/2002 3.75 3.75 3.75 FALSE FALSE New Listing
329983 3/1/2002 0 0 0 FALSE FALSE Delisted
329991 5/16/1994 1/11/1995 23.72 23.72 23.72 FALSE FALSE New Listing
329991 1/11/1995 3/1/1996 23.72 23.72 25.32 FALSE FALSE Change +Price
329991 3/1/1996 3/1/1999 11.1 22.8 22.8 FALSE FALSE Change -Subsidy -Price -Alternate
329991 3/1/1999 2/1/2000 8.88 22.8 22.8 FALSE FALSE Change -Subsidy
329991 2/1/2000 12/1/2002 5.32 22.8 22.8 FALSE FALSE Change -Subsidy
329991 12/1/2002 2/1/2003 22.8 22.8 22.8 FALSE FALSE Change +Subsidy
329991 2/1/2003 4/1/2008 5.32 22.8 22.8 FALSE FALSE Change -Subsidy
329991 4/1/2008 0 0 0 FALSE FALSE Delisted
330019 5/16/1994 1/1/1996 4.33 4.33 4.33 TRUE FALSE New Listing
330019 1/1/1996 0 0 0 FALSE FALSE Delisted
330027 5/16/1994 6/1/1995 8.66 8.66 8.66 TRUE FALSE New Listing
330027 6/1/1995 1/1/1996 8.67 8.67 8.67 TRUE FALSE Change +Subsidy +Price +Alternate
330027 1/1/1996 0 0 0 FALSE FALSE Delisted
330116 5/16/1994 6/1/1996 28.38 28.38 43.56 FALSE FALSE New Listing
330116 6/1/1996 1/1/2004 9.45 14.52 14.52 FALSE FALSE Change -Subsidy -Price -Alternate
330116 1/1/2004 6/1/2007 6.62 14.52 14.52 FALSE FALSE Change -Subsidy
330116 6/1/2007 6.62 6.62 6.62 FALSE FALSE Change -Price -Alternate
330167 8/16/1994 10/1/2007 3.44 3.44 3.44 FALSE TRUE New Listing
330167 10/1/2007 1/1/2008 3.33 3.33 3.44 FALSE TRUE Change -Subsidy -Alternate
330167 1/1/2008 0 0 0 FALSE FALSE Delisted
330175 5/1/1996 2/1/2000 4.77 4.77 4.77 FALSE FALSE New Listing
330175 2/1/2000 8/1/2000 2.86 2.86 4.77 FALSE FALSE Change -Subsidy -Alternate
330175 8/1/2000 0 0 0 FALSE FALSE Delisted
330183 7/1/1997 1/1/2002 28.2 28.2 28.2 FALSE FALSE New Listing
330183 1/1/2002 0 0 0 FALSE FALSE Delisted
330191 7/1/1997 7/1/1999 13.9 13.9 13.9 FALSE FALSE New Listing
330191 7/1/1999 11/1/1999 7.3 7.3 7.3 FALSE FALSE Change -Subsidy -Price -Alternate
330191 11/1/1999 0 0 0 FALSE FALSE Delisted
330221 7/1/1997 1/1/2002 7.9 7.9 7.9 FALSE FALSE New Listing
330221 1/1/2002 0 0 0 FALSE FALSE Delisted
330248 7/1/1997 7/1/1999 4.35 4.35 4.35 FALSE FALSE New Listing
330248 7/1/1999 11/1/1999 2.44 2.44 2.44 FALSE FALSE Change -Subsidy -Price -Alternate
330248 11/1/1999 0 0 0 FALSE FALSE Delisted
330299 7/1/1997 7/1/1999 3.9 3.9 3.9 FALSE FALSE New Listing
330299 7/1/1999 11/1/1999 2.31 2.31 2.31 FALSE FALSE Change -Subsidy -Price -Alternate
330299 11/1/1999 0 0 0 FALSE FALSE Delisted
330302 6/8/1995 9/1/1996 3.2 3.2 3.2 FALSE FALSE New Listing
330302 9/1/1996 1/1/1998 3.2 3.2 3.51 FALSE FALSE Change +Price
330302 1/1/1998 10/1/1998 1.5 1.5 3.51 FALSE FALSE Change -Subsidy -Alternate
330302 10/1/1998 3/1/2001 1.5 1.5 4.04 FALSE FALSE Change +Price
330302 3/1/2001 0 0 0 FALSE FALSE Delisted
330310 5/16/1994 10/1/1996 3.17 3.17 3.17 FALSE FALSE New Listing
330310 10/1/1996 0 0 0 FALSE FALSE Delisted
330329 6/27/1995 8/1/1999 9.68 9.68 10.24 FALSE FALSE New Listing
330329 8/1/1999 0 0 0 FALSE FALSE Delisted
331007 10/4/1997 8/1/1999 4.46 4.46 4.46 FALSE FALSE New Listing
331007 8/1/1999 0 0 0 FALSE FALSE Delisted
331740 12/1/1994 8/1/2002 12.82 12.82 12.82 FALSE TRUE New Listing
331740 8/1/2002 12/1/2007 11.79 11.79 11.79 FALSE TRUE Change -Subsidy -Price -Alternate
331740 12/1/2007 3/1/2008 6.33 6.33 11.79 FALSE TRUE Change -Subsidy -Alternate
331740 3/1/2008 0 0 0 FALSE FALSE Delisted
331759 5/16/1994 7/1/1999 5.58 5.58 5.58 FALSE FALSE New Listing
331759 7/1/1999 1/1/2003 3.98 3.98 3.98 FALSE FALSE Change -Subsidy -Price -Alternate
331759 1/1/2003 10/1/2005 5.5 5.5 5.5 FALSE FALSE Change +Subsidy +Price +Alternate
331759 10/1/2005 12/1/2009 5.9 5.9 5.9 FALSE FALSE Change +Subsidy +Price +Alternate
331759 12/1/2009 0 0 0 FALSE FALSE Delisted
331767 5/16/1994 10.45 10.45 10.45 FALSE TRUE New Listing
331791 5/16/1994 1/18/1995 9.97 9.97 9.97 FALSE FALSE New Listing
331791 1/18/1995 5/25/1995 8.52 8.52 8.52 FALSE FALSE Change -Subsidy -Price -Alternate
331791 5/25/1995 5/1/1998 8.53 8.53 8.53 FALSE FALSE Change +Subsidy +Price +Alternate
331791 5/1/1998 12/1/2001 5.97 5.97 5.97 FALSE FALSE Change -Subsidy -Price -Alternate
331791 12/1/2001 3/1/2002 4.78 4.78 5.97 FALSE FALSE Change -Subsidy -Alternate
331791 3/1/2002 0 0 0 FALSE FALSE Delisted
331848 5/16/1994 9/1/1999 10.1 10.1 10.1 FALSE FALSE New Listing
331848 9/1/1999 10/1/2008 0 0 0 FALSE FALSE Delisted
331848 10/1/2008 9/1/2011 9 9 9 FALSE FALSE New Listing
331848 9/1/2011 7/1/2014 10.86 10.86 10.86 FALSE FALSE Change +Subsidy +Price +Alternate
331848 7/1/2014 8.8 8.8 8.8 FALSE FALSE Change -Subsidy -Price -Alternate
331856 5/16/1994 1/1/1998 17.5 17.5 17.5 FALSE FALSE New Listing
331856 1/1/1998 9/1/1999 15.8 15.8 15.8 FALSE FALSE Change -Subsidy -Price -Alternate
331856 9/1/1999 10/1/2008 0 0 0 FALSE FALSE Delisted
331856 10/1/2008 9/1/2011 10.4 10.4 10.4 FALSE FALSE New Listing
331856 9/1/2011 7/1/2014 11.32 11.32 11.32 FALSE FALSE Change +Subsidy +Price +Alternate
331856 7/1/2014 9.2 9.2 9.2 FALSE FALSE Change -Subsidy -Price -Alternate
331872 5/16/1994 6/27/1995 3.33 3.33 5 FALSE FALSE New Listing
331872 6/27/1995 0 0 0 FALSE FALSE Delisted
331899 5/16/1994 5/1/1999 65 65 65 FALSE FALSE New Listing
331899 5/1/1999 0 0 0 FALSE FALSE Delisted
331902 5/16/1994 6/27/1995 3.52 3.52 3.6 FALSE TRUE New Listing
331902 6/27/1995 3/1/1998 3.52 3.52 4.46 FALSE TRUE Change +Price
331902 3/1/1998 0 0 0 FALSE FALSE Delisted
331929 5/16/1994 1/1/1998 30 30 30 FALSE FALSE New Listing
331929 1/1/1998 9/1/1999 27 27 27 FALSE FALSE Change -Subsidy -Price -Alternate
331929 9/1/1999 10/1/2008 0 0 0 FALSE FALSE Delisted
331929 10/1/2008 9/1/2011 14 14 14 FALSE FALSE New Listing
331929 9/1/2011 7/1/2014 14.28 14.28 14.28 FALSE FALSE Change +Subsidy +Price +Alternate
331929 7/1/2014 11.6 11.6 11.6 FALSE FALSE Change -Subsidy -Price -Alternate
331937 5/16/1994 3/1/1996 32.76 32.76 32.76 FALSE FALSE New Listing
331937 3/1/1996 9/1/1998 19.66 19.66 19.66 FALSE FALSE Change -Subsidy -Price -Alternate
331937 9/1/1998 6/1/1999 6 6 19.66 FALSE FALSE Change -Subsidy -Alternate
331937 6/1/1999 0 0 0 FALSE FALSE Delisted
331945 5/16/1994 3/1/1996 29.89 29.89 32.71 FALSE FALSE New Listing
331945 3/1/1996 8/1/1998 22.55 32.71 32.71 FALSE FALSE Change -Subsidy +Alternate
331945 8/1/1998 3/1/1999 20.77 30.93 30.93 FALSE FALSE Change -Subsidy -Price -Alternate
331945 3/1/1999 2/1/2000 16.2 30.93 30.93 FALSE FALSE Change -Subsidy
331945 2/1/2000 0 0 0 FALSE FALSE Delisted
332062 5/16/1994 2/1/2010 49.02 49.02 49.02 FALSE FALSE New Listing
332062 2/1/2010 52.45 52.45 52.45 FALSE FALSE Change +Subsidy +Price +Alternate
332070 5/16/1994 4/1/2001 97.67 97.67 97.67 FALSE FALSE New Listing
332070 4/1/2001 0 0 0 FALSE FALSE Delisted
332232 5/16/1994 4/1/1996 6 6 6 FALSE TRUE New Listing
332232 4/1/1996 10/1/1997 5.91 5.91 6 FALSE TRUE Change -Subsidy -Alternate
332232 10/1/1997 1/1/1998 5.38 5.38 6 FALSE TRUE Change -Subsidy -Alternate
332232 1/1/1998 3/1/2001 5.38 5.38 5.38 FALSE TRUE Change -Price
332232 3/1/2001 1/1/2010 5 5 5 FALSE TRUE Change -Subsidy -Price -Alternate
332232 1/1/2010 2.3 2.3 2.3 FALSE TRUE Change -Subsidy -Price -Alternate
332623 6/1/1995 7/1/1999 5.25 5.25 5.25 FALSE TRUE New Listing
332623 7/1/1999 12/1/2005 4.69 4.69 4.69 FALSE TRUE Change -Subsidy -Price -Alternate
332623 12/1/2005 0 0 0 FALSE FALSE Delisted
332631 12/1/1995 11/1/2002 25.26 25.26 25.26 FALSE TRUE New Listing
332631 11/1/2002 12/1/2011 17.68 17.68 17.68 FALSE TRUE Change -Subsidy -Price -Alternate
332631 12/1/2011 0 0 0 FALSE FALSE Delisted
332658 1/9/1995 12/1/1995 24.06 24.06 24.06 FALSE FALSE New Listing
332658 12/1/1995 6/1/2004 25.26 25.26 25.26 FALSE TRUE Change +Subsidy +Price +Alternate +OP
332658 6/1/2004 0 0 0 FALSE FALSE Delisted
332690 5/16/1994 8/1/2001 516.12 516.12 516.12 FALSE FALSE New Listing
332690 8/1/2001 1/1/2004 413 413 413 FALSE FALSE Change -Subsidy -Price -Alternate
332690 1/1/2004 340.73 340.73 340.73 FALSE FALSE Change -Subsidy -Price -Alternate
332704 5/16/1994 8/1/2001 516.12 516.12 516.12 FALSE FALSE New Listing
332704 8/1/2001 1/1/2004 413 413 413 FALSE FALSE Change -Subsidy -Price -Alternate
332704 1/1/2004 340.73 340.73 340.73 FALSE FALSE Change -Subsidy -Price -Alternate
332712 5/16/1994 612.2 612.2 612.2 FALSE FALSE New Listing
332771 1/1/2006 132.59 132.59 132.59 FALSE FALSE New listing
332798 1/1/2006 399.15 399.15 399.15 FALSE FALSE New listing
332801 1/1/2006 204.13 204.13 204.13 FALSE FALSE New listing
332917 6/1/1995 5/1/1999 7.41 7.41 7.41 FALSE TRUE New Listing
332917 5/1/1999 2/1/2002 7.41 7.41 15.5 FALSE TRUE Change +Price
332917 2/1/2002 0 0 0 FALSE FALSE Delisted
332925 5/16/1994 7/1/2004 31.8 31.8 31.8 FALSE FALSE New Listing
332925 7/1/2004 4/1/2011 41.34 41.34 41.34 FALSE FALSE Change +Subsidy +Price +Alternate
332925 4/1/2011 65.39 65.39 65.39 FALSE FALSE Change +Subsidy +Price +Alternate
332984 5/16/1994 4/1/1998 133 133 133 FALSE FALSE New Listing
332984 4/1/1998 3/1/1999 133 133 190 FALSE FALSE Change +Price
332984 3/1/1999 5/1/2001 190 190 190 FALSE FALSE Change +Subsidy +Alternate
332984 5/1/2001 0 0 0 FALSE FALSE Delisted
333026 5/16/1994 5/1/1998 13.05 13.05 13.05 FALSE FALSE New Listing
333026 5/1/1998 8/1/1998 8.88 8.88 9.53 FALSE FALSE Change -Subsidy -Price -Alternate
333026 8/1/1998 0 0 0 FALSE FALSE Delisted
333042 5/16/1994 6/23/1995 35.7 35.7 35.7 FALSE FALSE New Listing
333042 6/23/1995 8/1/1995 35.7 35.7 37.5 FALSE FALSE Change +Price
333042 8/1/1995 1/1/1997 35.7 35.7 38.5 FALSE FALSE Change +Price
333042 1/1/1997 11/1/1997 35.7 35.7 42.5 FALSE FALSE Change +Price
333042 11/1/1997 8/1/2001 35.7 35.7 44.8 FALSE FALSE Change +Price
333042 8/1/2001 2/1/2002 119.5 119.5 119.5 FALSE FALSE Change +Subsidy +Price +Alternate
333042 2/1/2002 0 0 0 FALSE FALSE Delisted
333085 5/16/1994 8/1/2001 5 5 5.66 FALSE FALSE New Listing
333085 8/1/2001 5/1/2005 7.5 7.5 7.5 FALSE FALSE Change +Subsidy +Price +Alternate
333085 5/1/2005 10/1/2008 7.5 7.5 7.85 FALSE FALSE Change +Price
333085 10/1/2008 11/1/2008 7.5 7.5 9.5 FALSE FALSE Change +Price
333085 11/1/2008 9.5 9.5 9.5 FALSE FALSE Change +Subsidy +Alternate
333131 5/16/1994 1/16/1995 21.5 21.5 21.5 FALSE FALSE New Listing
333131 1/16/1995 5/23/1995 21.1 21.1 21.5 FALSE FALSE Change -Subsidy -Alternate
333131 5/23/1995 8/1/1995 21.1 21.1 21.1 FALSE FALSE Change -Price
333131 8/1/1995 4/1/1996 21.1 21.1 21.5 FALSE FALSE Change +Price
333131 4/1/1996 2/1/2001 21.1 21.1 22.6 FALSE FALSE Change +Price
333131 2/1/2001 3/1/2001 22.6 22.6 22.6 FALSE FALSE Change +Subsidy +Alternate
333131 3/1/2001 6/1/2006 22.6 22.6 22.6 FALSE FALSE Change
333131 6/1/2006 4/1/2014 21.5 21.5 21.5 FALSE FALSE Change -Subsidy -Price -Alternate
333131 4/1/2014 7/1/2014 12.9 12.9 21.5 FALSE FALSE Change -Subsidy -Alternate
333131 7/1/2014 0 0 0 FALSE FALSE Delisted
333158 5/23/1995 4/1/1996 31 31 31 FALSE FALSE New Listing
333158 4/1/1996 2/1/2001 31 31 32.6 FALSE FALSE Change +Price
333158 2/1/2001 3/1/2001 32.6 32.6 32.6 FALSE FALSE Change +Subsidy +Alternate
333158 3/1/2001 6/1/2006 32.6 32.6 32.6 FALSE FALSE Change
333158 6/1/2006 4/1/2014 31 31 31 FALSE FALSE Change -Subsidy -Price -Alternate
333158 4/1/2014 7/1/2014 17.98 17.98 31 FALSE FALSE Change -Subsidy -Alternate
333158 7/1/2014 0 0 0 FALSE FALSE Delisted
333174 5/16/1994 12/1/2005 18.24 18.24 18.24 FALSE FALSE New Listing
333174 12/1/2005 0 0 0 FALSE FALSE Delisted
333182 5/16/1994 9/1/2001 57.45 57.45 57.45 FALSE FALSE New Listing
333182 9/1/2001 7/1/2009 55.6 55.6 55.6 FALSE FALSE Change -Subsidy -Price -Alternate
333182 7/1/2009 0 0 0 FALSE FALSE Delisted
333190 7/1/2001 10/1/2002 5 5 5 FALSE FALSE New listing
333190 10/1/2002 1/1/2003 2.85 2.85 5 FALSE FALSE Change -Subsidy -Alternate
333190 1/1/2003 0 0 0 FALSE FALSE Delisted
333204 1/1/1997 2/1/1999 93.65 93.65 93.63 FALSE FALSE New Listing
333204 2/1/1999 8/1/2001 124 124 124 FALSE FALSE Change +Subsidy +Price +Alternate
333204 8/1/2001 6/1/2006 138.65 138.65 138.65 FALSE FALSE Change +Subsidy +Price +Alternate
333204 6/1/2006 0 0 0 FALSE FALSE Delisted
333212 5/16/1994 8/16/1994 20.33 20.33 20.33 FALSE FALSE New Listing
333212 8/16/1994 8/1/1995 17.1 17.1 17.1 FALSE FALSE Change -Subsidy -Price -Alternate
333212 8/1/1995 1/1/1997 17.1 17.1 17.55 FALSE FALSE Change +Price
333212 1/1/1997 11/1/1997 17.1 17.1 18.45 FALSE FALSE Change +Price
333212 11/1/1997 8/1/2001 17.1 17.1 19.45 FALSE FALSE Change +Price
333212 8/1/2001 17.1 17.1 17.1 FALSE FALSE Change -Price
333220 5/16/1994 8/16/1994 91.36 91.36 91.36 FALSE FALSE New Listing
333220 8/16/1994 1/1/2007 57.2 57.2 57.2 FALSE FALSE Change -Subsidy -Price -Alternate
333220 1/1/2007 0 0 0 FALSE FALSE Delisted
333239 5/16/1994 8/16/1994 64.44 64.44 64.44 FALSE FALSE New Listing
333239 8/16/1994 1/18/1995 45.3 45.3 45.3 FALSE FALSE Change -Subsidy -Price -Alternate
333239 1/18/1995 1/19/1995 64.44 64.44 64.44 FALSE FALSE Change +Subsidy +Price +Alternate
333239 1/19/1995 8/1/2001 45.3 45.3 45.3 FALSE FALSE Change -Subsidy -Price -Alternate
333239 8/1/2001 9/1/2006 29.95 29.95 29.95 FALSE FALSE Change -Subsidy -Price -Alternate
333239 9/1/2006 12/1/2006 7.6 7.6 29.95 FALSE FALSE Change -Subsidy -Alternate
333239 12/1/2006 0 0 0 FALSE FALSE Delisted
333247 4/19/1995 4/1/1996 0 0 0 TRUE FALSE New Listing
333247 4/1/1996 1/1/1997 21.35 21.35 21.35 FALSE FALSE Change +Subsidy +Price +Alternate -CBS
333247 1/1/1997 11/1/1997 21.35 21.35 22.45 FALSE FALSE Change +Price
333247 11/1/1997 9/1/2001 21.35 21.35 23.65 FALSE FALSE Change +Price
333247 9/1/2001 23.65 23.65 23.65 FALSE FALSE Change +Subsidy +Alternate
333255 9/1/1996 9/1/2001 53.5 53.5 53.5 FALSE FALSE New Listing
333255 9/1/2001 9/1/2010 46.1 46.1 46.1 FALSE FALSE Change -Subsidy -Price -Alternate
333255 9/1/2010 7/1/2013 48 48 48 FALSE FALSE Change +Subsidy +Price +Alternate
333255 7/1/2013 20.2 20.2 20.2 FALSE FALSE Change -Subsidy -Price -Alternate
333263 9/1/1996 9/1/2010 80.25 80.25 80.25 FALSE FALSE New Listing
333263 9/1/2010 7/1/2013 90 90 90 FALSE FALSE Change +Subsidy +Price +Alternate
333263 7/1/2013 27.78 27.78 27.78 FALSE FALSE Change -Subsidy -Price -Alternate
333271 5/16/1994 1/18/1995 118.14 118.14 118.14 FALSE FALSE New Listing
333271 1/18/1995 6/1/2006 92.5 92.5 92.5 FALSE FALSE Change -Subsidy -Price -Alternate
333271 6/1/2006 0 0 0 FALSE FALSE Delisted
333298 5/16/1994 1/1/1997 27.2 27.2 27.2 FALSE FALSE New Listing
333298 1/1/1997 9/1/2001 27.2 27.2 28.55 FALSE FALSE Change +Price
333298 9/1/2001 10/1/2006 28.55 28.55 28.55 FALSE FALSE Change +Subsidy +Alternate
333298 10/1/2006 0 0 0 FALSE FALSE Delisted
333328 5/16/1994 1/18/1995 55.9 55.9 55.9 FALSE FALSE New Listing
333328 1/18/1995 4/1/1996 0 0 0 TRUE FALSE Change -Subsidy -Price -Alternate +CBS
333328 4/1/1996 1/1/1997 68.28 68.28 68.28 FALSE FALSE Change +Subsidy +Price +Alternate -CBS
333328 1/1/1997 12/1/1997 68.28 68.28 71.7 FALSE FALSE Change +Price
333328 12/1/1997 8/1/2001 68.28 68.28 84.35 FALSE FALSE Change +Price
333328 8/1/2001 8/1/2005 68 68 68 FALSE FALSE Change -Subsidy -Price -Alternate
333328 8/1/2005 73.12 73.12 73.12 FALSE FALSE Change +Subsidy +Price +Alternate
333336 3/1/1995 8/1/1995 58 58 58 FALSE FALSE New Listing
333336 8/1/1995 4/1/1996 58 58 59.5 FALSE FALSE Change +Price
333336 4/1/1996 1/1/1997 58 58 62.63 FALSE FALSE Change +Price
333336 1/1/1997 11/1/1997 58 58 67.75 FALSE FALSE Change +Price
333336 11/1/1997 8/1/2001 58 58 71.3 FALSE FALSE Change +Price
333336 8/1/2001 5/1/2005 58 58 58 FALSE FALSE Change -Price
333336 5/1/2005 7/1/2007 58 58 62.37 FALSE FALSE Change +Price
333336 7/1/2007 3/1/2008 62.37 62.37 62.37 FALSE FALSE Change +Subsidy +Alternate
333336 3/1/2008 4/1/2008 1595 1595 1595 FALSE FALSE Change +Subsidy +Price +Alternate
333336 4/1/2008 1500 1500 1500 FALSE FALSE Change -Subsidy -Price -Alternate
333344 5/16/1994 2/1/1995 35.4 35.4 38.05 FALSE FALSE New Listing
333344 2/1/1995 4/1/1996 35.4 35.4 40 FALSE FALSE Change +Price
333344 4/1/1996 1/1/1997 35.4 35.4 43.15 FALSE FALSE Change +Price
333344 1/1/1997 8/1/2001 35.4 35.4 45.3 FALSE FALSE Change +Price
333344 8/1/2001 12/1/2005 55.2 55.2 55.2 FALSE FALSE Change +Subsidy +Price +Alternate
333344 12/1/2005 0 0 0 FALSE FALSE Delisted
333956 5/16/1994 6/23/1995 3.57 3.57 3.57 FALSE FALSE New Listing
333956 6/23/1995 8/1/1995 3.57 3.57 3.75 FALSE FALSE Change +Price
333956 8/1/1995 1/1/1997 3.57 3.57 3.85 FALSE FALSE Change +Price
333956 1/1/1997 11/1/1997 3.57 3.57 4.25 FALSE FALSE Change +Price
333956 11/1/1997 8/1/2001 3.57 3.57 4.48 FALSE FALSE Change +Price
333956 8/1/2001 8/1/2005 11.95 11.95 11.95 FALSE FALSE Change +Subsidy +Price +Alternate
333956 8/1/2005 9/1/2011 12.84 12.84 12.84 FALSE FALSE Change +Subsidy +Price +Alternate
333956 9/1/2011 53.75 53.75 53.75 FALSE FALSE Change +Subsidy +Price +Alternate
333964 1/11/1995 3/1/1996 45.1 45.1 47.48 FALSE FALSE New Listing
333964 3/1/1996 8/1/1998 45.1 45.1 45.1 FALSE FALSE Change -Price
333964 8/1/1998 3/1/1999 41.54 41.54 41.54 FALSE FALSE Change -Subsidy -Price -Alternate
333964 3/1/1999 2/1/2000 32.4 32.4 32.4 FALSE FALSE Change -Subsidy -Price -Alternate
333964 2/1/2000 11/1/2000 19.46 32.4 32.4 FALSE FALSE Change -Subsidy
333964 11/1/2000 3/1/2001 17.52 32.4 32.4 FALSE FALSE Change -Subsidy
333964 3/1/2001 9/1/2001 15.77 32.4 32.4 FALSE FALSE Change -Subsidy
333964 9/1/2001 4/1/2002 13.44 32.4 32.4 FALSE FALSE Change -Subsidy
333964 4/1/2002 4/1/2003 13.44 35.64 35.64 FALSE FALSE Change +Price +Alternate
333964 4/1/2003 4/1/2004 13.44 39.2 39.2 FALSE FALSE Change +Price +Alternate
333964 4/1/2004 7/1/2011 13.44 43.12 43.12 FALSE FALSE Change +Price +Alternate
333964 7/1/2011 9/1/2014 43.12 43.12 43.12 FALSE FALSE Change +Subsidy
333964 9/1/2014 0 0 0 FALSE FALSE Delisted
334111 5/16/1994 4/3/1995 19.66 19.66 19.66 FALSE FALSE New Listing
334111 4/3/1995 7/1/1996 17.24 17.24 17.24 FALSE FALSE Change -Subsidy -Price -Alternate
334111 7/1/1996 7/1/1997 16.38 16.38 16.38 FALSE FALSE Change -Subsidy -Price -Alternate
334111 7/1/1997 12/1/1997 15.56 15.56 15.56 FALSE FALSE Change -Subsidy -Price -Alternate
334111 12/1/1997 5/1/1998 14.78 14.78 14.78 FALSE FALSE Change -Subsidy -Price -Alternate
334111 5/1/1998 8/1/1998 6.85 6.85 14.78 FALSE FALSE Change -Subsidy -Alternate
334111 8/1/1998 0 0 0 FALSE FALSE Delisted
334138 5/16/1994 7/1/1996 8.82 8.82 8.82 FALSE FALSE New Listing
334138 7/1/1996 7/1/1997 8.38 8.38 8.38 FALSE FALSE Change -Subsidy -Price -Alternate
334138 7/1/1997 12/1/1997 7.96 7.96 7.96 FALSE FALSE Change -Subsidy -Price -Alternate
334138 12/1/1997 5/1/1998 7.56 7.56 7.56 FALSE FALSE Change -Subsidy -Price -Alternate
334138 5/1/1998 8/1/1998 4.62 4.62 7.56 FALSE FALSE Change -Subsidy -Alternate
334138 8/1/1998 0 0 0 FALSE FALSE Delisted
334405 5/16/1994 12/1/2007 38 38 38 FALSE FALSE New Listing
334405 12/1/2007 0 0 0 FALSE FALSE Delisted
335142 5/16/1994 12/1/1999 2.52 2.52 2.52 FALSE TRUE New Listing
335142 12/1/1999 4/1/2000 1.1 1.1 2.52 FALSE TRUE Change -Subsidy -Alternate
335142 4/1/2000 7/1/2002 0 0 0 FALSE FALSE Delisted
335142 7/1/2002 9/1/2002 1.1 1.1 1.1 FALSE TRUE New Listing
335142 9/1/2002 10/1/2006 1.02 1.02 1.02 FALSE TRUE Change -Subsidy -Price -Alternate
335142 10/1/2006 4/1/2010 1.4 1.4 1.4 FALSE TRUE Change +Subsidy +Price +Alternate
335142 4/1/2010 12/1/2010 2.4 2.4 2.4 FALSE TRUE Change +Subsidy +Price +Alternate
335142 12/1/2010 3/1/2011 1.28 1.28 2.4 FALSE TRUE Change -Subsidy -Alternate
335142 3/1/2011 0 0 0 FALSE FALSE Delisted
335150 5/16/1994 7/1/1999 2.77 2.77 2.77 FALSE TRUE New Listing
335150 7/1/1999 9/1/2002 1.85 1.85 1.85 FALSE TRUE Change -Subsidy -Price -Alternate
335150 9/1/2002 10/1/2006 1.8 1.8 1.8 FALSE TRUE Change -Subsidy -Price -Alternate
335150 10/1/2006 7/1/2009 2.48 2.48 2.48 FALSE TRUE Change +Subsidy +Price +Alternate
335150 7/1/2009 11/1/2012 2.37 2.37 2.37 FALSE TRUE Change -Subsidy -Price -Alternate
335150 11/1/2012 2.76 2.76 2.76 FALSE TRUE Change +Subsidy +Price +Alternate
335320 5/16/1994 4/1/1995 23.7 23.7 23.7 FALSE FALSE New Listing
335320 4/1/1995 2/1/1996 23.7 23.7 27.25 FALSE FALSE Change +Price
335320 2/1/1996 2/1/2000 4.74 4.74 6.87 FALSE FALSE Change -Subsidy -Price -Alternate
335320 2/1/2000 3/1/2001 4.74 4.74 7.9 FALSE FALSE Change +Price
335320 3/1/2001 4/1/2003 4.74 4.74 8.69 FALSE FALSE Change +Price
335320 4/1/2003 9/1/2003 4.74 4.74 9.56 FALSE FALSE Change +Price
335320 9/1/2003 4/1/2004 4.74 4.74 11.95 FALSE FALSE Change +Price
335320 4/1/2004 7/1/2006 4.74 4.74 13.15 FALSE FALSE Change +Price
335320 7/1/2006 5/1/2007 4.74 4.74 14.47 FALSE FALSE Change +Price
335320 5/1/2007 8/1/2007 4.5 4.5 14.47 FALSE FALSE Change -Subsidy -Alternate
335320 8/1/2007 0 0 0 FALSE FALSE Delisted
335339 2/1/1996 2/1/2000 2.37 2.37 4 FALSE FALSE New Listing
335339 2/1/2000 3/1/2001 2.37 2.37 4.65 FALSE FALSE Change +Price
335339 3/1/2001 7/1/2002 2.37 2.37 5.12 FALSE FALSE Change +Price
335339 7/1/2002 4/1/2003 2.37 2.37 5.63 FALSE FALSE Change +Price
335339 4/1/2003 10/1/2003 2.37 2.37 6.19 FALSE FALSE Change +Price
335339 10/1/2003 1/1/2005 2.37 2.37 7.74 FALSE FALSE Change +Price
335339 1/1/2005 5/1/2007 2.37 2.37 8.51 FALSE FALSE Change +Price
335339 5/1/2007 8/1/2007 2.25 2.25 8.51 FALSE FALSE Change -Subsidy -Alternate
335339 8/1/2007 0 0 0 FALSE FALSE Delisted
335347 2/1/1996 2/1/2000 1.19 1.19 3.6 FALSE FALSE New Listing
335347 2/1/2000 3/1/2001 1.19 1.19 3.95 FALSE FALSE Change +Price
335347 3/1/2001 7/1/2002 1.19 1.19 4.35 FALSE FALSE Change +Price
335347 7/1/2002 4/1/2003 1.19 1.19 4.79 FALSE FALSE Change +Price
335347 4/1/2003 6/1/2003 1.19 1.19 5.98 FALSE FALSE Change +Price
335347 6/1/2003 1/1/2005 1.19 1.19 5.98 FALSE FALSE Change
335347 1/1/2005 8/1/2007 1.19 1.19 6.58 FALSE FALSE Change +Price
335347 8/1/2007 0 0 0 FALSE FALSE Delisted
335355 5/16/1994 4/1/1995 11.86 11.86 11.86 FALSE FALSE New Listing
335355 4/1/1995 2/1/1996 11.86 11.86 13.64 FALSE FALSE Change +Price
335355 2/1/1996 2/1/2000 2.37 2.37 4.5 FALSE FALSE Change -Subsidy -Price -Alternate
335355 2/1/2000 3/1/2001 2.37 2.37 5.15 FALSE FALSE Change +Price
335355 3/1/2001 4/1/2003 2.37 2.37 5.67 FALSE FALSE Change +Price
335355 4/1/2003 6/1/2003 2.37 2.37 6.24 FALSE FALSE Change +Price
335355 6/1/2003 4/1/2004 2.37 2.37 7.09 FALSE FALSE Change +Price
335355 4/1/2004 7/1/2006 2.37 2.37 7.8 FALSE FALSE Change +Price
335355 7/1/2006 8/1/2007 2.37 2.37 8.58 FALSE FALSE Change +Price
335355 8/1/2007 0 0 0 FALSE FALSE Delisted
335363 10/1/1996 7/1/1997 2.92 2.92 6.95 FALSE FALSE New Listing
335363 7/1/1997 8/1/1999 2.92 2.92 7.65 FALSE FALSE Change +Price
335363 8/1/1999 0 0 0 FALSE FALSE Delisted
335428 3/1/1998 12/1/1998 10 10 10 FALSE FALSE New Listing
335428 12/1/1998 2/1/1999 10 10 10.5 FALSE FALSE Change +Price
335428 2/1/1999 5/1/1999 6.4 6.4 10.5 FALSE FALSE Change -Subsidy -Alternate
335428 5/1/1999 0 0 0 FALSE FALSE Delisted
335665 7/1/1997 5/1/1999 1.62 1.62 1.62 FALSE TRUE New Listing
335665 5/1/1999 5/1/2001 1.33 1.33 1.62 FALSE TRUE Change -Subsidy -Alternate
335665 5/1/2001 0 0 0 FALSE FALSE Delisted
336025 5/16/1994 6/1/1997 7.52 7.52 7.52 FALSE FALSE New Listing
336025 6/1/1997 10/1/1998 7.52 7.52 8.73 FALSE FALSE Change +Price
336025 10/1/1998 8/1/1999 7.52 7.52 9.89 FALSE FALSE Change +Price
336025 8/1/1999 9/1/2002 7 7 7 FALSE FALSE Change -Subsidy -Price -Alternate
336025 9/1/2002 1/1/2009 3.25 3.25 3.25 FALSE FALSE Change -Subsidy -Price -Alternate
336025 1/1/2009 11/1/2014 6.77 6.77 6.77 FALSE FALSE Change +Subsidy +Price +Alternate
336025 11/1/2014 0 0 0 FALSE FALSE Delisted
336262 1/1/1997 2/1/2007 41.67 41.67 41.67 FALSE FALSE New Listing
336262 2/1/2007 0 0 0 FALSE FALSE Delisted
336351 7/1/1997 5/1/1999 1.62 1.62 1.62 FALSE TRUE New Listing
336351 5/1/1999 5/1/2001 1.33 1.33 1.62 FALSE TRUE Change -Subsidy -Alternate
336351 5/1/2001 0 0 0 FALSE FALSE Delisted
336416 7/1/1996 8/1/2000 0 0 0 TRUE FALSE New Listing
336416 8/1/2000 11/1/2011 7.13 7.13 7.13 FALSE FALSE Change +Subsidy +Price +Alternate -CBS
336416 11/1/2011 1/1/2012 7.13 7.13 9.77 FALSE FALSE Change +Price
336416 1/1/2012 0 0 0 FALSE FALSE Delisted
336548 5/16/1994 9/1/1995 25.7 25.7 25.7 FALSE FALSE New Listing
336548 9/1/1995 5/1/1996 38.55 38.55 38.55 FALSE FALSE Change +Subsidy +Price +Alternate
336548 5/1/1996 9/1/1999 19.28 19.28 19.28 FALSE FALSE Change -Subsidy -Price -Alternate
336548 9/1/1999 1/1/2006 0 0 0 FALSE FALSE Delisted
336548 1/1/2006 7/1/2009 133 133 133 FALSE FALSE New Listing
336548 7/1/2009 6/1/2014 225 225 225 FALSE FALSE Change +Subsidy +Price +Alternate
336548 6/1/2014 498 498 498 FALSE FALSE Change +Subsidy +Price +Alternate
336874 3/1/1999 10/1/2005 298.54 298.54 298.54 FALSE FALSE New Listing
336874 10/1/2005 7/1/2008 269.98 269.98 269.98 FALSE FALSE Change -Subsidy -Price -Alternate
336874 7/1/2008 5/1/2012 179 179 179 FALSE FALSE Change -Subsidy -Price -Alternate
336874 5/1/2012 8/1/2012 71.5 71.5 71.5 FALSE FALSE Change -Subsidy -Price -Alternate
336874 8/1/2012 0 0 0 FALSE FALSE Delisted
337285 5/16/1994 5/17/1995 4.26 4.26 4.26 FALSE TRUE New Listing
337285 5/17/1995 6/15/1995 4.45 4.45 4.45 FALSE TRUE Change +Subsidy +Price +Alternate
337285 6/15/1995 5/1/2010 4.26 4.26 4.45 FALSE TRUE Change -Subsidy -Alternate
337285 5/1/2010 8/1/2010 3.79 3.79 4.45 FALSE TRUE Change -Subsidy -Alternate
337285 8/1/2010 0 0 0 FALSE FALSE Delisted
337307 3/1/1997 12/1/2004 23.65 23.65 23.65 FALSE TRUE New Listing
337307 12/1/2004 2/1/2008 22.47 22.47 22.47 FALSE TRUE Change -Subsidy -Price -Alternate
337307 2/1/2008 2/1/2010 20.78 20.78 20.78 FALSE TRUE Change -Subsidy -Price -Alternate
337307 2/1/2010 12/1/2011 20.22 20.22 20.22 FALSE TRUE Change -Subsidy -Price -Alternate
337307 12/1/2011 16 16 16 FALSE TRUE Change -Subsidy -Price -Alternate
337315 3/1/1997 12/1/2004 39.52 39.52 39.52 FALSE TRUE New Listing
337315 12/1/2004 2/1/2008 37.54 37.54 37.54 FALSE TRUE Change -Subsidy -Price -Alternate
337315 2/1/2008 2/1/2010 34.72 34.72 34.72 FALSE TRUE Change -Subsidy -Price -Alternate
337315 2/1/2010 5/1/2013 33.79 33.79 33.79 FALSE TRUE Change -Subsidy -Price -Alternate
337315 5/1/2013 0 0 0 FALSE FALSE Delisted
337455 7/1/2012 10/1/2014 0 0 0 FALSE FALSE New listing
337455 10/1/2014 0 0 0 FALSE FALSE Delisted
337463 1/1/1996 12/1/1997 3 3 3.6 FALSE TRUE New Listing
337463 12/1/1997 0 0 0 FALSE FALSE Delisted
337471 1/1/1996 12/1/1997 3 3 3.6 FALSE TRUE New Listing
337471 12/1/1997 0 0 0 FALSE FALSE Delisted
337951 5/16/1994 5/12/1995 35.8 35.8 35.8 FALSE FALSE New Listing
337951 5/12/1995 2/1/1998 27.44 27.44 27.44 FALSE FALSE Change -Subsidy -Price -Alternate
337951 2/1/1998 11/1/2001 17.84 17.84 17.84 FALSE FALSE Change -Subsidy -Price -Alternate
337951 11/1/2001 2/1/2002 8.5 8.5 17.84 FALSE FALSE Change -Subsidy -Alternate
337951 2/1/2002 0 0 0 FALSE FALSE Delisted
338001 5/16/1994 2/1/1998 35.6 35.6 35.6 FALSE TRUE New Listing
338001 2/1/1998 0 0 0 FALSE FALSE Delisted
338052 10/4/1997 5/1/1998 29.63 29.63 29.63 FALSE FALSE New Listing
338052 5/1/1998 8/1/1998 11.67 11.67 11.67 FALSE FALSE Change -Subsidy -Price -Alternate
338052 8/1/1998 0 0 0 FALSE FALSE Delisted
338192 5/16/1994 67.18 67.18 67.18 FALSE FALSE New Listing
338435 5/16/1994 6/1/1997 9.66 9.66 9.66 FALSE FALSE New Listing
338435 6/1/1997 2/1/1998 7 7 7 FALSE FALSE Change -Subsidy -Price -Alternate
338435 2/1/1998 8/1/2000 5.6 5.6 5.6 FALSE FALSE Change -Subsidy -Price -Alternate
338435 8/1/2000 12/1/2000 3.88 5.6 5.6 FALSE FALSE Change -Subsidy
338435 12/1/2000 0 0 0 FALSE FALSE Delisted
338583 5/16/1994 12/1/1995 3.44 3.44 3.64 FALSE FALSE New Listing
338583 12/1/1995 4/1/1997 3.44 3.44 3.78 FALSE FALSE Change +Price
338583 4/1/1997 11/1/2003 3.44 3.44 3.89 FALSE TRUE Change +Price +OP
338583 11/1/2003 0 0 0 FALSE FALSE Delisted
339326 5/16/1994 4/1/2000 9.45 13.86 13.86 FALSE TRUE New Listing
339326 4/1/2000 8/1/2001 9.45 13.86 13.86 FALSE FALSE Change -OP
339326 8/1/2001 1/1/2004 9.45 13.8 13.8 FALSE FALSE Change -Price -Alternate
339326 1/1/2004 1/1/2007 6.62 13.8 13.8 FALSE FALSE Change -Subsidy
339326 1/1/2007 0 0 0 FALSE FALSE Delisted
339350 5/16/1994 3/1/1998 7.58 7.58 8.7 FALSE TRUE New Listing
339350 3/1/1998 7/1/2002 4.36 4.36 8.7 FALSE TRUE Change -Subsidy -Alternate
339350 7/1/2002 0 0 0 FALSE FALSE Delisted
339431 5/16/1994 3/1/1996 13.33 13.33 13.33 FALSE FALSE New Listing
339431 3/1/1996 12/1/1997 11.25 11.25 11.25 FALSE FALSE Change -Subsidy -Price -Alternate
339431 12/1/1997 8/1/2000 8.44 8.44 8.44 FALSE FALSE Change -Subsidy -Price -Alternate
339431 8/1/2000 12/1/2000 5 5 8.44 FALSE FALSE Change -Subsidy -Alternate
339431 12/1/2000 0 0 0 FALSE FALSE Delisted
339458 12/1/1997 8/1/2000 42.2 42.2 42.2 FALSE FALSE New Listing
339458 8/1/2000 12/1/2000 25 25 42.2 FALSE FALSE Change -Subsidy -Alternate
339458 12/1/2000 0 0 0 FALSE FALSE Delisted
339466 5/16/1994 3/1/1996 23.75 23.75 23.75 FALSE FALSE New Listing
339466 3/1/1996 12/1/1997 22.51 22.51 22.51 FALSE FALSE Change -Subsidy -Price -Alternate
339466 12/1/1997 8/1/2000 16.88 16.88 16.88 FALSE FALSE Change -Subsidy -Price -Alternate
339466 8/1/2000 12/1/2000 6.5 6.5 16.88 FALSE FALSE Change -Subsidy -Alternate
339466 12/1/2000 0 0 0 FALSE FALSE Delisted
339474 12/1/1997 8/1/2000 84.4 84.4 84.4 FALSE FALSE New Listing
339474 8/1/2000 12/1/2000 32.5 32.5 84.4 FALSE FALSE Change -Subsidy -Alternate
339474 12/1/2000 0 0 0 FALSE FALSE Delisted
339482 5/16/1994 3/1/1996 34.17 34.17 34.17 FALSE FALSE New Listing
339482 3/1/1996 12/1/1997 33.76 33.76 33.76 FALSE FALSE Change -Subsidy -Price -Alternate
339482 12/1/1997 11/1/2003 25.32 25.32 25.32 FALSE FALSE Change -Subsidy -Price -Alternate
339482 11/1/2003 0 0 0 FALSE FALSE Delisted
340405 10/1/2006 7/1/2007 168.17 168.17 168.17 FALSE FALSE New listing
340405 7/1/2007 10/1/2008 73.38 73.38 73.38 FALSE FALSE Change -Subsidy -Price -Alternate
340405 10/1/2008 9/1/2009 35 35 73.38 FALSE FALSE Change -Subsidy -Alternate
340405 9/1/2009 11/1/2010 25 25 73.38 FALSE FALSE Change -Subsidy -Alternate
340405 11/1/2010 2/1/2011 5.06 5.06 73.38 FALSE FALSE Change -Subsidy -Alternate
340405 2/1/2011 0 0 0 FALSE FALSE Delisted
340413 9/1/1999 7/1/2004 22.26 22.26 22.26 FALSE TRUE New Listing
340413 7/1/2004 10/1/2007 45 45 45 FALSE TRUE Change +Subsidy +Price +Alternate +OP
340413 10/1/2007 4/1/2012 50.4 50.4 50.4 FALSE TRUE Change +Subsidy +Price +Alternate
340413 4/1/2012 4/1/2013 50.4 50.4 50.4 FALSE FALSE Change -OP
340413 4/1/2013 56.45 56.45 56.45 FALSE FALSE Change +Subsidy +Price +Alternate
340529 5/16/1994 2/1/1996 26.64 26.64 26.64 FALSE FALSE New Listing
340529 2/1/1996 11/1/1997 31.99 31.99 31.99 FALSE FALSE Change +Subsidy +Price +Alternate
340529 11/1/1997 2/1/2000 31.97 31.97 31.97 FALSE FALSE Change -Subsidy -Price -Alternate
340529 2/1/2000 6/1/2001 25.92 25.92 31.97 FALSE FALSE Change -Subsidy +Price -Alternate
340529 6/1/2001 0 0 0 FALSE FALSE Delisted
340537 5/16/1994 4/1/1996 7.16 7.16 7.16 FALSE FALSE New Listing
340537 4/1/1996 3/1/1997 5.97 5.97 5.97 FALSE FALSE Change -Subsidy -Price -Alternate
340537 3/1/1997 5/1/1998 5.97 5.97 11.45 FALSE FALSE Change +Price
340537 5/1/1998 3/1/1999 5.97 5.97 14 FALSE FALSE Change +Price
340537 3/1/1999 3/1/2008 5.97 5.97 14.42 FALSE FALSE Change +Price
340537 3/1/2008 5.97 5.97 15 FALSE FALSE Change +Price
341010 6/1/1997 9/1/1998 19.66 19.66 32.76 FALSE FALSE New Listing
341010 9/1/1998 1/1/1999 10.2 10.2 19.66 FALSE FALSE Change -Subsidy -Price -Alternate
341010 1/1/1999 4/1/2000 6 6 19.66 FALSE FALSE Change -Subsidy -Alternate
341010 4/1/2000 6/1/2001 6 6 6 FALSE FALSE Change -Price
341010 6/1/2001 10/1/2003 3.5 3.5 3.5 FALSE FALSE Change -Subsidy -Price -Alternate
341010 10/1/2003 1/1/2004 1.67 1.67 1.67 FALSE FALSE Change -Subsidy -Price -Alternate
341010 1/1/2004 0 0 0 FALSE FALSE Delisted
341126 7/1/1999 2/1/2002 1.38 1.38 1.38 FALSE FALSE New Listing
341126 2/1/2002 0 0 0 FALSE FALSE Delisted
341614 7/1/2005 1/1/2007 29 29 29 FALSE FALSE New listing
341614 1/1/2007 0 0 0 FALSE FALSE Delisted
341622 7/1/2005 1/1/2007 136.5 136.5 136.5 FALSE FALSE New listing
341622 1/1/2007 0 0 0 FALSE FALSE Delisted
341711 7/1/2005 2/1/2007 118 118 118 FALSE FALSE New listing
341711 2/1/2007 34.47 34.47 34.47 FALSE FALSE Change -Subsidy -Price -Alternate
341754 5/16/1994 8/16/1994 64.44 64.44 64.44 FALSE FALSE New Listing
341754 8/16/1994 1/18/1995 45.3 45.3 45.3 FALSE FALSE Change -Subsidy -Price -Alternate
341754 1/18/1995 1/19/1995 64.44 64.44 64.44 FALSE FALSE Change +Subsidy +Price +Alternate
341754 1/19/1995 8/1/2001 45.3 45.3 45.3 FALSE FALSE Change -Subsidy -Price -Alternate
341754 8/1/2001 2/1/2002 29.95 29.95 29.95 FALSE FALSE Change -Subsidy -Price -Alternate
341754 2/1/2002 0 0 0 FALSE FALSE Delisted
341770 5/26/1995 9/1/2001 275 275 275 FALSE FALSE New Listing
341770 9/1/2001 12/1/2001 72 72 275 FALSE FALSE Change -Subsidy -Alternate
341770 12/1/2001 11/1/2004 0 0 0 FALSE FALSE Delisted
341770 11/1/2004 4/1/2006 64 64 64 FALSE FALSE New Listing
341770 4/1/2006 7/1/2006 47 47 64 FALSE FALSE Change -Subsidy -Alternate
341770 7/1/2006 0 0 0 FALSE FALSE Delisted
341878 5/16/1994 9/1/1995 53 53 53 FALSE FALSE New Listing
341878 9/1/1995 7/1/1997 49 49 49 FALSE FALSE Change -Subsidy -Price -Alternate
341878 7/1/1997 7/1/1999 13.88 13.88 39.2 FALSE FALSE Change -Subsidy -Price -Alternate
341878 7/1/1999 0 0 0 FALSE FALSE Delisted
341940 ######## 2/1/1998 83.73 83.73 83.74 FALSE FALSE New Listing
341940 2/1/1998 2/1/1999 41.87 41.87 41.87 FALSE FALSE Change -Subsidy -Price -Alternate
341940 2/1/1999 8/1/2000 20.93 20.93 20.93 FALSE FALSE Change -Subsidy -Price -Alternate
341940 8/1/2000 12/1/2000 8.67 8.67 20.93 FALSE FALSE Change -Subsidy -Alternate
341940 12/1/2000 0 0 0 FALSE FALSE Delisted
341967 5/16/1994 2/1/1998 159 159 159 FALSE FALSE New Listing
341967 2/1/1998 2/1/1999 79.5 79.5 79.5 FALSE FALSE Change -Subsidy -Price -Alternate
341967 2/1/1999 8/1/2000 39.77 39.77 39.77 FALSE FALSE Change -Subsidy -Price -Alternate
341967 8/1/2000 12/1/2000 9.97 9.97 39.77 FALSE FALSE Change -Subsidy -Alternate
341967 12/1/2000 0 0 0 FALSE FALSE Delisted
342289 5/27/1995 3/1/1996 61 61 65.98 FALSE FALSE New Listing
342289 3/1/1996 7/1/1996 56.38 56.38 65.98 FALSE FALSE Change -Subsidy -Alternate
342289 7/1/1996 5/1/1998 56.38 56.38 56.38 FALSE FALSE Change -Price
342289 5/1/1998 1/1/2001 36.65 36.65 36.65 FALSE FALSE Change -Subsidy -Price -Alternate
342289 1/1/2001 4/1/2002 32 32 32 FALSE FALSE Change -Subsidy -Price -Alternate
342289 4/1/2002 0 0 0 FALSE FALSE Delisted
342939 2/1/1999 11/1/2003 136.7 224 224 FALSE FALSE New Listing
342939 11/1/2003 0 0 0 FALSE FALSE Delisted
343021 5/16/1994 6/2/1995 32.82 32.82 32.82 FALSE TRUE New Listing
343021 6/2/1995 0 0 0 FALSE FALSE Delisted
343048 3/1/1996 8/1/1998 18.5 18.5 18.5 FALSE FALSE New Listing
343048 8/1/1998 10/1/2000 7.19 18.5 18.5 FALSE FALSE Change -Subsidy
343048 10/1/2000 11/1/2000 7.19 17.47 17.47 FALSE FALSE Change -Price -Alternate
343048 11/1/2000 4/1/2001 7.19 18.5 18.5 FALSE FALSE Change +Price +Alternate
343048 4/1/2001 5/1/2013 3 18.5 18.5 FALSE FALSE Change -Subsidy
343048 5/1/2013 8/1/2013 3.75 3.75 18.5 FALSE FALSE Change +Subsidy -Alternate
343048 8/1/2013 3.75 18.5 18.5 FALSE FALSE Change +Alternate
343072 5/16/1994 3/31/1995 21.21 21.21 21.21 FALSE FALSE New Listing
343072 3/31/1995 2/1/1996 25.21 25.21 25.21 FALSE FALSE Change +Subsidy +Price +Alternate
343072 2/1/1996 7/1/1997 23.03 23.03 23.03 FALSE FALSE Change -Subsidy -Price -Alternate
343072 7/1/1997 8/1/1998 23.03 23.03 23.03 FALSE FALSE Change -Subsidy -Price -Alternate
343072 8/1/1998 12/1/2000 8.58 23.03 23.03 FALSE FALSE Change -Subsidy +Alternate
343072 12/1/2000 0 0 0 FALSE FALSE Delisted
343129 3/1/1996 2/1/1997 42.32 42.32 42.32 TRUE FALSE New Listing
343129 2/1/1997 0 0 0 FALSE FALSE Delisted
343773 5/16/1994 12/1/2004 76.8 76.8 76.8 FALSE TRUE New Listing
343773 12/1/2004 0 0 0 FALSE FALSE Delisted
343889 5/16/1994 6/1/1997 15.4 15.4 15.4 FALSE FALSE New Listing
343889 6/1/1997 0 0 0 FALSE FALSE Delisted
344303 5/1/1999 7/1/2010 4 4 4 FALSE TRUE New Listing
344303 7/1/2010 4.5 4.5 4.5 FALSE TRUE Change +Subsidy +Price +Alternate
344338 6/1/1999 4/1/2011 5.62 5.62 6 FALSE TRUE New Listing
344338 4/1/2011 6 6 6 FALSE TRUE Change +Subsidy +Alternate
344540 3/1/1998 12/1/1998 2.5 2.5 4 FALSE FALSE New Listing
344540 12/1/1998 2/1/1999 2.5 2.5 2.63 FALSE FALSE Change -Price
344540 2/1/1999 5/1/1999 1.6 1.6 2.63 FALSE FALSE Change -Subsidy -Alternate
344540 5/1/1999 0 0 0 FALSE FALSE Delisted
344621 3/1/1996 2/1/1998 16.46 16.46 16.46 FALSE FALSE New Listing
344621 2/1/1998 2/1/2002 10.7 10.7 10.7 FALSE FALSE Change -Subsidy -Price -Alternate
344621 2/1/2002 12/1/2008 5.1 5.1 5.1 FALSE FALSE Change -Subsidy -Price -Alternate
344621 12/1/2008 6/1/2009 4.72 4.72 4.72 FALSE FALSE Change -Subsidy -Price -Alternate
344621 6/1/2009 2/1/2013 4.34 4.34 4.34 FALSE FALSE Change -Subsidy -Price -Alternate
344621 2/1/2013 5/1/2013 1.91 1.91 4.34 FALSE FALSE Change -Subsidy -Alternate
344621 5/1/2013 1/1/2014 0 0 0 FALSE FALSE Delisted
344621 1/1/2014 1.91 1.91 1.91 FALSE FALSE New Listing
344710 3/1/1996 12/1/1999 21 21 21 FALSE TRUE New Listing
344710 12/1/1999 10/1/2002 23 23 23 FALSE TRUE Change +Subsidy +Price +Alternate
344710 10/1/2002 1/1/2005 24.95 24.95 24.95 FALSE TRUE Change +Subsidy +Price +Alternate
344710 1/1/2005 1/1/2012 26.2 26.2 26.2 FALSE TRUE Change +Subsidy +Price +Alternate
344710 1/1/2012 30 30 30 FALSE TRUE Change +Subsidy +Price +Alternate
344729 3/1/1996 3/1/2003 6.75 6.75 6.75 FALSE TRUE New Listing
344729 3/1/2003 0 0 0 FALSE FALSE Delisted
344818 3/1/1996 12/1/1999 18 18 18 FALSE TRUE New Listing
344818 12/1/1999 10/1/2002 19.8 19.8 19.8 FALSE TRUE Change +Subsidy +Price +Alternate
344818 10/1/2002 1/1/2005 21.5 21.5 21.5 FALSE TRUE Change +Subsidy +Price +Alternate
344818 1/1/2005 1/1/2012 22.6 22.6 22.6 FALSE TRUE Change +Subsidy +Price +Alternate
344818 1/1/2012 26 26 26 FALSE TRUE Change +Subsidy +Price +Alternate
344842 3/1/1996 12/1/1999 25.5 25.5 25.5 FALSE TRUE New Listing
344842 12/1/1999 10/1/2002 35 35 35 FALSE TRUE Change +Subsidy +Price +Alternate
344842 10/1/2002 1/1/2005 38 38 38 FALSE TRUE Change +Subsidy +Price +Alternate
344842 1/1/2005 1/1/2012 39.9 39.9 39.9 FALSE TRUE Change +Subsidy +Price +Alternate
344842 1/1/2012 45 45 45 FALSE TRUE Change +Subsidy +Price +Alternate
344850 3/1/1996 12/1/1999 16 16 16 FALSE TRUE New Listing
344850 12/1/1999 9/1/2002 18.5 18.5 18.5 FALSE TRUE Change +Subsidy +Price +Alternate
344850 9/1/2002 1/1/2005 20.05 20.05 20.05 FALSE TRUE Change +Subsidy +Price +Alternate
344850 1/1/2005 1/1/2012 21.05 21.05 21.05 FALSE TRUE Change +Subsidy +Price +Alternate
344850 1/1/2012 24 24 24 FALSE TRUE Change +Subsidy +Price +Alternate
344877 3/1/1996 9/1/2002 23.5 23.5 23.5 FALSE TRUE New Listing
344877 9/1/2002 1/1/2005 25.5 25.5 25.5 FALSE TRUE Change +Subsidy +Price +Alternate
344877 1/1/2005 1/1/2012 26.8 26.8 26.8 FALSE TRUE Change +Subsidy +Price +Alternate
344877 1/1/2012 30 30 30 FALSE TRUE Change +Subsidy +Price +Alternate
344885 3/1/1996 5/1/1998 30.1 30.1 30.1 FALSE FALSE New Listing
344885 5/1/1998 8/1/1998 20.47 20.47 30.1 FALSE FALSE Change -Subsidy -Alternate
344885 8/1/1998 0 0 0 FALSE FALSE Delisted
344893 3/1/1996 5/1/1998 39.16 39.16 39.16 FALSE FALSE New Listing
344893 5/1/1998 8/1/1998 26.63 26.63 39.16 FALSE FALSE Change -Subsidy -Alternate
344893 8/1/1998 0 0 0 FALSE FALSE Delisted
345571 4/11/1995 7/1/1997 22.4 22.4 22.4 FALSE FALSE New Listing
345571 7/1/1997 0 0 0 FALSE FALSE Delisted
345628 4/1/1998 6/1/1998 0.62 0.62 2.61 FALSE FALSE New Listing
345628 6/1/1998 9/1/1999 0.55 0.55 0.55 FALSE FALSE Change -Subsidy -Price -Alternate
345628 9/1/1999 0 0 0 FALSE FALSE Delisted
345881 7/1/1999 11/1/1999 22.48 22.48 46.75 FALSE FALSE New Listing
345881 11/1/1999 0 0 0 FALSE FALSE Delisted
345946 4/1/1996 10/1/1997 12.18 12.18 13.24 FALSE FALSE New Listing
345946 10/1/1997 4/1/1998 11.57 11.57 13.24 FALSE FALSE Change -Subsidy -Alternate
345946 4/1/1998 6/1/1998 11.57 11.57 17.24 FALSE FALSE Change +Price
345946 6/1/1998 11/1/1998 9.15 9.15 17.24 FALSE FALSE Change -Subsidy -Alternate
345946 11/1/1998 6/1/2000 9.15 9.15 18.95 FALSE FALSE Change +Price
345946 6/1/2000 3/1/2002 8.1 8.1 18.95 FALSE FALSE Change -Subsidy -Alternate
345946 3/1/2002 0 0 0 FALSE FALSE Delisted
346373 6/14/1995 2/1/1998 16.46 16.46 16.46 FALSE FALSE New Listing
346373 2/1/1998 2/1/2000 10.7 10.7 10.7 FALSE FALSE Change -Subsidy -Price -Alternate
346373 2/1/2000 0 0 0 FALSE FALSE Delisted
346381 6/14/1995 2/1/1998 24.69 24.69 24.69 FALSE FALSE New Listing
346381 2/1/1998 2/1/2000 16.06 16.06 16.06 FALSE FALSE Change -Subsidy -Price -Alternate
346381 2/1/2000 0 0 0 FALSE FALSE Delisted
346403 6/14/1995 2/1/1998 32.93 32.93 32.93 FALSE FALSE New Listing
346403 2/1/1998 8/1/2000 21.41 21.41 21.41 FALSE FALSE Change -Subsidy -Price -Alternate
346403 8/1/2000 0 0 0 FALSE FALSE Delisted
346632 5/16/1994 5/1/1998 34.4 34.4 34.4 FALSE FALSE New Listing
346632 5/1/1998 8/1/1998 17.55 17.55 17.55 FALSE FALSE Change -Subsidy -Price -Alternate
346632 8/1/1998 0 0 0 FALSE FALSE Delisted
346659 5/16/1994 8/1/2001 22.5 22.5 22.5 FALSE FALSE New Listing
346659 8/1/2001 2/1/2002 49.5 49.5 49.5 FALSE FALSE Change +Subsidy +Price +Alternate
346659 2/1/2002 0 0 0 FALSE FALSE Delisted
346756 3/1/1995 6/1/1996 13.62 13.62 13.62 FALSE FALSE New Listing
346756 6/1/1996 12/1/1996 6.81 6.81 6.81 FALSE FALSE Change -Subsidy -Price -Alternate
346756 12/1/1996 2/1/2004 4 4 4 FALSE FALSE Change -Subsidy -Price -Alternate
346756 2/1/2004 8/1/2004 1.8 4 4 FALSE FALSE Change -Subsidy
346756 8/1/2004 11/1/2011 1.8 1.8 1.8 FALSE FALSE Change -Price -Alternate
346756 11/1/2011 0 0 0 FALSE FALSE Delisted
346764 3/1/1995 6/1/1996 30.86 30.86 30.86 FALSE FALSE New Listing
346764 6/1/1996 12/1/1996 15.43 15.43 15.43 FALSE FALSE Change -Subsidy -Price -Alternate
346764 12/1/1996 2/1/2004 12 12 12 FALSE FALSE Change -Subsidy -Price -Alternate
346764 2/1/2004 8/1/2004 3.6 12 12 FALSE FALSE Change -Subsidy
346764 8/1/2004 8/1/2011 3.6 3.6 3.6 FALSE FALSE Change -Price -Alternate
346764 8/1/2011 11/1/2011 3.15 3.15 3.6 FALSE FALSE Change -Subsidy -Alternate
346764 11/1/2011 0 0 0 FALSE FALSE Delisted
346772 3/1/1995 6/1/1996 47.86 47.86 47.86 FALSE FALSE New Listing
346772 6/1/1996 12/1/1996 23.93 23.93 23.93 FALSE FALSE Change -Subsidy -Price -Alternate
346772 12/1/1996 2/1/2004 16.75 16.75 16.75 FALSE FALSE Change -Subsidy -Price -Alternate
346772 2/1/2004 8/1/2004 7.2 16.75 16.75 FALSE FALSE Change -Subsidy
346772 8/1/2004 11/1/2011 7.2 7.2 7.2 FALSE FALSE Change -Price -Alternate
346772 11/1/2011 0 0 0 FALSE FALSE Delisted
346780 3/1/1995 6/1/1996 58.08 58.08 58.08 FALSE FALSE New Listing
346780 6/1/1996 12/1/1996 29.04 29.04 29.04 FALSE FALSE Change -Subsidy -Price -Alternate
346780 12/1/1996 2/1/2004 25.5 25.5 25.5 FALSE FALSE Change -Subsidy -Price -Alternate
346780 2/1/2004 8/1/2004 8.5 25.5 25.5 FALSE FALSE Change -Subsidy
346780 8/1/2004 8/1/2011 8.5 8.5 8.5 FALSE FALSE Change -Price -Alternate
346780 8/1/2011 11/1/2011 7.85 7.85 8.5 FALSE FALSE Change -Subsidy -Alternate
346780 11/1/2011 0 0 0 FALSE FALSE Delisted
346802 6/1/1996 8/1/1998 38.6 38.6 38.6 FALSE FALSE New Listing
346802 8/1/1998 2/1/2000 15.01 38.6 38.6 FALSE FALSE Change -Subsidy
346802 2/1/2000 4/1/2001 15.01 23.93 23.93 FALSE FALSE Change -Price -Alternate
346802 4/1/2001 9/1/2001 9.57 9.57 9.57 FALSE FALSE Change -Subsidy -Price -Alternate
346802 9/1/2001 12/1/2001 1.95 1.95 7.33 FALSE FALSE Change -Subsidy -Price -Alternate
346802 12/1/2001 0 0 0 FALSE FALSE Delisted
346829 5/16/1994 4/1/2002 47.5 47.5 47.5 FALSE FALSE New Listing
346829 4/1/2002 0 0 0 FALSE FALSE Delisted
346845 5/16/1994 4/1/2002 51.6 51.6 51.6 FALSE FALSE New Listing
346845 4/1/2002 0 0 0 FALSE FALSE Delisted
346853 5/16/1994 7/1/1999 39.9 39.9 39.9 FALSE FALSE New Listing
346853 7/1/1999 4/1/2002 34 34 34 FALSE FALSE Change -Subsidy -Price -Alternate
346853 4/1/2002 0 0 0 FALSE FALSE Delisted
346861 4/1/1996 8/1/2001 43.7 43.7 46 FALSE FALSE New Listing
346861 8/1/2001 4/1/2002 43.5 43.5 43.5 FALSE FALSE Change -Subsidy -Price -Alternate
346861 4/1/2002 0 0 0 FALSE FALSE Delisted
346888 7/1/1999 4/1/2002 38 38 38 FALSE FALSE New Listing
346888 4/1/2002 0 0 0 FALSE FALSE Delisted
346896 7/1/1996 8/1/2000 0 0 0 TRUE FALSE New Listing
346896 8/1/2000 8/1/2007 71.71 71.71 71.71 FALSE FALSE Change +Subsidy +Price +Alternate -CBS
346896 8/1/2007 0 0 0 FALSE FALSE Delisted
346942 5/16/1994 11/1/1997 50.3 50.3 50.3 FALSE FALSE New Listing
346942 11/1/1997 8/1/2001 50.3 50.3 55.9 FALSE FALSE Change +Price
346942 8/1/2001 12/1/2005 100.6 100.6 100.6 FALSE FALSE Change +Subsidy +Price +Alternate
346942 12/1/2005 0 0 0 FALSE FALSE Delisted
346950 5/16/1994 8/1/2000 0 0 0 TRUE FALSE New Listing
346950 8/1/2000 8/1/2005 10.8 10.8 10.8 FALSE FALSE Change +Subsidy +Price +Alternate -CBS
346950 8/1/2005 10/1/2006 11.12 11.12 11.12 FALSE FALSE Change +Subsidy +Price +Alternate
346950 10/1/2006 0 0 0 FALSE FALSE Delisted
346977 6/1/1999 11/1/1999 16.25 16.25 30.1 FALSE FALSE New Listing
346977 11/1/1999 3/1/2012 36.5 36.5 36.5 FALSE FALSE Change +Subsidy +Price +Alternate
346977 3/1/2012 0 0 0 FALSE FALSE Delisted
346993 5/1/1994 5/16/1994 5.62 5.62 6.21 FALSE FALSE New Listing
346993 5/16/1994 5/1/1996 6.21 6.21 6.21 FALSE FALSE Change +Subsidy +Alternate
346993 5/1/1996 9/1/2001 5.62 5.62 6.21 FALSE FALSE Change -Subsidy -Alternate
346993 9/1/2001 12/1/2001 3.93 3.93 11 FALSE FALSE Change -Subsidy +Price -Alternate
346993 12/1/2001 0 0 0 FALSE FALSE Delisted
347027 5/16/1994 7/1/2009 21.9 21.9 21.9 FALSE FALSE New Listing
347027 7/1/2009 0 0 0 FALSE FALSE Delisted
347051 5/1/1996 9/1/2001 5.62 5.62 6.24 FALSE FALSE New Listing
347051 9/1/2001 12/1/2001 3.5 3.5 6.24 FALSE FALSE Change -Subsidy -Alternate
347051 12/1/2001 0 0 0 FALSE FALSE Delisted
347086 6/1/1996 8/1/1998 23 23 23 FALSE FALSE New Listing
347086 8/1/1998 2/1/2000 8.94 23 23 FALSE FALSE Change -Subsidy
347086 2/1/2000 4/1/2001 8.94 17.86 17.86 FALSE FALSE Change -Price -Alternate
347086 4/1/2001 9/1/2001 7.14 7.14 7.14 FALSE FALSE Change -Subsidy -Price -Alternate
347086 9/1/2001 12/1/2001 1.33 1.33 6.71 FALSE FALSE Change -Subsidy -Price -Alternate
347086 12/1/2001 0 0 0 FALSE FALSE Delisted
347140 4/12/1995 11/1/2006 161.4 161.4 161.4 FALSE FALSE New Listing
347140 11/1/2006 0 0 0 FALSE FALSE Delisted
347159 11/1/1997 8/1/2001 60 60 79.5 FALSE FALSE New Listing
347159 8/1/2001 2/1/2002 104.5 104.5 104.5 FALSE FALSE Change +Subsidy +Price +Alternate
347159 2/1/2002 0 0 0 FALSE FALSE Delisted
347183 6/1/1996 8/1/1998 14.6 14.6 14.6 FALSE FALSE New Listing
347183 8/1/1998 4/1/2001 5.68 14.6 14.6 FALSE FALSE Change -Subsidy
347183 4/1/2001 9/1/2001 5.68 5.68 5.68 FALSE FALSE Change -Price -Alternate
347183 9/1/2001 12/1/2001 0.92 0.92 6.3 FALSE FALSE Change -Subsidy +Price -Alternate
347183 12/1/2001 0 0 0 FALSE FALSE Delisted
347876 6/1/1997 10/1/1998 1.25 1.25 1.46 FALSE FALSE New Listing
347876 10/1/1998 8/1/1999 1.25 1.25 1.65 FALSE FALSE Change +Subsidy +Price +Alternate
347876 8/1/1999 12/1/2001 1.17 1.17 1.17 FALSE FALSE Change -Subsidy -Price -Alternate
347876 12/1/2001 9/1/2002 1.17 1.17 5.18 FALSE FALSE Change +Price
347876 9/1/2002 12/1/2002 0.54 0.54 5.18 FALSE FALSE Change -Subsidy -Alternate
347876 12/1/2002 0 0 0 FALSE FALSE Delisted
347914 8/1/2005 8/1/2006 8.62 8.62 8.62 FALSE FALSE New listing
347914 8/1/2006 0 0 0 FALSE FALSE Delisted
347922 5/16/1994 7/1/2004 7.23 7.23 7.23 FALSE FALSE New Listing
347922 7/1/2004 0 0 0 FALSE FALSE Delisted
347930 5/16/1994 9/1/2011 5.17 5.17 5.17 FALSE FALSE New Listing
347930 9/1/2011 5.51 5.51 5.51 FALSE FALSE Change +Subsidy +Price +Alternate
348554 5/16/1994 7/1/1999 4.49 4.49 4.49 FALSE FALSE New Listing
348554 7/1/1999 12/1/2002 4.19 4.19 4.19 FALSE FALSE Change -Subsidy -Price -Alternate
348554 12/1/2002 2/1/2008 4.19 4.19 5.2 FALSE FALSE Change +Price
348554 2/1/2008 1/1/2012 5.46 5.46 5.46 FALSE FALSE Change +Subsidy +Price +Alternate
348554 1/1/2012 6.86 6.86 6.86 FALSE FALSE Change +Subsidy +Price +Alternate
348562 5/16/1994 7/1/1999 22.45 22.45 22.45 FALSE FALSE New Listing
348562 7/1/1999 10/1/2000 20.95 20.95 20.95 FALSE FALSE Change -Subsidy -Price -Alternate
348562 10/1/2000 0 0 0 FALSE FALSE Delisted
348570 5/16/1994 7/1/1999 9 9 9 FALSE FALSE New Listing
348570 7/1/1999 2/1/2008 6.99 6.99 6.99 FALSE FALSE Change -Subsidy -Price -Alternate
348570 2/1/2008 1/1/2012 7.34 7.34 7.34 FALSE FALSE Change +Subsidy +Price +Alternate
348570 1/1/2012 8.55 8.55 8.55 FALSE FALSE Change +Subsidy +Price +Alternate
348880 6/1/1998 11/1/2000 620 620 620 FALSE FALSE New Listing
348880 11/1/2000 0 0 0 FALSE FALSE Delisted
349186 6/1/1996 6/1/1999 6.75 6.75 12.65 FALSE TRUE New Listing
349186 6/1/1999 1/1/2001 5.66 5.66 12.65 FALSE TRUE Change -Subsidy -Alternate
349186 1/1/2001 4/1/2001 5.66 5.66 14.39 FALSE TRUE Change +Price
349186 4/1/2001 8/1/2006 5.66 5.66 13.08 FALSE TRUE Change -Price
349186 8/1/2006 4/1/2011 5.66 5.66 17.95 FALSE TRUE Change +Price
349186 4/1/2011 0 0 0 FALSE FALSE Delisted
349291 11/1/1996 6/1/1998 4.33 4.33 9.12 FALSE FALSE New Listing
349291 6/1/1998 4/1/2002 4.33 4.33 9.87 FALSE FALSE Change +Price
349291 4/1/2002 7/1/2002 1.63 1.63 9.87 FALSE FALSE Change -Subsidy -Alternate
349291 7/1/2002 0 0 0 FALSE FALSE Delisted
349453 5/16/1994 12/1/1996 32.64 32.64 32.64 FALSE TRUE New Listing
349453 12/1/1996 0 0 0 FALSE FALSE Delisted
349658 12/1/1996 2/1/2002 21.15 21.15 21.15 FALSE FALSE New Listing
349658 2/1/2002 0 0 0 FALSE FALSE Delisted
349933 5/16/1994 1/12/1995 46.88 46.88 46.88 FALSE FALSE New Listing
349933 1/12/1995 9/2/1995 46.64 46.64 46.64 FALSE FALSE Change -Subsidy -Price -Alternate
349933 9/2/1995 0 0 0 FALSE FALSE Delisted
349941 5/16/1994 9/1/1995 88.95 88.95 88.95 FALSE FALSE New Listing
349941 9/1/1995 0 0 0 FALSE FALSE Delisted
350125 5/16/1994 2/1/2000 14.12 14.12 14.12 FALSE FALSE New Listing
350125 2/1/2000 0 0 0 FALSE FALSE Delisted
350133 10/1/1994 7/1/1999 130 130 130 FALSE FALSE New Listing
350133 7/1/1999 11/1/1999 27.5 27.5 130 FALSE FALSE Change -Subsidy -Alternate
350133 11/1/1999 0 0 0 FALSE FALSE Delisted
350338 10/1/2000 10/1/2007 487.38 487.38 487.38 FALSE TRUE New Listing
350338 10/1/2007 0 0 0 FALSE FALSE Delisted
350516 6/1/1998 10/1/2010 206.66 206.66 206.66 FALSE FALSE New Listing
350516 10/1/2010 9/1/2013 70 70 70 FALSE FALSE Change -Subsidy -Price -Alternate
350516 9/1/2013 25 25 25 FALSE FALSE Change -Subsidy -Price -Alternate
351806 5/16/1994 1/1/1995 88.47 88.47 88.47 FALSE FALSE New Listing
351806 1/1/1995 6/1/1996 87.1 87.1 87.1 FALSE FALSE Change -Subsidy -Price -Alternate
351806 6/1/1996 2/1/1999 46.66 46.66 46.66 FALSE FALSE Change -Subsidy -Price -Alternate
351806 2/1/1999 2/1/2000 33.6 33.6 33.6 FALSE FALSE Change -Subsidy -Price -Alternate
351806 2/1/2000 8/1/2000 13.44 13.44 33.6 FALSE FALSE Change -Subsidy -Alternate
351806 8/1/2000 9/1/2000 8.5 8.5 33.6 FALSE FALSE Change -Subsidy -Alternate
351806 9/1/2000 1/1/2001 7.5 7.5 33.6 FALSE FALSE Change -Subsidy -Alternate
351806 1/1/2001 9/1/2001 4.05 4.05 33.6 FALSE FALSE Change -Subsidy -Alternate
351806 9/1/2001 12/1/2001 1.75 1.75 33.6 FALSE FALSE Change -Subsidy -Alternate
351806 12/1/2001 0 0 0 FALSE FALSE Delisted
351830 7/1/1994 8/1/2000 0 0 0 TRUE FALSE New Listing
351830 8/1/2000 1/1/2006 25.26 25.26 25.26 FALSE TRUE Change +Subsidy +Price +Alternate +OP -CBS
351830 1/1/2006 0 0 0 FALSE FALSE Delisted
351857 7/1/1996 8/1/2000 0 0 0 TRUE TRUE New Listing
351857 8/1/2000 6/1/2007 25.26 25.26 25.26 FALSE TRUE Change +Subsidy +Price +Alternate -CBS
351857 6/1/2007 0 0 0 FALSE FALSE Delisted
351865 7/1/1996 8/1/2000 0 0 0 TRUE FALSE New Listing
351865 8/1/2000 6/1/2007 25.26 25.26 25.26 FALSE TRUE Change +Subsidy +Price +Alternate +OP -CBS
351865 6/1/2007 0 0 0 FALSE FALSE Delisted
351970 4/11/1995 12/1/1997 36.08 36.08 36.08 FALSE FALSE New Listing
351970 12/1/1997 11/1/1999 17.4 17.4 17.4 FALSE FALSE Change -Subsidy -Price -Alternate
351970 11/1/1999 4/1/2001 11.88 11.88 11.88 FALSE FALSE Change -Subsidy -Price -Alternate
351970 4/1/2001 4/1/2002 11.2 11.2 11.88 FALSE FALSE Change -Subsidy -Alternate
351970 4/1/2002 0 0 0 FALSE FALSE Delisted
352004 5/16/1994 7/1/2001 3.61 3.61 3.61 FALSE FALSE New Listing
352004 7/1/2001 8/1/2005 3.97 3.97 3.97 FALSE FALSE Change +Subsidy +Price +Alternate
352004 8/1/2005 2/1/2009 9.5 9.5 9.5 FALSE FALSE Change +Subsidy +Price +Alternate
352004 2/1/2009 0 0 0 FALSE FALSE Delisted
352292 5/1/1997 12/1/2003 6.9 6.9 6.9 FALSE FALSE New Listing
352292 12/1/2003 3/1/2004 3.5 3.5 6.9 FALSE FALSE Change -Subsidy -Alternate
352292 3/1/2004 0 0 0 FALSE FALSE Delisted
352500 5/1/1996 6/1/1998 68.45 68.45 68.45 FALSE FALSE New Listing
352500 6/1/1998 2/1/2000 42 42 42 FALSE FALSE Change -Subsidy -Price -Alternate
352500 2/1/2000 6/1/2000 39.5 39.5 42 FALSE FALSE Change -Subsidy -Alternate
352500 6/1/2000 0 0 0 FALSE FALSE Delisted
352691 6/1/2004 6/1/2011 180 180 180 FALSE FALSE New listing
352691 6/1/2011 9/1/2011 123 123 123 FALSE FALSE Change -Subsidy -Price -Alternate
352691 9/1/2011 0 0 0 FALSE FALSE Delisted
352713 9/1/2000 5/1/2001 39.85 39.85 39.85 FALSE FALSE New Listing
352713 5/1/2001 7/1/2003 39.85 39.85 44.6 FALSE FALSE Change +Price
352713 7/1/2003 10/1/2006 52.42 52.42 52.42 FALSE FALSE Change +Subsidy +Price +Alternate
352713 10/1/2006 62.9 62.9 62.9 FALSE FALSE Change +Subsidy +Price +Alternate
352802 6/17/1995 2/1/1999 82.3 82.3 82.3 FALSE FALSE New Listing
352802 2/1/1999 3/1/1999 57.6 57.6 82.3 FALSE FALSE Change -Subsidy -Alternate
352802 3/1/1999 7/1/1999 57.6 57.6 57.6 FALSE FALSE Change -Price
352802 7/1/1999 8/1/2002 36.13 36.13 36.13 FALSE FALSE Change -Subsidy -Price -Alternate
352802 8/1/2002 7/1/2005 33.24 33.24 33.24 FALSE FALSE Change -Subsidy -Price -Alternate
352802 7/1/2005 6/1/2010 32.08 32.08 32.08 FALSE FALSE Change -Subsidy -Price -Alternate
352802 6/1/2010 0 0 0 FALSE FALSE Delisted
353582 10/1/1997 4/1/1998 13.77 13.77 13.77 FALSE FALSE New Listing
353582 4/1/1998 7/1/2000 12.05 12.05 12.05 FALSE FALSE Change -Subsidy -Price -Alternate
353582 7/1/2000 11/1/2000 2.78 2.78 2.78 FALSE FALSE Change -Subsidy -Price -Alternate
353582 11/1/2000 0 0 0 FALSE FALSE Delisted
353701 10/1/1997 4/1/1998 13.73 13.73 13.73 FALSE FALSE New Listing
353701 4/1/1998 7/1/2000 12.01 12.01 12.01 FALSE FALSE Change -Subsidy -Price -Alternate
353701 7/1/2000 11/1/2000 2.8 2.8 2.8 FALSE FALSE Change -Subsidy -Price -Alternate
353701 11/1/2000 0 0 0 FALSE FALSE Delisted
353760 6/1/1996 3/1/1999 15 15 15 FALSE FALSE New Listing
353760 3/1/1999 12/1/1999 9.56 9.56 9.56 FALSE FALSE Change -Subsidy -Price -Alternate
353760 12/1/1999 9/1/2002 5.25 5.25 5.25 FALSE FALSE Change -Subsidy -Price -Alternate
353760 9/1/2002 ######## 3.46 3.46 5.25 FALSE FALSE Change -Subsidy -Alternate
353760 ######## 3/1/2003 5.25 5.25 5.25 FALSE FALSE Change +Subsidy +Alternate
353760 3/1/2003 ######## 8.58 8.58 8.58 FALSE FALSE Change +Subsidy +Price +Alternate
353760 ######## 7/1/2005 12.81 12.81 12.81 FALSE FALSE Change +Subsidy +Price +Alternate
353760 7/1/2005 7/1/2006 11.27 11.27 11.27 FALSE FALSE Change -Subsidy -Price -Alternate
353760 7/1/2006 7/1/2012 10.38 10.38 10.38 FALSE FALSE Change -Subsidy -Price -Alternate
353760 7/1/2012 2.9 2.9 2.9 FALSE FALSE Change -Subsidy -Price -Alternate
354333 11/1/1997 11/1/1998 21 21 21 FALSE FALSE New Listing
354333 11/1/1998 3/1/1999 16.8 16.8 16.8 FALSE FALSE Change -Subsidy -Price -Alternate
354333 3/1/1999 1/1/2001 15 15 15 FALSE FALSE Change -Subsidy -Price -Alternate
354333 1/1/2001 3/1/2002 11.25 11.25 11.25 FALSE FALSE Change -Subsidy -Price -Alternate
354333 3/1/2002 2/1/2006 8 8 8 FALSE FALSE Change -Subsidy -Price -Alternate
354333 2/1/2006 4/1/2009 7.6 7.6 7.6 FALSE FALSE Change -Subsidy -Price -Alternate
354333 4/1/2009 5.7 5.7 5.7 FALSE FALSE Change -Subsidy -Price -Alternate
354619 7/1/1997 519.75 519.75 519.75 FALSE FALSE New Listing
354627 7/1/1997 1/1/2001 519.75 519.75 519.75 FALSE FALSE New Listing
354627 1/1/2001 12/1/2001 0 0 0 FALSE FALSE Delisted
354627 12/1/2001 519.75 519.75 519.75 FALSE FALSE New Listing
355488 5/1/2001 10/1/2007 55 55 55 FALSE FALSE New listing
355488 10/1/2007 10/1/2010 46.2 46.2 46.2 FALSE FALSE Change -Subsidy -Price -Alternate
355488 10/1/2010 7 7 7 FALSE FALSE Change -Subsidy -Price -Alternate
355518 6/27/1995 2/1/2001 22.73 22.73 22.73 FALSE TRUE New Listing
355518 2/1/2001 3/1/2001 18.2 18.2 22.73 FALSE TRUE Change -Subsidy -Alternate
355518 3/1/2001 3/1/2002 18.2 18.2 18.2 FALSE TRUE Change -Price
355518 3/1/2002 3/1/2004 17 17 17 FALSE TRUE Change -Subsidy -Price -Alternate
355518 3/1/2004 5/1/2004 14.9 14.9 17 FALSE TRUE Change -Subsidy -Alternate
355518 5/1/2004 0 0 0 FALSE FALSE Delisted
356522 5/16/1994 7/1/1997 19.6 19.6 19.6 FALSE FALSE New Listing
356522 7/1/1997 7/1/1999 5.55 5.55 15.68 FALSE FALSE Change -Subsidy -Price -Alternate
356522 7/1/1999 11/1/1999 3.99 3.99 15.68 FALSE FALSE Change -Subsidy -Alternate
356522 11/1/1999 0 0 0 FALSE FALSE Delisted
356921 12/1/2000 10/1/2002 4 4 4 FALSE TRUE New Listing
356921 10/1/2002 2/1/2003 3.63 3.63 3.63 FALSE TRUE Change -Subsidy -Price -Alternate
356921 2/1/2003 0 0 0 FALSE FALSE Delisted
357251 5/16/1994 8/1/2000 26.92 26.92 26.92 FALSE FALSE New Listing
357251 8/1/2000 7/1/2003 26.92 26.92 39.1 FALSE FALSE Change +Price
357251 7/1/2003 0 0 0 FALSE FALSE Delisted
358061 1/1/1996 3/1/1999 108 108 108 FALSE FALSE New Listing
358061 3/1/1999 6/1/1999 93.96 93.96 93.96 FALSE FALSE Change -Subsidy -Price -Alternate
358061 6/1/1999 0 0 0 FALSE FALSE Delisted
358088 9/1/1996 3/1/1999 36 36 36 FALSE FALSE New Listing
358088 3/1/1999 6/1/1999 31.32 31.32 31.32 FALSE FALSE Change -Subsidy -Price -Alternate
358088 6/1/1999 0 0 0 FALSE FALSE Delisted
358096 9/1/1996 3/1/1999 54 54 54 FALSE FALSE New Listing
358096 3/1/1999 6/1/1999 46.98 46.98 46.98 FALSE FALSE Change -Subsidy -Price -Alternate
358096 6/1/1999 0 0 0 FALSE FALSE Delisted
358118 9/1/1996 3/1/1999 72 72 72 FALSE FALSE New Listing
358118 3/1/1999 6/1/1999 62.64 62.64 62.64 FALSE FALSE Change -Subsidy -Price -Alternate
358118 6/1/1999 0 0 0 FALSE FALSE Delisted
358215 5/16/1994 12/1/1996 15.89 15.89 15.89 FALSE FALSE New Listing
358215 12/1/1996 10/1/2002 14 14 14 FALSE FALSE Change -Subsidy -Price -Alternate
358215 10/1/2002 1/1/2003 10.8 10.8 10.8 FALSE FALSE Change -Subsidy -Price -Alternate
358215 1/1/2003 11/1/2008 0 0 0 FALSE FALSE Delisted
358215 11/1/2008 6/1/2014 8.24 8.24 8.24 FALSE FALSE New Listing
358215 6/1/2014 0 0 0 FALSE FALSE Delisted
358223 5/16/1994 12/1/1996 10.41 10.41 10.41 FALSE FALSE New Listing
358223 12/1/1996 1/1/2003 8.24 8.24 8.24 FALSE FALSE Change -Subsidy -Price -Alternate
358223 1/1/2003 6/1/2008 0 0 0 FALSE FALSE Delisted
358223 6/1/2008 6/1/2014 8.24 8.24 8.24 FALSE FALSE New Listing
358223 6/1/2014 0 0 0 FALSE FALSE Delisted
358258 5/16/1994 8/1/1999 14.63 14.63 14.63 FALSE FALSE New Listing
358258 8/1/1999 12/1/2001 4.2 4.2 4.2 FALSE FALSE Change -Subsidy -Price -Alternate
358258 12/1/2001 10/1/2002 4.2 4.2 15.36 FALSE FALSE Change +Price
358258 10/1/2002 4/1/2003 4.4 4.4 15.36 FALSE FALSE Change +Subsidy +Alternate
358258 4/1/2003 0 0 0 FALSE FALSE Delisted
358312 5/16/1994 6/1/2013 60.84 60.84 60.84 FALSE FALSE New Listing
358312 6/1/2013 0 0 0 FALSE FALSE Delisted
358347 4/11/1995 2/1/1998 34.3 34.3 34.3 FALSE FALSE New Listing
358347 2/1/1998 0 0 0 FALSE FALSE Delisted
358355 5/16/1994 10/1/1995 10.21 10.21 11.03 FALSE FALSE New Listing
358355 10/1/1995 11/1/1996 8.17 8.17 8.82 FALSE FALSE Change -Subsidy -Price -Alternate
358355 11/1/1996 2/1/1998 7.15 7.15 7.8 FALSE FALSE Change -Subsidy -Price -Alternate
358355 2/1/1998 8/1/2000 5.36 5.36 6 FALSE FALSE Change -Subsidy -Price -Alternate
358355 8/1/2000 12/1/2000 1.18 1.18 6 FALSE FALSE Change -Subsidy -Alternate
358355 12/1/2000 0 0 0 FALSE FALSE Delisted
358444 5/16/1994 11/1/2003 7.42 7.42 8.53 FALSE FALSE New Listing
358444 11/1/2003 11/1/2011 7.42 7.42 9.38 FALSE FALSE Change +Price
358444 11/1/2011 0 0 0 FALSE FALSE Delisted
358797 5/1/2001 10/1/2007 110 110 110 FALSE FALSE New listing
358797 10/1/2007 10/1/2010 92.4 92.4 92.4 FALSE FALSE Change -Subsidy -Price -Alternate
358797 10/1/2010 14 14 14 FALSE FALSE Change -Subsidy -Price -Alternate
358800 5/1/2001 7/1/2004 210 210 210 FALSE FALSE New listing
358800 7/1/2004 10/1/2007 189 189 189 FALSE FALSE Change -Subsidy -Price -Alternate
358800 10/1/2007 10/1/2010 158.76 158.76 158.76 FALSE FALSE Change -Subsidy -Price -Alternate
358800 10/1/2010 24 24 24 FALSE FALSE Change -Subsidy -Price -Alternate
358827 5/1/2000 12/1/2003 3 3 3 FALSE FALSE New Listing
358827 12/1/2003 2/1/2007 3 3 5 FALSE FALSE Change +Price
358827 2/1/2007 6/1/2011 4 4 4 FALSE FALSE Change +Subsidy -Price +Alternate
358827 6/1/2011 5 5 5 FALSE FALSE Change +Subsidy +Price +Alternate
358975 8/1/1997 5/1/1998 11.1 11.1 11.1 FALSE FALSE New Listing
358975 5/1/1998 1/1/2001 7.22 7.22 7.22 FALSE FALSE Change -Subsidy -Price -Alternate
358975 1/1/2001 1/1/2003 6 7.22 7.22 FALSE FALSE Change -Subsidy
358975 1/1/2003 2/1/2003 6 6 6 FALSE FALSE Change -Price -Alternate
358975 2/1/2003 11/1/2004 5.3 5.3 5.3 FALSE FALSE Change -Subsidy -Price -Alternate
358975 11/1/2004 0 0 0 FALSE FALSE Delisted
358991 5/16/1994 2/1/1998 8.62 8.62 8.62 FALSE FALSE New Listing
358991 2/1/1998 8/1/2000 5.17 5.17 5.17 FALSE FALSE Change -Subsidy -Price -Alternate
358991 8/1/2000 12/1/2000 2.65 2.65 5.17 FALSE FALSE Change -Subsidy -Alternate
358991 12/1/2000 0 0 0 FALSE FALSE Delisted
359009 8/1/1999 10/1/2002 4.9 4.9 4.9 FALSE TRUE New Listing
359009 10/1/2002 7/1/2005 4.66 4.66 4.66 FALSE TRUE Change -Subsidy -Price -Alternate
359009 7/1/2005 7/1/2008 4.5 4.5 4.5 FALSE TRUE Change -Subsidy -Price -Alternate
359009 7/1/2008 7/1/2011 4.38 4.38 4.38 FALSE TRUE Change -Subsidy -Price -Alternate
359009 7/1/2011 4.34 4.34 4.34 FALSE TRUE Change -Subsidy -Price -Alternate
359017 5/16/1994 3/1/1998 19.59 19.59 23.5 FALSE TRUE New Listing
359017 3/1/1998 0 0 0 FALSE FALSE Delisted
359122 6/8/1995 11/1/1996 9.07 9.07 9.07 FALSE FALSE New Listing
359122 11/1/1996 6/1/1997 9.06 9.06 9.06 FALSE FALSE Change -Subsidy -Price -Alternate
359122 6/1/1997 1/1/1998 9.06 9.06 11.33 FALSE FALSE Change +Price
359122 1/1/1998 12/1/2000 4.5 4.5 11.33 FALSE FALSE Change -Subsidy -Alternate
359122 12/1/2000 3/1/2002 4.5 4.5 12.45 FALSE FALSE Change +Price
359122 3/1/2002 6/1/2002 4.5 4.5 12.08 FALSE FALSE Change -Price
359122 6/1/2002 2/1/2004 4.5 4.5 12.45 FALSE FALSE Change +Price
359122 2/1/2004 0 0 0 FALSE FALSE Delisted
359335 5/16/1994 9/1/2008 6.88 6.88 6.88 FALSE FALSE New Listing
359335 9/1/2008 0 0 0 FALSE FALSE Delisted
359823 5/16/1994 2/1/2010 75.63 75.63 75.63 FALSE FALSE New Listing
359823 2/1/2010 80.92 80.92 80.92 FALSE FALSE Change +Subsidy +Price +Alternate
359866 5/16/1994 2/1/1998 19.06 19.06 19.06 FALSE TRUE New Listing
359866 2/1/1998 0 0 0 FALSE FALSE Delisted
359912 4/11/1995 2/1/1998 19.45 19.45 19.45 FALSE FALSE New Listing
359912 2/1/1998 0 0 0 FALSE FALSE Delisted
360023 8/1/1996 10/1/1997 6.4 6.4 10.34 FALSE FALSE New Listing
360023 10/1/1997 9/1/2000 10.34 10.34 10.34 FALSE FALSE Change +Subsidy +Alternate
360023 9/1/2000 11/1/2010 12.1 12.1 12.1 FALSE FALSE Change +Subsidy +Price +Alternate
360023 11/1/2010 2/1/2011 4.7 4.7 12.1 FALSE FALSE Change -Subsidy -Alternate
360023 2/1/2011 0 0 0 FALSE FALSE Delisted
360082 5/16/1994 4/1/2001 11.45 11.45 11.45 FALSE FALSE New Listing
360082 4/1/2001 7/1/2001 11.45 11.45 14.58 FALSE FALSE Change +Price
360082 7/1/2001 7/1/2004 14.58 14.58 14.58 FALSE FALSE Change +Subsidy +Alternate
360082 7/1/2004 0 0 0 FALSE FALSE Delisted
360597 12/1/1999 6/1/2001 760 760 760 FALSE FALSE New Listing
360597 6/1/2001 0 0 0 FALSE FALSE Delisted
360619 12/1/1999 6/1/2001 380 380 380 FALSE FALSE New Listing
360619 6/1/2001 0 0 0 FALSE FALSE Delisted
360694 4/12/1995 8/1/1999 0.05 0.05 0.05 TRUE FALSE New Listing
360694 8/1/1999 0 0 0 FALSE FALSE Delisted
360805 1/1/1999 8/1/1999 0.44 0.44 0.44 FALSE FALSE New Listing
360805 8/1/1999 0 0 0 FALSE FALSE Delisted
361372 7/1/1996 5/1/2000 10.8 10.8 10.8 FALSE FALSE New Listing
361372 5/1/2000 9/1/2002 6.2 10.8 10.8 FALSE FALSE Change -Subsidy
361372 9/1/2002 5/1/2009 6.55 6.55 6.55 FALSE FALSE Change +Subsidy -Price -Alternate
361372 5/1/2009 7/1/2012 5.95 5.95 5.95 FALSE FALSE Change -Subsidy -Price -Alternate
361372 7/1/2012 5.55 5.55 5.55 FALSE FALSE Change -Subsidy -Price -Alternate
361399 7/1/1996 9/1/1998 211.48 211.48 211.48 FALSE TRUE New Listing
361399 9/1/1998 10/1/1998 105.74 105.74 105.74 FALSE TRUE Change -Subsidy -Price -Alternate
361399 10/1/1998 11/1/1998 84.59 84.59 105.74 FALSE TRUE Change -Subsidy -Alternate
361399 11/1/1998 4/1/1999 60 60 105.74 FALSE TRUE Change -Subsidy -Alternate
361399 4/1/1999 0 0 0 FALSE FALSE Delisted
361461 3/1/1997 8/1/2000 4.34 4.34 8.53 FALSE FALSE New Listing
361461 8/1/2000 0 0 0 FALSE FALSE Delisted
361925 5/16/1994 4/2/1995 34.27 34.27 34.27 FALSE TRUE New Listing
361925 4/2/1995 2/1/2001 22.73 22.73 22.73 FALSE TRUE Change -Subsidy -Price -Alternate
361925 2/1/2001 3/1/2001 18.2 18.2 22.73 FALSE TRUE Change -Subsidy -Alternate
361925 3/1/2001 3/1/2002 18.2 18.2 18.2 FALSE TRUE Change -Price
361925 3/1/2002 3/1/2004 17 17 17 FALSE TRUE Change -Subsidy -Price -Alternate
361925 3/1/2004 5/1/2004 14.9 14.9 17 FALSE TRUE Change -Subsidy -Alternate
361925 5/1/2004 0 0 0 FALSE FALSE Delisted
361933 5/16/1994 7/1/1999 18.33 18.33 22 FALSE FALSE New Listing
361933 7/1/1999 11/1/1999 10.99 10.99 22 FALSE FALSE Change -Subsidy -Alternate
361933 11/1/1999 0 0 0 FALSE FALSE Delisted
362069 3/1/1997 5/1/1998 1.19 1.19 4.5 FALSE FALSE New Listing
362069 5/1/1998 3/1/1999 1.19 1.19 2.8 FALSE FALSE Change -Price
362069 3/1/1999 12/1/2000 1.19 1.19 2.88 FALSE FALSE Change +Price
362069 12/1/2000 4/1/2002 1.19 1.19 4.63 FALSE FALSE Change +Price
362069 4/1/2002 0 0 0 FALSE FALSE Delisted
362107 2/1/1998 7/1/2006 739.6 739.6 739.6 FALSE FALSE New Listing
362107 7/1/2006 7/1/2007 591.68 591.68 591.68 FALSE FALSE Change -Subsidy -Price -Alternate
362107 7/1/2007 2/1/2010 554.7 554.7 554.7 FALSE FALSE Change -Subsidy -Price -Alternate
362107 2/1/2010 2/1/2011 500 500 500 FALSE FALSE Change -Subsidy -Price -Alternate
362107 2/1/2011 443.76 443.76 443.76 FALSE FALSE Change -Subsidy -Price -Alternate
362948 2/1/2000 8/1/2000 13.44 13.44 13.44 FALSE FALSE New Listing
362948 8/1/2000 9/1/2000 8.5 8.5 8.5 FALSE FALSE Change -Subsidy -Price -Alternate
362948 9/1/2000 1/1/2001 7.5 7.5 7.5 FALSE FALSE Change -Subsidy -Price -Alternate
362948 1/1/2001 9/1/2001 4.05 4.05 4.05 FALSE FALSE Change -Subsidy -Price -Alternate
362948 9/1/2001 12/1/2001 1.75 1.75 1.75 FALSE FALSE Change -Subsidy -Price -Alternate
362948 12/1/2001 0 0 0 FALSE FALSE Delisted
363707 7/1/1996 9/1/1997 0 0 0 TRUE FALSE New Listing
363707 9/1/1997 0 0 0 FALSE FALSE Delisted
363804 5/16/1994 2/1/2001 9.48 9.48 9.48 FALSE FALSE New Listing
363804 2/1/2001 0 0 0 FALSE FALSE Delisted
364304 6/1/1997 1/1/1998 0.6 0.6 0.76 FALSE FALSE New Listing
364304 1/1/1998 12/1/2000 0.3 0.3 1.79 FALSE FALSE Change -Subsidy +Price -Alternate
364304 12/1/2000 3/1/2002 0.3 0.3 2.45 FALSE FALSE Change +Price
364304 3/1/2002 6/1/2002 0.3 0.3 2.38 FALSE FALSE Change -Price
364304 6/1/2002 4/1/2004 0.3 0.3 2.45 FALSE FALSE Change +Price
364304 4/1/2004 0 0 0 FALSE FALSE Delisted
365041 10/1/1997 5/1/1999 220 220 220 FALSE FALSE New Listing
365041 5/1/1999 8/1/1999 85.5 85.5 220 FALSE FALSE Change -Subsidy -Alternate
365041 8/1/1999 0 0 0 FALSE FALSE Delisted
365068 8/1/1996 5/1/2000 10.8 10.8 10.8 FALSE FALSE New Listing
365068 5/1/2000 0 0 0 FALSE FALSE Delisted
365769 8/1/1995 12/1/1997 8.84 8.84 8.84 FALSE TRUE New Listing
365769 12/1/1997 0 0 0 FALSE FALSE Delisted
367958 12/1/2000 6/1/2004 4 4 4 FALSE TRUE New Listing
367958 6/1/2004 7/1/2004 2.68 2.68 3.48 FALSE TRUE Change -Subsidy -Price -Alternate
367958 7/1/2004 2.68 2.68 2.68 FALSE TRUE Change -Price
368466 6/1/1997 7/1/1999 3.93 3.93 3.93 FALSE FALSE New Listing
368466 7/1/1999 11/1/1999 1.89 1.89 3.93 FALSE FALSE Change -Subsidy -Alternate
368466 11/1/1999 0 0 0 FALSE FALSE Delisted
368830 4/11/1995 8/1/1999 3.33 3.33 3.33 FALSE FALSE New Listing
368830 8/1/1999 6/1/2001 3.13 3.13 3.13 FALSE FALSE Change -Subsidy -Price -Alternate
368830 6/1/2001 0 0 0 FALSE FALSE Delisted
369470 5/1/2002 5/1/2007 242.1 242.1 242.1 FALSE FALSE New listing
369470 5/1/2007 10/1/2012 108.6 108.6 108.6 FALSE FALSE Change -Subsidy -Price -Alternate
369470 10/1/2012 76 76 76 FALSE FALSE Change -Subsidy -Price -Alternate
369543 3/1/2002 2/1/2004 39 39 39 FALSE FALSE New listing
369543 2/1/2004 5/1/2004 24 24 39 FALSE FALSE Change -Subsidy -Alternate
369543 5/1/2004 0 0 0 FALSE FALSE Delisted
369659 4/1/1997 6/1/1997 686.84 686.84 686.84 FALSE FALSE New Listing
369659 6/1/1997 3/1/2009 519.75 519.75 519.75 FALSE FALSE Change -Subsidy -Price -Alternate
369659 3/1/2009 0 0 0 FALSE FALSE Delisted
369748 6/1/1995 5/1/1999 8.02 8.02 8.02 FALSE TRUE New Listing
369748 5/1/1999 4/1/2002 8.02 8.02 13.43 FALSE TRUE Change +Price
369748 4/1/2002 0 0 0 FALSE FALSE Delisted
370010 10/4/1997 12/1/1997 20.26 20.26 20.26 FALSE FALSE New Listing
370010 12/1/1997 8/1/2000 15.19 15.19 15.19 FALSE FALSE Change -Subsidy -Price -Alternate
370010 8/1/2000 12/1/2000 3.54 3.54 13.11 FALSE FALSE Change -Subsidy -Price -Alternate
370010 12/1/2000 0 0 0 FALSE FALSE Delisted
370215 10/1/1996 4/1/1998 2.64 2.64 3.05 FALSE FALSE New Listing
370215 4/1/1998 5/1/1999 2.64 2.64 4.45 FALSE FALSE Change +Price
370215 5/1/1999 0 0 0 FALSE FALSE Delisted
370223 9/1/1999 11/1/1999 4.35 4.35 4.35 FALSE FALSE New Listing
370223 11/1/1999 11/1/2002 2.97 2.97 2.97 FALSE FALSE Change -Subsidy -Price -Alternate
370223 11/1/2002 2/1/2003 2.65 2.65 2.97 FALSE FALSE Change -Subsidy -Alternate
370223 2/1/2003 0 0 0 FALSE FALSE Delisted
370517 9/1/1999 11/1/1999 6.35 6.35 6.35 FALSE FALSE New Listing
370517 11/1/1999 11/1/2002 4.18 4.18 4.18 FALSE FALSE Change -Subsidy -Price -Alternate
370517 11/1/2002 2/1/2003 4.09 4.09 4.18 FALSE FALSE Change -Subsidy -Alternate
370517 2/1/2003 0 0 0 FALSE FALSE Delisted
370614 2/1/1998 11/1/2001 14.99 14.99 14.99 FALSE FALSE New Listing
370614 11/1/2001 0 0 0 FALSE FALSE Delisted
371114 9/1/1996 12/1/1996 10.73 10.73 10.73 FALSE FALSE New Listing
371114 12/1/1996 3/1/2002 4.12 10.73 10.73 FALSE FALSE Change -Subsidy
371114 3/1/2002 1/1/2007 4.12 11.53 11.53 FALSE FALSE Change +Price +Alternate
371114 1/1/2007 8/1/2010 4.12 13.18 14.5 FALSE FALSE Change +Price +Alternate
371114 8/1/2010 4.12 13.18 13.18 FALSE FALSE Change -Price
371122 9/1/1996 12/1/1996 13.53 13.53 13.53 FALSE FALSE New Listing
371122 12/1/1996 3/1/2002 7.05 13.53 13.53 FALSE FALSE Change -Subsidy
371122 3/1/2002 1/1/2007 7.05 14.33 14.33 FALSE FALSE Change +Price +Alternate
371122 1/1/2007 8/1/2010 7.05 16.14 17.75 FALSE FALSE Change +Price +Alternate
371122 8/1/2010 7.05 16.14 16.14 FALSE FALSE Change -Price
371289 1/12/1998 2/1/2002 21.41 21.41 21.41 FALSE FALSE New Listing
371289 2/1/2002 3/1/2002 10.2 10.2 21.41 FALSE FALSE Change -Subsidy -Alternate
371289 3/1/2002 6/1/2009 10.2 10.2 10.2 FALSE FALSE Change -Price
371289 6/1/2009 0 0 0 FALSE FALSE Delisted
371297 1/12/1998 2/1/2002 16.06 16.06 16.06 FALSE FALSE New Listing
371297 2/1/2002 3/1/2002 7.65 7.65 16.06 FALSE FALSE Change -Subsidy -Alternate
371297 3/1/2002 6/1/2009 7.65 7.65 7.65 FALSE FALSE Change -Price
371297 6/1/2009 0 0 0 FALSE FALSE Delisted
372366 7/1/2005 705 705 705 FALSE FALSE New listing
372382 7/1/2005 115 115 115 FALSE FALSE New Listing
372412 8/1/1998 9/1/2002 6.15 6.15 6.15 FALSE FALSE New Listing
372412 9/1/2002 12/1/2002 5.8 5.8 5.8 FALSE FALSE Change -Subsidy -Price -Alternate
372412 12/1/2002 0 0 0 FALSE FALSE Delisted
373427 6/1/2000 4/1/2001 2.29 2.29 2.54 FALSE FALSE New Listing
373427 4/1/2001 9/1/2001 2.29 2.29 2.45 FALSE FALSE Change -Price
373427 9/1/2001 12/1/2001 1.5 1.5 2.45 FALSE FALSE Change -Subsidy -Alternate
373427 12/1/2001 0 0 0 FALSE FALSE Delisted
373540 5/1/2002 5/1/2007 121.35 121.35 121.35 FALSE FALSE New listing
373540 5/1/2007 54.44 54.44 54.44 FALSE FALSE Change -Subsidy -Price -Alternate
374296 5/10/1996 3/1/1999 2.22 2.22 2.22 FALSE FALSE New Listing
374296 3/1/1999 2/1/2000 1.78 2.22 2.22 FALSE FALSE Change -Subsidy
374296 2/1/2000 1/1/2004 1.07 2.22 2.22 FALSE FALSE Change -Subsidy
374296 1/1/2004 2/1/2004 1.05 1.05 1.05 FALSE FALSE Change -Subsidy -Price -Alternate
374296 2/1/2004 8/1/2006 0 0 0 FALSE FALSE Delisted
374296 8/1/2006 11/1/2006 1.05 1.05 1.05 FALSE FALSE New Listing
374296 11/1/2006 0 0 0 FALSE FALSE Delisted
374326 9/1/1996 8/1/1998 9.9 9.9 9.9 FALSE FALSE New Listing
374326 8/1/1998 6/1/1999 6.93 9.9 9.9 FALSE FALSE Change -Subsidy
374326 6/1/1999 9/1/1999 6.23 9.9 9.9 FALSE FALSE Change -Subsidy
374326 9/1/1999 0 0 0 FALSE FALSE Delisted
374334 5/10/1996 8/1/1998 5.93 5.93 5.93 FALSE FALSE New Listing
374334 8/1/1998 9/1/1998 4.16 5.93 5.93 FALSE FALSE Change -Subsidy
374334 9/1/1998 6/1/1999 4.16 4.16 4.16 FALSE FALSE Change -Price -Alternate
374334 6/1/1999 7/1/1999 3.74 3.74 4.16 FALSE FALSE Change -Subsidy -Alternate
374334 7/1/1999 2/1/2000 3.74 3.74 3.74 FALSE FALSE Change -Price
374334 2/1/2000 3/1/2001 2.49 2.49 2.49 FALSE FALSE Change -Subsidy -Price -Alternate
374334 3/1/2001 9/1/2001 2.24 2.49 2.49 FALSE FALSE Change -Subsidy
374334 9/1/2001 3/1/2002 1.51 1.51 1.51 FALSE FALSE Change -Subsidy -Price -Alternate
374334 3/1/2002 0 0 0 FALSE FALSE Delisted
374466 12/1/2003 7/1/2005 35.41 35.41 35.41 FALSE FALSE New listing
374466 7/1/2005 11/1/2008 30.56 30.56 30.56 FALSE FALSE Change -Subsidy -Price -Alternate
374466 11/1/2008 29.03 29.03 29.03 FALSE FALSE Change -Subsidy -Price -Alternate
374474 5/16/1994 8/1/2000 10.63 10.63 10.63 FALSE FALSE New Listing
374474 8/1/2000 12/1/2000 6.66 6.66 10.63 FALSE FALSE Change -Subsidy -Alternate
374474 12/1/2000 0 0 0 FALSE FALSE Delisted
374482 7/1/1995 8/1/2000 3.85 3.85 3.85 FALSE FALSE New Listing
374482 8/1/2000 10/1/2000 3.85 3.85 4.65 FALSE FALSE Change +Price
374482 10/1/2000 5/1/2005 3.85 3.85 5.21 FALSE FALSE Change +Price
374482 5/1/2005 0 0 0 FALSE FALSE Delisted
374741 4/1/2001 7/1/2010 5 5 5 FALSE TRUE New listing
374741 7/1/2010 0 0 0 FALSE FALSE Delisted
375519 5/16/1994 10/1/1998 16.91 16.91 16.91 FALSE FALSE New Listing
375519 10/1/1998 0 0 0 FALSE FALSE Delisted
376574 12/6/1995 6/1/1996 66.63 66.63 66.63 FALSE FALSE New Listing
376574 6/1/1996 8/1/1998 69 69 69 FALSE FALSE Change +Subsidy +Price +Alternate
376574 8/1/1998 2/1/2000 26.82 69 69 FALSE FALSE Change -Subsidy
376574 2/1/2000 4/1/2001 26.82 53.58 53.58 FALSE FALSE Change -Price -Alternate
376574 4/1/2001 9/1/2001 21.42 21.42 21.42 FALSE FALSE Change -Subsidy -Price -Alternate
376574 9/1/2001 12/1/2001 3.98 3.98 20.13 FALSE FALSE Change -Subsidy -Price -Alternate
376574 12/1/2001 0 0 0 FALSE FALSE Delisted
376671 4/1/2001 8/1/2008 2 2 2.63 FALSE TRUE New listing
376671 8/1/2008 0 0 0 FALSE FALSE Delisted
376744 4/1/2001 1/1/2009 2 2 2.63 FALSE TRUE New listing
376744 1/1/2009 2 2 2.92 FALSE TRUE Change +Price
376779 4/1/2001 9/1/2001 2 2 4.28 FALSE TRUE New listing
376779 9/1/2001 3/1/2002 1.2 1.2 4.28 FALSE TRUE Change -Subsidy -Alternate
376779 3/1/2002 0 0 0 FALSE FALSE Delisted
377074 5/16/1994 7/1/1995 17.73 17.73 17.73 FALSE TRUE New Listing
377074 7/1/1995 8/1/1996 15.96 15.96 15.96 FALSE TRUE Change -Subsidy -Price -Alternate
377074 8/1/1996 5/1/1999 14.36 14.36 14.36 FALSE TRUE Change -Subsidy -Price -Alternate
377074 5/1/1999 0 0 0 FALSE FALSE Delisted
377090 10/1/2005 2/1/2007 59.2 59.2 59.2 FALSE FALSE New listing
377090 2/1/2007 1/1/2013 19 19 19 FALSE FALSE Change -Subsidy -Price -Alternate
377090 1/1/2013 15 15 15 FALSE FALSE Change -Subsidy -Price -Alternate
377449 11/1/2000 12/1/2009 5.29 5.29 5.29 FALSE TRUE New Listing
377449 12/1/2009 0 0 0 FALSE FALSE Delisted
377481 11/1/2000 5.29 5.29 5.29 FALSE TRUE New Listing
377546 1/9/1995 12/1/1995 24.06 24.06 24.06 FALSE FALSE New Listing
377546 12/1/1995 6/1/2004 25.26 25.26 25.26 FALSE TRUE Change +Subsidy +Price +Alternate +OP
377546 6/1/2004 0 0 0 FALSE FALSE Delisted
377937 5/16/1994 5/10/1995 3.6 3.6 5.16 FALSE FALSE New Listing
377937 5/10/1995 3/1/1997 3.6 3.6 5.45 FALSE FALSE Change +Price
377937 3/1/1997 12/1/1999 3.6 3.6 5.7 FALSE FALSE Change +Price
377937 12/1/1999 7/1/2000 3.6 3.6 5.99 FALSE FALSE Change +Price
377937 7/1/2000 10/1/2001 3.6 3.6 6.29 FALSE FALSE Change +Price
377937 10/1/2001 1/1/2003 3.6 3.6 6.6 FALSE FALSE Change +Price
377937 1/1/2003 1/1/2005 3.6 3.6 6.8 FALSE FALSE Change +Price
377937 1/1/2005 4/1/2012 3.6 3.6 7.14 FALSE FALSE Change +Price
377937 4/1/2012 3.6 3.6 8.5 FALSE FALSE Change +Price
377953 8/1/2000 10/1/2002 7 7 7 FALSE TRUE New Listing
377953 10/1/2002 4/1/2006 5.4 5.4 7 FALSE TRUE Change -Subsidy -Alternate
377953 4/1/2006 0 0 0 FALSE FALSE Delisted
378038 1/1/2001 5/1/2011 458 458 458 FALSE FALSE New Listing
378038 5/1/2011 229 229 229 FALSE FALSE Change -Subsidy -Price -Alternate
378127 10/1/1999 7/1/2004 58 58 58 FALSE TRUE New Listing
378127 7/1/2004 12/1/2010 55 55 55 FALSE TRUE Change -Subsidy -Price -Alternate
378127 12/1/2010 0 0 0 FALSE FALSE Delisted
378135 7/1/2000 2/1/2002 15.39 15.39 15.39 FALSE FALSE New Listing
378135 2/1/2002 10/1/2002 0 0 0 FALSE FALSE Delisted
378135 10/1/2002 4/1/2003 15.39 15.39 15.39 FALSE FALSE New Listing
378135 4/1/2003 0 0 0 FALSE FALSE Delisted
378186 7/1/2000 2/1/2002 50.46 50.46 50.46 FALSE FALSE New Listing
378186 2/1/2002 0 0 0 FALSE FALSE Delisted
378224 7/1/2001 9/1/2001 4.76 4.76 4.76 FALSE FALSE New listing
378224 9/1/2001 8/1/2010 3.96 3.96 3.96 FALSE FALSE Change -Subsidy -Price -Alternate
378224 8/1/2010 0 0 0 FALSE FALSE Delisted
378275 1/1/2001 9/1/2008 271 271 271 FALSE FALSE New Listing
378275 9/1/2008 0 0 0 FALSE FALSE Delisted
378690 2/1/2001 9/1/2008 2.6 2.6 2.6 FALSE FALSE New Listing
378690 9/1/2008 0 0 0 FALSE FALSE Delisted
379042 5/16/1994 8/1/1995 140.63 140.63 140.63 FALSE FALSE New Listing
379042 8/1/1995 7/1/2003 147.65 147.65 147.65 FALSE FALSE Change +Subsidy +Price +Alternate
379042 7/1/2003 177.18 177.18 177.18 FALSE FALSE Change +Subsidy +Price +Alternate
379050 5/16/1994 7/1/1999 15.83 15.83 15.83 FALSE FALSE New Listing
379050 7/1/1999 11/1/1999 11.1 11.1 11.1 FALSE FALSE Change -Subsidy -Price -Alternate
379050 11/1/1999 0 0 0 FALSE FALSE Delisted
380008 5/16/1994 11.4 11.4 11.4 FALSE TRUE New Listing
380032 7/1/2000 7/1/2003 27.5 27.5 27.5 FALSE FALSE New Listing
380032 7/1/2003 11/1/2010 26 26 26 FALSE FALSE Change -Subsidy -Price -Alternate
380032 11/1/2010 0 0 0 FALSE FALSE Delisted
380075 7/1/2000 7/1/2003 29.5 29.5 29.5 FALSE FALSE New Listing
380075 7/1/2003 7/1/2006 27 27 27 FALSE FALSE Change -Subsidy -Price -Alternate
380075 7/1/2006 25 25 25 FALSE FALSE Change -Subsidy -Price -Alternate
380148 7/1/2000 2/1/2004 39.9 39.9 39.9 FALSE FALSE New Listing
380148 2/1/2004 9/1/2004 34.25 34.25 34.25 FALSE FALSE Change -Subsidy -Price -Alternate
380148 9/1/2004 0 0 0 FALSE FALSE Delisted
380342 7/1/2000 8/1/2003 5.18 5.18 5.18 FALSE FALSE New Listing
380342 8/1/2003 4/1/2011 5.5 5.5 5.5 FALSE FALSE Change +Subsidy +Price +Alternate
380342 4/1/2011 0 0 0 FALSE FALSE Delisted
380423 5/16/1994 7/1/1997 14.07 14.07 14.07 FALSE TRUE New Listing
380423 7/1/1997 0 0 0 FALSE FALSE Delisted
380431 7/1/2000 8/1/2003 11.65 11.65 11.65 FALSE FALSE New Listing
380431 8/1/2003 11/1/2006 8.25 8.25 8.25 FALSE FALSE Change -Subsidy -Price -Alternate
380431 11/1/2006 9/1/2007 9 9 9 FALSE FALSE Change +Subsidy +Price +Alternate
380431 9/1/2007 1/1/2008 8 8 8 FALSE FALSE Change -Subsidy -Price -Alternate
380431 1/1/2008 0 0 0 FALSE FALSE Delisted
380482 7/1/2000 8/1/2003 13.89 13.89 13.89 FALSE FALSE New Listing
380482 8/1/2003 11/1/2006 11.75 11.75 11.75 FALSE FALSE Change -Subsidy -Price -Alternate
380482 11/1/2006 9/1/2007 12.5 12.5 12.5 FALSE FALSE Change +Subsidy +Price +Alternate
380482 9/1/2007 1/1/2008 9.75 9.75 9.75 FALSE FALSE Change -Subsidy -Price -Alternate
380482 1/1/2008 0 0 0 FALSE FALSE Delisted
380539 7/1/2000 7/1/2003 11.2 11.2 11.2 FALSE FALSE New Listing
380539 7/1/2003 7/1/2006 9.5 9.5 9.5 FALSE FALSE Change -Subsidy -Price -Alternate
380539 7/1/2006 11/1/2010 12 12 12 FALSE FALSE Change +Subsidy +Price +Alternate
380539 11/1/2010 0 0 0 FALSE FALSE Delisted
380571 7/1/2000 7/1/2003 8.68 8.68 8.68 FALSE FALSE New Listing
380571 7/1/2003 7/1/2011 8.1 8.1 8.1 FALSE FALSE Change -Subsidy -Price -Alternate
380571 7/1/2011 7/1/2014 7.95 7.95 7.95 FALSE FALSE Change -Subsidy -Price -Alternate
380571 7/1/2014 6.75 6.75 6.75 FALSE FALSE Change -Subsidy -Price -Alternate
380636 7/1/2000 10/1/2003 13.26 13.26 13.26 FALSE FALSE New Listing
380636 10/1/2003 4/1/2004 15.25 15.25 15.25 FALSE FALSE Change +Subsidy +Price +Alternate
380636 4/1/2004 7/1/2004 10.5 10.5 15.25 FALSE FALSE Change -Subsidy -Alternate
380636 7/1/2004 11/1/2004 13.26 13.26 13.26 FALSE FALSE Change +Subsidy -Price +Alternate
380636 11/1/2004 10/1/2005 14.26 14.26 14.26 FALSE FALSE Change +Subsidy +Price +Alternate
380636 10/1/2005 3/1/2009 11.45 11.45 11.45 FALSE FALSE Change -Subsidy -Price -Alternate
380636 3/1/2009 6/1/2009 10.88 10.88 11.45 FALSE FALSE Change -Subsidy -Alternate
380636 6/1/2009 0 0 0 FALSE FALSE Delisted
380679 7/1/2000 10/1/2003 27 27 27 FALSE FALSE New Listing
380679 10/1/2003 4/1/2004 31.05 31.05 31.05 FALSE FALSE Change +Subsidy +Price +Alternate
380679 4/1/2004 7/1/2004 21.58 21.58 31.05 FALSE FALSE Change -Subsidy -Alternate
380679 7/1/2004 11/1/2004 27 27 27 FALSE FALSE Change +Subsidy -Price +Alternate
380679 11/1/2004 10/1/2005 28 28 28 FALSE FALSE Change +Subsidy +Price +Alternate
380679 10/1/2005 3/1/2009 21.2 21.2 21.2 FALSE FALSE Change -Subsidy -Price -Alternate
380679 3/1/2009 6/1/2009 20.15 20.15 21.2 FALSE FALSE Change -Subsidy -Alternate
380679 6/1/2009 0 0 0 FALSE FALSE Delisted
380776 10/1/1999 12/1/1999 46.89 46.89 46.89 FALSE FALSE New Listing
380776 12/1/1999 2/1/2003 45.94 45.94 45.94 FALSE FALSE Change -Subsidy -Price -Alternate
380776 2/1/2003 5/1/2003 32.79 32.79 45.94 FALSE FALSE Change -Subsidy -Alternate
380776 5/1/2003 0 0 0 FALSE FALSE Delisted
380814 10/1/1999 12/1/1999 2.52 2.52 2.52 FALSE TRUE New Listing
380814 12/1/1999 9/1/2002 1.1 1.1 1.1 FALSE TRUE Change -Subsidy -Price -Alternate
380814 9/1/2002 12/1/2002 1.02 1.02 1.1 FALSE TRUE Change -Subsidy -Alternate
380814 12/1/2002 0 0 0 FALSE FALSE Delisted
381152 4/2/1995 5/1/1998 6.84 6.84 6.84 FALSE FALSE New Listing
381152 5/1/1998 0 0 0 FALSE FALSE Delisted
381454 5/16/1994 5/1/1998 6.88 6.88 6.87 FALSE FALSE New Listing
381454 5/1/1998 9/1/2001 3.51 3.51 3.51 FALSE FALSE Change -Subsidy -Price -Alternate
381454 9/1/2001 12/1/2001 2.99 2.99 2.99 FALSE FALSE Change -Subsidy -Price -Alternate
381454 12/1/2001 0 0 0 FALSE FALSE Delisted
381470 5/16/1994 5/1/1998 12.2 12.2 12.2 FALSE FALSE New Listing
381470 5/1/1998 9/1/2001 6.22 6.22 6.22 FALSE FALSE Change -Subsidy -Price -Alternate
381470 9/1/2001 12/1/2001 4.49 4.49 4.49 FALSE FALSE Change -Subsidy -Price -Alternate
381470 12/1/2001 0 0 0 FALSE FALSE Delisted
381500 5/16/1994 5/1/1998 30.42 30.42 30.42 FALSE FALSE New Listing
381500 5/1/1998 9/1/2001 15.51 15.51 15.51 FALSE FALSE Change -Subsidy -Price -Alternate
381500 9/1/2001 12/1/2001 7.49 7.49 7.49 FALSE FALSE Change -Subsidy -Price -Alternate
381500 12/1/2001 0 0 0 FALSE FALSE Delisted
381543 5/16/1994 6/2/1995 5.13 5.13 5.13 FALSE TRUE New Listing
381543 6/2/1995 6/27/1995 4.75 4.75 5.13 FALSE TRUE Change -Subsidy -Alternate
381543 6/27/1995 2/1/1998 4.38 4.38 5.13 FALSE TRUE Change -Subsidy -Alternate
381543 2/1/1998 4/1/2001 3.72 3.72 5.13 FALSE TRUE Change -Subsidy -Alternate
381543 4/1/2001 0 0 0 FALSE FALSE Delisted
381586 7/1/2000 2/1/2005 15.5 15.5 15.5 FALSE FALSE New Listing
381586 2/1/2005 0 0 0 FALSE FALSE Delisted
381624 7/1/2000 2/1/2005 39.93 39.93 39.93 FALSE FALSE New Listing
381624 2/1/2005 0 0 0 FALSE FALSE Delisted
382167 5/16/1994 1/11/1995 26.92 26.92 26.92 FALSE FALSE New Listing
382167 1/11/1995 5/10/1995 26.92 26.92 30.2 FALSE FALSE Change +Price
382167 5/10/1995 2/1/1998 26.92 26.92 37.75 FALSE FALSE Change +Price
382167 2/1/1998 0 0 0 FALSE FALSE Delisted
382175 5/16/1994 12/1/1998 27.45 27.45 27.45 FALSE FALSE New Listing
382175 12/1/1998 27.44 27.44 27.44 FALSE FALSE Change -Subsidy -Price -Alternate
383007 10/1/1997 2/1/1998 17.97 17.97 17.97 FALSE FALSE New Listing
383007 2/1/1998 9/1/2000 13.48 13.48 13.48 FALSE FALSE Change -Subsidy -Price -Alternate
383007 9/1/2000 1/1/2001 3.85 3.85 3.85 FALSE FALSE Change -Subsidy -Price -Alternate
383007 1/1/2001 0 0 0 FALSE FALSE Delisted
383015 10/1/1997 2/1/1998 89.85 89.85 89.85 FALSE FALSE New Listing
383015 2/1/1998 9/1/2000 67.39 67.39 67.39 FALSE FALSE Change -Subsidy -Price -Alternate
383015 9/1/2000 1/1/2001 19.25 19.25 19.25 FALSE FALSE Change -Subsidy -Price -Alternate
383015 1/1/2001 9/1/2004 0 0 0 FALSE FALSE Delisted
383015 9/1/2004 7/1/2007 17.33 17.33 17.33 FALSE FALSE New Listing
383015 7/1/2007 12/1/2010 17.3 17.3 17.3 FALSE FALSE Change -Subsidy -Price -Alternate
383015 12/1/2010 3/1/2011 16.18 16.18 17.3 FALSE FALSE Change -Subsidy -Alternate
383015 3/1/2011 1/1/2014 0 0 0 FALSE FALSE Delisted
383015 1/1/2014 16.18 16.18 16.18 FALSE FALSE New Listing
383031 10/1/1997 2/1/1998 34.9 34.9 34.9 FALSE FALSE New Listing
383031 2/1/1998 9/1/2000 26.17 26.17 26.17 FALSE FALSE Change -Subsidy -Price -Alternate
383031 9/1/2000 1/1/2001 6.3 6.3 6.3 FALSE FALSE Change -Subsidy -Price -Alternate
383031 1/1/2001 0 0 0 FALSE FALSE Delisted
383678 7/1/2009 8/1/2013 65 65 65 FALSE FALSE New listing
383678 8/1/2013 0 0 0 FALSE FALSE Delisted
383864 10/4/1997 11/1/1999 30.58 30.58 32.1 FALSE FALSE New Listing
383864 11/1/1999 3/1/2003 30.58 30.58 42 FALSE FALSE Change +Price
383864 3/1/2003 0 0 0 FALSE FALSE Delisted
383872 5/16/1994 11/1/1998 9.89 9.89 9.89 FALSE FALSE New Listing
383872 11/1/1998 6/1/2003 9.89 9.89 11.3 FALSE FALSE Change +Price
383872 6/1/2003 12/1/2005 9.89 9.89 12.95 FALSE FALSE Change +Price
383872 12/1/2005 8/1/2008 9.89 9.89 14.24 FALSE FALSE Change +Price
383872 8/1/2008 7/1/2009 9.89 9.89 15.66 FALSE FALSE Change +Price
383872 7/1/2009 9.89 9.89 17.23 FALSE FALSE Change +Price
384305 5/16/1994 3/1/1996 34.17 34.17 34.17 FALSE FALSE New Listing
384305 3/1/1996 12/1/1997 33.76 33.76 33.76 FALSE FALSE Change -Subsidy -Price -Alternate
384305 12/1/1997 4/1/2003 25.32 25.32 25.32 FALSE FALSE Change -Subsidy -Price -Alternate
384305 4/1/2003 0 0 0 FALSE FALSE Delisted
384313 6/7/1995 4/1/2002 3.63 3.63 3.63 FALSE TRUE New Listing
384313 4/1/2002 0 0 0 FALSE FALSE Delisted
384909 10/1/1997 2/1/1999 93.65 93.65 147.6 FALSE FALSE New Listing
384909 2/1/1999 3/1/2001 124 124 147.6 FALSE FALSE Change +Subsidy +Alternate
384909 3/1/2001 0 0 0 FALSE FALSE Delisted
385034 7/1/1998 7/1/1999 11.93 11.93 11.93 FALSE FALSE New Listing
385034 7/1/1999 11/1/2002 4.56 4.56 4.56 FALSE FALSE Change -Subsidy -Price -Alternate
385034 11/1/2002 2/1/2003 4.16 4.16 4.16 FALSE FALSE Change -Subsidy -Price -Alternate
385034 2/1/2003 0 0 0 FALSE FALSE Delisted
385220 7/1/1998 2/1/2004 11.33 11.33 11.33 FALSE FALSE New Listing
385220 2/1/2004 0 0 0 FALSE FALSE Delisted
386561 7/1/2000 9/1/2000 26.17 26.17 26.17 FALSE FALSE New Listing
386561 9/1/2000 11/1/2004 6.3 6.3 6.3 FALSE FALSE Change -Subsidy -Price -Alternate
386561 11/1/2004 2/1/2005 5.54 5.54 5.54 FALSE FALSE Change -Subsidy -Price -Alternate
386561 2/1/2005 0 0 0 FALSE FALSE Delisted
386596 7/1/2000 9/1/2000 67.39 67.39 67.39 FALSE FALSE New Listing
386596 9/1/2000 11/1/2004 19.25 19.25 19.25 FALSE FALSE Change -Subsidy -Price -Alternate
386596 11/1/2004 2/1/2005 17.33 17.33 17.33 FALSE FALSE Change -Subsidy -Price -Alternate
386596 2/1/2005 0 0 0 FALSE FALSE Delisted
386731 10/1/2010 22.89 22.89 22.89 FALSE TRUE New listing
387118 5/16/1994 2/1/1998 25.12 25.12 25.12 FALSE FALSE New Listing
387118 2/1/1998 2/1/1999 12.56 12.56 12.56 FALSE FALSE Change -Subsidy -Price -Alternate
387118 2/1/1999 8/1/2000 6.28 6.28 6.28 FALSE FALSE Change -Subsidy -Price -Alternate
387118 8/1/2000 10/1/2003 2.6 2.6 2.6 FALSE FALSE Change -Subsidy -Price -Alternate
387118 10/1/2003 4/1/2005 2.1 2.1 2.1 FALSE FALSE Change -Subsidy -Price -Alternate
387118 4/1/2005 0 0 0 FALSE FALSE Delisted
387177 8/1/1997 5/1/1998 22.55 22.55 22.55 FALSE FALSE New Listing
387177 5/1/1998 1/1/2001 14.66 14.66 14.66 FALSE FALSE Change -Subsidy -Price -Alternate
387177 1/1/2001 1/1/2003 12 14.66 14.66 FALSE FALSE Change -Subsidy
387177 1/1/2003 2/1/2003 12 12 12 FALSE FALSE Change -Price -Alternate
387177 2/1/2003 11/1/2004 10.6 10.6 10.6 FALSE FALSE Change -Subsidy -Price -Alternate
387177 11/1/2004 0 0 0 FALSE FALSE Delisted
387231 5/16/1994 12/1/2003 44.69 44.69 44.69 FALSE FALSE New Listing
387231 12/1/2003 0 0 0 FALSE FALSE Delisted
387509 9/1/2000 2/1/2004 4.1 4.1 4.1 FALSE FALSE New Listing
387509 2/1/2004 5/1/2004 4.04 4.04 4.04 FALSE FALSE Change -Subsidy -Price -Alternate
387509 5/1/2004 0 0 0 FALSE FALSE Delisted
387630 9/1/2000 10/1/2003 3.99 3.99 3.99 FALSE FALSE New Listing
387630 10/1/2003 12/1/2003 3.99 3.99 5 FALSE FALSE Change +Price
387630 12/1/2003 3/1/2010 5 5 5 FALSE FALSE Change +Subsidy +Alternate
387630 3/1/2010 0 0 0 FALSE FALSE Delisted
387851 1/1/1997 2/1/1998 4.83 4.83 4.83 FALSE FALSE New Listing
387851 2/1/1998 8/1/2000 2.9 2.9 4.83 FALSE FALSE Change -Subsidy -Alternate
387851 8/1/2000 9/1/2003 2.9 2.9 6 FALSE FALSE Change +Price
387851 9/1/2003 0 0 0 FALSE FALSE Delisted
387886 10/1/1996 1/1/2004 11.22 11.22 11.22 FALSE FALSE New Listing
387886 1/1/2004 5/1/2005 11.22 11.22 13.46 FALSE FALSE Change +Price
387886 5/1/2005 0 0 0 FALSE FALSE Delisted
387908 10/1/1996 1/1/2004 32.5 32.5 32.5 FALSE FALSE New Listing
387908 1/1/2004 5/1/2005 32.5 32.5 39 FALSE FALSE Change +Price
387908 5/1/2005 0 0 0 FALSE FALSE Delisted
387924 5/22/1995 10/1/1998 5.4 5.4 8.34 FALSE FALSE New Listing
387924 10/1/1998 0 0 0 FALSE FALSE Delisted
387959 7/1/1997 8/1/1999 30 30 22 FALSE FALSE New Listing
387959 8/1/1999 9/1/1999 34 34 22 FALSE FALSE Change +Subsidy +Alternate
387959 9/1/1999 12/1/2000 34 34 23.6 FALSE FALSE Change +Price
387959 12/1/2000 8/1/2003 34 34 24.9 FALSE FALSE Change +Price
387959 8/1/2003 0 0 0 FALSE FALSE Delisted
387967 7/1/1997 8/1/1999 75 75 49.2 FALSE FALSE New Listing
387967 8/1/1999 8/1/2003 85 85 49.2 FALSE FALSE Change +Subsidy +Alternate
387967 8/1/2003 0 0 0 FALSE FALSE Delisted
387983 4/11/1995 8/1/1999 15.45 15.45 15.45 FALSE FALSE New Listing
387983 8/1/1999 0 0 0 FALSE FALSE Delisted
388130 5/16/1994 7/1/2003 180.9 180.9 180.9 FALSE FALSE New Listing
388130 7/1/2003 9/1/2006 217.08 217.08 217.08 FALSE FALSE Change +Subsidy +Price +Alternate
388130 9/1/2006 6/1/2013 238 238 238 FALSE FALSE Change +Subsidy +Price +Alternate
388130 6/1/2013 520 520 520 FALSE FALSE Change +Subsidy +Price +Alternate
388181 8/1/1996 12/1/2004 5.81 5.81 7.8 FALSE TRUE New Listing
388181 12/1/2004 0 0 0 FALSE FALSE Delisted
388238 10/1/1996 10/1/2001 52.31 52.31 52.31 FALSE FALSE New Listing
388238 10/1/2001 0 0 0 FALSE FALSE Delisted
388513 4/1/2002 3/1/2005 45 45 45 FALSE FALSE New listing
388513 3/1/2005 33.75 33.75 33.75 FALSE FALSE Change -Subsidy -Price -Alternate
388548 4/1/2002 3/1/2005 28 28 28 FALSE FALSE New listing
388548 3/1/2005 21 21 21 FALSE FALSE Change -Subsidy -Price -Alternate
388610 5/16/1994 3/1/2002 3.9 6.95 6.95 FALSE FALSE New Listing
388610 3/1/2002 7/1/2010 3.9 7.99 7.99 FALSE FALSE Change +Price +Alternate
388610 7/1/2010 5/1/2012 7.99 7.99 7.99 FALSE FALSE Change +Subsidy
388610 5/1/2012 3/1/2013 11.99 11.99 11.99 FALSE FALSE Change +Subsidy +Price +Alternate
388610 3/1/2013 6/1/2013 3.25 3.25 11.99 FALSE FALSE Change -Subsidy -Alternate
388610 6/1/2013 0 0 0 FALSE FALSE Delisted
388874 6/1/1997 4.95 4.95 4.95 FALSE TRUE New Listing
388920 5/16/1994 2/1/1999 16.88 16.88 16.88 FALSE FALSE New Listing
388920 2/1/1999 9/1/2002 16.88 16.88 21.83 FALSE FALSE Change +Price
388920 9/1/2002 0 0 0 FALSE FALSE Delisted
389072 5/16/1994 10/1/1997 22.46 22.46 22.46 FALSE FALSE New Listing
389072 10/1/1997 2/1/1998 17.97 17.97 17.97 FALSE FALSE Change -Subsidy -Price -Alternate
389072 2/1/1998 9/1/2000 13.48 13.48 13.48 FALSE FALSE Change -Subsidy -Price -Alternate
389072 9/1/2000 1/1/2001 3.85 3.85 13.48 FALSE FALSE Change -Subsidy -Alternate
389072 1/1/2001 0 0 0 FALSE FALSE Delisted
389099 5/16/1994 10/1/1997 43.63 43.63 43.63 FALSE FALSE New Listing
389099 10/1/1997 2/1/1998 34.9 34.9 34.9 FALSE FALSE Change -Subsidy -Price -Alternate
389099 2/1/1998 9/1/2000 26.17 26.17 26.17 FALSE FALSE Change -Subsidy -Price -Alternate
389099 9/1/2000 1/1/2001 6.3 6.3 26.17 FALSE FALSE Change -Subsidy -Alternate
389099 1/1/2001 0 0 0 FALSE FALSE Delisted
389366 8/1/2009 7/1/2012 168 168 168 FALSE FALSE New listing
389366 7/1/2012 155.4 155.4 155.4 FALSE FALSE Change -Subsidy -Price -Alternate
389390 8/1/2009 7/1/2012 192 192 192 FALSE FALSE New listing
389390 7/1/2012 177.6 177.6 177.6 FALSE FALSE Change -Subsidy -Price -Alternate
389439 6/1/1997 4.95 4.95 4.95 FALSE TRUE New Listing
389447 12/1/1999 6/1/2001 100.5 100.5 100.5 FALSE FALSE New Listing
389447 6/1/2001 0 0 0 FALSE FALSE Delisted
389455 12/1/1999 6/1/2001 335 335 335 FALSE FALSE New Listing
389455 6/1/2001 0 0 0 FALSE FALSE Delisted
389498 5/16/1994 6/1/2001 46.5 46.5 46.5 FALSE FALSE New Listing
389498 6/1/2001 0 0 0 FALSE FALSE Delisted
389536 8/1/2000 2/1/2004 8.2 8.2 8.2 FALSE TRUE New Listing
389536 2/1/2004 5/1/2004 7 7 8.2 FALSE TRUE Change -Subsidy -Alternate +OP
389536 5/1/2004 0 0 0 FALSE FALSE Delisted
389579 12/1/1999 6/1/2001 201 201 201 FALSE FALSE New Listing
389579 6/1/2001 0 0 0 FALSE FALSE Delisted
389587 12/1/1999 6/1/2001 670 670 670 FALSE FALSE New Listing
389587 6/1/2001 0 0 0 FALSE FALSE Delisted
389749 6/15/1995 1/1/1997 9.7 9.7 18.05 FALSE FALSE New Listing
389749 1/1/1997 5/1/2003 9.7 9.7 20.15 FALSE FALSE Change +Price
389749 5/1/2003 1/1/2011 9.7 9.7 29.6 FALSE FALSE Change +Price
389749 1/1/2011 0 0 0 FALSE FALSE Delisted
389781 6/9/1994 12/1/1995 20.32 20.32 27.3 FALSE FALSE New Listing
389781 12/1/1995 8/1/1996 21.34 21.34 27.3 FALSE FALSE Change +Subsidy +Alternate
389781 8/1/1996 0 0 0 FALSE FALSE Delisted
390003 5/16/1994 7/1/1999 89.11 89.11 89.11 FALSE FALSE New Listing
390003 7/1/1999 12/1/2009 25 25 25 FALSE FALSE Change -Subsidy -Price -Alternate
390003 12/1/2009 10/1/2010 26.75 26.75 26.75 FALSE FALSE Change +Subsidy +Price +Alternate
390003 10/1/2010 1/1/2011 18.45 18.45 18.45 FALSE FALSE Change -Subsidy -Price -Alternate
390003 1/1/2011 4/1/2014 0 0 0 FALSE FALSE Delisted
390003 4/1/2014 13.22 13.22 13.22 FALSE FALSE New Listing
390119 8/1/2000 9/1/2003 8 8 8 FALSE TRUE New Listing
390119 9/1/2003 7 7 7 FALSE TRUE Change -Subsidy -Price -Alternate
390178 11/1/1997 8/1/2001 5.03 5.03 5.59 FALSE FALSE New Listing
390178 8/1/2001 10/1/2006 10.06 10.06 10.06 FALSE FALSE Change +Subsidy +Price +Alternate
390178 10/1/2006 0 0 0 FALSE FALSE Delisted
390291 8/1/2000 2/1/2001 8.2 8.2 8.2 FALSE TRUE New Listing
390291 2/1/2001 0 0 0 FALSE FALSE Delisted
390305 5/16/1994 3/1/1995 4.77 4.77 6.87 FALSE FALSE New Listing
390305 3/1/1995 10/1/2002 4.77 4.77 7.21 FALSE FALSE Change +Price
390305 10/1/2002 5/1/2008 4.77 4.77 8.11 FALSE FALSE Change +Price
390305 5/1/2008 0 0 0 FALSE FALSE Delisted
390313 5/16/1994 3/1/1995 9.54 9.54 13.76 FALSE FALSE New Listing
390313 3/1/1995 10/1/2002 9.54 9.54 14.45 FALSE FALSE Change +Price
390313 10/1/2002 2/1/2008 9.54 9.54 16.26 FALSE FALSE Change +Price
390313 2/1/2008 5/1/2008 8.6 8.6 16.26 FALSE FALSE Change -Subsidy -Alternate
390313 5/1/2008 0 0 0 FALSE FALSE Delisted
390321 5/16/1994 3/1/1995 19.08 19.08 27.52 FALSE FALSE New Listing
390321 3/1/1995 10/1/2002 19.08 19.08 28.9 FALSE FALSE Change +Price
390321 10/1/2002 2/1/2008 19.08 19.08 32.51 FALSE FALSE Change +Price
390321 2/1/2008 5/1/2008 15.7 15.7 32.51 FALSE FALSE Change -Subsidy -Alternate
390321 5/1/2008 0 0 0 FALSE FALSE Delisted
390372 9/1/2009 31.45 31.45 31.45 FALSE FALSE New listing
390534 8/1/2000 10/1/2000 5.97 5.97 5.97 FALSE FALSE New Listing
390534 10/1/2000 2/1/2007 1.38 1.38 1.38 FALSE FALSE Change -Subsidy -Price -Alternate
390534 2/1/2007 5/1/2007 1.27 1.27 1.38 FALSE FALSE Change -Subsidy -Alternate
390534 5/1/2007 12/1/2009 0 0 0 FALSE FALSE Delisted
390534 12/1/2009 1.1 1.1 1.1 FALSE FALSE New Listing
390623 8/1/2000 10/1/2000 3.19 3.19 3.19 FALSE FALSE New Listing
390623 10/1/2000 2/1/2007 1.08 1.08 1.08 FALSE FALSE Change -Subsidy -Price -Alternate
390623 2/1/2007 5/1/2007 1 1 1.08 FALSE FALSE Change -Subsidy -Alternate
390623 5/1/2007 12/1/2009 0 0 0 FALSE FALSE Delisted
390623 12/1/2009 1.55 1.55 1.55 FALSE FALSE New Listing
391646 8/1/2000 77.27 77.27 77.27 FALSE FALSE New Listing
391654 8/1/2000 69.24 69.24 69.24 FALSE FALSE New Listing
391727 1/9/1995 9/1/2001 3.32 3.32 3.75 FALSE FALSE New Listing
391727 9/1/2001 9/1/2009 3.12 3.12 3.12 FALSE FALSE Change -Subsidy -Price -Alternate
391727 9/1/2009 0 0 0 FALSE FALSE Delisted
392006 5/16/1994 8/1/1997 68.6 68.6 68.6 FALSE FALSE New Listing
392006 8/1/1997 0 0 0 FALSE FALSE Delisted
392235 10/1/1997 6/1/1998 2.31 2.31 2.69 FALSE FALSE New Listing
392235 6/1/1998 6/1/2000 1.83 1.83 6.84 FALSE FALSE Change -Subsidy +Price -Alternate
392235 6/1/2000 12/1/2000 1.62 1.62 6.84 FALSE FALSE Change -Subsidy -Alternate
392235 12/1/2000 3/1/2001 1.62 1.62 7.95 FALSE FALSE Change +Price
392235 3/1/2001 3/1/2002 1.62 1.62 8.35 FALSE FALSE Change +Price
392235 3/1/2002 6/1/2002 1.62 1.62 8.34 FALSE FALSE Change -Price
392235 6/1/2002 7/1/2003 1.62 1.62 8.6 FALSE FALSE Change +Price
392235 7/1/2003 11/1/2003 1.75 1.75 8.6 FALSE FALSE Change +Subsidy +Alternate
392235 11/1/2003 2/1/2004 1.46 1.46 8.6 FALSE FALSE Change -Subsidy -Alternate
392235 2/1/2004 0 0 0 FALSE FALSE Delisted
392243 10/1/1997 6/1/1998 1.16 1.16 1.35 FALSE FALSE New Listing
392243 6/1/1998 6/1/2000 0.92 0.92 5.04 FALSE FALSE Change -Subsidy +Price -Alternate
392243 6/1/2000 12/1/2000 0.81 0.81 5.04 FALSE FALSE Change -Subsidy -Alternate
392243 12/1/2000 3/1/2002 0.81 0.81 5.85 FALSE FALSE Change +Price
392243 3/1/2002 6/1/2002 0.81 0.81 5.87 FALSE FALSE Change +Price
392243 6/1/2002 7/1/2003 0.81 0.81 6.05 FALSE FALSE Change +Price
392243 7/1/2003 11/1/2003 0.88 0.88 6.05 FALSE FALSE Change +Subsidy +Alternate
392243 11/1/2003 2/1/2004 0.73 0.73 6.05 FALSE FALSE Change -Subsidy -Alternate
392243 2/1/2004 0 0 0 FALSE FALSE Delisted
392391 10/1/1996 5/1/2000 9.95 9.95 9.95 FALSE FALSE New Listing
392391 5/1/2000 10/1/2004 6.5 6.5 6.5 FALSE FALSE Change -Subsidy -Price -Alternate
392391 10/1/2004 0 0 0 FALSE FALSE Delisted
393037 5/16/1994 8/1/2000 8.36 8.36 8.36 FALSE FALSE New Listing
393037 8/1/2000 7/1/2003 6.2 6.2 6.2 FALSE FALSE Change -Subsidy -Price -Alternate
393037 7/1/2003 6/1/2004 6.6 6.6 6.6 FALSE FALSE Change +Subsidy +Price +Alternate
393037 6/1/2004 0 0 0 FALSE FALSE Delisted
393088 5/16/1994 8/1/2000 10.63 10.63 10.63 FALSE FALSE New Listing
393088 8/1/2000 3/1/2001 6.66 6.66 6.66 FALSE FALSE Change -Subsidy -Price -Alternate
393088 3/1/2001 0 0 0 FALSE FALSE Delisted
393118 10/1/1994 8/1/2000 53.15 53.15 53.15 FALSE FALSE New Listing
393118 8/1/2000 7/1/2003 33.3 33.3 33.3 FALSE FALSE Change -Subsidy -Price -Alternate
393118 7/1/2003 7/1/2006 35 35 35 FALSE FALSE Change +Subsidy +Price +Alternate
393118 7/1/2006 10/1/2009 34.75 34.75 34.75 FALSE FALSE Change -Subsidy -Price -Alternate
393118 10/1/2009 54.06 54.06 54.06 FALSE FALSE Change +Subsidy +Price +Alternate
393584 5/16/1994 5/1/1998 20.82 20.82 20.82 FALSE FALSE New Listing
393584 5/1/1998 7/1/2001 8.75 8.75 8.75 FALSE FALSE Change -Subsidy -Price -Alternate
393584 7/1/2001 8/1/2003 9.63 9.63 9.63 FALSE FALSE Change +Subsidy +Price +Alternate
393584 8/1/2003 12/1/2010 10.59 10.59 10.59 FALSE FALSE Change +Subsidy +Price +Alternate
393584 12/1/2010 10.06 10.06 10.06 FALSE FALSE Change -Subsidy -Price -Alternate
393592 5/16/1994 5/1/1998 38.11 38.11 38.11 FALSE FALSE New Listing
393592 5/1/1998 7/1/2001 15.26 15.26 15.26 FALSE FALSE Change -Subsidy -Price -Alternate
393592 7/1/2001 8/1/2003 16.79 16.79 16.79 FALSE FALSE Change +Subsidy +Price +Alternate
393592 8/1/2003 12/1/2010 18.47 18.47 18.47 FALSE FALSE Change +Subsidy +Price +Alternate
393592 12/1/2010 17.55 17.55 17.55 FALSE FALSE Change -Subsidy -Price -Alternate
393991 8/1/1995 11/1/1998 8.44 8.44 8.44 FALSE TRUE New Listing
393991 11/1/1998 12/1/1998 8.44 8.44 13.5 FALSE TRUE Change +Price
393991 12/1/1998 1/1/2008 13.5 13.5 13.5 FALSE TRUE Change +Subsidy +Alternate
393991 1/1/2008 6/1/2011 18.3 18.3 18.3 FALSE TRUE Change +Subsidy +Price +Alternate
393991 6/1/2011 0 0 0 FALSE FALSE Delisted
394467 5/11/1995 2/1/2000 2.56 2.56 5.16 FALSE FALSE New Listing
394467 2/1/2000 11/1/2000 2.07 2.07 5.16 FALSE FALSE Change -Subsidy -Alternate
394467 11/1/2000 0 0 0 FALSE FALSE Delisted
394920 1/1/1996 8/1/2001 8.32 8.32 30.81 FALSE FALSE New Listing
394920 8/1/2001 6/1/2005 16.64 16.64 30.81 FALSE FALSE Change +Subsidy +Alternate
394920 6/1/2005 10/1/2007 16.64 16.64 33.9 FALSE FALSE Change +Price
394920 10/1/2007 0 0 0 FALSE FALSE Delisted
394947 5/16/1994 6/1/2012 16.08 16.08 16.08 FALSE FALSE New Listing
394947 6/1/2012 5.87 5.87 5.87 FALSE FALSE Change -Subsidy -Price -Alternate
394971 5/16/1994 7/1/1999 4.1 4.1 4.1 FALSE FALSE New Listing
394971 7/1/1999 8/1/2005 3.8 3.8 3.8 FALSE FALSE Change -Subsidy -Price -Alternate
394971 8/1/2005 7/1/2009 4.18 4.18 4.18 FALSE FALSE Change +Subsidy +Price +Alternate
394971 7/1/2009 9/1/2011 5.5 5.5 5.5 FALSE FALSE Change +Subsidy +Price +Alternate
394971 9/1/2011 5.83 5.83 5.83 FALSE FALSE Change +Subsidy +Price +Alternate
394998 5/16/1994 6/1/2008 5.16 5.16 5.16 FALSE FALSE New Listing
394998 6/1/2008 9/1/2011 4.98 4.98 4.98 FALSE FALSE Change -Subsidy -Price -Alternate
394998 9/1/2011 5.3 5.3 5.3 FALSE FALSE Change +Subsidy +Price +Alternate
395005 5/16/1994 9/1/2011 4.7 4.7 4.7 FALSE FALSE New Listing
395005 9/1/2011 5.01 5.01 5.01 FALSE FALSE Change +Subsidy +Price +Alternate
395013 5/16/1994 6/1/2008 4.75 4.75 4.75 FALSE FALSE New Listing
395013 6/1/2008 9/1/2011 4.5 4.5 4.5 FALSE FALSE Change -Subsidy -Price -Alternate
395013 9/1/2011 4.79 4.79 4.79 FALSE FALSE Change +Subsidy +Price +Alternate
395080 5/16/1994 7/1/2009 2.19 2.19 2.19 FALSE FALSE New Listing
395080 7/1/2009 0 0 0 FALSE FALSE Delisted
395250 5/16/1994 2/1/2008 29.28 29.28 29.28 FALSE FALSE New Listing
395250 2/1/2008 0 0 0 FALSE FALSE Delisted
395528 7/1/1996 12/1/2000 0 0 0 TRUE FALSE New Listing
395528 12/1/2000 0 0 0 FALSE FALSE Delisted
395552 5/16/1994 5/1/2000 37.4 37.4 37.4 FALSE FALSE New Listing
395552 5/1/2000 4/1/2008 37.4 37.4 43 FALSE FALSE Change +Price
395552 4/1/2008 0 0 0 FALSE FALSE Delisted
395587 5/16/1994 5/1/1998 31.26 31.26 31.26 FALSE FALSE New Listing
395587 5/1/1998 7/1/2001 10.2 10.2 10.2 FALSE FALSE Change -Subsidy -Price -Alternate
395587 7/1/2001 10/1/2003 11.22 11.22 11.22 FALSE FALSE Change +Subsidy +Price +Alternate
395587 10/1/2003 1/1/2004 11.11 11.11 11.11 FALSE FALSE Change -Subsidy -Price -Alternate
395587 1/1/2004 0 0 0 FALSE FALSE Delisted
395633 5/16/1994 7/1/1999 3.46 3.46 3.46 FALSE FALSE New Listing
395633 7/1/1999 12/1/2002 2.49 2.49 2.49 FALSE FALSE Change -Subsidy -Price -Alternate
395633 12/1/2002 10/1/2005 2.75 2.75 2.75 FALSE FALSE Change +Subsidy +Price +Alternate
395633 10/1/2005 3/1/2009 3 3 3 FALSE FALSE Change +Subsidy +Price +Alternate
395633 3/1/2009 0 0 0 FALSE FALSE Delisted
395838 12/1/2001 2/1/2005 13.49 13.49 13.49 FALSE FALSE New listing
395838 2/1/2005 4/1/2014 16.85 16.85 16.85 FALSE FALSE Change +Subsidy +Price +Alternate
395838 4/1/2014 9.75 9.75 9.75 FALSE FALSE Change -Subsidy -Price -Alternate
396303 9/1/1997 9/1/1998 14.21 14.21 14.95 FALSE TRUE New Listing
396303 9/1/1998 5/1/2000 13.93 13.93 14.95 FALSE TRUE Change -Subsidy -Alternate
396303 5/1/2000 0 0 0 FALSE FALSE Delisted
396524 5/1/1999 9/1/2010 19.65 19.65 19.65 FALSE FALSE New Listing
396524 9/1/2010 0 0 0 FALSE FALSE Delisted
396842 5/16/1994 11/1/2008 3.88 3.88 3.88 FALSE TRUE New Listing
396842 11/1/2008 2/1/2009 3.75 3.75 3.75 FALSE TRUE Change -Subsidy -Price -Alternate
396842 2/1/2009 0 0 0 FALSE FALSE Delisted
397083 5/16/1994 18.65 18.65 18.65 FALSE FALSE New Listing
397148 3/1/1996 8/1/1998 12.63 12.63 12.63 FALSE FALSE New Listing
397148 8/1/1998 3/1/1999 11.63 11.63 11.63 FALSE FALSE Change -Subsidy -Price -Alternate
397148 3/1/1999 2/1/2000 9.07 9.07 9.07 FALSE FALSE Change -Subsidy -Price -Alternate
397148 2/1/2000 11/1/2000 5.45 9.07 9.07 FALSE FALSE Change -Subsidy
397148 11/1/2000 3/1/2001 4.91 9.07 9.07 FALSE FALSE Change -Subsidy
397148 3/1/2001 9/1/2001 4.42 9.07 9.07 FALSE FALSE Change -Subsidy
397148 9/1/2001 4/1/2002 3.76 9.07 9.07 FALSE FALSE Change -Subsidy
397148 4/1/2002 4/1/2003 3.76 9.98 9.98 FALSE FALSE Change +Price +Alternate
397148 4/1/2003 12/1/2004 3.76 10.98 10.98 FALSE FALSE Change +Price +Alternate
397148 12/1/2004 3/1/2014 0 0 0 FALSE FALSE Delisted
397148 3/1/2014 12.07 12.07 12.07 FALSE FALSE New Listing
397172 4/8/1995 8/1/1999 1.39 1.39 1.39 FALSE FALSE New Listing
397172 8/1/1999 0 0 0 FALSE FALSE Delisted
397202 12/1/1995 9/1/1999 14.46 14.46 14.46 FALSE FALSE New Listing
397202 9/1/1999 12/1/2000 14.46 14.46 16.6 FALSE FALSE Change +Price
397202 12/1/2000 6/1/2001 14.46 14.46 17.9 FALSE FALSE Change +Price
397202 6/1/2001 0 0 0 FALSE FALSE Delisted
397210 12/1/1995 9/1/1999 2.89 2.89 3.35 FALSE FALSE New Listing
397210 9/1/1999 12/1/2000 2.89 2.89 3.32 FALSE FALSE Change -Price
397210 12/1/2000 6/1/2001 2.89 2.89 3.58 FALSE FALSE Change +Price
397210 6/1/2001 0 0 0 FALSE FALSE Delisted
398322 6/16/1995 7/1/1996 26.1 26.1 36 FALSE FALSE New Listing
398322 7/1/1996 7/2/1996 26.1 26.1 39 FALSE FALSE Change +Price
398322 7/2/1996 11/1/2002 8.7 13 13 FALSE FALSE Change -Subsidy -Price -Alternate
398322 11/1/2002 9/1/2005 9.1 9.1 9.1 FALSE FALSE Change +Subsidy -Price -Alternate
398322 9/1/2005 7/1/2012 7.15 7.15 7.15 FALSE FALSE Change -Subsidy -Price -Alternate
398322 7/1/2012 6 6 6 FALSE FALSE Change -Subsidy -Price -Alternate
398462 5/16/1994 5/1/2000 19.1 19.1 19.1 FALSE FALSE New Listing
398462 5/1/2000 7/1/2000 19.1 19.1 26 FALSE FALSE Change +Price
398462 7/1/2000 9/1/2002 26 26 26 FALSE FALSE Change +Subsidy +Alternate
398462 9/1/2002 4/1/2014 25.71 25.71 25.71 FALSE FALSE Change -Subsidy -Price -Alternate
398462 4/1/2014 5/1/2014 0 0 0 FALSE FALSE Delisted
398462 5/1/2014 9/1/2014 25.71 25.71 25.71 FALSE FALSE New Listing
398462 9/1/2014 0 0 0 FALSE FALSE Delisted
398608 5/16/1994 4/1/2000 2.07 2.07 2.07 FALSE FALSE New Listing
398608 4/1/2000 0 0 0 FALSE FALSE Delisted
398837 5/16/1994 5/1/1997 28.73 28.73 28.73 FALSE FALSE New Listing
398837 5/1/1997 9/1/1997 17.24 17.24 28.73 FALSE FALSE Change -Subsidy -Alternate
398837 9/1/1997 1/1/1998 28.73 28.73 28.73 FALSE FALSE Change +Subsidy +Alternate
398837 1/1/1998 2/1/1998 23 23 23 FALSE FALSE Change -Subsidy -Price -Alternate
398837 2/1/1998 9/1/1998 17.24 17.24 17.24 FALSE FALSE Change -Subsidy -Price -Alternate
398837 9/1/1998 8/1/2000 16.73 16.73 16.73 FALSE FALSE Change -Subsidy -Price -Alternate
398837 8/1/2000 2/1/2004 10.29 10.29 10.29 FALSE FALSE Change -Subsidy -Price -Alternate
398837 2/1/2004 9/1/2004 8.16 8.16 8.16 FALSE FALSE Change -Subsidy -Price -Alternate
398837 9/1/2004 0 0 0 FALSE FALSE Delisted
398845 5/16/1994 5/1/1997 28.6 28.6 28.6 FALSE FALSE New Listing
398845 5/1/1997 9/1/1997 17.16 17.16 28.6 FALSE FALSE Change -Subsidy -Alternate
398845 9/1/1997 1/1/1998 28.6 28.6 28.6 FALSE FALSE Change +Subsidy +Alternate
398845 1/1/1998 2/1/1998 21.5 21.5 21.5 FALSE FALSE Change -Subsidy -Price -Alternate
398845 2/1/1998 9/1/1998 17.16 17.16 17.16 FALSE FALSE Change -Subsidy -Price -Alternate
398845 9/1/1998 8/1/2000 16.73 16.73 16.73 FALSE FALSE Change -Subsidy -Price -Alternate
398845 8/1/2000 3/1/2001 7.98 7.98 7.98 FALSE FALSE Change -Subsidy -Price -Alternate
398845 3/1/2001 0 0 0 FALSE FALSE Delisted
398969 5/16/1994 7/1/1995 2.79 2.79 2.79 FALSE FALSE New Listing
398969 7/1/1995 8/1/2000 3.36 3.36 3.36 FALSE FALSE Change +Subsidy +Price +Alternate
398969 8/1/2000 10/1/2000 3.36 3.36 4.1 FALSE FALSE Change +Price
398969 10/1/2000 8/1/2006 3.36 3.36 4.59 FALSE FALSE Change +Price
398969 8/1/2006 0 0 0 FALSE FALSE Delisted
399019 5/16/1994 5/30/1995 4.16 4.16 4.95 FALSE FALSE New Listing
399019 5/30/1995 8/1/1995 4.16 4.16 5.2 FALSE FALSE Change +Price
399019 8/1/1995 4/1/1996 4.16 4.16 5.33 FALSE FALSE Change +Price
399019 4/1/1996 1/1/1997 4.16 4.16 5.6 FALSE FALSE Change +Price
399019 1/1/1997 11/1/1997 4.16 4.16 5.9 FALSE FALSE Change +Price
399019 11/1/1997 3/1/2001 4.16 4.16 7.37 FALSE FALSE Change +Price
399019 3/1/2001 8/1/2001 4.16 4.16 19.44 FALSE FALSE Change +Price
399019 8/1/2001 8/1/2005 8.32 8.32 8.32 FALSE FALSE Change +Subsidy -Price +Alternate
399019 8/1/2005 9.24 9.24 9.24 FALSE FALSE Change +Subsidy +Price +Alternate
399027 10/1/1997 2/1/1998 11.45 11.45 11.45 FALSE FALSE New Listing
399027 2/1/1998 7/1/1998 10.42 10.42 10.42 FALSE FALSE Change -Subsidy -Price -Alternate
399027 7/1/1998 7/1/2000 6.87 6.87 6.87 FALSE FALSE Change -Subsidy -Price -Alternate
399027 7/1/2000 11/1/2000 1.95 6.87 6.87 FALSE FALSE Change -Subsidy
399027 11/1/2000 0 0 0 FALSE FALSE Delisted
399043 11/1/1996 2/1/2004 8 8 8 FALSE FALSE New Listing
399043 2/1/2004 8/1/2004 2.4 8 8 FALSE FALSE Change -Subsidy
399043 8/1/2004 0 0 0 FALSE FALSE Delisted
399051 11/1/1996 2/1/2004 16 16 16 FALSE FALSE New Listing
399051 2/1/2004 8/1/2004 6 16 16 FALSE FALSE Change -Subsidy
399051 8/1/2004 0 0 0 FALSE FALSE Delisted
399108 11/1/1996 2/1/2004 25.5 25.5 25.5 FALSE FALSE New Listing
399108 2/1/2004 8/1/2004 8.5 25.5 25.5 FALSE FALSE Change -Subsidy
399108 8/1/2004 0 0 0 FALSE FALSE Delisted
399485 11/1/1996 5/1/2010 307.2 307.2 307.2 FALSE FALSE New Listing
399485 5/1/2010 2/1/2014 153.6 153.6 153.6 FALSE FALSE Change -Subsidy -Price -Alternate
399485 2/1/2014 5/1/2014 52.5 52.5 153.6 FALSE FALSE Change -Subsidy -Alternate
399485 5/1/2014 0 0 0 FALSE FALSE Delisted
399930 8/1/1997 7/1/2004 154.82 154.82 154.82 FALSE FALSE New Listing
399930 7/1/2004 12/1/2014 77.41 77.41 77.41 FALSE FALSE Change -Subsidy -Price -Alternate
399930 12/1/2014 0 0 0 FALSE FALSE Delisted
400483 2/1/1999 7/1/1999 10.94 10.94 10.94 FALSE FALSE New Listing
400483 7/1/1999 11/1/1999 8.21 8.21 10.94 FALSE FALSE Change -Subsidy -Alternate
400483 11/1/1999 0 0 0 FALSE FALSE Delisted
400564 12/1/1996 4/1/1999 27.07 27.07 27.07 FALSE FALSE New Listing
400564 4/1/1999 10/1/2001 0 0 0 FALSE FALSE Delisted
400564 10/1/2001 4/1/2002 12.07 12.07 12.07 FALSE FALSE New Listing
400564 4/1/2002 11/1/2002 5.95 5.95 5.95 FALSE FALSE Change -Subsidy -Price -Alternate
400564 11/1/2002 0 0 0 FALSE FALSE Delisted
400572 12/1/1996 6/1/1998 31.55 31.55 31.85 FALSE FALSE New Listing
400572 6/1/1998 4/1/1999 31.55 31.55 31.55 FALSE FALSE Change -Price
400572 4/1/1999 0 0 0 FALSE FALSE Delisted
401692 8/1/1996 10/1/1997 58.64 58.64 75.85 FALSE FALSE New Listing
401692 10/1/1997 3/1/2001 58.64 58.64 75.8 FALSE FALSE Change -Price
401692 3/1/2001 0 0 0 FALSE FALSE Delisted
402281 6/1/1998 4/1/2002 220.47 220.47 220.47 FALSE FALSE New Listing
402281 4/1/2002 0 0 0 FALSE FALSE Delisted
402303 6/1/1998 4/1/2002 95.4 95.4 95.4 FALSE FALSE New Listing
402303 4/1/2002 0 0 0 FALSE FALSE Delisted
402516 12/1/1996 10/1/1999 10.25 10.25 10.25 FALSE TRUE New Listing
402516 10/1/1999 2/1/2003 8.67 8.67 8.67 FALSE TRUE Change -Subsidy -Price -Alternate
402516 2/1/2003 4/1/2003 5.12 5.12 8.67 FALSE TRUE Change -Subsidy -Alternate
402516 4/1/2003 8/1/2005 5.12 5.12 5.12 FALSE TRUE Change -Price
402516 8/1/2005 0 0 0 FALSE FALSE Delisted
402699 12/1/1996 10/1/1999 15 15 15 FALSE TRUE New Listing
402699 10/1/1999 4/1/2001 10.03 10.03 10.03 FALSE TRUE Change -Subsidy -Price -Alternate
402699 4/1/2001 0 0 0 FALSE FALSE Delisted
402702 12/1/1996 9/1/1998 27.2 27.2 27.2 TRUE TRUE New Listing
402702 9/1/1998 0 0 0 FALSE FALSE Delisted
402710 12/1/1996 8/1/1997 54.2 54.2 54.2 TRUE TRUE New Listing
402710 8/1/1997 9/1/1998 54.4 54.4 54.4 TRUE TRUE Change +Subsidy +Price +Alternate
402710 9/1/1998 0 0 0 FALSE FALSE Delisted
402737 12/1/1996 6/1/1998 14.16 14.16 14.16 FALSE FALSE New Listing
402737 6/1/1998 8/1/2001 8.67 8.67 8.67 FALSE FALSE Change -Subsidy -Price -Alternate
402737 8/1/2001 10/1/2001 5.1 5.1 8.67 FALSE FALSE Change -Subsidy -Alternate
402737 10/1/2001 7/1/2002 3.9 3.9 8.67 FALSE FALSE Change -Subsidy -Alternate
402737 7/1/2002 0 0 0 FALSE FALSE Delisted
402761 12/1/1996 6/1/1998 19.26 19.26 19.26 FALSE FALSE New Listing
402761 6/1/1998 8/1/2001 13.87 13.87 13.87 FALSE FALSE Change -Subsidy -Price -Alternate
402761 8/1/2001 10/1/2001 9.45 9.45 13.87 FALSE FALSE Change -Subsidy -Alternate
402761 10/1/2001 2/1/2004 6.75 6.75 13.87 FALSE FALSE Change -Subsidy -Alternate
402761 2/1/2004 0 0 0 FALSE FALSE Delisted
402796 12/1/1996 6/1/1998 40.13 40.13 40.13 FALSE FALSE New Listing
402796 6/1/1998 5/1/2001 34.43 34.43 34.43 FALSE FALSE Change -Subsidy -Price -Alternate
402796 5/1/2001 8/1/2001 24.51 24.51 24.51 FALSE FALSE Change -Subsidy -Price -Alternate
402796 8/1/2001 10/1/2001 18.38 18.38 24.51 FALSE FALSE Change -Subsidy -Alternate
402796 10/1/2001 2/1/2004 14.46 14.46 24.51 FALSE FALSE Change -Subsidy -Alternate
402796 2/1/2004 0 0 0 FALSE FALSE Delisted
402826 12/1/1996 5/1/2001 75.25 75.25 75.25 FALSE FALSE New Listing
402826 5/1/2001 8/1/2001 45.11 45.11 45.11 FALSE FALSE Change -Subsidy -Price -Alternate
402826 8/1/2001 10/1/2001 36.76 36.76 45.11 FALSE FALSE Change -Subsidy -Alternate
402826 10/1/2001 9/1/2003 28.92 28.92 45.11 FALSE FALSE Change -Subsidy -Alternate
402826 9/1/2003 0 0 0 FALSE FALSE Delisted
402958 8/1/1998 8/1/2001 8.67 8.67 8.67 FALSE TRUE New Listing
402958 8/1/2001 10/1/2001 5.1 5.1 8.67 FALSE TRUE Change -Subsidy -Alternate
402958 10/1/2001 7/1/2004 3.9 3.9 8.67 FALSE TRUE Change -Subsidy -Alternate
402958 7/1/2004 2/1/2012 5.1 5.1 8.67 FALSE TRUE Change +Subsidy +Alternate
402958 2/1/2012 7.5 7.5 7.5 FALSE TRUE Change +Subsidy -Price +Alternate
402974 8/1/1998 8/1/2001 13.87 13.87 13.87 FALSE TRUE New Listing
402974 8/1/2001 10/1/2001 9.45 9.45 13.87 FALSE TRUE Change -Subsidy -Alternate
402974 10/1/2001 7/1/2004 6.75 6.75 13.87 FALSE TRUE Change -Subsidy -Alternate
402974 7/1/2004 8/1/2006 5.7 5.7 13.87 FALSE TRUE Change -Subsidy -Alternate
402974 8/1/2006 2/1/2012 7.5 7.5 13.87 FALSE TRUE Change +Subsidy +Alternate
402974 2/1/2012 7.5 7.5 7.5 FALSE TRUE Change -Price
402990 8/1/1998 5/1/2001 34.43 34.43 34.43 FALSE TRUE New Listing
402990 5/1/2001 8/1/2001 24.5 24.5 24.5 FALSE TRUE Change -Subsidy -Price -Alternate
402990 8/1/2001 10/1/2001 18.38 18.38 24.51 FALSE TRUE Change -Subsidy +Price -Alternate
402990 10/1/2001 7/1/2004 14.46 14.46 24.51 FALSE TRUE Change -Subsidy -Alternate
402990 7/1/2004 8/1/2006 12 12 24.51 FALSE TRUE Change -Subsidy -Alternate
402990 8/1/2006 2/1/2012 13.6 13.6 24.51 FALSE TRUE Change +Subsidy +Alternate
402990 2/1/2012 13.6 13.6 13.6 FALSE TRUE Change -Price
403490 8/1/2000 7/1/2008 25.26 25.26 25.26 FALSE TRUE New Listing
403490 7/1/2008 0 0 0 FALSE FALSE Delisted
403660 8/1/2000 6/1/2007 25.26 25.26 25.26 FALSE TRUE New Listing
403660 6/1/2007 0 0 0 FALSE FALSE Delisted
403903 10/1/1994 2/1/1998 93.32 93.32 93.32 FALSE FALSE New Listing
403903 2/1/1998 7/1/2000 65.32 65.32 65.32 FALSE FALSE Change -Subsidy -Price -Alternate
403903 7/1/2000 7/1/2003 4.19 4.19 4.19 FALSE FALSE Change -Subsidy -Price -Alternate
403903 7/1/2003 10/1/2009 3.75 3.75 3.75 FALSE FALSE Change -Subsidy -Price -Alternate
403903 10/1/2009 3/1/2013 4.75 4.75 4.75 FALSE FALSE Change +Subsidy +Price +Alternate
403903 3/1/2013 4/1/2013 5.1 5.1 5.1 FALSE FALSE Change +Subsidy +Price +Alternate
403903 4/1/2013 3.85 3.85 3.85 FALSE FALSE Change -Subsidy -Price -Alternate
403989 4/12/1995 8/1/1999 0 0 0 TRUE FALSE New Listing
403989 8/1/1999 0 0 0 FALSE FALSE Delisted
405663 8/1/2000 3/1/2001 5.26 5.26 8.9 FALSE FALSE New Listing
405663 3/1/2001 4/1/2002 5.26 5.26 9.79 FALSE FALSE Change +Price
405663 4/1/2002 4/1/2003 5.26 5.26 10.77 FALSE FALSE Change +Price
405663 4/1/2003 5.26 5.26 11.85 FALSE FALSE Change +Price
405701 9/1/2000 9/1/2001 112.49 112.49 112.49 FALSE FALSE New Listing
405701 9/1/2001 1/1/2004 90 90 90 FALSE FALSE Change -Subsidy -Price -Alternate
405701 1/1/2004 10/1/2008 74.25 74.25 74.25 FALSE FALSE Change -Subsidy -Price -Alternate
405701 10/1/2008 0 0 0 FALSE FALSE Delisted
406287 2/1/1997 4/1/1999 14.75 14.75 14.75 FALSE FALSE New Listing
406287 4/1/1999 2/1/2002 11.2 11.2 11.2 FALSE FALSE Change -Subsidy -Price -Alternate
406287 2/1/2002 5/1/2002 10.45 10.45 11.2 FALSE FALSE Change -Subsidy -Alternate
406287 5/1/2002 0 0 0 FALSE FALSE Delisted
406708 7/1/1997 6/1/1998 15.4 15.4 15.4 FALSE FALSE New Listing
406708 6/1/1998 9/1/1999 13.75 13.75 13.75 FALSE FALSE Change -Subsidy -Price -Alternate
406708 9/1/1999 0 0 0 FALSE FALSE Delisted
406716 7/1/1997 11/1/1999 26.4 26.4 26.4 FALSE FALSE New Listing
406716 11/1/1999 0 0 0 FALSE FALSE Delisted
406732 7/1/1997 6/1/1998 18.6 18.6 18.6 FALSE FALSE New Listing
406732 6/1/1998 9/1/1999 16.25 16.25 16.25 FALSE FALSE Change -Subsidy -Price -Alternate
406732 9/1/1999 0 0 0 FALSE FALSE Delisted
407860 9/1/1997 8/1/2000 12 12 12 FALSE FALSE New Listing
407860 8/1/2000 10/1/2000 12 12 13.8 FALSE FALSE Change +Price
407860 10/1/2000 9/1/2001 12 12 16.15 FALSE FALSE Change +Price
407860 9/1/2001 10/1/2006 16.15 16.15 16.15 FALSE FALSE Change +Subsidy +Alternate
407860 10/1/2006 7/1/2011 17.6 17.6 17.6 FALSE FALSE Change +Subsidy +Price +Alternate
407860 7/1/2011 16.54 16.54 16.54 FALSE FALSE Change -Subsidy -Price -Alternate
408050 7/1/1995 5/1/1999 1.3 1.3 1.3 FALSE TRUE New Listing
408050 5/1/1999 9/1/2011 1.3 1.3 5.29 FALSE TRUE Change +Price
408050 9/1/2011 5.29 5.29 5.29 FALSE TRUE Change +Subsidy +Alternate
408638 2/1/1996 11/1/1997 30.71 30.71 30.71 FALSE FALSE New Listing
408638 11/1/1997 2/1/2000 30.69 30.69 30.69 FALSE FALSE Change -Subsidy -Price -Alternate
408638 2/1/2000 9/1/2002 24.88 24.88 30.69 FALSE FALSE Change -Subsidy -Price -Alternate
408638 9/1/2002 4/1/2005 30.53 30.53 30.69 FALSE FALSE Change +Subsidy +Alternate
408638 4/1/2005 8/1/2006 30.69 30.69 30.69 FALSE FALSE Change +Subsidy +Alternate
408638 8/1/2006 11/1/2006 25.92 25.92 30.69 FALSE FALSE Change -Subsidy -Alternate
408638 11/1/2006 0 0 0 FALSE FALSE Delisted
409200 7/1/2000 12/1/2003 3.36 3.36 3.36 FALSE FALSE New Listing
409200 12/1/2003 0 0 0 FALSE FALSE Delisted
409308 9/1/2000 10/1/2006 3.51 3.51 3.51 FALSE FALSE New Listing
409308 10/1/2006 1/1/2007 2.49 2.49 3.51 FALSE FALSE Change -Subsidy -Alternate
409308 1/1/2007 0 0 0 FALSE FALSE Delisted
409324 7/1/2014 0 0 0 FALSE FALSE New listing
409359 6/1/1995 5/1/1999 7.5 7.5 7.5 FALSE TRUE New Listing
409359 5/1/1999 6/1/1999 7.5 7.5 8.3 FALSE TRUE Change +Price
409359 6/1/1999 9/1/1999 7.5 7.5 8.6 FALSE TRUE Change +Price
409359 9/1/1999 11/1/2003 6.13 6.13 8.6 FALSE TRUE Change -Subsidy -Alternate
409359 11/1/2003 0 0 0 FALSE FALSE Delisted
409367 6/1/1995 5/1/1999 7.5 7.5 7.5 FALSE TRUE New Listing
409367 5/1/1999 6/1/1999 7.5 7.5 8.3 FALSE TRUE Change +Price
409367 6/1/1999 9/1/1999 7.5 7.5 8.6 FALSE TRUE Change +Price
409367 9/1/1999 6/1/2004 6.13 6.13 8.6 FALSE TRUE Change -Subsidy -Alternate
409367 6/1/2004 10/1/2010 4.75 4.75 7.22 FALSE TRUE Change -Subsidy -Price -Alternate
409367 10/1/2010 3/1/2012 4.22 4.22 4.22 FALSE TRUE Change -Subsidy -Price -Alternate
409367 3/1/2012 0 0 0 FALSE FALSE Delisted
409375 7/1/1996 5/1/1999 7.5 7.5 7.5 FALSE TRUE New Listing
409375 5/1/1999 6/1/1999 7.5 7.5 8.3 FALSE TRUE Change +Price
409375 6/1/1999 9/1/1999 7.5 7.5 8.6 FALSE TRUE Change +Price
409375 9/1/1999 6/1/2004 6.13 6.13 8.6 FALSE TRUE Change -Subsidy -Alternate
409375 6/1/2004 10/1/2010 4.75 4.75 7.22 FALSE TRUE Change -Subsidy -Price -Alternate
409375 10/1/2010 3/1/2012 4.22 4.22 4.22 FALSE TRUE Change -Subsidy -Price -Alternate
409375 3/1/2012 0 0 0 FALSE FALSE Delisted
409448 2/1/2010 2/1/2013 13.34 13.34 13.34 FALSE TRUE New listing
409448 2/1/2013 0 0 0 FALSE FALSE Delisted
409499 10/1/1997 2/1/1998 100 100 100 FALSE FALSE New Listing
409499 2/1/1998 8/1/2000 50 50 50 FALSE FALSE Change -Subsidy -Price -Alternate
409499 8/1/2000 10/1/2003 8.9 8.9 8.9 FALSE FALSE Change -Subsidy -Price -Alternate
409499 10/1/2003 5/1/2004 22.1 22.1 22.1 FALSE FALSE Change +Subsidy +Price +Alternate
409499 5/1/2004 8/1/2004 16.91 16.91 22.1 FALSE FALSE Change -Subsidy -Alternate
409499 8/1/2004 0 0 0 FALSE FALSE Delisted
409510 3/1/1997 2/1/1999 46.66 46.66 46.66 FALSE FALSE New Listing
409510 2/1/1999 2/1/2000 33.6 33.6 33.6 FALSE FALSE Change -Subsidy -Price -Alternate
409510 2/1/2000 8/1/2000 13.44 13.44 33.6 FALSE FALSE Change -Subsidy -Alternate
409510 8/1/2000 9/1/2000 8.5 8.5 33.6 FALSE FALSE Change -Subsidy -Alternate
409510 9/1/2000 12/1/2000 7.5 7.5 33.6 FALSE FALSE Change -Subsidy -Alternate
409510 12/1/2000 11/1/2002 16.8 16.8 33.6 FALSE FALSE Change +Subsidy +Alternate
409510 11/1/2002 2/1/2003 4.9 4.9 33.6 FALSE FALSE Change -Subsidy -Alternate
409510 2/1/2003 0 0 0 FALSE FALSE Delisted
409634 5/16/1994 5/12/1995 38.11 38.11 38.11 FALSE FALSE New Listing
409634 5/12/1995 5/1/1998 38.11 38.11 38.89 FALSE FALSE Change +Price
409634 5/1/1998 8/1/1998 15.27 15.27 15.27 FALSE FALSE Change -Subsidy -Price -Alternate
409634 8/1/1998 0 0 0 FALSE FALSE Delisted
409642 5/16/1994 5/12/1995 20.82 20.82 20.82 FALSE FALSE New Listing
409642 5/12/1995 5/1/1998 20.82 20.82 21.24 FALSE FALSE Change +Price
409642 5/1/1998 8/1/1998 8.75 8.75 8.75 FALSE FALSE Change -Subsidy -Price -Alternate
409642 8/1/1998 0 0 0 FALSE FALSE Delisted
410225 12/1/1996 3/1/1998 8.25 8.25 11 FALSE TRUE New Listing
410225 3/1/1998 8/1/2000 7.75 7.75 11 FALSE TRUE Change -Subsidy -Alternate
410225 8/1/2000 12/1/2000 7 7 11 FALSE TRUE Change -Subsidy -Alternate
410225 12/1/2000 0 0 0 FALSE FALSE Delisted
410268 5/1/1995 12/1/1996 10 10 10 FALSE TRUE New Listing
410268 12/1/1996 3/1/1998 8.25 8.25 10 FALSE TRUE Change -Subsidy -Alternate
410268 3/1/1998 8/1/2000 7.75 7.75 10 FALSE TRUE Change -Subsidy -Alternate
410268 8/1/2000 12/1/2000 7 7 10 FALSE TRUE Change -Subsidy -Alternate
410268 12/1/2000 0 0 0 FALSE FALSE Delisted
410284 12/1/1996 4/1/2006 4.12 4.12 4.12 FALSE FALSE New Listing
410284 4/1/2006 6/1/2009 4.12 4.12 5.14 FALSE FALSE Change +Price
410284 6/1/2009 1/1/2014 4.12 4.12 11.48 FALSE FALSE Change +Price
410284 1/1/2014 0 0 0 FALSE FALSE Delisted
410292 12/1/1996 4/1/2006 3.01 3.01 3.01 FALSE FALSE New Listing
410292 4/1/2006 6/1/2009 3.01 3.01 3.75 FALSE FALSE Change +Price
410292 6/1/2009 1/1/2014 3.01 3.01 11.48 FALSE FALSE Change +Price
410292 1/1/2014 0 0 0 FALSE FALSE Delisted
410314 12/1/1996 5/1/2006 7.05 7.05 7.05 FALSE FALSE New Listing
410314 5/1/2006 0 0 0 FALSE FALSE Delisted
410322 3/1/1995 6/27/1995 10 10 10 FALSE TRUE New Listing
410322 6/27/1995 5/1/1996 30 30 30 FALSE TRUE Change +Subsidy +Price +Alternate
410322 5/1/1996 12/1/1996 10 10 10 FALSE TRUE Change -Subsidy -Price -Alternate
410322 12/1/1996 3/1/1998 8.25 8.25 10 FALSE TRUE Change -Subsidy -Alternate
410322 3/1/1998 8/1/2000 7.75 7.75 7.75 FALSE TRUE Change -Subsidy -Price -Alternate
410322 8/1/2000 10/1/2002 7 7 7.75 FALSE TRUE Change -Subsidy -Alternate
410322 10/1/2002 5/1/2004 5.4 5.4 7.75 FALSE TRUE Change -Subsidy -Alternate
410322 5/1/2004 0 0 0 FALSE FALSE Delisted
410357 3/1/1995 6/27/1995 7.07 7.07 7.07 FALSE TRUE New Listing
410357 6/27/1995 5/1/1996 21.21 21.21 21.21 FALSE TRUE Change +Subsidy +Price +Alternate
410357 5/1/1996 10/1/1996 7.07 7.07 7.07 FALSE TRUE Change -Subsidy -Price -Alternate
410357 10/1/1996 12/1/1996 7.07 7.07 8.5 FALSE TRUE Change +Price
410357 12/1/1996 3/1/1998 8.25 8.25 8.5 FALSE TRUE Change +Subsidy +Alternate
410357 3/1/1998 8/1/2000 7.75 7.75 7.75 FALSE TRUE Change -Subsidy -Price -Alternate
410357 8/1/2000 10/1/2002 7 7 7.75 FALSE TRUE Change -Subsidy -Alternate
410357 10/1/2002 5/1/2004 5.4 5.4 7.75 FALSE TRUE Change -Subsidy -Alternate
410357 5/1/2004 0 0 0 FALSE FALSE Delisted
410470 6/1/1995 5/1/1999 4.47 4.47 4.47 FALSE TRUE New Listing
410470 5/1/1999 7/1/1999 4.47 4.47 5.15 FALSE TRUE Change +Price
410470 7/1/1999 6/1/2001 2.81 2.81 5.15 FALSE TRUE Change -Subsidy -Alternate
410470 6/1/2001 0 0 0 FALSE FALSE Delisted
410691 3/1/1997 4/1/2000 9.45 9.45 9.45 FALSE TRUE New Listing
410691 4/1/2000 4/1/2003 9.45 9.45 9.45 FALSE FALSE Change -OP
410691 4/1/2003 6.62 6.62 6.62 FALSE FALSE Change -Subsidy -Price -Alternate
411388 3/1/1997 8/1/1998 2.48 2.48 2.48 FALSE FALSE New Listing
411388 8/1/1998 2/1/2000 1.75 1.75 2.48 FALSE FALSE Change -Subsidy -Alternate
411388 2/1/2000 6/1/2000 1.1 1.1 2.48 FALSE FALSE Change -Subsidy -Alternate
411388 6/1/2000 0 0 0 FALSE FALSE Delisted
412325 6/1/1997 5/1/2000 19.9 19.9 19.9 FALSE FALSE New Listing
412325 5/1/2000 9/1/2002 9 19.9 19.9 FALSE FALSE Change -Subsidy
412325 9/1/2002 5/1/2009 9.5 9.5 9.5 FALSE FALSE Change +Subsidy -Price -Alternate
412325 5/1/2009 7/1/2012 8.95 8.95 8.95 FALSE FALSE Change -Subsidy -Price -Alternate
412325 7/1/2012 6.55 6.55 6.55 FALSE FALSE Change -Subsidy -Price -Alternate
412341 6/1/1997 5/1/2000 9.95 9.95 9.95 FALSE FALSE New Listing
412341 5/1/2000 9/1/2002 6.5 9.95 9.95 FALSE FALSE Change -Subsidy
412341 9/1/2002 1/1/2005 6.86 6.86 6.86 FALSE FALSE Change +Subsidy -Price -Alternate
412341 1/1/2005 5/1/2009 6.52 6.52 6.52 FALSE FALSE Change -Subsidy -Price -Alternate
412341 5/1/2009 5.55 5.55 5.55 FALSE FALSE Change -Subsidy -Price -Alternate
413453 6/1/1995 7/1/1997 1.8 1.8 1.8 FALSE TRUE New Listing
413453 7/1/1997 5/1/1999 1.36 1.36 1.36 FALSE TRUE Change -Subsidy -Price -Alternate
413453 5/1/1999 12/1/2006 1.12 1.12 1.12 FALSE TRUE Change -Subsidy -Price -Alternate
413453 12/1/2006 0 0 0 FALSE FALSE Delisted
413631 6/1/1995 7/1/1997 1.8 1.8 1.8 FALSE TRUE New Listing
413631 7/1/1997 5/1/1999 1.36 1.36 1.36 FALSE TRUE Change -Subsidy -Price -Alternate
413631 5/1/1999 12/1/2006 1.12 1.12 1.12 FALSE TRUE Change -Subsidy -Price -Alternate
413631 12/1/2006 0 0 0 FALSE FALSE Delisted
413658 11/1/1997 9/1/2006 1.5 1.5 1.5 FALSE TRUE New Listing
413658 9/1/2006 0 0 0 FALSE FALSE Delisted
413739 6/1/1995 5/1/1998 2.78 2.78 2.78 FALSE TRUE New Listing
413739 5/1/1998 0 0 0 FALSE FALSE Delisted
413755 6/1/1995 12/1/2000 4.75 4.75 4.75 FALSE TRUE New Listing
413755 12/1/2000 4/1/2006 3.5 3.5 3.5 FALSE TRUE Change -Subsidy -Price -Alternate
413755 4/1/2006 0 0 0 FALSE FALSE Delisted
413763 6/1/1995 12/1/2000 9.5 9.5 9.5 FALSE TRUE New Listing
413763 12/1/2000 4/1/2006 7 7 7 FALSE TRUE Change -Subsidy -Price -Alternate
413763 4/1/2006 4/1/2012 0 0 0 FALSE FALSE Delisted
413763 4/1/2012 7 7 7 FALSE FALSE New Listing
413798 11/1/1997 12/1/2000 6.5 6.5 6.5 FALSE TRUE New Listing
413798 12/1/2000 9/1/2002 6.08 6.08 6.08 FALSE TRUE Change -Subsidy -Price -Alternate
413798 9/1/2002 0 0 0 FALSE FALSE Delisted
413844 6/1/1995 11/1/1999 12.04 12.04 12.04 FALSE TRUE New Listing
413844 11/1/1999 0 0 0 FALSE FALSE Delisted
413852 6/1/1995 11/1/1999 6.02 6.02 6.02 FALSE TRUE New Listing
413852 11/1/1999 0 0 0 FALSE FALSE Delisted
413860 6/1/1995 11/1/1999 5.86 5.86 5.86 FALSE TRUE New Listing
413860 11/1/1999 0 0 0 FALSE FALSE Delisted
413933 6/1/1995 6/1/2008 25 25 25 FALSE TRUE New Listing
413933 6/1/2008 30 30 30 FALSE TRUE Change +Subsidy +Price +Alternate
413992 6/1/1995 7/1/1999 2.78 2.78 2.78 FALSE TRUE New Listing
413992 7/1/1999 9/1/2013 2.65 2.65 2.65 FALSE TRUE Change -Subsidy -Price -Alternate
413992 9/1/2013 0 0 0 FALSE FALSE Delisted
414018 6/1/1995 7/1/1999 5.55 5.55 8.5 FALSE TRUE New Listing
414018 7/1/1999 5.29 5.29 5.29 FALSE TRUE Change -Subsidy -Price -Alternate
414085 10/1/1997 10/1/2004 5.38 5.38 5.38 FALSE TRUE New Listing
414085 10/1/2004 0 0 0 FALSE FALSE Delisted
414093 10/1/1997 10/1/2004 5.38 5.38 5.38 FALSE TRUE New Listing
414093 10/1/2004 0 0 0 FALSE FALSE Delisted
415855 5/1/1997 6/1/2001 123 123 123 FALSE FALSE New Listing
415855 6/1/2001 2/1/2002 123 123 160 FALSE FALSE Change +Price
415855 2/1/2002 0 0 0 FALSE FALSE Delisted
416762 4/1/1997 10/1/1998 47.7 47.7 47.7 FALSE FALSE New Listing
416762 10/1/1998 4/1/1999 46.02 46.02 47.7 FALSE FALSE Change -Subsidy -Alternate
416762 4/1/1999 0 0 0 FALSE FALSE Delisted
416991 8/1/2009 7/1/2012 78.85 78.85 78.85 FALSE FALSE New listing
416991 7/1/2012 74.91 74.91 74.91 FALSE FALSE Change -Subsidy -Price -Alternate
417009 8/1/2009 7/1/2012 105.12 105.12 105.12 FALSE FALSE New listing
417009 7/1/2012 99.86 99.86 99.86 FALSE FALSE Change -Subsidy -Price -Alternate
417017 8/1/2009 7/1/2012 135.2 135.2 135.2 FALSE FALSE New listing
417017 7/1/2012 125.06 125.06 125.06 FALSE FALSE Change -Subsidy -Price -Alternate
417289 4/12/1995 8/1/1999 0.04 0.04 0.04 TRUE FALSE New Listing
417289 8/1/1999 0 0 0 FALSE FALSE Delisted
417300 4/12/1995 8/1/1999 0.02 0.02 0.02 TRUE FALSE New Listing
417300 8/1/1999 0 0 0 FALSE FALSE Delisted
417866 4/1/1997 9/1/2000 51.07 51.07 51.07 FALSE FALSE New Listing
417866 9/1/2000 7/1/2007 51.07 51.07 51.07 FALSE FALSE Change
417866 7/1/2007 29.09 29.09 29.09 FALSE FALSE Change -Subsidy -Price -Alternate
418021 4/1/1997 9/1/2000 86.82 86.82 86.82 FALSE FALSE New Listing
418021 9/1/2000 7/1/2007 86.82 86.82 86.82 FALSE FALSE Change
418021 7/1/2007 47.89 47.89 47.89 FALSE FALSE Change -Subsidy -Price -Alternate
418498 4/1/1997 9/1/2000 149.81 149.81 149.81 FALSE FALSE New Listing
418498 9/1/2000 7/1/2007 149.81 149.81 149.81 FALSE FALSE Change
418498 7/1/2007 79.16 79.16 79.16 FALSE FALSE Change -Subsidy -Price -Alternate
421405 2/1/1999 10/1/2001 153.06 153.06 153.06 FALSE FALSE New Listing
421405 10/1/2001 0 0 0 FALSE FALSE Delisted
421464 9/1/1997 3/1/2005 19.9 19.9 19.9 FALSE FALSE New Listing
421464 3/1/2005 1/1/2007 15.92 15.92 15.92 FALSE FALSE Change -Subsidy -Price -Alternate
421464 1/1/2007 0 0 0 FALSE FALSE Delisted
421472 9/1/1997 3/1/2005 19.9 19.9 19.9 FALSE FALSE New Listing
421472 3/1/2005 1/1/2007 15.92 15.92 15.92 FALSE FALSE Change -Subsidy -Price -Alternate
421472 1/1/2007 0 0 0 FALSE FALSE Delisted
421480 9/1/1997 3/1/2005 19.9 19.9 19.9 FALSE FALSE New Listing
421480 3/1/2005 1/1/2007 15.92 15.92 15.92 FALSE FALSE Change -Subsidy -Price -Alternate
421480 1/1/2007 0 0 0 FALSE FALSE Delisted
421812 7/1/1999 133 133 133 FALSE FALSE New Listing
421979 4/11/1995 8/1/1999 3.6 3.6 3.6 FALSE FALSE New Listing
421979 8/1/1999 0 0 0 FALSE FALSE Delisted
422428 4/12/1995 10/1/1996 0 0 0 TRUE FALSE New Listing
422428 10/1/1996 1/1/1997 11.94 11.94 11.94 TRUE FALSE Change +Subsidy +Price +Alternate
422428 1/1/1997 8/1/1999 13.2 13.2 13.2 TRUE FALSE Change +Subsidy +Price +Alternate
422428 8/1/1999 0 0 0 FALSE FALSE Delisted
422452 4/11/1995 12/1/1997 9.02 9.02 9.02 FALSE FALSE New Listing
422452 12/1/1997 11/1/1999 4.35 4.35 4.35 FALSE FALSE Change -Subsidy -Price -Alternate
422452 11/1/1999 4/1/2001 2.97 2.97 2.97 FALSE FALSE Change -Subsidy -Price -Alternate
422452 4/1/2001 5/1/2001 2.8 2.8 2.97 FALSE FALSE Change -Subsidy -Alternate
422452 5/1/2001 2/1/2007 2.8 2.8 4.35 FALSE FALSE Change +Price
422452 2/1/2007 7/1/2007 4.35 4.35 4.35 FALSE FALSE Change +Subsidy +Alternate
422452 7/1/2007 7/1/2010 3.5 3.5 3.5 FALSE FALSE Change -Subsidy -Price -Alternate
422452 7/1/2010 3.15 3.15 3.15 FALSE FALSE Change -Subsidy -Price -Alternate
422762 4/11/1995 8/1/1999 18 18 14.41 FALSE FALSE New Listing
422762 8/1/1999 0 0 0 FALSE FALSE Delisted
422770 4/11/1995 8/1/1999 4.2 4.2 4.2 FALSE FALSE New Listing
422770 8/1/1999 0 0 0 FALSE FALSE Delisted
422789 4/11/1995 8/1/1999 21 21 18.63 FALSE FALSE New Listing
422789 8/1/1999 0 0 0 FALSE FALSE Delisted
422851 5/1/1997 9/1/1997 17.24 17.24 17.24 FALSE FALSE New Listing
422851 9/1/1997 1/1/1998 28.73 28.73 17.24 FALSE FALSE Change +Subsidy +Alternate
422851 1/1/1998 2/1/1998 23 23 23 FALSE FALSE Change -Subsidy +Price -Alternate
422851 2/1/1998 9/1/1998 17.24 17.24 17.24 FALSE FALSE Change -Subsidy -Price -Alternate
422851 9/1/1998 8/1/2000 16.73 16.73 16.73 FALSE FALSE Change -Subsidy -Price -Alternate
422851 8/1/2000 12/1/2000 10.29 10.29 16.73 FALSE FALSE Change -Subsidy -Alternate
422851 12/1/2000 0 0 0 FALSE FALSE Delisted
423092 5/1/1997 9/1/1997 17.16 17.16 17.16 FALSE FALSE New Listing
423092 9/1/1997 1/1/1998 28.6 28.6 17.16 FALSE FALSE Change +Subsidy +Alternate
423092 1/1/1998 2/1/1998 21.5 21.5 21.5 FALSE FALSE Change -Subsidy +Price -Alternate
423092 2/1/1998 9/1/1998 17.16 17.16 17.16 FALSE FALSE Change -Subsidy -Price -Alternate
423092 9/1/1998 8/1/2000 16.73 16.73 16.73 FALSE FALSE Change -Subsidy -Price -Alternate
423092 8/1/2000 12/1/2000 7.98 7.98 16.73 FALSE FALSE Change -Subsidy -Alternate
423092 12/1/2000 0 0 0 FALSE FALSE Delisted
423351 5/1/2008 1.11 1.11 1.11 FALSE FALSE New listing
423378 7/1/2005 7/1/2006 500 500 500 FALSE FALSE New listing
423378 7/1/2006 8/1/2010 310 310 310 FALSE FALSE Change -Subsidy -Price -Alternate
423378 8/1/2010 100 100 100 FALSE FALSE Change -Subsidy -Price -Alternate
423416 7/1/1997 8/1/1998 25.04 25.04 25.04 FALSE FALSE New Listing
423416 8/1/1998 4/1/2001 9.32 25.04 25.04 FALSE FALSE Change -Subsidy
423416 4/1/2001 10/1/2001 3.88 25.04 25.04 FALSE FALSE Change -Subsidy
423416 10/1/2001 1/1/2002 1.86 1.86 25.04 FALSE FALSE Change -Subsidy -Alternate
423416 1/1/2002 0 0 0 FALSE FALSE Delisted
423424 7/1/1997 8/1/1998 47.57 47.57 47.57 FALSE FALSE New Listing
423424 8/1/1998 4/1/2001 17.71 47.57 47.57 FALSE FALSE Change -Subsidy
423424 4/1/2001 10/1/2001 7.38 47.57 47.57 FALSE FALSE Change -Subsidy
423424 10/1/2001 1/1/2002 3.36 3.36 47.57 FALSE FALSE Change -Subsidy -Alternate
423424 1/1/2002 0 0 0 FALSE FALSE Delisted
423432 7/1/1997 8/1/1998 15.35 15.35 15.35 FALSE FALSE New Listing
423432 8/1/1998 4/1/2001 5.72 15.35 15.35 FALSE FALSE Change -Subsidy
423432 4/1/2001 10/1/2001 2.38 15.35 15.35 FALSE FALSE Change -Subsidy
423432 10/1/2001 1/1/2002 1.32 1.32 15.35 FALSE FALSE Change -Subsidy -Alternate
423432 1/1/2002 0 0 0 FALSE FALSE Delisted
423440 7/1/1997 8/1/1998 13.7 13.7 13.7 FALSE FALSE New Listing
423440 8/1/1998 5/1/2000 5.26 5.26 13.7 FALSE FALSE Change -Subsidy -Alternate
423440 5/1/2000 0 0 0 FALSE FALSE Delisted
423947 1/1/2001 11/1/2002 9 9 9 FALSE FALSE New Listing
423947 11/1/2002 0 0 0 FALSE FALSE Delisted
424374 5/16/1994 7/1/1996 4.5 4.5 4.5 FALSE TRUE New Listing
424374 7/1/1996 9/1/1997 4.5 4.5 5.3 FALSE TRUE Change +Price
424374 9/1/1997 9/1/1999 4.5 4.5 6.3 FALSE TRUE Change +Price
424374 9/1/1999 0 0 0 FALSE FALSE Delisted
424463 6/1/1998 12/1/2000 27.15 27.15 27.15 FALSE FALSE New Listing
424463 12/1/2000 0 0 0 FALSE FALSE Delisted
424498 6/1/1998 4/1/2002 54.3 54.3 54.3 FALSE FALSE New Listing
424498 4/1/2002 0 0 0 FALSE FALSE Delisted
424501 6/1/1998 4/1/2002 75.89 75.89 75.89 FALSE FALSE New Listing
424501 4/1/2002 0 0 0 FALSE FALSE Delisted
424544 7/1/1997 8/1/1998 10.19 10.19 10.19 FALSE TRUE New Listing
424544 8/1/1998 3/1/1999 9.17 9.17 9.17 FALSE TRUE Change -Subsidy -Price -Alternate
424544 3/1/1999 4/1/1999 8.71 8.71 9.17 FALSE TRUE Change -Subsidy -Alternate
424544 4/1/1999 8.71 8.71 8.71 FALSE TRUE Change -Price
424730 7/1/1997 10/1/1997 7.29 7.29 10.85 FALSE TRUE New Listing
424730 10/1/1997 10/1/1998 6.55 6.55 10.85 FALSE TRUE Change -Subsidy -Alternate
424730 10/1/1998 1/1/2002 5.91 5.91 10.85 FALSE TRUE Change -Subsidy -Alternate
424730 1/1/2002 12/1/2002 5.91 5.91 11.95 FALSE TRUE Change +Price
424730 12/1/2002 11/1/2010 5.91 5.91 12.38 FALSE TRUE Change +Price
424730 11/1/2010 2/1/2011 4.05 4.05 12.38 FALSE TRUE Change -Subsidy -Alternate
424730 2/1/2011 0 0 0 FALSE FALSE Delisted
424803 1/1/2006 5249.72 5249.72 5249.72 FALSE FALSE New listing
425303 9/1/1997 8/1/2000 60 60 60 FALSE FALSE New Listing
425303 8/1/2000 2/1/2001 60 60 69 FALSE FALSE Change +Price
425303 2/1/2001 0 0 0 FALSE FALSE Delisted
425672 5/1/1999 6/1/1999 67.08 67.08 67.08 FALSE TRUE New Listing
425672 6/1/1999 4/1/2011 63.97 63.97 67.08 FALSE TRUE Change -Subsidy -Alternate
425672 4/1/2011 8/1/2012 56 56 56 FALSE TRUE Change -Subsidy -Price -Alternate
425672 8/1/2012 7/1/2013 53 53 53 FALSE TRUE Change -Subsidy -Price -Alternate
425672 7/1/2013 0 0 0 FALSE FALSE Delisted
425826 5/16/1994 12/1/2002 116.2 116.2 116.2 FALSE FALSE New Listing
425826 12/1/2002 0 0 0 FALSE FALSE Delisted
425869 3/1/1996 4/1/1998 32.38 32.38 32.38 FALSE FALSE New Listing
425869 4/1/1998 11/1/2007 32.38 32.38 32.38 FALSE FALSE Change +Subsidy +Price +Alternate
425869 11/1/2007 4/1/2009 33.89 33.89 33.89 FALSE FALSE Change +Subsidy +Price +Alternate
425869 4/1/2009 30.5 30.5 30.5 FALSE FALSE Change -Subsidy -Price -Alternate
425877 3/1/1996 11/1/2007 26.5 26.5 26.5 FALSE FALSE New Listing
425877 11/1/2007 4/1/2009 27.83 27.83 27.83 FALSE FALSE Change +Subsidy +Price +Alternate
425877 4/1/2009 25.05 25.05 25.05 FALSE FALSE Change -Subsidy -Price -Alternate
426202 6/1/1997 11/1/2008 242.55 242.55 242.55 FALSE FALSE New Listing
426202 11/1/2008 0 0 0 FALSE FALSE Delisted
426342 7/1/1997 8/1/2002 85.5 85.5 85.5 FALSE FALSE New Listing
426342 8/1/2002 59.86 59.86 59.86 FALSE FALSE Change -Subsidy -Price -Alternate
426350 7/1/1997 1/1/1998 72.8 72.8 72.8 FALSE FALSE New Listing
426350 1/1/1998 9/1/1998 56 56 56 FALSE FALSE Change -Subsidy -Price -Alternate
426350 9/1/1998 4/1/1999 36.4 36.4 36.4 FALSE FALSE Change -Subsidy -Price -Alternate
426350 4/1/1999 4/1/2001 39.2 39.2 39.2 FALSE FALSE Change +Subsidy +Price +Alternate
426350 4/1/2001 11/1/2002 26.13 26.13 26.13 FALSE FALSE Change -Subsidy -Price -Alternate
426350 11/1/2002 7/1/2004 13.23 13.23 26.13 FALSE FALSE Change -Subsidy -Alternate
426350 7/1/2004 7/1/2005 7.8 7.8 26.13 FALSE FALSE Change -Subsidy -Alternate
426350 7/1/2005 10/1/2006 6.51 6.51 26.13 FALSE FALSE Change -Subsidy -Alternate
426350 10/1/2006 3/1/2008 4.79 4.79 26.13 FALSE FALSE Change -Subsidy -Alternate
426350 3/1/2008 6/1/2008 3.36 3.36 26.13 FALSE FALSE Change -Subsidy -Alternate
426350 6/1/2008 0 0 0 FALSE FALSE Delisted
426393 7/1/1997 2/1/1998 25.12 25.12 25.12 FALSE FALSE New Listing
426393 2/1/1998 2/1/1999 12.56 12.56 12.56 FALSE FALSE Change -Subsidy -Price -Alternate
426393 2/1/1999 8/1/2000 6.28 6.28 6.28 FALSE FALSE Change -Subsidy -Price -Alternate
426393 8/1/2000 12/1/2000 2.6 2.6 6.28 FALSE FALSE Change -Subsidy -Alternate
426393 12/1/2000 0 0 0 FALSE FALSE Delisted
426482 7/1/1997 2/1/1998 47.7 47.7 47.7 FALSE FALSE New Listing
426482 2/1/1998 2/1/1999 23.85 23.85 23.85 FALSE FALSE Change -Subsidy -Price -Alternate
426482 2/1/1999 8/1/2000 11.93 11.93 11.93 FALSE FALSE Change -Subsidy -Price -Alternate
426482 8/1/2000 12/1/2000 2.99 2.99 11.93 FALSE FALSE Change -Subsidy -Alternate
426482 12/1/2000 0 0 0 FALSE FALSE Delisted
426490 7/1/1997 10/1/2007 8.11 8.11 8.11 FALSE FALSE New Listing
426490 10/1/2007 16.6 16.6 16.6 FALSE FALSE Change +Subsidy +Price +Alternate
426504 8/1/1997 9/1/2002 60 60 60 FALSE FALSE New Listing
426504 9/1/2002 10/1/2007 45 45 45 FALSE FALSE Change -Subsidy -Price -Alternate
426504 10/1/2007 0 0 0 FALSE FALSE Delisted
427365 4/12/1995 10/1/1996 14.6 14.6 14.6 FALSE FALSE New Listing
427365 10/1/1996 0 0 0 FALSE FALSE Delisted
427454 9/1/1997 6/1/1998 7 7 7 FALSE TRUE New Listing
427454 6/1/1998 9/1/2008 4.5 4.5 7 FALSE TRUE Change -Subsidy -Alternate
427454 9/1/2008 0 0 0 FALSE FALSE Delisted
427527 5/1/1999 9/1/2000 4.34 4.34 9.4 FALSE FALSE New Listing
427527 9/1/2000 0 0 0 FALSE FALSE Delisted
427721 7/1/1997 12/1/2004 4.5 4.5 4.5 FALSE TRUE New Listing
427721 12/1/2004 3/1/2005 1.45 1.45 4.5 FALSE TRUE Change -Subsidy -Alternate
427721 3/1/2005 0 0 0 FALSE FALSE Delisted
427748 7/1/1997 12/1/2004 11 11 11 FALSE FALSE New Listing
427748 12/1/2004 3/1/2005 5.8 5.8 11 FALSE FALSE Change -Subsidy -Alternate
427748 3/1/2005 7/1/2007 0 0 0 FALSE FALSE Delisted
427748 7/1/2007 6/1/2010 4.99 4.99 4.99 FALSE FALSE New Listing
427748 6/1/2010 10/1/2010 4.99 4.99 4.99 FALSE TRUE Change +OP
427748 10/1/2010 1/1/2011 3.79 3.79 4.99 FALSE TRUE Change -Subsidy -Alternate
427748 1/1/2011 0 0 0 FALSE FALSE Delisted
427802 2/1/1998 8/1/2000 2.9 2.9 4.83 FALSE FALSE New Listing
427802 8/1/2000 2.9 2.9 6 FALSE FALSE Change +Price
427918 2/1/1999 12/1/1999 163.5 163.5 163.5 FALSE FALSE New Listing
427918 12/1/1999 9/1/2004 120.49 120.49 120.49 FALSE FALSE Change -Subsidy -Price -Alternate
427918 9/1/2004 9/1/2007 108.44 108.44 108.44 FALSE FALSE Change -Subsidy -Price -Alternate
427918 9/1/2007 0 0 0 FALSE FALSE Delisted
427926 2/1/1999 12/1/1999 283.8 283.8 283.8 FALSE FALSE New Listing
427926 12/1/1999 9/1/2004 243.44 243.44 243.44 FALSE FALSE Change -Subsidy -Price -Alternate
427926 9/1/2004 9/1/2007 219.1 219.1 219.1 FALSE FALSE Change -Subsidy -Price -Alternate
427926 9/1/2007 0 0 0 FALSE FALSE Delisted
427942 5/16/1994 11/1/2002 291 291 291 FALSE FALSE New Listing
427942 11/1/2002 5/1/2003 240 240 240 FALSE FALSE Change -Subsidy -Price -Alternate
427942 5/1/2003 0 0 0 FALSE FALSE Delisted
427950 5/16/1994 11/1/2002 582 582 582 FALSE FALSE New Listing
427950 11/1/2002 5/1/2003 480 480 480 FALSE FALSE Change -Subsidy -Price -Alternate
427950 5/1/2003 0 0 0 FALSE FALSE Delisted
428736 4/11/1995 2/1/1998 32.1 32.1 32.1 FALSE FALSE New Listing
428736 2/1/1998 0 0 0 FALSE FALSE Delisted
428841 4/11/1995 8/1/1999 7.31 7.31 7.31 FALSE FALSE New Listing
428841 8/1/1999 0 0 0 FALSE FALSE Delisted
428914 6/8/1995 7/1/1997 14.2 14.2 14.2 FALSE FALSE New Listing
428914 7/1/1997 8/1/1999 14.2 14.2 15.62 FALSE FALSE Change +Price
428914 8/1/1999 4/1/2000 15.62 15.62 15.62 FALSE FALSE Change +Subsidy +Alternate
428914 4/1/2000 5/1/2001 15.62 15.62 16.9 FALSE FALSE Change +Price
428914 5/1/2001 7/1/2008 15.62 15.62 18.45 FALSE FALSE Change +Price
428914 7/1/2008 12/1/2010 10 10 18.45 FALSE FALSE Change -Subsidy -Alternate
428914 12/1/2010 8 8 8 FALSE FALSE Change -Subsidy -Price -Alternate
429198 4/12/1995 7/1/1997 65.78 65.78 65.78 FALSE FALSE New Listing
429198 7/1/1997 8/1/1999 65.78 65.78 72.36 FALSE FALSE Change +Price
429198 8/1/1999 0 0 0 FALSE FALSE Delisted
429317 4/12/1995 8/1/1999 0.14 0.14 0.14 TRUE FALSE New Listing
429317 8/1/1999 0 0 0 FALSE FALSE Delisted
429368 9/1/1997 503.8 503.8 503.8 FALSE FALSE New Listing
429376 9/1/1997 6/1/2013 377.8 377.8 377.8 FALSE FALSE New Listing
429376 6/1/2013 0 0 0 FALSE FALSE Delisted
429392 9/1/1997 8/1/2011 317.1 317.1 317.1 FALSE FALSE New Listing
429392 8/1/2011 0 0 0 FALSE FALSE Delisted
429406 9/1/1997 12/1/2000 283.1 283.1 283.1 FALSE FALSE New Listing
429406 12/1/2000 0 0 0 FALSE FALSE Delisted
429414 9/1/1997 1/1/1999 100.76 100.76 100.76 FALSE FALSE New Listing
429414 1/1/1999 8/1/2011 100.76 100.76 100.76 FALSE TRUE Change +OP
429414 8/1/2011 4/1/2013 0 0 0 FALSE FALSE Delisted
429414 4/1/2013 100.76 100.76 100.76 FALSE TRUE New Listing
431311 4/11/1995 2/1/1998 35.6 35.6 35.6 FALSE FALSE New Listing
431311 2/1/1998 0 0 0 FALSE FALSE Delisted
431842 11/1/1999 2/1/2000 43.75 43.75 43.75 FALSE FALSE New Listing
431842 2/1/2000 8/1/2001 27.5 27.5 27.5 FALSE FALSE Change -Subsidy -Price -Alternate
431842 8/1/2001 1/1/2003 43.75 43.75 43.75 FALSE FALSE Change +Subsidy +Price +Alternate
431842 1/1/2003 6/1/2006 29.5 29.5 29.5 FALSE FALSE Change -Subsidy -Price -Alternate
431842 6/1/2006 2/1/2010 19 19 19 FALSE FALSE Change -Subsidy -Price -Alternate
431842 2/1/2010 5/1/2010 19 19 19 FALSE TRUE Change +OP
431842 5/1/2010 8/1/2010 14.25 14.25 14.25 FALSE TRUE Change -Subsidy -Price -Alternate
431842 8/1/2010 0 0 0 FALSE FALSE Delisted
431877 11/1/1999 2/1/2000 43.75 43.75 43.75 FALSE FALSE New Listing
431877 2/1/2000 8/1/2001 27.5 27.5 27.5 FALSE FALSE Change -Subsidy -Price -Alternate
431877 8/1/2001 1/1/2003 43.75 43.75 43.75 FALSE FALSE Change +Subsidy +Price +Alternate
431877 1/1/2003 4/1/2003 29.5 29.5 43.75 FALSE FALSE Change -Subsidy -Alternate
431877 4/1/2003 0 0 0 FALSE FALSE Delisted
433667 2/1/2000 8/1/2000 13.44 13.44 13.44 FALSE FALSE New Listing
433667 8/1/2000 9/1/2000 8.5 8.5 8.5 FALSE FALSE Change -Subsidy -Price -Alternate
433667 9/1/2000 1/1/2001 7.5 7.5 7.5 FALSE FALSE Change -Subsidy -Price -Alternate
433667 1/1/2001 9/1/2001 4.05 4.05 4.05 FALSE FALSE Change -Subsidy -Price -Alternate
433667 9/1/2001 4/1/2002 1.75 1.75 1.75 FALSE FALSE Change -Subsidy -Price -Alternate
433667 4/1/2002 0 0 0 FALSE FALSE Delisted
433748 4/1/2001 12/1/2003 13.8 13.8 13.8 FALSE FALSE New listing
433748 12/1/2003 10/1/2008 6.99 6.99 6.99 FALSE FALSE Change -Subsidy -Price -Alternate
433748 10/1/2008 9/1/2011 10.49 10.49 10.49 FALSE FALSE Change +Subsidy +Price +Alternate
433748 9/1/2011 7/1/2014 11.5 11.5 11.5 FALSE FALSE Change +Subsidy +Price +Alternate
433748 7/1/2014 10.35 10.35 10.35 FALSE FALSE Change -Subsidy -Price -Alternate
433802 10/1/2004 3/1/2005 16.36 16.36 16.36 FALSE FALSE New listing
433802 3/1/2005 9/1/2009 13.09 13.09 13.09 FALSE FALSE Change -Subsidy -Price -Alternate
433802 9/1/2009 11.75 11.75 11.75 FALSE FALSE Change -Subsidy -Price -Alternate
433934 5/1/2000 11/1/2004 12.65 12.65 12.65 FALSE FALSE New Listing
433934 11/1/2004 2/1/2006 11.5 11.5 11.5 FALSE FALSE Change -Subsidy -Price -Alternate
433934 2/1/2006 0 0 0 FALSE FALSE Delisted
434434 4/11/1995 2/1/1998 35.9 35.9 35.9 FALSE FALSE New Listing
434434 2/1/1998 0 0 0 FALSE FALSE Delisted
434566 4/12/1995 8/1/1999 6.1 6.1 6.1 TRUE FALSE New Listing
434566 8/1/1999 0 0 0 FALSE FALSE Delisted
435031 7/1/1996 0 0 0 TRUE TRUE New Listing
435309 3/1/2002 4/1/2007 12.5 12.5 12.5 FALSE TRUE New listing
435309 4/1/2007 10/1/2008 12.5 12.5 12.5 FALSE FALSE Change -OP
435309 10/1/2008 11.6 11.6 11.6 FALSE FALSE Change -Subsidy -Price -Alternate
435333 2/1/2000 3/1/2001 29.4 29.4 29.4 FALSE FALSE New Listing
435333 3/1/2001 1/1/2002 12.3 12.3 12.3 FALSE FALSE Change -Subsidy -Price -Alternate
435333 1/1/2002 4/1/2002 9.3 9.3 9.3 FALSE FALSE Change -Subsidy -Price -Alternate
435333 4/1/2002 2/1/2007 9.3 9.3 9.3 FALSE FALSE Change
435333 2/1/2007 0 0 0 FALSE FALSE Delisted
435368 2/1/2000 3/1/2001 76.5 76.5 76.5 FALSE FALSE New Listing
435368 3/1/2001 1/1/2002 32.1 32.1 32.1 FALSE FALSE Change -Subsidy -Price -Alternate
435368 1/1/2002 4/1/2002 24 24 24 FALSE FALSE Change -Subsidy -Price -Alternate
435368 4/1/2002 1/1/2003 24 24 24 FALSE FALSE Change
435368 1/1/2003 0 0 0 FALSE FALSE Delisted
435686 2/1/2000 3/1/2001 8.31 8.31 8.31 FALSE FALSE New Listing
435686 3/1/2001 1/1/2004 7.48 7.48 7.48 FALSE FALSE Change -Subsidy -Price -Alternate
435686 1/1/2004 4/1/2004 5.46 7.48 7.48 FALSE FALSE Change -Subsidy
435686 4/1/2004 0 0 0 FALSE FALSE Delisted
435694 2/1/2000 11/1/2000 2.92 2.92 2.92 FALSE FALSE New Listing
435694 11/1/2000 3/1/2001 2.63 2.63 2.63 FALSE FALSE Change -Subsidy -Price -Alternate
435694 3/1/2001 1/1/2004 2.37 2.37 2.37 FALSE FALSE Change -Subsidy -Price -Alternate
435694 1/1/2004 4/1/2004 1.61 2.37 2.37 FALSE FALSE Change -Subsidy
435694 4/1/2004 8/1/2005 0 0 0 FALSE FALSE Delisted
435694 8/1/2005 2/1/2006 2.37 2.37 2.37 FALSE FALSE New Listing
435694 2/1/2006 0 0 0 FALSE FALSE Delisted
435716 4/11/1995 6/10/1995 21.36 21.36 21.36 FALSE FALSE New Listing
435716 6/10/1995 6/24/1995 21.35 21.35 21.35 FALSE FALSE Change -Subsidy -Price -Alternate
435716 6/24/1995 2/1/1998 21.36 21.36 21.36 FALSE FALSE Change +Subsidy +Price +Alternate
435716 2/1/1998 0 0 0 FALSE FALSE Delisted
435724 2/1/2000 3/1/2001 4.99 4.99 4.99 FALSE FALSE New Listing
435724 3/1/2001 1/1/2004 4.49 4.49 4.49 FALSE FALSE Change -Subsidy -Price -Alternate
435724 1/1/2004 4/1/2004 2.29 4.49 4.49 FALSE FALSE Change -Subsidy
435724 4/1/2004 0 0 0 FALSE FALSE Delisted
435732 2/1/2000 1/1/2004 3.55 3.55 3.55 FALSE FALSE New Listing
435732 1/1/2004 4/1/2004 3.51 3.55 3.55 FALSE FALSE Change -Subsidy
435732 4/1/2004 0 0 0 FALSE FALSE Delisted
436445 8/1/2006 10/1/2010 5.4 5.4 5.4 FALSE FALSE New listing
436445 10/1/2010 1/1/2011 2.1 2.1 5.4 FALSE FALSE Change -Subsidy -Alternate
436445 1/1/2011 0 0 0 FALSE FALSE Delisted
436461 8/1/2006 11/1/2010 3.99 3.99 3.99 FALSE FALSE New listing
436461 11/1/2010 2/1/2011 2.57 2.57 3.99 FALSE FALSE Change -Subsidy -Alternate
436461 2/1/2011 0 0 0 FALSE FALSE Delisted
436534 7/1/2000 4/1/2003 14.22 26.8 26.8 FALSE FALSE New Listing
436534 4/1/2003 7/1/2006 14.22 14.22 28.94 FALSE FALSE Change +Price -Alternate
436534 7/1/2006 14.22 14.22 29.81 FALSE FALSE Change +Price
437026 5/16/1994 5/1/1999 22.4 22.4 22.4 FALSE FALSE New Listing
437026 5/1/1999 0 0 0 FALSE FALSE Delisted
437204 7/1/2000 9/1/2000 14.04 14.04 14.04 FALSE FALSE New Listing
437204 9/1/2000 7/1/2003 6.88 6.88 6.88 FALSE FALSE Change -Subsidy -Price -Alternate
437204 7/1/2003 8/1/2006 5.95 5.95 5.95 FALSE FALSE Change -Subsidy -Price -Alternate
437204 8/1/2006 7/1/2009 4.29 4.29 4.29 FALSE FALSE Change -Subsidy -Price -Alternate
437204 7/1/2009 3 3 3 FALSE FALSE Change -Subsidy -Price -Alternate
437212 9/1/2000 9/1/2008 41.2 41.2 41.2 FALSE FALSE New Listing
437212 9/1/2008 20.84 20.84 20.84 FALSE FALSE Change -Subsidy -Price -Alternate
437239 9/1/2000 9/1/2008 51.5 51.5 51.5 FALSE FALSE New Listing
437239 9/1/2008 26.04 26.04 26.04 FALSE FALSE Change -Subsidy -Price -Alternate
437271 5/1/2000 3/1/2001 39.48 39.48 39.48 FALSE FALSE New Listing
437271 3/1/2001 40.87 40.87 40.87 FALSE FALSE Change +Subsidy +Price +Alternate
437298 5/1/2000 3/1/2001 12.94 12.94 12.94 FALSE FALSE New Listing
437298 3/1/2001 13.14 13.14 13.14 FALSE FALSE Change +Subsidy +Price +Alternate
437301 5/1/2000 3/1/2001 20.18 20.18 20.18 FALSE FALSE New Listing
437301 3/1/2001 20.9 20.9 20.9 FALSE FALSE Change +Subsidy +Price +Alternate
437328 5/1/2000 6/1/2003 22.67 22.67 22.67 FALSE TRUE New Listing
437328 6/1/2003 0 0 0 FALSE FALSE Delisted
437352 5/1/2000 10/1/2008 145.6 145.6 145.6 FALSE TRUE New Listing
437352 10/1/2008 11/1/2011 174.72 174.72 174.72 FALSE TRUE Change +Subsidy +Price +Alternate
437352 11/1/2011 0 0 0 FALSE FALSE Delisted
438111 5/1/1996 9/1/2005 0 0 0 TRUE TRUE New Listing
438111 9/1/2005 0 0 0 FALSE FALSE Delisted
438138 6/1/2000 8/1/2000 7.75 7.75 10 FALSE TRUE New Listing
438138 8/1/2000 10/1/2002 7 7 10 FALSE TRUE Change -Subsidy -Alternate
438138 10/1/2002 7/1/2006 5.4 5.4 10 FALSE TRUE Change -Subsidy -Alternate
438138 7/1/2006 0 0 0 FALSE FALSE Delisted
438146 6/1/2000 8/1/2000 23.25 23.25 30 FALSE FALSE New Listing
438146 8/1/2000 10/1/2002 21 21 30 FALSE FALSE Change -Subsidy -Alternate
438146 10/1/2002 1/1/2003 16.2 16.2 30 FALSE FALSE Change -Subsidy -Alternate
438146 1/1/2003 0 0 0 FALSE FALSE Delisted
438154 6/1/2000 8/1/2000 7.75 7.75 10 FALSE TRUE New Listing
438154 8/1/2000 10/1/2002 7 7 11 FALSE TRUE Change -Subsidy +Price -Alternate
438154 10/1/2002 7/1/2006 5.4 5.4 11 FALSE TRUE Change -Subsidy -Alternate
438154 7/1/2006 0 0 0 FALSE FALSE Delisted
438162 6/1/2000 8/1/2000 23.25 23.25 30 FALSE FALSE New Listing
438162 8/1/2000 2/1/2002 21 21 33 FALSE FALSE Change -Subsidy +Price -Alternate
438162 2/1/2002 0 0 0 FALSE FALSE Delisted
438189 9/1/2000 3/1/2001 22.85 22.85 22.85 FALSE TRUE New Listing
438189 3/1/2001 7/1/2001 3.86 12.5 12.5 FALSE FALSE Change -Subsidy -Price -Alternate -OP
438189 7/1/2001 10/1/2003 12.5 12.5 12.5 FALSE FALSE Change +Subsidy
438189 10/1/2003 12/1/2003 3.86 3.86 3.86 FALSE FALSE Change -Subsidy -Price -Alternate
438189 12/1/2003 6/1/2004 2.5 2.5 2.5 FALSE FALSE Change -Subsidy -Price -Alternate
438189 6/1/2004 0 0 0 FALSE FALSE Delisted
438197 9/1/2000 3/1/2001 45 45 45 FALSE FALSE New Listing
438197 3/1/2001 7/1/2001 9.9 28.5 28.5 FALSE FALSE Change -Subsidy -Price -Alternate
438197 7/1/2001 10/1/2003 28.5 28.5 28.5 FALSE FALSE Change +Subsidy
438197 10/1/2003 12/1/2003 9.9 9.9 9.9 FALSE FALSE Change -Subsidy -Price -Alternate
438197 12/1/2003 6/1/2004 8.4 8.4 8.4 FALSE FALSE Change -Subsidy -Price -Alternate
438197 6/1/2004 0 0 0 FALSE FALSE Delisted
438227 9/1/2000 3/1/2001 54 54 54 FALSE TRUE New Listing
438227 3/1/2001 7/1/2001 12.24 29.5 29.5 FALSE FALSE Change -Subsidy -Price -Alternate -OP
438227 7/1/2001 10/1/2003 29.5 29.5 29.5 FALSE FALSE Change +Subsidy
438227 10/1/2003 12/1/2003 12.24 12.24 12.24 FALSE FALSE Change -Subsidy -Price -Alternate
438227 12/1/2003 9/1/2007 9.35 9.35 9.35 FALSE FALSE Change -Subsidy -Price -Alternate
438227 9/1/2007 0 0 0 FALSE FALSE Delisted
438243 4/12/1995 10/1/1996 15.8 15.8 15.8 FALSE FALSE New Listing
438243 10/1/1996 0 0 0 FALSE FALSE Delisted
439118 6/1/2000 1/1/2004 9.45 9.45 9.45 FALSE FALSE New Listing
439118 1/1/2004 6/1/2012 6.62 6.62 6.62 FALSE FALSE Change -Subsidy -Price -Alternate
439118 6/1/2012 9/1/2012 2.45 2.45 6.62 FALSE FALSE Change -Subsidy -Alternate
439118 9/1/2012 0 0 0 FALSE FALSE Delisted
439169 6/1/2000 9/1/2001 1500 1500 1500 FALSE FALSE New Listing
439169 9/1/2001 1/1/2003 1392.13 1392.13 1392.13 FALSE FALSE Change -Subsidy -Price -Alternate
439169 1/1/2003 11/1/2003 1347.26 1347.26 1347.26 FALSE FALSE Change -Subsidy -Price -Alternate
439169 11/1/2003 11/1/2004 1267.09 1267.09 1267.09 FALSE FALSE Change -Subsidy -Price -Alternate
439169 11/1/2004 1/1/2006 1292.63 1292.63 1292.63 FALSE FALSE Change +Subsidy +Price +Alternate
439169 1/1/2006 2/1/2007 1202.99 1202.99 1202.99 FALSE FALSE Change -Subsidy -Price -Alternate
439169 2/1/2007 10/1/2007 1364.09 1364.09 1364.09 FALSE FALSE Change +Subsidy +Price +Alternate
439169 10/1/2007 8/1/2008 1270.23 1270.23 1270.23 FALSE FALSE Change -Subsidy -Price -Alternate
439169 8/1/2008 8/1/2009 1378.71 1378.71 1378.71 FALSE FALSE Change +Subsidy +Price +Alternate
439169 8/1/2009 8/1/2010 1436.79 1436.79 1436.79 FALSE FALSE Change +Subsidy +Price +Alternate
439169 8/1/2010 12/1/2010 1407.33 1407.33 1407.33 FALSE FALSE Change -Subsidy -Price -Alternate
439169 12/1/2010 1322.89 1322.89 1322.89 FALSE FALSE Change -Subsidy -Price -Alternate
439177 6/1/2000 8/1/2001 2.99 2.99 2.98 FALSE FALSE New Listing
439177 8/1/2001 3/1/2004 3.65 3.65 3.65 FALSE FALSE Change +Subsidy +Price +Alternate
439177 3/1/2004 0 0 0 FALSE FALSE Delisted
439886 5/16/1994 1/1/2010 24.59 24.59 24.59 FALSE FALSE New Listing
439886 1/1/2010 1/1/2013 26 26 26 FALSE FALSE Change +Subsidy +Price +Alternate
439886 1/1/2013 29 29 29 FALSE FALSE Change +Subsidy +Price +Alternate
440507 6/1/2000 3/1/2004 21 21 21 FALSE FALSE New Listing
440507 3/1/2004 9/1/2004 16.21 16.21 16.21 FALSE FALSE Change -Subsidy -Price -Alternate
440507 9/1/2004 0 0 0 FALSE FALSE Delisted
440515 6/1/2000 3/1/2004 18.5 18.5 18.5 FALSE FALSE New Listing
440515 3/1/2004 9/1/2004 14.84 14.84 14.84 FALSE FALSE Change -Subsidy -Price -Alternate
440515 9/1/2004 0 0 0 FALSE FALSE Delisted
440612 8/1/2007 7/1/2010 6.78 6.78 6.78 FALSE TRUE New listing
440612 7/1/2010 7/1/2013 6.75 6.75 6.75 FALSE TRUE Change -Subsidy -Price -Alternate
440612 7/1/2013 0 0 0 FALSE FALSE Delisted
440701 6/1/2000 4/1/2001 36.55 36.55 56.4 FALSE FALSE New Listing
440701 4/1/2001 11/1/2002 27.48 27.48 56.4 FALSE FALSE Change -Subsidy -Alternate
440701 11/1/2002 7/1/2004 12.91 12.91 56.4 FALSE FALSE Change -Subsidy -Alternate
440701 7/1/2004 7/1/2005 8.09 8.09 53.6 FALSE FALSE Change -Subsidy -Price -Alternate
440701 7/1/2005 10/1/2006 6.74 6.74 53.6 FALSE FALSE Change -Subsidy -Alternate
440701 10/1/2006 12/1/2006 5.11 5.11 53.6 FALSE FALSE Change -Subsidy -Alternate
440701 12/1/2006 0 0 0 FALSE FALSE Delisted
443123 4/12/1995 8/1/1999 0.31 0.31 0.31 TRUE FALSE New Listing
443123 8/1/1999 0 0 0 FALSE FALSE Delisted
443131 4/12/1995 8/1/1999 0.31 0.31 0.31 TRUE FALSE New Listing
443131 8/1/1999 0 0 0 FALSE FALSE Delisted
452866 8/1/2000 9/1/2001 3.66 3.66 3.66 FALSE TRUE New Listing
452866 9/1/2001 7/1/2004 2.93 2.93 2.93 FALSE TRUE Change -Subsidy -Price -Alternate
452866 7/1/2004 1/1/2012 2.37 2.37 2.37 FALSE TRUE Change -Subsidy -Price -Alternate
452866 1/1/2012 4/1/2012 2.08 2.08 2.37 FALSE TRUE Change -Subsidy -Alternate
452866 4/1/2012 0 0 0 FALSE FALSE Delisted
452955 8/1/2000 9/1/2001 4.19 4.19 4.19 FALSE TRUE New Listing
452955 9/1/2001 7/1/2004 3.14 3.14 3.14 FALSE TRUE Change -Subsidy -Price -Alternate
452955 7/1/2004 1/1/2012 2.29 2.29 2.29 FALSE TRUE Change -Subsidy -Price -Alternate
452955 1/1/2012 4/1/2012 2.08 2.08 2.29 FALSE TRUE Change -Subsidy -Alternate
452955 4/1/2012 0 0 0 FALSE FALSE Delisted
454680 2/1/1999 11/1/2000 62.5 62.5 62.5 FALSE FALSE New Listing
454680 11/1/2000 12/1/2002 55 55 55 FALSE FALSE Change -Subsidy -Price -Alternate
454680 12/1/2002 2/1/2008 22 22 22 FALSE FALSE Change -Subsidy -Price -Alternate
454680 2/1/2008 1/1/2009 17.6 17.6 17.6 FALSE FALSE Change -Subsidy -Price -Alternate
454680 1/1/2009 13.37 13.37 13.37 FALSE FALSE Change -Subsidy -Price -Alternate
454699 2/1/1999 11/1/2000 152.5 152.5 152.5 FALSE FALSE New Listing
454699 11/1/2000 12/1/2002 135 135 135 FALSE FALSE Change -Subsidy -Price -Alternate
454699 12/1/2002 2/1/2008 57 57 57 FALSE FALSE Change -Subsidy -Price -Alternate
454699 2/1/2008 1/1/2009 45.6 45.6 45.6 FALSE FALSE Change -Subsidy -Price -Alternate
454699 1/1/2009 34.65 34.65 34.65 FALSE FALSE Change -Subsidy -Price -Alternate
454745 5/16/1994 7/1/2003 6.78 6.78 6.78 FALSE FALSE New Listing
454745 7/1/2003 12/1/2008 12 12 12 FALSE FALSE Change +Subsidy +Price +Alternate
454745 12/1/2008 0 0 0 FALSE FALSE Delisted
455024 3/1/1999 2/1/2001 4.8 4.8 7.7 FALSE TRUE New Listing
455024 2/1/2001 3/1/2002 4.8 4.8 8.86 FALSE TRUE Change +Price
455024 3/1/2002 7/1/2002 4.8 4.8 8.85 FALSE TRUE Change -Price
455024 7/1/2002 8/1/2006 4.8 4.8 9.45 FALSE TRUE Change +Price
455024 8/1/2006 7/1/2008 4.8 4.8 9.38 FALSE TRUE Change -Price
455024 7/1/2008 11/1/2009 3.19 3.19 9.38 FALSE TRUE Change -Subsidy -Alternate
455024 11/1/2009 3/1/2014 3.19 3.19 6.94 FALSE TRUE Change -Price
455024 3/1/2014 4.13 4.13 6.94 FALSE TRUE Change +Subsidy +Alternate
455091 3/1/1999 2/1/2001 4.8 4.8 7.7 FALSE TRUE New Listing
455091 2/1/2001 7/1/2002 4.8 4.8 8.85 FALSE TRUE Change +Price
455091 7/1/2002 5/1/2007 4.8 4.8 9.45 FALSE TRUE Change +Price
455091 5/1/2007 7/1/2008 4.8 4.8 8.82 FALSE TRUE Change -Price
455091 7/1/2008 5/1/2010 3.19 3.19 8.82 FALSE TRUE Change -Subsidy -Alternate
455091 5/1/2010 0 0 0 FALSE FALSE Delisted
455563 6/1/1997 7/1/2001 419.31 419.31 419.31 FALSE FALSE New Listing
455563 7/1/2001 7/1/2002 377.38 377.38 377.38 FALSE FALSE Change -Subsidy -Price -Alternate
455563 7/1/2002 1/1/2010 377.38 377.38 377.38 FALSE TRUE Change +OP
455563 1/1/2010 8/1/2012 264.17 264.17 264.17 FALSE TRUE Change -Subsidy -Price -Alternate
455563 8/1/2012 198.13 198.13 198.13 FALSE TRUE Change -Subsidy -Price -Alternate
455571 6/1/1997 7/1/2001 94.45 94.45 94.45 FALSE FALSE New Listing
455571 7/1/2001 1/1/2010 85 85 85 FALSE FALSE Change -Subsidy -Price -Alternate
455571 1/1/2010 1/1/2013 59.5 59.5 59.5 FALSE FALSE Change -Subsidy -Price -Alternate
455571 1/1/2013 44.63 44.63 44.63 FALSE FALSE Change -Subsidy -Price -Alternate
455598 6/1/1997 7/1/2001 376.32 376.32 376.32 FALSE FALSE New Listing
455598 7/1/2001 1/1/2010 338.69 338.69 338.69 FALSE FALSE Change -Subsidy -Price -Alternate
455598 1/1/2010 1/1/2013 237.08 237.08 237.08 FALSE FALSE Change -Subsidy -Price -Alternate
455598 1/1/2013 177.81 177.81 177.81 FALSE FALSE Change -Subsidy -Price -Alternate
456128 12/1/1995 2/1/2001 8.4 8.4 8 FALSE FALSE New Listing
456128 2/1/2001 0 0 0 FALSE FALSE Delisted
456152 12/1/1995 8/1/2000 2.52 2.52 3.95 FALSE FALSE New Listing
456152 8/1/2000 2/1/2001 2.52 2.52 4.15 FALSE FALSE Change +Price
456152 2/1/2001 3/1/2001 2.52 2.52 4.28 FALSE FALSE Change +Price
456152 3/1/2001 3/1/2002 2.52 2.52 4.3 FALSE FALSE Change +Price
456152 3/1/2002 6/1/2007 2.52 2.52 4.45 FALSE FALSE Change +Price
456152 6/1/2007 0 0 0 FALSE FALSE Delisted
456160 10/1/2010 22.89 22.89 22.89 FALSE TRUE New listing
456241 10/1/1994 7/1/1999 4.22 4.22 4.22 FALSE FALSE New Listing
456241 7/1/1999 11/1/1999 1.83 1.83 1.83 FALSE FALSE Change -Subsidy -Price -Alternate
456241 11/1/1999 0 0 0 FALSE FALSE Delisted
456756 6/1/1995 5/1/1999 4.1 4.1 4.1 FALSE TRUE New Listing
456756 5/1/1999 11/1/1999 4.1 4.1 4.8 FALSE TRUE Change +Price
456756 11/1/1999 0 0 0 FALSE FALSE Delisted
456845 6/1/1995 7/1/1995 102 102 102 FALSE TRUE New Listing
456845 7/1/1995 5/1/1999 49.5 49.5 49.5 FALSE TRUE Change -Subsidy -Price -Alternate
456845 5/1/1999 4/1/2002 28 28 28 FALSE TRUE Change -Subsidy -Price -Alternate
456845 4/1/2002 0 0 0 FALSE FALSE Delisted
457809 6/1/1995 5/1/1999 3.93 3.93 3.93 FALSE TRUE New Listing
457809 5/1/1999 1/1/2001 3.93 3.93 4.43 FALSE TRUE Change +Price
457809 1/1/2001 2/1/2001 3.93 3.93 4.61 FALSE TRUE Change +Price
457809 2/1/2001 5/1/2001 3.93 3.93 4.43 FALSE TRUE Change -Price
457809 5/1/2001 3/1/2006 3.93 3.93 4.61 FALSE TRUE Change +Price
457809 3/1/2006 12/1/2006 3.93 3.93 4.77 FALSE TRUE Change +Price
457809 12/1/2006 11/1/2007 3.93 3.93 5.21 FALSE TRUE Change +Price
457809 11/1/2007 2/1/2008 3.93 3.93 5.43 FALSE TRUE Change +Price
457809 2/1/2008 4/1/2009 3.93 3.93 6.73 FALSE TRUE Change +Price
457809 4/1/2009 12/1/2009 3.93 3.93 6.88 FALSE TRUE Change +Price
457809 12/1/2009 3.93 3.93 7.32 FALSE TRUE Change +Price
457833 6/2/1995 3/1/2002 17.76 17.76 17.76 FALSE FALSE New Listing
457833 3/1/2002 10/1/2002 16.6 16.6 16.6 FALSE FALSE Change -Subsidy -Price -Alternate
457833 10/1/2002 0 0 0 FALSE FALSE Delisted
457841 6/2/1995 3/1/2002 17.76 17.76 17.76 FALSE TRUE New Listing
457841 3/1/2002 10/1/2002 16.6 16.6 16.6 FALSE TRUE Change -Subsidy -Price -Alternate
457841 10/1/2002 0 0 0 FALSE FALSE Delisted
458015 7/1/1996 5/1/1999 2.56 2.56 2.56 FALSE TRUE New Listing
458015 5/1/1999 6/1/2004 1.9 1.9 1.9 FALSE TRUE Change -Subsidy -Price -Alternate
458015 6/1/2004 7/1/2004 1.27 1.27 1.65 FALSE TRUE Change -Subsidy -Price -Alternate
458015 7/1/2004 10/1/2009 1.27 1.27 1.27 FALSE TRUE Change -Price
458015 10/1/2009 0 0 0 FALSE FALSE Delisted
458023 6/1/1995 5/1/1999 2.56 2.56 2.56 FALSE TRUE New Listing
458023 5/1/1999 6/1/2004 1.9 1.9 1.9 FALSE TRUE Change -Subsidy -Price -Alternate
458023 6/1/2004 7/1/2004 1.27 1.27 1.65 FALSE TRUE Change -Subsidy -Price -Alternate
458023 7/1/2004 10/1/2009 1.27 1.27 1.27 FALSE TRUE Change -Price
458023 10/1/2009 0 0 0 FALSE FALSE Delisted
458767 5/16/1994 2/1/2003 15.76 15.76 15.76 FALSE FALSE New Listing
458767 2/1/2003 3/1/2003 15.76 15.76 15.76 FALSE FALSE Change
458767 3/1/2003 5/1/2003 7.82 7.82 15.76 FALSE FALSE Change -Subsidy -Alternate
458767 5/1/2003 5/12/2003 0 0 0 FALSE FALSE Delisted
458767 5/12/2003 7/1/2003 7.82 7.82 7.82 FALSE FALSE New Listing
458767 7/1/2003 0 0 0 FALSE FALSE Delisted
458872 5/16/1994 1/2/1996 6.84 6.84 6.84 FALSE FALSE New Listing
458872 1/2/1996 0 0 0 FALSE FALSE Delisted
459046 5/16/1994 4/1/2002 9.35 9.35 9.35 FALSE FALSE New Listing
459046 4/1/2002 0 0 0 FALSE FALSE Delisted
459348 4/12/1995 8/1/1999 10.8 10.8 10.8 FALSE FALSE New Listing
459348 8/1/1999 0 0 0 FALSE FALSE Delisted
459410 6/1/1995 5/1/1999 9 9 9 FALSE TRUE New Listing
459410 5/1/1999 7/1/1999 9 9 11.25 FALSE TRUE Change +Price
459410 7/1/1999 11/1/2001 5.6 5.6 11.25 FALSE TRUE Change -Subsidy -Alternate
459410 11/1/2001 1/1/2007 7 7 7 FALSE TRUE Change +Subsidy -Price +Alternate
459410 1/1/2007 0 0 0 FALSE FALSE Delisted
459771 9/1/1997 9/1/1998 28.42 28.42 28.42 FALSE TRUE New Listing
459771 9/1/1998 3/1/2003 27.85 27.85 27.85 FALSE TRUE Change -Subsidy -Price -Alternate
459771 3/1/2003 7/1/2003 26.95 26.95 27.85 FALSE TRUE Change -Subsidy -Alternate
459771 7/1/2003 0 0 0 FALSE FALSE Delisted
459801 6/1/1995 11/1/1997 209.53 209.53 209.53 FALSE TRUE New Listing
459801 11/1/1997 10/1/2008 195 195 195 FALSE TRUE Change -Subsidy -Price -Alternate
459801 10/1/2008 221 221 221 FALSE TRUE Change +Subsidy +Price +Alternate
459828 12/1/1997 10/1/2008 305 305 305 FALSE TRUE New Listing
459828 10/1/2008 320 320 320 FALSE TRUE Change +Subsidy +Price +Alternate
460265 9/1/1997 3/1/2005 4.91 4.91 4.91 FALSE FALSE New Listing
460265 3/1/2005 7/1/2009 3.93 3.93 3.93 FALSE FALSE Change -Subsidy -Price -Alternate
460265 7/1/2009 3.15 3.15 3.15 FALSE FALSE Change -Subsidy -Price -Alternate
461148 9/1/1997 3/1/2005 1.99 1.99 1.99 FALSE FALSE New Listing
461148 3/1/2005 1/1/2007 1.59 1.59 1.99 FALSE FALSE Change -Subsidy -Alternate
461148 1/1/2007 0 0 0 FALSE FALSE Delisted
461156 9/1/1997 3/1/2005 1.99 1.99 1.99 FALSE FALSE New Listing
461156 3/1/2005 1/1/2007 1.59 1.59 1.99 FALSE FALSE Change -Subsidy -Alternate
461156 1/1/2007 0 0 0 FALSE FALSE Delisted
461164 9/1/1997 3/1/2005 1.99 1.99 1.99 FALSE FALSE New Listing
461164 3/1/2005 1/1/2007 1.59 1.59 1.99 FALSE FALSE Change -Subsidy -Alternate
461164 1/1/2007 0 0 0 FALSE FALSE Delisted
461253 2/1/2011 14.85 14.85 14.85 FALSE TRUE New listing
461288 10/1/1997 5/1/2000 27 27 27 FALSE FALSE New Listing
461288 5/1/2000 9/1/2002 15.5 27 27 FALSE FALSE Change -Subsidy
461288 9/1/2002 3/1/2003 16.38 16.38 16.38 FALSE FALSE Change +Subsidy -Price -Alternate
461288 3/1/2003 0 0 0 FALSE FALSE Delisted
461504 2/1/1999 7/1/1999 8.58 8.58 8.58 FALSE TRUE New Listing
461504 7/1/1999 3/1/2004 5.25 5.25 5.25 FALSE TRUE Change -Subsidy -Price -Alternate
461504 3/1/2004 6/1/2004 4.69 4.69 5.25 FALSE TRUE Change -Subsidy -Alternate
461504 6/1/2004 8/1/2008 0 0 0 FALSE FALSE Delisted
461504 8/1/2008 7/1/2011 3.48 3.48 3.48 FALSE TRUE New Listing
461504 7/1/2011 3.08 3.08 3.08 FALSE TRUE Change -Subsidy -Price -Alternate
461598 9/1/1997 10/1/1998 232 232 232 FALSE FALSE New Listing
461598 10/1/1998 9/1/2001 185.6 185.6 185.6 FALSE FALSE Change -Subsidy -Price -Alternate
461598 9/1/2001 12/1/2001 130 130 130 FALSE FALSE Change -Subsidy -Price -Alternate
461598 12/1/2001 7/1/2004 0 0 0 FALSE FALSE Delisted
461598 7/1/2004 99 99 99 FALSE FALSE New Listing
461946 10/1/1997 4/1/1998 13.73 13.73 13.73 FALSE FALSE New Listing
461946 4/1/1998 7/1/2000 12.01 12.01 12.01 FALSE FALSE Change -Subsidy -Price -Alternate
461946 7/1/2000 11/1/2000 2.8 2.8 2.8 FALSE FALSE Change -Subsidy -Price -Alternate
461946 11/1/2000 0 0 0 FALSE FALSE Delisted
461954 10/1/1997 4/1/1998 13.77 13.77 13.77 FALSE FALSE New Listing
461954 4/1/1998 7/1/2000 12.05 12.05 12.05 FALSE FALSE Change -Subsidy -Price -Alternate
461954 7/1/2000 11/1/2000 2.78 2.78 2.78 FALSE FALSE Change -Subsidy -Price -Alternate
461954 11/1/2000 0 0 0 FALSE FALSE Delisted
461962 5/1/1994 8/1/2001 95.28 95.28 95.28 FALSE FALSE New Listing
461962 8/1/2001 1/1/2002 57.8 57.8 57.8 FALSE FALSE Change -Subsidy -Price -Alternate
461962 1/1/2002 7/1/2002 52.02 52.02 52.02 FALSE FALSE Change -Subsidy -Price -Alternate
461962 7/1/2002 1/1/2003 50.4 50.4 50.4 FALSE FALSE Change -Subsidy -Price -Alternate
461962 1/1/2003 4/1/2010 49.14 49.14 49.14 FALSE FALSE Change -Subsidy -Price -Alternate
461962 4/1/2010 32.92 32.92 32.92 FALSE FALSE Change -Subsidy -Price -Alternate
462519 3/1/1997 7/1/2012 27 27 27 FALSE FALSE New Listing
462519 7/1/2012 32 32 32 FALSE FALSE Change +Subsidy +Price +Alternate
462535 4/1/1998 11/1/2003 8.13 8.13 8.13 FALSE TRUE New Listing
462535 11/1/2003 9/1/2006 7.9 7.9 7.9 FALSE TRUE Change -Subsidy -Price -Alternate
462535 9/1/2006 12/1/2006 6.7 6.7 7.9 FALSE TRUE Change -Subsidy -Alternate
462535 12/1/2006 0 0 0 FALSE FALSE Delisted
462543 2/1/1999 10/1/2007 27.95 27.95 27.95 FALSE FALSE New Listing
462543 10/1/2007 7/1/2011 25.2 25.2 25.2 FALSE FALSE Change -Subsidy -Price -Alternate
462543 7/1/2011 22.8 22.8 22.8 FALSE FALSE Change -Subsidy -Price -Alternate
462675 12/1/1997 10/1/1998 63.48 63.48 63.48 FALSE TRUE New Listing
462675 10/1/1998 4/1/1999 25.39 25.39 63.48 FALSE TRUE Change -Subsidy -Alternate
462675 4/1/1999 12/1/2006 0 0 0 FALSE FALSE Delisted
462675 12/1/2006 6/1/2007 54.63 54.63 54.63 FALSE FALSE New Listing
462675 6/1/2007 9/1/2007 1.58 1.58 54.63 FALSE FALSE Change -Subsidy -Alternate
462675 9/1/2007 0 0 0 FALSE FALSE Delisted
462756 10/1/1997 10/1/1998 6.34 6.34 6.34 FALSE TRUE New Listing
462756 10/1/1998 8/1/2003 5.72 5.72 5.72 FALSE TRUE Change -Subsidy -Price -Alternate
462756 8/1/2003 4/1/2006 0 0 0 FALSE FALSE Delisted
462756 4/1/2006 11/1/2010 5.72 5.72 5.72 FALSE TRUE New Listing
462756 11/1/2010 2/1/2011 3.91 3.91 5.72 FALSE TRUE Change -Subsidy -Alternate
462756 2/1/2011 0 0 0 FALSE FALSE Delisted
462764 10/1/1997 10/1/1998 8.3 8.3 8.3 FALSE TRUE New Listing
462764 10/1/1998 2/1/2002 7.48 7.48 7.48 FALSE TRUE Change -Subsidy -Price -Alternate
462764 2/1/2002 0 0 0 FALSE FALSE Delisted
462829 10/1/1997 10/1/2006 19.06 19.06 19.06 FALSE TRUE New Listing
462829 10/1/2006 10/1/2009 21.1 21.1 21.1 FALSE TRUE Change +Subsidy +Price +Alternate
462829 10/1/2009 11/1/2012 23 23 23 FALSE TRUE Change +Subsidy +Price +Alternate
462829 11/1/2012 25.3 25.3 25.3 FALSE TRUE Change +Subsidy +Price +Alternate
463493 11/1/1997 11/1/1998 64 64 64 FALSE TRUE New Listing
463493 11/1/1998 5/1/2000 58 58 58 FALSE TRUE Change -Subsidy -Price -Alternate
463493 5/1/2000 0 0 0 FALSE FALSE Delisted
464988 8/1/2007 7/1/2010 6.66 6.66 6.66 FALSE TRUE New listing
464988 7/1/2010 7/1/2013 6.6 6.6 6.6 FALSE TRUE Change -Subsidy -Price -Alternate
464988 7/1/2013 0 0 0 FALSE FALSE Delisted
465070 11/1/1997 9/1/2000 143.16 143.16 143.16 FALSE FALSE New Listing
465070 9/1/2000 8/1/2004 143.16 143.16 143.16 FALSE FALSE Change
465070 8/1/2004 0 0 0 FALSE FALSE Delisted
465631 8/1/1999 4/1/2000 22.61 22.61 22.61 FALSE FALSE New Listing
465631 4/1/2000 12/1/2000 22.61 22.61 24.5 FALSE FALSE Change +Price
465631 12/1/2000 12/1/2003 22.61 22.61 39.9 FALSE FALSE Change +Price
465631 12/1/2003 8/1/2004 22.61 22.61 42 FALSE FALSE Change +Price
465631 8/1/2004 22.61 22.61 22.61 FALSE FALSE Change -Price
466050 4/12/1995 8/1/1999 0 0 0 TRUE FALSE New Listing
466050 8/1/1999 0 0 0 FALSE FALSE Delisted
468185 5/11/1995 2/1/2000 1.28 1.28 3.44 FALSE FALSE New Listing
468185 2/1/2000 11/1/2000 1.04 1.04 2.58 FALSE FALSE Change -Subsidy -Price -Alternate
468185 11/1/2000 7/1/2001 1.04 1.04 3.9 FALSE FALSE Change +Price
468185 7/1/2001 3/1/2002 1.04 1.04 4.06 FALSE FALSE Change +Price
468185 3/1/2002 9/1/2002 1.04 1.04 4.34 FALSE FALSE Change +Price
468185 9/1/2002 12/1/2002 1.27 1.27 4.45 FALSE FALSE Change +Subsidy +Price +Alternate
468185 12/1/2002 4/1/2005 1.27 1.27 4.32 FALSE FALSE Change -Price
468185 4/1/2005 5/1/2005 1.28 1.28 4.32 FALSE FALSE Change +Subsidy +Alternate
468185 5/1/2005 5/1/2006 1.28 1.28 4.45 FALSE FALSE Change +Price
468185 5/1/2006 8/1/2006 1.28 1.28 4.54 FALSE FALSE Change +Price
468185 8/1/2006 11/1/2006 1.08 1.08 4.54 FALSE FALSE Change -Subsidy -Alternate
468185 11/1/2006 0 0 0 FALSE FALSE Delisted
469149 6/10/1995 10/1/2000 3.39 3.39 4.24 FALSE TRUE New Listing
469149 10/1/2000 7/1/2008 3.39 3.39 5.89 FALSE TRUE Change +Price
469149 7/1/2008 3/1/2014 2.55 2.55 5.89 FALSE TRUE Change -Subsidy -Alternate
469149 3/1/2014 3.3 3.3 5.89 FALSE TRUE Change +Subsidy +Alternate
469513 7/1/1996 9/1/1999 14.4 14.4 14.4 FALSE TRUE New Listing
469513 9/1/1999 11/1/2001 12.23 12.23 14.4 FALSE TRUE Change -Subsidy -Alternate
469513 11/1/2001 1/1/2004 12.23 12.23 12.23 FALSE TRUE Change -Price
469513 1/1/2004 0 0 0 FALSE FALSE Delisted
469521 11/1/1997 11/1/2004 1.75 1.75 1.75 FALSE TRUE New Listing
469521 11/1/2004 0 0 0 FALSE FALSE Delisted
469548 11/1/1997 7/1/1999 2.78 2.78 2.78 FALSE TRUE New Listing
469548 7/1/1999 9/1/2013 2.65 2.65 2.65 FALSE TRUE Change -Subsidy -Price -Alternate
469548 9/1/2013 0 0 0 FALSE FALSE Delisted
469556 11/1/1997 5/1/1999 5.55 5.55 5.55 FALSE TRUE New Listing
469556 5/1/1999 7/1/1999 5.55 5.55 8.5 FALSE TRUE Change +Price
469556 7/1/1999 5.29 5.29 5.29 FALSE TRUE Change -Subsidy -Price -Alternate
469564 11/1/1997 7/1/2008 364.35 364.35 364.35 FALSE TRUE New Listing
469564 7/1/2008 437.22 437.22 437.22 FALSE TRUE Change +Subsidy +Price +Alternate
469572 11/1/1997 4/1/2006 110.12 110.12 110.12 FALSE TRUE New Listing
469572 4/1/2006 0 0 0 FALSE FALSE Delisted
469580 11/1/1997 2/1/2004 9 9 9 FALSE TRUE New Listing
469580 2/1/2004 0 0 0 FALSE FALSE Delisted
469602 1/1/1998 5/1/2000 5.04 5.04 5.04 FALSE FALSE New Listing
469602 5/1/2000 8/1/2000 2.35 5.04 5.04 FALSE FALSE Change -Subsidy
469602 8/1/2000 9/1/2000 1.4 5.04 5.04 FALSE FALSE Change -Subsidy
469602 9/1/2000 1/1/2001 1.22 5.04 5.04 FALSE FALSE Change -Subsidy
469602 1/1/2001 3/1/2001 0.66 5.04 5.04 FALSE FALSE Change -Subsidy
469602 3/1/2001 0 0 0 FALSE FALSE Delisted
469610 1/1/1998 5/1/2000 40.32 40.32 40.32 FALSE FALSE New Listing
469610 5/1/2000 8/1/2000 18.82 40.32 40.32 FALSE FALSE Change -Subsidy
469610 8/1/2000 9/1/2000 11.18 40.32 40.32 FALSE FALSE Change -Subsidy
469610 9/1/2000 1/1/2001 9.75 40.32 40.32 FALSE FALSE Change -Subsidy
469610 1/1/2001 9/1/2001 5.26 40.32 40.32 FALSE FALSE Change -Subsidy
469610 9/1/2001 11/1/2004 1.86 40.32 40.32 FALSE FALSE Change -Subsidy
469610 11/1/2004 0 0 0 FALSE FALSE Delisted
470694 1/1/1997 3/1/2009 154.3 154.3 154.3 FALSE TRUE New Listing
470694 3/1/2009 285 285 285 FALSE TRUE Change +Subsidy +Price +Alternate
470988 9/1/2000 9/1/2008 51.5 51.5 51.5 FALSE FALSE New Listing
470988 9/1/2008 26.04 26.04 26.04 FALSE FALSE Change -Subsidy -Price -Alternate
470996 9/1/2000 9/1/2008 87.54 87.54 87.54 FALSE FALSE New Listing
470996 9/1/2008 44.26 44.26 44.26 FALSE FALSE Change -Subsidy -Price -Alternate
471003 9/1/2000 9/1/2008 148.83 148.83 148.83 FALSE FALSE New Listing
471003 9/1/2008 75.25 75.25 75.25 FALSE FALSE Change -Subsidy -Price -Alternate
471011 9/1/2000 9/1/2008 256.82 256.82 256.82 FALSE FALSE New Listing
471011 9/1/2008 129.85 129.85 129.85 FALSE FALSE Change -Subsidy -Price -Alternate
471038 3/1/1998 2/1/2004 504 504 504 FALSE FALSE New Listing
471038 2/1/2004 2/1/2005 454 454 454 FALSE FALSE Change -Subsidy -Price -Alternate
471038 2/1/2005 11/1/2014 428 428 428 FALSE FALSE Change -Subsidy -Price -Alternate
471038 11/1/2014 0 0 0 FALSE FALSE Delisted
471046 3/1/1998 2/1/2004 1260 1260 1260 FALSE FALSE New Listing
471046 2/1/2004 2/1/2005 1135 1135 1135 FALSE FALSE Change -Subsidy -Price -Alternate
471046 2/1/2005 11/1/2014 1070 1070 1070 FALSE FALSE Change -Subsidy -Price -Alternate
471046 11/1/2014 0 0 0 FALSE FALSE Delisted
471151 2/1/2002 6/1/2006 159 159 159 FALSE FALSE New listing
471151 6/1/2006 0 0 0 FALSE FALSE Delisted
471259 3/1/1995 5/1/1996 30 30 30 FALSE TRUE New Listing
471259 5/1/1996 10/1/1996 10 10 10 FALSE TRUE Change -Subsidy -Price -Alternate
471259 10/1/1996 12/1/1996 10 10 11 FALSE TRUE Change +Price
471259 12/1/1996 3/1/1998 8.25 8.25 11 FALSE TRUE Change -Subsidy -Alternate
471259 3/1/1998 8/1/2000 7.75 7.75 11 FALSE TRUE Change -Subsidy -Alternate
471259 8/1/2000 12/1/2001 7 7 11 FALSE TRUE Change -Subsidy -Alternate
471259 12/1/2001 0 0 0 FALSE FALSE Delisted
471267 3/1/1995 12/1/1996 10 10 10 FALSE TRUE New Listing
471267 12/1/1996 3/1/1998 8.25 8.25 10 FALSE TRUE Change -Subsidy -Alternate
471267 3/1/1998 8/1/2000 7.75 7.75 10 FALSE TRUE Change -Subsidy -Alternate
471267 8/1/2000 5/1/2001 7 7 10 FALSE TRUE Change -Subsidy -Alternate
471267 5/1/2001 0 0 0 FALSE FALSE Delisted
471631 8/1/2000 6/1/2007 14 14 14 FALSE TRUE New Listing
471631 6/1/2007 7/1/2007 8.95 8.95 14 FALSE TRUE Change -Subsidy -Alternate
471631 7/1/2007 9/1/2007 8.95 8.95 8.95 FALSE TRUE Change -Price
471631 9/1/2007 0 0 0 FALSE FALSE Delisted
471674 10/1/2004 7/1/2010 3.92 3.92 3.92 FALSE FALSE New listing
471674 7/1/2010 3.53 3.53 3.53 FALSE FALSE Change -Subsidy -Price -Alternate
471690 10/1/1998 11/1/1998 82.18 82.18 82.18 FALSE TRUE New Listing
471690 11/1/1998 10/1/1999 50 50 50 FALSE TRUE Change -Subsidy -Price -Alternate
471690 10/1/1999 9/1/2000 50 50 50 FALSE FALSE Change -OP
471690 9/1/2000 3/1/2001 45 45 45 FALSE FALSE Change -Subsidy -Price -Alternate
471690 3/1/2001 7/1/2001 9.9 28.5 45 FALSE FALSE Change -Subsidy -Alternate
471690 7/1/2001 10/1/2006 0 0 0 FALSE FALSE Delisted
471690 10/1/2006 7/1/2013 6.64 6.64 6.64 FALSE FALSE New Listing
471690 7/1/2013 5.98 5.98 5.98 FALSE FALSE Change -Subsidy -Price -Alternate
471704 10/1/1998 9/1/2000 25.39 25.39 25.39 FALSE TRUE New Listing
471704 9/1/2000 3/1/2001 22.85 22.85 22.85 FALSE TRUE Change -Subsidy -Price -Alternate
471704 3/1/2001 7/1/2001 3.86 12.5 22.85 FALSE FALSE Change -Subsidy -Alternate -OP
471704 7/1/2001 10/1/2006 0 0 0 FALSE FALSE Delisted
471704 10/1/2006 7/1/2013 1.98 1.98 1.98 FALSE FALSE New Listing
471704 7/1/2013 1.78 1.78 1.78 FALSE FALSE Change -Subsidy -Price -Alternate
471712 10/1/1998 11/1/1998 84.59 84.59 84.59 FALSE TRUE New Listing
471712 11/1/1998 9/1/2000 60 60 60 FALSE TRUE Change -Subsidy -Price -Alternate
471712 9/1/2000 3/1/2001 54 54 54 FALSE TRUE Change -Subsidy -Price -Alternate
471712 3/1/2001 7/1/2001 12.24 29.5 54 FALSE FALSE Change -Subsidy -Alternate -OP
471712 7/1/2001 10/1/2006 0 0 0 FALSE FALSE Delisted
471712 10/1/2006 7/1/2013 7.38 7.38 7.38 FALSE FALSE New Listing
471712 7/1/2013 6.64 6.64 6.64 FALSE FALSE Change -Subsidy -Price -Alternate
471739 5/16/1994 5/1/1998 12.37 12.37 12.38 FALSE FALSE New Listing
471739 5/1/1998 8/1/1998 2.38 2.38 7.06 FALSE FALSE Change -Subsidy -Price -Alternate
471739 8/1/1998 0 0 0 FALSE FALSE Delisted
471747 7/1/1996 9/1/1999 14.4 14.4 14.4 FALSE TRUE New Listing
471747 9/1/1999 11/1/2001 12.23 12.23 14.4 FALSE TRUE Change -Subsidy -Alternate
471747 11/1/2001 1/1/2004 12.23 12.23 12.23 FALSE TRUE Change -Price
471747 1/1/2004 0 0 0 FALSE FALSE Delisted
471755 7/1/1996 9/1/1999 14.4 14.4 14.4 FALSE TRUE New Listing
471755 9/1/1999 11/1/2001 12.23 12.23 14.4 FALSE TRUE Change -Subsidy -Alternate
471755 11/1/2001 1/1/2004 12.23 12.23 12.23 FALSE TRUE Change -Price
471755 1/1/2004 0 0 0 FALSE FALSE Delisted
471828 6/17/1995 12/1/1996 320 320 320 FALSE FALSE New Listing
471828 12/1/1996 10/1/2002 277 277 277 FALSE FALSE Change -Subsidy -Price -Alternate
471828 10/1/2002 0 0 0 FALSE FALSE Delisted
472212 2/1/1998 4/1/1998 8.11 8.11 15.7 FALSE FALSE New Listing
472212 4/1/1998 7/1/2013 5.79 5.79 12.05 FALSE FALSE Change -Subsidy -Price -Alternate
472212 7/1/2013 5.79 12.05 12.05 FALSE FALSE Change +Alternate
472476 5/16/1994 1/11/1995 6.46 6.46 6.46 FALSE FALSE New Listing
472476 1/11/1995 2/1/1998 6.16 6.16 6.16 FALSE FALSE Change -Subsidy -Price -Alternate
472476 2/1/1998 8/1/2000 3.7 3.7 3.7 FALSE FALSE Change -Subsidy -Price -Alternate
472476 8/1/2000 12/1/2000 1.62 1.62 3.7 FALSE FALSE Change -Subsidy -Alternate
472476 12/1/2000 0 0 0 FALSE FALSE Delisted
472514 3/1/1996 11/1/1999 1.16 1.16 1.71 FALSE FALSE New Listing
472514 11/1/1999 7/1/2000 1.16 1.16 2.2 FALSE FALSE Change +Price
472514 7/1/2000 8/1/2000 1.16 1.16 2.5 FALSE FALSE Change +Price
472514 8/1/2000 3/1/2001 1.16 1.16 2.48 FALSE FALSE Change -Price
472514 3/1/2001 6/1/2004 2.5 2.5 2.5 FALSE FALSE Change +Subsidy +Price +Alternate
472514 6/1/2004 0 0 0 FALSE FALSE Delisted
472530 10/1/1998 7/1/1999 20 20 20 FALSE FALSE New Listing
472530 7/1/1999 12/1/2002 9.38 9.38 9.38 FALSE FALSE Change -Subsidy -Price -Alternate
472530 12/1/2002 10/1/2003 9.38 9.38 12.94 FALSE FALSE Change +Price
472530 10/1/2003 0 0 0 FALSE FALSE Delisted
472565 6/1/1995 5/1/1999 5.55 5.55 5.55 FALSE TRUE New Listing
472565 5/1/1999 7/1/1999 5.55 5.55 10.1 FALSE TRUE Change +Price
472565 7/1/1999 9/1/1999 5.29 5.29 10.1 FALSE TRUE Change -Subsidy -Alternate
472565 9/1/1999 4/1/2000 5.29 5.29 8.7 FALSE TRUE Change -Price
472565 4/1/2000 11/1/2006 5.29 5.29 5.29 FALSE TRUE Change -Price
472565 11/1/2006 0 0 0 FALSE FALSE Delisted
472735 1/1/1998 9/1/1998 38.22 38.22 38.22 FALSE FALSE New Listing
472735 9/1/1998 4/1/2001 22.73 22.73 37.88 FALSE FALSE Change -Subsidy -Price -Alternate
472735 4/1/2001 6/1/2001 17.48 17.48 17.48 FALSE FALSE Change -Subsidy -Price -Alternate
472735 6/1/2001 1/1/2009 17.37 17.37 17.37 FALSE FALSE Change -Subsidy -Price -Alternate
472735 1/1/2009 3/1/2009 2.14 2.14 8.43 FALSE FALSE Change -Subsidy -Price -Alternate
472735 3/1/2009 5/1/2009 2.14 2.14 4.4 FALSE FALSE Change -Price
472735 5/1/2009 0 0 0 FALSE FALSE Delisted
472743 1/1/1998 9/1/1998 98.28 98.28 98.28 FALSE FALSE New Listing
472743 9/1/1998 4/1/2001 58.45 58.45 97.42 FALSE FALSE Change -Subsidy -Price -Alternate
472743 4/1/2001 6/1/2001 44.96 44.96 44.96 FALSE FALSE Change -Subsidy -Price -Alternate
472743 6/1/2001 1/1/2006 44.66 44.66 44.66 FALSE FALSE Change -Subsidy -Price -Alternate
472743 1/1/2006 1/1/2009 29.05 29.05 29.05 FALSE FALSE Change -Subsidy -Price -Alternate
472743 1/1/2009 3/1/2009 3.59 3.59 11.25 FALSE FALSE Change -Subsidy -Price -Alternate
472743 3/1/2009 5/1/2009 3.59 3.59 5.9 FALSE FALSE Change -Price
472743 5/1/2009 0 0 0 FALSE FALSE Delisted
472786 2/1/2013 9.95 9.95 9.95 FALSE TRUE New listing
472794 1/1/1998 2/1/1998 5.52 5.52 5.52 FALSE FALSE New Listing
472794 2/1/1998 4/1/1998 4.14 4.14 5.52 FALSE FALSE Change -Subsidy -Alternate
472794 4/1/1998 9/1/1998 4.14 4.14 4.14 FALSE FALSE Change -Price
472794 9/1/1998 8/1/2000 4.02 4.02 4.14 FALSE FALSE Change -Subsidy -Alternate
472794 8/1/2000 6/1/2006 2.47 2.47 4.14 FALSE FALSE Change -Subsidy -Alternate
472794 6/1/2006 9/1/2009 2.47 2.47 4.35 FALSE FALSE Change +Price
472794 9/1/2009 0 0 0 FALSE FALSE Delisted
472808 1/1/1998 2/1/1998 10.32 10.32 10.32 FALSE FALSE New Listing
472808 2/1/1998 4/1/1998 8.24 8.24 10.32 FALSE FALSE Change -Subsidy -Alternate
472808 4/1/1998 9/1/1998 8.24 8.24 8.24 FALSE FALSE Change -Price
472808 9/1/1998 8/1/2000 8.03 8.03 8.24 FALSE FALSE Change -Subsidy -Alternate
472808 8/1/2000 6/1/2006 3.83 3.83 8.24 FALSE FALSE Change -Subsidy -Alternate
472808 6/1/2006 9/1/2009 3.83 3.83 8.65 FALSE FALSE Change +Price
472808 9/1/2009 0 0 0 FALSE FALSE Delisted
472816 1/1/1998 8/1/1999 1.8 1.8 1.8 FALSE FALSE New Listing
472816 8/1/1999 6/1/2001 1.77 1.77 1.8 FALSE FALSE Change -Subsidy -Alternate
472816 6/1/2001 0 0 0 FALSE FALSE Delisted
472824 1/1/1998 8/1/1999 3.6 3.6 3.6 FALSE FALSE New Listing
472824 8/1/1999 8/1/2005 3.55 3.55 3.6 FALSE FALSE Change -Subsidy -Alternate
472824 8/1/2005 1/1/2008 3.55 3.55 4.1 FALSE FALSE Change +Price
472824 1/1/2008 0 0 0 FALSE FALSE Delisted
472832 1/1/1998 8/1/2000 7.9 7.9 7.9 FALSE FALSE New Listing
472832 8/1/2000 1/1/2004 6.8 6.8 7.9 FALSE FALSE Change -Subsidy -Alternate
472832 1/1/2004 1/1/2008 5.45 5.45 5.45 FALSE FALSE Change -Subsidy -Price -Alternate
472832 1/1/2008 0 0 0 FALSE FALSE Delisted
472840 1/1/1998 8/1/2000 13.5 13.5 13.5 FALSE FALSE New Listing
472840 8/1/2000 1/1/2004 10.2 10.2 13.5 FALSE FALSE Change -Subsidy -Alternate
472840 1/1/2004 1/1/2008 7.54 7.54 7.54 FALSE FALSE Change -Subsidy -Price -Alternate
472840 1/1/2008 0 0 0 FALSE FALSE Delisted
472859 1/1/1998 10/1/1999 27.2 27.2 27.2 FALSE TRUE New Listing
472859 10/1/1999 2/1/2003 22.79 22.79 22.79 FALSE TRUE Change -Subsidy -Price -Alternate
472859 2/1/2003 4/1/2003 13.6 13.6 22.79 FALSE TRUE Change -Subsidy -Alternate
472859 4/1/2003 13.6 13.6 13.6 FALSE TRUE Change -Price
472867 1/1/1998 10/1/1999 54.4 54.4 54.4 FALSE TRUE New Listing
472867 10/1/1999 2/1/2003 41.95 41.95 41.95 FALSE TRUE Change -Subsidy -Price -Alternate
472867 2/1/2003 4/1/2003 27.2 27.2 41.95 FALSE TRUE Change -Subsidy -Alternate
472867 4/1/2003 27.2 27.2 27.2 FALSE TRUE Change -Price
472875 12/1/2010 9/1/2013 14 14 14 FALSE FALSE New listing
472875 9/1/2013 17.6 17.6 17.6 FALSE FALSE Change +Subsidy +Price +Alternate
472891 7/1/2005 10/1/2007 333 333 333 FALSE FALSE New listing
472891 10/1/2007 10/1/2008 299.7 299.7 299.7 FALSE FALSE Change -Subsidy -Price -Alternate
472891 10/1/2008 0 0 0 FALSE FALSE Delisted
472905 3/1/1999 1/1/2006 153.57 153.57 153.57 FALSE FALSE New Listing
472905 1/1/2006 7/1/2008 185 185 185 FALSE FALSE Change +Subsidy +Price +Alternate
472905 7/1/2008 0 0 0 FALSE FALSE Delisted
472956 4/1/2005 7/1/2008 19 19 19 FALSE FALSE New listing
472956 7/1/2008 0 0 0 FALSE FALSE Delisted
472972 1/1/1998 12/1/2000 1.5 1.5 5.34 FALSE FALSE New Listing
472972 12/1/2000 4/1/2002 1.5 1.5 6.5 FALSE FALSE Change +Price
472972 4/1/2002 0 0 0 FALSE FALSE Delisted
474088 5/16/1994 9/1/1996 36.26 36.26 36.26 FALSE FALSE New Listing
474088 9/1/1996 3/1/1999 36 36 36.26 FALSE FALSE Change -Subsidy -Alternate
474088 3/1/1999 6/1/2006 31.32 31.32 36.26 FALSE FALSE Change -Subsidy -Alternate
474088 6/1/2006 0 0 0 FALSE FALSE Delisted
474134 3/1/1998 8/1/2000 7.75 7.75 11.45 FALSE TRUE New Listing
474134 8/1/2000 10/1/2002 7 7 11.45 FALSE TRUE Change -Subsidy -Alternate
474134 10/1/2002 6/1/2009 5.4 5.4 11.45 FALSE TRUE Change -Subsidy -Alternate
474134 6/1/2009 5.4 5.4 22.96 FALSE TRUE Change +Price
474142 3/1/1998 8/1/2000 7.75 7.75 11.45 FALSE TRUE New Listing
474142 8/1/2000 10/1/2002 7 7 11.45 FALSE TRUE Change -Subsidy -Alternate
474142 10/1/2002 6/1/2009 5.4 5.4 11.45 FALSE TRUE Change -Subsidy -Alternate
474142 6/1/2009 5.4 5.4 22.96 FALSE TRUE Change +Price
474150 3/1/1998 8/1/2000 7.75 7.75 10.45 FALSE TRUE New Listing
474150 8/1/2000 10/1/2002 7 7 10.45 FALSE TRUE Change -Subsidy -Alternate
474150 10/1/2002 5/1/2006 5.4 5.4 10.45 FALSE TRUE Change -Subsidy -Alternate
474150 5/1/2006 0 0 0 FALSE FALSE Delisted
474223 11/1/1997 4/1/1998 23.36 23.36 23.36 FALSE FALSE New Listing
474223 4/1/1998 11/1/1998 23.36 23.36 23.36 FALSE FALSE Change -Subsidy -Price -Alternate
474223 11/1/1998 3/1/1999 18.69 18.69 18.69 FALSE FALSE Change -Subsidy -Price -Alternate
474223 3/1/1999 7/1/1999 15.7 15.7 15.7 FALSE FALSE Change -Subsidy -Price -Alternate
474223 7/1/1999 1/1/2001 13.35 13.35 13.35 FALSE FALSE Change -Subsidy -Price -Alternate
474223 1/1/2001 12/1/2002 10 10 10 FALSE FALSE Change -Subsidy -Price -Alternate
474223 12/1/2002 3/1/2003 7.8 7.8 7.8 FALSE FALSE Change -Subsidy -Price -Alternate
474223 3/1/2003 1/1/2013 0 0 0 FALSE FALSE Delisted
474223 1/1/2013 9.7 9.7 9.7 FALSE FALSE New Listing
474320 1/1/2001 5/1/2010 100 100 100 FALSE TRUE New Listing
474320 5/1/2010 9/1/2013 50 50 50 FALSE TRUE Change -Subsidy -Price -Alternate
474320 9/1/2013 102.5 102.5 102.5 FALSE TRUE Change +Subsidy +Price +Alternate
474398 10/1/1999 6/1/2004 34.54 34.54 34.54 FALSE TRUE New Listing
474398 6/1/2004 3/1/2005 24.18 24.18 34.54 FALSE TRUE Change -Subsidy -Alternate
474398 3/1/2005 8/1/2005 24.18 24.18 24.18 FALSE TRUE Change -Price
474398 8/1/2005 1/1/2008 19.5 19.5 24.18 FALSE TRUE Change -Subsidy -Alternate
474398 1/1/2008 12/1/2009 19.5 19.5 19.5 FALSE TRUE Change -Price
474398 12/1/2009 3/1/2010 9.75 9.75 19.5 FALSE TRUE Change -Subsidy -Alternate
474398 3/1/2010 0 0 0 FALSE FALSE Delisted
474436 4/1/1998 3/1/1999 0.43 0.43 0.61 FALSE FALSE New Listing
474436 3/1/1999 12/1/1999 0.43 0.43 0.8 FALSE FALSE Change +Price
474436 12/1/1999 2/1/2000 0.43 0.43 1.04 FALSE FALSE Change +Price
474436 2/1/2000 10/1/2001 0.43 0.43 1.56 FALSE FALSE Change +Price
474436 10/1/2001 3/1/2002 0.43 0.43 1.64 FALSE FALSE Change +Price
474436 3/1/2002 0.43 0.43 1.72 FALSE FALSE Change +Price
474703 5/16/1994 8/1/2001 17.65 17.65 17.65 FALSE FALSE New Listing
474703 8/1/2001 1/1/2003 12.36 12.36 12.36 FALSE FALSE Change -Subsidy -Price -Alternate
474703 1/1/2003 0 0 0 FALSE FALSE Delisted
474711 5/16/1994 8/1/2001 8.81 8.81 8.81 FALSE FALSE New Listing
474711 8/1/2001 9/1/2002 6.17 6.17 6.17 FALSE FALSE Change -Subsidy -Price -Alternate
474711 9/1/2002 1/1/2003 4.8 4.8 4.8 FALSE FALSE Change -Subsidy -Price -Alternate
474711 1/1/2003 0 0 0 FALSE FALSE Delisted
475017 7/1/1998 3/1/2001 51.5 51.5 51.5 FALSE FALSE New Listing
475017 3/1/2001 0 0 0 FALSE FALSE Delisted
475238 6/1/1995 6/1/1999 81.25 81.25 81.25 FALSE FALSE New Listing
475238 6/1/1999 11/1/1999 81.25 81.25 112.5 FALSE FALSE Change +Price
475238 11/1/1999 3/1/2012 182.5 182.5 182.5 FALSE FALSE Change +Subsidy +Price +Alternate
475238 3/1/2012 0 0 0 FALSE FALSE Delisted
475378 12/1/1998 12/1/1999 13.33 13.33 13.33 FALSE TRUE New Listing
475378 12/1/1999 2/1/2000 5.9 5.9 13.33 FALSE TRUE Change -Subsidy -Alternate
475378 2/1/2000 4/1/2000 5.9 5.9 5.9 FALSE TRUE Change -Price
475378 4/1/2000 12/1/2003 0 0 0 FALSE FALSE Delisted
475378 12/1/2003 2/1/2007 5.5 5.5 5.5 FALSE TRUE New Listing
475378 2/1/2007 0 0 0 FALSE FALSE Delisted
475963 5/1/1999 7/1/1999 7.7 7.7 11.91 FALSE TRUE New Listing
475963 7/1/1999 4/1/2011 10.65 10.65 11.91 FALSE TRUE Change +Subsidy +Alternate
475963 4/1/2011 11.91 11.91 11.91 FALSE TRUE Change +Subsidy +Alternate
475971 4/1/2001 7/1/2005 126.23 126.23 126.23 FALSE FALSE New listing
475971 7/1/2005 8/1/2007 88.36 88.36 88.36 FALSE FALSE Change -Subsidy -Price -Alternate
475971 8/1/2007 9/1/2010 47 47 47 FALSE FALSE Change -Subsidy -Price -Alternate
475971 9/1/2010 39.76 39.76 39.76 FALSE FALSE Change -Subsidy -Price -Alternate
475998 6/1/1995 9/1/2000 92.83 92.83 92.83 FALSE TRUE New Listing
475998 9/1/2000 0 0 0 FALSE FALSE Delisted
476005 6/1/1995 11/1/1997 209.53 209.53 209.53 FALSE TRUE New Listing
476005 11/1/1997 10/1/2008 195 195 195 FALSE TRUE Change -Subsidy -Price -Alternate
476005 10/1/2008 221 221 221 FALSE TRUE Change +Subsidy +Price +Alternate
476285 6/1/1995 6/1/2008 30 30 30 FALSE TRUE New Listing
476285 6/1/2008 1/1/2011 36 36 36 FALSE TRUE Change +Subsidy +Price +Alternate
476285 1/1/2011 0 0 0 FALSE FALSE Delisted
476552 8/1/2009 5/1/2012 14.14 14.14 14.14 FALSE TRUE New listing
476552 5/1/2012 0 0 0 FALSE FALSE Delisted
476579 6/1/1998 7/1/2000 6.87 6.87 6.87 FALSE FALSE New Listing
476579 7/1/2000 11/1/2003 1.95 1.95 1.95 FALSE FALSE Change -Subsidy -Price -Alternate
476579 11/1/2003 5/1/2004 1.45 1.45 1.45 FALSE FALSE Change -Subsidy -Price -Alternate
476579 5/1/2004 11/1/2005 0 0 0 FALSE FALSE Delisted
476579 11/1/2005 1/1/2006 1.45 1.45 1.45 FALSE FALSE New Listing
476579 1/1/2006 7/1/2006 1.45 1.45 1.9 FALSE FALSE Change +Price
476579 7/1/2006 0 0 0 FALSE FALSE Delisted
476587 3/1/1995 2/1/2001 1.37 1.37 1.7 FALSE FALSE New Listing
476587 2/1/2001 3/1/2001 0 0 0 FALSE FALSE Delisted
476587 3/1/2001 9/1/2001 1.37 1.37 1.87 FALSE FALSE New Listing
476587 9/1/2001 12/1/2001 0.68 0.68 1.87 FALSE FALSE Change -Subsidy -Alternate
476587 12/1/2001 0 0 0 FALSE FALSE Delisted
476625 1/30/1995 8/1/1999 0 0 0 TRUE FALSE New Listing
476625 8/1/1999 0 0 0 FALSE FALSE Delisted
476986 4/1/2001 7/1/2005 168.3 168.3 168.3 FALSE FALSE New listing
476986 7/1/2005 8/1/2007 117.81 117.81 117.81 FALSE FALSE Change -Subsidy -Price -Alternate
476986 8/1/2007 9/1/2010 62.66 62.66 62.66 FALSE FALSE Change -Subsidy -Price -Alternate
476986 9/1/2010 53.01 53.01 53.01 FALSE FALSE Change -Subsidy -Price -Alternate
477028 5/1/1999 6/1/2008 50.4 50.4 50.4 FALSE TRUE New Listing
477028 6/1/2008 60.48 60.48 60.48 FALSE TRUE Change +Subsidy +Price +Alternate
477672 4/1/1998 8/1/2000 3.25 3.25 3.25 FALSE TRUE New Listing
477672 8/1/2000 3/1/2002 3.25 3.25 3.4 FALSE TRUE Change +Price
477672 3/1/2002 9/1/2007 3.25 3.25 4.18 FALSE TRUE Change +Price
477672 9/1/2007 3/1/2013 4.47 4.47 4.47 FALSE TRUE Change +Subsidy +Price +Alternate
477672 3/1/2013 0 0 0 FALSE FALSE Delisted
478008 1/1/1999 0 0 0 FALSE FALSE New Listing
478369 7/1/1998 9/1/1998 205.44 205.44 205.44 FALSE TRUE New Listing
478369 9/1/1998 10/1/1998 102.72 102.72 102.72 FALSE TRUE Change -Subsidy -Price -Alternate
478369 10/1/1998 11/1/1998 82.18 82.18 102.72 FALSE TRUE Change -Subsidy -Alternate
478369 11/1/1998 4/1/1999 50 50 102.72 FALSE TRUE Change -Subsidy -Alternate
478369 4/1/1999 12/1/2006 0 0 0 FALSE FALSE Delisted
478369 12/1/2006 6/1/2007 163.8 163.8 163.8 FALSE FALSE New Listing
478369 6/1/2007 9/1/2007 4.74 4.74 163.8 FALSE FALSE Change -Subsidy -Alternate
478369 9/1/2007 5/1/2008 0 0 0 FALSE FALSE Delisted
478369 5/1/2008 7/1/2008 163.8 163.8 163.8 FALSE FALSE New Listing
478369 7/1/2008 7/1/2009 0 0 0 FALSE FALSE Delisted
478369 7/1/2009 102.72 102.72 102.72 FALSE FALSE New Listing
478474 1/1/1997 3/1/2009 154.3 154.3 154.3 FALSE TRUE New Listing
478474 3/1/2009 285 285 285 FALSE TRUE Change +Subsidy +Price +Alternate
478490 8/1/2012 18.48 18.48 18.48 FALSE FALSE New listing
478504 8/1/2012 18.48 18.48 18.48 FALSE FALSE New listing
478547 5/1/1999 4/1/2005 2.75 2.75 2.75 FALSE TRUE New Listing
478547 4/1/2005 3/1/2006 2.75 2.75 2.85 FALSE TRUE Change +Price
478547 3/1/2006 9/1/2006 2.75 2.75 3.06 FALSE TRUE Change +Price
478547 9/1/2006 12/1/2010 3.06 3.06 3.06 FALSE TRUE Change +Subsidy +Alternate
478547 12/1/2010 12/1/2012 3.87 3.87 3.87 FALSE TRUE Change +Subsidy +Price +Alternate
478547 12/1/2012 3/1/2013 2.68 2.68 3.87 FALSE TRUE Change -Subsidy -Alternate
478547 3/1/2013 0 0 0 FALSE FALSE Delisted
478717 11/1/1998 3/1/1999 18.69 18.69 18.69 FALSE FALSE New Listing
478717 3/1/1999 7/1/1999 15.7 15.7 15.7 FALSE FALSE Change -Subsidy -Price -Alternate
478717 7/1/1999 11/1/1999 13.35 13.35 13.35 FALSE FALSE Change -Subsidy -Price -Alternate
478717 11/1/1999 0 0 0 FALSE FALSE Delisted
479209 5/1/1998 7/1/2001 28.46 28.46 28.46 FALSE FALSE New Listing
479209 7/1/2001 8/1/2003 31.31 31.31 31.31 FALSE FALSE Change +Subsidy +Price +Alternate
479209 8/1/2003 6/1/2011 34.44 34.44 34.44 FALSE FALSE Change +Subsidy +Price +Alternate
479209 6/1/2011 0 0 0 FALSE FALSE Delisted
479217 5/1/1998 7/1/2001 25.12 25.12 25.12 FALSE FALSE New Listing
479217 7/1/2001 3/1/2008 27.63 27.63 27.63 FALSE FALSE Change +Subsidy +Price +Alternate
479217 3/1/2008 0 0 0 FALSE FALSE Delisted
479233 6/1/1998 2/1/2001 4.5 4.5 4.5 FALSE TRUE New Listing
479233 2/1/2001 8/1/2004 4.5 4.5 10 FALSE TRUE Change +Price
479233 8/1/2004 7/1/2007 3.8 3.8 3.8 FALSE TRUE Change -Subsidy -Price -Alternate
479233 7/1/2007 2/1/2010 4.2 4.2 4.2 FALSE TRUE Change +Subsidy +Price +Alternate
479233 2/1/2010 5/1/2010 3.65 3.65 4.2 FALSE TRUE Change -Subsidy -Alternate
479233 5/1/2010 7/1/2011 0 0 0 FALSE FALSE Delisted
479233 7/1/2011 4.2 4.2 4.2 FALSE TRUE New Listing
479438 10/1/2000 4/1/2001 42 42 42 FALSE FALSE New Listing
479438 4/1/2001 11/1/2002 28 28 28 FALSE FALSE Change -Subsidy -Price -Alternate
479438 11/1/2002 7/1/2004 14.17 14.17 28 FALSE FALSE Change -Subsidy -Alternate
479438 7/1/2004 7/1/2005 8.36 8.36 28 FALSE FALSE Change -Subsidy -Alternate
479438 7/1/2005 10/1/2006 6.97 6.97 28 FALSE FALSE Change -Subsidy -Alternate
479438 10/1/2006 3/1/2008 5.12 5.12 28 FALSE FALSE Change -Subsidy -Alternate
479438 3/1/2008 6/1/2008 3.6 3.6 28 FALSE FALSE Change -Subsidy -Alternate
479438 6/1/2008 0 0 0 FALSE FALSE Delisted
479446 5/1/1996 9/1/2001 1.12 1.12 1.25 FALSE FALSE New Listing
479446 9/1/2001 12/1/2001 0.7 0.7 1.25 FALSE FALSE Change -Subsidy -Alternate
479446 12/1/2001 0 0 0 FALSE FALSE Delisted
479489 8/1/1998 5/1/2001 41.05 41.05 41.05 FALSE TRUE New Listing
479489 5/1/2001 8/1/2006 35.8 35.8 35.8 FALSE TRUE Change -Subsidy -Price -Alternate
479489 8/1/2006 26.46 26.46 26.46 FALSE TRUE Change -Subsidy -Price -Alternate
479497 ######## 8/1/1998 0 0 0 TRUE FALSE New Listing
479497 8/1/1998 6/1/2004 10.15 10.15 10.15 FALSE FALSE Change +Subsidy +Price +Alternate -CBS
479497 6/1/2004 0 0 0 FALSE FALSE Delisted
479616 5/16/1994 2/1/1999 2.15 2.15 2.15 FALSE FALSE New Listing
479616 2/1/1999 7/1/1999 1.82 1.82 1.82 FALSE FALSE Change -Subsidy -Price -Alternate
479616 7/1/1999 5/1/2000 1.37 1.37 1.37 FALSE FALSE Change -Subsidy -Price -Alternate
479616 5/1/2000 1/1/2003 1.37 1.37 2.06 FALSE FALSE Change +Price
479616 1/1/2003 0 0 0 FALSE FALSE Delisted
480223 5/1/2001 3/1/2002 45 45 45 FALSE TRUE New listing
480223 3/1/2002 0 0 0 FALSE FALSE Delisted
480304 2/1/1999 12/1/1999 100 100 100 FALSE FALSE New Listing
480304 12/1/1999 9/1/2004 60.8 60.8 60.8 FALSE FALSE Change -Subsidy -Price -Alternate
480304 9/1/2004 9/1/2007 54.72 54.72 54.72 FALSE FALSE Change -Subsidy -Price -Alternate
480304 9/1/2007 0 0 0 FALSE FALSE Delisted
480533 6/1/1998 7/1/2004 13.54 13.54 13.54 FALSE TRUE New Listing
480533 7/1/2004 11/1/2010 18.2 18.2 18.2 FALSE TRUE Change +Subsidy +Price +Alternate
480533 11/1/2010 22 22 22 FALSE TRUE Change +Subsidy +Price +Alternate
480541 6/1/1998 9/1/2000 27.07 27.07 27.07 FALSE FALSE New Listing
480541 9/1/2000 4/1/2001 21.56 21.56 21.56 FALSE FALSE Change -Subsidy -Price -Alternate
480541 4/1/2001 4/1/2002 12.07 12.07 21.56 FALSE FALSE Change -Subsidy -Alternate
480541 4/1/2002 2/1/2003 5.95 5.95 21.56 FALSE FALSE Change -Subsidy -Alternate
480541 2/1/2003 0 0 0 FALSE FALSE Delisted
480568 6/1/1998 9/1/2000 31.55 31.55 31.55 FALSE FALSE New Listing
480568 9/1/2000 4/1/2001 25.2 25.2 25.2 FALSE FALSE Change -Subsidy -Price -Alternate
480568 4/1/2001 4/1/2002 14.11 14.11 25.2 FALSE FALSE Change -Subsidy -Alternate
480568 4/1/2002 2/1/2003 7.01 7.01 25.2 FALSE FALSE Change -Subsidy -Alternate
480568 2/1/2003 0 0 0 FALSE FALSE Delisted
480576 12/1/1998 11/1/2001 14.5 14.5 14.5 FALSE FALSE New Listing
480576 11/1/2001 2/1/2003 14.5 14.5 20.5 FALSE FALSE Change +Price
480576 2/1/2003 8/1/2010 14.5 14.5 22.5 FALSE FALSE Change +Price
480576 8/1/2010 0 0 0 FALSE FALSE Delisted
480797 6/1/1998 2/1/1999 59.84 59.84 59.84 FALSE FALSE New Listing
480797 2/1/1999 5/1/2000 56.4 56.4 56.4 FALSE FALSE Change -Subsidy -Price -Alternate
480797 5/1/2000 8/1/2000 24.68 56.4 56.4 FALSE FALSE Change -Subsidy
480797 8/1/2000 9/1/2000 14.24 56.4 56.4 FALSE FALSE Change -Subsidy
480797 9/1/2000 1/1/2001 12.42 56.4 56.4 FALSE FALSE Change -Subsidy
480797 1/1/2001 9/1/2001 6.71 39.48 39.48 FALSE FALSE Change -Subsidy -Price -Alternate
480797 9/1/2001 2/1/2004 2.24 39.48 39.48 FALSE FALSE Change -Subsidy
480797 2/1/2004 5/1/2004 15.67 15.67 39.48 FALSE FALSE Change +Subsidy -Alternate
480797 5/1/2004 0 0 0 FALSE FALSE Delisted
481017 6/1/1998 9/1/2000 40.59 40.59 40.59 FALSE FALSE New Listing
481017 9/1/2000 11/1/2000 35.1 35.1 35.1 FALSE FALSE Change -Subsidy -Price -Alternate
481017 11/1/2000 9/1/2001 32.99 32.99 32.99 FALSE FALSE Change -Subsidy -Price -Alternate
481017 9/1/2001 4/1/2002 28.4 28.4 28.4 FALSE FALSE Change -Subsidy -Price -Alternate
481017 4/1/2002 10/1/2002 28.4 28.4 28.4 FALSE FALSE Change
481017 10/1/2002 5/1/2003 24.91 24.91 24.91 FALSE FALSE Change -Subsidy -Price -Alternate
481017 5/1/2003 9/1/2003 23.94 23.94 23.94 FALSE FALSE Change -Subsidy -Price -Alternate
481017 9/1/2003 6/1/2004 19.21 19.21 19.21 FALSE FALSE Change -Subsidy -Price -Alternate
481017 6/1/2004 12/1/2004 4.38 18.5 18.5 FALSE FALSE Change -Subsidy -Price -Alternate
481017 12/1/2004 2/1/2006 4.38 18.32 18.32 FALSE FALSE Change -Price -Alternate
481017 2/1/2006 9/1/2010 4.03 18.32 18.32 FALSE FALSE Change -Subsidy
481017 9/1/2010 12/1/2012 18.32 18.32 18.32 FALSE FALSE Change +Subsidy
481017 12/1/2012 1/1/2013 0.84 0.84 18.32 FALSE FALSE Change -Subsidy -Alternate
481017 1/1/2013 0 0 0 FALSE FALSE Delisted
481076 6/1/1998 9/1/2000 57.75 57.75 57.75 FALSE FALSE New Listing
481076 9/1/2000 11/1/2000 50.1 50.1 50.1 FALSE FALSE Change -Subsidy -Price -Alternate
481076 11/1/2000 9/1/2001 48.09 48.09 48.09 FALSE FALSE Change -Subsidy -Price -Alternate
481076 9/1/2001 4/1/2002 41.39 41.39 41.39 FALSE FALSE Change -Subsidy -Price -Alternate
481076 4/1/2002 10/1/2002 41.39 41.39 41.39 FALSE FALSE Change
481076 10/1/2002 5/1/2003 36.3 36.3 36.3 FALSE FALSE Change -Subsidy -Price -Alternate
481076 5/1/2003 9/1/2003 34.89 34.89 34.89 FALSE FALSE Change -Subsidy -Price -Alternate
481076 9/1/2003 6/1/2004 28 28 28 FALSE FALSE Change -Subsidy -Price -Alternate
481076 6/1/2004 12/1/2004 6.38 26.96 26.96 FALSE FALSE Change -Subsidy -Price -Alternate
481076 12/1/2004 2/1/2006 6.38 26.7 26.7 FALSE FALSE Change -Price -Alternate
481076 2/1/2006 9/1/2010 5.87 26.7 26.7 FALSE FALSE Change -Subsidy
481076 9/1/2010 12/1/2012 26.7 26.7 26.7 FALSE FALSE Change +Subsidy
481076 12/1/2012 1/1/2013 1.39 1.39 26.7 FALSE FALSE Change -Subsidy -Alternate
481076 1/1/2013 0 0 0 FALSE FALSE Delisted
481084 6/1/1998 9/1/2000 82.5 82.5 82.5 FALSE FALSE New Listing
481084 9/1/2000 11/1/2000 70.95 70.95 70.95 FALSE FALSE Change -Subsidy -Price -Alternate
481084 11/1/2000 9/1/2001 66.69 66.69 66.69 FALSE FALSE Change -Subsidy -Price -Alternate
481084 9/1/2001 4/1/2002 57.4 57.4 57.4 FALSE FALSE Change -Subsidy -Price -Alternate
481084 4/1/2002 10/1/2002 57.4 57.4 57.4 FALSE FALSE Change
481084 10/1/2002 5/1/2003 50.35 50.35 50.35 FALSE FALSE Change -Subsidy -Price -Alternate
481084 5/1/2003 9/1/2003 48.39 48.39 48.39 FALSE FALSE Change -Subsidy -Price -Alternate
481084 9/1/2003 6/1/2004 38.83 38.83 38.83 FALSE FALSE Change -Subsidy -Price -Alternate
481084 6/1/2004 12/1/2004 8.85 37.39 37.39 FALSE FALSE Change -Subsidy -Price -Alternate
481084 12/1/2004 2/1/2006 8.85 37.02 37.02 FALSE FALSE Change -Price -Alternate
481084 2/1/2006 9/1/2010 8.14 37.02 37.02 FALSE FALSE Change -Subsidy
481084 9/1/2010 12/1/2012 37.02 37.02 37.02 FALSE FALSE Change +Subsidy
481084 12/1/2012 1/1/2013 2.44 2.44 37.02 FALSE FALSE Change -Subsidy -Alternate
481084 1/1/2013 0 0 0 FALSE FALSE Delisted
481114 9/1/2008 9/1/2011 110.4 110.4 110.4 FALSE FALSE New listing
481114 9/1/2011 62 62 62 FALSE FALSE Change -Subsidy -Price -Alternate
481386 9/1/1998 10/1/1998 102.72 102.72 102.72 FALSE TRUE New Listing
481386 10/1/1998 11/1/1998 82.18 82.18 82.18 FALSE TRUE Change -Subsidy -Price -Alternate
481386 11/1/1998 10/1/1999 50 50 50 FALSE TRUE Change -Subsidy -Price -Alternate
481386 10/1/1999 9/1/2000 50 50 50 FALSE FALSE Change -OP
481386 9/1/2000 3/1/2001 45 45 45 FALSE FALSE Change -Subsidy -Price -Alternate
481386 3/1/2001 7/1/2003 9.9 9.9 9.9 FALSE FALSE Change -Subsidy -Price -Alternate
481386 7/1/2003 0 0 0 FALSE FALSE Delisted
481394 9/1/1998 10/1/1998 105.74 105.74 105.74 FALSE TRUE New Listing
481394 10/1/1998 11/1/1998 84.59 84.59 84.59 FALSE TRUE Change -Subsidy -Price -Alternate
481394 11/1/1998 9/1/2000 60 60 60 FALSE TRUE Change -Subsidy -Price -Alternate
481394 9/1/2000 3/1/2001 54 54 54 FALSE TRUE Change -Subsidy -Price -Alternate
481394 3/1/2001 7/1/2003 12.24 12.24 12.24 FALSE FALSE Change -Subsidy -Price -Alternate -OP
481394 7/1/2003 0 0 0 FALSE FALSE Delisted
481599 2/1/1999 1/1/2005 146.46 230.7 230.7 FALSE FALSE New Listing
481599 1/1/2005 12/1/2009 146.46 200 200 FALSE FALSE Change -Price -Alternate
481599 12/1/2009 4/1/2010 146.46 146.46 146.46 FALSE FALSE Change -Price -Alternate
481599 4/1/2010 7/1/2010 26.55 26.55 146.46 FALSE FALSE Change -Subsidy -Alternate
481599 7/1/2010 0 0 0 FALSE FALSE Delisted
481793 3/1/2001 10/1/2004 1772.5 1772.5 1772.5 FALSE FALSE New Listing
481793 10/1/2004 0 0 0 FALSE FALSE Delisted
481807 3/1/2001 10/1/2004 2358.75 2358.75 2358.75 FALSE FALSE New Listing
481807 10/1/2004 0 0 0 FALSE FALSE Delisted
481815 3/1/2001 10/1/2004 2951.25 2951.25 2951.25 FALSE FALSE New Listing
481815 10/1/2004 0 0 0 FALSE FALSE Delisted
482188 5/16/1994 8/1/2000 20.56 20.56 20.56 FALSE FALSE New Listing
482188 8/1/2000 0 0 0 FALSE FALSE Delisted
482358 5/1/1996 9/1/2001 2.29 2.29 2.54 FALSE FALSE New Listing
482358 9/1/2001 12/1/2001 1.6 1.6 2.54 FALSE FALSE Change -Subsidy -Alternate
482358 12/1/2001 0 0 0 FALSE FALSE Delisted
482412 6/1/1997 9/1/1998 32.77 32.77 54.6 FALSE FALSE New Listing
482412 9/1/1998 1/1/1999 17 17 32.77 FALSE FALSE Change -Subsidy -Price -Alternate
482412 1/1/1999 4/1/2000 10 10 32.77 FALSE FALSE Change -Subsidy -Price -Alternate
482412 4/1/2000 6/1/2001 10 10 10 FALSE FALSE Change -Price
482412 6/1/2001 8/1/2001 5.83 5.83 5.83 FALSE FALSE Change -Subsidy -Price -Alternate
482412 8/1/2001 0 0 0 FALSE FALSE Delisted
482420 6/1/1997 9/1/1998 65.53 65.53 109.2 FALSE FALSE New Listing
482420 9/1/1998 1/1/1999 34 34 65.53 FALSE FALSE Change -Subsidy -Price -Alternate
482420 1/1/1999 4/1/2000 20 20 65.53 FALSE FALSE Change -Subsidy +Price -Alternate
482420 4/1/2000 6/1/2001 20 20 20 FALSE FALSE Change -Price
482420 6/1/2001 8/1/2001 11.67 11.67 11.67 FALSE FALSE Change -Subsidy -Price -Alternate
482420 8/1/2001 0 0 0 FALSE FALSE Delisted
483206 7/1/1998 3/1/1999 36 36 36 FALSE FALSE New Listing
483206 3/1/1999 31.32 31.32 31.32 FALSE FALSE Change -Subsidy -Price -Alternate
483214 9/1/1998 3/1/1999 54 54 54 FALSE FALSE New Listing
483214 3/1/1999 8/1/2010 46.98 46.98 46.98 FALSE FALSE Change -Subsidy -Price -Alternate
483214 8/1/2010 0 0 0 FALSE FALSE Delisted
483222 7/1/1998 3/1/1999 72 72 72 FALSE FALSE New Listing
483222 3/1/1999 2/1/2014 62.64 62.64 62.64 FALSE FALSE Change -Subsidy -Price -Alternate
483222 2/1/2014 0 0 0 FALSE FALSE Delisted
483230 8/1/1998 3/1/1999 108 108 108 FALSE FALSE New Listing
483230 3/1/1999 2/1/2014 93.96 93.96 93.96 FALSE FALSE Change -Subsidy -Price -Alternate
483230 2/1/2014 0 0 0 FALSE FALSE Delisted
483451 6/1/1995 11/1/2000 194.95 194.95 194.95 FALSE TRUE New Listing
483451 11/1/2000 0 0 0 FALSE FALSE Delisted
483540 7/1/1999 11/1/2002 22.79 22.79 22.79 FALSE FALSE New Listing
483540 11/1/2002 2/1/2003 20.8 20.8 20.8 FALSE FALSE Change -Subsidy -Price -Alternate
483540 2/1/2003 0 0 0 FALSE FALSE Delisted
483699 4/1/1999 9/1/2006 5.83 5.83 5.83 FALSE TRUE New Listing
483699 9/1/2006 6/1/2008 6.39 6.39 6.39 FALSE TRUE Change +Subsidy +Price +Alternate
483699 6/1/2008 6.97 6.97 6.97 FALSE TRUE Change +Subsidy +Price +Alternate
483966 5/1/1999 5/1/2000 30.45 30.45 30.45 FALSE FALSE New Listing
483966 5/1/2000 8/1/2000 16.88 27 27 FALSE FALSE Change -Subsidy -Price -Alternate
483966 8/1/2000 9/1/2000 7.99 27 27 FALSE FALSE Change -Subsidy
483966 9/1/2000 1/1/2001 6.97 27 27 FALSE FALSE Change -Subsidy
483966 1/1/2001 3/1/2001 3.76 27 27 FALSE FALSE Change -Subsidy
483966 3/1/2001 9/1/2001 3.76 31.45 31.45 FALSE FALSE Change +Price +Alternate
483966 9/1/2001 5/1/2003 1.58 31.45 31.45 FALSE FALSE Change -Subsidy
483966 5/1/2003 6/1/2005 1.58 10 31.45 FALSE FALSE Change -Alternate
483966 6/1/2005 0 0 0 FALSE FALSE Delisted
484547 5/16/1994 9/1/2002 6.91 6.91 6.91 FALSE FALSE New Listing
484547 9/1/2002 3/1/2007 6 6 6 FALSE FALSE Change -Subsidy -Price -Alternate
484547 3/1/2007 0 0 0 FALSE FALSE Delisted
484555 5/16/1994 9/1/2002 13.63 13.63 13.63 FALSE FALSE New Listing
484555 9/1/2002 7/1/2006 10.9 10.9 10.9 FALSE FALSE Change -Subsidy -Price -Alternate
484555 7/1/2006 0 0 0 FALSE FALSE Delisted
485268 6/1/1999 12/1/1999 13.33 13.33 13.33 FALSE TRUE New Listing
485268 12/1/1999 1/1/2003 5.9 5.9 5.9 FALSE TRUE Change -Subsidy -Price -Alternate
485268 1/1/2003 0 0 0 FALSE FALSE Delisted
485276 6/1/1998 2/1/2000 9.15 9.15 9.15 FALSE FALSE New Listing
485276 2/1/2000 0 0 0 FALSE FALSE Delisted
485284 6/1/1998 2/1/2000 9.15 9.15 9.15 FALSE FALSE New Listing
485284 2/1/2000 0 0 0 FALSE FALSE Delisted
485357 10/1/1998 10/1/2001 519.75 519.75 519.75 FALSE FALSE New Listing
485357 10/1/2001 7/1/2008 600 600 600 FALSE FALSE Change +Subsidy +Price +Alternate
485357 7/1/2008 0 0 0 FALSE FALSE Delisted
485365 10/1/1998 1/1/1999 55.44 55.44 55.44 FALSE FALSE New Listing
485365 1/1/1999 7/1/2008 55.44 55.44 55.44 FALSE TRUE Change +OP
485365 7/1/2008 0 0 0 FALSE FALSE Delisted
485403 7/10/1998 4/1/1999 4.25 4.25 4.25 FALSE FALSE New Listing
485403 4/1/1999 0 0 0 FALSE FALSE Delisted
485411 4/1/2013 141.8 141.8 141.8 FALSE TRUE New listing
485772 10/1/1998 1/1/1999 1.83 1.83 1.83 FALSE TRUE New Listing
485772 1/1/1999 9/1/2002 1 1 1.83 FALSE TRUE Change -Subsidy -Alternate
485772 9/1/2002 12/1/2002 0.6 0.6 1.83 FALSE TRUE Change -Subsidy -Alternate
485772 12/1/2002 0 0 0 FALSE FALSE Delisted
485780 10/1/1998 1/1/1999 4.38 4.38 4.38 FALSE TRUE New Listing
485780 1/1/1999 9/1/2001 2.75 2.75 4.38 FALSE TRUE Change -Subsidy -Alternate
485780 9/1/2001 12/1/2001 1.89 1.89 4.38 FALSE TRUE Change -Subsidy -Alternate
485780 12/1/2001 0 0 0 FALSE FALSE Delisted
485799 10/1/1998 1/1/1999 4.38 4.38 4.38 FALSE TRUE New Listing
485799 1/1/1999 9/1/2001 2.75 2.75 4.38 FALSE TRUE Change -Subsidy -Alternate
485799 9/1/2001 7/1/2004 4.2 4.2 4.2 FALSE TRUE Change +Subsidy -Price +Alternate
485799 7/1/2004 1/1/2009 3.99 3.99 3.99 FALSE TRUE Change -Subsidy -Price -Alternate
485799 1/1/2009 3/1/2009 3.44 3.44 3.99 FALSE FALSE Change -Subsidy -Alternate -OP
485799 3/1/2009 4/1/2009 3.44 3.44 5.71 FALSE TRUE Change +Price +OP
485799 4/1/2009 0 0 0 FALSE FALSE Delisted
485802 10/1/1998 1/1/1999 4.38 4.38 4.38 FALSE TRUE New Listing
485802 1/1/1999 3/1/2004 2.75 2.75 4.38 FALSE TRUE Change -Subsidy -Alternate
485802 3/1/2004 0 0 0 FALSE FALSE Delisted
485810 10/1/1998 1/1/1999 1.83 1.83 1.83 FALSE TRUE New Listing
485810 1/1/1999 9/1/2002 1 1 1.83 FALSE TRUE Change -Subsidy -Alternate
485810 9/1/2002 12/1/2002 0.68 0.68 1.83 FALSE TRUE Change -Subsidy -Alternate
485810 12/1/2002 0 0 0 FALSE FALSE Delisted
485837 5/1/2001 6/1/2008 65.81 65.81 65.81 FALSE TRUE New listing
485837 6/1/2008 8/1/2013 78.97 78.97 78.97 FALSE TRUE Change +Subsidy +Price +Alternate
485837 8/1/2013 0 0 0 FALSE FALSE Delisted
485896 5/16/1994 5/1/1996 2.54 2.54 2.54 FALSE FALSE New Listing
485896 5/1/1996 5/1/2000 2.29 2.29 2.29 FALSE FALSE Change -Subsidy -Price -Alternate
485896 5/1/2000 9/1/2001 2.29 2.29 2.5 FALSE FALSE Change +Price
485896 9/1/2001 9/1/2006 1.6 1.6 1.6 FALSE FALSE Change -Subsidy -Price -Alternate
485896 9/1/2006 12/1/2006 1.15 1.15 1.6 FALSE FALSE Change -Subsidy -Alternate
485896 12/1/2006 0 0 0 FALSE FALSE Delisted
485926 5/16/1994 5/1/1996 7.45 7.45 7.45 FALSE FALSE New Listing
485926 5/1/1996 5/1/2000 6.74 6.74 6.74 FALSE FALSE Change -Subsidy -Price -Alternate
485926 5/1/2000 9/1/2001 6.74 6.74 7.3 FALSE FALSE Change +Price
485926 9/1/2001 4.72 4.72 4.72 FALSE FALSE Change -Subsidy -Price -Alternate
485942 8/1/1998 1/1/2001 7.29 7.29 7.29 FALSE TRUE New Listing
485942 1/1/2001 0 0 0 FALSE FALSE Delisted
485950 8/1/1998 2/1/2000 35 35 35 FALSE FALSE New Listing
485950 2/1/2000 6/1/2000 22 22 35 FALSE FALSE Change -Subsidy -Alternate
485950 6/1/2000 0 0 0 FALSE FALSE Delisted
485985 1/1/1999 6/1/2001 2 2 2 FALSE FALSE New Listing
485985 6/1/2001 9/1/2001 1.5 1.5 1.5 FALSE FALSE Change -Subsidy -Price -Alternate
485985 9/1/2001 12/1/2001 1.17 1.17 1.17 FALSE FALSE Change -Subsidy -Price -Alternate
485985 12/1/2001 0 0 0 FALSE FALSE Delisted
486329 10/1/1998 1/1/2013 319.8 319.8 319.8 FALSE FALSE New Listing
486329 1/1/2013 4/1/2013 95.94 95.94 319.8 FALSE FALSE Change -Subsidy -Alternate
486329 4/1/2013 0 0 0 FALSE FALSE Delisted
486396 6/1/1995 11/1/2000 103.86 103.86 103.86 FALSE TRUE New Listing
486396 11/1/2000 0 0 0 FALSE FALSE Delisted
486566 5/1/2000 12/1/2002 9 9 9 FALSE FALSE New Listing
486566 12/1/2002 0 0 0 FALSE FALSE Delisted
486574 5/1/2000 12/1/2002 6.2 6.2 6.2 FALSE FALSE New Listing
486574 12/1/2002 0 0 0 FALSE FALSE Delisted
486582 5/1/2000 12/1/2002 6.5 6.5 6.5 FALSE FALSE New Listing
486582 12/1/2002 0 0 0 FALSE FALSE Delisted
487074 3/1/2005 7/1/2009 26 26 26 FALSE FALSE New listing
487074 7/1/2009 6/1/2014 10.5 10.5 26 FALSE FALSE Change -Subsidy -Alternate
487074 6/1/2014 0 0 0 FALSE FALSE Delisted
487139 6/1/1998 3/1/2001 25.19 25.19 25.19 FALSE FALSE New Listing
487139 3/1/2001 0 0 0 FALSE FALSE Delisted
487163 11/1/1997 2/1/2004 180 180 180 FALSE TRUE New Listing
487163 2/1/2004 0 0 0 FALSE FALSE Delisted
487171 6/1/1995 5/1/1999 7.7 7.7 7.7 FALSE TRUE New Listing
487171 5/1/1999 7/1/1999 7.7 7.7 11.91 FALSE TRUE Change +Price
487171 7/1/1999 4/1/2011 10.65 10.65 11.91 FALSE TRUE Change +Subsidy +Alternate
487171 4/1/2011 11.91 11.91 11.91 FALSE TRUE Change +Subsidy +Alternate
487236 7/1/1998 3/1/2004 171.67 171.67 171.67 FALSE FALSE New Listing
487236 3/1/2004 7/1/2011 128.75 128.75 128.75 FALSE FALSE Change -Subsidy -Price -Alternate
487236 7/1/2011 126.2 126.2 126.2 FALSE FALSE Change -Subsidy -Price -Alternate
Trial Version
Not all rows exported
Stamp
18060934239615975424
17988876645578047488
17916819051540119552
17844761457502191616
17772703863464263680
1659133359500034048
1731190953537961984
7352737720147378176
7280680126109450240
7208622532071522304
7240505070742142976
7168447476704215040
7096389882666287104
7024332288628359168
6952274694590431232
6848334561881882624
6776276967843954688
6704219373806026752
6632161779768098816
6560104185730170880
6488046591692242944
6415988997654315008
6343931403616387072
6271873809578459136
6199816215540531200
6127758621502603264
6055701027464675328
5983643433426747392
5911585839388819456
5839528245350891520
5767470651312963584
5695413057275035648
5623355463237107712
5551297869199179776
5479240275161251840
5407182681123323904
5335125087085395968
5263067493047468032
5191009899009540096
5118952304971612160
2610451710572756992
2538394116534829056
2466336522496901120
13290195068137766912
4830721928819900416
4758664334781972480
4686606740744044544
4614549146706116608
4542491552668188672
1183779298440380416
1111721704402452480
1039664110364524544
967606516326596608
895548922288668672
823491328250740736
751433734212812800
1255836892478308352
13624001300772421632
13551943706734493696
13479886112696565760
13407828518658637824
13335770924620709888
13263713330582781952
13191655736544854016
13119598142506926080
3533685236137197568
3461627642099269632
3389570048061341696
3317512454023413760
3245454859985485824
3173397265947557888
3101339671909629952
3029282077871702016
2957224483833774080
2885166889795846144
2813109295757918208
2741051701719990272
2668994107682062336
2596936513644134400
2524878919606206464
2452821325568278528
2380763731530350592
2308706137492422656
2236648543454494720
2164590949416566784
2092533355378638848
2020475761340710912
1948418167302782976
1876360573264855040
1804302979226927104
1732245385188999168
6217122528561725440
6145064934523797504
6289180122599653376
15487494289457414144
15415436695419486208
15343379101381558272
15271321507343630336
15199263913305702400
15127206319267774464
1444015009037287424
1371957414999359488
1299899820961431552
1227842226923503616
1155784632885575680
1083727038847647744
1011669444809719808
939611850771791872
867554256733863936
795496662695936000
723439068658008064
651381474620080128
579323880582152192
9660552153709674496
9588494559671746560
9516436965633818624
16431994568926298112
16359936974888370176
16287879380850442240
16215821786812514304
16143764192774586368
16071706598736658432
15999649004698730496
15927591410660802560
15855533816622874624
15783476222584946688
15711418628547018752
15639361034509090816
15567303440471162880
15495245846433234944
15423188252395307008
15351130658357379072
15279073064319451136
15207015470281523200
15134957876243595264
15062900282205667328
14990842688167739392
14918785094129811456
14846727500091883520
14774669906053955584
14702612312016027648
14630554717978099712
14558497123940171776
14486439529902243840
14414381935864315904
14342324341826387968
14270266747788460032
14198209153750532096
14126151559712604160
14054093965674676224
13982036371636748288
13909978777598820352
13837921183560892416
13765863589522964480
13693805995485036544
13218137474099838976
13549690807409180672
13477633213371252736
13405575619333324800
13333518025295396864
13261460431257468928
5095683340392988672
5023625746355060736
4951568152317132800
4879510558279204864
12973230055105757184
12901172461067829248
12829114867029901312
12757057272991973376
12684999678954045440
12612942084916117504
12540884490878189568
12468826896840261632
12396769302802333696
12324711708764405760
12252654114726477824
12180596520688549888
12108538926650621952
12036481332612694016
11964423738574766080
11892366144536838144
11820308550498910208
13012356176380166144
12940298582342238208
11676193362423054336
11604135768385126400
12969312495175991296
12897254901138063360
13441972752747593728
13369915158709665792
13297857564671737856
13514030346785521664
11387962986271342592
11315905392233414656
11243847798195486720
11171790204157558784
11099732610119630848
11027675016081702912
10955617422043774976
10883559828005847040
10811502233967919104
10739444639929991168
10667387045892063232
10595329451854135296
10523271857816207360
10451214263778279424
10379156669740351488
10307099075702423552
10235041481664495616
10162983887626567680
10090926293588639744
10018868699550711808
9946811105512783872
9874753511474855936
3282133468376465408
3210075874338537472
9802695917436928000
9730638323399000064
9658580729361072128
9586523135323144192
9514465541285216256
9442407947247288320
9370350353209360384
9298292759171432448
9226235165133504512
9154177571095576576
9082119977057648640
9010062383019720704
8938004788981792768
8865947194943864832
8793889600905936896
8721832006868008960
8649774412830081024
8577716818792153088
8505659224754225152
8433601630716297216
8361544036678369280
8289486442640441344
8217428848602513408
8145371254564585472
4254641607539687424
4326699201577615360
17628588675388407808
17556531081350479872
17484473487312551936
17412415893274624000
17340358299236696064
17268300705198768128
18132991833653903360
9444379371595890688
9372321777557962752
9732609747747602432
146978316354584576
74920722316656640
18377268132973641728
18305210538935713792
18233152944897785856
18161095350859857920
18089037756821929984
18016980162784002048
17944922568746074112
17872864974708146176
17800807380670218240
17728749786632290304
17656692192594362368
17584634598556434432
17512577004518506496
17440519410480578560
17368461816442650624
15409231051792318464
15337173457754390528
15265115863716462592
15193058269678534656
15481288645830246400
4047778390378283008
3975720796340355072
3903663202302427136
3831605608264499200
4119835984416210944
17008173846253010944
16936116252215083008
16864058658177155072
16792001064139227136
16719943470101299200
16647885876063371264
16575828282025443328
6016681558818160640
5944623964780232704
5872566370742304768
5800508776704376832
5728451182666448896
5656393588628520960
5584335994590593024
16215540311835803648
16143482717797875712
16071425123759947776
15999367529722019840
15927309935684091904
15855252341646163968
6665199905159512064
6593142311121584128
6521084717083656192
6449027123045728256
6376969529007800320
6304911934969872384
6232854340931944448
15494964371456524288
15422906777418596352
15350849183380668416
15278791589342740480
15206733995304812544
15134676401266884608
15062618807228956672
14990561213191028736
14918503619153100800
14846446025115172864
14774388431077244928
14702330837039316992
14630273243001389056
14558215648963461120
14486158054925533184
14414100460887605248
14342042866849677312
14269985272811749376
14197927678773821440
14125870084735893504
14053812490697965568
13981754896660037632
13909697302622109696
13837639708584181760
13765582114546253824
13693524520508325888
13621466926470397952
13549409332432470016
13477351738394542080
13405294144356614144
13333236550318686208
5943175907966451712
5871118313928523776
5799060719890595840
5727003125852667904
4734460785319739392
4662403191281811456
12900890986091118592
12828833392053190656
12756775798015262720
12684718203977334784
12612660609939406848
12540603015901478912
12468545421863550976
12396487827825623040
12324430233787695104
12252372639749767168
12180315045711839232
12108257451673911296
12036199857635983360
11964142263598055424
11892084669560127488
11820027075522199552
11747969481484271616
6548936446126850048
6476878852088922112
6404821258050994176
6332763664013066240
6260706069975138304
6981282010354417664
6909224416316489728
6837166822278561792
6765109228240633856
6693051634202705920
11243566323218776064
11171508729180848128
11099451135142920192
11027393541104992256
10955335947067064320
10051350472058470400
9979292878020542464
9907235283982614528
9835177689944686592
9763120095906758656
10123408066096398336
9619004907830902784
3841337385681944576
3769279791644016640
3697222197606088704
3625164603568160768
3553107009530232832
10234760006687784960
10162702412649857024
10090644818611929088
10018587224574001152
9946529630536073216
9874472036498145280
9802414442460217344
9730356848422289408
9658299254384361472
9586241660346433536
9514184066308505600
139458756332224512
18441806166989209600
18369748572951281664
18297690978913353728
13506367850251550720
13578425444289478656
13650483038327406592
9009780908043010048
8937723314005082112
8865665719967154176
8793608125929226240
8721550531891298304
8649492937853370368
8577435343815442432
8505377749777514496
13722540632365334528
13794598226403262464
8289204967663730688
8217147373625802752
8145089779587874816
8073032185549946880
8000974591512018944
7928916997474091008
7856859403436163072
7784801809398235136
7712744215360307200
7640686621322379264
7568629027284451328
7496571433246523392
10951686667974475776
7424513839208595456
7352456245170667520
7280398651132739584
7208341057094811648
7136283463056883712
7064225869018955776
13866655820441190400
13938713414479118336
6848053086905171968
8392336959325863936
8320279365287936000
8248221771250008064
8176164177212080128
8104106583174152192
8032048989136224256
7959991395098296320
7887933801060368384
18009225307273297920
17937167713235369984
17865110119197442048
17793052525159514112
17720994931121586176
17648937337083658240
1515873591470587904
1443815997432659968
1371758403394732032
1299700809356804096
1227643215318876160
6055419552487964672
5983361958450036736
5911304364412108800
5839246770374180864
5767189176336252928
5695131582298324992
5623073988260397056
5551016394222469120
14010771008517046272
14082828602554974208
14154886196592902144
5262786018070757376
5190728424032829440
5118670829994901504
5046613235956973568
4974555641919045632
4902498047881117696
4830440453843189760
4758382859805261824
4686325265767333888
4614267671729405952
11810179849383837696
11738122255345909760
11666064661307981824
11594007067270053888
4398094889615622144
4326037295577694208
4253979701539766272
4181922107501838336
4109864513463910400
4037806919425982464
3965749325388054528
3893691731350126592
3821634137312198656
3749576543274270720
1140880752771072000
1068823158733144064
996765564695216128
924707970657288192
852650376619360256
3461346167122558976
3389288573084631040
3317230979046703104
3245173385008775168
3173115790970847232
3101058196932919296
3029000602894991360
2956943008857063424
2884885414819135488
2812827820781207552
2740770226743279616
2668712632705351680
8010356724231831552
7938299130193903616
8082414318269759488
14217637524213334016
15357903649984479232
15285846055946551296
15213788461908623360
15718191620174118912
15646134026136190976
15574076432098263040
15502018838060335104
2092251880401928192
2020194286364000256
1948136692326072320
1876079098288144384
1804021504250216448
1731963910212288512
12715182372648124416
12643124778610196480
12571067184572268544
14764259729962172416
14692202135924244480
14620144541886316544
14548086947848388608
1371675940022648832
1299618345984720896
1227560751946792960
1155503157908865024
15124547700151812096
15052490106113884160
14980432512075956224
14908374918038028288
10434673210850017280
10362615616812089344
10290558022774161408
10218500428736233472
10146442834698305536
10074385240660377600
10002327646622449664
9930270052584521728
10506730804887945216
11227306745267224576
11155249151229296640
11083191557191368704
11011133963153440768
10939076369115512832
10867018775077584896
10794961181039656960
10722903587001729024
11299364339305152512
18232871469921075200
18160813875883147264
18088756281845219328
18016698687807291392
14226943790630830080
17872583499731435520
17800525905693507584
14299001384668758016
17656410717617651712
17584353123579723776
17512295529541795840
17440237935503867904
17368180341465939968
10194584951320477696
10266642545358405632
17224065153390084096
17152007559352156160
17079949965314228224
17007892371276300288
16935834777238372352
16863777183200444416
14371058978706685952
16719661995124588544
16647604401086660608
16575546807048732672
16503489213010804736
16431431618972876800
16359374024934948864
11868762928423370752
11796705334385442816
16215258836859092992
16143201242821165056
16071143648783237120
15999086054745309184
15927028460707381248
15854970866669453312
15782913272631525376
15710855678593597440
14443116572744613888
15566740490517741568
15494682896479813632
15422625302441885696
15350567708403957760
15278510114366029824
15206452520328101888
15134394926290173952
9704018047378915328
9631960453340987392
9559902859303059456
9487845265265131520
14515174166782541824
14587231760820469760
14774106956100534272
12084935710537154560
12012878116499226624
14629991768024678400
14557934173986750464
14485876579948822528
14413818985910894592
14341761391872966656
14269703797835038720
12301108492650938368
12229050898613010432
14125588609759182848
14053531015721254912
13981473421683326976
13909415827645399040
13837358233607471104
13765300639569543168
13693243045531615232
13621185451493687296
13549127857455759360
13477070263417831424
13405012669379903488
13332955075341975552
12517281274764722176
12445223680726794240
13188839887266119680
13116782293228191744
13044724699190263808
12972667105152335872
12900609511114407936
12828551917076480000
12756494323038552064
12684436729000624128
12612379134962696192
12540321540924768256
12468263946886840320
12396206352848912384
12324148758810984448
12252091164773056512
7595956289281196032
14659289354858397696
14731346948896325632
11963860788621344768
14803404542934253568
11819745600545488896
2237028974477705216
2309086568515633152
14875462136972181504
14947519731010109440
11531515224393777152
15019577325048037376
15091634919085965312
11315342442279993344
15163692513123893248
11171227254204137472
15235750107161821184
11027112066128281600
6231406284118163456
6159348690080235520
6087291096042307584
10810939284014497792
10738881689976569856
10666824095938641920
10594766501900713984
10522708907862786048
10450651313824858112
10378593719786930176
10306536125749002240
10234478531711074304
10162420937673146368
10090363343635218432
10018305749597290496
9946248155559362560
9874190561521434624
9802132967483506688
9730075373445578752
9658017779407650816
9585960185369722880
16454531258760822784
16382473664722894848
16310416070684966912
16238358476647038976
16166300882609111040
9153614621142155264
9081557027104227328
9009499433066299392
8937441839028371456
8865384244990443520
8793326650952515584
8721269056914587648
8649211462876659712
8577153868838731776
8505096274800803840
8433038680762875904
8360981086724947968
8288923492687020032
8216865898649092096
8144808304611164160
8072750710573236224
8000693116535308288
7928635522497380352
7856577928459452416
7784520334421524480
7712462740383596544
7640405146345668608
7568347552307740672
7496289958269812736
7424232364231884800
7352174770193956864
7280117176156028928
7208059582118100992
16693778391895113728
16621720797857185792
16549663203819257856
6991886800004317184
6919829205966389248
6847771611928461312
6775714017890533376
6703656423852605440
6631598829814677504
6559541235776749568
15307807701199749120
15379865295237677056
8388589823698403328
15451922889275604992
8532705011774259200
6127195671549181952
15523980483313532928
5983080483473326080
8676820199850115072
8748877793888043008
15596038077351460864
8892992981963898880
5622792513283686400
15668095671389388800
9037108170039754752
5406619731169902592
15740153265427316736
15812210859465244672
15884268453503172608
5118389355018190848
17066555714664660992
16994498120626733056
16922440526588805120
16850382932550877184
17138613308702588928
17643016466968084480
17570958872930156544
17498901278892228608
17426843684854300672
17354786090816372736
17715074061006012416
15956326047541100544
4541928602714767360
4469871008676839424
4397813414638911488
4325755820600983552
4253698226563055616
4181640632525127680
4109583038487199744
4037525444449271808
3965467850411343872
3893410256373415936
3821352662335488000
3749295068297560064
3677237474259632128
3605179880221704192
3533122286183776256
3461064692145848320
3389007098107920384
3316949504069992448
3244891910032064512
3172834315994136576
3100776721956208640
3028719127918280704
2956661533880352768
2884603939842424832
2812546345804496896
2740488751766568960
2668431157728641024
2596373563690713088
16028383641579028480
2452258375614857216
2380200781576929280
2308143187539001344
2236085593501073408
7473777457691099136
7401719863653171200
1844627568175611904
1772569974137683968
1700512380099756032
1628454786061828096
1556397192023900160
1484339597985972224
1412282003948044288
1340224409910116352
1268166815872188416
1587567247159721984
1515509653121794048
1443452059083866112
1371394465045938176
1299336871008010240
1227279276970082304
1155221682932154368
1083164088894226432
1011106494856298496
3630894158660501504
3558836564622573568
3486778970584645632
3414721376546717696
794933712742514688
722876118704586752
650818524666658816
578760930628730880
506703336590802944
434645742552875008
16100441235616956416
290530554477019136
218472960439091200
146415366401163264
16172498829654884352
9397396140229394432
18304647588982292480
18232589994944364544
18160532400906436608
18088474806868508672
18016417212830580736
17944359618792652800
17872302024754724864
17800244430716796928
17728186836678868992
17656129242640941056
17584071648603013120
17512014054565085184
17439956460527157248
17367898866489229312
17295841272451301376
13099971859951124480
13027914265913196544
12955856671875268608
12883799077837340672
12811741483799412736
12739683889761484800
12667626295723556864
12595568701685628928
7564493764052385792
7492436170014457856
7420378575976529920
7636551358090313728
13425931977609969664
13353874383572041728
13281816789534113792
13209759195496185856
13786219947799609344
13714162353761681408
13642104759723753472
13570047165685825536
16431150143996166144
16359092549958238208
16287034955920310272
16214977361882382336
16142919767844454400
16070862173806526464
15998804579768598528
15926746985730670592
15854689391692742656
15782631797654814720
15710574203616886784
15638516609578958848
15566459015541030912
15494401421503102976
14705270931131990016
14633213337094062080
14561155743056134144
14489098149018206208
14417040554980278272
14344982960942350336
14272925366904422400
14200867772866494464
14128810178828566528
14056752584790638592
14777328525169917952
14917940669199679488
14845883075161751552
14773825481123823616
14701767887085895680
15155349418892328960
15083291824854401024
15011234230816473088
14939176636778545152
14867119042740617216
14795061448702689280
14723003854664761344
14650946260626833408
14578888666588905472
14506831072550977536
15227407012930256896
14125307134782472192
14053249540744544256
13981191946706616320
13909134352668688384
16506710782080188416
16434653188042260480
16362595594004332544
16290537999966404608
16218480405928476672
16146422811890548736
16074365217852620800
16002307623814692864
15930250029776764928
16578768376118116352
4057516764865495040
3985459170827567104
3913401576789639168
14403971759772532736
14331914165734604800
14259856571696676864
13116500818251481088
13044443224213553152
12972385630175625216
12900328036137697280
12828270442099769344
12756212848061841408
12684155254023913472
12612097659985985536
12540040065948057600
12467982471910129664
17056309365805416448
16984251771767488512
16912194177729560576
16840136583691632640
16460729205806596096
12107694501720489984
12035636907682562048
11963579313644634112
11891521719606706176
16532786799844524032
16604844393882451968
11675348937492922368
11603291343454994432
11531233749417066496
11459176155379138560
11387118561341210624
11315060967303282688
11243003373265354752
11170945779227426816
11098888185189498880
11026830591151570944
10954772997113643008
10882715403075715072
10810657809037787136
10738600214999859200
10666542620961931264
10594485026924003328
10522427432886075392
10450369838848147456
10378312244810219520
10306254650772291584
10234197056734363648
10162139462696435712
10090081868658507776
10018024274620579840
9945966680582651904
9873909086544723968
9801851492506796032
9729793898468868096
9657736304430940160
16645459253900869632
16573401659862941696
16501344065825013760
16717516847938797568
9441563522317156352
9369505928279228416
9297448334241300480
9225390740203372544
9153333146165444608
9081275552127516672
4370272847386378240
4298215253348450304
4226157659310522368
4154100065272594432
8865102770013732864
8793045175975804928
8720987581937876992
8648929987899949056
10167852525114359808
10095794931076431872
10023737337038503936
9951679743000576000
9879622148962648064
9807564554924720128
10239910119152287744
10816370871455711232
10744313277417783296
10672255683379855360
10600198089341927424
10528140495303999488
10456082901266071552
10888428465493639168
7856296453482741760
7784238859444813824
15782140315957198848
15710082721919270912
15638025127881342976
15565967533843415040
15493909939805487104
15421852345767559168
15349794751729631232
7351893295217246208
7279835701179318272
7207778107141390336
7135720513103462400
7063662919065534464
6991605325027606528
6919547730989678592
6847490136951750656
6775432542913822720
6703374948875894784
6631317354837966848
6559259760800038912
6487202166762110976
6415144572724183040
6343086978686255104
6271029384648327168
6198971790610399232
6126914196572471296
6054856602534543360
5982799008496615424
5910741414458687488
5838683820420759552
5766626226382831616
5694568632344903680
4807139603427360768
4735082009389432832
4663024415351504896
4590966821313576960
4518909227275649024
4446851633237721088
5334280662155264000
5262223068117336064
5190165474079408128
5118107880041480192
5046050286003552256
4973992691965624320
4901935097927696384
4829877503889768448
4757819909851840512
4685762315813912576
4613704721775984640
4541647127738056704
4469589533700128768
4397531939662200832
4325474345624272896
4253416751586344960
4181359157548417024
4109301563510489088
4037243969472561152
3965186375434633216
3893128781396705280
3821071187358777344
18050492177686986752
17978434583649058816
17906376989611130880
17834319395573202944
17762261801535275008
17690204207497347072
3388725623131209728
3316668029093281792
3244610435055353856
3172552841017425920
3100495246979497984
3028437652941570048
2956380058903642112
11302229666607136768
11230172072569208832
11158114478531280896
11374287260645064704
2812264870827786240
2740207276789858304
2668149682751930368
2596092088714002432
2524034494676074496
2451976900638146560
2379919306600218624
2307861712562290688
2235804118524362752
2163746524486434816
2091688930448506880
2019631336410578944
12313543969161084928
12241486375123156992
12169428781085229056
12097371187047301120
12025313593009373184
11953255998971445248
11881198404933517312
11809140810895589376
11737083216857661440
11665025622819733504
1371112990069227520
1299055396031299584
1226997801993371648
13145303624852701184
13073246030814773248
13001188436776845312
12929130842738917376
12857073248700989440
12785015654663061504
17180810365953376256
17108752771915448320
17036695177877520384
16964637583839592448
16892579989801664512
794652237765804032
722594643727876096
650537049689948160
578479455652020224
16676901987920379904
16748959581958307840
362306673538236416
290249079500308480
218191485462380544
146133891424452608
74076297386524672
18376423708043509760
18304366114005581824
13150575783107887104
13078518189069959168
13006460595032031232
12934403000994103296
12862345406956175360
13222633377145815040
12058720054796091392
11986662460758163456
11914604866720235520
11842547272682307584
11770489678644379648
11698432084606451712
17511732579588374528
17439674985550446592
17367617391512518656
17295559797474590720
17223502203436662784
17151444609398734848
17079387015360806912
17007329421322878976
16935271827284951040
16863214233247023104
16791156639209095168
16719099045171167232
16647041451133239296
16574983857095311360
16502926263057383424
16430868669019455488
16358811074981527552
16286753480943599616
16214695886905671680
16142638292867743744
16821017175996235776
16893074770034163712
15926465510753959936
14115741383620820992
14043683789582893056
13971626195544965120
13899568601507037184
13827511007469109248
13755453413431181312
13683395819393253376
4599205461940502528
4527147867902574592
4455090273864646656
4383032679826718720
4310975085788790784
4238917491750862848
4166859897712934912
4094802303675006976
17862310762593124352
17790253168555196416
17718195574517268480
17646137980479340544
17574080386441412608
17502022792403484672
17429965198365556736
17934368356631052288
14629428818071257088
14557371224033329152
14485313629995401216
14413256035957473280
14341198441919545344
14269140847881617408
14197083253843689472
14125025659805761536
14052968065767833600
13980910471729905664
13908852877691977728
13836795283654049792
11057579533333954560
10985521939296026624
10913464345258098688
10841406751220170752
10769349157182242816
10697291563144314880
11129637127371882496
7048307139672014848
6976249545634086912
6904191951596158976
6832134357558231040
6760076763520303104
540778301447208960
468720707409281024
396663113371353088
324605519333425152
252547925295497216
12827988967123058688
12755931373085130752
12683873779047202816
12611816185009274880
12539758590971346944
12467700996933419008
12395643402895491072
12323585808857563136
12251528214819635200
12179470620781707264
12107413026743779328
12035355432705851392
11963297838667923456
11891240244629995520
11819182650592067584
11747125056554139648
11675067462516211712
11603009868478283776
11530952274440355840
11458894680402427904
11386837086364499968
18367276870812041216
18295219276774113280
18223161682736185344
11170664304250716160
11098606710212788224
11026549116174860288
10954491522136932352
10882433928099004416
10810376334061076480
10738318740023148544
10666261145985220608
10594203551947292672
10522145957909364736
10450088363871436800
10378030769833508864
10305973175795580928
10233915581757652992
10161857987719725056
10089800393681797120
10017742799643869184
9945685205605941248
2554155615718998016
2482098021681070080
2410040427643142144
2337982833605214208
2626213209756925952
2193867645529358336
9585397235416301568
9513339641378373632
9441282047340445696
9369224453302517760
9297166859264589824
9225109265226661888
9153051671188733952
9080994077150806016
9008936483112878080
16965132364072091648
17037189958110019584
8792763700999094272
8720706106961166336
8648648512923238400
8576590918885310464
8504533324847382528
5528222418667044864
5456164824629116928
5384107230591188992
5312049636553261056
8288360542733598720
8216302948695670784
8144245354657742848
8072187760619814912
8000130166581886976
7928072572543959040
7856014978506031104
7783957384468103168
7711899790430175232
7639842196392247296
18356232276511031296
18284174682473103360
18212117088435175424
18140059494397247488
18068001900359319552
17995944306321391616
414172836043685888
342115242005757952
270057647967830016
198000053929902080
125942459891974144
6919266256012967936
6847208661975040000
6775151067937112064
5330426873899909120
5258369279861981184
5186311685824053248
5402484467937837056
6558978285823328256
6486920691785400320
1082672607196610560
1010615013158682624
938557419120754688
6270747909671616512
6198690315633688576
6126632721595760640
6054575127557832704
5982517533519904768
1511374389889728512
1439316795851800576
1367259201813872640
1295201607775944704
1583431983927656448
5620360393563045888
5548302799525117952
5476245205487190016
5404187611449262080
5332130017411334144
5260072423373406208
108432737219641344
18410780147876626432
18338722553838698496
18266664959800770560
18194607365762842624
1132462891748818944
1060405297710891008
988347703672963072
916290109635035136
844232515597107200
4757538434875129856
4685480840837201920
4613423246799273984
4541365652761346048
4469308058723418112
4397250464685490176
4325192870647562240
4253135276609634304
14946779759684616192
15018837353722544128
15235010135836327936
15307067729874255872
15523240511988039680
15595298106025967616
3964904900457922560
3892847306419994624
3820789712382066688
14483909553646731264
14411851959608803328
14339794365570875392
14555967147684659200
14195679177495019520
3532559336230354944
3460501742192427008
3707099110558400512
3635041516520472576
3562983922482544640
3490926328444616704
16463635215038808064
16391577621000880128
16319520026962952192
16535692809076736000
2956098583926931456
2884040989889003520
2811983395851075584
17547295183677161472
17475237589639233536
17403179995601305600
6392913547122180096
6320855953084252160
6248798359046324224
2523753019699363840
2451695425661435904
2120528020933443584
2048470426895515648
1976412832857587712
1904355238819659776
1832297644781731840
1760240050743803904
1688182456705875968
1616124862667948032
1544067268630020096
1472009674592092160
2192585614971371520
2696988773236867072
2624931179198939136
2552873585161011200
2480815991123083264
2408758397085155328
2769046367274795008
3561679901692002304
3489622307654074368
3417564713616146432
3345507119578218496
3273449525540290560
3201391931502362624
3129334337464434688
3057276743426506752
2985219149388578816
3633737495729930240
866428356827021312
794370762789093376
722313168751165440
650255574713237504
578197980675309568
506140386637381632
434082792599453696
362025198561525760
289967604523597824
217910010485669888
145852416447741952
73794822409814016
18376142233066799104
18304084639028871168
18232027044990943232
18159969450953015296
18087911856915087360
18015854262877159424
17943796668839231488
17871739074801303552
17799681480763375616
1708694945633665024
1636637351595737088
1564579757557809152
1492522163519881216
1420464569481953280
1780752539671592960
17439393510573735936
17367335916535808000
17295278322497880064
17223220728459952128
17151163134422024192
17079105540384096256
17007047946346168320
16934990352308240384
16862932758270312448
16790875164232384512
16718817570194456576
16646759976156528640
8963061559467180032
8891003965429252096
8818946371391324160
8746888777353396224
16430587194042744832
16358529600004816896
16286472005966888960
16214414411928961024
16142356817891033088
15552120284403204096
15480062690365276160
15408005096327348224
17109247552147947520
15854126441739321344
15782068847701393408
15710011253663465472
15637953659625537536
15565896065587609600
17181305146185875456
15421780877511753728
15349723283473825792
15277665689435897856
15205608095397969920
15133550501360041984
15061492907322114048
14989435313284186112
14917377719246258176
14845320125208330240
14773262531170402304
14701204937132474368
14629147343094546432
14557089749056618496
14485032155018690560
14412974560980762624
14340916966942834688
14268859372904906752
14196801778866978816
14124744184829050880
8247289385389654016
14052686590791122944
13980628996753195008
13908571402715267072
13836513808677339136
13764456214639411200
13692398620601483264
13620341026563555328
13548283432525627392
13476225838487699456
13404168244449771520
13332110650411843584
13260053056373915648
13187995462335987712
13115937868298059776
13043880274260131840
12971822680222203904
17253362740223803392
12827707492146348032
4850143702212935680
4778086108175007744
4706028514137079808
4633970920099151872
4561913326061223936
4489855732023296000
4417798137985368064
12323304333880852480
12251246739842924544
17325420334261731328
17397477928299659264
12035073957729140736
11963016363691212800
11890958769653284864
11818901175615356928
11746843581577428992
11674785987539501056
14717886727549091840
14645829133511163904
14789944321587019776
11458613205425717248
11386555611387789312
11314498017349861376
11242440423311933440
4633977517168918528
4561919923130990592
4489862329093062656
17469535522337587200
10954210047160221696
10882152453122293760
10810094859084365824
10738037265046437888
10665979671008509952
10593922076970582016
10521864482932654080
10449806888894726144
10377749294856798208
10305691700818870272
10233634106780942336
6125570593363329024
6053512999325401088
10089518918705086464
10017461324667158528
9945403730629230592
12368665785596379136
12296608191558451200
12224550597520523264
12152493003482595328
12080435409444667392
12008377815406739456
11936320221368811520
11864262627330883584
11792205033292955648
12440723379634307072
11503974657141243904
11431917063103315968
11359859469065388032
11287801875027460096
11215744280989532160
11143686686951604224
11071629092913676288
11576032251179171840
8720424631984455680
8648367037946527744
8576309443908599808
8504251849870671872
8432194255832743936
8360136661794816000
8288079067756888064
8216021473718960128
8143963879681032192
8071906285643104256
7999848691605176320
7927791097567248384
7855733503529320448
7783675909491392512
7711618315453464576
7639560721415536640
7567503127377608704
7495445533339680768
7423387939301752832
7351330345263824896
7279272751225896960
7207215157187969024
7135157563150041088
12469488802840182784
12397431208802254848
12541546396878110720
17541593116375515136
17613650710413443072
17685708304451371008
17757765898489298944
17829823492527226880
17901881086565154816
17973938680603082752
18045996274641010688
9292961227288346624
9220903633250418688
18118053868678938624
18190111462716866560
6270466434694905856
14195739650634547200
14123682056596619264
14051624462558691328
2278610305216937984
2206552711179010048
2134495117141082112
2062437523103154176
1990379929065226240
1918322335027298304
2350667899254865920
2709668341328379904
5621948088353554432
5549890494315626496
5477832900277698560
5405775306239770624
5333717712201842688
18406284244830650368
103936834173665280
5117544930088058880
2781725935366307840
175994428211593216
248052022249521152
4901372147974275072
4829314553936347136
4757256959898419200
4685199365860491264
320109616287449088
392167210325377024
464224804363304960
4396968989708779520
4324911395670851584
536282398401232896
11054720803101736960
4108738613557067776
608339992439160832
680397586477088768
752455180515016704
3820508237405356032
824512774552944640
896570368590872576
968627962628800512
3532277861253644288
3460220267215716352
1040685556666728448
3316105079139860480
3244047485101932544
1112743150704656384
1184800744742584320
1256858338780512256
2955817108950220800
2883759514912292864
2811701920874364928
7033123983604056064
6961066389566128128
6889008795528200192
7105181577641984000
6744893607452344320
2595529138760581120
2523471544722653184
9658628008361066496
9586570414323138560
9514512820285210624
9442455226247282688
9370397632209354752
9298340038171426816
9226282444133498880
9154224850095570944
9082167256057643008
9730685602398994432
8938052067981787136
5614715500866043904
5542657906828115968
5470600312790188032
5398542718752260096
5326485124714332160
5254427530676404224
5182369936638476288
5110312342600548352
5038254748562620416
4966197154524692480
13352946395758198784
13280888801720270848
13208831207682342912
13136773613644414976
13064716019606487040
12992658425568559104
12920600831530631168
12848543237492703232
12776485643454775296
8645076199644594176
8573018605606666240
8500961011568738304
8428903417530810368
9365652140023873536
9293594545985945600
9221536951948017664
9149479357910089728
505858911660670976
433801317622743040
361743723584815104
289686129546887168
217628535508959232
11775296743481016320
73513347433103360
18375860758090088448
18303803164052160512
18231745570014232576
18159687975976304640
18087630381938376704
18015572787900448768
17943515193862520832
17871457599824592896
17799400005786664960
16128578837683372032
16200636431721299968
13468993251000188928
13396935656962260992
13541050845038116864
17727342411748737024
17655284817710809088
17583227223672881152
17511169629634953216
1328915932818440192
1400973526856368128
17294996847521169408
17222939253483241472
1473031120894296064
11991469525594800128
17006766471369457664
1545088714932224000
1617146308970151936
16790593689255673856
16718536095217745920
1689203903008079872
12207642307708583936
16502363313103962112
1761261497046007808
16358248125028106240
16286190530990178304
5939476051338985472
16142075342914322432
1833319091083935744
15997960154838466560
15925902560800538624
15853844966762610688
15781787372724682752
1905376685121863680
15637672184648826880
15565614590610898944
15493556996572971008
15421499402535043072
15349441808497115136
15277384214459187200
15205326620421259264
15133269026383331328
15061211432345403392
14989153838307475456
14917096244269547520
14845038650231619584
14772981056193691648
14700923462155763712
14628865868117835776
14556808274079907840
14484750680041979904
14412693086004051968
14340635491966124032
14268577897928196096
14196520303890268160
14124462709852340224
14052405115814412288
13980347521776484352
13908289927738556416
13836232333700628480
13764174739662700544
13692117145624772608
13620059551586844672
13548001957548916736
13475944363510988800
13403886769473060864
13331829175435132928
13259771581397204992
13187713987359277056
1977434279159791616
13043598799283421184
2049491873197719552
12899483611207565312
1518325502400528384
2121549467235647488
2193607061273575424
2265664655311503360
2337722249349431296
3615124962894938112
3543067368857010176
3471009774819082240
3398952180781154304
3326894586743226368
3254836992705298432
3182779398667370496
3110721804629442560
3038664210591514624
2966606616553586688
2894549022515658752
4479816091350073344
4407758497312145408
4335700903274217472
4263643309236289536
4191585715198361600
4119528121160433664
4047470527122505728
3975412933084577792
3903355339046649856
3831297745008721920
3759240150970793984
3130355783766638592
3202413377804566528
3274470971842494464
11170101354297294848
11098043760259366912
11025986166221438976
10953928572183511040
10881870978145583104
16492884423360905216
16420826829322977280
16348769235285049344
16276711641247121408
16204654047209193472
16132596453171265536
16060538859133337600
15988481265095409664
15916423671057481728
3922989318183845888
10233352631804231680
3995046912221773824
4067104506259701760
10017179849690447872
9945122255652519936
9873064661614592000
9801007067576664064
9728949473538736128
9656891879500808192
9584834285462880256
9512776691424952320
9440719097387024384
9368661503349096448
9296603909311168512
4139162100297629696
9152488721235312640
9080431127197384704
9008373533159456768
8936315939121528832
8864258345083600896
8792200751045672960
8720143157007745024
8648085562969817088
8576027968931889152
8503970374893961216
4211219694335557632
4283277288373485568
8287797592780177408
8215739998742249472
8143682404704321536
8071624810666393600
7999567216628465664
7927509622590537728
7855452028552609792
7783394434514681856
7711336840476753920
7639279246438825984
7567221652400898048
7495164058362970112
7423106464325042176
7351048870287114240
7278991276249186304
7206933682211258368
7134876088173330432
7062818494135402496
6990760900097474560
6918703306059546624
6846645712021618688
6774588117983690752
13043154596585799680
12971097002547871744
4355334882411413504
4427392476449341440
4499450070487269376
4571507664525197312
4643565258563125248
10291915919634464768
10219858325596536832
6342242553756123136
6270184959718195200
6198127365680267264
6126069771642339328
6054012177604411392
5981954583566483456
5909896989528555520
5837839395490627584
5765781801452699648
5693724207414771712
5621666613376843776
5549609019338915840
5477551425300987904
5405493831263059968
5333436237225132032
5261378643187204096
5189321049149276160
5117263455111348224
5045205861073420288
4973148267035492352
4901090672997564416
4829033078959636480
4756975484921708544
4684917890883780608
4612860296845852672
4540802702807924736
4468745108769996800
4396687514732068864
8366694149142872064
8294636555104944128
8222578961067016192
8150521367029088256
8078463772991160320
8006406178953232384
7934348584915304448
7862290990877376512
7790233396839448576
3748169168390717440
3676111574352789504
3604053980314861568
4715622852601053184
3459938792239005696
3387881198201077760
3315823604163149824
3243766010125221888
3171708416087293952
3099650822049366016
3027593228011438080
9913879632749264896
9841822038711336960
9769764444673409024
9697706850635481088
10274167602938904576
10202110008900976640
10130052414863048704
10057994820825120768
6359501587777323008
6287443993739395072
6215386399701467136
6143328805663539200
2379074881670086656
2307017287632158720
2234959693594230784
2162902099556302848
2090844505518374912
2018786911480446976
1946729317442519040
1874671723404591104
1802614129366663168
1730556535328735232
1658498941290807296
1586441347252879360
1514383753214951424
1442326159177023488
1370268565139095552
1298210971101167616
4787680446638981120
1154095783025311744
1082038188987383808
1009980594949455872
937923000911527936
865865406873600000
793807812835672064
721750218797744128
649692624759816192
577635030721888256
4859738040676909056
433519842646032384
8775947770163888128
8703890176125960192
8631832582088032256
8559774988050104320
8487717394012176384
8415659799974248448
73231872456392704
18375579283113377792
18303521689075449856
18231464095037521920
18159406500999593984
18087348906961666048
18015291312923738112
17943233718885810176
4812780098077851648
4740722504039923712
4668664910001995776
4596607315964067840
17727060936772026368
17655003342734098432
17582945748696170496
17510888154658242560
17438830560620314624
17366772966582386688
17294715372544458752
17222657778506530816
17150600184468602880
17078542590430674944
17006484996392747008
16934427402354819072
16862369808316891136
16790312214278963200
16718254620241035264
16646197026203107328
16574139432165179392
16502081838127251456
16430024244089323520
16357966650051395584
16285909056013467648
16213851461975539712
16141793867937611776
16069736273899683840
15997678679861755904
15925621085823827968
3389617327061336064
3317559733023408128
3245502138985480192
3173444544947552256
3101386950909624320
3029329356871696384
2957271762833768448
2885214168795840512
2813156574757912576
15421217927558332416
15349160333520404480
15277102739482476544
15205045145444548608
15132987551406620672
15060929957368692736
14988872363330764800
14916814769292836864
14844757175254908928
14772699581216980992
14700641987179053056
2062537578661281792
1990479984623353856
1918422390585425920
1846364796547497984
1774307202509570048
2134595172699209728
1486076826357858304
1414019232319930368
1341961638282002432
1269904044244074496
1197846450206146560
1125788856168218624
1558134420395786240
12929167126622633984
12857109532584706048
12785051938546778112
13001224720660561920
13980066046799773696
13908008452761845760
4931795634714836992
13763893264685989888
13691835670648061952
13619778076610134016
13547720482572206080
13475662888534278144
7719855856568762368
7647798262530834432
7575740668492906496
7503683074454978560
7431625480417050624
7359567886379122688
2882171820121784320
2810114226083856384
2738056632045928448
2665999038008000512
2593941443970072576
2521883849932144640
2449826255894216704
2377768661856288768
2305711067818360832
2233653473780432896
2161595879742504960
2089538285704577024
12683029354117070848
12610971760079142912
12538914166041214976
12466856572003287040
12394798977965359104
12322741383927431168
12250683789889503232
12178626195851575296
12106568601813647360
9197598384788078592
9125540790750150656
9053483196712222720
8981425602674294784
8909368008636366848
8837310414598438912
9702001543053574144
9629943949015646208
9557886354977718272
9485828760939790336
9413771166901862400
9341713572863934464
11746280631624007680
11674223037586079744
7215452698303266816
7143395104265338880
7071337510227410944
6999279916189483008
6927222322151555072
6855164728113627136
5224240438935814144
5152182844897886208
5080125250859958272
5008067656822030336
4936010062784102400
4863952468746174464
4791894874708246528
4719837280670318592
5296298032973742080
10881589503168872448
10809531909130944512
10737474315093016576
10665416721055088640
10593359127017160704
10521301532979232768
10449243938941304832
10377186344903376896
10305128750865448960
10233071156827521024
10161013562789593088
10088955968751665152
10016898374713737216
9944840780675809280
9872783186637881344
5075910822790692864
5147968416828620800
5220026010866548736
5292083604904476672
5364141198942404608
5436198792980332544
5508256387018260480
9440437622410313728
5580313981056188416
5652371575094116352
5724429169132044288
13432621406353358848
9080149652220674048
9008092058182746112
8936034464144818176
8863976870106890240
8791919276068962304
8719861682031034368
8647804087993106432
8575746493955178496
8913885901914898432
8985943495952826368
9202116278066610176
9274173872104538112
12566035819363565568
12493978225325637632
12421920631287709696
12349863037249781760
12277805443211853824
12638093413401493504
10548423186301583360
10476365592263655424
10404307998225727488
10332250404187799552
10620480780339511296
11989575067060142080
11917517473022214144
11845459878984286208
11773402284946358272
11701344690908430336
11629287096870502400
12061632661098070016
9755789651884376064
9683732057846448128
9611674463808520192
9539616869770592256
9467559275732664320
9827847245922304000
11341056720718790656
11268999126680862720
11196941532642934784
11124883938605006848
11052826344567078912
11413114314756718592
11433973149847257088
11361915555809329152
11506030743885185024
17270239144198537216
17198181550160609280
9726707569329700864
9081660381197238272
9009602787159310336
16416650884160684032
16344593290122756096
16272535696084828160
16200478102046900224
7296250310270386176
7224192716232458240
7152135122194530304
15479902161667620864
15407844567629692928
15335786973591764992
15263729379553837056
15840190131857260544
15768132537819332608
15696074943781404672
15624017349743476736
10591771432226652160
8717901252798709760
12426629839589474304
12498687433627402240
9240031837038837760
9167974243000909824
9095916648962981888
9023859054925053952
5540411604572569600
5468354010534641664
5396296416496713728
6053730702627700736
5981673108589772800
898086595125575680
13347701725293707264
13419759319331635200
5837557920513916928
5765500326475988992
5693442732438061056
5621385138400133120
6372947515473395712
6445005109511323648
5405212356286349312
4403526477056835584
4331468883018907648
4259411288980979712
4475584071094763520
1873891070148870144
1945948664186798080
3366301083482718208
3294243489444790272
3222185895406862336
3150128301368934400
3078070707331006464
4735395370203348992
4663337776165421056
4591280182127493120
4519222588089565184
4447164994051637248
4375107400013709312
4303049805975781376
4230992211937853440
4540521227831214080
4468463633793286144
10792728072923643904
10720670478885715968
10648612884847788032
10576555290809860096
10864785666961571840
11297131231189139456
11225073637151211520
11153016043113283584
11080958449075355648
11369188825227067392
3819945287451934720
3747887693414006784
3675830099376078848
3603772505338150912
3531714911300222976
3459657317262295040
16298931671732846592
16226874077694918656
16154816483656990720
16370989265770774528
16731277235960414208
16659219641922486272
16587162047884558336
16803334829998342144
9539034128607870976
9466976534569943040
9394918940532015104
9611091722645798912
1379338436556619776
1451396030594547712
2955254158996799488
2883196564958871552
2811138970920943616
2739081376883015680
2667023782845087744
2594966188807159808
2522908594769231872
2450851000731303936
2378793406693376000
2306735812655448064
2234678218617520128
2162620624579592192
6517062703549251584
2018505436503736320
1946447842465808384
6589120297587179520
1802332654389952512
6661177891625107456
1658217466314096640
11030603015546470400
10958545421508542464
10886487827470614528
11102660609584398336
11462948579774038016
11390890985736110080
11318833391698182144
11535006173811965952
11895294144001605632
11823236549963677696
11751178955925749760
11967351738039533568
12327639708229173248
12255582114191245312
12183524520153317376
12399697302267101184
4369991372409667584
4297933778371739648
4225876184333811712
4153818590295883776
4081760996257955840
4009703402220027904
3937645808182099968
4442048966447595520
12131165776438624256
12059108182400696320
11987050588362768384
11554705024135200768
11482647430097272832
11410589836059344896
11708950012837756928
11636892418799828992
11564834824761901056
11492777230723973120
11781007606875684864
12213353171103252480
12141295577065324544
12069237983027396608
11997180388989468672
12285410765141180416
11842935400286912512
11770877806248984576
11698820212211056640
6733235485663035392
649411149783105536
577353555745177600
505295961707249664
433238367669321728
361180773631393792
289123179593465856
217065585555537920
145007991517609984
72950397479682048
18375297808136667136
18303240214098739200
18231182620060811264
18159125026022883328
18087067431984955392
18015009837947027456
17942952243909099520
17870894649871171584
3676745992562016256
3604688398524088320
434154260855259136
362096666817331200
17654721867757387776
17582664273719459840
17510606679681531904
17438549085643603968
11110784901002035200
11038727306964107264
11182842495039963136
17294433897567748096
17222376303529820160
11471072871191674880
11399015277153746944
11543130465229602816
17078261115453964288
17006203521416036352
6805293079700963328
6877350673738891264
16790030739302252544
16717973145264324608
6414717962212605952
6342660368174678016
6270602774136750080
6198545180098822144
6126487586060894208
6054429992022966272
5982372397985038336
6486775556250533888
16285627581036756992
16213569986998829056
16141512392960901120
16069454798922973184
15997397204885045248
15925339610847117312
15853282016809189376
15781224422771261440
15709166828733333504
14813796027328364544
14741738433290436608
14669680839252508672
14597623245214580736
14525565651176652800
14453508057138724864
14381450463100796928
14309392869062868992
15132706076429910016
15060648482391982080
14988590888354054144
13028465121238712320
12956407527200784384
12884349933162856448
13100522715276640256
13460810685466279936
13388753091428352000
13316695497390424064
13532868279504207872
14628302918164414464
14556245324126486528
14484187730088558592
14412130136050630656
14340072542012702720
14268014947974774784
2376846171600584704
2304788577562656768
2232730983524728832
2448903765638512640
7911256641708752896
7839199047670824960
7767141453632897024
7695083859594969088
7623026265557041152
13763611789709279232
13691554195671351296
13619496601633423360
13547439007595495424
13475381413557567488
13403323819519639552
13331266225481711616
13259208631443783680
13187151037405855744
13115093443367927808
13043035849329999872
12970978255292071936
12898920661254144000
12826863067216216064
12754805473178288128
12682747879140360192
12610690285102432256
12538632691064504320
12466575097026576384
12394517502988648448
12322459908950720512
11127622822069796864
12178344720874864640
12106287126836936704
12034229532799008768
11962171938761080832
11199680416107724800
11818056750685224960
15911050357732540416
15838992763694612480
15766935169656684544
15694877575618756608
15622819981580828672
15550762387542900736
15478704793504972800
15406647199467044864
15334589605429116928
11241595998381801472
11169538404343873536
11097480810305945600
11025423216268017664
10953365622230089728
10881308028192161792
10809250434154233856
10737192840116305920
10665135246078377984
10593077652040450048
10521020058002522112
10448962463964594176
10376904869926666240
10304847275888738304
10232789681850810368
10160732087812882432
9084372876382961664
9012315282345033728
10016616899737026560
9944559305699098624
9872501711661170688
9800444117623242752
9728386523585314816
9656328929547386880
13114068698530840576
13042011104492912640
12969953510454984704
12897895916417056768
12825838322379128832
12753780728341200896
13186126292568768512
1875306141613817856
9296040959357747200
9223983365319819264
9151925771281891328
9079868177243963392
9007810583206035456
8935752989168107520
8863695395130179584
8791637801092251648
8719580207054323712
8647522613016395776
8575465018978467840
8503407424940539904
8431349830902611968
8359292236864684032
8287234642826756096
8215177048788828160
8143119454750900224
8071061860712972288
7999004266675044352
7926946672637116416
7854889078599188480
7782831484561260544
6949408267776819200
7021465861814747136
7566658702447476736
7494601108409548800
7422543514371620864
3001178560665747456
2929120966627819520
2857063372589891584
2785005778551963648
2712948184514035712
7062255544181981184
6990197950144053248
666951658781016064
594894064743088128
522836470705160192
450778876667232256
739009252818944000
6701967573992341504
6629909979954413568
6557852385916485632
6485794791878557696
162548500515520512
90490906477592576
18392838317134577664
18320780723096649728
234606094553448448
6197564415726845952
6125506821688918016
6053449227650990080
1057106762827563008
985049168789635072
912991574751707136
1129164356865490944
5837276445537206272
5765218851499278336
5693161257461350400
5621103663423422464
5549046069385494528
5476988475347566592
5404930881309638656
5332873287271710720
5260815693233782784
5188758099195854848
5116700505157926912
5173636515779051520
5101578921741123584
5029521327703195648
4957463733665267712
4885406139627339776
4813348545589411840
4684354940930359296
4612297346892431360
4540239752854503424
4468182158816575488
4396124564778647552
4324066970740719616
4252009376702791680
4179951782664863744
4107894188626935808
4035836594589007872
3963779000551079936
3891721406513152000
3819663812475224064
3747606218437296128
6879978506529275904
6807920912491347968
6735863318453420032
6663805724415492096
6591748130377564160
6519690536339636224
6447632942301708288
6375575348263780352
6303517754225852416
6231460160187924480
892404319033229312
820346724995301376
748289130957373440
676231536919445504
604173942881517568
532116348843589632
460058754805661696
3099087872095944704
3027030278058016768
2954972684020088832
2882915089982160896
2810857495944232960
15528476386359508992
15456418792321581056
15384361198283653120
15312303604245725184
15240246010207797248
15168188416169869312
15096130822131941376
15600533980397436928
2234396743640809472
2162339149602881536
2090281555564953600
2018223961527025664
1946166367489097728
1874108773451169792
1802051179413241856
11636617540892884992
11564559946854957056
11492502352817029120
11420444758779101184
11348387164741173248
11276329570703245312
11204271976665317376
11708675134930812928
11060156788589461504
7093523455852675072
1153532833071890432
1081475239033962496
11487910792259436544
937360050958106624
1329176517074223104
1257118923036295168
1185061328998367232
1113003734960439296
1040946140922511360
577072080768466944
505014486730539008
432956892692611072
360899298654683136
15205679563653775360
15133621969615847424
17982420313299746816
17910362719261818880
17838305125223890944
17766247531185963008
17694189937148035072
18375016333159956480
18302958739122028544
18230901145084100608
18158843551046172672
18086785957008244736
18014728362970316800
17942670768932388864
17870613174894460928
17798555580856532992
17726497986818605056
11754786453576482816
11682728859538554880
11826844047614410752
7380732385702182912
7308674791664254976
7236617197626327040
7164559603588399104
7452789979740110848
7885135543967678464
7813077949929750528
7741020355891822592
7668962761853894656
7957193138005606400
10457762955033313280
10385705360995385344
10313647766957457408
10241590172919529472
10169532578881601536
17150037234515181568
17077979640477253632
17005922046439325696
16933864452401397760
16861806858363469824
16789749264325541888
16717691670287613952
16645634076249686016
16573576482211758080
16501518888173830144
16429461294135902208
11825458662963412992
11753401068925485056
11681343474887557120
11609285880849629184
12185746633153052672
12113689039115124736
12041631445077196800
11969573851039268864
15925058135870406656
15853000541832478720
15780942947794550784
12546034603342692352
12473977009304764416
12401919415266836480
12329861821228908544
15492712571642839040
15420654977604911104
15348597383566983168
15276539789529055232
15204482195491127296
15132424601453199360
15060367007415271424
14988309413377343488
14916251819339415552
14844194225301487616
14772136631263559680
14700079037225631744
14628021443187703808
14555963849149775872
14483906255111847936
14411848661073920000
14339791067035992064
14267733472998064128
14195675878960136192
14123618284922208256
14051560690884280320
13979503096846352384
13907445502808424448
11366674242134343680
11294616648096415744
11438731836172271616
13309314475833163776
13237256881795235840
13165199287757307904
13093141693719379968
13619215126656712704
13547157532618784768
13475099938580856832
13403042344542928896
7279842298249084928
7207784704211156992
7135727110173229056
7063669516135301120
6991611922097373184
6919554328059445248
6847496734021517312
6775439139983589376
6703381545945661440
6631323951907733504
6559266357869805568
5850580536233295872
5778522942195367936
5706465348157440000
5922638130271223808
12466293622049865728
12394236028011937792
10408802801760075776
10336745207722147840
10264687613684219904
10192630019646291968
10120572425608364032
10048514831570436096
9976457237532508160
11652590146309586944
11580532552271659008
11508474958233731072
11436417364195803136
10841148365987643392
10769090771949715456
10697033177911787520
10624975583873859584
10552917989835931648
7380696101818466304
7308638507780538368
7236580913742610432
2842407982103265280
2770350388065337344
2698292794027409408
2626235199989481472
2554177605951553536
6614219949026050048
6542162354988122112
6470104760950194176
6398047166912266240
6325989572874338304
6253931978836410368
6181874384798482432
7478911077481185280
7406853483443257344
7334795889405329408
7262738295367401472
7190680701329473536
7118623107291545600
10592796177063739392
10520738583025811456
10448680988987883520
10376623394949955584
10304565800912027648
10232508206874099712
10160450612836171776
10088393018798243840
10016335424760315904
9944277830722387968
9872220236684460032
9800162642646532096
9728105048608604160
9656047454570676224
9583989860532748288
9511932266494820352
9439874672456892416
9367817078418964480
9295759484381036544
9223701890343108608
4624239142681706496
4552181548643778560
4480123954605850624
4408066360567922688
4336008766529994752
4696296736719634432
7043500074835378176
6971442480797450240
6899384886759522304
6827327292721594368
6755269698683666432
6683212104645738496
6611154510607810560
6087344972112068608
6015287378074140672
8575183544001757184
8503125949963829248
4108804584254734336
4036746990216806400
3964689396178878464
3892631802140950528
3820574208103022592
8413412398207074304
8341354804169146368
8269297210131218432
7998722791698333696
7926665197660405760
7854607603622477824
7782550009584549888
7710492415546621952
7638434821508694016
7566377227470766080
14453867597441007616
14381810003403079680
14309752409365151744
14237694815327223808
14165637221289295872
14525925191478935552
7134031663243198464
7061974069205270528
6989916475167342592
15030328349744431104
14958270755706503168
14886213161668575232
14814155567630647296
14742097973592719360
15102385943782359040
5549164816641294336
5477107222603366400
5405049628565438464
5332992034527510528
5260934440489582592
5188876846451654656
5116819252413726720
5044761658375798784
5621222410679222272
6125225346712207360
6053167752674279424
6774143915286069248
6702086321248141312
6630028727210213376
6557971133172285440
6485913539134357504
6413855945096429568
6341798351058501632
6269740757020573696
6846201509323997184
5548764594408783872
5476707000370855936
5404649406332928000
5332591812295000064
5260534218257072128
5188476624219144192
5116419030181216256
5044361436143288320
4972303842105360384
4900246248067432448
4828188654029504512
4756131059991576576
4684073465953648640
4612015871915720704
4539958277877792768
4384651160942804992
4312593566904877056
4240535972866949120
4168478378829021184
4096420784791093248
4024363190753165312
4889054319208300544
4816996725170372608
4744939131132444672
4672881537094516736
4600823943056588800
4528766349018660864
3747324743460585472
3675267149422657536
3603209555384729600
3531151961346801664
3459094367308873728
3387036773270945792
3314979179233017856
3242921585195089920
3170863991157161984
3098806397119234048
3026748803081306112
2954691209043378176
2882633615005450240
5767851082336174080
5695793488298246144
5623735894260318208
5839908676374102016
2666460832891666432
2594403238853738496
6182442832310042624
6110385238272114688
6038327644234186752
5966270050196258816
5894212456158330880
5822154862120402944
5750097268082475008
2162057674626170880
2090000080588242944
2017942486550315008
2970739680762396672
2898682086724468736
2826624492686540800
2754566898648612864
4488251544558370816
4416193950520442880
4344136356482514944
2532024645675122688
2459967051637194752
2387909457599266816
2604082239713050624
1441481734246891520
1369424140208963584
1297366546171035648
1225308952133107712
1153251358095179776
1081193764057251840
1009136170019323904
937078575981395968
865020981943468032
792963387905540096
720905793867612160
648848199829684224
576790605791756288
17835525559828873216
17763467965790945280
17691410371753017344
17974199264858865664
17902141670820937728
17830084076783009792
17758026482745081856
17685968888707153920
17613911294669225984
218836898787885056
146779304749957120
74721710712029184
18377069121369014272
18302677264145317888
18230619670107389952
18158562076069462016
14174658714195197952
14102601120157270016
14030543526119342080
13958485932081414144
13886428338043486208
13814370744005558272
17798274105879822336
17726216511841894400
17654158917803966464
17582101323766038528
17510043729728110592
17437986135690182656
5525531913713876992
5453474319675949056
17293870947614326784
17221813353576398848
17149755759538470912
17077698165500542976
17005640571462615040
16933582977424687104
16861525383386759168
16789467789348831232
16717410195310903296
16645352601272975360
16573295007235047424
16501237413197119488
16429179819159191552
16357122225121263616
16285064631083335680
16213007037045407744
16140949443007479808
16068891848969551872
15996834254931623936
15924776660893696000
15852719066855768064
15780661472817840128
15708603878779912192
6354424043080253440
6282366449042325504
6210308855004397568
15564488690704056320
15492431096666128384
15420373502628200448
15348315908590272512
7165581049890603008
15204200720514416640
2756617487834415104
2684559893796487168
2612502299758559232
2540444705720631296
2468387111682703360
2396329517644775424
2324271923606847488
300475637150253056
228418043112325120
156360449074397184
84302855036469248
18386650265693454336
18314592671655526400
18242535077617598464
18170477483579670528
14339509592059281408
14267451998021353472
14195394403983425536
14123336809945497600
14051279215907569664
13979221621869641728
13907164027831713792
13835106433793785856
13763048839755857920
13690991245717929984
13618933651680002048
13546876057642074112
13474818463604146176
13402760869566218240
13330703275528290304
13258645681490362368
10190978553181372416
10118920959143444480
10046863365105516544
9974805771067588608
10263036147219300352
13042472899376578560
12970415305338650624
9686575394915876864
9614517800877948928
9542460206840020992
9470402612802093056
9758632988953804800
8317481108195246080
8245423514157318144
8173365920119390208
8389538702233174016
12538069741111083008
7237638643928530944
12393954553035227136
12321896958997299200
12249839364959371264
12177781770921443328
9182172236650381312
9110114642612453376
9038057048574525440
8965999454536597504
9254229830688309248
11889551394769731584
11817493800731803648
7309696237966458880
11673378612655947776
7381753832004386816
7453811426042314752
11457205830542163968
14668897986973532160
14596840392935604224
14524782798897676288
11241033048428380160
11168975454390452224
11096917860352524288
7525869020080242688
7597926614118170624
10880745078238740480
10808687484200812544
10736629890162884608
10664572296124956672
14957128363125243904
14885070769087315968
14813013175049388032
10448399514011172864
10376341919973244928
10304284325935316992
10232226731897389056
10160169137859461120
7669984208156098560
10016053949783605248
9943996355745677312
9871938761707749376
9799881167669821440
9727823573631893504
9655765979593965568
9583708385556037632
9511650791518109696
9439593197480181760
4343910956598820864
4271853362560892928
4199795768522964992
4127738174485037056
4055680580447109120
3983622986409181184
3911565392371253248
3839507798333325312
3767450204295397376
5136544491016028160
5064486896978100224
4992429302940172288
4920371708902244352
4848314114864316416
4776256520826388480
4704198926788460544
4632141332750532608
4560083738712604672
1283699616637779968
1355757210675707904
8791074851138830336
8719017257100902400
8646959663062974464
8574902069025046528
8502844474987118592
8430786880949190656
8358729286911262720
8286671692873334784
8214614098835406848
8142556504797478912
8070498910759550976
7998441316721623040
7926383722683695104
7854326128645767168
7782268534607839232
4446883519074926592
4374825925036998656
4302768330999070720
4230710736961142784
4158653142923214848
4086595548885286912
4014537954847358976
3942480360809431040
3870422766771503104
4518941113112854528
5311574647530061824
5239517053492133888
5167459459454205952
5095401865416278016
5023344271378350080
4951286677340422144
4879229083302494208
4807171489264566272
4735113895226638336
5383632241567989760
6845519812114776064
6773462218076848128
6701404624038920192
6629347030000992256
6557289435963064320
6485231841925136384
6413174247887208448
6341116653849280512
6269059059811352576
6197001465773424640
6124943871735496704
6052886277697568768
5980828683659640832
5908771089621712896
5836713495583784960
5764655901545857024
5692598307507929088
5620540713470001152
6354983694498791424
6282926100460863488
6210868506422935552
6138810912385007616
6427041288536719360
14447612475790589952
14375554881752662016
14303497287714734080
14231439693676806144
14159382099638878208
14519670069828517888
10385648186390740992
10313590592352813056
10457705780428668928
4827907179052793856
4755849585014865920
4683791990976937984
4611734396939010048
4539676802901082112
4467619208863154176
4395561614825226240
4323504020787298304
4251446426749370368
4179388832711442432
4107331238673514496
4035273644635586560
3963216050597658624
3891158456559730688
3819100862521802752
3747043268483874816
3674985674445946880
3602928080408018944
3530870486370091008
3458812892332163072
3386755298294235136
3314697704256307200
3242640110218379264
3170582516180451328
3098524922142523392
3026467328104595456
2954409734066667520
2882352140028739584
2810294545990811648
7742041802194026496
7814099396231954432
2594121763877027840
16796856507487485952
16724798913449558016
16652741319411630080
16580683725373702144
2305891387725316096
2233833793687388160
7193718651957018624
7121661057919090688
7049603463881162752
6977545869843234816
8875047852686966784
8802990258649038848
8730932664611110912
8947105446724894720
1729430635421892608
1657373041383964672
1585315447346036736
1513257853308108800
1441200259270180864
1369142665232252928
1297085071194324992
1225027477156397056
1152969883118469120
1080912289080541184
1008854695042613248
936797101004685312
864739506966757376
792681912928829440
720624318890901504
648566724852973568
16775741486187675648
16703683892149747712
11934370787252764672
11862313193214836736
11790255599176908800
360336348701261824
288278754663333888
216221160625405952
8217476127602507776
8145418533564579840
8073360939526651904
18446509877732835328
18374452283694907392
8505706503754219520
8433648909716291584
8361591315678363648
18158279501581123584
18086221907543195648
18014164313505267712
17942106719467339776
17870049125429411840
15598904504165072896
15526846910127144960
15454789316089217024
15382731722051289088
15310674128013361152
15238616533975433216
15166558939937505280
15670962098203000832
17365645967163916288
17293588373125988352
17221530779088060416
17149473185050132480
17077415591012204544
9859409826709241856
9787352232671313920
9715294638633385984
9643237044595458048
9571179450557530112
9499121856519602176
16861242808898420736
16789185214860492800
16717127620822564864
16645070026784636928
16573012432746708992
16500954838708781056
16428897244670853120
16356839650632925184
16284782056594997248
16212724462557069312
16140666868519141376
13597544851984875520
13525487257946947584
4586445629500162048
4514388035462234112
15924494086405357568
15852436492367429632
15780378898329501696
15708321304291573760
15636263710253645824
15564206116215717888
15492148522177789952
15420090928139862016
15348033334101934080
15275975740064006144
15203918146026078208
15131860551988150272
15059802957950222336
14987745363912294400
2953575204741185536
2881517610703257600
2809460016665329664
2737402422627401728
2665344828589473792
2593287234551545856
2521229640513617920
2449172046475689984
2377114452437762048
2305056858399834112
2232999264361906176
14195111829495087104
14123054235457159168
14050996641419231232
13978939047381303296
13906881453343375360
13834823859305447424
13762766265267519488
13690708671229591552
13618651077191663616
13546593483153735680
13474535889115807744
13402478295077879808
13330420701039951872
13258363107002023936
13186305512964096000
13114247918926168064
14128404459037917184
14056346864999989248
16394373679070314496
16322316085032386560
16250258490994458624
16178200896956530688
16106143302918602752
16034085708880674816
15962028114842746880
17042892025411665920
16970834431373737984
16898776837335810048
16826719243297882112
16754661649259954176
16682604055222026240
16610546461184098304
16538488867146170368
12609844760660672512
12537787166622744576
12465729572584816640
12393671978546888704
12321614384508960768
12249556790471032832
12177499196433104896
12105441602395176960
18362205923184738304
18290148329146810368
18218090735108882432
18146033141070954496
18073975547033026560
18001917952995098624
17929860358957170688
17857802764919242752
17785745170881314816
11745153632205537280
11673096038167609344
708376858869104640
636319264831176704
564261670793248768
492204076755320832
420146482717392896
348088888679464960
276031294641537024
203973700603609088
131916106565681152
6055241431604264960
5983183837566337024
5911126243528409088
5839068649490481152
5767011055452553216
6127299025642192896
16031289650811240448
15959232056773312512
15887174462735384576
15815116868697456640
15743059274659528704
15671001680621600768
15598944086583672832
16103347244849168384
6631702183907688448
6559644589869760512
6487586995831832576
6415529401793904640
6343471807755976704
6703759777945616384
10520174533560762368
10448116939522834432
10376059345484906496
16127223139846324224
16055165545808396288
10231944157409050624
10159886563371122688
10087828969333194752
10015771375295266816
9943713781257338880
9871656187219410944
9799598593181483008
9727540999143555072
9655483405105627136
9583425811067699200
9511368217029771264
9439310622991843328
9367253028953915392
9295195434915987456
8390560148535377920
9151080246840131584
9079022652802203648
9006965058764275712
8934907464726347776
8862849870688419840
8790792276650491904
8718734682612563968
8646677088574636032
8574619494536708096
8502561900498780160
8430504306460852224
8358446712422924288
8286389118384996352
8214331524347068416
8142273930309140480
8070216336271212544
7998158742233284608
7926101148195356672
7854043554157428736
7781985960119500800
7709928366081572864
7637870772043644928
7565813178005716992
7493755583967789056
7421697989929861120
9516543618261712896
9444486024223784960
9372428430185857024
7277582801854005248
7205525207816077312
7133467613778149376
7061410019740221440
6989352425702293504
6917294831664365568
6845237237626437632
6773179643588509696
6701122049550581760
6629064455512653824
6557006861474725888
6484949267436797952
6412891673398870016
6340834079360942080
6268776485323014144
6196718891285086208
6124661297247158272
6052603703209230336
5980546109171302400
5908488515133374464
5836430921095446528
10093179192913952768
10021121598876024832
9949064004838096896
9877006410800168960
9804948816762241024
9732891222724313088
9660833628686385152
9588776034648457216
9516718440610529280
9444660846572601344
9372603252534673408
9300545658496745472
9228488064458817536
4899682198602383360
4827624604564455424
4755567010526527488
4683509416488599552
4611451822450671616
10957870321369088000
10885812727331160064
10813755133293232128
10741697539255304192
10669639945217376256
10597582351179448320
10525524757141520384
10453467163103592448
10381409569065664512
10309351975027736576
10237294380989808640
3818818288033464320
3746760693995536384
5599805023681773568
5671862617719701504
3602645505919680512
3530587911881752576
3458530317843824640
8462617742573305856
8534675336611233792
8606732930649161728
3170299941692112896
8678790524687089664
8750848118725017600
8822905712762945536
2882069565540401152
2810011971502473216
2737954377464545280
2665896783426617344
2593839189388689408
2521781595350761472
2449724001312833536
2377666407274905600
2305608813236977664
2233551219199049728
2161493625161121792
2089436031123193856
2017378437085265920
8894963306800873472
1873263249009410048
1801205654971482112
1729148060933554176
1657090466895626240
1585032872857698304
1512975278819770368
1440917684781842432
1368860090743914496
5815382970004930560
5743325375967002624
5671267781929074688
5599210187891146752
5527152593853218816
5887440564042858496
6391843722308354048
6319786128270426112
6247728534232498176
6175670940194570240
6103613346156642304
6463901316346281984
576226556326707200
504168962288779264
432111368250851328
360053774212923392
287996180174995456
215938586137067520
143880992099139584
18446228402756124672
18374170808718196736
18302113214680268800
18230055620642340864
3793812095082954752
3721754501045026816
4009984877196738560
3937927283158810624
18013882838528557056
17941825244490629120
17869767650452701184
17797710056414773248
17725652462376845312
17653594868338917376
17581537274300989440
17509479680263061504
17437422086225133568
17365364492187205632
17293306898149277696
17221249304111349760
17149191710073421824
17077134116035493888
17005076521997565952
16933018927959638016
16860961333921710080
16788903739883782144
16716846145845854208
16644788551807926272
6795782304120700928
6723724710082772992
6651667116044845056
6579609522006917120
6507551927968989184
8967020900838801408
9039078494876729344
16140385393542430720
16068327799504502784
15996270205466574848
15924212611428646912
15852155017390718976
15780097423352791040
15708039829314863104
15635982235276935168
15563924641239007232
15491867047201079296
15419809453163151360
15347751859125223424
15275694265087295488
15203636671049367552
15131579077011439616
15059521482973511680
14987463888935583744
14915406294897655808
7584480686422097920
7512423092384169984
7440365498346242048
2431532581431279616
2359474987393351680
2287417393355423744
2215359799317495808
2143302205279567872
2071244611241639936
1999187017203712000
1927129423165784064
2503590175469207552
14266887948556304384
14194830354518376448
3258970056914108416
3186912462876180480
3114854868838252544
13978657572404592640
13906599978366664704
13834542384328736768
13762484790290808832
13690427196252880896
13618369602214952960
13546312008177025024
13474254414139097088
13402196820101169152
13330139226063241216
13258081632025313280
13186024037987385344
13113966443949457408
13041908849911529472
12713994900090126336
12641937306052198400
12569879712014270464
12786052494128054272
12425764523938414592
5337800198875774976
5265742604837847040
14979393473587707904
15051451067625635840
15267623849739419648
15339681443777347584
12438850911332204544
12366793317294276608
12510908505370132480
15555854225891131392
15627911819929059328
12393390503570178048
12321332909532250112
12249275315494322176
12177217721456394240
15844084602042843136
15916142196080771072
12033102533380538368
11961044939342610432
7154157124078010368
7082099530040082432
7010041936002154496
3972847772456976384
3900790178419048448
3828732584381120512
3756674990343192576
3684617396305264640
3612559802267336704
3468444614191480832
3396387020153552896
3324329426115624960
3252271832077697024
3180214238039769088
3108156644001841152
11240468998963331072
11168411404925403136
11096353810887475200
11024296216849547264
10952238622811619328
10880181028773691392
10808123434735763456
10736065840697835520
10664008246659907584
10591950652621979648
10519893058584051712
10447835464546123776
10375777870508195840
10303720276470267904
10231662682432339968
14425434226746720256
14497491820784648192
8855818493828792320
8783760899790864384
8711703305752936448
8639645711715008512
8567588117677080576
8495530523639152640
8927876087866720256
9655201930128916480
9583144336090988544
9511086742053060608
9439029148015132672
9366971553977204736
9294913959939276800
9222856365901348864
9150798771863420928
9078741177825492992
1420693267900530688
1348635673862602752
1276578079824674816
8862568395711709184
8790510801673781248
8718453207635853312
8646395613597925376
8574338019559997440
8502280425522069504
8430222831484141568
8358165237446213632
8286107643408285696
8214050049370357760
8141992455332429824
8069934861294501888
7997877267256573952
7925819673218646016
11937977185391869952
11865919591353942016
11793861997316014080
12226207561543581696
12154149967505653760
12082092373467725824
7565531703029006336
7493474108991078400
7421416514953150464
16874551297641021440
16802493703603093504
7277301326877294592
7205243732839366656
7133186138801438720
7061128544763510784
13447657227863195648
13375599633825267712
13303542039787339776
13231484445749411840
13519714821901123584
6371301546566615040
6299243952528687104
6443359140604542976
6628782980535943168
6556725386498015232
17413899134460493824
17341841540422565888
17269783946384637952
17197726352346710016
17125668758308782080
17053611164270854144
17485956728498421760
17990359886763917312
17918302292725989376
17846244698688061440
17774187104650133504
17702129510612205568
18062417480801845248
5980264634194591744
5908207040156663808
7217723189814624256
7145665595776696320
7073608001738768384
7001550407700840448
7289780783852552192
5619976664004952064
5547919069967024128
5475861475929096192
5403803881891168256
5331746287853240320
5259688693815312384
5187631099777384448
5115573505739456512
5043515911701528576
4971458317663600640
4899400723625672704
4827343129587744768
4755285535549816832
4683227941511888896
4611170347473960960
4539112753436033024
4467055159398105088
4394997565360177152
14050515055326265344
13978457461288337408
13906399867250409472
13834342273212481536
13762284679174553600
3765423804365406208
3693366210327478272
3621308616289550336
3549251022251622400
3477193428213694464
3029083066267074560
2957025472229146624
2884967878191218688
2812910284153290752
2740852690115362816
14916315591013826560
14844257996975898624
14772200402937970688
14700142808900042752
14628085214862114816
17710257100564725760
17638199506526797824
17566141912488869888
17494084318450941952
17422026724413014016
9447558059711791104
9375500465673863168
9303442871635935232
9231385277598007296
9159327683560079360
3025903278639546368
2953845684601618432
2881788090563690496
2809730496525762560
2304007924306935808
2231950330269007872
2159892736231079936
2087835142193152000
2376065518344863744
2808411082572431360
2736353488534503424
2664295894496575488
2592238300458647552
2880468676610359296
2305327338260267008
2233269744222339072
2161212150184411136
2089154556146483200
2017096962108555264
1945039368070627328
1872981774032699392
1800924179994771456
1728866585956843520
1656808991918915584
1584751397880987648
1512693803843059712
1440636209805131776
1368578615767203840
1296521021729275904
1224463427691347968
1152405833653420032
1080348239615492096
1008290645577564160
936233051539636224
3584735561014837248
3512677966976909312
3440620372938981376
3368562778901053440
3296505184863125504
3224447590825197568
3152389996787269632
3080332402749341696
359772299236212736
287714705198284800
215657111160356864
143599517122428928
1138985194724786176
1066927600686858240
994870006648930304
922812412611002368
1211042788762714112
634582036459290624
562524442421362688
490466848383434752
418409254345506816
706639630497218560
17869486175475990528
17797428581438062592
17725370987400134656
17653313393362206720
17581255799324278784
17509198205286350848
17437140611248422912
17365083017210494976
17293025423172567040
9327308871028441088
17148910235096711168
17076852641058783232
9399366465066369024
16932737452982927360
16860679858944999424
16788622264907071488
16716564670869143552
16644507076831215616
16572449482793287680
16500391888755359744
16428334294717431808
16356276700679503872
16284219106641575936
16212161512603648000
16140103918565720064
16068046324527792128
15995988730489864192
15923931136451936256
15851873542414008320
9471424059104296960
15707758354338152448
9543481653142224896
15563643166262296576
3324658180092329984
3252600586054402048
3180542992016474112
3108485397978546176
3036427803940618240
2964370209902690304
2892312615864762368
2820255021826834432
3396715774130257920
1062409707408326656
990352113370398720
918294519332470784
12660796129491812352
12588738535453884416
12516680941415956480
12444623347378028544
12372565753340100608
14843067225883017216
14771009631845089280
5908877742249607168
5836820148211679232
5764762554173751296
5692704960135823360
5620647366097895424
5980935336287535104
15346432445171892224
15274374851133964288
15202317257096036352
15418490039209820160
16211123573627027456
16139065979589099520
16283181167664955392
14122491285503737856
14050433691465809920
10839496899522723840
10911554493560651776
13906318503389954048
13834260909352026112
13762203315314098176
13690145721276170240
13618088127238242304
9615539247180152832
13473972939162386432
13401915345124458496
13329857751086530560
9687596841218080768
13185742563010674688
13113684968972746752
13041627374934818816
12969569780896890880
12897512186858962944
12825454592821035008
12753396998783107072
12681339404745179136
12609281810707251200
12537224216669323264
12465166622631395328
12393109028593467392
12321051434555539456
12248993840517611520
12176936246479683584
12104878652441755648
12032821058403827712
11960763464365899776
11888705870327971840
11816648276290043904
11744590682252115968
11672533088214188032
9759654435256008704
11528417900138332160
11456360306100404224
11384302712062476288
11312245118024548352
11240187523986620416
11168129929948692480
11096072335910764544
11024014741872836608
10951957147834908672
10879899553796980736
10807841959759052800
10735784365721124864
10663726771683196928
10591669177645268992
10519611583607341056
10447553989569413120
10375496395531485184
10303438801493557248
10231381207455629312
10159323613417701376
10087266019379773440
10015208425341845504
9943150831303917568
9871093237265989632
9799035643228061696
9726978049190133760
15827148824440209408
15755091230402281472
15683033636364353536
15610976042326425600
15538918448288497664
9366690079000494080
9294632484962566144
9222574890924638208
9150517296886710272
9078459702848782336
9006402108810854400
8934344514772926464
8862286920734998528
8790229326697070592
8718171732659142656
8646114138621214720
8574056544583286784
8501998950545358848
8429941356507430912
8357883762469502976
8285826168431575040
8213768574393647104
8141710980355719168
8069653386317791232
7997595792279863296
7925538198241935360
7853480604204007424
7781423010166079488
7709365416128151552
7637307822090223616
7565250228052295680
7493192634014367744
7421135039976439808
7349077445938511872
7277019851900583936
7204962257862656000
7132904663824728064
7060847069786800128
9831712029293936640
9903769623331864576
6844674287673016320
6772616693635088384
6700559099597160448
6628501505559232512
6556443911521304576
6484386317483376640
6412328723445448704
6340271129407520768
6268213535369592832
6196155941331664896
6124098347293736960
9975827217369792512
5979983159217881088
5907925565179953152
5835867971142025216
5763810377104097280
5691752783066169344
5619695189028241408
5547637594990313472
5475580000952385536
5403522406914457600
5331464812876529664
5259407218838601728
5187349624800673792
5115292030762745856
5043234436724817920
4971176842686889984
4899119248648962048
4827061654611034112
4755004060573106176
4682946466535178240
4610888872497250304
4538831278459322368
4466773684421394432
4394716090383466496
4322658496345538560
10551511714464006144
10479454120426078208
10407396526388150272
10335338932350222336
4034428120193826816
3962370526155898880
3890312932117970944
3818255338080043008
3746197744042115072
3674140150004187136
3602082555966259200
3530024961928331264
3457967367890403328
3385909773852475392
3313852179814547456
3241794585776619520
3169736991738691584
3097679397700763648
3025621803662835712
2953564209624907776
5407229960123318272
5335172366085390336
5263114772047462400
5191057178009534464
5118999583971606528
6555405972544684032
6483348378506756096
6411290784468828160
6339233190430900224
6267175596392972288
6195118002355044352
6123060408317116416
6051002814279188480
2088873081169772544
2016815487131844608
1944757893093916672
1872700299055988736
1800642705018060800
1728585110980132864
1656527516942204928
1584469922904276992
1512412328866349056
1440354734828421120
1368297140790493184
1296239546752565248
1224181952714637312
12214108535591534592
12142050941553606656
12069993347515678720
1080066764638781440
1008009170600853504
8160941438725521408
8088883844687593472
8016826250649665536
7944768656611737600
7872711062573809664
7800653468535881728
719778794449141760
647721200411213824
575663606373285888
16531097949984260096
16603155544022188032
359490824259502080
287433230221574144
215375636183646208
143318042145718272
18445665452802703360
18373607858764775424
18301550264726847488
18229492670688919552
18157435076650991616
18085377482613063680
18013319888575135744
17941262294537207808
17869204700499279872
17797147106461351936
17725089512423424000
17653031918385496064
4804383127776526336
4732325533738598400
4660267939700670464
17436859136271712256
17364801542233784320
17292743948195856384
17220686354157928448
17148628760120000512
17076571166082072576
17004513572044144640
16932455978006216704
16860398383968288768
17040095967342231552
17112153561380159488
10745936156580380672
10673878562542452736
10817993750618308608
16572168007816577024
16500110413778649088
17810778851622518784
17738721257584590848
17666663663546662912
17594606069508734976
17522548475470807040
17450490881432879104
17378433287394951168
17306375693357023232
16067764849551081472
15995707255513153536
15923649661475225600
15851592067437297664
15779534473399369728
15707476879361441792
15635419285323513856
15563361691285585920
15491304097247657984
15419246503209730048
15347188909171802112
15275131315133874176
15203073721095946240
15131016127058018304
15058958533020090368
14986900938982162432
14914843344944234496
14842785750906306560
14770728156868378624
14698670562830450688
14626612968792522752
14554555374754594816
14482497780716666880
14410440186678738944
14338382592640811008
14266324998602883072
14194267404564955136
14122209810527027200
14050152216489099264
13978094622451171328
13906037028413243392
13833979434375315456
13761921840337387520
13689864246299459584
13617806652261531648
13545749058223603712
13473691464185675776
13401633870147747840
13329576276109819904
13257518682071891968
13185461088033964032
13113403493996036096
13041345899958108160
12969288305920180224
12897230711882252288
12825173117844324352
12753115523806396416
12681057929768468480
12609000335730540544
12536942741692612608
12464885147654684672
12392827553616756736
12320769959578828800
12248712365540900864
12176654771502972928
12104597177465044992
12032539583427117056
11960481989389189120
11888424395351261184
11816366801313333248
11744309207275405312
11672251613237477376
11600194019199549440
9343730077189275648
9271672483151347712
9199614889113419776
9127557295075491840
4930774188412633088
4858716594374705152
4786659000336777216
4714601406298849280
5002831782450561024
11095790860934053888
11023733266896125952
10951675672858198016
10879618078820270080
10807560484782342144
10735502890744414208
10663445296706486272
10591387702668558336
10519330108630630400
10447272514592702464
10375214920554774528
10303157326516846592
10231099732478918656
10159042138440990720
8983442106999635968
8911384512961708032
8839326918923780096
8767269324885852160
8695211730847924224
8623154136809996288
1187706753974796288
1115649159936868352
1043591565898940416
1259764348012724224
9798754168251351040
9726696574213423104
9654638980175495168
9582581386137567232
9510523792099639296
9438466198061711360
9366408604023783424
9294351009985855488
9222293415947927552
9150235821909999616
9078178227872071680
9006120633834143744
8934063039796215808
8862005445758287872
8789947851720359936
8717890257682432000
8645832663644504064
8573775069606576128
8501717475568648192
8429659881530720256
8357602287492792320
3039516332103041024
2967458738065113088
2895401144027185152
2823343549989257216
8069371911341080576
7997314317303152640
7925256723265224704
7853199129227296768
7781141535189368832
7709083941151440896
7637026347113512960
7564968753075585024
7492911159037657088
7420853564999729152
7348795970961801216
7276738376923873280
16853172393550544896
16781114799512616960
16709057205474689024
16636999611436761088
7060565594810089472
6988508000772161536
6916450406734233600
6844392812696305664
6999549296538288128
6927491702500360192
6855434108462432256
6783376514424504320
6711318920386576384
6639261326348648448
6567203732310720512
7071606890576216064
6267932060392882176
6195874466354954240
6123816872317026304
6051759278279098368
5979701684241170432
5907644090203242496
5835586496165314560
5763528902127386624
1727828646980222976
1655771052942295040
1583713458904367104
1511655864866439168
1439598270828511232
1367540676790583296
1799886241018150912
5331183337899819008
5259125743861891072
5187068149823963136
5115010555786035200
5042952961748107264
4970895367710179328
4898837773672251392
4826780179634323456
4754722585596395520
4682664991558467584
4610607397520539648
4538549803482611712
4466492209444683776
4394434615406755840
17061457279246663680
16989399685208735744
16917342091170807808
16845284497132879872
16773226903094951936
17133514873284591616
3962089051179188224
3890031457141260288
3817973863103332352
3745916269065404416
3673858675027476480
3601801080989548544
3529743486951620608
3457685892913692672
3385628298875764736
3313570704837836800
3241513110799908864
3169455516761980928
3097397922724052992
3025340328686125056
10047884811407720448
10119942405445648384
10191999999483576320
10264057593521504256
2665052358496485376
2533162640209870848
2461105046171942912
2389047452134014976
2316989858096087040
2244932264058159104
2172874670020231168
2100817075982303232
2028759481944375296
1956701887906447360
1884644293868519424
2605220234247798784
2088591606193061888
2016534012155133952
1944476418117206016
1872418824079278080
1800361230041350144
1728303636003422208
1291863490474016768
1219805896436088832
1147748302398160896
1075690708360232960
1363921084511944704
1512130853889638400
1440073259851710464
5239745751910711296
5167688157872783360
5095630563834855424
5023572969796927488
4951515375758999552
4879457781721071616
4807400187683143680
4735342593645215744
4663284999607287808
5311803345948639232
6278755652856709120
6206698058818781184
9065039063920148480
8992981469882220544
8920923875844292608
8848866281806364672
431266943320719360
359209349282791424
287151755244863488
215094161206935552
143036567169007616
10408172781597360128
10480230375635288064
10418282791014760448
10850628355242328064
10778570761204400128
10706513167166472192
10552287969673216000
18085096007636353024
6441140326139691008
6369082732101763072
6297025138063835136
6224967544025907200
6152909949987979264
6080852355950051328
17652750443408785408
17580692849370857472
17508635255332929536
14940189286987726848
14868131692949798912
14796074098911870976
14651958910836015104
14579901316798087168
10624345563711143936
17148347285143289856
17076289691105361920
17004232097067433984
16932174503029506048
16860116908991578112
16788059314953650176
16716001720915722240
16643944126877794304
16571886532839866368
16499828938801938432
16427771344764010496
16790946632488189952
16718889038450262016
16646831444412334080
16574773850374406144
16502716256336478208
16430658662298550272
16067483374574370816
15995425780536442880
13764527682895216640
13692470088857288704
13620412494819360768
13836585276933144576
15851310592460587008
15779252998422659072
15707195404384731136
15635137810346803200
10696403157749071872
10768460751786999808
15418965028233019392
15346907434195091456
15274849840157163520
15202792246119235584
6807867036421586944
6735809442383659008
6663751848345731072
6591694254307803136
6519636660269875200
6447579066231947264
6375521472194019328
8497341419290099712
8425283825252171776
8353226231214243840
8281168637176315904
8209111043138387968
8569399013328027648
14554273899777884160
14482216305739956224
14410158711702028288
14338101117664100352
14266043523626172416
14193985929588244480
14121928335550316544
14049870741512388608
13977813147474460672
13905755553436532736
13833697959398604800
13761640365360676864
13689582771322748928
13617525177284820992
13545467583246893056
13473409989208965120
13401352395171037184
13329294801133109248
13257237207095181312
13185179613057253376
13113122019019325440
13041064424981397504
12969006830943469568
12896949236905541632
14766918349078134784
14694860755040206848
14622803161002278912
14550745566964350976
12608718860753829888
12536661266715901952
12464603672677974016
12392546078640046080
12320488484602118144
12248430890564190208
10840518345824927744
12104315702488334336
12032258108450406400
11960200514412478464
11888142920374550528
11816085326336622592
11744027732298694656
15850835603437387776
15778778009399459840
15706720415361531904
15634662821323603968
15922893197475315712
13907845725040934912
14124018507154718720
14914086880944324608
14842029286906396672
14769971692868468736
14697914098830540800
14986144474982252544
11095509385957343232
11023451791919415296
10951394197881487360
10879336603843559424
10890332819632947200
10818275225595019264
10746217631557091328
10962390413670875136
536564972889571328
464507378851643392
392449784813715456
320392190775787520
248334596737859584
176277002699931648
104219408662003712
1689486477496418304
1617428883458490368
1545371289420562432
1473313695382634496
1401256101344706560
1329198507306778624
1257140913268850688
8768651411001966592
8696593816964038656
8624536222926110720
8552478628888182784
8480421034850254848
8408363440812326912
8336305846774398976
8264248252736471040
15231885323790188544
15159827729752260608
15087770135714332672
15015712541676404736
14943654947638476800
14871597353600548864
15303942917828116480
15952461264169467904
15880403670131539968
15808346076093612032
15736288482055684096
15664230888017756160
15592173293979828224
15520115699941900288
16024518858207395840
9149954346933288960
9077896752895361024
9005839158857433088
8933781564819505152
8861723970781577216
8789666376743649280
8717608782705721344
8645551188667793408
8573493594629865472
8501436000591937536
8429378406554009600
10912575939862855680
8285263218478153728
8213205624440225792
8141148030402297856
8069090436364369920
7997032842326441984
7924975248288514048
7852917654250586112
7780860060212658176
7708802466174730240
16722871469566066688
16650813875528138752
16578756281490210816
16506698687452282880
16794929063603994624
17443447409945346048
17371389815907418112
17299332221869490176
17227274627831562240
17515505003983273984
7204399307909234688
7132341713871306752
7060284119833378816
6988226525795450880
6916168931757522944
6844111337719595008
6772053743681667072
6699996149643739136
6627938555605811200
6555880961567883264
6483823367529955328
6411765773492027392
6339708179454099456
6267650585416171520
6195592991378243584
6123535397340315648
6051477803302387712
5979420209264459776
5907362615226531840
9634763108480188416
9562705514442260480
9490647920404332544
9418590326366404608
9346532732328476672
9274475138290548736
6255673605254807552
6183616011216879616
6111558417178951680
6039500823141023744
5475017050998964224
5402959456961036288
5330901862923108352
5258844268885180416
5186786674847252480
5114729080809324544
5042671486771396608
4970613892733468672
4898556298695540736
4826498704657612800
4754441110619684864
4682383516581756928
4610325922543828992
4538268328505901056
4466210734467973120
4394153140430045184
4322095546392117248
4250037952354189312
4177980358316261376
4105922764278333440
6710463500340166656
3961807576202477568
3889749982164549632
3817692388126621696
3745634794088693760
3673577200050765824
3601519606012837888
11056691127938711552
3457404417936982016
5272449625767280640
5200392031729352704
5128334437691424768
5056276843653496832
4984219249615568896
4912161655577640960
4840104061539713024
4768046467501785088
4695988873463857152
4623931279425929216
2101915488098451456
2029857894060523520
1957800300022595584
1885742705984667648
1813685111946739712
1741627517908811776
1669569923870883840
1597512329832955904
1525454735795027968
1453397141757100032
1381339547719172096
1309281953681244160
2304482913330135040
2232425319292207104
4521202808531189760
4449145214493261824
4377087620455333888
4305030026417405952
4593260402569117696
1944194943140495360
1872137349102567424
1800079755064639488
15772308482981625856
15700250888943697920
15628193294905769984
15556135700867842048
15484078106829914112
15412020512791986176
15339962918754058240
15267905324716130304
15195847730678202368
1223619002761216000
1151561408723288064
1079503814685360128
1007446220647432192
935388626609504256
863331032571576320
791273438533648384
3270606188470861824
3198548594432933888
3126491000395005952
575100656419864576
503043062381936640
430985468344008704
358927874306080768
6112854741388099584
6040797147350171648
5968739553312243712
5896681959274315776
18445102502849282048
18373044908811354112
18300987314773426176
3158493385833054208
3086435791795126272
3014378197757198336
2942320603719270400
5536393989084676096
5464336395046748160
5392278801008820224
5320221206970892288
4383472484477829120
4311414890439901184
4239357296401973248
4167299702364045312
17580411374394146816
17508353780356218880
17436296186318290944
17364238592280363008
17292180998242435072
17220123404204507136
17148065810166579200
17076008216128651264
17003950622090723328
11906535550883987456
11834477956846059520
11762420362808131584
11690362768770203648
11618305174732275712
11546247580694347776
11474189986656419840
11978593144921915392
18085388477729341440
18013330883691413504
17941273289653485568
17869215695615557632
17797158101577629696
17725100507539701760
17653042913501773824
17580985319463845888
17508927725425917952
15995144305559732224
15923086711521804288
15741930076217802752
15813987670255730688
15778971523445948416
15706913929408020480
15634856335370092544
15562798741332164608
15490741147294236672
15418683553256308736
15346625959218380800
15274568365180452864
15202510771142524928
15130453177104596992
15058395583066669056
14986337989028741120
14914280394990813184
14842222800952885248
14770165206914957312
11489036692166279168
11561094286204207104
11633151880242135040
11705209474280062976
14409877236725317632
11777267068317990912
14265762048649461760
11849324662355918848
11921382256393846784
14049589266535677952
13977531672497750016
13538523067805859840
13466465473767931904
13394407879730003968
13322350285692076032
13250292691654148096
13178235097616220160
13106177503578292224
13034119909540364288
13401070920194326528
13329013326156398592
13256955732118470656
13184898138080542720
13112840544042614784
11524041843859783680
11451984249821855744
11379926655783927808
11307869061745999872
11235811467708071936
12824610167890903040
12752552573852975104
12680494979815047168
12608437385777119232
12536379791739191296
12464322197701263360
12392264603663335424
12320207009625407488
12248149415587479552
12176091821549551616
12104034227511623680
12031976633473695744
11959919039435767808
11887861445397839872
11815803851359911936
11743746257321984000
11671688663284056064
11599631069246128128
11527573475208200192
11455515881170272256
11383458287132344320
11311400693094416384
11239343099056488448
12065497444469702656
11095227910980632576
11023170316942704640
10951112722904776704
10879055128866848768
10806997534828920832
12137555038507630592
12209612632545558528
10590824752715137024
12281670226583486464
12353727820621414400
10374651970601353216
10302594376563425280
10230536782525497344
10158479188487569408
10086421594449641472
10014364000411713536
9942306406373785600
9870248812335857664
9798191218297929728
9726133624260001792
9654076030222073856
9582018436184145920
9509960842146217984
9437903248108290048
5205460780333400064
5133403186295472128
6405102733027704832
6333045138989776896
9221730465994506240
9149672871956578304
9077615277918650368
9005557683880722432
8933500089842794496
8861442495804866560
8789384901766938624
8717327307729010688
8645269713691082752
8573212119653154816
8501154525615226880
8429096931577298944
8357039337539371008
8284981743501443072
8212924149463515136
8140866555425587200
8068808961387659264
7996751367349731328
7924693773311803392
7852636179273875456
11560318030994997248
11488260436957069312
14083740097694400512
14011682503656472576
7636463397160091648
7564405803122163712
7492348209084235776
7420290615046307840
7348233021008379904
7276175426970451968
7256862505228566528
7184804911190638592
7112747317152710656
7040689723114782720
6968632129076854784
6896574535038926848
6824516941000998912
3457696888029970432
3385639293992042496
3313581699954114560
3241524105916186624
12425785414659342336
6627657080629100544
6555599486591172608
6483541892553244672
6411484298515316736
6339426704477388800
8989873150510497792
8917815556472569856
8845757962434641920
6123253922363604992
6051196328325677056
8701642774358786048
8629585180320858112
8557527586282930176
15069673273832767488
14997615679794839552
14925558085756911616
14853500491718983680
14781442897681055744
14709385303643127808
14637327709605199872
5474735576022253568
5402677981984325632
5330620387946397696
5258562793908469760
7133288393382821888
7061230799344893952
7205345987420749824
8824682523553431552
8752624929515503616
8680567335477575680
8608509741439647744
8536452147401719808
4826217229680902144
4754159635642974208
4682102041605046272
4610044447567118336
4537986853529190400
4465929259491262464
4393871665453334528
4321814071415406592
175254456886099968
103196862848172032
18405544273505157120
18333486679467229184
13119991767669669888
13047934173631741952
12975876579593814016
12903818985555886080
13192049361707597824
3961526101225766912
3889468507187838976
835821251644620800
763763657606692864
691706063568764928
619648469530836992
547590875492909056
3529180536998199296
3457122942960271360
3385065348922343424
3313007754884415488
3240950160846487552
3168892566808559616
3096834972770631680
3024777378732703744
2952719784694775808
2880662190656847872
4999988445381132288
4927930851343204352
4855873257305276416
4783815663267348480
4711758069229420544
4639700475191492608
4567642881153564672
4495585287115636736
14836173287976861696
14764115693938933760
14692058099901005824
14620000505863077888
14908230882014789632
14025708973492011008
13953651379454083072
13881593785416155136
13809536191378227200
13737478597340299264
13665421003302371328
13593363409264443392
13521305815226515456
13449248221188587520
14097766567529938944
7646118208763592704
7574060614725664768
7502003020687736832
7429945426649808896
7357887832611880960
1367452715860361216
1295395121822433280
1223337527784505344
17277911536337158144
17205853942299230208
17133796348261302272
17061738754223374336
16989681160185446400
863049557594865664
790991963556937728
718934369519009792
646876775481081856
574819181443153920
12497843008697270272
12569900602735198208
358646399329370112
286588805291442176
214531211253514240
142473617215586304
18444821027872571392
18372763433834643456
18300705839796715520
18228648245758787584
18156590651720859648
18084533057682931712
12641958196773126144
12714015790811054080
17868360275569147904
17796302681531219968
17724245087493292032
17652187493455364096
17580129899417436160
18344977675489116160
18272920081451188224
18200862487413260288
18128804893375332352
17363957117303652352
17291899523265724416
17219841929227796480
10736736542790778880
10664678948752850944
10592621354714923008
10520563760676995072
10808794136828706816
16859553959038156800
16787496365000228864
16715438770962300928
16643381176924372992
16571323582886445056
16499265988848517120
2099679081447555072
2027621487409627136
1955563893371699200
2171736675485483008
3736132814601453568
3664075220563525632
3592017626525597696
3519960032487669760
16211035612696805376
16138978018658877440
16066920424620949504
15994862830583021568
15922805236545093632
15850747642507165696
15778690048469237760
15706632454431309824
15634574860393381888
17990815084577816576
17918757490539888640
17846699896501960704
336986020262182912
264928426224254976
15346344484241670144
15274286890203742208
15202229296165814272
15130171702127886336
15058114108089958400
14986056514052030464
14913998920014102528
14841941325976174592
14769883731938246656
14697826137900318720
14625768543862390784
14553710949824462848
12786073384848982016
14409595761748606976
14337538167710679040
6562172367102017536
6490114773064089600
6418057179026161664
6615961575444447232
6543903981406519296
6471846387368591360
6399788793330663424
14049307791558967296
13977250197521039360
13905192603483111424
13833135009445183488
13761077415407255552
13689019821369327616
13616962227331399680
13544904633293471744
13472847039255543808
13400789445217615872
13328731851179687936
13256674257141760000
13184616663103832064
13112559069065904128
13040501475027976192
12968443880990048256
12896386286952120320
12824328692914192384
12752271098876264448
12680213504838336512
12608155910800408576
12536098316762480640
12464040722724552704
12391983128686624768
14566780844543836160
14494723250505908224
14422665656467980288
14350608062430052352
14278550468392124416
14206492874354196480
14134435280316268544
4964845854734155776
5036903448772083712
11627884120033460224
11555826525995532288
11483768931957604352
11411711337919676416
11339653743881748480
11267596149843820544
11699941714071388160
11599349594269417472
11527292000231489536
11455234406193561600
11383176812155633664
11311119218117705728
11239061624079777792
11167004030041849856
11094946436003921920
11022888841965993984
10950831247928066048
10878773653890138112
10806716059852210176
10734658465814282240
10662600871776354304
10590543277738426368
10518485683700498432
10446428089662570496
10374370495624642560
10302312901586714624
10230255307548786688
10158197713510858752
10086140119472930816
10014082525435002880
9942024931397074944
9869967337359147008
9797909743321219072
9725852149283291136
9653794555245363200
9581736961207435264
9509679367169507328
9437621773131579392
9365564179093651456
9293506585055723520
9221448991017795584
10375577759391940608
10303520165354012672
10591750541505724416
10519692947467796480
9005276208904011776
8933218614866083840
8861161020828155904
8789103426790227968
8717045832752300032
8644988238714372096
8572930644676444160
8500873050638516224
8428815456600588288
8356757862562660352
8284700268524732416
8212642674486804480
8140585080448876544
8068527486410948608
7996469892373020672
7924412298335092736
7852354704297164800
7780297110259236864
7708239516221308928
7636181922183380992
7564124328145453056
7492066734107525120
7420009140069597184
7347951546031669248
7275893951993741312
7203836357955813376
17436093876178780160
17364036282140852224
17291978688102924288
17219921094064996352
17147863500027068416
11344145248881213440
11272087654843285504
11200030060805357568
11127972466767429632
11055914872729501696
5323957347482075136
5251899753444147200
5179842159406219264
5107784565368291328
5396014941520003072
6997305193305997312
6925247599268069376
6853190005230141440
6781132411192213504
6709074817154285568
6637017223116357632
6564959629078429696
6492902035040501760
6420844441002573824
16319480444544352256
16247422850506424320
16175365256468496384
16103307662430568448
16031250068392640512
15959192474354712576
15887134880316784640
16391538038582280192
3901354227884097536
3829296633846169600
3757239039808241664
3685181445770313728
3613123851732385792
13506649325228261376
13578706919266189312
5474454101045542912
5402396507007614976
5330338912969687040
5258281318931759104
5186223724893831168
5114166130855903232
5042108536817975296
4970050942780047360
16751865591190519808
16823923185228447744
5936737167874195456
5864679573836267520
5792621979798339584
5720564385760411648
5648506791722483712
6277023922042961920
6204966328005033984
6132908733967106048
6060851139929178112
5988793545891250176
4393590190476623872
4321532596438695936
4249475002400768000
4177417408362840064
4105359814324912128
4033302220286984192
3961244626249056256
3889187032211128320
3817129438173200384
3745071844135272448
3673014250097344512
3600956656059416576
3528899062021488640
361299520887193600
289241926849265664
217184332811337728
145126738773409792
73069144735481856
18375416555392466944
3312726279907704832
3240668685869776896
3168611091831848960
3096553497793921024
13650764513304117248
2952438309718065152
2880380715680137216
2808323121642209280
2736265527604281344
2664207933566353408
13722822107342045184
2520092745490497536
2448035151452569600
2375977557414641664
2303919963376713728
2231862369338785792
2159804775300857856
2087747181262929920
4901941694997463040
4829884100959535104
4757826506921607168
4685768912883679232
4613711318845751296
4541653724807823360
3134377797301043200
3062320203263115264
2990262609225187328
2918205015187259392
2846147421149331456
2774089827111403520
1583344022997434368
1511286428959506432
1439228834921578496
1367171240883650560
1295113646845722624
1223056052807794688
1150998458769866752
1078940864731938816
1006883270694010880
934825676656082944
862768082618155008
790710488580227072
718652894542299136
646595300504371200
574537706466443264
502480112428515328
3000897085689036800
2928839491651108864
2856781897613180928
3072954679726964736
214249736276803584
142192142238875648
18444539552895860736
18372481958857932800
18300424364820004864
18228366770782076928
13794879701379973120
18084251582706221056
13455420879466921984
13383363285428994048
13527478473504849920
13239248097353138176
16201864586209525760
16129806992171597824
16057749398133669888
15985691804095741952
15913634210057814016
15841576616019886080
15769519021981958144
15697461427944030208
16273922180247453696
17579848424440725504
17507790830402797568
17435733236364869632
17363675642326941696
17291618048289013760
17219560454251085824
17147502860213157888
17075445266175229952
2760480072182792192
2688422478144864256
2616364884106936320
2544307290069008384
2472249696031080448
2400192101993152512
2328134507955224576
2256076913917296640
2184019319879368704
2111961725841440768
2039904131803512832
16354869325795950592
16282811731758022656
16210754137720094720
16138696543682166784
16066638949644238848
15994581355606310912
15922523761568382976
15850466167530455040
15778408573492527104
15706350979454599168
15634293385416671232
15562235791378743296
13866937295417901056
15418120603302887424
15346063009264959488
15274005415227031552
15201947821189103616
15129890227151175680
15057832633113247744
14985775039075319808
14913717445037391872
14841659850999463936
14769602256961536000
13161017845036875776
13088960250998947840
13016902656961019904
12944845062923091968
12872787468885164032
13233075439074803712
14481371880809824256
14409314286771896320
14337256692733968384
14265199098696040448
14193141504658112512
14121083910620184576
14049026316582256640
13976968722544328704
13904911128506400768
13832853534468472832
13760795940430544896
13688738346392616960
13616680752354689024
13544623158316761088
13472565564278833152
13400507970240905216
13328450376202977280
13256392782165049344
13340617571875946496
13268559977838018560
13112277594089193472
13040220000051265536
12968162406013337600
12896104811975409664
12824047217937481728
12751989623899553792
12679932029861625856
12607874435823697920
12535816841785769984
12463759247747842048
12391701653709914112
12319644059671986176
12247586465634058240
12175528871596130304
12103471277558202368
12031413683520274432
11959356089482346496
11887298495444418560
11815240901406490624
11743183307368562688
11671125713330634752
11599068119292706816
11527010525254778880
11454952931216850944
11382895337178923008
11310837743140995072
11238780149103067136
11166722555065139200
11094664961027211264
11022607366989283328
10950549772951355392
10878492178913427456
10806434584875499520
10734376990837571584
10662319396799643648
10590261802761715712
10518204208723787776
10446146614685859840
10374089020647931904
10302031426610003968
10229973832572076032
5255826109466935296
5183768515429007360
10085858644496220160
10013801050458292224
9941743456420364288
9869685862382436352
9797628268344508416
9725570674306580480
9653513080268652544
9581455486230724608
9509397892192796672
9437340298154868736
9365282704116940800
9293225110079012864
16073678023085260800
16001620429047332864
15929562835009404928
15857505240971476992
15785447646933549056
15713390052895621120
15641332458857693184
16145735617123188736
8716764357775589376
8644706763737661440
8572649169699733504
8500591575661805568
8428533981623877632
8356476387585949696
8284418793548021760
8212361199510093824
8140303605472165888
8068246011434237952
15106291409084219392
15034233815046291456
14962176221008363520
14890118626970435584
14818061032932507648
14746003438894579712
14673945844856651776
15178349003122147328
7563842853168742400
7491785259130814464
7419727665092886528
7347670071054958592
7275612477017030656
7203554882979102720
7131497288941174784
7059439694903246848
6987382100865318912
6915324506827390976
6843266912789463040
6771209318751535104
6699151724713607168
6627094130675679232
4053654180517117952
3981596586479190016
3909538992441262080
14317350034713083904
14389407628751011840
2812054864106881024
2739997270068953088
16623193043926777856
16695250637964705792
13219307354471792640
13147249760433864704
8227118844578103296
8155061250540175360
8083003656502247424
8010946062464319488
6122690972410183680
6050633378372255744
17199653796230201344
17271711390268129280
8587406814767742976
8515349220729815040
8443291626691887104
8371234032653959168
5834460596258471936
5762403002220544000
5690345408182616064
5618287814144688128
5546230220106760192
5474172626068832256
9553591662559625216
9481534068521697280
9409476474483769344
9337418880445841408
5185942249917120512
5113884655879192576
5041827061841264640
4969769467803336704
4897711873765408768
4825654279727480832
4753596685689552896
4681539091651624960
4609481497613697024
4537423903575769088
4465366309537841152
4393308715499913216
13740889282409660416
13812946876447588352
14114983820109283328
14042926226071355392
13970868632033427456
13898811037995499520
13826753443957571584
13754695849919643648
13682638255881715712
13198503494962642944
3816847963196489728
3744790369158561792
3672732775120633856
3600675181082705920
3528617587044777984
3456559993006850048
3384502398968922112
3312444804930994176
3240387210893066240
3168329616855138304
3096272022817210368
3024214428779282432
2952156834741354496
13938994889455828992
14011052483493756928
2735984052627570688
2663926458589642752
2591868864551714816
2519811270513786880
2447753676475858944
2375696082437931008
2303638488400003072
16446163975273447424
16374106381235519488
16302048787197591552
16229991193159663616
16157933599121735680
16085876005083807744
17238797509690654720
17166739915652726784
17094682321614798848
17022624727576870912
16950567133538942976
16878509539501015040
1799235330134507520
1727177736096579584
1655120142058651648
1583062548020723712
1511004953982795776
1438947359944867840
1366889765906939904
1294832171869011968
1222774577831084032
1150716983793156096
1078659389755228160
1006601795717300224
934544201679372288
862486607641444352
790429013603516416
718371419565588480
646313825527660544
574256231489732608
502198637451804672
430141043413876736
358083449375948800
286025855338020864
213968261300092928
141910667262164992
18444258077919150080
18372200483881222144
18300142889843294208
14371340453683396608
18156027701767438336
14443398047721324544
18011912513691582464
8262866166620356608
8190808572582428672
8118750978544500736
8046693384506572800
7974635790468644864
7902578196430716928
7455588236832800768
7383530642794872832
7311473048756944896
7239415454719016960
7167357860681089024
7095300266643161088
14587513235797180416
17291336573312303104
14659570829835108352
14731628423873036288
17075163791198519296
14803686017910964224
1399284676996104192
16858991009084735488
16786933415046807552
16714875821008879616
16642818226970951680
16570760632933023744
16498703038895095808
1471342271034032128
16354587850819239936
16282530256781312000
16210472662743384064
16138415068705456128
14875743611948892160
1615457459109888000
15922242286591672320
2982375812319150080
2910318218281222144
15778127098515816448
15706069504477888512
2853783529404235776
15634011910439960576
15561954316402032640
15489896722364104704
15417839128326176768
15345781534288248832
15273723940250320896
15201666346212392960
15129608752174465024
15057551158136537088
14985493564098609152
14913435970060681216
14841378376022753280
14769320781984825344
14697263187946897408
14625205593908969472
14553147999871041536
14481090405833113600
14409032811795185664
14336975217757257728
12682469702698532864
12610412108660604928
12538354514622676992
12466296920584749056
2460202347125538816
2388144753087610880
2316087159049682944
2244029565011755008
6647717670277873664
6575660076239945728
6503602482202017792
13760514465453834240
13688456871415906304
13616399277377978368
13544341683340050432
13472284089302122496
13400226495264194560
13328168901226266624
13256111307188338688
13184053713150410752
14947801205986820096
13039938525074554880
12967880931036626944
12895823336998699008
12823765742960771072
15019858800024748032
12679650554884915200
12607592960846987264
12535535366809059328
12463477772771131392
12391420178733203456
794225627254226944
722168033216299008
650110439178371072
578052845140443136
505995251102515200
866283221292154880
14534293574477938688
14462235980440010752
14390178386402082816
14318120792364154880
14246063198326226944
14174005604288299008
104197418429448192
18406544829086433280
18334487235048505344
18262429641010577408
18190372046972649472
18118314452934721536
13835391207305379840
13763333613267451904
13691276019229523968
13619218425191596032
13547160831153668096
13475103237115740160
11271842463750291456
11199784869712363520
11127727275674435584
11343900057788219392
17408228952996052992
17336171358958125056
5463040070837600256
5390982476799672320
5318924882761744384
5246867288723816448
5174809694685888512
10806153109898788864
10734095515860860928
10662037921822932992
10589980327785005056
17760393731279683584
17688336137241755648
17616278543203827712
17544220949165899776
17472163355127971840
17400105761090043904
10157634763557437440
10085577169519509504
10013519575481581568
9941461981443653632
9869404387405725696
9797346793367797760
9725289199329869824
9653231605291941888
9581174011254013952
9509116417216086016
9437058823178158080
9365001229140230144
9292943635102302208
9220886041064374272
9148828447026446336
9076770852988518400
9004713258950590464
8932655664912662528
11721367897161859072
11649310303123931136
11577252709086003200
11505195115048075264
11433137521010147328
11361079926972219392
11289022332934291456
11216964738896363520
11144907144858435584
11072849550820507648
11000791956782579712
10928734362744651776
8140022130495455232
8067964536457527296
7995906942419599360
7923849348381671424
7851791754343743488
7779734160305815552
7707676566267887616
7635618972229959680
7563561378192031744
7491503784154103808
7419446190116175872
7347388596078247936
7275331002040320000
7203273408002392064
7131215813964464128
7059158219926536192
6987100625888608256
6915043031850680320
6842985437812752384
6770927843774824448
6698870249736896512
6626812655698968576
6554755061661040640
6482697467623112704
6410639873585184768
6338582279547256832
10825953115291779072
10753895521253851136
10681837927215923200
10609780333177995264
10898010709329707008
6050351903395545088
5978294309357617152
5906236715319689216
5834179121281761280
5762121527243833344
5690063933205905408
17782865549928169472
17710807955890241536
17638750361852313600
17566692767814385664
17494635173776457728
17854923143966097408
5329775963016265728
5257718368978337792
5185660774940409856
5113603180902481920
5041545586864553984
4969487992826626048
4897430398788698112
4825372804750770176
4753315210712842240
4681257616674914304
4609200022636986368
4537142428599058432
4465084834561130496
4393027240523202560
4320969646485274624
4248912052447346688
4176854458409418752
4104796864371490816
4032739270333562880
3960681676295634944
3888624082257707008
3816566488219779072
3744508894181851136
3672451300143923200
3600393706105995264
3528336112068067328
3456278518030139392
3384220923992211456
3312163329954283520
3240105735916355584
3168048141878427648
3095990547840499712
3023932953802571776
2951875359764643840
2879817765726715904
2807760171688787968
2735702577650860032
2663644983612932096
2591587389575004160
2519529795537076224
2447472201499148288
2375414607461220352
2303357013423292416
2231299419385364480
2159241825347436544
2087184231309508608
2015126637271580672
1943069043233652736
1871011449195724800
1798953855157796864
1726896261119868928
1654838667081940992
1582781073044013056
1510723479006085120
1438665884968157184
1366608290930229248
1294550696892301312
1222493102854373376
1150435508816445440
1078377914778517504
1006320320740589568
934262726702661632
862205132664733696
790147538626805760
718089944588877824
646032350550949888
573974756513021952
501917162475094016
429859568437166080
357801974399238144
285744380361310208
213686786323382272
141629192285454336
18443976602942439424
18026362295503814656
17954304701465886720
17882247107427958784
17810189513390030848
17738131919352102912
17666074325314174976
17594016731276247040
17521959137238319104
17449901543200391168
17939573444676943872
17867515850639015936
17148639755236278272
17076582161198350336
15452204364252315648
15524261958290243584
17579285474487304192
7557742762657841152
7485685168619913216
7413627574581985280
17435170286411448320
17363112692373520384
17291055098335592448
17218997504297664512
17146939910259736576
17074882316221808640
17002824722183880704
16930767128145952768
16858709534108024832
16786651940070096896
16714594346032168960
16642536751994241024
16570479157956313088
16498421563918385152
16426363969880457216
17428238965109948416
17356181371072020480
17284123777034092544
14057551929744031744
13985494335706103808
13913436741668175872
13841379147630247936
13769321553592320000
15994018405652889600
15921960811614961664
10776660909506953216
10704603315469025280
10632545721431097344
10848718503544881152
10344315345279385600
10272257751241457664
10200200157203529728
10416372939317313536
15417557653349466112
15345500059311538176
15273442465273610240
15201384871235682304
15129327277197754368
15057269683159826432
14985212089121898496
14913154495083970560
14841096901046042624
14769039307008114688
14696981712970186752
14624924118932258816
14552866524894330880
15596319552328171520
15668377146366099456
14336693742780547072
14264636148742619136
15740434740404027392
15812492334441955328
15884549928479883264
13976405772590907392
13904348178552979456
13832290584515051520
13760232990477123584
13688175396439195648
13616117802401267712
13544060208363339776
13472002614325411840
4828013831680688128
4755956237642760192
4683898643604832256
4611841049566904320
4539783455528976384
4900071425718616064
13183772238173700096
13111714644135772160
13039657050097844224
14607004278422765568
14534946684384837632
14462889090346909696
14390831496308981760
14318773902271053824
12823484267984060416
12751426673946132480
12679369079908204544
12607311485870276608
12535253891832348672
12674870977838972928
12602813383801044992
12530755789763117056
12458698195725189120
12386640601687261184
12314583007649333248
18300512325750226944
18228454731712299008
18156397137674371072
18372569919788154880
11958793139528925184
11886735545490997248
11814677951453069312
11742620357415141376
11670562763377213440
11598505169339285504
11526447575301357568
11454389981263429632
11382332387225501696
11310274793187573760
11238217199149645824
11166159605111717888
11094102011073789952
11022044417035862016
10949986822997934080
10877929228960006144
15956607522517811200
10733814040884150272
10661756446846222336
10589698852808294400
10517641258770366464
10445583664732438528
10373526070694510592
16813686731973853184
16741629137935925248
16669571543897997312
16597513949860069376
16525456355822141440
16453398761784213504
16381341167746285568
287816959779667968
215759365741740032
143701771703812096
18446049182360797184
18373991588322869248
359874553817595904
9580892536277303296
9508834942239375360
9436777348201447424
9364719754163519488
9292662160125591552
9220604566087663616
9148546972049735680
17462205078315204608
17390147484277276672
17318089890239348736
17246032296201420800
17173974702163492864
17101917108125564928
17029859514087636992
16957801920049709056
8572086219746312192
8500028625708384256
8427971031670456320
8355913437632528384
8283855843594600448
8211798249556672512
8139740655518744576
8067683061480816640
7995625467442888704
7923567873404960768
7851510279367032832
15869049013551497216
15796991419513569280
15724933825475641344
15652876231437713408
15941106607589425152
7491222309177393152
7419164715139465216
16244837898669522944
7275049527063609344
15300477257177366528
15228419663139438592
15156362069101510656
15084304475063582720
6986819150911897600
6914761556873969664
6842703962836041728
6770646368798113792
16316895492707450880
16388953086745378816
16073959498061971456
17437242865829806080
17365185271791878144
17293127677753950208
17509300459867734016
6410358398608474112
6338300804570546176
6266243210532618240
16461010680783306752
16533068274821234688
16605125868859162624
13185203802313064448
5978012834380906496
5905955240342978560
5833897646305050624
5761840052267122688
5689782458229194752
5617724864191266816
16677183462897090560
5473609676115410944
16749241056935018496
5329494488039555072
5257436894001627136
5185379299963699200
5113321705925771264
7385775845538791424
7313718251500863488
7241660657462935552
7169603063425007616
7097545469387079680
7025487875349151744
6953430281311223808
6881372687273295872
8444653921598701568
8372596327560773632
8300538733522845696
8228481139484917760
8156423545446989824
8516711515636629504
16099701264291463168
16027643670253535232
15955586076215607296
1216955962296893440
1144898368258965504
1072840774221037568
1000783180183109632
928725586145181696
856667992107253760
784610398069325824
17717863522005680128
17645805927967752192
17573748333929824256
17501690739891896320
17429633145853968384
17357575551816040448
17285517957778112512
3600112231129284608
3528054637091356672
3455997043053428736
3383939449015500800
3311881854977572864
3239824260939644928
3167766666901716992
3095709072863789056
3023651478825861120
16821298650972946432
2879536290750005248
2807478696712077312
2735421102674149376
13741999789153714176
13669942195115786240
13814057383191642112
2519248320560365568
2447190726522437632
2375133132484509696
2303075538446581760
2231017944408653824
17037471433086730240
2086902756332797952
17109529027124658176
1942787568256942080
1870729974219014144
1798672380181086208
1726614786143158272
1654557192105230336
1582499598067302400
1510442004029374464
1438384409991446528
1366326815953518592
1294269221915590656
1222211627877662720
1150154033839734784
1078096439801806848
1006038845763878912
933981251725950976
861923657688023040
789866063650095104
717808469612167168
645750875574239232
573693281536311296
501635687498383360
429578093460455424
357520499422527488
285462905384599552
213405311346671616
9546387662374436864
9474330068336508928
9402272474298580992
9330214880260653056
9258157286222725120
9186099692184797184
9114042098146869248
14691444572412706816
14619386978374778880
14547329384336850944
14475271790298923008
14403214196260995072
14331156602223067136
14259099008185139200
17867234375662305280
17795176781624377344
17723119187586449408
17651061593548521472
13467079001256230912
13395021407218302976
13322963813180375040
13250906219142447104
13178848625104519168
13106791031066591232
13034733437028663296
13539136595294158848
17218716029320953856
17146658435283025920
17074600841245097984
17002543247207170048
16930485653169242112
17181586621162586112
17253644215200514048
17325701809238441984
16642255277017530368
16570197682979602432
16498140088941674496
16426082494903746560
16354024900865818624
16281967306827890688
16209909712789962752
793363610138050560
721306016100122624
865421204175978496
16065794524714106880
15993736930676178944
15921679336638251008
15849621742600323072
15777564148562395136
8261352139108909056
8189294545070981120
8117236951033053184
8045179356995125248
7973121762957197312
17397759403276369920
3128666933906374656
15273160990296899584
17469816997314297856
15129045802221043712
15056988208183115776
14984930614145187840
14912873020107259904
14840815426069331968
14768757832031404032
14696700237993476096
14624642643955548160
14552585049917620224
14480527455879692288
14408469861841764352
14336412267803836416
14264354673765908480
14192297079727980544
14120239485690052608
14048181891652124672
13976124297614196736
13904066703576268800
14640244713953689600
14568187119915761664
14496129525877833728
6034412283327676416
5962354689289748480
5890297095251820544
5818239501213892608
5746181907175964672
6106469877365604352
13543778733386629120
6610873035631099904
6538815441593171968
6466757847555244032
6394700253517316096
6322642659479388160
6682930629669027840
7856681282552463360
7928738876590391296
8144911658704175104
8216969252742103040
1123770152819621888
1051712558781693952
979654964743766016
907597370705838080
1195827746857549824
3200724527944302592
3272782121982230528
12967317981083205632
15779951188306296832
15707893594268368896
15635836000230440960
15563778406192513024
15491720812154585088
4552725806899527680
4480668212861599744
6415227036096266240
6343169442058338304
6487284630134194176
12679087604931493888
291755410430361600
219697816392433664
147640222354505728
363813004468289536
12390857228779782144
12318799634741854208
12246742040703926272
12174684446665998336
12102626852628070400
12030569258590142464
11958511664552214528
11886454070514286592
11814396476476358656
11742338882438430720
11670281288400502784
11598223694362574848
11526166100324646912
11454108506286718976
11382050912248791040
11309993318210863104
11237935724172935168
11165878130135007232
11093820536097079296
11021762942059151360
10949705348021223424
10877647753983295488
17613932185390153728
3850087299215785984
10661474971869511680
11241139701056274432
11169082107018346496
11097024512980418560
11024966918942490624
11313197295094202368
5622517635376742400
5550460041338814464
5478402447300886528
5406344853262958592
3818279527335854080
3746221933297926144
3674164339259998208
3602106745222070272
3530049151184142336
3457991557146214400
3890337121373782016
7898640845291651072
7826583251253723136
7754525657215795200
7682468063177867264
9436495873224736768
9364438279186808832
9292380685148880896
9220323091110952960
9148265497073025024
9076207903035097088
9004150308997169152
8932092714959241216
8860035120921313280
8787977526883385344
8715919932845457408
8643862338807529472
8571804744769601536
8499747150731673600
8427689556693745664
17488654930032984064
17416597335995056128
17344539741957128192
17272482147919200256
17200424553881272320
14704865211341340672
14632807617303412736
14560750023265484800
14488692429227556864
14416634835189628928
14344577241151700992
14272519647113773056
7707113616314466304
7635056022276538368
7562998428238610432
7490940834200682496
7418883240162754560
7346825646124826624
7274768052086898688
7202710458048970752
7130652864011042816
7058595269973114880
6986537675935186944
6914480081897259008
7459703708855566336
3922144893253713920
7315588520779710464
7243530926741782528
7171473332703854592
12396021634895446016
12323964040857518080
12251906446819590144
12179848852781662208
15613313604047077376
15541256010009149440
15469198415971221504
15685371198085005312
18407800471365353472
18335742877327425536
18263685283289497600
4086877023861997568
4014819429824069632
3942761835786141696
3870704241748213760
3798646647710285824
3726589053672357888
3654531459634429952
3582473865596502016
3510416271558574080
2933955519255150592
2861897925217222656
2789840331179294720
2717782737141366784
2645725143103438848
5689500983252484096
5617443389214556160
12104621366720856064
12032563772682928128
11960506178645000192
4645911616376799232
4573854022338871296
4501796428300943360
4429738834263015424
4717969210414727168
688060083011059712
616002488973131776
543944894935203840
471887300897275904
11233293586080464896
11161235992042536960
11089178398004609024
11017120803966681088
10945063209928753152
11305351180118392832
16845565972109590528
16773508378071662592
16701450784033734656
16629393189995806720
1662255972522917888
1590198378484989952
1518140784447062016
1734313566560845824
1480693617428267008
1408636023390339072
559134648072929280
487077054035001344
415019459997073408
342961865959145472
631192242110857216
4248349102493925376
4176291508455997440
4104233914418069504
4032176320380141568
3960118726342213632
3888061132304285696
3816003538266357760
3743945944228429824
3671888350190501888
3599830756152573952
3527773162114646016
3455715568076718080
3383657974038790144
3311600380000862208
3239542785962934272
3167485191925006336
3095427597887078400
3023370003849150464
2951312409811222528
2879254815773294592
2807197221735366656
1793416714600316928
1721359120562388992
1649301526524461056
1577243932486533120
1505186338448605184
1433128744410677248
1361071150372749312
2369877466903740416
2297819872865812480
2225762278827884544
2153704684789956608
2081647090752028672
2009589496714100736
1937531902676172800
2946338219207163904
2874280625169235968
2802223031131308032
2730165437093380096
2658107843055452160
2586050249017524224
2513992654979596288
3522798971510587392
3450741377472659456
3378683783434731520
3306626189396803584
3234568595358875648
3162511001320947712
3090453407283019776
4099259723814010880
4027202129776082944
3955144535738155008
3883086941700227072
3811029347662299136
3738971753624371200
3666914159586443264
4675720476117434368
4603662882079506432
4531605288041578496
4459547694003650560
4387490099965722624
4315432505927794688
4243374911889866752
5252181228420857856
5180123634382929920
5108066040345001984
5036008446307074048
4963950852269146112
4891893258231218176
4819835664193290240
213123836369960960
141066242332033024
18443413652989018112
18371356058951090176
18299298464913162240
18227240870875234304
18155183276837306368
18083125682799378432
18011068088761450496
17939010494723522560
17866952900685594624
17794895306647666688
17722837712609738752
17650780118571810816
17578722524533882880
17506664930495954944
17434607336458027008
17362549742420099072
17290492148382171136
17218434554344243200
17146376960306315264
17074319366268387328
17002261772230459392
16930204178192531456
16858146584154603520
16786088990116675584
16714031396078747648
10470965890659647488
10398908296621719552
10326850702583791616
10254793108545863680
10182735514507935744
10543023484697575424
11047426642963070976
10975369048925143040
10903311454887215104
10831253860849287168
10759196266811359232
11119484237000998912
11623887395266494464
11551829801228566528
11479772207190638592
11407714613152710656
11335657019114782720
11695944989304422400
12200348147569917952
12128290553531990016
12056232959494062080
11984175365456134144
11912117771418206208
12272405741607845888
18294324274309103616
18222266680271175680
18150209086233247744
18078151492195319808
18006093898157391872
17934036304119463936
17861978710081536000
496380021917614080
424322427879686144
352264833841758208
280207239803830272
208149645765902336
136092051727974400
18438439462384959488
17685989779428081664
17758047373466009600
3705127686209798144
14264073198789197824
14192015604751269888
14119958010713341952
14047900416675414016
13975842822637486080
13903785228599558144
13831727634561630208
13759670040523702272
13687612446485774336
17830104967503937536
13543497258409918464
13471439664371990528
13399382070334062592
13327324476296134656
13255266882258206720
13183209288220278784
13111151694182350848
13039094100144422912
12967036506106494976
12894978912068567040
12822921318030639104
12750863723992711168
12678806129954783232
12606748535916855296
12534690941878927360
12462633347840999424
12390575753803071488
12318518159765143552
12246460565727215616
17902162561541865472
12102345377651359744
17974220155579793408
18046277749617721344
18118335343655649280
11814115001499648000
11742057407461720064
11669999813423792128
11597942219385864192
11525884625347936256
11453827031310008320
11381769437272080384
11309711843234152448
11237654249196224512
18190392937693577216
3993358062361509888
11021481467082440704
2741432132743200768
2669374538705272832
2597316944667344896
2525259350629416960
2813489726781128704
10733251090930728960
10661193496892801024
10589135902854873088
3245835291008696320
3173777696970768384
3101720102932840448
3029662508894912512
3317892885046624256
17036449986784526336
16964392392746598400
16892334798708670464
16820277204670742528
10156790338627305472
10084732744589377536
10012675150551449600
9940617556513521664
9868559962475593728
9796502368437665792
9724444774399737856
9652387180361809920
9580329586323881984
9508271992285954048
9436214398248026112
9364156804210098176
9292099210172170240
9220041616134242304
9147984022096314368
16039692118670704640
15967634524632776704
15895576930594848768
15823519336556920832
15751461742518992896
15679404148481064960
15211589438653071360
15139531844615143424
15067474250577215488
14995416656539287552
14923359062501359616
14851301468463431680
8355350487679107072
8283292893641179136
8211235299603251200
8139177705565323264
8067120111527395328
7995062517489467392
7923004923451539456
7850947329413611520
7778889735375683584
7706832141337755648
7634774547299827712
7562716953261899776
7490659359223971840
7418601765186043904
7346544171148115968
7274486577110188032
7202428983072260096
7130371389034332160
7058313794996404224
6986256200958476288
6914198606920548352
6842141012882620416
6770083418844692480
6698025824806764544
6625968230768836608
6553910636730908672
6481853042692980736
6409795448655052800
9827264504759582720
9755206910721654784
6337737854617124864
6265680260579196928
6193622666541268992
6121565072503341056
6049507478465413120
5977449884427485184
5905392290389557248
5833334696351629312
5761277102313701376
5689219508275773440
5617161914237845504
5545104320199917568
5473046726161989632
5400989132124061696
5328931538086133760
5256873944048205824
5184816350010277888
5112758755972349952
5040701161934422016
4968643567896494080
4896585973858566144
4824528379820638208
4752470785782710272
4680413191744782336
4608355597706854400
4536298003668926464
4464240409630998528
4392182815593070592
18262450531731505152
18334508125769433088
4176010033479286784
345777715237879808
273720121199951872
201662527162023936
129604933124096000
417835309275807744
10329725925490425856
10257668331452497920
10185610737414569984
10113553143376642048
10041495549338714112
3671606875213791232
3599549281175863296
14300127284575600640
14228069690537672704
14156012096499744768
14083954502461816832
14011896908423888896
4209530844475293696
4281588438513221632
4353646032551149568
4425703626589077504
4497761220627005440
2878973340796583936
2027248752967811072
1955191158929883136
1883133564891955200
1811075970854027264
1739018376816099328
1666960782778171392
2099306347005739008
2374570182531088384
2302512588493160448
2230454994455232512
2158397400417304576
2086339806379376640
2014282212341448704
1942224618303520768
1870167024265592832
1798109430227664896
1726051836189736960
9130340159005392896
9058282564967464960
9202397753043320832
8914167376891609088
13108705280810549248
13036647686772621312
12964590092734693376
13180762874848477184
1437821460038025216
1365763866000097280
1293706271962169344
15227371828558168064
15155314234520240128
1149591083886313472
1077533489848385536
1005475895810457600
933418301772529664
861360707734601728
320391091264159744
4641876408702861312
4713934002740789248
573130331582889984
392448685302087680
429015143507034112
356957549469106176
464506279340015616
4858049190816645120
140784767355322368
18443132178012307456
18371074583974379520
18299016989936451584
18226959395898523648
10911799684653645824
10839742090615717888
10767684496577789952
10695626902539862016
16044804847739863040
16116862441777790976
15615529119977046016
15543471525939118080
15471413931901190144
15399356337863262208
15327298743825334272
15255241149787406336
15183183555749478400
15687586714014973952
17578441049557172224
17506383455519244288
17434325861481316352
17362268267443388416
17290210673405460480
17218153079367532544
17146095485329604608
17074037891291676672
17001980297253748736
16929922703215820800
16857865109177892864
16785807515139964928
16713749921102036992
16641692327064109056
16569634733026181120
16497577138988253184
16425519544950325248
16353461950912397312
16281404356874469376
16209346762836541440
7650068754042191872
7578011160004263936
7505953565966336000
7722126348080119808
6186140489914253312
6114082895876325376
6042025301838397440
5969967707800469504
5897910113762541568
15849058792646901760
15777001198608973824
9315884945215848448
9243827351177920512
9171769757139992576
9099712163102064640
8955596975026208768
8883539380988280832
8811481786950352896
8739424192912424960
15560828416495190016
15488770822457262080
15416713228419334144
15344655634381406208
15272598040343478272
15200540446305550336
15128482852267622400
14459992976719347712
14387935382681419776
14315877788643491840
14243820194605563904
14171762600567635968
14327138986735173632
14255081392697245696
14399196580773101568
13966851016545533952
13894793422507606016
14038908610583461888
7157969130891509760
7085911536853581824
7013853942815653888
6941796348777725952
7590314695119077376
7518257101081149440
7446199507043221504
7374141913005293568
7302084318967365632
13617050188261621760
13544992594223693824
13472935000185765888
13400877406147837952
13328819812109910016
13256762218071982080
13184704624034054144
13112647029996126208
9401712822880043008
9329655228842115072
9257597634804187136
9185540040766259200
9113482446728331264
9041424852690403328
9473770416917970944
13471158189395279872
13399100595357351936
13327043001319424000
13254985407281496064
13182927813243568128
13110870219205640192
13038812625167712256
12966755031129784320
12894697437091856384
12822639843053928448
12750582249016000512
12678524654978072576
12606467060940144640
8851989994340876288
8779932400302948352
8707874806265020416
8635817212227092480
8563759618189164544
8491702024151236608
8419644430113308672
8347586836075380736
9500508340682227712
9428450746644299776
9356393152606371840
9284335558568443904
9212277964530515968
9140220370492588032
9068162776454660096
8996105182416732160
11813833526522937344
11741775932485009408
11669718338447081472
11597660744409153536
11525603150371225600
11453545556333297664
11381487962295369728
11309430368257441792
11237372774219513856
12332995429368070144
12260937835330142208
12188880241292214272
12116822647254286336
11021199992105730048
10949142398067802112
10877084804029874176
10805027209991946240
10732969615954018304
10660912021916090368
10588854427878162432
10516796833840234496
10444739239802306560
10372681645764378624
10300624051726450688
10228566457688522752
10156508863650594816
10084451269612666880
10012393675574738944
9940336081536811008
9868278487498883072
9796220893460955136
9724163299423027200
9652105705385099264
9580048111347171328
9507990517309243392
9435932923271315456
9363875329233387520
9291817735195459584
9219760141157531648
9147702547119603712
9075644953081675776
9003587359043747840
536563873377943552
8859472170967891968
8787414576929964032
8715356982892036096
8643299388854108160
8571241794816180224
8499184200778252288
8427126606740324352
608621467415871488
8283011418664468480
8210953824626540544
8138896230588612608
8066838636550684672
7994781042512756736
7922723448474828800
7850665854436900864
7778608260398972928
7706550666361044992
7634493072323117056
7562435478285189120
7490377884247261184
7418320290209333248
7346262696171405312
7274205102133477376
7202147508095549440
7130089914057621504
7058032320019693568
12958044700014542848
12885987105976614912
13030102294052470784
12741871917900759040
6841859537905909760
6769801943867981824
6697744349830053888
6625686755792125952
6553629161754198016
16643469137854595072
16571411543816667136
16499353949778739200
16715526731892523008
6409513973678342144
6337456379640414208
6265398785602486272
6193341191564558336
6121283597526630400
6049226003488702464
5977168409450774528
5905110815412846592
5833053221374918656
5760995627336990720
5688938033299062784
5616880439261134848
5544822845223206912
7950602665308717056
7878545071270789120
7806487477232861184
7734429883194933248
12170467819573477376
12098410225535549440
12026352631497621504
11954295037459693568
10050231169221394432
9978173575183466496
9906115981145538560
9834058387107610624
9762000793069682688
9689943199031754752
10122288763259322368
4896304498881855488
4824246904843927552
4752189310805999616
13507493750158393344
13435436156120465408
13363378562082537472
824794249529655296
896851843567583232
968909437605511168
1040967031643439104
1113024625681367040
4175728558502576128
4103670964464648192
4031613370426720256
3959555776388792320
3887498182350864384
3815440588312936448
3743382994275008512
3671325400237080576
3599267806199152640
3527210212161224704
3455152618123296768
3383095024085368832
3311037430047440896
3238979836009512960
3166922241971585024
3094864647933657088
3022807053895729152
2950749459857801216
2878691865819873280
2806634271781945344
2734576677744017408
2662519083706089472
2590461489668161536
2518403895630233600
2446346301592305664
2374288707554377728
8382948229536284672
8310890635498356736
8238833041460428800
8166775447422500864
8094717853384572928
2086058331402665984
2014000737364738048
1941943143326810112
1869885549288882176
1797827955250954240
1725770361213026304
1653712767175098368
1581655173137170432
1509597579099242496
1437539985061314560
1365482391023386624
1293424796985458688
1221367202947530752
1149309608909602816
1077252014871674880
10470354562194604032
10398296968156676096
10326239374118748160
10254181780080820224
10182124186042892288
10110066592004964352
10542412156232531968
4382050815943114752
4309993221905186816
4237935627867258880
4165878033829330944
4093820439791403008
4021762845753475072
3949705251715547136
17944723557141446656
17872665963103518720
17800608369065590784
17728550775027662848
8449171814877233152
8377114220839305216
8305056626801377280
18154620326883885056
18082562732845957120
18010505138808029184
1185082219719294976
1257139813757222912
1329197407795150848
17722274762656317440
10105095699935789056
10033038105897861120
9960980511859933184
9888922917822005248
9816865323784077312
10177153293973716992
17361986792466677760
17289929198428749824
17217871604390821888
16712188614590595072
17011383320694489088
16939325726656561152
16867268132618633216
17083440914732417024
1401255001833078784
1473312595871006720
16785526040163254272
16713468446125326336
1545370189908934656
1617427783946862592
16497295664011542528
16425238069973614592
7110457034432053248
7038399440394125312
6966341846356197376
6894284252318269440
6822226658280341504
6750169064242413568
7686917786735476736
7614860192697548800
7542802598659620864
7470745004621692928
7398687410583764992
7326629816545837056
7254572222507909120
8263378539038900224
8191320945000972288
8119263350963044352
8047205756925116416
7975148162887188480
7903090568849260544
7831032974811332608
15128201377290911744
15056143783252983808
14984086189215055872
1562022293511602176
14912028595177127936
14839971001139200000
14767913407101272064
14695855813063344128
14623798219025416192
14551740624987488256
16485278001919950848
16413220407882022912
16341162813844094976
14335567842873704448
14263510248835776512
14191452654797848576
14119395060759920640
14047337466721992704
13975279872684064768
13903222278646136832
13831164684608208896
13759107090570280960
13687049496532353024
13614991902494425088
1689485377984790528
1761542972022718464
15444592445253222400
12943254069597700096
12871196475559772160
12799138881521844224
12727081287483916288
13015311663635628032
14932968794128121856
14860911200090193920
14788853606052265984
14716796012014338048
13182646338266857472
13110588744228929536
13038531150191001600
12966473556153073664
12894415962115145728
12822358368077217792
12750300774039289856
12678243180001361920
12606185585963433984
6516218278619119616
12462070397887578112
12390012803849650176
12317955209811722240
12245897615773794304
5506567537157996544
12101782427697938432
12029724833660010496
11957667239622082560
11885609645584154624
11813552051546226688
11741494457508298752
11669436863470370816
11597379269432442880
11525321675394514944
11453264081356587008
11381206487318659072
11309148893280731136
11237091299242803200
5578625131195924480
11092976111166947328
11020918517129019392
15615157485046857728
15543099891008929792
15471042296971001856
15398984702933073920
15326927108895145984
15254869514857218048
10588572952901451776
10516515358863523840
10444457764825595904
10372400170787667968
10300342576749740032
10228284982711812096
10156227388673884160
10084169794635956224
10012112200598028288
9940054606560100352
9867997012522172416
9795939418484244480
9723881824446316544
9651824230408388608
9579766636370460672
9507709042332532736
9435651448294604800
9363593854256676864
9291536260218748928
9219478666180820992
9147421072142893056
9075363478104965120
9003305884067037184
8931248290029109248
8859190695991181312
8787133101953253376
8715075507915325440
8643017913877397504
8570960319839469568
5397335454984962048
5325277860947034112
8498902725801541632
8426845131763613696
8354787537725685760
17247164793178030080
17175107199140102144
17103049605102174208
17030992011064246272
16958934417026318336
7922441973498118144
7850384379460190208
7778326785422262272
7706269191384334336
7634211597346406400
7562154003308478464
7490096409270550528
829008677598920704
756951083560992768
684893489523064832
7273923627156766720
7201866033118838784
7129808439080910848
7057750845042982912
2810921267618643968
2738863673580716032
2666806079542788096
2594748485504860160
2522690891466932224
2450633297429004288
2378575703391076352
2306518109353148416
6481290092739559424
6409232498701631488
6337174904663703552
6265117310625775616
6193059716587847680
9911969781051817984
9839912187013890048
9767854592975962112
9984027375089745920
12250184611610492928
12178127017572564992
12106069423534637056
5832771746398208000
5760714152360280064
5688656558322352128
5616598964284424192
5544541370246496256
5472483776208568320
5400426182170640384
5328368588132712448
5256310994094784512
5184253400056856576
5112195806018928640
1833600566060646400
4968080617943072768
4896023023905144832
1905658160098574336
4751907835829288960
4679850241791361024
4607792647753433088
4535735053715505152
4463677459677577216
4391619865639649280
4319562271601721344
4247504677563793408
4175447083525865472
4103389489487937536
1977715754136502272
3959274301412081664
433867288320409600
361809694282481664
289752100244553728
217694506206625792
748008755492290560
675951161454362624
603893567416434688
531835973378506752
459778379340578816
3526928737184514048
3454871143146586112
3382813549108658176
3310755955070730240
3238698361032802304
3166640766994874368
3094583172956946432
17721010324284375040
17648952730246447104
17576895136208519168
17504837542170591232
17793067918322302976
18297471076587798528
18225413482549870592
18153355888511942656
18081298294474014720
18009240700436086784
18369528670625726464
2121830942212358144
2590180014691450880
2518122420653522944
2446064826615595008
2374007232577667072
2301949638539739136
2229892044501811200
643642012272164864
571584418234236928
499526824196308992
427469230158381056
355411636120453120
715699606310092800
1941661668350099456
1869604074312171520
1797546480274243584
1725488886236315648
1653431292198387712
1581373698160459776
1509316104122531840
1437258510084603904
1365200916046675968
9490346654218321920
9562404248256249856
1221085727970820096
1149028133932892160
502568073358737408
430510479320809472
358452885282881536
286395291244953600
214337697207025664
574625667396665344
267171429944918016
195113835906990080
123056241869062144
13041729629516201984
12969672035478274048
12897614441440346112
428452193553612800
356394599515684864
284337005477756928
212279411439828992
140221817401901056
18442569228058886144
18370511634020958208
18298454039983030272
18226396445945102336
18154338851907174400
6556173431660871680
6772346213774655488
6123827867433304064
18082281257869246464
18010223663831318528
17938166069793390592
18089418187845140480
18017360593807212544
18161475781883068416
17721993287679606784
17649935693641678848
17577878099603750912
17505820505565822976
2193888536250286080
2265946130288214016
17289647723452039168
17217590129414111232
17145532535376183296
17073474941338255360
17001417347300327424
16929359753262399488
16857302159224471552
16785244565186543616
2864131033333235712
2792073439295307776
2720015845257379840
2647958251219451904
2936188627371163648
10901152014050263040
10829094420012335104
10757036825974407168
10684979231936479232
10612921637898551296
10540864043860623360
10468806449822695424
10396748855784767488
10324691261746839552
10252633667708911616
11477612766353686528
11405555172315758592
11333497578277830656
11261439984239902720
11189382390201974784
11117324796164046848
11045267202126118912
17704827712146767872
17632770118108839936
8125182022055362560
8053124428017434624
7981066833979506688
15560265466541768704
15488207872503840768
15416150278465912832
3120768042372431872
3048710448334503936
2976652854296576000
2904595260258648064
15127919902314201088
15055862308276273152
14983804714238345216
14911747120200417280
14839689526162489344
14767631932124561408
14277039739415560192
14204982145377632256
14132924551339704320
5702186048902135808
5630128454864207872
5558070860826279936
5486013266788352000
5413955672750424064
5341898078712496128
5269840484674568192
14191171179821137920
14119113585783209984
14047055991745282048
13974998397707354112
13902940803669426176
2012439430853296128
1940381836815368192
1868324242777440256
2084497024891224064
2372727401042935808
2300669807005007872
2444784995080863744
6075129397927477248
6003071803889549312
5931014209851621376
18242173338292060160
18170115744254132224
18098058150216204288
18026000556178276352
3523556535022125056
3451498940984197120
3379441346946269184
3307383752908341248
3235326158870413312
3163268564832485376
3595614129060052992
11922270661789089792
11850213067751161856
11778155473713233920
11706097879675305984
11634040285637378048
11561982691599450112
11489925097561522176
11417867503523594240
11345809909485666304
11994328255827017728
16696021395615776768
16623963801577848832
16551906207539920896
16479848613501992960
16407791019464065024
16335733425426137088
702431799497719808
630374205459791872
558316611421863936
486259017383936000
414201423346008064
342143829308080128
270086235270152192
774489393535647744
12730174213692850176
12658116619654922240
12586059025616994304
12514001431579066368
12441943837541138432
12369886243503210496
12297828649465282560
12225771055427354624
12153713461389426688
12081655867351498752
12009598273313570816
11937540679275642880
11865483085237714944
10804464260038524928
10732406666000596992
10660349071962669056
10588291477924741120
10516233883886813184
10444176289848885248
10372118695810957312
10300061101773029376
10228003507735101440
10155945913697173504
10083888319659245568
10011830725621317632
9939773131583389696
5588795613752852480
5516738019714924544
9745089204722860032
9673031610684932096
9600974016647004160
9528916422609076224
9456858828571148288
9384801234533220352
9312743640495292416
9240686046457364480
9168628452419436544
12716362148624728064
12644304554586800128
12572246960548872192
12500189366510944256
12428131772473016320
12788419742662656000
14276802244903960576
14204744650866032640
14132687056828104704
14060629462790176768
13988571868752248832
13916514274714320896
13844456680676392960
13772399086638465024
13700341492600537088
13628283898562609152
13556226304524681216
14997378185283239936
14925320591245312000
14853262997207384064
14781205403169456128
14709147809131528192
14637090215093600256
14565032621055672320
14492975027017744384
14420917432979816448
15645896531624591360
15573838937586663424
15501781343548735488
15429723749510807552
15357666155472879616
15285608561434951680
15213550967397023744
15141493373359095808
16438530066041798656
16366472472003870720
16294414877965942784
16222357283928014848
16150299689890086912
16078242095852158976
16006184501814231040
15934126907776303104
15862069313738375168
15790011719700447232
7201584558142128128
7129526964104200192
7057469370066272256
6985411776028344320
6913354181990416384
6841296587952488448
6769238993914560512
6697181399876632576
6625123805838704640
6553066211800776704
5121627416761991168
5049569822724063232
4977512228686135296
4905454634648207360
4833397040610279424
4761339446572351488
4689281852534423552
16993272165161762816
16921214571123834880
6048663053535281152
5976605459497353216
5904547865459425280
17077804818128437248
17005747224090509312
16933689630052581376
16861632036014653440
8113987894172975104
8041930300135047168
7969872706097119232
7897815112059191296
7825757518021263360
7753699923983335424
8186045488210903040
14572680823938482176
14500623229900554240
14428565635862626304
14356508041824698368
14284450447786770432
10327455433979068416
10255397839941140480
10183340245903212544
10111282651865284608
10039225057827356672
13222159487634243584
13150101893596315648
13078044299558387712
13005986705520459776
13294217081672171520
5871172189998284800
5799114595960356864
5727057001922428928
5654999407884500992
5582941813846573056
11593300081293393920
11521242487255465984
4967799142966362112
4895741548928434176
4823683954890506240
4751626360852578304
4679568766814650368
4607511172776722432
4535453578738794496
4463395984700866560
4391338390662938624
4319280796625010688
4247223202587082752
4175165608549154816
4103108014511226880
4031050420473298944
3958992826435371008
3886935232397443072
3814877638359515136
3742820044321587200
3670762450283659264
3598704856245731328
3526647262207803392
3454589668169875456
3382532074131947520
3310474480094019584
16681397890966355968
16609340296928428032
16537282702890500096
16465225108852572160
16393167514814644224
2950186509904379904
2878128915866451968
2806071321828524032
2734013727790596096
2661956133752668160
2589898539714740224
2517840945676812288
2445783351638884352
2373725757600956416
2301668163563028480
2229610569525100544
2157552975487172608
2085495381449244672
2013437787411316736
1941380193373388800
1869322599335460864
1797265005297532928
1725207411259604992
1653149817221677056
1581092223183749120
1509034629145821184
1436977035107893248
1364919441069965312
10930379232139804672
10858321638101876736
10786264044063948800
10714206450026020864
10642148855988092928
10570091261950164992
5520740242040029184
5448682648002101248
5376625053964173312
5304567459926245376
5592797836077957120
1148746658956181504
1076689064918253568
2842406882591637504
2914464476629565440
860516282804469760
16417987890300059648
16345930296262131712
16273872702224203776
16201815108186275840
16129757514148347904
16490045484337987584
428170718576902144
356113124538974208
284055530501046272
211997936463118336
139940342425190400
2986522070667493376
18370230159044247552
18298172565006319616
18226114970968391680
17329916237307707392
17257858643269779456
17546089019421491200
17474031425383563264
11143405211974893568
11215462806012821504
18154057376930463744
18081999782892535808
18009942188854607872
17937884594816679936
17865827000778752000
17793769406740824064
12261393033144041472
12189335439106113536
12117277845068185600
12045220251030257664
11973162656992329728
11901105062954401792
17433481436551184384
17361423842513256448
17289366248475328512
17217308654437400576
3058579664705421312
3130637258743349248
3202694852781277184
3274752446819205120
16857020684247760896
16784963090209832960
16712905496171905024
3346810040857133056
3418867634895060992
16496732714058121216
6659489041764843520
3490925228932988928
3562982822970916864
16208502337906409472
16136444743868481536
16064387149830553600
15992329555792625664
15920271961754697728
15848214367716769792
15776156773678841856
4534457421204029440
4462399827166101504
4390342233128173568
4318284639090245632
4246227045052317696
4174169451014389760
4606515015241957376
15343811209451274240
15271753615413346304
15199696021375418368
3635040417008844800
6947719417916555264
14983523239261634560
14911465645223706624
14839408051185778688
14767350457147850752
14695292863109922816
14623235269071994880
14551177675034066944
5900418099785498624
5972475693823426560
9298673190194642944
9370730784232570880
14335004892920283136
7019777011954483200
7091834605992411136
14118832110806499328
2542185232627400704
2470127638589472768
2398070044551544832
2326012450513616896
2253954856475688960
2181897262437761024
2109839668399833088
2037782074361905152
4251553079377264640
4179495485339336704
4107437891301408768
4035380297263480832
4323610673415192576
13614428952541003776
13542371358503075840
6845626464742670336
6773568870704742400
6701511276666814464
6629453682628886528
6917684058780598272
7350029623008165888
7277972028970237952
7205914434932310016
7133856840894382080
7422087217046093824
3747149921111769088
3675092327073841152
3603034733035913216
3530977138997985280
3819207515149697024
6341223306477174784
6269165712439246848
6197108118401318912
6413280900515102720
12677680230047940608
12605622636010012672
12533565041972084736
12461507447934156800
12389449853896228864
12317392259858300928
12245334665820372992
12173277071782445056
3707098011046772736
12029161883706589184
11957104289668661248
3779155605084700672
11812989101592805376
11740931507554877440
11668873913516949504
11596816319479021568
11524758725441093632
11452701131403165696
11380643537365237760
11308585943327309824
11236528349289381888
11164470755251453952
11092413161213526016
11020355567175598080
10948297973137670144
10876240379099742208
10804182785061814272
10732125191023886336
10660067596985958400
10588010002948030464
10515952408910102528
10443894814872174592
10371837220834246656
10299779626796318720
10227722032758390784
14647546570673750016
14575488976635822080
14503431382597894144
14431373788559966208
14359316194522038272
14287258600484110336
15800468075280596992
15728410481242669056
15656352887204741120
15584295293166813184
15512237699128885248
15440180105090957312
15368122511053029376
16304871233546092544
16232813639508164608
16160756045470236672
16088698451432308736
16016640857394380800
15944583263356452864
17457792738152939520
17385735144115011584
17313677550077083648
17241619956039155712
17169562362001227776
17097504767963299840
17025447173925371904
8714512557961904128
8642454963923976192
8570397369886048256
8498339775848120320
3851213199122628608
8354224587772264448
8282166993734336512
8210109399696408576
8138051805658480640
8065994211620552704
7993936617582624768
7921879023544696832
7849821429506768896
7777763835468840960
7705706241430913024
7633648647392985088
7561591053355057152
7489533459317129216
2352660214324396032
2280602620286468096
2208545026248540160
14029890416212443136
13957832822174515200
13885775228136587264
13813717634098659328
17017194239647285248
16945136645609357312
16873079051571429376
16801021457533501440
4881772253697540096
4809714659659612160
4737657065621684224
6768957518937849856
6696899924899921920
6624842330861993984
6552784736824066048
6480727142786138112
7620778863789867008
7548721269751939072
6336611954710282240
6264554360672354304
6192496766634426368
6120439172596498432
6048381578558570496
5976323984520642560
5904266390482714624
3923270793160556544
5760151202406858752
2771193713483841536
2699136119445913600
5616036014331002880
5543978420293074944
5471920826255147008
5399863232217219072
5327805638179291136
5255748044141363200
5183690450103435264
5111632856065507328
3995328387198484480
4067385981236412416
4139443575274340352
4211501169312268288
4283558763350196224
4679287291837939712
16237225979670429696
16165168385632501760
4607229697800011776
4535172103762083840
11654904618286055424
11726962212323983360
12466118799701049344
12394061205663121408
12322003611625193472
12249946017587265536
12538176393738977280
4174884133572444160
4102826539534516224
4030768945496588288
12898464363928616960
12826406769890689024
12754349175852761088
12970521957966544896
3814596163382804480
3742538569344876544
5048962892305530880
4976905298267602944
4904847704229675008
4832790110191747072
4760732516153819136
4688674922115891200
4355616357388124160
4427673951426052096
4499731545463980032
3166077817041453056
3094020223003525120
3021962628965597184
2949905034927669248
2877847440889741312
2805789846851813376
2733732252813885440
2661674658775957504
2589617064738029568
2517559470700101632
2445501876662173696
2373444282624245760
2301386688586317824
2229329094548389888
2157271500510461952
2256400170335862784
2184342576297934848
1922652211817480192
1850594617779552256
1994709805855408128
1941098718396678144
1869041124358750208
1796983530320822272
1724925936282894336
1652868342244966400
1580810748207038464
1508753154169110528
1436695560131182592
1364637966093254656
1292580372055326720
3547200433065820160
3475142839027892224
3403085244989964288
4283559862861824000
4211502268823896064
4139444674785968128
4571790239013535744
4499732644975607808
4427675050937679872
788177213789831168
716119619751903232
644062025713975296
572004431676047360
499946837638119424
4452492127888211968
4380434533850284032
4308376939812356096
4236319345774428160
283774055524335616
4571789139501907968
139658867448479744
18442006278105464832
18369948684067536896
18297891090029608960
18225833495991681024
2102767609609977856
2030710015572049920
1958652421534121984
15707219593640542208
15635161999602614272
15563104405564686336
15779277187678470144
3065960686262681600
2993903092224753664
2921845498186825728
2849787904148897792
2777730310110969856
2705672716073041920
2633615122035113984
17505257555612401664
17433199961574473728
9470579634174164992
17289084773498617856
17217027179460689920
17144969585422761984
9542637228212092928
17000854397346906112
12615588609404174336
12543531015366246400
12471473421328318464
12399415827290390528
12327358233252462592
12255300639214534656
12183243045176606720
12111185451138678784
12039127857100750848
12687646203442102272
3067079989099757568
2995022395061829632
2922964801023901696
2850907206985973760
2778849612948045824
2706792018910117888
3139137583137685504
16064105674853842944
15992048080815915008
15919990486777987072
15847932892740059136
5960092993871413248
5888035399833485312
6032150587909341184
15703817704664203264
15631760110626275328
15559702516588347392
15487644922550419456
15415587328512491520
15343529734474563584
15271472140436635648
15199414546398707712
15127356952360779776
15055299358322851840
14983241764284923904
14911184170246995968
14839126576209068032
14767068982171140096
14695011388133212160
14622953794095284224
14550896200057356288
14478838606019428352
14406781011981500416
14334723417943572480
14262665823905644544
14190608229867716608
14118550635829788672
14046493041791860736
13974435447753932800
13902377853716004864
13830320259678076928
13758262665640148992
17348612333026410496
17276554738988482560
17204497144950554624
17132439550912626688
17060381956874698752
16988324362836770816
16844209174760914944
16772151580722987008
16700093986685059072
16628036392647131136
16555978798609203200
13181801913336725504
13109744319298797568
13037686725260869632
12965629131222941696
12893571537185013760
18026951633736302592
17954894039698374656
12749456349109157888
12677398755071229952
4715904327577763840
4787961921615691776
4860019515653619712
4932077109691547648
12317110784881590272
12245053190843662336
5504391603646627840
5432334009608699904
5360276415570771968
6320380964061052928
6248323370023124992
6392438558098980864
6752726528288620544
6680668934250692608
6608611340212764672
6824784122326548480
17811041634901557248
17738984040863629312
17666926446825701376
17883099228939485184
11668592438540238848
5004134703729475584
5076192297767403520
11452419656426455040
11380362062388527104
11308304468350599168
11236246874312671232
5148249891805331456
5220307485843259392
11020074092198887424
17004897301602238464
16932839707564310528
16860782113526382592
16788724519488454656
17076954895640166400
10803901310085103616
10731843716047175680
10659786122009247744
10587728527971319808
10515670933933391872
10443613339895463936
10371555745857536000
10299498151819608064
10227440557781680128
10155382963743752192
8059306981900419072
7987249387862491136
8625655525763186688
8697713119801114624
9939210181629968384
9867152587592040448
9795094993554112512
9723037399516184576
9777457727532957696
9705400133495029760
9633342539457101824
9561284945419173888
9489227351381245952
9434807023364472832
9362749429326544896
9290691835288616960
9218634241250689024
9146576647212761088
9074519053174833152
9002461459136905216
8930403865098977280
5292365079881187328
8786288677023121408
8714231082985193472
8642173488947265536
3032210077336469504
2960152483298541568
2888094889260613632
2816037295222685696
3104267671374397440
8353943112795553792
8281885518757625856
8209827924719697920
8137770330681769984
8065712736643842048
5364422673919115264
7921597548567986176
7849539954530058240
7777482360492130304
7705424766454202368
7633367172416274432
7561309578378346496
7489251984340418560
7417194390302490624
7345136796264562688
7273079202226634752
7201021608188706816
5436480267957043200
5508537861994971136
5580595456032899072
5652653050070827008
6840733637999067136
16614768585834758144
16542710991796830208
16470653397758902272
16398595803720974336
16686826179872686080
6696618449923211264
6624560855885283328
6552503261847355392
6480445667809427456
6408388073771499520
6336330479733571584
6264272885695643648
6192215291657715712
6120157697619787776
6048100103581859840
5724710644108754944
5903984915506003968
5831927321468076032
5759869727430148096
5687812133392220160
5615754539354292224
5796768238146682880
8172698516561330176
5399581757240508416
5327524163202580480
5255466569164652544
5183408975126724608
5111351381088796672
5039293787050868736
4967236193012940800
4895178598975012864
5868825832184610816
5940883426222538752
4679005816861229056
4606948222823301120
4534890628785373184
4462833034747445248
1369824362441474048
1297766768403546112
1441881956479401984
4318717846671589376
4246660252633661440
4174602658595733504
18345535127884398592
18273477533846470656
18201419939808542720
3958429876481949696
3886372282444021760
3814314688406093824
6012941020260466688
6084998614298394624
3598141906292310016
3526084312254382080
3454026718216454144
3381969124178526208
3309911530140598272
3237853936102670336
3165796342064742400
3093738748026814464
3021681153988886528
2949623559950958592
2877565965913030656
2805508371875102720
2733450777837174784
6157056208336322560
2589335589761318912
3994270657012563968
3922213062974636032
3850155468936708096
3778097874898780160
4066328251050491904
4498673815278059520
4426616221240131584
4354558627202203648
4282501033164275712
4570731409315987456
5943468378059440128
5871410784021512192
5799353189983584256
5727295595945656320
5583180407869800448
5511122813831872512
5439065219793944576
5367007625756016640
14355839538755010560
13851436380489515008
1652586867268255744
1580529273230327808
1508471679192399872
1436414085154471936
1364356491116544000
1292298897078616064
1220241303040688128
11394498483386843136
11466556077424771072
2149689268325318656
11055846703008579584
11127904297046507520
6229113802374250496
1861458892173606912
1789401298135678976
1717343704097751040
715838144775192576
11272019485122363392
11344077079160291328
499665362661408768
6301171396412178432
6373228990450106368
6445286584488034304
6517344178525962240
6589401772563890176
6661459366601818112
6733516960639746048
18297609615052898304
18225552021014970368
15329531851941347328
15257474257903419392
15401589445979275264
18081436832939114496
18009379238901186560
17937321644863258624
6805574554677673984
6877632148715601920
6949689742753529856
17649091268711546880
6771578754658467840
6699521160620539904
17504976080635691008
17432918486597763072
17360860892559835136
17288803298521907200
17216745704483979264
17144688110446051328
17072630516408123392
7021747336791457792
16928515328332267520
11991793881524994048
11919736287487066112
16334962667775066112
16407020261812994048
16712342546218483712
16640284952180555776
16568227358142627840
16496169764104699904
16424112170066771968
16352054576028844032
16279996981990916096
2137970673396482048
2065913079358554112
2210028267434409984
10807923323619508224
10735865729581580288
16135881793915060224
16063824199877132288
15991766605839204352
15919709011801276416
874699982802780160
802642388764852224
730584794726924288
658527200688996352
586469606651068416
514412012613140480
442354418575212544
370296824537284608
946757576840708096
7257604675577315328
7185547081539387392
7113489487501459456
16745094798586675200
16817152392624603136
11129378742139355136
11057321148101427200
10985263554063499264
14982960289308213248
14910902695270285312
14838845101232357376
14766787507194429440
14694729913156501504
14622672319118573568
13093226356114718720
13021168762076790784
12949111168038862848
1370616010813472768
1298558416775544832
13733849109457010688
13661791515419082752
14262384348928933888
14190326754891005952
14118269160853078016
14046211566815150080
13974153972777222144
13902096378739294208
13830038784701366272
16740581303354654720
16668523709316726784
16596466115278798848
9115069042007212032
9043011447969284096
9187126636045139968
13469750814511726592
13397693220473798656
13325635626435870720
5816259280772268032
5744201686734340096
5672144092696412160
13109462844322086912
13037405250284158976
11961954235458781184
11889896641420853248
11817839047382925312
11745781453344997376
11673723859307069440
11529608671231213568
11457551077193285632
11385493483155357696
11313435889117429760
11241378295079501824
14434738294140960768
14362680700103032832
14290623106065104896
14218565512027176960
16423973631601672192
16351916037563744256
16279858443525816320
16496031225639600128
15045245423998468096
14973187829960540160
14901130235922612224
14829072641884684288
14757015047846756352
14684957453808828416
15117303018036396032
14540842265732972544
15765821364377747456
15693763770339819520
15621706176301891584
15549648582263963648
15477590988226035712
15405533394188107776
15837878958415675392
15261418206112251904
11524195775487672320
11452138181449744384
7165862524867313664
11308022993373888512
11235965399335960576
11163907805298032640
11091850211260104704
11019792617222176768
10947735023184248832
10875677429146320896
10803619835108392960
10731562241070465024
10659504647032537088
10587447052994609152
10515389458956681216
10443331864918753280
10371274270880825344
10299216676842897408
10227159082804969472
10155101488767041536
10083043894729113600
10010986300691185664
9938928706653257728
9866871112615329792
9794813518577401856
9722755924539473920
9650698330501545984
9578640736463618048
9506583142425690112
9434525548387762176
9362467954349834240
9290410360311906304
9218352766273978368
9146295172236050432
9074237578198122496
9002179984160194560
8930122390122266624
8858064796084338688
7237920118905241600
8713949608008482816
8641892013970554880
3262761173006680064
3190703578968752128
3118645984930824192
3046588390892896256
2974530796854968320
2902473202817040384
2830415608779112448
2758358014741184512
2686300420703256576
8209546449742987264
8137488855705059328
8065431261667131392
7993373667629203456
15811470888139751424
15739413294101823488
7921316073591275520
7849258479553347584
7777200885515419648
2380283244949012480
2308225650911084544
2236168056873156608
2164110462835228672
2092052868797300736
2452340838986940416
7488970509363707904
7416912915325779968
7344855321287852032
7272797727249924096
7200740133211996160
7128682539174068224
7056624945136140288
6984567351098212352
6912509757060284416
6840452163022356480
7309977712943169536
6696336974946500608
6624279380908572672
6552221786870644736
6480164192832716800
6408106598794788864
6336049004756860928
6263991410718932992
6191933816681005056
6119876222643077120
6047818628605149184
5975761034567221248
5903703440529293312
10283267161170378752
5831645846491365376
5759588252453437440
5687530658415509504
5615473064377581568
5543415470339653632
5471357876301725696
7382035306981097472
5327242688225869824
5255185094187941888
5183127500150013952
5111069906112086016
5039012312074158080
4966954718036230144
4894897123998302208
4822839529960374272
4750781935922446336
4678724341884518400
3116905458024054784
3044847863986126848
2972790269948198912
2900732675910270976
4390493965732806656
4318436371694878720
4246378777656950784
4174321183619022848
4102263589581094912
4030205995543166976
3958148401505239040
3886090807467311104
3814033213429383168
3741975619391455232
3669918025353527296
3597860431315599360
3525802837277671424
3453745243239743488
3381687649201815552
3309630055163887616
3237572461125959680
3165514867088031744
3093457273050103808
3021399679012175872
2949342084974247936
2877284490936320000
12313859528998256640
12241801934960328704
12169744340922400768
12385917123036184576
2661111708822536192
2589054114784608256
2516996520746680320
2444938926708752384
15229254192464920576
15301311786502848512
14652793440161497088
14724851034199425024
7971260289771372544
7899202695733444608
7827145101695516672
7755087507657588736
7683029913619660800
7610972319581732864
2084650956519112704
2012593362481184768
1940535768443256832
1868478174405328896
1796420580367400960
1724362986329473024
7454092901019025408
9541792803281960960
1508190204215689216
1436132610177761280
1364075016139833344
1292017422101905408
1219959828063977472
1147902234026049536
1230488751411560448
1302546345449488384
1518719127563272192
1590776721601200128
1075844639988121600
1003787045950193664
931729451912265728
859671857874337792
787614263836409856
715556669798481920
643499075760553984
571441481722626048
499383887684698112
427326293646770176
355268699608842240
283211105570914304
211153511532986368
139095917495058432
15051732542602346496
14979674948564418560
14907617354526490624
14835559760488562688
18225270546038259712
18153212952000331776
18081155357962403840
6865926747926298624
6793869153888370688
6721811559850442752
6649753965812514816
6577696371774586880
6505638777736658944
17864982575848620032
17792924981810692096
17305424615798996992
17233367021761069056
17161309427723141120
17576752199696908288
17504694605658980352
10478584406728507392
10406526812690579456
10334469218652651520
10262411624614723584
10910929970956075008
10838872376918147072
10766814782880219136
10694757188842291200
10622699594804363264
11343275535183642624
11271217941145714688
11199160347107786752
11127102753069858816
11055045159031930880
8593001129929867264
7893538011827142656
7821480417789214720
7749422823751286784
7677365229713358848
7605307635675430912
4795342943172952064
4723285349135024128
4651227755097096192
4579170161059168256
4507112567021240320
16495888289127989248
16423830695090061312
6470673208461754368
6398615614423826432
6326558020385898496
16207657912976277504
16135600318938349568
7598208089094881280
15991485130862493696
15919427536824565760
15847369942786637824
15775312348748709888
15703254754710781952
15631197160672854016
15559139566634926080
7670265683132809216
15415024378559070208
7742323277170737152
7814380871208665088
15198851596445286400
15126794002407358464
15054736408369430528
14982678814331502592
7886438465246593024
7958496059284520960
14766506032217718784
14694448438179790848
14622390844141862912
14550333250103934976
14478275656066007040
14406218062028079104
14334160467990151168
14262102873952223232
14190045279914295296
14117987685876367360
14045930091838439424
7766309123330670592
7694251529292742656
7622193935254814720
7550136341216886784
7838366717368598528
9024231789366870016
8952174195328942080
8880116601291014144
8808059007253086208
9096289383404797952
9528634947632365568
9456577353594437632
9384519759556509696
9312462165518581760
9600692541670293504
3548136117461057536
3476078523423129600
3404020929385201664
3331963335347273728
3259905741309345792
8174668841398304768
8246726435436232704
12820950993193664512
8656018539364220928
8583960945326292992
8728076133402148864
8439845757250437120
15453699700066091008
15525757294104018944
14032805221537677312
13960747627499749376
13888690033461821440
13816632439423893504
14104862815575605248
12951941310968758272
12879883716930830336
13023998905006686208
12519595746741190656
12591653340779118592
12159307776551550976
12087250182513623040
12231365370589478912
7836951645903650816
7764894051865722880
15214115016862072832
15142057422824144896
12028317458776457216
11956259864738529280
3603554802035851264
3531497207997923328
3459439613959995392
11740087082624745472
11668029488586817536
11595971894548889600
11523914300510961664
11451856706473033728
403475687417053184
331418093379125248
259360499341197312
187302905303269376
115245311265341440
3479219828143685632
3407162234105757696
3551277422181613568
11091568736283394048
11019511142245466112
10947453548207538176
5999213617587683328
5927156023549755392
6066193666928541696
5994136072890613760
5922078478852685824
10731280766093754368
17053348380991815680
16981290786953887744
16909233192915959808
16837175598878031872
16765118004840103936
16693060410802176000
16621002816764248064
16548945222726320128
16476887628688392192
16404830034650464256
16332772440612536320
9938647231676547072
9866589637638619136
9794532043600691200
9722474449562763264
9650416855524835328
9578359261486907392
8895244781777584128
8967302375815512064
9039359969853440000
9290128885335195648
16218468311300571136
16146410717262643200
16074353123224715264
16002295529186787328
15930237935148859392
16290525905338499072
12471502008630640640
12399444414592712704
12327386820554784768
12255329226516856832
12183271632478928896
12111214038441000960
12039156444403073024
8641610538993844224
8569552944955916288
8497495350917988352
8425437756880060416
8353380162842132480
8281322568804204544
8209264974766276608
8137207380728348672
8065149786690420736
7993092192652492800
7921034598614564864
7848977004576636928
7776919410538708992
7704861816500781056
7632804222462853120
7560746628424925184
7488689034386997248
7416631440349069312
7344573846311141376
16021053197556645888
15948995603518717952
15876938009480790016
15804880415442862080
15732822821404934144
8207300147487440896
8135242553449512960
8063184959411585024
7991127365373657088
7919069771335729152
7847012177297801216
7774954583259873280
7702896989221945344
8279357741525368832
6407825123818078208
6335767529780150272
6263709935742222336
6191652341704294400
6119594747666366464
6047537153628438528
5975479559590510592
5903421965552582656
5831364371514654720
5759306777476726784
5687249183438798848
5615191589400870912
5543133995362942976
5471076401325015040
17065169230502035456
16993111636464107520
17137226824539963392
16848996448388251648
3287817943492067328
3215760349454139392
3143702755416211456
5182846025173303296
5110788431135375360
5038730837097447424
4966673243059519488
4894615649021591552
4822558054983663616
4750500460945735680
4678442866907807744
4606385272869879808
4534327678831951872
4462270084794023936
4390212490756096000
4318154896718168064
4246097302680240128
4174039708642312192
4101982114604384256
4029924520566456320
3957866926528528384
13444701740607733760
13372644146569805824
13300586552531877888
13228528958493949952
13156471364456022016
3597578956338888704
3525521362300960768
3453463768263032832
3381406174225104896
3309348580187176960
3237290986149249024
3165233392111321088
3093175798073393152
3021118204035465216
2949060609997537280
2877003015959609344
2804945421921681408
2732887827883753472
2660830233845825536
2588772639807897600
2516715045769969664
2444657451732041728
2372599857694113792
2300542263656185856
2228484669618257920
2156427075580329984
2084369481542402048
2012311887504474112
1940254293466546176
1868196699428618240
1796139105390690304
1724081511352762368
1652023917314834432
1579966323276906496
16027621680020979712
15955564085983051776
15883506491945123840
15811448897907195904
16099679274058907648
16604082432324403200
16532024838286475264
16459967244248547328
16387909650210619392
16315852056172691456
16676140026362331136
17252600778665754624
17180543184627826688
17108485590589898752
17036427996551970816
16964370402514042880
16892312808476114944
17324658372703682560
15190474417353261056
15118416823315333120
4787963021127319552
4715905427089391616
6169258588381380608
6097200994343452672
6025143400305524736
5953085806267596800
5881028212229668864
5808970618191740928
6241316182419308544
138814442518347776
18441161853175332864
18369104259137404928
18297046665099476992
18224989071061549056
18152931477023621120
13579595324661432320
13507537730623504384
13435480136585576448
13363422542547648512
17864701100871909376
17792643506833981440
17720585912796053504
17648528318758125568
17576470724720197632
17504413130682269696
17432355536644341760
17360297942606413824
17288240348568485888
17216182754530557952
17144125160492630016
17072067566454702080
864277712083091456
792220118045163520
720162524007235584
648104929969307648
576047335931379712
936335306121019392
2143583680256278528
2071526086218350592
2215641274294206464
9111417563891367936
9183475157929295872
9931627949444825088
9859570355406897152
9787512761368969216
9715455167331041280
9643397573293113344
16279434032037494784
16207376437999566848
10663469485962297344
10591411891924369408
10519354297886441472
1938426905141182464
16063261249923710976
15991203655885783040
15919146061847855104
15847088467809927168
15775030873771999232
5818520976190603264
5746463382152675328
5674405788114747392
5602348194076819456
5530290600038891520
5458233006000963584
5386175411963035648
6467039322531954688
6394981728494026752
6322924134456098816
6250866540418170880
6178808946380242944
6106751352342315008
6034693758304387072
5127517500551987200
5055459906514059264
14982397339354791936
14910339745316864000
14838282151278936064
14766224557241008128
14694166963203080192
14622109369165152256
14550051775127224320
14477994181089296384
14405936587051368448
14333878993013440512
14261821398975512576
14189763804937584640
14117706210899656704
14045648616861728768
9255532751967223808
9327590346005151744
13829475834747944960
13757418240710017024
9399647940043079680
9471705534081007616
13541245458596233216
13469187864558305280
13397130270520377344
13325072676482449408
13253015082444521472
13180957488406593536
13108899894368665600
13036842300330737664
12964784706292809728
12892727112254881792
12820669518216953856
14622518387490684928
14550460793452756992
14478403199414829056
14406345605376901120
14262230417301045248
14190172823263117312
14118115229225189376
14046057635187261440
5838690417490526208
5766632823452598272
12532439142065242112
12460381548027314176
12388323953989386240
12316266359951458304
12244208765913530368
12172151171875602432
12100093577837674496
12028035983799746560
11955978389761818624
11883920795723890688
11811863201685962752
11739805607648034816
11667748013610106880
11595690419572178944
11523632825534251008
11451575231496323072
11379517637458395136
11307460043420467200
11235402449382539264
11163344855344611328
11091287261306683392
11019229667268755456
10947172073230827520
10875114479192899584
9543763128118935552
10982944684040519680
11055002278078447616
10586884103041187840
3536613235601965056
3464555641564037120
3392498047526109184
3320440453488181248
3608670829639892992
10691955633214717952
10619898039176790016
10547840445138862080
10475782851100934144
10764013227252645888
3807011732174405632
3734954138136477696
3662896544098549760
3590838950060621824
4959933236781252608
4887875642743324672
4815818048705396736
4743760454667468800
13811474630377996288
13739417036340068352
9578077786510196736
9506020192472268800
8626698962297946112
8554641368260018176
8482583774222090240
10530417583885123584
10458359989847195648
10386302395809267712
10314244801771339776
9145732222282629120
9073674628244701184
9001617034206773248
8929559440168845312
8857501846130917376
8785444252092989440
8713386658055061504
8641329064017133568
8569271469979205632
3898828649675096064
3970886243713024000
3994306940896280576
3922249346858352640
3850191752820424704
8281041093827493888
8208983499789565952
8136925905751638016
8064868311713710080
7992810717675782144
7920753123637854208
7848695529599926272
7776637935561998336
7704580341524070400
7632522747486142464
7560465153448214528
7488407559410286592
293740028918497280
365797622956425216
581970405070209024
654027999108136960
942258375259848704
1014315969297776640
9615820722156863488
7344292371334430720
9687878316194791424
7200177183258574848
5167146098640289792
5095088504602361856
5239203692678217728
5527434068829929472
5455376474792001536
5599491662867857408
5887722039019569152
5815664444981641216
5959779633057497088
6695774024993079296
6623716430955151360
14375836356729372672
14303778762691444736
14231721168653516800
2317738625514602496
2245681031476674560
2173623437438746624
14952297109032796160
14880239514994868224
14808181920956940288
6335486054803439616
6263428460765511680
6191370866727583744
6119313272689655808
6047255678651727872
5975198084613799936
5903140490575872000
8998613168439689216
8926555574401761280
8854497980363833344
8782440386325905408
8710382792287977472
8638325198250049536
8566267604212121600
9070670762477617152
5470794926348304384
5398737332310376448
5326679738272448512
5254622144234520576
5182564550196592640
5110506956158664704
5038449362120736768
4966391768082808832
4894334174044880896
4822276580006952960
4750218985969025024
4678161391931097088
4606103797893169152
4534046203855241216
4461988609817313280
4389931015779385344
4317873421741457408
4245815827703529472
4173758233665601536
4101700639627673600
1345849511397818368
7236862388719321088
7164804794681393152
7308919982757249024
4029643045589745664
3957585451551817728
3885527857513889792
9759935910232719360
3741412669438033920
3669355075400105984
3597297481362178048
3525239887324250112
9831993504270647296
3381124699248394240
3309067105210466304
3237009511172538368
3164951917134610432
9904051098308575232
3020836729058754560
2948779135020826624
2876721540982898688
2804663946944970752
2732606352907042816
2660548758869114880
2588491164831186944
2516433570793259008
2444375976755331072
2372318382717403136
2300260788679475200
2228203194641547264
2156145600603619328
2084088006565691392
2012030412527763456
1939972818489835520
1867915224451907584
1795857630413979648
1723800036376051712
1651742442338123776
9345112163305390080
9273054569267462144
9200996975229534208
9128939381191606272
9056881787153678336
8984824193115750400
8912766599077822464
7925267718381502464
1219396878110556160
1147339284072628224
1075281690034700288
11073112334099546112
11001054740061618176
10928997146023690240
10856939551985762304
10784881957947834368
859108907920916480
787051313882988544
1567380213673754624
1495322619635826688
1423265025597898752
1639437807711682560
1135034649446187008
1062977055408259072
1207092243484114944
8983954479418179584
8911896885380251648
426763343693348864
354705749655420928
709713865008480256
637656270970552320
565598676932624384
493541082894696448
421483488856768512
349425894818840576
277368300780912640
205310706742984704
133253112705056768
18435600523362041856
18363542929324113920
18152650002046910464
18080592408008982528
18008534813971054592
17936477219933126656
17864419625895198720
17792362031857270784
17720304437819342848
17648246843781414912
17576189249743486976
17504131655705559040
4684418712604770304
4756476306642698240
527017913425592320
454960319387664384
382902725349736448
17215901279553847296
17143843685515919360
2943499280184246272
2871441686146318336
2799384092108390400
16927670903402135552
16855613309364207616
1535494376468250624
1463436782430322688
1391379188392394752
17633423228015738880
17561365633977810944
17489308039939883008
17417250445901955072
17345192851864027136
17273135257826099200
17201077663788171264
16639440527250423808
16567382933212495872
4398423643592327168
4326366049554399232
4254308455516471296
4182250861478543360
4758711613781966848
4686654019744038912
4614596425706110976
4542538831668183040
16062979774947000320
15990922180909072384
15918864586871144448
15846806992833216512
15774749398795288576
15702691804757360640
15630634210719432704
15558576616681504768
15486519022643576832
15414461428605648896
10321549957026283520
10249492362988355584
10177434768950427648
10105377174912499712
10033319580874571776
9961261986836643840
10393607551064211456
14982115864378081280
14910058270340153344
14838000676302225408
10048166286384431104
14693885488226369536
14621827894188441600
18243124415850086400
18171066821812158464
181696495513239552
109638901475311616
14405655112074657792
14333597518036729856
5717492350272405504
5645434756234477568
5573377162196549632
5501319568158621696
14117424735922946048
14045367141885018112
15020488820187463680
14948431226149535744
14876373632111607808
14804316038073679872
14732258444035751936
14660200849997824000
15092546414225391616
14516085661921968128
13685079171695378432
13613021577657450496
13540963983619522560
13468906389581594624
13396848795543666688
13324791201505738752
13252733607467810816
13180676013429882880
13108618419391954944
13036560825354027008
12964503231316099072
7414241102070284288
7342183508032356352
7270125913994428416
7198068319956500480
7486298696108212224
8881231506081579008
8809173912043651072
8953289100119506944
17872308621824491520
17800251027786563584
17728193433748635648
12532157667088531456
12460100073050603520
12388042479012675584
12315984884974747648
12243927290936819712
13132901133691387904
13060843539653459968
13204958727729315840
9707035107285532672
9634977513247604736
9562919919209676800
9490862325171748864
9418804731133820928
11811581726709252096
11739524132671324160
11667466538633396224
11595408944595468288
11523351350557540352
11451293756519612416
11379236162481684480
11307178568443756544
11235120974405828608
15074727728785653760
15002670134747725824
14930612540709797888
15379302345284255744
14786497352633942016
14714439758596014080
14642382164558086144
10802775410178260992
10730717816140333056
10658660222102405120
10586602628064477184
10514545034026549248
10442487439988621312
15451359939322183680
10298372251912765440
10226314657874837504
10154257063836909568
10082199469798981632
17056962475712315392
16984904881674387456
16912847287636459520
11723012766557011968
11650955172519084032
11578897578481156096
8322716982566715392
8250659388528787456
8394774576604643328
9866026687685197824
9793969093647269888
7496372421641895936
7424314827603968000
7352257233566040064
7280199639528112128
7568430015679823872
6023686547398721536
6095744141436649472
6311916923550433280
6383974517588361216
9361623529419702272
9289565935381774336
9217508341343846400
9145450747305918464
9073393153267990528
9001335559230062592
8929277965192134656
8857220371154206720
8098464989012033536
8026407394974105600
7954349800936177664
12851353589213298688
12779295995175370752
719789789565419520
647732195527491584
575674601489563648
503617007451635712
8424874806926639104
8352817212888711168
8280759618850783232
8208702024812855296
359501819375779840
287444225337851904
215386631299923968
143329037261996032
7920471648661143552
7848414054623215616
7776356460585287680
7704298866547359744
7632241272509431808
7560183678471503872
7488126084433575936
7416068490395648000
7344010896357720064
7271953302319792128
7199895708281864192
7127838114243936256
7055780520206008320
6983722926168080384
6911665332130152448
10983575803714863104
10911518209676935168
10839460615639007232
10767403021601079296
10695345427563151360
10623287833525223424
6479319767902584832
6407262173864656896
8898428967451623424
8826371373413695488
8970486561489551360
8682256185337839616
14500608936249393152
14428551342211465216
14356493748173537280
14284436154135609344
14212378560097681408
14140320966059753472
14068263372021825536
13996205777983897600
13924148183945969664
13852090589908041728
13780032995870113792
14572666530287321088
5830801421561233408
5758743827523305472
5686686233485377536
624761198599995392
552703604562067456
696818792637923328
5542571045409521664
5470513451371593728
5398455857333665792
5326398263295737856
5254340669257809920
5182283075219881984
2580736309320482816
2508678715282554880
2436621121244626944
8573517783885676544
8501460189847748608
8429402595809820672
8357345001771892736
8285287407733964800
8645575377923604480
8141172219658108928
10192281474460286976
4749937510992314368
10264339068498214912
4605822322916458496
1081300416685146112
1009242822647218176
937185228609290240
865127634571362304
793070040533434368
1513645980912713728
1441588386874785792
1369530792836857856
1297473198798929920
1225415604761001984
17924733336236851200
17852675742198923264
17780618148160995328
17708560554123067392
17996790930274779136
18429136494502346752
18357078900464418816
18285021306426490880
18212963712388562944
126789083845361664
15499819814804783104
15427762220766855168
15355704626728927232
1056843979548524544
984786385510596608
912728791472668672
840671197434740736
768613603396812800
696556009358884864
624498415320956928
1128901573586452480
16063066636365594624
15991009042327666688
15918951448289738752
15846893854251810816
15774836260213882880
15702778666175954944
2268570664543715328
2196513070505787392
2124455476467859456
2052397882429931520
2340628258581643264
4227640900496392192
4155583306458464256
4083525712420536320
4299698494534320128
5092332028951527424
5020274434913599488
4948216840875671552
5164389622989455360
2516152095816548352
2444094501778620416
3346811140368760832
3274753546330832896
3202695952292904960
3130638358254977024
3058580764217049088
2986523170179121152
10499439943284162560
10408454256574070784
1939691343513124864
1867633749475196928
1795576155437268992
1723518561399341056
1651460967361413120
1579403373323485184
1507345779285557248
1435288185247629312
1363230591209701376
14378721475240656896
14306663881202728960
14234606287164801024
14162548693126873088
14090491099088945152
14018433505051017216
13946375911013089280
13874318316975161344
13802260722937233408
13730203128899305472
14450779069278584832
930885026982133760
858827432944205824
786769838906277888
3261010750495260672
3188953156457332736
3116895562419404800
426481868716638208
354424274678710272
282366680640782336
1940904104838561792
16893979668103823360
402918235021770752
330860640983842816
258803046945914880
186745452907986944
114687858870059008
18224426121108127744
18152368527070199808
18080310933032271872
18008253338994343936
17936195744956416000
17864138150918488064
17792080556880560128
17720022962842632192
17647965368804704256
17575907774766776320
17503850180728848384
17431792586690920448
1045462934689415168
973405340651487232
901347746613559296
829290152575631360
757232558537703424
17071504616501280768
16999447022463352832
16927389428425424896
16855331834387496960
15438462667928371200
15366405073890443264
15510520261966299136
14357598757359452160
14429656351397380096
18245620307245137920
18173562713207209984
18317677901283065856
14664066732881084416
14592009138843156480
14519951544805228544
15240527485184507904
15168469891146579968
15096412297108652032
2605969001666314240
2533911407628386304
2461853813590458368
11350342096415358976
16278871082084073472
16206813488046145536
10480511850611998720
16062698299970289664
6484770047041470464
6412712453003542528
6340654858965614592
6268597264927686656
6196539670889758720
6556827641079398400
15702410329780649984
15630352735742722048
15558295141704794112
15486237547666866176
15414179953628938240
15342122359591010304
15270064765553082368
15955763097587679232
15125949577477226496
15053891983439298560
14981834389401370624
16027820691625607168
14837719201325514752
12956149141968257024
12884091547930329088
12812033953892401152
12739976359854473216
12667918765816545280
13028206736006184960
15929956460172148736
16002014054210076672
2459594317195378688
2387536723157450752
2315479129119522816
2243421535081594880
13329960005667913728
13257902411629985792
13402017599705841664
3859413356842582016
3787355762804654080
3715298168766726144
3643240574728798208
3571182980690870272
3499125386652942336
7111326748129624064
7039269154091696128
6967211560053768192
6895153966015840256
6823096371977912320
6751038777939984384
13684797696718667776
13612740102680739840
13540682508642811904
3853278081959591936
3781220487921664000
3709162893883736064
3925335675997519872
13396567320566956032
13324509726529028096
13252452132491100160
2868966685472194560
2796909091434266624
2724851497396338688
13180394538453172224
13108336944415244288
13036279350377316352
12964221756339388416
12892164162301460480
12820106568263532544
12748048974225604608
12675991380187676672
12603933786149748736
12531876192111820800
10552569444649926656
10624627038687854592
10696684632725782528
10768742226763710464
10840799820801638400
10912857414839566336
10984915008877494272
14038910809606717440
13966853215568789504
13894795621530861568
13822738027492933632
13750680433455005696
336268039169245184
264210445131317248
192152851093389312
408325633207173120
11811300251732541440
11739242657694613504
11667185063656685568
11595127469618757632
11523069875580829696
11451012281542901760
4282537317047992320
4210479723010064384
4138422128972136448
11234839499429117952
11162781905391190016
11090724311353262080
14629218811350351872
14701276405388279808
8842871744411729920
8770814150373801984
10874551529239478272
10802493935201550336
10730436341163622400
10658378747125694464
16604281443929030656
16676339037966958592
16748396632004886528
10370148370973982720
10298090776936054784
10226033182898126848
10153975588860198912
10081917994822270976
10009860400784343040
9937802806746415104
9865745212708487168
3444254258868781056
3516311852906708992
6600147299702145024
6672204893740072960
6888377675853856768
6960435269891784704
7176608052005568512
7248665646043496448
7464838428157280256
7536896022195208192
13480308325161631744
13408250731123703808
13336193137085775872
13264135543047847936
13840596295351271424
13768538701313343488
13696481107275415552
13624423513237487616
12416197673265135616
12344140079227207680
9073111678291279872
9001054084253351936
8928996490215424000
8856938896177496064
8784881302139568128
8712823708101640192
8640766114063712256
8568708520025784320
8496650925987856384
8424593331949928448
8352535737912000512
8280478143874072576
13453769413002002432
13381711818964074496
13309654224926146560
13237596630888218624
11808859335918878720
11880916929956806656
10226723676200370176
10154666082162442240
10082608488124514304
10010550894086586368
9938493300048658432
9866435706010730496
9794378111972802560
10298781270238298112
15559267109983748096
15487209515945820160
15415151921907892224
15343094327869964288
15271036733832036352
15631324704021676032
10875242022541721600
10803184428503793664
10731126834465865728
10659069240427937792
10587011646390009856
10514954052352081920
10947299616579649536
11056972602915422208
11919693406533582848
6839326263115513856
6767268669077585920
6695211075039657984
6623153481001730048
6551095886963802112
6479038292925874176
6406980698887946240
6334923104850018304
6262865510812090368
6190807916774162432
6118750322736234496
6046692728698306560
13793857155566141440
13721799561528213504
13865914749604069376
5830519946584522752
5758462352546594816
5686404758508666880
5614347164470738944
5542289570432811008
11129030196953350144
11201087790991278080
11273145385029206016
11345202979067133952
5182001600243171328
5109944006205243392
5037886412167315456
4965828818129387520
4893771224091459584
4821713630053531648
10855425524474314752
10783367930436386816
10711310336398458880
10639252742360530944
10567195148322603008
10495137554284675072
9857098653267656704
9785041059229728768
9712983465191800832
9640925871153872896
9568868277115944960
9929156247305584640
9424753089040089088
11514423316139999232
11442365722102071296
11370308128064143360
11298250534026215424
11226192939988287488
11154135345950359552
11586480910177927168
11010020157874503680
2677559303262437376
8560061960584953856
8488004366547025920
8415946772509097984
8343889178471170048
8271831584433242112
8199773990395314176
8127716396357386240
7983601208281530368
7911543614243602432
7839486020205674496
7767428426167746560
7695370832129818624
7623313238091890688
7551255644053962752
3092331373143261184
3020273779105333248
2948216185067405312
3582160504782585856
3510102910744657920
3438045316706729984
3365987722668802048
3942448474972225536
3870390880934297600
3798333286896369664
3726275692858441728
4302736445161865216
4230678851123937280
4158621257086009344
4086563663048081408
2299697838726053888
2227640244688125952
2155582650650198016
2083525056612270080
2011467462574342144
1939409868536414208
1867352274498486272
1795294680460558336
13739816159060951040
13811873753098878976
10865617997263798272
10793560403225870336
10721502809187942400
2080214427101036544
2008156833063108608
1936099239025180672
2099914376935899136
2027856782897971200
1651179492384702464
1579121898346774528
1507064304308846592
6435417368117116928
6363359774079188992
6291302180041261056
6219244586003333120
13113766332833202176
13041708738795274240
12969651144757346304
13185823926871130112
13546111897060769792
13474054303022841856
13401996708984913920
13618169491098697728
6198978387680165888
6126920793642237952
6054863199604310016
5982805605566382080
18062698955778555904
17990641361740627968
17918583767702700032
17846526173664772096
17774468579626844160
17702410985588916224
17630353391550988288
17558295797513060352
17486238203475132416
14100104129250590720
14028046535212662784
14172161723288518656
327772112821420032
255714518783492096
183656924745564160
111599330707636224
18413946741364621312
18341889147326693376
18269831553288765440
11921663731370557440
11993721325408485376
12065778919446413312
12137836513484341248
12209894107522269184
12281951701560197120
17719741487865921536
17647683893827993600
17575626299790065664
17503568705752137728
12354009295598125056
17359453517676281856
17287395923638353920
17215338329600425984
17143280735562498048
5242060223887179776
5170002629849251840
5097945035811323904
5025887441773395968
17785905699578970112
17713848105541042176
17641790511503114240
17569732917465186304
17497675323427258368
17425617729389330432
7929578903474012160
7857521309436084224
8001636497511940096
18314311196678815744
18242253602640887808
18170196008602959872
18386368790716743680
16278589607107362816
16206532013069434880
15078174697738731520
15006117103700803584
15150232291776659456
10223873742061174784
10151816148023246848
10079758553985318912
17140008588958236672
17067950994920308736
5187079144940240896
5115021550902312960
5042963956864385024
4970906362826457088
4898848768788529152
4826791174750601216
4754733580712673280
12426066889636052992
15558013666728083456
12498124483673980928
12570182077711908864
15341840884614299648
15269783290576371712
15197725696538443776
372251756211470336
300194162173542400
228136568135614464
444309350249398272
800352106044194816
872409700082122752
5753794925686685696
5681737331648757760
5609679737610829824
5537622143572901888
5465564549534973952
14765380132310876160
8649575401225453568
8577517807187525632
8505460213149597696
8433402619111669760
8361345025073741824
8289287431035813888
8217229836997885952
8145172242959958016
8073114648922030080
8001057054884102144
7928999460846174208
3732484635020492800
3804542229058420736
7240544653160742912
7024371871046959104
10532961853791797248
10460904259753869312
10388846665715941376
10316789071678013440
10244731477640085504
10172673883602157568
10100616289564229632
14188919380007452672
14116861785969524736
14044804191931596800
13972746597893668864
4629000028029976576
4556942433992048640
4484884839954120704
4412827245916192768
11786594225456414720
11714536631418486784
11642479037380558848
10375598650112868352
10303541056074940416
10231483462037012480
10159425867999084544
10087368273961156608
10015310679923228672
9943253085885300736
1358232211349831680
1286174617311903744
1214117023273975808
1142059429236047872
1070001835198119936
997944241160192000
925886647122264064
853829053084336128
12642239671749836800
13144672505178357760
12891882687324749824
5968460277358788608
5896402683320860672
6040517871396716544
12675709905210966016
12603652311173038080
12531594717135110144
12714297265787764736
12786354859825692672
12858412453863620608
12930470047901548544
12171306746945470464
12099249152907542528
12027191558869614592
4038135673402687488
3966078079364759552
3894020485326831616
3821962891288903680
6030462837560705024
5958405243522777088
6102520431598632960
11594845994642046976
11522788400604119040
13002527641939476480
11378673212528263168
11306615618490335232
11234558024452407296
11162500430414479360
11090442836376551424
11018385242338623488
10946327648300695552
13065644007420329984
12993586413382402048
12921528819344474112
12849471225306546176
10658097272148983808
10586039678111055872
10513982084073127936
10441924490035200000
10369866895997272064
10297809301959344128
10225751707921416192
13074585235977404416
10081636519845560320
8371515507630669824
8299457913592741888
8227400319554813952
8155342725516886016
8083285131478958080
8011227537441030144
7939169943403102208
7867112349365174272
7795054755327246336
7722997161289318400
7650939567251390464
7578881973213462528
7506824379175534592
7434766785137606656
10533243328768507904
10461185734730579968
10389128140692652032
10317070546654724096
10245012952616796160
10172955358578868224
10100897764540940288
10028840170503012352
9956782576465084416
9884724982427156480
9812667388389228544
9740609794351300608
9668552200313372672
9596494606275444736
12694971149906345984
12622913555868418048
12550855961830490112
12478798367792562176
12406740773754634240
12334683179716706304
12262625585678778368
12190567991640850432
12118510397602922496
12046452803564994560
11974395209527066624
11902337615489138688
11830280021451210752
11758222427413282816
6899103411782811648
6971161005820739584
8064023886783578112
7991966292745650176
7919908698707722240
7847851104669794304
7775793510631866368
7703735916593938432
7631678322556010496
7559620728518082560
7487563134480154624
7415505540442226688
7343447946404298752
7271390352366370816
7199332758328442880
3372770609900552192
3300713015862624256
3228655421824696320
3156597827786768384
3084540233748840448
7055217570252587008
6983159976214659072
6911102382176731136
6839044788138803200
6766987194100875264
6694929600062947328
6622872006025019392
6550814411987091456
6478756817949163520
6406699223911235584
6334641629873307648
13146642830015332352
13218700424053260288
13577018069405925376
6046411253721595904
5974353659683667968
5902296065645740032
13290758018091188224
13362815612129116160
13793190851519709184
5614065689494028288
5542008095456100352
5469950501418172416
5397892907380244480
5325835313342316544
13597629514380214272
13525571920342286336
13453514326304358400
17901141115239661568
17829083521201733632
17757025927163805696
18189371491391373312
18117313897353445376
18045256303315517440
4821432155076820992
4749374561038893056
4677316967000965120
4605259372963037184
4533201778925109248
12617516053287665664
12545458459249737728
12689573647325593600
178787187746144256
106729593708216320
18409077004365201408
18337019410327273472
18264961816289345536
18192904222251417600
18120846628213489664
18048789034175561728
17976731440137633792
13434873206167044096
15934364402287902720
15862306808249974784
13506930800204972032
1512423323982626816
1440365729944698880
3524395462394118144
3452337868356190208
3380280274318262272
3308222680280334336
3236165086242406400
3164107492204478464
3092049898166550528
9068394773408120832
8996337179370192896
8924279585332264960
8780164397256409088
8708106803218481152
8636049209180553216
13578988394242899968
2659704333938982912
16689385842942148608
2587646739901054976
2515589145863127040
2443531551825199104
2371473957787271168
2299416363749343232
2227358769711415296
2155301175673487360
2083243581635559424
13892323919391621120
13820266325353693184
13748208731315765248
13676151137277837312
13604093543239909376
13964381513429549056
13459978355164053504
1722955611445919744
1650898017407991808
1578840423370063872
1506782829332135936
1434725235294208000
13651045988280827904
1290610047218352128
1668752986731446272
1596695392693518336
1524637798655590400
9953584097139884032
9881526503101956096
9809468909064028160
9737411315026100224
10025641691177811968
9593296126950244352
13723103582318755840
13795161176356683776
13867218770394611712
13939276364432539648
570034106839072768
497976512801144832
425918918763216896
353861324725288960
281803730687361024
209746136649433088
137688542611505152
18440035953268490240
18367978359230562304
6821714285861797888
6749656691823869952
6677599097785942016
18223863171154706432
18151805577116778496
18079747983078850560
18007690389040922624
17935632795002994688
17863575200965066752
17791517606927138816
17719460012889210880
15347605624078729216
15275548030040801280
15203490436002873344
17647402418851282944
17575344824813355008
17503287230775427072
17431229636737499136
8433982061739507712
8361924467701579776
8289866873663651840
8506039655777435648
14339047797175615488
14266990203137687552
14411105391213543424
Code Name AbbreviationPhone Fax Post Site Type
1 3M Pharmaceuticals (NZ) Ltd 3M 0 9 444 5289 0 9 444 5770 C P O Box 2201Shortland Street Auckland 1015 3M Building 250 Archers RoadGlenfieldAuckland Manufacturer
2 Abbott Laboratories (NZ) Ltd Abbott 0 4 567 0039 0 4 567 0032 P O Box 35-128NaenaeLOWER HUTT 227 Cambridge TerraceNaenaeLOWER HUTT Manufacturer
3 Alcon Laboratories Ltd Alcon 0 9 579 7923 0 9 579 3698 P O Box 14-562PanmureAUCKLAND 67 Leonard RoadMt WellingtonAUCKLAND Manufacturer
4 New Zealand Distributors Ltd NZ Distributors 0 9 815 1031 P O Box 41-014St LukesAUCKLAND 2-6 Argyle Street MorningsideAUCKLAND Importer
5 Allergan New Zealand Ltd Allergan 0 9 573 0609 0 9 573 0622 PO Box 1873Mt WellingtonAUCKLAND 10 8D Sylvia Park RoadMt WellingtonAUCKLAND 10 Manufacturer
6 New Zealand Medical and Scientific Ltd NZ Medical0 9 634 1036 0 9 634 5146 P O Box 24-138Royal OakAUCKLAND 90 Mays RoadTakapunaAUCKLAND Importer
7 Ansell International Ansell 0 9 267 9897 0 9 267 6343 P O Box 97-041South Auckland Mail CentreAUCKLAND 67 Dalgety DriveManakau CityAUCKLAND Manufacturer
8 Novo-Nordisk Pharmaceuticals Ltd Novo-Nordisk 0 9 579 0653 0 9 579 0654 P O Box 51-268PakurangaAUCKLAND 642 Great South RoadEllerslieAUCKLAND Manufacturer
9 Pacific Pharmaceuticals Ltd Pacific 0 9 573 2792 0 9 579 7072 P O Box 11-183EllerslieAUCKLAND 76 Leonard RoadMt Wellington AUCKLAND Importer
10 Apotex (NZ) Inc Apotex 0 9 444 2073 0 9 444 2951 Private Bag 102-995North Shore Mail CentreAUCKLAND 32 Hillside RoadGlenfieldAUCKLAND Manufacturer
11 Astra Pharmaceuticals (NZ) Ltd Astra 0 9 623 6300 0 9 623 6301 PO Box 1301AUCKLAND 303 Manukau RoadEpsomAUCKLAND Manufacturer
12 Baxter Healthcare Ltd Baxter 0 9 527 1489 0 9 527 3614 Private Box 14-062PanmureAUCKLAND 18 Allright PlaceMt Wellington AUCKLAND Manufacturer
13 Bayer Diagnostics Bayer 0 9 634 6000 0 9 634 6005 P O Box 59-174Mangere BridgeAUCKLAND 51-53 Hastie AvenueMangere BridgeAUCKLAND Manufacturer
14 Pfizer Laboratories Ltd Pfizer 0061 2 858 9444 0061 2 858 1347 P O Box 57West RydeNSW 2114AUSTRALIA 38-42 Wharf RoadWest RydeNSW 2114AUSTRALIA Manufacturer
15 Bayer New Zealand Ltd (Pharmaceutical Division) Bayer 09 443 309309 443 5491C P O Box 2825AUCKLAND 10 3 Argus PlaceGlenfieldAUCKLAND Manufacturer
16 Pharmaceutical Sales and Marketing Ltd PSM 0 9 444 6898 0 9 444 1986 P O Box 40-079GlenfieldAUCKLAND 10 31-39 Hillside RoadGlenfieldAUCKLAND Manufacturer
17 Boehringer Ingelheim (NZ) Ltd Boehringer Ingelheim 0 9 262 1356 0 9 262 1462 P O Box 76-216Manakau CityAUCKLAND 47 Druces RoadWiriAUCKLAND Manufacturer
19 Pharmaco (NZ) Ltd Pharmaco 0 9 377 3336 0 9 307 1307 P O Box 4079ParnellAUCKLAND 49 George Street ParnellAUCKLAND Importer
20 Boehringer Mannheim (NZ) Ltd Boehringer Mannheim 0 9 276 4157 0 9 276 8917 P O Box 62-089Sylvia ParkAUCKLAND 15 Rakino WayMt WellingtonAUCKLAND Manufacturer
21 Procter & Gamble New Zealand (Pharmacia & Upjohn) Procter & Gamble 09 270 032809 276 5209PO Box 11-282EllerslleAUCKLAND 3 Fisher Crescent Mt WellingtonAUCKLAND Manufacturer
22 Bristol-Myers Squibb BMS 0 9 571 5250 0 9 571 5251 P O Box 62 663Central AucklandAUCKLAND Stanaway Business ParkTower 2 Level 1646 Great South RoadEllerslieAUCKLAND Manufacturer
23 Reckitt & Colman Pharmaceuticals Reckitt & Colman 0 9 828 4129 0 9 828 4648 Private Bag 19-990AvondaleAUCKLAND 550 Rosebank RoadAvondaleAUCKLAND Manufacturer
24 REM Systems Limited REM 0 9 570 2033 0 9 570 5389 P O Box 90-147Auckland Mail CentreAUCKLAND 69 Elizabeth Knox PlaceGlen InnesAUCKLAND 6 Importer
25 Ciba VisionCiba Vision0 9 358 4312 0 9 358 4311 P O Box 8061Symonds Street AUCKLAND 47-53 Patiki RoadAvondaleAUCKLAND 7 Manufacturer
26 Resorba Pharmaceuticals Ltd Resorba 0 3 366 3245 P O Box 2781CHRISTCHURCH 171A Wordsworth Street SydenhamCHRISTCHURCH Importer
27 Ciba-Geigy New Zealand Ltd Ciba-Geigy0 9 828 3149 0 9 828 3877 Private Bag 19-999AvondaleAUCKLAND 47-53 Patiki RoadAvondale AUCKLAND Manufacturer
28 Rhone-Poulenc Rorer New Zealand Ltd RPR 09-480-3770 09-480-3799 PO Box 34010BirkenheadAUCKLAND Highpont Shopping CentreLevel Two35 Mokoia RoadBirkenhead AUCKLAND Manufacturer
29 CSL Pharmaceuticals NZ Ltd CSL 0 9 579 8105 0 9 579 8106 P O Box 62-590Central ParkAUCKLAND Level 1, Building 5666 Great South RoadEllerslieAUCKLAND Manufacturer
30 Roche Products (New Zealand) Ltd Roche 0 9 633 0700 0 9 633 0749 P O Box 12-492PenroseAUCKLAND 8 Henderson PlaceTe PapapaAUCKLAND Manufacturer
31 Cyanamid (NZ) Ltd / Lederle Cyanamid 09 276 939309 276 9292Private Bag 92-903OnehungaAUCKLAND 4 Fisher Crescent Mt WellingtonAUCKLAND Importer
33 Russells Pharmaceuticals Ltd Russells 0 9 623 6116 09 623 6155P O Box 9591Newmarket AUCKLAND 110 Mt Eden RoadMt EdenAUCKLAND Importer
34 Salmond Smith Biolab Salmond Smith Biolab 0 9 579 9119 0 9 579 1878 PO Box 1332EllerslieAUCKLAND 4 Sultan Street EllerslieAUCKLAND Manufacturer
35 Douglas Pharmaceuticals Ltd Douglas 09 837 544709 837 5446O Box 45-027LincolnAUCKLAND r Te Pai Place & Central Park DriveHendersonAUCKLAND Manufacturer
36 Sandoz Pharma Ltd Sandoz 0 9 356 1700 0 9 356 1717 O Box 8961Symonds Street AUCKLAND 1 New North RoadEden TerraceAUCKLAND Manufacturer
37 Duncan Flockhart Duncan Flockhart 06 350 179406 356 9064Private BagPALMERSTON NORTH Importer
38 Schering (NZ) Ltd Schering 0 9 415 6342 0 9 415 6497 O Box 65-051AlbanyAUCKLAND 1310 William Pickering DriveNorth HarbourAUCKLAND Manufacturer
39 Ebos Group Ltd Ebos 03 366 219903 379 3248PO Box 411CHRISTCHURCH 4 Cashel Street CHRISTCHURCH Importer
40 Schering-Plough Pty Ltd Schering-Plough 0061 2 852 7444 0061 2 852 7500 PO Box 231Baulkham HillsNSW 2153AUSTRALIA Gibbon RoadBaulkham HillsNSW 2153AUSTRALIA Manufacturer
42 Schwarzkopf NZ Ltd Schwarzkopf 0800 731 137 0 9 309 7512 PO Box 6519Wellesley Street AUCKLAND 1 Khyber Pass RoadNewmarket AUCKLAND Importer
43 EFAMOL (NZ) Ltd Efamol 0 9 415 8477 0 9 415 8478 PO Box 33-118TakapunaNorth Shore CityAUCKLAND atrice Tinsely Crescent North Harbour Industrial EstateAlbanyAUCKLAND Importer
44 Self Care (NZ) Ltd Self Care 0 9 579 5188 0 9 579 7921 PO Box 14-460PenroseAUCKLAND Bassant AvenuePenroseAUCKLAND Importer
45 Eli Lilly & Company (NZ) Limited Eli Lilly 0 9 262 1370 0 9 262 1408 PO Box 97-046South Auckland Mail CentreAUCKLAND Gladding PlaceManukau CitySOUTH AUCKLAND Importer
46 Servier Laboratories (NZ) Servier 0 9 358 1870 0 9 358 1849 PO Box 6675Wellesley Street AUCKLAND 3 Wellesley Street AUCKLAND Manufacturer
47 SmithKline Beecham (NZ) Ltd SKB 0 9 573 1740 0 9 573 1745 O Box 62-043Sylvia ParkAUCKLAND 6a Pacific RosePacific Business CentreMt WellingtonAUCKLAND Manufacturer
48 Faulding Pharmaceuticals Faulding 0 9 570 3206 0 9 570 3208 Private Bag 14-062PanmureAUCKLAND 18 Allright PlaceMt WellingtonAUCKLAND Importer
49 Stafford-Miller (NZ) Ltd Stafford-Miller 0 9 415 8365 0 9 415 9628 P O Box 100-490North Shore Mailing CentreAUCKLAND 2 Rothwell RoadNorth Harbour Industrial EstateAlbanyAUCKLAND Manufacturer
50 Sterling Winthorp (Parmaceuticals) NZ Ltd Sterling Winthorp 0 9 302 0608 0 9 302 0613 Private Bag 93-224ParnellAUCKLAND 60 Stanley Street ParnellAUCKLAND Manufacturer
51 Fisons (NZ) Ltd Fisons 0 9 444 3540 0 9 444 0767 P O Box 31-123MilfordAUCKLAND 235 Archers RoadGlenfieldAUCKLAND Manufacturer
52 Syntex Laboratories (NZ) Ltd Syntex 0 9 622 4000 0 9 622 4049 P O Box 12-492PenroseAUCKLAND 8 Henderson PlaceTe PapapaAUCKLAND Manufacturer
53 The Boots Company (NZ) Ltd Boots 0 4 384 3859 0 4 385 2706 O Box 27-341WELLINGTON 1 d Floor, Sieman House263 Wakefield Street WELLINGTON Manufacturer
54 Upjohn New Zealand Upjohn 0 9 270 0328 0 9 276 5209 P O Box 11-282EllerslieAUCKLAND 3 Fisher Crescent Mt WellingtonAUCKLAND Manufacturer
55 G D Searle (NZ) Ltd Searle 09 376 103209 378 1435P O Box 3872AUCKLAND 316 Richmond RoadGrey LynnAUCKLAND Importer
57 W M Bamford & Co Ltd Bamford 0 4 566 1212 0 4 569 6489 Private Bag 31-346LOWER HUTT 419 Cuba Street AUCKLAND Importer
58 Warner-Lambert (Parke Davis) (NZ) Ltd Warner-Lambert 0 9 270 4170 0 9 276 1172 P O Box 22-071OtahuhuAUCKLAND 731-737 Great South RoadOtahuhuAUCKLAND Manufacturer
59 Healtheries of NZ Ltd Healtheries0 9 573 3730 0 9 573 3731 PO Box 22-045OtahuhuAUCKLAND 505 Mt Wellington HighwayMt WellingtonAUCKLAND Manufacturer
60 Watson Victor Ltd Watson Victor 0 4 385 7699 0 4 384 4651 P O Box 1180WELLINGTON 4 Adelaide RoadAUCKLAND Importer
63 Horley's Health NZ Ltd Horley's 09 570 9389 P O Box 11-131EllerslieAUCKLAND 103-105 Morrin RoadPanmureAUCKLAND Importer
64 Wyeth (NZ) Ltd Wyeth 0800 734 076 0 9 525 6080 P O Box 12-736PenroseAUCKLAND 477 Great South RoadPenroseAUCKLAND Manufacturer
65 ICI New Zealand Limited ICI 0 9 573 2800 0 9 573 2809 P O Box 900Mt WellingtonAUCKLAND Pacific Business Centre8 Pacific RiseMt WellingtonAUCKLAND Manufacturer
66 Zuellig Pharma New Zealand Zuellig 0 9 361 0444 0 9 361 0431 P O Box 413AUCKLAND 316 Richmond RoadGrey LynnAUCKLAND Wholesaler
67 J & W Medical Limited J & W Medical 09 410 5746 PO Box 101-103North Shore Mail CentreAUCKLAND 10 26 Seine RoadMilfordAUCKLAND 9 Importer
68 Jackson Allison Jackson Allison 0 9 303 2859 0 9 309 2132 P O Box 4261AUCKLAND 53 Fort Street AUCKLAND Manufacturer
69 Janssen-Cilag Pty Ltd Janssen-Cilag 0 9 524 5012 0 9 523 1646 P O Box 9222Newmarket AUCKLAND 3 Melrose Street Newmarket AUCKLAND 1 Manufacturer
71 Medica Medica 09 625 5261 09 625 4396P O Box 24-421Royal OakAUCKLAND Importer
72 Merck Sharp & Dohme (NZ) Ltd MSD 0 9 262 3004 0 9 262 2993 P O Box 23-244PapatoetoeAUCKLAND Cnr Wiri Station Rd and Plunkett AveManukau CityAUCKLAND Manufacturer
73 New Zealand Bakels Ltd NZ Bakels 0 9 579 6079 0 9 525 0978 P O Box 12-844PapatoetoeAUCKLAND 6 421-429 Church Street PenroseAUCKLAND Manufacturer
74 New Zealand Diagnostics Ltd NZ Diagnostics 0800 503 060 04 293 1029Private Bag WAIKANAE WAIKANAEManufacturer
75 Edinburgh Pharmaceutical Industries Edinburgh 0 9 367 2933 0 9 367 2910 Division of Allen & Hanburys (NZ) LtdPrivate Bag 106-600DowntownAUCKLAND AUCKLANDManufacturer
76 Allen & Hanbury's Allen & Hanbury's 0 9 367 2934 0 9 367 2910 Private Bag 106-600DowntownAUCKLAND Level 8Quay TowerCnr Customs & Albert StsAUCKLAND Manufacturer
78 Origen Pharmaceuticals Ltd Origen 0 6 356 4373 0 6 356 6726 P O Box 2075PALMERSTON NORTH PALMERSTON NORTH Manufacturer
81 L J Eccles Ltd L J Eccles 0 9 625 4456 0 9 625 9102 Private Bag Mt RoskillAUCKLAND AUCKLANDManufacturer
83 Allied Pharmaceuticals Allied 0 6 350 1749 0 6 356 9064 Private Bag 11-018PALMERSTON NORTH PALMERSTON NORTH Manufacturer
85 Serono Serono 0 9 836 5594 0 9 579 7921 P O Box 45-027AUCKLAND AUCKLANDManufacturer
86 OHL CORPORATION CHL 0 9 828 5145 0 9 528 5938 P O Box 19-129AUCKLAND AUCKLANDManufacturer
87 Smith & Nephew (NZ) Limited Smith & Nephew 0 9 828 4059 0 9 828 0162 P O Box 442AUCKLAND 621 Rosebank RoadAvondaleAUCKLAND Manufacturer
88 Hirst Lens Hirst Lens 0 9 849 5527 0 9 846 2755 Private Bag 9St LukesAUCKLAND AUCKLANDManufacturer
89 Ajax Chemicals Ajax 0 9 573 1479 0 9 5731489PO Box 14-147AUCKLAND 6 AUCKLANDManufacturer
90 Unknown Unknown 00 000 000000 000 0000Unknown Unknown Manufacturer
91 Alpha Pharmaceuticals Ltd Alpha 0 6 355 1066 0 6 356 6293 P O Box 705PALMERSTON NORTH 1st FloorWestpac Building18 Rangitikei Street PALMERSTON NORTH Importer
92 The Asthma and Respiratory Foundation of NZ Asthma Foundation 0 4 499 4592 0 4 499 4594 P O Box 1459WELLINGTON 7th FloorRossmore House123 Molesworth Street WELLINGTON Importer
93 MediSense Australia Pty Ltd MediSense0061 3 836 6111 0061 3 836 6900 P O Box 105BalwynVIC 3103AUSTRALIA 1A Weston Street BalwynVIC 3103AUSTRALIA Manufacturer
94 Scotia Pharmaceuticals (NZ) Ltd Scotia 0 9 415 7310 0 9 415 8478 P O Box 33-118TakapunaAUCKLAND Beatrice Tinsely Crescent North Harbour Industrial EstateAlbanyAUCKLAND Manufacturer
95 Athene International Ltd Athene 0 9 575 6698 0 9 575 8400 PO Box 55-044Mission BayAUCKLAND Mission BayAUCKLAND Importer
96 Medisafe Ltd Medisafe 0 9 302 2637 0 9 358 3607 P O Box 90-346AUCKLAND AUCKLANDImporter
97 Medic Corporation Ltd Medic 04 04 Private BagLOWER HUTT Private BagLOWER HUTT Importer
98 Mondos NZ Ltd Mondos 0 4 232 7847 0 4 232 7847 P O Box 56-059TawaWELLINGTON TawaWELLINGTON Importer
99 Colgate Colgate 0 4 568 6018 0 4 568 8835 P O Box 38-077Wellington Mail Centre Nevis Street Petone Manufacturer
101 Pharmacy Wholesalers Ltd PWL xx xxx xxxxxx xxx xxxxPWL Ltd PWL Ltd Wholesaler
102 Biomed Laboratories Ltd Biomed 0 9 815 2602 0 9 815 2621 P O Box 44-069Pt ChevalierAUCKLAND 52 Carrington RoadPt ChevalierAUCKLAND Manufacturer
103 Intermed Scientific Ltd Intermed 0 9 443 1284 0 9 443 8419 PO Box 101-253AUCKLAND 3A Marken PlaceGlenfieldAUCKLAND Importer
104 Glaxo Wellcome Ltd GlaxoWellcome 0 9 367 2900 0 9 358 1096 Private Bag 106-600DowntownAUCKLAND Level 8Quay TowerCnr Customs & Albert StsAUCKLAND Manufacturer
105 Hoechst Marion Roussel New Zealand Limited HMR 0 9 526 4102 0 9 526 4109 PO Box 112 042PenroseAUCKLAND 101 Station RoadPenroseAUCKLAND Manufacturer
106 Pharmacia & Upjohn New Zealand Pharmacia and Upjohn 0 9 270 0328 0 9 276 5209 PO Box 11-282EllerslieAUCKLAND Fisher Crescent Mt WellingtonAUCKLAND Manufacturer
107 Knoll Australia Pty Limited (Pharmaco) Knoll 0 9 486 4220 0 9 486 4221 O Box 331-486TakapunaAUCKLAND vel 1Soverign Assurance House33-45 Hurstmere RoadTakapunaAUCKLAND Importer
108 Artex Ltd Artex (06) 858-8011 (06) 858-8012 PO Box 249WAIPUKURAU 15 Ruataniwha St WAIPUKURAU Importer
110 Nutralife Nutrallife 999-9999 999-9999 unknown unknown Manufacturer
111 New Zealand Bakels Ltd. NZ Bakels 09-579-6079 09-525-0978 1-2429 Church Street PenroseAUCKLAND 1-2429 Church Street PenroseAUCKLAND Manufacturer
112 Pharmabrokers Sales Ltd Pharmabrokers 09 524 8814 PO Box 9726Newmarket AUCKLAND 1031 Importer
113 Lincoln Pharmaceuticals, A Division of Douglas Lincoln 09 837 544709 837 5446PO Box 45 027AUCKLAND Central Park DriveLincolnAUCKLAND * Importer
114 Medra Services Medra 06 323 857306 323 8573PO Box 115FEILDING Makino RoadFEILDING Importer
115 Health Support Services Ltd HSSL 09 849 220509 815 2634PO Box 44 027Point ChevalierAUCKLAND 2 56 Carrington RoadPoint ChevalierAUCKLAND 2 Importer
116 Novartis New Zealand Limited Novartis 09 828 314909 828 387743-45 Patiki RoadAvondaleAUCKLAND 7 Manufacturer
Trial Version
Not all rows exported
ParentCodeCode Memoranda
1908063938 1138 <Request To="HealthPAC" For="Subsidy" Form="SA1138"> <Title> <range>Raloxifene</range> </Title> <Case When="Initial application"> <math> <apply> <or/> <ci type="logical" class="indication">History of one significant osteoporotic fracture demonstrated radiologically and documented bone mineral density (BMD) &#8805;2.5 standard deviations below the mean normal value in young adults (i.e. T-Score &#8804; -2.5) (see Notes)</ci> <ci type="logical" class="indication">History of one significant osteoporotic fracture demonstrated radiologically, and either the patient is elderly, or densitometry scanning cannot be performed because of major logistical, technical or pathophysiological reasons. It is unlikely that this provision would apply to many patients under 75 years of age</ci> <ci type="logical" class="indication">History of two significant osteoporotic fractures demonstrated radiologically</ci> <ci type="logical" class="indication">Documente
2207023934 1125 <Request To="HealthPAC" For="Subsidy" Form="SA1125"> <Title> <range>Lacosamide</range> </Title> <Case When="Initial application"> <math> <apply> <and/> <ci type="logical" class="Indication">Patient has partial-onset epilepsy</ci> <ci type="logical" class="Trial">Seizures are not adequately controlled by, or patient has experienced unacceptable side effects from, optimal treatment with all of the following: sodium valproate, topiramate, levetiracetam and any two of carbamazepine, lamotrigine and phenytoin sodium (see Note)</ci> </apply> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="month">15</Term> <Note> <Para>"Optimal treatment" is defined as treatment which is indicated and clinically appropriate for the patient, given in adequate doses for the patient's age, weight and other features affecting the pharmacokinetics of the drug with good evidence of compliance. Women of childbearing age are not re
420202 1376 <Request To="HealthPAC" For="Subsidy" Form="SA1376"> <Title> <range>Carbohydrate and Fat<instance>Duocal Super Soluble Powder</instance></range> </Title> <Case When="Initial application" Category="Cystic fibrosis"> <math> <apply> <and/> <ci type="logical" class="Indication">Infant or child aged four years or under</ci> <ci type="logical" class="Indication">cystic fibrosis</ci> </apply> </math> <Applicant>dietitian</Applicant> <Applicant>relevant specialist</Applicant> <Applicant>vocationally registered general practitioner</Applicant> <Term Measure="year">3</Term> </Case> <Case When="Initial application" Category="Indications other than cystic fibrosis"> <math> <apply> <and/> <ci type="logical" class="Indication">infant or child aged four years or under</ci> <apply> <or/> <ci type="logical" class="Indication">cancer in children</ci> <ci type="logica
310309198707 895 <Request To="HealthPAC" For="Subsidy" Form="SA0895"> <Title> <range>Pilocarpine &#8211; Eye drops 2% single dose</range> </Title> <Case When="Initial application"> <math> <apply> <or/> <ci type="logical" class="Indication">Patient has to use an unpreserved solution due to an allergy to the preservative</ci> <ci type="logical" class="Indication">Patient wears soft contact lenses</ci> </apply> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="year">2</Term> <Note> <Para>Minims for a general practice are considered to be &#8220;tools of trade&#8221; and are not approved as special authority items.</Para> </Note> </Case> <Case When="Renewal" Form="SA0121 SA0895"> <math> <ci type="logical" class="Indication">The treatment remains appropriate and the patient is benefiting from treatment</ci> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="year">2<
2207021004 1072 <Request To="HealthPAC" For="Subsidy" Form="SA1072"> <Title> <range>Vigabatrin</range> </Title> <Case When="Initial application"> <math> <apply> <and/> <apply> <or/> <ci type="logical" class="Indication">Patient has infantile spasms</ci> <apply> <and/> <ci type="logical" class="Indication">Patient has epilepsy</ci> <apply> <or/> <ci type="logical" class="Indication">Seizures are not adequately controlled with optimal treatment with other antiepilepsy agents</ci> <ci type="logical" class="Indication">Seizures are controlled adequately but the patient has experienced unacceptable side effects from optimal treatment with other antiepilepsy agents</ci> </apply> </apply> </apply> <apply> <or/> <ci type="logical" class="Indication">Patient is, or will be, receiving regular automated visual fiel
2234013793 1408 <Request To="HealthPAC" For="Subsidy" Form="SA1408"> <Title> <range>Naltrexone</range> </Title> <Case When="Initial application"> <math> <apply> <and/> <ci type="logical" class="Indication">Patient is currently enrolled in a recognised comprehensive treatment programme for alcohol dependence</ci> <ci type="logical" class="Therapy">Applicant works in or with a community Alcohol and Drug Service contracted to one of the District Health Boards or accredited against the New Zealand Alcohol and Other Drug Sector Standard or the National Mental Health Sector Standard</ci> </apply> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="month">6</Term> </Case> <Case When="Renewal" Form="SA0714 SA0909 SA1397 SA1408"> <math> <apply> <and/> <ci type="logical" class="Indication">Compliance with the medication (prescriber determined)</ci> <apply> <or/> <ci type="log
0407043893 1174 <Request To="HealthPAC" For="Subsidy" Form="SA1174"> <Title> <range>Enoxaparin sodium</range> </Title> <Case When="Initial application" Category="Pregnancy or Malignancy"> <math> <apply> <or/> <ci type="logical" class="Indication">Low molecular weight heparin treatment is required during a patients pregnancy</ci> <ci type="logical" class="Treatment">For the treatment of venous thromboembolism where the patient has a malignancy</ci> </apply> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="year">1</Term> </Case> <Case When="Initial application" Category="Venous thromboembolism other than in pregnancy or malignancy"> <math> <apply> <or/> <ci type="logical" class="Indication">For the short-term treatment of venous thromboembolism prior to establishing a therapeutic INR with oral anti-coagulant treatment</ci> <ci type="logical" class="Treatment">For the prophylaxis and tre
2231013887 1416 <Request To="HealthPAC" For="Subsidy" Form="SA1416"> <Title> <range>Atomoxetine</range> </Title> <Case When="Initial application"> <math> <apply> <and/> <ci type="logical" class="Indication">Patient has ADHD (Attention Deficit and Hyperactivity Disorder) diagnosed according to DSM-IV or ICD 10 criteria</ci> <ci type="logical" class="Indication">Once-daily dosing</ci> <apply> <or/> <ci type="logical" class="Indication">Treatment with a subsidised formulation of a stimulant has resulted in the development or worsening of serious adverse reactions or where the combination of subsidised stimulant treatment with another agent would pose an unacceptable medical risk</ci> <ci type="logical" class="Indication">Treatment with a subsidised formulation of a stimulant has resulted in worsening of co-morbid substance abuse or there is a significant risk of diversion with subsidised stimulant therapy</ci> <ci type="log
0740013975 1263 <Request To="HealthPAC" For="Subsidy" Form="SA1263"> <Title> <range>Nicorandil</range> </Title> <Case When="Initial application"> <math> <apply> <and/> <ci type="logical" class="Indication">Patient has refractory angina</ci> <ci type="logical" class="Trial">Patient is on the maximal tolerated dose of a beta-blocker, a calcium channel blocker and a long acting nitrate</ci> </apply> </math> <Applicant>cardiologist</Applicant> <Applicant>general physician</Applicant> <Term Measure="year">2</Term> </Case> <Case When="Renewal" Form="SA1263"> <math> <ci type="logical" class="Indication">The treatment remains appropriate and the patient is benefiting from treatment</ci> </math> <Applicant>cardiologist</Applicant> <Applicant Referring="cardiologist">any relevant practitioner</Applicant> <Term Measure="year">2</Term> </Case></Request>
2222011011 927 <Request To="HealthPAC" For="Subsidy" Form="SA0927"> <Title> <range>Risperidone orally disintegrating tablets</range> </Title> <Case When="Initial application" Category="Acute situations"> <math> <apply> <and/> <ci type="logical" class="Use">For a non-adherent patient on oral therapy with standard risperidone tablets or risperidone oral liquid</ci> <ci type="logical" class="Therapy">The patient is under direct supervision for administration of medicine</ci> </apply> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="week">6</Term> </Case> <Case When="Initial application" Category="Chronic situations"> <math> <apply> <and/> <ci type="logical" class="Indication">The patient is unable to take standard risperidone tablets or oral liquid, or once stabilized refuses to take risperidone tablets or oral liquid</ci> <ci type="logical" class="Therapy">The patient is under direct
420632 1195 <Request To="HealthPAC" For="Subsidy" Form="SA1195"> <Title> <range>High Calorie Products<instance>Two Cal HN</instance><instance>Nutrison Concentrated</instance></range> </Title> <Case When="Initial application" Category="Cystic fibrosis"> <math> <apply> <and/> <ci type="logical" class="Indication">Cystic fibrosis</ci> <ci type="logical" class="Trial">other lower calorie products have been tried</ci> <ci type="logical" class="Indication">patient has substantially increased metabolic requirements</ci> </apply> </math> <Applicant>dietitian</Applicant> <Applicant>relevant specialist</Applicant> <Applicant>vocationally registered general practitioner</Applicant> <Term Measure="year">3</Term> </Case> <Case When="Initial application" Category="Indications other than cystic fibrosis"> <math> <apply> <and/> <apply> <or/> <ci type="logical" class="Indication">any cond
1414012062 1199 <Request To="HealthPAC" For="Subsidy" Form="SA1199"> <Title> <range>Propylthiouracil</range> </Title> <Case When="Initial application"> <math> <apply> <and/> <ci type="logical" class="Indication">The patient has hyperthyroidism</ci> <ci type="logical" class="Indication">The patient is intolerant of carbimazole or carbimazole is contraindicated</ci> </apply> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="year">2</Term> </Case> <Case When="Renewal" Form="SA1199"> <math> <ci type="logical" class="Indication">the treatment remains appropriate and the patient is benefitting from the treatment</ci> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="year">2</Term> </Case></Request>
0115123968 1237 <Request To="PHARMAC" For="Subsidy" Form="SA1237"> <Title> <range>Insulin Pumps</range> </Title> <Case When="Initial application"> <math/> <Applicant>medical practitioner</Applicant> <Term Measure="year">1</Term> </Case> <Note> <Para>Application details may be obtained from PHARMAC's website <a href="http://www.pharmac.govt.nz/">http://www.pharmac.govt.nz</a> or:</Para> <Table> <TR> <TD> <Para>The IPP Co-ordinator</Para> </TD> <TD> <Para>Phone: (04) 460 4990</Para> </TD> </TR> <TR> <TD> <Para>PHARMAC</Para> </TD> <TD> <Para>Facsimile: (04) 974 7806</Para> </TD> </TR> <TR> <TD> <Para>PO Box 10 254</Para> </TD> <TD> <Para>Email: <a href="mailto:ipp@pharmac.govt.nz">ipp@pharmac.govt.nz</a></Para> </TD> </TR> <TR> <TD> <Para>Welli
1619053855 829 <Request To="HealthPAC" For="Subsidy" Form="SA0829"> <Title> <range>Adefovir dipivoxil</range> </Title> <Case When="Initial application"> <math> <apply> <and/> <ci type="logical" class="Trial">Patient has confirmed Hepatitis B infection (HBsAg+)</ci> <mi class="heading">Documented resistance to lamivudine, defined as:</mi> <ci type="logical" class="Trial">Patient has raised serum ALT (&gt; 1 &#215; ULN)</ci> <ci type="logical" class="Trial">Patient has HBV DNA greater than 100,000 copies per mL, or viral load &#8805; 10 fold over nadir</ci> <ci type="logical" class="Trial">Detection of M204I or M204V mutation</ci> <apply> <or/> <apply> <and/> <ci type="logical" class="Trial">Patient is cirrhotic</ci> <ci type="logical" class="Trial">adefovir dipivoxil to be used in combination with lamivudine</ci> </apply> <apply> <and/>
1319043902 998 <Request To="HealthPAC" For="Subsidy" Form="SA0998"> <Title> <range>Solifenacin succinate</range> </Title> <Case When="Initial application"> <math> <ci type="logical" class="Indication">The patient has overactive bladder and a documented intolerance of, or is non-responsive to oxybutynin</ci> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="patient's lifetime"/> </Case></Request>
1603103999 1332 <Request To="HealthPAC" For="Subsidy" Form="SA1332"> <Title> <range>Tetracycline</range> </Title> <Case When="Initial application"> <math> <apply> <and/> <ci type="logical" class="Indication">For the eradication of helicobacter pylori following unsuccessful treatment with appropriate first-line therapy</ci> <ci type="logical" class="Indication">For use only in combination with bismuth as part of a quadruple therapy regimen</ci> </apply> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="month">3</Term> </Case></Request>
420608 1379 <Request To="HealthPAC" For="Subsidy" Form="SA1379"> <Title> <range>Paediatric Products<instance>Nutrini</instance><instance>Pediasure</instance><instance>Fortini</instance></range> </Title> <Case When="Initial application"> <math> <apply> <and/> <ci type="logical" class="Indication">Child is aged one to ten years</ci> <apply> <or/> <ci type="logical" class="Indication">the child is being fed via a tube or a tube is to be inserted for the purposes of feeding</ci> <ci type="logical" class="Indication">any condition causing malabsorption</ci> <ci type="logical" class="Indication">faltering growth in an infant/child</ci> <ci type="logical" class="Indication">increased nutritional requirements</ci> <ci type="logical" class="Indication">the child is being transitioned from TPN or tube feeding to oral feeding</ci> </apply> </apply> </math> <Applicant>dietitian</Applicant>
0407014008 1382 <Request To="HealthPAC" For="Subsidy" Form="SA1382"> <Title> <range>Ticagrelor</range> </Title> <Case When="Initial application" Category="acute coronary syndrome"> <math> <apply> <and/> <ci type="logical" class="Indication">Patient has recently been diagnosed with an ST-elevation or a non-ST-elevation acute coronary syndrome</ci> <ci type="logical" class="Indication">Fibrinolytic therapy has not been given in the last 24 hours and is not planned</ci> </apply> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="month">12</Term> </Case> <Case When="Renewal" Category="subsequent acute coronary syndrome" Form="SA1382"> <math> <apply> <and/> <ci type="logical" class="Indication">Patient has recently been diagnosed with an ST-elevation or a non-ST-elevation acute coronary syndrome</ci> <ci type="logical" class="Indication">Fibrinolytic therapy has not been given in the last 24
0122011126 1383 <Request To="HealthPAC" For="Subsidy" Form="SA1383"> <Title> <range>Ursodeoxycholic Acid</range> </Title> <Case When="Initial application" Category="Alagille syndrome or progressive familial intrahepatic cholestasis"> <math> <apply> <or/> <ci type="logical" class="Indication">Patient has been diagnosed with Alagille syndrome</ci> <ci type="logical" class="Indication">Patient has progressive familial intrahepatic cholestasis</ci> </apply> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="patient's lifetime"/> </Case> <Case When="Initial application" Category="Chronic severe drug induced cholestatic liver injury"> <math> <apply> <and/> <ci type="logical" class="Indication">Patient has chronic severe drug induced cholestatic liver injury</ci> <ci type="logical" class="Indication">Cholestatic liver injury not due to Total Parenteral Nutrition (TPN) use in adults</ci>
2507043818 1192 <Request To="HealthPAC" For="Subsidy" Form="SA1192"> <Title> <range>Trastuzumab</range> </Title> <Case When="Initial application" Category="metastatic breast cancer"> <math> <apply> <or/> <apply> <and/> <ci type="logical" class="Indication">The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology)</ci> <ci type="logical" class="Treatment">The patient has not previously received lapatinib treatment for HER 2 positive metastatic breast cancer</ci> <ci type="logical" class="Indication">Trastuzumab not to be given in combination with lapatinib</ci> <ci type="logical" class="Treatment">Trastuzumab to be discontinued at disease progression</ci> </apply> <apply> <and/> <ci type="logical" class="Indication">The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology
2207021062 1071 <Request To="HealthPAC" For="Subsidy" Form="SA1071"> <Title> <range>Gabapentin</range> </Title> <Case When="Initial application" Category="Epilepsy"> <math> <apply> <or/> <ci type="logical" class="Indication">Seizures are not adequately controlled with optimal treatment with other antiepilepsy agents</ci> <ci type="logical" class="Indication">Seizures are controlled adequately but the patient has experienced unacceptable side effects from optimal treatment with other antiepilepsy agents</ci> </apply> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="month">15</Term> <Note> <Para>"Optimal treatment with other antiepilepsy agents" is defined as treatment with other antiepilepsy agents which are indicated and clinically appropriate for the patient, given in adequate doses for the patient's age, weight, and other features affecting the pharmacokinetics of the drug with good evidence of compliance.</Para>
0407073924 1066 <Request To="HealthPAC" For="Subsidy" Form="SA1066"> <Title> <range>Rivaroxaban</range> </Title> <Case When="Initial application"> <math> <apply> <or/> <ci type="logical" class="Indication">For the prophylaxis of venous thromboembolism following a total hip replacement</ci> <ci type="logical" class="Use">For the prophylaxis of venous thromboembolism following a total knee replacement</ci> </apply> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="week">5</Term> <Note> <Para>Rivaroxaban is only currently indicated and subsidised for up to 5 weeks therapy for prophylaxis of venous thromboembolism following a total hip replacement and up to 2 weeks therapy for prophylaxis of venous thromboembolism following a total knee replacement.</Para> </Note> </Case> <Case When="Renewal" Form="SA1066"> <math> <ci type="logical" class="Indication">Prophylaxis for venous thromboembolism is requir
011515 1240 <Request To="PHARMAC" For="Subsidy" Form="SA1240"> <Title> <range>Insulin pump consumables</range> </Title> <Case When="Initial application"> <math/> <Applicant>medical practitioner</Applicant> <Term Measure="year">1</Term> </Case> <Note> <Para>Application details may be obtained from PHARMAC's website <a href="http://www.pharmac.govt.nz/">http://www.pharmac.govt.nz</a> or:</Para> <Table> <TR> <TD> <Para>The IPP Co-ordinator</Para> </TD> <TD> <Para>Phone: (04) 460 4990</Para> </TD> </TR> <TR> <TD> <Para>PHARMAC</Para> </TD> <TD> <Para>Facsimile: (04) 974 7806</Para> </TD> </TR> <TR> <TD> <Para>PO Box 10 254</Para> </TD> <TD> <Para>Email: <a href="mailto:ipp@pharmac.govt.nz">ipp@pharmac.govt.nz</a></Para> </TD> </TR> <TR> <TD>
190501385426 1289 <Request To="HealthPAC" For="Subsidy" Form="SA1289"> <Title> <range>Capsaicin</range> </Title> <Case When="Initial application"> <math> <ci type="logical" class="Indication">The patient has osteoarthritis that is not responsive to paracetamol and oral non-steroidal anti-inflammatories are contraindicated</ci> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="patient's lifetime"/> </Case></Request>
190802 1039 <Request To="HealthPAC" For="Subsidy" Form="SA1039"> <Title> <range>Alendronate Tab 70 mg - with or without Cholecalciferol</range> </Title> <Case When="Initial application" Category="Underlying cause -- Osteoporosis"> <math> <apply> <or/> <ci type="logical" class="Indication">History of one significant osteoporotic fracture demonstrated radiologically and documented bone mineral density (BMD) &#8805; 2.5 standard deviations below the mean normal value in young adults (i.e. T-Score &#8804; -2.5) (see Note)</ci> <ci type="logical" class="Indication">History of one significant osteoporotic fracture demonstrated radiologically, and either the patient is elderly, or densitometry scanning cannot be performed because of major logistical, technical or pathophysiological reasons. It is unlikely that this provision would apply to many patients under 75 years of age</ci> <ci type="logical" class="Indication">History of two significant osteoporotic fractures
160310182801 1355 <Request To="HealthPAC" For="Manufacturers Price" Form="SA1355"> <Title> <range>Minocycline hydrochloride Tab 50 mg</range> </Title> <Case When="Initial application"> <math> <ci type="logical" class="Indication">The patient has rosacea</ci> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="patient's lifetime"/> </Case></Request>
1603133998 1324 <Request To="HealthPAC" For="Subsidy" Form="SA1324"> <Title> <range>Paromomycin</range> </Title> <Case When="Initial application"> <math> <ci type="logical" class="Indication">the patient has confirmed cryptosporidium infection</ci> </math> <Applicant>infectious disease specialist</Applicant> <Applicant>clinical microbiologist</Applicant> <Term Measure="month">1</Term> </Case> <Case When="Renewal" Form="SA1324"> <math> <ci type="logical" class="Indication">the patient has confirmed cryptosporidium infection</ci> </math> <Applicant>infectious disease specialist</Applicant> <Applicant>clinical microbiologist</Applicant> <Term Measure="month">1</Term> </Case></Request>
2231013935 1126 <Request To="HealthPAC" For="Subsidy" Form="SA1126"> <Title> <range>Modavigil</range> </Title> <Case When="Initial application"> <math> <apply> <and/> <ci type="logical" class="Indication">The patient has a diagnosis of narcolepsy and has excessive daytime sleepiness associated with narcolepsy occurring almost daily for three months or more</ci> <apply> <or/> <ci type="logical" class="Indication">The patient has a multiple sleep latency test with a mean sleep latency of less than or equal to 10 minutes and 2 or more sleep onset rapid eye movement periods</ci> <ci type="logical" class="Indication">The patient has at least one of: cataplexy, sleep paralysis or hypnagogic hallucinations</ci> </apply> <apply> <or/> <ci type="logical" class="Indication">An effective dose of a subsidised formulation of methylphenidate or dexamphetamine has been trialled and discontinued because of intolerabl
1319013881 928 <Request To="HealthPAC" For="Subsidy" Form="SA0928"> <Title> <range>Finasteride</range> </Title> <Case When="Initial application"> <math> <apply> <and/> <ci type="logical" class="Indication">Patient has symptomatic benign prostatic hyperplasia</ci> <apply> <or/> <ci type="logical" class="Indication">The patient is intolerant of non-selective alpha blockers or these are contraindicated</ci> <ci type="logical" class="Indication">Symptoms are not adequately controlled with non-selective alpha blockers</ci> </apply> </apply> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="patient's lifetime"/> </Case> <Note> <Para>Patients with enlarged prostates are the appropriate candidates for therapy with finasteride.</Para> </Note></Request>
420607 1099 <Request To="HealthPAC" For="Subsidy" Form="SA1099"> <Title> <range>Paediatric Product For Children With Chronic Renal Failure<instance>Kindergen</instance></range> </Title> <Case When="Initial application"> <math> <ci type="logical" class="Indication">The patient is a child (up to 18 years) with acute or chronic kidney disease</ci> </math> <Applicant>dietitian</Applicant> <Applicant>relevant specialist</Applicant> <Applicant>vocationally registered general practitioner</Applicant> <Term Measure="year">3</Term> </Case> <Case When="Renewal" Form="SA0606 SA1099"> <math> <apply> <and/> <ci type="logical" class="Indication">The treatment remains appropriate and the patient is benefiting from treatment</ci> <ci type="text" class="Endorsement">General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted</ci> </apply> </mat
1319043977 1272 <Request To="HealthPAC" For="Subsidy" Form="SA1272"> <Title> <range>Tolterodine</range> </Title> <Case When="Initial application"> <math> <ci type="logical" class="Indication">Patient has overactive bladder and a documented intolerance of, or is non-responsive to oxybutynin</ci> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="patient's lifetime"/> </Case></Request>
420604 1381 <Request To="HealthPAC" For="Subsidy" Form="SA1381"> <Title> <range>Fat Modified Products<instance>Monogen</instance></range> </Title> <Case When="Initial application"> <math> <apply> <or/> <ci type="logical" class="Indication">Patient has metabolic disorders of fat metabolism</ci> <ci type="logical" class="Indication">Patient has a chyle leak</ci> <ci type="logical" class="Indication">Modified as a modular feed for adults</ci> </apply> </math> <Applicant>dietitian</Applicant> <Applicant>relevant specialist</Applicant> <Applicant>vocationally registered general practitioner</Applicant> <Term Measure="year">1</Term> </Case> <Case When="Renewal" Form="SA0593 SA0615 SA1096 SA1381"> <math> <apply> <and/> <ci type="logical" class="Indication">The treatment remains appropriate and the patient is benefiting from treatment</ci> <ci type="text" class="Endorsement">General Practitio
141301172426 782 <Request To="HealthPAC" For="Subsidy" Form="SA0782"> <Title> <range>Levonorgestrel &#8211; releasing intrauterine system 20mcg/24 hr</range> </Title> <Case When="Initial application" Category="No previous use"> <math> <apply> <and/> <ci type="logical" class="Indication">The patient has a clinical diagnosis of heavy menstrual bleeding</ci> <ci type="logical" class="Trial">The patient has failed to respond to or is unable to tolerate other appropriate pharmaceutical therapies as per the Heavy Menstrual Bleeding Guidelines</ci> <apply> <or/> <apply> <lt/> <ci type="real" class="test">serum ferritin level</ci> <cn>16<mi> mcg/l (within the last 12 months)</mi></cn> </apply> <apply> <lt/> <ci type="real" class="test">haemoglobin level</ci> <cn>120<mi> g/l</mi></cn> </apply> </apply> </apply> </math>
1319023910 1032 <Request To="HealthPAC" For="Subsidy" Form="SA1032"> <Title> <range>Tamsulosin</range> </Title> <Case When="Initial application"> <math> <apply> <and/> <ci type="logical" class="Indication">Patient has symptomatic benign prostatic hyperplasia</ci> <ci type="logical" class="Indication">The patient is intolerant of non-selective alpha blockers or these are contraindicated</ci> </apply> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="patient's lifetime"/> </Case></Request>
1019012363 954 <Request To="HealthPAC" For="Subsidy" Form="SA0954"> <Title> <range>Acitretin</range> </Title> <Case When="Initial application"> <math> <apply> <and/> <ci type="logical" class="Indication">Applicant is a vocationally registered dermatologist, vocationally registered general practitioner, or nurse practitioner working in a relevant scope of practice</ci> <ci type="logical" class="Indication">Applicant has an up to date knowledge of the treatment options for psoriasis and of disorders of keratinisation and is aware of the safety issues around acitretin and is competent to prescribe acitretin</ci> <apply> <or/> <ci type="logical" class="Indication">Patient is female and has been counselled and understands the risk of teratogenicity if acitretin is used during pregnancy and the applicant has ensured that the possibility of pregnancy has been excluded prior to the commencement of the treatment and that the patient is informed that
2216013899 987 <Request To="HealthPAC" For="Subsidy" Form="SA0987"> <Title> <range>Aprepitant</range> </Title> <Case When="Initial application"> <math> <ci type="logical" class="Indication">The patient is undergoing highly emetogenic chemotherapy and/or anthracycline-based chemotherapy for the treatment of malignancy</ci> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="month">12</Term> </Case> <Case When="Renewal" Form="SA0987"> <math> <ci type="logical" class="Indication">The patient is undergoing highly emetogenic chemotherapy and/or anthracycline-based chemotherapy for the treatment of malignancy</ci> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="month">12</Term> </Case></Request>
3504083914 1042 <Request To="HealthPAC" For="Subsidy" Form="SA1042"> <Title> <range>Deferiprone</range> </Title> <Case When="Initial application"> <math> <ci type="logical" class="Indication">The patient has been diagnosed with chronic transfusional iron overload due to congenital inherited anaemia</ci> </math> <Applicant>relevant specialist</Applicant> <Term Measure="patient's lifetime"/> </Case> <Note> <Para>For the purposes of this Special Authority, a relevant specialist is defined as a haematologist.</Para> </Note></Request>
010404116809 1155 <Request To="HealthPAC" For="Subsidy" Form="SA1155"> <Title> <range>Budesonide - Cap 3 mg Controlled Release</range> </Title> <Case When="Initial application" Category="Crohn's disease"> <math> <apply> <and/> <ci type="logical" class="Indication">Mild to moderate ileal, ileocaecal or proximal Crohn's disease</ci> <apply> <or/> <ci type="logical" class="Indication">Diabetes</ci> <ci type="logical" class="Indication">Cushingoid habitus</ci> <ci type="logical" class="Indication">Osteoporosis where there is significant risk of fracture</ci> <ci type="logical" class="Indication">Severe acne following treatment with conventional corticosteroid therapy</ci> <ci type="logical" class="Indication">History of severe psychiatric problems associated with corticosteroid treatment</ci> <ci type="logical" class="Indication">History of major mental illness (such as bipolar affective disorder) where
2837043967 1421 <Request To="HealthPAC" For="Subsidy" Form="SA1421"> <Title> <range>Montelukast</range> </Title> <Case When="Initial application" Category="Pre-school wheeze"> <math> <apply> <and/> <ci type="logical" class="Indication">To be used for the treatment of intermittent severe wheezing (possibly viral) in children under 5 years</ci> <ci type="logical" class="Indication">The patient has had at least three episodes in the previous 12 months of acute wheeze severe enough to seek medical attention</ci> </apply> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="year">1</Term> </Case> <Case When="Renewal" Category="Pre-school wheeze" Form="SA1227 SA1409 SA1421"> <math> <ci type="logical" class="Indication">The treatment remains appropriate and the patient is benefiting from treatment</ci> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="year">2</Term> </Case> <Case
2207021060 973 <Request To="PHARMAC" For="Subsidy" Form="SA0973"> <Title> <range>Neurontin</range> </Title> <Case When="Initial application"> <math> <ci type="logical" class="Indication">Subsidy for patients pre-approved on 1 August 2009</ci> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="patient's lifetime"/> </Case> <Note> <Para>Subsidy for patients pre-approved by PHARMAC on 1 August 2009. Approvals valid without further renewal unlessnotified.</Para> <Para>No new approvals will be granted from 1 August 2009.</Para> </Note></Request>
420615 1196 <Request To="HealthPAC" For="Subsidy" Form="SA1196"> <Title> <range>Paediatric enteral feed with fibre 0.75 kcal/ml<instance>Nutrini Low Energy Multi Fibre</instance></range> </Title> <Case When="Initial application"> <math overflow="scroll"> <apply> <and/> <ci type="logical" class="Indication">Child aged one to eight years</ci> <ci type="logical" class="Indication">The child has a low energy requirement but normal protein and micronutrient requirements</ci> </apply> </math> <Applicant>dietitian</Applicant> <Applicant>relevant specialist</Applicant> <Applicant>vocationally registered general practitioner</Applicant> <Term Measure="year">1</Term> </Case> <Case When="Renewal" Form="SA1196"> <math overflow="scroll"> <apply> <and/> <ci type="logical" class="Indication">The treatment remains appropriate and the patient is benefiting from treatment</ci> <ci type="text" class="Endorsement
1017013964 1225 <Request To="HealthPAC" For="Subsidy" Form="SA1225"> <Title> <range>Ivermectin</range> </Title> <Case When="Initial application" Category="Scabies"> <math> <apply> <and/> <ci type="logical" class="Indication">Applying clinician has discussed the diagnosis of scabies with a dermatologist, infectious disease physician or clinical microbiologist</ci> <apply> <or/> <apply> <and/> <ci type="logical" class="Indication">The patient is in the community</ci> <apply> <or/> <ci type="logical" class="Indication">Patient has a severe scabies hyperinfestation (Crusted/ Norwegian scabies)</ci> <ci type="logical" class="Indication">The community patient is physically or mentally unable to comply with the application instructions of topical therapy</ci> <ci type="logical" class="Indication">The patient has previously tried and failed to clear infestation
160401280325 1322 <Request To="HealthPAC" For="Subsidy" Form="SA1322"> <Title> <range>Itraconazole</range> </Title> <Case When="Initial application"> <math> <ci type="logical" class="Indication">The patient has a congenital immune deficiency</ci> </math> <Applicant>infectious disease specialist</Applicant> <Applicant>clinical microbiologist</Applicant> <Applicant>clinical immunologist</Applicant> <Applicant Referring="infectious disease physician, clinical microbiologist or clinical immunologist">any relevant practitioner</Applicant> <Term Measure="month">6</Term> </Case> <Case When="Renewal" Form="SA1322"> <math> <ci type="logical" class="Indication">The treatment remains appropriate and the patient is benefitting from the treatment</ci> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="month">6</Term> </Case></Request>
0707031254 1223 <Request To="HealthPAC" For="Subsidy" Form="SA1223"> <Title> <range>Candesartan</range> </Title> <Case When="Initial application" Category="ACE inhibitor intolerance"> <math> <apply> <or/> <ci type="logical" class="Indication">Patient has persistent ACE inhibitor induced cough that is not resolved by ACE inhibitor retrial (same or new ACE inhibitor)</ci> <ci type="logical" class="Indication">Patient has a history of angioedema</ci> </apply> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="patient's lifetime"/> </Case> <Case When="Initial application" Category="Unsatisfactory response to ACE inhibitor"> <math> <ci type="logical" class="Indication">patient is not adequately controlled on maximum tolerated dose of an ACE inhibitor</ci> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="patient's lifetime"/> </Case></Request>
040101 922 <Request To="HealthPAC" For="Subsidy" Form="SA0922"> <Title> <range>Erythropoietin</range> </Title> <Case When="Initial application"> <math> <apply> <and/> <apply> <and/> <ci type="logical" class="Indication">patient in chronic renal failure</ci> <apply> <leq/> <ci type="real" class="test">Haemoglobin</ci> <cn>100<mi>g/L</mi></cn> </apply> </apply> <apply> <or/> <apply> <and/> <ci type="logical" class="Indication">patient is not diabetic</ci> <apply> <leq/> <ci type="real" class="test">glomerular filtration rate</ci> <cn>30<mi>ml/min</mi></cn> </apply> </apply> <apply> <and/> <ci type="logical" class="Indication">patient is diabetic</ci> <apply> <leq/> <ci type
4218023948 1198 <Request To="HealthPAC" For="Subsidy" Form="SA1198"> <Title> <range>Preterm post-discharge infant formula powder<instance>S-26 Gold Premgro</instance></range> </Title> <Case When="Initial application"> <math overflow="scroll"> <apply> <and/> <ci type="logical" class="Indication">The infant was born before 33 weeks gestation or weighed less than 1.5 kg at birth</ci> <apply> <or/> <ci type="logical" class="Indication">The infant has faltering growth (downward crossing of percentiles)</ci> <ci type="logical" class="Indication">The infant is not maintaining, or is considered unlikely to maintain, adequate growth on standard infant formula</ci> </apply> </apply> </math> <Applicant>dietitian</Applicant> <Applicant>relevant specialist</Applicant> <Applicant>vocationally registered general practitioner</Applicant> <Term Measure="month">6</Term> </Case></Request>
2501073845 1124 <Request To="HealthPAC" For="Subsidy" Form="SA1124"> <Title> <range>Thalidomide</range> </Title> <Case When="Initial application"> <math> <apply> <or/> <ci type="logical" class="indication">The patient has multiple myeloma</ci> <ci type="logical" class="indication">The patient has systemic AL amyloidosis*</ci> </apply> </math> <Applicant>relevant specialist</Applicant> <Applicant Referring="relevant specialist">medical practitioner</Applicant> <Term Measure="month">12</Term> </Case> <Case When="Renewal" Form="SA1124 SA0817 SA0882"> <math> <ci type="logical" class="indication">The patient has obtained a response from treatment during the initial approval period</ci> </math> <Applicant>relevant specialist</Applicant> <Applicant Referring="relevant specialist">medical practitioner</Applicant> <Term Measure="patient's lifetime"/> </Case> <Note> <Para>Prescription must be written by a re
074001160401 1321 <Request To="HealthPAC" For="Subsidy" Form="SA1321"> <Title> <range>Hydralazine</range> </Title> <Case When="Initial application"> <math> <apply> <or/> <ci type="logical" class="Indication">For the treatment of refractory hypertension</ci> <ci type="logical" class="Indication">For the treatment of heart failure in combination with a nitrate, in patients who are intolerant or have not responded to ACE inhibitors and/or angiotensin receptor blockers</ci> </apply> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="patient's lifetime"/> </Case></Request>
0722021949 1260 <Request To="HealthPAC" For="Subsidy" Form="SA1260"> <Title> <range>Perhexiline Maleate</range> </Title> <Case When="Initial application"> <math> <apply> <and/> <ci type="logical" class="Indication">Patient has refractory angina</ci> <ci type="logical" class="Trial">Patient is on the maximal tolerated dose of a beta-blocker, a calcium channel blocker and a long acting nitrate</ci> </apply> </math> <Applicant>cardiologist</Applicant> <Applicant>general physician</Applicant> <Term Measure="year">2</Term> </Case> <Case When="Renewal" Form="SA0256 SA1260"> <math> <ci type="logical" class="Indication">The treatment remains appropriate and the patient is benefiting from treatment</ci> </math> <Applicant>cardiologist</Applicant> <Applicant Referring="cardiologist">any relevant practitioner</Applicant> <Term Measure="year">2</Term> </Case></Request>
1610014002 1326 <Request To="HealthPAC" For="Subsidy" Form="SA1326"> <Title> <range>Primaquine</range> </Title> <Case When="Initial application"> <math> <apply> <and/> <ci type="logical" class="Indication">The patient has vivax or ovale malaria</ci> <ci type="logical" class="Indication">Primaquine is to be given for a maximum of 21 days</ci> </apply> </math> <Applicant>infectious disease specialist</Applicant> <Applicant>clinical microbiologist</Applicant> <Term Measure="month">1</Term> </Case></Request>
1604013989 1285 <Request To="HealthPAC" For="Subsidy" Form="SA1285"> <Title> <range>Posaconazole </range> </Title> <Case When="Initial application"> <math> <apply> <or/> <ci type="logical" class="Indication">Patient has acute myeloid leukaemia and is to be treated with high dose remission induction, re-induction or consolidation chemotherapy</ci> <ci type="logical" class="Indication">Patient has received a stem cell transplant and has graft versus host disease and is on significant immunosuppressive therapy*</ci> </apply> </math> <Applicant>haematologist</Applicant> <Applicant>infectious disease specialist</Applicant> <Term Measure="week">6</Term> </Case> <Case When="Renewal" Form="SA1285"> <math> <apply> <or/> <ci type="logical" class="Indication">Patient has acute myeloid leukaemia and is to be treated with high dose remission induction, re-induction or consolidation therapy</ci> <ci type="logical" c
2228011956 1386 <Request To="HealthPAC" For="Subsidy" Form="SA1386"> <Title> <range>Phenobarbitone</range> </Title> <Case When="Initial application"> <math> <apply> <and/> <ci type="logical" class="Indication">For the treatment of terminal agitation that is unresponsive to other agents</ci> <ci type="logical" class="Indication">The applicant is part of a multidisciplinary team working in palliative care</ci> </apply> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="patient's lifetime"/> </Case></Request>
074007 1293 <Request To="HealthPAC" For="Subsidy" Form="SA1293"> <Title> <range>Sildenafil</range> </Title> <Case When="Initial application" Category="Raynaud&#8217;s Phenomenon* - for Pulmonary Arterial Hypertension see note below)"> <math> <apply> <and/> <ci type="logical" class="Indication">Patient has Raynaud&#8217;s Phenomenon*</ci> <ci type="logical" class="Indication">Patient has severe digital ischaemia (defined as severe pain requiring hospital admission or with a high likelihood of digital ulceration; digital ulcers; or gangrene)</ci> <ci type="logical" class="Indication">Patient is following lifestyle management (avoidance of cold exposure, sufficient protection, smoking cessation support, avoidance of sympathomimetic drugs) </ci> <ci type="logical" class="Indication">Patient is being treated with calcium channel blockers and nitrates (or these are contraindicated/not tolerated)</ci> </apply> </math> <Applicant>any relevant
2205093785 1061 <Request To="HealthPAC" For="Subsidy" Form="SA1061"> <Title> <range>Venlafaxine</range> </Title> <Case When="Initial application"> <math> <apply> <and/> <ci type="logical" class="Indication">The patient has 'treatment-resistant' depression</ci> <apply> <or/> <ci type="logical" class="Trial">The patient must have had a trial of two different antidepressants and have had an inadequate response from an adequate dose over an adequate period of time (usually at least four weeks)</ci> <apply> <and/> <ci type="logical" class="Indication">The patient is currently a hospital in-patient as a result of an acute depressive episode</ci> <ci type="logical" class="Trial">The patient must have had a trial of one other antidepressant and have had an inadequate response from an adequate dose over an adequate period of time</ci> </apply> </apply> </apply> </math> <Appl
2501093916 1411 <Request To="HealthPAC" For="Subsidy" Form="SA1411"> <Title> <range>Erlotinib</range> </Title> <Case When="Initial application"> <math> <apply> <or/> <apply> <and/> <ci type="logical" class="Indication">Patient has locally advanced or metastatic, unresectable, non-squamous Non Small Cell Lung Cancer (NSCLC)</ci> <ci type="logical" class="Indication">There is documentation confirming that the disease expresses activating mutations of EGFR tyrosine kinase</ci> <apply> <or/> <ci type="logical" class="Indication">Patient is treatment naive</ci> <apply> <and/> <ci type="logical" class="Indication">Patient has documented disease progression following treatment with first line platinum based chemotherapy</ci> <ci type="logical" class="Indication">Patient has not received prior treatment with gefitinib</ci> </apply> </apply>
1411 1018 <Request To="HealthPAC" For="Alternate Subsidy" Form="SA1018"> <Title> <range>Hormone Replacement Therapy - Systemic</range> </Title> <Case When="Initial application"> <math> <apply> <or/> <ci type="logical" class="Indication">acute or significant liver disease - where oral oestrogens are contraindicated as determined by a gastroenterologist or general physician. The applicant must keep written confirmation from such a specialist with the patient's record</ci> <ci type="logical" class="Indication">oestrogen induced hypertension requiring antihypertensive therapy - documented evidence must be kept on file that raised blood pressure levels or inability to control blood pressure adequately occurred post oral oestrogens</ci> <ci type="logical" class="Indication">hypertriglyceridaemia - documented evidence must be kept on file that triglyceride levels increased to at least 2 &#215; normal triglyceride levels post oral oestrogens</ci> <ci type=
0113013996 1320 <Request To="HealthPAC" For="Subsidy" Form="SA1320"> <Title> <range>Diazoxide</range> </Title> <Case When="Initial application"> <math> <ci type="logical" class="Indication">used for the treatment of confirmed hypoglycaemia caused by hyperinsulinism</ci> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="month">12</Term> </Case> <Case When="Renewal" Form="SA1320"> <math> <ci type="logical" class="Indication">The treatment remains appropriate and the patient is benefiting from treatment</ci> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="patient's lifetime"/> </Case></Request>
1601013990 1318 <Request To="HealthPAC" For="Subsidy" Form="SA1318"> <Title> <range>Albendazole</range> </Title> <Case When="Initial application"> <math> <ci type="logical" class="Indication">The patient has hydatids</ci> </math> <Applicant>infectious disease specialist</Applicant> <Applicant>clinical microbiologist</Applicant> <Term Measure="month">6</Term> </Case> <Case When="Renewal" Form="SA1318"> <math> <ci type="logical" class="Indication">The treatment remains appropriate and the patient is benefitting from the treatment</ci> </math> <Applicant>infectious disease specialist</Applicant> <Applicant>clinical microbiologist</Applicant> <Term Measure="month">6</Term> </Case></Request>
0740012451 1271 <Request To="HealthPAC" For="Subsidy" Form="SA1271"> <Title> <range>Minoxidil</range> </Title> <Case When="Initial application"> <math> <ci type="logical" class="Indication">patient has severe refractory hypertension which has failed to respond to extensive multiple therapies</ci> </math> <Applicant>relevant specialist</Applicant> <Term Measure="patient's lifetime"/> </Case></Request>
420603 1095 <Request To="HealthPAC" For="Subsidy" Form="SA1095"> <Title> <range>Diabetic products<instance>Diason RTH</instance><instance>Glucerna Select RTH</instance><instance>Diasip</instance><instance>Glucerna Select</instance><instance>Resource Diabetic</instance></range> </Title> <Case When="Initial application"> <math> <ci type="logical" class="Indication">The patient is a type I or and II diabetic who is suffering weight loss and malnutrition that requires nutritional support</ci> </math> <Applicant>dietitian</Applicant> <Applicant>relevant specialist</Applicant> <Applicant>vocationally registered general practitioner</Applicant> <Term Measure="year">1</Term> </Case> <Case When="Renewal" Form="SA0594 SA1095"> <math> <apply> <and/> <ci type="logical" class="Indication">The treatment remains appropriate and the patient is benefiting from treatment</ci> <ci type="text" class="Endorsement">General Practitioners must includ
190401 1038 <Request To="PHARMAC" For="Manufacturers Price" Form="SA1038"> <Title> <range>Anti-inflammatory Non Steroidal Drugs (NSAIDs)</range> </Title> <Case When="Initial application"> <math> <ci type="logical" class="Indication">Subsidy for patients with existing approvals prior to 1 September 2010</ci> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="patient's lifetime"/> </Case> <Note> <Para>Subsidy for patients with existing approvals prior to 1 September 2010. Approvals valid without further renewal unlessnotified. No new approvals will be granted from 1 September 2010.</Para> </Note></Request>
013719233025 1002 <Request To="HealthPAC" For="Subsidy" Form="SA1002"> <Title> <range>Vitabdeck</range> </Title> <Case When="Initial application"> <math> <apply> <or/> <ci type="logical" class="Indication">Patient has cystic fibrosis with pancreatic insufficiency</ci> <ci type="logical" class="Indication">Patient is an infant or child with liver disease or short gut syndrome</ci> </apply> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="patient's lifetime"/> </Case></Request>
2507043836 1449 <Request To="HealthPAC" For="Subsidy" Form="SA1449"> <Title> <range>Adalimumab</range> </Title> <Case When="Initial application" Category="rheumatoid arthritis"> <math> <apply> <or/> <apply> <and/> <ci type="logical" class="Indication">The patient has had an initial Special Authority approval for etanercept for rheumatoid arthritis</ci> <apply> <or/> <ci type="logical" class="Indication">The patient has experienced intolerable side effects from etanercept</ci> <ci type="logical" class="Indication">The patient has received insufficient benefit from etanercept to meet the renewal criteria for etanercept for rheumatoid arthritis</ci> </apply> </apply> <apply> <and/> <ci type="logical" class="Indication">Patient has had severe and active erosive rheumatoid arthritis for six months duration or longer</ci> <ci type="logical" class="Treatmen
310315 1388 <Request To="HealthPAC" For="Subsidy" Form="SA1388"> <Title> <range>Preservative Free Ocular Lubricants</range> </Title> <Case When="Initial application"> <math> <apply> <and/> <ci type="logical" class="Indication">Confirmed diagnosis by slit lamp of severe secretory dry eye</ci> <apply> <or/> <ci type="logical" class="Indication">Patient is using eye drops more than four times daily on a regular basis</ci> <ci type="logical" class="Indication">Patient has had a confirmed allergic reaction to preservative in eye drop</ci> </apply> </apply> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="month">12</Term> </Case> <Case When="Renewal" Form="SA1388"> <math> <ci type="logical" class="Indication">The patient continues to require lubricating eye drops and has benefited from treatment</ci> </math> <Applicant>any relevant practitioner</Applicant>
0407013945 1201 <Request To="HealthPAC" For="Subsidy" Form="SA1201"> <Title> <range>Prasugrel</range> </Title> <Case When="Initial application" Category="coronary angioplasty and bare metal stent"> <math> <ci type="logical" class="Treatment">The patient has undergone coronary angioplasty in the previous 4 weeks and is clopidogrel-allergic*</ci> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="month">6</Term> </Case> <Case When="Initial application" Category="drug eluting stent"> <math> <ci type="logical" class="Treatment">The patient has had a drug-eluting cardiac stent inserted in the previous 4 weeks and is clopidogrel-allergic*</ci> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="month">12</Term> </Case> <Case When="Initial application" Category="stent thromobosis"> <math> <ci type="logical" class="Treatment">patient has experienced cardiac stent thrombosis whilst on clopidogrel</ci>
2501074005 1325 <Request To="HealthPAC" For="Subsidy" Form="SA1325"> <Title> <range>Pegaspargase</range> </Title> <Case When="Initial application"> <math> <apply> <and/> <ci type="logical" class="Indication">The patient has newly diagnosed acute lymphoblastic leukaemia</ci> <ci type="logical" class="Indication">Pegaspargase to be used with a contemporary intensive multi-agent chemotherapy treatment protocol</ci> <ci type="logical" class="Indication">Treatment is with curative intent</ci> </apply> </math> <Applicant>relevant specialist</Applicant> <Applicant Referring="relevant specialist">medical practitioner</Applicant> <Term Measure="month">12</Term> </Case> <Case When="Renewal" Form="SA1325"> <math> <apply> <and/> <ci type="logical" class="Indication">The patient has relapsed acute lymphoblastic leukaemia</ci> <ci type="logical" class="Indication">Pegaspargase to be used with a contemporar
130802 500 <Request To="HealthPAC" For="Alternate Subsidy" Form="SA0500"> <Title><range>Combined oral contraceptives</range><range>Progestogen-only contraceptives</range> (Circle one)</Title> <Case When="Initial application"> <math> <apply> <and/> <apply> <or/> <ci type="logical" class="Target">Patient is on a Social Welfare benefit</ci> <ci type="logical" class="Target">Patient has an income no greater than the benefit</ci> </apply> <ci type="logical" class="Trial">Has tried at least one of the fully funded options and has been unable to tolerate it</ci> </apply> </math> <Applicant>medical practitioner</Applicant> <Term Measure="year">2</Term> </Case> <Case When="Renewal" Form="SA0265 SA0500"> <math> <apply> <or/> <ci type="logical" class="Target">Patient is on a Social Welfare benefit</ci> <ci type="logical" class="Target">Patient has an income no greater than the be
420203 1374 <Request To="HealthPAC" For="Subsidy" Form="SA1374"> <Title> <range>Fat<instance>Calogen</instance><instance>Liquigen</instance><instance>MCT oil (Nutricia)</instance></range> </Title> <Case When="Initial application" Category="Inborn errors of metabolism"> <math> <ci type="logical" class="Indication">The patient has inborn errors of metabolism</ci> </math> <Applicant>dietitian</Applicant> <Applicant>relevant specialist</Applicant> <Applicant>vocationally registered general practitioner</Applicant> <Term Measure="year">3</Term> </Case> <Case When="Initial application" Category="Indications other than inborn errors of metabolism"> <math> <apply> <or/> <ci type="logical" class="Indication">faltering growth in an infant/child</ci> <ci type="logical" class="Indication">bronchopulmonary dysplasia</ci> <ci type="logical" class="Indication">fat malabsorption</ci> <ci type="logical" class="Indication">lym
420204 1375 <Request To="HealthPAC" For="Subsidy" Form="SA1375"> <Title> <range>Protein<instance>Protifar</instance><instance>Promod</instance><instance>Resource Beneprotein</instance></range> </Title> <Case When="Initial application"> <math> <apply> <or/> <ci type="logical" class="Indication">protein losing enteropathy</ci> <ci type="logical" class="Indication">high protein needs</ci> <ci type="logical" class="Indication">for use as a component in a modular formula</ci> </apply> </math> <Applicant>dietitian</Applicant> <Applicant>relevant specialist</Applicant> <Applicant>vocationally registered general practitioner</Applicant> <Term Measure="year">1</Term> </Case> <Case When="Renewal" Form="SA0582 SA1093 SA1375"> <math> <apply> <and/> <ci type="logical" class="Indication">The treatment remains appropriate and the patient is benefiting from treatment</ci> <ci type="text" class="Endor
2501093921 1266 <Request To="HealthPAC" For="Subsidy" Form="SA1266"> <Title> <range>Sunitinib</range> </Title> <Case When="Initial application" Category="RCC"> <math> <apply> <and/> <ci type="logical" class="Indication">The patient has metastatic renal cell carcinoma</ci> <apply> <or/> <ci type="logical" class="Trial">The patient is treatment naive</ci> <ci type="logical" class="Trial">The patient has only received prior cytokine treatment</ci> <ci type="logical" class="Trial">The patient has only received prior treatment with an investigational agent within the confines of a bona fide clinical trial which has Ethics Committee approval</ci> <apply> <and/> <ci type="logical" class="Trial">The patient has discontinued pazopanib within 3 months of starting treatment due to intolerance</ci> <ci type="logical" class="Trial">The cancer did not progress whilst on pazopanib</ci>
1604013978 1273 <Request To="HealthPAC" For="Subsidy" Form="SA1273"> <Title> <range>Voriconazole</range> </Title> <Case When="Initial application" Category="invasive fungal infection"> <math> <apply> <and/> <ci type="logical" class="Indication">Patient is immunocompromised</ci> <ci type="logical" class="Indication">Applicant is part of a multidisciplinary team including an infectious disease specialist</ci> <apply> <or/> <ci type="logical" class="Indication">Patient has proven or probable invasive aspergillus infection</ci> <ci type="logical" class="Indication">Patient has possible invasive aspergillus infection</ci> <ci type="logical" class="Indication">Patient has fluconazole resistant candidiasis</ci> <ci type="logical" class="Indication">Patient has mould strain such as Fusarium spp. and Scedosporium spp</ci> </apply> </apply> </math> <Applicant>haematologist</Applicant> <App
420631 1228 <Request To="HealthPAC" For="Subsidy" Form="SA1228"> <Title> <range>Standard Supplements<instance>Ensure</instance><instance>Fortisip</instance><instance>Isosource</instance><instance>Jevity</instance><instance>Nutrison</instance><instance>Osmolite</instance><instance>Sustagen</instance></range> </Title> <Case When="Initial application" Category="Children"> <math> <apply> <and/> <ci type="logical" class="Indication">The patient is under 18 years of age</ci> <apply> <or/> <ci type="logical" class="Indication">The patient has a condition causing malabsorption</ci> <ci type="logical" class="Indication">The patient has failure to thrive</ci> <ci type="logical" class="Indication">The patient has increased nutritional requirements</ci> </apply> <ci type="logical" class="Indication">Nutrition goal has been set (eg reach a specific weight or BMI)</ci> </apply> </math> <Applicant>dietitia
0732083853 1046 <Request To="HealthPAC" For="Subsidy" Form="SA1046"> <Title> <range>Ezetimibe with Simvastatin<instance>Vytorin</instance></range> </Title> <Case When="Initial application"> <math> <apply> <and/> <ci type="logical" class="Indication">Patient has a calculated absolute risk of cardiovascular disease of at least 15% over 5 year</ci> <ci type="logical" class="Trial">Patient's LDL cholesterol is 2.0 mmol/litre or greater</ci> <ci type="logical" class="Trial">The patient has not reduced their LDL cholesterol to less than 2.0 mmol/litre with the use of the maximal tolerated dose of atorvastatin</ci> </apply> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="year">2</Term> <Note> <Para>A patient who has failed to reduce their LDL cholesterol to &#8804; 2.0 mmol/litre with the use of a less potent statin should use a more potent statin prior to consideration being given to the use of non-statin therapi
2849021010 611 <Request To="Cystic Fibrosis Advisory Panel" For="Subsidy" Form="SA0611"> <Title> <range>Dornase Alfa</range> </Title> <Case When="Initial application"> <math> <ci/> </math> <Applicant>medical practitioner</Applicant> <Term Measure="year">1</Term> </Case> <Note> <Para>Application details may be obtained from PHARMAC's website <a href="http://www.pharmac.govt.nz/">http://www.pharmac.govt.nz</a> or:</Para> <Table> <TR> <TD> <Para>The Co-ordinator, Cystic Fibrosis Advisory Panel</Para> </TD> <TD> <Para>Phone: (04) 460 4990</Para> </TD> </TR> <TR> <TD> <Para>PHARMAC, PO Box 10 254</Para> </TD> <TD> <Para>Facsimile: (04) 916 7571</Para> </TD> </TR> <TR> <TD> <Para>Wellington</Para> </TD> <TD> <Para>Email: <a href="mailto:CFPanel@pharmac.govt.nz">CFPanel@pharmac.
1416022509 1451 <Request To="HealthPAC" For="Subsidy" Form="SA1451"> <Title> <range>Somatropin</range> </Title> <Case When="Initial application" Category="growth hormone deficiency in children"> <math> <apply> <or/> <apply> <and/> <ci type="logical" class="Indication">Growth hormone deficiency causing symptomatic hypoglycaemia, or with other significant growth hormone deficient sequelae (e.g. cardiomyopathy, hepatic dysfunction) and diagnosed with GH &lt; 5 mcg/l on at least two random blood samples in the first 2 weeks of life, or from samples during established hypoglycaemia (whole blood glucose &lt; 2 mmol/l using a laboratory device)</ci> </apply> <apply> <and/> <ci type="logical" class="Indication">Height velocity &lt; 25th percentile for age adjusted for bone age/pubertal status if appropriate over 6 or 12 months using the standards of Tanner and Davies (1985)</ci> <ci type="logical" class="Indication
1908063939 1139 <Request To="HealthPAC" For="Subsidy" Form="SA1139"> <Title> <range>Teriparatide</range> </Title> <Case When="Initial application"> <math> <apply> <and/> <ci type="logical" class="indication">The patient has severe, established osteoporosis</ci> <ci type="logical" class="indication">The patient has a documented T-score less than or equal to -3.0 (see Notes)</ci> <ci type="logical" class="indication">The patient has had two or more fractures due to minimal trauma</ci> <ci type="logical" class="indication">The patient has experienced at least one symptomatic new fracture after at least 12 months&#8217; continuous therapy with a funded antiresorptive agent at adequate doses (see Notes)</ci> </apply> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="month">18</Term> </Case> <Note> <List Type="Alpha"> <Item> <Para>The bone mineral density (BMD) measurement used to derive the
011507380225281291 <Request To="PHARMAC" For="Subsidy" Form="SA1291"> <Title> <range>Optium blood glucose test strips</range> </Title> <Case When="Initial application"> <math> <ci type="logical" class="Indication">Patient identified as eligible for subsidy for FreeStyle Optium blood glucose test strips</ci> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="patient's lifetime"/> </Case> <Note> <Para>Application details may be obtained from PHARMAC's website http://www.pharmac.govt.nz and can be sent to:</Para> <Table> <TR> <TD> <Para>PHARMAC</Para> </TD> <TD> <Para/> </TD> </TR> <TR> <TD> <Para>PO Box 10 254</Para> </TD> <TD> <Para>Facsimile: (04) 974 4788</Para> </TD> </TR> <TR> <TD> <Para>Wellington</Para> </TD> <TD> <Para>Email: <a href="mailto:bgstrip
420606 1098 <Request To="HealthPAC" For="Subsidy" Form="SA1098"> <Title> <range>Paediatric Product For Children Awaiting Liver Transplant<instance>Heparon Junior</instance></range> </Title> <Case When="Initial application"> <math> <ci type="logical" class="Indication">The patient is a child (up to 18 years) who requires a liver transplant</ci> </math> <Applicant>dietitian</Applicant> <Applicant>relevant specialist</Applicant> <Applicant>vocationally registered general practitioner</Applicant> <Term Measure="year">3</Term> </Case> <Case When="Renewal" Form="SA0607 SA1098"> <math> <apply> <and/> <ci type="logical" class="Indication">The treatment remains appropriate and the patient is benefiting from treatment</ci> <ci type="text" class="Endorsement">General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted</ci> </apply> </math
1621033859 845 <Request To="HealthPAC" For="Subsidy" Form="SA0845"> <Title> <range>Enfuvirtide</range> </Title> <Case When="Initial application"> <math> <apply> <and/> <ci type="logical" class="Indication">Confirmed HIV infection</ci> <ci type="logical" class="Indication">Enfuvirtide to be given in combination with optimized background therapy (including at least 1 other antiretroviral drug that the patient has never previously been exposed to) for treatment failure</ci> <apply> <or/> <ci type="logical" class="Indication">Patient has evidence of HIV replication, despite ongoing therapy</ci> <ci type="logical" class="Indication">Patient has treatment-limiting toxicity to previous antiretroviral agents</ci> </apply> <ci type="logical" class="Indication">Previous treatment with 3 different antiretroviral regimens has failed</ci> <apply> <and/> <ci type="logical" class="Indication">Prev
1001011688 955 <Request To="HealthPAC" For="Subsidy" Form="SA0955"> <Title> <range>Isotretinoin</range> </Title> <Case When="Initial application"> <math> <apply> <and/> <ci type="logical" class="Indication">Patient has had an adequate trial on other available treatments and has received an inadequate response from these treatments or these are contraindicated</ci> <ci type="logical" class="Indication">Applicant is a vocationally registered dermatologist, vocationally registered general practitioner, or nurse practitioner working in a relevant scope of practice</ci> <ci type="logical" class="Indication">Applicant has an up to date knowledge of the treatment options for acne and is aware of the safety issues around isotretinoin and is competent to prescribe isotretinoin</ci> <apply> <or/> <ci type="logical" class="Indication">Patient is female and has been counselled and understands the risk of teratogenicity if isotretinoin is used d
2205093901 994 <Request To="HealthPAC" For="Subsidy" Form="SA0994"> <Title> <range>Mirtazapine</range> </Title> <Case When="Initial application"> <math> <apply> <and/> <ci type="logical" class="Indication">The patient has a severe major depressive episode</ci> <apply> <or/> <ci type="logical" class="Trial">The patient must have had a trial of two different antidepressants and was unable to tolerate the treatments or failed to respond to an adequate dose over an adequate period of time (usually at least four weeks)</ci> <apply> <and/> <ci type="logical" class="Indication">The patient is currently a hospital in-patient as a result of an acute depressive episode</ci> <ci type="logical" class="Trial">The patient must have had a trial of one other antidepressant and either could not tolerate it or failed to respond to an adequate dose over an adequate period of time</ci> </apply> </appl
1619073979 1404 <Request To="HealthPAC" For="Subsidy" Form="SA1404"> <Title> <range>Valganciclovir</range> </Title> <Case When="Initial application" Category="transplant cytomegalovirus prophylaxis"> <math> <ci type="logical" class="Indication">the patient has undergone a solid organ transplant and requires valganciclovir for CMV prophylaxis</ci> </math> <Applicant>relevant specialist</Applicant> <Term Measure="month">3</Term> </Case> <Case When="Renewal" Form="SA1274 SA1404" Category="transplant cytomegalovirus prophylaxis"> <math> <apply> <and/> <ci type="logical" class="Indication">Patient has undergone a solid organ transplant and received anti-thymocyte globulin and requires valganciclovir therapy for CMV prophylaxis</ci> <ci type="logical" class="Indication">Patient is to receive a maximum of 90 days of valganciclovir prophylaxis following anti-thymocyte globulin</ci> </apply> </math> <Applicant>relevant specialist</A
Trial Version
Not all rows exported
<Request To="HealthPAC" For="Subsidy" Form="SA1138"> <Title> <range>Raloxifene</range> </Title> <Case When="Initial application"> <math> <apply> <or/> <ci type="logical" class="indication">History of one significant osteoporotic fracture demonstrated radiologically and documented bone mineral density (BMD) &#8805;2.5 standard deviations below the mean normal value in young adults (i.e. T-Score &#8804; -2.5) (see Notes)</ci> <ci type="logical" class="indication">History of one significant osteoporotic fracture demonstrated radiologically, and either the patient is elderly, or densitometry scanning cannot be performed because of major logistical, technical or pathophysiological reasons. It is unlikely that this provision would apply to many patients under 75 years of age</ci> <ci type="logical" class="indication">History of two significant osteoporotic fractures demonstrated radiologically</ci> <ci type="logical" class="indication">Documente
<Request To="HealthPAC" For="Subsidy" Form="SA1125"> <Title> <range>Lacosamide</range> </Title> <Case When="Initial application"> <math> <apply> <and/> <ci type="logical" class="Indication">Patient has partial-onset epilepsy</ci> <ci type="logical" class="Trial">Seizures are not adequately controlled by, or patient has experienced unacceptable side effects from, optimal treatment with all of the following: sodium valproate, topiramate, levetiracetam and any two of carbamazepine, lamotrigine and phenytoin sodium (see Note)</ci> </apply> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="month">15</Term> <Note> <Para>"Optimal treatment" is defined as treatment which is indicated and clinically appropriate for the patient, given in adequate doses for the patient's age, weight and other features affecting the pharmacokinetics of the drug with good evidence of compliance. Women of childbearing age are not re
<Request To="HealthPAC" For="Subsidy" Form="SA1376"> <Title> <range>Carbohydrate and Fat<instance>Duocal Super Soluble Powder</instance></range> </Title> <Case When="Initial application" Category="Cystic fibrosis"> <math> <apply> <and/> <ci type="logical" class="Indication">Infant or child aged four years or under</ci> <ci type="logical" class="Indication">cystic fibrosis</ci> </apply> </math> <Applicant>dietitian</Applicant> <Applicant>relevant specialist</Applicant> <Applicant>vocationally registered general practitioner</Applicant> <Term Measure="year">3</Term> </Case> <Case When="Initial application" Category="Indications other than cystic fibrosis"> <math> <apply> <and/> <ci type="logical" class="Indication">infant or child aged four years or under</ci> <apply> <or/> <ci type="logical" class="Indication">cancer in children</ci> <ci type="logica
<Request To="HealthPAC" For="Subsidy" Form="SA0895"> <Title> <range>Pilocarpine &#8211; Eye drops 2% single dose</range> </Title> <Case When="Initial application"> <math> <apply> <or/> <ci type="logical" class="Indication">Patient has to use an unpreserved solution due to an allergy to the preservative</ci> <ci type="logical" class="Indication">Patient wears soft contact lenses</ci> </apply> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="year">2</Term> <Note> <Para>Minims for a general practice are considered to be &#8220;tools of trade&#8221; and are not approved as special authority items.</Para> </Note> </Case> <Case When="Renewal" Form="SA0121 SA0895"> <math> <ci type="logical" class="Indication">The treatment remains appropriate and the patient is benefiting from treatment</ci> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="year">2<
<Request To="HealthPAC" For="Subsidy" Form="SA1072"> <Title> <range>Vigabatrin</range> </Title> <Case When="Initial application"> <math> <apply> <and/> <apply> <or/> <ci type="logical" class="Indication">Patient has infantile spasms</ci> <apply> <and/> <ci type="logical" class="Indication">Patient has epilepsy</ci> <apply> <or/> <ci type="logical" class="Indication">Seizures are not adequately controlled with optimal treatment with other antiepilepsy agents</ci> <ci type="logical" class="Indication">Seizures are controlled adequately but the patient has experienced unacceptable side effects from optimal treatment with other antiepilepsy agents</ci> </apply> </apply> </apply> <apply> <or/> <ci type="logical" class="Indication">Patient is, or will be, receiving regular automated visual fiel
<Request To="HealthPAC" For="Subsidy" Form="SA1408"> <Title> <range>Naltrexone</range> </Title> <Case When="Initial application"> <math> <apply> <and/> <ci type="logical" class="Indication">Patient is currently enrolled in a recognised comprehensive treatment programme for alcohol dependence</ci> <ci type="logical" class="Therapy">Applicant works in or with a community Alcohol and Drug Service contracted to one of the District Health Boards or accredited against the New Zealand Alcohol and Other Drug Sector Standard or the National Mental Health Sector Standard</ci> </apply> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="month">6</Term> </Case> <Case When="Renewal" Form="SA0714 SA0909 SA1397 SA1408"> <math> <apply> <and/> <ci type="logical" class="Indication">Compliance with the medication (prescriber determined)</ci> <apply> <or/> <ci type="log
<Request To="HealthPAC" For="Subsidy" Form="SA1174"> <Title> <range>Enoxaparin sodium</range> </Title> <Case When="Initial application" Category="Pregnancy or Malignancy"> <math> <apply> <or/> <ci type="logical" class="Indication">Low molecular weight heparin treatment is required during a patients pregnancy</ci> <ci type="logical" class="Treatment">For the treatment of venous thromboembolism where the patient has a malignancy</ci> </apply> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="year">1</Term> </Case> <Case When="Initial application" Category="Venous thromboembolism other than in pregnancy or malignancy"> <math> <apply> <or/> <ci type="logical" class="Indication">For the short-term treatment of venous thromboembolism prior to establishing a therapeutic INR with oral anti-coagulant treatment</ci> <ci type="logical" class="Treatment">For the prophylaxis and tre
<Request To="HealthPAC" For="Subsidy" Form="SA1416"> <Title> <range>Atomoxetine</range> </Title> <Case When="Initial application"> <math> <apply> <and/> <ci type="logical" class="Indication">Patient has ADHD (Attention Deficit and Hyperactivity Disorder) diagnosed according to DSM-IV or ICD 10 criteria</ci> <ci type="logical" class="Indication">Once-daily dosing</ci> <apply> <or/> <ci type="logical" class="Indication">Treatment with a subsidised formulation of a stimulant has resulted in the development or worsening of serious adverse reactions or where the combination of subsidised stimulant treatment with another agent would pose an unacceptable medical risk</ci> <ci type="logical" class="Indication">Treatment with a subsidised formulation of a stimulant has resulted in worsening of co-morbid substance abuse or there is a significant risk of diversion with subsidised stimulant therapy</ci> <ci type="log
<Request To="HealthPAC" For="Subsidy" Form="SA1263"> <Title> <range>Nicorandil</range> </Title> <Case When="Initial application"> <math> <apply> <and/> <ci type="logical" class="Indication">Patient has refractory angina</ci> <ci type="logical" class="Trial">Patient is on the maximal tolerated dose of a beta-blocker, a calcium channel blocker and a long acting nitrate</ci> </apply> </math> <Applicant>cardiologist</Applicant> <Applicant>general physician</Applicant> <Term Measure="year">2</Term> </Case> <Case When="Renewal" Form="SA1263"> <math> <ci type="logical" class="Indication">The treatment remains appropriate and the patient is benefiting from treatment</ci> </math> <Applicant>cardiologist</Applicant> <Applicant Referring="cardiologist">any relevant practitioner</Applicant> <Term Measure="year">2</Term> </Case></Request>
<Request To="HealthPAC" For="Subsidy" Form="SA0927"> <Title> <range>Risperidone orally disintegrating tablets</range> </Title> <Case When="Initial application" Category="Acute situations"> <math> <apply> <and/> <ci type="logical" class="Use">For a non-adherent patient on oral therapy with standard risperidone tablets or risperidone oral liquid</ci> <ci type="logical" class="Therapy">The patient is under direct supervision for administration of medicine</ci> </apply> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="week">6</Term> </Case> <Case When="Initial application" Category="Chronic situations"> <math> <apply> <and/> <ci type="logical" class="Indication">The patient is unable to take standard risperidone tablets or oral liquid, or once stabilized refuses to take risperidone tablets or oral liquid</ci> <ci type="logical" class="Therapy">The patient is under direct
<Request To="HealthPAC" For="Subsidy" Form="SA1195"> <Title> <range>High Calorie Products<instance>Two Cal HN</instance><instance>Nutrison Concentrated</instance></range> </Title> <Case When="Initial application" Category="Cystic fibrosis"> <math> <apply> <and/> <ci type="logical" class="Indication">Cystic fibrosis</ci> <ci type="logical" class="Trial">other lower calorie products have been tried</ci> <ci type="logical" class="Indication">patient has substantially increased metabolic requirements</ci> </apply> </math> <Applicant>dietitian</Applicant> <Applicant>relevant specialist</Applicant> <Applicant>vocationally registered general practitioner</Applicant> <Term Measure="year">3</Term> </Case> <Case When="Initial application" Category="Indications other than cystic fibrosis"> <math> <apply> <and/> <apply> <or/> <ci type="logical" class="Indication">any cond
<Request To="HealthPAC" For="Subsidy" Form="SA1199"> <Title> <range>Propylthiouracil</range> </Title> <Case When="Initial application"> <math> <apply> <and/> <ci type="logical" class="Indication">The patient has hyperthyroidism</ci> <ci type="logical" class="Indication">The patient is intolerant of carbimazole or carbimazole is contraindicated</ci> </apply> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="year">2</Term> </Case> <Case When="Renewal" Form="SA1199"> <math> <ci type="logical" class="Indication">the treatment remains appropriate and the patient is benefitting from the treatment</ci> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="year">2</Term> </Case></Request>
<Request To="PHARMAC" For="Subsidy" Form="SA1237"> <Title> <range>Insulin Pumps</range> </Title> <Case When="Initial application"> <math/> <Applicant>medical practitioner</Applicant> <Term Measure="year">1</Term> </Case> <Note> <Para>Application details may be obtained from PHARMAC's website <a href="http://www.pharmac.govt.nz/">http://www.pharmac.govt.nz</a> or:</Para> <Table> <TR> <TD> <Para>The IPP Co-ordinator</Para> </TD> <TD> <Para>Phone: (04) 460 4990</Para> </TD> </TR> <TR> <TD> <Para>PHARMAC</Para> </TD> <TD> <Para>Facsimile: (04) 974 7806</Para> </TD> </TR> <TR> <TD> <Para>PO Box 10 254</Para> </TD> <TD> <Para>Email: <a href="mailto:ipp@pharmac.govt.nz">ipp@pharmac.govt.nz</a></Para> </TD> </TR> <TR> <TD> <Para>Welli
<Request To="HealthPAC" For="Subsidy" Form="SA0829"> <Title> <range>Adefovir dipivoxil</range> </Title> <Case When="Initial application"> <math> <apply> <and/> <ci type="logical" class="Trial">Patient has confirmed Hepatitis B infection (HBsAg+)</ci> <mi class="heading">Documented resistance to lamivudine, defined as:</mi> <ci type="logical" class="Trial">Patient has raised serum ALT (&gt; 1 &#215; ULN)</ci> <ci type="logical" class="Trial">Patient has HBV DNA greater than 100,000 copies per mL, or viral load &#8805; 10 fold over nadir</ci> <ci type="logical" class="Trial">Detection of M204I or M204V mutation</ci> <apply> <or/> <apply> <and/> <ci type="logical" class="Trial">Patient is cirrhotic</ci> <ci type="logical" class="Trial">adefovir dipivoxil to be used in combination with lamivudine</ci> </apply> <apply> <and/>
<Request To="HealthPAC" For="Subsidy" Form="SA0998"> <Title> <range>Solifenacin succinate</range> </Title> <Case When="Initial application"> <math> <ci type="logical" class="Indication">The patient has overactive bladder and a documented intolerance of, or is non-responsive to oxybutynin</ci> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="patient's lifetime"/> </Case></Request>
<Request To="HealthPAC" For="Subsidy" Form="SA1332"> <Title> <range>Tetracycline</range> </Title> <Case When="Initial application"> <math> <apply> <and/> <ci type="logical" class="Indication">For the eradication of helicobacter pylori following unsuccessful treatment with appropriate first-line therapy</ci> <ci type="logical" class="Indication">For use only in combination with bismuth as part of a quadruple therapy regimen</ci> </apply> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="month">3</Term> </Case></Request>
<Request To="HealthPAC" For="Subsidy" Form="SA1379"> <Title> <range>Paediatric Products<instance>Nutrini</instance><instance>Pediasure</instance><instance>Fortini</instance></range> </Title> <Case When="Initial application"> <math> <apply> <and/> <ci type="logical" class="Indication">Child is aged one to ten years</ci> <apply> <or/> <ci type="logical" class="Indication">the child is being fed via a tube or a tube is to be inserted for the purposes of feeding</ci> <ci type="logical" class="Indication">any condition causing malabsorption</ci> <ci type="logical" class="Indication">faltering growth in an infant/child</ci> <ci type="logical" class="Indication">increased nutritional requirements</ci> <ci type="logical" class="Indication">the child is being transitioned from TPN or tube feeding to oral feeding</ci> </apply> </apply> </math> <Applicant>dietitian</Applicant>
<Request To="HealthPAC" For="Subsidy" Form="SA1382"> <Title> <range>Ticagrelor</range> </Title> <Case When="Initial application" Category="acute coronary syndrome"> <math> <apply> <and/> <ci type="logical" class="Indication">Patient has recently been diagnosed with an ST-elevation or a non-ST-elevation acute coronary syndrome</ci> <ci type="logical" class="Indication">Fibrinolytic therapy has not been given in the last 24 hours and is not planned</ci> </apply> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="month">12</Term> </Case> <Case When="Renewal" Category="subsequent acute coronary syndrome" Form="SA1382"> <math> <apply> <and/> <ci type="logical" class="Indication">Patient has recently been diagnosed with an ST-elevation or a non-ST-elevation acute coronary syndrome</ci> <ci type="logical" class="Indication">Fibrinolytic therapy has not been given in the last 24
<Request To="HealthPAC" For="Subsidy" Form="SA1383"> <Title> <range>Ursodeoxycholic Acid</range> </Title> <Case When="Initial application" Category="Alagille syndrome or progressive familial intrahepatic cholestasis"> <math> <apply> <or/> <ci type="logical" class="Indication">Patient has been diagnosed with Alagille syndrome</ci> <ci type="logical" class="Indication">Patient has progressive familial intrahepatic cholestasis</ci> </apply> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="patient's lifetime"/> </Case> <Case When="Initial application" Category="Chronic severe drug induced cholestatic liver injury"> <math> <apply> <and/> <ci type="logical" class="Indication">Patient has chronic severe drug induced cholestatic liver injury</ci> <ci type="logical" class="Indication">Cholestatic liver injury not due to Total Parenteral Nutrition (TPN) use in adults</ci>
<Request To="HealthPAC" For="Subsidy" Form="SA1192"> <Title> <range>Trastuzumab</range> </Title> <Case When="Initial application" Category="metastatic breast cancer"> <math> <apply> <or/> <apply> <and/> <ci type="logical" class="Indication">The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology)</ci> <ci type="logical" class="Treatment">The patient has not previously received lapatinib treatment for HER 2 positive metastatic breast cancer</ci> <ci type="logical" class="Indication">Trastuzumab not to be given in combination with lapatinib</ci> <ci type="logical" class="Treatment">Trastuzumab to be discontinued at disease progression</ci> </apply> <apply> <and/> <ci type="logical" class="Indication">The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology
<Request To="HealthPAC" For="Subsidy" Form="SA1071"> <Title> <range>Gabapentin</range> </Title> <Case When="Initial application" Category="Epilepsy"> <math> <apply> <or/> <ci type="logical" class="Indication">Seizures are not adequately controlled with optimal treatment with other antiepilepsy agents</ci> <ci type="logical" class="Indication">Seizures are controlled adequately but the patient has experienced unacceptable side effects from optimal treatment with other antiepilepsy agents</ci> </apply> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="month">15</Term> <Note> <Para>"Optimal treatment with other antiepilepsy agents" is defined as treatment with other antiepilepsy agents which are indicated and clinically appropriate for the patient, given in adequate doses for the patient's age, weight, and other features affecting the pharmacokinetics of the drug with good evidence of compliance.</Para>
<Request To="HealthPAC" For="Subsidy" Form="SA1066"> <Title> <range>Rivaroxaban</range> </Title> <Case When="Initial application"> <math> <apply> <or/> <ci type="logical" class="Indication">For the prophylaxis of venous thromboembolism following a total hip replacement</ci> <ci type="logical" class="Use">For the prophylaxis of venous thromboembolism following a total knee replacement</ci> </apply> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="week">5</Term> <Note> <Para>Rivaroxaban is only currently indicated and subsidised for up to 5 weeks therapy for prophylaxis of venous thromboembolism following a total hip replacement and up to 2 weeks therapy for prophylaxis of venous thromboembolism following a total knee replacement.</Para> </Note> </Case> <Case When="Renewal" Form="SA1066"> <math> <ci type="logical" class="Indication">Prophylaxis for venous thromboembolism is requir
<Request To="PHARMAC" For="Subsidy" Form="SA1240"> <Title> <range>Insulin pump consumables</range> </Title> <Case When="Initial application"> <math/> <Applicant>medical practitioner</Applicant> <Term Measure="year">1</Term> </Case> <Note> <Para>Application details may be obtained from PHARMAC's website <a href="http://www.pharmac.govt.nz/">http://www.pharmac.govt.nz</a> or:</Para> <Table> <TR> <TD> <Para>The IPP Co-ordinator</Para> </TD> <TD> <Para>Phone: (04) 460 4990</Para> </TD> </TR> <TR> <TD> <Para>PHARMAC</Para> </TD> <TD> <Para>Facsimile: (04) 974 7806</Para> </TD> </TR> <TR> <TD> <Para>PO Box 10 254</Para> </TD> <TD> <Para>Email: <a href="mailto:ipp@pharmac.govt.nz">ipp@pharmac.govt.nz</a></Para> </TD> </TR> <TR> <TD>
<Request To="HealthPAC" For="Subsidy" Form="SA1289"> <Title> <range>Capsaicin</range> </Title> <Case When="Initial application"> <math> <ci type="logical" class="Indication">The patient has osteoarthritis that is not responsive to paracetamol and oral non-steroidal anti-inflammatories are contraindicated</ci> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="patient's lifetime"/> </Case></Request>
<Request To="HealthPAC" For="Subsidy" Form="SA1039"> <Title> <range>Alendronate Tab 70 mg - with or without Cholecalciferol</range> </Title> <Case When="Initial application" Category="Underlying cause -- Osteoporosis"> <math> <apply> <or/> <ci type="logical" class="Indication">History of one significant osteoporotic fracture demonstrated radiologically and documented bone mineral density (BMD) &#8805; 2.5 standard deviations below the mean normal value in young adults (i.e. T-Score &#8804; -2.5) (see Note)</ci> <ci type="logical" class="Indication">History of one significant osteoporotic fracture demonstrated radiologically, and either the patient is elderly, or densitometry scanning cannot be performed because of major logistical, technical or pathophysiological reasons. It is unlikely that this provision would apply to many patients under 75 years of age</ci> <ci type="logical" class="Indication">History of two significant osteoporotic fractures
<Request To="HealthPAC" For="Manufacturers Price" Form="SA1355"> <Title> <range>Minocycline hydrochloride Tab 50 mg</range> </Title> <Case When="Initial application"> <math> <ci type="logical" class="Indication">The patient has rosacea</ci> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="patient's lifetime"/> </Case></Request>
<Request To="HealthPAC" For="Subsidy" Form="SA1324"> <Title> <range>Paromomycin</range> </Title> <Case When="Initial application"> <math> <ci type="logical" class="Indication">the patient has confirmed cryptosporidium infection</ci> </math> <Applicant>infectious disease specialist</Applicant> <Applicant>clinical microbiologist</Applicant> <Term Measure="month">1</Term> </Case> <Case When="Renewal" Form="SA1324"> <math> <ci type="logical" class="Indication">the patient has confirmed cryptosporidium infection</ci> </math> <Applicant>infectious disease specialist</Applicant> <Applicant>clinical microbiologist</Applicant> <Term Measure="month">1</Term> </Case></Request>
<Request To="HealthPAC" For="Subsidy" Form="SA1126"> <Title> <range>Modavigil</range> </Title> <Case When="Initial application"> <math> <apply> <and/> <ci type="logical" class="Indication">The patient has a diagnosis of narcolepsy and has excessive daytime sleepiness associated with narcolepsy occurring almost daily for three months or more</ci> <apply> <or/> <ci type="logical" class="Indication">The patient has a multiple sleep latency test with a mean sleep latency of less than or equal to 10 minutes and 2 or more sleep onset rapid eye movement periods</ci> <ci type="logical" class="Indication">The patient has at least one of: cataplexy, sleep paralysis or hypnagogic hallucinations</ci> </apply> <apply> <or/> <ci type="logical" class="Indication">An effective dose of a subsidised formulation of methylphenidate or dexamphetamine has been trialled and discontinued because of intolerabl
<Request To="HealthPAC" For="Subsidy" Form="SA0928"> <Title> <range>Finasteride</range> </Title> <Case When="Initial application"> <math> <apply> <and/> <ci type="logical" class="Indication">Patient has symptomatic benign prostatic hyperplasia</ci> <apply> <or/> <ci type="logical" class="Indication">The patient is intolerant of non-selective alpha blockers or these are contraindicated</ci> <ci type="logical" class="Indication">Symptoms are not adequately controlled with non-selective alpha blockers</ci> </apply> </apply> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="patient's lifetime"/> </Case> <Note> <Para>Patients with enlarged prostates are the appropriate candidates for therapy with finasteride.</Para> </Note></Request>
<Request To="HealthPAC" For="Subsidy" Form="SA1099"> <Title> <range>Paediatric Product For Children With Chronic Renal Failure<instance>Kindergen</instance></range> </Title> <Case When="Initial application"> <math> <ci type="logical" class="Indication">The patient is a child (up to 18 years) with acute or chronic kidney disease</ci> </math> <Applicant>dietitian</Applicant> <Applicant>relevant specialist</Applicant> <Applicant>vocationally registered general practitioner</Applicant> <Term Measure="year">3</Term> </Case> <Case When="Renewal" Form="SA0606 SA1099"> <math> <apply> <and/> <ci type="logical" class="Indication">The treatment remains appropriate and the patient is benefiting from treatment</ci> <ci type="text" class="Endorsement">General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted</ci> </apply> </mat
<Request To="HealthPAC" For="Subsidy" Form="SA1272"> <Title> <range>Tolterodine</range> </Title> <Case When="Initial application"> <math> <ci type="logical" class="Indication">Patient has overactive bladder and a documented intolerance of, or is non-responsive to oxybutynin</ci> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="patient's lifetime"/> </Case></Request>
<Request To="HealthPAC" For="Subsidy" Form="SA1381"> <Title> <range>Fat Modified Products<instance>Monogen</instance></range> </Title> <Case When="Initial application"> <math> <apply> <or/> <ci type="logical" class="Indication">Patient has metabolic disorders of fat metabolism</ci> <ci type="logical" class="Indication">Patient has a chyle leak</ci> <ci type="logical" class="Indication">Modified as a modular feed for adults</ci> </apply> </math> <Applicant>dietitian</Applicant> <Applicant>relevant specialist</Applicant> <Applicant>vocationally registered general practitioner</Applicant> <Term Measure="year">1</Term> </Case> <Case When="Renewal" Form="SA0593 SA0615 SA1096 SA1381"> <math> <apply> <and/> <ci type="logical" class="Indication">The treatment remains appropriate and the patient is benefiting from treatment</ci> <ci type="text" class="Endorsement">General Practitio
<Request To="HealthPAC" For="Subsidy" Form="SA0782"> <Title> <range>Levonorgestrel &#8211; releasing intrauterine system 20mcg/24 hr</range> </Title> <Case When="Initial application" Category="No previous use"> <math> <apply> <and/> <ci type="logical" class="Indication">The patient has a clinical diagnosis of heavy menstrual bleeding</ci> <ci type="logical" class="Trial">The patient has failed to respond to or is unable to tolerate other appropriate pharmaceutical therapies as per the Heavy Menstrual Bleeding Guidelines</ci> <apply> <or/> <apply> <lt/> <ci type="real" class="test">serum ferritin level</ci> <cn>16<mi> mcg/l (within the last 12 months)</mi></cn> </apply> <apply> <lt/> <ci type="real" class="test">haemoglobin level</ci> <cn>120<mi> g/l</mi></cn> </apply> </apply> </apply> </math>
<Request To="HealthPAC" For="Subsidy" Form="SA1032"> <Title> <range>Tamsulosin</range> </Title> <Case When="Initial application"> <math> <apply> <and/> <ci type="logical" class="Indication">Patient has symptomatic benign prostatic hyperplasia</ci> <ci type="logical" class="Indication">The patient is intolerant of non-selective alpha blockers or these are contraindicated</ci> </apply> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="patient's lifetime"/> </Case></Request>
<Request To="HealthPAC" For="Subsidy" Form="SA0954"> <Title> <range>Acitretin</range> </Title> <Case When="Initial application"> <math> <apply> <and/> <ci type="logical" class="Indication">Applicant is a vocationally registered dermatologist, vocationally registered general practitioner, or nurse practitioner working in a relevant scope of practice</ci> <ci type="logical" class="Indication">Applicant has an up to date knowledge of the treatment options for psoriasis and of disorders of keratinisation and is aware of the safety issues around acitretin and is competent to prescribe acitretin</ci> <apply> <or/> <ci type="logical" class="Indication">Patient is female and has been counselled and understands the risk of teratogenicity if acitretin is used during pregnancy and the applicant has ensured that the possibility of pregnancy has been excluded prior to the commencement of the treatment and that the patient is informed that
<Request To="HealthPAC" For="Subsidy" Form="SA0987"> <Title> <range>Aprepitant</range> </Title> <Case When="Initial application"> <math> <ci type="logical" class="Indication">The patient is undergoing highly emetogenic chemotherapy and/or anthracycline-based chemotherapy for the treatment of malignancy</ci> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="month">12</Term> </Case> <Case When="Renewal" Form="SA0987"> <math> <ci type="logical" class="Indication">The patient is undergoing highly emetogenic chemotherapy and/or anthracycline-based chemotherapy for the treatment of malignancy</ci> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="month">12</Term> </Case></Request>
<Request To="HealthPAC" For="Subsidy" Form="SA1042"> <Title> <range>Deferiprone</range> </Title> <Case When="Initial application"> <math> <ci type="logical" class="Indication">The patient has been diagnosed with chronic transfusional iron overload due to congenital inherited anaemia</ci> </math> <Applicant>relevant specialist</Applicant> <Term Measure="patient's lifetime"/> </Case> <Note> <Para>For the purposes of this Special Authority, a relevant specialist is defined as a haematologist.</Para> </Note></Request>
<Request To="HealthPAC" For="Subsidy" Form="SA1155"> <Title> <range>Budesonide - Cap 3 mg Controlled Release</range> </Title> <Case When="Initial application" Category="Crohn's disease"> <math> <apply> <and/> <ci type="logical" class="Indication">Mild to moderate ileal, ileocaecal or proximal Crohn's disease</ci> <apply> <or/> <ci type="logical" class="Indication">Diabetes</ci> <ci type="logical" class="Indication">Cushingoid habitus</ci> <ci type="logical" class="Indication">Osteoporosis where there is significant risk of fracture</ci> <ci type="logical" class="Indication">Severe acne following treatment with conventional corticosteroid therapy</ci> <ci type="logical" class="Indication">History of severe psychiatric problems associated with corticosteroid treatment</ci> <ci type="logical" class="Indication">History of major mental illness (such as bipolar affective disorder) where
<Request To="HealthPAC" For="Subsidy" Form="SA1421"> <Title> <range>Montelukast</range> </Title> <Case When="Initial application" Category="Pre-school wheeze"> <math> <apply> <and/> <ci type="logical" class="Indication">To be used for the treatment of intermittent severe wheezing (possibly viral) in children under 5 years</ci> <ci type="logical" class="Indication">The patient has had at least three episodes in the previous 12 months of acute wheeze severe enough to seek medical attention</ci> </apply> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="year">1</Term> </Case> <Case When="Renewal" Category="Pre-school wheeze" Form="SA1227 SA1409 SA1421"> <math> <ci type="logical" class="Indication">The treatment remains appropriate and the patient is benefiting from treatment</ci> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="year">2</Term> </Case> <Case
<Request To="PHARMAC" For="Subsidy" Form="SA0973"> <Title> <range>Neurontin</range> </Title> <Case When="Initial application"> <math> <ci type="logical" class="Indication">Subsidy for patients pre-approved on 1 August 2009</ci> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="patient's lifetime"/> </Case> <Note> <Para>Subsidy for patients pre-approved by PHARMAC on 1 August 2009. Approvals valid without further renewal unlessnotified.</Para> <Para>No new approvals will be granted from 1 August 2009.</Para> </Note></Request>
<Request To="HealthPAC" For="Subsidy" Form="SA1196"> <Title> <range>Paediatric enteral feed with fibre 0.75 kcal/ml<instance>Nutrini Low Energy Multi Fibre</instance></range> </Title> <Case When="Initial application"> <math overflow="scroll"> <apply> <and/> <ci type="logical" class="Indication">Child aged one to eight years</ci> <ci type="logical" class="Indication">The child has a low energy requirement but normal protein and micronutrient requirements</ci> </apply> </math> <Applicant>dietitian</Applicant> <Applicant>relevant specialist</Applicant> <Applicant>vocationally registered general practitioner</Applicant> <Term Measure="year">1</Term> </Case> <Case When="Renewal" Form="SA1196"> <math overflow="scroll"> <apply> <and/> <ci type="logical" class="Indication">The treatment remains appropriate and the patient is benefiting from treatment</ci> <ci type="text" class="Endorsement
<Request To="HealthPAC" For="Subsidy" Form="SA1225"> <Title> <range>Ivermectin</range> </Title> <Case When="Initial application" Category="Scabies"> <math> <apply> <and/> <ci type="logical" class="Indication">Applying clinician has discussed the diagnosis of scabies with a dermatologist, infectious disease physician or clinical microbiologist</ci> <apply> <or/> <apply> <and/> <ci type="logical" class="Indication">The patient is in the community</ci> <apply> <or/> <ci type="logical" class="Indication">Patient has a severe scabies hyperinfestation (Crusted/ Norwegian scabies)</ci> <ci type="logical" class="Indication">The community patient is physically or mentally unable to comply with the application instructions of topical therapy</ci> <ci type="logical" class="Indication">The patient has previously tried and failed to clear infestation
<Request To="HealthPAC" For="Subsidy" Form="SA1322"> <Title> <range>Itraconazole</range> </Title> <Case When="Initial application"> <math> <ci type="logical" class="Indication">The patient has a congenital immune deficiency</ci> </math> <Applicant>infectious disease specialist</Applicant> <Applicant>clinical microbiologist</Applicant> <Applicant>clinical immunologist</Applicant> <Applicant Referring="infectious disease physician, clinical microbiologist or clinical immunologist">any relevant practitioner</Applicant> <Term Measure="month">6</Term> </Case> <Case When="Renewal" Form="SA1322"> <math> <ci type="logical" class="Indication">The treatment remains appropriate and the patient is benefitting from the treatment</ci> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="month">6</Term> </Case></Request>
<Request To="HealthPAC" For="Subsidy" Form="SA1223"> <Title> <range>Candesartan</range> </Title> <Case When="Initial application" Category="ACE inhibitor intolerance"> <math> <apply> <or/> <ci type="logical" class="Indication">Patient has persistent ACE inhibitor induced cough that is not resolved by ACE inhibitor retrial (same or new ACE inhibitor)</ci> <ci type="logical" class="Indication">Patient has a history of angioedema</ci> </apply> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="patient's lifetime"/> </Case> <Case When="Initial application" Category="Unsatisfactory response to ACE inhibitor"> <math> <ci type="logical" class="Indication">patient is not adequately controlled on maximum tolerated dose of an ACE inhibitor</ci> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="patient's lifetime"/> </Case></Request>
<Request To="HealthPAC" For="Subsidy" Form="SA0922"> <Title> <range>Erythropoietin</range> </Title> <Case When="Initial application"> <math> <apply> <and/> <apply> <and/> <ci type="logical" class="Indication">patient in chronic renal failure</ci> <apply> <leq/> <ci type="real" class="test">Haemoglobin</ci> <cn>100<mi>g/L</mi></cn> </apply> </apply> <apply> <or/> <apply> <and/> <ci type="logical" class="Indication">patient is not diabetic</ci> <apply> <leq/> <ci type="real" class="test">glomerular filtration rate</ci> <cn>30<mi>ml/min</mi></cn> </apply> </apply> <apply> <and/> <ci type="logical" class="Indication">patient is diabetic</ci> <apply> <leq/> <ci type
<Request To="HealthPAC" For="Subsidy" Form="SA1198"> <Title> <range>Preterm post-discharge infant formula powder<instance>S-26 Gold Premgro</instance></range> </Title> <Case When="Initial application"> <math overflow="scroll"> <apply> <and/> <ci type="logical" class="Indication">The infant was born before 33 weeks gestation or weighed less than 1.5 kg at birth</ci> <apply> <or/> <ci type="logical" class="Indication">The infant has faltering growth (downward crossing of percentiles)</ci> <ci type="logical" class="Indication">The infant is not maintaining, or is considered unlikely to maintain, adequate growth on standard infant formula</ci> </apply> </apply> </math> <Applicant>dietitian</Applicant> <Applicant>relevant specialist</Applicant> <Applicant>vocationally registered general practitioner</Applicant> <Term Measure="month">6</Term> </Case></Request>
<Request To="HealthPAC" For="Subsidy" Form="SA1124"> <Title> <range>Thalidomide</range> </Title> <Case When="Initial application"> <math> <apply> <or/> <ci type="logical" class="indication">The patient has multiple myeloma</ci> <ci type="logical" class="indication">The patient has systemic AL amyloidosis*</ci> </apply> </math> <Applicant>relevant specialist</Applicant> <Applicant Referring="relevant specialist">medical practitioner</Applicant> <Term Measure="month">12</Term> </Case> <Case When="Renewal" Form="SA1124 SA0817 SA0882"> <math> <ci type="logical" class="indication">The patient has obtained a response from treatment during the initial approval period</ci> </math> <Applicant>relevant specialist</Applicant> <Applicant Referring="relevant specialist">medical practitioner</Applicant> <Term Measure="patient's lifetime"/> </Case> <Note> <Para>Prescription must be written by a re
<Request To="HealthPAC" For="Subsidy" Form="SA1321"> <Title> <range>Hydralazine</range> </Title> <Case When="Initial application"> <math> <apply> <or/> <ci type="logical" class="Indication">For the treatment of refractory hypertension</ci> <ci type="logical" class="Indication">For the treatment of heart failure in combination with a nitrate, in patients who are intolerant or have not responded to ACE inhibitors and/or angiotensin receptor blockers</ci> </apply> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="patient's lifetime"/> </Case></Request>
<Request To="HealthPAC" For="Subsidy" Form="SA1260"> <Title> <range>Perhexiline Maleate</range> </Title> <Case When="Initial application"> <math> <apply> <and/> <ci type="logical" class="Indication">Patient has refractory angina</ci> <ci type="logical" class="Trial">Patient is on the maximal tolerated dose of a beta-blocker, a calcium channel blocker and a long acting nitrate</ci> </apply> </math> <Applicant>cardiologist</Applicant> <Applicant>general physician</Applicant> <Term Measure="year">2</Term> </Case> <Case When="Renewal" Form="SA0256 SA1260"> <math> <ci type="logical" class="Indication">The treatment remains appropriate and the patient is benefiting from treatment</ci> </math> <Applicant>cardiologist</Applicant> <Applicant Referring="cardiologist">any relevant practitioner</Applicant> <Term Measure="year">2</Term> </Case></Request>
<Request To="HealthPAC" For="Subsidy" Form="SA1326"> <Title> <range>Primaquine</range> </Title> <Case When="Initial application"> <math> <apply> <and/> <ci type="logical" class="Indication">The patient has vivax or ovale malaria</ci> <ci type="logical" class="Indication">Primaquine is to be given for a maximum of 21 days</ci> </apply> </math> <Applicant>infectious disease specialist</Applicant> <Applicant>clinical microbiologist</Applicant> <Term Measure="month">1</Term> </Case></Request>
<Request To="HealthPAC" For="Subsidy" Form="SA1285"> <Title> <range>Posaconazole </range> </Title> <Case When="Initial application"> <math> <apply> <or/> <ci type="logical" class="Indication">Patient has acute myeloid leukaemia and is to be treated with high dose remission induction, re-induction or consolidation chemotherapy</ci> <ci type="logical" class="Indication">Patient has received a stem cell transplant and has graft versus host disease and is on significant immunosuppressive therapy*</ci> </apply> </math> <Applicant>haematologist</Applicant> <Applicant>infectious disease specialist</Applicant> <Term Measure="week">6</Term> </Case> <Case When="Renewal" Form="SA1285"> <math> <apply> <or/> <ci type="logical" class="Indication">Patient has acute myeloid leukaemia and is to be treated with high dose remission induction, re-induction or consolidation therapy</ci> <ci type="logical" c
<Request To="HealthPAC" For="Subsidy" Form="SA1386"> <Title> <range>Phenobarbitone</range> </Title> <Case When="Initial application"> <math> <apply> <and/> <ci type="logical" class="Indication">For the treatment of terminal agitation that is unresponsive to other agents</ci> <ci type="logical" class="Indication">The applicant is part of a multidisciplinary team working in palliative care</ci> </apply> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="patient's lifetime"/> </Case></Request>
<Request To="HealthPAC" For="Subsidy" Form="SA1293"> <Title> <range>Sildenafil</range> </Title> <Case When="Initial application" Category="Raynaud&#8217;s Phenomenon* - for Pulmonary Arterial Hypertension see note below)"> <math> <apply> <and/> <ci type="logical" class="Indication">Patient has Raynaud&#8217;s Phenomenon*</ci> <ci type="logical" class="Indication">Patient has severe digital ischaemia (defined as severe pain requiring hospital admission or with a high likelihood of digital ulceration; digital ulcers; or gangrene)</ci> <ci type="logical" class="Indication">Patient is following lifestyle management (avoidance of cold exposure, sufficient protection, smoking cessation support, avoidance of sympathomimetic drugs) </ci> <ci type="logical" class="Indication">Patient is being treated with calcium channel blockers and nitrates (or these are contraindicated/not tolerated)</ci> </apply> </math> <Applicant>any relevant
<Request To="HealthPAC" For="Subsidy" Form="SA1061"> <Title> <range>Venlafaxine</range> </Title> <Case When="Initial application"> <math> <apply> <and/> <ci type="logical" class="Indication">The patient has 'treatment-resistant' depression</ci> <apply> <or/> <ci type="logical" class="Trial">The patient must have had a trial of two different antidepressants and have had an inadequate response from an adequate dose over an adequate period of time (usually at least four weeks)</ci> <apply> <and/> <ci type="logical" class="Indication">The patient is currently a hospital in-patient as a result of an acute depressive episode</ci> <ci type="logical" class="Trial">The patient must have had a trial of one other antidepressant and have had an inadequate response from an adequate dose over an adequate period of time</ci> </apply> </apply> </apply> </math> <Appl
<Request To="HealthPAC" For="Subsidy" Form="SA1411"> <Title> <range>Erlotinib</range> </Title> <Case When="Initial application"> <math> <apply> <or/> <apply> <and/> <ci type="logical" class="Indication">Patient has locally advanced or metastatic, unresectable, non-squamous Non Small Cell Lung Cancer (NSCLC)</ci> <ci type="logical" class="Indication">There is documentation confirming that the disease expresses activating mutations of EGFR tyrosine kinase</ci> <apply> <or/> <ci type="logical" class="Indication">Patient is treatment naive</ci> <apply> <and/> <ci type="logical" class="Indication">Patient has documented disease progression following treatment with first line platinum based chemotherapy</ci> <ci type="logical" class="Indication">Patient has not received prior treatment with gefitinib</ci> </apply> </apply>
<Request To="HealthPAC" For="Alternate Subsidy" Form="SA1018"> <Title> <range>Hormone Replacement Therapy - Systemic</range> </Title> <Case When="Initial application"> <math> <apply> <or/> <ci type="logical" class="Indication">acute or significant liver disease - where oral oestrogens are contraindicated as determined by a gastroenterologist or general physician. The applicant must keep written confirmation from such a specialist with the patient's record</ci> <ci type="logical" class="Indication">oestrogen induced hypertension requiring antihypertensive therapy - documented evidence must be kept on file that raised blood pressure levels or inability to control blood pressure adequately occurred post oral oestrogens</ci> <ci type="logical" class="Indication">hypertriglyceridaemia - documented evidence must be kept on file that triglyceride levels increased to at least 2 &#215; normal triglyceride levels post oral oestrogens</ci> <ci type=
<Request To="HealthPAC" For="Subsidy" Form="SA1320"> <Title> <range>Diazoxide</range> </Title> <Case When="Initial application"> <math> <ci type="logical" class="Indication">used for the treatment of confirmed hypoglycaemia caused by hyperinsulinism</ci> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="month">12</Term> </Case> <Case When="Renewal" Form="SA1320"> <math> <ci type="logical" class="Indication">The treatment remains appropriate and the patient is benefiting from treatment</ci> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="patient's lifetime"/> </Case></Request>
<Request To="HealthPAC" For="Subsidy" Form="SA1318"> <Title> <range>Albendazole</range> </Title> <Case When="Initial application"> <math> <ci type="logical" class="Indication">The patient has hydatids</ci> </math> <Applicant>infectious disease specialist</Applicant> <Applicant>clinical microbiologist</Applicant> <Term Measure="month">6</Term> </Case> <Case When="Renewal" Form="SA1318"> <math> <ci type="logical" class="Indication">The treatment remains appropriate and the patient is benefitting from the treatment</ci> </math> <Applicant>infectious disease specialist</Applicant> <Applicant>clinical microbiologist</Applicant> <Term Measure="month">6</Term> </Case></Request>
<Request To="HealthPAC" For="Subsidy" Form="SA1271"> <Title> <range>Minoxidil</range> </Title> <Case When="Initial application"> <math> <ci type="logical" class="Indication">patient has severe refractory hypertension which has failed to respond to extensive multiple therapies</ci> </math> <Applicant>relevant specialist</Applicant> <Term Measure="patient's lifetime"/> </Case></Request>
<Request To="HealthPAC" For="Subsidy" Form="SA1095"> <Title> <range>Diabetic products<instance>Diason RTH</instance><instance>Glucerna Select RTH</instance><instance>Diasip</instance><instance>Glucerna Select</instance><instance>Resource Diabetic</instance></range> </Title> <Case When="Initial application"> <math> <ci type="logical" class="Indication">The patient is a type I or and II diabetic who is suffering weight loss and malnutrition that requires nutritional support</ci> </math> <Applicant>dietitian</Applicant> <Applicant>relevant specialist</Applicant> <Applicant>vocationally registered general practitioner</Applicant> <Term Measure="year">1</Term> </Case> <Case When="Renewal" Form="SA0594 SA1095"> <math> <apply> <and/> <ci type="logical" class="Indication">The treatment remains appropriate and the patient is benefiting from treatment</ci> <ci type="text" class="Endorsement">General Practitioners must includ
<Request To="PHARMAC" For="Manufacturers Price" Form="SA1038"> <Title> <range>Anti-inflammatory Non Steroidal Drugs (NSAIDs)</range> </Title> <Case When="Initial application"> <math> <ci type="logical" class="Indication">Subsidy for patients with existing approvals prior to 1 September 2010</ci> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="patient's lifetime"/> </Case> <Note> <Para>Subsidy for patients with existing approvals prior to 1 September 2010. Approvals valid without further renewal unlessnotified. No new approvals will be granted from 1 September 2010.</Para> </Note></Request>
<Request To="HealthPAC" For="Subsidy" Form="SA1002"> <Title> <range>Vitabdeck</range> </Title> <Case When="Initial application"> <math> <apply> <or/> <ci type="logical" class="Indication">Patient has cystic fibrosis with pancreatic insufficiency</ci> <ci type="logical" class="Indication">Patient is an infant or child with liver disease or short gut syndrome</ci> </apply> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="patient's lifetime"/> </Case></Request>
<Request To="HealthPAC" For="Subsidy" Form="SA1449"> <Title> <range>Adalimumab</range> </Title> <Case When="Initial application" Category="rheumatoid arthritis"> <math> <apply> <or/> <apply> <and/> <ci type="logical" class="Indication">The patient has had an initial Special Authority approval for etanercept for rheumatoid arthritis</ci> <apply> <or/> <ci type="logical" class="Indication">The patient has experienced intolerable side effects from etanercept</ci> <ci type="logical" class="Indication">The patient has received insufficient benefit from etanercept to meet the renewal criteria for etanercept for rheumatoid arthritis</ci> </apply> </apply> <apply> <and/> <ci type="logical" class="Indication">Patient has had severe and active erosive rheumatoid arthritis for six months duration or longer</ci> <ci type="logical" class="Treatmen
<Request To="HealthPAC" For="Subsidy" Form="SA1388"> <Title> <range>Preservative Free Ocular Lubricants</range> </Title> <Case When="Initial application"> <math> <apply> <and/> <ci type="logical" class="Indication">Confirmed diagnosis by slit lamp of severe secretory dry eye</ci> <apply> <or/> <ci type="logical" class="Indication">Patient is using eye drops more than four times daily on a regular basis</ci> <ci type="logical" class="Indication">Patient has had a confirmed allergic reaction to preservative in eye drop</ci> </apply> </apply> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="month">12</Term> </Case> <Case When="Renewal" Form="SA1388"> <math> <ci type="logical" class="Indication">The patient continues to require lubricating eye drops and has benefited from treatment</ci> </math> <Applicant>any relevant practitioner</Applicant>
<Request To="HealthPAC" For="Subsidy" Form="SA1201"> <Title> <range>Prasugrel</range> </Title> <Case When="Initial application" Category="coronary angioplasty and bare metal stent"> <math> <ci type="logical" class="Treatment">The patient has undergone coronary angioplasty in the previous 4 weeks and is clopidogrel-allergic*</ci> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="month">6</Term> </Case> <Case When="Initial application" Category="drug eluting stent"> <math> <ci type="logical" class="Treatment">The patient has had a drug-eluting cardiac stent inserted in the previous 4 weeks and is clopidogrel-allergic*</ci> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="month">12</Term> </Case> <Case When="Initial application" Category="stent thromobosis"> <math> <ci type="logical" class="Treatment">patient has experienced cardiac stent thrombosis whilst on clopidogrel</ci>
<Request To="HealthPAC" For="Subsidy" Form="SA1325"> <Title> <range>Pegaspargase</range> </Title> <Case When="Initial application"> <math> <apply> <and/> <ci type="logical" class="Indication">The patient has newly diagnosed acute lymphoblastic leukaemia</ci> <ci type="logical" class="Indication">Pegaspargase to be used with a contemporary intensive multi-agent chemotherapy treatment protocol</ci> <ci type="logical" class="Indication">Treatment is with curative intent</ci> </apply> </math> <Applicant>relevant specialist</Applicant> <Applicant Referring="relevant specialist">medical practitioner</Applicant> <Term Measure="month">12</Term> </Case> <Case When="Renewal" Form="SA1325"> <math> <apply> <and/> <ci type="logical" class="Indication">The patient has relapsed acute lymphoblastic leukaemia</ci> <ci type="logical" class="Indication">Pegaspargase to be used with a contemporar
<Request To="HealthPAC" For="Alternate Subsidy" Form="SA0500"> <Title><range>Combined oral contraceptives</range><range>Progestogen-only contraceptives</range> (Circle one)</Title> <Case When="Initial application"> <math> <apply> <and/> <apply> <or/> <ci type="logical" class="Target">Patient is on a Social Welfare benefit</ci> <ci type="logical" class="Target">Patient has an income no greater than the benefit</ci> </apply> <ci type="logical" class="Trial">Has tried at least one of the fully funded options and has been unable to tolerate it</ci> </apply> </math> <Applicant>medical practitioner</Applicant> <Term Measure="year">2</Term> </Case> <Case When="Renewal" Form="SA0265 SA0500"> <math> <apply> <or/> <ci type="logical" class="Target">Patient is on a Social Welfare benefit</ci> <ci type="logical" class="Target">Patient has an income no greater than the be
<Request To="HealthPAC" For="Subsidy" Form="SA1374"> <Title> <range>Fat<instance>Calogen</instance><instance>Liquigen</instance><instance>MCT oil (Nutricia)</instance></range> </Title> <Case When="Initial application" Category="Inborn errors of metabolism"> <math> <ci type="logical" class="Indication">The patient has inborn errors of metabolism</ci> </math> <Applicant>dietitian</Applicant> <Applicant>relevant specialist</Applicant> <Applicant>vocationally registered general practitioner</Applicant> <Term Measure="year">3</Term> </Case> <Case When="Initial application" Category="Indications other than inborn errors of metabolism"> <math> <apply> <or/> <ci type="logical" class="Indication">faltering growth in an infant/child</ci> <ci type="logical" class="Indication">bronchopulmonary dysplasia</ci> <ci type="logical" class="Indication">fat malabsorption</ci> <ci type="logical" class="Indication">lym
<Request To="HealthPAC" For="Subsidy" Form="SA1375"> <Title> <range>Protein<instance>Protifar</instance><instance>Promod</instance><instance>Resource Beneprotein</instance></range> </Title> <Case When="Initial application"> <math> <apply> <or/> <ci type="logical" class="Indication">protein losing enteropathy</ci> <ci type="logical" class="Indication">high protein needs</ci> <ci type="logical" class="Indication">for use as a component in a modular formula</ci> </apply> </math> <Applicant>dietitian</Applicant> <Applicant>relevant specialist</Applicant> <Applicant>vocationally registered general practitioner</Applicant> <Term Measure="year">1</Term> </Case> <Case When="Renewal" Form="SA0582 SA1093 SA1375"> <math> <apply> <and/> <ci type="logical" class="Indication">The treatment remains appropriate and the patient is benefiting from treatment</ci> <ci type="text" class="Endor
<Request To="HealthPAC" For="Subsidy" Form="SA1266"> <Title> <range>Sunitinib</range> </Title> <Case When="Initial application" Category="RCC"> <math> <apply> <and/> <ci type="logical" class="Indication">The patient has metastatic renal cell carcinoma</ci> <apply> <or/> <ci type="logical" class="Trial">The patient is treatment naive</ci> <ci type="logical" class="Trial">The patient has only received prior cytokine treatment</ci> <ci type="logical" class="Trial">The patient has only received prior treatment with an investigational agent within the confines of a bona fide clinical trial which has Ethics Committee approval</ci> <apply> <and/> <ci type="logical" class="Trial">The patient has discontinued pazopanib within 3 months of starting treatment due to intolerance</ci> <ci type="logical" class="Trial">The cancer did not progress whilst on pazopanib</ci>
<Request To="HealthPAC" For="Subsidy" Form="SA1273"> <Title> <range>Voriconazole</range> </Title> <Case When="Initial application" Category="invasive fungal infection"> <math> <apply> <and/> <ci type="logical" class="Indication">Patient is immunocompromised</ci> <ci type="logical" class="Indication">Applicant is part of a multidisciplinary team including an infectious disease specialist</ci> <apply> <or/> <ci type="logical" class="Indication">Patient has proven or probable invasive aspergillus infection</ci> <ci type="logical" class="Indication">Patient has possible invasive aspergillus infection</ci> <ci type="logical" class="Indication">Patient has fluconazole resistant candidiasis</ci> <ci type="logical" class="Indication">Patient has mould strain such as Fusarium spp. and Scedosporium spp</ci> </apply> </apply> </math> <Applicant>haematologist</Applicant> <App
<Request To="HealthPAC" For="Subsidy" Form="SA1228"> <Title> <range>Standard Supplements<instance>Ensure</instance><instance>Fortisip</instance><instance>Isosource</instance><instance>Jevity</instance><instance>Nutrison</instance><instance>Osmolite</instance><instance>Sustagen</instance></range> </Title> <Case When="Initial application" Category="Children"> <math> <apply> <and/> <ci type="logical" class="Indication">The patient is under 18 years of age</ci> <apply> <or/> <ci type="logical" class="Indication">The patient has a condition causing malabsorption</ci> <ci type="logical" class="Indication">The patient has failure to thrive</ci> <ci type="logical" class="Indication">The patient has increased nutritional requirements</ci> </apply> <ci type="logical" class="Indication">Nutrition goal has been set (eg reach a specific weight or BMI)</ci> </apply> </math> <Applicant>dietitia
<Request To="HealthPAC" For="Subsidy" Form="SA1046"> <Title> <range>Ezetimibe with Simvastatin<instance>Vytorin</instance></range> </Title> <Case When="Initial application"> <math> <apply> <and/> <ci type="logical" class="Indication">Patient has a calculated absolute risk of cardiovascular disease of at least 15% over 5 year</ci> <ci type="logical" class="Trial">Patient's LDL cholesterol is 2.0 mmol/litre or greater</ci> <ci type="logical" class="Trial">The patient has not reduced their LDL cholesterol to less than 2.0 mmol/litre with the use of the maximal tolerated dose of atorvastatin</ci> </apply> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="year">2</Term> <Note> <Para>A patient who has failed to reduce their LDL cholesterol to &#8804; 2.0 mmol/litre with the use of a less potent statin should use a more potent statin prior to consideration being given to the use of non-statin therapi
<Request To="Cystic Fibrosis Advisory Panel" For="Subsidy" Form="SA0611"> <Title> <range>Dornase Alfa</range> </Title> <Case When="Initial application"> <math> <ci/> </math> <Applicant>medical practitioner</Applicant> <Term Measure="year">1</Term> </Case> <Note> <Para>Application details may be obtained from PHARMAC's website <a href="http://www.pharmac.govt.nz/">http://www.pharmac.govt.nz</a> or:</Para> <Table> <TR> <TD> <Para>The Co-ordinator, Cystic Fibrosis Advisory Panel</Para> </TD> <TD> <Para>Phone: (04) 460 4990</Para> </TD> </TR> <TR> <TD> <Para>PHARMAC, PO Box 10 254</Para> </TD> <TD> <Para>Facsimile: (04) 916 7571</Para> </TD> </TR> <TR> <TD> <Para>Wellington</Para> </TD> <TD> <Para>Email: <a href="mailto:CFPanel@pharmac.govt.nz">CFPanel@pharmac.
<Request To="HealthPAC" For="Subsidy" Form="SA1451"> <Title> <range>Somatropin</range> </Title> <Case When="Initial application" Category="growth hormone deficiency in children"> <math> <apply> <or/> <apply> <and/> <ci type="logical" class="Indication">Growth hormone deficiency causing symptomatic hypoglycaemia, or with other significant growth hormone deficient sequelae (e.g. cardiomyopathy, hepatic dysfunction) and diagnosed with GH &lt; 5 mcg/l on at least two random blood samples in the first 2 weeks of life, or from samples during established hypoglycaemia (whole blood glucose &lt; 2 mmol/l using a laboratory device)</ci> </apply> <apply> <and/> <ci type="logical" class="Indication">Height velocity &lt; 25th percentile for age adjusted for bone age/pubertal status if appropriate over 6 or 12 months using the standards of Tanner and Davies (1985)</ci> <ci type="logical" class="Indication
<Request To="HealthPAC" For="Subsidy" Form="SA1139"> <Title> <range>Teriparatide</range> </Title> <Case When="Initial application"> <math> <apply> <and/> <ci type="logical" class="indication">The patient has severe, established osteoporosis</ci> <ci type="logical" class="indication">The patient has a documented T-score less than or equal to -3.0 (see Notes)</ci> <ci type="logical" class="indication">The patient has had two or more fractures due to minimal trauma</ci> <ci type="logical" class="indication">The patient has experienced at least one symptomatic new fracture after at least 12 months&#8217; continuous therapy with a funded antiresorptive agent at adequate doses (see Notes)</ci> </apply> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="month">18</Term> </Case> <Note> <List Type="Alpha"> <Item> <Para>The bone mineral density (BMD) measurement used to derive the
<Request To="PHARMAC" For="Subsidy" Form="SA1291"> <Title> <range>Optium blood glucose test strips</range> </Title> <Case When="Initial application"> <math> <ci type="logical" class="Indication">Patient identified as eligible for subsidy for FreeStyle Optium blood glucose test strips</ci> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="patient's lifetime"/> </Case> <Note> <Para>Application details may be obtained from PHARMAC's website http://www.pharmac.govt.nz and can be sent to:</Para> <Table> <TR> <TD> <Para>PHARMAC</Para> </TD> <TD> <Para/> </TD> </TR> <TR> <TD> <Para>PO Box 10 254</Para> </TD> <TD> <Para>Facsimile: (04) 974 4788</Para> </TD> </TR> <TR> <TD> <Para>Wellington</Para> </TD> <TD> <Para>Email: <a href="mailto:bgstrip
<Request To="HealthPAC" For="Subsidy" Form="SA1098"> <Title> <range>Paediatric Product For Children Awaiting Liver Transplant<instance>Heparon Junior</instance></range> </Title> <Case When="Initial application"> <math> <ci type="logical" class="Indication">The patient is a child (up to 18 years) who requires a liver transplant</ci> </math> <Applicant>dietitian</Applicant> <Applicant>relevant specialist</Applicant> <Applicant>vocationally registered general practitioner</Applicant> <Term Measure="year">3</Term> </Case> <Case When="Renewal" Form="SA0607 SA1098"> <math> <apply> <and/> <ci type="logical" class="Indication">The treatment remains appropriate and the patient is benefiting from treatment</ci> <ci type="text" class="Endorsement">General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted</ci> </apply> </math
<Request To="HealthPAC" For="Subsidy" Form="SA0845"> <Title> <range>Enfuvirtide</range> </Title> <Case When="Initial application"> <math> <apply> <and/> <ci type="logical" class="Indication">Confirmed HIV infection</ci> <ci type="logical" class="Indication">Enfuvirtide to be given in combination with optimized background therapy (including at least 1 other antiretroviral drug that the patient has never previously been exposed to) for treatment failure</ci> <apply> <or/> <ci type="logical" class="Indication">Patient has evidence of HIV replication, despite ongoing therapy</ci> <ci type="logical" class="Indication">Patient has treatment-limiting toxicity to previous antiretroviral agents</ci> </apply> <ci type="logical" class="Indication">Previous treatment with 3 different antiretroviral regimens has failed</ci> <apply> <and/> <ci type="logical" class="Indication">Prev
<Request To="HealthPAC" For="Subsidy" Form="SA0955"> <Title> <range>Isotretinoin</range> </Title> <Case When="Initial application"> <math> <apply> <and/> <ci type="logical" class="Indication">Patient has had an adequate trial on other available treatments and has received an inadequate response from these treatments or these are contraindicated</ci> <ci type="logical" class="Indication">Applicant is a vocationally registered dermatologist, vocationally registered general practitioner, or nurse practitioner working in a relevant scope of practice</ci> <ci type="logical" class="Indication">Applicant has an up to date knowledge of the treatment options for acne and is aware of the safety issues around isotretinoin and is competent to prescribe isotretinoin</ci> <apply> <or/> <ci type="logical" class="Indication">Patient is female and has been counselled and understands the risk of teratogenicity if isotretinoin is used d
<Request To="HealthPAC" For="Subsidy" Form="SA0994"> <Title> <range>Mirtazapine</range> </Title> <Case When="Initial application"> <math> <apply> <and/> <ci type="logical" class="Indication">The patient has a severe major depressive episode</ci> <apply> <or/> <ci type="logical" class="Trial">The patient must have had a trial of two different antidepressants and was unable to tolerate the treatments or failed to respond to an adequate dose over an adequate period of time (usually at least four weeks)</ci> <apply> <and/> <ci type="logical" class="Indication">The patient is currently a hospital in-patient as a result of an acute depressive episode</ci> <ci type="logical" class="Trial">The patient must have had a trial of one other antidepressant and either could not tolerate it or failed to respond to an adequate dose over an adequate period of time</ci> </apply> </appl
<Request To="HealthPAC" For="Subsidy" Form="SA1404"> <Title> <range>Valganciclovir</range> </Title> <Case When="Initial application" Category="transplant cytomegalovirus prophylaxis"> <math> <ci type="logical" class="Indication">the patient has undergone a solid organ transplant and requires valganciclovir for CMV prophylaxis</ci> </math> <Applicant>relevant specialist</Applicant> <Term Measure="month">3</Term> </Case> <Case When="Renewal" Form="SA1274 SA1404" Category="transplant cytomegalovirus prophylaxis"> <math> <apply> <and/> <ci type="logical" class="Indication">Patient has undergone a solid organ transplant and received anti-thymocyte globulin and requires valganciclovir therapy for CMV prophylaxis</ci> <ci type="logical" class="Indication">Patient is to receive a maximum of 90 days of valganciclovir prophylaxis following anti-thymocyte globulin</ci> </apply> </math> <Applicant>relevant specialist</A
<Request To="HealthPAC" For="Subsidy" Form="SA1138"> <Title> <range>Raloxifene</range> </Title> <Case When="Initial application"> <math> <apply> <or/> <ci type="logical" class="indication">History of one significant osteoporotic fracture demonstrated radiologically and documented bone mineral density (BMD) &#8805;2.5 standard deviations below the mean normal value in young adults (i.e. T-Score &#8804; -2.5) (see Notes)</ci> <ci type="logical" class="indication">History of one significant osteoporotic fracture demonstrated radiologically, and either the patient is elderly, or densitometry scanning cannot be performed because of major logistical, technical or pathophysiological reasons. It is unlikely that this provision would apply to many patients under 75 years of age</ci> <ci type="logical" class="indication">History of two significant osteoporotic fractures demonstrated radiologically</ci> <ci type="logical" class="indication">Documente
<Request To="HealthPAC" For="Subsidy" Form="SA1125"> <Title> <range>Lacosamide</range> </Title> <Case When="Initial application"> <math> <apply> <and/> <ci type="logical" class="Indication">Patient has partial-onset epilepsy</ci> <ci type="logical" class="Trial">Seizures are not adequately controlled by, or patient has experienced unacceptable side effects from, optimal treatment with all of the following: sodium valproate, topiramate, levetiracetam and any two of carbamazepine, lamotrigine and phenytoin sodium (see Note)</ci> </apply> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="month">15</Term> <Note> <Para>"Optimal treatment" is defined as treatment which is indicated and clinically appropriate for the patient, given in adequate doses for the patient's age, weight and other features affecting the pharmacokinetics of the drug with good evidence of compliance. Women of childbearing age are not re
<Request To="HealthPAC" For="Subsidy" Form="SA1376"> <Title> <range>Carbohydrate and Fat<instance>Duocal Super Soluble Powder</instance></range> </Title> <Case When="Initial application" Category="Cystic fibrosis"> <math> <apply> <and/> <ci type="logical" class="Indication">Infant or child aged four years or under</ci> <ci type="logical" class="Indication">cystic fibrosis</ci> </apply> </math> <Applicant>dietitian</Applicant> <Applicant>relevant specialist</Applicant> <Applicant>vocationally registered general practitioner</Applicant> <Term Measure="year">3</Term> </Case> <Case When="Initial application" Category="Indications other than cystic fibrosis"> <math> <apply> <and/> <ci type="logical" class="Indication">infant or child aged four years or under</ci> <apply> <or/> <ci type="logical" class="Indication">cancer in children</ci> <ci type="logica
<Request To="HealthPAC" For="Subsidy" Form="SA0895"> <Title> <range>Pilocarpine &#8211; Eye drops 2% single dose</range> </Title> <Case When="Initial application"> <math> <apply> <or/> <ci type="logical" class="Indication">Patient has to use an unpreserved solution due to an allergy to the preservative</ci> <ci type="logical" class="Indication">Patient wears soft contact lenses</ci> </apply> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="year">2</Term> <Note> <Para>Minims for a general practice are considered to be &#8220;tools of trade&#8221; and are not approved as special authority items.</Para> </Note> </Case> <Case When="Renewal" Form="SA0121 SA0895"> <math> <ci type="logical" class="Indication">The treatment remains appropriate and the patient is benefiting from treatment</ci> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="year">2<
<Request To="HealthPAC" For="Subsidy" Form="SA1072"> <Title> <range>Vigabatrin</range> </Title> <Case When="Initial application"> <math> <apply> <and/> <apply> <or/> <ci type="logical" class="Indication">Patient has infantile spasms</ci> <apply> <and/> <ci type="logical" class="Indication">Patient has epilepsy</ci> <apply> <or/> <ci type="logical" class="Indication">Seizures are not adequately controlled with optimal treatment with other antiepilepsy agents</ci> <ci type="logical" class="Indication">Seizures are controlled adequately but the patient has experienced unacceptable side effects from optimal treatment with other antiepilepsy agents</ci> </apply> </apply> </apply> <apply> <or/> <ci type="logical" class="Indication">Patient is, or will be, receiving regular automated visual fiel
<Request To="HealthPAC" For="Subsidy" Form="SA1408"> <Title> <range>Naltrexone</range> </Title> <Case When="Initial application"> <math> <apply> <and/> <ci type="logical" class="Indication">Patient is currently enrolled in a recognised comprehensive treatment programme for alcohol dependence</ci> <ci type="logical" class="Therapy">Applicant works in or with a community Alcohol and Drug Service contracted to one of the District Health Boards or accredited against the New Zealand Alcohol and Other Drug Sector Standard or the National Mental Health Sector Standard</ci> </apply> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="month">6</Term> </Case> <Case When="Renewal" Form="SA0714 SA0909 SA1397 SA1408"> <math> <apply> <and/> <ci type="logical" class="Indication">Compliance with the medication (prescriber determined)</ci> <apply> <or/> <ci type="log
<Request To="HealthPAC" For="Subsidy" Form="SA1174"> <Title> <range>Enoxaparin sodium</range> </Title> <Case When="Initial application" Category="Pregnancy or Malignancy"> <math> <apply> <or/> <ci type="logical" class="Indication">Low molecular weight heparin treatment is required during a patients pregnancy</ci> <ci type="logical" class="Treatment">For the treatment of venous thromboembolism where the patient has a malignancy</ci> </apply> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="year">1</Term> </Case> <Case When="Initial application" Category="Venous thromboembolism other than in pregnancy or malignancy"> <math> <apply> <or/> <ci type="logical" class="Indication">For the short-term treatment of venous thromboembolism prior to establishing a therapeutic INR with oral anti-coagulant treatment</ci> <ci type="logical" class="Treatment">For the prophylaxis and tre
<Request To="HealthPAC" For="Subsidy" Form="SA1416"> <Title> <range>Atomoxetine</range> </Title> <Case When="Initial application"> <math> <apply> <and/> <ci type="logical" class="Indication">Patient has ADHD (Attention Deficit and Hyperactivity Disorder) diagnosed according to DSM-IV or ICD 10 criteria</ci> <ci type="logical" class="Indication">Once-daily dosing</ci> <apply> <or/> <ci type="logical" class="Indication">Treatment with a subsidised formulation of a stimulant has resulted in the development or worsening of serious adverse reactions or where the combination of subsidised stimulant treatment with another agent would pose an unacceptable medical risk</ci> <ci type="logical" class="Indication">Treatment with a subsidised formulation of a stimulant has resulted in worsening of co-morbid substance abuse or there is a significant risk of diversion with subsidised stimulant therapy</ci> <ci type="log
<Request To="HealthPAC" For="Subsidy" Form="SA1263"> <Title> <range>Nicorandil</range> </Title> <Case When="Initial application"> <math> <apply> <and/> <ci type="logical" class="Indication">Patient has refractory angina</ci> <ci type="logical" class="Trial">Patient is on the maximal tolerated dose of a beta-blocker, a calcium channel blocker and a long acting nitrate</ci> </apply> </math> <Applicant>cardiologist</Applicant> <Applicant>general physician</Applicant> <Term Measure="year">2</Term> </Case> <Case When="Renewal" Form="SA1263"> <math> <ci type="logical" class="Indication">The treatment remains appropriate and the patient is benefiting from treatment</ci> </math> <Applicant>cardiologist</Applicant> <Applicant Referring="cardiologist">any relevant practitioner</Applicant> <Term Measure="year">2</Term> </Case></Request>
<Request To="HealthPAC" For="Subsidy" Form="SA0927"> <Title> <range>Risperidone orally disintegrating tablets</range> </Title> <Case When="Initial application" Category="Acute situations"> <math> <apply> <and/> <ci type="logical" class="Use">For a non-adherent patient on oral therapy with standard risperidone tablets or risperidone oral liquid</ci> <ci type="logical" class="Therapy">The patient is under direct supervision for administration of medicine</ci> </apply> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="week">6</Term> </Case> <Case When="Initial application" Category="Chronic situations"> <math> <apply> <and/> <ci type="logical" class="Indication">The patient is unable to take standard risperidone tablets or oral liquid, or once stabilized refuses to take risperidone tablets or oral liquid</ci> <ci type="logical" class="Therapy">The patient is under direct
<Request To="HealthPAC" For="Subsidy" Form="SA1195"> <Title> <range>High Calorie Products<instance>Two Cal HN</instance><instance>Nutrison Concentrated</instance></range> </Title> <Case When="Initial application" Category="Cystic fibrosis"> <math> <apply> <and/> <ci type="logical" class="Indication">Cystic fibrosis</ci> <ci type="logical" class="Trial">other lower calorie products have been tried</ci> <ci type="logical" class="Indication">patient has substantially increased metabolic requirements</ci> </apply> </math> <Applicant>dietitian</Applicant> <Applicant>relevant specialist</Applicant> <Applicant>vocationally registered general practitioner</Applicant> <Term Measure="year">3</Term> </Case> <Case When="Initial application" Category="Indications other than cystic fibrosis"> <math> <apply> <and/> <apply> <or/> <ci type="logical" class="Indication">any cond
<Request To="HealthPAC" For="Subsidy" Form="SA1199"> <Title> <range>Propylthiouracil</range> </Title> <Case When="Initial application"> <math> <apply> <and/> <ci type="logical" class="Indication">The patient has hyperthyroidism</ci> <ci type="logical" class="Indication">The patient is intolerant of carbimazole or carbimazole is contraindicated</ci> </apply> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="year">2</Term> </Case> <Case When="Renewal" Form="SA1199"> <math> <ci type="logical" class="Indication">the treatment remains appropriate and the patient is benefitting from the treatment</ci> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="year">2</Term> </Case></Request>
<Request To="PHARMAC" For="Subsidy" Form="SA1237"> <Title> <range>Insulin Pumps</range> </Title> <Case When="Initial application"> <math/> <Applicant>medical practitioner</Applicant> <Term Measure="year">1</Term> </Case> <Note> <Para>Application details may be obtained from PHARMAC's website <a href="http://www.pharmac.govt.nz/">http://www.pharmac.govt.nz</a> or:</Para> <Table> <TR> <TD> <Para>The IPP Co-ordinator</Para> </TD> <TD> <Para>Phone: (04) 460 4990</Para> </TD> </TR> <TR> <TD> <Para>PHARMAC</Para> </TD> <TD> <Para>Facsimile: (04) 974 7806</Para> </TD> </TR> <TR> <TD> <Para>PO Box 10 254</Para> </TD> <TD> <Para>Email: <a href="mailto:ipp@pharmac.govt.nz">ipp@pharmac.govt.nz</a></Para> </TD> </TR> <TR> <TD> <Para>Welli
<Request To="HealthPAC" For="Subsidy" Form="SA0829"> <Title> <range>Adefovir dipivoxil</range> </Title> <Case When="Initial application"> <math> <apply> <and/> <ci type="logical" class="Trial">Patient has confirmed Hepatitis B infection (HBsAg+)</ci> <mi class="heading">Documented resistance to lamivudine, defined as:</mi> <ci type="logical" class="Trial">Patient has raised serum ALT (&gt; 1 &#215; ULN)</ci> <ci type="logical" class="Trial">Patient has HBV DNA greater than 100,000 copies per mL, or viral load &#8805; 10 fold over nadir</ci> <ci type="logical" class="Trial">Detection of M204I or M204V mutation</ci> <apply> <or/> <apply> <and/> <ci type="logical" class="Trial">Patient is cirrhotic</ci> <ci type="logical" class="Trial">adefovir dipivoxil to be used in combination with lamivudine</ci> </apply> <apply> <and/>
<Request To="HealthPAC" For="Subsidy" Form="SA0998"> <Title> <range>Solifenacin succinate</range> </Title> <Case When="Initial application"> <math> <ci type="logical" class="Indication">The patient has overactive bladder and a documented intolerance of, or is non-responsive to oxybutynin</ci> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="patient's lifetime"/> </Case></Request>
<Request To="HealthPAC" For="Subsidy" Form="SA1332"> <Title> <range>Tetracycline</range> </Title> <Case When="Initial application"> <math> <apply> <and/> <ci type="logical" class="Indication">For the eradication of helicobacter pylori following unsuccessful treatment with appropriate first-line therapy</ci> <ci type="logical" class="Indication">For use only in combination with bismuth as part of a quadruple therapy regimen</ci> </apply> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="month">3</Term> </Case></Request>
<Request To="HealthPAC" For="Subsidy" Form="SA1379"> <Title> <range>Paediatric Products<instance>Nutrini</instance><instance>Pediasure</instance><instance>Fortini</instance></range> </Title> <Case When="Initial application"> <math> <apply> <and/> <ci type="logical" class="Indication">Child is aged one to ten years</ci> <apply> <or/> <ci type="logical" class="Indication">the child is being fed via a tube or a tube is to be inserted for the purposes of feeding</ci> <ci type="logical" class="Indication">any condition causing malabsorption</ci> <ci type="logical" class="Indication">faltering growth in an infant/child</ci> <ci type="logical" class="Indication">increased nutritional requirements</ci> <ci type="logical" class="Indication">the child is being transitioned from TPN or tube feeding to oral feeding</ci> </apply> </apply> </math> <Applicant>dietitian</Applicant>
<Request To="HealthPAC" For="Subsidy" Form="SA1382"> <Title> <range>Ticagrelor</range> </Title> <Case When="Initial application" Category="acute coronary syndrome"> <math> <apply> <and/> <ci type="logical" class="Indication">Patient has recently been diagnosed with an ST-elevation or a non-ST-elevation acute coronary syndrome</ci> <ci type="logical" class="Indication">Fibrinolytic therapy has not been given in the last 24 hours and is not planned</ci> </apply> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="month">12</Term> </Case> <Case When="Renewal" Category="subsequent acute coronary syndrome" Form="SA1382"> <math> <apply> <and/> <ci type="logical" class="Indication">Patient has recently been diagnosed with an ST-elevation or a non-ST-elevation acute coronary syndrome</ci> <ci type="logical" class="Indication">Fibrinolytic therapy has not been given in the last 24
<Request To="HealthPAC" For="Subsidy" Form="SA1383"> <Title> <range>Ursodeoxycholic Acid</range> </Title> <Case When="Initial application" Category="Alagille syndrome or progressive familial intrahepatic cholestasis"> <math> <apply> <or/> <ci type="logical" class="Indication">Patient has been diagnosed with Alagille syndrome</ci> <ci type="logical" class="Indication">Patient has progressive familial intrahepatic cholestasis</ci> </apply> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="patient's lifetime"/> </Case> <Case When="Initial application" Category="Chronic severe drug induced cholestatic liver injury"> <math> <apply> <and/> <ci type="logical" class="Indication">Patient has chronic severe drug induced cholestatic liver injury</ci> <ci type="logical" class="Indication">Cholestatic liver injury not due to Total Parenteral Nutrition (TPN) use in adults</ci>
<Request To="HealthPAC" For="Subsidy" Form="SA1192"> <Title> <range>Trastuzumab</range> </Title> <Case When="Initial application" Category="metastatic breast cancer"> <math> <apply> <or/> <apply> <and/> <ci type="logical" class="Indication">The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology)</ci> <ci type="logical" class="Treatment">The patient has not previously received lapatinib treatment for HER 2 positive metastatic breast cancer</ci> <ci type="logical" class="Indication">Trastuzumab not to be given in combination with lapatinib</ci> <ci type="logical" class="Treatment">Trastuzumab to be discontinued at disease progression</ci> </apply> <apply> <and/> <ci type="logical" class="Indication">The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology
<Request To="HealthPAC" For="Subsidy" Form="SA1071"> <Title> <range>Gabapentin</range> </Title> <Case When="Initial application" Category="Epilepsy"> <math> <apply> <or/> <ci type="logical" class="Indication">Seizures are not adequately controlled with optimal treatment with other antiepilepsy agents</ci> <ci type="logical" class="Indication">Seizures are controlled adequately but the patient has experienced unacceptable side effects from optimal treatment with other antiepilepsy agents</ci> </apply> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="month">15</Term> <Note> <Para>"Optimal treatment with other antiepilepsy agents" is defined as treatment with other antiepilepsy agents which are indicated and clinically appropriate for the patient, given in adequate doses for the patient's age, weight, and other features affecting the pharmacokinetics of the drug with good evidence of compliance.</Para>
<Request To="HealthPAC" For="Subsidy" Form="SA1066"> <Title> <range>Rivaroxaban</range> </Title> <Case When="Initial application"> <math> <apply> <or/> <ci type="logical" class="Indication">For the prophylaxis of venous thromboembolism following a total hip replacement</ci> <ci type="logical" class="Use">For the prophylaxis of venous thromboembolism following a total knee replacement</ci> </apply> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="week">5</Term> <Note> <Para>Rivaroxaban is only currently indicated and subsidised for up to 5 weeks therapy for prophylaxis of venous thromboembolism following a total hip replacement and up to 2 weeks therapy for prophylaxis of venous thromboembolism following a total knee replacement.</Para> </Note> </Case> <Case When="Renewal" Form="SA1066"> <math> <ci type="logical" class="Indication">Prophylaxis for venous thromboembolism is requir
<Request To="PHARMAC" For="Subsidy" Form="SA1240"> <Title> <range>Insulin pump consumables</range> </Title> <Case When="Initial application"> <math/> <Applicant>medical practitioner</Applicant> <Term Measure="year">1</Term> </Case> <Note> <Para>Application details may be obtained from PHARMAC's website <a href="http://www.pharmac.govt.nz/">http://www.pharmac.govt.nz</a> or:</Para> <Table> <TR> <TD> <Para>The IPP Co-ordinator</Para> </TD> <TD> <Para>Phone: (04) 460 4990</Para> </TD> </TR> <TR> <TD> <Para>PHARMAC</Para> </TD> <TD> <Para>Facsimile: (04) 974 7806</Para> </TD> </TR> <TR> <TD> <Para>PO Box 10 254</Para> </TD> <TD> <Para>Email: <a href="mailto:ipp@pharmac.govt.nz">ipp@pharmac.govt.nz</a></Para> </TD> </TR> <TR> <TD>
<Request To="HealthPAC" For="Subsidy" Form="SA1289"> <Title> <range>Capsaicin</range> </Title> <Case When="Initial application"> <math> <ci type="logical" class="Indication">The patient has osteoarthritis that is not responsive to paracetamol and oral non-steroidal anti-inflammatories are contraindicated</ci> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="patient's lifetime"/> </Case></Request>
<Request To="HealthPAC" For="Subsidy" Form="SA1039"> <Title> <range>Alendronate Tab 70 mg - with or without Cholecalciferol</range> </Title> <Case When="Initial application" Category="Underlying cause -- Osteoporosis"> <math> <apply> <or/> <ci type="logical" class="Indication">History of one significant osteoporotic fracture demonstrated radiologically and documented bone mineral density (BMD) &#8805; 2.5 standard deviations below the mean normal value in young adults (i.e. T-Score &#8804; -2.5) (see Note)</ci> <ci type="logical" class="Indication">History of one significant osteoporotic fracture demonstrated radiologically, and either the patient is elderly, or densitometry scanning cannot be performed because of major logistical, technical or pathophysiological reasons. It is unlikely that this provision would apply to many patients under 75 years of age</ci> <ci type="logical" class="Indication">History of two significant osteoporotic fractures
<Request To="HealthPAC" For="Manufacturers Price" Form="SA1355"> <Title> <range>Minocycline hydrochloride Tab 50 mg</range> </Title> <Case When="Initial application"> <math> <ci type="logical" class="Indication">The patient has rosacea</ci> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="patient's lifetime"/> </Case></Request>
<Request To="HealthPAC" For="Subsidy" Form="SA1324"> <Title> <range>Paromomycin</range> </Title> <Case When="Initial application"> <math> <ci type="logical" class="Indication">the patient has confirmed cryptosporidium infection</ci> </math> <Applicant>infectious disease specialist</Applicant> <Applicant>clinical microbiologist</Applicant> <Term Measure="month">1</Term> </Case> <Case When="Renewal" Form="SA1324"> <math> <ci type="logical" class="Indication">the patient has confirmed cryptosporidium infection</ci> </math> <Applicant>infectious disease specialist</Applicant> <Applicant>clinical microbiologist</Applicant> <Term Measure="month">1</Term> </Case></Request>
<Request To="HealthPAC" For="Subsidy" Form="SA1126"> <Title> <range>Modavigil</range> </Title> <Case When="Initial application"> <math> <apply> <and/> <ci type="logical" class="Indication">The patient has a diagnosis of narcolepsy and has excessive daytime sleepiness associated with narcolepsy occurring almost daily for three months or more</ci> <apply> <or/> <ci type="logical" class="Indication">The patient has a multiple sleep latency test with a mean sleep latency of less than or equal to 10 minutes and 2 or more sleep onset rapid eye movement periods</ci> <ci type="logical" class="Indication">The patient has at least one of: cataplexy, sleep paralysis or hypnagogic hallucinations</ci> </apply> <apply> <or/> <ci type="logical" class="Indication">An effective dose of a subsidised formulation of methylphenidate or dexamphetamine has been trialled and discontinued because of intolerabl
<Request To="HealthPAC" For="Subsidy" Form="SA0928"> <Title> <range>Finasteride</range> </Title> <Case When="Initial application"> <math> <apply> <and/> <ci type="logical" class="Indication">Patient has symptomatic benign prostatic hyperplasia</ci> <apply> <or/> <ci type="logical" class="Indication">The patient is intolerant of non-selective alpha blockers or these are contraindicated</ci> <ci type="logical" class="Indication">Symptoms are not adequately controlled with non-selective alpha blockers</ci> </apply> </apply> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="patient's lifetime"/> </Case> <Note> <Para>Patients with enlarged prostates are the appropriate candidates for therapy with finasteride.</Para> </Note></Request>
<Request To="HealthPAC" For="Subsidy" Form="SA1099"> <Title> <range>Paediatric Product For Children With Chronic Renal Failure<instance>Kindergen</instance></range> </Title> <Case When="Initial application"> <math> <ci type="logical" class="Indication">The patient is a child (up to 18 years) with acute or chronic kidney disease</ci> </math> <Applicant>dietitian</Applicant> <Applicant>relevant specialist</Applicant> <Applicant>vocationally registered general practitioner</Applicant> <Term Measure="year">3</Term> </Case> <Case When="Renewal" Form="SA0606 SA1099"> <math> <apply> <and/> <ci type="logical" class="Indication">The treatment remains appropriate and the patient is benefiting from treatment</ci> <ci type="text" class="Endorsement">General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted</ci> </apply> </mat
<Request To="HealthPAC" For="Subsidy" Form="SA1272"> <Title> <range>Tolterodine</range> </Title> <Case When="Initial application"> <math> <ci type="logical" class="Indication">Patient has overactive bladder and a documented intolerance of, or is non-responsive to oxybutynin</ci> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="patient's lifetime"/> </Case></Request>
<Request To="HealthPAC" For="Subsidy" Form="SA1381"> <Title> <range>Fat Modified Products<instance>Monogen</instance></range> </Title> <Case When="Initial application"> <math> <apply> <or/> <ci type="logical" class="Indication">Patient has metabolic disorders of fat metabolism</ci> <ci type="logical" class="Indication">Patient has a chyle leak</ci> <ci type="logical" class="Indication">Modified as a modular feed for adults</ci> </apply> </math> <Applicant>dietitian</Applicant> <Applicant>relevant specialist</Applicant> <Applicant>vocationally registered general practitioner</Applicant> <Term Measure="year">1</Term> </Case> <Case When="Renewal" Form="SA0593 SA0615 SA1096 SA1381"> <math> <apply> <and/> <ci type="logical" class="Indication">The treatment remains appropriate and the patient is benefiting from treatment</ci> <ci type="text" class="Endorsement">General Practitio
<Request To="HealthPAC" For="Subsidy" Form="SA0782"> <Title> <range>Levonorgestrel &#8211; releasing intrauterine system 20mcg/24 hr</range> </Title> <Case When="Initial application" Category="No previous use"> <math> <apply> <and/> <ci type="logical" class="Indication">The patient has a clinical diagnosis of heavy menstrual bleeding</ci> <ci type="logical" class="Trial">The patient has failed to respond to or is unable to tolerate other appropriate pharmaceutical therapies as per the Heavy Menstrual Bleeding Guidelines</ci> <apply> <or/> <apply> <lt/> <ci type="real" class="test">serum ferritin level</ci> <cn>16<mi> mcg/l (within the last 12 months)</mi></cn> </apply> <apply> <lt/> <ci type="real" class="test">haemoglobin level</ci> <cn>120<mi> g/l</mi></cn> </apply> </apply> </apply> </math>
<Request To="HealthPAC" For="Subsidy" Form="SA1032"> <Title> <range>Tamsulosin</range> </Title> <Case When="Initial application"> <math> <apply> <and/> <ci type="logical" class="Indication">Patient has symptomatic benign prostatic hyperplasia</ci> <ci type="logical" class="Indication">The patient is intolerant of non-selective alpha blockers or these are contraindicated</ci> </apply> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="patient's lifetime"/> </Case></Request>
<Request To="HealthPAC" For="Subsidy" Form="SA0954"> <Title> <range>Acitretin</range> </Title> <Case When="Initial application"> <math> <apply> <and/> <ci type="logical" class="Indication">Applicant is a vocationally registered dermatologist, vocationally registered general practitioner, or nurse practitioner working in a relevant scope of practice</ci> <ci type="logical" class="Indication">Applicant has an up to date knowledge of the treatment options for psoriasis and of disorders of keratinisation and is aware of the safety issues around acitretin and is competent to prescribe acitretin</ci> <apply> <or/> <ci type="logical" class="Indication">Patient is female and has been counselled and understands the risk of teratogenicity if acitretin is used during pregnancy and the applicant has ensured that the possibility of pregnancy has been excluded prior to the commencement of the treatment and that the patient is informed that
<Request To="HealthPAC" For="Subsidy" Form="SA0987"> <Title> <range>Aprepitant</range> </Title> <Case When="Initial application"> <math> <ci type="logical" class="Indication">The patient is undergoing highly emetogenic chemotherapy and/or anthracycline-based chemotherapy for the treatment of malignancy</ci> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="month">12</Term> </Case> <Case When="Renewal" Form="SA0987"> <math> <ci type="logical" class="Indication">The patient is undergoing highly emetogenic chemotherapy and/or anthracycline-based chemotherapy for the treatment of malignancy</ci> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="month">12</Term> </Case></Request>
<Request To="HealthPAC" For="Subsidy" Form="SA1042"> <Title> <range>Deferiprone</range> </Title> <Case When="Initial application"> <math> <ci type="logical" class="Indication">The patient has been diagnosed with chronic transfusional iron overload due to congenital inherited anaemia</ci> </math> <Applicant>relevant specialist</Applicant> <Term Measure="patient's lifetime"/> </Case> <Note> <Para>For the purposes of this Special Authority, a relevant specialist is defined as a haematologist.</Para> </Note></Request>
<Request To="HealthPAC" For="Subsidy" Form="SA1155"> <Title> <range>Budesonide - Cap 3 mg Controlled Release</range> </Title> <Case When="Initial application" Category="Crohn's disease"> <math> <apply> <and/> <ci type="logical" class="Indication">Mild to moderate ileal, ileocaecal or proximal Crohn's disease</ci> <apply> <or/> <ci type="logical" class="Indication">Diabetes</ci> <ci type="logical" class="Indication">Cushingoid habitus</ci> <ci type="logical" class="Indication">Osteoporosis where there is significant risk of fracture</ci> <ci type="logical" class="Indication">Severe acne following treatment with conventional corticosteroid therapy</ci> <ci type="logical" class="Indication">History of severe psychiatric problems associated with corticosteroid treatment</ci> <ci type="logical" class="Indication">History of major mental illness (such as bipolar affective disorder) where
<Request To="HealthPAC" For="Subsidy" Form="SA1421"> <Title> <range>Montelukast</range> </Title> <Case When="Initial application" Category="Pre-school wheeze"> <math> <apply> <and/> <ci type="logical" class="Indication">To be used for the treatment of intermittent severe wheezing (possibly viral) in children under 5 years</ci> <ci type="logical" class="Indication">The patient has had at least three episodes in the previous 12 months of acute wheeze severe enough to seek medical attention</ci> </apply> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="year">1</Term> </Case> <Case When="Renewal" Category="Pre-school wheeze" Form="SA1227 SA1409 SA1421"> <math> <ci type="logical" class="Indication">The treatment remains appropriate and the patient is benefiting from treatment</ci> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="year">2</Term> </Case> <Case
<Request To="PHARMAC" For="Subsidy" Form="SA0973"> <Title> <range>Neurontin</range> </Title> <Case When="Initial application"> <math> <ci type="logical" class="Indication">Subsidy for patients pre-approved on 1 August 2009</ci> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="patient's lifetime"/> </Case> <Note> <Para>Subsidy for patients pre-approved by PHARMAC on 1 August 2009. Approvals valid without further renewal unlessnotified.</Para> <Para>No new approvals will be granted from 1 August 2009.</Para> </Note></Request>
<Request To="HealthPAC" For="Subsidy" Form="SA1196"> <Title> <range>Paediatric enteral feed with fibre 0.75 kcal/ml<instance>Nutrini Low Energy Multi Fibre</instance></range> </Title> <Case When="Initial application"> <math overflow="scroll"> <apply> <and/> <ci type="logical" class="Indication">Child aged one to eight years</ci> <ci type="logical" class="Indication">The child has a low energy requirement but normal protein and micronutrient requirements</ci> </apply> </math> <Applicant>dietitian</Applicant> <Applicant>relevant specialist</Applicant> <Applicant>vocationally registered general practitioner</Applicant> <Term Measure="year">1</Term> </Case> <Case When="Renewal" Form="SA1196"> <math overflow="scroll"> <apply> <and/> <ci type="logical" class="Indication">The treatment remains appropriate and the patient is benefiting from treatment</ci> <ci type="text" class="Endorsement
<Request To="HealthPAC" For="Subsidy" Form="SA1225"> <Title> <range>Ivermectin</range> </Title> <Case When="Initial application" Category="Scabies"> <math> <apply> <and/> <ci type="logical" class="Indication">Applying clinician has discussed the diagnosis of scabies with a dermatologist, infectious disease physician or clinical microbiologist</ci> <apply> <or/> <apply> <and/> <ci type="logical" class="Indication">The patient is in the community</ci> <apply> <or/> <ci type="logical" class="Indication">Patient has a severe scabies hyperinfestation (Crusted/ Norwegian scabies)</ci> <ci type="logical" class="Indication">The community patient is physically or mentally unable to comply with the application instructions of topical therapy</ci> <ci type="logical" class="Indication">The patient has previously tried and failed to clear infestation
<Request To="HealthPAC" For="Subsidy" Form="SA1322"> <Title> <range>Itraconazole</range> </Title> <Case When="Initial application"> <math> <ci type="logical" class="Indication">The patient has a congenital immune deficiency</ci> </math> <Applicant>infectious disease specialist</Applicant> <Applicant>clinical microbiologist</Applicant> <Applicant>clinical immunologist</Applicant> <Applicant Referring="infectious disease physician, clinical microbiologist or clinical immunologist">any relevant practitioner</Applicant> <Term Measure="month">6</Term> </Case> <Case When="Renewal" Form="SA1322"> <math> <ci type="logical" class="Indication">The treatment remains appropriate and the patient is benefitting from the treatment</ci> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="month">6</Term> </Case></Request>
<Request To="HealthPAC" For="Subsidy" Form="SA1223"> <Title> <range>Candesartan</range> </Title> <Case When="Initial application" Category="ACE inhibitor intolerance"> <math> <apply> <or/> <ci type="logical" class="Indication">Patient has persistent ACE inhibitor induced cough that is not resolved by ACE inhibitor retrial (same or new ACE inhibitor)</ci> <ci type="logical" class="Indication">Patient has a history of angioedema</ci> </apply> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="patient's lifetime"/> </Case> <Case When="Initial application" Category="Unsatisfactory response to ACE inhibitor"> <math> <ci type="logical" class="Indication">patient is not adequately controlled on maximum tolerated dose of an ACE inhibitor</ci> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="patient's lifetime"/> </Case></Request>
<Request To="HealthPAC" For="Subsidy" Form="SA0922"> <Title> <range>Erythropoietin</range> </Title> <Case When="Initial application"> <math> <apply> <and/> <apply> <and/> <ci type="logical" class="Indication">patient in chronic renal failure</ci> <apply> <leq/> <ci type="real" class="test">Haemoglobin</ci> <cn>100<mi>g/L</mi></cn> </apply> </apply> <apply> <or/> <apply> <and/> <ci type="logical" class="Indication">patient is not diabetic</ci> <apply> <leq/> <ci type="real" class="test">glomerular filtration rate</ci> <cn>30<mi>ml/min</mi></cn> </apply> </apply> <apply> <and/> <ci type="logical" class="Indication">patient is diabetic</ci> <apply> <leq/> <ci type
<Request To="HealthPAC" For="Subsidy" Form="SA1198"> <Title> <range>Preterm post-discharge infant formula powder<instance>S-26 Gold Premgro</instance></range> </Title> <Case When="Initial application"> <math overflow="scroll"> <apply> <and/> <ci type="logical" class="Indication">The infant was born before 33 weeks gestation or weighed less than 1.5 kg at birth</ci> <apply> <or/> <ci type="logical" class="Indication">The infant has faltering growth (downward crossing of percentiles)</ci> <ci type="logical" class="Indication">The infant is not maintaining, or is considered unlikely to maintain, adequate growth on standard infant formula</ci> </apply> </apply> </math> <Applicant>dietitian</Applicant> <Applicant>relevant specialist</Applicant> <Applicant>vocationally registered general practitioner</Applicant> <Term Measure="month">6</Term> </Case></Request>
<Request To="HealthPAC" For="Subsidy" Form="SA1124"> <Title> <range>Thalidomide</range> </Title> <Case When="Initial application"> <math> <apply> <or/> <ci type="logical" class="indication">The patient has multiple myeloma</ci> <ci type="logical" class="indication">The patient has systemic AL amyloidosis*</ci> </apply> </math> <Applicant>relevant specialist</Applicant> <Applicant Referring="relevant specialist">medical practitioner</Applicant> <Term Measure="month">12</Term> </Case> <Case When="Renewal" Form="SA1124 SA0817 SA0882"> <math> <ci type="logical" class="indication">The patient has obtained a response from treatment during the initial approval period</ci> </math> <Applicant>relevant specialist</Applicant> <Applicant Referring="relevant specialist">medical practitioner</Applicant> <Term Measure="patient's lifetime"/> </Case> <Note> <Para>Prescription must be written by a re
<Request To="HealthPAC" For="Subsidy" Form="SA1321"> <Title> <range>Hydralazine</range> </Title> <Case When="Initial application"> <math> <apply> <or/> <ci type="logical" class="Indication">For the treatment of refractory hypertension</ci> <ci type="logical" class="Indication">For the treatment of heart failure in combination with a nitrate, in patients who are intolerant or have not responded to ACE inhibitors and/or angiotensin receptor blockers</ci> </apply> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="patient's lifetime"/> </Case></Request>
<Request To="HealthPAC" For="Subsidy" Form="SA1260"> <Title> <range>Perhexiline Maleate</range> </Title> <Case When="Initial application"> <math> <apply> <and/> <ci type="logical" class="Indication">Patient has refractory angina</ci> <ci type="logical" class="Trial">Patient is on the maximal tolerated dose of a beta-blocker, a calcium channel blocker and a long acting nitrate</ci> </apply> </math> <Applicant>cardiologist</Applicant> <Applicant>general physician</Applicant> <Term Measure="year">2</Term> </Case> <Case When="Renewal" Form="SA0256 SA1260"> <math> <ci type="logical" class="Indication">The treatment remains appropriate and the patient is benefiting from treatment</ci> </math> <Applicant>cardiologist</Applicant> <Applicant Referring="cardiologist">any relevant practitioner</Applicant> <Term Measure="year">2</Term> </Case></Request>
<Request To="HealthPAC" For="Subsidy" Form="SA1326"> <Title> <range>Primaquine</range> </Title> <Case When="Initial application"> <math> <apply> <and/> <ci type="logical" class="Indication">The patient has vivax or ovale malaria</ci> <ci type="logical" class="Indication">Primaquine is to be given for a maximum of 21 days</ci> </apply> </math> <Applicant>infectious disease specialist</Applicant> <Applicant>clinical microbiologist</Applicant> <Term Measure="month">1</Term> </Case></Request>
<Request To="HealthPAC" For="Subsidy" Form="SA1285"> <Title> <range>Posaconazole </range> </Title> <Case When="Initial application"> <math> <apply> <or/> <ci type="logical" class="Indication">Patient has acute myeloid leukaemia and is to be treated with high dose remission induction, re-induction or consolidation chemotherapy</ci> <ci type="logical" class="Indication">Patient has received a stem cell transplant and has graft versus host disease and is on significant immunosuppressive therapy*</ci> </apply> </math> <Applicant>haematologist</Applicant> <Applicant>infectious disease specialist</Applicant> <Term Measure="week">6</Term> </Case> <Case When="Renewal" Form="SA1285"> <math> <apply> <or/> <ci type="logical" class="Indication">Patient has acute myeloid leukaemia and is to be treated with high dose remission induction, re-induction or consolidation therapy</ci> <ci type="logical" c
<Request To="HealthPAC" For="Subsidy" Form="SA1386"> <Title> <range>Phenobarbitone</range> </Title> <Case When="Initial application"> <math> <apply> <and/> <ci type="logical" class="Indication">For the treatment of terminal agitation that is unresponsive to other agents</ci> <ci type="logical" class="Indication">The applicant is part of a multidisciplinary team working in palliative care</ci> </apply> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="patient's lifetime"/> </Case></Request>
<Request To="HealthPAC" For="Subsidy" Form="SA1293"> <Title> <range>Sildenafil</range> </Title> <Case When="Initial application" Category="Raynaud&#8217;s Phenomenon* - for Pulmonary Arterial Hypertension see note below)"> <math> <apply> <and/> <ci type="logical" class="Indication">Patient has Raynaud&#8217;s Phenomenon*</ci> <ci type="logical" class="Indication">Patient has severe digital ischaemia (defined as severe pain requiring hospital admission or with a high likelihood of digital ulceration; digital ulcers; or gangrene)</ci> <ci type="logical" class="Indication">Patient is following lifestyle management (avoidance of cold exposure, sufficient protection, smoking cessation support, avoidance of sympathomimetic drugs) </ci> <ci type="logical" class="Indication">Patient is being treated with calcium channel blockers and nitrates (or these are contraindicated/not tolerated)</ci> </apply> </math> <Applicant>any relevant
<Request To="HealthPAC" For="Subsidy" Form="SA1061"> <Title> <range>Venlafaxine</range> </Title> <Case When="Initial application"> <math> <apply> <and/> <ci type="logical" class="Indication">The patient has 'treatment-resistant' depression</ci> <apply> <or/> <ci type="logical" class="Trial">The patient must have had a trial of two different antidepressants and have had an inadequate response from an adequate dose over an adequate period of time (usually at least four weeks)</ci> <apply> <and/> <ci type="logical" class="Indication">The patient is currently a hospital in-patient as a result of an acute depressive episode</ci> <ci type="logical" class="Trial">The patient must have had a trial of one other antidepressant and have had an inadequate response from an adequate dose over an adequate period of time</ci> </apply> </apply> </apply> </math> <Appl
<Request To="HealthPAC" For="Subsidy" Form="SA1411"> <Title> <range>Erlotinib</range> </Title> <Case When="Initial application"> <math> <apply> <or/> <apply> <and/> <ci type="logical" class="Indication">Patient has locally advanced or metastatic, unresectable, non-squamous Non Small Cell Lung Cancer (NSCLC)</ci> <ci type="logical" class="Indication">There is documentation confirming that the disease expresses activating mutations of EGFR tyrosine kinase</ci> <apply> <or/> <ci type="logical" class="Indication">Patient is treatment naive</ci> <apply> <and/> <ci type="logical" class="Indication">Patient has documented disease progression following treatment with first line platinum based chemotherapy</ci> <ci type="logical" class="Indication">Patient has not received prior treatment with gefitinib</ci> </apply> </apply>
<Request To="HealthPAC" For="Alternate Subsidy" Form="SA1018"> <Title> <range>Hormone Replacement Therapy - Systemic</range> </Title> <Case When="Initial application"> <math> <apply> <or/> <ci type="logical" class="Indication">acute or significant liver disease - where oral oestrogens are contraindicated as determined by a gastroenterologist or general physician. The applicant must keep written confirmation from such a specialist with the patient's record</ci> <ci type="logical" class="Indication">oestrogen induced hypertension requiring antihypertensive therapy - documented evidence must be kept on file that raised blood pressure levels or inability to control blood pressure adequately occurred post oral oestrogens</ci> <ci type="logical" class="Indication">hypertriglyceridaemia - documented evidence must be kept on file that triglyceride levels increased to at least 2 &#215; normal triglyceride levels post oral oestrogens</ci> <ci type=
<Request To="HealthPAC" For="Subsidy" Form="SA1320"> <Title> <range>Diazoxide</range> </Title> <Case When="Initial application"> <math> <ci type="logical" class="Indication">used for the treatment of confirmed hypoglycaemia caused by hyperinsulinism</ci> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="month">12</Term> </Case> <Case When="Renewal" Form="SA1320"> <math> <ci type="logical" class="Indication">The treatment remains appropriate and the patient is benefiting from treatment</ci> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="patient's lifetime"/> </Case></Request>
<Request To="HealthPAC" For="Subsidy" Form="SA1318"> <Title> <range>Albendazole</range> </Title> <Case When="Initial application"> <math> <ci type="logical" class="Indication">The patient has hydatids</ci> </math> <Applicant>infectious disease specialist</Applicant> <Applicant>clinical microbiologist</Applicant> <Term Measure="month">6</Term> </Case> <Case When="Renewal" Form="SA1318"> <math> <ci type="logical" class="Indication">The treatment remains appropriate and the patient is benefitting from the treatment</ci> </math> <Applicant>infectious disease specialist</Applicant> <Applicant>clinical microbiologist</Applicant> <Term Measure="month">6</Term> </Case></Request>
<Request To="HealthPAC" For="Subsidy" Form="SA1271"> <Title> <range>Minoxidil</range> </Title> <Case When="Initial application"> <math> <ci type="logical" class="Indication">patient has severe refractory hypertension which has failed to respond to extensive multiple therapies</ci> </math> <Applicant>relevant specialist</Applicant> <Term Measure="patient's lifetime"/> </Case></Request>
<Request To="HealthPAC" For="Subsidy" Form="SA1095"> <Title> <range>Diabetic products<instance>Diason RTH</instance><instance>Glucerna Select RTH</instance><instance>Diasip</instance><instance>Glucerna Select</instance><instance>Resource Diabetic</instance></range> </Title> <Case When="Initial application"> <math> <ci type="logical" class="Indication">The patient is a type I or and II diabetic who is suffering weight loss and malnutrition that requires nutritional support</ci> </math> <Applicant>dietitian</Applicant> <Applicant>relevant specialist</Applicant> <Applicant>vocationally registered general practitioner</Applicant> <Term Measure="year">1</Term> </Case> <Case When="Renewal" Form="SA0594 SA1095"> <math> <apply> <and/> <ci type="logical" class="Indication">The treatment remains appropriate and the patient is benefiting from treatment</ci> <ci type="text" class="Endorsement">General Practitioners must includ
<Request To="PHARMAC" For="Manufacturers Price" Form="SA1038"> <Title> <range>Anti-inflammatory Non Steroidal Drugs (NSAIDs)</range> </Title> <Case When="Initial application"> <math> <ci type="logical" class="Indication">Subsidy for patients with existing approvals prior to 1 September 2010</ci> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="patient's lifetime"/> </Case> <Note> <Para>Subsidy for patients with existing approvals prior to 1 September 2010. Approvals valid without further renewal unlessnotified. No new approvals will be granted from 1 September 2010.</Para> </Note></Request>
<Request To="HealthPAC" For="Subsidy" Form="SA1002"> <Title> <range>Vitabdeck</range> </Title> <Case When="Initial application"> <math> <apply> <or/> <ci type="logical" class="Indication">Patient has cystic fibrosis with pancreatic insufficiency</ci> <ci type="logical" class="Indication">Patient is an infant or child with liver disease or short gut syndrome</ci> </apply> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="patient's lifetime"/> </Case></Request>
<Request To="HealthPAC" For="Subsidy" Form="SA1449"> <Title> <range>Adalimumab</range> </Title> <Case When="Initial application" Category="rheumatoid arthritis"> <math> <apply> <or/> <apply> <and/> <ci type="logical" class="Indication">The patient has had an initial Special Authority approval for etanercept for rheumatoid arthritis</ci> <apply> <or/> <ci type="logical" class="Indication">The patient has experienced intolerable side effects from etanercept</ci> <ci type="logical" class="Indication">The patient has received insufficient benefit from etanercept to meet the renewal criteria for etanercept for rheumatoid arthritis</ci> </apply> </apply> <apply> <and/> <ci type="logical" class="Indication">Patient has had severe and active erosive rheumatoid arthritis for six months duration or longer</ci> <ci type="logical" class="Treatmen
<Request To="HealthPAC" For="Subsidy" Form="SA1388"> <Title> <range>Preservative Free Ocular Lubricants</range> </Title> <Case When="Initial application"> <math> <apply> <and/> <ci type="logical" class="Indication">Confirmed diagnosis by slit lamp of severe secretory dry eye</ci> <apply> <or/> <ci type="logical" class="Indication">Patient is using eye drops more than four times daily on a regular basis</ci> <ci type="logical" class="Indication">Patient has had a confirmed allergic reaction to preservative in eye drop</ci> </apply> </apply> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="month">12</Term> </Case> <Case When="Renewal" Form="SA1388"> <math> <ci type="logical" class="Indication">The patient continues to require lubricating eye drops and has benefited from treatment</ci> </math> <Applicant>any relevant practitioner</Applicant>
<Request To="HealthPAC" For="Subsidy" Form="SA1201"> <Title> <range>Prasugrel</range> </Title> <Case When="Initial application" Category="coronary angioplasty and bare metal stent"> <math> <ci type="logical" class="Treatment">The patient has undergone coronary angioplasty in the previous 4 weeks and is clopidogrel-allergic*</ci> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="month">6</Term> </Case> <Case When="Initial application" Category="drug eluting stent"> <math> <ci type="logical" class="Treatment">The patient has had a drug-eluting cardiac stent inserted in the previous 4 weeks and is clopidogrel-allergic*</ci> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="month">12</Term> </Case> <Case When="Initial application" Category="stent thromobosis"> <math> <ci type="logical" class="Treatment">patient has experienced cardiac stent thrombosis whilst on clopidogrel</ci>
<Request To="HealthPAC" For="Subsidy" Form="SA1325"> <Title> <range>Pegaspargase</range> </Title> <Case When="Initial application"> <math> <apply> <and/> <ci type="logical" class="Indication">The patient has newly diagnosed acute lymphoblastic leukaemia</ci> <ci type="logical" class="Indication">Pegaspargase to be used with a contemporary intensive multi-agent chemotherapy treatment protocol</ci> <ci type="logical" class="Indication">Treatment is with curative intent</ci> </apply> </math> <Applicant>relevant specialist</Applicant> <Applicant Referring="relevant specialist">medical practitioner</Applicant> <Term Measure="month">12</Term> </Case> <Case When="Renewal" Form="SA1325"> <math> <apply> <and/> <ci type="logical" class="Indication">The patient has relapsed acute lymphoblastic leukaemia</ci> <ci type="logical" class="Indication">Pegaspargase to be used with a contemporar
<Request To="HealthPAC" For="Alternate Subsidy" Form="SA0500"> <Title><range>Combined oral contraceptives</range><range>Progestogen-only contraceptives</range> (Circle one)</Title> <Case When="Initial application"> <math> <apply> <and/> <apply> <or/> <ci type="logical" class="Target">Patient is on a Social Welfare benefit</ci> <ci type="logical" class="Target">Patient has an income no greater than the benefit</ci> </apply> <ci type="logical" class="Trial">Has tried at least one of the fully funded options and has been unable to tolerate it</ci> </apply> </math> <Applicant>medical practitioner</Applicant> <Term Measure="year">2</Term> </Case> <Case When="Renewal" Form="SA0265 SA0500"> <math> <apply> <or/> <ci type="logical" class="Target">Patient is on a Social Welfare benefit</ci> <ci type="logical" class="Target">Patient has an income no greater than the be
<Request To="HealthPAC" For="Subsidy" Form="SA1374"> <Title> <range>Fat<instance>Calogen</instance><instance>Liquigen</instance><instance>MCT oil (Nutricia)</instance></range> </Title> <Case When="Initial application" Category="Inborn errors of metabolism"> <math> <ci type="logical" class="Indication">The patient has inborn errors of metabolism</ci> </math> <Applicant>dietitian</Applicant> <Applicant>relevant specialist</Applicant> <Applicant>vocationally registered general practitioner</Applicant> <Term Measure="year">3</Term> </Case> <Case When="Initial application" Category="Indications other than inborn errors of metabolism"> <math> <apply> <or/> <ci type="logical" class="Indication">faltering growth in an infant/child</ci> <ci type="logical" class="Indication">bronchopulmonary dysplasia</ci> <ci type="logical" class="Indication">fat malabsorption</ci> <ci type="logical" class="Indication">lym
<Request To="HealthPAC" For="Subsidy" Form="SA1375"> <Title> <range>Protein<instance>Protifar</instance><instance>Promod</instance><instance>Resource Beneprotein</instance></range> </Title> <Case When="Initial application"> <math> <apply> <or/> <ci type="logical" class="Indication">protein losing enteropathy</ci> <ci type="logical" class="Indication">high protein needs</ci> <ci type="logical" class="Indication">for use as a component in a modular formula</ci> </apply> </math> <Applicant>dietitian</Applicant> <Applicant>relevant specialist</Applicant> <Applicant>vocationally registered general practitioner</Applicant> <Term Measure="year">1</Term> </Case> <Case When="Renewal" Form="SA0582 SA1093 SA1375"> <math> <apply> <and/> <ci type="logical" class="Indication">The treatment remains appropriate and the patient is benefiting from treatment</ci> <ci type="text" class="Endor
<Request To="HealthPAC" For="Subsidy" Form="SA1266"> <Title> <range>Sunitinib</range> </Title> <Case When="Initial application" Category="RCC"> <math> <apply> <and/> <ci type="logical" class="Indication">The patient has metastatic renal cell carcinoma</ci> <apply> <or/> <ci type="logical" class="Trial">The patient is treatment naive</ci> <ci type="logical" class="Trial">The patient has only received prior cytokine treatment</ci> <ci type="logical" class="Trial">The patient has only received prior treatment with an investigational agent within the confines of a bona fide clinical trial which has Ethics Committee approval</ci> <apply> <and/> <ci type="logical" class="Trial">The patient has discontinued pazopanib within 3 months of starting treatment due to intolerance</ci> <ci type="logical" class="Trial">The cancer did not progress whilst on pazopanib</ci>
<Request To="HealthPAC" For="Subsidy" Form="SA1273"> <Title> <range>Voriconazole</range> </Title> <Case When="Initial application" Category="invasive fungal infection"> <math> <apply> <and/> <ci type="logical" class="Indication">Patient is immunocompromised</ci> <ci type="logical" class="Indication">Applicant is part of a multidisciplinary team including an infectious disease specialist</ci> <apply> <or/> <ci type="logical" class="Indication">Patient has proven or probable invasive aspergillus infection</ci> <ci type="logical" class="Indication">Patient has possible invasive aspergillus infection</ci> <ci type="logical" class="Indication">Patient has fluconazole resistant candidiasis</ci> <ci type="logical" class="Indication">Patient has mould strain such as Fusarium spp. and Scedosporium spp</ci> </apply> </apply> </math> <Applicant>haematologist</Applicant> <App
<Request To="HealthPAC" For="Subsidy" Form="SA1228"> <Title> <range>Standard Supplements<instance>Ensure</instance><instance>Fortisip</instance><instance>Isosource</instance><instance>Jevity</instance><instance>Nutrison</instance><instance>Osmolite</instance><instance>Sustagen</instance></range> </Title> <Case When="Initial application" Category="Children"> <math> <apply> <and/> <ci type="logical" class="Indication">The patient is under 18 years of age</ci> <apply> <or/> <ci type="logical" class="Indication">The patient has a condition causing malabsorption</ci> <ci type="logical" class="Indication">The patient has failure to thrive</ci> <ci type="logical" class="Indication">The patient has increased nutritional requirements</ci> </apply> <ci type="logical" class="Indication">Nutrition goal has been set (eg reach a specific weight or BMI)</ci> </apply> </math> <Applicant>dietitia
<Request To="HealthPAC" For="Subsidy" Form="SA1046"> <Title> <range>Ezetimibe with Simvastatin<instance>Vytorin</instance></range> </Title> <Case When="Initial application"> <math> <apply> <and/> <ci type="logical" class="Indication">Patient has a calculated absolute risk of cardiovascular disease of at least 15% over 5 year</ci> <ci type="logical" class="Trial">Patient's LDL cholesterol is 2.0 mmol/litre or greater</ci> <ci type="logical" class="Trial">The patient has not reduced their LDL cholesterol to less than 2.0 mmol/litre with the use of the maximal tolerated dose of atorvastatin</ci> </apply> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="year">2</Term> <Note> <Para>A patient who has failed to reduce their LDL cholesterol to &#8804; 2.0 mmol/litre with the use of a less potent statin should use a more potent statin prior to consideration being given to the use of non-statin therapi
<Request To="Cystic Fibrosis Advisory Panel" For="Subsidy" Form="SA0611"> <Title> <range>Dornase Alfa</range> </Title> <Case When="Initial application"> <math> <ci/> </math> <Applicant>medical practitioner</Applicant> <Term Measure="year">1</Term> </Case> <Note> <Para>Application details may be obtained from PHARMAC's website <a href="http://www.pharmac.govt.nz/">http://www.pharmac.govt.nz</a> or:</Para> <Table> <TR> <TD> <Para>The Co-ordinator, Cystic Fibrosis Advisory Panel</Para> </TD> <TD> <Para>Phone: (04) 460 4990</Para> </TD> </TR> <TR> <TD> <Para>PHARMAC, PO Box 10 254</Para> </TD> <TD> <Para>Facsimile: (04) 916 7571</Para> </TD> </TR> <TR> <TD> <Para>Wellington</Para> </TD> <TD> <Para>Email: <a href="mailto:CFPanel@pharmac.govt.nz">CFPanel@pharmac.
<Request To="HealthPAC" For="Subsidy" Form="SA1451"> <Title> <range>Somatropin</range> </Title> <Case When="Initial application" Category="growth hormone deficiency in children"> <math> <apply> <or/> <apply> <and/> <ci type="logical" class="Indication">Growth hormone deficiency causing symptomatic hypoglycaemia, or with other significant growth hormone deficient sequelae (e.g. cardiomyopathy, hepatic dysfunction) and diagnosed with GH &lt; 5 mcg/l on at least two random blood samples in the first 2 weeks of life, or from samples during established hypoglycaemia (whole blood glucose &lt; 2 mmol/l using a laboratory device)</ci> </apply> <apply> <and/> <ci type="logical" class="Indication">Height velocity &lt; 25th percentile for age adjusted for bone age/pubertal status if appropriate over 6 or 12 months using the standards of Tanner and Davies (1985)</ci> <ci type="logical" class="Indication
<Request To="HealthPAC" For="Subsidy" Form="SA1139"> <Title> <range>Teriparatide</range> </Title> <Case When="Initial application"> <math> <apply> <and/> <ci type="logical" class="indication">The patient has severe, established osteoporosis</ci> <ci type="logical" class="indication">The patient has a documented T-score less than or equal to -3.0 (see Notes)</ci> <ci type="logical" class="indication">The patient has had two or more fractures due to minimal trauma</ci> <ci type="logical" class="indication">The patient has experienced at least one symptomatic new fracture after at least 12 months&#8217; continuous therapy with a funded antiresorptive agent at adequate doses (see Notes)</ci> </apply> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="month">18</Term> </Case> <Note> <List Type="Alpha"> <Item> <Para>The bone mineral density (BMD) measurement used to derive the
<Request To="PHARMAC" For="Subsidy" Form="SA1291"> <Title> <range>Optium blood glucose test strips</range> </Title> <Case When="Initial application"> <math> <ci type="logical" class="Indication">Patient identified as eligible for subsidy for FreeStyle Optium blood glucose test strips</ci> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="patient's lifetime"/> </Case> <Note> <Para>Application details may be obtained from PHARMAC's website http://www.pharmac.govt.nz and can be sent to:</Para> <Table> <TR> <TD> <Para>PHARMAC</Para> </TD> <TD> <Para/> </TD> </TR> <TR> <TD> <Para>PO Box 10 254</Para> </TD> <TD> <Para>Facsimile: (04) 974 4788</Para> </TD> </TR> <TR> <TD> <Para>Wellington</Para> </TD> <TD> <Para>Email: <a href="mailto:bgstrip
<Request To="HealthPAC" For="Subsidy" Form="SA1098"> <Title> <range>Paediatric Product For Children Awaiting Liver Transplant<instance>Heparon Junior</instance></range> </Title> <Case When="Initial application"> <math> <ci type="logical" class="Indication">The patient is a child (up to 18 years) who requires a liver transplant</ci> </math> <Applicant>dietitian</Applicant> <Applicant>relevant specialist</Applicant> <Applicant>vocationally registered general practitioner</Applicant> <Term Measure="year">3</Term> </Case> <Case When="Renewal" Form="SA0607 SA1098"> <math> <apply> <and/> <ci type="logical" class="Indication">The treatment remains appropriate and the patient is benefiting from treatment</ci> <ci type="text" class="Endorsement">General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted</ci> </apply> </math
<Request To="HealthPAC" For="Subsidy" Form="SA0845"> <Title> <range>Enfuvirtide</range> </Title> <Case When="Initial application"> <math> <apply> <and/> <ci type="logical" class="Indication">Confirmed HIV infection</ci> <ci type="logical" class="Indication">Enfuvirtide to be given in combination with optimized background therapy (including at least 1 other antiretroviral drug that the patient has never previously been exposed to) for treatment failure</ci> <apply> <or/> <ci type="logical" class="Indication">Patient has evidence of HIV replication, despite ongoing therapy</ci> <ci type="logical" class="Indication">Patient has treatment-limiting toxicity to previous antiretroviral agents</ci> </apply> <ci type="logical" class="Indication">Previous treatment with 3 different antiretroviral regimens has failed</ci> <apply> <and/> <ci type="logical" class="Indication">Prev
<Request To="HealthPAC" For="Subsidy" Form="SA0955"> <Title> <range>Isotretinoin</range> </Title> <Case When="Initial application"> <math> <apply> <and/> <ci type="logical" class="Indication">Patient has had an adequate trial on other available treatments and has received an inadequate response from these treatments or these are contraindicated</ci> <ci type="logical" class="Indication">Applicant is a vocationally registered dermatologist, vocationally registered general practitioner, or nurse practitioner working in a relevant scope of practice</ci> <ci type="logical" class="Indication">Applicant has an up to date knowledge of the treatment options for acne and is aware of the safety issues around isotretinoin and is competent to prescribe isotretinoin</ci> <apply> <or/> <ci type="logical" class="Indication">Patient is female and has been counselled and understands the risk of teratogenicity if isotretinoin is used d
<Request To="HealthPAC" For="Subsidy" Form="SA0994"> <Title> <range>Mirtazapine</range> </Title> <Case When="Initial application"> <math> <apply> <and/> <ci type="logical" class="Indication">The patient has a severe major depressive episode</ci> <apply> <or/> <ci type="logical" class="Trial">The patient must have had a trial of two different antidepressants and was unable to tolerate the treatments or failed to respond to an adequate dose over an adequate period of time (usually at least four weeks)</ci> <apply> <and/> <ci type="logical" class="Indication">The patient is currently a hospital in-patient as a result of an acute depressive episode</ci> <ci type="logical" class="Trial">The patient must have had a trial of one other antidepressant and either could not tolerate it or failed to respond to an adequate dose over an adequate period of time</ci> </apply> </appl
<Request To="HealthPAC" For="Subsidy" Form="SA1404"> <Title> <range>Valganciclovir</range> </Title> <Case When="Initial application" Category="transplant cytomegalovirus prophylaxis"> <math> <ci type="logical" class="Indication">the patient has undergone a solid organ transplant and requires valganciclovir for CMV prophylaxis</ci> </math> <Applicant>relevant specialist</Applicant> <Term Measure="month">3</Term> </Case> <Case When="Renewal" Form="SA1274 SA1404" Category="transplant cytomegalovirus prophylaxis"> <math> <apply> <and/> <ci type="logical" class="Indication">Patient has undergone a solid organ transplant and received anti-thymocyte globulin and requires valganciclovir therapy for CMV prophylaxis</ci> <ci type="logical" class="Indication">Patient is to receive a maximum of 90 days of valganciclovir prophylaxis following anti-thymocyte globulin</ci> </apply> </math> <Applicant>relevant specialist</A
<Request To="HealthPAC" For="Subsidy" Form="SA1138"> <Title> <range>Raloxifene</range> </Title> <Case When="Initial application"> <math> <apply> <or/> <ci type="logical" class="indication">History of one significant osteoporotic fracture demonstrated radiologically and documented bone mineral density (BMD) &#8805;2.5 standard deviations below the mean normal value in young adults (i.e. T-Score &#8804; -2.5) (see Notes)</ci> <ci type="logical" class="indication">History of one significant osteoporotic fracture demonstrated radiologically, and either the patient is elderly, or densitometry scanning cannot be performed because of major logistical, technical or pathophysiological reasons. It is unlikely that this provision would apply to many patients under 75 years of age</ci> <ci type="logical" class="indication">History of two significant osteoporotic fractures demonstrated radiologically</ci> <ci type="logical" class="indication">Documente
<Request To="HealthPAC" For="Subsidy" Form="SA1125"> <Title> <range>Lacosamide</range> </Title> <Case When="Initial application"> <math> <apply> <and/> <ci type="logical" class="Indication">Patient has partial-onset epilepsy</ci> <ci type="logical" class="Trial">Seizures are not adequately controlled by, or patient has experienced unacceptable side effects from, optimal treatment with all of the following: sodium valproate, topiramate, levetiracetam and any two of carbamazepine, lamotrigine and phenytoin sodium (see Note)</ci> </apply> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="month">15</Term> <Note> <Para>"Optimal treatment" is defined as treatment which is indicated and clinically appropriate for the patient, given in adequate doses for the patient's age, weight and other features affecting the pharmacokinetics of the drug with good evidence of compliance. Women of childbearing age are not re
<Request To="HealthPAC" For="Subsidy" Form="SA1376"> <Title> <range>Carbohydrate and Fat<instance>Duocal Super Soluble Powder</instance></range> </Title> <Case When="Initial application" Category="Cystic fibrosis"> <math> <apply> <and/> <ci type="logical" class="Indication">Infant or child aged four years or under</ci> <ci type="logical" class="Indication">cystic fibrosis</ci> </apply> </math> <Applicant>dietitian</Applicant> <Applicant>relevant specialist</Applicant> <Applicant>vocationally registered general practitioner</Applicant> <Term Measure="year">3</Term> </Case> <Case When="Initial application" Category="Indications other than cystic fibrosis"> <math> <apply> <and/> <ci type="logical" class="Indication">infant or child aged four years or under</ci> <apply> <or/> <ci type="logical" class="Indication">cancer in children</ci> <ci type="logica
<Request To="HealthPAC" For="Subsidy" Form="SA0895"> <Title> <range>Pilocarpine &#8211; Eye drops 2% single dose</range> </Title> <Case When="Initial application"> <math> <apply> <or/> <ci type="logical" class="Indication">Patient has to use an unpreserved solution due to an allergy to the preservative</ci> <ci type="logical" class="Indication">Patient wears soft contact lenses</ci> </apply> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="year">2</Term> <Note> <Para>Minims for a general practice are considered to be &#8220;tools of trade&#8221; and are not approved as special authority items.</Para> </Note> </Case> <Case When="Renewal" Form="SA0121 SA0895"> <math> <ci type="logical" class="Indication">The treatment remains appropriate and the patient is benefiting from treatment</ci> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="year">2<
<Request To="HealthPAC" For="Subsidy" Form="SA1072"> <Title> <range>Vigabatrin</range> </Title> <Case When="Initial application"> <math> <apply> <and/> <apply> <or/> <ci type="logical" class="Indication">Patient has infantile spasms</ci> <apply> <and/> <ci type="logical" class="Indication">Patient has epilepsy</ci> <apply> <or/> <ci type="logical" class="Indication">Seizures are not adequately controlled with optimal treatment with other antiepilepsy agents</ci> <ci type="logical" class="Indication">Seizures are controlled adequately but the patient has experienced unacceptable side effects from optimal treatment with other antiepilepsy agents</ci> </apply> </apply> </apply> <apply> <or/> <ci type="logical" class="Indication">Patient is, or will be, receiving regular automated visual fiel
<Request To="HealthPAC" For="Subsidy" Form="SA1408"> <Title> <range>Naltrexone</range> </Title> <Case When="Initial application"> <math> <apply> <and/> <ci type="logical" class="Indication">Patient is currently enrolled in a recognised comprehensive treatment programme for alcohol dependence</ci> <ci type="logical" class="Therapy">Applicant works in or with a community Alcohol and Drug Service contracted to one of the District Health Boards or accredited against the New Zealand Alcohol and Other Drug Sector Standard or the National Mental Health Sector Standard</ci> </apply> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="month">6</Term> </Case> <Case When="Renewal" Form="SA0714 SA0909 SA1397 SA1408"> <math> <apply> <and/> <ci type="logical" class="Indication">Compliance with the medication (prescriber determined)</ci> <apply> <or/> <ci type="log
<Request To="HealthPAC" For="Subsidy" Form="SA1174"> <Title> <range>Enoxaparin sodium</range> </Title> <Case When="Initial application" Category="Pregnancy or Malignancy"> <math> <apply> <or/> <ci type="logical" class="Indication">Low molecular weight heparin treatment is required during a patients pregnancy</ci> <ci type="logical" class="Treatment">For the treatment of venous thromboembolism where the patient has a malignancy</ci> </apply> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="year">1</Term> </Case> <Case When="Initial application" Category="Venous thromboembolism other than in pregnancy or malignancy"> <math> <apply> <or/> <ci type="logical" class="Indication">For the short-term treatment of venous thromboembolism prior to establishing a therapeutic INR with oral anti-coagulant treatment</ci> <ci type="logical" class="Treatment">For the prophylaxis and tre
<Request To="HealthPAC" For="Subsidy" Form="SA1416"> <Title> <range>Atomoxetine</range> </Title> <Case When="Initial application"> <math> <apply> <and/> <ci type="logical" class="Indication">Patient has ADHD (Attention Deficit and Hyperactivity Disorder) diagnosed according to DSM-IV or ICD 10 criteria</ci> <ci type="logical" class="Indication">Once-daily dosing</ci> <apply> <or/> <ci type="logical" class="Indication">Treatment with a subsidised formulation of a stimulant has resulted in the development or worsening of serious adverse reactions or where the combination of subsidised stimulant treatment with another agent would pose an unacceptable medical risk</ci> <ci type="logical" class="Indication">Treatment with a subsidised formulation of a stimulant has resulted in worsening of co-morbid substance abuse or there is a significant risk of diversion with subsidised stimulant therapy</ci> <ci type="log
<Request To="HealthPAC" For="Subsidy" Form="SA1263"> <Title> <range>Nicorandil</range> </Title> <Case When="Initial application"> <math> <apply> <and/> <ci type="logical" class="Indication">Patient has refractory angina</ci> <ci type="logical" class="Trial">Patient is on the maximal tolerated dose of a beta-blocker, a calcium channel blocker and a long acting nitrate</ci> </apply> </math> <Applicant>cardiologist</Applicant> <Applicant>general physician</Applicant> <Term Measure="year">2</Term> </Case> <Case When="Renewal" Form="SA1263"> <math> <ci type="logical" class="Indication">The treatment remains appropriate and the patient is benefiting from treatment</ci> </math> <Applicant>cardiologist</Applicant> <Applicant Referring="cardiologist">any relevant practitioner</Applicant> <Term Measure="year">2</Term> </Case></Request>
<Request To="HealthPAC" For="Subsidy" Form="SA0927"> <Title> <range>Risperidone orally disintegrating tablets</range> </Title> <Case When="Initial application" Category="Acute situations"> <math> <apply> <and/> <ci type="logical" class="Use">For a non-adherent patient on oral therapy with standard risperidone tablets or risperidone oral liquid</ci> <ci type="logical" class="Therapy">The patient is under direct supervision for administration of medicine</ci> </apply> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="week">6</Term> </Case> <Case When="Initial application" Category="Chronic situations"> <math> <apply> <and/> <ci type="logical" class="Indication">The patient is unable to take standard risperidone tablets or oral liquid, or once stabilized refuses to take risperidone tablets or oral liquid</ci> <ci type="logical" class="Therapy">The patient is under direct
<Request To="HealthPAC" For="Subsidy" Form="SA1195"> <Title> <range>High Calorie Products<instance>Two Cal HN</instance><instance>Nutrison Concentrated</instance></range> </Title> <Case When="Initial application" Category="Cystic fibrosis"> <math> <apply> <and/> <ci type="logical" class="Indication">Cystic fibrosis</ci> <ci type="logical" class="Trial">other lower calorie products have been tried</ci> <ci type="logical" class="Indication">patient has substantially increased metabolic requirements</ci> </apply> </math> <Applicant>dietitian</Applicant> <Applicant>relevant specialist</Applicant> <Applicant>vocationally registered general practitioner</Applicant> <Term Measure="year">3</Term> </Case> <Case When="Initial application" Category="Indications other than cystic fibrosis"> <math> <apply> <and/> <apply> <or/> <ci type="logical" class="Indication">any cond
<Request To="HealthPAC" For="Subsidy" Form="SA1199"> <Title> <range>Propylthiouracil</range> </Title> <Case When="Initial application"> <math> <apply> <and/> <ci type="logical" class="Indication">The patient has hyperthyroidism</ci> <ci type="logical" class="Indication">The patient is intolerant of carbimazole or carbimazole is contraindicated</ci> </apply> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="year">2</Term> </Case> <Case When="Renewal" Form="SA1199"> <math> <ci type="logical" class="Indication">the treatment remains appropriate and the patient is benefitting from the treatment</ci> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="year">2</Term> </Case></Request>
<Request To="PHARMAC" For="Subsidy" Form="SA1237"> <Title> <range>Insulin Pumps</range> </Title> <Case When="Initial application"> <math/> <Applicant>medical practitioner</Applicant> <Term Measure="year">1</Term> </Case> <Note> <Para>Application details may be obtained from PHARMAC's website <a href="http://www.pharmac.govt.nz/">http://www.pharmac.govt.nz</a> or:</Para> <Table> <TR> <TD> <Para>The IPP Co-ordinator</Para> </TD> <TD> <Para>Phone: (04) 460 4990</Para> </TD> </TR> <TR> <TD> <Para>PHARMAC</Para> </TD> <TD> <Para>Facsimile: (04) 974 7806</Para> </TD> </TR> <TR> <TD> <Para>PO Box 10 254</Para> </TD> <TD> <Para>Email: <a href="mailto:ipp@pharmac.govt.nz">ipp@pharmac.govt.nz</a></Para> </TD> </TR> <TR> <TD> <Para>Welli
<Request To="HealthPAC" For="Subsidy" Form="SA0829"> <Title> <range>Adefovir dipivoxil</range> </Title> <Case When="Initial application"> <math> <apply> <and/> <ci type="logical" class="Trial">Patient has confirmed Hepatitis B infection (HBsAg+)</ci> <mi class="heading">Documented resistance to lamivudine, defined as:</mi> <ci type="logical" class="Trial">Patient has raised serum ALT (&gt; 1 &#215; ULN)</ci> <ci type="logical" class="Trial">Patient has HBV DNA greater than 100,000 copies per mL, or viral load &#8805; 10 fold over nadir</ci> <ci type="logical" class="Trial">Detection of M204I or M204V mutation</ci> <apply> <or/> <apply> <and/> <ci type="logical" class="Trial">Patient is cirrhotic</ci> <ci type="logical" class="Trial">adefovir dipivoxil to be used in combination with lamivudine</ci> </apply> <apply> <and/>
<Request To="HealthPAC" For="Subsidy" Form="SA0998"> <Title> <range>Solifenacin succinate</range> </Title> <Case When="Initial application"> <math> <ci type="logical" class="Indication">The patient has overactive bladder and a documented intolerance of, or is non-responsive to oxybutynin</ci> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="patient's lifetime"/> </Case></Request>
<Request To="HealthPAC" For="Subsidy" Form="SA1332"> <Title> <range>Tetracycline</range> </Title> <Case When="Initial application"> <math> <apply> <and/> <ci type="logical" class="Indication">For the eradication of helicobacter pylori following unsuccessful treatment with appropriate first-line therapy</ci> <ci type="logical" class="Indication">For use only in combination with bismuth as part of a quadruple therapy regimen</ci> </apply> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="month">3</Term> </Case></Request>
<Request To="HealthPAC" For="Subsidy" Form="SA1379"> <Title> <range>Paediatric Products<instance>Nutrini</instance><instance>Pediasure</instance><instance>Fortini</instance></range> </Title> <Case When="Initial application"> <math> <apply> <and/> <ci type="logical" class="Indication">Child is aged one to ten years</ci> <apply> <or/> <ci type="logical" class="Indication">the child is being fed via a tube or a tube is to be inserted for the purposes of feeding</ci> <ci type="logical" class="Indication">any condition causing malabsorption</ci> <ci type="logical" class="Indication">faltering growth in an infant/child</ci> <ci type="logical" class="Indication">increased nutritional requirements</ci> <ci type="logical" class="Indication">the child is being transitioned from TPN or tube feeding to oral feeding</ci> </apply> </apply> </math> <Applicant>dietitian</Applicant>
<Request To="HealthPAC" For="Subsidy" Form="SA1382"> <Title> <range>Ticagrelor</range> </Title> <Case When="Initial application" Category="acute coronary syndrome"> <math> <apply> <and/> <ci type="logical" class="Indication">Patient has recently been diagnosed with an ST-elevation or a non-ST-elevation acute coronary syndrome</ci> <ci type="logical" class="Indication">Fibrinolytic therapy has not been given in the last 24 hours and is not planned</ci> </apply> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="month">12</Term> </Case> <Case When="Renewal" Category="subsequent acute coronary syndrome" Form="SA1382"> <math> <apply> <and/> <ci type="logical" class="Indication">Patient has recently been diagnosed with an ST-elevation or a non-ST-elevation acute coronary syndrome</ci> <ci type="logical" class="Indication">Fibrinolytic therapy has not been given in the last 24
<Request To="HealthPAC" For="Subsidy" Form="SA1383"> <Title> <range>Ursodeoxycholic Acid</range> </Title> <Case When="Initial application" Category="Alagille syndrome or progressive familial intrahepatic cholestasis"> <math> <apply> <or/> <ci type="logical" class="Indication">Patient has been diagnosed with Alagille syndrome</ci> <ci type="logical" class="Indication">Patient has progressive familial intrahepatic cholestasis</ci> </apply> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="patient's lifetime"/> </Case> <Case When="Initial application" Category="Chronic severe drug induced cholestatic liver injury"> <math> <apply> <and/> <ci type="logical" class="Indication">Patient has chronic severe drug induced cholestatic liver injury</ci> <ci type="logical" class="Indication">Cholestatic liver injury not due to Total Parenteral Nutrition (TPN) use in adults</ci>
<Request To="HealthPAC" For="Subsidy" Form="SA1192"> <Title> <range>Trastuzumab</range> </Title> <Case When="Initial application" Category="metastatic breast cancer"> <math> <apply> <or/> <apply> <and/> <ci type="logical" class="Indication">The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology)</ci> <ci type="logical" class="Treatment">The patient has not previously received lapatinib treatment for HER 2 positive metastatic breast cancer</ci> <ci type="logical" class="Indication">Trastuzumab not to be given in combination with lapatinib</ci> <ci type="logical" class="Treatment">Trastuzumab to be discontinued at disease progression</ci> </apply> <apply> <and/> <ci type="logical" class="Indication">The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology
<Request To="HealthPAC" For="Subsidy" Form="SA1071"> <Title> <range>Gabapentin</range> </Title> <Case When="Initial application" Category="Epilepsy"> <math> <apply> <or/> <ci type="logical" class="Indication">Seizures are not adequately controlled with optimal treatment with other antiepilepsy agents</ci> <ci type="logical" class="Indication">Seizures are controlled adequately but the patient has experienced unacceptable side effects from optimal treatment with other antiepilepsy agents</ci> </apply> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="month">15</Term> <Note> <Para>"Optimal treatment with other antiepilepsy agents" is defined as treatment with other antiepilepsy agents which are indicated and clinically appropriate for the patient, given in adequate doses for the patient's age, weight, and other features affecting the pharmacokinetics of the drug with good evidence of compliance.</Para>
<Request To="HealthPAC" For="Subsidy" Form="SA1066"> <Title> <range>Rivaroxaban</range> </Title> <Case When="Initial application"> <math> <apply> <or/> <ci type="logical" class="Indication">For the prophylaxis of venous thromboembolism following a total hip replacement</ci> <ci type="logical" class="Use">For the prophylaxis of venous thromboembolism following a total knee replacement</ci> </apply> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="week">5</Term> <Note> <Para>Rivaroxaban is only currently indicated and subsidised for up to 5 weeks therapy for prophylaxis of venous thromboembolism following a total hip replacement and up to 2 weeks therapy for prophylaxis of venous thromboembolism following a total knee replacement.</Para> </Note> </Case> <Case When="Renewal" Form="SA1066"> <math> <ci type="logical" class="Indication">Prophylaxis for venous thromboembolism is requir
<Request To="PHARMAC" For="Subsidy" Form="SA1240"> <Title> <range>Insulin pump consumables</range> </Title> <Case When="Initial application"> <math/> <Applicant>medical practitioner</Applicant> <Term Measure="year">1</Term> </Case> <Note> <Para>Application details may be obtained from PHARMAC's website <a href="http://www.pharmac.govt.nz/">http://www.pharmac.govt.nz</a> or:</Para> <Table> <TR> <TD> <Para>The IPP Co-ordinator</Para> </TD> <TD> <Para>Phone: (04) 460 4990</Para> </TD> </TR> <TR> <TD> <Para>PHARMAC</Para> </TD> <TD> <Para>Facsimile: (04) 974 7806</Para> </TD> </TR> <TR> <TD> <Para>PO Box 10 254</Para> </TD> <TD> <Para>Email: <a href="mailto:ipp@pharmac.govt.nz">ipp@pharmac.govt.nz</a></Para> </TD> </TR> <TR> <TD>
<Request To="HealthPAC" For="Subsidy" Form="SA1289"> <Title> <range>Capsaicin</range> </Title> <Case When="Initial application"> <math> <ci type="logical" class="Indication">The patient has osteoarthritis that is not responsive to paracetamol and oral non-steroidal anti-inflammatories are contraindicated</ci> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="patient's lifetime"/> </Case></Request>
<Request To="HealthPAC" For="Subsidy" Form="SA1039"> <Title> <range>Alendronate Tab 70 mg - with or without Cholecalciferol</range> </Title> <Case When="Initial application" Category="Underlying cause -- Osteoporosis"> <math> <apply> <or/> <ci type="logical" class="Indication">History of one significant osteoporotic fracture demonstrated radiologically and documented bone mineral density (BMD) &#8805; 2.5 standard deviations below the mean normal value in young adults (i.e. T-Score &#8804; -2.5) (see Note)</ci> <ci type="logical" class="Indication">History of one significant osteoporotic fracture demonstrated radiologically, and either the patient is elderly, or densitometry scanning cannot be performed because of major logistical, technical or pathophysiological reasons. It is unlikely that this provision would apply to many patients under 75 years of age</ci> <ci type="logical" class="Indication">History of two significant osteoporotic fractures
<Request To="HealthPAC" For="Manufacturers Price" Form="SA1355"> <Title> <range>Minocycline hydrochloride Tab 50 mg</range> </Title> <Case When="Initial application"> <math> <ci type="logical" class="Indication">The patient has rosacea</ci> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="patient's lifetime"/> </Case></Request>
<Request To="HealthPAC" For="Subsidy" Form="SA1324"> <Title> <range>Paromomycin</range> </Title> <Case When="Initial application"> <math> <ci type="logical" class="Indication">the patient has confirmed cryptosporidium infection</ci> </math> <Applicant>infectious disease specialist</Applicant> <Applicant>clinical microbiologist</Applicant> <Term Measure="month">1</Term> </Case> <Case When="Renewal" Form="SA1324"> <math> <ci type="logical" class="Indication">the patient has confirmed cryptosporidium infection</ci> </math> <Applicant>infectious disease specialist</Applicant> <Applicant>clinical microbiologist</Applicant> <Term Measure="month">1</Term> </Case></Request>
<Request To="HealthPAC" For="Subsidy" Form="SA1126"> <Title> <range>Modavigil</range> </Title> <Case When="Initial application"> <math> <apply> <and/> <ci type="logical" class="Indication">The patient has a diagnosis of narcolepsy and has excessive daytime sleepiness associated with narcolepsy occurring almost daily for three months or more</ci> <apply> <or/> <ci type="logical" class="Indication">The patient has a multiple sleep latency test with a mean sleep latency of less than or equal to 10 minutes and 2 or more sleep onset rapid eye movement periods</ci> <ci type="logical" class="Indication">The patient has at least one of: cataplexy, sleep paralysis or hypnagogic hallucinations</ci> </apply> <apply> <or/> <ci type="logical" class="Indication">An effective dose of a subsidised formulation of methylphenidate or dexamphetamine has been trialled and discontinued because of intolerabl
<Request To="HealthPAC" For="Subsidy" Form="SA0928"> <Title> <range>Finasteride</range> </Title> <Case When="Initial application"> <math> <apply> <and/> <ci type="logical" class="Indication">Patient has symptomatic benign prostatic hyperplasia</ci> <apply> <or/> <ci type="logical" class="Indication">The patient is intolerant of non-selective alpha blockers or these are contraindicated</ci> <ci type="logical" class="Indication">Symptoms are not adequately controlled with non-selective alpha blockers</ci> </apply> </apply> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="patient's lifetime"/> </Case> <Note> <Para>Patients with enlarged prostates are the appropriate candidates for therapy with finasteride.</Para> </Note></Request>
<Request To="HealthPAC" For="Subsidy" Form="SA1099"> <Title> <range>Paediatric Product For Children With Chronic Renal Failure<instance>Kindergen</instance></range> </Title> <Case When="Initial application"> <math> <ci type="logical" class="Indication">The patient is a child (up to 18 years) with acute or chronic kidney disease</ci> </math> <Applicant>dietitian</Applicant> <Applicant>relevant specialist</Applicant> <Applicant>vocationally registered general practitioner</Applicant> <Term Measure="year">3</Term> </Case> <Case When="Renewal" Form="SA0606 SA1099"> <math> <apply> <and/> <ci type="logical" class="Indication">The treatment remains appropriate and the patient is benefiting from treatment</ci> <ci type="text" class="Endorsement">General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted</ci> </apply> </mat
<Request To="HealthPAC" For="Subsidy" Form="SA1272"> <Title> <range>Tolterodine</range> </Title> <Case When="Initial application"> <math> <ci type="logical" class="Indication">Patient has overactive bladder and a documented intolerance of, or is non-responsive to oxybutynin</ci> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="patient's lifetime"/> </Case></Request>
<Request To="HealthPAC" For="Subsidy" Form="SA1381"> <Title> <range>Fat Modified Products<instance>Monogen</instance></range> </Title> <Case When="Initial application"> <math> <apply> <or/> <ci type="logical" class="Indication">Patient has metabolic disorders of fat metabolism</ci> <ci type="logical" class="Indication">Patient has a chyle leak</ci> <ci type="logical" class="Indication">Modified as a modular feed for adults</ci> </apply> </math> <Applicant>dietitian</Applicant> <Applicant>relevant specialist</Applicant> <Applicant>vocationally registered general practitioner</Applicant> <Term Measure="year">1</Term> </Case> <Case When="Renewal" Form="SA0593 SA0615 SA1096 SA1381"> <math> <apply> <and/> <ci type="logical" class="Indication">The treatment remains appropriate and the patient is benefiting from treatment</ci> <ci type="text" class="Endorsement">General Practitio
<Request To="HealthPAC" For="Subsidy" Form="SA0782"> <Title> <range>Levonorgestrel &#8211; releasing intrauterine system 20mcg/24 hr</range> </Title> <Case When="Initial application" Category="No previous use"> <math> <apply> <and/> <ci type="logical" class="Indication">The patient has a clinical diagnosis of heavy menstrual bleeding</ci> <ci type="logical" class="Trial">The patient has failed to respond to or is unable to tolerate other appropriate pharmaceutical therapies as per the Heavy Menstrual Bleeding Guidelines</ci> <apply> <or/> <apply> <lt/> <ci type="real" class="test">serum ferritin level</ci> <cn>16<mi> mcg/l (within the last 12 months)</mi></cn> </apply> <apply> <lt/> <ci type="real" class="test">haemoglobin level</ci> <cn>120<mi> g/l</mi></cn> </apply> </apply> </apply> </math>
<Request To="HealthPAC" For="Subsidy" Form="SA1032"> <Title> <range>Tamsulosin</range> </Title> <Case When="Initial application"> <math> <apply> <and/> <ci type="logical" class="Indication">Patient has symptomatic benign prostatic hyperplasia</ci> <ci type="logical" class="Indication">The patient is intolerant of non-selective alpha blockers or these are contraindicated</ci> </apply> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="patient's lifetime"/> </Case></Request>
<Request To="HealthPAC" For="Subsidy" Form="SA0954"> <Title> <range>Acitretin</range> </Title> <Case When="Initial application"> <math> <apply> <and/> <ci type="logical" class="Indication">Applicant is a vocationally registered dermatologist, vocationally registered general practitioner, or nurse practitioner working in a relevant scope of practice</ci> <ci type="logical" class="Indication">Applicant has an up to date knowledge of the treatment options for psoriasis and of disorders of keratinisation and is aware of the safety issues around acitretin and is competent to prescribe acitretin</ci> <apply> <or/> <ci type="logical" class="Indication">Patient is female and has been counselled and understands the risk of teratogenicity if acitretin is used during pregnancy and the applicant has ensured that the possibility of pregnancy has been excluded prior to the commencement of the treatment and that the patient is informed that
<Request To="HealthPAC" For="Subsidy" Form="SA0987"> <Title> <range>Aprepitant</range> </Title> <Case When="Initial application"> <math> <ci type="logical" class="Indication">The patient is undergoing highly emetogenic chemotherapy and/or anthracycline-based chemotherapy for the treatment of malignancy</ci> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="month">12</Term> </Case> <Case When="Renewal" Form="SA0987"> <math> <ci type="logical" class="Indication">The patient is undergoing highly emetogenic chemotherapy and/or anthracycline-based chemotherapy for the treatment of malignancy</ci> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="month">12</Term> </Case></Request>
<Request To="HealthPAC" For="Subsidy" Form="SA1042"> <Title> <range>Deferiprone</range> </Title> <Case When="Initial application"> <math> <ci type="logical" class="Indication">The patient has been diagnosed with chronic transfusional iron overload due to congenital inherited anaemia</ci> </math> <Applicant>relevant specialist</Applicant> <Term Measure="patient's lifetime"/> </Case> <Note> <Para>For the purposes of this Special Authority, a relevant specialist is defined as a haematologist.</Para> </Note></Request>
<Request To="HealthPAC" For="Subsidy" Form="SA1155"> <Title> <range>Budesonide - Cap 3 mg Controlled Release</range> </Title> <Case When="Initial application" Category="Crohn's disease"> <math> <apply> <and/> <ci type="logical" class="Indication">Mild to moderate ileal, ileocaecal or proximal Crohn's disease</ci> <apply> <or/> <ci type="logical" class="Indication">Diabetes</ci> <ci type="logical" class="Indication">Cushingoid habitus</ci> <ci type="logical" class="Indication">Osteoporosis where there is significant risk of fracture</ci> <ci type="logical" class="Indication">Severe acne following treatment with conventional corticosteroid therapy</ci> <ci type="logical" class="Indication">History of severe psychiatric problems associated with corticosteroid treatment</ci> <ci type="logical" class="Indication">History of major mental illness (such as bipolar affective disorder) where
<Request To="HealthPAC" For="Subsidy" Form="SA1421"> <Title> <range>Montelukast</range> </Title> <Case When="Initial application" Category="Pre-school wheeze"> <math> <apply> <and/> <ci type="logical" class="Indication">To be used for the treatment of intermittent severe wheezing (possibly viral) in children under 5 years</ci> <ci type="logical" class="Indication">The patient has had at least three episodes in the previous 12 months of acute wheeze severe enough to seek medical attention</ci> </apply> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="year">1</Term> </Case> <Case When="Renewal" Category="Pre-school wheeze" Form="SA1227 SA1409 SA1421"> <math> <ci type="logical" class="Indication">The treatment remains appropriate and the patient is benefiting from treatment</ci> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="year">2</Term> </Case> <Case
<Request To="PHARMAC" For="Subsidy" Form="SA0973"> <Title> <range>Neurontin</range> </Title> <Case When="Initial application"> <math> <ci type="logical" class="Indication">Subsidy for patients pre-approved on 1 August 2009</ci> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="patient's lifetime"/> </Case> <Note> <Para>Subsidy for patients pre-approved by PHARMAC on 1 August 2009. Approvals valid without further renewal unlessnotified.</Para> <Para>No new approvals will be granted from 1 August 2009.</Para> </Note></Request>
<Request To="HealthPAC" For="Subsidy" Form="SA1196"> <Title> <range>Paediatric enteral feed with fibre 0.75 kcal/ml<instance>Nutrini Low Energy Multi Fibre</instance></range> </Title> <Case When="Initial application"> <math overflow="scroll"> <apply> <and/> <ci type="logical" class="Indication">Child aged one to eight years</ci> <ci type="logical" class="Indication">The child has a low energy requirement but normal protein and micronutrient requirements</ci> </apply> </math> <Applicant>dietitian</Applicant> <Applicant>relevant specialist</Applicant> <Applicant>vocationally registered general practitioner</Applicant> <Term Measure="year">1</Term> </Case> <Case When="Renewal" Form="SA1196"> <math overflow="scroll"> <apply> <and/> <ci type="logical" class="Indication">The treatment remains appropriate and the patient is benefiting from treatment</ci> <ci type="text" class="Endorsement
<Request To="HealthPAC" For="Subsidy" Form="SA1225"> <Title> <range>Ivermectin</range> </Title> <Case When="Initial application" Category="Scabies"> <math> <apply> <and/> <ci type="logical" class="Indication">Applying clinician has discussed the diagnosis of scabies with a dermatologist, infectious disease physician or clinical microbiologist</ci> <apply> <or/> <apply> <and/> <ci type="logical" class="Indication">The patient is in the community</ci> <apply> <or/> <ci type="logical" class="Indication">Patient has a severe scabies hyperinfestation (Crusted/ Norwegian scabies)</ci> <ci type="logical" class="Indication">The community patient is physically or mentally unable to comply with the application instructions of topical therapy</ci> <ci type="logical" class="Indication">The patient has previously tried and failed to clear infestation
<Request To="HealthPAC" For="Subsidy" Form="SA1322"> <Title> <range>Itraconazole</range> </Title> <Case When="Initial application"> <math> <ci type="logical" class="Indication">The patient has a congenital immune deficiency</ci> </math> <Applicant>infectious disease specialist</Applicant> <Applicant>clinical microbiologist</Applicant> <Applicant>clinical immunologist</Applicant> <Applicant Referring="infectious disease physician, clinical microbiologist or clinical immunologist">any relevant practitioner</Applicant> <Term Measure="month">6</Term> </Case> <Case When="Renewal" Form="SA1322"> <math> <ci type="logical" class="Indication">The treatment remains appropriate and the patient is benefitting from the treatment</ci> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="month">6</Term> </Case></Request>
<Request To="HealthPAC" For="Subsidy" Form="SA1223"> <Title> <range>Candesartan</range> </Title> <Case When="Initial application" Category="ACE inhibitor intolerance"> <math> <apply> <or/> <ci type="logical" class="Indication">Patient has persistent ACE inhibitor induced cough that is not resolved by ACE inhibitor retrial (same or new ACE inhibitor)</ci> <ci type="logical" class="Indication">Patient has a history of angioedema</ci> </apply> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="patient's lifetime"/> </Case> <Case When="Initial application" Category="Unsatisfactory response to ACE inhibitor"> <math> <ci type="logical" class="Indication">patient is not adequately controlled on maximum tolerated dose of an ACE inhibitor</ci> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="patient's lifetime"/> </Case></Request>
<Request To="HealthPAC" For="Subsidy" Form="SA0922"> <Title> <range>Erythropoietin</range> </Title> <Case When="Initial application"> <math> <apply> <and/> <apply> <and/> <ci type="logical" class="Indication">patient in chronic renal failure</ci> <apply> <leq/> <ci type="real" class="test">Haemoglobin</ci> <cn>100<mi>g/L</mi></cn> </apply> </apply> <apply> <or/> <apply> <and/> <ci type="logical" class="Indication">patient is not diabetic</ci> <apply> <leq/> <ci type="real" class="test">glomerular filtration rate</ci> <cn>30<mi>ml/min</mi></cn> </apply> </apply> <apply> <and/> <ci type="logical" class="Indication">patient is diabetic</ci> <apply> <leq/> <ci type
<Request To="HealthPAC" For="Subsidy" Form="SA1198"> <Title> <range>Preterm post-discharge infant formula powder<instance>S-26 Gold Premgro</instance></range> </Title> <Case When="Initial application"> <math overflow="scroll"> <apply> <and/> <ci type="logical" class="Indication">The infant was born before 33 weeks gestation or weighed less than 1.5 kg at birth</ci> <apply> <or/> <ci type="logical" class="Indication">The infant has faltering growth (downward crossing of percentiles)</ci> <ci type="logical" class="Indication">The infant is not maintaining, or is considered unlikely to maintain, adequate growth on standard infant formula</ci> </apply> </apply> </math> <Applicant>dietitian</Applicant> <Applicant>relevant specialist</Applicant> <Applicant>vocationally registered general practitioner</Applicant> <Term Measure="month">6</Term> </Case></Request>
<Request To="HealthPAC" For="Subsidy" Form="SA1124"> <Title> <range>Thalidomide</range> </Title> <Case When="Initial application"> <math> <apply> <or/> <ci type="logical" class="indication">The patient has multiple myeloma</ci> <ci type="logical" class="indication">The patient has systemic AL amyloidosis*</ci> </apply> </math> <Applicant>relevant specialist</Applicant> <Applicant Referring="relevant specialist">medical practitioner</Applicant> <Term Measure="month">12</Term> </Case> <Case When="Renewal" Form="SA1124 SA0817 SA0882"> <math> <ci type="logical" class="indication">The patient has obtained a response from treatment during the initial approval period</ci> </math> <Applicant>relevant specialist</Applicant> <Applicant Referring="relevant specialist">medical practitioner</Applicant> <Term Measure="patient's lifetime"/> </Case> <Note> <Para>Prescription must be written by a re
<Request To="HealthPAC" For="Subsidy" Form="SA1321"> <Title> <range>Hydralazine</range> </Title> <Case When="Initial application"> <math> <apply> <or/> <ci type="logical" class="Indication">For the treatment of refractory hypertension</ci> <ci type="logical" class="Indication">For the treatment of heart failure in combination with a nitrate, in patients who are intolerant or have not responded to ACE inhibitors and/or angiotensin receptor blockers</ci> </apply> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="patient's lifetime"/> </Case></Request>
<Request To="HealthPAC" For="Subsidy" Form="SA1260"> <Title> <range>Perhexiline Maleate</range> </Title> <Case When="Initial application"> <math> <apply> <and/> <ci type="logical" class="Indication">Patient has refractory angina</ci> <ci type="logical" class="Trial">Patient is on the maximal tolerated dose of a beta-blocker, a calcium channel blocker and a long acting nitrate</ci> </apply> </math> <Applicant>cardiologist</Applicant> <Applicant>general physician</Applicant> <Term Measure="year">2</Term> </Case> <Case When="Renewal" Form="SA0256 SA1260"> <math> <ci type="logical" class="Indication">The treatment remains appropriate and the patient is benefiting from treatment</ci> </math> <Applicant>cardiologist</Applicant> <Applicant Referring="cardiologist">any relevant practitioner</Applicant> <Term Measure="year">2</Term> </Case></Request>
<Request To="HealthPAC" For="Subsidy" Form="SA1326"> <Title> <range>Primaquine</range> </Title> <Case When="Initial application"> <math> <apply> <and/> <ci type="logical" class="Indication">The patient has vivax or ovale malaria</ci> <ci type="logical" class="Indication">Primaquine is to be given for a maximum of 21 days</ci> </apply> </math> <Applicant>infectious disease specialist</Applicant> <Applicant>clinical microbiologist</Applicant> <Term Measure="month">1</Term> </Case></Request>
<Request To="HealthPAC" For="Subsidy" Form="SA1285"> <Title> <range>Posaconazole </range> </Title> <Case When="Initial application"> <math> <apply> <or/> <ci type="logical" class="Indication">Patient has acute myeloid leukaemia and is to be treated with high dose remission induction, re-induction or consolidation chemotherapy</ci> <ci type="logical" class="Indication">Patient has received a stem cell transplant and has graft versus host disease and is on significant immunosuppressive therapy*</ci> </apply> </math> <Applicant>haematologist</Applicant> <Applicant>infectious disease specialist</Applicant> <Term Measure="week">6</Term> </Case> <Case When="Renewal" Form="SA1285"> <math> <apply> <or/> <ci type="logical" class="Indication">Patient has acute myeloid leukaemia and is to be treated with high dose remission induction, re-induction or consolidation therapy</ci> <ci type="logical" c
<Request To="HealthPAC" For="Subsidy" Form="SA1386"> <Title> <range>Phenobarbitone</range> </Title> <Case When="Initial application"> <math> <apply> <and/> <ci type="logical" class="Indication">For the treatment of terminal agitation that is unresponsive to other agents</ci> <ci type="logical" class="Indication">The applicant is part of a multidisciplinary team working in palliative care</ci> </apply> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="patient's lifetime"/> </Case></Request>
<Request To="HealthPAC" For="Subsidy" Form="SA1293"> <Title> <range>Sildenafil</range> </Title> <Case When="Initial application" Category="Raynaud&#8217;s Phenomenon* - for Pulmonary Arterial Hypertension see note below)"> <math> <apply> <and/> <ci type="logical" class="Indication">Patient has Raynaud&#8217;s Phenomenon*</ci> <ci type="logical" class="Indication">Patient has severe digital ischaemia (defined as severe pain requiring hospital admission or with a high likelihood of digital ulceration; digital ulcers; or gangrene)</ci> <ci type="logical" class="Indication">Patient is following lifestyle management (avoidance of cold exposure, sufficient protection, smoking cessation support, avoidance of sympathomimetic drugs) </ci> <ci type="logical" class="Indication">Patient is being treated with calcium channel blockers and nitrates (or these are contraindicated/not tolerated)</ci> </apply> </math> <Applicant>any relevant
<Request To="HealthPAC" For="Subsidy" Form="SA1061"> <Title> <range>Venlafaxine</range> </Title> <Case When="Initial application"> <math> <apply> <and/> <ci type="logical" class="Indication">The patient has 'treatment-resistant' depression</ci> <apply> <or/> <ci type="logical" class="Trial">The patient must have had a trial of two different antidepressants and have had an inadequate response from an adequate dose over an adequate period of time (usually at least four weeks)</ci> <apply> <and/> <ci type="logical" class="Indication">The patient is currently a hospital in-patient as a result of an acute depressive episode</ci> <ci type="logical" class="Trial">The patient must have had a trial of one other antidepressant and have had an inadequate response from an adequate dose over an adequate period of time</ci> </apply> </apply> </apply> </math> <Appl
<Request To="HealthPAC" For="Subsidy" Form="SA1411"> <Title> <range>Erlotinib</range> </Title> <Case When="Initial application"> <math> <apply> <or/> <apply> <and/> <ci type="logical" class="Indication">Patient has locally advanced or metastatic, unresectable, non-squamous Non Small Cell Lung Cancer (NSCLC)</ci> <ci type="logical" class="Indication">There is documentation confirming that the disease expresses activating mutations of EGFR tyrosine kinase</ci> <apply> <or/> <ci type="logical" class="Indication">Patient is treatment naive</ci> <apply> <and/> <ci type="logical" class="Indication">Patient has documented disease progression following treatment with first line platinum based chemotherapy</ci> <ci type="logical" class="Indication">Patient has not received prior treatment with gefitinib</ci> </apply> </apply>
<Request To="HealthPAC" For="Alternate Subsidy" Form="SA1018"> <Title> <range>Hormone Replacement Therapy - Systemic</range> </Title> <Case When="Initial application"> <math> <apply> <or/> <ci type="logical" class="Indication">acute or significant liver disease - where oral oestrogens are contraindicated as determined by a gastroenterologist or general physician. The applicant must keep written confirmation from such a specialist with the patient's record</ci> <ci type="logical" class="Indication">oestrogen induced hypertension requiring antihypertensive therapy - documented evidence must be kept on file that raised blood pressure levels or inability to control blood pressure adequately occurred post oral oestrogens</ci> <ci type="logical" class="Indication">hypertriglyceridaemia - documented evidence must be kept on file that triglyceride levels increased to at least 2 &#215; normal triglyceride levels post oral oestrogens</ci> <ci type=
<Request To="HealthPAC" For="Subsidy" Form="SA1320"> <Title> <range>Diazoxide</range> </Title> <Case When="Initial application"> <math> <ci type="logical" class="Indication">used for the treatment of confirmed hypoglycaemia caused by hyperinsulinism</ci> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="month">12</Term> </Case> <Case When="Renewal" Form="SA1320"> <math> <ci type="logical" class="Indication">The treatment remains appropriate and the patient is benefiting from treatment</ci> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="patient's lifetime"/> </Case></Request>
<Request To="HealthPAC" For="Subsidy" Form="SA1318"> <Title> <range>Albendazole</range> </Title> <Case When="Initial application"> <math> <ci type="logical" class="Indication">The patient has hydatids</ci> </math> <Applicant>infectious disease specialist</Applicant> <Applicant>clinical microbiologist</Applicant> <Term Measure="month">6</Term> </Case> <Case When="Renewal" Form="SA1318"> <math> <ci type="logical" class="Indication">The treatment remains appropriate and the patient is benefitting from the treatment</ci> </math> <Applicant>infectious disease specialist</Applicant> <Applicant>clinical microbiologist</Applicant> <Term Measure="month">6</Term> </Case></Request>
<Request To="HealthPAC" For="Subsidy" Form="SA1271"> <Title> <range>Minoxidil</range> </Title> <Case When="Initial application"> <math> <ci type="logical" class="Indication">patient has severe refractory hypertension which has failed to respond to extensive multiple therapies</ci> </math> <Applicant>relevant specialist</Applicant> <Term Measure="patient's lifetime"/> </Case></Request>
<Request To="HealthPAC" For="Subsidy" Form="SA1095"> <Title> <range>Diabetic products<instance>Diason RTH</instance><instance>Glucerna Select RTH</instance><instance>Diasip</instance><instance>Glucerna Select</instance><instance>Resource Diabetic</instance></range> </Title> <Case When="Initial application"> <math> <ci type="logical" class="Indication">The patient is a type I or and II diabetic who is suffering weight loss and malnutrition that requires nutritional support</ci> </math> <Applicant>dietitian</Applicant> <Applicant>relevant specialist</Applicant> <Applicant>vocationally registered general practitioner</Applicant> <Term Measure="year">1</Term> </Case> <Case When="Renewal" Form="SA0594 SA1095"> <math> <apply> <and/> <ci type="logical" class="Indication">The treatment remains appropriate and the patient is benefiting from treatment</ci> <ci type="text" class="Endorsement">General Practitioners must includ
<Request To="PHARMAC" For="Manufacturers Price" Form="SA1038"> <Title> <range>Anti-inflammatory Non Steroidal Drugs (NSAIDs)</range> </Title> <Case When="Initial application"> <math> <ci type="logical" class="Indication">Subsidy for patients with existing approvals prior to 1 September 2010</ci> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="patient's lifetime"/> </Case> <Note> <Para>Subsidy for patients with existing approvals prior to 1 September 2010. Approvals valid without further renewal unlessnotified. No new approvals will be granted from 1 September 2010.</Para> </Note></Request>
<Request To="HealthPAC" For="Subsidy" Form="SA1002"> <Title> <range>Vitabdeck</range> </Title> <Case When="Initial application"> <math> <apply> <or/> <ci type="logical" class="Indication">Patient has cystic fibrosis with pancreatic insufficiency</ci> <ci type="logical" class="Indication">Patient is an infant or child with liver disease or short gut syndrome</ci> </apply> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="patient's lifetime"/> </Case></Request>
<Request To="HealthPAC" For="Subsidy" Form="SA1449"> <Title> <range>Adalimumab</range> </Title> <Case When="Initial application" Category="rheumatoid arthritis"> <math> <apply> <or/> <apply> <and/> <ci type="logical" class="Indication">The patient has had an initial Special Authority approval for etanercept for rheumatoid arthritis</ci> <apply> <or/> <ci type="logical" class="Indication">The patient has experienced intolerable side effects from etanercept</ci> <ci type="logical" class="Indication">The patient has received insufficient benefit from etanercept to meet the renewal criteria for etanercept for rheumatoid arthritis</ci> </apply> </apply> <apply> <and/> <ci type="logical" class="Indication">Patient has had severe and active erosive rheumatoid arthritis for six months duration or longer</ci> <ci type="logical" class="Treatmen
<Request To="HealthPAC" For="Subsidy" Form="SA1388"> <Title> <range>Preservative Free Ocular Lubricants</range> </Title> <Case When="Initial application"> <math> <apply> <and/> <ci type="logical" class="Indication">Confirmed diagnosis by slit lamp of severe secretory dry eye</ci> <apply> <or/> <ci type="logical" class="Indication">Patient is using eye drops more than four times daily on a regular basis</ci> <ci type="logical" class="Indication">Patient has had a confirmed allergic reaction to preservative in eye drop</ci> </apply> </apply> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="month">12</Term> </Case> <Case When="Renewal" Form="SA1388"> <math> <ci type="logical" class="Indication">The patient continues to require lubricating eye drops and has benefited from treatment</ci> </math> <Applicant>any relevant practitioner</Applicant>
<Request To="HealthPAC" For="Subsidy" Form="SA1201"> <Title> <range>Prasugrel</range> </Title> <Case When="Initial application" Category="coronary angioplasty and bare metal stent"> <math> <ci type="logical" class="Treatment">The patient has undergone coronary angioplasty in the previous 4 weeks and is clopidogrel-allergic*</ci> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="month">6</Term> </Case> <Case When="Initial application" Category="drug eluting stent"> <math> <ci type="logical" class="Treatment">The patient has had a drug-eluting cardiac stent inserted in the previous 4 weeks and is clopidogrel-allergic*</ci> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="month">12</Term> </Case> <Case When="Initial application" Category="stent thromobosis"> <math> <ci type="logical" class="Treatment">patient has experienced cardiac stent thrombosis whilst on clopidogrel</ci>
<Request To="HealthPAC" For="Subsidy" Form="SA1325"> <Title> <range>Pegaspargase</range> </Title> <Case When="Initial application"> <math> <apply> <and/> <ci type="logical" class="Indication">The patient has newly diagnosed acute lymphoblastic leukaemia</ci> <ci type="logical" class="Indication">Pegaspargase to be used with a contemporary intensive multi-agent chemotherapy treatment protocol</ci> <ci type="logical" class="Indication">Treatment is with curative intent</ci> </apply> </math> <Applicant>relevant specialist</Applicant> <Applicant Referring="relevant specialist">medical practitioner</Applicant> <Term Measure="month">12</Term> </Case> <Case When="Renewal" Form="SA1325"> <math> <apply> <and/> <ci type="logical" class="Indication">The patient has relapsed acute lymphoblastic leukaemia</ci> <ci type="logical" class="Indication">Pegaspargase to be used with a contemporar
<Request To="HealthPAC" For="Alternate Subsidy" Form="SA0500"> <Title><range>Combined oral contraceptives</range><range>Progestogen-only contraceptives</range> (Circle one)</Title> <Case When="Initial application"> <math> <apply> <and/> <apply> <or/> <ci type="logical" class="Target">Patient is on a Social Welfare benefit</ci> <ci type="logical" class="Target">Patient has an income no greater than the benefit</ci> </apply> <ci type="logical" class="Trial">Has tried at least one of the fully funded options and has been unable to tolerate it</ci> </apply> </math> <Applicant>medical practitioner</Applicant> <Term Measure="year">2</Term> </Case> <Case When="Renewal" Form="SA0265 SA0500"> <math> <apply> <or/> <ci type="logical" class="Target">Patient is on a Social Welfare benefit</ci> <ci type="logical" class="Target">Patient has an income no greater than the be
<Request To="HealthPAC" For="Subsidy" Form="SA1374"> <Title> <range>Fat<instance>Calogen</instance><instance>Liquigen</instance><instance>MCT oil (Nutricia)</instance></range> </Title> <Case When="Initial application" Category="Inborn errors of metabolism"> <math> <ci type="logical" class="Indication">The patient has inborn errors of metabolism</ci> </math> <Applicant>dietitian</Applicant> <Applicant>relevant specialist</Applicant> <Applicant>vocationally registered general practitioner</Applicant> <Term Measure="year">3</Term> </Case> <Case When="Initial application" Category="Indications other than inborn errors of metabolism"> <math> <apply> <or/> <ci type="logical" class="Indication">faltering growth in an infant/child</ci> <ci type="logical" class="Indication">bronchopulmonary dysplasia</ci> <ci type="logical" class="Indication">fat malabsorption</ci> <ci type="logical" class="Indication">lym
<Request To="HealthPAC" For="Subsidy" Form="SA1375"> <Title> <range>Protein<instance>Protifar</instance><instance>Promod</instance><instance>Resource Beneprotein</instance></range> </Title> <Case When="Initial application"> <math> <apply> <or/> <ci type="logical" class="Indication">protein losing enteropathy</ci> <ci type="logical" class="Indication">high protein needs</ci> <ci type="logical" class="Indication">for use as a component in a modular formula</ci> </apply> </math> <Applicant>dietitian</Applicant> <Applicant>relevant specialist</Applicant> <Applicant>vocationally registered general practitioner</Applicant> <Term Measure="year">1</Term> </Case> <Case When="Renewal" Form="SA0582 SA1093 SA1375"> <math> <apply> <and/> <ci type="logical" class="Indication">The treatment remains appropriate and the patient is benefiting from treatment</ci> <ci type="text" class="Endor
<Request To="HealthPAC" For="Subsidy" Form="SA1266"> <Title> <range>Sunitinib</range> </Title> <Case When="Initial application" Category="RCC"> <math> <apply> <and/> <ci type="logical" class="Indication">The patient has metastatic renal cell carcinoma</ci> <apply> <or/> <ci type="logical" class="Trial">The patient is treatment naive</ci> <ci type="logical" class="Trial">The patient has only received prior cytokine treatment</ci> <ci type="logical" class="Trial">The patient has only received prior treatment with an investigational agent within the confines of a bona fide clinical trial which has Ethics Committee approval</ci> <apply> <and/> <ci type="logical" class="Trial">The patient has discontinued pazopanib within 3 months of starting treatment due to intolerance</ci> <ci type="logical" class="Trial">The cancer did not progress whilst on pazopanib</ci>
<Request To="HealthPAC" For="Subsidy" Form="SA1273"> <Title> <range>Voriconazole</range> </Title> <Case When="Initial application" Category="invasive fungal infection"> <math> <apply> <and/> <ci type="logical" class="Indication">Patient is immunocompromised</ci> <ci type="logical" class="Indication">Applicant is part of a multidisciplinary team including an infectious disease specialist</ci> <apply> <or/> <ci type="logical" class="Indication">Patient has proven or probable invasive aspergillus infection</ci> <ci type="logical" class="Indication">Patient has possible invasive aspergillus infection</ci> <ci type="logical" class="Indication">Patient has fluconazole resistant candidiasis</ci> <ci type="logical" class="Indication">Patient has mould strain such as Fusarium spp. and Scedosporium spp</ci> </apply> </apply> </math> <Applicant>haematologist</Applicant> <App
<Request To="HealthPAC" For="Subsidy" Form="SA1228"> <Title> <range>Standard Supplements<instance>Ensure</instance><instance>Fortisip</instance><instance>Isosource</instance><instance>Jevity</instance><instance>Nutrison</instance><instance>Osmolite</instance><instance>Sustagen</instance></range> </Title> <Case When="Initial application" Category="Children"> <math> <apply> <and/> <ci type="logical" class="Indication">The patient is under 18 years of age</ci> <apply> <or/> <ci type="logical" class="Indication">The patient has a condition causing malabsorption</ci> <ci type="logical" class="Indication">The patient has failure to thrive</ci> <ci type="logical" class="Indication">The patient has increased nutritional requirements</ci> </apply> <ci type="logical" class="Indication">Nutrition goal has been set (eg reach a specific weight or BMI)</ci> </apply> </math> <Applicant>dietitia
<Request To="HealthPAC" For="Subsidy" Form="SA1046"> <Title> <range>Ezetimibe with Simvastatin<instance>Vytorin</instance></range> </Title> <Case When="Initial application"> <math> <apply> <and/> <ci type="logical" class="Indication">Patient has a calculated absolute risk of cardiovascular disease of at least 15% over 5 year</ci> <ci type="logical" class="Trial">Patient's LDL cholesterol is 2.0 mmol/litre or greater</ci> <ci type="logical" class="Trial">The patient has not reduced their LDL cholesterol to less than 2.0 mmol/litre with the use of the maximal tolerated dose of atorvastatin</ci> </apply> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="year">2</Term> <Note> <Para>A patient who has failed to reduce their LDL cholesterol to &#8804; 2.0 mmol/litre with the use of a less potent statin should use a more potent statin prior to consideration being given to the use of non-statin therapi
<Request To="Cystic Fibrosis Advisory Panel" For="Subsidy" Form="SA0611"> <Title> <range>Dornase Alfa</range> </Title> <Case When="Initial application"> <math> <ci/> </math> <Applicant>medical practitioner</Applicant> <Term Measure="year">1</Term> </Case> <Note> <Para>Application details may be obtained from PHARMAC's website <a href="http://www.pharmac.govt.nz/">http://www.pharmac.govt.nz</a> or:</Para> <Table> <TR> <TD> <Para>The Co-ordinator, Cystic Fibrosis Advisory Panel</Para> </TD> <TD> <Para>Phone: (04) 460 4990</Para> </TD> </TR> <TR> <TD> <Para>PHARMAC, PO Box 10 254</Para> </TD> <TD> <Para>Facsimile: (04) 916 7571</Para> </TD> </TR> <TR> <TD> <Para>Wellington</Para> </TD> <TD> <Para>Email: <a href="mailto:CFPanel@pharmac.govt.nz">CFPanel@pharmac.
<Request To="HealthPAC" For="Subsidy" Form="SA1451"> <Title> <range>Somatropin</range> </Title> <Case When="Initial application" Category="growth hormone deficiency in children"> <math> <apply> <or/> <apply> <and/> <ci type="logical" class="Indication">Growth hormone deficiency causing symptomatic hypoglycaemia, or with other significant growth hormone deficient sequelae (e.g. cardiomyopathy, hepatic dysfunction) and diagnosed with GH &lt; 5 mcg/l on at least two random blood samples in the first 2 weeks of life, or from samples during established hypoglycaemia (whole blood glucose &lt; 2 mmol/l using a laboratory device)</ci> </apply> <apply> <and/> <ci type="logical" class="Indication">Height velocity &lt; 25th percentile for age adjusted for bone age/pubertal status if appropriate over 6 or 12 months using the standards of Tanner and Davies (1985)</ci> <ci type="logical" class="Indication
<Request To="HealthPAC" For="Subsidy" Form="SA1139"> <Title> <range>Teriparatide</range> </Title> <Case When="Initial application"> <math> <apply> <and/> <ci type="logical" class="indication">The patient has severe, established osteoporosis</ci> <ci type="logical" class="indication">The patient has a documented T-score less than or equal to -3.0 (see Notes)</ci> <ci type="logical" class="indication">The patient has had two or more fractures due to minimal trauma</ci> <ci type="logical" class="indication">The patient has experienced at least one symptomatic new fracture after at least 12 months&#8217; continuous therapy with a funded antiresorptive agent at adequate doses (see Notes)</ci> </apply> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="month">18</Term> </Case> <Note> <List Type="Alpha"> <Item> <Para>The bone mineral density (BMD) measurement used to derive the
<Request To="PHARMAC" For="Subsidy" Form="SA1291"> <Title> <range>Optium blood glucose test strips</range> </Title> <Case When="Initial application"> <math> <ci type="logical" class="Indication">Patient identified as eligible for subsidy for FreeStyle Optium blood glucose test strips</ci> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="patient's lifetime"/> </Case> <Note> <Para>Application details may be obtained from PHARMAC's website http://www.pharmac.govt.nz and can be sent to:</Para> <Table> <TR> <TD> <Para>PHARMAC</Para> </TD> <TD> <Para/> </TD> </TR> <TR> <TD> <Para>PO Box 10 254</Para> </TD> <TD> <Para>Facsimile: (04) 974 4788</Para> </TD> </TR> <TR> <TD> <Para>Wellington</Para> </TD> <TD> <Para>Email: <a href="mailto:bgstrip
<Request To="HealthPAC" For="Subsidy" Form="SA1098"> <Title> <range>Paediatric Product For Children Awaiting Liver Transplant<instance>Heparon Junior</instance></range> </Title> <Case When="Initial application"> <math> <ci type="logical" class="Indication">The patient is a child (up to 18 years) who requires a liver transplant</ci> </math> <Applicant>dietitian</Applicant> <Applicant>relevant specialist</Applicant> <Applicant>vocationally registered general practitioner</Applicant> <Term Measure="year">3</Term> </Case> <Case When="Renewal" Form="SA0607 SA1098"> <math> <apply> <and/> <ci type="logical" class="Indication">The treatment remains appropriate and the patient is benefiting from treatment</ci> <ci type="text" class="Endorsement">General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted</ci> </apply> </math
<Request To="HealthPAC" For="Subsidy" Form="SA0845"> <Title> <range>Enfuvirtide</range> </Title> <Case When="Initial application"> <math> <apply> <and/> <ci type="logical" class="Indication">Confirmed HIV infection</ci> <ci type="logical" class="Indication">Enfuvirtide to be given in combination with optimized background therapy (including at least 1 other antiretroviral drug that the patient has never previously been exposed to) for treatment failure</ci> <apply> <or/> <ci type="logical" class="Indication">Patient has evidence of HIV replication, despite ongoing therapy</ci> <ci type="logical" class="Indication">Patient has treatment-limiting toxicity to previous antiretroviral agents</ci> </apply> <ci type="logical" class="Indication">Previous treatment with 3 different antiretroviral regimens has failed</ci> <apply> <and/> <ci type="logical" class="Indication">Prev
<Request To="HealthPAC" For="Subsidy" Form="SA0955"> <Title> <range>Isotretinoin</range> </Title> <Case When="Initial application"> <math> <apply> <and/> <ci type="logical" class="Indication">Patient has had an adequate trial on other available treatments and has received an inadequate response from these treatments or these are contraindicated</ci> <ci type="logical" class="Indication">Applicant is a vocationally registered dermatologist, vocationally registered general practitioner, or nurse practitioner working in a relevant scope of practice</ci> <ci type="logical" class="Indication">Applicant has an up to date knowledge of the treatment options for acne and is aware of the safety issues around isotretinoin and is competent to prescribe isotretinoin</ci> <apply> <or/> <ci type="logical" class="Indication">Patient is female and has been counselled and understands the risk of teratogenicity if isotretinoin is used d
<Request To="HealthPAC" For="Subsidy" Form="SA0994"> <Title> <range>Mirtazapine</range> </Title> <Case When="Initial application"> <math> <apply> <and/> <ci type="logical" class="Indication">The patient has a severe major depressive episode</ci> <apply> <or/> <ci type="logical" class="Trial">The patient must have had a trial of two different antidepressants and was unable to tolerate the treatments or failed to respond to an adequate dose over an adequate period of time (usually at least four weeks)</ci> <apply> <and/> <ci type="logical" class="Indication">The patient is currently a hospital in-patient as a result of an acute depressive episode</ci> <ci type="logical" class="Trial">The patient must have had a trial of one other antidepressant and either could not tolerate it or failed to respond to an adequate dose over an adequate period of time</ci> </apply> </appl
<Request To="HealthPAC" For="Subsidy" Form="SA1404"> <Title> <range>Valganciclovir</range> </Title> <Case When="Initial application" Category="transplant cytomegalovirus prophylaxis"> <math> <ci type="logical" class="Indication">the patient has undergone a solid organ transplant and requires valganciclovir for CMV prophylaxis</ci> </math> <Applicant>relevant specialist</Applicant> <Term Measure="month">3</Term> </Case> <Case When="Renewal" Form="SA1274 SA1404" Category="transplant cytomegalovirus prophylaxis"> <math> <apply> <and/> <ci type="logical" class="Indication">Patient has undergone a solid organ transplant and received anti-thymocyte globulin and requires valganciclovir therapy for CMV prophylaxis</ci> <ci type="logical" class="Indication">Patient is to receive a maximum of 90 days of valganciclovir prophylaxis following anti-thymocyte globulin</ci> </apply> </math> <Applicant>relevant specialist</A
<Request To="HealthPAC" For="Subsidy" Form="SA1138"> <Title> <range>Raloxifene</range> </Title> <Case When="Initial application"> <math> <apply> <or/> <ci type="logical" class="indication">History of one significant osteoporotic fracture demonstrated radiologically and documented bone mineral density (BMD) &#8805;2.5 standard deviations below the mean normal value in young adults (i.e. T-Score &#8804; -2.5) (see Notes)</ci> <ci type="logical" class="indication">History of one significant osteoporotic fracture demonstrated radiologically, and either the patient is elderly, or densitometry scanning cannot be performed because of major logistical, technical or pathophysiological reasons. It is unlikely that this provision would apply to many patients under 75 years of age</ci> <ci type="logical" class="indication">History of two significant osteoporotic fractures demonstrated radiologically</ci> <ci type="logical" class="indication">Documente
<Request To="HealthPAC" For="Subsidy" Form="SA1125"> <Title> <range>Lacosamide</range> </Title> <Case When="Initial application"> <math> <apply> <and/> <ci type="logical" class="Indication">Patient has partial-onset epilepsy</ci> <ci type="logical" class="Trial">Seizures are not adequately controlled by, or patient has experienced unacceptable side effects from, optimal treatment with all of the following: sodium valproate, topiramate, levetiracetam and any two of carbamazepine, lamotrigine and phenytoin sodium (see Note)</ci> </apply> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="month">15</Term> <Note> <Para>"Optimal treatment" is defined as treatment which is indicated and clinically appropriate for the patient, given in adequate doses for the patient's age, weight and other features affecting the pharmacokinetics of the drug with good evidence of compliance. Women of childbearing age are not re
<Request To="HealthPAC" For="Subsidy" Form="SA1376"> <Title> <range>Carbohydrate and Fat<instance>Duocal Super Soluble Powder</instance></range> </Title> <Case When="Initial application" Category="Cystic fibrosis"> <math> <apply> <and/> <ci type="logical" class="Indication">Infant or child aged four years or under</ci> <ci type="logical" class="Indication">cystic fibrosis</ci> </apply> </math> <Applicant>dietitian</Applicant> <Applicant>relevant specialist</Applicant> <Applicant>vocationally registered general practitioner</Applicant> <Term Measure="year">3</Term> </Case> <Case When="Initial application" Category="Indications other than cystic fibrosis"> <math> <apply> <and/> <ci type="logical" class="Indication">infant or child aged four years or under</ci> <apply> <or/> <ci type="logical" class="Indication">cancer in children</ci> <ci type="logica
<Request To="HealthPAC" For="Subsidy" Form="SA0895"> <Title> <range>Pilocarpine &#8211; Eye drops 2% single dose</range> </Title> <Case When="Initial application"> <math> <apply> <or/> <ci type="logical" class="Indication">Patient has to use an unpreserved solution due to an allergy to the preservative</ci> <ci type="logical" class="Indication">Patient wears soft contact lenses</ci> </apply> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="year">2</Term> <Note> <Para>Minims for a general practice are considered to be &#8220;tools of trade&#8221; and are not approved as special authority items.</Para> </Note> </Case> <Case When="Renewal" Form="SA0121 SA0895"> <math> <ci type="logical" class="Indication">The treatment remains appropriate and the patient is benefiting from treatment</ci> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="year">2<
<Request To="HealthPAC" For="Subsidy" Form="SA1072"> <Title> <range>Vigabatrin</range> </Title> <Case When="Initial application"> <math> <apply> <and/> <apply> <or/> <ci type="logical" class="Indication">Patient has infantile spasms</ci> <apply> <and/> <ci type="logical" class="Indication">Patient has epilepsy</ci> <apply> <or/> <ci type="logical" class="Indication">Seizures are not adequately controlled with optimal treatment with other antiepilepsy agents</ci> <ci type="logical" class="Indication">Seizures are controlled adequately but the patient has experienced unacceptable side effects from optimal treatment with other antiepilepsy agents</ci> </apply> </apply> </apply> <apply> <or/> <ci type="logical" class="Indication">Patient is, or will be, receiving regular automated visual fiel
<Request To="HealthPAC" For="Subsidy" Form="SA1408"> <Title> <range>Naltrexone</range> </Title> <Case When="Initial application"> <math> <apply> <and/> <ci type="logical" class="Indication">Patient is currently enrolled in a recognised comprehensive treatment programme for alcohol dependence</ci> <ci type="logical" class="Therapy">Applicant works in or with a community Alcohol and Drug Service contracted to one of the District Health Boards or accredited against the New Zealand Alcohol and Other Drug Sector Standard or the National Mental Health Sector Standard</ci> </apply> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="month">6</Term> </Case> <Case When="Renewal" Form="SA0714 SA0909 SA1397 SA1408"> <math> <apply> <and/> <ci type="logical" class="Indication">Compliance with the medication (prescriber determined)</ci> <apply> <or/> <ci type="log
<Request To="HealthPAC" For="Subsidy" Form="SA1174"> <Title> <range>Enoxaparin sodium</range> </Title> <Case When="Initial application" Category="Pregnancy or Malignancy"> <math> <apply> <or/> <ci type="logical" class="Indication">Low molecular weight heparin treatment is required during a patients pregnancy</ci> <ci type="logical" class="Treatment">For the treatment of venous thromboembolism where the patient has a malignancy</ci> </apply> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="year">1</Term> </Case> <Case When="Initial application" Category="Venous thromboembolism other than in pregnancy or malignancy"> <math> <apply> <or/> <ci type="logical" class="Indication">For the short-term treatment of venous thromboembolism prior to establishing a therapeutic INR with oral anti-coagulant treatment</ci> <ci type="logical" class="Treatment">For the prophylaxis and tre
<Request To="HealthPAC" For="Subsidy" Form="SA1416"> <Title> <range>Atomoxetine</range> </Title> <Case When="Initial application"> <math> <apply> <and/> <ci type="logical" class="Indication">Patient has ADHD (Attention Deficit and Hyperactivity Disorder) diagnosed according to DSM-IV or ICD 10 criteria</ci> <ci type="logical" class="Indication">Once-daily dosing</ci> <apply> <or/> <ci type="logical" class="Indication">Treatment with a subsidised formulation of a stimulant has resulted in the development or worsening of serious adverse reactions or where the combination of subsidised stimulant treatment with another agent would pose an unacceptable medical risk</ci> <ci type="logical" class="Indication">Treatment with a subsidised formulation of a stimulant has resulted in worsening of co-morbid substance abuse or there is a significant risk of diversion with subsidised stimulant therapy</ci> <ci type="log
<Request To="HealthPAC" For="Subsidy" Form="SA1263"> <Title> <range>Nicorandil</range> </Title> <Case When="Initial application"> <math> <apply> <and/> <ci type="logical" class="Indication">Patient has refractory angina</ci> <ci type="logical" class="Trial">Patient is on the maximal tolerated dose of a beta-blocker, a calcium channel blocker and a long acting nitrate</ci> </apply> </math> <Applicant>cardiologist</Applicant> <Applicant>general physician</Applicant> <Term Measure="year">2</Term> </Case> <Case When="Renewal" Form="SA1263"> <math> <ci type="logical" class="Indication">The treatment remains appropriate and the patient is benefiting from treatment</ci> </math> <Applicant>cardiologist</Applicant> <Applicant Referring="cardiologist">any relevant practitioner</Applicant> <Term Measure="year">2</Term> </Case></Request>
<Request To="HealthPAC" For="Subsidy" Form="SA0927"> <Title> <range>Risperidone orally disintegrating tablets</range> </Title> <Case When="Initial application" Category="Acute situations"> <math> <apply> <and/> <ci type="logical" class="Use">For a non-adherent patient on oral therapy with standard risperidone tablets or risperidone oral liquid</ci> <ci type="logical" class="Therapy">The patient is under direct supervision for administration of medicine</ci> </apply> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="week">6</Term> </Case> <Case When="Initial application" Category="Chronic situations"> <math> <apply> <and/> <ci type="logical" class="Indication">The patient is unable to take standard risperidone tablets or oral liquid, or once stabilized refuses to take risperidone tablets or oral liquid</ci> <ci type="logical" class="Therapy">The patient is under direct
<Request To="HealthPAC" For="Subsidy" Form="SA1195"> <Title> <range>High Calorie Products<instance>Two Cal HN</instance><instance>Nutrison Concentrated</instance></range> </Title> <Case When="Initial application" Category="Cystic fibrosis"> <math> <apply> <and/> <ci type="logical" class="Indication">Cystic fibrosis</ci> <ci type="logical" class="Trial">other lower calorie products have been tried</ci> <ci type="logical" class="Indication">patient has substantially increased metabolic requirements</ci> </apply> </math> <Applicant>dietitian</Applicant> <Applicant>relevant specialist</Applicant> <Applicant>vocationally registered general practitioner</Applicant> <Term Measure="year">3</Term> </Case> <Case When="Initial application" Category="Indications other than cystic fibrosis"> <math> <apply> <and/> <apply> <or/> <ci type="logical" class="Indication">any cond
<Request To="HealthPAC" For="Subsidy" Form="SA1199"> <Title> <range>Propylthiouracil</range> </Title> <Case When="Initial application"> <math> <apply> <and/> <ci type="logical" class="Indication">The patient has hyperthyroidism</ci> <ci type="logical" class="Indication">The patient is intolerant of carbimazole or carbimazole is contraindicated</ci> </apply> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="year">2</Term> </Case> <Case When="Renewal" Form="SA1199"> <math> <ci type="logical" class="Indication">the treatment remains appropriate and the patient is benefitting from the treatment</ci> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="year">2</Term> </Case></Request>
<Request To="PHARMAC" For="Subsidy" Form="SA1237"> <Title> <range>Insulin Pumps</range> </Title> <Case When="Initial application"> <math/> <Applicant>medical practitioner</Applicant> <Term Measure="year">1</Term> </Case> <Note> <Para>Application details may be obtained from PHARMAC's website <a href="http://www.pharmac.govt.nz/">http://www.pharmac.govt.nz</a> or:</Para> <Table> <TR> <TD> <Para>The IPP Co-ordinator</Para> </TD> <TD> <Para>Phone: (04) 460 4990</Para> </TD> </TR> <TR> <TD> <Para>PHARMAC</Para> </TD> <TD> <Para>Facsimile: (04) 974 7806</Para> </TD> </TR> <TR> <TD> <Para>PO Box 10 254</Para> </TD> <TD> <Para>Email: <a href="mailto:ipp@pharmac.govt.nz">ipp@pharmac.govt.nz</a></Para> </TD> </TR> <TR> <TD> <Para>Welli
<Request To="HealthPAC" For="Subsidy" Form="SA0829"> <Title> <range>Adefovir dipivoxil</range> </Title> <Case When="Initial application"> <math> <apply> <and/> <ci type="logical" class="Trial">Patient has confirmed Hepatitis B infection (HBsAg+)</ci> <mi class="heading">Documented resistance to lamivudine, defined as:</mi> <ci type="logical" class="Trial">Patient has raised serum ALT (&gt; 1 &#215; ULN)</ci> <ci type="logical" class="Trial">Patient has HBV DNA greater than 100,000 copies per mL, or viral load &#8805; 10 fold over nadir</ci> <ci type="logical" class="Trial">Detection of M204I or M204V mutation</ci> <apply> <or/> <apply> <and/> <ci type="logical" class="Trial">Patient is cirrhotic</ci> <ci type="logical" class="Trial">adefovir dipivoxil to be used in combination with lamivudine</ci> </apply> <apply> <and/>
<Request To="HealthPAC" For="Subsidy" Form="SA0998"> <Title> <range>Solifenacin succinate</range> </Title> <Case When="Initial application"> <math> <ci type="logical" class="Indication">The patient has overactive bladder and a documented intolerance of, or is non-responsive to oxybutynin</ci> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="patient's lifetime"/> </Case></Request>
<Request To="HealthPAC" For="Subsidy" Form="SA1332"> <Title> <range>Tetracycline</range> </Title> <Case When="Initial application"> <math> <apply> <and/> <ci type="logical" class="Indication">For the eradication of helicobacter pylori following unsuccessful treatment with appropriate first-line therapy</ci> <ci type="logical" class="Indication">For use only in combination with bismuth as part of a quadruple therapy regimen</ci> </apply> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="month">3</Term> </Case></Request>
<Request To="HealthPAC" For="Subsidy" Form="SA1379"> <Title> <range>Paediatric Products<instance>Nutrini</instance><instance>Pediasure</instance><instance>Fortini</instance></range> </Title> <Case When="Initial application"> <math> <apply> <and/> <ci type="logical" class="Indication">Child is aged one to ten years</ci> <apply> <or/> <ci type="logical" class="Indication">the child is being fed via a tube or a tube is to be inserted for the purposes of feeding</ci> <ci type="logical" class="Indication">any condition causing malabsorption</ci> <ci type="logical" class="Indication">faltering growth in an infant/child</ci> <ci type="logical" class="Indication">increased nutritional requirements</ci> <ci type="logical" class="Indication">the child is being transitioned from TPN or tube feeding to oral feeding</ci> </apply> </apply> </math> <Applicant>dietitian</Applicant>
<Request To="HealthPAC" For="Subsidy" Form="SA1382"> <Title> <range>Ticagrelor</range> </Title> <Case When="Initial application" Category="acute coronary syndrome"> <math> <apply> <and/> <ci type="logical" class="Indication">Patient has recently been diagnosed with an ST-elevation or a non-ST-elevation acute coronary syndrome</ci> <ci type="logical" class="Indication">Fibrinolytic therapy has not been given in the last 24 hours and is not planned</ci> </apply> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="month">12</Term> </Case> <Case When="Renewal" Category="subsequent acute coronary syndrome" Form="SA1382"> <math> <apply> <and/> <ci type="logical" class="Indication">Patient has recently been diagnosed with an ST-elevation or a non-ST-elevation acute coronary syndrome</ci> <ci type="logical" class="Indication">Fibrinolytic therapy has not been given in the last 24
<Request To="HealthPAC" For="Subsidy" Form="SA1383"> <Title> <range>Ursodeoxycholic Acid</range> </Title> <Case When="Initial application" Category="Alagille syndrome or progressive familial intrahepatic cholestasis"> <math> <apply> <or/> <ci type="logical" class="Indication">Patient has been diagnosed with Alagille syndrome</ci> <ci type="logical" class="Indication">Patient has progressive familial intrahepatic cholestasis</ci> </apply> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="patient's lifetime"/> </Case> <Case When="Initial application" Category="Chronic severe drug induced cholestatic liver injury"> <math> <apply> <and/> <ci type="logical" class="Indication">Patient has chronic severe drug induced cholestatic liver injury</ci> <ci type="logical" class="Indication">Cholestatic liver injury not due to Total Parenteral Nutrition (TPN) use in adults</ci>
<Request To="HealthPAC" For="Subsidy" Form="SA1192"> <Title> <range>Trastuzumab</range> </Title> <Case When="Initial application" Category="metastatic breast cancer"> <math> <apply> <or/> <apply> <and/> <ci type="logical" class="Indication">The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology)</ci> <ci type="logical" class="Treatment">The patient has not previously received lapatinib treatment for HER 2 positive metastatic breast cancer</ci> <ci type="logical" class="Indication">Trastuzumab not to be given in combination with lapatinib</ci> <ci type="logical" class="Treatment">Trastuzumab to be discontinued at disease progression</ci> </apply> <apply> <and/> <ci type="logical" class="Indication">The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology
<Request To="HealthPAC" For="Subsidy" Form="SA1071"> <Title> <range>Gabapentin</range> </Title> <Case When="Initial application" Category="Epilepsy"> <math> <apply> <or/> <ci type="logical" class="Indication">Seizures are not adequately controlled with optimal treatment with other antiepilepsy agents</ci> <ci type="logical" class="Indication">Seizures are controlled adequately but the patient has experienced unacceptable side effects from optimal treatment with other antiepilepsy agents</ci> </apply> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="month">15</Term> <Note> <Para>"Optimal treatment with other antiepilepsy agents" is defined as treatment with other antiepilepsy agents which are indicated and clinically appropriate for the patient, given in adequate doses for the patient's age, weight, and other features affecting the pharmacokinetics of the drug with good evidence of compliance.</Para>
<Request To="HealthPAC" For="Subsidy" Form="SA1066"> <Title> <range>Rivaroxaban</range> </Title> <Case When="Initial application"> <math> <apply> <or/> <ci type="logical" class="Indication">For the prophylaxis of venous thromboembolism following a total hip replacement</ci> <ci type="logical" class="Use">For the prophylaxis of venous thromboembolism following a total knee replacement</ci> </apply> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="week">5</Term> <Note> <Para>Rivaroxaban is only currently indicated and subsidised for up to 5 weeks therapy for prophylaxis of venous thromboembolism following a total hip replacement and up to 2 weeks therapy for prophylaxis of venous thromboembolism following a total knee replacement.</Para> </Note> </Case> <Case When="Renewal" Form="SA1066"> <math> <ci type="logical" class="Indication">Prophylaxis for venous thromboembolism is requir
<Request To="PHARMAC" For="Subsidy" Form="SA1240"> <Title> <range>Insulin pump consumables</range> </Title> <Case When="Initial application"> <math/> <Applicant>medical practitioner</Applicant> <Term Measure="year">1</Term> </Case> <Note> <Para>Application details may be obtained from PHARMAC's website <a href="http://www.pharmac.govt.nz/">http://www.pharmac.govt.nz</a> or:</Para> <Table> <TR> <TD> <Para>The IPP Co-ordinator</Para> </TD> <TD> <Para>Phone: (04) 460 4990</Para> </TD> </TR> <TR> <TD> <Para>PHARMAC</Para> </TD> <TD> <Para>Facsimile: (04) 974 7806</Para> </TD> </TR> <TR> <TD> <Para>PO Box 10 254</Para> </TD> <TD> <Para>Email: <a href="mailto:ipp@pharmac.govt.nz">ipp@pharmac.govt.nz</a></Para> </TD> </TR> <TR> <TD>
<Request To="HealthPAC" For="Subsidy" Form="SA1289"> <Title> <range>Capsaicin</range> </Title> <Case When="Initial application"> <math> <ci type="logical" class="Indication">The patient has osteoarthritis that is not responsive to paracetamol and oral non-steroidal anti-inflammatories are contraindicated</ci> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="patient's lifetime"/> </Case></Request>
<Request To="HealthPAC" For="Subsidy" Form="SA1039"> <Title> <range>Alendronate Tab 70 mg - with or without Cholecalciferol</range> </Title> <Case When="Initial application" Category="Underlying cause -- Osteoporosis"> <math> <apply> <or/> <ci type="logical" class="Indication">History of one significant osteoporotic fracture demonstrated radiologically and documented bone mineral density (BMD) &#8805; 2.5 standard deviations below the mean normal value in young adults (i.e. T-Score &#8804; -2.5) (see Note)</ci> <ci type="logical" class="Indication">History of one significant osteoporotic fracture demonstrated radiologically, and either the patient is elderly, or densitometry scanning cannot be performed because of major logistical, technical or pathophysiological reasons. It is unlikely that this provision would apply to many patients under 75 years of age</ci> <ci type="logical" class="Indication">History of two significant osteoporotic fractures
<Request To="HealthPAC" For="Manufacturers Price" Form="SA1355"> <Title> <range>Minocycline hydrochloride Tab 50 mg</range> </Title> <Case When="Initial application"> <math> <ci type="logical" class="Indication">The patient has rosacea</ci> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="patient's lifetime"/> </Case></Request>
<Request To="HealthPAC" For="Subsidy" Form="SA1324"> <Title> <range>Paromomycin</range> </Title> <Case When="Initial application"> <math> <ci type="logical" class="Indication">the patient has confirmed cryptosporidium infection</ci> </math> <Applicant>infectious disease specialist</Applicant> <Applicant>clinical microbiologist</Applicant> <Term Measure="month">1</Term> </Case> <Case When="Renewal" Form="SA1324"> <math> <ci type="logical" class="Indication">the patient has confirmed cryptosporidium infection</ci> </math> <Applicant>infectious disease specialist</Applicant> <Applicant>clinical microbiologist</Applicant> <Term Measure="month">1</Term> </Case></Request>
<Request To="HealthPAC" For="Subsidy" Form="SA1126"> <Title> <range>Modavigil</range> </Title> <Case When="Initial application"> <math> <apply> <and/> <ci type="logical" class="Indication">The patient has a diagnosis of narcolepsy and has excessive daytime sleepiness associated with narcolepsy occurring almost daily for three months or more</ci> <apply> <or/> <ci type="logical" class="Indication">The patient has a multiple sleep latency test with a mean sleep latency of less than or equal to 10 minutes and 2 or more sleep onset rapid eye movement periods</ci> <ci type="logical" class="Indication">The patient has at least one of: cataplexy, sleep paralysis or hypnagogic hallucinations</ci> </apply> <apply> <or/> <ci type="logical" class="Indication">An effective dose of a subsidised formulation of methylphenidate or dexamphetamine has been trialled and discontinued because of intolerabl
<Request To="HealthPAC" For="Subsidy" Form="SA0928"> <Title> <range>Finasteride</range> </Title> <Case When="Initial application"> <math> <apply> <and/> <ci type="logical" class="Indication">Patient has symptomatic benign prostatic hyperplasia</ci> <apply> <or/> <ci type="logical" class="Indication">The patient is intolerant of non-selective alpha blockers or these are contraindicated</ci> <ci type="logical" class="Indication">Symptoms are not adequately controlled with non-selective alpha blockers</ci> </apply> </apply> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="patient's lifetime"/> </Case> <Note> <Para>Patients with enlarged prostates are the appropriate candidates for therapy with finasteride.</Para> </Note></Request>
<Request To="HealthPAC" For="Subsidy" Form="SA1099"> <Title> <range>Paediatric Product For Children With Chronic Renal Failure<instance>Kindergen</instance></range> </Title> <Case When="Initial application"> <math> <ci type="logical" class="Indication">The patient is a child (up to 18 years) with acute or chronic kidney disease</ci> </math> <Applicant>dietitian</Applicant> <Applicant>relevant specialist</Applicant> <Applicant>vocationally registered general practitioner</Applicant> <Term Measure="year">3</Term> </Case> <Case When="Renewal" Form="SA0606 SA1099"> <math> <apply> <and/> <ci type="logical" class="Indication">The treatment remains appropriate and the patient is benefiting from treatment</ci> <ci type="text" class="Endorsement">General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted</ci> </apply> </mat
<Request To="HealthPAC" For="Subsidy" Form="SA1272"> <Title> <range>Tolterodine</range> </Title> <Case When="Initial application"> <math> <ci type="logical" class="Indication">Patient has overactive bladder and a documented intolerance of, or is non-responsive to oxybutynin</ci> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="patient's lifetime"/> </Case></Request>
<Request To="HealthPAC" For="Subsidy" Form="SA1381"> <Title> <range>Fat Modified Products<instance>Monogen</instance></range> </Title> <Case When="Initial application"> <math> <apply> <or/> <ci type="logical" class="Indication">Patient has metabolic disorders of fat metabolism</ci> <ci type="logical" class="Indication">Patient has a chyle leak</ci> <ci type="logical" class="Indication">Modified as a modular feed for adults</ci> </apply> </math> <Applicant>dietitian</Applicant> <Applicant>relevant specialist</Applicant> <Applicant>vocationally registered general practitioner</Applicant> <Term Measure="year">1</Term> </Case> <Case When="Renewal" Form="SA0593 SA0615 SA1096 SA1381"> <math> <apply> <and/> <ci type="logical" class="Indication">The treatment remains appropriate and the patient is benefiting from treatment</ci> <ci type="text" class="Endorsement">General Practitio
<Request To="HealthPAC" For="Subsidy" Form="SA0782"> <Title> <range>Levonorgestrel &#8211; releasing intrauterine system 20mcg/24 hr</range> </Title> <Case When="Initial application" Category="No previous use"> <math> <apply> <and/> <ci type="logical" class="Indication">The patient has a clinical diagnosis of heavy menstrual bleeding</ci> <ci type="logical" class="Trial">The patient has failed to respond to or is unable to tolerate other appropriate pharmaceutical therapies as per the Heavy Menstrual Bleeding Guidelines</ci> <apply> <or/> <apply> <lt/> <ci type="real" class="test">serum ferritin level</ci> <cn>16<mi> mcg/l (within the last 12 months)</mi></cn> </apply> <apply> <lt/> <ci type="real" class="test">haemoglobin level</ci> <cn>120<mi> g/l</mi></cn> </apply> </apply> </apply> </math>
<Request To="HealthPAC" For="Subsidy" Form="SA1032"> <Title> <range>Tamsulosin</range> </Title> <Case When="Initial application"> <math> <apply> <and/> <ci type="logical" class="Indication">Patient has symptomatic benign prostatic hyperplasia</ci> <ci type="logical" class="Indication">The patient is intolerant of non-selective alpha blockers or these are contraindicated</ci> </apply> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="patient's lifetime"/> </Case></Request>
<Request To="HealthPAC" For="Subsidy" Form="SA0954"> <Title> <range>Acitretin</range> </Title> <Case When="Initial application"> <math> <apply> <and/> <ci type="logical" class="Indication">Applicant is a vocationally registered dermatologist, vocationally registered general practitioner, or nurse practitioner working in a relevant scope of practice</ci> <ci type="logical" class="Indication">Applicant has an up to date knowledge of the treatment options for psoriasis and of disorders of keratinisation and is aware of the safety issues around acitretin and is competent to prescribe acitretin</ci> <apply> <or/> <ci type="logical" class="Indication">Patient is female and has been counselled and understands the risk of teratogenicity if acitretin is used during pregnancy and the applicant has ensured that the possibility of pregnancy has been excluded prior to the commencement of the treatment and that the patient is informed that
<Request To="HealthPAC" For="Subsidy" Form="SA0987"> <Title> <range>Aprepitant</range> </Title> <Case When="Initial application"> <math> <ci type="logical" class="Indication">The patient is undergoing highly emetogenic chemotherapy and/or anthracycline-based chemotherapy for the treatment of malignancy</ci> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="month">12</Term> </Case> <Case When="Renewal" Form="SA0987"> <math> <ci type="logical" class="Indication">The patient is undergoing highly emetogenic chemotherapy and/or anthracycline-based chemotherapy for the treatment of malignancy</ci> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="month">12</Term> </Case></Request>
<Request To="HealthPAC" For="Subsidy" Form="SA1042"> <Title> <range>Deferiprone</range> </Title> <Case When="Initial application"> <math> <ci type="logical" class="Indication">The patient has been diagnosed with chronic transfusional iron overload due to congenital inherited anaemia</ci> </math> <Applicant>relevant specialist</Applicant> <Term Measure="patient's lifetime"/> </Case> <Note> <Para>For the purposes of this Special Authority, a relevant specialist is defined as a haematologist.</Para> </Note></Request>
<Request To="HealthPAC" For="Subsidy" Form="SA1155"> <Title> <range>Budesonide - Cap 3 mg Controlled Release</range> </Title> <Case When="Initial application" Category="Crohn's disease"> <math> <apply> <and/> <ci type="logical" class="Indication">Mild to moderate ileal, ileocaecal or proximal Crohn's disease</ci> <apply> <or/> <ci type="logical" class="Indication">Diabetes</ci> <ci type="logical" class="Indication">Cushingoid habitus</ci> <ci type="logical" class="Indication">Osteoporosis where there is significant risk of fracture</ci> <ci type="logical" class="Indication">Severe acne following treatment with conventional corticosteroid therapy</ci> <ci type="logical" class="Indication">History of severe psychiatric problems associated with corticosteroid treatment</ci> <ci type="logical" class="Indication">History of major mental illness (such as bipolar affective disorder) where
<Request To="HealthPAC" For="Subsidy" Form="SA1421"> <Title> <range>Montelukast</range> </Title> <Case When="Initial application" Category="Pre-school wheeze"> <math> <apply> <and/> <ci type="logical" class="Indication">To be used for the treatment of intermittent severe wheezing (possibly viral) in children under 5 years</ci> <ci type="logical" class="Indication">The patient has had at least three episodes in the previous 12 months of acute wheeze severe enough to seek medical attention</ci> </apply> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="year">1</Term> </Case> <Case When="Renewal" Category="Pre-school wheeze" Form="SA1227 SA1409 SA1421"> <math> <ci type="logical" class="Indication">The treatment remains appropriate and the patient is benefiting from treatment</ci> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="year">2</Term> </Case> <Case
<Request To="PHARMAC" For="Subsidy" Form="SA0973"> <Title> <range>Neurontin</range> </Title> <Case When="Initial application"> <math> <ci type="logical" class="Indication">Subsidy for patients pre-approved on 1 August 2009</ci> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="patient's lifetime"/> </Case> <Note> <Para>Subsidy for patients pre-approved by PHARMAC on 1 August 2009. Approvals valid without further renewal unlessnotified.</Para> <Para>No new approvals will be granted from 1 August 2009.</Para> </Note></Request>
<Request To="HealthPAC" For="Subsidy" Form="SA1196"> <Title> <range>Paediatric enteral feed with fibre 0.75 kcal/ml<instance>Nutrini Low Energy Multi Fibre</instance></range> </Title> <Case When="Initial application"> <math overflow="scroll"> <apply> <and/> <ci type="logical" class="Indication">Child aged one to eight years</ci> <ci type="logical" class="Indication">The child has a low energy requirement but normal protein and micronutrient requirements</ci> </apply> </math> <Applicant>dietitian</Applicant> <Applicant>relevant specialist</Applicant> <Applicant>vocationally registered general practitioner</Applicant> <Term Measure="year">1</Term> </Case> <Case When="Renewal" Form="SA1196"> <math overflow="scroll"> <apply> <and/> <ci type="logical" class="Indication">The treatment remains appropriate and the patient is benefiting from treatment</ci> <ci type="text" class="Endorsement
<Request To="HealthPAC" For="Subsidy" Form="SA1225"> <Title> <range>Ivermectin</range> </Title> <Case When="Initial application" Category="Scabies"> <math> <apply> <and/> <ci type="logical" class="Indication">Applying clinician has discussed the diagnosis of scabies with a dermatologist, infectious disease physician or clinical microbiologist</ci> <apply> <or/> <apply> <and/> <ci type="logical" class="Indication">The patient is in the community</ci> <apply> <or/> <ci type="logical" class="Indication">Patient has a severe scabies hyperinfestation (Crusted/ Norwegian scabies)</ci> <ci type="logical" class="Indication">The community patient is physically or mentally unable to comply with the application instructions of topical therapy</ci> <ci type="logical" class="Indication">The patient has previously tried and failed to clear infestation
<Request To="HealthPAC" For="Subsidy" Form="SA1322"> <Title> <range>Itraconazole</range> </Title> <Case When="Initial application"> <math> <ci type="logical" class="Indication">The patient has a congenital immune deficiency</ci> </math> <Applicant>infectious disease specialist</Applicant> <Applicant>clinical microbiologist</Applicant> <Applicant>clinical immunologist</Applicant> <Applicant Referring="infectious disease physician, clinical microbiologist or clinical immunologist">any relevant practitioner</Applicant> <Term Measure="month">6</Term> </Case> <Case When="Renewal" Form="SA1322"> <math> <ci type="logical" class="Indication">The treatment remains appropriate and the patient is benefitting from the treatment</ci> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="month">6</Term> </Case></Request>
<Request To="HealthPAC" For="Subsidy" Form="SA1223"> <Title> <range>Candesartan</range> </Title> <Case When="Initial application" Category="ACE inhibitor intolerance"> <math> <apply> <or/> <ci type="logical" class="Indication">Patient has persistent ACE inhibitor induced cough that is not resolved by ACE inhibitor retrial (same or new ACE inhibitor)</ci> <ci type="logical" class="Indication">Patient has a history of angioedema</ci> </apply> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="patient's lifetime"/> </Case> <Case When="Initial application" Category="Unsatisfactory response to ACE inhibitor"> <math> <ci type="logical" class="Indication">patient is not adequately controlled on maximum tolerated dose of an ACE inhibitor</ci> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="patient's lifetime"/> </Case></Request>
<Request To="HealthPAC" For="Subsidy" Form="SA0922"> <Title> <range>Erythropoietin</range> </Title> <Case When="Initial application"> <math> <apply> <and/> <apply> <and/> <ci type="logical" class="Indication">patient in chronic renal failure</ci> <apply> <leq/> <ci type="real" class="test">Haemoglobin</ci> <cn>100<mi>g/L</mi></cn> </apply> </apply> <apply> <or/> <apply> <and/> <ci type="logical" class="Indication">patient is not diabetic</ci> <apply> <leq/> <ci type="real" class="test">glomerular filtration rate</ci> <cn>30<mi>ml/min</mi></cn> </apply> </apply> <apply> <and/> <ci type="logical" class="Indication">patient is diabetic</ci> <apply> <leq/> <ci type
<Request To="HealthPAC" For="Subsidy" Form="SA1198"> <Title> <range>Preterm post-discharge infant formula powder<instance>S-26 Gold Premgro</instance></range> </Title> <Case When="Initial application"> <math overflow="scroll"> <apply> <and/> <ci type="logical" class="Indication">The infant was born before 33 weeks gestation or weighed less than 1.5 kg at birth</ci> <apply> <or/> <ci type="logical" class="Indication">The infant has faltering growth (downward crossing of percentiles)</ci> <ci type="logical" class="Indication">The infant is not maintaining, or is considered unlikely to maintain, adequate growth on standard infant formula</ci> </apply> </apply> </math> <Applicant>dietitian</Applicant> <Applicant>relevant specialist</Applicant> <Applicant>vocationally registered general practitioner</Applicant> <Term Measure="month">6</Term> </Case></Request>
<Request To="HealthPAC" For="Subsidy" Form="SA1124"> <Title> <range>Thalidomide</range> </Title> <Case When="Initial application"> <math> <apply> <or/> <ci type="logical" class="indication">The patient has multiple myeloma</ci> <ci type="logical" class="indication">The patient has systemic AL amyloidosis*</ci> </apply> </math> <Applicant>relevant specialist</Applicant> <Applicant Referring="relevant specialist">medical practitioner</Applicant> <Term Measure="month">12</Term> </Case> <Case When="Renewal" Form="SA1124 SA0817 SA0882"> <math> <ci type="logical" class="indication">The patient has obtained a response from treatment during the initial approval period</ci> </math> <Applicant>relevant specialist</Applicant> <Applicant Referring="relevant specialist">medical practitioner</Applicant> <Term Measure="patient's lifetime"/> </Case> <Note> <Para>Prescription must be written by a re
<Request To="HealthPAC" For="Subsidy" Form="SA1321"> <Title> <range>Hydralazine</range> </Title> <Case When="Initial application"> <math> <apply> <or/> <ci type="logical" class="Indication">For the treatment of refractory hypertension</ci> <ci type="logical" class="Indication">For the treatment of heart failure in combination with a nitrate, in patients who are intolerant or have not responded to ACE inhibitors and/or angiotensin receptor blockers</ci> </apply> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="patient's lifetime"/> </Case></Request>
<Request To="HealthPAC" For="Subsidy" Form="SA1260"> <Title> <range>Perhexiline Maleate</range> </Title> <Case When="Initial application"> <math> <apply> <and/> <ci type="logical" class="Indication">Patient has refractory angina</ci> <ci type="logical" class="Trial">Patient is on the maximal tolerated dose of a beta-blocker, a calcium channel blocker and a long acting nitrate</ci> </apply> </math> <Applicant>cardiologist</Applicant> <Applicant>general physician</Applicant> <Term Measure="year">2</Term> </Case> <Case When="Renewal" Form="SA0256 SA1260"> <math> <ci type="logical" class="Indication">The treatment remains appropriate and the patient is benefiting from treatment</ci> </math> <Applicant>cardiologist</Applicant> <Applicant Referring="cardiologist">any relevant practitioner</Applicant> <Term Measure="year">2</Term> </Case></Request>
<Request To="HealthPAC" For="Subsidy" Form="SA1326"> <Title> <range>Primaquine</range> </Title> <Case When="Initial application"> <math> <apply> <and/> <ci type="logical" class="Indication">The patient has vivax or ovale malaria</ci> <ci type="logical" class="Indication">Primaquine is to be given for a maximum of 21 days</ci> </apply> </math> <Applicant>infectious disease specialist</Applicant> <Applicant>clinical microbiologist</Applicant> <Term Measure="month">1</Term> </Case></Request>
<Request To="HealthPAC" For="Subsidy" Form="SA1285"> <Title> <range>Posaconazole </range> </Title> <Case When="Initial application"> <math> <apply> <or/> <ci type="logical" class="Indication">Patient has acute myeloid leukaemia and is to be treated with high dose remission induction, re-induction or consolidation chemotherapy</ci> <ci type="logical" class="Indication">Patient has received a stem cell transplant and has graft versus host disease and is on significant immunosuppressive therapy*</ci> </apply> </math> <Applicant>haematologist</Applicant> <Applicant>infectious disease specialist</Applicant> <Term Measure="week">6</Term> </Case> <Case When="Renewal" Form="SA1285"> <math> <apply> <or/> <ci type="logical" class="Indication">Patient has acute myeloid leukaemia and is to be treated with high dose remission induction, re-induction or consolidation therapy</ci> <ci type="logical" c
<Request To="HealthPAC" For="Subsidy" Form="SA1386"> <Title> <range>Phenobarbitone</range> </Title> <Case When="Initial application"> <math> <apply> <and/> <ci type="logical" class="Indication">For the treatment of terminal agitation that is unresponsive to other agents</ci> <ci type="logical" class="Indication">The applicant is part of a multidisciplinary team working in palliative care</ci> </apply> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="patient's lifetime"/> </Case></Request>
<Request To="HealthPAC" For="Subsidy" Form="SA1293"> <Title> <range>Sildenafil</range> </Title> <Case When="Initial application" Category="Raynaud&#8217;s Phenomenon* - for Pulmonary Arterial Hypertension see note below)"> <math> <apply> <and/> <ci type="logical" class="Indication">Patient has Raynaud&#8217;s Phenomenon*</ci> <ci type="logical" class="Indication">Patient has severe digital ischaemia (defined as severe pain requiring hospital admission or with a high likelihood of digital ulceration; digital ulcers; or gangrene)</ci> <ci type="logical" class="Indication">Patient is following lifestyle management (avoidance of cold exposure, sufficient protection, smoking cessation support, avoidance of sympathomimetic drugs) </ci> <ci type="logical" class="Indication">Patient is being treated with calcium channel blockers and nitrates (or these are contraindicated/not tolerated)</ci> </apply> </math> <Applicant>any relevant
<Request To="HealthPAC" For="Subsidy" Form="SA1061"> <Title> <range>Venlafaxine</range> </Title> <Case When="Initial application"> <math> <apply> <and/> <ci type="logical" class="Indication">The patient has 'treatment-resistant' depression</ci> <apply> <or/> <ci type="logical" class="Trial">The patient must have had a trial of two different antidepressants and have had an inadequate response from an adequate dose over an adequate period of time (usually at least four weeks)</ci> <apply> <and/> <ci type="logical" class="Indication">The patient is currently a hospital in-patient as a result of an acute depressive episode</ci> <ci type="logical" class="Trial">The patient must have had a trial of one other antidepressant and have had an inadequate response from an adequate dose over an adequate period of time</ci> </apply> </apply> </apply> </math> <Appl
<Request To="HealthPAC" For="Subsidy" Form="SA1411"> <Title> <range>Erlotinib</range> </Title> <Case When="Initial application"> <math> <apply> <or/> <apply> <and/> <ci type="logical" class="Indication">Patient has locally advanced or metastatic, unresectable, non-squamous Non Small Cell Lung Cancer (NSCLC)</ci> <ci type="logical" class="Indication">There is documentation confirming that the disease expresses activating mutations of EGFR tyrosine kinase</ci> <apply> <or/> <ci type="logical" class="Indication">Patient is treatment naive</ci> <apply> <and/> <ci type="logical" class="Indication">Patient has documented disease progression following treatment with first line platinum based chemotherapy</ci> <ci type="logical" class="Indication">Patient has not received prior treatment with gefitinib</ci> </apply> </apply>
<Request To="HealthPAC" For="Alternate Subsidy" Form="SA1018"> <Title> <range>Hormone Replacement Therapy - Systemic</range> </Title> <Case When="Initial application"> <math> <apply> <or/> <ci type="logical" class="Indication">acute or significant liver disease - where oral oestrogens are contraindicated as determined by a gastroenterologist or general physician. The applicant must keep written confirmation from such a specialist with the patient's record</ci> <ci type="logical" class="Indication">oestrogen induced hypertension requiring antihypertensive therapy - documented evidence must be kept on file that raised blood pressure levels or inability to control blood pressure adequately occurred post oral oestrogens</ci> <ci type="logical" class="Indication">hypertriglyceridaemia - documented evidence must be kept on file that triglyceride levels increased to at least 2 &#215; normal triglyceride levels post oral oestrogens</ci> <ci type=
<Request To="HealthPAC" For="Subsidy" Form="SA1320"> <Title> <range>Diazoxide</range> </Title> <Case When="Initial application"> <math> <ci type="logical" class="Indication">used for the treatment of confirmed hypoglycaemia caused by hyperinsulinism</ci> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="month">12</Term> </Case> <Case When="Renewal" Form="SA1320"> <math> <ci type="logical" class="Indication">The treatment remains appropriate and the patient is benefiting from treatment</ci> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="patient's lifetime"/> </Case></Request>
<Request To="HealthPAC" For="Subsidy" Form="SA1318"> <Title> <range>Albendazole</range> </Title> <Case When="Initial application"> <math> <ci type="logical" class="Indication">The patient has hydatids</ci> </math> <Applicant>infectious disease specialist</Applicant> <Applicant>clinical microbiologist</Applicant> <Term Measure="month">6</Term> </Case> <Case When="Renewal" Form="SA1318"> <math> <ci type="logical" class="Indication">The treatment remains appropriate and the patient is benefitting from the treatment</ci> </math> <Applicant>infectious disease specialist</Applicant> <Applicant>clinical microbiologist</Applicant> <Term Measure="month">6</Term> </Case></Request>
<Request To="HealthPAC" For="Subsidy" Form="SA1271"> <Title> <range>Minoxidil</range> </Title> <Case When="Initial application"> <math> <ci type="logical" class="Indication">patient has severe refractory hypertension which has failed to respond to extensive multiple therapies</ci> </math> <Applicant>relevant specialist</Applicant> <Term Measure="patient's lifetime"/> </Case></Request>
<Request To="HealthPAC" For="Subsidy" Form="SA1095"> <Title> <range>Diabetic products<instance>Diason RTH</instance><instance>Glucerna Select RTH</instance><instance>Diasip</instance><instance>Glucerna Select</instance><instance>Resource Diabetic</instance></range> </Title> <Case When="Initial application"> <math> <ci type="logical" class="Indication">The patient is a type I or and II diabetic who is suffering weight loss and malnutrition that requires nutritional support</ci> </math> <Applicant>dietitian</Applicant> <Applicant>relevant specialist</Applicant> <Applicant>vocationally registered general practitioner</Applicant> <Term Measure="year">1</Term> </Case> <Case When="Renewal" Form="SA0594 SA1095"> <math> <apply> <and/> <ci type="logical" class="Indication">The treatment remains appropriate and the patient is benefiting from treatment</ci> <ci type="text" class="Endorsement">General Practitioners must includ
<Request To="PHARMAC" For="Manufacturers Price" Form="SA1038"> <Title> <range>Anti-inflammatory Non Steroidal Drugs (NSAIDs)</range> </Title> <Case When="Initial application"> <math> <ci type="logical" class="Indication">Subsidy for patients with existing approvals prior to 1 September 2010</ci> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="patient's lifetime"/> </Case> <Note> <Para>Subsidy for patients with existing approvals prior to 1 September 2010. Approvals valid without further renewal unlessnotified. No new approvals will be granted from 1 September 2010.</Para> </Note></Request>
<Request To="HealthPAC" For="Subsidy" Form="SA1002"> <Title> <range>Vitabdeck</range> </Title> <Case When="Initial application"> <math> <apply> <or/> <ci type="logical" class="Indication">Patient has cystic fibrosis with pancreatic insufficiency</ci> <ci type="logical" class="Indication">Patient is an infant or child with liver disease or short gut syndrome</ci> </apply> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="patient's lifetime"/> </Case></Request>
<Request To="HealthPAC" For="Subsidy" Form="SA1449"> <Title> <range>Adalimumab</range> </Title> <Case When="Initial application" Category="rheumatoid arthritis"> <math> <apply> <or/> <apply> <and/> <ci type="logical" class="Indication">The patient has had an initial Special Authority approval for etanercept for rheumatoid arthritis</ci> <apply> <or/> <ci type="logical" class="Indication">The patient has experienced intolerable side effects from etanercept</ci> <ci type="logical" class="Indication">The patient has received insufficient benefit from etanercept to meet the renewal criteria for etanercept for rheumatoid arthritis</ci> </apply> </apply> <apply> <and/> <ci type="logical" class="Indication">Patient has had severe and active erosive rheumatoid arthritis for six months duration or longer</ci> <ci type="logical" class="Treatmen
<Request To="HealthPAC" For="Subsidy" Form="SA1388"> <Title> <range>Preservative Free Ocular Lubricants</range> </Title> <Case When="Initial application"> <math> <apply> <and/> <ci type="logical" class="Indication">Confirmed diagnosis by slit lamp of severe secretory dry eye</ci> <apply> <or/> <ci type="logical" class="Indication">Patient is using eye drops more than four times daily on a regular basis</ci> <ci type="logical" class="Indication">Patient has had a confirmed allergic reaction to preservative in eye drop</ci> </apply> </apply> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="month">12</Term> </Case> <Case When="Renewal" Form="SA1388"> <math> <ci type="logical" class="Indication">The patient continues to require lubricating eye drops and has benefited from treatment</ci> </math> <Applicant>any relevant practitioner</Applicant>
<Request To="HealthPAC" For="Subsidy" Form="SA1201"> <Title> <range>Prasugrel</range> </Title> <Case When="Initial application" Category="coronary angioplasty and bare metal stent"> <math> <ci type="logical" class="Treatment">The patient has undergone coronary angioplasty in the previous 4 weeks and is clopidogrel-allergic*</ci> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="month">6</Term> </Case> <Case When="Initial application" Category="drug eluting stent"> <math> <ci type="logical" class="Treatment">The patient has had a drug-eluting cardiac stent inserted in the previous 4 weeks and is clopidogrel-allergic*</ci> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="month">12</Term> </Case> <Case When="Initial application" Category="stent thromobosis"> <math> <ci type="logical" class="Treatment">patient has experienced cardiac stent thrombosis whilst on clopidogrel</ci>
<Request To="HealthPAC" For="Subsidy" Form="SA1325"> <Title> <range>Pegaspargase</range> </Title> <Case When="Initial application"> <math> <apply> <and/> <ci type="logical" class="Indication">The patient has newly diagnosed acute lymphoblastic leukaemia</ci> <ci type="logical" class="Indication">Pegaspargase to be used with a contemporary intensive multi-agent chemotherapy treatment protocol</ci> <ci type="logical" class="Indication">Treatment is with curative intent</ci> </apply> </math> <Applicant>relevant specialist</Applicant> <Applicant Referring="relevant specialist">medical practitioner</Applicant> <Term Measure="month">12</Term> </Case> <Case When="Renewal" Form="SA1325"> <math> <apply> <and/> <ci type="logical" class="Indication">The patient has relapsed acute lymphoblastic leukaemia</ci> <ci type="logical" class="Indication">Pegaspargase to be used with a contemporar
<Request To="HealthPAC" For="Alternate Subsidy" Form="SA0500"> <Title><range>Combined oral contraceptives</range><range>Progestogen-only contraceptives</range> (Circle one)</Title> <Case When="Initial application"> <math> <apply> <and/> <apply> <or/> <ci type="logical" class="Target">Patient is on a Social Welfare benefit</ci> <ci type="logical" class="Target">Patient has an income no greater than the benefit</ci> </apply> <ci type="logical" class="Trial">Has tried at least one of the fully funded options and has been unable to tolerate it</ci> </apply> </math> <Applicant>medical practitioner</Applicant> <Term Measure="year">2</Term> </Case> <Case When="Renewal" Form="SA0265 SA0500"> <math> <apply> <or/> <ci type="logical" class="Target">Patient is on a Social Welfare benefit</ci> <ci type="logical" class="Target">Patient has an income no greater than the be
<Request To="HealthPAC" For="Subsidy" Form="SA1374"> <Title> <range>Fat<instance>Calogen</instance><instance>Liquigen</instance><instance>MCT oil (Nutricia)</instance></range> </Title> <Case When="Initial application" Category="Inborn errors of metabolism"> <math> <ci type="logical" class="Indication">The patient has inborn errors of metabolism</ci> </math> <Applicant>dietitian</Applicant> <Applicant>relevant specialist</Applicant> <Applicant>vocationally registered general practitioner</Applicant> <Term Measure="year">3</Term> </Case> <Case When="Initial application" Category="Indications other than inborn errors of metabolism"> <math> <apply> <or/> <ci type="logical" class="Indication">faltering growth in an infant/child</ci> <ci type="logical" class="Indication">bronchopulmonary dysplasia</ci> <ci type="logical" class="Indication">fat malabsorption</ci> <ci type="logical" class="Indication">lym
<Request To="HealthPAC" For="Subsidy" Form="SA1375"> <Title> <range>Protein<instance>Protifar</instance><instance>Promod</instance><instance>Resource Beneprotein</instance></range> </Title> <Case When="Initial application"> <math> <apply> <or/> <ci type="logical" class="Indication">protein losing enteropathy</ci> <ci type="logical" class="Indication">high protein needs</ci> <ci type="logical" class="Indication">for use as a component in a modular formula</ci> </apply> </math> <Applicant>dietitian</Applicant> <Applicant>relevant specialist</Applicant> <Applicant>vocationally registered general practitioner</Applicant> <Term Measure="year">1</Term> </Case> <Case When="Renewal" Form="SA0582 SA1093 SA1375"> <math> <apply> <and/> <ci type="logical" class="Indication">The treatment remains appropriate and the patient is benefiting from treatment</ci> <ci type="text" class="Endor
<Request To="HealthPAC" For="Subsidy" Form="SA1266"> <Title> <range>Sunitinib</range> </Title> <Case When="Initial application" Category="RCC"> <math> <apply> <and/> <ci type="logical" class="Indication">The patient has metastatic renal cell carcinoma</ci> <apply> <or/> <ci type="logical" class="Trial">The patient is treatment naive</ci> <ci type="logical" class="Trial">The patient has only received prior cytokine treatment</ci> <ci type="logical" class="Trial">The patient has only received prior treatment with an investigational agent within the confines of a bona fide clinical trial which has Ethics Committee approval</ci> <apply> <and/> <ci type="logical" class="Trial">The patient has discontinued pazopanib within 3 months of starting treatment due to intolerance</ci> <ci type="logical" class="Trial">The cancer did not progress whilst on pazopanib</ci>
<Request To="HealthPAC" For="Subsidy" Form="SA1273"> <Title> <range>Voriconazole</range> </Title> <Case When="Initial application" Category="invasive fungal infection"> <math> <apply> <and/> <ci type="logical" class="Indication">Patient is immunocompromised</ci> <ci type="logical" class="Indication">Applicant is part of a multidisciplinary team including an infectious disease specialist</ci> <apply> <or/> <ci type="logical" class="Indication">Patient has proven or probable invasive aspergillus infection</ci> <ci type="logical" class="Indication">Patient has possible invasive aspergillus infection</ci> <ci type="logical" class="Indication">Patient has fluconazole resistant candidiasis</ci> <ci type="logical" class="Indication">Patient has mould strain such as Fusarium spp. and Scedosporium spp</ci> </apply> </apply> </math> <Applicant>haematologist</Applicant> <App
<Request To="HealthPAC" For="Subsidy" Form="SA1228"> <Title> <range>Standard Supplements<instance>Ensure</instance><instance>Fortisip</instance><instance>Isosource</instance><instance>Jevity</instance><instance>Nutrison</instance><instance>Osmolite</instance><instance>Sustagen</instance></range> </Title> <Case When="Initial application" Category="Children"> <math> <apply> <and/> <ci type="logical" class="Indication">The patient is under 18 years of age</ci> <apply> <or/> <ci type="logical" class="Indication">The patient has a condition causing malabsorption</ci> <ci type="logical" class="Indication">The patient has failure to thrive</ci> <ci type="logical" class="Indication">The patient has increased nutritional requirements</ci> </apply> <ci type="logical" class="Indication">Nutrition goal has been set (eg reach a specific weight or BMI)</ci> </apply> </math> <Applicant>dietitia
<Request To="HealthPAC" For="Subsidy" Form="SA1046"> <Title> <range>Ezetimibe with Simvastatin<instance>Vytorin</instance></range> </Title> <Case When="Initial application"> <math> <apply> <and/> <ci type="logical" class="Indication">Patient has a calculated absolute risk of cardiovascular disease of at least 15% over 5 year</ci> <ci type="logical" class="Trial">Patient's LDL cholesterol is 2.0 mmol/litre or greater</ci> <ci type="logical" class="Trial">The patient has not reduced their LDL cholesterol to less than 2.0 mmol/litre with the use of the maximal tolerated dose of atorvastatin</ci> </apply> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="year">2</Term> <Note> <Para>A patient who has failed to reduce their LDL cholesterol to &#8804; 2.0 mmol/litre with the use of a less potent statin should use a more potent statin prior to consideration being given to the use of non-statin therapi
<Request To="Cystic Fibrosis Advisory Panel" For="Subsidy" Form="SA0611"> <Title> <range>Dornase Alfa</range> </Title> <Case When="Initial application"> <math> <ci/> </math> <Applicant>medical practitioner</Applicant> <Term Measure="year">1</Term> </Case> <Note> <Para>Application details may be obtained from PHARMAC's website <a href="http://www.pharmac.govt.nz/">http://www.pharmac.govt.nz</a> or:</Para> <Table> <TR> <TD> <Para>The Co-ordinator, Cystic Fibrosis Advisory Panel</Para> </TD> <TD> <Para>Phone: (04) 460 4990</Para> </TD> </TR> <TR> <TD> <Para>PHARMAC, PO Box 10 254</Para> </TD> <TD> <Para>Facsimile: (04) 916 7571</Para> </TD> </TR> <TR> <TD> <Para>Wellington</Para> </TD> <TD> <Para>Email: <a href="mailto:CFPanel@pharmac.govt.nz">CFPanel@pharmac.
<Request To="HealthPAC" For="Subsidy" Form="SA1451"> <Title> <range>Somatropin</range> </Title> <Case When="Initial application" Category="growth hormone deficiency in children"> <math> <apply> <or/> <apply> <and/> <ci type="logical" class="Indication">Growth hormone deficiency causing symptomatic hypoglycaemia, or with other significant growth hormone deficient sequelae (e.g. cardiomyopathy, hepatic dysfunction) and diagnosed with GH &lt; 5 mcg/l on at least two random blood samples in the first 2 weeks of life, or from samples during established hypoglycaemia (whole blood glucose &lt; 2 mmol/l using a laboratory device)</ci> </apply> <apply> <and/> <ci type="logical" class="Indication">Height velocity &lt; 25th percentile for age adjusted for bone age/pubertal status if appropriate over 6 or 12 months using the standards of Tanner and Davies (1985)</ci> <ci type="logical" class="Indication
<Request To="HealthPAC" For="Subsidy" Form="SA1139"> <Title> <range>Teriparatide</range> </Title> <Case When="Initial application"> <math> <apply> <and/> <ci type="logical" class="indication">The patient has severe, established osteoporosis</ci> <ci type="logical" class="indication">The patient has a documented T-score less than or equal to -3.0 (see Notes)</ci> <ci type="logical" class="indication">The patient has had two or more fractures due to minimal trauma</ci> <ci type="logical" class="indication">The patient has experienced at least one symptomatic new fracture after at least 12 months&#8217; continuous therapy with a funded antiresorptive agent at adequate doses (see Notes)</ci> </apply> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="month">18</Term> </Case> <Note> <List Type="Alpha"> <Item> <Para>The bone mineral density (BMD) measurement used to derive the
<Request To="PHARMAC" For="Subsidy" Form="SA1291"> <Title> <range>Optium blood glucose test strips</range> </Title> <Case When="Initial application"> <math> <ci type="logical" class="Indication">Patient identified as eligible for subsidy for FreeStyle Optium blood glucose test strips</ci> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="patient's lifetime"/> </Case> <Note> <Para>Application details may be obtained from PHARMAC's website http://www.pharmac.govt.nz and can be sent to:</Para> <Table> <TR> <TD> <Para>PHARMAC</Para> </TD> <TD> <Para/> </TD> </TR> <TR> <TD> <Para>PO Box 10 254</Para> </TD> <TD> <Para>Facsimile: (04) 974 4788</Para> </TD> </TR> <TR> <TD> <Para>Wellington</Para> </TD> <TD> <Para>Email: <a href="mailto:bgstrip
<Request To="HealthPAC" For="Subsidy" Form="SA1098"> <Title> <range>Paediatric Product For Children Awaiting Liver Transplant<instance>Heparon Junior</instance></range> </Title> <Case When="Initial application"> <math> <ci type="logical" class="Indication">The patient is a child (up to 18 years) who requires a liver transplant</ci> </math> <Applicant>dietitian</Applicant> <Applicant>relevant specialist</Applicant> <Applicant>vocationally registered general practitioner</Applicant> <Term Measure="year">3</Term> </Case> <Case When="Renewal" Form="SA0607 SA1098"> <math> <apply> <and/> <ci type="logical" class="Indication">The treatment remains appropriate and the patient is benefiting from treatment</ci> <ci type="text" class="Endorsement">General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted</ci> </apply> </math
<Request To="HealthPAC" For="Subsidy" Form="SA0845"> <Title> <range>Enfuvirtide</range> </Title> <Case When="Initial application"> <math> <apply> <and/> <ci type="logical" class="Indication">Confirmed HIV infection</ci> <ci type="logical" class="Indication">Enfuvirtide to be given in combination with optimized background therapy (including at least 1 other antiretroviral drug that the patient has never previously been exposed to) for treatment failure</ci> <apply> <or/> <ci type="logical" class="Indication">Patient has evidence of HIV replication, despite ongoing therapy</ci> <ci type="logical" class="Indication">Patient has treatment-limiting toxicity to previous antiretroviral agents</ci> </apply> <ci type="logical" class="Indication">Previous treatment with 3 different antiretroviral regimens has failed</ci> <apply> <and/> <ci type="logical" class="Indication">Prev
<Request To="HealthPAC" For="Subsidy" Form="SA0955"> <Title> <range>Isotretinoin</range> </Title> <Case When="Initial application"> <math> <apply> <and/> <ci type="logical" class="Indication">Patient has had an adequate trial on other available treatments and has received an inadequate response from these treatments or these are contraindicated</ci> <ci type="logical" class="Indication">Applicant is a vocationally registered dermatologist, vocationally registered general practitioner, or nurse practitioner working in a relevant scope of practice</ci> <ci type="logical" class="Indication">Applicant has an up to date knowledge of the treatment options for acne and is aware of the safety issues around isotretinoin and is competent to prescribe isotretinoin</ci> <apply> <or/> <ci type="logical" class="Indication">Patient is female and has been counselled and understands the risk of teratogenicity if isotretinoin is used d
<Request To="HealthPAC" For="Subsidy" Form="SA0994"> <Title> <range>Mirtazapine</range> </Title> <Case When="Initial application"> <math> <apply> <and/> <ci type="logical" class="Indication">The patient has a severe major depressive episode</ci> <apply> <or/> <ci type="logical" class="Trial">The patient must have had a trial of two different antidepressants and was unable to tolerate the treatments or failed to respond to an adequate dose over an adequate period of time (usually at least four weeks)</ci> <apply> <and/> <ci type="logical" class="Indication">The patient is currently a hospital in-patient as a result of an acute depressive episode</ci> <ci type="logical" class="Trial">The patient must have had a trial of one other antidepressant and either could not tolerate it or failed to respond to an adequate dose over an adequate period of time</ci> </apply> </appl
<Request To="HealthPAC" For="Subsidy" Form="SA1404"> <Title> <range>Valganciclovir</range> </Title> <Case When="Initial application" Category="transplant cytomegalovirus prophylaxis"> <math> <ci type="logical" class="Indication">the patient has undergone a solid organ transplant and requires valganciclovir for CMV prophylaxis</ci> </math> <Applicant>relevant specialist</Applicant> <Term Measure="month">3</Term> </Case> <Case When="Renewal" Form="SA1274 SA1404" Category="transplant cytomegalovirus prophylaxis"> <math> <apply> <and/> <ci type="logical" class="Indication">Patient has undergone a solid organ transplant and received anti-thymocyte globulin and requires valganciclovir therapy for CMV prophylaxis</ci> <ci type="logical" class="Indication">Patient is to receive a maximum of 90 days of valganciclovir prophylaxis following anti-thymocyte globulin</ci> </apply> </math> <Applicant>relevant specialist</A
<Request To="HealthPAC" For="Subsidy" Form="SA1138"> <Title> <range>Raloxifene</range> </Title> <Case When="Initial application"> <math> <apply> <or/> <ci type="logical" class="indication">History of one significant osteoporotic fracture demonstrated radiologically and documented bone mineral density (BMD) &#8805;2.5 standard deviations below the mean normal value in young adults (i.e. T-Score &#8804; -2.5) (see Notes)</ci> <ci type="logical" class="indication">History of one significant osteoporotic fracture demonstrated radiologically, and either the patient is elderly, or densitometry scanning cannot be performed because of major logistical, technical or pathophysiological reasons. It is unlikely that this provision would apply to many patients under 75 years of age</ci> <ci type="logical" class="indication">History of two significant osteoporotic fractures demonstrated radiologically</ci> <ci type="logical" class="indication">Documente
<Request To="HealthPAC" For="Subsidy" Form="SA1125"> <Title> <range>Lacosamide</range> </Title> <Case When="Initial application"> <math> <apply> <and/> <ci type="logical" class="Indication">Patient has partial-onset epilepsy</ci> <ci type="logical" class="Trial">Seizures are not adequately controlled by, or patient has experienced unacceptable side effects from, optimal treatment with all of the following: sodium valproate, topiramate, levetiracetam and any two of carbamazepine, lamotrigine and phenytoin sodium (see Note)</ci> </apply> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="month">15</Term> <Note> <Para>"Optimal treatment" is defined as treatment which is indicated and clinically appropriate for the patient, given in adequate doses for the patient's age, weight and other features affecting the pharmacokinetics of the drug with good evidence of compliance. Women of childbearing age are not re
<Request To="HealthPAC" For="Subsidy" Form="SA1376"> <Title> <range>Carbohydrate and Fat<instance>Duocal Super Soluble Powder</instance></range> </Title> <Case When="Initial application" Category="Cystic fibrosis"> <math> <apply> <and/> <ci type="logical" class="Indication">Infant or child aged four years or under</ci> <ci type="logical" class="Indication">cystic fibrosis</ci> </apply> </math> <Applicant>dietitian</Applicant> <Applicant>relevant specialist</Applicant> <Applicant>vocationally registered general practitioner</Applicant> <Term Measure="year">3</Term> </Case> <Case When="Initial application" Category="Indications other than cystic fibrosis"> <math> <apply> <and/> <ci type="logical" class="Indication">infant or child aged four years or under</ci> <apply> <or/> <ci type="logical" class="Indication">cancer in children</ci> <ci type="logica
<Request To="HealthPAC" For="Subsidy" Form="SA0895"> <Title> <range>Pilocarpine &#8211; Eye drops 2% single dose</range> </Title> <Case When="Initial application"> <math> <apply> <or/> <ci type="logical" class="Indication">Patient has to use an unpreserved solution due to an allergy to the preservative</ci> <ci type="logical" class="Indication">Patient wears soft contact lenses</ci> </apply> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="year">2</Term> <Note> <Para>Minims for a general practice are considered to be &#8220;tools of trade&#8221; and are not approved as special authority items.</Para> </Note> </Case> <Case When="Renewal" Form="SA0121 SA0895"> <math> <ci type="logical" class="Indication">The treatment remains appropriate and the patient is benefiting from treatment</ci> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="year">2<
<Request To="HealthPAC" For="Subsidy" Form="SA1072"> <Title> <range>Vigabatrin</range> </Title> <Case When="Initial application"> <math> <apply> <and/> <apply> <or/> <ci type="logical" class="Indication">Patient has infantile spasms</ci> <apply> <and/> <ci type="logical" class="Indication">Patient has epilepsy</ci> <apply> <or/> <ci type="logical" class="Indication">Seizures are not adequately controlled with optimal treatment with other antiepilepsy agents</ci> <ci type="logical" class="Indication">Seizures are controlled adequately but the patient has experienced unacceptable side effects from optimal treatment with other antiepilepsy agents</ci> </apply> </apply> </apply> <apply> <or/> <ci type="logical" class="Indication">Patient is, or will be, receiving regular automated visual fiel
<Request To="HealthPAC" For="Subsidy" Form="SA1408"> <Title> <range>Naltrexone</range> </Title> <Case When="Initial application"> <math> <apply> <and/> <ci type="logical" class="Indication">Patient is currently enrolled in a recognised comprehensive treatment programme for alcohol dependence</ci> <ci type="logical" class="Therapy">Applicant works in or with a community Alcohol and Drug Service contracted to one of the District Health Boards or accredited against the New Zealand Alcohol and Other Drug Sector Standard or the National Mental Health Sector Standard</ci> </apply> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="month">6</Term> </Case> <Case When="Renewal" Form="SA0714 SA0909 SA1397 SA1408"> <math> <apply> <and/> <ci type="logical" class="Indication">Compliance with the medication (prescriber determined)</ci> <apply> <or/> <ci type="log
<Request To="HealthPAC" For="Subsidy" Form="SA1174"> <Title> <range>Enoxaparin sodium</range> </Title> <Case When="Initial application" Category="Pregnancy or Malignancy"> <math> <apply> <or/> <ci type="logical" class="Indication">Low molecular weight heparin treatment is required during a patients pregnancy</ci> <ci type="logical" class="Treatment">For the treatment of venous thromboembolism where the patient has a malignancy</ci> </apply> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="year">1</Term> </Case> <Case When="Initial application" Category="Venous thromboembolism other than in pregnancy or malignancy"> <math> <apply> <or/> <ci type="logical" class="Indication">For the short-term treatment of venous thromboembolism prior to establishing a therapeutic INR with oral anti-coagulant treatment</ci> <ci type="logical" class="Treatment">For the prophylaxis and tre
<Request To="HealthPAC" For="Subsidy" Form="SA1416"> <Title> <range>Atomoxetine</range> </Title> <Case When="Initial application"> <math> <apply> <and/> <ci type="logical" class="Indication">Patient has ADHD (Attention Deficit and Hyperactivity Disorder) diagnosed according to DSM-IV or ICD 10 criteria</ci> <ci type="logical" class="Indication">Once-daily dosing</ci> <apply> <or/> <ci type="logical" class="Indication">Treatment with a subsidised formulation of a stimulant has resulted in the development or worsening of serious adverse reactions or where the combination of subsidised stimulant treatment with another agent would pose an unacceptable medical risk</ci> <ci type="logical" class="Indication">Treatment with a subsidised formulation of a stimulant has resulted in worsening of co-morbid substance abuse or there is a significant risk of diversion with subsidised stimulant therapy</ci> <ci type="log
<Request To="HealthPAC" For="Subsidy" Form="SA1263"> <Title> <range>Nicorandil</range> </Title> <Case When="Initial application"> <math> <apply> <and/> <ci type="logical" class="Indication">Patient has refractory angina</ci> <ci type="logical" class="Trial">Patient is on the maximal tolerated dose of a beta-blocker, a calcium channel blocker and a long acting nitrate</ci> </apply> </math> <Applicant>cardiologist</Applicant> <Applicant>general physician</Applicant> <Term Measure="year">2</Term> </Case> <Case When="Renewal" Form="SA1263"> <math> <ci type="logical" class="Indication">The treatment remains appropriate and the patient is benefiting from treatment</ci> </math> <Applicant>cardiologist</Applicant> <Applicant Referring="cardiologist">any relevant practitioner</Applicant> <Term Measure="year">2</Term> </Case></Request>
<Request To="HealthPAC" For="Subsidy" Form="SA0927"> <Title> <range>Risperidone orally disintegrating tablets</range> </Title> <Case When="Initial application" Category="Acute situations"> <math> <apply> <and/> <ci type="logical" class="Use">For a non-adherent patient on oral therapy with standard risperidone tablets or risperidone oral liquid</ci> <ci type="logical" class="Therapy">The patient is under direct supervision for administration of medicine</ci> </apply> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="week">6</Term> </Case> <Case When="Initial application" Category="Chronic situations"> <math> <apply> <and/> <ci type="logical" class="Indication">The patient is unable to take standard risperidone tablets or oral liquid, or once stabilized refuses to take risperidone tablets or oral liquid</ci> <ci type="logical" class="Therapy">The patient is under direct
<Request To="HealthPAC" For="Subsidy" Form="SA1195"> <Title> <range>High Calorie Products<instance>Two Cal HN</instance><instance>Nutrison Concentrated</instance></range> </Title> <Case When="Initial application" Category="Cystic fibrosis"> <math> <apply> <and/> <ci type="logical" class="Indication">Cystic fibrosis</ci> <ci type="logical" class="Trial">other lower calorie products have been tried</ci> <ci type="logical" class="Indication">patient has substantially increased metabolic requirements</ci> </apply> </math> <Applicant>dietitian</Applicant> <Applicant>relevant specialist</Applicant> <Applicant>vocationally registered general practitioner</Applicant> <Term Measure="year">3</Term> </Case> <Case When="Initial application" Category="Indications other than cystic fibrosis"> <math> <apply> <and/> <apply> <or/> <ci type="logical" class="Indication">any cond
<Request To="HealthPAC" For="Subsidy" Form="SA1199"> <Title> <range>Propylthiouracil</range> </Title> <Case When="Initial application"> <math> <apply> <and/> <ci type="logical" class="Indication">The patient has hyperthyroidism</ci> <ci type="logical" class="Indication">The patient is intolerant of carbimazole or carbimazole is contraindicated</ci> </apply> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="year">2</Term> </Case> <Case When="Renewal" Form="SA1199"> <math> <ci type="logical" class="Indication">the treatment remains appropriate and the patient is benefitting from the treatment</ci> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="year">2</Term> </Case></Request>
<Request To="PHARMAC" For="Subsidy" Form="SA1237"> <Title> <range>Insulin Pumps</range> </Title> <Case When="Initial application"> <math/> <Applicant>medical practitioner</Applicant> <Term Measure="year">1</Term> </Case> <Note> <Para>Application details may be obtained from PHARMAC's website <a href="http://www.pharmac.govt.nz/">http://www.pharmac.govt.nz</a> or:</Para> <Table> <TR> <TD> <Para>The IPP Co-ordinator</Para> </TD> <TD> <Para>Phone: (04) 460 4990</Para> </TD> </TR> <TR> <TD> <Para>PHARMAC</Para> </TD> <TD> <Para>Facsimile: (04) 974 7806</Para> </TD> </TR> <TR> <TD> <Para>PO Box 10 254</Para> </TD> <TD> <Para>Email: <a href="mailto:ipp@pharmac.govt.nz">ipp@pharmac.govt.nz</a></Para> </TD> </TR> <TR> <TD> <Para>Welli
<Request To="HealthPAC" For="Subsidy" Form="SA0829"> <Title> <range>Adefovir dipivoxil</range> </Title> <Case When="Initial application"> <math> <apply> <and/> <ci type="logical" class="Trial">Patient has confirmed Hepatitis B infection (HBsAg+)</ci> <mi class="heading">Documented resistance to lamivudine, defined as:</mi> <ci type="logical" class="Trial">Patient has raised serum ALT (&gt; 1 &#215; ULN)</ci> <ci type="logical" class="Trial">Patient has HBV DNA greater than 100,000 copies per mL, or viral load &#8805; 10 fold over nadir</ci> <ci type="logical" class="Trial">Detection of M204I or M204V mutation</ci> <apply> <or/> <apply> <and/> <ci type="logical" class="Trial">Patient is cirrhotic</ci> <ci type="logical" class="Trial">adefovir dipivoxil to be used in combination with lamivudine</ci> </apply> <apply> <and/>
<Request To="HealthPAC" For="Subsidy" Form="SA1332"> <Title> <range>Tetracycline</range> </Title> <Case When="Initial application"> <math> <apply> <and/> <ci type="logical" class="Indication">For the eradication of helicobacter pylori following unsuccessful treatment with appropriate first-line therapy</ci> <ci type="logical" class="Indication">For use only in combination with bismuth as part of a quadruple therapy regimen</ci> </apply> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="month">3</Term> </Case></Request>
<Request To="HealthPAC" For="Subsidy" Form="SA1379"> <Title> <range>Paediatric Products<instance>Nutrini</instance><instance>Pediasure</instance><instance>Fortini</instance></range> </Title> <Case When="Initial application"> <math> <apply> <and/> <ci type="logical" class="Indication">Child is aged one to ten years</ci> <apply> <or/> <ci type="logical" class="Indication">the child is being fed via a tube or a tube is to be inserted for the purposes of feeding</ci> <ci type="logical" class="Indication">any condition causing malabsorption</ci> <ci type="logical" class="Indication">faltering growth in an infant/child</ci> <ci type="logical" class="Indication">increased nutritional requirements</ci> <ci type="logical" class="Indication">the child is being transitioned from TPN or tube feeding to oral feeding</ci> </apply> </apply> </math> <Applicant>dietitian</Applicant>
<Request To="HealthPAC" For="Subsidy" Form="SA1382"> <Title> <range>Ticagrelor</range> </Title> <Case When="Initial application" Category="acute coronary syndrome"> <math> <apply> <and/> <ci type="logical" class="Indication">Patient has recently been diagnosed with an ST-elevation or a non-ST-elevation acute coronary syndrome</ci> <ci type="logical" class="Indication">Fibrinolytic therapy has not been given in the last 24 hours and is not planned</ci> </apply> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="month">12</Term> </Case> <Case When="Renewal" Category="subsequent acute coronary syndrome" Form="SA1382"> <math> <apply> <and/> <ci type="logical" class="Indication">Patient has recently been diagnosed with an ST-elevation or a non-ST-elevation acute coronary syndrome</ci> <ci type="logical" class="Indication">Fibrinolytic therapy has not been given in the last 24
<Request To="HealthPAC" For="Subsidy" Form="SA1383"> <Title> <range>Ursodeoxycholic Acid</range> </Title> <Case When="Initial application" Category="Alagille syndrome or progressive familial intrahepatic cholestasis"> <math> <apply> <or/> <ci type="logical" class="Indication">Patient has been diagnosed with Alagille syndrome</ci> <ci type="logical" class="Indication">Patient has progressive familial intrahepatic cholestasis</ci> </apply> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="patient's lifetime"/> </Case> <Case When="Initial application" Category="Chronic severe drug induced cholestatic liver injury"> <math> <apply> <and/> <ci type="logical" class="Indication">Patient has chronic severe drug induced cholestatic liver injury</ci> <ci type="logical" class="Indication">Cholestatic liver injury not due to Total Parenteral Nutrition (TPN) use in adults</ci>
<Request To="HealthPAC" For="Subsidy" Form="SA1192"> <Title> <range>Trastuzumab</range> </Title> <Case When="Initial application" Category="metastatic breast cancer"> <math> <apply> <or/> <apply> <and/> <ci type="logical" class="Indication">The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology)</ci> <ci type="logical" class="Treatment">The patient has not previously received lapatinib treatment for HER 2 positive metastatic breast cancer</ci> <ci type="logical" class="Indication">Trastuzumab not to be given in combination with lapatinib</ci> <ci type="logical" class="Treatment">Trastuzumab to be discontinued at disease progression</ci> </apply> <apply> <and/> <ci type="logical" class="Indication">The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology
<Request To="HealthPAC" For="Subsidy" Form="SA1071"> <Title> <range>Gabapentin</range> </Title> <Case When="Initial application" Category="Epilepsy"> <math> <apply> <or/> <ci type="logical" class="Indication">Seizures are not adequately controlled with optimal treatment with other antiepilepsy agents</ci> <ci type="logical" class="Indication">Seizures are controlled adequately but the patient has experienced unacceptable side effects from optimal treatment with other antiepilepsy agents</ci> </apply> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="month">15</Term> <Note> <Para>"Optimal treatment with other antiepilepsy agents" is defined as treatment with other antiepilepsy agents which are indicated and clinically appropriate for the patient, given in adequate doses for the patient's age, weight, and other features affecting the pharmacokinetics of the drug with good evidence of compliance.</Para>
<Request To="HealthPAC" For="Subsidy" Form="SA1066"> <Title> <range>Rivaroxaban</range> </Title> <Case When="Initial application"> <math> <apply> <or/> <ci type="logical" class="Indication">For the prophylaxis of venous thromboembolism following a total hip replacement</ci> <ci type="logical" class="Use">For the prophylaxis of venous thromboembolism following a total knee replacement</ci> </apply> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="week">5</Term> <Note> <Para>Rivaroxaban is only currently indicated and subsidised for up to 5 weeks therapy for prophylaxis of venous thromboembolism following a total hip replacement and up to 2 weeks therapy for prophylaxis of venous thromboembolism following a total knee replacement.</Para> </Note> </Case> <Case When="Renewal" Form="SA1066"> <math> <ci type="logical" class="Indication">Prophylaxis for venous thromboembolism is requir
<Request To="PHARMAC" For="Subsidy" Form="SA1240"> <Title> <range>Insulin pump consumables</range> </Title> <Case When="Initial application"> <math/> <Applicant>medical practitioner</Applicant> <Term Measure="year">1</Term> </Case> <Note> <Para>Application details may be obtained from PHARMAC's website <a href="http://www.pharmac.govt.nz/">http://www.pharmac.govt.nz</a> or:</Para> <Table> <TR> <TD> <Para>The IPP Co-ordinator</Para> </TD> <TD> <Para>Phone: (04) 460 4990</Para> </TD> </TR> <TR> <TD> <Para>PHARMAC</Para> </TD> <TD> <Para>Facsimile: (04) 974 7806</Para> </TD> </TR> <TR> <TD> <Para>PO Box 10 254</Para> </TD> <TD> <Para>Email: <a href="mailto:ipp@pharmac.govt.nz">ipp@pharmac.govt.nz</a></Para> </TD> </TR> <TR> <TD>
<Request To="HealthPAC" For="Subsidy" Form="SA1039"> <Title> <range>Alendronate Tab 70 mg - with or without Cholecalciferol</range> </Title> <Case When="Initial application" Category="Underlying cause -- Osteoporosis"> <math> <apply> <or/> <ci type="logical" class="Indication">History of one significant osteoporotic fracture demonstrated radiologically and documented bone mineral density (BMD) &#8805; 2.5 standard deviations below the mean normal value in young adults (i.e. T-Score &#8804; -2.5) (see Note)</ci> <ci type="logical" class="Indication">History of one significant osteoporotic fracture demonstrated radiologically, and either the patient is elderly, or densitometry scanning cannot be performed because of major logistical, technical or pathophysiological reasons. It is unlikely that this provision would apply to many patients under 75 years of age</ci> <ci type="logical" class="Indication">History of two significant osteoporotic fractures
<Request To="HealthPAC" For="Subsidy" Form="SA1324"> <Title> <range>Paromomycin</range> </Title> <Case When="Initial application"> <math> <ci type="logical" class="Indication">the patient has confirmed cryptosporidium infection</ci> </math> <Applicant>infectious disease specialist</Applicant> <Applicant>clinical microbiologist</Applicant> <Term Measure="month">1</Term> </Case> <Case When="Renewal" Form="SA1324"> <math> <ci type="logical" class="Indication">the patient has confirmed cryptosporidium infection</ci> </math> <Applicant>infectious disease specialist</Applicant> <Applicant>clinical microbiologist</Applicant> <Term Measure="month">1</Term> </Case></Request>
<Request To="HealthPAC" For="Subsidy" Form="SA1126"> <Title> <range>Modavigil</range> </Title> <Case When="Initial application"> <math> <apply> <and/> <ci type="logical" class="Indication">The patient has a diagnosis of narcolepsy and has excessive daytime sleepiness associated with narcolepsy occurring almost daily for three months or more</ci> <apply> <or/> <ci type="logical" class="Indication">The patient has a multiple sleep latency test with a mean sleep latency of less than or equal to 10 minutes and 2 or more sleep onset rapid eye movement periods</ci> <ci type="logical" class="Indication">The patient has at least one of: cataplexy, sleep paralysis or hypnagogic hallucinations</ci> </apply> <apply> <or/> <ci type="logical" class="Indication">An effective dose of a subsidised formulation of methylphenidate or dexamphetamine has been trialled and discontinued because of intolerabl
<Request To="HealthPAC" For="Subsidy" Form="SA0928"> <Title> <range>Finasteride</range> </Title> <Case When="Initial application"> <math> <apply> <and/> <ci type="logical" class="Indication">Patient has symptomatic benign prostatic hyperplasia</ci> <apply> <or/> <ci type="logical" class="Indication">The patient is intolerant of non-selective alpha blockers or these are contraindicated</ci> <ci type="logical" class="Indication">Symptoms are not adequately controlled with non-selective alpha blockers</ci> </apply> </apply> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="patient's lifetime"/> </Case> <Note> <Para>Patients with enlarged prostates are the appropriate candidates for therapy with finasteride.</Para> </Note></Request>
<Request To="HealthPAC" For="Subsidy" Form="SA1099"> <Title> <range>Paediatric Product For Children With Chronic Renal Failure<instance>Kindergen</instance></range> </Title> <Case When="Initial application"> <math> <ci type="logical" class="Indication">The patient is a child (up to 18 years) with acute or chronic kidney disease</ci> </math> <Applicant>dietitian</Applicant> <Applicant>relevant specialist</Applicant> <Applicant>vocationally registered general practitioner</Applicant> <Term Measure="year">3</Term> </Case> <Case When="Renewal" Form="SA0606 SA1099"> <math> <apply> <and/> <ci type="logical" class="Indication">The treatment remains appropriate and the patient is benefiting from treatment</ci> <ci type="text" class="Endorsement">General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted</ci> </apply> </mat
<Request To="HealthPAC" For="Subsidy" Form="SA1381"> <Title> <range>Fat Modified Products<instance>Monogen</instance></range> </Title> <Case When="Initial application"> <math> <apply> <or/> <ci type="logical" class="Indication">Patient has metabolic disorders of fat metabolism</ci> <ci type="logical" class="Indication">Patient has a chyle leak</ci> <ci type="logical" class="Indication">Modified as a modular feed for adults</ci> </apply> </math> <Applicant>dietitian</Applicant> <Applicant>relevant specialist</Applicant> <Applicant>vocationally registered general practitioner</Applicant> <Term Measure="year">1</Term> </Case> <Case When="Renewal" Form="SA0593 SA0615 SA1096 SA1381"> <math> <apply> <and/> <ci type="logical" class="Indication">The treatment remains appropriate and the patient is benefiting from treatment</ci> <ci type="text" class="Endorsement">General Practitio
<Request To="HealthPAC" For="Subsidy" Form="SA0782"> <Title> <range>Levonorgestrel &#8211; releasing intrauterine system 20mcg/24 hr</range> </Title> <Case When="Initial application" Category="No previous use"> <math> <apply> <and/> <ci type="logical" class="Indication">The patient has a clinical diagnosis of heavy menstrual bleeding</ci> <ci type="logical" class="Trial">The patient has failed to respond to or is unable to tolerate other appropriate pharmaceutical therapies as per the Heavy Menstrual Bleeding Guidelines</ci> <apply> <or/> <apply> <lt/> <ci type="real" class="test">serum ferritin level</ci> <cn>16<mi> mcg/l (within the last 12 months)</mi></cn> </apply> <apply> <lt/> <ci type="real" class="test">haemoglobin level</ci> <cn>120<mi> g/l</mi></cn> </apply> </apply> </apply> </math>
<Request To="HealthPAC" For="Subsidy" Form="SA1032"> <Title> <range>Tamsulosin</range> </Title> <Case When="Initial application"> <math> <apply> <and/> <ci type="logical" class="Indication">Patient has symptomatic benign prostatic hyperplasia</ci> <ci type="logical" class="Indication">The patient is intolerant of non-selective alpha blockers or these are contraindicated</ci> </apply> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="patient's lifetime"/> </Case></Request>
<Request To="HealthPAC" For="Subsidy" Form="SA0954"> <Title> <range>Acitretin</range> </Title> <Case When="Initial application"> <math> <apply> <and/> <ci type="logical" class="Indication">Applicant is a vocationally registered dermatologist, vocationally registered general practitioner, or nurse practitioner working in a relevant scope of practice</ci> <ci type="logical" class="Indication">Applicant has an up to date knowledge of the treatment options for psoriasis and of disorders of keratinisation and is aware of the safety issues around acitretin and is competent to prescribe acitretin</ci> <apply> <or/> <ci type="logical" class="Indication">Patient is female and has been counselled and understands the risk of teratogenicity if acitretin is used during pregnancy and the applicant has ensured that the possibility of pregnancy has been excluded prior to the commencement of the treatment and that the patient is informed that
<Request To="HealthPAC" For="Subsidy" Form="SA0987"> <Title> <range>Aprepitant</range> </Title> <Case When="Initial application"> <math> <ci type="logical" class="Indication">The patient is undergoing highly emetogenic chemotherapy and/or anthracycline-based chemotherapy for the treatment of malignancy</ci> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="month">12</Term> </Case> <Case When="Renewal" Form="SA0987"> <math> <ci type="logical" class="Indication">The patient is undergoing highly emetogenic chemotherapy and/or anthracycline-based chemotherapy for the treatment of malignancy</ci> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="month">12</Term> </Case></Request>
<Request To="HealthPAC" For="Subsidy" Form="SA1042"> <Title> <range>Deferiprone</range> </Title> <Case When="Initial application"> <math> <ci type="logical" class="Indication">The patient has been diagnosed with chronic transfusional iron overload due to congenital inherited anaemia</ci> </math> <Applicant>relevant specialist</Applicant> <Term Measure="patient's lifetime"/> </Case> <Note> <Para>For the purposes of this Special Authority, a relevant specialist is defined as a haematologist.</Para> </Note></Request>
<Request To="HealthPAC" For="Subsidy" Form="SA1155"> <Title> <range>Budesonide - Cap 3 mg Controlled Release</range> </Title> <Case When="Initial application" Category="Crohn's disease"> <math> <apply> <and/> <ci type="logical" class="Indication">Mild to moderate ileal, ileocaecal or proximal Crohn's disease</ci> <apply> <or/> <ci type="logical" class="Indication">Diabetes</ci> <ci type="logical" class="Indication">Cushingoid habitus</ci> <ci type="logical" class="Indication">Osteoporosis where there is significant risk of fracture</ci> <ci type="logical" class="Indication">Severe acne following treatment with conventional corticosteroid therapy</ci> <ci type="logical" class="Indication">History of severe psychiatric problems associated with corticosteroid treatment</ci> <ci type="logical" class="Indication">History of major mental illness (such as bipolar affective disorder) where
<Request To="HealthPAC" For="Subsidy" Form="SA1421"> <Title> <range>Montelukast</range> </Title> <Case When="Initial application" Category="Pre-school wheeze"> <math> <apply> <and/> <ci type="logical" class="Indication">To be used for the treatment of intermittent severe wheezing (possibly viral) in children under 5 years</ci> <ci type="logical" class="Indication">The patient has had at least three episodes in the previous 12 months of acute wheeze severe enough to seek medical attention</ci> </apply> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="year">1</Term> </Case> <Case When="Renewal" Category="Pre-school wheeze" Form="SA1227 SA1409 SA1421"> <math> <ci type="logical" class="Indication">The treatment remains appropriate and the patient is benefiting from treatment</ci> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="year">2</Term> </Case> <Case
<Request To="PHARMAC" For="Subsidy" Form="SA0973"> <Title> <range>Neurontin</range> </Title> <Case When="Initial application"> <math> <ci type="logical" class="Indication">Subsidy for patients pre-approved on 1 August 2009</ci> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="patient's lifetime"/> </Case> <Note> <Para>Subsidy for patients pre-approved by PHARMAC on 1 August 2009. Approvals valid without further renewal unlessnotified.</Para> <Para>No new approvals will be granted from 1 August 2009.</Para> </Note></Request>
<Request To="HealthPAC" For="Subsidy" Form="SA1196"> <Title> <range>Paediatric enteral feed with fibre 0.75 kcal/ml<instance>Nutrini Low Energy Multi Fibre</instance></range> </Title> <Case When="Initial application"> <math overflow="scroll"> <apply> <and/> <ci type="logical" class="Indication">Child aged one to eight years</ci> <ci type="logical" class="Indication">The child has a low energy requirement but normal protein and micronutrient requirements</ci> </apply> </math> <Applicant>dietitian</Applicant> <Applicant>relevant specialist</Applicant> <Applicant>vocationally registered general practitioner</Applicant> <Term Measure="year">1</Term> </Case> <Case When="Renewal" Form="SA1196"> <math overflow="scroll"> <apply> <and/> <ci type="logical" class="Indication">The treatment remains appropriate and the patient is benefiting from treatment</ci> <ci type="text" class="Endorsement
<Request To="HealthPAC" For="Subsidy" Form="SA1225"> <Title> <range>Ivermectin</range> </Title> <Case When="Initial application" Category="Scabies"> <math> <apply> <and/> <ci type="logical" class="Indication">Applying clinician has discussed the diagnosis of scabies with a dermatologist, infectious disease physician or clinical microbiologist</ci> <apply> <or/> <apply> <and/> <ci type="logical" class="Indication">The patient is in the community</ci> <apply> <or/> <ci type="logical" class="Indication">Patient has a severe scabies hyperinfestation (Crusted/ Norwegian scabies)</ci> <ci type="logical" class="Indication">The community patient is physically or mentally unable to comply with the application instructions of topical therapy</ci> <ci type="logical" class="Indication">The patient has previously tried and failed to clear infestation
<Request To="HealthPAC" For="Subsidy" Form="SA1322"> <Title> <range>Itraconazole</range> </Title> <Case When="Initial application"> <math> <ci type="logical" class="Indication">The patient has a congenital immune deficiency</ci> </math> <Applicant>infectious disease specialist</Applicant> <Applicant>clinical microbiologist</Applicant> <Applicant>clinical immunologist</Applicant> <Applicant Referring="infectious disease physician, clinical microbiologist or clinical immunologist">any relevant practitioner</Applicant> <Term Measure="month">6</Term> </Case> <Case When="Renewal" Form="SA1322"> <math> <ci type="logical" class="Indication">The treatment remains appropriate and the patient is benefitting from the treatment</ci> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="month">6</Term> </Case></Request>
<Request To="HealthPAC" For="Subsidy" Form="SA1223"> <Title> <range>Candesartan</range> </Title> <Case When="Initial application" Category="ACE inhibitor intolerance"> <math> <apply> <or/> <ci type="logical" class="Indication">Patient has persistent ACE inhibitor induced cough that is not resolved by ACE inhibitor retrial (same or new ACE inhibitor)</ci> <ci type="logical" class="Indication">Patient has a history of angioedema</ci> </apply> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="patient's lifetime"/> </Case> <Case When="Initial application" Category="Unsatisfactory response to ACE inhibitor"> <math> <ci type="logical" class="Indication">patient is not adequately controlled on maximum tolerated dose of an ACE inhibitor</ci> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="patient's lifetime"/> </Case></Request>
<Request To="HealthPAC" For="Subsidy" Form="SA0922"> <Title> <range>Erythropoietin</range> </Title> <Case When="Initial application"> <math> <apply> <and/> <apply> <and/> <ci type="logical" class="Indication">patient in chronic renal failure</ci> <apply> <leq/> <ci type="real" class="test">Haemoglobin</ci> <cn>100<mi>g/L</mi></cn> </apply> </apply> <apply> <or/> <apply> <and/> <ci type="logical" class="Indication">patient is not diabetic</ci> <apply> <leq/> <ci type="real" class="test">glomerular filtration rate</ci> <cn>30<mi>ml/min</mi></cn> </apply> </apply> <apply> <and/> <ci type="logical" class="Indication">patient is diabetic</ci> <apply> <leq/> <ci type
<Request To="HealthPAC" For="Subsidy" Form="SA1198"> <Title> <range>Preterm post-discharge infant formula powder<instance>S-26 Gold Premgro</instance></range> </Title> <Case When="Initial application"> <math overflow="scroll"> <apply> <and/> <ci type="logical" class="Indication">The infant was born before 33 weeks gestation or weighed less than 1.5 kg at birth</ci> <apply> <or/> <ci type="logical" class="Indication">The infant has faltering growth (downward crossing of percentiles)</ci> <ci type="logical" class="Indication">The infant is not maintaining, or is considered unlikely to maintain, adequate growth on standard infant formula</ci> </apply> </apply> </math> <Applicant>dietitian</Applicant> <Applicant>relevant specialist</Applicant> <Applicant>vocationally registered general practitioner</Applicant> <Term Measure="month">6</Term> </Case></Request>
<Request To="HealthPAC" For="Subsidy" Form="SA1124"> <Title> <range>Thalidomide</range> </Title> <Case When="Initial application"> <math> <apply> <or/> <ci type="logical" class="indication">The patient has multiple myeloma</ci> <ci type="logical" class="indication">The patient has systemic AL amyloidosis*</ci> </apply> </math> <Applicant>relevant specialist</Applicant> <Applicant Referring="relevant specialist">medical practitioner</Applicant> <Term Measure="month">12</Term> </Case> <Case When="Renewal" Form="SA1124 SA0817 SA0882"> <math> <ci type="logical" class="indication">The patient has obtained a response from treatment during the initial approval period</ci> </math> <Applicant>relevant specialist</Applicant> <Applicant Referring="relevant specialist">medical practitioner</Applicant> <Term Measure="patient's lifetime"/> </Case> <Note> <Para>Prescription must be written by a re
<Request To="HealthPAC" For="Subsidy" Form="SA1321"> <Title> <range>Hydralazine</range> </Title> <Case When="Initial application"> <math> <apply> <or/> <ci type="logical" class="Indication">For the treatment of refractory hypertension</ci> <ci type="logical" class="Indication">For the treatment of heart failure in combination with a nitrate, in patients who are intolerant or have not responded to ACE inhibitors and/or angiotensin receptor blockers</ci> </apply> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="patient's lifetime"/> </Case></Request>
<Request To="HealthPAC" For="Subsidy" Form="SA1260"> <Title> <range>Perhexiline Maleate</range> </Title> <Case When="Initial application"> <math> <apply> <and/> <ci type="logical" class="Indication">Patient has refractory angina</ci> <ci type="logical" class="Trial">Patient is on the maximal tolerated dose of a beta-blocker, a calcium channel blocker and a long acting nitrate</ci> </apply> </math> <Applicant>cardiologist</Applicant> <Applicant>general physician</Applicant> <Term Measure="year">2</Term> </Case> <Case When="Renewal" Form="SA0256 SA1260"> <math> <ci type="logical" class="Indication">The treatment remains appropriate and the patient is benefiting from treatment</ci> </math> <Applicant>cardiologist</Applicant> <Applicant Referring="cardiologist">any relevant practitioner</Applicant> <Term Measure="year">2</Term> </Case></Request>
<Request To="HealthPAC" For="Subsidy" Form="SA1326"> <Title> <range>Primaquine</range> </Title> <Case When="Initial application"> <math> <apply> <and/> <ci type="logical" class="Indication">The patient has vivax or ovale malaria</ci> <ci type="logical" class="Indication">Primaquine is to be given for a maximum of 21 days</ci> </apply> </math> <Applicant>infectious disease specialist</Applicant> <Applicant>clinical microbiologist</Applicant> <Term Measure="month">1</Term> </Case></Request>
<Request To="HealthPAC" For="Subsidy" Form="SA1285"> <Title> <range>Posaconazole </range> </Title> <Case When="Initial application"> <math> <apply> <or/> <ci type="logical" class="Indication">Patient has acute myeloid leukaemia and is to be treated with high dose remission induction, re-induction or consolidation chemotherapy</ci> <ci type="logical" class="Indication">Patient has received a stem cell transplant and has graft versus host disease and is on significant immunosuppressive therapy*</ci> </apply> </math> <Applicant>haematologist</Applicant> <Applicant>infectious disease specialist</Applicant> <Term Measure="week">6</Term> </Case> <Case When="Renewal" Form="SA1285"> <math> <apply> <or/> <ci type="logical" class="Indication">Patient has acute myeloid leukaemia and is to be treated with high dose remission induction, re-induction or consolidation therapy</ci> <ci type="logical" c
<Request To="HealthPAC" For="Subsidy" Form="SA1386"> <Title> <range>Phenobarbitone</range> </Title> <Case When="Initial application"> <math> <apply> <and/> <ci type="logical" class="Indication">For the treatment of terminal agitation that is unresponsive to other agents</ci> <ci type="logical" class="Indication">The applicant is part of a multidisciplinary team working in palliative care</ci> </apply> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="patient's lifetime"/> </Case></Request>
<Request To="HealthPAC" For="Subsidy" Form="SA1293"> <Title> <range>Sildenafil</range> </Title> <Case When="Initial application" Category="Raynaud&#8217;s Phenomenon* - for Pulmonary Arterial Hypertension see note below)"> <math> <apply> <and/> <ci type="logical" class="Indication">Patient has Raynaud&#8217;s Phenomenon*</ci> <ci type="logical" class="Indication">Patient has severe digital ischaemia (defined as severe pain requiring hospital admission or with a high likelihood of digital ulceration; digital ulcers; or gangrene)</ci> <ci type="logical" class="Indication">Patient is following lifestyle management (avoidance of cold exposure, sufficient protection, smoking cessation support, avoidance of sympathomimetic drugs) </ci> <ci type="logical" class="Indication">Patient is being treated with calcium channel blockers and nitrates (or these are contraindicated/not tolerated)</ci> </apply> </math> <Applicant>any relevant
<Request To="HealthPAC" For="Subsidy" Form="SA1061"> <Title> <range>Venlafaxine</range> </Title> <Case When="Initial application"> <math> <apply> <and/> <ci type="logical" class="Indication">The patient has 'treatment-resistant' depression</ci> <apply> <or/> <ci type="logical" class="Trial">The patient must have had a trial of two different antidepressants and have had an inadequate response from an adequate dose over an adequate period of time (usually at least four weeks)</ci> <apply> <and/> <ci type="logical" class="Indication">The patient is currently a hospital in-patient as a result of an acute depressive episode</ci> <ci type="logical" class="Trial">The patient must have had a trial of one other antidepressant and have had an inadequate response from an adequate dose over an adequate period of time</ci> </apply> </apply> </apply> </math> <Appl
<Request To="HealthPAC" For="Subsidy" Form="SA1411"> <Title> <range>Erlotinib</range> </Title> <Case When="Initial application"> <math> <apply> <or/> <apply> <and/> <ci type="logical" class="Indication">Patient has locally advanced or metastatic, unresectable, non-squamous Non Small Cell Lung Cancer (NSCLC)</ci> <ci type="logical" class="Indication">There is documentation confirming that the disease expresses activating mutations of EGFR tyrosine kinase</ci> <apply> <or/> <ci type="logical" class="Indication">Patient is treatment naive</ci> <apply> <and/> <ci type="logical" class="Indication">Patient has documented disease progression following treatment with first line platinum based chemotherapy</ci> <ci type="logical" class="Indication">Patient has not received prior treatment with gefitinib</ci> </apply> </apply>
<Request To="HealthPAC" For="Alternate Subsidy" Form="SA1018"> <Title> <range>Hormone Replacement Therapy - Systemic</range> </Title> <Case When="Initial application"> <math> <apply> <or/> <ci type="logical" class="Indication">acute or significant liver disease - where oral oestrogens are contraindicated as determined by a gastroenterologist or general physician. The applicant must keep written confirmation from such a specialist with the patient's record</ci> <ci type="logical" class="Indication">oestrogen induced hypertension requiring antihypertensive therapy - documented evidence must be kept on file that raised blood pressure levels or inability to control blood pressure adequately occurred post oral oestrogens</ci> <ci type="logical" class="Indication">hypertriglyceridaemia - documented evidence must be kept on file that triglyceride levels increased to at least 2 &#215; normal triglyceride levels post oral oestrogens</ci> <ci type=
<Request To="HealthPAC" For="Subsidy" Form="SA1320"> <Title> <range>Diazoxide</range> </Title> <Case When="Initial application"> <math> <ci type="logical" class="Indication">used for the treatment of confirmed hypoglycaemia caused by hyperinsulinism</ci> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="month">12</Term> </Case> <Case When="Renewal" Form="SA1320"> <math> <ci type="logical" class="Indication">The treatment remains appropriate and the patient is benefiting from treatment</ci> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="patient's lifetime"/> </Case></Request>
<Request To="HealthPAC" For="Subsidy" Form="SA1318"> <Title> <range>Albendazole</range> </Title> <Case When="Initial application"> <math> <ci type="logical" class="Indication">The patient has hydatids</ci> </math> <Applicant>infectious disease specialist</Applicant> <Applicant>clinical microbiologist</Applicant> <Term Measure="month">6</Term> </Case> <Case When="Renewal" Form="SA1318"> <math> <ci type="logical" class="Indication">The treatment remains appropriate and the patient is benefitting from the treatment</ci> </math> <Applicant>infectious disease specialist</Applicant> <Applicant>clinical microbiologist</Applicant> <Term Measure="month">6</Term> </Case></Request>
<Request To="HealthPAC" For="Subsidy" Form="SA1095"> <Title> <range>Diabetic products<instance>Diason RTH</instance><instance>Glucerna Select RTH</instance><instance>Diasip</instance><instance>Glucerna Select</instance><instance>Resource Diabetic</instance></range> </Title> <Case When="Initial application"> <math> <ci type="logical" class="Indication">The patient is a type I or and II diabetic who is suffering weight loss and malnutrition that requires nutritional support</ci> </math> <Applicant>dietitian</Applicant> <Applicant>relevant specialist</Applicant> <Applicant>vocationally registered general practitioner</Applicant> <Term Measure="year">1</Term> </Case> <Case When="Renewal" Form="SA0594 SA1095"> <math> <apply> <and/> <ci type="logical" class="Indication">The treatment remains appropriate and the patient is benefiting from treatment</ci> <ci type="text" class="Endorsement">General Practitioners must includ
<Request To="PHARMAC" For="Manufacturers Price" Form="SA1038"> <Title> <range>Anti-inflammatory Non Steroidal Drugs (NSAIDs)</range> </Title> <Case When="Initial application"> <math> <ci type="logical" class="Indication">Subsidy for patients with existing approvals prior to 1 September 2010</ci> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="patient's lifetime"/> </Case> <Note> <Para>Subsidy for patients with existing approvals prior to 1 September 2010. Approvals valid without further renewal unlessnotified. No new approvals will be granted from 1 September 2010.</Para> </Note></Request>
<Request To="HealthPAC" For="Subsidy" Form="SA1002"> <Title> <range>Vitabdeck</range> </Title> <Case When="Initial application"> <math> <apply> <or/> <ci type="logical" class="Indication">Patient has cystic fibrosis with pancreatic insufficiency</ci> <ci type="logical" class="Indication">Patient is an infant or child with liver disease or short gut syndrome</ci> </apply> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="patient's lifetime"/> </Case></Request>
<Request To="HealthPAC" For="Subsidy" Form="SA1449"> <Title> <range>Adalimumab</range> </Title> <Case When="Initial application" Category="rheumatoid arthritis"> <math> <apply> <or/> <apply> <and/> <ci type="logical" class="Indication">The patient has had an initial Special Authority approval for etanercept for rheumatoid arthritis</ci> <apply> <or/> <ci type="logical" class="Indication">The patient has experienced intolerable side effects from etanercept</ci> <ci type="logical" class="Indication">The patient has received insufficient benefit from etanercept to meet the renewal criteria for etanercept for rheumatoid arthritis</ci> </apply> </apply> <apply> <and/> <ci type="logical" class="Indication">Patient has had severe and active erosive rheumatoid arthritis for six months duration or longer</ci> <ci type="logical" class="Treatmen
<Request To="HealthPAC" For="Subsidy" Form="SA1388"> <Title> <range>Preservative Free Ocular Lubricants</range> </Title> <Case When="Initial application"> <math> <apply> <and/> <ci type="logical" class="Indication">Confirmed diagnosis by slit lamp of severe secretory dry eye</ci> <apply> <or/> <ci type="logical" class="Indication">Patient is using eye drops more than four times daily on a regular basis</ci> <ci type="logical" class="Indication">Patient has had a confirmed allergic reaction to preservative in eye drop</ci> </apply> </apply> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="month">12</Term> </Case> <Case When="Renewal" Form="SA1388"> <math> <ci type="logical" class="Indication">The patient continues to require lubricating eye drops and has benefited from treatment</ci> </math> <Applicant>any relevant practitioner</Applicant>
<Request To="HealthPAC" For="Subsidy" Form="SA1201"> <Title> <range>Prasugrel</range> </Title> <Case When="Initial application" Category="coronary angioplasty and bare metal stent"> <math> <ci type="logical" class="Treatment">The patient has undergone coronary angioplasty in the previous 4 weeks and is clopidogrel-allergic*</ci> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="month">6</Term> </Case> <Case When="Initial application" Category="drug eluting stent"> <math> <ci type="logical" class="Treatment">The patient has had a drug-eluting cardiac stent inserted in the previous 4 weeks and is clopidogrel-allergic*</ci> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="month">12</Term> </Case> <Case When="Initial application" Category="stent thromobosis"> <math> <ci type="logical" class="Treatment">patient has experienced cardiac stent thrombosis whilst on clopidogrel</ci>
<Request To="HealthPAC" For="Subsidy" Form="SA1325"> <Title> <range>Pegaspargase</range> </Title> <Case When="Initial application"> <math> <apply> <and/> <ci type="logical" class="Indication">The patient has newly diagnosed acute lymphoblastic leukaemia</ci> <ci type="logical" class="Indication">Pegaspargase to be used with a contemporary intensive multi-agent chemotherapy treatment protocol</ci> <ci type="logical" class="Indication">Treatment is with curative intent</ci> </apply> </math> <Applicant>relevant specialist</Applicant> <Applicant Referring="relevant specialist">medical practitioner</Applicant> <Term Measure="month">12</Term> </Case> <Case When="Renewal" Form="SA1325"> <math> <apply> <and/> <ci type="logical" class="Indication">The patient has relapsed acute lymphoblastic leukaemia</ci> <ci type="logical" class="Indication">Pegaspargase to be used with a contemporar
<Request To="HealthPAC" For="Alternate Subsidy" Form="SA0500"> <Title><range>Combined oral contraceptives</range><range>Progestogen-only contraceptives</range> (Circle one)</Title> <Case When="Initial application"> <math> <apply> <and/> <apply> <or/> <ci type="logical" class="Target">Patient is on a Social Welfare benefit</ci> <ci type="logical" class="Target">Patient has an income no greater than the benefit</ci> </apply> <ci type="logical" class="Trial">Has tried at least one of the fully funded options and has been unable to tolerate it</ci> </apply> </math> <Applicant>medical practitioner</Applicant> <Term Measure="year">2</Term> </Case> <Case When="Renewal" Form="SA0265 SA0500"> <math> <apply> <or/> <ci type="logical" class="Target">Patient is on a Social Welfare benefit</ci> <ci type="logical" class="Target">Patient has an income no greater than the be
<Request To="HealthPAC" For="Subsidy" Form="SA1374"> <Title> <range>Fat<instance>Calogen</instance><instance>Liquigen</instance><instance>MCT oil (Nutricia)</instance></range> </Title> <Case When="Initial application" Category="Inborn errors of metabolism"> <math> <ci type="logical" class="Indication">The patient has inborn errors of metabolism</ci> </math> <Applicant>dietitian</Applicant> <Applicant>relevant specialist</Applicant> <Applicant>vocationally registered general practitioner</Applicant> <Term Measure="year">3</Term> </Case> <Case When="Initial application" Category="Indications other than inborn errors of metabolism"> <math> <apply> <or/> <ci type="logical" class="Indication">faltering growth in an infant/child</ci> <ci type="logical" class="Indication">bronchopulmonary dysplasia</ci> <ci type="logical" class="Indication">fat malabsorption</ci> <ci type="logical" class="Indication">lym
<Request To="HealthPAC" For="Subsidy" Form="SA1375"> <Title> <range>Protein<instance>Protifar</instance><instance>Promod</instance><instance>Resource Beneprotein</instance></range> </Title> <Case When="Initial application"> <math> <apply> <or/> <ci type="logical" class="Indication">protein losing enteropathy</ci> <ci type="logical" class="Indication">high protein needs</ci> <ci type="logical" class="Indication">for use as a component in a modular formula</ci> </apply> </math> <Applicant>dietitian</Applicant> <Applicant>relevant specialist</Applicant> <Applicant>vocationally registered general practitioner</Applicant> <Term Measure="year">1</Term> </Case> <Case When="Renewal" Form="SA0582 SA1093 SA1375"> <math> <apply> <and/> <ci type="logical" class="Indication">The treatment remains appropriate and the patient is benefiting from treatment</ci> <ci type="text" class="Endor
<Request To="HealthPAC" For="Subsidy" Form="SA1266"> <Title> <range>Sunitinib</range> </Title> <Case When="Initial application" Category="RCC"> <math> <apply> <and/> <ci type="logical" class="Indication">The patient has metastatic renal cell carcinoma</ci> <apply> <or/> <ci type="logical" class="Trial">The patient is treatment naive</ci> <ci type="logical" class="Trial">The patient has only received prior cytokine treatment</ci> <ci type="logical" class="Trial">The patient has only received prior treatment with an investigational agent within the confines of a bona fide clinical trial which has Ethics Committee approval</ci> <apply> <and/> <ci type="logical" class="Trial">The patient has discontinued pazopanib within 3 months of starting treatment due to intolerance</ci> <ci type="logical" class="Trial">The cancer did not progress whilst on pazopanib</ci>
<Request To="HealthPAC" For="Subsidy" Form="SA1273"> <Title> <range>Voriconazole</range> </Title> <Case When="Initial application" Category="invasive fungal infection"> <math> <apply> <and/> <ci type="logical" class="Indication">Patient is immunocompromised</ci> <ci type="logical" class="Indication">Applicant is part of a multidisciplinary team including an infectious disease specialist</ci> <apply> <or/> <ci type="logical" class="Indication">Patient has proven or probable invasive aspergillus infection</ci> <ci type="logical" class="Indication">Patient has possible invasive aspergillus infection</ci> <ci type="logical" class="Indication">Patient has fluconazole resistant candidiasis</ci> <ci type="logical" class="Indication">Patient has mould strain such as Fusarium spp. and Scedosporium spp</ci> </apply> </apply> </math> <Applicant>haematologist</Applicant> <App
<Request To="HealthPAC" For="Subsidy" Form="SA1228"> <Title> <range>Standard Supplements<instance>Ensure</instance><instance>Fortisip</instance><instance>Isosource</instance><instance>Jevity</instance><instance>Nutrison</instance><instance>Osmolite</instance><instance>Sustagen</instance></range> </Title> <Case When="Initial application" Category="Children"> <math> <apply> <and/> <ci type="logical" class="Indication">The patient is under 18 years of age</ci> <apply> <or/> <ci type="logical" class="Indication">The patient has a condition causing malabsorption</ci> <ci type="logical" class="Indication">The patient has failure to thrive</ci> <ci type="logical" class="Indication">The patient has increased nutritional requirements</ci> </apply> <ci type="logical" class="Indication">Nutrition goal has been set (eg reach a specific weight or BMI)</ci> </apply> </math> <Applicant>dietitia
<Request To="HealthPAC" For="Subsidy" Form="SA1046"> <Title> <range>Ezetimibe with Simvastatin<instance>Vytorin</instance></range> </Title> <Case When="Initial application"> <math> <apply> <and/> <ci type="logical" class="Indication">Patient has a calculated absolute risk of cardiovascular disease of at least 15% over 5 year</ci> <ci type="logical" class="Trial">Patient's LDL cholesterol is 2.0 mmol/litre or greater</ci> <ci type="logical" class="Trial">The patient has not reduced their LDL cholesterol to less than 2.0 mmol/litre with the use of the maximal tolerated dose of atorvastatin</ci> </apply> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="year">2</Term> <Note> <Para>A patient who has failed to reduce their LDL cholesterol to &#8804; 2.0 mmol/litre with the use of a less potent statin should use a more potent statin prior to consideration being given to the use of non-statin therapi
<Request To="Cystic Fibrosis Advisory Panel" For="Subsidy" Form="SA0611"> <Title> <range>Dornase Alfa</range> </Title> <Case When="Initial application"> <math> <ci/> </math> <Applicant>medical practitioner</Applicant> <Term Measure="year">1</Term> </Case> <Note> <Para>Application details may be obtained from PHARMAC's website <a href="http://www.pharmac.govt.nz/">http://www.pharmac.govt.nz</a> or:</Para> <Table> <TR> <TD> <Para>The Co-ordinator, Cystic Fibrosis Advisory Panel</Para> </TD> <TD> <Para>Phone: (04) 460 4990</Para> </TD> </TR> <TR> <TD> <Para>PHARMAC, PO Box 10 254</Para> </TD> <TD> <Para>Facsimile: (04) 916 7571</Para> </TD> </TR> <TR> <TD> <Para>Wellington</Para> </TD> <TD> <Para>Email: <a href="mailto:CFPanel@pharmac.govt.nz">CFPanel@pharmac.
<Request To="HealthPAC" For="Subsidy" Form="SA1451"> <Title> <range>Somatropin</range> </Title> <Case When="Initial application" Category="growth hormone deficiency in children"> <math> <apply> <or/> <apply> <and/> <ci type="logical" class="Indication">Growth hormone deficiency causing symptomatic hypoglycaemia, or with other significant growth hormone deficient sequelae (e.g. cardiomyopathy, hepatic dysfunction) and diagnosed with GH &lt; 5 mcg/l on at least two random blood samples in the first 2 weeks of life, or from samples during established hypoglycaemia (whole blood glucose &lt; 2 mmol/l using a laboratory device)</ci> </apply> <apply> <and/> <ci type="logical" class="Indication">Height velocity &lt; 25th percentile for age adjusted for bone age/pubertal status if appropriate over 6 or 12 months using the standards of Tanner and Davies (1985)</ci> <ci type="logical" class="Indication
<Request To="HealthPAC" For="Subsidy" Form="SA1139"> <Title> <range>Teriparatide</range> </Title> <Case When="Initial application"> <math> <apply> <and/> <ci type="logical" class="indication">The patient has severe, established osteoporosis</ci> <ci type="logical" class="indication">The patient has a documented T-score less than or equal to -3.0 (see Notes)</ci> <ci type="logical" class="indication">The patient has had two or more fractures due to minimal trauma</ci> <ci type="logical" class="indication">The patient has experienced at least one symptomatic new fracture after at least 12 months&#8217; continuous therapy with a funded antiresorptive agent at adequate doses (see Notes)</ci> </apply> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="month">18</Term> </Case> <Note> <List Type="Alpha"> <Item> <Para>The bone mineral density (BMD) measurement used to derive the
<Request To="PHARMAC" For="Subsidy" Form="SA1291"> <Title> <range>Optium blood glucose test strips</range> </Title> <Case When="Initial application"> <math> <ci type="logical" class="Indication">Patient identified as eligible for subsidy for FreeStyle Optium blood glucose test strips</ci> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="patient's lifetime"/> </Case> <Note> <Para>Application details may be obtained from PHARMAC's website http://www.pharmac.govt.nz and can be sent to:</Para> <Table> <TR> <TD> <Para>PHARMAC</Para> </TD> <TD> <Para/> </TD> </TR> <TR> <TD> <Para>PO Box 10 254</Para> </TD> <TD> <Para>Facsimile: (04) 974 4788</Para> </TD> </TR> <TR> <TD> <Para>Wellington</Para> </TD> <TD> <Para>Email: <a href="mailto:bgstrip
<Request To="HealthPAC" For="Subsidy" Form="SA1098"> <Title> <range>Paediatric Product For Children Awaiting Liver Transplant<instance>Heparon Junior</instance></range> </Title> <Case When="Initial application"> <math> <ci type="logical" class="Indication">The patient is a child (up to 18 years) who requires a liver transplant</ci> </math> <Applicant>dietitian</Applicant> <Applicant>relevant specialist</Applicant> <Applicant>vocationally registered general practitioner</Applicant> <Term Measure="year">3</Term> </Case> <Case When="Renewal" Form="SA0607 SA1098"> <math> <apply> <and/> <ci type="logical" class="Indication">The treatment remains appropriate and the patient is benefiting from treatment</ci> <ci type="text" class="Endorsement">General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted</ci> </apply> </math
<Request To="HealthPAC" For="Subsidy" Form="SA0845"> <Title> <range>Enfuvirtide</range> </Title> <Case When="Initial application"> <math> <apply> <and/> <ci type="logical" class="Indication">Confirmed HIV infection</ci> <ci type="logical" class="Indication">Enfuvirtide to be given in combination with optimized background therapy (including at least 1 other antiretroviral drug that the patient has never previously been exposed to) for treatment failure</ci> <apply> <or/> <ci type="logical" class="Indication">Patient has evidence of HIV replication, despite ongoing therapy</ci> <ci type="logical" class="Indication">Patient has treatment-limiting toxicity to previous antiretroviral agents</ci> </apply> <ci type="logical" class="Indication">Previous treatment with 3 different antiretroviral regimens has failed</ci> <apply> <and/> <ci type="logical" class="Indication">Prev
<Request To="HealthPAC" For="Subsidy" Form="SA0955"> <Title> <range>Isotretinoin</range> </Title> <Case When="Initial application"> <math> <apply> <and/> <ci type="logical" class="Indication">Patient has had an adequate trial on other available treatments and has received an inadequate response from these treatments or these are contraindicated</ci> <ci type="logical" class="Indication">Applicant is a vocationally registered dermatologist, vocationally registered general practitioner, or nurse practitioner working in a relevant scope of practice</ci> <ci type="logical" class="Indication">Applicant has an up to date knowledge of the treatment options for acne and is aware of the safety issues around isotretinoin and is competent to prescribe isotretinoin</ci> <apply> <or/> <ci type="logical" class="Indication">Patient is female and has been counselled and understands the risk of teratogenicity if isotretinoin is used d
<Request To="HealthPAC" For="Subsidy" Form="SA0994"> <Title> <range>Mirtazapine</range> </Title> <Case When="Initial application"> <math> <apply> <and/> <ci type="logical" class="Indication">The patient has a severe major depressive episode</ci> <apply> <or/> <ci type="logical" class="Trial">The patient must have had a trial of two different antidepressants and was unable to tolerate the treatments or failed to respond to an adequate dose over an adequate period of time (usually at least four weeks)</ci> <apply> <and/> <ci type="logical" class="Indication">The patient is currently a hospital in-patient as a result of an acute depressive episode</ci> <ci type="logical" class="Trial">The patient must have had a trial of one other antidepressant and either could not tolerate it or failed to respond to an adequate dose over an adequate period of time</ci> </apply> </appl
<Request To="HealthPAC" For="Subsidy" Form="SA1404"> <Title> <range>Valganciclovir</range> </Title> <Case When="Initial application" Category="transplant cytomegalovirus prophylaxis"> <math> <ci type="logical" class="Indication">the patient has undergone a solid organ transplant and requires valganciclovir for CMV prophylaxis</ci> </math> <Applicant>relevant specialist</Applicant> <Term Measure="month">3</Term> </Case> <Case When="Renewal" Form="SA1274 SA1404" Category="transplant cytomegalovirus prophylaxis"> <math> <apply> <and/> <ci type="logical" class="Indication">Patient has undergone a solid organ transplant and received anti-thymocyte globulin and requires valganciclovir therapy for CMV prophylaxis</ci> <ci type="logical" class="Indication">Patient is to receive a maximum of 90 days of valganciclovir prophylaxis following anti-thymocyte globulin</ci> </apply> </math> <Applicant>relevant specialist</A
<Request To="HealthPAC" For="Subsidy" Form="SA1138"> <Title> <range>Raloxifene</range> </Title> <Case When="Initial application"> <math> <apply> <or/> <ci type="logical" class="indication">History of one significant osteoporotic fracture demonstrated radiologically and documented bone mineral density (BMD) &#8805;2.5 standard deviations below the mean normal value in young adults (i.e. T-Score &#8804; -2.5) (see Notes)</ci> <ci type="logical" class="indication">History of one significant osteoporotic fracture demonstrated radiologically, and either the patient is elderly, or densitometry scanning cannot be performed because of major logistical, technical or pathophysiological reasons. It is unlikely that this provision would apply to many patients under 75 years of age</ci> <ci type="logical" class="indication">History of two significant osteoporotic fractures demonstrated radiologically</ci> <ci type="logical" class="indication">Documente
<Request To="HealthPAC" For="Subsidy" Form="SA1125"> <Title> <range>Lacosamide</range> </Title> <Case When="Initial application"> <math> <apply> <and/> <ci type="logical" class="Indication">Patient has partial-onset epilepsy</ci> <ci type="logical" class="Trial">Seizures are not adequately controlled by, or patient has experienced unacceptable side effects from, optimal treatment with all of the following: sodium valproate, topiramate, levetiracetam and any two of carbamazepine, lamotrigine and phenytoin sodium (see Note)</ci> </apply> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="month">15</Term> <Note> <Para>"Optimal treatment" is defined as treatment which is indicated and clinically appropriate for the patient, given in adequate doses for the patient's age, weight and other features affecting the pharmacokinetics of the drug with good evidence of compliance. Women of childbearing age are not re
<Request To="HealthPAC" For="Subsidy" Form="SA1376"> <Title> <range>Carbohydrate and Fat<instance>Duocal Super Soluble Powder</instance></range> </Title> <Case When="Initial application" Category="Cystic fibrosis"> <math> <apply> <and/> <ci type="logical" class="Indication">Infant or child aged four years or under</ci> <ci type="logical" class="Indication">cystic fibrosis</ci> </apply> </math> <Applicant>dietitian</Applicant> <Applicant>relevant specialist</Applicant> <Applicant>vocationally registered general practitioner</Applicant> <Term Measure="year">3</Term> </Case> <Case When="Initial application" Category="Indications other than cystic fibrosis"> <math> <apply> <and/> <ci type="logical" class="Indication">infant or child aged four years or under</ci> <apply> <or/> <ci type="logical" class="Indication">cancer in children</ci> <ci type="logica
<Request To="HealthPAC" For="Subsidy" Form="SA0895"> <Title> <range>Pilocarpine &#8211; Eye drops 2% single dose</range> </Title> <Case When="Initial application"> <math> <apply> <or/> <ci type="logical" class="Indication">Patient has to use an unpreserved solution due to an allergy to the preservative</ci> <ci type="logical" class="Indication">Patient wears soft contact lenses</ci> </apply> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="year">2</Term> <Note> <Para>Minims for a general practice are considered to be &#8220;tools of trade&#8221; and are not approved as special authority items.</Para> </Note> </Case> <Case When="Renewal" Form="SA0121 SA0895"> <math> <ci type="logical" class="Indication">The treatment remains appropriate and the patient is benefiting from treatment</ci> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="year">2<
<Request To="HealthPAC" For="Subsidy" Form="SA1072"> <Title> <range>Vigabatrin</range> </Title> <Case When="Initial application"> <math> <apply> <and/> <apply> <or/> <ci type="logical" class="Indication">Patient has infantile spasms</ci> <apply> <and/> <ci type="logical" class="Indication">Patient has epilepsy</ci> <apply> <or/> <ci type="logical" class="Indication">Seizures are not adequately controlled with optimal treatment with other antiepilepsy agents</ci> <ci type="logical" class="Indication">Seizures are controlled adequately but the patient has experienced unacceptable side effects from optimal treatment with other antiepilepsy agents</ci> </apply> </apply> </apply> <apply> <or/> <ci type="logical" class="Indication">Patient is, or will be, receiving regular automated visual fiel
<Request To="HealthPAC" For="Subsidy" Form="SA1408"> <Title> <range>Naltrexone</range> </Title> <Case When="Initial application"> <math> <apply> <and/> <ci type="logical" class="Indication">Patient is currently enrolled in a recognised comprehensive treatment programme for alcohol dependence</ci> <ci type="logical" class="Therapy">Applicant works in or with a community Alcohol and Drug Service contracted to one of the District Health Boards or accredited against the New Zealand Alcohol and Other Drug Sector Standard or the National Mental Health Sector Standard</ci> </apply> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="month">6</Term> </Case> <Case When="Renewal" Form="SA0714 SA0909 SA1397 SA1408"> <math> <apply> <and/> <ci type="logical" class="Indication">Compliance with the medication (prescriber determined)</ci> <apply> <or/> <ci type="log
<Request To="HealthPAC" For="Subsidy" Form="SA1174"> <Title> <range>Enoxaparin sodium</range> </Title> <Case When="Initial application" Category="Pregnancy or Malignancy"> <math> <apply> <or/> <ci type="logical" class="Indication">Low molecular weight heparin treatment is required during a patients pregnancy</ci> <ci type="logical" class="Treatment">For the treatment of venous thromboembolism where the patient has a malignancy</ci> </apply> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="year">1</Term> </Case> <Case When="Initial application" Category="Venous thromboembolism other than in pregnancy or malignancy"> <math> <apply> <or/> <ci type="logical" class="Indication">For the short-term treatment of venous thromboembolism prior to establishing a therapeutic INR with oral anti-coagulant treatment</ci> <ci type="logical" class="Treatment">For the prophylaxis and tre
<Request To="HealthPAC" For="Subsidy" Form="SA1416"> <Title> <range>Atomoxetine</range> </Title> <Case When="Initial application"> <math> <apply> <and/> <ci type="logical" class="Indication">Patient has ADHD (Attention Deficit and Hyperactivity Disorder) diagnosed according to DSM-IV or ICD 10 criteria</ci> <ci type="logical" class="Indication">Once-daily dosing</ci> <apply> <or/> <ci type="logical" class="Indication">Treatment with a subsidised formulation of a stimulant has resulted in the development or worsening of serious adverse reactions or where the combination of subsidised stimulant treatment with another agent would pose an unacceptable medical risk</ci> <ci type="logical" class="Indication">Treatment with a subsidised formulation of a stimulant has resulted in worsening of co-morbid substance abuse or there is a significant risk of diversion with subsidised stimulant therapy</ci> <ci type="log
<Request To="HealthPAC" For="Subsidy" Form="SA1263"> <Title> <range>Nicorandil</range> </Title> <Case When="Initial application"> <math> <apply> <and/> <ci type="logical" class="Indication">Patient has refractory angina</ci> <ci type="logical" class="Trial">Patient is on the maximal tolerated dose of a beta-blocker, a calcium channel blocker and a long acting nitrate</ci> </apply> </math> <Applicant>cardiologist</Applicant> <Applicant>general physician</Applicant> <Term Measure="year">2</Term> </Case> <Case When="Renewal" Form="SA1263"> <math> <ci type="logical" class="Indication">The treatment remains appropriate and the patient is benefiting from treatment</ci> </math> <Applicant>cardiologist</Applicant> <Applicant Referring="cardiologist">any relevant practitioner</Applicant> <Term Measure="year">2</Term> </Case></Request>
<Request To="HealthPAC" For="Subsidy" Form="SA0927"> <Title> <range>Risperidone orally disintegrating tablets</range> </Title> <Case When="Initial application" Category="Acute situations"> <math> <apply> <and/> <ci type="logical" class="Use">For a non-adherent patient on oral therapy with standard risperidone tablets or risperidone oral liquid</ci> <ci type="logical" class="Therapy">The patient is under direct supervision for administration of medicine</ci> </apply> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="week">6</Term> </Case> <Case When="Initial application" Category="Chronic situations"> <math> <apply> <and/> <ci type="logical" class="Indication">The patient is unable to take standard risperidone tablets or oral liquid, or once stabilized refuses to take risperidone tablets or oral liquid</ci> <ci type="logical" class="Therapy">The patient is under direct
<Request To="HealthPAC" For="Subsidy" Form="SA1195"> <Title> <range>High Calorie Products<instance>Two Cal HN</instance><instance>Nutrison Concentrated</instance></range> </Title> <Case When="Initial application" Category="Cystic fibrosis"> <math> <apply> <and/> <ci type="logical" class="Indication">Cystic fibrosis</ci> <ci type="logical" class="Trial">other lower calorie products have been tried</ci> <ci type="logical" class="Indication">patient has substantially increased metabolic requirements</ci> </apply> </math> <Applicant>dietitian</Applicant> <Applicant>relevant specialist</Applicant> <Applicant>vocationally registered general practitioner</Applicant> <Term Measure="year">3</Term> </Case> <Case When="Initial application" Category="Indications other than cystic fibrosis"> <math> <apply> <and/> <apply> <or/> <ci type="logical" class="Indication">any cond
<Request To="HealthPAC" For="Subsidy" Form="SA1199"> <Title> <range>Propylthiouracil</range> </Title> <Case When="Initial application"> <math> <apply> <and/> <ci type="logical" class="Indication">The patient has hyperthyroidism</ci> <ci type="logical" class="Indication">The patient is intolerant of carbimazole or carbimazole is contraindicated</ci> </apply> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="year">2</Term> </Case> <Case When="Renewal" Form="SA1199"> <math> <ci type="logical" class="Indication">the treatment remains appropriate and the patient is benefitting from the treatment</ci> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="year">2</Term> </Case></Request>
<Request To="PHARMAC" For="Subsidy" Form="SA1237"> <Title> <range>Insulin Pumps</range> </Title> <Case When="Initial application"> <math/> <Applicant>medical practitioner</Applicant> <Term Measure="year">1</Term> </Case> <Note> <Para>Application details may be obtained from PHARMAC's website <a href="http://www.pharmac.govt.nz/">http://www.pharmac.govt.nz</a> or:</Para> <Table> <TR> <TD> <Para>The IPP Co-ordinator</Para> </TD> <TD> <Para>Phone: (04) 460 4990</Para> </TD> </TR> <TR> <TD> <Para>PHARMAC</Para> </TD> <TD> <Para>Facsimile: (04) 974 7806</Para> </TD> </TR> <TR> <TD> <Para>PO Box 10 254</Para> </TD> <TD> <Para>Email: <a href="mailto:ipp@pharmac.govt.nz">ipp@pharmac.govt.nz</a></Para> </TD> </TR> <TR> <TD> <Para>Welli
<Request To="HealthPAC" For="Subsidy" Form="SA0829"> <Title> <range>Adefovir dipivoxil</range> </Title> <Case When="Initial application"> <math> <apply> <and/> <ci type="logical" class="Trial">Patient has confirmed Hepatitis B infection (HBsAg+)</ci> <mi class="heading">Documented resistance to lamivudine, defined as:</mi> <ci type="logical" class="Trial">Patient has raised serum ALT (&gt; 1 &#215; ULN)</ci> <ci type="logical" class="Trial">Patient has HBV DNA greater than 100,000 copies per mL, or viral load &#8805; 10 fold over nadir</ci> <ci type="logical" class="Trial">Detection of M204I or M204V mutation</ci> <apply> <or/> <apply> <and/> <ci type="logical" class="Trial">Patient is cirrhotic</ci> <ci type="logical" class="Trial">adefovir dipivoxil to be used in combination with lamivudine</ci> </apply> <apply> <and/>
<Request To="HealthPAC" For="Subsidy" Form="SA1332"> <Title> <range>Tetracycline</range> </Title> <Case When="Initial application"> <math> <apply> <and/> <ci type="logical" class="Indication">For the eradication of helicobacter pylori following unsuccessful treatment with appropriate first-line therapy</ci> <ci type="logical" class="Indication">For use only in combination with bismuth as part of a quadruple therapy regimen</ci> </apply> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="month">3</Term> </Case></Request>
<Request To="HealthPAC" For="Subsidy" Form="SA1379"> <Title> <range>Paediatric Products<instance>Nutrini</instance><instance>Pediasure</instance><instance>Fortini</instance></range> </Title> <Case When="Initial application"> <math> <apply> <and/> <ci type="logical" class="Indication">Child is aged one to ten years</ci> <apply> <or/> <ci type="logical" class="Indication">the child is being fed via a tube or a tube is to be inserted for the purposes of feeding</ci> <ci type="logical" class="Indication">any condition causing malabsorption</ci> <ci type="logical" class="Indication">faltering growth in an infant/child</ci> <ci type="logical" class="Indication">increased nutritional requirements</ci> <ci type="logical" class="Indication">the child is being transitioned from TPN or tube feeding to oral feeding</ci> </apply> </apply> </math> <Applicant>dietitian</Applicant>
<Request To="HealthPAC" For="Subsidy" Form="SA1382"> <Title> <range>Ticagrelor</range> </Title> <Case When="Initial application" Category="acute coronary syndrome"> <math> <apply> <and/> <ci type="logical" class="Indication">Patient has recently been diagnosed with an ST-elevation or a non-ST-elevation acute coronary syndrome</ci> <ci type="logical" class="Indication">Fibrinolytic therapy has not been given in the last 24 hours and is not planned</ci> </apply> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="month">12</Term> </Case> <Case When="Renewal" Category="subsequent acute coronary syndrome" Form="SA1382"> <math> <apply> <and/> <ci type="logical" class="Indication">Patient has recently been diagnosed with an ST-elevation or a non-ST-elevation acute coronary syndrome</ci> <ci type="logical" class="Indication">Fibrinolytic therapy has not been given in the last 24
<Request To="HealthPAC" For="Subsidy" Form="SA1383"> <Title> <range>Ursodeoxycholic Acid</range> </Title> <Case When="Initial application" Category="Alagille syndrome or progressive familial intrahepatic cholestasis"> <math> <apply> <or/> <ci type="logical" class="Indication">Patient has been diagnosed with Alagille syndrome</ci> <ci type="logical" class="Indication">Patient has progressive familial intrahepatic cholestasis</ci> </apply> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="patient's lifetime"/> </Case> <Case When="Initial application" Category="Chronic severe drug induced cholestatic liver injury"> <math> <apply> <and/> <ci type="logical" class="Indication">Patient has chronic severe drug induced cholestatic liver injury</ci> <ci type="logical" class="Indication">Cholestatic liver injury not due to Total Parenteral Nutrition (TPN) use in adults</ci>
<Request To="HealthPAC" For="Subsidy" Form="SA1192"> <Title> <range>Trastuzumab</range> </Title> <Case When="Initial application" Category="metastatic breast cancer"> <math> <apply> <or/> <apply> <and/> <ci type="logical" class="Indication">The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology)</ci> <ci type="logical" class="Treatment">The patient has not previously received lapatinib treatment for HER 2 positive metastatic breast cancer</ci> <ci type="logical" class="Indication">Trastuzumab not to be given in combination with lapatinib</ci> <ci type="logical" class="Treatment">Trastuzumab to be discontinued at disease progression</ci> </apply> <apply> <and/> <ci type="logical" class="Indication">The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology
<Request To="HealthPAC" For="Subsidy" Form="SA1071"> <Title> <range>Gabapentin</range> </Title> <Case When="Initial application" Category="Epilepsy"> <math> <apply> <or/> <ci type="logical" class="Indication">Seizures are not adequately controlled with optimal treatment with other antiepilepsy agents</ci> <ci type="logical" class="Indication">Seizures are controlled adequately but the patient has experienced unacceptable side effects from optimal treatment with other antiepilepsy agents</ci> </apply> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="month">15</Term> <Note> <Para>"Optimal treatment with other antiepilepsy agents" is defined as treatment with other antiepilepsy agents which are indicated and clinically appropriate for the patient, given in adequate doses for the patient's age, weight, and other features affecting the pharmacokinetics of the drug with good evidence of compliance.</Para>
<Request To="HealthPAC" For="Subsidy" Form="SA1066"> <Title> <range>Rivaroxaban</range> </Title> <Case When="Initial application"> <math> <apply> <or/> <ci type="logical" class="Indication">For the prophylaxis of venous thromboembolism following a total hip replacement</ci> <ci type="logical" class="Use">For the prophylaxis of venous thromboembolism following a total knee replacement</ci> </apply> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="week">5</Term> <Note> <Para>Rivaroxaban is only currently indicated and subsidised for up to 5 weeks therapy for prophylaxis of venous thromboembolism following a total hip replacement and up to 2 weeks therapy for prophylaxis of venous thromboembolism following a total knee replacement.</Para> </Note> </Case> <Case When="Renewal" Form="SA1066"> <math> <ci type="logical" class="Indication">Prophylaxis for venous thromboembolism is requir
<Request To="PHARMAC" For="Subsidy" Form="SA1240"> <Title> <range>Insulin pump consumables</range> </Title> <Case When="Initial application"> <math/> <Applicant>medical practitioner</Applicant> <Term Measure="year">1</Term> </Case> <Note> <Para>Application details may be obtained from PHARMAC's website <a href="http://www.pharmac.govt.nz/">http://www.pharmac.govt.nz</a> or:</Para> <Table> <TR> <TD> <Para>The IPP Co-ordinator</Para> </TD> <TD> <Para>Phone: (04) 460 4990</Para> </TD> </TR> <TR> <TD> <Para>PHARMAC</Para> </TD> <TD> <Para>Facsimile: (04) 974 7806</Para> </TD> </TR> <TR> <TD> <Para>PO Box 10 254</Para> </TD> <TD> <Para>Email: <a href="mailto:ipp@pharmac.govt.nz">ipp@pharmac.govt.nz</a></Para> </TD> </TR> <TR> <TD>
<Request To="HealthPAC" For="Subsidy" Form="SA1039"> <Title> <range>Alendronate Tab 70 mg - with or without Cholecalciferol</range> </Title> <Case When="Initial application" Category="Underlying cause -- Osteoporosis"> <math> <apply> <or/> <ci type="logical" class="Indication">History of one significant osteoporotic fracture demonstrated radiologically and documented bone mineral density (BMD) &#8805; 2.5 standard deviations below the mean normal value in young adults (i.e. T-Score &#8804; -2.5) (see Note)</ci> <ci type="logical" class="Indication">History of one significant osteoporotic fracture demonstrated radiologically, and either the patient is elderly, or densitometry scanning cannot be performed because of major logistical, technical or pathophysiological reasons. It is unlikely that this provision would apply to many patients under 75 years of age</ci> <ci type="logical" class="Indication">History of two significant osteoporotic fractures
<Request To="HealthPAC" For="Subsidy" Form="SA1324"> <Title> <range>Paromomycin</range> </Title> <Case When="Initial application"> <math> <ci type="logical" class="Indication">the patient has confirmed cryptosporidium infection</ci> </math> <Applicant>infectious disease specialist</Applicant> <Applicant>clinical microbiologist</Applicant> <Term Measure="month">1</Term> </Case> <Case When="Renewal" Form="SA1324"> <math> <ci type="logical" class="Indication">the patient has confirmed cryptosporidium infection</ci> </math> <Applicant>infectious disease specialist</Applicant> <Applicant>clinical microbiologist</Applicant> <Term Measure="month">1</Term> </Case></Request>
<Request To="HealthPAC" For="Subsidy" Form="SA1126"> <Title> <range>Modavigil</range> </Title> <Case When="Initial application"> <math> <apply> <and/> <ci type="logical" class="Indication">The patient has a diagnosis of narcolepsy and has excessive daytime sleepiness associated with narcolepsy occurring almost daily for three months or more</ci> <apply> <or/> <ci type="logical" class="Indication">The patient has a multiple sleep latency test with a mean sleep latency of less than or equal to 10 minutes and 2 or more sleep onset rapid eye movement periods</ci> <ci type="logical" class="Indication">The patient has at least one of: cataplexy, sleep paralysis or hypnagogic hallucinations</ci> </apply> <apply> <or/> <ci type="logical" class="Indication">An effective dose of a subsidised formulation of methylphenidate or dexamphetamine has been trialled and discontinued because of intolerabl
<Request To="HealthPAC" For="Subsidy" Form="SA0928"> <Title> <range>Finasteride</range> </Title> <Case When="Initial application"> <math> <apply> <and/> <ci type="logical" class="Indication">Patient has symptomatic benign prostatic hyperplasia</ci> <apply> <or/> <ci type="logical" class="Indication">The patient is intolerant of non-selective alpha blockers or these are contraindicated</ci> <ci type="logical" class="Indication">Symptoms are not adequately controlled with non-selective alpha blockers</ci> </apply> </apply> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="patient's lifetime"/> </Case> <Note> <Para>Patients with enlarged prostates are the appropriate candidates for therapy with finasteride.</Para> </Note></Request>
<Request To="HealthPAC" For="Subsidy" Form="SA1099"> <Title> <range>Paediatric Product For Children With Chronic Renal Failure<instance>Kindergen</instance></range> </Title> <Case When="Initial application"> <math> <ci type="logical" class="Indication">The patient is a child (up to 18 years) with acute or chronic kidney disease</ci> </math> <Applicant>dietitian</Applicant> <Applicant>relevant specialist</Applicant> <Applicant>vocationally registered general practitioner</Applicant> <Term Measure="year">3</Term> </Case> <Case When="Renewal" Form="SA0606 SA1099"> <math> <apply> <and/> <ci type="logical" class="Indication">The treatment remains appropriate and the patient is benefiting from treatment</ci> <ci type="text" class="Endorsement">General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted</ci> </apply> </mat
<Request To="HealthPAC" For="Subsidy" Form="SA1381"> <Title> <range>Fat Modified Products<instance>Monogen</instance></range> </Title> <Case When="Initial application"> <math> <apply> <or/> <ci type="logical" class="Indication">Patient has metabolic disorders of fat metabolism</ci> <ci type="logical" class="Indication">Patient has a chyle leak</ci> <ci type="logical" class="Indication">Modified as a modular feed for adults</ci> </apply> </math> <Applicant>dietitian</Applicant> <Applicant>relevant specialist</Applicant> <Applicant>vocationally registered general practitioner</Applicant> <Term Measure="year">1</Term> </Case> <Case When="Renewal" Form="SA0593 SA0615 SA1096 SA1381"> <math> <apply> <and/> <ci type="logical" class="Indication">The treatment remains appropriate and the patient is benefiting from treatment</ci> <ci type="text" class="Endorsement">General Practitio
<Request To="HealthPAC" For="Subsidy" Form="SA0782"> <Title> <range>Levonorgestrel &#8211; releasing intrauterine system 20mcg/24 hr</range> </Title> <Case When="Initial application" Category="No previous use"> <math> <apply> <and/> <ci type="logical" class="Indication">The patient has a clinical diagnosis of heavy menstrual bleeding</ci> <ci type="logical" class="Trial">The patient has failed to respond to or is unable to tolerate other appropriate pharmaceutical therapies as per the Heavy Menstrual Bleeding Guidelines</ci> <apply> <or/> <apply> <lt/> <ci type="real" class="test">serum ferritin level</ci> <cn>16<mi> mcg/l (within the last 12 months)</mi></cn> </apply> <apply> <lt/> <ci type="real" class="test">haemoglobin level</ci> <cn>120<mi> g/l</mi></cn> </apply> </apply> </apply> </math>
<Request To="HealthPAC" For="Subsidy" Form="SA0954"> <Title> <range>Acitretin</range> </Title> <Case When="Initial application"> <math> <apply> <and/> <ci type="logical" class="Indication">Applicant is a vocationally registered dermatologist, vocationally registered general practitioner, or nurse practitioner working in a relevant scope of practice</ci> <ci type="logical" class="Indication">Applicant has an up to date knowledge of the treatment options for psoriasis and of disorders of keratinisation and is aware of the safety issues around acitretin and is competent to prescribe acitretin</ci> <apply> <or/> <ci type="logical" class="Indication">Patient is female and has been counselled and understands the risk of teratogenicity if acitretin is used during pregnancy and the applicant has ensured that the possibility of pregnancy has been excluded prior to the commencement of the treatment and that the patient is informed that
<Request To="HealthPAC" For="Subsidy" Form="SA0987"> <Title> <range>Aprepitant</range> </Title> <Case When="Initial application"> <math> <ci type="logical" class="Indication">The patient is undergoing highly emetogenic chemotherapy and/or anthracycline-based chemotherapy for the treatment of malignancy</ci> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="month">12</Term> </Case> <Case When="Renewal" Form="SA0987"> <math> <ci type="logical" class="Indication">The patient is undergoing highly emetogenic chemotherapy and/or anthracycline-based chemotherapy for the treatment of malignancy</ci> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="month">12</Term> </Case></Request>
<Request To="HealthPAC" For="Subsidy" Form="SA1042"> <Title> <range>Deferiprone</range> </Title> <Case When="Initial application"> <math> <ci type="logical" class="Indication">The patient has been diagnosed with chronic transfusional iron overload due to congenital inherited anaemia</ci> </math> <Applicant>relevant specialist</Applicant> <Term Measure="patient's lifetime"/> </Case> <Note> <Para>For the purposes of this Special Authority, a relevant specialist is defined as a haematologist.</Para> </Note></Request>
<Request To="HealthPAC" For="Subsidy" Form="SA1155"> <Title> <range>Budesonide - Cap 3 mg Controlled Release</range> </Title> <Case When="Initial application" Category="Crohn's disease"> <math> <apply> <and/> <ci type="logical" class="Indication">Mild to moderate ileal, ileocaecal or proximal Crohn's disease</ci> <apply> <or/> <ci type="logical" class="Indication">Diabetes</ci> <ci type="logical" class="Indication">Cushingoid habitus</ci> <ci type="logical" class="Indication">Osteoporosis where there is significant risk of fracture</ci> <ci type="logical" class="Indication">Severe acne following treatment with conventional corticosteroid therapy</ci> <ci type="logical" class="Indication">History of severe psychiatric problems associated with corticosteroid treatment</ci> <ci type="logical" class="Indication">History of major mental illness (such as bipolar affective disorder) where
<Request To="HealthPAC" For="Subsidy" Form="SA1421"> <Title> <range>Montelukast</range> </Title> <Case When="Initial application" Category="Pre-school wheeze"> <math> <apply> <and/> <ci type="logical" class="Indication">To be used for the treatment of intermittent severe wheezing (possibly viral) in children under 5 years</ci> <ci type="logical" class="Indication">The patient has had at least three episodes in the previous 12 months of acute wheeze severe enough to seek medical attention</ci> </apply> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="year">1</Term> </Case> <Case When="Renewal" Category="Pre-school wheeze" Form="SA1227 SA1409 SA1421"> <math> <ci type="logical" class="Indication">The treatment remains appropriate and the patient is benefiting from treatment</ci> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="year">2</Term> </Case> <Case
<Request To="PHARMAC" For="Subsidy" Form="SA0973"> <Title> <range>Neurontin</range> </Title> <Case When="Initial application"> <math> <ci type="logical" class="Indication">Subsidy for patients pre-approved on 1 August 2009</ci> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="patient's lifetime"/> </Case> <Note> <Para>Subsidy for patients pre-approved by PHARMAC on 1 August 2009. Approvals valid without further renewal unlessnotified.</Para> <Para>No new approvals will be granted from 1 August 2009.</Para> </Note></Request>
<Request To="HealthPAC" For="Subsidy" Form="SA1196"> <Title> <range>Paediatric enteral feed with fibre 0.75 kcal/ml<instance>Nutrini Low Energy Multi Fibre</instance></range> </Title> <Case When="Initial application"> <math overflow="scroll"> <apply> <and/> <ci type="logical" class="Indication">Child aged one to eight years</ci> <ci type="logical" class="Indication">The child has a low energy requirement but normal protein and micronutrient requirements</ci> </apply> </math> <Applicant>dietitian</Applicant> <Applicant>relevant specialist</Applicant> <Applicant>vocationally registered general practitioner</Applicant> <Term Measure="year">1</Term> </Case> <Case When="Renewal" Form="SA1196"> <math overflow="scroll"> <apply> <and/> <ci type="logical" class="Indication">The treatment remains appropriate and the patient is benefiting from treatment</ci> <ci type="text" class="Endorsement
<Request To="HealthPAC" For="Subsidy" Form="SA1225"> <Title> <range>Ivermectin</range> </Title> <Case When="Initial application" Category="Scabies"> <math> <apply> <and/> <ci type="logical" class="Indication">Applying clinician has discussed the diagnosis of scabies with a dermatologist, infectious disease physician or clinical microbiologist</ci> <apply> <or/> <apply> <and/> <ci type="logical" class="Indication">The patient is in the community</ci> <apply> <or/> <ci type="logical" class="Indication">Patient has a severe scabies hyperinfestation (Crusted/ Norwegian scabies)</ci> <ci type="logical" class="Indication">The community patient is physically or mentally unable to comply with the application instructions of topical therapy</ci> <ci type="logical" class="Indication">The patient has previously tried and failed to clear infestation
<Request To="HealthPAC" For="Subsidy" Form="SA1322"> <Title> <range>Itraconazole</range> </Title> <Case When="Initial application"> <math> <ci type="logical" class="Indication">The patient has a congenital immune deficiency</ci> </math> <Applicant>infectious disease specialist</Applicant> <Applicant>clinical microbiologist</Applicant> <Applicant>clinical immunologist</Applicant> <Applicant Referring="infectious disease physician, clinical microbiologist or clinical immunologist">any relevant practitioner</Applicant> <Term Measure="month">6</Term> </Case> <Case When="Renewal" Form="SA1322"> <math> <ci type="logical" class="Indication">The treatment remains appropriate and the patient is benefitting from the treatment</ci> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="month">6</Term> </Case></Request>
<Request To="HealthPAC" For="Subsidy" Form="SA1223"> <Title> <range>Candesartan</range> </Title> <Case When="Initial application" Category="ACE inhibitor intolerance"> <math> <apply> <or/> <ci type="logical" class="Indication">Patient has persistent ACE inhibitor induced cough that is not resolved by ACE inhibitor retrial (same or new ACE inhibitor)</ci> <ci type="logical" class="Indication">Patient has a history of angioedema</ci> </apply> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="patient's lifetime"/> </Case> <Case When="Initial application" Category="Unsatisfactory response to ACE inhibitor"> <math> <ci type="logical" class="Indication">patient is not adequately controlled on maximum tolerated dose of an ACE inhibitor</ci> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="patient's lifetime"/> </Case></Request>
<Request To="HealthPAC" For="Subsidy" Form="SA0922"> <Title> <range>Erythropoietin</range> </Title> <Case When="Initial application"> <math> <apply> <and/> <apply> <and/> <ci type="logical" class="Indication">patient in chronic renal failure</ci> <apply> <leq/> <ci type="real" class="test">Haemoglobin</ci> <cn>100<mi>g/L</mi></cn> </apply> </apply> <apply> <or/> <apply> <and/> <ci type="logical" class="Indication">patient is not diabetic</ci> <apply> <leq/> <ci type="real" class="test">glomerular filtration rate</ci> <cn>30<mi>ml/min</mi></cn> </apply> </apply> <apply> <and/> <ci type="logical" class="Indication">patient is diabetic</ci> <apply> <leq/> <ci type
<Request To="HealthPAC" For="Subsidy" Form="SA1198"> <Title> <range>Preterm post-discharge infant formula powder<instance>S-26 Gold Premgro</instance></range> </Title> <Case When="Initial application"> <math overflow="scroll"> <apply> <and/> <ci type="logical" class="Indication">The infant was born before 33 weeks gestation or weighed less than 1.5 kg at birth</ci> <apply> <or/> <ci type="logical" class="Indication">The infant has faltering growth (downward crossing of percentiles)</ci> <ci type="logical" class="Indication">The infant is not maintaining, or is considered unlikely to maintain, adequate growth on standard infant formula</ci> </apply> </apply> </math> <Applicant>dietitian</Applicant> <Applicant>relevant specialist</Applicant> <Applicant>vocationally registered general practitioner</Applicant> <Term Measure="month">6</Term> </Case></Request>
<Request To="HealthPAC" For="Subsidy" Form="SA1124"> <Title> <range>Thalidomide</range> </Title> <Case When="Initial application"> <math> <apply> <or/> <ci type="logical" class="indication">The patient has multiple myeloma</ci> <ci type="logical" class="indication">The patient has systemic AL amyloidosis*</ci> </apply> </math> <Applicant>relevant specialist</Applicant> <Applicant Referring="relevant specialist">medical practitioner</Applicant> <Term Measure="month">12</Term> </Case> <Case When="Renewal" Form="SA1124 SA0817 SA0882"> <math> <ci type="logical" class="indication">The patient has obtained a response from treatment during the initial approval period</ci> </math> <Applicant>relevant specialist</Applicant> <Applicant Referring="relevant specialist">medical practitioner</Applicant> <Term Measure="patient's lifetime"/> </Case> <Note> <Para>Prescription must be written by a re
<Request To="HealthPAC" For="Subsidy" Form="SA1321"> <Title> <range>Hydralazine</range> </Title> <Case When="Initial application"> <math> <apply> <or/> <ci type="logical" class="Indication">For the treatment of refractory hypertension</ci> <ci type="logical" class="Indication">For the treatment of heart failure in combination with a nitrate, in patients who are intolerant or have not responded to ACE inhibitors and/or angiotensin receptor blockers</ci> </apply> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="patient's lifetime"/> </Case></Request>
<Request To="HealthPAC" For="Subsidy" Form="SA1260"> <Title> <range>Perhexiline Maleate</range> </Title> <Case When="Initial application"> <math> <apply> <and/> <ci type="logical" class="Indication">Patient has refractory angina</ci> <ci type="logical" class="Trial">Patient is on the maximal tolerated dose of a beta-blocker, a calcium channel blocker and a long acting nitrate</ci> </apply> </math> <Applicant>cardiologist</Applicant> <Applicant>general physician</Applicant> <Term Measure="year">2</Term> </Case> <Case When="Renewal" Form="SA0256 SA1260"> <math> <ci type="logical" class="Indication">The treatment remains appropriate and the patient is benefiting from treatment</ci> </math> <Applicant>cardiologist</Applicant> <Applicant Referring="cardiologist">any relevant practitioner</Applicant> <Term Measure="year">2</Term> </Case></Request>
<Request To="HealthPAC" For="Subsidy" Form="SA1326"> <Title> <range>Primaquine</range> </Title> <Case When="Initial application"> <math> <apply> <and/> <ci type="logical" class="Indication">The patient has vivax or ovale malaria</ci> <ci type="logical" class="Indication">Primaquine is to be given for a maximum of 21 days</ci> </apply> </math> <Applicant>infectious disease specialist</Applicant> <Applicant>clinical microbiologist</Applicant> <Term Measure="month">1</Term> </Case></Request>
<Request To="HealthPAC" For="Subsidy" Form="SA1285"> <Title> <range>Posaconazole </range> </Title> <Case When="Initial application"> <math> <apply> <or/> <ci type="logical" class="Indication">Patient has acute myeloid leukaemia and is to be treated with high dose remission induction, re-induction or consolidation chemotherapy</ci> <ci type="logical" class="Indication">Patient has received a stem cell transplant and has graft versus host disease and is on significant immunosuppressive therapy*</ci> </apply> </math> <Applicant>haematologist</Applicant> <Applicant>infectious disease specialist</Applicant> <Term Measure="week">6</Term> </Case> <Case When="Renewal" Form="SA1285"> <math> <apply> <or/> <ci type="logical" class="Indication">Patient has acute myeloid leukaemia and is to be treated with high dose remission induction, re-induction or consolidation therapy</ci> <ci type="logical" c
<Request To="HealthPAC" For="Subsidy" Form="SA1386"> <Title> <range>Phenobarbitone</range> </Title> <Case When="Initial application"> <math> <apply> <and/> <ci type="logical" class="Indication">For the treatment of terminal agitation that is unresponsive to other agents</ci> <ci type="logical" class="Indication">The applicant is part of a multidisciplinary team working in palliative care</ci> </apply> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="patient's lifetime"/> </Case></Request>
<Request To="HealthPAC" For="Subsidy" Form="SA1293"> <Title> <range>Sildenafil</range> </Title> <Case When="Initial application" Category="Raynaud&#8217;s Phenomenon* - for Pulmonary Arterial Hypertension see note below)"> <math> <apply> <and/> <ci type="logical" class="Indication">Patient has Raynaud&#8217;s Phenomenon*</ci> <ci type="logical" class="Indication">Patient has severe digital ischaemia (defined as severe pain requiring hospital admission or with a high likelihood of digital ulceration; digital ulcers; or gangrene)</ci> <ci type="logical" class="Indication">Patient is following lifestyle management (avoidance of cold exposure, sufficient protection, smoking cessation support, avoidance of sympathomimetic drugs) </ci> <ci type="logical" class="Indication">Patient is being treated with calcium channel blockers and nitrates (or these are contraindicated/not tolerated)</ci> </apply> </math> <Applicant>any relevant
<Request To="HealthPAC" For="Subsidy" Form="SA1061"> <Title> <range>Venlafaxine</range> </Title> <Case When="Initial application"> <math> <apply> <and/> <ci type="logical" class="Indication">The patient has 'treatment-resistant' depression</ci> <apply> <or/> <ci type="logical" class="Trial">The patient must have had a trial of two different antidepressants and have had an inadequate response from an adequate dose over an adequate period of time (usually at least four weeks)</ci> <apply> <and/> <ci type="logical" class="Indication">The patient is currently a hospital in-patient as a result of an acute depressive episode</ci> <ci type="logical" class="Trial">The patient must have had a trial of one other antidepressant and have had an inadequate response from an adequate dose over an adequate period of time</ci> </apply> </apply> </apply> </math> <Appl
<Request To="HealthPAC" For="Subsidy" Form="SA1411"> <Title> <range>Erlotinib</range> </Title> <Case When="Initial application"> <math> <apply> <or/> <apply> <and/> <ci type="logical" class="Indication">Patient has locally advanced or metastatic, unresectable, non-squamous Non Small Cell Lung Cancer (NSCLC)</ci> <ci type="logical" class="Indication">There is documentation confirming that the disease expresses activating mutations of EGFR tyrosine kinase</ci> <apply> <or/> <ci type="logical" class="Indication">Patient is treatment naive</ci> <apply> <and/> <ci type="logical" class="Indication">Patient has documented disease progression following treatment with first line platinum based chemotherapy</ci> <ci type="logical" class="Indication">Patient has not received prior treatment with gefitinib</ci> </apply> </apply>
<Request To="HealthPAC" For="Alternate Subsidy" Form="SA1018"> <Title> <range>Hormone Replacement Therapy - Systemic</range> </Title> <Case When="Initial application"> <math> <apply> <or/> <ci type="logical" class="Indication">acute or significant liver disease - where oral oestrogens are contraindicated as determined by a gastroenterologist or general physician. The applicant must keep written confirmation from such a specialist with the patient's record</ci> <ci type="logical" class="Indication">oestrogen induced hypertension requiring antihypertensive therapy - documented evidence must be kept on file that raised blood pressure levels or inability to control blood pressure adequately occurred post oral oestrogens</ci> <ci type="logical" class="Indication">hypertriglyceridaemia - documented evidence must be kept on file that triglyceride levels increased to at least 2 &#215; normal triglyceride levels post oral oestrogens</ci> <ci type=
<Request To="HealthPAC" For="Subsidy" Form="SA1320"> <Title> <range>Diazoxide</range> </Title> <Case When="Initial application"> <math> <ci type="logical" class="Indication">used for the treatment of confirmed hypoglycaemia caused by hyperinsulinism</ci> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="month">12</Term> </Case> <Case When="Renewal" Form="SA1320"> <math> <ci type="logical" class="Indication">The treatment remains appropriate and the patient is benefiting from treatment</ci> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="patient's lifetime"/> </Case></Request>
<Request To="HealthPAC" For="Subsidy" Form="SA1318"> <Title> <range>Albendazole</range> </Title> <Case When="Initial application"> <math> <ci type="logical" class="Indication">The patient has hydatids</ci> </math> <Applicant>infectious disease specialist</Applicant> <Applicant>clinical microbiologist</Applicant> <Term Measure="month">6</Term> </Case> <Case When="Renewal" Form="SA1318"> <math> <ci type="logical" class="Indication">The treatment remains appropriate and the patient is benefitting from the treatment</ci> </math> <Applicant>infectious disease specialist</Applicant> <Applicant>clinical microbiologist</Applicant> <Term Measure="month">6</Term> </Case></Request>
<Request To="HealthPAC" For="Subsidy" Form="SA1095"> <Title> <range>Diabetic products<instance>Diason RTH</instance><instance>Glucerna Select RTH</instance><instance>Diasip</instance><instance>Glucerna Select</instance><instance>Resource Diabetic</instance></range> </Title> <Case When="Initial application"> <math> <ci type="logical" class="Indication">The patient is a type I or and II diabetic who is suffering weight loss and malnutrition that requires nutritional support</ci> </math> <Applicant>dietitian</Applicant> <Applicant>relevant specialist</Applicant> <Applicant>vocationally registered general practitioner</Applicant> <Term Measure="year">1</Term> </Case> <Case When="Renewal" Form="SA0594 SA1095"> <math> <apply> <and/> <ci type="logical" class="Indication">The treatment remains appropriate and the patient is benefiting from treatment</ci> <ci type="text" class="Endorsement">General Practitioners must includ
<Request To="PHARMAC" For="Manufacturers Price" Form="SA1038"> <Title> <range>Anti-inflammatory Non Steroidal Drugs (NSAIDs)</range> </Title> <Case When="Initial application"> <math> <ci type="logical" class="Indication">Subsidy for patients with existing approvals prior to 1 September 2010</ci> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="patient's lifetime"/> </Case> <Note> <Para>Subsidy for patients with existing approvals prior to 1 September 2010. Approvals valid without further renewal unlessnotified. No new approvals will be granted from 1 September 2010.</Para> </Note></Request>
<Request To="HealthPAC" For="Subsidy" Form="SA1449"> <Title> <range>Adalimumab</range> </Title> <Case When="Initial application" Category="rheumatoid arthritis"> <math> <apply> <or/> <apply> <and/> <ci type="logical" class="Indication">The patient has had an initial Special Authority approval for etanercept for rheumatoid arthritis</ci> <apply> <or/> <ci type="logical" class="Indication">The patient has experienced intolerable side effects from etanercept</ci> <ci type="logical" class="Indication">The patient has received insufficient benefit from etanercept to meet the renewal criteria for etanercept for rheumatoid arthritis</ci> </apply> </apply> <apply> <and/> <ci type="logical" class="Indication">Patient has had severe and active erosive rheumatoid arthritis for six months duration or longer</ci> <ci type="logical" class="Treatmen
<Request To="HealthPAC" For="Subsidy" Form="SA1388"> <Title> <range>Preservative Free Ocular Lubricants</range> </Title> <Case When="Initial application"> <math> <apply> <and/> <ci type="logical" class="Indication">Confirmed diagnosis by slit lamp of severe secretory dry eye</ci> <apply> <or/> <ci type="logical" class="Indication">Patient is using eye drops more than four times daily on a regular basis</ci> <ci type="logical" class="Indication">Patient has had a confirmed allergic reaction to preservative in eye drop</ci> </apply> </apply> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="month">12</Term> </Case> <Case When="Renewal" Form="SA1388"> <math> <ci type="logical" class="Indication">The patient continues to require lubricating eye drops and has benefited from treatment</ci> </math> <Applicant>any relevant practitioner</Applicant>
<Request To="HealthPAC" For="Subsidy" Form="SA1201"> <Title> <range>Prasugrel</range> </Title> <Case When="Initial application" Category="coronary angioplasty and bare metal stent"> <math> <ci type="logical" class="Treatment">The patient has undergone coronary angioplasty in the previous 4 weeks and is clopidogrel-allergic*</ci> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="month">6</Term> </Case> <Case When="Initial application" Category="drug eluting stent"> <math> <ci type="logical" class="Treatment">The patient has had a drug-eluting cardiac stent inserted in the previous 4 weeks and is clopidogrel-allergic*</ci> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="month">12</Term> </Case> <Case When="Initial application" Category="stent thromobosis"> <math> <ci type="logical" class="Treatment">patient has experienced cardiac stent thrombosis whilst on clopidogrel</ci>
<Request To="HealthPAC" For="Subsidy" Form="SA1325"> <Title> <range>Pegaspargase</range> </Title> <Case When="Initial application"> <math> <apply> <and/> <ci type="logical" class="Indication">The patient has newly diagnosed acute lymphoblastic leukaemia</ci> <ci type="logical" class="Indication">Pegaspargase to be used with a contemporary intensive multi-agent chemotherapy treatment protocol</ci> <ci type="logical" class="Indication">Treatment is with curative intent</ci> </apply> </math> <Applicant>relevant specialist</Applicant> <Applicant Referring="relevant specialist">medical practitioner</Applicant> <Term Measure="month">12</Term> </Case> <Case When="Renewal" Form="SA1325"> <math> <apply> <and/> <ci type="logical" class="Indication">The patient has relapsed acute lymphoblastic leukaemia</ci> <ci type="logical" class="Indication">Pegaspargase to be used with a contemporar
<Request To="HealthPAC" For="Alternate Subsidy" Form="SA0500"> <Title><range>Combined oral contraceptives</range><range>Progestogen-only contraceptives</range> (Circle one)</Title> <Case When="Initial application"> <math> <apply> <and/> <apply> <or/> <ci type="logical" class="Target">Patient is on a Social Welfare benefit</ci> <ci type="logical" class="Target">Patient has an income no greater than the benefit</ci> </apply> <ci type="logical" class="Trial">Has tried at least one of the fully funded options and has been unable to tolerate it</ci> </apply> </math> <Applicant>medical practitioner</Applicant> <Term Measure="year">2</Term> </Case> <Case When="Renewal" Form="SA0265 SA0500"> <math> <apply> <or/> <ci type="logical" class="Target">Patient is on a Social Welfare benefit</ci> <ci type="logical" class="Target">Patient has an income no greater than the be
<Request To="HealthPAC" For="Subsidy" Form="SA1374"> <Title> <range>Fat<instance>Calogen</instance><instance>Liquigen</instance><instance>MCT oil (Nutricia)</instance></range> </Title> <Case When="Initial application" Category="Inborn errors of metabolism"> <math> <ci type="logical" class="Indication">The patient has inborn errors of metabolism</ci> </math> <Applicant>dietitian</Applicant> <Applicant>relevant specialist</Applicant> <Applicant>vocationally registered general practitioner</Applicant> <Term Measure="year">3</Term> </Case> <Case When="Initial application" Category="Indications other than inborn errors of metabolism"> <math> <apply> <or/> <ci type="logical" class="Indication">faltering growth in an infant/child</ci> <ci type="logical" class="Indication">bronchopulmonary dysplasia</ci> <ci type="logical" class="Indication">fat malabsorption</ci> <ci type="logical" class="Indication">lym
<Request To="HealthPAC" For="Subsidy" Form="SA1375"> <Title> <range>Protein<instance>Protifar</instance><instance>Promod</instance><instance>Resource Beneprotein</instance></range> </Title> <Case When="Initial application"> <math> <apply> <or/> <ci type="logical" class="Indication">protein losing enteropathy</ci> <ci type="logical" class="Indication">high protein needs</ci> <ci type="logical" class="Indication">for use as a component in a modular formula</ci> </apply> </math> <Applicant>dietitian</Applicant> <Applicant>relevant specialist</Applicant> <Applicant>vocationally registered general practitioner</Applicant> <Term Measure="year">1</Term> </Case> <Case When="Renewal" Form="SA0582 SA1093 SA1375"> <math> <apply> <and/> <ci type="logical" class="Indication">The treatment remains appropriate and the patient is benefiting from treatment</ci> <ci type="text" class="Endor
<Request To="HealthPAC" For="Subsidy" Form="SA1266"> <Title> <range>Sunitinib</range> </Title> <Case When="Initial application" Category="RCC"> <math> <apply> <and/> <ci type="logical" class="Indication">The patient has metastatic renal cell carcinoma</ci> <apply> <or/> <ci type="logical" class="Trial">The patient is treatment naive</ci> <ci type="logical" class="Trial">The patient has only received prior cytokine treatment</ci> <ci type="logical" class="Trial">The patient has only received prior treatment with an investigational agent within the confines of a bona fide clinical trial which has Ethics Committee approval</ci> <apply> <and/> <ci type="logical" class="Trial">The patient has discontinued pazopanib within 3 months of starting treatment due to intolerance</ci> <ci type="logical" class="Trial">The cancer did not progress whilst on pazopanib</ci>
<Request To="HealthPAC" For="Subsidy" Form="SA1273"> <Title> <range>Voriconazole</range> </Title> <Case When="Initial application" Category="invasive fungal infection"> <math> <apply> <and/> <ci type="logical" class="Indication">Patient is immunocompromised</ci> <ci type="logical" class="Indication">Applicant is part of a multidisciplinary team including an infectious disease specialist</ci> <apply> <or/> <ci type="logical" class="Indication">Patient has proven or probable invasive aspergillus infection</ci> <ci type="logical" class="Indication">Patient has possible invasive aspergillus infection</ci> <ci type="logical" class="Indication">Patient has fluconazole resistant candidiasis</ci> <ci type="logical" class="Indication">Patient has mould strain such as Fusarium spp. and Scedosporium spp</ci> </apply> </apply> </math> <Applicant>haematologist</Applicant> <App
<Request To="HealthPAC" For="Subsidy" Form="SA1228"> <Title> <range>Standard Supplements<instance>Ensure</instance><instance>Fortisip</instance><instance>Isosource</instance><instance>Jevity</instance><instance>Nutrison</instance><instance>Osmolite</instance><instance>Sustagen</instance></range> </Title> <Case When="Initial application" Category="Children"> <math> <apply> <and/> <ci type="logical" class="Indication">The patient is under 18 years of age</ci> <apply> <or/> <ci type="logical" class="Indication">The patient has a condition causing malabsorption</ci> <ci type="logical" class="Indication">The patient has failure to thrive</ci> <ci type="logical" class="Indication">The patient has increased nutritional requirements</ci> </apply> <ci type="logical" class="Indication">Nutrition goal has been set (eg reach a specific weight or BMI)</ci> </apply> </math> <Applicant>dietitia
<Request To="HealthPAC" For="Subsidy" Form="SA1046"> <Title> <range>Ezetimibe with Simvastatin<instance>Vytorin</instance></range> </Title> <Case When="Initial application"> <math> <apply> <and/> <ci type="logical" class="Indication">Patient has a calculated absolute risk of cardiovascular disease of at least 15% over 5 year</ci> <ci type="logical" class="Trial">Patient's LDL cholesterol is 2.0 mmol/litre or greater</ci> <ci type="logical" class="Trial">The patient has not reduced their LDL cholesterol to less than 2.0 mmol/litre with the use of the maximal tolerated dose of atorvastatin</ci> </apply> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="year">2</Term> <Note> <Para>A patient who has failed to reduce their LDL cholesterol to &#8804; 2.0 mmol/litre with the use of a less potent statin should use a more potent statin prior to consideration being given to the use of non-statin therapi
<Request To="Cystic Fibrosis Advisory Panel" For="Subsidy" Form="SA0611"> <Title> <range>Dornase Alfa</range> </Title> <Case When="Initial application"> <math> <ci/> </math> <Applicant>medical practitioner</Applicant> <Term Measure="year">1</Term> </Case> <Note> <Para>Application details may be obtained from PHARMAC's website <a href="http://www.pharmac.govt.nz/">http://www.pharmac.govt.nz</a> or:</Para> <Table> <TR> <TD> <Para>The Co-ordinator, Cystic Fibrosis Advisory Panel</Para> </TD> <TD> <Para>Phone: (04) 460 4990</Para> </TD> </TR> <TR> <TD> <Para>PHARMAC, PO Box 10 254</Para> </TD> <TD> <Para>Facsimile: (04) 916 7571</Para> </TD> </TR> <TR> <TD> <Para>Wellington</Para> </TD> <TD> <Para>Email: <a href="mailto:CFPanel@pharmac.govt.nz">CFPanel@pharmac.
<Request To="HealthPAC" For="Subsidy" Form="SA1451"> <Title> <range>Somatropin</range> </Title> <Case When="Initial application" Category="growth hormone deficiency in children"> <math> <apply> <or/> <apply> <and/> <ci type="logical" class="Indication">Growth hormone deficiency causing symptomatic hypoglycaemia, or with other significant growth hormone deficient sequelae (e.g. cardiomyopathy, hepatic dysfunction) and diagnosed with GH &lt; 5 mcg/l on at least two random blood samples in the first 2 weeks of life, or from samples during established hypoglycaemia (whole blood glucose &lt; 2 mmol/l using a laboratory device)</ci> </apply> <apply> <and/> <ci type="logical" class="Indication">Height velocity &lt; 25th percentile for age adjusted for bone age/pubertal status if appropriate over 6 or 12 months using the standards of Tanner and Davies (1985)</ci> <ci type="logical" class="Indication
<Request To="HealthPAC" For="Subsidy" Form="SA1139"> <Title> <range>Teriparatide</range> </Title> <Case When="Initial application"> <math> <apply> <and/> <ci type="logical" class="indication">The patient has severe, established osteoporosis</ci> <ci type="logical" class="indication">The patient has a documented T-score less than or equal to -3.0 (see Notes)</ci> <ci type="logical" class="indication">The patient has had two or more fractures due to minimal trauma</ci> <ci type="logical" class="indication">The patient has experienced at least one symptomatic new fracture after at least 12 months&#8217; continuous therapy with a funded antiresorptive agent at adequate doses (see Notes)</ci> </apply> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="month">18</Term> </Case> <Note> <List Type="Alpha"> <Item> <Para>The bone mineral density (BMD) measurement used to derive the
<Request To="PHARMAC" For="Subsidy" Form="SA1291"> <Title> <range>Optium blood glucose test strips</range> </Title> <Case When="Initial application"> <math> <ci type="logical" class="Indication">Patient identified as eligible for subsidy for FreeStyle Optium blood glucose test strips</ci> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="patient's lifetime"/> </Case> <Note> <Para>Application details may be obtained from PHARMAC's website http://www.pharmac.govt.nz and can be sent to:</Para> <Table> <TR> <TD> <Para>PHARMAC</Para> </TD> <TD> <Para/> </TD> </TR> <TR> <TD> <Para>PO Box 10 254</Para> </TD> <TD> <Para>Facsimile: (04) 974 4788</Para> </TD> </TR> <TR> <TD> <Para>Wellington</Para> </TD> <TD> <Para>Email: <a href="mailto:bgstrip
<Request To="HealthPAC" For="Subsidy" Form="SA1098"> <Title> <range>Paediatric Product For Children Awaiting Liver Transplant<instance>Heparon Junior</instance></range> </Title> <Case When="Initial application"> <math> <ci type="logical" class="Indication">The patient is a child (up to 18 years) who requires a liver transplant</ci> </math> <Applicant>dietitian</Applicant> <Applicant>relevant specialist</Applicant> <Applicant>vocationally registered general practitioner</Applicant> <Term Measure="year">3</Term> </Case> <Case When="Renewal" Form="SA0607 SA1098"> <math> <apply> <and/> <ci type="logical" class="Indication">The treatment remains appropriate and the patient is benefiting from treatment</ci> <ci type="text" class="Endorsement">General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted</ci> </apply> </math
<Request To="HealthPAC" For="Subsidy" Form="SA0845"> <Title> <range>Enfuvirtide</range> </Title> <Case When="Initial application"> <math> <apply> <and/> <ci type="logical" class="Indication">Confirmed HIV infection</ci> <ci type="logical" class="Indication">Enfuvirtide to be given in combination with optimized background therapy (including at least 1 other antiretroviral drug that the patient has never previously been exposed to) for treatment failure</ci> <apply> <or/> <ci type="logical" class="Indication">Patient has evidence of HIV replication, despite ongoing therapy</ci> <ci type="logical" class="Indication">Patient has treatment-limiting toxicity to previous antiretroviral agents</ci> </apply> <ci type="logical" class="Indication">Previous treatment with 3 different antiretroviral regimens has failed</ci> <apply> <and/> <ci type="logical" class="Indication">Prev
<Request To="HealthPAC" For="Subsidy" Form="SA0955"> <Title> <range>Isotretinoin</range> </Title> <Case When="Initial application"> <math> <apply> <and/> <ci type="logical" class="Indication">Patient has had an adequate trial on other available treatments and has received an inadequate response from these treatments or these are contraindicated</ci> <ci type="logical" class="Indication">Applicant is a vocationally registered dermatologist, vocationally registered general practitioner, or nurse practitioner working in a relevant scope of practice</ci> <ci type="logical" class="Indication">Applicant has an up to date knowledge of the treatment options for acne and is aware of the safety issues around isotretinoin and is competent to prescribe isotretinoin</ci> <apply> <or/> <ci type="logical" class="Indication">Patient is female and has been counselled and understands the risk of teratogenicity if isotretinoin is used d
<Request To="HealthPAC" For="Subsidy" Form="SA0994"> <Title> <range>Mirtazapine</range> </Title> <Case When="Initial application"> <math> <apply> <and/> <ci type="logical" class="Indication">The patient has a severe major depressive episode</ci> <apply> <or/> <ci type="logical" class="Trial">The patient must have had a trial of two different antidepressants and was unable to tolerate the treatments or failed to respond to an adequate dose over an adequate period of time (usually at least four weeks)</ci> <apply> <and/> <ci type="logical" class="Indication">The patient is currently a hospital in-patient as a result of an acute depressive episode</ci> <ci type="logical" class="Trial">The patient must have had a trial of one other antidepressant and either could not tolerate it or failed to respond to an adequate dose over an adequate period of time</ci> </apply> </appl
<Request To="HealthPAC" For="Subsidy" Form="SA1404"> <Title> <range>Valganciclovir</range> </Title> <Case When="Initial application" Category="transplant cytomegalovirus prophylaxis"> <math> <ci type="logical" class="Indication">the patient has undergone a solid organ transplant and requires valganciclovir for CMV prophylaxis</ci> </math> <Applicant>relevant specialist</Applicant> <Term Measure="month">3</Term> </Case> <Case When="Renewal" Form="SA1274 SA1404" Category="transplant cytomegalovirus prophylaxis"> <math> <apply> <and/> <ci type="logical" class="Indication">Patient has undergone a solid organ transplant and received anti-thymocyte globulin and requires valganciclovir therapy for CMV prophylaxis</ci> <ci type="logical" class="Indication">Patient is to receive a maximum of 90 days of valganciclovir prophylaxis following anti-thymocyte globulin</ci> </apply> </math> <Applicant>relevant specialist</A
<Request To="HealthPAC" For="Subsidy" Form="SA1138"> <Title> <range>Raloxifene</range> </Title> <Case When="Initial application"> <math> <apply> <or/> <ci type="logical" class="indication">History of one significant osteoporotic fracture demonstrated radiologically and documented bone mineral density (BMD) &#8805;2.5 standard deviations below the mean normal value in young adults (i.e. T-Score &#8804; -2.5) (see Notes)</ci> <ci type="logical" class="indication">History of one significant osteoporotic fracture demonstrated radiologically, and either the patient is elderly, or densitometry scanning cannot be performed because of major logistical, technical or pathophysiological reasons. It is unlikely that this provision would apply to many patients under 75 years of age</ci> <ci type="logical" class="indication">History of two significant osteoporotic fractures demonstrated radiologically</ci> <ci type="logical" class="indication">Documente
<Request To="HealthPAC" For="Subsidy" Form="SA1125"> <Title> <range>Lacosamide</range> </Title> <Case When="Initial application"> <math> <apply> <and/> <ci type="logical" class="Indication">Patient has partial-onset epilepsy</ci> <ci type="logical" class="Trial">Seizures are not adequately controlled by, or patient has experienced unacceptable side effects from, optimal treatment with all of the following: sodium valproate, topiramate, levetiracetam and any two of carbamazepine, lamotrigine and phenytoin sodium (see Note)</ci> </apply> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="month">15</Term> <Note> <Para>"Optimal treatment" is defined as treatment which is indicated and clinically appropriate for the patient, given in adequate doses for the patient's age, weight and other features affecting the pharmacokinetics of the drug with good evidence of compliance. Women of childbearing age are not re
<Request To="HealthPAC" For="Subsidy" Form="SA1376"> <Title> <range>Carbohydrate and Fat<instance>Duocal Super Soluble Powder</instance></range> </Title> <Case When="Initial application" Category="Cystic fibrosis"> <math> <apply> <and/> <ci type="logical" class="Indication">Infant or child aged four years or under</ci> <ci type="logical" class="Indication">cystic fibrosis</ci> </apply> </math> <Applicant>dietitian</Applicant> <Applicant>relevant specialist</Applicant> <Applicant>vocationally registered general practitioner</Applicant> <Term Measure="year">3</Term> </Case> <Case When="Initial application" Category="Indications other than cystic fibrosis"> <math> <apply> <and/> <ci type="logical" class="Indication">infant or child aged four years or under</ci> <apply> <or/> <ci type="logical" class="Indication">cancer in children</ci> <ci type="logica
<Request To="HealthPAC" For="Subsidy" Form="SA0895"> <Title> <range>Pilocarpine &#8211; Eye drops 2% single dose</range> </Title> <Case When="Initial application"> <math> <apply> <or/> <ci type="logical" class="Indication">Patient has to use an unpreserved solution due to an allergy to the preservative</ci> <ci type="logical" class="Indication">Patient wears soft contact lenses</ci> </apply> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="year">2</Term> <Note> <Para>Minims for a general practice are considered to be &#8220;tools of trade&#8221; and are not approved as special authority items.</Para> </Note> </Case> <Case When="Renewal" Form="SA0121 SA0895"> <math> <ci type="logical" class="Indication">The treatment remains appropriate and the patient is benefiting from treatment</ci> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="year">2<
<Request To="HealthPAC" For="Subsidy" Form="SA1072"> <Title> <range>Vigabatrin</range> </Title> <Case When="Initial application"> <math> <apply> <and/> <apply> <or/> <ci type="logical" class="Indication">Patient has infantile spasms</ci> <apply> <and/> <ci type="logical" class="Indication">Patient has epilepsy</ci> <apply> <or/> <ci type="logical" class="Indication">Seizures are not adequately controlled with optimal treatment with other antiepilepsy agents</ci> <ci type="logical" class="Indication">Seizures are controlled adequately but the patient has experienced unacceptable side effects from optimal treatment with other antiepilepsy agents</ci> </apply> </apply> </apply> <apply> <or/> <ci type="logical" class="Indication">Patient is, or will be, receiving regular automated visual fiel
<Request To="HealthPAC" For="Subsidy" Form="SA1408"> <Title> <range>Naltrexone</range> </Title> <Case When="Initial application"> <math> <apply> <and/> <ci type="logical" class="Indication">Patient is currently enrolled in a recognised comprehensive treatment programme for alcohol dependence</ci> <ci type="logical" class="Therapy">Applicant works in or with a community Alcohol and Drug Service contracted to one of the District Health Boards or accredited against the New Zealand Alcohol and Other Drug Sector Standard or the National Mental Health Sector Standard</ci> </apply> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="month">6</Term> </Case> <Case When="Renewal" Form="SA0714 SA0909 SA1397 SA1408"> <math> <apply> <and/> <ci type="logical" class="Indication">Compliance with the medication (prescriber determined)</ci> <apply> <or/> <ci type="log
<Request To="HealthPAC" For="Subsidy" Form="SA1174"> <Title> <range>Enoxaparin sodium</range> </Title> <Case When="Initial application" Category="Pregnancy or Malignancy"> <math> <apply> <or/> <ci type="logical" class="Indication">Low molecular weight heparin treatment is required during a patients pregnancy</ci> <ci type="logical" class="Treatment">For the treatment of venous thromboembolism where the patient has a malignancy</ci> </apply> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="year">1</Term> </Case> <Case When="Initial application" Category="Venous thromboembolism other than in pregnancy or malignancy"> <math> <apply> <or/> <ci type="logical" class="Indication">For the short-term treatment of venous thromboembolism prior to establishing a therapeutic INR with oral anti-coagulant treatment</ci> <ci type="logical" class="Treatment">For the prophylaxis and tre
<Request To="HealthPAC" For="Subsidy" Form="SA1416"> <Title> <range>Atomoxetine</range> </Title> <Case When="Initial application"> <math> <apply> <and/> <ci type="logical" class="Indication">Patient has ADHD (Attention Deficit and Hyperactivity Disorder) diagnosed according to DSM-IV or ICD 10 criteria</ci> <ci type="logical" class="Indication">Once-daily dosing</ci> <apply> <or/> <ci type="logical" class="Indication">Treatment with a subsidised formulation of a stimulant has resulted in the development or worsening of serious adverse reactions or where the combination of subsidised stimulant treatment with another agent would pose an unacceptable medical risk</ci> <ci type="logical" class="Indication">Treatment with a subsidised formulation of a stimulant has resulted in worsening of co-morbid substance abuse or there is a significant risk of diversion with subsidised stimulant therapy</ci> <ci type="log
<Request To="HealthPAC" For="Subsidy" Form="SA1263"> <Title> <range>Nicorandil</range> </Title> <Case When="Initial application"> <math> <apply> <and/> <ci type="logical" class="Indication">Patient has refractory angina</ci> <ci type="logical" class="Trial">Patient is on the maximal tolerated dose of a beta-blocker, a calcium channel blocker and a long acting nitrate</ci> </apply> </math> <Applicant>cardiologist</Applicant> <Applicant>general physician</Applicant> <Term Measure="year">2</Term> </Case> <Case When="Renewal" Form="SA1263"> <math> <ci type="logical" class="Indication">The treatment remains appropriate and the patient is benefiting from treatment</ci> </math> <Applicant>cardiologist</Applicant> <Applicant Referring="cardiologist">any relevant practitioner</Applicant> <Term Measure="year">2</Term> </Case></Request>
<Request To="HealthPAC" For="Subsidy" Form="SA0927"> <Title> <range>Risperidone orally disintegrating tablets</range> </Title> <Case When="Initial application" Category="Acute situations"> <math> <apply> <and/> <ci type="logical" class="Use">For a non-adherent patient on oral therapy with standard risperidone tablets or risperidone oral liquid</ci> <ci type="logical" class="Therapy">The patient is under direct supervision for administration of medicine</ci> </apply> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="week">6</Term> </Case> <Case When="Initial application" Category="Chronic situations"> <math> <apply> <and/> <ci type="logical" class="Indication">The patient is unable to take standard risperidone tablets or oral liquid, or once stabilized refuses to take risperidone tablets or oral liquid</ci> <ci type="logical" class="Therapy">The patient is under direct
<Request To="HealthPAC" For="Subsidy" Form="SA1195"> <Title> <range>High Calorie Products<instance>Two Cal HN</instance><instance>Nutrison Concentrated</instance></range> </Title> <Case When="Initial application" Category="Cystic fibrosis"> <math> <apply> <and/> <ci type="logical" class="Indication">Cystic fibrosis</ci> <ci type="logical" class="Trial">other lower calorie products have been tried</ci> <ci type="logical" class="Indication">patient has substantially increased metabolic requirements</ci> </apply> </math> <Applicant>dietitian</Applicant> <Applicant>relevant specialist</Applicant> <Applicant>vocationally registered general practitioner</Applicant> <Term Measure="year">3</Term> </Case> <Case When="Initial application" Category="Indications other than cystic fibrosis"> <math> <apply> <and/> <apply> <or/> <ci type="logical" class="Indication">any cond
<Request To="HealthPAC" For="Subsidy" Form="SA1199"> <Title> <range>Propylthiouracil</range> </Title> <Case When="Initial application"> <math> <apply> <and/> <ci type="logical" class="Indication">The patient has hyperthyroidism</ci> <ci type="logical" class="Indication">The patient is intolerant of carbimazole or carbimazole is contraindicated</ci> </apply> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="year">2</Term> </Case> <Case When="Renewal" Form="SA1199"> <math> <ci type="logical" class="Indication">the treatment remains appropriate and the patient is benefitting from the treatment</ci> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="year">2</Term> </Case></Request>
<Request To="PHARMAC" For="Subsidy" Form="SA1237"> <Title> <range>Insulin Pumps</range> </Title> <Case When="Initial application"> <math/> <Applicant>medical practitioner</Applicant> <Term Measure="year">1</Term> </Case> <Note> <Para>Application details may be obtained from PHARMAC's website <a href="http://www.pharmac.govt.nz/">http://www.pharmac.govt.nz</a> or:</Para> <Table> <TR> <TD> <Para>The IPP Co-ordinator</Para> </TD> <TD> <Para>Phone: (04) 460 4990</Para> </TD> </TR> <TR> <TD> <Para>PHARMAC</Para> </TD> <TD> <Para>Facsimile: (04) 974 7806</Para> </TD> </TR> <TR> <TD> <Para>PO Box 10 254</Para> </TD> <TD> <Para>Email: <a href="mailto:ipp@pharmac.govt.nz">ipp@pharmac.govt.nz</a></Para> </TD> </TR> <TR> <TD> <Para>Welli
<Request To="HealthPAC" For="Subsidy" Form="SA0829"> <Title> <range>Adefovir dipivoxil</range> </Title> <Case When="Initial application"> <math> <apply> <and/> <ci type="logical" class="Trial">Patient has confirmed Hepatitis B infection (HBsAg+)</ci> <mi class="heading">Documented resistance to lamivudine, defined as:</mi> <ci type="logical" class="Trial">Patient has raised serum ALT (&gt; 1 &#215; ULN)</ci> <ci type="logical" class="Trial">Patient has HBV DNA greater than 100,000 copies per mL, or viral load &#8805; 10 fold over nadir</ci> <ci type="logical" class="Trial">Detection of M204I or M204V mutation</ci> <apply> <or/> <apply> <and/> <ci type="logical" class="Trial">Patient is cirrhotic</ci> <ci type="logical" class="Trial">adefovir dipivoxil to be used in combination with lamivudine</ci> </apply> <apply> <and/>
<Request To="HealthPAC" For="Subsidy" Form="SA1379"> <Title> <range>Paediatric Products<instance>Nutrini</instance><instance>Pediasure</instance><instance>Fortini</instance></range> </Title> <Case When="Initial application"> <math> <apply> <and/> <ci type="logical" class="Indication">Child is aged one to ten years</ci> <apply> <or/> <ci type="logical" class="Indication">the child is being fed via a tube or a tube is to be inserted for the purposes of feeding</ci> <ci type="logical" class="Indication">any condition causing malabsorption</ci> <ci type="logical" class="Indication">faltering growth in an infant/child</ci> <ci type="logical" class="Indication">increased nutritional requirements</ci> <ci type="logical" class="Indication">the child is being transitioned from TPN or tube feeding to oral feeding</ci> </apply> </apply> </math> <Applicant>dietitian</Applicant>
<Request To="HealthPAC" For="Subsidy" Form="SA1382"> <Title> <range>Ticagrelor</range> </Title> <Case When="Initial application" Category="acute coronary syndrome"> <math> <apply> <and/> <ci type="logical" class="Indication">Patient has recently been diagnosed with an ST-elevation or a non-ST-elevation acute coronary syndrome</ci> <ci type="logical" class="Indication">Fibrinolytic therapy has not been given in the last 24 hours and is not planned</ci> </apply> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="month">12</Term> </Case> <Case When="Renewal" Category="subsequent acute coronary syndrome" Form="SA1382"> <math> <apply> <and/> <ci type="logical" class="Indication">Patient has recently been diagnosed with an ST-elevation or a non-ST-elevation acute coronary syndrome</ci> <ci type="logical" class="Indication">Fibrinolytic therapy has not been given in the last 24
<Request To="HealthPAC" For="Subsidy" Form="SA1383"> <Title> <range>Ursodeoxycholic Acid</range> </Title> <Case When="Initial application" Category="Alagille syndrome or progressive familial intrahepatic cholestasis"> <math> <apply> <or/> <ci type="logical" class="Indication">Patient has been diagnosed with Alagille syndrome</ci> <ci type="logical" class="Indication">Patient has progressive familial intrahepatic cholestasis</ci> </apply> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="patient's lifetime"/> </Case> <Case When="Initial application" Category="Chronic severe drug induced cholestatic liver injury"> <math> <apply> <and/> <ci type="logical" class="Indication">Patient has chronic severe drug induced cholestatic liver injury</ci> <ci type="logical" class="Indication">Cholestatic liver injury not due to Total Parenteral Nutrition (TPN) use in adults</ci>
<Request To="HealthPAC" For="Subsidy" Form="SA1192"> <Title> <range>Trastuzumab</range> </Title> <Case When="Initial application" Category="metastatic breast cancer"> <math> <apply> <or/> <apply> <and/> <ci type="logical" class="Indication">The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology)</ci> <ci type="logical" class="Treatment">The patient has not previously received lapatinib treatment for HER 2 positive metastatic breast cancer</ci> <ci type="logical" class="Indication">Trastuzumab not to be given in combination with lapatinib</ci> <ci type="logical" class="Treatment">Trastuzumab to be discontinued at disease progression</ci> </apply> <apply> <and/> <ci type="logical" class="Indication">The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology
<Request To="HealthPAC" For="Subsidy" Form="SA1071"> <Title> <range>Gabapentin</range> </Title> <Case When="Initial application" Category="Epilepsy"> <math> <apply> <or/> <ci type="logical" class="Indication">Seizures are not adequately controlled with optimal treatment with other antiepilepsy agents</ci> <ci type="logical" class="Indication">Seizures are controlled adequately but the patient has experienced unacceptable side effects from optimal treatment with other antiepilepsy agents</ci> </apply> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="month">15</Term> <Note> <Para>"Optimal treatment with other antiepilepsy agents" is defined as treatment with other antiepilepsy agents which are indicated and clinically appropriate for the patient, given in adequate doses for the patient's age, weight, and other features affecting the pharmacokinetics of the drug with good evidence of compliance.</Para>
<Request To="HealthPAC" For="Subsidy" Form="SA1066"> <Title> <range>Rivaroxaban</range> </Title> <Case When="Initial application"> <math> <apply> <or/> <ci type="logical" class="Indication">For the prophylaxis of venous thromboembolism following a total hip replacement</ci> <ci type="logical" class="Use">For the prophylaxis of venous thromboembolism following a total knee replacement</ci> </apply> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="week">5</Term> <Note> <Para>Rivaroxaban is only currently indicated and subsidised for up to 5 weeks therapy for prophylaxis of venous thromboembolism following a total hip replacement and up to 2 weeks therapy for prophylaxis of venous thromboembolism following a total knee replacement.</Para> </Note> </Case> <Case When="Renewal" Form="SA1066"> <math> <ci type="logical" class="Indication">Prophylaxis for venous thromboembolism is requir
<Request To="PHARMAC" For="Subsidy" Form="SA1240"> <Title> <range>Insulin pump consumables</range> </Title> <Case When="Initial application"> <math/> <Applicant>medical practitioner</Applicant> <Term Measure="year">1</Term> </Case> <Note> <Para>Application details may be obtained from PHARMAC's website <a href="http://www.pharmac.govt.nz/">http://www.pharmac.govt.nz</a> or:</Para> <Table> <TR> <TD> <Para>The IPP Co-ordinator</Para> </TD> <TD> <Para>Phone: (04) 460 4990</Para> </TD> </TR> <TR> <TD> <Para>PHARMAC</Para> </TD> <TD> <Para>Facsimile: (04) 974 7806</Para> </TD> </TR> <TR> <TD> <Para>PO Box 10 254</Para> </TD> <TD> <Para>Email: <a href="mailto:ipp@pharmac.govt.nz">ipp@pharmac.govt.nz</a></Para> </TD> </TR> <TR> <TD>
<Request To="HealthPAC" For="Subsidy" Form="SA1039"> <Title> <range>Alendronate Tab 70 mg - with or without Cholecalciferol</range> </Title> <Case When="Initial application" Category="Underlying cause -- Osteoporosis"> <math> <apply> <or/> <ci type="logical" class="Indication">History of one significant osteoporotic fracture demonstrated radiologically and documented bone mineral density (BMD) &#8805; 2.5 standard deviations below the mean normal value in young adults (i.e. T-Score &#8804; -2.5) (see Note)</ci> <ci type="logical" class="Indication">History of one significant osteoporotic fracture demonstrated radiologically, and either the patient is elderly, or densitometry scanning cannot be performed because of major logistical, technical or pathophysiological reasons. It is unlikely that this provision would apply to many patients under 75 years of age</ci> <ci type="logical" class="Indication">History of two significant osteoporotic fractures
<Request To="HealthPAC" For="Subsidy" Form="SA1324"> <Title> <range>Paromomycin</range> </Title> <Case When="Initial application"> <math> <ci type="logical" class="Indication">the patient has confirmed cryptosporidium infection</ci> </math> <Applicant>infectious disease specialist</Applicant> <Applicant>clinical microbiologist</Applicant> <Term Measure="month">1</Term> </Case> <Case When="Renewal" Form="SA1324"> <math> <ci type="logical" class="Indication">the patient has confirmed cryptosporidium infection</ci> </math> <Applicant>infectious disease specialist</Applicant> <Applicant>clinical microbiologist</Applicant> <Term Measure="month">1</Term> </Case></Request>
<Request To="HealthPAC" For="Subsidy" Form="SA1126"> <Title> <range>Modavigil</range> </Title> <Case When="Initial application"> <math> <apply> <and/> <ci type="logical" class="Indication">The patient has a diagnosis of narcolepsy and has excessive daytime sleepiness associated with narcolepsy occurring almost daily for three months or more</ci> <apply> <or/> <ci type="logical" class="Indication">The patient has a multiple sleep latency test with a mean sleep latency of less than or equal to 10 minutes and 2 or more sleep onset rapid eye movement periods</ci> <ci type="logical" class="Indication">The patient has at least one of: cataplexy, sleep paralysis or hypnagogic hallucinations</ci> </apply> <apply> <or/> <ci type="logical" class="Indication">An effective dose of a subsidised formulation of methylphenidate or dexamphetamine has been trialled and discontinued because of intolerabl
<Request To="HealthPAC" For="Subsidy" Form="SA0928"> <Title> <range>Finasteride</range> </Title> <Case When="Initial application"> <math> <apply> <and/> <ci type="logical" class="Indication">Patient has symptomatic benign prostatic hyperplasia</ci> <apply> <or/> <ci type="logical" class="Indication">The patient is intolerant of non-selective alpha blockers or these are contraindicated</ci> <ci type="logical" class="Indication">Symptoms are not adequately controlled with non-selective alpha blockers</ci> </apply> </apply> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="patient's lifetime"/> </Case> <Note> <Para>Patients with enlarged prostates are the appropriate candidates for therapy with finasteride.</Para> </Note></Request>
<Request To="HealthPAC" For="Subsidy" Form="SA1099"> <Title> <range>Paediatric Product For Children With Chronic Renal Failure<instance>Kindergen</instance></range> </Title> <Case When="Initial application"> <math> <ci type="logical" class="Indication">The patient is a child (up to 18 years) with acute or chronic kidney disease</ci> </math> <Applicant>dietitian</Applicant> <Applicant>relevant specialist</Applicant> <Applicant>vocationally registered general practitioner</Applicant> <Term Measure="year">3</Term> </Case> <Case When="Renewal" Form="SA0606 SA1099"> <math> <apply> <and/> <ci type="logical" class="Indication">The treatment remains appropriate and the patient is benefiting from treatment</ci> <ci type="text" class="Endorsement">General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted</ci> </apply> </mat
<Request To="HealthPAC" For="Subsidy" Form="SA1381"> <Title> <range>Fat Modified Products<instance>Monogen</instance></range> </Title> <Case When="Initial application"> <math> <apply> <or/> <ci type="logical" class="Indication">Patient has metabolic disorders of fat metabolism</ci> <ci type="logical" class="Indication">Patient has a chyle leak</ci> <ci type="logical" class="Indication">Modified as a modular feed for adults</ci> </apply> </math> <Applicant>dietitian</Applicant> <Applicant>relevant specialist</Applicant> <Applicant>vocationally registered general practitioner</Applicant> <Term Measure="year">1</Term> </Case> <Case When="Renewal" Form="SA0593 SA0615 SA1096 SA1381"> <math> <apply> <and/> <ci type="logical" class="Indication">The treatment remains appropriate and the patient is benefiting from treatment</ci> <ci type="text" class="Endorsement">General Practitio
<Request To="HealthPAC" For="Subsidy" Form="SA0782"> <Title> <range>Levonorgestrel &#8211; releasing intrauterine system 20mcg/24 hr</range> </Title> <Case When="Initial application" Category="No previous use"> <math> <apply> <and/> <ci type="logical" class="Indication">The patient has a clinical diagnosis of heavy menstrual bleeding</ci> <ci type="logical" class="Trial">The patient has failed to respond to or is unable to tolerate other appropriate pharmaceutical therapies as per the Heavy Menstrual Bleeding Guidelines</ci> <apply> <or/> <apply> <lt/> <ci type="real" class="test">serum ferritin level</ci> <cn>16<mi> mcg/l (within the last 12 months)</mi></cn> </apply> <apply> <lt/> <ci type="real" class="test">haemoglobin level</ci> <cn>120<mi> g/l</mi></cn> </apply> </apply> </apply> </math>
<Request To="HealthPAC" For="Subsidy" Form="SA0954"> <Title> <range>Acitretin</range> </Title> <Case When="Initial application"> <math> <apply> <and/> <ci type="logical" class="Indication">Applicant is a vocationally registered dermatologist, vocationally registered general practitioner, or nurse practitioner working in a relevant scope of practice</ci> <ci type="logical" class="Indication">Applicant has an up to date knowledge of the treatment options for psoriasis and of disorders of keratinisation and is aware of the safety issues around acitretin and is competent to prescribe acitretin</ci> <apply> <or/> <ci type="logical" class="Indication">Patient is female and has been counselled and understands the risk of teratogenicity if acitretin is used during pregnancy and the applicant has ensured that the possibility of pregnancy has been excluded prior to the commencement of the treatment and that the patient is informed that
<Request To="HealthPAC" For="Subsidy" Form="SA0987"> <Title> <range>Aprepitant</range> </Title> <Case When="Initial application"> <math> <ci type="logical" class="Indication">The patient is undergoing highly emetogenic chemotherapy and/or anthracycline-based chemotherapy for the treatment of malignancy</ci> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="month">12</Term> </Case> <Case When="Renewal" Form="SA0987"> <math> <ci type="logical" class="Indication">The patient is undergoing highly emetogenic chemotherapy and/or anthracycline-based chemotherapy for the treatment of malignancy</ci> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="month">12</Term> </Case></Request>
<Request To="HealthPAC" For="Subsidy" Form="SA1155"> <Title> <range>Budesonide - Cap 3 mg Controlled Release</range> </Title> <Case When="Initial application" Category="Crohn's disease"> <math> <apply> <and/> <ci type="logical" class="Indication">Mild to moderate ileal, ileocaecal or proximal Crohn's disease</ci> <apply> <or/> <ci type="logical" class="Indication">Diabetes</ci> <ci type="logical" class="Indication">Cushingoid habitus</ci> <ci type="logical" class="Indication">Osteoporosis where there is significant risk of fracture</ci> <ci type="logical" class="Indication">Severe acne following treatment with conventional corticosteroid therapy</ci> <ci type="logical" class="Indication">History of severe psychiatric problems associated with corticosteroid treatment</ci> <ci type="logical" class="Indication">History of major mental illness (such as bipolar affective disorder) where
<Request To="HealthPAC" For="Subsidy" Form="SA1421"> <Title> <range>Montelukast</range> </Title> <Case When="Initial application" Category="Pre-school wheeze"> <math> <apply> <and/> <ci type="logical" class="Indication">To be used for the treatment of intermittent severe wheezing (possibly viral) in children under 5 years</ci> <ci type="logical" class="Indication">The patient has had at least three episodes in the previous 12 months of acute wheeze severe enough to seek medical attention</ci> </apply> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="year">1</Term> </Case> <Case When="Renewal" Category="Pre-school wheeze" Form="SA1227 SA1409 SA1421"> <math> <ci type="logical" class="Indication">The treatment remains appropriate and the patient is benefiting from treatment</ci> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="year">2</Term> </Case> <Case
<Request To="HealthPAC" For="Subsidy" Form="SA1196"> <Title> <range>Paediatric enteral feed with fibre 0.75 kcal/ml<instance>Nutrini Low Energy Multi Fibre</instance></range> </Title> <Case When="Initial application"> <math overflow="scroll"> <apply> <and/> <ci type="logical" class="Indication">Child aged one to eight years</ci> <ci type="logical" class="Indication">The child has a low energy requirement but normal protein and micronutrient requirements</ci> </apply> </math> <Applicant>dietitian</Applicant> <Applicant>relevant specialist</Applicant> <Applicant>vocationally registered general practitioner</Applicant> <Term Measure="year">1</Term> </Case> <Case When="Renewal" Form="SA1196"> <math overflow="scroll"> <apply> <and/> <ci type="logical" class="Indication">The treatment remains appropriate and the patient is benefiting from treatment</ci> <ci type="text" class="Endorsement
<Request To="HealthPAC" For="Subsidy" Form="SA1225"> <Title> <range>Ivermectin</range> </Title> <Case When="Initial application" Category="Scabies"> <math> <apply> <and/> <ci type="logical" class="Indication">Applying clinician has discussed the diagnosis of scabies with a dermatologist, infectious disease physician or clinical microbiologist</ci> <apply> <or/> <apply> <and/> <ci type="logical" class="Indication">The patient is in the community</ci> <apply> <or/> <ci type="logical" class="Indication">Patient has a severe scabies hyperinfestation (Crusted/ Norwegian scabies)</ci> <ci type="logical" class="Indication">The community patient is physically or mentally unable to comply with the application instructions of topical therapy</ci> <ci type="logical" class="Indication">The patient has previously tried and failed to clear infestation
<Request To="HealthPAC" For="Subsidy" Form="SA1322"> <Title> <range>Itraconazole</range> </Title> <Case When="Initial application"> <math> <ci type="logical" class="Indication">The patient has a congenital immune deficiency</ci> </math> <Applicant>infectious disease specialist</Applicant> <Applicant>clinical microbiologist</Applicant> <Applicant>clinical immunologist</Applicant> <Applicant Referring="infectious disease physician, clinical microbiologist or clinical immunologist">any relevant practitioner</Applicant> <Term Measure="month">6</Term> </Case> <Case When="Renewal" Form="SA1322"> <math> <ci type="logical" class="Indication">The treatment remains appropriate and the patient is benefitting from the treatment</ci> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="month">6</Term> </Case></Request>
<Request To="HealthPAC" For="Subsidy" Form="SA1223"> <Title> <range>Candesartan</range> </Title> <Case When="Initial application" Category="ACE inhibitor intolerance"> <math> <apply> <or/> <ci type="logical" class="Indication">Patient has persistent ACE inhibitor induced cough that is not resolved by ACE inhibitor retrial (same or new ACE inhibitor)</ci> <ci type="logical" class="Indication">Patient has a history of angioedema</ci> </apply> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="patient's lifetime"/> </Case> <Case When="Initial application" Category="Unsatisfactory response to ACE inhibitor"> <math> <ci type="logical" class="Indication">patient is not adequately controlled on maximum tolerated dose of an ACE inhibitor</ci> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="patient's lifetime"/> </Case></Request>
<Request To="HealthPAC" For="Subsidy" Form="SA0922"> <Title> <range>Erythropoietin</range> </Title> <Case When="Initial application"> <math> <apply> <and/> <apply> <and/> <ci type="logical" class="Indication">patient in chronic renal failure</ci> <apply> <leq/> <ci type="real" class="test">Haemoglobin</ci> <cn>100<mi>g/L</mi></cn> </apply> </apply> <apply> <or/> <apply> <and/> <ci type="logical" class="Indication">patient is not diabetic</ci> <apply> <leq/> <ci type="real" class="test">glomerular filtration rate</ci> <cn>30<mi>ml/min</mi></cn> </apply> </apply> <apply> <and/> <ci type="logical" class="Indication">patient is diabetic</ci> <apply> <leq/> <ci type
<Request To="HealthPAC" For="Subsidy" Form="SA1198"> <Title> <range>Preterm post-discharge infant formula powder<instance>S-26 Gold Premgro</instance></range> </Title> <Case When="Initial application"> <math overflow="scroll"> <apply> <and/> <ci type="logical" class="Indication">The infant was born before 33 weeks gestation or weighed less than 1.5 kg at birth</ci> <apply> <or/> <ci type="logical" class="Indication">The infant has faltering growth (downward crossing of percentiles)</ci> <ci type="logical" class="Indication">The infant is not maintaining, or is considered unlikely to maintain, adequate growth on standard infant formula</ci> </apply> </apply> </math> <Applicant>dietitian</Applicant> <Applicant>relevant specialist</Applicant> <Applicant>vocationally registered general practitioner</Applicant> <Term Measure="month">6</Term> </Case></Request>
<Request To="HealthPAC" For="Subsidy" Form="SA1124"> <Title> <range>Thalidomide</range> </Title> <Case When="Initial application"> <math> <apply> <or/> <ci type="logical" class="indication">The patient has multiple myeloma</ci> <ci type="logical" class="indication">The patient has systemic AL amyloidosis*</ci> </apply> </math> <Applicant>relevant specialist</Applicant> <Applicant Referring="relevant specialist">medical practitioner</Applicant> <Term Measure="month">12</Term> </Case> <Case When="Renewal" Form="SA1124 SA0817 SA0882"> <math> <ci type="logical" class="indication">The patient has obtained a response from treatment during the initial approval period</ci> </math> <Applicant>relevant specialist</Applicant> <Applicant Referring="relevant specialist">medical practitioner</Applicant> <Term Measure="patient's lifetime"/> </Case> <Note> <Para>Prescription must be written by a re
<Request To="HealthPAC" For="Subsidy" Form="SA1260"> <Title> <range>Perhexiline Maleate</range> </Title> <Case When="Initial application"> <math> <apply> <and/> <ci type="logical" class="Indication">Patient has refractory angina</ci> <ci type="logical" class="Trial">Patient is on the maximal tolerated dose of a beta-blocker, a calcium channel blocker and a long acting nitrate</ci> </apply> </math> <Applicant>cardiologist</Applicant> <Applicant>general physician</Applicant> <Term Measure="year">2</Term> </Case> <Case When="Renewal" Form="SA0256 SA1260"> <math> <ci type="logical" class="Indication">The treatment remains appropriate and the patient is benefiting from treatment</ci> </math> <Applicant>cardiologist</Applicant> <Applicant Referring="cardiologist">any relevant practitioner</Applicant> <Term Measure="year">2</Term> </Case></Request>
<Request To="HealthPAC" For="Subsidy" Form="SA1285"> <Title> <range>Posaconazole </range> </Title> <Case When="Initial application"> <math> <apply> <or/> <ci type="logical" class="Indication">Patient has acute myeloid leukaemia and is to be treated with high dose remission induction, re-induction or consolidation chemotherapy</ci> <ci type="logical" class="Indication">Patient has received a stem cell transplant and has graft versus host disease and is on significant immunosuppressive therapy*</ci> </apply> </math> <Applicant>haematologist</Applicant> <Applicant>infectious disease specialist</Applicant> <Term Measure="week">6</Term> </Case> <Case When="Renewal" Form="SA1285"> <math> <apply> <or/> <ci type="logical" class="Indication">Patient has acute myeloid leukaemia and is to be treated with high dose remission induction, re-induction or consolidation therapy</ci> <ci type="logical" c
<Request To="HealthPAC" For="Subsidy" Form="SA1293"> <Title> <range>Sildenafil</range> </Title> <Case When="Initial application" Category="Raynaud&#8217;s Phenomenon* - for Pulmonary Arterial Hypertension see note below)"> <math> <apply> <and/> <ci type="logical" class="Indication">Patient has Raynaud&#8217;s Phenomenon*</ci> <ci type="logical" class="Indication">Patient has severe digital ischaemia (defined as severe pain requiring hospital admission or with a high likelihood of digital ulceration; digital ulcers; or gangrene)</ci> <ci type="logical" class="Indication">Patient is following lifestyle management (avoidance of cold exposure, sufficient protection, smoking cessation support, avoidance of sympathomimetic drugs) </ci> <ci type="logical" class="Indication">Patient is being treated with calcium channel blockers and nitrates (or these are contraindicated/not tolerated)</ci> </apply> </math> <Applicant>any relevant
<Request To="HealthPAC" For="Subsidy" Form="SA1061"> <Title> <range>Venlafaxine</range> </Title> <Case When="Initial application"> <math> <apply> <and/> <ci type="logical" class="Indication">The patient has 'treatment-resistant' depression</ci> <apply> <or/> <ci type="logical" class="Trial">The patient must have had a trial of two different antidepressants and have had an inadequate response from an adequate dose over an adequate period of time (usually at least four weeks)</ci> <apply> <and/> <ci type="logical" class="Indication">The patient is currently a hospital in-patient as a result of an acute depressive episode</ci> <ci type="logical" class="Trial">The patient must have had a trial of one other antidepressant and have had an inadequate response from an adequate dose over an adequate period of time</ci> </apply> </apply> </apply> </math> <Appl
<Request To="HealthPAC" For="Subsidy" Form="SA1411"> <Title> <range>Erlotinib</range> </Title> <Case When="Initial application"> <math> <apply> <or/> <apply> <and/> <ci type="logical" class="Indication">Patient has locally advanced or metastatic, unresectable, non-squamous Non Small Cell Lung Cancer (NSCLC)</ci> <ci type="logical" class="Indication">There is documentation confirming that the disease expresses activating mutations of EGFR tyrosine kinase</ci> <apply> <or/> <ci type="logical" class="Indication">Patient is treatment naive</ci> <apply> <and/> <ci type="logical" class="Indication">Patient has documented disease progression following treatment with first line platinum based chemotherapy</ci> <ci type="logical" class="Indication">Patient has not received prior treatment with gefitinib</ci> </apply> </apply>
<Request To="HealthPAC" For="Alternate Subsidy" Form="SA1018"> <Title> <range>Hormone Replacement Therapy - Systemic</range> </Title> <Case When="Initial application"> <math> <apply> <or/> <ci type="logical" class="Indication">acute or significant liver disease - where oral oestrogens are contraindicated as determined by a gastroenterologist or general physician. The applicant must keep written confirmation from such a specialist with the patient's record</ci> <ci type="logical" class="Indication">oestrogen induced hypertension requiring antihypertensive therapy - documented evidence must be kept on file that raised blood pressure levels or inability to control blood pressure adequately occurred post oral oestrogens</ci> <ci type="logical" class="Indication">hypertriglyceridaemia - documented evidence must be kept on file that triglyceride levels increased to at least 2 &#215; normal triglyceride levels post oral oestrogens</ci> <ci type=
<Request To="HealthPAC" For="Subsidy" Form="SA1320"> <Title> <range>Diazoxide</range> </Title> <Case When="Initial application"> <math> <ci type="logical" class="Indication">used for the treatment of confirmed hypoglycaemia caused by hyperinsulinism</ci> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="month">12</Term> </Case> <Case When="Renewal" Form="SA1320"> <math> <ci type="logical" class="Indication">The treatment remains appropriate and the patient is benefiting from treatment</ci> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="patient's lifetime"/> </Case></Request>
<Request To="HealthPAC" For="Subsidy" Form="SA1318"> <Title> <range>Albendazole</range> </Title> <Case When="Initial application"> <math> <ci type="logical" class="Indication">The patient has hydatids</ci> </math> <Applicant>infectious disease specialist</Applicant> <Applicant>clinical microbiologist</Applicant> <Term Measure="month">6</Term> </Case> <Case When="Renewal" Form="SA1318"> <math> <ci type="logical" class="Indication">The treatment remains appropriate and the patient is benefitting from the treatment</ci> </math> <Applicant>infectious disease specialist</Applicant> <Applicant>clinical microbiologist</Applicant> <Term Measure="month">6</Term> </Case></Request>
<Request To="HealthPAC" For="Subsidy" Form="SA1095"> <Title> <range>Diabetic products<instance>Diason RTH</instance><instance>Glucerna Select RTH</instance><instance>Diasip</instance><instance>Glucerna Select</instance><instance>Resource Diabetic</instance></range> </Title> <Case When="Initial application"> <math> <ci type="logical" class="Indication">The patient is a type I or and II diabetic who is suffering weight loss and malnutrition that requires nutritional support</ci> </math> <Applicant>dietitian</Applicant> <Applicant>relevant specialist</Applicant> <Applicant>vocationally registered general practitioner</Applicant> <Term Measure="year">1</Term> </Case> <Case When="Renewal" Form="SA0594 SA1095"> <math> <apply> <and/> <ci type="logical" class="Indication">The treatment remains appropriate and the patient is benefiting from treatment</ci> <ci type="text" class="Endorsement">General Practitioners must includ
<Request To="PHARMAC" For="Manufacturers Price" Form="SA1038"> <Title> <range>Anti-inflammatory Non Steroidal Drugs (NSAIDs)</range> </Title> <Case When="Initial application"> <math> <ci type="logical" class="Indication">Subsidy for patients with existing approvals prior to 1 September 2010</ci> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="patient's lifetime"/> </Case> <Note> <Para>Subsidy for patients with existing approvals prior to 1 September 2010. Approvals valid without further renewal unlessnotified. No new approvals will be granted from 1 September 2010.</Para> </Note></Request>
<Request To="HealthPAC" For="Subsidy" Form="SA1449"> <Title> <range>Adalimumab</range> </Title> <Case When="Initial application" Category="rheumatoid arthritis"> <math> <apply> <or/> <apply> <and/> <ci type="logical" class="Indication">The patient has had an initial Special Authority approval for etanercept for rheumatoid arthritis</ci> <apply> <or/> <ci type="logical" class="Indication">The patient has experienced intolerable side effects from etanercept</ci> <ci type="logical" class="Indication">The patient has received insufficient benefit from etanercept to meet the renewal criteria for etanercept for rheumatoid arthritis</ci> </apply> </apply> <apply> <and/> <ci type="logical" class="Indication">Patient has had severe and active erosive rheumatoid arthritis for six months duration or longer</ci> <ci type="logical" class="Treatmen
<Request To="HealthPAC" For="Subsidy" Form="SA1388"> <Title> <range>Preservative Free Ocular Lubricants</range> </Title> <Case When="Initial application"> <math> <apply> <and/> <ci type="logical" class="Indication">Confirmed diagnosis by slit lamp of severe secretory dry eye</ci> <apply> <or/> <ci type="logical" class="Indication">Patient is using eye drops more than four times daily on a regular basis</ci> <ci type="logical" class="Indication">Patient has had a confirmed allergic reaction to preservative in eye drop</ci> </apply> </apply> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="month">12</Term> </Case> <Case When="Renewal" Form="SA1388"> <math> <ci type="logical" class="Indication">The patient continues to require lubricating eye drops and has benefited from treatment</ci> </math> <Applicant>any relevant practitioner</Applicant>
<Request To="HealthPAC" For="Subsidy" Form="SA1201"> <Title> <range>Prasugrel</range> </Title> <Case When="Initial application" Category="coronary angioplasty and bare metal stent"> <math> <ci type="logical" class="Treatment">The patient has undergone coronary angioplasty in the previous 4 weeks and is clopidogrel-allergic*</ci> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="month">6</Term> </Case> <Case When="Initial application" Category="drug eluting stent"> <math> <ci type="logical" class="Treatment">The patient has had a drug-eluting cardiac stent inserted in the previous 4 weeks and is clopidogrel-allergic*</ci> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="month">12</Term> </Case> <Case When="Initial application" Category="stent thromobosis"> <math> <ci type="logical" class="Treatment">patient has experienced cardiac stent thrombosis whilst on clopidogrel</ci>
<Request To="HealthPAC" For="Subsidy" Form="SA1325"> <Title> <range>Pegaspargase</range> </Title> <Case When="Initial application"> <math> <apply> <and/> <ci type="logical" class="Indication">The patient has newly diagnosed acute lymphoblastic leukaemia</ci> <ci type="logical" class="Indication">Pegaspargase to be used with a contemporary intensive multi-agent chemotherapy treatment protocol</ci> <ci type="logical" class="Indication">Treatment is with curative intent</ci> </apply> </math> <Applicant>relevant specialist</Applicant> <Applicant Referring="relevant specialist">medical practitioner</Applicant> <Term Measure="month">12</Term> </Case> <Case When="Renewal" Form="SA1325"> <math> <apply> <and/> <ci type="logical" class="Indication">The patient has relapsed acute lymphoblastic leukaemia</ci> <ci type="logical" class="Indication">Pegaspargase to be used with a contemporar
<Request To="HealthPAC" For="Alternate Subsidy" Form="SA0500"> <Title><range>Combined oral contraceptives</range><range>Progestogen-only contraceptives</range> (Circle one)</Title> <Case When="Initial application"> <math> <apply> <and/> <apply> <or/> <ci type="logical" class="Target">Patient is on a Social Welfare benefit</ci> <ci type="logical" class="Target">Patient has an income no greater than the benefit</ci> </apply> <ci type="logical" class="Trial">Has tried at least one of the fully funded options and has been unable to tolerate it</ci> </apply> </math> <Applicant>medical practitioner</Applicant> <Term Measure="year">2</Term> </Case> <Case When="Renewal" Form="SA0265 SA0500"> <math> <apply> <or/> <ci type="logical" class="Target">Patient is on a Social Welfare benefit</ci> <ci type="logical" class="Target">Patient has an income no greater than the be
<Request To="HealthPAC" For="Subsidy" Form="SA1374"> <Title> <range>Fat<instance>Calogen</instance><instance>Liquigen</instance><instance>MCT oil (Nutricia)</instance></range> </Title> <Case When="Initial application" Category="Inborn errors of metabolism"> <math> <ci type="logical" class="Indication">The patient has inborn errors of metabolism</ci> </math> <Applicant>dietitian</Applicant> <Applicant>relevant specialist</Applicant> <Applicant>vocationally registered general practitioner</Applicant> <Term Measure="year">3</Term> </Case> <Case When="Initial application" Category="Indications other than inborn errors of metabolism"> <math> <apply> <or/> <ci type="logical" class="Indication">faltering growth in an infant/child</ci> <ci type="logical" class="Indication">bronchopulmonary dysplasia</ci> <ci type="logical" class="Indication">fat malabsorption</ci> <ci type="logical" class="Indication">lym
<Request To="HealthPAC" For="Subsidy" Form="SA1375"> <Title> <range>Protein<instance>Protifar</instance><instance>Promod</instance><instance>Resource Beneprotein</instance></range> </Title> <Case When="Initial application"> <math> <apply> <or/> <ci type="logical" class="Indication">protein losing enteropathy</ci> <ci type="logical" class="Indication">high protein needs</ci> <ci type="logical" class="Indication">for use as a component in a modular formula</ci> </apply> </math> <Applicant>dietitian</Applicant> <Applicant>relevant specialist</Applicant> <Applicant>vocationally registered general practitioner</Applicant> <Term Measure="year">1</Term> </Case> <Case When="Renewal" Form="SA0582 SA1093 SA1375"> <math> <apply> <and/> <ci type="logical" class="Indication">The treatment remains appropriate and the patient is benefiting from treatment</ci> <ci type="text" class="Endor
<Request To="HealthPAC" For="Subsidy" Form="SA1266"> <Title> <range>Sunitinib</range> </Title> <Case When="Initial application" Category="RCC"> <math> <apply> <and/> <ci type="logical" class="Indication">The patient has metastatic renal cell carcinoma</ci> <apply> <or/> <ci type="logical" class="Trial">The patient is treatment naive</ci> <ci type="logical" class="Trial">The patient has only received prior cytokine treatment</ci> <ci type="logical" class="Trial">The patient has only received prior treatment with an investigational agent within the confines of a bona fide clinical trial which has Ethics Committee approval</ci> <apply> <and/> <ci type="logical" class="Trial">The patient has discontinued pazopanib within 3 months of starting treatment due to intolerance</ci> <ci type="logical" class="Trial">The cancer did not progress whilst on pazopanib</ci>
<Request To="HealthPAC" For="Subsidy" Form="SA1273"> <Title> <range>Voriconazole</range> </Title> <Case When="Initial application" Category="invasive fungal infection"> <math> <apply> <and/> <ci type="logical" class="Indication">Patient is immunocompromised</ci> <ci type="logical" class="Indication">Applicant is part of a multidisciplinary team including an infectious disease specialist</ci> <apply> <or/> <ci type="logical" class="Indication">Patient has proven or probable invasive aspergillus infection</ci> <ci type="logical" class="Indication">Patient has possible invasive aspergillus infection</ci> <ci type="logical" class="Indication">Patient has fluconazole resistant candidiasis</ci> <ci type="logical" class="Indication">Patient has mould strain such as Fusarium spp. and Scedosporium spp</ci> </apply> </apply> </math> <Applicant>haematologist</Applicant> <App
<Request To="HealthPAC" For="Subsidy" Form="SA1228"> <Title> <range>Standard Supplements<instance>Ensure</instance><instance>Fortisip</instance><instance>Isosource</instance><instance>Jevity</instance><instance>Nutrison</instance><instance>Osmolite</instance><instance>Sustagen</instance></range> </Title> <Case When="Initial application" Category="Children"> <math> <apply> <and/> <ci type="logical" class="Indication">The patient is under 18 years of age</ci> <apply> <or/> <ci type="logical" class="Indication">The patient has a condition causing malabsorption</ci> <ci type="logical" class="Indication">The patient has failure to thrive</ci> <ci type="logical" class="Indication">The patient has increased nutritional requirements</ci> </apply> <ci type="logical" class="Indication">Nutrition goal has been set (eg reach a specific weight or BMI)</ci> </apply> </math> <Applicant>dietitia
<Request To="HealthPAC" For="Subsidy" Form="SA1046"> <Title> <range>Ezetimibe with Simvastatin<instance>Vytorin</instance></range> </Title> <Case When="Initial application"> <math> <apply> <and/> <ci type="logical" class="Indication">Patient has a calculated absolute risk of cardiovascular disease of at least 15% over 5 year</ci> <ci type="logical" class="Trial">Patient's LDL cholesterol is 2.0 mmol/litre or greater</ci> <ci type="logical" class="Trial">The patient has not reduced their LDL cholesterol to less than 2.0 mmol/litre with the use of the maximal tolerated dose of atorvastatin</ci> </apply> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="year">2</Term> <Note> <Para>A patient who has failed to reduce their LDL cholesterol to &#8804; 2.0 mmol/litre with the use of a less potent statin should use a more potent statin prior to consideration being given to the use of non-statin therapi
<Request To="Cystic Fibrosis Advisory Panel" For="Subsidy" Form="SA0611"> <Title> <range>Dornase Alfa</range> </Title> <Case When="Initial application"> <math> <ci/> </math> <Applicant>medical practitioner</Applicant> <Term Measure="year">1</Term> </Case> <Note> <Para>Application details may be obtained from PHARMAC's website <a href="http://www.pharmac.govt.nz/">http://www.pharmac.govt.nz</a> or:</Para> <Table> <TR> <TD> <Para>The Co-ordinator, Cystic Fibrosis Advisory Panel</Para> </TD> <TD> <Para>Phone: (04) 460 4990</Para> </TD> </TR> <TR> <TD> <Para>PHARMAC, PO Box 10 254</Para> </TD> <TD> <Para>Facsimile: (04) 916 7571</Para> </TD> </TR> <TR> <TD> <Para>Wellington</Para> </TD> <TD> <Para>Email: <a href="mailto:CFPanel@pharmac.govt.nz">CFPanel@pharmac.
<Request To="HealthPAC" For="Subsidy" Form="SA1451"> <Title> <range>Somatropin</range> </Title> <Case When="Initial application" Category="growth hormone deficiency in children"> <math> <apply> <or/> <apply> <and/> <ci type="logical" class="Indication">Growth hormone deficiency causing symptomatic hypoglycaemia, or with other significant growth hormone deficient sequelae (e.g. cardiomyopathy, hepatic dysfunction) and diagnosed with GH &lt; 5 mcg/l on at least two random blood samples in the first 2 weeks of life, or from samples during established hypoglycaemia (whole blood glucose &lt; 2 mmol/l using a laboratory device)</ci> </apply> <apply> <and/> <ci type="logical" class="Indication">Height velocity &lt; 25th percentile for age adjusted for bone age/pubertal status if appropriate over 6 or 12 months using the standards of Tanner and Davies (1985)</ci> <ci type="logical" class="Indication
<Request To="HealthPAC" For="Subsidy" Form="SA1139"> <Title> <range>Teriparatide</range> </Title> <Case When="Initial application"> <math> <apply> <and/> <ci type="logical" class="indication">The patient has severe, established osteoporosis</ci> <ci type="logical" class="indication">The patient has a documented T-score less than or equal to -3.0 (see Notes)</ci> <ci type="logical" class="indication">The patient has had two or more fractures due to minimal trauma</ci> <ci type="logical" class="indication">The patient has experienced at least one symptomatic new fracture after at least 12 months&#8217; continuous therapy with a funded antiresorptive agent at adequate doses (see Notes)</ci> </apply> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="month">18</Term> </Case> <Note> <List Type="Alpha"> <Item> <Para>The bone mineral density (BMD) measurement used to derive the
<Request To="PHARMAC" For="Subsidy" Form="SA1291"> <Title> <range>Optium blood glucose test strips</range> </Title> <Case When="Initial application"> <math> <ci type="logical" class="Indication">Patient identified as eligible for subsidy for FreeStyle Optium blood glucose test strips</ci> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="patient's lifetime"/> </Case> <Note> <Para>Application details may be obtained from PHARMAC's website http://www.pharmac.govt.nz and can be sent to:</Para> <Table> <TR> <TD> <Para>PHARMAC</Para> </TD> <TD> <Para/> </TD> </TR> <TR> <TD> <Para>PO Box 10 254</Para> </TD> <TD> <Para>Facsimile: (04) 974 4788</Para> </TD> </TR> <TR> <TD> <Para>Wellington</Para> </TD> <TD> <Para>Email: <a href="mailto:bgstrip
<Request To="HealthPAC" For="Subsidy" Form="SA1098"> <Title> <range>Paediatric Product For Children Awaiting Liver Transplant<instance>Heparon Junior</instance></range> </Title> <Case When="Initial application"> <math> <ci type="logical" class="Indication">The patient is a child (up to 18 years) who requires a liver transplant</ci> </math> <Applicant>dietitian</Applicant> <Applicant>relevant specialist</Applicant> <Applicant>vocationally registered general practitioner</Applicant> <Term Measure="year">3</Term> </Case> <Case When="Renewal" Form="SA0607 SA1098"> <math> <apply> <and/> <ci type="logical" class="Indication">The treatment remains appropriate and the patient is benefiting from treatment</ci> <ci type="text" class="Endorsement">General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted</ci> </apply> </math
<Request To="HealthPAC" For="Subsidy" Form="SA0845"> <Title> <range>Enfuvirtide</range> </Title> <Case When="Initial application"> <math> <apply> <and/> <ci type="logical" class="Indication">Confirmed HIV infection</ci> <ci type="logical" class="Indication">Enfuvirtide to be given in combination with optimized background therapy (including at least 1 other antiretroviral drug that the patient has never previously been exposed to) for treatment failure</ci> <apply> <or/> <ci type="logical" class="Indication">Patient has evidence of HIV replication, despite ongoing therapy</ci> <ci type="logical" class="Indication">Patient has treatment-limiting toxicity to previous antiretroviral agents</ci> </apply> <ci type="logical" class="Indication">Previous treatment with 3 different antiretroviral regimens has failed</ci> <apply> <and/> <ci type="logical" class="Indication">Prev
<Request To="HealthPAC" For="Subsidy" Form="SA0955"> <Title> <range>Isotretinoin</range> </Title> <Case When="Initial application"> <math> <apply> <and/> <ci type="logical" class="Indication">Patient has had an adequate trial on other available treatments and has received an inadequate response from these treatments or these are contraindicated</ci> <ci type="logical" class="Indication">Applicant is a vocationally registered dermatologist, vocationally registered general practitioner, or nurse practitioner working in a relevant scope of practice</ci> <ci type="logical" class="Indication">Applicant has an up to date knowledge of the treatment options for acne and is aware of the safety issues around isotretinoin and is competent to prescribe isotretinoin</ci> <apply> <or/> <ci type="logical" class="Indication">Patient is female and has been counselled and understands the risk of teratogenicity if isotretinoin is used d
<Request To="HealthPAC" For="Subsidy" Form="SA0994"> <Title> <range>Mirtazapine</range> </Title> <Case When="Initial application"> <math> <apply> <and/> <ci type="logical" class="Indication">The patient has a severe major depressive episode</ci> <apply> <or/> <ci type="logical" class="Trial">The patient must have had a trial of two different antidepressants and was unable to tolerate the treatments or failed to respond to an adequate dose over an adequate period of time (usually at least four weeks)</ci> <apply> <and/> <ci type="logical" class="Indication">The patient is currently a hospital in-patient as a result of an acute depressive episode</ci> <ci type="logical" class="Trial">The patient must have had a trial of one other antidepressant and either could not tolerate it or failed to respond to an adequate dose over an adequate period of time</ci> </apply> </appl
<Request To="HealthPAC" For="Subsidy" Form="SA1404"> <Title> <range>Valganciclovir</range> </Title> <Case When="Initial application" Category="transplant cytomegalovirus prophylaxis"> <math> <ci type="logical" class="Indication">the patient has undergone a solid organ transplant and requires valganciclovir for CMV prophylaxis</ci> </math> <Applicant>relevant specialist</Applicant> <Term Measure="month">3</Term> </Case> <Case When="Renewal" Form="SA1274 SA1404" Category="transplant cytomegalovirus prophylaxis"> <math> <apply> <and/> <ci type="logical" class="Indication">Patient has undergone a solid organ transplant and received anti-thymocyte globulin and requires valganciclovir therapy for CMV prophylaxis</ci> <ci type="logical" class="Indication">Patient is to receive a maximum of 90 days of valganciclovir prophylaxis following anti-thymocyte globulin</ci> </apply> </math> <Applicant>relevant specialist</A
<Request To="HealthPAC" For="Subsidy" Form="SA1138"> <Title> <range>Raloxifene</range> </Title> <Case When="Initial application"> <math> <apply> <or/> <ci type="logical" class="indication">History of one significant osteoporotic fracture demonstrated radiologically and documented bone mineral density (BMD) &#8805;2.5 standard deviations below the mean normal value in young adults (i.e. T-Score &#8804; -2.5) (see Notes)</ci> <ci type="logical" class="indication">History of one significant osteoporotic fracture demonstrated radiologically, and either the patient is elderly, or densitometry scanning cannot be performed because of major logistical, technical or pathophysiological reasons. It is unlikely that this provision would apply to many patients under 75 years of age</ci> <ci type="logical" class="indication">History of two significant osteoporotic fractures demonstrated radiologically</ci> <ci type="logical" class="indication">Documente
<Request To="HealthPAC" For="Subsidy" Form="SA1125"> <Title> <range>Lacosamide</range> </Title> <Case When="Initial application"> <math> <apply> <and/> <ci type="logical" class="Indication">Patient has partial-onset epilepsy</ci> <ci type="logical" class="Trial">Seizures are not adequately controlled by, or patient has experienced unacceptable side effects from, optimal treatment with all of the following: sodium valproate, topiramate, levetiracetam and any two of carbamazepine, lamotrigine and phenytoin sodium (see Note)</ci> </apply> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="month">15</Term> <Note> <Para>"Optimal treatment" is defined as treatment which is indicated and clinically appropriate for the patient, given in adequate doses for the patient's age, weight and other features affecting the pharmacokinetics of the drug with good evidence of compliance. Women of childbearing age are not re
<Request To="HealthPAC" For="Subsidy" Form="SA1376"> <Title> <range>Carbohydrate and Fat<instance>Duocal Super Soluble Powder</instance></range> </Title> <Case When="Initial application" Category="Cystic fibrosis"> <math> <apply> <and/> <ci type="logical" class="Indication">Infant or child aged four years or under</ci> <ci type="logical" class="Indication">cystic fibrosis</ci> </apply> </math> <Applicant>dietitian</Applicant> <Applicant>relevant specialist</Applicant> <Applicant>vocationally registered general practitioner</Applicant> <Term Measure="year">3</Term> </Case> <Case When="Initial application" Category="Indications other than cystic fibrosis"> <math> <apply> <and/> <ci type="logical" class="Indication">infant or child aged four years or under</ci> <apply> <or/> <ci type="logical" class="Indication">cancer in children</ci> <ci type="logica
<Request To="HealthPAC" For="Subsidy" Form="SA0895"> <Title> <range>Pilocarpine &#8211; Eye drops 2% single dose</range> </Title> <Case When="Initial application"> <math> <apply> <or/> <ci type="logical" class="Indication">Patient has to use an unpreserved solution due to an allergy to the preservative</ci> <ci type="logical" class="Indication">Patient wears soft contact lenses</ci> </apply> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="year">2</Term> <Note> <Para>Minims for a general practice are considered to be &#8220;tools of trade&#8221; and are not approved as special authority items.</Para> </Note> </Case> <Case When="Renewal" Form="SA0121 SA0895"> <math> <ci type="logical" class="Indication">The treatment remains appropriate and the patient is benefiting from treatment</ci> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="year">2<
<Request To="HealthPAC" For="Subsidy" Form="SA1072"> <Title> <range>Vigabatrin</range> </Title> <Case When="Initial application"> <math> <apply> <and/> <apply> <or/> <ci type="logical" class="Indication">Patient has infantile spasms</ci> <apply> <and/> <ci type="logical" class="Indication">Patient has epilepsy</ci> <apply> <or/> <ci type="logical" class="Indication">Seizures are not adequately controlled with optimal treatment with other antiepilepsy agents</ci> <ci type="logical" class="Indication">Seizures are controlled adequately but the patient has experienced unacceptable side effects from optimal treatment with other antiepilepsy agents</ci> </apply> </apply> </apply> <apply> <or/> <ci type="logical" class="Indication">Patient is, or will be, receiving regular automated visual fiel
<Request To="HealthPAC" For="Subsidy" Form="SA1408"> <Title> <range>Naltrexone</range> </Title> <Case When="Initial application"> <math> <apply> <and/> <ci type="logical" class="Indication">Patient is currently enrolled in a recognised comprehensive treatment programme for alcohol dependence</ci> <ci type="logical" class="Therapy">Applicant works in or with a community Alcohol and Drug Service contracted to one of the District Health Boards or accredited against the New Zealand Alcohol and Other Drug Sector Standard or the National Mental Health Sector Standard</ci> </apply> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="month">6</Term> </Case> <Case When="Renewal" Form="SA0714 SA0909 SA1397 SA1408"> <math> <apply> <and/> <ci type="logical" class="Indication">Compliance with the medication (prescriber determined)</ci> <apply> <or/> <ci type="log
<Request To="HealthPAC" For="Subsidy" Form="SA1174"> <Title> <range>Enoxaparin sodium</range> </Title> <Case When="Initial application" Category="Pregnancy or Malignancy"> <math> <apply> <or/> <ci type="logical" class="Indication">Low molecular weight heparin treatment is required during a patients pregnancy</ci> <ci type="logical" class="Treatment">For the treatment of venous thromboembolism where the patient has a malignancy</ci> </apply> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="year">1</Term> </Case> <Case When="Initial application" Category="Venous thromboembolism other than in pregnancy or malignancy"> <math> <apply> <or/> <ci type="logical" class="Indication">For the short-term treatment of venous thromboembolism prior to establishing a therapeutic INR with oral anti-coagulant treatment</ci> <ci type="logical" class="Treatment">For the prophylaxis and tre
<Request To="HealthPAC" For="Subsidy" Form="SA1416"> <Title> <range>Atomoxetine</range> </Title> <Case When="Initial application"> <math> <apply> <and/> <ci type="logical" class="Indication">Patient has ADHD (Attention Deficit and Hyperactivity Disorder) diagnosed according to DSM-IV or ICD 10 criteria</ci> <ci type="logical" class="Indication">Once-daily dosing</ci> <apply> <or/> <ci type="logical" class="Indication">Treatment with a subsidised formulation of a stimulant has resulted in the development or worsening of serious adverse reactions or where the combination of subsidised stimulant treatment with another agent would pose an unacceptable medical risk</ci> <ci type="logical" class="Indication">Treatment with a subsidised formulation of a stimulant has resulted in worsening of co-morbid substance abuse or there is a significant risk of diversion with subsidised stimulant therapy</ci> <ci type="log
<Request To="HealthPAC" For="Subsidy" Form="SA1263"> <Title> <range>Nicorandil</range> </Title> <Case When="Initial application"> <math> <apply> <and/> <ci type="logical" class="Indication">Patient has refractory angina</ci> <ci type="logical" class="Trial">Patient is on the maximal tolerated dose of a beta-blocker, a calcium channel blocker and a long acting nitrate</ci> </apply> </math> <Applicant>cardiologist</Applicant> <Applicant>general physician</Applicant> <Term Measure="year">2</Term> </Case> <Case When="Renewal" Form="SA1263"> <math> <ci type="logical" class="Indication">The treatment remains appropriate and the patient is benefiting from treatment</ci> </math> <Applicant>cardiologist</Applicant> <Applicant Referring="cardiologist">any relevant practitioner</Applicant> <Term Measure="year">2</Term> </Case></Request>
<Request To="HealthPAC" For="Subsidy" Form="SA0927"> <Title> <range>Risperidone orally disintegrating tablets</range> </Title> <Case When="Initial application" Category="Acute situations"> <math> <apply> <and/> <ci type="logical" class="Use">For a non-adherent patient on oral therapy with standard risperidone tablets or risperidone oral liquid</ci> <ci type="logical" class="Therapy">The patient is under direct supervision for administration of medicine</ci> </apply> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="week">6</Term> </Case> <Case When="Initial application" Category="Chronic situations"> <math> <apply> <and/> <ci type="logical" class="Indication">The patient is unable to take standard risperidone tablets or oral liquid, or once stabilized refuses to take risperidone tablets or oral liquid</ci> <ci type="logical" class="Therapy">The patient is under direct
<Request To="HealthPAC" For="Subsidy" Form="SA1195"> <Title> <range>High Calorie Products<instance>Two Cal HN</instance><instance>Nutrison Concentrated</instance></range> </Title> <Case When="Initial application" Category="Cystic fibrosis"> <math> <apply> <and/> <ci type="logical" class="Indication">Cystic fibrosis</ci> <ci type="logical" class="Trial">other lower calorie products have been tried</ci> <ci type="logical" class="Indication">patient has substantially increased metabolic requirements</ci> </apply> </math> <Applicant>dietitian</Applicant> <Applicant>relevant specialist</Applicant> <Applicant>vocationally registered general practitioner</Applicant> <Term Measure="year">3</Term> </Case> <Case When="Initial application" Category="Indications other than cystic fibrosis"> <math> <apply> <and/> <apply> <or/> <ci type="logical" class="Indication">any cond
<Request To="HealthPAC" For="Subsidy" Form="SA1199"> <Title> <range>Propylthiouracil</range> </Title> <Case When="Initial application"> <math> <apply> <and/> <ci type="logical" class="Indication">The patient has hyperthyroidism</ci> <ci type="logical" class="Indication">The patient is intolerant of carbimazole or carbimazole is contraindicated</ci> </apply> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="year">2</Term> </Case> <Case When="Renewal" Form="SA1199"> <math> <ci type="logical" class="Indication">the treatment remains appropriate and the patient is benefitting from the treatment</ci> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="year">2</Term> </Case></Request>
<Request To="PHARMAC" For="Subsidy" Form="SA1237"> <Title> <range>Insulin Pumps</range> </Title> <Case When="Initial application"> <math/> <Applicant>medical practitioner</Applicant> <Term Measure="year">1</Term> </Case> <Note> <Para>Application details may be obtained from PHARMAC's website <a href="http://www.pharmac.govt.nz/">http://www.pharmac.govt.nz</a> or:</Para> <Table> <TR> <TD> <Para>The IPP Co-ordinator</Para> </TD> <TD> <Para>Phone: (04) 460 4990</Para> </TD> </TR> <TR> <TD> <Para>PHARMAC</Para> </TD> <TD> <Para>Facsimile: (04) 974 7806</Para> </TD> </TR> <TR> <TD> <Para>PO Box 10 254</Para> </TD> <TD> <Para>Email: <a href="mailto:ipp@pharmac.govt.nz">ipp@pharmac.govt.nz</a></Para> </TD> </TR> <TR> <TD> <Para>Welli
<Request To="HealthPAC" For="Subsidy" Form="SA0829"> <Title> <range>Adefovir dipivoxil</range> </Title> <Case When="Initial application"> <math> <apply> <and/> <ci type="logical" class="Trial">Patient has confirmed Hepatitis B infection (HBsAg+)</ci> <mi class="heading">Documented resistance to lamivudine, defined as:</mi> <ci type="logical" class="Trial">Patient has raised serum ALT (&gt; 1 &#215; ULN)</ci> <ci type="logical" class="Trial">Patient has HBV DNA greater than 100,000 copies per mL, or viral load &#8805; 10 fold over nadir</ci> <ci type="logical" class="Trial">Detection of M204I or M204V mutation</ci> <apply> <or/> <apply> <and/> <ci type="logical" class="Trial">Patient is cirrhotic</ci> <ci type="logical" class="Trial">adefovir dipivoxil to be used in combination with lamivudine</ci> </apply> <apply> <and/>
<Request To="HealthPAC" For="Subsidy" Form="SA1379"> <Title> <range>Paediatric Products<instance>Nutrini</instance><instance>Pediasure</instance><instance>Fortini</instance></range> </Title> <Case When="Initial application"> <math> <apply> <and/> <ci type="logical" class="Indication">Child is aged one to ten years</ci> <apply> <or/> <ci type="logical" class="Indication">the child is being fed via a tube or a tube is to be inserted for the purposes of feeding</ci> <ci type="logical" class="Indication">any condition causing malabsorption</ci> <ci type="logical" class="Indication">faltering growth in an infant/child</ci> <ci type="logical" class="Indication">increased nutritional requirements</ci> <ci type="logical" class="Indication">the child is being transitioned from TPN or tube feeding to oral feeding</ci> </apply> </apply> </math> <Applicant>dietitian</Applicant>
<Request To="HealthPAC" For="Subsidy" Form="SA1382"> <Title> <range>Ticagrelor</range> </Title> <Case When="Initial application" Category="acute coronary syndrome"> <math> <apply> <and/> <ci type="logical" class="Indication">Patient has recently been diagnosed with an ST-elevation or a non-ST-elevation acute coronary syndrome</ci> <ci type="logical" class="Indication">Fibrinolytic therapy has not been given in the last 24 hours and is not planned</ci> </apply> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="month">12</Term> </Case> <Case When="Renewal" Category="subsequent acute coronary syndrome" Form="SA1382"> <math> <apply> <and/> <ci type="logical" class="Indication">Patient has recently been diagnosed with an ST-elevation or a non-ST-elevation acute coronary syndrome</ci> <ci type="logical" class="Indication">Fibrinolytic therapy has not been given in the last 24
<Request To="HealthPAC" For="Subsidy" Form="SA1383"> <Title> <range>Ursodeoxycholic Acid</range> </Title> <Case When="Initial application" Category="Alagille syndrome or progressive familial intrahepatic cholestasis"> <math> <apply> <or/> <ci type="logical" class="Indication">Patient has been diagnosed with Alagille syndrome</ci> <ci type="logical" class="Indication">Patient has progressive familial intrahepatic cholestasis</ci> </apply> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="patient's lifetime"/> </Case> <Case When="Initial application" Category="Chronic severe drug induced cholestatic liver injury"> <math> <apply> <and/> <ci type="logical" class="Indication">Patient has chronic severe drug induced cholestatic liver injury</ci> <ci type="logical" class="Indication">Cholestatic liver injury not due to Total Parenteral Nutrition (TPN) use in adults</ci>
<Request To="HealthPAC" For="Subsidy" Form="SA1192"> <Title> <range>Trastuzumab</range> </Title> <Case When="Initial application" Category="metastatic breast cancer"> <math> <apply> <or/> <apply> <and/> <ci type="logical" class="Indication">The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology)</ci> <ci type="logical" class="Treatment">The patient has not previously received lapatinib treatment for HER 2 positive metastatic breast cancer</ci> <ci type="logical" class="Indication">Trastuzumab not to be given in combination with lapatinib</ci> <ci type="logical" class="Treatment">Trastuzumab to be discontinued at disease progression</ci> </apply> <apply> <and/> <ci type="logical" class="Indication">The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology
<Request To="HealthPAC" For="Subsidy" Form="SA1071"> <Title> <range>Gabapentin</range> </Title> <Case When="Initial application" Category="Epilepsy"> <math> <apply> <or/> <ci type="logical" class="Indication">Seizures are not adequately controlled with optimal treatment with other antiepilepsy agents</ci> <ci type="logical" class="Indication">Seizures are controlled adequately but the patient has experienced unacceptable side effects from optimal treatment with other antiepilepsy agents</ci> </apply> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="month">15</Term> <Note> <Para>"Optimal treatment with other antiepilepsy agents" is defined as treatment with other antiepilepsy agents which are indicated and clinically appropriate for the patient, given in adequate doses for the patient's age, weight, and other features affecting the pharmacokinetics of the drug with good evidence of compliance.</Para>
<Request To="HealthPAC" For="Subsidy" Form="SA1066"> <Title> <range>Rivaroxaban</range> </Title> <Case When="Initial application"> <math> <apply> <or/> <ci type="logical" class="Indication">For the prophylaxis of venous thromboembolism following a total hip replacement</ci> <ci type="logical" class="Use">For the prophylaxis of venous thromboembolism following a total knee replacement</ci> </apply> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="week">5</Term> <Note> <Para>Rivaroxaban is only currently indicated and subsidised for up to 5 weeks therapy for prophylaxis of venous thromboembolism following a total hip replacement and up to 2 weeks therapy for prophylaxis of venous thromboembolism following a total knee replacement.</Para> </Note> </Case> <Case When="Renewal" Form="SA1066"> <math> <ci type="logical" class="Indication">Prophylaxis for venous thromboembolism is requir
<Request To="PHARMAC" For="Subsidy" Form="SA1240"> <Title> <range>Insulin pump consumables</range> </Title> <Case When="Initial application"> <math/> <Applicant>medical practitioner</Applicant> <Term Measure="year">1</Term> </Case> <Note> <Para>Application details may be obtained from PHARMAC's website <a href="http://www.pharmac.govt.nz/">http://www.pharmac.govt.nz</a> or:</Para> <Table> <TR> <TD> <Para>The IPP Co-ordinator</Para> </TD> <TD> <Para>Phone: (04) 460 4990</Para> </TD> </TR> <TR> <TD> <Para>PHARMAC</Para> </TD> <TD> <Para>Facsimile: (04) 974 7806</Para> </TD> </TR> <TR> <TD> <Para>PO Box 10 254</Para> </TD> <TD> <Para>Email: <a href="mailto:ipp@pharmac.govt.nz">ipp@pharmac.govt.nz</a></Para> </TD> </TR> <TR> <TD>
<Request To="HealthPAC" For="Subsidy" Form="SA1039"> <Title> <range>Alendronate Tab 70 mg - with or without Cholecalciferol</range> </Title> <Case When="Initial application" Category="Underlying cause -- Osteoporosis"> <math> <apply> <or/> <ci type="logical" class="Indication">History of one significant osteoporotic fracture demonstrated radiologically and documented bone mineral density (BMD) &#8805; 2.5 standard deviations below the mean normal value in young adults (i.e. T-Score &#8804; -2.5) (see Note)</ci> <ci type="logical" class="Indication">History of one significant osteoporotic fracture demonstrated radiologically, and either the patient is elderly, or densitometry scanning cannot be performed because of major logistical, technical or pathophysiological reasons. It is unlikely that this provision would apply to many patients under 75 years of age</ci> <ci type="logical" class="Indication">History of two significant osteoporotic fractures
<Request To="HealthPAC" For="Subsidy" Form="SA1324"> <Title> <range>Paromomycin</range> </Title> <Case When="Initial application"> <math> <ci type="logical" class="Indication">the patient has confirmed cryptosporidium infection</ci> </math> <Applicant>infectious disease specialist</Applicant> <Applicant>clinical microbiologist</Applicant> <Term Measure="month">1</Term> </Case> <Case When="Renewal" Form="SA1324"> <math> <ci type="logical" class="Indication">the patient has confirmed cryptosporidium infection</ci> </math> <Applicant>infectious disease specialist</Applicant> <Applicant>clinical microbiologist</Applicant> <Term Measure="month">1</Term> </Case></Request>
<Request To="HealthPAC" For="Subsidy" Form="SA1126"> <Title> <range>Modavigil</range> </Title> <Case When="Initial application"> <math> <apply> <and/> <ci type="logical" class="Indication">The patient has a diagnosis of narcolepsy and has excessive daytime sleepiness associated with narcolepsy occurring almost daily for three months or more</ci> <apply> <or/> <ci type="logical" class="Indication">The patient has a multiple sleep latency test with a mean sleep latency of less than or equal to 10 minutes and 2 or more sleep onset rapid eye movement periods</ci> <ci type="logical" class="Indication">The patient has at least one of: cataplexy, sleep paralysis or hypnagogic hallucinations</ci> </apply> <apply> <or/> <ci type="logical" class="Indication">An effective dose of a subsidised formulation of methylphenidate or dexamphetamine has been trialled and discontinued because of intolerabl
<Request To="HealthPAC" For="Subsidy" Form="SA0928"> <Title> <range>Finasteride</range> </Title> <Case When="Initial application"> <math> <apply> <and/> <ci type="logical" class="Indication">Patient has symptomatic benign prostatic hyperplasia</ci> <apply> <or/> <ci type="logical" class="Indication">The patient is intolerant of non-selective alpha blockers or these are contraindicated</ci> <ci type="logical" class="Indication">Symptoms are not adequately controlled with non-selective alpha blockers</ci> </apply> </apply> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="patient's lifetime"/> </Case> <Note> <Para>Patients with enlarged prostates are the appropriate candidates for therapy with finasteride.</Para> </Note></Request>
<Request To="HealthPAC" For="Subsidy" Form="SA1099"> <Title> <range>Paediatric Product For Children With Chronic Renal Failure<instance>Kindergen</instance></range> </Title> <Case When="Initial application"> <math> <ci type="logical" class="Indication">The patient is a child (up to 18 years) with acute or chronic kidney disease</ci> </math> <Applicant>dietitian</Applicant> <Applicant>relevant specialist</Applicant> <Applicant>vocationally registered general practitioner</Applicant> <Term Measure="year">3</Term> </Case> <Case When="Renewal" Form="SA0606 SA1099"> <math> <apply> <and/> <ci type="logical" class="Indication">The treatment remains appropriate and the patient is benefiting from treatment</ci> <ci type="text" class="Endorsement">General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted</ci> </apply> </mat
<Request To="HealthPAC" For="Subsidy" Form="SA1381"> <Title> <range>Fat Modified Products<instance>Monogen</instance></range> </Title> <Case When="Initial application"> <math> <apply> <or/> <ci type="logical" class="Indication">Patient has metabolic disorders of fat metabolism</ci> <ci type="logical" class="Indication">Patient has a chyle leak</ci> <ci type="logical" class="Indication">Modified as a modular feed for adults</ci> </apply> </math> <Applicant>dietitian</Applicant> <Applicant>relevant specialist</Applicant> <Applicant>vocationally registered general practitioner</Applicant> <Term Measure="year">1</Term> </Case> <Case When="Renewal" Form="SA0593 SA0615 SA1096 SA1381"> <math> <apply> <and/> <ci type="logical" class="Indication">The treatment remains appropriate and the patient is benefiting from treatment</ci> <ci type="text" class="Endorsement">General Practitio
<Request To="HealthPAC" For="Subsidy" Form="SA0782"> <Title> <range>Levonorgestrel &#8211; releasing intrauterine system 20mcg/24 hr</range> </Title> <Case When="Initial application" Category="No previous use"> <math> <apply> <and/> <ci type="logical" class="Indication">The patient has a clinical diagnosis of heavy menstrual bleeding</ci> <ci type="logical" class="Trial">The patient has failed to respond to or is unable to tolerate other appropriate pharmaceutical therapies as per the Heavy Menstrual Bleeding Guidelines</ci> <apply> <or/> <apply> <lt/> <ci type="real" class="test">serum ferritin level</ci> <cn>16<mi> mcg/l (within the last 12 months)</mi></cn> </apply> <apply> <lt/> <ci type="real" class="test">haemoglobin level</ci> <cn>120<mi> g/l</mi></cn> </apply> </apply> </apply> </math>
<Request To="HealthPAC" For="Subsidy" Form="SA0954"> <Title> <range>Acitretin</range> </Title> <Case When="Initial application"> <math> <apply> <and/> <ci type="logical" class="Indication">Applicant is a vocationally registered dermatologist, vocationally registered general practitioner, or nurse practitioner working in a relevant scope of practice</ci> <ci type="logical" class="Indication">Applicant has an up to date knowledge of the treatment options for psoriasis and of disorders of keratinisation and is aware of the safety issues around acitretin and is competent to prescribe acitretin</ci> <apply> <or/> <ci type="logical" class="Indication">Patient is female and has been counselled and understands the risk of teratogenicity if acitretin is used during pregnancy and the applicant has ensured that the possibility of pregnancy has been excluded prior to the commencement of the treatment and that the patient is informed that
<Request To="HealthPAC" For="Subsidy" Form="SA0987"> <Title> <range>Aprepitant</range> </Title> <Case When="Initial application"> <math> <ci type="logical" class="Indication">The patient is undergoing highly emetogenic chemotherapy and/or anthracycline-based chemotherapy for the treatment of malignancy</ci> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="month">12</Term> </Case> <Case When="Renewal" Form="SA0987"> <math> <ci type="logical" class="Indication">The patient is undergoing highly emetogenic chemotherapy and/or anthracycline-based chemotherapy for the treatment of malignancy</ci> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="month">12</Term> </Case></Request>
<Request To="HealthPAC" For="Subsidy" Form="SA1155"> <Title> <range>Budesonide - Cap 3 mg Controlled Release</range> </Title> <Case When="Initial application" Category="Crohn's disease"> <math> <apply> <and/> <ci type="logical" class="Indication">Mild to moderate ileal, ileocaecal or proximal Crohn's disease</ci> <apply> <or/> <ci type="logical" class="Indication">Diabetes</ci> <ci type="logical" class="Indication">Cushingoid habitus</ci> <ci type="logical" class="Indication">Osteoporosis where there is significant risk of fracture</ci> <ci type="logical" class="Indication">Severe acne following treatment with conventional corticosteroid therapy</ci> <ci type="logical" class="Indication">History of severe psychiatric problems associated with corticosteroid treatment</ci> <ci type="logical" class="Indication">History of major mental illness (such as bipolar affective disorder) where
<Request To="HealthPAC" For="Subsidy" Form="SA1421"> <Title> <range>Montelukast</range> </Title> <Case When="Initial application" Category="Pre-school wheeze"> <math> <apply> <and/> <ci type="logical" class="Indication">To be used for the treatment of intermittent severe wheezing (possibly viral) in children under 5 years</ci> <ci type="logical" class="Indication">The patient has had at least three episodes in the previous 12 months of acute wheeze severe enough to seek medical attention</ci> </apply> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="year">1</Term> </Case> <Case When="Renewal" Category="Pre-school wheeze" Form="SA1227 SA1409 SA1421"> <math> <ci type="logical" class="Indication">The treatment remains appropriate and the patient is benefiting from treatment</ci> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="year">2</Term> </Case> <Case
<Request To="HealthPAC" For="Subsidy" Form="SA1196"> <Title> <range>Paediatric enteral feed with fibre 0.75 kcal/ml<instance>Nutrini Low Energy Multi Fibre</instance></range> </Title> <Case When="Initial application"> <math overflow="scroll"> <apply> <and/> <ci type="logical" class="Indication">Child aged one to eight years</ci> <ci type="logical" class="Indication">The child has a low energy requirement but normal protein and micronutrient requirements</ci> </apply> </math> <Applicant>dietitian</Applicant> <Applicant>relevant specialist</Applicant> <Applicant>vocationally registered general practitioner</Applicant> <Term Measure="year">1</Term> </Case> <Case When="Renewal" Form="SA1196"> <math overflow="scroll"> <apply> <and/> <ci type="logical" class="Indication">The treatment remains appropriate and the patient is benefiting from treatment</ci> <ci type="text" class="Endorsement
<Request To="HealthPAC" For="Subsidy" Form="SA1225"> <Title> <range>Ivermectin</range> </Title> <Case When="Initial application" Category="Scabies"> <math> <apply> <and/> <ci type="logical" class="Indication">Applying clinician has discussed the diagnosis of scabies with a dermatologist, infectious disease physician or clinical microbiologist</ci> <apply> <or/> <apply> <and/> <ci type="logical" class="Indication">The patient is in the community</ci> <apply> <or/> <ci type="logical" class="Indication">Patient has a severe scabies hyperinfestation (Crusted/ Norwegian scabies)</ci> <ci type="logical" class="Indication">The community patient is physically or mentally unable to comply with the application instructions of topical therapy</ci> <ci type="logical" class="Indication">The patient has previously tried and failed to clear infestation
<Request To="HealthPAC" For="Subsidy" Form="SA1322"> <Title> <range>Itraconazole</range> </Title> <Case When="Initial application"> <math> <ci type="logical" class="Indication">The patient has a congenital immune deficiency</ci> </math> <Applicant>infectious disease specialist</Applicant> <Applicant>clinical microbiologist</Applicant> <Applicant>clinical immunologist</Applicant> <Applicant Referring="infectious disease physician, clinical microbiologist or clinical immunologist">any relevant practitioner</Applicant> <Term Measure="month">6</Term> </Case> <Case When="Renewal" Form="SA1322"> <math> <ci type="logical" class="Indication">The treatment remains appropriate and the patient is benefitting from the treatment</ci> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="month">6</Term> </Case></Request>
<Request To="HealthPAC" For="Subsidy" Form="SA1223"> <Title> <range>Candesartan</range> </Title> <Case When="Initial application" Category="ACE inhibitor intolerance"> <math> <apply> <or/> <ci type="logical" class="Indication">Patient has persistent ACE inhibitor induced cough that is not resolved by ACE inhibitor retrial (same or new ACE inhibitor)</ci> <ci type="logical" class="Indication">Patient has a history of angioedema</ci> </apply> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="patient's lifetime"/> </Case> <Case When="Initial application" Category="Unsatisfactory response to ACE inhibitor"> <math> <ci type="logical" class="Indication">patient is not adequately controlled on maximum tolerated dose of an ACE inhibitor</ci> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="patient's lifetime"/> </Case></Request>
<Request To="HealthPAC" For="Subsidy" Form="SA0922"> <Title> <range>Erythropoietin</range> </Title> <Case When="Initial application"> <math> <apply> <and/> <apply> <and/> <ci type="logical" class="Indication">patient in chronic renal failure</ci> <apply> <leq/> <ci type="real" class="test">Haemoglobin</ci> <cn>100<mi>g/L</mi></cn> </apply> </apply> <apply> <or/> <apply> <and/> <ci type="logical" class="Indication">patient is not diabetic</ci> <apply> <leq/> <ci type="real" class="test">glomerular filtration rate</ci> <cn>30<mi>ml/min</mi></cn> </apply> </apply> <apply> <and/> <ci type="logical" class="Indication">patient is diabetic</ci> <apply> <leq/> <ci type
<Request To="HealthPAC" For="Subsidy" Form="SA1198"> <Title> <range>Preterm post-discharge infant formula powder<instance>S-26 Gold Premgro</instance></range> </Title> <Case When="Initial application"> <math overflow="scroll"> <apply> <and/> <ci type="logical" class="Indication">The infant was born before 33 weeks gestation or weighed less than 1.5 kg at birth</ci> <apply> <or/> <ci type="logical" class="Indication">The infant has faltering growth (downward crossing of percentiles)</ci> <ci type="logical" class="Indication">The infant is not maintaining, or is considered unlikely to maintain, adequate growth on standard infant formula</ci> </apply> </apply> </math> <Applicant>dietitian</Applicant> <Applicant>relevant specialist</Applicant> <Applicant>vocationally registered general practitioner</Applicant> <Term Measure="month">6</Term> </Case></Request>
<Request To="HealthPAC" For="Subsidy" Form="SA1124"> <Title> <range>Thalidomide</range> </Title> <Case When="Initial application"> <math> <apply> <or/> <ci type="logical" class="indication">The patient has multiple myeloma</ci> <ci type="logical" class="indication">The patient has systemic AL amyloidosis*</ci> </apply> </math> <Applicant>relevant specialist</Applicant> <Applicant Referring="relevant specialist">medical practitioner</Applicant> <Term Measure="month">12</Term> </Case> <Case When="Renewal" Form="SA1124 SA0817 SA0882"> <math> <ci type="logical" class="indication">The patient has obtained a response from treatment during the initial approval period</ci> </math> <Applicant>relevant specialist</Applicant> <Applicant Referring="relevant specialist">medical practitioner</Applicant> <Term Measure="patient's lifetime"/> </Case> <Note> <Para>Prescription must be written by a re
<Request To="HealthPAC" For="Subsidy" Form="SA1260"> <Title> <range>Perhexiline Maleate</range> </Title> <Case When="Initial application"> <math> <apply> <and/> <ci type="logical" class="Indication">Patient has refractory angina</ci> <ci type="logical" class="Trial">Patient is on the maximal tolerated dose of a beta-blocker, a calcium channel blocker and a long acting nitrate</ci> </apply> </math> <Applicant>cardiologist</Applicant> <Applicant>general physician</Applicant> <Term Measure="year">2</Term> </Case> <Case When="Renewal" Form="SA0256 SA1260"> <math> <ci type="logical" class="Indication">The treatment remains appropriate and the patient is benefiting from treatment</ci> </math> <Applicant>cardiologist</Applicant> <Applicant Referring="cardiologist">any relevant practitioner</Applicant> <Term Measure="year">2</Term> </Case></Request>
<Request To="HealthPAC" For="Subsidy" Form="SA1285"> <Title> <range>Posaconazole </range> </Title> <Case When="Initial application"> <math> <apply> <or/> <ci type="logical" class="Indication">Patient has acute myeloid leukaemia and is to be treated with high dose remission induction, re-induction or consolidation chemotherapy</ci> <ci type="logical" class="Indication">Patient has received a stem cell transplant and has graft versus host disease and is on significant immunosuppressive therapy*</ci> </apply> </math> <Applicant>haematologist</Applicant> <Applicant>infectious disease specialist</Applicant> <Term Measure="week">6</Term> </Case> <Case When="Renewal" Form="SA1285"> <math> <apply> <or/> <ci type="logical" class="Indication">Patient has acute myeloid leukaemia and is to be treated with high dose remission induction, re-induction or consolidation therapy</ci> <ci type="logical" c
<Request To="HealthPAC" For="Subsidy" Form="SA1293"> <Title> <range>Sildenafil</range> </Title> <Case When="Initial application" Category="Raynaud&#8217;s Phenomenon* - for Pulmonary Arterial Hypertension see note below)"> <math> <apply> <and/> <ci type="logical" class="Indication">Patient has Raynaud&#8217;s Phenomenon*</ci> <ci type="logical" class="Indication">Patient has severe digital ischaemia (defined as severe pain requiring hospital admission or with a high likelihood of digital ulceration; digital ulcers; or gangrene)</ci> <ci type="logical" class="Indication">Patient is following lifestyle management (avoidance of cold exposure, sufficient protection, smoking cessation support, avoidance of sympathomimetic drugs) </ci> <ci type="logical" class="Indication">Patient is being treated with calcium channel blockers and nitrates (or these are contraindicated/not tolerated)</ci> </apply> </math> <Applicant>any relevant
<Request To="HealthPAC" For="Subsidy" Form="SA1061"> <Title> <range>Venlafaxine</range> </Title> <Case When="Initial application"> <math> <apply> <and/> <ci type="logical" class="Indication">The patient has 'treatment-resistant' depression</ci> <apply> <or/> <ci type="logical" class="Trial">The patient must have had a trial of two different antidepressants and have had an inadequate response from an adequate dose over an adequate period of time (usually at least four weeks)</ci> <apply> <and/> <ci type="logical" class="Indication">The patient is currently a hospital in-patient as a result of an acute depressive episode</ci> <ci type="logical" class="Trial">The patient must have had a trial of one other antidepressant and have had an inadequate response from an adequate dose over an adequate period of time</ci> </apply> </apply> </apply> </math> <Appl
<Request To="HealthPAC" For="Subsidy" Form="SA1411"> <Title> <range>Erlotinib</range> </Title> <Case When="Initial application"> <math> <apply> <or/> <apply> <and/> <ci type="logical" class="Indication">Patient has locally advanced or metastatic, unresectable, non-squamous Non Small Cell Lung Cancer (NSCLC)</ci> <ci type="logical" class="Indication">There is documentation confirming that the disease expresses activating mutations of EGFR tyrosine kinase</ci> <apply> <or/> <ci type="logical" class="Indication">Patient is treatment naive</ci> <apply> <and/> <ci type="logical" class="Indication">Patient has documented disease progression following treatment with first line platinum based chemotherapy</ci> <ci type="logical" class="Indication">Patient has not received prior treatment with gefitinib</ci> </apply> </apply>
<Request To="HealthPAC" For="Alternate Subsidy" Form="SA1018"> <Title> <range>Hormone Replacement Therapy - Systemic</range> </Title> <Case When="Initial application"> <math> <apply> <or/> <ci type="logical" class="Indication">acute or significant liver disease - where oral oestrogens are contraindicated as determined by a gastroenterologist or general physician. The applicant must keep written confirmation from such a specialist with the patient's record</ci> <ci type="logical" class="Indication">oestrogen induced hypertension requiring antihypertensive therapy - documented evidence must be kept on file that raised blood pressure levels or inability to control blood pressure adequately occurred post oral oestrogens</ci> <ci type="logical" class="Indication">hypertriglyceridaemia - documented evidence must be kept on file that triglyceride levels increased to at least 2 &#215; normal triglyceride levels post oral oestrogens</ci> <ci type=
<Request To="HealthPAC" For="Subsidy" Form="SA1318"> <Title> <range>Albendazole</range> </Title> <Case When="Initial application"> <math> <ci type="logical" class="Indication">The patient has hydatids</ci> </math> <Applicant>infectious disease specialist</Applicant> <Applicant>clinical microbiologist</Applicant> <Term Measure="month">6</Term> </Case> <Case When="Renewal" Form="SA1318"> <math> <ci type="logical" class="Indication">The treatment remains appropriate and the patient is benefitting from the treatment</ci> </math> <Applicant>infectious disease specialist</Applicant> <Applicant>clinical microbiologist</Applicant> <Term Measure="month">6</Term> </Case></Request>
<Request To="HealthPAC" For="Subsidy" Form="SA1095"> <Title> <range>Diabetic products<instance>Diason RTH</instance><instance>Glucerna Select RTH</instance><instance>Diasip</instance><instance>Glucerna Select</instance><instance>Resource Diabetic</instance></range> </Title> <Case When="Initial application"> <math> <ci type="logical" class="Indication">The patient is a type I or and II diabetic who is suffering weight loss and malnutrition that requires nutritional support</ci> </math> <Applicant>dietitian</Applicant> <Applicant>relevant specialist</Applicant> <Applicant>vocationally registered general practitioner</Applicant> <Term Measure="year">1</Term> </Case> <Case When="Renewal" Form="SA0594 SA1095"> <math> <apply> <and/> <ci type="logical" class="Indication">The treatment remains appropriate and the patient is benefiting from treatment</ci> <ci type="text" class="Endorsement">General Practitioners must includ
<Request To="HealthPAC" For="Subsidy" Form="SA1449"> <Title> <range>Adalimumab</range> </Title> <Case When="Initial application" Category="rheumatoid arthritis"> <math> <apply> <or/> <apply> <and/> <ci type="logical" class="Indication">The patient has had an initial Special Authority approval for etanercept for rheumatoid arthritis</ci> <apply> <or/> <ci type="logical" class="Indication">The patient has experienced intolerable side effects from etanercept</ci> <ci type="logical" class="Indication">The patient has received insufficient benefit from etanercept to meet the renewal criteria for etanercept for rheumatoid arthritis</ci> </apply> </apply> <apply> <and/> <ci type="logical" class="Indication">Patient has had severe and active erosive rheumatoid arthritis for six months duration or longer</ci> <ci type="logical" class="Treatmen
<Request To="HealthPAC" For="Subsidy" Form="SA1388"> <Title> <range>Preservative Free Ocular Lubricants</range> </Title> <Case When="Initial application"> <math> <apply> <and/> <ci type="logical" class="Indication">Confirmed diagnosis by slit lamp of severe secretory dry eye</ci> <apply> <or/> <ci type="logical" class="Indication">Patient is using eye drops more than four times daily on a regular basis</ci> <ci type="logical" class="Indication">Patient has had a confirmed allergic reaction to preservative in eye drop</ci> </apply> </apply> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="month">12</Term> </Case> <Case When="Renewal" Form="SA1388"> <math> <ci type="logical" class="Indication">The patient continues to require lubricating eye drops and has benefited from treatment</ci> </math> <Applicant>any relevant practitioner</Applicant>
<Request To="HealthPAC" For="Subsidy" Form="SA1201"> <Title> <range>Prasugrel</range> </Title> <Case When="Initial application" Category="coronary angioplasty and bare metal stent"> <math> <ci type="logical" class="Treatment">The patient has undergone coronary angioplasty in the previous 4 weeks and is clopidogrel-allergic*</ci> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="month">6</Term> </Case> <Case When="Initial application" Category="drug eluting stent"> <math> <ci type="logical" class="Treatment">The patient has had a drug-eluting cardiac stent inserted in the previous 4 weeks and is clopidogrel-allergic*</ci> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="month">12</Term> </Case> <Case When="Initial application" Category="stent thromobosis"> <math> <ci type="logical" class="Treatment">patient has experienced cardiac stent thrombosis whilst on clopidogrel</ci>
<Request To="HealthPAC" For="Subsidy" Form="SA1325"> <Title> <range>Pegaspargase</range> </Title> <Case When="Initial application"> <math> <apply> <and/> <ci type="logical" class="Indication">The patient has newly diagnosed acute lymphoblastic leukaemia</ci> <ci type="logical" class="Indication">Pegaspargase to be used with a contemporary intensive multi-agent chemotherapy treatment protocol</ci> <ci type="logical" class="Indication">Treatment is with curative intent</ci> </apply> </math> <Applicant>relevant specialist</Applicant> <Applicant Referring="relevant specialist">medical practitioner</Applicant> <Term Measure="month">12</Term> </Case> <Case When="Renewal" Form="SA1325"> <math> <apply> <and/> <ci type="logical" class="Indication">The patient has relapsed acute lymphoblastic leukaemia</ci> <ci type="logical" class="Indication">Pegaspargase to be used with a contemporar
<Request To="HealthPAC" For="Alternate Subsidy" Form="SA0500"> <Title><range>Combined oral contraceptives</range><range>Progestogen-only contraceptives</range> (Circle one)</Title> <Case When="Initial application"> <math> <apply> <and/> <apply> <or/> <ci type="logical" class="Target">Patient is on a Social Welfare benefit</ci> <ci type="logical" class="Target">Patient has an income no greater than the benefit</ci> </apply> <ci type="logical" class="Trial">Has tried at least one of the fully funded options and has been unable to tolerate it</ci> </apply> </math> <Applicant>medical practitioner</Applicant> <Term Measure="year">2</Term> </Case> <Case When="Renewal" Form="SA0265 SA0500"> <math> <apply> <or/> <ci type="logical" class="Target">Patient is on a Social Welfare benefit</ci> <ci type="logical" class="Target">Patient has an income no greater than the be
<Request To="HealthPAC" For="Subsidy" Form="SA1374"> <Title> <range>Fat<instance>Calogen</instance><instance>Liquigen</instance><instance>MCT oil (Nutricia)</instance></range> </Title> <Case When="Initial application" Category="Inborn errors of metabolism"> <math> <ci type="logical" class="Indication">The patient has inborn errors of metabolism</ci> </math> <Applicant>dietitian</Applicant> <Applicant>relevant specialist</Applicant> <Applicant>vocationally registered general practitioner</Applicant> <Term Measure="year">3</Term> </Case> <Case When="Initial application" Category="Indications other than inborn errors of metabolism"> <math> <apply> <or/> <ci type="logical" class="Indication">faltering growth in an infant/child</ci> <ci type="logical" class="Indication">bronchopulmonary dysplasia</ci> <ci type="logical" class="Indication">fat malabsorption</ci> <ci type="logical" class="Indication">lym
<Request To="HealthPAC" For="Subsidy" Form="SA1375"> <Title> <range>Protein<instance>Protifar</instance><instance>Promod</instance><instance>Resource Beneprotein</instance></range> </Title> <Case When="Initial application"> <math> <apply> <or/> <ci type="logical" class="Indication">protein losing enteropathy</ci> <ci type="logical" class="Indication">high protein needs</ci> <ci type="logical" class="Indication">for use as a component in a modular formula</ci> </apply> </math> <Applicant>dietitian</Applicant> <Applicant>relevant specialist</Applicant> <Applicant>vocationally registered general practitioner</Applicant> <Term Measure="year">1</Term> </Case> <Case When="Renewal" Form="SA0582 SA1093 SA1375"> <math> <apply> <and/> <ci type="logical" class="Indication">The treatment remains appropriate and the patient is benefiting from treatment</ci> <ci type="text" class="Endor
<Request To="HealthPAC" For="Subsidy" Form="SA1266"> <Title> <range>Sunitinib</range> </Title> <Case When="Initial application" Category="RCC"> <math> <apply> <and/> <ci type="logical" class="Indication">The patient has metastatic renal cell carcinoma</ci> <apply> <or/> <ci type="logical" class="Trial">The patient is treatment naive</ci> <ci type="logical" class="Trial">The patient has only received prior cytokine treatment</ci> <ci type="logical" class="Trial">The patient has only received prior treatment with an investigational agent within the confines of a bona fide clinical trial which has Ethics Committee approval</ci> <apply> <and/> <ci type="logical" class="Trial">The patient has discontinued pazopanib within 3 months of starting treatment due to intolerance</ci> <ci type="logical" class="Trial">The cancer did not progress whilst on pazopanib</ci>
<Request To="HealthPAC" For="Subsidy" Form="SA1273"> <Title> <range>Voriconazole</range> </Title> <Case When="Initial application" Category="invasive fungal infection"> <math> <apply> <and/> <ci type="logical" class="Indication">Patient is immunocompromised</ci> <ci type="logical" class="Indication">Applicant is part of a multidisciplinary team including an infectious disease specialist</ci> <apply> <or/> <ci type="logical" class="Indication">Patient has proven or probable invasive aspergillus infection</ci> <ci type="logical" class="Indication">Patient has possible invasive aspergillus infection</ci> <ci type="logical" class="Indication">Patient has fluconazole resistant candidiasis</ci> <ci type="logical" class="Indication">Patient has mould strain such as Fusarium spp. and Scedosporium spp</ci> </apply> </apply> </math> <Applicant>haematologist</Applicant> <App
<Request To="HealthPAC" For="Subsidy" Form="SA1228"> <Title> <range>Standard Supplements<instance>Ensure</instance><instance>Fortisip</instance><instance>Isosource</instance><instance>Jevity</instance><instance>Nutrison</instance><instance>Osmolite</instance><instance>Sustagen</instance></range> </Title> <Case When="Initial application" Category="Children"> <math> <apply> <and/> <ci type="logical" class="Indication">The patient is under 18 years of age</ci> <apply> <or/> <ci type="logical" class="Indication">The patient has a condition causing malabsorption</ci> <ci type="logical" class="Indication">The patient has failure to thrive</ci> <ci type="logical" class="Indication">The patient has increased nutritional requirements</ci> </apply> <ci type="logical" class="Indication">Nutrition goal has been set (eg reach a specific weight or BMI)</ci> </apply> </math> <Applicant>dietitia
<Request To="HealthPAC" For="Subsidy" Form="SA1046"> <Title> <range>Ezetimibe with Simvastatin<instance>Vytorin</instance></range> </Title> <Case When="Initial application"> <math> <apply> <and/> <ci type="logical" class="Indication">Patient has a calculated absolute risk of cardiovascular disease of at least 15% over 5 year</ci> <ci type="logical" class="Trial">Patient's LDL cholesterol is 2.0 mmol/litre or greater</ci> <ci type="logical" class="Trial">The patient has not reduced their LDL cholesterol to less than 2.0 mmol/litre with the use of the maximal tolerated dose of atorvastatin</ci> </apply> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="year">2</Term> <Note> <Para>A patient who has failed to reduce their LDL cholesterol to &#8804; 2.0 mmol/litre with the use of a less potent statin should use a more potent statin prior to consideration being given to the use of non-statin therapi
<Request To="Cystic Fibrosis Advisory Panel" For="Subsidy" Form="SA0611"> <Title> <range>Dornase Alfa</range> </Title> <Case When="Initial application"> <math> <ci/> </math> <Applicant>medical practitioner</Applicant> <Term Measure="year">1</Term> </Case> <Note> <Para>Application details may be obtained from PHARMAC's website <a href="http://www.pharmac.govt.nz/">http://www.pharmac.govt.nz</a> or:</Para> <Table> <TR> <TD> <Para>The Co-ordinator, Cystic Fibrosis Advisory Panel</Para> </TD> <TD> <Para>Phone: (04) 460 4990</Para> </TD> </TR> <TR> <TD> <Para>PHARMAC, PO Box 10 254</Para> </TD> <TD> <Para>Facsimile: (04) 916 7571</Para> </TD> </TR> <TR> <TD> <Para>Wellington</Para> </TD> <TD> <Para>Email: <a href="mailto:CFPanel@pharmac.govt.nz">CFPanel@pharmac.
<Request To="HealthPAC" For="Subsidy" Form="SA1451"> <Title> <range>Somatropin</range> </Title> <Case When="Initial application" Category="growth hormone deficiency in children"> <math> <apply> <or/> <apply> <and/> <ci type="logical" class="Indication">Growth hormone deficiency causing symptomatic hypoglycaemia, or with other significant growth hormone deficient sequelae (e.g. cardiomyopathy, hepatic dysfunction) and diagnosed with GH &lt; 5 mcg/l on at least two random blood samples in the first 2 weeks of life, or from samples during established hypoglycaemia (whole blood glucose &lt; 2 mmol/l using a laboratory device)</ci> </apply> <apply> <and/> <ci type="logical" class="Indication">Height velocity &lt; 25th percentile for age adjusted for bone age/pubertal status if appropriate over 6 or 12 months using the standards of Tanner and Davies (1985)</ci> <ci type="logical" class="Indication
<Request To="HealthPAC" For="Subsidy" Form="SA1139"> <Title> <range>Teriparatide</range> </Title> <Case When="Initial application"> <math> <apply> <and/> <ci type="logical" class="indication">The patient has severe, established osteoporosis</ci> <ci type="logical" class="indication">The patient has a documented T-score less than or equal to -3.0 (see Notes)</ci> <ci type="logical" class="indication">The patient has had two or more fractures due to minimal trauma</ci> <ci type="logical" class="indication">The patient has experienced at least one symptomatic new fracture after at least 12 months&#8217; continuous therapy with a funded antiresorptive agent at adequate doses (see Notes)</ci> </apply> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="month">18</Term> </Case> <Note> <List Type="Alpha"> <Item> <Para>The bone mineral density (BMD) measurement used to derive the
<Request To="PHARMAC" For="Subsidy" Form="SA1291"> <Title> <range>Optium blood glucose test strips</range> </Title> <Case When="Initial application"> <math> <ci type="logical" class="Indication">Patient identified as eligible for subsidy for FreeStyle Optium blood glucose test strips</ci> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="patient's lifetime"/> </Case> <Note> <Para>Application details may be obtained from PHARMAC's website http://www.pharmac.govt.nz and can be sent to:</Para> <Table> <TR> <TD> <Para>PHARMAC</Para> </TD> <TD> <Para/> </TD> </TR> <TR> <TD> <Para>PO Box 10 254</Para> </TD> <TD> <Para>Facsimile: (04) 974 4788</Para> </TD> </TR> <TR> <TD> <Para>Wellington</Para> </TD> <TD> <Para>Email: <a href="mailto:bgstrip
<Request To="HealthPAC" For="Subsidy" Form="SA1098"> <Title> <range>Paediatric Product For Children Awaiting Liver Transplant<instance>Heparon Junior</instance></range> </Title> <Case When="Initial application"> <math> <ci type="logical" class="Indication">The patient is a child (up to 18 years) who requires a liver transplant</ci> </math> <Applicant>dietitian</Applicant> <Applicant>relevant specialist</Applicant> <Applicant>vocationally registered general practitioner</Applicant> <Term Measure="year">3</Term> </Case> <Case When="Renewal" Form="SA0607 SA1098"> <math> <apply> <and/> <ci type="logical" class="Indication">The treatment remains appropriate and the patient is benefiting from treatment</ci> <ci type="text" class="Endorsement">General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted</ci> </apply> </math
<Request To="HealthPAC" For="Subsidy" Form="SA0845"> <Title> <range>Enfuvirtide</range> </Title> <Case When="Initial application"> <math> <apply> <and/> <ci type="logical" class="Indication">Confirmed HIV infection</ci> <ci type="logical" class="Indication">Enfuvirtide to be given in combination with optimized background therapy (including at least 1 other antiretroviral drug that the patient has never previously been exposed to) for treatment failure</ci> <apply> <or/> <ci type="logical" class="Indication">Patient has evidence of HIV replication, despite ongoing therapy</ci> <ci type="logical" class="Indication">Patient has treatment-limiting toxicity to previous antiretroviral agents</ci> </apply> <ci type="logical" class="Indication">Previous treatment with 3 different antiretroviral regimens has failed</ci> <apply> <and/> <ci type="logical" class="Indication">Prev
<Request To="HealthPAC" For="Subsidy" Form="SA0955"> <Title> <range>Isotretinoin</range> </Title> <Case When="Initial application"> <math> <apply> <and/> <ci type="logical" class="Indication">Patient has had an adequate trial on other available treatments and has received an inadequate response from these treatments or these are contraindicated</ci> <ci type="logical" class="Indication">Applicant is a vocationally registered dermatologist, vocationally registered general practitioner, or nurse practitioner working in a relevant scope of practice</ci> <ci type="logical" class="Indication">Applicant has an up to date knowledge of the treatment options for acne and is aware of the safety issues around isotretinoin and is competent to prescribe isotretinoin</ci> <apply> <or/> <ci type="logical" class="Indication">Patient is female and has been counselled and understands the risk of teratogenicity if isotretinoin is used d
<Request To="HealthPAC" For="Subsidy" Form="SA0994"> <Title> <range>Mirtazapine</range> </Title> <Case When="Initial application"> <math> <apply> <and/> <ci type="logical" class="Indication">The patient has a severe major depressive episode</ci> <apply> <or/> <ci type="logical" class="Trial">The patient must have had a trial of two different antidepressants and was unable to tolerate the treatments or failed to respond to an adequate dose over an adequate period of time (usually at least four weeks)</ci> <apply> <and/> <ci type="logical" class="Indication">The patient is currently a hospital in-patient as a result of an acute depressive episode</ci> <ci type="logical" class="Trial">The patient must have had a trial of one other antidepressant and either could not tolerate it or failed to respond to an adequate dose over an adequate period of time</ci> </apply> </appl
<Request To="HealthPAC" For="Subsidy" Form="SA1404"> <Title> <range>Valganciclovir</range> </Title> <Case When="Initial application" Category="transplant cytomegalovirus prophylaxis"> <math> <ci type="logical" class="Indication">the patient has undergone a solid organ transplant and requires valganciclovir for CMV prophylaxis</ci> </math> <Applicant>relevant specialist</Applicant> <Term Measure="month">3</Term> </Case> <Case When="Renewal" Form="SA1274 SA1404" Category="transplant cytomegalovirus prophylaxis"> <math> <apply> <and/> <ci type="logical" class="Indication">Patient has undergone a solid organ transplant and received anti-thymocyte globulin and requires valganciclovir therapy for CMV prophylaxis</ci> <ci type="logical" class="Indication">Patient is to receive a maximum of 90 days of valganciclovir prophylaxis following anti-thymocyte globulin</ci> </apply> </math> <Applicant>relevant specialist</A
<Request To="HealthPAC" For="Subsidy" Form="SA1138"> <Title> <range>Raloxifene</range> </Title> <Case When="Initial application"> <math> <apply> <or/> <ci type="logical" class="indication">History of one significant osteoporotic fracture demonstrated radiologically and documented bone mineral density (BMD) &#8805;2.5 standard deviations below the mean normal value in young adults (i.e. T-Score &#8804; -2.5) (see Notes)</ci> <ci type="logical" class="indication">History of one significant osteoporotic fracture demonstrated radiologically, and either the patient is elderly, or densitometry scanning cannot be performed because of major logistical, technical or pathophysiological reasons. It is unlikely that this provision would apply to many patients under 75 years of age</ci> <ci type="logical" class="indication">History of two significant osteoporotic fractures demonstrated radiologically</ci> <ci type="logical" class="indication">Documente
<Request To="HealthPAC" For="Subsidy" Form="SA1125"> <Title> <range>Lacosamide</range> </Title> <Case When="Initial application"> <math> <apply> <and/> <ci type="logical" class="Indication">Patient has partial-onset epilepsy</ci> <ci type="logical" class="Trial">Seizures are not adequately controlled by, or patient has experienced unacceptable side effects from, optimal treatment with all of the following: sodium valproate, topiramate, levetiracetam and any two of carbamazepine, lamotrigine and phenytoin sodium (see Note)</ci> </apply> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="month">15</Term> <Note> <Para>"Optimal treatment" is defined as treatment which is indicated and clinically appropriate for the patient, given in adequate doses for the patient's age, weight and other features affecting the pharmacokinetics of the drug with good evidence of compliance. Women of childbearing age are not re
<Request To="HealthPAC" For="Subsidy" Form="SA1376"> <Title> <range>Carbohydrate and Fat<instance>Duocal Super Soluble Powder</instance></range> </Title> <Case When="Initial application" Category="Cystic fibrosis"> <math> <apply> <and/> <ci type="logical" class="Indication">Infant or child aged four years or under</ci> <ci type="logical" class="Indication">cystic fibrosis</ci> </apply> </math> <Applicant>dietitian</Applicant> <Applicant>relevant specialist</Applicant> <Applicant>vocationally registered general practitioner</Applicant> <Term Measure="year">3</Term> </Case> <Case When="Initial application" Category="Indications other than cystic fibrosis"> <math> <apply> <and/> <ci type="logical" class="Indication">infant or child aged four years or under</ci> <apply> <or/> <ci type="logical" class="Indication">cancer in children</ci> <ci type="logica
<Request To="HealthPAC" For="Subsidy" Form="SA0895"> <Title> <range>Pilocarpine &#8211; Eye drops 2% single dose</range> </Title> <Case When="Initial application"> <math> <apply> <or/> <ci type="logical" class="Indication">Patient has to use an unpreserved solution due to an allergy to the preservative</ci> <ci type="logical" class="Indication">Patient wears soft contact lenses</ci> </apply> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="year">2</Term> <Note> <Para>Minims for a general practice are considered to be &#8220;tools of trade&#8221; and are not approved as special authority items.</Para> </Note> </Case> <Case When="Renewal" Form="SA0121 SA0895"> <math> <ci type="logical" class="Indication">The treatment remains appropriate and the patient is benefiting from treatment</ci> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="year">2<
<Request To="HealthPAC" For="Subsidy" Form="SA1072"> <Title> <range>Vigabatrin</range> </Title> <Case When="Initial application"> <math> <apply> <and/> <apply> <or/> <ci type="logical" class="Indication">Patient has infantile spasms</ci> <apply> <and/> <ci type="logical" class="Indication">Patient has epilepsy</ci> <apply> <or/> <ci type="logical" class="Indication">Seizures are not adequately controlled with optimal treatment with other antiepilepsy agents</ci> <ci type="logical" class="Indication">Seizures are controlled adequately but the patient has experienced unacceptable side effects from optimal treatment with other antiepilepsy agents</ci> </apply> </apply> </apply> <apply> <or/> <ci type="logical" class="Indication">Patient is, or will be, receiving regular automated visual fiel
<Request To="HealthPAC" For="Subsidy" Form="SA1408"> <Title> <range>Naltrexone</range> </Title> <Case When="Initial application"> <math> <apply> <and/> <ci type="logical" class="Indication">Patient is currently enrolled in a recognised comprehensive treatment programme for alcohol dependence</ci> <ci type="logical" class="Therapy">Applicant works in or with a community Alcohol and Drug Service contracted to one of the District Health Boards or accredited against the New Zealand Alcohol and Other Drug Sector Standard or the National Mental Health Sector Standard</ci> </apply> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="month">6</Term> </Case> <Case When="Renewal" Form="SA0714 SA0909 SA1397 SA1408"> <math> <apply> <and/> <ci type="logical" class="Indication">Compliance with the medication (prescriber determined)</ci> <apply> <or/> <ci type="log
<Request To="HealthPAC" For="Subsidy" Form="SA1174"> <Title> <range>Enoxaparin sodium</range> </Title> <Case When="Initial application" Category="Pregnancy or Malignancy"> <math> <apply> <or/> <ci type="logical" class="Indication">Low molecular weight heparin treatment is required during a patients pregnancy</ci> <ci type="logical" class="Treatment">For the treatment of venous thromboembolism where the patient has a malignancy</ci> </apply> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="year">1</Term> </Case> <Case When="Initial application" Category="Venous thromboembolism other than in pregnancy or malignancy"> <math> <apply> <or/> <ci type="logical" class="Indication">For the short-term treatment of venous thromboembolism prior to establishing a therapeutic INR with oral anti-coagulant treatment</ci> <ci type="logical" class="Treatment">For the prophylaxis and tre
<Request To="HealthPAC" For="Subsidy" Form="SA1416"> <Title> <range>Atomoxetine</range> </Title> <Case When="Initial application"> <math> <apply> <and/> <ci type="logical" class="Indication">Patient has ADHD (Attention Deficit and Hyperactivity Disorder) diagnosed according to DSM-IV or ICD 10 criteria</ci> <ci type="logical" class="Indication">Once-daily dosing</ci> <apply> <or/> <ci type="logical" class="Indication">Treatment with a subsidised formulation of a stimulant has resulted in the development or worsening of serious adverse reactions or where the combination of subsidised stimulant treatment with another agent would pose an unacceptable medical risk</ci> <ci type="logical" class="Indication">Treatment with a subsidised formulation of a stimulant has resulted in worsening of co-morbid substance abuse or there is a significant risk of diversion with subsidised stimulant therapy</ci> <ci type="log
<Request To="HealthPAC" For="Subsidy" Form="SA1263"> <Title> <range>Nicorandil</range> </Title> <Case When="Initial application"> <math> <apply> <and/> <ci type="logical" class="Indication">Patient has refractory angina</ci> <ci type="logical" class="Trial">Patient is on the maximal tolerated dose of a beta-blocker, a calcium channel blocker and a long acting nitrate</ci> </apply> </math> <Applicant>cardiologist</Applicant> <Applicant>general physician</Applicant> <Term Measure="year">2</Term> </Case> <Case When="Renewal" Form="SA1263"> <math> <ci type="logical" class="Indication">The treatment remains appropriate and the patient is benefiting from treatment</ci> </math> <Applicant>cardiologist</Applicant> <Applicant Referring="cardiologist">any relevant practitioner</Applicant> <Term Measure="year">2</Term> </Case></Request>
<Request To="HealthPAC" For="Subsidy" Form="SA0927"> <Title> <range>Risperidone orally disintegrating tablets</range> </Title> <Case When="Initial application" Category="Acute situations"> <math> <apply> <and/> <ci type="logical" class="Use">For a non-adherent patient on oral therapy with standard risperidone tablets or risperidone oral liquid</ci> <ci type="logical" class="Therapy">The patient is under direct supervision for administration of medicine</ci> </apply> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="week">6</Term> </Case> <Case When="Initial application" Category="Chronic situations"> <math> <apply> <and/> <ci type="logical" class="Indication">The patient is unable to take standard risperidone tablets or oral liquid, or once stabilized refuses to take risperidone tablets or oral liquid</ci> <ci type="logical" class="Therapy">The patient is under direct
<Request To="HealthPAC" For="Subsidy" Form="SA1195"> <Title> <range>High Calorie Products<instance>Two Cal HN</instance><instance>Nutrison Concentrated</instance></range> </Title> <Case When="Initial application" Category="Cystic fibrosis"> <math> <apply> <and/> <ci type="logical" class="Indication">Cystic fibrosis</ci> <ci type="logical" class="Trial">other lower calorie products have been tried</ci> <ci type="logical" class="Indication">patient has substantially increased metabolic requirements</ci> </apply> </math> <Applicant>dietitian</Applicant> <Applicant>relevant specialist</Applicant> <Applicant>vocationally registered general practitioner</Applicant> <Term Measure="year">3</Term> </Case> <Case When="Initial application" Category="Indications other than cystic fibrosis"> <math> <apply> <and/> <apply> <or/> <ci type="logical" class="Indication">any cond
<Request To="PHARMAC" For="Subsidy" Form="SA1237"> <Title> <range>Insulin Pumps</range> </Title> <Case When="Initial application"> <math/> <Applicant>medical practitioner</Applicant> <Term Measure="year">1</Term> </Case> <Note> <Para>Application details may be obtained from PHARMAC's website <a href="http://www.pharmac.govt.nz/">http://www.pharmac.govt.nz</a> or:</Para> <Table> <TR> <TD> <Para>The IPP Co-ordinator</Para> </TD> <TD> <Para>Phone: (04) 460 4990</Para> </TD> </TR> <TR> <TD> <Para>PHARMAC</Para> </TD> <TD> <Para>Facsimile: (04) 974 7806</Para> </TD> </TR> <TR> <TD> <Para>PO Box 10 254</Para> </TD> <TD> <Para>Email: <a href="mailto:ipp@pharmac.govt.nz">ipp@pharmac.govt.nz</a></Para> </TD> </TR> <TR> <TD> <Para>Welli
<Request To="HealthPAC" For="Subsidy" Form="SA0829"> <Title> <range>Adefovir dipivoxil</range> </Title> <Case When="Initial application"> <math> <apply> <and/> <ci type="logical" class="Trial">Patient has confirmed Hepatitis B infection (HBsAg+)</ci> <mi class="heading">Documented resistance to lamivudine, defined as:</mi> <ci type="logical" class="Trial">Patient has raised serum ALT (&gt; 1 &#215; ULN)</ci> <ci type="logical" class="Trial">Patient has HBV DNA greater than 100,000 copies per mL, or viral load &#8805; 10 fold over nadir</ci> <ci type="logical" class="Trial">Detection of M204I or M204V mutation</ci> <apply> <or/> <apply> <and/> <ci type="logical" class="Trial">Patient is cirrhotic</ci> <ci type="logical" class="Trial">adefovir dipivoxil to be used in combination with lamivudine</ci> </apply> <apply> <and/>
<Request To="HealthPAC" For="Subsidy" Form="SA1379"> <Title> <range>Paediatric Products<instance>Nutrini</instance><instance>Pediasure</instance><instance>Fortini</instance></range> </Title> <Case When="Initial application"> <math> <apply> <and/> <ci type="logical" class="Indication">Child is aged one to ten years</ci> <apply> <or/> <ci type="logical" class="Indication">the child is being fed via a tube or a tube is to be inserted for the purposes of feeding</ci> <ci type="logical" class="Indication">any condition causing malabsorption</ci> <ci type="logical" class="Indication">faltering growth in an infant/child</ci> <ci type="logical" class="Indication">increased nutritional requirements</ci> <ci type="logical" class="Indication">the child is being transitioned from TPN or tube feeding to oral feeding</ci> </apply> </apply> </math> <Applicant>dietitian</Applicant>
<Request To="HealthPAC" For="Subsidy" Form="SA1382"> <Title> <range>Ticagrelor</range> </Title> <Case When="Initial application" Category="acute coronary syndrome"> <math> <apply> <and/> <ci type="logical" class="Indication">Patient has recently been diagnosed with an ST-elevation or a non-ST-elevation acute coronary syndrome</ci> <ci type="logical" class="Indication">Fibrinolytic therapy has not been given in the last 24 hours and is not planned</ci> </apply> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="month">12</Term> </Case> <Case When="Renewal" Category="subsequent acute coronary syndrome" Form="SA1382"> <math> <apply> <and/> <ci type="logical" class="Indication">Patient has recently been diagnosed with an ST-elevation or a non-ST-elevation acute coronary syndrome</ci> <ci type="logical" class="Indication">Fibrinolytic therapy has not been given in the last 24
<Request To="HealthPAC" For="Subsidy" Form="SA1383"> <Title> <range>Ursodeoxycholic Acid</range> </Title> <Case When="Initial application" Category="Alagille syndrome or progressive familial intrahepatic cholestasis"> <math> <apply> <or/> <ci type="logical" class="Indication">Patient has been diagnosed with Alagille syndrome</ci> <ci type="logical" class="Indication">Patient has progressive familial intrahepatic cholestasis</ci> </apply> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="patient's lifetime"/> </Case> <Case When="Initial application" Category="Chronic severe drug induced cholestatic liver injury"> <math> <apply> <and/> <ci type="logical" class="Indication">Patient has chronic severe drug induced cholestatic liver injury</ci> <ci type="logical" class="Indication">Cholestatic liver injury not due to Total Parenteral Nutrition (TPN) use in adults</ci>
<Request To="HealthPAC" For="Subsidy" Form="SA1192"> <Title> <range>Trastuzumab</range> </Title> <Case When="Initial application" Category="metastatic breast cancer"> <math> <apply> <or/> <apply> <and/> <ci type="logical" class="Indication">The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology)</ci> <ci type="logical" class="Treatment">The patient has not previously received lapatinib treatment for HER 2 positive metastatic breast cancer</ci> <ci type="logical" class="Indication">Trastuzumab not to be given in combination with lapatinib</ci> <ci type="logical" class="Treatment">Trastuzumab to be discontinued at disease progression</ci> </apply> <apply> <and/> <ci type="logical" class="Indication">The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology
<Request To="HealthPAC" For="Subsidy" Form="SA1071"> <Title> <range>Gabapentin</range> </Title> <Case When="Initial application" Category="Epilepsy"> <math> <apply> <or/> <ci type="logical" class="Indication">Seizures are not adequately controlled with optimal treatment with other antiepilepsy agents</ci> <ci type="logical" class="Indication">Seizures are controlled adequately but the patient has experienced unacceptable side effects from optimal treatment with other antiepilepsy agents</ci> </apply> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="month">15</Term> <Note> <Para>"Optimal treatment with other antiepilepsy agents" is defined as treatment with other antiepilepsy agents which are indicated and clinically appropriate for the patient, given in adequate doses for the patient's age, weight, and other features affecting the pharmacokinetics of the drug with good evidence of compliance.</Para>
<Request To="HealthPAC" For="Subsidy" Form="SA1066"> <Title> <range>Rivaroxaban</range> </Title> <Case When="Initial application"> <math> <apply> <or/> <ci type="logical" class="Indication">For the prophylaxis of venous thromboembolism following a total hip replacement</ci> <ci type="logical" class="Use">For the prophylaxis of venous thromboembolism following a total knee replacement</ci> </apply> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="week">5</Term> <Note> <Para>Rivaroxaban is only currently indicated and subsidised for up to 5 weeks therapy for prophylaxis of venous thromboembolism following a total hip replacement and up to 2 weeks therapy for prophylaxis of venous thromboembolism following a total knee replacement.</Para> </Note> </Case> <Case When="Renewal" Form="SA1066"> <math> <ci type="logical" class="Indication">Prophylaxis for venous thromboembolism is requir
<Request To="PHARMAC" For="Subsidy" Form="SA1240"> <Title> <range>Insulin pump consumables</range> </Title> <Case When="Initial application"> <math/> <Applicant>medical practitioner</Applicant> <Term Measure="year">1</Term> </Case> <Note> <Para>Application details may be obtained from PHARMAC's website <a href="http://www.pharmac.govt.nz/">http://www.pharmac.govt.nz</a> or:</Para> <Table> <TR> <TD> <Para>The IPP Co-ordinator</Para> </TD> <TD> <Para>Phone: (04) 460 4990</Para> </TD> </TR> <TR> <TD> <Para>PHARMAC</Para> </TD> <TD> <Para>Facsimile: (04) 974 7806</Para> </TD> </TR> <TR> <TD> <Para>PO Box 10 254</Para> </TD> <TD> <Para>Email: <a href="mailto:ipp@pharmac.govt.nz">ipp@pharmac.govt.nz</a></Para> </TD> </TR> <TR> <TD>
<Request To="HealthPAC" For="Subsidy" Form="SA1039"> <Title> <range>Alendronate Tab 70 mg - with or without Cholecalciferol</range> </Title> <Case When="Initial application" Category="Underlying cause -- Osteoporosis"> <math> <apply> <or/> <ci type="logical" class="Indication">History of one significant osteoporotic fracture demonstrated radiologically and documented bone mineral density (BMD) &#8805; 2.5 standard deviations below the mean normal value in young adults (i.e. T-Score &#8804; -2.5) (see Note)</ci> <ci type="logical" class="Indication">History of one significant osteoporotic fracture demonstrated radiologically, and either the patient is elderly, or densitometry scanning cannot be performed because of major logistical, technical or pathophysiological reasons. It is unlikely that this provision would apply to many patients under 75 years of age</ci> <ci type="logical" class="Indication">History of two significant osteoporotic fractures
<Request To="HealthPAC" For="Subsidy" Form="SA1126"> <Title> <range>Modavigil</range> </Title> <Case When="Initial application"> <math> <apply> <and/> <ci type="logical" class="Indication">The patient has a diagnosis of narcolepsy and has excessive daytime sleepiness associated with narcolepsy occurring almost daily for three months or more</ci> <apply> <or/> <ci type="logical" class="Indication">The patient has a multiple sleep latency test with a mean sleep latency of less than or equal to 10 minutes and 2 or more sleep onset rapid eye movement periods</ci> <ci type="logical" class="Indication">The patient has at least one of: cataplexy, sleep paralysis or hypnagogic hallucinations</ci> </apply> <apply> <or/> <ci type="logical" class="Indication">An effective dose of a subsidised formulation of methylphenidate or dexamphetamine has been trialled and discontinued because of intolerabl
<Request To="HealthPAC" For="Subsidy" Form="SA1099"> <Title> <range>Paediatric Product For Children With Chronic Renal Failure<instance>Kindergen</instance></range> </Title> <Case When="Initial application"> <math> <ci type="logical" class="Indication">The patient is a child (up to 18 years) with acute or chronic kidney disease</ci> </math> <Applicant>dietitian</Applicant> <Applicant>relevant specialist</Applicant> <Applicant>vocationally registered general practitioner</Applicant> <Term Measure="year">3</Term> </Case> <Case When="Renewal" Form="SA0606 SA1099"> <math> <apply> <and/> <ci type="logical" class="Indication">The treatment remains appropriate and the patient is benefiting from treatment</ci> <ci type="text" class="Endorsement">General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted</ci> </apply> </mat
<Request To="HealthPAC" For="Subsidy" Form="SA1381"> <Title> <range>Fat Modified Products<instance>Monogen</instance></range> </Title> <Case When="Initial application"> <math> <apply> <or/> <ci type="logical" class="Indication">Patient has metabolic disorders of fat metabolism</ci> <ci type="logical" class="Indication">Patient has a chyle leak</ci> <ci type="logical" class="Indication">Modified as a modular feed for adults</ci> </apply> </math> <Applicant>dietitian</Applicant> <Applicant>relevant specialist</Applicant> <Applicant>vocationally registered general practitioner</Applicant> <Term Measure="year">1</Term> </Case> <Case When="Renewal" Form="SA0593 SA0615 SA1096 SA1381"> <math> <apply> <and/> <ci type="logical" class="Indication">The treatment remains appropriate and the patient is benefiting from treatment</ci> <ci type="text" class="Endorsement">General Practitio
<Request To="HealthPAC" For="Subsidy" Form="SA0782"> <Title> <range>Levonorgestrel &#8211; releasing intrauterine system 20mcg/24 hr</range> </Title> <Case When="Initial application" Category="No previous use"> <math> <apply> <and/> <ci type="logical" class="Indication">The patient has a clinical diagnosis of heavy menstrual bleeding</ci> <ci type="logical" class="Trial">The patient has failed to respond to or is unable to tolerate other appropriate pharmaceutical therapies as per the Heavy Menstrual Bleeding Guidelines</ci> <apply> <or/> <apply> <lt/> <ci type="real" class="test">serum ferritin level</ci> <cn>16<mi> mcg/l (within the last 12 months)</mi></cn> </apply> <apply> <lt/> <ci type="real" class="test">haemoglobin level</ci> <cn>120<mi> g/l</mi></cn> </apply> </apply> </apply> </math>
<Request To="HealthPAC" For="Subsidy" Form="SA0954"> <Title> <range>Acitretin</range> </Title> <Case When="Initial application"> <math> <apply> <and/> <ci type="logical" class="Indication">Applicant is a vocationally registered dermatologist, vocationally registered general practitioner, or nurse practitioner working in a relevant scope of practice</ci> <ci type="logical" class="Indication">Applicant has an up to date knowledge of the treatment options for psoriasis and of disorders of keratinisation and is aware of the safety issues around acitretin and is competent to prescribe acitretin</ci> <apply> <or/> <ci type="logical" class="Indication">Patient is female and has been counselled and understands the risk of teratogenicity if acitretin is used during pregnancy and the applicant has ensured that the possibility of pregnancy has been excluded prior to the commencement of the treatment and that the patient is informed that
<Request To="HealthPAC" For="Subsidy" Form="SA1155"> <Title> <range>Budesonide - Cap 3 mg Controlled Release</range> </Title> <Case When="Initial application" Category="Crohn's disease"> <math> <apply> <and/> <ci type="logical" class="Indication">Mild to moderate ileal, ileocaecal or proximal Crohn's disease</ci> <apply> <or/> <ci type="logical" class="Indication">Diabetes</ci> <ci type="logical" class="Indication">Cushingoid habitus</ci> <ci type="logical" class="Indication">Osteoporosis where there is significant risk of fracture</ci> <ci type="logical" class="Indication">Severe acne following treatment with conventional corticosteroid therapy</ci> <ci type="logical" class="Indication">History of severe psychiatric problems associated with corticosteroid treatment</ci> <ci type="logical" class="Indication">History of major mental illness (such as bipolar affective disorder) where
<Request To="HealthPAC" For="Subsidy" Form="SA1421"> <Title> <range>Montelukast</range> </Title> <Case When="Initial application" Category="Pre-school wheeze"> <math> <apply> <and/> <ci type="logical" class="Indication">To be used for the treatment of intermittent severe wheezing (possibly viral) in children under 5 years</ci> <ci type="logical" class="Indication">The patient has had at least three episodes in the previous 12 months of acute wheeze severe enough to seek medical attention</ci> </apply> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="year">1</Term> </Case> <Case When="Renewal" Category="Pre-school wheeze" Form="SA1227 SA1409 SA1421"> <math> <ci type="logical" class="Indication">The treatment remains appropriate and the patient is benefiting from treatment</ci> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="year">2</Term> </Case> <Case
<Request To="HealthPAC" For="Subsidy" Form="SA1196"> <Title> <range>Paediatric enteral feed with fibre 0.75 kcal/ml<instance>Nutrini Low Energy Multi Fibre</instance></range> </Title> <Case When="Initial application"> <math overflow="scroll"> <apply> <and/> <ci type="logical" class="Indication">Child aged one to eight years</ci> <ci type="logical" class="Indication">The child has a low energy requirement but normal protein and micronutrient requirements</ci> </apply> </math> <Applicant>dietitian</Applicant> <Applicant>relevant specialist</Applicant> <Applicant>vocationally registered general practitioner</Applicant> <Term Measure="year">1</Term> </Case> <Case When="Renewal" Form="SA1196"> <math overflow="scroll"> <apply> <and/> <ci type="logical" class="Indication">The treatment remains appropriate and the patient is benefiting from treatment</ci> <ci type="text" class="Endorsement
<Request To="HealthPAC" For="Subsidy" Form="SA1225"> <Title> <range>Ivermectin</range> </Title> <Case When="Initial application" Category="Scabies"> <math> <apply> <and/> <ci type="logical" class="Indication">Applying clinician has discussed the diagnosis of scabies with a dermatologist, infectious disease physician or clinical microbiologist</ci> <apply> <or/> <apply> <and/> <ci type="logical" class="Indication">The patient is in the community</ci> <apply> <or/> <ci type="logical" class="Indication">Patient has a severe scabies hyperinfestation (Crusted/ Norwegian scabies)</ci> <ci type="logical" class="Indication">The community patient is physically or mentally unable to comply with the application instructions of topical therapy</ci> <ci type="logical" class="Indication">The patient has previously tried and failed to clear infestation
<Request To="HealthPAC" For="Subsidy" Form="SA1322"> <Title> <range>Itraconazole</range> </Title> <Case When="Initial application"> <math> <ci type="logical" class="Indication">The patient has a congenital immune deficiency</ci> </math> <Applicant>infectious disease specialist</Applicant> <Applicant>clinical microbiologist</Applicant> <Applicant>clinical immunologist</Applicant> <Applicant Referring="infectious disease physician, clinical microbiologist or clinical immunologist">any relevant practitioner</Applicant> <Term Measure="month">6</Term> </Case> <Case When="Renewal" Form="SA1322"> <math> <ci type="logical" class="Indication">The treatment remains appropriate and the patient is benefitting from the treatment</ci> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="month">6</Term> </Case></Request>
<Request To="HealthPAC" For="Subsidy" Form="SA1223"> <Title> <range>Candesartan</range> </Title> <Case When="Initial application" Category="ACE inhibitor intolerance"> <math> <apply> <or/> <ci type="logical" class="Indication">Patient has persistent ACE inhibitor induced cough that is not resolved by ACE inhibitor retrial (same or new ACE inhibitor)</ci> <ci type="logical" class="Indication">Patient has a history of angioedema</ci> </apply> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="patient's lifetime"/> </Case> <Case When="Initial application" Category="Unsatisfactory response to ACE inhibitor"> <math> <ci type="logical" class="Indication">patient is not adequately controlled on maximum tolerated dose of an ACE inhibitor</ci> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="patient's lifetime"/> </Case></Request>
<Request To="HealthPAC" For="Subsidy" Form="SA0922"> <Title> <range>Erythropoietin</range> </Title> <Case When="Initial application"> <math> <apply> <and/> <apply> <and/> <ci type="logical" class="Indication">patient in chronic renal failure</ci> <apply> <leq/> <ci type="real" class="test">Haemoglobin</ci> <cn>100<mi>g/L</mi></cn> </apply> </apply> <apply> <or/> <apply> <and/> <ci type="logical" class="Indication">patient is not diabetic</ci> <apply> <leq/> <ci type="real" class="test">glomerular filtration rate</ci> <cn>30<mi>ml/min</mi></cn> </apply> </apply> <apply> <and/> <ci type="logical" class="Indication">patient is diabetic</ci> <apply> <leq/> <ci type
<Request To="HealthPAC" For="Subsidy" Form="SA1198"> <Title> <range>Preterm post-discharge infant formula powder<instance>S-26 Gold Premgro</instance></range> </Title> <Case When="Initial application"> <math overflow="scroll"> <apply> <and/> <ci type="logical" class="Indication">The infant was born before 33 weeks gestation or weighed less than 1.5 kg at birth</ci> <apply> <or/> <ci type="logical" class="Indication">The infant has faltering growth (downward crossing of percentiles)</ci> <ci type="logical" class="Indication">The infant is not maintaining, or is considered unlikely to maintain, adequate growth on standard infant formula</ci> </apply> </apply> </math> <Applicant>dietitian</Applicant> <Applicant>relevant specialist</Applicant> <Applicant>vocationally registered general practitioner</Applicant> <Term Measure="month">6</Term> </Case></Request>
<Request To="HealthPAC" For="Subsidy" Form="SA1124"> <Title> <range>Thalidomide</range> </Title> <Case When="Initial application"> <math> <apply> <or/> <ci type="logical" class="indication">The patient has multiple myeloma</ci> <ci type="logical" class="indication">The patient has systemic AL amyloidosis*</ci> </apply> </math> <Applicant>relevant specialist</Applicant> <Applicant Referring="relevant specialist">medical practitioner</Applicant> <Term Measure="month">12</Term> </Case> <Case When="Renewal" Form="SA1124 SA0817 SA0882"> <math> <ci type="logical" class="indication">The patient has obtained a response from treatment during the initial approval period</ci> </math> <Applicant>relevant specialist</Applicant> <Applicant Referring="relevant specialist">medical practitioner</Applicant> <Term Measure="patient's lifetime"/> </Case> <Note> <Para>Prescription must be written by a re
<Request To="HealthPAC" For="Subsidy" Form="SA1260"> <Title> <range>Perhexiline Maleate</range> </Title> <Case When="Initial application"> <math> <apply> <and/> <ci type="logical" class="Indication">Patient has refractory angina</ci> <ci type="logical" class="Trial">Patient is on the maximal tolerated dose of a beta-blocker, a calcium channel blocker and a long acting nitrate</ci> </apply> </math> <Applicant>cardiologist</Applicant> <Applicant>general physician</Applicant> <Term Measure="year">2</Term> </Case> <Case When="Renewal" Form="SA0256 SA1260"> <math> <ci type="logical" class="Indication">The treatment remains appropriate and the patient is benefiting from treatment</ci> </math> <Applicant>cardiologist</Applicant> <Applicant Referring="cardiologist">any relevant practitioner</Applicant> <Term Measure="year">2</Term> </Case></Request>
<Request To="HealthPAC" For="Subsidy" Form="SA1285"> <Title> <range>Posaconazole </range> </Title> <Case When="Initial application"> <math> <apply> <or/> <ci type="logical" class="Indication">Patient has acute myeloid leukaemia and is to be treated with high dose remission induction, re-induction or consolidation chemotherapy</ci> <ci type="logical" class="Indication">Patient has received a stem cell transplant and has graft versus host disease and is on significant immunosuppressive therapy*</ci> </apply> </math> <Applicant>haematologist</Applicant> <Applicant>infectious disease specialist</Applicant> <Term Measure="week">6</Term> </Case> <Case When="Renewal" Form="SA1285"> <math> <apply> <or/> <ci type="logical" class="Indication">Patient has acute myeloid leukaemia and is to be treated with high dose remission induction, re-induction or consolidation therapy</ci> <ci type="logical" c
<Request To="HealthPAC" For="Subsidy" Form="SA1293"> <Title> <range>Sildenafil</range> </Title> <Case When="Initial application" Category="Raynaud&#8217;s Phenomenon* - for Pulmonary Arterial Hypertension see note below)"> <math> <apply> <and/> <ci type="logical" class="Indication">Patient has Raynaud&#8217;s Phenomenon*</ci> <ci type="logical" class="Indication">Patient has severe digital ischaemia (defined as severe pain requiring hospital admission or with a high likelihood of digital ulceration; digital ulcers; or gangrene)</ci> <ci type="logical" class="Indication">Patient is following lifestyle management (avoidance of cold exposure, sufficient protection, smoking cessation support, avoidance of sympathomimetic drugs) </ci> <ci type="logical" class="Indication">Patient is being treated with calcium channel blockers and nitrates (or these are contraindicated/not tolerated)</ci> </apply> </math> <Applicant>any relevant
<Request To="HealthPAC" For="Subsidy" Form="SA1061"> <Title> <range>Venlafaxine</range> </Title> <Case When="Initial application"> <math> <apply> <and/> <ci type="logical" class="Indication">The patient has 'treatment-resistant' depression</ci> <apply> <or/> <ci type="logical" class="Trial">The patient must have had a trial of two different antidepressants and have had an inadequate response from an adequate dose over an adequate period of time (usually at least four weeks)</ci> <apply> <and/> <ci type="logical" class="Indication">The patient is currently a hospital in-patient as a result of an acute depressive episode</ci> <ci type="logical" class="Trial">The patient must have had a trial of one other antidepressant and have had an inadequate response from an adequate dose over an adequate period of time</ci> </apply> </apply> </apply> </math> <Appl
<Request To="HealthPAC" For="Subsidy" Form="SA1411"> <Title> <range>Erlotinib</range> </Title> <Case When="Initial application"> <math> <apply> <or/> <apply> <and/> <ci type="logical" class="Indication">Patient has locally advanced or metastatic, unresectable, non-squamous Non Small Cell Lung Cancer (NSCLC)</ci> <ci type="logical" class="Indication">There is documentation confirming that the disease expresses activating mutations of EGFR tyrosine kinase</ci> <apply> <or/> <ci type="logical" class="Indication">Patient is treatment naive</ci> <apply> <and/> <ci type="logical" class="Indication">Patient has documented disease progression following treatment with first line platinum based chemotherapy</ci> <ci type="logical" class="Indication">Patient has not received prior treatment with gefitinib</ci> </apply> </apply>
<Request To="HealthPAC" For="Alternate Subsidy" Form="SA1018"> <Title> <range>Hormone Replacement Therapy - Systemic</range> </Title> <Case When="Initial application"> <math> <apply> <or/> <ci type="logical" class="Indication">acute or significant liver disease - where oral oestrogens are contraindicated as determined by a gastroenterologist or general physician. The applicant must keep written confirmation from such a specialist with the patient's record</ci> <ci type="logical" class="Indication">oestrogen induced hypertension requiring antihypertensive therapy - documented evidence must be kept on file that raised blood pressure levels or inability to control blood pressure adequately occurred post oral oestrogens</ci> <ci type="logical" class="Indication">hypertriglyceridaemia - documented evidence must be kept on file that triglyceride levels increased to at least 2 &#215; normal triglyceride levels post oral oestrogens</ci> <ci type=
<Request To="HealthPAC" For="Subsidy" Form="SA1095"> <Title> <range>Diabetic products<instance>Diason RTH</instance><instance>Glucerna Select RTH</instance><instance>Diasip</instance><instance>Glucerna Select</instance><instance>Resource Diabetic</instance></range> </Title> <Case When="Initial application"> <math> <ci type="logical" class="Indication">The patient is a type I or and II diabetic who is suffering weight loss and malnutrition that requires nutritional support</ci> </math> <Applicant>dietitian</Applicant> <Applicant>relevant specialist</Applicant> <Applicant>vocationally registered general practitioner</Applicant> <Term Measure="year">1</Term> </Case> <Case When="Renewal" Form="SA0594 SA1095"> <math> <apply> <and/> <ci type="logical" class="Indication">The treatment remains appropriate and the patient is benefiting from treatment</ci> <ci type="text" class="Endorsement">General Practitioners must includ
<Request To="HealthPAC" For="Subsidy" Form="SA1449"> <Title> <range>Adalimumab</range> </Title> <Case When="Initial application" Category="rheumatoid arthritis"> <math> <apply> <or/> <apply> <and/> <ci type="logical" class="Indication">The patient has had an initial Special Authority approval for etanercept for rheumatoid arthritis</ci> <apply> <or/> <ci type="logical" class="Indication">The patient has experienced intolerable side effects from etanercept</ci> <ci type="logical" class="Indication">The patient has received insufficient benefit from etanercept to meet the renewal criteria for etanercept for rheumatoid arthritis</ci> </apply> </apply> <apply> <and/> <ci type="logical" class="Indication">Patient has had severe and active erosive rheumatoid arthritis for six months duration or longer</ci> <ci type="logical" class="Treatmen
<Request To="HealthPAC" For="Subsidy" Form="SA1388"> <Title> <range>Preservative Free Ocular Lubricants</range> </Title> <Case When="Initial application"> <math> <apply> <and/> <ci type="logical" class="Indication">Confirmed diagnosis by slit lamp of severe secretory dry eye</ci> <apply> <or/> <ci type="logical" class="Indication">Patient is using eye drops more than four times daily on a regular basis</ci> <ci type="logical" class="Indication">Patient has had a confirmed allergic reaction to preservative in eye drop</ci> </apply> </apply> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="month">12</Term> </Case> <Case When="Renewal" Form="SA1388"> <math> <ci type="logical" class="Indication">The patient continues to require lubricating eye drops and has benefited from treatment</ci> </math> <Applicant>any relevant practitioner</Applicant>
<Request To="HealthPAC" For="Subsidy" Form="SA1201"> <Title> <range>Prasugrel</range> </Title> <Case When="Initial application" Category="coronary angioplasty and bare metal stent"> <math> <ci type="logical" class="Treatment">The patient has undergone coronary angioplasty in the previous 4 weeks and is clopidogrel-allergic*</ci> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="month">6</Term> </Case> <Case When="Initial application" Category="drug eluting stent"> <math> <ci type="logical" class="Treatment">The patient has had a drug-eluting cardiac stent inserted in the previous 4 weeks and is clopidogrel-allergic*</ci> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="month">12</Term> </Case> <Case When="Initial application" Category="stent thromobosis"> <math> <ci type="logical" class="Treatment">patient has experienced cardiac stent thrombosis whilst on clopidogrel</ci>
<Request To="HealthPAC" For="Subsidy" Form="SA1325"> <Title> <range>Pegaspargase</range> </Title> <Case When="Initial application"> <math> <apply> <and/> <ci type="logical" class="Indication">The patient has newly diagnosed acute lymphoblastic leukaemia</ci> <ci type="logical" class="Indication">Pegaspargase to be used with a contemporary intensive multi-agent chemotherapy treatment protocol</ci> <ci type="logical" class="Indication">Treatment is with curative intent</ci> </apply> </math> <Applicant>relevant specialist</Applicant> <Applicant Referring="relevant specialist">medical practitioner</Applicant> <Term Measure="month">12</Term> </Case> <Case When="Renewal" Form="SA1325"> <math> <apply> <and/> <ci type="logical" class="Indication">The patient has relapsed acute lymphoblastic leukaemia</ci> <ci type="logical" class="Indication">Pegaspargase to be used with a contemporar
<Request To="HealthPAC" For="Alternate Subsidy" Form="SA0500"> <Title><range>Combined oral contraceptives</range><range>Progestogen-only contraceptives</range> (Circle one)</Title> <Case When="Initial application"> <math> <apply> <and/> <apply> <or/> <ci type="logical" class="Target">Patient is on a Social Welfare benefit</ci> <ci type="logical" class="Target">Patient has an income no greater than the benefit</ci> </apply> <ci type="logical" class="Trial">Has tried at least one of the fully funded options and has been unable to tolerate it</ci> </apply> </math> <Applicant>medical practitioner</Applicant> <Term Measure="year">2</Term> </Case> <Case When="Renewal" Form="SA0265 SA0500"> <math> <apply> <or/> <ci type="logical" class="Target">Patient is on a Social Welfare benefit</ci> <ci type="logical" class="Target">Patient has an income no greater than the be
<Request To="HealthPAC" For="Subsidy" Form="SA1374"> <Title> <range>Fat<instance>Calogen</instance><instance>Liquigen</instance><instance>MCT oil (Nutricia)</instance></range> </Title> <Case When="Initial application" Category="Inborn errors of metabolism"> <math> <ci type="logical" class="Indication">The patient has inborn errors of metabolism</ci> </math> <Applicant>dietitian</Applicant> <Applicant>relevant specialist</Applicant> <Applicant>vocationally registered general practitioner</Applicant> <Term Measure="year">3</Term> </Case> <Case When="Initial application" Category="Indications other than inborn errors of metabolism"> <math> <apply> <or/> <ci type="logical" class="Indication">faltering growth in an infant/child</ci> <ci type="logical" class="Indication">bronchopulmonary dysplasia</ci> <ci type="logical" class="Indication">fat malabsorption</ci> <ci type="logical" class="Indication">lym
<Request To="HealthPAC" For="Subsidy" Form="SA1375"> <Title> <range>Protein<instance>Protifar</instance><instance>Promod</instance><instance>Resource Beneprotein</instance></range> </Title> <Case When="Initial application"> <math> <apply> <or/> <ci type="logical" class="Indication">protein losing enteropathy</ci> <ci type="logical" class="Indication">high protein needs</ci> <ci type="logical" class="Indication">for use as a component in a modular formula</ci> </apply> </math> <Applicant>dietitian</Applicant> <Applicant>relevant specialist</Applicant> <Applicant>vocationally registered general practitioner</Applicant> <Term Measure="year">1</Term> </Case> <Case When="Renewal" Form="SA0582 SA1093 SA1375"> <math> <apply> <and/> <ci type="logical" class="Indication">The treatment remains appropriate and the patient is benefiting from treatment</ci> <ci type="text" class="Endor
<Request To="HealthPAC" For="Subsidy" Form="SA1266"> <Title> <range>Sunitinib</range> </Title> <Case When="Initial application" Category="RCC"> <math> <apply> <and/> <ci type="logical" class="Indication">The patient has metastatic renal cell carcinoma</ci> <apply> <or/> <ci type="logical" class="Trial">The patient is treatment naive</ci> <ci type="logical" class="Trial">The patient has only received prior cytokine treatment</ci> <ci type="logical" class="Trial">The patient has only received prior treatment with an investigational agent within the confines of a bona fide clinical trial which has Ethics Committee approval</ci> <apply> <and/> <ci type="logical" class="Trial">The patient has discontinued pazopanib within 3 months of starting treatment due to intolerance</ci> <ci type="logical" class="Trial">The cancer did not progress whilst on pazopanib</ci>
<Request To="HealthPAC" For="Subsidy" Form="SA1273"> <Title> <range>Voriconazole</range> </Title> <Case When="Initial application" Category="invasive fungal infection"> <math> <apply> <and/> <ci type="logical" class="Indication">Patient is immunocompromised</ci> <ci type="logical" class="Indication">Applicant is part of a multidisciplinary team including an infectious disease specialist</ci> <apply> <or/> <ci type="logical" class="Indication">Patient has proven or probable invasive aspergillus infection</ci> <ci type="logical" class="Indication">Patient has possible invasive aspergillus infection</ci> <ci type="logical" class="Indication">Patient has fluconazole resistant candidiasis</ci> <ci type="logical" class="Indication">Patient has mould strain such as Fusarium spp. and Scedosporium spp</ci> </apply> </apply> </math> <Applicant>haematologist</Applicant> <App
<Request To="HealthPAC" For="Subsidy" Form="SA1228"> <Title> <range>Standard Supplements<instance>Ensure</instance><instance>Fortisip</instance><instance>Isosource</instance><instance>Jevity</instance><instance>Nutrison</instance><instance>Osmolite</instance><instance>Sustagen</instance></range> </Title> <Case When="Initial application" Category="Children"> <math> <apply> <and/> <ci type="logical" class="Indication">The patient is under 18 years of age</ci> <apply> <or/> <ci type="logical" class="Indication">The patient has a condition causing malabsorption</ci> <ci type="logical" class="Indication">The patient has failure to thrive</ci> <ci type="logical" class="Indication">The patient has increased nutritional requirements</ci> </apply> <ci type="logical" class="Indication">Nutrition goal has been set (eg reach a specific weight or BMI)</ci> </apply> </math> <Applicant>dietitia
<Request To="HealthPAC" For="Subsidy" Form="SA1046"> <Title> <range>Ezetimibe with Simvastatin<instance>Vytorin</instance></range> </Title> <Case When="Initial application"> <math> <apply> <and/> <ci type="logical" class="Indication">Patient has a calculated absolute risk of cardiovascular disease of at least 15% over 5 year</ci> <ci type="logical" class="Trial">Patient's LDL cholesterol is 2.0 mmol/litre or greater</ci> <ci type="logical" class="Trial">The patient has not reduced their LDL cholesterol to less than 2.0 mmol/litre with the use of the maximal tolerated dose of atorvastatin</ci> </apply> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="year">2</Term> <Note> <Para>A patient who has failed to reduce their LDL cholesterol to &#8804; 2.0 mmol/litre with the use of a less potent statin should use a more potent statin prior to consideration being given to the use of non-statin therapi
<Request To="Cystic Fibrosis Advisory Panel" For="Subsidy" Form="SA0611"> <Title> <range>Dornase Alfa</range> </Title> <Case When="Initial application"> <math> <ci/> </math> <Applicant>medical practitioner</Applicant> <Term Measure="year">1</Term> </Case> <Note> <Para>Application details may be obtained from PHARMAC's website <a href="http://www.pharmac.govt.nz/">http://www.pharmac.govt.nz</a> or:</Para> <Table> <TR> <TD> <Para>The Co-ordinator, Cystic Fibrosis Advisory Panel</Para> </TD> <TD> <Para>Phone: (04) 460 4990</Para> </TD> </TR> <TR> <TD> <Para>PHARMAC, PO Box 10 254</Para> </TD> <TD> <Para>Facsimile: (04) 916 7571</Para> </TD> </TR> <TR> <TD> <Para>Wellington</Para> </TD> <TD> <Para>Email: <a href="mailto:CFPanel@pharmac.govt.nz">CFPanel@pharmac.
<Request To="HealthPAC" For="Subsidy" Form="SA1451"> <Title> <range>Somatropin</range> </Title> <Case When="Initial application" Category="growth hormone deficiency in children"> <math> <apply> <or/> <apply> <and/> <ci type="logical" class="Indication">Growth hormone deficiency causing symptomatic hypoglycaemia, or with other significant growth hormone deficient sequelae (e.g. cardiomyopathy, hepatic dysfunction) and diagnosed with GH &lt; 5 mcg/l on at least two random blood samples in the first 2 weeks of life, or from samples during established hypoglycaemia (whole blood glucose &lt; 2 mmol/l using a laboratory device)</ci> </apply> <apply> <and/> <ci type="logical" class="Indication">Height velocity &lt; 25th percentile for age adjusted for bone age/pubertal status if appropriate over 6 or 12 months using the standards of Tanner and Davies (1985)</ci> <ci type="logical" class="Indication
<Request To="HealthPAC" For="Subsidy" Form="SA1139"> <Title> <range>Teriparatide</range> </Title> <Case When="Initial application"> <math> <apply> <and/> <ci type="logical" class="indication">The patient has severe, established osteoporosis</ci> <ci type="logical" class="indication">The patient has a documented T-score less than or equal to -3.0 (see Notes)</ci> <ci type="logical" class="indication">The patient has had two or more fractures due to minimal trauma</ci> <ci type="logical" class="indication">The patient has experienced at least one symptomatic new fracture after at least 12 months&#8217; continuous therapy with a funded antiresorptive agent at adequate doses (see Notes)</ci> </apply> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="month">18</Term> </Case> <Note> <List Type="Alpha"> <Item> <Para>The bone mineral density (BMD) measurement used to derive the
<Request To="PHARMAC" For="Subsidy" Form="SA1291"> <Title> <range>Optium blood glucose test strips</range> </Title> <Case When="Initial application"> <math> <ci type="logical" class="Indication">Patient identified as eligible for subsidy for FreeStyle Optium blood glucose test strips</ci> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="patient's lifetime"/> </Case> <Note> <Para>Application details may be obtained from PHARMAC's website http://www.pharmac.govt.nz and can be sent to:</Para> <Table> <TR> <TD> <Para>PHARMAC</Para> </TD> <TD> <Para/> </TD> </TR> <TR> <TD> <Para>PO Box 10 254</Para> </TD> <TD> <Para>Facsimile: (04) 974 4788</Para> </TD> </TR> <TR> <TD> <Para>Wellington</Para> </TD> <TD> <Para>Email: <a href="mailto:bgstrip
<Request To="HealthPAC" For="Subsidy" Form="SA1098"> <Title> <range>Paediatric Product For Children Awaiting Liver Transplant<instance>Heparon Junior</instance></range> </Title> <Case When="Initial application"> <math> <ci type="logical" class="Indication">The patient is a child (up to 18 years) who requires a liver transplant</ci> </math> <Applicant>dietitian</Applicant> <Applicant>relevant specialist</Applicant> <Applicant>vocationally registered general practitioner</Applicant> <Term Measure="year">3</Term> </Case> <Case When="Renewal" Form="SA0607 SA1098"> <math> <apply> <and/> <ci type="logical" class="Indication">The treatment remains appropriate and the patient is benefiting from treatment</ci> <ci type="text" class="Endorsement">General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted</ci> </apply> </math
<Request To="HealthPAC" For="Subsidy" Form="SA0845"> <Title> <range>Enfuvirtide</range> </Title> <Case When="Initial application"> <math> <apply> <and/> <ci type="logical" class="Indication">Confirmed HIV infection</ci> <ci type="logical" class="Indication">Enfuvirtide to be given in combination with optimized background therapy (including at least 1 other antiretroviral drug that the patient has never previously been exposed to) for treatment failure</ci> <apply> <or/> <ci type="logical" class="Indication">Patient has evidence of HIV replication, despite ongoing therapy</ci> <ci type="logical" class="Indication">Patient has treatment-limiting toxicity to previous antiretroviral agents</ci> </apply> <ci type="logical" class="Indication">Previous treatment with 3 different antiretroviral regimens has failed</ci> <apply> <and/> <ci type="logical" class="Indication">Prev
<Request To="HealthPAC" For="Subsidy" Form="SA0955"> <Title> <range>Isotretinoin</range> </Title> <Case When="Initial application"> <math> <apply> <and/> <ci type="logical" class="Indication">Patient has had an adequate trial on other available treatments and has received an inadequate response from these treatments or these are contraindicated</ci> <ci type="logical" class="Indication">Applicant is a vocationally registered dermatologist, vocationally registered general practitioner, or nurse practitioner working in a relevant scope of practice</ci> <ci type="logical" class="Indication">Applicant has an up to date knowledge of the treatment options for acne and is aware of the safety issues around isotretinoin and is competent to prescribe isotretinoin</ci> <apply> <or/> <ci type="logical" class="Indication">Patient is female and has been counselled and understands the risk of teratogenicity if isotretinoin is used d
<Request To="HealthPAC" For="Subsidy" Form="SA0994"> <Title> <range>Mirtazapine</range> </Title> <Case When="Initial application"> <math> <apply> <and/> <ci type="logical" class="Indication">The patient has a severe major depressive episode</ci> <apply> <or/> <ci type="logical" class="Trial">The patient must have had a trial of two different antidepressants and was unable to tolerate the treatments or failed to respond to an adequate dose over an adequate period of time (usually at least four weeks)</ci> <apply> <and/> <ci type="logical" class="Indication">The patient is currently a hospital in-patient as a result of an acute depressive episode</ci> <ci type="logical" class="Trial">The patient must have had a trial of one other antidepressant and either could not tolerate it or failed to respond to an adequate dose over an adequate period of time</ci> </apply> </appl
<Request To="HealthPAC" For="Subsidy" Form="SA1404"> <Title> <range>Valganciclovir</range> </Title> <Case When="Initial application" Category="transplant cytomegalovirus prophylaxis"> <math> <ci type="logical" class="Indication">the patient has undergone a solid organ transplant and requires valganciclovir for CMV prophylaxis</ci> </math> <Applicant>relevant specialist</Applicant> <Term Measure="month">3</Term> </Case> <Case When="Renewal" Form="SA1274 SA1404" Category="transplant cytomegalovirus prophylaxis"> <math> <apply> <and/> <ci type="logical" class="Indication">Patient has undergone a solid organ transplant and received anti-thymocyte globulin and requires valganciclovir therapy for CMV prophylaxis</ci> <ci type="logical" class="Indication">Patient is to receive a maximum of 90 days of valganciclovir prophylaxis following anti-thymocyte globulin</ci> </apply> </math> <Applicant>relevant specialist</A
<Request To="HealthPAC" For="Subsidy" Form="SA1138"> <Title> <range>Raloxifene</range> </Title> <Case When="Initial application"> <math> <apply> <or/> <ci type="logical" class="indication">History of one significant osteoporotic fracture demonstrated radiologically and documented bone mineral density (BMD) &#8805;2.5 standard deviations below the mean normal value in young adults (i.e. T-Score &#8804; -2.5) (see Notes)</ci> <ci type="logical" class="indication">History of one significant osteoporotic fracture demonstrated radiologically, and either the patient is elderly, or densitometry scanning cannot be performed because of major logistical, technical or pathophysiological reasons. It is unlikely that this provision would apply to many patients under 75 years of age</ci> <ci type="logical" class="indication">History of two significant osteoporotic fractures demonstrated radiologically</ci> <ci type="logical" class="indication">Documente
<Request To="HealthPAC" For="Subsidy" Form="SA1125"> <Title> <range>Lacosamide</range> </Title> <Case When="Initial application"> <math> <apply> <and/> <ci type="logical" class="Indication">Patient has partial-onset epilepsy</ci> <ci type="logical" class="Trial">Seizures are not adequately controlled by, or patient has experienced unacceptable side effects from, optimal treatment with all of the following: sodium valproate, topiramate, levetiracetam and any two of carbamazepine, lamotrigine and phenytoin sodium (see Note)</ci> </apply> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="month">15</Term> <Note> <Para>"Optimal treatment" is defined as treatment which is indicated and clinically appropriate for the patient, given in adequate doses for the patient's age, weight and other features affecting the pharmacokinetics of the drug with good evidence of compliance. Women of childbearing age are not re
<Request To="HealthPAC" For="Subsidy" Form="SA1376"> <Title> <range>Carbohydrate and Fat<instance>Duocal Super Soluble Powder</instance></range> </Title> <Case When="Initial application" Category="Cystic fibrosis"> <math> <apply> <and/> <ci type="logical" class="Indication">Infant or child aged four years or under</ci> <ci type="logical" class="Indication">cystic fibrosis</ci> </apply> </math> <Applicant>dietitian</Applicant> <Applicant>relevant specialist</Applicant> <Applicant>vocationally registered general practitioner</Applicant> <Term Measure="year">3</Term> </Case> <Case When="Initial application" Category="Indications other than cystic fibrosis"> <math> <apply> <and/> <ci type="logical" class="Indication">infant or child aged four years or under</ci> <apply> <or/> <ci type="logical" class="Indication">cancer in children</ci> <ci type="logica
<Request To="HealthPAC" For="Subsidy" Form="SA0895"> <Title> <range>Pilocarpine &#8211; Eye drops 2% single dose</range> </Title> <Case When="Initial application"> <math> <apply> <or/> <ci type="logical" class="Indication">Patient has to use an unpreserved solution due to an allergy to the preservative</ci> <ci type="logical" class="Indication">Patient wears soft contact lenses</ci> </apply> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="year">2</Term> <Note> <Para>Minims for a general practice are considered to be &#8220;tools of trade&#8221; and are not approved as special authority items.</Para> </Note> </Case> <Case When="Renewal" Form="SA0121 SA0895"> <math> <ci type="logical" class="Indication">The treatment remains appropriate and the patient is benefiting from treatment</ci> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="year">2<
<Request To="HealthPAC" For="Subsidy" Form="SA1408"> <Title> <range>Naltrexone</range> </Title> <Case When="Initial application"> <math> <apply> <and/> <ci type="logical" class="Indication">Patient is currently enrolled in a recognised comprehensive treatment programme for alcohol dependence</ci> <ci type="logical" class="Therapy">Applicant works in or with a community Alcohol and Drug Service contracted to one of the District Health Boards or accredited against the New Zealand Alcohol and Other Drug Sector Standard or the National Mental Health Sector Standard</ci> </apply> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="month">6</Term> </Case> <Case When="Renewal" Form="SA0714 SA0909 SA1397 SA1408"> <math> <apply> <and/> <ci type="logical" class="Indication">Compliance with the medication (prescriber determined)</ci> <apply> <or/> <ci type="log
<Request To="HealthPAC" For="Subsidy" Form="SA1174"> <Title> <range>Enoxaparin sodium</range> </Title> <Case When="Initial application" Category="Pregnancy or Malignancy"> <math> <apply> <or/> <ci type="logical" class="Indication">Low molecular weight heparin treatment is required during a patients pregnancy</ci> <ci type="logical" class="Treatment">For the treatment of venous thromboembolism where the patient has a malignancy</ci> </apply> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="year">1</Term> </Case> <Case When="Initial application" Category="Venous thromboembolism other than in pregnancy or malignancy"> <math> <apply> <or/> <ci type="logical" class="Indication">For the short-term treatment of venous thromboembolism prior to establishing a therapeutic INR with oral anti-coagulant treatment</ci> <ci type="logical" class="Treatment">For the prophylaxis and tre
<Request To="HealthPAC" For="Subsidy" Form="SA1416"> <Title> <range>Atomoxetine</range> </Title> <Case When="Initial application"> <math> <apply> <and/> <ci type="logical" class="Indication">Patient has ADHD (Attention Deficit and Hyperactivity Disorder) diagnosed according to DSM-IV or ICD 10 criteria</ci> <ci type="logical" class="Indication">Once-daily dosing</ci> <apply> <or/> <ci type="logical" class="Indication">Treatment with a subsidised formulation of a stimulant has resulted in the development or worsening of serious adverse reactions or where the combination of subsidised stimulant treatment with another agent would pose an unacceptable medical risk</ci> <ci type="logical" class="Indication">Treatment with a subsidised formulation of a stimulant has resulted in worsening of co-morbid substance abuse or there is a significant risk of diversion with subsidised stimulant therapy</ci> <ci type="log
<Request To="HealthPAC" For="Subsidy" Form="SA0927"> <Title> <range>Risperidone orally disintegrating tablets</range> </Title> <Case When="Initial application" Category="Acute situations"> <math> <apply> <and/> <ci type="logical" class="Use">For a non-adherent patient on oral therapy with standard risperidone tablets or risperidone oral liquid</ci> <ci type="logical" class="Therapy">The patient is under direct supervision for administration of medicine</ci> </apply> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="week">6</Term> </Case> <Case When="Initial application" Category="Chronic situations"> <math> <apply> <and/> <ci type="logical" class="Indication">The patient is unable to take standard risperidone tablets or oral liquid, or once stabilized refuses to take risperidone tablets or oral liquid</ci> <ci type="logical" class="Therapy">The patient is under direct
<Request To="HealthPAC" For="Subsidy" Form="SA1195"> <Title> <range>High Calorie Products<instance>Two Cal HN</instance><instance>Nutrison Concentrated</instance></range> </Title> <Case When="Initial application" Category="Cystic fibrosis"> <math> <apply> <and/> <ci type="logical" class="Indication">Cystic fibrosis</ci> <ci type="logical" class="Trial">other lower calorie products have been tried</ci> <ci type="logical" class="Indication">patient has substantially increased metabolic requirements</ci> </apply> </math> <Applicant>dietitian</Applicant> <Applicant>relevant specialist</Applicant> <Applicant>vocationally registered general practitioner</Applicant> <Term Measure="year">3</Term> </Case> <Case When="Initial application" Category="Indications other than cystic fibrosis"> <math> <apply> <and/> <apply> <or/> <ci type="logical" class="Indication">any cond
<Request To="PHARMAC" For="Subsidy" Form="SA1237"> <Title> <range>Insulin Pumps</range> </Title> <Case When="Initial application"> <math/> <Applicant>medical practitioner</Applicant> <Term Measure="year">1</Term> </Case> <Note> <Para>Application details may be obtained from PHARMAC's website <a href="http://www.pharmac.govt.nz/">http://www.pharmac.govt.nz</a> or:</Para> <Table> <TR> <TD> <Para>The IPP Co-ordinator</Para> </TD> <TD> <Para>Phone: (04) 460 4990</Para> </TD> </TR> <TR> <TD> <Para>PHARMAC</Para> </TD> <TD> <Para>Facsimile: (04) 974 7806</Para> </TD> </TR> <TR> <TD> <Para>PO Box 10 254</Para> </TD> <TD> <Para>Email: <a href="mailto:ipp@pharmac.govt.nz">ipp@pharmac.govt.nz</a></Para> </TD> </TR> <TR> <TD> <Para>Welli
<Request To="HealthPAC" For="Subsidy" Form="SA0829"> <Title> <range>Adefovir dipivoxil</range> </Title> <Case When="Initial application"> <math> <apply> <and/> <ci type="logical" class="Trial">Patient has confirmed Hepatitis B infection (HBsAg+)</ci> <mi class="heading">Documented resistance to lamivudine, defined as:</mi> <ci type="logical" class="Trial">Patient has raised serum ALT (&gt; 1 &#215; ULN)</ci> <ci type="logical" class="Trial">Patient has HBV DNA greater than 100,000 copies per mL, or viral load &#8805; 10 fold over nadir</ci> <ci type="logical" class="Trial">Detection of M204I or M204V mutation</ci> <apply> <or/> <apply> <and/> <ci type="logical" class="Trial">Patient is cirrhotic</ci> <ci type="logical" class="Trial">adefovir dipivoxil to be used in combination with lamivudine</ci> </apply> <apply> <and/>
<Request To="HealthPAC" For="Subsidy" Form="SA1379"> <Title> <range>Paediatric Products<instance>Nutrini</instance><instance>Pediasure</instance><instance>Fortini</instance></range> </Title> <Case When="Initial application"> <math> <apply> <and/> <ci type="logical" class="Indication">Child is aged one to ten years</ci> <apply> <or/> <ci type="logical" class="Indication">the child is being fed via a tube or a tube is to be inserted for the purposes of feeding</ci> <ci type="logical" class="Indication">any condition causing malabsorption</ci> <ci type="logical" class="Indication">faltering growth in an infant/child</ci> <ci type="logical" class="Indication">increased nutritional requirements</ci> <ci type="logical" class="Indication">the child is being transitioned from TPN or tube feeding to oral feeding</ci> </apply> </apply> </math> <Applicant>dietitian</Applicant>
<Request To="HealthPAC" For="Subsidy" Form="SA1382"> <Title> <range>Ticagrelor</range> </Title> <Case When="Initial application" Category="acute coronary syndrome"> <math> <apply> <and/> <ci type="logical" class="Indication">Patient has recently been diagnosed with an ST-elevation or a non-ST-elevation acute coronary syndrome</ci> <ci type="logical" class="Indication">Fibrinolytic therapy has not been given in the last 24 hours and is not planned</ci> </apply> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="month">12</Term> </Case> <Case When="Renewal" Category="subsequent acute coronary syndrome" Form="SA1382"> <math> <apply> <and/> <ci type="logical" class="Indication">Patient has recently been diagnosed with an ST-elevation or a non-ST-elevation acute coronary syndrome</ci> <ci type="logical" class="Indication">Fibrinolytic therapy has not been given in the last 24
<Request To="HealthPAC" For="Subsidy" Form="SA1383"> <Title> <range>Ursodeoxycholic Acid</range> </Title> <Case When="Initial application" Category="Alagille syndrome or progressive familial intrahepatic cholestasis"> <math> <apply> <or/> <ci type="logical" class="Indication">Patient has been diagnosed with Alagille syndrome</ci> <ci type="logical" class="Indication">Patient has progressive familial intrahepatic cholestasis</ci> </apply> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="patient's lifetime"/> </Case> <Case When="Initial application" Category="Chronic severe drug induced cholestatic liver injury"> <math> <apply> <and/> <ci type="logical" class="Indication">Patient has chronic severe drug induced cholestatic liver injury</ci> <ci type="logical" class="Indication">Cholestatic liver injury not due to Total Parenteral Nutrition (TPN) use in adults</ci>
<Request To="HealthPAC" For="Subsidy" Form="SA1192"> <Title> <range>Trastuzumab</range> </Title> <Case When="Initial application" Category="metastatic breast cancer"> <math> <apply> <or/> <apply> <and/> <ci type="logical" class="Indication">The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology)</ci> <ci type="logical" class="Treatment">The patient has not previously received lapatinib treatment for HER 2 positive metastatic breast cancer</ci> <ci type="logical" class="Indication">Trastuzumab not to be given in combination with lapatinib</ci> <ci type="logical" class="Treatment">Trastuzumab to be discontinued at disease progression</ci> </apply> <apply> <and/> <ci type="logical" class="Indication">The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology
<Request To="HealthPAC" For="Subsidy" Form="SA1071"> <Title> <range>Gabapentin</range> </Title> <Case When="Initial application" Category="Epilepsy"> <math> <apply> <or/> <ci type="logical" class="Indication">Seizures are not adequately controlled with optimal treatment with other antiepilepsy agents</ci> <ci type="logical" class="Indication">Seizures are controlled adequately but the patient has experienced unacceptable side effects from optimal treatment with other antiepilepsy agents</ci> </apply> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="month">15</Term> <Note> <Para>"Optimal treatment with other antiepilepsy agents" is defined as treatment with other antiepilepsy agents which are indicated and clinically appropriate for the patient, given in adequate doses for the patient's age, weight, and other features affecting the pharmacokinetics of the drug with good evidence of compliance.</Para>
<Request To="HealthPAC" For="Subsidy" Form="SA1066"> <Title> <range>Rivaroxaban</range> </Title> <Case When="Initial application"> <math> <apply> <or/> <ci type="logical" class="Indication">For the prophylaxis of venous thromboembolism following a total hip replacement</ci> <ci type="logical" class="Use">For the prophylaxis of venous thromboembolism following a total knee replacement</ci> </apply> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="week">5</Term> <Note> <Para>Rivaroxaban is only currently indicated and subsidised for up to 5 weeks therapy for prophylaxis of venous thromboembolism following a total hip replacement and up to 2 weeks therapy for prophylaxis of venous thromboembolism following a total knee replacement.</Para> </Note> </Case> <Case When="Renewal" Form="SA1066"> <math> <ci type="logical" class="Indication">Prophylaxis for venous thromboembolism is requir
<Request To="PHARMAC" For="Subsidy" Form="SA1240"> <Title> <range>Insulin pump consumables</range> </Title> <Case When="Initial application"> <math/> <Applicant>medical practitioner</Applicant> <Term Measure="year">1</Term> </Case> <Note> <Para>Application details may be obtained from PHARMAC's website <a href="http://www.pharmac.govt.nz/">http://www.pharmac.govt.nz</a> or:</Para> <Table> <TR> <TD> <Para>The IPP Co-ordinator</Para> </TD> <TD> <Para>Phone: (04) 460 4990</Para> </TD> </TR> <TR> <TD> <Para>PHARMAC</Para> </TD> <TD> <Para>Facsimile: (04) 974 7806</Para> </TD> </TR> <TR> <TD> <Para>PO Box 10 254</Para> </TD> <TD> <Para>Email: <a href="mailto:ipp@pharmac.govt.nz">ipp@pharmac.govt.nz</a></Para> </TD> </TR> <TR> <TD>
<Request To="HealthPAC" For="Subsidy" Form="SA1039"> <Title> <range>Alendronate Tab 70 mg - with or without Cholecalciferol</range> </Title> <Case When="Initial application" Category="Underlying cause -- Osteoporosis"> <math> <apply> <or/> <ci type="logical" class="Indication">History of one significant osteoporotic fracture demonstrated radiologically and documented bone mineral density (BMD) &#8805; 2.5 standard deviations below the mean normal value in young adults (i.e. T-Score &#8804; -2.5) (see Note)</ci> <ci type="logical" class="Indication">History of one significant osteoporotic fracture demonstrated radiologically, and either the patient is elderly, or densitometry scanning cannot be performed because of major logistical, technical or pathophysiological reasons. It is unlikely that this provision would apply to many patients under 75 years of age</ci> <ci type="logical" class="Indication">History of two significant osteoporotic fractures
<Request To="HealthPAC" For="Subsidy" Form="SA1126"> <Title> <range>Modavigil</range> </Title> <Case When="Initial application"> <math> <apply> <and/> <ci type="logical" class="Indication">The patient has a diagnosis of narcolepsy and has excessive daytime sleepiness associated with narcolepsy occurring almost daily for three months or more</ci> <apply> <or/> <ci type="logical" class="Indication">The patient has a multiple sleep latency test with a mean sleep latency of less than or equal to 10 minutes and 2 or more sleep onset rapid eye movement periods</ci> <ci type="logical" class="Indication">The patient has at least one of: cataplexy, sleep paralysis or hypnagogic hallucinations</ci> </apply> <apply> <or/> <ci type="logical" class="Indication">An effective dose of a subsidised formulation of methylphenidate or dexamphetamine has been trialled and discontinued because of intolerabl
<Request To="HealthPAC" For="Subsidy" Form="SA1099"> <Title> <range>Paediatric Product For Children With Chronic Renal Failure<instance>Kindergen</instance></range> </Title> <Case When="Initial application"> <math> <ci type="logical" class="Indication">The patient is a child (up to 18 years) with acute or chronic kidney disease</ci> </math> <Applicant>dietitian</Applicant> <Applicant>relevant specialist</Applicant> <Applicant>vocationally registered general practitioner</Applicant> <Term Measure="year">3</Term> </Case> <Case When="Renewal" Form="SA0606 SA1099"> <math> <apply> <and/> <ci type="logical" class="Indication">The treatment remains appropriate and the patient is benefiting from treatment</ci> <ci type="text" class="Endorsement">General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted</ci> </apply> </mat
<Request To="HealthPAC" For="Subsidy" Form="SA1381"> <Title> <range>Fat Modified Products<instance>Monogen</instance></range> </Title> <Case When="Initial application"> <math> <apply> <or/> <ci type="logical" class="Indication">Patient has metabolic disorders of fat metabolism</ci> <ci type="logical" class="Indication">Patient has a chyle leak</ci> <ci type="logical" class="Indication">Modified as a modular feed for adults</ci> </apply> </math> <Applicant>dietitian</Applicant> <Applicant>relevant specialist</Applicant> <Applicant>vocationally registered general practitioner</Applicant> <Term Measure="year">1</Term> </Case> <Case When="Renewal" Form="SA0593 SA0615 SA1096 SA1381"> <math> <apply> <and/> <ci type="logical" class="Indication">The treatment remains appropriate and the patient is benefiting from treatment</ci> <ci type="text" class="Endorsement">General Practitio
<Request To="HealthPAC" For="Subsidy" Form="SA0782"> <Title> <range>Levonorgestrel &#8211; releasing intrauterine system 20mcg/24 hr</range> </Title> <Case When="Initial application" Category="No previous use"> <math> <apply> <and/> <ci type="logical" class="Indication">The patient has a clinical diagnosis of heavy menstrual bleeding</ci> <ci type="logical" class="Trial">The patient has failed to respond to or is unable to tolerate other appropriate pharmaceutical therapies as per the Heavy Menstrual Bleeding Guidelines</ci> <apply> <or/> <apply> <lt/> <ci type="real" class="test">serum ferritin level</ci> <cn>16<mi> mcg/l (within the last 12 months)</mi></cn> </apply> <apply> <lt/> <ci type="real" class="test">haemoglobin level</ci> <cn>120<mi> g/l</mi></cn> </apply> </apply> </apply> </math>
<Request To="HealthPAC" For="Subsidy" Form="SA0954"> <Title> <range>Acitretin</range> </Title> <Case When="Initial application"> <math> <apply> <and/> <ci type="logical" class="Indication">Applicant is a vocationally registered dermatologist, vocationally registered general practitioner, or nurse practitioner working in a relevant scope of practice</ci> <ci type="logical" class="Indication">Applicant has an up to date knowledge of the treatment options for psoriasis and of disorders of keratinisation and is aware of the safety issues around acitretin and is competent to prescribe acitretin</ci> <apply> <or/> <ci type="logical" class="Indication">Patient is female and has been counselled and understands the risk of teratogenicity if acitretin is used during pregnancy and the applicant has ensured that the possibility of pregnancy has been excluded prior to the commencement of the treatment and that the patient is informed that
<Request To="HealthPAC" For="Subsidy" Form="SA1155"> <Title> <range>Budesonide - Cap 3 mg Controlled Release</range> </Title> <Case When="Initial application" Category="Crohn's disease"> <math> <apply> <and/> <ci type="logical" class="Indication">Mild to moderate ileal, ileocaecal or proximal Crohn's disease</ci> <apply> <or/> <ci type="logical" class="Indication">Diabetes</ci> <ci type="logical" class="Indication">Cushingoid habitus</ci> <ci type="logical" class="Indication">Osteoporosis where there is significant risk of fracture</ci> <ci type="logical" class="Indication">Severe acne following treatment with conventional corticosteroid therapy</ci> <ci type="logical" class="Indication">History of severe psychiatric problems associated with corticosteroid treatment</ci> <ci type="logical" class="Indication">History of major mental illness (such as bipolar affective disorder) where
<Request To="HealthPAC" For="Subsidy" Form="SA1421"> <Title> <range>Montelukast</range> </Title> <Case When="Initial application" Category="Pre-school wheeze"> <math> <apply> <and/> <ci type="logical" class="Indication">To be used for the treatment of intermittent severe wheezing (possibly viral) in children under 5 years</ci> <ci type="logical" class="Indication">The patient has had at least three episodes in the previous 12 months of acute wheeze severe enough to seek medical attention</ci> </apply> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="year">1</Term> </Case> <Case When="Renewal" Category="Pre-school wheeze" Form="SA1227 SA1409 SA1421"> <math> <ci type="logical" class="Indication">The treatment remains appropriate and the patient is benefiting from treatment</ci> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="year">2</Term> </Case> <Case
<Request To="HealthPAC" For="Subsidy" Form="SA1196"> <Title> <range>Paediatric enteral feed with fibre 0.75 kcal/ml<instance>Nutrini Low Energy Multi Fibre</instance></range> </Title> <Case When="Initial application"> <math overflow="scroll"> <apply> <and/> <ci type="logical" class="Indication">Child aged one to eight years</ci> <ci type="logical" class="Indication">The child has a low energy requirement but normal protein and micronutrient requirements</ci> </apply> </math> <Applicant>dietitian</Applicant> <Applicant>relevant specialist</Applicant> <Applicant>vocationally registered general practitioner</Applicant> <Term Measure="year">1</Term> </Case> <Case When="Renewal" Form="SA1196"> <math overflow="scroll"> <apply> <and/> <ci type="logical" class="Indication">The treatment remains appropriate and the patient is benefiting from treatment</ci> <ci type="text" class="Endorsement
<Request To="HealthPAC" For="Subsidy" Form="SA1223"> <Title> <range>Candesartan</range> </Title> <Case When="Initial application" Category="ACE inhibitor intolerance"> <math> <apply> <or/> <ci type="logical" class="Indication">Patient has persistent ACE inhibitor induced cough that is not resolved by ACE inhibitor retrial (same or new ACE inhibitor)</ci> <ci type="logical" class="Indication">Patient has a history of angioedema</ci> </apply> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="patient's lifetime"/> </Case> <Case When="Initial application" Category="Unsatisfactory response to ACE inhibitor"> <math> <ci type="logical" class="Indication">patient is not adequately controlled on maximum tolerated dose of an ACE inhibitor</ci> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="patient's lifetime"/> </Case></Request>
<Request To="HealthPAC" For="Subsidy" Form="SA1198"> <Title> <range>Preterm post-discharge infant formula powder<instance>S-26 Gold Premgro</instance></range> </Title> <Case When="Initial application"> <math overflow="scroll"> <apply> <and/> <ci type="logical" class="Indication">The infant was born before 33 weeks gestation or weighed less than 1.5 kg at birth</ci> <apply> <or/> <ci type="logical" class="Indication">The infant has faltering growth (downward crossing of percentiles)</ci> <ci type="logical" class="Indication">The infant is not maintaining, or is considered unlikely to maintain, adequate growth on standard infant formula</ci> </apply> </apply> </math> <Applicant>dietitian</Applicant> <Applicant>relevant specialist</Applicant> <Applicant>vocationally registered general practitioner</Applicant> <Term Measure="month">6</Term> </Case></Request>
<Request To="HealthPAC" For="Subsidy" Form="SA1124"> <Title> <range>Thalidomide</range> </Title> <Case When="Initial application"> <math> <apply> <or/> <ci type="logical" class="indication">The patient has multiple myeloma</ci> <ci type="logical" class="indication">The patient has systemic AL amyloidosis*</ci> </apply> </math> <Applicant>relevant specialist</Applicant> <Applicant Referring="relevant specialist">medical practitioner</Applicant> <Term Measure="month">12</Term> </Case> <Case When="Renewal" Form="SA1124 SA0817 SA0882"> <math> <ci type="logical" class="indication">The patient has obtained a response from treatment during the initial approval period</ci> </math> <Applicant>relevant specialist</Applicant> <Applicant Referring="relevant specialist">medical practitioner</Applicant> <Term Measure="patient's lifetime"/> </Case> <Note> <Para>Prescription must be written by a re
<Request To="HealthPAC" For="Subsidy" Form="SA1260"> <Title> <range>Perhexiline Maleate</range> </Title> <Case When="Initial application"> <math> <apply> <and/> <ci type="logical" class="Indication">Patient has refractory angina</ci> <ci type="logical" class="Trial">Patient is on the maximal tolerated dose of a beta-blocker, a calcium channel blocker and a long acting nitrate</ci> </apply> </math> <Applicant>cardiologist</Applicant> <Applicant>general physician</Applicant> <Term Measure="year">2</Term> </Case> <Case When="Renewal" Form="SA0256 SA1260"> <math> <ci type="logical" class="Indication">The treatment remains appropriate and the patient is benefiting from treatment</ci> </math> <Applicant>cardiologist</Applicant> <Applicant Referring="cardiologist">any relevant practitioner</Applicant> <Term Measure="year">2</Term> </Case></Request>
<Request To="HealthPAC" For="Subsidy" Form="SA1285"> <Title> <range>Posaconazole </range> </Title> <Case When="Initial application"> <math> <apply> <or/> <ci type="logical" class="Indication">Patient has acute myeloid leukaemia and is to be treated with high dose remission induction, re-induction or consolidation chemotherapy</ci> <ci type="logical" class="Indication">Patient has received a stem cell transplant and has graft versus host disease and is on significant immunosuppressive therapy*</ci> </apply> </math> <Applicant>haematologist</Applicant> <Applicant>infectious disease specialist</Applicant> <Term Measure="week">6</Term> </Case> <Case When="Renewal" Form="SA1285"> <math> <apply> <or/> <ci type="logical" class="Indication">Patient has acute myeloid leukaemia and is to be treated with high dose remission induction, re-induction or consolidation therapy</ci> <ci type="logical" c
<Request To="HealthPAC" For="Subsidy" Form="SA1293"> <Title> <range>Sildenafil</range> </Title> <Case When="Initial application" Category="Raynaud&#8217;s Phenomenon* - for Pulmonary Arterial Hypertension see note below)"> <math> <apply> <and/> <ci type="logical" class="Indication">Patient has Raynaud&#8217;s Phenomenon*</ci> <ci type="logical" class="Indication">Patient has severe digital ischaemia (defined as severe pain requiring hospital admission or with a high likelihood of digital ulceration; digital ulcers; or gangrene)</ci> <ci type="logical" class="Indication">Patient is following lifestyle management (avoidance of cold exposure, sufficient protection, smoking cessation support, avoidance of sympathomimetic drugs) </ci> <ci type="logical" class="Indication">Patient is being treated with calcium channel blockers and nitrates (or these are contraindicated/not tolerated)</ci> </apply> </math> <Applicant>any relevant
<Request To="HealthPAC" For="Subsidy" Form="SA1061"> <Title> <range>Venlafaxine</range> </Title> <Case When="Initial application"> <math> <apply> <and/> <ci type="logical" class="Indication">The patient has 'treatment-resistant' depression</ci> <apply> <or/> <ci type="logical" class="Trial">The patient must have had a trial of two different antidepressants and have had an inadequate response from an adequate dose over an adequate period of time (usually at least four weeks)</ci> <apply> <and/> <ci type="logical" class="Indication">The patient is currently a hospital in-patient as a result of an acute depressive episode</ci> <ci type="logical" class="Trial">The patient must have had a trial of one other antidepressant and have had an inadequate response from an adequate dose over an adequate period of time</ci> </apply> </apply> </apply> </math> <Appl
<Request To="HealthPAC" For="Alternate Subsidy" Form="SA1018"> <Title> <range>Hormone Replacement Therapy - Systemic</range> </Title> <Case When="Initial application"> <math> <apply> <or/> <ci type="logical" class="Indication">acute or significant liver disease - where oral oestrogens are contraindicated as determined by a gastroenterologist or general physician. The applicant must keep written confirmation from such a specialist with the patient's record</ci> <ci type="logical" class="Indication">oestrogen induced hypertension requiring antihypertensive therapy - documented evidence must be kept on file that raised blood pressure levels or inability to control blood pressure adequately occurred post oral oestrogens</ci> <ci type="logical" class="Indication">hypertriglyceridaemia - documented evidence must be kept on file that triglyceride levels increased to at least 2 &#215; normal triglyceride levels post oral oestrogens</ci> <ci type=
<Request To="HealthPAC" For="Subsidy" Form="SA1095"> <Title> <range>Diabetic products<instance>Diason RTH</instance><instance>Glucerna Select RTH</instance><instance>Diasip</instance><instance>Glucerna Select</instance><instance>Resource Diabetic</instance></range> </Title> <Case When="Initial application"> <math> <ci type="logical" class="Indication">The patient is a type I or and II diabetic who is suffering weight loss and malnutrition that requires nutritional support</ci> </math> <Applicant>dietitian</Applicant> <Applicant>relevant specialist</Applicant> <Applicant>vocationally registered general practitioner</Applicant> <Term Measure="year">1</Term> </Case> <Case When="Renewal" Form="SA0594 SA1095"> <math> <apply> <and/> <ci type="logical" class="Indication">The treatment remains appropriate and the patient is benefiting from treatment</ci> <ci type="text" class="Endorsement">General Practitioners must includ
<Request To="HealthPAC" For="Subsidy" Form="SA1388"> <Title> <range>Preservative Free Ocular Lubricants</range> </Title> <Case When="Initial application"> <math> <apply> <and/> <ci type="logical" class="Indication">Confirmed diagnosis by slit lamp of severe secretory dry eye</ci> <apply> <or/> <ci type="logical" class="Indication">Patient is using eye drops more than four times daily on a regular basis</ci> <ci type="logical" class="Indication">Patient has had a confirmed allergic reaction to preservative in eye drop</ci> </apply> </apply> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="month">12</Term> </Case> <Case When="Renewal" Form="SA1388"> <math> <ci type="logical" class="Indication">The patient continues to require lubricating eye drops and has benefited from treatment</ci> </math> <Applicant>any relevant practitioner</Applicant>
<Request To="HealthPAC" For="Subsidy" Form="SA1201"> <Title> <range>Prasugrel</range> </Title> <Case When="Initial application" Category="coronary angioplasty and bare metal stent"> <math> <ci type="logical" class="Treatment">The patient has undergone coronary angioplasty in the previous 4 weeks and is clopidogrel-allergic*</ci> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="month">6</Term> </Case> <Case When="Initial application" Category="drug eluting stent"> <math> <ci type="logical" class="Treatment">The patient has had a drug-eluting cardiac stent inserted in the previous 4 weeks and is clopidogrel-allergic*</ci> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="month">12</Term> </Case> <Case When="Initial application" Category="stent thromobosis"> <math> <ci type="logical" class="Treatment">patient has experienced cardiac stent thrombosis whilst on clopidogrel</ci>
<Request To="HealthPAC" For="Subsidy" Form="SA1325"> <Title> <range>Pegaspargase</range> </Title> <Case When="Initial application"> <math> <apply> <and/> <ci type="logical" class="Indication">The patient has newly diagnosed acute lymphoblastic leukaemia</ci> <ci type="logical" class="Indication">Pegaspargase to be used with a contemporary intensive multi-agent chemotherapy treatment protocol</ci> <ci type="logical" class="Indication">Treatment is with curative intent</ci> </apply> </math> <Applicant>relevant specialist</Applicant> <Applicant Referring="relevant specialist">medical practitioner</Applicant> <Term Measure="month">12</Term> </Case> <Case When="Renewal" Form="SA1325"> <math> <apply> <and/> <ci type="logical" class="Indication">The patient has relapsed acute lymphoblastic leukaemia</ci> <ci type="logical" class="Indication">Pegaspargase to be used with a contemporar
<Request To="HealthPAC" For="Alternate Subsidy" Form="SA0500"> <Title><range>Combined oral contraceptives</range><range>Progestogen-only contraceptives</range> (Circle one)</Title> <Case When="Initial application"> <math> <apply> <and/> <apply> <or/> <ci type="logical" class="Target">Patient is on a Social Welfare benefit</ci> <ci type="logical" class="Target">Patient has an income no greater than the benefit</ci> </apply> <ci type="logical" class="Trial">Has tried at least one of the fully funded options and has been unable to tolerate it</ci> </apply> </math> <Applicant>medical practitioner</Applicant> <Term Measure="year">2</Term> </Case> <Case When="Renewal" Form="SA0265 SA0500"> <math> <apply> <or/> <ci type="logical" class="Target">Patient is on a Social Welfare benefit</ci> <ci type="logical" class="Target">Patient has an income no greater than the be
<Request To="HealthPAC" For="Subsidy" Form="SA1374"> <Title> <range>Fat<instance>Calogen</instance><instance>Liquigen</instance><instance>MCT oil (Nutricia)</instance></range> </Title> <Case When="Initial application" Category="Inborn errors of metabolism"> <math> <ci type="logical" class="Indication">The patient has inborn errors of metabolism</ci> </math> <Applicant>dietitian</Applicant> <Applicant>relevant specialist</Applicant> <Applicant>vocationally registered general practitioner</Applicant> <Term Measure="year">3</Term> </Case> <Case When="Initial application" Category="Indications other than inborn errors of metabolism"> <math> <apply> <or/> <ci type="logical" class="Indication">faltering growth in an infant/child</ci> <ci type="logical" class="Indication">bronchopulmonary dysplasia</ci> <ci type="logical" class="Indication">fat malabsorption</ci> <ci type="logical" class="Indication">lym
<Request To="HealthPAC" For="Subsidy" Form="SA1375"> <Title> <range>Protein<instance>Protifar</instance><instance>Promod</instance><instance>Resource Beneprotein</instance></range> </Title> <Case When="Initial application"> <math> <apply> <or/> <ci type="logical" class="Indication">protein losing enteropathy</ci> <ci type="logical" class="Indication">high protein needs</ci> <ci type="logical" class="Indication">for use as a component in a modular formula</ci> </apply> </math> <Applicant>dietitian</Applicant> <Applicant>relevant specialist</Applicant> <Applicant>vocationally registered general practitioner</Applicant> <Term Measure="year">1</Term> </Case> <Case When="Renewal" Form="SA0582 SA1093 SA1375"> <math> <apply> <and/> <ci type="logical" class="Indication">The treatment remains appropriate and the patient is benefiting from treatment</ci> <ci type="text" class="Endor
<Request To="HealthPAC" For="Subsidy" Form="SA1273"> <Title> <range>Voriconazole</range> </Title> <Case When="Initial application" Category="invasive fungal infection"> <math> <apply> <and/> <ci type="logical" class="Indication">Patient is immunocompromised</ci> <ci type="logical" class="Indication">Applicant is part of a multidisciplinary team including an infectious disease specialist</ci> <apply> <or/> <ci type="logical" class="Indication">Patient has proven or probable invasive aspergillus infection</ci> <ci type="logical" class="Indication">Patient has possible invasive aspergillus infection</ci> <ci type="logical" class="Indication">Patient has fluconazole resistant candidiasis</ci> <ci type="logical" class="Indication">Patient has mould strain such as Fusarium spp. and Scedosporium spp</ci> </apply> </apply> </math> <Applicant>haematologist</Applicant> <App
<Request To="HealthPAC" For="Subsidy" Form="SA1228"> <Title> <range>Standard Supplements<instance>Ensure</instance><instance>Fortisip</instance><instance>Isosource</instance><instance>Jevity</instance><instance>Nutrison</instance><instance>Osmolite</instance><instance>Sustagen</instance></range> </Title> <Case When="Initial application" Category="Children"> <math> <apply> <and/> <ci type="logical" class="Indication">The patient is under 18 years of age</ci> <apply> <or/> <ci type="logical" class="Indication">The patient has a condition causing malabsorption</ci> <ci type="logical" class="Indication">The patient has failure to thrive</ci> <ci type="logical" class="Indication">The patient has increased nutritional requirements</ci> </apply> <ci type="logical" class="Indication">Nutrition goal has been set (eg reach a specific weight or BMI)</ci> </apply> </math> <Applicant>dietitia
<Request To="HealthPAC" For="Subsidy" Form="SA1046"> <Title> <range>Ezetimibe with Simvastatin<instance>Vytorin</instance></range> </Title> <Case When="Initial application"> <math> <apply> <and/> <ci type="logical" class="Indication">Patient has a calculated absolute risk of cardiovascular disease of at least 15% over 5 year</ci> <ci type="logical" class="Trial">Patient's LDL cholesterol is 2.0 mmol/litre or greater</ci> <ci type="logical" class="Trial">The patient has not reduced their LDL cholesterol to less than 2.0 mmol/litre with the use of the maximal tolerated dose of atorvastatin</ci> </apply> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="year">2</Term> <Note> <Para>A patient who has failed to reduce their LDL cholesterol to &#8804; 2.0 mmol/litre with the use of a less potent statin should use a more potent statin prior to consideration being given to the use of non-statin therapi
<Request To="Cystic Fibrosis Advisory Panel" For="Subsidy" Form="SA0611"> <Title> <range>Dornase Alfa</range> </Title> <Case When="Initial application"> <math> <ci/> </math> <Applicant>medical practitioner</Applicant> <Term Measure="year">1</Term> </Case> <Note> <Para>Application details may be obtained from PHARMAC's website <a href="http://www.pharmac.govt.nz/">http://www.pharmac.govt.nz</a> or:</Para> <Table> <TR> <TD> <Para>The Co-ordinator, Cystic Fibrosis Advisory Panel</Para> </TD> <TD> <Para>Phone: (04) 460 4990</Para> </TD> </TR> <TR> <TD> <Para>PHARMAC, PO Box 10 254</Para> </TD> <TD> <Para>Facsimile: (04) 916 7571</Para> </TD> </TR> <TR> <TD> <Para>Wellington</Para> </TD> <TD> <Para>Email: <a href="mailto:CFPanel@pharmac.govt.nz">CFPanel@pharmac.
<Request To="HealthPAC" For="Subsidy" Form="SA1451"> <Title> <range>Somatropin</range> </Title> <Case When="Initial application" Category="growth hormone deficiency in children"> <math> <apply> <or/> <apply> <and/> <ci type="logical" class="Indication">Growth hormone deficiency causing symptomatic hypoglycaemia, or with other significant growth hormone deficient sequelae (e.g. cardiomyopathy, hepatic dysfunction) and diagnosed with GH &lt; 5 mcg/l on at least two random blood samples in the first 2 weeks of life, or from samples during established hypoglycaemia (whole blood glucose &lt; 2 mmol/l using a laboratory device)</ci> </apply> <apply> <and/> <ci type="logical" class="Indication">Height velocity &lt; 25th percentile for age adjusted for bone age/pubertal status if appropriate over 6 or 12 months using the standards of Tanner and Davies (1985)</ci> <ci type="logical" class="Indication
<Request To="HealthPAC" For="Subsidy" Form="SA1139"> <Title> <range>Teriparatide</range> </Title> <Case When="Initial application"> <math> <apply> <and/> <ci type="logical" class="indication">The patient has severe, established osteoporosis</ci> <ci type="logical" class="indication">The patient has a documented T-score less than or equal to -3.0 (see Notes)</ci> <ci type="logical" class="indication">The patient has had two or more fractures due to minimal trauma</ci> <ci type="logical" class="indication">The patient has experienced at least one symptomatic new fracture after at least 12 months&#8217; continuous therapy with a funded antiresorptive agent at adequate doses (see Notes)</ci> </apply> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="month">18</Term> </Case> <Note> <List Type="Alpha"> <Item> <Para>The bone mineral density (BMD) measurement used to derive the
<Request To="PHARMAC" For="Subsidy" Form="SA1291"> <Title> <range>Optium blood glucose test strips</range> </Title> <Case When="Initial application"> <math> <ci type="logical" class="Indication">Patient identified as eligible for subsidy for FreeStyle Optium blood glucose test strips</ci> </math> <Applicant>any relevant practitioner</Applicant> <Term Measure="patient's lifetime"/> </Case> <Note> <Para>Application details may be obtained from PHARMAC's website http://www.pharmac.govt.nz and can be sent to:</Para> <Table> <TR> <TD> <Para>PHARMAC</Para> </TD> <TD> <Para/> </TD> </TR> <TR> <TD> <Para>PO Box 10 254</Para> </TD> <TD> <Para>Facsimile: (04) 974 4788</Para> </TD> </TR> <TR> <TD> <Para>Wellington</Para> </TD> <TD> <Para>Email: <a href="mailto:bgstrip
<Request To="HealthPAC" For="Subsidy" Form="SA1098"> <Title> <range>Paediatric Product For Children Awaiting Liver Transplant<instance>Heparon Junior</instance></range> </Title> <Case When="Initial application"> <math> <ci type="logical" class="Indication">The patient is a child (up to 18 years) who requires a liver transplant</ci> </math> <Applicant>dietitian</Applicant> <Applicant>relevant specialist</Applicant> <Applicant>vocationally registered general practitioner</Applicant> <Term Measure="year">3</Term> </Case> <Case When="Renewal" Form="SA0607 SA1098"> <math> <apply> <and/> <ci type="logical" class="Indication">The treatment remains appropriate and the patient is benefiting from treatment</ci> <ci type="text" class="Endorsement">General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted</ci> </apply> </math
<Request To="HealthPAC" For="Subsidy" Form="SA0955"> <Title> <range>Isotretinoin</range> </Title> <Case When="Initial application"> <math> <apply> <and/> <ci type="logical" class="Indication">Patient has had an adequate trial on other available treatments and has received an inadequate response from these treatments or these are contraindicated</ci> <ci type="logical" class="Indication">Applicant is a vocationally registered dermatologist, vocationally registered general practitioner, or nurse practitioner working in a relevant scope of practice</ci> <ci type="logical" class="Indication">Applicant has an up to date knowledge of the treatment options for acne and is aware of the safety issues around isotretinoin and is competent to prescribe isotretinoin</ci> <apply> <or/> <ci type="logical" class="Indication">Patient is female and has been counselled and understands the risk of teratogenicity if isotretinoin is used d
<Request To="HealthPAC" For="Subsidy" Form="SA1404"> <Title> <range>Valganciclovir</range> </Title> <Case When="Initial application" Category="transplant cytomegalovirus prophylaxis"> <math> <ci type="logical" class="Indication">the patient has undergone a solid organ transplant and requires valganciclovir for CMV prophylaxis</ci> </math> <Applicant>relevant specialist</Applicant> <Term Measure="month">3</Term> </Case> <Case When="Renewal" Form="SA1274 SA1404" Category="transplant cytomegalovirus prophylaxis"> <math> <apply> <and/> <ci type="logical" class="Indication">Patient has undergone a solid organ transplant and received anti-thymocyte globulin and requires valganciclovir therapy for CMV prophylaxis</ci> <ci type="logical" class="Indication">Patient is to receive a maximum of 90 days of valganciclovir prophylaxis following anti-thymocyte globulin</ci> </apply> </math> <Applicant>relevant specialist</A

Das könnte Ihnen auch gefallen